Fauci Emails

From: Fauci, Anthony (NIH/NIAID) [El
Sent: Fri, 6 Mar 2020 03:49:45 +0000

To: Haskins, Melinda (NIH/NIAID) [El
Cc: Selgrade, Sara (NIH/NIAID) [E);Crawford, Chase (NIH/NIAID) [E];Conrad, Patricia
(NIH/NIAID) [E]
Subject: RE: Please review: House Oversight Letter on Coronavirus Diagnostics
I do not understand why you are asking me to "review" this. Is this an FYI??
From: Haskins, Melinda (NIH/NIAID) [El (b)( >

Sent: Thursday, March 5, 2020 9:53 AM
To: Fauci, Anthony (NIH/NIAID) [E] ------~=
Cc:Selgrade, Sara (NIH/NIAID) [E] ;.!::::======~= ; Crawford, Chase (NIH/NIAID) [E]
(b)(6)>; Conrad, Patricia (NIH/NIAID) [E]
---------
Subject: Please review: House Oversight Letter on Coronavirus Diagnost ics
(b)(6)
NIH-000960
From: Fauci, Anthony (NIH/NIAIO) [E)
Sent : Fri, 6 Mar 2020 03:00:23 +0000
To: Muniz, Maria de Los Angeles
Cc: 'Birx, Deborah L'
Subject: RE: National Blood Supply
Maria:
Thanks for the note . I will bring this us in our discussions
Best regards,
Tony
From : Muniz, Maria de Los Angeles <MMuniz@vitalant.org>

Se nt : Thursday, March 5, 2020 9:53 AM
To: Fauci, Anthony (NIH/NIAID)
------
[E]=====~~ ~=
Cc: Fauci, Anthony (NIH/NIAID) [E)
Subject : National Blood Supply
--------
Dear Dr. Fauci: I am an ex-alumni from the Department of Transfusion Medicine at the NIH. I am sorry to
bother but I wanted to not ify the Coronavirus Task force about potential blood shortages if blood
centers get blood drive cancellations due to the fear in the public.
We are starting to see this locally and my concern is that other blood centers in the country are facing
the same issue.
I tried to contact the office of the vice president, and all I could do was to send an email, which might
get lost among thousands .
I am hoping you see this and perhaps br ing this to the table. Blood centers use updated federal
information when educating donors, staff and hospitals but the current fea r is tr iggering blood drive
cancellations. This might be experienced nationally and will impact the national blood invento ry.
Thank you
Maria De Los Angeles Muniz (Angie) , MD

Medical Director
o 201.389.0439 I c ._____ Cb
_
H_ (please call cell phone first)
mmun iz@v italant. org
Vitalant Mon tvale V italant Cleveland Vitalant Cord Blood
Bank
102 Chestnut Ridge Road 333 East Bridge Street 1 Pearl Court
Montva le, NJ 07645 Elyria, OH 44035 Allendale, NJ 07401
Community Blood Serv ices, Lifeshare & Blood Systems are now Vi talant.
NIH-000964
From: Conrad, Patricia (NIH/NIAID) [El on behalf of Fauci, Anthony (NIH/NIAIO) [El
Sent: Thu, 5 Mar 2020 21:27:53 +0000
To: NIAIDODAM
Subject: FW: 03 04 2020 Or. Anthony Fauci RE Invite to join my head table at Global's
AcceptAbility Gala on Wed S/20
Attachment s: 2020 03 GLOBALAcceptAbility Gala Save the Date.pdf
Importance: High
Patricia L. Conrad
Public Health Ana lyst and
Special Assistant to the Direc tor
Nat ional Institute of A ller gy and Infectious Diseases
Th e National Institutes of Hea lth
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b)(6)
30 1-496-4409 fax
Disclaimer :
The informat ion in this e-ma il and any of its attachments is confidentia l and may conta in sensi tive information. It should not be used
by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it
from your mailbox or any other storage devices. Nationa l Institute of Allergy ancl Infectious Diseases (NIAID) shall not accept
liabil ity for any statement macle that are sencler"s own ancl not expressly macle on behalf of the NIAID by one of its representatives.
From: M ichelle Whitten - Global <mswhitten@gl oba ldownsynd rome.org>

Sent: Wednesday, March 4, 2020 10:35 PM
To: Fauci, Anthony (NIH/NIAID) [E]------ --=-
(b=)(=6)
Cc: Ashley Sparhawk <asparhawk@globaldownsyndrome .org>; Marisa Cucuzzella
<mcucuzzella@ajsfoundation .com>; Rotrosen, Daniel (NIH/NIA ID) [El
--------~
(b)(6l;
=
Deckhut, Alison (NIH/NIAID) [El CbH6)>;Rothermel, Annette (NIH/N IAID) [El
(b) (6) >
Subject: 03 04 2020 Dr. Anthony Fauci RE Invite to jo in my head table at Global's AcceptAbi lity Gala on
Wed S/20
Importance: High
Dear Dr. Fauci,
First let me say we are very grateful to everyone at NIH for working to contain the coronavirus,
especially your team at the NIAID. Your interviews are articulate and informative - they give Americans
some comfort and some concrete ways to t hink about protecting themselves and what to expect. It
must be a stressful ti me and we want you to know that we have confidence in our NIH and CDCto
contain it and to help stave it off globally as well.
NIH-000965
On a happier note, I wanted to reach out and THANK YOU for all you do for our Down Syndrome
research through the transformative trans-NIH INCLUDEprogram. It is making a HUGE difference!!
To this end, I am writing today in hopes you will be able to join us on Wednesday, May 20th for our
AcceptAbili ty Gala at my head table. Attached is our save the date for the event . We are excited to have
Caroline Cardenas as our 2020 Ambassador, Rep Pete Stauber as our keynote (b)(6)
•--• , and Reps Lucille Roybal-Allard and Jaime Herrera Beutler are Global's Quincy Jones
Exceptional Advocacy Awardees. We believe the gala will be quite lovely and meaningfu l to so many .
We do understand that attendance cannot be considered if the coronavirus situation worsens. However,
if things are look ing much better (touch wood) we wou ld be deeply honored if you and our friends from
NIAID could attend. Looking forward to hearing from you soon.
All the Best, Michelle and family
NIH-000966
From: Fauci, Anthony (NIH/NIAID) [E)
Sent : Thu, 5 Mar 2020 11:00:39 +0000
To : (b)(6)
Cc: Conrad, Patricia (NIH/NIAID) [E);Greg Folkers
-------~=
________ Cb)
_C_
6);Marston, Hilary (NIH/NIAID) [E)
Subject: FW: New concerns for our randomized trial
What do you think? I see the FDACommissioner every day in person.
From: Kalil, Andre C (b)(6)>

To: Seigel, John (NIH) (El (b)(6)•>; Davey, Richard (NIH/N IAID) [E]
(b)(6)>; Lane, Cliff (NIH/NIAID) [E] (b)(6); Marston, Hilary {NIH/NIAID)
~======~~
[E] (b)(6)>; Fauci, Anthony (NIH/NIAID) [E] (b)(6)>
Subject: New concerns for our randomized trial
I want to share with you my concerns before the situation gets worse.
I have received many calls from physicians from all over the country about how to get
"compassionate use" remdesivir. (b)(4).(b)(5)
(b) (4). (b) (5)
I would appreciate hearing your thoughts on this critical issue.
NIH-000967
Best,
Andre
Andre Kalil, MD, MPH , FACP , FIDSA , FCCM

Professor
Departmentof Internal Medicine
Division of InfectiousDiseases
Director, Transplant ID Program
Associate Editor, CMI, Official Journal of ESCMID
Editorial Board, CCM, Official Journal of SCCM
~ UNMc ·
~ rcitlflL •
University of Nebraska Med ical Center
985400 Nebraska Medical Center, Omaha, NE 68198-5400
=== (b= 6)~1=fax 402.559-5581
)( ~
(b)(6)
UNMC I Facebook I Tw itter I YouTube I Flickr

"Lucky? Obv iously you haven 't heard anyth ing I've said . It was a matter of app lying Bayes' Theo rem to
est imate the condit ional probab ilities . Giving due we ight to the prio r probabi lities ..."
Robert Ludlum - The Amble r Warn ing
The informat ion in th is e-mail may be privileged and confidentia l, intended only for the use of the
addressee(s) above. Any unauthorized use or disclosure of this information is prohibited. If you have
received this e-ma il by mistake, please delete it and immediately contact the sender.
NIH-000968
From: Fauci,Anthony (NIH/NIAID) [E)
Sent: Thu, 5 Mar 2020 03:29:00 +0000
To: Dave Doern
Subject : RE:Go Tony
Dave:
Many thanks for your kind note. I hope that all is well with you.
Best regards ,
Tony
-----Original Message- ----

From: Dave Doern.=-------- (b
=)~(=
6)
Sent: Wednesday, March 4, 2020 12:l..9-'-
P.;;...
M.;;......
___ ~~
To: Fauci, Anthony (NTH/NIAID) [E] (b)(6) ; Fauci, Anthony (NIH/NIA ID) [E]
(b)(6)>
Subject: Go Tony
Tony,
You always do the right thing ......comforting for all your
coronavirus attack ....
We'll do the praying and you go Keep doing the liard work .... .
Thanks,
Dave
DavidDoem
Sent from my iPhone
(b)(6)
NIH-000969
Sent : Thu, 5 Mar 2020 03:19:47 +0000
To: (b)(6)
Cc:
Subject:
Greg Folkers
--------- Cb)<)
RE: Conference Planning with respect to coronavirus.
There is no way of knowing for sure. I would wait unti l May and see what the dynamics of the
outbreak are globally and make your decision then whether or not to cancel.
From : (b)(6)
Sent : Wednesday, March 4, 2020 5:46 PM
To : Fauci, Anthony (NIH/NIAID) -------
[E ~=
(b)(6)
Subject : Conference Planning wit h respect to coronavirus.
Dear Dr. Fauci
Dr. Miriam Ke lty forme rly of NIH referred me to you . I am on the board of d irectors and planning
committee of the Applied Superconductivity Conference that is planned to be held in Tampa, Florida the
last week of July. Over 50% of our expected 1500 attendees are from outside the continental US. Our
planning committee appears to have three options :
1. Hold the conference on the original dates
2. Postpone the conference a few months
3. Cancel the confe rence
It would be most helpful to decision process if you can give us a prediction (anonymously of co urse) of
how the effects of the virus will pan out.
I look forward to your reply .
Bruce Strauss
ScD, MBA, PE, F-IEEE
NIH-000970
From: Fauci,Anthony (NIH/NIAIO) [E)
Sent: Thu, 5 Mar 2020 02:59:22 +0000
To : Aliantha Angel
Subject: RE:A humble request for your wisdom
(b)(6)
From: Aliantha Angel (b)(6)

To: Fauci,Anthony (NIH/NIAID) [E) ----- --:a
(b
=H=6)>
Subject : Re: A humble request for your wisdom
Oh my God ...
I honestly never expected you to reply and I thank you from the bottom of my heart for being so
generous!
(b)(6)
Is there anything I can do for you besides being grateful?
You and yours are in my prayers!
much love,
Aliantha
On Wed, Mar 4, 2020 at 9:45 PM Fauci, Anth ony (NIH/N IAID) [E)
-------- (b) ~ > wrote :
Dear Ms. Angel:

The severe complication of coronavirus are heavily skewed towards the elderly and those
with underlying conditions (Heart disease, Chronic lung disease, kidney disease, diabetes,
etc.) Most of the pneumon ias are pu re viral pneumonia and so this vaccination w ill not help
that. However, on the chance that you have a pure viral pneumonia that gets secondari ly
complicated by a bacterial pneumonia (pneumococcal) the vaccine would be beneficial. If
you are 65 years of age or older, you shou ld get the pneumonvax23 vaccine anyway
regardless of the risk of coronavirus infection.
Thanks,
Tony
From: Aliantha Angel (b)(6)

NIH-00097 1
To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)>
--------
Subject: A humble request for your wisdom
Good evening!
I know you must be completely busy and inundated with people want ing your time. I apologize that I
have nothing to offer in return and completely understand if you don't have time to answer. I called
the CDCbut they were totally unhelpful. I have a question that makes sense to me and I was hoping
you could answer and the answer might help a lot of people.
I understand that over time I, and everyone else, will very likely get COVI0-19 and that most people
won't even realize it because it will be minor. I get that, so th is is not a panicked q uestion.
I also understand that while most cases wil l not be severe, the bad cases are compl icated by
pneumonia .
So my question is: If someone has been vaccinated against pneumonia, will that offer any protection
in the event that they do contract COVID-19 and perhaps provide some barrier against the worst
effects?
Thank you for your time if you have read this and I apologize if this is just another in a long line of
ignorant questions, but it made sense in my brain so I thought I would at least ask.
Be well, be happy, and may life be kind and generous to you, those you love, and those who love
you!
sincerely,
Aliantha Angel
NIH-000972
Sent : Thu, 5 Mar 2020 02:50:29 +0000
To: Gordon, Joshua (NIH/NIMH) [E]
Subject : RE:Question re:
------- (b)(6) coronavirus case
Josh:
You should counsel the rabbi to cancel the services this (b)(6) Are the
local/city/state health departments (b)(6) doing any contact tracing?
Tony
From:Gordon, Joshua (N IH/NIMH) [El

Sent : Wednesday, March 4, 2020 9:44 PM -------- (b)(6)>
To: Fauci, Anthony (NIH/NIAID) [E]------~=

:;.::::======~~Collins, Francis (NIH/OD) [E]
(b)(6)
Cc: Tabak, Lawrence (NIH/OD) [E]
(b)( --------- (b)(6)>;
Subject : Question re:

------- (b) (6) coronavirus case
Dear Tony,
I know you are swamped but

--------------- (b)(6)
(b)(6)
Is my reasoning sound? Should I counsel them to cancel services this Friday/Saturday? I'm hoping you
can spare a bit of time for this advice, (b)(
Best,
Josh
PS (b)(6)
-----------------------------
PPSgreat job today in the hearing
NIH-000973
Joshua A Gordon, MD, PhD
Director
National Institute of Mental Health
NIH-000974
Sent: Thu, 5 Mar 2020 02:47:27 +0000
To: Conrad, Patricia (NIH/NIAID) [El
Subject : FW: Or. Fauci for ABC News 20/20, Friday 9pm Ashton/ Muir
Do you think that we can do this? I like Jennifer Ashton.
From: Strauss, Eric M.< Eric.M .St rauss@abc.com>

Sent: Wed nesday, Marc h 4, 2020 9:45 PM
To: Oplinger, Anne {NIH/NIAID) [E)-------=-c (b)
'""'
(6)
= >; Conrad, Patricia {NIH/NIAID) [E)
(b)(6) ; Fauci, Anthony {NIH/NIAID) [El
======~ (b~
)( ~6);----------
Subject : Dr. Fauci for ABC News 20/20, Friday 9pm Ashton/ Muir
Hello:
I wanted to make sure you are still consideri ng our request for Dr. Ashton and David Muir to interview
Dr. Fauci for our 2 hour program ABC News 20/20 Friday from 9pm to 11pm.
If a remot e interv iew from a studio -on-t he go mobile unit is prefer able we can certa inly arrange t hat .
Thank you for your consideration .
Keep up with our latest on the developingnovel coronavirusoutbreak:

https ://abcnews.go.com/Health/coronavirus
Eric M. Strauss, ABC News

Managing Editor, Medical Unit
www.ericmstrauss.com
Phone: Cb) (6)
Connecton Social: T/1/F = @ericMstrauss
NIH-000975
Sent: Thu, 5 Mar 2020 02:36:30 +0000
To : RichSilverman
Subject: RE:CoronavirusQuestion
Richard:
Right!! Even if there was no coronavirus threat, (b)(6)
----------------
Best regards,
Tony
From:RichSilverman (b)(6)
Sent: Wednesday,March 4, 2020 8:56 PM
To : Fauci, Anthony {NIH/NIAID) [E] --------=-:-:-=(b)(6)>
Subject: Coronavir us Question
Dear Dr. Fauci,

I apologize in advance for this email. I am sure you are too busy these days to answer
coronavirus questions from the general public. However, you are the only individual I know of
who can be trusted to speak intelligently about the pandemic.
I know there is no preventive vaccine or cure, and there probably won't be for quite some time-
-despite what our ersatz President says. But there is something I don't understand. Since the
coronavirus causes pneumonia, wouldn't it be a good idea to vaccinate more of the general
population with Pneumova x 23 or Prevnar 13? That certainly wouldn't prevent people from
catching coronavirus, but perhaps the resulting penumonia onsets might be a little
weaker/short-lived? (b)(6)
I figured it couldn't hurt, right?
Bravo for your efforts to keep our population intelligen tly informed on this situation.
Sincerely
Richard E. Silverman
(b)(6)
NIH-000976
From: Fauci,Anthony (NIH/NIAIO)[E)
Sent: Thu, 5 Mar 2020 00:10:39 +0000
To : Basser, Peter (NIH/NICHD) [E]
Subject: RE: genetic screen ing
Peter:
Thanks for the note. This would not be feasib le in an outbreak setting if you are
talking about GWAS or any kind of sequencing. Things would be moving too
quickly .
Best,
Tony
Anthony S. Fauci , MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda , MD 20892-2520
Phone : (b)(6)
FAX: (301) 496-4409
E-mail : (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive
information . It should not be used by anyone who is not the original intended recipient. If you
have received this e-mail in error please inform the sender and delete it from your mailbox or any
other storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall not
accept liability for any statements made that are the sender's own and not expressly made on
behalf of the NIAID by one of its representatives .
From: Basser, Peter (NIH/NICHD) [E] (b)(6)

---------
Sent: Wednesday, Marc h 4, 2020 6:59 PM
------~~
To : Fauci, Anthony (NIH/NIAID) [E]
Subject ; genetic screening
-------- (b)(6)
Dear Dr. Fauci,

I watched you and Dr. Collins (via videocast) with admiration and pride yesterday during
President Trump's visit to the NIH.
This morning, (b)(6) and I were discussing the spread of COVID-19. We were opining
about why some people only have mild symptoms while others go on to develop ARDS. While
we understand that age is a factor, we wondered 5>
CbH
(b) (5)
NIH-000978
(b) (5)
Regards,
Peter J. Basser, Ph.D.

Senior Investigator, Intramural Research Program (IRP), NIH
Head , Section on Quantitative lm aging and Tissue Sciences (SQ ITS)
Associate Scientific Director (ASD), Division oflmaging, Behavior and Genomic Integrity (DIBGI)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (N1CHD)
National Institut es of Health (NIH)

13 South Drive, MSC 5772
Bldg. 13,Rm.3W16
Bethesda , MD 20892-5772 USA
(b) (6) (0)

(30 I) 480-0 I 63 (office FAX)
(b)(6)
https :f/science.nicb d.nih .gov/confluence /disp lay/sq its/Home
*****************************
**************
********************
*******
This email and any files transmitted with it are confident ial and intended sole ly for the use of the individual or
entity to whom they are addressed . If you have received this email in error please notify me a11dthe system
manager immedi ate ly.
NIH-000979
From: (b)(6)
Sent: Wed, 4 Mar 2020 18:25:52 -0500
To: Marc Reinoso
Subject : Re: Coronavirus Covid 19 and smoking
Smoking is terr ible under any circumstance
> On Mar 4, 2020, at 6:04 PM, Marc Reinoso wrote:

> -------- (b) (6) >
> Hello Dr. Fauci ,

> 1u my review of data it appears there is a negative associat ion with smoki ng . Shou Id smoking cessat ion be
menti oned during public announcement s to help discourage smoking ?
>
> Thank you,
>
> Marc Reinoso MD
NIH-000980
From: Conrad, Patricia (NIH/NIAID) [El on behalf of Fauci, Anthony (NIH/NIAIO) [El
Sent: Wed, 4 Mar 2020 21:27:42 +0000
To: NIAIDODAM
Subject: FW: Meeting to AssessEvaluation of COVID-19vaccine candidates for risk of
enhanced disease
Attachments: March 12th-Tentative list of questions to be discussed_JPCmg-sb[16212l-
version4March-1239-CLEAN.docx,Draft agenda.AceAssessED.4Mar20201l_w ith annexes.pdf
Patricia L. Conrad
Nat ional Inst itute of Allergy and Infectious Diseases
The National Institutes of Health
(b)(6)
301-496-4409 fax
Disclaimer :
from your mailbox or any other storage devices. National Institute of Allergy ancl Infectious Diseases (NIAID ) shall not accept
liabil ity for any statement macle that are sencler"s own ancl not expressly macle on behalf of the NIAID by one of its representatives.
From:Steve Black (b)(6)

---------
To: Fauci, Anthony (NIH/NIAID) [E] ------~~
Cc: Robert Chen <robert.chen@cepi.net>
--------
(b)(6)>
Subject: Meeting to AssessEvaluation of COVI0-19 vaccine candidates for risk of enhanced disease
Dear Doctor Fauci,
I am writing to you as a member of the SPEACproject which CEPI has funded to assist with the
evaluation of the safety of vaccines in their portfolio. As part of this effort, we are assisting
with developing preclinical and clinical test ing criteria to evaluate the risk of enhanced disease
fol lowing vaccination with COVID-19 vaccine cand idat es. As you know, this had been an issue
with some prior SARSvaccine candidates.
We are convening a two day virtual meeting of experts via video conference next week on
March 12 and 13 between 8 am and 1 pm Eastern tim e each day. Participants in the meet ing
are shown in the attached agenda but include Paul Henri Lambert from Geneva and Barney
Graham from NIH. The meeting will actively invo lve the partic ipants on the agenda the first day
NIH-000981
and on the second day the meeting will be open for several peer reviewers including Stanley
Plotkin and Andy Pollard to review and comment on possible small and NHP animal models as
well as appropriate immunologic testing to be done in early phase one trials.
I am wanted to make you aware of the meeting so that you could attend all or part as an
observer if you wish but also to invit e you to consider joining on day two as one of our formal
peer reviewers. The goal of the meeting would be to share recommendations with CEPI
COVID-19 developers as well as other interested parties.
Any comments you have on the agenda or draft questions for consideration would be greatly
appreciated.
I look forward to hear ing back from you.
ATTACHMENTS: DRAFTAGENDA; DRAFTQUESTIONSFORCONSIDERATION
Steve
Steven Black MD
SPEACProject work package lead for CEPI
NIH-000982
From: Conrad, Patricia (NIH/NIAID) [E)on behalf of Fauci,Anthony (NIH/NIAID) [E)
Sent : Wed, 4 Mar 2020 21:16:44 +0000
To : NIAIDODAM
Subject : FW: TIME 100 Summit
Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
The Nationa l Institutes of Health
31 Center Drive, MSC 2520- Room 7A03
Bethesda, Mary land 20892
(b)(6)
301-496-4409 fax
Disclaime r:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information . It should not be used
from your mailbox or any other storage devices . National Institute of Allergy and Infectious Diseases (NIAID ) shall not accept
liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.
From: Alice Park <alice.park@time.com>

Sent : Monday, March 2, 2020 6:19 PM
To: Faud, Anthony (NIH/NIAID) [E]______ Cb
_H_6)
Subject : TIME 100 Summit
Hi Dr. Fauci -- as we discussed, sending along an invitation for you to partic ipate in our TIME
100 Summit, which will be held in New York on April 21-22 . We would welcome your insights on
a panel addressing COVID-19, like ly moderated by me.
I certa inly hope you wi ll be able to join us; please let me know eithe r way. Looking forward to
hear ing from you. Best, Alice
PLEASENOTE NEW PHONE NUMBER

Alice Park
TI ME
(b)(6)
alice.park@time.com
@aliceparkny
NIH-000983
From: (b)(6)
Sent : Wed, 4 Mar 2020 09:46:55 -0500
To : M ichael Gerson
Subject : Re: Coronavirus Live Updates: Fatality Rate of Covid-19 Is Higher Than the Flu -
The New York Times
Talk later. Am in Hearing
>
>
On Mar 4, 2020, at 8: LOAM, Michael Gerson
> Can this be true?

---------- (b) (6) > wrote:
> https://www.nytimes.com/2020/03/04/worlcVcoronavirus
-news.html
NIH-000984
Sent: Wed, 4 Mar 2020 11:21:47 +0000
To : Emanuel, Ezekiel J
Subject: RE: RE:
No evidence in this regard, but you would assume that their would be substantial immunity
post infection. It is an RNA virus and so you can expect mutations, but not sure how much is
going on. Will have to check.
From: Emanuel, Ezekiel J (b)(6)

Sent: Wednesday, March 4, 2020 5:58 AM
------
To: Fauci, Anthony (NIH/NIAID) (E] -:-::~
(b)(6)
Subject: Re: RE:
Sorry the phone. Is a person likely to be immune once they caught the corocnav irus once? Do
we know anything about likely drift?
Ezek iel J. Emanuel, M.D. , Ph.D.
Vice Provost of Global Initiatives
Chair, Department of Medical Ethics and Health Policy (on Leave 2019-2020)
Levy University Professor
Co-Director , Healthcare Transformation Institute
Perelman School of Medicine and The Wha1ton School
University of Pennsylvania
Phone: (b)(6)
From : Fauci, Anthony (NIH/NIAID) [E]

--------
Sent : Tuesday, March 3, 2020 10:57 PM
(b)(6)>
NIH-000985
To: Emanuel, Ezekiel J
Subject : RE: --------- (b)(6)
Thanks for the note. I do not understand your question , See spelling below
-----Original Message-----
-------~~
From: Emanuel, Ezekiel J
---------
Sent: Tuesday, March 3, 2020 9:59 AM
To: Fauci, Anthony (NIH/N IAID) [E] -------=-
(b)(6)
(be-
)( = >
Subject:
Tony
Hope they are greatng you better about media appearances after my call with trump.
You were great at then press conference yesterday
Question:. Lilelynimmunitynince a person has the Coronavirus infection?.

Ari is pestering me
Ezekiel J. Emanuel, M.D. Ph.D.
(b)(6)
NIH-000986
From: (b)(6)
Sent: Wed, 4 Mar 2020 06:19:58 -0500
To: NIAID Public Inquiries
Subject: Fwd:
------------- (b)(6)
Sent from my iPhone
Begin forwarded message:
From: Patti Taylor (b) C

Date: March 4, 2020 at 12:30 :52 AM EST
To: "Fauci , Anthony (NIH/NlAID ) [E]"
-------~~ (b)(6 J:-
Subject: (b) (6)
Dr Fauci
My name is Patt i Tay lor and I' m a nurse. Been one for 30 years . (b)(6)
. Sounds too simple. Anyway I was

thinking of the Coronavirus and maybe it has some thing like an autoinunune part to
it that makes a person unable to fight back. ....
Just a thought. I think a lot.
Sent from my iPhone
NIH-000987
From: (b)(6)
Sent : Wed, 4 Mar 2020 06:19:08 -0500
To: Cassetti, Cristina (NIH/NIA ID) [E]
Subject:
Attachments :
Fwd:
------------------------
___
PastedGraphic-1.tiff, ATT0000l.htm, _.
(b)(4)Executive Summary.pdf,
(b)(4)
ATT00002.htm
Pls respond
Sent from my iPhone
Begin forwarded m essage:
From: "Gupta, Sanchay" (b)(6)

-------------
Date: March 4, 2020 at l :40:30 AM EST
To: "Fauci , Anthony (NIH/NIAID) [E]" -------= = (bH6J
Cc: Shaheer Piracha
---
Subject: Meeting Request -
(b)(6)
(b) (4)
Hi Dr. Fauci,
(b) (4)
I1iaiiKyou m advance for your lllle.

Very Best,
Sanch ay Gupta
(b) (4)
NIH-000988
Ce ll (b)( 6J
NIH-000989
From: (b)(6)
Sent: Wed, 4 Mar 2020 06:17:35 -0500
To: Conrad, Patricia (NIH/NIAID) [E)
Subject: Fwd: Pressinquiry_Russia
Sent from my iPhone
Beg in forwarded messag e:
From: Banepm1 Ilonoaa (b) (6)

---------------
Date: March 4, 2020 at 5: 13:38 AM EST
,------- --;;-~
To: "Fauci, Anthony (NIH/NlAID) (E]"
Subject: Press inquiry_Russia -------- (b)(
Dear Dr Anthony S Fauci ,
My name is Vale ria Popova , I am the senior editor of Channe l One (Russia). We
would like to invite you to take part in the popular international Russian-American
projec t on Channe l One. The big game is a televis ion program, within the
framewo rk of which two p oints of view on international eve nts are presented :
American and Russian.
One of the presenters of the program is Dmitry Simes, chairman of the Nixon
Center, a US citizen. He was foreign policy adviser to former US President Richard
N ixon .
Only high-ranking officia ls part icipate in this discussion : presidents, diplomat s,
heads of ministries.
This is an honest and reasona ble discussion. It would be a great honor for us if you
j oined her and discass w ith our experts about situation with coronavi rns. We work
live and can use teleconference or skype for comm unication .
Hope to cooperate!
Channel One is the broadcasting leader in the Russian Federation. 250 million
viewers in Russia and abroad. Today, Channel One programs have the opportunity
to watc h 98.8% of Russians and more than 250 million people in the world.
Channel One is the recognized leader of the Russian telev ision, the most popular and
favorite Russian-language channel in the world. It started broadcasting in April 1995
NIH-000990
and became the successo r to the state television and radio company Ostankino ,
which was the main broadcaster in the USSR and covered 99.8% of the population
of Russia. Channel One' s daily programs: the best entertainment shows, unique
docum entaries , latest news and analytics , the most headline movies and TV
premieres , exclusive sports broadcasts and popular Russian music. Channe l One
combines innovative television broadcasting concepts, the vastest national traditions
and cutting-ed ge global trends in a unique format.
Hope to cooperate!
Sincerely ,
Val eria Po~
r (b) (6)
NIH-00099 1
Sent : Wed, 4 Mar 2020 03:09:35 +0000
Cc: Routh, Jennifer {NIH/NIAID) [El ;Folkers, Greg (NIH/NIAID) [E]
Subject: RE:CNN Global Coronavirus Town Hall/ Thursday/ Dr. Fauci
Let us discuss the feasibi lity, desirability and potentia l for clearance or not.
From: Conrad, Patricia (NIH/NIAID) [E]

Se nt: Tuesday, March 3, 2020 8:06 PM
To: Fauci, Anthony (NIH/ NIAID) [El
---------
------~~ (b)(6)>
(b)(6)]
Cc: Routh, Jennifer {NIH/NIAID) [El======= (b

~~~(6)
= >; Folkers, Greg {NIH/NIA ID) [El
(b)(6)>
Subject : FW: CNN Global Coronavirus Town Hall/ Thursday/ Dr. Fauci
Is this what you are talking about? Seriously recommend from wdc but again -
this is really late - 10 pm to midnight .
From : Johnson, Christie <Christ ie.Johnson@turne r.co m>

-------~~
To: Conrad, Patricia {NIH/NIA ID) [E) (b)(6)
Subject : Re: CNN Global Coronavirus Town Hall/ Thursday/ Dr. Fauci
Just making sure you received
Christie Johnson
CNN Worldwide
Senior Editoria l Producer
C: CbH6)
Christie.Johnson@tumer.com
www.cnn.com
From : Johnson, Christie

Se nt: Tuesday, March 3, 2020 11:16:51 AM
-------~~
To: Conrad, Patricia {NIH/NIA ID) [E) (b)(6)
Subject : CNN Global Coronavirus Town Hall/ Thursday/ Dr. Fauci
As promised, here is the big ticket item I wanted to flag for you . I was wait ing to get through
yesterday's hits to loop you in as to not overwhelm you. I have been speak ing with the WH and
VP's office to see if Dr. Fauci is availab le to join CNN this Thursday for our global town hall but
wanted to make sure you have the info. Would you mind checking to see if he's avail?
Info :
NIH-000992
We are reaching out to invite Dr. Fauci to join Anderson Coope r and Dr. Sanjay Gupta as our
featured guest on th e upcom ing CNN specia l town hall - Coronavirus: Facts and Fears .
TH E LA TEST :
This Global Town Hall program will broadcast in front of a live audience from IOprn-
Midn ight EST on Th urs day March 5 from th e CNN studios in New York City. We would cove r
all expenses for someone from the task force to join us live in NY. If Dr. Fauci is unable to come
to NY, we will take him remote ly from DC.
Coronavirus: Facts and Fea rs will fea ture interviews wi th a wide range of front-line experts
fighting to contain coronavirus , along with patien ts and others who have been directly impacted
by it 's spread. We 're rea lly hoping to includ e a voice from the administration in order to comfo rt
and inform our worldwide audience.
Tho ughts?
Thank you!
Christie John son

CNN Worldwide
Sen ior Editorial Producer
C: CbH6J
Chris tie.John son@tumer.com
www .cnn.com
NIH-000993
Sent: Wed, 4 Mar 2020 03:08:49 +0000
Subject: RE:CNN Global Coronavirus Town Hall/ Thursday/ Dr. Fauci
No. This is not what I was talking about. I received a text from Governor Cuomo of NY State
and he wants me to come up to NYCfor a Press Conference with his Heal th Commissioner,
Howard Zuycker.
From: Conrad, Patricia (NIH/NIAID) [E] (b)(6)

Sent: Tuesday, March 3, 2020 8:06 PM
To: Fauci, Anthony (NIH/NIAID) (E) ------ ==
(b)(6)>
Cc: Routh, Jennifer (NIH/NIAID) (E)=======~ (b~) =
~; Folkers, Greg (NIH/N IAID) [E)
(b)(6)>
Subject: FW: CNN Global Coronavirus Town Hall/ Thursday/ Dr. Fauci
Is this what you are talking about? Seriously recommend from wdc but again -
this is really late - 10 pm to midnight .
From: Johnson, Christie <Christie.Johnson@t urner .com >

To: Conrad, Patricia (NIH/NIA ID) [EJ --------,;- (b""
H=6>
Subject: Re: CNN Global Coronavirus Town Hall/ Thursday/ Dr. Fauci
Just making sure you received
Christie John son

CNN Worldwide
Senior Editorial Producer
C: (bH6>
Christie .Johnso n@tumer.c om
www.cm 1.com
From: Johnson, Christie

Sent : Tuesday, March 3, 2020 11:16:51 AM
To: Conrad, Patricia (NIH/NIA ID) [EJ------~ (b)
,....,
(=
6>>
Subject : CNN Global Coronavirus Town Hall/ Thursday/ Or. Fauci
As promised, here is the big ticket item I wanted to flag for you . [ was waiting to get through
yesterday 's hits to loop you in as to not overwhelm you. I have been speaking with the WH and
VP's office to see if Dr. Fauci is available to join CNN this Thursday for our global town hall but
wanted to make sure you have the info. Would you mind checking to see if he ' s avail?
Info:
NIH-000994
We are reac hing out to invite Dr. Fauc i to join Anderson Coope r and Dr . Sanjay Gupta as our
featu red guest on the upcoming CNN spec ial town hall - Coronavirus : Facts and Fears.
THE LATEST:
Th is Global Town Hall program will broadcast in front of a live audience from l Opm-
M idnig ht EST on T hursday March 5 from th e CNN studios in New York City. We would cover
all expenses for someone from the task force to j oin us live in NY. If Dr. Fa uci is unable to come
to NY, we will take him remotely from DC.
Coronavirus: Facts and Fears will feature interviewswith a wide range of front-line experts
fighting to contain corona virus, along with patients and others who have been djrectly impacte d
by it 's spread. We're rea lly hoping to include a vo ice from the administra tion in order to comfort
and inform our worldwide audience.
Thoughts ?
Thank you!
Christie John son

CNN Worldwide
Senior Editori al Produc er
C (b)C6)
Christie.Johnson@turner.com
www .cnn .com
NIH-000995
Sent : Wed, 4 Mar 2020 02 :55:36 +0000
To : Cassetti, Cristina (NIH/NIAID) [E]
Subject : FW: Covid-19 Vaccine
Attachment s: Press Release Preview - EIN Presswire - Press Release Distribution Service.pdf
Please t ake a look at this and act accordingly
From : KUMAR SHAH, MD (b)(6)>

Sent : Tuesday, March 3, 2020 9 :48 PM
To: Fauci, Anthony (NIH/NIAID) [E)______ """
(b""""
)(=6)
Subject : Re: Covid-19 Vaccine
To
Dr Anthony Fauci,
Director
NIAID/NIH
(b)(6)
Dear Sir,
Humbly, Endocrine Technology, LLCis pleased to forward the enclosed press release for your comments
and advice.
Best,
Kuma r Shah, M .D.

Diplomate American Board of Internal Medicine
Endocrinology, Diabetes & Metabolism
326 Livingston St, Suite A
Brooklyn, N. Y 11217
Office: 718-222-1065; c: (b)(6):
Fx:718-222-1350
www .etdiabetes .com
NIH-000996
Sent : Wed, 4 Mar 2020 02:27:43 +0000
To : Siegel, Marc
Subject : RE: Dr. Marc Siegel: Coronavirus public health response has been handled well;
we have right leaders at helm I Fox News
Thanks, Marc
-----OriginalMessage-----
From: Siegel, Marc <Marc.Siegel@nyulangone.org>
To: Fauci, Anthony (NTH/NlAID) [E] ------. ~=
(b)(6) >
Subject: Dr. Marc Siegel: Coronavirus public health response hasbeen handled well; we have right leaders at helm I
Fox News
https ://www.fox.news .com/op inion/ dr-marc-s i egel -corouaviru s-p ublic-hea Ith-respo nse- bas-b een-ha ndl ed-we! 1-we-
ha ve-right-leade rs-a t-helm
Sent from my iPhone
NIH-000997
From : Fauci, Anthony (NIH/NIAIO) [E)
Sent : Tue, 3 Mar 2020 22:52:20 +0000
Subj ect : FW: COVID-19 Webinar
Director
31 Center Drive , MSC 2520
Phone (b) (6)
FAX: (301 496-4409
E-mail Cb)(6)
information . It should not be used by anyone who is not the original intended recipient . If you
From: Donna Prosser <donna .prosser@patientsafetymovement .org>

To: Fauci, Anthony (NIH/NIAID) [E)
-------~~ Cb)( ; Mike Ramsay
<michael.ramsay@bswhealth .org>; David 8. Mayer <david .mayer@patientsafetymovemen t .org>
Subject : COVID-19 Web inar
Hello, Dr. Fauci,
My name is Donna Prosser, and I am the Chief Clinical Officer at the Patient Safety Movement
Foundation. We are planning to host a webinar on Friday, March 6 at 8:00am PSTto update our network
on the coronavirus outbreak . Our network consists of 4,710 healthcare organizations across 46
countries, as well as patients, families, individual clinicians, and technology companies across the globe,
who partner with us to achieve our goal of eliminating deaths from medica l erro r.
During Friday's webinar, we plan to focus on how to keep patients safe from harm during this outbrea k,
and would love to have someone with your expertise join the call for a brief comment. Would you by
any chance be available and will ing to speak with our network sometime between 8-9am PST?We
would be grat eful for any amount of time that you could spare during that hour.
Thank you for your consideration!
Donna
NIH-000998
Donna M. Prosser, DNP, RN, NE-BC , FACHE, BCPA
Chief Clinical Officer
Patient Safety Movement Foundation
p: 949.297. 7066 m: (b)(6)
a: 15776 Laguna Canyon Road, Irvine, CA 92618
w: patientsafet y movement. or g e: donna. prosser @patientsafet y movement.or g
NIH-000999
Sent : Tue, 3 Mar 2020 22:51:35 +0000
To : Bob lsman
Subject : RE: How to put COVID-19 statistics in perspective
Thank yo u fo r yo ur not e.
AS Fauci
Anthony S. Fauci, MD
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
accept liability for any statements made that are the sender 's own and not expressly made on
From: Bob lsman CbH6>t>

Se nt : Tuesday, March 3, 2020 5 :12 PM
To : Fauci,
___ _;_Anthony (NIH/NIAID)
__ _,:_,;___:.. [E] ---------=-c-=
__ .:,_,:_...:..!:::=~~-:--~--- (b)(6) Redfield, Robert R. (CDC/OD)
briefing@nytimes .com
---------------- (b) (6);
Subject : How to put COVID-19 stat istics in perspective
Today (March 3), CNN featured a discussion with NY Gov. Cuomo regard ing a new COVID-19 case in NY
City. He happened to note that there are currently about 15,000 patients in NY hospitals with the flu.
Although multiple government agencies, scientists and health experts keep remind ing us that there are
far more cases, hospitalizations and deat hs each year from influenza tha n t his coronavirus, it strikes me
that a more effective, more visual and less fear-producing way of presenting t his information would be
to present the current number of cases, hospitalizations and deaths from EACHof these diseases side by
side. If the number of flu cases, hospitalizations and/or deaths isn't available on a daily basis, we could
use extrapolations based on known rates. I think this would certain ly go a long way to putting the
relative risks of t hese diseases in clearer focus.
Bob lsman, DDS, MPH
NIH-001000
Sent : Tue, 3 Mar 2020 22:50:50 +0000
To : Jlevyusa
Subject : RE: Idea to help with Coronavirus infection
Thank yo u fo r yo ur not e.
AS Fauci
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not
From: Jlevyusa (b)(6)>

-------=c-c=
--------
Subject : Idea to help with Coronavirus infection
(b)(6)>
Dr. Fauci,
I first want to thank you for your service and efforts in combating this international health problem.
I'm neither a physician or a scientist so please accept my apology if my idea is simplistic or isn't feasible.
But I was thinking about some of the information presented on why it seems to be less prevalent in
children. One theory is that they are exposed to so many other coronavirus's that they experience cross-
protection . So I was wondering if anyone had investigated the idea to flood adults with other, less lethal,
coronavirus's as a way to develop some level of immunity? Ideally coronavirus's that are a mat ch to
what child ren wou ld be exposed to is what I'm suggesting here. I wou ldn't expect that this wi ll totally
protect an adult but it might reduce t he severity of the illness if an adult becomes ill and help while a
vaccine and treatments are launched.
Thank you for considering this idea.
Best,
Jeff
NIH-00100 1
Jeffrey Levy
NIH-001002
Sent : Tue, 3 Mar 2020 22:50:07 +0000
Subject : FW: my feeble attempt
Attachment s: COVID-19.docx
Director
Phone : (b) (6)
FAX : (301 496-4409
E-mai (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sen sitive
have received this e -mail in error please inform the sender and delete it from your mailbox or any
From: Tai Te Wu (b)(6)

To: Fauci, Anthony (NIH/NIAID) [E)-------~=
Subject : my feeble attemp t
--------- (b)(6)
Dear Dr. Fauci,
I have seen you on the television commenting about COVID-19.
Therefore, I have decided to squeeze some information out of their nucleotide and amino acid
sequences as enclosed. Hope that you may soon find a cure with all the available data on this
virus.
Best regards.
Tai Te Wu
NIH-001003
From: (b)(6)
Sent : Tue, 3 Mar 2020 13:36 :59 -0500
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject : Fw d: Informal coro navirus teleconference: agenda+ background documen ts
Attachment s: imageOOl.png , ATT00001.htm, 01 March_Chapeau_Crit ical preparedness
readiness and response actions for COVID 19_ DRAFT.pdf, ATT00002 .htm , 01 Ma rch_ COVID 2019
response scenarios _DRAFT.pdf, ATT00003.htm , 01 March _Preparing for Widespread Commu nity
Transmission _ DRAFT.pdf, ATT00004.htm, 18624 Swisscom Call code.docx, ATTOOOOS.htm
For the7 am folder pls
Sent from my iPh one
From: "KABIR, Sophia" (bH6>l

Dat e: March 3, 2020 at 1:35:53 PM EST
To: SHOC <shoc@who.int>, Office of the Director-General <DGOffice@who.int>,
"Redfield, Robert R. (CDC/OD)" (b)(6)
(b)(6) "Felicity Harvey

(b)(6) "Chris.Elias"
(b)(6)
, Jeremy Farrar (b)( >

(b)(6) '
"GREIN, Thomas" (bH , "COX, Paul Michael" .------- '

"SCHWARTLANDER, Bernhard F." (b)(6) , "MINHAS,
Rama n" (b)(6)
R. Frieden"
-=============-::c:;------------
Ly nn Banks (b)(6) , President I Resolve to Save Lives
'---:-----:-:---~-====£:....--~
<president@resolvetosavelives.org>,
~
(b) (6)
, Roby nn Leidig
(bH6), "Dr VAN KERK.HOVE, Maria"
-------
NIH-001004
(b)(6)
"GRAAFF, Peter Jan"

Cb)
(6), "POOLE, Marcia" (b)(6).
, Tarik Mohammed
(b)(6)
"(SPmig) Carlos Navarro Colorado" (b)(6)
Ryan Morhard
Cb>C6l, "BRIAND, Sylvie" _______ Cb
_H_6)
"MORGAN, Oliver" CbH6)
"Harries, Jenny"
.-----
(b)(6)nAwwad , David (NIH/NIAID) [C]"
________ Cb
>_<6>
_ , , "SIMONSON, Stewart" CbH6),
"SINGER, Pet er Alexander" (b)(6) -...., "(SPmig) Carlos Navarro
Colorado" ______ (b)(6)
Cc: "RYAN, Michael J." ____ CbH,___"""""' = , Christine Youssef'
CbH6),
"BOKO, Ivana"
------- -------
Subject: Informal coronavirus teleconference: agenda+ background
documents
Dear colleagues,
On behalf of Mike Ryan, allow me to share with you the following background documents
ahead of the informal coronavirus te leconferenc e tomorrow at 13.00 CET:
(b) (4)
Please find below, the key questions for your consideration and input tomorrow. We do
not expect you all to address/speak on all the questions but just as a guide to your thinking
and the ones you have views/advice/ideas.
(b) (4)
NIH-001005
(b) (4)
The dial-in number and passcode are attached.
If you exper ience any technical difficulties joining this conference call, please contact the
WHO HQ EOC operator at: +41 227 912 4 90
Best,
Sophia
-----Ori ginal Appointment---- -

From: RYAN, Michael J.
Se nt: Tuesday, February 25, 2020 10:07 AM
To: RYAN, Michael J.; SHOC; Office of the Director -General;
Farrar;
GREIN,
Thomas; COX, Paul Michael; SCHWARTLANDER, Bernhard F.; M INHAS, Raman;
----------------- (b)(6) MAHJOUR, Jaouad; FALL, lbrahima Soce;

Thom as R. Frieden; Elhadj SY; Lynn Banks; President I Resolve to Save Lives;
(b)(6) AL-SHORBAJI,Farah;
========~~-:-~--:--:""'.":"'"---:--:--:~
(b)(6); Robynn Leidig; DRURY, Patrick Anthony; Dr VAN KERKHOVE,
(b)(6)
Cheryl Cohen; GRAAFF, Peter Jan; POOLE, Marcia; Tarik Mohammed ;

__________________________ Cb
_>_
<6JRyan
Morhard; BRIAND, Sylvie; MORGAN, Oliver; Harries, Jenny; Awwad, David (NIH/NIAID) [C];
SIMONSON, Stewart
Cc: SINGER,Peter Alexander
Subje ct : Informal coronavirus teleconference
When: Wednesday, February 26, 2020 1:00 PM-2:00 PM (UTC+0l:00) Amsterdam , Berlin,
Bern, Rome, Stockholm, Vienna.
Wh ere: Upper SHOC {For Call in: please see dial in details attached)
Dear colleagues,
Dr Tedros would like to invite you to the next informal discussion about the ongoing 2019
novel coronavirus.
NIH-001006
The te leconference will be hosted tomorrow Wednesday, 26 February at 13:00 CETand
the dial-in number with a passcode is attached .
If you experience any technical difficulties joining this conference call, please contact the
WHO HQ EOCoperator at; +41227912490
It wou ld be appreciated if you could kindly confirm your participation to Ms Sophia Kabir,
email: (b)(6) mobi le no. (bH
Best,
Mike
Sophia Kabir
Executive Officer
Office of the Executive Director
WHO Health Emergencies Programme (WHE)
Tel. (b) (6)
Mobile
------ (b)(6)
Website: WHO in eme rgencies I WHO Facebook I WHO Tw itte r
HEALTH
EMERGENCIES
prograi ne 11
NIH-001007
From: (b)(6)
Sent: Tue, 3 Mar 2020 12:42:58 -0500
To : Oplinger, Anne (NIH/NIAID) [E]
Subject: Fwd: Interview request from the Jesuits
From Patty on Fauci email. Not for several weeks
Sent from my iPhone
Begin forwarded mes sage:
From: Mike Jordan Laskey <JCUcommunica tions@jesuits .org>

Date: March 3, 2020 at 12:32:38 PM EST
To: "Fauci , Anthony (NIH/NIAID) [E ] " -------~= CbH6>:
Subject: Interview request from the Jesuits
Dear Dr. Fauci,
I host the AMDG Jesuit Podcast , which reaches a faith-based audience connected to Jesuit
institutions around the country . I would love to welcome you onto the show to discuss the
coronavirus and how your Jesuit education has shaped your career. It would be great to
have 15-20 minutes of your time. Thanks very much for your consideration .
Best,
Mike
Mike Jordan Laskey

Senior Communications Manager
Jesuit Conference of Canada and the United States
1016 16th Street NW 3rd Floor
Washington , DC 20036
202.629.5933
jcucommunications@jesuits .org
NIH-001008
Sent : Tue, 3 Mar 2020 13:57:03 +0000
Subject : FW: Corona Virus and a possible path to a vaccine?
Attachments : Origi n of Co-Vid 19 and possible path to vaccination.pdf, PastedGrap hic-10.tiff
Pis res pond
Director
Phone : (b) (6)
FAX : (301 496-4409
E-mail : (b)(6)
From : expand@omcasa .com <expand@omcasa .com>

Sent : Tuesday, March 3, 2020 5:00 AM
To : Fauci, Anthony (NIH/NIAID) [E)
-------~~ (b)(6)>
Subject : Corona Virus and a possible path to a vaccine?
Importance: High
Dear Dr. Fauci -
Thank you for helping millions of peop le with your research over the years.
The following information was culled from http://poleshift.ning.oom.
Perhaps this article may help you and your colleagues develop a vaccine that may combat the Corona Virus.
You were the first one I thought of who may be able to deem its worth and explo re its research for practical
purposes.
Some of the links have included nih.gov so maybe your colleagues have already read this.
With my limited medical know ledge, I have taken the liberty to highlight key points that seem important.
Wishing you and yours all the best for remaining healthy in Mind, Body & Spirit.
Warm Regards & Appreciation,
NIH-001009
LizJan
LIZ JAN BAmst, CAPS

Vaastu Homes instill Harmony, Tranquility, Abundance & Love; featuring
Universal Design & Aging in Place for safety, comfort & accessibility.
Design & Consultations

540.300.0638
expa nd@OmCasa.com
www .OmCasa .com
NIH-001010
From: Fauci, Anthony {NIH/NIAID) [E]
Sent : Tue, 3 Mar 2020 13:55:34 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Covid-19 - Navigating the Uncharted
Director
Bethesda, MD 20892 -2520
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(
(b)( >
From : El Bcheraoui, Charbel
--------
Se nt: Tuesday, March 3, 2020 3 :26 AM
To: Fauci, Anthony (NIH/NIAID) [E]------ ...-
(b..-
)(=6)
Subjec t: Re: Covid-19 - Navigating the Uncharted
Dear Dr. Fauci,
Thank you for your useful edito rial published in NEJM last week, it helps confirming that the situation
does not need to be as glim as the panic that most people are experiencing.
I am writing an editorial and hoping to submit it to The Lancet soon. Differently from NIH/US
Government institutes, I have more room for reflection in my viewpoint.
For that reason, I was wondering if I can have a call with you to get your opinion/advice on the direction
of my editorial. I know how busy you are and I can understand if you do not have the time, but if by
chance you are willing to have this call, I'll be happy to share my editorial's draft first.
As a background, I am an EISgraduate {class of 2009), and trained by Robert T. Chen.
Thanks,
Charbel El Bcheraoui, PhD, MSc
Head of Evidence-Based Public Health,
Center for Internat ional Health Protection,
Robert Koch Institute,
Nordufer 20, 13353 Berlin,
Telephone: (b)(
(b)(6)
NIH-00 1011
Sent: Tue, 3 Mar 2020 13:54 :16 +0000
Subject : FW: Zinc gluconate by inhalation for early coronavirus in elderly?
Director
National Institu te of Allergy and Infectious Diseases
Building 31, Room 7 A-03
31 Center Driv e, MSC 2520
National Institu tes of Health
Bethesda , MD 20892 -2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail (b)(6)
The informa tion in this e-mail and any of its attachments is confidential and may contain sens itive infom1ation. It
should not be used by anyone who is not the original intended recip ient. lf you have received this e-mail in eITor
please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of
Allergy and Infectious Disease s (NIAID) shall not accept liability for any statements made that are the sender's own
and not express ly made on behalf of the NlAID by one of its representatives.
From: Arthur --=----- (b
~)- (=
Sent: Tuesday , March 3, 2020 I :48 AM
To: Fauci , Anthony (NlH/NlAID) [E] ------~~ (b)(6) >
Subject: Zinc gluconate by inhalation for early coronavirus in elderly?
Dr Fauci,
Since the elderly 's response to pulmonary coronavirus infection may be impaired, especially in those with a chronic
disord er, is ther e any information re: deliverin g by inhalati on, low concentrations of a Zinc salt. Tsthere a potential
rati onale in early coronavirus infection to try to minimize serious pneumonia , were such inhalation shown to be
reasonably safe?
Thank you,
Arthur Bobrove , MD
Stanford and Palo Alto VA
Sent from my iPhone
NIH-0010 12
Sent: Tue, 3 Mar 2020 13:53 :42 +0000
Subject : FW: Coronavirus: Six Eyed Sand Spider , Habanero, water , Qi
Director
Bui ldin g 31, Room 7 A-03
31 Cen ter Driv e, MSC 2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b)(6)
The informa tion in this e-ma il and any of its attachments is confidential and may contain sensitive infom1ation. It
should not be used by anyone who is not the original intended recipie nt. l f you have received this e-mail in eITor
please inform the sen der and delete it from your mai lbox or any other storage devices. The National Institute of
Allergy and Infe ctio us Diseases (NIAID) shall not accept liability for any statements made that are the send er's own
and not expressly made on behalf of the NlAID by one of its representatives.
..=---~~=
From : Lily Carnie (b) (
Sent: Tues day, March 3, 2020 12:07 AM
Subject: Coronavirus: Six Eyed Sand Spider , Habanero . water , Qi
Dr.Fauci ,
(b)(6)
---------- . I am an author on a Chinese form of healin g called Qigong (a field l have studied for
over 30 years) , and am exp loring Corona virus from the perspective of a combination of tbe venom of the
Vietname se Six Eyed Sand Spider (entering the cells externally), Habanero capsaicin enteri ng cells internally , the
eleva ted water levels of infants and children and their higher levels of Qi in relat ion to them not getting the diseas e,
and Qi from Tradit ional Chinese Medicine, Acupuncture, and Qigong.
l believe that the above combination can be beneficial in the study of Corona virus. lam sure you are extremely
busy and I am but a simpl e author but I just wanted to lry to touch bases in case the above might help.
l live in (b)(6)_
I would be truly honored to hear from you.
Lily of the Valley Carnie
NIH-0010 13
From: Fauci, Anthony (NIH/NIAIO) [El
Sent: Tue, 3 Mar 2020 13:52:17 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Possible treatment of COVID-19 pneumonia
Pis respond
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail (b) (6)
information . It should not be used by anyone who is not the origina l intended recipient . If you
other storage devi ces . The National Institute of Allergy and Infectious Diseases (NIAID) shall not
behalf of the NIAID by one of its represent atives .
From: Paul Tone, MD (b)(6)>

Sent: Monday, March 2, 2020 11:10 PM
To: Fauci, Anthony {NIH/NIAID) [El-------=-,-:-= (b)(6)
Subject : Possible treatment of COVID-19 pneumon ia
Dear Dr. Fauci,
Nitric Oxide (NO) has been shown to contribute to the pathogenesis of influenza virus-
induced pneumonia in mouse model (Zablockiene et al., 2012).
Zablockiene B, Ambrozaitis A, Kacergius T, Gravenstein S. Implication of nitric

oxide in the pathogenesis of influenza virus infection . Biologija 2012; 58(1): 15-25 .
NO overproduction in influenza virus pneumonia results from a sustained stimulation of

inducible Nitric Oxide Synthase (iNOS) (Akaike et al., 1996).
Akaike T, Nog uchi Y, ljiri S, Seto guchi K, Suga M, Zheng YM, Dietzschold 8,
Maeda H. Pathogenesis of influenza virus-induced pneumonia: involvement of
both nitric oxide and oxygen radicals. Proc Natl Acad Sci US A. 1996 Mar 19;
93(6) :2448-53.
NO overproduction in influenza virus-induced pneumonia can generate highly reactive

oxygen species, peroxynitrite, via radical coupling reaction of NO with superoxide
NIH-00 1014
[resulting from influenza virus-induced increased levels of xanthine oxidase (XO)
(Maeda and Akaike, 1998).
Maeda H, Akaike T. Nitric oxide and oxygen radicals in infection, inflammation,

and cancer. Biochemistr y (Mose ). 1998 Jul; 63(7):854-65
Peroxynitrite causes oxidative tissue injury through potent oxidation and nitration
reactions of various biomolecules (Akaike and Maeda , 2000) .
Akaike T, Maeda H. Nitric oxide and virus infection. Immunolo gy. 2000 Nov;
101 (3):300-8 .
The crucial role of NO in influenza virus-induced

pneumonia was demonstrated on iNOS gene knockout
mice: at inocula sufficient to cause consolidating
pneumonia and death in the wild-type control mice, iNOS
gene deficient mice survived with little histopathologic
evidence of pneumonia (Karupiah et al., 1998).
Karu piah G, Chen JH, Mahalin gam 5, Nathan CF, MacMickin g JD. Rapid interferon
gamma-dependent clearance of influenza A virus and protection from
consolidating pneumonitis in nitric oxide synthase 2-deficient mice. J Exp Med.
1998 Oct 19; 188(8):1541-6 .
Both influenza and coronaviruses could have the same pathogenetic mechanism
of inducing pneumonia, namely harmful overproduction NO.
I would like to present you my innovative idea: Suppressing NO overproduction in

COVID-19 complicated to pneumonia with Methylene Blue (MB)
Arguments pro:
MB is known as a guanylate/guanylyl cyclase inhibitor but it is mainly a NOS inhibitor

(nNOS and iNOS) .
MB is an inhibitor of superoxide generation by xanthine oxidase and NADH/NADPH

oxidases.
MB is a small molecule capable to penetrate in tissues and cells
MB was administered intravenously in patients with refractory septic shock and

Hepatopulmonary Syndrome of advanced liver cirrhosis .
MB administered intravenously will definitively reach the cells where NOS is induced by
COVID-19 complicated by pneumonia both in animals and humans:
NIH-001015
-Airway epithelium (includ ing alveolar epithe lial cells);
-Alveolar macrophages ;
-Capillary/vascular endothel ium (endothelial cells).
MB is an inexpensive medication .
MB is non-toxic molecu le in humans
There are only a few cases of MB toxicity published in the literature. These cases
occurred in very peculiar situations:
Hemolytic anemia in patients with G6-PD deficiency
Severe neuropathology after intrathecal administration of MB
Eye injury after topical use of MB
Tissue necrosis due to the extravasation of injected MB
Jejunal atresia following intra-amniotic MB
Serotonin reuptake inhibit ors (SRl's) interact with MB, causing a serious adver se
reaction consistent with serotonin syndrome .
Very truly yours,
Paul Tone , MD, PhD
Internal Medicine and Gastroenterology

(b)(6)
NIH-001016
Sent : Tue, 3 Mar 2020 13:51:29 +0000
Subject : FW: Dr. Fauci. I have a possible reason children are immune to the coronavirus.
Please read
Pis res pond
Director
Phone : (b) (6)
FAX : (301 496-4409
E-mail : (b)(6)
From: Rob Klein (b)(6)>

Se nt: Monday, March 2, 2020 10:25 PM
To: Fauci, Anthony (NIH/NIAID) [E) ------~~ (b)(6)>
Subject : Dr. Fauci. I have a possible reason childre n are immune to the coronavirus. Please read
Hello Dr. Fauci. I am a (b) (6) phar macist from Ontario, Canada. I was just reading an article that stated
covid-19 cases in children under nine y.o . are almost non-existant . I wondered why , and then an answer
dawned o n me . They have an immunity because one of the childhood vaccines all children get is giving
them cross immunity to coronavirus as well. A study should be done immediately t o see which one gives
cross immuni ty, if indeed tha t is the reason for their seeming immuni ty to this virus. The immunity must
wear off over time which is why adults and seniors seem to lack prior immunity and get sick. This
hypothesis is certa inly worth investigating . If this is what is happening, maybe millions of lives could be
saved by a simple booster of an existing vaccine. Please let me know your t houghts on this matt er.
Thanks for your time . Rob
Sent from Ma il for Windows 10
NIH-00 1017
Sent : Tue, 3 Mar 2020 13:21:11 +0000
Subj ect : FW: Sky News
We shou ld discuss
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Szweda, Jakub (Interviews producer) <jakub.szweda2@sky.uk>

Sent : Tuesday, March 3, 2020 6 :16 AM
To : Fauci, Anthony (NIH/NIAID) [El -------::-:-,=
(b)((;)>
Subj ect : Sky News
Import ance: High
Hello Dr Fauci,
Hope you're well. I'm a producer for Sky News, looking after our flagship evening programme Sky News
Tonight 7-lOpm UK time (2-Spm ET).
I was wondering if you might be available for an interview on the coronavirus outbreak? Either today or
another day this week.
Happy to exp lain in more detail.
Any questions, please let me know .
Best,
Jakub
Jakub Szweda
NIH-0010 18
Inten,iews Producer I Sky News
Phone : +44 (0)2070320436 I Mobile : (b)(6)

Address: 2nd Floor, 4 Millbank , Westminster, SWIP 3JA
Watched by 169m people in 138 countries
Information in this email including any attachments may be privileged, confidential and is intended
exclusively for the addressee. The views expressed may not be official policy, but the personal views of
the originator. If you have received it in error, please notify the sender by return e-mail and delete it
from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to
anyone. Please note we reserve the right to monitor all e-mail communicat ion through our internal and
externa l networks . SKYand the SKYmarks are trademarks of Sky Limited and Sky International AG and
are used under licence.
Sky UK Limited (Registration No. 2906991), Sky-In-Home Service Limited (Registration No. 2067075), Sky
Subscribers Services Limited (Registration No. 2340150) and Sky CP Limited (Registration No. 9513259)
are direct or indirect subsidiaries of Sky Limited (Registration No. 2247735). All of the compan ies
mentioned in this paragraph are incorporated in England and Wales and share the same registered
office at Grant Way, lsleworth, Middlesex TW7 SQD
NIH-001019
Sent : Tue, 3 Mar 2020 13:10:22 +0000
To: George GAO
Cc: Mascola, John (NIH/VRC) [E);Conrad, Patricia (NIH/NIAID) [E);Gr aham, Barney
(NIH/VRC) [ E);Conrad, Patricia (NIH/NIAID) [E)
Subject: FW: Vaccine - confidential PPT
Attachments : 2020 0303 For Gao laoshi.p ptx
George:
Thanks for the note. I will send this to Dr. John M ascola Director of the NIAID
Vaccine Research Center and Dr. Barney Graham to fo llow-u p with you.
Best regard s,
Tony
Director
Building 31 , Room 7A-03
Phone Cb)(6)
FAX : (301) 496-4409
E-mail: (b)(6)
From: George GAO Cb)(6)
______
Sent : Tuesday, March 3, 2020 7 :12 AM
------~~
To: Fauci, Anthony (NIH/NIAID) [E),_ _ (b)(6)
Subject: Vaccine - confidential PPT
DearTony
Hope this email finds you wel l and the US will soon get the COVID-19 down.
(b) (4)
NIH-001020
All the best
George
~ 13ft~ iPhone
NIH-001021
Sent: Tue, 3 Mar 2020 10:57:14 +0000
To : Mascola, John (NIH/VRC)[E)
Cc: Conrad, Patricia (NIH/NIAID) [E);Graham, Barney (NIH/VRC)[E)
Subject: Important - POYUSand VP visit slides
Attachments: VIP visit to VRCCoronavirus Short version - for 3-3-2020.pptx
John :
Yesterday when I spoke to your IT/audio visual guy I to ld him to pull out the single slide with
the comparative time lines for various vaccines over the years and show it on the screen. I
then asked him to have the full set of slides ready for me to show . I have now abridged that
"fu ll" set so that I can whip through them if it looks like the discuss slows down. I am attaching
th is abridged version here. Please ask him to subst itu te this shorter version for the full set
from yesterday. Call me if you have any questions.
Thanks ,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
have rece ived this e-mail in error please inform the sender and delete it from your mailbox or any
behalf of the NIA ID by one of its representatives .
NIH-00 1023
Sent : Tue, 3 Mar 2020 03:40:19 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject : RE: Can we get comment please?
I am not going to comment. (b)(S)
From: Billet, Courtney (NIH/NIAID) [E] (b)(6)>

--------
To: Fauci, Anthony (NIH/NIAID) [E]-------= (b")(=
'""6); Lane, Cliff (NIH/NIAID) [E]
(b) (6)'>
Cc: Routh, Jennifer (NIH/NIAID) [E] (b)(6)>; Folkers, Greg (NIH/NIA ID) [E]
-------- Conrad, Patricia (NIH/NIAID) [E]

(b)(6)>;
Subject : Re: Can we get comment please?
(b)(6)>
(b) (5)
From: "Burton, Tom" <t om .bur t on@wsj .com >

Date : Monday, March 2, 2020 at 3:09:17 PM
To: "Fauci, Anthony (NIH/N IAID) [El" --------=- c-="Lane, Cliff (NIH/NIAID) [E]"
(b)(6),
(b)( , " Billet, Courtney (NIH/NIAID) [El" (b)(6)
--------
Subject : Can we get comment please?
Folks, we're doing a story that focuses in part on the administration's conference call from last Thursday
noon about a decision to send out more CDC coronavirus assays despite the fact that they had become
contaminated and compromised. We understand that Dr. Fauci was one of four federal doctors (the
others being Drs. Hahn, Shuren and Shah) who strong ly recommended the assays not be sent out.
I want to give Dr. Fauci a chance, on or off the record, to comment on the story please.
Thank you,
Tom Burton
Thomas M. Burton, Staff Reporter

The Wall Street Journal
1025 Connecticut Ave. N.W., #800
Washington, D.C. 20036
W: 202 862-6611
Follow me @TomBurtonWSJ
NIH-001024
Sent : Tue, 3 Mar 2020 03:11:52 +0000
To: Eisinger, Robert (NIH/NIAID) [El
Subject : FW: Alert: Questions from Sen. Alexander for tomorrow's hearing
Bob:
Please do me a favor and provide answers to the questions below from Sen. Alexander
Thanks,
Tony
From: Haskins, Melinda {NIH/NIAID) [El

-------- (b)( >
To: Fauci, Anthony (NIH/NIAID) [El ------ ..-.-,=

CbH6J>
Cc: Crawford, Chase (NIH/NIAID) [El (b)( ; Selgrade, Sara (NIH/NIAID) [El
CbH >; Conrad, Patricia (NIH/NIA ID) [E] (b)(6) >; Marston, Hilary
(NIH/NIAID) [El (b)(6); Folkers, Greg (NIH/N IAID) [El (b)( >
Subj ect : Alert: Questions from Sen. Alexander for tomorrow's hear ing
Dr. Fauci,
We just received a number of questions from Senat e HELPthat Sen. Alexander plans to ask you at the
hearing. Chase will pull together the epi info . Let us know if you want to discuss these.
Melinda
Sent from my iPhone
From: "Hallett, Adrienne (NIH/OD) [El" (b)( >

To: "Haskins, Melinda {NIH/NIAID) [E]"
---------... ~
(bH >, "Selgrade, Sara
(NIH/NIAID) [E]" (b)(6)>, "LaMontagne, Karen (NIH/OD) [E)"
---------- (b)(6)>, "Berkson, Laura (NIH/OD) [E]"

Subject: Fwd: Questi ons from Sen. Alexander
(b)(6)
See an ticipated questions below.
From: "Coulter, Margaret (HELP Committee)"

(b)(6)
Date : March 2, 2020 at 7:29:15 PM EST

--------=-cc-c=
To: "Pence, Laura (HHS/ASL)"
-------- (b)(6), "Bradsher, Kris
NIH-001030
(HHS/ASL)" (b)(6)>, "Berkson, Laura (NIH/OD) [E]"
,;___:_ __:_..=:==~::::;;----::~-:-:---
(b)( 6) >, "Hallett, Adrienne (NIH/OD) [E]"
======== (b
~ )~(6)
~>
Cc: "Bell, Kathryn (HELPCommittee)"

" Pfaff, Melissa (HELPCommittee)" ,.:.....:========~:;;-~
CbH >, "Vogt,
_ _.:......========~"""'.".""'."""
(b)(6)
Andrew (HELPCommittee)" (b)(6)>, "Graham,

Grace (HELPCommittee)" (b)(6)>
Subject: Questions from Sen.Alexander
Hi Laura and team,
Thanks for all your work in advance of tomorrow's HELP hearing. Below are
specific questions that Sen. Alexander plans to ask Dr. Fauci and would
greatly appreciate concise answers to - he is happy to allow Dr. Fauci to
elaborate if there is additional time. Add itionally, he plans to ask Dr. Schuchat
a few ques tions abo ut CDC covering patient costs from quarantine .
Thank you very much and look forward to seeing you all or your colleagues
tomorrow.
Best,
HELP team
Questions for Dr. Fauci:
1. How many cases are there in the world? 1nthe U.S.?
2. How many deaths so far in the wo rld? In the U.S.?
3. How many countries have cases of the corona virus?
4 . How do you know if you have the coronav irus?
5. What are the symptoms?
6. How do you protect yourself?
7. Should we all be wearing masks?
8. If not, why should health care workers have to wear masks?
9. What are the most effect ive ways to protect your families?
10. If someone has coronavirus symptoms, what should they do?
NIH-001031
11. If a doctor has a patient with these symptoms, what should they
do?
12. Who is most at risk ?
13. What is the mortality rate?
14. Can you explain why there have been relatively few reports of
cases in children?
15. Th is is the peak of the flu season -

a. How many flu cases have we had this year so far?
b. How many deaths have we had this year from the flu?
c. How is the coronavirus different from the seasonal flu?
d. Is it possible that we could reduce the infectio ns or
deaths from the seasona l flu because you need to do the
same things to protect yourself for both types of viruses?
16. Can a person transmit the virus even if they are not showing
symptoms?
17. Are your agencies doing any research to determine when exactly
an individua l may transmit the virus to others?
QUESTION FOR DR. SCHUCHA T:
• If a patient is under a federal government-required quarantine ,

who pays the bills?
• Does their insurance pay first, and then does the CDC cover the
remaining bills as the payer of last resort?
• If CDC is the payer of last resort, does the agency pay the doctor
or the hospital directly - or is the patient obligated to send their
bills to the CDC?
• How and when is this infom1ation made available to the patients

under a federal government-required quarantine?
NIH-001032
From: (b)(6)
Sent: Mon, 2 Mar 2020 19:06:49 -0500
To: Johnson, Richard Allen,M .D.
Subject: Re:Telecast today
Thanks, D ick.
On Mar 2, 2020, at 6:57 PM , Johnson, Richard Allen,M.D.
------------- (b) (6)>wrote:
Tony,
You were the star of the broadcast today! Your in tell igence, confidence, warmth ,
and humor are what we all need with COVID-19. Please keep these coming. You
appear to have a great working relationsh ip with Dr. Burks.
Very best,
Dick
NIH-001033
Sent: Mon, 2 Mar 2020 17:56:05 +0000
To: M ichael Gerson
Subject: RE: Q
See my edits in red for accuracy
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
behalf of the NIAID by on e of its represent atives .
From: Michael Gerson

---------
Sent: Monday, March 2, 2020 11:41 AM
------=
(b)(6)>
Subject : Re: Q ------- =

To: Fauci, Anthony (NIH/NIAID) [El (b)(6J>
Th is is the descript ive portion of my column. I don't want to over or under-state:
America is entering a disturbing new stage in the coronavirus

outbreak. There has been community spread in at least one and likely two
locations in Washington State. And it appears the virus was being
transmitted for at least a few weeks before current cases were recognized.
So we can expect dozens or hundreds of cases in those locations unl ess
contact tracing is especially efficient.
That means the disease is loose and easily tran smitted.
The crucial issue now is the real mortality rate, which remains
uncertain. The stated mortality is 2 percent. American experts are hoping
the rate turns out to be considerably lower. But the math remains tro ubling
in any case. If only 5 percent of th e population eventually gets infected
(which is on the low side of some estimates) and the mortality rat e is 1
perc ent, th ere still would be a few hundred thou sand deaths.
NIH-001034
At this stage, the main tool that public health experts have is social
distancing - the attempt to keep as many people as possible in affected
areas out of sneezing distance from one another. This means measures such
as closing schools, cancelling events in theaters and stadiums and
encouraging employees to telework. States and localities ultimately make
such decisions rather than the federal government. But according to some
health experts I consulted, Washington State should be taking such
measures right now. The effectiveness of social distancing is limit ed when
action comes too late or ends too early.
The goal of such policies is to keep the Ro (reproduction ratio) as low
as possible. When people are in close proximity, a single infected person
can spread the disease to several others, boosting the Ro of the disease as
high as 2 to 3 and causing an exponential increase in cases. If the Ro is less
than one, the epidemic will gradually decline and stop on its own, with or
without a vaccine.
A vaccine, however, would be tremendously helpful. There are at least
ten vaccine development projects underway. But the one furthest along at
the National Institutes of Health (NIH) is still about six weeks away from
starting the process of a phase 1 trial in human volunteers that will
take 3 to 4 months to complete and to show that the vaccine safe
and produces specific antibodies. A phase 2 trial will follow and
will take at least 6 to 8 months to determine if the vaccine is
efficacious in people at risk for infection . Then production would
need to be scaled up by a willing pharmaceutical company to deal with a
global crisis. All this in total will take at least a year - assuming there are
no unpredicted scientific obstacles in th e way.
On Mar 2, 2020, at 7:54 AM, Fauci, Anthony (NIH/NIAID) [E] CbH>

wrote:
Mike:
Social distancing is not really geared to wait for a vaccine. The major point is to prevent
easy spread of infections in schools (closing them), crowded events such as theaters,
stadiums (cancel events), work places (do te lewor king where possible). States and
localities make these decisions, not the Federal government. The goal of social distancing
is to prevent a single person who is infected to readily spread to several others, which is
facilitated by close contact in crowds. Close proximity of people will keep the ROhigher
than 1 and even as high as 2 to 3. If we can get the ROto less than 1, the epidemic will
gradually decline and stop on its own without a vaccine.
(b)(6)
NIH-001035
Best regards,
Tony
Director
Bethesda, MD 20892-2520
Phone: (b)(6)
FAX:(301) 496-4409
E-mail, (b)(~
The information in this e-mail and any of its attachments is confidential and may contain
sensitive information. It should not be used by anyone who is not the original intended
recipient . If you have received this e-mail in error please inform the sender and delete it
from your mailbox or any othe r storage devices. The National Institute of Allergy and
Infectious Diseases (NIAID) shall not accept liability for any statements made that are the
sender's own and not expressly made on behalf of the NIAID by one of its representatives.
-----Origi naI Message-----

From: Michael Gerson--------~ (b
~)~(6)
=>
To: Fauci, Anthony (NIH/NIAID) [E]------ -=
(b=H=6)
Subject: Re: Q
Is the overall strategy for social distancing just to keep the percentage of Americans who
get the disease low until a vaccine is available? This seems much harder to do in a free
society . Does this mean closing schools? Public transport? Do states and localities make
such decisions?
(b)(6)
On Mar 2, 2020, at 6:11 AM, Fauci, Anthony (NIH/NIA ID) [E]
--------- (b)(6)wrote:
Mike:
Thanks for the note. We are clearly getting "community spread" in at least
one and likely two non-contiguous locations. It was likely spreading in
Washington State for at least a few weeks before the current cases were
recognized, which means we can expect dozens and dozens of cases (or
more) in that locat ion unless we are vey lucky and/or the contact tracing is
highly efficient. The precise mortality rate is stil l uncertain. The stated
NIH-001036
mortality is 2%; however, even if it is half that (1%) and only 5% of the
popu lation get infected, you are correct in that we can have a few hundred
thousand deaths. The really critical issue is what the mortality rate actually
turns out to be. I am hoping for a considerably lower mortality rate, but that
might be wishful thinking . Whatever it turns out to be, the major tools that
we have are public health measures, particularly social distancing, which we
have to start doing right now in Washington State and thinking about in other
locations. That is really the major weapon that we have. Even though we go
into phase 1 with one candidate vaccien in about 6 weeks, vaccine is out of
the question for at least a year or more if you want to make sure that you
have an effective vaccine, i.e. some efficacy data before massive deployment.
We are meeting with pharmaceutical execut ive today and I will bring up the
issue of what the fastest possible time line would be to have a deployable
vaccine.
(b)(6)
----------
Best regards,
. I hope that you are well.
Tony
From: Michael Gerson -----------=- (b'"'"'
)=(6)

To: Fauci, Anthony (NIH/N IAID) (El
--------:a~ aa,
(bH >
Subject : Q
---------
Tony,
I was with Francis yesterday , and t he news seemed pret t y sobering. It seems
like the virus is out in the general population in the Pacific Northwest and
Silicon Valley. A pandemic now appears likely. Francis gave me a guesstimate
that 5 to 20 percent of t he US population may end up infected . Depending on
the mortality rate, this could result in hundreds of thousands of deaths.
Not for att ribution in any way, is this a fair summary? How and when wi ll we
know if the disease is on this track? Do we have any better info on mortality
yet?
And is there any news on the vaccine front? As I understand it, we are not
even to Phase 1 trials on anything. If a vaccine is promising, are well talking
about late Fall as the earliest possibility? And are there any substantive
measures that could be taken to make sure pharma steps up to produce a
vaccine on a massive scale once we have It?
I'm not sure Americans have been adequately prepared for this possibility.
That is partl y a political problem (in my view). But what needs to happen
soon to get people prepared?
Hope you are hold ing up well under all of this and taking care of yourself .
NIH-001037
NIH-001038
Sent: Mon, 2 Mar 2020 17:26:54 +0000
To: Reddy, Sumathi
Subject: RE:?
For COVID-19 the mortality rate is approximately 2%. For seasonal influenza it is
approximately 0.1%
Director
Phone: (b)(6)
FAX : (301) 496-4409
E-mail: (b)(6)
behalf of the NIAID by one of its representatives.
From: Reddy, Sumathi <sumathi.reddy@wsj.com>

Sent : Monday, March 2, 2020 10:49 AM
To: Fauci, Anthony (NIH/NIAID) [E] --------, .....,..,=
(b)(6)
Subject :?
Hi there
Wanted to see what's the most up-to-date info you have on mortality rate for covid-19 versus
influenza?
Sumathi Reddy
The Wall Stree t Journal
"Y our Hea lth" co lumnist
M:.__ _ (..,,, 0 : +1212416 2945

_, ,..,~c..,
E: sumathi.reddy@wsj.com
T: @rddys um
A: 121 1 Avenue of the Ame ricas. New York, NY 10036
NIH-00104 1
From: (b)(6)
Sent: Mon, 2 Mar 2020 09:24:45 -0500
Subject: Fwd: 60 Minutes/ COVID -19
Let us discuss
From: Denise Cetta (b) ~

Date: March 2, 2020 at 9:20:42 AM EST
To: "Fauci, Anthony (NIH/NlAID ) (E]" ------~~ (b)(6J:
Cc: Jon LaPook (b)( , "Stover, Kathy (NIH/NIAID) [E]"
(b)(6)>,"Routh, Jenn ifer (NIH/NIAID) [E]"
(b)(6), Katie Brennan <BrennanK @cbsnews.com >
---------
Subject: 60 Minutes/ COVID -19
Dr. Fauci:
Good morning .
I know you are busy, so forgive me for reaching out directly , but time is of the
essence.
I know you spoke with Jon about doing a 60 Minutes story on COVID-19.
We are interested in potentially cra.c;;hinga story for this weekend.
Is it possible for us to have a quick brainstorming phone call on what such a story
might include if based at NIH with you?
Some idea s ...
Fallo wing you closely as you engage in meetings, ge ttin g up to date info, giving
you1 opinion , going to task force meeting at WH or elsewhere.
Are you using the same "DNA platform" you showed us in the Zika story to build a
potential vaccine for COVID-19? Or is it another approach?
Will you be meeting with any patients who are currently infected? Bringing any
patients to the NIH for care/evaluation?
Let us know when you can talk .

Denise
Denise Schrier Cetta

Producer CBS News, 60 Minutes
Cell : (b)(6)
NIH-001042
From: (b)(6)
Sent : Mon, 2 Mar 2020 09:20:56 -0500
To : Shlomchik , Mark Jay
Subject : Re: Is this true?
I have been very explicit in stating publicly that I am not being muzzled or censored. I say
exactly what I want to say based on scientific evidence, I have stated this on multiple TV
programs over the pas t few days including at a major press conference with many, many
reporters present including several TV cameras . I could not possibly be more public about this.
No censor. No muzzle. Free to speak out.
On Mar 2, 2020, at 9 : 11 AM, Shlomchik , Mark Jay

<MSHLOMCH @pitt.edu >wrote:
OK, well that is good to know. It has been reported by many outlets including the
NYT . So if not true I think it is cr itica lly important for you to say so publicly and
show that it is not the case. It is critical, critical that we all have faith in the science
and medical leadership. Your personal integrity is at stake here in the community
and the world, and is a proxy for the integrity of science and medicine.
According to one house member, the following :
Garamendi told MSNBC's Hallie Jackson that Anthony Fauci was
scheduled to do all five major Sunday talk shows, but says Fauci
canceled the appearances after Vice President Pence took over the
administration's response to the disease.
Trump on Wednesday named Pence as the official overseeing the

government's response.
"I can repeat what he said, he said, 'I was not muzzled. However, I
was to go on the Sunday talk shows five of them. The vice
president's office then took over the control of this situation, and told
me to stand down, not to do those shows,'" Garamendi said, quoting
Fauci.
We cannot mince words about this or have nuances. If you were told not to appear
on Sunday talk shows, then a reasonable person would have to assume your speech
indeed is being contro lled. Whether you call it " muzzled" or censored is a matter of
semant ics. Is it factual that you were told/asked not to appear on these shows as had
been scheduled?
NIH-001043
I hope you understand my reason for and level of concern. I am certain it is shared
by many of your colleagues and citizens.
Be st,
Mark
Mark Shlomchik, MD, PhD

UPMC Endowed and Distingu ished Professor of Immunology
Chair, Department of Immunology
University of Pittsburgh School of Medicine
W1052 Biomed ical Science Tower

200 Lothrop St
Pittsburgh, PA 15261
Phone: Cb)(6)
Fax: 412-383-8098
(b)(6)
https://www.immunology.pi tt.edu
http://immunology.pitt.edu/person/mark- jay-shlomchik-md-phd
Check out our gene targeting and flow cores: http ://immunology .pitt.edu/department-
resources
On Mar 2, 2020, at 9:03 AM, Fauci, Anthony (NIH/NIAID) [E]

Cb)(6)>wrote:
The story is not true. I am not being muzzled or censor ed.
On Mar 2, 2020 , at 8:51 AM, Shlomchik , Mark Jay

<MSHLOMCH@pitt.edu>wrote:
Dear Ton y,
Is the inform ation in this article true?
https ://www .businessins ider .com/who-is-anthony-fa uci-
speech-controlled-by-trump-coronavirus-2020-2
If it is, I think that-in the interests of public health and the
integrity of science in the US- you must not acquiesce but
instead resign and sp eak out.
If it is not tru e, then plea se refute it and set the record
straight.
Sincerel y,
Mark Shlomchik, MD, PhD

UPMC Endowed and Distinguished Professor of Immunology
Chair , Department of Immunology
Unive rsity of Pittsburgh School of Medicine
NIH-001044
W1052 Biomedical Science Tower
200 Lothrop St
Phone: 412-648-8771
Fax: 412-383-8098
mshlomch@p itt.edu
https://www .immunoloqy.pitt.edu
http://immu noloqy.pitt.edu/pe rson/ma rk-jay-shlomch ik-md-phd
Check out our gene targeting and flow

cores: http://immuno logy .pitt.edu/department-resources
NIH-001045
From: (b)(6)
Sent : Mon, 2 Mar 2020 09:10:54 -0500
Subject : Fwd: lay info for people who are at risk for COVID-19
Attachments : Wuhan Coronavirus for Mama.20020301.pdf, ATT000Ol.htm
Plea se take a look at this and respond.
Begin fo1warded message:
From: Cynthia Bristow CbH

To: "Fauci , Anthony (NJH/NIAID) [E]" ---------=---c-
CbH6)
Subject: lay info for people who are at risk for COVID -19
Dear Tony,
I would like to respectfully ask if someone in your Institute could kindly review the
attached precis regard ing the current COVID-19situation and recommend any revisions
prior to my disseminating this to my at risk family members including (b) (6) and
others in retirement communities who are concerned.
I appreciate that this would not be an official endorsement by you . I am only asking if there
is anything that you or others think I could add or subtract from this precis to give solace to
those who are in need of knowledge and comfo rt.
Thank you kindly for your attention to th is matter .
Best wishes,
Cynthia L. Bristow, PhD

Chief Executive Officer
Alpha-1 Biologics
25 Health Sciences Drive, Suite 110
Stony Brook, NY 11790-3383
Office (b)(6J
Cell phone: (b)(6)
(b)(6)
www .alphalb iologics.com
NIH-001046
Sent : Mon, 2 Mar 2020 10:43:27 +0000
To : Marston, Hilary (NIH/NIAID) [El
Subject : FW: GPMB: MESSAGEON BEHALFOF THE CO-CHAIRS: UPDATE: CONFIRMING 4
MARCH TELECONFERENCE
Attachment s: Agenda Board telcon 4 Mar Fnl.p df, Local_Access_en .pdf
FYI
From:Amel ie RIOUX (b)(6)>

Sent: Monday, Ma rch 2, 2020 5:29 AM
To: Dzau, Victor J. (b)( ; Fauci,
Anthony ( NIH/ N IAI ~
D:-
) [:E
-::":'"
] -:======~ )~(6)
(b,:,,: ~;~F-o-re-:H
"'."
e_n_r":,e-
- tt-a-=====~ (b
")~
'.=
(6)
,:,::-
;-:G
::-a-o-:F:-u--
(b)(6) Gashumba Diane (b)(6); Ilona Kiekbusch
~====== (b-::::!
)('-=--
6)>; Suzuki Yasuhiro-========== (b=)=c ..--
(b)(6) Vega Morales Jeanette (b)(6); VijayRaghavan
------======-- _:::~=
Krishnaswamy (b)( ; Skvortsova Veronika (b)(6)
Cc: Gro Brund t land (b)(6)>; As Sy (b)(6)>; Elhadj SY
(b)(6) Tore Godal (b)(6)> ; Godal, Tore (b)(6);
(b)(6) SCHWARTLANDER,Bernhard F. (b)(6) ; RYAN,
----:;=====~--
Mich ae I J < >; Pate M uha med ----=--------'=-==---::--------
(b)(6); Kanarek, Morgan
(b)(6) Conrad, Patricia
-~---~-:-:====================~~---
(NIH/NI A ID) [E) (b)(6);
(b)( ; 'Sheila Austria' (b)(6)
===========~ ---------------
(b)(6) Teresa M iller de Vega
~==========:-::=-;------.- (b)(6)>; Marston, Hilary (NIH/NIAID) [El
--------~~
Palu
---------
Subject: RE: GPMB: MESSAGEON BEHALFOF THE CO-CHAIRS:UPDATE: CONFIRMING 4 MARCH
TELECONFERENCE
Dear Board membe rs,
We are confirming the Board te leconfe rence on Wedne sday, 4 March at 14:00 Geneva time .
Please find attached the agenda (also copied below) and the call-in numbe rs. The Access code is (b)( 4)
Please let us know if you have any questions .
Thank you very much,
NIH-00105 1
Amel ie Rioux
On behalf of the Co-Chairs
Participant access
Optional dial-in numbers
(b) (4)
international
+41 58 262 07 22 (English) +41 58
262 07 44 (Italiano) +41 58 262
07 11 (Deutsch) +41 58 262 07 33
(Fran~ais)
Loca l Access
Access via Web
Global Preparedness Monitoring Board

Teleconference
4 March 2020, 14:00- 15:00 CET
Agenda
1. Welcome and Roll call

2. Updates and stock taking on the COVID-19 outbreak
o Update from George Fu Gao (TBC)
o Update and Proposal from Jeremy Farrar
3. Discussion ; Actions from the Board on the COVID-19 outbreak (30 minutes)
4. Adjourn
From: Amelie RIOUX

Sent : Tuesday, 25 February 2020 10:18
Anthony Fauci --======~-:-----:-:---:----:::::===~~--:::---::------

To: Dzau, Victor J.
(b)(6); Fore Henrietta -o. CbH~ > ; Gao Fu
(b) (6)·
--"'==,::---------
(b)( 6) >; Gashumba Diane (b)(6); Ilona Kiekbusch
~======:,ot,_;.,,.
(b)(6)>; Suzuki Yasuhiro (b)(6);
'========~.;,..= Vega Morales Jeanette VijayRaghavan
-----~====~-
Krishnaswamy :':'.-
= Skvortsova Veronika
(b)(6)·
(b)(6)>;
(b)(6)>;
(b)(6)
Cc: Gro Brundtland (b)(6); As Sy (b)(6)>; Elhadj SY
(b)(6)>; Tore Godal Godal, Tore
(b)( >; (b)(6)>;
(b)(6); SCHWARTLANDER,Bernhard F. < (b)(6)>; RYAN,
~-:----:--:====~~;---=--
Mich ae I J._____ Cb _ >; Pate Muha med <1
_ >_C6) CbH6l>; Kanarek, Morgan
NIH-001052
Subject: GPMB : MESSAGEON BEHALFOF THE CO-CHAIRS:UPDATE
MESSAGEON BEHALFOF THE GPMB CO-CHAIRSDR BRUNDTLANDAND MR SY
Dear Board members,
Thank you to those of you who joined the call on Thursday on short notice.
In light of our discussion, we would like to update you on a few matters :

(b) (4)
• Coronavirus outbreak. We have asked Jeremy Farrar to act as t he Board' s focal point on the
COVID-19 outbreak, to represent and advise the Board on the science of the outbreak and the
financing of the response. We thank Jeremy for agreeing to take on this role.
• Follow -up Board teleconference call. Since many of you were unable to attend Thursday's call,
we wish to propose to hold a follow-up Board teleconference call on 4 March at 14 :00 Geneva
time . The purpose of the call will be to discuss the coronav irus outbreak, including Jeremy's
proposal for Board action on financing. We would appreciate if you could confirm you r
participation to Amelie Rioux (b)(6)). A more deta iled agenda and call-in details
wi ll be shared shortly.
• In-person Board meeting . We wish to confirm that the next in-person Board meeting will take
place Tuesday-Wednesday, 5-6 May 2020, in Geneva. The meeting will be an important
oppo rtunit y to further discuss strategic issues as well as a draft of the annual report. We will
communicate further on logistical detail s.
As always, thank you for your support and continued engagement.
NIH-001053
With kind regards,
Gro and As
NIH-001054
Sent : Sun, 1 Mar 2020 23:25 :39 +0000
To: Lerner, Andrea (NIH/NIAID) [El
Cc: Mars ton, Hilary (NIH/NIAID) [El ;Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia
(NIH/NIAID) [El
Subject : RE: event ru ndown for 3/2 webcast event
There is no attachment with this e-mail
Director
Phone : (b)(6)
FAX : (301 ) 496-4409
E-mail : (b)(6l
The information in this e-m ail and any of its attachments is confidential and may contain sensitive
information . It should not be used by anyone who is not the origi nal intended recipient . If you
From: Lerner, Andre a (NIH/N IAID) [El

Sent : Sunday, March 1, 2020 6:01 PM
--------- (b) ~ >
To: Fauci, Anthony (NIH/NIAID) [El --------, .....,....,=

(b)(6)
Cc: Marston , Hilary (NIH/NIAID) [El ; Folkers, Greg (NIH/NIAID ) [El
_______ CbH_6)>; Conrad, Patricia (NIH/NIAID) [E]________
_ _ )_C_6)
Cb
Subject : Re: event rundown for 3/2 webcast event
Sending th is again as it is for tomorrow.
Sent from my iPhone
On Feb 28, 2020, at 9:10 PM, Lerner, And rea (NIH/N IAID) [El
wrote : --------- (b)(6)
Dear Dr. Fauci (and Hilary, if you end up doing this event as ASF' s back-up),
NIH-001060
I've attached an "event rundown" for the Harv ard Forum Webcast, which is scheduled
from 11:40-lpm on Monday 3/2- a moderated panel discussion. This is a document
prepared by the event organizers outlining the run of show, noting what questions the
moderator will pose, and some suggested points the organizers thought you might touch
on in your answers.
Although the organizers prepared this document fo llowing a planning call, they have made
it clear that the "talking points" in this document are of course not a script. I have taken
their document and highlighted where you appear . I have also added some comments.
Let me know what you think. There are no slides for this event.
Let me know if you would like to discuss further over the weekend or if you'd like anything
for preparation.
Sincerely,
Andrea
Andrea Lerner, MD
Medical Officer
Office of the Director
NIAID/NIH
31 Center Drive, Room 7A10A
Bethesda, MD 20892
Cb)(6) cell
<2020.3.2-Coronavirus-rundown _tony _AL highlights.docx>
NIH-00106 1
Sent : Sun, 1 Mar 2020 22:53:00 +0000
Subject : FW: Proposal to Mitigate Spread of COVID-19
Attachments : Urgent Proposal to Mitigate Spread Fauci.pdf, HCQ,A Modest Proposal for
Mitigating COVID-19 2.0.pdf
Please take a look and do what you fe el is appropr iate.
Director
Phone: (b)(6)
FAX : (301) 496-4409
E-mail (b)(6l
info rmation. It should not be used by anyone who is not the original intended recipient. If you
>
From: Alexander Morden MD
----------
(b)(
To: Fauci, Anthony (NIH/NIAID) [E] ------~= (b)(6)>

Subject : Proposal to Mit igate Spread of COVID-19
Enclosed is an article I have subm itted which may offer an immediate stra tegy to help infection control
in t he general public (and possibly in Oregon & California).
NIH-001062
Sent : Sun, 1 Mar 2020 22:52:21 +0000
To : Tsang, John (NIH/NIAID) [E]
Cc:
Subject: ------- (b)( •;Conrad, Patricia (NIH/NIAID) [E)
RE: personal Immune baseline and its impact on infection and vaccine
responses
John:
Thanks for yo ur not e. I am copying Cliff Lane here since he and his tea m is
in vol ved in a clin ical pro t oco l with COVID-19 pat ient s. He may be abl e to point
yo u in the right dir ection.
Best regards,
Tony
Director
Phone : (b)(6)
FAX: (301 ) 496-4409
E-mail ( (b) <
6J
information . It should not be used by anyone who is not the origina l intended recipient. If you
accept liability for any statements made that are the sender's own and not express ly made on
From: Tsang, John (NIH/NIAID) [E] (b)(6)>

Sen t: Sunday, March 1, 2020 2:46 PM
-----~ ~
(b)( >
Subject: personal Immune baseline and its impact on infection and vaccine responses
Dear Or. Fauci,
Hope you are doing well despite the rapidly evolving situation w ith COVID-19 .
I wanted to send you a paper we just published last week that you might find relevant- please find
attached and a NIAID piece below.
https://www .niaid .nih.gov/news -events/immune -system-status -predicts -future -responses
NIH-001063
Th is paper asks the question of why do ind ividuals mount variab le immune responses to vaccines ,
infections , and diseases. This extends from our ear lier work on baseline predicto rs of influenza
vaccination responses that you hig hlighted as a NIAIO Advance in 2014. A key message is that genetics is
often unlikely the answer, but the status of the immu ne system before the pe rt urbation m ay offer clues
- here we ident ified such an immune cell circuit involving pOCs-Type I IFNs prior to perturbation in
humans and found that its status can predict vaccinat ion and lupus disease activ ities and is temporally
stable within individuals for months.
(b) (5)
Many thanks !
Best w ishes,
John.
John Tsang,PhD, Senior Investigator I Chief, Multiscale Systems Biology Section, Laboratory of Immune System
Biology I Co-Director, Center for Human Immunology (CHI) I National Institute of Allergy and Infectious Diseases
(NIAID), National Institutes of Health (.lli.!:i) I emai (b)(6) I off ice: (b)(6) I cell: (b)(
)(6) I web : tsang lab I address: (b)(6) 4 Memorial Drive, Bethesda, MD, 20892 USA
The information 1nthis e-mail and any of Its attachments 1sconfidential and may contain sensitive nformat1on. It should not be
used by ariyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and
delete it from your mailbox or any othf?r storag1:>devicPs. National Institute of AIIPrgy and Infectious Diseases shall not accept
liability for anystatementsmadethat are sender'sown and not expresslymadeon behaf of the N AIDby one of its
representatives.
From: "Fauci, Anthony (NIH/NIAID) [E]" CbH6)

Date : Wednesday, December 19, 2018 at 9:43 PM
To: "Tsang, John (NIH/NIAID) [E]" (b)(6)
Subject : Congratulations
John:
Congratula tions on being gra nted tenure by the NIH Central Tenure Committee. Well-deserved!
Keep up your te rrific work.
NIH-001064
Best regards,
Tony
Director
B uilding 31, Room 7A-03
Nation al Institutes of Health
Phone : (b)(6)
FAX: (301) 496-4409
E-mail (b)(6)
The information in this e-mail and any of its atta chments is confidential and may contain sensitive
NIH-001065
Sent : Sun, 1 Mar 2020 22:50:11 +0000
To: NIAIDODAM
Subj ect : FW: Out reach from STAT
Let us di scuss.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Berke, Rick <Rick.Berke@statnews .com>

Sent : Sunday, March 1, 2020 10:10 AM
-------~~
Subject : Outreach from STAT
--------- (b)(6)
Tony,
I know you're swamped but I'm wondering if we could arrange for you this week to take questions from
our readers about coronavirus. All of our coronavirus coverage is in front of STAT's paywall and we'd see
your contribution as an enormous public service.
We would solicit questions for a "live chat" from readers -- and you could pick and choose which ones
you want to answer -- and write most of them in advance.
Among other leadi ng figures, we 've done this format twice with Nobel winners and it's quite popular .
https ://www .statnews .com/events/stat -live-chat -chat-w ith -a-2019-nobel-winn ing-scient ist/
With Helen Branswell, Sharon Begley, Matt Herper , and our whole team, we pride ourselves on covering
the coronavirus in the most authoritative and fair-minded way. We've developed a tremendous
audience for this coverage. https://www.statnews.com/tag/coronav irus/
Our readers are fairly sophist icated on health and medicine, and we're looking to focus on the health
aspects, not the White House polit ics.
NIH-001066
In addit ion, I'd be grateful if you 'd consider writing another First Opinion fo r us, maybe on lessons
you've learned regarding other outbreaks and how that might be relevant with coronavirus -- or
whatever you 'd like.
Your vo ice of course is very important and authoritative and we'd be grateful to have it again in STAT.
Allbest,
Rick
Rick BerkeCo -fo under & Exec utiv e Edito r0: (617) 929-7056 M :._(___ (b.;..
.;..
)(.;..
6j;.io
@~ ric=k=b=e~r
k=e
STAT Reporting from the fr ontiers of health and

m ed ic in e@st at new s st at ne w s.com fac eboo k .com / stat news
SUBSCRI BE TO ST AT PWS for an all-access pass to exclusive stories. SIGN UP HERE for free news letters with
the latest in hea lth , biopharma, and science coverage.
NIH-001067
Sent : Sun, 1 Mar 2020 22:47:57 +0000
To: Jeffrey Sachs
Cc: Conrad, Patricia (NIH/NIAID) [E);Barasch,Kimberly (NIH/NIAID) [CJ
Subject: RE: Might we speak briefly about the coronavirus vaccine development?
Jeff:
Thanks for th e not e. Happy to chat. Please give my office a call to morr ow AM
CbH6) to set up a time w hen we can chat by phone.
--------
Best rega rds,
Tony
Director
Bu il ding 31, Room 7A-03
Phone : Cb)(6)
FAX: (301 496-4409
E-mail : (b)(6)
The infor mation in this e-mail and any of its attachments is confidential and may conta in sensitive
informat ion. It shou ld not be used by anyone who is not the original intended recipient . If you
From: Jeffrey Sachs (b)(6)

------~~
-------- (b)(6)>
Subject : Might we speak briefly about the coronavirus vaccine development?
Dear Tony,
Thanks as always for your leadership.
Deja vu of our highly productive discussions 20 years ago!
Jeff
NIH-001068
Sent : Sun, 1 Mar 2020 22:46:11 +0000
To : pascal goldschmidt
Cc: Sara Sigel;NIAID OD AM
Subject: RE:
----------- (b)(6)
(b)(6)
Best regards,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail 1 (b)(6)
information . It should not be used by anyone who Is not the original Intended recipient . If you
From : pascal goldschmidt __________ (b_) _

(6J>
Sent : Friday, February 28, 2020 9:00 PM

To: Fauci, Anthony (NIH/NIAID) [E)______ (b
-=")'""'
(6)
= >
Cc: Sara Sigel (b)(6)>

Subj ect : Cb)<
Greetings Tony,
I know how incredibly busy you are with the coronavirus challenge.
I admire so much your cool and effectiveness in the middle of a public health hurricane.
(b)(6)
With warmest regards,

Pascal
NIH-001069
Pascal J. Goldschmidt , M.D., Fellow A.C.C ., Fellow A.H .A.
President and CEO , Alzady International , LLC.
President and CEO , American Healthcare System Ltd.
Dean Emeritus, Professor of Medicine Emeritus
University of Miami Miller School of Medicine USA
AMERICAN HEALTHCARE
SYSTEM
European Core Global & Alzody lniornotionol
NIH-001070
Sent: Sun, 1 Mar 2020 22:44:16 +0000
To : Silverberg, Kristen
Subject: RE:question from BRT
Kristen:
Thanks for the note. Would your companies be able to effectively advocate for
improved health care systems in low and middle income countries?
Best,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
information. It should not be used by anyone who is not the original intended recipient. If you
From:Silverberg, Kristen <KSilverberg@brt.org>

Sent: Thursday, February 27, 2020 11:40 AM
------=--c=
To: Fauci, Anthony (NIH/NIAID) [El
Subject : question from BRT
-------- CbH6)>
Dr. Fauci,
I hope you are well.
Last February, I moved to Business Roundtable, which represents CEOsof large U.S. companies. Josh is
the BRTCEO,and it's been great to work with him again.
We wanted to check with yo u on something quickly . Traditionally, BRT has not weighed in on global
health security policy, but COVID-19 has served as a reminder that global companies need to be strong
advocates for global public health and security. If you had your choice, what would you want to see
our companies advocating for, specifical ly?
No worries at all if you don't have time to respond. We fully appreciate how important your time is.
NIH-00 1071
Best,
Kristen
NIH-001072
Sent: Sun, 1 Mar 2020 22:32:44 +0000
To: Cassetti, Cr istina (NIH/NIAID) [E]
Subject: FW: ARB therapy in Covid - 19 infection
Please respond.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Tom Leopold Cb)(6>i>

Sent: Sunday, March 1, 2020 8:48 AM
-------=-=--==
To: Fauci, Anthony {NIH/NIAID) [El
--------
Subject: ARB therapy in Covid -19 infection
(b)((;)>
Thank you for responding to my email yesterday about the possibility of ARB therapy
in treatment of coronavirus infection. I realize that your research is ongoing. Would you
anticipate, however, that the ARB with the most potential role in preventing virus
attachment would be the one that has the greatest affinity for the AT2 receptor? Am i
correct that losartan is the ARB with the lower receptor (AT1 vs AT2) selectivity and
might logically be the most promising ARB to investigate? Thanks . Dr Thomas Leopold
Sent from my iPhone
NIH-001074
From: Fauci, Anthony (NIH/ NIAIO) [E)
Sent: Sun, 1 Mar 2020 22:31:42 +0000
To: JP Hanke
Subject: RE: Coronavirus
Thank s for the note. CDC is alr eady preparing simi lar public serv ice
announcemen t s, which I am sure will find its way to YouTube
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: JP Hanke (b)(6)>

Sent: Sunday, March 1, 2020 5:30 PM
------
To: Fauci, Anthony (NIH/NIAID) [E]
--------
..,.....,...=
(b)(6)
Subject: Coronavirus
Dear Dr Fauci,
I heard this idea on a radi o interview with Laurie Garrett this morning - how about
getting your committee (or one of the government health agencie s) to produ ce a
series of short YouTube videos on how to combat the coronavirus: such things as
proper handwa shing technique , when to wear a mask , how to ride the subway
safely, etc, etc. I think this would be an excellent way to reach the public in the
digital age (provided that Mike Pence doesn't try to turn them into campaign ads
for Donald Trump), and I strongly urge you to give the strategy serious
considerat ion. I know I would watch them and I'm sure millions of other people
would too .
Sincerely,
NIH-001075
Paul Hank e
CbH6)VT
NIH-001076
Sent : Sun, 1 Mar 2020 22:29:32 +0000
Subject : RE: Report from 'HHS COVI0-19 Situation Update' call today
Thanks. Very helpful.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Lerner, Andrea (NIH/N IAID) [E] (b)(6)

Sent : Sunday, March 1, 2020 4 :06 PM
To: Fauci, Anthony (NIH/NIAID) [E] -------=-:--:= (b)(6)
Cc: Marston, Hilary (NIH/NIAID) [E] (b)(6)>; Folkers, Greg (NIH/NIAID) [E]
(b)(6)>; Doepel, Laurie (NIH/NIAID) [E] (b)(6)>; Eisinger, Robert
(NIH/NIAID) (El (b)((;); Conrad, Patricia (NIH/NIAID) (E) (b)(6)>
Subject : Report from 'HHS COVID-19 Situation Update' call today
Passing on some main points from of an "HHS COVI0 -19 Situation Update" call that took place at 3pm
today, FYI.
• The meat of the call was a situation update by Nancy Messonnier (with epi numbers below).
• She noted that the national strategy is still containment .
• However, since there are some US locales wit h evidence of community spread, there is
considerat ion if some "commun ity level act ion" may be appropr iate, with a move towards a
blend of mitigat ion/containment in certain areas.
Global epi update:

China lab/clinically confirmed cases: 79,824 (+573 in last 24h)
China deaths: 2,870
61 international locations with 7,102 cases so far (Armenia, Ecuador, Ireland, Luxembourg new in last
24h)
NIH-001077
107 international deaths
Widespread community transmission occurring in:

China, Iran, Italy, Japan, S. Korea
US epi update:
63 confirmed US cases (16 diagnosed here, 3 in Hubei repatriates, 44 in Diamond princess repatriates)
11 presumptive cases (meaning they tested+ at state public health labs, but confirmatory test at CDCis
pending)
663 Persons Under Investigation
Andrea Lerner, MD
Medical Officer
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases (NIAID)
31 Center Drive, Room 7A10A
Bethesda, MD 20892
NIH-001078
Sent: Sun, 1 Mar 2020 22:22:15 +0000
To: Francis V. Chisari
Subject: RE:
----------------- (b)(6)
Given what is going on with coronavirus, I cannot guarantee that I will be able to
attend the Section meeting . I will try my best.
Director
Phone : (b)(6)
FAX : (301 ) 496-4409
E-mail : (b)(6)
information . It should not be used by anyone who is not the or iginal intended recipient . If you
From: Francis V. Chisari <fchisari@scripps.edu>

To: PAUL G AHLQUIST<ahlqu ist@wisc.edu>; Zhijian (James) Chen <zhijian .chen @utsouthwestern .edu>;
Fauci, Anthony (NIH/NIAID) [E) (b)(6J; Michael Oldstone <mbaobo@scripps.edu>;
Eckard Wimmer <eckard.wimmer@stonybrook.edu>
Cc: Charles Rice <ricec@mail.rockefe ller.edu>; Chisari. Francis <fchisari@scripps.edu>
Subject : (b) (6)
Dear colleagues,
(b)(6)
. Please let me
know if you will attend the Section meeting this year and if you're willing to say a few words of
support.
Best regards,
Frank
NIH-001079
Sent : Sun, 1 Mar 2020 20:32:36 +0000
Subject : FW: SARS-CoV-19
Please respond
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail (b) (6)
From: Peter Panus (b)(6)>

To: Fauci, Anthony {NIH/NIAID) [El -------::-:-,(b)((;)>
=
Subject : SARS-CoV-19
Although outside my main area of expertise I have been keeping up with CoVid-19 discussion. One item
I have noted is that the disease appears to have a lower incidence in children . The other is t hat the virus
appears to at least in part attach through cell membrane angiotensin II type 1 recepto rs. Is the lower
incidence of the disease in children possibly due to th is cohort having a higher proportion of angiotensin
II type 2 receptors compared to the adult cohort?
Sincerely,
Peter C. Panus PhD, PT
Professor Emeritus
Pharmaceutical Sciences Dept.
Gatton on College of Pharmacy
NIH-001080
Sent : Sun, 1 Mar 2020 20:23:14 +0000
To: NIAIDODAM
Subject: FW: Invita t ion to speak to the National Economists Club
Let us discuss. Unlikely I will have time depend ing on how thi ngs evolve .
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Sanchez, Emily <Emily_Sanchez@americanchemistry .com>

To: Fauci, Anthony (NIH/NIAID) [El---------=c:-:-=s
(b)((;)>
Cc: Doepel, Laurie (NIH/NIAID) [El (b)(6)>; Routh, Jennifer (NIH/N IAID) [El
(b)(
Subject: Invitation to speak to the National Economists Club
Dear Dr. Fauci,
My name is Emily Sanchez and I am an economist at the American Chemistry Council. I am reaching out
to you in my capacity as President of th e National Economists Club (NEC}, which is an organ izat ion of
over 1000 government and private sector economists based in DC. The NECholds weekly luncheon
events which feature notable experts and economists in Washington.
Increasingly, econom ists are being asked to assesst he economic impacts around the incidence and
spread of the corona virus as well as the impact of reduced economic activity due to behavioral changes
{e.g. people not leaving their homes to work or shop, supply chain disruptions, etc.) . As economists are
tasked in assessments, scenario planning and communicating their estimates, accuracy around thei r
assumpt ions and understanding of the corona virus and Covid-19 is imperative . We are incredib ly
appreciate of the important work and research that the Nationa l Institute of Allergy and Infect ious
Diseases provides and we are wondering if you would be willing to speak at one of our luncheons about
Covid-19 and the latest developments .
NIH-001081
Do you think you might have t ime in your schedule t o spea k to the National Econom ist Club t his
month ? We would love to have you speak during the week of March 16-20.
Our luncheons typically take place at the Chinatown Garden Restaurant, 618 H St. NW, w ith lunch at
noon and your presentation from 12:30 p.m. til 1:30 p.m. Talks are normally on the record and open to
the press, unless you request otherwise.
Thank you for your consideration.
Best regards,
Emily
Emily Sanchez I American Chemistry Council

Director, Economics & Data Analytics
Economics & Statistics Department
emil y sanchez@americanchemist ry .com
700 2nd Street, NE I Washington, DC I 20002
0: (202) 249-6183
www.americanchem i stry. com
++ +++++++++++++++++++++++++++ This message may contain confidential informat ion and is intended
only for the individual named. If you are not the named addressee do not disseminate, distribute or
copy this email. Please notify the sender immediately by email if you have received this email by mistake
and delete this email from your system. E-mail transmission cannot be guaranteed to be secure or error-
free as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete, or
contain viruses. The sender therefore does not accept liability for any errors or omissions in the contents
of this message which arise as a result of email transmission . American Chemistry Council, 700 - 2nd
Street NE, Washington, DC 20002, www .americanchem istry .com
NIH-001082
Sent: Sun, 1 Mar 2020 20:17:45 +0000
To : Thomas Murray
Subject: RE: Have you been muzzled?
Mr. Murray:
Thanks for the note. Please stay silent since I have not been muzzled. I will be
on multiple TV shows tomorrow and was on FOXthis AM. No one is censoring
me.
Best regards,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
From:Thomas Murray
----------
-------=cc-c=
(b)(6)

Subject : Have you been muzzled?
-------- CbH6)>
Reference: I'm the nuclear/aerospace engineer who subsequent ly obtained an MPH at the University of
Washington since I was working disease transmission within commercial airlines when I was a Boeing
employee. And, my undergraduate degree is in chemistry with a minor in microbiology. I've engaged you
previously.
Hi Dr. Fauci,
You've kindly allowed me to engage you, and I'll take advantage of that kindness.
The news media is reporting that the White House has muzzled you. Is that true? Before entering the
science/engineeri ng world, I was a newspape r city editor in Southern CA (in the 1970s). Therefore, I get
and understand the idea of coordinated messaging. (Plus, due to my media background, Boeing used me
to help executives prepare for media engagements on challenging topics.) However, if it's true that you
are muzzled, then I will initiate a "campaign" with my congressional representatives and the media to
NIH-001083
-
stop that action.
-------------------
(b)(
However, before I initiate sucha campaign, will my actionspossibly cause you harm? I recognize tha t
you may have backchannels that I may disru pt by engaging.
As I related previously, I trust you since you focus on facts and data, you prov ide context for the
information that you share, and you avoid emotion in your engagements. I think that residents of the US
(and, fran kly the worl d) need your insights regard ing COVID-19. Plus, you're one of the wor ld leaders
with regard to infectious diseases. And, if you don't know, you know whom to ask.
Please let me know if I should stay silent or become noisy.
Thank you. And, t hanks for your service to the US and the world during this very interesting time.
Thomas Murray
Sent from my iPad
NIH-001084
Sent : Sun, 1 Mar 2020 20:13:01 +0000
To: D.A. Sonneborn
Subject : RE: News about SARS-CoV-2ad Covid-19
You can tru st CDC.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail Cb)(6)
From: D.A. Sonneborn CbH6J>

To: Fauci, Anthony (NIH/NIAID) [E) ------~~ Cb)( >
--------
Subject : News about SARS-CoV-2ad Covid-19
Dear Dr. Fauci,
It would be good to know if you still believe Americans can trust CDC's public -facing authority or
whether we'd best look to WHO for reliable information about the virus, the disease and any
new mutations which might arise. Mike Pence does not have appropriate credentials .
Sincerely,
D.A. Sonneborn, Ph.D.

(b)(6)
NIH-001085
Sent: Sun, 1 Mar 2020 20:09:38 +0000
To: Corey MD, Larry
Subject : RE:Mike Pence?
I am not going to CROI. I am sending in a taped short discu ss ion of NIH research response to COYID-19
Director
Bethe sda , MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail (b)(6)
The informa tion in this e-mail and any of its attachments is confidential and may contain sensitive infom1ation. It
should not be used by anyone who is not the original intended recipie nt. lf you have received this e-mail in e1TOr
Allergy and infectio us Diseases (NIAID) shall not accept liability for any statements made that are the send er's own
------~~ Cb_)_(_.>
From : Corey MD, Larry _______
Sent: Sunday , March 1, 2020 3:00 PM
------~~
To: Fauci, Anthony (NlH/NlAID) [E] (b)( ·
Subject: Mike Pence ?
Ah the great communicator of infectious di,ease epidemiology and pathogenesi s.

On way back from (b) (
We need a POW wow w ith John and Carl on the path to

_________________
. News travels fast among the aficionados.
_,
(b)( 4) J will
schedule. You coming to CROI '? lfnot 1 could pop down to you.
Excuse the I phone typing. On the runway leaving (b) (~
Sent from my iPhone
NIH-001086
Sent : Sun, 1 Mar 2020 19:49:51 +0000
To : Jon LaPook
Subject : RE: My 11CBSSunday Morning" 5-mi nutes shpiel on coronavirus and COVID-19
Outstanding!!
Director
Bui Iding 31, Room 7 A-03
Phone: (b) (6)
FAX: (301 496-4409
E-mail
-------- (b)(6)
The inform ation in this e-ma il and any of its attachments is confiden tial and may contain sensitive infom1ation. It
should not be used by anyone who is not the original intended recipient. If you have received this e-mail in eITor
Allergy and Infectious Diseases (NIAID) shall not accept liability for any stateme nts made that are the sender's own
and not expressly made on behalf of the NIAID by one of its representatives.
From: Jon LaPook_____ ""'
(b"')"""
(=
To: Fauci, Anthony (N1H/N1AID)[E] -------c,-,-c c=,,
(b)(6)
Subject: My "CBS Sunday Morning" 5-minutes shpiel on coronavirns and COVID-19
Tony,
Here you go. You can enjoy it in al your spare time. Hope you managed to clear your desk last night.
https://vimeo.com/user 10844306 /rev iew/394 766243/cbaS l 43d0d
Best,
Jon
Jonathan LaPook, M.D.

Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook
NIH-00 1089
Sent: Sun, 1 Mar 2020 19:31:54 +0000
To : Jeffrey V. Ravetch
Cc: Stelios Bournazos
Subject : RE: Fe modifications for protective anti-COVID-19 ant ibodies
Jeff:
Thanks for the note and the slide. Very interesting. Please send me the
preprint when it becomes available.
Best,
Tony
Director
Phone : (b) (6)
FAX: (301 496-4409
E-mail , (b)(6)
From:Jeffrey V. Ravetch
-----------
Sent : Sunday , March 1, 2020 12:43 PM
(b)(6)
To: Fauci, Anthony (NIH/NIAID) [E]------~~

,....;..
__ .:....:....:.::::=====~~ (b)(6)
Cc: Stelios Bournazos
------------ (b) (6)
Subject : Fe modifications for protective anti -COVID-19 antibodies
Dear Tony,
I wanted to share a very recent and surprising result we've obtained on the
mechanism of antibody protection for anti-viral antibodies. We've previously shown
that bNAbs to flu and HIV require FcRengagement for their in vivo potency.
Enhancing activating FcR engagement increases the potency of these antibodies by
an order of magnitude, on average, and thus are significant contributors to anti-viral
protection.
NIH-001090
(b) (4)
We'll be writing up this story shortly and would be happy to share a pre-print with
you .
Sincerely,
Jeff
NIH-001091
Sent: Sun, 1 Mar 2020 19:30:12 +0000
To: Grandi, Paola
Subject: RE:
------- (b)(
Dr. Grandi:
(b)(6)
Best regards ,
A.S. Fauci
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail Cb)(6)
behalf of the NIAID by on e of its representatives .
From: Grandi, Paola (b) (

------~~
To: Fauci, Anthony (NIH/NIAID) [E)______ Cb
_H_6)
Subject : (b) (
Dear Dr . Fauci,
(b)(6)
NIH-00 1092
(b)(6)
Please let me know if you would like to discuss this further . I was a former professor at the University of
Pittsburgh and now (b) (6)
would also be available to discuss. My cell phone is

-----
Best Wishes,
Paola Grandi PhD M BA
(b)(6)
NIH-001093
Sent : Sun, 1 Mar 2020 19:22:37 +0000
Subject: FW: Novel Treatment for Reducing Symptoms Associated with Coronavirus
(COVID-19) - " Non-Confidential"
Attachments : (O) The Science of Exulta for the Common Cold.pdf, 1) METHODSAND
COMPOSITIONSTO INHIBIT SYMPTOMSASSOCIATEDWITH VIRAL UPPERRESPIRATORY TRACT
INFECTIONS.pdf
Please handl e .
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From : Jim Iversen (b)(6)

To: Fauci, Anthony ( NI_H.:..
------~~
/N_I_A_ID..:.
) .:.
[ E..:.).::::::=-~;---- (b-) _(6) >
Cc: Jacqueline Iversen (b)(6)>
Subject: Novel Treatment for Reducing Symptoms Associated with Coronavirus (COVID-19) - "No n-
Confidential"
Dear Dr. Fauci,
Sen-Jam Pharmaceutica l has a product under development to reduce the symptoms associated with
Uppe r Respiratory Infection (URI). We believe it could provide relief to a large number of people dur ing
the COVI0-19 pandemic. Our produc t SJP-002is a combination of an NSAID and a non-sedating
antih istamine and does not include a decongestant. Removing the decongestant makes our product
ideal for treating the symptoms associated with COVID-19 in pat ients with cardiac conditions who
cannot tolerate taking a decongestant.
What makes our product novel is that it can be administered early in the treatment phase, thereby
reducing the excessive accumulation of inflammat ion, w hich typically results in head congestion,
pulmonary congestion, coughing, & sneezing. Our experience has shown that at the 1st signs of
experiencing symptoms of URI an indivi dual's symptoms can be drasti cally reduced after ta king our
NIH-001094
product twice a day for 3 days. The dramatic reduction in inflammation has the potential to reduce the
spreading of the virus by means of cough, sneezing, and spreading of germs through cont act. Current ly,
when individuals experience the start of a URI,there is little effective intervention available to change
the course of the infection . Individuals delay administer ing pharmaceutical agents, until their
congestio n becomes intolerable and excessive.
Attached is a copy of our early research and a copy of our non-provisional patent. I share this
information with the hope of providing some background for an immediately accessible, safe treatment,
alternative to slow the pace and impact of the pandemic .
le t me now if we can be of any additional help?
Thanks and all the best,
Jim
seN-JaM ,,_.._ I U C JII
Jim Iversen
CEO
Sen-Jam Pharmaceutical
223 Wall St., #130
Huntin ton , NY 11743
(b)(6)
--- ~--c=
sen- jam .com

Linkedin : llnkedin .com/in/jimiversen
NIH-001095
Sent : Sun, 1 Mar 2020 19:21:51 +0000
To: Lawrence 0. Brown, Ph.D.
Subject : RE: Info re Covid-19
I can assure you that I am not being censo red.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Lawrence 0. Brown, Ph.D.

---------
(b)(6)

Subject : Info re Covid-19
--------
Dear Dr. Fauci,
Those of us who seek factual, scientifically -based information to the highest degree that it is possible to
obtain it will remain hungry and on the alert for whatever complete, up-to -the-moment info rmation
that you may have as humanity proceeds deeper into the Covid-19 potential pandemic. We have trusted
you through several previous epidemics to provide such information. Therefore, I know I'm not alone in
being appalled and frightened by President Trump wanting you to issue info rmation about the current
crises only after it has been cleared by his administration. In his off ice as President, Donald Trump may
be de facto, Commander-in Chief. There is nothing about his office that confers Expert-in-Chief on him,
and what he chooses to say or not say about Covid-19 and its spread should not be treated by the media
or anyone as information that is trustworthy for being factual and scientifica lly-based information to
the highest degree tha t it is possible to obtain.
I hope that you will find it in yourself and in the mission of your office to publicly assure the American
public in no uncertain terms that you will not be censored, and that you will honor the public's trust to
continue to provide real, research-based information about the frightening health nightmare that all
humans are facing in a way that distinguishes us from China's government in its disgraceful and
destructive efforts to muzzle those experts who might be able to save lives by merely speaking truth to a
population whose health depends on having fact-based, totally un-massaged know ledge as soon as it is
available.
NIH-001096
It is with our lives, the lives of our families, and the lives that make up our nation that we are count ing
on you.
Sincerely yours,
Lawrence 0 . Brown, Ph.D.
Clinical Psychologist/Psychoanalyst
(b)(6)
(b)(6J
NIH-001097
Sent : Sun, 1 Mar 2020 16:25 :41 +0000
Cc: Conrad, Patricia (NIH/NIAID) [E);Folkers, Greg (NIH/N IAID) [E];Mascola, John
(NIH/VRC) [E];Lerner, Andrea (NIH/NIAID) [E)
Subject: RE: Background briefer
Attachments : 20200229_VRCModerna mRNA candidate briefer - with Fauci edits.docx
Here it is.
From: Marston , Hilary (NIH/NIAID) [E] (b)(6)>

To: Fauci, Anthony (NIH/NIAID) [E] ------ ..,.....,..-=
(b)(6)
Cc:Conrad, Patricia (NIH/NIAID) [E] (b) ( ; Folkers, Greg (NIH/NIAID) [E]
(bH6J>; Masco la, John (NIH/VRC) [E] (bH6J>; Lerner, Andrea
(NIH/NIAID ) [E) (b)(6)
Subject: Background briefer
ASF:
Attached please find a proposed background briefer for the visit to the YRC (big thanks to John, Barney,
Kizzmekia, the rest of their team and Andrea and Greg). We focused on the VRCitself and the mRNA
candidate, figuring tha t the VPOTUSoffice would have a tick tock etc. VRC also prepared ta lking points
for the round table should those be requested (I have those if you'd like to see them now, but so far the
White House has not asked for this).
Available by cell.
----- (b)(6)
NIH-001098
Sent : Sun, 1 Mar 2020 15:48:15 +0000
To: Sharon Eblen
Subject: RE:Thank You
Sharon:
Many thanks for your kind words.
Best regards,
Tony
From:Sharon Eblen
--------
sent: Sunday, March l, 2020 10:45 AM
(b)(6)>
To: Fauci, Anthony (NIH/NIAID) [E)------= (b)

""'(6J
=>
Subject: Thank You
Good Morning Dr. Fauci,

I just wanted to say a quick thank you for your recent words to the public. I am a high school physics
teacher, and I recognize the importance and the challenges of conveying scientifically accurate
informati on to the public. I watched you speak in the two recent press conferences held by t he
President, and I appreciated the way in which you communicated difficult information regarding the
novel coronavirus. Please keep up the good work during what I'm sure is a very stressful time for you
and everyone at the NIH.
Sincerely,
Sharon M. Eblen
NIH-00 1099
From: (b)(6)
Sent: Sun, 1 Mar 2020 10:34 :15 -0500
To : Conrad, Patricia (NIH/NIAID) [E)
Subject: Fwd: NPR interview request: Or. Fauci
Sent from my iPhone
From: HJ Mai <HMai@npr.org>

To: "Fauci, Anthony (NIH/NIAID) [E]"
-------~~
Cc: "Billet , Courtney (NIH/NIAID) [E]"
Subject: NPR interview request: Dr. Fauci ----------
Dear Dr. Fauci,
I'm sorry to bother you on a Sunday, but with t he fi rst coronavirus death of a U.S. patient
in Washington state, we are wondering if you would be available for a live interview
tomorrow morning our show.
We would like to tal k t o you about the significance of the death in Washington and what
states can/must do to prevent a widespread outbreak.
Kind regards,
HJ
From: HJ Mai <HMai@npr .org>

Sent: Friday, February 28, 2020 6:54 AM
To: Fauci, Ant hony (NIH/NIAID ) [El ':::=====~~
Cc:Billet, Courtney (NIH/NIAID) [El
Subject: Re: Confirmat ion of report
--------
Thank you for your reply Dr. Fauci.
Sent from my iPhone
On Feb 27, 2020, at 10:57 PM, Fauci, Anthony (NIH/N IAID) [E)
(b) (6), wrote:
---------
NIH-001100
This is really not true . It was taken vey much out of context .

Sent: Thursday, February 27, 2020 2:09 PM
_______
To : Fauci, Anthony (NIH/NIAID) [E] ------~= _,
(b)(6)>
Subject : Confirmation of report
Dear Dr . Fauci,
This is HJ from NPRagain. I was wondering if you could confirm a NYTreport

that says the White House has instructed you not to say anything about the
co ronavirus outbreak without prior approval.
Kind regards,
HJ
<image00 l .jpg>
I HJ Mai I Editor, Morning Edition I hmai@npr .org I____ Cb
>
_C_
6)
NIH-001 101
Sent : Sun, 1 Mar 2020 12:39:59 +0000
Subject : RE:VIP visit
I hope that someone in Building 1 is letting the Secretary's office know that the VP and POTUS
are coming to NIH.

Se nt : Sunday, March 1, 2020 6:58 AM
----------
To: Fauci, Anthony (NIH/NIAID) [El ------~~ (b)(6)
,..;.!:======~~
Cc: Folkers, Greg (NIH/NIAID) [El
Subject : Fwd: VIP visit --------- (b)(6)
Sent from my iPhone
From : "Blackburn, Amy (NIH/OD) [El" (b)(6)>

Date: February 29, 2020 at 8:16 :21 PM EST
To: "Conrad, Patricia (NIH/NIAID) [E]" ------- ~= CbH >, "Burklow, John {NIH/OD)
[E)" (b)( >, "Folkers, Gr_eg
:::..:...
(N_IH_;/_N_IA
_I_
D:)...:
[:....
El:...
"=~:;----- (b-)(-6)
Cc: "Daucher, Marybeth (NIH/NIAID) [E)"
Subject: RE: VIP visit --------- (b)(6)>
Hi Patty,
(b)(5)
This is just my really rough draft of an agenda.
-------------
Just let me know the timing of things .
-----Origi naI Message-----

From: Conrad, Patricia (NIH/NIAID) [E] (b)( >
Sent: Saturday, February 29, 2020 7:53 PM
To: Burklow, John (NIH/OD) [E] ------~~ (b)(6); Blackburn, Amy (NIH/OD) [E]
-------- (b)(6); Folkers, Greg (NIH/NIAID) [E]

Cc: Daucher, Marybeth (NIH/NIAID) [E] (b)(6)
(b)(6)
Subject: VIP visit
NIH-001 102
Per Dr Fauci- for the round table - he is thinking that
tomorrow.
Sent from my iPhone
NIH-001 103
Sent : Sun, 1 Mar 2020 12:12:35 +0000
To : Bob Franken
Subject : RE: I'd like to ta lk
Bob:
Thanks for the note. I look forward to seeing you again soon.
Best regards ,
Tony
----- Origina l Message -----

From: Bob Fra nken ------~ (b~)~(6)
=>
Sent: Sunday , March 1, 2020 7: 11 AM
To: Fauci , Anthony (NTH/NIAID) [E] ------ --....-,..--
(b)(6)
Subject: Re: I'd like to talk
Tony,
First of all, thank you for getting back to me, in spite of the fact that you are so busy.
Secondly, it's nice to know they're not muzzled, since you are so incredibly good at making science speak so easy to
understand for dummies like me .
Once the dust settles , I'd live to see you , to pay attention to our long friendship . Meanw hile, best ofluck.
Bob
Bob Franken
,V\ VW .bobfranken.tv
> On Mar 1, 2020, at 6:53 AM, Fauci, Anthony (NlH/NIAlD) [E]

> --------- Cb)(6)> wrote:
> Bob:
> Thanks for tbe note . I hope that all is well with you. I have never been given orders to get approval from the
VP's people to speak publicly about coronavirus. Ever since I have been doing this since the Reagan
administration, whenever a member of the Executive Branch such as me gets invited and goes on National TV suc h
as the Sunday Talk shows, there is always a routine proces s of clearing it with your department (in this case HHS)
who then clears it with the White House. This is routine and has been true for the Reagan , Bush '41 , Clinto n,
Bush'43, Obama, and oow the Trump administrat ion. Tt is merely a forma lity so that they know what is comi ng out
from the executive branch. I have always gotten clearance with very few exceptions over the past 35 years (usually
because they do not want you on TV al the same time that the Pre sident is making an importan t announcement). 1
ha ve never been muz zled or told that I could not spea k out publicly about any thing during this administration.
> I hope that thi s is he lpful.
> Bes t regard s,
> Tony
>
> -----Original Message-----
> From:Bob Franken-------~ (b-)~(6)
=>
> Sent: Saturday, February 29, 2020 6:12 AM
> To: Fauci, Anthony (NTH/NIAID) [E]-----~ (b~)(~6)
> Subject: I'd like to talk
>
>Tony,
>
> 1 know you're busy, but I'd like to have a brief conve rsation with you.
NIH-001 104
> I'm now a syndicated political columnist , writing for King Features. You don 't be surprised to hear that my
column is described as "an extended middle finger pointed in all directions".
>
> Notwithstanding tgat , what I'd like to discuss with you is any orders you've received to get approva l from the
Vice President's people to speak pub licly about the coronavirus.
>
> It ca n be on any basis you choose , on the record, or off. On background (knowledgeable sources) , deep
background (sources) , whatever.
>
> May I call you?
>
> Best,
>
> Bob
>
> Bob Franken
> www .bobfranken .tv
NIH-001105
Sent : Sun, 1 Mar 2020 12:03 :24 +0000
Subject : FW: Connecting you two
Let us d iscuss.
From:Collins, Francis (NIH/OD) [El _______

.... (b)( '>
Sent: Wednesday, Febru ary 26, 20 20 7:59 AM
To : M ichael Milken (mm ilken@knowledgeu .com) <mm ilken@knowledgeu .com>
Cc: Fauci, Antho ny (NIH/ NIAID) [El (bH >
Subject: Connecting you two
Hi Mike,
Thanks for your call on Monday evening . I've reached out to Tony Fauci and he is interested in speaking
with you about how your connections with philanthropy and industry might help as we face a major
challenge from coronavirus. I'm ccing To ny on this e-mail and his cell pho ne is (b)(6). I've also
given him your coordinates.
Best, Francis
NIH-001 106
Sent : Sun, 1 Mar 2020 12:02:07 +0000
Subject : RE:VIP visit
We can discuss.
From : Conrad, Patricia (NIH/NIAID) [E) (b)(6)>

Se nt: Sunday, March 1, 2020 6:58 AM
To: Fauci, Anthony (NIH/NIAID) [E]--------=- (b)
'""'
(=
6)>
Cc: Folkers, Greg (NIH/NIAID) [El (b)(6)
Subject : Fwd: VIP visit
Sent from my iPhone
From : "Blackburn, Amy (NIH/OD) [El" CbH >

Date : February 29, 2020 at 8:16:21 PM EST
To: "Conrad, Patricia (NIH/NIAID) [El" ------- -== "Burklow , John (NIH/OD)
CbH6J,
[El" (b)(6), "Folkers, Greg (NIH/NIAID) [El" (b)(6)
Cc: "Daucher, Marybeth (NIH/NIAID) [El" (b)(6)
Subject : RE: VIP visit
Hi Patty,
(b)(5)
This is just my really rough draft of an agenda.
--------------
Just let me know the timing of things.
-----Origi na I Message-----
From: Conrad, Patricia (NIH/NIAID) [E] CbH >
Sent: Saturday , February 29, 2020 7:53 PM
To: Burklow, John (NIH/OD) [El ----- -=- 6J>;Blackburn, Amy (NIH/OD ) [El
(b"""'
)(=
(b)( >; Folkers, Greg (NIH/NIAID) [El
-------
Cc: Daucher, Marybeth (NIH/NIAID) [El (b)(6)>
(b)(6)
Subject: VIP visit
Per Dr Fauci- for the round table -

----------------- (b)(S',
NIH-001 107
(b) (5)
-------------------- · This will get more fleshed out

tomorrow.
Sent from my iPhone
NIH-001 108
Sent: Sun, 1 Mar 2020 12:01:19 +0000
To: Geller, Robert D.
Subject: RE:COVID-19 Questions
Bob:
Thanks for the note. I hope that all is well with you. Use an N95 if you have them available.
Transmission is similar to influenza: respiratory droplets and likely a bit more as aerosol than
with influenza . People can transmit even when they are asymptomatic . No approved
t herapies; however, we are doing clinical trials on 're-purposed" drugs such as remdesivi r
(Gilead), Vaccine going into phase 1 trial in about 6 weeks, but w ill no t be ready for at least 1.5
years.
Hope that this is helpful.
Best regards,
tony
From: Geller, Robert D. <RGeller@fhn.org>

Sent: Wednesday, February 26, 2020 1:10 PM
-------~~
Subject: COVID-19 Questions
--------- (b)(6J>
Tony
Thanks for everything you are saying and doing. I'm writing to ask for the latest. Thanks Bob.
What about general care of a patient suspected or confirmed COVID-19. N95 or surgical mask? Any
news on how this disease is being transmitted? Anything new on vaccine or treatmen t?
This e-m.ail messageand any attached file(s) is intended for the use of the individualor entity 10 which it is addressed and may contain information that is pri,~legcd
and confidential. If the reader of this message is not the intended recipient or an agent or employee of the intended entity, you are hereby notified that any
dissem i.natio n, d istribution , or copying of this com municati on is strictly prohib ited . If you have received the message in error . please notify th e sen der imm ediately
for instruct ions . Than k yo u.
NIH-001109
Sent : Sun, 1 Mar 2020 11:55:59 +0000
To : Anderson, Jennifer (NIH/NIAID) [El
Subject : FW: Opportunity for a Research Position
Attachment s: (b)(6)
Please take a look and hand le.
From: M. Burhan Majeed Rana <1 (b)(

--------------
Sent : Thursday, February 27, 2020 9:07 AM
To : Fauci, Anthony {NIH/NIAID) [E] ------ ..,.....,..-=
(b)(6)
(b)(6)
------------
Subj ec t :
Dear Dr. Fauci,

(b)(6)
Kindest regards,
Rana, M uhammad Burhan Majeed
NIH-001 110
Sent : Sun, 1 Mar 2020 04:14:20 +0000
To : Winnie Stachelberg
Subject : RE: POSTED:Think ing CAP: Dr. Anthony Fauci: The Global Fight Against HIV/AIDS
W innie:
Thanks for your note .
Best regards,
Tony
From : Winnie Stachelberg <wstachelberg@americanprogress.org>

--------,
.----..-.=
(b)(6)
Subject : RE: POSTED:Thinking CAP: Dr. Anthony Fauci: The Global Fight Against HIV/AIDS
Tony - sending you an email to say thanks for your steady hand at the helm in this current challenge
with Coronavirus . You are such an essential part of our government's response to this public health
challenge .
Please let us know if there's anyth ing we can do at CAP to assist. We plan on hosting an event next week
and I'll send you details as they come togethe r.
Again, thank you .
Winnie
From : Winnie Stachelberg

Sent : Monday, August 19, 2019 10:42 AM
Toi (b)(6)
Subject : FW: POSTED:Thinking CAP: Dr. Anthony Fauci: The Global Fight Against HIV/AIDS
Tony -
Thank you so much for participating in CAP's podcast, Thinking CAPearlier t his month . We think the
interview turned out very we ll and hope you think so, too .
Have a good rest of the month and Labor Day and I hope our paths cross again soon - either in the
neighborhood or at work.
Winnie
From : Steve Bonitatibus <sbonitat ibus@americanprogress.org >

Se nt : Thursday, August 15, 2019 11:21 AM
To: Posted Products <postedproducts@ame ricanp rogress.org>
Cc: Kyle Epstein <kepstein@am er icanp rogress.org >; Chris Ford <cford@ame ricanprogress.org>; Daniella
NIH-001111
Leger <dleger@americanprogress.org >
Subject: POSTED:Thinking CAP: Dr. Anthony Fauci: The Global Fight Against HIV/AIDS
Daniella sits down with renowned immunologist Dr. Anthony Fauci to discuss how the United
States has and can continue to combat the HIV/ AIDS epidemic, both domesticall y and abroad.
https://www.americanprog ress .org/issues/hea lthcare/news/20 19/08 /15/473666/ dr-anthony-

fauci-global-fight-hiva ids/
For decades , the HIV/AIDS epidemic has been among the most challenging global
health issues to contain. Enter Dr. Anthony Fauci , immunologist and director of the
National Institute of Allergy and Infectious Diseases at the National Institutes of Health.
As one of the foremost experts and advocates against the HIV/AIDS epidemic , Dr.
Fauci exuded optimism when talking about the progress being made in both global and
domestic containment of the disease. He sat down with Daniella for an interview to
discuss his work fighting HIV/AIDS and to share his thoughts on the growing , dangerous
anti-vaccination movement.
Learn more about the podcast here.
Daniella Gibbs Leger is the executive vice president for Communications and
Strategy at the Center for American Progress. Ed Chung is the vice president for
Criminal Justice Reform at the Center. Kyle Epstein is the media relations
manager at the Center . Chris Ford is the broadcast coordinator at the Center.
NIH-001112
Sent : Sun, 1 Mar 2020 04:13 :25 +0000
To: Howard Schatz
Subject : RE:Commiserating
Howard:
Many thanks for your note. Much appreciated.
Best regards,
Tony
From:Howard Schatz
-------------
------~~
(b)(6J>
CbH6J>
Subject : Commiserating
--------
Tony,
Watching the spread of the Coronavirus worldwide(?), I can't help but feel for you, as well as the world's
population .
It must be both challenging as well frustrating to be unable to control every important "leak" and then
watching the consequences.
I wou ld think it's also sort of exciting, while also being horrib le, given this is what you've trained for
most of your professiona l life.
And, I would think that most of your other important works need to be put on hold?
Wishing you (and all of us) the best of luck,
Howard
NIH-001 113
Sent: Sun, 1 Mar 2020 04:02:52 +0000
To: David Folkenflik
Subject : RE:Following up
I have never been inhibited from interacting with the press.
-----Original Message -----

From: David Folkenflik <DFolkenflik@npr.org >
------~~
To: Fauci , Anthony (NIH/NIAID) [E]...______ Cb
_)_C
_.
6l
Subject: Following up
Dr Fauci - Tcover media and flow ofinfomiation to public for NPR and am also a host. (You and I once spoke years
ago when T covered Johns Hopkins over a science research issue.)
You told a colleague the report you couldn't comment on Corona virus was taken out of context. In what way?
Tbankyou -
D
David Folkenflik
Host and Editor, NPR's On Point
Media Correspondent, NPR News
11 W 42nd St
19th Floor
New York NY 10036
o) 212.880 .3438
m) (b)(
e) dfolkenflik@npr.org
Sent from my iPhone
NIH-001 114
Sent: Sun, 1 Mar 2020 04:01 :29 +0000
To: Andrew Cvon Eschenbach
Subject : RE: Question
Andy:
Thanks for the note. l am sure that the Chinese are looking at this, but I have not seen any data in th.is regard,
will try to find out if anyone is looking at th.is in the USA patients.
Best regards,
Tony
From: Andrew C von Eschenbach__________ (b_~_(6)
_,
To: Fauci, Anthony NTH/NIAID) [E]______------~~ (b_H_6J>; Fauci, Anthony (NfH/NIAID) [E]
(b)(6) >
Subject: Question
Tony
Does anyone know what the NK cell profile was like in patients who succumbedto Coronavirus? Is there a
difference in imm une profile betwe en mild and severe cases?
Anyone looking at that?
Miss being there at your side in this battle Andy PS Thank you and your team for guiding the Celularity team to get
it right. Also you have as always, my utmo st respect for being the "good and faithful servant''
Andrew C. von Eschenbach MD

Samaritan Health Init iati ves
NIH-001 115
Sent: Sun, 1 Mar 2020 03:57 :44 +0000
To : Strauss, Eric M.
Subject : RE:500k dead? (Background)
That number seems exceptionally high.
From: Strauss, Eric M . <Eric.M .Strauss@abc .com>

Se nt : Friday, February 28, 2020 10:34 AM
To: Fauci, Anthony {NIH/NIAID) [E] ------~~ (b)(6)
Subject: SO0k dead? {Background)
Hello Dr Fauci: Hope you're holding up well. Remember to rest and hydrate!
We had a DHS person tell us epidemiology models for US show worst case scenario 98m get COVID-19
and S0Ok dead .
I've seen models all over the board. And Dr Jen and I are keeping our coverage on point on what we
know and what we don't know .
If that a possible number for our plann ing? Or is that outlandish?
Thx.
- EMS
EricM. Strauss,ABCNews
(b)(6)
@ericM strauss
NIH-001 116
Sent : Sun, 1 Mar 2020 03:49:57 +0000
Subject : FW: coronavirus
Please take a look and hand le. Thanks.
From: William H. Sherman, MD (b)(6)

------------
Se nt: Friday, February 28, 2020 11:11 AM
To: Fauci, Anthony (NIH/NIAID) [E]-------= (b-c-
)(c-=
6)
Subject : coronavirus
William H. Sherman M.D.

(b)(6)
Anthony Fauci, M.D.

(b)(6)
Dear Dr. Fauci:
I reviewed the publications about the last 2 coronavirus infections. Both MERSand SARSwere severe,
short lived problems that have not recurred. One would expect Covir-19 to follow a simi lar path : infect
a wide group of susceptible people and then disappear, If that is so, anything that is more than six
months away may not be of value-remdisivir or a vaccine. Even if remdisivir works, it will take months
to produce sufficient amounts to treat this illness.
Has ribavirin been assessed for an ability to slow down the replication of this virus? We do not need to
eradicate the virus. Just slowing down the rate of symptoms progression would allow time for the
immune system to mount a curative response.
Ribivirin is the only approved anti-viral that may have shown some clinical benefit against similar
coronavirus infections, but the reports are anecdotal and the benefit short term . It was only
administered to a few patients who were already on respirator support, and most still died. If their lungs
were already destroyed, eliminating the virus would not change the outcome. There were no studies of
treating mild illnesses before they progressed to needing respirator support. If the 50 year old
coronavirus patient described in the Lancet had been treated in first week of symptoms, before needing
respiratory support, he may have survived . On autopsy, most of his lung had been destroyed .
If ribavirin has even marginal benefit, decreasing hospitalization by 10% yields an enormous savings. I do
not have accessto the data on this virus and the possible effects of the antivirals that have been
evaluated. However, ribavirin has any effect on viral pro liferation, we can write and a randomized trial
of ribav irin (b) (4)
(b) (4)
NIH-001 120
I look forward to hearing from you about the data on ribavirin against this virus and your thought on this
clinical study.
Sincerely,
William H. Sherman , M.D.
NIH-001121
Sent : Sun, 1 Mar 2020 03:49:28 +0000
Subject: FW: The Aspen Institute event today
Let us discuss.
From : Sabrina Ma lhi <smalhi@thehill .com>

To: Fauci, Anthony (NIH/NIAID) [E] ------
-------- -=~ (b)( 6J>
Subject : Re: The Aspen Institute event today
Hi Or. Fauci,
The whole country is in a panic, could you write on beha lf of the NIH regarding the coronavirus, please?
Your vo ice is very impor ta nt on this topic .
Thanks,
Sabrina
On Tue, Feb 11, 2020 at 7:12 PM Fauci, Anthony (NIH/NIAID) [El C > wrote:
-------- (b)
Sabrina:
Many thanks. It was nice to meet you today. I certainly will keep your offer
in mind .
Best rega rds ,
Tony
Director
Building 31, Room 7A -03
Phone (b) (6)
FAX: (301) 496-4409
E-mail :
-------- (b)( 6)
sensitive information . It should not be used by anyone who is not the original intended
recipient. If you have received this e-mail in error please inform the sender and delete it from
your mailbox or any other storage devices . The National Institute of Allergy and Infec tious
Diseases (NIAID) shall not accept liability for any statements made that are the sender 's own
and not expressly made on behalf of the NIAID by one of its representatives .
From: Sabrina Malhi <smalhi @t hehi ll.com >

Sent: Tuesday, February 11, 2020 2:58 PM
NIH-001122
To: Fauci, Anthony (NIH/NIAID) [E] ~..._____ Cb
_H.....
~>
Subject: RE:The Aspen Institute event today
Hi Or . Fauci,
It was nice meeting you at the event regarding the coronavirus today at The Aspen Institute. Your
expert voice on the virus would be great to have in o ur publication.
As I mentioned, I am an opinion editor at The Hill and one of the areas that I focus on is health care.
Please let me know if you 'd like to discuss some ideas. I loo k forward to hearing from you!
Best,
Sabrina
Best,
SabrinaMalhi Associate Editor IThe Hill
*Please note that my email address is now smalhi@thehi ll.com.
Best,
SabrinaMalhi Associate Editor IThe Hill
*Please note that my email address is now srnalhi@thehill.com.
NIH-001 123
Sent : Sun, 1 Mar 2020 03:24:03 +0000
To: Gallin, John (OD) [El
Cc: (b)(6)
Subject: RE: Coronavirus vaccine center
(b) (5'
From: Gall in, John (OD) [El Cb)( >

To: Lane, Cliff (NIH/NIAID) [El --------(b)(
...=>; Davey, Richard (NIH/NIAID) [El
(b) (6) >
Cc: Fauci, Anthony (NIH/NIAID) [El (b)(6J>
Subjec t : Fwd: Coronavirus vaccine center
Cliff and Rick (and Tony if you have time)
My friend Barry Coller is (b) (4) (see

below). Do you know if there is any need for this?
Thanks.
John
Sent from my iPhone
From : Barry Coller (b)(6)>

To: "Gallin, John (OD) [El" (b)(6)
Cc : Barry Coller
-----------
Subje ct : Coronaviru s vaccin e ce nte r
(b)(6)
John,
I suspect that this is an incredibly busy time for you and the Clinical Center .
Tony was fantastic last night. Please let him know that he is my hero!
(b) (4)
NIH-001 127
(b)(4)
If you know of any organizations or companies that are looking for sites to conduct vaccine
studies, or if you would like us to collaborate with you to get studies completed more
rapidly, please keep us in mind.
I am going crazy writing our
------------ ~=
(bH4J n d .1t Just
. ge t s h ar der.
Best regards to (b) (6)
Barry
NIH-001 128
Sent: Sun, 1 Mar 2020 03:17:42 +0000
Subject: RE: Brookings Invit ation
Let us disc uss.
From:Conrad, Patricia (NIH/NIAID) [E)

Sent: Friday, February 28, 2020 2:26 PM --------- (b)(6)>
To: NIAID OD AM <NIAIDODAM @niaid .nih .gov>

Subject: FW: Brookings Invitation
Patric ia L. Conrad
Public Health Ana ly st and
Special Assista nt to the Director
National Institute of Allergy an d Infectious Diseases
The National Inst itutes of Health
Bethesda , Maryland 20892
(b)(6)
301-496-4409 fax
Disc laime r:
The information in this e-mail and any of its attachme nts is confidential and may contain sens itive info rmation. It should not be used
by anyone who is not the original intended recipient. If you have received this e-ma il in error please inform the sender and delete it
fro m your mailbox or any other storage devices. Nationa l Institu te of Allergy and Infectious Diseases (NIAID) shall not accept
liability for any statement made that are sender"s own and not expressly made on behalf of the NIAID by one of its representatives.
From: John Allen <JAllen@brook ings.edu>

Sent: Friday, February 28, 2020 2:23 PM
To: Fauci, Anthony (NIH/NIAID) [El ------= (bs-.-
H=6)>; Conrad, Patricia {NIH/NIAID) [El
(b)(6)
Cc: Lucy Kim <LKim@brookings.edu>
Subject : Brookings Invitation
Dr. Fauci,
Greetings from the Brookings Instit uti on. I'm writing to share the attached invitation
for you to speak to our Board of Trustees at th eir annual dinner on Thur sday, March 5
here in Washington, DC. The Brookings Board is a distinguished group of business and
community leaders ... I know they would be very eager to hear your thou ghts, especially
on the coronavirus crisis given its spr ead into th e U.S. If thi s date does not work with
NIH-001129
your sch edul e, we'd be glad to welcome you to Brookin gs at a mor e convenient tim e.
I very much appreciate you considering our request, Dr. Fauci!
My very best,
John R. Allen
Pre sid ent
Th e Brookings Institution
NIH-001130
Sent : Sun, 1 Mar 2020 02:58 :01 +0000
To: Hodes, Richard (NIH/N IA) [E]
Cc: Cassetti, Cristina (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [El
Subject: RE:SASPand Coronovirus 19
Richard:
Let me refer the e-mail to Cristina Cassetti who is in charge of the COVID-19 issues in our program. By this e-
mail I will ask her to look into this and get back to Jim Kirkland.
Best regards ,
Tony
Cr istin a :
See my note above to Dr. Hodes.
Thanks,
To ny
From: Hodes, Richard (NIH/NlA) [E]
,__ ______
_ (b)(
-------=-::-=,
To: Fauci, Anthony (NIH/NIAlD) [El ______ _>
Cb
_<_·
Subject: FW : SASP and Coronovirus 19
m Tony,
Please f~e me for intrudjwu>~our oven¥he lmin g_OJiorities. If ou have a moment to read the emai l below
(b) (4)
""
B-e-st______________________ _
(b) (4) Thanks for any suggestions.
Richard
From: Kirkland, James L., M.D., Ph.D.
Sent: Saturday, February 29, 2020 8_:5
_8_P----------
_M_____ ~~
(b)(
To: Hodes , Richard (NI H/NIA) [E]

Cc: Sierr a, Felipe (NlH/NIA) [E]
Subject: SASP and Coronovirus 19 -------
Dear Richard ,
1 am sorry to bother you late on a Saturday, but I wanted to let you know that we are finding in as yet unpublished
(b) (4)
NIH-001133
(b) (4)
Jim
Sent from my iPad
NIH-001 134
Sent: Sun, 1 Mar 2020 01:27:44 +0000
To: Barton Haynes,M.D.
Subject : RE:
Than.ks, Bart.
Director
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b)(6)
From : B arton Haynes , M.D. (b)(6)
Sent: Saturday , February 29 , 2020 8:25 PM
To: Fauci , Anthony (NlH/NlAID) [E] --------=
Subject: RE: --------- (b)(
Great job in the press conference today.
Tough and high pressure situations it seems .
Thanks for being there and representing truth and scie nce ... best b

From: Fauci , Anthony (NTH/NIAID) [E] (b)(6) >
Sent : Saturday, February 29, 2020 7: 14 PM
To: Barton Hay nes, M.D. (b)( ; Marovich, Mary (NlH/NIAID) [E]
_______ Cb _ > ; Dieffenbach, Carl (NlH/NWD) [E) <
_~_(6) (b) (6) >
Subject: RE:
Impressive!
Director
National Institu te of Allergy and Infectious Diseases Building 31, Room 7A-03
Phone : (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It
NIH-001 135
should not be used by anyone who is not the original intended recip ient. If you have received this e-mail in error
Allergy and Infectious Diseases (NI AID) shall not accept liability for any statements made that are the sender's own
and not express ly made on behalf of the NIA TDby one of its representatives.

From: Barton Haynes , M.D. (b)(
Sent: Saturday, February 29, 2020 2:29_ P_M_____ ~~
To: Fauci , Anthon (NIH/NIAJD) [E]
----------
Subject: FW:
(b) (6) ; Dieffenbach , Carl (NII-1/NIAID) [E]__________
(b)( ; Marovich, Mai
--------------=-:=i
__,,
Hi Tony, Mary and Carl:
Every Saturday am, the DHVI team meets in my office to work on moving the HIV vaccine work forward, and now
a new contingent is also working on coronavirus vaccine and new therapeutics.
This picture was from 9 am this Saturday morning. Great and dedicated crew listening to the presentation of data!
Best bart
From : Barton Haynes , M.D.
Sent: Saturday , Febrnary 29, 2020 2:25 PM
To: (b)(6)
Subject:
NIH-001 136
Sent : Sun, 1 Mar 2020 01:09:29 +0000
To : Routh, Jennifer (NIH/NIAID) [E]
Subject : RE: Clips
Thanks.
Director
Phone: (b) (6)
FAX: (30 I) 496-4409
E-mail:
-------- (b)(6)
The inform ation in this e-ma il and any of its attachments is confiden tial and may contain sensitive infom1ation. It
Allergy and Infectious Diseases (NIA ID) shall not accept liability for any stateme nts mad e that are the sender's own
From: Routh, Jennifer (NIH/NIAID) (E] (b) (
Sent: Saturday , February 29, 2020 10:32 AM
------~-~
Cc: Billet, Courtney (NlH/NlAID) [E] (b)(6) ; Stover , Kathy (NTH/NIAID) [E]
______ ..,.H6) >; Folkers, Greg (NIB/NI AID) [E]
Cb (b)(6) ; Conrad , Patricia
(NTH/NlAID) [E] Cb)(6)1>
Subject: RE: Clips
Dr. Fauci - the clips l've been able to pu ll so far are listed below:
Hardball (MSNBC last night) : http s://www .msnbc.co m/ hard bal l/ watc h/ dr-anthony -fauci-i-m-not-being-muzzled-
7965037375 6?c id=sm npd ms tw hb
Lou Dobbs (Fox Business last night) : https ://tw itte r.com/Lo uDobbs /stat us/ 1233555383 J9050752 0
Today (NBC this morning ): https:// www .today .com/v ideo/ drfauci -on-coronavi rus- fcars-no-nccd-to-changc -
lifesty le-yet-7968 4677 6 16
Thanks,
Jen
.Jennifer Routh [E]

News and Science Writ ing Branch
O ffice of Communications and Government Re lations National Institute of Allergy and Infectio us Diseases (NIAJD)
NIH/HHS
31 Center Dri ve Room 7Al 7C
Bethesda, Jv(D 20892
Direct: (b) (6)
(b)(6)
Disclaimer: The information in this e-mai l and any of its attachments is confidential and may contain sensitive
NIH-001141
information. It should not be used by anyone who is not the original intended recipient. If you have received this e-
mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National
l nstitute of Allergy and Infectio us Diseases shall not accept liability for any statem ents made that are sender's own
and not express ly made on behalf of the NIA TDby one of its representatives.

From: Fa uci , Anthony (NIH/NJATD) [E] ______ Cb
_)_(6J
_,>
Sent: Saturday, February 29, 2020 8:42 AM
To: Routh, Jennifer (NIH/NlAI D ) [E] ...--------, (b
.-,)""'
(=
Subject: Clips
Jen:
This AM I did NBC Today and MSNBC. Please make sure that I get the clips.
Thanks
Tony
NIH-001 142
Sent : Sun, 1 Mar 2020 01:05:03 +0000
To: Holland, Steven (NIH/NIAID) [E]
Subject : RE: Human lung m ice
Lease the decision up to HHS.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Holland, Steven (NIH/NIAID) [El

---------
To :
(b)(6)
(b)(6) Fauci, Anthony (NIH/N IAID) [E]

-..!:=====::;: (b-=
)('="=
6):--------------
Subject : Re: Human lung mice
(b)(5)
Steve
Director, Division of Intramural Research

Bldg. 10/11N248 MSC 1960
-------- (b)(6)voice
301-480 -4507 fax
----- Cb)(6) email
Assistant lab:
NIH-001143
Assistan t to SD: ~~
(b) (C>
f
From: ' (b)(6)

------------------------
Date: Saturday, February 29, 2020 at 10:55 AM
To: Anthony Fauci Cb)( >, Steven Holland
Subject: Human lung mice
---------- (b)(6)
Hi Ton and Steve I thoug ht I'd bette r fil l ou in on some recent communications. Dr.
(b) (5)
(b)
(GI
NIH-001 144
Sent : Sun, 1 Mar 2020 00:55:28 +0000
To : (b)(6)
Subject : RE: in case you need to hear it
Mi chael :
Thanks fo r t he note. I hope that all is we ll w it h yo u.
Best rega rds,
Tony
Director
Bethesda MD 20892-2520
Phone : (b)(6)
FAX: (301 496-4409
E-mail Cb)(6)
The information in this e-mail and any of its attachments is confidential and may conta in sensitive
other storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) sha ll not
accept liability for any statements made t hat are the sender's own and not expressly made on
From: Michael Specter (b)(6)

Sent : Saturday, February 29, 2020 12:39 PM
------ --.~
Subject : in case you need to hear it-------- CbH >
You are one of my very few heroes.

And in case you have not seen it, here is my personal love letter to the president (in which you feature
semi prominent ly)
https://www .newyo rker.com/news/da ily-comment/donald -trumps -ant i-globa list-response -to -a-global-
coronav irus
Michael Specter
Staff Writer
The New Yorker
Adjunct Professor of Bioengineering
Stanford University
(b)(6)
Phone: (Work, Cell, SMS) (b)(6)
------
NIH-001 145
Sent: Sun, 1 Mar 2020 00:53:55 +0000
To: Cassetti, Cristina (NIH/NIAID) [El
Subject : FW: COVID-19
Please take a look and respond. Thanks.
Director
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b)(6)
should not be used by anyone who is not the original intended recip ient. lf you have received this e-mail in e1TOr
Allergy and Infectio us Diseases (NIAID) shall not accept liability for any statements made that are the sender's own
From : Fred Schaich <fred.schaich @ifaratv.org >
Sent: Saturday, February 29 , 2020 12:55 PM
To: Fauci , Anthony (NlH/NlAID) [E] --------=
Subject: COVID-19 --------- (b)( ·
Dear Dr. Fauci,
1'11not be at the CROl this year (b)(6)

So 1hope I may be able to ask
you a few questions as a concerned citizen.
Will we learn:
Why there are new cases in the US of unknown origin?
Could this virus infect carriers who do not present with :.,ymptoms or present in various levels of very mild
infect ion and never get identified as infected?
Could individuals host the virus di fferently due to genet ics or ethnici ty?
ls this virus consistently sim ilar after multip le generation or is it capable of mutating?
Ts the re an ability to develop an antibody immunity through in fect ion? Can one be reinfected?
Could the level of infection be detenn ined by the amount of inoculant?
Could we leam the level of infect ability of this virus by testing everyone in a given geographic area where
there is a deep outbreak? We might also learn about the pathogenesis in a way that we cannot learn otherwise.
If this virus is so transmissible could we end up with almost everyone eventually being infected and present
with various levels of serious acute infection and death to indistinguishable cases or just carriers?
With the clamp /filter on infonnation from this administration, please tell us where we may find regular reports at
va1ious levels of current science on what we learn about this virus and vaccine progress, and where we may ask
question s? I hope there is place for formal and infonna l community input into treatment , care and vaccine
development.
Thank you for all your help over the years with your wise perspective through our interviews and leadership at the
NIH-001 146
NlH in such a reasonableand responsibleway.
Warm regards ,
Fred
Fred Schaich
(b)(6) OR
NIH-001 147
Sent: Sun, 1 Mar 2020 00:27:0 4 +0000
To: Cassetti , Cristina (NIH/NIAID) [E]
Subject: FW: Coronav iru s - New Idea for treatment & clin ical study
Attachments : The Nine Lives of Hydroxychloroquine .docx, Chloroquine & COVID-19
pneumonia.pdf, Remdesivir & Chloroquine Effective lnVitro Against COVID-19.pdf, 6-27-19 (5).jp g
Please take a look and respond to them. Thanks.
Director
Phone : (b)(6)
FAX: (301 ) 496-4409
E-mail : (b)(6l
info rmation. It should not be used by anyone who is not the origi nal intended recipient. If you
From:
----------------
To: vice.president@whitehouse.gov
(b)(6)>
Cc: Fauci, Anthony {NIH/NIAID) (E] ------ ::;..,...,=

(b)(6J>; Redfield, Robert R. (CDC/OD)
____ _ Secretary@HHS.gov
_ >_C6J
Cb
Subject: Coron avirus - New Idea for treatment & clinical study
Importance: High
Dear Vice President Pence,
We are thankful for your leadership of the Wh ite House Coronavirus Task Force in
gathering the latest information about the outbreak, working with doctors and
scientists to find solution s, and communicat ing with t he general publi c regarding
the situation . We were blessed to meet with you back in August, 2019, when ~
had expressed a desire to meet
you . I have attached a picture from our meeting to help you remember . We pray
for you often.
NIH-001152
Since we are both physicians, we have been following the details of the COVID-
19 outbreak closely. My husband was researching the anti-viral drug remdesivir
this morning, and he came across some articles from Chinese studies that
indicated a very well-known drug called hydroxychloroquine {already widely
used for 70 years to treat malaria and rheumatological diseases) had very
potent activity against COVID-19 infection and pneumonia. This was rather
surprising to us, but as we read about the study and the characteristics of
hydroxychloroquine, we realized that this could be a very good drug to use for the
treatment of high-risk patients infected with COVID-19, who might deteriorate
rapidly and progress to hospitalization and need for ICU care. Remdesivir also
seems like an excellent anti-viral drug, but it is given intravenously, and is
probably reserved for COVID-19 patients who are already entering into severe
respiratory distress in the hospital.
Hydroxychloroguine, on the other hand, is given orally, and is cheap and readily
available.
Low doses (6.5 mg/ kg) have been effective in the management of Systemic
Lupus Erythematosus and Rheumatoid Arthritis. 200 mg tablets are usually
prescribed twice a day with meals; dosage can be increased up to the
recommended 6.5 mg/kg if the patient tolerates the lower dose. We wondered if
the low dose hydroxychloroquine would be able to be studied quickly in various
COVID-19 patients, especially those who are older and / or with medical
conditions that put them at higher risk for pneumonia and complications
{cardiovascular disease, chronic pulmonary disease, hypertension, diabetes,
etc.). In addition, hydroxychloroquine may even be a useful drug to prevent the
development of pneumonia in patients diagnosed with COVID-19.
Because hydroxychloroquine in an older drug that is generic, current

pharmaceutical companies have no incentive to do studies or research on its
effectiveness for any new medical conditions. Therefore, the federal
government would most likely have to construct and fund the studies. Perhaps
Dr. Fauci has already considered this kind of study with hydroxychloroquine.
We understand that vaccines are already being studied, and Israel is working on
an oral (pill) vaccine. Vaccines take time to go through testing and trials, which is
why we are suggesting to you that studies be done on hydroxychloroquine, a
readily-available oral drug that could "bridge the gap" to provide some potential
NIH-001153
treatment and mitigation of the COVID-19 infections while vaccines are being
developed and mass produced.
We have attached several articles, which are electronic publications made

available in advance (Feb. 4 th & Feb 19th , 2020) of the printed journal
publications . We wi ll send a copy of this emai l to Dr. Fauci, Dr. Redfield, and Dr.
Azar.
Sincerely yours ,
Drs. Paul & Karyl Stanton
(b)( 6)
NIH-001154
Sent : Sun, 1 Mar 2020 00:14:14 +0000
Subject : FW: One solution in the armoury to protect Health Care Sector Workers against
Covid-19
Please handle . Thanks.
Director
Phone : (b) (6)
FAX : (301 496-4409
E-mail : (b)(6)
From: (b)(6)
-------------------------
------~~ =
--------- (b)(6)>
Subject : One solut ion in the armoury to protect Health Care Sector Workers against Covid-19
Dear Dr Fauci
A PPE device, tested and proven at Public Health England Porton Down (PHE), based on innovative
technology could be ready to go into production within 20 weeks. It sterilises all airborne pathogens as
air is inhaled by the wearer. See www .medi-immun e.com and in part icular the published report on the
tests, by clicking on the report under "The Science" The device is due to undergo further tests, at PHE
within the next week, specifically against Covid-19. For verification please contact Professor Nigel
Silman at PHEPorton Down.
Health Services around the world are doing wha t they can to prepare for a significant increase in
infections from this highly transmissible virus and if those people in the Health Care Sectors are infected
the situation could become untenable.
The production of vaccines is under way but no one expects them to be available within the next 12 to
18 months. The Medi-Immune "Protect ivAir ®", which has been under development for some years and
could be available within a few mo nths, will give a far greater level of protection than the current masks
and respirators and more importantly can remain in use in the future for other emerg ing airborne
pathogens - known, unknown or mutating .
NIH-001 155
Please take a little time to investigate this option, via the website, or pass it on to those who you believe
need to be made aware of it. I will be happy to answer any questions, technical or otherwise, at my
emai l address below or on my mobile num ber, also below.
Kind regards
James Love
James Love
Director
m: (b)(6)
t:
www .med i-immune .com
www .revaxb iotech .com
MEDI-IMMUNE
Groundbreaking Protec tion & Immunity
Medi-Imm une Limited , registered in Eng land and Wales I Company reg istrat ion No: 04554706 1Registered Office : 4 Lady Bank I
Tamworth Staffo rdshire I B79 7NB I UK
DISCLA IMER: Privileged/COnfidential informat ion and/or Copyright Material may be contained in this email. The informat ion and
materia l is intended for the use of the addressee(s ) only . If you are not the addressee or the person responsible for del ivering it to
the intended addressee(s) , you may not copy or deliver it to anyone else or use it in any unaut horised manne r. To do so is
prohibited and may be unlawful. If you rece ive this ema il by mistake, advise the sender immediate ly by using the reply facility in your
emai l softwa re. Any views or opin ions presented are solely those of the author and do not necessarily represent those of Medi-
Immune Lid . Although this email and attachments are believed to be free of any virus or other defects wh ich might affect any
computer or IT systems into which they are received, no responsibility is accepted by Medi- Immune Ltd for any loss of damage
arising in any way from the receipt or use thereof .
NIH-001156
Sent : Sun, 1 Mar 2020 00:12:45 +0000
Subject: FW: A sharing on COVID ARDS research
Attachments : Dexa_ARDS_COVID-19 for Dr. Tugwell.doc, Tsai 2020_Ann of Intensive
Care_ARDS_corticosteroid .pdf
Please take a look at this and handle. Thanks.
Director
Phone : (b)(6)
FAX : (301 ) 496-4409
E-mail : (b)(6)
---------
From: Paul Elias Alexander
(b) (6)>
------
--------
::;.,...,=
(b)(6J>
Subject: A sharing on COVID ARDS research
Hi Dr. Fauci, I am a trained epidemiologist and expert in evidence based medicine. Particularly
in developing clinical practice guidelines and I teach EBM and GRADE methods.
You have no idea how much 1 have ad.mired you across the year s, yoW' intelligence and poise.
May I ask how I may help you in this matter, this response, I am not talking about money, 1 wish
to help, volunteer.
I draw your attention to 2 attachments...
1) one is a one page 1 wrote to summarize a meta analysis my team just completed and seeking to
publish. It pertains to corticosteroids and ARDS. We are raising that this suggests indirect
evidence that we may be able to extrapolate to the COVID patient with severe illness. This
within the life threatening issue and emergency and no effective treatment. I share if this can
NIH-001 157
help you as I know you are leading this and listened to you today with the president. I support
th is p resident fully.
2) I share a paper published today , it on the other hand raises serious questions on the use of
corticosteroids in influenza associated ARDS , and one may argue this patient set, is the closes t to
the COV ID 19 pat ient.
My sense is that the accumulated evidence thus far is weak and argues against corticosteroids.
For example, this recently published multicenter retrospective cohort study in medical center
ICUs across Ta iwan sought to assess the effect iveness of cort icostero ids in patients presenting
w ith influenza-associated ARDS (viro logy -proven ARDS and are on mechanical vent ilation).
Researchers examined the impact of early corticosteroid treatment (2:200 mg hydrocortisone
equivalent dose within 3 days after ICU admission , determined by a sensitivity analysis) on
subseque nt hosp ita l mortality. The study revea led that of the 241 pat ients with in fluenza-
associated ARDS , those rece iving early cort icostero id had a sign ificantly highe r hosp ital
mortality rate than those who did not get early corticos teroid [43.5% (37/85) vs. 19.2% (30/ 156),
p < 0.001 ). Early corticosteroid treatment was independently associated with increased hospital
morta lity in overall patients [an adjus ted OR of 5.02 (95% CI 2 .39- 10 .54), p < 0 .001) and in all
examined subgroups . Researchers found that a higher dose and earli er treatment was linked to
higher hospital mortality. Moreover, they found that earlier trea tment was related to a
significantly increased odds of subsequent bacteremia [an adjusted OR of 2.37 (95% CI 1.01-
5.56)]. These resu lts underscore the urge ncy for robust comparat ive randomized researc h given
th is study is based on weake r observat iona l evidence that is confounded by select ion bias and
confounded. However this was a stronger study that used statistical adjustment and propensity
score matching. Thus this study suggests caution with corticosteroid and thus the importance for
caut ion by clin icians as to the potential harms of cort icosteroids in th is po pulat ion . These results ,
whil e based on weake r methodology , have revea led large estimates of effect, is the stro ngest
evidence to date on treatment for ARDS , and brings us closest to the COVID- 19 ARDS patient.
Best,
Paul E. Alexander, MSc , MHSc, PhD

Assistant Professor
http://hei .mcmas ter .ca/
McMaster University, 1280 Main Street W,
Hamilton, ON L8S 4KI
GUIDE Research Methods Group
http://guidecanad a.org/
NIH-001158
Sent: Sat, 29 Feb 2020 23:56:39 +0000
To : Les Gardonyi
Subject: RE: Suggestion
Leslie:
Thank you for your note . We are actually looking into the effect of ACE
inhibitors on the coronavirus.
Best regards ,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail (b)(6)
From : Les Gardonyi (b)(6)>

------~~
To: Fauci, Anthony (NIH/NIAID) [E)______ Cb
_)_C6)
_>
Subject : Suggestion
Dear Mr. Fauci,
This may be way too presumptive of a note ...

As an engineer I've always liked to und erstand the mechan ics of how things work so I looked into
educating myself about the coronavirus and it's mechanics. (b)(6)
I've correlated a possible research route for your organization regarding the
prevent ion aspect.
A quick overlook on this strategy is the follow ing:
Coronaviruses are RNA virnses that typically enter human cells when their glycoproteins bind
proteins on the cell surface. In the case of the virus that cau ses SARS , that human pro tein is
angiotensin-converting enzyme 2 (ACE2). A t this time , scientists think the novel coronavirns is
similar enough to SARS that its entry point is likely ACE2 as well.
NIH-001 159
source: h ttps: // cen. acs. org/b io Iogical -chemis try/infectio us-disease /novel -corona virus -hi ts-
Chin a/98/web /2020 /0 l
Irbesartan is used to treat high blood pressure (hypertens ion) and to help protect the kidneys from
damage due to diabetes . Lowering hig h blood pressure helps prevent strokes, heart attacks ,
and kidney problems . Irb esartan belongs to a class of drugs called angiotensin receptor blockers
(ARBs). It works by relaxing bloo d vesse ls so that blood can flow more easily.
source: https ://www .webmd.com / drugs /2/drug-4720 /irbesartan -oral/ details
Idea:
Can Irbesartan, being an angiotensin receptor blocker , possib ly help prevent Coronavirus infections ...
since the Coronavirus entry to humans is via ACE-2?
I share this suggestion with you in the hopes that it may help your department in the research to
prevent the spread of the coronavirus ... or to a presumptuous email slated for deletion .
Sincerely,
-Leslie Gardonyi
NIH-001160
Sent: Sat, 29 Feb 2020 23:54:27 +0000
To : Ellen Butler
Subject: RE: (b) (6)
Ellen:
(b)(6)
Thank you for your kind note. Very nice family pictures!
----- but in any event, thanks for the note.

Best regards ,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b) (6)
The information in this e-ma il and any of its attachments is confidential and may c ontain sensit ive
From: Ellen Butler (b) (6)

------~~
Subject: (b) (6)
-------- (b)(6)
I just watched you this afternoon at the press conference. Over the years I have seen
you and wondered along with family members if (b)(6l
Also I just wanted to say how professional you are and that I don't believe what #45 or
his administration have to say regarding the coronavirus but have 100% confidence in
what you say and do. Thank you for being the adult in the room.
I am very proud of you .

---------- (b)(6)
Sincerely,
Ellen Butler
NIH-001161
Sent: Sat, 29 Feb 2020 23:44:17 +0000
To: Margaret Liu
Subject: RE: kudos and comment about JAMA Coronavirus article
Margaret:
Thanks for the note. You make a valid point and I appreciate what you are
saying. . On that issue, I have been vocal about making sure that we do not
stigmatize Chinese people here in the USA or anywhere in relationship to the
COVI0-19 outbreak.
Best regards ,
Tony
Director
Phone : (b)(6)
FAX: (301) 496-4409
E-mail : (b) (6)
From: Margaret Liu <liu@protherimmune.com>

To: Fauci, Anthony (NIH/NIAID) [E)r------ --..(b.._..
)=
c >; Marston, Hilary (NIH/N IAID) [E]
(b)(6)>
Cc: Alice Huang <stephen.lin@80-20ef.org>; president@80-20.us
Subject: kudos and comment about JAMA Coronavirus article
Dear Tony,
Wonderful articles in JAMA and NE JM. So glad you are still heading NIAID - it is comforting that there
are experts of your caliber still in the room. And thrilled that the NIAID has done so much to develop
rapid timelines for DNA vaccines and that you highlighted that progress in the article, since people call me
the "Mother of DNA vaccines,".
As a former NIAID Council member, I felt I should wr ite to raise an issue that I am sensitized to as a
scientist who is ethnically Chinese wh ile American:
Why in the JAMA article was it necessary to state that the first travel-related case to the US was a
Chinese man (italics mine) w ho had visited Wuhan. Did his being Chinese either ethnically or by
citizenship affect anything biologically?
NIH-001162
I ask because not only have many Asian people now encountered increased racism in public places
(due to fear that any Asian person is a source of COVID-19), but now that the President is turning this
epidemic into additional fear-mongering about "borders" it seems all the more important that scientists do
not inadvertently add to "xenophobia" (even though non-white skin does not mean a person is foreign)
and do not seem to advance any political perspective.
Sincerely and with best personal regards,

Margaret
Margaret A. Liu, MD, DSchc, MDhc, FISV

ProTherlmmune &
Foreign Adjunct Professor, Karolinska Institute
Stockholm, Sweden
Adjunct Full Professor , UCSF
San Francisco, CA USA
President Emeritus, International Society for Vaccines
Liu@ProTherimmune.com
NIH-001163
Sent : Sat, 29 Feb 2020 23:40:04 +0000
To: Tom Leopold
Cc: Cassetti, Cristina (NIH/NIAID) [E]
Subjec t: RE:? Al TERNATIVE/SUPPLEMENTALrx for COVID-19: Angiotensin Receptor
Blockers
l have received this message and we are in fact looking into this.
Director
Buildio g 31, Room 7 A-03
31 Ce nter Driv e, MSC 2520
Bet hesda , MD 20892 -2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b)(6)
should not be used by anyone who is not the original intended recipie nt. If you have received this e-mail in eITor
please inform the sen der and delete it from your mailbox or any other storage devices. The National Institute of
Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own
and not express ly made on behalf of the NIALD by one of its representatives.
From : Tom Leopold ----~~= (b) (6)
Sent : Saturday, February 29 , 2020 4:24 PM
To: Fauci , Anthony (NlH/NlAlD) [E] -------~~(b) (
Subject: ? ALTERNATIVE /SUPPL EMEN TAL rx for COVID - 19: Angiotensin Receptor Blockers
Much appreciation for all of your wo rk past and pre sent. I am a cardio logist in New Jersey and whe n I read that the
virus attache s to the AT2 receptors in the lungs 1 couldn 't help but think that maybe the class of ARB 's that we use
so frequently for HTN and heart failure management could possibly block entry of virus into cell s and prevent or
mit igate the severity of infection. Has this approach ever been stud ied and is it wo11h looking into? lma gine if ARBs
could lessen the severity of infection how 1eadily available and relatively inexpensive this class of medication is!
Would appreciate if someone could get back to infonn me whether you recei ved th is message. Thanks . Dr Thomas
Leopold Ema il: (b)(6)
Sent from my iPhone
NIH-001 164
Sent: Sat, 29 Feb 2020 23:34:59 +0000
To: Tom Leopold
Subject : RE:Angiotensin Receptor Blockers: a possible therapy for Covid-19
Than.ksfor the note. We are looking into this possibility.
Director
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b)(6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive infom1ation. It
should not be used by anyone who is not the original intended recipient. lf you have received this e-mail in e1TOr
.,...---- -:.,._.-,. --,
From : Tom Leopold (b) (
Sent: Saturday, February 29 , 2020 5:01 PM
To: Fauci, Anthony (NlH/NlAID) [E] --------= (b)( ·
Subject: Angiotensin Receptor Blockers: a possible therapy for Covid- l 9
Much appreciation for all of your work past and present. I am a cardiologist in New Jersey and when I read that the
virus attaches to the AT2 receptors in the lungs I couldn't help but think that maybe the class of ARB's that we use
so frequently for HTN and heart failure management could possibly block entry of virus into cells and prevent or
mitigate the severity of infection. Has this approach ever been studied and is it wo11hlooking into? Imagine if ARBs
could lessen the severity of infoction how 1eadilyavailable and relatively inexpensive this class of medication is!
Would appreciate if someone could get back to infonn me whether you received this message. Thanks. Dr Thomas
Leopold Email: (b)(6)
Sent from my iPhone
NIH-001 165
Sent : Sat, 29 Feb 2020 23:29:47 +0000
To : Richard Goodman
Subject : RE:Coronavirus question
Richard:
There are no CDC-issued trave l restrict ions w it hin the USA. The CDC made thi s
clear at t he W hit e House press conf erence t his aft ernoon .
Best regards,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Richard Goodman <goodmanr@ohsu .edu>

-------=-,-=,
Subject : Coronavirus question -------- (b)(6)
We met many years ago, Tony,

... at an event marking Shelly Wolff's 10 year anniversary at New England Medica l Center. (I had the
distinction of being the first medical intern in that program who he reamed out.)
My question relates to travel restrictions . The current restr ict ions appear to be quite lim ited, but several
organizations, including Google, Amazon, and the HHMI have restricted, or cancelled, even domestic
meet ings. As a result of the HHMI cancelation, my own program director indicated his intention to
cancel our upcoming Scientific Advisory meeting and, in the non-academic world, (b)(6)
(which is ironic since there are
more coronavirus infections in my town of (b)(6)Oregon than there are in all of New York).
In addition to announcing the new travel restrictions, could you also say something publicly about what
doesn't need to be restricted? In part icular, is domestic travel OK, or not? Does the HHMI know
something the rest of us don't?
Sincerely,
Richard Goodman MD PhD
NIH-001 166
Vollum Institute
Oregon Health & Science University
Sent from my iPad
NIH-001167
Sent : Sat, 29 Feb 2020 23:06:38 +0000
Subject : FW: Rapid Collaborat ion for Hand & Nasal Decontamination Formulation
Attachment s: NORS-viral review_ V3.pdf, 1998 Reiss NO plays a role in viral infections .pdf,
2005 Akerstrom NO inhibits Corona Viral replication.pdf, 2010 Jung Nitric & SARScorona virus.pdf , 2013
Regev Nitric reduces viral infectivity.pdf, 2015Regev Nitric cattle vs antibiotics BRD.pdf
Director
Phone : (b) (6)
FAX: (301 496-4409
E-mail : (b)(6)
accept liability for any statements made that are the sender 's own and n ot expressly made on
From: Gilly Regev (b)(

Se nt: Saturday, February 29, 2020 5:50 PM
To : Fauci, Anthony {NIH/NIAID) [E] --------, .....,....,=
(b)(6)
Cc: Chris Miller (b)(
Subject : Fwd: Rapid Collaboration for Hand & Nasal Decontamination Formulation
Dear Dr Fauci,
Dr Murad sits on our BOD and has suggested t hat we contact you to help expedite a rapid testing of our
product on the COVID-19 virus. I know you are probably overwhelmed but hope you might pass this
along or suggest a strategy that would be a win-win for us all.
We have developed a non-alcohol based formulation that utilizes the nanomolecule nitric oxide (NO). as
you know, NO is produced in our body and is our first line of defense against microbes . We have
harnessed this in a patented formulation called nitric oxide releasing solution/gel (NORGS).We are
focused on the development of products for chronic sinusitis, diabetic foot wounds, warts and toenail
fungus.
However, internally & personally, we have been using NORGSas an extremely effective natural hand
sanitizer and nasal spray to protect ourselves from the common cold and flu for years.
There are strong independen t published research that NO is antiviral against Corona viral species. We
hae data showing definite virucidal characteristics and moderate antiviral effects in host cells.
NIH-001 168
With the recent concern w ith COVID-19, we felt we should try to rapidly test the hand rub and nasal
spray against the COVID-19 but need to collaborate with a laboratory that could test this fo r us. Funding
collaborators are welcome too, as this was not in our budget but we feel a social responsibility to move
this forward .
I have included a short white paper of our data and a few articles to support our claims .
Feel free to contact me any time (b)(6) ) or have one of your senior staff contact me.
Sincerely,
Chris Miller and Gilly Regev
Gilly Regev, Ph.D.
CEO/ Co-founder
SaNOtize Research and Development Corp .
Phone: (b)(6)
emai l-!::====~~ (b)(6)
htt ps://www .linkedin.com / in/gi lly-regev-694b4a16/
http s://www .sanot ize.com
NIH-001 169
From: (b)(6)
Sent: Sat, 29 Feb 2020 06:58:29 -0500
To: Heather DaVia
Subject : Re:Thank You
Joseph and Heathe r:

Many thanks for your kind words. Much appreciated.
Be st rega rds,
Tony
> On Feb 28 , 2020, at 8:45 PM, Heather OaVia

>
---------- (b) (6) > wrote:
> Dear Or. Fauci:

>
> Please accept my personal and heartfelt thanks for your continued efforts to keep the American public informed
concerning the coronavims. While listening to you on the radio or at press conferences , your calm, thoughtful, and
measured words are very comforting and reassuring. Both your caring response and scientific /medica l expertise are
an examp le of the very best in the Federal Government.
>
> Again, thank you for your pub lic service and your efforts to keep us as safe as possible.
>
> Sincerely,
>
> Joseph P. DaVia
> (b)(6)
(b)(6)
NIH-001170
Sent : Sat, 29 Feb 2020 03:15:14 +0000
To : Tabak , Lawrence (NIH/OD) [E)
Cc: Collins, Francis (NIH/OD) [El;Schwetz, Tara (NIH/OD) [El
Subject: RE:OSTP call
Larry :
Than ks you ve ry much.
Tony
From:Tabak, Lawre nce (NIH/OD) [El (b)(6)

----------
Sent: Friday, Februa ry 28, 2020 8:22 PM
To: Fauci, Ant hony (NIH/ NIAID) [E]
-----~~ (b)( >
Cc:Collins, Francis (NIH/OD) [El .;...;.======~ (b"='
)("='
6)-Schwe
-" tz, Tara (NIH/ OD) [El
(b)( >
Subject: OSTP call
Tony,
Tara and I took the call with Kelvin Droegeme ier, France Cordova (NSF), and Paul Dabbar (DOE).
(b) (5)
Please let me know if you need anyt hing else. (Tara -if I left anything out please add).
Larry
NIH-001171
Sent from my iPhone
NIH-001172
From: (b)(6)
Sent: Fri, 28 Feb 2020 19:48:05 -0500
To: Harris, Kara (NIH/NIAID) [E];Haskins,Melinda (NIH/NIAID) [E]
Subject: Fwd: Coronaviruson surfaces
Public inq pls
Sent from my iPhone
Beg in forwarded message:
From: Deborah Greene (b) (6)

Date: February 28, 2020 at 7:38:44 PM EST
To: "Fauci , Anthony (NIH/NlAID ) (E]" <{------ (b-H~6J;>
Subject: Coronavirus on surfaces
Hello Dr Fauci,
I am trying to find out how long the coronav irus can remain infect ious on the
surface of an object handled by someone with the virus.
My concern is with purcha sing items for my jewelry shop that come from China ,
South Korea, and Turkey.
I have no t been able to find anything that addresses this question and hope you can
clarify this for me. Thank you.
Since rely yours,

Deborah Greene
Sent from my iPhone
NIH-001173
Sent: Fri, 28 Feb 2020 23:18:10 +0000
Subject : FW: Corona Virus
At t achment s: US Biotest Letter re COVID-19 Fauci, A.pdf, Coronavirus (b)( 4)
Rationale.pptx, US Biotest Regulatory History o (b)( 4) pdf, US Biotest COVID-19
___ Cb _) References.pdf
_ >_C4
Director
Phone : (b)(6)
FAX: (301 ) 496-4409
E-mail : (b)(
The information in this e-mail and any of its attachments is confidential and may contain sens itive
accept liability for any statements made that are the sender 's own and not express ly made on
From : Samant ha Mauro

-------------
(b)( 6)>
To: Fauci, Anth ony {NIH/NIAID) (E] -------~=

;...,;.._.;.__....:..,.:....:..====-~;;----(b)(6)
Cc: Gere diZerega
-----------
Subject : Corona Virus
Cb
H6J>
Dear Dr. Fauci:

(b)( 4)
NIH-001 174
(b) (4)
Please contact us if we can be of any help in moving t his potential life-support initiative forwa rd .
Sincerely,
NIH-001 175
Gere diZerega MD
Professor
Keck School of Medicine
University of Southern California
And
President and CEO
US Biotest, LLC
San Luis Obispo, CA
(b)(
Kathleen Rodgers PhD

Professor, Depart men t of Pharmacology
College of Medicine
Center for Innovation in Brain Sciences
Associate Director of Translational Neurosciences
University of Arizona
Tucson, AZ
(b)(
NIH-001 176
From: (b)(6)
Sent: Fri, 28 Feb 2020 16:54:13 -0500
Subject: Fwd: Urgent Email/Strategy to attack 2019-nCoV coronavirus
Attachments : Nucleotide_Analogues_as_lnhibitors of SARS-CoVPolymerase_2_28_2020.pdf,
ATT000Ol.htm, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus
(2019-nCoV) in vitro.pdf, ATT00002.htm
Pls handle
Sent from my iPhone
From: Jingyue Ju Cb)C >

Date: February 28, 2020 at 4:46:04 PM ES T
To: "Fauci, Anthony (NIH/NIAID) [E]" --------::-:--:-=
CbH6)~~~
Cc: "Barasch, Kimberly (NIH/NIAID) [C]" CbH6J,

"direc torsincoming @cdc.gov" <directorsincomi ng@cdc.gov> , "Redfie ld, Robert R.
(CDC /OD)" ., "Davis , Mindy (NIH/NIAID) [E]"
Cb)(6)
CbH6), "Eakin, Ann (NIH/NIAID) [E]"
......
-------=-cc-c=CbH6)
---------
"Stemmy, Erik (NIH/NIAI D) [E]" CbH6J>,"Sciotti, Rick
(NIH/N IAID ) [E]" "Schiltz, Helen (NIH/N IAID) [E]"
Cb)C6J
> , "Krafft , Amy (NIH/N IAID) [E]"
CbH6J
(b)(6)
Subject: Re: Urgent Email/Strategy to attack 2019-nCoV coronavirus
Dear Dr. Fauci ,
Following my previous ema il regarding our work on developing strategies to attack

the 2019-nCo V coronavirus, I am attaching in this email our experimental results
demonstrating that 2 nucleotide analogues are inhibitors of the SARS-Co V
polymerase. Since the SARS-Co V polymerase has over 96% similarity to the
polymerase from SARS-Co V-2, we expect that the nucleotide analogues, 2 '-F ,Me-
UTP and 3' -F-dTTP, w ill also inhibit the SARS -CoV -2 polymerase.
At this point, it is imperative that the prodrug forms (one is Sofosbuvir that is FDA
approved for HepC) of these molecules begin immediate in vitro testing with
infected cells (similar to the studies carried out for Remdesivir and chloroquine in
the Cell Research article at the link, https :// www.natu r e.com /articles/s41422-02 0-
0282-0 ; PDF file of the article also attached) followed by animal testing trials
ASAP. Since we do not have access to the SARS-CoV-2 viral strains, we need your
assistance to identify resources at the NIH laboratories to embark on this next step
NIH-001177
invest igation ASAP. We can provide the prodrugs to the labs at NIH that you
identify for carrying out these studi es. In view of the worldwide SARS-Co V-2
emergency , we'd like yom assistance in getting this off the ground ASAP.
(b)(6)
I can be reached any time at
-----
All the best,
Jingyue Ju, Ph .D.

Samuel Ruben-Peter G. Viele Professor of Engineering
Professor of Chemical Engineering and Pharmacology
Director , Cente r for Genome Technology &Biomolecular Engineering
Columbia University
No rthwe st Corner Building , Room lO0OMl
550 West I 20th Street
New York, NY 10027
Phone:
-------- (b)(6)>wrote:
De ar Drs. Fauci and Redfield,
Scientist s in my laboratory at Columbia Un iversity are actively engaged in design

strategies to cope with the new strain of corona virus, 20 l 9-nCo V, which has
caused a global public health emergency. We have embarked on a project ent itled
"Nuc leotide Analogues as Inhibitors of Viral Polymerases". We provide
a summary of this work below.
Coronaviruses such as the newly discovered virus from Wuhan, China, 2019-
nCo V , and th e viruses that cause SARS and MERS, have resulted in regional and
global public health emergencies. Based on our molecular insight that the
hepatitis C virus and the coronavirus use a simil ar viral genome replication
mechanism, we reasoned that the FDA-approved drug EPCLUSA
(Sofosbuvir /Velpa tasvir) for the treatment of hepatitis C will also inhibit the
above coronaviruses, including 2019-nCoV . To develop broad spectrum ant i-viral
agents, we fmther describe a novel strategy to design and synthesize viral
polymerase inhibitor s, by comb ining the ProTide Prodrug approach used in the
development of Sofosbuvir with the use of 3 ' -blockin g groups that we have
previously built into nucleotide analogues that function as polymerase
terminator s.
Please let me know if you would like to receive the full manusc ript.
Thank you very much for your consideration .
NIH-001178
Sincerely,
Jingyue
Jingyue Ju, Ph.D.

Samuel Ruben-Peter G. Viele Professo r of Engineering
Director , Center for Genome Technology &Biomolecular Engineering
Columbia Univers ity
No rthwest Corne r Bui lding, Room l000Ml
Phone:
NIH-001179
Sent : Fri, 28 Feb 2020 21:27:35 +0000
Subj ect : FW: Corona Virus
Attachment s: US Biotest Regulatory History of (b)(4).pdf, US Biotest COVID-19
---- (b)(4) References .pdf , US Biotest Letter re COVID-19 Fauci, A.pdf
Please t ake a look and handle if necessa ry.
Director
Phone : (b)(6)
FAX: (301) 496-4409
E-mail : (b)(6l
info rmation. It should not be used by anyone who is not the o rigi nal intended recipient. If you
have re ce ived this e-mail in error please inform the sender and delete it from your mailbox or any
From : Gere diZerega (b)(6)

;__;_ -------= (b)(6J>

=--
__ .:....;.-=.:===~~---
Cc: Gere diZerega CbH6J>
Subj ect : Corona Virus
Dear Dr . Fauci:
(b)(4)
NIH-001 180
(b) (4)
Please contact us if we can be of any help in moving this potential life-support initiative forwa rd .
Sincerely,
Gere
G E RE DI Z E R EG A
P RE S ID EN T A N D C E O
US B lOT ES T, ] NC .
231 BON ETT I DRLVE, SUIT E 240

SAN LULS OBISPO, CA 93401-73 10
TEL : (b)(6) "} FAX : 805.595 . 1350
The information transmitted is intended onlyfor the person or entity to which it is addressedand may contain confidential
and/or privilegedmaterial. Any review,retransmission,dissemination or other use of, or taking of any actionin relianceupon,
this information by persons or entities other than the intended recipientis prohibited.If you received this in error,please contact
the sender and delete the materialf rom any computer.
NIH-001181
From: (b)(6)
Sent: Fri, 28 Feb 2020 13:41:02 -0500
Subject: Fwd: As bad as measles?
Please handl e
From: Ed Charlt on (b)(6 )>

Date: Februa ry 28, 2020 at l :07:32 PM EST
To: "Fauci , Anthon y (NIH/N IAID) [E]"
-------~~
Subject: As bad as measles?
--------- (b)(6)
Dr Fauci, you are the pre-eminent infectious disease physician in the world. I'm
concerned the public has lost perspec tive on COVID-19.At this point, it would
seem the r0 and CFR are more simila r to rubeo la than they are to Ebo la. Can we
rem ind the public of that? Commu nicat ing that influenza will kill more Amer icans
than SARS-2 hasn't gained traction. Might someone like yourself or Dr Carson
comm unicate more strongly to the public the risk s compared to othe r viruses they
are familiar w ith, like rubeola , rubella, varicella, etc?
NIH-001182
From: (b)(6)
Sent: Fri, 28 Feb 2020 13:39:34 -0500
Subject: Fwd: Experimental vaccine for Covid-19
Please respond. M ention risk of enhancement
From: "William J. Buikema" (b)(6)>

Date: February 28, 2020 at l :08:50 PM EST
To: "Fauci , Anthon y (NIH/NIAID ) [E]" -------~~
---------
Subject: Experimental vaccine for Covid-19
(b)(6J:
Dear Dr. Fauci,

I understand the need for the variom stages of testing a new experimentalvaccine, but in listeningto
you give a timeline for any new vaccine for the coronavirus, it struck me that perhaps a modified
approachmight be considered. Why not allow early use of a vaccine that has passed a phase 1 safety
testing, similarto what was done for the Ebola vaccines. If a vaccine is shown to be reasonably safe,
why not allow its use it in more at-risk people (elderly , smokers) before phase 2 trials are finished . It
could also be helpfu l as with the Ebola vaccines to prevent transmission in hot spots of community
acquired infections. There doesn't seem to be much downside compa red to the potential for
preventing many more deaths than was seen in the Ebola situation.
Sincerely yours,
Bill Buikema
William J. Buikema, PhD, ResearchAssociate
Technical Director, DNASequencing& Genotyping Core
University of Chicago, KCBD1230H&I
900 E 57th Street, Chicago, IL 60637
773-702-1088, cancer-seqbase.uchicago.edu
NIH-001183
From: (b)(6)
Sent: Fri, 2 8 Fe b 2020 1 1:21 :22 -0500
To : Co nr ad , Patr icia (NIH/ NIA ID) [E)
Subject: Fwd : co ron av irus vacc ine st ory ?
Sent from my iPhone
From: Olga Khazan <olga@theatlantic.com>

Date: February 28, 2020 at 11:09:49 AM EST
------~~
To: "Fauci , Anthony (NIH/NIAID) [E]" CbH6>:
Subject: coronavirus vaccine story?
Hi Tony -- It's Olga at the Atla ntic ... I'm hearing that there's a coronavirus
vaccine trial in the works at the VTEU sites. We'd love to tell the story, but
everyone is directing me to you and NIA ID. Would you be able to talk with
me about this today for a story? My cell is CbH6J,and my desk is
202-266-7387.
Thanks,
Olga
OlgaKhazan
Staff Wr iter
The Atlantic
olga@theatlantic .com
cell : (b)(6J
NIH-001 184
From: (b)(6)
Sent: Fri, 28 Feb 2020 08:59 :04 -0500

Subject: Fwd: MEDIA INQUIRY
Sent from my iPhone
Begin forwardedmessage:
From: Lemonov Alexander <anlemonov @rttv.ru>

--------=-=--:-=
Subject: MEDIA INQUIRY --------- Cb)C6)
Dear Dr. Fauci,
My name is Alexander Lemonov, I am a producer for RT International TV channel.
I would like to invite you to appear on "Worlds Apart", RT's 26-minute uncensored one -on-one
interview show .
We would like to talk about t he spread of the COVID-19 coronavirus, the response measures
countries should take, the world's general preparedness for pandemics, COVID-19's possible
consequences for other areas: healthcare, economy, security, etc.
Would you be available?
FYI: "Worlds Apart" is an uncensored interview show that is aired on RT International, RT

America, RT UK, and RT Russia (in Russian).
All episodes get featured on RTsocial media accounts, watched by the ir multimillion
international crowd .
Our guests endorse widely diffe rent views, and we are happy to broadcast different opinions.
Here's the link to our show: https://www .rt.com/shows/worlds-apart-oksana-boyko/
"Worlds Apart" has featured:

businessman Richard Branson, lawyer Alan Dershowitz, former Israeli FM Tzipi Livni, UN
Secretary General Antonio Guterres, UN Women Executive Director Phumzile Mlambo-Ngcuka,
former Prime Min ister of Italy Giuliano Amato, former U.S. State Department coordinator for
JCPOAJarrett Blanc, foreign minister of Iran Javad Zarif, adviser on international affairs to
Supreme Leader of Iran Ali Akbar Velayati, former chief economist of the World Bank Anne
Krueger, Secretary General of OSCEThomas Greminger, special adviser to PM of Japan
Tomohiko Taniguchi, senior fellow at the Brookings Institution Mike O'Hanlon, etc.
I would appreciate a reply.
NIH-001 185
Kind regards,
Alexander Lemonov
Producer
'Worlds A art ", RT
Mobile: .._ _____ Cb
_H_.
6)
Office: +7 (499) 75-000-75, ext. 2492
AlleKcaHAP neMoHoB
npoAiocep
"Worlds A art", RT
Mo6. : (b)(6)
Pa6.: +7 (499} 75-000-75, A06. 2492
rt .com
twitt er.com /rt com

facpbook.com/RTnPw~
youtub e .com/use r/ RussiaToday
plus.google .com/102728491 539958 529040/post s
CONFIDENTIALITY.
The Informationcontained in this transm,ssionIs Intendedexclusively for tho proper use by the Intended addresseesand may contain
confidenbaland/or privileged material.Any views expressedin this transmission are those of the individualsender, except where the
transmission states otherwise and the senderbeing authorisedappropriately. My review, dissemination and other use of this
information, as well as any act ion in reliance upon this info rmation by persons and/or entitles ot he r lh an the intended add ressees ,s
prohibited. If you received this information In error, please note lhat no confidentiality or pnv1lege ,s waived or lost by any miss-
transrn,ssion Note that we monitor e-mails sent or recerved Further co'!lmunicationwill signify your consent to the above.
NIH-001 186
Sent : Fri, 28 Feb 2020 11:50:04 +0000
To : Kaplan, Edward H
Subject : RE: Coronavirus
Ed:
Thanks for the note. Great to hear from you. I hope that all is well.
Best regards ,
Tony

From: Kaplan , Edward H -------~~ (b) (6) =
Sent: Thursday, February 27, 2020 I 0:42 AM
To: Fauci, Anthony (NTH/NIAID) [E] ------ -,.-.,-,,=
(b)(6) >
Subje ct: RE: Coronaviru:s
Hi again Tony. Here's a link to a non-technical exp lanation of the paper I shared with you earlier:
https:// insights.so m.yale.edu/insights/new -outbrea ks-of-coronavirus-can-bc-halted-,vith-isolation-m easures -

according -to-study
I have seen predictions stating that upward s of 30% of the wor ld's popu lation will be infected , but I don't see this
happening. What I do see are lots of local outbreaks from imported cases, some larger than others , but all headin g
towards containment. I find Israel to be an interesting test case. A group of infected Korean tourists who visited the
country only tested positive for coronavirus after their re turn to Korea, joining the large outbreak that has been
reported there. The itinerary of their travel group has been made public so that retrospectively, [sraeli public health
officials could ascertain who was exposed where and when (see
https://www .hea ltb.gov.il/E nglish/News and Events/Spokesper sons Messages/Page s/23 02202 0 J.aspx). Already
1,600 Israelis have been quarantined on account of possible exposure. It has been twelve days since this group of
tourists returned to Korea , and no new infect ions have been reported in Israel associated with this group (there are
two Israelis who were infected on the Diamond Princess cruise ship , and one infected while in ltaly). See
https://www .ynetn ews.com/artic1e/H l nXPa7E8 . lt will be interesting (and important) to see how many new
infections are detected in the days ahead, and if such new infections are found among those already under preventive
watch.
Nonetheless I totally concur with preparing as if major tran smission will occur. Much better to err by over- rather
than under- preparing (a familiar perspect ive from those bygo ne smallpox debates).
Finally, a reporter asked me yesterday afternoon what I wanted the Pres ident to say last n.ight. Here was my
response :
In a sober way summaiize the facts of lhe ou tbreak, state that the US has an excellent preparedness team between
CDC and NIH, that at the advice of this team travel restriction s and quarantine measures have already been enact.ed,
but as of now the public is at very low risk of infection. Still, citizens should go to cdc.gov now to learn from our
experts how to prepare in the event that more extreme measures are needed , stay abreast of the situation here and
abroad and follow the advice of our experts , get a flu shot(!), and know that the US has a very strong public health
sy stem that can withstand this cha llenge .
Anyway,just wanted to share all this with you. Keep up the good work and good luck with the vaccine research, Ed
From: Kaplan , Edward H
Sent: Saturday , February 8, 2020 I 0: 13 PM
---------- (b)(
NIH-001 187
Subject: Coronavirus containment modeling
Dear Dr. Fauci ,
It has been many years since we corresponded regarding smallpox bioten-orism and vaccinat ion control.
The attached paper on containing a commun ity coronavirus outbreak from a few initial cases via isolation and
quarantine might interest you. The news is mostly good - isolation and quarantine can get the transmission rate
below epidemic threshold - bur the key is rapid detection of infected persons. Also discussed are some ideas for
alleviating congestion in the hospital. ! hope that you find it helpful.
Best, Ed Kaplan
Edward H. Kaplan, Ph.D.

William N. and Marie A. Beach Professor of Operations Research Professor of Public Health Professor of
Engineering Yale School of Management Box 208200 New Haven, Connecticut 06520 -8200
Phone: (b)(6)
e-mai l (b)(6)
https://nam05.safelinks.pro tection.outlook.comnu rl=http%3A%2F%2 Ffaculty.som.ya le.edu%2FEdKap lan%2F&am

p;data= 02% 7C0 I%7Ce dward.kaplan%40y ale.edu%7Cb00 l l 9dcdbe24bc635d2 08d 7bb9b24c7%7Cdd8c bebb2 l 394d
f8b4 114e3e87abeb5c%7C0%7C0% 7C6371841473 15834392&amp:sdata =l l LC4xAuAc %2BjdNuG%2BA2o GxcS9
LS95PoOR i7yO0dLR d0%3D &reserved=0
NIH-001 188
From : Fauci, Anthony (NIH/NIAID) [El
Sent: Fri, 28 Feb 2020 11:25:43 +0000
To : Conrad, Patricia (NIH/NIAID) [El
Subject : FW: Coronavirus update for your upcom ing Keystone Symposia meeting
FYI
From : Allison Ogdon <Allison0@keystonesymposia.org>

To : Allison Ogdon <AllisonO@keystonesymposia.org>
Cc: Heidi Daetwyler <HeidiD@keystonesymposia .org>
Subject : Coronavirus update for your upcoming Keystone Symposia meeting
Imp ortance: High
,ffSYMPOSIA
KEYSTONE
on Molecular and Cellular Biology
Accelerating Life Science Discovery
Greetings,
In light of th e current coronavirus situ at ion, w e would like to provide an updat e on your upcom ing
Keyston e Symposia confere nce.
The health and safety of our meeting attendees and speakers is our top priority , and we are carefully
monitoring the coronavirus situation around the world to ensure we take the necessary precautions as
recommended by healthcare providers and public health organizations .
Currently, your meet ing will procee d as scheduled, and we will contact you immediately if anyth ing
changes. Decisions will be made on a moment to moment basis, as new information becomes available .
We assure you that the leadersh ip team at Keystone Symposia is closely monitoring global
developments and will take swift action to ensure the health and safety of all meeting participants .
As a speaker, you hold a very special role at the meeting as a field leader. We very much appreciate
your contribution to both the scientific program, and the community of luminary scientists who w ill
convene to direct the future of the field. Your presentation will be a highlight for many attendees, and
your insights will inspire others to take on new and innovative directions in their own work . This is the
essence of Keystone Symposia -- convening communities of leading scientists to inspire each other to
advance biomed icine, and this would not be possible without your engagement .
We realize the current situation may add some inconveniences to travel at this time, but we also remind
you that each and every one of our speakers is hand-selected by a committee of the world's leading
experts to represent their field at the meeting . You are among a very select few to receive this honor.
NIH-001189
The meeting organizers, and our team at Keystone Symposia, have put a great deal oftime and effort
ov er the last tw o years into designing th e program, and your presentation is a key part of that. We hope
you will take these though ts into consideration as the meeting approaches.
W hile th is is a t ime we must all be vigilant about publ ic health measures, we are remind ing conference
attendees that this is also a t ime to remain calm, rat ional and scient ific in addressing the situatio n. We
encourage you to engage w ith your fello w colleagues at the meeting as you normally would, to forge
new collaborations and novel ideas that w ill dri ve your research and the field in innovative and fruitfu l
di rections . At the meet ing, we are prov iding the follo w ing suggestions based on reco mmendations from
t he Nat ional Foundation of Infect ious Disease:
• The best way to protect yourself aga inst COVID-19is similar to how you would take
precaution s against the cold or flu. Wash your hands of ten using soap and wate r for at least 20
seconds. Cover yo ur cough or sneeze with a t issue or the crook of your elbo w rather than your
hands.
• There is no need to wear a face mask if you are well and do not have symptoms- masks
protect the sick from spread ing germs but wi ll not prevent you from gett ing sick.
• Do not assume that anyone of Asian descent is more likely to have coronavirus - do not forget
about the importance of inclusivity and evidence-based information.
Again, we t hank you for your contributions and commitment to Keystone Symposia and w ish for a very
successful and inspiring meet ing.
Sincerely,
(b)( 6)
Debora h L. Johnso n, Ph.D.

President and Chief Executive Off icer
Keystone Symposia on Molecular and Cellula r Biology
KEYSTONE~ SYMPOSIA~
on Molecular and Ce l lular Biology
Accelerating Life Science Discovery
D I VERS I T Y IN T H E SC IE N TIF IC W O Rl< F OR C E
POBox 1630 I Silverthorne I co 80498 I USA (regular mail only)

160 usHighway 6, Ste. 200 I Silverthorne I CO80498 I USA (courier only)
970.262 .1230 I 800.253.0685 I www.keystonesympos ia.org
Visit virtual.keystonesymposia .orgto view our digital content.
NIH-001 190
OC, 0 0
NIH-001191
Sent : Fri, 28 Feb 2020 04:25:27 +0000
To: Kline, Lydia (NIH/OD) [El
Subject : RE:thank you
Lydia:
Thanks for your kind note.
Best regards,
Tony
From:Kline, Lydia (NIH/OD) [El CbH6J>

------~~ (b)(6J>
Subject : thank you
Tony,
I'm sure many people are telling you this, but I wanted to add my thanks to you for everyth ing you do to
keep the world safer and healthier! You are doing an incredible job (as always) out there with
coronavirus.
Best,
Lydia
NIH-001 192
Sent: Fri, 28 Feb 2020 04:23:12 +0000
Subject: FW: inv itation to speak on COVIO19 at the International ATS Conference in May
Attachments: imageOOl.png, image003.png
Sorry no
From: Fennelly, Kevin (NIH/NHLBI) [E]_______ Cb

_>
_<_ >
To: Fauci, Anthony (NIH/NIAID) [E]______ """
(b""""
)( =6)
Subject: invita t ion to speak on COVID 19 at the Inte rnational ATS Conference in May
Dear Dr. Fauci,
I don't believe that we've formally met, but I have seen you frequent ly on SSEas I admit patients there
and often participate in the ward rounds. I am an Al on several of Steve Hollands protocols, and I often
help with the drug-res istant TB cases. I have been at the NIH now for over 4 years, although I still fee l
like the new guy on the block! Most of my career has been focused on quantifying the infectious
aerosols generated by TB patients . I am very involved in the leadership of the American Thoracic
Society (ATS) as the Past Chair of the Assembly on Pulmonary Infections and TB. I am writing to invite
you to be a keynote speaker at a special Scientific Session being added to our Internat iona l Conference
May 16-20 due to the emerging pandemic of COVID-19. The exact time and data are not yet known,
but the conference is relatively close in Philadelphia. This would be an opportunity to address and
educate global academic leaders in pulmonary and critical medicine, infectious diseases, and public
health . We usually have over 15,000 attendees at the ATS meeting. I am attaching the email string
below to give you an idea of other speakers being considered.
I can only imagine how busy you must be now, so I apologize if this invitation is a distraction or a
nuisance. And I would certainly understand if you are unable to jo in us given the demands on your time,
but we would be absolutely delighted if you could speak.
Please feel to call or contact me at any time with questions or comments.
Sincerely,
Kevin Fennelly
Mobile (b)(6)
Kevin P Fennelly, MD, MPH, ATSF

Senior Research Clinician
Laboratory of Chronic Airway Infect ion
Pulmonary Branch
Division of Intr amural Research
Nationa l Heart, Lung, and Blood Institute (NHLBI)
Nationa l Institutes of Health {NIH)
NIH-001193
Build ing 10, Room 5-1421
10 Center Drive
Bethesda, MD 20892
From : Saukkonen, Jussi J >

(b)(
Sent : Wednesday, February 26, 2020 7:15 PM
To: Dela Cruz, Charles (b) ( >
Cc : Kristina Crothers (b)(6b; Nahid, Payam
Saukkone n, Jussi
-!========::::::=:-::;~-----
(b)( >; Maria Novozhilova
(b)(6) ;
(b)(6); M iriam
Rodriguez (b)(6); Fennelly, Kevin (NIH/NHLBI) [E)
(b)(6)
Hicks, Lauri (CDC/0D10/NCEZID/DHQP)

(b)(6)>; Yeligar,
-----:--:~============~-__:__--2~======--=~- (b)( 6) McGinniss, John E
----!:==========; (b
.:;:
),;;,
(6)
:::a;-
> --------------
Subject; Re: Pl-TB Executive Committee Call
This looks like a great program . Hope you can get these speakers who will be in demand.
On Feb 26, 2020, at 2:44 PM, Dela Cruz, Charles

----------- (b)(6) wrote:
Thank you all for your great suggestions ...
Here is a possible Agenda for the Special Session on Coronavirus.

Ideally, we should have some ATS attendees to be speakers. If anyo ne knows possible
candidate, please let us know. I also know that ATS would like to encourage some high
profile speakers if possible. Someone from CDC,NIAID, etc.
Please let us know additional suggestions.

I highlighted bold are possible speakers.
We wi ll need to wait until the ATS BOD this week to get t he go ahead to invite the
speakers.
(b) (4)
NIH-001 194
(b) (4)
NIH-001 195
(b) (4)
Charles S. Dela Cruz, MD, PhD

Associate Professor
Section of Pulmonary, Critical Care and Sleep Medic ine
Department of Internal Medicine
Department of Microbial Pathogenesis
Director , Center of Pulmonary Infection Research and Treatment (CPIRT)
Yale University
300 Cedar Street TAC S441-D
New Haven, CT 06513
Phone: Cb)(6)
FAX: 203 785-5952
Email: Cb)(6)
Faculty
profile: http://medicine.ya le.edu/ intmed/pulrnonary/people/charles delacruz.profile
Lab website: http ://rnedicine.yaJe.edu /la b/delacruz/index.aspx
CPIRT website: cpirt.yale.edu
<irnage00 1.png>
<image003.png>
From: "Crothers, Kristina" (b)(6)
Date: Tuesday , February 25, 2020 at 8:52 PM

To: "Saukkonen , Jussi J"
Cc: "Dela Cruz, Charles'
Cb)( >, "Nahid, Payam"
-------
(b)(6) "Saukkonen, Jussi"
(b)(6)
(b)(6)>, Maria Novozh ilova (b)(6),

(b)(6)
>, "Kevin P. Fennelly, MD" (b) (6)>,
NIH-001 196
(b) (6)>
Subject : Re: Pl-TB Executive Committee Call
Hi - these are great suggestions. (b) (4)

(b) (4)
Kristina
From: Saukkonen, Jussi J (b)(6)

Sent: Tuesday, February 25, 2020 9:02 :43 AM
To: Nahid, Payam
Cc: Dela Cruz, Charles; Saukkonen, Jussi; Crothers, Kristina; Maria Novozhilova; Miriam
Rodriguez; (b)(6) · Kevin P. Fennelly, MD; (b)(6J.
; Evans,Scott; Yeligar, Samantha M.;
-----------------
Subject : Re: Pl-TB Executive Committee Call
(b)(6); McGinniss, John E
These would be excellent speakers to also try to get!
NIH-001 197
> On Feb 25, 2020, at 11:50 AM, Nahid, Payam
>
______ _, wrote:
(b) (6)
> Agree, these are excellent suggestions.An FYIbelow on what CROIhas assembled for ad hoc
session on COVID-19:
(b) (4)
>
> ------------------------------------------------------------------------
> Payam Nahid, MD, MPH
> Professor of Medicine
> University of California, San Francisco
> Associate Director, Clinical Trials Operations, UCSFOffice of Research
> Medical Director, UCSFCTSITrial s Innovation Network (TIN)
> Director, UCSFCenter for Tuberculosis (http :// t b.ucsf.edu )
UCSFCenter for TuberculosisI UCSFCenter for TB

tb.ucsf .edu
>
> Zuckerberg San Francisco General Hospital
> Division of Pulmonary & Critical Care Medicine
> 1001 Potrero Avenue, Room SKl
> San Francisco, CA 94110
> Email: (b) (
> UCSF Profile: htt p:// pro fil es.ucsf .edu/ payam .nahi d
PayamNahid I UCSFProfiles
profiles. ucsf.edu
Payam N_ahid'~ profile, public~tions, research topi~s, an~ co-autho~s
------
> Tel : (b)(6) .
> Pronouns: he, him, his
NIH-001198
>
>
>
> On 2/25/20, 6:47 AM, "De la Cruz, Charles"
> ---------- (b)(6) wrote:
> Thank s Jussi for your great suggestions . W e will try to incorporat e these into the final session.
> Much appreciated
> Charles
>
>
>
> ------------------------------------------
> Charles S. Dela Cruz, MD, PhD
> Associate Professor
> Section of Pulmonary , Critical Care and Sleep Medicine
> Departme nt of Internal Medicine
> Department of Microbial Pathogenesis
> Director, Center of Pulmonary Infection Research and Treatment (CPIRT)
> Yale University
> 300 Cedar Street TAC S441-D
> New Haven, CT 06513
> Phone : (b)(6)
> FAX: 203 785-5952
>
> Email: (b)(6)
> Faculty profile: https ://urldefense .proofpo int.com/v2/ur l?u=http -
3A med icine.yale.edu intm ed pulmonary peop le charles -
SFde Iacru z.p rofile&d =Dw IGaQ& c=iO RugZIs2LIYyCAZRB3Xlg & r=Xo HvlYAp U j67iV1KyA lzSg&m=OCAE
Xv-43B0vEiVl nTNd--DXvFYATIj FpvUftbD e3o4&s =XbJr53zM ilg0yYn -iXh9t9 vBPfjcNC8h-jRJ2lihVk& e=
CharlesDela Cruz,MD,
PhD < Pulmonary,
CriticalCare and Sleep
Medicine
X urldefense.proofpoint.com
Dr. Dela Cruz completed his research

training through an MD/PhD program
in the area of immunologyand
virology from Universityof Toronto
and Yale. Clinically, he is trained in
internal medicine, and specializesin
pulmonaryand critical care medicine
NIH-001199
and is currently an Associate
Professorat Yale Universityin the
> Lab website: https ://u rldefe nse.proofpoi nt. com/v2/ur l?u=http -
3A med icine .yale .edu lab delacr uz index .aspx&d=DwlGaQ&c= iORugZIs2LIYyCAZRB3XLg&r=Xo Hvl
YApUi67iV1KyA l zSg&m =OCAEXv-43BOvEiVlnTNd--
DXvFYATl iFpvUf tbDe3o4&s=F7cVz fOPwSt mglz95Y984or0dPHCoEYBNsv iP7GA2g& e=
Dela Cruz Lab

urldefense.proofpoint.com
Dr. Dela Cruz completed his research train ing through an MD/PhD program in the
area of immunologyand virology from Universityof Toronto and Yale. Clinically, he
is trained in internal medicine,and specializesin pulmonaryand critical care
medicineand is currently an AssistantProfessorat Yale Universityin the
> CPIRTwebsite: cp irt .ya le.edu

>
>
>
>
> On 2/25/20, 9 :34 AM, "Saukkone n, Jussi" _______ .., wrote :
_.C.,.b)_(6)
>
> Grea
,~•'---------------------------- ~=
(b)(4)
NIH-001200
(b)(4l
FirstUS MERS-CoV
CasesUnderscoreNeed
X for PreparednessI
Global Health I JAMA I
JAMA Network
urldefense.proofpoint.com
Confirmation of the first 3 us cases

of Middle East respiratory syndrome
coronavirus (MERS-CoV) infection
highlighted the importance of
preparedness plans and infection
control policies for hospitals and
other facilities in dealing with a
potentially dangerous infectious
disease.
.....
.__________________________ __~,._,
(b (4)
NIH-001201
2019 Novel
Coronavirus-Im portant
Informationfor
X Cliniciansl Global
Health l JAMAl JAMA
Network
urldefense .proofpoint.com
This Viewpoint summarizes the

epidemiology and clinical features of
2019-nCoV infection and reviews
CDC criteria to guide evaluation and
management of patients with
possible infection.
(b) (4)
NIH-001202
(b) (4)
> ----- Origi naI Message-----

> ---------~~
From: Dela Cruz, Charles __________ (b_) _(6)
_,
> Sent: Monday, February 24, 2020 9:49 PM
>
______To: Crothers,;.__Krist ina
(b
-=-)~ ("=1""'
>___________ ___ Ma ria Novozhi lova
(b)(6)>;
> c : Miriam Rodrigu
(b)(6)
; Saukkonen, Jussi (b)(6)
McGinniss, John E (b) (6)
> Subject: [EXTERNAL)Re: Pl-TB Executive Committee Call
>
> Dear colleagues
>
> Hope all is well .
>
> As part of ATS 2020 in May, PITB Programming has been requesting to see if there wou ld be a
venue for a coronavirus session.
>
> The ICC chair and ATS was able to seek out a possib le forum for a Special Session on
Coronavirus on the Monday Afternoon during ATS.
>
> Payam and I have been d iscussing a possible session title, content and speakers.
>
> The session ti t le could be --
(b) (4)
NIH-001203
(b) (4)
> Many t hank s

> Charles
>
>
>
> Charles S. Dela Cruz, MD, PhD
> Associate Professor
> Sect ion of Pulmonary, Critical Care and Sleep Medic ine Depa rtment of Internal Medicine
Department of Microbial Pathogenesis Director , Cente r of Pulmonary Infection Research and
Treatment (CPIRT)Yale University
> 300 Cedar Stre et TAC S441-D
> New Have n, CT 06513
> Phone: (b) (6)
> FAX: 203 785 -5952
>
> Email: (b)(6)
> Faculty profile: https ://urld efe nse.proofp oint. com/v2/ url?u=ht tps-
3A nam OS.safe links.protect ion .ou t look .com -3Furl-3Dhttp -253A -252F-252Fmed icine.ya le .edu -
252 Fintmed -25 2 Fpu Imo nary-252 Fpeo pie-25 2Fcha rle s-5Fde lacruz. profi le-2 6a m p-3 Bdata -3D02 -
2 S7C01-25 7Cchar les.de lacruz -2540ya le.edu -25 7C07f 45 f4dbd77 4 f4a3d cc08d7b9 ffcld2 -
257Cdd8cbebb21394df8 b4114e3 e87a beb5c-257C0-257C0-257C6371823804254 42155 -26a mp-
3Bsdata -3DQW W L8cDOcYtHaxgi lDZfU7dywm TyCbpPS4bl002Rp Hs-253 D-26amp -3Breserv ed-
3DO&d= Dw IGaQ&c = iORugZ1s2 LIYyCAZRB3XLg& r=XoHv lYAp Ui6 7iV1 KyA l zSg& m =OCAEXv-
43 BOvEiVlnTNd--
DXvFYATIj FpvUftb De 3o4&s=TVWeA9SztU xTEK8JSyHFc0kt3 CyA rZW DsYQDZPge u EQ&e=
NIH-001204
CharlesDela Cruz, MD,
PhD < Pulmonary ,
CriticalCare and Sleep
Medicine
X urldefense.proofpoint.com
Dr. Dela Cruz completed his research

training through an MD/PhD program
in the area of immunology and
virology from University of Toronto
and Yale. Clinically, he is trained in
internal medicine, and specializes in
pulmonary and critical care medicine
and is currently an Associate
Professor at Yale University in the
> Lab website : https:// url defe nse.proofpo int .com/v2/u rl?u=https -
3A nam OS.safelinks.protect ion .ou t look.co m -3Furl-3Dht tp -253A -252F-252 Fmed icine.yale.ed u-
252Flab-252Fdelacruz-252 Findex.aspx -26amp -38 data -3D02 -257C01-257Ccharles .delacruz-
2540yale.edu-257C07f45f4d bd774f4 a3dcc08d7 b9ff cld2 -
257Cdd8c bebb2139 4d f8 b4114 e3 e87a beb5c-257C0-257C0-257C637182380425442155 -26am p-
3Bsdata-3DaUEJSTgiaCXmTQiuABOKOYrM iqFxdd2HiPhGuq8Psig-253D-26am p-3Breserve d-
3DO&d=Dw lGaQ&c=iORugZls2LIYyCAZRB3Xl g&r =XoHvlYApUj67iV1KyA l zSg&m=OCAEXv-
43BOvEiV l nTNd--DXvFYATlj FpvUft bDe3o4&s =s6rn KnYlg iuU r8011 HRKyYFhvJwdc4 t9rmpZzq ixY&e=
Dela Cruz Lab

urldefense .proof point.com
Dr. Dela Cruz completed his research train ing through an MD/PhD program in the
area of immunology and virology from University of Toron to and Yale. Clinically, he
is trained in internal medicine, and specializes in pulmonary and critical care
medicine and is currently an Assistant Professor at Yale University in the
> CPIRT website: cpirt.yale.edu

>
>
>
NIH-001205
>
>
>
>
On 2/22/20, 7:47 PM, "Crothers, Krist ina"
--------------- (b) (6)wrote:
Hi all - we need to reschedu le the call as bot h Rachel and I will be t raveling t o the ATS board
meeting next Wednesday. Please let me and Mar ia know if you could join a call Wednesday March 4
at 4pm eastern instead.
> Kristina
>
> Sent from my iPhone
>
» On Feb 21, 2020, at 12:20 PM, Mar ia Novozhilova
__________ _.
(b) (6)> wrote:
>>
>>
» <Pl-TB Executive Committee Call>
>
>
>
> Privileged, confidential or patient identifiable information may be contained in this
message. This information is meant only for the use of the intended recipients. If you are not the
intended recipient, or if the message has been addressed to you in error, do not read, disclose,
rep roduce, distr ibute, disseminate or otherwise use this t ransmission. Instead, please notify the
sender by reply e-mail, and then destroy all copies of t he message and any attachments.
>
>
>
>
>
>
NIH-001206
NIH-001207
8
From: Fauci, Anthony (NIH/NIAID) [E]
Sent : Fri, 28 Feb 2020 04:21:24 +0000
Subject: FW: Invitation to Spanih meeting
RSVPsorry no.
From:Jose Alcami Pertejo <ppalcami@isciii .es>

To: Fauci, Anthony (NIH/NIAID) [E] ------ ~=
--------
Cc:Jose Alcami Pertejo <ppalcami@isciii.es>
(b)(6)>
Subject: Invitation to Spanih meeting
Dear Dr Fauci ,
Hope this mail finds you well. We had the opporttmity to meet in Madrid dur ing the R4P
meeting. I was the local chair of the Confe rence and had the privi lege of introducing your talk to
the plenary.
I wou ld like lo invite you as plenary speaker to the meeting of the Spanish AIDS Society
(GESIDA) that will take place in Malaga , Spa in next 30th November 2020. GESIDA Congress is
the mos t important HIV national meetings in Spain that brings together the full "HIV
Community" including clinicians , basic researchers , experts in epidemiology and public hea lth
and member from NGOs and patien ts' associa tions. Overall 700 attendees are expected to come
to the meeting.
We would love to have you as a speaker in the Opening Plenary Sess ion in evening the 30th
November. Your challenging articles regarding the strategies to end the HIV epidemic in the
United States , will be a great topic to be addressed in such session and an inspiration to Spanish
researchers. If you prefer to talk about a different top ic as the co-morbid ities scenar io in HIV
infection it will be welcome too.
We would be more than happy if you could participate in this meeting .
If know your agenda is always full, even more these days with the current Coronavirus outbreak ,
NIH-001209
but if you could accept this invitation I think this can represent a real boost in the fight against
HIV epidem ics in Spain, a field in which the Spanish AIDS Society is strongly committed .
It would we wonderful if we can have you as a speaker.
Best wishes
Jose Alcarni
************************* AVISO LEGAL************************* Este mensaje

electr6nico esta dirigido exclusivamente a sus destinatarios, pudiendo contener documentos
anexos de caracter privado y confidencial. Si por error ha recibido este mensaje y nose
encuentra entre los destinatarios, por favor no use, informe, distribuya, imprima o copie su
contenido por ningun medio. Le rogamos lo comunique al remitente y borre completamente el
mensaje y sus anexos. El lnstituto de Salud Carlos Ill no asume ningun tipo de responsabilidad
legal por el contenido de este mensaje cuando no responda a las funciones atribuidas al
remitente del mismo por la normativa vigente.
NIH-001210
Sent: Fri, 28 Feb 2020 04:13:52 +0000
Subject: RE: David Rubenstein's invitation to Dr. Fauci
I always like to do things with David Rubenstein
From:Conrad, Patricia (NIH/NIAID) [El (b)(6)>

To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: David Rubenstein's invitation to Dr. Fauci
Patricia L. Conrad
(b)(6)
301-496-4409 fax
Disclaime r:
by anyone w ho is not the original intended recipient. If you have received this e-ma il in error please inform the sender and delete it
from your ma ilbox or any other storage devices . National Institute of Aller gy and Infectious Diseases (NIAID) shall not accept
liabi lity for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.
From: Mary Brady <MBrady@economicclub.org>

To: Conrad, Patricia (NIH/NIAID) [El -------- :7'C= (b)(6)>
Cc: (b)(6); Judi lrastorza <Judi.l rastorza@economicclub.org>
Subject : David Rubenstein's invitation to Dr. Fauci
Patricia,
David Rubenstein asked that we reach out to you in an effort to schedule an Economic Club of
Washington event that would feature Dr. Fauci in a conversation with David on COVID-19. It is
my understanding that David had a sim ilar interview with Dr. Fauci in the last week or so.
Below are several dates from David's calendar for your consideration.
Wednesday, April 22 - Breakfast
NIH-001211
Tuesday, April 28- Breakfast or lunch
Tuesday, May 5 - Breakfast or Lunch
Friday, May 15 - Lunch
Additionally, I have attached an invitation letter from Mr. Rubenstein to Dr. Fauci for your
convenience. The Economic Club has the ability to turn around an event in a relatively short
period of time. As you may recall, our events typically take place at breakfast, lunch or dinner,
at downtown Washington, D.C. hotels. Events that feature a prominen t world leader, such as
Dr. Fauci, generally attract a select audience of over 500 members and guests from among
Washington 's business and government leaders, as well as the diplomatic corps.
We understand the complexities and constraints of Dr. Fauci's schedule and can be responsive
to his needs. If none of the dates above work with Dr. Fauci's schedule, please suggest some
that will and we wil l work with David to confirm a date and begin the process. I have copied
Judi lrastorza, who I believe you have worked with in the past, and she will coord inate anything
you need.
Sincerely,
Mary
Mary C. Brady
Executive Director
The Economic Club of Washington, D.C.
1601 K Street NW, Suite 210, Washington, DC 20006

I Mobile:
Office: (202) 481-3260 (b)(6)
mbradv@economicclub.org
Our SponsorsI www.EconomjcC1ub.org

@TheEconomicClub I LinkedlnI YouTube
NIH-001212
Sent : Fri, 28 Feb 2020 04:10:35 +0000
Subject : FW: Invita ti on to join Scientific Advisory Board
Please handle.
From: Ajay Gupta (b)( >

Se nt: Thursday, February 27, 2020 1:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] -------= (b-c-
)(c-=
6)
Subject : Re: Invitation to join Scientific Advisory Board
Hi Dr. Fauci,
thanks,
Ajay
From: "Fauci, Anthony (NIH/ NIAID) [E]"

0 at e: Monday, February 17, 2020 at 3:59 AM --------- (b)(6)
To: Ajay Gupta (b)(6)

Subject: RE: Invitation to join Scientific Advisory Board
Thanks for the note . My position in the US Government does not allow me to join such
Boards .
From: Ajay Gupta (b)(6)>

Se nt: Sunday, February 16, 2020 10:21 PM
------
To: Fauci, Anthony {NIH/NIAID) [E]
-------- ::;..,..-,=
Subject ; Invitation to join Scientific Advisory Board
(b)(6)>
Dear Dr. Fauci,
By way of this email, I wou ld like to introduce our new biotech company based in California , Celestial
Therapeut ics Inc.
(b)(4l
NIH-0012 13
(b) (4)
We wou ld like to extend an invitation to you to join our company's Scientific Advisory Board .
Please see attached herewith the executive summary and a slide deck of our company.
Thanks and looking forward to hearing from you shortly.
Best regards,
Ajay Gupta, Ph.D.

President, Chairman & CEO
Celestial Therapeutics Inc.
Tel: (b)(6)
NIH-0012 14
Sent: Fri, 28 Feb 2020 04:07:36 +0000
Subject: FW: lack of preparedness for the coronavirus pandemic
FYI. Does this deserve a response.
From:Nejat Duzgunes (b) (6)

To: Collins, Francis (NIH/OD) [E] (b)( >; Fauci, Anthony (NIH/NIAID) [E]
(b)(6)>
Cc: Nejat Duzgunes
--------
(b)(
Subject: lack of preparedness for the coronavirus pandemic
Importance: High
Dear Dr. Collins and Dr. Fauci,
I am sorry to say that our lack of preparedness for the coronavirus pandemic has
its roots in the way biomedical research is funded in the United States, as well as
in the lack of leadership and vision on the part of NIH and its institutes since the
SARScoronavirus outbreak in 2003. I try to expand on these problems in the
article below. I would welcome your response to my thesis.
Sincerely,
Nejat Duzgune~, Ph.D.

Professor of Microbiology
Department of Biomed ical Sciences
Arthur A. Dugoni School of Dentistry
University of the Pacific
155 Fifth Street, Room 412
San Francisco, CA 94103
(b)(6)
lJ',;fVl~'-fTYI>J 1111
PACIFIC
\ r I h 11 , \ I)" ~ ,, n 1
"t..ht,,)I nl lltn11,lr\
The Wuhan Coronavirus(COVID-19):Why there is no cure or vaccine
NIH-001215
In their Medical Virology text published in 1994, 0 .0 . White and F.J. Fenner stated
"No convincing evidence has yet been obtained to link human coronaviruses with
serious disease ..., but they are an important cause of that trivial but annoying
disease, the common cold." This generalization changed drastically with the
emergence of the severe acute respiratory syndrome coronavirus in 2002-2003
(SARS-CoV), and the National Institutes of Health (NIH) immediately sought the
expertise of these two scientists at the time. Now, 17 years later, we still do not
have an antiviral medicine or a vaccine against the novel coronavirus that
originated in China, now designated as COVID-19 by the World Health
Organization (WHO). On February 21, there were 75,567 cases and 2,239 deaths
in China; and 1,152 cases outside China, with 8 deaths, according to the Director-
General of the WHO. The two viruses appear to use the same gate (or "receptor")
on host cells to infect them. Despite such expected similarities between new and
old strains of the viru s, research on coronaviruses has not been a priority for the
National Institute of Allergy and Infectious Diseases (NIAID). In the end, all that
the Director of NIAID was able offer is "good healthcare" as a remedy for COVID-
19 infections.
The major reason we do not have a cure for coronaviruses is that there has been
no coordinated effort by the NIAID to establish long-term research programs
focused on coronaviruses . Realizing the insufficient progress in this area,
the NIAID announced on February 6 a "Notice of Special Interest to highlight the
urgent need for research on the 2019 novel Coronavirus." Grants have indeed
been awarded to some scientists since 2003, but such grants are highly
competitive, with success rates of applications to NIAID between 14 and 18%,
indicating that 82-86% of applicants are unable to obtain funding to carry out
research. The time and effort spent on preparing grant applications to NIH are
enormous, diverting these precious resources from actual research to what some
scientists call "grantsmanship" (essentially, the ability to sell your idea to a review
committee!). These "games scientist play" to procure funding are a hindrance to
the progress of science. The fact that we do not have a cure or a vaccine against
coronaviruses over the past 17 years since the SARS epidemic, attests to this
detrimental effect .
Development of a vaccine against COVJD-19tis also not straightforward.SARS

was probably not considered by NIH to be an important pathogen on which to
NIH-001216
spend resources. Even if the biomedical research community had developed a
vaccine against coronaviruses, pharmaceutical companies would probably not
have considered it a profitable endeavor. Therefore, it is essential for public funds
to be used by NIH and the CDCto both discover an effective vaccine and to
manufacture it.
We need to ensure that long-term projects to develop antivirals and vaccines

against coronaviruses and other infectious agents, including tuberculosis and
influenza virus, are implemented and fully funded. We need to have a funding
system that does not depend on the often unfounded criticism or whims of grant
reviewers . Although the current peer review system is touted generally as the
best way to allocate funding , it has never been tested scientifically against an
alternative. While half of the NIH budget (currently $39 billion) may still be
allocated for high-cost projects, including clinical trials , the other half should be
awarded for periods of 10 years or longer to established scientists who have a
track-record of scientific work, as well as to young scientists who are starting their
first independent position . The budgets of these grants would be somewhat
limited, but would provide uninterrupted funding and alleviate the stress of
competing for renewals every 3-5 years. Scientists opting for these grants will not
have to submit extensive grant applications. More importantly , this system will
more than double the number of independent investigators . After a 10-12 year
period, the scientific productivity (per grant dollar) of scientists on the classical
grant system would be compared with that of scientists on long-term funding.
After all, the way we choose the mode of science funding should conform to the
way science progresses , by experimentation and analysis .
NIH-001217
Sent : Fri, 28 Feb 2020 04:05:11 +0000
To : Robert Durr
Subject : RE:Covid-19
We will be looking at this.
From: Robert Durr

------------
Sent : Thursday, February 27, 2020 2:03 PM
------
(b)(6)
::;..,..-,=
Subject : Covid-19
-------- (b)(6 )1>
Dr. Fauci,
This may be terribly simp listic, but if Covid-19 binds to ACE2 recep tors in host cells, has anyone looked
at ACE2 recep tor blockers as potent ially ameliorating disease severity or infectivity?
Sincerely,
Robert Alan Durr, M.D.
NIH-0012 18
Sent : Fri, 28 Feb 2020 04:04:26 +0000
To : HMS-Faculty Affairs Senior Appointments
Subject : RE: Confidential Evaluation Request on behalf of Harvard Medical School Dean
George Q. Daley, MD, PhD (b)(6)
Dear Dr. Cotti:

I am very sor ry, but I just do not have time to do this right now. I am inundated 24/7 with
coronav irus issues. I hope thatyou understand.
Best regards,
Tony
From: HMS-Faculty Affairs Senior Appointments

<FacultyAffairs _SeniorAppointments@hms.harvard.edu>
Sent : Thursday , February 27, 2020 1:59 PM
To: Fauci>Anthony (NIH/NIAID) [E] ------- (b
= )- (~6)>
Cc: Cott i, Dagmara <Dagmara_Cotti@hms .harvard .edu>; Tekleab, Sarah
<Sarah_Tekleab@hms.harvard .edu>
Subject : Confidential Evaluation Request on behalf of Harvard Medical School Dean George Q. Daley,
MD, PhD - (b)(6]
Dear Dr. Fauci,
-
Attached is a letter from George Q . Daley, MD, PhD, Dean of the Faculty of Medicine at Harvard
University and Caroline Shields Walker Professor of Medicine, requesting your evaluation of H
- academic accomplishments. The fol lowing materials are also attached: (b)(6)
curriculum vitae, an annotated bib liography of(b)(6)'self-selected 10 most significant scholarly works , and
the criteria by which 'CbH
6>:
qualifications are to be evaluated .
Please confirm receipt of this communication and let me know if you will be able to complete an
evaluation. When composing your evaluation, please address the questions in Dean Daley's letter . We
would greatly appreciate receiving letters of evaluation by Thursday, March 26, 2020. We are grateful
for your time and expertise and we apprec iate your conside ration of this request.
Warm regards,
Dagmara
DAGMARACOTT
I, PhD
NIH-0012 19
Program Director for Academic Affairs
Harvard Medical School I Office for Faculty Affairs

Gordon Hall, 25 Shattuck Street, Suite 206 I Boston, MA 02115
office : 617.432.6889 I fax: 617.734.4382 I Hours: M-F 8:30am-4:00pm
fa.hms.harvard.edu
Executive Assistant : Sarah Tekleab
Sarah Tekleab@hms.harva rd.edu I office: 617.432 .7438
NIH-001220
Sent : Fri, 28 Feb 2020 03:57:45 +0000
To: HJ Mai
Cc: Billet, Courtney (NIH/NIAID) [El
Subject: RE: Confirma tion of report
This is really not true. It was taken vey much out of context.

To: Fauci, Anthony (NIH/NIAID) [El _______
------~~ _.
(b)(6)>
Subject : Confirmation of report
Dear Dr. Fauci,
This is HJ from NPR again. I was wondering if you could confirm a NYT report that says the Wh ite House
has instructed you not to say anything about the coronavirus outbreak without prior approval.
Kind regards,
HJ
I HJ Mai I Editor, Morning Edition I hma i@npr.org I

-----
(b)(6)
NIH-001221
Sent: Fri, 28 Feb 2020 03:54:23 +0000
Subject: FW: Idea for coronavirus contention
NIAID inquiries, Please
From: Blanco, Luz {NIH/NIAMS) [E] _______ '> (b) ( _.

Sent: Thursday, Febru ary 27, 2020 2:51 PM
To: Collins, Francis (NIH/OD) (E]
Cc:Gottesman, Michael {NIH/0D~)-:[~E]:-=====~- ""'~""'(= >; Fauci, Anthony {NIH/NIAID) [E]
(b
(b)(6) >
Subject: Idea for coronavirus contention
Importance: High
Dears Dr Collins, Dr Gottesman, and Dr. Fauci:

I am reaching to you with t his idea that might sound weird but I th ink it might be helpful. I have this idea
to reduce the coronavirus infection and spread ing. It is very simple but can get more complex as well.
(b)(5)
(b)(5 . I do not have the capacity to work or promote these ideas but
---------------
hope f u IIy you have the power for doing so. Thanks, regards
Luz P. Blanco PhD.
Staff Scientist
SAB, NIAMS, NIH
NIH-001222
Sent : Fri, 28 Feb 2020 03:54:22 +0000
Subject : FW: Coronavirus: CONFIDENTIAL: (b)( 4) info
Attachment s: image00l.png , 2018_Book_ UnderstandingTheHostl mmuneResp.pdf, Advances
in Clinical Chemistry 2018.pdf, BBASR-2016.pdf, Ch-22-francisandtaylor-2017.pdf, chapter-2012.pdf,
GSH2005.pdf, HIVclinical trial2015.pdf, HIVclinical trial2017.pdf, macrophages2012.pdf,
macrop hages2013 .pdf , NKCELLS2008.pdf, NKCELLS2012.pdf, RBC-HIV paper_2014 .pdf
Please take a look at this.

From: ParikJ1, Purvi_ ________ (b.,...
.,...
)(=6)>
Sent: Thursday, Febrnary 27, 2020 10:39 PM

To: Fauci, Anthony (NTH/NIAID) [E] ------~~ (b)(6);
Subject: Coronavin.1s: CONFIDENTIAL: (b)( 4) info
Hi Dr Fauci
You must be swampe d with corona virus related correspondence but wanted to pass on some resea rch that may prove
helpfu l with coronavirus_
This pham1acist also plans to meet with Trump administration in upcoming weeks .
Jt may prove useful. l havent had a chance to dive deeply into the science of it so dont know efficacy but they are
preparing a proof concept.
Main researcher is Nayan Patel and his email is ________ Cb

_ )_(_,
6)
Sincererely,
Purvi Parikh , M.D., FACP

Allcrgy /lmrmmology Attending Physician
Clini cal Assistant Profe ssor , Department of Medicine and Department of Pediatrics Division oflnfectious Diseases
and Immunolo&'YDivision of Rh eumato logy Allergy and Asthma Associa tes of Murray Hill
212-685-4225 (office numb er)
212-696-5682 (fax)
From: Purvi Parikh (b)(

Sent: Thursday, February 27, 2020 9:43:18 PM
To: Parikh, Purvi
Subject: Fwd: CONFIDENTIAL: (b) (4) info
(EXTERNA L]
Sent from my iPhone
NIH-001223
From: Heather Pixton (b) (6)
Date: Februa 3, 2020 at 12:43:59 PM EST
To: ___________ _ (b)(6)
Subj ect: FW: Fwd: CONFTDENTTAL: (b) (4) info
Hi Purvi,
Here is the email from Dr Patel with his research and other relevant PubMed links. The body of the emai l provides
an idea of what he has been working on and how he hopes to conu·ibute to the CWTentoutbreak.
I would be happy to connect Dr Patel with you (or someone you suggesl) should you find the informa tion provided
warrants further inquiry.
Warm Regards,
Heather
Heather Pixton
CSO Pharmacology & Compliance r CABODf
[bttps://res.cloudinary.com/drasifo1s/image/upload/vl5449 l 0436/ 1130-cedrecfc.elI.jpg) <tel: (b) (
----- (b) (6) I Q1ttps://res.cloudinary.com/drasifolsiimage/upload/v1544910437/ 1130-cedrec/mail.jpg]

<mailto:Cedrec@SpectrumHP.com> Heather@CabodiCo.com<mailto:Heather@CabodiCo.com> L
[https://res.cloudinary.com/drasifo 1s/image/upload/vl5449 l 0436/ l l 30-cedrec/web.ipg)
http://www.bestefekt.com<https:/furl defense.proofpoint.com/v2/url?u=http-
3A www.bestefekt.com &d=DwMFaO&c=j5oPpO0eBHl iio48DtsedeEIZfc04rx3ExJHeIIZuCs&r=TxeKofMBvU
AkTP9Z8swJDuMT3NwOKJuoZJ8jdtz5TG0&m=yoSwihtDg3ar56w 9cgDSwhynOlH-
OCP4NL4AZXwE63E&s=eCWhMiiUaJaCzK ImNZOpB2IpoltX9tSrTR2KsTm Rof&e=>
(b)(6)
From: Heather (b)(6) >

Sent: Monday , Februar 03, 2020 12:21 PM
To: Heather Pixton --------. (b)( ..._--~~
Subject: FW: Fwd: CONFIDENTIAL : (b)( 4) info
Sent from Mai l<https:// go.micro soft.com/fwlink/?Linkld = 550986> for Window s 10
From: Cedrec Sumimoto <mailto

-_,..,---------(b)(
Sent: Saturday , Febrnary I, 2020 12:30 PM
To : Heather Pixton<mailto (b)(6)
Subject: Fwd: CONFfDENTlAL: (b)(4) info
(b)(6)
-------- ForwardedMessage --------

Subject:
CONFIDENTIAL: (b)(4 info
Date:
F1i, 3 I Jan 2020 15:25:40 -0800
NIH-001224
From:
Nay an Pate I______________________ (b

_~
_<_,
To:
Cedrec Sum imoto (b)(
Hello Cedr ic,
(b) (4)
NIH-001225
(b) (4)
Best Wishes,
(b) (4)
CONFIDENTIALITY NOTICE: This e-ma il message from Cent11tlDrugs (including all attachments) is for the sole
use of the intended recipient(s) and may contai n confidential and privileged information. Any w1authorized review ;
use, disclosure, copying or distribut ion is st.rictly prohibi ted. If you are not the intended recipient, please contact the
sender by reply e-mail and destroy all copies of the original message."
felt
·--
NIH-001226
Sent : Fri, 28 Feb 2020 03:53:06 +0000
To : Leonard Schleifer
Cc: Erbelding, Emily (NIH/NIAID) [E);Mascola, John (NIH/VRC) [E];Cassetti, Cristina
(NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [El
Subject : RE: Regeneron COVID-19 update
Len:
Thanks for the note . Of course, we would be interested in working w ith you as you develop
t hese antibodies.
Best regards,
Tony
From: Leonard Schleifer

--------------
Sen t : Thursday, February 27, 2020 3:25 PM
------~~
To : Fauci, Anthony {NIH/NIAID) [E] (b)(6)>
(b)(6)
Cc: Conrad, Patricia (NIH/NIAID) [E!.

] =======~ (b'"""
)(6)
Subject: Regeneron COVID-19 update
Tony,
Obviously you are swamped and the country is likely safer for it ! I wanted to be sure you were up to
date on our efforts re COVID-19. (b)(4 )
(b)(4)
We have had discussions with our part ners at BARDAand have had contact with the Wh ite House.
(b) (4)
In the near future we will have a cocktail of antibodies ready for testing and we would be delighted to
work with you and the NIH if that makes sense.
-----
If you would like to discuss further, please call my cell (b)(6) at anyti me.
Len
* *** ** *** **** ******** ***** **** *** ** *** ********* **** **** **** *** ** **** This e-mail and any
attachment hereto, is intended only for use by the addressee(s) named above and may contain legally
privileged and/or confidential information . If you are not the intended recipient of this e-mail, any
dissemination , distribution or copying of this email, or any attachment hereto, is strictly prohibited . If
you receive this email in error please immediately notify me by return electronic mail and permanently
delete this email and any attachment hereto, any copy of this e-mail and of any such attachment, and
any printout thereof . Finally, please note that only authorized representatives of Regeneron
NIH-001227
Pharmaceuticals, Inc. have the power and authority to enter into business dealings with any third party.
********************************************************************
NIH-001228
Sent: Fri, 28 Feb 2020 03:42:11 +0000
To: Phillips, Kyra
Subject : RE:Confidential
Than.ks, Kyra.

From: Phillips, Kyra <Kyra.Ph illips@abc.com>
------~~
To: Fauci , Anthony (NIH/NIAID) [E] ...______ Cb
_)_C
=
_.
6l
Subject: Confidential
Dear Tony,
This note is between long time colleagues.
This entire Coronavirus sto1y, and the handling of it, has really escalated into an unexpected journey. [ want you to
know how much I have respected you professionally and medically for nearly 20 years. I also wan t you to know that
J have appreciated how we have communicated through the years about threats to om world's health and how
honest and transparent you have aJways been. l know you are in a unique situation and I want you to know that 1
respec t that and would never put you in a situation with my co1Tes pondence that would j eopard ize you in anyway.
With that said, I hope you can keep me informed, off the record if need be, so I ca n continue to cover this story
honestly and fairly.
With utmost respect,
Kyra
@KyraPbillips
AB C News
lnvestigative Correspon dent
KyraPhillips.Com
(b)(6)
NIH-001229
Sent: Fri, 28 Feb 2020 03:16:38 +0000
To : Alice Park
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject : RE: Time follow up
Alice:
I am so sorry that I have not gotten back to you. I have been inundated 18 to 19 hours per
day. By the t ime I get to e-mail it is late at night. I will try to connect with you tomorrow.
Best,
Tony
From: Alice Park <alice.park@time.com>

------~~
To: Fauci,Anthony (NIH/NIAID) [E]
Subject : Re: Time follow up -------- (b)(6)
Hi -- do you have a few minutes to talk about the following? Happy to chat whenever you're
free. Best, Alice
On Wed, Feb 26, 2020 at 11:50 AM Alice Park <alice.park@t ime.com> wrote:
Hi Dr. Fauci -- have a couple of requests for you, one of which is to speak at our
upcoming Time 100 Summit in April -- about COVID-19. I'l l be sending a formal invite but
wanted to explore your interest and availability.
Also wanted to speak to you about a story I'm work ing on concern ing the risk of community
spread of COVID-19 in the US. Wanted to get your perspective on the CDC warning and
where those cases might come from. Happy to chat whenever you 're free; I'm relatively free
today and this evening. Best, Alice
PLEASE NOTE NEW PHONE NUMBER

Alice Park
TIME
212 522 9830
alice.park@time.com
@aliceparkny
NIH-001230
Sent: Fri, 28 Feb 2020 02:49:34 +0000
To: SuzanneBradley
Subject : RE:URGENT
There is much misinformation. I actually bave not been muzzled at all by the Vice President. And BTW, it is safe
to fly domestically (b) ( ·.
---------~~
From: Suzanne Bradley
-----------
Sent: Thursday , February 27 , 2020 5:32 PM
-----~~=
(b) ( >
To: Fauci, Anthony (NTH/NTAID)[E]

Subject: URGENT -------- (b)(6) >
Dear Dr. Fauci ,
J understand Vice President Pence has ordered you to not inform the public about Coronavirus without approval.
This is quite terrifying, espec ially since Trump has already shown his desire to spread false or incomplete
information about this public healtJ1 crisis.
J'm planning to fly dom estica lly TOMORROW

-------- (b) ( ·. Is it safe??
Thank you,
Suzanne Bradley
NIH-001233
Sent : Fri, 28 Feb 2020 02:46:07 +0000
To : NIAIDODAM
Subject : FW: question
Let us discuss, but almost certain ly no.
From: Fleisher, Thomas {NIH/CC/DLM) [VJ (b) (6) >

Se nt : Thursday, February 27, 2020 5:36 PM
--------
To: Fauci, Anthony {NIH/NIAID) [E]------- ~=
--------- (b)(6)
Cc: Lang, David <LANGD@ccf.org>; Kay Whalen <KWhalen@aaaai.org>; Rebecca Brandt (AAAAI)
<rbrandt@aaaai.org>
Subject: question
Tony,
As you are acute ly aware , the COVID-19situation is on everyone's mind and accordingly there have
been questions raised by members of the AAAAI about what the organization can do to provi de more
guidance in this evolving situation. In light of this linked to the fact that our annual meet ing begins
March 13 in Philadelphia, we have made the decision to have a 45-60 minute session in the main hall on
Saturday (March 14) morning from 7:00-8:00 prior to the scheduled plenary session slated to start at
8:15. My question is whether you would consider taking the Acela up Friday evening returning Saturday
morning to host this session w ith a presenta tion followed by a Q&A session. If that is not possible,
would you be willing to provide a 10-15 minute (shorter if you deem that appropriate) video generated
as close to the 14th as possible that we would have projected in the main hall as noted above . If the
latter, would you have a suggestion of an ID person in Philadelphia who would be knowledgeable and
could field quest ions following your video . I recognize t hat even if you are willing to come to
Philadelphia, that circumstances could arise that would preclude you r traveling in which case we would
ask for a video if at all possible . Finally, if neither option is possible, is there somebody in DC (includ ing
NIH), Baltimore or Philadelphia who could provide the short review and then sit for 30-45 minutes of
Q&A. I am well aware that this is last minute and you have been incredibly busy with issues related to
th e pandemic, any help you could provide would be much appreciated by my colleagues and me.
Regards,
Tom
Thomas A. Fleisher, M.D.

Scientist Emeritus
Department of Laboratory Medicine
NIH Clinical Center
Bethesda, MD 20892
(b) (6) (tel)
301 -402 -1612 (fax)
The contents of this message,together with any attachments, are intended only for the use of the person(s)
to wh ich they are addressed and may contain confidentia l and/or privileged information . Further, any
medical information herein is confidential and protected by law. It is unlawful for unauthorized persons to
NIH-001234
use, review, copy, disclose, or disseminate confidentia l medical information. If you are not the intended
recipient, immediately advise the sender and delete this message and any attachments. Any distribution, or
copying of this message, or any attachment, is prohibited.
NIH-001235
Sent : Fri, 28 Feb 2020 02:43:32 +0000
To: NIAIDODAM
Subject : FW: Invita tion to speak at National Academies workshop
Attac hments : FMT Vaccines SOT 12.20.pdf
Let us discuss.
From: Pavlin, Julie <JPavlin@nas.edu>

-------~= (b)(6)>
Cc: Conrad, Patricia (NIH/NIA ID) [El!.=======~ (b..-
H=6)>
Subject : Invitation to speak at Nationa l Academies workshop
Dear Dr. Fauci,
It is my pleasure to invite you to present at the National Academies of Sciences, Engineering, and
M edicine workshop on "The Critical Public Healt h Value of Vaccines -Tackling Issues of Access and
Hesitancy." This workshop will be held on May 28-29, 2020 at the Pan American Healt h Organization
(PAHO) headquarters in Washington, DC. The statement of task for the workshop is attached.
The 1.5-day workshop will provide a venue to examine the current state of vaccine preventable diseases
and the impact of vaccine access and hesitancy on vaccine preventable diseases globally, as well as the
multidimensional drivers and impacts of declining vaccine confidence . This workshop wi ll explore health
systems, research opportunities , communication strategies, and policies that could be considered to
address access, perceptions, att itudes, and behaviors towa rd vaccination. The workshop will be
broadcast live over the web to an international audience, and is being hosted by the National
Academies' Forum on Microbial Threats .
Due to your in-depth expertise in this field, we would like to invite you to give a plenary presentation on
the developmentof new vaccinesin the midst of an outbreak, specificallyon the prospects of a
coronavirusvaccine.The primary audience for the event w ill be researchers, health practitioners,
industry leaders, and policy makers in infectious diseases and global health, so we are looking to initia te
this workshop with relevant discussions of barri ers to accessing vaccines. Your responsib ilit ies would be
to prepare and del iver a 15-minute presentat ion. We would cover your travel expenses in accordance
with U.S. federal government rules. We would be thankful to have your involvement in this workshop.
Please let me know if you might be interested. I would be happy to answer any questions you may have.
Thank you in advance for your time and considerat io n. We understand that th is is a very busy time and
your calendar may be in flux.
Best w ishes,
Julie
Julie A. Pavlin, MD, PhD, MPH
Director, Board on Globa l Health
Health and Medicine Division - Find us at nationa lacademies .org /HMD
The National Academies of Sciences, Engineering, and Medicine
NIH-001236
500 Fifth Street, NW
Washin gton, DC 20001
Phone: 202-334-2171
Follow Us
The National Academi of

CIE G · M DIC!
-------- ------
--------------
ORGANIZING COMM ITTEE-THE CRITICALPUBLICHEALTHVALUE OF VACCINES-TACKLING ISSUESOF
ACCESSAND HESITANCY
HEIDI LARSON (Co-Chair), Professor of Anthropology, Risk and Decision Science, London School of
Hygiene & Trop ical Medicine
MATTHEW ZAHN (Co-Chair), Medical Director , Division of Epidem iology and Assessment, Orange County
Health Care Agency
KEVIN ANDERSON, Senior Program Manager, Chemical & Biological Defense Division, Science &
Technology Directorate, Department of Homeland Security
ALISON BUTTENHEIM, Associate Professor, Family and Commun ity Health, School of Nursing, University
of Pennsylvania
ANDREW CLEMENTS, Deputy Directo r, Pandemic Influenza and Othe r Emerging Threats Unit, USAID
AMANDA COHN, Executive Secretariat, Adv isory Comm ittee on Immun izat ion Practices, US Centers for
Disease Control and Prevent ion
PETER DASZAK, President, EcoHealth Alliance
EVA HARRIS, Professor and Director, Division of Infectious Diseases and Vaccino logy, Center for Global
Public Health, University of Californ ia, Berkeley
ELIZABETH D. HERMSEN, Head, Globa l Antim icrob ial Stewardship , Merck & Co., Inc.
NONI MACDONALD, Professor, Department of Pediatrics, Dalhous ie University, Nova Scotia, Canada
WALT ORENSTEIN, Professor and Associate Director , Emory Vaccine Center
NIH-001237
Sent : Fri, 28 Feb 2020 02:42:42 +0000
To: Jon Cohen
Cc: Conrad, Patricia (NIH/NIAID) [El
Subjec t: RE: Interview request--typo fixed
Jon:
I am drowning right now. However , I am always happy to speak with you. Cannot do it until I dig out from
under. Hopefully, soon.
Best,
Tony
----- Original Message- ----

From : Jon Coh en <jcohen@aaas.org>
Sent: Thursday, February 27. 2020 5:48 PM
To : Fauci, Anthony (NTH/NIAJD) [E] ------::-::-:-=
(b)( >
Su~ject: Interview request- -typo fixed
Dr.Fauci,
J was most pleased to bear Sec. Azar 's commitment to "radical transparen cy." 1n that vein, l would like to interview
you about COVID-19 for a Science magazine article! am preparing .
Thanks in advance,
Jon Cohen
Science
NIH-001238
Sent: Fri, 28 Feb 2020 02:32:50 +0000
To : Billet, Courtney (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject : RE:Question on report Dr. Fauci told he cannot speak with media unless cleared
by White House
That is not what I said. I said for SARSthe virus went from bat to civet cat to human; for MERS
it went from bat to camel to human. I said we did not know what the animal reservoir was for
the jump from animal to human with the nove l coronavirus. Please tell her that. Thanks.
From: Billet, Courtney (NIH/NIAID) [E]

-------- (b)(6)

Cc: Folkers, Greg (NIH/NIAID) [E ] ..:.::====== (b
~ ~~(6)
"" Conrad, Patricia (NIH/NIAID) [E]
(b) (6) >
Subject: Fwd: Question on report Dr. Faucitold he cannot speak with media unless cleared by White
House
Q from Donna Young re comments In VP pool report:
Do they now know the novel coronavirus jumped from a bat to a civet cat [skunk]
served at feasts in China and then jumped to humans?
Is that the source for certain? Or was he just giving an example? Is there
something you can provide to show that in formation?
From: "Young, Donna" <Donna.Young@spglobal.com>

Date: Thursday, February 27, 2020 at 7:01:00 PM
To: "Billet, Courtney (NIH/NIAID) [E]" <
------~~ (b)(6)
Cc: "Stover , Kathy (NIH/NIAID) [E]" (b)(6) _>, "NIAID NEWS(NIH/NIAID)"
<NIAIDNEWS@niaid.nih.gov>, "My les, Renate (NIH/OD) [E]" (b)(6)
Subject : Re: Question on report Dr. Faucitold he cannot speak with media unless cleared by White
House
Thank you. Also, can you please clar ify what was in the VP pool report today.
Do they now know the novel coronavi rus j umped from a bat to a civet cat [skunk] served at
feasts in China and then jumped to humans?
Is that the source for certain? Or was he just giving an example? Is there something you can
prov ide to show that information?
Than k you again.
NIH-001239
Donna Young
Senior Reporter , Healthcare (Washington , DC)
S&P Global News
donna .young@sp global.com
301.216 .2433 desk
Cb)(6) cell
@DonnaYoungDC - 'the pharma diviner'
http ://market intelligence .spg loba l.com/our-thinking/news .html
From: Billet, Courtney (NIH/NIAID) [El

Sent : Thursday, February 27, 2020 6:55 PM-------- (b)(6)>
To: Young, Donna <Donna.Young@spglobal. com>

Cc: Stover, Kathy (NIH/NIAID) [E] (b)(6)>; NIAID NEWS (NIH/NIAID)
<NIAIDNEWS@niaid .nih .gov>; Myles, Renate (NIH/OD) [El CbH ; Billet , Courtney
(NIH/NIAID) [El Cb)( >
Subject : Re: Question on report Dr. Fauci told he cannot speak with media unless cleared by White
House
Can you just attribute to NIAID spox? I ask because he's on meetings and calls ..,,
From: "Young, Donna" <Donna .Young@spglo bal.com >

Date : Thursday, February 27, 2020 at 6:52:48 PM
To: "Billet, Courtney (NIH/N IAID) [El"
Cc: "Stover, Kathy (NIH/NIAID) [El"
;-l.======~~ (b)(6), "NIAID NEWS (NIH/NIAID)"
<NIAIDNEWS@niaid .nih .gov>, "My les, Renate (NIH/OD) [E]" (b)(6)>
Subject : Re: Question on report Dr. Fauci told he cannot speak with media unless cleared by White
House
Thank you . Is Dr. Fauci stating it is not tru e? Do I attribute to him or you stating the New York
Times report is not true?
Thank you for your help.
Donna Young
Senior Reporter , Healthca re (Washington , DC)
S&P Global News
donna.young@sp global.com
NIH-001240
301.216.2433 desk
(b) (6) cell
http://mark etintelligen ce .spg loba l.co m/our-thinking/news .html
From: Billet, Courtney (NIH/NIAID) [El (b)(6)

--------
To: Young, Donna <Donna .Young@spg loba l.com >
Cc: Stover, Kathy (NIH/NIAID) [E] (b)(6)>; NIAID NEWS (NIH/NIAID)
< NIAIDNEWS@niaid .nih .gov>; Myles, Renate (NIH/OD) [El (b)( >
Subject: Re: Question on report Dr. Fauci told he cannot speak with media unless cleared by White
House
Donna, so sorry, it's been a crazy day. We are not sure exactly where this came from. It's not true.
From: "Young, Donna" <Donna .Young@spg loba l.com >

Date: Thursday, February 27, 2020 at 5:32:22 PM
To: "NIAID NEWS (NIH/NIAID)" (b)(6)>, "Stover, Kathy (NIH/NIAID) [E]"
(bH6J>, "Myles, Renate (NIH/OD) [El " (b)(6)>, "Billet, Courtney
(NIH/NIAID) [El" (b)(6)
Subject: Re: Question on report Dr. Fauci told he cannot speak with media unless cleared by White
House
Hi. I'm still waiting for a response on th is. Could you at lest tell me me you are going to
respond?
Thank you.
Donna Young
Senior Reporter , Healthcare (Washington, DC)
S&P Global News
donna.you ng@spglobal .co m
301.216.2433 desk
(b) (6) cell
NIH-001241
http ://marke ti ntelliqence .s pg loba l.com/our -th i nkinq/news .htm I
From: Young, Donna

To: NIAID NEWS (NIH/N IAID) <NIAIDNEWS@niaid.nih .gov>; Stover, Kathy (NIH/NIAID) [El
CbH6J>;Myles, Renate (NIH/OD) [El (b)(6) ; Billet, Courtney
(NIH/NIAID) [E] (b)( >
Subject: Question on report Dr. Fauci told he cannot speak with media unless cleared by White House
Good Day: Could you please comment on this report from the New York Times that Dr. Fauci
has been told that he must clear anything he plans to say about the coronavirus outbreak with
the White House before he speaks to any media?
https://www .nyt imes.com/2020/02/27 /us/ po lit ics/us -coron avi rus -pen ce.htm I
"Dr. Anthony S. Fauci, one of the country's leading experts on viruses and the director of the
National Institute of Allergy and Infections Diseases, told associates that the White House had
instructed him not to say anything else without clearance."
Has Dr. Fauci or any other NIH official been told by the White House t hey cannot speak to the
media unless cleared by the White House?
Please do le t me know.
Donna Young
Senior Reporter , Healthcare (Washington, DC)
S&P Global News
donna.young@spgloba l.com
301.216.2433 desk
(b) (6) cell
http://ma rketintelligence .spg loba l.com/our-thinking/news .html
NIH-001242
The information contained in this message is intended only for the recipient, and may be a confidential attorney-client communication or may
otheiwise be privileged and confidential and protected from disclosure. If the reader of this message is not the intended recipient. or an
employee or agent responsible for delivering this message to the intended recipient. please be aware that any dissemination or copying of
this communication is strictly prohibited. If you have received this communication in error, please immediately notify us by replying to the
message and deleting it from your computer. S&P Global Inc. reserves the right, subject to applicable local law, to monitor, review and
process the content of any electronic message or informat ion sent lo or from S&P Global Inc. e-mail addresses without informing the sender
or recipient of the message. By sending electronic message or Information to S&P Global Inc. e-mail addresses you, as the sender, are
consenting to S&P Global Inc. processing any of your personal data therein .
NIH-001243
Sent: Fri, 28 Feb 2020 00:4 7:19 +0000
To : Mar k Zuckerberg
Subject: RE:
Mark:
Thanks for the note . If we start in April ( ~6-7 weeks from now ) with a phase 1
trial of 45 subjects, it will take another 3-4 months to determ ine safety and some
immunogenicity . The next step is phase 2 for efficacy . We may need help with
resources for the phase 2 tria l if we do not get our requested budget
supplement. I believe that we will be OK. If thi s goes off track, I will contact
you. Many thanks for t he offer . Much app reciated .
Best regard s,
Tony
Director
Build ing 31, Room 7A-03
National Institutes of Hea lth
Phone : (b)(6)
FAX : (301 496-4409
E-mail : (b)(6)
From: Mar k Zuckerberg Cb)(6)

Sent : Thur sday, Febru ary 27, 2020 7: 16 PM
To: Fauci, Anth ony (NIH/ NIAID) [E]_______
------~= _.
(b)(6)>
Subject :
Tony :
I was glad to hear your statement that the covid -19 vaccine w ill be ready for human trials in six weeks.
Are there any resources o ur found ation can help provide to pot ent ially acceler ate t his or at least make
sure it stays on track ?
Mark
NIH-001245
From: (b)(6)
Sent : Thu, 27 Feb 2020 17:43:18 -0500
Subject : Fwd: Or. Fauci--Coronavirus comment 3/2 Healthline MEDIA
Sent from my iPhone
From: Kristen Fischer Cb)(

To : "Fauci , Anthony (NIH/NIAID) [E]" --------~= CbH6)
Subject: Dr. Fauci--C oronavirus comment 3/2 Healthlin e ME DIA
Hi there,
I'm writing for Healthline abou t coronavirus and how the virus spread may be differen t in the
Southern Hemisphere (they mention that in the story below). Care to weigh in?
I'd love to know :

I. W ill coro naviru s be any less severe in the Sout hern Hemisp here due to the summe r weather there
at the moment?
2. W ill the virus spread in No rth America slow down due to geog raph y or wam1er weather at all?
What can we expect in 3 months --and in one year as far as coronav irus in the U.S .?
3. Will it differ in how it spreads /tapers off in As ia, due to proximity of the outbreak?
4. Will this event ually be gone or will it be som ething that is a new health threat that could return in a
year or so?
5. Any insight inl'o the outlook of coronavir us, how it will sprea d or how long it will be active?
Lookin g for a brief email response by Monda y morn ing at 10a.m. Let me know if you can assist !
Warmly,
Kris ten Fischer
Kristen Fischer
v,rww . kristenfischer .com
(b) (6j
Find your family fun at the Jersey Sbore --get yourfree weekly e-news letter today!
See your produ ct or serv ice Re-viewed by Kr isten Fisc her
NIH-001246
Sent : Thu, 27 Feb 2020 16:29:44 +0000
Subject : FW: Covid-19--Conference Call Invitation
Let us di scuss. Likely do not have tim e fo r t his.
Director
Phone (b) (6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Buono, Lucia <LBUONO@imf.org> On Behalf Of Gopinath, Gita

To: Fauci, Anthony (NIH/NIAID) [El -------::-::-=, (b)((;)>
Cc: Gopinath, Gita <GGopinath@imf.org>; Milesi -Ferretti, Gian Maria <GMILESIFERRETT
l@imf.org>;
Celasun, Oya <0Celasun@imf .org>; Nabar, Malhar Shyam <MNabar@imf .org>; Christiansen, Lone Engbo
<LChristiansen@imf .org>; Buono, Lucia <LBUONO@imf.org>
Subject : Covid- 19--Conference Call Invitation
On behalf of Ms. Gopinath:
Dear Professor Fauci:
We are contacting you in the context of the evolving spread of Covid-19, which is already impacting
livelihoods and economic activity in several countries. As you may know, the IMF publ ishes forecasts of
economic growth for member countries four ti mes a year, as we ll as macroeconomic pol icy
recommendations. In that context, it would be invaluable for us to hear public health experts' views on
the likely trajectory of the virus-the number of people that are likely to get infected in different
countries and the likely time path. We would also benefit from heari ng experts' views on the optimal
public health policy response in different types of countries (countries w ith stronger or weaker health
systems, different development levels, etc.), and the implied resource needs.
We are planning to set up a conference call with several experts to discuss these issues and were
wondering if you would be available to join us. If you would be interested in joining, would you be able
NIH-001247
to let my assistant Lucia Buono (lbuono@imf.org ) know of some dates and times that would work for
you this week or early next week?
We would be extremely grateful for any guidance you might be able to offer as we strive to do our part
in helping member countries respond to the epidemic.
Best regards,
Gita Gopinath
Economic Counsellor and Director
Research Department
International Monetary Fund
NIH-001248
Sent : Thu, 27 Feb 2020 13:31:19 +0000
To: Conrad, Patricia (NIH/NIAID) [E);Barasch, Kimberly (N IH/NIAID) [C]
Subject : FW: The global health leaders call, Wednesday 4 March at 13:00 CET
Attachment s: (b)(4) Swisscom Call code.pdf
FYI
Director
Phone : (b) (6)
FAX : (301 496-4409
E-mail: (b)(6)
From: RYAN, Michael J. (b)(6b

------
To: Redfield, Robert R. (CDC/OD)--------------------~~
(b)(6); Jeremy Farrar

(b) (6); Fauci, Anthony
(b)(6)
Conrad, Patricia (NIH/NIAID) [E]
(b)(6)
(b) (6); President I Resolve to Save Lives
(b)(6)
Tarik Mohammed
------------
Cc: SHOC <shoc@who.int>; Office of the Director-General <DGOffice@who .int>; SCHWARTLANDER,
Bernhard F. (b)(6h; MAHJOUR, Jaouad (b)( ; FALL, lbrahima Soce
CbH >; GREIN, Thomas (b)(6) M INHAS, Raman (b)(6); COX, Paul
Michael (b)( >; AL-SHORBAJI,Farah (b)(6) _>; POOLE, Marcia
(b)(6); DRURY,Patrick Anthony CbH ; GRAAFF, Peter Jan
""'::::====~~
____ _ ,>; Dr VAN KERKHOVE,Maria
_ )_C6)
Cb (b)(6); KABIR, Sophia
NIH-001252
(b)(6)'> ; FARES,Christine Youssef
------ (b)(6)
Subject : The global health leaders call, Wednesday 4 March at 13:00 CET
Dear colleagues,
Dr Tedros would like to invite you to the next informal discussion about the ongoing 2019 novel
coronavirus.
The teleconference will be hosted on Wednesday, 4 March at 13:00 CET and the dial-in number
with a passcode is attached.
If you experience any technical difficult ies joining this conference call, please contact the WHO
HQ EOC operator at: +41227912490
It wou ld be appreciated if you could kindly confirm your participat ion to Ms Sophia Kabir, email :
CbH6Jt; mobile no.
------- (b)(6)
The agenda and background documents will be shared ahead of t he call.
Best,
M ike
NIH-001253
Sent: Thu, 27 Feb2020 04:44:07 +0000
Subject : FW: [EXTERNAL) RE:Hardball Tonight
FYI. (b)( .
----- Original Message -----

From: Matthews , Chris (NBCUniversal, MSNBC) <k ennedynixon @m snbc.com >
Sent: Wednesday , Febrnary 26 , 2020 2:39 PM
To: Fauci , Anthony (NIH/NIAID) [E] ------~~ (b)( >
Subject: Re: [EXT ERNAL] RE: Hardba ll Tonight
When you can and are ready , Twould love to have you on Hardball anytime in the 7pm hour tonight , tomorrow or
Friday.
Sent from my iPhone
> On Feb 26, 2020, at 11:34 AM, Fauci, Anthony (NlH/NlAID) [EJ ______ Cb_
H_,
6)> wrote:
>
> Chris:
> I am always happy to be on your show . I am hearing that they want us to hold on doing any interviews for the
time being since the POTUS might do a press conference tonight. And so the decision is still in flux.
> Tony
>
> Anthony S. Fauci , MD
> Director
> National Institute of Allergy and Infectious Diseases Building 31,
> Room 7A-03
> 3 LCenter Drive , MSC 2520
> National Institutes of Health
> Bethesda , MD 20892-2520
> Phone (b) (6)
> FAX: (301) 496-4409
> E-mail:
-------- (b)(6)
> The inf orma tion in this e-ma il and any of its attachments is confiden tial and may contain sensitive infonnation. It
should not be used by anyone who is not the original intended recip ie nt . Tfyou have received this e-mail in error
plea~e inform the sender and delet e it from your mail box or any other storage devices. The National lm;titule of
Allergy and Infectious Diseases (NIAID) shaJI not accept liability for any statements made that are the send er's own
and not exp ressly made on behalf of the NIAID by one of its representatives.
>
> ----- Original Message ---- -
> From: Matthews , Chris (NBC Universa l, MSNBC) <kenn edynixon @msn bc.com >
> Sent: Wednesday, February 26, 2020 9:04 AM
> To: Fauci, Anthony (NlH/NIAlD) [E) ------~= (b) ( >
> Subject: Hardball Tonight
>
> Dear Tony-
>
> Coul d you come on tonight to address the coronavirus? We'd like to
> have you on anytime in the 7 hour. (b) (6)
>
> Best, Chri s
NIH-001254
>
NIH-001255
Sent : Thu, 27 Feb 2020 04:35:33 +0000
Subject : FW: Can you chat?
Please set this up. Thanks.
From:Fox, Lauren <Lauren.Fox@turner .com>

Sent: Wed nesday, February 26, 2020 5:41 PM
To: Fauci, Anthony (NIH/NIAID) [E]-------=- (b)c-c
(= >
Subject : Can you chat?
Hey Dr. Fauci,

I wanted to reach out because I am working on a big piece about the effort behind the scenes to contain
the coronavirus and I was hoping you could talk on background about that,
Best,
Lauren Fox
Lauren Fox
Congre ssional Reporter
CNN Politics
Lauren.Fox@turner.com
(b)(6)
NIH-001256
Sent : Thu, 27 Feb 2020 04:34:46 +0000
To : Arturo Casadevall
Subject : RE: My OpEd on the WSJ coming out Friday on convalescent serum fo r
Coronavirus
Arturo:
Thank you for your note and for sending the Op Ed. Nice Job! I hope that all is well w ith
you.
Best,
Tony
From: Arturo Casadevall (b)(6)>

Se nt: Wednesday, February 26, 2020 5:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] ------=-c (b)'""'
(6)
=
Subject : My OpEd on the WSJ com ing out Friday on convalescent serum for Coronavirus
Dear Tony,
I just had an OpEd accepted in the WSJ proposing the use of convalescent sera to stem the coronavirus
epidemic. The text of the OpEd is below in blue font (scroll down). I am sure the WSJ will shorten it and
edit it but at least you have an advance copy of it. I just wanted you to have it since the WSJ is read
widely in DC and I don't want anyone blindsiding you with quest ions about it.
As you know I have been long proponent of passive antibody therapies in infectious diseases and there
is a huge body of historical data support ing this approach. Certainly, with modern blood banking
techniques this option can be made quite safe and administration of a few cc' s of serum could confer
immediate immun ity to those who will be exposed - like ER staff . I hope you agree with the message
and like it.
Thank you for all you are doing for the country and humanity . If you need me for anything in this crisis
rest assured that I am here.
Warm regards,
Arturo
From: Taranto, James <james.tarant o@wsj.com>

To: Arturo Casadevall (b)(6)>
Subject : Re: Asking for a quick decision on the submitted OpEd on stemming coronavirus epidemic
OK, we'll take this and aim to get it out in Fr iday's paper, though it will likely need some
trimming for space.
Dear Mr. Varadara jan,
NIH-001257
I wonder if the WSJ is interes ted in my OpEd. I am trying to get a message out that
conva lescen t serum (e .g . serum from people who recover) can be used to stem the coronavirus
epidemic if admini stered to exposed people. This has been known for ove r a century, and is
well accepted, but not wide ly known, even among experts today. There was one report that
China was beg inning to stockpile serum but there has been almost no discuss ion of this option
among world public health authorities . Although I can get this published in a medical journal
my hope is to publish it instead in a venue of high readership since this is something that can
be done today to stem the epidemic. I am hoping that given the econom ic consequences of the
outbreak that the WSJ is interested . I included a brief bio below. Thanks for looking at this.
Arturo
Prop osed op-ed.

To Stem the Coronavirus Epidemic use Survivors Blood.
(b) (4)
NIH-001258
(b)(4)
Arturo Casadevall MD, PhD
Author's brief bio

Arturo Casadevall, M.D., Ph.D., is a Bloomberg Di stinguished Profes sor and Chair of the
Molecular Microbiology and Immunology at Johns Hopkin s School of Public Health. He
received his M.D . and Ph.D. degrees from New York University. He completed his
internship/residency in internal medicine at Bellevue Hospital and specialized in Infectious
Diseases at the Albert Einstein College of Medkine . The author of over 800 papers , books and
chapters, bis major research interests are in fungal pathogenesi s and the mechanisms of
antibody action. He is also interested in the problems with scientific enterprise and with
collaborators showed that misconduct accounts for the majority of retracted publications. He
is editor-in-chief of mBio, Depu ty Editor of the Journal of Clinical Investigation and serves on
several editoria l boards . He has served on severa l NIH committees including the NIA ID
Strategic Plan , the Blue Ribbon Panel on Biodefense Research , the NAS panel tha t reviewed
the FBI investigation on anthrax attacks, the NAS Federal Regulations and Reporting
committee and the National Science Advisory Board for Biosecurity . He was a Commissioner
NIH-001259
in the National Commission on Forensic Science and previously served as President of the
Medical Mycology Society of the Americas. He is currently the Chair the Board of Governors
of the American Academy of Microbiology. He has received numerous honors including
election to the American Society for Clinical Investigation , American Academy of Physicians ,
American Academy of Microbiology , Fellow of the American Academy for the Advancement
of Science , American Academy of Alts and Sciences and the National Academy of Medicine .
Arturo Casadevall MD, PhD

Chair, Molecular Microbiology & Immunology
Alfred & Jill Sommer Professor and Chair
Bloomberg Distinguished Professor
Johns Hopkins School of Public Health
615 N. Wolfe Street
Room E5132
Baltimore, Maryland 21205
NIH-001260
Sent: Fri, 6 Mar 2020 03:48:12 +0000
To: Marston, Hilary (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E];Lane, Cliff
(NIH/NIAID) [E]
(b)(5)
Thanks .
From:Marston, Hilary (NIH/NIAID) [E] (b)(6)>

Sent: Thursday, March 5, 2020 10:15 PM
To: Fauci, Anth ony (NIH/NIAID) [E]----- --=
(b-"
H= 6J>; Lerner, Andrea (NIH/NIAID) [E]
(b)(6); Lane, Cliff (NIH/NIAID) [E] (b)(6)
(b) (5}
Importance:High
(b) (5l
From: "DLGDESK (HHS/ASPR/OPP)" <DLGDESK@hhs.gov>

Date: Thursday, March 5, 2020 at 6 :19 PM
________
To: "Stannard, Paula (HHS/I0S)"
Robert (OS/ASPR/I0)"
__._
--------~=
CbH >, "Trueman, Laura (HHS/IEA)"
CbH6)
1
(b)(6) "Agnew, Ann (HHS/10S)"
>, "Bird, Catherine (OS/OGC)"

(b)(6)"Kadlec,
CbH >, "Hittle, Taylor (HHS/ASFR)" CbH6J>, "Arbes , Sarah

---:-"""""".'"."."'::======~~~
(HHS/ASL)" CbH6)>,"Murphy, Ryan (OS/ASPA)" CbH6)>,
"Destro, Brenda (HHS/ASPE)" CbH >, "Nevel, Amy (HHS/ASPE)"
-------- CbH6J>,
11Giroir, Brett (HHS/OASH)"
"Tobias, Constance (HHS/DAB)"
CbH >, "Schwartz, Erica (HHS/OASH)"
CbH6J>,
CbH6J , "Severino, Roger (HHS/OCR)" CbH6J>, "Grigsby,

Garrett (HHS/OS/OGA)" CbH6J>, "Kerr, Lawrence (HHS/OS/OGA)"
--------- CbH >, "Chang, Wi llia m (HHS/OGC)"

11Tait sman, Julie K (OIG/I0)"
CbH6J 1
>,
CbH6)>,"Gr iswold, Nancy (HHS/OMHA HQ)"
--:-'."""'.'~-=====:...:...
Lynn (ACF)"
__ (b)(6)>,"Rucke r, Donald (OS/ONC)"
....;.,=
CbH6>1>,"Meyers , David (AHRQ/ I00) "
(b)(6J
1>, "Johnson,
(b)(6) "McNellis, Robert (AHRQ/CEPI)"

==========:-;:~ (b)(6)>, "Patel, Anita (CDC/DDID/NCIRD/0D)" (b)(6),
-------------
11 Et hier, Kathleen (CDC/DDID/NCHHSTP/DASH)" CbH6)>,"Brookes, Brady (CMS/DA)"
(b)(6) "H inton, Denise
(FDA/OC)"
---------- CbH6)>,"Cheever, Laura (HRSA)" (b)(6)
NIH-00096 1
"Espinosa, Diana (HRSA)" Cb)( >, "Macrae, Jim (HRSA)" Cb)( >,
"Weahkee, Michael (IHS/HQ)" CbH6)>,"McCollum, Jeffrey T (IHS/HQ)"
CbH6)>, "Frazier, Francis (IHS/HQ)"
Francis (NIH/OD) [El" CbH>, Anthony Fauci CbH6)>,
Hilary
Marston CbH6J
1>, "Mccance-Katz, Elinore (SAMHSA/OAS)"
(b)(6) "Shuy, Bryan (OS/ASPR/10)" -----~~ CbH6)>,
":':""'.'"-:---.---".""'.""':~~-:--:'"'.""."'.":====--__;_~
"Yeskey, Kevin (OS/ASPR/10)"
~ CbH6), Rick Bright CbH6)>,
"Disbrow, Gary (OS/ASPR/BARDA)" CbH6J>, "Phillips, Sally (OS/ASPR/SPPR)"
CbH >, "Greene, Jonathan (OS/ASPR/EMMO)" CbH6),
-------
11 DeBord, Kristin (OS/ASPR/SPPR)" CbH6)>, "Vineyard, Michael
(OS/ASPR/10)" CbH6)>, "Dodgen, Daniel (OS/ASPR/SPPR)"
--------- (b)(6), "Imbriale, Samuel (OS/ASPR/SIIM)"

"Donne IIy, Kelsey (OS/ASPR/SPPR)(CTR)" CbH6)>,"Haris, Mariam
(b)(6),
(OS/ASPR/SPPR)(CTR)" CbH6)>, "Fucci, Michael (OS/ASPR/SPPR)(CTR)"
-------- (b)(6)>,"Roman-Stolte, Claudia (05/ASPR/SPPR) (CTR)"

, "Austin, Meredith (uscg.mil)" CbH6J>,"Perdue,
(b)(6)
Christopher (OS/ASPR/SPPR)" CbH6)>, "Herrmann, Jack

(OS/ASPR/OEA)"_ __:__ _:_======:: (b ~)(~6):,- ~R'o""'.'
b_e_rt'""'.'
Jo-:h-n-so- n (b)(6)
11 Wong, Diana (OS/ASPR/SIIM)" ----------
CbH6J> , "Robertson, Lance (ACL)"
CbH6)>, "Nicholls, Richard (ACL)" (b)(6)
"Phillips, Christine (ACL)" CbH6)>, "Blatner, Gretta (OS/ASPR/BARDA)"
CbH6)>, "Feeney, Kathryn (OS/ASPR/10}(CTR)" CbH6J>,
--------
11ShirIe y, Mayo (FDA/OC)" CbH>, "Sheehy, Janice (FDA/ORA)"
(b)(6)"McDaniel, Eileen (HHS/OMHA)" CbH6)>,
--:----:-----::======~~~
Linda Lambert Cb)( >, "Gin, Julia (OS/ASPR/SPPR)" CbH6),
"Adams, Steven A. (CDC/SNS/DSNS)" (b)(6),"Wolf, Laura (OS/ASPR/SIIM)"
CbH6J>, "Lee, Scott (OS/ASPR/EMMO)" CbH6)>,
"Cooper, Kevin
(OS/ASPR/ORM)" CbH6)>, "Moudy, Robin (OS/ASPR/SPPR)"
CbH6)>, "Lawrence, Theresa (OS/ASPR/SPPR)"
-:========~.......,
= CbH6J, "Baker, Michael (OS/IEA)" ------- .-..----.-.-=
CbH6J>
-----------
Cc: "Holland, Tara (OS/ASPR/EMMO)" CbH>, "Delvecchio, Paolo
(SAMHSA/OMTO}" CbH6), "Lobos, Elisa (SAMHSA/OFR/0D)"
-:-----:---:----:-::--::====:....:.__..:.,_ >, "Bell, March
__ (HHS/OCR)"
.:..,__..:,_~~ CbH6),"Frohboese,
Robinsue (HHS/OCR)" (b)(6),"Knutson, Donna
(CDC/DDNID/NCEH/OD)'
;____;,_ __
~====~~-~-----:-"
·
..:.,__...:____;,_.=-~~-----=~
(b)(6)"Mackay, Thomas (OS/ASPR/EEAA)"
.......~--~----"".'":"."':== Cb=H=6)'.....
M_a_n.:::.
g...:
o'....:
P_a_u....:
I (....:
H_H~S/:....
l~OS)" CbH6)>,"Blackford,
Carol W. (CMS/CM)" CbH6J>, "Bradsher, Kris (HHS/ASL)"
CbH6)>, "Payne, Skip (CMS/OA)" CbH6J,"Gettinger ,
Andrew (OS/ONC)" CbH6)>, "Abbey, Rachel (OS/OSCP)"
"Cosgrove, Sandra (OS/ASPR/EEAA)"-------~=
--------
11Cha put, Daniel (OS/ONC)"
CbH6)>,
CbH6)
CbH6)>,
(b)(5)
NIH-000962
Dear Disaster Leadership Group (DLG) Members ,
(b) (5)
We are asking that you review this draft and
provide feedback to us by 8 :00am on Friday, March 6. Please note that we are looking for subst antive
feedback only .
If you have any quest ions or concerns, please reach out to me a Cb)(6) and kindly
copy the DLGDESK@hhs.gov .
----------
Thank you,
Daniel Dodgen, Ph.D.

Senior Advisor
Office of the Assistant Secretary for Preparedness and Response (ASPR)
Office of Strategy, Policy, Planning and Requirements {SPPR)
(DHHS) I O'Neill House Office Building

HEALTHAND HUMAN SERVICES I 200 C Street SW I Washington,
DC 20515
o. (b)(
--------- (b)(6) I www .phe .gov
NIH-000963
Sent : Tue, 3 Mar 2020 11:12:55 +0000
To : (b)(6) (OS/IOS)
Subject : RE: Single-cell RNA expression profiling of ACE2,the putative receptor of Wuhan
2019-nCov I bioRxiv
Oh, I see what they are getting at. They examined at the single cell level the expression of RNA for ACH2, which
is the receptor for the Coronavirus in the lung ,and found that when they looked at various demographic groups there
was greater expression of this recep tor in Asian males. They are thus hinting that this is the reason why there was
such an explos ion of infections in China. This is possible, but the lowest level was in Northern Ltalians and take a
look at what is happening in Nort hern Ttaly. I do not mean to put the paper down since there may be some truth in
it. However, this journal (bioRxiv) is not peer reviewed and the data are skimpy. Someone should do a more
scholarly st udy.

From: (b) (6) (OS/1OS) -------=,.,..,.=(b) (
Sent: Tuesday, March 3, 2020 5:54 AM-----~~
To: Fauci, Anthony (NIH/NlAID) [E] (b)(6) >
Subject: Re : Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-oCov I bioRxiv
They asked if this proved certain ethnic groups more likely to get the disease and 1 said I had never anything like
that suggested to me by our leading scientists.
> On Mar 2, 2020, at L0:44 PM , Fauci, Anthony (NIH/N[AJD) (E) (b) ( wrote:
>
I do not know what question they asked you about th is paper , but any question about this gene expression paper to a
non-scientist wou ld be unfair and inappropriate.
From: Cb)(6) (OS/IOS) -------=~=-- Cb)(6)>
To: Fauci, Anthony (NlH/NIAID [filJ Cb)(6)> ; Redfield , Robert R. (CDC /OD) Cb)(6)
Cc: Harrison , Brian (HHS /IOS) (b) (6),
Subject: Single-cell RNA expression profiling of ACE2 , the putative receptor of Wuhan 2019 -nCov I bioRx iv
Was asked about this on tv tonight.
https: //www .biorxiv .org/co ntent/ 10.110 1/2020.01.26.9 19985vl
NIH-001022
Sent : Tue, 3 Mar 2020 03:26:29 +0000
To : Collins, Francis (NIH/OD) [E);Giroir, Brett (HHS/OASH)
Cc: Steele, Danielle (HHS/IOS);Tabak, Lawrence (NIH/OD) [E]
Subject: RE: SARSCoV-2 in humanized mice
Ditto.
From: Collins, Francis (NIH/OD) [E] (b)(6)

To: Giroir, Brett (HHS/OASH)
------~=
Cc: Fauci, Anthony (NIH/NIAl ~ D:-'. ~:::::::::~
) [:::E':""
] :::·>; Steele, Danielle (HHS/10S)
--------- (b)( ; Tabak, Lawrence (NIH/OD) [E]

Subject : RE: SARSCoV-2 in humanized mice
(b)(
Larry has it right . Tony may want to add.
Francis
From: Tabak, Lawrence (NIH/OD) [El (b)(6)

To : Giroir, Brett (HHS/OASH) -------=-=-=-
Cc: Collins, Francis (NIH/OD) ~
[E:':"
) ====== 6)>; Fauci, Anthony (NIH/NIAID) [E]
~ )~(~
(b
-------- CbH >; Stee le, Danielle (HHS/10S)

Subject : Re: SARSCoV-2 in humanized mice
(b)(6)
Brett,
I hope this helps.

Larry
--------
From : "Giroi r, Brett (HHS/OASH)" <
Date: Monday, March 2, 2020 at 7:25 PM
(b) (6) ,
To: "Tabak, Lawrence (N IH/OD) [E]"

_ _:__;___;_::...:,~~"""'.'""--:---:--".-::::==------=..,..=,
Cc: Francis Collins Anthony Fauci
(b)(6) 1>, (b)(6)>, "Stee le,
Danielle
---=======::::!..~~
(HHS/ 10S)" "Giroir, Brett CbH6)>, (HHS/OASH)"
(b)(6)
Subject : RE:SARSCoV-2 in human ized mice
NIH-001025
Dear Larry,
I appreciate your will ingness to cont inue to work on this and respond to the questions that I am
receiving .
V/r
Brett
Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: (b) (6)
From: Tabak, Lawrence (NIH/OD) [E] (b)(6)

Sent : Thu rsday, February 20, 2020 5:29 PM
~ :.:======;:~
Cc: Collins, Francis (NIH/OD) [E] (b)(6)>; Fauci, Ant hony (NIH/N IAID) [E]
(b)(6); Steele, Danielle (HHS/10S)
--------
Subject : Re: SARSCoV-2 in humani zed mice
(b)(6)>
Brett ,
I have discussed w ith both Francis and Ton (b) (5l
·-----------------
W ith regard to your questions:
(b) (5)
NIH-001026
(b) (5)
Hope this is helpf ul. Please let me know if you require additional info r mat ion .
Best wishes,
Larry
From: "Giroir, Brett (HHS/OASH)" (b)(6)

--------
0 ate : Thursday, February 20, 2020 at 12:32 PM
To: "Tabak, Lawrence (NIH/OD) [E]" -------- ..----.-.-=
Cc:"Stee le, Danielle (HHS/10S)"
;.....:.
___..!======~~- (b)(6)
----------
Subje ct: RE: SARSCoV-2 in human ized mice
(b)(6)
(b)(5)
Brett P. Giro ir, MO

Washington, DC20201

To : Giroir, Brett (HHS/OASH) (b)( >
Cc: Steele, Danielle (HHS/10S) (b)(6) ,>
Subject : Re: SARSCoV-2 in humanized mice
NIH-001027
(b) (5)
Thanks
Larry
From: "Giro ir, Brett (HHS/OASH)" (b) (6) 1>

-----------
Date: Thursday, Februa ry 20, 2020 at 12:17 PM
To: " Tabak, Lawrence (NIH/OD) [El" ---------=--=-=
;.....:.-=======~~- (b)(6)
Cc: "Stee le, Danielle (HHS/10S)"
Subject:
----------
RE:SARSCoV-2 in human ized mice
(b)(6)
Larr
(b)(5)
Brett P. Giroir, MO
ADM, USPublic Health Service
From: Tabak, Lawrence (NIH/OD) [E] (b)(6)

Sent: Wednesday,February 19, 202011 :04 PM
To: Giroir, Brett (HHS/OASH) (b)(6)
Cc: Steele, Danielle (HHS/10S) (b)(6)
Subject : FW: SARSCoV-2in humanized mice
Brett,
(b) (5)
Thanks for your consideration,

Larry
From: "Hasenk rug, Kim (NIH/N IAID) [El" (b)(6)

-----------
Date: Wednesday, February 19, 2020 at 5:50 PM
NIH-001028
To: "Tabak,Lawrence(NIH/OD)[E)" ,__ ________ (b)( 6)
Subject: SARSCoV- 2 in human ized mice
(b) (5)
Hi Dr. Tabak
(b) (5)
Best regards ,
Kim
Kim J Hasenkrug, Ph.D.

Senior Investigator
Chief, Retroviral Immunology Section
Laboratory of Persistent Viral Diseases
Rocky Mountain Laboratories
903 S. 4th Street
Hamilton, MT 59840
(b)(6)
Disclaimer:
The information in this e-mail and any of its attachments is confidential
and may contain sensitive information. It should not be used by anyone who
is not the original intended recipient. If you have received this e-mail in
error please inform the sender and delete it from your mailbox or any other
storage devices. National Institute of Allergy and Infectious Diseases
shall
not accept liability for any statements made that are sender's own and not
expressly made on behalf of the NIAi D by one of its representatives
NIH-001029
Sent : Mon, 2 Mar 2020 00:48:25 +0000
To : Cassetti, Cristina (NIH/NIAID) [E];Giroir, Brett (HHS/OASH)
Subject: RE: COVIDand Chloroquine
Thanks, Cristina
From: Cassetti, Cristina (NIH/NIA ID) [E)

Se nt: Sunday, March 1, 2020 7:06 PM
---------
------~~
(b)(6)>
Giroir, Brett (HHS/OASH)

(b)( 6)
-------- (b)(6)
Cc: Conrad, Patricia {NIH/NIA ID) [El

Subject : RE: COVIDand Chloroqu ine
--------- (b) (6) >
Hi,
NIAD doesn't have ongoing trials with chloroquine and I heard that such tr ials are being conducted in
China.
We are planning to evaluate chloroquine in animal models ASAP. If any the rapeutic with a good clinical
safety profile ( like chloroquine) appears to be effective in vivo against COVID-19, we are planning to
quickly add to them to the Remdesivi r therapeutic trial as another arm.
Let me know if you have other questions .
Kind regards,
Cristina
Cristina Cassetti, Ph.D.

Deputy Director
Division of Microbiology and Infectious Diseases
Nationa l Institute of Allergy and Infectious Diseases, NIH
560 1 Fishers Lane, Room 7GS1
Rockville , MD 20852
Tel: (b)(6)
(b)(6)
From: Fauci, Anthony {NIH/N IAID) [El

Se nt: Saturday, February 29, 2020 8:20 PM-------- (b)(6)
NIH-001057
To: Giroir, Brett {HHS/OASH) (b) (6l>
"":"::-"'.""":"::-::.::=====--=--c-:-=
Cc: Cassetti, Cristina {NIH/NIAID) [E]
(b) (6)>
Subject: RE: COVID and Chloroquine
--------- (b)(6)>; Conrad, Patricia (NIH/NIAID) [E]
Importance: High
Brett:
Thanks for the note. I will run this by the people in our Program and get back to
you.
Best,
Tony
Cristina:
Are we or anyone else doing anything with clinical trials and chloroquine for
COVID-19? Please respond directly to ADM Giro ir .
Thanks,
Tony
Director
Phone : (b)(6)
FAX : (301 ) 496-4409
E-mail : (b)(6)
information. It should not be used by anyone who is not the original intended recipient . If you
From: Giroir, Brett {HHS/OASH)

--------
(b) (6)>
-------=-,--==
To: Fauci, Anthony {NIH/NIAID) [E)
Subject: COVID and Chloroqu ine
-------- (b)(6)
You know the old data and the new data. New in vitro look promising.
Do you have good visibility on the trials being conducted? Or is NIH runn ing any of these?
Your time is precious, so 10 word response sufficient.
NIH-00 1058
Brett P. Giroir, MD
NIH-001059
Sent: Sun, 1 Mar 2020 22:35:38 +0000
To : Kadlec, Robert (OS/ASPR/10)
Subject: RE: Your thoughts
My thoughts -
----- (b) (5)
Directo r
Phone : Cb)(6)
FAX : (301 496-4409
E-mail : (b)(6)
From: Kadlec, Robert (OS/ASPR/IO)

----------
(b)( >
To: Fauci, Anthony (NIH/NIAID) [ E]------~~

Subject: Your thoughts
-------- CbH6)>
Importance: High
Tony I don't know if you saw t his but wanted to ask your thought. Cb)<5>
Your t houghts always appreciated
bob
<< File: CCDCEpi Report.pptx >> << File:

The+Epidemiological+Characteristics+of+an+Outbreak+of+2019+ Novel +Coronavi rus+Diseases+(
COVID-19)+-+China,+2020.pdf >>
NIH-00 1073
Sent: Sun, 1 Mar 2020 03:55:20 +0000
To : Collins, Francis (NIH/OD) [E]
Cc: Tabak, Lawrence (NIH/OD) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject : RE:HHSCOVID-19 Response· alignment of OPDIV/STAFDIVEfforts
I would recommend Dr. Hilary Marston from my immediate office. Larry should go to the
hear ing with us
From: Collins, Francis (NIH/O D) [ E] (b)(6)

Sent: Saturday, February 29, 202010:48 PM
To: Fauci, Anthony (NIH/NIAID) [ E] ---------.., ~
(b)(6)
Cc: Tabak , Lawrence (NIH/OD) [E] (bH6)>
Subject: FW: HHS COVID-19 Response - alignment of OPDIV/STAFDIV Efforts
Hi Tony ,
Quick question - who would you suggest is the appropriate NIH representa tive for this ASPR-led
trans-HHS effort to coordinate COVID-19 response? You and I will be testifying in front of the
House Approps Subcommittee on Wednesday morning . Would it be best for Larry to represent
NIH for the ASPR gathering (though he would normally attend the House hearing), or is there
someone from NIAID that would be most appropriate?
Thanks , Francis
From: Kadlec, Robert (OS/ ASPR/10)

Sent: Friday, February 28, 2020 10 :23 AM
--------- (b)(6)
To: Tru eman, Laura (HHS/IEA) -------~= (b)(6)>; Rowell, Scott (OS/ASA)
(b)( >; Bird, Catherine (OS/OGC) (b)(6b; Moughalian,
Jen (HHS/ASFR) (b)(6) , ; Arbes, Sarah (HHS/ ASL) (bH6)>;
Murphy, Ryan (OS/ASPA) (b)(6)>; Destro, Brenda (HHS/ASPE)
(bH >; Giroir, Brett (HHS/OASH) (bH6)>; Severino, Roger
":":"':-:--:-:-'.:-=--::::-:-;====::::::.._;__ _ __,;_=
(HHS/OCR) (bH >; Grigsby, Garrett (HHS/0S/OGA)
,,:___;_ _ _;_:====;: (b-;:;
)(;;6);--;K
::--
>"-".e-r-r,-:--
L-awrence ( HHS/0S/OGA) --------- (b..-
H=6);
Charrow, Robert (HHS/OGC) (b)( ; Grimm, Christi A (OIG/10)

(b)(
.....
-----:=======-..:._~= (bH6J>; Griswold, Nancy (HHS/OMHA HQ)
__::_.!:::::======~~-
0 p Divs
Robe rt son,
___ _;___
(b)(6)>; Johnson, Lynn (ACF)
Lance _;__;_::::::~;;--=-----:::--:-:---:--:----:::-:-=.
(ACL) ----------
(bH6)>; Khanna, Gopal (AHRQ/100)
(b)(6)
(b)(6)>; Redfield, Robert R. (CDC/OD) (b)(6) Verma, Seema

":'":-:--:-:-~-:-::::=====~_:_-~~
(CMS/OA) (b)( Saxon, Bobby (CMS/CCIIO)
,,:____:_..:..:::==========::::...-----.-.c,.;
(b)(6) Hinton , Denise (FDA/OC)
-----------------
NIH-001117
(b)(6)>; Engels, Thomas (HRSA) ; Weahkee, Michael
CbH6)
":'-----:---:---'.=======-..:.._
(IHS/HQ) <
-=-~ --------
(b)(6)>; McColl um, Jeffrey T (IHS/HQ)
~....:...-.;.....:=====~~:;----
(b)( 6)>; Frazier, Francis (IHS/HQ) (b)(6)>; Collins,
:.,,.,.=
~-".""""'.'"."'"'"'"-:"".:~~~=::::!...:,_
__
Francis (NIH/OD) [El CbH6) Fauci, Anthony (NIH/NIAID) [E]
1 ;
-------- CbH6)>;Mars ton, Hilary (NIH/NIAID) [E] CbH6)>;McCance-

Katz, Elinore (SAMHSA/OAS)
(b)(6) --------------- (b)(6); Krohmer, Jon (dot.gov)
Cc: Ford-Barnes, Arwenthia (OS/ASPR/IO)

(OS/ASPR/OEA) CbH6);Shuy, Bryan (OS/ASPR/IO) ________
Waters, Cicely
Cb)C6J1;
_,
(b)(6)
Subject: HHS COVI0-19 Response - alignment of OPDIV/STAFDIV Efforts
Dear ASPRColleagues,
We are at a critical juncture in our nation's response to COVID-19. As we pivot from

containment of the virus to mitigation of its impacts, it is imperative that HHS moves
swiftly, transparent ly, and in a unified manner to protect lives and save Americans. The
Secretary has charged my office to lead efforts across the Department to prepare and
defend our health care system during the novel coronavirus outbreak through the
Health Care System Resilience Task Force.
To date, this task force has engaged with public and private sector stakeholders to
broadly identify efforts that can be taken to help ensure preparedness in response to a
domestic COVID-19 outbreak, and more importantly their gaps, challenges, and
potential areas of need from the federal government. Now, we must build on that
knowledge to expedite and execute a whole of HHS response to support protection of
the health care system that spans public health, health care, and human services.
Please join Dr. Kevin Yeskey, ASPR's Principal Deputy Assistant Secretary for
Preparedness and Response, and Dr. Nancy Messonnier, CDC's Director of the National
Center for Immunization and Respirato ry Diseases, on Wednesday, March 4 from 9:00
AM -10:15 AM , at the O'Neill House Office Building for a working session to align
current activities and next steps to be executed as part of a coordinated HHS response
to COVID-19.
Please provide the following information to ASPR.HCSRTF@hhs .gov no later than

Monday, March 2 at 12:00 PM, and be prepared to share and discuss at Wednesday's
session.
• Your Designee(s) name, t itle, and contact information
• OPDIV/STAFFDIVname
• OPDIV/STAFFDIVcurrent and future top five priorities related to

COVID-19 (priority leads, descriptions, timelines)
NIH-001 118
• OPDIV/STAFFDIVkey activities and workgroups (current and under
consideration) related to COVID-19 response (include activity/workgroup
leads, key purpose, timelines)
• OPDIV/STAFFDIVkey areas of concern or challenges identified to

date
• OPDIV/STAFFDIVcore competencies or other assets it can bring to

COVID-19 response efforts
We look forward to working with you on this critical effort to defend the nation's health
care system. Thank you in advance for your support and participation.
Respectfully,
Bob Kadlec
ASPR
NIH-001119
Sent: Sun, 1 Mar 2020 03:26:56 +0000
Subject: RE: HHS COVI0 -19 Response - alignment of OPDIV/STAFDIV Efforts
Francis:
You are correct about the Israeli vaccine. I cannot imagine that they would have a safe and
effective vaccine deployable in 90 days.
Tony
From: Collins, Francis (NIH/OD) [E] (b)(6)>

---------
Sent : Friday, February 28, 2020 12 :56 PM
To: Fauci, Anthony (NIH/NIA ID) [ E].------- -,_.(b-_.,-;
)(= >; Tab ak, Lawrence (NIH/OD) [E]
(b)(6)
Subject: FW: HHS COVID-19 Response - alignment of OPDIV/STAFDIV Efforts
Hi Tony and Larry,
See below for a new Health Care Resilience Task Force being convened by ASPR.
The initial meeting overlaps with our House approps hearing.
Tony, who shall we send to this one?
FC
P.S. to Tony- I'm gett ing a lot of buzz about the Israeli claim to have fast track vaccine:
https:// israelb .org/2020/02/israel-to-have-coronavirus-vaccine-within-3-weeks/ It looks to me
that they are conflating having something ready to put into voluntee rs for a phase 1 trial, and
having full scale production ready to go for the global needs. That still seems like it's a year
away. Am I right?
From: Kadlec, Robert (OS/ASPR/10) (b)(6)

Sent: Friday, February 28, 2020 10 :23 AM
To: Trueman, laura (HHS/IEA) _______ -,;
Cb
..,...
H=6)>; Rowell, Scott (OS/ASA)
(b)( · Bird, Catherine (OS/OGC) (b)( >; Moughalian,
Jen (HHS/ASFR) (b)(6)Arbes, Sarah (HHS/ASL) (b)(6)
Murphy, Ryan (OS/ASPA) (b)(6)>; Destro, Brenda (HHS/ASPE)
(b)(6);Giroir, Brett (HHS/OASH) <: (b)( >; Severino, Roger
":""":":--:"':"":'."':~=====::...-__,; ~
(HHS/OCR) CbH6)>; Grigsby, Garrett (HHS/OS/OGA)
NIH-001 124
CbH >; Kerr, Lawrence (HHS/OS/OGA) CbH6)>;
---------
Charrow, Robert (HHS/OGC) Grimm, Christi A (OIG/I0)
(b)(6)>;
Griswold, Nancy (HHS/OMHA HQ) (b)( >;
--~--=========--.:__~=
Op Divs
---~-"."'-::::====::!....:..
___
CbH6)>;
Johnson, Lynn (ACF) <
(b)( >;
.:.........:~ (b)(6)>;
Robertson, Lance (ACL) (b)(6)>; Khanna, Gopal (AHRQ/10D)
CbH6);Redfield, Robert R. (CDC/OD) CbH6)>;Verma, Seema
":"".'"'""'."":""':"':'.""':"-:-"=======~--..~
(CMS/OA} CbH >; Saxon, Bobby (CMS/CCIIO)
<_ _;___;_:::=========:::::...;_ ..,,)(~6) Hinton , Denise ( FDA/OC)
(b..,...
CbH6)>; Engels, Thoma s (HRSA) -co. CbH6?j>; Weahkee, Michael
7
S/7H::-:
(1-:-:
H-:- Q7) ======:::....:..-,; H=6)>; McColl um, Jeffrey T (IHS/HQ)
(b;.,
Francis (NIH/OD) [El ---------

(b)(6); Frazier, Francis (IHS/HQ)
(b)(6), ; Fauci, Anthony (NIH/NIAID) [El
(b)(6) Collins,
(b)(6)>; Marston, Hilary (NIH/NIAID} [El (b)(6); Mccance-

--------
Katz, Elinore (SAMHSA/OAS)
(b)( > -------------- (b)(6)>; Krohmer, Jon (dot.gov)
Cc: Ford-Barnes, Arwenthia (OS/ASPR/10) (b)(6)>; Waters, Cicely

--:-----:---:----:--:-::=~...:_ __ ...:_~ ~
(OS/ASPR/OEA) CbH6)>;Shuy, Bryan (OS/ASPR/10)
Subject: HHS COVID-19 Response - alignment of OPDIV/STAFDIV Efforts
--------
CbH6)>
Dear ASPR Colleagues,
We are at a critical juncture in our nation's response to COVID-19. As we pivot from

containment of the virus to mitigation of its impacts, it is imperative that HHS moves
swiftly, transparent ly, and in a unified manner to protect lives and save Americans. The
Secretary has charged my office to lead effo rt s across the Department to prepare and
defend our health care system during the novel coronavirus outbreak through the
Health Care System Resilience Task Force.
To date, this task force has engaged with public and private sector stakeholders to
broadly identify efforts that can be taken to help ensure preparedness in response to a
domestic COVID-19 outbreak, and more importantly their gaps, challenges, and
potential areas of need from the federal government. Now, we must build on that
knowledge to expedite and execute a whole of HHS response to support protection of
the health care system that spans public health, health care, and human services.
Please join Dr. Kevin Yeskey, ASPR's Principal Deputy Assistant Secretary for
Preparedness and Response, and Dr. Nancy Messonnier, CDC's Director of the National
Center for Immunization and Respirato ry Diseases, on Wednesday, March 4 from 9:00
AM -10:15 AM , at the O'Neill House Office Building for a working session to align
current activities and next steps to be executed as part of a coordinated HHS response
to COVID-19.
NIH-001125
Please provide the following information to ASPR.HCSRTF@hhs.gov no later than
Monday, March 2 at 12:00 PM, and be prepared to share and discuss at Wednesday's
session.
• Your Designee(s) name, title, and contact information
• OPDIV/STAFFDIV name
• OPDIV/STAFFDIVcurrent and future top five priorities related to

COVID-19 (priority leads, descriptions, timelines)
• OPDIV/STAFFDIVkey activities and workgroups (current and under

consideration) related to COVID-19 response (include activity/workgroup
leads, key purpose, timelines)
• OPDIV/STAFFDIVkey areas of concern or challenges identified to

date
• OPDIV/STAFFDIVcore competencies or other assets it can bring to

COVID-19 response efforts
We look forward to working with you on this critical effort to defend the nation's health
care system. Thank you in advance for your support and participation.
Respectfully,
Bob Kadlec
ASPR
NIH-001126
Sent : Thu, 27 Feb 2020 15:45:23 +0000
To : Zebley, Kyle (HHS/0S/OGA)
Cc: Ker r, Lawrence (HHS/0S/OGA)
Subject: RE: Current TF Agenda Draft/Request fo r AMA High -level Talkers
Att achments: Task Force VP Briefing 2-13-20 - with Fauci TP.docx
Kyle:
Here is a t alking point fo r t he messaging secti on.
Best,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Zebley , Kyle (HHS/05/0GA)

--------
sent: Thursday, February 27, 2020 9:11 AM
(b)(6)
To: Hall, Bill (HHS/ASPA) (b)(6)>; Murphy, Ryan (OS/ASPA) (b)(6);

Trueman, Laura (HHS/I EA) (b)( >; Johnston, Darcie (HHS/I EA)
(b)(6)]; Arbes, Sarah (HHS/ASL) (b)( ; Morse , Sara (HHS/ ASL)
=======::~;;---::--" (b)(6)>; Twomey, John K. (HHS/ASL) (b)(6)>; Pence, Laura
':':
(H""."'.
H
-:-:
S:-:-
/A"."".
S
:"."
L-:;
) :====::!-:....._~ (b.,...
)(,;; >
Cc: Mango, Paul (HHS/10S) (b)(6) ; Bird, Catherine (OS/OGC)

(b)(6) Grigsby, Garrett (HHS/OS/OGA) ,__"."""""''""""":":-""':-::::==(b
= )~(~ >; Kerr , Lawrence
(HHS/0S/OGA) (b)(6); Redfield , Robert R. (CDC/OD) (b)( >; McGowan ,
Robert (Kyle) (CDC/0D/OCS) (b)(6)>; Fauci, Anthony (NIH/NIAID) [E] (b)(6) >;
Conrad, Patri cia (NIH/NIAID) [E) (b)( 6); Kadlec, Robert (OS/ ASPR/10)
-------- (b)( >; Shuy, Bryan (OS/ ASPR/10)

Subject : Current TF Agenda Draft/Request for AMA High-leve l Talkers
(b)(6)
Import ance: High
Good morning,
NIH-001249
Attached, please find a current draft of an agenda for a TF Briefing fo r VPOTUSthis afternoon. Note that
t his is a draft and is not final. However, in order to prepare the Secretary, can ASPA, IEA, and ASL please
help with 2-3 high-level talkers each the Secretary could highlight under the External Activity/Messaging
section of the agenda ? Could you please send to me and Dr. Larry Kerr by 11 AM t his morning?
Apologies for t he quick turnaround .
Dr. Redfield, Dr. Fauci, and Dr. Kadlec, please note your presence on the agenda and please be prepared
to speak to the topics assigned.
Let me know if you have any questions. Thanks for your help.
Kyle Zebley
Chief of Staff
Office of Global Affairs (OGA)
Office of the Secretary
U.S. Department of Health and Human Services
Direct: (b)(6)/Mobile: (b)(6)
Confidential and pre-d ecisiona l communi cation
NIH-001250
Sent: Sun, 1 Mar 2020 20:08:22 +0000
To : Messonnier, Nancy (CDC/DDID/NCIRD/0D)
Subject: RE: mitigation in communi t ies
Attachments : COVID-19 Targeted Layered Mit igation Strategy_lnterim.022820.pdf
I assume that you are OK with the document that Garrett just sent around. See
attached.
Director
Phone : (b) (6)
FAX: (301 496-4409
E-mail : (b) (6)
information . It should not be used by anyone who is not the or iginal intended recipient. If you
From: Messonnier, Nancy (CDC/DDID/NCIRD/00) (b)( >

To: Fauci, Anthony (NIH/NIAID) [E) ------~= (b)( >
Subject: FW: mitigation in communities
From: Messonnier, Nancy (CDC/DDID/NCIRD/0D)

To: Redfield, Robert R. (CDC/OD)
---~~ (b)(6)>
Cc: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <l,.._____ Cb ~ Schuchat,
_ >_<.... Anne MD (CDC/OD)
(b)(6)>
Subject : mitigat ion in communities
Here are the basic high level principles of a miti ation strate y. (b) (5)
(b) (Sl
NIH-00 1087
(b) (5l
NIH-001088
Sent : Fri, 28 Feb 2020 03:02:24 +0000
To: Grigsby, Garrett (HHS/OS/OGA)
Subject : RE:
----------------- (b) (5)
It is a tough decision, (b)(5) ·,

------------
From: Grigsby, Garrett (HHS/OS/OGA) ________
.... (b)( >
To: Fauci, Anthony (NIH/NIAID) [E]-------=- c-c=>; Kadlec, Robert (OS/ASPR/I0)
(b)(6) ; Adams, Jerome (HHS/OASH)
---------
Cc: Harrison, Brian {HHS/I0S) (b)(
(b)(6) •>
Zebley, Kyle (HHS/0S/OGA)
(b)( >
Subject : FW: (b) (5)
-----------------
1mpor tance: High
Gentlemen,
Any problem with this - see Marty's below. Need to know asap as I'd like to
forward to NSCimmediately. Many thanks!
From : Cetron, Marty (CDC/DDID/NCEZID/DGMQ) (b)(6)

------
To: Grigsby, Garrett (HHS/05/0GA ) ------- ........,
=
(b)(6 )>
Cc: Walker, Allison Taylor. (CDC/DDID/NCEZID/DGMQ) (b)(6) McGowan , Robert (Kyle)
(CDC/0D/OCS (b)( Roohi, Shahrokh (CDC/0D1D/NCEZID/DGMQ) (b)(6)
Elvander, Erika (05/0GA) (b)(6)>; Zebley, Kyle (HHS/05/0GA)
(b)(6)>; Jernigan, Daniel 8. (CDC/DDID/NCIRD/ID) (b)(6)
~~~= 00~
Hi Garrett,
CDC intends (b) (5)

(b)(5)
Thanks,
Marty
(b) (5)
NIH-001231
(b)(5)
NIH-001232
From: Fa11ci,Anthony (NIH/N IAID) [E)
Sent : Thu, 27 Feb 2020 04:31:21 +0000
To: MsP
Subject: RE;A note from Sharon Perlman
Sharon:
Thanks for your note. It was great to hear from you. All is wel l with me and my family.
hope the same for you This whole coronavirus situation is rather exhausting since I am
work ing 24/7 with no breaks at all. However , it needs to be done since this virus is a true
t hreat to global heath.
Best regards,
Tony
From: Ms P (b)(6)
Sent: Wed nesday, February 26 , 2020 6:07 PM
-----~~
Subject: A note from Sharon Perlman
------- (b)(6)>
Hi Dr. Fauci,
As I was watching my favorite CNN news show starring Chris Cuomo last night , to
my delight, there you were! And again, this morn ing with John Berman and Alisyn
Camerota on New Day.
I do hope all that all is well with you and your family. We are all do ing fine. My
(b)(6)
NIH-001266
I would love to hear from you, when you have time.
With best regards,

Sharon
NIH-001267
Sent : Thu, 27 Feb 2020 04:27:18 +0000
To: Bennett Werner
Subject: RE: Clinical question, Sir....
Dear Drs. Werner and Ubl: --------------------------- =

(b~, =
,""'
Thank you for your note. , \V~
(b)(6)
----- Original Message--_-_

--_______ _
From: Bennett Werner (b) ( >
-------=-::-=,
To: Fauci, Anthony (NIH/NIAJD) [E] .__ _____ _ )_C... ·
(b
Su~ject: Clinical question, Sir. ...
Dear Dr. Fauci

(b)(6)
By the way, we both feel you are an outstanding spokesperson and really appreciate both the work you do and your
clear explanations on Public TV (and elsewhe re).
Warm regards,
Bennett E. Werner , M.D. F ACC FACP

Cleveland Clinic Cardiology (b) (
Michelle D. Uhl, M.D.

Cleveland Clinic - medical oncology (b) (6)
NIH-001268
Sent: Thu, 27 Feb2020 04:06:03 +0000
To: Morgan Fairchild
Cc: Conrad, Patricia (NIH/NIAID)[El
Subject: RE: Covid-19
Morgan:
Thanks for the note and the offer to help. It would be great if you could tweet to your many
Twitter followers that although the current risk of coronavirus to the American public is low,
t he fact that there is community spread of virus in a number of countries besides China and
including South Korea, Japan, Italy, Iran among others poses a risk that we may progress to a
global pandemic of COVID-19. If that occurs we will surely have many more cases in the USA.
And so for that reason, the American public should not be frightened, but should be prepared
to mitigate an outbreak in this country by measures that include social distancing, teleworking,
t emporary closure of schools, etc. There is nothing to be done right now since there are so few
cases in this country and these cases are being prope rly isolated, and so go about your daily
business. However, be aware that behavioral adjustments may need to be made if a pandemic
occurs.
Best regards,
Tony
From: Morgan Fairchild (b)(

Sent: Wednesday,February26, 2020 8:31 PM
-----~~ (b)(6)>
Subject: Covid - 19
Hi Dr. Fauci. I'm reaching out to see if I can help in any way to get good information out to the public , as I
tried to do with AIDS. I have almost 10D,000 Twitter followers and have been tweeting articles to them
that I feel are helpfu l, but if you have any info I can help disseminate, please let me know.
Also , a great job today and this week!!
Hope you're well!
Thanks!
Best,
Morgan
NIH-001269
Sent : Thu, 27 Feb 2020 03:00:14 +0000
To: Laura Landerman-Ga rber
Subject :
Follow up 2/26/20
RE: Dr Sheldon Wolff Dr Fauci NIH
--------------- (b)(6)
Laura:
Many thanks for your kind note . It was great to hear from you.
Warm regards,
Tony
From : Laura Landerman-Garber (b)(6)>

----------
-----~ ~
(b)(6)>
Subject : Re: Dr Sheldon Wolff Dr Fauci NIH CbH6JFollow up
2/26/20 ---------------
Greetings from New Hampshire. Today I was watch ing the news and there you were , once again
popping up in my life and making me not only smile by your kind and approachable style that I
truly remembe r from the Cb)(6), but also taken care of by your expertise. Thank you for
your medica l leadership during these days as the Coronavirus spread s. Please know that your
legacy of research and practice will live on for generations to come!
I hope that these complex days are soon quieted for us here in the US and around the Globe
Ps (b)(
---------------------------------
Amazing to th ink that so many of my que stions were answered all those decades ago with you
and Sheldon Wolff I remain forever gratefu l. Since I saw you last, CbH6)who you
met, moved to DC and works at American Psychologica l Association. Cb)(6)
. Life marches 011. I hope you and
your family are well
Best,
Laura Landerman-Garber, Ph .D.
On Apr 7, 20 15, at 12: 18 PM , Fauci, Anthony (NIH/NIAID) [E]

CbH6Jwrote:
Laura:
Thank you so much for your beautiful note . I do remember you and am so happy that
you reached out to communicate with me. I am very pleased to hear that you are doing so
well. You have "made my day" by your note . I wish you and your family all the best.
NIH-001270
Warm regards,
Tony
From: Laura Landerman-Garber

~~~-------
Sent: Tuesday,April 07, 2015 10:31 AM
(b)(6)
To: Fauci,Anthony (NIH/NIAID)[E]

Subject: Dr SheldonWolff Dr FauciNIH Follow
up
-------------- (b) (6)
See below please. Thank you!!
Sent from my iPhon e
From: Laura Landerman (b)(

Date: April 7, 2015 at 10:06 :28 AM EDT
To: "niaidnews @nia id.nih.gov " <niaidnews @nia id.nih.gov >
Subject: Dr Anthony Fa uci/ NIH/ Dr SHeldon Wolff l (b)(6) '
followup
Reply-To: Laura Landerman (b) (6)
Greetings from NH. I am trying to contact Dr Fauci after many

~ears . I have followed his career like so man others do... (b)(6)
I am not sure if this can find its way to Dr Fauci but I would so
appreciate it if it could. To let him know that all those years ago ,
NIH-001271
he left n outstanding impression on CbH6)
___ I want to thank him from the bottom of my heart .
Sincerely ,
Laura M. Landerman-Garber , Ph.D.

(b)(6)
(b)(6)
NIH-001272
From : Fauci, Anthony (NIH/NIAID) [E)
Sent : Thu, 27 Feb 2020 02:57:57 +0000
To: LOUIS FORTUNATO
Subject : RE: Dear Tony: Will you take the lead in the Coronavirus prob lem/ we always
love you/Saw you on CNN/
Lou:
I do not believe that there is a chance to republish Harrison Practice .
Best regards,
Tony
From : LOUIS FORTUNATO

------------
------- ~=
(b)(6)
To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)

Subject : Fwd: Dear Tony: Will you take the lead in the Coronavirus problem/ we always love you/Saw
you on CNN/
From: LOUIS FORTUNATO (b)(6)>

Subject : Fwd: Any Chance of Harri son Practice being updated and replaced on the
market ? I loved it Tony/ Better than Harri son's Textbook
To: Cb)(6)
Dear Tony Fauci MD:

Any chance for Harrison Practice being republished again and
updated with the newest Pathophysiology and Treatments?
It was better than Harrisons Textbook/More Precise and Succinct
Please email me/

I would greatly appreciate your response
either wayYes or No//
Dr Lou Fortunato
(b) (6);
NIH-001273
From : LOUIS FORTUNATO
----------- (b)(6)>
Subject : HERETONY IS ANOTHER CHAPTEROF MY FUTURE NUC MED BOOK
Date : November 3, 2019 at 5:11:19 AM EST
To : (b)(6)
HERE TONY IS MY NOTES IN BONE

IMAG ING FO R MY FUTURE BOOK
LOU FORTUNATO
NIH-001274
From: (b)(6)
Sent: Wed, 26 Feb 2020 20:24:59 -0500
Subject: Fwd: [EXTERNAL]Gene-RADAR platform for Real time Mobile (POC)Coronavirus
detection/ viral load monitoring/ Followup to our meeting at the ASPENideas festival -
Please bandle.
Sent from my iPhone
From: "Dr. Anita Goel , M.D., Ph.D. " (bH6)>

Date: Februa ry 26, 2020 at 7:58:54 PM EST
To: "Fauci , Anthony (NIH/NlAI D ) [E]" ---------=-:-:-=
(b)(6)
Subject: FW: [EXTERNAL! Gene-RADAR platform for Real time Mobile
(POC) Coronavirus detection/ viral load monitoring / Followup to our meeting
at the ASPEN ideas festival -
Dear Dr. Anthony Fauci,
It was a great pleasure meeting you all a couple of years ago when we were both speaking
at the Aspen Ideas Festival. Some of my contacts at the CDC recently briefed me about the
rapidly emerging threat of the coronavirus to the US and have been urging us to develop
an app for detecting coronavirus with high sensitivity and specificity on our Gene-RADAR
platform . Our platform has the ability to quantify vi ral loads in ' real-time' which would be a
much more precise and accurate solution in deciding quarantine than the current
thermometers or even the current CDC coronavirus test which has a very poor Limit of
detection (ie low sensitivity).
We have a strong track record of responding to previous pandemic threats and rapidly
building Gene RADARapplications for Ebola and Zika and then getting them through
clinical validation as per the the FDA EUA approval process. Our Gene-RADARZika test was
FDA EUA certified right as the Zika crisis was coming to an end .
I would love to work with you to see how we can help in your efforts to rapidly respond to
this deadly threat to the US and the world. Here are some of the capabilities of our
platform that we believe could be an enabler for helping to stop this out break from
becoming a full-fledged global pandemic.
NIH-001278
• Gene-RADAR platfo rm for Real time M obile (POC)Coronavirus detection/ viral load
monitoring
o Highly sensitive and specif ic - minimize false positives and false negatives
o With very good LOD'swe could potent ially start to catch people
presymptomatically and enable the early detection, early quaran ti ne
would limit the spread and early intervention could lead to better
outcomes
o More precise viral load mon itoring could help determine when to release
people from quarantine or ICU beds
o Our platform's ability to quantify vial loads could change clinical trial
endpoints fo r new drug candidat es or (repurposed drug formulation s),
thereby accelerating FDA approvals for novel therapeutic regimen
o We already have an ISO 13485 certified manufactur ing facility (currently in
Boston) that we are prepared to move as fast as possible to ramp up our
production
We would love to work with you to repurpose our FDA approved platform
for the above coronav irus applications assay and help your noble efforts
to stop th is o utb reak from becoming a full blown global pandem ic that
could costs t housands of lives and cause trillions of dollars of economic
damage to the global economy.
We would love to speak with you to br ief on o ur capabilit ies and discuss how we can
qualify for some of the emergency funding being made available to help tackle this
pandemic threa t .
Happy t o j ump on a phone call to discuss furthe r how we can help
How Nanobiophysics can Stop Ebolaand Other Global Pandemics

• Forbes
• Wired Magazine
Best Wishes,
Dr. Anita Goel, MD, PhD

Chairman &CEO
Nanobiosym
---------------------------------
---------------------------------
www .nanobiosym .com
email : (b)(6)
Mobile : (b)(6)
http ://www. people.fas.ha rvard .edu/~goel/
email: goel@physics.harvard.edu
--------------------------------
--------------------------------
Selected Media links:
Nanobiosym Gene-RADAR® X Prize Grand Prize Winner Video
NIH-00127 9
Dr. Gael's Article in Scientific American Worldview
Nanobiosym Chairman &CEO Named 2018 Uber ELITEAward Winner
FDA Grants Emergency Use Authorization for Gene -RADAR® Zika Test
BBC Feature : The Genius Behind the "Tricorder that could revolutionize medicine"
Nanobiosym Selected As One Of The Top Growth Stage Ventures By The 'Unreasonable '
Group
Dr. Anita Goel, MD, PhD awarded 2019 SEEMA Entrepreneur of the Year Awa rd
How Nanobiophysics can Stop Ebola and Other Global Pandemics

• Forbes
• Wired Magazine
Nanobiosym Global Initiative Summit Website

Wall Street Journal
Washington Post
Boston Globe GameChangers
National Geographic
Forbes
Nanobiosym Space News

CBS News
Boston Business Journal
CNN
DailyMail
Space.com
Popular Mechanics
Forbes
US News and World Report
W ired
Daily Press
CBC Radio
Boston Globe STAT
CONFIDENTIALITY: This email and attachments are intended for the above name only and are confidential. If you are not
the intended addressee. or the person responsible for delivering it to the intended addressee, you may neither copy,
disseminate, nor distribute it to anyone else or use It in a11yunauthorized manner. To do so is strictly prohibited and may
be unlawful. If you receive this email by mistake, please advise the sender immediately by using the reply facility in your
mail software and delete it from your computer
CONFIDENTIALITY: This email and attachments are intended for the above name only and are confidentlal. If you are not
the intended addressee, or the person responsible for delivering it to the intended addressee, you may neither copy,
disseminate, nor distribute it to anyone else or use it in any unauthorized manner. To do so Is strictly prohibited and may
mail software and delete it from your computer.
NIH-001280
disseminate , nor distribute it to anyone else or use it in any unauthorized manner . To do so is strictly prohibited and may
disseminate, nor distribute it to anyone else or use it in any unauthorized manner. To do so Is strictly prohibited and may
CONFIDENTIALITY · This email and attachments are intended for the above name only and are confidential. If you are not
disseminate, nor distribute it to anyone else or use it in any unauthorized manner. To do so is strictly prohibited and may
be unlawful . If you receive this email by mistake, please advise the sender immedia tely by using the reply facility in your
mail software and delete it from your computer
CONFIDENTIALITY : This email and attachments are intended for the above name only and are confidential. If you are not
the intended addressee , or the person responsible for delivering it to the intended addressee, you may neither copy,
disseminate, nor distribute it to anyone else or use It in any unauthorized manner . To do so Is strictly prohibited and may
NIH-001281
From: (b)(6)
Sent: Wed, 26 Feb 2020 19:24:48 -0500
Subject: Fwd: Interview request from WTOP [Please reply all ]
Sent from my iPhone
Beg in forwarded me ssag e:
From: "Ander son, Liz" <landerson @wtop .com >

,------- -;;-c-;=
To: "Fauci , Anthony (NIH/NlAID ) (E]" (b)(
Cc: "Spitaln iak, Law·a" <lspitalniak @wtop.com >
Subject: Interview request from WTOP [Please reply all]
Good Even ing Dr. Fauci,
My name is Liz Anderson, and I'm working the editor's desk

tonight at W TOP .
Are you available for a brief live interview (about 2 minu tes
long) about wh at the latest COVID- 19 dev eloprne nts? During
this evening' s press conference, Pre sident Trump said you two
spok e about it.
The Washington Post is also reporting that the CDC ha s been

informed about the first corona virus case of unknown origin
confirmed in North ern California. We'd also like to talk about
that and what that coul d mean about the spre ad of this virus in
the state s.
We have the following time slots open tonight:
9:l0p
9:40p
NIH-001282
10:lOp
10:40p
11 :I Op
ll:40p
Many thanks for your time.
Sincerely,
Liz Anderson
AE/Editor/Reporter, WTOP News
202-895-5060 (newsroo m)
landerson@wtop .com
Twitter: @planetnoun
http://wtop .com/autho r/ landerson/
http ://wtop .com/autho r/ liz-ande rson/
103.5 FM
. 1 WTOP.COM
NIH-001283
From: (b)(6)
Sent: Wed, 26 Feb 2020 19:24:09 -0500
Subject: Fwd: Interview request from WTOP [Please reply all)
Sent from my iPhone
From: "Anderson, L iz" <landerson @wtop.com >

To: "Fauci , Anthony (NIH/NIAID) [E]"
------~~ CbH6>:
Subject: RE: Interview request from WTOP !Please reply all]
Wait- - I see you're at the press conference, too. If you have availability at one of the ti mes
listed , we'd love to have you.
Many thanks,
Liz
From:Anderson, Liz
To: (b)(6)>
Cc: Spitalniak, Laura <lspitalniak@wtop.com>
Subject: Interview request from WTOP [Please reply all]
Good Evening Dr. Fauci,
My name is Liz Anderson, and I'm working the editor's desk

tonight at WTOP.
Are you available for a brief live interview (about 2 minutes

long) about what the latest COVID-19 developments? During
this evening's press conference, President Trmnp said you two
spoke about it.
NIH-001284
The Washington Post is also reporting that the CDC has been
informed about the first coronavirus case of unknown origin
confirmed in Northern California. We'd also like to talk about
that and what that could mean about the spread of this virus in
the states.
We have the following time slots open tonight:
9:l0p
9:40p
10:l0p
10:40p
11:l0p
11 :40p
Many thanks for your time.
Sincerely,
Liz Anderson
AE/Editor/Reporter, WTOP News
202-895- 5060 (newsroom)
lande rson@w top .com
Tw itte r: @planetnoun
http ://wtop .com/au t hor/ landerson/
http://wtop .com/au t ho r/ liz-anderson/
103.5 FM
1 WTOP.COM
NIH-001285
From: (b)(6)
Sent: Wed, 26 Feb 2020 19:22:28 -0500

Subject: Fwd: AM 970 the Answer Radio Request Re: Coronavirus Response from POTUS
and NIH
Sent from my iPhone
Begin forwa rded message:
From: A lex Gan ett < agar rett @nycradio.com >

To: "Fauci , Anthony (NIH/NlAI D ) [E]" ---------=-:-:-=
CbH6)
Subject: AM 970 the Answer Radio Request Re: CoronavirusResponse from
POTUS and NIH
Hi Dr. Fauci,
I hope you are well! Would love to welcome you to Kevin McCullough Radio on AM
970 the Answer tom orrow to discuss the steps the White House and the NIH are
taking to combat coronavirus. Kevin is our drive-time host at 5 PM and he is
nationally syndicated as well with 300+ affiliates fo r his broadcast!
Look forward to hearing from you . Thanks Dr. Fauci!
Alex Garrett
Producer: Kevin McCullough Radio

AM 570 the Mission WMCA: 3-4 PM
AM 970 the Answer: 5-6 PM
NIH-001286
From: Folkers, Greg (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E)
Sent : Wed, 26 Feb 2020 21:50:05 +0000
To : Laurencot, Elizabeth;Fauci, Anthony (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID)
[E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Eisinger, Robert (NIH/NIAID) [E];Lane, Cliff
(NIH/NIAID) [E]
Subject : RE: NEJM content proof (Fauci)
Eli ,
(b)(5)
Thanks,
Tony
From: Laurencot, Elizabeth <elaurencot@nejm .org>

To: Fauci, An thony (NIH/NIAID) [El------~ (b~)(~6)
Cc: Conrad, Patricia (NIH/NIA ID) [El (b)(6)>; Eisinger, Robert (NIH/NIAID) [El
(bH ; Lane, Cliff (NIH/N IAID) [E) (b)(6) Folkers, Greg (NIH/N IAID)
~-======~~
[El (b)( >
--------
Subject : RE: NEJM co ntent proof (Fauci)
Dear Dr Fauci,
Regarding the following information --

(b)(5)
Please clarify--- thank you!
Best,
Eli
NIH-001287
From: Folkers, Greg {NIH/ NIAID) [E)
[El
-------- (b)~ > On Behalf Of Fauci, Ant hony (NIH/ NIAID)
Sent : Wed nesday, February 26, 2020 3:48 PM

To: Laurencot, Elizabeth <elaurencot@nejm.org> ; Fauci, Anthony (NIH/N IAID) [El
(b)(6)>
Cc: Conrad, Patricia (NIH/NIAID) [El ~-~--~=== (b:::
)(:::
6):!:..
; _E_is_
in.:::.
ge~r~, ~
Robert (NIH/NI AID) [El
(b)( ; Lane, Cliff (NIH/NIAI D) [El (b)(6)>; Folkers, Greg (NIH/N IAID)
":"
[E
:-:-
l.::=======. (b
~~~(6)
--------
Dear Eli,
(b)(5)
NIH-001288
Thanks,
Tony
From: Laurencot, Elizabeth <elaurencot@nejm .org >

Sent: Wednesday, February 26, 2020 9:04 AM
------~=
Cc: Folkers, Greg (NIH/NIAID) [E] ~======'~~
CbH >; Conrad, Patricia (NIH/NIAID) [E]
(b)(6)>; Eisinger, Robert (NIH/NIAID) [El (b)(6)>; Lane, Cliff
":":
(N H/7N"."."
"'.".'
l'."'." IA
'."'."
l':"'.
D):-:[~E]:-===~-~ (b~H=6)
Subject: RE: NEJM content proof (Fauci)
Dear Dr Fauci,
Many thanks for your quick reply and for the clear list of responses regarding the proof. I will rev iew
today and will let you know if there are any items needing fur ther discussion.
The current plan is for publication early Friday afternoon. As I mentioned yesterday, there is a new
article on Covid-19 that is also scheduled for publication that day, and the Journal editors would like you
to mention it in your editorial. I expect to be able to send you a proof of that article sometime today.
Best,
Eli
From: Fauci, Anthony (NIH/N IAID) [E] (b)(6)

To: Laurencot, Elizabeth <elaurencot@nejm .org >
Cc: Folkers, Greg (NIH/NIAID) [E] (b)(6)· Conrad, Patricia (NIH/NIAID) [E]
Eisinger, Robert (NIH/NIAID) [El
(b)(6)>; (b)(6); Fauci, Anthony
"'.'--.---~~===:!._;__...:::..~=
{NIH/NIAID) [E] (b)(6); Lane, Cliff (NIH/NIAID) [E] (b)(6)
Subject : RE: NEJM content proof {Fauci)
Dear Eli,
Here are my answers to you r queries, and co upl e other minor changes:
(b)(5)
NIH-001289
(b) (5)
NIH-001290
(b) (5)
Thanks,
Tony
Director
Phone: (b)(6)
FAX: (301) 496-4409
E-mail (b)(6)
NIH-001291
From: Laurencot, Elizabeth <elaurencot@nejm.org >
Sent : Tuesday, February 25, 2020 8:51 AM
------~~ (b)(6)>
=
Subj ect : NEJM content proof (Fauci)
Imp ort ance: High
Dear Dr Fauci,
Attached is the content proof of your editorial. Please rea d *A LL* of th e fo llowi ng instr uctions and
inform ati on carefull y befo re you begin reviewing your proofs .
First, please st op and take a moment now to confirm receipt, so that we can be assured that your
proofs did not end up in a spam folder .
Your editoria l has been edited for grammar, consiste ncy, readab ility, adherence to Journal style, and
clarity for nonspecialist readers. To expedite publication , we do not ask authors for specific approval of
routine changes; please read the entire article to make sure your meaning has been retained. Note that
we may be unable to make changes that conflict w ith Journal style or create grammat ical or other
problems. Finally, please note that a delayed or incomplete response may delay publicatio n of your
ed itorial.
Please read the entire proof carefully, including all queries. Please return your query rep lies and proof
corrections ** before 12pm (US Eastern) thi s Friday, February 28, 2020 **.
Instruct ions are provided below . Note that you will be reading for content only; the article will be
rendered for print after the content has been finalized .
The Journal's senior medical editors will be reading your article at th is stage. If they have any additional
comments or queries for you, I will forward them to you in the next few days.
TO ANSWER THE QUERIES: The proof contains in-line numbered query markers and a numbered list of
queries at the end. The query markers and the queries are linked, so you can jump back and forth within
the file. Please respond to all the queries (see below for instructions; please do ** NOT** use e-
annotation tools) and convey any additional changes as needed.
TO RESPOND BY E-MAIL : If your corrections and your responses to the queries are straightforwa rd, we
encourage you to respond by replying to this message. Please copy and paste the list of queries into an
e-ma il message or a Word document and type your responses there . You may also include a list of
changes (e.g., page 1, line 20, change xxx to yyy). Again, please do ** NOT** use e-annotation tools in
the PDFfile; the marks are small and easy to miss, which may lead to errors in your article.
Please note that this material is confidential and embargoed until publication. If you have questions
about our embargo policy, please contact NEJM Media Relations at 781-434-7847 or at
Mediasupport@nejm.org .
Again, please do confirm receipt at this time . Thank you very much for your efforts with these content
proofs!
NIH-001292
Best,
Eli
Elizabeth Lauren~ot
Senior Manuscript Editor
New England Journal of Medicine
617-487-6547
elaurencot@nejm.org
TO READ THE PROOF : You will need Adobe Acrobat Reader software (version 4.0 or later) to view this
file. Acrobat Reader is available free of charge at the Adobe Web site
(http://www .adobe .com/products/acrobat/readerma in.htm l ).
This email message is a private communication . The information transmitted, including attachments, is
intended only for the person or entity to which it is addressed and may contain confidential, privileged,
and/or proprietary material. Any review, duplication, retransmission, distrib ution, or ot her use of, or
taking of any action in reliance upon, this information by persons or entities other than the intended
recipient is unauthorized by the sender and is prohibited. If you have received this message in error,
please contact the sender immediately by return email and delete the original message from all
computer systems. Thank you .
and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or
recipient is unauthorized by the sender and is prohibited . If you have received this message in error,
computer systems. Thank you.
This email message is a private communication. The information transmitted, including attachments, is
NIH-001293
NIH-001294
From: (b)(6)
Sent: Wed, 26 Feb 2020 15:29:21 -0500
Subject: Re: Seeking Or. Fauci for coronavi rus webina r
Let us discuss
On Feb 26, 2020, at 11:59 AM, Conrad, Patricia (NIH/NIAID) [E]
----------- (b) C6Jwrote:
Patricia L. Conrad
31 Center Drive, MSC 2520 - Room 7 A03
(b)(6)
301-496-4409 fax
Disclaimer:
T he informat ion in this e-mail and any of its attachments is confiden tial and may contain sensitive information. It
shou ld not be used by anyone who is nol the orig inal intended recipient. If you have rece ived this e-ma il in error
please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy
and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not
expressly made on behalf of the NIAID by one of its representatives.
From: Chris Adams <cadams@nationalpress.org>

Sent : Wednesday, February 26, 2020 11:01 AM
To: Conrad, Patricia (NIH/NIAID) [E] ________ --------~~ (b_H_6)
Subject: Seeking Dr. Fauci for coronavirus webinar
Patricia:
I hope you are doing well. Dr. Fauci has been a wonderfu l speaker for us in the past, and
I'm reaching out to him today for a discussion on coronavirus.
When the re are major news stories, we often will try to do a live webinar on the top ic with
a leading expert or two.
NIH-001295
This is something we would do in our stud io at our office near Dupont Circle. We normally
do them for 45-60 minutes, and we take questions (visa Twitter) from our audience. The
audience would be reporters who cover the topic, as well as others interested in the topic .
It is a way to have an in-depth, thoughtful conversation about a pressing topic.
Here are a couple we've done (the first is on Zika a few years ago):
Zika panel discussion: https://nationalpress .org/topic/understanding -the -zika-

threat/?st =O&t=&mm=Video
Ted Koppel: https ://nat ionalpress.org/ t oolbox-topic/ lights-out -risks-t o-t he-power -
grid/?st =7042&mm =Video
Autonomous vehicles panel discussion: https://nat ionalpress.org/top ic/wha t s-new-w it h-
autonomous -veh icles/?st =8474& t= Automat ion&mm =Story
We'd like to do one of these on coronavirus . We'd love to have Dr. Fauci as our prime
guest .
We can schedule it around his demands, but would of course love to do it as soon as
possible.
We know he is in demand at this moment. But he is such a singular expert on the topic
we'd love to have a discussion with him - one that would help get his message out to
journalists (and others) who need to be informed to best cover the topic.
Is it possible to check with Dr. Fauci to see if this is possible?
Thanks,
Chris Adams
National Press Foundation
NIH-001296
From: (b)(6)
Sent : Wed, 26 Feb 2020 15:01:39 -0500
To: Folkers, Greg (NIH/NIAID) [E)
Cc: Eisinger, Robert (NIH/NIAID) [El
Subject: Re: ASF and CLIFF------- DRAFT response to Eli at NEJM
Please send this to Eli. Thanks
On Feb 26, 2020 , at 12:49 PM, Folkers, Greg (NIH/N IAID) [E]
(b) (6) wrote:
----------
Dear Eli,
(b)(5)
NIH-001297
From: Laurencot, Elizabeth <elaurencot@nejm.org>
Se nt : Wednesday, February 26, 2020 11:54 AM
To: Fauci, Antho ny (NIH/NIAID) [E] (b)(6)>
Cc: Folkers, Greg (NIH/NIAID) [E] (b)(6) >; Conrad, Patricia (NIH/NIAID)
[E] (b)( >; Eisinger, Robert (NIH/NIA ID) [E] (b)(6)>;
Lane, Cliff (NIH/NIAID) [E) (b)(6)
Importan ce : High
Dear Dr Fauci,
(b)(5)
Thank you very much for your consideration!
Best,
Eli
From : Laurencot, Elizabeth

To: Fauci, Anthony (NIH/N IAID) [El ----- -----=
(b)(6)>
Cc: Folkers, Greg (NIH/NIAID) [El (b)(6)>; Conrad, Patricia (NIH/NIAID)
[El CbH >; Eisinger, Robert (NIH/NIA ID) [El (b)(6);
Lane, Cliff (NIH/NIAID) [El (b)(6)
Dear Dr Fauci,
NIH-001298
Many thanks for your quick reply and for the clear list of responses regarding the proof . I
will review today and will let you know if the re are any items needing further discussion.
The current plan is for publication early Friday afternoon. As I mentioned yesterday, there
is a new article on Covid-19 that is also scheduled for publication that day, and the Journal
editors would like you to mention it in your editorial. I expect to be able to send you a
proof of that article sometime today.
Best,
Eli
From: Fauci, Anthony (NIH/NIAID) [El (b)(6)

To: laurencot, Elizabeth <elaurencot@ne jm .org>
Cc: Folkers, Greg (NIH/NIAID) [El (b)(6); Conrad, Patricia (NIH/NIAIO)
[El Cb)( >; Eisinger, Robert (NIH/NIAID) [El (b)(6);
Fauci, Anthony (NIH/NIAID) [El (b)(6); lane, Cliff (NIH/NIAID) [E]
(b)(6)
Subject : RE;NEJM content proof (Fauci)
Dear Eli,
Here are my answe rs to your queries, and couple other minor changes:
(b) (5)
NIH-001299
(b) (5)
NIH-001300
(b) (5)
Than ks,
Tony
Anthony S . Fauci , MD
Director
Phone : (b) (6)
FAX: (301) 496-4409
E-mail : (b)(6)
The information in this e-mail and any of its attachments is confidential and may
contain sensitive information . It should not be used by anyone who is not the original
intended recipient. If you have received this e-mail in error please inform the sender
and delete it from your mailbox or any other storage devices . The National Institute of
Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements
made that are the sender 's own and not expressly made on behalf of the NIAID by
one of its representatives .
From: Laurencot, Elizabeth <elaurenco t @nejm .org >

Sent : Tuesday, February 25, 2020 8:5 1 AM
------~~
To: Fauci, Ant hony (NIH/NIAID ) [El (b)(6)
Subject : NEJM conte nt proof (Fauci)
Importance : High
Dear Dr Fauci,
NIH-00130 1
Attached is the content proof of your editorial. Please read *ALL* of the following
instructions and information carefully before you begin reviewing your proofs.
First, please stop and take a moment now to confirm receipt , so that we can be assured
that your proofs did not end up in a spam folder.
Your editoria l has been edited for grammar, consistency, readability, adherence to Journal
style, and clarity for nonspecialist readers. To expedite publication, we do not ask authors
for specific approval of routine changes; please read the entire article to make sure your
meaning has been retained. Note that we may be unable to make changes that conflict
with Journal style or create grammatical or other problems. Finally, please note that a
delayed or incomplete response may delay publication of your editorial.
Please read the entire proof carefully, inclu ding all queries. Please return your query
replies and proof corrections **before 12pm (US Eastern) th is Friday, February 28,
2020**.
Instructions are provided below . Note that you will be reading for content only; the article
w ill be rendered for print after the content has been finalized .
The Journal's senior medical editors w ill be reading your article at th is stage. If they have
any additional comments or queries for you, I w ill forward them to you in the next few
days.
TO ANSWER THE QUERIES:The proof contains in-line numbered query markers and a
numbered list of queries at the end. The query markers and the queries are linked, so you
can jump back and forth within the file . Please respond to all the queries (see below for
instructions; please do **NOT** use e-annotation tools) and convey any additional
changes as needed .
TO RESPOND BY E-MAIL : If your corrections and your responses to the queries are
straightforward, we encourage you to respond by replying to this message. Please copy
and paste the list of queries into an e-mail message or a Word document and type your
responses there . You may also include a list of changes (e.g., page 1, line 20, change xxx to
yyy). Again, please do * *NOT* * use e-annotation tools in the PDFfile; the marks are small
and easy to miss, which may lead to errors in your article .
Please note that this material is confidential and embargoed until publication. If you have
questions about our embargo policy, please contact NEJM Media Relations at 781-434-
7847 or at Med iasupport@ne jm.org .
Again, please do confirm receipt at this time. Thank you very much for your efforts with
these content proofs!
Best,
Eli
NIH-001302
Elizabeth Lauren~ot
617-487-6547
elaurencot@nejm.org
TO READTHE PROOF: You will need Adobe Acrobat Reader software (version 4.0 or later)
to view this file. Acrobat Reader is available free of charge at the Adobe Web site
(http ://www .adobe .com/products/acrobat/readermain .html ).
This email message is a private communication. The information transmitted, including

attachments, is intended only for the person or entity to which it is addressed and may
contain confidential, privileged, and/or proprietary material. Any review, duplication,
retransmission, distribution, or other use of, or taking of any action in reliance upon, this
information by persons or entities other than the intended recipient is unauthorized by the
sender and is prohibited . If you have received this message in error, please contact the
sender immediately by return email and delete the original message from all computer
systems. Thank you.
contain confidential, privileged, and/or proprietary material. Any review, duplication,
retransmission, distribution, or other use of, or taking of any action in reliance upon, this
information by persons or entities other than the intended recipient is unauthorized by the
sender and is prohibited. If you have received this message in error, please contact the
sender immediately by return email and delete the original message from all computer
systems. Thank you .
<NEJMoa2002032_Guan_Content2_Author.pdf>
NIH-001303
From: Fauci, Anthony (NIH/NIAI0) [E)
Sent : Wed, 26 Feb 2020 17:33:08 +0000
Cc: Billet, Courtney (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E];Conrad, Patricia
(NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Marston , Hilary (NIH/NIAID) [E]
Subject: RE: remarks for White House press conference
Attachments : Fauci remarks Feb 26 - with minor edit .docx
I have made a minor tweak .
Director
Phone : (b) (6)
FAX: (301 496-4409
E-mail : (b)(6)
information . It shou ld not be used by anyone who is not the original intended recipient . If you
other storage devices . The National Institute of Allergy and Infectious Diseases (NIA ID) shall not
From : Routh, Jennifer (NIH/NIAID) [E] (b)(6)>

Sent : Wed nesday, February 26, 2020 12 :26 PM
·'======~~
Cc: Billet , Courtney (NIH/N IAID) [El (b)(6) >; Stover, Kathy (NIH/NIAID) [E)
(b)(6J>; Conrad, Patricia (NIH/NIAID ) [E] (b)(6); Folkers, Greg
(NIH/NIAID) [E] (b)(6); Ma rston, Hilary (NIH/NIAID) [El (b)( >
Subject: remarks for White House press conference
Dr. Fauci,
Attached for review are proposed remarks (in bullet format) for t he White House press conference.
Thanks,
Jen
Jennifer Routh [E]

News and Science Writing Branch
Office of Communications and Government Relations
NIH/HHS
31 Center Drive Room 7A17C
NIH-001309
Bethesda , MD 20892
Direct: Cb)(
Disclaimer: The information in this e-mail and any of its attachmentsis confidentialand may contain sensitive information. It should not be
used by anyonewho is not the original intendedrecipient. If you have received this e-mail in error please informthe sender and delete it
from your mailboxor any other storage devices. The National Institute of Allergy and Infectious Diseases shall not acceptliability for any
statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.
NIH-001310
Sent : Wed, 26 Feb 2020 16 :49:43 +0000
Subj ect : FW: BBC Radio
What say you?
Director
Phone : (b)(6)
FAX: (301 ) 496-4409
E-mail : (b)(6)
From: Paul Coletti <paul.coletti@bbc.co .uk>

Sent : Wednesday, February 26, 2020 11 :47 AM
To : Fauci, Anthony (NIH/NIAID) [El
Subject : BBCRadio --------- (b)(6)
Dear Dr. Fauci,
Newshour on the BBCWorld Service is today cover ing the US preparedness on the Coronavirus
Would you be available for int erview on this topic?
We're on air at 3pm eastern and could speak to you live at around 3:10pm or alternat ively we could
record a few minutes between now and then . About 8 minutes duration and we've many ways to
connect to get good audio (no video as we are radio) .
If there is interest from your side then I'm on+

------ (b)(6)
Yours sincerely,
Paul Coletti
Tel: (b)(6)
Tv. itter: @bbcworldservice, @pcoletti
Newshour podcasts: www.bbc.eo.uk/ podcasts/series/newshour
NIH-001311
BBC World Service listen live: www.bbc.eo.uk/worldserviceradio/on-air
Newshour is the award-winning news and current affairs programme 011 BBC World Sen·ice English. the radio and
011/ine network which reaches 75 million listene,:f each week, including 11.5 million in the USA 011 National Public
Radio.
Paul Coletti
Tel: Cb)(6)
Twillcr: fa)bbcworldscrvice, @pcolettl
Newshour podcasts: www.bbc.eo.uk/podcasts/sc1ies/newshour
BBC World Service listen live: www.bbc.eo.uk/worldscrviceradio/on-air
Newshour is the l/\Vard-11'i1111i11g

news allll cw·rent affairs programme 011BBC World Sen•ice English, the radio a11d
011li11e
network which reaches 75 million listene,~~each week, including 12.5 million in the USA 011 National Public
Radio.
NIH-0013 12
Sent : Wed, 26 Feb 2020 16:37:50 +0000
To : Johnson, Martin S. (NIH/NIAID) [E];Auchincloss, Hugh (NIH/NIAID) [E];Harper, Jill
(NIH/NIAID) [E]
Subject : RE:Appropriators going to have a call at 3:30 in Larry's office with HHSOp divs
on the COVID-19Supplemental Request
Martin :
You and Hugh shoul d be on t he call.
Thanks,
Tony
Director
Phone : (b)(6)
FAX : (301 496-4409
E-mail : (b)(
From: Johnson, Martins. (NIH/NIAID) [El (b)(6)

Sent : Wednesday, February 26, 202011 :17 AM
To: Fauci, Anthony (NIH/NIAID) [E] Cb~>; Auchincloss, Hugh (NIH/N IAID) [E]
(b)(6J>; Harper, Jill (NIH/NIAID) [E]
-----------
Cc: Conrad, Patricia (NIH/NIA IO) [E] (b)(6)
(b)(6)>
Subject : Appropriators going to have a call at 3:30 in Larry's office with HHSOp divs on the COVID-19
Supplementa l Request
Tony,
Appropriators going to have a call at 3:30 in Larry's office with HHSOp Divs concerning the
2020suplemental request.
Larry wants someone from NIAID to also be on the call. Please advise who you want to attend .
Thanks
NIH-0013 13
Martin
NIH-001314
Sent: Wed, 26 Feb 2020 16:36:36 +0000
Subject: FW: SIBFinquiry
Please say no to this. Too busy.
Director
Phone : (b)(6)
FAX: (301) 496-4409
E-mail : (b)(6)
From:Shannon Williams <shannon.w illiams@sibf.org>

To : Fauci, Anthony (NIH/NIAID) [El (b)(6J>
Subject : SIBFinqui ry
Importance: High
Dear Dr. Fauci,
I am writing to inquire about your willingness to address the Society of

Internat io nal Business Fellows (SIBF)as part of our webinar series. SIBFis a
distinguished organization of nearly 1600 global executives and senior leaders.
Our C-level global membership would appreciate getting your perspectives on the
coronavirus outbreak. We are open to topics which could include ....What we
know and don't know ...As business and community leaders what SIBFmembers
can do to prepare and educate t heir employees ...Safety of travel, etc.
We were thinking the webinar could be approximately 30 minutes in length (15

minutes of rema rks followed by 15 minutes of Q&A). SIBF'sCommun icat ions
Manager could work with someone on your team to set-up the webinar. SIBFis a
NIH-001315
non-profit, but we are able to provide a $2k honorarium to you or a charity of
your choice .
Thank you for your graciou s consideration and att ention to our request . It is our
sincere hope that you w ill be able to participate.
Best regard s,
Mr. Shannon George Williams I Director of Programs

Society of International BusinessFellows (SIBF)
715 Peachtree Street NE, Suite 200
Atlanta, GA 30308
P: (470) 378-1151 W : www.sibf.org
NIH-001316
Sent : Wed, 26 Feb 2020 16:27:37 +0000
Subject : FW: MSNBC Guest Request 2/26
FYI. Please hand le as you see fit.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Hirsch, Nancy (NBCUniversal) <Nancy.Hirsch@nbcuni.com>

--------::.:-=..
To: Conrad, Patricia (NIH/NIA ID) [E) (b)(6)>; Fauci, Anthony (NIH/NIAID) [El
(b) ( >
Subject : MSNBC Guest Request 2/26
Hello Dr. Fauci

I hope this finds you well and I am sure receiving numerous
requests
Would you be avail to join anchor Ari Melber tonight 6 pm EST to
speak to Trumps presser and the latest on Coronavirus ?
Thank you for letting me know if you can join soonest possible.
Nancy
Nancy Hir sch
NIH-0013 17
The Beat with Ari Melber
Mavericks with Ari Melber
Booking Producer
30 Rockefeller Plaza I New York, NY 10112
(T) 212-664-4097
(C) (b)(6)
.q,,MSNBC
NIH-0013 18
Sent : Wed, 26 Feb 2020 15:22:0 1 +0000
To: Eisinger, Robert (NIH/NIAID) [El;Greg Folkers (b)(6)
Subject : FW: NEJM content proof {Fauci)
----------
See below. I w ill need your help on thi s.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)

To: Fauci, Anthony {NIH/NIAID) [El --------, ...,....,= (b)(6)
Cc: Folkers, Greg {NIH/N IAID) [E] (b)(6); Conrad, Patricia (NIH/NIAID) [E]
(b)(6); Eisinger, Robert (NIH/NIAID) [El (b)(6)>; l ane, Cliff
"."'
(N
- I-H-/ :-
N-IA
- l~
D~) [~E]~===.;..- ~ (b~H=6)
Dear Dr Fauci,
Many thanks for your quick reply and for the clear list of responses regarding the proof. I will review
today and will let you know if there are any items needing fur ther discussion.
The current plan is for publication early Friday afternoon . As I mentioned yesterday, there is a new
article on Covid-19 that is also scheduled for publication that day, and the Journal editors would like you
to mention it in your editorial. I expect to be able to send you a proof of that article sometime today.
Best,
Eli
From: Fauci, Anthony (NIH/N IAID) [E] ________

(b)(6) _,
Se nt: Wednesday, February 26, 2020 7:37 AM
To: Laurencot, Elizabeth <elaurencot @nejm .org>
NIH-0013 19
Cc: Folkers, Greg (NIH/NIAID) [E] Cb)( >; Conrad , Patricia (NIH/NIAID) [E]
---:----:-~~= (b
=)=(6)
:!..
>..:..
; _E_is_
in.::::.
ge~r;_ Robert (NIH/NIAID) [E] ~
,= (b)(6) .>; Fauci, Anthony
(NIH/NIAID) [E] (b)(6); Lane, Cliff (NIH/NIAID) [E] (b)(6)>
Dear Eli,
Here are my answe rs t o you r que ri es, and couple ot her min or changes:
(b)(5)
NIH-001320
(b) (5)
NIH-001321
Tha nks,
Tony
Director
Phone : (b)(6)
FAX : (301) 496-4409
E-mail : (b) (6)
The information in this e-ma il and any of its attachments is confidential and may contain sensitive
accept liability for any statements made that are the sende r's own and not expressly made on
From: Laurencot, Elizabeth <elaurencot@nejm .org>

Sent : Tuesday, February 25, 2020 8:5 1 AM
To: Fauci, Anthony (NIH/ NIAID) [E)
------~~ (b)(6)
=
Subject: NEJM content proof (Fauci)
Importance: High
Dear Dr Fauci,
Attached is the content proof of your editorial. Please read *ALL* of the following instructions and
information carefully befor e you begin reviewing your proofs.
First, please stop and take a moment now to confirm receipt, so t hat w e can be assured that your
proofs did not end up in a spam folder.
Your ed itorial has been edited for grammar, consistency, readability, adherence to Journal style, and
clarity fo r nonspecialist readers. To expedite publication , we do not ask authors for specific approva l of
routine changes; please read the enti re article to make sure your meaning has been retained. Note that
problems. Finally, please note that a delayed or incomplete response may delay publication of your
ed itorial.
Please read the entire proof carefu lly, including all queries . Please return your query rep lies and proof
corrections **before 12pm (US Eastern) this Friday,February28, 2020** .
Instruct ions are prov ided below . Note that you will be reading for content only; the art icle will be
The Journal's senior medical editors will be reading your article at t his stage. If they have any additional
comments or queries for you, I will forward them to you in the next few days.
NIH-001322
TO ANSWERTHE QUERIES: The proof contains in-line numbered query markers and a numbered list of
queries at the end. The query markers and the queries are linked, so you can jump back and forth within
the file. Please respond to all the queries (see below for instructions; please do ** NOT** use e-
annotation tools) and convey any additional changes as needed.
TO RESPONDBY E-MAIL: If your corrections and your responses to the queries are straightforward, we
e-mail message or a Word document and type your responses there. You may also include a list of
changes (e.g., page 1, line 20, change xxx to yyy) . Again, please do ** NOT** use e-annotation tools in
the PDFfile; the marks are small and easy to miss, wh ich may lead to errors in your art icle.
Please note that this material is confidential and embargoed until publication . If you have questions
about our embargo policy, please contact NEJM Media Relations at 781 -434-7847 or at
Mediasupport@nejm.org .
Again, please do confirm receipt at this time . Thank you very much for your efforts w ith these content
proofs!
Best,
Eli
Elizabeth Lauren<;:ot
New England Journal of Medici ne
617 -487 -6547

elaurencot@nejm .org
TO READTHE PROOF: You will need Adobe Acrobat Reader software (version 4.0 or later) to view this
fi le. Acrobat Reader is available free of charge at the Adobe Web site
(http://www .adobe.com/products/acrobat/readermain.html ).
NIH-001323
intended only for the person or entity to which it is addressed and may contain confidential, privi leged,
NIH-001324
Sent : Wed, 26 Feb 2020 15:18:06 +0000
Subject : FW: First in class, hemostatic drug - potential therapeutics for COVID-19
Attachment s: NIAID EEEV- SP16_ Jan 28, 2020 - Read-Only - Read-Only.pdf, JACCmanuscript
Oct 2017 SP16 AM I (1).pdf , Serpin Pharma - Non-Confident ial Partnering Deck v29.pdf
Please t ake a look at this. Thanks .
Director
Phone : (b)(6)
FAX : (301) 496-4409
E-mail : (b)(6l
have rece ived this e -mail in error please inform the sender and delete it from your mailbox or any
From: Cohava Gelber

------------
Sent : Tuesday, February 25, 2020 8:45 PM
--------,
(b)(
.....,....,=
(b)(6)
----------
Subject : First in class, hemostatic drug - potential therapeutics for COVID-19
Import ance: High
Dear Dr. Fauci,

(b) (4)
NIH-001327
(b) (4)
Please let us know how we can he lp.

I have attache d a manuscript and company presentations for your review.
Sincere ly,
Cohava
Cohava Gelber , PhD , MBA

Execu tive Chairperson & CEO
Serpin Pharma
www .serpinpharma .com
(b)(6)
NIH-001328
Sent: Wed, 26 Feb 202015 :17:35 +0000
To : Mehta, Nehal N. (NIH/NHLBI) [E)
Cc:
Subject :
Conrad, Patricia (NIH/NIAID) [E);Greg Folkers
---------
RE: Guidance for users of biologics in the age of Coronavirus.
(b)( ·)
I am sorry Nehal, but I am really swamped right now and cannot make this a
priority . I hope that you understand .
Director
Phone : (b) (6)
FAX: (301 496-4409
E-mail : (b) (6)
From: Mehta , Nehal N. (NIH/NHLBI) [E] (b)(6)>

To: Fauci, Anthony (NIH/NIAID) [E)------~= (b)( >
Subject: Fwd: Guidance for users of biologics in the age of Coronavirus.
DearTony -
1 wonder if you would be willing to participate in a short piece regarding use of biologics with
looming Coronavirus for JAMA Dermato logy or JAMA Internal Medicine?
Please see the email sent below to me by my colleague and collaborator Joel Gelfand from
Penn.
I understand there are fierce demands on your time but we would be happy to draft for your
approval.
Many thanks for your consideration!
All my best,
Nehal
NIH-001329
Nehal N. Mehta, MD MSCEFAHA
Lasker Senior Investigator
Chief, Lab of Inflamm at ion and Cardiometaboli c Diseases
National Heart, Lung and Blood Institute
Bethesda MD 20892
Email (b)(6)
Phone :
"""':====~~-- (b)(6J1
Begin forwa rded message :
Fro m: "Gelfand, Joel"

-----------------
(b)(6)
----------
To: "Mehta, Nehal N. (NIH/ NHLBI) [E]" (b)(6)
Subject: Guidance for user s of biologics in the age of Coro navirus.
Dear Nehal,
With the coronavirus border ing on a pandemic and the expectat ion that it will affect the US at some
point, it seems to me we should be prepared to provide guidance to patients who are on im mune
modulators for inflammatory disease. Specifically, many will wonder if patients should stop th eir
biologic if the vi rus becomes prevalent in their commun ity. There w ill also be quest ions about stopping
biologics in the setting of acute infectio n with coronavirus.
Any thoughts on this? My specific inte rests relates to patients with psoriasis or psoriatic arthr itis on
biologics but it's also relevant to patients w ith IBD, RA and other inflammatory diseases.
Joel
Joel M. Gelfand MD, MSCE

Professor of Dermatology
Professor of Epidemio logy
Vice Chair for Clinical Research(Dermatology)
University of Pennsylvania, Perelman School of Medicine
https ://www .med.upenn.edu/gelfand/
NIH-001330
Sent : Wed, 26 Feb 2020 15:14:43 +0000
To: Stover, Kathy (NIH/N IAID) [El
Cc: Billet , Courtney (NIH/NIAID) [El;Folke rs, Greg (NIH/NIAID) [El;Conrad , Patricia
(NIH/NIAID) [El
Subject : RE: FORASF REVIEW: Draft MA re: Fauci/Eisi nger/Redfield COVID-19 paper
This look s fine. Thanks.
Director
Phone : (b)(6)
FAX : (301 ) 496-4409
E-mail (b)(6l
info rmation . It should not be used by anyone who is not the origi nal intended recipient. If you
From: Stover , Kathy (NIH/NIAID) [El (b)(6)

To: Fauci, Anthony (NIH/NIAID) [El --------, .....,..,= (b)(6)
Cc: Billet , Courtney (NIH/N IAID) [El (b)(6); Folkers, Greg (NIH/NIAID) [E]
_______ Cb
_>_C6);Conrad, Patric ia (NIH/NIAID) [E) (b)(6)
Subject : FORASF REVIEW: Draft MA re : Fauci/Eisinger/Redfield COVID-19 paper
Hi Dr. Fauci,
Please find attached for your review a draf t med ia availab ility about you r imm inent NEJM paper on
COVID-19. We have name d you as the spokespe rson in t he MA.
Thanks much,
Kathy
Kathy Stover
Branch Chief
Office of Communications and Governmen t Relations
National Institute of Allergy and Infec tio us Diseases
31 Center Drive, Room 7A17F
NIH-001331
Bethesda, MD 20892
(b)(6)
Media line: (301) 402 -1663
NIH-001332
From: (b)(6)
Sent : Wed, 26 Feb 2020 09:23:22 -0500
To : Thomas R. Frieden
Subject : Re: FYI
Thanks, Tom.
On Feb 25, 2020, at 3:41 PM, Thomas R. Fr ieden
------------ Cb)(6)> wrote:
Tony,
Nothing you don't already know....
Tom
(b) (6)>
From: Tom Frieden
-------------
Date: Tuesday, February 25, 2020 at 3:39 PM
To : Tom Frieden (b)(6)
Subject : A COVID-19 Pandemic is Inevitable. Now what?
Dear Colleague,
It's now clear that COVID-19 will become a pandemic. We don't know if it will be
mi ld, moderate o r severe, or how many countr ies it will reach.
As we shift from the initiation phase of the pandem ic to the acceleration stage, I've
highlighted 8 things we must do now in a new CNN OpEd:
htt p:// www .cnn.com / 2020/ 02/ 25/ health / coronavirus- pandemic-
frieden / index. html
Please share, and thank you for what you continue to do for pub lic health .
All the best,
Tom
If you'd like to retweet, here's a link.
NIH-001336
Sent: Wed, 26 Feb 2020 12:47:09 +0000
To: Collins, Francis (NIH/OD) [El
Subject: RE: Milken outreach
Thanks, Francis. It might be better for you to make an e-mail introduct ion and I
will take it from there .
Director
Phone : (b)(6)
FAX : (301 496-4409
E-mail : (b)(6)
-------
From: Collins, Francis (NIH/OD) [E]
(b)(6)>
------= =
To: Fauci, Anthony (NIH/NIAID) [E] <l.
.______ ~>
_ )_~...
Cb
Subject: RE: Milken outreach
He's at
make an e- mail introduction?
(b)(6) and
------ (b)(6) Want to reach out directly or shall I
Francis
From: Fauci, Anthony (NIH/NIAID) [E] (b)(6)

To: Collins, Francis (NIH/OD) [El (b)(6)
Subject: Re: Milken outreach
Francis:
Thanks for the note. Milken can help in a number of ways including directly supporting the VRC. Also,
as we start looking for Pharma to step up with us, his connections could be helpful.
Tony
On Feb 25, 2020, at 12:58 PM, Collins, Francis (NIH/OD) [E] Cb)~ > wrote:
-------
NIH-001337
Hi Tony,
I'm sure you know Michael Milken. I've worked with him over many years, and though he
is a somewhat controversial figure he has certainly helped NIH in many ways. He reached
out to me last night to ask if there is anything he could do to help with the coronavirus
vaccine effort. He had seen press reports that finding a pharma partner had been
challenging - and wanted to volunteer his help in that regard, since he has deep
connections in the private sector. He also said that he'd be glad to help with any
philanthropic needs, both through his own resources and his influence over members of
the Giving Pledge.
Are there useful actions that I can suggest to him?
FC
NIH-001338
Sent: Wed, 26 Feb 2020 10:59:30 +0000
To : *'@ ~
Subject : RE: Questions abou t the coronavirus-Chinese Media Inquiry :
See answers below in red
From: $.~~~ <xinenbo@thepaper.cn>

To: Fauci, Anthony (NIH/NIAID) [E) ----- -..
(b=H= >
Subject: Questions about the coronavirus-Chinese Media Inquiry:
Dear Dr Fauci,
My Name is Paul Xin, I'm a journalist from Pengpai News(ThePaper) of Shanghai, which is one of the
most important new medai in China. I 'm Sorry to bother you as you must be very busy. I noticed your
comment about coronavirus on American media, I deeply hope you could answer few of my
questions.Your answers will be very helpful to me. The questions are below.
Thank you very much!
Sincerly ,
Paul Xin
1/You said on CNN that US have had pandemic preparedness plan that developed in preparation for
pandemic influenza . Could you provide some detai ls of this plan? The plan outlinesthe differences
between containmentand mitigation. It speaks of the thing that shouldbe done if an outbreak
occurs in the USA. Thes incluesocial distancing,useof telecommunicationand telework, temporarily
closing schools, avoidingcrowed placessuch as indoor arenas and theaters.
2/To prepare for potent ial communities spread of coronavirus in US, do you thin k that US need take the
measures similar with China? China was in the "reactive " mode of responding to an explo sion of cases
in Wuhan Cityand Hubei provincewith spreadthroughoutChina. Chinahad to resort to very
dramatic measuressuchas shutting down cities. The USAis now in a preparativemode and not a
reactivemode and so our responseis muchdifferent than that of China.
NIH-001339
$}!.;Ji
cp,t,f~ ~~Wfrfijjfm
~;JUJr[i:i]/8"1~~Jr[i:i]
..t.;fifmN~cpns39~
NIH-001340
Sent: Wed, 26 Feb 2020 10:46:23 +0000
Subject: RE: Confirma tion from CNN's New Day
Got it. Thanks .
From: Conrad, Patricia (NIH/NIAID) [E) (b)(6)

To: Fauci, Anthony (NIH/NIAID) [E] -------=- (bc--
H= >
Subject: Fwd : Confirmation from CNN's New Day
Firm for 650 am hit today at med arts as per below.
Sent from my iPhone
From: "Figliola, Mike" <M ike.Figliola@turner .com >

To: "Conrad, Patricia (NIH/NIAID) [E]"
-------~~ (b)(6)>, "Daniels, Ronnel
)(56)'>,-::":-:-
(NI H/0D /0 RS)[CJ",,....;._;...__.;..;....:.......;::;:
(b;:; R-:-
yl-an-d:-, K
:-:-
e-n-:-(-:--
N IH/0D/ORS) [El"
(b)(6)>, Jonathan Bennett (b)((;), "Jackson
---------
Farrar, Joy (NIH/OD/ORS) [E)'-------===~~.--------
________ (b_H_6)
Subject: RE: Confirmation from CNN's New Day
Hi everyone,
This is Mike with CNN's New Day. Hope you are well.
This is to confirm Dr. Fauci will be a guest today, Wednesday 02.26.20 at around 6:50am
ESTto discuss:
Coronavirus latest - are we facing an outbreak?
You will be solo at 6:45am ESTfor the segments.
John Berman, will both be conducting today's interview.
Please arrive at the studio no later than 6:40am EST.
Here is your studio confirmation:
NIH-00134 1
SHOW MANAGER : VENDOR STUDIO #2018562
NIH Events Management (Medical Arts) Studio Info
NIH Control Room numbers are 301-827-8478 and 8479
Encompass Booking and Circuit Number:
Booking: 1-800-243-1995
Circuit: 36TBGS 104492
Our IFB: 30 1-496-1811 (we prefer to call into the station's IFB)
Video : 1080i (59.94 ) - the audio is embedded .
Please call the TOC with any technical questions at 301-827-8478
Please confirm you have received this and are all set to go!
Best,
Mike Figliola
Editorial Producer
CNN's New Day
212-275-8161
mike.figliola@ turner .com
CONF IDENTIALITY NOT ICE: This e-mail transmission, and any documents , files or
previous e-mail messages attached to it, may contain confidential information that is legally
privileged. If you are not the intended recipient , or a person responsible for delivering it to
the intended recipient , you are hereby notified that any disclosure , copy ing, distribution or
use of any of the information contained in or attached to this message is STRICTLY
PROH IBITED . If you have received this transmission in error, please immediately notify us
by reply e-mail at mike.fiq liola@turner .com or by telephone at (917) 670-9410, and destroy
the original transmission and its attachments without reading them or saving them to disk.
Tha nk you.
NIH-001342
Sent: Wed, 26 Feb 2020 01:32:22 +0000
To: Jon LaPook
Subject : RE:CBSSunday Morning
Jon:
The message would have to be that the situat ion continues to evolve and people need to follow the news and the
reports from CDC. For example , a few weeks ago if you wanted to travel to Japan or South Korea , it was fine since
there were few is any cases there. Now both cotmtries have a travel alert that says "Avoid all but essential travel".
You should tell people that travel to places with few or no reported cases is fine. Only when you have community
spread (person to person to person) shou ld you be concerned about a specific travel destination. Also , you cou ld
explain to people that pandemics evo lve when a new infectious disease is spreading by sustained community spread
in multiple countries in different regions of the globe. Once a [)andemic erupts. it is virtually impossible for any
country to be free of cases. Peop le need to understand that. You can mitigate the effects , but you cannot avoid
having infections since you cannot shut off the country from the rest of the world. Also, you need to speak of the
rea l and present danger of seasonal influenza every year. Do not let the fear of the unknown (i.e. a pandemic of a
new infectious agent) distor t your evaluation of the 1isk of the pandemic to you relative to the risks that you face
every day. The only thing that we can do is to prepare as best as possible and do not yield to wrreasonable fear.
Best,
Tony
•··•-Original Message-----
From : Jon LaPook ,,;::;...
---~ (b
~)~(= >
Sent: Tues day, February 25, 2020 6:34 PM
To: Fauci, Anthony (N1H/NlAID) [E] ------ ~~>
(b)(
Subject: CBS Sunday Morning
Hi Tony,
1 have an unusual opportunity: the executive producer of CBS Sunday Morning has asked me to do a straight to
camera shpiel about COVID-L9for this Sunday. 1did something similar when people are panicking about Ebola.
You and 1have spoken enough about th is so that I feel comfortable with the basics. But I would love you to give
some thought to whether there are any misunderstandin gs that you would like cleared up or information you would
like disseminated.
l would love to give some logical travel advice. I know there are so many unknown s, but r have had multiple people
ask me whether they should cancel their upcoming to trip to ... you name it (ltal y, Israel, San Francisco). T know it
comes down to risk/benefit , and - as you told me during the Ebola outbreak - people hav e all sor ts of vary ing leve ls
of comfort with risk. But what do fac tually SAY to the 6 million people who will be watc hing people? :)
Thanks,
Jon

NYU Langone Health
Twitter @DrLa Pook
NIH-001344
From: (b)(6)
Sent: Tue, 25 Fe b 2020 19:07:15 -0500
To : McNeil Jr, Donald G
Subject: Re: thought from a kibb itzer ...
You make some very good points , Donald.
On Feb 25, 2020, at 4:48 PM, McNeil Jr, Donald G <mcnei l@nytimes.com>w rote :
I was j ust watching the HHS briefing online, and thinking about an article I read this
morning , and Bruce Aylward's description of what he saw in China, and a lot of
videos I've w atched on the South China Morning Post website (they're doing great
coverage .) .
In China, we in the med ia tend to report the horr ors a nd the lockdown and the
governme nt's early lies ...
But the truth is that a lot of average Chinese behaved incredibly heroically in the
face of the virus: 25,000 doctors and nurses wen t into Wuhan to help, knowing they
might die. Average people gave up their stockpiles of masks so they could be
shipped to Wuhan . Ne ighb orhood committees brought food to thousands of little old
ladies and checked on them eve ry day, even as they asked them to stay behind their
doors for fear of infection.
Meanwhile , in America, people tend to act like selfish pigs interested only in saving
themselves. How can I hoard a mask? Where's my vaccine? This morning , I
read this appa lling article from A la bama . Here you have Americans com ing back
from a horrifying experience overseas, and the President -- who is popula r in
Alabama -- asks Alabama ns to take some of those fellow Amer icans in. There is
zero risk because they're going to be housed on a naval base.
And yet, the answer is "No! Keep them out!" And their legislators encourage it....
I dunno -- that's the kind of behavior I expect from my fellow New Yorker s, not
from Alabama.
If the virus arrives -- and we both know it wilJ -- America is going to have to do
better than that. Like the Chinese, Americans are going to have to look out for each
other the way we haven't since 9/ 11. Or maybe since World War II .
But that's not the tone of the HHS briefings . Th ey're an aggressive, defensiv e,
almost smart-alecky "we got this" tone. The only time the tone was right when you
NIH-001345
were the third to take the mike and explain things to that kid shouting from the back
without a mike about "What's the real message? What do we do?"
Maybe there could be some thought given to mentally preparing Americans to work
together in the face of the crisis? Quarantines are a very aggressive approach -- but
they require a lot of compassion or the people quarantined suffer.
I might get around to writing an article about this, but my editors keep grabbing me
for minute by minute stuff and I'm way behind.
Donald
NIH-001346
From: (b)(6)
Sent: Tue, 25 Feb 2020 18:59:02 -0500
Subject: Fwd: Surfactant Protein-D against coronavirus
Please handle.
From: Marc Salzberg Cb)(6J

Date: February 25 , 2020 at 4:42:47 PM EST
------~~ CbH6J
Subject: Surfactant Protein-D against coronavirus
Dear Dr. Fauci,
We are developing a recombinant human form of Surfactant Protein-D (AT-100), an

endogenous collectin w ith strong irnrnune-modu latory properties. AT-100 shows
anti-inflammatory and ant i-infectious properties. CbH4>
There are data indicatin that SP-D clears coronavirus
(b)(4)
While we are discussing this with a number of academic institutions, I was

wondering, though, whether you and the NIH are interested to collaborate on
eva luating AT-100 against coronavirus. Please let me know , if you are willing to
schedule a phone ca ll with our Chief Medical Officer Dr. Paul Kingma and I to
discuss. There is obviously a sense of urgency behind this request.
Best regards,
Marc Salzberg
Airway Therapeutics , Inc.

Marc Salzberg, MD
President &CEO
1200 Johnson Ferry Rd., Suite 300
Marietta, GA 30068
Ph
(b)(
NIH-001347
: : AIRWAY
( • • THH"l..A I T ~
NIH-001348
From: (b)(6)
Sent: Tue, 25 Feb 2020 18:33:00 -0500
To: David - Gmail
Subject: Re: David Pyrce Reconnecting - Coronavirus Task Force
David:
Thanks for your note and your keen interest in this important challenge of coronavirus. The
White House Task Force is chosen by the President upon the advice of his senior staff. I am
afraid that there will not be any additionalmembers for now. Again, thank you for your interest.
Best regards ,
Tony
On Feb 25, 2020, at 5:29 PM, David - wrote:

----------- (b)(
Hello Dr. Fauci,
I know you are extremely busy and will get right to the point. I would like to jo in the
coronavirus taskforce.
I worked on the Ebola task force about six years ago, which had a similar sense of urgency,
and recognize that assembling a SWAT team overnight is critically important in order to
monitor, contain and mitigate the spread of the coronavirus, not just for the United States,
but on a worldwide basis.
I've done a significant amount of work in infectious disease vaccine development at a

number of biotech firms (Vical, lnovio and lntrexon) in partnership with the NIH, Vaccine
Research Center, DOD and the CDC.
I also (b) (6) we discuss preparedness on a daily basis. Those

conversations clearly indicate that the knowledge and expertise is severely lacking at both
the academic medical center level, as we ll as the community health level.
I believe my assistance can be deployed in several areas where my experience in virology ,

immunology, antivirals , Ebola, product development and strategic partnering could be of
immediate value to research scientists, medical professionals and healthcare systems.
1. Identification of emerging therapeut ics.

2. Fast track emerging therapeutics from pre-clinical to IND and fast-track clinical trials.
3. Identify opportunities to accelerate the product ion of commercial quantities of therapeutic
material.
4. Identify unique genomic fingerprints of responders and patients undergoing treatment to
guide therapeutic selection and optimize interven tions.
5. Interface with public and/or institutional stakeholders on a worldwide basis (24/7)
regarding safety procedures, diagnostics, therapeutic interventions, etc.
6. Other initiatives, representing areas where there is an immediate need to bring on board
and deploy an individual with deep expertise, who can provide leadership , drop in and
rapidly advance those initiatives .
NIH-001349
With the urgently required , in order to provide a Navy SEAL like response , I would propose
a consulting arrangement where I'm avai lable 24/7 , anywhere/a nytime , for as long as
needed . Please let me know your thoughts .
Here is a brief snapshot of my C.V.

1. SVP , Innovation and Chief Commercia l Officer - NantKwest (gene/cell therap ies ,
immunotherapeutics and molecular diagnost ics)
2. SVP, Innovation and Chief Commercia l Officer - NantHealth {A l/bioinformatics-based
multi-omics based molecular diagnostics and neoant igen-based therapeutics)
3. Founder/CEO - Genomic Principles (neoantigen-based , individualized therapeut ic
vaccines)
4. Founder/CEO Canton Biotechnologies {DNA-based therapeutics and vaccines)
5. Chief Business Officer - lntrexon {gene/protein-based therapeutics and vaccines)
6. Chief Business Officer - lnovio {gene-based therapeutics and vacc ines)
7. VP, Business Development - Vical (gene-based therapeutics and vaccines) .
I know you are busy and you can feel free to forward th is emai l to the appropriate individual.
I can also be reached by ce ll phone (b)(6) to discuss furthe r.
Best Wishes,
David
(b)(6)
NIH-001350
From : Fauci, Anthony (NIH/NIAIO) [El
Sent : Tue, 25 Feb 2020 22:10:15 +0000
To: NIAIDODAM
Subj ect : FW: Hello from
---------- (b)(6)
Let us di scuss.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Groslyn Burton <burton@theasiagroup.com>

To : Fauci, Anthony (NIH/NIAID) [El------ -==--
(b)(6J>
Subject : Hello from (b)(6)
----------
Dr. Fauci -
(b)(6)
I apologize for the direct
out of the blue message, however, my company The Asia Group has a pod cast called Tea Leaves and we
would be interested in having you as a guest to speak about the Coronavirus. I mentioned to my CEO
that you are the leading expert and that I had a connection with you. We would only take about 30-45
mins of your time and would be happy to work around your schedule if this is something that you would
be willing to do. Below is a short description of the podcast and a link to our episodes. If able, I'd be
happy to coordinate with your assistant.
Looking forward to hearing back soon.
Thanks,
Groslyn "Foster" Burton
Vice President, Culture and Values
Executive Assistant to the Chairman
Dr. Kurt M . Campbell, Chairman and CEO
The Asia Group, LLC
NIH-001351
202-350-3285 - Office
----- Cb)(6) - M obile

202-750-29 44 - Fax
he Asia Group announc ed the launch of Tea Leaves, a new podcas t that will focus on the
current affa irs, foreign policy, business, and arts of As ia. The podcasts' hosts, Dr. Kurt M.
Campbell and Ambassador Richard Verma, will lead a series of revealing interviews with
policymakers , business leaders, journalists, and artists exploring the most dynamic and
consequentia l region in the world.
In a j oint statement, Campbell and Verma said, "We wanted to share our passion for
Asia with listeners , both accomplished Asia hands and those with a budding interest in
the dynamic region. Our aim is to provide listeners with a greater understanding of the
individuals who focus on and live in the region, and how Asia affects our world. "
The ho sts bring sign ificant experience and expe rtise to the podcast. Campbell is CEO
and Chairman of The Asia Group, and served as Assistant Secretary of State for East
Asian & Pacific Affa irs from 2009 to 2013. Richard Verma is Vice Ch airman and
Partner at The Asia Group, and served as the United States Ambas sador to India from
2015 to 2017.
The first episode of Tea Leaves is now live on major podcast platforms , including
iTunes , Stitcher, and Overcast. Subsequent episodes will be animated by conversat ions
with the movers, doers, and thinkers who are driv ing today's Indo-Pacific. "We hope
that you will subscr ibe and give our first episode a listen," sa id Campbell and Verma.
Th e link to the podcast is available here: https://itunes.apple.com/us/podcast/the-tea -

leaves -podcast /id 135 5207045
NIH-001352
From: (b)(6)
Sent: Tue, 25 Feb 2020 16:08:53 -0500
Subject: Fwd: The last Word with Lawrence O'Donnell
Let us discuss
From: "Shuster, Amy (NBCUniversal , MSNBC)" < amy.shuster @msnbc.com >

To: "Conrad , Patricia (NIH/NIAID) [E]" --------~~
(b)( , "Fauci,
Anthony (NIH/NIAID ) [E]" (b)C
Subject: The Last Word with Lawrence O'Donnell
Good afternoon,
I wonder if Dr. Fauci could join our program this evening at 10 pm to discuss the best
measures for the government and the American peop le to prepare for a coronavirus
pandemic.
Ali Velshi is hosting our show tonight on MSNBC.
This would be a panel discussion this evening -w e're still working through details of the
panel.
Interview would be from 10-10:20 pm EST.
Please let me know if anything would be possible tonight.
Many thanks,
Amy
Amy Shuster
Senior Producer
The last Word
0. 212 -664-1657
C. (b)(6)
NIH-001353
From: (b)(6)
Sent: Tue, 25 Feb 2020 14:03:48 -0500
To : Ziady, Hanna (NE)
Subject: Re: Questions on coronavirus vaccine
45 people. It will take 3 to 4 months to complete.
On Feb 25, 2020, at 11:12 AM , Ziady , Hanna (NE)

<Hanna.Ziady @tum er.com >wro te:
Thanks very much for the quick response.
Do you know at this stage when the phase 1 trial will be completed and how many people
will participate in it?
Many thanks,
Hanna
Hanna Ziady
Writer I CNN Business
0: +44 207 693 1884
M: + (b)(6)
@hannaziady
From: "Fauci, Anthony (NIH/NIAID) [E]" (b)(6)
Date: Tuesday, 25 February 2020 at 15:58

----------
To: "Ziady, Hanna (NE)" <Han na.Z iady@turner.com>
Subject: RE: Questions on coronav irus vaccine
The phase 1 trial to determine safety for the mRNA vaccine platform
that NIH is doing with Moderna is scheduled to start within 2 months
(some time in April) . However, this is just the first step in attempting to
have a vaccine available for use. Even proceeding at an emergency
speed, a vaccine would not be available for use for at least 1 to 1.5
years. It is characterized as a "vaccine".
Director
Nat ional Institute of Allergy and Infectious Diseases
NIH-001354
Phone : Cb)(6)
FAX: (301) 496-4409
E-mail : Cb)(6)
and delete it from your mailbox or any other storage devices. The National Institute of
made that are the sender's own and not expressly made on behalf of the NIAID by
one of its representatives.
From: Ziady, Hanna (NE) <Hanna.Ziady@turner .com>

Sent: Tuesday, February 25, 2020 5:56 AM
Subject : Questions on coronav irus vaccine
Dear Dr Fauci,
Trust this mail finds you well .
I have a few questions regarding the Moderna vaccine, which it wou ld be great to get your
input on.
Is it true that trials of the possible vaccine will start in April, but that, even if the first study
is positive, the vaccine might not become wide ly available until next year because of the
need for further studies and regulatory clearances?
The company is characterizing this as a vaccine. Strictly speaking, what should it be

referred to as?
If you have time for a quick telephone call this morning as soon as you're able that would
be great.
Many thanks,
Hanna
Hanna Ziady
Wri ter, CNN Business
Office : +44 207 693 1884
Mobile :
------
@hannaziady
(b)(6)
Information in this email includ ing any attachments may be privileged or confidentia l and
is intended exclusively for the addressee. The views expressed may not be official policy,
but the personal views of the originator. If you have received this email in error, please
NIH-001355
notify the sender by return e-mail and delete it from your system . You shou ld not
reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note
we reserve the right to monitor all e-mail communication through our internal and
external networks. Turner and the Turner marks are trade marks of Turner Broadcasting
System Inc and are used under licence.
Turner Broadcasting System Europe Limited (Company No. 1927955), Turner

Entertainment Networks International Limited (Company No. 2803512), Turner
Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable
News International Limited (Company No. 5001368) are incorporated in England and
Wa les and share the same registered office at Turner House, 16 Great Marlborough Street,
London WlF 7HS.
Information in this email includjng any attachment s may be privileged or

confidential and is intended exclusively for the addressee . The views expressed may
not be official policy , but the personal views of the originator. If you have received
this email in error, please notify the sender by return e-mail and delete it from your
system. You should not reproduce , distribute, store, retransmit , use or disclose its
contents to anyone. Please note we reserve the right to monitor all e-mail
communication through our internal and external networks. Turner and the Turner
marks are trade marks of Turner Broadcasting System Inc and are used under
licence.

Entertaimnent Networks International Limited (Company No. 2803512), Turner
Broadcas ting System Holdings (Europe) Limited (Company Number 2802926) and
Cable News International Limited (Company No. 5001368) are incorporated in
England and Wales and share the same registered office at Turner House , 16 Great
Marlborough Street, London Wl F ?HS.
NIH-001356
From: (b)(6)
Sent: Tue, 25 Feb 2020 13:56:38 -0500
Subject: Re: cdc coronavirus
This does not change anything I said this AM. It is perfectly compatible with what I said. No
conflict at all.
On Feb 25, 2020, at 1:32 PM, Conrad, Patricia (NIH/NIAID) [E]

(6)>wrote:
----------- (b)
Pis advise
Patr icia L. Conrad

(b)(6)
301-496-4409 fax
Disclaimer :
The informat ion in this e-mail and any of its attachments is confident ial and may contain sensitive information. It
shou ld not be used by anyone who is nol the original intended recipient. If you have received this e-mail in error
please inform the sender and delete it from your mailbox or any other storage devices . National Institute of Allergy
expressly made on behalf of the NIAID by one of its representatives .
From: Jakaitis, Mike <mjakait is@wtop.com>

Subject: cdc coronavirus ---------- (b)(6)
The CDCtoday alerted Americans to begin to prepare for community spread of the
coronavirus .....does t his changes Dr. Fauci's view on the virus? If so can he join us. If this
doesn't change anything. We can use what he said this morning ....or if he wants to come
on and ta lk about the new CDC warning ...we would like to speak to him.
NIH-001357
From: (b)(6)
Sent: Tue, 25 Feb 2020 13:52:31 -0500
To: James Rae
Subject : Re: touch screens transmitting Coronavirus
Mr.Rae:
Tha nk you for your note.
Best rega rds,
A.S. Fauci
> On Feb 25, 2020, at l: 36 PM, James Rae

>
------ (b)(6) wrote:
> Dear Dr. Fauci-

>
> Thanks for your tv appearance s to educate.
>
> Cell phone and other touch screens cou ld be a major vector of transmission for Corona virus .
>
> Please suggest frequent cleaning of devices with alcoho l on your next tv appearance.
>
> Keep up the good work. I've watched you over the years. Your public education is much appreciated.
>
> Best regards,
>
> Jim Rae
> Boston area
> (b) (6) mobile
NIH-001358
From: (b)(6)
Sent : Tue, 25 Feb 2020 13:09:02 -0500
To: Emanuel, EzekielJ
Cc: (b)(6)
Subject: Re:
lt may well dimin ish somewha t as weather gets warme r. However, there is no guarantee that this
will occur. More likely that it will become seasonal and go down in our summer and resurge
next winter
On Feb 25, 2020, at 12:48 PM, Em anue l, Ezekiel J (b)(6) wro te:
--------
To get 1 million deaths of 1957 would requi re 200 million infections at a

death rate of 0.5 % . That seems high number of infections .
But what is the worldwide seasonal flu death numbers if the USA has 50 ,000
deaths in a bad year and the 1957 number of deaths was 116 ,000 ? The
WH O says 650 ,000 death s w orldwid e from seasonal flu. So this could be
worse but by about 40 % not an order of magnit ude . Okay so I should be
more concerned .
And do you think it will go down in late spring with warme r weather?
Ezekiel J. Emanuel , M.D., Ph.D .
Vice Provost for Global Initiativ es

Diane v.S. Levy and Robert M. Levy University Professor
Chair , Department of Medical Ethics and Health Policy (
----~~ (b)( ~
1111
) --------
Co-Dire ctor, Health care Transformation Institute
Phone : (b)(6)
Fax : 2 15-898-6567
From: Fauci,Anthony (NIH/NIAID) [E] ______ (b_H _ >

To: Emanuel, Ezekiel J (b)(6)>
Subject : RE:
Zek e:
NIH-001359
Ari is also calling me frequently . The virus has adapted itself very well
to humans with considerable community transmission (certainly in
China) now in other countries such as South Korea, Japan, Iran, Italy,
etc. If it continues to spread via multiple generations of human to
human transmission, then we will not be able to avoid considerable
amounts of infect ions and spread in the USA. Seasonal influenza has a
mortality of 0.1%. The calculated mortality of COVID-19 to about 2.5
%. It is probably lower since the denominator is likely larger than we
appreciate due to asymptomatic infections . Even if the mortality goes
down to 0.5%, that is still equivalent to a pandemic influenza of 1957
or 1968. In other words, it could be worse than you think.
Tony
Anthony S. Fauci, MO
Director
Nat ional Institutes of Health
Phone : (b) (6)
FAX : (301 496-4409
E~mail : (b) (6)
The information in this e-mai l and any of its attachments is confidential and may
contain sensitive information. It should not be used by anyone who is not the original
intended recipient. If you have received this e -mail in error please inform the sender
and dele te it from your mailbox or any other storage devices . The National Institut e of
Allergy and Infectious Diseases (NIAi □) shall not accept liability for any statements
made that are the sender 's own and not expressly made on behalf of the NIAID by
From: Emanuel, Ezekiel J (b) (6)

Sent: Tuesday , February 25, 2020 10:47 AM
-----~~
To: Fauci, Ant hony (NIH/NIAID} [E] (b)(6)>
Subject:
Tony,
Ari is pestering me endlessly. What is your latest update and assessment on

coronavirus? I still am having a hard time seeing this as serious as everyone
else. Am I blind? Yes very transmissible but low mortality like flu in many
ways-the elderly , those with comorbidities, and total impact is likely to be
less than flu . Also travel restrictions are delaying but not stopping virus.
NIH-001360
Am I missing something big or small?
Thanks
Ezekiel J . Emanuel, M.D ., Ph.D.
Vice Provost for Global Initiatives

Diane v.S. Levy and Robert M. Levy University Professor
Chair, Department of Medical Ethics and Health Policy (
- ---~= CbH~
1111
) --------
Co-Director, Healthca re Transformation Institute
Phone: Cb)(6)
Fax: 215-898-6567
NIH-00136 1
From: (b)(6)
Sent: Tue, 25 Feb 2020 13:04:40 -0500
Subject: Fwd: DDP4 Inhibitors and ACE2 Inhibitors :: Spike Protein Bind ing in MERSand
SARS
Please bandle. Thanks
From: JoelMeyer (b) (6)

Date: Februar y 25, 2020 at 12:32:24 PM EST
To: "Fauci , Anthony (NIH/NlAID ) [E]" -------=-c-=
(b)(
Subject: DDP4 Inhibitors and ACE2 Inhibitors:: Spike Protein Binding in
MERS and SARS
Dear Dr. Fauci,

Is it possible that DDP4 and ACE2 inhibitors would be effective in preventing
coronavirus entry and thereby 'de -rail' the infectious cycle?
Thank you fo r your work and guidance to NIAID!
Sincerely,
Joel R.L. Meyer
(b)(
(b)(6)
-------------------------------------------
https:/ /www .ncbi.nlm.nih.gov/ pmc/articles/ PMC5891363/
"Coronavirus entry is initiated by the binding of the spike
protein (S) to cell receptors, specifically, dipeptidyl peptidase 4
(DDP4) and angiotensin converting enzyme 2 (ACE2) for MERS-
CoV and SARS-CoV, respectively [1-5]"
References
1. Masters , PS., Perlman , S. Coronaviridae in Field 's Virology. Knipe , OM.,
Howley, PM. , editors. Vol. 1. Lippincott, Williams &Wilk ins; Philadelphia:
2013. p . 825-858.
2. Coleman CM, Frieman MB. Coronaviruses: important emerging human
pathogens. J Virol. 2014 ; 88:5209-5212 . [PubMed : 24600003]
3 . De Wit E, van Doremalen N, Falzarano D, Munster VJ . SARS and MERS :
recent insights into emergi ng coro naviru ses . Nature Rev Microbiol. 2016;
14:523-534. [PubMed : 27344959]
NIH-001362
4. Greenberg SB. Update on human rhinovirus and coronavirus infections.
Sem Respir Crit Care Med. 2016 ; 37:555-571 .
5. Vijay R, Perlman S. Middle East respiratory syndrome and severe acute
respiratory syndrome. Curr Opin Virol. 2016; 16:70-76 . [PubMed : 26855039)
NIH-001363
From: (b)(6)
Sent: Tue, 25 Feb 2020 13:02:20 -0500
Subject: Fwd: Doctor Radio followup special
Please see if this is possible. Thanks
From: "Siege l, Marc" < Marc.Si ege l@nyul angone.org>

Date: Februa ry 25, 2020 at 12:07: 19 PM EST
To: "Fauci , Anthony (NIH/N IAID ) [E]" ------~~ (b)(6J:
Cc: "Conrad , Patricia (NIH/NIAID) [E]" (bH6J > , Beth Ameen
<beth.ameen @siriusxm.com>
Subject: Doctor Radio followup special
Hi Tony
Am wonde ring if you might have a few minute s to join us by phone again this
Friday between
3 and 4 on coronavirus
Would mean alot.
Ma rc
Sent from my iPhone
NIH-001364
Sent: Tue, 25 Feb 2020 17:25:40 +0000
To : Gary Simon
Cc: Graham, Barney (NIH/VRC) [E);Ledgerwood, Julie (NIH/NIAID) [E];'Chen, Grace
(NIH/NIAID) [E)';Conrad, Patricia (NIH/N IAID) [E);Mascola, John (NIH/VRC) [E)
Subject : RE: Coronavirus vaccine
Tha nks, Garry . I w ill pass you r note on to the peop le w ho wil l be cond uct ing th e
phase 1 vaccine tri al here at NIH.
Best rega rds,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Gary Simon (b)(6)>

sent: Tuesday, February 25, 2020 10:42 AM
------~~
To: Fauci, Anthony (NIH/NIAID) [E)_______ Cb
_H_6); Fauci, Anthony (NIH/N IAID) [E]
(b)(6)
Subject: Coronavirus vaccine
Dear Tony,
samples to NIH for immune assays.
gary
Gary L. Simon, MD, PhD, MACP

Walter G. Ross Profe ssor of Medici ne
NIH-001365
Director, Division of Infectious Diseases
Vice-Chairman, Department of Medicine
(b)(6)
F 202 741-2241
Confidentiality Note: Th is e- mail is intended only for the person or entity to which it
is addressed and may contain infor mation that is privileged, confidential or
otherwise prote cted from disclosure. Dissem inat ion, distri buti on or copying of this
e-mail or the informat ion herein by anyone other than the intended recipient, or an
employee or agent responsible for delivering the message to the intended rec ipient,
is prohibit ed. If you have received this e-mail in error, please call (202) 741-3636
and destroy the original message and all copies.
NIH-001366
Sent : Tue, 25 Feb 2020 17:15:43 +0000
Subject : FW: Collaboration proposal on -----------------=
----------------- = (b)(4)
variants
Attachments : Macrogen (Dr. Jeong-sun Seo) letter to Dr. Anthony Fauci.pdf
Please handle and res po nd to thi s person. Thanks.
Director
Phone : (b)(6)
FAX : (301) 496-4409
E-mail : (b)(6)
From: Ogan Gurel, MD (b)(6J>

To: Fauci, Anthony (NIH/NIAID) [E] ------~~ (b)(6)>
_...;...;...;;.::::====~~-:'.'
Cc: Jeongsun Seo MD PhD (b)(6); Changhoon Kim PhD
(b)(6); Moon -Young Shin
---------- (b)(6)
Subject : Collaboration proposal o
Dear Dr. Fauci,

--------------------- (b)(4 )
Greetings and thank you for all your outstand ing scientific and policy leadership regarding the evolving
Covid-19 situation.
I am writing to you from South Korea where, as you well know, we are experiencing a very difficult
phase of the epidemic. Among t he several groups I have been engaged with to address this crisis, I am
work ing w ith the genome sequencing company, Macrogen, w hich you may already be fami liar with
(https ://dna.macrogen .com/eng /l . Dr. Jeongsun Seo, the Chairman of Macrogen, along with other
company leaders and myself have been discussing (b)(4)
(b) (4)
NIH-001367
(b) (4)
Barring the institution of any extreme travel restrictions, I am planning to visit the Bethesda area next
week (Macrogen U.S.HQ is located in Rockville). I know you are extraordinarily busy but if yo u (or key
colleagues) have time, I and other senior Macrogen colleagues would be happy to discuss the project, its
necessary next steps, along with any other matters related to Korea as you wish. [Please note that I do
not have any clinical symptoms or signs of Covid-19 nor any relevant contact history .]
Thank you ve ry much for your attention to this matter and I hope that we may have a chance to advance
this important project together.
Please take care and thanks again,
Ogan
(b)(6)
m:Ihttp ://www .linkedin.com/i n/ ogangurel
NIH-001368
Sent : Tue, 25 Feb 2020 17:08:19 +0000
To : Eisinger, Robert (NIH/NIAID) [E];Greg Folkers (b)(6)
Subject: FW: NEJM content proof {Fauci) ----------
Attachments : N EJMe2002387 _Fauci_ Content2_Author. pdf
Let us di scuss.
Directo r
Phone : (b) (6)
FAX : (301 496-4409
E-mail : (b)(6)

------~~ (b)(6)
=
Importance: High
Dear Dr Fauci,
Attached is the content proof of your editorial. Please read *ALL* of the following instructions and
information carefully before you begin review ing your proofs.
First, please stop and take a moment now to confirm receipt, so that we can be assured that your
Your editorial has been edited for grammar, consistency, readabi lity, adherence to Journal style, and
clarity for nonspecialist readers. To expedite publication, we do not ask authors for specific approval of
routine changes; please read the entire article to make sure your meaning has been retained . Note that
problems . Finally, please note that a delayed or incom plete response may delay publication of your
editorial.
Please read the entire proof carefully, including all queries. Please return your query replies and proof
co rrections **before 12pm (US Eastern) this Friday, February 28, 2020** .
NIH-001369
Instructions are provided below . Note that you wi ll be reading for content only; the article will be
The Journal' s senior medical editors will be reading your article at this stage. If they have any additional
comments or queries for you, I wi ll forward them to you in the next few days.
queries at the end . The query markers and the queries are linked, so you can jump back and forth within
the file . Please respond to all the queries (see below for instructions ; please do ** NOT** use e-
annotation too ls) and convey any additional changes as needed .
TO RESPOND BY E-MAIL: If your corrections and your responses to the queries are straightforward, we
the PDFfile; the marks are small and easy to miss, which may lead to errors in your article .
Med iasupport@nejm.org .
proofs!
Best,
Eli
Elizabeth Lauren~ot
617-487 -6547
TO READ THE PROOF: You will need Adobe Acrobat Reader software (version 4.0 or later) to view this
file . Acrobat Reader is available free of charge at the Adobe Web site
(http://www .adobe.com/products/acrobat/readerma in.htm l ).
NIH-001370
and/or proprietary material. Any review, duplication, retransmission, distribution, or ot her use of, or
NIH-001371
Sent : Tue, 25 Feb 2020 17:07:30 +0000
To : Eisinger, Robert (NIH/NIAID) [E];Greg Folkers (b)(6)
Subject: FW: NEJM content proof {Fauci) -----------
Attachments : N EJMe2002387 _Fauci_ Content2_Author. pdf
Please tak e a look at thi s fo r me and proof to th e extent th at yo u ca n. Thank s.
Directo r
Phone : (b) (6)
FAX : (301 496-4409
E-mail : (b)(6)
From : Laurencot, Elizabeth <elaurencot@nejm.org>

To : Fauci, Anthony (NIH/NIAID) [E] ------~= (b)(6)>
Importance: High
Dear Dr Fauci,
Attached is the content proof of your editorial. Please read *ALL*of the following instructions and
information carefully befor e you begin review ing your proofs.
First, please stop and take a moment now to confirm receipt, so that we can be assured that your
Your editorial has been edited for grammar, consistency, readab ility, adherence to Journal style, and
clarity for nonspecialist readers. To expedite publication, we do not ask authors for specific approval of
routine changes; please read the entire article to make sure your meaning has been retained . Note that
problems . Finally, please note that a delayed or incom plete response may delay publication of your
editorial.
Please read the entire proof carefully, including all queries. Please return your query replies and proof
co rrections * * before 12pm (US Eastern) this Friday, February 28, 2020** .
NIH-001372
Instructions are provided below . Note that you wi ll be reading for content only; the article will be
The Journal' s senior medical editors will be reading your article at this stage. If they have any additional
comments or queries for you, I wi ll forward them to you in the next few days.
queries at the end . The query markers and the queries are linked, so you can jump back and forth within
the file . Please respond to all the queries (see below for instructions ; please do ** NOT** use e-
annotation too ls) and convey any additional changes as needed .
TO RESPOND BY E-MAIL: If your corrections and your responses to the queries are straightforward, we
the PDFfile; the marks are small and easy to miss, which may lead to errors in your article .
Med iasupport@nejm.org .
proofs!
Best,
Eli
Elizabeth Lauren~ot
617-487 -6547
TO READ THE PROOF: You will need Adobe Acrobat Reader software (version 4.0 or later) to view this
file . Acrobat Reader is available free of charge at the Adobe Web site
(http://www .adobe.com/products/acrobat/readerma in.htm l ).
NIH-001373
and/or proprietary material. Any review, duplication, retransmission, distribution, or ot her use of, or
NIH-001374
Sent : Tue, 25 Feb 2020 15:55:19 +0000
To : Barasch, Kimberly (NIH/NIAID) [C]
Subject : FW: The global health leaders call, Wednesday 26 February at 13:00 CET
Attachments : (b)(4)Swisscom Call code.pdf
Please print out for tomorrow AM.
Directo r
Phone : (b)(6)
FAX : (301 496-4409
E-mail : (b)(6)
From: RYAN, Michael J. (b)(6)

-------
To: Redfield, Robert R. (CDC/OD)--------------------~~
(b)(6) Chris.Elias
===================-~ (b)(6); Jeremy Farrar
Cb)(6) Fauci, Anthony
(b)(6)
Conrad, Patricia (NIH/NIAID) [E]
(b)(6)
------- >; Lynn Banks

<president@resolvetosavelives.org> __________________
(b)(6); Presiden t I Resolve to
Cb
_)_(6)
Save Lives
Tarik Mohammed
------------
Cc: SHOC<shoc@who.int>; Office of the Director-General <DGOffice@who .int>; SCHWARTLANDER,
Bernhard F. CbH6l>;MAHJOUR, Jaouad (b)( ·>; FALL, lbra hima Soce
(b)( >; GREIN, Thomas (b)(6); MI NHAS, Raman (b)(6):>; COX, Paul
Michael (b)(6); AL-SHORBAJI,Farah CbH6J.>; POOLE,Marcia
(b)(6) ·>; DRURY,Patrick Anthony (b)(6J,.> ; GRAAFF,Peter Jan
::=====~~
------- (b)( ; Dr VAN KERKHOVE,Mar ia (b)(6J:>; KABIR, Sophia
NIH-001375
(b)(6)
Subject : The global health leaders call, Wednesday 26 February at 13:00 CET
Dear colleagues,
coronavirus .
The teleconference will be hosted tomorrow Wednesday, 26 February at 13:00 CETand the dial- in
number with a passcode is attached.
If you experience any technical difficulties joining this conference call, please contact the WHO HQ EOC
operator at: +41227912490
It would be appreciated if you could kindly confirm your participation to Ms Sophia Kabir, email:
------ (b)(6); mobi le no. (b)(6)
Best,
Mike
NIH-001376
From: (b)(6)
Sent: Tue, 25 Feb 2020 07:30:31 -0500
Subject: Fwd: Bloomberg Radio 2/25
Let us discuss
From: "Jameelah D Robinson (BLOOMBERG / NEWSROOM:)"

<jrobinsonl58@b loomberg .net>
To: "NIAID NEWS (NIH/NIAID)" <NIAID NEWS@nia id.nih.gov>
Cc: "Fauci, Anthony (NIH/NIAID) [E]" (b)(6) 1.
Subject: Bloomberg Radio 2/25
Reply-To: "Jameelah D Robinson" <jrobinson158@bloomberg.net>
Hi Dr. Fauci!
I Hope this email finds you well. I'm emailing to see if you can join Tom Keene , Bloomberg
Suveillance Anchor/Editor-at-Large on his radio show tomorrow morning as a PHONER at
8:15am Et to discuss the Coronavirus. Please let me know if we can make this happen.
Many thanks!
-Jameelah
NIH-001377
Sent: Tue, 25 Feb 2020 03:27:11 +0000
Subject: FW: NIAF and coronavirus
Let us discuss.
From: Elvis Oxley <eoxley@bdo.com>

Sent: Monday, February 24, 2020 9:42 PM
)(c=
6)
Cc: Eric Jia-Sobota <esobota@bdo.com>
Subject: NIAF and coronavirus
Dr. Fauci, I trust this email f inds you well. It has been a few years since we've seen one another
on the Hill or at a NIAF event but hopefully we will rectify that soon.
I know you have a lot on your plat e, especially with the coronavirus, but I am curious if you have
five minutes for a call tomorrow so I can introduce you to my boss at BDO, Eric Jia-Soboda
(https://www.linkedin .com/in/ eric-jia-sobota -02156036/ ). Eric is an expert in cost accounting
for Life Sciences companies and he wants to glean your perspect ive on the likely structure of the
emergency coronavi rus budget request so that NIH and others can maximize those research and
implementation dollars at the most rapid pace. We would certainly appreciate your time.
My best, Elvis
ElvisOxley
Managing Director
Industry Specialty Services
----- (b)(6)(Mobile)
703-245-8665 (Direct )
eoxley@bdo.com
BOO
Greater Washington D.C.
8401 Greensboro Drive, Suite 800
McLean, VA 22102
www .bdo.com
BDO USA, LLP,a Delaware limited liability partnership, is the U.S. member of BDO International Limited, a UK
company limited by guarantee , and forms part of the international BDO network of independent member firms.
BDO is the brand name for the BDO network and for each of the BDO Member Firms.
IMPORTANT NOTICES
The contents of this email and any attachments to it may contain privileged and confidential information from
NIH-001383
BOO USA, LLP.This information is only for the viewing or use of the intended recipient. If you are not the
intended recipient, you are hereby notified that any disclosure, copying, distribution or use ot or the taking of
any action in reliance upon, the information contained in this e-mail, or any of the attachments to this e-mail, is
strictly prohibited and that this e-mail and all of the attachments to this e-mail, if any, must be immediately
returned to BOO USA, LLPor destroyed and, in either case, this e-mail and all attachments to this e-mail must be
immediately deleted from your computer without making any copies hereof. If you have received this e-mail in
error, please notify BOO USA, LLPby e-mail immediately.
NIH-001384
Sent: Tue, 25 Feb 2020 03:26:06 +0000
To: Tabak, Lawrence (NIH/OD) [E)
Subject: RE: Close of Day Note for 2/24/2020 re: coronavirus preparedness
No, I did not see this. You should tell Jim Gillman to copy me on everything that relates to this
issue since I am the one who will be dealing with the Congress, the President and the press
about all of this.
From: Tabak, Lawrence (NIH/OD) [El

---------
Sent: Monday, February 24, 2020 9:4 1 PM
To: Fauci, Anthony (NIH/NIAID) (E] -------,;-, = (b)(6)>
(b)(6)
Subject: FW: Close of Day Note for 2/24/2020 re: coronavirus preparedness
Tony,
I assume you have already seen this, but just in case....
Larry
From: "Gilman, James (NIH/CC/OD) [E]" CbH6)>

Date: Monday , February 24, 2020 at 5:50 PM
To: "Tabak, Lawrence (NIH/OD) [El"
--------~~ CbH >, Francis Collins
--------
Subject:
CbH6),"Gottesman,
Close of Day Note for 2/24/2020
Michael (NIH/OD) [El"
re : coronavirus preparedness
CbH >
Francis/ Larry/ Michael:

(b)(5)
NIH-001385
(b) (5)
Jim
NIH-001386
Sent : Mon, 24 Feb 2020 23:38:09 +0000
Subject : FW: LA Magazine/ Interv iew request
Let us discuss.
From: jmcgahan (b) (6l

Sent : Monday, February 24, 2020 6:03 PM
To : Fauci, Anthony (NIH/NIAID) [E]------
--------
::;..,..-,=
(b)(6)1>
Subject : LA Magazine/ Interview request
Dear Dr. Fauci,
You and I haven't met. I'm a long-time wr iter for Los Angeles Magazine. We're doing a cover story for
the April issue on the threat of the new coronavirus poses to the 10 mill ion inhabitants of metropolitan
Los Angeles. Would you be available for an interview on Wednesday?
Thanks,
Jason
NIH-001387
Sent: Mon, 24 Feb 2020 22:42:57 +0000
Subject : FW: Welcome packet & consent form I The Coronavirus Outbreak: Tracking
COVID-19 I Forum
Att achments: 3.2.20 Consent form .pdf, 3.2.20 Forum welcome document .pdf, 3.2.20 Green
room agenda .pdf
Let us di scuss.
Director
Phone : (b) (6)
FAX: (301 496-4409
E-mail : (b)(6)
From : Dweck, Kristen <kdweck@hsph.harvard .edu>

To : (b)(6) Lipsitch, Marc (b)(6)
----:----========~~------
Yip, Winnie Chi-Man ""-""".""".---:-:=======~
>; Fauci, Anthony {NIH/NIAID) [E] _______ Cb_
H_6)
Cc: (b)(6)Osborn, Elizabeth (b)(6)>; Conrad, Patricia
,;..
(N_I_
H;/_N_IA
_ I_D.:..
) .:...
[E~) ===~:--:--:-:-- (b Barasch, Kimberly (NIH/N IAID)
_ )~(6)>; [CJ
(b)(6) ; Folkers, Greg (NIH/NIAID) [E] (b)(6) •>; Lerner, Andrea
..( N
- 1-H-/:-N- IA
_ I...
D~) ".""'
[E~) ===~:.:..._-- (b
~)~(6)
---------
Subject : Welcome packet & consent form I The Coronavirus Outbreak : Tracking COVID-19 I Forum
Imp ort ance : High
Good evening ,
Please find attached , The Forum welcome document , green room agenda and consent form .
The welcom e packet includes information about our production along with what to wear while on camera. The
Harv ard T.H. Chan School of Public Health consent form is required for productio n ofwebcast series.
Please sign and scan a copy of the consent fonn back by March 2, 202 0.
We look forward to an excit ing event!
NIH-001388
Best,
Kristen Dweck
Kristen A. Dweck
Digital Media and Engagement Manager, The Leadership Studio
Harvard T.H. Chan School of Public Health
677 Huntingto n Avenue, Kresge 329 I Boston, MA 02115
o: 617-432-1268 I f: 617-432-1780
kdweck@hsph.harvard .edu
~ HARVARD SCHOOL
OF PUBLICHEALTH
~ T.H.CHAN
Join the conversation:
The Forum I Twitter I YouTube I iPhone and iPad
NIH-001389
Sent : Mon , 24 Feb 2020 22:34:05 +0000
Subj ect : FW: Re:Following up on NIH visit
W hat is t his?
Director
Phone : (b)(6)
FAX: (301 ) 496-4409
E-mail : (b)(6)
From: Jason Gale (BLOOMBERG/ NEWSROOM:) <j.gale@bloomberg.net>

To : Conrad, Patricia (NIH/NIA ID) [E)
(b) (6) >
------- --=~
(b)( 6) ; Hoffman, Hillary (NIH/NIAID) [El
Cc: Fauci, Anthony (NIH/NIAID) [El

(b)( 6) -------- (b)(6) Seg re, Julie (NIH/NHGRI) [El
Subject : RE: Re:Following up on NIH visit
Dear Hillary ,
Thanks for you r email .
I a m in de e d l ooki n g forward t o my NIH v isi t on F r i day, a nd am
st ill h opi n g I migh t ge t some t ime wi t h Dr . Fauc i, t h ough I ca n
app re ciate he might be b usie r than either of us expected to be
back when we firs t sc he du le d my in t er v iew wi t h him!
Warm regards ,
Jason
Jason Gale, MHlthSec

Senior editor I Bloomberg News
Level 30, 120 Collins St., Melbourne VIC 3000
NIH-001390
Tel. (landline ) +61-3-9228-8783 I Mobile CbH6)
@jwgale I Linkedin : http://www .linkedin .com/pub/jason-ga le/6/249/a56
F r o m: (b)(6) At : 02 / 2 5 /20 06 : 4 7 : 17
To ; Jaso n Ga l e (BLOOMBERG/ NEWSROOM ; )
Subjec t : RE: Re :F o ll owin g up o n NIH v i s i t
Hi Jason ,
Hope you have/had safe travels to DC this week ! I wanted to check in to

confirm that you 're still planning on coming to visit us at NIH this Friday?
Currently , Dr. Myles is holding 10am and Dr. Belkaid is holding 1:30pm to
discuss their microbiome-related research with you. Dr. Fauci's schedule
has been very fluid lately due to the coronavirus outbreak-we 'll likely need
to check in with his assistant Patty Conrad on Thursday to see how his
Friday calendar looks (unless you hear otherwise from Patty directly).
Best,
Hillary
Hillary Hoffman, Ph.D. , Writer/Editor

Office of Communications and Government Relations , NIAID , NIH
5601 Fishers Lane #6G38
(b)(6)
(b)(6)
From: Jason Gale (BLOOMBERG/ NEWSROOM:) <j.gale@b loombe rg.net>

Sent: Tuesday , January 28, 2020 4:39 PM
To: Hoffman , Hillary (NIH/NIAID) [E] --------=-:=
CbH6)>
Subject: RE: Re:Following up on NIH visit
Sounds good . Many thanks.

From : Hillary Hoffman
-------
To: JASON GALE
----------
At: 29-Jan-2020 08:38:46
Sounds good - I'll ask Dr. Myles to hold 1Oam, so you can chat
with him before you meet Dr. Fauci at 11. We can re-confirm
timing closer to the date. I'll tag along , and can make sure you
get where you need to - you'll get to visit several different
buildings, fortunately all close by!
NIH-001391
From: Jason Gale (BLOOMBERG/ NEWSROOM :)
<j .gale@bloom berg .net>
Sent: Tuesday, January 28, 2020 4:32 PM
To: Hoffman, Hillary (NIH/NIAID) [E] ------- -------=
(bH 6
J>
Hi Hillary
Late night for me on 2019-nCoV ...
Shall we say before DrFauci? Then I'll know better how to get to
him. ~
Thank s a lot. Jason
________
----- Original Message-----
--------~=
From: Hillary Hoffman ,__ (b)( _,
To : JASON GALE
CC: (b)(6)
At: 29-Jan-2020 06:34:55
Hi Jason ,
Great speaking with you last week. I wanted to follow

up to let you know that Yasmine Belkaid and Ian
Myles-whose work we discussed on host-microbe
interactions and developing a bacteria-based
treatment for eczema, respectively-are willing to
meet with you on Feb. 28.
Here are links to some background info:
• Dr. Belkaid's lab page , and recent NIA ID press

release about a skin microbiome study from
her lab
• Dr. Myles' lab page, and NIA ID press release
about findings from a Ph 1/2 trial assessing the
R. mucosa treatment for eczema
Dr. Belkaid is available at 1:30pm (her building is next
to the Clinical Center, where you'll be meeting with
Julie Segre I believe from 12-1ish). Dr. Myles'
schedule is a bit more flexible, and he's currently
available to meet either in the morning before you
speak with Dr. Fauci or later in the afternoon after Dr.
Belkaid (Dr. Myles is in the Clinical Center, about a 5
min walk from Dr. Fauci's building)- let me know if
you have a timing preference. We can firm up times a
bit closer to the date, but wanted to give you an
update.
NIH-001392
Best,
Hillary
Hillary Hoffman , Ph.D., Writer/Editor

Office of Communications and Government Relations, NIAID ,
NIH
5601 Fishers Lane #6G38
Rockville, MD 20852
(b)( 6)
(b)(6)
From: Jason Gale (BLOOMBERG/ NEWSROOM :)

<j .gale@bloo mberg .net >
Sent: Thursday , January 23, 2020 4:09 PM
To: Hoffman , Hillary (NIH /NIAID ) [E]
<hillary.hoffman@ nih.gov>
Cc: Routh, Jennifer (NIH/NIAID) [E]
<jennife r.routh@nih .gov >
Sorr y!! Ge t t ing on no w
From : At:
01/ 24 /20 --------------
08 : 07 : 4 8
(b)(6)
To: J aso n Ga l e (BLOOMB

ERG/ NEWSROOM
:
Cc: ( Cb)(~
Subject : RE: Re : Following up on NIH
visit
Hi Jason ,
Wanted to check that you're still able to

join us this afternoon/morning -- and that
you aren't having issues calling into the
conference line. Jen and I are both on.
Thanks , and hope to talk soon!

Hillary
From: Jason Gale (BLOOMBERG/

NEWSROOM :) <j.gale@bloombe rg.net>
Sent: Friday , January 17, 2020 3:02 PM
To: Hoffman, Hillary NIH/NIAID) [E]
(b)( 6)
Cc: Routh, Jennifer (NIH/NIAID) [E]
NIH-001393
(b)(6 )>
Subject: RE: Re:Following up on NIH

visit
Awesome. Thanks a lot.
----- Original Message-----

From: Hillary Hoffman
(b)(6)
To: JASON GALE

cc (b) (6)
At: 18-Jan-2020 01 :31 :40
Hi Jason ,
Yes , 4pm next Thursday (8am

Friday for you) works for us. I
will send out a calendar
invitation with call-in
information later today.
Enjoy your time off, and looking

forward to speaking with you
next week!
Best,
Hillary
From: Jason Gale

(BLOOMBERG/
NEWSROOM:)
<j.gale@bloombe rg.net>
Sent: Thursday , January 16,
2020 6:24 PM
To: Hoffman , Hillary
(NIH/NIAID) [E]
(b)(6)>
Cc: Routh, Jennifer

NIH/NIAID [E]
'---,;- (b=H =6)>
Subject: RE: Re:Following up

on NIH visit
Dear Hillar y,
Than ks for your email .
I am on vaca t ion Mon-
NIH-001394
Thursday next week .
Woul d a 4 pm call on
Thur sday Jan . 23 (8 am
Friday for me) work?
I jus t saw ha p pened t o
see this report , FYI :
h ttp s : //med i ca l xpr ess . c
om/news/2020 - 01 - gu t -
bacter i a -
park inson . h t ml ?fbc lid = I
wAR20XNzDroX9za HhP 73A22
pK2zOP 2 cR Q6 YJ j dQo -
ic bKrNKr j oPrQ9Z0
I t' s a good exam p le of
t he growing awareness
that the Human
Micro b iome Project is
hel p ing t o p rovide of
the complex
int erac tions with
various b iological
processes that un derp in
health and disease.
Have a grea t weekend ,
jason
From :
(b)(6)
At: 01/17/20 03 : 22 : 49
To : Jaso n Ga le
(BLOOM BERG/ NEWSROOM :
Cc :
(b)(6)
Subject: RE :
Re:Following up on NIH
visit
Hi Jason,
Great to hear of
yourinterest in
microbiomeand flu
research. Jen and I
would be happy to
chat about what
NIAID may be able
NIH-001395
to offer in terms of
subjec t matter
exp erts and
storylines in those
areas.
Might you be
available for a short
call next week
between 4 -5pm
EST on either
Tues., Wed ., or
Thurs . afternoon -
corresponding to 8-
9am Melbourne
time on Wed.,
Thurs. , or Fri.
morning (assuming
I've got my time
zones correct)? If
we can 't find a
mutually convenient
time , happy to
continue
discussions over
email.
Best ,
Hilla ry
Hillary Hoffman, Ph.D.,

Write r/Editor
Office of
Communications and
Government Relations,
NIAID, NIH
(b)(6)
Media line : 301-402 -

1663
From: Jason Gale

(BLOOMBERG /
NEWSROOM :)
<j .gale@b loo m berg .
net >
Sent: Wednesday,
NIH-001396
January 15, 2020
11:56 PM
To: Rancourt , Anne
(NIH/NIAID) [E]
(b)(6)
Cc: Leitman , Laura

(NIH/NIAID) [E]
)(6)
Hoffman ,
Hilla ry (NIH/NIAID)
[E]
(b)(6)
; Routh,
Jennifer
(NIH/NIAID) [E]
(b)(6)
Lave lle,
Judi th (NIH/NIAID)
[El
(b)(6)
Segre, Julie
(NIH/NHGRI) [E]
)(6)
Subject: RE:
Re :Following up on
NIH visit
Hi Anne,
Thanks a lo t
for yo ur ema il
a nd your
sugges t ions!
After my last
vi sit to NIH
( a nd mee t in g
with Lisa
Pr octor and
J u l ie Segre
yea r s ago }, we
d i d t he
attac he d s to r y
on the gu t
mic r obiome .
We ' r e ve ry
keen t o l oo k
NIH-001397
at do in g a
podcast ser ies
on the
microbiome
(skin, gut ,
other
anatomical
b i ts ) a nd ho w
it ' s informing
our views on
he a l t h,
disease and
the way we
prevent a nd
treat
diseases .
It would be
coo l t o
works ho p t hi s
theme with you
a nd your
co ll eagues
before my
v i s i t , if you
h ave some
t ime?
I cut my teeth
in medica l
sc ien ce
writing on
(bird) fl u and
wou l d be
interested in
the re search
Jeffrey
Taubenberger 's
lab is doing ,
but my
un derstanding
(and I could
be wro ng) i s
t h at t he re ' s
still a lot of
work to be
done in
producing a
universa l flu
NIH-001398
s h ot . I f suc h
vacc in e
candidates are
st ill y e ars
fro m en t e r in g
clinical
trials , we
probab l y wou l d
p u sh that
lower down the
list .
Hop e t h at
helps , and
thanks again !
Jaso n
Hi Jaso n,
Ahead of yo u r
visit , here
are a f e w l abs
that are doing
innovative
work a nd may
present
interesting
backgrou nds t o
become f u t u re
stories , or
in for m your
report in g . For
antimicrobial
res i stance
spec i f i ca ll y ,
Dr . Fa u ci is
your best
source . Bu t
the below are
exci t in g areas
of researc h at
NIAID , and may
be a f i t for
Prog n os i s . Le t
me know if any
of the below
p i que your
NIH-001399
in t eres t a n d
we ca n s h are
more detail
a n d/or arrange
time .
• Skin
microbiom
e: NI AI D
researc he
rs
deve l oped
a t op i ca l
therap y
for
eczem a
that
in vo l ves
tr ea t in g
skin with
"goo d "
bacter i a .
If proven
effective
, t hi s
strategy
co ul d
offer an
inexpensi
ve
tr ea t men t
that
req u ires
l ess
frequen t
applicati
on t h an
many
c u rrent
eczema
medica t i o
ns . A
Phase 1 /2
tr i a l at
NIH
in d i cated
NIH-001400
t h at t his
no ve l
therapy
i s safe ,
a nd mos t
participa
nts
experienc
ed
imp r oveme
n ts in
their
eczema .
NI H h as
excl u sive
ly
l i ce n sed
the
technolo g
y to
Fo rte
Bioscienc
es t o
adva n ce
this
pote n t i a l
ne w
therapy
t h roug h
fur t he r
clinical
deve l opme
nt .
• Gene
therapy:
NI AI D is
developin
g a nd
app l y in g
gene
corr e ct i o
n
techniq u e
s to
tr ea t a
NIH-001401
var ie ty
of
g enetic
immune
d i sord e rs
. For
example ,
NI AI D
scientist
s co -
deve l oped
a
lentivira
l gene
therapy
to treat
inf a n ts
with X-
SCID , a
rar e a n d
fa ta l
genetic
immune
d efi c ien c
y . In
c l ini ca l
tr i a l s ,
the g ene
t he rapy
s uc cessfu
lly
restored
t he
immune
systems
of
infants
newly
d i agnosed
with X-
SCID , as
we ll as
olde r
children
a nd you n g
adu l ts
with the
NIH-001402
co n d i t i o n
wh o
experienc
ed
comp l ex
medical
problems
after
receiving
standard
t h erapy .
Mu stang
Bio is
h and l i ng
commercia
l
deve l opme
nt of the
lentivira
l ge n e
t h erapy
for X-
SCI D.
• Flu: Dr .
Jeffrey
Taube nber
ger is a
1918
in f l ue n za
expert
who
sequenced
the 1918
pandemic
v i ra l
ge n ome
u sing
arc hi va l
autopsy
specimens
from t h e
Armed
Forces
I n stitute
of
NIH-001403
Pa t holog y
a nd
frozen
l ung
b io ps ie s
from 1918
fl u
v i ct im s
interred
in
permafros
t .
Lear ning
about
1918
pandemic
f l u ca n
help us
better
prepare
for a n d
target
fu t u re
pa ndem i c
strains .
Dr .
Taubenber
ge r ' s lab
is
deve l op in
g a so -
ca ll ed
universa l
fl u
vaccine
t h at
incl udes
4
in act i vat
ed
infl u enza
v i ruses
and is
expected
to
undergo
clinical
NIH-001404
t es t in g
soo n.
Also , Dr .
Matt h ew
Memoli
l e ads
NIAI D' s
in f l ue n za
challenge
st u dies
in whi c h
healthy
vol u ntee r
s are
pu rp os e ly
exposed
to
infl u enza
in a
carefu ll y
co n t ro l l e
d
e nv i ronme
nt .
Challenge
stud i es
offer a
u niq u e
oppor t u ni
ty t o ask
foc u sed
q ues t i ons
regard in g
infl u enza
vi r u s
pat h oge n e
sis and
vaccine
e ff i cacy
in a
cont r ol le
d mann er .
• Mosquitoe
s:
NI AI D' s
NIH-001405
Laborator
y of
Malaria
a nd
Vector
Research
investiga
tes
disease -
transmitt
ing
insects
and broad
areas of
malaria
biology
and
pathogene
sis . Dr .
Tov i
Le hma n
st udies
mosqui t o
eco l ogy,
covering
broad
popu l at io
n biology
questio ns
re l evant
to
patterns
of
malaria
transmiss
ion a nd
vector
control .
Recent l y ,
Dr .
Le hman
a nd
colleague
sin Mali
found
t h at a
single
NIH-001406
mosqu i t o
ca n
tra v el u p
t o 2 00
mi l e s in
a sin g le
ni g ht
wi t h t he
ri g ht
prevaili n
g win d
speed .
Th e
re s e a rc h
involved
collect in
g f l y in g
i n sects
u sing
s t i cky
ne t s on
h eli um-
fi ll ed
ba ll oo n s
s u spended
at
vary in g
h e i g hts .
• Eating
for the
immune
system:
Dr .
Yasmin
Be l ka i d
is
researc hi
ng
co nne c t i o
ns
b e t ween
t he
mic r obiom
~,
nu t r i t i o n
NIH-001407
, f at ,
a nd
immunity .
Thi s work
is e ar l y
stage ,
b ut
pot en t i a l
ly
paradi gm-
shif t ing
as she
uncov ers
co nnec t io
ns
bet ween
d ie t a nd
immunity ,
with
im p l i cat i
ons fo r
us in g
nu tr i t ion
t o boos t
immune
in t erven t
ion s ,
including
vacc ine s .
• RSV:
Multiple
r ese arc he
rs are
workin g
to
deve l op
vaccines
aga in st
resp i rato
ry
sy n cyt i a l
v i rus
(RSV) -
so met hin g
most
NIH-001408
pare n t s
h ave
heard of ,
bu t i s
no t
covered
by media .
RSV
u s u ally
ca u ses
mi l d
cold - like
symptoms
in
healthy
ad u lts ;
h owever ,
RSV can
be
s e r i ous ,
part i cu l a
rly for
in fa n ts
a nd t h e
elderly .
I t i s t he
mos t
common
cause of
bro n c hi o l
itis and
pneumon i a
in
children
yo u nger
t h a n 1 in
the US .
Scientist
s h ave
spent
decades
try in g t o
develop
an
urge n t l y
n eeded
safe and
NIH-001409
effec t i ve
vacci ne.
One
ca nd i date
kn own as
DS- Cavl
developed
by Dr .
Barney
Graham ' s
t eam at
NIAID ' s
Vaccine
Researc h
Center
has shown
ear l y
promise
in a
Ph as e 1
c li ni ca l
trial .
I' m CCin g my
pub li c affa i rs
colleagues who
li aise wi t h
t he se top i cs
in case there
i s fo ll ow up .
Look in g
forward to
hopef u lly
mee t in g you
when you
visit .
Thanks ,
Anne
From: Jason
Gale
(BLOOMBERG/
NEWSROOM :)
<j . gale@bloomb
erg . n e t >
NIH-001410
Sent:
Thursday ,
December 19 ,
20 1 9 4 : 24 PM
To: Ra n court ,
Anne
(NIH/NIAID )
[ E]
)(6)
>
Subject:
Re : Followin g
up on NIH
visit
Hi Anne ,
Tha nks for

your ema il a nd
offer to
ass i s t wi t h
o t h er
in t e rv ie ws .
I ' m "old
sch ool ," and
s ee mer i t in
b u ilding
relationships
wi t h
researchers
and hearin g
about t hei r
work wi t hou t
t he
e xpec tat i o n of
n ecessar il y
g ettin g a
sto r y .
My interests
ar e pr e tty
eclectic --
from
a nt imi crob i a l
resistance to
NIH-001411
a nes t hesi a . I f
t he r e ' s some
interesting
stuff
h appe nin g t h at
hasn ' t been
reported on in
muc h d e ta il
that speaks to
t h e futu re of
he a l t h care
(that co ul d
would fo r ou r
Prog n os i s
platform) , I 'd
be keen t o
hea r abo u t it .
Ma n y t h a n ks
aga in a n d
happy
holidays,
Jason
Ut l
01
T l .
(1 . lJ.. ""
(b)(6)
l
_ J.. l . - ·.<.l l I
h t t p : //www . l i n
kedin . com/p u b/
jaso n -
g ale/6/2 4 9/a56
NIH-0014 12
F rom :
)(6)
At :
1 2 / 20 / 1 9
0 2 : 54 : 3 0
To : Jaso n Ga l e
(BLOOMBERG/
NEWSROOM : )
Subj e ct :
Fo l low in g u p
on NI H visit
Hi
J ason ,
I
he a r d
you ' ll
be
vi s i t i
ng us
a t NIH
on
Feb .
2 8 fo r
an
inte r v
i ew
wi t h
Dr .
Fa uci .
Please
le t me
know
if I
can
he l p
connec
t you
with
o t her
e xp er t
s
whil e
y ou
are
NIH-001413
here .
I 'd be
h appy
to
arrang
e for
you t o
see
a ny
l abs
or
he ar
from
expert
so n
HIV or
other
d ise as
es -
ju st
let me
k no w
what
you 're
in t ere
ste d
in
he ar in
g and
seeing
Thanks
Loo k in
g
forwar
d to
i t.
Anne
Anne
Rancou
rt,
MPS
Sec t io
n
NIH-001414
Chief ,
Office
of
Commun
icatio
ns and
Govern
ment
Relati
ons
Nat ion
al
Ins t i t
u t e of
Allerg
y and
Infe c t
ious
Diseas
es
Nat ion
al
Instit
u t es
of
Hea l t h
Pronou
ns :
She/He
r
(b)(6)
office
(b)(6)
mob ile
(b)( 6)
NIH-001415
Madonna 's Secret
for Longevity Seen
Aiding Bacteria
Boom: Health
2012-05-08
21 :34:07 .963 GMT
By Kaneko
Matsuyama and
Jason Gale
May 9 (Bloomberg)
-- The secret to
Madonna's staying
power
may be surprisingly
simple: gardening.
What the pop star
does involves no
trowel or soil.
Thanks
to dishes of
fermented soy
beans , millet and
brown rice prepared
by her personal
chef, Mayumi
Nishimura ,
Madonna practices
a form
of inner horticulture
-- cultivating her
intestinal flora in a
burgeoning
alternative
approach to health .
Studies of the
trillions of bacteria
living on and in the
body suggest the
Material Girl , 53,
may be onto
something. By
eating foods rich in
fiber and laced with
so-called good
NIH-001416
bacteria , she may
be encouraging
helpful microbes to
flourish in
her bowel, aiding in
food digestion and
vitamin extraction
and
possibly staving off
diseases from
asthma to colon
cancer .
"This diet that
Madonna is
following is very
sensible, "
says David
Topping, chief food-
nutrition researcher
at
Australia's
Commonwealth
Scientific and
Industrial Research
Organization in
Adelaide, who
studied gut biology
for 25 years .
"The bacteria that
live inside you are
fulfilling very
important
functions ."
While scientists try
to understand the
ecology of the
bacteria and their
interactions with
diet and disease ,
companies
are looking for ways
to profit.
The health benefits
of gut germs have
spawned a global
market for products
NIH-001417
that contain friendly
bacteria , called
probiotics , in the
form of tablets or
supplements added
to foods
by companies
including Danone ,
Nestle SA, and
Yakult Honsha Co.
The market for
supplemented dairy
products such as
Danone's
Activia yoghurts
and Yakult's
fermented drinks ,
worth $14 .7
billion six years
ago, will probably
expand 32 percent
to $33.5
billion by 2016 ,
Euromonitor
International
estimated last
month.
Quinoa, Not Coffee
Studies published in
the past year have
linked certain
bowel-dwelling
bacteria to a
stronger immune
system , while
others have been
associated with
autism and obesity.
In one
paper published in
the journal Nature,
scientists showed
that a
type of white blood
NIH-001418
cell that produces
antibodies only
acquired
its infection-fighting
ability after
spending time in the
gut.
Nishimura, who has
cooked for cancer
patients before
being
hired by Madonna ,
serves quinoa and
other whole grains
as
staples , along with
vegetables and soy
sauce, she said in a
telephone interview
from New York. She
also tries to offer
seaweed every
second day --
usually sauteed or
boiled.
"We eat food
processed as little
as possible ,"
Nishimura,
55 , says of her
dietary approach ,
known as
macrobiotic. She
doesn't recommend
meat, dairy and
coffee. An agent for
Madonna
didn't respond to a
request for
comment.
Whole grains and
fiber act as both
food and fertilizer to
the bacteria in the
bowel, according to
Mark Morrison , a
NIH-001419
microbiologist with
Australia's CSIRO
in Brisbane
studying ways
to improve gut
function and health.
'Terrific Interest'
There are 10 times

as many bacteria in
the human intestinal
tract as there are
cells in the body. As
coordinator of the
Human Microbiome
Project, Lita Proctor
is helping to
organize
collaboration from
hundreds of
scientists around
the world
trying to map and
study microbial
communities living
on the skin ,
in the mouth and
bowel, and in other
parts of the body.
"It's extremely
heartening and
healthy to have so
much
attention now paid
to the diet ," says
Proctor, who works
at the
National Human
Genome Institute in
Bethesda,
Maryland .
Even so, Proctor
says the research is
still in its infancy,
and products based
NIH-001420
on partial
understanding may
not deliver what
they promise .
"That's not holding
up the industry ,"
she says. "It's a
very fluid , ill-defined
area , but with a lot
of terrific
interest."
Flowers and Weeds
The term probiotic

is vague and there's
no accepted
definition for it.
Measuring results
may be even more
of a grey
area and some
supplements are
destroyed by
stomach acid
before
entering the gut ,
according to
Proctor.
Nishimura relies on
fermented foods
such as miso, soy
sauce
and tempeh to play
the role of
probiotics and says
the benefits
of her diet can be
quickly noticed.
"I feel better than I
did 20 years ago,"
Madonna wrote in
a preface to the
cookbook her chef
had published in
2010. "I am
NIH-001421
very grateful to you
for this."
The garden analogy
is helpful when it
comes to describing
the complex
ecology of the
bacteria living on
humans, says Julie
Segre, the lead
investigator working
on the skin
microbiome at
the National Human
Genome Research
Institute.
"There are some
flowers that make it
easier for other
flowers to grow in
the same soil,"
Segre says. The
most
important thing is to
keep out the
invasive weeds, she
says.
'Transpoosions '
When the weeds

take over ,
Australian
gastroenterologist
Thomas Borody has
a radical approach
to reestablishing the
balance of intestinal
flora in his patients:
he transplants
fecal germs from
disease-free
individuals directly
into the
upper reach of the
colon , in a pouch
NIH-001422
known as the
cecum.
His Sydney clinic
has done 1,800 of
the procedures ,
which
he jokingly dubs
"transpoosions ,"
over 25 years.
Borody , 62 ,
says the treatment
has helped patients
with ailments
ranging
from autism to
pseudomembranou
s colitis, a resilient
infection
that causes
abdominal pain,
loose bowel
movements and
fever.
"The next day their
diarrhea stops, " the
doctor says .
After the procedure ,
he asks patients to
avoid treatments
that
may damage their
gut flora. Three
studies presented
at the
American College
of
Gastroenterology 's
meeting in October
indicate fecal
transplants can help
with bouts of
diarrhea
associated with the
bacterium
Clostridium difficile.
NIH-001423
When Weeds Take
Over
Keeping inner bugs

healthy is crucial
because otherwise
they risk taking over
more than the
garden . If intestinal
bacteria aren't able
to survive on the
food their host
consumes ,
the germs will try to
feed on what they
can find -- "mucus
as
well as anything
else ," according to
CSIRO 's Topping.
That may
lead to
inflammatory bowel
disease, a painful
condition that can
evolve into colon
cancer , he says .
Staving off disease
is one reason
people have turned
to
Nishimura 's cooking
in the past. The
chef, who prepared
meals
for cancer patients
in Boston, says the
diet helps with
constipation,
menstrual pain and
body odor . When
she first
changed the way
she ate, Nishimura
says she also found
that her
NIH-001424
allergic skin rash
improved .
'So Fresh '
Typically, Nishimura
tailors her meals
each day to suit the
way her employer
feels , she says,
adding that
Madonna prefers
the chef herself to
shop for
ingredients. Popular
dishes include
seaweed in miso
soup ; hijiki -- a type
of brown seaweed -
served with carrots

and onions and
seasoned with soy
sauce; and
cooked oats for
breakfast ,
Nishimura says .
Whole grains
demand harder
work for bowel
bacteria , which
help the body
extract vitamins and
nutrients from food,
because
the insoluble fiber
they contain is only
broken down in the
lower reaches of
the digestive tract in
a fermentation
process
that delivers
different quantities
and varieties of
inflammation -
NIH-001425
fighting short-chain
fatty acids to the
body's
cells.
There is "solid
evidence" that
microbes play a role
in
tuning the immune
system , says Ian
Lipkin, director of
the
Center for Infection
and Immunity at
Columbia
University 's
Mailman School of
Public Health,
where scientists
showed in
January that
children with autism
and gastrointestinal
disturbances have a
bacterial species
not found in non-
autistic
children with tummy
upsets.
Madonna and
others making
similar diet choices
may not know
they 're pushing the
science frontier.
They may just feel
better.
"When you cut out
animal products,
white sugar and
coffee
for 10 days you
start to feel the
difference ,"
Nishimura said.
"When I first began
NIH-001426
this diet, I
remember how my
head became
clearer, I woke up
earlier and felt so
fresh in the morning
that
I didn 't want to stay
in bed."
Madonna herself
isn't lacking in
stamina . Her world
tour ,
which starts in Tel
Aviv this month and
ends next March ,
includes 75
concerts in Europe
and North America .
Her previous
world tour was in
2008 and 2009 ,
when she also
published six
children's books
and directed or
produced two
movies .
For Related News

and Information:
Most-read health-
care stories : MNI
HEA <GO>
Bloomberg 's top
health stories:
HTOP <GO>
Bloomberg 's top
stories on Japan:
TOPY <GO>
Bloomberg drug
database: BORG
<GO>
--Editors: Marthe
Fourcade, Rick
NIH-001427
Schine.
To contact the
reporters
responsible for this
story :
Kanoko Matsuyama
in Tokyo at +81-3-
3201-3490 or
kmatsuyama2@b lo
om berg .net;
Jason Gale in
Melbourne at CbH6)
or
j .ga le@bloomberg .n
et
To contact the
editor responsible
for this story :
Jason Gale at +65-
6212-1579 or
j.gale@bloomberg .n
et.
NIH-001428
Sent: Mon, 24 Feb 2020 22:33:02 +0000
Subject : FW: Virus Transmission
NIAID inquiries, please
Director
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b)(6)
should not be used by anyone who is not the original intended recipie nt. If you have received this e-mail in eITor
and not express ly made on behalf of the NIAID by one of its representatives.
From : DANIEL GAGNON
----------
Sent: Monday , February 24 , 2020 3:49 PM
------~~
(b) (6)
To: Fauci , Anthony (NlH/NlAID) [E]

Subject: Virus Transmission -------- (b)(6) >
Hi Dr. Fauci:
1 have been a long time admire r of you in the field of modern medicine. This question l have relates to the current
Coronavirus circulating around the world. For many years r have informed people that the ways a virus can be
passed from person to person isn' t always by a sneeze, cough or by touching someones face with their hands. Has
anyone in your medical community though t that if someone were smoki ng and was an infec ted person that once they
expel the smoke particles into the air that those micro s moke panicles may contain viruse s that were in the
respiratory system ofan infected perso n. Everyone T mention this to don ' t believe that this is poss ible. Whal are your
thoughts on this matter? lfso why hasn' t tbe medica l comm unity warned the public about this possibility as T stay
away from all establis hments that allow smok ing on their prem ises .
Thank you,
Daniel Gagnon
(b)(6)
NIH-00142 9
Sent : Mon, 24 Feb 2020 19:55:2 1 +0000
To: Conrad, Patricia (NIH/NIAID) [E);Barasch, Kimberly (NIH/NIAID) [C]
Subject : FW: interv iew with Dr Fauci
Here is th e reason for t he con f usion .,
Director
Phone : (b)(6)
FAX: (301 ) 496-4409
E-mail : (b)(6l
From: RABIN, RONI <roni.rabin@nytimes.com>

Subject : Re: interv iew with Dr Fauci
--------
I 'm sorry -- I thought you had canceled this time this morning when you said you needed to reschedule.
I'm so sorry . I'm in the middle of a meeting with editors at the Times about coronavirus coverage.
On Mon, Feb 24, 2020 at 2:42 PM Fauci, Anthony (NIH/NIAID) [E]

-------- CbH6)>wrote:
Hi Roni,
We just tried calling you a_t !:::::==~ (b
=-)~(6)
:- for our 2:30pm ET interview w ith Dr. Fauci. Please give us a
call as soon as possible at (b)(6) _
Thank you,
Kim
Kim Bara sch [CJ

Office of the Directo r
Nati onal Inst itu te of Allergy & Infe ct ious Diseases
(b)(6)
(b)(6)
NIH-001433
To: (b)(6)
(CJ CbH ; Robinson, Whitney (NIH/N IAID)
Cc: Deatrick, Elizabeth (NIH/NIAID)
[CJ (b)(6)> -----------
Subject: interview wi t h Dr Fauci
Dr Fauci can be available for your interview as per below on Monday Feb 24t h at 2:30 pm ET- 3:00
-
pm ET. Please let us know asap if that time works. The number to call for the interview will be (b'll
Thank you,
-patty
(6)
Roni Rabin
New York Times
(b)(6)
Roni.rabin@nyt imes.com
Seeking: Phone interview
Subject: asymptomatic transmission of coronavirus
Patricia L. Conrad
The Nationa l Inst itutes of Health
(b)(6)
301-496-4409 fax
Discla imer:
The informat ion in this e-mail and any of its attachments is confiden lia l and may contain sensitive information . It should not be
used by anyone who is not the original intended recip ient. If you have received this e-mail in error please inform the sender and
delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not
accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its
representatives.
Roni Caryn Rabin

New York Ti mes Staff Writer
(212) 556-8314
NIH-001434
-----
Cell: (b)(6)
NIH-001435
Sent : Mon, 24 Feb 2020 18:07:33 +0000
To: Doepel, Laurie (NIH/NIAID) [E]
Subject : FW: ASF---- measles - aerosol / contact/ drople t
Attac hment s: 1-s2.0-51879625717301773-main.pdf
From: Folkers, Greg {NIH/N IAID) [El (b)(6)

Se nt: Tuesday, September 4, 2018 3:15 PM
To: Fauci, Anthony (NIH/NIAID) [E]----- -=(b)""'~= >
Cc: Conrad, Patricia (NIH/NIA ID) [El (b)( 6); Doepel, Laurie (NIH/NIAID) [El
Cb)( ; Eisinger, Robert (NIH/NIAID) [E] H6J Folkers, Greg
Cb
~-':'""'."'.'"'.""'.""-:-:~ ;::::::==:::::.;_- .....;;;.___;
-..-.--.=
(NIH/NIAID) [E] (b)(6)>; Marston, Hilary (NIH/N IAID) [E] (b)( 6)
Subjec t : ASF ---- measles - aerosol /contact/ droplet
And per CDC -- rrequ ires airbornes precautions

http s://www .cdc.gov/infect ionco ntrol/ba sics/tran smission-based-precaution s.htm l
Table2
Ovel'lliew of the evide nce on trans mission routes of respiratory viruses based on expe rim ent al data and the transmi ssion route acco rding
to infec tion prevention guidelin es
V1rus Virus family" Transmission route

Expe-imental and observational data Guidelines b
Measles virus Paramyxoviridas Aerosol [75-n ,78° ,79"]. Contact [3,110) , droplet [3 ,109-111 ],
aerosol (3, 109-111 ).
Parainfluenza virus Paramyxovirfdas Limited data, contact (by fom ite) [83,841 ". Contact (3,109-111 ], droplet [3,109-111 ),
aeroso l (3,109).
HMPV Pnevmoviridae Limited data. c on tact (by fomite) " (30] Contact [3,110 .111). droplet [3,110 , 111].
RSV Pnevmoviridae Contact [89 .88] , ci'up let (88], ae rosol Contact [3,109-111 ), droplet [3,109 ,110],
[90,91"1- aerosol (109, 111].
HCoV Coronaviridae Umited data , contact (by fomite) [~6 7] 8
, Contact (3,110.11 i), droplet [3,110,111].
MERS-CoV Coronavlridae Contact (84 ) • [89) • [91.. J. droplet (89] " . Contact (111]. drop let [3,111]
aerosol (917 .
SAAS,CoV Coronaviridae Contact [70 ) • [73,79, 101], drople t Contact [3,110,111 ), dropl et [3, 110, 111),
[73, 78°,79•, 1171, aerosol (76, 118] c (82 ) c.d, aerosol (3 ,110, 111).
Rhin ovlrus Picomaviridae Contact [35.36.42 ]. aerosol [37 ,40 , 119). Contact [109-111 ], droplet [109,1 11).
aerosol (109-111 ].
Adenovirus Ad8novlrf<1ae Contact [100]
0
[100, 1011 droplet (103 1, Contact (3,109-111 ), droplet (3,109 ,11 OJ,
aerosol (102 , 103 1 . aerosol (110, 111].
Influenza virus Orthomyxovirldae Droplet/aerosol [55,56,sr,59 ] Contact (109-111 ], droplet [3, 109-111 ),
aerosol (3, 109-111 ).
a Taxonom y was based on [621 airtlorne t ransmission is see mingly linked to:
b WIP [108], ' Blue Book ' (109), 'Red Book ' [110). CDC [3]and Up-To-D ate [111]. The conclusions on experimental data as presented in this table
reflect me conclusions from the auttlOrs .
c Supersp reade r events.
Ona nosooomial situation).
d Aerosol-genera 6ng proced ure s
• Conclusions w ere drawn based on stability expe riments.
Disclaimer: Any third -part y mMerial in thi s email has been shared under fair use provisions of U .S.
cop y right law , without furth er verifi cation of its accura cy/ve raci ty_ It do es not necessarily repre se nt my
views nor tho se ofNTAJD , NIT-I, HHS , or th e U.S. government.
NIH-001442
Sent : Mon, 24 Feb 2020 17:21:34 +0000
To: Van Hoof, Johan [JRDBE];Erbelding , Emily (NIH/NIAID) [E)
Cc: Stoffels, Paul [JJCUS)
Subject: RE: as26 based COVID-19 vaccine candidate
Joha n :
Thanks for t he note . I enjoye d and learne d fro m yo ur pr esentat ion thi s
morn ing. The best way to keep in t ouch w it h NIAID wo uld be t hrou gh Emily and
Barney.
Best regards,.
Tony
Director
Build ing 31 , Room 7A-03
Phone : (b) (6)
FAX : (301 496-4409
E-mail : (b)(6)
other storage dev ices . The Nationa l Institute of Allergy and Infectious Diseases (NIAID) shall not
From: Van Hoof, Johan [JRDBE]

---------
Sent: Monday, February 24, 2020 11:58 AM
(b)(6)
To: Erbelding, Emily (NIH/NIAID) [E),-------- (b

=)~(= >
Cc: Fauci, Anthony (N IH/NIAID) [E] (b)(6)
---------
Subject: as26 based COVID-19 vaccine candidate
(b)(6) Stoffels, Paul [JJCUS)
--------
Dear Emily,
Dear Dr. Fauci,
First of all, I want to thank NIAID and its team for spending time with us going through the Janssen plans
for Ad 26 COVID-19 vaccine development.
In follow up of our call earl ier today, please find herewith the key action points I noted from our
discussion. I would welcome your perspectives/comments, as well as the best way to keep in touch with
NIAID.
Looking forward to your feedback,
NIH-001443
Best regards,
Johan
Johan Van Hoof, M.D.
Managing Director , Janssen Vaccines and Prevention B.V.

Global Therapeutic Area Head IDV, Vaccines, Janssen Pharmaceuticals R&D
Phone (b)(6) (b) ( Fax : +32 14 60 2841

E- mail (b)(6)
(b)(6)
Assistant
Phone
*************************************************************************************
*********************************** ************************
Follow Up to Ad26 COVID-19 call with NIAID; February 24 th 2020
(b) (4)
NIH-001444
(b) (4)
NIH-001445
Sent : Mon, 24 Feb 2020 16:53:04 +0000
To : Folkers, Greg (NIH/NIAID) [E]
Subject : RE:ASF ------ - NEJM commentary -- change title?
You are correct.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)( 6)
From: Folkers, Greg (NIH/NIA ID) [El

---------
Sent : Monday, February 24, 2020 11:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] -------::-::-=,
(b) (6)>
(b)( (;)>
~=======~~
Cc: Eisinger, Robert (NIH/NIAID) [E) ________ _H_, ; Folkers, Greg (NIH/NIAID) [E]
Cb
(b)(6)>
Subject : ASF ------- NEJM commentary -- change title?
(b)(5)
Disclaim er: Any third -party mat erial in this email has been sha red for intern al use under fair use pr ovisions
of U.S. copyri ght law, without furth er verific ation of its accurac y/veracit y. It does not necessaril y re pre sent
my views n or th ose of NIAlD, NIH, HHS, or th e U.S. govern ment.
NIH-00144 6
Sent : Mon, 24 Feb 2020 16:51:09 +0000
To : Faye Li
Cc: Billet, Courtney (NIH/NIAID) [E);Conrad, Patricia (NIH/NIAID) [E);Barasch,
Kimberly (NIH/NIAID) [C]
Subject : RE: Interview Request from China
Faye :
Thank you for yo ur not e. Please send me you r questions by e-mail and I w ill tr y
t o answe r th em by e- mail.
Best regards,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From : Faye Li (b)(6)>

Se nt: Monday, February 24, 2020 11:41 AM
--------, _...._..,=
---------
Subject : Interview Request from China
(b)(6)
Dear Dr. Fauci,
I'm Faye Li,journalist from the Portrait, a national magazine in China. My beat is science and technology.
Since the outbreak of the 2019 novel coronavirus (COVID-19) in China, I'm covering feature stories about
the outbreak, hoping to explain to readers what it is, especially since the virus is evolving daily at an
unexpected high speed, and in so many confusing ways.
Now in China we are getting conflicting information about the new virus and thus become confused
about it. For example, we are seeing more and more cases that a patient with negative test results for 2
non-continuous days, still infected with the virus and tested positive afterwards. It makes the treatment
really difficult because it seems hard to determine whether the patient is fully cured or not. Since you
are an experienced immunologist, I'm wondering if you could share your insights with the Chinese
readers and take an interview . The Interview could be via phone or email, whichever works fine for you.
NIH-001447
If possible, I'd love to send you the questions before we talk. Since we have time difference, I might not
be available dur ing the early afternoon (your time) but I could make it in the morning, noon and maybe
late in the afternoon and evening (your time).
I'm sorry for bothering you on this subject, but we face severe difficulty in understanding this new virus
and taking measures properly. We have quite limited sources and perspectives for understanding this
new virus . However, as a science reporter, I believe in a crisis of public health, the informat ion is the key
for the public. They should have the opportunity to hear more perspectives from different specialists.
Since you are experienced in fighting against so many viruses, especially SARS,I believe your opinions
wi ll be inspiring to the readers.
It would be of great help and great honor for us to invite you for an interview. A phone call interview
would be preferred but if t ime doesn't work for you, is it possible for you to reply via email? I'll list all
the questions in deta il.
I could be reached by (b)(6) or ______ Cb _, I'm

_)_C6) looking forward to your reply.
Best wishes,
Faye
The Portrait
Beijing, China
NIH-001448
Sent : Mon, 24 Feb 2020 16:01:59 +0000
Subject : RE: Call for Dr. Fauci
Cristina , please.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Conrad, Patricia (NIH/NIAID) [El

---------
-------::-::-=,
(b)(6)>
~---:::======!.,._~~ (b)((;)>
Cc: Barasch, Kimberly (NIH/NIAID) [C)
(b) ( >
---------- Haskins, Me linda (NIH/NIAID) [El
(b)(6) >;
Subject: Fwd: Call for Dr. Fauci
Is this a friend or do u just want to pass to Cristina. Pis advise
Sent from my iPhone
From: "Haskins, Melinda (NIH/NIAID) [El"

0 ate: February 24, 2020 at 10:40:37 AM EST
To: "Conrad, Patricia (NIH/NIAID)
---------
[E]" --------=- (bc-
(b) (
)( = >
>
Cc: "Harr is, Kara (NIH/NIAID) [El" (b)(6)>

Subject : FW: Call for Dr. Fauci
---------
From: Harris, Kara (NIH/NIA ID) [El (b)(6)>

--------
NIH-001449
To: Barasch, Kimberly (NI H/N IAI D) [ C] Cb)(6J>
Cc: Correa, Meylin (NIH/NIA ID) [C] (b)(6J>; Forde, Michae l (NIH/N IAID)
[C] (b)(6J>; McCullough, Claire (NIH/NIAID) [E]
--------. a""S"'"7=
---------- (b)(6J>; Haskins, Melinda (NIH/N IAID) [E]
Subject: RE; Call for Dr. Fauci
(b)(6)
Hi, Kim-
I spoke to Dr. Jacobs directly . He said that Dr. Michael Lockshin is a good frie nd/fellow
Cornell graduate (Dr. Jacobs also noted he went to Cornell) and gave him Dr. Fauci's
number.
Dr. Jacobs and Dr. Alexander Tarakhovsky, a virologist at The Rockefe ller Institute, would
like to speak to Dr. Fauci about the coronavirus. They have a theory that there may be
yeast invo lved because it is sticky and perhaps it came from the Chinese government.
They want to share their ideas and perhaps start a U.S. government effort "similar to The
Manhattan Project." They do not want funding.
I thanked Dr. Jacobs for sharing his ideas and stated that I would pass along the message.
Should Dr. Fauci wish to speak to them, Dr. Jacobs can be reached at the number below
and Dr. Tarakhovsky can be reached at (b)(6)
Please let me know if you have any question s.
Thanks,
Kara
From: McCullough, Claire (NIH/NIAID) [E] (b)(6)
To: Barasch, Kimber ly (NIH/NIAID) [C] --------~~ CbH6J>
Cc: Harr is, Kara (NIH/NIAID) [E] (b)(6J>; Correa, Meylin (NIH/NIAID) [C]
(b)(6)>; Forde, Michae l (NIH/NIAID) [C] (b)(6)>
---------
Subject: Call for Dr. Fauci
Hi, Kim--I got some additional information from Dr. Michael Jacobs office. He is a
dermatologist in New York City and said that Dr. Fauci is expecting his call. The secretary
provided no further information.
Dr. Michael Jacobs

(b)(
Thank you.
Claire A. McCullough
Legislative Affairs and Correspondence Management Branc h
5601 Fishers Lane, Rm. 6F27 - MSC 9806
Bethesda, MD 20892
Tel : (b)(6)
The information in this e-mail and any of its attachments is confident ial and may contain sensitive information. It
shou ld not be used by anyone who is not the original intended recipient. If you have rece ived this e-mai l in error
NIH-001450
and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly
made on behalf of the NIAID.
NIH-001451
Sent : Mon , 24 Feb 2020 15:14:10 +0000
Cc: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: New England Journal of Medicine 20-02387
Attachme nts: Fauci-20-02387-Text.docx, Embargo-Guidelines-5.13.pdf, Production-and-
proof.pdf
fyi
Director
Nat ional Institute of Allergy and Tnfectious Diseases
Bet hesda , MD 20892 -2520
Phone: (b) (6)
FAX: (30 I) 496-4409
E-mail: (b)(6)
The i11formation in this e-mail and any of its attachments is confiden tial and may contai n sensitive info1111ation. It
should not be used by anyone who is not the original intended recipie nt. If you have r eceive d this e-mail in eITor
please inform the sender and delete it from your mailbox or any other storage de vices . The National Institu te of
Allergy and Infec tious Diseases (NlAlD) sha ll not accept liability for any statements made that are the sender's own
and not express ly made on behal f of the NIAID by on e of its representa1ives.
-----Orig ina l Message-----

From: New England Journal of Medicine <onbehalfof @ma nuscriptcentral. com>
Sent : Monday,Febrnary 24, 2020 10:00 AM
------
To : Fau ci, Anthony (NlH/NIAID) [E] _____ "="'~
...,Cb)( >; Lane, Cliff(NlH/NIAlD) [E]
-------- (b)(6) ; Redfield , Robert R. (CDC / OD)

Subj ect: New England Journal of Medicine 20-02387
(b)(6)
Dear Dr. Fauci,
Tha nk you for the aiiicle , "COVTD- 19: Nav igat ing the U nchartered," which the .Journal is plea sed to accept for
pub) ication.
Th is accept ance is made w ith the unde rstand ing that neither the artic le itself nor any part of its essentia l sub stance,
tables or figures has been pub lished or will be s ubrni t1ed for publication elsew here before it appears in the J ournal.
The accepta nce is also made with the understanding that all the auth ors, the data, and its pres entation meet the
requirements as desc,ibed in the Recomme nda tions for the Conduct, Reporting , Edi ting and Publication of Scholarly
Work in Medica l Journals (www .icm je.org).
Please note that the acceptanc e of your comme ntary should be considered confide ntial infonnation to be shared only
with your coauthors until its fina l publication. To ensure that no news repo rts about the article appear prematurely in
any fonn, do not speak to the media, hold press conferences, or issue news re leases about your paper before the
week of publication . You must receive an explicit commitment to w ithhold release of the information until the
em bargo is lifted at 5:00 p.m. (Eastern T ime in lhe United States) on the day before. the date of publication. If there
are any questions about this policy, you shou ld discus s them with the Editor.
We assume that financial relationships creating possible conflicts of interest for all authors have been fully disclo sed
to the Editor , including (but not limited to) any relevant rela tionships listed in the Open Payments database at
NIH-001452
https://openpaymentsdata.cms. gov/sea rch/phys icians/by-name-and -location for physicians practicing in the United
States. For information on what would qualify as a 'relevant' disclosure, please review tbe instructions on page l of
your disclosure form.
Authors are rem inded that all material published in the Journal is copyrig hted by the Massach usetts Medical Society,
that by agreeing to have their manuscript published in the Journa l they !:,>rant
to the Society full right and authority to
sec ure copyright for the full tenn and any renewals or extensio ns thereof, and that pennission for reprinting must be
obta ined in writing from the Journal.
The Journal will edit your manuscript in accordance with its estab lished sty le. You will receive a proof of the ed ited
manusc1ipt by e-mail; the proof stage will be your next opportunity to make changes . For important info1mation
about production and proofs , see the attached document. In the meantime, please do not make any changes or send
any new material to us. Tbank you for your contribut ion to the Journal.
Sincerely yours,
Eric J. Rubin, MD , PhD

Editor-in-Chief

10 Shattuck Street
Boston, MA 02115
(617) 734-9800
Fax: (617) 739-9864
http://W\vw.ne jm.org
NIH-001453
Sent : Mon, 24 Feb 2020 14:22:21 +0000
To: (b)(6)
Cc: Barasch, Kimberly (NIH/NIAID) [Cl;Conrad, Patricia (NIH/NIAID) [El
Subjec t: RE: COVID-19 Quarantine
Ming:
Thank you for your note and offer to help. I will ask my Staff Ass istant, Kim Barasc h, co set up a brief call for you
to relate your impressions to me.
Best regards ,
Tony
Director
Bu ildin g 31, Room 7 A-03
Bethe sda, MD 20892 -2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b)(6)
should not be used by anyone who is not the original intended recip ient. If you have 1·eceived this e-mail in error
please inform the sender and delete it from your mailbox or any other storage devices. The National Institu te of
Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the send er's own
~m 00~
Sent: Sunday , February 23, 2020 7:52 PM
To:
Cc : Fauci, Anthony
(b)(6)
-------=-:-:-=
(NlWNlAID) [El ..._ _____ CbH
__. >
Subject: COVID-19 Qua rantine
Dear Dr. Fauci ,
My name is M ing Lei, a Division Director at the NIGMS . I am writing to you as a private citizen , to thank you for
your leade rship in yet anoth er public health eme rgency, and to make myself ava ilable to you if you have the time for
my in-person observations oftbe COVID-19 caused quarantine in Hub ei Province, China ; the evacuation of
Amc1icans; and the quarantine in the US.
(b)(6)
As the virus sti ll roams around , and a possibili ty
of caus ing a pandemic , I want to let you know that I am willing to share with you my direct observations in case
such information is of value in the developing of our responses going forward, which you will undoubtedly playing
a critical role.
l will send you a reminder through my NIH email account, in case this message is put into the junk mail folder.
Sincerely ,
NIH-001454
NIH-001455
Sent : Mon , 24 Feb 2020 14:03:36 +0000
To : Billet, Courtney (NIH/NIAID) [El;Marston, Hilary (NIH/NIAID) [El
Cc: Folkers, Greg (NIH/NIAID) [El;Conrad , Patri cia (NIH/NIAID) [El;Routh, Jennifer
(NIH/NIAID) [El
Subject: RE: FORYOUR REVIEW:Draft Rollout, A ll Staff, and Statement on Preparing for
Potential Patients w/ COVID-19
Loo ks fin e t o me.
Director
Phone (b) (6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Billet, Courtney (NIH/NIAID) [El (b)(6)>

To : Fauci, Anthony (NIH/NIAID) [El <O. -------= = i>; Marston,
(b)( Hilary (NIH/N IAID) [El
(b)(6)>
Cc : Folkers, Greg (NIH/NIAID) [E) (b)( >; Conrad , Patricia (NIH/NIAID) [E]
________ _H_6); Routh, Jennifer (NIH/NIAID) [El
Cb (b)(6)
Subject: FW: FORYOUR REVIEW: Draft Roilout, All Staff, and Statement on Preparing for Potential
Pat ients w/ COVID-19
Renate is asking that I confirm that Dr. Collins' changes (tracked in attachments) sync with what we 've
been saying. They look ok to me . What say you?
From: Coll ins, Francis (NIH/OD) [El (b)(6)>

Sent : Monday, February 24, 2020 6:45:07 AM
To : Myles, Renate (NIH/OD) [El (b)(6); Fauci, Anthony (NIH/NIAID) [E]
(b)(6); Tabak, Lawrence (NIH/OD ) [E] (b)( >; Gilman, James
(NIH/CC/OD) [E] CbH6)>
NIH-001456
Cc : Burklow, John (NIH/OD) [El CbH6)>;Hallett, Adrienne (NIH/OD) [El
(b)(6)1
>; Allen-Gi fford, Patrice (NIH/OD) [E] (b)( >; Billet,
Courtney (NIH/NIAID) [E] (b)(6); Davey, Richard (NIH/NIAID) [E]
(b)( >; Palmore, Tara (NIH/CC/OD) [E] CbH >; Cohen, Justin
(NIH/CC/OD) [E] (b)(6)>
Subject : RE: FORYOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential
Patients w/ COVID-19
Hi all,
N icely done, Renate. I made a few edits in two of the documents, see attached.
(b)(5)
FC
From : Myles, Renate (NIH/OD) [E] (b)(

Se nt: Sunday, Februa ry 23, 2020 8:56 PM
To: Fauci, Anthony (NIH/NIAID) [E]------ =(b=
H=6) Collins, Francis (N IH/OD) [E]
(b)(6)>; Tabak, Lawrence {NIH/OD) [E] (b)(6)>; Gilman, James
(NIH/CC/OD) [El CbH6)>
Cc: Burklow, John (NIH/OD) [E] (b)(6)>; Hallett , Adrienne {NIH/OD) [E]
(b)(6)>; Allen-Gi fford, Patrice (NIH/OD) [El (b)( >; Billet,
Courtney {NIH/NIAID) [E] (b)(6); Davey, Richard {NI H/N IA ID) [E]
(b)(6)>; Palmore, Tara (NIH/CC/OD) (E] (b)(6)>; Cohen, Justin
(NIH/CC/OD) [El (b)(6)>
Subject : RE: FORYOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential
Thanks, all. (b) (5)

(b) (5)
Latest rollout, all staff and statement are attached .
Best,
Renate
From : Fauci, Anthony (NIH/N IAID) [E] ______ _ )_C6)

Cb _>
Sent : Sunday, Februa ry 23, 2020 8 :15 PM
To: Myles, Renate (NIH/OD) [E] Cb)( >; Collins, Francis (NIH/OD) [E]
(b)(6JTabak, Lawrence (NIH/OD) [El (b)(6)>; Gilman , James
(NIH/CC/OD) [El --.-.~-== (b
=)=(6)
~>--~ =
Cc: Burklow, John (NIH/OD) [E] (b)( >; Hallett, Adrienne (NIH/OD) [E]
NIH-001457
Allen -Gifford, Patrice (NIH/OD) [E]
(b)(6) 1>; (b)(6) Billet ,
Courtney (NIH/NIAID) [E) (b)(6)>; Davey, Richard (NIH/NIAID) [E]
(b)(6l; Palmore, Tara (NIH/CC/OD) [E] (b)(6); Cohen, Justin
(NIH/CC/OD) [E) (b)(6) >
Subject: RE; FORYOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential
Renate:
The rollout plan looks fine except that I would include
-------------- (b) (5)
Thanks ,
Tony
From: Myles, Renate (NIH/OD) [E] (b)(6)>

Sent: Sunday, February 23, 2020 7:23 PM
To: Collins , Francis (NIH/OD) [E]_____ _.,.(b..._.
)=(6); Tabak, Lawrence (NIH/OD) [E]
(b)(6)>; Fauci, Anthony (NIH/NIAID) [E] (b)(6)>; Gilman, James
":":'
( N--IH
--/-:-:-
C-:-
C/-:-:-
0-:-
D:--:
) [~E]:-===..;__- ~ (bc--c
)( =6)>
Cc : Burklow, John (NIH/OD) [E] CbH6)>; Hallett, Adrienne (NIH/OD) [E)

(b)(6)>; Allen-Gi fford, Patr ice (NIH/OD) [E) (b)(6) ; Billet,
Courtney (NIH/NIAID ) [E) (b)(6); Davey, Richard (NIH/NIAID) [E]
(b)(6)>; Palmore, Tara (NIH/CC/OD) [E) (b)( Cohen, Justin
(NIH/CC/OD) [E] (b)(6)
Subject: FORYOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients
w/ COVID-19
Importance: High
Good evening :
At tached for your review are draft materia ls to communicate NI H's preparation for potential receipt of
patients with COVID-19 to the NIH Clinical Center (timing TBD), including:
1. Rollout plan
2. All staff emai l
3. Statement
These materials were reviewed by Rick Davey, Tara Palmor e, and Courtney Billet. I am developing a list
of potenti al Qs and will work with CCand NIAID folks to develop responses, but I wanted to get t hese
products into review in the interest of time.
Best,
Renate
Renate Myles, MBA

DeputyDirectorfor Public Affairs
Office of Communications and Public Liaison
NIH-001458
Tel:
-----
(b)(6)
NIH-001459
Sent: Mon , 24 Feb 2020 12:59:47 +0000
To: Leggio, Lorenzo (NIH/NIDA) [E]
Subject: RE: Question from the Italian Embassy in DC re: coronavirus
Lorenzo
Thanks for the note. Unfortunately , I cannot be of any help to you since I
myself have no access to this equipment. The best person to contact would be
Dr . Robert Kadlec of ASPR at HHS.
Best regards,
Tony
Director
Phone : (b)(6)
FAX: (301 ) 496-4409
E-mail r (b) (6Y
From: Leggio, Lorenzo (NIH/NIDA) [E] (b)(6)

----------
To: Fauci, Anthony (NIH/NIAID) [E] ------~~ (b)( >
Cc: (b)(6)
Subject: Question from t he Italian Embassy in DC re: coronavirus
Dear Dr . Fauci,
I apologize in advance if I write yo u directly to ask this question. I know you are super busy but I thought
you cou ld provide some guidance on someone I could contact about this matter.
(b) (5)
NIH-001460
(b) (5)
I know this seems a very technical quest ion and I appre ciate you have many other things on your plate,
so I hope you don't mind if I decided to reach you out. I do know that Filippo and his team will be very
grateful for any gu idance that they could receive .
Thanks in advance-
Loren zo
Lorenzo Leggio, M.D., Ph.D.

Senior Investigator (Clinical), NIDA IRP and NIAAA DICBR
Chief, Section on Clinical Psychoneuroendocrino logy and Neuropsychopharmacology , NIDA IRP and
NMA DICBR
Associate Director for Clinical Research, M edication Development Program, NIDA IRP
Senior Medical Advisor to the Director, NIAAA
Nationa l Institutes of Health
10 Center Drive {l0CRC/15330) Room 1-5429

251 Bayview Blvd, Room 01A844

Baltimore, MD 21224
Office Phone: (b)(6) (Bethesda); ____ (b)_ C_

6) (Baltimore)
Cell: (b)(6)
E-mail: (b)(6)
---------
Confidentiality Notice: This e-mail message, including any attachments, is for the sole use of the
intended recipient(s) and may contain confidential and privileged information. Any unauthorized
review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact
the sender by reply e-mail and dest roy all copies of the original message.
NIH-001461
Sent: Mon, 24 Feb 2020 12:42:02 +0000
To : STEWARTSIMONSON
Cc: ____ (b_H_ (NIH/CC/BEP) [E]
Subject : RE: Our story today
Thanks, Stewart. We will do it again after Cliff returns from China and fin ishes his
14 day self-quarantine
Director
Phone : (b) (6)
FAX: (301 496-4409
E-mail (b) (6)
From: STEWARTSIMONSON
-----------
------~~
(b) (6) >
To: Fauci, Anthony (NIH/NIAID) [E_______ (b>_ <_ >

Subject: Re: Our story today
Thank you-he is grateful for your help, Tony. He is in a unwindable situation but he is doing what is
right and with integrity . (b)( . As do
I (b)(6). I really appreciate it.
On Feb 24, 2020, at 7:23 AM, Fauci, Anthony (NIH/NIAID) [E]

wrote:
-------- (b)(6)
Stewart:
Here is another article in which I strongly support Tedros.
Tony
NIH-001462
Director
Phone : Cb)(6)
FAX : (301) 496-4409
E-mail : (b)(6)
contain sensitive information . It should not be used by anyone who is not the
original intended recipient. If you have received this e-mail in error please inform the
sender and delete it from your mailbox or any other storage devices . The National
Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any
statements made that are the sender's own and not expressly made on behalf of the
NIAID by one of its representatives .
From: John Lauerman (BLOOMBERG/ NEWSROOM:) <jlauerman@bloombe rg.net >

Sent: Mo nday, February 24, 2020 7:04 AM
To: Fauci, Anthony (NIH/NIAID ) [E)--------=-<'"-=->
CbH6J>
Subje ct: Our story today
Hi Dr . Fauci: here ' s o u r story on Te d ros to d ay , in case

you h ave n 't se en i t.
h ttps:/ / www. b lo omberg . c o m/n ews/fea tu res / 2 0 2 0 - 0 2-

23/ c or o n av iru s - ne ws - who - d ire ct or - g ener a l - r ac e s - a g a in st -
ti me
Th a n ks aga in for a ll y our help wi t h t hi s o ne . Hop e we

get a c h ance t o ta l k aga in soo n .
Re gards , J L
John Lauerman , Bloomberg News

3 Queen Victoria Street , London, UK
tel. +44 (0) 2035 251028 cell
htt p://www . bIoom berg .com ---------
http://www .bloomberg .com/prognosis
(b)(6)
NIH-001463
Sent : Mon , 24 Feb 2020 12:24:0 1 +0000
To: John Lauerman
Subject : RE: Our story today
Thanks, John.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)( 6)
From : John Lauerma n (BLOOMBERG/ NEWSROOM:) <j lauerm an@b loomberg.net>

To: Fauci, Anthony (NIH/NIAID) [El -------=-:-:=
(b)(6)
Subject : Our story today
Hi Dr . Fa u ci : h ere ' s o u r sto r y on Te dr os to d ay , in cas e yo u

h a v en ' t s ee n it .
https : // www. bloombe r g . com/news/features/2020 - 02 - 23/co r onavi r us -

n e ws - who - d ir ector - g e n era l - races - against - time
Th a n ks a g a in fo r a ll y o u r h e lp with thi s on e . Hop e we g e t a

c h ance to ta l k a g a in soon .
Re gards , JL
John Lauerman, Bloomberg News

3 Queen Victoria Street , London, UK
tel. +44 (0) 2035 25 1028 cell ---------=-c-c-='I
______ Cb
_>_<6)
http://www .bloo mberg .com
http://www .bloomberg .com /prog nosis
NIH-001464
Sent: Tue, 25 Feb 2020 11:07:01 +0000
Cc: Erbelding, Emily {NIH/NIAID) [E]
Subject : FW: ACT Additional reading material and developments
Attachments: About ACT.Global and its Premium Purity.pdf, ATTOOOOl.htm,ACT CleanCoat
February 2020.pdf, ATT00002.htm, ACT ECASystem Februar 2020.pdf, ATT00003.htm, Dr.Brill and
Or.Steinmann - ACT CleanCoat Viruzidie englisch EN14476 08.01.2015 Logo Brill.pdf, ATT00004.htm
Cristina:
Please se if we can engage this person (Richard Tubb) and see what he has to offer. He used
to be the White House physician
Than ks,
Tony

To: Biegun, Stephen E (b)( >
Cc: Cassetti, Cristina (NIH/NIAID) [El (b)( ; Erbelding, Emily (NIH/NIAID) (El
--------- (b)(6)>; Conrad, Patricia (NIH/N IAID) [E]

Subject: FW: ACT Additional reading material and developments
(b)(6)
Steve:
Thanks for the note. I do indeed know Dr. Tubb. He sent me similar material and I am going
to connect him with our program people here at NIAIO to see if we can help in any way.
Best regards,
Tony
From: Biegun, Stephen E (b)(6)

------~~
--------- (b)(6)>
Subject : Fwd: ACT Additional reading materia l and developments
Tony,
I expect you know Or. Richard Tubb. He and I worked closely together in the White House 18 years ago. I
have a lot of confidence in his judgment, and therefore am forwarding the materials he sent me for your
considerat ion.
I know nothing about the technologies involved, but I know this is a time to w rite off no good options.
Warm regards,
NIH-001378
Steve
Sent from my iPhone
From: Richard Tubb (b)(6)>

To: "Biegun, Stephen E" (b)( , Robert Kadkec (b)(6),
(b)(6)
Subject: ACTAdditionalreadingmaterial and developments
NIH-001379
Sent : Mon, 24 Feb 2020 20:22:42 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject : FW: chloroquine in COVID-19
Attachment s: chloroquine.pdf
Let us discuss
Directo r
Bui lding 31, Room 7A-03
Phone : (b) (6)
FAX : (301 496-4409
E-mail : (b)(6)
From: Gatti, Philip (b)( >

--------
(b)(6)>
Dear Dr. Fauci,

Is there any indication/data to substantiate this claim from China (attached publication) that
ch loroquine/hydroxychloroquine can decrease COVID-19 infections and lung disease?
Thank you,
Philip Gatti, Ph.D.
Pharmacologist
FDA
CDER
OND
Silver Spring, MD
(b)(6)
NIH-001430
Sent : Mon, 24 Feb 2020 20:21:35 +0000
To: Marston, Hilary (N IH/NIAID) [E]
Attachment s: Chloroquine and SARS.pdf
Let us di scuss.
Director
Phone : (b) (6)
FAX : (301 496-4409
E-mail (b)(6)
The information in this e-mail and any of its attachments is confiden tial and may contain sen sitive
have received this e -mail in error please inform the sender and de lete it from your mailbox or any
From: Gatti, Philip (b)(6)

To: Fauci, Anthony (NIH/NIAID) [E] -------~=
Subject : RE: chloroquine in COVID-19
--------- (b)(6)
Tony ,
Thanks fo r the quick response . There are data from 2005 showing inhibition of SARS infection and
sp read from 2005 . Please see atta ched .
Regards ,
Phil
From: Fauci, Anthony (NIH/N IAID) [E) CbH >

Se nt: Monday, February 24, 2020 3:00 PM
To: Gatti, Philip (b)( >
Cc: Lane, Henry C (NIH) (b)(6)>; Cassetti, Cristina G (NIH) CbH6J
;
Erbelding, Emily J (NIH) (b)(6)>
----------
Subj ect : RE: chloroquine in COVID-19
Phil:
NIH-001431
There are no data in this brief report and so I have no way of evaluating their
claim. There are a lot of these types of claims going around. I would love to see
their data.
Best regards,
Tony
Director
Phone : Cb)(6)
FAX: (301) 496-4409
E-mail Cb
) (6)
information . It should not be used by anyone who is not the orig inal intended recipient. If you
othe r storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not
From:Gatti, Philip (b)(6)

-------:,,:,--==
Subject: FW: chloroquine in COVID-19-------- (b)(6)
Dear Dr . Fauci,
Is there any indication/data to substantiate this claim from China (attached publicat ion) t hat
ch loroquine/hydroxychloroquine can decre ase COVID-19 infections and lung disease?
Thank you ,
Philip Gatt i, Ph.D.
Pharmaco logist
FDA
CDER
ONO
Silver Spring , MD
(b)( 6)
NIH-001432
Sent : Wed, 26 Feb 2020 19:07:38 +0000
To : Tabak, Lawrence (NIH/OD) [E)
Subject : RE: URGENT- Need your input
(b) (5)
Director
Phone : (b)(6)
FAX : (301 496-4409
E-mail Cb)(6)
From : Tabak, Lawrence (NIH/OD) [E] (b)(6)

________ Cb>
------ -== (b)( ; Hallett, Adrienne (NIH/OD) [E]
_C_6); Conrad, Patricia (NIH/NIAID) [El (b)( >
Subject : Re: URGENT-Need your input
Yes- that was the main thing- but any other issues that you can think of in our space?
Thanks
Get Out loo k for iOS
From : Fauci, Anthony (NIH/N IAID) [El (b)(6)

Sent : Wednesday, February 26, 2020 2:04:38 PM
To: Tabak, Lawrence (NIH/OD) (E] CbH6J>; Hallett , Adrienne (NIH/OD) (El
--------- (b)(6) 1>; Conrad, Patricia (NIH/NIAID) [E]

Subject : RE: URGENT-Need your input
(b)(6)>
(b) (5)
NIH-001304
Director
National Insti t ute of Allergy and Infectious Diseases
Phone : (b)(6)
FAX : (301 ) 496-4409
E-mail : Cb)(6)
information . It should not be used by anyone who Is not the original intended recipient . If you
other storage devices . The National Institute of Allergy and Infect ious Diseases (NIAID) shall not
Fro m : Tabak, Lawrence (NIH/OD) [El (b)( >

To: Fauci, Anthony (NIH/NIAID) [El ------~= Cb)(6)>; Hallett, Adrienne (NIH/OD) [El
---------- (b)(6); Conrad, Patricia (NIH/NIAID) [E]

Subject : Fwd: URGENT- Need your input
(b)(6)
I will join call- anything you want brought up?

Larry
From: Pollard, Ashton (05/10S) (b)( >

Sent: Wednesday, February 26, 2020 1:44:56 PM
To: Mango, Paul (HHS/10S) CbH6)>; Lenihan, Keagan (FDA/OC)
Cb)( >; Tabak, Lawrence (NIH/OD) [E] (b)(6) ; McGowan,
Robert (Kyle) (CDC/0D/OCS)
Zeb Iey, Kyle (HHS/0S/OGA)
(b)(6)>; Shuy, Bryan (OS/ASPR/10)
--------
(b)(6)>; Charrow , Robert (HHS/OGC)
(b) (6).
Subject: RE: URGENT- Need your input
Hi All ,
I am about to send this invite. Please confirm your attendance via email or by accepting the calendar
invite.
Thank you,
Ashton
From: Mango , Paul (HHS/IOS) Cb)(6)
Sent: Wednesday, February 26, 2020 I :43 PM
To: Lenihan, Keagan (FDA/OC) --------- ~=
(b)(6) ; Tabak , Lawrence (NIH/OD) [E]
--------- (b)(6) ; McGowan, Robert (Kyle ) (CDC/ OD/OCS) CbH > ; Shuy, Bryan
NIH-001305
(OS/ASPR/10) Cb><; Zebley , Kyle (HHS/OS/OGA) (b)(
Charrow, Rober t (HHS/OGC) (b)( >
Cc: Pollard, Ashton (OS/IOS) (b)(6)
Subject: URGENT- Need your input
Team- Urgen t, how prio rity request: '

--------------------- (b) (5)
Ashton will invite you to a 230pm call to discuss. Plea se organize your responses into bullet points to
di scuss with the group.
Sent from my iPhone
NIH-001306
Sent : Wed, 26 Feb 2020 18:25:04 +0000
Cc: Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Marston, Hilary
(NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E]
Subject : RE:Sec. Azar press briefing remarks
Att achment s: 2 26 20 press briefing remarks - with Fauci edits .docx
Here are my edit s.
Director
Phone : (b) (6)
FAX: (301 496-4409
E-mail : (b)(6)

--------
To : Fauci, Anthony (NIH/NIAID) [E] ------ -:-::~
(b)(6)
Cc: Folkers, Greg (NIH/NIA ID) [El (b)(6)>; Conrad, Patricia (NIH/NIAID) [El
(b)( >; Marston, Hilary (NIH/NIAID) [El (b)(6)>; Routh, Jennifer
-:--.-----:-:---:--:;:::::::==-...:....--_;,~
(NIH/NIAID) [El (b)(6); Stover, Kathy (NIH/NIAID) [E] (b)( >
Subject: ASF:Sec. Azar press briefing remarks
These are SecAzar's remarks for press tonight . (Plan still evolving.)
They are asking for our comments back by 2:45 pm. New content is highlighted to make it easier on
reviewers .
We're sending your talk ing points down there momentarily.
From : Brennan, Patrick (05/ASPA) (b)(6)

----------
-------~~
To: Conrad, Patricia (NIH/NIA ID) [E)~':":"":":"'.:-:-::-:-:===
(b
=)=(6)
::..
>..;
; S"'"'.
B=
onds, Miche lle E. (CDC/00/0ADC)
Galatas, Kate (CDC/0D/OADC)
CbH6J>; CbH >; Billet, Courtney (NIH/NIAID) [E]
=====--!_ Cb)(6):>;Michael, Gretchen (OS/ASPR/OEA) Cb)(6):>;
Janik,
Heather (FDA/OC) CbH6J>;
Caliguiri, Laura (FDA/OC)
NIH-001307
(b)(6J>; Lepore, Loretta (CDC/00/0CS) (b)(
":"."":".-:-:-:;-:-:-:-:-:;:::======-~~
(HHS/OGC) (b)(6J>; Arbes, Sarah (HHS/ASL) (b)( >; Morse, Sara
(HHS/ASL) (b)(6J>; Pence, Laura (HHS/ASL)
,..:..!:====="==~-(b)(6)>; Moughalian, Jen
(HHS/ASFR) (b)(6); Shuy, Cait rin (HHS/ASFR} (b)(6); Trueman,
Laura (HHS/I EA) (b)(6J v >; Mango, Paul (HHS/105) (b)(6)>; Johnston,
Darcie (HHS/IEA) (b)(6)>; Kane, EIieen (OS/ASPR/OEA) (b)((;) ;
Shuy, Caitrin (HHS/ASFR) (b)(6)>; Zebley, Kyle (HHS/OS/OGA) (b)(6)
Grigsby, Garrett (HHS/OS/OGA) (b)(6J
Cc : ASPA-Deput ies (b)(6)>; Foster, Timothy (OS/ASPA) (b)(6)>;
McGowan, Robert (Kyle) (CDC/00/0CS) (b)(6)>
Subject : For review by 2:45 PM: Sec. Azar press briefing remarks
Hi all ,
Attached is a draft of the Secretary's remarks for this evening 's potential press briefing. Some of this is
ro te/ repeated from yesterday or this morning's testimony; I have put the new content in yellow to
accelerate review.
Please let me know if you have edit s to th is by 2:45 PM .
Thank you !
Best,
Patrick
NIH-001308
Sent : Wed, 26 Feb 2020 15:18:25 +0000
Subject : RE: For review by 10:00 AM Weds: Peter Navarro coronavirus op-ed
I do not have time for thi s. Sorry.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6l
From : Billet, Courtney (NIH/NIAID) [E] (b)(6)

To: Fauci, Anthony (NIH/NIAID) [E] -------=-=-~
(b)(6l>; Marston, Hilary (NIH/N IAID) [E]
(b)(6)>
Cc: Folkers, Greg (NIH/NIAID) [E] (b)(6)>; Conrad , Patricia (NIH/NIAID) [E]
(b)(6); Routh, Jennifer (NIH/NIAID) [E] (b)(6lf>;Stover, Kathy
"':'--.-----:-:---:-:::::===~-__:~~
(NIH/NIAID) [E) (b)(6)
Subject : Fwd: For review by 10:00 AM Weds: Peter Navarro coronavirus op-ed
This is an oped for Peter Navarro . We are asked for comments by 10am Weds.
(Complicating things a little, he was apparently just on with Tucker Carlson stating parts of it verbat im .
So, hopefully th is is accura te!)
From : "Brennan, Patr ick (OS/ASPA)" (b)(6)>

Date : Tuesday, February 25, 2020 at 8:27:03 PM
To: "Conrad, Patricia (NIH/N IAID) [E]" --------=c--,=,
(b)(6)>, "Bonds, Michelle E. (CDC/0D/OADC)"
(b)(6)>, "Galatas, Kate (CDC/0D/OADC)" (b)(6)> , "Billet, Courtney (NIH/NIAID)
[E]" (b)(6)>, "Michae l, Gretchen (OS/ASPR/OEA)" (b)(6) , "Janik,
_H_e_
at_h_er_ (:_
F_
D.A..:
/_O_C.:..
)'.'..!:
=~~------- _<_6)>, "Caliguiri, Laura (FDA/OC)"
Cb>
CbH6J>,"Lepore, Loretta (CDC/00/0CS) " CbH6J,"Stimson, Brian
"':'-~::-:-::-::-::.======:...:...-~=
(HHS/OGC)"
--------- (b)(6), "Arbes, Sarah (HHS/ASL)" Cb)( >, " Morse, Sara
NIH-001325
(HHS/ASL)" (b)(6J>, "Pence, Laura {HHS/ASL)" (b)(6)>, "Moughalian,
Jen {HHS/ASFR)" (b)(6)>, "Shuy, Caitrin {HHS/ASFR)" (b)(6)>,
"Trueman, Laura {HHS/IEA)" (b)(6) v >, "Mango, Paul {HHS/10S)"
(b)(6), "Johnston, Darcie {HHS/IEA)" (b)(6), "Kane, EIieen
(OS/ASPR/OEA)"
Kyle {HHS/0S/OGA)".""".":"~=====~
= (b)(6)>, "Shuy, Caitrin (HHS/ASFR)"
(b)(6)>, " Grigsby, Garrett (HHS/0S/OGA)"
(b)(6)>, "Zebley,
(b)(
Cc: "ASPA-Deputies" <ASPA-Deput ies@hhs.gov>, "Foster, Timothy (OS/ASPA)"
---------- (b)(6), "McGowan, Robert (Kyle) (CDC/OD/OCS)"------=-

Subject: For review by 10:00 AM Weds: Peter Navarro coronavirus op-ed
(b"""'
)(=
6)
Hi all ,
Attached is a draft op-ed from the WH's Peter Navarro regarding the administration's coronavirus
response - covering PPE,vaccines, therapeutics, and diagnostics.
There is a lot going on here so we'd like to have edit s/ recomm endati ons/ affirmativ e clea rance from
FDA, CDC, NIAID, ASFR, and ASPR.
Please send edits to me and Tim Foster by 10:00 AM tomorrow {Wednesday}. Thank you!
Best,
Patrick
NIH-001326
Sent: Wed, 26 Feb 2020 02 :19:38 +0000
To: Tabak, Lawrence (N IH/OD) [E)
Subject : RE: LHHSappropriators coronavirus supplemental brief 3:30p Wednesday
Than.ks, Lany !

From: Tabak , Lawrence (NIH/OD) [E] (b) (6)
Sent: Tuesday, February 25 , 2020 9:0 l PM
To: Fauci , Anthony (NIH/NIAID) [E]
-----~~= (b)( >
Subject: FW : LHHS appropriators coronav irus supp lemental brief3:30p Wednesday
Tony,
l will be able to do this . hopefully we can move this back in the correct direction.
La rry
On 2/25/20, 9:00 PM, "Cochran , Norris (HHS/ASFR)"

------------ (b)( wrote:
Correc tion,
Norris
---- (b) (5). Thank you in advance.
> On Feb 25, 2020, at 8:55 PM, Cochran, Non -is (HHS/ASFR)
> --------- (b)(6) > wrote:
(b)(5)
> Dr. Tabak , Neil - would you be available to brie
(b) (5)
We would ha ve CDC on the line as well. ASPR
by phone or in person. We will be in person. Please let me know either way. Thank you in advance.
>
> Norr is
NIH-001343
Sent : Tue, 25 Feb 2020 03:46:47 +0000
To: Davey, Richard (NIH/NIAID) [El;Palmore, Tara (NIH/CC/OD) [E]
Cc:
Subject: ------- (b)( ;Conrad, Patricia (NIH/NIAID) [El
FW: 4 Add itional COVID-19 Asymptomatic Positive Indiv iduals Identified at
Travis AFB
Rick/Tara:
Please give me a call (b)(5Ji. If during business hours, please call
-----=~-::;---:---:-----:-:----:-:-
my office at (b)(6) If in the evening/night call my cell phone at (b)(6). My
home phone is (b)(6).
Thanks,
Tony

---------
(b)(6)>
--------=-c-=
To: Kadlec, Robert (OS/ASPR/10)
(b)( 6)> -------- (b)( >; Stecker, Judy (OS/10S)
Cc: Harrison, Brian (HHS/10S) (b)(6); Fauci, Anthony {NIH/N IAID) [El
(b)(6)>; Palmore, Tara (NIH/CC/OD) [El CbH6l>;Yeskey, Kevin
(OS/ASPR/10) (b)(6); Greene, Jonathan (OS/ASPR/EMMO)
________ _>_C6);Lee, Scott (OS/ASPR/EMMO)
Cb (b)(6)>
Subject : Re: 4 Additional COVI0-19 Asymptomatic Positive Individuals Identified at Travis AFB
thanks
From: "Kad lec, Robert (OS/ASPR/ 10)"

---------
Dat e: Monday, Feb rua ry 24, 2020 at 10 :37 PM
(b)(6)>
To: " Tabak, Lawrence (N IH/OD) [E)" ---------:a =

CbH6J>,"Stecker, Judy (OS/10S) "
(b)(6)> ---------
Cc: "Harrison, Brian (HHS/10S)" (b)(6) Anthony Fauci
CbH6)"Palmore, Tara (N IH/CC/OD) (E]"
----------
Kevin (OS/ASPR/10)" <Kev in.Yeskey@hhs.gov >, "Greene, Jonathan
CbH6)>,"Yeskey,
(OS/ASPR/E M MO)"
---------- Cb)( ·>, "Lee, Scott (OS/ASPR/EMMO)" (b)(6)

Subject: RE: 4 Additional COVID-19 Asymptomatic Positive Individuals Identified at Travis AFB
Larry would be
------------------- (b)(5J. Best Bob
From : Tabak, Lawrence (NIH/OD) [El

---------
Se nt : Monday, February 24, 2020 10:28 PM
(b)( >
------~~
To: Kadlec, Robert (OS/ASPR/IO)_______ Cb
_H_6)>; Stecker, Judy (OS/10S)
(b)(6)>
Cc: Harrison, Brian (HHS/10S) CbH6);Fauci, Anthony (NIH/N IAID) [El
(b)(6) Palmore, Tara (NIH/CC/OD) [El CbH6J;
Yeskey, Kevin
----------
NIH-001380
(OS/ASPR/I0) CbH6)> ; Greene , Jonathan (OS/ASPR/EMMO)
~..;.__..;._...;....!==~ (b:;::
)( 5"'">-; L
:--
e-e-, S
:--cott ( OS/ ASPR/EM MO ) Cb)(6)>
Subject: Re: 4 Additional COVID-19 Asymptomatic Positive Individuals Identified at Travis AFB
-
Any idea on t iming? - please let me know
Thanks
Larry
--------------------- (b)(S )
From: "Kad lec, Robe rt (OS/ASPR/ 10)" (b)(6)
Date : Monday, February 24, 2020 at 10:26 PM

To: "Stecker, Judy (OS/ 10S)" CbH6)>
Cc: "Harrison, Brian (HHS/10S)" CbH6)>, Anthony Fauci
CbH6)>, " Tabak, Lawrence (NI H/OD) [E]" (b)(6) "Pa lmore,
Tara (N IH/CC/OD) [E]" CbH6)> , "Yeskey, Kevin (OS/ASPR/ 10)"
--------~~
---------
"Lee, Scott (OS/ASPR/EMMO)"
CbH6)>, "Greene, Jonathan (OS/ASPR/EMMO)"
CbH6)1
CbH6)>,
Subject: FW: 4 Additional COVID- 19 Asymptomatic Posit ive Individuals Identified at T ravis AFB
(b) (5)
From : Kadlec, Robert (OS/ASPR/I0 )

To : Harrison, Brian (HHS/I0S) (b)(6)>; Stecker, Judy (OS/10S)
(b)(6)> ; Mango, Paul (HHS/10S) (b)( >; Murphy, Ryan {OS/ASPA)
=======~~ ;_
"'.""'"'---:'"'"""".'""".'.""'.-:".'.".:-:=== A_
(b): (:6)::.. r b_e...;
s,~S=arah
(HHS/ASL) (b)(6)>; Fauci, Anthony
(NIH/NIAID) [E) (b)(6)>; Tabak, Lawrence (NIH/OD) (E] (b)(6)>;
Redfield , Robert R. (CDC/OD) (b)(6); McGowan , Robert (Kyle) (CDC/OD/OCS)
(b)(6)>; Trueman, Laura (HHS/I EA) (b)( ; Mougha lian, Jen (HHS/ ASFR)
(b)(6)>; Johnston, Darcie (HHS/IEA)
---------
Cc: Lee, Scott {05/ASPR/EMMO) (b)(6)>; Yeskey, Kevin (OS/ASPR/I0)
(b)(6)>
(b)(6) 1>; Waters, Cicely (OS/ASPR/OEA) (b)(6)>; Shuy, Bryan

-~-~~===t.....:....-~~
(OS/ASPR/I0) (b)(6)>; Greene, Jonathan {OS/ASPR/EMMO )
CbH >; Imbria le, Samuel (OS/ASPR/SIIM) ---------= ~
(b)(6)>; Austin,
Meredith (uscg.m il) (b)(6) 1>; Herrmann, Jack {HHS/ASPR/OPP)
(b)(6) Ferro, Phil J. EOP/NSC
========~-:;;---:--:-------:----:-:':-"
----------
Cavanaugh, Brian J. EOP/NSC
CbH6)>; Ruggiero, Anthony J. EOP/NSC
(b)(6)>
CbH6)>;
Subject : 4 Additional COVID-19 Asymptomatic Positive Individuals Identified at Travis AFB

Importance : High
Th is evening, we were advised by the State of California that 4 passengers from the Diamond Princess
tested positive by the CDCfor COVID-19.
NIH-00138 1
One ind ividua l who tested positive by the CDChad been tested positive in Japan and is already in
hospital in CA.
We are developing the following possible Courses of Act ion as the State of CA cannot absorb these 3
addit ional asymptomatic ind ividua ls:
..__ ________________________ ""~'"'(""'
(b S)
NIH-001382
Sent : Mon, 24 Feb 2020 18:46:26 +0000
To : Moughalian, Jen (HHS/ASFR)
Subject : RE:Close Hold Review - Send comments by 1:40 pm
Jen :
(b) (5)
I had cha nge d th e
Thanks,
---------------
Tony
Director
Bu ilding 31 , Room 7A-03
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b) (6)
informat ion . It shou ld not be used by anyone who is not the original intended recipient . If you
From : Moughalian, Jen (HHS/ASFR)

---------
------~~
(b) (6>r>
(b)( ; McGowan, Robert (Kyle) (CDC/0D/OCS)

(b) (6)>; Shuy, Bryan (os·~ ; A"."".
S
~P-::
R-:'.
/ 1-::
0':":
) ====~- (b
"")'""'
(-="; Kadlec, Robert (OS/ASPR/10)
(b)(6) •> ; Grigsby, Garrett {HHS/0S/OGA) (b)(6); Zebley, Kyle
~---::---:--'"""'":'-==-~
(HHS/0S/OGA) (b)(6) Lenihan, Keagan (FDA/OC) (b)(6)>;
Redfield, Robert R. (CDC/OD) (b)(6)>
Cc: Cochran, Norris (HHS/ASFR) (b)(6)>; Cabezas, Miriam (HHS/ASFR)
(b)( >; Hittle, Taylor (HHS/ASFR) (b)(6)
---------
Subject : RE:Close Hold Review - Send comments by 1:40 pm
Thanks for the quick response!
From : Fauci, Anthony {NIH/N IAID) [El (b) ( >

To : Moughalian, Jen {HHS/ASFR) ---------=-:--:= (b)(6)>; McGowan, Robert (Kyle) (CDC/0D/OCS)
(b)(6)>; Shuy, Bryan (O ~S :-:
/ :--:-
A:-:
SP:-:R:-:
/ :-:
10:-:-
)=====-~ (b"'" ( >; KadIec, Robert (05/ ASPR/10)
) "C-="I
(b)( >; Grigsby, Garrett {HHS/0S/OGA) (b)(6) Zebley, Kyle
":"""."~:-:-:-:-:-":""'."'':'-::===~..:.........:::__;:;.,..,=
(HHS/OS/OGA)______ Cb
_>_C6); Lenihan, Keagan {FDA/OC) CbH6)>;
NIH-001439
Redfield, Robert R. (CDC/OD) (b)(6)
Cc: Cochran, Norris (HHS/ASFR) (b)(6)> ; Cabezas, Miriam (HHS/ASFR)
(b)(6)>; Hittle, Taylor (HHS/ASFR) (b)(6)>
---------
Subject: RE: Close Hold Review - Send comments by 1:40 pm
Jen:
See my sugges ted edits in red.
Thanks,
Tony
Director
Phone Cb)(6)
FAX: (301) 496-4409
E-mail
-------- (b)(6)
From: Moughalian , Jen (HHS/ASFR) (b)(6)

To: McGowan , Robert (Kyle) (CDC/O0/OCS) (b)(6)>; Shuy, Bryan (OS/ASPR/IO)
(b)( >; Kadlec, Robert (OS/ASPR/1O) (b)(6) Grigsby, Garrett
(HHS/OS/OGA)_~~====
Anthony (NIH/NIAID) [E)
(b=)(:6)~>;_Z=ebley, Kyle (HHS/OS/OGA)
-------
(b)(6)>; Lenihan, Keagan (FDA/OC)
(b) ( >; Fauci,
-----------
Cc: Cochran, Norris {HHS/ASFR)
>; Redfield , Robert R. (CDC/OD)
(b)(6)>; Hittle, Taylor (HHS/ASFR)

(b)(6)
(b)(6); Cabezas, Miriam {HHS/ASFR)
---------
Subject: Close Hold Review - Send comments by 1:40 pm
(b)(6)>
Importance: High
Close hold . Please see below draft 0MB language for a possible emergency supplemental request. Due
to the fast moving nature of this process, please send comments by 1:40 PM. Numbers are still under
discussion, and we will share more info in the daily update.
NIH-001440
(b) (5)
Jen Moughalian
Assistant Secretary for Financial Resources (ASFR)
US Department of Health and Human Services
----- (b)(6) (Office)
----- (b)(6) (Cell)
NIH-001441
Sent: Mon, 24 Feb 2020 02:00:10 +0000
To: Myles, Renate {NIH/OD) [El
Subject: RE: FORYOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for
Potential Patients w/ COVID-19
----------------------- (b)(5) Thanks.
From: Myles , Renate (NIH/OD) [E] (b)(6)

Sent: Sunday, Februa ry 23, 2020 8:56 PM
------~~ (b)(6)>; Collins, Francis (NIH/OD) [E]
(b)(6)>; Tabak, Lawrence {NIH/OD) [E] (b)(6)>; Gilman, James
{NIH/CC/OD) [El (b)(6)1
Cc: Burklow, John (NIH/OD) [El (b)(6); Hallett, Adrienne {NIH/OD) [El
(b)(6)>; Allen-Gifford, Patrice {NIH/OD) [El (b)( >; Billet,
Courtney (NIH/NIAID) [E) (b)( ; Davey, Richard {NIH/NIAID) [El
(b)( >; Palmore, Tara (N IH/CC/OD) [El (b)(6)>; Cohen, Justin
":'"
{ N- IH
- /':"':'
C-:-
C/':"':'
0-:-
0 -:-::
) [~E]:-=~ (b)(6) >
Subject: RE: FORYOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potent ial
Latest rollout, all staff and statement are attached.
Best,
Renate
From: Fauci, Anthony {NIH/NIAID) [E] <afauci@niaid.nih .gov >

To: Myles, Renate (NIH/OD) [E] <mylesr@mail.nih.gov >; Collins, Francis (NIH/OD) [E]
<collinsf@od .nih.gov >; Tabak, Lawrence {NIH/OD) [E) <lawrence.tabak@nih .gov>; Gilman, James
(NIH/CC/OD) [El <james .gilman@n ih.gov >
Cc: Burklow, John (NIH/OD) [E) <burklowj@od .nih .gov >; Hallett , Adrienne (NIH/OD) [E)
<adrienne.hallett@nih .gov>; Allen-Gifford, Patr ice (NIH/OD) [El <patr ice .allen -giffor d@nih.gov >; Billet,
Courtney (NIH/NIAID) [E) <billetc@nia id .nih .gov>; Davey, Richard {NIH/NIAID) [E]
<r davey@ niaid.n ih.gov>; Palmore, Tara (N IH/CC/OD) (E] <t pal more @cc.nih.gov >; Cohen, Justin
{NIH/CC/OD) [El <justin .cohen@nih .gov >
Subject: RE: FORYOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potent ial
Renate :
The rollout plan looks fine except that I would include (b)(6)
Thanks,
NIH-001603
Tony
From: Myles, Renate (NIH/OD) [E] (b)(6)>

------~~
To: Collins, Francis (NIH/OD) [E] (b)(6); Tabak, Lawrence (NIH/OD) [E]
CbH6)>; Fauci, Anthony (NIH/NIAID) [El CbH6)>; Gilman, James
----:-~---:-:===!.-..:....
(NIH/CC/OD) [El
_ ___:_~~ CbH6)>
Cc: Burklow, John (NIH/OD) [El (b)(6); Hallett, Adrienne (NIH/OD) [El
(b)(6) 1>; Allen-Gi fford, Patri ce (NIH/OD) [El (b)(6); Billet,
Courtney (NIH/NIAID) [E) (b)(6); Davey, Richard (NIH/NIAID) [El
(b)(6); Palmore, Tara (NIH/ CC/OD) [E] (b)(6J>; Cohen, Justin
{NIH/CC/OD) [E] (b)(6)>
Subject : FORYOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients
w/ COVID-19
Importance: High
Good evening:
Atta ched for your review are draft materia ls to commun icate NI H's preparation for potential receipt of
patients with COVID-19 to the NIH Clinical Center (timing TBD),including:
1. Rollout plan
2. All staff emai l
3. Statement
These materials were reviewed by Rick Davey, Tara Palmor e, and Courtney Billet. I am developing a list
of potential Qs and will work with CCand NIAID folks to develop responses, but I wanted to get these
products into review in the interest of time.
Best,
Renate
Renate Myles, MBA

Deputy Directorfor Public Affairs
Office of Communicationsand Public Liaison
NationalInstitutesof Health
Tel: (b) (6)
NIH-001604
Sent : Sun, 23 Feb 2020 23:14:18 +0000
Subject : FW: Important regarding CoronaVir us
Please handle.
(b) (6) >

From:
----------------
Sent : Sunday, February 23, 2020 6:10 PM
------~~
(b)( 6) -------- (b)(6)>; Fauci, Anthony (NIH/N IAID) [E]
Subject: Important regarding CoronaVirus
Respected Dr. Anthony
It was great to know about you and your institution, for efforts in combating any emerging infectious
disease.
I am writing this email regarding our preliminary observation about the coronav irus genome .
I wish to share with you we have foun d 12 mirro r DNA sequence wit hin the genome of Coronavirus . We
have named it (MRl to MR12) . we are highly interested in MR2 as this mirror DNA sequence is absent
in the human genome. (b)(4)
I wish to add here t here are few studies which state t hat mirror DNA has the potentiality to fo rm H-DNA
and later has a potent iality to induce mutations. We strongly believe a future study on mirror DNA can
answer " Why some virus mutates faster? " "Can we stop them from mutating? (b)(4)
(b) (4)
I will be than kful to you, If you can give me your valuable
t ime to discuss telephonically or through skype our ideas. I can be reached at (b)( .
I look forward to hearing from you.
with regards and Best wishes
Dr Vikash Bhardwaj (PhD JNU India)

Asst Professor Biotechnology
Starex University Gurugram India.
NIH-001605
Sent : Sun, 23 Feb 2020 23:11:59 +0000
Subjec t: RE: COVID-19 clinical care team
l am totally aware of all of this and have been directly involved in sening it up. You have my OK to partic ipa te to
the extent that you desire.
-----Original Mcssage-----
From: Lerner, Andrea (NTH/NJAJD)[E] _______ (b
_ )_ (_6) >
To: Fauci , Anthony (NIH/NIAlD) [E) _____ _, (b
""'
)""'
(= >
Subject: COVID-19 clinical care team
Dear Dr. Fauci ,
l got a call a few minute s ago from Veronique Nussenblatt , Chie f of the Clinica l Center ID Consult Service,
regarding me being a part of the clinical care team of COVID-19 patients if they come to the NIH.
She did not have any definitive infonnation but said there was a chance patients could be coming from California
this week - this is the first J had heard of that, and l'm guessing you may know more about it than 1 do.
The work would include either day or night shifts, likely a couple a week. People on the clinical care team are not
instrncted to separate themselves from others and will be per tested for the virus daily when working clinically.
l wanted to ask for your OK to do this clinical work - of course I will maintain my responsibilities in the office
while doing so. Please let me know and happy to discuss further if you'd like.
Sincere ly,
Andrea
Sent from my iPhone
NIH-001606
Sent: Sun, 23 Feb 2020 21:35:02 +0000
To : Haskins, Melinda (NIH/NIAID) [E];Selgrade, Sara (NIH/NIAID) [E];Crawford,
Chase (NIH/NIAID) [El
Cc: Marston, Hilary (NIH/NIAID) [E];Eisinger, Robert (NIH/NIAID) [E];Lerner, Andrea
(NIH/NIAID) [El;Conrad, Patricia (NIH/NIAID) [El
Subject: Flip Cards
I have gone over the Flip cards. I note that we have only 2 cards fo r
Coronavirus. I want to have a separate flip fo lder for coronavirus with a ful l set
of cards for the specific coronavirus hearings that are coming up. You should sit
down with me and also work with Hilary to prepare this set of cards. They should
contain all the current epi as well as the dollar numbers for the proposed
supplemental budget that we are putting together- I will get asked about that
and I have clearance from the department to talk about it. Also, I want a set of
cards for what we are doing in the area of research, i.e. basic research (eg animal
models, etc.), diagnostics, therapeutics (remdesivir trials in China, Japan, and
Nebraska), and the whole menu of vaccines. In other words, I want an entire set
of cards for coronavirus. That is what I am going to get asked in both the
coronavirus hearings as well as in the NIH Appropriations hearing s.
Director
Phone : (b)(6)
FAX : (301 496-4409
E-mail Cb)(6)
ac cept liability for any statements made that are the sender 's own and not expressly made on
NIH-001607
Sent: Sun, 23 Feb 2020 21:22:40 +0000
To: Jon LaPook
Subject : RE:Coronavirus reality check
How about a pastrami sandwich on rye and a potato knish?
Director
Bethe sda , MD 20892 -2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b)(6)
should not be used by anyone who is not the original intended recipie nt. lf you have received this e-mail in eITor
please inform the sender and delete it from your mai lbox or any other storage devices. The National Institute of
Allergy and Infe ctio us Diseases (NIAI D) shall not accept liability for any statements made that are the send er's own
From : Jon LaPook ,,;:;-----~ (b~)~(6)
=
To: Fauci , Anthon y (NlH/NlAID) [E] ------~~ (b)( ·
Subject: Re: Coronav irus reality check
Thanks , Tony.
1 would love you to cons ider my request to "tag along " with you some day - not to join you for meeti ngs (I would
wait outside unless invited in) or listen in on conference calls but to chat with you in between to give people an
inside look at how serio usly the gove rnm ent is taking the outbreak. And Tcould bring down a shmear from Barn ey
Greengrass for lunch. How could you pass that up???
Jon

Professor of Medicin e
NYU Langone Health
Tw itter @ DrLaPook
On Feb 23, 2020, at 4:05 PM, Fauci, Anthony (NIH/NIAID) [E] .__ _____ Cb
_H__> wrote:
Jon :
The current appearance of community transmissions in Japan , South Korea , Italy and Iran is troublesome . As I
have repeatedly said over the past couple of weeks , if and when (looks more like when now) a numbe r of other
countries besides China have sustained human to human transmissions , then we will be on the briJJk of a pandemic,
NIH-001608
if not already there. The reason to say this is that when several countries have widespread transmissions, then spill-
over to other countries is inevitable since one cannot shut out the rest of the world and so you can expect increasing
world-wide transmissions among progressively more countries. In esse nce , you will be expe1iencing a pandemic.
We are not quite there yet, but we are getting disturb ingly close. It will soon be a matter of se mantic s regarding
who would be willing to call it since it is not a mathematically precbe definition. I am not so sure that WHO will
have the will to declare this a "pandemic" before a number ofrespected epide mi ologists around the world start
rcfciTing publicly to it as a pandemic regardle ss of what WHO docs or does not declare. WHO will likely be behind
the curve here and wi ll wait until it is patently obviou s what we are dealing with.
Best,
Tony
Director
National lnstitute of Allergy and Infectious Diseases
Building 31 , Room 7 A-03
National lostitutes of Health
Phone:
------ (b)(6)
FAX: (301) 496-4409
E-mail: (b)(6)
--------
The information in this e-ma il and any of its attachments is confidential and may contain sensitive i11fom1ation. It
Allergy and Infectious Diseases (N IAID) shall not accept liability for any statements made that are the sender's own
From:Jon LaPook ,.:::;...----. (b
~)~(6)
=
To: Fauci , Anthony (NIH/NIAJD) [E] --------,;;..,....,.
(b)( =
Subject: Coronavims reality check
Hi Tony,
Why do I not think that this is a relaxing S1mday for you?
NIH-001609
This definitely feels like an inflection point in the coronavirus outbreak - both in the unsurprising way it's spreading
and the equally unsurprising misinfom1ation and public alann/panic we are seeing. Unsurprising but here we are.
Can you give me a quick brain dump on where you think we are and how r can best inform the pub lic?
Thanks,
Jon
P.S. please let me know whenever I can report that the outbreak is officially being called a pandemic.
Jonathan LaPook , M.D.
Chief Medical Correspondent , CBS News
NYU Langone Health
Twitter @DrLaPook
NIH-001610
Sent: Sun, 23 Feb 2020 20:01:51 +0000
To: Richard Allen Johnson
Subject: RE: 2020.02.23 Sunday
Dick:
Transmission is definitely by respiratory droplet. Still unclear about aerosol
transmission although there are anecdotal reports that this occurs similar to what
we saw in individual episodes with SARSback in 2002-2003. Almost certainly
contact transmission occurs with hand to mucosa (mouth, eyes, nasal mucosa).
Unclear about fomites, doorknobs, etc. Virus can live for a couple of hours on
certain inanimate objects. Virus definite ly isolated from stool and urine, but not
sure of role in transmission. No information about Transm ission to fetus.
Children have very low rate of infection . No good serologic test at this point
although they are rapidly being developed .
Best,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Richard Allen Johnson

---------
To: Fauci, Anthony (NIH/NIAID) [E]-------..
CbH >
(b...
)=(6>l>;Richard Allen Johnson
(b)( >
Subject: Re: 2020 .02.23 Sunday
Thanks, Tony. Please continue communication with me by email. But rest your voice for a short whlle.
I am having tro uble understanding the exact mode of transmission of COVID-19.
NIH-001611
-Sneeze or cough produces respiratory droplet or aerosolized respiratory secretion which make contract
with upper or lower respiratory mucosa, which results in infection of human cells. Seems most likely.
- What about contact transmission, contaminated hand to conjunctivae, nasal mucosa, or mouth
- Fecal/oral
- transmission to fetus
-What are the diagnostic tests to confirm diagnosis of novel coronavirus? PCRof secretions? Who in the
world has these test kit; who manufactures kit.
-Are follow up serologies begin done?
Interest ing questions to us and to Shelly Wolf if he were with us.
Thanks, Tony. My voice is also a little raspy.
Best,
Dick
On Sun, Feb 23, 2020 at 10:46 AM Fauci, Anthony (NIH/NIAID) [El

-------- (b)(6) wrote:
Dick:
My voice is hoarse since I have been giving so many Congressional and White House
briefings and TV and radio interviews. I just need to shut up for a while .
Best,
Tony
From: Richard Allen Johnson (b)(

-----------
Sent: Sunday, February 23, 2020 5:25 AM
______ Cb)
_C6)
_ >
Subject: 2020 .02.23 Sunday
Hi, Tony
I continue to follow the Cobid-19 epidemic .
What is the problem with your voice. It crackles like mine. I attribute mine to 'postnasal drip.'
WHO and Dr. Tedros are looking much better on TV. He has the WHO logo in the background . His tie
show be tighter . His slouch is better . He still puts his elbows on the table in front of him.
Looking forward to lunch with you.
Best,
Dick
NIH-0016 12
Sent : Sun, 23 Feb 2020 15:56:48 +0000
To : Margolis, Leonid (NIH/NICHD) [E]
Cc: Cassetti , Cristina (NIH/NIAID) [E];Erbelding, Emily (NIH/NIA ID) [E];Conrad,
Patricia (NIH/NIAID) [E]
Subject: RE: Coronavirus tissue test system: a suggestion
Thanks , Leonid. I will pass this on to appropriate associates.

Best regards,
Tony
From: Margolis, Leon id (NIH/N ICHD) [E]

Sent: Sunday, Februa ry 23, 2020 5:50 AM
-------- (b)(6)>
------~~
--------
Subject: Coronavirus tissue test system: a suggestion
(b)(6)
Importance: High
Dear Tony,
As you may know, for many years we study HIV pathogenesis in human tissues ex vivo.
(Among my many papers, there is one, may be not the best, but that I am most proud of. This is
where my co-author is Dr. Fauci ©)
(b)(5)
Regards,
Leonid
Leonid Margolis, Ph .D.

Head,
Section of lnte rcellular Interactions
Eunice Kennedy -Shriver National Institute of Child Health and Human Development
Building 29B, Room 1H16D
29 Lincoln Drive
Bethesda, MD 20892
Phone: (b)(6)
Fax: 301-480-0857
e-mail: (b)(6)
---------
NIH-001613
Sent : Sun, 23 Feb 2020 15:53:48 +0000
To: john won
Subject : RE: KAMA
John:
Thank you very much for your kind note . I hope that all is well with you.
Best regards,
Tony
From : john won (b) (6) >

To: Fauci, Anthony (NIH/NIAID) [E] ------ ..-.-,=
Subject : Re: KAMA
-------- (b)(6)>
Dear Dr. Fauci,
I hope you are doing well . Your participation during our Washington DC 20 17 convent ion was one of the
most memorable events of our organization's history.
United Stat es and t he world now turns to you for your help as Coronavirus crisis is becoming pandemic.
All of us here at KAMA are thinking about you and all those affected . Thank you very much for all your
contributions.
Warm regards,
John Won
On Oct 24, 2017, at 10:42 AM, Fauci, Anthony (NIH/NIAID) [E] (b)(6)
wrote:
--------
John:
Thank you for your kind note. It was a pleasure to be with you.
Best regards,
Tony
From: john won (b)(6)

Sent: Tuesday, October 24, 20 17 10:12 AM
To: Fauci, Anthony (NIH/NIAID) [E) _____ __..,_
(b_..
)(=6)>
Subje ct: KAMA
NIH-0016 14
Dear Dr. Fauci,
Thank you very much for speaking to us at the 43rd Annual KAMAConvention . It was a
tremendous privilege for all of us. You were also so kind to stay afterwards to take pictures
with all those who asked.
To be honest, having you there was very surreal. You symbolize the best of American
medicine. I grew up idolizing your accomplishments as college and medical student. You
saved and touched the lives of so many around the world . It is still hard to believe that I
had this special opportunity to welcome you.
We will continue to do our best to serve the pub lic and mentor medical studen t s. I hope
you can speak to us again in the near future . Thank you very much. I hope you continue in
your position for another 40 years.
Warmest regards,
John H. Won
NIH-001615
Sent: Sun, 23 Feb 2020 15:52:06 +0000
To: Julia Belluz
Subject: RE: Comment?
Julia:
The appearance of community transmissions in Japan, South Korea, Italy and Iran is
troublesome. As I have repeatedly said over the past coup le of weeks, if and when (looks more
like when now) a number of other countries besides China have sustained human to human
transm issions, then we are on the brink of a pandemic, if not already there. The reason to say
th is is that when several countries have widespread transmission, then spill-over to other
countries is inev itable since one cannot shut out the rest of the world and so you can expect
increasing world-wide t ran smissions . Hence, you will be experiencing a pandemic. We are not
quite there yet, but we are getting disturbingly close.
I hope that this is helpful.
Best,
Tony
From:Julia Belluz <julia.belluz@vox.com>

Sent : Sunday, February 23, 2020 4:13 AM
To: Fauci, Anthony {NIH/NIAID) [E] ------ -=~ (b)(6J>
Cc: julia.belluz@voxmedia.com; Conrad, Patricia {NIH/NIAID) [E] Barasch,
Kimber Iy {NIH/NIAID) [CJ (b)(6) --------- (b)(6J>;
Subject : Comment?
Dear Dr. Fauci,
Just over a week ago we talked for th is story about how the outbreak is likely larger than we know now :
https://www .goog le .com/amp/s/www .vox.com/p latform/amp/2020/2/ 14/2113 4473/coronavirus -

outbreak -singapore-us-symptoms-pandemic
Given the developments in Singapore, Iran, Italy, and on the Diamond Princess cruise ship, I'm just
wondering how your opinion about the possibility of conta inment and how fast we are approaching a
pandemic has changed. Do these developments suggest we've entered a new phase in the outbreak?
If you have a few minutes to chat or email today, let me know. We'll be aiming to run a story on this
today.
Thank you for considering.
Julia
NIH-001616
On Feb 15, 2020, at 12:10 AM, Julia Belluz <julia.belluz@vox.com > wrote:
Thank you so much for making the t ime to comment at w hat I know is a crushingly busy
time . As usual don't hesitate to ping if you have any further comments or questions ! Julia
https :ljwww .vox.com/2020/2/14/21134473/coronav irus-outbreak -singapore-us-

symptoms-pandemic
Sent from my iPhone
On Feb 14, 2020, at 1:21 PM, Fauci, Anthon y (NIH/NIAID) [E]
--------- (b)(6) wrote:
Julia:
I just called you now {7:20 AM Washington , DC time) and
got mvoice mail in German that I could not understand. You
can call me at CbH
Thanks,
Tony
Director
Phone : (b)(6)
FAX: (301) 496-4409
E-mail : (b)(6)
and may contain sensitive information . It should not be used by anyone
who is not the original intended recipient. If you have received this e-
mail in error please inform the sender and delete it from your mailbox or
any other storage devices . The National Institute of Allergy and
Infectious Diseases (NIAID) shall not accept liability for any statements
made that are the sender 's own and not expressly made on behalf of the
NIAID by one of its representativ es.
NIH-001617
From: Fauci,Anthony (NIH/NIAID)[E)
Sent: Sun,23 Feb2020 14:26:22+0000
To: Theodore Li
Subject: RE:Covid-19question
Ted:
Thanks for the note. Since she is 22 days out of Singapore she would be well beyond the 14
day quarantine used for people who are coming out of risk zones. And so although her risk is
never zero, it is really very low . If she were coming from Japan or South Korea, which are
experiencing an emerging outbreak, I might feel a litt le different, but Singapore has good
infection control despite the number of cases in that country Given her history of recent
Shingrix vaccination, I would wait another day to see if her fever breaks. I agree that I would
keep her at home for now. I do not think it would come to that, but if you want to get testing
done , it still would have to go to the CDCvia the Virginia department of health . Bottom line is
that I wou ld sit tight fo r now and see how she does over the next day or so. If things change,
do not hesitate to call or e-mail me.
Best,
Tony
From: Theodore Li (b)(6)>

Sent : Sunday,February23, 2020 9:11 AM
To: Fauci,Anthony (NIH/NIAID)[E)------ --=-
(b""""
)(=6)
Subjec t : Covid-19 question
Hi Tony,
The wife of one of my patients received the Shingrix vaccine on Thursday 2/20 and developed
fever to 101.4 the following day with malaise, headache, mild nausea (no respiratory
symptoms). She's taken ibuprofen with transient temperature reduction; the fever and
symptoms are the same today.
BUT ... she and her daughter were in Singapore (b)(6)where they stayed at the
;....~========---=-=-:-=
------ (b)(6), visited (b)(6) and the
Colombo, Sri Lanka before returning via Europe last
(b)(6). They then flew to
(b)(6)to (b)(6). So her
fever began 3 weeks plus 1 day after being in Singapore.
I've to ld her to keep treating the fever and symptoms but to stay at home for now. The fever
after Shingrix usually resolves after 2-3 days so I'd expect it to abate today or tomorrow. My
question is whether there's enough of a concern, viz. the time in Singapore, for her to be tested
for covid-19 . If so, what's the best way to conduct the testing? Or is it okay to see if her fever
breaks by tomorrow?
(You must be getting lots of these questions).
Best,
Ted
NIH-0016 18
Sent: Sun, 23 Feb 2020 04:27:10 +0000
To: Tabak, Lawrence (NIH/OD) [El
-------=-:-=,;Conrad, Patricia (NIH/NIAID)
Cc:
[El
-------
Colli ns, Francis {NIH/OD) [El (b)(6)
Subject: Heads Up
Larry :
I need to speak with you tomorrow (Sunday) about a request that we (NIH) will get from
ASPR(Kadlec) regarding the housing of asymptomatic coronavirus positive individuals. I am
copy ing Francis since the discussion will ultimately get to him.
Best,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
NIH-001619
Sent : Sat, 22 Feb 2020 21:06:45 +0000
Subject : FW: Coronavirus
Please han dle. Tha nks.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail (b) (6l
From: OB Roberts Cb)~ >

To: Fauci, Anthony (NIH/NIAID) [E) ------~~ >
Subject : Coronavirus
-------- Cb)(
To: Dr. Fauci
FM: Oliver B Roberts

(b)(6)
Dr. Fauci; I attended a small water seminar, put on by local (Seventh Day Adventist) medical profes-
sionals, in the mid 1970's at Elms Haven, California .
This seminar taught the participants how to eliminate the flu with the use of water treatments, ie
(steam baths, etc).
I have now for these past 40 some-odd years, been taking two treatment 's; one in the evening and
another in the middle of the night, whenever I have contacted the flu: AND have had the facilities to do
so; and each time I was well the next morning. No temperature, no symptoms whatsoever.
With the high rate that this Coronavirus is spreading, one can see what a great tool these treatments
can be for medical professionals. To have those who are sick with the flu, complete ly free of all
symptoms after two treatments would greatly ease the burden on Dr's and other medical professiona ls
AND each facility.
NIH-001627
Dr. I am asking for a few minutes of your time to explain this. I would like to share this with you and
others. I just want to help by sharing what I learned and have been doing all these years. I feel so guilty,
knowing this and not having a way to get this information to those needing it, when there so many out
there sick and dying.
Note: I have been trying to reach out, hoping someone wi ll hear me. Alas I do not have the education,
pedigree nor the contacts: But you Dr. have all three! I ask not that you believe in me, but that you
believe in these treatments.
Thank You for your time, please feel free to contact me via email or by phone or text or even have
someone up here talk with me.
Sincerely;
OB Roberts
{Ben)
NIH-001628
Sent : Sat, 22 Feb 2020 21:04:58 +0000
Subject : FW: Congratulations and time to speak: Researchers Are Racing to Make a
Coronavirus Vaccine. Will It Help? - The New York Times
Please set up a call w ith Hannah
Director
31 Cente r Drive, MSC 2520
Phone : (b)(6)
FAX : (301 ) 496-4409
E-mail : (b)(6l
have rece ived this e -mail in error please inform the sender and delete it from your mailbox or any
From: Valant ine, Hannah (NIH/OD) [El

-----------
--------, .....,....,=
(b)(6)

--------- (b)(6)
Subject : Congratulations and time to speak: Researchers Are Racing to Make a Coronavirus Vaccine. Will
It Help?- The New York Times
Import ance: High
Hi Tony,
I have been following this terrific work by NIAID scientists in the VRC- congratulations!
htt ps://www .nyt imes.com/2 020/ 01/28/he alth/c oronavirus-vaccin e.htm l
As you can imagine I am delighted see Dr. Kizzmekia Corbett playing a leading role in these activities .
Most importantly she is de lighted with the mentorship, sponsorship and opportunity she has received at
NIH, particularly from Barney Graham. (b)(6), (b)(S)
Please let me know when you might be availab le to speak with me .

Best,
Hannah
NIH-001629
Sent: Sat, 22 Feb 2020 20:53:35 +0000
To: NIAIDODAM
Subject: FW: CUGH Annual Meeting
Let bus discuss.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Thomas Quinn (b)(6)

To: Fauci, Anthony (NIH/NIAID) [El -------=-=--==
(b)((;)>
Cc: Folkers, Greg (NIH/NIAID) [E] (b)(6); Conrad , Patricia (NIH/NIAID) [E]
(b)(6J>; Barasch, Kimberly (NIH/NIAID) [CJ (b)(6)>; Judith
-----:-~::======--
Wasserhei t ~= Cb)<>
Subject: CUGHAnnual Meeting
Hi Tony,
I know how busy you are but I wanted to give you a brief update on the Annual
Conference of the Consortium of Universities fo r Global Health (CUGH) based in
Washington, DC. Here is the link to the overall CUGH meeting which provides an
overview of the whole conference https ://www .cugh2020 .org/program . As we
discussed months ago you agreed to be in the opening day plenary session on
April 18th , entitled "Emerging Infectious Diseases and their Impact on Global
Health Security". The details and other speakersare listed below. I may try to
organize a call of all speakers in a month to coordinate talks/topics as the session
is 90 minutes with 5 speakers, and a lot of ground to cover, especially with the
COVID19 outbreak.
NIH-001630
Judy Wasserheit, copied here, would also like to invite you to a special session she
is organizing on the coronavirus epidemic at the same CUGH conference in a late-
breaker session on Sunday, April 19 (the second day of the conference) from
8:4Sam-10:1Sam at the Washington Hilton Hotel (Monroe Room). This talk would
be slightly different from the plenary session and you could expand on COVID19
research prior ities and update on progress. We realize your schedule is very
busy but your insights and knowledge on both of these topic s is unparalleled. If
you cannot speak at the second session we would appreciate your
recommendation as to an alternative who could address this latter topic.
Thanks and all the best,

Tom
Plenary Session Details:
Session Day: Saturday, April 18, 2020

Session Time : 11:30am-1:00pm
Location: Washington Hilton Hotel, International Ballroom
Panel Title: "Emerging Infectious Diseases and their Impact on Global Health
Security"
Short Panel Description: This Plenary Panel will highlight the continual threats of
emerging and re-emerging infectiou s diseases, and their impact on global security
for surveillance, detection, treatment and prevention of these diseases. Over
recent decades, multiple epidemic events have underscored how highly
vulnerable we are to viral threat s. Our world is globally connected-and an
"emerging threat" in one part of the world can pose a threat everywhere and to
everyone. About 75 percent of new human diseases are caused by microbes that
originate in animals. These include HIV, influenza (including pandemic HlNl,
HSNl , and H7N9), Severe Acute Respiratory Syndrome (SARS),Middle East
Respiratory Syndrome-Coronavirus (MERS-CoV),Ebola, Marburg, and Nipah. The
recent emergence of COVID from China clearly illustrates the magnitude , rapidity
NIH-001631
and impact that a new infectious agent can have on global health security. This
panel of leading experts will discuss the emergence of these microbial threats,
and our ability to detect, respond and prevent future epidemics of these
pathogens .
Moderator(s) Info: Tom Quinn, Chief, NIAID, International HIV/STD Section and
Man Charurat, Director, Division of Epidemiology and Prevention, Institute of
Human Virology (IHV)
Speaker(s) Info:
1. Anthony Fauci, Director, NIAID

2. Chikwe lhekweazu, Director General, Nigeria CDC
3. Peter Hotez, Dean, National School of Tropical Medicine, Baylor College of
Medicine
4. Jonna Mazet, Executive Director, One Health Institute, and Pl, PREDICTproject,
UC Davis
5. Jennifer Nuzzo, Senior Scholar, Center for Health Security, Johns Hopkins
University
NIH-001632
Sent: Sat, 22 Feb 2020 20:51:00 +0000
To : Stover, Kathy (NIH/N IAID) [El
Cc: Billet, Courtney (NIH/NIAID) [El;Conrad, Patricia (NIH/NIAID) [El;Folkers, Greg
(NIH/NIAID) [El
Subject: RE: FORASF REVIEW:Draft PR re: launch of remdesivir COVID-19 trial
Attachments : NIAID press release COVID-19 treatment trial FOG- with fauci tracked
edits.docx
See my minor tracked edits. Thanks.
Director
Phone : (b)(6)
FAX : (301 496-4409
E-mail (b) (6)
From: Stover, Kathy (NIH/NIAID) [El (b)(6)

------~= (b)(6)>
Cc: Billet, Courtney (NIH/NIAID) [E] (b)(6); Conrad, Patricia (NIH/NIA ID) [El
_______ (b)_C_ >; Folkers, Greg (NIH/NIAID) [El (b)(6)>
Subject: FORASF REVIEW:Draft PR re: launch of remdesivir COVID-19 trial
Hi Dr. Fauci,
Please find attached for your review a draft press release to announce the launch of the
remdesivir COVID-19 treatment trial, which enrolled its first patient today. It's been reviewed
by the following individuals/groups:
• FOG
• OCGR(Kathy Stover, Courtney Billet)
• DMID: Emily Erbelding, John Beige!
• OCR: Cliff Lane, Libby Higgs
• U Nebraska {Ch ristop her Kratochvil, Andre Kalil, comms dept)
• Awaiting comments from Gilead and WHO.
NIH-001633
For ease of reference, the following is the quote we have drafted for your use:
(b) (5)
Thanks much,
Kathy
Kathy Stover
Branch Chief
Bethesda, MD 20892
(b)(6)
Media line: (301) 402- 1663
NIH-001634
Sent: Sat, 22 Feb 2020 20:38:12 +0000
Cc: Routh, Jennifer {NIH/NIAID) [El
Subject : RE: interview request: draft responses for Greek newspaper
Good j ob! See my minor edits in red. Thanks.
Directo r
Phone : (b) (6)
FAX : (301 496-4409
E-mail : (b)(6)
From: Conrad, Patricia (NIH/NIAID) [E] (b)(

Sent: Friday, February 21, 2020 4:57 PM ----------
To: Fauci, Anthony (NIH/NIAID) [El-------~~
---------
(b)(6)
Subject: FW: interview request: draft responses for Greek newspaper
Do you want to edit these ..greek paper/pring?
Patric ia L. Conrad
Nation al Institute of Allergy and Infectious Diseases
(b)(6)
301-496-4409 fax
Disclaimer:
Th e information in this e- mail and any of its attachments is confidential and may contain sens itive information. It should not be used
by anyone w ho is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it
NIH-001635
from your mailbox or any other storage devices . National Institute of Aller gy and Infectious Diseases (NIAID) shall not accept
From: Routh, Jenn ifer (NIH/NIAID) [E) CbH6J>

To: Conrad, Patricia (NIH/NIA ID) [E) ------~~ (b)(6)>; NIAID FOG <fog@niaid.nih.gov >
Cc: NIAID COGCORE<COGCORE@mail.nih.gov>; NIAID Media Inquir ies <mediainqu iries@niai d.nih .gov>
Subject : int erview request : d raft responses for Greek newspaper
Reporter: Theodora Tsoli

Organization : Greek newspaper To VIMA (www.tovima .gr)
Phone #(s): CbH6),thtsoli@tovima .gr
Subject: COVID-19
Deadline: Monday 2/24
The reporter emailed questions for ASF. I have drafted proposed responses for his
review , also attached.
1. Do you believe that SARS-COV2 is capable of causing a pandemic? Are

you expecting many secondary transmissions of the virus outside China?
A pandemic is generally defined as sustained transmission of a new pathogen in
multiple regions of the world. COVID-19 does not yet meet that definition , and I
hope that China and other countries in Asia with some transmission are able to
contain the outbreak. However , it is possible that COVID-19 could become a
pandemic. It would not be surprising to see additional secondary transmissions of
the virus outside of China.
2. Chinese authorities are reporting a decline of new cases. Could we say that
the virus has peaked and maybe it will slow down? When are you expecting
to have a clearer picture about the evolution of this epidemic?
Although the number of daily cases in China appears to have gone down , it is
too early to tell if this is really a decline in the outbreak.
3. Could the virus become endemic and give seasonal outbreaks?

If China is not able to contain the outbreak, it is possible COV ID-19 could
become endemic and lead to seasonal outbreaks. However, it is too early to
know the likelihood of this scenario.
4. What about its transmissibility? Some experts say that WHO is

underestimating it's transmissibility. Could the reality be different maybe
because, among other things, many cases stay undetected?
Because of the many unknowns about SARS-CoV-2 , it is difficult to make any
firm conclusions regarding overall transmissibili ty and severity. However , it
appears to be much more transmissible than SARS. Also , there are likely
asymptomatic COVID-19 infections that are not getting counted because people
do not go to the doctor for testing or treatment if they are not sick.
NIH-001636
s. Do you believe that the measures taken by China and countries around the
world are adequate to stop SARS-COV2 spread? There is a lot of
discussion about thermal cameras and travel restrictions for example.
China has taken extreme measures to control the outbreak. Restricting the
movement of 50 million people is unprecedented. However, it might ultimately
have an effect on slowing transmission. Precautions implemented in the U.S. are
not intended to detect every person with COVID-19 entering the country.
Howev er, our approach has allowed us time to better plan and prepare our health
system .
6. What is the key to stop the worldwide spread of the virus?

Though we have mobilized a rapid research response to quickly develop
effective countermea sures, right now, the outbreak response remains focused on
the proven public health practices of identifying cases , isolating patients and
tracing contacts.
7. In the northern hemisphere we have a flu outbreak - in Greece as well.

Some experts say that this is the real danger and not the coronavirus. What
is your view?
I am always concerned about influenza . Every flu season , millions of people are
at risk of getting very sick or dying. Currently people in the U.S. and most
countries in the northern hemisphere are at a much higher risk of being exposed
to influenza than SARS-CoV-2. However , the COVID-19 outbreak is an evolving
situation and we are treating it as a very serious public health threat.
8. Many efforts are being in process for the development of a vaccine for the
new coronavirus . Are you coordinating any of them and which ones? Are
there any efforts more promising than others? Which platforms of vaccine
development are more promising? When do you believe that we could have
a vaccine available for clinical trials and then for human use?
NIAID is exp loring multiple candidates and is on track to test an experimental
messenger RNA (mRNA) vaccine in a Phase 1 clinical trial this spring. This first
phase of clinical testing will involve giving the vaccine to healthy adults in the
United States to see if it is safe and if it can induce an immune response in
recipients. It is important to realize that the development of investigational
vaccines and the clinical testing to establish their safety and effectiveness takes
time. A vaccine against the novel coronavirus will likely not be widely available
for more than a year.
9. What about therapies? Dozens are being tried - from plasma to herbal
medicines in China. Which are the most promising?
NIAID is pursuing the development of antivirals and monoclonal antibodies for
potential use against COVID-19. NIAID is preparing protocols for in vitro and in
vivo studies of the antivi ral remdesivir, which has shown promise agains t other
coronaviruses in animal models . NIAID also plans to evaluate Kaletra
(lopinavir/ritonavir) and interferon-beta for their activity against SARS-CoV-2 . In
addition, NIAID scientists are working to identify monoclonal antibodies with
NIH-001637
therapeutic potential from stored SARS patient samples as well as COVID-19
patient samples .
10. Are the things we know about this new virus more than the ones we don't
know? Which are the main questions about it that remain to be answered?
New data are published about SARS-CoV-2 every day. However, we still have a
lot to learn. For example, we do not know why there are so few cases among
children, which is uncommon for a respiratory virus.
11. How worried should people outside China be about SARS-COV2? What is
the biggest danger from this virus?
. The risk to the general American public remains low at this time ; however , this
could change and that is why we are treating the emergence of a novel
coronavirus as a very serious public health threat. We understand that
people may be worried . We ask that people not let fear or panic guide their
actions.
12. Which are the protective measures anyone should take against the new
virus? Do masks work?
The vast majori ty of people outside of China do not need to wear a mask. A
mask is more appropriate for someone who is infected than for people trying to
protect against infection .
Jennifer Routh [E]

Office of Communicatio ns and Government Relations
National Institute of Allergy a nd Infectious Diseases (NIAID)
NIH/HHS
Bethesda , MD 20892
Direct: Cb)C
Disclaimer : The informatio n in this e-mail and any of its attachments is confidential an d may contain sensitive informati on. It should not be
used by anyone who is not the original intended recipient. If you have rece ived this e-mail in error please inform the se nder and d elete it
from you r mailbox or any other storage dev ices. The National Institu te of Allerg y and Infectious Diseases shall not accept liab ility for any
sta tements made that are sender's own and not express ly made on behalf of the NIAID by one of its rep resentat ives.
NIH-001638
Sent : Sat, 22 Feb 2020 19:41:48 +0000
To : Cassetti, Cristina (NIH/NIAID) [El
Subj ect : RE: HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus
Vaccine
Tha nks.
Director
Phone : (b) (6)
FAX : (301 496-4409
E-mail (b)(6)
---------
From : Cassett i, Cristina (NIH/NIAID) [El
(b)(6)>
To : Fauci, Anthony (NIH/NIAID) [El ------~~ (b)(6)>

Cc: Erbelding, Emily (NIH/NIAID) [El ~=======
----------
~= CbH >
Subject : Fwd: HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine
This is the press release from ASPR, in case you need more information on the Sanofi CoV efforts
Cristina
---------
From: "Folke rs, Greg (NIH/NIAID) [E]"
0 at e: February 18, 2020 at 3:07 :21 PM EST
(b)(6)
Subject : HHS Engages Sanofi' s Recombinant Techn ology for 201 9 Nov el Coronav iru s
Vaccine
FORIMMEDIATERELEASE
February 18, 2020
Conta ct: ASPR Press Offic e
202 -205 -8117
aspr m ed ia@hh s.gov
NIH-001639
HHS EngagesSanofi's Recombinant
Technologyfor 2019 Novel Coronavirus
Vaccine
Racing to develop a vaccine against the 2019 novel coronavirus, the U.S. Department of
Health and Human Services' Office of the Assistant Secretary for Preparedness and
Response has engaged Sanofi Pasteur, the vaccines global business unit of Sanofi.
The Biomedical Advanced Research and Development Author ity (BARDA), a component of
ASPR,will provide expertise and reallocated funds to support the vaccine's development .
Sanofi will use its egg-free, recombinant DNA platform to produce a recombinant 2019
novel coronavirus vaccine candidate.
The technology produces an exact genetic match to proteins of the virus . The protein's
DNA will be combined with DNA from a virus harmless to humans, and used to rapidly
produce large quantities of antigen which stimulate the immune system to protect against
the virus . The antigens will be separated and collected from these cells and purified to
create working stocks of vaccine for advanced development.
"Flexibility and scalability are cornerstones of rapid response to an emerging infectious
disease," said BARDADirector Rick A. Bright, Ph.D. "Using this proven technology, we can
pivot immediately to address this new global health threat. Our goal is a licensed vaccine
to provide long-term health security against this latest virus and prevent future
coronavirus outbreaks ."
BARDA has worked with Sanofi since 2004 and in 2009 began collaborating with Protein
Sciences of Meridian , Connecticut, now owned by Sanofi, to develop a recombinant
technology with the flexib ility to make millions of doses of vaccine quickly in an influenza
pandemic. In 2016, BARDA added this vaccine to the U.S. National Pre-pandemic Influenza
Vaccine Stockpile. When Sanofi purchased the company and its technology in 2017, BARDA
continued working with Sanofi on pandemic vaccine development , and in December 2019
the partners began focusing on increasing manufactu ring capacity for recombinant
influenza vaccine in the United States, in accordance with a president ial execut ive order to
enhance national security and the public health by modernizing influenza vaccines and
technologies .
This expanded collaboration with Sanofi is BARDA'ssecond program to focus on
developing a novel coronavirus vaccine candidate in the past few weeks. There is currently
no approved vaccine, treatment, or diagnostic for novel coronavirus infections; however,
the U.S. Food and Drug Administration has issued an emergency use authorization (EUA) to
enable emergency use of a diagnostic test developed by the Centers for Disease Control
and Prevention.
BARDAalso is working with counterparts across the government, including within HHSand
with the Department of Defense. The team is reviewing potential vaccines, treatments and
diagnostics from across the public and private sectors, particularly products in
development for Middle East Respiratory Syndrome (MERS) or Severe Acute Respiratory
Syndrome (SARS),to identify promising candidates for development and licensure to
detect, protect against or treat novel coronavirus infections.
To obtain information about any potential products in development in the private sector
that could be used in responding to the novel coronavirus outbreak, the U.S. government
NIH-001640
launched a single point-of -entry website for innovators and product developers to submit
brief descriptions of their diagnostics, therapeutics, vaccines, and other products or
technologies relevant to this new virus.
Federal agencies are particularly interested in identifying products and technologies that
have progressed into or beyond non-clinical studies, have established large-scale
commercial Good Manufacturing Practices (cGMP) manufacturing capability, and/or have
utilized a platform already approved by the U.S. Food and Drug Administration (FDA).
BARDAalso opened an easy broad agency announcement, an EZ-BAA, specific to
diagnostics that utilize platforms already cleared by the FDA, w ith a viable plan to meet
requirements for the FDAto consider Emergency Use Authorization (EUA) within 12 weeks
of an award.
About HHS, ASPR, and BARDA
HHS works to enhance and protect the health and well-being of all Americans , providing
for effective health and human services and fostering advances in medicine. public health,
and social services. The mission of ASPRis to save lives and protect Americans from 21st
century health security threats . Within ASPR,BARDA invests in innovation , advanced
research and development , acquisition, and manufacturing of medical countermeasures -
vaccines, drugs, therapeutics, diagnostic tools , and non-pharmaceutical products needed
to combat health security threats . To date, 54 BARDA-supported products have achieved
regulat ory approval, licensure or clearance. BARDA DRIVe brings together the best ideas
from the medical and scient ific communities, together with government and venture
capital investment, to drive innovation that will strengthen our nation's health security . To
learn more about preparing for and responding to publ ic health emergencies, from new
infectious diseases to natural disasters and bioterrorism, by visiting the HHS public health
emergency website, www .phe.gov. For more information on partnering with BARDAon
developing medical countermeasures , visit www .medicalcount ermeasu res.gov, and for
more on DRIVe, visit dr ive.hhs.gov .
###
Note: All HHS press releases, fact sheets and other news materials are available at
https://www .hhs.gov/news .
Like HHS on Facebook @, follow HHSon Twitter @HHSgov@, and sign up for HHS Email
Updates .
Last revised: February 18, 2020
Disclaimer: Any thfrd-part y material in this ema il has been shared for internal use under fair
use provisions of U.S. copyright law, without further verification of its accuracy/veracity . It
does not necessarily represent my views nor those ofNIAID , NIH, HHS , or the U.S.
govern ment.
NIH-001641
Sent : Sat, 22 Feb 2020 19:41:42 +0000
To: David Willman
Subject : FW: HHS EngagesSanofi's Recombinant Technology for 2019 Novel Coronavirus
Vaccine
Davi d :
See press release below regardin g BARDA and Sanof i.
Best,
Tony
Antho ny S. Fauci , MD
Director
Phone Cb)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From : Cassetti , Cristina (NIH/N IAID) (E] (b)(6)

----------
To: Fauci, Anthony (NIH/NIAID) [E]______ (b
'"'~..-.
(6)
= >
Cc: Erbelding, Emily (NIH/NIA ID) [E)

---------- (b)(6)
Subject : Fwd: HHS EngagesSanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine
This is the press release from ASPR,in case you need more information on the Sanofi CoV efforts
Cristina
From: " Folkers, Greg (NIH/NIAID) [E]" (b)(6)>

Subject : HHS Engages Sanofi's Recombinant Technology for 2019 Nov el Coronav iru s
Vaccine
NIH-001642
FOR IMMEDIATE RELEASE
February 18, 2020
Cont act: ASPR Press Off ice
202-205 -8 117
asprm edi a@hh s.gov
HHS EngagesSanofi's Recombinant

Technologyfor 2019 Novel Coronavirus
Vaccine
Racing to develop a vaccine against the 2019 novel coronavirus, the U.S. Department of
Health and Human Services' Office of the Assistant Secretary for Preparedness and
Response has engaged Sanofi Pasteur, the vaccines global business unit of Sanofi.
The Biomedical Advanced Research and Development Author ity (BARDA), a component of
ASPR, will provide expertise and reallocated funds to support the vaccine's development .
Sanofi will use its egg-free, recombinant DNA platform to produce a recombinant 2019
novel coronavirus vaccine candidate.
The technology produces an exact genetic match to proteins of the virus . The protein 's
DNA will be combined with DNA from a virus harmless to humans, and used to rapidly
produce large quantities of antigen which stimulate the immune system to protect against
the virus. The antigens will be separated and collected from these cells and purified to
create working stocks of vaccine for advanced development.
"Flexibility and scalability are cornerstones of rapid response to an emerging infectious
disease," said BARDADirector Rick A. Bright, Ph.D. "Using this proven technology, we can
pivot immediate ly to address this new global health threat. Our goal is a licensed vaccine
to provide long-term health security against this latest virus and prevent future
coronavirus outbreaks. "
BARDA has worked with Sanofi since 2004 and in 2009 began collaborating with Protein
Sciences of Meridian , Connecticut, now owned by Sanofi, to develop a recombinant
technology with the flexibility to make millions of doses of vaccine quickly in an influenza
pandemic . In 2016, BARDAadded this vaccine to the U.S. National Pre-pandemic Influenza
Vaccine Stockpile . When Sanofi purchased the company and its technology in 2017, BARDA
continued working with Sanofi on pandemic vaccine development, and in December 2019
the partners began focusing on increasing manufa ct uring capacity for recombinant
influenza vaccine in the United States, in accordance with a president ial execut ive order to
enhance national security and the public health by modernizing influenza vaccines and
technologies .
This expanded collaboration with Sanofi is BARDA'ssecond program to focus on
developing a novel coronavirus vaccine candidate in the past few weeks. There is currently
no approved vaccine, treatment , or diagnostic for novel coronavirus infect ions; however,
the U.S. Food and Drug Administration has issued an emergency use authorization (EUA) to
enable emergency use of a diagnostic test developed by the Centers for Disease Control
and Prevention.
BARDAalso is working with counterparts across the government, including within HHS and
with the Department of Defense. The team is reviewing potential vaccines, treatments and
diagnostics from across the public and private sectors, particularly products in
NIH-001643
development for Middle East Respiratory Syndrome (MERS)or Severe Acute Respiratory
Syndrome (SARS),to identify promising candidates for development and licensure to
detect , protect against or treat novel coronavirus infections .
To obtain information about any potential products in development in the private sector
that could be used in responding to the novel coronavirus outbreak, the U.S. government
launched a single point-of-entry website for innovators and product developers to submit
brief descriptions of their diagnostics, therapeutics, vaccines, and other products or
technologies relevant to this new virus.
Federal agencies are particularly interested in identifying products and technologies that
have progressed into or beyond non-clinical studies, have established large-scale
commercial Good Manufacturing Practices (cGMP) manufacturing capability, and/or have
utilized a platform already approved by the U.S. Food and Drug Administration (FDA).
BARDAalso opened an easy broad agency announcement, an EZ-BAA, specific to
diagnostics that utilize platforms already cleared by the FDA, w ith a viable plan to meet
requirements for the FDAto consider Emergency Use Authorization (EUA) within 12 weeks
of an award.
About HHS, ASPR, and BARDA
HHS works to enhance and protect the health and well-being of all Americans , providing
for effective health and human services and fostering advances in medicine, public health,
and social services. The mission of ASPRis to save lives and protect Americans from 21st
century health security threats. Within ASPR,BARDA invests in innovation, advanced
research and development , acquisition , and manufacturing of medical countermeasures -
vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products needed
to combat health security threats. To date, 54 BARDA-supported products have achieved
regulatory approval, licensure or clearance. BARDA DRIVe brings together the best ideas
from the medical and scientific communities, together with government and venture
capital investment, to drive innovation that will strengthen our nat ion's health security . To
learn more about preparing for and responding to publ ic health emergencies, from new
infectious diseases to natural disasters and bioterrorism, by visiting the HHS public health
emergency website, www .phe.gov . For more information on partnering with BARDAon
developing medical countermeasures, visit www .medicalcountermeasures .gov, and for
more on DRIVe, visit drive .hhs.gov .
###
Note : All HHS press releases, fact sheets and other news materials are available at
https://www.hhs .gov/news .
Like HHSon Facebook @, fo llow HHSon Twitter @HHSgov@, and sign up for HHS Email
Updates .
Last revised: February 18, 2020
Disclaimer: Any third-party material in this email has been shared for internal use under fair
use provisions of U.S. copyright law, without further verification of its accuracy /veracity . 1t
does not necessarily represent my views nor those of N.lAJD, NIH, HHS, or the U.S.
government .
NIH-001644
Sent : Sat, 22 Feb 2020 19:39:17 +0000
To : Kevin Thurm
Subject : RE:Thanks
Kevin :
M any t hanks for yo ur kind note. Mu ch appreciated. I hope that all is we ll w ith
yo u.
Best rega rds,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Kevin Thurm Cb)(6) >

Se nt : Saturday, February 22, 2020 12:45 PM
-------=-c-s-=
(b) ( > -------- CbH >; Fauci, Anthony (NIH/NIAID) [El
Subject : Thanks
Tony
Good afternoon.
Just wanted to write and say how much I deeply appreciate your on-going public service; you've made
extraordinary contributions over the course of your career and, as I've watched you on TV in the context
of the current public health threat of the coronavirus , I know you're continuing to do so...
No need to respond; you have a lot going on.
From one citizen and a former colleague, extending my thanks and deep appreciation.
Best wishes.
NIH-001645
Kevin Thurm
NIH-001646
Sent: Sat, 22 Feb 2020 19:36:40 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Subject: RE: For review: ASM presentation for 26Feb2020
Attachments: ASM Public and Scientific Affairs Committee Meeti ng 2nd FINAL for
26Feb2020 .pptx
I mistaken ly put it into my Documents. Here it is, and I will put it into the OD
now
Director
Phone : (b)(6)
FAX : (301 496-4409
E-mail : (b)(6)
From: Folkers, Greg (NIH/NIA ID) [E) (b)(6)>

To: Fauci, Anthony (NIH/NIAID) [E] ------~~ (b)(6)
Subject: RE:For review : ASM presentation for 26Feb2020
I don't see it in OD
From: Fauci, Anthony (NIH/N IAID) [E]

-------- (b)(6)>
To: Schneider, Johanna (NIH/NIAID) [E] -------~= (b)(6)>

Cc: Folkers, Greg (NIH/NIAID) [E] ,.;...;;.....:.....====::a: ~ ;;-
(b~) ;; >-; -=
c -on_r_a~
d , Patricia (NIH/NIAID) [E]
(b) (6) >
Subject: RE: For review : ASM presentation for 26Feb2020
This is now "2 nd FINAL" in the OD folder. You just need to remove the instruction
slides and do the required updates on several of the slides and then it is ready to
go . Thanks.
NIH-001647
Director
Phone : (b)(6)
FAX : (301 496-4409
E-mail : (b) (6)
other storage devices . The National Institute of Allergy and Infectious Diseases (NIA ID) sha ll not
From : Schneider, Johanna (NIH/NIAID) [El

Se nt : Friday, February 21, 2020 4:05 PM
To: Fauci, Anthony (NIH/NIAID) [El ------~~
---------- (b)(6)

..:.::=======:~~
>; Conrad, Patricia (NIH/NIAID) [El
(b)(6)
---------
Subject : For review: ASM presentation for 26Feb2020
Dr. Fauci,
Attached is the presentation to the American Society for Microb iology (ASM) Public and Scientific Affairs
Committee on Wednesday Feb 26th.
The top ics they have expressed interest in are:

• NIAID Budget Request FY2021
• Novel Coronavirus
• Progress on a Universal Flu Vaccine
The talk is 30 minutes plus 15-20 for discussion.
I've scheduled 30 minutes Monday morning at 10AM to review the slides with you as well.
The presentation has been uploaded to the shared dr ive. As indicated we wil l update the necessary
slides on Monday afternoon before sending them to ASM on Tuesday.
Thanks,
Johanna
NIH-001648
Sent: Sat, 22 Feb 2020 19:33:57 +0000
Subject: RE: Question
Thanks.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
---------
From: Cassetti, Cristina (NIH/NIAID) [El
To: Fauci, Anthony {NIH/NIAID) [El -------=-,-:-= (b)(6)
(b)(6)>
~=======~Cb_>_C6>l
Cc: Erbelding , Emily (NIH/NIAID) [E)_______ _. >
Subject : Re: Questio n
Hi Dr. Fauci,
This effort is completely driven by BARDA. DMID is not involved.
Crist ina
On Feb 22, 2020, at 2:18 PM, Fauci, Anthony (NIH/NIAID) [E) (b)( >
wrote:
Cristina:
What is the relationship that we (DMID/NIAID) has with Sanofi in the
development of a coronavirus vaccine? Are we funding them? Do we
NIH-001649
have any agreement with them to develop a coronavirus vaccine, or is
it BARDA who is dealing w ith them?
Thanks,
Tony
Anthony S. Fauci , MO
Director
Bethesda , MO 20892-2520
Phone: Cb)(6)
FAX : (301) 496-4409
E-mail: Cb
) (6)
sender and delete it from your mailbox or any other storage devices. The Nationa l
NIAID by one of its representatives.
NIH-001650
Sent: Sat, 22 Feb 2020 18:32:37 +0000
Subject: Nabel NAS nom ination
Attachments: (b)(6) 2020 NAS Nomination - Section 44 - 02 -22-2020.docx
Bob:
Here is CbH6)NAS nomination. Let us touch bases on Monday to get it
uploaded to the website.
Thanks,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
NIH-001652
Sent : Sat, 22 Feb 2020 14:08: 16 +0000
To : Marlene Colucci
Cc: David Rubenstein;Ginni Rometty;Donahoe, John
Subject : RE: Business Council - Dr. Anthony Fauci "fireside chat" with David Rubenstein -
Thank you !
Marlene : Thanks for the note. It was my pleasure, and I never m iss an opportun it y to interact
with David. He is an incomparable interviewer.
Best,
Tony
From: Marlene Colucci <mcolucci@businesscouncil.com>

To: Fauci, Anthony (NIH/NIAID) [E]_____ _____,
(b).-.(=6)>
Donaho e, John
__________
Cc: David Rubenstein
_,
(b) (6) >
(b) (6); Ginni Rometty (b)( >;
Subject : Business Council - Dr. Anthony Fauci "fireside chat" with David Rubenstein - Thank you!
Dr. Fauci,
We wanted to send a quick note to thank you for join ing us today. Your discussion with David was so
interesting and we ll received .
The coronavirus alone was o n the minds of so many CEOsas it impacts thei r supply chain.
David, it goes w ithout saying that you are the best interviewer! You make everything substanti ve and
enterta ining .
Wish ing everyone an enjoyable weekend!
Warmest regards,
Marlene
Marlene Colucci
EXECUTIVE
DIRECTOR
NIH-001653
T : 202-298-7650
1 C:
'I BUSl ESS (b)(6)
~ (. <. L \,( l L F: 202-785-0296
NIH-00 1654
From: Fauci, Anthony (NIH/N IAID) [El
Sent: Sat, 22 Feb 2020 14:06:21 +0000
Subject : FW: CoVid-19 In Infants
Please hsandle.

Fr om: JF K (b) (6)
Sent : Friday , February 21, 2020 2 :44 PM
------~~
To: Fauci, Anthony (NIH/NIAID) [E]..._ _____ _ )_ <....
(b
Subject: CoVid- 19 In Infan ts
Dr. Fauc i,
Infants and childr en infected with CoVid-19 seem to be an anomaly. Could it be as simp le as childhood
vaccinations? Are Chinese childr en vaccinated with anti malarial drugs such as Chloroqu ine phosphate , which is
proving effective in older patients for CoVid-19?
If infants and childr en are not getting severe infections, why?
Jonathan F. King
NIH-001655
Sent : Sat, 22 Feb 2020 14:00:30 +0000
Cc: Conrad, Patricia (NIH/NIAID) [E];Greg Folkers (GFOLKERS@niaid.nih.gov)
Subject: FW: Session Planning fo r COVID-19 at CROI; Tuesday March 10, at 12:10 PM
Eastern Daylight Time
fyi
From: Kevin Bowen <kbowen@iasusa .org>

Se nt: Friday, February 21, 2020 6:31 PM
To: Donna Jacobsen <djacobsen@iasusa .org>; Zunyou Wu Brooks, John T.
{CDC/DDID/NCHHSTP/DHPSE)
-'."";:::======~~
(b)(6);
Fauci, Anthony
(b)(6)
(NIH/NIAID) [E]
'""""":-:-:-.:::=====::.....----------------- (b
-...)""'
(6)
=
El-Sadr, Wafaa M . (b)(6)>; Schooley, Robert

(b)( ·; Schooley, Chip (b)(6)>; Eron, Joseph J Jr
========""'"';'"~;-' (b)(6)>; Genesis Regalado (b)( >; Barie, Toni C
==========!...;..~
------------ (b)(6); Conrad, Patricia (NIH/NIAID) [E) (b)(6)>
Subject : RE: Session Planning for COVID-19 at CROI; Tuesday March 10, at 12:10 PM Eastern Daylight
Time
Dear CROI Speakers and Moderators:
We would like to schedule a planning call for next week to COVID-19 session at the 2020 Conference on
Retroviruses and Oppor t unistic Infections (CROI). Please submit your availability using the poll at
http://whenisgood.net/ksy42az . The poll should automatically adjust to your local time zone, but you
can adjust the setting using the "Select your location" dropdown if needed.
We will confirm the call as soon as possible.
Regards,
Kevin Bowen
Program Director
CROI Scientific Program and IAS-USAProduction
From: Donna Jacobsen

To: Zunyou Wu (b)( >; John T. Brooks MD Barie,
RaIp h S >; Fauci, Anthony (NIH/NIAID) [El ~=======~:;;----
(b)( ,>
(b)(6)>;
Cc: Sharon Hillier PhD (b)(6)

El-Sadr, Wafaa M. (b)(6)>; Kevin Bowen
<kbowen@iasusa.org >; Schooley, Robert
---------------- (b)(6)>; Eron, Joseph J J ,. _________
_
'RobertT. Schooley, MD
(b)(6)
Bowen <kbowen@iasusa.org >; Genesis Regalado <gregalado@iasusa .org >; Barie, Toni C
(b)(6)>; Kevin
NIH-001658
-------------- Cb)( >; Conrad, Patricia (NIH/NIAID) [E] CbH6J>
Subject : Session Planning for COVID-19 at CROI;Tuesday March 10, at 12 :10 PM Eastern Daylight Time
Import ance: High
Dear Drs Wu, Brooks, Barie, and Fauci:
It is more than incredibly imp ressive at how all of you, in just the past few days, have rearranged your
schedules and agreed to participate in this special session in on ly about 2 weeks. We are all very
grateful , and know t his will be tremendously impactful for the CROIaudience.
Below is the final list of present ations , although the order and titles may well change. We are hoping to
have a conference call with the session liaisons and speakers next week if possible, to go over each of
the talks to address the overall plan and discuss any overlap. Shortly we will send out a poll for
availabi lity for early morning in China, early-mid afte rnoon in the US West Coast, and late afternoon-
evening in the US East Coast. If you can respond to the poll by Monday we would greatly apprec iate it;
things are moving quick ly.
Many thanks again,
All of us at CROI!
SPECIAL
LUNCHllllESESSIONONCXMJ 19
Tue. 3/ 10: 12:10 PM -1 :20 PM EASTE~ DAYLIGHTTIME
Auditorium
Preliminary Sess
i onAgenda {Order andtalk.titlesto be confirmed)
1, FOCUSON THE EPIDEMIOLOGYOF COVID-19 AND EFFORTSIN CHINA
a. zY.Jrt.qy.
Wu, ChineseCenter for OiseaseContro~ China
1.5-minute live video (Skyll" or Zoom)updote from Ch'no
2. FOCUS ON THE GLOBAL EPIDEM IO LOGY OF COVI0 - 19 AN D EFFORTSTO CO NTROL TH E OVT6REA,C:
a. John Brooks, VS Cente<sfor DiseaseControl, USA
15-minute update
3. FOCUSON TliE VIROLOGY OF COROII OVlW SESOVERAL~ M OLECULA R ASPE CTSOF TRANSM ISSION TO HUMANS, PATHOGENESIS IN M ICE MODELSIINO PAI\ALLElS tNIHUMANS,ETC
a. Ralph Saric, University of North carolina, USA
25-m invt e lecture
4, FOCUSON NIAID/HIH EFFORTSTO STUDYNOVEL CORONOV IRVSESAND DEVELOP DIAGNOSTICS.THERAP EI/TICS, ANOVACCINES
a. Anthony Fautt, National lnstttute of AJ!
ergyand 1nfecuouso1seases, Nat1on
al Instit utes of Hea!th, USA
l ~ inute recorded vpdate
NIH-001659
Sent: Sat, 22 Feb 2020 12:13:45 +0000
Subject : FW: Triple E letter
Let us discuss. Likely no.

From: Br idbord, Ken (NJH/FIC) [VJ (b) (6):>
To: Fauci, Anthony (NIH/NIAID) [E] -----~ ~=>
(b)(
Cc: Marietta Ethier (b)(6
t Emily Lane <ELane@:.. ____ (b 6>;>; Fauci, Anthony
_ )_(_.
(NIH/NIAID) [E] (b)(6)
Subject: Re: Triple E letter
Tony, my condominiumcommunity has established a program in which prominent members of the Washingtonarea
are invited to make presentationson subjects of great public interest. Shown in the email below is a descriptionof
this program. In this regard I have been asked to contact you to see, recognizing your incrediblybusy schedule, if
you would be interested and able to provide an update on the Coronavirus situation to our residents. Most likely you
_____________________ __.,
Cb (6) If you have a potential interest in sharing your
,)......,
great expenise on this subj ect with our residents could you please have your staff contact Emily Lane who is copied
on this email to explore possible dates and limes thal would work for you . Thank you so much for your
consideration of this request. Ken
On 2/2 1/20, 3:36 PM, "Emily Lane" <ELane@t..,_____ Cb

_)_@
... wrote:
Dear Ken,
The (b) (6) . Committee greatly appreciatesyour willingnessto approach Dr. Anthony Fauci on our
behalf, asking him to address the residents of the----,---, (b) (6) on the Coronavirus. It would perhaps be
hel ful to Dr.Fauci, to ex lain who we are and what we do. (b) ( ,
(b)(6)
The (b) ( Committee was ormed recently to create and orgamze events to e ucate, enlighten and
entertain members of the Somerset community.A few weeks ago (b)(6) spoke to a sold out crowd on
impeachment. We've featured authors on a variety of topics; invited doctors with specialtiesof interest to our
communityorganized trips to the KennedyCenter and theaters for attendanceat ballets and plays and sponsored
visits, led by experts, to various museums and the Library of Congress to view special exhibitions. An example of
the latter is a tour of the Folger Library (b) (6). A
presentationby Dr. Fauci on the coronaviruswould be of great interest to our constituencywho keep informed by
reading both national and internationaljournals. We are flexible on the date for such an appearanceneeding only a
few days' notice to inform our residents.
I need not tell you that it wou ld our great honor to welcome Dr. Fauci to the (b) (6):.
NIH-001660
Sincerely
(b)(6)
NIH-00166 1
Sent : Sat, 22 Feb 2020 12:08:24 +0000
To : Conrad, Patricia (NIH/NIAID) [E);Folkers, Greg (NIH/NIAID) [E)
Cc: Marston, Hilary (NIH/NIAID) [E);Barasch, Kimber ly (NIH/NIAID) [CJ
Subject : RE: Session Planning for COVID-19 at CROI; Tuesday March 10, at 12:10 PM
Eastern Daylight Time
I totally agree. I do not want to be on a "session planning" call. Please have Hilary do this as
suggested by Patty since she is preparing t he talk . T hanks.

Sent : Friday, February 21, 2020 4:44 PM ---------
To : Folkers, Greg (NIH/NIAID) [E] -------~~ (b)(6Jr>;Fauci, Anthony (NIH/NIAID) [El
(b)( 6) ---------
Subject : FW: Session Planning for COVID-19 at CROI; Tuesday March 10, at 12:10 PM Eastern Daylight
Time
Import ance: High
Since this is a taping fo r his remark s - can hi lary do thi s call since she is doin g the
slides? hate to waste ASFt ime on this with all our other moving part s....ju st a
thought.
Patricia L. Conrad
Public Hea lt h Analyst and
National Institute of Alle rgy and Infectious Diseases
Th e Nationa l Institutes of Hea lth
(b)(6)
30 1-496-4409 fax
Disclaime r:
The information in this e-mail and any of its attachments is confidential and may conta in sensitive info rmatio n. It sh ould not be used
by anyone who is not the orig inal intended recipient. If you have rece ived this e-mail in error please inform the sender and de lete it
from your ma ilbox or any other storage devices . National Institute of Allergy and Infectious Diseases (NiAID ) shall not accept
liabi lity for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives .
From: Donna Jacobsen <djacobsen@iasusa .org >

To : Zunyou Wu (b)( >; Brooks, John T. (CDC/DDID/NCHHSTP/DHPSE)
(b)(6)>; Barie, Ralph (b)(6)>; Fauci, A nt hony (NIH/NIA ID) [El
~=====~~ (b)( >
Cc: Sharon Hillier PhD (b)(6] .
---------------------------
NIH-001662
(b)(~ EI-Sadr, Wafaa M. (b)(6J>; Kevin Bowen
========-~;5""-:--'.~-:--.
(b) (6); Schooley, Robert (b) (6); Schooley, Chip
; Eron, Joseph J Jr ";::::=======-~~-=-
.....
_;
Kevin Bowen
______________ ; Genesis Regalado
CbH_,
(b) (6)> ; Barie, Toni C
6));Conrad, Patricia (NI H/NIAID) [E] (b)(6)
---------~~ =
Subject: Session Planning for COVID-19 at CROI;Tuesday March 10, at 12 :10 PM Eastern Daylight Time
Importance : High
Dear Ors Wu, Brooks, Barie, and Fauci:
It is more than incredibly imp ressive at how all of you, in just the past few days, have rearranged your
schedules and agreed to participate in th is special session in only about 2 weeks. We are all very
grateful , and know this will be tremendously impactful for the CROIaudience.
Below is the final list of presentations, although the order and titles may well change. We are hoping to
have a conference call with the session liaisons and speakers next week if possible, to go over each of
the talks to address the overall plan and discuss any overlap. Shortly we will send out a poll for
availabi lity for early morning in China, early-mid afternoon in the US West Coast, and late afternoon-
evening in the US East Coast. If you can respond to the poll by Monday we would greatly appreciate it;
things are moving quick ly.
Many thanks again,
All of us at CROI!
SPECIAL WNCH111\E SESSION ONCOV[) 19

Tue, 3/10: 12:10 PM - 1:20 PM EASTE~ DAYLIGHT TIME
Auditorium
Preliminory Sc>:.ionAgendo (Orde1 1md tol k.title, to be con firmed)

1. FOCU~ON TliE EPIDEM IOLOGYOF COVID-19AND EFFORTSIN CHINA
a. ?uoxouWu, ChineseCenter for OiseaseContro~China
15-minvte livevideo (Skypeor Z.oom)vpdatefromCh:fl(I
2. FOCUSON fHE GLOBAi.EPIDEMIOLOGY OFCOI/ID-19 AND EFFORTSTO CONTROLTHE OIJT6REA~
a. John Ofo<>
k!I, VS Cent~o fo,- Di)C~ C<.mt,d,.USA
15-minute update
3. FOCUSON rHE VIROLOGY OF COROtl OVIWS6 OVERAL~MOLECULARASPECT
S OF TRANSM
ISSION TO HUMANS. PATHOGENES
IS IN M ICE MODELStl NOPARALLE
lS INIHUMANS,ETC
a. Ralph Sar ic. Universityof North carolina, U SA
25-minute lecture
4, FOCUS ON N fA I0/HIH EFFORTS TO STUDY NOVE L CORONOV IRVSESAN O OEVElO P DIAGN OSTICS. TH ERAPEUTICS, ANO VACCINES
a. Anthony Fauti, National Institute of AJlergyandInfectiousDiseases,.
National InstitutesoJHea!th, USA
15-minute recordedupdate
NIH-001663
Sent : Sat, 22 Feb 2020 12:06:10 +0000
Subject : FW: DEARTONY: CORONAVIRUS
Please handle.
From: Dr. Michael Jacobs

----------
-------= ~
(b)(6)>
Cc: Alexander Tarakhovsky

_..:....:....:.!:=======;=(b)(6 )1>
Lockshin, Michael MD
(b)(6);
-------- (b)(6); Dr. Michael Jacobs

Subject : DEARTONY: CORONAVIRUS ---------- (b)(6) >
dear tony:
i am a cornell medical school cum~

cornell in private practice. -----------------------=-~
raduate. i am associate professor of dermato logy at wei ll-
---.---.---:====~~-~-~----~-.----- (b)(6)
aIexand er tarakhovsky is and a professor at rockefeller university. he
is a virologist.
------ (b)(
we have been fo llowing the corona virus pandemic closely, and a few days ago became alarmed at t he
news that the chinese government is sterilizing their paper money from hube i province .
we th ink that there is a possibility that the virus was released from a lab in wuhan, the
biotech area of china. we also th ink that the vi rus might be complexed with another organism , such as a
yeast or fungus, to make it more sticky.
we would like to discuss this with you further. we feel that immediate action must be taken by united
states scientists to try to neutralize this t hreat .
please contact alexander and me at your earliest convenience at above emails or my mobile
----- (b)(6) or office (b)(6) michael lockshin gave me you r email.
with kind regards
michael jacobs
NIH-001664
From: Fauci,Anthony (NIH/NIAID) [El
Sent : Sat, 22 Feb 2020 11:49:36 +0000
Subject: FW: coronavirus
Attachments : Cai & Garen 1995.pdf, Cai & Garen 1996 .pdf, Cai & Garen 1997.pdf
Please handle. Thanks .
From:Garen, Alan (b)( >

Sent: Friday, Feb ruary 21, 2020 7:46 PM
To: Fauci, Anthony (NIH/NIAID) [E]------ (b
=)""'
(6)
=>
Cc: Garen, Alan (b)(6)>
Subject: coronavirus
Dear D. Fauci,
I want to suggest t hat NIAID arrange to collect serum samp les from Coronavirus patients who
have survived a major infection and probably have genera te d antiviral antibod ies. My
laboratory showed in the attached papers that such antibodies could be cloned from sera using
a powerfu l technology called Phage Display. The project cou ld be initiated in this country with
as few as 2 patients.
Sincerely, Afan Garen, Yale Univers ity
NIH-001665
Sent: Sat, 22 Feb 2020 11:39:57 +0000
To: Antoniak, Cynthia (NBCUniversal, MSNBC)
Cc: Goldner, Shannah (NBCUniversal);Conrad, Patricia (NIH/NIAID) [E]
Subject : RE: MSNBC Reconfirming
No problem . Seeyou then.
From:Antoniak, Cynthia {NBCUniversal, MSNBC) <Cynth ia.Antoniak@MSNBC.COM>

------~~ (b)(6)>
Cc: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>; Conrad, Patricia (NIH/NIAID) [El
(b)(6)
If you could get there by 7:3Oam ...that would be great!
From: Fauci, Anthony (NIH/NIAID) [El (b)( >

Sent : Saturday, February 22, 2020 6:38 AM
To: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia .Anton iak@MSNBC.COM>
Cc: Goldner, Shannah (NBCUniversal) <shannah .goldne r@nbcun i.com >; Conrad, Patricia (NIH/NIAID) [El
(b)(6)>
Subject: [EXTERNAL)RE: MSNBC Reconfirming
I have received this e-mail and confirm 7 :45 AM hit . What time do you want me at the studio?
From:Antoniak, Cynt hia (NBCUniversal, MSNBC) <Cynth ia.Antoniak@MSNBC.CO M >

------~= (b)(6J>
Cc: Goldner, Shannah (NBCUniversal) <shannah .goldner@nbcun i.com >; Conrad, Patricia (NIH/NIAID) [El
(b)(6)
Subject : MSNBC Reconfirming
Good Morning Dr . Fauci,
I am just reconfirming you for your segment on MSNBC this morning with Kendis Gibson and Cori
Coffin .
You ore hitting at 7:45am from the NBC News Bureau at 4001 Nebraska Avenue .
Topics:
-Coronavirus-infected Americans flown home against CDCadvice
ht tps://w ww.washingt onpost .com/h ealt h/ coro navirus- diamond-princess-cru ise-
amer icans/2020/02/20/b6f 54cae-52 79-11ea-b119-4faabac66 74f st or y.ht ml
-Decision to quarant ine cruise ship-was that a misstep?
-Long term effects of decision to bring U.S. passengers back
NIH-001
666
Please reply that you got this .
Thank you!
Cyndi
From: Goldner, Shannah (NBCUniversal) <shannah .gold ner@nbcuni.com >

To: Conrad, Patricia (NIH/NIA ID) [E) --------=--:-~
(b)(6)>
Cc: Antoniak, Cynthia (NBCUniversal, MSNBC} <Cynth ia.Antoniak@MSNBC.COM >; Fauci, Anthony
{NIH/NIAID) [E] (b)(6)
Subject: RE: contact at the studio tomorrow/MSNBC intv
We absolutely will do. Thank you so much and thank you for your patience. We will be in touch first
thing in the morning .
From: Conrad, Patricia {NIH/NIAID) [E] (b)((;)

To: Goldner, Shannah (NBCUniversal) <shannah .goldne r @nbcuni.com >
Cc: Antoniak, Cynthia (NBCUniversal, MSNBC} <Cynth ia.Antoniak@MSNBC.COM>; Fauci, Anthony
Subject: [EXTERNAL]RE:contact at the studio tomorrow/MSNBC intv
Ok- I am adding Dr Fauci to this email - please confirm to both of us in the

morning. Thank you
Patricia L. Conrad
(b)(6)
301-496-4409 fax
Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive info rmation. It should not be used
from your ma ilbox or any other storage devices . National Institute of Allergy and Infectious Diseases (NIAID) shall not accept
From: Goldner, Shannah (NBCUniversal) <shannah .gold ner@nbcuni .com>

To: Conrad, Patricia (NIH/NIA ID) [E) ---------=-c-c-=
(b)(6)
Cc: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoni ak@M SNBC.COM >
NIH-001667
We won't have an exact hit time until the morn ing BUT as of now, it's 7:30am . It might be 7:35am but
that is the hit time.
Cyndi wi ll send it to you by Sam tomorrow.

(b)(6)>
---------
To: Goldner, Shannah (NBCUniversal) <shannah .goldner@nbcuni.com >
Cc: Antoniak, Cynthia (NBCUniversal, MSNBC)<Cynth ia.Anton iak@MSNBC.COM>
Subject : [EXTERNAL]RE:cont act at the studio tomorrow/MSNBC intv
Will you or Cyndi send exact hit tim e toni ght ? What is th e approx . t ime we will get
that?
Patrici a L. Conrad
Pub lic Hea lth Analyst and
Speci a l Assist ant to the Direc tor
Natio nal Institute of Allergy and Infect ious Diseases
The Nationa l Instit ut es of Health
31 Cent e r Drive, M SC 2520- Roo m 7A03
Bethesda, M ary land 20892
(b)(6)
301-496-4409 fax
Disclaime r:
from your mailbox or any other storage devices . Nationa l Institute of Allergy and Infectious Diseases (NIAID) shall not accept
liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives .
From: Goldne r, Shannah (NBCUniversal) <shannah .goldne r@nbcuni.com >

Sent : Friday, February 21, 2020 10:42 AM
To: Conrad, Patricia (NIH/NIAID) [E) -------- ==
~-========:=..~~ (b)(6)
Cc: Robinson, Whitney (NIH/ NIAID) [C] (b)(6) Deatrick, Elizabeth (NIH/NIAID) [C]
----------- (b)(6); Lavelle, Jud ith (NIH/NIAID) [E]

Subject : RE: contact at the studio tomorrow/MSNBC intv --------- (b)(6)>
Thank you so much

To: Goldner, Shannah (NBCUniversal) <shannah.goldne r @nbcuni.com >
Cc: Robinson, Whitney (NIH/ NIAID) [C] (b)(6)>; Deatrick, Elizabeth (NIH/ NIAID) [C]
----------- (b)(6); Lavelle, Jud ith (NIH/NIAID) [E]

Subject : [EXTERNAL]RE:contact at the studio tomorrow/MSNBC intv
CbH6J>
NIH-001668
Great - t hanks.
Please j ust let us know th e exact him t im e and we w ill have him arr ive 20 mins
pri or.
His cell is CbH6)and mine is (b)(6)
Patricia L. Conrad
Special Assistant to the Directo r
(b)(6)
301-496-4409 fax
Disclaimer:
The informat ion in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used
by anyone who Is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it
from your mailbox or any other storage devices . National Institute of Allergy and Infectious Diseases (NIAID) shall not accept
From: Goldner, Shannah (NBCUniversal) <shannah .goldner@nbcun i.com>

To : Conrad, Patricia (NIH/NIA ID) [E) --------= = (b)(6J>
__________
Cc: Robinson, Whitney (NIH/NIAID) [CJ
(b)(6J>;
_, Lavelle, Jud ith
Subject: contact at the studio tomorrow/MSNBC intv
(NIH/NIAID) [E]
(b)(6) Deatrick, Elizabeth (NIH/NIAID) [CJ
-----------
(b)(6)>
Importance: High
Patricia, hi,
The contact at the studio in the morning is Natalia Abrams. The number at the office is 202 -885 -4800.
Also, Cyndi Antoniak will be in touch wit h you in the morning and send you an email about the segment
and just to touch base. If you need to reach Cyndi before she reaches you, her numbe r is 212-664 - 1450
and her email is Cynthia .ant oniak@nbc uni.com .
Thank you so much for making the interview work out, we appreciate it.
Shannah
From : Conrad, Patricia (NIH/NIAID) [E] (b)(6)>

To: Goldner, Shannah (NBCUniversal) <shannah .goldne r @nbcuni.com >
Cc: Robinson, Whitney {NIH/NIAID) [CJ CbH6)>;Deatrick, Elizabeth {NIH/NIAID) [C]
NIH-00166 9
CbH6J>;Lavelle, Jud ith (NIH/NIAID) [E] CbH6J>
----------
Subject : [EXTERNAL) RE:hi and request for Dr. Fauci this w eekend on MSNBC
Hi Shannah
Sat urday M ornin g betw een 7:30 am ET- 8 am ET is best for Dr Fauci and wi ll
need to be from th e NBC Studi o at 4001 Nebraska Ave NW st udio . He has a hard
st op no lat er th an 8:15 am. Please send us th e onsit e contact name and numb er
and firm hit t im e wh en you can .
Thanks,
-patty
Patricia L. Conrad
Special Assistant to the Directo r
National Institute of A ll ergy and Infectious Diseases
The Nat iona l Institutes of Hea lth
Bethesda, M aryland 20892
(b)(6)
30 1-496-4409 fax
Disclaime r:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used
by anyone who is not the original intended recipient. If you have received !his e-mail in error please inform the sender and delete it
from your mailbox or any other storage devices. Nationa l Institute of Alle rgy and Infectious Diseases (NIAID) shall not accept
From:Goldner, Shannah (NBCUniversal) <shannah .goldner@nbcuni.com >

Sent : Thursday, February 20, 2020 4 :17 PM
To: Conrad, Patricia (NIH/NI AID) [E) --------=-c--c=
(b)(6)>
Cc: Barasch, Kimberly (NIH/N IAID) [CJ (b)(6J>; Deatrick, Elizabeth (NIH/N IAID) [C]
(b)(6)
Subject : RE: hi and request for Dr. Fauci this weekend on MSNBC
That's terr ific and yes, that studio is best if he can join us. Thank you so much. Shannah
From : Conrad, Patricia (NIH/NIAID) [E)

20, 2020 4 :16----------
(b)(
Sent : Thursday, February PM
To : Goldner, Shannah (NBCUniversal) <shannah .goldner@nbcuni.com >
Cc: Barasch, Kimbe rly (NIH/N IAID) (CJ (b)(6)>; Oeatrick, Elizabeth (NIH/N IAID) [CJ
(b)(6)
Subject : [EXTERNAL] RE:hi and request for Dr. Fauci this weekend on MSNBC
NIH-001670
I am sure we can make one of these work - will let you know tomorrow .
We would do from the NBC Nebraska Ave NW Studio.
thx
Patricia L. Conrad
Th e Nat ion al Institutes of Hea lth
3 1 Center Drive, MSC 2520 - Room 7 A03
Bethesda, Maryl and 20892
(b)(6)
301-496-4409 fax
Disclaime r:
The informatio n in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used
from your mailbox or any other storage dev ices. National Institute of Aller gy and Infectious Diseases (NIAID ) shall not accept
liability fo r any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.
From: Goldner, Shannah (NBCUniversal) <shannah.gold ner@nbcuni .com>

Sent: Thu rsday, February 20, 2020 4:12 PM
To: Conrad, Patricia (NIH/NIA ID) [E)~======= -------- ~=
(b)
=(=6):>~=
:,_
Cc: Barasch, Kimberly (NIH/N IAID) [C]________ _<_ Deatrick, Elizabeth (NIH/NIAID) [C]
Cb)
(b)(6)
Subject : hi and request for Dr. Fauci this weekend on MSNBC
Importance: High
Patricia, hi, I hope all is well with you.

Is Dr. Fauci available this weekend to be on MSNBCto discuss the latest re Corona virus -
https ://www .washingtonpost.com/ health/co ronavi rus-diamond -pri ncess-cruise-
a mericans/2020/02/20/b6 f54cae-5279- l lea -bl 19-4faabac667 4f story .htm I
We'd like him on eit her on Saturday, in the 7:30am to 8am half hour, with Kendis Gibson/Cori Coffin, or
on Sunday in the 12pm or 1pm hour with Alex Witt. Whatever day/hour that is good fo r him, we'll make
work.
Thank you so much for yo ur help in this matter.
All the best,
Shannah
NIH-001671
Shannah Goldner
MSNBC
W: 212 -664 -1289
C: Cb)(6)
NIH-001672
Sent : Sat, 22 Feb 2020 11:39:06 +0000
I just did reconfirm with a copy to you. Did you not get it?
(b)(6)>
From: Conrad, Patricia (NIH/NIAID) [E)
---------
Se nt: Saturday, February 22, 2020 6:38 AM
To: Fauci, Anthony (NIH/NIAID) [E] -------=- (be-
)(= >
Subject : Fwd: MSNBC Reconfirming
You need to respond to this . It's in your on box
Sent from my iPhone
From: "Antoniak, Cynthia (NBCUniversal, MSNBC)" <Cynt hia.Anton iak@MSNBC.COM>

To: "Fauci, Anthony (NIH/NIAID) [E)"
------~~ CbH6)>
Cc: "Goldner, Shannah (NBCUniversal)" <shannah .goldne r@nbcun i.com>, "Conrad, Patricia
{NIH/NIAID) (E]" (b)(6)
Subject : MSNBC Reconfirming
Good Morning Dr. Fauci,
I am just reconfirming you for your segment on MSNBC this morning wit h Kendis
Gibson and Cori Coffin .
You are hitting at 7:45am from the NBC News Bureau at 4001 Nebraska Avenue.
Topics:
-Coronavirus-infected Americans f lown home against CDCadvice
ht tp s:/ /www .washingtonpost .com/healt h/ coronavir us-diamond-princess-cr uise-
amer icans/2020/02/20/ b6f 54cae-5279 - 11ea- b119-4faabac66 7 4f story .htm l
-Decision to quaranti ne cruise ship-was t hat a misst ep?
- Long term effects of decision to bring U.S. passengers back
Please reply that you got this.

Thank you!
Cyndi
From: Goldner, Shannah (NBCUniversal) <shannah .goldner@n bcuni.com>

To: Conrad, Patricia (NIH/NIAID) [El -------~~ CbH6)
NIH-001673
Cc:Antoniak, Cynthia (NBCUniversal, MSNBC)<Cynthia.Antonia k@MSNBC.COM>; Fauci,
Anthony (NIH/NIAID) [E] (b)(6)
Subject: RE:contact at the studio tomorrow/MSNBC intv
We absolutely will do. Thank you so much and thank you for your pat ience. We will be in
touch first thing in the morning .

To: Goldner, Shannah (NBCUniversal) <shannah .goldner@nbcun i.com>
Cc: Antoniak, Cynthia (NBCUniversal, MSNBC)<Cynthia .Anto niak@MSNBC.COM>; Fauci,
Anthony (NIH/ NIAID) [E] (b)( >
Subject : [EXTERNAL]RE: contact at the studio tomorrow/MSNBC intv
Ok- I am adding Dr Fauci to this email - please confirm to both of us in

the morn ing. Thank you
Patricia L. Conrad
Nat ional Inst itute of Allergy and Infectious Diseases
The Nat ional Institutes of Heal t h
31 Center Drive , MSC 2520 - Room 7A03
(b)(6)
301-496-4409 fax
Disclaimer :
The information in this e-mail and any of its attachments is confidential and may conta in sensitive information . It
should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error
please inform the sender and delete it from your mailbox or any other storage devices. National Institute or Allergy
and Infectious Diseases (NIAID } shall not accept lia bility for any statement made that are sender's own and not
expressly made o n behalf of the NIA ID by one of its represent atives.
From: Goldner, Shannah (NBCUniversal) <shannah.go ldner@nbcun i.com >

To: Conrad, Patricia (NIH/NIAID) [E] --------~=
(b)( >
Cc: Antoniak, Cynthia (NBCUniversal, MSNBC)<Cynthia .Antonia k@MSNBC.COM>
We won't have an exact hit time until the morning BUT as of now, it's 7:30am. It might be
7:35am but that is the hit time.
Cyndi will send it to you by Sam tomorrow .

Sent: Friday, February 21, 2020 2:48 PM ---------- (b)(6)
NIH-001674
Cc:Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Anton iak@MSNBC.COM>
Subject: [EXTERNAL]RE: contact at the studio tomorrow/MSNBC intv
Will you or Cyndi send exact hit time tonight? What is the approx. time
we will get t hat?
Patricia L. Con rad

The National In stitutes of Health
(b)(6)
301-496-4409 fax
Disclaimer:
The info rmation in this e-mail and any of its attachments is confidenti al and may contai n sens itive information. It
should not be used by anyone who is not the origina l intended recipient. If you have received this e -ma il in error
and Infectious Diseases (NIAID} shall not accept liability for any statement made that are sender's own and not

To: Conrad, Patricia (NIH/NIAID) [E]_______ """
Cb"H=
'"" >
Cc: Robinson, Whitney (NIH/NIAID) [CJ (b)(6)>; Deatrick, Elizabeth
(NIH/NIAID) [CJ (b)(6); Lavelle, Judith (NIH/NIAID) [E]
,;__;_ _ ___;_,.;_;,_::::~(b;:::
)( :::;:
6).-------
Thank you so much

Sent: Friday, February 21, 2020 10 :35 AM ---------- (b)(6)
To: Goldner , Shannah (NBCUniversal) <shannah.go ldner@nbcun i.com>

Cc: Robinson, Whitney (NIH/NIAID) [C] (b)( Deatrick, Elizabeth
(NIH/NIAID) [C) (b)(6) Lavelle, Judith (NIH/NIAID) [E]
(b)(6)
Subject: [EXTERNAL]RE: contact at the studio tomorrow/MSNBC intv
Great -thanks.
NIH-001675
Please just let us know the exact him time and we will have him arrive
20 mins prior.
His cell is (b)(6) and mine is (b)(6)

------- -------
Patricia L. Con rad
(b)(6)
301-496-4409 fax
Disclaimer:
T he information in this e-ma il and any of its attachments is confident ial and may contain sensitive information. It
shou ld not be used by anyone who is not the origina l intended recipient. If you have received this e-ma il in error
plea se inform the sender and delete it from your mailbox or any other storage devices. National Institut e of A llergy
and Infect ious Diseases (NIAID) shall not accept liabil ity for any statement made that are sender's own and not
express ly made on behalf of the NIAID by one of its representat ives .

--------~=
To: Conrad, Patricia (NIH/NIAID) [El > (b)(
Cc: Robinson, Whitney (NIH/NIAID) ~-========:::::..-:;;;-;,-=,
[C] Deatrick, Elizabeth (b)(6J>;
(NIH/NIAID) [C) (b)(6); Lavelle, Judith (NIH/NIAID) [El
,;_ ___ ;;-
;_;_..;..==-(b~) :;,;
~ >----------
Subject: contact at the studio tomorrow/MSNBC intv
Importance : High
Patricia, hi,
The contact at the studio in the morning is Natalia Abrams. The numbe r at the office is
202-885-4800.
Also, Cyndi Antoniak will be in t ouch with you in the morning and send you an email about
the segment and just to touch base. If you need to reach Cyndi before she reaches you, her
number is 212-664- 1450 and her email is Cynth ia.anton iak@nbcun i.com .
Thank you so much for making the interview work out, we appreciate it.
Shannah
From: Conrad, Patricia (NIH/NIAID) [El (b)(6)

Cc: Robinson, Whitney (NIH/NIAID) [CJ CbH6J>;Deatrick, Elizabeth
{NIH/NIAID) [C) (b)(6)>; Lavelle, Judith {NIH/NIAID) [E]
NIH-001676
(b)(6)
Subject : [EXTERNAL]RE: hi and request for Dr. Fauci th is weekend on M SNBC
Hi Shannah
Saturd ay M ornin g betw een 7:30 am ET - 8 am ET is best for Dr Fauci

and w ill need t o be fr om th e NBCStudi o at 4001 Nebraska Ave NW
studi o. He has a hard stop no lat er th an 8:1 5 am. Please send us t he
onsit e conta ct name and numb er and fi rm hit tim e w hen you can.
Than ks,
-patt y
Patricia L. Con rad

Specia l Assistant to the Director
31 Cente r Dr ive, M SC 2520 - Room 7 A03
(b)(6)
30 1-496- 4 409 fax
Disclaimer:
The information in this e-mai l and any of its attachments is confidential and may conta in sensitive information . It
please inform the sender and delete it from your mailbox or any other storage devices. National Institute of A llergy
express ly made on behal f of the NIAID by one of its representatives.
From: Goldner, Shannah (NBCUniversal) <shannah .goldner@nbcun i.com >

To: Conrad, Patricia (NIH/NIA ID) [E] --------~=
(b)(6)
Cc: Barasch, Kimber ly (NIH/NIA ID) [C] (b)(6)>; Deatrick, Elizabeth
(NIH/N IAID) [C) (b)(6)
Subject : RE: hi and request for Dr. Fauci this weekend on MSNBC
That's te rrific and yes, that st udio is best if he can jo in us. Thank you so much. Shannah
From: Conrad, Patricia (NIH/NIA ID) [E] (b)(6)

To: Goldner , Shannah (NBCUniversal) <shannah.goldner@nbcun i.com>
Cc: Barasch, Kimber ly (NIH/NIAID ) [CJ (b)(6) ; Deatrick, Elizabeth
NIH-001677
(NIH/NIAID) [C) (b)(6)
Subject : [EXTERNAL]RE: hi and request for Dr. Fauci this weekend on MSNBC
I am sure we can make one of these work - will let you know
tomorrow.
We would do from the NBC Nebra ska Ave NW Studio.
thx
Patricia L. Conrad
(b)(6)
301-496-4409 fax
Disclaimer:
The information in this e-mai l and any of its attachments is confidential and may contain sensitive information . It
should not be used by anyone who is not the original intended recipient. If you have received this e-ma il in error
please inform the sender and delete it from your mailbox or any other storage devices. Nationa l Institute of A llergy
and Infect ious Diseases (NIAID) shall not accept liabil ity for any statement made that are sender's own and not
express ly made on behalf of the NIAID by one of its representatives .
From: Goldner, Shannah (NBCUniversal) <shannah.go ldner@nbcun i.com>

To: Conrad, Patricia (NIH/NIAID) [E] ---------=- (b"'""
)( =6)
Cc: Barasch, Kimber ly (NIH/NIAID ) [C] (b)(6)>; Deatrick, Elizabeth
{NIH/NIAID) [C] (b)(6)>
Subject: hi and request for Dr. Fauci this weekend on MSNBC
Importance : High
Patricia, hi, I hope all is well wi th you.

Is Dr. Fauci available this weekend to be on MSNBC to discuss the latest re Corona virus -
https://www .washingtonpost.com/health/coronavirus -d iamond -princess-cruise-
ameri cans/2020/02/20/b6 f54cae-5279- l le a-b 119-4faa bac6674f sto ry.htm l
We'd like him on either on Saturday, in the 7:30am to 8am half hour, with Kendis
Gibson/Cori Coffin , or on Sunday in the 12pm or 1pm hour with Alex Witt. Whatever
day/hour that is good for him, we'll make work.
Thank you so much for your help in this matter.
NIH-00167 8
Allthe best,
Shannah
Shannah Goldner
MSNBC
W: 212-664-1289
C: (b)(6)
NIH-001679
Sent: Sat, 22 Feb 2020 02:39:22 +0000
To: Morens, David (NIH/NIAID) [El
Subject : FW: So what do you guys think? (I no it 's not influenza, but a lot of your 2007
conclusions seem very valid now ...)
David:
Please respond to this person.
Thanks,
Tony

From:
--------------
Sent: Friday , February 21, 2020 9:32 PM
---------------~~
To: Fauci, Anthony (NTH/NIAlD) [E]
00(
(b)(6)
Subject: So what do you guys think ? (Tno it's not influenz a, but a lot of your 2007 conclusions seem very val id
now ...)
Dear David Morens, dear Anthony Fauci ,
J realise it is not an influenza virus, but the outlook of your 2007 paper ("The 1918 lntluenza Pandemic: Insights for
the 21st Century") seems to me to be very valid for the current coronavirus outbreak. Or put differently - your
statements and concerns from then mostly coincide with my thinking and wonies now ... :( .
So a question - what is your thinking now? Are the hospitals you're affiliated w ith hiring additiona l staff (yet)? Any
personal preparations?
Good luck to you and all the best for those close to you, kind regards , Sean Scherer
P.S. I guess part of the the reason I'm asking is, because I (a non-institutionally affiliated biologist), am in touch with
the university-hospital here (b) ( Germany), but my concerns are so far falling on deaf ears ... But also just
reading the paper and seeing others come to the same conclus ions - albeit on more theore tical grounds and multip le
years ago - made me want to reach out. Plu 5 I guess I'm simp ly curious about what you think !
NIH-00168 1
From: (b)(6)
Sent : Fri, 21 Feb 2020 14:38:56 -0500
Cc: Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E]
Subject: Re: Work related question
You are correct. No chance that I would accept. Thanks
On Feb 21, 2020, at 2:23 PM, Billet , Courtney (NIH/NIAID) [E]

Cb)(6) wrote:
In the interest of fu ll disclosure: Stephanie Cb)(6) used to work here at HHS and is
now a VP with the American College of Preventive Medicine . For the life of me I couldn't
see you saying yes to a weekend trip to Denver in May, and I wou ld hate to have them
waste their time sending an invite when they could be pursuing someone more likely to
accept. Hope this is OK.
From : Billet, Courtney (NIH/NIAID) [E]

To: Stephanie Marshall ----------~~ >
-------------
Subject : RE:Work related question
(b)(
Hi -good to hear from you! I hesitate to speak definitively for him and his scheduler, but
to be perfectly honest I think it's really unlikely that'd he'd be able to accept a speaking
invite for Denver. The schedule is insane for the foreseeable future and isn't letting up on
the weekends. He's turning invitations down left and right, unfortunately - especially
those involving travel!
From: Stephanie Marsha ll

-------------
To: Billet, Courtney (NIH/NIAID) [E] ______ (b
-=-=
)'""'
(6)
(b)(6)
= >
Subject : Work related question
Hi Courtney,
I hope you're doing well despite the ongoing craziness whether it's coronavirus or
politics. Yikes, these are unsett led t imes.
I have a quick question for you. Our annua l meeting is May 14 - 17 in Denver. Many
of the sessions are in place but there's talk about doing a session around
NIH-001682
coronavirus and invit ing Dr. Fauci as the speaker. The meeting is a Thursday
through Sunday and they 're look ing at inviting him to speak potentially on Sunday
morning. Is this something he would even consider and would he commit this far
out given everything that's going on? Any quick thoughts you might have would be
helpful.
Thank you, thank you! Have a great weekend.
Stephanie
NIH-001683
From: (b)(6)
Sent : Fri, 21 Feb 2020 10:40:17 -0500
To: Collins, Francis (NIH/OD) [E]
Cc: Hallett , Adrienne (NIH/OD) [E];Tabak, Lawrence (NIH/OD) [El
Subjec t: Re: FYI on Senate staff visit
Thanks, Francis.
On Feb 21, 2020 , at 10:30 AM, Collins, Francis (NIH/OD) [E]

(b)(6)
Hi Tony,
I got asked by Alex Keenan what the NIH needs for the coro navirus response. I said that
this had been looked at with great care by you and your staff . If you are asking me for
technical assistance, I said, we need about (b)(5)for FY20-21, and more in the long run.
ASFRwas in the room but did not have a visible seizure.
Just thought you'd want to know before you meet with the staffers later today.
FC
NIH-001684
Sent: Fri, 21 Feb 2020 14:31:08 +0000
To: Donna Jacobsen
Cc: Conrad, Patricia (NIH/NIAID) [E);Greg Folkers
-------~=
_______ Cb
_)_C6)
_. );Marston, Hilary (NIH/NIAID) [E)
Subject: RE: CROI COVID 19 Session; Tuesday March 10 lunch
Donna:
Thanks for the note . I will be able to provide a 15 minute video with slides that
discusses the NIH/NIAID efforts to study the novel coronavirus and to develop
countermeasures in the form of diagnostics, therapeutics, and vaccines. Your
team can work with Patty Conrad, Hilary Marston and Greg Folkers on the
logistics. In the meantime, we will prepare the video.
Best regards,
Tony
Director
Nation al Institute of Allergy and Infectious Diseases
Phone : Cb)(6)
FAX : (301 496-4409
E-mail Cb) (6)
information . It should not be used by anyone w ho is not the origina l intended recipient. If you
other storage device s. The Nationa l Institute of Allergy and Infectiou s Diseases (NIAID) shall not
acce pt liability for any statem ents made that are the se nder's own and not expressly made on
From: Donna Jacobsen <djacobsen@iasusa.org>

------~= (b)(6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] CbH
Subject: RE: CROI COVID 19 Session; Tuesday March 10 lunch
Importance: High
Dear Dr Fauci:
W e've had a lot of discussion around our COVID-19 session today. An idea t hat came up was possib ly
having you do something remotely. Either a live feed in from your office at approximately 1:05 PM to
1:20 PM EDT on Tuesday, March 10 if you have that time avai lable, or have you send in a video recorded
present ation a day or 2 before that we can show at the session. Having some way to commun icat e the
NIH-001685
high priority NIH/NIAID has on developing a vaccine and treatment would help bring the content
togethe r.
We know this is like ly not possible, with the very short notice and your even more tremendously busy
schedule around all of this. But it's worth the ask.
Please let me know if you think either of these is possible. And Patty, sorry for butchering your email
address earlier.
Best,
Donna
Donna M. Jacobsen
Executive Director /President
International Antiviral (formerly AIDS) Society-USA
Executice Manager, CROI
131 Steuart St, Ste 500
415-544-9400
https ://www .iasusa .o rg
About IAS- USA : Established in 1992, the IAS-USA is a not-for-profit , professional education
organization. The mission of the IAS -USA is to improve the prevention , treatment , care, and quality of life
for people with or at risk of HIV, hepatitis C virus , or other viral infec tions through high-quality, relevant,
balanced , and needs-orien ted educatio n and information for practitioners who are actively involved in
medica l care . The organization's educational activities are particular ly intended to bridge clinical research
and patient care .
Confident iality Notice: This e-mail and its attac hments may contain privileged and confidentia l
information intended solely for the use of the IAS-USA and the recipient(s) named above. If you are not
the intended recipient, or the employee or agent respons ible for delivering this message to the intended
recipien ts, you are hereby notified that any review, dissemination , distribution , printing , or copying of this
e-mail message and/or any attachments is strictly prohibited . If you have received this transmission in
error , please notify the sender immediately and permanent ly delete this e-mai l and any attachments.
From: Fauci, Anthony (NIH/N IAID) [E] ________ _>

Cb
_C6)
_
Sent: Thursday, February 20, 2020 7 :12 AM
NIH-001686
To: Donna Jacobsen <djacobsen@iasusa .org >
Cc: (b)(6) 'Elaine J. Abrams, MD (b)(6) >;
Sharon Hillier PhD (b) (6) Hoxie, James
--------======~~-:------:---:-:.:======~~
-------------
<kbowen@iasusa .org>
(b)(6); Benson, Conn ie
--------- (b)(6); Kevin Bowen
Subject : RE: CROI COVID 19 Session; Tuesday March 10 lunch
Donna:
Thanks for t he note. Unfortunat ely, I need t o be in Washington, DC on March
10, and so I will regrettabl y have to decline your kind inv itation . Thank you f or
thin king of me.
Best regards,
Tony
Director
Phone (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
From: Donna Jacobsen <djacobsen@iasusa .org >

To : Fauci, Anthony (NIH/ NIAID) (E] -------=-:--:=
------~==-------------~=(b)(6)
Cc: (b)(6); 'Elaine J. Abrams, M D (b)(6)
Sha-ro- n
---:-'.
H~il~lie_r_P
~h- D
-;::::===:;....-----...:...--======. (b
~)~(6)
~ >;~H
~o- x~ie
- ,~J-a_m_e_s___ _
-------=====~~------:;;::::====~~ ;,
------------- (b)(6); Benson, Connie
<kbowen@iasusa .org> -------- (b)(6)>; Kevin Bowen
Subject : RE: CROI COVID 19 Session; Tuesday M arch 10 lunch
Dear Dr Fauci:
As I mentioned on the phone, we just today decided that we will have a special session on COVID 19 at
CROI. It wi ll be on Tuesday, M arch 10, during the lunch break ; the init ial general structure will be a 10-
to 15- minute overview (CDC), a 25-min talk by Ralph Barac (UNC) about the viro logy of coronavi ruses,
and a 10- to 15-minute summary on what NIAID/ NIH is doing and planning. We thought that this being
NIH-001687
one of the first large medical conferences in infectious diseases this year, that we address COVID 19 at
CROI
We know that this is terribly last minute , but the CROI Chairs and Foundation are hoping you are free to
give the NIAID/NIH update. CROI is in Boston, Mar ch 8 to 11.
If you think you would be able to do this, we will send a more formal communication with details and
work with Patty on the specifics . Thank you so much Dr Fauci; we hope you will be ab le to join us.
Best,
Donna
Donn a M. Jacobsen
Internationa l Antiviral (formerly AIDS) Society-USA
415-544-9400
https://www .iasusa .org
ACCME
About IAS- USA : Established in 1992, the IAS-USA is a not-for-p rof it, professional education
organization . The mission of the IAS-USA is to improve the prevention , treatment , care , and quality of life
for people with or at risk of HIV , hepat itis C virus , or other viral infec tions through high-quality , relevant,
balanced, and needs -oriented education and information for practitioners who are actively involved in
medica l care . The organization's educational activities are partic ularly intended to bridge clinical research
and patient care.
Confident iality Notice: This e-mail and its attachments may contain privileged and confidentia l
the intended recipient, or the employee or agent respons ible for delivering this message to the intended
recipien ts, you are hereby notified that any review, dissemination , distribution , printing, or copying of this
e-mail message and/or any attachments is strictly prohibited . If you have received this transmission in
error, please notify the sender immediately and permanently delete this e-mail and any attachments.
NIH-001688
Sent : Fri, 21 Feb 2020 13:33:20 +0000
Subject : FW: FDA Request
Attachment s: FDA Clearance Letter.pdf, Nepal Corona Vi rus Paper.pdf
Please han dle .
Director
Phone : (b) (6)
FAX : (301 496-4409
E-mail : (b)(6)
From: Jeff Fischer (b)(6)

To: Messonnier, Nancy (CDC/DDID/NCIRD/0D) (b)( >; Khabbaz, Rima
(CDC/DDID/NCEZID/0D) (b)(6)'> ; Fauci, Anthony (NIH/NIAID) [E)______ ..,...
(b"'""
)( =6)
Cc: Chris Helm >

--------
Subject : FDA Request
(b) (6)
Ors Messonnier, Khabbaz, and Fauci,
The Center for Devices and Radiological Health at the FDA suggested that we reach out to COVID-19 EUA
develo ers to (b) (4~
(b) (4)
NIH-001689
(b) (4)
Respectfu lly,
Jeff
Jeff Fischer
President
Longhorn Vaccines and Diagnostics LLC
2 Bethesda Metro Center Suite 910
Bethesda, MD 20814
(b)(6)
NIH-001690
Sent : Fri, 21 Feb 202010:47:53 +0000
Subject : FW: Fwd:
Attac hment s: Notes for NIH.docx
Pleasehandle.
From : RICK SAWAYA (b)(6)>

To: Fauci, Anthony (NIH/NIAID) [E) .------ -,,-
Cb--.
H= >; Cassetti, Cristina (NIH/NIAID) [E)
(b)(6)
Subject : Fwd:
2202020
Dr. Fauci:
This is Dr. Rick Sawaya :
Dr. Tom Betz is (b)(6) and his training is more in line with yours than mine.
He submitted this mini-endorsement to you for me and my work. He has seen most of my works
and the NIH data protocol from 2016-2017.
I think his background gives credibility to my ideas and lends a public health opinion which I did not have
until
calling him .
Hope you enjoy th is.

I have treated cancers, herpes, acne easily with this stuff and honestly and confidentially
it will do anything but your income tax.
Thanks, Rick Sawaya M.D.
(b)(6)
call between 10am and 10pm EST,
---------- Forwarded message ---------

From: Tom Betz (b)(6)
Date: Thu, Feb 20, 2020 at 10:32 PM
Subject : Re:
(b)(6)
To: RICKSAWAYA
----------
Rick,
I am attaching suggested notes for NIH. They may t hink we're both crazy but I imagine you have already
been down that road and I'm interested to see what happens . Hang in there,
NIH-001698
Tom
On Tue, Feb 18, 2020 at 2 :01 PM RICK SAWAYA

---------- (b)(6 b wrote:
THIS HAS THE CELL WITH LEARS SIGNATURE ABOVE IT

AND A CYSTEINE RANDOM DIAGRAM
NIH-001699
Sent : Fri, 21 Feb 2020 02:42:07 +0000
To: NIAIDODAM
Subject : FW: CROICOVID 19 Session; Tuesday March 10 lunch
Impo rt ance: High
Let us discuss.

To: Fauci, Anthony (NIH/NIAID) [El ------~~ (b)(6)>
Cc: Conrad, Patricia (NIH/NIA ID) [El!. =======~ (b"""
)('="
6)>
Subject : RE: CROICOVID 19 Session; Tuesday March 10 lunch
Import ance: High
Dear Dr Fauci:
We've had a lot of discussion around our COVID-19 session today. An idea that came up was possibly
having you do something remotely. Either a live feed in from your office at approximately 1:05 PM to
1:20 PM EDTon Tuesday, March 10 if you have that time available, or have you send in a video recorded
presentation a day or 2 before that we can show at the session. Having some way to commun icat e the
high priority NIH/NIAID has on developing a vaccine and treatment would help bring the content
togethe r.
We know this is likely not possible, with the very short notice and your even more tremendously busy
schedule around all of this. But it 's worth the ask.
Please let me know if you think either of these is possible. And Patty, sorry for butchering your email
address earlier .
Best,
Donna
Donna M. Jacobsen
Executice Manager, CROI
415-544-9400
NIH-001700
https://www .iasusa.org
About IAS- USA : Established in 1992, the IAS-U SA is a not-for-prof it, professional educat io n
organizat ion . The mission of the IAS-USA is to improve the prevention , treatme nt, care , and qua lity of life
for people with or at risk of HIV , hepatitis C virus , or other vira l infections through high-quality , relevant,
balanced , and needs-orien ted education and information for practitioners who are active ly involved in
medica l care . The organ ization's educational activities are particularly intended to bridge clinical research
and patient care.
Confid entiality Notice : This e-mail and its attachmen ts may contain priv ileged and confidentia l
the intended recipient, or the employee or agent respons ible for deliveri ng this message to the intended
recipien ts, you are hereby notified that any review , dissemination , distribution , printing, or copying of this
e-mail message and/or any attach ments is strict ly prohibited . If you have received this transmissio n in
error, pleas e notify the sende r immediate ly and permanently delete this e-mail and any attachments.
From : Fauci, Anthony (NIH/N IAID) [E]

----------
(b)(6)]
To : Donna Jacobsen <djacobsen@iasusa .org >

Cc: (b)(6) 'Elaine J. Abrams, M D (b)(6)
Sharon Hillier PhD (b)(6)>; Hoxie, James
_..,,...===~~;--::-------::-----:---:======~ ~
< (b)(6); Benson, Conn ie (b)(6) >; Kevin Bowe n
<kbowen@ iasusa.org>
Subject : RE: CROI COVID 19 Session; Tuesday M arch 10 lunch
Donna:
Thanks for t he note . Unfortunat ely, I need t o be in Washingt on, DC on March
10, and so I will regrett ably have to decline your kind invit ation . Thank you f or
thin king of me.
Best rega rds,
Tony
Director
Phone : (b)(6)
NIH-00170 1
FAX : (301 496-4409
E-mail : (b)(6)

To: Fauci, Anthony (NIH/NIAID) [E]------= (b)
'""(=
6)>
---:-:-----:-:-::-.::::=t.....------------'="'""=
Cc: (b)(6)'ElaineJ. Abrams, MD (b)(6)
Sharon Hillier PhD Cb)(6) >; Hoxie, James
--------======~~-:-----:---:-.:======~ ~
-------------
<kbowen@iasusa.org>
(b)(6); Benson, Connie
--------- (b)(6); Kevin Bowen
Subject : RE:CROICOVID19 Session;Tuesday March 10 lunch
Dear Dr Fauci:
As I mentioned on the phone, we just today decided that we will have a special session on COVID19 at
CROI. It will be on Tuesday, March 10, during the lunch break; the init ial general structure will be a 10-
to 15- minute overview (CDC),a 25-min talk by Ralph Barac (UNC) about the viro logy of coronavi ruses,
and a 10- to 15-minute summary on what NIAID/NIH is doing and planning. We thought that this being
one of the first large medical conferences in infectious diseases this year, that we address COVID19 at
CROI
We know that this is terribly last minute, but the CROI Chairs and Foundation are hoping you are free to
give the NIAID/NIH update. CROIis in Boston, March 8 to 11.
If you think you would be able to do this, we will send a more formal communication with details and
work with Patty on the specifics. Thank you so much Dr Fauci; we hope you will be able to join us.
Best,
Donna
Donna M. Jacobsen
415-544-9400
https://www .iasusa.org
NIH-001702
About IAS-USA: Established in 1992, the IAS-USA is a not-for-profit , professional education
organization . The mission of the IAS-USA is to improve the prevent ion, treatment , care , and quality of life
for people with or at risk of HIV, hepatitis C virus , or other viral infections through high-quality, relevant,
balanced , and needs-oriented education and information for practitioners who are actively involved in
medical care. The organization's educational activities are particularly intended to bridge clinical research
and patient care.
Confidentiality Notice: This e-mail and its attachments may contain privileged and confidentia l
the intended recipient, or the employee or agent responsible for delivering this message to the intended
recipients, you are hereby notified that any review, dissemination , distribution , printing, or copying of this
e-mail message and/or any attachments is strict ly prohibited . If you have received this transm ission in
error, please notify the sender immediately and permanently delete this e-mail and any attachments.
NIH-001703
Sent : Fri, 21 Feb 2020 01:47:03 +0000
To: McNeil Jr, Dona ld G
Subject : RE: question re the Wash Post story
Donald:
You know that I always answer your calls and e-mails, but this one I want to stay away from.
Sorry.
Best,
Tony
From : McNei l Jr, Donald G <mcneil@nytimes.com>

Subject : Re: question re the Wash Post story
Now that I've had a chance to read the whole story -- after editors finished whirl ing --1 see it also
contains these grafs:
Are they accurate?
Thanks
During one call, the CDC's principal deputy direc tor , Anne Schuchat, argued agains t
taking the infected Americans on the plane, according to two participants. She noted the
U.S. government had already told passengers they would not be evacuated with anyone
who was infected or showed symptoms. She was also concerned about infection control.
Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases, who
was also on the calls, recalled saying her points were valid and should be considered.
But Robert Kadlec, assistant secretary for preparedness and response for the
Department of Health and Human Services and a member of the coronavirus task force,
pushed back: Officials had already prepared th e plane to handle passengers who might
develop symptoms on the Jong flight, he argued. The two Boeing 74 7s had 18 seats
cordoned off with 10-foot-high plastic on all four sides. Infectious disease doctors would
also be onboard .
On Thu, Feb 20, 2020 at 4:24 PM McNeil Jr, Donald G <mcneil @nyt imes.com> wrote:
Hi, Tony:
The Washington Post has just put up a story saying that the 14 infected passengers on the buses
containing 238 American passengers from th e Diamond Princess were flown home AGAINST the
CDC's advice . And that the States Department overru led the CDC on this.
Can you confirm whether that's true?
NIH-001704
Thanks ...
Donald
Story contains these cruc ial grafs:
In Washington, where it was still Sunday afternoon, a fierce debate

broke out: The State Department and a top Trump administration
health official wanted to forge ahead. The infected passengers had no
symptoms and could be segregated on the plane in a plastic-lined
enclosure. But officials at the Centers for Disease Control and
Prevention disagreed, contending they could still spread the virus .
The CDC believed the 14 should not be flown back with uninfected
passengers.
"It was like the worst nightmare," said a senior U.S. official involved
in the decision, speaking on the condition of anonymity to describe
private conversations. "Quite frankly, the alternative could have
been pulling grandma out in the pouring rain, and that would have
been bad, too."
Donald G. McNeil Jr.

Science Correspon dent
(i;~t:Xt\u Uork{;imts
Tel: +l 212 556 1142

mcneil@nytim es.com
Articles: https://www .nytime s.com/by /donald-g-mc neil-jr
NIH-001705
Sent : Fri, 21 Feb 2020 00:13:55 +0000
To : Richard Al len Johnson
Subject : RE: 02.20.2020 Thursday
Dick:
Tha nks for the note. Always good to hear from you.
Best,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b) (6)
From: Richard Allen Johnson

----------
-------=-c-c=
(b)(6)

Subject : 02 .20.2020 Thursday -------- (b)( >; Sandra Goldste in
---------
(b)(6)
Hi, Tony,
------------- (b) (6) this week.
We watched a life size ASF as you discussed and reassured us about Covid-19. You are simply the best.
Were you ru nning for president, I am sure t hat you would win the yote .
Don't forget our lunch in Boston .
Best,
Dick
NIH-001706
Sent : Thu, 20 Feb 2020 23:48:29 +0000
Subject: FW: Urgent- Phone Interview Request on Coronavirus
Done!
Directo r
Phone : (b) (6)
FAX : (301 496-4409
E-mail : (b)(6)
have received this e -mail i n error please inform the sender and delete it from your mailbox or any
From: Qi Zhang <qizhang@caixin.com>

------~~ =
--------- (b)(6)>
Subject : Urgent- Phone Interview Request on Coronavirus
Dear Dr. Fauci,
Good afternoon . I am Olivia Zhang with Caixin Media, which is the front-liner of the Coronavirus
reporting in China. We spoke at the very beginning of the virus and I wanted to talk to you regarding the
latest situation, especially from test, treatment point of view. I also left you a voice message. Feel free to
call me via (b) ( whenever you're free .
Best,
Olivia
Qi ZHANG {Olivia)
U.S. Correspondent
Caixin Media Company Limited
NIH-001707
Email: qizhang@caixin.com
Mobile:-+- (b)(6)
Twitter: @zhang_qiii
www .caixin.com I caixingloba l.com
NIH-001708
Sent: Thu, 20 Feb 2020 23:28:04 +0000
To: Achenbach, Joel
Subject: RE: quick question: when does an epidemic become a "pandemic" officially?
It is impossible to predict at this point if the current outbreak will progress to a

true pandemic. The future of this outbreak and whether it will progress to a
pandem ic will be determined by two factors: 1) the degree to which China
controls infect ions in China, which will ultimately impact how many infect io ns
leak out to other countries in the world. 2) The success or not of other countries
that have received travel-related cases from China in preventing the development
of sustained transmission of infections in their own country. If these other
countries are successful in containing the transmissions, then a pandemic will be
avoided. If a large number of countries are unsuccessful in preventing sustained
multi -generation transmissions , then we could witness the next pandemic .
Anthony S. Fauc i, MD
Dire cto r
Building 31 , Room 7A -03
Phone : (b)(6)
FAX: (301 496-4409
E-mail Cb)(6)
information . It should not be used by anyone who is not the or igina l intended recipient. If you
From:Achenbach, Joel <Joel.Achenbach@washpost.com>

------~~ (b)( >
Subject : RE: quick question: when does an epidemic become a "pandemic" officially?
Oh....and...the big question: How likely is it that covid-19 will become a pandemic? Would love an on-
the-record assessment. Thanks...joel

--------
(b)(6)>
To: Achenbach, Joel <Joel.Achenbach@washpost.com>

Subject : RE: quick question: when does an epidemic become a "pandemic" officially?
NIH-001709
ICAUTION: EXTERNALSENDER
Joel:
There are many iteration s of t he definition of a "pandemic" . However , one
that I use that is simple and under standable is as follows: An outbreak of a
serious infectious disease with substantial global health consequences (usually
one that has never before been experienced by the human populat ion) that is
transmitted readily from person to person and where there is sustained
transmission (i.e . mu ltiple generations of person to person to person) in mu ltiple
countries and regions of the world. In this regard, the coronavirus outbreak in
China is an "epidemic" in China, but it is not yet a pandemic since there is not
"sustained" person to person transmission throughout the world. There are
infections in other countries (more than 25 countries), but these started as travel
relate d cases from China and although there are several human to human
infections in these other countries, these infections have not yet been
"sustained". If we start seeing sustained, multiple generations of transmissions
in many countries throughout the world, then the outbreak will have progressed
to fill the criteria of a true pandemic.
Best regards,
Tony
Director
Phone : (b)(6)
FAX : (301 496-4409
E-mail (b) (6)
The information in this e-mail and any of its atta chments is confidential and may contain sensitive
information . It should not be used by anyone who is not the origi nal intended recipient . If you
From: Achenbach, Joel <Joel.Achenbach@washpost .com >

Sent: Thu rsday, February 20, 2020 5:51 PM
NIH-001710
Subject : quick question: when does an epidemic become a " pandemic " officia lly?
Dear Tony Fauci:

Hi! Busy times . Hope you are well. Can you explain to me how we will know if and when covid -19 has
become pandemic, versus whatever you' d call the current situatio n? Just in general , what ' s the
defin ition of a pandemic?
Thank you ... best, Joel
(and thanks for calling me back last weekend , sorry I missed you )
NIH-001711
Sent: Thu, 20 Feb 2020 16:45:39 +0000
Subject: RE:Tony, I'm still working on th is, but need your react ion
Attachments : Gerson wi t h minor Fauci edits .docx
Mike:
Thanks for sending this. It looks good . I have copied it to a WORD document
and have made some minor suggested edits for your consideration.
Best regards ,
Tony
Director
Phone : (b) (6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Michael Gerson (b)(6)>

Sent: Thursda y, February 20, 2020 11:04 AM
Subject: Tony, I'm still working on this, but need your reaction
Meanwhile , on the other side of the earth, th ere have been 73,000
cases of coronavirus and more than 2000 deaths. This leaves American
hea lth experts hoping that the number of infections has been dramatically
underreported.
That is not a typo. If the current nu1nbers are close to accurate, it
indicates a coronavirus mortality rate upwards of 2 percent. The morality
rate for the seasonable flu is gen erally .1 percent. The mortality rate for
pandemic flu is .3 percent. The particularly deadly flu pandemic of 1918 -
NIH-001714
which took the lives of more than 100 million people around the world -
had a mortality rate of 1.8 to 2 percent.
So, if 2000 deaths is the numerator, scientists hope that the
denominator is actually much larger. And that is probable, given the
likelihood that there are many more people who have the infection but
don't know it, or are not showing symptoms.
The good news? The outbreak started in a single location and seems
largely contained there. There have been several hundred cases in more
than 25 countries outside of China. But the overwhelming majority have
been travel related. The containment measures of Singapore, Hong Kong
and Japan - which have the most cases - seem to have been successful. Of
the 15 American cases (before the arrival of the cruise ship passengers), 13
are travel related. The two others are spouses of people in that group. We
still have not seen widespread, sustained transmission from person to
person outside of China.
The Chinese reaction to the virus has shown the weaknesses and
advantages of authoritarianism. The immediate response of a system built
on fear is to a problem like this one is denial and deception. No one wants
to carry bad news. So local Chinese officials spent the first week of the
outbreak - as the disease was spreading under the radar - insisting that the
transmission of the virus was all animal to human.
But only in a society like China could you have the effective lockdown
of 50 million people, including the entire city of Wuhan, to slow the spread
of the disease. Public health officials in most places - who are required to
balance health needs with civil liberties - would not even consider such a
measure. Yet it appears to be working.
The danger? "All that is needed is for a few countries in the
developing world that can't contain the coronavirus," Tony Fauci told me.
"This could be the second wave of the pandemic."
Pandemic diseases tend to attack the weakest links - the most
vulnerable health systems - in the global chain. If there is sustained
transmission in those places , says Fauci , "even countries with best practices
will suffer." Countries in Africa are of particular concern. There are millions
of Chinese in Africa, and many Africans study in China. Countries such as
Ethiopia, Senegal and South Africa seem to be doing a good job at testing
random samples for coronavirus in key cities. But Liberia? Guinea? Sierra
Leone?
Seldom has there been a stronger argument for American global
engagement to strengthen African health systems, which constitute part of
own immune system against pandemics. Seldom has there been a better
NIH-001715
argument to abandon "America First" posturing and to recognize that our
own fate is closely tied to the fate of other nations.
Much about the future course of the disease depends on the answer to
a scientific question: Is someone who has the virus but lacks symptoms - or
has symptoms so mild they hardly notice - capable of transmitting the
virus to others? "It looks like the answer is yes," says Fauci. Which would
make the virus far harder to control.
"We may find that the virus is highly transmissible, but less lethal
than we thought in the beginning," Fauci told me . In this case, the danger
would be similar to a particularly bad influenza. And the outbreaks could be
seasonal, like the flu as well. "I would not be surprised if that happened,"
Fauci concluded.
NIH-001716
Sent: Thu, 20 Feb 2020 15:15:05 +0000
Subject: FW: inquiry/suggestion re Corona virus->
Please handle.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Alan DiCara Cb)(6)

-----~~
To: Fauci, Anthony (NIH/NIAID) [E) (b)(6)
Cc: NIAID Ocpostoffice (NIH/NIAID } <OCPOSTOFFICE@niaid.nih.gov>
Subject: inqu iry/s uggestion re Corona virus->
2.19.2020
Dear Dr Fauci,
Thanks so much for being who you are and for dedicating your
life to protecting all of us. I write because I saw your interview
on PBS tonight and had a question pertaining to denominators
and numerators. Please know that I profess absolutely no
expertise in areas pertaining to biology nor medicine nor disease
and while I understood and agree with your estimation that the
fatality rate of the Corona virus to date may be somewhat
inflated of the number of cases is understated, I have a related
NIH-001717
question for you regarding info I was able to find at this
site https://www .worldometers.info/coronav irus/
Regarding data this site reports, among many things, and as
one scrolls down, that the 'number of active cases' reported
today is 57,228 and the number of these that are 'serious or
critical' is 12,064. In a worst case scenario, and taking the
12,064 as the numerator and dividing it by a denominator of
57,228, we get 21 .08, or about 21 %, much higher that the 1%
based on total deaths over total cases so far. Of course this is not
fair but my question is this: can we know better how many of
the patients (cases) who are 'serious or critical' and still being
treated will recover?
Thanks much for any reply-
Alan DiCara, Winsted, CT
NIH-001718
Sent: Thu, 20 Feb 2020 12:39:25 +0000
To : David Katz
Subject: RE: CoronaVirus Epidemic -- a Thought
David:
Thanks for the note. I hope that all is well with you. Although allogeneic/semi-
allogeneic blood transfus io ns could be an interesting approach to serious COVID-
19 disease, there are a number of existing drugs such as remde sivir (nucleotide
analogue) and Kaletra (protease inhib itor) that have some pre-clinical activity
against the virus and these are now being tested in randomized clinical trials.
Best regards,
Tony
Director
Phone : (b)(6)
FAX : (301 496-4409
E-mail : (b)(6)
From: David Katz Cb)(6)

-----~~
-------
Subject: CoronaVirus Epidem ic -- a Though t
(b)(6)>
Dear Tony,
It has been some time since we last spoke, but this current
catastrophe has provoked my thinking about possible
therapeutic interventions that could be immediately
employed -- in advance of therapies/vaccines that will take
NIH-001723
many months to create. And I need to share those
thoughts with you.
My suggestion is to treat actively-infected, and acutely ill,

patients (under carefully controlled procedures) with
allogeneic/ semi-allogeneic blood transfusions . The
resulting GVHD response should theoretically combat, and
eradicate the viral infection.
I look forward to your thoughts on this suggestion.
With best wishes to you and your family,
David
NIH-001724
Sent : Thu, 20 Feb 2020 10:51:23 +0000
Cc: Mars ton, Hilary (N IH/NIAID) [El
Subject: FW: GPMB: MESSAGEON BEHALFOF THE CO-CHAIRS: PROPOSEDBOARD
TELECONFERENCE
TODAY
FYI
From: Amelie RIOUX (b)(6)>

----------
To: As Sy (b)(6)>; Gro Harlem Brundtland (b) (6); 'Dzau Victor'
------- (b)(6); Chris Elias

Anthony (NIH/NIAID) [El (b)(6); Fore Henrietta
(b)(6); Fauci,
(b)(6l:>; Gao Fu
(b)( ; Gashumba Diane (b)(6); Ilona Kiekbusch
=======:::'-= (b)(6); Suzuki Yasuhiro (b)(6)
======== ~=
-.-:------======-- CbH6J
; Vega Morales Jeanette (b)(6); VijayRaghavan
Krishna swam y (bT(6h ; Skvortsova Veronika (b)(
Cc: (b)(6)Tore Goda! (b)( ; Godal, Tore (b)(6)
Subject : GPMB: MESSAGEON BEHALFOF THE CO-CHAIRS: PROPOSED BOARD TELECONFERENCE TODAY
Import ance: High
MESSAGEON BEHALFOF THE GPMB CO-CHAIRSDR BRUNDTLAND AND MR SY
Dear Board Members,
We would like to hold a teleconference of the Board today, 20 February at 13:00 Geneva time.
The agenda for the call would be as follows:
• Short update and stock taking on the coronavirus outbreak ;

• Functioning of the Secretariat and improving effect iveness of the Board ;
• Way forward
Please note that this call wou ld be a closed discussion, for Board members only.
We would appreciate if you could confirm your partic ipation to Amelie Rioux (at
We will share with you shortly the call-in details .

-------- (b)(6)
Thank you for your support and continued engagement . We look forward to the call.
With kind regards ,
Gro and As
NIH-001725
Sent : Thu, 20 Feb 2020 03:43:40 +0000
To: Sharon Rockefeller
Subject : RE:This evening's broadcast
Thanks, Sharon. It is always a pleasure to be on the PBS NewsHour. They are high on honesty
and integrity.
Best regards,
Tony
From:Sharon Rockefeller <srockefeller@we ta.org>

Subject : This evening's broadcast
Dear Dr. Fauci,
Thank you, once again, for appearing on the PBS News Hour and for treating so many Coronavirus
patients. Your gift of calm and clear explanations to normal people is unparalleled. Please do not
exhaust yourself as you help so many others. (b) (6).
Very sincerely ,
Sharon
Sent from my iPhone
NIH-001729
Sent: Thu, 20 Feb 2020 00:54:10 +0000
To : Crawford, Chase (NIH/NIAID) [El
Cc: Billet, Courtney (NIH/NIAID) [El;Folke rs, Greg (NIH/NIAID) [El;Conrad, Patricia
(NIH/NIAID) [El;Haskins, Melinda (NIH/NIAID) [E];Selgrade, Sara (NIH/NIAID) [El
Subject: RE: Requesting your assistance: Draft NIAID Insert for Upcoming Coronavirus
Hearings
Attachments: Draft NIAID insert for COVID-19 hearings_to ASF - with Fauci tracked edits.docx
Here it is. Thanks.
Director
Phone . (b)(6)
FAX : (301 496-4409
E-mail (b) (6)
From: Crawford , Chase (NIH/NIAID) [El (b)(6)

---------
------ ~=
(b)(6)
Cc: Billet, Courtney (NIH/N IAID) [El (b)(6)>; Folkers, Greg (NIH/NIAID) [E]
(b)(6)>; Conrad, Patricia (NIH/NIAID) [El (b)( ; Haskins, Me linda
(NIH/NIAID) [El (b)(6)>; Selgrade, Sara (NIH/NIAID) [El (b)(6)>
Subject: Requesting your assistance: Draft NIAID Insert for Upcoming Coronavirus Hearings
Dr. Fauci:
In preparation for the upcoming COVID-19 hearings of the House Committee on

Energy and Commerce Health Subcommittee and the Senate Committee on Health,
Education, Labor and Pensions, we have drafted the attached N1AID insert for
inclusion in the combined HHS statement for the record. The Department plans to
use the same combined statement for both the House and Senate hearings.
NIH-001735
The attached draft ha s been reviewed by the Divisions and Drs. Harper, Eisinger,
Lerner, and Marston , as well as Courtney Billet, Martin Johnson, Greg Folkers,
and Laurie Doepel.
The Deparb.nen t has asked to receive your statement by COB tomorrow, Feb .
20th .
Cha se
Chase Crawford, D.V.M., M.S.
Public Health Analyst
Legislat ive Affairs and Correspondence Ma nagement Branch
Office of Com municat ions and Government Relations
NIAID/NIH/DHHS
Bldg. 31, Room 7A17, MSC2520
(b)(6J
Disclaim er:
The information in this e-mail and ony of its attachments is confidential and may contain sensitive information. It should not be
used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and
delete it from your mailbox or any other storage devices. National Institute of Allergy and Infec tious Diseases shall not accept
liability for any statements made that are sender 's own and not expressly made on behalf of the NIAID by one of its
representatives.
NIH-001736
Sent : Wed, 19 Feb 2020 23:03:23 +0000
Subject : FW: BioCentury coverage of mAbs to treat COVID-19
Please han dle.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Karen Tkach Tuzman <ktkach@biocentury .com>

To: Fauci, Anthony {NIH/NIAID) [El -------=-:--:= (b)(6)
Cc: Conrad, Patricia (NIH/NIA ID) [E] (b)(6)
Subject: BioCentury coverage of mAbs to treat COVID-19
Import ance: High
Dear Dr. Fauci,
I hope all is well. BioCentury is doing a roundup of companies and institutions developing antibodies
against the SARS-CoV-2 virus to treat patients with COVID-19. Since you told my colleague Steve Usdin
NIAID is developing its own mAbs against the virus, we'd like to include informat ion about that program
in our roundup .
Would you or one of your colleagues be able to answer the following questions? Any information you
could share by 5 PM Pacific Time on Thursday, Feb. 20 would be greatly appreciated .
1. Are your mAb candidates being developed against specific targets on SARS-CoV
-2? If so, what
are those targets?
2. What platforms or processes are you using to identify mAb candidates?
3. Do you have multiple mAb programs against SARS-CoV-2proceeding in parallel, and if so, how
are they distinguished?
NIH-001737
4. What is that status of each of your mAb programs? For example, have you nominated any lead
candidates, are you awaiting patient samples, etc.?
5. Do you have any metrics on lead candidates available yet, such as neutra lization titers? If so,
what are they?
All the best,

Karen
Karen Tkach Tuzman, Ph.D.

Head, Discovery & Preclinical Development
Associate Editor, BioCentury Inc.
650-595-5333 x 144 (office )
www .biocentu ry.com
Notice: This communication (including any attachments) constitutes an electronic communication within
the meaning of the Electronic Communications Privacy Act, 18 USC2510, and its disclosure is strict ly
limited to the recipient(s) intended by the sender of this message. This communication (including any
attachments) contains proprietary information, is protected under U.S. and foreign copyright and other
intellectual property law, and may contain confidential material for the sole use of the intended
recipient. Any unauthorized review, use, disclosure, dissemination, copying or distribution of this
communication (including any attachments), or any of their respective contents, is strictly prohibited. If
you are not the intended recipient, please contact the sender by return email and destroy all copies of
the original message.
NIH-001738
Sent: Wed, 19 Feb 2020 20:27:04 +0000
Cc: Greg Folkers (b) (6)
Subject : FW: Invita ti on to Speak
Attachments: lnvitation_Dr. Anthony Fauci.pdf
Patty/Greg:
Let us discuss.
ASF
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail · (b)(6)
From : Crow, Hilary <HCrow@USChamber.com>

Sent: Wed nesday, February 19, 2020 12 :35 PM
Subject : Invitation to Speak -------- (b) (6)>
Dear Dr. Fauci,
I'm writing to share the attached invitation with you to speak at the U.S. Chamber Foundation's program
on March 10 on the future of medicine.
Our audience of CEOs, market leaders, and opinion leaders would be thr illed to learn more about your
perspective on the future of medicine, current issues like the Coronavirus , and futu re challenges in
health and med icine.
Please let me know if you have any questions. I'm happy to schedule a quick call to provide more detail
over the phone with you o r someone on your team.
I hope you will be able to join us.
NIH-001739
Best,
Hilary
Hilary Crow
Executive Director, Programs
U.S. Chamber of Commerce Foundation
1615 H Street, NW I Washington, DC I 20062-2000
Office: 202.463.5710
----
Mobile: (b)(
G U.S.Chamber
-~'&
ofCommerce
Foundation
www .uschamberfoun dation .org
NIH-001740
Sent: Wed, 19 Feb 2020 16:51:27 +0000
Cc: Conrad, Patricia (NIH/NIAID) [El;Folkers, Greg (NIH/NIAID) [El;Handley, Gray
(NIH/NIAID) [El
Subject: RE: Invitat ion to the Consultation on Financing Coronavirus Disease 2019
(COVID-19) Vaccine Development I Thursday, February 20, 2020 I 9:30am to 1:30pm I World Bank
Headquarters, Washington DC
If they accept two people, you should go with Gray. Obviously, you should make
no commitments and when asked about policy issues, say that you will convey to
me and we will get back to them.
Directo r
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(
information . It should not be used by anyone w ho is not the original intended recipient. If you
From : Marston, Hilary (NIH/NIAID) [E] (b)(6)>

To : Fauci, Anthony (NIH/NIAID) [El (b)(6)
Cc: Conrad, Patricia (NIH/NIAID) [El (b)( ; Folkers, Greg (NIH/NIAID) [El
(b)(6); Handley, Gray (NIH/NIAID) [E)
--------- (bH
Subject : Re: Invitation to the Consultation on Financing Coronavirus Disease 2019 (COVID-19) Vaccine
Development I Thursday, February 20, 2020 I 9:30am to 1:30pm I World Bank Headquarters,
Washington DC
Have you had a chance to discuss this world bank conference? You, Cliff and Libby received invites. As
Gray has mentioned, this is a pledging conference, so we will need to be prepared to address funding
(the person that attends wou ld need to be in sync with you on that).
Obviously Cliff is on travel. Who would you like to have at the conference, if anyone?
-h ilary
NIH-001741
From: Anthony Fauci (b)(6)>
Date: Friday, February 14, 2020 at 9:25 PM
To: NIAID AM <NIAIDODAM@niaid .nih.gov >
Subject: FW: Invitation to the Consultation on Financing Coronavirus Disease 2019 (COVID-19)
Vaccine Development I Thu rsday, Februa ry 20, 2020 I 9:30am to 1:30pm I World Bank
Headquarters, Washington DC
Let us discuss.
From : Feng Zhao <fzhao@wor ldbank.org >

To: Fauci, Anthony (NIH/NIAID) [E]------- ~=
Cc:
--------- (b)(6)
(b)(6); Mu kesh Chawla <mchawla@worldbank .org>; Rocio Schmunis
<rschmunis@worldbank .org>; Adrienne Kate Mcmanus <amcmanus@worldbank .o rg>; Gabrielle Lynn
Williams <gw ill iams1@wor ldbank.org >; WB Health Events <wbhea lthevents@worldban k.org>;
Muhammad Ali Pate <mpate@worldba nk.org>
Subject : Invitation to the Consultation on Financing Coronavirus Disease 2019 (COVID-19) Vaccine
Development I Thursday, February 20, 2020 I 9:30am to 1:30pm I World Bank Headquarters,
Washington DC
Dear Dr. Fauci,
On behalf of the World Bank health team, in coordination with the Coalition for Epidemic Preparedness
Innovations (CEPI),it is our pleasure to invite you to a half-day consultation on Financing Coronavirus
Disease 2019 (COVID -19} Vaccine Development . The meeting is set to take place on Thursday, February
20, 2020 from 9:30am to 1:30pm at the World Bank Offices in Washington DC (located at 1818 H St
NW) on floor C2, conference room MC C2-125.
As you know, the novel Coronavirus outbreak, which started in Wuhan, China, is evolving rapidly. As of
today, the number of confirmed cases has increased significantly to over 60,000 and the virus has
reached 25 countries. The outbreak, a Public Health Emergency of International Concern (PHEIC), poses
a threat to countries worldwide, especially those with weak health systems and low levels of pandemic
preparedness.
It is of urgent importance that we move quickly to finance the development of the appropriate
countermeasures for a disease that risks becoming endemic across the globe. Two critical issues are
necessary to address: i) immediate financing for the development and scale-up of a diversified portfolio
of vaccines, and ii) financing the manufacturing and procurement of vaccine for global distribution.
To enhance our discussions we are working on a background paper which we will share along with an
agenda at the earliest. Recognizing the short notice, we will provide remote connection details for those
unable to travel for the meeting. A working lunch will also be provided.
We hope that you will be able to participate in this important meeting. Kindly confi rm your participation
to Ms. Gabrielle Williams, Health, Nutrition and Population Global Practice, World Bank
(wbheal t hevents@wo rl dbank.org ). Please do not hesitate to reach out with any questions .
NIH-001742
Looking forward to your posit ive response.
Best regards,
Feng Zhao
NIH-001743
Sent : Wed, 19 Feb 2020 16:16:33 +0000
Subject : FW: Potentia l Speaking Engagement: Winter 2021
Please RSVP sor ry no. Too busy.
Director
Phone : (b)(6)
FAX: (301) 496-4409
E-mail : (b)(6)
From: Andrew Turley Cb)(6)

Sent: Wed nesday, February 19, 2020 10:26 AM
To: Fauci, Anthony (NIH/NIAID) [El (b) (6J>
,...:__:...._
_ _:__.:....:..!=::=~~---- ..
Cc : Andrew Turl ey (b)(6)>
Subject : Potential Speaking Engagement: Winter 2021
Dear Dr Fauci
I know th ings must be impossibly busy right now with the current coronavirus issues but w anted to
touch base to see whether you may be interested in a speaking engagement next Spring as part of our
(b)(6)
A bit about me : I am a (b)(6)Air Force Major General and retired SESfrom the Department of Defense.
(b)(6)
is an associate professor emeritus from the School of Medicine and Healt h
Sciences at the George Washington University . We are both longtime adm irers.
_____
.. consists of people drawn from a wide variety of backgrounds, including doctors, lawyers
(b)(6)
and many from the senior tiers of the finance and corpo rate worlds up to and including former CEOs and
other executives (and even a few retired senior government folks like me). It is an active, well-read and
learned community with a keen interest in current events . As an example, we have a very active Foreign
Policy Association chapter that always draws folks from across the spectrum of political and policy
perspectives for interesting and well -info rmed discussions.
NIH-001744
Ou (b)( speaker series consists of presentations on a vast array of subjects, from literature and art
to current events and public policy issues. Typically held on Tuesdays nights from December t hrough
April, these sessions consist of a presentation of an hour or so followed by Q&A and general discussion.
We always draw standing room only crowds.
Recent and upcoming speakers have included:

(b)(6)
The recent coronavirus outbreak has captured the interest of the nation and the world. Our folks would
be extremely interested in how organizations such as NIH respond and address these incredible
challenges. A presentation by you about your work on t hese issues, from your groundbreaking work on
AIDS onward or any other topic of your choosing, would be absolutely the height of our season.
We pay transportation, lodging, an honorarium, and could even arrange for a round of golf at one of our
outstanding golf courses! (Of equal importance is that we can offer you a brief respite from the cold of
winter.). There are direct flights from Washington DC to West Palm Beach. We have openings in
January, February and March 2021.
We wou ld be deeply appreciat ive of your favorable consideration. Please feel free to contact me if I can
answer any questions
F. ANDREWTURLEY
(b)(6)
CELL:
HOM E:
NIH-001745
Sent: Wed, 19 Feb 2020 14 :42:50 +0000
To: Greg Folkers (b)(6)
Subject: FW: Clip of Or. Fauci on NPR
Good interview on NPR. Possible for Director's Page.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Lindsey Beall <lbeall@scgcorp.com>

To: Deatrick, Elizabeth (NIH/NIA ID) [C] ---------=- (b.,..
)(= >; Pekoe, Ken (NIH/NIAID) [El
(b)( Conrad, Patricia (NIH/NIAID) [El (b)( ; Fauci, Anthony
":"
(N
""'."'
1"."".
H"':"
/N-:-1""'."'
A~ID-:-)-:-
[E~l ====----~ (b"""
)("=",>; Ooepel, Laurie (NIH/NIAID ) [El
Fo Iker s, Greg (NIH/NIAID) [El ---------
(b)( ; Hoffman, Hillary (NIH/NIAID) [El
(b)(6);
(b)(6); Oplinger, Anne (NIH/NIAID) [El (b)(6); Rancourt, Anne

":':
(N"".".'
l'."':'
H/7N .'"."."'
IA
'."".'
l':".
D):--:
[~E):-===:::::.:._:,__,:;:~ (b..,...
H= ; Lavelle, Judith (NIH/NIAID) [El (b)( ;
Leitman, Laura (NIH/NIAID ) [E) (b)(6)•>; Stover, Kathy (NIH/NIAID) [El
-------- (b)( •>; Routh, Jennifer (NIH/NIAID) [El

<NI A100 DAM@ n iaid. n i h.gov>; Awwad, David (NIH/NIAID) [CJ
(b)( >; NIAID OD AM
(b)(6)
Cc: Osvald, Maria <mosvald@scgcorp.com>; Fabry, Cynthia (NIH/NIAID) [El
--------
Meyl in Correa <mcorrea@scgcorp.com>; Ma rcia Bache <mbache@scgcorp.com>; Megan Schartner
<MSchartner@scgcorp .com>
(b)(6);
Subject: Clip of Dr. Fauci on NPR
Good morning,
Below is a clip of Dr. Fa uci discussing corona virus on NPR's Morning Edition. This clip aired
earlier this morning .
NIH-001746
https://app.criticalment ion .com/a pp/#/clip/publ ic/ 1b0d a 123-0cd? -40 12-90a6-
b82d27c73 l 91 ?show sentiment=fa lse
Thanks,
Lindsey
From: Critical Mention <do-not -reply@crit icalment ion .com>

To: Lindsey Beall
Subject: Critical Ment ion: Megan Schartner has shared a Radio Ment ion w ith you
e critical • You're always on it w ith Critical Mention .

e e ment1on
Megan Schartner has shared a Radio

Mention with you!
From Megan Schartner (mschartner@scgcorp .com)
NIH-001747
No Program Name Available
Radio
Program Name No Program Name Available

Source WLRNFM
Market OMA: 16 Miami, FL
Time Feb 19, 2020 8:07 AM EST
Clip Length 07: 16.852
it's morning edition from n. p. r. news on david green in culver city califomia and a
militant in washington d. c. good morning in china the death toll from the corona virus
has hit two thousand world leaders in public health officials are trying to contain it but
new infections keep showing up earl golden for example he was a passenger on the
diamond princess that's the cruise ship where hundreds of people got the virus we
took an aquatic clues to also alone what went wrong who knew we were going and
the crew and beautiful omar here's how he ended up in omaha earl his wife jerry
were quarantined on that ship for twelve days in a felt fine the whole time but then
the gun on a flight back to the u. s. and earl started feeling sick or wind burke from
japan to this day about two hours into the flight they woke up with a high fever after
napping a little bit and the doctors on board confirmed the and then on the flight
landed he tested positive for the coronavirus he's recovering now in a bio contain
mean unit at the university of nebraska's medical center he's going to have to spend
fourteen days there and isolation well you know working %hesitation %hesitation
catering we've heard on a but one of the two days of the different doctors each day i
NIH-001748
didn't have a clue but got a little cough still you can you might want to debate left me
and i'm a little to keep but maybe also because of the jet lag in the travels and
everything else on top of it no it doesn't feel any different than you know recuperating
from a regular coal earl's wave jerry hasn't been diagnosed with the virus is she's
being monitored in a different part of the hospital but their case is a good example of
some things we know and some things we don't know about how this virus is
spreading so we have called doctor anthony fauci he's director of the national
institute of allergy and infectious diseases good morning sir good morning so earl
coleman was fine all those days on the ship then he gets on a plane and he gets a
fever what does that tell us about how this virus is spreading well the virus has the
ability to bind it to certain cells in your body particularly in your long so you can get
anything from miles a symptomatic illness to a cough and a fever to some people
about oh about twenty percent of the people come to the attention of medical than
physicians in health care providers can get serious pneumonias requiring intensive
care it sounds like this individual is on the %hesitation mild side of the illness
because as he said it doesn't feel much more than just a common cold and as a
matter of fact corona viruses in general prior to this all one of the causes of the
common cold okay so what does that tell us i mean bleary often looking at the cases
we're looking at a rising death toll which is tragic we look much less at the people like
early say you know my voice is raspy a had a fever had a cough the years a wide
range of stuff symptoms with this virus did do do we know why some people seem to
be doing okay and other people are getting hit really hard well whether a couple
things about that for the first thing is that any any kind of viral infection or any
pathogen infection there's always a wide range of responses in the sense almost like
a bill shaped curve some people get no sim is at all and we do have a symptomatic
corona virus infection with this particular episode and then there's the bulk of people
who get some sort of symptoms and then a small percentage of people do really
really very poorly now that relates to the ability of the body to handle the virus and
the one thing we know when it's not unique to this virus is that the elderly those with
underlying conditions like chronic heart disease lung disease diabetes obesity they
tend to get more complications much more than for example and otherwise healthy
individual and that's the reason why if you look at the death rate which is around two
percent for this disease at this time it is disproportionately high are among the elderly
and particularly those who have underlying conditions this is interesting question
carlin is wave terry presumably they work together the entire time they were
quarantined right and if he gets the virus she does not did she just get lucky do some
people have some sort of immune undefended don't it's a combination that's a good
question it's a combination of both there is no virus that has one hundred percent
attack rate even the most of infectious of all viruses like measles doesn't get a
hundred percent of of %hesitation vulnerable people but respiratory viruses
particularly things like influenza or the corona virus the attack rate is burying
percentage and it was if he was really likely that his wife i don't think she necessarily
had any on the line immune protection though that's possible the maybe some cross
reaction of immune protection with other %hesitation microbes that she came into
contact with but in most likely is as you suggest the luck of the draw okay interesting
NIH-001749
and they got to patching wondered if you could clear something up because we've
been hearing reports about so called super spread ours these you who spread the
virus to a very high a number of other people and it sounds like a scary thing but and
i just under is this a real phenomenon there that there are people who give the virus
to more people than most and why is that happening well it is certainly the
phenomenon of the super spreading israel we story with sars back in two thousand
two and two thousand in three and they're episodes already with this particular new
corona virus and it's a combination of two things it's an individual whose either at a
particular moment in time shedding a very large amount of virus which makes it
much easier to infect a group of people who are around him but you also see it
sometimes in the hospital setting when you have a number of health care providers
taking care of someone and that person is shedding a lot of virus so the short
answer to your question is there are super spread is and it's a real phenomenon
okay okay what we would you say at this moment is the most important or the most
pressing question about this virus that we don't have answers to yet well what we
don't know for sure we know that there are people who are infected will without
symptoms or very minimal symptoms they hardly notice they're infected well we don't
know is the extent to which people who have no symptoms are spreading it so we do
know that this can occur because we have anecdotal documented cases of people
who do not have symptoms who actually have infected someone usually a family
member but we don't know the extent to which this cars in the broad component of
this outbreak doctor anthony fauci the director of the national institute of allergy and
infectious diseases sir thanks for joining us it was a pleasure to be with you
Cntical Me111ionallows users to SP,archglobal TV Radio. Onlire News & Social from the United States Canada. and Eur:ipe watch
video, edit and share coverage rere1ve real-lime emai alerts. build reports, and analyze coverage through word clouds and graphs.
·Nant lO learn more about Crittcal Menton? Sign up ror a den,c ~ -
NIH-001750
NIH-001751
From: Fauci, Anthony (NIH/N IAID) [E)
Sent : Wed, 19 Feb 2020 13:03:08 +0000
To : bdoherty@mrns.org
Cc: lbaden@nejm.org;Fauci, Anthony (N IH/NIAID) [E];Redfield, Robert R.
(C0C/O D); Lane, Cliff (NIH/NIAI D) [E];Eisinger, Robert (NIH/NIA ID) [E]
Subject : RE: New England Journal of Medicine Editoria l
Attachment s: H. Cliffo rd Lane's ICMJE-2013 - For Coronavirus Editorial Fauci et al -.pdf
Briana:
Cliff Lane has separately sent his signe d CTA. I am attach ing his ICMJE Form. And so you should have all the
forms for all 3 authors: Fauci, Lane, and Redfield. Please let me know if you have any questions.
Best regards ,
Tony
Directo r
Nat iona l Ins titute of Allergy and Infectious Disease s
Bui lding 31, Room 7 A-03
Nat iona l Institutes of Health
Bethe sda , MD 20892 -2520
Phone: (b) (6)
FAX : (301) 496-4409
E-mail: (b)(6)
The information in this e-ma il and any of its attachments is confidential and may contain sensitive infom1ation . It
sho uld not be used by anyone who is not the orig ina l intended recip ient. If you have received this e-mai l in error
please inform the sender and delete it from your mai lbox or any other storage devices. The Nationa l Institu te of
Allergy and Infectious Diseases (NIAID ) shall not accept liability for any statements made that are the sender's own
and not express ly made on behalf of the NIAID by one of its repre sentatives.

From : Br iana Doherty <onbehalfof @ manu scriptcentral.com >
Sent : Monday , Febrnary 10, 2020 11:11 AM
To: Fauci , Anthony (NlH /NlAID) [E] ------~~ (b)( >
Cc: lbaden @nej m.org
Subject: New England Jou rnal of Med icine Edito rial
Dea r Dr. Fauci ,
I am delighted that you have agreed to write a signed editorial to accompany the article on the initial estima tes of
key transm ission parame ters associated with nCoV -2019 virus by Li et al.
The genera l purpose of the Journ al's editorials is to provi de the reader with an authoritative interpretation or
elaboration based on the substance of the article. Since thi s substance is usually not within the average reader's
special com petence, such readers wi ll particularly benefit if the editorial avo ids techn ical jargon, exp lains the
artic le's contribution to a field of knowledg e, and em phasizes, whene ver possible, its clinical implications. Th e
editorial commentary shoul d not be concerned excl usively with the article in question but rather should use the
artic le as a starting point for a more genera l di scussion .
Because editorials invo lve interpretation and opinion, you and your potentia l coauthor must be free of significant
relevant financia l associations (including equity interest, regular consultancies, or major research support) with a
company , or wi th a competi ng company , that stands to gain from the use of a product discus sed in the editorial.
Please contact me immediately if you are conside ring a coauthor , sol can ensure that your candidate meets our
NIH-001756
criteria. Additional information about disclosure of financial and other associations appe ars below this letter.
Please bear in mind that your editorial represents your (and any coauthor's) personal opi nion. The Journal does not
include statements of grant or other support or acknowledgments with editorials.
Journal policy dictates that we must have on file a signed Copyright Transfer and Authorship Agreement from each
author before a manu script can be accepted. Therefore, the enclosed form sho uld be signed by all authors and faxed
to (781) 207-6529.
Your editor ial is due at the Journa l on Monday, February 17, at the very latest if the deadlin e imposed by our
p1inting schedule is to be met. If the editorial is to include a figure, please submi t the figure at least one week before
the due date for the editorial itself.
*** Additional information about preparing and submitting your editorial is given below; please read it carefully.
***
The editors must reserve the right to edit (or even reject) your editorial, but whether we use it or not, the Journal
currently offers a modest stipend of $300 .
Thanks again for agreeing to write this editorial for the Journal. l look forward to receiving it.
Sincerely yours,
Lindsey R. Baden, M.D.

Deputy Editor
New Eng land Journal of Medicine

10 Shattuck Street
Boston, MA 02115
(617) 734-9800
Fax: (617) 739 -9864
http:// www.ne jm.org
LENGTH OF YOUR EDITOR IAL

NEJM editorials should not exceed two printed pages. This means that your word count before editing should not
exceed 750 words (approx imately 4500 characters) . Note that we spell out tiia l names and most other abbreviations
for our readers, and we include trial registration numbers for any clinical trials mentioned; these will lengthen your
editorial if you have not included them. Please provide a title not exceeding 45 characters and a word count for the
text; the entire manuscript, including references, should be double-spaced.
REFERENCES
Cite no more than 10 references, including the article you are writing about. The average collection of 10 references
requires about a quarter of a printed page.
TABLE OR FIGURE
A table or a figure in your editorial will requ ire a reduction in the number of words; because figures and table s vary
in size, you may be asked to shmten the text of your editorial during the production process. A quarter-page table
roughly equals 250 words , and a half-page table roughly equals 500 words.
DISCLOSURES
When completing your disclosure form, please indicate, in the "Comments" field next to the type ofre lationship
being disclosed , the amount (in U.S. dollars) of any support you have received. Please also indicate how much of
this support has been received over the past 2 years. Please e-mail your completed disclosure form to
editorial @nejm.org.
NIH-001757
ln the event of publication, each author's submitted disclosure form will be posted on the Web (with any dollar
amounts redacted).
COPYR IGHT TRANSFER

Each author must complete a copyright transfer agreement form. Please sign it and fax it back to 78 1-207-6529 as
soon as possib le.
TO SUBMIT YOUR EDITORIA L

*** It is important that you follow the instructions below to ensure that you r article enters the correct queue. ***
When you are ready to submi t your manuscript, please log in to the New England Journal of Medicine - Manuscript
Centra l site Q1ttp:// mc05.manuscriptcen tral.com /nejm). Your case -sensitive USER ID is afauci @ niaid .nih.gov. For
sec urity purposes, your password is not listed in this message. If you are unsure of your password , please visit
hltps ://mc05.manuscr iptccntral.com /nejm and enter your e-ma il address in the "Forgot Your Password?" field.
Once you are logged in, the Main Menu will be displayed. Please click on the Author Center, where you will find
the manuscript listed under "Invited Manuscripts ." You can click on the "Continue Submission" button to begin
submitting your article.
NIH-001758
Please wait. ..
If this message is not eventually replaced by the proper contents of the document, your PDF
viewer may not be able to display this type of docume nt.
You can upgrade to the latest version of Adobe Reader for Windows®, M ac, or Linux ® by
visiting http ://www.adob e.com/go/reader_downl oad.
For more assistance with Adobe Reader visit http ://www .adobe.com/go/acrreader.
Windows is eithe r a registered trademark or a trndemark of M icrosoft Corporation in the United States and/or other co untries. Mac is a trademark
of Apple Inc ., registered in the United S1ates and other countries . Linux is !he registered trademar k of Linus Torvalds in the U.S . and other
countries.
NIH-001759
Sent: Wed, 19 Feb 2020 12:37:58 +0000
To: Jon LaPook
Subject: RE:Coronavirus
It means that you are an outstanding and committed journal ist . Q
Director
Phone : CbH6J
FAX: (301) 496-4409
(b)(6)
E-mail:
The informat ion in this e-mail and any of its attachment s is confidential and may
contain sensitive informat io n. It should not be used by anyone who is not the
original intend ed recipient. If you have received thi s e-mail in error please inform
the sender and delete it from your mailbox or any other storage devices. The
National Institute of Allergy and Infectious Diseases (NIAID) shall not accept
liability for any statements made tha t are the sender's own and not expressly
made on behalf of the NIAID by one of its representatives.
From: Jon laPook -------=-:-= (b)(6)
-------~~
Subject: Re: Coronavirus --------- CbH6)
Got it . What does it mean that I'm waking up th inking about coronavirus?
:)

Chief Medi cal Correspondent, CBSNews
Professor of Med icine
NIH-001760
NYU Langone Health
Twitter @DrlaPook

CbH > wrote:
--------
Jon:
Your hypothesis is certainly possible, but I think unlikely. In a NEJM paper for
which I have just written an editorial, there were 400+ patients and none younger
than 15 years old. I am certain that children from birth to 15 years were exposed
to and primed by coronaviruses multiple times and so if 2nd infection
enhancement were an important issue, we should have seen it in children and
adolescents 15 years old and younger. Just a thought, but anything is possible.
Best,
Tony
Director
National Institute of Allergy and Infectious Diseases Building 31, Room 7A-03
Phone: CbH6J
FAX: (301) 496-4409
E-mail: CbH6)
original intended recipient. If you have received this e-mail in error please inform
liability for any statements made that are the sender's own and not expressly
From: Jon LaPook-------="'"'="CbH6J
To: Fauci, Anthony (NIH/NIAID) [E] ----------=-c-~
CbH6)
----------
NIH-001761
Good morning, Tony,

I woke up thinking this: given the relative sparing of young people during the
COVID-19 outbreak, could something similar to what happens with dengue be
going on? Could a second coronavirus infection - albeit with a genetically different
variant than the first - bring about worse disease than the first? And, since up to a
third of the common cold is caused by a variant of coronavirus, could older people
somehow have been primed by an earlier coronavirus infection?
Jon

Chief Medical Correspondent, CBSNews
NYU Langone Health
Twitter @DrlaPook
NIH-001762
Sent : Wed, 19 Feb 2020 03 :41:52 +0000
To : Grigsby, Garrett (HHS/0S/OGA);Redfiel d, Robert R. (CDC/0D);Cetron, Marty
(CDC/DDIO/NCEZID/DGMQ)
Cc: Billet, Courtney (NIH/NIAID) [E]
Subject : FW: Todays report from Dr Iwata From Kobe univ on Diamond Princess SHIP
COVID-19
Folks:
You should take a look at this video (see link). The person, who is a Japanese in fectious
diseases specialist, is a b it inarticu late in the beginn ing o f the video, but he provides a vivid and
disturbing description of the conditions on the Diamond Princess.
Tony
From: Larry Washburn< (b)(6)>

To: Fauci, Anthony (NIH/NIAID) [El------= (b)
""'c=
6J>
Cc: Hodes, Richard (NIH/NIA) [El (b)(6)
Subject : Todays report from Dr Iwata From Kobe univ on Diamond Princess SHIP COVID-19
Dr. Fauci,
I am living in Japan (b)(6) and this morning I saw t his video released by
Dr. Kentaro Iwata a infectious disease contro l.specialist
Please have somebody on your staff review this ASAP short description of Dr lwata's 1 day visit on the
ship. He has experience with Ebola, Sars etc . He describes an alarming condition that you and CDC
must be aware of . Japan has no CDCand they tend to be very bureaucratic.
https ://www .you tu be .com/wa t ch?v=vt HYZkl u Kcl &featu re=youtu . be
I apologize if you already have this information .
Respectfu lly
Larry Washburn ______ _, Living in Japan
(b)(6)
NIH-001765
Sent : Wed, 19 Feb 2020 01 :32:37 +0000
To : Conrad, Patricia (NIH/NIAID) [E);NIAID OD AM
Subject : RE: CROI COVID-19 Session; Tuesday March 10 lunch
I am not that excited about doing this. They have CDCdoing the Epi, which is fun. They have
Ralph Bar ie doing the virology, which I easily can do , and they have me talking about what
NI A ID is doing, which is important, but boring from a lecture standpoint.
Greg:
What say you?
From : Conrad , Patricia (NIH/NIAID) [E] (b)(6)>

Se nt : Tuesday, February 18, 2020 8:22 PM
To: NIAID OD AM <NIAIDODAM @niaid.nih .gov>
Subject: Fwd: CROI COVID-19 Session; Tuesday March 10 lunch
Sent from my iPhone
From: Donna Jacobsen <djacobsen@ iasusa.org >

To: "Fauci, Anthony (NIH/NIAID) [E)" 1
Cc: "Conrad, Patr icia (NIH/N IAID) [E)" I ~=======:.~= CbH6>i, "Elaine J. Abrams, MD
____ ..;__
__ ..,;_......;
__ ..:..;...:...::::::::e
(b
;:;)="'
c6)
::;;
ij-"-:-
::S:-
ha_r_o_n_H-::
il".".'
Iie
_r_P:-:-"
hD.
(b)(6)1>, "Hoxie, James"

============-~~:--:----:--:-:.
------------ CbH6)], "Benson, Connie" !
<kbowen@iasusa.org >
CbH6)]>, Kevin Bowen
Subject : RE: CROI COVID- 19 Session; Tuesday M arch 10 lunch
(resending with Patty's correct email address)
Dear Dr Fauci:
As I mentioned on the phone, we just today decided that we w ill have a special session on
COVID-19 at CROI. It will be on Tuesday, March 10, dur ing the lunch break; the initial
general structure will be a 10- to 15- minute overview of the epidemic (CDC), a 25-min talk
by Ralph Sarac (UNC) about the viro logy of coronaviruses, and a 10- to 15-minute
summary on what NIAID/NIH is doing and planning. We thought that this being one of the
first large med ical conferences in infec t ious diseases this year, t hat it is important that we
address COVID 19 at CROI.
NIH-001768
We know that this is terribly last minute, but the CROI Chairs and Foundation are hoping
you are free to give the NIAID/NIH update . CROI is in Boston, March 8 to 11.
If you think you would be able to do this, we will send a more formal communication w ith
details and wo rk with Patty on the specifics. Thank you so much Dr Fauci; we hope you will
be ab le to join us.
Best,
Donna
Donna M . Jacobsen
International Ant iviral (formerly AIDS) Society - USA
415 -544-9400
https ://www.iasusa .org
ACCMf
About IAS-USA : Established in 1992, the IAS- USA is a not-for-profit ,
professiona l education organization. The mission of the IAS-USA is to improve the
prevention, treatment, care , and quality of life for people with or at risk of HIV, hepatitis C
virus, or other viral infections through high -quality, relevant, balanced, and needs-oriented
education and information for practitioners who are actively involved in medical care. The
organizat ion's educational activities are particularly intended to bridge clinical research and
patient care .
Confidentiality Notice : This e-mail and its attachments may contain privileged and
confident ial informat ion intended solely fo r the use of the IAS-USA and the recipient(s)
named above . If you are not the intended recipient. or the employee or agent responsible
for de livering th is message to the intended recipients , you are hereby notified that any
review , dissemination, distribution, printing, or copying of this e-mai l message and/or any
attachments is strictly prohibited . If you have received this transmission in error , please
notify the sender immediately and permanently de lete this e-ma il and any attachments.
NIH-001769
Sent: Wed, 19 Feb 2020 00:28:47 +0000
To: Retzlaff, Jon
Subject: RE:ACTION: Invit ation to Provide Opening Remarks at the NIH-AACR Cancer,
Autoimmunity, and Immunology Conference on March 23rd (on the NIH campus)
Not inte rested right now. Too busy. Have Hugh or someone else do this.
Directo r
Phone : (b) (6)
FAX : (301 496-4409
E-mail : (b)(6)
From: Retzlaff, Jon <jon.retzlaff@aacr.org>

~-========~-==Conrad, Patricia (NIH/NIAID) [E)
(b) (6}> ---------- (b)(6)>;
Subject: ACTION: Invitation to Provide Opening Remarks at the NIH-AACRCancer, Autoimmunity, and
Immunology Conference on March 23rd (on the NIH campus)
Dear Dr. Fauci ,
It's pretty clear that you have been ridiculously busy over the past month+ serving as our nation's
top infectious disease doctor! Thanks so much for yom leadership and dedicat ion, Dr. Fauci!
I'm actuallyreaching out to you on a topic other than the coronavirus,as I am writing on behalf
of the co-chairs for an important NIB-American Association for Cancer Research (AACR)
conference (the NIH-AACR Cancer, Autoimmunity, and Immunology Conference) that will
be taking place on March 23-24, 2020 , on the NIH campus (in the Masur Auditorium in the
NIH Clinical Center).
The co-chairs would like to invite you to be the opening speaker on Monday, March 23rd . Dr.
Sharpless will be the open ing speake r on Tuesday, March 24 th . Please see the attached draft
agenda.
NIH-001770
Now in its third year , the Cancer, Autoimm unity, and Immunology Conference focuses on: 1)
understanding the biology of immune-related adverse events which have occurred in cancer
patients trea ted with immunotherapies and how that might inform the study of autoimmune
disease , and 2) defining the potential for the study of autoimmune disease to lead to greater
understanding of the treatment and management of immune-related adverse events during and
following cancer therapies. The goal of this interdisciplinary conference is to bring together
people who might not typically interact to promote cross-fertilization for the betterment of both
research and clinical care, which is why there are four NIH !Cs very much involved in the
Conference, including: NCI, NIAID, NIAMS, and NIDDK.
Chairing this effort on behalf of the AACR is Julie R. Brahmer, MD, Johns Hopkins Un ivers ity.
From the NIH, we have Elad Sharon , MD, MPH, NCI; Ravi Madan , MD, NCI ; Connie
Sommers, PhD, NCI; Howard Young , PhD, NCI; Katarzyna Bourc ier , PhD, NCI; Marie
Mancini , PhD, NIAMS; Annette Rothermel , PhD , NIAID; and Lisa Spain , PhD , NIDDK.
I know the diverse audience, including patients , researchers , clinicians, industry , regulators, and
others, would be thrilled by your presence. Of couTse, we also know that you have pa1ticipated
in the previous two conference on this topic, which underscores why they would love to have
you participate again!
Plea se let us know at your earliest convenience if you are interes ted and able to participate in the
conference on Monday, March 23rd. ff you have additiona l questions or concerns, you can
contact me at jon .retz laff@aacr.org or (b)(6)
Thanks again , Dr. Fauci , and I look forward to hearing from you !
Jon
Jon Retzlaff, MBA, MPA

CHIEF POLICY OFFICER
VICE PRESIDENT, SCIENCE POLICY AND GOVERNM ENT AFFAIRS
Office of Science Policy and Government Affairs
AmericanAssociation
AAG for cancer Research
FlNDINGCURES TOGETI;ER '
American Association for Cancer Research

1401 H Street. NW. Suite 740 I Washin gton . DC 20005
202-898-6499 Direct I 267-765-1087 Fax I (b)( Cell
jo n.retzlaff@aac r.org I www .AAC R.org
11c miam•+:Pili
Please note that this e-mail and any files transm itted w ilh it may be privileged , confidentia l, and protected from d isclosure under applicable law. This
information is intended only for the person or entity to which it is addressed and may contain confidential or privileged material. Any review,
NIH-001771
retransmission, dissemination, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended
recipient is prohibited. If you received this in error, please contact the sender and delete the material from any computer.
NIH-001772
Sent : Wed, 19 Feb 2020 00:23:40 +0000
To : Eisinger, Robert (NIH/NIAID) [E]
Subject : FW: New England Journal of Medicine - 20-02387
FYI. Just to keep an eye on this. Thanks.
Director
BuiIding 31, Room 7A-03
Phone: (b) (6)
FAX: (30 I) 496-4409
(b)(6)
E -mail:
--------
Allergy and Infectious Diseas es (NIAID) shall not accep t liability for any stat em ents mad e that are the sender's own
and not expressly made on behalf of the NIAID by on e of its representa tives.
From: New England Journal of Medicine <onbehalfof@manuscriptcentral.com>
-------~~
To: Fauci, Anthony (N1H/N1AID)[E] _______ (b)(6);Lane, Cliff(NIH/NIAJD) [E]
_
.,....,....,.. (b)( >; Redfield, Robert R. (CDC/OD)
__,_.....,....__,__.
Subject: New England Journal of Medicine - 20-02387
(b)(
Dear Dr. Fauci,
Thank you for submitting your manuscript, "COYID-19: Navigating the Unchartered" to the New England Journal
of Medicine.
Your manuscript has been fo1warded to members of our editorial staff, wbo will make an initial evaluation and
decide whether it merits further consideration. You will be notified of the decision as soon as possible.
Your manu script TD is 20-02387.
Please mention th e abov e manuscript ID in all future conespondence or when calling the of.fice for questions. If
there are any change s in yow· street address or e-mail addre ss, plea se log in to ScholarOne Manuscript s at
h tt:ps://mc0 5.manuscr ip tcentra l.com/nejm and edit your user infom1a tion as appropriat e. You may al so view the
sta tus of your manuscript at any time by checking For Authors section of the site.
We are undert aking evaluation o f y our manu script with the understanding tha t neither the substance of the article
nor the figures or tables have been published or will be submitted for publication elsewhere during the period of
review.
Please provide the editors with copies of other manuscripts by you or your coauthors addressing similar or related
research questions that are in preparation or under consideration at other journals. This does not apply to abstracts
published in connection with sdentific meetings or to news reports based on presentations at such meetings.
The Journal's policy is explained more fully at http://www.nejm.org/page/author-center/editorial-policies.
NIH-001773
Please call us at 617-734-9800 if you have any questions.
Sincerely,
Eric J. Rubin , MD, PhD

Editor- in-Ch ief

IO Shattuck Street
Boston, MA 02115
(617) 734 -9800
Fax: (617) 739 -9864
http: // www .ne jm.org
NIH-001774
Sent: Tue, 18 Feb 2020 23:57:32 +0000
Subject: RE: draft response fo r NBC on line
See my minor tweek
Director
Phone : (b)(6)
FAX: (301 ) 496-4409
E-mail : (b)(6)

----------
________
--------:a ~aa, ,.
(b)(6J>
(b)(6)
Subject : FW: draft response for NBC on line
Ok any edits? Pis advise
Patricia L. Conrad
(b)(6)
301-496-4409 fax
Disclaimer:
from your mailbox or any other storage devices. National Institute of Aller gy and Infectious Diseases (NIAID ) shall not accept
liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representalives.
NIH-001775
From: Routh, Jennifer (NIH/NIAID) (E] (b)(6)
Sent: Tuesday, February 18, 2020 2:47 PM ----------
To: Conrad, Patricia (NIH/NIA ID) (E) --------~~
<0 CPLPressTeam@ o d. ni h.gov> ----------
(b)(6J1
>; OCPLPressTeam
Cc: NIAID COGCORE<COGCORE@mail.nih.gov>; NIAID Media Inquiries <mediaingu iries@niaid .nih .gov>
Subject: draft response for NBC on line
Reporter : Jacqueline Stenson

Organization: NBC online
(b)(6)
Phone #(s):
-------------------
Subject: COVI0-19
NBC on line asked, "What is NIAID's position on whether the SARS-CoV-2is transmiss ible in
asymptomatic people?"
I would propose that we send a response to Jacqueline attributed to ASF:
Early case reports indicate in certain circumstances SARS-CoV-2is transmissible in asymptomatic

people. We do not know the extent to which asymptomatic transmissionis impacting the outbreak.
However, we know that people w ith symptoms are usuallythe main driver of outbreaks of other
respiratory diseases.
Jennifer Routh [E]

News and Science W riting Branch
Office of Communications and Government Rela tions
NIH/HHS
Bethesda, MD 20892
Direct: (b) (
Disclaimer : The information in this e-mail and any of its attachments is confidential and may conta in sensitive informat ion. It should not be
used by anyone who is not the original intended recipient. If you have rece ived this e-ma il in error please inform the sender and delete it
from your mailbox or any other storage devices . The National Institute of Allergy and Infectious Diseases shall not accept liab ility for any
statements made that are sender's own and not express ly made on behalf of the NIAID by one of its representatives.
NIH-001776
Sent : Tue, 18 Feb 2020 23:32:19 +0000
To: Dennis Golden
Cc: Monica A Golden
Subjec t: RE:Coronavirus
Denny and Monica:

Many thank s for your kind note. l hope that all is well wi th you.
Warm regards ,
Tony
Dir ector
National Ins titutes of Health
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive infom1ation . It
please inform the sender and delete il from your mai lbox or any other storage devices. The National Institu te of
From: Dennis Golden ------- (b
~)~(= >
Sent: Tuesday , February 18, 2020 4:39 PM
------~~
To: Fauci, Anthony (NlH/NlAID) [E]
Cc : Monica A Golden
Subject: Coronavirus ----------
Tony,
Our thoug hts and prayers are with you as you profe ssionally address the horrid coro navirus transmission.
We salute you for not "s uga rcoating" or trying to be "diplomatic " about the Diamond Princess Cruises ship
quarantine process .
As always, you proved yourself to be a courageous, honest and ethical man. A man who has always done the right
thing s .
We standwith you !
In Hoc Signo Vinces,
Denny and Monica Golden
NIH-001777
Sent: Tue, 18 Feb 2020 22:06:38 +0000
To: Selgrade, Sara (NIH/NIAID) [E)
Cc: Billet, Courtney (NIH/NIAID) [E);Folkers, Greg (NIH/NIAID) [E);Conrad, Patricia
(NIH/NIAID) [E);NIAID OCGRleg
Subject: RE: Requesting your assistance: Draft NIAID Statement for Upcoming
Appropriations Hearings
Attachments: Draft_NIAIO FY2021 Statement for the Record_to ASF- with Fauci tracked
edits.docx
Here it is. Thanks.
Director
Phone : Cb)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Selgrade, Sara (NIH/NIAID) (E) (b)(6)>

To: Fauci, Anthony (NIH/NIAID) [E]------ --=-
(b=)(=6)
Cc:Billet, Courtney (NIH/N IAID) [E) (b)(6); Folkers, Greg (NIH/NIAID) [E]
--------- (b)( ; Conrad, Patricia (NIH/NIAID) [E)

<NIAIDOCGRLeg@mail.nih .gov>
(b)( >; NIAID OCGRleg
Subject: Requesting your assistance: Draft NIAID Statement for Upcoming Appropriations Hearings
Dr. Fauci:
In preparation for the upcoming NIH budget hearings of the House and Senate
Appropriations Subcommittees on Labor, HHS, Education, and Related Agencies,
we have drafted the attached NIAJD statement for the record, highlighting the
topics that you previously selected.
NIH-001778
We have a finn 3-page limit for the statement. It has been reviewed by the
Divisions and Drs. Harper, Eisinger, Lerner, and Marston, as well as Courtney
Billet, Martin Johnson, Greg Folkers, and Laurie Doepel.
NIH OLPA has asked to receive your statement by this Wednesday, Feb. 19th.
Please let us know if you would like us to request additional ti1ne for your review,
given competing priorities.
Sara
Sara Selgrade, Ph.D.

Section Chief for Legislative Activities
Legislative Affairs and Con-espondence Management Branch
NIATD/NTH
/DHHS
Bldg. 31, Room 7Al7, MSC 2520
Phone: (b) (6)
(b)(6)
Disclui m e,-:
The i1!formation in this e -mail and any<?( its al/ac!1mc11tsis co1!ficlc11tia!and may contain sen s itive informatio11. It should not be
used hv a11yo11e who is no/ the original intended recipient . /f you have received this e-mail in error please i,iform the sender and
delete fiji-0111
your mailbox or anv 01herstorage devices. Nationallnslitule o/Allergy and InfectiousDiseasesshall not accept
liabi!ityfor any statements made that are sender'.f own and not express(y made on behalf of the NIAID by one of ifs
represe111ativ
es.
NIH-001779
Sent: Tue, 18 Feb 2020 14:37:35 +0000
To: Venigalla B Rao
Cc: Cassetti , Cristina {NIH/NIAID) [E]
Subject : RE: Wuhan coronavirus vaccine candidates
Rao:
Best to contact Cristina Cassetti in DMID. I have copied her here .
Best,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
information. It should not be used by anyone who Is not the original Intended recipient . If you
From:Venigalla B Rao Cb)(6)

------~~
--------
Subject : Wuhan coronavirus vaccine candidates
(b)(6)
Dear Tony,
Good morning!
Sorry for taking your time at t his very super busy time. Greatly appreciate your service
and leadership!!
(b)(4)
NIH-001785
(b)(4)
With best regards,

Rao
On Tue, May 23 , 2017 at 11:03 AM Ven iga lla B Rao <i.____ ~ w rote:
(b_H....
Dear Tony ,
Just a quick update.
(b) (4)
(b) <4 • Re as accepte aoofnf he papers and t e

-------------
NIH-001786
papers should come out back-to-back in Virology soon. I am attaching both the
pdfs for your interest.
From scientific perspective, it is very satisfying to see that both the papers
using completely different approaches arrived at the same virion capture model.
That was not ant icipated when we initiated the work 5-years ago because the
reasons to develop these assays were very different. I have mentioned to
Emerman to consider highlighting the papers in the journal issue, and that you
and Jim might be will ing tom write a short piece but I have not heard about this.
With best regards,

Rao
On Mon, May 1, 2017 at 11:33 PM, Venigalla B Rao ____ (b)( _, > wrote :
Dear Tony,
(b) (4)
With best regards,

Rao
On Mon, May 1, 2017 at 9:40 PM, Fauci, Anthony (NIH/ NIAID) [E]
------- (b)( 6) wrote :
Rao:
ao Wo.Ll: he.n.ate..aadJo (b) (4)'--- ~ =
(b) (4)
e t'i'ega"'fi ,
Tony
From:Venigalla B Rao [mailto:, Cb) (6)J

Sent: Thursday, April 27, 2017 8:24 PM
Cc: Arthos, James(NIH/NIAID) [E]; ----- =(b=)( =
6)
Subject: Request
NIH-001787
Dear Dr. Fauci,
This is Venigalla Rao from The Catholic University of America, Washington , DC. I have
communicated with you a couple of times in the past years for different reasons. Having been
involved in administrative duties (miniscu le compared to yours ), I can only imagine the demands
on your time . I make this request despite this trepidation and I hope that you understand .
(b) (4)
Thank you for consideration.
With best regards,
Rao
Dr. Venigalla B. Rao

Professor and Chairman
Department of Biology
The Catholic University of America
620 Michigan Ave., NE
Washington, DC, 20064
http://faculty.cua.edu/rao/
Phone: (b) (6)
NIH-001788
Sent: Tue, 18 Feb 202014:12:48 +0000
To: SuzannePeskin
Subject : RE:Visiting !
Suzanne:
Thanks for the note. lam very, very sorry, but I do not think that we w ill be able to connect on Sunday. The
White House and HHS have me going 24/7 including Saturday and Sunday with the coronavirus crisis. I have seen
my witi (b) (6) for a total of about 45 minutes over the past l 0 days. Hopefully , we can do this at some other
opportunity , but th is is a very bad time. I hope that you understand.
Best regards ,
Tony
Director
National Jnstitute of Allergy and Infectious Diseases
Building 3 I, Room 7 A-03
Phone: (b) (6)
FAX: (301)496-4409
E-mail: (b)(6)
The infom1ation in this e-mail and any of its attachments is confidential and may cont ain sensitive infom1ation. It
please inform the sender and delete it from your mai lbox or any other storage devices. The National Jnstitute of
Allergy and Infectious Diseases (NfAID) shall not accept liability for any statements made that are the sender's own
from : Suzanne Peskin -------~ (b~)-(=
Sent: Monday , February 17, 2020 9:56 PM
------~~=
To: Fauci , Anthony (NTH/NTAID) [E] ._ _____ (b_H_ >
Subject: Visiting !
Hi Tony, r hop e all is well with you and your family. r know you are busy these days witb the Coro novir us, bu t was
wonderin g if you' re in town this weeke nd! (b)(6llives in DC and works for Mary land CASA as a legal fellow . J'm
com ing in Friday even ing and was planning on taking her down memory lane. She has heard so much about (b)(6)
that I would love to introduce you two. (b) (6)
'e are free most of Sunday if you 're in town. It's been way too
long. Would love to see you.
Let me know if that is at all possible.
Love,
Suzanne
Sent from my iPad
NIH-001789
Sent: Tue, 18 Feb 2020 13:17:03 +0000
Subject: FW: (b) (4) for coronavirus
Attachments : (b)(4)
Please handle. Thanks.
Director
Phone : Cb)(6)
FAX : (301 496-4409
E-mail : (b)(6)
From: Li,Qiuhong (b) (6)

To : Fauci, Anthony (NIH/NIAID) [E) ------~~
Subject :
--------
(b)(4) for coronavirus
(b)(6)>
----------
Dear Dr. Fauci,
I'm writing to you to seek advice on potential collaborations with NIAID-funded facilit ies or other
private sectors to Cb)(4)
(b) (4)
NIH-001790
(b) (4)
Please feel free to contact me if you have any questions .

Best regards,
Qiuhong
Qiuhong Li, Ph.D ,

Dept. of Ophthalmology
University of Florida
Gainesville FL
32610-0284
Phone (b)(6)
Email:
----(b)(6)
NIH-00179 1
From: (b)(6)
Sent: Tue, 18 Feb 2020 07:00:32 -0500
Subject : Re: Funds for CoV
Francis:
(b) (5)
Tony
On Feb 18, 2020 , at 6:22 AM , Collins, Francis (NIH/OD) [E]

(b) <6J
>wrote:
Hi Tony,
Larry and I will have our regular meet ing with the Secretary today . (b) (5)
--- =(b~)( =5)
I will see you th is afternoon for our regular catch up, unless other events in our intensely
busy lives intervene .
Francis
NIH-001792
Sent : Tue, 18 Feb 2020 11:15:14 +0000
To : Bernice Mika Huang
Subject : RE: Singapore Coronavirus Updates
Bernice:
Thank you for this important update of information.
Best regards,
Tony
From: Bernice Mika Huang

-----------
------ --.~
(b)(6)

--------
Subject : Singapore Coronavirus Updates
(bH >
I'm Bernice (b) (6) .

------
I had read your online discussion details on USA Today which says:
"Another thing that we don't know is why, w ith a respiratory-borne illness, are there virtually no
children getting infected . I mean, there are no cases of kids less than 15 years old . Does that mean for
some strange reason they're not getting infected, or the illness is so mild in child ren that we're not
notic ing it? It's very clear the median age is 56 or 59."
I thought it would be crucial to share updates on Singapore's coronavirus situation for your reference,
because you are the expert who could help analyze the cur rent situation . Till date, in Singapore ><
6>have
two young child ren who are infected:
ONE YEAROLD
"Case 76 is a one-year-old Singaporean who was among the group evacuated from Wuhan on Feb 9.
The toddler was without symptoms when he boarded the flight back to Singapore. He was put under
quarantine upon landing in Singapore, and was confirmed to be infected with COVID-19 on Sunday
afternoon . Advertisement He is currently warded in an isolation room at KK Women's and Children's
Hospital, said MOH." Quoted from https://www .channe lnewsasia.com/news/singapore/cov id19-
coronav irus-singapore -update-feb- 17-12441176
SIX-MONTH OLD
"COUPLE, BABYAND MAID INFECTEDThe 28-year-old mother - whose infection was announced on
Tuesday - works at Yong Thai Hang, a health product shop that primarily serves Chinese touris t s. Her
husband, a 45-year-old Singaporean tested positive on Wednesday at about 2pm, and is currently
warded in an isolation room at the National Centre for Infectious Diseases (NCID). Both have no recent
travel history to China. The couple's child, a six-month-old boy, tested positive at the same time and is
currently warded in an isolation room at KK Women's and Children's Hospital. The family's domestic
helper was one of the confirmed cases on Tuesday. MOH said in an update on Thursday that the child
NIH-001793
was not in any infant care facility and was cared for at home, prior to being admitted to the hospital." -
Quot ed from
http s://www .channe lnewsasia.com/new s/s ingapore/w uhan-virus-coronavirus-singapore-numbe r-cases-
12395928
Thanks,Best Regards& God Bless,

BerniceHuang
(b)(6)
Best Regards, Bernice
NIH-001794
Sent: Tue, 18 Feb 2020 11:12:55 +0000
To : Sheeley, Colin (NBCUniversal)
Subject: RE: NBC News Inquiry
I know that it is frustrating for you, but they still have not changed the official number , even
though we know that it is certainly more than 44. Sorry .
From: Sheeley, Colin (NBCUniversal) <Colin.Sheeley@nbcuni.com>

To : Fauci, Anthony (NIH/NIAID) [E]------~= (b)( >
Cc: Chirbas, Kurt (NBCUniversal) <Kurt.Chirbas@nbcuni.com> ; Varela, Jay (NBCUniversal)
<jay.varela@nbcuni.com>; Santana, Cristian (NBCUniversal) <Cristian.Santana@nbcuni.com>; Mitchell,
Alexander (NBCUniversal) <Alexander .Mitchell@nbcuni.com>; DiCasimirro, Gemma (NBCUniversal)
<Gemma .DiCasimirro@nbcuni.com>; Studley, Joe (NBCUniversal) <Joe.Studley@nbcuni.com> ; Metsch,
Abigail (NBCUniversal) <Abigail.Metsch@nbcuni.com>
Subject : RE:NBC News Inquiry
Thank you Tony,
We heard th is evening that there were 169 new confirmed cases aboard the cruise ship . Do you know if
this changes the "officia l public" number at all?
Thanks,
Colin

To : Sheeley, Colin (NBCUniversal) <Colin.Sheeley@nbcuni.com >
Cc: Chirbas, Kurt (NBCUniversal) <Kurt.Chi rbas@nbcuni.com >; Varela, Jay (NBCUniversal)
<jay.varela@nbcuni.com >; Santana, Cristian (NBCUniversal) <Cristian.Santana@nbcun i.com>; Mitchell,
Alexander (NBCUniversal) <Alexander.Mitche ll@nbcun i.com>; DiCasimirro, Gemma (NBCUniversal)
<Gemma .DiCasimirro@nbcun i.com>; Studley, Joe (NBCUniversal) <Joe.Studley@nbcuni.com >; Metsch,
Abigail (NBCUniversal) <Abigail. Metsch@nbcuni.com >
Subject : [EXTERNAL)RE:NBC News Inquiry
Colin:
Thanks for the note. The number 44 is in flux. When I checked a couple of days ago, the
"officia l public" number was 44. However, it was clear that there was likely more than that
since the results of the tests were st ill coming back on some individuals. And so, it is a
minimum of 44 infected from the cruise ship, but it is un certain how many more than 44 are
infected . I do not know where the Americans are staying
Best,
Tony
NIH-001795
From: Sheeley, Colin {NBCUniversal) <Colin.Sheeley@nbcuni.com >
To : Fauci, Anthony (NIH/NIAID) [E] ------ ~=
(b)(6)>
Cc: Chirbas, Kurt (NBCUniversal) <Kurt.Chirbas@nbcuni.com >; Varela, Jay (NBCUniversal )
<jay.va rela@nbcun i.com >; Santana, Cristian (NBCUn iversa I) <Cristian.Santana@nbcu ni .com>; Mitchell ,
Alexander {NBCUniversal) <Alexander.Mitche ll@nbcuni.com >; DiCasimir ro, Gemma (NBCUniversal)
<Gemma.DiCasimi rro@nbcun i.com >; Studley, Joe (NBCUniversal) <Joe.Stud ley@nbcuni.com >; Metsch,
Abigail (NBCUniversal) <Abiga il.Met sch@nbcun i.com >
Subjec t : NBC News Inquiry
Hi there,
I'm reaching out on behalf of NBC National News -would you be able to confirm that 44 Americans
aboard t he Diamond Princess cruises ship have tested positive for coronavirus?
Also, would you be able to say where the Americans are staying as they are being treated for the virus?
Please REPLYALL with your response, or give us a call at (212) 664-5222.
Thank you,
Colin
NIH-001796
Sent : Tue, 18 Feb 2020 11:08:19 +0000
Subject : FW: CNNi Interview Request: Anthony Fauci
Let us discuss.
From: Hynds, Joanna (NE) <Joanna.Hynds@turner .com>

(6)
=
Cc:Pfeifer, Hazel <Hazel.Pfeifer@turner .com>; Roobeek, Rosanne <Rosanne.Roobeek@turner .com>;
Avramova, Nina (NE) <Nina .Avramova@turner.com>
Subject : CNNi Interview Request: Anthony Fauci
Dear Mr Fauci,
I hope this finds you well.
I'm writing to you from CNN International to see if you are available to join Becky Anderson on her
prime time flagship show 'Connect the World' for a live interv iew on today to discuss the coronavirus.
The show airs live between 10amET- 12pmET- do you have any availability dur ing these hours to come
to a convenient bureau?
We really loved having you on the show last Sunday! As the director of the National institute of Allergy
and Infectious Diseases your insight is always great fo r our global audience.
Migh t it be possible to arrange something?
Background on CNN
• CNN Int ernational reaches more than 250 million households worldwide including in the US via
DIRECTV.
• CNN Int ernational is the number one internat ional TV news channel according to all major
media surveys across Europe, the Middle East and Africa, the Asia Pacific region and Latin
America.
• In September 2019 CNN.com had 162 million unique readers globa lly per month and 114 million
mobile reade rs a month, leading the BBC, Yahoo and New York Times .
Best,
Joanna Hynds
Planning Desk
CNN International
+ 44 207 693 1640 (office)
+ Cb)(6) ( cell)
joanna .hynds@turner .com
NIH-001797
amtherego
Information in this email including any attachments may be privileged or confidential and is intended
the originator. If you have received this email in error, please notify the sender by return e-mail and
delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its
contents to anyone. Please note we reserve the right to monitor all e-mail communication through our
internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting
Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks
International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited
(Company Number 2802926) and Cable News International Limited (Company No. 5001368) are
incorporated in England and Wales and share the same registered office at Turner House, 16 Great
Marlborough Street, London WlF 7HS.
NIH-001798
Sent: Tue, 18 Feb 2020 10:44:58 +0000
Subject : RE: Confirmation from CNN's New Day
OK. Thanks.

Sent: Tuesday, February 18, 2020 5:42 AM ---------
)(c-=
6)
Subject: Fwd: Confirmation from CNN's New Day
Firm hit for this morning in med arts studio at 715 am
Be in studio at 7 am
Sent from my iPhone
From: "Steinfe ld, Alix" <Alix.St einf eld @t urn er .co m>
To: "Figliola, Mike" <M ike.Figlio la@turne r.com >, Jonathan Bennett
(b)(6)>
Cc: "Conrad, Patr ici...
a..:,
(_
N_IH..:.
/_N_IA_I_D.:..
) .:..
[E..:.
)'.'..!==~~':'."""'-:--:--- (b-:-(6)>, "Daniels, Ronne!
) __,
(NIH/OD/ORS) [C]" (b)(6) "Ryland, Ken (NIH/OD/ORS) [E)"
======= (b~)(~6)~>, "Jackson Farrar, Joy (NIH/OD/ORS) [El"
(b)(6)
Subject: RE: Confirmation from CNN's New Day
Good Morning
We have OR. ANTHONY FAUCI on New Day
Hit Time; 715aEST
IFB: 212.275.9225
PL: 212.275.9325
CONTROL: 212-275-9053
PO: 660980
Thanks
Alix
From: Figliola, Mike <M ike.F igliol a@t urn er .co m>
To: Jonathan Bennett
----------- (b)(6) Steinfeld, Alix
NIH-001799
<Alix.Steinfeld@ t urner .com>
Cc:Conrad, Patricia (NIH/NIAID) [E] (b)(6) ; Daniels, Ronnel
(NI H/0 D/0 RS) [ C] _:..___;_ ___;:....:.....::__::s:
(b= 6)~> ;- R
)( .-.:: -y'."" N-1H/0 D/0 RS) [E]
la-nd~,-K-en- ('.""
(b)(6)>; Jackson Farrar, Joy (NIH/OD/ORS) [E]
=======~ (b~)(~6)
Subject : RE: Confirmat ion from CNN's New Day

Importance : High
Add ing Alix who has that info
Mike Fi g liol a
Editorial Producer
CNN's New Day
(b)(6)
mike .figl iola@turner .com
CONF IDENT IALITY NOT ICE: This e-ma il transmission , and any documents , files or
previous e-mail messages attached to it, may contain confidential informa tion that is legally
privileged. If you are not the intended recipient , or a person responsible for de livering it to
the intended recipient , you are hereby notified that any disclosure , co pying , distr ibution or
use of any of the information contained in or attached to this message is STRIC TLY
PROH IBITED. If you have received this transmissio n in error , please immediately notify us
by reply e-mail at mike.fig liola@turner .com or by telephone at {917) 670 -9410, and destroy
the origina l transmission and its attachments without reading them or savi ng them to disk.
Thank yo u.
From: Jonatha n Bennett

-----------
5 ent: Tuesday, February 18, 2020 5 :05 AM
(b)(6)
To: Figlio la, Mike <M ike .Figlio la@tu rn er.co m>
Cc: Conrad, Patricia (NIH/NIAID) [El CbH6>> ; Daniels, Ronnel
(NIH/ OD/0 RS) [ C] _.;...___;
__ :...;...;~= (b
~ ):::c
(6)
~;-:R:-y :-
la-nd-:-,-:-:
K-en- (:-:-
N'."."'
I H/0D/0 RS) [E]
(b)(6); Jackson Farrar, Joy (NIH/OD/ORS) [E]
=======- (b
~~;,;,
(6)
~>
Subject : Re: Confirma t ion fro m CNN's New Day
Mike,
Received and noted . What are the contro l room and and IFB numbers?
Jonathan
On Tue, Feb 18, 2020, 3:14 AM Figliola , Mike <Mike .Figliola@tu rn er .com > wrote :
Hi eve ryone ,
NIH-001800
This is Mike with CNN's New Day. Hope you are well.
This is to confirm Dr. Fauci will be a guest today, Tuesday 02 .18 .20 at around 7am EST
to discuss:
Latest on Americans who tested positive after evacuation from cruise ship; What we
know about how coronavirus spreads https:// www.cbsnews.com / news/ transcript-dr-
anthony-fauci-on-face-the-nat ion-februa ry-16-2020 /
You will be solo at 7am ESTfor the segments.
Alisyn Camerota and Jim Sciutto, in for John Berman, will both be conduct ing today's
interview.
Please arrive at the studio no later than 6:50am EST.
Here is your studio confirmation:
STUDIO INFO 2013424

THIS INTERVIEW WILL B E FROM their NIH MED ARTS STUDIO with a direct IFB
connection
Control Room numbers are 301-827 -8478 and 8479
Encompass Booking and Circuit Number :
Booking : 1-800-243-1995
Circuit: 36TBGS104492
Our IFB: 301-496-1811 (we prefer to call into the station's IFB)
Video : 1080i - the audio is embedded .
Please confi rm you have received this and are all set to go !
Best,
Mike Figliola
Editorial Producer
CNN's New Day
NIH-001801
(b)(6)
mike.fiqlio la@turner .com
CONFIDENTIALITY NOTICE: This e-mail transmission. and any documents. files or

previous e-mail messages attached to it, may contain confidential information that is
legally privileged. If you are not the intended recipient, or a person responsible for
delivering it to the intended recipient, you are hereby notified that any disclosure ,
copying, distribution or use of any of the information contained in or attached to this
message is STRICTLY PROHIBITED. If you have received this transmission in error ,
please immediately notify us by reply e-mail at mike.fiqliola@turner .com or by telephone
at (917) 670-9410, and destroy the original transmission and its attachments without
reading them or saving them to disk. Thank you.
NIH-001802
Sent : Tue, 18 Feb 2020 03:08:59 +0000
Subject : RE: New Coronavirus Draft Messaging
Short and sweet. Looks fine. Thanks.
From: Holland, Steven (NIH/NIAID) [E] ________ _, ,

(b)(6)
)(c-=
6)
Subject : FW: New Coronavirus Draft Messaging
Tony ,
When you get a moment could I get your take on th is most recent iteration . Apolog ies for the
intrusions.
Thanks
Steve

Bldg. 10/11N248 MSC 1960
301-402-7684 voice
(b)(6) fax
(b)( email
Assistant lab: Eva Portillo
___ Cb ---
_)_(6)
_ voice
(b)( email
Assistant to SD: Beth Schmidt

(b)(6)
(b)(6)
From: "Bailin, Heike (NIH/OD/ORS) [E]" (b)(6)>

Date : Monday, February 17, 2020 at 10:01 PM
To: "Moss, Bradley (N IH/OD/ORS) [E]" ---------.. (b=)(=6)
Cc: "Gottesman, Michae l (NIH/OD) [E]" CbH6)
1
, Steven Holland
"Schmitt, James (NIH/OD/ORS) IE]"
~=======~~CbH6J,
(b)(6) "Johnson, A lfred (NIH/OD) [E] "
--------~~ Cb)(
----------
"Pa Imo re, Tara (NIH/CC/OD) [E]" CbH6)>," McGowan, Colleen
NIH-001803
(NIH/OD/ORS) [El" CbH6), "Cullen, William (NIH/OD/ORS) [El"
CbH6)>,
"Newcomer, Derek (NIH/OD/ORS) [E]"
========~~ CbH6)>,
"Tosten, Timothy (NIH/OD/ORS) [E]"
=======~ (b);;(-;;
6)~
Subject: Re: New Coronavirus Draft Messaging
Brad- thank you . I liked much of what you did . And thanks to all who've commented and edited .
Your points are well taken.
For the sake of clarity and effectively steering fo lks to OMS for the proposed ICP measures I
favor focusing the message even more. Pease find attached OMS ed its:
NIH-001804
Sent : Tue, 18 Feb 2020 03:05:47 +0000
Subject : FW: COVID 19 Diamond Princess Patients Possible Transmission by Fomites
Attachments : SARSTransm ission Fomites Temperature and Humidity Variables.pdf
Please have someone respond
From : Angela Moore (b)(6);,

To: Fauci, Anthony (NIH/NIAID) [E)------~~ (b)( >
Subject : COVID 19 Diamond Princess Patients Possible Transmission by Fomites
I am a dermatologist but also a clinical researcher and scientist.

I was reading all of the news regarding concerns and questions on how the fellow patients are being
infected .
A few questions arose, based on the NIH data on SARSCoronavirus , that has been much more stud ied,
and most likely less viru lent than the current COVID 19, wh ich supposedly has HIV traits as well as t raits
to increase transmission.
I have wondered if COVID-19 is like Legionella, and possibly transmitted in the airborne water droplets
in the air conditioning units of the Diamond Princess ship.
Even with the SARSCoronavirus, it was shown to be infective on fomites for up to 28 days unless 40
degrees Celsius and 80% humidity, when it was then inactivat ed in a few hours (see the attached
article). I am wonder ing if the trays of food, after being passed to passengers on the ships, were then
washed in suboptimal conditions (NOT at 40 degrees Celsium for several hours at 80% hum idity)
I AM concerned , that based on the reinfection of those in Wuhan, China, after they returned home, on
whether 14 days of quarantine is enough, based on the modeling and studies on the SARSCoronavirus,
and whether 28 days of quarantine may actually be needed.
With the HIV virus component of COVID 19, one must also wonder if the T cells are being infected and
passing the infection along with in an infected pat ient . In the U.S., we may need to beware of blood
trans fusions from anyone infected, even asymptomatically, w ith COVID 19.
I am sure that you have teams of clinicians and scientists working on this, and I don't know if any of the
original scientis ts working on the SARSmodels are still around at Chapel Hill to perform these related
studies and modeling .
Angela Moore
Angela Yen Moore, MD

Arlington Center for Dermatology
Arlington Research Center
NIH-001805
711 East Lamar Blvd., Suite 200
Arlington , Texas 76011
phone 817-795 -7546
fax 817-226-7546
NIH-001806
From: Fauci, Ant hony (NIH/N IA ID) [E)
Sent : Tue, 18 Feb 2020 02:48: 13 +0000
To : bdohe rty@mrns.org
Cc: lbaden@nejm. or g;Redfiel d, Robert R. (CDC/OD); (b)(6) ;Eisinger,
Robert (NIH/ NIAID) [E];Greg Fol kers (b)(6)·Conrad, Pat ri cia (NIH/ NIAID) [El
Subject : RE: New England Journal of M edicin e Edito ria l
Attachment s: NEJM Edito ria l - Fauc i et al - FINAL - 02-1 8-2020.docx
Briana and Lindsey :

As promised, lam attaching the invited Editorial related to the COYID-19 manuscript that we had discussed.
Should l also submit it through the NEJM online website or will you talce care of this? We will send in the COi and
authorship forms in the next day or 2. Please let me know if you have any questions. Thank you.
Best regards,
Tony
Director
Nationa l Institute of Allergy and Infectious D iseases
Nat iona l Institutes of Health
Bethe sda, M D 20892-2520
Phone : (b) (6)
FAX : (301) 496-4409
E-mai l (b) (6)
The informa tion in this e-mail and any of its attachmen ts is confidential and may contain sensitive infom1ation. It
should not be used by anyone who is not the origina l intended recip ient. lf you have received this e-mai l in error
please inform the sender and delete it from your mailbox or any other storage devices. The Nationa l Institu te of
Allergy and lnfectious Disease s (NIAID) shall not accept liability for any statements made that are the sender's own
and not express ly made on behalf of ihe NIAID by one of its representatives.
-----Orig inal Message-----

From: B riana Doherty <onbehalfof@manuscriptcentral.com>
Sent: Monday, February 10, 2020 11: I I AM
To: Fauci, Anthony (NIH/NTAlD) [El ------~~ (b)( 6) >
Cc: lbaden@nej m.org
Subject: New England Jou rnal of Medicine Editorial
Dear Dr. Fauci,
I am delighted t:hat you have agreed to write a signed editorial to accompany the article on the initial estimates of
key transmission parameters associated with nCoV-2019 virus by Li et al.
The general purpose of the Journal's editorials is to provide the reader with an authoritati ve interpretat ion or
elaboration based on the substance of the article. Since this substance is usually not within the average reader's
special competence, such readers will particularly benefit if the editorial avoids technical jargon , explains the
article's contribu tion to a field of knowledg e, and emphasizes , whenever possibl e, its clinical implications. The
editorial commentary should not be concerned exclusively with the article in question but rather should use the
article as a starting point for a more genera l discussion.
Because editorials involve interpretation and opinion, you and your potential coauthor must be free of significant
NIH-001807
relevant financial associations (including equity interest, regular consultancies , or major research support) with a
company, or with a competing company, that stands to gain from the use of a product discussed in the editorial.
Please contact me immediate ly if you are considering a coauthor , so I can ensure that your candidate meets our
criteria. Additional information about disclosure of financial and other associations appears below this letter.
Please bear in mind that your editoria l represents your (and any coautho r's) personal opinion. The Journal does not
include statements of grant or other support or acknowledgments with editorials.
Journal po licy dictates that we must have on file a signed Copyright Transfer and Authorship Agreement from each
author before a manuscript can be accepted. Therefore, the enclosed form should be signed by all authors and faxed
to (781) 207 -6529.
Your editorial is due at the Journa l on Monday, February 17, at the very latest if the deadline imposed by our
printing schedule is to be met. ff the editorial is to include a figure, please submit the figure at least one week before
the due date for the editorial itself.
*** Additional information about preparing and submitting your editorial is given below; please read it carefully.
***
The editors must reserve the right to edit (or even reject) your editorial , but whether we use it or not, the Journal
currently offers a modest stipend of$300.
Thanks agaw for agreeing to write this editorial for the Journal. I look forward to receiving it.
Sincerely yours,
Lindsey R. Baden, M.D.

Deputy Editor
New England Journal of Med icine

IOShattuck Street
Boston, MA 02115
(617) 734-9800
Fax: (617) 739 -9864
http ://www .nejm.org
LENGTH OF YOUR EDITORIAL

NEJM editorials should not exceed two printed pages. This means that your word count before editing should not
exceed 750 words (approximately 4500 characters). Note that we spell out trial names and most other abbreviations
for our readers, and we include trial registration numbers for any clinical trials mentioned; these will lengthen your
editorial if you have not included them. Please provide a title not exceeding 45 characters and a word count for the
text; the entire manuscript , including references , should be double-spaced.
REFERENCES
Cite no more than 10 references , including the article you are writing about. The average collection of 10 references
requires about a quarter of a printed page.
TABLE OR FIGURE
A table or a figure in your edito,ial will require a reduction in the number of words ; because figures and tables vary
in size, you may be asked to shorten the text of your editorial during the production process. A quarter-page table
roughly equals 250 words , and a half-page table roughly equals 500 words.
DISCLOSURES
When completing your disclosure fonn , please indicate, in the "Comments" field next to the type of relationship
being disclosed, the amount (in U.S. dollars) of any support you have received. Please also indicate how much of
NIH-001808
this support has been received over the past 2 years. Please e-mail your completed disclosure form to
editorial @nejm.org.
ln the event of publication, each author's submitted disclos ure form will be posted on the Web (with any dollar
amounts redacted) .
COPYRIGHT TRANSFER
Each author must complete a copyright transfer agreement form. Please sign it and fax it back to 781-207-6529 as
soon as possib le.
TO SUBMIT YOUR EDITORIAL

*** It is important that you follow the instructions below to ensure that your article enters the con-eel.queue. ***
When you are ready to subm it your manuscript, please log in to the New England Journal of Medicin e - Manuscript
Centra l site (http ://mc05.manuscriptcen tral.com/nejm). Your case-sensitive USER ID is afauci@niaid.nih.gov. For
security purposes, your password is not listed in this message. If you are unsure of your password , please visit
https://mc05 .manuscr iptcentral.com/nejm and enter your e-mail address in the "Forgot Your Password ?" field.
Once you are logged in, the Main Menu will be displa yed. Please click on the Author Center, where you will find
the manuscript listed under "Invited Manuscripts ." You can click on the "Continue Submission" button to begin
submitting your article.
NIH-001809
Sent : Tue, 18 Feb 2020 02:09:48 +0000
Subject : FW: Comment s on Tedros
FYI
From: John Lauerman (BLOOMBERG/ NEWSROOM:) <jlauerman@bloomberg.net>

To: Fauci, Anthony (NIH/NIAID) [E]------ -=
(b-c-
)(c=
6)
Subject : Comments on Tedros
BTW, I just saw t h at you tr ie d me ear lie r a n d I d idn ' t respond .

I was in Geneva and evidently didn ' t have service . Hope we can
connect t hi s t im e . Bes t number i s my desk , +44 2035 2 5 1 028 .
Thanks aga in , JL
From : John Laue rman (BLOOMBERG/NEWSROOM

: ) At : 02/17/2 0
1 4 : 37 : 11
To : AFAUCI @N
I AI D. NIH . GOV
Sub j ect : Comments on Tedros
Hi Dr . Fauci : I ' m work in g on a story about WHO DG Tedros a nd t h e

work that he ' s doing to contain the coronavir u s epidemic . I ' m
planning on disc ussing a number of themes , incl uding that
respo nding t o outbreaks has become t he mos t v i sib le job of t he
DG in the past couple of decades . I ' d also like to explore the
issue of how important it is t hat countries be as ope n as
poss ible about d isease outbreaks , and t h at i t ' s t he DG' s job to
enco u rage that and mov e countries toward gr eater transparency
and participation in battling outbreaks . Would you ca r e to
comment on t he job t hat Tedros is doi ng in t he se areas? Ple ase
giv e me a call at + 44 2035 251028 or let me know when and at
what number to call you . Thanks and re ga rds , John Lau er man ,
Bloomberg News

3 Queen Vrctona Street London UK
te + l4 ,r) 20 2 12 •t:)11 -------~= (b)(6)
http ://www .bloombe rg .com ---------
http://www .bloombe rg .com /prog nos is
NIH-0018 10
Sent : Tue, 18 Feb 2020 02:09:18 +0000
Subject : FW: Comment s on Tedros
Please t ry to set up a call with John Lauerman
From: John Lauerman (BLOOMBERG/ NEWSROOM:) <jlauerman@bloomberg.net>

)(c=
6)
Subject : Comments on Tedros
Hi Dr . Fauc i: I ' m work ing on a s t ory about WHO DG Tedros a nd t h e

work that he ' s doin g to contain the co r onavirus epide mic . I ' m
p l a nning on d i scuss in g a number of t h emes , in c l ud in g t h at
respo n ding t o ou t breaks h as become t he mos t v i sib le job of t he
DG in the past couple of decades . I ' d also like to explore the
issue of h ow im porta n t i t is t h at coun t ries be as o p en as
poss ible abo u t d isease ou tb reaks , a n d t h a t i t ' s t he DG' s job t o
enco u rage that and move co u ntries toward greater transparency
and participation in battlin g outbreaks . Would yo u ca r e to
comme n t o n t he job t h at Te dros is do ing in t he se areas? Pl ease
giv e me a call at +44 2035 251028 or let me know when and at
what number to call you . Thanks and re ga rds , J ohn La u er man ,
Bloomberg News

3 Queen Victoria Street , London , UK
tel. +44 (0) 2035 251028 cell -------~= (b)(6)
http :// www .bloomberq.com ------------
http://www .bloomberg .com /prognos is
NIH-001811
Sent : Tue, 18 Feb 2020 02:02:35 +0000
Subj ect : (b) (5)
Cristina:
(b) (5)
Tony
Director
Phone : (b)(6)
FAX : (301 496-4409
E-mail : (b)(6)
NIH-0018 12
From: (b)(6)
Sent: Mon, 17 Feb 2020 20:56:50 -0500
To: Collins, Francis(NIH/OD) [E]
Subject : Re:
---------- (b) (5 for SARS
-CoV-2
(b) (5)
On Feb 17, 2020, at 8:48 PM, Collins, Francis (NIH/OD) [E]

------- (b) (6)>wro t e:
Hi Tony,
(b) (5)
Francis
NIH-0018 13
Sent: Tue, 18 Feb 2020 00:20:01 +0000
To: Townsend, Frances
Subject : RE:This ongoing 2019 novel coronavirus, or COVID-19,outbreak has a number ...
Fran:
Thanks for the note. You certainly have covered a lot of ground with your questions. I look forward to seeing
you tomorrow.
Best rega rds,
Tony
Director
National Institu te of Allergy and Iofectious Diseases
Phone: (b) (6)
FAX: (301) 496-4409
E-mail (b)(6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It
please inform the sen der and delete it from your mailbox or any other storage devices. The National Institute of
Allergy and Infectious Diseases (NJAID) shall not accept liability for any statements made that are the sender's own
from : Townsend, Frances <FTownsend @l\1AFGRP.COM>
To: (b)(6) ; Shuy, Bryan (OS/ASPR/IO) (b)(6)
Fa uci, Anthony (NlH/NIAID) [E) Cb)(6) Conrad , Patricia (NJWNIAlD)[E]
(b)(6)
Cc: Hanson, E lizabet h <ebanson @MAFGRP.COM >
Subject: This ongoing 2019 no ve l coronavirus , or COVID -19 , outbreak has a number ...
All: Below is an outline of questions for tomorrow at CFR . Sorry to get this to you late but it seems the news
changes everyday. As you will see I focus mostly on coro navirus as 1 suspect that's where the interest will be but get
to bio weapons toward the end.
l am happy to take additional questions or suggestio ns. These sess ions go quickly and we ha ve time for Q and A so I
doubt I will get through it all but wanted you all to have something to look at.
Thanks again for doing this tomorrow.
Best
Fran
NIH-0018 14
This ongoing 2019 novel coronavirus, or COVID-19 , outbreak has a number of historic firsts. It's the largest
quarantine in world history with China locking down over 60 million people. It's the first mass repatriation of
Ame1ican citizens into a quarantine , climbing over 1,000.
Let's start with some quick basics: what is coronavirus? How contagious? What is the morbidity rate?
How does it compare to SARs and MERs? More/less infectious? Lethal?
Just to put this in perspective every year here in the US we deal with the flu. How many Americans on average die
each year from the flu?
But as I mentioned corona virus has resulted in a number of historic firsts , talk about what you expect could be our
scientific firsts and what roadblocks do those scientific firsts confront?
Over the years, global economic interdependence has grown in nearly every industrial sector, including health care.
But that means our health care is also globally interdependent on other systems less equipped, less transparent and
perhaps less responsible global actors .
China closed the wet market where the coronavirus outbreak began on 1/l , gene sequenced the virus on l/9 so they
could develop a diagnostic test but did not share the gene sequence with the global hea lth community until 1/ 12.
How transparent and quick was the Chinese response? What should the have done that they failed to do? What were
the consequences?
China now claims more than 70K infected and almost 1800 deaths from the virus. But Jt has been widely reported
that the Chinese have underreported both numbers. what are Countries international obligations to report accurately?
To whom? How do you know the numbers are accurate?
How does the cwTent outbreak impact the domestic medical supply chain? What steps could or should we consider
to enhance supply chain resilience?
What do the numbers suggest to you about what to expect regionally and worldwide? Have numbers peaked? Will
they continue to 1ise? With the cruise ship there re now a total of 15 Americans infected. Do you expect additional
cases? What scale? How prepared are we nationally? Locally?
Looking back over the roughly past decade , emerging infectious diseases played a recurring ominous theme . Be it
from HlNl, to ebo la, then Zika, and now the 2019 novel coronavirus, the threat is clearly not dissipating. When it
comes to non-disease natural disasters , the Stafford Act provides a Disaster Relief Fund to enable immediate
response. By comparison , there is a small Infectious Diseases Rapid Response Reserve Fund. Do we need a more
Stafford Act-like mechanism to enable quicker response and research to these new threats? What other actions can
we take to better prepare ?
While often we see folks painting emerging infectious diseases and biodefense into separate categories , the truth is
that there is significant crossove r in terms of preparedness and research. Understanding that this is a sensitive topic,
could you talk about how we should approach these risks in a comprehensive manner that can achieve public health
and national security objectives concurrent ly?
I'd like to use this to transition to the topic of bio weapons which is what we originally planned to talk about. The
landscape here has also transfom1ed. When BioShield was written and the Strategic National Stockpile established
we worried about State actors deploy ing banned weapons like small pox; plague and hemorrhag ic fever. And you
NIH-001815
still must prepare against those things as well as new and emerging threats like the toxins we have seen deployed by
Russia and North Korea in more targeted assassinations.
How do you stay ahead of these threats? Do we have the resources and surveillance that we need to stay ahead of the
threat? And ensure the necessary vaccines and therapeutics?
The ebola outbreak may be an instructive example , it seems to be coming under some control despite the precarious
security situation in the Democratic Republic of Congo. But the ongo ing 2018 outbreak was the second largest in
history following the 2013-2016 West African outbreak. As a result of these outbreaks, the United States
government has pioneered new FDA-approved diagnostics and vaccines , with promising therapeutics seemingly
around the approval comer too. What lessons can we draw from the ebola outbreaks? How do you work with and
incentivize industry to develop what you need in the event of a catastrophic bio attack? And How do you make the
best possible decisions about the stockpile?
I always worried that because we are global leaders if there was a bio attack or outbreak anywhere in the world,
others would look to us and to our stockpile for the answer. Are our global allies doing enough to prepare against
these tbreats--whether they be manmade or natural? Are they maintaining adequate stockpi les of medical
countermeasures and research bases--and should they be?
Lastly (if we have time) ....the FBI recently arrested a Harvard scientist for accepting undisclosed grant money from
China for scientific research. It bas now been reported that there are similar investigations at a number of US
universities including Yale and MIT to name two and that the grant monies are in the billions. What are foreign
governments looking for? Why in the US? Clearly a national security risk, is it a bio weapons concern?
DISCLAIMER: This e-mail message and any attachments are intended solely for the use of the person(s) named in
the message header to whom the email is addressed and may contain information that is confidential or legally
privileged. rfyou are not the intended recipient , you are hereby notified that any dissemination , distribution,
copying , or other use of this message or its attachments is strictly prohibited . Jf you have received this message in
error , please notify the sender immediately and pennanently delete this e-mail message and any attachments (and
any copies or printouts of the same).
NIH-001816
Sent : Mon, 17 Feb 2020 20:29:27 +0000
Subject: FW: COVID-1
Attachme nts: letter to NIAID-ICIS.pdf
Please res pond to th e m. Tha n ks.
Director
Phone : (b)(6)
FAX : (301 ) 496-4409
E-mail (b)(6)
info rmation . It should not be used by anyone who is not the o riginal intended recipient . If you
have re ce ived this e -mail in error please inform the sender and delete it from your mailbox or any
From : Fitzgerald, Kate <Kate.Fitzgerald@umassmed.edu>

To: Fauci, Anthony {NIH/NIAID) [El --------:a =a<i
(b)(6)>
Cc: Eleanor Fish <en.fish@utoronto.ca>
Subject : COVI0-1
Dear Dr. Fauci,
On behalf of the International Cytokine and Interferon Society, p lease find attached a letter from us
as clinic ians and scient ists committed to deve loping and implementing therapeutic interventions targeted
against global viral infection outbreaks. We propose that high priority be given to evaluating the
therapeutic antiviral activities ofIFN -as/bc(clinically appro ved formulation s) against COVID - 19 which
poses a potent ial threat to globa l health. Further informat ion is deta iled in the attached. Tbe ICJS would
be happy to provide the scientific and clinical expe1tise for this program and welcome further discussion.
In particular Dr. Eleanor Fish copied above has the track record and expertise in this area.
Sincerely ,
Kate A. Fitzgerald IProfessor of Me dicine

President I International Cytokine and Interfero n Society (ICIS)
NIH-0018 17
www.cytokinesociety.org
Join us @ Cytokines 2020
iCIS
NIH-001818
Sent: Mon, 17 Feb 2020 20:22:39 +0000
Subject : FW: Happenings Radio Q+A ...
Let us discuss. She called me up today and I told her to send me an e-mail since I was on a cal l. (b) (5)
For discussion.
Director
National Institu te of Allergy and Iofecrious Diseases
31 Cen ter Driv e. MSC 2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b)(6)
Tbe informa tion in tbis e-mail and any of its attachments is confidential and may contain sensitive infom1ation. It
should not be used by anyone who is not the original intended recipien t. If you have received this e-mail in eITor
Allergy and lnfectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own

From: cassidy @ happeningsmag.com <cassidy @ happeningsmag.com >
Sent: Monda y, Febrnary l 7, 2020 3: 15 PM
To: Fauci, Anthony (NlH/NlAID) [E]_____ ""°'
(b"""
)(~6) >
Subject: Happenings Radio Q+A ...
Hi there,
This is Cassidy G-D from Happenings Magazine & Radio in Kenosha , Wl- we ever so briefly spoke on the phone
earlier today.
l was reaching out with the hope of getting you on our radio program for a 20-30 min ute Q+A in which we would
talk abou t the Coronavirus and more specifically the impact it is having on the Diamond Princ ess Cruise ship along
with anything you would like to talk about regarding infectious diseases and or your position as director of the
National Institu te of Allergy and Infectious Diseases .
Please let me know if you ha.ve any interest in being on the air with us a.nd I wou ld be happy to provide further
details. You ca n also get ahold ofme by our office phone at 262-564 -8800 .
Ho pe you are well and I look forward to hearing back from you, Cassidy G-D
NIH-0018 19
Sent: Mon , 17 Feb 2020 19:50:25 +0000
To : Cassetti, Cr istina (NIH/NIAID) [E]
Cc: Erbeldi ng, Emily (NIH/NIAID) [E];Mascola, John (NIH/VRC) [E];Conrad , Patricia
(NIH/NIAID) [E]
Subject: BMGF
Cristina:
I just spoke with Chris Carp and Trevor Mundel of the BMGF and they want to
try and coordinate some of the things that they and we are doing regarding
COVID-19. I told them to give you a call to set up a teleconference to discuss
respective R & D agendas of NIAID and BMGF.
Thanks,
Tony
Director
Phone : (b)(6)
FAX: (301 ) 496-4409
E-mail ( Cb
) C6J
NIH-001822
Sent: Mo n, 17 Feb 2020 18:58:46 +0000
Subject : FW: Info from China
Please have someone respond to this person.
Director
31 Cen ter Dri ve, MSC 2520
Bet hesda , MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b)(6)
The informatio n in this e-ma il and any of its attachmen ts is confidential and may contai n sensitive infom1ation. It
should not be used by anyone who is not the orig inal intended recipie nt. lf you have received this e-mai l in eITor
please inform the sen der and delete it from your mailbox or any other storage devices. The Nationa l Institute of
Allergy and Infe ctio us Diseases (NIAID) shall not accept liability for any stateme nts made that are the send er's own
From : Jodie Dillman --------~ (b
~)~(6)
=>
To: Fauci, Anthony (NlH/NlAID) [E] ------~~ (b)(6) >
Subject: Info from China
Dear Dr. Fauci,

lt is with trepidation that I reach out to you with information that has been shared with me regarding the real status
of the Coronavirus in China. My information comes to me from a (b) (6) who has correspondence from
a nurse in Harbin , Ch ina.
____ Cb _. is here on an H l V visa, employed for the past seve ral yea rs at
_~_(6)
the international studen t program. _____________________________ _
T have no reason to doubt the authent icity of the correspondence that she shared with me.
This corresponde nce shows a lung X -ray, a glass containe r of bloody fluid removed from an infected lung, and a
map of Harbin , China dep icting many areas of the coronaviru s outb reaks. The written correspondence reveals that
the numbers bein g release d of confirmed deaths is drastical ly low due to the spread be ing too fast to test. Deaths in
hospital hallway s and of medical staff is not being shared in order to preve nt pan ic.
Protec tive gear is unavai lab le and the nurse w 1iting the correspon dence is fearfu l for her life . She states that there
are five levels of screenings (tests?) before a person is reported as testing positive or o f being infected with the virus .
If someone dies before being confirmed , these suspected deaths are covered up and not report ed. Report ed numbers,
even of conftnned cases are gross ly undercounted .
l figure you and our government realize the infonnation and numbers coming out of China are highly inaccurate, but
this correspon dence on (b) (6) confirms it. I felt it was only ethical and moral to report this, despite
____ Cb _, plea that the two people involved in the correspo ndence fear governmental retribution if it was
_)_(6)
discovered that they discussed or pas sed on this confidential information .
1 report this and swear it to be true and confidential. l am tnisting it will help in some way and 11otjust stir panic.
NIH-001823
Jolonda Dillman
(b)(6)
Sent from my iPhone
NIH-001824
Sent : Mon, 17 Feb 202018:51:17 +0000
Subject : FW: Al supplementation of influenza surveillance system for COVID-19
outbreak.
FYI
Director
Phone : (b) (6)
FAX : (301 496-4409
E-mail : (b)(6)
From: Ed Peshko <esp@hedviginc.com>

-------::-::-=,
-------- (b)(6)>
Subject : Re: Al supplementat ion of influenza surveillance system for COVID-19 outbreak.
ps - feel free to contact me at this address, or my personal email address, that is

(b) (6).
again, I have no dog in this fight aside from wanting to avoid a large scale pandemic worldwide.
And I'm sincerely hoping that we throw the rulebook out - and develop a new one - to deal wi t h this the
same way we did when we dealt with the 1918-1919 pandemic.
On Mon, Feb 17, 2020 at 10:09 AM Ed Peshko <esp@hedvigin c.com> wrote:
Dr. Fauci,
Like you, I've been watching the COVID-19 out break with great alarm . Given the current data, I'm
almost positive at this point that it will hit the US hard at some point and as a student of history that
terrifies me.
NIH-001825
So I'm hoping that your department has contacted the Bill and Melinda Gates foundation and see if
you could make the following idea national or international. It is a supplemental health system based
on Al and mobile technology and consists oftwo planks:
First:
- train an Al to be able to detect COVID-19 by measurements that can be done by cell phone (for
example pictures of patients, recordings of patient's respiratory system)
Second:
- develop and release a smart-phone application that does the following :
- turns on location tracking so health authorities can see where the cell phone owner is.
- allows for people to upload health measurements from their cell phone.
- keeps TRACKof where the cell phone owner is. If that person then tests positive for COVID later
on, it can then automatically figure out all the contacts of that person for the last 14 days.
- notifies those contacts that they have been in contact with someone with COVID-19, to isolate
themselves and regularly test themselves.
The goal would be to prevent hundreds of thousands of people from descending on hospitals and
overwhelming them, and to allow for the CDCor other medical personnel to go OUT and get them -
or isolate them for treatment in their own homes - rather than having them come in and infect
everybody.
Now th is all hinges on the idea that Al could detect COVID-19 based on an audio recording or a simple
picture and do it reliably, but I'm fairly sure that it can based of the peer-reviewed literature. It is not
a difficult Al problem assuming that the microphone can pick up sounds well enough - if not, there are
already integrated stethoscopes for cell phones that could be mass produced - and once developed
to enough precision it could be deployed nationally or internationally fairly easily.
For all I know something like this is already in the works but I haven't heard of anything like it - apart
from the chinese app which AFAICTdoes not use any Al but DOESallow for automatic contact
tracing.
I sincerely hope this is already in the works. Ultimately it could be used both for detection and
treatment - assuming the current antivirals work out they could be distributed to the same
coordinates that positive diagnoses come in, perhaps by cheap drone so that nobody actually needs
to be exposed to the virus to effect treatment .
Anyways, thanks for your time and efforts. Personally I'm a software developer but I'm hoping that
perspective his helpful - for I view the fight against this virus as an INFORMATIONALfight. It's like a
fire-suppression system or food safety measures. Again, I have no clue whether or not this is already
being done, and I apologize in advance if I'm missing something and this all seems obvious .
I just think that in this case it is prudent for us to be safe rather than sorry.
Thanks much,
NIH-001826
~
NIH-001827
Sent : Mon , 17 Feb 202018:47:09 +0000
Subject : FW: Al supplementat ion of influenza surve illance system for COVID-19
outbreak.
Please han dle .
Director
Phone : (b) (6)
FAX : (301 496-4409
E-mail : (b)(6)
From: Ed Peshko <esp@hedv iginc.com>

To: Fauci, Anthony (NIH/NIAID) [E) -------=-:--:=
--------- (b)(6)
Subject : Al supplement ation of influenza surveillance system for COVID-19 outbreak .
Dr . Fauci,
Like you , I've been watc hi ng the COVID-19 outbreak with great alarm . Given the curre nt data, I'm almost
pos itive at th is point that it will hit the US hard at some point and as a st udent of history that ter rifies
me.
So I'm hop ing that your department has contacted the Bill and Melinda Gates foundation and see if you
co uld make the fo llowing idea national or international. It is a supp lemental hea lth system based on Al
and mobile technology and con sists of two planks:
First:
- trai n an Al to be able to detect COVID-19 by measurements tha t can be done by cell phone (for
example pictures of patients, recordings of patient's respiratory system)
Second:
- develop and release a smart -phone applicat ion that does the following:
NIH-001828
- turns on location tracking so health authorities can see where the cell phone owner is.
- allows for people to upload health measurements from their cell phone .
- keeps TRACKof where the cell phone owner is. If that person then tests positive for COVID later
on, it can then automatically figure out all the contacts of that person for the last 14 days.
- notifies those contacts that they have been in contact with someone with COVID- 19, to isolate
themselves and regularly test themselves.
The goal would be to prevent hundreds of thousands of people from descending on hospitals and
overwhelming them, and to allow for the CDCor other medical personnel to go OUT and get them - or
isolate them for treatment in their own homes - rather than having them come in and infect everybody.
Now this all hinges on the idea that Al could detect COVID-19 based on an audio recording or a simple
picture and do it reliably, but I'm fairly sure that it can based of the peer-reviewed lite rature. It is not a
difficult Al problem assuming that the microphone can pick up sounds well enough - if not, there are
already integrated stethoscopes for cell phones that could be mass produced - and once developed to
enough precision it could be deployed nationally or internationally fairly easily.
For all I know something like this is already in the works but I haven't heard of anything like it - apart
from the chinese app which AFAICTdoes not use any Al but DOESallow for automatic contact tracing.
I sincerely hope th is is already in the works. Ultimately it could be used both for detection and
treatment - assuming the current antivirals work out they could be distr ibuted to the same coordinates
that positive diagnoses come in, perhaps by cheap drone so that nobody actually needs to be exposed
to the virus to effect treatment .
Anyways, thanks for your time and efforts. Personally I'm a software developer but I'm hop ing that
perspective his helpful - for I view the fight against this virus as an INFORMATIONALfight. It's like a fire -
suppression system or food safety measures. Again, I have no clue whether or not this is already being
done, and I apologize in advance if I'm missing something and this all seems obvious.
I just think that in th is case it is prudent for us to be safe rather than sorry.
Thanks much,
Ed
NIH-001829
Sent : Mon, 17 Feb 202017:42:47 +0000
Subject : FW: PBSNewsHour inquiry for today
FYI
Let us discuss after I get off the AMA call, which is going long
From: David Coles <dcoles@newshour .org>

Se nt : Monday, February 17, 2020 11:51 AM
To : Fauci, Anthony (NIH/NIAID) [El------~~ >
--------
Subject : PBSNewsHour inqui ry for today
(b)(
Dr. Fauci,
Might you be available to update our viewers on the latest developments in the coronav irus story
today/tonight? We are particularly interested in getting your evaluation of the passengers who have
been released from two cruise ships. The first, in Yokohama, Japan, where over 300 Americans released
from the ship have now arrived back in the US, to go into 14 days of quarantine. 14 of those people
t ested positive at some point after leaving the ship, but before they boarded the plane . The second ship
we want to focus on is in Cambodia. Something in the neighborhood of 1,000 passengers released from
that ship have been reported to be in some state of travel to their homes, presumably around the globe.
One woman who made it as far as Malaysia tested positive there and is hospitalized in Kuala Lumpur.
We do know that the CDCis working with WHO and the cruise ship line to track down those traveling
people .
We would ve ry much like to hear from you what level of concern we should have over those many
hundreds of people traveling right now, how well quarantine works, how important it is to maintain it ,
etc. We would also like to touch on the methods of containment and treatment being done inside China
and how well those methods have worked.
I realize it is a holiday, and that could complicate things. But please let me know whether you could
consider this, Doctor, and we wi ll begin to work out the logist ics.
Thank you.
Very best regards,

Dave
David Coles
Deputy Senior Producer, National Affairs
() PBSNEWSHOUR
703 998 2104
NIH-001830
Sent: Mon, 17 Feb 2020 16:35:20 +0000
To : Smith, Steven
Subject: Re: i've been th inking about you
Attachments : image003.png
Steven:
Thanks for the note. Much appreciated. It has been 24/7 for me for the past 4 weeks. Hop e
that all is well with you.
Best,
Tony
On Feb 17, 2020, at 10:39 AM , Smith , Steven <Steven .Smith@....__ Cb 1

..... wrote:
_><
Having just come back from Australia where coronavirus is hands down a national
emergency, I've been thinking about you again and all the good work you do to
keep us safe.
I was with someone who's a diplomat with the Australian government who said
"it's much, much worse than the Chinese would have you believe. Much worse."
Melbourne and Sydney were deserted almost immediately of Chinese tourists and
students. I luckily flew through DOHA.
Hang in there. It's always something.
Steven
Steven W. Smith (b)(6) ~

(b)(6)
<image003.png >
This message
, including attachments, is confidential and may be privileged. If you received this in error. pleasenotify me by
reply email and delete this messaae
.
(b)(6)
NIH-00183 1
Sent : Mon , 17 Feb 2020 14:14:34 +0000
Subject : Re: Request from CNN's New Day
Attachment s: image001 .jpg
Thanks
On Feb 17, 2020 , at 9: 11 AM , Conrad, Patr icia (NIH/N IAID ) [E]

(b) (6) wrot e:
Working on this from med arts for tomorrow as well. Just FYI
Begi n forward ed message:
From: "Figliola , Mike" <Mike .Figliola @turner.com >

Date: Februar y 17, 2020 at 8:42:38 AM EST
To: "Conrad, Patric ia (NI H/NIAID) [E]" ,--------- ~=
(b) <
Subject: RE: Request from CNN's New Day ----------
Copy will be back soonest
Mike Figliola
Editorial Producer
CNN 's New Day
(b)(6)
mike .figliola@turner .com
<i mage00 I .jpg>
CON FIDENTIALITY NOTICE : This e-ma il transmission , and any documents,

files or previous e-mail messages attached to it, may contain confident ial
informatio n that is legally privileged . If you are not the intended recipient , or a
person responsi ble for delive ring it to the intended recipient , you are hereby
notified that any disclos ure, copy ing, distrib ution or use of any of the
informatio n contained in or attached to this message is STRICTLY
PROHIB ITED. If you have received this transmission in error , please
NIH-001833
immediately notify us by reply e-mai l at mike.figliola@turner. com or by
telephone at (917) 670-9410 , and destroy the original transmission and its
attachments without reading them or saving them to disk . Thank you.
From : Conrad, Patricia (NIH/NIAID) [El (b)(6)>
Se nt : Monday, February 17, 2020 8:42 AM---------

To : Figliola, Mike <Mike.Figliola@turner .com>
Subject : RE: Request from CNN's New Day
Between 7 am - 7:50 am ET
From : Figliola, Mike <M ike.Figliola@turne r.com >

To : Conrad, Patricia (NIH/NIA ID) [E)------- ~~ >
---------
(b)(
Working on timing- is there a preferred time?
Mike Figliola
Editoria l Producer
CNN 's New Day
(b)(6)
mike .figliola@turner .com
<image00l .jpg>
CONF IDENTIALITY NOTICE: This e-ma il transmission , and any documents ,

files or previous e-mail messages attached to it, may contain confident ial
information that is legally privileged. If you are not the intended recipient, or a
person responsible for delivering it to the intended recipient. you are hereby
notified that any disclosure , copying, distribution or use of any of the
information contained in or attached to this message is STRICTLY
PROHIB ITED. If you have received this transmission in error, please
immediately notify us by reply e-mai l at mike.figl iola@turner .com or by
telephone at (917) 670-9410, and destroy the original transmission and its
attachments without reading them or saving them to disk . Thank you.
From : Conrad, Patricia (NIH/NIAID) [El (b)(6)

To : Figliola, Mike <M ike.Figliola@turne r.com >
Subject : Re: Request from CNN's New Day
Would hit time be I. The 7 am hour? Do I have exact time?
Sent from my iPhone
NIH-001834
On Feb 17, 2020, at 4:16 AM, Figliola, Mike
<M ike.Figliola@turner .com > wrote:
Hi Patty,
Mike with cnn and new day here
Hope all is well
We are interested in checking Dr Fauci's availability for

Tuesday's show.
May you let me know if he is avail and what time frame works
best?
Topic is Coronavirus
Thanks!
Sent from my iPhone
On Jan 30, 2020, at 10:05 AM, Figliola, Mike

<Mike .Fig lio la@tu rner .com> wrote:
Hi Patty!
Morning
If we want Fauci for tomorrow, is he avail?
Barring maj breaking news we are not planning to

cancel
Thoughts?
Mi ke Figliola
Editorial Producer
CNN 's New Day
(b)(6)
mike.figliola@turner .com
NIH-001835
<image001.jpg>
CONFIDENT IALITY NOTICE: This e-mail

transmission, and any documents, files or previous
e-mail messages attached to it, may contain
confidential information that is legally privileged . If
you are not the intended recipient, or a person
responsible for delive ring it to the intended
recipien t, you are hereby notified that any
disclosure , copying, distribution or use of any of the
information contained in or attached to this
message is STRICTLY PROHIB ITED . If you have
received this transmission in error, please
immediately notify us by reply e-mail at
mike.fiq liola@turner .com or by telephone at (917)
670-9410, and destroy the original transmission
and its attachments withou t reading them or saving
them to disk. Thank you.
From: Figliola, Mike

Sent: Thursday, January 23, 2020 10:22 AM
To: Conrad, Patricia (NIH/NIA ID) [E)
(b)(6)
Subject: RE: Request from CNN's New Day
Copy thank you!
Mike Figliola
Edito rial Producer
CNN's New Day
(b)(6)
mike .fiqliola@turner .com
<image0Ol.jpg>

transmission , and any documen ts, files or previous
responsible for delivering it to the intended
message is STRICTLY PROHIB ITED. If you have
mike.figliola@turne r.com or by telephone at (917)
NIH-001836
and its attachments without reading them or saving
From:Conrad, Patricia (NIH/NIAID) [E]

(b)(6)>
To: Figliola, Mike <M ike.Figliola@turner .com>
Subject: RE: Request from CNN's New Day
Per our chat just now - can have him

avail between 6 am - 8:15. Hard stop
at 815 am ET
Patricia L. Conrad
Nat ional Institute of Allergy and Infectiou s
Diseases
(b)(6)
301-496-4409 fax
Disclaime r:
The information in this e-mail and any of its attachmentsis
confidential and may contain sensitive information. It should not
be used by anyone who is not the original intended recipient. If
you have received this e-mail in error please inform the sender
and delete it from your mailbox or any other storage devices.
shall not accept liability for any statement made that are
sender 's own and not expressly made on behal f of the NIAID by
From: Figliola, Mike <Mike .Figliola@turner .com >

(b)(6)
Ok- we wont know until 1030a meeting - is it ok

to hold 6 and 7a until then?
Mike Figliola
NIH-001837
Editorial Producer
CNN 's New Day
(b)(6)
mike.figlio la@turne r.com
<image00l.jpg>

confidential information that is legally privileged. If
responsib le for delivering it to the intended
disclosure , copying, distribu tion or use of any of the
message is STRICTLY PROHIB ITED . If you have
m ike.figliola@turne r.com or by telephone at (917)
670-9410 , and destroy the original transmission

(b)(6)
Sent: Thur sday, January 23, 2020 10:00 AM
To : Figliola, Mike <Mike .Figliola@turner .com >
Sorry to be a pain-if you think it will be

in the 6 am hour - we might need to
use a diff erent studi o ...if its in th e 7 am
hou r we can use our remote studio ...
Any thoughts as to which hour again,

sorry
Patricia L. Conrad
Special Assista nt to the Director
Nation al Institute of Allergy and Infectious
Diseases
Th e National Inst itutes of Health
3 1 Center Driv e, MSC 2520 - Room 7A03
NIH-001838
Bethesda, M aryland 20892
(b)(6)
30 1-496-4409 fax
Discla imer:
The information in this e-mail and any of its attachments is
co nfidential and may contain sensit ive informati on. It should not
be used by anyo ne who is not the original intended recip ient. If
and dele te it from your mailbox or any othe r storage devices.
sende r's own and not expressly made on beha lf of the NIAID by
From: Figliola , Mike <M ike.Figliola@turne r.com >

(b)(6)>
Copy thank you
Mike Figliola
Editoria l Producer
CNN 's New Day
(b)(6)
mike.figlio la@turner .com
<image001 .jpg>
CONF IDENTIALITY NOTICE: This e-mail

transmissio n, and any documents, files or previous
e-mail messages attached to it, may contai n
confidentia l information that is legally privileged . If
respons ible for delivering it to the intend ed
message is STRICT LY PROHIBITED . If you have
immediately notify us by reply e-mai l at
mike.figlio la@turner .com or by telephone at (917)
and its attachme nts withou t reading them o r saving
them to disk. Than k you.
NIH-00183 9
(b) ~ >
To: Figliola, Mike <M ike .Figliola@turne r.com>
Subject:RE:Request from CNN's New Day
Checking now for all t imes between 6-

9 will let you know soonest
Patricia L. Conrad
National Institute of Allergy and Infe ctious
Diseases
(b)(6)
301-496-4409 fax
Disclaime r:
The information in this e-mail and any of its attachmen ts is
confidential and may contain sensit ive informat ion. It should not
sender 's own and not expressly made on behalf of the NIAID by
From : Figliola, Mike <M ike.Figliola@turne r.com >

Sent : Thursday, January 23, 2020 9:10 AM
To: Conrad, Patricia (NIH/NIA ID) [El
(b)(6)
Subject: RE:Request from CNN's New Day
Hi again
Could be back half of 7am but if this gets much

worse we may play it higher in the hour - is there
any time that doesn't work?
Mike Figliola
Editorial Producer
CNN 's New Day
(b)(6)
NIH-001840
mike.fiqliola@turner .com
<image00l.jpg>

responsible for delivering it to the intended
message is STRICTLY PROHIB ITED. If you have
received this transmission in error , please
mike.fiqliola@turner.com or by telephone at (917)

(b)(6)

To: Figliola, Mike <Mike .Figliola@turner .com>
Subject: FW: Request from CNN's New Day
Hi Mike - we can make this happen .

The 7 am hour is best for us but will get
back to you. do you have an idea of the
hit t ime? need to make sure our nih
studio is available.
thx
Patricia L. Conrad
Nat ional Institute of Allergy and Infectious
Diseases
(b)(6)
301-496-4409 fax
NIH-00184 1
Disc laime r:
The informat ion in this e-mail and any of its attachmen ts is
confidential and may conta in sensitive informat ion. It sho uld not
be used by anyone who is not the original intended recip ient . If
and delete it from your mailbox or any other storage devices .
sender 's own and not expressly made on beha lf of the NIAID by
From: "Figliola , Mike"

<M ike.Fig!iola@tumer.com >
Date: January 23, 2020 at 8 :36:15
AM EST
To: "Fauci, Ant hony (NIH/NIAID) [E]"
(b)(6)
Subject : RE: Request from CNN's
New Day
Hi everyone,
This is Mike with CNN's New Day
Hope yo u are well
We would like t o invit e Dr, Fauci

back to the program to discuss
coronavirus
Might he be availab le tomorrow
We air 6-9am and happy to provide

car service to and from the stud io
wherever you are located . John
Berman and Alisyn Camerota anchor
f rom NY.
Thoughts?
best,
NIH-001842
Mike Figliola
Editorial Producer
CNN 's New Day
(b)(6)
mike.figliola@turner.com
<image00l. jpg>
CONF IDENTIALITY NOT ICE: This e-

mail transmission, and any
documen ts, files or previous e-mail
messages attached to it, may contain
confident ial informatio n that is legally
privileged. If you are not the intended
recipient, or a person responsible for
deliver ing it to the intended recipient ,
you are hereby notified that any
disclosure, copying , distribution or
use of any of the information
contained in or attached to this
message is STRICTLY
PROH IBITED. If you have received
this transmission in error, please
immediately notify us by reply e-mail
at mike .figliola@turner.com or by
telephone at (917) 670-9410 , and
destroy the original transmission and
its attachments w ithout reading them
or saving them to disk. Thank you.
NIH-001843
m
NIH-001844
Sent : Mon , 17 Feb 202013:50:10 +0000
To : Natalie Rahhal
Cc: Kadlec, Robert (OS/ ASPR/10)
Subject: FW: Comments re: 14 US passengers with coronavirus and updates
Nata lie :
I sent the incorrect e- ma il address for Dr. Kadlec. Here is the correct one.
Tony

To: Natalie Rahhal (b)(6)>
Cc:
---------
(b)( ·; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Comments re : 14 US passengers with coronavi rus and updates
(b)( >
N ata lie:
Thank you for your note. Dr. Robert Kadlec, the Assistant Secretary for Preparedness and
Response (ASPR) at HHS could either answer this question or point you in the direction of
someone who could. I am copying him on this e-mail.
Best regards,
Tony
From: Natalie Rahhal (b)(6)

------------
------~= (b)(6)
Subject : Comments re: 14 US passengers with coronavirus and updates
Hi Dr Fauci,
I hope this note finds you well and that you've gotten a little rest over the weekend, during what I'm
sure is an inordinately busy time . Would you be able to elaborate on the measures taken to keep the 14
US evacuees who have coronavi rus from infecting others on board the plane? I know that remdesivir,
under compassionate use, was given to at least the first Amer ican coronavirus patient, and last week
NIH researchers published results early that it had preventive effec t s for macaques exposed to MERS.
Has the US considered using this drug to protect those exposed to but not yet infected with
coronavirus?
Thank you,
Natalie A Rahhal
Acting USHealth Editor
Daily
lltail.com
-
NIH-001845
Daily M ail Online I51 Astor Place, 9th floor, New York NY 10003
Tel: +1212402 9086

Mobile : (b) (6)
Tw itter : https ://twi t ter .co m/nata lier78?1ang=en
Email: Natalie.rahhal@mailonline.com
Disclaimer
This e-mail and any attached files are intended for the named addressee only. It contains information, which may
be confidential and legally privileged and also protected by copyright. Unless you are the named addressee ( or
authorised to receive for the addressee) you may not copy or use it, or disclose it to anyone else. If you received it
in error please notify the sender im mediately and then delete it from your system. Associated Newspapers Ltd.
Registered Office: Northcliffe House, 2 Derry St, Kensington, London, W8 STT. Registered No 84121 England.
NIH-001846
From : Fauci, Anthony (NIH/NIAI0) [E)
Sent : Mon, 17 Feb 202013:24:34 +0000
Cc: Conrad, Patricia (NIH/NIAID) [E];Doepel, Laurie (NIH/NIAID) [E];Eisinger, Robert
(NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID ) [E);Marston, Hilary (NIH/NIAID) [El
Subject : RE:ASF ------ attached for your rev iew is draft abstract for Florence vaccine
meet ing
Attachments : Keystone abstract --transform ing vaccinology- - 3-16-2020 - with minor Fauci
edits.docx
Greg:
This looks great. I have made some min or edits that are trac ked in the document. Please
accept these and then it is ready to go. Thanks.
Best,
Tony
From : Folkers, Greg (NIH/N IAID) [El

---------
(b)(6)
To: Fauci, Anthony (NIH/NIAID) (E] ------~= (b)( 6)>

Cc: Conrad, Patricia (NIH/NIA ID) [E] (b)(6) >; Doepel, Laurie (NIH/NIAID) [E]
(b)(6)>;Eisinger, Robert (NIH/NIAID) [E) (b)( ; Folkers, Greg
(NIH/NIAID) [E] CbH6J; Lerner, Andrea {NIH/NIAID) [El (b)(6);
Marston, Hilary {NIH/NIAID) [E] (b116)1>
Subject : ASF ------ attached for you r review is draft abstract for Florence vaccine meet ing
Disclaimer : Any third -party material in this emaiJ has been shared for internal use under fair use provisions
of U.S. copyright law, without further verification of its accuracy /veracit) '. It does not necessarily repre sent
my views nor tbose of NlAlD, NIH, HHS, or th e U.S. government.
NIH-001847
Sent: Sun, 16 Feb 2020 22:28:19 +0000
To: Jon LaPook
Subject : RE:Coronavirus
Jon:
I have no idea what this guy is talking about. 1 have never said the RO was close to 5 or 6. The RO is about 2.0
to 2.2. Also, the situation is as we have discussed on several occasions . In the USA, the travel restrictions seem to
be working with only 15 cases in the USA (13 travel and 2 spouses) . But, as I have said, this could change. Ifwe
get substantial sustained transmission in a numbe r of countries throughout the world, including the developing
world, then sooner or later there will be significant leakage of infect ed individuals into the US A since you can not
restr ict inco ming travel from the w hole woild. T he way we might be able to avoid a real globa l pandemic is if t he
non -Chfoa countr ies can co nta in the infect ions in their respec tive count ries before there is widely distrib uted
sustained transmissions. Once w idely d istributed sustained transmissions happen, a g loba l pandemic is inevitable.
What would a global pand emic mean? ft depends on the true rate s of morbidity and mortality. The curre nt ly
repo rted mortality of COVI D-19 is about 21/o. However, there are seve ra l folds more cases than a re com in g to the
official attention of h ea lth autho1ities, i.e . asymptomatic or minima lly symptomatic in fections . If yo u cou nt these,
the denominator gets much larger and the case fa ta lity rate could drop to 1% of even 0 .5 % or less. If that is the
case, then this could be a very severe seasona l flu (0.2% to 0.4% ; regular seaso nal flu is 0.1 %) or a typical pandemic
lik e 1957 or 1968 (0.5% -0.9 %). We are not sur e w here it is goi ng to land .
Hope this is helpful .
Best,
Tony
D irector
National lnstih1te of Allergy and Infectious Diseases
Bethesda, MD 20892-252 0
Phone: (b) (6)
FAX: (301) 496-4409
E-mail (b)(6)
The informatio n in this e-mail and any of its attachments is confidential and may contain sensitive infom1at ion. It
should not be used by anyone w ho is n ot the o rig inal intended recipie nt . lfyou have received this e-ma il in e rror
ple ase inform the se nder and delet e it from your mailbox or any ot her storage devices. T he Nationa l Institute of
Allergy and Jnfectio u~ Diseas es (NTAID) shall not accept liability for any stateme nts made that ar e the sender's ow n
and not expr essly made on behalf of the NIAID by one of its representatives.
---- -Original Message- ----

Fr om: Jon LaPook ______ __,(b""'
)..,.
(= >
To: F auci, Ant hon y (NI H/NIAID) [El -------.,;
---------
== (b)(
Hi Tony,
l thought you would be interested to see a text (be lo w my ema il) I j ust got from a very smart Wall Street guy who
has been filling me in on reaction there. l 've been doing my best on air to put the current situation in perspective -
communicating that the risk in the U .S . is still re lative ly low while letting viewers know the situation is fluid and
could change. How would you sum up where we are now?
Thanks ,
Jon
NIH-001848
TEXT I JUST RECEIVED:
"Doc, total panic mode setting in . Tony Fauci talking R nought at closer to 5 or 6. Good biotech guys saying it
might not die down in April. People talking about 60% ofus will get it ; unstoppable in Africa. r can't scare people
but this is really bad. I hate bothering you on this but I know I need to take my cue from what you will say on CBS"

Chief Medical Corresponde nt, CBS News
NYU Langone Health
Twitte r @DrLaPo ok
NIH-001849
Sent: Sun, 16 Feb 2020 21:16:02 +0000
To: Lucassen,Elisabeth B
Subj ect : RE: Coronavirus patient--secure
Elisabet h:
Do yo u have t ime for a qu ick ph one call?
Best,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Lucassen,Elisabeth B <Elisabeth.Lucassen@providence.org>

-------=---c-c=
Subj ect : Coronavirus patient--secure
Impo rt anc e: High
Dear Dr. Fauci,

(b)(6)
NIH-00185 0
(b)(6)
------- (b)(6) _ Any input would be mostappreciated.Many thanksin advance!
Sincerely,
ElisabethLucassen
This message is intended for the sole use of the addressee , and may contain information that is privileged, oonfldential and exempt from
disclosure under applicablelaw. If you are not the addressee you are herebynotified that you may not use, copy, disclose.or distribute to
anyonethe messageor any information contained in the message.If you havereceivedthis messagein error, please immediately advise the
senderby replyemail and delete this message.
NIH-001851
Sent : Sun, 16 Feb 2020 20:40:58 +0000
To : Redfield, Robert R. (CDC/OD)
Cc: Greg Folkers (b) ( ·)
Attachments : nejmoa2001316.pdf, NEJM Editorial - Fauci et al - clean with Fauci edits
accepted.docx
Bob:
As per our discussion, I am attaching the Editoria l together with the NEJM paper
upon which t he editorial is base d . Please take a look and give your approval. Of
course if you have any comm ents or edits, th ey are most welcome. As
mentioned, the NEJM wants the manuscript by COB tomorrow (Monday).
Thanks,
Tony
Director
Bethesda MD 20892 -2520
Phone: (b)(6)
FAX:(301 496-4409
E-mail (b)(6)
NIH-001852
Sent: Sun, 16 Feb 2020 20:20:29 +0000
To: Arthos, James (NIH/NIAID) [E)
Subject: RE: one on one
No prob lem. I am drowning in coronavirus and our meeting likely would have
wound up being cancelled anyway. Hopefu lly, we will soon get back to some sort
of normality in our meetings. Thanks.
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail Cb)(6)
From: Arthos, James (NIH/NIAID) [El

---------
(b)(6)
-------=-,--=,
Subject : one on one --------
Hi Tony ,
I'm very sorry to bother you when you are so busy. Regarding this Tuesday, we are on your
schedule for a one on one and unit head meeting. something came up last minute andl am
going to be away from Tuesday through Friday, so I won't be able to make either. Sorry for the
late notice.
Jim
NIH-001853
Sent: Sun, 16 Feb 2020 20:17:53 +0000
To : Lane,Cliff (NIH/NIAID) [El
Cc: Gr eg Folker s Conrad, Patricia (NIH/N IAID) [El
(b)(6)c,
Subject : NEJM manuscript
Attachments: NEJM Editorial - Fauci et al - clean wuth additional Fauciedits - 02-15-
2020.docx, NEJM Editorial - Fauciet al - clean wit h Fauci edits accepted.docx
Cliff ;
I am attaching 2 documents: 1) The revised manuscript t hat Greg worked on in which I have
added a number of t racked changes including deleting a substantial amount to get it between
800 and 900 words; and 2) A clean vers ion where I have accepted all the t racked changes
(Greg's and mine). Right now I lik e it the way it is and would not change it much if at all. What
it needs now is references. Greg will take a shot at adding the references . If you have
references, please send them to Greg and me. In the meant ime, I will send it without
references to Bob Redfield for his review/approval. Let us discuss by phone if you wish.
Than ks,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
other storage dev ices . The National Institute of Allergy and Infectious Diseases (NIAID) shall not
NIH-001854
Sent: Sun, 16 Feb 2020 19:19:00 +0000
To: Greg Folkers (b)(6))
Subject: NEJM manuscript
Attachments: NEJM Editorial - Fauci et al - clean wuth addit ional Fauci edits - 02- 15-
2020 .docx, NEJM Editorial - Fauci et al - clean wi t h Fauci edits accepted.docx
Greg;
I am attaching 2 documents: 1) The revised manuscript that you sent to me in which I have
added a number of tracked changes includ ing deleting a substantial amount to get it between
800 and 900 words; and 2) A clean version where I have accepted all the tracked changes (yours
and mine. Right now I like it the way it is and would not change it much if at all. What it needs
now is references. Can you add up to 10 references? It might be easier for you to do that
rather than Cliff. If not, I will send to Cliff and see if he can do it. In the meantime, I will send it
without references to Bob Redfield for his review/approval. Let us discuss by phone if you
wish .
Thanks,
Tony
Director
Phone : (b)(6)
FAX : (301 496-4409
E-mail : (b) (6)
The information in this e -mail and any of its attachments is confidential and may contain sensitive
have received this e-mail in error please info rm the sender and delete it from your mailbox or any
NIH-001855
Sent: Sun, 16 Feb 2020 12:12:58 +0000
Subject : FW: COVID-19 therapy
Please handle.

From: Cesare Cocchi _______ _.,(b
,..,,
~...,.
(6)
=>
-----~~=
To: Fauci , Anthony (NIH/NIAID) [E] ..._ _____ (b
_)_C_,>
Subject: COVTD-19therapy
Dear Doctor Fauci,

J am a pediatrician from (b)(6) (IT) .
J was wondering if high doses of vitamin A have been tried in the therapy of COVID- 19.
Do you remember the cases of viral pneumonia due to measles that take place in African infants in the late seventies.
Jt seemed to work.
Many sorry to bother you.
Have a good job!
Best regards
Cesare Coccbi MD
NIH-001856
Sent : Sat, 15 Feb 2020 22:21:34 +0000
Subject : FW: To VIMA newspaper-Greece-interview request-coronavirus
FYI
From: 0woropa Tcrw1c11 <thtsoli@tovima.gr>
To: NlAID NEWS (NJH/NJATD) <NIAIDNEWS @niaid.nih.gov >
Cc: Fauci , Anthony (NTH/NIAID) [E] (b)(6) >
Subje ct: To VIMA newsp aper-Greece-interview request-coronavirus
Hallo
My name is Th eodora Tsoli and I am a sc ience editor for the greck newspaper To VIMA (www .tovima.gr )one of the
biggest Sunday papers in my country.I would like lo hav e,ifpo ss ible,a telephon e interview with dr Fauci on the
corona virus outbreak for next Sunday' s paper.If he won't be ab le to speak ,could 1 sen d question s to which he could
answer?
Looking fotward to yo ur reply
Thank you in advance
Theodora Tsoli
:EtaA0l'lKE
arr6 to iPhone µou
:E1iµavnK6: llapaKcu.ro8Eite111voi]1ccocrn
anonoincrnc;1m8uvrov
<www.alteregomedia.org/disclaimer.html
>
Important: Please read our disclaimer<www.alteregomedia.org/di
sclaimer.html>
NIH-001857
From : Fauci, Anthony {NIH/N IAID) [E)
Sent : Tue, 5 May 2020 22:26:27 +0000
To: Foikers, Greg (NIH/NIAID) [E);Billet, Courtney (NIH/ NIAID) [E];Stover, Kathy
(NIH/N IAID) [E);Routh , Jennifer (NIH/N IAID) [E];Awwad , David (NIH/NIAID) [C]
Cc: NIAID OD AM
Subject : RE:ASF RE: Dr . Fauci video reque st: Public Service Recognit ion Week
Attachment s: ASF pub lic service recognition - w ith tracked edits -05-0 5-2020 .docx
0
See minor tr acked changes.
Director
Phone : (b)(6)
FAX : (301) 496-4409
E-mail Cb
) (6)
information. It should not be used by anyone who is not the orig inal intended recipient . If you
other storage devices . The Nat ional Institute of Allergy and Infectious Diseases (NIAID) shall not
From:Folkers, Greg (N IH/ NIAID) [E] CbH >

Sent: Tuesday, May 5, 2020 6 :16 PM
To : Billet, Courtney (NI H/NIAID) [E] -----~ ~H=6)>; Stover, Kathy (N IH/NIA ID) [E]
Cb
; Routh, Jennifer {NIH/ NIAID) [E]
CbH6J> CbH
6>1;Awwad,
David (NIH/NIA ID) [C] CbH6J>
Cc: NIA ID OD AM <NIA IDODAM@niaid.n ih.gov>
Subject : ASF RE: Dr . Fauci v ideo request: Pub lic Service Recognition Wee k
ASF-
Here is a sho rt script for Public Serv ice Recognition Week . We agreed to do a short video
ASF - can u tweak as needed?
David, could u record in some format that is easy? Cell phone or other I just learned they want by COB
tomorrow
<< File : ASF public service recogn ition.docx >>

From: Seigfreid , Kim (NIH/OD) [E] CbH6J>
Sent: Monday, Apri l 27 , 2020 4:30 PM
To : Billet, Courtney (NIH/NIAID) [E] --------=-~ (b)(6J>; Stover, Kathy (NIH/NIA ID) [E]
---------
Cc:
Routh, Jennifer (NIH/ NIAID) [E]
(b)(6)>;
Fine, Amanda (NIH/OD) [E]
(b)(6)>
Cb)( >; Polimeni, Lydia (NIH/OD) [E]
(b)(6)
Subject : Dr . Fauci video requ est : Public Service Recognition Week
Hi there,
Please see below. HHS is taking over the Partnership for Public Service IG accoun t next week for Public
Service Recogn ition Week . They asked if Dr . Fauci would be willing to do a short 30-second or less pre-
recorded video thanki ng public servants for their work . It would be featured during the takeover , and also
on NIH's other sm handles next week . It can be taken on a cell phone as sm does not require higher
resolution . Let me know if you would like to accept or decline the request.
Many thanks ,
Kim
Kim Seigfreid
Social Media Lead
NIH Office of Communications and Public Liaison
ph: (b)(6)
(b)(6)
From: Muhammad, Janell (HHS/ ASPA) (b)(6),

Sent : M onday, Apri l 27, 2020 4:10 PM
To: Seigfre id, Kim (NIH/OD) [E]
---------~~ ; Channer, Am ber (OS/OASH)
CbH6J>
---------- CbH6J>;Foster, Timothy (OS/ ASPA)

Cc: Palczewski, And rew (HHS/ASPA)
CbH6)>
CbH6J>;Pratt, Michael (OS/ASPA)
(b)(6J>; Sherman, Jennifer (HHS/OASH) (b)(6)
---------
Wi lker, Michael (HHS/ASPA) (b)(6); Dine, Brooke (HHS/ASPA)
(b)( 6)
Subject: Public Service Recognition Week
Hello All,
Hope eve ryone is ho lding up well !
OHR is taking ov er the Partnersh ip for Public Service (PPS) lnstag ram account during Public
Service Recognit ion Week (May 3-9, 2020). The OHR team has reached out about want ing to
develop a senio r leade r " mashup " video -perhaps including the DepSec. T
They asked about the feasibility of this request. They also inquired about perhaps Dr. Fauci and
the SG doing a pre-recorded video thank ing public servants for their work.
I wanted to gathe r the troops so we can identify what all is being planned for this week of
recognition and provide a POCfor OHRif the request is feasible .
Happy to set up a call, if tha t is needed to discuss further .
Thanks,
Janell
Janell Muhammad
ASPA Digital Engagement (Team Lead)
Email: (b) (6)
Office: (b) (6)
iPhone: Cb)
(6)
HHS on Facebook I HHS on Twitter I HHSLatino
Sent : Tue, 5 May 2020 22:05:41 +0000
To: Stover, Kathy (NIH/NIAID ) [E)
Cc: Billet, Courtney (NIH/ NIAID) [El;Folkers, Greg (NIH/NIAID) [El;Conrad , Patricia
(NIH/N IAID) [El
Subject: RE: FORASF REVIEW:Draft PR re: launch of ACTT 2 COVIO treatment study
See my minor change of my comment in red.
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: __ __,.,_, (b)(6)
The information inlh ,s e-mail and any of its attachments is confidential and may contain sensitive
information. It should not be used by anyone who is not the orig inal intended recipient. If you
From: Stover, Kathy (NIH/NIAID) [El (b)( 6)r>

Sent : Tuesday, May 5, 2020 1:52 PM
To: Fauci, Anthony (NIH/NIAID) [El ------ ::;..,..-,=
';::::=====~~
Cc: Billet , Courtney {NIH/NIAID) [El (b)( >; Folkers, Greg (NIH/NIAID) [El
_______ Cb C6); Conrad, Patricia (NIH/NIAID) [E)
_> _ (b)(6)
Subject: FORASF REVIEW: Draft PR re: launch of ACTT 2 COVID treatment study
Hi Dr. Fauci,
Please find at tached fo r your review a draft press release to announce the launch of the ACTT 2
COVID- 19 treatment trial (remdesivir and baricitinib). Below is your draft quote:
"We now have solid data showing that remdesiv ir dimin ishes to a modest degree the
time to recovery for people hospitalized with COYID-1 9," said NlAID Director Anthony S.
Fauci, M.D. "AC TT 2 will examine if adding an anti-inflamma tory agent to the remdes ivir
regimen can prov ide addi tional benefit for patients , including improv ing morta lity outcome s."
The trial may start enrollment tomorrow.

Thanks much,
Kathy
Kathy Stover
Branch Chief
National Institutes of Health/HHS
31 Center Drive, Room 7A17E
Bethesda, MD 20892
Phone: (b)(6)
E-mail: (b)(6)
NIAID Media Line: (301) 402-1663
Sent : Tue, 5 May 2020 22:00:53 +0000
To: Cassetti,Cristina (NIH/NIAID) [El
Subject : FW: COVID-19, (b)( 4)
Attachme nts: Bi rman_Fauci_Aza r_Adams_Hahn_letter _May _OS_2020.docx
Please take a look at this.
Director
Building 31, Room 7 A -03
Phone: (b) (6)
FA X: (301 496-4409
E-mail: (b) (6)
should not be used by anyone who is not the original intended recip ient. If you have rece ived this e-mail in en-or
please infonn the sender and delete it from your mai lbox or any other storage devices. The National Institut e of
Allergy and Infectious Diseases (NJAlD) shall not accept liability for any statements made that are the sender's own
-----Original Messag'-e_- -_-------~~

From: (b)(4
Sent: Tuesday, May 5, 2020 2:51 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b)( >
------=-:--:-::, ---------
Cc: Azar, Alex M. (b)(6) > ; Adams , Jero me M (b) ( ; Hahn , Stephen (FDA)
.,_.,....,.._..,,...,,,,.........,...,..,.,.-,--,..,....,
(b)(6)
Subject: RE:COVID-19 ,
-------- (b)( 4)
Dr. Anthony S. Fauci , M.D.

Director , NIATD
Mr. Alex M . Azar TI
Secretary , HHS
Dr. Jerome M. Adam s, M.D.
Surgeon General , HHS
Dr. Stephen M. Hahn, M.D.
Commissioner of FDA , HHS
Dear Dr. Fauci ,

Dear Mr. Azar,
Dear Dr. Adams,
Dear Dr. Hahn,
(b) (4)
(b)(4
From: Fauci, Anthony (NIH/N IA ID) [El
Sent : Tue, 5 May 2020 21:17:33 +0000
To: Ma scola, John (NIH/VRC) [El
Cc: Conrad, Patricia (NIH/N IAID) [E);Erbeld ing, Emily (NIH/NIAID) [E];Dieffen bach,
Carl (NIH/NIAID) [E];Marsto n, Hilary (NIH/NIAID) [E];Billet, Court ney (NIH/N IAID) [E);Graham, Barney
(NIH/VRC) [E];Marovich , Mary (NIH/NIAID) [E]
Subject: RE: 0614G mutation paper
(b) (5)
Than ks, Jo hn .
(b) (5)
Director
Phone: (b)( 6)
FAX: (301 496-4409
E-mail: (b) (6)
other storage devices . The Nat ional Institute of Alle rgy and Infectious Diseases (NIAID) shall not
From : Mascola, John (NIH/VRC) [E] CbH >

Sent : Tuesday, May 5, 2020 5:0 4 PM
To : Fauci, Anthony (NIH/NIA ID) [E] ------~= (b)(6)>
Cc: Conrad, Patricia (NIH/ NIAID) [E] (b)( ; Erbelding, Emily (NIH/NIAID) [E]
(b)(6) ; Dieffenbach , Carl {NIH/NIAID ) [E] (b)( 6)f>; Marston ,
Hilary (NIH/NIAID) [E] (b)( >; Billet, Courtney (NIH/NIAID) [E]
-----=~ _H _6); Graham, Barney (NIH/VRC) [El
Cb (b)( 6)> ; Marovic h, Mary
(NIH/N IAID) [El (b)(6)
Subject : FW: 0614G mutation paper
Tony,
David M ontefio ri w ill be on CNN tonigh t related to t his paper - and sto ry in in majo r newspapers.
spoke with David to get some advance info . The paper is out in BioRxiV.
Few key points
(b) (5)
John
Spike mutation pipeline reveals the emergence of a more

transmissible form of SARS-CoV-2
Korber 81, FischerWM 1, GnanakaranS1, Yoon Ht, Theiler Ji, Abfalterer Wt , Foley 8 1, GiorgiEEi,
Bhattacharya T1, Parke r M0 3, Partridg e DG4, Evans CM 4, de Silva Tl4,s, on beh alf of t he Sheffi eld
COVID -19 Ge nomics Group #, LaBranche CC2, and Mont efiori DC2
Summary
We have developed an analysis pipelin e to facilitate real-time mutation tracking in SARS-CoV-2, focusing
initia lly on the Spike (S) protein because it mediates infect ion of human cells and is the target of most
vaccine strategies and antibody-based therapeutics. To date we have identified fourteen mutations in
Spike that are accumulating. Mutations are considered in a broader phylogenetic context,
geographically , and over time, to provide an early warn ing system to reveal mutations that may confer
selective advantages in transmissio n or resistance to interventions. Each one is evaluated for evidence
of positive selection, and the implications of the mutation are explored t hrough structural modeling . The
mutation Spike 0614G is of urgent concern; it began spreading in Europe in early February, and when
introduced to new regions it rapidly becomes the dominant form . Also, we present evidence of
recombination between locally circulating strains, indicative of multiple stra in infections . These finding
have important implications for SARS-CoV - 2 transmission, pathogenesis and immune interventions .
From : David Montefiori, Ph.D. (b)(6)

-----------
To : Mascola, John (NIH/VRC) [E]______ --,;-(b"'""'
)( =6)
Subject: RE: 0614G
John ,
I thought you should know that the 0614G story is getting a lot of press attention today. I story came
out in the LA Times this morning that probably started it all. It will likely be on CNN tonight , and maybe
other networks.
Just a heads-up.
David
From: Fauci, Ant hony (NIH/ NIA ID) [E)
Sent : Tue, 5 May 2020 20:43:3 9 +0000
To: Bill et, Courtn ey (NIH/ NIA ID) [E];N IA ID OD AM
Subject: RE: Dr. Anth o ny Fauci & Avi Schiffm an/T he Webby Awards
Attachments : Scri pt to honor Avi Schiff mann - 05-05-202 0.docx
Here is my tracked version of the Schiffmann script.
Director
Phone: (b)( 6)
FAX: (3 96':44li9
E-mail: (b) (6)
other storage devi ces. The National Institute of Alle rgy and Infectious Diseases (NIAID) shall not
From: Billet, Courtney (NIH/N IAID) [E] (b)(6) >

--------
To : NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: Dr. Ant hony Fauci & Avi Schiffm an/The W ebby Awards
OK- so th is is the ask from the Webby awards : a short recorded video message. They have sent a
propo sed scri pt below -- just an example - obvious ly we're free to change it . Avi is a pretty
extrao rdinary kid . 17 years old I
Here is th e site he create d, back in early January. He's aggregati ng data from W HO, CDC, and ot her
sources: https:ljncov2019. live/
NBCToday st ory: https://www.toda y.com/parents/17-vear -old -built -website -track-coronavirus -

t175 245
New Yo rker art icle about him: https://www.newyorker.com/magazine/2020/03/30/the -high-schooler-
who-beca me-a-covid-19-watchdog
From: lesley lesleycahill roy. com <lesley@leslevcahillroy.com>

To: Billet, Courtney {NIH/NIAID) [E]
==========:,::.:=
Cc: Conrad, Patricia (NIH/NIAID) [E]________ >
Subject: Re: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards
HI Courtney,
This would be a pre-recorded messagewith Dr Fauci solo . He would set up Avi's award and help to
celebrate his Webby moment for him. Avi will be sending us his 5 word Webby speech which will then
follow Dr. Fauci's intro . Below is a draft of the introduc tion for him, let us know if he would like to make
any edits/changes. I've also attached the format for taping on his phone/computer. Please let me know
if you need any additional information and hoping we can make it work .
Thank you so much
Best
Lesley
DR. FAUCI:
I'm Dr. Anthony Fauci. Unfortunately, you've seen a lot of me lately . But thankfully, I'm here to present
some good news and I'm excited for the opportunity to shine some light on one of the many young
people who have stepped up and helped us throughout a difficult time.
The 24t h Annual Webby Awards would like to honor Avi Schiffmann as the 2020 Person of the Year to
recognize his creation of ncov2019.live to track the spread of COVID-19 across the world.
As we collectively navigate the severe impact of COVID-19, including the difficult, but critica l calls for
nationwide social distancing, the Internet has become the lifeblood of people looking for accurate
information about the novel coronavirus and the necessary steps to combat it.
Since launching the site on December 29th, Schiffmann ' s tracking tool has been an invaluable resource
that sounded the alarm on the virus and its spread, notably calling attention to its severity long before
many global officials .
At a time when the spread of misinformation can be so detrimental to our efforts, the site has provided
over 600 million visitors wit h accurate real-t ime data. Schiffmann has helped people around the globe
understand COVID-19 and the necessity of upgrades to current health care systems and the importance
of measures to flatten the curve .
For having the foresight to track the global spread of COVID-19 and for creating an essential website to
provide real-time data about the virus to people everywhere , it is my great privilege to honor Avi
Schiffmann as the 2020 Webby Person of the Year.
On May 5, 2020, at 10:31 AM, Billet, Courtney (NIH/NIAID) [El
wrote:
--------- (b)(6)
Lesley- we've been discussing this. Can you tell us exactly what would be involved in
this? How many minutes would you be looking for Dr. Fauci to speak? Would this be pre-
recorded, with Dr. Fauci solo? Or would it be done as a Zoom or something like that, wit h
an interaction between Dr. Fauci and Avi?

Sent : Monday, May 4, 2020 5:31 PM
To: lesley lesleycahillroy.com <lesley@lesleycahillroy.com>
Cc: Conrad, Patricia (NIH/NIA ID) [E) (b)(6)>
Subject : RE: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards
HI Lesley- thanks so much for reaching out. Avi is so impre ssive! I am connecting you
with Dr. Fauci's assistant and scheduler, Patty Conrad, for follow-up.
From: lesley lesleycahillroy.com <lesley@lesleycahillroy.com>

Sent : Monday, May 4, 2020 5:10 PM
To: Billet, Courtney (NIH/NIAID) [E] ------ --=
(b)(6)
Subject : Fwd: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards
Hi Courtney,
Hope you are staying well during these uncertain times . I am a Talent Producer for The
Webby Awards and had reached out to Dr. Fauci regarding being involved in our "vir tua l"
internet celebration wh ich will showcase the artists, organizations, and creators using their
platforms to imagine a better tomorrow through information, educat ion, movement,
comedy, all whi le inspiring audiences to take action to enact positive change.
Avi Schiffman is being celebrated as our Person of the Year and we would be honored if Dr
Fauci wou ld "virtually" present him his honor. The official letter is below and would love
to discuss in more detail when you have a chance to review.
Thank you
Best
Lesley
From : Les ley Cah ill Roy <lesle y@ lesle y cah ill roy .com >
Subj ect: Re: Dr. Anthony Fauci & Avi Schiffman/The Webby
Awards
Date: May 1, 2020 at 12:13: 10 PM EDT
To: CbH6)
HI Dr Fauci
I just wanted to follow up on below regarding Avi and The Webby Awards .
Would be wonderful if you could be a part of this moment for him.
Thanks so much
Lesley
On Apr 20, 2020, at 1:57 PM,

lesley lesleycahil lroy.com <lesley @lesleycahil lroy .com > wrote:
<6EDD370A-6106-4603-B55 7-7AAEE9A9EF79.png>
Dear Dr. Fauci,
I hope you and t he family are all safe and healthy during t hese
challenging times. Hailed by The New York Times as "the
Internet's highest honor," The Webby Awards has been the
premiere award fo r online excellence for over two decades,
honoring t he companies and people who have critically shaped
digital technology and culture .
This year, due to the impact of the coronavirus The Web by

Awards are moving t hei r renowned awa rd show to an on line
experience . On May 19th, 2020, the 24th Annual Webby Awards
will bring togetherWebby Winners from around the world in an
Internet Celebration wh ich will showcase the artists,
organizations, and creators using their platforms to imagine a
better tomorrow through information, education, movement,
comedy, all while inspiring audiences to take action to enact
positive change .
The 24th Annual Webby Awards are proud to honor Avi

Schiffmann as the 2020 Person of the Year to recognize his
creation of ncov2019.live to track the spread of COVID-19
across the world . We would be honored if Dr. Fauci would
"virtually" present Avi with his award.
As we collectively navigate the severe impact of COVID-19 on

the world and late calls for nation-wide social distancing , the
Internet has become the lifeblood for people looking for
accurate information about the novel coronav irus. Since
launching the site on December 29th , Avi Schiffmann' s
tr acking site was a necessary tool that sounded the alarm on
the novel coronavirus and its spread, notably calling attention
to its severity long before many global officials. By providing
over 100 million visitors with real -time data on the virus'
spread, Schiffmann has helped peopl e around the globe
understand COVID-19 and the necessity of upgrades to current
health care systems and measures to flatten the curve.
For having the foresight to track the global spread of COVID-19

and for creating a website to provide real -time data about the
virus to people everywhere, it is our great privilege to honor
Avi Schiffmann as the 2020 Webby Person of the Year. The
celebration will highlight the important work Avi and his
fellow winners are doing, and will mark his hallmark Webby 5-
Word acceptance speech in Internet history. Dr. Fauci's
presenter speech could be recorded on his phone and we can
send you through a script for him to review, edit and details
for format and deadline.
This year's Webby Awards will also take action, the impact of
COVID-19 and government responses around the world, has
brought the importance of voting into sharp focus . The Webby
Awards has partnered with Vote.or and aim to check the voter
registration status of 1 million voters in the United States,
promoting the importance of voting to help ensure voter
turnout this November is the highest it has ever been . This
partnership will integrate into all elements of this year's online
celebration.
Our thoughts are with all of you in this difficult t ime.
Best
LesleyCahill Roy
(b)(6)
Sent: Tue, 5 May 2020 19:49:36 +0000
Cc: Billet, Courtney (NIH/ NIAID) [El
Subject : FW:
unlikely
Director
Phone: (b)(6)
FAX: (3 96':44li9
E-mail: Cb)(6)
other storage devices. Th e National Institute of Allergy and Infectious Diseases (NIAID) shall not
From : Konstantin Vulkov <kv@egoist .bg>

To : NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>
Cc: NIAID Ocpostoffice (NIH/NIAID) <OCPOSTOFFICE@niaid.nih.gov>; Fauci, Anthony (NIH/NIAID) [El
(b)(6) >; Harper, Jill (NIH/NIAID) [El Cb)( >
--------
Subject:
Dear Sir/ M adam ,
My name is Konstantin Vulkov and I am Program director of the biggest Bulgarian private radio station,
Darik radio (www .darikradio.bg). This is a news/talk radio station . I am a regular contributo r to Bulgarian
National TV as w ell as several on line and print publ ications , editor -in -chief of egoist.bg as well as editor -
in-chief of the biannual Darik-owned publication called Dolce Far Niente .
I am a document photographer as well , focusing mainly on portraits .
I am covering the coronavirus pandemic extensively - visiting COVID-19units across the country,
making my daily radio programme "Mind games", writing stories for our
websites www.darikradio.bg. www.dnews.bgand egoist.bg.
It would be an honour if I can make a short te leph o ne int erview with Mr. Anthony S. Fauci, M .D.
Please let me know if I can call and make the interview . I promise I won't take more than 10 minutes of
Mr. Fauci's time .
Your help is much appreciated.
Best,
Konstantin
***
Konstantin Vulkov
Program Director
Darik Radio
82, Dondukov blvd.
Sofia 1504
Bulgaria
Sent: Tue, 5 May 2020 19:48 :10 +0000
To: Lerner, Andrea {NIH/NIAID) [E]
Subject: RE: AUSTRIA- Try to support - COVID 19 - Strategy
Looks fin e.
Director
Bethesda, MD20892-2520
Phone: (b)(6)
FAX: {301 496-4409
E-mail: (b)(
have received this e-mail in er ror please inform the sender and delete it from your mailbox or any
other storage devices. The Nationa l Institute of Allergy and Infectious Diseases (NIA ID) shall not
From: Lerner, Andrea {NIH/NIAID ) [E) (b)(6)

Sent: Tuesday , May 5, 2020 3:37 PM
To: Fauci, Anthony {NIH/NIAID ) [E)_____ ---,;;(b..,..
~= c >
Subject: Re: AUSTRIA - Try to support -COVID 19 - Strategy
Dr . Fauci,
I will respond. Here is what I propose to say {in addition to thanki ng him) . Let me know if you'd change
anything:
(b) (5)
Sincerely ,
Andrea
From: "Fauci, Anthony {NIH/NIAID) [E]" (b)(6)

Date: Tuesday, May 5, 2020 at 10 :40 AM
To: "Lerner, Andrea (NIH/NIA ID) [E]"
-------. (b)(6)
=,
Subject: Fwd: AUSTRIA - Try to support - COVID 19 - Strategy
Not a crazy note. Please respond on my behalf. Thanks
Froml (b)(6)
Date: May 5, 2020 at 8:19:48 AM EDT
To: "Fauci, Anthony {NIH/NIAID) [E]" -------,; (b-,-.-
)(=6)
Subject:AUSTRIA - Try to support - COVID 19 - Strategy
Dear - highly respected - Dr. Fauci
Why do I try to childishly support a respected expert and personally

highly honored Gentleman like you - Dr. Fauxi ?
Because for me - it is heartbreaking and unbelievably disturbing, what

was and is going on in the course of the last 4 months in the USA.
I talk about the USA, that relieved my country - AUSTRIA - 75 years

ago from the hell of the NAZI-Regime - with American Lifes and
Blood.
With all my respect, my hopes, my passion, my tears, my mourning-

May Grace and Blessing be with You and the USA.
After running the numbers available on COVID 19 pandemic data - my

experiences as an Economist led to following analysis and proposed
strategy:
COVID 19 is a true threat for humans >65 years of age with pre-
existing illnesses,
but nearly influenza-like for humans< 65 years of age and humans>
65 years of age without pre -existing illnesses
AUSTRIA: Deaths by age Deaths as of 100.000 inhabitants by age
Germany- Death by age - men and women Comparison - Italy and China
- mortality rat e in %
. .,_
(3:fri,fi?@D~hr
---Id
MJnntr untcr don To~n
Jr.;CC! 1"\,t,"MII-,. ft
--~-~- ~- C..,,lt•lt--
~~~- f<s"'1
I
O•CO --
lullen: mehrCovld·l~TotealsIn China

tn ProitntderErkrantten
HortalltJtsratt
Alttrs·
gruppe11 ITAllEN CHINA
0·9 0 0
10· 19 0 0,2
20· 29 0 0,2
30-39 0,3 0,2
40· 49 0;4 0,4
S0-59
60·69 3,S
70- 79 1'2,8 8,0
~80 20,l l4,8
er Vvsto1t>ent11
A.nttllCl Obtt 80 J•hrt
• 52,3%
Proposed Strategy
1. Keep the virus 100% (totally) away from people older than 60
with pre-existing illnesses
Identify, Testing, Shelter, Preserve from contact w ith v irus, Preserve from
Hospitalizat ion and ICU
2 . Minimize possible contact with virus for people older than 60

without pre-existing illnesses
Identify , Testing, Partial Stay at Home, Social Distancing,, Preserve from
Hospitalization and ICU
Once 1 and 2 are warranted:
3. Handle the rest of the population with care, but keep them
going and working - as you would do in an influenza -season
The criti cal fact or for furth er int ervent ion is th e capacit y of th e
region ally available ICU-capacit y
Interventions : Social Distancing, Masks, Testing, Tracing, Stay at home when ill,
Quarantine at home when ill
Respectfully Yours
Gerald Glockenstein
Ma . Gerald Glockenstein
(b)(6)
From: (b)(6)
Sent : Tue, 5 May 2020 10:47:11-0400
Subject: Fwd: request of interview by Giuseppe Sarcina,corriere della Sera
Please try to get clearance. This is tb.etop newspaper in Italy
From: Sarcina Giuseppe <gsa rcina @rc s.it>

To: "Fauci , Anthony (NIH/NlAID) [E]" --------=-=--= (b)(6)
Subject: Re: request of intervi ew by Giuseppe Sarcina, corriere della Sera
Inviato da iPhone
Dear Doc. Fauci,

this is Giuseppe Sarcina, the us correspondent of Corriere della Sera,
the main italian newspaper.
I understood that you are looking at the ital ian case with great
attention.
I wonder if you can grant me a short inte rview.
I have sent an email march 21. But then I saw that you spoke with an
other italian newspape r. So I would like to have a chance to have your
voice for our Readers as well . Corriere della Sera is a newspaper based
in Milano, Lombardy , The region most affected by the coronavirus.
Thank you
Warm Regards
Giuseppe Sarcina
Washington de
(b)(6)
Oggetto: request of interview by GiuseppeSarcina,corriere della Sera
Dear Doc. Fauci,

this is Giuseppe Sarcina, the us correspondent of Corriere della Sera,
the main italian newspaper.
I understood that you are looking at the italian case with great
attention.
I wonder if you can grant me a short inte rview .
That would be really helpful fo r our readers
Thank you
Warm Regards
Giuseppe Sarcina
Washington de
From: (b)(6)
Sent : Tue, 5 May 2020 10:43:37 -0400
To: NIAIDODAM
Subject: Fwd: Invitation to Participate in Book Project on COVID-19
L et us discuss. (b) (5)

---------------------
From: Dawinder Sidhu <dss @ umbc.edu >

To: "Fauci, Anthony (NIH/NlAID ) [E]" -------~~ (b)(6)
Subject: Invitation to Participate in Book Project on COVID-19
Dr. Fauci,
I hope this email finds you well . I am a professor at the University

of Maryl and, an elected term member in the Counci l on Foreign
Relations, and a former fellow at the Supreme Court of the Un ited
States.
I am writing because I am preparing a book, tentatively ent itled

"Rebuilding America: A Blueprint for Post-COVID-19 America,"
consis tin g of essays by leading figures on (1) how COVID-19 has
impact ed their particu lar field , and (2) how that field shou ld be
reimagined in light of the crisis. The essays will reconsider all
sectors of socie ty, includin g law, education, healthcare, fash ion,
mus ic, etc. , and collectively will be the first comprehensive guide
for post-coronavirus reconstruction efforts.
I am very hopeful that you may be willing to contribute a short essay

on how the curren t coronavirus has impacted public health policy , and
how such policies can and should evolve moving forward.
Only 50 industry leaders are being asked to contribute. Commitments

have been secured from an impressive group, including a retired
four-star general and a preeminent constitutiona l scholar. I very much
hope you will take part in this inno vative projec t given you r historic
and unparalleled contributions to the public' s understanding of the
current crisis.
With respect to logistics , I am hoping to receive commitments from all

authors this month , with essays due within one month, and with the
essays availab le through Amazon's expedited publishing platform
rough ly one month after that. Each essay should be no more than 1,000
words , and I may offer light edits for the author's final approva l. A
final note: all proceeds from the sa le of the book will be donated.
I am very hopeful that you will give eve ry serious cons iderat ion to
this invitation, and will lend your voice towards reirnagining and
revitalizing a new America.
Best,
Dave
Dawindcr S. Sidhu
University of Maryland
(b)(6)
dss@umbc.edu
Sent : Tue, 5 May 2020 13:00:29 +0000
To : Lipkin, Ian W.
Subject : RE:SARS-CoV-2
Thanks, Ian. I hope that you are we ll.

Best,
Tony
Director
Build ing 31, Room 7A-O3
Phone: (b)(6)
FAX: (301 496-4409
E-mail (b) (6)
From: Lipkin, Ian W

------------
Sent : Tuesday, May 5, 2020 8:39 AM
-------=-:--:=
(b)(6)

Subject: Fwd: SARS-CoV-2 --------- (b)(6)
Tony,
(b)( 4) This
prompted the letter I sent to him last evening to which he responded this morn ing. I dont expect a
response but wanted to keep you updated. We deeply appreciate your efforts in steering and
messaging.
Allmy best,
Ian
Ps . Skell ju st invested $SM in pilot ing the GI DEoN internat io na l capacity bu ild ing and
surve illance netwo rk that includes Cliff and others in your intramu ral team .
Begin forwarded message :

From : Zh uChen Cb)(6)>
Subj ect: Re :SARS -CoV-2
Date : May 5, 2020 at 8:16:23 AM EDT
To: Lipkin, Ian W .
Dear Ian,
----------- (b)(6) >
Thank ou for our ema il detailing the (b) (4)

(b) (4)
4>. I shall keep you informed of any

--------------------
progress in the coming weeks .
Best,
CbH
Zhu
---- ------------- Original ------------------

----------~~
From: "Lipkin , Ian W "-~-- - -- -...
~---.-.---------- Cb
_H....
Date: Tue, Ma
y 5, 2020 06:06 AM
To: "ZhuChen t Cb
H ~ >;
Subj ect: SARS-CoV -2
Dear Zhu ,
The COVI D-19 pandemic poses an unprecedented threat not only to globa l public health but
also to economic and political stability . Uncerta inty about the origin of COVID-19 pandemic is
caus ing friction worldw ide, particular ly between China and the United States . There is
agreement that th e causative agent , SARS -CoV -2 originated in a bat. There is also a high level
of confidence that the virus was not deliberately modified in any labo ratory. What we do not
know is the answers to two questio ns : (1) whether a precu rsor virus circulated in the human
popu lation before it evolved to become a pandem ic virus and 2 whether a recursor virus
ada ted to humans by first passing through another animal. 4>
CbH
(b) (4)
With great affection,

Ian
W. Ian Lipkin, MD
John Snow Professor of Epidemiology and Director
Center for Infection and Immunity
Mailman School of Public Health
Professor of Pathology and Neurology

College of Physicians & Surgeons
Columb ia University
722 West 168th Street, 17th Floor
New York, NY 10032
Voice : Cb)(6)
Fax: (212) 342-9044
Email: CbH~
droi oJstrntLveCoo cdinato~

(b)(6)
www.cii .columb ia.edu

Follow CII on Twitter: CII_Columb ia I Facebook : GIi.Coiumbia
Frmn : Fauci, Anthony {NIH/N IAID) [E)
Sent : Tue, 5 May 2020 12:40:52 +0000
To: Barasch, Kimberly {NIH/NIAI D) [C)
Eiubject: FW: VP slides
Attachments: VP bri ef VRCSmay2020v2 .pptx
Director
Phone: Cb)
(6)
FAX: (301 496-4409
E-mail: (b)(6)
From: Mascola, John (NIH/VRC) [E] (b)(6)
Sent: Monday, May 4, 2020 7:07 PM ----------

To: Fauci, Anthony (NIH/NIAID) [E] < ------ --=:=
,.:::::=======6-:-
=
Subject: VP slides ----------
Tony, here are slides, including changes we discussed. Patty and all have them.
John
Sent : Tue, 5 May 2020 12:06:24 +0000
To: Harris, Mary (NIH/NIAID) [El
Subject : RE:Thank you, Dr. Fauci, Thank you so very much !
Mary:
Many t hanks fo r you r kind not e. It is much appr eciat ed. St ay we ll.
Best regards,
Tony
Anthony S . Fauci, MD
Director
Phone : (b)( 6)
FAX: (301 496-4409
E-mail : Cb)(6)
behalf of t he NIAID by one of its representatives.
From: Harris, Mary (NIH/NIAID) [El

Sen t: Tuesday, May 5, 2020 8:04 AM
--------- (b)( >
To: Fauci, Anthony {NIH/NIAID) [El------- ~=

--------- (b)(6)
Subject: Than k you, Dr. Fauci, Than k you so very much !
Dr. Fauci,
I wanted to personally thank you for being the voice of reason, security , comfort and insight. (b)(6)
As much
as I miss bein g in the office, I am grateful to say my Director is Dr. Anthony Fauci and share with my
family, friends, and church that if you said it, it's gospel. They can bank on it ! You have given comfort to
my family and myself. You will never know how much ! I want you and those who in researchers who
are hard at work withou t much rest but tons of sacrifice including that of your fami lies to find a vaccine,
give the Natio n a sense of safety and security in this unprecedented time are great ly appreciated. My
family, friend and myself are send our prayers for yo ur continued strength. Thank you doesn' t seem like
enough . I couldn't be prouder to work at NIAID and specifically on the ih floor of Buildi ng 31.
Simply Grateful,
Mary Harris
NIAID Travel Policy Specialist
NIAID Travel Card Coordinator
(b)(6)
Sent : Tue, 5 May 2020 00:37:21 +0000
To: Lerner, Andrea (NIH/N IAID) [El
Subject: FW: CORONA and BACTERIALSUPERINFECTION
Attachments : 1918 influenza insight- fauci.pdf, ESPel arroz epidemol.pdf, Infection and
lmmunity-2015-Rynda-Apple-3764.full.pdf, JClinsightco -infection.pdf, lancet.png, Mail Esp.pdf, mai l
germany 1.pdf, piramide.png, PLEASEFORWARDTHIS MESSAGETO error.pdf, portugal.pdf,
Predomi nant Role of Bacter ial Pneumonia as a Cause of Death in Pandemic Influenza - Dr Fauci.pdf,
press usa.pdf, Recuperados.pdf, spanish f lu 1918 - eng original.pdf , tyska pres mail.pdf, US error
message.pdf, Us mail 0408 .pdf, WHO-2019-nCoV-clinical-2020.4 -eng.pdf, virus piramdie eng.png
Pleas e take a look and decide. Thanks.
From:Ola Me lhus (b)(

Sent: Monday, May 4, 2020 12:25 PM
To: (b)(6) Fauci, Anthony
.-------------------------
Subject: CORONA and BACTERIALSUPERINFECTION
Dear Doctors,
I don't know if you have got this infomation.
A truly deadly virus

cannot spread very far . Why? Because people qu ickly get sick and die. In
other words, they cannot spread the virus further , which is a prerequisite for
a large spread like corona. Covid-19 has spread throughout the world.
The premise is that it is not very dangerous, it causes mild symptoms for
most people, many do not even notice that they were sick. But the virus has
different phases in the body, after a while it goes into a resting phase, you
fee l better, but the virus is still present and can pass on. Covid-19 is an
optimally developed virus that spreads rap id ly around the world. But if it
were really deadly, almost everyone would die.
So far in our 4 billion long history, there have been no airborne viruses or
bacteria. Yes, in the hollywood movie "outbreak" there was, but it was a
movie. Why hasn't it?
If it had existed, this planet would have been a dead planet without life. It
would have killed all living. It is possible that there is somewhere else in the
universe, but not here on planet Earth. Not now. Remember, this is not the
first time a new virus is spreading in the world. What is happening now has
happened earlier in our long history .
But people are die you say. Yes, but the virus don't kill them . The virus open
a "door" in the cell wall thats allows for bacterias, how always are present,
to invade the body and create an aggressiv bacterial superinfection. That's
what kills them . See,
1. Influenza and Bacterial Superinfection: Illuminating the Immunologic Mechanisms of

Disease.
Reducedsusceptlbllity Increasedsusceptibility
(d1y 2-3 post-lAVI {clay6-7 post•IAV)
FIG I Common pathw.!)'S of $umptibilit}'to postinfluenu bacterialsupennfectioru.Earlyafter influenu Virusinfection,miceshow reducedrusccpt.ibilityto

supainfection that is at leastin pan due to lncreasedprodurtlon of IL- 13.This IL-I3-ricbem'lronmentdoes not permnIFN•'Yproduction.allo\'oingunaltered
phagocytosls md clearance of bacteria. The rol, for either neutropbili. or macrophages (phagocytes) in lnnerbl dearance early dwing lnfluenu virus Infection
Im not bttn hillyinvestigated.Progres.sionof inRu,nz:aviTUSinfl'Ctionresullsin increasrosu.1apnbilit)• to secondaryinftction.Typt I IFN (or lL-27)signaling
initialedin respo03eto inlluenz.aVirusinftction rer.ultsin downrtgulatedproduction of IL-111 and 11-23and impairedtype 17 immunerespo~. Inhibitionof
IL- 17and IL-ll nduces production of antimiaobW peptides. Type I IFN signal ing also reduces levels of neu trophil diemoattr.ict:mts Cxdl and Cxc12md can
induce fonnation of NETs.lL-27rnduced during influenza virus infectionfurthersuppresses11..-17
producuon but stimulatesproductionof regulatory cytoklne
IL-10,whichcontribwes to increasedsusctptibility to superinfection,presumablyby alterationof lh• anti-influenz;iinflammatoryrt5ponse.IAV, innuenu A
virusin~ction.
and thi s reports:
2 . Deaths from Bacterial Pneumonia dur ing 1918-19 Influenza Pandemic
3. The 1918 Influenza Pandemic: Insights for the 21st Century
4. Interactions between influenza and bacterial respiratory pathogens : implica t ions for
pandemic preparedness
5. Survival duri ng influenza -associated bacterial superinfection improves follow ing viral- and
bacterial-spec ific monoclonal antibody treatment
6. Predominant Role of Bacteria l Pneumonia as a Cause of Death in Pandemic Influenza :
Implications for Pandemic Influenza Preparedness
How can this happen? How can the doctors be so blind . I have a t heory
about this and here it comes:
My
--- CbH6)was a psychologist. May she rest in peace in heaven.
It seems that the corona virus has affected the brain more in a certain group
in society, name ly politicians, doctors, journalists and other with power and
positions in the society. The virus is not dangerous for this group, but it's
opens a door in t he brain's cell wall that allows it to enter the fear center of
t he brain.
This door has been closed for many years. We haven't had any major wars
and nothing has threatened them. They have felt invulnerable. Convinced of
t heir own superior abil ity and grea t ness. Not only can they cont rol t he
people, they can now control the climate by turning the carbon dioxide tap.
If they close it, the temperature drops, if they open it the temperature goes
up. They don't know tha t the sun is 109 t ime s as big as our planet. 109
times . It seams so small when we look up in the sky. They thought they
could cont rol everything.
Then came the VIRUS, they receive an abrupt awakening. They get
sca red. Polit icans get sick and die. Doctors die. The brain is attacked by fear
virus. They can no longer think clearly and logically. The pan ic is near, they
are reminded of their own morta lity. Just like a virus in a computer. It's
slows it down and it becomes unusable. Tha ts whats happen when a fear
virus attacks the brain.
Here where I live, there are panic over 1600 confirmed cases. The telev ison
is talking "infected persons" when t here is "confirmed laboratory cases". It's
two different things. Misleading the people . Why panic over 1 600 infected?
Closing all not nessecary bui ssness, all school s, all excep t for supe rmarket,
gas station, banks. You can't go out after 5.00 pm. If you do, you get
arrested.
Why? They are scared. Because the ruling class is afraid. Everyone with
this masks. Doctors crying on television. The President with mask. They are
scared . Doctors. Journalists. Polices.
2020. The year when the world got completely crazy.
You have an medical obligation to inform the world about

the truth.
Kind regards,
Ola Melhus
Sent : Tue, 5 May 2020 00:36:13 +0000
To: Barasch, Kimberly (NIH/NIAID) [C)
Subject: FW: Therapeu tics and vax
Attachments : NIAID SARS-CoV-2Tx and Vax overview.docx
Please print out and put in folder labelled "COVID-19 Ther apeutics and Vaccines"
From: Marston , Hilary (NIH/NIAID) [E]________ Cb

_H_6)
Sent: Monday, May 4, 2020 12:32 PM
To: Fauci, Anthony {NIH/NIAID) [El -------:a- (b=
H=6)>
(b)(6)> --------- (b)(6)•>; Barasch, Kimberly {NIH/NIAID) [CJ
Subject: Therapeutics and vax
For your Therapeutics discussion lat er to day

From: (b)(6)
Sent: Mon, 4 May 2020 19:52: 45 -0400
To: Troye, Olivia EOP/NSC
Cc: Hurst, Natalie R. EOP/OVP;Mascola, John (NIH/VRC) [E);Graham , Barney
(NIH/VRC) [E);Francis Collins
Subject : Re: Emai l connecting us
Here they are. Thanks
On May 4, 2020, at 7:46 PM, Troye, Olivia EOP/NSC

(b)(6)
Hi Dr. Fauci,
Per our conversation, sending you a note. I'm copying Natalie who will he lp get them
cleared in .
Tha nk you!
Olivia
Olivia Trove
Special Advisor to the Vice President for
Homeland Security, Countert errorism, and North America
Office of the Vice President, National Security Affairs
Whit e House Coronavirus Task Force
0: (b)(6) I M: (b)(6) (Does not receive texts)
(b)(6)
(bX5) -PCI
From: Fauci, Anthony (NIH/N IA ID) [E)
Sent : Mo n, 4 May 2020 21:05:39 +0000
Subject : FW: Invitation to join (virtua lly) the ACTIV Leadership Meeting 5/6
Please see me about thi s.
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)

Sent : Monday, May 4, 2020 11:18 AM
To: ICDDIR-L@LIST.NIH.GOV
______
Cc: Parker, Ashley (NIH/OD) [E)
_,
(b)( >; Melencio, Cheryl (FNIH) [T)
(b)(6); Whalley, David (FNIH) [T]
(b)(6J>
Subject: Invitation to join (virtua lly) the ACTIV Leadership Meeting 5/6
Dear Colleagues,
As you may be aware, the Accelerating COVID-19 Therape ut ic Interventions and Vaccines (ACTIV) public-
pr ivate partnership has been moving forw ard rapidly to address the global pandemic. We held our
initial ACTIV leadership meeting on April 3rd including, NIH, FDA, BARDA, EMA, and industry heads of
research and development . Four work ing grou ps were formed out of this meeti ng to focus on
precli nical therapeutics, clinical therapeutics, clinical trial capacity, and vaccines.
Although some ICs have representatives participating in t he working groups, we recognize there is a
need to keep everyone looped in to the various activities and prog ress of the partnership, particula rly in
view of all of the concurrent IC projects about COVID-19. The ACTIV working groups will be delivering
t heir second report to the ACTIV Leadership Group on W ednesday, M ay 6, from 3:30-5:00 pm. I am
writing to invite the ICDsto list en-in on this meeting. There will be a lot to cover during the meet ing and
th e members of t he Leadership Group will be asking the questions . But to give a chance for us NIHers to
discuss what has been presented, I am scheduling a separate ICD call for 5:05-5:30pm, immediately
follow ing the ACTIV leadership meeting.
If you are available to take part, please send your responses to David Wholley and Cheryl Melencio of
FNIH (cc'd here) by noon tomorrow , May 5th . Once you confirm your attendance, Cheryl will send you
a calendar invite for both the ACTIV leadership meeting and the ICD follow-up call.
Best regards,
Francis
Sent : Mon, 4 May 2020 15:28:08 +0000
Subject: RE:Need your help Covid-19 CAS-1O685
I do not know this person. We should refer him to Brett Giroir.
Director
Phone: (b)(6)
FAX: (30 496"'4409
E-mail Cb)(6)
informat ion. It should not be used by anyone who is not the orig inal intended recipient. If you
From: Conrad , Patricia (NIH/NIAID) [E] (b)(6) •>

Sent: Monday, May 4, 2020 10:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] ------ -=-:-=
(b)(6)>
Subject: FW: Need your help Covid-19 CAS-10685
Do you know this person?
Patricia L. Conrad
31 Center Drive, MSC 2520 - Room 7AO3
(b)(6)
301-496 -4409 fax
Disclaimer :
The informat ion in this e-mail and any of its attachments is confidentia l and may contain sens itive information. It should not be used
from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept
liability for any statement made that are sender's own and not expressly made on behalf of the NIAi D by one of its representatives.
From : Harris, Kara (NIH/NIAID) [El (bH >
Sent : Friday, May 1, 2020 8:38 AM
Cc:Auchincloss, Hugh (NIH/NIAID) [El >; Billet, Courtney (N IH/NIAID) [El
(b)(6)>; Haskins, Melinda (NIH/NIAID) [El (b)(6)
--------
Subject: FW: Need your help Covid -19 CAS-10685
----------
Hi, Patty-
This individua l states that he previously worked with Dr. Fauci and that he knows him. Please let me
know if you would like Public Inquiries to handle .
Thanks,
Kara
From: Ray Rosa (b)(6)>

Sent : Thursday , April 30, 2020 5:58 PM
To: NIAID Ocpostoffice (NIH/NIAID) <0CPOSTOFFICE@niaid. nih.gov>
Subject: Need your he lp Covid-19
I am working with a group of physicians whom need your guidance on Serum Covid-19 tests. I need
someone to call me so I can ask specific questions . I worked with Dr Fauci back in 1998 when I was in
the Air Force. So he does know me. Ray Rosa is the name . Can you please call me.
(b)(6) cell
Scot from AOL Mobile Mail

Get the new /\OL app· mail.mobile.aol.com
From: Auchincloss, Hugh (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent : Mo n, 4 May 2020 14:00:23 +0000
To : NIAIDODAM
Subject: FW: inquiry
Anot her one that he will probably want to do.
From:Augustine M. K. Choi (b)(

----------
Sent: Monday, May 4, 2020 9:21 AM
To: Fauci, Anthony {NIH/NIAID) [E] ------ (b
=)""'(6J
=>
Cc: Conrad, Patric ia (NIH/NIAID) [E] >
Subje ct; inquiry
---------- (b)(
Hi Tony,
I can only imagine your schedule. Thank you for all you are doing for the country in our fight against this
virus.
Weill Cornell would like to invite you for a 3 min remarks to the Class of 2020 at their upcoming
graduation if your schedule allows. The virtual graduation is on May 28th . We can tape your remarks at
any time which fits your schedule, from now or up to right befo re May 28.
If you able to accept this invitation, please let me know. If not, totally understandable and we would
love to have you back again after covid subsides.
Thanks again!
Augustine M.K. Choi, M.D.

Stephen and Suzanne Weiss Dean, Weill Cornell Medicine
Provost for Medical Affairs, Cornell University
Weill Cornell Medicine

1300 York Avenue, Suite F-113 Box 83 I New York, NY 10065
Telephone: 212-746-6005
Fax: 212 -746 -8424
Email: amc2056@med.cornell.edu
From: Anthony Fauc i (b) (6)

Date: Monday, March 30, 2020 at 12:19 PM
To: Augustine Choi (b)(6)
Subject: [EXTERNAL]RE: all wearing masks
My work with the Coronavirus Task Force and the large volume of incoming
emails precludes me or my staff from answering each individual message. I would
encourage you to visit www .coronavirus.gov for the latest information and
guidance related to COVID-19.
Thank you, and best regards.
Anthony S. Fauci, M .D.

Sent : Mo n, 4 May 2020 12:28:04 +0000
To : Corey, Larry
Subject : FW: [EXTERNAL]RE: OK to contac t Joe Mene t ski to discuss opport unities for
alignment/ col laborat ion on ACTIV act ivities ?
As an FYI for the 9:00 AM meet ing.
Director
Build ing 31, Room 7 A-03
Phone: (b)( 6)
FAX: (3 96':44li9
E-mail: Cb)(6)
From : Dolsten, Mikael (b)(6)>

Sent : Monday, May 4, 2020 8:15 AM
------~
To : Collins, Francis (NIH/OD) [E] =
Cc: Fauci, Anthony (NIH/NIAID) [E]
~ -;:::=====:::::.., ;;-s-r;,=
>; Mascola, John (NIH/VRC) [E]
(b)(6)>; Lane, Cliff (NIH/N IAID) [E) CbH >; Lowy, Douglas (NIH/NCI)
":":"::-::=:======~
[E)
~
(b)(6) ; Jansen, Kathrin (b)( >
Subject: Re: [EXTERNAL) RE:OK to contact Joe Menetski t o d iscuss opportunities for alignment/
collaborat ion on ACTIV act ivities?
Francis
Thanks for the response
We appreciate the federal initiative and opportunity to influence it's design . I know Kathrin Jansen (ccd
here) from PFEis working w the team on t his.
________
..... 4
CbH
(b)(4 )
>It 's great to be collaborating w NIH-FDA for the best of our nation and global
health.
In the master protocol, I hope the work ing comm ittee is discussing (b) (5)
(b)( 5)
(b)(5)
These are just two exampleswe can discusson Wednesday in the leadership meeting of times permits.
(b)(5)
I look forward to the meeting
Best
Mikael
Sent from my iPhone
On May 4, 2020, at 04:26, Collins,Francis(NIH/OD) [E]______ H_6)> wrote:

(b_
Hi Mikael,
Wow, sounds like you are making fantastic progress with the vaccine program, and
we would certain ly not want to do anything to slow you down! I understand that
you are evaluating several mRNA formats with BioNTech. If one of those turned
out t o be ready for phase 11/1 11in late June, we would be most interested in the
possibility of includ ing that in the master protocol. Please keep Tony and me in
touch with Pfizer's progress, including which mRNA format you choose to move
into advanced development.
Hope to hear your voice at the ACTIVLeadership Group meeting on Wednesday .

There will be a lot to ta lk about!
Best, Francis
Fro m : Dolsten, Mikael (b)(6)>
Sent : Sunday, May 3, 2020 6:26 PM
To: Collins, Francis (NIH/OD) [El------~ (b)( >
=
Subject : Re: [EXTERNAL]RE: OK to contact Joe Menetski to discuss opportunities for
alignment/ collaboration on ACTIVactivities?
Hi Francis
We certainly enjoy taking part in ACTIV
I will check if we did get our drugs on the lists below
(b)(4)
I will d iscuss w Kathrin Jansen if we may have an option to add one of ou r several vaccine
formats that is less advanced or a refined format of our most advanced in the master
protocol etc
If we can agree about shared key endpoints, we can include that cross all studies Whethe r
master protocol or more advanced sponsor trials which helps comparison
Happy to discuss w you and welcome your advice

Mikael
Mikael Dolsten, M.D., Ph.D.

Chief Scientific Officer and President,
Wor ldwide Research, Development and Medical
Pfizer Inc.
235 East 42nd Street
New York, NY 10017
On May 3, 2020, at 5:16 PM, Collins, Francis (NIH/OD) [El
--------
Mats
(b)(6)> wrote:
Hi Mikael,
Thanks for your note and this update on exciting progress on several
fronts. ACTIV is moving forward with gratifying speed and
commitment. With regard to vaccines, tomorrow the ACTIV vaccines
WG will be discussing a master protocol for a phase 11/111 trial with
adaptive design, multiple arms , and a shared placebo arm, aiming to
launch on or about July 1. FDA is strongly supportive. The Moderna,
Sanofi, and JnJ vaccines are likely to be included - might Pfizer also
join?
4
CbH>- I trust that compound is
-----------------
0n the list of therapeutic candidates that the Clinical Therapeutics WG
of ACTIV is reviewing? They are supposed to put forward a tentative
list for the Wednesday Leadership Group meeting. Ditto with the
(b)(4 option!
Looking forward to catching up soon!
Best, Francis
From: Dolsten, Mikael

----------
Sent: Sunday, May 3, 2020 12:06 PM
(b)(6) 1>
-----
------- -==
To: Collins, Francis {NIH/OD} [E] (b)( >
Subject: Re: [EXTERNAL]RE:OK to contact Joe Menetski to discuss
opportunities for alignment/ collaboration on ACTIVactivities?
Hi Francis
I trust you are well but likely working too many hours as we all experience in
the difficult Covid t imes.
In the vaccine space we have progressed rapidly and are already in phase 1/2
studies dose escalation phase testing multiple format of mRNA vaccine . Key
for us is (b) (4 .
-
(b) (4)
How are things going w ACTIV.

Any issues to discuss ?
I hope our PFErepresentatives in ACTIV are helping out well
Pis let me know if there is anything particular to discuss or I can help you
with
Best personal regards

Mikael
Sent from my iPhone
On May 3, 2020, at 10:49, Collins, Francis (NIH/OD) [E]

(b) (6)> wrote:
Hi Morten,
Thanks for your note. It would be great to have this

connection - but let me suggest that you start with David
Wholley (cc'd here), as he oversees all four of the ACTIV
working groups. Joe is the program lead for the group on
preclinical therapeutics/repurposing.
Best, Francis
From: Sogaard, Morten (b)(6)

-----------
Sent : Sunday, May 3, 2020 10:46 AM
To: Collins, Francis (NIH/OD) [E] _____ --,;Cb
..,.,.
H=6)
Cc: Dolsten, Mikael (b)(6); Prof Trevor
M Jones CBEFMedSci (b)( >;
Sogaard, Morten Cb)(6)>
Subje ct : OK to contact Joe Menetski to discuss opportunities for
alignment/ collaboration on ACTIV activities?
Francis,
I hope you are having a good weekend .
Quick question: Would you be OK if I/we reached out to Joe

Menetski, who I understand leads many of the ACTIV efforts.
We have come to know Joe very well as a great collaborator on
the AMP gene therapy initiative and It would be very easy I
think working informally with Joe to look a bit more under the
hood and identify/ map opportun it ies for alignment with the
other initiatives.
All the Best,

Morten
Sent : Mon, 4 May 2020 10:53:14 +0000
To : Haskins, Melinda (NIH/NIAID) [El
Subject : RE: EOP/OMB Alert: May Hearing Guidance
What does this mean for the May 12 Senate Hearing?
From: Haskins, Melinda (NIH/NIAID) [El (b)(6)

Se nt : Monday, May 4, 2020 6:20 AM
To : Fauci, Anthony {NIH/NIAID) [E] -----~~ (b)(6)>
Cc:Billet, Courtney {NIH/NIAID) [E] (b)(6)>
Subject: EOP/OMB Alert: May Hearing Guidance
I have highlighted in yellow the fundaments of the 0MB guidance below.
Melinda
From: Hallett, Adrienne (NIH/OD) [E] (b)( >

Se nt : Sunday, May 3, 2020 9:54 PM
To : OD-OLPA-Leg Contacts <00-0LPA-LegContacts@OD .NIH.GOV>
Subject: Fwd: May Hearing Guidance
FYI. New 0MB hear ing guidance.
From : Yaworske, Jason A. EOP/OMB (b) (6)>

------------
--------~ =
( ov p.eop.gov)
__ __;_
__ -=======~~--
Cc: Ueland, Eric M . EOP/WHO
(b)(6)
(b)(6)>; Hodgson, Christophe r
Subject : May Hearing Guidance

Importance: High
Agency legislative affairs teams,

(bX5)-PCI
Thank you, and please let us know if you have any questions .
Jason
Jason Yaworske
Associate Director for Legislative Affa irs
Office of Management and Budget
(b)(6) ( 0)
(b)(6) (c)
Sent : Mon, 4 May 2020 00:50:18 +0000
To: Collins, Francis (NIH/OD) [E);Mascola, John (NIH/VRC) [E);Lane, Cliff (NIH/NIAID)
[El
Cc: Tabak, Lawrence (NIH/OD) [E];Parker, Ashley (NIH/OD) [E]
Subject: RE:[EXTERNAL ] RE:OK to contact Joe Menetski to discuss opportunities for
We need to find out precisely what he is ta lking about when he says "vaccine formats" and
"refined formats". I really do not know what he is talking about. (b)(4),(b)(5)
John/Cliff:
Let us discuss this at our morning meet ing .
Thanks,
Tony
From: Collins, Francis (NIH/OD) [El (b)(6)>

To: Mascola, John (NIH/VRC) [E]______ --,;- )( =6); Lane, Cliff (NIH/NIAID) IE]
(b"'""'
-------- (b)( ; Fauci, Anthony (NIH/NIAID) [E]

Cc:Tabak, Lawrence {NIH/OD) [E)
(b)( >
(b)(6J>; Parker, Ashley (NIH/OD) [E)
(b)(
Subject: FW: [EXTERNAL]RE:OK to contact Joe Menetski to discuss opportunities for alignment/
collaboration on ACTIV activities?
Hi John, Cliff, and Tony ,
See note below, where Mikael Dolsten indicates Pfizer is planning to 4>
CbH
. He intends to discuss our master protocol possibility with Kathrin Jensen.
am not qu ite sure what he means by "several vaccine formats".
Does this timetable sound realist ic?
Any suggestion about a response?
Francis
From: Dolsten, Mikael (b)(6)

----------
-----~~
------- (b)(6)
Subject: Re: [EXTERNAL]RE:OK to contact Joe Menetski to d iscuss opportunities for alignment/
collaboration on ACTIVactivities?
Hi Francis
We certainly enjoy taking part in ACTIV
I will check if we did get our drugs on the lists below
(b) (4)
I will discuss w Kathrin Jansen if we may have an option to add on e of our several vaccine formats that
is less advanced or a refined format of our most advanced in the master protocol etc
If we can agree about shared key endpoints , we can include that cross all studies Whether master
protocol or more advanced sponsor trials which helps comparison
Happy to discuss w you and welcome your advice

Mikael
Mikael Dolsten, M.D., Ph.D.

Chief Scientific Officer and President,
Worldwide Research, Development and Medical
Pfizer Inc.
235 East 42nd Street
New York, NY 10017
On May 3, 2020, at 5 :16 PM, Collins, Francis (NIH/OD) [E]

Mats
-------- (b)(6) wrote :
Hi Mikael,
Thanks for your note and this update on exciting progress on several fronts. ACTIV
is moving forward with gratifying speed and commitment. With regard to vaccines,
tomorrow the ACTIV vaccines WG will be discussing a master protocol for a phase
11/111
trial wi t h adaptive design, multiple arms, and a shared placebo arm, aiming to
launch on or about July 1. FDA is strongly supportive. The Moderna, Sanofi, and
JnJ vaccines are likely to be inc lud ed - might Pfizer also join?
I trust that compound is on the list
------------------
0
(b)( 4)-
f therapeutic candidates that the Clinical Therapeutics WG of ACTIV is reviewing?
They are supposed to put forward a tentative list for the Wednesday Leadership
Group meeting. Ditto with the CbH 4> option!
Looking forward to catching up soon!
Best, Francis
From: Dolsten, Mikael

-----------
(b)(
To: Collins, Francis (NIH/OD) [E] ______ .,,.

(b"""
)(=6)
Subject: Re: [EXTERNAL]RE: OK to contact Joe Menetski to discuss opportunities for

HI Francis
I trust you are well but likely working too many hours as we all experience in the difficult
Covid times .
(b) (4)
(b) (4)
How are things going w ACTIV.

Any issuesto discuss?
I hope our PFErepresentatives in ACTIV are helping out well
Pis let me know if there is anything particular to discuss or I can help you with
Best personal regards

Mikael
Sent from my iPhone
On May 3, 2020, at 10:49, Collins, Francis (NIH/OD) [E] (b)(6)

wrote :
--------
Hi Morten,
Thanks for your note. It would be great to have this connection - but
let me suggest that you start with David Whalley (cc'd here), as he
oversees all four of the ACTIV working groups. Joe is the program lead
for the group on preclinical therapeutics/repurposing.
Best, Francis
From:Sogaard, Morten
-----------
Sent: Sunday, May 3, 2020 10:46 AM
(b)(6)>
To: Collins, Francis (NIH/OD) [E] ------=- (b)'""(=6)>

Cc: Dolsten, Mikael (b)( ; Prof Trevor M Jones CBE
FMedSci (b)(6); Sogaard, Morten
------!=======; (b:;::
)(c"=
6);;----
Subject: OK to contact Joe Menetski to discuss opportunities for alignment/

collaboration on ACTIVactivities?
Francis,
I hope you are having a good weekend.
Quick question: Would you be OK if I/we reached out to Joe Menetsk i, who I
understand leads many of the ACTIVefforts. We have come to know Joe very
well as a great collaborator on t he AMP gene therapy initiative and It would
be very easy I think working informally with Joe to look a bit more under the
hood and identify/ map opportunities for alignment with the other initiatives.
All the Best,

Morten
Sent: Sun, 3 May 2020 21:45:43 +0000
To: Greg Folkers (b)( 6) );Doe pel, Laurie (NIH/NIAID) [El
Subject: Pitt and INC
Attachments: Commenc ement Remark s, generic 30-sec for UPitt and UNC SOM, - FINAL - for
5-08-2020 (videos) .docx
See attachment with remarks for UPitt and UNC. I have left the tracked changes
showing so that you can see what I have done . Please accept these and then
proof it. It is now marked FINAL(tracking needs to be accepted) in the OD
folder . Thanks .
Director
Phone : (b)( 6)
FAX: (301 496-4409
E-mail : (b)( 6)
Sent : Sun, 3 May 2020 21 :28:33 +0000
To: Greg Folkers (b)(6) ;Doepel, Laurie (NIH/NIAID) [El
Subject: USUHS
Attachments : Commencement Remark s, USUHS 2-min -FINA L- for 5-16-2020 (Vid eo).docx
See attachment with USUHS remarks . I have left the tracked changes showing
so that you can see what I have done. Please accept these and then proof it. It is
now marked FINAL {tracking needs to be accepted) in t he OD folder . Thanks.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
Sent: Sun, 3 May 2020 21:21:04 +0000
To: Greg Folkers (b)(6) );Doe pel, Laurie (NIH/NIAID) [El
Subject: AMA
Attachments : Commencement Remark s, AMA 3-min - FINAL - fo r May 2020 (Video).docx
See attachment with AMA remarks. I have left the tracked changes showing so
that you can see what I have done . Please accept these and then proof it. It is
now marked FINAL (tracking needs to be accepted) in the OD folder. Thanks.
Anthony S . Fauci , MO
Director
Phone: (b)(6)
FAX: (301) 496-4409
E-mail: (b)(6)
Sent :
To:
Sun, 3 May 2020 20:58:32 +0000
________
Doepel, Laurie (NIH/ NIAID) [E);Greg Folkers .... (b)( )
Subject: UCSF
Attachments : Commencement Remark s, UCSF SOM - FINAL- for May 2020 (Vide o) .do cx
Greg/Laurie:
I am attaching the UCSF3 minute talk. I labeled it as "FINAL" and it is in the OD
folder. However, I have left in the tracked changes fo r you to see what I did.
Please accept the changes and then go over it one last time . I like it the way it is
and so please no trivial corrections.
Thanks,
Tony
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
Sent: Sun, 3 May 2020 20:11:08 +0000
To : Doepel, Laurie (NIH/ NIAID) [E);Greg Folkers (b)( )
Subject: Holy Cross
Attachments : Commenc ement Remark s, Holy Cross - FINAL- for 05-22-2020 (video) .docx
The Holy Cross video script is in th e OD File mar ked as " FINAL". I have left the
tracked changes showin g so tha t you will know w hat I have do ne. Please accept
t he changes and tak e a final look. I am also attaching for your look.
Thanks,
Tony
Director
Phone: (b)( 6)
FAX: (301 496-4409
E-mail: (b)(6)
Sent : Sun, 3 May 2020 18:34:28 +0000
To : Tromberg, Bruce (NIH/N IBIB) [E);'Sharpless, Ned
-----------, (b
=~=(6)) '
Cc: Conrad, Patricia (NIH/N IAID) [E)

Subject : RE:2 quick point s
Thanks, Bruce.
Director
Phone: (b)( 6)
FAX: (301 496-4409
E-mail: _ __,.,_, (b)( 6)
From: Tromberg, Bruce (NIH/NIBIB) [E)

---------- (b)( 6)>
To: Fauci, Anthony (NIH/NIA ID) [E) --------, a-s-r,=

'Sharp less, Ned
(b)( ;
(b)( 6)
Cc:Conrad, Patr icia (NIH/NIAID) [E]_______ _ )_ <_ >
(b
Subject: Re: 2 quick points
Hi Tony,
Thanks! Hope you are doing well.
This is basically exactly wha t we are working to facilitate wit h our RADx and digita l health (app) platform
initiatives ...greatly expanding test ing and creating a digita l backbone to provide peopl e with way s to
access tests and interpret results . For expanding test ing platforms, see https://www.nibib .nih.gov/news -
events/newsroorn/nih-mobil izes-national -innovation -initiative -covid-19-diagnostics We have > 700
applicat ions that have been started in just a few days. For the digital healt h (e.g. app) platform we 've
put a lot of thought into the design and are hoping a contractor wil l be able to launch a pilot st udy of
healthcare workers soon . Ned and I plan on issuing additional calls in this area w ith mul tiple institute s
as stakeho lders in t he coming weeks.
Best,
Bruce
Bruce J. Tromberg, Ph.D.

Director
National Institute of Biomedical Imaging and Bioengineering
Building 31, Room 1C14
(b)(6)
301-480-0679 - FAX
(b)(6)
http://www.nibib.nih .gov
From: "Fauc i, Anthony (NIH/ N IAID) [E]" < (b)(6)
Date : Sunday, May 3, 2020 at 1:55 PM

---------
To: "'Sharpless, Ned --------------------------~~
11
~~~":""":"'.~========~;------------
Tro m berg, Bruce (NIH/N IBIB) [E]" (b)(6)>
(b)(6)
~-=========~
Cc: "Conrad , Patric ia (NIH/NIAID) [E]" ________ Cb
_H_6J
Subje ct : FW: 2 quick points
Ned/ Bruce:
I t hought that I w ou ld pass thi s on to you in case yo u have int erest. Thanks.
Best ,
Tony
Director
Phone: (b)(6)
FAX: (301) 496-4409
E-mail: Cb)(6)
From: Eric Ottesen (b)(6)>

Sent: Saturday, May 2, 2020 8:23 AM
To: Fauci, Anthony (NIH/NIAID) [El ------~~ >
Subject: 2 quick points -------- (b)(
Dear Tony,
l. I had planned to wr ite to thank you for giving an interview (b)(6)for the
Washingt on Post last month. Your generosity with time was 'all Tony,' and I did appreciate it.
was waiting for the chaos around you to subside before writing but... ..
2. Last evening I was asked to forward the message below to you. You might already know Jack
Warren, Professor of Medicine and Infectious Diseasesat U. Maryland (b) (6)
As his email says, (b)(6) with Samsung's venture capital group, which has
an idea for a future , comprehensive surveillance system for COVID-19 (b)(4)
It is interesting,
but all I know is what I read in the power-point attached. I cannot imagine you would have time
to look at it yourself, but perhaps it could be shared with other systems-orien t ed individuals
working towards 'opening up' responsibly.
Pardon me for stepping out of my normal NTD 'swim lane' but I did want to help out Cb)<
_ , and certainly nothing is more important these days t han COVID-19 and the outstanding wor k
you are doing to manage it .
All the very best,
-Eric
From: Warren, John [ma ilto

------------
(b)(6)]
To: (b)(6)
Subject: Jack Warren
Eric
A voice from the past. Covid-19 prevented us from meeting up

because it might yet bring at least the two of us together. -------- (b)(6)but I'm writing
------ (b)(6)Samsung'sventure capital group and his team has what I think is an incredibly useful idea
for contact tracing for covid-19 as well as actually open ing the economy up again. The idea is contained
within the attachment.
I wonder if you still have any contacts with Anthony Fauci. Is so, could you see your way clear to
forwarding the attachment to him? The group has ident ified some appropriate test manufacturers but
is at the point where they need to know the spectrum so as to focus on the optimal ones. The thought
was that Tony Fauci might be the best person to know what tests are in development stage.
What are your thoughts?

Don't worry about confidentiality; they want to widely share this idea so as to get it out as quickly as
possible.
Thanks
Jack Warren MD
Division of Infect ious Diseases
University of Maryland School of Medicine
Baltimore MD 21201
(b)(6)
Sent : Sun, 3 May 2020 17 :56:39 +0000
To : NIAIDODAM
Subject: RE:Dr. Antho ny Fauci & Avi Schiffm an/The Webby Awards
????? Who is this person?
Director
Phone: (b)(6)
FAX:(301) 496~ 09
E-mail (b)(6)
From: Auchincloss , Hugh (N IH/NIAID) [El

(NIH/NIAID) [El
----------- (b)(6)> On Behalf Of Fauci, Anthony

To : NIAID OD AM <NIAIDODAM@niaid .nih .gov>
Subject: FW: Dr. Anthony Fauci & Avi Schiffman/T he Webby Awards
From: lesley lesleycahillroy.com <lesley@lesleycahillroy.com>

Sent: Friday, May 1, 2020 12:13 PM
-------~~ (b)(6)
Subject: Re: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards
HI Dr Fauci
I just wa nted to follow up on below regarding Avi and The Webby Awards. Would be wo nderful if you
cou ld be a part of this moment for him.
Thanks so much
Lesley
On Apr 20, 2020, at 1:57 PM, lesley lesleycahillroy.com <lesley@lesleycahillroy .com>
wrote :
<6EDD370A-6106-4603-B557-7AAEE9A9EF79.png>
Dear Dr. Fauci,
I hope you and th e family are all safe and healthy dur ing these challenging times. Hailed
by The New York Times as "the Internet's highest honor," The Web by Awards has been t he
premiere award for on line excellence for over two decades, honor ing the companies and
people who have crit ically shaped digital techno logy and culture.
This year, due to the impact of the coronavirus The Web by Awards are mov ing their
renowned award show to an onli ne experience. On May 19th, 2020, the 24th Annual
Webby Awar ds wi ll bring together Webby Winners from around the world in an Int ernet
Celebration whic h wi ll showcase t he artists, organi zations, and creators using th eir
platforms to imagine a bette r tomorrow th rough informa t ion, educatio n, movemen t,
comedy, all while inspiring audiences to take action to enact posit ive change.
The 24th Annual Webby Awa rds are proud to honor Avi Schiffmann as the 2020 Person
of the Year to recognize his creation of ncov2019.liv e to track the spread of COVID-19
across the world. W e would be honored if Dr. Fauci would "virtually" present Avi with
his award .
As we collectively navigate the severe impact of COVID-19 on the world and late calls for
nation-wide social distancing, the Internet has become the lifeblood for people looking
for accurate information about the novel coronavirus. Since launching the site on
December 29th , Avi Schiffmann's tracking site was a necessary tool that sounded the
alarm on the novel coronavirus and its spread, notably calling attention to its severity
long before many global officials. By providing over 100 million visitors with real-time
data on the virus' spread, Schiffmann has helped people around the globe understand
COVID-19 and the necessity of upgrades to current health care systems and mea sures to
flatten the curve.
For having the fore sight to track the global spread of COVID-19 and for creating a
website to provide real-time data about the virus to people everywhere, it is our great
privilege to honor Avi Schiffmann as the 2020 Webby Person of the Year. The
celebration will highlight the important work Avi and his fellow winners are doing, and
will mark his hallmark Webby 5-Word acceptance speech in Int ernet history. Dr. Fauci's
presenter speech could be recorded on his phone and we can send you through a script
for him to review, edit and details for format and deadline.
This year's Webby Aw ards w ill also take action, t he impact of COVID-19 and govern ment
responses around the world, has brought the importance of vot ing into sharp focus. The
Webby Awards has partnered with Vote.or and aim to check the voter registration status
of 1 million voters in the United States, promoting the importance of voting to help ensure
vote r turnout this November is the highest it has ever been. This partnership will integrate
into all elements of this year's on line celebration.
Our thoughts are with all of you in this difficult time.
Best
Lesley Cahill Roy

(b)(6)
Sent: Sun, 3 May 2020 17:55:14 +0000
'Sharpless,Ned (b)(6)';Tromberg, Bruce
To:
(NIH/N IBIB) [El ------------
Cc: Conrad, Patricia (NIH/NIAID) [E)
Subject : FW: 2 quick points
Attachments : covid contact tracing.pdf
Ned/ Bruce:
I thou ght that I wou ld pass thi s on to you in case you have int erest . Thanks.
Best,
Tony
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
From: Eric Ottesen (b)(6)

------~~
To: Fauci, Ant hony (NIH/ NIAID) [E]_______ Cb
_H_ >
Subject:2 quick points
Dear Tony,
1. I had planned to wr ite to thank you for giving an interview for the
(b)(6)
Washington Post last month. Your generosity with time was 'all Tony,' and I did appreciate it. I
was waiting for the chaos around you to subside before writing but .....
Warren, Professor of Medicine and Infectious Diseasesat U. Maryland (b)(6)
As his email says (b)(6) Samsung'sventure capital group, which has
an idea for a future, comprehensive surveillance system for COVID-19 (b)( 4)
. It is interesting,
to look at it yourself, but perhaps it could be shared with other systems-oriented individuals
Pardon me for stepping out of my normal NTD 'swim lane' but I did want to help out (b)~
- and certainly nothing is more important these days than COVID-19 and the outstanding work
you are doing to manage it.
All the very best,
-Eric
From: Warren, John [ma ilto

-----------
To: (b)(6)
(b)(6)
Subject: Jack Warren
Eric
A voice from the past. Covid-19 prevented us fro m meeting up (b)( ut I'm writing
because it might yet bri ng at least the two of us together.
--------
(b)(6)Samsung'sventure capital group and his team has what I th ink is an incredibly useful idea
------
forwarding the attachment t o him? The group has identified some appropriate test manufacturers but
is at the point where they need to know the spectrum so as to focus on th e optima l ones. The thought
possible.
Thanks
Jack Warren MD
Baltimore MD 21201
(b)(6)
Sent : Sun, 3 May 2020 17:53:55 +0000
To: Eric Otte sen
Subject: RE:2 quick points
Eric:
Thanks for your note . No problem . I will forward this to people here at NIH
who are pursuing such approaches. I hope that all is well with you.
Best regards ,
Tony
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: Cb)(6)
From: Eric Ottesen (b)( >

-------~~
Subject: 2 qu ick points --------- (b)(6)
Dear Tony,
1. I had planned to write to thank you for giving an inte rview for the
(b)(6)
Washington Post last month. Your generosity with time was 'all Tony,' and I did appreciate it .
was waiting for the chaos around you to subside before writing but .....
Warren, Professor of Medicine and Infectious Diseasesat U. Maryland (b)(6)
As his email says, (b)(6) Samsung's venture capital group, whic h has
an idea for a future, comprehensive surveillance system for COVID-19 (b)(4)
. It is interesting,
to look at it yourself, but perhaps it could be shared with other systems-oriented individuals
Pardon me for stepping out of my normal NTD 'swim lane' but I did want to help out (b)~
_ , and certainly nothing is more important these days than COVID-19 and the outstanding work
you are doing to manage it.
All the very best,
-Eric
l=rom : Warren , John [ma ilta

-----------
Sent : Thursday, April 30, 2020 6:52 PM
(b)(6)]
To : (b) (6)
Subject : Jack Warren
Eric
A voice from the past. Covid-19 prevented us from meeting up (b)(6l b ut I' m writing
..
because it might yet bri ng at least the two of us together. -------
----- (b)(6) Samsung's venture capital group and his team has what I think is an incredibly useful idea
forwarding the attachment to him? The group has identified some appropriate test manufacturers but
is at the point where they need to know the spectrum so as to focus on the optima l ones. The thought
possible.
Thanks
Jack Warren MD
Baltimore MO 21201
(b)(6)
From : Auch incloss, Hugh (NIH/NIAID) [E] on beh alf of Fau.ci, Ant hony (NIH/ NIAID) [E]
Sent : Sun, 3 May 2020 17 :52:37 +0000
To : NIAIDODAM
Subject : FW: INVITE- Ame rican College of Cardiolog y
Impo rt ance: High
From: Kim, Jonathan Ho-Youn (b)(6)

Sent: Friday, May 1, 20 20 3:09 PM
To : Fauci, Anthony {NIH/NIAID) [E]------ ..,.....,..-=
(b)(6)
Cc; Ryan Meye r (b)(6) Roby n Snyde
Subject: Re: INVITE- American College of Cardiology ------- (b)(6)
Importance: High
Dr. Fauci- Of course, I appreciate how busy you are, so just reaching out again on behalf
of the American College of Cardiology as noted below. We were hopeful we could steal
just an hour of your t ime in June for an important discussion on COVID-19 and exercise
training. This is part of a virtual agenda for one of our national conferences (Care of the
Athletic Heart) with outreach around the world given this is a part of the ACC
educational platform.
We hope th is is something you have the bandwidth for, and simply apprec iate your
consideration. I hope to hear from you and thank you for all your service once again.
My best, Jonathan Kim
Jonathan H. Kim MD, MSc, FACC

Chief of Sports Cardiology
Department of Medicine, Division of Cardiology
Department of Orthopedics
Emory University
Adju nct Assistant Professor
Division of Applied Physiology
Georgia Inst itute of Technology
Team Cardiologist for Emory Athlet ics, Georgia Tech Athletics , Atlanta Falcons, Atlanta Hawks, Atlanta
Braves, and Atlanta Dream
Office Phone: Cb)(6)
Research Profile: http: // medicine .emorv .edu/cardiology/emory-first- faculty-
djrectory/profi le.htmi?f=JKIM10
Email Cb)(6)
From: Kim, Jonathan Ho-Youn

To: (b)(6)
Cc:----======;-----
RyanMeyer Cb)(·>; RobynSnyder_____ Cb
_>_<_,>
Subject:INVITE- American Collegeof Cardiology
Dr. Fauci-
On behalf of the American College of Cardiology (ACC), first I would like to thank you for your
tremendous service throughout your incredible career and certainly during these present and
challenging times. We are indebted to your service and thankful everyday we have you to help
guide public health measures through the COVID-19 pandemic .
I am a member of the Sports and Exercise Council for the ACC and the Course Chair for our
annual ACC Care of the Athletic Heart Conference. Originally scheduled June 18-20, 2020 at ACC
Heart House in Washington DC. I am also faculty at Emory University and direct our sports
cardiology program in Atlanta.
Of course, we have made the difficult decision to cancel our live meeting in June, but myself
along with the staff at ACC are working very hard transitioning the course to a virtual course
and agenda. This course will be a much shorter version and the agenda w ill all be pre-recorded
and distributed as a 'live simulated version' on June 20, 2020.
With the impact of COVID-19 on all aspects of life and society, in our academic world of sports
cardiology, we are dealing with how COVID has impacted exercise and athletes. As you can
imagine, there are a multitude of different issues and questions that colleagues are raising.
One new session for our virtual agenda that we think will generate a lot of interest and is of
high importance will be a panel discussion on sports, exercise, and COVID-19. We would like to
get additional expertise on the panel from the ID/pub lic health and Sports Medic ine arenas, in
addition to sports cardiology. Of course, there is no one that carries the expertise you do from
t he ID and publ ic health perspective and we would be extremely honored if you could be a part
of this one session and join our faculty for the course.
Before getting into more details and a formal invite from the ACC, I wanted to first see if you
had the bandwidth for this. Understanding you are as busy, if not busier, than anyone in the
world right now. This session would be pre-recorded and we would certainly work to be flexible
with anytime you had for this in early June to record.
I hope this is something that could work- again we would be honored to host you virtually.
Many thanks for considering, and hope to hear from you soon. Best, Jonathan Kim
Jonathan H. Kim MD, MSc,FACC

Chief of Sports Cardiology
Departmentof Medicine,Divisionof Cardiology
Departmentof Orthopedics
Emory University
Adjunct AssistantProfessor
Divisionof Applied Physiology
GeorgiaInstitute of Technology
Team Cardiologistfor EmoryAthletics, GeorgiaTech Athletics, Atlanta Falcons,Atlanta Hawks,Atlanta
Braves,and Atlanta Dream
ResearchProfile: http://medicine.emory.edu/cardiology/emory-first-fac
ulty-
directory/profile.html?f=JKIM1O
Email (b) (6)
This e-mail message (including any attachments) is 'or the sole use of
lhe intended recipient(s) and may contain confidential and privileged
information. If the reader of this message is not the Intended
recipient, you are hereby notified that any dissemination distribution
or copying of this message (including any attachments) is strictly
prohibited.
If you have received this message in error, please contact

the sender by reply e-mail message and destroy all copies of the
original message (including attachments).
Sent : Sun, 3 May 2020 17:50:45 +0000
To: Jon LaPook
Subject : RE:Today's segment on CBSSunday Morning
Jon:
Tenific piece on ":No time to abandon science"! Keep up this great work . We need to stay on course.
Best rega rds,
Tony
Director
National Institute of Allergy and lofectious Diseases
National Jnslirutes of Health
Phone: (b)(6)
f AX: (301) 496-4409
E- mail: (b) (6)
The informa1ion in this e-mail and any of its a1tachmen1sis confidential and may contain sensitive infom1ation. It
please inform the sender and delete it from your mailbo x or any other storage devices. The National Institute of
Allergy and Infectiou s Disease s (NIAID) shall not accept liability for any statements made that are the sender's own
From: Jon LaPook.------ (b
=)...,
-=
(6)
.,,,
Sent: Sunday, May 3, 2020 I :31 PM
(b)(6) >
To: Fauci, Anthony (NIH/NlAfD) [E)...,.._,.-,---,-----
Subject: Today's segment on CBS Sunday Morning
Dear Tony,
l hope (though would not bet my life that) you are getting at least a modicum of down time today.
Here's a Iink to the segment l told you about. No commercial!
htt:ps://www .youtube.com /watch?v-OjCohlBICgO
[http://img.y outube.com /vi/OjCohlBICgO/O.jpg]<https: //www .yout ube.com /watch?v=OjCoh lBICgO>
Dr. Jon LaPook: No time to abandon science - YouTube<https://www.youtube.com/watch?v=OjCohlBICgO>

www.youtube.com
As we reach a point in the COVID-19 pandemic when some states are tempted to open sooner than health experts
say they should, Dr. Jon LaPook notes thatthis ...
Jon
Chief Medical Correspondent, CBS Even ing News Professor of Medici ne NYU Langone Health
(bXS) - PCP.
(bX5) -PCI
From: Fauci, Anthony {NIH/N IAID) [E]
Sent: Sun, 3 May 2020 17:23 :12 +0000
To: Paola Dama
Cc: Conrad , Patricia (NIH/N IA ID) [E)
Subject: RE: White House Coronav irus Task Force
Dr. Dama :
Thank you for your note. I am attaching a slide of the members of the USA Task
Force and as you can see, Dr. Antonio Gio rdano is not a member.
Best regards,
A.S. Fauci
White House Coronavirus Task Force -

Announced Jan. 29, 2020
Chair: VP Mike Pence
Response Coordinator: Deborah Birx
■ Jerome Adams ■ Stephen Hahn
■ Alex Azar ■ Derek Kan
■ Stephen Biegun ■ Larry Kudlow
■ Robert Bla ir ■ Ch ris Liddell
■ Ben Carson ■ Steven Mnuch ln
■ Ken Cuccinelli ■ Robert O'Brien
■ Kelvin Oroegeme ier ■ Matthew Pott inger
■ Anthony Fauci ■ Robert Redfi eld ■ Seema Verma
■ Joe Grogan ■ Joel Szabat ■ Robert Wllkle
Director
Bethesda, MO 20892-2520
Phone: (b) (6)
FAX: (301 496-4409
E-mail: (b)(6)
The information in this e-mail and any of its attachments is confidentia l and may contain sensitive
information. It should not be used by anyone who is not the original intended recipient. If you have
received th is e-mail in error please inform the sender and delete it from your mailbox or any other
storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept
liability for any statements made that are the sender's own and not expressly made on behalf of the
Fro m : Paola Dama (b)(6)>
Se nt : Sunday, May 3, 2020 10:55 AM
Subject : White House Coronavirus Task Force
Dear Dr. Fauci,
I hope to find you well with this ema il.

I take the liberty to write you because I have some concern about the misinformation
that can discredit you r task and honors.
On many occasions in tv and press, Antonio Giordano , Director of Sbarra Institute in Philadelphia,
Keeps saying that he is a member of the USATask Force.
I'm wondering if it's true.
I work in UK, but I'm originally from Naples (Italy).

I he ld my PhD in Carlo Croce's lab at OSU and I specialized in immunotherapy at University of Chicago.
Currently I'm a research fellow at University of Sussex.
I apologize if you find this email inopportune, the time is unfortunate, I grant you .
I don't like t he idea that some people might take advantage of this very unpleasant moment for all the world.
So I wish that I made a mistake this time.
I'm also wondering if you are willing to release a brief in te rview.

I stand with you and USA that I miss very much
I really appreciate your time

Thank you
Kind Regards
Ciao O
Paola Dama, Ph D
Molecula r Oncology and Pharmacology
Universityof Sussex
School of Life Sciences
John Maynard Smith (JMS) Building
Room 4B13
Falmer, Brighton BNl 9QG
(USA)
-------- (b)(6)
Email: (b)(6)
Skype :
----- (b)(6)
website www .taskforcepandora .com

Sent : Sun, 3 May 2020 15:44:23 +0000
(b)( 6)
Subject : Great phot o of Mommy and me in this article
https://ww w. usatoday.com/story/ne ws/nation/2020/05/03/coronavirus-white-house -expert -dr-

anthony-fauci-americans-trust/3042991 001/
Director
Phone: (301) (b)( 6)
FAX:(301) 4 6~09
E-mail: .__....,.,___ (b)(6)
have received this e-mail in error please info r m the sender and delete it from your mailbox or any
From: (b)(6)
Sent: Sun, 3 May 2020 10:30:04 -0400
To: Collins, Francis (NIH/OD) [E)
Cc: Mascola, John (NIH/VRC) [E);Lane, Cliff (NIH/NIAID) [E);Wholley, David (FNIH)
[Tl;Tabak, Lawrence (NIH/OD) [El;Denny, Joshua (NIH/OD) [E);Gebo, Kelly (NIH/OD) [Gl;lowy, Douglas
(NIH/NCI) [El;Devaney, Stephanie (NIH/OD) [E];Adam, Stacey (FNIH) [T);Santos, Michael (FNIH)
[T];Freire, Maria (FNIH) [T)
Subject: Re: crazy idea
(b) (5)
On May 3, 2020, at 9 :47 AM, Collins, Francis (NIH/OD) [E]

(b) (6) >wro te:
Hi John, Cliff, and Tony,
As we contemplate ways to stand up a master protocol that could enroll 50 - lOOK

part icipants in a multi-arm COVID-19 trial th is summer, I wondered if (b)(5)
See below -
you think? --------------------- (b) <5 . What do
Francis
From: Denny, Joshua (NIH/OD) [El (b)(6)>

--------
Sent : Saturday, May 2, 2020 11:22 PM
-----~~ (b)(6)
Cc: Tabak, Lawrence (NIH/OD) [El
Subject: Re: crazy idea --------- (b)(6)>
Hi Francis,
This is exciting to hear! Fabulous to hear we may be approaching such a trial.

(b)(5)
Best,
Josh
Sent from my iPhone
On May 2, 2020, at 8:34 PM, Collins, Francis (NIH/OD) [E]

(b) (6J>wrote:
-------
Hi Josh,
- (b) (5l
Francis
Sent : Sun, 3 May 2020 12:31:13 +0000
To : Handley, Gray (NIH/NIAID) [El
Cc: Conrad, Patricia (NIH/NIA ID) [El
Subject: RE:form Jorge Pere z IPK Cuba
Thanks.
From: Handley , Gray {NIH/NIAID) [E] ________ Cb

_H_
Sent: Saturd ay, May 2, 2020 11:04 PM
To: Fauci, Anthony {NIH/NIAID) [El -------:a- (b.,....
H=6J>
---------
Subject: RE:form Jorge Perez IPK Cuba
(b)(6)•>
Will send a reply tomorrow morn ing.
I have spoken to State Department and have approved response . Someone w ill listen in.
Will copy you.
Gray
From: Fauci, Anthony (NIH/NIAID) [E] (6Jr>

Sent: Saturday, May 2, 2020 3:18 PM
-------- (b)
To: Handley, Gray {NIH/NIAID) [El -------'='"'""'=

Cc: Conrad, Patricia {NIH/NIAID) [El
---------
Subject: FW: form Jorge Perez IPK Cuba
Gray:
Wou ld you please handle this .
Thanks,
Tony
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: Cb)(6)
From: Perez Avila, Jorge (b)(6)

Sent : Friday, May 1, 2020 12:13 PM
------~~
To: Fauci, Anthony (NIH/NIAID) [E]______ Cb>
_C_6)>
Subject: form Jorge Perez IPK Cuba
Dear Dr. Fauci
Hello from Cuba.
Have been a long time we haven't been in touch.
Now the whole world is facing a new epidemic and in Cuba we are working in order to controling. We
will like to re-new our contact regarding this disease Covid 19, we prepare a telephone conference in
order to exchange ideas to have a better understanding to control the epidemic. This conference will be
held from Cuba next tuerday 05/05/2020 at 4 :30pm Cuban time. In douse I am sending the topics. We
will like to have you and Dr. Handle y in th is activity if it is possible to attend this conference. If you are in
agreement we will like to know by answering this email and them we will you any other detail.
If you have any other person to contac t in order to participate will be helpful! for us.
Waiting for your answer.
Dr. Jorge Perez

IPK
Cuba
Preliminary program
Objectives:
Updating COVID-19 situation at global , regional and mainly in Cuba and USA
To sharing data of how our two countries are facing this emergency including research studies , etc
Topics for the discussion:

• The main strategies that both countries are developing to face COVID-19 .
• Diagnostic strategy
• Clinical management in adults and children
• Innovative Cuban biotechnology products incorporated into the treatment models used in the
different stages of treatment
• Some other research studies
• Discussion
Events and courses at the following address :

http://instituciones.sld.cu/ipk/
Sent : Sat, 2 May 2020 20:17 :31 +0000
Subject : RE:
Thanks
Director
Phone: (b)(6)
FAX:(301) 496~ 09
E-mail: (b)(6)
From: Cassetti, Cristina (NIH/NIAID) [E]

Sent: Saturday, May 2, 2020 4:10 PM
---------
--------= ~ (b)(6)>
~======:=:!~= Conrad, Patr icia (NIH/N IAID) [El
Cc: Erbelding, Emily (NIH/NIAID) [E]
(b)(6)
---------- (b)(6)>;
Subject: RE:
Hi,
I already reached out to Dr. Bolognesi and some of us in Program have a call scheduled with him to
discuss th is propos al.
I will let you know t he outcome.
Kind regards,
Cristina
From: Fauci, Anthony (NIH/NIAID) [El (b)(6))

Se nt: Saturday, May 2, 2020 3:39 PM
-------~~
Cc: Erbelding, Emily {NIH/NIAID) [El
(b)(6)
__________
To: Cassetti, Cristina {NIH/NIAID) [E]
';========~CbH6>1; (b)(6)>
~ Conrad, Patricia (NIH/N IAID) [E]
,
Subj ect: RE:

Import ance: High
Cristina:
It would be a good idea for you to show this to a couple of other NIAID people
for their opinion, and then out of courtesy to get back to Dr. Bolognesi one way
or another.
Thanks,
Tony
Direc tor
Build ing 31, Room 7A -03
Phone: (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
The information in this e-mail and any of its attachments is confiden t ial and may contain sens itive
have received this e-mail in error please inform t he sender and delete it from your mailbox or any
other storage devices . The National Inst itute of Allergy and Infectious Diseases (NIA ID) shall not
behalf of the NIAID by one of its represen tatives.
From: Cassetti, Crist ina (NIH/NIAID) (E] (b)( >

Sent: Thursday , April 30, 2020 11:36 PM
=)""'(6)
=>
Cc: Erbelding, Emily (NIH/NIAID) [E)
Subject: RE: --------- (b)(6)>
Dear Dr. Fauci,
I reviewed this proposal (b)(5)

(b)(5). (b)(4)
(b) (5), (b) (4l
informative
------------------------------- (b)(5)
to discuss the project directly with them. Wou ld you like for me to put together a small group at NIAID
(w ith reps from DMID and DAIDS)to talk with Dr. Bolognesi and his colleagues?
Kind regards,
Cristina

--------
(b)(6)
To: Cassetti, Cristina (NIH/NIAID) [E]--------=-=-=

..!=======~~ (b)(6)
Cc: Erbelding, Emily (NIH/NIAID) [E] (b)(6)>
Subject : FW:
Importanc e: High
Cristina :
Please take a good look at th is. It is from Dani Bo lognesi, one of our top HIV/ AIDS
investigators from a few years back . He is a serious scientist. Let me know what you think.
Thanks,
Tony
From : Eisinger, Robert (NIH/NIAID) [E] (b) (6)> On Behalf Of Fauci, Anthony
(NIH/NIAID) [E]
Sent : Monday, April 27, 2020 6:57 PM
Subject : FW:
Email from Dani Bolognesi.
Robert W. Eisinger, Ph.D.

Special Assistant for Scientific Projects
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b)(6)
Email: (b)(
From: Dani Bolognesi, Ph.D.
----------
------~~
(b)(6)
To : Fauci, Anthony (NIH/ NIAID) [E] ______ Cb _ >; Barasch, Kimberly (NIH/NIAID) [C]
_)_(6J
(b)(6)
Subje ct: FW:
Kimberly: Please see that this reaches Tony as per our call today.
TX in advance.
Dani
Hi Tony:
In advance of getting together with you and your team, I am forwarding a short presentation for you
guys to look at. The key elements are follows:
(b) (4). (b) (5)
We are prepared to discuss this with you and your team at any time that is convenient for you. As you
may know, we are locked down here in the Research Triangle until May 15. If it makes sense, wecould
arrange a WebEx as an initial step.
Many thanks for the opport unity to share th is with you !
All the very best,
Dani
(b)(6)
Best,
Dani
Sent from Dani Bolognesi
From: "Dani Bolognesi, Ph.D ." (b)(6)

-----------
Date: Monday, April 27, 2020 at 2:53 PM
"Matthias Gromeier, M .D." -----------~
To : >
Subject : Please review this draft------------
(b)(
email to Tony--TX
Matthias: Please review and edit the proposed email to Tony.
Dani
Hi Tony: In advance of getting together with you and your team, I am forwarding a short presentation
for you guys to look at. The key elements are follows:
(b) (4). (b) (5)
(b) (4), (b) (5)
We are prepared to discuss this with you and your tea at any time that is convenient for you. As you may
know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could
arrange a WebEX as an initial step.
All the best ,
Dani
Best,
Dani
The in formation in this electron ic mail is sensitive, pro t ected inform ation int ended only for the addressee(s). Any other person,
including anyone who believes he/she might have received it due to an addressing error, is requested to notify the sender
immed iate ly by return electr onic mail, and to delete it without further reading or retention . The information is not to be
forwarded to or shared un less in compliance with Duke Health policies on confidentiality and/or with the approva l of the
sender.
Sent : Sat, 2 May 2020 19:08:58 +0000
To : Lerner, Andrea (NIH/NIAID) [El
Subject: FW: Validated precise prediction of remdesivir's clinical efficacy on SARS-CoV-2
viral load
Please take a look at this and respond if appropriate.
Director
Phone: (b)(6)
FAX: (3 96':44li9
E-mail Cb)(6)
From: ldonae Lovetrue (b)(6)>

Sent: Friday, May 1, 2020 2 :25 PM
Cc: Beigel, John (NIH) [E] H ; Booth, Mason (NIH/NIAID) [C]
Cb
Kim, Sonnie (NIH/NIAID) [E]
--------- (b)(6) (b)(6)
Subject: Validated precise prediction of remdesivir's clinical effi cacy on SARS-CoV-2viral load
Dear Dr . Fauc i,
I'd like to share with you that the recent clinical trial results on remdesivir have validated our
prediction of the remdesivir-specific post -treatment viral rebound in human COVID - 19 pat ients.
More details can be found in our off icial announcement https ://b it. ly/RRemdesivir.
This prediction of remdesivir's clinical efficacy on viral load made on Fe b. 23 2020 (b) (4)
(b)(4)
(b) (4)
We appreciate and respectall the effortsyourhave made towardsthe COVID-19 pandemic.
Bestregards,
ldonae
ldonae Lovetrue I CEO, Demiurge TechnologiesAG, Switzerland

www.demiurge.technology
This email and any attachments thereto may contain private, confidential. and privileged material for the sole use of the
intended recipient. Any reV1ew,copying, or distribution of this email (or any attachments thereto) by others is strictly
prohibited. If you are not the intended recipient, please contact the sender immediately and pe, manently delete the original and
any copies of this email and any attachments thereto. This email is intended for information purposes only and is provided
without any warranty of any kind, either expres1edor implied. While some mformat1on used on this document may have been
obtained from various published and unpublished sources considered to be reliable, Demiurge Technologies AG neither
guarantees 1t5ac..cur"cy01 completene55 nor accepts liability for any direct or comequential lo5se5arning from its use.Thank
you
Sent: Sat, 2 May 2020 19:00 :06 +0000
To : Fetalvo, Ninio J. EOP/OVP
Subject: RE:Back to CMS
Ninio:
Thank s for all your good work in th e White House . Stay safe and well.
Best regards,
Tony
Director
National Institute of Allergy and Infectiou s Diseases
Phone : (b)( 6)
FAX: (301) 496-4409
E-mail : Cb)(6)
information . It should not be used by anyone who is not the orig inal intended recipient . If you
From: Fetalvo, Ninio J. EOP/OVP

To:
-----------
(b)(6); Fetalvo, Ninio (CMS/OC}
(b)(
(b)(6)
Subject:Back to CMS
-----------
All,
Today is my last day on detail to the Office of the Vice President. I am heading back to CMS to cont inue
supporting the Trump Adm inistration's response to the coronavirus . It has been an incredible hono r
serving the Vice President and the Coronavirus Task Force, and a pleasure working alongside all of you . I
look forward to our o ngoing work together .
Best,
Ninio
Ninio J.H. Fetalvo

Personal: ------ (b
~)-(6)
~ I Cb)(6)
CMS: ________ _~_C6)I ___
Cb Cb
_~_C6)
_
Sent: Sat, 2 May 2020 18:27 :23 +0000
To : Johnson, M artin S. (NIH/NIAID) [E];Auchincloss . Hugh (NIH/ NIAID) [E];NIAID
OCGRLeg;McGowan, John J. (NIH/NIAID) [E];Erbelding, Emily (NIH/NIA ID) {E];tane-, Cliff (NIH/N IAID)
[E];Rotrosen, Daniel (NIH/N IAID) [E];Crum, Wayne (NIH/NIAID) [El ;Harper, Jill (NIH/NIAID) [El
Cc: Eisinger, Robert (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia
(NIH/NIAID) [El;Mar ston, Hilary (NI H/ NIAID) [El;Lerner, Andrea (NIH/N IAID) [E];Doepel, Laurie
(N IH/NIAID) [El;Gilles, Sharon (NIH/NIAID ) [E];Routh, Jennifer (NIH/N IAID) [E];Stover, Kathy (NIH/NIAID)
[E];Law, Kim (NIH/NIAID) [E]; Lee, Kun- Lin (NIH/NIAID) [E];Bushar, Nicholas (NIH/NIAID) [E];Schneider,
Johanna (N IH/NIAID) [El
Subject: RE: FY2020 - COVID-19 - Actua l and Forecasted Spending - W eekly Report
Ending 4/24/ 20
Thanks , Mart in .
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From:Johnson, Martin S. (NIH/NIAID) [E] ________ Cb

_>_C6)
_
To: Fauci, Anthony (NIH/NIAID) [El ------~= (b)( ; Auchincloss , Hugh (NIH/NIAID) [El
---------
(b)(6)> ; NIAID OCGRLeg <NIAIDOCGRLeg@mail.nih.gov>; M cGowan, John J.
":'--.-~""."""'.~====-..;._-_,,,:-=\
(NIH/ NIAID) [El
_.:....._....:_:~==:e=,:;-----~--- (b)( >; Erbeld ing, Emily (NIH/NIAID} [El
--:--"""".'"":"""'.":== =)=( 6)
(b =->
...:
;_L_a_
ne ,_c_1i""
...: ff~( N
= IH/ NIAID) [El (b)( ·; Rotro sen, Daniel
(NIH/NIAID) [El (b)( >; Crum, Wayne (NIH/NIAID) [El <wcrum@niaid .nih .gov>;
Harper, Jill (NIH/NIAID) [El (b)( >
Cc:Eisinger, Robert {NIH/NIAID) [El (b)( >; Folkers, Greg (NIH/NIAID) [El
(b)(6)>; Conrad, Patricia (NIH/NIAID) [El (b)(6); Marston, Hilary
(NIH/ NIAID) [El (b)(6)>; Lerner, Andrea (NIH/N IAID) IE] Cb)(
Doepel, Laurie (NIH/NIAID) [El CbH6)>;Gilles, Sharon (NIH/N IAID) [El
Cb)( >; Routh, Jennifer (NIH/NIAID ) [El CbH6)> ; Stover , Kathy
(NIH/NIAID) [El (b)(6}; Law, Kim (NIH/NIAID) [El (b)(6)>; Lee, Kun-Lin
(NIH/NIAID) [El
======e:="':;----' (b)(6)>; Bushar, Nicholas {NIH/NIAID) [El (b)(6)v>;
Schneider, Johanna (NIH/NIAID) [E] (b)(
Subject : RE: FY2020 - COVI0-19 -Actual and Forecasted Spending - Weekly Report Ending 4/24/20
Tony,
YTD spending is $110.8M, increasing $24.lM from last wee k.
Spending driven by implementation of3 epidemiological studies, ramp up of resources necessary for
vaccine candidate testing and vaccine candidate development.
Martin
From : Johnson, Martin S. (NIH/NIAID) [El

Sent : Friday, April 24, 2020 7:11 PM
To: Fauci, Anthony (NIH/NIAID) [El --------=-:~ (b)( >; Auch incloss, Hugh (NIH/NIAID) [El
(b)(6)>; NIAID OCGRLeg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J.
--:-:-:--.:-:-:-:-:-::-:--:-::".:.::::::====-.;._--.
(NIH/NIAID) [El
~
(b)(6)>; Erbelding, Emily (NIH/NIAID) [El
(b)(6); Lane, Cliff (NIH/NIAID) [E] (b)( >; Rotrosen, Daniel
--.--~~===:.:....._..:..__.;___..;,
(NIH/NIAID) [E] (bH6l>; Crum, Wayne (NIH/NIAID) [E] (b)(6);
Harper, Jill (NIH/NIAID) [E] (b)(6)>
Cc:Eisinger, Robert (NIH/NIAID) [El (b)( >; Folkers, Greg (NIH/NIAID) [El
(b)(6)>; Conrad, Patricia (NIH/N IAID) [El (b)(6); Marston,
Hilary (NIH/NIAID) [El (b)(6)>; Lerner, Andrea (NIH/NIAID) [El
(b)(6)>; Doepel, Laurie (NIH/NIAID) [El (b)(6)>; Gilles, Sharon
------~~==:!....:.,.
(NIH/NIAID) [El
_ _;_...:.....~
(b)(6)>; Routh, Jennifer (NIH/NIAID) [El (b)(6)> ;
Stover, Kathy (NIH/NIAID) [El (b)(6)>; Law, Kim (NIH/NIAID) [El (b)(6)>;
Lee, Kun-Lin (NIH/NIAID) [El (b)(6)>; Bushar, Nicho las (NIH/NIAID) [El
(b)(6J> ; Schneider, Johanna (NIH/NIAID) [E) (bH ,>
----------
Subject: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 4/24/20
Tony,
YTD spending is $86 .7M , an increase of $8.3M from last week.
Spending driven by foundat ional research including the characterizat ion of factors associated with
severe disease, transmission dynamics, structural analysis of SARS-CoV-2 proteins . Small awards to
support vaccine and therapeutic discovery.
Martin

Sent: Friday, April 17, 2020 6:15 PM
To: Fauci, Anthony (NIH/NIAID) [El ------~~ (b)( ; Auch incloss, Hugh (NIH/NIAID) [E]
(b)(6); NIAID OCGRLeg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J.
"":"--.----:-:--.:.::::::====:;._---,
{NIH/NIAID) (El
~
(b)(6)>; Erbelding, Emily (NIH/NIAID) [El
(b)(6)> ; Lane, Cliff {NIH/NIAID) [E] (b)(6); Rotrosen, Daniel
--------
(NIH/NIAID) [El (bH6l>; Crum, Wayne (NIH/NIAID) [El (b)(6)>;
Harper, Jill (NIH/NIAID) [El (b)(6)>
Cc: Eisinger, Robert (NIH/NIAID) [El (b)(6); Folkers, Greg (NIH/NIAID) [El
(b)(6)>; Conrad, Patricia (NIH/N IAID) [E] (b)(6)>; Marston,
Hilary (NIH/NIAID) [E] (b)(6)>; Lerner, Andrea (NIH/NIAID) [El
(b)(6); Doepel, Laurie (NIH/NIAID) [E] (b)(6); Gilles, Sharon
":"--.--.-:-.:-::====:...-_;_~~
(NIH/NIAID) [E] (b)(6)>; Routh, Jennifer (NIH/NIAID) [El (b)(6)
Stover, Kathy (NIH/NIAID) [E] (b)(6); Law, Kim (NIH/NIAID) [E] (b)(6)>;
Lee, Kun-Lin (NIH/NIAID) [E] (b)(6)>; Bushar, Nicho las (NIH/NIAID) [E]
(b)(6)>; Schneider, Johanna (NIH/NIAID) [El
----------
Subject: RE: FY2020 - COVID-19 -Actual and Forecasted Spending - Weekly Report Ending 4/17 /20
(b)(6)>
Tony,
YTD spending is $78.4M, an increase of $10.9M from last week including costs to evaluate the rapeutics
in humans and NHPs, manufacture of a protype virus-like vaccine candidate developed by
Taubenberger/Memoli, and spending to accelerate discovery of new therapeutics , vaccines and
diagnostics .
(b)(5)
Martin
Se nt : Friday, April 10, 2020 8:22 PM
------~~ (b)( >; Auchincloss, Hugh (NIH/NIAID) [El
NIAID OCGRLeg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J.
(b)(6)>;
.....
-.----:-:-:-:-:;:::=====~--~~
(NIH/NIAID) [El Erbelding, Emily (NIH/NIAID) [El
(b)(6);
CbH6) 1
>; Lane, Cliff (NIH/NIAID) [El Cb)( >; Rotrosen, Daniel
":":""'-.-:-:-:----:-:-::--:;::::::="="".!_
(NIH/NIAID) [El CbH6); Crum, Wayne (NIH/NIAID) [El CbH6);
Harper, Jill (NIH/NIAID) [E) (b)(6)
Cc: Eisinger, Robert (NIH/NIAID) [El CbH >; Folkers, Greg (NIH/NIAID) [El
(b)(6)>; Conrad, Patricia (NIH/N IAID) [El (b)(6)>; Marston,
Hilary (NIH/NIAID) [E] (b)(6)::>; Lerner, Andrea (NIH/NIAID) [El
(b)(6)>; Doepel, Laurie (NIH/NIAID) [El (b)(6)>; Gilles, Sharon
(NIH/NIAID) [El (b)(6); Routh, Jennifer (NIH/NIAID) [El (b)(6)
Stover, Kathy (NIH/NIAID) [El (b)(6)>; Law, Kim (NIH/NIAID) [El (b)(6)>;
Lee, Kun-Lin (NIH/NIAID) [El (b)(6)>; Bushar, Nicholas (NIH/NIAID) [El
---------- (b)(6); Schneider, Johanna (NIH/NIAID) [E)

Subject: RE: FY2020 - COVID-19 -Actual and Forecasted Spending- Weekly Report Ending 4/10/20
CbH ,>
Tony,
YTD spending is $67 .SM, unchanged* from last week . A summary is attached .
I have also attached an updated budget plan reflecting our projected spending by research category by
fiscal year. We are updating this weekly as we receive updates from the divisions on the timing of
clinical trials, observat ional studies, natural history studies and research resource needs.
We w ill report mid-week on our YTD spending which will be in sync with the data the Dept. extracts.
Martin
• The reason that we have reported no weekly increase is to match our reported spending with the
financial information that the Department is now extracting from our accounting system. We have
always included spending from our regular appropriat ion, as directed by the Department. Now the
guidance from the Dept. has been updated to report only spending from the supplemental COVID-
19 appropriations.
From : Johnson, Martin S. (NIH/NIAID) (E]

Sent : Friday, April 3, 2020 8 :54 PM
To: Fauci, Anthony (NIH/NIAID) [E] ,r------- =)- c='>; Auch incloss, Hugh (NIH/NIAID) [E]
(b
(b)(6J>;NIAID 0CGR Leg <NIAIDOCGRLeg@mail.nih.gov >; McGowan, John J.
":":'"'."."."'.'"':"."".".""'."".":"":"7:":'--.:====::::....;.---::-,~
(NIH/NIAID) [E] (b)( >; Erbelding, Emily (NIH/NIAID) [E]
CbH6J> ; Lane, Cliff (NIH/NIAID) [E] CbH6J>; Rotrosen, Daniel
(NIH/NIAID) [E] (b)(6l>; Crum , Wayne (NIH/NIAID) [E] (b)(6)
Harper, Jill (NIH/NIAID) [E] (b)(6)>
Cc: Eisinger, Robert (NIH/NIAID) [El CbH >; Folkers, Greg (N IH/NIAID) [E]
(b)(6)>; Conrad, Patricia (NIH/N IAID) [E] (b)(6J>; Marston,
Hilary (NIH/NIAID) [E] CbH6l>;Lerner, Andrea (NIH/NIAID) [El
(b)(6)>; Doepel, Laurie (NIH/NIAID) [E] (b)(6)>; Gilles, Sharon
"".".
(N
""'."
l"."".
H-:'.
/N""'."
l""'."
A~ID'."'."'
)":".
[E~]===..:....-:..,_ :::-
(b.,..,
)(= >; Routh, Jennifer (NIH/NIAID) [E] (b)(6);
Stover, Kathy (NIH/NIAID) [E] (b)(6)>; law, Kim (NIH/NIAID) [E] (b)(6);
lee, Kun-Lin (NIH/NIAID) [E] (b)(6)>; Bushar, Nicho las (NIH/NIAID) [E]
--------- CbH6J; Schneider, Johanna (NIH/NIAID) [E) CbH ,>

Subject: RE: FY 2020 - COVID-19 -Actual and Forecasted Spending - Weekly Report Ending 4/3/20
Tony,
YTD spending is $67.SM, a weekly increase of $45 .9M mostly for initial fund ing for set-up of
clinical tria ls for eva luat i.on ofremdesivir in patients with ear ly disea se stage and a placebo-
controlled clinical trial of intravenous hyperimmune immunoglobu lin (IVIG) in patients with
COVID-1.9.
I've provided a summary spending plan the team worked on and a table for the $ l .532B that we
have received in supplemental appropriations
• $82 6M NIAID received 3/5/20 - the Coronavirus Preparedness and Response
Supplemental Appropriation s Act
• $706M NIAID received 3/25/20 - the Coronavirus A id, Relief , and. Economic Security
(CARES) Act
In the last document I've also included narrative summarizing activities funded by the $249 M
Other NIH Institutes received in the CARES Act
Martin
From: Johnson, Martin S. (NIH/NIAID) [E]

Sent : Friday, March 27, 2020 7:39 PM
------~~
To: Fauci, Anthony (NIH/NIAID) [E] CbH6l>;Auch incloss, Hugh (NIH/NIAID) [E]
(b)(6); NIAID 0CGR l eg <NIAIDOCGRLeg@mail.nih .gov >; McGowan, John J.
---:---~====::::!.:.--~~
(NIH/NIAID) [E] (b)( >; Harper , Jill (NIH/NIAID) [E] (b)(6)>;
Crum, Wayne (NIH/NIAID) [E] CbH6l>;Erbelding, Emily (NIH/NIAID) [El
(b)(6); Lane, Cliff (NIH/NIAID) [E] (b)( >; Rotrosen, Daniel
":"'
(N
-:'l"."".'
H/-:-N"."'."'
IA
"."".'
l':""
D:--:
) [~E]:-====-_;__...;. (b
"'"')~(6l>
Cc: Eisinger, Robert (NIH/NIAID) [El (b)( >; Folkers, Greg (N IH/NIAID) [E]
(b)(6)· Conrad, Patricia (NIH/N IAID) [E] CbH6l>;Marston,
---------
Hilary (NIH/NIAID) [E] (b)(6)>; Lerner, Andrea (NIH/NIAID) [EJ
Doepel, Laurie (NIH/NIAID) [E]
(b)(6) 1 ; (b)(6)>; Gilles, Sharon
(NIH/NIAID) [E] (b)(6); Routh, Jennifer {NIH/NIAID) [E] CbH6J> ;
Stover, Kathy (NIH/NIAID) [El (b)( >; Law, Kim (NIH/NIAID) [El CbH6J> ;
Lee, Kun-Lin {NIH/NIAID) [E] CbH6J>;Bushar, Nicho las (NIH/NIAID) [El
(b)(6J; Schneider, Johanna (NIH/NIA ID) [E) CbH ,>
---------
Subject: RE: FY2020 - COVID-19 -Actual and Forecasted Spending- Weekly Report Ending 3/26/20
Tony,
YTD spending is $2 1.6M, a weekly increa se of $4.0M for clinica l trial site set-up for
therapeutics, further vaccine development, small animal development, and therapeutic
development (mAhs) and basic research.
Most of the $50M -$60M we listed last week we expect to be awarded before March 31 . In many
cases contractors have begun work without the award so as to not stall work.
Early next week I' 11prov ide a summary spending plan for the addi tional $706M that NIAID
rece ived in the suppl ementa l appropriation signed by the President today.
Martin
From:Johnson, Mart in S. (NIH/NIAID) [El

Sent: Friday, March 20, 2020 4:54 PM
-----~~ (b)(6J>;Auchincloss, Hugh (NIH/NIAID) [El
(b)(6)>; NIAID OCGRl eg <NIAIDOCGRleg@mail.nih.gov >; McGowan, John J.
":"---:-----:-~=====!.-:.--~=
(NIH/NIAID) [El (b)(6)>; Harper, Jill (NIH/NIAID) [E] (b)(6J>;Crum,
Wayne (NIH/NIAID) [El (b)( >; Erbelding, Emily (NIH/NIAID) [E]
--------- (b)(6)>; Lane, Cliff(NIH/NIAID) [El

Cc: Eisinger, Robert (NIH/NIAID) [El
(b)( >
(b)(6)>; Folkers, Greg (NIH/NIAID) [El
---:-----===:!.:.,_
(NIH/NIAID) [El
_ ____:~~
(b)(6J; Conrad, Patricia (NIH/NIAID) [El
(b)( >; Lerner, And rea (NIH/N IAID) (El
(b)(6J>; Marston, Hilary
(b)(6);
Doepel, Laurie (NIH/NIAID) [El (b)(6) ; Gilles, Sharon (NIH/NIAID) [El
(b)(6J>;Routh, Jennifer (NIH/NIAID) [El CbH >; Stover , Kathy
(NIH/NIAID) [El (b)(6)>; Law, Kim (NIH/NIAID) [El (b)(6)>; Lee, Kun-Lin
(NIH/NIAID) [El (b)(6)>; Bushar, Nicholas (NIH/NIAID) [E] (b)(6)
Schneider, Johanna (NIH/NIAID) [E) CbH6J>
Subject: RE: FY2020 - COVID-19 -Ac tual and Forecasted Spending - Weekly Report Ending 3/19/20
Tony ,
YTD spending is $ l 7.6M, a weekly increase of $3.SM for clinica l trial site set-up, therapeutic
development (mAbs ) and basic research.
(b)(5)
We greatly appreciate all your hard work.
Martin
From: Johnson, Martin S. (NIH/NIAID) [E]

To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)>; Auchincloss, Hugh (NIH/NIAID) [E]
---:---~-==== (b
=)=(6)
~>....:.
;_N_IA_I_D_O~C~GR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J.
(NIH/NIAID) [E] (b)(6)>; Harper, Jill (NIH/NIAID) [El (b)(6);
""."":""::-'."."'"-:-=":--:-:"::.======-..;-~~
Crum, Wayne (NIH/N IAID) [El (b)(6)>; Erbelding, Emily (NIH/NIAID) [El
(b)(6)>
Cc: Eisinger, Robert (NIH/NIAID) [El (b)(6)>;Folkers, Greg (NIH/NIAID) [El
(b)(6)>; Conrad, Patricia (NIH/N IAID) [El (b)( ; Marston,
Hilary (NIH/NIAID) [El (bH6l>; Lerner, Andrea (NIH/NIAID) [E)
~~~~~== (b
=)=(6)
::::=,
>
..:,
;_o_o_e;_
pe_l,:.:-
L.,..,
a=urie (NIH/NIAID) [El (b)(6)>; Gilles, Sharon
(NIH/NIAID) [El (b)( >; Routh, Jennifer (NIH/NIAID) [E) (b)(6)> ;
Stover, Kathy (NIH/NIAID) [E] (b)(6)>; Law, Kim (NIH/NIAID) [E] (b)(6)>;
Lee, Kun-Lin (NIH/NIAID) [E] (b)(6); Bushar, Nicholas (NIH/NIAID) [E]
--------- (b)(6)>; Schneider, Johanna (NIH/NIAID) [E)

Subject: RE: FY2020 - COVID-19 -Actual and Forecasted Spending - Weekly Report Ending 3/12/20
(b)( >
Tony,
Since we our last report we have increased spending on the COV ID-19 response by $1.SM for a
total YID spending of $14.lM.
The $ I .SM increase is for the following:
$ 1.0M awarded to set-up clinical sites at Emory and U. Washington Seattle for adaptable
RCT of rerndesivir.
$0.4M supported data analysis of rhesus animal model and grant to gain understanding of the
host pathways that regu late viral gene expression and viral subversion of the host immune
system.
$0. lM funded vaccine development at VRC and DIR
(b)(5)
Martin
From:Johnson, Martin S. (NIH/NIAID) [El

------~~
To : Fauci, Anthony (NIH/NIAID) [E] (b)(6)>; Auch incloss, Hugh (NIH/NIAID) [El
(b)(6)>; NIAID OCGRl eg <NIAIDOCGRleg@mail.nih.gov >; McGowan, John J.
---:----:-~====:!...:.--~~
(NIH/NIAID) [E] (b)(6)>; Harper , Jill (NIH/NIAID) [El (b)( >;
Crum, Wayne (NIH/NIAID) [El (b)(6)
Cc:Eisinger, Robert (NIH/NIAID) [El (b)( >; Folkers, Greg (NIH/NIAID) [El
(b)(6J>; Conrad, Patricia (NIH/N IAID) [E] CbH ; Marston,
Hilary (NIH/NIAID) [E] CbH6l>;Lerner, Andrea (NIH/NIAID) [El
CbH6J; Doepel, Laurie (NIH/NIAID) [E] (b)(6) Gilles, Sharon
-:-:
(N-:-:
l:-:-
H/";".'
N"."'."
IA
-:-:-
1-:-
D:-:
) [:':".
E]:-===::;.___;,~ (b
,....,.
)-:-=
(6)>; Routh, Jennifer (NIH/NIAID) [El (b)(6);
Stover, Kathy (NIH/NIAID) [El CbH6J;Law, Kim (NIH/NIAID) [El CbH6J>;
Lee, Kun-Lin (NIH/NIAID) [El (b)(6)
Subject: RE: FY 2020 - COVID-19 -Actual and Forecasted Spending - Weekly Report Ending 3/5/20
Tony,
Since we our last report we have increased spending on the COVID-19 response by $0.2M for a
total YTD spending of $ 12.6M.
The $0.2M increase is for vaccine candidate development at NIA ID Intramural Labs including
RML. Costs are mostly for staffing and overhead and include a preclinical immunogen icity
study designed to test the mRNA-1273 nCoV vaccine two -dose schedule in mice. The study will
measure the immune response to this vaccine in an animal model in anticipat ion of clinical test in
humans.
(b)(5)
Martin
From:Johnson, Martin S. (NIH/NIAID) [El

------~~
To: Fauci, Anthony (NIH/NIAID) [E] CbH6>>; Auch incloss, Hugh (NIH/NIAID) [E]
--------
(b)(6)>; NIAID OCGRLeg <NIAIDOCGRLeg@mail.nih.gov>; M cGowan, John J.
---:---~---::====::!......:.--~~
(NIH/NIAID) [El (b)(6)>; Harper , Jill (NIH/NIAID) [E] (b)(6);
Crum, Wayne (NIH/NIAID) [El (b)(6)>
Cc: Eisinger, Robert (NIH/NIAID) [El (b)( >; Folkers, Greg (NIH/NIAID) [El
(b)(6)>; Conrad, Patricia (NIH/N IAID) [E (b)(6)>; Marston,
Hilary (NIH/NIAID) [El (b)(6)>; Lerner, Andrea (NIH/NIAID) [E)
(b)(6)>; Gilles, Sharon (NIH/NIAID) [E] (b)(6)1
>; Routh, Jennifer
(NIH/NIAID) [El CbH6>>;Stover, Kathy (NIH/NIAID) [El CbH6>>; Law,
Kim (NIH/NIAID) [El CbH6>>;Lee, Kun-Lin (NIH/NIAID) [E] (b)(6)
Subject:FY2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 2/27 /20
Tony,
Since we our last report we have increased spending on the COVID- 19 response by $2 .3M for a
total YTD spending of $ 12.4M.
A recap of the $2.3 million spent in the last week is as follows :

• $ 1.9M to set-up a Phase I trial (45 subjects) of the VRC/Modema mRNA platform
candidate at Kaiser Pennanente Washington Heal th Research Institute (One of the
VTEUs )
• $0.3M that supported University of Hong Kong research ers in the developme nt of a RT-
PCR test to detect SARSCo V2 from human samp les. The group has now shared the tests
and relevant reage nts with over 30 labs globally to enab le diagn osis of COVID- 19.
• $0.lM vaccine candida te development at NIAID Intramura l Labs
(b)(5)
Mart in
From : Johnson, Ma rtin S. (NIH/NIAID) [El

(b.~=c6)>;Auch incloss, Hugh (NIH/NIAID) [El
.,..
NIAID OCGRl eg <NIAIDOCGRleg@mail.nih.gov >; McGowan, John J.
-----.~~===~..:__--~
(NIH/NIAID) [El
(b)(6)> ;
Harper , Jill (NIH/NIAID) [E]
(b)(6)>; (b)(6)>;
Crum, Wayne (NIH/NIAID) [El (b)(6)>
Cc: Eisinger, Robert (NIH/NIAID) [El (b)(6)>; Folkers, Greg (N IH/NIAID) [El
(b)(6)>; Conrad, Patricia (NIH/N IAID) [E] (b)(6)> ; Marston,
Hilary (NIH/NIAID) (E] (b)(6)> ; Lerner, Andrea {NIH/NIAID) (E)
-------- (b)(6)>; Gilles, Sharon (NIH/NIAID) [E]

Subject: FY2020 - COVID-19 - Actual and Forecasted Spending as of 2/13/20
(b)(6)
Dr. Fauci,
Attached is a narrative we are updating weekly for NIAID's COV ID-19 response.
The accomp anying spreadsheet summar izes the figures and includes a summa ry of our
supplemental request.
We' II provide an update by Thursday of next week.
Martin
Resource Planning and Mission Integration Branch (RPMIB) - NIAID
NIH Bldg . 3 1 Room 7A47
Tel: (b)(6)
Sent : Sat, 2 May 2020 18:22 :37 +0000
To : Fauci, Anthony (NIH/N IAID) [El
Cc: (b)(6)
Subject: RE:RE:
Zeke:
Thanks for your note. CbH6)and I would love to get together with you all
for dinner. Let us try to do so within a reasonab ly soon time frame.
Best regards,
Tony
Director
Phone : (b)(6)
FAX : (301 496-4409
E-mail: (b)(6)
From: Eisinger, Robert (NIH/NIAID) [E] > On Behalf Of Fauci, Anthony

(NIH/NIAID) [E]
---------- (b)(
Sent: Saturd ay, May 2, 2020 7:24 AM

------~=
Subject: FW: RE:
-------- (b)(6)>
Email from Zeke Emanue l.

Special Assistant for Scie ntific Projects
Nat iona l Institute of Allergy and Infectiou s Diseases
Bethesda MD 20892
Telephone : (b)(6)
Email: (b)(
(b)( >
--------
------ ~=
Cc:
-------------------
Subject: Re: RE:
Tony
You are national--internationa l --treasure . And we are depending upon your sanity and smarts.
We can have you and CbH6)overfor dinner on the porch and order in from Cb)(6) or
something. Anytime you are ready.
Eze kiel .J. Emanu el, M.D., Ph.D.
Vice Provo st of Global Initi atives
Chair, Departmen t of Medical Ethics and Hea lth Policy (b)(6)

--------
Co-Director , Heal thcare Transformation Institute
Perelman School of Medicine and The Wharton School
Phone: Cb>
(6)
From: Fauci, Anthony (NIH/NIAID) [E] (b)( >

To: Emanuel , Ezekiel J (b)(6)
Cc:
-------------------
Subject: RE: RE:
(b)(6)
Zeke:
Thanks for the note. Indeed, we do agree. (b)(6)
- I look forweard tochatting with you some time soon.
Best,
Tony
>
--------
(bH
Fauci, Anthony (NIH/NIAID) [E] ------ -==,

To :
Subject: Re: RE: -------- (b)(6)>
Sorry for misreading what you said--1 think maybe I overin tepreted- -lots of f inance people
called and seemed like I was a downer compared to you. But I think we agree.
Are you and

--- (b)(6) doing okay?
Ezekie l J. Emanuel, M.D., Ph .D.
Chair, Departm ent of Medical Ethics and Health Policy (b)(6)

--------
Co-Director , Heal thcare Transform ation Institute
University of Penn sylvania
(b)(6)
Phone:
-----------
From: Fauci, Anthony (NIH/NIAID) [E] ______ _)_C6)

(b _>
To: Emanuel, EzekielJ (b)~ >
Subject: RE:
Zeke:
I did not "strongly " endorse it. I specifically said tha t it was not a knockout drug
and was only a baby step in the direction of develop ing more and better drugs. I
said that it was important because it proved in a well-powered, randomized ,
placebo-contro lled clinical tria l tha t one can suppress t he virus enough t o see a
clinical effect, as modest as the effect was. I do not think I forced anything.
Happy to chat with you about it.
Best,
Tony
Anthony S . Fauci, MO
Director
Phone: (b)( 6)
FAX: (301) 496-4409
E-mail :
-------- (b)(6)
From: Emanuel, Ezekiel J (b)(6)>

--------
Sent: Thursday, Apr il 30, 2020 2:12 PM
To: Fauci,Anthony (NIH/NIAID) [E]--------=-=~
______ _>
Cb
_<_ >
Subject:
Tony ,
I hope you and (b)(6) are doing well. You are doing an amazing job under difficult
circumstances . And just know we prefer the "real" Tony to the Brad Pitt version!!!
I am a bit perplexed by your seeming strong endorsement of remdesivir . Was it just a bit
forced?
My reading was the data were weak and in normal times for norma l disease it is not enough to
to approve. And very unlikely to really impact COVID-19 disease pattern --regardless of supply
issues.
Stay safe
Ezek iel J. Emanuel , M .D., Ph.D .
Chair, Departm ent of Medical Ethics and Health Policy

-------- Cb)< )
Levy Unive rsity Profe ssor
Co-Director, Healthcare Transformat ion Institute
Perelman School of Medicine and The Wharton Schoo l
University of Penns ylvania
Phone : (b)(6)
From : Fauci, Anthony (NIH/N IA ID) [E)
Sent : Sat, 2 May 2020 18:00 :31 +0000
To : Hurst , Natalie R. EOP/OVP
Subje ct: RE: Update - Whi te House Coronavir us Task Force Meet ing
Thanks, Nata lie !
Director
Build ing 31, Room 7A -O3
Phone Cb)(6)
FAX: (30 496"'4409
E-mail: (b)(6)
informat ion. It should not be used by anyone who is not the orig inal intended recip ient. If you
(bX5)-PCE
From: Faud,Anthony (NIH/N IAID) [E)
Sent: Sat, 2 May 2020 17:57 :11 +0000
Cc: B~rasch, Kir,1bt?rly(NIH/NIAID) [C]
Subject: FW: Greetings from India
Let us discuss.
Director
Phone : (b)(6)
FAX: (3 96':44li9
E-mail Cb)(6)
other storage devi ces . The National Institute of Alle rgy and Infectious Diseases (NIAID) shall not
behalf of the NIAID by one of it s representatives.
From: Prof. Chirantan Chatterjee (b)(6)>

-------::-::-:-=
_________
----====!---~~=
Cc: Deepak Bhatt Manager - Communicat ions
(b)(6)>
... (b)(6)
Subject: Greetings from India
Dear Dr Fauci,
My greetings from India. I am a health econom ist and management professor at the Indian Institute of
Management, Ahmedabad, India's premier management schoo l. Also, i am a avid fan of your work even
fr om pre-covid19 days.
I write to you requesting some time if possible to do a podcast of 45 minutes with you over zoom. The
science and policy ecosystem in India i think would immensely benefit if you can offer your thoughts on
what should be India's 12-month strategy going forward for COVID-19.
We have done some recent podcasts relate dly and they are listed her
(https://m .soundcloud.com/healthcastbycmhs/l.
If you agree, and we are flexible all of May, my communication head Mr. Deepak marked in the email
will arrange the zoom logistics and make it as seamless as possible for you.
We w ill also go per your t ime zone conveniences and do this ov er webex/hangout/skype or phone call if
t hat helps.
It would be a del ight Dr. Fauci if you can j oin us in th e conversation, loo king forward to hearing from
you. Our respectful namaste g
from India for all th e brave work you are doing.
My best, Chirant an
ChIran tan Chatterjee (PhD, Carnegie Mellon ) 11Associate Professor (Economics & Business Polley) & ICICI Bank Chai r In Strategic Managemen t 11
Chairperson, Center fo r Managemen t of Health Services at IIM A 112019 -2020 Visiting Fellow, 20 18-2019 Campbell & Edward Teller Nati onal Fellow,
Hoover Inst itu tion , Stanford University 11Office Address Wing lS F, Indian Institu te of Management 11Ahmedabad, 380 015 Gujarat, India ! I Skvpe:
--- ~"-"'~ 11Email:____ _. =--= ____ _,_!?}-® I I Hoover Inst it ution Website I IIMA Official Website
What is laid down, ordered,factual is never enough to erobrocethe whole truth: life alwaysspills over the rim of everycup. - Boris Pasterna k in Bridges to
Infi nity: Th e Human Side of Mathematics (1983) by Michael Guillen
Sent : Sat, 2 May 2020 12:08 :00 +0000
Cc: Billet, Courtney (NIH/NIA ID) [E);Haskins, Melinda (NIH/NIA ID) [E]; Barasch,
Kimberly (NIH/NIAID) [CJ
Subject: FW : Congresswoman Sheila Jackson Lee invites your participation in a Virt ual
Town Hall meeting hosted by ABC affiliate Channel 13 in Houston, Texas on Thursday, May 7, 2020 at
7:00 PM CDT
Attachments : Dr. Anthony Fauci - Town Hall lnvite.pdf
Please take a look at this . We obviously will have to get clearance through HHS and White
House Leg. This is for Th ursd.iy .ind so we would need to submit soon.
From:Coney, Lillie
------------
(b)(6)>
--------------~=
.,;,__;_
_ __;,,..;;_:-======,;:~;-:-----:-::-::---.:======----
=-=- (b)(
Cc: Rushing, Glenn
----------- ----------
(b)( ; Coney, Lillie (b)(6)
Subject: Congresswoman Sheila Jackson Lee invites your participation in a Virtual Town Hall meeting
hosted by ABC affiliate Channel 13 in Houston, Texas on Thursday, May 7, 2020 at 7:00 PM CDT
May 1, 2020
Dr. Anthony Fauci, M.D.

Director of the National Institute of Allergy and Infectious Diseases
Department of Health and Human Services
5601 Fishers Lane
Dear Dr. Fauci:
Thank you for your tremendous steadfast leadership during this pandemic and
health crisis. Our nation has not faced a crisis of this magnitude since the 1918
Spanish Flu, but we will travel this journey together and defeat this virus . In the end, the
nation will become stronger and more prepared.
Your participation is requested in a Virtual Town Hall meeting hosted by

ABC affiliate Channel 13 in Houston, Texas on Thursday, May 7, 2020 at 7:00 PM
CDT. This town hall meeting will focus on testing and guidelines for re-opening
our nation. It is scheduled to last an hour with 2 or 3 guests including yourself. Houston
is the fourth largest city in the country and your knowledge and expert ise would be most
helpful in our fight to keep our infection and fatality rates low for this entire region and
the State of Texas .
My offic e has been pushing testing and setting up testing sites since the first
notification of the coronavirus . We currently have seven active testing sites and
expanding each week to get to the mass testing necessary to flatten the infection rate .
Thank you for your consideration of this request and I look forward to participating
with you in the Virtual Town Hall meeting. Again, thank you for your leadership. Please
RSVP or if you have questions regarding this request with Glenn Rushing, my Chief of
Staff at .___ ____, CbH6)and Lillie Coney , my Chief
Policy Advisor a Cb
H6)
Very truly yours ,
J
Sheila Jackson Lee
Member of Congres s
Regar ds,
Lillie Con ey
Policy Director
Congre sswoman Sheila J ackson Lee (TX-18)
2079 Rayburn HOB
Washingto n , DC 205 15
(b)(6)
Sent : Sat, 2 May 2020 12:01 :04 +0000
To : (b)(6)
Subject : FW: RE:
Let us try to do this next weekend.
From: Eisinger, Robert (NIH/NIAID) [E]..._________ ~90n Behalf Of Fauci, Anthony

(NIH/NIAID) [E]
Sen t: Saturday, May 2, 2020 7:24 AM
To: Fauci, Anthony {NIH/NIAID) [E]------ --=-
(b=)(=6)
Subject: FW : RE:
Email from Zeke Emanuel.

Bethesda MD 20892
Telephone : (b)(6)
Email: (b)(
From: Emanuel, Ezekiel J (b)( >

--------
Sen t : Friday, May 1, 2020 8:04 PM
To: Fauci, Anthony {NIH/NIAID) [E] ------~= (b)(6)>
Cc: (b)(6)>
-------------------
Subject: Re: RE:
Tony
You are national--internationa l --treasure. And we are depending upon your sanity and sma rts.
We can have you and CbH6)overfor dinner on the porch and order in from (b)(6) or
someth ing. Anytime you are ready .
Ezekiel J. Emanuel , M.D., Ph.D .

Chair, Departm ent of Medical Ethics and Hea lth Policy ______ Cb
_>'_
<6j)
Levy University Pro fessor
Co-Dir ector , Hea lthcar e Transform ation Institut e
Univer sity of Penn sylvania
Phone: (b)(6)

_______ ,....
(b) (6lv >
To: Emanuel , Ezekiel J (b)(6)>

Cc:
------------------
Subject : RE: RE:
(b) ( >
Zeke:
Thanks for the note . Indeed, we do agree . (b)(6)
- I look forweard tochatting with you some time soon.

Best,
Tony
From: Emanuel, Ezekiel J >

--------
(b)(

------~~ (b)(6)>
Subject: Re: RE:
Sorry for misreading what you said--1 think maybe I overin t epreted-- lots of finance people
called and seemed like I was a downer compared to you. But I think we agree.
Are you and

---- CbH6Jdoing
okay?
Ezekiel J. Emanuel, M.D., Ph.D.

Chair, Depa1tment of Medical Ethics and H ealth Policy ______ Cb

_>_
<)
L evy University Professor
Co-Director , Healthcar e Transform ation Institut e
Pe relman Schoo l of Medicine and The Wharto n Schoo l
Univer sity of Pennsylvania
Phon e:
----------- (b)(6)

To: Emanuel , Ezekiel J (b) ( >
Subject: RE:
Zeke:
I did not "strongly" endorse it. I specifically said tha t it was not a knockout drug
and was only a baby step in the direction of develop ing more and bette r drugs. I
said that it was important because it proved in a well-powered, randomized ,
placebo-controlled clinical tria l tha t one can suppress t he virus enough to see a
clinical effect, as modest as the effect was. I do not think I forced anything.
Happy to chat w ith you about it.
Best,
Tony
Director
Phone: (b)(6)
FAX: (301) 496-4409
E-mail:
-------- (b)(6)
From: Emanuel, Ezekiel J (b)(6)

Sent: Thursday, April 30, ---------
2020 2:12 PM
Fauci, Anthony (NIH/NIA ID) [E]-------
To:
Subject: --------- == (b)( 6)
Tony,
I hope you and

----
(b)(6) are doing we ll. You are doing an amazi ng job unde r difficult
circumstances. And ju st know we prefer the "real" Tony to the Brad Pitt version!!!
I am a bit perplexed by your seeming strong endorsement of remdesivir. Was it just a bit
forced?
My reading was the dat a were weak and in normal times for normal disease it is not enoug h to
t o approve. And very unlikely to really impact COVID-19 disease pattern--rega rdless of supply
issues.
Stay safe
Eze kiel J. Emanu el, M.D ., Ph.D.
Chair , Departm ent of Medical Ethic s and Health Policy Cb)< )

--------
Co-Director, Healthcare Transformation Institute
University of Penn sylv ania

----------....1
Phone: Cb>
(6)
Sent : Sat, 2 May 2020 02:04:00 +0000
To: Selgrade, Sara (NIH/NIAID) [El
Cc: NIAID OCGRLeg;Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/N IAID)
[E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Requesting your assistance : Draft NIAID Statement for May 12 Senate HELP
Hearing
Attachments : 2020 .05.12 NIAID Senate HELPtestimony COVID 19 - with Fauci tracked
changes.docx
I am attac hing the document with minor tracked edits. Nice jo b! Thanks.
From:Selgrade, Sara (NIH/NIA ID) [E) (b)(6)>

Sent: Thu rsday, April 30, 2020 5:24 PM
To: Fauci, Anthony (NIH/ NIAID) [E] <f-----~ Cb
-H=6J>
Cc:NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; Billet, Courtney (NIH/NIAID) [El
CbH6J>;Folkers, Greg (NIH/ NIAID) [E (b)( >; Conrad, Patricia
(NIH/ NIAID) [E] (b)(6)
Subject: Requesting your assistance : Draft NIAID Statement for May 12 Senate HELPHearing
Dr. Fauci:
In preparat ion for the upcoming May l ih COVID-19 hearing of the Senate Health,
Educa tion , Labor, and P ens ions Committee (Chair : Sen. Lamar Alexander, R-TN),
we have drafted the attached NIAID testimon y, bu ilding on your prior testimony
on COVID-19. Dr s. Giroi r, Hahn, and Redfield also have been invited to the
hea ring.
We expect that your testimon y will be included as an insert to an HHS-wide

testimony. At the request of NCH OD, we ha ve incorporated into the draft COVID-
19 activ ities across N IH .
The testimon y ha s been reviewed by the Divi sions and Dr s. Lane , Harpe r,
Marston, and Lerner , as well as Courtney Billet , Greg Folkers, Martin Johnson ,
and Lauri e Doepel.
NIH OLPA has aske d to receive your testimony for clearance by tomorrow, if
possi ble .

Sara
Sara Selgrade, Ph .D .
Sect ion Chief for Legislative Activities
Legislative Affairs and Con-espondenceManagementBranch
Office of Communicationsand GovernmentRelations
NIAJD/NIH/DHHS
Bldg. 31,Room 7Al7, MSC 2520
Phone: (b) (6)
(b)(6)
Disclaimer:
The i11for111atio11in this e -111ail and a.11yof its altac/1111c11ts is co ,!fide:ntial and ,nay c:ontai n sensitive i11fon11,1tio11.it ,-,·l,ou/d not b e
used by anyone who is not the original intended recipienl. lf you have rr?ceivedthis e-mail i11error please inform the sender and
delete it from y our mailbox or any other storaw; devices. National Institute ofA!lerf!)' and Infectious Dise,ases shall not accept
liabili(v,(orany slatements made !hat are sender's own and not e,xpresslymade 011behalf of ,he NJAID by one o/ils
representatives ,
Sent : Fri, 1 May 2020 15:28:23 +0000
To: Routh, Jennifer (NIH/NIAID) [El
Subject : RE:cl ips
Thanks.
Director
Phone: (b)(6)
FAX:(301) 496~ 09
E-mail: (b)(6)
From : Routh, Jennifer (NIH/ NIAID) [E] (b)( >

Se nt : Friday, May 1, 2020 8:56 AM
To: Fauci, Anthony (NIH/NIAID) [E] --------, .....,....,=
(b)(6)
Cc: Billet, Courtn ey (NIH/NIA ID) [E] (b)(6); Conrad, Patricia (NIH/NIAID) [E]
---------
Subject: RE:clips
(b)(6)>; Folkers, Greg (NIH/NIAID) [E] (b)( >
Dr. Fauci-
I have requested the full clips from our clipping service . I found t he following on line in the meantime:
Today Show:
https://www .today .com/video/ d r-a ntho ny-fa uci-rem d esivir-is-a-very -i m port ant -fi rst-step-in-fighti ng-
coronavirus-82800 197863
CNN Town Hall (clip discussing federal "reopening" guidel ines):

https://twitter .com/CNN/status/1256023483638669313
CNN Town Hall (clip discussing vaccines) :

htt ps:// twitter .com / CNN/ status / 1256044817093558272
Thanks,
Jen
Jennifer Routh [E]
News and Science Writing Branc h
Office of Commu nications and Government Relations
NIH/HHS
31 Center Drive Room 7A 17C
Bethesda, MD 20892
Direct: (b) (6)
(b)(6)
Disclaimer : The information in this e-mail and any of its attachmen ts is confidential and may con tain sensit ive information. It should not be
used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it
from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any
statementsmade that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Sent: Friday, May 1, 2020 7:44 AM --------- (b)(6)
---------=--:-=
To: Routh, Jennifer (NIH/NIAID) [E]
Subject: clips --------- > (b)(
Jen:
Can we please make sure that I get the lip s from yesterday from NBC Today
Show and CNN Town Hall with Sanjay and Anderson.
Thanks,
Tony
Director
Phone: (b)(6)
FAX: (301) 496-4409
E-mail: (b)(6)
information_ It should not be used by anyone who is not the orig inal intended recipient_ If you
other storage devices _ The National Institute of Allergy and Infectious Diseases (NIAID) shall not
behalf of the NIAID by one of its representatives_
From: Eisinger, Robert (NIH/NIAID) [El on behalf of Fauci, Anthony (NIH/NIAID) [El
Sent : Fri, 1 May 2020 12:26:55 +0000
Subject : FW: (b)( 4)
Another email from Andre Kalil.

Bethesda MD 20892
Telephone (b)(6)
Email : (b)(

To: Beigel, John (NIH) [El--:-:-::-:--:.=======.:.'"""'""-:-= (b)( ;
Davey, Richard (NIH/NIAID) [El (b)( ; Lane, Cliff (NIH/NIAID) [El
(b)(6)>; Proschan, Michael (NIH/NIAID) [E] (b)(6l>; Marston, Hilary
(NIH/NIAID) [E] (b)( ·>; Fauci, Anthony (NIH/N IAID) [El (bH >
Subject : RE: (b) (4)
(b) (4)
Thanks,
Andre
Andre Kalil , MD, MPH, FACP, FIDSA , FCCM

Professor
Department of Internal Medicine
Division of Infectious Diseases
Director, Transp lant ID Program
Associate Editor. CMI. Official Journa l of ESCMID
Editoria l Board. CCM. Official Journal of SCCM
l' UNMC.
-,- t(JltUt.•
Univers ity of Neb raska Medical Center
985400 Nebraska Medical Center. Omaha. NE 68198-5400
(b)(6) I fax 402.559-5581
(b)(6)
UNMC I Facebook I Twitter I You Tube I~

"Lucky? Obviously you haven't heard anything I've said . It was a matter of app lying Bayes' Theorem to
estimate the conditional probabilit ies . Giving due weight to the prior probabilities ..."
Robert Ludlum - The Amb ler Warning
From : Beige!, John (NIH) (E]

Sent : Thursday, April 30, 2020 5:25 AM
-------- (b)( >
To : Dodd, Lori {NIH/NIAID) [E] ------ --,;-,,=

(b)(6)>; Kalil, Andre C (b)(6)>; Davey, Richard
(NIH/NIAID) [E] (b)(6) ; Lane, Cliff (NIH/NIAID) [E]
~====~~ (b)( >; Proschan,
Michael (NIH/NIAID) [E] (b)( >; Marston, Hilary (NIH/NIAID) [E]
(b)(6); Fauci, Anthony (NIH/NIA ID) [E] (b)( >
Subje ct: Re:
------------- (b)( 4
Non-UNMC email
(b) (4)
John B eige), M.D.

Associate Direc tor for Clinical Research
Division o f Microbiology and Infectious Disea~es
National Institute of Allergyand Infectious Diseases(NIAID)
From: Lori Dodd CbH6)>

Date : Thursday , Apr il 30, 2020 at 6:05 AM
To: John Seigel (b)(6)>, Andre Kalil (b)(6)>, Richard Davey
(b)( >, Cliff Lane (b)(6), Michael Proschan
=========~~ Hilary Mars ton
(NIH/ N IAID) ,;..IE-=-]'..::
' ======
(b)(6)>,
(b)=C6)
----------
::_--=-:-.,.,,,,
(b)(6)> , "Fauci, Anthony
Subject: RE:
Andre-
-------------- (b)(4)
i like what you wrote, and partic ularly like the first two sentences.
From: Beigel, Jo hn (NIH) (E] (b)( >

Sent: Thursday, April 30, 2020 5:53 AM
To: Kalil, Andre C (b)(6)> ; Davey, Richard {NIH/NIAID) [E] (b)(6)>; Lane,
Cliff {NIH/NIAID) [El (b)( >; Dodd, Lori (NIH/NIAID) [El (b)(6)> ;
Proschan, Michael (NIH/NIAID) [El (b)(6); Marston, Hilary (NIH/NIAID) [El
(b)(6)>; Fauci, Anthony (NIH/NIA ID) [El (b)( >
Subject: Re: (b) (4
Andr e,
(b) (4)
We too are open for further edits

John
John Beige), M.D.

AssociateDirector for Clinical Research
Div ision of Microbiology and Infectious Diseases
NationalInstitute of Allergy and Infectious Diseases (NIAID)
Phone:
email::=.=====:: ~=
From: Andre Kalil (b)(6)>
Date : Thu rsday, April 30, 2020 at 3:19 AM
To: John Seigel CbH6J>,Richard Davey CbH >, Cliff Lane
(b)(6), Lori Dodd CbH6)>,Michael Proschan
~=======~~ (b)( >, Hilary Marston (b)(6)>, "Fauci, Anthony
"':'---:--:-:--:--:-::.====:::;_;,--..;...,;
(NIH/NIA ID) [E)"
=
CbH6)>
Subject:
-------------- (b) (4)
(b) (4)
Please let me know your t hough t s and suggestions.
Andre
Andre Kalil, MD, MPH, FACP, FIDSA , FCCM

Professor
Department of Interna l Medicine
Director, Transp lant ID Prog ram
Associate Edito r, CMI , Official Journal of ESCMID
Editorial Board , CCM , Official Journal of SCCM
~ UNMc· ~ f<)\U:,_.
University of Neb raska Medical Center

985400 Nebraska Medical Center , Omaha , NE 68198-5400
___ (b)_ (_,
6) I fax 402.559-5581
(b)(6)
UNMC I Facebook[facebook.com) I Twitter (twitter.com) I YouTube [youtube.com)I Flickr [flickr.coml
"Lucky? Obviously you haven't heard anything I've said . It was a matter of applying Bayes' Theorem to
estimate the conditiona l probabilit ies. Giving due weight to the prior probabil ities ..."
The information in this e-mail may be privileged and confidential, intended only for the use of the
addressee(s) above. Any unauthorized use or disclosure of this information is prohibited. If you have
received this e-mail by mistake, please delete it and immediately contact the se nder .
The information in this e-mail may be privileged and confidential, intended only for the use of the
addressee(s) above. Any unauthorized use or disclosu re of this informat io n is prohibit ed. If you have
received this e-mail by m istake, please delete it and immediately contact the sender.
From : Eisinger, Robert (NIH/NIAID) [El on behalf of Fauci, Anthony (NIH/NIAID) [El
Sent : Fri, 1 May 2020 12:25:50 +0000
Subject : FW:

Bethesda MD 20892
Telephone: (b)(6)
Email: (b)(
From : Dani Bolognesi, Ph.D.

----------
Se nt : Thursday, April 30, 2020 8:13 PM
-------=-:-:=
(b)(6)
To : Fauci, Anthony {NIH/NIAID) [E]

Subje ct : RE: -------- (b)(6)>
TX Tony. Nice touch reminding fo lks of how AZT propelled the pharmas and great to see things moving
with this beast!
Sei un campione !
Dani
From: Fauci, Anthony (NIH/NIAID) [E] (b) ( >

------~~
To: Cassetti, Cristina (NIH/NIAID) [E:,.!:
] ======= (b
=)~(6);',.>=
Cc: Erbelding, Emily (NIH/NIAID) [E).__ _______ Cb
_H_6J
Subject: FW:
Cristina:
Please take a good look at th is. It is from Dani Bo lognesi, one of our top HIV/ A IDS
invest igators from a few years back . He is a ser ious scientist. Let me know what you th ink.
Thanks,
Tony
From: Eisinger, Robert (NIH/NIAID) [E) (6J> On Behalf Of Fauci, Anthony

(NIH/NIAID) [E]
----------- (b)

To: Fauci, Anthony (NIH/NIAID) [E].__ _____ (b_H""""'"'"
v>
Subject : FW:

Immediate Office o f the Director
Bethesda MD 20892
Telephone: (b)(6)
Email: (b)(
From: Dani Bolognesi, Ph.D. (b)(6)>

----------
To: Fauci, Anthony (NIH/NIAID) [E] ------~= (b)(6)>; Barasch, Kimberly (NIH/NIAID) [C]
(b)(6) --------
Subjec t : FW:
Kimberly: Please see that t his reaches Tony as per our call today.
TX in advance.
Dani
Hi Tony:
In advance of getti ng together wi t h you and your team, I am forwarding a short presentation for you
guys to look at. The key elements are follows :
(b) (4), (b) (5)
(b) (4). (b) (5)
We are prepared to discuss this with you and your team at any time that is convenien t for you . As you
may know, we are locked down here in the Research Triangle unt il May 15. If it makes sense, we could
arrange a WebEx as an initial step .
Many thanks for the opport unity to share th is with you !
All the very best,
Dani
(b)(6)
Best,
Dani
From:"Dani Bolognesi, Ph.D." (b)(6 )>
Date : Monday, April 27, 2020 at 2:53 PM

To: "Matthias Gromeier, M.D." ------------=-:-=,
------------- (b)(6)
Subject : Please review th is draft email to Tony -- TX
Dani
for you guys to look at. The key elements are follows :
(b) (4). (b) (5)
We are prepared to discuss this with you and your tea at any time that is convenient for you . As you may
arrange a WebEX as an initial step .
Allthe best,
Dani
Best,
Dani
The information in this electronic mail is sensiti •,e, protec ted information intended only for the addressee(s). Any other person,
immed iate ly by return electronic mail, and to delete it without further reading or retent ion . The informat ion is not to be
forwarded to or shared unless in compliance with Duke Healt h policies on confidentiality and/o r wit h the approva l of the
sender .
Sent : Fri, 1 May 2020 12:10:09 +0000
Subject : FW: ACTT pub lication
Importance: High
Another email from Andre Kalil.

Bethesda MD 20892
Telephone: (b)(6)
Email (b)(

Sent : Friday, May 1, 2020 2:59 AM
To: Seigel, John (NIH) [El ------~~ > ; Davey, Richard (NIH/NIAID) [E]
(b)(
(b)(6)>; Lane, Cliff (NIH/NIAID) [E] (b)(6l; Dodd, Lori (NIH/NIAID) [E]
======~~ (b)(6)>; Proschan, Mic hael {NIH/NIAID) [E) (b)(6) Marston , Hilary
(NIH/NIAID) [E] (b)( ; Fauci, Anthony (NIH/N IAID) [El (b)(6)
Subject : FW: ACTT publication
Impo rt ance: High
Not my first choice, but I want to share the invitation email below with you.
Andre
Andre Kalil , MD, MPH , FACP , FIDSA , FCCM

Professor
Department of Interna l Medi cine
Director, Transp lant ID Prog ram
Associate Edito r, CMI , Official Journa l of ESCMID
Editoria l Board , CCM , Official Journal of SCCM
If UNMC- -.ut1BIUGHl !'MIA.·

Uni vers ity of Nebr aska Medi ca l Cen ter
985400 Nebraska Medical Center , Omaha , NE 68198-5400
(b)(6) I fax402.559-5581
===~ (b):..:c
(=
6)
UNMC I Facebook I Twitter I YouTube I Flickr

"Lucky? Obviously you haven't heard anything I've said . It was a matter of app lying Bayes' Theorem to
estimate the conditional probabilit ies . Giving due weight to the prior probab ilities ..."
From:
------------------
To: Kalil, Andre C (b)(6)
(b) (4)
Subje ct: ACTTpublication

Importance: High
Non-UNMC email
Dear Dr. Kalil,
(b) (4)
Sent : Fri, 1 May 2020 11:38:53 +0000
Subject: FW: int erview request by Greek newspaper Ethnos
FYI
Director
Phone (b) (6)
FAX:(301)4 96~ 09
E-mail: (b)(6)
behalf of the NIAID by one of its representative s.
From: ru.:.,pyo<;ha¢u5ac; <gskafidas@ethnos.gr>

Sent: Friday, May 1, 2020 6:07 AM
To: Fauci, Anthony (NIH/NIAID) [E]------ --=~
(b)(6)>
Subject: inte rview request by Greek newspaper Ethnos
Dear Dr. Fauci,
my name is George Skafidas and I'm a journal ist working for the Greek nationa l weekly ETHNOS
(www.ethnos.g r).
We would be very much interested in doing an interv iew with you, to be published in the
Sunday edition of the paper, regarding the developments surrounding t he COVID-19
pandemic.
Best regards
EG>NOE
George Skafidas
Senioreditor, World Affairs
tel: +30 210 6510550
mob: (b)(6)
o, n>-ripocpopiE<;nou ToxuopoµEiou (e-mail)

nEp1txovT01 aE OUTOTO µ~vuµo 11>-E><Tpov1Kou KoOw~ KOi aE Tuxov ouv11µµtvo
EiVOIEµmOTEUTIKE<;KOi npoopi~OVTOIy10 XPrt<JronoKAEIOTIKCI one>TO OUVKEKplµEVO nopoArimr, (-E<;). o, nAr,pocpopiE<;OUTE<;
µnopEi VO KOAUnTOVTOI on6 EnlXEIPrJOIOKO ri 6>>.oon6pprJTOri oAAouc;v6µouc; KOiOEVEnlTpEOETOI VO OVOKOIVW9ouv <JE
ono1ovo,;noTETpiTo. !E nEpimwori nou OEVEiOTEo nopoAr'lnTric;Tou µrivuµoroc; ri ro npoawno nou Eivo1opµ6o10 y,o TrJV
nopooooii TOU OTOVnopo>-r'lnTfJ, anoyopt:U€TOI VO TO OVOKOIVWO"E:Tt,OVTIYPOljJE:"TE:, ri OIOTrJPriOE:TE:
o,ovciµE:"TE: E:V6Awv ri EV
UEPEI.
Sent : Fri, 1 May 2020 11:38:08 +0000
To: (b)(6)
Subject: RE:Coronavir us: Covid 19
Ato:
Thank you for you note . We will know soon whether hydroxychloroquine has
any beneficial effec ts as the results of randomized, controlled trials become
available. The pathogenesis of COVID-19 is sti ll an open question . You are correct
in that ther e is a mor e recent tendency to use ventilators only as a very last resort
since oxygenation rathe r than ventilation appears to be key to recovery.
Best regards ,
Tony
Direc tor
National Inst itutes of Health
Phone : (b)(6)
FAX : (301 496-4409
E-mail: (b)(6)
From: gabriel stephens (b)(

----------
Sent: Friday, May 1, 2020 4:53 AM
To : Fauci, Anthony {NIH/ NIAID) [E] _______(b)(6)>_.
------~=
Subject: Coronavir us: Covid 19
Hi Dr Fauci,
Please find an audio attached of a doctor descr ibing the experience with regards to covid 19 in the
hospital. She seems to suggest covid 19 is a virus tha t rather attacks the blood cell, le ading to respi ratory
and other organ comp lications, hence they need to loom at tre atme nt in a differ ent light. In the UK
some hospitals have moved away from using ventilators due to the high death rate of those on
ventilators, and are rat her using ventilators for sleep apnea, as they are less invasive, and the resu lts are
much much better compared to invasive ve ntilators
There are some anecdotal observations I have also made. The infection rate in most African countries
seem to be comparatively low, w hich could possibly due to the rate of testing being conducted.
However t he death rates are also comparative ly very low. From in itial informat ion with regards to
hydroxychloroquine and some antimalaria drugs usage, it was suggested that those who were alleged
to have had some benefits had mild symptoms of covid 19. I know some clinical trials have shown
hydroxychloroquine not to be effect ive in the treatment of covid 19 in very ill patients. However, my
hypothesis is, are the low death rates in Africa linked to the fact that malaria is very prevelant in Africa,
and lots of Africans take antimalarial drugs, making them less susceptible to covid 19, hence the low
death rate. Is there a similar trend in other countries where malaria is prevalent? Is there an unintended
benefit of taking antimalarial drug (or other medication) before covid infection, or at the onset, making
people less susceptible to covid19 .
As I said, this is based on anecdota l observations.
Yours sincerely
Ato Stephens
Sent : Thu, 30 Apr 2020 23:58 :07 +0000
Cc: Erbelding, Emily (NIH/NIAID) [El
Bee: Dani Bolognesi, Ph.D.
Subject : FW:
Attachment s: Brown et al submitted .pdf, NIH Presentation final.pptx,
prepr ints202002.0147.v2 (1).pdf, Mosaheb et al 2020.pdf
Cristina :
Please take a good look at th is. It is from Dani Bolognesi, one of our top HIV/A IDS
investigators from a few years back. He is a serious scientist. Let me know what you think.
Thanks,
Tony
From: Eisinger, Robert (NIH/NIAID) (El (b)(6)> On Behalf Of Fauci, Anthony

(NIH/NIAID) [El
Se nt : Monday, April 27, 2020 6:57 PM
To: Fauci, Anthony (NIH/NIAID) [El ------~= (b)(6)>
Subject: FW:
Robert W . Eisinger, Ph.D.

31 Center Drive, Room ?A-03
Bethesda MD 20892
Telephone (b)(6)9
Email (b)(
From : Dani Bolognesi, Ph.D.________ Cb

_>_<6)
_>
To: Fauci, Anthony (NIH/NIAID) [El ------~=
______ _ >; Barasch, Kimberly (NIH/NIAID) [C]
Cb>
_C6)
(b)(6)>
Subject: FW:
TX in advance.
Dani
Hi Tony:
In advance of getting together wi t h you and your team, I am forwarding a short presentation for you
(b) (4), (b) (5)
may know, we are locked down here in the Research Triangle until May 15 . If it makes sense, we could
Many thanks for the opportunity to share th is with you !
Allthe very best,
Dani
(b)(6)
Best,
Dani
From:"Dani Bolognesi, Ph.D." (bH6J>
To : "Matthias Gromeier, M .D." ------------,; ~ >

(bH
Subject : Please review this draft email to Tony--TX
Dani
for you guys to look at. The key elements are follows :
(b) (4), (b) (5)
We are prepare c!Tciaiscuss this wit h you and your tea at any time tnaf 1sconvenient for you . As you may
arrange a WebEX as an initial step.
All the best ,
Dani
Best,
Dani
The information in this electronic mail is sensitive, protected information intended only for the addressee(s). Any other person,
immediate ly by return electronic mail, and to delete it without further reading or retention. The information is not to be
forwarded to or shared unless in compliance w ith Duke Health polic ies on confidentiality and/or w it h the approva l of the
sender.
Sent: Thu, 30 Apr 2020 22:35 :34 +0000
To: Jeremy Farrar ;Dzau, Vi ctor J.;George GAO
Cc: Richard
(b)(6);Hannon, Emma;Conrad,
......."""'.""":--:'~~:--"'""":""':'".':""'."~-"'."-:".~----------===~~"'.:"""""---:"'-.--
Patricia (NIH/NIAID ) [E];Teresa M iller de Vega;
-----
(b)( 6);Rebek a Yasmin -
CEPl;ben.t inker@cnn .com;Amanda.Sealy@cnn .com;Neel.Khairzada@turner.com;T ia.M iller@turner .com
(b)(6)McGinnis, J. Michae l;Balatbat, Celynn e;Mun , Jenny; CbH ;Redfield ,
-------
Robert R. (CDC/OD)
Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regard ing your
Saturday April 25 part icipat ion
Jeremy:
Many thanks for the update. Please continue to keep me informed.
Best,
Tony
Director
Phone : (b)(6)
FAX : (301 496-4409
E-mail: (b)(6)
other storage devices. The Nat ional Institute of Allergy and Infectious Diseases (NIAID) shall not
From:Jere my Farrar _________ Cb

_>_<6)
_
Sent: Tuesday, April 28, 2020 10:39 Arvl
-------, ~=; Dzau, Victor J. <VDzau@nas.edu>; George
GAO (b)(6) > --------- (b)(
Cc: Richard Hatchett (b)(6)

(b)(6); Hannon, Emma <EHannon@nas .edu>; Conrad, Patri cia
"':'-""."'."":-'.'"-:-'.'-:-:"::.:=======:;....,.
(NIH/N IAID) [E]
=
(b)(6); Teresa Miller de Vega (b)(
___ Cb _ ; Rebeka Yasmin - CEPI
_>_<6) (b)(6) ; ben .tinker@cnn .com;
Amanda .Sealy@cnn.com ; Neel.Khairzada@turner .com; Tia.M iller@turner. com; (b)( 6) ----- ~=
McGinnis, J. Michael (b)(6)>; (b)( >; Mun, Jenny
<JMun@nas .edu> (b)( ; Redfie ld, Robert R. (CDC/OD) (b)( 6)
Subject: Re: NAS Annual Meeting Session on COVID-19 -- Informat ion regarding your Saturday April 25
participation
Quick update
Update in confidence
European network from this morning:
16 Paris, 2 Geneva, few Madrid last 10 days - nothing like this usually seen even with seasonal
KD or TSS
Barcelona have slightly different experience of 6 'Kawasaki' in last 2 weeks - couple now who
have large coronary aneu rysms, as have one child South London and one in Bristol.
Most UK PICU have 1-2 of these type of cases
Phenotype seems Diarrhoea and abdominal pain, refractory shock then various degrees of
heart invo lvement and inflammation ++ - several have had their normal appendix whipped out
Most negative respiratory and stool PCRfor anything, some positive resp PCRCOVID - GOSH
early case has seroconverted, but had immunog lobu lin
We are establishing database UK and Europe and trying to define what the clinician features are
and agree investigat ions.
Notably , none in US reported (just 0/W Boston childrens who have been running shared
international COVID experience web calls) and none in Rome, unsure about rest of Italy yet
Does seem BAME preponderance-?? immune related or social phenomenon, in terms of
deprivation prevalence and ability to isolate
From: "F auci, Anthony (NIH/NIAID) (E]" CbH6)

Date: Monday , 27 April 2020 at 12:36
To: Jeremy Farrar (b)(6) , Victor Dzau <VDzau@nas.edu> , George Gao
(b)(6) >
Cc: Richard Hatchett Cb)

(6)
"Hann on, Emma " <EHannon@nas.edu> , "Conrad ,

Patricia (NIH/N IAID) [E]" CbH6),Teresa de Vega
Cb)(6) Rebeka Yasmin - CEPI
Cb)(6) , "ben. tinker @cnn.com " <ben. tinker@cnn.com>,
----------
"Amanda.Se aly@c nn.com " <Amanda.Sealy@cnn.com >, "Neel.Kbairzada(a),turner.com "
<Neel.Khairzada@turner.com> , "Tia.Miller@turner.com " <Tia.Miller @turner.com> ,
Cb)(6) "McGinnis, J.Mic hael" <MMcGinnis@nas.edu> ,
CbH6)>, ''Mun , Jenny" <JMun @nas.edu >,
(b)( ----------
>
CbH6l, "Redfield , Robert R. (CDC/OD)"
Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your
Saturday April 25 participation
Jeremy:
Thanks for the heads up. Is there any more detail ed description of th e precise
clinical manifestations? They describe a "mul t isystem infl ammatory state 11 • It is
vasculitis or anything more specific ? Could be an infe ctiou s agent that has
nothing to do with SARS-CoV-2infection even though some children are
circum stanti ally inf ected with SARS-CoV-2orit could be a post-SARS-CoV-2
inflammatory syndrome, perhaps a Kawasaki syndrome- like disease. Please keep
me inform ed if you hear any further inform ation .
Best regards,
Tony
Director
Phone· (b)(6)
FAX: (301) 496-4409
E-mail: (b)(6)
From: Jeremy Farrar

---------
Sent : Monday, April 27, 2020 7:13 AM
-------=-=--==
(b)(6)>

GAO (b)(6)>
-------- (b)(6)>; Dzau, Victor J. <VDzau@nas.edu>; George
(b)(6)
____ _,,
(b)(6)· Rebeka Yasmin - CEPI
; Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia
(b)(6) > ; Teresa Mil ler de Vega
(b)( t >; ben.ti nker@cnn.com ;
Amanda.Sealy@cnn.com ; Neel.Khairzada@turner.com ; Tia.Miller@turner.com ;
(b)(6);
(b) (6)
McGinnis, J.Michael< M McGinnis@nas.edu>; (b)(6)>; Mun, Jenny
<JMun@nas.edu > (b)(6)
Subject: Re: NAS Annual Meeting Sessionon COVID-19 -- Informat ion regarding your Saturday April 25
participation
To be aware of- news over night so a huge amount of uncertainty - important for COVID19 now, and a
potentia l concern for how we view immunity, prot ection, post-infectiou s immunopathology.
https://www.hsj.eo.uk/acute-care/exclusive-national-alert-as-coronavirus-related-condition-may-be-
emerging-in-children/7027496 .article
https://t .co/Bj6YH U8zi
From: "Fauci, Anthony (NIH/NIAID) [E]" CbH6)

>
Date : Sunday , 26 Ap1i l 2020 at 19:52
To: Victor Dzau <VD zau@nas.edu >, George Gao CbH
L---------~ =
Cc: Jerem y Farrar CbH , Rich ard Hatchett CbH6)
(b)(6) -----------
"Hannon,
Emma" <EHannon@nas.edu >, "Conrad , Patricia (NIH/NTAJD) [E]" Cb)( >,
Teresa de Vega CbH6)
>, Rebeka
Yasmin - CEP I (b)(6)"ben.tinker@cnn.com " <ben.tinker@cnn .com> ,
"Amanda.Sealy@cnn .com " <Amanda.Sealy@cnn.com> , "Neel.Khairzada@turner.com "
<Neel.Kh airzada@tumer.com >, "Tia.Miller@tumer.com " <Tia.Miller@tumer.com> ,
(b)(6)"McGinnis, J.Mic hael" < MMcGinn is@nas.edu > ,
(b)(6)"Mun , Jenny" <JMun@nas.edu >,
(b)(6)
Subject: RE: NAS Annual Meeti ng Sess ion on COV ID- 19 -- Information regarding your
Saturda y Ap ril 25 participation
It was a real pleasure to join all of you on this impor ta nt session. Many tha nks for
inviting me.
Director
National Institute of Alle rgy and Infectio us Diseases
31 Ce nter Drive , MSC 2520
Phone: (b)(6)
FAX : (301) 496-4409
E-mail Cb)(6)
information. It should not be used by anyone who is not the orig inal intended recipie nt. If you
From: Dzau, Victor J. <VDzau@nas.edu>

Sent: Saturday, Apr il 25, 2020 3:59 PM
Hannon ,
Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIA ID) [El
----------------- ----------
(b)( ; rebeka.yasmin@cepi.net; ben.tinker@cnn.com ;
Amanda.SeaIy@ cn n.com ; Neel.Khairzada@turner.com ; Tia.Miller@turner.com ; (b)(6)
McGinnis, J.Michael< MMcGinnis@nas.edu >; (b)(6)>; Mun, Jenny
------ (b)(6)>; haja.bally@cepi.net

Subject: Re: NAS Annual Meeting Session on COVID-19 -- Informat ion regarding your Saturday April 25
part icipation
Dear Jeremy, Tony, Sanjay,George, Susan and Richard,

Thank yo u so much fo r your superh contri hutions. Ttwas a spectacu lar session- a trnl y inspi rin g
one. I am grateful to all of you.
Hope to see you soon.
Warm est regards,
Victor
On Apr 25, 2020 , at 1:22 PM, George GAO CbH6)wrote:

-------
I am waiting for being connected and will use s lides w hich we re sent to yo ur office
George
'&.§ it IY:l
iPhone
t£ 2020~4 ~ 24 B . 0 I :49, Dzau, Victor J. <VDzau@nas.edu>

'.ij'.~ :
Dear Jeremy, Tony, Sanjay, George, Susan, and Richard,
I'm really looking forward to this panel on COVID-19 at the NAS Annual
Meeting on Saturday, April 25th at 2:00-3:30 pm ET. There is tremendous
excitement and enthusiasm, and registrat ion is through the roof.
I am sending this note to do a last minute check to see if there is anyt hing you
need from me. I also want to check whether you are planning to use slides.
Wi ll you be sending your slides to us to project or use the share screen
feature to advance your own slides? Regardless, it would be helpful to me if
you could send me your slides for my preparation.
I would greatly appreciate it if you wou ld respond to this email.

Best,
Victor
PS,
------ ·
(b)(6) , my special assistant, will be sending you additional
information about the session logistics shortly.
From : Dzau, Victor J. <VDzau@nas.edu>

Se nt : Thursday, Apr il 9, 2020 11:01 AM
To : Mun, Jenny <JMun@nas.edu >, ------~~ (b)(6)
; 'ben.tinker@cnn .com ' <ben.tinker@cnn.com >;

'Amanda.Sealy@cnn .com' <Amanda.Sealy@cnn.com >;
'Tia.Mi ller@turner.com' <Tia. M iller@turner.com >;

______
'Neel . Khairzada@turner.com' <Neel .Khairzada@tumer.com >;
.... (b)(6)
Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information

regar ding your Saturday April 25 participation
Dear all,
Thank you for agreeing to participate in a special late breaking session

on the COVID-19 pandemic at the NAS annual meeting. Knowing how
busy you are, l am sending this email in lieu of a call to prepare for the
session.
As you know , this is a 90 minute session which aims to provide our

audience with deeper insights into the latest developments in the
COVID-19 response. I plan to hold an engaging discussion that covers
the whole experience on dealing with this pandemic - from US to
international, to preparedness and response, the biology of the vims, the
state of diagnostic , treatment and vaccine development, and the
importance of commun ication.
I will begin the session by providing brief (~3 min) opening remarks
describing the circumstances of the pandemic . Then, I will introduce the
panelists and you will each have 7 minutes to provide remarks. You
may use a limited number of slides for illustration. I hope that each
panelist will provide their own perspective and speak to the issues
proposed below.
• Jeremy Farrar will discuss the global response to the pandemic,
drawing from his experience as a globa l leader, the chair of the
Scientific Advisory Group for the WHO's R&D Blueprint and as
a member of the Global Preparedness Monitoring Board.
• Tony Fauci will discuss the US pandemic and provide his
perspective as a member of the White House Coronavirus Task
Force addressing the 2019-20 coronavirus pandemic.
• George Gao will discuss China's response to the pandem ic and
lessons learned for the rest of the globe .
• Susan Weiss will discuss the viral characteristics of SARS
COV2 , insights into its pathobiology, immunity and
development of a pan-CoV antiviral.
• Richard Hatchett will discuss the development of new vaccines
and treatments against COV ID-19 .
• Sanjay Gupta will comment on the health system response to the
pandemic and challenges related to communication and public
engagement in responding to COVID-19.
Following remarks from each panelist, we will have a moderated

discussion amongst ourselves - I will ask you a set of questions ( 15
mins) and then we will take questions from the web (25 mins). To
prepare me to be your moderator, please send me any questions you
would like me to ask you. For those of you who would like to have a
prep call, please let me know and I will set it up.
Best,
Victor
From: Mun, Jenny

Sent: Wednesday, April 8, 2020 10:56 AM
ben .ti nker@cnn .com'; 'Amanda.Sealy @cnn.com'

; 'Nee l.Khairzada@turner .com'; 'Tia.Miller@turner.com'
Subject: NAS An nu al Meeting Session on COVID-19 -- Information regarding
your Saturday April 25 participation
Dear Speakers:
I am the logistical contact for the COVID-19 session that will be held as part of
the Annual Meeting (online) program on Saturday, April 25 at 2:00 pm EDT.
Thank you for agreeing to participate in this session. To help you with your
planning, I have provided additional details below.
Please note that the session will be live webcast and the general public will
also be able to watch the session. Video from the session will also be
uploaded on the NASYouTube channe l
(https://www.youtube.com/user/theNASciences ) after the meeting . We will
need to obtain signed speaker release forms for your participation in this
session. I have attached the speaker release form for your review and
submission. Please return the signed speaker release form by Monday, April
13.
Session speakers are asked to connect 30 minutes prior to the session start
time (by Saturday , April 25 at 1 :30 pm EDT) to allow the technical staff to
check connections and prepare for the session. Details on how to connect will
be sent before the meeting .
We will list you in our promotional materials as noted below . If this is

incorrect, please let me know .
Anthony S. Fauci, Director, National Institute of Allergy and Infectious

Diseases
Jeremy Farrar, Director, Wellcome Trust
George F. Gao, Director-General, Chinese Center for Disease Control &
Prevention
Sanjay Gupta, Chief Medica l Correspondent, CNN
Richard J. Hatchett, CEO,Coalition for Epidemic Preparedness Innovations
Susan R. Weiss, Professor of Microbiology, Perelman School of Med icine,
Since many of us have moved to remote work environments, you may

already be proficient with Zoom and other online meeting/collaboration
applications. I am attaching a 'speaker guidelines' file in case you have any
questions on how best to prepare for and stage your remote talk . We have
technical staff available to help you become familiar with Zoom and its
settings - such as "sharing your screen" (if you have slide presentations that
need to be shown during your talk) . We can arrange for a training session this
week or next week. If you would like to schedule a session, please let me
know as soon as possible.
Dr. Dzau's office will be in touch regarding the agenda for this session. If you
have any other questions, please let me know.
Regards, Jenny
Jenny Mun
Membership Director
National Academy of Sciences
(b)(6)
Sent : Thu, 30 Apr 2020 22:19 :19 +0000
To : Alexander Patterso n
Subject : RE: (b)(6) made a Video Game of Yo: "Fauci's Revenge"
Thanks, Alex! Mu ch apprecia t ed.

Best rega rds,
Tony
Director
Building 31, Room 7A-O3
Phone: (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
From: Alexander Patterson <alex.patterson@beatthebomb .com>

Se nt : Thursday, April 30, 2020 11:26 AM
To : Fauci, Anthony (NIH/NIAID) [E) (b)(6)>
Cc: Daniel Lahart <dlahar t@r egis.org>
Subject: (b)( made a Video Game of Yo: "Fauci 's Revenge"
Dear Dr. Fauci -
My name is Alex Patte rson and I'm (b)(6) I made a v ideo game about you called Fauci 's
Revenge. Link to play : https://beatthebomb .com/beatthevirus
We are stream ing the Finals of a tournament live tonight at 8 PM EST o n Tw itch , FB, and YouTube.
Twitch Stream Link (free to watch): https://www .tw itch.tv/beatthebomb1000
Also available on:

Facebook : https://www.facebook .com/ BeatTheBomb/
YouTube: https ://www.youtube .com/channel/UCOyh7vo1knuKuaaCKUssAzA
Please watch the Twitch Stream if you can! Otherw ise I will follow up tomorrow w ith a video!
Media coverage of the Fauci's Revengein the News:
• NBC New York
Spectrum NY1 News
Timeout New York
News 12 New York
Bushwick Daily
Fox 5 Good Day New York
To date we've raised over $6,150 for New York City's Public Health System (NYC Heal th +
Hospita ls). We've created limited edition t-shirts (including a Fauci's Revenge one). We've
donated 6,150 Protective Suits and 4,500 Gloves to the NYC Mayor's Office and face shields to
Maimonides Medical Center. Men for others!
Looking forward to be ing back in the halls soon at a Jug Night or Career Day. Enjoy the game!
Best,
Alex Patterson~
Alex Patterson
CEO BEAT TH E BOMB
www.beatthebomb.com
Follow us on instagram: @beatthebomb
247 Water Street, Suite 106, Brooklyn, 11201
work : 718-643-0200 I I cell: (b)(6)
Sent : Thu, 30 Apr 2020 22:18 :45 +0000
(b)( 6)
Grad made a Video Game of Vo: "Fauci's Revenge"

(b)( 6)
Att achment s: Fauci's Revenge Game Logo.png
Yikes!
Director
Phone: (b)( 6)
FAX: (301 496-4409
E-mail: .___,. _.
_, (b)( 6)
The information in t ,s e-mail and any of its attachments is confidential and may contain sensitive
From: Alexander Patterson <alex.patte rson@beatthebomb .com>

Sent : Thursday , April 30, 2020 11:26 Alvl
To: Fauci, Anthony (NIH/NIAID) [E] <afauci@niaid .nih.gov >
Cc: Daniel Lahart <dlahar t @regis.org>
Subject: (b)(6) made a Video Game of Yo: "Fauci's Revenge"
Dear Dr. Fauci -
My name is Alex Patterson and I'm (b)(6) I made a video game about you called Fauci's
Revenge . Link to play : https:/Jbeatthebomb.com/beatthevirus
We are str eaming the Finals of a tournamen t live to night at 8 PM ESTon Twit ch, FB, and YouTube .
Twitch Stream Link (free to watch): httos://w w w.t w itch.t v/beatthebom b1000
Also available on:

Facebook: https://www.facebook.com/BeatTheBomb/
YouTube: https:// w w w .yout ube.com/channel/UCOyh7vo1knu KuaaCKUssAzA
Please watch the Tw itch Stream if you can! Otherwise I will follow up tomorrow w ith a video!
Med ia coverage of the Fauci's Revenge in the News:

• NBC New York
Spectrum NY1 News
Timeout New York
News 12 New York
Bushwick Daily
Fox 5 Good Day New York
To date we've raised over $6,150 for New York City's Public Health System (NYC Health +
Hospita ls). We've created limited edition t-shirts (including a Fauci's Revenge one). We've
donated 6,150 Protective Suits and 4,500 Gloves to the NYC Mayor's Office and face shields to
Maimonides Medical Center. Men for others!
Looking forward to be ing back in the halls soon at a Jug Night or Career Day. Enjoy the game!
Best,
Alex Patterson Cb)(6)
Alex Patterson
CEO BEAT THE BOMB
www.beatthebomb.com
Follow us on instag ram : @beatthebomb
247 Water Street, Suite 106, Brooklyn, 11201
work: 718-643-0200 I I cell: (b)(6)
Sent: Thu, 30 Apr 2020 22:14 :57 +0000
To : (b)( 6)
Cc: Tromberg , Bruce (NIH/NIBIB ) [E];Sharpless, Norman (NIH/NCI) [E];Birx, Deborah
L. EOP/NSC;Redfi eld, Robert R. (CDC/OD);Colli ns, Francis {NIH/O D) [E) ( CbH 6>11);
Conrad,
Patricia {NIH/NIAID ) [E]
Subject: FW: Stanford National Daily Health Survey for COVID - "Open Up America
Again"
Attachments: 4.28.20 NDHSOverview Slides-Rusty-Fauci_ 1.ppt x
Rod:
Great to hear from you. Thanks very much for sending this . Very impressive! I
will forward this to Bruce Tromberg and Ned Sharple ss who have been working on
COVID-related apts . In addition, I have cc'd Deb Birx {Coordinator of the White
House COVID-19 Task Force) as we ll as CDC Director Bob Redfield and Francis
Collins. I hope that all is well with you. Stay well and safe.
Best regards,
Tony
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
From: Pett igrew, Roderic I

Sent: Thursday, Apr il 30, 2020 4:20 AM
To: Anthony S. Fauci {NIH/NIAID) ---------- ~=
(b)(6)
Subject: Stanford Nat ional Daily Health Survey for COVID - "Open Up America Again"
Hi Tony ,
Greetings from Houston, wher e the numb er of cases peak ed ~2 w eeks ago, dropped 35 -40%
and see m ed to have plateaued since. Grea t to see you on TV and see t he na t ion (includi ng Brad
Pitt©) get to know the rigorously informed, keenly rationale and consistent ly clear Tony your
coll eagues have long known.
(b) (4), (b) (5)
Thank you , Tony . Very proud to know you. Kind regards ta

----- (b)( .
Rod
Roderic I Pettigrew , PhD, MD

CEO EnHealth I Health Science Center and College of Engineering
Robert A Welch Professor and Executive Dean EnMed I Colleges of Medicine, Engineering and Houston Methodist
Hospital
Texas A&M University ALKEK Building ISuite 1103
2121 W Holcombe Blvd I Houston , TX 770?/J
www.enmed.tamu.edu
Ph:___ ...>
Cb _<~
.- 1- ____ ...>
Cb _<~
.....
MAKING WHAT IF POS SIBLE I whatif.tamu.edu
From: Hofmann, Lawrence, M .D. (b)(6)
Sent: Tuesday, April 28, 2020 11:19 Atvl
To : Pettigrew, Roderic I (b)(6)
Cc: Pelc, Norbert J (b) (6)
Subject: [EXTERNAL]NationalDaily Health Survey for COVID- "Open Up America Again"
(b) (4), (b) (5)
Best,
R
Lawrence "Rusty" Hofmann , MD
Professor and Chief, lntervent ional Radiology
Medical Director, Digital Health Integration
Medical Director, Cardiac and lnte rventional Services
@rustyhofmannMD
(ml CbH6l
Assistant: (b)(6)
(b)(6)
Sent : Thu, 30 Apr 2020 22:05 :19 +0000
To: Barillas, Carolina (N IH/NIAID) [El
Cc: Auchi ncloss, Hugh (NIH/NIAID) [E]
RE:
-------------------------- (b) (5)
Caroli na:
(b) (5)
Thanks for se ndin g thi s
Best regards,
------
To ny
Director
Phone Cb)
(6)
FAX: (301 496-4409
E-mail: (b)( 6)
---------
From: Baril las, Carolina (NIH/NIAID) [E]
Sent : Thursday , April 30, 2020 11:25 AM
(b)(6)
~-=======---~=
Cc: Auchinclo ss, Hugh {NIH/ NIAID) [E] (b)(6)
Subj ect: (b) (5)
Dea r Tony,
(b) (5)
All the best,
Carolina
(b)(S)
(b)(5
Sent : Thu, 30 Apr 2020 21:47 :05 +0000
To: (b)(6)
Subject : FW: Autopsy data suppor t ing Remdesivir trial

(b) (4)
(b) (5)
Take a look at t he Figures in th e manuscript.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail ,___,,. __ _, (b)(6)
The in ormation in t ,s e-mail and any of its attachments is confidential and may contain sensitive
From: Timothy Schacker (b)(6)

To: Fauci, Anthony (NIH/NIAID) [E] -------~ =
Subject: Autopsy data supporting
----------
Remdesivir trial
(b)(6l!>
Tony.,__________________________________ ~=
(b) (4)
Stay we ll (please) and thank you for all you are doing!
Tim
Timot hy Schacker , M.D.
Vice Dean for Research , Medical School
Director, Program in HIV Medicine
Unive rsity of Minnesota
Mail:
MMC250
420 Delaware Street SE
Minneapolis, MN 55455
FedEx/UPS:
Mayo C688
420 Delaware Street SE
Minneapolis, MN 55455
Phone: Cb)(6)
Fax: 612-626-5599
email: (b)(6)
-------
(bX5) -PCI
(bXS) - PCP
Sent: Thu, 30 Apr 2020 14:17:43 +0000
Cc: Billet, Court ney (NIH/N IAID) [El
Subject: FW: May th e Official Nobel documentary program at Swedish Television get an
interv iew with you Dr Fauci about Covid-19 before May 7t h please?
Please get clearance and set it up if possible.
Director
Phone: (b)( 6)
FAX: (301 496-4409
E-mail: .___,. ,._, (b)(6)
From: Johan Bergendorff <johan.bergendorff@svt.se>

------
To: Fauci, Anthony (NIH/NIA ID) [E] ::;..,..-,=
(b)(6)>
Cc:NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>; Barasch, Kimberly (NIH/NIAID) ICJ
________ Cb _ >; Stover, Kathy (NIH/NIAID) [El
_>_C6) (b)(6)
Subject: May t he Officia l Nobel documentary program at Swedish Television get an int erview with you
Dr Fauci about Covid-19 before May 7th please?
Dear Dr . Fauci,
I had the honor to interview you in april 2016 about the zika ep idem ic at your off ice for a
program for national Swedish radio as their global health cor respondent. I hope I may have the
ho no r again now Sir?
I am now working as science corresponden t for the nat ional Swedish Te levis ion (non
commercial public service, half the populat ion as daily viewe rs) in our official Nobel prize
laureau t e documentary program "Vetenskapens Va rid" (the World of Science) and wonder if
you have any chance to g ive us a 10 minute interview by web video before May 7th please?
I would like to ask you two questions: What is most crucial now to suceed with an covid-19
pandemic exit in the US? How do you find the Swedish strategy against Covid-19 so far (Dr.
Mike Ryan praised it yeasterday at the WHO press conference as a model for an exit strategy,
what is your view)?
In this one hour program aired on May 11th we will have other prominent scientists as well
talking about exit strategies, among others Nobel prize winner prof. Paul Krugman, prof. Bengt
Holmstrom MIT, prof. Angus Deaton Princeton, as well as Prof Gabriel Leung Dean University
Hongkong etc.
Here you can see the reports I did from my earlier interview with you about the zika epidemic
in 2016 (in Swedish). News report: https://sverigesrad io.se/artikel/642089120 min
docu men ta ry : https ://sverigesrad io.se/ avsnitt/712016
One option is that I send you a link for a web video Conference call. Another option is that I call
you on the phone and your media department may have the oportunity to record a video of
your anseers with HD quality that is better to air.
Please let me know if you are available and when.
Best regards,
Johan Bergendorff
Science correspondent, Swedish Television
(b)(6)
Sent : Thu, 30 Apr 2020 13:31 :50 +0000
To: Julie.Steen huysen@thomsonreuters .com
Cc: Greg Folkers Cb)(6)
Subjec t : FW: Fauci says leak concern s fueled his W hite House reve lation of Gilead drug
result s
Juli e:
You di d a goo d j o b in repo rtin g our conversati on last night . Thanks.
Best regards,
To ny
Director
Phone: (b)(6)
FAX: (301) 496-4409
E-mail: (b)(6)
information. It should not be used by anyone who is not the orig ina l intended recipient. If you
From : Folkers, Greg (NIH/NIAID) [E] (b)(6J>

To: NIAID COGCORE<COGCORE@mail.nih.gov>; NIAID OCGRLeg <NIAIDOCGRLeg@mail.nih.gov>; NIAID
OD AM <NIAIDODAM@niaid.nih .gov>
Subject : Fauci says leak concerns fueled his White House revelation of Gilead drug results
Health News
April 30, 2020 / 1:07 AM/ Updated 4 hours ago
Faucisays leak concernsfueled his White

House revelation of Gilead drug results
Julie Steenhuysen
5 Min Read
CHICAGO (Reute rs) - Concerns over leaks compelled the top U.S. infectious disease of fi cial to reveal data
on Gilead Sciences Inc's experimental drug remdesiv ir, t he first in a scientifically rigorous clinical tr ial to
show benefit in t reating COVID-19.
National Institute of Allergy and Infectious Diseases Director Dr. Ant hony Fauci attends a coronavirus
response meet ing between U.S. President Donald Trump and Louisiana Governor John Bel Edwards in
the Oval Office at the White House in Wash ington , U.S., April 29, 2020 . REUTERS/CarlosBarria
The dramatic announcement by Dr Anthony Fauci in the Oval Office on Wednesday prompted concerns
among scientists that the Trump administration was raising hopes about a coronav irus treatment before
sharing the full data with researchers.
As a cautionary example of inflating the potential value of a therapy, some pointed to President Donald
Trump's repeated endorsements of malaria drug hydroxychloroquine as a treatment , with no evidence
that it works .
Newer data suggests the malaria treatments may carry significant risks for some sufferers of the
respiratory disease caused by the virus.
Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), which is running the
trial, said he took the first opportunity to get the word out that patients taking a dummy treatment or
placebo should be switched to remdesivir in hopes of benefiting from it .
He expressed concern that leaks of partial information would lead to confusion . Since the White House
was not planning a daily virus briefing, Fauci said he was invited to release the news at a news
conference with Louisiana Gov. John Bel Edwards(D). "It was purely driven by ethical concerns," Fauci
told Reuters in a telephone interview.
"I would love to wait to present it at a scientific meeting, but it's just not in the cards when you have a
situation where the ethical concern about getting the drug to people on placebo dominates the
conver sation ."
An independent data safety and monitoring board , which had looked at the preliminary results of the
NIAID trial, determined it had met its primary goal of reducing hospital stays.
On Tuesday evening, that information was conveyed in a conference call to scientists studying the drug
globally.
"There are literally dozens and dozens of investigators around the wo rld/' Fauci said. "People were
starting to leak it." But he did not give details of where the unreported data was being shared.
Several scientists interviewed by Reuters felt the White House sett ing seemed inappropriate for the
release of highly anticipated government-funded trial data on the Gilead therapy .
They had expected it to be presented simultaneously in a detailed news release, a briefing at a medical
meet ing or in a scientific journal, allowing researchers to review the data.
Informat ion from various trials of remdesivir has been leaked to media in recent weeks . In a statement
on Wednesday, Gilead said the NIAi D's much anticipated trial had met its primary goal, but gave no
details .
Data in a separate NIAID statement after Fauci spoke detailed preliminary results showing that patients
who got the drug had a 31 percent faster t ime to recovery than those who got a placebo, cutting
hospital stays by four days.
The trial also came close to showing the drug helped people survive the disease, but the data fell just
short of statistical significance.
"I want to see the full data . I want to understand the statistics. I want to understand the benefit and risk.
I want to understand the structure of the study, and all of it," said Dr. Steven Nissen, the chief academic
officer at the Cleveland Clinic.
"Am I encouraged from what I've heard? Yes, I'm encouraged . But I want to get a full understanding of
what happened here, and not get it via a photo opportunity from the Oval Office ."
Data Gilead released on its own trial of remdesivir drew less attention, as it did not compare outcomes
between those receiving therapy and those who did not .
Results from a third study in China suggesting remdesivir failed to help COVID-19 patients were released
in the British medical journal the Lancet after review by a peer group of scientists .
"That's the only thing I'll hang my hat on, and that was negative ," said Dr. Eric Topol, directo r and
founder of the Scripps Research Translational Institute in La Jolla, California.
He was unimpressed by remdesivir's modest benefit .
"It was expected to be a whopping effect," Topol added . "It clearly does not have that ."
At the Oval Office news conference, Fauci compared the study findings to AZT, the fi rst drug to show any
benefit against HIV, decades ago.
"We know that was an imperfect drug. It was the first step," Fauci said in the interview.
"Similar to AZT, it's (remdesivir) the first baby step towards what hopefully will be a number of better
11
drugs that will come in and be able to treat people with COVID-19.
11
(This story has been refiled to correct spelling of "clinical in paragraph one)
Reporting by Julie Steenhuysen; Editing by M ichele Gershberg and Clarence Fernandez
Our Standards :The Thomson Reuters Trust Principles .
Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions
of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent
my views nor those of NIAlD , NIB, HHS, or the U.S. government.
Sent : Thu, 30 Apr 2020 10:20:32 +0000
To: STEWARTSIMONSO Cb)(
Cc: Masur, Henry (NIH/CC/CCMD) [E);STEWARTSIMONSON
Subject : RE:COVID-19 and Haiti
Bill:
--------------------------------- (b)(6)
with him. As per our prior conversation and as you know better than anyone, Haiti is struggling
Work
and I know that Stewart wi ll do whatever he can to assist you.

Warm regards,'
Tony
From: STEWARTSIMONSON
------------
(b)(6)
To : (b)(6)
Cc: Fauci, Anthony (NIH/NIAID) [E Masur, Henry (NIH/CC/CCMD) [E]
(b)(6)>; STEWARTSIMONSON
.,,_~~~-=====--~ ~
(b)(6)
(b)(6)
-------
Subject : COVID-19 and Hait i
Dear Dr. Pape:
I lead the World Health Organization (WHO) delegation to the United Nations and know of you through
Tony Fauci and Henry Masur, (b)(6). For nearly 5 years immediately
preceding my appointment at WHO,, I was an technical advisor at Hop ital Sacre-Cawr in Milot and
remain in close contact with institution. Because of this, PAHO leadership asked me to join their COVID-
19 planning discussions related to Haiti. I understand from Henry that you have been appointed by
MSPPto coordinate COVID-19 preparedness and response activities. If you have some time available on
Friday, it would be good to talk via Zoom or Webex. I can arrange th is and would plan to have the
PAHO deputy director as well as other PAHO officials on the line. Would you be available Friday
afternoon for such a discussion? If not Friday, anytime over the weekend would also likely work on our
end.
Thanks so much for conside ring t his.
With best regards,
Stewart Simonson
STEWART SIMONSON
W ashington, DC/ N ew York
Cb)(6) or
(b)(6)
Cb)(6)1S)
IS)
------ (Switzerland)
From : Fauci,Anthony (NIH/NIAID) [El
Sent : Thu, 30 Apr 2020 01:24:46 +0000
Subject : FW: Has anyone tried palivizumab (Synagis)
Please respond.
From: Rich May (b)(6)

Se nt : Wednesday, April 29, 2020 10:21 AM
------~=
--------
Subject: Has anyone tried palivizumab (Synagis)
(b)(6)
Good morning Dr. Fauci,
Has anyone tried palivizumab (Synagis) on any new COVID-19 patients?
Thank you for your time,

Richard May, MD, PhD, D.H.Sc
--- (b)(6)
Sent : Wed, 29 Apr 2020 22:42:24 +0000
To : Lerner, Andrea (NIH/N IAID) [El
Subject : FW: NAO repl etion for Covid-19
Please t ake a look and respond if approp riate
Director
Phone: (b)(6)
FAX: (30 496"'4409
E-mail Cb)(6)
From: Mel Cohen (b)(6)

Se nt: Wednesday, April 29, 2020 1:52 PM
------
-------- --=~
Subject : NAD repletion for Covid-19
(b)(6)>
Import ance: High
Dear Dr. Fauci,
Recent research has shown that SARS-CoV

- 2 plays havoc with NAOfunction wit hin cells.
Coronavirus Infe ct ion and PARPExpression Dysregulate the NAO Metabolome: A Potentially Actionable
Component of Innate Immunity:
http s://www .bio rxiv.org/content/10 .1101/2020.04.17.047480v3
The Molecular Story of COVID-19; NAD+ Depletion Add resses All Questions in th is Infection :
https://www.preprints.org/manuscript/202003.0346/vl
Other research has show n that NAD+ levels decline from aging and obesity, both significant factors in
Covid-19 severity. But it has also been demonstrated that NAD levels can be replenished through oral
administration of nicotin amide ribo side (NR) and nicotinamide mononucleotide (NMN). NR in particular
has had several human studies demonstrating its safety and efficacy, and roughly 50 human studies
listed on clinicaltrials.gov fo r all manner of disorders.
There is at least one anecdotal repo rt of dramatic improvement in a Covid-19 patient after
administration of NMN.
NMN shows great promise in case studies of humans with COVID-19:

https://alivebynature.com/nmn-shows-promise-for-treatment-of-covid-19-in-case-
studies/?utm campaign=NMN%20for%20covid%20%28TqFTyz%29&utm medium=email&utm source=
Main%20List& ke=eyJrbF91bWFpbCl61CJtZWx/l2.GlzdHJpYnVOZWwuY2EiLCAia2xfY29tcGFueV9pZCl61CJS
bWROWFoifQ%3D%3D
That article begins with the disclaimer, "There are no human trials that prove effectiveness of any NAO+
boost ing suppfements for preventing or curing COV/0-19."
That is a problem . When I see the resources that have been wasted pursuing hydroxychloroquine, I am
saddened to learn that there are no clinical trials of nicotinamide riboside as part of a treatment
regimen for Covid-19. Can you do anything about getting such a study done?
Regards,
Mel Cohen
(b)(6)
Sent: Wed, 29 Apr 2020 22:01:22 +0000
To : Folkers, Greg (NIH/NIAID) [E);NIAID OD AM
Subject: RE:ASF----- slides for Business Roundtable, Friday 5-1-2020, 12-1 / FOR REVIEW
IN OD
Now FINAL in the OD fo lder. Thanks.
Director
Phone: (b)(6)
FAX: (3 96':44li9
E-mail: (b) (6)
From: Folkers, Greg (NIH/NIAID) [E] (b)(6)>

Sent: Wednesday, April 29, 2020 5:03 PM
To : NIAID OD AM <NIAIDODAM@niaid .nih.gov>
Subject: ASF----- slides for Business Roundtable, Friday 5-1-2020, 12-1 / FORREVIEW IN OD
• This is a zoom call.

• I think you will be able to use slides.
• I have put in OD a draft "curtain-raiser" set that you could show to kick things off - or
use them as TPs if you prefer.
• I will update any epi or other numbers tomorrow night
• The "ask"is below
From: Silverberg , Kristen <K5ilverberg@brt .org >

Sent: Tuesday, April 14, 2020 4:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] ------~ (b)(
=>
Subject: invitation from BRT
Dr. Fauci,
First, t hank you for everyth ing you are doing . I have always been grat eful for yo ur public service, but
feel part icular ly indebted to you these days.
To add to the debt ...Josh and I wanted to see if you would be willing to join a call with Business
Roundtable CEOs. We have been doing COVID-19 calls with them every Friday at 1:30pm . Typically,
about 100-125 CEOSof large, U.S.-based firms will join. They are all managing and planning for difficult
issues around employee and customer safety . They would love to hear from you directly and to ask a
few questions . It might also be a good place to deliver any messages you want them to hear.
We completely understand if it isn't doable, of course. If you are able, we would love to host you
sometime between 1:30pm -2:30pm this Friday (or any Friday on which your schedule wou ld allow it).
Best,
Kristen
Sent: Wed, 29 Apr 2020 15:09:44 +0000
To : Antho ny Fauci
Subject: FW: Potential slides fo r Remdesivir presentation
Attachments : Remdesivir bullet slides - FAUCI - FINAL.pptx
Director
Phone: (b)( 6)
FAX: (3 96':44li9
E-mail: Cb)(6)

Sent : Wednesday, April 29, 2020 11:02 AM
___ : Short,
To ..;_Ma rc T. EOP/OVP
____
--------~~
-- (b)'"'"'
(~6)'>_________ __ 'Mi ller, Katie R. EOP/OVP'
(b)(6),;
Subject: Potential slides for Remdesiv ir presentation
Marc/Katie:
Here are 3 slides that I might use in the press briefing. If necessary, I could
make the presentat io n without them, but it might be clearer to have them just in
case.
Thanks,
Tony
Director
Phone Cb)(6)
FAX: (301 496-4409
E-mail:
--------- (b)( 6)
Sent : Wed, 29 Apr 2020 14:18:44 +0000
To : Billet, Courtney (NIH/N IAID) [E]
Subject: RE:two things
Thanks.
Director
Phone: (b)(6)
FAX:(301) 496~ 09
E-mail: (b)(6)
From: Billet, Courtney (NIH/NIAID) [E (b)(6)

To: Fauci, Anthony (NIH/NIAID) [El ------ --=-=
(b)(6)
Cc: Folkers, Greg (NIH/NIAID) [El (b)(6);; Conrad, Patricia (NIH/NIAID) [El
(b)(6) >; Stover, Kathy (NIH/NIAID) [El CbH ; Rout h, Jennifer
"'.".---:------:-~~==~_;_-- ~~
(NIH/NIAID) [E] (b)( >; Marston, Hilary (NIH/NIAID) [El CbH >
Subject: ASF: two things
Talked to FDA. They have w ritten (and cleared with Gilead) a new sentence in place of what we had in
there about an EUA. Our release has been updated (attached) w it h the sentence highlighted below .
ALSO: Bill Hall called me to ask if you had alerted the Secretary to th is (so the press release clearance
process isn't t he way he first learns of it). I told him I wasn't sure. If you haven't done so, perhaps you
wish to now?
As part of the U.S. Food and Drug Administration's commitmentto expediting the development
and availability of potential COVID-19treatments,the agency has been engaged in sustained and
ongoing discussions with Gilead Sciences regarding making remdesiviravailable to patients as
quick ly as possible , as a_p_propriate.
Sent: Wed, 29 Apr 2020 10:45:24 +0000
To: Billet, Courtney (NIH/NIAID) [El
Cc: Folkers, Greg (NIH/NIAID) [El;Conrad, Patricia (NIH/NIAID) [El;Marston, Hilary
(NIH/NIAID) [El;Routh, Jennifer (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [El;Lane, Cliff (NIH/NIAID)
[El;Erbelding, Emily (NIH/NIAID) [El
Subject: RE:please read, Gilead statement
Looks fine. Thanks.
From: Billet, Courtney (NIH/NIAID) [E] <billetc@niaid.nih.gov>

To: Fauci, Anthony (NIH/NIAID) [E] <afauci@niaid.nih.gov>
Cc: Folkers, Greg (NIH/NIAID) [El <gfolkers@niaid.nih .gov>; Conrad, Patricia (NIH/NIAID) [El
<conradpa@niaid .nih.gov>; Marston, Hilary (NIH/NIAID) [El <hilary .marston@nih.gov>; Routh, Jennifer
(NIH/NIAID) [El <jennifer.routh@nih.gov>; Stover, Kathy (NIH/NIAID) [El <kathy .stover@nih .gov>; Lane,
Cliff (NIH/NIAID) [El <clane@niaid.nih.gov>; Erbelding, Emily (NIH/NIAID) [El <emily .erbelding@nih.gov>
Subject: ASF: please read, Gilead statement
FYI- this will go out before markets open this morning:
GILEAD SCIENCES STATEMENT ON POSITIVE DATA EMERGING

FROM NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
DISEASES' STUDY OF REMDESIVIR
Foster City, Calif., April 29, 2020 - Gilead Sciences. Inc. (Nasdaq: GILD) is aware
of the positive data emerging from the National Institute of Allergy and Infectious
Diseases' (NIAID) study of remdesivir. We understand that the trial has met its
primary endpoint and that NIAID will provide detailed information at an upcoming
briefing.
In addition to the NIAID trial, Gilead expects to share additiona l remdesivir data
from the company's open-label Phase 3 SIMPLE trial in patients with severe COVID-
19 disease shortly. This study will provide information on whether a shorter, 5-day
duration of therapy may have simi lar efficacy and safety as the 10-day treatment
course evaluated in the NIAID trial and other ongoing tria ls. Gilead expects data at
the end of May from the second SIMPLE study evaluating the 5- and 10-day dosing
durations of remdesivir in patients with moderate COVID-19 disease.
Gilead will continue to discuss with regulatory authorities the growing data set
regarding remdesivir as a potential treatment for COVID-19.
Sent : Wed, 29 Ap r 2020 03:09:03 +0000
To: Berkowitz, Avrahm J. EOP/WHO
Subject : RE:Jared Kushner Defends Dr. Fauci After Fox News Host Criticises Top
Coronav irus Task Force Expert
Thanks , A vi.
From: Be rkowitz , Avra hm J. EOPfWHO (b)(6)
------.
Scot : T uesday , April 28, 2020 I 0:00 PM
To : Fauci , Anthony (N1H/NIAlD) [E] ;;-s-r;o=
CbH >
Subject: Jar ed Kushn er D efend s Dr . Fauc i After Fox News Host Criticises T op Coronavirus Task Force Expert
Just wanted to share an article- all the best!

Avi
htt:ps://www.newsweek.conv'jared-kushner-defends-dr-fauci- fox-news-host-Iittle-tough-I 500339
Sent from my iPhone

Sent: Wed, 29 Apr 2020 03:08:36 +0000
To: Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E);Routh, Jennifer
(NIH/NIAID) [El;Erbelding, Emily (NIH/NIAID) [E);Lane, Cliff (NIH/NIAID) [El;Marston, Hilary (NIH/NIAID)
[El
Cc: Conrad, Patricia (NIH/NIA ID) [E)
Subject: RE: DRAFTNIAID statement on remdesivir , ACTT 2
Attachments: SHORTENEDNIAID statement NEW NEW -with Fauci edits .docx
See my minor edits. (b)(5)

To: Folkers, Greg {NIH/NIAID) [E) ------~ =
(b)( •>; Fauci, Anthony {NIH/NIAID) [E)
CbH6>>;Routh, Jennifer (NIH/NIA ID) [E] CbH6);Erbelding, Emily
(NIH/NIAID ) [E) CbH6l> ; Lane, Cliff (NIH/NIAID ) [E) (b)(6)>; Marston,
Hilary (NIH/NIAID) [El (b)( >
Cc: Conrad, Patricia (NIH/NIAID) [El (b)(6)
Subject: RE: DRAFTNIAID statement on remdes ivir, ACTT2
From: Billet , Courtney (NIH/NIAID) [El

To: Folkers, Greg {NIH/NIAID) [El ------- -==
(b)(6);Fauci, Anthony (NIH/NIAID) [El
(b)(6)v>; Routh, Jennifer (NIH/NIAID) [El (b)(6)>;Erbeldlng, Emily
(NIH/NIAID) [E) CbH6)>; Lane, Cliff (NIH/NIAID ) [E] CbH6>> ;
Marston , Hilary (NIH/NIAID) [E] Cb)( >
Cc:Conrad, Patricia (NIH/NIAID) [E) Cb)( v>
Subject: RE: DRAFTNIAID statement on remdesivir, ACTT 2
(not sure what happened with spacing). Cliff- I got your suggestion too . I'll blend yours, mine, and
Gregs and send a clean new one shortly.

To: Folkers, Greg (NIH/NIAID) [El -------~ = (b)( >; Fauci, Anthony (NIH/NIAID) [E]
(b)(6b ; Routh, Jennifer (NIH/NIAID) [El< CbH6)>;Erbelding, Emily
(NIH/NIAID) [El (b)(6)>;Lane, Cliff (NIH/NIAID ) [El (b)(6);
Marston , Hi la ry_(_
N_I H..,
/_N-IA-1D
...)...[-E)-::::::===:::!...:~___.:.~ (b
~)~( >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b)(6)
I took a crack at a revision as well. We can blend these.
From: Folkers, Greg (NIH/NIAID) [El (b)(6)

To : Fauci, Anthony (NIH/NIAID) [El .ef-----~ (b~)( =6J; Routh, Jennifer (NIH/NIAID) [E]
(b)(6)>; Billet, Courtney (NIH/NIA ID) [El (b)(6); Erbelding, Emily
(NIH/NIAID) [El (b)(6)>; Lane, Cliff (NIH/NIAID) [E] (b)(6); Marston,
Hilary (NIH/NIAID) [E] (b)(6):,.
Cc: Conrad, Patricia (NIH/NIAID) [E] (b)(6)>
Here is my suggested edit to the short version.

Sent:Tuesday, April 28, 2020 9:21 PM
-------
To : Routh, Jennifer (NIH/NIAID) [El ------~~ (b)(6); Billet, Courtney (NIH/NIAID) [El
(b)(6)>; Folkers, Greg (NIH/NIAID) [E] (b)( >; Erbelding, Emily
(NIH/NIAID ) [El
Hilary (NIH/NIAID) [El
(b)(6)>; Lane, Cliff (NIH/NIAID) [E]
(b)(6)>
------- (b)(6); Marston ,
Cc: Conrad, Patricia (NIH/NIAID) [El (b)( >

Subject: FW: DRAFTNIAID statement on remdesivir, ACTT 2
Importance: High
Th anks for all your work.
ange
this.

-------- (b)(6)
To: Fauci, Anthony {NIH/NIAID) [E] -------= =

(b)(6)>
Cc: Routh , Jennifer {NIH/NIAID) [El (b)(6)>; Stover, Kathy (NIH/NIA ID) [El
(b)(6)>; Conrad , Patricia (NIH/NIAID) [El (bH >; Folkers, Greg
(NIH/NIAID) [El (b)( >; Erbelding, Emily (NIH/NIAID) [El (b)(6)>;
'.":"":":"::-'.'::"":-:-:::":--:::====--~~
Lane, Cliff (NIH/NIA ID) [E] (b)(6)>; Marston, Hilary (NIH/NIAID) [El
(b)(6)
Subject:ASF: DRAFTNIAID statement on remdesivir, ACTT 2
Importance:High
There are two versions for your consideration here, as discussed.
Sent : Wed, 29 Apr 2020 01:53:28 +0000
To : Lane, Cliff (NIH/NIAID) [El
Subject: RE: Bullets
Attachments : Rendesivir bul let slides - FAUCl.pptx
I added another bullet.
From:Lane, Cliff (NIH/NIAID) [El _______ Cb

_H_6)
To: Fauci, Anthony {NIH/NIAID) [El______ """
(b""""
)(=6)
Subject: Re: Bullets
Graph inserted.
From: Anthony Fauci (b)(6 )>

Date: Tuesday, April 28, 2020 at 9:47 PM
-------=-:~
To: "Lane, Cliff (NIH/NIAID) [E]"
Subject: RE: Bullets
-------- (b)(6) ,>
I made some m inor changes
(b)(6)
--------
From:Lane, Cliff (NIH/NIAID) [El
------~~
Subject: Bulle ts
--------- (b)(6J>
For comment
Sent : Wed, 29 Apr 2020 01:50:16 +0000
To : Lane, Cliff (NIH/NIAID) [El
Attachments : ACTT 2 NIAID statement CB KSEEHM HCLl - with minor edits.docx
(b)(5) I made some minor edits.
From: Lane, Cliff (NIH/NIAID) [E] ______ (b

_)_(_ >
To: Fauci, Anthony {NIH/NIAID) [E] ------ --=-
(b=)(=6)
Subject: Re: DRAFTNIAID statement on remdesivir, ACTT 2
Attached for consideration.
From: Anthony Fauci (b)(6)>

Date: Tuesday , April 28, 2020 at 9:21 PM
To: "Routh, Jennifer (N IH/NIAID) [E]" ------- -== (b)(6)>, "Billet, Courtney (NIH/NIAID)
[E]" (b)(6)>, "Folke rs, Greg (NIH/NIAID) [El" (b)(6)
"Erbelding, Emily (NIH/NIA ID) IE]" (b)(6), " Lane, Cliff (NIH/NIAID) [E]"
(b)(6)>, Hila ry Marston
---------
Cc: "Conrad, Patricia (NIH/NIAID) [E]"
--========:e:=~
(b)(6)>
Subject: FW: DRAFT NIAID st atement on remdesivir, ACTT 2
Thanks fo r all your work. (b)(5)

(b) (5)
--------------------------
t his.
(b)(5) Please change
From: Billet, Courtn ey (NIH/NIAID) [El

------- (b)(6)>
To : Fauci, Anthony {NIH/NIAID) [El ------= = (b)(6)>

Cc: Routh, Jennifer (NIH/NIAID) [E] (b)(6) ,; Stover, Kathy (NIH/NIAID) [E]
(b)(6)>; Conrad, Patricia (NIH/NIAID) [El (b)(6); Folkers, Greg
(NIH/NIAID) [El~---:~-=== (b
=)=(6)
::!..
>..:..
; _Er~b_el~ding, Emily (NIH/NIAID) IE] (b)(6);
Lane, Cliff (NIH/NIAID) [E) (b)(6); Marston, Hilary (NIH/NIAID) [El
(b)(6)
Subject: ASF: DRAFTNIAID statement on remdesivir, ACTT 2
Importance: High

Sent: Wed, 29 Apr 2020 01:21:27 +0000
To : Routh , Jennifer (NIH/NIAID) [E);Billet, Courtney (NIH/NIAID) [E];Greg Folkers
(GFOLKERS@niaid.nih.gov);Erbelding, Emily (NIH/NIAID) [El; Lane, Cliff (NIH/NIAID) [El;Marston , Hilary
(NIH/NIAID) [El
Cc: Conrad, Patricia (NIH/NIA ID) [E)
Subject: FW: DRAFT NIAID statement on remdesivir, ACTT 2
Attachments: ACTT 2 NIAID statement CB KSEE HM.docx, SHORTENED NIAID statement .docx
Thanks for all our work. However
Please change
---------------------------
this.
Cb)(5).
From: Billet , Courtney (NIH/NIAID) [El (b)(6)

Sent: Tuesday, April 28, 2020 7 :29 PM
---------
To: Fauci, Anthony (NIH/NIAID) [El -------=-:-= (b)(6)
Cc: Routh , Jennifer (NIH/NIAID) [E) (b)(6h; Stover , Kathy (NIH/NIA ID) [E)
(b)(6)>; Conrad, Patricia {NIH/NIAID) [E) (b)(6); Folkers, Greg
":'----:-------:--:--:-.:==~
(NIH/NIAID) [E)~-~-==== (b=
)(= ; E~r_
6l->:.....be~lding, Emily {NIH/NIAID) [E) (b)(6)>;
Lane, Cliff (NIH/NIAID) [E] Cb)( >; Marston, Hilary (NIH/NIAID) [E)
(b)(6)>
Subject: ASF: DRAFTNIAID statement on remdesivir, ACTT 2
Importance: High

Sent : Wed, 29 Apr 2020 00:56:02 +0000
Subject : FW: Coronavirus info about a program that can help.
Attachme nts: BCA_id_Vl (wecompress.com) .pdf
Please take a look and respond if appropria te
From: Alex Holbus .:-------- (b
~)~(=6)
Scot: Tuesday , April 28, 2020 6:59 PM
To: Fauci , Anthony (N1H/NIAlD) [E] ------ --,;;..,....,-=
CbH >
Subj ec t: Cor onavirn s info about a pr ogram that ca n he lp.
Dear Dr Fauci
lt's a pleasure to send you this email my name is Alex Holbu s I am from the UK I currently live in Serbia or ex
Yugoslavia.
l am a Economist and Humanitarian. I can talk about my Biography but. at this time the subject I want to share with
you I much more important.
l n January 2016 1 sent a letter to Mr Trump (b) (6) telling him that 1was happy that he
will bring change to America and the world and that ifhe needed my expertise that I wou ld help your count ry and
the world. As 1 have not got any responses from him nor his people I can see that he might not be interes ted. But as I
have been following you over the media and be read ing about your carrier as a Doctor I believe you know wha t your
doing and would like to take this opportuni ty to help you and your country at this time when it' s the worst then ever
before in the modem world. I have a program that can help with the co ronavirus in the way of identifying people
and following there movement that can help you collect data faster and more suffic ien t. The progr am is based on an
app so every one can use it. Countries in Europe are starting to use it by the end of May the Europe Union has made
it mandatory that all member state, need to use it and the future members like Serb ia. So you w ill see attached a
presentation about the program and if you or your country is interes ted please let me know and I will put you in
contact with the company making this program. I did not send this email to you so we make money on people it's to
help I ju st wanted to help. I will be contacting my contacts in the USA from Thursday morning but first 1wanted to
talk with you and give you the opportunity to see if Mr Trump would interested in this program for your country. Tf
nothing com es back from you anyway my friend and contact in the USA will talk with the white house but l want ed
to do it the proper way by talking to you as you are the main medical person in the USA for the coronavirus .
Anyway wish you and your country all the best and that the world will become a better place after this epidemic is
over .
Jt's one life one world one human we arc all one on this planet no one is bigger or better the all of us as human ity as
one.
Kind regards
Alex Holbus
Director at Real Five Compan y.

Sent : Tue, 28 Apr 202017 :41:52 +0000
To: (b)(6)
Subject : RE:worrisome
Yes. Please call t o th eir att enti on. ___________ Cb

_>_<6> It is merely
a nasa l swab
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
From :
-------------------
Sent : Tuesday, April 28, 2020 10:32 AM
To: Fauci, Anthony (NIH/NIAID) [E] -------= (b=)(=6)
(b)(6)
Subject: worrisome
From today's Medscape .

https://www.medscape.com/viewarticle/929407?nlid=135287 5653&src=wnl newsalrt daily 200427
MSCPEDIT&uac=71367AK&impl0=2361940&faf=1
Older adults with COVID-19, the illness caused by the coronavirus , have several "atypical " symptoms,
complicating efforts to ensure they get time ly and appropriate treatment, according to physicians.
COVID-19 is typically signaled by three symptoms: a fever, an insistent cough and shortnes s of breath.
But older adults - t he age group most at risk of severe complications or death from t his cond ition -
may have none of these characte ristics.
Instead, seniors may seem "off" - not acting like themselves - early on afte r being infected by the
coronavirus . They may sleep more than usual or stop eating. They may seem unusually apathetic or
confused, losing orientation to their surroundings. They may become dizzy and fall. Sometimes, seniors
stop speaking or simply collapse.
(b)(6)
Sent : Tue, 28 Apr 2020 17:39:34 +0000
To: Janet Tob ias;Conrad, Patricia (NIH/NIAID) [El
Subject: RE: Riding along tomorrow am
OK
Director
Phone: (b)(6)
FAX: (30 496"'4409
E-mail: (b)(6)
From: Janet Tobias <jane t @ikanamedi a.co m>

(b)(6) --------
To: Fauci, Anthony (NIH/NIAID) [El ------ (b •>; Conrad , Patr icia (N IH/NIAID) [El
=)(6)1
Subject: Riding along tomorrow am
Hi Tony and Patty :
Would it be ok to do the 6:45 am ride to NIH tomorrow? We would also get there
early to do one more paper throw. And last night was great!
Janet
From:"Fauci, Anthony (NIH/NIAID) [E]" <______ Cb>

_<6)
_>
Date: Sunday, April 26, 2020 at 4:30 PM
To: Janet Tob ias <janet@ ikanamedia.com >
Subject: RE: Quick question
ema ils precludes me or my staff from answering each individual message. I would
encourage you to visit www.coronavirus.gov for the latest information and
Anthony S. Fauci, M .D.

From: Auchincloss, Hugh (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent : Tue, 28 Apr 2020 15:50:24 +0000
To: NIAIDODAM
Subject : FW: Invitation from the Investment Community
Attachme nts: Letter of invitation_Dr. Anthony Fauci from UBS Investment Bank (1).pdf
I don't think so.
From: Elizabeth Haenle

---------
------
-------- -=~
Subject: Invitation from the Investment Community
(bH6J>
Dear Dr. Fauci,
I am t he co-founder of SAGEWor ldwide, a global speaker and consulting company. I am reaching out on
behalf of one of my partners, Robert Karofsky, Co-President of UBS Investment Bank, with an invitat ion
to join the UBS Global response to Covid-19 in a live streaming moderated discussion on May 18.
Alternatively your conversation could be pre-recorded to accommodate your busy schedule. At this
critically important time in our nation's history, the investment community wants to help our nation
fight Covid-19 and use our country's economic engine to find a cure and solutions for Covid-19. They
also are thinking through how to help our nation's businesses going forward. Your expertise is
important to this conversation .
By way of background, I served in the White House for eight years in the Bush Administration as the
Social Secretary to Vice President Cheney. In that capacity, I had the privilege of curating a range of
discussions with global thinkers and thought leaders on the world's most pressing topics. At SAGE,we
bring t hat level of excellence t o our business partners as we help curate discussions that have an impact
on public awareness and investor sentiment, which is part icular ly impor tant as the U.S. responds t o
Covid-19.
Participants at the UBSGlobal Healthcare Conference provide critical funding to pharmaceuticals and
healthcare research and are the businesses on the frontline of the Covid-19 healthcare response.
Attached please find an invitat ion from UBS with further details of the event. I welcome the opportunity
to hear from you at your earliest convenience, and thank you for your important work and dedication to
our country's we ll being over the course of your distinguished career and service at NIAID.
Warmest regards,
Elizabeth Haenle
Co-Founder, SAGEWorldwide
Phone: (b)(6)
Attachment 1
Elizabeth Haenle CmH!l.
Co-founder and Presjdeot
M:
------- (b)(6)
E:
--------- (b)(6)
W: SAGEworldwide.com
cotm
This email and any files transmitted with it are confidential and intended solely for the use of the
individual or entity to whom they are addressed. If you have received this email in error please notify
the system manager. This message contains confidential information and is intended only for the
individual named. If you are not the named addressee you should not disseminate, distribute or copy
this e-mail. Please notify the sender immediately by e-mail if you have received this e-ma il by mistake
and delete this e-mail from your system. If you are not the intended recipient you are notified that
disclosing, copying, distributing or taking any action in reliance on the contents of this information is
strictly prohibited.
From: Au chincloss, Hugh (NIH/ NIAID) [E] on beh alf of Fauci, Ant hony (NIH/NIAID) [El
Sent : Tue, 28 Apr 2020 14:46:56 +0000
To : NIAID ODAM
Subject: FW: HIGH SCHOOL MUN CONFERENCE
For d iscussio n
From: Dane Cohn (b)(6)>

To: Fauci, Anthony (NIH/ NIAID) [El
-----~= (b)( >; Barasch, Kimberly (NIH/ NIAID) [C]
(b)(6); Conrad, Patricia (NIH/NIAID ) [El (b)(6) ; Fauci,
--:---:----:----:--:--:-;::::::::::c.:..._ _ ___,:__~=
An t ho ny (NIH/ NIAID) [E] (b)( 6)
Subject: HIGH SCHOOL M UN CON FERENCE
Dear Dr. Anthony Fauci ,
My name is Dane Cohn , and I am an (b)( 6). I have often

listened to your inspiring words on the news and followed your assiduous work to help
us through this pandemic. Our school participates in Model UN, an event in which high
school studen ts represent various countries in debates on international issues from the
past and present. Colorado's final Model UN conference was canceled , so our school
----------- (bH6) ) decided to host an online conference for the whole state
of Colorado and beyond . Our team would like to formally invite you to give a short
address (be it pre-recorded or live onlin e) to the student s during our opening
ceremony .
We hope that our conference will inspire the youth of our nation and the world to stan d
up and fight for our futu re rather than resign their aspirations to lockdown . We host this
conference because we see the importance of keeping our academ ic passions going
while staying safe within the confines of our homes . We host this conference because
we want to contribut e to the fight again st COVID -19 - money raised from our
conference will go towards buying masks, food, and other resources for those wh o need
it most.
This is why we ask you , a hero during this troubling time, to speak to the students of our
confer ence, who not only include the youth of Colora do , but also the youth of our
country and w orld. Any type of address would be greatly and wholeheartedly
appreciated. If your address is pre-recorded , we would appreciate it if we could receive
it by May 1st, as our conference is the morning of May 2nd . We believe you can bring
true inspiration into our hearts and minds . We know you are very busy, but if it were at
all possib le to share with us even a short 2-3 minute pre-recor ded greeting and
message to the students participating in this Model UN conference , it would be truly
inspirational. Thank you so much for your time , we hope to hear from you soon .
Most Respectfully,
Dane Cohn and the entire
--------- (b)( 6) Model UN Team
Sent : Tue, 28 Apr 202011 :25:09 +0000
To : Haskins, Meli nda (NIH/NIAID) [El
Subject: RE: Please advise LHHS Hearing w / Dr. Fauci -- Wednesday, May 6
8:30 AM would be good. Thanks.
Director
Phone: (b)(6)
FAX: (3 96':44li9
E-mail: (b) (6)
From: Haskins, Mel inda (NIH/NIA ID) [El (b) ( '>

Sent: Tuesday, April 28, 2020 7:08 AM ----------
Cc: Conrad, Patricia (NIH/NIAID) [E] (b)(6):>
Subject: RE: Please advise LHHS Hearing w/ Dr. Fauci -- Wed nesday, May 6
Let me know when you ' d like me to call please.
From: Fauci, Anthony (NIH/NIAID) [E] CbH >

To : Haskins, Melinda (NIH/NIAID) [E] ------- -,a-s-r=
(b)(6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b)(6)
Subject: Re: Please advise LHHS Hearing w/ Dr. Fauci -- Wednesday, May 6
Let us chat by phone t his morning
On Apr 28, 2020, at 5:51 AM, Haskins, Melinda (NIH/NIAID) [E] (b) ( >
w rote:
We do not know if the Dela uro hearing would be remote. The Senate HELPone would be
in person w it h some form of social distanc ing.
Sent from my iPhone
On Apr 27, 2020, at 10:36 PM, Fauci, Anthony (NIH/NIA ID) [E)
-------- (b) (6) wro te :
E should make sure that we schedule it at a time of day that does not
conflict with the COS visit.
From: Conrad, Patricia (NIH/NIAID) [E] (b)(6)>

To : Fauci, Anthony (NIH/NIAID) [E] ------ (b)(6)--=-<=
Subject : Fwd: Please advise LHHSHearing w/ Dr. Fauci -- Wednesday, May 6
This is the day of the VIP visit-whoever it is. VP or COS.Pis advise. And not
sure if these are I person or not. I suspect remote right??
Sent from my iPhone
From: "Haskins, Melinda (NIH/N IAID) [E]"

(b)(6)
Dat e: Apri l 27 , 2020 at 8:10:52 PM EDT
(b) ~ >
Cc: NIAID OCGRLeg <NIAIDOCGRLeg@mail.nih.gov>, " Billet ,
Courtney (NIH/NIAID) [E)" (b)( , "Harper, Jill
(NIH/NIAID) [E]" (b)(6)
Subject: Please advise LHHS Hearing w/ Dr. Fauci --
Wednesday, May 6
Patty,
See below . Another hearing.
Thank you,
Melinda
Sent from my iPhone
From: " Hallett, Adrienne (NIH/OD) [E]"

(b)(6)
Dat e: April 27, 2020 at 7:57:36 PM EDT

To : "Haskins, Melinda (NIH/NIAID) [E]"
(NIH/NIAID) [E)" (b)(6)>,
"LaMontagne, Karen (NIH/OD) [E]"
(b)(6)>, "Higgins, Lauren
-( N
- I-H/-:-
0-D"'.""
)-:-
[E-:-
] ,:-::
' ====~ ~) ~( >
(b
--------
Subject : Fwd: LHHS Hea ring w / Dr . Fa uci --
W e dnesday, May 6
Guess they really are coming back.
From: "Steigleder, Stephen"

(b)(6)
>
Date: April 27, 2020 at 7:41:56 PM
EDT
To : "Hallett, Adrienne (NIH/OD) [E]"
(b) ( >
Subject : LHHS Hea ring w/ Dr. Fa uci -
- W ednesday, Ma y 6
Hi Adrienne,
I hope you're doing well.
I'm reaching out because Chair

Delauro would like to invite Dr. Fauci
to a hearing next Wednesday, May 6,
with the House LHHSappropriations
subcommittee . The focus of the
hearing, not surprisingly, would be
COVID-19. Members of the
subcommittee wo uld very much like
to hear from Dr. Fauci on anything
related to COVID-19, but I think the
main topics would be:
• Mitigation and Testing; and
• Progress on vaccines,
therapeutics, and
diagnostics, as well as
necessary preparations to
manufacture and
disseminate a vaccine once it
is ready.
Chair Delaura is flexible about a
starting time for the hearing on
Wednesday , so she would be happy
to accommodate a t ime that works
for Dr. Fauci's schedule.
Please let me know as soon as

possible, so we can plan accordingly.
Thanks so much,
Stephen
Stephen Steigleder
House Appropriations Committee
Labor/HHS/Education Subcommittee
Sent : Tue, 28 Apr 2020 00:22:50 +0000
To : (b)(6)
Subject: FW: Remdesiv ir--good news

Attachments : 20-0006 _DSMB_primary _analysis_report_for _OMI D.pd f
From: Erbelding, Emily {NIH/NIAID) IE] _______ Cb

_>_<_ >
Sent: Monday, April 27, 2020 8:05 PM
To: Fauci, Anthony {NIH/NIAID) [E] ______ (b
""~""(6)
= >
Subject: Remdesivir--good news
Ton'l,,_______________________________ --~
(b) (5)
Emily
Emily Erbelding, M .D., M.P.H.

Director, Division of Microb iology and Infectious Diseases
NIAID/N IH
5601 Fishers Lane
Rockville, MD 20852
Tel: (b)(6)
Sent : Mon, 27 Apr 2020 22:56:59 +0000
Subject : FW:
Attachme nts: Brown et al submitted .pdf, NIH Presentation final.pp tx,
prepr ints202002.0147.v2 (1) .pdf, Mosaheb et al 2020.pdf

Special Assistant for Scientific Project s
Bethesda MD 20892
Telephone: (b)(6)
Email : (b)(
From : Dani Bolognesi , Ph.D.

----------
(b)(6)>

(b)( 6)
-------=
-------- = CbH6l;Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW:
TX in advance.
Dani
Hi Tony:
In advance of getting together wi t h you and your team, I am forwarding a short presentation for you
(b) (4). (b) (5)
(b) (4), (b) (5)
may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could
Many thanks for the opportun ity to share this with you !
All the very best,
Dani
(b)(6)
Best,
Dani
From: "Dani Bolognesi, Ph.D." (b)(6)>

Date: Monday, April 27, 2020 at 2:53 PM
To : "Matthias Gromeie r, M.D." -----------~~ (b)(6)
Subje ct : Please review this draft email to Tony--TX

Dani
for you guys to look at. The key elements are follows:
(b) (4). (b) (5)
We are prepared to discuss this with you and your tea at any time that is convenient for you . As you may
arrange a WebEX as an initial step .
All the best,
Dani
Best,
Dani
The infor matio n in this electronic mail is sensitive, protected information inte nded only for the addressee(s). Any othe r person,
including anyone who believes he/she might have received it du e to an address ing error, is requeste d to notify the sender
imm ed iate ly by return electronic mail, and to delete it without further reading or retention . The information is not to be
forwarded to or shared unless i n compli ance with Duke Health policies on confidentiality and/o r w ith th e approva l of the
sender.
Sent : Mo n, 27 Apr 2020 22:17:19 +0000
To: Folkers, Greg (NIH/NIAID) [E);NIAID OD AM
Subject : RE: COVID/ Transportation Impacts
Ok. Let us discuss forwarding to CDC>
Director
Bui lding 3 I, Room 7 A-03
31 Center Dri ve, MSC 2520
Nationa l Ins titutes of Health
Bet hesda , MD 20892-2520
Phone: (b) (6)
FA X: (301) 496-4409
E-mail (b) (6)
The informati on in this e-ma il and any of its attachme nts is confidential and may contai n sensitive infom1ation. It
should not be used by anyone who is not the original intended recipie nt. l f you have received this e-mail in erro r
please inform the sender and delete it from your mai lbox or any other storage devices. The Nationa l Institute of
Allergy and Infectio us Diseases (NlAI D) shall not accept liability for any stateme nts made that are the send er's own
From: Folkers, Greg (NlH/NlAID) (E]
Sent: Monday , Apri l 27, 2020 6:15 PM ---------
To: Fauci, Anthon y (NTH/NlAID) [E] --------=
(b)(
Subject: RE : COY ID/fransportation Impacts--------- (b)( ; NJAID OD AM <NIAJD0DAM @niaid.nih.gov >
this seems like CDC issue
They address some of the issues here:
What Ridesbare, Tax i, Limo, and other Passenger Driv ers -for-Hire Need to Know about COVJD - 19
https://www.cdc.gov / coronavi ms/ 20 I 9-ncov / community / orga nizati ons/ ridesbare-drivers -for-h ire.htm I
Communication Too lkit for Transpo1tat ion Parto el'S to Inform Road Travelers Monday, April 27, 2020
https: //www .cdc.gov / coronav irus/2019 -ncov /travelers /transportat ion-toolkit.htm l
Cleani ng and Disinfect ion for Non-eme rge ncy T ranspo rt Vehicles Tuesday, Ap ril 14, 2020
https: //www .cdc .gov/ coronav iru s/? 019-ncov / community /orga nizations /d isin fectinQ.-transport-vch icles. h tm I
-----Original Mcssage-----
From:
[E] Conrad, Patricia (NIH/N IAID) [E] ....______ ___, On Beha l f OfF auci, Anthony (NIH/NIA ID)
(b)(6)
Sent: Monday, Apri l 27, 2020 6:05 PM

To: NIAID OD AM <N IAID0DAM @niaid.nih.gov >
Subject: FW: COVID/Transportation Impacts
From: Anthony Foxx (b)(6) >
To: Fauci , Anthony (NIH/NIATD) [E] -------~~
Subject: COVID/Transportation Impacts --------- (b)(
Dr. Fauci:
Thi s is Anthony Foxx, immediate former US Transportation Secretary, and Tgreat ly enjoyed our interactions (brief
tho ughts they were) during my time in the last Admi nistrat ion.
I write to request your help in advising the transportation community about how to manage through the present
crisis, particularly as some areas are easing restrictions. I would welcome an opportunity to join you in a Q/ A, which
could be valuable for rideshare companies (b) (6l), transit agencies, airlines etc. I would
think that a I0-15 minute chat would do wonders. That said, I know you are terribly busy and have so many things
to do but would appreciate any opportunityto help you get important infonnation out.
This could be pulled together rapidly and done within the next week or so,
Thanks for your attention to this matter. All my best,
Anthony.
Sent from my iPhone
Sent : Mo n, 27 Ap r 2020 22:00:13 +0000
Subject : FW: Update - White House Coronavirus Task Force Mee t ing - 4.28.20
FYI
Director
Phone: (b)( 6)
FAX: (30 496"'4409
E-mail: (b)(6)
Sent : Mo n, 27 Apr 2020 21:57:57 +0000
To : Lusso, Paolo (NIH/N IAID) [El
Subject : RE:Covid t hrombi
Than ks, Paolo .
Director
Phone: (b)( 6)
FAX: (30 496"'4409
E-mail: (b)(6)
From: Lusso, Paolo (NIH/NIAID) [E]

---------.....,....,=
--------,
(b)(6)
(b)(6)
Cc: Kovacs, Joseph (NIH/CC/CCMD) (E] -~"."':=======~~ (b)(6) Masur, Henry (NIH/CC/CCMD) [E]
(b)( ; Lane, Cliff (NIH/':':"
N"."."
IA
':""'.
l':"'
D:-"".
)[ :'::'
E:.
] ====::-
--------
Subject: Re: Covid thrombi
..,...
(b,....,
)( ,:;;,
6)>
Dear Tony,
I talked with Dr. Viecca this morning who shared additional info rmation about his pro tocol. They started
fr om the pathologica l observation that all patients dying of Covid- 19 pneumo nia had diffuse pulmonary
microthrombosis . Since th ey detect ed almost exclusively white th rombi, they reasoned that they had to
block platelet activation/aggregation, whi le heparin would be ineffective at that stage. Thus, they
t reated a first group of five critica l pati ents with potent anti-aggregant t herapy (Tirofiban/ Aggrastat) and
apparen t ly in all of t hem the p02 started to rise within less than 2 hours, they got off the vent ilators and
went on to full recovery. Viecca is an intervent io nal cardiologis t (b)( 4)
I sent copy of his protocol and contact information to Joe.
Let m e know if I can be of any further help. All the best,
Paolo
Paolo Lusso, M.D., Ph.D.
Chief, Section of Viral Pathogenesis
Laboratory of lmmuno regulation
Bldg. 10, Rm. 6All
NIAID, NIH
Bethesda, MD 20892
Phone: (b)(6) (personal)

(b)(6) (lab)
Fax: (301) 480 -5291
E-mail:
-------- (b)(6)
The information in this e-mail and any of its attachments is confident ial and may contain sensitive
received this e-ma il in error please inform the sender and delete it from your mailbox or any other
storage devices. The Natio nal Institute of Allergy and Infect ious Diseases (NIAID) shall not accept
liability for any statement made tha t are the sender's own and not expressly made on behalf of the
******************************~
Sent: Mon, 27 Apr 2020 21:57:23 +0000
-----~~
Cc: Mascola, John (NIH/VRC)[E)
------- (b)(6)
Subje ct: FW : Revised Slid es

Attachment s: Vacci ne Development Slides Revised Draft 042720.pptx
Pleas respond for both of us. I already cc' d you on an em ail t hat I sent to John
wi t h a m inor comm ent about slide #2.
Director
Phone (b) (6)
FAX: (301 496-4409
E-mail: (b)(6)
information . It should not be used by anyone who is not the orig inal intended re cipient. If you
From: Marks, Peter

----------
(b)(6)
To: Fauci, Anthony (NIH/ NIAID) [El ------~~ >; Collins, Francis (NIH/OD) [El
(b)( 6)
-------- (b)(
Cc: M ascola, John (NIH/VRC)[E]

Subje ct : Revised Slides
-------- (b)( >
Dear Francis and Tony,
Apologize that t he prior slides were too busy. John conveyed that message. Pleasesee t hese versions
t hat may be more along the lines that you are loo king for . (b) (5)
Best Regards,
Peter
Sent : Mo n, 27 Apr 2020 21:54:37 +0000
To: Schwetz, Tara (NIH/OD) [El
Subject: RE: Flagging NIH Media Product for Release Tomorrow
You could play the role in the movie of my medical school girl friend, which wou ld
give you the possibility of working with Brad Pitt Q
Director
Phone: (b)(6)
FAX : (301 496-4409
E-mail : (b)(6)
From: Schwetz, Tara (NIH/OD) [E] (b)(6)

Sent: Monday , Apri l 27, 2020 5:49 PM
Subject: Re: Flagging NIH Media Product for Release Tomorrow
Now, you also have the answer to who would play you in a mov ie! ©
Tara A. Schwetz , PhD

Acting Director, NINR
Associate Deputy Director, NIH
A: Building 1, Room 138
--- --,;-,-=
P:
-----
(b)(6) I M: (b)(6)
From:"Fauci , Anthony (N IH/NIAID) [E]" CbH6)

To: Tara Schwetz (b)(
Subject: RE: Flagging NIH Media Product for Release Tomorrow
Thanks, Tara. Pitt was amazing. One reviewer of the SNLshow said that Pitt
looked "exact ly like me". That stateme nt made my year. (Q)
Director
Phone: (b)(6)
FAX: (301) 496-4409
E-mail:
-------- (b)(6)
Information. It should not be used by anyone who Is not the orig inal Intended recipient . If you
From: Schwetz, Tara (NIH/OD) [El (b)( >

To: Fauci, Anthony (NIH/NIAID) [El --------, .....,....,=
(b)(6)
Cc:Marston , Hilary (NIH/NIAID) [E] (b)(6) ; Conrad, Patricia (NIH/NIAID ) [E]
(b)(6)>; Barasch, Kimberly (NIH/NIAID) [CJ (b)(6) Myles,
Renate (NIH/OD) [El (b)( ; Walsh, Elizabeth (NIH/OD) [El (b)(6)
Subject: Flagging NIH Media Product for Release Tomorrow
Tony,
Please see below and attached a ti me-sensit ive COVID-19 item for your awareness and sharing wit h t he
rema inder of the Task Force, as appropriate. The plan is to release this tomorrow.
Item 1: Title : Rapid Acceleration of Diagnostics (RADx) Initiative

Activity Type : Funding of new research program
Summary: W ith a (b)(5) investment from fede ral st imulus fund ing, RADx initiat ive w ill infuse
fund ing into early innovation techno logies to speed deve lopment of rapid and widely accessible
COVID-19 tes ting. At the same time, NIH will seek opportunit ies to move more advanced
d iagnost ic technolog ies swiftly through the development pipeline towa rd commercialization and
broad availabil ity. As part of the init iat ive, NIH is urging scientists and inventors with a rapid
test ing tec hnology to compete in a nat ional COVID-19 test ing challenge for a share of up to $500
million over all phases for further deve lopmen t. The goal is to add tens of m illions per month of
accurate and easy-to-use tests to all Americ ans by Fall 2020.
Impact on COVID-19 Pandemic Response: RADx will accelerate the development, validation, and
commercializ ati on of innovative new testing methods that can be deployed in point-of-care and
home settings. These technologies are urgently needed to guide and inform safe return to work,
schoo l, and life activities.
Office : National Institute of Biomedical Imaging and Bioengineering
Action Date: Solicitation announcement April 28, 2020
Type of Action: Research Program Award
Potential for Press Coverage: Mainstream Press
Press Release in Development? : Yes
Do let me know if you have any questions.
(Also, Brad Pitt?! Wow, that was a real ly nice shout out/thank you.)
Best,
Tara A. Schwetz, PhD

P: (b)(6) I M:
---~~ (b)(6)
Sent : Mo n, 27 Ap r 2020 21:48:46 +0000
To : Birx, Deborah L. EOP/NSC
Cc: Redd, Stephen (CDC/DDPHSIS/OD);Hahn, Stephen
Subject : Flagging NIH l'vledia Product fo r Release Tom orrow
Att achment s: 2020 -04-27_COVID-19Week lyReport _ NIBIB OD_tas .docx
Deb:
As an FYI. This is an initia ti ve fr om NBIB/N IH on developm ent of POC
diagnost ics for SARS-CoV-2.
Best ,
Tony
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail (b) (6)
Sent : Mo n, 27 Apr 2020 21:39:57 +0000
To: Stover, Kathy (NIH/NIAID) [E)
Cc: Billet, Courtney (NIH/ NIAID) [El;Folkers, Greg (NIH/NIAID) [El;Conrad, Patricia
(NIH/N IAID) [El
Subject: RE:FORASF REVIEW:Draft PR re: SARS-CoV-2 incidence in children
Looks fine. Thanks.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail ,___,,. __ _, (b)(6)
The in ormation inlh ,s e-mail and any of its attachments is confidential and may contain sensitive
From: Stover, Kathy (NIH/NIAID) [El (b)(6)>

To: Fauci, Anthony (NIH/NIAID) [El ------= = (b)(6)>
Cc: Billet, Courtney {NIH/NIAID) [El (b)(6)>; Folkers, Greg (NIH/NIAID) [El
_______ Cb
_> _, ; Conrad, Patricia (NIH/NIAID) [E)
_C6) (b)(6)>
Subject: FORASF REVIEW:Draft PR re: SARS-CoV-2incidence in children
Hi Dr . Fauci,
Please find at tached fo r your review a draft release about the launch o f t he Human
Epidemiology and Response to SARS-CoV-2(HEROS)study, which is intended to help determine
t he percentage of children infected with SARS-CoV-2and the percentage of infected children
who develop COVID. In addition , the study will examine whether rates of SARS-CoV-2infection
differ between children who have asthma or other allergic conditions and children who do not.
Your draft quote is as follows :
11
0ne interesting feature of this novel coronavirus pandemic is that very few children
have become sick with COVID-19 compared to adults," said NIAID Director Anthony S. Fauci,
M.O. "Is this because children are resistant to infection with SARS-CoV-2, or because they are
infected but do not develop symptoms? The HEROSstudy will help us begin to answer these
and other key questions."
Thanks much,
Kathy
Kathy Stover
Branch Chief
31 Center Drive, Room 7Al 7E
Bethesda, MD 20892
Phone: (b)(6)
E-mai l (b) (6)
Sent : Mo n, 27 Apr 2020 21:04:24 +0000
To : Auch incloss, Hugh (NIH/N IA ID) [C)
---------~~
Cc:
-----------
Conrad, Patricia NIH/NIA ID [E);Jean W Pape
(b)( 6)
(b) (4)
Subject :
Attachment s:
Hugh:
(b) (6), (b) (4)
Please t ake care of it.

Than ks,
To ny
Direc tor
Phone: (b)(6)
FAX: (301 496-4409
E-mail (b) (6)
information. It should not be used by anyone who is not th e orig inal intended recipient. If you
other storage devi ces . The Nat ional Institute of Allergy and Infectious Diseases (NIAID) shall not
From :
----------------
Sent: Monday , April 27, 2020 3:0 1 PM
---------=-=--:-=
(b)(6)
Subject : ---------
(b) (4)
(b)(6)
To ny ,
(b) (4), (b) (6)
Best,
Bill
JEAN W ILLIAM PAPE, M D

Howard and Carol Holtzmann Professor of Clinical Medicine,
Center for Global Health, Division of Infectious Diseases, Department of Medicine,
Weill Cornell Medical College, New York, New York, USA
402 East 67th Street, New York, NY 10065
Tel (Office) (b)(6)
Director,
Les Centres GHESKIO,
33, Blvd. Harry Truman, Port-au-Prince, Ha'iti.
Tel (Office): (b)(
Voip: (b)(6)
From: Conrad, Patricia (NIH/NIAID) [El on behalf of Fauci, Anthony (NIH/NIAID) [El
Sent: Mon, 27 Apr 2020 16:09:04 +0000
To: NIAIDODAM
Subject: FW: The National Organization of Ital ian Americans in Film & Television
(NOIAFT) - Int erview Request
Patricia L. Conrad
Pub lic Health Ana lyst and
National Inst itut e of Allergy and Infectious Diseases
The National Institutes of Heal t h
(b)(6)
301-496-4409 fax
Disclaimer :
by anyone who is not the original intended recipient. If you have rece ived this e-mail in error please inform the sender and delete it
from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID ) shall not accept
liab ility for any statement made that are sender's own a nd not expressly made on behalf of the NIAID by one of its representatives.
From:Taylor Taglianetti <taylor@noiaft.org>

-------~~
________
.:=========~~
...
Subject: The National Organization of Italian Americans in Film & Television (NOIAFT) - Interview
Request
Dear Dr. Fauci,
I hope this email finds you wel l. My name is Taylor Taglianetti and I am the founder of the Nationa l
Organization of Italian Americans in Film & Television (NOIAFT).
Our organization is so very proud of the work you are doing for our country and sends tremendous
thanks for the hope and reassurance you have instilled during these trying times.
It would be an honor to conduct a short inte rview with you. Our organization includes many young
Italia n Americans breaking into the entertainment industry and with the coronavirus dramatically
impact ing our field, I'd love to ask you a few questions about what the future of the
entertainmen t business looks like. We'd be happy to send the questions in advance for your approval. If
you don't have time for a phone call, the questions can be answered via email at your leisure .
Thank you for your time and consideration.
Sincerely,
Taylor Taglianetti
Founder, The National Organization of Italian Americans in Film & Television (NO/AFT)
(347) 686-4968
www.noiaft.org
taylor@noiaft.org
(bX5)-PCl1
(bX5) -PCP.
(bXS) - PCP.
Sent : Mon, 27 Apr 2020 14:19:38 +0000
Subject: RE:Media query: CNN, re: ASF'sNASweb briefing on Saturday
I was referring only to animal (macaque) models. I never said t hat it loo ked good
in humans . Human clinical trials are ongoing to answer t hat question . Thanks.
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)

Sent: Monday, April 27, 2020 9:30 AM
To: Fauci,Anthony (NIH/NIAID) [E]------= (b)
""(=6J>
Subject: Fwd: Media query: CNN, re: ASF'sNASweb briefing on Sat urday
Pis advise
Sent from my iPhone
(b)(6),>
From: "Leifman, Laura (NIH/NIAID) [E]"
Date: April 27, 2020 at 9:27:13 AM EDT
---------
To: "Conrad, Patricia (NIH/NIAIO} [E]" -------~~ CbH6J>,
NIAID FOG
<fog@ niaid .nih.gov>
-----------
Cc:NIAID COGCORE<COGCORE@mail.nih.gov>, NIAID Media Inquir ies
<mediainquiries@niaid.nih.gov>
Subject: Media query: CNN, re: ASF's NAS web briefing on Saturday
Elizabeth Cohen
CNN
Elizabeth.Cohen@turner.com
Topic: Statement by ASF during Saturday NAS web briefing
Deadline: urgent
Hi Patty,
Elizabeth would like to clarify something that Dr. Fauci apparently said about remdesiv ir
during his NAS web briefing on Saturday. The transcribed segment of the talk that she is
focused on says:
"Remdesivir is the one that's gotten the most publicity. It is interesting that if you look at it
in a prophylactic therapeutic model in MERScoronavirus infection, it looked pretty good.
There was clinical benefits just reported a couple of weeks ago of SARScoronavirus 2 in
rhesus macaques."
She wants to clarify what Dr. Fauci meant by looking at remdesivir " in a prophylactic
therapeutic model in MERS"-whether this means in an animal model or something else. It
sounds like that phrase is referring to the RML study in which remdesivir successfully
prevented disease in MERS-infected rhesus macaques, as reported in the Feb. 13 NIAID
media availability pasted below . Is that correct?
Best,
Laura
Remdesivir Prevents MERS Coronavirus Disease in Monkeys

Results Support Testing Antiviral Against 2019 Novel Coronavirus
February 13, 2020
The exper imen tal antiviral remdesivir successfully prevented disease in rhesus macaques
infected with Middle East respiratory syndrome coronavirus (MERS-CoV),according to a
new study from National Institutes of Health scientists. Remdesivir prevented disease
when administered before infection and improved the condition of macaques when given
after the animals already were infected.
The new report from NI H's National Institute of Allergy and Infectious Diseases (NIAID)
appears in the Proceedings of the National Academy of Sciences.
MERS-CoVis closely related to the 2019 novel coronavirus (SARS-CoV-2,previously known
as 2019-nCoV) that has grown to be a global public health emergency since cases were first
detected in Wuhan, China, in December.
Remdesivir has previously protected animals against a variety of viruses in lab
experiments . The drug has been shown experimentally to effectively treat monkeys
infected with Ebola and Nipah viruses. Remdesivir also has been invest igated as a
treatment for Ebola virus disease in people.
The current study was conducted at NIAID's Rocky Mountain Laboratories in Hamilton,
Montana. The work involved three groups of animals: those treated with remdesivir 24
hours before infection with MERS-CoV; those treated 12 hours after infection (close to the
peak time for MERS-CoVreplication in these animals); and untreated control animals.
The scientists observed the animals for six days. All control animals showed signs of
respiratory disease. Animals treated before infection fared well: no signs of respiratory
disease, significantly lower levels of virus replication in the lungs compared to control
animals, and no lung damage. Animals treated after infection fared significantly better
than the control animals: disease was less severe than in control animals, their lungs had
lower levels of virus than the control animals, and the damage to the lungs was less
severe .
The scientists indicate that the promising study results support additional clinical trials of
remdesivir for MERS-CoVand COVID-19, the disease that SARS-CoV-2 causes. Several
clinical trials of remdesivir for COVID-19 are under way in China, and ot her patients with
COVID-19 have received the drug unde r a compassionate use protocol.
The Biomedical Advanced Research and Development Aut hority (BARDA), part of the U.S.
Department of Health and Human Services, also provided support for this study . Gilead
Sciences, Inc., developed remdesivir, also known as GS-5734, and collaborated in the
research .
MERS-CoVemerged in Saudi Arabia in 2012 . Through December 2019, the World Health
Organization had confirmed 2,499 MERS-CoVcases and 861 deaths (or about 1 in 3).
Because about one-third of MERS-CoVcases spread from infected people being t reated in
healthcare settings, the scientists suggest that remdesivir could effectively prevent disease
in other patients , contacts of patients , and healthca re workers . They also note the drug
might help patients who are diagnosed with MERSor COVID-19 if given soon after
symptoms start.
ARTICLE:
Ede Wit et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus
macaque model of MERS-CoV infection. PNAS DOI: 10.1073/pnas .1922083117 .
WHO :
NIAID Director Anthony S. Fauci, M .D., and Emmie de Wit, Ph.D., a principal investigator in
NIAi D's Laboratory of Virology, are available to comment on this study.
Sent : Mo n, 27 Apr 2020 14:11:59 +0000
Subject : FW: Coronavirus Antigen Mi croarray
Please t ake a look and handle .
Director
Phone: (b)(6)
FAX: (30 496"'4409
E-mail: (b)(6)
From: Anderson, Cassandra (NIH/NI DDK) [E]

Sent: Monday, Apri l 27, 2020 8:17 AM ------------
------ --=~
(b) (6)•>

--------
Subject : FW: Coronavi rus Antigen Microarray
(b)(6)>
Good morning Dr. Fauci,
I work in NIDDK in bldg. 50 in the Laboratory Endocrinology and Receptor Biology.
Thank you for all the information yo u have provided to our nation . I also want to say you are doing a
terr ifi c job in handl ing the COVID-19 v irus, without you and your staff I don't know wher e our country
would be.
I received the ema il below this morning from Jiang Yufei from Sino Biological. Not sure why I was sent
this email, but I tho ught of you and your staff . Please see the email below .
Thank you again for all that you are doing to help keep us safe !
Stay safe!
Cassandra Anderson
Admin istrative Professional
Bldg. SO Room 4133
301-402-7845
From: Yufei Jiang <yufei.jiang@sinobio logical.info>
>
To : Anderson, Cassandra (NIH/NIDDK) [E)
Subjec t : Coronavirus Antigen Microarray ------------- (b)(
Hi Cassandra,
Happy Day! I am excited to let you know that Sino Biological jus t released Coronavirus antigen
Microarray (CoVAM) which belongs to our Sinommune™ Mu ltiplex Antigen Microarray product line. You
may get more details from the following link:
https ://www. sinobio logica I.com/ research/virus/ coronavi rus-array
Currently the standard pre-printed CoVAM array is sold in the unit of slide, 16 arrays/slide. In each array
there are 65 antigens related to the viruses that can cause upper respiratory tract infections including
the most recent SARS-CoV-2.The list price is $3,200/slide . Please contact me for how to place the order
if you are interested or need more information.
So far, this array has mainly been used for two purposes: 1) Sero-surveillance studies of COVID-19
infect ion, and 2) Evaluating antibody reactiv ity in animals (monkeys and mice) after vaccination . Please
be advised that our array is for research use only (RUO), not for the diagnostic purpose which needs the
FDA approval.
After you run the samples on the slide, you may read the slide on the following compatible machines:
https://www.innopsys .com/en /lifesciences-products/m icroarrays/innoscan
https://www.moleculardev ices.com/produc ts/additional -products/genepix-microarray-systems-

scanners#gref
https://www.agilent .com/en /produ ct/cgh -cgh-snp-microarray-platform/cgh- cgh-snp-microarray-

scanners-equipment/surescan-m icroarray-scanne r-228493
Thanks.
-Yufei
Yufe i Jiang, PhD

Manager, NY, MD, DC, VA
Sales & Business Development
Sino Biological US Inc.
1400 Liberty Ridge Dr., Suite 101
Wayne, PA 19087
Celli (b) (6)
Email: yufei jia ng@sinobiological.com
www.sinobiological.com
Sent : Mo n, 27 Apr 2020 14:11:06 +0000
Subject: FW: Otto e Mezzo - Ita lian Show
Let us discuss.
Director
Phone : (b)(6)
FAX: (30 496"'4409
E-mail: (b)(6)
behalf of the NIAID by one of its representative s.
From: Torchia Patrizia <Patrizia.Torchia@la7.it>

Sent: Monday, Apri l 27, 2020 8:05 AM
--------, .....,....,=
Subject: Otto e Mezzo - Italian Show --------- (b)(6)
Dear Mr. Fauci,
I'm Patrizia Torchia, I'm a journalist and I am a member of the team on the It alian show Otto e Mezzo,
hosted daily by journa list Lilli Gruber on La7 channel.
I'm reaching out to invite you in our show. Mrs. Gruber would be honored to have you, Dr. Fauci explore
in more depth the challenges Coronavirus has forced th e world to face. Can make this happen?
Below is Lilli Grube r's bio and a brief descript ion of the show.
WHO :
Lilli Gruber is the editor-in-chief and host of Italy's most influential political daily talk show, "Otto e
mezzo", airing on prime-t ime on La7 TV. She's received Italy's most prestigio us journalism awards for
her work and was the first woman to ever conduct the prime -time News broadc ast in Italy (RAI TV,
1987). As a foreign correspondent she covered most of last 30 years' maj or world events, from the fall of
t he Berlin wall to 9/11 to the Iraq war. Beside her te lev ision work, Ms. Gruber wrot e eleven bestseller
books includ ing "Eredita", which was top seller for 20 weeks and ran 14 reprints. In 2004, Ms. Gruber
won a head-to-head campaign against Silvio Berlusconi by a large margin of votes and was elected to the
European Parliament. There, among other appointments, she was the Head of the EU Delegation to the
Gulf States and Yemen and a member of the EU Delegation to Iran.
"Otto e m ezzo"
Italy's most influential political daily ta lk show shown on prime-time on La7 TV. Through interviews with
elected political figures and candidates for office, commentators, and journal ists, the show focuses on
international political news and economy wi th a special focus on Italy and Europe. Beginning in
2008 "Otto e Mezzo" became Lilli Gruber's way to keep her commitment to holding those in power
accountable by asking questions and touching on topics citizens are curious about. Otto e
Mezzo airs Monday to Saturday from 8:35pm to 9:10pm. Within this time-frame Paolo Pagliaro's news
column "II Punto" stands out for accuracy and thoughtfulness by pulling the thread on the highest rated
issues in an agenda. During the current season Otto e Mezzo has become Italy's most watched political
talk show reaching an average of 7.3% of share wi t h 2.5 million viewers per day.
Production location( s): La7 studios, via Umberto Navaro 32, Rome, Italy
Presen t ed by : Lilli Gruber
Origina l net w or k: La7
Executiv e produ cers: Stefania Bucciarelli
Directed by: Lorenzo Font ana
www.live.la7.it
www.ottoemezzo.la 7 .it
Twitt er: @OttoemezzoTW)
Face book : Ottoemezzola7)
Thank you in advance for t he considering. Looking forward to hearing from you.
Patty Torchia
Otto e Mezzo
(b)(6)
Sent : Mo n, 27 Apr 2020 14:08:24 +0000
Subject: RE: Fauci and PayPal
Not really.
Director
Phone: (b)(6)
FAX: (30 496"'4409
E-mail: (b)(6)
From: Conrad , Patricia (NIH/NIAID) [E]

To: NIAID OD AM <NIAIDODAM@niaid .ni h.gov>
---------- (b)(6)
Subject: FW: Fauci and PayPal
Patricia L. Conrad
(b)(6)
301-496 -4409 fax
Disclaimer:
The information in this e-mail and any of its attachmentsis confidential and may contain sensitive information. It should not be used
from your mailbox or any other storage devices. Nationa l Institute of Allergy and Infectious Diseases (NIAID ) shall not accept
liab ility for any statement made that are sender's own and not expressly made on behalf of the NIAi D by one of its representatives.
From: Fetalvo , Ninio J. EOP/OVP ___________
... (b)(6)
--------
---------- ==
To: Conrad, Patricia (NIH/ NIAID) [E] (b)(6)
Subject: FW: Fauci and PayPal
FYI-Defer to you on this.
From : Miller , Amanda <amanmiller@paypal.com >

To: Fetalvo , Ninio J. EOP/OVP__________ (b
""'~"'(=
6)
Cc: Walters, Lindsay <Lindsay.Walte rs@edelman.com >

Subject: [EXTERNAL] Re: Fauci and PayPal
Hi Ninio,
We are wondering if Dr. Fauci would like to have a taped Skype conversation with PayPal CEOand
President Dan Schulman to talk about safety measures, health and science tied to COVID-19. We wou ld
air the conversation during a global employee all hands to o ur 23,000 employees and then we could
syndicate parts of it externally on our social channels.
Thanks for any help in reaching Fauci's team .
Thanks,
Amanda
Amanda Christine Mill er

Senior Director, Corporate Communications
408.219.0563
@PayPalNews
• PayPal
Sent : Mon, 27 Apr 2020 14:07:40 +0000
To : Lerner, Andrea {NIH/NIAID) [E]
(b) (4)
Subjec t : RE:
------------------------
Thanks.
Director
Phone: (b)(6)
FAX: {301 496-4409
E-mail: (b)(
The info rmation in this e-mail and any of its attachments is confidential and may contain sensitive
information. It should not be used by anyone who is not the original intend ed recipient. If you
From: Lerner, Andrea {NIH/NIAID) [E) (b)( >

---------
To : Fauci, Anthony {NIH/NIAID) [E) ------ -=
(b-s-r
)( =6)
Subjec t: Re:
------------------------
I will make sure they get a response!
(b)(4
Fr om : "Fauci, Anthony (NIH/NIAID) (E]"

To: "Lerner, Andr ea (NIH/NIAID) [E]"
---------
----------=-:-:-=
(b)(6) >
Cb)(6)
Subject: FW: Upd ate: (b)(4
--------------------------
Please respond to this person. Thanks.
From: Kircheis Dr. Ralf <RKircheis@syntacoll.de >

Se nt: Wednesday, Apr il 22, 2020 9:41 AM
To : Coomes, Ste phanie {NIH/NIAID) [E)_________ --------~~ Cb
_H_6)>; Fauci, Anthony {NIH/NIAID) [E)
(b)(6)
Cc:'-:-""'."""".~-:----::== (b=) =(6) ; K

:.:.:
:::::..:i.:..:
rc:.:.
h~e.:.:
is..:D:.;.
r.:..
. :.:.
Ra:.;l.:..
f<..:R
=K=i=
rc=h=e=
is:=
@:::s::::
y::::
nt=a=co
::::
1
:1.
::::::
d:::.
e>____ ,.._,,._,
Subje ct: Update:
1mportan ce: High ------------------------ (b)( 4)
Dear Dr. Fauci,

dear Dr. Coomes,
thank you for your reply from 13. April with the notice that the information has been shared with NIAID's
COVID-19research team.
Has the project already been initially evaluate d by the team?
Are there any quest ions or need for additional information?
(b) (4)
Looking forward to hearing from you.
Kind regards,
Ralf
Mit freundlichen Gru~en / Kind regards
Dr. Ralf Kircheis

Director R&D
Research & Deve lopment
Mail: RKircheis@syntacoll.de
Phone : +49 9441 686048
s~ntacoll
Syntacoll GmbH, Donaustrasse 24, 0·93342 Saal a. cl. Dcnau
Tel: +499441 / 68 60 0, Fax: +49 9441/6860 30
Handelsreg ister : Amtsgericht Regensburg - HRS 1612
USt- JdNr. DE 128580796
Gesch3ftsfuhrerin: Dr. Alexandra Dietr ich
Unsere Hinweise zum Datenschutz, insbesondere zu den Jhnen zustehenden Rechten, finden Sie unter
wwwsvotacon.
deJdatenschutz
Von: Coomes, Stephanie (NIH/NIAID) [El (b)(6)
Ge send et : Montag, 13 . Apri l 2020 02:37 --------------
An: Kircheis Dr. Ralf <RKircheis@syntacoll.de>
Betr eff: RE: ____________________ Cb
_H_4)_,_
C_H
b _5)
Dear Dr. Kircheis,
Thank you for your recent email to Dr. Anthony Fauci. Your message was forwarded to the Division of
Microbiology and Infectious Diseases (DMID) at the National Institute of Allergy and Infectious Diseases
(NIAID). As a member of DMID's Office of Scientific Coordination and Program Operations, I am pleased
to respond .
I want to thank you for reaching out to share this informat ion and let you know that your mes:;age ha:;
been shared with NIAi D's COVID-19 research team .
Sincerely,
Stephanie
Stephanie M. Coomes, Ph.D.

Health Scientist Administrator
Office of Scientific Coordinat ion and Program Operations
National Institute of Allergy and Infect ious Diseases
5601 Fishers Lane, Room 7G68
Rockville, MD 20892
(b)(6)
(b)(6)
Disclaime r: The informat ion in this email and any of its attachments is confidential and may contain sensitive
information. It should not be used by anyone who is not the orig inally intended recipient. If you have received th is
emai l in erro r, please inform t he sender and delete it from your mailbox or any ot her storage devices. The Nationa l
Institu te of Allergy and Infectious Diseases shal l not accept liability for any statements made that are the sender 's
own and not express ly made on behalf of NIAID by one of its represe ntatives .
From: Kircheis Dr. Ralf ') (b)( ~ >

Sent : Wednesday, Apr il 8, 2020 2:49 AM
To : Fauci, Anthony (NIH/NIAID) [El ..------ --,.(b.._-
)=
c >; Billet, Courtney (NIH/NIAID) [El
(b)(6)>; NIAID Ocpostoffice (NIH/NIAID) <OCPOSTOF FICE@niaid.nih.gov>
--------
Cc: Fischer, Elizabeth (NIH/NIA ID) [El (b)(6>i>; Foster, Erin (NIH/NIAID) [El
(b)(6) Foster, Sarah {NIH/NIAID) [El CbH >; Vasilenko, Olga
{NIH/NIAID) [El (b)( >; Vasquez, Aurelio (NIH/NIAID) [El
CbH >; Vostal, Alexander (NIH/VRC) [Fl
----------
Maldonado , Nancy (NIH/NIAID) [El
(b)(6J>;Vazquez-
(b)( >; Austin, James (NIH/NIAID) [El
CbH '>; Agulto, Liane (NIH/NIAID) [E] CbH6J;Deckhut, Alison
(NIH/NIA ID) [El (b)(6) Kircheis Dr. Ralf <RKircheis@syntacoll.de>
Subject: WG: (b) (4), (b) (5)
------------------------
1mportance: High
(b) (4), (b) (5)
Dear Dr. Fauci,

dear Madams/Sirs,
I want to bring to your attension some pote nt ially impo rtant exper imenta l data and a new proposa l for
treatment of COVID-19 patients with acute respiratory distress syndrome and o rgan failure. Sorry fo r
the broad distribution but I wanted to make sure tha t my message reaches you.
(b) (4), (b) (5)
(b) (4). (b) (5)
Please forward this mail to the colleages you cons ider relevant for evaluation, discussion and
consideration for your clinical strategy for COVID-19 .
Please let me know if additional informations are necessary.
To my person: I have MD PhD degree and have many years experience in phar maceutical development
{Boehringer lngelheim ), Biotech {lgeneon , Aphton , Virolog ik GmbH) {for reference see also PubMed
Kircheis r) currently leading R&D activities at Syntacoll {part of lnnocoll). I am providing this information
personally in order to help to find a treatment for COVID-19 patients .
Looking forward to getting feedback from you,
With kind regards,
Ralf Kircheis {MD PhD)
(b)(6)
rkircheis@svn ta coll .de

(b) (4), (b) (5)
(b) (4). (b) (5)
Mit freundlichen Grur..en / Kind regards
Dr. Ralf Kircheis

Director R&D
Research & Development
Phone: +49 9441 686048
s~ntacoll
Syntacoll CmbH, Donoustrasse 24, D 93342 Saa l a. d. Dcnau
Tel: +49 9441 / 68 60 O, Fax: +49 9441 / 68 60 30
Handelsregister: Amtsgericht Regensburg - HRB 1612
USt-ldNr DE 128580796
Gescha~sfuhrenn: Dr . Alexandra Dietr ich
Unsere Hinweise zum Datenschutz, insbesondere zu den Ihnen zustehenden Rechten, finden Sie unter
www .syntacoll .de/da tenschutz
(bX5) -PCP.
Sent : Mo n, 27 Apr 2020 12:33:44 +0000
To: Jeremy Farrar
Subject: RE:NAS Annual Meeting Session on COVID-19-- Information regarding your
Saturday April 25 part icipati on
Thanks, Jeremy. I saw the report in the Post from Saturday. These children had
mostly respiratory disease and diarrhea . I wi ll check with t he docs at DC
Children's Hospital about the presence of " mult isystem inf lammatory state". This
could just be the advanced stage of their disease compatible with advanced
SARS-COV-2
Best,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
have received this e-mail in error please inform the sender and dele te it from your mailbox or any
From: Jeremy Farrar

_________
.... (b)(6)
Sent : Monday, Apri l 27, 2020 7:38 AM
To: Fauci, Anthony (NIH/NIAID) [E] _____ --,a(b.~=
,...
c6)>; Dzau, Victor J.<VDzau@nas.edu>; George
GAO (b)(6)>
(b)(6)
; Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia
========-=-~(b)( >; Teresa Miller de Vega (b)( >;
(b)(6); Rebeka Yasmin - CEPI (b)(6); ben.tinker@cnn.com;
----
Amanda.Sealy@cnn.com; Neel.Khairzada@turner .com; Tia.Miller@turner.com; -----~= (b) (6)
McGinnis, J. Michael <MMcGinnis@nas.edu>; (b)(6) Mun, Jenny
<JMun@nas.edu>; (b)( Redfield, Robert R. (CDC/OD) (b)( '>
Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25
participation
Thanks Tony- have asked for that and wi ll share as soon as I can.
I believe the re have been reports in the Washington Post.
https://www .washingtonpost .com/local/new-dc-hospital-numbers-suggest-kids-do -face-some-risk-

of-coronavi rus-hospitalization/2020/04/25/Se 78c268 -86fe-11ea-878a-86477 a724bdb story.html
From: "Fauci, Anthony (NIH/NIAID) [E]" <f CbH6)

>
Date: Monday, 27 April 2020 at 12:36
To: Jeremy Farrar (b)(6) , Victo r Dzau <VDzau@nas.edu >, Geo rge Gao
(b)(
Cc: Ric hard Hatchett (b)(6)
" ann n, Emma" <EHannon@nas.edu> , "Conrad,

Patricia (NIH/NIAID) [E]" Cb)<>, Teresa de Vega
---------- -------------
(b) (6)
Cb>< , Rebeka Yasmin - CEPI
"ben.tinker@cnn.com" <ben.tinker@cnn.com>,
"Amanda. Sealy@cnn .com " <Amanda.Sealy@cnn.com >, "Neel. Kha irzada@turne r.com "
<Neel.Khairzada@turner.com >, "Tia.Miller@turner.com " <Tia .Miller@turner.com >,
(b)(6) "McGinnis, J.Mic hael" <MMcGinn is@nas.edu > ,
(b)(6)"Mun , Jenn y" <JMun@nas.edu>,
CbH6)"Redfield , Rob ert R. (CDC/OD)"
(b)(6)r------------
Subject: RE: NAS Annual Meeting Session on COVID-19-- Information regarding your
Jeremy:
Thanks for the heads up. Is t here any more detailed description of the precise
clinical manif estation s? They describe a "mul t isystem inflammatory state 11 • It is
vasculitis or anything more specific? Could be an infectious agent that has
nothing to do with SARS-CoV-2 infection even though some children are
circumstantially infected with SARS-CoV-2orit could be a post-SARS-CoV-2
inflammatory syndrome , perhaps a Kawasaki syndrome-like disease. Please keep
me informed if you hear any further information.
Best regards,
Tony
Director
Phone: Cb)(6)
FAX: (301) 496-4409
(b)(6)
E-mail
---------
From: Jeremy Farrar ________ (b

_)_(_
6)>
To: Fauci, Anthony (NIH/NIA ID) [E]-------
_______ ~=
(b
_H_6); Dzau, Victor J.<VDzau@nas.edu>; George
GAO (b)(6) >
Cc: Richard Hatchett (b)(6)
--=====~--~--~--~:----:--~
____
"':""""-:---"".'"":"-:.:=======-~~
(NIH/NIAID)[E]
_,,
(b)(6)· Rebeka Yasmin - CEPI
Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia
(b)(6) Teresa Miller de Vega
(b)( >; ben.tinker@cnn.com;
Amanda.Sealy@cnn.com: Neel.Khairzada@turner.com; Tia.Miller@turner.com;
(b)(6) ;
(b) (6);
McGinnis, J.Michael< MMcGinnis@nas.edu>; (b)(6)> ; Mun, Jenny
<JMun@nas.edu>; (b)(6)
Subject: Re: NASAnnual Meeting Session on COVID -19 -- Information regarding your Saturday April 25
pa rticipat ion
To be aware of - news over night so a huge amount of uncertainty - important for COVID19now, and a
potenti al concern for how we view immunity, protection, post-infect ious immunopathology.
https://www .hsj.co.uk/acute-care/exclusive-national-alert-as-coronavirus-related-condition-may-be-
emerging-in-children/7027496.article
https://t.co/Bj6YHU8zi
From: "Fauci, Antho ny (NIH/NIAID) [E]" (b)(6)

Date: Sunda y, 26 April 2020 at 19:52
To: VictorD zau <VDzau@nas.edu >, George Gao ______ ...--------~ =
Cc: Jerem y Farrar (b)( 6} , Rich ard Hat chett _________ (b
_>_<6)
_
"Hanno n,
E mma" <EHan non@ nas.edu >, "Conrad , Patricia (NIH /NIA ID) [E]" (b) (6)>,
Teresa de Vega (b) (6)>, Rebeka
Yasm in - CEPI (b)( , "ben. tinker@cnn.com " <ben. tinker@cnn.com >,
"Amanda.Sealy@cnn.com " <Amanda.Sealy@cnn.com >, "Neel.Khairzada@turner.com "
<Nee l.Khairzada@turner .com >, "T ia.Mi ller@t urner.com " <Tia .Miller@turner.com > ,
(b)( 6) "McGinni s, J.Mi chael" <MMcG innis@nas.edu >,
----------------
CbH6)
>, "Mun, Jenny" <JMun@nas.edu>,
(b)( 6)
Subject: RE : NA S Annual Meeting Sess ion on COVID-19 -- Information regardin g your

Saturda y April 25 participation
It was a real pleasure to join all of you on this important session. Many thanks for
inviting me.
Director
Phone Cb)
(6)
FAX : (301) 496-4409
E-mail
-------- (b)(6)
From: Dzau, Victor J.< VDzau@nas.edu>

To: George GAO (b)(6)
Cc:Fauci, Anthony (NIH/NIA ID) [E]----------------~~
; Hannon ,
Emm a <EHannon@nas.edu >; Conrad, Patricia (NIH/NIA ID) [El
-------------------------
McGinnis, J.Michael< MMcGinnis@nas.edu >;
(b) (6) ben.tinker@cnn .com;
Amanda.Se aIy@ cn n.com ; Neel.Khairzada@turner.com ; Tia.Miller@turner.com ; (b)(6)
(b)(6J>; Mun, Jenny
------ (b)(6); haja.bally@cepi.net

Subject: Re: NASAnnual Meet ing Session on COVID-19 -- Informat ion regarding your Saturday April 25
participation
Dear Jeremy, Tony, Sanjay, George, Susan and Richard,

Than k you so much for your sup erb contributions. It wa s a spectacular sessi on- a tmly inspirin g
one . I am grateful to all of you .
Hop e to see you soon .
Warm est regards,
Victor
On Apr 25, 2020 , at 1:22 PM, George GAO
------- > wrote:
CbH6)
I am waiting for being connected and w ill use slides which were sent to your office
George
~§ ilt1¥-JiPhone
1±2020~4 Fl24 B . 0 l :49, Dzau , Victor J. <VDzau @nas.edu>

~Ji:
I'm really looking forward to this panel on COVID-19 at the NAS Annual
Meeting on Saturday, April 25th at 2:00-3:30 pm ET. There is tremendous
excitement and enthusiasm, and registrat ion is through the roof.
I am sending this note to do a last minute check to see if there is anything you
need from me . I also want to check whether you are planning to use slides.
Will you be sending your slides to us to project or use the share screen
feature to advance your own slides? Regardless, it would be helpful to me if
you could send me your slides for my preparation.
I would greatly appreciate it if you wou ld respond to this email.
Best,
Victor
PS, (b)(6) my special assistant, will be sending you additional

information about the session logistics short ly.

Sent: Thursday, Apr il 9, 2020 11:01 AM
(b)(6); 'ben .tinker@cnn.com ' <ben.tinker@cnn.com >;
----------
'Amanda.Sealy@cnn.com ' <Amanda .Sealy@cnn.com >;
'Neel. Khairzada@turner .com' <Neel.Khairzada@turner.com >;
'Tia.Miller@turner .com' <Tia.Miller@turner .com>; 'hujr@chinacdc.cn'
(b)(6)
Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information
regarding your Saturday April 25 par t icipa t ion
Dear all,
Thank you for agreeing to participate in a special late breaking session

on the COVID-19 pandemic at the NAS annual meeting. Knowing how
busy you are , I am sending this email in lieu of a call to prepare for the
session.
As you know, this is a 90 minute session which aims to provide our

audience with deeper insights into the latest developments in the
COVlD-19 response. I plan to hold an engaging discussion that covers
the whole experience on dealing with this pandemic - from US to
international, to preparedness and response, the biology of the virus, the
state of diagnostic , treatment and vaccine development , and the
importance of commun ication.
I will begin the session by providing brief (~3 min) opening remarks
describing the circumstances of the pandem ic. Then , I will introduce the
panelists and you will each have 7 minutes to provide remarks. You
may use a limited number of slides for illustration . I hope that each
panelist will provide their own perspective and speak to the issues
proposed below.
• Jeremy Farrar will discuss the global response to the pandemic,
drawing from his experience as a global leader, the chair of the
Scientific Advisory Group for the VvHO's R&D Blueprint and as
a member of the Global Preparedness Monitoring Board .
• Tony Fauci will discuss the US pandemic and provide his
perspective as a member of the White House Coronavirus Task
Force addressing the 2019- 20 coronavirus pandemic.
• George Gao will discuss China 's response to the pandemic and
lessons learned for the rest of the globe.
• Susan Weiss will discuss the viral characteristics of SARS
COV2, insights into its pathobiology, immunity and
development ofa pan-CoV antiviral.
• Richard Hatchett will discuss the development of new vaccines
and treatments against COVID-19.
• Sanjay Gupta wtll comment on the health system response to the
pandemic and challenges related to communication and public
engagement in responding to COVID-19.
Following remarks from each panelist, we will have a moderated
discussion amongst ounelves - I will ask you a set of questions ( 15
mins) and then we will take questions from the web (25 mins). To
prepare me to be your moderator , please send me any questions you
would like me to ask you. For those of you who would like to have a
prep call, please let me know and I will set it up.
Best,
Victor
From: Mun, Jenny

sent: Wednesday, April 8, 2020 10:56 AM
To:
(b)(6)
'ben .tinker@cnn .com' ; 'Amanda .Sealy@cnn.com'
; 'Nee l.Khairzada@turner.com'; 'Tia.Miller@turner .com'
Subject: NAS Annual Meeting Session on COVID-19 -- Information regarding
your Saturday April 25 participation
Dear Speakers:
I am the logist ical contact for the COVID-19 session that will be held as part of
the Ann ual Meet ing (online) program on Saturday, Apri l 25 at 2:00 pm EDT
Thank you for agreeing to participate in this session. To help you with your
planning, I have provided additional details below .
Please note that the session wi ll be live webcast and the general publ ic will
also be able to watch t he session. Video from the session will also be
uploaded on the NAS YouTube channel
(https://www.youtube.com/user/theNASciences ) after the meeting. We will
need to obtain signed speaker release forms for your participation in this
session. I have attached the speaker release form for your review and
submission. Please return the signed speaker release form by Monday , April
13.
Session speakers are asked to connect 30 minutes prior to the session start
time (by Saturday , April 25 at 1:30 pm EDT) to allow the technical staff to
check connect ions and prepare for the session. Detai ls on how to connect will
be sent before t he meeting .
We w ill list you in our promotional materials as noted below . If this is

incorrect , please let me know .
Anthony S. Fauci, Directo r, National Institute of Allergy and Infectious
Diseases
George F. Gao, Director-General, Chinese Center for Disease Control &
Prevention
Sanjay Gupta, Chief Medical Correspondent, CNN
Susan R. Weiss, Professor of Microbiology , Perelman School of Medicine,
Since many of us have moved to remote work environments, you may

already be proficient with Zoom and other on line meeting/collaboration
applications . I am attaching a 'speaker guidelines' file in case you have any
questions on how best to prepare for and stage your remote talk. We have
technical staff available to help you become familiar with Zoom and its
settings - such as "sharing your screen" (if you have slide presentations that
need to be shown during your talk). We can arrange for a training session this
week or next week. If you wou ld like to schedule a session, please let me
know as soon as possible.
Dr. Dzau's office will be in touch regarding the agenda for this session. If you
have any othe r questions , please let me know.
Regards, Jenny
********************~***********
Jenny Mun
Membership Director
jmun@nas.edu
(b)(6)
Sent: Sun, 26 Apr 2020 18:45:27 +0000
(b)(6)
Subject: SNL revi ew
OKAY, so here is something even better than having Brad Pitt portray me on
SNL. It is a recent review of Pitt ' s performance in which the TV reviewer said :
" Kicking things off, the Oscar winner dropped jaws during the cold open with
his monologue about President Donald Trump's recent (and concerning)
comments about COVID-19.
"Good evening, I'm Dr. Anthony Fauci," Pitt began his monologue and looked
nearly identical to the director of the Nationa l Institute of Allergy and Infectious
Diseases."
Someone said Pitt looked "nearly identical" to me. Yikes!! Q

Director
Be thesda, MD 20892-2520
Phone: Cb)(6)
FAX : (301 496-4409
E-mail: (b)( 6)
information . It should not be used by anyone who is not the orig inal intended recipient . If you
Sent : Sun, 26 Apr 2020 18:37:57 +0000
To: Barnes, Freddie
Subject: RE:Appr eciation
Freddie:
Many thanks fo r your kind note . It is much appreciated .
Best regar ds,
Tony
Director
Phone : (b)(6)
FAX: (301) 496-4409
E-mail : Cb)(6)
From: Barnes, Freddie <freddie.barnes@ncdps.gov>

Sent: Sunday, April 26, 2020 10:48 AM
To: Fauci, Anthony {NIH/NIAID) [E] ------~~ (b)(6)>
Subject: Appreciation
Dr. Fauci I just wanted to express my profo und appreciat ion to you for your work during this COVID-19
pandemic. I especially appreciate how you have spent considerable time and capital reaching out to the
Black and brown communities. I saw exerts of your snapchat w ith W ill Smith and saw nearly all of your
interview on the Breakfast Club. I regret I have to send an email to you re this matter. But t his is the
day we live in. Minority communities continue to be over-looked in crises and the impact of such crises
on their respective communities. For you to be int entional about keeping the minor ity communities in
th e loop is commendable, especially since these communities will be absorbing the disproport ionate
share of the sicknesses and deaths coming from COVID-19.
Thanks for all of what your are doing in keeping the nation informed. Thanks for informing based on the
facts, data, and truth.
Take care and "Cover your six."

Email correspondence to and from this address may be subject to the North Carolina Public Records Law and may be disclosed to third
parties by an authorized state official.
Sent : Sun, 3 May 2020 13:29:53 +0000
Adams, Jerome (HHS/OASH) --------~~ CbH6)
1Giroir, Brett
To :
(HHS/OASH)
----------
Cc: (b)(6)
Subject : RE: High touch points
(b) (5)
From: Adams, Jerome (HHS/OASH)

Sent : Sunday, May 3, 2020 7:37 AM ---------
To : Fauci, Anthony (NIH/NIAID) (E]------ ~=
(b) ( ">
(HHS/OASH)
Cc:
(b)(6)>
CbH6J
(b)(6J>;
---------- (b)( ; Giroir, Brett
Subject: Fwd : High touch points
Please see short thread below. Senator Young reached out to me about this and I forwarded to CDC. As
(b)(5
Jerome
VADM Jerome Adams

20th US Surgeon General
From: "Adams, Jerome (HHS/OASH)" >

--------- (b)(
0 at e: May 3, 2020 at 7:32:46 AM EDT
Cc: "Schuchat, Anne MD (CDC/OD)"

Subj ect : Re: High touch po ints
__
To : "Jernigan, Daniel B. (CDC/DDID/NCIRD/1 D)"
.;._.:...::~~---
(b)(6)
(b)(6)>
Thank ou. (b) (5)

(b) (5)
Please keep me posted . And should I refer the senator to you or someone at CDCto close
the loop?
Thanks!
J
VADM Jerome Adams
On May 2, 2020, at 7:08 PM, Jernigan, Daniel B. {CDC/DDID/NCIRD/ID)
------ (b)(6)> wrote :
ADM Adams:
Thank s for sending this. There has been a lot of guidance on disinfection and
cleaning, notably some very recent collaborative work we have done with
EPA(https://www .cdc.gov/coronavirus/2019-n cov/communi ty/ reo pen-
guidance.html) . Attached are two documents focused on re-opening America
with emphasis on cleaning and disinfection, including high-to uch surfaces.
Also below are a number of websites that address cleaning and disinfection
which point out the importance of disinfecting high-touch locations like
doorknobs. They give guidance how to clean them, but they don't address
methods fo r using a paper towel or Kleenex to first turn the knob and then
discard the towel. (b)(5)
Thanks
Dan.
Daniel B. Jernigan, MD MPH

Director, Influenza Division; HHS CDC Lead, FEMA-HHS COVID-19 Response
Captain, USPHS(RET)
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
1600 Clifton Rd NE, Atlan ta, GA 30329
Phone (b) (6) , Cell (b) (6)
(b) (6) www.cdc.gov/flu
-------
https://www.cdc.gov/coronavirus/2019-ncov/community/disinfecting-
bu ildi ng-facil ity. html
https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-
sick/disinfecting-your-home.html
https://www.cdc.gov/ coronavirus /2019-ncov / community/disinfecting-
bu i ldi ng-facil it y-H.pdf
Sent : Friday, May 1, 2020 5:35 PM ---------

From : Adams, Jerome (HHS/OASH) (b) (6)>
To:
Cc:Schuchat, Anne MD {CDC/OD)
__ .:.._~~~---
Jernigan, Daniel B. (CDC/DDID/NCIRD/ID)
> (b)(
Subject: High touch points
Dr. Jernigan,
I got a message from a Senat or asking why we didn't have specific reopening
recommendations for "high touch" points like door knobs/ handles/ elevator
buttons . The Senator sta ted that (b) (5)
Jerome
VADM Jerome Adams, M D, MPH
20 th U.S. Surgeon General
<Reopening_America_Guidance.pdf>
<ReOpening_America_Cleaning_Disinfection_Decision_Tool.pdf>
Sent : Thu, 30 Apr 2020 22:37 :05 +0000
To : Hahn, Stephe n;Debi Birx;Redfie ld, Robert R. (CDC/OD);Verma , Seema (CMS/OA)
Subject : RE:Serology Studies in Germany
Than ks, St eve !
Director
Phone: (b)(6)
FAX: (30 496"44 09
E-mail: (b)(6)
From: Hahn, Stephen (b)( •>

To: Debi Birx
Seem a (CMS/OA )
(b)(6)
(b)(6l>; Redfi eld, Robert R. (CDC/OD)
---------
(b)( >; Fauci, Anthony (NIH/NIAID) [E)
(b)( ,
Subject: Fwd : Serology Studies in Germany
Interesting information from Germany
From: Shuren, Jeff

---------
Date : Apr il 30, 2020 at 5:46 :27 PM EDT
(b) (6)>
___ ....:,__:...,__..!:::=~~~--
To : Hahn , Stephen
--........!=====~~---
(b)(6J>, Shah, Anand
(b)( >, Guram, Jeet
Lenihan , Keagan
>, Rom, Colin (b)(
(b)(6J>,
======== (b~)(~6)~>--
Subject: Serology Studies in Germany
FYSAregarding serology studies being conducted in Germany, including status of tests to be used for
t hose studies. This is the follow up to what I sent you last week . (b)( 5
From: Hoshi, Ryan (b)(6)
To: Shuren, Jeff (b)(6)
Cc: Nalubola, Ritu (b)(6); louati, Claudia (FSN)*
.:=:::::========~~ .;.....!:::========~;;-"
O'Leary, Brendan
StenzeI, Timothy
(b) < >; Torres, Melissa A
(b) ( > -----------
Subject: FW: PLEASEREVIEW» Meeting Notes - Call with (b)(5
(b)(5)
(b)(S )
(b) (5)
Thank you,
Ryan
.,______
Ryan A. Hoshi , Ph.D.
Int ernat ional Po licy Analyst
(b) (6)1 mobil e
I Center for Devices and Radiological
Cb)(6)
Health I_______ Cb
.., .., I phon e
.).,..,
(6)
U.S. FOOD& DRUG

ADM IHISTUTION
Excellent customer service ,s ,mporta~t to us
Please take a moment to provl:fe feedback regarding the customer service you have received
click here for survey
Sent : Mo n, 27 Apr 2020 14:14:36 +0000
To: Halkovich, Townshe nd Connie
Subject : RE:Appr eciation to my hero --Dr. Fauci--our country 's voice of reason in th ese
unsett ling, uncertai n t imes--We NEED YOU!!!! Please don' t leave us now wh en w e need you most!!!
Conn ie:
Many t hanks fo r you r kind note . Mu ch appreciat ed .
Best regards,
Tony
Director
Phone: (b)( 6)
FAX : (301 496-4409
E-mail Cb)(6)
From: Halkovi ch, Towns hend Connie (b)(6)

Sent : Monday , April 27, 2020 9:04 AM
To : Fauci, Anthony (NIH/NIAID) [E]______ (b
""'~""'(6)
= >
Cc: Halkovich , Tow nshend Connie (FDA/OC) (b)(6)

Subject: RE:Appreciat ion to my hero -- Dr. Fauci--our country 's voice of reason in these unsett ling,
uncertain t imes--We NEEDYOU!!!! Please don 't leave us now w hen we need you most!!!
Wher e is Dr. Fauci?

I know where Dr. Fauci is-I saw him on SNL- remarkably he looked like Brad Pitt - except [to many of
us] Dr. Fauci is better looking . Smile, wink Why? We look with our hearts
I remember someone asked Dr. Fauci [in jest ] who would he like to represent him in a movie ...Dr. F. said
Brad Pitt . Well - Dr. F. Your dream suggesti on came t rue. But, in ma ny of ou r hear ts- NO ONE can take
t he place of our beloved , we ll respected, honored Dr. Anthony Fauci !!! !
God Bless Amer ica, God Bless Dr. Fauci !! !
From: Halkovich , Townshend Connie (b) (6)>

Se nt : Friday, Ma rch 13, 2020 11:06 AM
To: 'anthony .fauci@nih.gov ' (b)(6)
Cc: Halkovich , Townshend Connie <Constance.Halkovich@fda.hhs.gov>
Subject: Appreciation
Dear Dr. Fauci:

1st & foremost - please keep you rself healthy ....get more rest than 3 hrs/nigh t.© Why? We need you!
THANK YOU for all you r very informat ive updates . YOU are voice of reason...in t ime of coronavirus
fear ...you give us hope ...saying that action is what is needed ... not fear!
You are someone w e can be proud of ...you provide service we can coun t on!!!!
God bless You & Your Family!! !
Warmest Regards from:

Connie Leigh Townshend Halkovich, Management Analyst, 410-867 -0878,
#FDA OIMT D10 Proud: Peo le & Service ou can count on!©
(b)(6)
My Wish 4 U: Peace, Love. Laugher -blessed Z work with U ALL! Abe Lincoln: "folks are as happy as they choose 2be" -B
happy all circumstances -H ope all well with you, yours--ifnot, pretend it is.
FDA M ission: Responsible for protecting public hea lth by ensuring safety, efficacy/sec urity of human & vet. drugs, biol. products, med.
devices, aur nation 's food supply, cosmetics, & products that emit radiation.
D10 Mission: -Provide excellent implementation, aperatian , maintenance of IT {equipment, services} to promote FDA's Public
Health Mission.
D/0 Vision: Provide state -of-the -art IT services-inclusive of surrounding policy, planning, customer service, in tegration, &
oversight necessary to make the mission successful & sustainable.
From : Fauci, Anthony {NIH/N IAID) [E)
Sent : Tue, 5 May 2020 22:26:27 +0000
To: Foikers, Greg (NIH/NIAID) [E);Billet, Courtney (NIH/ NIAID) [E];Stover, Kathy
(NIH/N IAID) [E);Routh , Jennifer (NIH/N IAID) [E];Awwad , David (NIH/NIAID) [C]
Cc: NIAID OD AM
Subject : RE:ASF RE: Dr . Fauci video reque st: Public Service Recognit ion Week
Attachment s: ASF pub lic service recognition - w ith tracked edits -05-0 5-2020 .docx
0
See minor tr acked changes.
Director
Phone : (b)(6)
FAX : (301) 496-4409
E-mail Cb
) (6)
From:Folkers, Greg (N IH/ NIAID) [E] CbH >

Sent: Tuesday, May 5, 2020 6 :16 PM
To : Billet, Courtney (NI H/NIAID) [E] -----~ ~H=6)>; Stover, Kathy (N IH/NIA ID) [E]
Cb
; Routh, Jennifer {NIH/ NIAID) [E]
CbH6J> CbH
6>1;Awwad,
David (NIH/NIA ID) [C] CbH6J>
Cc: NIA ID OD AM <NIA IDODAM@niaid.n ih.gov>
Subject : ASF RE: Dr . Fauci v ideo request: Pub lic Service Recognition Wee k
ASF-
Here is a sho rt script for Public Serv ice Recognition Week . We agreed to do a short video
ASF - can u tweak as needed?
David, could u record in some format that is easy? Cell phone or other I just learned they want by COB
tomorrow
<< File : ASF public service recogn ition.docx >>

From: Seigfreid , Kim (NIH/OD) [E] CbH6J>
Sent: Monday, Apri l 27 , 2020 4:30 PM
To : Billet, Courtney (NIH/NIAID) [E] --------=-~ (b)(6J>; Stover, Kathy (NIH/NIA ID) [E]
---------
Cc:
Routh, Jennifer (NIH/ NIAID) [E]
(b)(6)>;
Fine, Amanda (NIH/OD) [E]
(b)(6)>
Cb)( >; Polimeni, Lydia (NIH/OD) [E]
(b)(6)
Subject : Dr . Fauci video requ est : Public Service Recognition Week
Hi there,
Please see below. HHS is taking over the Partnership for Public Service IG accoun t next week for Public
Service Recogn ition Week . They asked if Dr . Fauci would be willing to do a short 30-second or less pre-
recorded video thanki ng public servants for their work . It would be featured during the takeover , and also
on NIH's other sm handles next week . It can be taken on a cell phone as sm does not require higher
resolution . Let me know if you would like to accept or decline the request.
Many thanks ,
Kim
Kim Seigfreid
Social Media Lead
NIH Office of Communications and Public Liaison
ph: (b)(6)
(b)(6)
From: Muhammad, Janell (HHS/ ASPA) (b)(6),

Sent : M onday, Apri l 27, 2020 4:10 PM
To: Seigfre id, Kim (NIH/OD) [E]
---------~~ ; Channer, Am ber (OS/OASH)
CbH6J>
---------- CbH6J>;Foster, Timothy (OS/ ASPA)

Cc: Palczewski, And rew (HHS/ASPA)
CbH6)>
CbH6J>;Pratt, Michael (OS/ASPA)
(b)(6J>; Sherman, Jennifer (HHS/OASH) (b)(6)
---------
Wi lker, Michael (HHS/ASPA) (b)(6); Dine, Brooke (HHS/ASPA)
(b)( 6)
Subject: Public Service Recognition Week
Hello All,
Hope eve ryone is ho lding up well !
OHR is taking ov er the Partnersh ip for Public Service (PPS) lnstag ram account during Public
Service Recognit ion Week (May 3-9, 2020). The OHR team has reached out about want ing to
develop a senio r leade r " mashup " video -perhaps including the DepSec. T
They asked about the feasibility of this request. They also inquired about perhaps Dr. Fauci and
the SG doing a pre-recorded video thank ing public servants for their work.
I wanted to gathe r the troops so we can identify what all is being planned for this week of
recognition and provide a POCfor OHRif the request is feasible .
Happy to set up a call, if tha t is needed to discuss further .
Thanks,
Janell
Janell Muhammad
ASPA Digital Engagement (Team Lead)
Email: (b) (6)
Office: (b) (6)
iPhone: Cb)
(6)
HHS on Facebook I HHS on Twitter I HHSLatino
Sent: Tue, 5 May 2020 21:58:55 +0000
To: Adams, Jerome (HHS/OASH)
Subject: RE:Update on Sara Alert
------------------------ (b) (5)

What do you mean by
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
From: Adams, Jerome (HHS/OASH)

Sent : Tuesday, May 5, 2020 2:49 PM ---------
To: Birx, Deborah L. EOP/NSC --------
(b)(
""'
Cb
.H"""'
>
.,...6J ; Fauci, Anthony (NIH/NIAID) [E)

(b)(6)>
Subject: FW: Update on Sara Alert
Importance: High
(b) (5)
Jerome
VADM Jerome Adams, M D, MPH
20th U.S. Surgeon General
From: Jarris, Paul (b)(6J>

To: Adams, Jerome (HHS/OASH) -------~~ CbH6)>
...;..::=======-~:a;-
Cc: W right, Janet (HHS/OASH)
---------- CbH6)
Subject: Update on Sara Alert
Importance: High
Dear Jerome,
I hope you are well. Thank you for all you are doing to represent public health and our nation. It is very
comforting knowing you are informing the nations COVID-19 response.
I wanted to give you an update on called Sara Alert, the software program I am leading at MITRE. Sara
Alert is being provided free of any costs and deployed in state, tribal, and local health departments to
support public health in contact tracing and active monitoring of individuals in isolation and quarantine.
We are engaged with ASTHO, NACCHO,CSTE,and the application is hosted live on APHL's AIMS
platform. Sara Alert officially launched on April 3 and is currently supporting multiple jurisdictions
including Commonwealth of the Northern Mariana Islands, Danbury, CT, and the State of Arkansas. It is
also being rolled out in Washington, Arizona, Pennsylvania, Virginia, Maine and Vermont. We are getting
ready to launch in additional jurisdictions over the next couple of weeks.
We have recently responded to questions we were told came from the White House so I wanted to
make sure you have background materials. I imagine you are the person that the President and Vice
President would turn to for information. I am happy to arrange any briefing mater ials or demo that
would be helpful for you to respond.
As I mentioned previously, Sara Alert is a standards -based, open source tool that automates the process
of mon itoring individuals exposed to or infected w ith COVID-19 (or any disease, it's configurable) - and
wi ll serve as an enduring national resource to contain disease. Sara Alert is free for use by public health
organizations.
Best wishes to you. Stay healthy for all of us.
Paul
ABOUT SARA ALERT

In response to the COVID- 19 pandemic, the MITRECorporat ion, a not-for-profit that works in the publ ic
interest, developed Sara Alert, a standards-based, open source tool in partnership with national public
health organizations. Sara Alert automates the process of monitoring individuals exposed to or infected
with COVID-19 (or any disease, it's configurable) - and will serve as an enduring national resource to
contain disease. Sara Alert is free for use by public health organizations .
• Sara Alert allows public health officials to import and enroll individuals (or households) at risk of
developing or infected with COVID-19.
• Individuals enter their symptoms daily via web, text, email or phone, allowing public health
officials to focus on high risk and non-reporting individuals .
• The web-based tool enables increased efficiency in tracking cases, leading to earlier
containment of the virus and reduction of burden on public health resources.
• Sara Alert is a national system and allows transferal of monitorees across jurisdictions for tighte r
contact tracing.
Sara Alert launched on April 3 and is now supporting multiple jurisdictions .
Sara Alert YouTube Video : https://youtu.be/lQxAuNsg-RA
Paul E. Jarris, MD, MBA
Chief Medical Advisor
Health Transformation Center
MITRECorporation
(b) (bJj
(b) (6)] Off ice
====;::~
-----(b)( 6)] Mobile
From : Fauci, Anthony (NIH/N IA ID) [El
Sent : Sun, 3 May 2020 17:45:26 +0000
To : Lane, Cliff (NIH/NIAID) [El;Collins, Francis (NIH/OD) [El
Cc: Lowy, Douglas (NIH/NCI) [E);Mascola, John (NIH/VRC) [El
Subjec t : RE:Gallo and OPV
(b) (5)
Director
Phone: (b)(6)
FAX: (3 96':44li9
E-mail: (b) (6)
From : Lane, Cliff (NIH/NIAID) [El (b) ( >

--------
Se nt : Sunday, May 3, 2020 1:22 PM
To : Collins, Francis (NIH/OD) [El
-----~~ (b)( >
Cc: Lowy, Douglas (NIH/NCI) [El (b)(6) ; Fauci, Anthony (NIH/NIAID) [El
(b)(6) >; Mascola, John {NIH/VRC) [El
--------
Subject: Re: Gallo and OPV
(b)(6)>
Francis,
(b)( 5)
Cliff
On May 3, 2020, at 12:55 PM, Collins, Francis (NIH/OD) [El _______ Cb

_H_6) wrot e:
Hi all,
I'm a bit at a loss to know how to respond to Bob Gallo.
Francis
From: Gallo, Robert >

----------
Sent: Sunday , May 3, 2020 12:07 PM
(b)(
------~~
To: Collins, Francis (NIH/OD) (E] ..._______ Cb
_) _(6)
Subject: RE: Your query to Dr. Kadlec
Dear Francis,
It was a pleasure to hear from you, and yes, it has been a long time since we met or
even spoke. Moons ago I was set to write to you after reading your wonderful
book, but I ended up instead speaking with others about it. I should add at this
point that I did not quickly respond to your email of a few days ago because I
simply missed it.
It is true that I strongly suggest that OPV be quickly (already it is not quickly)
brought forward for induction of a strong innate immune response to prevent or
markedly reduce SARS-CoV-2infection and/or severity until the field obtains a
proven safe and efficacious vaccine producing a long lasting, adaptive immunity .
OPV is very safe (notably for OPV 1 and 3 as bOPV which we will use and
completely safe in a vaccinated population), simple, cheap, rather obvious, yet
unique among the massive number of vaccines many (maybe most) of which are
the same or at least if not exactly the same aiming at the same mechanism
(targeting the spike and searching for the putative correlate of neutralizing Abs.).
OPV should work for a few months and possibly longer. Also it should be working
multip le times so I think could cover more than a few months, giving us time for a
proven vaccine of adaptive immunity, which might be very long lasting as is hoped.
In the main the WHO comments are correct. Of course we sought and have letters
of support from them as well as from many others . Though they are again
supportive in their notes to you, there is one item that surprises me. They add
that there was no clinical efficacy results as yet. They know or certainly should
know that there is plenty of clinical data for this concept with BCG,OPV, and live
Measles vaccine. Needless to say this is what turned me on during our regular
Global Virus Network (GVN)conference calls. (Incidentally GVN is an organization I
have thought of bring ing to your attention. I th ink you would find it impressive and
useful) . I would be happy to share with you the clinical observations with OPV if
you wish.
I would like to take a small diversion, but I suspect you are aware of these things.
My colleagues and I respect the WHO because of its representation and because
we have colleagues/friends there as well. However, sometimes bureaucracy of a
massive degree leads to inaction or even much worse-- political expediency. I won't
bother you with details of these unless you ask, but I had such experiences with
HTLV-1 which we discovered in 1980 as the 1st human retrovirus and which cause
not only the highest incidence of cancer(% of infections) of any virus and other
fatal diseases as well but mainly in less developed countries (plus Japan) and again
with HIV in 1984. Behavior was not beneficial. Perhaps it will be of relevance in the
future because a few at WHO took a position to remove OPV (Sabin) in favor of IPV
(Salk) in their polio eradication scheme. It was a huge failure. As my FDA
collaborator, Konstantin Chumakov, says "Blessed be Bill Gates" because he saved
OPV and saved the day and in so doing has produced a still better OPV.
There is indeed data also for BCGas well as live Measles though I know less of the
latter. BCG is less available, requires injection, harder to make, not as safe, and we
think unlikely to be as effective as OPV. Nonetheless, we favor its use too. The
mechanisms will be similar.
You asked whether monkey trials are planned. For several reasons definitely not --
though we are planning some monkey experiments, but not large enough for
"clinical" conclusions. The main reasons are: 1) cost; 2) that billions not thousands
or millions have received OPV safely and in our collective view (and we know the
studies pretty well) protection has been clinically shown; 3) In a pandemic we
wished to move quickly (so far we must say that has not been achieved). A typical
monkey vaccine study will take time, but 4) in this case it would be a huge amount
of lost time as monkeys require great doses of polio for infection and monkeys
have to be trained to drink their orange juice. It would be hard to imagine that such
studies would even give us useful information.
On a final digression Francis I have had 36 years of on/off experiences with

glycosylated spike proteins-their analyses immunologically and especially
regarding use in vaccines and developing neutralizing Abs. I believe it will be a
mistake to put most eggs in that basket. The risks: shortened antibody half life; 2)
protection NOT correlating with neutralizing Abs; 3) sometimes hazards from them.
Admittedly, they might work, but I trust and hope that not everything is going in
this bag. If you wish to discuss this again I will be available.
Finally, I hd no idea you were into vaccines or SARS-2nor any part of CoVID-19
disease, but I am very happy to learn this.
Thanks.
Bob Gallo
From: Collins, Francis (NIH/OD) [E] (b)( >

To: Gallo, Robert Cb)(6J>
Cc: Disbrow, Gary (OS/ASPR/BARDA) Kadlec,Robert
CbH6J>;
(OS/ASPR/I0) Cb)( >; Tabak, Lawrence (NIH/OD) [E)
CbH6J>; Shuy, Bryan (OS/ASPR/I0) Cb)( >; Johnson,
Robert (OS/ASPR/BARDA) Cb)( >; Mascola, John (NIH/VRC)[E)
(b)(6b ; Lane,Cliff (NIH/NIAID) (E] (b)(6J>
---------
Subject: You r query to Dr. Kadlec
CAUT ION; Tbis message 01iginnted from II oon UMB, UMSOM, FPI , or UMMS cmnil sys tem . Wheth er the
sender is known or not known, hover over any links before c]jcking and use caution opening attachments.
Dear Bob,
It's been quite a while since we've chatted. Bob Kadlec asked me to respond to
your query about the possible use of OPV to activate innate immunity and provide
COVID-19 protection. Has t his been tested in a non-human primate model? I note
the recommendation below that says a clinical trial is planned - can you tell me
more about that?
As you can imag ine, we are all flat out on the vaccine development pathway!
Franc is
The use of oral polio vaccine(OPV) to prevent SARS-CoV2(Polio Eradication

Campaign)
There is no ev idence that ora l poliovirus vaccine (OPV) protects people against
infection with COVID-19 virus.
A clinical trial address ing this question is planned in the USA, and WHO w ill
evaluate the evidence when it is available.
In the absence of evidence , WHO does not recommend OPV vaccination for the
prevention of COVID-19. WHO continues to recommend OPV as part of essentia l
immunization services to prevent poliomyeli tis and as part of global polio
eradication efforts.
There are experimental signals from various studies over the years that OPV has
non-spec ific effects on the immune system. These effects have not been well
charac t erized and the ir clinical relevance is unknown. Such non-specific effects may
not be limited to OPV, as other live vaccines have also been associated with non-
specific protective effects (such as BCGvaccine against tuberculosis). No n live
vaccines in contrast do not seem to have the same effects.
The exact mechanism of non-specific protection induced by live vaccines needs to

be elucidated f urther. Clinical studies could begin immed iately because the
vaccines in question are licensed and have an excellent safety record. Clinical tria ls
involving off-label use of various drugs licensed for other indications are currently
underway. The existing scientific rationale suggests that the same should be done
for OPV and other live vaccines. A study is currently be ing discussed with various
partners and vaccine manufacturers, including the US FDA,the outcomes of which
will be carefully assessed to determine potential use in the context of the spread of
SARS-CoV2 until the time when specific vaccines and antiviral therapies are ready.
From: Kadlec, Robert (OS/ASPR/10) (b)(6)

To: Gallo, Robert CbH6l;Collins, Francis (NIH/OD) IE]
(b)(6); Tabak, Lawrence (NIH/OD) [E] (b)( >; Shuy,
Bryan {OS/ASPR/10) (b)( >
Subject: Re: Respone
Dr Gallo thank you for your note and I appreciate you reaching out to me. I have copied Dr
Collins and Dr Tabak to consider the ACTIV forum they have created to br ing industry
academia and government to consider scientific base approaches That you have
described. Dr Collins has organ ized a vaccine group and I assess could be the best and
fastest place to discuss your concept. I am sure they will connect with you soonest
Best
Bob Kadlec.
Sent from my iPhone
On Apr 30, 2020, at 10:02 AM, Gallo, Robert

wrote: ---------- (b)(6)>
Dear Dr. Kaldec ,
I have not heard from you in over a week. You mentioned getting back
to me in a day or two. l ime is passing. I am asking you to look at OPV 1
plus 3 serotypes as a bivalent, completely safe vaccine with powerful
stimulation of innate immunity lasting several weeks, which can be
given a second or third time, and with a historical track record of
preventing other infections from entirely different RNA viruses (such as
protecting against influenza). Therefore, it should be really helpful for
some months, and I think get us past a second wave of SARS-CoV-2,
and help people return to work safely. I don't understand delays or
apparent lack of interest . Who can possibly be against this? If you hear
of hypothetical prob lems we can show you that these are false . Just
ask the questions, and we can give you the evidence.
However , no answer from you suggests no interest and must quickly

make alternative pathways. I am though quite surprised and fear you
are receiving "fake news" if you w ill pardon the expression . Some have
been against th is who defend their old and fai led position on polio
eradication w ith their promotion of the use of the inactivated polio
virus vaccine. Please note that in the US between 1962 and 1985 we
received (safely) the oral polio (OPV). Moreover, if vaccinated already
there has not been a single case of a complication and BILLIONShave
received it . No it will not last long as innate immunity is short lived, but
we strongly believe that we can break the back of the SARS-CoVID-2
spread. Also note that this is what Bill Gates is doing now in India and
much of the Eastern hemisphere .
There are countries outside the US wanting to move fast on th is. We

are waiting for your reply .
Robert Gallo
Director, Institute of Human Virology,
Professor of Medicine and Professor of Microbio logy,
UMB, School of Medicine , Baltimore,
And
Co-founder and International Science Advisor of the Global Virus
Network (GVN)
Sent : Thu, 30 Apr 2020 15:17:01 +0000
To : Collins, Francis (NIH/OD) [E);Mascola, John (NIH/VRC) [E);Lane,Cliff (NIH/NIAID)
[El
Subje ct: RE: Respone
Francis:
(b) (5 '
Thanks for th e not e. I will let Cliff speak for himself ,
(b) (5)
5> but I w ill let him speak for him self . We can discuss further if
Cb><
---------
you wish.
Best ,
Tony
Director
Phone: (b)( 6)
FAX: (301 496-4409
E-mail: (b)(6)
From: Collins, Francis (NIH/OD) [El
Sent : Thursday, April 30, 2020 10:58 AM -------
(b)(6)>
To: Mascola, John (NIH/VRC) [El ------~~ (b)( >; Lane, Cliff (NIH/NIAID} [El
(bH ; Fauci, Anthony (NIH/NIAID) [El (b)(6)•>
---------
Cc: Tabak, Lawrence (NIH/OD) [El (b)( >
Subje ct: FW: Respone
Hi John, Cliff, and Tony,
(b)(5)
Ignore the silly part of the message be low, where
. But let me ask you guys whether -:-~============~
~
Francis

To: Kadlec, Robert (OS/ASPR/10) -------..,,.,..., =
~======~~ >; Shuy, Bryan (OS/ASPR/10)
(b)(6); Disbrow, Gary (OS/ASPR/BARDA) (b)( >; Johnson, Alfred
(NIH/OD) [El (b)(6)
Subje ct: RE: Respone
Bob,
I I I I .: .. • • • • I I • I I I • I I• (b) (5)
.. • • I
Francis
From : Kadlec, Robert (OS/ASPR/10) (b)(6)

Sent : Thursday, April 30, 2020 10 :28 AM
To: Gallo, Robert (b)(6)>; Collins, Francis (NIH/OD) [El
Tabak, Lawrence (NIH/OD) [El
--------
(b)(6)> ; Shuy, Bryan (OS/ASPR/10)
(bH6J;
(b)(6)
Subje ct: Re: Respone
Dr Gallo thank you for your note and I appreciate you reaching out to me . I have copied Dr Collins and
Dr Tabak to consider the ACTIV forum they have created to bring industry academia and government to
consider scientific base approaches That you have described. Dr Collins has organized a vaccine group
and I assesscould be the best and fastest place to discuss your concept. I am sure they will connect
with you soonest
Best
Bob Kadlec.
Sent from my iPhone
On Apr 30, 2020, at 10:02 AM, Gallo, Robert wrote:

---------- (b) (6)>
Dear Dr. Kaldec,
I have not heard from you in over a week. You ment ioned getting back to me in a
day or two. Time is passing. I am asking you to look at OPV 1 plus 3 serotypes as a
bivalent, completely safe vaccine with powerful stimulation of inna t e immunity
lasting several weeks, which can be given a second or thi rd time , and with a
historical track record of preventing other infections from entirely differen t RNA
viruses (such as protecting against influenza). Therefore, it should be really helpful
for some mon t hs, and I think get us past a second wave of SARS-CoV-2, and help
people return to work safely . I don't understand delays or apparent lack of inte rest.
Who can possibly be against this? If you hear of hypothetical problems we can
show you that these are fa lse. Just ask the questions, and we can give you the
evidence .
However , no answer from you suggests no interest and must quickly make
alternative pathways. I am though quite surprised and fear you are receiving "fake
news" if you will pardon the expression . Some have been against this who defend
their old and failed position on polio eradication wit h their promotion of the use of
the inactivated polio virus vaccine. Please note that in t he US between 1962 and
1985 we received (safely) the oral polio (OPV). Moreover, if vaccinated already
there has not been a single case of a comp lication and BILLIONShave received it.
No it will not last long as innate immunity is short lived, but we strongly believe
that we can break the back of the SARS-CoVID-2spread. Also note that this is what
Bill Gates is doing now in India and much of the Eastern hemisphere.
There are countr ies outside the US wanting to move fast on this. We are wait ing for
your reply.
Robert Gallo
Director, Institute of Human Virology,
Professor of Medicine and Professor of Microbiology,
UMB, School of Medicine, Baltimore,
And
Co-founder and International Science Adv isor of the Global Virus Network (GVN)
From: (b)(6)
Sent : Wed, 29 Ap r 2020 13:39:44 -0400
Subject: Fwd: ASF: For review ASAP: draft Sec. Azar Remdesivir statement
Attachments : 4 29 20 remedesivir.docx, ATTOOOOl.htm
Cann ot do right now. Go without me
From: "Billet, Courtney (NIH/NIAID) [E]" (b)(6)

Date: April 29, 2020 at 1: 11: 19 PM EDT
To: "Fauci , Anthony (NIH/NlAID) [E]" --------=-::-:-=
Cc: "Routh , Jennifer (NIH/NIAID) [E]" (b)(6) , "Stover, Kathy
(NIH/ NIAID) [E]" (b)(6) "Lane, Cliff (NIH/NIAID) [E]"
(bH6) >, "Marston, Hil ary (NIH /NIAID) [E]"
(bH6) >, "Conrad,Patricia (NIH/NIAID) [E]"
(b)( >, "Folkers , Greg (NIH/NIA.ID) [E]"
(b)(6) >
Subject: ASF: For review ASAP: draft Sec. Azar Remdesivir statement
From: Fritz, Craig (NIH/OD ) [E] (b)(

To: Billet, Courtney (NIH/NIAID) [El -------= (b""" 6>r>; Stover,
)("=" Kat hy (NIH/N IAID) [El
(b)(6) Routh, Jennifer (NIH/N IAID) [ El (b)( >
--------
Cc: Burklow, John (NIH/OD) [El (b)( ; Myles, Renate (NIH/OD) [El
(b)(6) ; Fine, Ama nda (NIH/OD) [El (b)(6)>; Wojtowicz,
Emma (NIH/OD) [El (b)(6)>; NIH News Clearance (NIH/OD)
<NIHNewsClearance@mail.nih.gov>
Subject: FW: For review ASAP: draft Sec. Azar Remdesivir statement
Importance: High
Hi all - please let us know if you have any comments to the attached.
Thanks !
Craig
Fro m : Brennan, Patrick (OS/ASPA) (b)(6)>
To : Fritz, Craig (NIH/OD) [El CbH6J>; Burklow, John (NIH/OD) [El
(b)(6)>; Myles, Renate (NIH/OD) [El (b)(6); Fine,
Amanda (NIH/OD) [El CbH >; Wojtowicz, Emma (NIH/OD) [El
(b)(6)>; Charrow, Robert (HHS/OGC) (b)(6)
Cc: Pence, Laura (HHS/ASL) (b)(6J>; Hall, Bill (HHS/ASPA)
(b)(6);,; Pratt, Michael (OS/ASPA) (b)(6);,; Blakeman,
Scott (05/ASPA ) (b)(6)>
Subject : For review ASAP: draft Sec. Azar Remdesiv ir statement
NIH and Mr . Charrow,
Below and in the attached is a draft statement from the Secretary regarding the
Remdesivir trial - please let me know as soon as you can if this looks OK. (I pulled the
frontmatter from the NIH press release.) Thank you!
- Patrick
(b) (5)
Patrick Brennan
Director of Speechwriting
Office: Cb)(6) I Cell Cb)(6)
Frmn: Fauci,Anthony {NIH/NIAID) [E)
Sent: Wed, 29 Apr 2020 01:56:42 +0000
To: (b)(6)v
Eiubject: FW: DRAFTdocument for WH Briefing Tomorrow
Attachments: Development-Medical-Countermeasures-WH-B riefing 29 Apr il.pptx
Here it is.
From: Collins, Francis (NIH/OD) [E] Cb)( '>

To: Fauci, Anthony {NIH/NIAID) [E) ------ (bH > ==
Subject: FW: DRAFTdocument for WH Briefing Tomo rrow
Hi Tony,
Francis
From: Mango, Paul (HHS/1OS) CbH6)>

-------::-,--:=,
To: Collins , Francis (NIH/OD) [E] CbH6)>;Kadlec, Robert (OS/ASPR/1O)
CbH6)>;Fauci, Anthony (NIH/NIAID) [E] Cb)( >; Marks,
Peter {FDA/CBER) CbH6);Woodcock, Janet (FDA/CDER)
CbH >; Tromberg, Bruce (NIH/NI BIB) [E] --------~~ CbH6)
-----------
Subject: DRAFTdocument for WH Briefing Tomorrow
Thank you all for your timely responses for contributions to this today. Please give this a look
and let us know if there is anything glaringly out of place. We will have time to address edits
du ring and after our 930am check in tomorrow. The Secretary may or may not use page 1
du ring his introdu ctory remarks.
Sent: Sun, 26 Apr 2020 18:14:04 +0000
To: Gibbo ns, Gary(NIH/NHLB I) [E]
Cc: Koroshetz, Walt er (NIH/NINOS) [E); (b)(6) ;Auch incloss, Hugh
(NIH/N IAID) [CJ (b)(6) ;Coll ins, Francis (NIH/ OD) [E) (b)(6) ;Tabak,
Lawrence (NIH/OD) [E];Conrad, Patricia (NIH/N IAID) [E);Barasch, Kimberly (NIH/NIAID) [C]
Subject: Thrombotic phenomena in COVID-19
Gary:
In follow -up of our recent conversation regarding the growing evidence that the
extremely catastrophic course of many patients with COVID-19 seems to me
pathogenically associated with the find ings of microthrombi in the lungs and
often a mu lt isystem process resembling DIC. In addition, there have been
growing numbers of cases of indiv iduals (some young and otherwise healthy)
who have had unexplained strokes , only to find out t hat they actually have
COVID-19. I 5
(bH ~
(b)( 5)
I (bH 5l Thanks.
------
Best,
Tony
Director
Phon e: (b) (6)
FAX: (301 496-4409
E-mail: (b)(6)
From: Auchincloss, Hugh (NIH/NIAID) [E]on behalf of Fauci, Anthony (NIH/NIAID) [El
Sent : Sun, 26 Apr 202017 :42:12 +0000
To : NIAIDODAM
Subject: FW: Invitation to Webinar as keynote speaker.
I wou ldn't think so.
From:Secretary ARP (b)(6)>

Sent : Saturday, Apr il 25, 2020 2:07 PM
------- ~=
---------
Subject: Invitation to Webinar as keynote speaker.
(b)(6)
To,
Anthony S. Fauci,
Office of the Director,
Nationa l Institute of Allergy and Infect ious Diseases,
National Institutes of Health, 9000 Rockville Pike, Bldg 31, Room 7A03,
Bethesda MD 20892
Subject: Invitat ion to Webinar as keynote speaker.
Dear Sir,
On behalf of ASSOCIATIONOF REGISTERED PHARMACIST(An association working for Pharmacy

Profession and having more than 2000 membe rs) in collaboration with Divine Internationa l, Gwalior (A
Pioneer Pharmacy Institute) I am pleased to invite you to our Web inar having THEME "CHALLENGESAND
OPPORTUNITIESFOR PHARMACISTIN THE PRESENTEPIDEMIC COVID-19" that will be held from 2nd
May 2020 to 3rd May 2020. This Web inar is the get toge ther of Pharma professionals through the we b.
The vision of this Webinar is to Aware, Prepare and strengthen our Pharmacy professionals in our
country to th is epidemic COVID-19 for present and future aspect and exports more real istic ideas and
present scenario of this epidemic COVID-19.
You are one of the legends of Pharma Expert of our country, it is a great pr ivilege for us to see if you
share yo ur experience with us, we rea lly expect and want t hat you join our Web inar and share with us
th e great exper ience of you r life, we want to learn something from you so that we can create a great
ideas, opportunity, and roll of Pharma profession al for our country in th e present scenario .
We wou ld be pleased to have you present at th is point at this web inar to listen to what the role and
importance in the Pharmacist advancement and thei r impact on our society and daily life we would also
love to hear your thoughts and opinion about the Pharma professional that is a dream of our pharmacy
fraternity .
Therefore you are requested to send your recorded Lecture/ presentation of 30-40 min
Sincerely,
Thanks
RajeshSinghJadon
Secretary (National)
Association of Registered Pharmacists
Gwalior MP
Mob: (b)(6)
Sent : Sun, 26 Apr 2020 15:43:25 +0000
To : (b)(6)
Subject: RE (b) (6), (b) (4)
Attachments : (b) (6), (b) (4)
From:
-------------------
To: Fauci, Anthony {NIH/NIAID) [E]______ """
(b) (
(b""""
)(=6)
>
Subject: FW:
---------------
To work on at home
(b)(6), (b)(4)
From: Ulrich, Connie M (b)(6)

To: Cynda Rushton (b)(6)>; (b)(6)
Subject (b) (6), (b) (4)
Hi Christine and Cynda,
I finished my sectio n and unfortunately have to keep changing the COVID numbers! I will add some
thoughts to the last section . Not sure how much we can add there but maybe some reflections would
be helpful. Enjoy the sunshine today! I
Best.
Connie
From : Fauci, Anthony (NIH/N IAID) [El
Sent : Sun, 26 Apr 2020 02:57:3 1 +0000
Bee: Mascola, John (NIH/VRC) [El
-----~~
Subject :
------- (b)(6)
RE:agenda for Kadlec et al., Sun noon meeting
Francis:
Sorry that I took so long to respond . (b) (5)1,,.,
(b) (5)
(b)(5) [ et us connect
by phone first th ing in the A M>
Thanks,
Tony
From : Collins, Francis (NIH/OD) [El (b) (6)·>

Se nt : Saturday, Apr il 25, 2020 2:55 PM
To: Fauci, Anthony (NIH/NIAID) (El '°.
-----~~
._______ _H_~ ; Tabak, Lawrence (NIH/OD) (E]
Cb
(b)(6)>
Subject: RE: agenda for Kadlec et al., Sun noon meet ing
(b) (5)
From: Collins, Francis (NIH/OD) (El

------~~
To: Fauci, Anthony (NIH/NIAID) (El
(b)( 6) -------- (b)(6)>; Tabak, Lawrence {NIH/OD) [E)
Subject: agenda for Kadlec et al., Sun noon meeting
Hi Tony and Larry,
For the meeting tomorrow at noon (currently invitees are Kadlec, Disbrow, Johnson, Woodcock, Marks ,
and us three), I would propose the following framework :
(b) (5)
(b)( 5)
Thoughts? Tony , should
Francis
--------------------- (b) (5)
Sent : Sun, 26 Apr 2020 01:22:2 1 +0000
To: Corey MD, Larry
Subject:
--------------
RE: (b)(
Let us talk tomorrow (Sunday). I am sorry that I did not get back to you today.
From: Corey MD, Larry _______ Cb

_) _(6)
To: Mascola, John {NIH/VRC) [E] ______ --,;(b""'"'
H= >

(b)( -------- (b)(6)!; Collins, Francis (NIH/OD) (E]
Subject: Re: (b)(6)

---------------
Agree. ______________ _>
Cb
_ <_6l
Sent from my iPhone
On Apr 25, 2020, at 1:59 PM, Mascola, John (NIH/VRC) [E) (b)(6)>
wrote:
------ (b)(6) seem reasonable
Sent from my iPhone
On Apr 25, 2020, at 15:54, Corey MD, Larry wrote:

--------- (b)(6)
A do have to say I am surprised . but ok

Sent: Saturday, April 25, 2020 12:53 PM
To: Corey MD, Larry (b)(6l; Mascola, John (NIH/VRC) [E)
(b)(6)>
Cc: Collins, Francis {NIH/OD) [E] (b)(6)
Subject: Fwd: New England Journal of Medicine 20-13479
Let us discuss next steps

(b)(6)
From: (b)(6)
Sent : Sat, 25 Apr 2020 13:05 :04 -0400
To: Collins, Francis (NIH/OD) [E)
Cc: Tabak , Lawrence (NIH/OD) [E]
Subjec t : Re: White House Task Force Briefing Monday
(b) (5)
On Apr 25, 2020, at 11:42 AM, Collins, Franc is (NIH/OD) [E]

(b)(6):
FC
From: Collins, Francis (NIH/OD) [E)

Se nt : Saturday, April 25, 2020 10:36 AM
To: (b)( (OS/IOS) (b)(
Cc: Tabak, Lawrence----:-::
(N"'."'.
l".""'.
H"7.
/0::"".
D
:-:)-:[~E]:.====--------=- (b-:-
)(-:-=
6); Fauci, Anthony (NIH/NIAID)
[E] (b)(6)>; Pence, Laur a (HHS/ASL) (b)( ; Harrison,
Brian (HHS/10S) (b)(6J>; Wood, Gretc hen (NIH/OD) (E]
(b)(6) McManus, Ayanna (N IH/OD) [E] (b)(6J
--------
Subject : FW: White House Task Force Briefing Monday
Hi Mr. Secretary,
(b)(5)-Prn
Glad to speak with you about how best to handle, if
(b)(6)
Francis
(b)(5)-PCE
(bX5)-PCI
Sent: Fri, 24 Apr 2020 14:25:16 +0000
To: Conrad, Patricia (NIH/NIAID)[E)
Subject: FW: Italy Covid-19
La Stam pa is one of the two most important newspapers in Ita ly.
Director
Phone: (b)(6)
FAX: (30 496"'4409
E-mail: (b)(6)
From: Mastro lilli Paolo <Paolo .MASTROLILLl@lastampa.it>

Sent: Friday, April 24, 2020 10 :08 AM
--------
To: Fauci, Anthony (NIH/NIAID) [EJ(
Subject: Italy Covid -19 1,
--------
Dear Doctor Fauci,
My name is Paolo Mastro lilli, I am the US Bureau Chief for the Italian daily La Stampa.
I am writing because we would appreciate very much the opportunity to have a phone or
wr itten Q&As interview with you to discuss the Covid 19 pandemic. Considering the difficult
situation Italy is experiencing, the help President Trump is send ing to Italy, and the plan to open
America again, it would be very helpful for Italy to hear from your experience and competence
t o address the Covid 19. We think that your advices would be very helpfu l to help our country
and our citizens in dealing with the pandemic .
We understand that you are very busy and this request has no deadline.
La Stampa is a leading Italian daily, it is owned by the Agnelli Elkann family, owner of Fiat
Chrysler as well.
I am also a contributor for the Vatican Radio and the official news portal of the Holy See, I
would share the interview with them as well, if you like.
My cellphone number ief CbH 6Y
Please let me know if you need any further information.
Best regards
Paolo Mastrolilli
e
II presente messagglo (inclusi gli allegati) contiene informazloni riservate esclusivamente al destinatario/ai destlnatari lndicato/i nel messaggio, ed
protetto dalla legge. La diffusione, distribuzlone e/o la copia del contenuto del presente messaggio da parte di qualsias i soggetto diverso dal
e
destinatario severamente vletata ai sensi dell'art. 616 c.p. e delle vigenti normative in materia di protezione dei datl personali . Se non siete i
destinatari del presente messaggio, vi preghiamo di distruggerlo e di darcene immed ial a comunicazione inviando un messaggio di ritorno all'indirizzo
e-ma il del mittente.
This message (including any attachments) contains confidential information inte nded only for the reclpient(s) named above, and is protected by law.
Any disclosu re, distribution and/or copying of this message by any subject different from the named recipient(s) is strictly prohibited according to art
616 c.p, and to the applicable data protection laws . If you are not the intended recipient, please delete this message and inform us immediately about
the deletion by sending a message lo the sender's e-mail address.
Sent : Fri, 24 Apr 2020 10:33:49 +0000
To: Holland, Steven (NIH/NIA ID) [E]
Cc: Marston, Hilary (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E]
Subjec t : RE:Successful Submission of a Manuscript to Science (abc4208)
Thanks, Steve.
From: Holland , Steven (NIWNIAID) [E]
Scn t: T hur sday, April 23 , 2020 11:48 PM -----------:a-,-=
------
(b)(
To: Fauci, Anthony (N1H/NIAlD) [E] _':======= (b

=~~
- (6)
~
Cc: Marston , Hilary (NIH/NJ AID ) [E] (b)( ; Lerner , Andr ea (NIH/NT AID) [E]
(b)(6)
Subject: FW: Successful Submission of a Manuscript to Science (abc4208)
This is the acalabrutinibpaper today submitted to Science. NEJM was interestedbut wanted a month delay to be
sure about the results but some of the authors (Not the NIAID one) balked and have gone elsewhere. Just keeping
you in the loop.
Steve
Director, Divisi on of Intramural Research Nat ional Institu te of Allergy and Infectious Diseases National Institute s of
Hea lth
Bldg. IO/ l IN248 MSC 1960
(b) ( voice
.,.
3..,..
0-l-..,.
4"'"
80,....
-...,.
45
""'0,..,.
7 fax
(b)(6)
Assistant lab: Eva Portillo

____ (b)( _,, voice
(b)(6)

____ _,,
(b) (6) voice
(b)(6)
On 4/ 23/20, 1:59 PM, "Lionakis, Michail (Nll-1/NIAID) [E]" ________ (b

_)_(6J
_> wrote:
Attached the submitted paper, which wil l be deposited to MedRx iv.org today I think.
Mihali s
On 4/23/20, I :34 PM, "science_editors@aaas.org"<science:.._

editors@aaas.org> wrote:
ManuscriptTitle: Inhibition of Bruton Tyrosine Kinase in Patients with Severe Covid-19

Author: Lionakis
Manuscript Number: abc4208
Dear Dr. Lionakis:
You are listed as a coauthor on the above manuscript,which has recently been submitted to Science.
According to Science policy, all authors must have seen and approved the submission of their manuscript. If you
have seen the manuscript and approved its submission, no action is necessary.
Tfyou have not read this paper or do not approve its submission to Science, please let us know as soon as
possible. Please refer to the manuscript number listed above in any correspondence (you can just reply to this
message) .
You can see the status of your manuscript at any time by logging into your account at the Science Journals
Submission and lnfonnation Portal at https://cts.sciencemag.org.
If you do not yet have an account, please go to https://cts.sciencemag.org/scc /#/ forgot-passwo rd and use the
email at which you received this correspondence because that is linked to your manuscript. Then, follow the prompts
to set your password and login. After login, you can access your manuscript and monitor its status.
Once you are registered, we encourage you to link your account to your ORCID ID, an identifier that facilitates
the correct attribution of your publications to you. To learn more about ORCID or to obtain an ORCID ID, visit their
site at: http ://orcid.org.
Your manuscript is now undergoing an initial screening to detennine whether it will be sent for in-depth
review. If the manuscript is sent to review , its status will change to "To Review".
Sincerely ,
The Editors
Science
Sent : Fri, 24 Apr 2020 01:58:36 +0000
To : Greg Folkers (b)(6)
Subject : FW: HIVR4P postponed to 17-21 January 2021
FYI. See yellow highlighted request.
From: HIVR4P- Secretariat <secretariat@hivr4p.org>

To : Fauci, Anthony {NIH/NIAID) [E]-------~=
Cc:Conrad, Patricia (NIH/NIAID) [E~ =======~ =;Dieffenbach, Carl (NIH/NIAID) [E]
)
(b) (6) >
Subject: HIVR4P postponed to 17-21 January 2021
HIV RESEARCH
FOR PREVENTION
Cb.PETOWN SOUTHAFRICA·17-21JANUA'.-lV
2021
Dear Dr. Fauci ,
As the research commun ity responds to the global challenges of the COVID-19 pandemic, HIV prevention
science matters as much as ever. Our priority as organizers of the HIV Research for Prevention (HIVR4P)
conference remains the safety and wellbeing of all participants .
After careful consideration, we have decided to postpone the HIVR4P conference to 17-21 Janua ry
2021 . Updated details for the session(s) are listed below :
Session titl e: HIV prevention 2020 - Where are we now and where are we
going?
Sess ion type: Opening plenary
Suggested presen tation Much accompl ished ; Much to do -An overview on HIV
title/topi c: prevention research
Sess ion descr ipt ion: Today's plenary sets the stage for the conference week ahead,
outlining the big-picture chal lenges we face in research, product
development and access to prevention . Speakers will provide
diverse perspectives on the state of the field today , the
opportunities and obstacles ahead and priorities for action
moving forward .
Session date and time: Monday, 18 January 2021 -16:00-18:00
Meet the Expert s lunches

We invite you to host an informal table discussion at a Meet the Experts lunch on 20 January 2021 ,
12:00-13:00. Daily meet the expe rts lunches provide early-ca reer investigators and community advocates
with valuab le opportunities for informal , in-depth exchange with experts represen ting a cross-section of
research issues, implementation challenges and HIV-affected communities.
Please reply to this email by Wednesday, 6 May if you are still available to deliver this important
presentation and, if so, please also include a photo and a brief biography.
We are acutely aware many researchers and research organizations with critica l studies and submissions
to HIVR4P are now also heavily engaged in the COV ID-19 response. Our hope is that postponing the
confe rence , rather than presenting it virtually in October, will allow for the broadest participation to foster
knowledge-exchange, debate and direction-setting in the field of HIV prevention research that HIVR4P is
known for.
Since rely ,
HIVR4P - Secretariat
HIV Research for Prevention
W:
------- (b)(6)
Avenue de France23 I CH-1202 GenevaI Switzerland
HIVR4P Conferenc e 117-21 January 2021 I Cape Town , South

Afri ca
HIVR4P.org 0 @HIVR4Px 0 /HIVR4P
From : HIVR4P- Secretariat

Sen t : 21 February 2020 16:57
To: (b) (6)
Cc: Bargavi Thyagarajan
----------------------
Subject : HIVR4P 2020 - Invitation to present
(b)(6)
HIV RESEARCH
FOR PREVENTION
UF>i OWN. ~JTH Af~ICA · 11-·&OCTOB~ 2020
Dear Dr. Fauci,
We are writing with great pleasure to invite you to present at the 4th HIV Research for Prevention
Conference (HIVR4P 2020 ) in Cape Town, South Africa, from 11-15 October 2020. HIV Research for
Prevention is the only global scientific conference focused exclusively on the challenging and fast-
growing field of HIV prevention research. HIVR4P fosters interdisciplinary knowledge-exchange on
HIV vaccines, microbicides, PrEP, treatment as prevention and biomedical interventions as well as
their related socia l and behavioura l implicat ions .
Details for the session(s) are listed below:
Session title: HIV prevention 2020 - Where are we now and where are we going?
Session type : Opening plenary
Suggested presentation Much accomplished ; Much to do - An overview on HIV prevention
title/topic: research
Today 's plenary sets the stage for the conference week ahead,
outlining the big-picture challenges we face in research, product
Session description: development and access to prevention . Speakers will provide diverse
perspectives on the state of the field today, the opportunities and
obstacles ahead and priorities for act ion moving forward.
Sess ion date and time: Monday , 12 October 2020 - 16:00-18:00
Meet the Experts lunches

We invite you to host an informal table discuss ion at a Meet the Experts lunch on 14 October 2020,
12:00-13:00 . Daily meet the experts lunches provide early-career investigators and community
advocates with valuable opportunities for informal, in-depth exchange with experts representing a
cross-section of research issues, implementation challenges and HIV-affected commun ities.
As an invited-speaker , you would be eligible to receive:

• Complimentary conference registration ;
• Roundtr ip economy airfare arranged through the HIVR4P travel agency; and
• Accommodation at one of the hotels pre-blocked by the conference secretar iat.
To accept this invitation , please reply to this email by Thursday, 27 February and include a photo
and a brief biography . Please find also attached for your record the official invitation sig ned by the
HIVR4P 2020 Co-Chairs.
We ask that you please send any questions to the HIVR4P Secretariat at secretariat@hivr4p.org .
Thank you for your consideration. We look forward to you joining us in Cape Town!
Sincerely ,
Sent : Fri, 24 Apr 2020 01:30:49 +0000
To: blonda quir ico
Subject : RE:estimation of dynam ics of COVID-19 in USA new simulations at 23 Apri l 2020
Thanks.
From: blonda qu irico (b)(6 b

Se nt : Thursd ay, Apr il 23, 2020 5:02 PM
------ ~=
To : Fauci, Ant hony {NIH/NIAID) [E]
(b) (6)> -------- (b)(6)>; COPPIET ERS'TWALLANT Yves
Subject: est imat ion of dy namics of COVID-19 in USA new simulations at 23 Apri l 2020
Tony,
We send you our simu lations.
Best regards.
Quirico
Le mercred i 22 avril 2020 a 00:09:50 UTC+2, Fauci, Anthony (NIH/NIAID) [E) (b)(6) > a
ecrit:
Thanks.
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
From: blonda quirico Cb)(6)
Sent: Tuesday , April 21, 2020 11:18_ A
_M____ ~~
To : Fauci, Antho ny (NIH/N IAID) [E] Cb)( ; COPPIETERS'T WALLANT Yves
(b) (6)>
Subject: Re: estimation of dynamics of COVID-19 in USA new simulations at 21 April 2020
Tony,
Professor COPPIETERS and I, we send you our new simulations :
In summary, the USA COVID-19epidemic model says :
- the final size of epidemic= more than 85061 0 people infected and detected;
- date of epidemic peak=+/- 7 April 2020 with theorical new cases - in one day during
this peak - about +/- 35520;
- end of epidemic=+/- 19-28 June 2020 (we use two methods) ;
- morta lity at the end of epidemic :
** if death rate 5% = +/- 42.530 deceased people (for the moment the death rate= 5%)
** if death rate 10% = +/- 85.060 deceased people
You reached 91, 1 % of the theorical logist ic curve .
Best regards .
Quirico
00 32 475 48 68 42
Le dimanche 19 avril 2020 a 15:57:50 UTC+2, Fauci, Anthony (NIH/NIAID) [E] Cb)( > a
ecrit:
Quirico :
Thanks again! Please keep this information coming to me.
Best regards,
Tony
--------
From: blonda qu irico
Sent: Sunday . April 19, 2020 5:04 AM
-----
To : Fauci, Anthony (NIH/NIAID) [E] -=-<'"=
CbH >; COPPIETERS'T WALLANT Yves
(b)(6) -------
Subject: Re: estimation of dynamics of COVI D-19 in USA new simulations at 18 April 2020
Tony,
We send you our new simulations.
In summary, the USA COVID-19 epidemic model says:
- the final size of epidemic = more than 779000 people infected and detected;
- date of epidemic peak=+/- 7 April 2020 with theorical new cases - in one day during
this peak - about +/- 35063;
- end of epidemic=+/- 4-13 June 2020 (we use two methods);
- mortality at the end of epidemic :
** if dead rate 5% = +/- 40000 deceased people
** if dead rate 10% = +/- 80.000 deceased people
You reached 87 .5 % of the theorica I logistic curve.
Best regards.
Quirico
00 32 475 48 68 42
Le lundi 6 avril 2020 a 03:32:35 UTC+2, Fauci , Anthony (NIH/NIAID) [E]______ _>_C6)
Cb _ > a ecrit:
Dr. Bionda:
Thank you for sending me this information. I appreciate it.
Best regards,
Tony
From: blonda quirico .....,,.,=-e-..,,....,,-,,--,:,-,-,---- (b)( ....

Sent: Sunday , April 5, 2020 9:23 PM
To : Fauci, Anthon NIH/NIAID) [E]
-----~~ (b)( >; COPPIETERS'T WALLANT Yves
(b)(6)> -------
Subject: estimat ion of dynamics of COVID-19 in USA
Professor Anthony FAUCY,
Sorry to disturb during the COVID-19 in USA.
But I would you inform about the COVID-19 in USA.
I'm medical doctor in Belgium.
With my teacher Professor Yves COPPIETERS ( Ecole de sante publique - ULB -

Brussels) , we make simulations about the COVID-19 for many countries.
In summary, the USA COVID-19 epidemic model says:

- the final size of epidemic=+/- 462760 people infected and detected;
- date of epidemic peak = +/- 1- 2 April 2020 with theorical new cases - in one day
during this peak - about +/- 28390;
- end of epidemic = +/- 15 May 2020;
- morta lity :
If you are interrested by our simulations, you can contact us.
Best regards.
Dr Quirico BLONDA
(b)(6)
Sent : Fri, 24 Apr 2020 00:50:12 +0000
(b)(6)
Subject: FW: The Tablet I find myself thinking back to his father, Stephen Fauci, whose
drugstore our family relied on back in the 1950s.
You have got to read this!!!
From: Folkers, Greg {NIH/NIAID) [E]

(b)(6)>
---------
To: NIAID COGCORE<COGCDRE@mail.nih.gov> ; NIAID OCGR Leg <N IAIDO CGRLeg@mail.nih.gov>; NIAID
OD AM <NIAIDODA M @niaid.nih .gov>
Subject: The Tablet I find myself thinking back to his fathe r, Stephen Fauci, whose drugstore our family
relied on back in the 1950s.
https://thetablet.org/only-in-print-dr-faucis-roots-in-dyker-heights/
~ I 0,A™F uz, I jiQ!ftACi vs
THE~LET
Nt:WS O.PINIO.N PJUUSHa SCHOOLS SPORl'S AIIOUNI> THC OIOCES£
CCIIIONAVUtU.S
Only in Print; Dr. Fauci's Roots in Dyker Heights

:.,,,, a 2Q'20
D CJSCJ
CATHOLIC NEWS SERVICE
tOUcallon COfflinUtsin dlffnntfOffllal

RiMQIOUS
Ou!lnQPllldem.tC
81$hop" ,~ ~ IJ•Qt Peru to QU4td tnaigenou$

Plil<l3 du!lng pano.m1c
DI A/IIIIOllyFaucimlH!l$ •!II Rf9,$ H,O,, Stl'>OOI

NudelltS a1t11,,ucll00/l
Pf~ FJU>er~ Ill U ~an
$ J ,,t 20•ll 4uc• ,_.,,_ t;,m ty OWNld • ,,..g1,bomood pl,.rmKf ,n Oy/(fl' i-.gt,ta/ ISa 19$4 f}<8<1,;atecl
tl>t Jew.I WtOOI(Phelo COIIIWf of FIM:I t;Jm#f)
From the Neighborhood
by Frank Derosa
Frank DeRosa retired as Associate Publisher of The

Tablet and director of the Diocesan Public
Information Office in 2008
When I see Dr. Anthony Fauci on the TV screen

explaining expertly
everything we need to know about the
coronavirus pandemic, I find myself thinking
back to his father, Stephen Fauci, whose
drugstore our family relied on back in the 1950s.
Steve Fauci was the neighborhood pharmacist.
The Fauci Pharmacy stood on the southwest

corner of 13th Ave. and 83 rd St., in the Dyker
Heights section of Brooklyn, diagonally across
from the Shrine Church of St. Bernadette. We
lived two blocks away on 85 th .
Long ago parishioners like me remember what
the store looked like, the
soda fountain that ran along the right wall, the
telephone booths at the left close to the
entrance and the counter straight ahead down
the center.
Whenever my mother sent me there, Mr. Fauci
would be behind the
counter, but it was a family enterprise. They
lived in an apartment above the store, and if the
patriarch wasn't serving you, his wife, Eugenia,
or daughter, Denise, was there. Young Anthony,
I've since learned, pitched in too, his father
sending him out on his bike to deliver items to
customers.
I've never met the man who has become the

most important medical voice in the country. Nor
have former parishioners that I've spoken to
about him in recent days, like boyhood pals
Anthony LoFrisco, from
80th St., now in Connecticut, and Bob Orlando,
who lived on 84th, now a New Jersey resident,
as well as Bishop Gerald Barbarito of the Palm
Beach Diocese, from 11th Ave. But each
remembers the pharmacy as a Dyker Heights
institution.
While we don't know him personally, in a sense
he's become everyone's
friend. With his steady television presence, he's
imparted his vast knowledge and
straightforward advice in a trademark,
sometimes gravelly or raspy, Brooklyn accent
that has endeared him to people far and wide.
You can't be anything but proud of someone of
his prominence who came from the parish.
Anthony became known as Tony, as he tells it,

when Father Flanagan,
principal of Regis High School, decided to call
him that on his first day as a freshman. The
name stuck.
Tony took buses and trains to the Jesuit school
in Manhattan, including the old Sea Beach
Express. He traveled 70 minutes each way, did
three hours of homework, captained the
basketball team and excelled in the classroom.
I remember hearing that when Tony was a high

schooler, he had a part-
time job working in St. Bernadette's rectory,
answering the phone and doing whatever else
parishioners wanted him to do to put them in
touch with one of the parish priests. In those
days, the rectory had a priestly bonanza. There
were four of them.
Because St. Bernadette's School had not yet

been established, Tony went to Our Lady of
Guadalupe School, where he was taught by
Dominican Sisters. It was, and is, St.
Bernadette's neighboring parish.
Like most kids, he loved sports. He played CYO

baseball and basketball. At Dyker Park on 86th
St., he and his friends developed skills in
imitation of their heroes. A Yankee follower
living in the midst of Brooklyn Dodgers fans who
adored The Boys of Summer, he's said his
favorite players were Joe DiMaggio and Mickey
Mantle.
Tony's father and mother married at 18, after

they graduated from New
Utrecht High School. Steve went on to Columbia
to study pharmacy.
Sometime after he opened his pharmacy, he
became friends with Father Al Varriale, one of St.
Bernadette's beloved parish priests. At one
point, Steve, as a parent, and the priest known
as Father V, who directed the parish's robust
CYO sports program for youths, shared a
concern. It was the easy availability of indecent
and immoral publications that they knew was a
threat to the moral development of young
people.
So, with the approval and support of the Diocese
of Brooklyn, together they formed a diocesan
commission against pornography. Both men are
now long gone, and so is the commission, but it
was a good idea, though it did not survive them.
Remarkably, just a few houses up the block from

where Steve established his pharmacy, lived the
Pellegrinos, another family of St. Bernadette's
parishioners that produced a renowned medical
professional. The eldest son, Edmund, became a
bioethicist, a "preeminent" one, as one
newspaper described him after he died. But he
was more. He helped develop medical programs
at Kentucky, Stony Brook and Tennessee
Universities. Later, he took on the presidency of
The Catholic University of America. Then, after
completing his tenure there, he became, as
physician and philosopher, the director of the
Kennedy Institute of Ethics at Georgetown
University.
Though years apart in age, both Dr. Fauci and

Dr. Pellegrino became
Hippocratic stars, nurtured on the same block.
Only in Brooklyn, I say, not without bias.
Steve Fauci was known by members of his

extended family and friends for his personality,
kindness, sense of humor and wit, and for telling
good stories. So they said in comments after he
died in 2008.
Tony appears to have inherited Steve's gene for

lightheartedness. His
daughter once told the Washington Post that her
dad could be a "goofball ... he works hard and
does his thing, but he comes home and he's
singing opera in the kitchen and dancing
around."
That kind of calm can help a man maintain his

balance as he deals with the pressure of talking
to millions of people every day about the
complexity of a global pandemic.
As one newsman said, "When Fauci appears on

the screen, you turn up the volume."
He once said the Jesuits at Regis and Holy

Cross College taught him the
importance of "precision of thought and
economy of expression."
That's what he delivers every day: accurate
information given concisely.
That's Tony Fauci, now a national treasure. And

to think, he came from the neighborhood.
Dr. Anthony Fauci He graduated from Regis

High School and the
College of Holy Cross.
He graduated number
one in his class at
Cornell Medical School
in 1966.
He completed his
medical residency at
New York Hospital
In 1984, he became
TOSLOW director of National
EAD
Institute of Allergy and
Infectious Diseases, a
position he holds today.
Front row, kneeling

U.it1lc Cr~ l
\ or r-,,,.,,
St~\, was on<c known as th< chmp ut y
sprmta nov. he u .tl' ls H lhc cla:.; K"~t J, . 1.-r
A r.?guhr fellow w11h ., re3dy <n,tl~ ,1td full
ot ~pun You could ilJ"ns count on St~\C bt:-
1n,: p:.•stnt .it cv~r\· cli-,5 .tnd sdmol affair
Disclaimer: Any third-part y material in thi s email h as been shared for internal use under fair use provi sions
of U.S. copyright law, without further verification of its accuracy/veracity. lt does not necessa rily repr esent
my views nor those ofNIAlD, NTH,HHS, or the U.S. government.
Sent: Fri, 24 Apr 2020 00:35:33 +0000
Subject: FW: Another PossibleTool in The Fight Against SARS-CoV-2
?
Pleas take a look and figure out where to send it.
From: Gary Radin <GRadin@dhs.lacounty.gov >

------ ~=
Subject:
-------- (b)(6)>
Another Possible Tool in The Fight Against SARS
-CoV-2
?
Dr. Fauci---Forgive the crude and unsolicited manner in which I am attempting to reach out to
you but I don't reall y KNOW any other way!
I am not a medical doctor nor am I a principle investigator. I am just a Cytologist employed in
the Anatomic Pathology department at LA County-USC Medical Center here in Southern
California.
But I have been read ing a lot- -- and in my own exploration I have come across several articles
which suggest the possibility of using a class of agents called
SPHINGOSINE-1-PHOSPHATERECEPTOR AGONISTSin combination with antivirals like
oseltamivir (or perhaps Remdesivir?) to treat both the viral pathogen responsibl e for the
current pandemic as well as the runaway immune response of the host leading to the oft fatal
cytokine storms.
Apparently these compounds have been approved for flare-ups of multiple sclerosis, and have
even been tried on Alzheimer's patients. The commonly known drug is FINGOLIMOD. But these
papers that I have cited for you below seem to indicate that structural analogs of this
compound could be important in damping down the dysregulated pro -inflammatory cascades
which seem to be leading to DIC, alveolar exudates and diffuse alveolar damage, capillary leak
syndrome and ultimately the multiple organ failure that is killing an unacceptably high number
of people.
The fly in the ointment Dr. Fauci here is that these 5-1-PR agonists have only been
demonstrated to be effective in non-human primates and other mammals. And much of these
studies on these compounds has been done not on coronaviruses but on influenza viruses .
So it would be a gamble. But is that not how we have learned much about human health and
disease is by the gracious sacrifice of our anim al cousins? And might it not be a general effect
that these sphingosine derivat ives have on viral sepsis so that maybe what works for influenza
might work for the coronavirus?
In the dire situation that many of the most critically ill COVID 19 patien ts find themselves, it
seems they are on the pr ecipice of a rapid demise once they begin to show certain key
laboratory resu lts---(sp ikes in 0-DIMER, C-Reactive Protein, Serum Ferritin, prolongation of
prothrombin and APTT, increased card iac troponin 1, surges in IL-6, IL-7, monocytic and
macrophage chemo-attractant cytokines etc) .
W ith pat ients isolated by these aberrant lab values, the window may be narrow but it may be a
time where application of antiviral compounds in combination with t hese inflamma t ory
mod ulat ors could have a striking impact on mor t ality? Indeed maybe even TWO different
antivirals with diff ering mechan isms of action in combination with these S1-PRAgonists would
even be better. And the possibilit ies of other combinat ions of course would be there for
further exploration .
Fully cognizant of the Hippocratic Oath to 'first do no harm' I still believe that at least the
medical rat ionale is sound for the inclusio n of these agents int o the possible arsena l of
therapeutics for the more severe COVID 19 patients.
Please refe r below to t he st udies I found particularly helpful or promis i ng. Perhaps yo u can put
together some 'teams ' to further explore investigate these opt ions??
We all appreciate everyt hi ng you have done, and continue to do !
Gary Radin
https://www .sciencedirect.com/science/article/pii/S0140673620303056
https ://www.pnas.org/ conte nt/108/29 /12 018
https://www .clinical key .com/# !/con tent/p layContent/1-s2. 0-

S0042682214000063 ?return ur l=http s:%2F%2Flinkinghu b.elsevier .com%2 Fretrieve%2Fpii%2FS0
042682214000063%3Fshowall%3Dtrue&referrer=
Suppression of cytok ine storm with a

sphingosine analog prov ides protection
against pathogenic influen za virus I
PNAS
Human pandemic H1N1 2009 influenza virus rapidly
infected millions worldwide and was associated with
significant mortality. Antiviral drugs that inhibit influenza
virus replication are the primary therapy used to diminish
disease; however, there are two significant limitations to
their effective use: ( i) antiviral drugs exert selective
pressure on the virus, resulting in the generation of ...
www.pnas.org
https://www.thelancet.com / journals/lancet/article/PIISOl 40-6736(20)30566-3 /fu lltext
Clinical course and risk factors for mortality of adult inpatients

with COVID-19 in Wuhan, China: a retrospective cohort study
1 - The Lancet
The potential riskfactorsof older age, high SOFAscore,and d-dimer greater than 1
µg/ml could help cliniciansto identify patientswith poor prognosisat an early stage.
Prolongedviral shedding providesthe rationalefor a strategy of isolationof infected
patients and optimal antiviral interventionsin the future.
www.thelancet.com
https://www.ncbi.nlm.nih.gov /pmc/articles/PMC317 6439 /
Endothelial cells are central

orchestrators of cytokine
amplification during
influenza virus infection -
PubMed Central (PMC)
Cytokine storm during viral infection is
a prospectivepredictor of morbidity
and mortality,yet the cellularsources
remain undefined. Here, using genetic
and chemicaltools to probe functions
of the S1P 1 receptor,we elucidate
cellularand signaling mechanisms
important in initiating cytokine storm.
While S1P 1 receptor is expressedon
endothelial cells and lymphocytes
within lung tissue ...
www.ncbi.nlm.nih.gov
Sent: Thu, 23 Apr 2020 22:47 :07 +0000
To: Billet, Courtney (NIH/N IAID) [E];Greg Folkers ;Conrad,
Patricia (NIH/NIAID ) [E];Routh, Jennifer (NIH/NIAID) [El
---------- (b)(6}
Cc: Barasch, Kimber ly (NIH/NIAID) [C]

Subject: FW : Sammies recognition th is year - congratulations
Attachments: AFauci, NIH.pdf
Please take a look at this and let us discuss. Thanks.
Direc;tor
Phone: (b)( 6)
FAX: (301 496-4409
E-mail (b) (6)
From: Max Stier <msti er@ourpubl icservice.org>

Sent: Thursd ay, Apr il 23, 2020 2:57 PM
To: Fauci, Anthony (NIH/NIAID) [E) --------,;- = (b)( 6)>
Cc:Barasch, Kimberly (NIH/NIAID) [C]_________ Cb
_H_ ; Sammies
<Sammies@ourpublicserv ice.org>
Subject: Sammies recognition t his year- congratulat ions
Dr. Fauci:
I hope you are healthy and well. The Partnership for Public Service is honored to inform you that we
have selected you as a fi nalist for the 2020 Samuel J. Heyman Service to America Medals, otherwise
known as the Oscars of government service.
You were nominated by Francis Collins for your o utstanding career at NIAID and th e wor k you are
currently do ing on behalf of th e American people to prepare, inform and protec t lives in our country and
around the wor ld during th is uncertain time . Your work truly embod ies th e best of governm ent tha t we
strive to recognize through t he Sammies program.
Attached, I've included the profi le we have drafted to summarize yo ur work and accomplishments -
both for recognizing you as a fina list and for having the select ion committee vote for the award
recipients . Should you have any edits or wish to add a personal quote, please send those to us at your
convenience. We will be releasing your profile publicly with the rest of the final ists on Sunday, May 3 .
Again, thank you for the work you do on behalf of the NIH and our country.
Best,
Max Stier
President and CEO
Partnersh ip for Public Service
Sent : Thu, 23 Apr 2020 22:37 :35 +0000
To : Greg Folkers Cb
H 6);Conrad, Patricia (NIH/NIAID) [El
Subject : FW: NAS Annual Meet ing Session on COVID-19 -- Information regarding your
Satur day April 25 part icipation
FYI
Director
Phone : (b)( 6)
FAX: (3 96':44li9
E-mail: Cb)(6)
behalf of the NIAID by one of it s representatives.

Se nt : Thursday, Apr il 23, 2020 1:49 PM
To : Fauci, Anthony (NIH/NIAID) [E]----------------~~
Cc: Hannon, Emma <EHannon@nas .edu>; Conrad , Patr icia {NIH/NIAID) [El (b) (6);
(b)(6)
'ben.t inker@cnn .com' <ben.t inker@cnn .com>;

'Amanda.Sealy@cnn.com' <Amanda.Sealy@cnn.com> ; 'Neel.Kh air zada@t urner .com'
<Neel.Khairzada@turner .com>; 'Tia.Mille r@turner.co m' <Tia.Mi ller@turner .com> ;
------; ~,s,
(b) (
>; McGinni s, J. Mic hael <MMcG innis@nas.edu>; (b)(
=======~
-------- (b)(6) ; Mu n, Jenny <JMun@nas .edu>; (b)(6)
Subject: RE: NASAnnual Meeting Session on COVID-19 -- Information regard ing you r Saturday April 25
part icipation
I'm really look ing for w ard to th is panel on COVID-19 at the NAS Annual Meeting on Saturday, April 25th
at 2:00 -3:3 0 pm ET.There is tremendous excitement and enthusiasm, and registr ati on is thr ough the
roof .
I am sending this note to do a last minute check to see if there is anything you need from me. I also want
to check whether you are planning to use slides. Will you be sending your slides to us to project or use
the share screen feature to advance your own slides? Regardless, it would be helpful to me if you could
send me your slides for my preparation.
I wou ld greatly appreciate it if you would respond to th is email.
Best,
Victor
PS,
------
logistics shortly.
Cb)~ , my special assistant, will be sending you additional information about the session

---------------~ ~
(b)(6)>; Hannon, Emma <EHannon@nas.edu>;

---:---:-:--:-:--:-:---:-======:...;_--=~
_________
'conradpa@niaid.nih.gov '
..
=========.~;;;--:-:-- (b)(6)>;
(b)(6)>; 'T.MillerdeVega@wellcome.ac
'jsi@cepi.net '
.uk'
(b)(6) 'rebeka.yasmin@cepi .net'
(b)( 6) >; 'b en.tinke r@cnn.com' <ben.tinker@cnn.com >; 'Amanda.Sealy@cnn.com'
<Amanda.Sealy@cnn.com >; 'Neel.Khairzada@turner .com' <Neel.Khairzada@t urne r.com>;
'Tia.M iller@turner .com' <Tia.Miller@turner.com >; (b)(6)
Subject: RE: NASAnnual Meeting Session on COVID-19 -- Information regarding your Saturday April 25
participation
Dear all,
Thank you for agreeing to participate in a spec ial late breaking session on the COVID-19
pandemic at the NAS annual meeting . Knowing how busy you are, I am sending this ema il in
lieu of a call to prepare for the session.
As you know, this is a 90 minute sess ion which aims to provide our audience with deeper
insights into the latest developments in the COVID-19 response . I plan to hold an engaging
discussion that covers the whole experience on dealing with this pandemic - from US to
internat ional, to preparedness and response , the biology of the virus, the state of diagnostic ,
treatmen t and vaccine development, and the importance of communication.
I will begin the session by providing brief (~3 min) opening remarks describing the
circumstances of the pandemic. Then, I will introduce the panelists and you will each have 7
minutes to provide remarks. You may use a limited number of slides for ilJustrat ion. I hope that
each panelist will provide their own perspective and spea k to the issues proposed below.
• Jeremy Farrar will discuss the global response to the pandemic, drawing from his
experience as a global leader, the chair of the Scientific Advisory Group for the WHO's
R&D Blueprint and as a member of the Global Preparedness Monitoring Board .
• Tony Fauci will discuss tbe US pandemic and provide his perspective as a member of the
White House Coronavirus Task Force addressing the 2019 - 20 coronavirus pandemic.
• George Gao will discuss China's responseto the pandemicand lessons learned for the
rest of the globe.
• Susan Weiss will discuss the viral characteristicsof SARS COV2 , insights into its
pathobiology , immunity and developmen t of a pan-CoV antiviral.
• Richard Hatchett will discuss the deve lopment of new vaccines and treatments against
COVID-19.
• Sanjay Guptawill commenton the health system response to the pandemic and
challenges related to communication and public engagement in responding to COVID-19.
Followingremarks from each panelist, we will have a moderateddiscussion amongst ourselves-

I will ask you a set of questions (15 mins) and then we will take questions from the web (25
mins) . To prepare me to be your mode rator, please send me any questions you would like me to
ask you. For those of you who would like to have a prep call, please let me know and I will set it
up.
Best,
Victor
From: Mun , Jenny

Sent : Wednesday, Apri l 8, 2020 10:56 AM
(b) (6) ;
---------------------------
1Amanda.Se aIy@c n n.com';
'ben.tinker@cnn.com';
(b)(6)
'Neel.Khai rzada@turne r.com' ; 'Tia.Miller@turn er.com'
Subject: NAS Annual Meeting Session on COVID-19 -- Information regarding you r Saturday Apri l 25
participa t ion
Dear Speakers:
I am t he logistical contact for the COVID-19 session that w ill be held as part of the Annual Meeting
(online) program on Saturday, April 25 at 2:00 pm EDT. Thank you for agreeing to participate in this
session. To help you with your planning, I have pro vided additional details below.
Please note that the session w ill be live w ebcast and the general public will also be able to watch the
session. Video from the session will also be uploaded on the NAS YouTube channel
(https://www.youtube.com/user/theNASciences ) after the meeting . We w ill need to obtain signed
speaker release forms for your participation in this session. I have attached the speaker release form for
your review and submission. Please return the signed speaker release form by Monday , April 13.
Session speakers are asked to connect 30 minutes prior to the session start time (by Saturday, April 25
at 1:30 pm EDT)to allow the technical staff to check connections and prepare for the session. Details on
how to connect will be sent before the meeting.
We w ill list you in our promotional materials as noted below . If this is incorrect, please let me know .
Anthony S. Fauci, Director, National Institute of Allergy and Infectious Diseases

George F. Gao, Director-General, Chinese Center for Disease Control & Prevention
Susan R. Weiss, Professor of Microb iology, Perelman School of Medicine, University of Pennsylvania
Since many of us have moved to remote work environments, you may already be proficient w ith Zoom
and other online meeting/collaboration applications. I am attaching a 'speaker guidelines' f ile in case
you have any questions on how best to prepare for and stage your remote talk . We have technical staff
available to help you become familiar with Zoom and its settings -such as "sharing your screen" (if you
have slide presentations that need to be shown during your talk). We can arrange for a t raining session
this week or next week . If you would like to schedule a session, please let me know as soon as possible.
Dr. Dzau's office will be in touch regarding the agenda for this session. If you have any othe r questions,
please let me know .
Regards, Jenny
******************* *************
Jenny Mun
Membership Director
jmun@nas.edu
(b)(6)
Sent : Thu, 23 Apr 2020 22:36 :33 +0000
To: Cassetti, Cristina (NIH/N IAID) [E);Lerner, Andre a (NIH/NIA ID)
[El
----- -=-a=,;Conrad, Patricia (NIH/NIAID) [El;Marston, Hilary (NIH/N IAID) [El
(b)(6)
Subject: FW : New sheet
Attachment s: COVID.docx
Director
Build ing 31, Room 7 A-O3
Phone : (b)( 6)
FAX: (301 496-4409
E-mail=--__,. _._, (b)(6)
From: Dani Bolognesi, Ph.D. (b)( 6)

Sent : Thursd ay, April 23, 2020 1:01 PM
To: Fauci, Anthony (NIH/ NIAID) [El ------- ==
~=======-~ =
Cc:Conrad, Patr icia (NIH/ NIAID) [E]
Subject: FW: New sheet
Hi Tony :
I hesitate to bother yo u with th is as I am sure that you are inundat ed w ith requests of this sort over and
abov e everyth ing else you are do ing whic h is tr uly magnific ent. I beli eve th at th ere is something of
potentia l importance in what is commun icated below but you are in the best position to tell me wh ethe r
it could fit in the toolb ox you are assembling for COVID 19 in both th e short and longe r term . I have to
acknowledge our fr iend Bob Gallo for triggering this
(b) (4)
(b) (4)
Reaching out to you to see if you think this approach has merit. Since your time is so precious, I do not
expect you to review this but perhaps you can forward to one of your trusted colleagues.
PPS. loved the interview with Coach K!
Con un forte abbraccio I
Dani
Sent: Thu, 23 Apr 2020 22:25 :14 +0000
To: (b)( 6)
Subject: FW: MSNBC: See Dr. Fauci's Stunning Pandemic Warn ing - long Before Trump
Min imized Coro naviru s I MSNBC http s://bit. ly/2yynEPf
I may have already sent this to you, but I do not think so. It is short (6 minutes)
but it has a segment that shows me 37 years ago. Yikes!!! You will get a
chuckle.
Director
Phone (b) (6)
FAX: (301) 496-4409
E-mail: (b)(6)
From: Barasch, Kimber ly (NIH/NIAID) [CJ

Sent: Thursday, April 23, 2020 9:04 AM ---------- (b)(6)

-------- (b)(6)
Subject: FW: MSNBC: See Dr. Fauci's Stunni ng Pandemic Warn ing - Long Before Trump Mi nimized
Coronavirus I MSNBC https ://b it.ly/2yyn EPf
Kim Barasch [Cl

National Institute of Allergy & Infectious Diseases
(b)(6)
(b)(6)
From: Folkers, Greg {NIH/NIAID) [E) (b) (6)>

--------
Subject: MSNBC: See Dr. Fauci's Stunning Pandemic Warn ing- Long Before Trump Minim ized
Coronav irus I MSNBC https :ljbit.ly /2yynEPf
of U.S. copyright law, without further verification of its accuracy /veracity. Tt does not necessarily represent
my views nor those ofNTAID, NIB , HHS, or the U.S. government.
Sent : Thu, 23 Apr 2020 22:14 :31 +0000
Subject : FW: A proposal to stop COVID-19 and reopen our schools and businesses
Attachme nts: Scientists_to_Stop_COVID19_2020_04_23_FINAL.pdf
Email below from David Liu.

Bethesda MD 20892
Telephone (b)(6)
Email: (b)(
From : David Liu (b)(

Se nt: Thursday, April 23, 2020 6:01 PM
To : Collins, Francis {NIH/OD) [E] ------=-::-:-= (b)( >; Fauci, Anthony {NIH/NIAID) [E]
(b)(6); Lane, Cliff (NIH/NIAID) [El (b)( >; Austin, Christopher
(NIH/NCATS) [E] (b)(6 )'>; Whalley, David (FNIH) [T]
(FNIH) [T] (b)(6); Tabak, Lawrence (NIH/OD) [El
__:....:......:..!::::====~~
Cc: Michael Rosbash '.=========~-= =
(b)(6)>; Ramnik Xavier (b)(6)>;
EDWARD SCOLNICK (b)(6); Stuart Schrei ber (b)(6)>; Michael Z Lin
(b)( 6) >; Ben Cravatt
-----~=---
(b)(6J>; Thomas Cahil l
":"'""~----:~----:.==::....;.-=-:~
R. Scott Kemp (b)(6)
(b)(6)
Subject: Re: A proposal to stop COVID-19 and reopen our schools and businesses
Dear Francis, Anthony , Cliff, Christopher, David, Maria , and Lawrence,
I hope you are all well. Attached is the updated set of four proposals on:
1) Rapid repurposing of antiviral drugs to treat COVID-19;

2) Expedited development of neutralizing monoclonal antibodies to t reat COVID-19;
3) Rapid COVID-19 vaccine development;
4) Risk-reduced ways to reopen schools and businesses, and the healt hcare system changes that are
needed to enable them.
We hope you find these updated proposals useful , and would be happy to engage in any way that could
be helpful.
Sincerely yours ,
Ben Cravatt (Scripps), Lynn Goldman (GWU),Akiko Iwasaki (Yale), Scott Kemp (MIT), Michael Lin
(Stanford), David Liu (Harvard/Broad), Michael Rosbash(Brandeis), Stuart Schreiber (Harvard/Broad), Ed
Scolnick (Broad), Jonathan Simons (PCF),and Ramnik Xavier (MGH/Broad)
David R. Liu
Richard Merkin Professor and Director of the Merk in Institute
ofTransformative Technolog ies in Healthcare
Director of the Chemical Biology and Therapeutic Sciences Program
Core Institute Member and Vice-Chair of the Faculty, Broad Institute
Investigator, Howard Hughes Medical Institute
Thomas Dudley Cabot Professor of th e Natu ral Sciences
and Prof essor of Chemistry & Chemical Biology, Harvard Unive rsity
75 Ames Street
Cambridge, MA 02142
On Apr 19, 2020, at 8:48 PM, Collins, Francis (NIH/OD) [E] wrote:
-------- (b)(6)>
Dear David et al.,
Thanks for forwarding this ve ry thoughtful document, which presents a series of

important recommendations - most of which I agree with. I don't know if you saw
Friday's announcement (attached) of the new public private partnership called
ACTIV (for Accelerating COVID-19 Therapeutic Interve ntions and Vaccines), but it
has t aken on most of the points you raise in sections 1- 3 of your letter. I share
your hopes that remdesivir will show benefit, and the current large NIH-sponsored
RCT has completed enrollment and shou ld reveal results in about a month. But of
course we want to t est multiple other interventions - both small molecules and
antibody-based therapies, so we need our tria l system to be optimized like never
before. I will share your letter with the leaders of ACTIV, who are working with
unprecedented speed to prioritize the next set of therapeutic candidates as well as
pushing vaccine development programs to adopt exceptionally creative trial
designs to test safety and efficacy (with full engagement by FDA).
Best regards , Francis
From: David Liu Cb)(6)

Sent : Sunday, April 19, 2020 5:20 PM
To: OD Labc (NIH/OD) (b)( •>; Collins, Francis(NIH/OD) [E]
(b)(6)
Cc:Michael Rosbash (b)(6)>;Ramnik Xavier

--------...!::===~~----___,.
":'"":'~~---:::====== (b
=):;:-
(~;~EDWARDSCOLNIC _K
------
--=====~~
~=
Schreiber (b)(6)>;Michael Z Lin CbH ; Ben Cravatt
-----=== (b
'a's
~::;(6)
~----
Subject: A proposal to stop COVID-19 and reopen our schools and businesses
Dear Francis,
I write on behalf of a group of citizen -scientists, most or all of whom you know. Motivated
solely by our desire to help defeat the serious threat our nation and the world now faces,
we wrote a set of four actionable, non-partisan proposa Is (attached) to produce safe and
effective COVID-19 therapeut ics and vaccines in the shortest possible timeframe, and to
reopen our society in a manner that reduces the risk of future COVID-19 outbreaks .
We hope you find these ideas interesting, and might be willing to share this set of
proposa ls with Dr. Tony Fauci, along with our willingness to discuss any part of the
proposals with him if we can be helpful. We understand from our efforts to contact Dr.
Fauci through emai l routes that his standard inbox may be too overwhelmed for our
proposa l to reach him.
The four proposals attached describe: (1) How to rapid ly repurpose an ant iviral drug to
treat COVID-19 patients; (2) How to expedite the development of human antibody drugs to
treat patients and to provide short-term protect ion for healthy individua ls; (3) How to
develop COVID-19 vaccines on an expedited t ime scale; and (4) How to reopen our
businesses and schools in a manner that reduces the risk of future outbreaks and deaths.
Thank you for any help or thoughts you might be able to provide.
Sincerely yours,
Ben Cravatt (Scripps), Lynn Goldman (GWU), Akiko Iwasaki (Yale), Scott Kemp (MIT),
Michael Lin (Stanford), David Liu (Harvard/Broad), Michae l Rosbash (Brande is), Stuart
Schreiber (Harvard/Broad), Ed Scolnick (Broad), Jonathan Simons (PCF),and Ramnik Xavier
(MGH/Broad)
David R. Liu
Richard Merkin Professor and Director of the Mer kin Institute
of Transformative Technolog ies in Healthcare
Director of th e Chemical Biology and Thera peut ic Sciences Program
Core Institut e M ember and Vice-Chair of th e Faculty, Broad Institute
Investigator, Howard Hughes Med ical Instit ute
Thoma s Dudley Cabot Professor of the Natural Sciences
and Professor of Chemistry & Chemical Biology, Harvard University
75 Ames Street
Cambridge, MA 02142
<NIH_ACTIV_Release_041720.docx>
Sent : Thu, 23 Apr 2020 21:47 :13 +0000
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject : FW: Whit e House Coronavir us Task Force M eet ing - 4.24.20
FYI
Director
Phone: (b)(6)
FAX: (3 96':44li9
E-mail: Cb)(6)
Sent: Thu, 23 Apr 2020 21:40 :33 +0000
Subject : FW: Updat e: Wh ite House Coronaviru s Task Force M eet ing
Heads-up! Change in schedule for t omorrow.
Director
Phone: (b)( 6)
FAX: (3 96':44li9
E-mail: Cb)(6)
(bX5) -l'U
Sent : Thu, 23 Apr 2020 21:29 :50 +0000
To : Fauci, Anthony (NIH/N IAID) [El
Subject : FW: MSNBC: See Dr. Fauci's Stunning Pandemic Warn ing - long Before Trump
Min imized Coro naviru s I MSNBC http s://bit. ly/2yynEPf
https://bit. ly/2yyn EPf
Director
Phone: (b)(6)
FAX: (3 96':44li9
E-mail: (b) (6)
From : Barasch, Kimberly (NIH/NIAID) [C]

Se nt : Thursday, Apr il 23, 2020 9:04 AM---------- (b)(6)
To : Fauci, Anthony (NIH/NIAID) [E]------~~

-------- (b)(6)>
Subject: FW: MSNBC: See Dr. Fauci's Stunni ng Pandemic Warn ing - Long Before Trump Mi nimized
Coronavirus I MSNBC https ://b it .ly/2yyn EPf
Kim Barasch [CJ

National Institute of Allergy & Infectious Diseases
(b)( 6)
(b)(6)
From: Folkers, Greg (NIH/NIAID) [E]

---------
Sent : Tuesday, April 21, 2020 11:06 PM
(b)( 6)>
Subje ct: MSNBC: See Dr. Fauci's Stunning Pandemic Warning- Long Before Trump Minim ized
Coronavirus I MSNBC https://bit .ly/2yynEPf
of U.S. copyright law, without further verification of its accuracy /veracity. Tt does not necessarily represent
my views nor those ofNTAID, NIB , HHS, or the U.S. government.
From: (b)(6)
Sent : Thu, 23 Apr 2020 14:34 :36 -0400
Subject: Fwd: Thank you, and...
Attachments : image002.png, ATT0000l.htm, PasstheMic Expert Outreach.pdf, ATT00002.htm
Let us discuss
From: Gay le Smith <g ayle .smith@one .org>

Date : April 23 , 2020 at 1:49 :04 PM EDT
_________
..
To: "Fauci, Anthony (NIH/NlAID ) [E]" ----------=:--:--:-=-
Cc: Tom Hart <tom.hart@one.org>
(b)(6)
Subject: Thank you, and ...
Dear Tony,
I have always felt reassured when the good Dr. Fauci speaks, and now more than ever. As
an American, a former colleague, a long-time admirer and student of your wisdom - thank
you. We are all safer because of you, and the world will be a better place because of
you. Again.
As you know , I am now leading the ONE Campaign. We' ve been quite active wi t h the
ONEWorld Campaign, dedicated to the fight against this newest virus, and focused on
Africa . We've made some progress on debt, and next up is a focus on ensuring that a
vaccine, when it comes, is available to everyone.
One of the things we want to do is educate people, in all of t he places we work. It won't
surp rise you that of particular urgency amongst our partners in Africa is that facts and
information get to people across the continent, but we also know that more facts are
needed everywhere . So next month we are going to launch #PassTheMic, where every day
for 19 days we will ask a celebrity to turn his or her social media channels over to an expert
on COVID-19 for one day. So Julia Roberts might turn her Twitter account to you to ta lk
about the critical elements needed to flatten the curve and slow t he spread. Or Idr is Elba
could give up his lnstagram to the head of the African CDCso that he can ill ustrate the
impact COVID-19 will have across Africa and what that means for the rest of the world .
We know artists wan t to be helpful right now, but that it is hard to know what to do. And
we know there are experts like you out there who have t he answers. We've thought about
this a lot at ONE and wanted to do something we felt would truly have an impact . As we
look ahead we know COVID-19 does not know borders and until it is beaten everywhere
we are not in the clear. We need a global response plan and we need it now. By turn ing
over their platforms for the day, celebrity influencers will be donating one of their biggest
assets - their followers - to YOU,giving you the platform you need (and we all need) to tell
the world why a global response is critical. Because none of us are safe until all of us are
safe.
We wi ll work with each expert/celebrity pair to personalize the content to our and our
celebrity partners' audiences - in North America, Europe and Africa, and help create
content that both part ies are happy with . We are now confirming our talent partners, and
so far are getting a terrific response.
We know you're a busy man, so we've planned it so that the amount of time on your end
would be minimal. But the impact wou ld be maximal.
I'm attaching more information about the campaign. Please let me know what you think
and if you have questions . Ideally we would like to get this off the ground in early May, so
are hoping to confirm folks by April 28th at the latest. Our team will be in touch with your
office to follow up.
Thanks as always for everything you do . All my best to you, Gayle

Gayle Smith I President & Chief Executive Officer I------- (b)(6)
ONE.ORG I Twitter I Facebook I lnstagram
ONE is a global movement campaigning to end extreme poverty and preventable disease by
2030 so that eve ryo ne, everywhere can lead a life of dignity and opportunity .
Sent: Thu, 23 Apr 2020 18:25 :56 +0000
To: Simmon s-Butler, Kirk (NIH/NIA ID) [C]
Subject: Re: Thank you Dr. Fauci!
Attachments : image001.png , image002.gif
Kirk:
Thank you for yom· kind note. Much appreciated.
Best regards ,
To ny
On Apr 23, 2020, at 2:16 PM , Simmons -Butler , Kirk (NIH/NIAID) [C]

Cb)( wrote:
Greetings Dr. Fauci,

I just wanted to take a moment to personally thank you for all of your support and
leadership during these unprecedented times. I am proud to be a part of the NIAD family
and you represent us and the country well ! God continue to bless and keep you and your
family! Thank you again sir!
Regards,
Kirk
Kirk D. Simmons-Butler, M.S.

Assistant Facility Manager 14DNR. Charles River Laboratories Inc.
NIH/NIAID
(Office)
----~~ (b)(6)
(fax) (301) 761-6013
Charles River website - www.criver.com
<image00 1.png>
<image002. gif>
recipient. If you have received this e-mail in error please inform the sender and delete it
from your mailbox or any other storagedevices. The National Institute of Allergyand
Infect iousDisease(NIAID) shallnot acceptliability for any statement made that are the
sender'sown and not expresslymade on behalf of the NIAID by one of its
representatives.
From: Fauci, Anthony (NIH/N IAID) [E] (b)( >

Sent: Friday, March 27, 2020 11:55 AM
To: NIAID Announcements <NIAID-announce@niaid .nih.gov>
Subject: Platelet Donations Down are Down Amid Coronavirus Outbreak -- Please Donate
Dear Colleagues:
The NIH Platelet Donor Center has an urgent need for healthy individuals to give lifesaving
platelets to patients. The need for platelet donations is especially acute now with the
coronavirus pandemic. While social distancing and increased telework are necessary to
contain and slow the spread of coronavirus, we have seen a marked decline in platelet and
blood donations for our patients.
To alleviate this shortage, NIAID and the Department of Transfusion Medicine (DTM) are
co-sponsoring a two-week Platelet Drive from March 30 -April 10. Platelet collections, as
well as whole blood and Double Red Cell donations, can only be made at the NIH Blood
Bank on campus in Building 10, Room 1(713 Monday t hrough Friday from 8 :00 am to 5:00
pm. The Platelet Center at Fishers lane is temporarily closed and plate let collections are
now on the main campus through at least the next 30 days. This move helps to ensure that
blood donors are protected by visitor screening, minimizing possible exposure to
individuals at risk.
What is a double red cell donation? A double red cell donation enables donors to donate
two units of red blood cells in one visit. During a procedure called apheresis, whole blood is
separated through a cell separator and red blood cells are collected. The remainder of the
blood components are returned to the donor along with saline to replace the lost volume.
I encourage participation of all employees who are eligib le to provide a donation to benefit
our NIH patients. I understand employees may be hesitant to participate under the current
conditions, but I would like to reassure you that blood donation is a safe process.
Additiona l precautions have been put in place at our Blood Bank to help prevent the
spread of infection and protect the health of donors and staff .
Thank you to all who support our quarterly platelet drives. Your efforts provide a lifeline
for our patients . Those who participated in the last drive are now eligible to help once
again. In appreciation of your dedication to helping others, NIAID grants admin istrative
leave to any NIAID federal employee who donates platelets at the NIH Blood Bank.
Specifically, you will be granted 4 hours of administrative leave to be used immediately
following your platelet donation appointment. As always with such activities, please notify
your supe rvisor for approval prior to donating at the NIH Platelet Center .. Contractor
employees should speak directly to their contract companies to determine what leave
options are available . Please contact the Donor Center at 301-496-4321 to schedule your
appointment. let the Donor Center staff know you are with t he NIAID Platelet/Double Red
Cell Drive. They will answer eligibility questi ons and provide information about the
donation process.
Thank you for consider ing donat ing during t his stressful t ime. Best regards.
Sincerely,
A.S. Fauci
Director
31 Center Drive, MSC2520
Phone (b)(6)
FAX:(301) 496-4409
E-mail:
-------- (b)(6)
The information in this e-ma il and any of its attachments is confidential and may
contain sensitive informat ion. It should not be used by anyone who is not the
original intended recipient. If you have received this e-mail in error please inform
National Institute of Allergy and Infectious Diseases (NIAID)shall not accept
liability for any statements made that are the sender's own and not expressly
made on behalf of the NIAI D by one of its representatives.
CHARLES
RIVER
lABOAATORIES
Sent : Thu, 23 Apr 2020 17:39 :48 +0000
Auchincloss, Hugh (NIH/NIAID) [C) --------~~
To :
Subject : FW : Wellness Initiat ive Proposal ---------- (b)(6)
Attachme nts: Wellness ln iti ative_POC_Sundar .zip, Wellness Initiative Proposal_Sundar .pdf,
Managing Anxiety Around COVID-19 March 27 {007) .pdf
Please take a look at th is and handle.
From: Sundar, Sachin {NIH/NIAAA) [F]

---------
(b)( >
To : Fauci, Anthony (NIH/NIAID) (E]------

-------- ~=
Subject: Wellness Initiative Proposal
(b)(6)>
Dear Dr. Fauci,
I have an idea regarding science commun icat ion and wellness . Here's a rough proposal and proof of
concept . At fu ll effect , I think it could have noteworthy potential. (b) (5)
Thank you for your time .
Respectfully,
Sachin Sundar
Sent : Thu, 23 Apr 2020 13:25 :22 +0000
To : Stephen L. Hoffman
Subject : RE:Follow Up Thanks
Thanks, St eve. I appreciate your not e.

Best rega rds,
Tony
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail (b) (6)
From: Stephen L.Hoffman<slhoffman@sanaria.com>

Sent : Wednesday, April 22, 2020 9:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] -------::-::-:-=
(b)( >
Subject: Follow Up Thanks
Dear Tony,
I hear continuously from people from all walks of life how grate ful they are for your presence on the
COVID-19 team . You are perform ing an incredible service to our country and the world.
Thanks again,
Steve
Stephen L. Hoffman, M .D.

Chief Executive and Scientific Officer
Sanaria Inc.
9800 Medical Center Dr. ste 209a
Rockville MD 20850
tel: (b)(6) (work)
tel : (bH (mobile)
fax: 301-770-5554
E-Mail: slhoffman@sanaria.com
www .sanaria.com
Sent: Thu, 23 Apr 2020 13:00 :55 +0000
To: Redfield , Robert R. (CDC/OD)
Cc: All ison Arwady ;David Barr;Conrad, Patr icia (NIH/N IA ID) [E)
Subject: FW: Dr. Fauci asked m e to send Chicago question
Attachments : Workforce _ Proposal_ Chicago_Ap ril2020. pdf
Bob:
Please take a look at this . This question evolved from a te leconference that I
had 2 nights ago with people "in the t renches" including Alison Arwady
(Chicago ). The question is what w ill be the relationsh ip between the public
health workforces at the federal and local levels. Youi had spoken of the CDC
people that will be assigned locally and that will help build up a local workforce.
How will COD interact and relate to the locals. Is there any possibility of Federal
funding of their proposal (see attachment). If not, do you have any suggestions
for them? I can discuss this with you today at the Task Force meet ing. Thanks.
Best,
Tony
Director
Phone Cb)(6)
FAX: (301 496 -4409
E-mail: Cb)(6)
other storage devi ces . The Nat ional Institute of Alle rgy and Infectious Diseases (NIAID) shall not

Sent: Wed nesday, Apr il 22, 2020 3:53 PM
To: Fauci, Anthony (NIH/NIAID) [E) ------
---------
..,.....,...=
(b)(6)
Subject: FW: Dr. Fauci asked me to send Chicago question
Pis advise .
From: Allison Arwady (b)(6)
--------~
To: Conrad, Patricia (NIH/NIAID) [E]________ Cb =
_>_<.,.>
Subject: Dr. Fauci asked me to send Chicago question
Dear Patty,
Last night on his call with public health leaders from cities across the country , Dr. Fauci asked me to
send him/you my follow -up question from Chicago:
How will the necessary public health workforce expansion (e.g. for wide-scale case investigation,
contact tracing, linkage to care, community testing, and vaccination) be supported at the federal
leve l?
Our unders tanding is that state or local ju risdictions will be able to deve lop their own workfor ces rather
than supporting a single workforce at the federal level, and we agree with this approach , but it would be
very helpfu l to understand next steps and potential timelines, particularly as the reopening drumbeat
gets louder.
For example, Chicago has developed a local plan/proposal (attached) that would meet our local needs,
help address some of our underlying race and economic equity concerns, and build on our existing
community and clinical partnerships. We have shared it with some partners, but it is not at all clear
how/whether/when/how much funding might be available. Given the need to quickly expand our
workforce and plan ahead, it would be very helpful to get a sense of:
a. How much funding/support might be available, and how that will be determined
b. Whether funding might come through HHS/CDC(our preferred mechanism), FEMA, or another
mechanism
c. Will support be available in weeks or months ...and for how long-we are strongly advocating
for 5 years, similar to what was done for Ebola
d. Any other information about how our local or state plans need to be adapted to fit into federal
thinking on this approach
Thank you so much; I deeply apprec iate Dr. Fauci taking the time to meet with us directly and hear our
concerns.
Allison
Allison Arwady, MD, MPH

Commissioner
Chicago Department of Public Health
(b)(6)
H EALT HY
C H IC A GO
From: David Barr
------------
To: Al lison Arwady
(b)(6)
Percak, Jeffrey M (b)(6)>; Fauci,

--:-:-:--:=====~~~--
Anthony (NIH/NIAID) [El
(b)(6);
-------
Conrad, Patricia (NIH/NIAID) [El
(b)(6)>;
Demetre Daskalakis
(b)(6)>; Mushatt,
(b)(6)>; David M
======~~- >; Barasch, (b)( 6) Kimberly (NIH/NIAID) [C] (b) (6)>; Iyengar,
Preetha (DOH) (b)(6)
Duchin, Jeff ....:..=========~~-----------------
(b)(6)
Subject : Notes from call with Dr. Fauci
Hello - Thank s for all for a very informa tive and sobering discussion last night. I've provided
bullets below to capture the main points. Please add or change as needed. I've kept this relatively
short but can supply a full recording of the call if you want it.
We will have another call next Tuesday.
David
PPE supplies:
- whi le hospitals are in better shape than a few weeks ago, significant shortages remain at long-
term care facilitates , skilled nursing facilitates , outpatient settings like doctors' offices and urgent
care clinics, shelters, prisons. Gowns are the biggest problem, but gloves, masks and shields are
also short. Doctors offices are closing for lack of PPE.
- each city is trying to solve these shortages in a short-term , piecemeal way. They need a longe r-
term solution to stab ilize availability. Outpatient settings are looking to health departments to
provide supplies , something HDs are not set up to do.
- testing in most places still requires PPE use (e.g. no avai lability of anterior nasal swabs) and the
PPE shortages are severely limiting testing scale up.
- even at hospitals , supply limitations make re-opening elective surgerie s and other procedures
impossible at this stage.
- If considering re-opening businesses, this will drastically increase PPE needs to a whole new
secto r.
TESTING challenges:
- Each city reported that, despite improvements, a very limited number of tests are being
perfom1ed compared to need.
- Supply shortages are the biggest challenge: swabs, PPE, sample kits, reagents are
the biggest obstacles. Not clear where this is going to come from or who is responsible
for addressing problems.
- Private labs limit number of sample kits distributed each week . In places where public
labs are available, there is a push to get providers to use the public labs. But many
places don't have public labs.
- There is no clear guidance on how to prioritize who gets tested first. So, in some places, that
means that people at lower-risk are being testing but people at greater risk (due to symptoms ,
exposure , high-risk living /work environment, etc) are not being testing. Guidelines are needed
to help prioritize where testing resources are used first.
- Public testing produces skewed results . Testing becomes available only to those who
can make an appointment and who can drive to the site. This means many lower-
priority people get tested but high-priority people do not. This skews understanding of
positivity rates.
- Some labs are underutilized - but the reason is that there are breakdowns in the supply chain
that make it difficult to test people and get tests to the labs. (e.g .) (b) <4)
- Reimbursement is an obstacle. CMS offering to cover test costs ($100 per test) would help get
labs to do more testing. It would not solve the problem , but it would help.
- Proliferation of unvalidated antibody tests is causing confusion. High rates of false results,
misinterpretation of what results mean (e .g. telling people who test antibody positive that they
must quarantine for two weeks). Ch icago spends a lot time shutting down these testing sites as
they make things harder and use up supplies.
- there is increasing pressure to reach a target nwnber of tests performed each day in order to get
to 're-opening'. But the number needed is contextual based on the environment, population -
there isn't one 'right' number for everywhere.
- Need better public messaging on difference between virology and serologic tests.
- Current testing capacity is no where near what is needed to make informed decisions about re-
operung.
TESTING: reporting challenges

- CwTent PoC tests have no link to provide results to health departments . Many outpatient
facili ties and SNF s have no system for repo rting test results to HDs. Need electronic link for
reporting PoC test results.
- While aggregate positive tests may be reported, negative result'>are not.
- Impossible to really understand population levels of infection because ( 1) number of tests
perfom1ed is too low and (2) not testing the 'right' people
- Every one is pushing for rapid scale up of an tibody tests, but we still don't know what the
results of these tests mean and bow to apply them to policy development.
- CDC and NIH will each coordinate sere-surveys. No details on CDC approach yet. NIH study
is up. Still not clear how to use the results of these studies , but useful to collect data now and
apply it as knowledg e grows. Locally-coordinate aero-surveys can be helpful but only if tests are
highly validated .
The Future:
- How many tests should we being doing? How much PPB/testings /beds/staff will be needed in
the coming year? Next winter, we will face dual flu and COVID outbreaks, without stable testing
capacity, how will we differentiate between the two?
- What are the plans for contact tracing? Who will recruit and train? Is there a federal p lan or
guidelines for this? How will it be paid for? What do we do to effectively isolate those infected?
This e-mail , and any attachments thereto , is intended only for use by the addressee(s) named
herein and may contain legally privileged and/or confidential information . If you are not the
intended recipient of this e-mail (or the person responsible for delivering this document to the
intended recipient ), you are hereby notified that any dissemination, distribution, printing or
copying of this e-mai l, and any attachment thereto, is strictly prohibited. If you have received
this e-mail in error, please respond to the individual sending the message, and permanently delete
the original and any copy of any e-mail and printout thereof.
Sent : Thu, 23 Apr 2020 12:53:24 +0000
To: Stover, Kathy (NIH/NIAID) [E)
Cc: Billet, Courtney (NIH/NIAID) [El;Folkers, Greg (NIH/NIAID) [El;Conrad, Patricia
(NIH/N IAID) [El
Subject: RE:FORASFREVIEW:Draft PRre: launch of hydroxychloroquine /azithromycin
study
Looks fine.
Direc;tor
Phone: (b)(6)
FAX: (301 496-4409
E-mail: Cb)(6)
From: Stover, Kathy (NIH/NIAID) [El (b)(6)

To: Fauci, Anthony (NIH/NIAID) [E) ------ --=-=
Cc:Billet, Courtney (NIH/NIAID) [E)·'======~~ (b)( ·; Folkers, Greg (NIH/NIAID) [E)
(b)(6)>; Conrad, Patricia {NIH/NIAID) [E)
--------
Subject: FORASFREVIEW:Draft PRre: launch of hydroxychloroquine/azithromycin study
(b)(6)
Hi Dr. Fauci,
Please find attached for your review a draft press rel ease describing the launc h of the ACTG
hydroxychloroqu ine/azithromycin study for COVID-19. NIAID will issue the release after the first
participant(s) has enrolled, which is currently anticipated around May 1.
The following is the quote we have drafted for you:
"We urgently need a safe and effective treat ment for COVID-19. Repurposing existing drugs is
an attractive option because these medications have undergone extensive testing, allow ing
t hem to move quickly into cli nical trials and accelerating thei r potential approval for COVID-19
t reatment ," said NIAID Director Anthony S. Fauci, M .D. "Although there is anecdota l evidence
t hat hydroxychloroquine and azithromycin may bene f it peop le with COVID-19, we need solid
data from a large random ized, control led clinical trial to determ ine whether this experimental
t reatment is safe and can improve clinical outcomes. "
Thanks much,
Kathy
Kathy Stover
Branch Chief
Nationa l Institute of Allergy and Infectious Diseases(NIAID)
Office of Communications and Government Relat ions
Nationa l Institutes of Health/HHS
Bethesda, MD 20892
Phone: (b)(6)
E-mai Cb)(6)
NIAID Med ia Line: (301) 402-1663
Sent: Thu, 23 Apr 2020 11:54 :41 +0000
To: Corey MD, Larry (b)( ;Masco la, John (NIH/VRC) [E]
Cc: Conrad, Patricia (NIH/NIA ID) [E);Fauci, Antho ny (N IH/NIA ID) [E]
Subject: NEJM m anu script
Attachments: COVID vaccine editoria l_ prefinal April2 1_7pm fsc - w ith minor Fauci edits. docx
Larry/John:
I have gone over the changes that Francis has inserted and I have edited some
of them. Please accept his changes and my edits of them (or any additional edits
that you have) and then it is OK to send in . Please let me know if you have any
questions.
Thanks,
Tony
Director
Phone: (b)( 6)
FAX: (301 496-4409
E-mail: (b)(6)
Sent : Thu, 23 Apr 2020 11:13 :29 +0000
Subject : FW: seeking your advice on a COVID-19 question
Email from Pardis Sabeti.

Bethesda MD 20892
Telephone: (b)(6)
Email: (b)(
From: Pardis Sabeti (b)(6)

----------
Se nt: Wednesday, April 22, 2020 9:47 PM
To: Fauci, Anthony (NIH/NIAID) [E)--------=- (b)
:--:
(6)
=>
Cc: Collins, Francis (NIH/OD) [E] (b)(6)
-------
Subject : Re: seeking your advice on a COVID-19question
Awe, thank you, here for you two any time, and grateful for the enormous positive impact you have on
the world, Pardis
On Wed, Apr 22, 2020 at 9:43 PM Fauci, Anthony (NIH/NIAID) [E]

------- (b)(6)> wrote:
Thanks, Pardis. It was great to spend time with you and your colleagues. We learned a lot.
Warm regards,
Tony
From: Collins, Francis (NIH/OD) [E] ______ Cb>

_C
_6)>
To: Pardis Sabeti (b)(6)>
Cc: Fauci, Anthony (NIH/NIAID ) [El (b)( >
--------
Subject : RE: seeking your advice on a COVID-19 question
Hey there Pardis,
You are much too kind - but we are grateful for YOU and your team!
It was fun to talk science for a litt le whi le. Q

Best, Francis
From : Pardis Sabeti (b)(6 )>

To: Collins, Francis (NIH/OD ) [El ------ ==>
(b)(
Cc; Fauci, Antho ny (NIH/NIAID) [El (b)(6)>
Subject : Re: seeking your advice on a COVID-19 questio n
Thank you for a great conversation. Jacob, Bronwyn, and I stayed on a moment after you left and
talked about how inspired we are by each of you and by the camaraderie between you two . Jacob
added thos e two are national treasure s, and Bronwyn and I whol eheartedly agreed.
Grateful for you both,
Pardis
On Wed, Apr 22, 2020 at 8:21 AM Collins, Francis (NIH/OD) [E]

Hi Pardis,
-------- (b)(6):> wrote:
See attached paper that argues there may be a significant difference in virulence of the COVI0- 19
clade that predominates on the west coast compared to the east coast. Tony Fauci and I would like
to kno (b) (5)
Also attached is a MedRxiv preprint that describes major differences in pathogenicity of different
viral st rains. I just got this (b)(5)
Can I talk with you later today after yo u have a chance to review this?
Thanks, Francis
Pardis Sabeti, MD, DPhil

Professor, Harvard University & Harvard T.H. Chan School of Public Healt h
Broad Institute of MIT and Harvard
Howard Hughes Medical Institute
Assistant: (b)(6)
Phone:_.!===~ (b~
H~-----------
Website: www .sabeti lab .org
Professor, Harvard University & Harvard T.H. Chan School of Public Health
Howard Hughes M edical Institute
,...!:==~~:;:;;------------ CbH >

Assistant
Phone:
------ (b)(6)
Website : www.sabetilab.org
From: (b)(6)
Sent: Thu, 23 Apr 2020 07:09 :44 -0400
Subject: Fwd: invitation to New Zealand conversation
Sent from my iPhone
Begin forwarded me ssag e:
From: Pat Brittenden < info@blindfi sh.medi a>

Date: April 23, 2020 at 12:02: 13 AM ED T
,------- --;;-~
To: "Fauci , Anthony (NIH/NIAID ) [E]"
--------
Subject: invitation to New Zealand conversation
(b)(
Good afternoon Dr Fauci,
We are intere sted in seeing if you would be ava ilable for a chat via Zoom to New
Zealand abou t COVID- 19
The US is an essential part of the NZ economy contr ibuting between $1.5 and $2
billion dollars annually from tourism alone and we would love to have a
conversation about where the US is at, how COVID-19 is being dealt with, and the
future of things that could lead up to opening our borde rs again.
We're happy to have you for any length of time, but if you hav e 10-20 minutes that
would be amazing.
Thank you for what you are doing in thi s global event, I hope we can connect
sometime soon
Sincer ely,
Pat Brittenden
www. theDOC.nz
www .patbrittenden.com /abou t
(b)(6)
From: (b)(6)
Sent : Thu, 23 Apr 2020 07:08:26 -0400
To: Barasch,Kimberly (NIH/NIAID) [CJ
Subject : Fwd: Global Healt h LeadersCall, Thursday, 23 April, 14:30 CET
Sent from my iPhone
Begin forwa rded me ssage:
From: "KABIR, Sophia" (b)( >

To: SHO C <shoc@who.int >, Office of the Director-Genera l <DGOffice @who .int> ,
"Redfie ld, Robert R. (CDC /OD) " (b) (6)
(b)( , "Felicity Harvey (b)(6)
, "Chris.Elias" (b)(6). ,
(b)(6)
"Fauci, Anthony (NIH/NIAID) [E]''
"GREIN , Thomas"
------ "COX , Paul Michael"

(b)(6).,
"SCHWARTLANDER, Bernha rd F ."
(b)(
, "MINHAS,
Raman" (b)(6)
----------.
"Conrad,Patricia (NIH/NIAID) [E]"
--------. (bH6) >, "MAHJOUR ,
Jaouad" (b)( , "FALL, Ibrahima Soce" (b) (6), "Thomas
(b)(6)
(b)(6) , Preside nt I Resolve to Save L ives

,--------
(b) (6), "Amadou.SAL L"
(b)(6) "AL-
SHORBAn, Farah" (b)(6)
1--c,~
Robynn Leidig (b) (6),
"DRURY, Patric k Anthony" (bH · , "Dr VAN KER.KHO VE, Maria"
(b)(6)
----------------- "GRAAFF , Pe ter Jan"

CbH6), "POOLE , Marcia" Cb)(6) , Tarik Mohammed
Cb)(6) Carlos
Navarro Co lorado
~
, Ryan Morhard
------ (b)(6)
~
"BRIAND, Sylvie"
"Ha JTi es, Jenny"
[C]" CbH6)
, "MORGAN, Oliv er'
CbH6)
--------
CbH , "Awwad, David (NIH/NIAID)
>, "SIMONSON, Stewart"
(b)(6)
CbH6)
"SINGER , Peter Alexander" CbH , "Jayatunga , Wikum"
(b)(6)
"Julie.HA LL"
RIOUX
, "SHIN, Young-Soo"
"SMITH, Ian Michael"

Raymond Bruce J."
Cc: SHOC <shoc@who.int >, Office of the Director-General <DG0ffice @who.int> ,

"SCHWARTLANDER, BernhardF." ....____ _,, CbH6)"MAHJOUR,
Jao uad" CbH , "FALL, Ibrahima Soce" CbH , "GREIN,
Thoma s" >, "MINHAS , Raman"
CbH6J CbH6), "COX, Paul
Michael" ____ CbH6J, "AL-SHORBAJI, Farah" CbH >,
"POOLE , Marcia" CbH6l , "DRURY, Patrick Anthony"
CbH · , "GRAAFF, Peter Jan" CbH6J, "Dr VAN
------
KERKHOVE , Maria" <6J, "FARES, Christine Youssef'
Cb>
(b)(6)
Subject: RE: Global Health Leaders Call, Thursday, 23 April, 14:30 CET
Dear colleagues,
Apologies for the mistake in the below subject line.
The meeting starts at 14.30 CET, as mentioned in the email.
Kind regards,
Sophia
From: KABIR, Sophia
To: SHOC <shoc@who .int>; Office of the Director -General <DG0ffice@who.int>;
(b)(6)
(b)(6)
, ,
TLANDER
, Be rd F. (b)(6); MINHAS,
"'.'--~==::!.....::..__ _____ .:_ ___ ..!::::======~ (b::-=
)( ~6);-
MAHJOUR,Jaouad (b)(6); FALL,lbrahima Soce

; 'Thomas R. Frieden'
:..--.....:=======::;..,:-:-=(b)( ; 'Elhadj SY'
======"=~ (b)(6); 'Lynn Banks' (b)( ·; 'President I
-------- (b)( 6)
AL-
n Leidig' (b)( ·; DRURY,

~-:-::-:-:::--:-:---:--;::::=====:::,;...-
r VAN KERKHOVE,Maria
--,;-s-=
(b)( 6)
(b)(6) SMITH, Ian Michael (b)(
Cc: SHOC<shoc@who.int>; Office of the Director-Gen eral <DGOffice@who .int>;

SCHWARTLANDER,Bernhard F. (b)(6) ; MAHJOUR, Jaouad
(b)(6)r>; FALL, lbrahima Soce (b)(6); GREIN,Thomas
====~~- - (b)(6J'c>; MINHAS, Raman -----===~~~ (b)(6); COX, Paul M ichael
::::::=====~-=(b)(6); Al -SHORBAJI, Farah (b)( ; POOLE,Marcia
====~~
::::::=====~~ (b)(6) >; DRURY,Patrick Anthony (b)(6)·> ; GRAAFF,Peter Jan
_____ (b
_J~(6)
~;_Dr VAN KERKHOVE,Maria _______ _~_<_.·>; FARES,
(b
Christine Youssef (b)(6)
Subject: Global Health leaders Call, Thursday, 23 April, 14:00 CET
Dear colleagues,
Ahead of the Global Health leaders Call at 14.30 CETtoday, please find an epidemiological
update and analysis attached , in addition to the "Consideration s in adjusting public health
and social measures in t he context of COVID-19" inte rim guidance document, which was
publ ished on the WHO website on 16 April.
Please find below, t he key questions for your consideration and input.
1. What is your view on the latest epidemiology, virus transmission and severity in
affected countries?
2. What are the emerging issues/challenges that you see as impo rtant?
3 . What should be the priorit ies for the 1-2 weeks?
4. Any other issues you see as important?
You will be able to connect via t he Webex connection below. If you experience any
technical difficulties, please contact the WHO HQ EOCoperator at: +41 22 79 15 533 or via
email: shoc@who.int.
Best,
Sophia
(b) (6), (b) (4)

Meeting number (access code):
------
(b)(6),(b)(4)
Meeting password
-------
Thursday , April 23, 2020
2:00 pm I (UTC+02:00) Brussels , Copenhagen, Madrid, Paris
Join meeting
Join by phone
Tap to call in from a mobile device (attendees only)

(bH6JTZERLAND
Toll
SToll
Global call-in numbers
Se nt: Thu, 23 Apr 2020 02: 16:12 +0000
To: Alice Park
Subjec t: FW: Time follow up
Attachment s: MedRxiv_ Mutat ions impact pathogenicity SARS-CoV-2_ Lanj uan Li et al.
2020 .04.14 ..pdf
Alice:
Here is anot her manuscript.
Tony
Sent: Thu,23 Apr 2020 02:11:27 +0000
To: Lou lgnarro
Subject: RE:Greeti ngs- NOT urgent
Lou:
Thank you for your kind note. It is much appreciated. I hope that you are well.
Best regards,
Tony
From: Lou lgnarro (b)(

sent: Tuesday, April 21, 2020 5:38 PM
To: Fauci, Anthony (NIH/NIAID) [E] -------= (b,.,..
)(=6)
Subject: Gr eet ings- NOT urgent
Hi Tony,
This is Lou lgnarro from UCLA. You and I shared the stage in the "Shoe" at the Ohio
State University a few years ago, where you gave the Graduation Address to the
undergraduate seniors . I was on stage with you, to receive an award for my basic
biomedical research which resulted in my being awarded the Nobel Prize in Medicine
in 1998. I recall the nice conversations we were enjoying with Sanjay Gupta while
robing for the event.
Thanks for the tru ly spectacular job you are doing, regarding the coronavirus
pandemic. We Nobel Laureates especially regard your work as the most important
during our lifetime. Thank you and God bless.
My best wishes,
Lou lgnarro
Sent : Thu, 23 Apr 2020 01:50:03 +0000
Subject: FW: letter from the Governor of Puerto Rico
Attachments: Dr. Anthony S. Fauci, MD[2].pdf
Heads up for a call from the Puerto Rican Health Minister.
From: Pablo L. Pena Antonmarch i <ppena@fortaleza.pr.gov>

To : Fauci, Anthony (NIH/NIAID) [E]------ (b
=)""'(6)
=>
Cc:Conrad, Patricia (NIH/NIAID) [E] (b)(6):>; Barasch, Kimberly (NIH/NIAID) [CJ
(b)(6J>; Jennifer M. Storipan <jstoripan@prfaa.pr .gov>; Juan L. Negron
----------
<j neg ron@ p rfaa.pr .gov>; Maria del C Reyes Crespo <mreyes@fortaleza.pr.gov>; Antonio L. Pabon
Batlle <apabon@forta leza.pr.gov>
Subject : letter from the Governor of Puerto Rico
Importance: High
Dear Dr. Anthony Fauci:
I am sending yo u for you r attention a letter from the Governor of Puerto Rico Hon. Wanda
Vazquez Garced.
Cordially,
Pablo L. Pena Antonmar chi

Executive Assistant
Ledo . Antonio Pabon Batlle
Chief of Staff Office
La Fortaleza
. * ., LA PORTALEZA
NOTA DE CONFIDENCIALIDAD:Esta transmisi6n electr6nica cont iene informaci6n perteneciente a

la Oficina del Gobernado r, que es confidencial, privilegiada y/o privada bajo las leyes aplicables.
Solamente podra ser util izada par la persona o entidad a la cual se dirige. Si usted no es el
destinatario intencional, se le notifica que se prohibe cualquier uso, disem inaci6n o copia de esta
comunicaci6n. Si usted recibe esta comunicaci6n por erro r, favor de notificar al remit ente y
eliminar este correo electr6nico de su sistema.
CONFIDENTIALITYNOTE: This electronic transmission contains information belonging to the
Governor's Office, which is confidential , privileged and exempt from disclosure under the
applicable law. It is intended solely for the use of the individual or entity to which it is addressed. If
you are not the intended recipient, you are hereby notified that any use, dissemination, or copying
of the communication is strictly prohibited. If you have received this communication by error,
please notify the sender and delete this e-mail from your system.
Sent : Thu, 23 Apr 2020 01:40:52 +0000
To: Alice Park;Conrad, Patricia {NIH/NIAID) [El
Subject: RE:Time follow up
Attachments : Viral Clades Brufsky 42020 Accepted Final.pdf
Alice:
It was great working w ith you today. Here is the reference. I believe that it will be in the
Journa l of M ed ical Virology . It has been accepted, but is no yet in print.
Best regards,
To ny
From:Alice Park <alice.park@time.com>

To: Fauci, Anthony (NIH/NIAID) [El <AFAUCl@niaid.nih.gov>;Conrad, Patricia {NIH/NIAID) [El
<conradpa@niaid.nih.gov>
Subject: Time follow up
Dear Dr. Fauci -- many thanks for your time today; we are thrilled to have you as part of the
TIME 100 Talks, which will go live tomorrow.
In the meantime, I wanted to double check the reference to the study you mentioned about the
east and west coast strains and their potentia l difference in virulence. Realize it's preliminary,
so just wanted t o confirm any references we make to it. I checked the biorxiv and medrx iv but
didn't find the citation. Would appreciate the journal if it was pub lished . Many thanks! Alice

Alice Park
TIME
(b)(6)
alice.park@time.com
@aliceparkny
Sent : Wed, 22 Apr 2020 16:29:19 +0000
-----~~ (b)(6)
Cc: Corey MD, Larry CbH6lMascola, John (NIH/VRC) [El
Subject: FW : "final draft"
Attachment s: COVID vaccine editorial _ prefinal April21_7pm.docx
Francis:
Here is t he paper th at I mention ed to you and t hat w e are plannin g to submit to
the NEJM. I have put you r name on it as the senior author. If you are
comfort able wit h th at , we will go wit h it. Please tak e a look at th e manu scrip t
and make any comment s or edits t hat you see fit.
Thanks,
Tony
Sent: Wed, 22 Apr 2020 14:41:09 +0000
To: Billet, Courtney (NIH/N IAID) [E]
Cc: Greg Folkers (b)( 6) ;Conrad, Patricia (NIH/NIAID) [El
Subject : RE:Request for Dr. Fauci + Ryan Zimm erman Pros For Heroes I COVID-19 Relief
Fund
I w as t hinking t he very same t hing.
Director
Phone (b) (6)
FAX: (301 496-4409
E-mail: (b)(6)
From : Billet, Courtn ey (NIH/NIAID) [E)

-------- (b)(6) >
To: Fauci, Anthony (NIH/NIA ID) [El ------ ::;..,..-,=

(b)(6)>
~======~ = >; Folkers, Greg (NIH/NIAID) [E]
Cc: Conrad , Patr icia (NIH/NIAID) [E]
(b)(6)
---------- (b)(
Subject: RE: Request for Dr. Fauci+ Ryan Zimmerman Pros For Heroes I COVID-19 Relief Fund
Ps - what do you want to bet you get invited to throw a first pitch next year?

To: Fauci, Anthony (NIH/NIAID) [E)______ """'
(b..,..
~= c6)>
Cc: Conrad, Patricia (NIH/NIAID) [E) (b)(6) •> ; Folkers, Greg (NIH/NIAID) [E)
(b)(6)>
Subject: FW: Request for Dr. Fauci+ Ryan Zimmerm an Pros For Heroes I COVID-19 R@lief Fund
We're a "go" on this . I'll circle back with his rep tomorrow.
On Apr 21, 2020, at 6:50 PM, Billet , Courtney (NIH/NIAID) [E]
w rote :
-------- (b) (6) >
Hi guys - as a huge Nats fan, Dr. Fauci very much wants to do this chat with Ryan
Zimmerman. Can I get a green light to work on this with them? I'll get the q's but it will be
the same general theme as with Steph Curry, YESNetwork, etc.
From: Judee Ann Williams <judeeann.williams@caa.com>

Se nt: Tuesday, April 21, 2020 5:54 PM
To: Billet, Courtney (NIH/NIAID) [E]--------=-s-= (b)(6)
Cc: Christine Lancman <christine .lancman@caa.com> ; Routh, Jennifer (NIH/NIAID) [E]
(b)(6)
Subject: Re: Request for Dr. Fauci+ Ryan Zimmerman Pros For Heroes I COVID-19 Relief
Fund
Absolute ly! We would 100% be able to work aro und that and avoid any association of
fund raising.
We wou ld set this up however he will be most comfo rtab le, seed questions in advance, etc.
and shed a light on what is most helpfu l.
Will wait to hear and if you need anything else ju st let us know . Thank yo u so much !
From: "Billet, Courtney (NIH/NIAID) [E]" (b)(6)
Date : Tuesday, Apr il 21, 2020 at 4:41 PM

---------
To : Judee Williams <judeeann .will iams@caa.com>
Cc: Christine Lancman <christine.lancman@caa.com>, "Routh, Jennifer (NIH/NIA ID)
[E]" (b)(6)
Subject : RE:Request for Dr. Fauci + Ryan Zimmerman Pros For Heroes I COVID-19
Relief Fund
I*Exte rnal Send er*

Hi - thanks for your message - we will check and someone will get back to you in the next
few days. One caveat is that as a Federal official, Dr. Fauci cannot be associated with
fundraising in any way . Please confirm that is someth ing you would be able to work
around?
From: Judee Ann Williams <judeeann.williams@caa.com>

Sent : Monday, Apri l 20, 2020 5:21 PM
To: Routh, Jennifer {NIH/ NIAID) [E] (b)(6)>; Billet, Courtney (NIH/N IAID)
[E] (b)( >
Cc:Christine Lancman <christ ine.lancman@caa.com >
Subject: Request for Dr. Fauci+ Ryan Zimmerman Pros For Heroes I COVID-19 Relief Fund
Jennife r & Courtney -
Hello! Our fr iends fr om Ste ph Curry's team passed along your contact info rmat ion t o us
and we work at CAA whe re we represent Wor ld Series Champion, Ryan Zimmerman.
Ryan wanted to exp ress his grat itude first & fo remost to Dr. Fauci, the ent ire te am and all
thos e beh ind th e scenes working arou nd the clock.
Ryan recent ly launc hed the Pros for Heroes Covid-1 9 Fund last week, w ith more tha n 30
pro fessional athle tes suppo rting and over $300,000 raised across 1,400 separate dona t ions.
(>www .prosforhe roes.org<). Since its launch last Tuesday, contribut ions from the Pros For
Heroes Fund have go ne directly :awards PPE needs throug hout th e Inova hospita l netw ork
t hroug hout the m id-Atlantic and have helped provide meals t o those cr it ical care fron t -line
workers - keeping these front -line heroes covered at work and comfortable at home .
If Dr. Fauci was up to it, Ryan would love to host eithe r a short 15 minute Q&A on his
Facebook to continue raising awareness for how we need to be respon ding to the ongoing
crisis. Or even simply thank Dr. Fauci for the tire less work he is doing and shine a light on
how fo lks can support these critical fron t line workers.
We are also open to what you th ink w ould work best ! Wou ld there any openings that
w ould work best?
We know Dr. Fauci is big baseball fan, and of course we are all huge fans of his! If we can
ever be support ive or help navigat e anything in the wo rld of pop cultur e, please do not
hesitate t o ask.
Warm est w ishes,
Judee Ann
Judee Ann Williams I Co-Head, CAASocial Impact

T: 2 12-277 -5294 I M: (b)(6) I Washington, DC
NEW YORK - LONDON -NASHVILLE-M UNICH - LOSANGELES-BEIJING - SHANGHAI
>https://www .caa.com/<
Pros For Heroes

"Teamwork is th e ability t o come t ogeth er tow ards a common goal. We are looking forward
t o at tra cting as many supporters t o help join this cause and give back as much as we can to
tho se who have given us so much," said Washington Nationa l All-Star, Ryan Zimmerman,
th e fu nd's fo under.
Social Links:
>https://www.instagram.com / prosforheroes/<
>http s://twitter.com/prosforheroes<
Today Show:
>https://www.today.com/video/ryan-zimmerman-talks-pros-for -heroes-fund -for -feeding-
hea lth-care-wor ke rs-82 2026935 77<
Washington Post Launch Article:

>https://www.washingtonpost .com/sports/2020 / 04/ 14/nationals-ryan-zimmerman-starts-
fund-hea Ith-care-workers -with- lO0k-gift/ <
This e-mail and any files transmitted with it are intended solely for the use of the individual
or entity to whom they are addressed. If the reader of this e-mail is not the intended
recipient or the employee or agent responsible for delivering the message to the intended
recip ient, you are hereby notified that any use dissemination, forwarding, printing or
copying of this e-mail is strictly prohibited. CAA is committed to ensuring that clients are
free to do their best work without experiencing harassment and want to ensure they have
the relevant resources they need. Clients can go to >https://www .caa.com/legal/sexual -
harassment-guidelines-caa-clients< to learn more about their rights, and how to report
violations.
This e-mail and any files transmitted with it are intended solely for the use of the individual
or entity to whom they are addressed. If the reader of this e-mail is not the intended
recipient or the employee or agent responsible for delivering the message to the intended
recipient, you are hereby notified that any use dissemination, forwarding, printing or
copying of this e-mail is strictly prohibited. CAA is committed to ensuring that clients are
free to do their best work without experiencing harassment and want to ensure they have
the relevant resources they need. Clients can go to >https://www .caa.com/legal/sexual-
harassment-guidelines-caa-clients< to learn more about their rights, and how to report
violations.
Sent : Wed, 22 Apr 2020 00:29:33 +0000
To: Colli ns, Francis (NIH/OD) [El
-----~~
Subject :
------- (b)(6)
FW: SCMP: Coronavirus's ability to mutate has been vastly underestimated, and
mutations aff ect dead liness of strains, Chinese study finds
More on mutations

Sen t: Tuesday, April 21, 2020 1:58 PM
To: Graham, Barney (NIH/VRC) [E)------- =(b=H=6)
Subject: FW: SCMP: Coronavirus's abi lity to mutate has been vast ly underestimated, and mutat ions
affect deadli ness of strains, Chinese study finds
Not peer reviewed, but w hat do yo u t hink?
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
From : Folkers, Greg {NIH/NIAID) [E] (b)( >

Sent : Monday , Apri l 20, 2020 1:53 PM
Subject: SCMP: Coronavirus's ability to mutate has been vast ly underestimated, and mutations affect
deadl iness of strains, Chinese study finds
China/ Science
Coronavirus'sability to mutate has been vastly

underestimated, and mutations affect
deadlinessof strains, Chinesestudy finds
• The most aggressive strains of Sars-CoV-2 could generate 270 times as much viral load as the
least potent type
• New York may have a deadlier stra in imported from Europe, compared to less deadly viruses
elsewhere in the United States
Stephen Chen in Beijing

Published: 10:41pm, 20 Apr, 2020
Updated: 1:33am, 21 Apr, 2020
A team led by Professor Li Lanjuan has studied how the novel coronavirus mutates and possible
implications for the pandemic . Photo: EPA-EFE
A new study by one of China's top scientists has found the ability of the new coronavirus to mutate has
been vastly underestimated and different strains may account for different impacts of the disease in
various parts of the wor ld .
Professor Li Lanjuan and her colleagues from Zhejiang University found within a small pool of patients
many mutations not previously reported. These muta tions included changes so rare that scientists had
never considered they might occur.
They also confirmed for the first time with laboratory evidence that certain mutations could create
strains deadlier than others.
"Sars-CoV-2 has acquired mutat ions capable of substantially changing its pathogenicity, " Li and her
collaborators wrote in a non-peer reviewed paper released on preprint service medRxiv.org on Sunday.
Li's study provided the first hard evidence that mutation could affect how severely t he virus caused
disease or damage in its host.
Li took an unusual approach to investigate the virus mutation. She analysed the viral strains isolated
from 11 randomly chosen Covid-19 patients from Hangzhou in the eastern province of Zhejiang, and
then tested how efficiently they could infect and kill cells.
The deadliest mutations in the Zhejiang patients had also been found in most patients across Europe,
while the milder strains were the predominant varieties found in parts of the United States, such as
Washington state, according to their paper.
A separate study had found that New York strains had been imported from Europe. The death rate in
New York was similar to that in many European countries, if not worse.
But the weaker mutation did not mean a lower risk for everybody, according to Li's study. In Zheji ang,
two pat ients in their 30s and 50s who contracted the weaker strain became severely ill. Although both
survived in the end, the elder patient needed treatment in an intensive care unit.
This finding could shed light on differences in regiona l mortality. The pandemic's infection and death
rates vary from one country to another, and many explanations have been proposed.
Genetic scientists had noticed that the dominant strains in different geograph ic regions were inherently
different. Some researchers suspected the varying mortality rates could, in part, be caused by mutations
but they had no direct proof .
The issue was further complicated because survival rates depended on many factors, such as age,
underlying health conditions or even blood type.
In hospitals, Covid-19 has been treated as one d isease and patients have received the same treatment
regardless of the stra in they have. Li and her col leagues suggested t hat defining mutations in a region
might determine actions to fight the virus .
"Drug and vaccine development , while urgent, need to take the impact of these accumulating mutations
... into account to avo id potential pitfalls," t hey said.
Li was the first scientist to propose the Wuhan lockdown ,accord ing to state media reports. The
government followed her advice and in late January, the city of more than 11 million residents was shut
down overnight.
The sample size in this most recent study was remarkably small. Other studies tracking the virus
mutation usually invo lved hundreds, or even thousands, of strains.
Li's team detected more than 30 mutations. Among them 19 mutations - or about 60 per cent - were
new.
They found some of these mutations could lead to functional changes in the v irus' spike protein, a
unique structure over the viral envelope enabling the coronavir us to bind with human cells. Computer
simulation pred icted that these mutations would increase its infectivity.
To verify the theory, Li and colleagues infected cells with strains carrying different mutat ions. The most
aggressive strains could generate 270 times as much viral load as the weakest type. These strains also
kil led the cells the fastest.
It was an unexpected result from fewer than a dozen patients, " indicating t hat the t rue diversity of the
viral strains is still largely underapprecia ted," Li wrote in the paper.
--
Professor Li Lanj uan is a leading Chinese epidemiologist. Photo: Xinhua
The mutat ions were genes different from the earliest strain isolated in Wuha n, where the virus was first
detected in late December last year.
The coronavirus changes at an average speed of about one mutation per month . By Monday, more than
10,000 strains had been sequenced by scientists around the globe, containing more than 4,300
mutations, according to the China National Centre for Bioinformation.
Most of these samples, t hough, were sequenced by a standard approach t hat could generate a result
quickly . The genes were read just once, for instance, and there was room for mistakes.
Li's team used a more sophisticated method known as ultra-deep sequencing. Each building block of the
virus genome was read more than 100 times, allowing the researchers to see changes that could have
been over loo ked by the conventional approach.
The researchers also found three consecutive changes - known as tri-nucleotide mutations - in a 60-
year-old patient , which was a rare event. Usually the genes mutated at one site at a time. This patient
spent more than 50 days in hospital, much longer than other Covid-19 patients, and even his faeces
were infectious with living viral strains.
"Investigating the functiona l impact of this tri-nucleotide mutation would be highly interesting," Li and
colleagues said in the paper .
Professor Zhang Xuegong, head of the bioinformatics division at the National Laboratory for Informat ion
Science and Technology at Tsinghua University, said ultra-deep sequencing could be an effective
strategy to track the virus' mutation.
"It can produce some useful information," he said.
But this approach could be much more time consuming and costly. It was unlikely to be applied to all
samples.
"Our understanding of the virus remains quite shallow," Zhang said. Questions such as where the virus
came from, why it could kill some healthy young people while generating no detectable symptoms in
many others still left scientists scratching their heads.
"If there is a discovery that overturns the prevailing perception, don't be surprised."
of U.S. copyright law, without further verification of its accuracy/veracity . It does not necessarily represent
my views nor those ofNIAID, NIH, HHS, or the U.S. government.
Sent : Wed, 22 Apr 2020 00:16:44 +0000
-----~~ (b)(6)
Subject : FW: For your attent ion
-------
Attachments : COVAX2020-A GLOBALEFFORTfor the ACCELERATED DEVELOPMENT,
PRODUCTIONand EQUITABLEACCESSto COVID-19 VACCINES_16Apr2020_0RAFT.docx
See attachment that Hilary sent me. (b)(5)
From: Marston, Hilary (NIH/NIAID) [El

________ _,
(b)(6)

Subject : Re: For your attent ion
(b) (5)
From:Anthony Fauc i Cb)<>

Date : Tue sday, April 21, 2020 at 7:30 PM
To: Hila ry Marston (b)( v>
Subject: FW: For your attention
Have you heard of this on any of the calls where you represent me??
From: Collins, Francis (NIH/OD) (El (b)(6)

To : Fauci, Anthony (NIH/ NIAID) (El--------=- (b"""
)(= ; Lane, Cliff (NIH/N IAID) (El
-------- (b)( Tabak, Lawrence (NIH/OD) (El

·;
(Tl <mfreire@fni h.org>; Wholley, David (FNIH) (T) <dwholley@fnih.org>
(b)(6)>; Freire, Maria (FNIH)
Subject: FW: For your attention
Hi all,
See note below from Victor Dzau about a g loba l effort on COVID-19. I can't tell if this is more
than a fund-raising effort. I know we have Gates reps on our ACTIV working groups- has any of
this p lan come up , David ?
Francis
From:Dzau, Victor J. <VDzau@nas.edu>

To: Collins, Francis (NIH/OD) [El ------=- (b'""'
)( =-
6)
Cc: Kanarek, Morgan <MKanar ek@nas.edu>
Subject: For your attenti on
Dear Francis,
Congratulat ions on your launch of Public Private Partnership to speed COVID 19 vaccine and treatment
options. This is very timely and much needed. Kudos to your leadership .
I am sure you are aware of a global coordinating effort to accelerate vaccines, diagnostics and
therapeutics. I have been part of the conversation and planning along with Jeremy Farrar, Richard
Hatchett , Seth Berkley, Chris Elias, Paul Stoffels etc . Recently WHO, Gates Foundation and European
Commission have been leading the planning. This has advanced rapidly and is in the final stages in
development that wil l be soon announced. It has involved European Commission, Germany, Japan, UK,
Norway , France, Saudi as well as Gates Foundation, WHO, World Bank, Wellcome Trust, GAVI, Global
Fund, CEPI,GPMB and private sector industry . The initiative will begin with a Pledge conference for $8B
as a starting point. This will be led by President van der Leyen and is co-chaired by the above country
leaders. This will occur on M ay 4 . In addition by the end of this week or early next week there will be an
announcement on the global coordinating structure with w ill involve Gates, WHO etc .
I am writing to be sure that you and the White House are aware of these upcoming events . Can you
share this information with the White House? Besides you, who else should I share this information
with? I will be happy to send you background documents if you wish .
Please call me anytime.
Best,
Victor
From: Eisinger, Robert (NIH/ NIAID) [El on behalf of Fauci, Ant hony (NIH/NIAID) [El
Sent : Tue, 21 Apr 2020 23:10:36 +0000
Subject: FW: Consideration of IM COVID Immune Globul in for Prevent ion of COV ID-19
Infect io n
Attachment s: Prophylact ic Intramuscular COVID- IG - Oxman.pdf, FURTHERARGUM ENTS IN
FAVOROF INTRAMUSCULARCOVID-IGVersion 4 - Oxman.pdf
Email from Gary Noble, advisor to Bob W indom in the 1980s.

Immediate Off ice of the Director
Bethesda M D 20892
Telephone: (b)(6)
Email : (b)(
From : Gary Noble (b)(6)

Sent : Tuesday, Apr il 21, 2020 4 :56 PM
To: Fauci, Ant hony (NIH/ NIAID) [E]-----~= (b)(6)>
Cc: M cGowan, John J. (NIH/ NIAID) [E] (b) (6); Conrad, Patricia (NIH/ NIAID) [E]
(b)(6J·; Oxman, M ichael
-------- (b)( ·
Subject : Consideration of IM COVID Immune Globulin for Prevention of COVID-19 Infection
Dear Tony,
I will always remember our amazing collaboration during the HIV/AIDS days in
the 1980s , when I served as AIDS Advisor to Bob Windom , the DHHS
Assistant Secretary for Health during President Reagan's administration. And
now, I am delighted and amazed to wat ch you so adroitly maneuver the
COVID-19 scientifi c policies and keep them front and center in the current
White House!!
Michael Oxman, has worked

---------------- Cb><6>\,
with John Zaia at City of Hope , and a Mayo/ Hopkins /Michigan State
consortium for a tria l of IM COVID-IG as a prefe rred method for treatment
and prevent ion of COVID-19.
This week , Mike expects to complete the protocol for a placebo (normal
IG)-controlled trial of IM COVID-IG prophylaxis in at-risk healthcare workers
who are engaged in direct patient care at UCSD, but they need a modicum
of support. Mike asked if I would reach out to see if NIAID might provide of
support for this effort, using IM, as opposed to IV, COVID-IG.
I've copied Mike, who has provided the attached background information.
Tony , with all my respect and admiration for what you are doing for the U.S.
and for all of us.
Gary
Gary R. Noble, MD, MPH, MA (Oxon)

Sent : Tue, 21 Apr 2020 22:14:24 +0000
To: NIAIDODAM
Subject: FW: Invitation to Speak at UC Berkeley COVID-19 Hackathon
Let us discuss.
Director
Phone: (b)( 6)
FAX: (30 496"'4409
E-mail Cb)(6)
From: Saahil Chadha <saahil@calhacks.io>

Sent: Tuesday, April 21, 2020 11:00 AM
To: Fauci, Anthony (NIH/NIAID) [E] _______
------~~ CbH6)>
_,
Subject: Inv itation to Speak at UC Berkeley COVID-19 Hackathon
Dear Dr Fauci,
My name is Saahil , and I'm a director at Cal Hacks , a student organization at the
University of California, Berkeley. This upcoming weekend, we will be hostingh ack:now ,
a 36-hour global online hackathon to foster innovative and technical solutions to tackle
the challenges faced around the current COVI D-19 pandemic. We're projected to have
1,500 participants from around the world. I'm reach ing out to invite you to be our
opening ceremony speaker.
Specifically , this Friday night, April 24 , from 7-8pm Pacific Daylight Time , we're going to
be hosting the opening ceremony of our event. At this time , we want to inspire our
hackers to help solve global challenges relate d to health and community. We would be
absolutely honored if you would join us to speak at our opening ceremony for
just a few minutes to share your experiences with and response to the COVID-19
pandemic. Your unique perspective and expanse of knowledge makes you the most
qualified person, and we would be humbled to include you as our opening ceremony
speaker. Please let us know if you are able to accept this invitation.
Stay safe ,
Saahil Chadha
(b)(6)
Calhacks .io
Sent : Tue, 21 Apr 2020 22:06:57 +0000
To: Folkers, Greg (NIH/NIAID) [E);Conrad, Patricia (NIH/NIAID) [El
Subject: RE: Message for Dr Anthony FAUCI
OK. Please take care of this. Thanks.
Director
Phone: (b)(6)
FAX: (30 496"'4409
E-mail: (b)(6)
From: Folkers, Greg (NIH/NIAID) [El

Sent: Tuesday, April 21, 2020 11:31 AM --------- (b)(6)
To : Conrad, Patricia (NIH/NIAID) [El --------,;- )(=6):>; Fauci, Anthony (NIH/NIAID ) [El
(b"'"'"'
(b)(6)
Subject: RE: Message for Dr Anthony FAUCI
I wou ld be extreme ly grateful to you if you can provide me with the most recent and pertinen t scientific
and population data concerning cov id-19. I know how extremely busy you are but maybe a collaborator
of yours whether he can send me the data via e-mail (b)(6)_
Not exactly sure what he wan ts but I can send him some links that will get him the latest CoV
info from pubmed, prepr ints, CDCetc
From: Conrad , Patricia (NIH/NIAID) [El (b)(6)>

Sent: Tuesday, April 21, 2020 11:16 Atvl
To: Fauci, Anthony (NIH/NIAID) [E]-------= (b)
""'
(=
6)>
Cc:Folkers, Greg {NIH/NIAID) [El _______ CbJ
_C6)
_
Subject: FW: Message for Dr Antho ny FAUCI
Can we direct her somewhere? Gray?

Patricia L. Conrad
(b)(6)
301-496-4409 fax
Disclaimer:
The information in this e-ma il and any of its attachments is confidentia l and may contain sensi tive information . It should not be used
from your mailbox or any other storage devices. Nationa l Institute of Allergy and Infectious Diseases (NIAID) shall not accept
liability for any statement made that are sender's own and not expressly made on behalf of the NIAIO by one of its representatives .
From: Jean-Louis Touraine

------------------
To: Conrad, Patricia (NIH/NIAID) [E]________ (b
"")'""'
(6)
=
(b)( >
Subject: Potential SPAM:Message for Dr Anthony FAUCI
I wou ld be very grateful to you if you can forward the following mail to Dr Anthony FAUCI.
Many thanks.
Sincerely yours,
Pr Jean-Louis TOURAINE,Lyon and Paris, France.
Dear Tony,
You may remember, that we have met repeatedly and worked in parallel and in association, during the
early years of the HIV epidemic .
You and I have been trained in immunoly. Both of us are much sollicitated to help facing and f ighting the
covid-19 epidemic .
During the past years, as well as recently, I have followed with great interest and respect your
accomplishments and your advices in the fights against epidemics. I would be extremely grateful to you
if you can provide me with the most recent and pertinent scientific and population data concerning
covid-19. I know how extremely busy you are but maybe a collaborator of yours whether he can send
me the data via e-mail (b) (6) This will allow me to give more
documented informations to the French President and Government. Cooperation between countries will
be crucial against covid-19 as it has been against HIV and other agents.
I look forward to seeing you again in quieter times.
Many thanks and very best personal regards.
Jean-Louis TOURAINE, M.D., Ph. D., M.P.
Ce message, ainsi que les pieces jointes, sont etablis, sous la

seule responsabilite de l'expediteur, a !'intention exclusive
de ses destinataires ; ils peuvent contenir des informations
confidentielles . Toute publication, utilisation ou diffusion
doit etre autorisee prealablement.
Ce message a fait l'objet d'un traitement anti-virus.
11est rappele que tout message electronique est susceptible
d'alteration au cours de son acheminement sm Internet.
Yous pouvez consulter le site de l'Assemblee nationale a

l'adresse suivante : http://www.assemblee-nationale.fr
Sent: Tue, 21 Apr 2020 21:39:30 +0000
To: Colli ns, Francis (NIH/OD) [El
-----~~ (b)(6)
Cc: Myles, Renate (NIH/OD) [E);Burk low , John (NIH/ OD) [E);Billet, Courtney
(NIH/N IAID) [E);Conrad, Patricia (NIH/ NIAID) [E]
Subject : FW: STAT: Director of U.S. agency key to hel ming vaccine deve lopme nt leaves
ro le suddenly amid coro naviru s pandemic https://bi t. ly/ 2XRZqKa
(b) (5)
Director
Phone: (b)( 6)
FAX: (301 496-4409
E-mail (b) (6)
From: Folkers, Greg (NIH/N IAID) [E) (b) (6) >

--------
Subject : STAT: Director of U.S. agency key to helmi ng vaccine deve lopment leaves role sudde nly am id
coro naviru s pandemic ht t ps:// bit .ly/2XRZqKa
Director of U.S. agency key to helming vaccine

development leaves role suddenly amid
coronavirus pandemic
By Nicholas Florko @NicholasFlo rko
April 21, 2020
Rick Bright HHS
WASHINGTON - Rick Bright, one of the nation's leading vaccine development experts and the director
of the Biomedical Advanced Research and Development Authori ty, is no longer leading the organization,
officials to ld STAT.
The shakeup at the agency, known as BARDA,couldn't come at a more inopportune time for the office,
which invests in drugs, devices, and other technologies that help address infectious disease out breaks
and which has been at t he center of the government's coronaviru s pandemic response.
Bright, whose departure was confirmed by th ree industry sources and two current Trump admin istration
sources, will instead move into a narrower role at the National Institutes of Health overseeing a similar
but lim ited public-pr ivate part nership aimed at vaccine development. Gary Disbrow, Bright's former
deputy at BARDA,wi ll serve as the acting director of the office, an HHSspokesperson confirmed to
STAT.
BARDAwas expected to play an even larger role in the coming months; Congress more than tripled
BARDA's budget in the most recent coronavirus stimulus package. Already, the office has a role in some
of the splashiest Covid-19 projects, including partnerships with Johnson & Johnson and Moderna
Therapeut ics, both of which are developing potent ial Covid-19 treatments .
Related:
This tiny federal agency was built to respond to a crisis like

coronavirus. Now that it's here, is BARDA ready?
BARDA has been plagued with management issues virtually since its creation in 2006, with much of the
criticism aimed at a contracting department that some say is unresponsive to industry partners. The
office has only had two permanent directo rs since its creation in 2006. Bright has led the organization
since 2016.
None of the sources articu lated the reason for Bright's departure, though several mentioned recent
chafing between Bright and Bob Kadlec, the HHSAssistant Secretary for Preparedness and Response,
which has oversight over BARDA.
An HHSspokesperson confirmed that Bright will work on a recently announced NIH public-private
partnership with 16 drug makers aimed at develop ing vaccines and treatments for Covid-19.
"Dr. Rick Bright will transfer the skills he has applied as Director of the [BARDA)to the [NIH) .... Dr. Bright
brings extensive experience and expertise in facilitating powerful pub lic-private partnerships tha t
advance the health and well -being of the American people," the spokesperson said.
Bright did not immed iately respond to requests for comment.
Bright's career has largely centered around vaccine and drug development . His work at the Centers for
Disease Control and Prevention focused on influenza viruses, antiviral drugs and tests . He has also
worked in the biotechnology industry and served as an advisor to the World Health Organization. Before
becoming BARDAdirector, he led the agency's Influenza and Emerging Infectious Diseases Division.
Lev Facher contributed reporting.
Disclaimer: Any third-party material in this email bas been shared for internal use under fair use provisions
of U.S. copyright law, without further verification of its accuracy /veracity. It does not necessarily represent
my views nor those of NlAID , NlH , HHS, or the U.S. government.
Sent: Tue, 21 Apr 2020 21 :18:24 +0000
To: Crawford , Chase (NIH/NIAID) [E);Auchincloss, Hugh (NIH/NIAID) [E); McGowan ,
John 1. (NIH/NIAID) [ E];Ha rper, Jill (NIH/NIAID) [E];Gilles, Sharon (NIH/NIAID) [E);Lane, Cliff (NIH/NIAID)
[E];John son, Martin S. (NIH/NIAID) [ E);Marston, Hil ary (NIH/NIA ID) [E];Bill et, Courtney (NIH/NIAID) [E]
Cc: Haskins, Melinda (N IH/NIAID) [E];Selgrade , Sara (NIH/NIAID) [E)
Subject: RE: Atte ntion: COVID-19 legislative package bill text released
Thanks.
Direc;tor
Phone: (b)(6)
FAX: (301) 496-4409
E-mail: (b) (6)
From: Crawfo rd, Chase (NIH/NIAID) [E] (b)(6)>

Sent: Tuesday, April 21, 2020 3:27 PM ---------
To: Fauci, Anthony (NIH/NIAID) [E) -------,;; CbH
= >; Auchi ncloss, Hugh (NIH/NIAID) [E)
(b)(6J> ; McGowan, John J. (NIH/NIAID) [E] "':"':"".".'.""."".~======-- =
-.J i':":"'
11":"'.'
( N"."'.'
l'.""."
H/":"'.'
N':":"'
IA
"."".
l~D:-:
) [~E:-::
] ==~~--= (b=H~ >; Gill es, Sharon (NI H/N JAi D) [ E] >;
"""-:--:-:--:-:::====:::::::......:..._~
_
Lane, Cliff (NIH/NIAID) [E]
__;__ __;__,;___..;..:,~'=i-':-:----:-::-:--::-:-:"
(b)(6) ; Johnson, Martin S. (N IH/NIAID) [E]
.
(b)( ; Marston, H ilary (NIH/NIAID) [El (b)( ; Bille t,
-C-o -ur-tn_e_y'"'.'
(_
N_ IH'"'.'
/ _N_IA-ID
-:-)'"'.'
[--:
El~!,;._--....,;_ _ _;,(b,.:) ~(6)
Cc: Haskins, Melinda (NIH~/ "."'.
N-:-:
IA-:-:
1D
~):-:[~E:-::
l ====--- (b
'""' 6); Selgrade , Sara (NIH/NIAID) [El
)"'~=
(b)(6)
Subject: Atte ntion: COVID-19 legislative package bill text released
Importance: High
Good Afternoon,
At 4p.m. today (4/21), the U.S. Senate is expected to hold a vote by unanimous
consent on the "Paycheck Protection Program and Health Care Enhancement Act"
(bill text attached). In particular please note that the legislat ive package includes
the following supplemental appropriations for diagnostic testing (pages 13-15 of
attached) :
• NIH/OD - not less than $1B to develop, validate, improve, and implement
testing and associated technologies; to accelerate research, development,
and implementation of point of care and other rapid testing; and for
partnerships with governmental and non-governmental entities to
research, develop, and implement the activities outlined in this proviso.
• funds in the preceding proviso may be transferred to the accounts of the
Institutes and Centers of the National Institutes of Health for the
purposes specified in the preceding proviso
• the transfer authority provided in the preceding proviso is in addition to
all other transfer authority available to the NIH
• NCI - not less than $306M to develop , validate, improve, and implement
serological testing and associated technologies for the purposes specified
under this paragraph in this Act:
• NIBIB - not less than $S00M to accelerate research, development, and
implementation of point of care and other rapid testing related to
coronavirus:
• CDC - not less than $1B for surveillance, epidemiology, laboratory capacity
expansion, contact tracing, public health data surveillance and analytics
infrastructure modernization, disseminating information about testing, and
workforce support necessary to expand and improve COVID-19 testing
• BARDA- not less than $1B for necessary expenses of advanced research,
development, manufacturing , production , and purchase of diagnostic ,
serologic, or other COVID-19 tests or related supplies, and other activities
related to COVID-19 testing at the discretion of the Secretary
• FDA-$22M to support activities associated with diagnostic, serological,
antigen, and other tests, and related administrative activities
We will keep you updated on any developments related to this legislation. Please
let us know if you have any questions.
Thanks,
Chase
Sent : Tue, 21 Apr 2020 21:01:27 +0000
Subject: RE: Ryan Zimmerman
(b)(5)- PC
If cleared, I would love to.
Director
Phone: (b)(6)
FAX: (30 496"'4409
E-mail Cb)(6)
From: Billet, Courtney (NIH/NIAID) [E] (b)(6)

To : Fauci, Anthony (NIH/NIAID) [E] ------ == (b)(6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] CbH6l>;Routh, Jennifer (NIH/NIAID) [E]
(b)(6); Stover, Kathy (NIH/NIAID) [E] (b)( ·; Folkers, Greg
"'.'"'
(N--1-H/-:-
N--IA--ID
~)-:-[E
::":'
]=====:!.;___...;._ =(b=
)(6)
~
Subject: Ryan Zimmerman
Would you be interested in do ing something with Ryan Zimmerman? Format TBD. We' ll pursue further
discussion if you give the green light.
From: Billet, Courtne y (NIH/NIAID) [E]

To: Judee Ann Wi lliams <judeeann.will iams@caa.com>
Cc: Christine Lancman <christine. lancman@caa.com >; Routh, Jennifer (NIH/NIAID) [E)
(b)(6)
Subject: RE: Request for Dr. Fauci+ Ryan Zimmerman Pros For Heroes I COVID-19 Relief Fund
Hi - thanks for your message - we will check and someone w ill get back to you in the next few days. One
caveat is that as a Federal official , Dr. Fauci cannot be associated with fundrais ing in any way . Please
confirm that is something you would be able to work around?
From: Judee Ann Williams <jude eann.will iams@caa.com>
Sent: Monday , April 20, 2020 5:21 PM
To: Routh, Jennifer (NIH/NIAID) [E] -------~~ (b)(6); Billet, Courtney (NIH/NIAID) [E]
(b)(6)>
Cc: Christine Lancman <christine. lancman@caa .com>
Subject: Request for Dr. Fauci+ Ryan Zimmerman Pros For Heroes I COVID-19 Relief Fund
Jennifer & Courtney -
Hello ! Our friends from Steph Curry's team passed along you r contact info rmation to us and we work at
CAA where we represe nt Wor ld Series Champion, Ryan Zimmerman .
Ryan wa nt ed to express his gratitud e first & fo remost t o Dr. Fauci, the entire team and all those behind
the scenes wo rkin g around the clock.
Ryan recent ly launched the Pros for Heroes Covid-19 Fund last week, with more than 30 pro fessiona l
athletes supporting and over $300,000 raised across 1,400 separate donat ions.
(www.prosforheroes.org). Since its launch last Tuesday, contributions from the Pros For Heroes Fund
have gone direct ly towards PPEneeds throug hout the Inova hospital netwo rk throug hout the mid -
Atlantic and have helped provide mea ls t o those critical care front -line wo rkers - keepi ng these front -line
heroes covered at wor k and comfo rtab eat home.
If Or. Fauci was up to it, Ryan would love to host eit her a short 15 minute Q&A on his Facebook t o
continue raising awareness for how we need to be responding to th e ongo ing crisis. Or even sim ply t hank
Dr. Fauci for the tir eless work he is doirg and shine a light on how folks can support th ese cr it ical fro ntline
workers.
We are also open to what you think would wo rk best I Would there any ope nings that would work best?
We know Dr. Fauci is big baseball fa n, and of course we are all huge fans of his! If we can ever be
support ive or help navigate anyth ing in the world of pop culture, please do not hesitate to ask.
Warmes t w ishes,
Judee Ann
Judee Ann Williams I Co-Head, CAASocial Impact

T: 212-277-5294 I M (b)(6) I Washington, DC
NEW YORK· LONDON -NASHVILLE·MUNICH - LOSANGELES-BEIJING · SHANGHAI
https://www.caa.com/
Pros For Heroes

"Teamwork is the ability t o come together towards a common goal. We are looking forward to attracting
as many supporters to help join this cause and give back as much as we can t o those who have given us
so much," said Washington National All-Star, Ryan Zimm erman, the fund's founder.
Social Links:
https://www.instagram.com/prosforheroes/
https ://twitter. com/prosforheroes
Today Show:
https://www.today .com/video/ryan-zimmerman-talks -pros-for -heroes-fund -for-feeding -health-care-
workers-82202693577
Washington Post Launch Article:

https ://www. wash i ngton post. com/sports/2020/04/14/nationa ls-ryan-zi mmerma n-sta rts-fund-hea Ith-
care-workers-with- lO0k-gift/
This e-mail and any files transmitted with it are intended solely for the use of the individua l or entity to
whom they are addressed. If the reader of this e-mail is not the intended recipient or the employee or
agent responsible for delivering the message t o the intended recipient, you are hereby not ified that any
use dissemination, forwarding, printing or copying of this e-mail is strictly prohibited . CAA is committed
t o ensuring that clients are free to do their best wo rk without experiencing harassment and want to
ensure they have the relevant resources they need. Clients can go to https://www.caa.com/legal/sexua l-
harassment-guidelines-caa -clients to learn more about their rights, and how to report violations .
Sent : Tue, 21 Apr 2020 20:44:40 +0000
Cc: Billet, Court ney (NIH/NIA ID) [E);clane@niaid .nih .gov
Subjec t : RE:urgent: CNN request
Cliff should do thi s.
Director
Phone : (b)(6)
FAX: (3 96':44li9
E-mail Cb)(6)
From : Conrad , Patricia (NIH/NIAID) [E) (b) (6):>

Se nt : Tuesday, April 21, 2020 4:41 PM ---------
To : Fauci, Anthony (NIH/NIAID) [E] -------~=
Subject: Fwd: urge nt: CNN request
--------- (b)(6)
Sent from my iPhone
From: "Conrad, Patricia (NIH/NIAID) [E]"

Dat e: April 21, 2020 at 4:31 :46 PM EDT ---------
------~~
To: "Billet , Courtney (NIH/NIAID) [ E]" (b)(6)>
(b) (6)>
Subje ct : Fw d: urgent: CNN request

--------
Sent from my iPhone

From: " Billet, Courtney (NIH/NIAID) [E]" (b)(6)
Date : April 21, 2020 at 2:49:39 PM EDT
To: "Con rad, Patricia (NIH/NIAID) [E]" -------~~ (b)(6)
Cc: "Routh, Jennifer (NIH/NIAID) [E]" ..:======= (b
~):::;,
(6)
~
Subject: FW: urgent : CNN request
Patty - can you please check with Dr. Fauci if he'd like to speak to Elizabeth
Cohen about the treatment guidelines.
From: Lane, Cliff (NIH/NIAID) [E]

-------
To: Billet , Courtney (NIH/NIAID) [E] ------~= (b)( ; Pau, Alice
(NIH/NIAID) [E] (b)(6)>
Cc: Doepel, Laurie (NIH/NIAID) [E] (b)(6); Masur, Henry
(NIH/ CC/CCMD) [E]_.:...__..:....:_.:..== (b"'":
)::"'"
(6)
~;-M_y_le-s,- R-e-na_t_
e ,_
(NI H/0 D) [ E]
(b)(6)>
Subject : Re: urgent: CNN request
I think Dr. Fauci would want the option of first refusal. He has anticipated he
will be asked about these.
From: "Bi ll et, Courtney (NIH/ NIAID) [E]" (b)(6)

Date : T uesday, Apr il 21, 2020 at 1:35 PM
----------
To: "Pau, Alice (NIH/NIA ID) [E]" -------= Cb
=H=6J>
Cc: Laur ie Doepe l CbH6)>,"Masur, Henry
(NI H/CC/CC MD ) [E
'":]-::-:
11
:.::======;;, (b,;:::
)(~6), " Lane, Cliff (N IH/NIA ID)
[E]" CbH6),"Myles, Renate (NIH/OD) [E]"
.;....:.--=====~~--
(b)( 6)>
Subject: RE: urgent: CNN request
HI Alice - thanks for sending this along. We will confer about how best to
handle media requests about the guidelines - we're calling them NIH
guidelines and the press release came from NIH, so I'd like to involve the NIH
media office in this, hence I've cc'd Renate Myles . I think it's sort of an
unsettled question as to who the spokespeople will be. Drs. Lane and Masur
- do you have a preference?
Also, who is Claire? (The person who forwarded the CNN request to you and
Dr. Masur. Would be good to have a last name so we can confer with her as
needed going forward.)
(b)(6)>
From: Pau, Alice (NIH/NIAID) [E]
-------
To: Billet, Courtney (NIH/NIAID) [E] (b)(6)
Cc: Doepel, Laurie (_N_IH..:..
/ _N_IA_ID
....:
.;.:::======~~
)..:[....:
E]:..!=-:-=;:-----."'."""."9 (b
_)_C6)
~ Masur, Henry
(NIH/CC/CCMD) [E] (b)(6)>; Lane, Cliff (NIH/NIAID) [E]
(b)(6)>
Subject: FW: urgent: CNN request
Hi Courtney,
Please see below the request from CNN. Per Laurie, I will forward
other reques t s to you.
Thanks, Alice
From : COVID19 Treatment Guidelines

<C0VID19TreatmentGuidelines@nih.gov >
To: Henry Masur (b)(6),Alice Pau
(b)(6)>
Subject: Fw: urgent: CNN request
Hi Henry and Alice,
I am not sure how we want to handle interview requests like this.

Would someone on the Panel want to/be allowed to speak to the press
about the guidelines?
I am happy to politely declin e if we want to handle it that way.
It is nice to see that we are being picked up by the press already

though. I am glad peop le are already expressing interest.
Just let me know!

Claire
From: Nigam, M inali <Minali.Nigam@turner.com >

To: COVID19Treatment Guidelines <C0VID19TreatmentGuidelines@nih.gov >
Cc: Cohen, Elizabeth <Elizabeth.Cohen@turner.com >; Fine, Amanda (NIH/OD)
[E] (b)( >
Subjec t : urgent: CNN request
To the NIH Covid- 19 Treatment Guidel ine Team:

My name is Minali Nigam and I work with Elizabeth Cohen at CNN
Health . We wanted to reach out and request to speak with someone
over the phone involved with the NIH treatment guidelines for covid-
19. Please let us know as soon as possible for an availab le time today.
We appreciate your help, as we inform our viewers of important health

information.
Best,
Minali
Dr. M inali Nigam

CNN Health
(b)(6)
(bXS) -PCl1
(b)(5) - Pe l
(bX5) -PCI
(bX5) -PCI
(bX5)-PCI
(bX5) -PCI
(bX5) -PCI
(bX5) -l'U
Sent : Tue, 21 Apr 202019 :42:03 +0000
To: Birx, Deborah L. EOP/NSC;Hahn, Stephen;Redfield , Robert R. (CDC/OD)
Subject : FW: SCMP: Coro navirus's ability to mutate has been vast ly underestimated, and
mutations aff ect dead liness of strains, Chinese st udy finds
See below
Director
Phone: (301) 496-2263
FAX: (301) 496-4409
E-mail: afauci @niaid.nih.gov
From: Folkers, Greg (NIH/NIAID) (E] (b)(6)

Subject: SCMP: Coronavirus's ability to mutate has been vastly underestimated, and mutations affect
deadl iness of strains, Chinese study finds
China/ Science
Coronavirus'sability to mutate has been vastly

underestimated, and mutations affect
deadlinessof strains, Chinesestudy finds
• The mos t aggressive strains of Sars-CoV-2 could generate 270 times as much viral load as the
least potent type
• New York may have a deadlier strain imported from Europe, compared to less deadly viruses
elsewhere in the United States
Stephen Chen in Beijing
Published: 10:41pm, 20 Apr, 2020
Updated: 1:33am, 21 Apr, 2020
A team led by Professor Li Lanjuan has studied how the novel coronavirus mutates and possible
implications for the pandemic. Photo: EPA-EFE
A new study by one of China's top scientists has found the ability of the new coronavirus to mutate has
been vastly underestimated and different strains may account for different impacts of the disease in
various parts of the world.
Professor Li Lanj uan and her colleagues from Zhejiang University found within a small pool of patients
many mutations not previously reported . These muta t ions included changes so rare that scientists had
never considered they might occur.
They also confirmed for the first time with laboratory evidence that certain mutations could create
strains deadlier than others.
"Sars-CoV-2 has acquired mutat ions capable of substantially changing its pathogenicity," Li and her
collaborators wrote in a non-peer reviewed paper released on preprint service medRxiv.org on Sunday.
Li's study provided the f irst hard evidence that mutation could affect how severely the virus caused
disease or damage in its host.
Li took an unusual approach to investigate the virus mutation . She analysed the viral strains isolated
from 11 randomly chosen Covid-19 patients from Hangzhou in the eastern province of Zhejiang, and
then tested how efficiently they could infect and kill cells.
The deadliest mutations in the Zhejiang patients had also been found in most patients across Europe,
while the milder strains were the predomina nt varieties found in parts of the United States, such as
Washington state, according to their paper.
A separate study had found that New York strains had been imported from Europe. The death rate in
New York was similar to that in many European countries, if not worse .
But the weaker mutation did not mean a lower risk for everybody, according to Li's study . In Zheji ang,
two patients in their 30s and 50s who cont racted the weaker strain became severely ill. Although both
survived in the end, the elder patient needed treatment in an intensive care unit .
This finding cou ld shed light on differences in regio nal mortality . The pandemic's infection and death
rates vary from one country to another , and many explanations have been proposed .
Genetic scientists had noticed that the dominant strains in different geograph ic regions were inherently
different. Some researchers suspected the varying mortality rates could, in part, be caused by mutations
but they had no direct proof.
The issue was f urther complicated because survival rates depended on many factors, such as age,
underlying health conditions or even blood type .
In hospitals, Covid-19 has been treated as one d isease and patients have received the same treatment
regardless of the strain they have. Li and her col leagues suggested t hat defining mutations in a region
might determine actions to fight the virus .
"Drug and vaccine development, while urgent, need to take the impact of these accumulating mutations
... into account to avoid pote ntial pitfalls," t hey said.
Li was the first scientist to propose the Wuhan lockdown.accord ing to state media reports. The
government followed her advice and in late January, the city of more than 11 million residents was shut
down overnight.
The sample size in this most recent study was remarkably small. Other studies tracking the virus
mutation usually involved hundreds, or even thousands, of strains.
Li's team detected more than 30 mutations. Among them 19 mutations - or about 60 per cent - were
new .
They found some of these mutations could lead to functional changes in the virus' spike protein, a
unique structure over the viral envelope enabling the coronavir us to bind with human cells. Computer
simulation pred icted that these mutations would increase its infectivity .
To verify the theory, Li and colleague s infected cells with strains carrying different mutat ions. The most
aggressive strains could generate 270 times as much viral load as the weakest type. These strains also
killed the cells the fastest.
It was an unexpected result from fewer t han a dozen patients, "ind icating that the true diversity of the
viral strains is still largely underappreciated," Li wrote in the paper.
-
Professor Li Lanjuan is a leading Chinese epidemiologist. Photo: Xinhua
The mutat ions were genes different from the earliest strain isolated in Wuhan, where the virus was first
detected in late December last year.
The coronavirus changes at an average speed of about one mutation per month. By Monday, more than
10,000 strains had been sequenced by scientists around the globe, containing more than 4,300
mutations, according to the China National Centre for Bioinformation.
Most of these samples, t hough, were sequenced by a standard approach that could generate a result
quickly. The genes were read just once, for instance, and there was room for mistakes.
Li's team used a more sophisticated method known as ultra-deep sequencing. Each building block of the
virus genome was read more than 100 times, allowing the researchers to see changes that could have
been overlooked by the conventional approach.
The researchers also found three consecutive changes - known as tri-nucleotide mutations - in a 60-
year-old patient, which was a rare event. Usually the genes mutated at one site at a time. This patient
spent more than 50 days in hospital, much longer than other Covid-19 patients, and even his faeces
were infectious with living viral strains.
"Investigating the functiona l impact of this tri-nucleotide mutation would be highly interesting," Li and
colleagues said in the paper.
Professor Zhang Xuegong, head of the bioinformatics division at the National Laboratory for Information
Science and Technology at Tsinghua University, said ultra-deep sequencing could be an effective
strategy to track the virus' mutation.
"It can produce some useful info rmation," he said.
But this approach could be much more time consuming and costly. It was unlikely to be applied to all
samples.
"Our understanding of the virus remains quite shallow," Zhang said. Questions such as where the virus
came from, why it could kill some healthy young people while generating no detectab le symptoms in
many others still left scientists scratching their heads.
"If there is a discovery that overturns the prevailing perception, don't be surprised."
my views nor those ofNIAID, NIH, HHS, or the U.S. government.
Sent : Tue, 21 Apr 202018:01:06 +0000
To : Jim Yong Kim
Subject : RE:My art icle
Jim :
Very nice pape r! Thanks f or sending it .
Best,
Tony
Director
Phone : (b)( 6)
FAX: (301) 496-4409
E-mail Cb)(6)
From: Jim Yong Kim <Jim.Yong.Kim@global -infra.com>

Sen t: Monday, April 20, 20 20 3:00 PM
To: Fauci, Anthony {NIH/NIAID) [E] ------- ~=
(b)(6):>
Subject: My article
Tony,
Hope you're well and thank yo u again for all that you are doi ng. I got this out today in the New Yorker
and I'll be ta lking to most of the Democra tic caucus today about w hat we're do ing in Mass and the
developing worl d.
Hang in there and let me know if there is anything more I can do . Mass is tough but we're going to have
a 1000 contac t tra cers very soon . Every day we learn so much, wh ich is why it's so im po rt ant for
everyone to get started .
Jim
Sent: Tue, 21 Apr 202017 :43:2 1 +0000
To: EDWARD SCOLNICK
Cc: Mascola , John (N IH/VRC) [El;Cassetti, Cristina (NIH/N IAID) [El;Marston , Hilary
(NIH/N IAID) [El
Subject : RE:for your consideration
Attachment s: Scient ists_to_Stop _COVID19_ 2020_04_ 15_ FINAL.pdf
Ed:
Thank you for your note and for sending this. The outline that you provide is exactly in sync with what we are
already doing and have definitive plans to do with regard to classic antivirals , monoclonal antibodies, and a variety
of vacci ne candid ates. As you know, the candidate developed here at Nll-1 in collaboration with Moderna is well
inco phase I crials and at lease 2 ochers are encer ing into phase 1 trials.
Best regard::;,
Tony
Director
National Tnslitu te of Allergy and Infectious Di seases
Nat iona l Tnslitutes of Health
Phone : (b) (6)
FAX : (301) 496-4409
E-mail: (b)(6)
The information in this e-ma il and any of its attachmen ts is confidential and may contain sensitive infom1ation . It
should not be used by anyone who is not the original intended recip ien t. If you have received this e-mai l in error
please infonn the sender and delete it from your mailbox or any other storage devices. The Nat iona l Institute of
From: EDWA RD SCOLNICK (b)(6)
Sent: Sunday, April I 9, 202 0 5: 18 PM
To: Fauci, Anthony (NIH/N IATD) [El ------~~
T""'!"'~~-!""' (b_) _C6)
,..>________ ~~
Cc: David R. Liu (b)(6) ; Schreiber, Stuart (b)(6) ; Michael Rosbash
_______ Cb _,> ; Ramnik Xav ier ___________
_)_(6) Cb
_)_(_
6)
Subject: for your consid erat ion
Tony . I hope your mail box is not so full that lhere is room for this. A group of concerned scient ists from different
parts of the country was organized to tr y to encap sulate and focus tbe national effott against Covid. This document
has been share d with the White House although we are not sure if it has had any effect on their plans. It has also
been shared with The Gates Foundation and a few other business and academic leaders . We rhink we have been
fairly comprehens ive in our cons iderations and recommendations . I hope you will find this helpful. We would
greatly appreciate a conversation with you after you have had an oppo1tunity to digest the content of the proposal.
lfthere is anything else we can do to help you in this National emergency, we stand ready to help. When I was at
Merck ,we led the successful
effort to make HIV a manageable disease and we dramatically lowered the death rate as a result of the dmgs we
made ,and the first triple therapy trial during the HIV pand emic. We hope we can help do the same for The Covid
Pandemic Best wishes Ed scolnick
Sent: Tue, 21 Apr 202015 :12:29 +0000
To: Grady, Christine (NIH/CC/BEP) [El
Subject: FW: Thank you
See part about you. Q

Director
Build ing 31 , Room 7 A-03
Phone : (b)( 6)
FAX: (30 96~ 09
E-mail: (b)(6)
The information m t 1se-mail and any of its attachments is confidential and may contain sensitive
From: Conrad, Patric ia (NIH/NIAID) (E] >

--------- (b)(

_______
------~= ..... (b)(6)
This is a cute note ...you can skip most of it and see highlight - that is the cute part
Patricia L. Conrad
(b)(6)
301-496-4409 fax
Disclaimer:
The informat ion in this e-mail and any of its attachments is confidential and may
contain sensitive informat ion . It should not be used by anyone who is not the
or iginal intended recipient. If you have received this e-mail in error please inform
the sender and delete it from your mailbox or any other storage devices. National
Instit ute of Allergy and Infectious Diseases (NIAID) shall not accept liability for
any statement made that are sender's own and not expressly made on behalf of
the NIAID by one of its representatives .
From: JOAN HUSSEY
--------,;- (bH6l
s--=,
To: Fauci, Anthony (NIH/NIAID) [E] ---------=-:- =
Subject: Thank you
--------- (bH 6)>
Dear Dr. Fauci,

I just wanted to say thank you for everything you are doing to educate us in this
country , and keep us safe during this horrendous coronavirus pandemic. I can't
even begin to imagine how difficult it is to maintain your composure and
persevere with your focus, bei ng constant ly in the public eye and also trying to
expert ly guide a president who seems more preoccupied with his own image (and
sound of his own voice), and political aspirations than with the actual well being
of his country's citizens.
By now, it should be perfectly clear to us t hat we can't have a healthy economy
wi t hout a healthy population.
(b)(6)
I (bH ~ We all have been

diligent about staying at home I (b)( ~
ordering food and other t hings to be delivered to our

house (we all wash our hands 'religiously') . (b)(6) is the only one of us
who occasionally goes to a grocery store or drug sto re if necessary and t hen, he
always wears a mask, gloves, and keeps at least six feet between himself and
anyone else, and gets in and out as quickly as possible. In addit ion, (b)( 6)
- are so intent on keeping me we ll and alive, we haven't even, any of us,

physically visited with each other , in person, inside our house for months .
In the past two months, I've been outside only four times - twice on our deck and
twice in my car, dropping off a couple of shopping bags at a friend's house and at
-------- CbH6) group home - both times leaving the bags in the dr iveway,
and then driving right back home .
I'm so t hankful for FaceTime, but we miss hugs and kisses. I know all this must
sound extreme, and it is, but I'm terr ified of becoming a statistic so we're doing
whatever we can to stay healthy for ourselves and one another.
(b)( 6)
H(i)jMy family is hearing what you're saying and taking your advice.
------ Cb
I'm sorry this email is so long but my intention, more than anything, is to thank
you for your wisdom and advice, both grounded in years of experience.
I worked at NIH for about 25 years - in the CC, in NCI, and in Human Genome. I
met you once, briefly , about 40 years ago(+/ -) in Bldg. 31's fitness room . I had
been working in the CC,in the Patient Activities Dep't. (on the POBout - and in-
patient units)at the time. I was incorrectly using a piece of equipment and you
were kind enough to come over and show me the correct way to use it. I
recognized you immediately , and have never forgotten that experience and how
gracious you were .
I'm well aware from the news that you are up against some very tough people
and some very tough times but please know you also have an army of grateful
followers in this country who are comp letely convinced that what you are
advising is in their very best interest.
Thank you again for all you've done for all of us over the years. My family and I
are more grateful than I can e><press .
PSI read all about your wife who sounds amazing also. You two make an "All-
Star" team .
Be well.
Gratefully, Joan ("Joanie") Hussey
Sent from my iPhone
Sent : Tue, 21 Apr 202015 :11:29 +0000
To: (b)(6)
Joanie:
Many thanks for your kind note . It is much appreciated . Stay safe !
Best,
Tony
Director
Phone : (b)( 6)
FAX: (301 496-4409
E-mail : (b) (6)
From: JOAN HUSSEY
-------~= CbH6l
--------~~
Subject: Thank you ---------- CbH6)
Dear Dr. Fauci,

I just wanted to say thank you for everything you are doing to educate us in this
country , and keep us safe during this horrendous coronavirus pandemic . I can't
even begin to imagine how difficult it is to maintain your composure and
persevere with your focus, bei ng constan t ly in the public eye and also trying to
expertly guide a president who seems more preoccupie d with his own image (and
sound of his own voice) , and political aspirations than with the actual well being
of his country's citizens.
By now, it should be perfectly clear to us t hat w e can't have a healthy economy
without a healthy population.
(b)(6)
(b)( • We all have been

(b)(6)
diligent about staying at home
-------------------
1 ordering food and other things to be delivered to our
house (we all wash our hands 'religiously'). (b)(6) is the only one of us
who occasionally goes to a grocery store or drug store if necessary and t hen, he
always wears a mask, gloves, and keeps at least six feet between himself and
anyone else, and gets in and out as quickly as possible. In addit ion, (b)(6)
1
- are so inten t on keeping me well and alive, we haven t even, any of us,
physically visited with each other, in person, inside our house for months.
In the past two months , I've been outside only four times - twice on our deck and
twice in my car1 dropping off a couple of shopping bags at a friend's house and at
(bH6l - both times leaving the bags in the dr iveway,
--------------
and then driving right back home.
I'm so thankful for FaceTime, but we miss hugs and kisses. I know all this must
sound extreme , and it is, but I'm terr ified of becoming a statistic so we're doing
wh af_e,ver w e._.
ca o_to_sia~he.aJtb.._v..fnr nu r.selve_c;_a
nd on e._.
anoib e ._______ ~~
(b)(6)
My family is hearing what you're saying and taking your advice.

------- (b)(6)
1'm sorry this email is so long but my intention , more than anything, is to thank
you fo r your wisdom and advice, both grounded in years of experience.
I worked at NIH for about 25 years - in the CC, in NCI, and in Human Genome. I
met you once, briefly , about 40 years ago(+/-) in Bldg. 31's fitness room . I had
been working in the CC,in the Patient Activities Dep't. (on the POBout- and in-
patient units)at the time. I was incorrectly using a piece of equipment and you
were kind enough to come over and show me the correct way to use it. I
recognized you immediately , and have never forgotten that experience and how
gracious you were.
I'm well aware from the news that you are up against some very tough people
and some very tough times but please know you also have an army of grateful
followers in this country who are completely convinced that what you are
advising is in their very best interest .
Thank you again for all you've done for all of us over the years. My family and I
are more grateful than I can express.
PSI read all about your wife who sounds amazing also. You two make an "All -
Star" team.
Be well.
Gratefully, Joan ("Joanie") Hussey
Sent from my iPhone

Sent : Tue, 21 Apr 202014 :52:49 +0000
To : Barasch,Kimberly (NIH/NIAID) [C)
Subj ect : FW: White HouseCoronavirus Task Force PowerPoint - 4.21.20
Att achm ent s: PowerPoint April 21.pptx
Director
Phone: (b)( 6)
FAX: (3 96':44li9
E-mail Cb)(6)
(bX5)-PCI
Sent: Tue, 21 Apr 2020 02 :52:55 +0000
To : Corey, Larry
Subject : manuscr ipt
Att achm ent s: COVID vaccine editoria l_prefinal April20 wfigur e -with Fauci trac ked edit s.docx
Here it is.
Director
Phone: (b)(6)
FAX: (301) 496-4409
E-mail: (b)(6)
From: (b)(6)
Sent : Mon, 20 Apr 2020 19:24:58 -0400
To: Mascola, John (NIH/VRC)[E]
Subject: Fwd: COVID-19vaccine
Le t us discuss. I am not sure how to answer Adrian.
F rom: Adr ian H ill (b)(6)

Dat e: Apr il 20, 2020 at 6: 16:30 PM EDT
To: "Fauci, Anthony (NIH/N IAID) [E]" ------~~
------. (b)(6J:
Cc: Hildegund Ertl
Subject: F,v: COVID-19 vaccine
(b)(6) , Sarah Gilbert
----------- (b)(
Dear Dr Fauci
(b) (4)
Thank you for your consideration of this at an exceptionally busy time.
Yours sincerely
Adrian Hil l
Professor Adrian V. S. Hill

Director, The Jenner Instit ute
Nuffield Department of Medicine
University of Oxford
Old Road Campus Research Building
Oxford OX3 70Q
Sent: Mo n, 20 Apr 2020 20:43:18 +0000
Subject : FW : Update: White House Coronavirus M eeting - 4.21.20
Yikes.......................... That wou ld make 4 days in a row w ithout a Press Conf erence
for me - Saturd ay, Sunday, Monda y and tom orrow QQ
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
From: Hurst, Natalie R. EOP/OVP (b)(6)

Sent: Monday , Apri l 20, 2020 4:38 PM
Subject : Update: Whit e House Coronavirus Meet ing - 4 .21.20
Importance: High
All -
There will be no Whit e House Coronavirus Task Force Me eting on Tuesday , Apri l 21st.
Enjoy your evening ,
Natalie Hur st
Operation s Coordin ator , Whi te House Coronaviru s Task Force
Executive Assist ant to the Ch ief of St aff
The Offi ce of th e Vice Pres ident
(b)(6)
From: (b)(6)
Sent: Mon, 20 Apr 2020 13:29:37 -0400
To: Charles McCall
Cc: Rotrosen, Daniel (NIH/NIAID) [E];Cassetti, Cristina (NIH/NIAID) [E];Marston,
Hilary (NIH/NIAID) [E]
Subject : Re: Tony and Dan, this is Cash. I seek your advice.
Dan:
Please bring this to the attention of appropriate NIAllD people.
Thanks ,
Tony
>
>
On Apr 19, 2020 , at 10:34 PM , Charles TvlcCall
--------- (b)(6) > wrote:
> Dear Tony and Dan,

>
>
(b) (4)
>
>
> Thank you for cons idering this idea. Be safe.
>
>
>
> Cash
>
>
>
> Sent from iPad
> Charles (Cash) McCall, MD
> Professor oflntema l Medicine, Translational Sciences , Microbiology & Immunology
> Wake Forest University School of Medic ine
> Wake Forest Biotech Place, su ite 350, room 3W-007
> 575 N. Patterson Avenue
> Winston-Salem , NC 27101
>
(bX5) -PCI
Sent: Mo n, 20 Apr 2020 15:03:51 +0000
Subject: FW: A Nat ional Test ing Action Plan by the Rockefeller Foundation: Embargoed
ti ll m idnight Monday Apr il 20
Attachments: RF National COVID-19 Testing Act ion Plan_LASTFINAL_04.20.2020.docx
Set up
Director
Phone Cb)(6)
FAX: (301 496-4409
E-mail=--__,. _._, (b)( 6)
From: O'Connor, Eileen <E0Connor@rockfound .org>

Sent: Monday , Apri l 20, 2020 7:47 AM
To: Fauci, Anthony (NIH/NIA ID) [E] <AFAUCl@niaid.nih .gov>; Anthony .s.fauci@n ih.gov;
AFAURCl@niaid.nih.gov
Subject: A Nat iona l Test ing Action Plan by the Rockefeller Foundation: Embargoed t ill m idn ight Monday
April 20
Dear Tony:
Thank you for all you are doin g. Not sure you r emembe r me Cb) ~
----------------- we talked a lot when 1 was at CNN. I have not

wanted to bother you but wanted to make sure you had the National Testing Action Pla n that we
have put together with top researchers from all the various roadmaps, etc. l joined The
Rockefell er Foundat ion after working in Afghanistan and Pakistan with State and coerced
Christy Feig to join me. We would be happy to get on a call today w ith Raj and Jonathan Quick
and other autho rs like Mike Pellini and Mark McLellan and Rick Klau sner.
Given our history with public health and our abil ity to convene, we hoped we could help by
working out a consensus plan . I have been briefing Caleb McCarry at the White House. We
have worked with industr y to also figure out the solution s to the supply chain issues and the
other logistical issues. We are going to put $10 million into helping this standup. This plan
doesn't just say what we need but the steps to get it done to open more safely.
Please let me know if you would like a call.
Regards
Eileen
Eileen O'Connor
Senior Vice President
Communications, Policy and Advocacy
The Rockefeller Foundation
Office: 212 852 8436
Mobile: Cb>C6J
eoconnor @rockfound.org
www.rockfound .org
(For sched uling purposes, please contact my assistant, CbH6),at
(b)(
From : Fauci, Anthony (NIH/N IAID) [E)
Sent: Mo n, 20 Apr 2020 14:22:57 +0000
To : Anderson, Jennifer (NIH/NIAID ) [E]
Subject : FW: Potential Postbac IRTA Fellowship
Att achm ent s: CV4.19.pdf
Please handle.
Director
Phone: (b)(6)
FAX: (3 96':44li9
E-mail: Cb)(6)
From : (b)(6)
--------=-:-:= >
---------
Subj ect : Potential Postbac IRTA Fellowshi p
(b)(
(b)(6)
(b)(6
Sent : Mo n, 20 Apr 2020 11:58:51 +0000
Subject : RE:ASF: Today's YES Network interview
Than ks.
Director
Phone : (b)(6)
FAX : (301 496-4409
E-mail : (b)(6)
From: Billet, Courtney {NIH/NIAID) [E)

Se nt : Monday, April 20, 2020 7:55 AM
-------- (b)( >
To : Fauci, Anthony (NIH/NIAID) [E]-------= (b-:-

)(=6)
(b)(6)> ---------
Subject: ASF: Today's YESNetwork intervi ew
(b)( ; Folkers, Greg (NIH/NIAID) [E]
You have an interview t oday with Jack Curry of the YES Network (Yankees) . Just last night, The
NY Post ran a story that includes Jack among the many sports broadcasting stars that have
come out of Fordha CbH6);Jack and I have
t alked about this). Thought you might like to see it. Parts of your interview are also going to
run on Michae l Kay's show, and Kay also features prominent ly in this piec e.
How Fordham has produced a generation of

sports media stars
April 19, 2020 I 4:04pm I Updated April 19. 2020 I 9:16pm
John Giannone , Michael Kay and Mike Breen; Chris Carrino Co urtesy of M ichael Kay, Chris Carrin o
Long before he was an electee to the Basketball Hall of Fame , Mike Breen was an intimidated
18-year-old freshman attending a workshop at Fordham's renowned college radio station,
WFUV, in the fall of 1979.
Breen felt sheepish next to the juniors and seniors leading the seminar and contemplated
delaying the start of his broadcasting training. Soon, a couple of upperclassmen, including future
NBA writer Dave D' Alesandro, made him feel more comfortable.
But he still didn't have any friends until one day on campus he saw a confident sophomore trying
to sweet talk a young woman. "I know you like me," he said. "I can see it in your eyes."
The woman responded by saying she would not date him if he were the last man on earth. She
essentially was saying, " See ya" .. . to Michael Kay.
That is how Breen first became friends with Kay.
"For him to have the confidence to do this in front of everybody with this beautiful student , I
thought, 'Man, this guy has a great sense of humor ,'" Breen said.
Four decades later, Breen and Kay are still good friends.
Michael Kay and Mike Breen Courtesy of Michael Kay
Fordham, the private Jesuit university in The Bronx that launched the legendary Vin Scully, for
decades has been a powerhouse sportscasting pipeline , especially in New York. And the school
ties that first united Breen and Kay are webbed throughout the industry .
Fordham is the alma mater for the voice of the NBA Finals/Knicks (Breen, Class of 1983), the
Yankees' lead TV play-by-player/ESPN New York afternoon radio host (Kay, '82), the voice of
the Giants (Bob Papa, '8 6), the radio voice of the Nets (Chris Carrino , '92) MSG 's John
Giannone ('86) , YES' Jack Curry ('86) , WFAN's Paul Dottino ('86) and YES/ESPN's Ryan
Ruocco ('08). And that's just New York-based sportscasters.
For good measure, the schoo l produced CBS' Spero Dedes ('01), ESPN's Tony Reali ('00) and
the Washington Nationals' Charlie Slowes ('83). There are many more, and not just in front of
the camera. If you need a field producer, Jim Johnson ('86) works for ESPN. A radio engineer?
WF AN's Chris Majkowski ('89) will set things up. Media relations? Louis Ban-icelli ('09) is
leading things at MLB Network.
Like everyone else, they are all dealing with the halt of sports due to the coronavirus pandemic.
It is a jan-ing timeout for people so used to being on the run.
~
Ryan Ruocco, Mike Breen Courtesy of Ryan Ruocco
Take Carrino, who has done so much to raise money and awareness for facio scapulo humeral
dystrophy (FSHD), a form of muscular dystrophy that afflicts him. A fundraising event was
supposed to take place in March at a Ne ts game at Barclays Center. His 10th annual fundraising
dinner, correspon ding with his 50th bi1thday, was slated for August, and now is in question.
"I don't know if it is going to be safe to have people together still," Carrino said. "Are the
restrictions going to be there in terms of how many people can gather in one place? The other
aspect of it for me is: How comfortab le am I asking peop le for money when I know the economy
and certain businesses are affected so badly?"
Ruocco was supposed to get married in Italy in June. He and his fiancee, Andrea Ferzoco, are
now going to punt the wedding until June 2021.
"It sucks," Ruocco said. "Arldrea and I were so excited and so were our guests. We have been
feeling all the joy leading us to this. There are people dealing with much more dire
circumstances than rescheduling a wedding. That is kind of the perspec tive we have tried to
take."
While most of the successful sports media alumni are worried about the current direction of
Fordham and WFUV because of a de-emphasis on sports during the pandemic , to a man they say
how Fordham molded them and led them to where they are today.
They were helpe d by famous names such as the legendary Marty Glickman, a mentor , and Stan
Fischler, who taught classes. Then there were the less famous, equa lly instrwnental figures in the
program, such as Bob Ahrens, who ran WFUV as its executive producer during many of these
notable students' formative years.
John Giannone punting at FordhamCourtesy of John Giannone
The experiences that they shared forged many of them , such as Breen and Kay, into close
friends.
Giannone went to Fordham after being recruited to be a punter on the football team. During
training camp his freshman year, he quickly figured out the third-string punter would never see
the field. He went to Kay, then the WFUV sports director as a senior, to try to help on the station.
Kay said Giannone could do stats for him during the football season.
Kay went on to work at The Post, and later helped Giannone land an entry-level position at the
paper. When Giannone transferred into television at CNN/Sports Illu strated, it was through a
Kay connection. And Giannone landed at MSG Network after Kay left to become the TV voice
of the Yankees when YES Network began.
When it was Giannone's turn as WFUV spo rts director, he made Papa and Curry a play-by-
player and an analyst when they were sophomore s.
WFUV also got its staff access to locker rooms at places like Yankee Stadium and Madison
Square Garden to learn the craft next to profes siona ls at the highest level. That remains largely
true today.
"WFUV allowed you to believe you were a profes sional broadcaster before you really were,"
Curry said. "We were in the heart of New York City, and, even ifwe weren't Marv Albert, we
felt as if what Marv Albert was doing for the Knicks, we were doing for Fordham."
There is a lineage that unites. Carrino learned how to describe the geography of a ba sketball
court from Glickman. Later , Carrino returned to Fordham and taught Ruocco the same lessons.
These days, at some Nets games, Ruocco is on TV , sitting next to Carrino, calling the game on
the radio.
Jack Curry Courtesy of Jack Curry
Papa also was mentored by Glickman. Papa and Carrino each were told by their fathers that if
they majored in communications, they would have to pay for schoo l themselves. Both ended up
in the Business School , but had their eyes on WFUV the whole time.
Carrino ended up working as a producer for Papa , beginning when Papa hosted a tailgate show
on WF AN . Carrino eventually followed Papa as the radio voice of the Nets.
The Fordham sports alums want everyone to be safe during this time - and they can't wait to
get back to what they love to do.
"I 'm desperate to get back to work ," Breen said. "I'm hoping there is NBA basketball. This is the
best time of the year ."
Sent : Mon, 20 Apr 2020 11:14:21 +0000
Subject : FW: the Strategy document
Attachme nts: COVIDvaccine editorial_prefinal April19 wfigure.docx
Email below is from Larry Corey.

Bethesda MD 20892
Telephone: (b)(6)
Email: (b)(
From: Corey MD, Larry (b)(6)>

------~~
To: Fauci, Anthony (NIH/ NIAID) [El ·>; Conrad, Patricia (NIH/NIAID) [El
(b) ~
>
-------- (b)(
Cc: Mascola, John (NIH/VRC) [E] >; Miner PhD, Mindy (b)(6)
Subject: the Strategy document
--------- (b)(
Here is the working draft of the article for the NEJM . It, in my opinion, reads really well . I have
embellished it today with a figure that conceptual ly outlines what we are talking about; the old
axiom that a picture is worth a thousand words .
The editorial guide lines of the NEJM has 2 potential categories. One is Perspectives which is 1200
words an 5 references . We are at 1750 words and I t hink losing 500 words takes away a lot
from the message . The other category is a special report wh ich is over 2500 words and allows lots
of references ( 40) I think this is best and was one reason I thought about adding the conceptua l
fig ure which does outli ne in a single picture what we are talking about .
Tony, If you feel its best to have Francis on this paper we both support it . Your call . I do however
lean on includ ing Francis . I would say politicly to achieve our goal and bring all these companies
into the ten t while you are away at the White House having him buy into t his plan through the
ACTIVprog ram seems important to us . I think we get to our goal if he is out there publ icly embracing
this; using the NIAID networks labs DSMB and the correlates programs . This type of granula rity
really puts him deep into understanding what we are doing . If this means you are first and he is
last author we are ok with that, For me I need to have him use me for interfacing with the
company in defining these collabo rations . If you were present all the time this would be
unnecessary , but as he will be the link with BARDA linking him to John and I increases the
likelihood of success.
(b)(6)
Ok enough .. as they say on the news Goodnight ..
Larry
Sent : Mo n, 20 Apr 2020 02:39:49 +0000
To : 'Thomas Quinn'
Subject : FW: Fauci pho to
Attachme nts: Fauci ISSTDR1983.pdf
Thanks, Tom!
From:
From: Thomas Quinn (b)(6)>
To : Fauci, Anthony (NIH/NIAID) (E]------ ~=
Cc: Hunter Handsfield <hhh@uw.edu >-------- (b)(6)>
Subject: FW: Fauci photo
Hi Tony,
It was great to see you and present our work to you this last Friday. I really enjoyed our discussion and
feedback.
As I said on zoom, we all really appreciate your leadership in the COVID-19 crisis . Thank you for
providing the guiding way through this .
(b) (4)
In the meantime, your photos are getting passed around and Hunter Handsfield wanted you to have this
one (from the HIV archives - 1983 in Seattle ).
All the best,

Tom
(b)(6)
Stay healthy!
From: Hunter Handsfie ld <hhh@uw.edu >

Date : Sunday, April 19, 2020 at 3:52 PM
To: Thomas Quinn (b)(6)
Subject: Fauci photo
Hi, Tom . Going through old boxes I came across this, from 5th ISSTDR, Seattle 1983. Give Tony my
greetings if you forward to him .
Cheers- Hunter
H. Hunter Handsfield, MD
Professor Emeritus of Medicine
Center for Al OSand STD
University of Washington
Phone +1 206 935-5225

Mobile (b)(6)
Sent : Mon, 20 Apr 2020 01:58:31 +0000
Subject : FW: Fauci photo
Attachme nts: Fauci ISSTDR1983.pdf
Email from Tom Quinn to you .

Bethesda MD 20892
Telephone: (b)(6)
Email: (b)(6)
From: Thomas Quinn (b)(

Cc: Hunter Handsfield <hhh@uw.edu>
Subject : FW: Fauci photo
Hi Tony,
It was great to see you and present our work to you this last Friday. I really enjoyed our discussion and
feedback.
As I said on zoom, we all really appreciate your leadership in the COVID-19 crisis. Thank you for
providing the guiding way through this .
(b) (4)
In the meantime, your photos are getting passed around and Hunter Handsfield wanted you to have this
one (from the HIV archives-1983 in Seattle).
All the best,

Tom
(b)(6)
. Stay healthy!
From : Hunter Handsfie ld (b)(6)
To: Thomas Qu inn Cb
H6J>
Subject: Fauci photo
Hi, Tom . Going through old boxes I came across t his, from 5th ISSTDR, Seattle 1983. Give Tony my
greetings if you forward to him.
Cheers- Hunter
H. Hunte r Handsfi eld, MD

Professor Emeritus of Med icine
Center for AIDS and STD
Univers ity of Washington
(b)( 6)
Phone ➔
Mob ile
Sent : Mon, 20 Apr 2020 01:56:21 +0000
Subject : FW: A proposal to stop COVID-19 and reopen our schools and businesses
Email from David Liu to FC with a cc to you .

National Institute of Alle rgy and Infectiou s Diseases
Bethesda MD 20892
Telephone: (b)(6)
Email: (b)(
From: David R. Liu (b)(6)

Se nt : Sunday, April 19, 2020 9:08 PM
-------::-::-=, >
To : Collins, Francis {NIH/OD) [E]
Cc : M ichael Rosbash
_:_....:....::....:.!===-=---::---
(b)(
(b)(6)>; Ramnik Xavier (b)(6J>;
EDWARD SCOLNICK (b)(6l>; Stuart Schrei ber (b)(6)>; Michael Z Lin
(b)(6) >; Ben Cravatt (b)( ; Fauci, Anthony (NIH/NIAID) [E]
======~~ (b)(6J>; Lane, Cliff (NIH/NIAID) [El (b)(6) •>; A usti n, Christopher
(NIH/NCATS) [E) (b)(6J>; W ha lley, David (FNIH) [T) (b)(6); Freire, Maria
(FNIH) [T) CbH6J;Tabak, Lawrence (NIH/OD) [El CbH6J>;Thomas Cahill
(b)( >
Subject: Re: A proposal to stop COVID-19 and reopen our schools and businesses
Thank you, Francis, for your speedy re ply. Please let us know if we can help ACTIV, Fauci, or any other
leaders who might want to engage.
Best,
David
David R. Liu
Richard Merkin Professor and Director of the Merkin Institute
of Transformative Technolog ies in Healthcare
Broad Institute Core Institute Member and Vice-Chair of the Faculty
Howa rd Hughes Medical Institute Investigator
Harvard University Professor of Che mistry and Chemical Biology
75 Ames Street
Cambrid ge, MA 02142
On Apr 19, 2020, at 8:48 PM, Collins, Francis (NIH/OD) [El wrote:
------- (b)(6)>
Dear David et al.,
Thanks for forwarding this ve ry thoughtful document, which presents a series of

important recommendations - most of which I agree with. I don't know if you saw
Friday's announcement (attached) of the new public private partne rship called
ACTIV (for Accelerating COVID-19 Therapeutic Interventions and Vaccines), but it
has taken on most of the points you raise in sections 1 - 3 of your letter. I share
your hopes that remdesivir w ill show benefit, and the current large NIH-sponsored
RCT has completed enrollment and should reveal results in about a month. But of
course we want to test multiple other interventions - both small molecules and
antibody-based therapies, so we need our trial system to be optimized like never
before. I will share your letter with the leaders of ACTIV, who are working with
unprecedented speed to prio ritize the next set of therapeutic candidates as well as
pushing vaccine development programs to adopt exceptionally creative trial
designs to test safety and efficacy (with fu ll engagement by FDA).
Best regards, Francis
From: David Liu (b)(6)>

Sent: Sunday, April 19, 2020 5:20 PM
To: OD Labc (NIH/OD) (b)(6) ; Collins, Francis (NIH/OD) [E]
(b)(6)
Cc:Michael Rosbash Ramnik Xavier (b)(6)>;
-------...!:===~~-------
EDWARDSCOLNICK -----~~
(b)(6)>; (b)(6)>; Stuart
-:--:-".":""""--;;:::========~~
Schreiber (b)(6) Michael Z Lin (b)(6); Ben Cravatt
----==== (b
~ )~(6)
~-----
Subjec t: A proposal to stop COVID-19and reopen our schools and businesses
Dear Francis,
I write on behalf of a group of citizen-scientists, most or all of whom you know. Motivated
solely by our desire to help defeat the serious threat our nation and the world now faces,
we wrote a set of four actionable, non-partisan proposals (attached ) to produce safe and
effective COVID-19therapeutics and vaccines in the shortest possible timeframe, and to
reopen our society in a manner that reduces t he risk of future COVID-19outbreaks.
We hope you find these ideas interesting, and might be willing to share this set of
proposals with Dr. Tony Fauci, along with our willingness to discuss any part of the
proposals with him if we can be helpful. We understand from our efforts to contact Dr.
Fauci through email routes that his standard inbox may be too overwhelmed for our
proposal to reach him.
The four proposals attached describe: (1) How to rapid ly repurpose an antiviral drug to
treat COVID-19 pat ients; (2) How to expedite the development of human antibody drugs to
treat patients and to provide short-term protect ion for healthy individuals; (3) How to
develop COVID-19 vaccines on an expedited time scale; and (4) How to reopen our
businesses and schools in a manner that reduces the risk of future outbreaks and deaths.
Thank you for any help or thoughts you might be able to provide.
Sincerely yours,
Ben Cravatt (Scripps), Lynn Goldman (GWU), Akiko Iwasaki (Yale), Scott Kemp (MIT),
Michael Lin (Stanford), David Liu (Harvard/Broad), Michael Rosbash (Brande is), Stuart
Schreiber (Harvard/Broad), Ed Scolnick (Broad), Jonathan Simons (PCF),and Ramnik Xavier
(MGH/Broad)
David R. Liu
Richard Merkin Professor and Director of the Merkin Institute
of Transformative Techno logies in Healthcare
Core Institute Member and Vice-Chair of the Faculty, Broad Institute
Investigator, Howard Hughes Medical Institute
Thomas Dudley Cabot Professor of the Natural Sciences
and Professor of Chemistry & Chemical Biology, Harvard University
75 Ames Street
Cambridge, MA 02142
<N IH_ACTIV_Release_041720 .docx>

Sent : Mo n, 20 Apr 2020 01:25:42 +0000
To: bgertz@wash ingtontimes.com
Cc: Mi ller, Katie R. EOP/OVP;Short, Marc T. EOP/OVP
Subjec t : Scientific paper on origin of coronav irus
Bill :
Here are the li nks to the scientific papers and a commentary about the scientific basis of the
origins of SARS-Cov-2.
The proxima l origin of SARS-CoV-2. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. Nat Med.
2020 Apr;26(4):450-452. do i: 10.1038/s41591 -020-0820-9 . No abstra ct availa ble.
A Genomic Perspective on the Origin and Emergence of SARS-CoV-2.Zhang YZ, Holmes EC.Cell. 2020 Apr
16;181(2):223-227 . do i: 10.1016/ j .cell.2020 .03.035. Epub 2020 Mar 26.
Also this statement from Eddie Ho lmes
ht tp s:/ / bit. ly/2 yml UGe
Best regards,
Tony
Director
Phone: (b)( 6)
FAX: (301 496-4409
E-mail: (b)(6)
On Apr 19, 2020, at 2:21 PM, Bill Gertz <bgertz@ w ashingtontimes.com >
wrote :
Katie,
Dr. Fauci on Friday said he would share a scientific paper with the press on
the origin of the coronav irus. Can you please help me get a copy of that
paper? Thanks in advance.
Bill Gertz
National Security Correspondent
@Bil!Gertz I direct 202-636-327 4
TheGertzFile .com
<t wtlo go.jpg >
3600 New York Ave NE I Washington DC, 20002
The inform ation contained in t his electronic transm ission is intended for t he exclusive use of the individuals to
whom it is addressed and may conta in informat ion that is pr ivileged and confidentia l, the disclosure of which is
proh ibited by law. If the reader of th is transm ission is not the intende d recipient , you are hereby not ified that any
disseminat ion, distr ibut ion or copying of th is commun icati on is str ictly prohibited. In addit ion, any unauthor ized
copying, disclosure or distribut ion of the materia l in th is e-mai l and any attachments is strict ly forbidden.
Sent : Mo n, 20 Apr 2020 01:22:40 +0000
To : Folkers, Greg (NIH/NIAID) [E);Conrad, Patricia (NIH/NIAID) [El
Cc: Barasch, Kimberly (NIH/NIAID) [Cl
Subjec t : RE: IMPORTANT
Thanks Greg.
Patty:
Please respond to Dr. Dzau's questions .
Thanks,
Tony
From: Folkers, Greg (NIH/NIAID) [El (b)( >

-------
To : Conrad, Patricia (NIH/NIAID) (El ----- (b
~ ) ~(6)'>; Fauci, An t hony (NIH/NIAID ) [ El
(b)(6)
Cc: Barasch, Kimberly (NIH/N IAID) [C]
Subject: RE: IMPOR TANT ------- (b)(
Patty I had spoken to ASFabout using a few slides and he said yes/ I will have them done
short;y
• V Dzau: I will begin the session by providing brief (~3

min) opening remarks describing the circumstances
of the pandemic. Then, I will introduce the panelists
and you will each have 7 minutes to provide
remarks. You may use a limited number of slides for
illustration. I hope that each panelist will provide
their own perspective and speak to the issues
proposed below .
• Jeremy Farrar wi ll discuss the global response to the
pandemic , drawi ng from his experience as a global
leader, the chair of the Scientific Advisory Group for
the WHO's R&D Blueprint and as a member of the
Global Preparedness Monitoring Board .
• Tony Fauci will discuss the US pandemic and provide
his perspective as a member of the White House
Coronavirus Task Force addressing the 2019-20
coronavirus pandemic .
• George Gao will discuss China's response to the
pandemic and lessons learned for the rest of the
globe .
• Susan Weiss will discuss the viral characteristics of
SARSCOV2, insights into its pathobiology, immunity
and development of a pan-CoV antiviral.
• Richard Hatchett will discuss the development of
new vaccines and treatments against COVID-19.
• Sanjay Gupta wil l comment on the health system
response to the pandemic and challenges related to
communication and public engagement in
responding to COVID-19.
From: Conrad , Patricia (NIH/NIAID) [E] (b)(6l>

------
----~
To: Folkers, Greg (NIH/NIA ID) [E] ~----- (b=
_H_'?)>; Fauci, Anthony (NIH/NIAID) [E]
(b)(6)>
Cc: Conrad, Patricia (NIH/ NIAID) [E] (b)(6)>;Barasch, Kimberly (NIH/NIAID ) [C]
(b)(6)>
------
Subject: FW: IMPORTANT
We need to discuss tomorrow on our daily meeting/call - do you want to do

slides.
Again this event is on a Saturday and is tentat ive as we do not know when the TF
meeting will be scheduled that day.
So - if you can do it - will you use slides?

So if you cant do th is - do you want a surrogate and who?
I w il l make sure David is o n board f or zoom .

Sent : Sunday, April 19, 2020 3 :11 PM
-------~~
To ; Conrad, Patricia (NIH/NIAID) [E]
Cc: Fauci, Anthony (NIH/NIAID) [E] ~=====:--=--;-~:!,._-----------~~
Mun, Jenny <JMun@nas.edu >
(b)(6J>;
---------------- (b)(6)
Subject: IMPORTANT
Dear Patty,
I hope this finds you well. I know how terribly busy Tony is and I hate to trouble him, however, the NAS
Annual Meeting panel on COVID-19 is less than a week away and my team needs answers to the
questions below . Can you call this to his attention or assist him in providing the signed form and
requested informat ion? We hope to have this by Tuesday {4/23) morning, if possible.
• Please provide a cell number where you can be reached in case you do not connect in time {if
you prefer, you can provide the number of your assistant if they w ill be able to reach you
directly by cell or at home).
• Will you have slides to display during your ta lk?
• Are you able to use Zoom 'share your screen' to show the slides directly during your talk or do
you need someone from NAS to show your slides for you?
• Will you need a test session with our Zoom techs? Please let me know as soon as possible as
staff are available to hold training sessions through Monday, April 20 (9 AM to 5 PM EDT).
• If you would like to promote your participation in our meeting on social media, please let me
know the contact of your social media contact from your institution .
Finally, because this is going to be a remote meeting, we would like panelists to log into Zoom 30
minutes before the session starts- that is at 1:30 pm ET to go over the technology and any last minute
speaker prep. So far, more than 800 Academy members have registered for the meeting and there wil l
be additional members of the public and possibly the press tuning in.
Best,
Victor
(bX5)-PCl1
Sent : Sun, 19 Apr 2020 03:29:42 +0000
To: Peter Daszak
Subject: RE:Thank you for your public comments re COVID-19's origins
Peter:
Many thanks for your kind note.
Best regards,
Tony
From: Peter Daszak

-----------
--------~~
To: Morens, David (NIH/NIAID) [El
(b)(6)
(b)( 6) > ---------- (b)(6); Fauci, Anthony (NIH/NIAID) [El
Cc: Stemmy, Erik (NIH/NIAID) [E] (b)(6)•>; Erbelding, Emily (NIH/NIAID) [El
--------- ------------
(b)(6)> ; Aleksei Chmura
Subject : Thank you for your public comments re COVID-19's origins
Importance: High
(b)(6)
Tony (cc'ing David so that you might pass th is on to Tony once he has a spare second)
As t he Pl of the ROl grant publ icly targeted by Fox News reporters at the President ial press briefing last
night, I just wanted to say a persona l thankyou on behalf of our staff and collaborators, for publicly
stand ing up and stat ing that the scientific evidence supports a natural origin for COVID-19 from a bat-to-
huma n spillover, not a lab release from the Wuhan Institu te of Virology.
(b) (7)(A)
From my perspective, your comments are brave, and coming from your t rusted voice, wi ll help dispel
the myths being spun around the v irus' origins .
Once this pandemic's over I look forward th anking you in person and let you know how important your
comments are to us all.
Cheers,
Peter
(b) (7)(A)
Sent: Sun, 19 Apr 2020 01:23:00 +0000
Subject : FW: cotton swabs
Followup email from Jake Tapper.

Bethesda MD 20892
Telephone: (b)(6)
Email: (b)(
From : Jake Tapper (b)(6)

-----~~
Subject: Re: cotton swabs
------- (b)(6)>
Got it
Thanks
On Sat, Apr 18, 2020 at 4 :52 PM Fauci, Anthony (NIH/NIAID) [E]

------- CbH > w rote:
This is w hat I was ref errin g t o. They are not ready fo r pr ime tim e, since th ey
have to get th e right med ia and w rapp ing.
Subje ct: Qtip announcement
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-gates-
foundation-unitedhealth-group-guantigen-and-us-cotton
Coronavirus (COVID-19) Update: FDA, Gates

Foundation, UnitedHealth Group, Quantigen,
and U.S. Cotton Collaborate to Address
Testing Supply Needs
The U.S. Food and Drug Administrat ion announced a further expansion of COVID-19testing options
through the recognition that spun synthetic swabs- with a design similar to Q-tips - could be used to
test patients by collecting a sample from the front of the nose.
As part of this effort, U.S. Cotton, the largest manufacturer of cotton swabs and a subsidiary of
Parkdale-Mills, developed a polyester-based Q-tip-type swab that is fully synthetic for compat ibility
with COVID-19 testing. Harnessing its large-scale U.S.-based manufacturing capabil ities, U.S. Cotton
plans to produce these new polyester swabs in large quantities to help meet the needs for
coronavirus diagnostic testing.
"This action today demonstrates the ingenuity that results from the FDA working in partnership with
the private sector . The Trump Administration has been working side-by-side with our industry
partners to fight this pandemic, and today is a great example of that work. We appreciate work by
UnitedHealth Group, Quantigen, and the Gates Foundation to perform and support the clinical
studies necessary for this advancement. We also want to acknowledge U.S. Cotton's efforts to
manufacture a new type of swab for COVID-19 testing tha t can be produced at scale. We appreciate
the work of these collaborators to consider how these test supplies could be broadly distributed to
meet not only the testing needs of t he United States but also global needs around the pandemic. All
of these actions by th ese American organizations will help continue to expand our testing capability,"
said FDA Commissioner Stephen M. Hahn, M .D.
This finding that spun synthetic swabs could be used for COVID-19 test ing is based on results from a
clinical investigation that represents a collaboration between the FDA, UnitedHealth Group, the Gates
Foundation, and Quant igen. The type of test ing at the front of the nose used in th is study is notable
because it allows self-collection by patients the reby limiting exposure of healthcare providers; it is
more comfortable fo r patients and it can be performed by a swab t hat is more readily available and
manufacturab le at scale.
Director
Phone : (b)(6)
FAX: (301) 496-4409
E-mail: Cb)(6}
your mailbox or any other storage devices. The National Institute of Allergy and Infectious
Diseases (NIAID) shall not accept liability for any statements made that are the sender's own
Sent: Sat, 18 Apr 2020 22 :21 :02 +0000
To: Corey MD, Larry;Conrad, Patricia (NIH/NIAID ) [El
Cc: Mascola, John (NIH/VRC) [E)
Subject: RE: (b)(6)
Attachments : COVIDvaccine editoria l_16April 7pm - with Fauci edits.docx
Larry:
I have gone over th e manuscript and have mad e a number of edits that are
tracked into the attached document. Please take a look, accept the changes
(unless you have issues with them) , add the references and then let us discuss
next steps, i.e. add or not Francis to authors and where in the order.
John:
Please also give it another good look.
Thanks,
Tony
Director
Phone : (b)(6)
FAX : (301 496-4409
E-mail: (b) (6)
From: Corey MD, Larry (b)(6);,

Sent: Saturday, Apr il 18, 2020 12:34 AM
To: Conrad, Patricia (NIH/NIAID) [El-------~ (b)(
=>; Fauci, Anthony (NIH/NIAID ) [El
(b)(6)>
Cc: Mascol a, John (NIH/VRC) [El Cb
>0'1>
Subject: work ing draft of NEJM
Here is the workin g dra ft . My manuscript ty pist too tired to work tonight so it reflects several
changes I made tonight ; it should be readable ;
Larry
Sent: Sat, 18 Apr 2020 20:40:34 +0000
To: Auchincloss, Hugh (NIH/NIA ID) [C) (b)(6)
--::--:-:-----;=======-
-==
Cc:
Subjec t :
Conrad, Patricia (NIH/NIAID) [E);Greg Folkers
FW : You are a Hero --------- (b)(6))
Please see me about thi s on Monday. Thanks.
Director
Phone: (b)(6)
FAX: (3 96':44li9
E-mail (b) (6)
From: Kathy Ireland

------------
--------=-=~
(b)(6)
Subject : You are a Hero ---------

To: Fauci, Anthony (NIH/NIAID) [E (b)(6)
Dear Dr. Fauci,
Thank you for everyth ing you 're doing for Amer ica and the world. I'm wr it ing to you today, rather than
calling, because it 's impossible to imagine the degree to wh ich leading science duri ng this COVID-19
pandem ic is impacting your life and your fami ly. Please know, that your wisdom and passion brings so
much comfort to millions, including our family and me, specifi cally. You may recall from our previous
talks, that (b)(6)
What a
vicious virus, Dr. Fauci ... unlike anything I've ever seen.
In addition to my work as Ambassador for the Elizabeth Taylor AIDS Foundation, it is also an honor and
responsibility to serve as International Youth Chair for the Nationa l Pediatric Cancer Foundation . In that
position , people approach with questions for our government t hat I am uncomfortabl e giving opinion s
on in ignorance. So reluctant to bother you - I'm seeking to learn who at the NIH I should bring this to ?
(b)(4)
Thank you so much for all that you do .
Always,
Kathy
Sent : Sat, 18 Apr 2020 20:21 :32 +0000
To: (b)(6)
(b)(6)
Subject: FW: article and bb rim
Attachments : The Mentor Who Mad e Dr. Anthony Fauci - WSJ - large text.pdf
This article about my relations hip with Shelly Wolff is worth reading
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail ,___,,. __ _, (b)(6)
From: Barton Haynes, M.D. <barton.haynes@duke.edu>

Sent : Thursday, Apr il 16, 2020 12:39 PM
To : Fauci, Anthony (NIH/NIAID) [E] --------, .....,..,= (b)(6)
Subject: article and bb rim
Hi tony:
Glad this worked out. Wonderful article. Great trib ute to both you and Shelly. But the socks in the last
picture .......
(b)(6)
So when the pandemic is over or when you are down there and
want a break, I can put you in touch wi th him to see the Regis bb goal.
He has been following your career for many years. Very nice fellow .
Thanks for all you are doing Tony , it on ly sounds like it is getting more and more difficult . But you are
doing an amazing job ....
So proud of you and that ._______ Cb
_>...,.
<
Best Bart
Sent : Sat, 18 Apr 2020 20:12:02 +0000
Cc: Greg Folkers (bH ;Billet, Courtney (NIH/NIAID) [El
Subjec t : FW: From Jack Curry/ YES Networ k (Yankees)
Have we decided t o set t his up. Let us discuss.
Director
Phone (b)(6)
FAX: (3 96':44li9
E-mail: (b)(6)
From : Billet, Courtney (NIH/NIAID) [E) (b)(6)

Se nt : Thursday, Apr il 16, 2020 1:45 PM
To : Fauci, Anthony (NIH/NIAID) [E] ------~~ (b)(6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b)(6>:>; Routh, Jennifer (NIH/NIAID) [E]
--------- (b)(6); Folkers, Greg {NIH/NIAID) [E]

Subject: ASF: From Jack Curry/ YESNetwork (Yankees)
(b)(6)>
Jack Curr y (broadcaster with the YESNetwork, which is like MASN, but for the Yankees) is appealing to
you as a New Yorker and lifelong Yankees fan for a 10-minute interview via Zoom. Jack covered the
Yankees for 22 years at the NYT. The interv iew would run on YES(largest regional sports network in the
country) as the focus of one of the or iginal shows they are producing 3x/week called "YES,WE'RE HERE."
It would be ru n across all of their social med ia platfo rms (reach of over 1M). They would also air clips on
the M ichael Kay Radio Show (TV play-by-play announcer for the Yankees), which is simulcast on YESand
is the highest-rated drive time talk show in New York.
Questions below , including a few at the end about your lifelong baseball fandom . Is this someth ing
you' d be willing to do? If so we will seek clearance.
POSSIBLEQUESTIONS
DOCTOR FAUCI , I KNOW YOUR DAYS ARE FILLED WITH OFFERING ADVICE AND COU SEL TO SO MANY
PEOPLE ABOUT THE CORONA VIRUS. WITH THE SOBERING POSITION WE HA VE BEEN IN FOR A WHILE, WHAT
WOULD BE YOUR MOST URGENT MESSAGE TO AMERICANS?
THE PHRASE 'FLATTENING THE CURVE' HAS BECOME COMMONPLACE IN OUR VERNACULAR IN RECENT
WEEKS. HOW MUCH CLOSER ARE WE GETTI G TO FLA TTENJNG THE CURVE?
YOU'VE SAID SEVERAL TIMES THAT THE VIRUS IS THE CLOCK. WHAT IS THE VIRUS TELLING YOU ABOUT
THAT TIME FRAME?
AS THE COUNTRY TR TESTO WORK ITS WAY BACK, THERE HAS BEEN SPECULA TTON ABOUT HOW
PROFESSIONAL SPORTS CAN RETURN. WHAT ARE YOUR THOUGHTS ON HOW, FOR INSTANC E, MAJOR LEAGUE
BASEBALL WOULD BE ABLE TO ST ART ITS SEASON?
BASEBALL IS A SPORT 1N WHICH SHAKING HANDS IS AS COMMON AS BALLS A D STRIKES. NOT JUST IN
BASEBALL , OBVIOUSLY, BUT IN LIFE OVERALL , HOW MUCH DO YOU ADVOCATE NOT SHAKIN G HANDS
ANYMOR E?
THE NEW YORK TIMES REFERRE D TO YOU AS THE EXPLAINER-IN-CHIEF IN COM PLIMENTING YOUR
ABILITY TO SPEAK BLUNTLY AND TRUTHFULLY. SO HOW SHOULD AMERICANS PLAN ON BEHA YING AS WE MOVE
FORWARD IN THESE UNCERTAIN TIMES?
AND ... lF DR FAUCI WAS COMFORTABLE WITH IT, A COUPLE OF QUESTIONS ABOUT HIS BASEBALL
FANDOM ...
WITH ALL THAT'S HAPPENING AROUND US AN D YOUR IMPORT ANT ROL E IN IT , JT MlG HT SEEM TRJTE TO
DISCUSS BASEBALL. BUT I KNOW YOU'VE BEEN A YANKEE FAN FOR MORE THAN 70 YEARS. AND I WOULD LIKE TO
ASK YOU A FEW BASEBALL QUESTIONS.
WHEN AND HOW DID YOUR YANKEE FANDOM BEGIN ?
YOU WERE A YOUNGSTER WHE THE YANKEES WON 5 STRAIGHT WORLD SERIES TITLES FROM 1949-1953,
THE ONLY TIME THAT'S EVER HAPPENED IN BASEBALL HISTORY . WHAT ARE YOUR MEMORIES OF THOSE YEARS?
HOW HAS YOUR BACKGROUND IN SPORTS HELPED YOU IN YOUR ROLE WITH THE NIALD?
AND, FINALLY, YOU ' VE SPOKEN ABOU T HOW NEW YORK IS THE EPICENTER OF THE VIRUS. FOR NEW
YORKERS WHO ARE LOOKING FOR SOME LIGHT AT THE END OF THE TUNNEL , WHAT WOULD YOU SAY TO THEM?
From: (b)(6)
Sent : Mon, 27 Apr 2020 07:00:08 -0400
Subject : Fwd: The global health leaders call, THURSDAY30 April at 14.30 CET
FYI
Fr om : "RYAN, Michael J." (b)(6J>

To : SHOC (b)(6) , Office of the Director-General <DG0ffice @who.int> ,
"Redfield Rober t R. CDC/OD " (b)(6)
(b)(6)
(b)(6)David Heymann
(bH6l>, "Felicity Harvey
(b)(6) "Chris .Elias"
(b)(6)
(b)(6) , "Fauci, Anthony (NIHINIAID) [E]"
"GREIN , Thomas"
(b)(6)"COX,Paul M_ichael" (bH > ,
------- i.....;_ ~=
"SCHWARTLANDER, BemhardF." (bH6l, "MINHAS ,

Raman" _________ __,, (b)(6J
"Conrad, Patricia (NIH/NIA ID) [E]" ------. (bH6J~, "MAH JOUR,
Jaouad" (b)(6J , "FALL, Ibrahima Soce" (b)( , "Thomas
R. Friede n" (b)(6)
Lynn Bank s (b)(6) , President I Reso lve to Save Live s
<pres ident@resolvetosave lives.org>, "Amadou .SALL"
SHORBATI, Farah"
, Robynn Leidig (b)(6)> ,
"DRURY, Patrick Anthony" , "Dr VAN KERKHOVE, Maria"
(b)C6lt>
(b)(6)
"GRAAFF, Peter Jan"

-------- (b)(6)"POOLE,Marcia"
-------- (b)(6)TarikMohammed
(b)(6) Carlos
Navarro Colorado _____ _, ~
Ryan Morhard_____ ___, Cb)(6)~
"BRI AN D, Sylvie" Cb>< , "MORGA N, Oliver' , (b)(6)
"Harries, Jenny" (b)( , "Awwad , David (NIH/NW D)
[C]" Cb)(6), "SIMONSON, Stewal1' CbH6)
"SINGER, Peter Alexande r" (b)(6) "Jayat unga, Wikum"
(b)(6)
"Julie.HALL" -----,, CbH6)>, Ame lie

RIOUX CbH6)>, "KABIR, Sophia" (b)(
(b)(6)
, "SHIN, Young-Soc"
(b)(6)
Feng Ding (b)(6)
------------ ASMA , Samira" (b)(6)

Cc: SHOC <shoc@who.int>, Office of the Dir ector-Genera l <DG0ffice @who.int>,
"SCHWARTLAN DER, Bernhard F ." ______ Cb)C6) , "MAHJOUR,
Jaouad'' Cb>< , "FAL L, lbrabima Soce" (b)(6) , "GREIN,
Thomas" CbH6) , "MINHAS, Raman" Cb>< , , "COX, Paul
Michael" ___ ..,, CbH6) , "AL-SHORBAJI, Farah" CbH6),
"POOLE, Marcia" CbH6) , "DRURY, Patrick Anthony"
(b)(6) , "GRAAFF , Peter Jan" CbH6)>, "Dr VAN
-------
KERK.HOVE , Maria" (6) , "KAB IR, Sophia"
Cb>
Cb)< , "FARES, Christine Youssef' Cb)<
-------
"AYLWA RD , Ray mond Bruce J." (b)(6) , "SMITH, Ian Michael"
(b)(6)
Subject: The global health leaders call, THURSDAY 30 April at 14.30 CET
Dear colleagues,
Dr Tedros would like to invite you to the next informal discussion about the
ongoing 2019 novel coronavirus.
The teleconference w ill be hosted on THURSDAY, 30 Apr il at 14:30 CETand Zoom

detai ls are copied below .
If you experience any technical difficulties joining th is conference call, please

contact the WHO HQ EOCoperator at: +4122791 5533
It would be appreciated if you could kindly confirm your participation to Ms Sophia
Kabir, email (b)(6); mobile no. (b)(6)
The agenda and background documents will be shared ahead of the call.
Best,
Mike
Join Zoom Mee ti ng

https:// w ho.zoom .us/j l Cb)(6),Cb)(4~
Meeting ID: (b)(6), (b)(4)
Password: H6>,(bH4>
Dial by your location
+41 43 210 71 08 Switzerland
+4143 210 70 42 Switzerland
0 800 561 252 Switzerland Toll-free
0 800 002 622 Switzerland Toll-free
+l 253 215 8782 US {Tacoma)
+l 213 338 8477 US {Los Angeles)
888 475 4499 USToll-free
877 853 5257 USToll-free
+33 7 5678 4048 France
+33 1 7095 0350 France
0 800 944 049 France Toll-fr ee
0 800 940 415 France Toll-fr ee
Meeting ID: (b)(6) , (b)(4)
Find your local number: https://who.zoom.us/u/ae FZfwUgUc
Join by SIP
I Cb)(6), Cb)(4~@zoomcrc.com
Frmn: Fauci,Anthony {NIH/NIAID) [E)
Sent: Mon, 27 Apr 2020 10:54:50 +0000
To: Duchin, Jeff
Eiubject : RE:High Praise
Jeff:
We ll- deserved recognition of your fine work. Keep it up.
Best regards,
Tony
From: Duchin, Jeff

-----------
Sen t : Sunday,April 26, 2020 11:58 PM
-------=-=--==
(b)(6)

Subject : High Praise -------- CbH6)>
Tony - in a recent shoddy "investigative journalism " piece about our work here in Seattle
(https://www.seattletimes.com/seattle-news/times-watchdog/why-the-seattle-sounders-
game-went-on-desp ite-coronavirus-emergency/) the reporter referred to me as being to the
Seattle area what Anthony Fauci would become to the country. So despite the crappy reporting
he bestowed upon me the highest of praise and rem inded me again of the incredible service
you are doing for our count ry . Hang in there and tak~ care of your self. We need you . Jeff
Why the Seatt le Sounders

game March 7 went on
X despite coronavirus
emergency
As virus fears grew, public officials and
sports execs debated health risks - and
PR messages - but let 33,000 into a
March 7 Sounders match. At what cost?
www.seattletimes.com
Jeffrey S. Duchin, MD (he/him)

Health Officer and Chief , Communicable Disease Epidemiology & [mmunization Section
Public Health - Seattle and King County
Professor in Medicine, Division of Infectious Diseases, University of Washington
Adjunct Professor, School of Public Health
401 5th Ave , Suite 1250, Seattle, WA 98104
Tel: (206) 296-4774; Direct (b)(6) ,; Fax: (206) 296-4803
E-mail: Cb)(6)
Sent: Mo n, 27 Apr 2020 02:47:49 +0000
To : Shapiro, Neil (NIH/OD) [E];Collins, Francis (NIH/OD) [E);Tabak, Lawrence
(NIH/OD) [El;Johnson, Alfred (NIH/OD) [El;Hallett, Adrien ne (NIH/OD ) [El
Subje ct: RE: NIAID fac ilities in the CARESAct spend plan
I suggest tha t _________________________ Cb

_H_6)
From:Shapiro, Neil (NIH/OD) (El (b)(6)>

Sent: Sunday, April 26 , 2020 10:32 PM
To: Collins, Francis (NIH/OD) [El ______ (b
""'),...,
(6)
= >; Tabak, Lawrence (NIH/OD) (El
(b)(6)>; Fauci, Anthony (NIH/NIAID) (E) (b)( ; Johnson, Alfred
":".":"~'.:"":"':-:":':'-:=====-..;,_- ~=
(NIH/OD) [E) (b)(6)>; Hallett, Adrienne (NIH/OD) [E) < CbH >
Subject: NIAID facilities in the CARESAct spend plan
Importance: High
Francis and Tony,
I have been working to get OMB/ASFR clearance for the 3rd Supplemental spend plan, and have
encountered a hitch with 0MB concerning the VRC/RML proposal. They say they (b)(5J
-
(b)(5) Thanks,
----------------
Neil
Sent : Mo n, 27 Apr 2020 02:46:32 +0000
Subject: RE: New England Journal of Medicine 20-13479
Yes, please.
From: Collins, Francis (NIH/OD) [E] (b)( '>

-------
------~ =
--------
Subject: FW: New England Journal of Medicine 20-13479
(b)(6)>
Want me to call CbH6)?
From: Corey MD, Larry (b)( >

-----~~ (b)(6)>; Fauci, Anthony (NIH/NIAID) [El
-------- CbH6);Mascola, John (NIH/YRC) [El

(b)(6).>
I think it would be very helpful , I see no downside ..

Sent : Sunday, April 26, 2020 6:38 AM -------
To: Fauci, Anthony (NIH/NIAID) [El------= (b)
""'(6)
= >; Mascola, John (NIH/VRC) [El
--------- (b)(6); Corey MD, Larry

(b)(6)>
If it would be helpful, I'd be glad t o do the outreach to Holden Thorp- Tony and I can discuss.
Francis
From: Fauci, Anthony (NIH/NIAID) [El< (b)(6)>

Sent: Sunday, April 26, 2020 8 :37 AM
To : Mascola, John (NIH/VRC) [E]
--------,; =,
(b)(6)>; Corey MD, Larry
Collins, Francis (NIH/OD) [El (b)(6)>
All good options. Let us go with Science first. If they do not want it , I am certain that Science
Translational Medicine will take it. I will discuss with Francis and John.
From: Mascola, John (NIH/VRC) [E] (b)(6)>

To : Corey MD, Larry (b)(6)>; Collins, Francis (NIH/OD) [El (b)(6)
--------
Cc: Fauci, Anthony (NIH/NIAID) [E] (b)(6)
Subject : RE: New England Journal of Med icine 20-13479
In looking at NEJM, they have had 4 COIVD-19 perspect ives in last 6 weeks, and they may have impacted
their thinking.
Agree with talking to editors . If inte rest in Science or Nature, suggestions below.
Priscilla Kelly, editor at science emai led me a w hile about their interest in papers. So if inte rest in
Science, we could check with her.
If Nature, Ursula Weiss.
John

To : Collins, Francis (NIH/OD) [E] -------= =
Cc: Fauci, Anthony (NIH/NIAID) [E] ~======~= >; Mascola, John (NIH/VRC) [E]
(b)(6)
---------
Subject: Re: New England Journal of Med icine 20-13479
You and Tony decide . Science or Nature accomplish the same but it seems we need a discussion with
the editor first to explain the importance of the manuscript.
Sent from my iPhone
On Apr 25, 2020, at 2:18 PM, Collins, Francis (NIH/OD) [El

------- (b)(6)> wrote:
Very surprised.
Do you want me to push back?
Francis

Sent : Saturday, April 25, 2020 3:55 PM
------~=
To: Fauci, Anthony (NIH/N IAID) [E] ______ Cb
_H_6J>;Mascola, John (NIH/VRC) [E]
(b)(6)
Cc: Collins, Francis (NIH/OD) [E] (b)(6J:
Subje ct: RE: New England Journal of Medic ine 20-13479
A do have to say I am surprised . but ok

--------
(b) (6)>
To: Corey MD, Larry (b)(6)>; Mascola, John (NIH/VRC) [El

(b) ~ >
Cc:Collins, Francis (NIH/OD) [El (b)(6)
Subject: Fwd: New England Journal of Med icine 20-13479
Let us discuss next steps
From: New England Journal of Medi cine

<onbeha lfo f@manuscriptcentral.com >
Date: April 25, 2020 at 12:31:26 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [El" <afauci@niaid.nih.gov >
Subject: New England Journal of Medicine 20-13479
Reply-To: " editorial@nejm.org " <editorial@nejm.org >
Dear Dr. Fauci,
I am sorry to info rm you that your submission , "A Strategic Approach to

Successful COVID-19 Vaccine Development," has not been accepted for
publication in the Journa l. It was evaluated by members of our editorial staff.
After considering its focus, content, and interest, we made the editorial
decision not to consider your submission further . We are informing you of
this promptly so that you can subm it it elsewhere.
Thank you for the opport unity to consider your submission.
Sincerely yours,
Eric Rubin, M .D., Ph.D.

Editor-in Chief

10 Shattuck Street
Boston, MA 02115
(617) 734-9800
Fax: (617) 739-9864
http://www.nejm.org
Sent: Mon, 27 Apr 2020 00:48:28 +0000
To: Adrian Hill
Cc: Hildegund Ertl;Sarah Gilbert;Redfield, Robert R. (CDC/OD)
Subject: RE:COVID-19 vaccine
Adrian:
Thank you for you note. Sorry that I took a few days to get back to you, but I
have been swamped. It is good to know of your work on t he chimpanzee
adenoviral vectors . The biosafety classification of viral vectors in the U.S. is within
the purview of the CDC, and so I have copied CDC Director Bob Redfield on this e-
mail. He would be able to point you in the right direction.
Best regards,
Tony
From:Adrian Hill (b)(6)

Cc: Hildegund Ertl
Subject: FW: COVID-19 vaccine
-----~~
(b)(6); Sarah Gilbert
_________
..
(b)(6)>
(b)( >
Dear Dr Fauci
(b)(4)
Thank you for your consideration of th is at an exceptionally busy time .

Yours sincerely
Adrian Hill
Professor Adrian V. S. Hill

Director, The Jenner Institute
Nuffield Department of Medicine
University of Oxford
Old Road Campus Research Building
Oxford OX3 7DQ
Sent : Mo n, 27 Apr 2020 00:45:21 +0000
To : Marston, Hilary (NIH/NIAID) [E)
Subject: FW: 260 County Models of COVID-19 Outbreaks across the US
Please see me or give me a call about this. Thank s.
From: Rubin, David M (b)(6)>

To: Fauci, Anthony {NIH/NIAID) [E]_______ (b
"""'
),,..,
(6>:
=>
Cc:Offit, Paul
(b)( 6) >
(b)(6); Tasian, Gregory E
Subject: 260 County Models of COVID-19 Outbreaks across the US

---------- (b)(6J>; Huang, Jing
Hi Dr. Fauci,
Jon Yewdell suggested I contact you directly to expedite a briefing on the new county-level models t hat
our center, Policylab, at CHOP, will be releasing tomorrow. He shared with us your note below about
including Ambassador Birx and Bob Redfield as well. We'd be happy to do so, and had been in touch
with Ambassador Birx last week. We have also stayed in contact with the analytics team led by Irum
Zaidi and Chuck Vitek. I am also taske d to Governor Wolfs crisis team in Pennsylvania and shared the
data with the Governor today.
Let us know next steps for arrang ing a video conference. Will arrange our schedule at your
convenience. Will have Ors. Paul Offit, Greg Tasian, and Jing Huang join from our team .
Best,
Dave
David Rubin, MD MSCE

Director of Population Health Inno vation
Dir ector of Policy Lab
Children's Hospital of Philadelphia

Office: (b) (6)
Cell: (b) (6)
www.policvlab.chop.edu I @PolicyLabCHOP
Children's Hospital
of Philadelphia
Pro fessor of Pediatri cs
Perelman School of Medicine
From: "Yewdell, Jon (NIH/NIAID) [E]" (b)(
Date: Tue sday, April 21, 2020 at 8:55 ---------

PM
To: "Rubin, David M" (b)(6)>
----!:====~~---
cc: Paul Offit
---------
Subject:<no subject>
·
CbH6)>
David,
At this point, I think it is best to contact Tony directly. He's at
(b)(6)
Good luck!
JOll
Jonathan Yewdell MD, PhD
Chief, Cellular Biology Section
Laboratory of Viral Diseases
NIAID, NIH
Truth ·wins: A Practical Guide to Succeeding in Bion1edical Research

free eBook download of my book
Link to Ohio State Science Sunday video on scientific method
From: Rubin, David M

--------
To : Yewdell, Jon (NIH/NIAID) [E] --------=-
(b)(6)
(b=)(=6)
Cc: Offit, Paul (b)(6)
Subject: FW: Heads up from Paul Offit and David Rubin on policy memorandum to reopen economy
Hi Jon,
Paul forwarded me your email back to him. Our team would be happy to present to him, Ambassador
Birx, and Bob Redfield . We have shared t he models with Governor Wolf in Pennsylvania today, and they
are informing strategy here . The 260 county models will post to our Policylab website tomorrow . Of
note, Paul and I had spoken to Ambassador Birx in the last couple of weeks, and we have been in
contact with Irum Zaidi, Chuck Vitek, and the analytics team.
Let us know how would be best to set up a group webinar to present the information. Or feel free to
connect us directly with their schedulers. Think the models illustrate the low margin of error in the
large cities for resurgence risk, even as other less densely populated counties may be tolerant to
reopening strategies.
Dave

Director of Population Health Innovation
Director of PolicyLab
Childr e n's Hospital of Philad elphia

Office: (b) (6)
Cell: (b) (6)
www.uo1icylah.cho_p.eduI @PolicyLahCHOP
Children's Hospital
of Philadelphia
Professor of Pediatric s
~V"'-' Per elman

Schoo l of rvtt.-cli
cini.:
l}l\l\ ► 1\1 'r 1/r1,,,10,, •
From: Paul Offit CbH6)>

To: "Rubin, David M" Cb)(6)
Subject: Fw: Heads up from Paul Offit and David Rubin on po licy memorandum to reopen
economy
Tony has seen our memo. His response is below.
From:Yewdell, Jon (NIH/NIAID) [E] (b)( >

Sent : Tuesday, April 21, 2020 5:45 PM ---------
To: Offit, Paul
Subject: FW: Heads up from Paul Offit and David Rubin on policy memorandum to reopen economy
Tony neve r ceases to amaze me . ...
See immediate reply below
Jonathan Yewdell MD, PhD
Chief, Cellular Biology Section
Laboratory of Viral Diseases
NTAID, NTH
Truth Wins: A Practical Guide to Succeeding in Biomedical Research

free eBook download of my book
Link to Ohio State Science Sundav video on scientific 1nethod
From: Fauci, Anthony (NIH/NIAID) [E] Cb> <6l

>
Sent: Tuesday , Apri l 2 l, 2020 5 :06 PM
To: Y ewdell , Jon (NIH/NIA ID) (E] ---------=-~ CbH ·>
.__...,,.,..=
Cc: Shaffer, Meredith (NIH/NIAID ) [E] CbH ; Conrad, Patricia
(NIH/NIAI D) [E] CbH >; Barasch, Kimberly (NIH/NIA ID) [C]
(b)(6)
Subject: RE: Heads up from Pau l Offit and David Rubin on policy memorandum to reopen
economy
Jon:
Thanks for the note. It would be even better if they could p resen t no t only to me,
but to Deb Birx and Bod Redfi eld.
Best ,
Tony
Director
Phone: (b)( 6)
FAX: (301) 496-4409
E-mail
-------- (b)(6)
information. It should not be used bv anyone who is not the original intended recipient. If you
From: Yewdell, Jon (NIH/NIAID) (E] (b)(6)

Sent: Tuesday, Apri l 21, 2020 4:29 PM
To: Fauci , Anthony (N IH/N[A[D) [E] -------~ =
(b)( 6)
..._~~
Cc: Shaffer, Meredith (NIH/NIAID) [E] (b)(6)
Subject: Heads up from Paul Offit and David Rubin on policy memorandum to reopen
econom y
Tony,
Paul and David asked me to pass this on to you.
Forwarded message from David:
"I think the time has come , with our models on 260 counties across the country relea sing in the
next 48 hour s, to offer Tony Fauci, and potent ially other ta sk force member s, a previ ew of the
work. Our models have incorporated local area differences due to weather, population and social
distanc ing. Th ey reveal that the large, densely popula ted cities will stru ggle to re-op en , and are
not well aided by weather effect s given their density. However, in less densely popula ted areas,
in which case count s are lower , wea ther has been a mitigating factor. These latter countie s may
have better success when they re-open assuming they are smart about workplace safety and have
testing and surveillance strategies in place"
Dave

Director of Pop ulation Healt h Inn ovation
Director of Policy Lab
Children 's Hospital of Philad elphia

Office: (b) (6)
Cell: (b)(6)
m,vw.policylab.chop.edu I @PolicyLabCHOP
Children's Hospital
of Philadelphia
Professor of Pediatrics
Sent : Mo n, 27 Apr 2020 00:43:24 +0000
To : Young, Neal S {NIH/NHLBI) [E)
Subject : RE:Lambris
Thanks, Neal.
Best regards,
Tony
From: Young, Neal S {NIH/NHLBI) [E]_______ Cb>

_<_.>
Se nt: Wednesday, April 22, 2020 8:07 AM
To: Fauci, Anthony (NIH/NIAID) [E) ------= (b)""'(6J
= >
Subject: FW: Lambris
Dear Tony
'Forwarding to you at the request of two colleagues, experts in anti -complemen t therapies .
Thanks, and 'stay health y.
Neal
From: "John D. Lambris" CbH6)>

Date : Tuesday, Apri l 21, 2020 at 2:43 PM
To: Skype CbH6)
Cc: Antonio M Risitano (b)(6)
--------
Subj e ct : Lambris
Hi Neal,
I hope all is well and you are staying healthy .

(b)(4)
Could you please bring us in contact with Antony Fauci t o see if he can help our program?
All the best and Stay Healthy
John
Sent: Mon, 27 Apr 2020 00:42:34 +0000
Subject: FW: Update: Inhibit cytokine storm in COVID-19 patients by Proteasome
Inhibitors
Attachm e nts : (b) (4)
Please respond to th is person. Thanks.
From: Kircheis Dr. Ralf <RKircheis@syntacoll.de>

Sent: Wednesday, Apr il 22, 2020 9:41 AM
To: Coomes, Stephani e (NIH/N IAID) [E] _________ (b
::-;
),.,.
(6)
= >; Fauci, Anthony (NIH/ NIAID) [E]
(b)(6)
Cc: (b)( Kircheis Dr. Ralf <RKircheis@syntacoll.de>
Subject: Update : Inhib it cytokine storm in COVID-19 patients by Proteasome Inhibitors
Importance: High
Dear Dr. Fauci,

dear Dr. Coomes,
thank you for your reply from 13. April with the notice that the information has been shared with NIAID's
COVID-19 research team .
Has the project already been initia lly evaluated by the team?
Are there any questions or need for additional information?
• I have summed up the relevant data regarding the use of proteasome inhibitors for treatment of
COVID-19 patients with acute lung and systemic organ failure in a position paper, please find a
Preview draft attached.
• With regard to currently ongoing t rials with monoclonal antibodies against the IL-6 receptor, i.e.
tocilizumab or sarilumab: These approaches go into the same direction as the present
suggestion, however, inhibit ion of NF-KB by proteasome inhibitors could provide the unique
potential to inhib it the release of multiple cytokines simultaneously, in particular strongly pro-
inflammatory cytokines including IL- 1, IL-6, T N Fa and chemokines, such as MIP-1 and CXCL1.
• This simultaneous inhibition of multiple cytokines/chemok ine seems to be advantege aus

compar ed to single ta rget approaches {as wit h the mAb) to compensate fo r redundant and
synergistic effects of multiple cytokines released during highly pathogenic CoV o r HSNl
infection .
Looking forward to hearing from you.
Kind regards,
Ralf
Mit freundlichen GrU~en / Kind regards
Dr. Ralf Kircheis

Director R&D
Research& Development
Phone:+49 9441 686048
s~ntacoll
<:;ynt:ittnll hmhH, Onn::u,c:tr;ic;c;.p
?4, n-CJ~~? <:;(4;\l ;;:1 rl l1tn.::u.1
Tel: +499441 / 68 60 o, Fax: +49 9441 / 68 60 30
Hande lsregister: Amtsgericht Regensburg· HRB 1612
USt· ldNr. DE 128580796
Geschaftsfuhrerin: Dr. Alexandra Dietr ich
Unsere Hinweise zum Datenschutz, lnsbesondere zu den Ihnen zustehenden Rechten, flnden Sle unte r
www .syntacoll.de/ datenschutz
Von: Coomes, Stephanie (NIH/NIAID) [E] (b)(6)

Gesendet: Montag, 13. Apri l 2020 02:37
An: Kircheis Dr. Ralf <RKircheis@syntacoll.de>
Betreff: RE:Inhibit cytokine storm in COVID-19 patients by Velcade Bortezomib
Dear Dr. Kircheis,
Thank you for your recent email to Dr. Anthony Fauci. Your message was forwarded to the Division of
Microbiology and Infectious Diseases (DMID) at the Nat ional Institute of Allergy and Infectious Diseases
(NIAID). As a member of DMID 's Office of Scientific Coo rdin ation and Program Operations, I am pleased
to respond.
I want to thank you for reaching out to share this informat ion and let you know that your message has
been shared with NIAi D's COVID-19 research team .
Sincerely,
Stephanie
Stephanie M. Coomes, Ph.D.

Health Scientist Administrator
Office of Scientific Coordination and Program Operations
5601 Fishers Lane, Room 7G68
Rockville. MD 20892
(b)(6)
V
Disclaimer: The informat ion in this email and any of its attachments is confidential and may contain sensitive
information. It should not be used by anyone who is not the originally intended recipient. If you have received this
email in error, please inform the sender and delete it from your mailbox or any other storage devices. The National
Institu te of Allergy and Infectious Diseasesshall not accept liability for any statements made that are the sender's
own and not expressly made on behalf of NIAID by one of its representatives.
From: Kircheis Dr. Ralf <RKircheis@syntacoll.de >
Sent: Wednesday, Apr il 8, 2020 2:49 AM
To: Fauci, Ant hony (NIH/NIAID ) [El ------ ==
(bH >; Billet, Courtney (NIH/N IAID) [El
______ (b
_)_C6)
_ >; NIAID Ocpostoffice (NIH/NIAID) <0CPOSTOFFICE@niaid .nih.gov>
Cc: Fischer, Elizabeth (NIH/NIA ID) [El (b)( >; Foster, Erin (NIH/NIAID) [El
(b)( >; Foster, Sarah (NIH/NIAID) [El (b)(6); Vasilenko, Olga
(NIH/NIAID ) [El (b)(6>:>; Vasquez, Aureli o (NIH/NIAID) [El
________ (b
_)_C6)
_,; Vostal, Alexander (NIH/VRC) [Fl (b)( >; Vazquez-
Ma ldonado , Nancy (NIH/NIAID ) [El (b)(6); Austi n, James (NIH/NIAID) [El
4 (b)( ·>; Agulto , Liane (NIH/NIAID) [E] (b)(6)>; Deckhut, Alison
(NIH/NIAID ) [E] (b)(6)>; Kircheis Dr. Ralf <RKircheis@syntacoll.de>
Subject: WG: Inhibit cytokine storm in COVID-19 patients by Velcade Bortezomib
Importance: High
Inhibition of cytokine storm in COVID-19 patients with acute respiratory distress syndrom by
PROTEASOME INHIBITORS e.g. Velcade {Bortezomib}
Dear Dr. Fauci,
dear Madams/Sirs,
I want to bring to your attension some potentially important experimental data and a new proposal for
treatment of COVID-19 patients with acute respiratory distress syndrome and organ failure . Sorry for
the broad distribution but I wanted to make sure tha t my message reaches you.
Similarly as has been described earlier for SARS-CoV, MERS-CoV (Channappanavar& Perlman,
2017) , H5Nl and some heavy HlNl Influ enza A infections, also COVID-19 patients have been
reported to show significantly increased systemic cytok ine release (i.e. cytoki ne storm), particularly
those patients with lung failure or system ic organ failure (Chao/in Huang et al. Lance t vol 395, 2020, ref
1).
Previous studies at VirologikGmbH, Erlangen, Germany, in colabo ration with the Friedrich-Loeffler-
lnstitut, Tuebingen,Germany have shown, that HSNl (or alternatively LPS) -induced Cytokinestorm in
vivo can be inhibited by applicationof ProteasomeInhibitors (E. Haasbach et al, Antivira l Res. 91,
2011, ref. 2), via the inhibition of translocationofthe NF-icBtranscriptionfactor to the nucleus (see
Fig. below ). The mechanism of NF-KB inhibition by proteasome inhibitors is well described, and works
via the inhibition of t he protea soma I degradation of t he cytosolic inhibitor IKB, this way keeping NF-KB
bound in the cytosol and there by inh ibit ing t he otherwi se induc ed (by cyto kine or LPS- or RNA vi rus)
translocat ion of NF-KB to the nucleus where it would initiate the transcr ipt ion of many cytok ines. This
effect of proteasome inh ibitors seems to wo rk in most cell ty pes, we could demonstrate this effect in
several different cell types (including macrophages) after stimulation w ith TN Fa in vitro and in HSNl (or
LPS)treated mice in vivo (see manuscript and Figs. attached) .
Inhibition of NF-KBby proteasome inhibitorsprovidesthe unique potential to inhibit the release of

many cytokinessimultaneously, in partic ular strongly pro inflammatory cytokines IL-lex.,IL-6,TNFa.,MIP-
1fL.) (w hereas some other cytokines involved in ant ivir al immune response, such as IFNy probably seem
to be not/less affected (because of diffe rent transcription pathway) .
Importantly, beside t he anti-inflammatory activity, prot easome inhibitors showed also significant anti-
fibrot ic activity (Lueftenegger et al., manuscript and figs attached) , which may be also important in the
treatment of COVID-19 patients with heavy lung disease.
Furthermore, there have been several publications showing tha t in particular early phases of the
replication cycle of Corona virus seem to be dependent on interaction with the ubiquitin-proteasomal
system (UPS) of the host cell, and were effectively inhibited by selective 20S proteasome inhibitors
(such as Velcade) (Wang et al. Viro logy J 2010 , 7:99 (ref . 3}; M. Raaben et al. J. Virology, 84(15), 2010,
ref. 4).
There are several registered proteasome inhibito rs (Bortezomib (Velcade Gt ) e.g. produced by
Mill ennium Pharmaceuticals (i.e Takeda Oncology); Carfilzomib (Kyprolis®), lxazomib (Ninlaro ®)) for
treatment of multiple myeloma and Mantel cell lymphoma, i.e. there are registered drugs with well
known side effects available to be tested in small clinical studies for evaluation of their therapeutic
efficacy in COVID-19 patients with heavy lung disease and other organ failure. Noteworthy: in contrast
to the chronical oncological indications where up to 8 trea t ment cycles (and sometimes even more) are
applied, it seems plausible that just one or two treatment cycles of proteasome inhibitors might be
sufficient to downregulate the cytok ine storm in COVID-19 patients, which would be associated also
with much lower side effects.
Early first experience on efficacy could be gained from compassionate use applications in heavily ill
COVID-19 patients very quick ly. Beside the registered application forms, i.e. infusions, probab ly also
inhalative application should be tested as well, because it may be better suited to reach the respecti ve
target cells in the lung, i.e. alveolar epithelial cell and alveolar macrophages. There are multiple
inhalative devices available, e.g. the Handyhaler by Boehringer lngelheim used for Spiriva (for COPD
treatment).
Alt hough t here are still many open questions, the potential to control the cytokine storm-induced heavy
lung and other organ failure by using already registered drugs, ie. proteasome inhibitors may be a real
chance to get an additional treatment option , hopefully decreasing the cases necessary for artificial
aeration.
Pleaseforward this mail to the colleages you consider relevant for evaluation, discussion and
consideration for your clinical strategy for COVID- 19.
Please let me know if additional info rmations are necessary.
To my person: I have MD PhD degree and have many years experience in pharmaceutical development
(Boehringer lngelheim ), Biotech (lgeneon, Aphton, Virologik GmbH) (for reference see also PubMed
Kircheis r) currently leading R&D activities at Syntacoll (part of lnnocoll). I am providing this information
personally in order to help to find a t reat ment for COVID-19 patients .
Looking forward to getting feedback from you,
With kind regards,
Ralf Kircheis (MD PhD)
(b)(6)
rkircheis@synt acoll.de
(b)(6)
Pis inhibit TNFa. Induced nuclear NFicB translocation
control
• PI inhibi t TNF« induced nuclear Nft.B cranslocation in a variety

of cells, Including tumor cells, stellate ceUs and macrophages
@ VIRO LoGI K
Antiviral Res. 2011 Sep;91(3):304-13. doi: 10.1016/j.antiviral.2011.07.006. Epub 2011 Jul 13.
Antiviral activity of the proteasome inhibitor VL-01
against influenza A viruses.
Haasbach E1, Pauli EK, Sprange r R, Mitzner D, Schubert U, Kircheis R, Planz 0.
Author information
Abstract
The appearance of highly pathogenic avian influenza A viruses of the H5N1 subtype being able to
infect humans and the 2009 H1N1 pandemic reveals the urgent need for new and efficient
countermeasures against these viruses . The long-term efficacy of current antivirals is often limited ,
because of the emergence of drug-resistant virus mutants. A growing understanding of the virus-host
interaction raises the possibility to explore alternative targets involved in the viral replication. In the
present study we show that the proteasome inhibitor VL-01 leads to reduction of influenza virus
replication in human lung adenocarcinoma epithelial cells (A549) as demonstrated with three
different influenza virus strains, A/Puerto Rico/8/34 (H1 N1) (EC50 value of 1.7 µM},
A/Regensburg/O6/09 (H1 N1v) (ECSOvalue of 2.4 µM) and A/Mallard/Bavaria/1 /2006 (H5N1) (EC50
value of 0.8 µM). In in vivo experiments we could demonstrate that VL-01-aerosol-treatment of
BALB/c mice with 14.1 mg/kg results in no toxic side effects, reduced progeny virus titers in the lung
(1.1 ± 0.3 log 10 pfu) and enhanced survival of mice after infection with a 5-fold MLD50 of the human
influenza A virus strain A/Puerto Rico/8/34 (H1 N1) up to 50%. Furthermore, treatmen t of mice with
VL-01 reduced the cytokine release of IL-a/~, IL-6, MIP-1 ~. RANTES and TNF-a induced by LPS or
highly pathogen avian HSN1 influenza A virus. The present data demonstrates an antiviral effect of
VL-01 in vitro and in vivo and the ability to reduce influenza virus induced cytokines and
chemokines.
Copyright© 2011 Elsevier B.V. All rights reserved.
PMID:21777621
DOl :10.1016/j.antiviral.2011.07.006
[Indexed for MEDLINE
Mit freundlichen Grul?,en/ Kind regards
Dr. Ralf Kircheis

Director R&D
Research & Deve lopment
Mail: RKircheis@syn tacoll.de

Phone: +49 9441 686048
s~ntocoll
Syntaco ll GmbH, Donaustrasse 24 , D-93342 Saal a . d. Donau
Tel: + 49 9441 / 68 60 o, Fax: + 4 9 9441 / 68 60 30
Hande lsregister: Am t sgeri cht Regensburg • HRB 1612
USt· ldNr. DE 128580796
Geschaftsfuhre rin: Dr. Alexand ra Dietr ich
Unsere Hinweose zum Datenschutz, insbesondere zu den Ih nen zustehenden Rechten, fi nden Sie unte r
wwwsvotacoll
de/datenscbut2
Sent : Mon, 27 Apr 2020 00:40:50 +0000
To : Xizhong, Cui (NIH/CC/CCMD) [El
Subject: RE:remdesivir and Present's wor ds on disinfectant
Brian:
Thank you for your note. (b) (5)
Best regards,
Tony
From:Xizhong, Cui (NIH/CC/CCM D) [E]

-------- (b)( >
-------=-=--==
-------- (b)(6)>
Subject: remdesivir and Present's words on disinfectan t
Dear Dr. Fauci,
I am an investigator in CCMD, CC, National Institutes of Health, I am studying coronav irus infection in
animal models on preclinical treatment. I was a doctor when I was in China, now I am just a preclinical
invest igator on infectious diseases.
(b) (5)
(b) (6), (b) (5)
Best wish to you and be safe. Thanks your efforts to all Americans!!
Brian X. Cui, MD, Ph.D
Critical Care Medcicine Department
Clinical Center
Phone: (b)(
From: Fauci, Anthony (NIH/N IA ID) [EJ
Sent : Sun, 26 Apr 2020 23 :13:59 +0000
To: Folkers, Greg (NIH/ NIAID) [E)
Subject : Re: Keynote Spea~er- Keystone Vac:cinology eSymposia (direct ions to record &
upload t alk)
Attachment s: image00 l. png, image002.png, image003.png, image004.png, imag e00S.png
Agree.
On Apr 26, 2020, at 6:38 PM, Folkers, Greg (NIH/NIAID) [E]

(b) (6) wrot e :
I think Hilary is closest to this and shou ld get the assignm ent
From: Fauci, Anthony {NIH/N IAID) (E] (b)(6)>

Sent : Sunday, Apr il 26, 2020 5:12 PM
To: NIAID OD AM <NIAIDODAM@n iaid.nih .gov>
Subject: FW : Keynote Speaker- Keystone Vaccinology eSymposia (directions to record &
upload tal k)
Greg and t eam:

Let us di scuss.
Tony
Director
Phone: (b)(6)
FAX : (301 496-4409
E-mail: Cb)(6)
The information in this e-mail and any of its attachments is confident ial and may
sender and delete it from your mailbox or any other storage devices . The Nationa l
NIAID by one of its representa tives.
Fro m : Kristina Horton <kr ist inah@keystonesymposia.org>
To: Fauci, Anthony (NIH/N IAID) [El .-------- -,.-
(b._..,
)(= >
Cc: rino.r.rappuol i@gsk.com; Conrad, Patricia (NIH/NIAID) [El (b)( >
----------
Subjec t: Keynote Speaker- Keystone Vaccinology eSymposi a (directions to record & upload
talk)
Greeti ngs Dr. Fauci:
Thank you for agreeing to participate as the keynote speaker for the Keystone
eSymposia: Vaccinology in the Age of Pandemics : Strategies Against COVID-
19 & Other Global Thr eats , a virtual conference which will be held on, Monday ,
June 15 and Tuesday, June 16, 2020 .
Understand ing how busy you are right now, we would like to make this process as
easy as possible. We are hoping to receive pre-recorded talks by Monday, May
18. Please keep us apprised on your timeline and we w ill work with your schedule .
Here are the details on next steps.
Next Steps:
• Keynote Talk Title: Transforming Vaccino logy: COVID-19 Emergency and

Conside rations for the Next Decade
o Please rev iew your talk title and return any changes. Changes
can be made up to two-weeks prior to the event.
• Please follow this link to upload your talk reco rding , by Monday, May
.1.!l.Click here to learn more about recording your presentation . Our media
team can assist you with record ing on your personal computer.
• Similar to the face -to-face conference , we env ision approx imately
50-60 minutes for the keynote lecture .
For questions about the scientific progra mming of this meeting, please contact Dr.
Rappuoli at rino.r.rappuoli@gsk .com and I will serve as the administ rative/logistics
contact at KristinaH@KeystoneSymposia.org.
Best,
Kristina
Kristina H. Richardson, MS
Scienti fi c Advisory Board Coord inator
Administrative Assistant: CSO& Global Developmen t
+ (b)( 6) I kristinah@keystonesymposia.org
<image0O1.png>
POBox 1630 I Silverthorne I CO80498 I USA (regular mail only)

160 USHighway 61 Ste. 200 I Silverthorne I CO80498 I USA (courier only)
970.262.1230 I 800 .253.0685 I www.keystonesymposia.o
rg
Visit virtual.keystonesymposia.org
to view our digital content .
<image002. png>
<image003.png>
<image004. png>
<image00 5.png>
KEYSTONE'" SYMPOSIA'
o n M o le c ul a r a nd Ce llul a r Bi ology
Accc/crari ng Life Scie nce Discovery
DIVERS I TY IN THE SCIENTIFIC WORKFORCE
0
0
0
KEYS IONE11A SYMPOS~
V1cellular JloJ01y
011Molecular an
Aee.,...IAMM• DIMM._,
•IY■lllff •• 1NI KIIITIPIC ·••11,oac■

Sent : Sun, 26 Apr 2020 23 :13:04 +0000
Cc: Barasch, Kimberly (NIH/NIAID) [C];Folkers, Greg (NIH/NIAID) [E];Routh, Jennifer
(NIH/NIAID) [E]
Subject: Re: Thank you , and ...
Attachments : image002. png
Gayle__ Cb _ and so I
_ >_<6) would like to do it if they clear it
On Apr 26, 2020, at 7 :08 PM , Conrad, Patri cia (NIH/NIAID) [E]

Cb)(6) wrote:
You sent this to me on Friday but we have not had a chance to discuss.
(bXS)- l'U
Please advise if you want to do this - again, adding others here as

well..
-p
From: Fauci, Anthony (NIH/N IAID) [E] (b)(6)

To: Folkers, Greg (NIH/NIA ID) [El ------ ==
(b)( >; Conrad, Patricia (NIH/NIAID)
[El CbH6)>
Cc:Barasch, Kimberly (NIH/N IAID) [C) (b)(6)
Subject : FW: Thank you, and ...
Have we discussed thi s already? Gayle CbH6J
Director
Phone : Cb)(6)
FAX: (301 496-4409
E-mail: (b)(6)
contain sensitive information. It should not be used by anyone who is not the
sender and delete it from your mailbox or any other storage devices. The National
NIAID by one of its representa tives .
From: Gayle Smith <gayle.smith ,@one.org>

To: Fauci, Anthony (NIH/N IAID) [E] -------
--------- ""7
= (b)(6) :,
Cc: Tom Hart <tom .hart@one.o rg>
Subje ct : Thank you, and ...
Dear Tony,
I have always felt reassured when the good Dr. Fauci speaks, and now more than ever. As
an American , a former colleague, a long-time admirer and student of your wisdom -thank
you . We are all safer because of you, and t he world will be a better place because of you .
Again.
As you know, I am now leading the ONE Campaign. We've been quite active w ith the
ONEWorld Campaign, dedicated to the fight against this newest virus, and focused on
Afr ica. We've made some progress on debt, and next up is a foc us on ensuring that a
vaccine, when it comes, is available to everyone.
One of the things we want to do is educate people, in all of the places we work. It won 't
surprise you that of particular urgency amongst our partners in Afr ica is that facts and
information get to people across the continent, but we also know t hat more facts are
needed everywhere. So next month we are going to launch #PassTheMic, where every day
for 19 days we willask a celebrity to turn his or her social media channels over to an expert
on COVID-19 for one day. So Julia Roberts might turn her Twitter account to you to talk
about t he critical elements needed to flatten the curve and slow t he spread. Or Idris Elba
could give up his lnstagram to the head of the African CDCso that he can illustrate the
imp act COVID-19 will have across Africa and what that means for the rest of the world .
We know artists wan t to be helpful right now, but that it is hard to know what to do. And
we know there are experts like you out there who have the answers. We've thought about
this a lot at ONE and wanted to do something we felt would truly have an impact. As we
look ahead we know COVID-19 does not know borders and until it is beaten everywhere
we are not in the clear. We need a global response plan and we need it now. By turning
over th eir platforms for the day, celebrity influencers will be donat ing one of their biggest
assets - their followers - to YOU, giving you the platfo rm you need (and we all need) to tell
the world why a global response is cri tical. Because none of us are safe unt il all of us are
safe.
We will work with each expert/celebrity pair to personalize the content to our and our
celebrity partners' audiences - in North Amer ica, Europe and Africa, and help create
content that both parties are happy with. We are now confirming our talent part ners, and
so far are getting a terrific response .
We know you're a busy man, so we've planned it so that the amount of time on your end
would be minimal. But the impact would be maximal.
I'm attaching more information about the campaign. Please let me know what you think
and if you have questions. Ideally we would like to get th is off the ground in early May, so
are hoping to conf irm folks by April 28th at the latest. Our team will be in touch with your
office to follow up.
Thanks as always for everything you do. All my best to you, Gayle
<image002.png>
Gayle Smith I President & Chief Executive Officer I (b)(6)

-------
ONE is a global movement campaigning to end extreme poverty and preventable disease by
2030 so that everyo ne, everywhere can lead a life of dignity and opportunity .
<PasstheMic Expert Outreach. pd f>

Sent : Sun, 26 Apr 2020 21 :50:57 +0000
To : Broas, Timothy
Cc: Grady , Christine (NIH/CC/BEP) [El
Subject: RE:Greeti ngs
Tim:
Thank you for your kind note . It was great to hear from you. I hope tha t all is
well with you and your family and that we get a chance to reOconnect when the
situation begins to return to some form of normal ity ..
Best regards ,
Tony
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: (b) (6)
From: Broas, Timothy <t imothy .broas@bclplaw .com>

Sent: Thursday, April 23, 2020 10 :26 AM
------- ==
To : Fauci, Anthony (NIH/NIAID) [El (b)(6)
Subject: Greetings
Dear Tony:
It's been a long time. Honestl y, I can't remembe r when we last saw each other. I recall that
wonderful day we went to the Nats game together, a lthough I cannot remembe r who else came
with us. And of course I will always remember when you came to my Partners in Health
fund raiser and introduced Paul Farmer. I will never forget yours eech (and neither will Paul!).
Ooce oo~
I apologize for dropping out of touch .
Those events were so many yea rs ago, (b) (6) no? So much has happened
and changed since then , and now, seeing you and listening to your wise words and advice
every day, I am reminded that we need to reconnect, when it's safe and you have time . We
have so much to catch up on! I have been meaning to write to you or call you , but I had
misplaced your email address and phone numbers. I hope this address works and this
message reaches you .
Meantime, thank you for your service to our country , indeed the world . You have been a solid,
wise, steady voice, Tony , and , despite all the naysayers and fools on social media , you have
earned the respect of billions of people. I am very proud of you , and am humbled and honored
that I can call you my friend .
I hope you and your family are well, and staying safe . The Broas family is doing well, thanks in
no small part to your dai ly advice and objective analysis . T hank you! Please let me know if
there is anyth ing I can do for you or your family.
Looking forward to seeing you on the other side of this, and having a good catch up. Who
knows, maybe at a Nats game?
Best regards,
Tim
BRYAN AMBASSADOR(RET) TIMOTHY M. BROAS

CAVE timothy .broas@bclplaw.com
LEIGHTONnr11~~pr=+1 202 sos611s M: (b)(6)
PAISNER
ul!,! ----
BRYAN
CAVELEIGHTON
PAISNERLLP.
1155 F Street NW, Washington, DC 20004-1357
bclplaw.com
COVID-19 / CORONAVIRUS RESOURCES ►
This electronic messageis from a law firm. It may containconfidential or privileged information. If you received this transmissionin error,
please reply to the senderto adviseof the error and delete this transmission and any attachments.
We may monitor and recordelectronic communicationsin accordancewith applicable laws and regulations. Whereappropriatewe may also
sharecertain information you give us with our other offices (including in otller countries) and select third parties. For further information
(includingdetails of your privacy rights and how to exercisethem), see our updatedPrivacyNoticeat www.bclplaw.com.
Sent : Sun, 26 Apr 2020 21:44:20 +0000
To : Greg Folkers H 6);Conrad, Patricia (NIH/NIAID) [El
Cb
Subjec t : FW: Thank you, and ...
Att achment s: PasstheM ic Expert Outreach.pdf
Have we discussed thi s already? Gayle (b)( 6)

--------
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail=--__,. _._, (b)(6)
From : Gayle Smith <gayle.smit h@one.org>
To: Fauci, Anthony (NIH/NIAID) [El -------

Sent : Thursd ay, April 23, 2020 1:48 PM
---,~
--------- (b)(6)
Cc: Tom Hart <tom .hart@one .org>
Subject: Than k you, and ...
Dear Tony,
I have always felt reassured when the good Dr. Fauci speaks, and now mo re than ever. As an American,
a former colleague, a long-t ime admirer and student of your w isdom - t hank you . We are all safer
because of you, and the world will be a better place because of you . Again.
As you know, I am now leading the ONECampaign. We've been qu ite active with the ONEWorld
Campaign, dedicated to the fight against this newest v irus, and focused on Afr ica. We've made some
progress on debt, and next up is a focus on ensuring that a vaccine, when it comes, is available to
everyone .
One of the things we want to do is educate people, in all of the places we work . It won't surpr ise you
t hat of particular urgency amongst our partners in Afr ica is that facts and informat ion get to people
across the cont inent, but we also know that more facts are needed everywhere . So next month we are
going to launch #PassTheMic, where every day for 19 days we w ill ask a celebrity to t urn his or her social
media channels over to an expert on COVID-19 for one day. So Julia Roberts might turn her Twitter
account to you to talk about the crit ical elements needed to flatten the curve and slow the spread. Or
Idris Elba could give up his lnstagram to the head of the African CDCso that he can ill ustrate the impact
COVID-19 will have across Africa and what that means for the rest of the world .
We know artists want to be helpful right now, but that it is hard to know what to do. And we know th ere
are experts like you out there who have the answers. We've thought about this a lot at ONE and wanted
to do something we felt would truly have an impact. As we look ahead we know COVID-19 does not
know borders and unt il it is beaten everywhere we are not in the clear. We need a global response plan
and we need it now . By turning over their platforms for the day, celebrity inf luencers will be donating
one of their biggest assets - their followers - to YOU, giving you the platform you need (and we all need)
to tell the world why a global response is crit ical. Because none of us are safe until all of us are safe.
We w ill work w ith each expert/celebrity pair to personal ize the content to ou r and our celebrity
partners ' audiences - in North Amer ica, Europe and Africa, and help create content that both parties are
happy with . We are now confirming our ta lent partners , and so far are getting a terrific response.
We know you're a busy man, so we've planned it so that the amount of time on your end would be
minimal. But the impact would be ma>:imal.
I'm attach ing more informa ti on about the campaign. Please let me know what you t hink and if you have
questions. Ideally we would like to get t his off the ground in early May, so are hoping to confirm folks by
April 28th at t he latest. Our team will be in touch with your office to follow up.
Thanks as always for everything you do. All my best to you, Gayle
Gayle Smith I President & Chief Execut ive Officer I

------- (b)(6)
ONE is a global moveme nt campa igning to end extreme poverty and preventable disease by 2030 so that
everyone , everywhere can lead a life of dignity ancl opportunity.
Sent : Sun, 26 Apr 2020 21:36:37 +0000
To : Lusso, Paolo (NIH/N IAID) [El
Subject : RE: Potentia l t reatment breakthrough fr om Milan
Thanks.
Director
Phone: (b)(6)
FAX: (30 496"'4409
E-mail Cb)(6)
From: Lusso, Paolo (NIH/NIAID) [E] (b)( >

Se nt: Sunday, April 26, 2020 5:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] ------ ==
Cc: Lane, Cliff (NIH/NIAID) [E]
.,...:.....:.-!====~~-
..
(b)(6)
(b)(6)>
Subject: Re: Potent ial t reatment breakthrough from Mi lan
Dear Tony :
I am trying to reach the Pl of the study, but on a Sunday afternoon/evening I doubt I will be successful.
should be able to get mo re information tomorrow morning and pass it on to you, Cliff and Joe Kovacs.
Allthe best,
Paolo
Paolo Lusso, M.D., Ph.D.

Chief, Section of Viral Pathogenesis
Laboratory of lmmunoregul at ion
Bldg. 10, Rm. 6All
NIAID, NIH
Bethesda, MD 20892
Phone: (b)(6) (personal)
--==~ (b;:;
H:;;;
6)-:-:
(1""""'.
ab)
Fax: (301) 480-5291
E-mail:
-------- (b)(6)
The information in this e-mail and any of its attachments is confident ial and may contain sensitive
information . It should not be used by anyone who is not the original int ended recipient. If you have
received this e-mail in error please inform the sender and delete it from your mailbox or any other
storage devices. The National Institute of Allergy and Infect ious Diseases(NIAID) shall not accept
liability for any statement made th at are the sender's own and not expressly made on behalf of the
NIAID by one of its representat ives.

Date: Sunday , Apr il 26, 2020 at 3:47 PM
To: "Lusso, Paolo (NIH/NIA ID) [E]" ---------=-~ (b)(6)
Cc:"Lane, Cliff (NIH/NIAID) [E]" (b)(6)
Subject: RE: Potential treatment breakthrough from Milan
Thanks, Paolo. (b)( S)

(b) (5)
Best,
Tony
Director
Build ing 31, Room 7A -03
Phone: (b)(6)
FAX: (301) 496-4409
(b)(6)
E-mail:
--------
From: l usso, Paolo (NIH/NIAID) [E]_______ Cb

_
H_6)
----------
Subject: Potential treatment breakthrough from Milan
Dear Tony:
(b) (5l
Congratulations to Brad Pitt for impersonating you! All the best,
Paolo
Sent : Sun, 26 Apr 2020 21 :17:22 +0000
Subject: FW: Wa shington Post story re: Sammie s finalist s
Please set up an interview as requested below. Thanks.
Director
Phone: (b)(6)
FAX: (3 96':44li9
E-mail: Cb)(6)
From: Davidson, Joe <joe.davidson@washpost.com>

To : Fauci, Anthony (NIH/NIAID) [El-------~~ (b)(6)
Cc: (b) (6)
Subject: Washington Post story re: Sammies finali sts
Hello Tony,
Congratu lations on being a Career Achievement finalist for the Samuel J. Heyman
Service to Am erica Medals (Sammies ). I'm writing a Federal Insid er column about th e
finalists and would like arrange a telephone interview with your for the sto ry.
My questions include :
Why did you j oin th e federal service?
Is ther e one example or anecdote that makes you particularly proud of you work?
What do you like most about your job?
What do you like least about your job?
Why would you recommend, or not, your agency and/or the federal governmen t to those
seeking career advice?
I know this is an incred ibly bus y time for you. I appreciate that th e life and death issues
related to the coronavirus are mor e important than any award. Nonetheless, I hope you
can spare 10 or 15 minutes for a telephone interview on Tuesday or Wednesday, April 28
or 29. I can also make other days that week work.
Thank you.
Best,
Joe
Joe Davidson, columnist

The Washington Post
1301 K Street, NW
202.334 .6415 - work
----- (b) (6) - cell

joe.davidson@washpost.com
Twitte r : @JoeoavidsonWP
Website: wapo.st/JoeDavidson
Sent : Sun, 26 Apr 2020 21:14:32 +0000
Cc:
Subject:
------- (b)( ;Grady, Christine (NIH/CC/BEP) [E]
FW: COG - Helen Branswell/STAT request / challenge studies
Please have her speak with Chris and/or Cliff. Thanks.
Director
Phone: (b)(6)
FAX: (3 96':44li9
E-mail: (b) (6)
other storage devices . Th e Nat ional Institute of Allergy and Infectious Diseases (NIAID) shall not

To : NIAID COGCORE<COGCORE@mail.nih.gov>
Cc: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: COG - Helen Branswell/STAT request/ challenge studies
Helen would like to speak w it h someone (ASF,Cliff , C Grady?) to discuss current thinking here
on challenge studies for COVID-19. Not sure of deadl ine.
(b)(6)
helen .branswell@statnews.com
Disclaimer : Any third-party mate rial in thi s email has been shar ed for internal use under fair use provi sions
of U.S. copyright law, without further verification of its accuracy /veracity. It does not necessarily represent
my views nor those of NIAID, NCH,HHS, or the U.S. governmen t.
Sent : Sun, 26 Apr 2020 21:12:06 +0000
To: NIAIDODAM
Subject: FW: Keynot e Speaker- Keystone Vaccino logy eSymposia (direct ions to reco rd &
upload t alk)
Attachments : Vaccino logy eSymposia_ DRAFTProgram Description & Schedule.pdf
Greg and team:

let us discuss.
Tony
Director
Phone: (b)(6)
FAX: (301) 496-4409
E-mail: (b)(6)
From: Kristina Horton <kristinah@keyston esymposia .org>

Sent: Friday, Apri l 24, 2020 4:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] ------- == (b)(6)
Cc: rino .r.rappuoli@gsk .com; Conrad, Patricia (NIH/NIAID) [El (b)(6)
Subject: Keynote Speaker- Keystone Vaccinology eSymposia (di rectio ns to reco rd & uplo ad talk)
Greetings Dr. Fauci:
Thank you for agreeing to participate as the keynote speaker for the Keystone
eSymposia : Vaccinology in the Age of Pandemics: Strategies Against COVID-19 & Other
Global Threats, a virtual conference which will be held on, Monday, June 15 and Tuesday,
June 16, 2020.
Understanding how busy you are right now , we would like to make th is process as easy as
possible. We are hoping to receive pre-recorded talks by Monday, May 18. Please keep us
apprised on your timeline and we will work with your schedule. Here are the details on next
steps.
Next Steps:
• Keynote Talk Title: Transforming Vaccinology : COV ID-19 Emergency and
Cons idera tions for the Next Decade
o Please review your talk title and return any changes. Changes can be made
up to two-weeks prior to the event.
• Please follow this link to upload your talk recording, by Monday, May 18. Cl ick
here to learn more about recording you r presenta tion . Our media team can assis t you
wit h recording on your pers onal compute r.
• Sim ilar to the face -to-face confe rence, we envision approximate ly 50-60 minutes
for the key note lecture .
For quest ions about the scien tific programming of th is meeting , please contact Dr. Rappuo li at
rino .r.rappuo li@gsk.com and I will serve as the administrat ive/logistics contact
at Kristi naH@KeystoneSympos ia. Org .
Best,
Kristina
Kristina H. Richardson, MS
Scientific Advisory Board Coordinat or
_____
Administrative Assist ant: CSO& Global Development
_,, I kristinah@keystonesymposia.org
(b) (6)
KEYSTONE ~ SYMPOSIA
o n M o l ec ul a r a nd C el l ul a r Bi o l ogy
Acc elerating Life Science Discovery
DIVERSITY IN THE SCIENTIFIC WORKFORCE
POBox1630 I Silverthorne I CO80498 I USA(regular mail only)

160 US Highway6, Ste. 200 I Silverthorne I CO80498 I USA (courier only)
970.262.1230 I 800.253.0685 I www.kevstonesymposia.org
Visit virtual.keystonesymposia
.orgto view our digital content.
oe o o
Sent: Sun, 26 Apr 2020 21:11:15 +0000
To: Hahn, Stephen
Subject: FW: Thank You! (FDA Submission: EUA200258)
Attachments : 2AML- COVID-19_ACCREDITATION 1 PAGER.PDF, IMG -20200330 -WA0002 .jpg
Steve:
They have contacted me, but have you seen this? I am sure that it is one of
many that you see.
Thanks,
Tony
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
behalf of the NIAIDby one of its representatives.
From: Eli J. Safdieh CbH6)>

__ [E] ------~~ (b)(6)
;...;;...;.::======"::::;:;;;-:----
Subject: Re: Thank You !
Dear Dr. Fauci,

---------- (b)(4 ) )
Hope all is we ll. Since this crisis has begun, I have been working
(b)(4)
Best Regards,
Eli J. Safdieh
From: "Conrad, Patricia (NIH/NIAID ) [E]" (b)( > on behalf of "Fauci,

_;__ _ _;_;;_;;_.:::=;~c,""-------
Anth on y (NIH/NIAID) [E]" (b)(6)
Date: Thursday , March 19, 2020 at 10:59 AM
To: EliSafdieh (bH6)>
Subject: RE: Thank You!
Dr. Fauci wanted me to thank you for you note.
Best regards,
Patricia L. Conrad
National Inst itute of Allergy and Infectious Diseases
(b)(6)
301-496-4409 fax
Disclaimer :
The information in this e-ma il and any of its attachments is confidentia l and may contain sensi tive information . It should not be used
by anyone who is not the original intended recipient. If you have received th is e-mail in error please inform the sender and delete it
rrom your mailbox or any otner storage oevices. National 1nslilute or Allergy ano 1nrec11ousDiseases (NIAID ) snau not accep1
liability ror any statement made that are sender's own and not expres sly made on behatr or the NIAID by one or its representatives .
From: Eli J. Safdieh

______
_,
(b)(6)>
To: Fauci, Anthony (NIH/NIAID) [E] -------~~

Subject: Thank You! --------- (b)(6)
Hi Dr.,
Hope all is we ll with you and your family.
You are a symbo l of integrity, nationalism , human ity, brilliance and perseverance. God bless you in all
that you do for our country, fo r human beings and society.
We are praying for your success in mitigating and destroying this epidemic!
Best Regards,
Eli J. Safdieh
Sent : Sun, 26 Apr 2020 21:06:30 +0000
To: Dieffenbach, Carl (NIH/NIAID) [El
Subject : RE:Documents as discussed
Thanks.
Director
Bui lding 3 I, Room 7 A-03
Phone (b) (6)
FAX: (301 496-4409
E-mail: (b) (6)
The informa tion in this e-mail and any of its attachments is confidential and may contain sensi tive infom1ation. It
should not be used by anyone who is not the original intended recip ient. lf you have received this e-mail in error
Allergy and Infectious Disease s (NlAID) shall not accept liability for any statements made that are the sender's own
From: Dieffenbach , Carl (NlH/NIAID) [E]
Sent: Friday, April 24, 2020 6: 13 PM ----------
-------=-:,-:-=
(b)(
To: Fauci, Anthony (NTH/ NlAID) [E]

Subject: FW: Documents as discussed -------- (b)(6) >
Dr. Fauci ,
l feel compelled to let you know directly when ever l talk to or correspond w ith an [C Director. I know you asked
him to reach out. Just closing the loop.
Carl

From: Dieffenbach, Carl (NTH/NTATD) [E]
Sent: F1;day, April 24, 2020 6: 11 _PM ______ ~=
To: Singer, Dinah (NIH/NC[) [E] ______ Cb
_>_ <_ ; Sharp less, Norman (NII-I/NC I) [E]
(b)( >
Cc: Fauci , Anthon (NTH/NTAlD) [E] (b)(6) Auchincloss , Hugh (NTH/NIATD) [E]
(b) (6)> ; Erbelding , Emily (NIH/NIAID) [E] (b) (6) ; Cassett i, Cr istina
(NIH/NIAID) [EJ...._____,, __ ,___ Cb _) _(6).>
Subject: Documen ts as discussed
Dinah and Ned,
Jt was a pleasure talking to you about what you are considering . As we discussed, here is the NIAID Strategic Plan
that was just published , and two models of funding opportunity announcements for you to consider as models. I also
think the Cancer Centers have aspects of collaboration , shared facilities, and research focus that you can borrow. So
much of what NlAlD has built is modeled on the Cancer Centers.
NWD strategic plan for COYID-19
https: //www .nia id.nih .gov /site s/ default / tiles/ NIA ID-COY 10-19-Strategic-P lan-2020. pdf
Current Cente rs for ATDS Research FOA

htips://grant~.nih.gov/grants lguide/pa -fi les/par-20-1 06.html
Thi s is a very old RF A. Tam sending it because it wa s NTAID's first attempt to build rese arch capacity for the Level
3 and Level 4 pathogens after the Anthrax events. The current versions of the RF As have been limited competitions
and are a Jess relavant.
https: //grants.nih .gov/ grants /guide/rfa-fi lesirfa-ai-04-032.html
With best rega rds,
Carl
Carl W. Die ffenbach, Ph.D.

Director
Division of AIDS, NIAID
560 l Fishers Lane , Room 8D34
{he, him, his)
Rockville , MD 20852-983 l
Phone: (b) (6)
Ce ll: (b)(6)
Fax: (240) 627-3466
The informa tion in th is e-mail and any of its attachm ents is confidential and may contain sensitive information . It
should not be used by anyone who is not the original intended recip ient. If you have rece ived this e-mail in en-or
please inform the sen der and delete ii from your maibox or any other storage devices. The NfAID shall not acc ept
liability for any statem ent made that are the sender 's own and not expressly mad e on behal f of the NIAID by one of
its representatives.
Sent : Sun, 26 Apr 2020 21 :05:18 +0000
Subject : RE:Interview - john lauermann
Yes.
Director
Phone: (b)(6)
FAX:(301) 496~ 09
E-mail: (b)(6)

---------
--------, .....,....,=
(b)(6)
(b) (6)•>
Cc: Conrad, Patricia (NIH/NIAID) [E]~=======~ (b)(6l>=

Subject: FW: Interview - john lauermann
Impo rt ance: High
Ok to schedu le? This is cleared
From : Joh n Lauerman (BLOOMBERG/ NEWSROOM

: ) At : 04/1 4 /20
1 8 : 46: 1 6
To : (b)(6)
Cc : (b) (6) ' (b)(6)

(b)(6)
Subject : RE : Inte r view
Hi J ennife r et a l : He r e ar e a few q ues ti ons fo r Dr . Fa uci .
Scientists from the Un i versity of Bri s tol found that the

coronavirus has u ne x p ec t ed t endenc y t o large mut a t i ons in t he
spi ke protein when its grown in monkey cells . This ha d been seen
b efore as a virus t h at was u n wi ll i ng t o mutat e . Does t h is crea t e
a n y co n cer n s about vaccine design a n d effec t ive n ess?
I t n ow appears t h at some peop l e wh o recover from Cov i d h ave n o

a n t ibodies to t h e SARS-Cov2. Wh at are t h e poss i b l e ex p l a n at i o n s
for this? Has it occurre d in other vira l d iseases? Does it have
any implications fo r the e ffectiveness of vaccines? Is NIAI D
i nves t i gati n g t hi s? I s th ere a poss i b il ity t h at t he v i rus
sequesters in cells ?
An o t h er fea tu r e of coro n av i ruses appears t o be ra p i d l y wa nin g

immunity . Has this been seen in any NIAID experiments? What does
t his s u ggest abo u t the vir u s ' s ability to evade the immu ne
syst em?
A l ab or at ory at Oxford h as suggested that , if al l go es we ll ,

t h e y may be f ini s h ed with p h ase 3 t r i a l s in 5000 p eo p l e by t h e
fall , which co u ld mean as early as Septe mber . Does that so u nd
realistic to you?
Some compa ni es are aski n g regu l ators t o ma ke sure t h at safe ty

standards are u pheld for ma ker s of Covid vaccin e s , and that
c o r ne rs aren ' t cu t . Is i t wor t h cut t ing some safe t y co r ne rs t o
ge t a Cov i d vacc ine read y for distr i bution?
How ma n y p eo p l e s h ou l d t he Mod erna va cc i n e be t es t ed in i n p h as e

3? How l o n g wou l d you e x p ec t t h o s e t r i als t o tak e?
Th a n ks very muc h, h o p e we ca n se t t hi s up soo n . All best , JL +44

2035 25 1 028
E'rom : At : 0 4 / 12 / 2 0
(b)( 6) 22 : 38 : 36
To : John -------------
La u er man (BLOOMBERG/ NEWSROOM : )
Cc : .----- Cb 6J
_H__ I (b)( ~ '
(b)( 6)
Subject : RE : Inte r view
Hi John - sorry we are still trying to get somethi ng arranged. Could you send
your questions .
Thanks,
Jen
Jennifer Routh [E]

News and Science Wri ting Bran ch
Office of Comm unications and Government Relations
NIH/HHS
Bethesda, MD 20892
Direct: (b) (6)
(b)(6)
Disclai m er: The informat ion in this e-m ail and any of its attach ments is confiden tial and may conta in sens itive informat ion .
It should not be used by anyo ne w ho is not the original intended recipient. If yo u have received th is e-mail in error please
inform the sender and delete it from you r mailbox or any other storage dev ices. The Nationa l Instit ute of Alle rgy and
Infect ious Diseases shall not accep t liabi lity for any state ments made tha t are se nde r's own and not express ly made on
behalf of til e N IAID by o ne of its represen tatives.
Sent : Sun, 26 Apr 2020 21 :00:27 +0000
To : Conrad, Patricia (NIH/NIAID) [E);Folker s, Greg (NI H/NIAID) [El
Subject : RE: BOLIVIAN COVID-19 GUIDELINES
I cannot co-aut hor anythi ng with th em. Make sure t hey do not slip my name in.
Director
Phone Cb)
(6)
FAX: (30 496"'4409
E-mail: (b)(6)

Se nt: Saturday, Apr il 25, 2020 7:20 AM---------
--------=-o:-=
(b) (6) > -------- (b)(6); Folkers, Greg (NIH/NIA ID) [E)
Subject: Fwd: BOLIVIAN COVID-19 GUIDELINES
Sent from my iPhone
From: Qu ispe Cornejo Armin Alvaro

-----------------
Dat e: April 25, 2020 at 5:30 :30 AM EDT
-------~
To: "Conrad, Patricia (N IH/NIAID) [E]"
= (b)(
(b)(
>, "Barasch, Kimberly

>
{NIH/N IAID) [C]" (b)(6)>
Subject: BOLIVIANCOVID-19GUIDELINES
Dear Ms. Patricia Conrad

Dear Ms. Kimber ly Marie Barasch
I hope you are well desp ite the current devastat ing world pandem ic.
The Bolivian Society of Intensive Care together with the Bolivian Healthcare
Ministry are writing the national guidelines for the manageme nt of COVID-19 in the
critically ill patient, an issue that is an emergency worldwide and may
become disastrous in the low-middle income countr ies of Latin America if not
managed since the beginning with prec ise , accurate and uniform approaches .
With our team in Erasme University Hospital in Brussels , Belgium, toget her with
Professors Jean - Louis Vincent, Fabio Taccone, Jean Charles Preiser,
Jacques Creteur, etc., we are preparing the mate rial with other Bolivian and
Mexican intensiv ists , internists , infe ctologists, imagenologists.
I wonder if Dr. Anthony Fauci would honor us coauthoring and reviewing our last
version of some chapters of our guidelines.
Best regards ,
SPE - CORNEJO,
~dicine PhD fellow (Fell.)
ritica f UNA MJ -
J
beto/og[a - Educaci6n
- SIZ member
1 8177
■
Erasme
I- Cliniquesunlve,silair~d
Ro 11£d lf n 11k 808 . 8
S \WM.erasme.ulb.ac.b
■
Erasme
I-
Lien vers Disclaimer
Cllniquesuniversitair~sde Bruxelles
~outedr '"" lk 808 8 10708 ux lie'>
sv.ww.erasme.ulb.ac,be
Sent : Sun, 26 Apr 2020 20:12:5 1 +0000
To: Alb ert i Saverio
Subject : RE:spreading determinants of SARS-CoV-2
Thank yo u !
Director
Phone: (b)(6)
FAX: (30 496"'4409
E-mail Cb)(6)
From: Alberti Saverio

------------
Sent : Sunday, April 26, 2020 9:10 AM
(b)(
---------~~
To: Auchincloss, Hugh (NIH/NIAID) [E]
-----------
Subje ct : spreading determinants of SARS-CoV-2
(b)(6)
Dear Tony,
we are all witnessing the great effort your collabo rators and yourself are investing over this pandemic
emergency .
As you well know, in Europe and Italy we had the unfortunate priv ilege of having been first hit hard by
t he pandemic, after China.
We had t he opportuni ty of meta -analyzing data from 170 .000 patients in European countries , for
associated determinants of the spread ing fo rce of COVID-19 .
If this may provide a useful, albei t non gratifying, contr ibution for the US and other countries, we wou ld
feel we had done our job .
best wishes
Saverio
Prof. Saverio Alberti
Genetica Medica
Dipartimento di Scie nze Biomediche
Universita di Messina
Po liclinico "G. Martino"
via Conso lare Valer ia
98 125 Messina
(b)(6)
Skype:
----- (b)(6) i
email : ______,.. (b)(6)

Sent : Sat, 18 Apr 2020 19:58 :06 +0000
To : (b)(6)
Subject: RE:Covid 19 Double Mechanism . By Dr Brogna Carlo
Thank you for sending this.

Best regar ds,
AS Fauci
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
other storage devices . The National Institute of Allergy and Infectious Diseases (NIAID ) shall not
From: c.brogna@libero .it

-------
Sent: Friday, April 17, 2020 7:51 AM
(b)(6)
-------=-:-=,
--------
To : Fauci, Anthony (NIH/NIAID) [E] (b)(6)
Subject: Covid 19 Double Mechanism . By Dr Brogna Carlo
Dear Dr A. Fau cy,
we don' t know each other. I was born (b)(6) I am a simple doctor in

Medicin and live in a remote Italian region. I am no one . I trust in God that you can read my
paper, being published. I send it to you to anticipat e the exit times becaus e I trust that we can
really unders tand what Covid 19 is. Being nobody , I did what nobod y would have done. I used
the few tools I had available and questioned all the papers and data published so far. I describe
what the dual mechanism of the Covid-19 can be. I anticipate that the resu lt conclusioni is not
to my credit but I have been helped. I wish you a good read. May God bless us.
Sincerely w ith love,

Dr. Carlo Brogna M.D.
(b)(6)
Italia
Avellino -lsernia
From : Fauci, Anthony {NIH/NIAID) [E]
Sent : Sat, 18 Apr 2020 19:56:13 +0000
To: Goletti Delia
Cc: Fabrizio Cantin i; (b)(6) Lerner, Andrea {NIH/NIAID) [E];Cassetti, Cristina
{NIH/NIAID) [E];Marston, Hilary {NIH/N IAID) [E];Greg Folkers (b)(6)
Subject : RE: impact of bari citini b in COVID-19-an off label study CONFIDENTIAL
Thank yo u, Delia. I appreciate t he info rmat io n.

Best regar ds,
Tony
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
The information in this e-mail and any of its attachments is confidentia l and may contain sensitive
received th is e-mail in error please inform the sender and delete it from your mailbox or any other
storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept
liability for any statements made that are the sender's own and not expressly made on behalf of the
NIAID by one of its representati ves.
From: Golett i Delia (b)(6h

Se nt : Friday, Apri l 17, 2020 8:03 AM
-------~= (b)(6)
Cc: Fabrizio Cantini (b)(6}
Subj ect : impact of baricitinib in COVID-19-an off label study CONFIDENTIAL
dear dr Fauci, good morn ing. I hope you are fine.
Apologies to dist urb you but it may be of your interest . I saw in the web t hat you {NIAID/Fauci)(
https ://investor. Iii ly .com/news-releases/news-release-details/Ii lly-begi ns-cli n ica1-testing-the rapies-covid-19 )
will be support a tria l using Baricit inib as part of the ACTTtria l ...
I collaborated with Fabrizio Cantini {he reads in cc), a reumathologist of Prato to write a letter to J Infection
{pdf attached). He conducted an off- label study in patients with mild -moderate pneumonia with COVID-19
[(SpO2) >92% at room -air, and rat io arterial oxygen part ial pressure/fractional inspired oxygen {PaO2/FiO2)
100-300 mm Hg] to evaluate the impact ofbaritinib {tablet 4 mg/day) in terms of safety, clinical respiratory
improvements, discharge, ICU tr ansfer in 2 we eks; these pati ents received also lopinavir/ritonavi r therapy.
The last consecutive patients with moderate COVID-19 pneumonia receiving standa rd of care therapy
(lopinavir/ri tonavir and hydroxychloroquine) admitted before the date of the fi rst baricitinib -treated patient
served as controls.
The results of this off-label study, with the limit of not been a RCT,are encouraging:
1. Safety: only 1/12 case of transaminase elevation at day 10, likely due to lopinavir ritonavir co-
administration because baricitinib is mainly renal secreted
2. Respiratory improvement : Sp02 and ratio arterial oxygen partial pressure/fractional inspired oxygen
(Pa02/Fi02) significant ly improved;
3. Discharge in 7/12 vs 1/12
4. ICU transfer (0/12 vs 4/12)
I do hope it may be a useful, although I am aware that it is a very preliminary info for you.
Thank you for your attent ion.
All the best

Delia
Oa: Fauci, Anthony (NIH/NIAID) [E]

1nviato: giovedl 16 aprile 2020 00:02
-------- (b)(6)
A: Goletti Delia (b)(6)

Oggetto : RE: Italian press...for you!
Delia:
Thank you very much for sending these.
Best regards,
Tony
From: Goletti Delia (b)(6)>

Sent: Wednesday, Apri l 15, 2020 2:51 PM
To: Fauci, Anthony (NIH/NIAID) [E] -------,a (b..,..
)= (6)
Subject: Italian press...for you!
Dear dr Fauci, I disturb you only to let you know that the Italian press is with you!
Dr Ippolito asked me to cont ribute to prepare a document in support of you which I did with all my hearth . I
gave my very minor contribution in supporting the scientific journalist, but with a lot of proud for you .
If you do not have it, below are the some of the links in your favor .
https://apnews.com/27feaca21519a5eaf555c01313d33b91
https://apnews.com/b59d0a2c4c53f1c63a074b0d375fec23
https://www.nytimes.com/aponl ine/2020/04/15/world/europe/ap-eu-virus-outbreak-italy-fauci.html
https://www .nytimes.com/aponline/2020/04/15/business/ap-virus-outbreak-the-latest.html
https://www.washingtonpost.com/world/europe/italian-virus-hospital-offers-fauci-work-if-trump-fires-
him/2020/04/15/9b9afac0-7f16-11ea-84c2-0792d8591911 story.html
https:// a bcnews .go. com/Health/wireStory/italian-virus-hospital-off ers-fa uci-work-trump-fires-70160122
https://www.ilfattoquotidiano.iU2020/04115/coronavirus-direttore-spallanzani-scrive-a-mattarella-e-
conte-il-licenziamento-di-fauci-sarebbe-un-disastro-e-non-solo-per-usa/5770793/
https://www.repubblica.it/salute/med icina-e-
ricerca/2020/04/15/news/per favore non silurate anthony fauci-254087254/
https://www.sanitainformazione.it/politica/emergenza-covid-19-negli-usa-anthony-fauci-rischia-il-
licenz iamento-lappello-di-ippolito-spallanzani/
https://www.adnkronos.com/fatti/cronaca/2020/04/15/coronavirus-pazienti-dimessi-dallo-
spallanzan i pu DuaZKkoJ NyLCZ 11DlgPN .html
all the best

Delia
Da: Goletti Delia
A: Fauci,Anthony (NIH/NIAID) [E] ______

lnviato: domenica 12 aprile 2020 19:57
Oggetto: R: all my gratitude and an update

____,
(b) (6)>
Thank you for your time!

Best regards
Da: Fauci,Anthony (NIH/NIAID) [E) (b)( >
lnviato: domenica 12 aprile 2020 19:53
--------
A: Galetti Delia (b)(6)
Oggetto: RE:all my gratitude and an update
Delia:
Many thanks for your kind note. It is much appreciated. I am pleased to see that you are getting
involved in COVID-19 work. Keep up your excellent work.
Best regards,
Tony
From: Goletti Delia (b)(6)

Sent:Sunday,April 12, 2020 11:02 AM
To: Fauci,Anthony (NIH/NIAID) [E] ----- --:a-
(b)""'(=
6).>
Subject:all my gratitude and an update
dear dr Fauci , apologies to write you in these busy days. It is only to express all my gratitude for what
you have done in your life to fight infectious diseases and what you are doing now for COVID-19.
Your efforts and achievement are in front of the whole world and for me it is a great honor to have
been with you in 1992-1996 at the time of HIV fight. As I told you many times , you are a model of
excellence!
Only to keep you updated in my life, I am fine , and I mainly work as an ID specialist and scientist at
the same place in Rome, the Nationa l Institute for Infectious Diseases L. Spallanzani. I am doing 2
days a week outpatients TB clinic and I run a small laboratory on TB research. However , given the
pandemia, I shifted the lab activities on COVID-19, in particular on:
1. the role of coinfection (COVID-19 coinfection with tuberculosis, or COVID - 19
coinfection with HIV) on the modulation of the in vitro immune specific-response to
SARS-CoV-2, or M. tuberculosis or HIV in cells from COVID-19 patients at different
clinical stage
2. in vitro evaluation of the immunological and virological effect of baricinib, an anti-JAK1
and -JAK2 drugs, used in reumathoid arthritis , that has shown using BenevolentAl 's
proprietary artificial intelligence-derived knowledge graph , as an agent that reduces the
SARS-CoV-2 endocytosis into target cells potentially inhibiting the entry.
Moreover , I would be happy to contribute in any activity you may think I am useful.
I wish you a happy Easter in this blessed day.
Thank you for your attention and fo r having had the possibility of working with you that has been
crucial in my personal and professional life.
All the best

Del ia
Delia Goletti, MD, PhD

Clinica l Inves tigator , Labo rat o rio d el Vecch io, Room 13
Head of Translat ional Research Uni t
Department of Epidemiology and Preclinical Research National Institute for Infectio us DiseasesL. Spallanzani
Via Portuense 292, Roma 00149 Italy
Tel:___ (b) (6), Fax: +39-06-5582-825
E-mail addr ess (
http://www .inmi .it/ ri cerca t r aslaziona le .htm l; h ttp://www. in m i.it/ ricerca tras lazionale e nglish.ht ml
Profes sor of Patho logy, Visiting Professor, Top Ital ian Wom en Scientist
Unicarnillus University Centre for lmmunobiology,
Rome, Italy B!izard Institute,
Que en M ary Un iv(?fSity of London, UK
®
LN ICAMILLUS
Sent : Wed, 22 Apr 2020 14:41:5 1 +0000
Subject: RE: Expert U.S. pan el develops NIH treatment guideline s for COVID-19
Please send me our press release related to the guidelines
Director
Phone: (b)(6)
FAX: (30 496"44 09
E-mail: (b)(6)

To: Fauci, Anthony (NIH/NIAID) [E] ------ ::;..,..-,=
(b)(6)>
Cc:Lane, Cliff (NIH/NIAID) [E] (b)( ; Folkers, Greg (NIH/NIAID) [E]
--------- (b)(6); Conrad, Patricia (NIH/NIAID) [E]

Subject: FW: Expert U.S. panel deve lops NIH treatment gu idelines for COVID-19
(b)(6)
Your thoughts o n Cliff et al do ing a COCAcall about the new guidel ines?
(COCA= CDC'sClinician Outrea ch and Commun icati on Activity)

------~~
To: Lane, Cliff (NIH/NIAID) [E]______ _H_6)>; Masur, Henry (NIH/CC/CCMD) [E]
Cb
(b)(6)
Cc: Pau, Alice (NIH/NIAID) [E)______ _H_6)>; Doepel, Laurie (NIH/NIAID) [E)
Cb
(b)(6)
Subject: RE: Expert U.S. panel develops NIH treatment guidelines for COVID-19
(b)(5)
------------------------
to night ....
(b)(5 We don' t have t o decide this
From: Lane, Cliff (NIH/NIAID) [E]
--------
(b)(6)
To: Billet, Courtney (NIH/NIAID) [E] -----

----------
--,;= Masur, Henry (NIH/CC/CCMD) [E]
(b)(6)>;
(b) (6) >
Cc: Pau, Alice {NIH/NIAID) [E_______ Cb)6) Doepel, Laurie (NIH/NIAID) [E)
_~...
(b)(6)>
Subject: Re: Expert U.S. panel develops NIH t reatment guidelines for COVID-19
(b) (5)
From: "Bi lle t, Courtney (NIH/NIAID) [El" (b)(6)

To: "Lane, Cliff (N IH/NIAID) [E]" L CbH6)j, "Masur, Henry (NIH/CC/CCMD) [E]"
(b)( >
Cc: "Pau, Alice (NIH/NIAID) [El" (b)(6), Laurie Doepel (b)(6)

Subject: FW: Expert U.S. panel develops NIH treatment gu idelines for COVID-19
Please advise?
From: Hall, Bill (HHS/ASPA) (b) (6)>

--------
-----~~ (b)(6)
Would Cliff and company want to participate in a COCAcall that CDCcould put on?
From: Bonds, Michelle E. (CDC/0D/OADC) (b)(6)>

------
To: Hall, Bill (HHS/ASPA) (b)(6)
Subject: FW: Expert U.S. panel deve lops NIH treatment guidelines for COVID-19
I see the NIH treatment guidelines news release is out. Are you still interested in hosting a COCAcan
on these guidelines?
Just out, press release from NIH:
Expert U.S . panel develops NIH treatment guidelines for COVID -19
04/21/2020 11:30 AM EDT
"Living document" expected to be updated often as new clinical data accrue.

ExpertU.S. panel developsNIH treatmentguidelinesfor
COVID-19
Colorized scanning electron micrograph ofan apoptotic cel l (green) infected with SARS-COV-2 virus particles
(orange), isolated from a patient sample. Image captured at the N LAID Integrated Research Facility {lRf) in F01t
Detrick . Maryland.N/A/D
A panel of U.S. physicians, statisticians, and other experts has developed treatment guidelines
for coronavirus disease 2019 (COV ID-1 9). These guidelines, intended for healthcare providers ,
are based on published and preliminaiy data and the clinical expertise of the panelists, many of
whom are frontline clinicians caring for patients during the rapidly evolving pandemic. The
guidelines are posted online (covid 19treatmentguidelines.nih.gov) and will be updated often as
new data are published in peer-reviewed scientific literature and other authoritative information
emerges.
The guidelines consider two broad categories of therapies currently in use by healthcare
providers for COVID-19: antivirals , which may target the coronavirus directly, and host
modifiers and immune-based therapies , which may influence the immune response to the virus or
target the virus.
The panel 's conclusions about treating COVJD-19 with various agents that fall into these two
classes of therapies are distilled in summary recommendations. Subsequently , the document
provides background information about each agent-such as clinical data about its use, ongoing
clinical trials, and known interactions with other drugs-that forms the basis for the
Recommendation. Tables briefly outline the same information.
The guidelines also describe the evaluation and stratification of patients based on their risk of
infection and severity of illness. Recommendations in this section address best practices for
managing patients at different stages of infection, for example:
• Outpatients who are either asymptomatic or who have mild to moderate symptoms and are self-
isolating
• Inpatients with severe illness or critical disease
Special considerations for pregnant women and for children who are infected are also included.
A comprehensive section of the guidelines addresses a range of considerations for clinicians

caring for the most c1itically ill hospitalized patients. This section includes multiple
recommendations for patients needing critical care, including infection control procedures,
hemodynamic and ventilatory support, and drug therapy.
Finally, the guidelines include recommendations concerning the use of concomitant medications.
These include statins; corticosteroids;non-steroidalanti-inflammatory drugs; and certain drugs
used to conlrnl hype rtension, known as ACE inhibitors and ARBs.
The treatment guidelines panel is co-chaired by Roy M. Gulick, M.D., chief of the Infectious
Disease Division at Weill Medical Hospital of Cornell University, New York City; H. Clifford
Lane , M.D., clinical director of the National Institute of Allergy and lnfectious Diseases,
National Institutes of Health; and Herny Masur, M.D., chief of the Critical Care Medicine
Department at the NIH Clinical Center. Members of the guidelines panel, appointed by the co-
chairs, were chosen based on their clinical experience and expertise in patient management,
translationa l and clinical science , and/o r the development of treatment guidelines. They include
30 experts drawn from U.S. healthcare and academjc organizations,federal agencies, and
professional societies.
About the National Institutes of Health (NIH) : NIH, the nation's medical research agency,
includes 27 Institutes and Centers and is a component of the U.S. Department of Health and
Human Services. NIH is the p1imary federal agency conducting and supporting basic, clinical,
and translational medical research, and is investigating the causes, treatments, and cures for both
common and rare diseases. For more informat ion about NIH and its programs, visi t
www.nih.gov.
From: National Institutes of Health (NIH) <nih.ocpl@service.gov deli very.com >

To: Bedrosian , Sara (CDC/0D/OADC) ----~ =
(b)(6)
Subject: Expert U.S. panel develops NIH treatment guidelines for COVID-19
Hav ing 1rouble view ing this emai l'.' View it as a Wch oage.
You are receiving 1his message because you are subscribe:!10 News Releases for Na1ional lnstitu1es of Heallh (NIH).
Expert U.S. panel develops NIH treatment guidelines for COVID-19
04/21/202011:30AM EDT
Update Your E-mail Address I Add Subscriptions I Unsubscribe
If you have questions or problems with the subscription service, please contact
subscriberhelp .govdelivery.com . For all other inquiries about NIH programs and activities,
please contact Ask NIH . Before writing, please view our Freguently Asked Questions page , our
Health Information page, or Search our website.
This service is provided to you by the National Institutes of Health .

NIH ...Turning Discovery Into Health ®
This email was sent to eri7@cdc .gov using GovDelivery Communications Cloud on behalf of: Nationa l Institutes of
Health (NIH) · 9000 Rockville Pike · Bethesda MD 20892 · 30 1-496-4000 I TTY 30 1-402-9612
D
Sent: Fri, 24 Apr 2020 01:11:10 +0000
To: Marks, Peter;Collins, Francis (NIH/OD) [El
Cc: Mascola, John (NIH/VRC) [E);Disbrow, Gary (OS/ASPR/BARDA);Conrad, Patricia
(NIH/NIAID) [E);Barasch, Kimberly (NIH/NIAID) [CJ (b)(6)
Subject: RE:Vaccine Development
Attachments: Warp Speed Brief Deck 0800 042220 .pptx
Peter:
Happy to discuss at your convenience - sooner rat her than later . Let us make sure that we
(b)(5)
-----------------------
with you.
CbHS
l . Happy to discuss this in deta il
Best regards,
Tony
From: Mar ks, Peter CbH >

To: Collins, Francis (NIH/OD) [El ------ (b
=),,..,
(6J
= >; Fauci, Anthony (NIH/NIAID) [E]
(b)(6)>
Cc:Mascola, John {NIH/VRC) [El (b)(6J; Disbrow, Gary {OS/ASPR/BARDA)
(b)(6)
Subject: Vaccine Development
I know that you have heard murmuring about Proj ect Warp Speed. We had a call today w ith John
Mascola, Carl Dieffenbach, Hilary Marston, Mary Marovich and Emily Erbelding to go through t he
proposal and discuss how it could feed into the ACTIV effort. Cb)(SJ
They suggested that I contact you to try to set up a brief call to

go over the plan. I am attaching a slide deck that provides an overview and am happy to find the time
whenever you are available.
Thanks so much for consideri ng,

Peter
Sent: Wed, 22 Apr 2020 00:29:08 +0000
To: Collins, Francis (NIH/OD) [El,------ -;;,
Cb"'""
H=
Subject : Viral Clades Brufsky 42020 Accepted Final.pdf
Att achments: Viral Clades Brufsky 42020 Accepted Final.pdf
Here is the paper fro m Pittsbu rg on the mutations. I will send on separate e-ma il the
commentary from China on another study

To: Graham, Barney (NIH/VRC) [El-------~ =
CbH6)>
Cc: Mascola, John {NIH/VRC) [El (b)(6)
Subject : FW: Viral Clades Brufsky 42020 Accepted Final.pdf
This is rea lly gett ing inte rest ing. See att achm ent.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
From: Hahn, Stephen (b)(6)>

To: Fauci, Anthony (NIH/NIAID) [El ------~~ (b)(6) Redfield, Robert R. {CDC/OD)
----- (b)(6)>; Debi Birx (b)(6)>

Subject : Viral Clades Brufsky 42020 Accepted Final.pdf
Sorry for all of th e emails. I spoke to Adam who is an oncologist . I t hought th is might be of int erest.
Steve
Sent : Tue, 21 Apr 2020 20:29:10 +0000
To: Birx, Deborah L. EOP/NSC
Subject: RE:Sero logy Test Calculator
(b)(5)
Director
Phone: (b)(6)
FAX: (30 496"'4409
E-mail Cb)(6)
From: Birx, Deborah L. EOP/NSC (b)(6)•>

To: Hahn, Stephen (b)(6)>; Fauci, Ant hony (NIH/NIAID) [E] (b)(
_:...:...:..!:====~;:---
Redfield, Robe rt R. (CDC/OD) (b)(6)>; Giroir, Brett (OS) (b)(6)l>
Subject: Re: Serology Test Calculator
(b)(5) Deb
From: "Hahn, St ephen" CbH >

Date: Tu esday, April 21, 2020 at 3:23 PM
To: "Birx, Deborah L. EOP/NSC" ---------~~ , "Fauci, Anthony S (NIH)"
CbH6)
CbH6)>,"Red fi eld, Robert R (CDC)" ____ Cb_H_6)>, "Giroir , Brett (OS)"
======== (b
')(
;::'
~6)
Subject: Fwd : Serology Test Calcula t or
From: Shuren, Jeff (b)(6)

To: Hahn, Stephen (b)(6)>, Lenihan, Keagan
----------- (b)(6)>, Shah, Anand
_________ (b_H_6)>, Rom, Colin...________ (b_~_<~
Subje ct : Serology Test Calculator
Attached is a very rudimentary calculator that you are welcome to share with the WHTF/HHS serology
WG to calculate the positive predict ive value and negative predictive value of individual serology tests
and the use of two tests by plugging in the known or estimated sensitivi ty, specificity, and population
prevalence of COVID-19. (b)(5)
Sent: Tue, 21 Apr 2020 20:28:43 +0000
To : (b)(6)
Subject : FW: Serology Test Calculator
Att achments: Calculat or for PPV and NPV for indiv idual tes ts and comb ined protect ed.x lsx
I w ill call you about thi s.
Director
Phone : (b)( 6)
FAX: (3 96':44li9
E-mail: (b) (6)
From : Hahn, Stephen (b)(6):>

Se nt : Tuesday, April 21, 2020 3:23 PM
To : Debi Birx (b)(6); Fauci, Anth ony (NIH/NIAID) [E] (b)(6)
---:---:-:-::-:~-:::-:-;;::::::===-~ ___ ;....;....;..:::=~~,-----
Redfie Id, Robert R. (CDC/OD) (b)( 6)•> ; Giroir, Brett (OS) CbH >
Subj ect: Fwd : Serology Test Calculator
--------
From: Shuren, Jeff

----------
Date : Apr il 20, 2020 at 6:26 :14 PM EDT
(b) (6)>
To : Hahn , Stephen (b)(6), Lenihan , Keagan (b)(6J>, Shah, Anand

___ .....:__:....____,!=~~~--- __ ___:,_ _:::, _~~~~-------
----------
Subject: Sero logy Test Calculato r
(b)( 6), Rom, Colin
--------- (b)(6)>
Attached is a very rudimentary calculator that yo u are welcome to share with the WHTF/HHS serology
WG to calculate the positive predict ive value and negat ive pred ictive va lue of individual serology tests
and the use of two tests by plugg ing in the known or estimated sensitivi ty, specificity, and population
preva lence of COVID-19 (b) (5)
Calculator for Positive Predictive Value (PPV) and NeQative Predictive Value (NPV) for individual tests and combined
Prevalence 5.0%
Test 1 Test 1
%Pos1 PPV1 for %Neg1 NPV1 for
Sen1 Sp1 (Test1 =pos) (Test1=pos) (Test1 =neg) (Test1 =neg)
97.0% 93.2% 11.3% 42.9% 88 .7% 99.8%
Test 2 Test2
%Pos2 PPV2 for %Neg2 NPV2 for
Sen2 Sp2 (Test2=pos) (Test2=pos) (Test2=neA) l(Test2=neA)
88.0% 96.0% 8.2% 53.7% 91.8% 99.3%
Combined
%Pos PPVfor %Discordant NPVfor
(Test1 =pos, (Test1=pos, (Test1 =pos, (Test1 =pos, %Neg NPV for
Test2=pos) Test2=pos) Test2=neg) Test2=neg) (Test1 =neg) (Test1 =neg)
4.5% 94.3% 6.8% 91.4% 88 .7% 99.8%

Sent: Sat, 18 Apr 2020 22:21:37 +0000
To : Hahn, Stephen
Cc: Birx, Deborah L. EOP/NSC;Redfield, Robert R. (CDC/OD);Kadlec, Robert
(OS/ASPR/IO);Caliguiri , Laura (FDA/OC);Lenihan, Keagan (FDA/OC);Shuren, Jeff (FDA/CDRH);Lane, Cliff
(NIH/NIAID) [E];Shah, Anand (FDA/OC)
Subje ct: RE:medRxiv: COVID-19 Antibody Seroprevalence in Santa Clara County,
California
Great idea!
Anthony s. Fauci, MD
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
From: Hahn, Stephen (b)(6):>

To: Fauci, Anthony (NIH/NIAID
,..:
)~[_;
------~~
E):.::======-~
Cc:Birx, Deborah L. EOP/NSC (b)( >; Redfi eld, Robert R. (CDC/OD)
(b)(6); Kadlec, Robert (OS/ASPR/1O) (b)( ; Caliguiri, Laura (FDA/OC)
(b)(6); Lenihan, Keagan (FDA/OC) (b)(6); Shuren, Jeff
":"'""-:--------:-:=======:!.:...-~____;
(FDA/CDRH) CbH6>:; Lane, Cliff (NIH/NIAID) [E] (b)(6) ; Shah, Anand
(FDA/OC)_;..:======::;: (b:;::,
)(c=:
6);-'
Subject: RE: medRxiv: COVID-19 Antibody Seroprevalence in Santa Clara County, Californ ia
Team,
Anand Shah, Deputy Commissioner, reached out to t he Stanford investigator s on our behalf. Very
interesti ng informa ti on regarding their research and the test that they are using. They are interested in
partnering with us. I'll let Anand give the detai ls.
Anand will be reaching out to the MGH fo lks, as we ll. (b)(5)
Steve
From: Fauci, Anthony (NIH/NIAID) [E] (b)( 6)
Date: April 18, 2020 at 3:38 :39 PM EDT
To : Hahn, Stephen (b)(6)
Cc : Birx, Deborah L. EOP/NSC (b)(6)>, Redfield, Robert R (CDC) (b)(6)
Kadlec, Robert P (OS) .....:.----=====~~~--:~
(b)(6), Caliguiri, Laura (b)(6),
-=======~~--
Lenihan , Keagan
c (NIH) .__ _____ _ ~_(6)
Cb _ >
(b)(6)>, Shuren, Jeff
--------- (b)(6)>, Lane, Henry
Subject: RE: medRxiv: COVID-19 Antibody Sero prevalence in Santa Clara County, Califo rni a
Steve:
John Ioann idis is the one that most of us know. He is the person one of your
people could reach out to .
Thanks,
Tony
Director
Phone : (b)(6)
FAX : (301) 496-4409
E-mail: (b)(6)
have received t his e-mail in er ror please inform the sender and delete it from your mailbox or any
accept liabi lity for any statements made that are the sender's own and not expressly made on
From: Hahn, Stephen (b)(6)

Sent : Saturd ay, Apr il 18, 2020 3:25 PM
------~~
Cc: Birx, Deborah L. EOP
__ ;_;;_.;..::;:======~
~ (b)(6)>
(b)(6)>; Redfie ld, Robert R. (CDC/OD)
(b)(6J>; Kadlec, Robert (OS/A5PR/IO} (b)(6)>; Caliguiri, Laura (FDA/OC}
"'.'"""'--:-------.=====:::_:-
(FDA/CDRH)
---,_,.....,_;
(b)(6)> ; Lenihan, Keagan (FDA/OC}
(b)(6); Lane, Cliff (NIH/NIAID) [El
(b)(6); Shuren , Jeff
(b)(6)
Subject: RE: medRxiv: COVID-19 Antibody Seroprevalence in Santa Clara County, California
We can certainly work with them . Does anyone know any of these folks?
From: Fauci, Anthony (NIH/NIAID) [E] _______ Cb

_H_6)
To : Hahn, Stephen (b)(6)
Cc: Birx, Deborah
--::-::-:--::-:-::-:-:.:===:------~=
L. EO
_:.P/_N_S_C.!::=====-=~:--~- Cb
_H_6) Redfield, Robert R (CDC) (b)( >,
Kadlec, Robert P (OS) (b)(6), Caliguiri , Laura (b)(6)>,
Lenihan, Keagan (b)(6) Shuren, Jeff (b)(6)>, Lane, Henry
C (NIH) ______ Cb
_H_6J
Subject : RE: medRxiv: COVID-19 Antibody Seroprevalence in Santa Clara County, California
St eve:
(b) (5)
Thanks for th e quick reply. The dat a from th e Stanford group
-------
Thanks,
Tony
Director
Phone: Cb)(6)
FAX: (301) 496-4409
E-mail: (b)(6)
From : Hahn, Stephen (b)( >

Sent : Saturday, Apr il 18, 2020 10:31 AM
To: Fauci, Anthony (NIH/NIAID) [E]____ ------~= ~_ Cb_) ~
(6)
~>~
Cc: Birx, Deborah L. EOP/NSC (b)(6)>; Redfie ld, Robert R. (CDC/OD)
(b)(6)>; Kadlec, Robert (OS/ASPR/1O) (b)(6)>; Caliguiri , Laura (FDA/OC)
(b)( v>; Lenihan, Keagan (FDA/OC) (b)(6); Shuren, Jeff
( F :::D-:-
A-:-:
/C:::D:--:-
R-:-:
H-:-:;
) ====:::!:::...:..:.:...;.,, (b;;.
)(;..;,
6)
L;-:
----------
Subject : Re: medRxiv: COVID-19 Ant ibody Sero prevalence in Santa Clara County, California
Tony,
(b) (5)
(b) (5)
(b)(5l.
Steve

To: Hahn, Stephen (b) (6)
Cc:Birx, Deborah L. EOP/NSC (b)(6)>, Redfield, Robert R (CDC) (b)(6)
Kad Iec, Robert P (OS) (b)(6)>
-------
Subject: FW: medRxiv : COVID-19 Antibody Seroprevalence in Santa Clara County, California
Steve:
(b) (5)
Thanks,
Tony
From: Folkers, Greg (NIH/NIAID) (E] (b)(6)

Subject: medRxiv: COVID-19 Antibody Seroprevalence in Santa Clara County, California
COVID-19 Antibody Seroprevalence in Santa Clara County, California

Eran Bendavid, Bianca Mulaney, Neeraj Sood, Soleil Shah, Emilia Ling, Rebecca Bromley-
Dulfano, Cara Lai, Zoe Weissberg, Rodrigo Saavedra, James Tedrow, Dona Tversky, Andrew Bogan,
Thomas Kupiec, Daniel Eichner, Ribhav Gupta, John Ioannidis, Jay Bhattacharya
doi: https://doi .org/10.1101/ 2020.04.1 4 .20062463

• Abstract
• Info / History
• Me t rics
• Preview PDF
Abstr act
Background Addressing COVID-19 is a pressing health and social concern . To date, many epidemic
projections and policies addressing COVID-19 have been designed without seroprevalence data to
inform epidemic parameters. We measured the seroprevalence of antibodies to SARS-CoV-2 in Santa
Clara County. Methods On 4/3 -4/4, 2020, we tested county residents for antibodies to SARS-CoV-2using
a lateral flow immunoassay. Participants were recruited using Facebook ads targeting a representative
sample of the county by demographic and geographic characteristics. We report the prevalence of
antibodies to SARS-CoV-2in a sample of 3,330 peop le, adjusting for zip code, sex, and race/ethnicity .
We also adjust for test performance characteristics using 3 different estimates : (i) the test
manufacturer's data, (ii) a sample of 37 positive and 30 negative controls tested at Stanford, and (iii) a
combination of both. Results The unadjusted prevalence of antibodies to SARS-CoV-2 in Santa Clara
County was 1.5% (exact binomial 95CI 1.11-1.97%), and the population -we ighted prevalence was 2.81%
(95CI 2.24-3.37%). Under the three scenarios for test performance characteristics, the populat ion
prevalence of COVID-19 in Santa Clara ranged from 2.49% (95CI 1.80-3.17%) to 4.16% (2.58-5.70%).
These prevalence estimates represent a range between 48,000 and 81,000 people infected in Santa
Clara County by early April, 50-85-fold more than the number of confirme d cases. Conclusions The
population prevalence of SARS-CoV-2 antibod ies in Santa Clara County implies that the infection is much
more widespread than indicated by the number of confirmed cases. Population prevalence estimates
can now be used to calibrate epidemic and mortality projections.
Sent : Tue, 21 Apr 2020 03:05:43 +0000
To : clane@niaid.nih.gov
Subject: FW: FYI- " Coronavirus Disease 2019 (COVID-19) Treatment Guidelines"
Go for it. Congratulations!!! Q
From: Hall, Bill (HHS/ASPA) (bH >

To : Fauci, Anthony (NIH/NIAID) [E] ------= (b)""'
(6)
= >
Cc: Billet, Courtney (NIH/NIAID) [E] (b)(6J>; Myles, Renate (NIH/OD) [E]
(b)(6); Burklow , John (NIH/OD) [E) (b)(6)
--------
Subject: Re: FYI- "Coronavirus Disease 2019 {COVID-19)Treatmen t Guidelines"
Hi Tony,
----------------
post first thing tomorrow morning.
(bX5)PCP.. I've told John B/Renate/Courtney that everything can
Best regards,
Bill
From:Fauci, Anthony (NIH/NIAID) [E]______ _ )_C6J

(b _ >
Sent: Monday, April 20, 2020 11:53 Afvl
--------r::-:-:=
To: Miller, Katie R. (ovp.eop.gov)
(b) ( > ---------- (b)(6); Short, Marc T. EOP/OVP
Cc: Birx, Deborah L. EOP/NSC

(b)( 6)j>; Billet, Court,_
----------=-:-~
n-ey- (':"'."
N'.".".
IH
""."
/':"."'
N'."."'
IA
'."".
l~D:-:
)[ :--:
E':"':
] ===~--
(b)(6)>; Redfield, Robert R. (CDC/OD)
(b
""' = ; Hall, Bill (HHS/ASPA)
);,(6)
====~ ~ (b)(6) J>; O'Malley, Devin M. EOP/OVP ----
(b)(6); ==
(b)(6)
~===~~
===== (b=)(=6)~1J>;.; =
Lane, Cliff {NIH/NIAID) [E] (b)( ; Myles, Renate (NIH/OD) [E]
(b)( 6)j
Subject: FYI - "Coronavirus Disease 2019 (COVID-19)Treatment Guide lines"
Katie/Marc:
Just as an FYI - "The Coronavirus Disease 2019 (COVID-19) Treatment
Guidelines" that were developed here at NIH, and a copy of which I provided to
Deb Birx and ult imate ly to Mark Meadows is moving forward . Mark Meadows
(b)(5)
(b) (5)
-----------------------------
w i I1come from NIH w ith clearance through the appropriate channels (see
(bH 5>
Press release
attachmen t as an FYI). I anticipate that this will happen in th e next day or two .
Thanks.
Tony
Director
Phone: (b)(6)
FAX: (301) 496-4409
E-mail
-------- (b)(6)
Sent : Mo n, 20 Apr 2020 23:05:49 +0000
To : Folkers, Greg (NIH/NIAID) [E)
Subject : RE:ask to highlight the incredib le work of key federa l workers
Corr ect again.
Director
Phone: (b)( 6)
FAX: (30 496"'4409
E-mail: (b)(6)
From : Folkers, Greg (NIH/NIAID) [El (b)(6)>

Sent : Monday, Apri l 20, 2020 5:04 PM
_______
_,,
------ == CbH >; Billet, Court ney (NIH/NIAID) [El
(b)(6)>; NIAID OD AM <NIAIDODAM@ni aid .nih .gov>
Cc: Stover, Kathy (NIH/NIAID) [El (b)(6)>; Routh, Jennifer (NIH/NIAID) [El
(b)(6)
Subject: RE: ask to highlight the incredible work of key federal worke rs
(b) (5)
From: Fauci, Anthony (NIH/NIAID) [E] CbH >

Sent : Monday , April 20, 2020 4:52 PM
To: Folkers, Greg (NIH/NIAID) [El ------- --==(b)(6) Billet , Court ney (NIH/NIAID) [E]
-------- (b)(6) ; NIAID OD AM <NIAIDODAM@niaid.nih .gov>

Cc: Stover, Kathy (NIH/NIAID) [El (b)(6); Routh, Jennifer (NIH/NIAID) [El
(b)(6)
Subject: RE: ask to highlight th e incred ible work of key federal worke rs
I agree.
Director
Phone: (b)(6)3
FAX: (301 496-4409
E-mail (b)(6)
From: Folkers, Greg {NIH/NIAID) [E] <gfolkers@niaid.nih.gov>

To: Billet, Courtney (NIH/NIAID) [E]<billetc@niaid .nih.gov>; NIAID OD AM <NIAIDODAM@niaid.nih .gov>
Cc: Stover, Kathy (NIH/NIAID) [E] <kathy.stover@nih .gov>; Routh, Jennifer (NIH/NIAID) [E]
<jennifer .routh@nih.gov >
Subject : RE:ask to highlight the incredible work of key federal worke rs
(b)(5)

Cc: Stover, Kathy (NIH/NIAID) [E] (bH >; Routh, Jennifer (NIH/NIAID) [E]
(b)(6)>
Subject : FW: askto highlight the incredible work of key federal workers
(b)(5)
Any suggestions?
From : Boyse, Natalie (OS/ASPA) (b)(6)>

To: Billet, Courtney (NIH/NIAID) [E]------ ::;..,..-,=
(bH >; Myles, Renate (NIH/OD) [E]
______ (b)
_C6)
_ >; Burklow, John (NIH/OD) [E] (b)( >
Cc: Bird, Catherine (OS/OGC) (b)(6);Brennan, Patrick (OS/ASPA)
(b)(6)>
Subject : FW: ask to highlight the incredible work of key federal workers
Hi John, Renate and Courtney -

(b)(5)
Let me know if you have any questions re: this request. I am avai lab le and happy to chat this afternoon.
Thanks,
Natalie
Natalie Boyse
Special Assistant, Immediate Office of the Secretary
U.S. Department of Health & Human Services
M,____ _
From: Baldw in, Brittany L. EDP/WHO (b)(6)>

Sent: Monday , April 20, 2020 3:00 PM
To: Boyse, Nata lie (OS/ASPA) --------~~ (b)(6)
Subject: ask to highlight the incredible work of key federal workers
Hi Natalie - reat talking ·ust now . (b)(S)~

(b) (5)
(b) (5)
Please do not hesitate to reach out with questions!
Brittany L. Baldwin
Special Assistant to the President
Speechwriter
0: (b)(6)
C:
----- (b)(6)
Sent: Mon, 20 Apr 2020 12:01:43 +0000
To: Collins, Francis (NIH/OD) [E);Mascola, John (NIH/VRC) [E)
Cc: Conrad, Patricia (NIH/NIAID) [E);McManus, Ayanna (NIH/OD) [E];Wood,
Gretch en (NIH/OD) [E];Tabak, Lawrence (NIH/OD) [E];Barasch, Kimb erly (N IH/NIAI D) [C]
Subject: RE: Pursuant to My Email on Friday
I agree. Let us do it another time.
Director
Phone : (b)( 6)
FAX: (301 496-4409
E-mail Cb)(6)
From: Collins, Francis (NIH/OD) [ E]

-------- > (b)(
------~:-:-=
(b)( 6) -------- CbH >; Mascola, John (NIH/VRC) [E]
Cc: Conrad, Patricia (NIH/NIAID) IE] CbH ; McManus, Ayan na (NIH/OD) IE]
H 6)>; Wood, Gretchen (NIH/OD) IE]
Cb CbH6);Tabak,
Lawrence (NIH/OD) IE] CbH >; Barasch, Kimber ly (NIH/NIAID) [C]
(b)(6)
With apologies , I jus t real ized that the ACTIV Vaccines working group (wh ich involves John in a
sign ificant way, and will be joined today by Tai Zaks from Modern a) meets this morning from 9
-10 am. Probably we need to pick another ti me for this pow -wow about the CVP?
Francis
From: Fauci, Anthony (NIH/NIAID) [E] CbH6J>
------=-cc-:-=(b)(6) 1
; Mascola, John (NIH/VRC) [E]
(b)(6)
Cc:Conrad, Patricia (NIH/NIAID) [E] CbH6J>;McManus, Ayanna (NIH/OD) [E]

1>; Wood, Gretchen (NIH/OD) [E]
CbH6J Tabak,
CbH6J;
Lawrence (NIH/OD) [E] CbH6J;Barasch, Kimber ly (NIH/NIAID) [C]
(b) (6) >
Patty:
Please see if we can incorporate this call into our regular ly scheduled 9:00 AM call that
actually includes some of the same cast of people.
Thanks,
Tony

To: Fauci, Anthony (NIH/NIAID) [E] < CbH6J>;Mascola, John (NIH/VRC) [E]
(b)(6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] CbH6J>;McManus, Ayanna (NIH/OD) [E]

1>; Wood, Gretchen (NIH/OD) [E]
CbH6J CbH6J>;Tabak,
---~--"':"""""""':"".~==-.:......-_;_
Lawrence (NIH/OD) [E]
__ ~
(b)( v>
Ill
Can we have a phone call about this tomorrow at 9:15 am? Anyone else to include (Emily?
Cliff?)
Francis
From: Fauci, Anthony {NIH/NIAID) [El

-------- (b)(6)>
To: Mascola, John (NIH/VRC) [El ______ --,;-

CbH=6J>; Collins, Francis (NIH/OD) [El
'""
(b)(6)
Cc:Conrad, Patric ia {NIH/NIAID) [E] (b)(6)
----------
Subject : RE: Pursuant to My Email on Friday
Francis:
(b) (5)
Best,
Tony
From: Mascola, John (NIH/VRC) [E] _______ Cb

_>_C6)
Sent : Sunday, Apri l 19, 2020 4:24 PM
To: Fauci, Anthony (NIH/ NIAID) [E]
------~= CbH >; Collins, Francis (NIH/OD) [E]
(b)(6) --------
Cc: Conrad, Pat ric ia {NIH/NIAID) [E]
---------
Subject : FW: Pursuant to My Email on Friday
CbH >
<< File : Cov Vaccine Program HHS (draf t) 19April20.pptx »
Tony, Francis,
(b)(5)
(b)(5)
Happy to discuss.
John
(b)(6)
From: Kadlec, Robert (OS/ASPR/10)

Sent: Sunday, April 12, 2020 8:59 PM--------- (b)(6)
To: Hassell, David (Chris) (OS/ASPR/10) (b)(6),>; Collins, Francis (NIH/OD) [El
=======--=:-;;--'
CbH6J;Mascola, John INIH/VRC) [El
CbH6J>;Bright , Rick (OS/ASPR/BARDA) ; Fauci,
CbH6J
Anthony (NIH/NIAID) [E] CbH6)>;Disbrow, Gary (OS/ASPR/BARDA)
(b)(6); Patrick, Vanessa (OS/ASPR/BARDA) (CTR)
=======~~ ---------=:-:-=
--------- (b)(6)1>; Moughalian, Jen (HHS/ASFR)
Redfie Id, Robert R. (CDC/OD)
CbH6)>;
CbH6J>;Messonnier, Nancy (CDC/DDID/NCIRD/OD)
CbH6)>;Lane, Cliff (NIH/NIAID) IE] CbH6);Marks, Peter (FDA/CSER)
--------- CbH6)>;
Cc: Harrison, Brian (HHS/10S)
Yeskey, Kevin (OS/ASPR/10) (b)(6)
CbH6J>;Dareshori, Zack (HHS/10S)
CbH6)>;Conrad, Patricia (NIH/NIAID) [E] (b)(6)
Stecker, Judy (OS/10S) ---------
CbH6)>;Shuy, Bryan (OS/ASPR/10)
(b)(6)
--------- CbH6J;Wolinetz, Carrie (NIH/OD) [E]
Subject: Pursuant to My Email on Friday
----------
I want to share with you the product of the BCGteam who drafted the attached briefing and
Decision Memo drafted for the Secretary's review t omorrow. I want to thank all those who
contributed over this holiday weekend to offer their ideas and concepts that is represented in
t hese products. This represents just a first step of many steps that first outlines a concept that
will then be operationalized int o a histor ic effort for not only the Department and agencies w ho
will contribute to it, but to our Nation. Again, thank you for your contributions and
commitment. Best Bob
<< File: Vaccine strategy-200411-v 13.pptx >> << File: Secretary Determination Memorandum-
Project Warp Speed-041120 1825 draft.doc>>
Sent: Mon, 20 Apr 2020 01:34:55 +0000
To: Mascola,John (NIH/VRC)[E)
Subje ct: RE: Pursuant to My Email on Friday
OK. Let us discuss tomorrow.
From : Mascola, John (NIH/VRC) [E] (b)( >

Sent: Sunda y, April 19, 2020 6:11 PM
---------
To: Fauci, Anthony (NIH/NIAID) [E) < -------:a=
".:::::======6-:--:=
Cc:Conrad, Patricia {NIH/NIAID) [E]
Subject: FW: Pursuant to My Email on Friday
Tony,
One key point that may be easie r to review w ith 5 min call , whenever you get the chance.
(b)(5)
John
From: Mascola, John (NI H/VRC) [E]

-------::-:--:-=
To: Collins , Francis {NIH/OD) [E] (b)(6) ,
Cc:Conrad, Patricia (NIH/N IAID)"":'
[~
E]~=====---=- 6); Fauci, Anthony (NIH/NIAID) [E]
(b"'""
)(=
(b)(6)>
Francis,
(b) (5)
If still not so clear , feel free to call.
John
(b)(6)

Sent : Sunday, April 19, 2020 5 :04 PM
-------- (b)(6)
To: Mascola, John (NIH/VRC) [E]

-------~ (b)( >
=
":'"":.:::=======..,.._
Cc:Conrad, Patricia (NIH/NIAID) [E] (bH6J>; Fauci, Anthony (NIH/NIAID)
(b)( 6) > --------- [E]
Hi John,
Thanks for your thoughtful note. (b) (5)

(b) (5)
Francis
From: Mascola, John (NIH/VRC) [E] < (b)(6)>

--------
------
(b)(6)>
-------- ~=>; (bH Collins, Francis (NIH/OD) [E]
Cc:Conrad, Patricia (NIH/NIAID) [E]

---------
Subject: FW: Pursuant to My Email on Friday
(b)(6)>
<< File: Cov Vaccine Program HHS (draft) 19April20.pptx »
Tony, Francis,
(b) (5)
Happy to discuss.
John
(b)(6)
From: Kadlec, Robert (OS/ASPR/IO) (b)(6)

----------
To: Hassell, David (Chris) (OS/ASPR/IO) CbH6)>;Collins, Francis (NIH/OD) [El
___ _;_ _ ___;_ _;_.:._.:.__.:._.:..:::::=====: Cb
~>:;;
<6) ; Mascola, John (N IHNRC) [El
~>"""'"'..
CbH6b ; Bright , Rick (OS/ASPR/BARDA) CbH6) ; Fauci,
Anthony (NIH/NIAID) [El (b)(6)>; Disbrow, Gary (OS/ASPR/BARDA)
CbH6J>;Patrick, Vanessa (OS/ASPR/BARDA) (CTR)
=========~~ --------~~
---------- (b)(6)1>; Moughalian, Jen (HHS/ASFR)
Redfield, Robert R. (CDC/ODJ
CbH6)>;
Messonnie r, Nancy (CDC/DDID/NCIRD/OD)
CbH6>;>;
CbH6)>;Lane, Cliff (NIH/NIAID) IE] CbH6);Marks, Peter (FDA/CSER)
CbH6);Yeskey, Kevin (OS/ASPR/IO) CbH6J>
----------
Cc: Harrison, Brian (HHS/IOS) CbH6)>;Dareshori, Zack (HHS/IOS)
CbH6)>;Conrad, Patricia (NIH/NIAID) [E] (b)(6J>;
Stecker, Judy (05/105) CbH6)>;Shuy, Bryan (OS/ASPR/IO)
CbH6)>;Wolinetz, Carrie {NIH/OD) [E] (b)(6)
--------
----------
Decision Memo drafted for the Secretary's review t omorrow . I want to thank all those who
contributed over this holiday weekend to offer their ideas and concepts that is represente d in
t hese products. This represents just a first step of many steps that first out lines a concept that
will then be operationalized int o a histor ic effort for not only the Department and agencies w ho
<< File: Vaccine strategy-200411-v 13.pptx >> << File: Secretary Determination Memorandum-
Project Warp Speed-041120 1825 draft .doc»
Sent : Wed, 22 Ap r 2020 14:55:57 +000 0
Subjec t : FW: Coronavirus Quest ions for th e Offic e of th e Surgeon General
(b)(
Please make sure th at I call thi s person t omorrow
-------------
Director
Phone: (b)(6)
FAX: (3 96':44li9
E-mail: (b) (6)
From : (b)(6) MEDCOM (USA)

Se nt : Tu esday, April 21, 2020 9:58 PM ---------- (b)(6)
To : Fauci, Anthony (NIH/NIAID) [E] ------~~ (b)(6)

Subject: RE: Coronavirus Questions for th e Office of the Surg eon Gener al
Dr. Fauci,
Thank you for responding to my request for information. Please be safe.
(b)(6)
(b) (6) My cell phone number is

(b)(6)-. ----------------------
r/
(b)(6)
From: Fauci, Anthony (NIH/NIAID) [E] _______ Cb_H_6)

To : (b)(6) M_
E_DC
_O_M
__:_
(U_S_A.:.!
) ==~~---- Cb
_H _6)
Cc: Lerner , Andrea (NIH/NIAID) [E]
--------- (b)(6)
Subjec t: [Non-DoD Source] FW : Coronavirus Questions for the Office of the Surgeon General
All active links contained in this email were disabled. Please verify the identity of the sender,
and confirm the authenticity of all links contained within the message prior to copying and
pasting the addres s to a Web browser.
(b)(6)
Thank you for your note . Shown below are my answers to your questions.
hope that you find them helpful.
1. How do you recommend I reassure our staff on dealing with the stressors of COVID-19?
This is indeed an unprecedented and stressful time. Stress can often come from the unknown.
In times of stress it is critical to take care of one's physical health, by eating well, getting enough
sleep, and exercising. In addition , maintaining connections with fami ly and friends (via phone
calls, email, or video chatting) while physically socially distancing is very important .
2. Can COVID-19 be contracted from a corpse?

Infect ion control measures should be undertaken when dealing with deceased individuals with
known or suspected COVID-19. The CDC provides guidance on this issue here:Caut ion-
https:// www.cdc.gov /coronavirus /2019-ncov /hcp/guidancc-postmort em-
specimens.html < Caution-https://www.cdc.gov/coronavirus/2019-ncov /hep/guidance-
postmortem-speci mens.html>
3. If someone has been a user of Hydroxychloroquine for years, are they susceptible to contracting
COVID-19?
Clinical trials are underway to determine if hydroxychloroquine is effective in preventing COVID-
19 in exposed persons. Until we know the answer to this question , persons who take
hydroxychloroqu ine on a daily basis for another medical condition should consider themselves
vulnerable to COVID-19 and take appropriate and recommended measures to protect
themselves.
4. Are masks and gloves tru ly effective, if so, why are so many medical professiona ls contracting
the virus?
I believe that infection control strategies which include proper use of personal protective
equipment (PPE)as recommended by the CDC are effective. _
Caution-https: // www.cdc.gov /coronavirus/2019-ncov /hcp/ infection-control-
recommendation s.html?CDC _AA _refVal =https%3A %2F%2FCaution-
www .cdc.gov %2Fcoronavirus%2 F20 l 9-ncov%2f infect ion-control %2Fcontro l-
rccommcndations.html < Caution-https :/ /www.cdc.gov/coronavi rus/2019-ncov /hcp/i nf ection-
control-recommen dations. html?CDC_AA_reNal= https%3A %2F%2FCaution-
www.cdc.gov%2Fcoronavirus%2F2019-ncov%2Finfection-control%2Fcontrol-
recommendat ions.html >
In cases where inadequate PPEis worn , or if is not put on/ t aken off according to proper
procedure, the risk of contract ing COVID is increased. In addition, healthcare workers on the
front lines can be exposed if they encounter a patient who is not initially suspected of having
COVID-19 without PPE,especially if they are exposed to aerosol generating processes.
5. What is th e most important th ing we should be do ing, other t han social distanc ing?
Social distancing is key in order to avoid coming into contact with someone with COVID-19, but
washing one's hands often (or using an alchohol-based hand sanitizer) and avoiding touching
one' s face with unwashed hands are cr itical as well, especially when coming into contact with
surfaces that may have been touched by others or public places.
6. Finally, wh at keeps you up at night, regard ing COVID-19?

I have said in the past that what keeps me up at night is the possibility of a pandemic respiratory
infection. We are in that reality now, and what keep s me up at night is the response, a major
part of which is the development of an effective vaccine and treatments for COVID-19.
Best rega rds ,

Tony
Director
Phone : (b)( 6)
FAX: 301 496-4409
E (b)( 6)
other storage devi ces. The National Institute of Allergy and Infectious Diseases (NIAID) shall not
accept liability for any statements made that are the sender' s own and not expressly made on
_F_
ro_m_:.!::::======~ (b=)(~6) MEDCOM (USA)___________ Cb
_>_< _ _
(b) (6) >>
Se nt : Tuesday, April 14, 2020 9:13 AM
To: Fauci, Anthony {NIH/NIAID) [E] -------------------- ~~ > >
(b)(6)
Subject: Coronavir us Questions for the Off ice of th e Surgeon General
Dr. Fauci,
I am
----, (b)(
~= , the antiterror ism and insider threat office r for the Office of the Surgeon General
(Army)/ U.S. Army Medical Command. I have been in government for nearly thirty-four years, and this
is new to me . I see and hear the concerns of many people. You are the voice of reason for mi llions of
concerned citizens . I have a few questions for you:
1. How do you recom mend I reassure our staff on dea ling w ith the stressors of COVID-19?
2. Can C0VID-19 be contracted from a corpse?
3. If someone has been a user of Hydroxychloroquine for years, are they susceptible to cont racting
C0VID-19?
4. Are masks and gloves tru ly effective, if so, why are so many medical professionals contracting
the virus?
5. What is the most important th ing we should be doing, other t han social distancing?
Finally, what keeps you up at night, regarding C0VID-19?
Thank you for your time and please be safe.
r/
------ Antiterror ism and Inside r Threat Officer

Cb)(6)
Office of the Surgeon General and U.S. Army Medica l Command
Mission Assurance and Protection Division
Fort Sam Houston, TX 78234
Cell phone: (b)(6)
(b)(
~NIPRNet: (b)(6)
~SIPR Net:
--------------------------------
Leve I I Antiterror ism Awareness Training:
Caution-http://jko .jten .mil/courses/at! 1/launc h. html < Caution-
http ://jko.jten .mil/courses/atl 1/launch. html >
Organizational Mailbox:
Cb)(6) < Caution-
mailto (b) (6) >
To submit contracts for AT/OPSEC review:

Caut ion Cb)~ Caution-
(b) (6).,..>___ _.
"Not on My Watch"
CONFIDENTIALITY NOTE: Thi s electronic transmiss ion , including all attachments,

is directed in confidence solely to the person(s) to whom it is addressed, or
an authorized recip ient , and may not otherwise be distributed, copied
or disclosed . The contents of the transmission may also be subject to
intellectua l property rights and all such rights are expressly claimed
and are not waived. If you received this transmission in error,
please notify the sender immediate ly by returning the electronic
transmission and then immediately delete this transm ission,
includ ing all attachments, without copying, distribut ing or disclosing same .
"PRIVACY ACT INFORMATION "
In compliance with the Privacy Act of 1974 , this informat ion is Personal Data and must be
protected from publ ic disclosure.
Sent : Tue, 21 Apr 2020 17:48:36 +0000
To: (b)(6)1
Cc: Lerner, Andrea (NIH/NIAID) [El
Subject: FW: Coronavirus Questions for the Office of the Surgeon General
(b)(6)
Thank you for your note. Shown below are my answers to your questions .
hope that you find them helpful.
This is indeed an unprecedented and stressful time. Stress can often come from the unknown.
In times of stress it is critical to take care of one's physical health, by eating well, getting enough
sleep, and exercising. In addition, maintaining connections with family and friends (via phone
calls, email, or video chatting) while physically socially distancing is very important.

Infection control measures should be undertaken when dealing with deceased individuals with
known or suspected COVID-19. The CDCprovides guidance on this issue here:
https ://www.cdc.gov / corona virus/20 l 9-ncov /hep/guidance-postmortem-specimens.html
3. If someone has been a user of Hydroxychloroquine for years, are they susceptible to contracting
COVID-19?
Clinical trials are underway to determine if hydroxychloroquine is effective in preventing COVID-
19 in exposed persons. Until we know the answer to this question, persons who take
hydroxychloroqu ine on a daily basis for another medical condition should consider themselves
vulnerable to COVID-19 and take appropriate and recommended measures to protect
themselves.
4. Are masks and gloves tru ly effective, if so, why are so many medical professiona ls contracting
the virus?
I believe that infection control strategies which include proper use of personal protective
equipment (PPE)as recommended by the CDCare effective._
https://www.cdc.gov /coronavirus /2019-ncov /hcp/infection-control-
recornmendations. h1rnl?CDC AA reNal=https% 3A %2F%2Fwww .cdc .gov%2Fcoronavirus%2F
20 l 9-ncov%2F infcction-control%2Fcontrol-recommcndations.h tml
In cases where inadequate PPEis worn, or if is not put on/taken off according to proper
procedure, the risk of contract ing COVID is increased. In addition, healthcare workers on the
front lines can be exposed if they encounter a patient who is not initially suspected of having
COVID-19 without PPE,especially if they are exposed to aerosol generating processes.
5. What is the most important thing we should be doing, other than social distancing?
Social distancing is key in order to avoid coming into contact with someone with COVID-19, but
washing one's hands often (or using an alchohol-based hand sanitizer) and avoiding touching
one's face with unwashed hands are critical as well, especially when coming into contact with
surfaces that may have been touched by others or public places.
6. Finally, wh at keeps you up at night; regarding COVID-·19?
I have said in the past that what keeps me up at night is the possibility of a pandemic respiratory
infection . We are in that reality now, and w hat keeps me up at night is the response, a major
part of which is the development of an effective vaccine and treatments for COVID-19.
Best regards,
Tony
Direc tor
Phone: (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
Information. It should not be used bV anyone who is not the orig inal intended recipient. If you
From : (b)(6)MEDCOM (USA) (b)(6)

Se nt: Tuesday, April 14, 2020 9:13 AM -----------
To : Fauci, Anthony (NIH/NIAID) [E] ------~ ~
(b)(6)>
Subject: Coronavir us Questions for the Office of the Surgeon General
Dr. Fauci,
I am --- -=-=-:=
(b)(6) the antiterror ism and insider threat officer for the Office of the Surgeon General
(Army)/ U.S. Army Medical Command . I have been in government for nearly thirty-four years, and this
is new to me. I see and hear the concerns of many people . You are the voice of reason for mi llions of
concerned citizens. I have a few quest ions for you:
3. If someone has been a user of Hydroxychloroquine for years, are they susceptible to contracti ng
COVID-19?
4. Are masks and gloves tru ly effective , if so, why are so many medical professiona ls contracting
the v irus?
5. What is the most important th ing we should be do ing, other than social distanc ing?
Finally, what keeps you up at night, regarding COVID-19?

_____
r/
.... Antiterrorism and Insider Threat Officer
(b)(6) ,
Office of the Surgeon General and U.S. Army Medica l Command
Fort Sam Houston, TX 78234
Cell phone: (b)(6)
z (b)(
s ':-'.
N:-:-:
IP::::
R::--::
N-:-e-:-: =======---
t-;: ...
Cb
"'>""
C6l
s SIPRNet:
-------------
Level I Antiterrorism Awareness Training:
http ://jko. jten.mil/courses/atl1 /launch.htm l
(b)(6)

(b)(6)
"Not on My Watch"
CONFIDENTIALITY NOTE: This electronic transmiss ion, includi ng all attachments,

an authorized recipient, and may not otherwise be distributed, copied
or disclosed. The contents of the transmission may also be subject to
intellectua l property rights and all such rights are expressly claimed
and are not waived. If you received this transmission in error,
please notify the sender immediately by returning the electronic
transmission and then immediately delete this transm ission,
including all attachments, without copying, distributing or disclosing same .
"PRIVACY ACT INFORMATION "
In compliance with the Privacy Act of 1974 , this information is Personal Data and must be
protected from public disclosure.
Sent : Sat, 18 Apr 2020 20:35 :32 +0000
Cc:
Subjec t :
Conrad, Patricia (NIH/NIA ID) [E);Greg Folkers
---------
FW : Coronavirus Quest ions for th e Offic e of th e Surgeon General
(b)( 6)
Please fa shion some responses t o his quest ions f or me t o send back t o him
Thanks .
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail (b) (6)
information . It should not be used by anyone who is not the orig inal intended recip ient. If you
accept liability for any statements made that are the sender's own and not expressly made o n
From : (b)(6)USARMY MEDCOM

(USA)
----------
(b)(6)>
(b)(6)>
Subject: Coronavir us Questions for the Office of the Surgeon General
Dr. Fauci,
I am --- :::-c-r,=
(b)(6) the antiterrorism and insider threat officer for the Office of the Surgeon General
(Army)/ U.S. Army Medical Command. I have been in government for nearly thirty -four years, and th is
is new to me. I see and hear the concerns of many people. You are the voice of reason for mi llions of
concerned citizens. I have a few quest ions for you:
3. If someone has been a user of Hydroxychloroquine for years, are they susceptible to cont racti ng
COVID- 19?
4. Are masks and gloves tru ly effective , if so, why are so many medical professiona ls con tracting
the virus?
5. What is the most important th ing we should be doing, other t han social distancing?
Finally, what keeps you up at night, regard ing COVID-19?

r/
------ Antite rrorism and Insider Threat Officer
CbH 6) ,
Office of the Surgeon Gene ral and U.S. Army Medica l Command
Fort Sam Houston , TX 78234
Cell phone : (b)(6)
z (b)(6)
s ':-
N:'7':
IP::-:
R
::-:
N --:t-:: =======~---
:-:-
e (b
--~,,_,
(6)
IS::ISIPRNet:
------------
Leve I I Antite rrorism Awareness Training:
http://jko.jten .mil/courses/at! 1/launch .html
(b)( 6)

(b)(6)
"Not on My Watch"
CONFIDENT IALITY NOTE : This electronic transmiss ion , including all attachments,
an authorized recipient, and may not otherwise be dist ributed, cop ied
or disclosed . The contents of the tr ansmiss ion may also be subject to
intellect ual property rights and all such rights are expressly claimed
and are not waived . If you received this transmission in error,
please notify the sender immed iately by returning the electron ic
transm ission and then immediately delete this transm ission,
includ ing all attachments , without copying, distribut ing or disclosing same .
"PRIVACY ACT INFORMA T ION"
In complianc e with the Privacy Act of 1974, th is information is Personal Data and must be
protected from public disclosure .
From: Fauci, Anthony (NIH/NIAID ) [E]
Sent: Sat, 18 Apr 2020 19:51:12 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subje ct: FW: COVID-19 - Potential Treatment
Please t ake a loo k and handle.
Director
Phone: Cb)(6)
FAX:(301)496-4409
E-mail: (b)(
from your mailbox or any other storage devices. The National Institute of Allergy and
Infectious Diseases (NIAID) shall not accept liability for any statements made that are the
From : Benoit Ponton <bponton@cpa -qc.ca>

To: Fauci, Anthony (NIH/N IAID) [E] ------~~ (b)(6)
Cc: Con t act Cb)(6)
Subject: COVID-19 - Poten tia l Trea tment
COVID-19 - Potentia l Treatment
April 17, 2020
Nation al Institu te of Allergy and Infectious Diseases,

Nationa l Inst itu tes of Health
31 Center Drive MSC 2520
Building 31, Room 7A03
C/0 Anthony S. Fauci, M .D.
Hello Dr. Fauci,

In the current state of medical knowledge and research in the pharmaceutical industry, there is
no short- or medium-term solution to prevent disease or cure patients with SARS-Cov-2(COVID-
19).
With this letter, I would like to make you aware of the preventive and curative potential of
essential oils (EOs); lives could be saved.
Scient ific aromather apy: use of aromatic compounds extracted from plants - essential oils - for
medical purposes; 'hard' science of nature, based among other things, on in-depth knowledge of
organic chemistry. We are not talking about perfumery or occult sciences.
According to Mr . Dominique BAUDOUX,an internationally known Belgian pharmacist and

"a romatologist": there is a multitude of research on the antiviral properties of essential oils.
The results are impressive and indisputable . Here are some viruses for which we have real
data:
■ Severe acute respiratory syndrome virus SARS-Cov(it is a coronavirus)

■ The H1Nl flu virus
■ Avian influenza virus type H5Nl and subtypes H7N3 and H9N2
■ The anti-infectious bronchitis virus (IBV)
■ Herpes simplex virus HSV
■ Dengue virus DEN
■ Newcastle disease virus NOV
■ Junin virus (an arena virus responsible for hemorrhagic fever)
Source: https://www.pranarom.com/blog/guide-des-huiles-essentielles/les-huiles-essentielles-
efficaces-contre-lecoronavirus-vrai-ou-faux : See references 1 to 28 below .
To add meat to the bone, if you visit the Nation al Cent er for Biotechnology Information (U.S.) :
■ You will find nearly 225 000 references on "essential oil."
See: https://www.ncbi.nlm.nih.gov/search/all/?term=essential%20oil
■ You will find approximately 22 000 references on "essential oil+ viral."
See: https://www.ncbi.nlm.nih.gov/search/all/?term=essential%20oil%20+%20viral
In addition, according to a brief email exchange with Mr. Pierre FRANCHOMME,a French
researcher, one of the leading experts in the field of medicinal essential oils, he informed me
that : a recent Indian study (March 31) highlights the potential activity of 1,8 cineo/e
(euca/yptol) on SARS-Cov-2, as I suspected from my experience on other enveloped viruses.
Note: the molecule 1,8 cineole is found in high concentration in eucalyptus EOs.
■ Sharma, A.D.; Kaur, I. Eucalyptol {1,8 cineole ) fr om Eucalyptus Essenti al Oil a Pot ential
Inh ibitor of COVID 19 Corona Viru s Infection by Mol ecular Docking Studi es .
Preprints 2020, 2020030455 (doi: 10.20944/preprints202003.0455.vl).
Source : https://www.preprints.org/manuscript/202003.0455/vl
Another study (2008) provided by Mr. Franchomme, shows a high antiviral activity of bay
laurel/leaf essential oil (Lourusnobilis)on SARS-Cov,which appeared in Nov ember 2002 in
Guangdong province, China and which prevailed until 2004.
• Loizzo, M. R., Saab, A. M ., Tundis, R., Statti , G. A., Menichini , F., Lampront i, I., ... Doerr ,
H. W. (2008) . Phytochemical Analysis and in vitro Antiviral Activities of the Essential
Oils of Seven Lebanon Species. Chem ist ry & Biodivers ity, 5(3), 461 -470 . doi
:10.1002/cbdv.20089 0045
Source: https://onlinelibrary.wiley.com/doi/abs/10.1002/cbdv.200890045
Since SARS-Covand SARS-Cov-2 {COVID-19) are close relatives, it is quite possible that Laurus
nobilisessential oil will be as effective on SARS-Cov-2.
Here are two other studies that should be of interest to researc hers, according to Mr.
FRANCHOMME :
• See reference 20 below Efficacy of cineole in patients suffering from acute bronchitis: a
placebo-controlled double-blind trial. Cough 9, 25 (2013) .
Source: https://doi.org/10.1186/1745-9974-9-25
Conclusions of this study : The effects of Cineole in the treatment of acute bronchitis were
clearly measurable and could be proven after a treatment period of merely 4 days. This study
corroborates the fact that cineole actively and significantly reduces cough frequency after four
days. Therefore it has been shown to have a great socioeconomic impact.
• See also refere nce 22 below.
Also, according to Mr. FRANCHOMME, a clinical study on the treatment of essential oils in
patients with COVID-19 has just been undertaken in a hospital setting (100 patients), double
blind against placebo . I w ill kno w th e results at the same time as everyo ne else and will inform
you.
Here is a summary of Mr. FRANCHOMME's analysis:

(b) (4)
The scientific commun ity is launc necl in searc no f a m iradeclru g in t he basket of molecu es
already known for ot he r i ndicat io ns. Our design is to t rust the plant world, a great provider of
remarkable mo lecules.
CONCLUSION
We need to think outside the box of allopath ic medicine and synthetic drugs that offer no
solution and put pre ssure on our leaders to release funds for clinical research on the treatment
of patients suffe rin g from COVID-19 using essential oils, as advocated by Mr . Franchomme .
To this end, M. FRANCHOMME confirmed to me this : / am at the disposal of your authorities
to provide and explain a protocol based on essential oils.
His email address is : (b)(6)
In terms of a double-blind placebo clinical study, there is, as of today, a huge cohort of
hospitalized pat ients, a significant portion of whom I suspect would be enthusiast ic about
voluntary enrolment.
For pat ients in critical care with a life-threatening prognosis, it is undoubtedly possible, given
the circumstances , to bypass the usual research protocols and offer a last-resort treatment to
these patients in an attempt to save their lives, with thei r permission or that of their legal
representatives in case of temporary or permanent incapacity .
Even if it doesn't work, I don't think patients or their loved ones will blame your government
for trying everything , but if you don't, I wouldn't like to be in your shoes!
Cordially,
Benoit Ponton
BP/bp
CC: M. Pierre FRANCHOMME
2150, rue Marianne-Baby

Chambly, QC, Canada J3L OA3
Off ice (450) 447-4872
Cell phone (b) (6)
Email bponton@cpa-qc.ca
SCIENTIFICPUBLICATIONS
Source : https ://www . pra narom.com/blog/guide-des-h u iles-essentielles/ les-hui les-essentielles-

efficaces-contre-1 ecoronavi rus-vrai-ou-fa ux
1. Garozzo, A., Timpanaro, R., Bisignano, B., Furneri, P. M., Bisignano, G., & Castro, A.
(2009). In vitro antiviral activity of Melaleuca alternifolia essential oil. Letters in
applied microbiology, 49(6), 806-808.
https://sfamjournals.onlinelibrary.wiley.com/doi/full/10.1111/j.1472-
765X.2009.027 40.x
2. Reichling, J., Schnitzler, P., Suschke, U., & Saller, R. (2009). Essential oils of aromatic
plants with antibacterial, antifungal, antiviral, and cytotoxic properties-an overview .
Complementary Medicine Research, 16(2), 79-90.
https://www.karger.com/Article/Abstract/207196
3. Schnit zler, P., Schon, K. and Reichling, J. (2001) Antiviral activity of Australian tea tree
oil and eucalyptus oil against herpes simplex virus in cell culture . Pharmazie 56, 343-
347. https://www.ncbi.nlm.nih.gov/pubmed/11338678
4. Mohammad, A., & Mehmood, D.ln Vivo Anti-Viral Effect of Melaleuca alternifolia (Tea
Tree Oil) and Olea europ aea (Olive Leaf Extract) on Vero Cell Adapted Avian Influenz a
Virus. Human Journals . Research Article December 2018 Vol.:14, lssue:1 Citation :
Mohammad Danish Mehmoo d et al. ljppr.Human , 2018; Vol. 14 (1): 7-19.
https://www.researchgate .net/publication/331149520 In Vivo Anti-
Viral Effect of Melaleuca alternifolia Tea Tree Oil and Olea europaea Olive Leaf
Extract on Vero Cell Adapted Avian Influenza Virus
5. Usachev, E. V., Pyankov, 0. V., Usacheva, 0. V., & Agranovski, I. E. (2013).

Antiviral activity of te a tr ee and eucalyptu s oil aerosol a nd vapour . Journal of aerosol
science, 59, 22-30.
https://www.sciencedirect.com/science/article/pii/S0021850213000086
6. Ank ita, S., Chandra, S.S., & Arti, T. (2013). Phytochemic al study and antimicrob ial
activities of cinnamomum camphora . Wo rld Journa l of Pharmaceutic al research
Volume 3, Issue 2, 2287-2294.
https://www.google .com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&ved=2ahUKE
wildfj5OHoAhUEZN8KHZDjBdMQFjABegQIBBAB&url=https%3A%2F%2Fwjpr .net%2Fdow
nload%2Farticle%2F1400323946 .pdf&usg=AOvVaw0WLdK22ogsjVQCt6bgmXeb
7. Astani, A., & Schnit zler, P. (2014). Antiviral activity of monot erpenes beta-pinen e and
limon ene against herpe s simplex virus in vitro. Iranian journal of microbio logy, 6(3),
149.
https://www.ncbi.nlm .nih .gov/pmc/articles/PMC4393490/
8. Astani, A., Reichling, J., & Schnitzler, P. (2010). Comparative study on the antiviral
activity of selected monoterpenes derived from essential oils. Phytotherapy Research:
An Internationa l Journal Devoted to Pharmacological and Toxico logical Evaluation of
Natural Product Derivatives, 24(5), 673-679 .
https://onlinelibrary.wiley .com/doi/abs/10 .1002/ptr.2955
9. Bisignano, B. (2009) . Attivit a antivirale e studio del meccanismo d'azione di estratti di

melaleuca alternifolia nei vonfronti del viru s dell'influenza A. Area 06 - Scienze
mediche.
http://hdl. hand le .net/10761/1767
10. Blanchard, J. M . (2007). Cinnamomum camphora a cineole (ravintsara), une plante au

service de la prevention des infection s nosocomiales en milieu hospitalier ?.
Phytotherap ie, 5(1), 15-20.
11. Carson, C.F., Ashton, L., Dry, L., Smith, D.W . and Riley, T.V. (2001) Melal euca alternifolia
(tea tree) oil gel (6%} for the treatment of recurrent herpes labial is. J Ant imicrob
Chemother 48, 450- 451. https://academic.oup.com/jac/article/48/3/450/736091
12. Carson, C.F., Smith, D.W., Lampacher, G.J. and Riley, T.V. (2008) Use of deception to
achieve double-blinding in a clinical trial of Melaleuca alternifolia (tea tree) oil for the
treatment of recurrent herpes labialis. Contemp Clin Trials 29, 9-12.
https ://www .contem pora rycli nica Itri als. com/ art icle/S1551- 7144( 07 )00053-5/ful Itext
13. Galan, D. M ., Ezeudu, N. E., ..., & Ma lcolm, B. J. (2020) . Eucalyptol (1, 8-cineole) : an
underutilized ally in respiratory disorders?. Journa l of Essential Oil Research, 1-8.
https://www.tandfonline.com/doi/abs/10.1080/10412905.2020.1716867?journa1Code=
tjeo20
14. Garozzo, A., Timpanaro, R., Stivala, A., Bisignano, G., & Castro, A. (2011).
Activity of Melaleuca alternifolia (tea tree) oil on Influenza virus A/PR/8: study on the
mechanism of action . Antiviral research, 89(1), 83-88.
https:ljwww.sciencedirect.com/science/article/abs/pii/50166354210008120?via%3Dih
ub
15. Hamidpour, R., Hamidpour, S., Hamidpour, M., & Shahlari, M . (201 4) .
Chemistry, Pharmacology and Medicinal Property of Camphor (Cinnamomum
Camphora) Traditional Remedy with the History of Treating Several Diseases. Global
Journal of Medical Research.
https://scholar.google.com/citations?user=xrGgDigAAAAJ&hl=en
16. Jean Michel Blanchard (2007 ). Cinnamomum camphora CT cineole (ravintsara), a plant
to help prevent nosocomial infections in the hospital environment. Inte rnational
Journa l of Clinical Aromatherapy Vol. 4 issue 1
17. Li, X., Duan, S., Chu, C., Xu, J., Zeng, G., Lam, A. K. Y., ... & Gu, H. (2013). Melaleuca
alternifolia concentrate inhibits in vitro entry of influenza virus into host cells.
Mo lecule s, 18(8), 9550-9566. https://www.mdpi.com/1420-3049/18/8/9550
18. Li, Y., Xu, Y. L., ... & Xu, P. P. (2017). Intranasal co-administration of 1, 8-cineole with
influenza vaccine provide cross-protection against influenza virus infection .
Phytomedicine, 34, 127-135.
https://www.sciencedirect.com/science/article/abs/pii/50944 711317301034 ?via%3Dih
ub
19. Loizzo, M. R., Saab, A. M ., Tundis, R., Statti, G. A., Menichini, F., Lampront i, I., ... & Doerr,
H. W. (2008) . Phytochemical analysis and in vitro antiviral activities of the essential
oils of seven Lebanon species. Chemistry & biodiversity, 5(3), 461-470.
https://onlinelibrary.wiley.com/doi/abs/10.1002/cbdv.200890045
20. Mansard, M., Laurain-Mattar, D., & Couic-Marin ier, F. (2019). Huile essentielle de
Ravintsara. Actualites Pharma ceutiques, 58(585), 57-59.
https://www.sciencedirect.com/science/article/pii/S0515370019300734?via%3Dihub
21. Morales - Rico, C. L., ... & Gonzalez -Camejo, I. (2012).Composicion qu1mica del aceite
esencial de las partes aereas de Melaleuca quinquenervia. Revista CENIC. Ciencias
Qufmicas , 43, 1-2.
https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&ved=2ahUKE
wig4qLa7uHoAhWhnuAKHSDZAasQFjABegQIAhAB&url=http%3A%2F%2Fwww.revistas.u
sach.cl%2Fojs%2Findex.php%2Fblacpma%2Farticle%2Fdownload%2F2401%2F2210%2F
& usg=AOvVaw3k2 Urazeofgeg ftc 7wd K
22. Janine Muller, Johannes F.W. Greiner, Mar ie Zeuner, Viktor ia Brotzmann, Johanna
Schafermann, Frederique Wieters, Darius Widera, Holger Sudhoff, Barbara Kaltschmidt,
Christian Kaltschmidt; Clin Sci (Lond) 1 August 2016; 130 (15): 1339- 1352. 1, 8-Cineole
potenti ate s IRF3-mediated antiviral response in human stem cells and in an ex vivo
mod el of rhinosinusitis. Clinical Science (Lond) 1 August 2016; 130 (15): 1339-135 2.
https://doi.org/10.1042/CS20160218 et https://portlandpress.com/clinsci/article-
abstract/130/15/1339/71448/1-8-Cineole-potentiates-lRF3-
mediatedantiviral?redirectedFrom=fulltext
23. Riley, T. V. (2005). Antivir al Activity of Tea Tree Oil-In Vitro and In Vivo . TV Riley-2005
- academia.edu https:ljwww .agrifutures.eom.au/product/antiviral -activity-of -tea-tree-
oil-in-vitro-and-in-vivo/
24. Siddique , S., et al. (2018) . Chemical characterization , antioxidant and antimicrobial
activiti es of essential oil from M elaleuca quinqu enervia leaves. Indian Journa l of
Experimen t al Biology, 56, 686-693 .
https:ljwww.researchgate.net/publ ication/327829462 Chemical characterization anti
oxidant and antimicrobial activities of essential oil from Melaleuca guinguenervia
leaves
25. Timpana ro, R., Garozzo, A., Bisignano, B., Stivala, A., Furneri, P. M ., Temp era, G., &
Cast ro, A. (2007) . Inhibitory effect of Melaleuca alternifolia (tea tree oil) on influenza
A/PR/8 viru s replication . Internatio nal Journa l of Ant imicrobial Agents, (29), S202-S203.
https://www.sciencedirect.com/science/article/abs/pii/S0166354210008120?via%3Dih
ub
26. Worth, H., ..& Deth lefsen, U. (2009). Concomitant therapy with Cineole (Eucalyptole)
reduces exacerbations in COPD: a placebo-controlled doubleblind trial. Respiratory
research, 10(1), 69. https://respiratory-
research.biomedcentral.com/articles/10.1186/1465-9921-10-69
27. Yang, Z., Wu, N., .. & Efferth, T. (2010). Anti-infectious bronchitis virus (IBV) activity of
1, 8-cineole: Effect on nucleocapsid (N) protein . Journal of Biomolecu lar Structu re and
Dynamics, 28(3), 323-330.
https://www.tandfonline .com/doi/abs/10.1080/07391102.2010 .10507362
28. Zamora, A. C. P. (2015). The Antiviral Properties of Mela leuca alternifolia concentrate
(MAC) against West Nile virus (Doctoral dissertation, Griffith University).
https://pdfs.semanticscholar.org/fc36/83837c5d872444e51c452bdd3f6a644fa079.pdf
OTHER SCIENTIFICPUBLICATIONS
Source : https://www.aude-maillard.fr/4-huiles-essentielles-contre -le-coronavirus/

29. Brun, P., Bernabe, G., Filippini, R. et al. In Vitro Antimicrobial Activities of Commercially
Available Tea Tree (Melaleuca a/ternifolia) Essential Oils. CurrMicrobial 76, 108-116
(2019) . https ://doi.org/10.1007 /s00284-018-1594-x
30. Shih-Yu Lee, Po-Yu Chen, Jung-Chun Lin, Nicholas S. Kirkby, Ching-Huei Ou and Tsu-
Chung Chang Melaleuca alternifolia Induces Heme Oxygenase-1 Expression in Murine
RAW264 .7 Cells through Activation of the Nrf2-ARE Pathway . The American Journal of
Chinese Med icineVol. 45, No. 08, pp. 1631-1648 {2017)
https://doi .org/10.1142/S0192415Xl 7500872
31. Akram Astani, Jurgen Reichling and Paul Schnitzler. Screening for antiviral activities of
isolated compounds from essential oils. Hindawi. Evidence-Based Complementary and
Alternative M edicine/ 2011 https://doi.org/10.1093/ecam/nep187
32. Schnitzler P. Essential Oils for the Treatment of Herpes Simplex Viru s Infection s.
Chemotherapy 2019;64 :l-7. https://doi.org/10.1159/000501062
CONFIDENTIALITY NOTICE: The information contained in this transm ission {including any files attached to it) is legally
privileged
and confidential and is intended solely for the use of the individual or entity to whom it is addressed. Any other use,
dissemination,
distribution, disclosure or copying of this message is strictly prohibited. If you have received this commun ication in
error, please
immediately notify the sender so that we may ensure the intended recipient receives a copy of the origina l
transm ission. We then
ask that you kindly destroy your copy and delete the ent ire message from your computer system.
AV IS DE CONFIDENTIALITE: L'information contenue dans cette transm ission {et tout document ci-jo int) est
confidentie Ile et
a a
privilegiee et est !'usage exclusif de la personne ou de l'entite qui elle est adressee. Tout autre usage, distribut ion,
divulgat ion,
ou cop ie de cette communication est strictement prohibe. Si vous avez re~u cette transmission par erreur, veuillez
nous en aviser
immediatement pour que nous puissions envoyer le message au destinataire. Aussi, nous vous demandons de
detruire toutes les
copies et le supprimer de votre systeme informatique.
Sent : Sat, 18 Apr 2020 19:46 :44 +0000
To : Del Rio, Carlos
Subject : RE:released.
Than ks, Carlos.
Director
Phone: (b)(6)
FAX: (30 496"44 09
E-mail: (b)(6)
From: Del Rio, Carlos (b)(6)>

Sent: Friday, April 17, 2020 11 :16 AM
----------
To: 'Birx, Deborah L. EOP/NSC'
(b)( 6) ------------.,.....,..= (b)( ; Fauci, Anthony (NIH/NIA ID) [E]
Cc: Rochelle Walensky MD, MPH

Subject: released. ------------ (b)(6)>
Here is link to the paper ent itled "From Mit igat io n to Conta inment of the COVID-19 Pandemic- Putting
th e SARS-CoV-2Genie Back in t he Bott le" that Rochelle and I wrote for JAMA. Hope you fi nd it useful.
Feel free to d istribute . Thanks again for all you are doing!
https://jamanetwork.com/journals/jama/fulla rticle/2764956
Sincerely,
Carlos
This e-mail message (including any attachments ) is 'or the sole use of
the intended rectpient(s) and may contain confidential and privileged
Information. If the reader of this message 1s not the intended
recipient, you are hereby notified !hat any dissemination distribution
prohibited.

Sent : Sat, 18 Apr 2020 19:40 :55 +0000
To : Walensky, Rochelle,M .D.,M .P.H.
Subject : RE:released .
Thanks, Rochelle!
Director
Phone: (b)( 6)
FAX: (30 496"'4409
E-mail: (b)(6)
informat ion. It should not be used by anyone who is not the original intended recipient. If you
From : Walens ky, Rochelle,M.D .,M .P.H. (b)(6)>

Se nt : Friday, April 17, 2020 11:54 AM
To: Carlos del Rio
Fauci, Anthony (NIH/NIAID) [E)
Subject: RE: released.
(b)(6)> ; 'Birx, Deborah L. EOP/NSC'
CbH61> ----------- (b)(6) ;
Dear Ors. Birx and Fauci (Debbie and Tony, if I may),

So grateful for all you are doing. Please let us know if there is any way we can help.
My best from Boston,
Rochelle
Rochelle P. Walensky, MD, MPH

Chief, Division of Infectious Diseases
Steve and Deborah Gorlin MGH Research Scholar
Massachusetts General Hospital
Division of Infect ious Disease
Professor, Harvard Medical School
55 Fruit Street, GRJ504J floor

Boston, MA 02114-2696
Phone: (b)(6)
Fax: 617-726-7416
Email:
-----------
Pronouns: she/her/hers
(b)(6)
From: Del Rio, Carlos _________ Cb
_) _(6)
... )
Sent : Friday, April 17, 2020 11:16 AM
----------~=
To: 'Birx, Deborah L. EOP/NSC'
(b) (6)> ------------ (b)( >; 'Fauci, Anthony (NIH/NIAID) [E)'
Cc:Walensky,Rochelle,M.D.,M.P.H.__________ Cb
_)_C_ >
Subject: released.
External Email - Use Caution
Here is link to the paper entitled "From Mitigation to Containment of the COVID-19 Pandemic- Putting
the SARS-CoV-2Genie Back in the Bottle" that Rochelle and I wrote for JAMA . Hope you find it useful.
Feel free to distribute. Thanks again for all you are doing!
https://jamanetwork.com/journals/jama/fullarticle/2764956
Sincerely,
Carlos
This e-mail message (including any anachmems) is 'or the sole use of
the intended recipient(s) and may contain confidential and privileged
infonnation. If the reader of this message is not the intended
recipient, you are hereby notified that any disseminat ion distribution
or copying of this message (including any attachmerts) is strictly
prohibited.

original message (including attachments)
Th e information in this e-mail is intended only for the person to whom it is

addressed. If you believe this e-mail was sent to you in error and the e-mail
contains patient information , please contact the Partners Compliance HelpLine at
http://www.partners.org/complianceline . If the e-mail was sent to you in error
but does not contain patient infonnation, please contact the sender and properly
dispose of the e-mail.
Sent: Sat, 18 Apr 2020 19:34 :53 +0000
To: Jeffrey V. Ravetch
Cc: Lusso, Paolo (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID)
[El
-----~~ (b)( 6) ;Cassetti, Cristina (N IH/NIAID) [El; Erb elding, Emi ly (NIH/N IAID) [El
Subject: FW: new manusc ript
Attachments: Bournazos, et al.docx, Extended Figures .pdf
Jeff:
Very interesting paper. Could have wide applicability in viral disease. I will pass
it on to our program people.
Best,
Tony
Director
Phone: (b)(6)
FAX: (301) 496-4409
E-mail: (b)(6)
From: Jeffrey V. Ravetch

-----------
Sent : Friday, Apri l 17, 2020 1:26 PM
(b)(6)>
-------~~
Subject: new manuscript --------- (b)(6)
Tony,
I've attached a pre-pr int of the story I briefly told you about related to Fe optim ization of anti-v iral
ant ibod ies to induce CD8 protective responses.
I'd be grate ful fo r your comments.
And my sincere grat it ude for keeping science at the front of th is pandemic.
Best regards,
Sent: Sat, 18 Apr 2020 19:30:56 +0000
Cc:
[E______ (b
:::-:
),..,.
(6)
=
Conrad, Patricia {NIH/NIAID) [E]; Cassetti, Cristina {NIH/NIAID)
Subject: FW: Concept Paper for NEJM on Novel Clinical Trial in COVID-19
Attachments: Composite EPOCOVID-19.pdf
Andrea :
This is a former post-doc in my lab. Please read this, get back to her apologizing
that I could not respond cs> I
Cb>
-----------------------
0 bvi o usIy can have no part in it.
Thanks,
Tony
Director
Phone: Cb)(6)
FAX: {301 496-4409
E-mail: (b)(
behalf of the NIAIO by one of its representatives.
From: Ehrenreich, Hannelore (b)( >

To: Fauci, Anthony (NIH/NIAID ) [E]------~= (b)(6)
Subject: Concept Paper for NEJM on Novel Clin ical Trial in COVID-19
Dear Tony,
I am aware of the heavy load that is on your shoulders these days but I sincerely hope to
get a brief answer to my E-mail.
In light of the present therapeutic situation in COVID-19, any measure to improve course
and outcome of seriously affected individuals is of utmost importance. In the attached
(b) (6), (b) (4)
(b) (6), (b) (4)
We all would be extremely grateful for your feedback and for your collaboration!
In fact, I personally would be so proud to have you as senior coauthor as in former
times! Please let me know what you think.
We could also discuss over the phone if you let me know which time would be
convenient.
All my best , Hannelore
-----Ursprungliche Nachricht-----
Von : Ehrenreich, Hannelore
Gesendet: Samstag, 21. Marz 2020 13:24
An: 'Fauci, Anthony (NIH/NIAID) [E]' ------~= (b)(6)>
Betreff: THANK YOU from Germany
Dear Tony,
J I I
I ~n?w you are extremely busy these days... now even more than befo Jil dOe to this ter:ribi ~ ~rona
cns1s! II" [J
Just a brief note to let you know that I watched your excellent interviews and that I am extremely proud
of you! For people here in our Max Planck Institute and the many biomedical institutions in Gottingen
you are the greatest hero indeed in a tough time ...
I wish you all strength and endurance needed to lead the world out of this crisis (despite questionable
politicians)!
STAY HEALTHY!
All my best, Hannelore
Professor Hannelore Ehrenreich, MD, DVM

Clinical Neuroscience
Max Planck Inst it ute of Experimental Medicine
Hermann-Rein-Str.3
37075 Gott ingen
GERMANY
Tel : (b)(
Fax: 49-551-3899 670
---------
E-Mai l: (b)(6)
Prof. hon . Univer sity of Gott ingen

Faculty of Biology & Psychology
Sent : Sat, 18 Apr 2020 19:21 :39 +0000
To : Stover, Kathy (NIH/NIAID ) [E)
Cc: Billet, Courtney (NIH/ NIAID) [El;Folkers, Greg (NIH/NIAID) [El;Conrad , Patricia
(NIH/N IAID) [El
Subject : RE: FOR ASF REVIEW: Draft MA re: NIAID COVID 19 Strategic Research Plan
Looks fin e. Thanks.
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: _ __,.,_, (b)(6)
From : Stover, Kathy (NIH/N IAID) [El (b)( 6)r>

(b)(6)>
Cc: Billet, Courtney {NIH/NIAID) [El (b)(6)>; Folkers, Greg (NIH/NIAID) [El
_______ Cb
H_ >; Conrad, Patricia (NIH/NIAID) [E)
_ (b)(6)>
Subject: FOR ASF REVIEW: Draft MA re: NIAID COVID 19 Strateg ic Research Plan
Hi Dr. Fauci,
Please find attached for your review a draft media availability about NIAi D's COVID-19 strateg ic research
plan . We've named you as t he spokesperson in the med ia avail.
Best,
Kathy
Kathy Stover
Branch Chief
Bethesda, MD 20892
Phone: (b)(6)
E-mail: (b)(6)
Sent : Sat, 18 Apr 2020 18:30 :03 +0000
To: Hahn, Stephe n;Birx, Deborah L. EOP/NSC;Redfield, Robert R. (CDC/OD);Kadlec,
Robert (OS/ASPR/10)
Subject :
------- (bH ·
FW: Boston Globe: Nearly a t hird of 200 blood samp les taken in Chelsea show
exposure to coronavirus
St eve :
(b)(5)
Tony
Director
Phone : (b)( 6)
FAX: (301 496-4409
E-mail : (b)(6)
other storage devices . The National Inst itute of Allergy and Infectious Diseases (NIAID) shall not
From : Folkers, Greg (NIH/N IAID) [E] (b)(6)

Subject : Boston Glob e: Nearly a th ird of 200 blood sam ples t aken in Chelsea show exposu re t o
coronavirus
Nearly a third of 200 blood samples taken in

Chelsea show exposure to coronavirus
Mass. General researcher says the results point to a 'raging
epidemic,' but may also indicate the city is further along the
disease curve than some other municipalities
ByJonathan Saltzman Globe Staff,Updated Apr il 17, 2020, 6:26 p.m.
First responders loaded a patient into an
ambulance from a nursing home whe re multiple people have contracted COID-19 in Chelsea, which has
the highest concentration of COVID-19 infections in the state.Scott Eisen/Getty
Nearly one third of 200 Chelsea residents who gave a drop of blood to researchers on the street this
week tested positive for antibodies linked to COVID-19, a startling indication of how widespread
infections have been in the densely populated city.
Sixty-four residents who had a finger pricked in Bellingham Square on Tuesday and Wednesday had
antibod ies that the immune system makes to fight off the coronavirus, according to Massachusetts
General Hospital physicians who ran the pilot study .
The 200 participants generally appeared healthy, but about half told the doctors they had had at least
one symptom of COVID-19 in t he past four weeks.
Public health experts already knew Chelsea hadthe state's highest rate of con fir med COVID-19 cases
and that the actua l rate was probably higher . At least 39 residents have died from the virus, and 712 had
tested positive as of Tuesday, a rate of about 1,900 cases per 100,000 residents, or almost 2 percent .
Get Talking Points in your inboxAn afternoon recap of the day's most important business news,
delivered Monday through Friday.
But the Mass. General researchers - who excluded anyone who had tested positive for the virus in the
standard nasal swab test - found that 32 percent of participants have had COVID-19, and many didn't
know it .
"I think it 's both good news and bad news," said Dr. John Iafrate, vice chairman of MGH's pathology
department and the study's principal investigator. 11The bad news is that there's a raging epidem ic in
Chelsea, and many people walking on the street don't know that they're carrying the virus and that they
may be exposing uninfected individuals in their families ."
"On the good-news side, it suggests that Chelsea has made its way through a good part of the
epidemic," he said. "They're probably further along than other towns."
Scientists suspect that people who recover from COVID-19 may be at least temporarily immune from
catching it again. Several biotechs and academic laboratories, in fact , are seeking blood do nations from
people who have recovered, in the hopes that their antibodies can help create a treatment or vaccine.
Chelsea's city manager, Thomas Ambrosino, said he learned the results of the pilot study Thursday in a
conference call with the researchers. He was dismayed, but not shocked.
Related: Chelsea city manager sounds urgent alarm, calls for residents to stay home 24 hours a day
"We've long thought that the reported numbers are vastly unde r-counting what the actual infection is,"
said Ambrosino, w ho has called his city the epicenter of the crisis in Massachusetts. "Those reported
numbers are based on positive COVID-19 tests, and we're all aware that a very, very small percentage of
people in Chelsea and everywhere are getting COVID-19 tests."
"Still," he added, "it's kind of sobering that 30 percent of a random group of 200 people that are
showing no symptoms are, in fact, infected. It's all the more reason for everyone to be practicing
physical distancing."
Indeed, one of the doctors who tested volunteers in Bellingham Square said it's possible that some of
the people who had the antibodies are still contagious.
"Just because you have the antibodies doesn't mean you've cleared the virus," said Dr. Vivek Naranbhai,
a clinical fellow in hematology and oncology.
Researchers said the test results, which had yet to be shared with state officials late Friday, couldn't
necessarily be extrapolated for the city's roughly 40,000 residents. Still, the findings provided a valuable
snapshot of a community that medical experts say is especially vulnerable to COVID-19.
Chelsea covers only about two square miles, across the Mystic River from Boston. For generations, it has
attracted new immigrants, and about 65 percent of its residents are Latino. Many live in three-decker
houses, Ambrosino said, where it's hard for people to isolate themselves. Many work in the hospitality
industry and health-related fields, where exposure to the virus is greater. And a lot of them must go to
work during the pandemic.
To get Chelsea residents to participate in the study - which included a questionnaire that was available
in English, Spanish, and Portuguese - investigators allowed them to remain anonymous. But that meant
none of the participants received the results of the blood tests.
The doctors used a diagnostic device made by BioMedomics, of Morrisville, N.C., to analyze drops of
blood. It resembled an over-the-counter pregnancy test and generated results on the street in about 10
minutes. Although the test hasn't won the approval of the Food and Drug Administration, Iafrate, the
principal investigator, said Mass. General determined it's reliable.
Within days, the physicians said, they hope to set up a medical tent outside the Mass. General Chelsea
Healthcare Center to perform more antibodies tests with the device. The site will be located near a tent
set up weeks ago to run standard PCR,or polymerase chain reaction, tests for people with active
coronavirus symptoms. The latter uses nasal swabs to detect whether the virus is present at the time;
the antibodies blood test reveals whether someone was infected in the past.
In addition to the new testing site, the researchers want to expand the study to other Massachusetts
cities and towns. For all of those studies, Mass. General doctors plan to obtain the identities of
participants so physicians can provide the results. But first the researchers need to come up with
guidelines for what participants should do if they test positive for antibodies.
Dr. Dean Xerras, medical director of the Mass. General Chelsea Healthcare Center and a co-investigator
in the study, said it illustrates why it's essential for Chelsea and other communities to perform more
tests, regardless of whether they detect antibodies or the virus itself.
"Knowing how many people are infected is critical," said Xerras, a longtime member of the city's board
of health. "We need to get them isolated. We need to get masks delivered to the city. We need to
launch more safe isolation sites. We need to be able to identify cases and then give people the things
they need to prevent perpetuation of the spread."
Chelsea and Revere officials, with help from the state Department of Public Health and the
Massachusetts Emergency Management Agency, secured almost 150 rooms at a Quality Inn in Revere
this week for residents who are recovering from COVID-19 and unable to isolate themselves at home,
according to Ambrosino. So far, only a handful of those rooms are occupied.
Governor Charlie Baker on Thursday staunch ly defended the state ' s handling of the escalating
outbreak in Chelsea, including asserting, without offering details, that city leaders have turned down
help from his administration.
The governor's claim surprised officials in Chelsea who told the Globe this week that the state, and even
health care providers, should have recognized the virus's rapid spread through the city sooner.
Jonathan Saltzman can be reached at jonathan .saltzman@globe.com

my views nor those ofNTAID, NIH, HHS, or the U.S. government.
From: (b)(6)
Sent : Sat, 18 Apr 2020 12:28 :50 -0400
Subject: Fwd: working draft of NEJM
Attachments : COVID vaccine editorial _ 16April 7pm.docx, ATT00001.htm
Sent from my iPhone
From: "Corey MD, Lany" (b)( ·>

Date: April 18, 2020 at 12:34:13 AM ED T
To: "Conrad, Patricia (NIH/NIAID) [E]" ---------=-:-:-="Fauci, (b)(6) >,
Anthony (NIH/NIA ID) [E]" ___ (bH .___~~
Cc: "Mascola, John (NIHNRC) [E]" _______ (b_H_6)
Subject: working draft of NEJM
Here is the working draft . My manuscript typist too tired to work tonight so it
reflects several changes I made tonight ; it should be readable;
Larry
From: (b)(6)
Sent : Sat, 18 Apr 2020 12:27:56 -0400
Subject: Fwd: JAMA- Heroes
Attachments : heroes. pdf, ATT00001.htm
Sent from my iPhone
From: Howard Bauchner <Howard .Bauchner @jamanetwork.org >

Date: April 18, 2020 at 5:10: 15 AM EDT
To: "Fauci, Anthony (NIH/NIAID ) [E]" --------=-=--
(b)(6) =
Cc: Phil Fontanarosa <Phil.Fontanarosa @jamanetwork.org >
Subject: JAMA - Heroes
There are many many heroes in this tragedy - but none more so than you, Maurizio, and
Dr. Wenilang.
Howard Bauchner, MD
Editor in Chief of JAMA and the JAMA Network
Please respect the confidentiality of this email
Listen to my chats wi t h authors
From: Howard Bauchner <Howard.Bauchner@jamanetwork.org>

Date: Saturday, April 18, 2020 at 4:07 AM
To: CECCONIHUNIMED (b)(6)
Subject: Re: Hello
I am well - (b)(6) - but you know all about that - remain in Chicago - at work
--"""".""~-=--....:..------------__;;~---, (b
=-<
)=(6)
- he will quarantine for

the 2 weeks he is up there.
Yes- NY, London, Paris - all diff icult times- great vector- the subway , underground, and
metro - unmasked folks who were asymptomatic carriers -terrible.
Most of t he US managing although still a heavy heavy lift in some p laces - NY, Boston,
some in Chicago - but most of the US managing. The big issue like everywhere is how do
we put society back toget her .
Will be published on Monday- our tr ibute to many peop le and 3 individua ls.
HCB
Howard Bauchner, MD
Editor in Chief of JAMA and the JAMA Networ k
Please respect the confide ntial ity of this emai l
Listen to my chats with authors
From: CECCONI HUN IMED

-------------
Date: Friday, April 17, 2020 at 2:07 PM
(b)(6)>
To : Howard Bauchn e r <Howa rd .Bauchn e r@jaman etwork.org>

Subject : Hello
[Warning External Email]

Hello Howard,
I hope you are well. Just a line to say that the podcasts are incredible.
I hope you are ok. I am very sorry for the colleagues in New York. I know it's very tough
t here and also in other parts of US.
Things are getting better here.
Keep up the amazing work.
Kind regards,
Mau ri zio
Mau ri zio Cecconi MD FRCAFFICM MD(Res)

Head of Department Anaesthe sia and Inte nsive Care Units
Human itas Research Hospital
Professor of Anaesthesia and Intensive Care
Humanitas University
President Elect ESICM

Nota ai riservatezza 11pre5ente messaggio, corredato deI relativi allegati, contIene lnforma.:ionl da considerarsI
e
strettamentc riservate, ed destinato esclusIvamente al destmatarlo sopra ind1cato, ii quale e l'unico autoriz.zato
ad usarlo, cop1arlo e, sotto la propna responsabillta, d1ffonderlo. Ch1unque ricevesse questo messaggI0 per errore o
comunque lo leggesse senza esserne ieg1tt1mato e avvertIto che trattenerlo, copIarI0. divuigarlo, dIstribuirlo a
persone diverse dal destinatarlo e e
severament.e proibito, ed pregato di rinviarlo 1mmedlatamente al mltter1le
distruggendone l'or19Inale.
Grazie
Conf1dent1allty Notice Tl1Is message, together wltl1 its annexes, contains Informat1on to be deemed smctly
confidential and is destined only to th,• addressee(s) identified above wl10 only ma., use, copy and, under l1is/tl1eir
responsibility, furl11er disseminate it. If anyone, received this message by mistake or reads It without entitlement Is
forewarned that keeping, copying, disseminating or distributing this message to persons other than the
addressee(s) ,s strictly forbidden and Is asked to transmit 1t 1rnmed1ately to thci sender and to erase the ongmal
message received
Thank You
Sent : Sat, 18 Apr 2020 13:46:56 +0000
To : Greg Folkers CbH6);Morens,David (NIH/NIAID) [El
FW: CDC:---------------------- Cb)(5)
https://bit .ly/2Ki5Ry4
We really need to talk about this. (b) (5)
From: Morens, David (NIH/NIAID) [E]

--------- (b)(6)
To: Folkers, Greg (NIH/NIAID) [El -----~ Cb

H= >
~
Cc: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject : Re: CDC: (b)(5
https://bit.ly/2Ki5Ry4
(b) (5)
Sent from my iPhone

David M Mo rens
OD, NIAID, NIH
On Apr 17, 2020, at 18:30, Folkers, Greg (NIH/NIAID) [El wrote:

-------- (b)(6)
(b) (5)
The estimates on this page have been updated from an earlier report published in
December 2018 based on more recently available information. There is a trade-off
between timeliness and accuracy of the burden estimates. To provide timely burden
estimates to the public, clinicians, and publ ic health decision-makers, we use preliminary
data that may lead to over- or under-estimates of the true burden. However, each
season's estimates will be finalized when data on testing practices and deaths for that
season are available.
For the revised 2017-2018 estimates, we included additional information in our estimation
regarding influenza testing practices. The surveil lance system used to estimate influenza-
related hospitalizations, FluSurv-NET,collects data on patients hospitalized with
laboratory-confirmed influenza. Influenza testing is done at the request of the clinician, but
not everyone is tested and influenza tests are not perfectly accurate. Thus, the reports of
laboratory-confirmed influenza-related hospitalizations to FluSurv-NETare likely
underestimates of the true number of hospitalizations. To adjust for this, CDCcollects data
annually from participating FluSurv-NET sites on the amount of influenza testing and the
type of test that is used at the site, and this information is used to correct for the possible
underestimate of influenza-related hospitalizations . These testing data are often not
available for up to two years after the end of an influenza season, and thus the estimates
are revised when additional testing data become available . For the orig inal preliminary
2017-2018 burden estimates, data on testing practices during the 2014-2015 season were
used to make preliminary estimates because this season had the highest levels of testing
among the prior seasons for which data were available and resulted in the most
conservative (lowest) estimates of burden. More recent data from the 2016-17 season
show that influenza testing has been increasing among most age groups. The current
estimates were made using the highest testing rate fo r each age-group during 2010-11 to
2016-17 and has resulted in some burden estimates being lower than previously
estimated.
Additionally, the method we use to estimate influenza -associated deaths relies on
additional data from FluSurv-NH and the National Center for Health Statistics (data on
cause of deaths and numbers of deaths that occur in versus outside the hospital) that are
also not available for up to two years after the end of the season being estimated .
The 2017-2018 estimates are still preliminary because not all of the required data are
currently available. When those data become available, these estimates will be updated
again and the results may change.
More answers to frequently asked questions about CDC's influenza burden estimates are
available.
Disclaimer: Any third-party mat erial in this email has been shared for internal use under fair
use provisions of U.S. copyright law, without further verification of its accuracy /veracity. It
does not necessarily represent my views nor tho se of NlAlD , NlH , HHS , or the U.S.
government .
From: (b)(6)
Sent : Fri, 17 Apr 2020 14:45:56-0400
Subject : Fwd: Invitation to speak at virtual TIME 100 event
Let us make sure that we discuss this.
Fr om : Alice Park <alice.p ark@ti me .com >

Date: April 17, 2020 at 2:07 : 17 PM EDT
To : "Fauci, Anthony (NIH/NIAID) [E]" -------~= (b)(6J:
Cc: Cate Matthews <cate .matthews@time.com >
Subject: Re: Invitation to speak at virtual TIME 100 event
Hi Dr. Fauci -- I also should have added that we are happy to pre-tape the interview so it does not
have to happen on April 23. ln order for it to run on that date, we would love to record it some time
Wed during the day or on Thurs morning.Hoping that helps with timing, and looking forward to
hearing from you. Best, Alice
Alice Park
TIME
(b)(6)
alice.park@time.com
@aliceparkny
On Fri, Apr 17, 2020 at 9:35 AM Alice Park <alice.park@time.com>w rote:

Dear
Dr. Fauci,
Thank
you for making time to talk to me during the early weeks of the pandemic. I know your
schedule is tight, but wanted to pass along an invitation to speak at a unique virtual
summit we're holding next week, that I hope we can make work.
Building
on the impact of our annual TIME
100 and TIME 100 Health summits, as well as our ongoing coverage of COVID-19, on
Thur sday, April 23 ,
TIME will launch its first-ever virtual event series, "TIME Talks: Finding Hope." Our goal
is to convene a group of the world's leading voices, including TIME 100 honorees, to
spotlight the important work they're doing to combat this crisis, and to help our
viewers navigate this new reality.
As part of our launch event , schedule d to take place between noon and 3 p.m. ET, we'd
like to invite you
to participate in a short, 10- to 20-minute video interview with a TIME editor on
public health policies that could be implemented at the national level to strengthen the
responses to this and fu ture pandemics - addressing in particular lessons learned from
the initial response to the coronavirus .
We would also welcome your thoughts on how we plan to navigate out of the pandemic
a nd what the new normal will look like . (Please note that we are open to discussing othe r
topics as wel l.)
Each conversation will be streamed and promoted across TIME 's platfo rms, which reach
a comb ined audience of 100 million people around
the world .
As
one of our invited speakers , you would also be part of an extraordinary community of
leaders who are shaping our world . Past speakers at T IME events include House
Speaker
Nancy Pelosi ,
Apple CEO
T im Cook ,
Primatologist
Jan e Goodall ,
White House Adviser
Jared Ku shner ,
Chef
Jos e A ndres,
Me Too Movement Founder Tarana Burk e,
Producer Director
Ryan Murphy ,
and many others .
T hank
you in adva nce for considering this invitatio n. Cate. our program coordinator . and I are
happy to help with any questions you may have.
Looking forward to hearing from you .
Best ,
Alice

Alice Park
TIME
(b)(6)
alice.park@time.com
@aliceparkny
Sent: Fri, 17 Apr 2020 16:00:09 +0000
To: Thomas R. Frieden
Subject : Re: Box It In
Att achments: image001.png , image002.png, image003.jpg
Thanks, Tom. I totally agree with this approach. I have been trying to catch you by phone but
have gotten a voicemail with a message that the mailbox is ful l. Do I have the con-ect number?
Thanks, Tony
On Apr 17, 2020 , at 11 :00 AM, Thomas R. Frieden

(b)(6). wrote:
Tony,
Wishing you well. Wanted you to be aware that we're releasing a repo rt at a media
briefing this morning on how to " Box in COVID." This plan includes priorit ized expansion of
testing and building a corps of contact tracers in the US, using tried-and-true public health
measures at scale. There are four essential actions to box in the virus: 1) Expand testing; 2)
Isolate infected people to prevent spread; 3) Identify contacts who may have exposed; 4)
Quarantine contacts. As you know, all four are crucial; if any one is lacking, the virus can
escape and spread explosively again. Success requires a massive expansion of our public
health capacity around the country and world.
The report is attached and can be downloaded here . Please let me know how we can
continue to be as supportive as possible.
All the best,
Tom
Tom Friede n, MD, MPH

President and CEO
www.DrTomFrieden.net
(b)(6)
<image0O1.png>
<image002 .png>
<image003.jp g>
RESOLVETO SAVE LIVES
An initiative of Vital Strategies
STAYCONNECTED
www.resolvetosavelives.org face book twitter
<COV035 _ BoxltlnBriefing _ FINAL.pd£>

~
TOSAVE
LIVES
AHINITIATIVE
OFVITAL
STRATEG
Sent : Fri, 17 Apr 2020 10:15:13 +0000
FW: (b)(4)
Please take a look at this and respond. Thanks.
From: Alfonso Arana <alfonso .arana@bizsecure .us>

To: Fauci, Anthony {NIH/NIAID) [E]______ """
(b""""
)(=6J
(b) (6J>;Robert .Thompson@crlcorp.com
(b) (4)
Dr. Fauci, good morning thank you for all you do for this great nat ion! We are very blessed to have you
at the forefront of this pandemic. Not sure if you recall, (b) (6J we have
(b) (4)
Alfonso Arana
President/ CEO
Craft Artisan Design Inc. HUBZone
DBA. BizSecure
https://bizsecure.us
(b)(6)
CONFIDENTIALITY NOTICE: This e-m ail message including attachments, if any, is in tended only for the person or
ent ity to which it is addressed and may contain confidential and /or privileged material. Any review, use, disclosure
or distribution of such confidenti al inform ation without the written authori zation of Craft Artisan Design Inc. DBA
A&A Solutions. is prohibited. If you are not the int ended recipient, please contact t he sender by reply e-mai l and
destroy all copies of the original message, by receiving this e-m ail you acknowledge that any breach by you and/or
your repr esentatives of th e above provisio ns may entit le A&A Solutions., to seek for damages.
Sent : Fri, 17 Apr 2020 02:48:07 +0000
Subjec t : FW: Hilary Marston's COVID-19 talk now archived for view ing
Greg:
Please see me tomorrow abo ut some ideas that l have about COBfD-19 slides.
Thanks,
Tony

From: Rob erts, Jacqueline (NIH/OD) (E] (b)(
To: NIH-STAFF@LJST.NIH.GOV
Subject: Hilary Marston's COVJD-19 talk now archived for viewing
Dear Colleagues,
Thank you all for your suppo rt as we launc h the new COV[D-19 lecture series. The live videocast of yeste rday's talk
was in high demand and, unfor tunately, many of you were unable to gain access. This was partly because of the
large number of viewers. We are working to remedy the issues in preparation for next week's lecture.
Dr. Marston's talk , "The Biomedical Research Response to COVID-19: A View from NIAID," is now archived at
https://videocast.ni h.gov/watcb=36375 .
- The COVID-19 SIG Moderators
For more infonnation about the COVTD-19 Scientific Interest Group, refer to httos://oir.nih.gov /s igs/cov id-19-
sci entifi c-i ntere st-gro up.
Sent : Fri, 17 Apr 2020 02:45:01 +0000
Subject : RE:conspiracy gains momentum
Francis:
(b) (5)
Best,
Tony

--------
(b)(6)

:;.=======~~ (b)(6)
Cc: Tabak, Lawrence {NIH/OD) [E]
--------- (b)( ; Burklow, John (NIH/OD) [E] ._
Subject: conspiracy gains momentum
_______ (b)(6JJ; Lane, Cliff {NIH/NIAID) [E]
(b)(6)
_.
(b) (5)
https :// www.mediaite.com/tv /foxs-bret-ba ier-so urces-i ncreasingly-confident-coronavi rus-o utb rea k-
started-in-wuha n-lab/
(b) (5)
Francis
Sent : Fri, 17 Apr 2020 02:28:05 +0000
To : Pottinger, Matthew F. EOP/WHO;Birx, Deborah L. EOP/NSC
Cc: (b)(6)
Subject: RE: [WARNING: UNSCANNABLE EXTRACTION FAILED][EXTERNAL) Using
grounded aircraf t to treat COVID patients
Matt:
(b) (5)
-----
Best regards,
(b)(5). Let us discuss further.
Tony
From: Pottinger, Matthew F. EOP/WHO

Sent: Thursday, April 16, 2020 7:54 PM ---------- (b)(6)
To: Birx, Deborah L. EOP/NSC -------- =(b=)(=6)>; Fauci, Anthony {NIH/NIAID) [E)
(b)(6)
Subject: FW: (WARNING: UNSCANNAB LE EXTRACTION FAILED)[EXTERNAL] Using grounded aircraft to
treat COVID patients
Deb, Tony,
(b) (5)
Best,
Matt
From: Skinner, James B. EOP/NSC (b)(6)

To : Pottinger, Matthew F. EOP/WHO -------~~ (b)(6)>
Cc: DL NSC NSA FO Staff <DL.NSAF0Staff@whmo.mil>
Subject: FW: [WARNING: UNSCANNAB LE EXTRACTION FAILED)[EXTERNAL] Using grounded aircraft to
treat COVID patients
Matt,
I spoke to Leland earlier this afternoon and he asked I pass this along to you .
James
From: Leland Schwartz >

-----------
(b) (
To: Skinner, James
___
B. EOP/NSC (bH >
.;.__--=======~;-:--:-:-::-:-::-:--:-:-:-:-~
_c_
c:_R_a..:..
Ip_h_C_ra_ft_s!:=======--=::"'";" (b_H_. ; BARBARASCHEIDE
(b)(6) ----- (b) C6l; Ed Betts
Subject : [WARNING: UNSCANNABLE

EXTRACTION
FAILED][EXTERNAL]
Using grounded aircraft to treat
COVIDpatients
Matt,
Oxygen therapy scientists can treat patients using the grounded airliners all over the
country as masstreatment chambers.
Please watch this explana t ion from Extivita in Durham :
> https:// www.youtube.com/watch?v=SWCHDuUOHSM&featur

e=youtu. be<
Pleasehelp us connect to the right people.
This could help save lives, get our economy restarted, and ensure continuity in the
government.
Hope you're good. Catch up on the other side. Have figured out how to save local
news.
Leland
(b)(6)
James,
Thanks very much for your help.
Leland
lelllndSchwartz
Edllor&Pui>hsher
F~ ChannelOne
$4042.213r6
eclllOff!lauqu,oichannoloorn
wwwfctUqUDR:himnel
CQfn
COY.M~ ITY eAOO.DCASTING
FORFAUOUIEA
April 16, 2020

Matt Pott inger
Deputy National Security Advisor
The Whit e House
1650 Pennsylvania Avenue, NW
Washin gton , DC 20502
Dear Sir,
Many of us in the hyperbaric medicine community believe that there exists a simple
therapy to halt the inflammatory proc ess and reverse the lung damage.
This process will also simultaneously provide many time s over the amount of
oxygenation offered by th e coma-inducing intubation
ventilator procedure.
We are reaching out to our network to make contact with the airlines to secure the use of
an airplane with an onboard APU (Auxiliary Power Unit--used to pressuriz e the aircraft)
for a month, to treat COVID-19 pati ents and show the effectiveness of th e concept.
Initial testin g indicat es in one trial study 100% improvement while all others und erway,
although small scale, are showing great benefit at extremely low cost and patient risk.
So what is this new procedure? Hyperbaric Oxygen Therapy or HBOT; first used
successfully in 1918 for Spanish Flu cases. HBOT is viable and appears to work well but
we do not have th e number of pressure vessels / HB chambers available to treat the
possibly
100,000+ who need the therap y now.
Several of us in our small community have arrived at the same idea in several
countrie s.
The idea is no longer new or uniqu e.
Again, I am proposing use an aircraft as the pressure vessel. Every airplane with a
pressurized cabin (i.e., all commercial airline aircraft) is routinely pressurized to around
9 psi (some go higher) while they are on the ground, as part of their norma l
airworthiness testing.
Myself and others have suggested that one or mor e of th e hundr eds of grounded aircraft
be provided to complete th e trial test .
737 Max are not flying but are a perfect pressure vessel for the proc edur e.
Could you help us contact Boeing, the airlines or the military?
No aircraft modification is required whatsoe ver so that is one of the issues off the table.
The aircraft remains parked on the ground with access for ambulatory patients via a
stairway. No jetway is required unless we expand this in the future for non-ambulatory
patien ts.
We would need to place stand ard DOT portabl e oxygen tank s in the cabin along with the
associated manifold, pressure regulator, flow-meters and tubing.
Each patient will have his / her own anesthesia mask and breathing circuit.
Ther e is no cross contamination between patients or the cabin environment atmosphere

as each mask incorporates a Viral Filter Kit to help protect the technicians who are also
brea thing from a sec ur e, clean so urc e.
All safety issues are addressed in the plan.
The same process, once proven could be utilized by our military and of course our Navy
who is experiencing possible outbreaks as we speak
The Patriot Clinic in Oklahoma City is my personal charity where we have provided over
15,000 free HBOT treatments for our beloved vets and 30,000+ at cost or below.
We are not asking for money. Nor, am I selling anything in this effort. With th e help of a
small group of supporters, ( Ralph Crafts & family ) my company is willing to provide
the equipment, training and technical support to begin the process.
Thank you for your ongoing service to our country, and thank you for reading and
considering my propo sal.
I sure would appreciate your help.
Semper Fi!
Sincerely,
Edward A Betts
Edward A Betts
ANDI American Nitrox Divers International
74 Woodcleft Avenue
Free ort, NY USA 11520
(b)(6)
>http: //www .andihq.com/ <

(b)(6)
Matt Pottinger
Deputy National Security Advisor
The ·white House
1650 Pennsylvania Ave., NW
Washington , DC 20502
Sir:
As one old Marine to another Ma rine, this letter contains the "straight scoop," and is intended to
provide infonnation that can help stop the spread of COVID-19, and ensure the continuity of
critical segments of government.
Hyperbaric Oxygen Therapy (HBOT) has been in use for over 100 years, and was the only
effective treatment for the 1918 flu pandemic. HBOT is being used worldwide to treat a variety
of serious disease s, and has been proven to be immediately effective in treating seve re COVID-
19 cases, with a success rate close to 100%.
HBOT is simply breathing high-pur ity oxygen (92% or higher) for 60-90 minutes in a
pressurized environment (typically between 8 and 15psi- the higher pressure is about the same
pressure as doing a SCUBA dive to 33 feet). HBOT chambers can be 1-2 person sizes and
portable, up to 12-seat chambe rs which are used for Navy operations. (b)(6) I have a one-
person chamber in our home , and we can attest to its effectiveness in treating severe breathing
problems, like pneumonia , infections , and wounds.
The currently publicized and widely accepted statement that there is no effective treatment for
COVID-19 is wrong. HBO T treatments, usually just a single one-hour session, provide
immediate improvements in lung function, blood-oxygen levels, and organ recovery . Unlike
respirators, which do more damage than good and are basically a death sentence, HBO T provides
an immediate path for recovery and healing.
A team of ve1y experienced scientists and HBOT experts have developed a concept that will
enable the effective treatment of large numbers of people by using some of the thousands of
grounded commercial aircraft as large HBOT chambers.
I'm an old Marine Corps jet pilot , and we use our (b) (6)
so I have the professional contacts to confirm and verify the efficacy
of the concept.
Every airp lane with a pressurized cabin (i.e., all airline aircraft) is routinely pressurized to
around 9psi (some go higher) while they are on the ground , as part of their normal airworthiness
testing.
We have equipment staged and ready to go now, to treat 25 COVID-19 patients ata time- we
need an airplane, and we can be treating people and saving lives in about 36 hours.
The aircraft we need remain park ed on the ground, no modifications are needed-we will simply
place portable oxygen tanks in the cabin with the associated tubing , manifold, and pressure
regulators, and each patient will have his/her own anesthesia mask.
There is no cross contamina tion between patients, because everyone is breathing oxygen from
their own persona l mask.
We are reaching out to our contacts in the airlines to ask for the use of an airplane and APU
(Auxiliary Power Unit- used to pressurize the aircraft) for a month, to treat COVID- 19 patients
and show the effectiveness of the concept.
We could do the same thing with a single military transport aircraft (many of which have been
configured for medical use).
As a Marine, and with my knowledge of HBOT, the recent death of the Theodore Roosevelt
sailor is part icularly upsetting, knowing that a couple of Senior Chiefs or Marine Master
Sergeants could have configured an aircraft in Guam in a couple of hours and be treating all the
sailors from the carrier.
We are not asking for money- my wife and I are paying for all the required equipment and
support personnel.
HBOT chambers are easily implemented and supported- you could have one in your office
(ours is 8' long and 34" in diameter when pressurized) and it would only take a couple of hours
to train your corpsmen to operate it. I don' t know of a better guarantee of continu ity in the
current pandemic.
Please note that (b)(6) I have no financial or political interests in the HBOT treatment
concept, companies , or manufacturers-we receive no benefits/rewards, other than helping to
save many lives.
You will receive a letter from Ed Betts- he's a good man, really knows his stuff, and I trust him
with my life- please take what he says seriously.
Thank you for your ongo ing service to our country , and thank you for reading and consid ering
the information in th is letter.
Semper Fi !
Respectf ully,
Ralph E. Crafts
Marsha ll, Virg inia
(b)(6)
Sent : Thu, 16 Apr 2020 12:37:38 +0000
To : Dr. Josh Backon
Subject : RE:Covid-19. thromboxane inhibitors, and heme binding (02 desaturation)
You are not being ignored. The Nationa l Heart Lung and Blood Institute will take a look at this.
From: Dr. Josh Backon <backon@mail.huji.ac.il>

To : Coleman, Amanda {N IH/NIAID) [CJ
____ ..:._ __ _:__:. __
--------
:...,:_.:.!:::========:::....:..-~
""=""'"'=
(b)( >; Fauci, Anthony
(b
~)~(6)
(NIH/NIA ID) [E)
Subject : Fwd: Covid-19. thromboxane inhibitors, and heme binding (02 desaturation)
Continue to ignore me.
http ://www .htct.com .br/en -hemog lobin -va lue-may -be-decreas ed-avance -
S2531137920300298?fbclid= lwAR3zdsUZE l MSgxNpqzr lf8621NlbRMFPJ9qfRLnsC2FqZNkjCrsw4KDtGc
Dr. Josh Backon

backon@mail.huj i.ac.il

From: Coleman, Amanda (NIH/ NIAI D) [C] (b)(6)
Date: Thu, Apr 9, 2020 at 6:18 PM
Subject: RE: Covid-19. thromboxane inhib itors, and heme binding (02 desaturation)
To: Dr. Josh Backon <backon@mail.huji .ac.il>
Dear Dr. Backon,
We very much appreciate the information you've provided, and I am sharing your updates with t he
relevant staff at NIH. We have directed you to the information we think is relevant for your request, and
we hope that this has been helpful. We have no additional information to provide at this time. NIAID
staff members will not be responding further .
Thank you,
Amanda Coleman, MPH [C)

Office of Scientific Coordination and Program Operations
NIAID, NIH, DHHS
From: Dr. Josh Backon <backon@mail.huji.ac.il>
Sent: W ednesday, April 8, 2020 7:37 AM
To: Coleman, Amanda (NIH/NIAID) [CJ ------~~ CbH6)>;
Fauci, Anthony (NIH/NIA ID) [E)
(b)(6)
Subject: Covid-19. thromboxane inhi bi tors, and heme binding (02 desaturation)
I have a suggestion for 3 potent antiviral agents, cheap and readily available, that
may prevent viral shedd ing. No viral shedding? No infectivity. The concept is that
EVERYONE should take these items. Two of the items also positively affect heme
binding. Covid-19 bind s to heme causing 02 desaturation, lung failure and death.
First a short bio:
Dr. Josh Backon was affiliated with the Hebrew University Faculty of Medicine
for over 33 years. He has a good track record (84+ publications quoted by over 750
other researchers
www.google.com /scholar?start=O&g=%22backon ++j.%22&hl=en&as sdt=0,5
and in over 250-300 texts as per
https://www.google.com /search?tbo=p&tbm =bks&q =%22backon+j .+%22&num =
100 ).
In the 1980's he was Consulting Editor of the Journal of Pedi atric Endocrinology,
Editor of Reviews in Pure and Applied Pharmacological Sciences, and Associate
Editor of the International Journal of Adolescent Medicine and Health. From 1990-
2004, he was a consultant on emergency planning and management at Israel 's
National Police Headquarters with Nitzav Mishneh Dann y Fisher.
Chloroquine, an antimalarial drug, is now being used to treat Covid- 19. Its
mechanism was found in the 1970's to inhibit thromboxane
https://scholar .google.com/scholar?hl=en&as sdt=0%2C5&q=chloroquine +thromb
oxane&btnG = The problem with chloroquine was that it also elevated levels of
prostaglandin F2alpha. In 1980, Srivastava, an Indian biochemist working in
Denmark found that GINGER is a potent inhibitor of thromboxane synthetase. I
wrote a number of pap ers in the J980's on use of ginger:
https:/ /scholar .google.com/scholar ?hl=en&as sdt=0%2C5&g =backon +ginge
r&btnG=
CHLOROQUINE FOR TREATING COVID-19

bttps://scbolar.google.com/scholar ?hl=en&as sdt=0%2C5&q=ch1oroquine+covid-
19&oq=c h&fbclid=IwAR llLe376M22 IUr3U sD6 yz-
sASmpGglp I3h3PTOpC HA4Y cu32 l ZPevD-A
GINGER IS A POTENT ANTIVIRAL

-
https: //scholar .google.com/scholar?hl =en&as sdt=0%2C5&q =ginger +anti viral&oq
=gm
THE SECOND ANTIVIRAL AGENT IS TURMERIC [add black pepper

since piperine dramatically increases oral bioavailability of turmeric)
https: //scholar .google.com/scholar?hl =en&as sdt=0%2C5&q =turmeric+antiviral&
oq=tur
Multisite inhibitors for enteric coronavirus: antiviral cationic carbon

dots based on curcumin
D Ting, N Dong , L Fang, J Lu, J Bi. .. -ACS Applied Nano ... , 2018 - ACS Publications
.. . These results offer theoretical support for the development of CCM-CDs as a hopeful
antivira l drug for the treatment of coronavirus infections, including PEDV ... Curcumin
(CCM) is a polyphenol compound obtained from turmeric roots ...
NAC AND PIPERINE TO INIDBIT INFLAMMATORY CYTOKINES

{iNOS, NF KappaB, TNFalpha) INVOLVED IN ARDS
Mortality in COVID-19 patients is usually from ARDS (acute respiratory distress

syndrome) via inflammatory cytokines. Apart from N-acetylcy steine which was
found 3 years ago to elevate atrial natriur etic factor [found by Kiemer in 2001 to
zap inflammatory cytokine s: iNOS , NF KappaB , and TNFalpha) now piperine in
black pepper was found to inhibit inflammatory cytokines [piperine also
dramatically increas es oral bioavailability of turm eric [which has been used as a
potent antiviral]:
N-ACETYLCYSTEINE
https://scholar.google .com/scholar ?hl=en&as sdt=0%2C5&g=n-
acetylcysteine+%22 inflammatory+cytokines%22&btnG=
PIPERINE
https://sc holar .google.com/ scholar ?hl=en&as sdt=0,5&q =piperine%20inflammato
ry%20cytokine s&btnG=&fbclid=IwAR0kXZxl66JPLFPry2MDTDxOAelgGnmB
ZdK.Bw7cl v78Hfi7t 0JJnx0Y2zuE
COVID -19 BINDS TO HEME

http://web.archive.org/web/20200405061401/https://medium.com/@agaiziunas/covid-19-had-us-all-
fooled-but-now-we-might-have-finally-found-its-secret-91182386efcb
COVID- 19: HYPOXIA , 02 DESATURATIO N, COVID-19 BINDS TO HEME.

THUS NO MAX PEEP ! ! IT'S A PROBLEM OF FREE RADICAL
BIOCH EMISTRY.
THROMBOXANE AND HEME BINDING

https://scholar.google.com/scholar?hl=en&as sdt=0%2CS&q=thromboxane+%27heme+binding%22&oq
=th&fbclid= lwAR3fSECaUUnrSSyhCA6kpJ9z0nPaMM3ba7HtuFPpQ9B1PVrF9kdwayATcY0
INDIA: POPULATION 1,300,000,000: as of Apr il 8th , only 5000 cases and 164 deaths :
[Ind ians eat GINGER,TURMERICand BLACKPEPPERplus other spices which are thromboxane
inhibitors ]:
https ://www. business-standard .com/ article/ current-affairs/ coro navi rus-I ive-u pdates -covid-19-cases -i n-
i ndia-gl oba I-death-to II-state -wi se-del hi-ma harasth ra-tabl igh i-niza m udd i n-lockdown-extension-latest-
news-120 040800236 1.html
11 classic Ind ian spices: saffron , fenugreek, cardamom , cloves, cassia, cumin, coriander, and nutmg
https ://www .thekitchn.com/11-essential-spices-for -indian-cooking-223152
Access http://scholar.google.com for THROMBOXANE (and the name of each spice) and you'll see that
each one is a thromboxane inh ibitor
ANTI PARASITICDRUG IVERMECTIN KILLSCOVID- 19

https://pharmafield.co.uk/pharma news/study shows anti-
parasitic drug ivermectin kills coronavirus/
IVERMECTINAFFECTSTHROMBOXANE
https://scholar.google.com/scholar?hl=en&as sdt=0%2CS&q=%22ivermectin%22+thromboxane+&btnG
CARBON DIOXIDE AS THROMBOXANE INHIBITORS

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1433448/
https://www.sciencedirect .com/science/article/abs/pii/0306987786900952
Effect of carbon dioxide on platelet aggregation in cats

ES Gabrielyan , EA Amroyan - Bulletin of Experimental Biology and ... , 1984 - Spri nger
Products of the arachidonic acid cascade have been shown to play an important role in
regulation of the blood supply to several organs, including the bra in [i, 8]. Cyclic derivatives
of arachidonic acid play a definite role in the mechanisms of action of many known ...
https ://Ii nk.springer .com/ article/10.1007 /BF0082963 7
WHY CATS (FELINES)ARE MORE SUSCEPTIBLE

TO COVID-19 THAN DOGS
https ://www. the -scientist. com/news -op inion/ cats-f e rrets -susce pt i b Ie-to -sars-cov-2 -st udy-
67374? utm campaign=TS DAILY+NEWSLETTER2020&utm source=hs email&utm med ium=emai l&ut
m content=85706789& hsenc=p2ANqtz --SZXoVVbO1SHcR025FPiWgMcM3 nz7fHSHOrKRp9f-
LxTy9Bxj0Jsl7hJtDQ oDM2xsozsH438n5c 1Mj-
78bT3Rz2mQ& hsmi=85706789&fbclid=lwAR3bW76GVl4rConuw7YPcDL91ZE9JkQQSm9Lu y-
RE4y2LNmo0o6v taFUk
https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/j.1476 -
5381.1983.tb09393.x?fbclid=lwAR1SzFkyOR4mVyVvh9ayQP U-
zj4Cwl Vo419b2jRHebfjmSQCD6BykteHqQ
Sent : Thu, 16 Apr 2020 11:48:56 +0000
To: (b)(6)
Subject: RE: Stand ing Up for Truth
David:
Ma ny hanks for your kind note. It is much appr eciat ed.
Best regards,
Tony (b)( 6)
Director
Phone : (b)( 6)
FAX : (301 496- 09
E-mail Cb)(6)
The Information in this e-mail and any of Its attachments Is confidential and may contain sensitive
behalf of t he NIAID by one of its representative s .
From:
-----------------
Sent: Monday , Ap ril 13, 2020 2:49 AM
--------:a-
(b)(6)
=
To : Fauci, Anthony (NIH/ NIAID) [E]
(b)( 6) -------- (b)(6); Fauci, Ant hony {NI H/ NIAID) [E]
Subject : Standing Up for Truth
4/ 13/20
Anthony S. Fauci, M.D.

Director , NIAID
Dear Dr. Fauci:
As a fellow graduate of Regis High Schoo l (b)(6) and very active
alumnu s, I am writing to you out of deep concern for our nation . I am

reading reports in The NY Times that President Trump may be con sidering
firing you for tell ing the truth about the negative consequences of delays in
mobilizing the Amer ican res ponse to the corona virus threat. The Times had
run article s in recent days detail ing the pertinent facts that place the blame
for this delay squarely on President Trump. We can reasonably infer that
significant loss of life and financial harm resulted from this delay.
The mission of Regis was to mold young men with leadersh ip potential to
be "men for others" in the Jesuit tradition. To achieve that goal Regis also
sought to hone our intellectual talents and imbue us with Christian morality
to succeed throughout our lives in a persistent pursuit of excellence, which
embodies the truth. A mission to relentlessly pursue and proclaim the
truth.
The fact that you have cons istently and courageously pursued that mission
during one of the darkest times in our history explains the extraordinary
admiration in which you are held by millions of Americans. You have won
their confidence , which has enabled so many to make exquisite sacrifices
to win this crucial battle. People will follow heroes, which is precisely how
the vast majority views you.
I am writing because I want you to know how important you are to America.
We cannot lose you and we can not lose the value of truth. Truth must
prevail or our precious democracy is in grave peril.
Consequently, and I know I speak for the vast majority of Americans whose
decency is beyond question, if Donald Trump seeks your removal, please
resist for the sake of our nation. An appeal to the populace will not go
unanswered. Religious leaders will flock to your defense, as will the media
and leading political leaders, including Biden and Cuomo. Republicans can
not afford to alienate what you stand for. Jeopardizing the Catholic vote
would be suicide.
In closing, know how proud all Regians are of you. You will always be an
inspiration to those who understand the value of service to others.
Our prayers are with you.

David G. O'Brien (b)(6)
Attorney at Law
(b)(6)
Sent : Thu, 16 Apr 2020 11:35 :55 +0000
To : Daniel Bednar ik
Cc: Lerner, And rea (NIH/NIAID) [El
Subjec t : RE: BARDA Presentation
Thanks, Dan.
Best,
Tony
From: Daniel Bednarik <dbednarik@neximmune .com>

Se nt : Tuesday, April 14, 2020 4:24 PM
Subject: BARDA Presentation
Dear Tony :
(b) (4)
Be well - we are all in your corne r (and you have your own bobble head likeness)!
Best,
Dan
Daniel Bednarik, Ph.D.

Senior Vice President
Molecular Engineering
Nexlmmune, Inc.
9119 Gaither Road
Gaithe rsburg MD 20877
(b)(6)(m)
www.neximmune.com
••
• Nexlmmune
Directing T cell function to restore natural immunity
Sent: Thu, 16 Apr 2020 11:33 :57 +0000
To : Schwetz, Tara (NIH/OD) [E)
Cc: Marston, Hilary (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Barasch,
Kimberly (NIH/NIAID) [C];Walsh, Elizabeth (NIH/OD) [E]
Subject : RE: Flagging NIH Media Products
Thanks, Tara . I appreciate the heads up. Stay well and saf e.
Best,
Tony
From:Schwetz, Tara (NIH/OD) [E) (b)(6)/>

-=-=
)'""'
(6)
=>
Cc: Marston , Hilary (NIH/NIAID) [E] (b)( ; Conrad, Patricia (NIH/NIAID ) [E]
(b)( >; Barasch, Kimberly (NIH/N IAID) [C] (b)( >; Walsh ,
Elizabeth (NIH/OD) [E] (b)( >
Subject: Flagging NIH Media Products
Tony,
Hope all is we ll and that you are staying safe and healt hy .
. Our plan is to batch and send these to Hilary, Patty, and Kim on Thursdays/Fridays
each week, unless there is a time sensitivity to them. For t he time-sensitive requests, I will flag them for
you (after a couple levels of filtering).
So, that said, I am reaching out to flag the following time-sensitive items for your awareness and sharing
with the remainder of the Task Force, as appropriate . You'll note that both of these are yours, so th is
email may be unnecessary. If so, apologies for adding to your (what much be crazy) inbox.
Item 1: National Institute of Allergy and Infectious DiseasesStrategic Plan for COVID-19 Research
(NEW)
Activity Type: Strategic Plan
Summary: A new strategic research plan from the National Institutes of Health aims to build on
- and accelerate - new and existing research efforts to prevent, diagnose, and treat COVID-19,
as well as understand the underlying causative agent of this disease, severe acute respi ratory
syndrome coronavirus 2 (SARS-CoV -2). The Plan prioritizes research to improve fundamental
knowledge of SARS-CoV-2vir us and COVID-19 disease, develop diagnostics and assays,
characterize and test t herapeutics, as well as develop safe and effective vaccines targeted to ward
decreasing disease incidence, mitigating morbidity, and preventio n mortality from this disease.
Impact on COVID-19 Pandem ic Response: The strategic plan outlines a research plan ta rgeted at
prevent ion and mitigation of COVID-19disease.
Office : NIAID, Office of the Director
NIH Point-of-Contact : Anthony Fauci, M .D.
NIH Point-of-Contact Email: (b)(6)
Action Date : Estimated 4/17 /2020 _

Type of Action : Publication
Potent ial for Press Coverage : Mainstream Press
Press
Release
in Development?
:Yes
Item 2: NIH study validates decontamination methods fo r re-use of N95 respirators
Activity Type : Significant scientific finding
Summary ; NIAID/NIH-funded study shows that N95 respirators can be decontaminated

effec tively and maintain funct io nal integrity fo r up to three uses. Researchers tested the
decontamination of small sections of N95 fi lter fabric that had been exposed to SARS-CoV-2.
Decontamination methods tested included vapor ized hydrogen peroxide {VHP), 70-degree Celsius
dry heat, ultraviolet light, and 70'/o ethanol spray . All four methods eliminated detectable viable
virus from the N95 fabric test samples. The results will be posted on a preprint server (timing
TBD). The findings are not yet peer-reviewed but are being shared to assist the public health
response to COVID-19.
Impact on COVID-19 Pandem ic Response: Study shows that respirators could be used multip le
times {2-3 times depend ing on decontamination method)
ICO: NIAID
NIH Point -of- Contact : Vincent Munster, Ph.D., and Marshall Bloom, M.D., from NIAID's Laboratory
of Virology are available to comment on this study .
POC Email:
-------------------
Action Date : TBD week of Apr il 13, 2020
(b)(6)
Type of Action: Report/Publication
Potential for Press Coverage: Mainstream Press
Press Release in Development? : Yes
Hope you're getting some rest and taking care of yourself!
Best,
Tara A. Schwetz,PhD
P: --- ~=
(b)(6) I M: (b)(6)
Sent : Thu, 16 Apr 2020 11:32:27 +0000
To: (b)(6)
Subject: FW: New web porta l ··· UW IDEA: COVID-19 Treatment https://bit. ly/3ckkv48
Please take a look at this and then let us talk.
From: Folkers, Greg {NIH/NIAID) (E] (b)(6)

Subject: New web portal --- UW IDEA: COVID-19 Treatment https://bit.ly/3ckkv48
Disclaimer : Any third-party material in this email bas been shared for internal use under fair use pro visions
my views nor those of NIAID, NlH , HHS, or the U.S. government.
Sent: Thu, 16 Apr 2020 11:24 :00 +0000
To : Auchincloss, Hugh (NIH/NIAID) [C) (b)(6)
Cc: Conrad, Patricia (NIH/NIAID) [E);Harper , Jill (NIH/NIAID) [E]
Subject : FW: Request: Proposal Summaries - POCsDue 4/15; Summaries Due 4/20
Attachments: 2020-04-14_ Proposal POCSign up.xlsx, IC Specific Proposals 4.14.pdf, ER
Proposals 4.14.pdf
Please handle.
From: Schwetz, Tara {NIH/OD) [E] (b)(6)

To : ICDDIR-L@list. nih.gov
Cc: List DEPDIR-L <DEPDIR-L@list .nih.gov>; NIH Director's Executive Committee <0D -
SmallStaff@mail.nih .gov>
Subject: Request: Proposal Summaries- POCsDue 4/15; Summaries Due 4/20
Colleagues,
As discussed this afternoon, please find attached the POCsign-up sheet (tab 1; tabs 2-3 list the various
proposals by category, theme, and IC), the IC-specific proposals, and t he economic recovery
proposals . We ask that you please complete the POCsign-up and send it to Jordan Glad man
(b)(6) by S pm on W ednesday April 15. We will t hen col late and distribute the
-----------
comp Iet ed spreadsheet to the Chairs for each of the themes and post it on the ICD SharePoint site . The
individual proposals are imbedded in the pdf as folders sorted by theme. If you fee l your proposal would
fit better w ith a different working group, please feel free to engage with them .
We ask tha t, once t he POCshave been have been ident ified, you quickly assemble to begin refining and
synergizing your proposa ls. Each Chair should coordinate with their group to develop a 2 page max
summary of the theme's research, along with a single combined budget. The summary should integrate
t he IC proposals as much as possible; however, it is fine (for valid/justifiable reasons) to describe a few
unique projects tha t fall under the theme as well. That is, if they don't make sense to integrate , you
don' t have to, but please be sure to include t hem in the summary . These summaries should be sent t o
Larry and me (cc Jordan Gladman) by noonon April 20. We wil l build off these summaries t o generate a
document for Francis' review, which we ultimately hope will be informative as we prepare for a
potentia l fourth supplement.
The ask in short:

• Ap ril 15 at 5 pm - send your POCsto Jordan, who will then distribute the completed
spreadsheet to the chairs
• April 20 at 12 pm -chairs to send a 2 page summary of their theme (with combined budget)
Best,

P: (b)(6) I M:
---~= (b)(6)
Sent : Thu, 16 Apr 2020 02:51:30 +0000
Subject: FW: Emergency clinica l tr ial COVID PE
Attachments : 4_ OVID_protocol_15042020.docx
Pleasetake a look at this and take care of it. Thanks.
From: Kucher Nils (b)(6)>

To: Fauci, Anthony {NIH/NIAID) [E] ______ (b
""~""'(6)
=>
Subject: Emergency clinical trial COVID PE
Dear Anthony
My background is clinical VTE research. I spent many years in Boston (Harvard Medical School).
We may have a solution for improving survival in COVID outpatients.

(b) (4), (b) (5)
Would you be willing to discuss this urgent clinical trial proposal wh ich was submitted today to Swiss
authorities
My mobile is
-------- (b)(6)
You can call me anytime.
Best regards
Nils
Prof. Dr. med. Nils Kucher

Director of Vacular Medicine
Univers ity Hospit al Zurich

Switzerland
Ramistrasse 100, RAE C 13
CH-8091 Zurich
Tel: Cb)C6)
www.angiologie.usz.c h
U Sz Universitats
Sp ital Zurich
Sent : Thu, 16 Apr 2020 02:50:34 +0000
To : DuBois, Raymond N.
Subject: RE: Mask wearing policy at our University Hospital
Ray:
Thank you for your note. I would keep the policy "voluntary" but I would "encourage"
employees to wear them.
Best regards,
Tony
From: DuBois, Raymond N.

--------
(b)(6)
--------=-:-:=
---------
To : Fauci, Anthony (NIH/NIAID) [E] (b)(
Subject: Mask wear ing policy at our University Hospital
>
Dear Dr. Fauci,
My name is Ray DuBois and in addition to being the Dean of Medicine here at the Medical University of
South Carolina in Charleston, I chair the Board of Scientific Councilors for the NCI. The mask wearing
policy fo r our Health System is developed by our inf ect ion control group and not by the College of
Medicine.
Currently, we have a "voluntary" mask wearing policy for the health system and our main University
Hospital. Based on your recent comments about asymptomatic and pre-symptomatic carriers of COVID-
19, do you agree that keep ing this voluntary is the correct approach?
Obviously, your opinion here is extremely well respected and I would like for us to prov ide the safest
environment possible for our faculty, employees and patients.
Ray DuBois, M.D., Ph.D.

Dean of Medicine
The Me dical University of South Carolina ....Charlesto n, SC
Memb er of the National Academy of Medicine
Sent : Thu, 16 Apr 2020 02:35:18 +0000
To : Bertuzzi, Stefano
Subject : RE:Announcement--ASM 's COVID-19 Research Registr y
Stefano:
Congratulations! Excellent idea and much needed. Our community will find it very
valuable.
Best regards,
Tony
From: Bertuzzi, Stefano <sbertuzzi@asmusa.org>

Sent : Wednesday, April 15, 2020 10 :21 AM
-------'="'""' =
To : Fauci, Anthony (NIH/NIAID) [E] (b)( >; Erbelding, Emily (NIH/NIAID) [E]
(b)(6) >; Cassetti , Cristina (NIH/NIA ID) [E] (b)( ; Beige!, John
~--~~======-::__=
(NIH) [E] (b)(6)>
Subject: Announ cement --ASM's COVID-19 Research Registry
Dear Tony and NIAID friends -
the miss ion of the American Society for Microbiology (ASM) to promote and advance the microbia l
sciences has perhaps never been more clearly in focus than during the current SARS-CoV-2 pandemic.
Accelerating basic research is key to ASM's mission - it is where cure and prevention begin. It is
impressive how rapidly research on SARS-CoV-2 /COV ID-19 has advanced in just a few weeks , but
easily accessing new and relevant research has been a challenge for basic researchers . When ASM's
Council on Microbial Sciences held a COVI D-19 summit to ident ify the most significant scientific work on
the virus , the coronavirus researc hers and clinical microbiologists raised the need for the scientific
commun ity to curate important COVID-19 research .
ASM is exc ited to announ ce the launch of the COVID-19 Research Registry , a platform curated
and vetted by experts in the field of virology and related discipline s to prov ide imm ediat e acce ss
to top COVID-1 9 research .
I am proud that Lynn Enquist, Ph.D ., Henry L. Hillman Professor in Molecular Biology , Princeton
Unive rsity and fo rmer ASM President , will serve as Chief Curator for this Registry. Dr. Harold Varm us ,
Lewis Thomas University Professor of Medicine , Weill Cornell Medicine has agreed to join us as Chief
Consultant on the project.
We are honored to have the following as Assistant Cura tors-in-Chief :

• Rozanne M. Sandri-Goldin, Ph.D. , Chancellor's Professor , Microbiology & Molecular Genetics,
University of California , Irvine and Editor-in-Chief of ASM's Journal of Virology
• Vaughn Cooper , Ph.D ., Professor , Microbiology & Molecular Genet ics , University of Pittsburgh ,
and current ASM Board member
The entire curatorial board is listed on the Registry site .

ASM is proud to add this initiative to our ongo ing efforts . Through its capillary network of clin ical
microbiologists around the country and the world, ASM has accelerated communica tion and cleared
roadblocks to ramp up SARS-CoV-2 testing . We continue to work closely with our dedicated colleagues ,
the indefatigable clinical microbiologists manning the front lines in hospitals and testing labs during this
unprecede nted global emergency. We send our thanks - and admirat ion--to these ASM members who
are contr ibuting directly to saving lives in this perilous time.
Our COVID-19 resource page provides important ASM updates and current inform ation on the
coronavirus. We are also working with the news media to provide authoritative ASM experts and reliable
material on the microb iology of viral epidemics. ASM journals is also providing free access to more
than 50 research articles published over the last year in our 16 scho larly journals and expediting review
for submitted papers related to coronavirus, ensuring that new research is quickly made available to the
scientific community .
We are hoping that researchers will find the COV ID-19 Research Registry a useful resource . We look
forward to your comments , questions or suggestions , since your input will be critical for improving this
platform and making it usef ul for the scientific community. All feedback can be sent to
covid 19reqistry@asmusa.org . We are all in this together.
Since rely ,
Stefano Bertuzzi
Chief Executive Officer, ASM
Stefano Bertuzzi, Ph.D., M.P.H.

Chief Executive Office r
Ame rican Society for Microbio logy (ASM)
1752 N St., NW
Washington, DC 20036 -2904
Phone (b) (6)
Sent : Thu, 16 Apr 2020 02:08:26 +0000
Auchincloss, Hugh (NIH/NIAID) [C)
To:
Cc: Conrad, Patricia (NIH/NIAID) [El ---------- (b)(6))
Subject: FW: Request: Proposal Summaries - POCsDue 4/ 15; Summaries Due 4/20
Attachments : 2020-04-14_ Proposal POCSign up v l. 0[1] .xlsx, IC Specific Proposals 4.15[1].pdf,
ERProposals 4.15[1] .pdf, COVID-19 Initiative Managemen t-revised[l][G] .docx
Please take a look at this and handle. Thanks .
From: Schwetz, Tara {NIH/OD) [E] CbH >

To: ICDDIR-L@list. nih.gov
Cc:List DEPDIR-L<DEPDIR-L@list .nih .gov>; NIH Director's Executive Committee <0D -
Smal1Staff@mail.nih.gov>; Gladman, Jordan (NIH/OD) [El (b)(6J>
Subject: Re: Request: Proposal Summaries - POCsDue 4/15; Summar ies Due 4/20
All,
Please find attached the comp iled sign-up sheet with IC POCsfor the 12 themes, as well as updated
packets to matc h the shifts that were brought to our attention (attachments #1-3) .
As a reminder , please send the 2 page summar ies for each theme (with comb ined budget), using the
attached template (attachment #4), to Jordan Gladman by April 20 at 12 pm. Thanks to you and your
staff for developing these!
Best,

P: (b)(6) I M:
---~~ (b)(6)
From:Tara Schwetz CbH6J>

Date: Tuesd ay, April 14, 2020 at 9:01 PM
To: " ICDDIR-L@list.nih.gov " <ICDDIR-L@list.nih.gov >
Cc: List DEPDIR-L <DEPDIR-L@list.nih.gov >, NIH Director's Executive Committee <0D-
Smal1Staff@mail.nih.gov >
Subject: Request: Proposal Summaries - POCsDue 4/15; Summaries Due 4/20
Colleagues,
As discussed this afternoon, please find attached the POCsign-up sheet (tab 1; tabs 2-3 list the various
proposals by category, theme, and IC), the IC-specific proposals, and t he economic recovery
proposals . We ask that you please complete the POCsign-up and send it to Jordan Glad man
{jordan .gladman@nih .gov) by 5 pm on Wednesday April 15. We will t hen col late and distribute the
completed spreadsheet to the Chairs for each of the themes and post it on the ICD SharePoint site . The
individual proposals are imbedded in the pdf as folders sorted by theme. If you fee l your proposal would
fit better w ith a different working group, please feel free to engage with them.
We ask tha t, once the POCshave been have been ident ified, you quickly assemble to begin refining and
synergizing your proposa ls. Each Chair should coordinate with their group to develop a 2 page max
summary of the theme's research, along with a single combined budget. The summary should integrate
the IC proposals as much as possible; however, it is f ine (for valid/justifiable reasons) to describe a few
unique projects that fall under th e theme as well. That is, if they don't make sense to int egrate , you
don't have to, but please be sure to include them in the summary. These summaries should be sent to
Larry and me (cc Jordan GIadman) by noon on April 20 . We wil l build off these summaries t o generate a
document for Francis' review, whic h we ultimately hope will be informative as we prepare for a
potentia l fourth supplement.
The ask in short :

• April 15 at 5 pm - send your POCsto Jordan, who will then distribute the completed
spreadsheet to the chairs
• April 20 at 12 pm - chairs to send a 2 page summary of their theme (with comb ined budget)
Best,

P: (b)(6) I M:
----=-:,~(b)(6)
Sent : Thu, 16 Apr 2020 01:58:31 +0000
To : My les, Renate (N IH/OD) [E)
Cc: Collins, Francis (NIH/OD) [El;Tabak, Lawrence (NIH/OD) [El;Wolinetz, Carrie
(NIH/OD) [El;Bur klow, John (NIH/O D) [El;Fine, Amanda (NIH/OD) [El;Lane, Cliff (NIH/NIA ID) [E];Billet,
Courtney (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [El;Routh, Jennifer (NIH/NIAID) [El
Subject: RE: FOR YOUR REVIEW: Draft ACTIV News Release
Attachments : OD_ACTIV_PPP_Release_4.15.2020 - with m inor trac ked edits.docx
Looks good. See my very minor t racked edits in attached document.

Than ks,
Tony
From: Myles, Renate (NIH/OD) [El

-------
Sent: Wednesday, Apr il 15, 2020 9:50 PM
(b)( >

------~~ (b)(6)>
Cc: Collins, Francis (NIH/OD) (El (b)( ; Tabak, Lawrence (NIH/OD) [El
(b)(6) Wol inetz, Carrie (NIH/OD) [El (b)(6)•>; Burklow, John
'":":"".".".""."':":-:-:-:-:-::-=====--=-=-:-=
(NIH/OD) [El (b)(6); Fine, Amanda (NIH/OD) [El (b)( >; Lane, Cliff
(NIH/NIAID) [El
~======="'=r:.. (b)(6Ji; Billet, Courtney (NIH/NIAID) (E] (b)(6J>; Stover,
Kathy (NIH/NIAID) [El CbH >; Routh, Jennifer (NIH/NIAID) [El
(b) (6) >
Subject: FOR YOUR REVIEW: Draft ACTIV News Release
Hi Dr. Fauci:
Dr. Collins asked that I send the draft ACTIV release for you review.
Best,
Renate
Renate Myles, MBA

Deputy Director for Public Affairs
Office of Communications and Public Liaison
Tel: (b)(6)
Sent : Wed, 15 Apr 2020 22:26:51 +0000
Cc: Greg Folkers (bH ;Billet, Courtney (NIH/NIAID)
[E];Barasch, Kimberly (NIH/NIAID ) [CJ
Subject: FW: AIRI Presents Dr. Fauci with 2020 Public Service Award
Attachments: Fauci 2020 AIRI Public Service Awar d Letter .pdf
Patty:
Please put together (or have Kim do so) a letter of thanks, honor, and appreciation ...yada
yada . So that they know I have received the lette r and look forward to receiving it at an
appropriate tim e.
Th anks,
Tony

To: Fauci, Anthony (NIH/NIAID) [El------~=
Cc: Tabak, Lawrence (NIH/OD) [El~======-~
Subject: FW: AIRI Presents Dr. Fauci with 2020 Public Service Award
Cong rats, Tony! Please try to take a minute to savor this. Or at lea st 15 seconds. Q
Francis
From: Parker, Nicole <Nicole@lewis -burke .com>

-----~~ (b)(6)>; Wolinetz, Carrie (NIH/OD) [E]
(b)(6) ; Hallett, Adrienne (NIH/OD) [El (b)(6) >; Lauer, Michael
1
"'.":
(N-:-:
l"."'.'
H/-:-::
0:-:D-:-
) -:-:: ] ;:::::=====:::;.___.,
[E ::-; (b~~(6) >
a"'<"
Cc: O'Hare, Libby <libby@lewis-burke.com >

Subject: AIRI Presents Dr. Fauci with 2020 Public Service Award
Good Afternoon ,
On the behalf of the Association of Independent Research Institutes (AIRI), I wa nted to notify you that
AIRI has awarded Dr. Tony Fauci with its 2020 Public Service Award in recognition of his exemplary
leadership during the novel coronav irus pandemic. The AIRI Public Service Award is the highest honor
awar ded by our organ izat ion and we're very pleased to present th is award to Dr. Fauci. A list of past
awardees can be fo und here .
Please see the official award letter attached and let us know any questions .
Regards,
Nicole Parker, Ph.D.
AIRI Washington Office - lewis-Burke Associates, LLC
440 1st Street NW Suite 700
202-289-7475
Nicole@lewis-burke.com
www.lewis-burke.com
Disclaimer: This message is intended only for the named recipient. If you are not the intended recipient
you are notified that disclosing, copying , distributing or taking any action in reliance on the contents of this
information is strictly prohibited.
Se nt: Wed, 15 Apr 2020 15:57:38 +0000
To: Awwad, David (NIH/NIAID} [C]
Subjec t: Threat assessment 4/14
Attachment s: Total Fauck Up, Re: Finis Covid Opus, Re: Total Fauck Up, Untitled
Sent: Wed, 15 Apr 2020 10:45:28 +0000
To: Birx, Deborah L. EOP/NSC;Troye, Olivia EOP/NSC
Subject: RE: Does G6PD Deficiency Relat e to COVID-19 Infection? I Med Page Today
The issue also comes up when people are on certain drugs.
From: Birx, Deborah L. EOP/NSC

-----------
Sent: Wed nesday, April 15, 2020 6:16 AM
(b)(6)>
To: Troye, Olivia EOP/NSC

(b)(6) --------- (b)( ; Fauci, Anthony (NIH/NIAID) [E)
Subject: Re: Does G6PD Deficiency Relate to COVID-19 Infection? I MedPage Today
This one always comes up when we have differential responses to an infection (bXS) PCP.
- in HIV there are genetic links to better outcomes.
---------
From: "Troye , Nsc" Cb)(6)
Date: Tuesday, April 14, 2020 at 11 :03 PM
To: "Birx, Deborah L. EOP/NSC " ----------~ CbH6J>,"Anth ony Fauci [E]"
(b) (6) > -----------
Subject: Does GGPD Deficiency Relate to COVID-19 Infection? I MedPage Today
Follow up article to some previous emails. Just wanted to send this your way.
https://www.medpagetoday.com/infect iousdisease/covi d19/85929
Olivia Troye
Special Advisor for Homeland Security and Counterterrorism
Office of the Vice President
White House Coronavirus Task Force
Office: (b) (6)
Mobile:
----- (b)(6) (Does not receive texts)
Sent : Wed, 15 Apr 2020 02:32:49 +0000
Cc: Billet, Courtney (NIH/NIA ID) [El;Conrad, Patricia (NIH/NIAID) [El
Subject: RE:ASF - here that proposed op-ed for you and Dr. Birx penned by VP office
Attachments : Birx.Fauci Op-Ed clean - with Fauci tracke d changes.docx
Greg:
Nice job. I have made a few edits that are tracked into the attached document. Please
accept the changes and submit back to them.
Thanks,
Tony
From: Folkers, Greg (NIH/NIAID) (El

-------- (b) ( >
To: Fauci, Anthony (NIH/NIAID) [El ------~~

--------- (b)(6)
Subject: ASF - here that proposed op-ed for you and Dr. Birx penned by VP office
ASF- 5> Please review if/when u have a chance .

CbH
CIea n ------------
vers ion and tracked version.
From: Fauci, Anthony (NIH/NIAID) [El (b) ( >

--------
To : Folkers, Greg (NIH/NIAID) [El ------~= (b)( >
Cc: Billet, Courtney (NIH/NIAID) [El (b)(6J>;Conrad, Patricia (NIH/NIAID) [El
(b)(6)
--------
Subject: RE: ASF/ FW: proposed op-ed for you and Dr. Birx?
(b) (5)
From: Folkers, Greg (NIH/NIAID) [El (b)(6)

To: Fauci, Anthony (NIH/NIAID) [El 4 ------= = CbH 6?i>
Subject: ASF / FW: proposed op-ed for you and Dr. Birx ?
From: Billet, Courtney (NIH/NIAID) [El (b)(6J>

(b) (5)
(b)(6)
From:Miller , Darin B. EOP/OVP
-----------
-------~~
To: Conrad, Patricia (NIH/NIAID) [E] <i
(b)( 6) --------- (b)( ; Billet, Courtney (N IH/ NIAID) [E]
Subject: Courtney, Patric ia - op-ed by Fauci/Birx?
Hi Courtney and Patr icia,

(b) (6). (b) (5)
Thanks!
Darin Mi ller
Deputy Press Secretary
Director of Strategic Communications
(b)(6)
Sent: Wed, 15 Apr 2020 01:44:02 +0000
To : Johnson, Carolyn
Cc: Collins, Francis (NIH/OD) [El
---------------
Courtney (NIH/NIAID) [El ;Conrad, Patricia (NIH/NIAID) [El
Subject: RE:Washington Post
(b)(6JBillet,
Attachments: NIAID COVI0-19Strategic Plan Final lOApril 2020.docx
Carolyn:
Thanks for the note. I understand that you will be hearing from Francis Collins on the Public
Private Partnership (PPP) that we have put together to comb ine the resources and assets of
ind ust ry and the academic commu nity that is largely supported by NIH, particu la rly NIAID in the
context of COBID-19. It is the functional equiva lent of a National Strategy. We at NIAID and to
some extent othe r institutes are leveraging our vast clinical trials networks that we built for
other infectious diseases, particularly, but not exclusive ly HIV/ AIDS, to provide the capacity to
conduct clinic al tr ials (NIH-sponsored as well as industry -sponsored) for both vaccines and
the rapeutics fo r COVID-19. For your interest, I am attaching a copy (not yet released) of the
NIAID Strategic Plan for COVID-19 Research. It is an outline that will be supplemented w it h an
implementation plan.
Best regards,
Tony
From:Johnson, Carolyn <Carolyn.Johnson@washpost.com>

Sent: Tuesday, April 14, 2020 10:23 Arvl
To: Fauci,Anthony (NIH/NIAID) [El------- (b
=-=
)...,
(6)
=>
Subject: Washington Post
Dear Tony,
Is there a national strategy at the task force level to coordinate clinical research efforts nationally? We
have heard lots of complaints that there isn't a national strategy. I talked to Cliff Lane about this, but we
want to give you the chance to respond.
Carolyn
Carolyn Johnson
Washington Post
202-334-6248 (desk)
----- (b)(6) (cell)

Sent : Wed, 15 Apr 2020 0 1:35:53 +0000
Subject : RE:Call w ith VP and Senators on Thursday 4/15
I guess in perso n since I will have to be down t here any way
From: Conrad, Patricia (NIH/NIAID) (E] (b)( >

Sent: Tuesday, Apr il 14, 2020 6:13 PM
To : Fauci, Anthony {NIH/ NIAID) (E] ------~~ (b)(6)
Subje ct: FW: Call w ith VP and Senat ors on Thu rsday 4/15
(b) (5)
From: Edwards , Sara L. EOP/OVP

To: M cGuffee, Tyler Ann A. EOP/OVP
----------
----------~~
(b) (6)>
(b)( ; Good-Cohn, Mered ith

(CM S/OA) (b)(6)>; Shirley.Gathers (b)(6)
.,;_~~...:..!:======~;:----~-
(b)(6); Amerau, Colin C LT USN JSJ4 (USA)
-"'."""':=========~(b)(6) ,;
Conrad, Pat ricia {NIH/NIAID) [E) (b)(6)>; Conrad, Patricia (NIH/ NIAID) [E)
--------- (b)(6)>; Rom, Colin (FDA/OC)

Cc:Lankfo rd, Hannah A. EOP/OVP
(b)(6)>
(b)( >
Subject: Call with VP and Senators on Thursday 4/15
Good afternoon,
Vice President w ill be joining a call with Senate Democrats on Thursday April 16 at 1:00pm. The call will
be routed through the (b)(5) similar to last week 's call. Please have your principal
dial into the (b) (5) at (b) (5) at 5 minutes prior to the start . They w ill be patched into the Vice
President and then together into the Senate calls.
1PM-2PM Senate Demo cratic Caucus

(b) (5l
Pleaseconfirm your principal Thursday4/16

Secretary Steven Mnuchin, Department of the Treasury -by phone
Administrator Seema Verm a, Center for Medicare and Medicaid Services {CMS) - by
phone
Dr. Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases - by phone
Dr. Stephen Hahn, Commissioner of Food and Drugs, Food and Drug Administration -by phone
Rear Admiral John Polowczyk, Vice Director for Logistics, J4 - by phone
Ambassador Debbie Birx, M.D ., White House Coronavirus Response Coordinator - in-person
Thank you,
Sara Edwards
From: (b)(6)
Sent : Tue, 14 Apr 2020 13:55:46 -0400
To: Lerner, Andrea (NIH/NIAID) [E)
Subject: Fwd: Dr. Fauci- FROMNBC4
Attachments : image001.png , ATTOOOOl.htm, manuscript final draft revised.pdf,
ATT00002.htm
Please check this out and respond as appropriate.
From: Melissa Moll et (b) < >

To: _____ (b)(6) , "Fauci, Anthony
(NIH/NIAID) [E]" "Fauci, Anthony (NIH/NIAID) [E]"
(b)(6) ,
(bH6) >, "Fauci, Anthony (NIH/NIAID) [E]"
'---~~
(b) (6) , Melissa Mollet (b) (6) "Mollet,
--------
Melissa (NBCUnive rsal, WRC)" <Melissa .Mollet @nbcuni.com> , Jeremy Schu lman
<jsch ulman @schulmanbh.com >
Subject: Dr. Fauci - FROM NBC4
Hello Dr. Fauci,

This is Melissa Mollet, reporter with NBC4 in Washington. I hope you are well -
and safe - and are hanging in there during this unprecedented time. You have been
doing an incredible job.
I know you 're ge ttin g a million emails, so my apo logies in advance. I really th ink
this information (attached and below) could help and I feel a re spon sibility to pass it
along .
There is an extremely promising COVID-19 therapy being used right now in Italy.
The creator is a client o (b) (6) Bethesda law firm. The managing member
of that firm, Jeremy Schulman, is CC'd on this e-mail. The creator is willing to work
with the NIH to quickly bring his therapy to the U.S.
Please reach out with any questions at all.
Best-
Melissa Molle t
NBC Washington
400 1 Nebraska Avenue NW
Washington, D.C. 20016
----- (b)(6) (Cellular)
Get Outlook for iOS
From: Jake Schaller <jschaller@schulmanbh.com>
Sent: Monday, April13, 2020 5:36 PM
To : Mollet, Me lissa {NBCUniversal, WRC)
Subject : [EXTERNAL]Therapy for COVID-19; Results of Trial in Italy
Melissa,
I wanted to expand a bit on the COVID-19 therapy I mentioned and provide some
information about the man who is developing it . Hoping that you can get this into the right
hands, as it seems like a very promising lead in this fight .
The therapy, invented by Professor Claudio De Simone, has shown extremely encouraging
results in a preliminary trial at the Infectious Diseases Clinic of the University "La Sapienza"
in Rome, Italy . Professor De Simone convinced the doctors there to start a trial on patients
affected by COVID-19. Considering the excellent results obtained, the number of patients
enrolled is increasing day after day. Our firm became aware of these results directly from
Professor De Simone, who has been a client of our managing partner, Jeremy Schulman,
since 2015.
The formulation employed in these patients at the La Sapienza Infectious Diseases Clinic is
manufactured in France and known as "SIVOMIXX." The product is a specialized blend of
eight different freeze-dried bacteria with considerable ant iviral and anti-inflammatory
activity. Patients admitted to the clinic at La Sapienza, presenting as positive for COVID-19
and with the typical symptoms of the disease, are being treated by oral bacteriotherapy
utilizing SIVOMIXX. In each case, SIVOMIXX administration was followed by a dramatic
improvement in their conditions. The key takeaways are that use of SIVOMIXX correlated
with fewer deaths (zero in the treated group), fewer patients transferred to the ICU, and a
dramatically reduced risk of patient intubations . The sponsors of the trial using SIVOMIXX
are now beginning to enroll patients with severe cases who have been admitted to the ICU.
Attached to this email is a confidential dossier about the SIVOMIXX product and a
summary of the ongoing study. Upon request, I am also able to send you an Excel file
containing the raw data from the study, so NIH can review them, with the understanding
that this should be treated as "highly confidential." Since the clinical tria l is continuing in
Italy, we expect to have results covering additional patients on a rolling basis. The
researchers conducting the study intend to publish their results in the coming weeks.
However, considering the pandemic and the lack of effective treatment options, we want
to make NIH aware of Professor De Simone's therapy without any delay.
SIVOMIXX is a relatively new formulation developed by Professor De Simone, currently in

limited commercial production at a manufacturing facility in France. Professor De Simone
has sufficient supply available to utilize with 100-150 COVID-19 patients immediately.
Professor De Simone could, on his own, arrange a small-scale supply to use with hundreds
of additional patients in the United States. He is willing to provide his current inventory of
the product to the United States government. He expects that the Trump administration
could quickly confirm the efficacy of SIVOMIXX to significantly improve symptoms of
COVID-19 and reduce the duration of patient hospital stays. After that , Professor De
Simone is willing to collaborate with the administration to bring a large-scale production of
SIVOMIXX for use throughout the United States, Italy (where he was born), and
Switzerland (where he lives). Professor De Simone already has ongoing partnerships with a
number of manufacturing companies, including one in the United States, for the
production of another one of his produc ts (Visbiome, referenced below). With appropr iate
guidance and instruction from the Trump administration, we believe the U.S.
manufacturing companies could re-tool to produce SIVOMIXX on a large scale within
several weeks .
Professor De Simone (more information about him below) and Jere my will do whatever it
takes to bring this critical therapy to as many Americans as possible on an urgent basis.
Jeremy can be reached at anytime on his cell phone - (b)(6)
Thanks so much for passing this on.
Best,
Jake
About Professor De Simone. Professor De Simone is a world-renowned expert in

gastroenterology and the inventor of several highly successful probiotic medical foods.
Until 2010, he was an Associate Professor for the Infectious Diseases Group at the
Department of Medicine and Surgery of the University of L'Aquila, Italy. Subsequently, he
was appointed Head of the Infectious Disease Department and Director of the AIDS
Coordinat ion Group of the Abruzzi region, Italy. He is currently a retired Professor of
Internal Medicine, still collaborating with the University, and a Fellow of the American
Gastroenterology Association . Professor De Simone's research specialt ies have been in the
fields of immuno -pathogenesis of infectious diseases. He has published the results of his
research activities in over 200 scientific articles, reviews, case reports, and book chapt ers.
Professor De Simone is both a researcher and a medical practitioner. He tests his
laboratory hypotheses in the university hospital clinic on patients w ith serious diseases. He
was responsible for controlling the AIDS pandemic in Italy's Abruzzi region in the 1990's.
Products developed according to Professor De Simone's know-how have shown positive

results in patients with serious diseases. One of his signature formulations , known as the
"De Simone Formulation," is now sold in the United States as "Vi sbiome ." The De Simone
Formulation has been the subject of more than 70 published huma n clinical trials
demonstrating its efficacy in managing severe gastrointestinal symptoms from such
diseases as ulcerative colit is, pouchitis, and liver diseases. Concerning pouchitis, the De
Simone Formulation is recognized by the world's professional gastroenterology societies as
a "standard of care," an achievement that no other probiotic substance previously has
attained. The De Simone Formulation became the "gold standard" in its therapeu ti c class.
Its role in patient care has been endorsed in the guidelines published by the American
Gastroenterology Association ("AGA"), the European Crohn's and Colitis Organization
("ECCO" ), and the British Society of Gastroenterology, as well as in t he New England
Journal of Medicine .
SCHULMAN
BHATTACHARYA
James "Jake" Schaller
Attorney
j schaller@schulmanbh.com
www.SchulmanBH.com
Direct: (240) 356-9508

Cell: Cb>(6)
Main Office:
The Clark Building

7500 Old Georgetown Road , Suite 901
Receptioni st: (240) 356-8550
Fax: (240) 356-8558
Bio-Tech Corridor Office:
The GSK Building

14200 Shady Grove Road , Suite 600
Rockville, Maryland 20850
The informa tion contained in this electronic message and any attached documents
may be privileged, confident ial, and protected from disclosure . If you are not the
intended recipient, please note that any review, disclosure, copying, distribution, or
use of the contents of this electronic message or any attached documents is
prohibited. If you have received this communication in error, please destroy it and
notify us immediately by telephone (240-356-8550 ) or by electronic mail to the
sender of this email. Thank you.
Internal Revenue Service Circular 230 Di sclosure: Schulman Bhattacharya , LLC

does not provide tax advic e. In comp liance with IRS requir ement s, you are on
notice that any adv ice contained in th is communication (including any attachments)
is not intended or written to be used, and cannot be used, for the purpose of (i)
avoiding penalties under the Internal Revenue Code or (ii) promoting, marketing or
recommending to another party, for tax purposes, any transaction or matter
addressed herein.
Sent : Tue, 14 Apr 202016:15:32 +0000
Cc: Barasch,Kimberly (NIH/NIAID) [C]
Subject: FW: Mike Milken new Podcast Series: COVID-19- will you join me as my guest?
All the best, Mike
What do you think? Let us discuss.
From: Michael Milken (mmilken@knowledgeu.com) <mmilken@knowledgeu.com>

To: Fauci,Anthony (NIH/NIAID) (E]------ ~~ (b)(6)>
Cc:Billie Griffin (bgriffin@knowledgeu.com) <bgriffin@knowledgeu.com>; Katie Dinsmore
(kdinsmore@knowledgeu.com) <kdinsmore@knowledgeu.com>
Subject: Mike Milken new PodcastSeries:COVID-19- will you join me as my guest? All the best, Mike
Dear Tony , I hope this email finds you well. I wanted to see if you had a few minutes to talk
over the next few weeks. I recently began hosting a daily podcast that focuses on the COVID-19
pandemic and responses from thought leaders across industries - I would like for you to join
me as my guest. I have also reached out to Hugh Auchincloss as well but still waiting to hear.
Our guests so far include Francis Collins, Alex Gorsky, David Baltimore(Nobe/ Laureate}, Jim
Allison(Nobe/ Laureate)/Pam Sharma, Jo Ann Jenkins, Eric Schmidt, Rod Hochman, Carmine Di
Sibio, Arie Belldegrun, Peggy Hamburg, Rodney McMullen, Bruce Broussard, Vas Narasimhan ,
Joe Tsai, Steve Ballmer, Jeff Skoll, Sue Desmond-Hellmann, Rob Manfred, Judy Faulkner, Bob
Bradway, Tai Zaks, Ray Dalio, David Solomon, Barbara Humpton, Dr. Steven Rosenberg, Dr.
Richard Stone, Dr. Kurt Newman, Vivek Ramaswamy, Francis deSouza
I record the interviews on Mondays, Wednesdays-Fridays start ing at 7:30 a.m. Pacific/10 :30
a.m. Eastern. Each episode will last 10-20 minutes . Our team would get you set-up to join
remotely by phone.
Th e inte rvi ews are available on the Milken Inst itute website as well as on Spotify and Apple
Pod casts .. I opened up the series with Francis Collins a few weeks ago, click here to have a
list en.
If you're interested in joining me, my team (copied) will circle back to you with another email
detailing the subject matter and technical informat ion.
Please stay safe & healthy.
All the best,

Mike
From: (b)(6)
Sent: Tue, 14 Apr 202010 :32:21-0 400
To: Tengiz Tsertsvadze
Subject: Re: US-Georgia biomedical collaboration
Tengiz:
Thank you for your kind note . I am pleased to see that Georgia has controlled the outbreak
very well. Stay well.
Best regards,
Tony
On Apr 14, 2020 , at 10:24 AM, Tengiz Tsertsvadze (b)(6)

,>wrote:
--------
Dear Dr. Fauci,
I am writing this letter on behalf of the community of infectious diseases specialists

of Georgia to express our deepest respect to you. I recall with great pleasure all our
previous meetings, espec ially the last one in 2017 , when 1, together with my team
members , had an opportunity to visit you at NIH.
We are grateful to you and your team for the most important contribution to
establishing US-Georgia biomedical collaboration that significantly increased our
country's research and practical capacities. Your personal role in combat ing HIV
and other emerging epidemics such as SARS , MERS , Zika, Ebola, canno t be
overestimated. I am confident that your leading role in this fight against COVID-19
will be crucial for defeating the pandemic not only in the United States, but around
the globe.
We close ly follow your briefings and interviews on COVID-19 (including recent

very interesting convers ation with Dr. Howard Bauchner at JAMA) and as always
your views are very apt and to the point. We fully agree that the approaches you
suggest are the mos t effective way to defeat the pandemic. Most importantly your
recomme ndations are applicable not only to the United States, but to other countries
as well and we eagerly take them into considerati on while planning our strategies
here in my country of Georgia .
I would like to use this opportunity to upd ate you on COVID-19 situation in my
home countty of Georgia : The country quickly responded to this threat fu st by
stopping flights with China in January, followed by more strict measures after the
first case was diagnosed on February 26. These measures included national
lockdown , active contact tracing, isolation and quarantine . The Government of
Georgia appointed me to lead the Nat ional Committee on the clin ical management
of COVI D- 19. Our effort to contain the spread of the virus had been effective so far
with 296 cases of COVID-19 and 3 lethal cases reported up to now .
We are impatiently awaiting results of vaccine and therapeutic trials supported by

NIAJD, which I am confident will help to defeat this pandemic disease . On our side,
Georgia is committed to make its modest but important contrib ution to the global
efforts.
Sincerely,
Tengiz Tsertsvadze , MD, PhD

Director General , Infectious Diseases, AIDS and Clin ical Immunology Research
Center
Professor of Medicine , I vane Javakhishvili Tbilisi State University
<photo.jpg >
Sent : Tue, 14 Apr 2020 03:29:04 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Covid- 19 logical treatment strategy based on patient's immunological
response
Attachments: MEDRXIV-2020-058420v1-Gali Filho.pdf
From:Julio Gali (b)(6)

To: Fauci, Anthony (NIH/NIAID) [E]-------= (b-:-
)(=6)
Subject: Covid-19 logical treatment strategy based on patient's immunological response
Good afternoon Dr. Anthony Fauci.
After reading a lot of papers and studying basic science we have elaborated a treatment
approach to the disease.
(b)(4)
(b) (4)
Julio C. Gali Filho, MD

Research and Development, JJMED,Sorocaba, SP, Brazil
(b)(6)
(b)(6)
Julio C. Gali , MD , PhD

Department of Orthopaedics
Faculty of Medical Science and Health
Catholic Un iversity of Sao Paulo
Sorocaba/SP- Brazil
(b)(6)
(b)(6)
Sent : Tue, 14 Apr 2020 02:13:45 +0000
To : Hiatt, Fred
Subject : RE:fred checking in
Fred:
Thank you for you kind note. Am glad to hear that Joe is working on COVID-19. We need all
the brightest minds we can get on th is problem. Stay safe and well.
Best regards
Tony
From: Hiatt, Fred <fred .hiatt@washpost .com>

---------=-:-=
---------
Subject: fred checking in
Tony,
I haven't wanted to bother you, but wanted to say thanks for all you are doing, and hope you are at least
to a small extent finding a way to take care of yourself .
H is hard at work at (b)(6)on a couple of coronavirus projects, so we're counting on him.
Of course any time you want to write something, our page is available .
Warmly,
Fred
Sent: Tue, 14 Apr 2020 02:03:49 +0000
To: Glass, Roger (NIH/FIC) [El
Cc: Kilmarx, Peter (NIH/FIC) [E];Redfield, Robert R. (CDC/OD);Birx, Deborah L.
EOP/NSC
Subject : RE:Support for a "U.S. COVID-19 Response Corps"
Great idea!!
From: Glass, Roger (NIH/Fie) (E]

------- (b) (6)>
To : Fauci, Anthony (NIH/NIAID) (E] ------ --~

(b)(6)
,_;_:....;;.=:::===,~~"""."".".'~
Cc: Glass, Roger (NIH/FIC) [El______ Cb
_~_
< >; Kilmarx, Peter (NIH/Fl() [E]
(b) (6) >
Subject: Support for a "U.S. COVID-19 Response Corps"
Hi Tony,
Greet ings from

--------------------- (b)(6)
It's been good to see all the calls for ramping up a public health workforce to manage contact tracing
and other aspects of the second phase of the response. I wanted to let you know that Peter Kilmarx has
been calling for the formation of a "U.S. COVID-19 Response Corps" since March 21 (unrelated to NIH
work). FEMA could hire thousands of tempo rary workers quickly with existing authorities and funding.
CDCcou ld provide training and technical assistance. The workforce would be deployed to and managed
by state and local health departments at their request. There's a lot of enthusiasm for this from Jeff
Duchin in Seattle, to Tom Frieden, CSIS, ASTHO, and 40 mem bers of Congress (bicameral, bipartisa n)
who sent a letter to FEMA asking them to do this. The 7,000+ recently evacuated Peace Corps
volunteers could be one recruiting source. Anoth er approach is for CDCto fund state and local
authorities for those who are able to hire at this speed and scale. There's more information in the string
below.
This workforce issue is now sucha critical part of the response, I wanted to share with you what
we've learned and offer to help in any way.
Tony, all of NIH is so proud of your leadership and rooting for you to get this outbreak under con trol.
Please keep up fight and let us know if and how we can help.
Warm w ishes,
Roger
From: Kilmarx, Peter {NIH/FIC) [E]

To: 'Conover, Craig' (b)(6) 'Angela Dunn' (b)(6)'Cindy
Burnett'
------- (b)(6J>; 'Duchin, Jeff'
---------- (b)(6Ji>;'Stephen Morrison'
(b)(6)l>; 'John Monahan '! (b)(6)j>; 'Charles Holm es'
(b)(~>; 'Jeremy Konyndyk I (b)(~'
(b)(<>~>; 'Rebecca Katz'( (b)(6)j;'Tom Inglesby'
(b)(6)]>;'Glenn Blumhorst' I (b) <6>t>; Glass, Roger (NIH/FIC) [El
(b)(6)j>;'Marcus Plescia'I (b)(6>;>; 'Vanessa Kerry'
(b)(6)Jg>; 'Kenyon, Thomas' (b)(6)j>; 'Anna Carro 11'
(b)(6)l>; 'Scott Dowell' ! (b)(6l>; 'Jonathan Pearson'
(b) (6));'suzannemarks@me.com ' (b)(6)j>; 'O'Connor,
Eileen' ! (b)(6)]>;'Myers, Michael' ! (b)(6)]>;'Robyn n Leidig'
(b)(6)j>; 'Ariel Pablos'I (b)(~; 'Gavin Varney'
(b) (6)J>; 'Jody Olsen' I (b) <6 ~>; Bialy, Kevin ( NIH/FIC) [E]
r (bH6)j>;'John Auerbach ' .r- (bT(lih; Brooks, John T.
(CDC/00I0/NCHHSTP/DHPSE)I (bH6>i>;'Dara Lieberman ' ! (b)( 6)>; David
Gittelman I (b)(li);>
Subje ct: RE: COVID-19 Response Corps
Hi all,
Updates:
1. Johns Hopkins and ASTHO released "A National Plan to Enable Comprehensive COVID-19 Case
Finding and Contact Tracing in the U.S." calling for 100,000 contact tracers . (Kudos!) "Potential
11
workforce recruits may include ... Peace Corps members.
http://www.centerforhealthsecurity.org/our-work/pubs archive/pubs-pdfs/2020/a-national-
pla n-to-enable-comprehens ive-COVI0-19-case-fi nd ing-a nd-contact-tracing-i n-the-US. pdf
2. WaPo article : "A plan to defeat coronavirus finally emerges, but it's not from the White House"
covers the JHU/ASTHO plan and notes: "Experts [CSIS]have proposed transforming the Peace
Corps into a nat ional response corps that could perform many tasks, including contact t racing."
(Not quite accurate. Peace Corps would be unchanged, but the evacuated volunteers would be
hired into COVI0-19 response.j
3. NY Times editorial from Tom Frieden calls for a "giant public health effort ." "Recruits could
include Peace Corps volunteers who were brought home when the pandemic spread."
https:l/www.nytimes.com/2020/04/12/opinion/cdc-coronavirus.html
4. Bill introduced by Sens. Susan Collins (R-ME), Chris Murphy (D-CT) and Dianne Feinstein (D-CA)
would require federal agencies and departments facing special hiring needs during the
pandemic to establish a process to expedite hiring of returned Peace Corps volunteers
https ://riponadva n ce.com/stories/ col Iins-bi partisa n-bill-wou ld-e nsu re-benefi ts-for-evacuated-
peace-corps-vol unteers/
5. From March 29: Policy report from former FDA Commissioners Scott Gottlieb and Mark
McClellan calls for "massively" scaling contact tracing. "Surge the existing public-health
workforce to conduct case finding and contact tracing." https;//www.aei.org/research-
products/report/na t ional-coronavirus-response-a-road -map -to-reopening/
6. Mark McClellan responded to my email yesterday: "I'd suggest adding outreach to mayors and
county execs if that hasn't happened yet. They are really on the front lines for this next phase."
7. I understand legislation is in the works, but don't have details.
8. No news from FEMA or indicat ion to my knowledge that they are planning a substantial ramping
up of staffing.
9. A key limitation on the impact of contact tracing will be the relative importance of
asymptomatic spread.
10. A note on serology: The current U.S. cumulative incidence is 0.169%. The specificity of FDA EUA
Cellex test is 95.6%. Not accounting for undiagnosed cases, Positive Predictive Value is only
3.5%. If underdiagnosis is 10:1, the PPVis sti ll only 26.8%. Will be higher in higher-risk
individuals, of course.
Any other updates please send to me.
Advocacy needed for scaling up public hea lth work fo rce especially wit h governors and mayors.
PK
From: Kilmarx, Peter (NIH/FIC) [E)

To : 'Conover, Craig' ( (b)(6J;>;'Angela Dunn' ! (b) (6)\;'Cindy
Burnett' ( (b) C6Ji>; 'Duch in, Jeff (b)(6),>;'Stephen Mor rison'
(b)(6);>; 'John Monahan '( (b)(6)]>; 'Charles Holm es'
Cb)(6)};'Jeremy Konyndyk r (b)(6)j)'
CbH6)j>;'Rebecca Katz'I CbH6)};'Tom Inglesby'
(b)(6)1>; 'Glenn Blumhorst' I (b)(6):>; Glass, Roger (NIH/FIC) [E]
(b)(6Ji;'Marcus Plescia'I (b)(6)t>; 'Vanessa Kerry'
(b)(6)1>; 'Kenyon , Thomas' ! (b)(6)};'Anna Carrol I'
(b)(6)J>; 'Scott Dowel l'r (b)(6)j;'Jonathan Pearson'
(b) (6)1>; 'suzannemarks@me.com ' (b) (6)]>; 'O'Connor,
(b)(6)}>; 'Myers , Michael' r (b)(6) 1>; 'Robynn Leidig'
(b)(6)h; 'Ariel Pablos'f (b)(6)}; 'Gavin Varney'
(b)(6)j >; 'Jody Olsen' I (b)(6)1>; Bialy, Kevin (NIH/FIC) [E]
CbH6)};'John Auerbach' I (b) (6Jf;Brooks, John T.
(CDC/OO1O/NCHHSTP/DHPSE )I (b)(~; 'Dara Lieberman ' ( (b)(6)j>
Subject: RE: COVID-19 Response Corps
+ John Auerbach, president and CEOofTrust for America's Health
Thanks all for the robust discussion. Some updates:

1. ASTHOsent the attached memo t o Congress today RE: Contact Tracing Workforce calling for
"flexible long term and emergency supplemental funding to expand the .. . contact t racing
workforce" at state, local, and related levels. It recommends against using FEMA for hiring.
ASTHOnotes tha t currently there are only 2,200 DIS nationw ide while JHU estimates that
100,000 contact tracing employees are needed to address COVID-19 in the immediate future.
The memo mainly calls for 1) $3.6 B emergency funding through the CDCCrisis Cooperative
Agreement to eligible jurisdictions, plus 2) a $4.5 B annual Public Health Infrastructure Fund.
2. Resolve to Save Lives (Tom Frieden) is advocating for CDCto have the needed authority and
political support to provide tra ining, systems, and technical expertise, while the CDC Foundation
and ASTHO provide staffing through direct assistance to health departments .
3. CDCcould support cur riculum development and training through the National Network of STD
Clinical Prevention Training Centers https://nnptc .org/ and/or TB Centers of Excellence
https://www.cdc.gov/tb/ education/tb coe/defau lt .htm
My take: We share the goal of rapid ly and substantially ramping up the public health workforce and
should emphasize that message. It would be very challenging for any of these potential approaches to
reach 100,000 in the short term. I don't have any special allegiance to FEMA, but their traditional role in
emergency response is quickly hiring many thousands of workers. They are hiring now, but not at this
speed and scale. CDC and FEMA should have an MOU through which FEMA can hire staff and detail to
CDC, bu t they don't seem to be pursuing. One model could be FEMA detailing staff to state and local
authorities to manage the hiring process. FEMA is proud of their ability to get people from "door to
desk" in one week . This would not be "federalizing" contact tracing or other public health activities. In
all cases, the invitations and the oversight wou ld come from the state and local authorities, who are
best able to decide what mechan ism(s) work for them. Lastly, this concept includes more than contact
tr acing. Congresswoman Susan Brooks (R-IN) in her podcast Wednesday noted that the state 211 call
line has gone from 2,000 to 25,000-35,000 calls per day. So this concept would still have a role even if
not direct public health functions .
Thanks,
PK
From: Kilmarx, Peter (NIH/FIC) [E]

To: Conover, Craig <f (b)(6J,>; Angela Dunn <f (b) (6));Cindy Burnett
CbH6)]>;Duchin, Jeff Cb)(6))>;Stephen Morrison
CbH6))>; John Monahan ( (b)(6)j_>;Charles Holm es
(b) (6)}>; Jeremy Konyndyk I (b) (6)))
(b)(6)];Rebecca KatzI (b)(6)1>; Tom Ingles by
CbH6))>;Glenn Blumhors t l CbH >; Glass, Roger (NIH/FIC) [E)
6>i
CbH (i)J>;Marcus Plescia 6)j>;Vanessa Kerry
CbH
CbH6))>; Kenyon, Thomas [ CbH6)); Anna Carroll
(b)(<>Jt>; Scott Dowell ! CbH6l>;Jonathan Pearson
(b)(6)j;[ Cb)(6));O'Connor, Eileen
Cb)(6)]>; Myers, Michael (b)(~>; Robynn Leidig
CbH6))>; Ariel Pablosr CbH6))>;Gavin Yamey
(b)(6)]>; Jody Olsen! CbH6))>;Bialy, Kevin (NIH/FIC) [E
(b) (6)]>
Subject: COVID-19 Response Corps - CDCcalling for public health army
Thanks Craig. This NEJM articl e is main ly about heath care workers, but does mention ot her roles in
social support.
Important development : CDC's Bob Redfield is calling for a publ ic health army for contact tracing after
this acute phase:
https://www.npr.org/sections/health-shots/2020/04/10/831200054/cdc-director-very-aggressive-
contact-tracing -needed-for -u-s-to-return-to -normal
It turns out that the Centers for Disease Control and Prevention has been working on a plan to allow the
U.S. to safely begin to scale back those policies . CDCDirector Robert Redfield spoke with NPR on
Thursday, saying that the plan relies on not only ramped -up testing but "very aggressive" contact tracing
of those who do test positive for the corona virus, and a maj or scale-up of per sonnel to do the necess ary
work.
I'm not sure CDChas the authority, capacity, or politica l support to hire an army at this t ime . This is a
t radit ional FEMA role. CDC can prov ide train ing and tec hnical assistance .
PK
From : Conover, Craig_________ Cb

_H_6)
To: Kilmarx , Peter (NIH/FIC) [E]1 (b)(6),>; Angela Dunn 1 (b)(ij >; Cindy
Burnett ( CbH6)]>; Duch in , Jeff I Cb)<~ >; Stephen Mo rrison
CbH6) 1>; John Monaha n <Jr Cb)(6)]; Charles Holmes
(b)(6)J; Jeremy Konyndyk I (b)(6>:)
(b)(6)]; Rebecca KatzI (b)(6)1>; Tom lnglesby
(b)(6)]; Glenn Blumhors tl (b)(6)]>; Glass, Roger {NIH/Fl C) [El
CbH6)];Marcus Plescia( (b)(6)j>; Vanessa Kerry
Cb)(6)]>; Kenyon, Thoma s! CbH6)]>; Anna Carroll
Cb)(6)]; Scott Dowell (b)(6)]>; Jonathan Pearson
CbH6)]O'Connor, Eileen
(b)(6)J>; Myers, Michae l I CbH6l>; Robynn Leidig
Cb)(6)1>; Ariel Pablos r CbH6)]>; Gavin Yamey
(b)(6)]
Subject: NEJM- ensuring and sustai ning a pandemic workforce
attached
Fro m: Kilmarx , Peter (NIH/FIC) [E]_______ Cb

_H_6)>
Sent : Wed nesday, April 8, 2020 5:53 PM
To: Conover, Craig( (b)(6), ; Angela Dunn I 6)]; Cindy Burnett
Cb)C
CbH6)]>; Duchin, Jeff ( (b)(6)>; Stephen Morrison
(b)(6)]>; John Monaha n( (b)(6))>; Charles Holmes
Cb)(6)1>; Jeremy Konyndyk r (b) (6)])
(b) (~ >; Rebecca KatzI (b)( 6)1>; Tom lnglesby
(b)(6)1>; Glenn Blumhors tl (b)(~ >; Glass, Roger (NIH/FIC) [El
(b)(6)]>; Marcus Plescia! (b) (6)]>; Vanessa Kerry
CbH6)]>; Kenyon, Thomas ! CbH6)]>; Anna Carroll
(b) (6h ; Scott Dowell CbH6>:>; Jonathan Pearson
(b)(6)j O'Connor,
Eileen( Cb)(6)]; Mye rs, M ichael I CbH6)]>; Robynn Leidig
CbH6)]>; Ariel Pablosl CbH6)]>; Gavin Yamey
(b) (6)1>
Subject : [Extern al] RE: UPDATE:COVI0-19 Response Corps
Welcome Marcus Plescia, chief med ical officer of ASTHO!
Updates:
1. CSISpodcast "Coronavirus Crisis Update" with Congresswoman Susan Brooks (R-IN). She
cosigned the CSISOpEd with Ami Bera on the CRCand opens the episode with a discussion of
engaging the returned Peace Corps volunteers httos://www.csis.org/oodcasts/take-
directed/coronavirus-crisis-update-hunker-down-hoosiers -congresswoman-susan-brooks (This is
a great series by the way.)
2. On Mar 27, 2020, Congressman Mike Quigley (D-IL-05) introduced the Mobilizing America to
Help Act, "which would direct President Trump to invoke his existing authority to detail Peace
Corps vo lunteers who have returned to the US from their posts, to the Federal Emergency
Management Agency (FEMA) to support emergency relief in the wake of COVID-19."
https:l/guigley.house.gov/media-center/press-releases/guigley-urges-trump-assign-peace-
corps-volunteers-covid-19-emergency
3. Baltimore Sun column DAN RODRICKS,APR 03, 2020, "Put Peace Corps volunteers to work on
U.S. soil to fight COVID-19": https://www.baltimoresun.com/op inion/co lumnists/dan-
rodricks/bs-md-rodricks-0405-20200403-viqbgjhwsnhe3fuqzy72nfcsoe-story.html
4. Good conversations w ith Marcus @ASTHOand others today. Important to emphasize that state
and local authorities have the lead. This would not be "federaliz ing" the response. It would be
making federal employees available by request to integ rate in state- and local-led activities.
Some will welcome the extra hands. Some will prefer to have funding to do their own hiring.
Paying salaries of state employees at risk for furlough to work on COVID-19 w ill make a lot of
sense, but won't be enough. Need a menu of options .
5. Many concepts and plans for public health and social response are being circulated. All of them
will need an expanded workforce.
Outreach:
6. I'm in touch with someone in Adam Boehler's office . Other outreach welcome.
7. I emailed Peggy Hamburg. No reply yet. Other outreach welcome.
8. Anyone who can contact Scott Gottlieb?
9. Here again is Monday's list: NGA and individual governors. Republicans who will be most
interested and helpful are Baker {MA),DeWine (OH) and Hogan (MD). Democrats: Cuomo,
Pritzker, Newsom, Wh itmer, lnslee. AMA, ASTHO (done), APHA all good potential champions
Please amplify these links on social media.
Other updates and suggestions welcome as always. Send to me and I can send to others in a digest to
reduce email traffic.
Thanks,
PK

To: 'Conover, Craig'< (b)(6)>; 'Angela Dunn' (b)(6) 'Cindy
Burnett' (b)(6)>; 'Duchin, Jeff (b)( >; Stephen Morrison
----==~~;--:-:---:----
(b)(6J_>; 'John Monahan'
----========~~:-" (b)(6J t>; 'Charles Holmes'
=======~~-:--~-
---======~~----:- _.!:=========~~-
(b)(6b; 'Jeremy Konyndyk
(b)( 6), ; 'Rebecca Katz' (b)(6);
'
(b)(6)'
'Tom lnglesby'
------- (b)(6)>; 'Glenn Blumhorst' (b)(6J>; Glass, Roger (NIH/FIC) (E]

(b)(6) 1>; 'Vanessa Kerry' (b)(6) · 'Kenyon, Thomas '
...:=========-.;....,:-:--:-= ""---:-:-:--.:=======:~;-'.":'"""'
(b)(6); 'Anna Carroll' (b)( >; 'Scott Dowell'
CbH6)>; 'Jonathan Pearson' CbH6)>;
(b)(6) ---~:-:":""-:.========...;_
CbH6); 'O'Connor, Eileen'
-=-,-=
----~~-===:!.=====:=~~""".""- _...:_
__ ..!:::=====:=.~~-- (b)(6)
'Myers, Michael'
PabIos'
'Robynn Leidig' (b)(6)>;
(b)(6)>; 'Gavin Varney'
_:..__.....:::..::=~~-------
>; 'Ariel
(b)( >
(b)(
Subject: UPDATE: COVID-19 Response Corps - FEMA challenges
Here's a report about a challenge I didn't see until this morning. I don't know if grants to state and local
authorities would be quicker than federal hiring by FEMA. Either way, the workforce is needed, but will
take longer than one would like.
https://www.nytimes.com/2020/04/03/climate/fema-staff-s hortage -coronavirus.html

FEMA, Racing to Provide Virus Reliet Is Running Short on Front-Line Staff
WASHINGTON- The Federal Emergency Management Agency, the office leading the federal
government's coronavirus response nationwide, is running short of employees who are trained in some
of its most important front -line jobs, according to interviews with current and former officials.
At the same time, the agency has been forced to halt a major hiring initiative, and has closed training
facilities to avoid spreading the infection.
The number of available personnel who are qualified to lead field operations has fallen to 19 from 44 in
less than six weeks, and staff members have been pulled from responding to other disasters, but training
centers in Maryland and Alabama have been shuttered until mid-May . In addition, an effort to recruit
new employees called "Harness" is on hold, according to a senior administration official with direct
knowledge of FEMA's operations . ...
Craig Fugate, who ran the agency during the Obama administration, said FEMA's ability to deploy
enough people was a significant challenge. "Can it be done? Yeah," Mr. Fugate said. "Will it be pretty?
No."

To : Conover, Craig (b)(6) ,>; Angela Dunn (b)(6)>; Cindy Burnett
____ ;___; ~~~-:--""".""'"'::-:-====~.....:::.......
_ __,~~--:--""""'.""~"":"'""-
(b)(6); Duchin, Jeff (b)(6); Stephen Morrison
=====~~:;--"
(b)(6)>; John Monahan --:;:::::::=========~~ = Charles Holmes
(b)(6);
(b)(6) >; Jeremy Konyndyk (b)(6)
...:========-~~-=--:---(b)( >; Rebecca Katz (b)(6) Tom lnglesby
=====~~-':""".""'
===== =) ~(6)~ >,;,; Glenn Blumhors t
(b
--!============:~~ Cb)( ; Glass, Roger (NIH/FIC) [E)
(b)(6); Vanessa Kerry (b)(6)>; Kenyon, Thomas
:'.i========~~ (b)( 6) >; Anna Carroll ----:-:.:::::=======:~;---
(b)( >; Scott Dowell
Cb)(6)>; Jonathan Pearson (b)(6)
...:::======~~;-:-:-:---
(b)(6) O'Connor, Eileen (b)(6)>; Myers, Michael
========~ :==========::,_;,.
~ Ariel Pablos
_______
=====~~
(b)( >; Robynn Leidig
........
_, Gavin Varney
(b)(6)>; (b)(
(b)(6)
Subject: NEWS: Bera-Brooks OpEd published in support of COVID-19 Response Corps

Welcome Vanessa Kerry!
Welcome Ariel Pablos-Mendez!
Welcome Gavin Yamey!
Hi all,
1. The OpEd is out on the CSISwebsite: https://www.csis.org/analysis/covid-19-response-corps-
can-help -stop-pandemic It is co-authored by Congresswoman Susan Brooks (R-IN) and
Congressman Ami Bera (D-CA), members of the CSISCommission on Strengthening America's
Health Security. Thanks very much to Steve Morrison for making this happen.
2. Here's the link to the press release on the 40-member letter to FEMA, Peace Corps, and CNCS
from Senator Van Hollen:
a. https ://www. vanhol len .senate.gov /news/press-releases/ sen-van-hol len-rep-ph ill ips-
1ead-bi pa rti san-bicam era1-1
etters- in-su pp ort-of-pea ce-co rps-am eri co rps-volunteers
b. Includes link to letter:
vanhollen.senate.gov/imo/media/doc/Peace%20Corps%20covid19%20service%20oppor
tunties%201etter%2004.02.20.pdf
Wi th this new, bipart isan OpEd, it's time to reach out to national, state and local author iti es and
opinion leaders to encourage implem entati on and create demand. Suggestions from one of us: NGA
and individual governors. Republicans who will be most interested and helpful are Baker (MA), DeWine
(OH) and Hogan (MD). Democrats: Cuomo, Pritzker, Newsom, Wh itmer , lnslee . AMA, ASTHO, APHA all
good potential champions .
Please also amplify on socia l media.
Updates and suggestions welcome as always.
PK
From: Kilmarx, Peter (NIH/FIC) [E]

To: Conover, Craig( CbH6)];Angela Dunn I (b)(6)]; Cindy Burnett
(b)(6); Duch in, Jeff <f (b)(6);> ; Stephen Morrison
Cb)(6}]_;John Monahan I (b)(6)J>; Charles Holm es
(b)(6)J>; Jeremy Konyndyk ~ (b) (6),)
(b) (~>; Rebecca Katz I (b)(~>; Tom Ingle sby
Glenn Blumhors t q
(b) (6}]_>; (b)(6) 1>; Glass, Roger (NIH/Fie) [E)
Cb)<6>i; Kenyon, Thomas I (b)(~ Anna Carroll
Cb)(6);>; Scott Dowell CbH6):>;Jonathan Pear son
CbH6)l; O'Connor, Eileen
(b)(6)l >; Myers, Michael I Cb)(6)1;Robynn Leidi g
(b)(~ >
Subject: UPDATES: Next steps on COVID-19 Response Corps
Thanks all for our call Friday. {Glenn, Jonathan, Craig, Jeremy, Roger, Anna, Suzanne, Eileen, Michi2iel.)
A few items from the call:
• Jonathan reported Sen Markey's office working on legislation for 10,000+ (?) response
workforce
• Michael reported positive response from National Governors Association
• Eileen reaching out to Tom Bossert. Adam Boehler not yet . Shared Op Ed in WSJ emphasizing
test ing - https://www.wsi.com/articles/testing-is-ou r-way-out-11585869705
• Jeremy has an OpEd in Daily Beast with Beth Cameron -
https://www.thedailybeast.com/coronavirus-shows-we-need -an-apollo-project-for-public-
health
• Craig in touch with Durbin's office. IL has ongoing need for large workforce. Much easier to get
staff from feds. Slower to hire at state level. MA implementing 1,000-person contact tracing
effort.
• John in touch with Pelosi's office, Delaura, Conf of Mayors, League of Cities.
• Other potential champions -AST HO, APHA, Josh Scharfstein @JHSPH
• General agreement that for bipartisan emergency approval should emphasize near-term (e.g., 2
year) impe ratives of COVID-19 and economic emergencies, not a new permanent wor k force.
• General agreement that Peace Corps is the low-hanging frui t, but not all 7,000 RPCVswould do
this and the need is much greate r.
• CSISOpEd with Ami Bera (D-CA) and Susan Brooks (R-IN) coming out in Politico or CSISwebsite
by Monday
Other updates:
• Telcon Friday with Brooks staffer. They are putting together legislation, ideally bipartisan w ith
Bera. Now fully briefed on CRCconcept and potential implementation model. Clarified not
duplicative of USPHS Ready Reserve Corps which is now authorized but not being implemented
(to my knowledge) and would be different profile, i.e., USPHShas physicians, nurses, engineers,
etc.
• Telcon Saturday with CDCCOVID-19 Chief Medical Officer . Confirms many are thinking about
the workforce issue. Notes that CDCunlikely to "own," but great suggestion to engage CDC-
funded National Network of STDClinical Prevention Training Centers for training.
https://nnptc.org/ with eight centers around the country. CRCconcept may be brought to
national response discussions with FEMA in Washington DC.
• FEMA contacts report they are hiring RPCVs,but do not report majo r speed up or scale up.
FEMA recruiting email attached.
• Charles shared Vanessa Kerry OpEd emphasizing same themes : response workforce and jobs:
https ://www. boston hera Id.com/2020/04/01/ massachu setts-genera I-hospita 1-infectio us-
d isease-tea m-ca Ils-on-state-to-harness-people-power/
Next steps:
• Executive - support/impetus to FEMA to increase speed and scale
• Legislation - new appropriations for FEMA or CDCif needed
• National advocacy- media, opinion leaders
• Demand signal - state and local authorities requests
• Implementation and management details working out
Over all goal: Greatly increase COVID-19 response workforce to control disease and provide jobs. A
COVID-19 Response Corps would be a (big) part of solution. RPCV ideal first cadre for CRC.
Please share any corrections, updates, suggestions.
Thanks,
PK
-----Original Appointment-----
From : Kilmarx, Peter (NIH/FIC) [E]
To: Conover, Craig; Angela Dunn; Cindy Burnett; Duchin, Jeff; Stephen Morr ison; John Monahan; Charles
Holmes; Jeremy Konyndyk (b)(6); Rebecca Katz; Tom lngl esby; Glenn Blumhorst;
Glass, Roger (NIH/FIC) [E]; Kenyon, Thomas; Anna Carroll; Scott Dowell; Jonathan Pearson;
--------- (b)(6); O'Connor, Eileen; Myers, M ichael; Robynn Leidig

Subject:* ** Time correction - 8 am**~ Next steps on COVID-19 Response Corps
When: Friday, Apr il 3, 2020 8:00 AM-9:00 AM (UTC-05:00) Eastern Time (US & Canada).
Wher e: Zoom meeting
Peter Kilmarx (Fie Zoom2) is inviting you to a scheduled Zoom meeting. Zoom link below.
Agenda:
1. We lcome and introdu ctions
2. Current status of advocacy
3. Implementation issues
4. Next steps:
a. Advocacy
b. Implement ation
5. AOB
Topic: Next steps on COVID-19 Response Corps

Time: Apr 3, 2020 08:00 AM Eastern Time (US and Canada)
Join Zoom Meeting

(b)(4)
Meet ing ID: ____ Cb>

_C_4)
One tap mobile

+16465588656, }--- ~ (b~
H=4>us(New York)
+13126266799 ,J US (Chicago)
Dial by vou r location

- CbH4J(New York)
(Chicago)
(Houston)
(San Jose)
Meeting ID:
----- (b) (4)
Find your local numbe r: https://zoom.us/u/adl j8UhXNS
From: Kilmarx , Peter (NIH/FIC) [El

To : 'Conover, Craig' (b)(6) > ; 'Angela Dunn' (b)( 6)>; 'Cindy
-----!==~~~~~·
Burnett'
,,.:....---========-~;-'
(b) (6); 'Duch in, Jeff
(b) (6) ; 'John Mon ahan '
>; Step hen Morrison
(b) (6J>; 'Charles Holmes'
=======~~--:~ (b:-) -(6J>; 'Jeremy Konyndyk (b)(6)'
CbH >; 'Rebecca Katz' (b)(6J>; 'Tom lnglesby'
=====~~----:~ (b)(6)>; 'Glenn Blumhorst' --=========~~- .
CbH6J>;Glass, Roger (NIH/FIC) [E]
====-~ ~- (b)(6)1>; 'Kenyon , Thomas' (b)( >; 'Anna Carroll'
(b)(6) 'Scott Dowell ' (b)( 6);
(b)(6)
; 'O'Connor, Eileen' (b)(6J>; 'Myers, Michael '
(b)( 6)> ----------
Subject: NEWS: Congressional letter to Peace Corps, CNCS,and FEMA on COVID-19 Response Corps
Hi all,
Big news. Herew ith is a letter signed by 40 members of Congress asking FEMA, Peace Corps, and
AmeriCorps to form a "COVID-19 Response Corps." This is now in the publ ic domain. Press release
forthcoming .
Please save the t ime for Zoom call 8 am tomorrow on next steps.
Also: Check out: http s://www.npr.or g/ sect ions/ goat sandsoda/202 0/04/0 1/8252 3 1838/co ron avirus-
sent-p eace-corp s-vo lunteers -home -it-could-also-give-t hem-a-n ew-missi
The National Peace Corps Association is hoping to create and fund a group that draws on the evacuated
volunteers and their skills to respond to the COVID-19 crisis in the United States. Workers would take on
work like tracing the contacts of diagnosed individuals, monitoring the hea lth of those in quarant ine and
staffing call centers . An agency such as the Federal Emergency Management Agency, the U.S. Centers for
Disease Control and Prevention or AmeriCorps could potentially manage the group, says Blumhorst, who
has been advocating for the project. Salaries could come from funding that's already been allotted to the
COV/0-19 response but hasn't yet been spen t. The NPCA has discussed the idea with the offices of several
members of Congress that are receptive and support ive, Blumhorst says, and they're planning to speak
with more congresspeople and federal agencies and also hope to draw public atten tion to this potent ial
project.
From: Kilmarx, Peter (NIH/ FIC) [E)

Sent: Sunday, Marc h 29, 2020 4:47 PM
To: Conover, Craigl (b) (6J,>; Angela Dunn I (b) (~ >; Cindy Burnett
CbH6)}>; Duchin, Jeff CbH6>;>; Stephen Morrison
=====~~::""" "':::==========~
~~
CbH6)/>; John Mona han! (b)(6)1>; Charles Holmes
Cb)(6));Jeremy Konyndyk I Cb)(6))
=======~~:::---"'.""""-
(b)( 6))>; Rebecca Katz (b)( ~ >; Tom lnglesby
=====.~;--~ CbH~ >; Glenn Blumhors t --========~~~ Cb
H6>i ; Glass, Roger (NIH/FIC) [E)
======~ =·
-------- (b)(6) ,> ; Kenyon, Thomas ( (b)(6)1>; Anna Carroll
(b) (6); Scott Dowell (b)(
Jonathan Pearson
-----------------------
Subje ct: INFO: Update on COVID-19 Response Corps
(b)(6)
Hi all and thanks for your support for a U.S. COVID-19 Response Corps engaging returned Peace Corps
volunteers (RPCV).The latest (March 26) 2-page concept note attached.
Updates:
l. Steve is working on getting the Op Ed out in press and/or on CSISwebsite by Tuesday . We'll let
you know.
2. Glenn and Charles have found very good recep t ivity on the Hill.
3. I've had a couple very good calls with FEMA folks at senior levels (extensive RPCVnetwork) .
They are already reaching out to RPCVand are well funded. They can get an RPCVon board in a
week. They have a few different hiring mechanisms that would be appropr iat e. The scale and
speed need to be ramped up substant ially.
4. I've reached out to contacts at nationa l mayors and governors associations with no reply. Also
no reply from CDC (Jernigan and Schuchat).
Next steps - when OpEd comes out, amplify multiple levels to publicize and create demand .
The need for this is great. The feasibility looks very good .
Please share you r suggestions .
Thanks to all,
PK
From: Kilmarx , Peter (NIH/Fie) [El

To: Charles Holmes (b)(6) ; Angela Dunn (b) (6J_>;Cindy
(b)(6) Duchin, Jeff
--....!:=====~~
Burnett (b)(6)> ; Conover, Craig
(b)(6)> ; Glass, Roger (NIH/FIC) [El (b)(6J_>; Glenn Blumhorst
"".""."'--:---:::===========-~--- (b_H_6); Stephen Morrison (b)(6)John

Monahan (b) <
Subje ct: RE: Call - follow -up: COVID-19 Response Corps
Hi again,
A draft Op Ed attached . It is largely drawn from the concept note .
Is there an appropriat e champion among us who can take thi s forward?
Please share your suggesti ons and comment s by noon tom orrow if possible .
Thanks,
PK

(b)(6)>
Cc: Angela Dunn .....;======~~--:-:---:--:--
To: Charles Holmes
(b)(6h ; Cindy Burnett (b)(6); Conover, Craig
__ .:::__
__ --===::; (b:;:
)(~6)-::-
D
- u-c-:-
h-in-, J
_eff
, ,.--___:_
__ ~) ~
_,,!::===::a (b < " >-; :::
G:-la-ss, Roger (NIH/FI C) [E]
=====~=----::-:---
(b)(6J>;Glenn Blumhorst -===========-;___;__~....:..___:-- ;..,..;,
(b)(6)
--------==-
Stephen Morr ison
':'"'":----:----"..:==========~;:;:;--:;;---
(b)(6); John Monahan (b)(6)
Subje ct: RE: Call - follow-up: COVID-19 Response Corps
Thanks Charles. This is very helpful.
I've updated the concept note - att ached. Now a two-pager. Added t raining and prevention bullet .
Decreased t he numbers and budget based on feed back to date . Draft OpEd fort hcoming .
Grate ful if others can advocate as they are able (and others of us are not ).
Glenn - please add anything on your meetings on the hill yesterday, the FEMA call, or advocacy plans.
My takeaway is that a FEMA disaste r corps or FEMA-Americorps Corps is feasible.
• Call yest erday with Glenn and former FEMA staff : George Haddow and Miche al Coen
o FEMA Corps is a partnership of FEMA and Americorps with about 1,200 -1,800
members . Part of Americorps. FEMA pays 100%. Mainly younger, lower-skilled
supervised wo rk.
o FEMA reservist disaster corps has 3,000 -4,000 members . Mostly sho rt er-term
deployments as temp employees. Many retired military. Can be activated with
State of Emergency declarat ions.
o FEMA currently has sent 3-4 liaisons to each state. Disaster corps not activated.
o Onboarding 5,000 would be a big lift. Peace Corps has seconded staf f to ot her
agencies in past, so t his could be an option .
o Only private sector partner for FEMA is Red Cross. Not recommended for this.
More input:
• Jen Kates (KFF)and her colleague Josh Michaud - "th ink it is a great idea"
• Tom Frieden -"It's a good idea."
o Robynn Leidig, Manager, Strateg ic Init iat ives, Resolve To Save Lives - "Compelling
idea and worth exploring"
• Concern about risk to RPCVs,training and oversight needed
• Lack of PPE, best to focus on tasks that don ' t need PPE
• Resentment of current staff worried about threat to their jobs
• Fairness: shou ld open to others - Amer icorps, VISTA,CDC PHAP,CSTE
fellows, USAID Global Health Fellows
• Manageme nt absor ptive capacity limited at CDC. Consider ASTHO/
NACCHOor PHI.
From: Charles Holmes
-------------
Sent: Tuesday, Mar ch 24, 2020 7:36 AM
To: Kilmarx, Peter (NIH/FIC) [El -------,; (b..,...
)(=6)>
(b)( 6)
__ ..;;;..
__ _::==~~---::-:-:--
Cc: Angela Dunn (b)( 6)> ; Cindy Burnett
>; Conover, Craig
(bH >; Duch in, Jeff
>; Glass, Roger (NIH/FIC} [El
(b)(
======~~--- -!:::=========~--:__..::...___:.__.:__~ .;,

Steph en Morr ison
(b)( 6) ; Glenn Blumhorst
(b)(6) --------------------
Subject: Re: Call - follow -up: COVID-19 Response Corps
(b)( 6)
Sen Van Hollen' s office is interested and I'm slated to ta lk w them later today or tomorrow. Interested to
know how the idea was received by others on the Hill. Best
On Mon, Mar 23, 2020 at 7:44 AM Kilmarx, Peter (NIH/FIC) [El

Thanks Charles.
--------- (b)(6) wrote :
Draft OpEd forthcom ing today. Everyone please think about autho rs.
Bill Frist and Tom Daschle? https://w w w.rollca ll.com/2018/07 /09/op inion-an-open-health-diplomacy-
hand-works-bette r-than-a-fist/ ByTom Daschle and Bill Frist, July 9, 2018.
From: Char les Holmes

------------
Sent: Monday , March 23, 2020 7:37 AM
(b)(6)>
To: ------~~
Kilmarx, Peter (NIH/FIC) [El (b)(6)
....,;._.;._......;...;....;.==~~-::---:--:--
Cc:A ngela Dunn
_ _..:
__ .;._~==~~-~ (b)(6); Cindy Burnett
>; Conover, Craig
>; Glass, Roger (NIH/FIC) [El
(b)( 6) > ; Duch in, Jeff (b)(
(b)( 6)
...:======-~~-::-:--
(b)(6)>; Glenn Blumhorst (b)(6J ;
Steph en Morr ison (b) (6)>
Subject: Re: Call - fo llow -up : COVID-19 Response Corps
Great feedback, Peter . More from Vanessa Kerry:
"Initial reaction is that this is fantastic and I would be happy to help in any capacity to support it.
Please let me know how. Devil is in the details and t he training of course. Truly a smart idea though"
Charles
On Mon, Mar 23, 2020 at 7:11 AM Kilmarx, Peter (NIH/FIC) [E] wrote:
-------- (b)( 6J>
Thanks Craig. This looks very comprehensive and someth ing a trained RPCV(return ed Peace Corps
Volun teer) could help imp lement.
Glenn - good luck on t he Hill tod ay. Wil l be eager t o hear about the reception.
Some feedbac k from others:
• John Monahan (Georgetow n) - "Very creativ e, kudos!"

o Try to get authority on one of these COVI0-19 response bills for returning Peace
Corps folks to be redeployed notwithstanding other provisions of law.
o Explore whether CRCcould be incorporated into the programs FEMA already has
to bring in short-term employees to help with emergency responses.
o Some functions (home-delivered meals, staffing call centers, home less populations
and shelters) would more sense to supplement programs run by Americorps.
o Cost seems high.
• Scott Dowe ll (Gates Foundation) - "A good and important idea"
o Need a massive surge in the public health and communi ty testing workforce over
the coming mont hs.
o They are considering engaging the 30,000 medical students through AMSA
(American Medical Student Association) .
• Tom lnglesby (Johns Hopkins) - "A fantastic idea and am very supportive"
o Important issue to be worked through : How to address risk to individuals invo lved?
(My response: training, equipping, and monitor ing. Will add to next iteration of
concept note. Note that Singapore has had no infections in HCW and in China after
January/Wuhan, most HCW infections were from home, not from work.)
o Tom's work ing on concept to engage presumably immune COVID-19 survivors (as
was done w ith Ebola).
• Jeremy Konyndyk {CGD) - "Great idea."
o Need to think creatively about how to expand the public health workforce for the
coming 18 months, especially for tasks like contact tracing . We 'll need to view CDC
and local health dept folks not as boots on the ground but rather as force
multipliers - sharing their skills with others and mentoring/managing larger teams
to extend their reach.
From : Conover, Craig_________ Cb

_>
_<_ >
sent: Sunday, March 22, 2020 5:01 PM
To: Kilmarx, Peter (NIH/FI_C:..: -------~~
)[ ~E:.!:
)l ====-=-----::-:-- (b _.; Stephen Morrison I___
- )-:-
<6>i _ (b)(6)
Glass, Roger (NIH/Fie) [E]I CbH6J
------------,,-:-=
r>; Charles Holmes
CbH6l;Glenn Blumhorst l (b)(6)j
(b)(6)l; Duchin, Jeff CbH6)J
>; Angela Dunn
=======- (b~
)(~6)1>; Cindy Burn""e-u•1======' (b
~~:::;
(6)]
~ :>__..
--------- --------
Subject : Re: Call - follow-up: COVID-19 Response Corps
Thanks for all your work on this, Peter !
Re LTCs--attached is a draft document listing all the capab ilities that need to be in place for
LTCFsto respond to Covid-19.
Develop ing and disseminating guidance aimed at LTCFsis relatively easy--the failures are
going to be around implementation .
This is one area where assistance wou ld be valuable.
cc
From : Kilmarx, Peter (NIH/FIC) [E] (b)( >

To: Stephen Morrison Glass, Roger (NIH/FIC) [E] I
CbH6>;>; (b)(6);
Charles Holmes I (b) (6)]>; Glenn Blumhorst
-----
ouch in, Jeff
(b)(6) J
:.===========------==========,::;;---
(b)( 6)]>; Conover, Craig I Angela Dunn
CbH6)];
:.========-~c,"'.:'.-:-" ;,.._...;:.:====-~~-----
--------- Cindy Burnett !
(b)(6)j; (b)(6)j
Subject : [External] RE:Call - follow-up: COVID-19 Response Corps
Thanks all for our call and support for t his concept. Please let me know any critical additions or
corrections to these notes .
• Jeff Duchin (Seattle) noted multiple possible roles in contact tracing, mitigation with
homeless and incarcerated, adverse consequences of social distancing, infection control
support, alternat ive care site coordinat ion, lab specimen collection and transport . He
shared concerns about infection prevention and thei r PPEshortage. CDChad 40 people
deployed, but they departed . Longer deployments (e.g., >90 days) needed to validate
onboarding and training effort . He will follow up with more detail on potential roles and
numbers.
• Angela Dunn (Utah) agreed wit h roles in contact tracing , also st affing a call center, rural
out reach and specimen collection. She said Utah was not a current priority for FEMA and
CDCwas conducting a transmission study. She shared Jeff's concern about the onboarding
effort .
• Cindy Burnett (Utah) mentioned the need for social support in rural settings.
• Craig Conover (Illinois) added that for them the long -te rm care centers and homeless
populations were priority concerns. It would be feasible and helpful to have staff able to
collect specimen swabs.
• Charles Holmes (Georgetown) made an analogy to community health workers in Zambia
and how much can be accomplished and enhanced with tablet-based approaches, work-
flow apps, and video instructions.
• Steve Morrison (CSIS)emphasized the importance of finding an organizationa l home,
mentioning potential challenges for both CDCand FEMA. He noted timing of response
packages being considered, the hunger for creative ideas, and urgency for this to be
brought forward. He noted potential champions, listed with others below. He thinks the
Peace Corps connectio n is a compelling factor.
• Glen Blumhorst (NPCA) expressed his support and insights on potential champions, e.g.,
three RPCVin the house. He is going to Capitol Hill tomorrow .
• Jody Olsen (Peace Corps) (prior to the call) expressed interest and noted that Peace Corps
has no authority to operate in the United States. (The possibility of an Executive Order
deta il ing returned volunteers from Peace Corps to state and local aut horities was
mentioned by others on the call.) She also noted that Barbara Stewart, Director of CNCS
(AmeriCorps and VISTA) has been inviting RPCVsto jo in.
Next steps :
1. Revise document (done, attached) to be shared w ith subject matter experts and potential
champ ions . (There was not an exact delineat ion of who would share with whom. I will aim
to CC: or ask for help w ith some contacts.)
2. Will draft Op-Ed in next 2 days.
Action: Share conceptsheet with SMEs and champions avoidingany obvious minefieldsand
duplication. Report backuseful feedback.
SM Es/champions:
• Tom lngelsby
• Beth Cameron
• Jeremy Konyndyk
• Rebecca Katz
• Scott Gottl ieb
• Tom Frieden
• Scott Dowe ll
• John Monahan
Champions:
• Paul Allen Foundation
• Dick Durbin
• Biden campaign
• Chris Christie
• Carrie Hessler-Radelet
• Aaron Williams
• Pat rick Leahy
• Chris Van Hollen
• Dick Durbin
• Debbi Birx
• Donna Shalala (RPCV- Iran 1962-64)
• Joseph P. Kennedy Ill (RPCVDominican Republic 2004-06)
• John Garamendi (Ethiopia 1966-68)
• Aumua Amata (PC staf f Northern Mariana Islands 1967-68)
Note - GS-7, Step 1 salary is $37,301, Step 5 is $42,273. I've re-set the budget at $100,000 per
person to account for benefits, train ing, travel, per diem, management, evaluation, PPE,phones,
laptops, etc .
From : Kilmarx, Peter (NIH/FIC) [E]

To : Stephen Morrison (b)(6)>; Glass, Roger (NIH/FIC) [El (b)(6J;
Charles Holmes (b)(6J; Blumhorst, Cathy (NIH/NINR) [El
CbH6)];Glenn Blumhorst (b)(6)>;
:;::::::=======c::,::;,:c;-:'."'.""""'
(b)(~ Olsen,
-----:=====!....:,..
Jody
(b)(6) J; Conover, Craig
__ ...:_~~ (b)(6)>;
Angela Dunn
Duchin, Jeff
(b)(
:.=======; (b
::;:
)~(6)
~1]>
-- ----------
Subject: RE: Call: COVID-19 Response Corps
Hi all,
I'm looking forward to our WebEx meeting in 90 minutes. The concept note (unchanged) is
attached. The Web Ex info is below.
Here's an updated agenda:
1. Welcome and introductions

2. Background and proposal
3. Round robin perspectives
a. Public health - WA, IL, UT
b. Peace Corps - Jody
c. Strengthening the concept - all
d. Advocacy - all
e. Implementat ion - all
4. Next steps and way forwa rd
-----Origi nal Appointment -----

From : Kilmarx, Peter (NIH/F ie) [El
Sent: Saturday, March 21, 2020 9:29 PM
To: Stephen Morrison; Glass, Roger (NIH/FIC) [E]; Charles Holmes; Blumhorst, Cathy (NIH/N INR)
(E]; Glenn Blumhorst; (b)(6) Olsen, Jody; Duchin, Jeff; Conover, Craig; Angela
Dunn
Subject: Call: COVID-19 Response Corps
When : Sunday, March 22, 2020 2:00 PM-3:00 PM (UTC-05 :00) Eastern Time (US & Canada).
Where: WebEx
Please join tomorrow for WebEx discussion of developing a U.S. COVID-19 Response Corps.
Concept sheet attached.
Agenda :
1. We lcome and introductions
2. Background and proposal
3. Round robin perspectives
4. Discussion
5. Next steps and way forward
-- Do not delete or change any of the following text. --
Join Webex meeting

Meeting number (access code):
---- (b)(4) Meeting password:
-------
(b) (4)
Join from a video system or application
Dial ------,, (b) (4)
You can also d ial
----- (b)( 4) and enter you r meeting numb er.
Join by phone
Tap to call in from a mobile device (attendees only)
1-650-479-3208 C all-in to ll number (US/Ca nada )
Global call-in numbers
Join using Microsoft Lyne or Microsoft Skype fo r Business
(b) (4)
Dial
-------------
Can't jo in the meeting ?
-
If you are a host, go here to view host informat ion. lv1PORTAW NOTICE:Please note that this Webex
service ~llows audio and other information sent during the session to be recorded. which rnay be d iscoverable rn a legal matter By
Joining this session, you automat1cally consent to such recordings If you do not co11sentto being recorded, discuss your concerns with
the host or do not join the session
State of Illinois - CONFIDENTIALITY NOTICE: The information contained in this commun ication is
confidential , may be attorney-client privileged or attorney work product, may constitute inside
information or internal deliberative staff communication, and is intended only for the use of the
addressee. Unauthorized use, disclosure or copying of this communication or any part thereof is
strictly prohibited and may be unlawful. If you have received this communication in error, please
notify the sender immediately by return e-ma il and destroy this communication and all copies
thereof, including all attachments. Receipt by an unintended recipient does not wa ive attorney-c lient
privilege, attorney work product privilege, or any other exemption from disclosu re .
Charles B. Holmes, MD, MPH

Faculty Co-Director, Center for Global Health Practice and Impact
Georgetown University Medical Center
Building D, Suite 120
4000 Reservoir Rd NW, Washington DC 20057
Phone (b) (6)
Charles B. Holmes, MD, MPH

Faculty Co-Director , Center for Global Health Practice and Impact
Georgetown University Medical Center
Building D, Suite 120
4000 Reservoir Rd NW, Washington DC 20057
Phone (b) (6)
Sent: Mo n, 13 Apr 2020 15:25:44 +0000
To: Corey, Larry
Subject : FW: perhaps useful in the physical mitigation battle to buy 6 weeks
Attachments: (b)(4 l
Larry:
(b) (4)
I will call yo u about t his to day. This is really im port ant.
Thanks,
To ny
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
informatio n. It should not be used by anyone who is not the orig inal intended recipient . If you
From: Eisinger, Robert (NIH/NIAID) [E) (b)(6)> On Behalf Of Fauci, Anthony

(NIH/NIAID) [E)
----------
Sent: Monday , April 13, 2020 7:10 AM
------
-------- ::;..,..-,=(b)(6)>
Subject : FW: perhaps usefu l in the physical mitigation battle to buy 6 weeks
An email below fr om Larry Corey.

Immed iate Office of t he Director
National Inst itute of Allergy and Infectious Diseases
Bethesda MD 20892
Telephone: (b)(6)
Email: (b)(
From: Corey MD, Larry CbH >
-------,
To : Conrad, Patricia (NIH/NIAID) [E] < ,a-s-r;=
Marston, Hilary (NIH/NIAID) [E]
(b)(6)>;
(b) (6)>
Cc:Fauci, Anthony (NIH/NIAID) [E] (b)(6)
Subject: perhaps useful in the physical mitigation batt le to buy 6 weeks
Here is data from Seattle up to this weekend

Sent : Mo n, 13 Apr 2020 14:37:16 +0000
To: Auchincloss, Hugh (NIH/N IA ID) [El
Subject: RE:Wayne and Catherine Reynolds and Bob Langer/MIT innovations
Thanks!
Director
Phone: (b)(6)
FAX: (30 496"'4409
E-mail: (b)(6)
From: Auchincloss , Hugh (NIH/NIAID) [El (b)(6)>

To : Fauci, Anthony (NIH/NIAID) [El--------, .....,..,=
(b)(6)
Cc: Conrad, Patricia (NIH/NIAID) [El (b)(6)
Subject: RE: Wayne and Catherine Reynolds and Bob Langer/MIT innovations
Possible response below :
Dear Wayne,
(b) (5)
Please give my best to Catherine and take care during these difficult times.
Best personal regards,
Tony

-------- (b)(6)>
To: Auchincloss, Hugh (NIH/NIAID) [E] (b)(6)>
Cc:Conrad, Patricia (NIH/NIAID) [E] (b)(6)
Subject:FW: Wayne and Catherine Reynolds and Bob Langer/MIT innovations
Hugh:
Please take a look at these 3 ideas. You may have heard of Bob Langer. He is somewhat of
an inventive genius with whom we have worked before . I need to get back to Wayne and
Catherine and I would like your help in my fashioning a response.
Thanks,
Tony
From:WAYNE REYNOLDS
--------
-------~=
(b)(6)
(b)(6)>
Cc:Grady, Christine {NIH/CC/BEP) ~[E::-::
] ;::====== ~ ):::;
(b (6)
~
Subject:Wayne and Catherine Reynolds and Bob Langer/MIT innovations
Tony,
Obviously, you have a few other issues on your daily agenda but, when you have a minute, we wou ld
appreciate your thoughts and guidance on three new Bob Langer biotech developments. We have
attached three links to recent MIT News art icles. These three innovations at the Langer Lab were
originally funded by the Gates Foundation. We thought the last two breakthroughs, in particular, may be
applicable to your current work. Thank you again for your continued guidance .
Best wishes,
Wayne Reynolds
Cell : (b)(6)
Home: (b)(6)
------
Heat stable micronutrientsfor better nutrition
http://news.mit.edu/2019/micro part ides-fight-malnutrit ion -1113
On-patient invisiblevaccinationrecord
http://news .mit .edu/2019/storing-vaccine-history-skin-1218
Self- boosting vaccine platform for faster and stronger immune response
http://news.mit.edu/2017 /one-vaccine-injection-could-ca rry-many-doses-0914
Sent: Mo n, 13 Apr 2020 13:03:45 +0000
To : Jenny Fauci
Cc: (b)(6)
(b)(6)
Subject: RE:FW: Google Alert - Fauci AND Tony ORAnthony
(b)( 6)
Director
National Institute of Allergy and Infectiou s Di seases
Phone : (b)(6)
FAX: (301 496-4409
E-mail ,___,,. __ _, (b)(6)
From:t >
Sent: k:,-o-n-da_y_, -A-p-ri-11
- 3-,-2-0-20
- 7-:S_S_A_M
__
To: Fauci, Anthony (NIH/NIAID) [E] -------~~ (b)(6)
Subject: Re: FW: Google Alert - Fauci AND Tony OR Anthony
(b)(6)
On Sat, Apr 11, 2020 at 1:27 PM Fauci,Anthony (NIH/N IAID) [E)______ _>_<_ > wrote:
Cb
If you have time, click to link on the bottom: "How Anthony Fauci Became
America's Doctor". It is a long article in New York magazine written by Michael
Spector a former Washington Post and NY Times writer who has known me for
over 30 years. It is the most comprehensive report on me and my career - very
insightfu l.
Anthony S . Fauc i, MD
Director
Phone : (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)
your mailbox or any other storage devices. The National Institute of Allergy and Infectious
From: Google Alerts <googlea lerts -norep ly@goog le.com >

Sent: Saturday, Apr il 11, 2020 11 :51 AM
To: Fauci, Anthony (NIH/NIAID ) [E] ------~~ (b)( >
Subject: Goog le Alert - Fauci AND Tony OR Anthony
Google Alerts
Fauci AND Tony OR Anthony

As-it-happens update• April 11, 2320
WEB
Fauci: Virus antibody tests expected next week

North Platte Post
Dr. Anthony Fauci answers questions during Thursday's Coronavirus Task Force briefing.
WASHI NGTON - The top U.S. infectious disease official ...
11 CJ Flaa as irrelevant
anthon y fauci
The Bulwark Podcast
anthony tauci, anti-anti-trumpism, china, coronavirus, covid-19 , donald trump , elections,
hydroxychloroquine, masks, navy peter navarro , white house, ...
11 CJ Flaa as irrelevant
CBS Evening News with Norah O'Donnell

Facebook
Dr. Anthony Fauci of the National Institute of Allergy and Infectious Diseases (NIAID) : "This is not
the time to feel that, since we have made such ...
11 CJ Flag as 1rreltwant
How Anthony Fauci Became America's Doctor by Michael Specter

Longform
A profile of the doctor who has run the National Institute of Allergy and Infectious Diseases for 36
years .
11 CJ Flao as irrelevant
You have received this email because you have subscribed to Google Alerts .
Unsubscribe
B!Receive this alert as RSS feed

Send Feedback
Sent : Mo n, 13 Apr 2020 10:16:00 +0000
To : Nicola Pizzoli
Subject : RE:COVID 19: Possible main cause of fatalities, it could be not respiratory
Thank you, Nicola
From: Nico la Pizzoli (b)(6)

Se nt : Monday, April 13, 2020 6:07 AM
------~~
-------- (b)(6)>
Subject: COVID 19: Possible main cause of fatalities , it could be not respiratory
Good morning Dr Fauci,
Ive been follow ing you on COVID brief ings from the White House every night. I trust yo ur experience ,
professionality and above all your wisdom in these weeks.
While I am a mechanical engineer and I run my food company fro living, I have been interested and
passionate to the global fight to the Coronavirus.
SUGGES TION: Could it be possible that peop le die of pulmonary micro t hrombo sis rather than
respiratory issues? If this is the case, this is more a cardiovascular issue than a respiratory, and
ventilation or intubation do not count as much as, instead, to give patients some drugs to prevent the
t hrombosis , such as ANTI-INFIAMMATORIES.If you ventilate a lung where blood doesn't get there, may
be it's useless! In fact 9 out of 10 die . If the problem were cardiovascula r and not respiratory, then it
could be a venous microthrombosis and not pneumonia that determines fata lity. And why are thrombi
formed? Because there is an inflammation that induces th rombosis through a complex but well-known
pathophysiological mechanisms.
I know this thesis is right the contrary of some recomm endations that several doctors all over the world
(in China first) had made so far: no ibuprofene, no anthibiotics etc etc.
But I bel ieve that some researches on the cardiovascular problem induced by inflammation would be
worth doing it.
An apology for my English.

Thank you for your attention,
Stay healthy!
Kindest regards
Nicola
Nicola Pizzoli
President & CEO
PinollSp.A.
\'b 1nulillo ~ ord I •..COOSA11.idrie• lloloi;u
----....
~
Sent: Mo n, 13 Apr 2020 02:17:18 +0000
To:
Cc: ----- (b)(6) (NIH/NHLBI) [E)
Redfield, Robert R. (CDC/OD)
Subject: RE:Comparison of COVID-19statistics in US vs. China
(b)(6)
Thank you for you note. This pandemic has been extremely challeng ing for many countries
around the globe including China and the USA. I can only say that I (and I am sure that Bob
Redfield feels the same way) prefer to look forward and not to assign blame or fault. There are
enough prob lems ahead that we must face together.
Best regards,
Tony
From: (NIH/NHLBI) [E]

(b)(6)
-------- (b)(6)>
To: Redfield, Robert R. (CDC/OD)

----~~ Fauci, Anthony (NIH/NIAID) [E)
(b) (6) >
------ (b)(6)
Cc: (b)(6) {NIH/NHLBI) [E]

-------- (b)( >
Subject: RE:Comparison of COVID-19 statist ics in US vs. China
Dear Dr. Redfield and Dr. Fauci,
Aft er some hesitation, I decided to write you this message anyway and hope you don't mind.
I am concerned about the recent fig ht between the US and WHO because it may adversely impact the
current global efforts in controlling the spread of COVID-19. As we all know, US has been leading WHO's
efforts for decades and essentially WHO's role is mostly coordinating responses in low- and middle -
income countries with support from the US and other high income countries. Frankly I was looking for
leadership from the US CDCrather than WHO when I was doing (b)(6)
. Until COVID-19 is controlled in all countries,
t he infection could come back to hit us in this country again. Therefore it is now the worst time to
undermine WHO's global coordinating capabilities.
What I learned from my former colleagues and friends in (b)(6) where I attended medical school
and obtained my MSc in epidemiology might offer some explanation for the differe nces in COVID-19
statistics in US vs. China. Please find attached a couple of articles published by my former colleague, Cb~
___ st
, of which the 1 attachment is a more updated version . (6)
• First, the maximum lockdown in Wuhan that started on January 23 and also in the rest of the
entire Hubei province of 59 million peop le during the subsequent 2-3 days, coupled with
maximum efforts in early identification, immediate isolation of identified infected individuals
and close monitoring of contacts, did work and had to work according to epidemiological
principles. China did it by invoking level 1 public health response that was historically reserved
for smallpox, plague or cholera, which essentially enabled the entire country to be completely
locked down for several weeks. Many vi llages and townships set up checkpoints to refuse
anyone to come in or go out; a driver from Hubei had to stay on an inter-provincial highway for
20 days surviving by begging instant noodles from people policing exits; all front doors of
residents in a township in Hubei were sealed by local government officials and volunteers to
prevent them from getting out of their houses.
• Second, there must be under -reporting of COVID-19 cases and deaths because the public
health and hospital systems in Wuhan and a few other hardest hit municipalities were
overwhelmed for one to two weeks; conceivably many infected individuals were not getting a
chance for testing and some of them must have died without being identified as COVID-19. I'd
say that this kind of under-reporting is unavoidable, especially in the epicenter of a new
pandemic. Actually I suspect that such under-reporting could have happened in this country as
well although perhaps to a lesser degree.
• Third, there could be a third category of casualties, that is, patients who were suffering from
chronic diseases but couldn't get necessary treatments because hospitals were overwhelmed.
I read a sad story in social media in which a patient who needed frequent dialysis comm itted
suicide by jump ing out of his window. It is highly likely that many such patients died during the
lockdown even though I couldn't confirm the specific case or find any statistics. There could be
many other collateral damages including socio-psychological effects .
Combined, the effect of the maximum lockdown, the under-report ing of COVID-19 cases and COVID- 19
deaths as well as collateral deaths of other causes that were associated with the lockdown could be
several times of the reported statistics from China. Here I'd not say that China purposely under-
reported COVID-19 cases or deaths but rather, China pursued an extreme approach and achieved an
extreme result, including severe collateral damages. Of note, Dr. LI Wenliang (the whistleb lower) voiced
concern on 12/30/2019 and was criticized for having not followed the legally proper reporting process
but nevertheless the WHO China Office was informed on 12/31/2019 of a pneumonia of unknown
cause, detected in the city of Wuhan in Hubei province, China
(https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen ).
We in the US and many other countries pursued different approaches, which are more humane but less
effective in terms of blocking transmissions. This is the reality, which needs to be commun icated with
and recognized by the public; to make the humane approaches work as effectively as possible, we need
everyone's support and cooperation, which cannot be achieved by blaming China or WHO. The public
has to understand that we are in a pandemic, which means that tens of millions are supposed to be
infected and millions are supposed to die from it, unless we take necessary actions to block the
transmission and to take good care of the infected.
Finally, I'd like to say a few words for public health colleagues in China. In my personal view, to be fair,
they have done their best to inform the global public health community of the COVID-19 outbreak in
Wuhan, China by briefing WHO and many count ries as soon as they identified COVID-19 (12/31/2019 -
1/3/2020) ; they shared the genetic sequence of the virus on 1/ 12/2020; and the numbe r of scientific
and medical publications in English shortly afterwards was unprecedented . I did a brief search and
identified the following:
A Novel Coronavirus from Pat ients with Pneumonia in China, 2019 (1/24/2020)
https://www.nejm.org/doi/full/10.1056/NEJMoa2001017
A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person -to -person
transmission : a study of a family cluster (1/24/2020)
https://www.sciencedirect.com/science/artic1e/pii/S0140673620301549?via%3Dihub
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China (1/24/2020)
https ://www.thelancet.com/journa ls/lancet/ article/Pl 1S0140-6736(20)30183-5/ f ulltext
Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-l nfected Pneumonia (1/29/2020)
https ://www.nejm.org/ doi/fu 11/10.1056/NEJMoa2001316
Genomic characterisation and epidemiology of 2019 novel coronavirus: implicat ions for virus origins and
receptor binding (1/30/2020)
https://www.thelancet.com/article/S0140-6736(20)30251-8/fulltext
A new coronavirus associated with human respiratory disease in China (2/3/2020)

https://www.nature.com/artic1es/s41586-020-2008-3
Early estimation of the case fatality rate of COVID-19 in main land China: a data-driven analysis
(2/12/2020)
http:ljatm.amegroups.com/article/view/36613/html
Characteristics of and Important Lessons From the Coronavi rus Disease 2019 (COVID-19) Outbreak in
China (2/24/2020)
https://jamanetwork.com/journals/ jama/fulla rticle/2 762130
It is my hope that US and China could join fo rces to help low- and middle-income countries to control
the pandemic so that it will not come back and hit us again after the current wave in this country is
controlled.
I am not sending th is message through the official channel because this is not part of my official duty
and is purely my personal opinion.
Sincerely,
(b)(6)
Doing human subjects research? New policies will impact you! Learn more .
Looking for NHLBI Clinical Trial Funding Opportunities? Learn more here.
Sent : Mon, 13 Apr 2020 01:37:27 +0000
Subject : FW: [COVID-19 Pneumon ia] Official Letter from lmmuneMed Inc.
Attachme nts: Off icial Letter from lmmuneMed-NIAID.pdf
Please take a look at this and respond.
From: Sungpill Park <sppark@immunemed .co.kr>

Sen t: Sunday, April 12, 2020 9:31 PM
To: Fauci, Anthony {NIH/NIAID) (E]------ --=-
(b""""
)(=6)
Subject: (COVID-19 Pneumonia] Official Letter from lmmuneMed Inc.
Dear Dr. Anthony S. Fauci,
My name 1s Sungpill Park, and I'm a representative of lmmuneMed, Inc. located 1n
Korea.
We specialize in diagnos ing and t reating the infectious diseases.
Our company's hzVSF(humanized Virus Suppressing Factor) v13 is under curable
usage for COVID-19 pneumonia, utiliz ing Korea's compassionate use system for
patients who do not have an alternative treatment.

I am writing with a strong conviction that t he partnership between the National
Institute of Allergy and Infectious Diseases and lmmuneMed , Inc. wil l bri ng the
decrease of death rate for COVID-19 pneumon ia.
I ask you humbly to please spend a minute of your busy time reading the attached
letter from our CEO, Dr. Yoon-Won Kim, to find out more about the hzVSF
treatment and how we can wor k together to cure COVID-19 pneumon ia pat ients.
With Regards,
Sungpill Park, MBA

Vice President, Global Business Development
lmmuneMed, Inc.
C: (b)(6) I E: sppark@ immunemed.co.kr
------
w: www.immunemed.eo.kr/en/
Notice : The above message (and any attachment) is intended solely for the named address and may contain
information that is privileged, confidential or otherwise protected under applicable law. Any unauthorized
dissemination, distribution, copying or use of the information contained in this communication is strictly
prohibited If you have received this communication in error, please notify the sender by email and erase this
communication immediately.
Sent : Sun, 12 Apr 2020 23:20:22 +0000
Subject : FW: NAS Annual Meeting Session on COVID-19 -- Information regarding your
Let us discuss.

To: Mun , Jenny <JMun@nas .edu>; Fauci, Anthony {NIH/NIAID) [E) (b)(6l;
>; Hannon, Emma <EHannon@nas .edu>; Conrad, Patr icia

(b)(6)
'ben.tinke r@cnn .com' <ben .tinker@cnn .com>; 'Amanda .Sealy@cnn.com'

<Amanda .Sealy@cnn.com>; 'Neel.Khairzada@turner.com' <Neel .Khairzada@t urner.com>;
'Tia.M iller@turner.com' <Tia.Miller@turner.com>; (b)(6)
Subject: RE:NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25
pa rtici pat ion
Dear a ll,
Thank you for agreeing to participate in a special late breaking session on the COVID-19
pandemic at the NAS annual meeting. Knowing how busy you are, I am sending this email in
lieu of a call to prepare for the session .
As you know, this is a 90 minute session which aims to provide our audience with deeper
insights into the latest developments in the COVID-19 response. I plan to hold an engaging
discu ssion that covers the whole experience on dealing with this pandemic - from US to
international, to preparedness and response, the biology of the virus, the state of diagnostic,
treatment and vaccine development, and the importance of communica6on.
l will begin the session by providing brief (~3 min) opening remarks describing the
circumstances of the pandemic . Then, I will introduce the panelists and you will each have 7
minutes to provide remarks. You may use a limited numbe r of slides for illustration. I hope that
each panelist will provide their own perspective and speak to the issues proposed below.
• Jeremy Farrar will discuss the global response to the pandemic, drawing from his
experience as a global leader, the chair of the Scientific Advisory Group for the WHO's
R&D Blueprint and as a member of the Global Preparedness Monitoring Board.
• Tony Fauci will discuss the US pandemic and provide his perspective as a member of the
White House Coronavirus Task Force addressing the 2019- 20 coronavirus pandemic.
• George Gao will discuss China's response to the pandemic and lessons learned for the
rest of the globe .
• Susan Weiss will discuss the viral characteristics of SARS COV2 , insights into its
patbobiology, immunity and development of a pan-CoV antiviral.
• Richard Hatchett will discuss the development of new vaccines and treatments against
COVID-19.
• Sanjay Gupta will comment on the health system response to the pandemic and
challenges re lated to communication and pub lic engagement in responding to COVID -19.
Following remarks from each panelist, we will have a moderated discussion amongst ourselves -
l will ask you a set of questions (15 mins) and then we wil! take questions from the web (25
mins). To prepare me to be your moderator, please send me any questions you would like me to
ask you. For those of you who would like to have a prep call, please let me know and I will set it
up.
Best,
Victor
From: Mun , Jenny <JMun@nas.edu>

'ben .tinker@cnn .com' <ben.tinker@cnn.com>; 'Amanda.Sea ly@cnn.com' <Amanda .Sealy@cnn.com>;

'Nee l.Khairzada@turner.com' <Neel. Khairzada@tumer.com>; 'Tia.M iller@turner.com'
<Tia.Miller@turner.com>
Subject: NAS Annual Meeting Session on COVID-19 -- Information regarding you r Saturday April 25
participation
Dear Speakers:
I am the logistical contact for the COVID-19 session that w ill be held as part of the Annual Meeting
(online) program on Saturday, April 25 at 2:00 pm EDT. Thank you for agreeing to participate in this
session. To help you with your planning, I have provided additional details below .
Please note that the session w ill be live webcast and the general public will also be able to watch the
session. Video from the session will also be uploaded on the NAS YouTube channel
(https://www.youtube.com/user/theNASciences ) after the meeting . We will need to obtain signed
speaker release forms for your participation in this session. I have attached the speaker release form for
your rev iew and subm ission . Please return the signed speaker release form by Monday , April 13.
Session speakers are asked to connect 30 minutes prior to the session start time (by Saturday, April 25
at 1:30 pm EDT)to allow the technical staff to check connections and prepare for the session. Details on
how to connect will be sent before the meeting.
We w ill list you in our promotional materials as noted below. If this is incorrect, please let me know .
Anthony 5. Fauci, Director, National Institute of Allergy and Infectious Diseases

Jeremy Farrar, Director, We llcome Trust
George F. Gao, Director-General, Chinese Center for Disease Control & Prevention
Susan R. Weiss, Professor of Microb iology, Perelman School of Medicine, University of Pennsylvania
Since many of us have moved to remote work environments, you may already be proficient w ith Zoom
and other online meeting/collaboration applications . I am attaching a 'speaker guidelines' file in case
you have any questions on how best to prepare for and stage your remote talk. We have technical staff
available to help you become familiar with Zoom and its settings - such as "sharing your screen" (if you
have slide presenta tions that need to be shown during your talk) . We can arrange for a training session
this week or next week . If you would like to schedule a session, please let me know as soon as possible.
Dr. Dzau's office will be in touch regarding the agenda for this session. If you have any othe r questions,
please let me know .
Regards, Jenny
********************************
Jenny Mun
Membership Director
jmun@nas.edu
(b)(6)
Sent : Sun, 12 Apr 2020 23:00:07 +0000
To : Seth Berkley (Private)
Subject: RE:Checking in
Thanks, Seth!
From: Seth Berkley (Private)

---------
To : Fauci, Anthony {NIH/NIAID) [E] ------~= (b)( >
Subject: Checking in
Hi Tony: You are doing an amazing job during these very diffic ult t imes!
Doing everything we can here to support WHO to work on global acceleration of SARS-CoV-2vaccine
development as well as support our 73 poorest countries for COVID-19 preparation and hopefully
keeping routine vaccine coverage as high as possible. We are prepared to ultimately roll out a vaccine
when one is ready. No need to respond, but wanted to give you a friendly shout-out. We are all
thinking of you!
Best,
Seth
The private email account of

Dr Seth Berkley
Chief Exec utiv e Officer

Gavi, the Vaccine Alliance
(b)(6)
Tel:
Skype
Twitter --------
@GaviSeth
(b)( ,
The Global Health Campus, Chemin du Pom mier 40,
1218Le Grand-Saconnex Swi tzerland
Tel: CbH6)
Web: http: //www .gavi.org
With the suppo rt of donors and pa1tners, Gav i, the Vacc ine A lliance is working to immunise an
additional 300 million children betwe en 2016 and 2020, preventing a further 5-6 million deat hs.
Join us and help to reach every child. Visit www. gavi.org . sign up for the Gavi newsletter and
follow us on Facebook and Twitter.
NOTIC E : This emai l, includin g any attachments to it, may be confide nt ial and does not create
any binding contract on behalf of Gavi or its partn ers . If this ema il was sent to you in error,
please notify the sender immediately by rep ly e-m ail, and please do not use , distribute , retain,
print or copy the e-mai l or any attachment.
Sent : Sun, 12 Apr 2020 22:58:02 +0000
To: Herbert Mathewson
Subject : RE:PERSONAL:My April 1 blog on Tony Fauci, CUMC
----- (b)(6)
Hub:
Warm regards,
Tony
From: Herbert Mathewson (b)(6)

Sent : Saturday, March 28, 2020 1:57 PM
Subject : PERSONAL:My April 1 blog on Tony Fauci, CUMC
----- (b)(6)
Tony, I have been writ ing an annual April 1 column for 30 years, first in my monthly newsletter at Cape
Cod Hospital and now as my biweek ly blog of medical fun facts at www. hubslist.org. This is a heads up
before publication of this year's Apr il lblog about you and Biden.
I suspect that most of our classmates are, like me, boasting a bit about having you as a classmate. Your
honesty and "truthiness" is most appreciated and greatly valued by us amidst the leadership chaos. Your
success at "walking the line" is extraordinary .
Enjoy. Hub
• Home
• Hub's List of Medical Fun Facts
Vol. 230 April 1, 2020 Biden Picks His Running Mate
Press Conference
For mer Vice President
Joe Biden
April 1, 2020
(Official Transc ript)
BIDEN : Good morning everyone. I am glad to see all you reporters sitting 6 feet from each other . I
know it is burdensome, but we must work together to defeat this awful Zika . . . Rebola ... the flu . . .
er, what?, ... I mean, you know, the Coroner virus .
Speaking of the current virus crisis . . . boy that has a nice ring to it, doesn't it? ... it almost rhymes
. .. I would like to announce my pick of a running mate; Dr . Anthony Fauci, Director of the National
Institute of Allergy and Infectious Disease of NIH since 1984 .. . almost twenty .. . er . . . many years
ago .
Now before I start to answer your quest ions, let me give you some reasons for my choice .
Number 1: Dr . Fauci is smarter than I am, but I am ta ller and younger than he is .
Number 2: He is very experienced. He has worked with many President ial administrat ions since he
came to Washington ... in the 1980's as I remember . He told Ronald Reagan about the AIDS
epidemic, advised two Bushs . . . one of them gave him the Presidential Meda l of Freedom ... by the
way, Ben Carson got his medal during that same ceremony, . . . where was I? Oh, yeh . . .two
Clintons .. . yes two, remember Hilary's Health Care Plan? . .. and, of course, Obama or two.
Number 3: He gives very good TV interviews , even on Fox News with Sean Hannity trying to mislead
the viewers.
Number 4: His medical training has given him that special skill that all physicians must have to
succeed - "Always sound right, and if you don't know an answer, make one up." But he is like one
of my famous namesakes on Dragnet . . . Sergeant Joe Friday . .. "Just the facts, Ma'am."
Now I'll take your questions.
[Sounds of shouting , general loud babbling , a baby crying , a chair falls over]
REPORTER : " Mr. Biden have you moved away from your promise to pick a female running mate?"
BIDEN : Did I say that? When was that? ... Oh, it was during one of those debates? ... I wouldn't
call it a promise. It was a statement from which I am now socially distancing myself, and that makes
it a very timely question. . .. This social distancing is for the pits. I haven't smelled a good head of
hair in weeks ... for the record, my test was negative ... and I will ensure that women's voices will
be heard in my administration by appointing several to my cabinet. Elizabeth Warren naturally will be
Secretary of the Treasury. Kamala Harris as an experienced prosecutor would be an excellent head of
the Department of Justice . .. I think she is Latino too, isn't she? ... I am not sure about Senator
Amy Kolbuchuck from Minnesota and she has great hair, but Marianne Williamson, ... remember,
the physic healer ... could serve as Chief of the Alternate Universe . . .excuse me, Alternate
Therapies within HHS. Adding Senator Gillibrand to the cabinet would weigh the group too heavily
towards New York, since Dr. Fauci is from Brooklyn. I will, of course, appoint Tulsi Gabbard as
Ambassador to America Samoa.
REPORTER : "Do you have any concerns about any regrettable incidents in Dr. Fauci's past?"
BIDEN : Not really. My staff has vetted him very thoroughly. The only whiff of scandal we found was
his medical school yearbook picture where he was being lifted by two of his taller classmates so as to
appear as even taller than they. None of them were in black face.
Also some people may have difficulty knowing how

to pronounce his name correctly. It is pronounced as "Fow-ch i" with the soft "c" sound common to
many Italian names, . . . and as the Senator from Nevada I wish to say that I have many Italian-
American friends who are hard-work ing, decent citizens, but I must excuse myself from this Corleone
hearing for another important committee meeting ... oh, sorry ... was I channeling the Godfather
again? ... a great movie.
There is another small concern, since he is from New York City and his name ends in a vowel people
may think he is associated with Rudy Giuliani .... but we know that he is taller than Mike.
We have completely debunked the New Yorker Magazine stories that Dr. Fauci has recommended
internal alcohol to kill the coronavirus since external alcohol really doesn't work. In fact, he only
recommended it as an antidote to the daily briefings of the White House Coronavirus Task Force. Dr.
Fauci also noted that internal alcohol effects may be briefer t han the briefings, so viewers may repeat
a dose PRN (as necessary).
REPORTER : " Is it true that as noted in your background Press Release just handed out that Dr. Fauci
was born on Christmas Eve, and are you concerned about any back lash from Trump supporters who
regard Trump as the Second Coming."
BIDEN: Dr. Fauci is an American . Even though he was born in Brooklyn, there is no question about his
citizenship eligibility for this office. I think that a resurgence of the Birther Movement which was so
viscously directed at my close friend and mentor, Barrack Obama, . . . there I final ly got his name out
there ... would be very unfortunate. Next question.
REPORTER : "Has Dr. Fauci made any significant contributions in fields other than virology and
infectious diseases."
BIDEN : Well let me tell you a down-to-earth, fascinating story of one of his most significant
contributions. It will be a short one, I promise. Since the Coroner virus pandemic has taken over all
the headlines, editorial pages, social media memes, political cartoons, TV shows, graphic artist shops,
and a lot of other things swamping articles about the Opioid Deaths epidemic, Dr. Fauci has developed
a new attention -getting graphic to replace the familiar 1-10 faces of pain levels; the 1-4 faces of
Pandemic Panic levels.
1 2 4
REPORTER: "But face 4 is the same as face 2. Isn't that a confusing message ."
BIDEN : Exactly
"Thank you Mr. Biden, and Happy April Fools Day. "
PS: (b)(6) yearbook picture that won't be in the blog.

(b)(6)
This entry was posted on Saturday, March 28th, 2020 at

10:01 AM and is filed under coronavirus, current events, humor, Infectious Disease. politics. You can follow any
responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site. Edit
this entry.
Post navigati
•
RECENTISSUES
o Vol. 229 March

15 2020
Beware the
Ides of March
o Vol . 228 March
1. 2020
Phvsician
Speeders,
Roundup Off
One Hook, and
Don't Shoot
the Cows
o Vol . 227
February 15.
2020 Milk is
NOT Good
For You?!
o Vol . 226
February 1,
2020 Current
Controversies
. .. other
than Impeach
ment .
•
• YOU
ARE FOLLOWING
THIS BLOG
You are fol lowi ng

this blog, along
with 216 other
amazing people
( mana ge).
Blog at WordPress.com.
Sent : Sun, 12 Apr 2020 22:38:10 +0000
To : Holdren, John P.
Subject: RE:Antiviral SNA w hit e paper
Thanks,John.
From: Holdren, John P.

------------
(b)(6)
-------~~
To : Fauci, Anthony {NIH/NIAID) [E] (b)(6)
Cc:Fauci, Anthony (NIH/NIAID) [E] ======= (b
~~~(6)
~
Subject: FW: Antiviral SNA white pape r
Dear Tony-
I know you are overwhelmed, but the attached whitepaper on a vaccine-development idea migh t be
worth a look . You may member Chad lv1irkin as a member of the Obama PCASTwhose extraordinary
contributions across a range of science and engineer ing issues have landed him in the NAS, NAE, and
NAM, among other distinctions - a verr smart guy.
Aside from that, thank you for your courageous truth-telling in the incredibly demanding situation in
which we find ourselves.
My best,
John
John P. Holdren
Teresa and John Heinz Professor of Environmental Policy
John F. Kennedy School of Government
Professor of Environmental Science and Policy
Department of Earth and Planetary Sciences
Affiliated Professor
John A. Paulson School of Engineering and Applied Science
HARVARDUNIVERSITY
Assistant:
--------------------------- (b)(6)
From: Chad A Mirkin (b)(6)

To : Holdren, John P. Cb)~ >
Cc: Robert A Lamb
Subject: Antivira l SNA white paper
CbH6);Andrew Lee
------------- (b)(6)
(b) (4)
Thanks and best regards, Chad

Vr. ~uci 5Mqrc.~ 1'1c.J,1es.sJ3r~<-/<c,tr,/°j)
p,·<:./<S N
rc:Jc
A NQc1t1.al
k
H£ (
' I\ (IVC•"""
11'ftvt,1.:>A
RI}//
Mo~k-)(
w
E:
s (Cf OIOVtN,S I 11
flvt1W1HIIIJ s
T SARS
W,stN le. 1
-I
MCl2.5 \Jest N,le
Ml/l..
S f<.ot
t'S
C.o01"1~ I \},) C:&ol«
'1
5 s ,..lfpo;
(0(0(10.\11 (\J!,
cf,olq l
0
u a, ,Jq...,f'O,<
5.....11 0
fT~An
--
,_
-- f:bol,
folio
1)
\J
Me~lc:.$
f
T Hcf..}i~,s B
s
Ht•ro g/)
H M('o.$1<} zko. T
Mo le> (b)( 6)
z ;kc.
t07:/Jtj
w
Cheers,
John T. Brooks, MD
Chief M edical Offi cer, CDC COVID-19 Respon se
Email (b)(6)
Apologies for error s in my messages that may be due to my need to

dictat e.
Sent : Sun, 12 Apr 2020 22:18:05 +0000
To: John Dirks
Subject : RE:Great leadership
John:
Thanks for the note, Much appreciated.
Best,
Tony
From: John Dirks (b)(6)

To: Fauci, Anthony (NIH/NIAID) [E] ------~= CbH6)>
Subject : Great leadership
--------
Tony, I admire the tremendous leadership and expertise you are provid ing during this COVID-19 crisis-I
know it not easy-but your advice is so credible and listened to, Best John Dirks
Sent : Sun, 12 Apr 2020 22:17:08 +0000
To: Lewis M Drusin
Thanks, Lew

From: Lewis M Dmsin _______ """
(b'""
)...,.
(6)
=>
Sent : Wednesday, March 18, 2020 11:24 AM
-------~~
To: Fauci , Anthony (NIH/NIAID) [E)._ ______ (b
_ )_ (_.
6)
Subject: Coronavirn s
Tony
When people ask me about coronavi rus, f j ust tel I them to listen to you. Your ca lm, steadfast exp lanation of tbe
science is a major factor in the public trusting government to resolve this incredible publ ic health cris is. Hope you
are do ing well.
Best wishes as alway s
Lew
Sent : Sun, 12 Apr 2020 20:21:16 +0000
To : EI-Gabalawy, Nadia (PHAC/ASPC)
Cc: (b)(6)
Subject: RE: Hello from Canada!
Nadia:
Best regards,
Tony
From: EI-Gabalawy, Nadia (PHAC/ASPC) (b)(6)

Sent: Monday, March 30, 2020 2:48 PM ------------
--------=-=--:-=
Subject: Hello from Canada! --------- (b)(6)
Hi Dr. Fauci,
I thought I would reach out to you amidst this crisis; I respect the work you're doing a great deal.
- Hani EI-Gabalawy, did a research sabbatical at NIH ________________________ _
Amazing work that you're doing. I've been following your discussions and scientific innovat ion regarding
COVID-19. I've been working for the federal government in Intelligence for about thirteen years and
recently moved to the Canadian Public Health Laboratory Network Secretariat to support the Emergency
Operations Centre at the National Microbiology Lab. I've been with the NML for almost my whole
career.
Just a quick hello and deep respect for your work. My colleagues and Director have said that we' re on
the exact same page as you, in terms of your perspective and assessment of the pandemic. Although
there is a border between us, know that we are in agreement with your work and I' m thrilled to see you
advising the public. There is no better person to do the job.
Kindest regards,
Nad ia EI-Gabalawy
Team Lead, Support Services, Canadian Network for Public Health Int elligence
Public Health Agency of Canada/Government of Canada
(b)(6)
(b)(6)
Chef d'equipe, Services de soutien, Reseaucanadien de renseignements sur la sante publique
Agence de la sante publique du Canada/ Gouvernement du Canada
(b)(6)
(b)(6)
Sent : Sun, 12 Apr 2020 20:19:01 +0000
To : Anderson, Jennifer (NIH/NIAID) [E]
Cc: Lane, Cliff (NIH/NIAID) [E];Clifton, Dawn (NIH/N IAID) IE]
Subjec t : RE: LIR Requests for DIR Supplemental Funding (non-COVID related) - PLEASE
REVIEW
Looks fine.
From: Anderson, Jennifer (NIH/NIA ID) [E]

To : Fauci, Anthony (NIH/NIAID) (E]------~
----------
= (b)(6)>
(b)(
,..;...;:...;;.!:====~~~~
Cc: lane, Cliff (NIH/NIAID) [E)______ Cb
_H_ ; Clifton, Dawn (NIH/NIAID) [E]
(b)(6)>
Subject: LIR Requests for DIR Supplemental Funding (non -COVID related) - PLEASEREVIEW
Hi Dr. Fauci,
Please review the attached requests for DIR Supplemental Funding on behalf of LIR investigators. I have
further summarized the requests in the table below . I took the liberty to provide a suggested ranking
based on funding need . Dr. Lane has reviewed the requests and agrees with the rankings as well.
(b)(5)
Sincerely,
Jennifer
Priority
Cost Order for
Pl Supplement Description LAB
(b) (5)
(b)(5)
Jennifer M. Anderson , PhD
Deputy Branch Chief

1AMB/OAS/N IAID
9000 Rockville Pike, Bldg. 10 Rm. 6A19A
Office Phone : Cb)(6)
NIH Cell: (b)(6)
PersonalCell: (b)(6)
FAX:301-402-4122
Sent : Sun, 12 Apr 2020 20:18:33 +0000
To : Brian Kelsall
Subject : RE:What can be done?
Thanks, Brian. That recommendation is in the works.
From: Brian Kelsall (b)(6).

-------~~
Subject: Fwd: What can be done? --------- (b)(6)
Dear Tony,
I'm lucky to have thoughtful neighbors . Please see the email that I received from Sue Edwards. Because
of the likelihood that there are so many asymptomatic cases, isn't it time to recommend everyone
where a mask of some kind? Not N95 masks or even surgical masks that should be reserved for first
responders and hospital staff, but some face covering?
Best, Brian
Sent from my iPhone
From: Sue Edwards (bH >

Date : March 30, 2020 at 1:15:06 PM EDT
To : Brian Kelsall (b)(6)
Subject: What can be don e?
Why can't the CDC make a public service announcement that everyone should be wear ing
some kind of mask @ in public? It doesn't have to be N95 or even surgical though that
wou ld be ideal (as is done in every Asian country) given that the virus is actually
aerosolized (several studies confirm this ) and that it can be spread by asymptomatic
carriers (which account for possibly more than half of the positive cases - we w ill never
know) it seems obvious that food markets are no different from hospitals and in many
cases worse since at least in hospitals people are wearing some protective equipment ...
just say wear a cotton mask, a scarf, a bandanna , a DIV paper towel mask .. whatever- but
no one should be going to a market without one and absolutely no one working in a store
or stocking supplies or delivering food, packages, mail etc should be allowed to work
w ithout something covering the face- th is includes pharmacists as well, obviously D wtf ls
w rong with this country?
What use are gloves? When the offending particles are escaping our faces and floating
around for several hours, landing on everything around us... the only place it shouldn't be
as critical is outdoors in the sunshine where UV light should deactivate viruses fairly
quickly ...
Sue
Hope you are all well - and can give me some hope that this message get through the thick
skulls of the so called experts ... even during the 1918 flu epidemic, everyone wore some
facial covering when out in public places - what is going on?
EVERYASIAN country is employing this approach with much greater success at slowing the
rate of transmission - even India!
https ://www.nytimes.com/202 0/03/2 7/hea Ith/ us-coronavir u s-face-masks.htm I
https://medium.com/better-humans/a -pract ical-guide-t o-covid -conta inment-orifice-by-

orifice-80c2f3f167be
Sent from my iPhone

Sent : Sun, 12 Apr 2020 20 :07:20 +0000
To : Harold Slavkin
Cc: Collins, Francis (NIH/OD) [El
Subject : RE: reaching out t hinking of you
Hal:
Thanks fo r your note. These divergent phenotypes are truly puzzling. I have copied Francis
on this e-mail in case he has any additiona l though ts.
Best regards,
Tony
From: Harold Slavkin

--------- (b)(6)>
To : Fauci, Anthony (NIH/ NIAID) [E] -------= (b"'""
)( =6)•>
Subject: Fwd : reaching out thinking of you
F rom : "Harold C. Slavkin"

-----
Subject: reac hin g out thinking of you
(b)(6)
Date: April 2, 2020 at 11:39:40 AM PDT

To: Cb)C6)
Cc: "Somerman, Ma1tha (NJH/NTDCR)[E]" (b)(6)
--------
Hi Toni,
You continue to be "the role model" for leader s in

biomed ical research these many decades. I am so
proud of your effort s during the se remarkable tim es in
history . Thank you! !! I cherish those 5 years {1995-
2000) that I served as Director of NIDR (that became
NIDCR) wh en we were able t o co-sponsor effort s to
uti lize saliva as an informative fluid for HIV detect ion .
For me that was an invaluable opportunity to be part of
Harold Varmus' leadership team and to continue my
research within NIAMS.
I was inspired by your public comments a few nights

ago on CNN regarding your observations of significant
variance in the pathogenesis or phenotypes noted for
subsets of critically ill patients with COVID-19 on
ventilators in ICU. I was immediately reminded of David
Feinberg (CEOof UCLA Health Sciences, more recently
5 years at Geisingers, and currently CEOof Google
Health Companies) who used genotyping for
populations around Lancaster PA and discovered about
3-4% with undiagnosed genetic diseases that translated
into reduced costs of hospitalization, treatments, etc.
Kaiser-Permanente Northern California, and many
other systems, have also used this approach since
sequencing has become cost effective . Perhaps a select
sample of people who require ICU, and another that
require ventilator, might inform the genotype of the
most susceptible people and might also inform a target
to use to discover what exist ing drug or therapy could
be mobilized. Through your position, might there
already be a large data set of whole genome sequences
(e.g. military) that could be rapidly explored using
bioinformatics?
As you may recall , my personal research activities have

focused on craniofacial diseases and disorders. For
example, Osteogenesis Imperfects (0.1.) presents
cardiopulmonary disorders in addition to bone and
tooth disorders. Since penetrance varies, cases of rare
cond itions can illuminate "hidden" SNP abnormalities
in key gene clusters (e.g. MHC gene clusters, etc.).
Considering lung disorders as you mentioned in your
comments about pathogenesis, already known gene
mutations that present several major phenotypes
including pulmonary diseases could become very
useful. Perhaps Francis and others at the NIH could
create a trans-NIH approach that is enabled to visit this
pandemic from the perspective of human phenotype
variance discovered via genomics?
I asked Martha Somerman to explore the talents

available at NIDCR (and beyond) related to connective
tissue genetic diseases that associate with Types 1 and
111 collagens, elastics, and hyaluronic acid
glycoproteins AND lung tissue fibrosis, etc . She may
also reach out to you.
Meanwhile, thank you for your untiring efforts to use

science to inform health policy. Of course, let me know
if I can be of any use to you .
Always, Hal
Sent : Sun, 12 Apr 2020 19:42:21 +0000
To: Susan Corrigan
Subject: RE:Coronavirus
Susan:
Thank for the note. I hope that all is well with you.
Best regards,
Tony
From:Susan Corrigan (b)(6);,,

sent: Wednesday, Apr il 1, 2020 10:29 AM
(b..,.,.
)(=6):>
Dear Dr. Fauci,

I have seen quite a bit of you on television. I live in Miami now. South Florida is the epicenter of the
coronavirus. I wish Governor Desantis would shut down the state of Florida. Thank you from (b)(6)
Susan Corrigan
Sent : Sun, 12 Apr 2020 19:41:04 +0000
To: Nader, Ralph
Subject : RE:COVID-19 Question
Ralph:
I am so sorry that I took so long to get back to you. I receive over 1000 e-mails per day and
even with staff screening, I do not see them for days. There is still an issue/prob lem with
serologic tests in that they need to be va lidated as being sensitive and specific. Many tests that
have been used t hus far are not accurate and ARE M ISLEADING. The UK bought millions of
these from China and found that they were inadequate. The FDA is in the process of validating
ce rtain tests this week and if they pass, then we can expect to have tests w ithin the next few
weeks to do the things that you have suggested.
Best regards,
Tony
From: Nader, Ralph (b)(6)

To: Fauci, Anthony (NIH/NIAID) [E] ------~~ >
Subject: COVID-19 Question
-------- (b)(
Dear Dr Fauci,
I hope this email finds you wel l.
Thank you for everyth ing you are doing for our country in these difficult times.
I realize your time is extremely valuable - especially dur ing these times.
I have one question - if you can help me answering it.
Why are serologic tests not made abundantly available during these times?
This will help in so many ways:
- Can it be used to triage healthcare workers? Naturally "vaccinated" healthcare workers may be bet ter
triaged to be on the front lines fo r example, taking care of COVID-19 patients. {In times of limited PPE,
documentation of natural immunity is probably one of the best PPE's out there)
-Another major use for it:
People can be asked to remain home, until they have documentation of natural immunization .
Serologic tests are very cheap, can be mailed, and done at home.
Immunized individuals can carry the test as "proof" of immunity - and may be able to go back to work
etc.
It is just a thought. It may be a very candid question that I am asking.
But while we are waiting for a vaccine (and this will take several months), some people may be able to
benefit from a very cheap test (that can be done at home) to short-circuit that waiting time.
Thank you for everything you are doing to our country,
You are such an inpiration to us all.
I wish you all the best.
Thank you.
Ralph
Ralph Nader, MD
Renal Fellow - Boston Medical Center
Instructor of Medicine - Boston University School of Medicine
Email
-------- (b)(
Phone:
----- (b)(6)
Pager: (b) (6)
This electronic transmission may conta in information that is privileged, confidentia l and exempt from
disclosure under applicable law. If you are not the intended recipient , please notify me immediately as
use of this information is strictly prohibited.
Sent : Sun, 12 Apr 2020 19:29:52 +0000
Cc: Conrad, Patricia (NIH/NIAID) [E);Folkers , Greg (NIH/N IAID) [E];Routh, Jennifer
(NIH/NIAID) [E];Stover, Kathy (NIH/NIA ID) [E)
Subject: RE: documentary interview request: PBS+ Topspin Productions
Let us discuss this tomorrow before we do anything. No one has any "exclusives" on anything
about me.

~======::---:'!..-~ Cb)( '>; Folkers, Greg (NIH/NIAID) [El
(b)(6)>; Routh, Jenn ifer (NIH/NIAID) [E] CbH >; Stover, Kathy
--------
Subject: RE: documentary interview request : PBS+ Topspin Productions
(b)(5)
From: Fauci, Anthony (NIH/NIAID) [El (b)( '>

-----~~ (b)(6)>
Cc: Conrad, Patricia (NIH/NIAID) [E]=======~ (b
")-:-=
"'C; Folkers, Greg (NIH/NIAID) [E]
(b)(6)>; Routh , Jennife r (NIH/NIAID) [E] (b)( ; Stover, Kathy
--------
(NIH/NIAID) [E]
-------- (b)(6)>
Subject: RE: documentary interview request: PBS+ Topspin Productions
(b)(S)
(b)(S Happy to discuss.
From: Billet, Courtney (NIH/NIAID) [E] ______ (b)_.~ >

To: Fauci, Anthony (NIH/NIAID) [El _____ __,..,
(b)...,
(6)
"" >
Cc: Conrad, Patricia (NIH/NIAID) [El CbH6J>;
Folkers, Greg (NIH/NIAID) [El
Routh, Jenn ifer (NIH/NIAID) [E)
(b)(6)>;
(NIH/NI A ID) [E)______ (b_H _6)> ----------- (b)( ; Stover, Kathy
Subject:ASF: documentary interview request: PBS+ Topspin Productions
We have received a request from the PBSprogram "American Masters" and Topspin Productions to do a
documentary about you. Their near-term ask is one or two brief video-l ink phone interviews during the
next few months. After the coronavirus pandemic has subsided, they would like to do "a proper sit-
down in which you could tell us the stories that speak to the key moments in your remarkable career."
On the face of it, this might seem to overlap with the Tobias/Hoffman project, but in the end I think
they'd be quite different products. Please let me know if you'd like us to seek clearance to proceed.
On Apr 7, 2020, at 9:26 AM, Lia Carney <lia@topspinconten t.com> wrote:
Hi Laura,
Nice to speak yesterday. See below for formal reque st and informat ion about the series. Jf
you wouldn ' t mind confirming receipt of th is email, I can make sure to let me partners in
this project know it is in the correct hands . Stay safe and thank you .
Dear Dr. Fauci,
To re-introd uce myself, I am Lia Dosik Carney , (b)(6) and an executive

producer in Los Angele s. As you'll remember, we filmed w ith you last summer as a major
participant in a documentary we were producing centered around infect ious disease. Than k
you again for parti cipati ng and taking the time . It was great to hear about your
extraordinary career as well as a few interesting stories abou t (b) (6)
Obviously even ts ha ve taken over all of our lives . Like everyone else in this country, I am
very grate ful for your honest and steadfast leaders hip as we navigate our new reality.
During this time , we 've been rethinking how we want to proceed with our docume ntary and
have come to reali ze focusing on you, your experi ences over the deca des, how you hav e met
every challenge presented to you, would give all of us a roadmap for the future.
To tha t end we are now in partn ership wi th AMERICAN MASTERS , PBS ' flagship series
that profiles and hon ors outstanding Americans. To gethe r we wo uld like to produce a
comprehen sive look at your life, your experiences and your ins ights into how to deal with
the recurring di seases that conti nue to plague our lives.
I have included below an introductory email from American Masters Executive Produce r,
Michael Kantor , which will give you a broader sense of that exceptional PBS series and the
extraordinary work they produce.
We all lrnow how limited your time is now - and all of us are so appreciative of what you
are doing. We re:spectfu lly hope you will allow u:s to chronicle your life in medicine. We
know that as we emerge from this late st crisi s - understanding how you were able to deal
with earlier plagues (HIV-Aids for instance) will - we hope - give all of us a better
understanding of the challeng es all of us will continue to face.
Appreciate your consideration. With respect, Lia
Dear Dr. Fauci,
My name is M ichael Kantor and I am the Executi ve Producer of the PBSAMERICAN

MASTERSseries. I believe you know (b)(6)
- I am writing today to see if you would allow us to make a film on your life and
career. We would require very little of your precious time right now, perhaps one
or two very brief video-l ink phone interviews over the next few months, just as you
have appeared on Trevor Noah's The Daily Show and spoken with basketball star
Steph Curry. Later this year, after the current crisis has subsided, we would find
time in your busy schedule for a proper sit-down in which you could tell us the
stories that speak to the key moments in your remarkable career.
I am excited to work with Lia Carney and Topspin Productions on this project,
because it has been important to me to expand the roster of AMERICAN MASTERS
films to include scient ists. Over its 33 year history , our series has profiled artists
such as Leonard Bernstein, Maya Angelou and Raul Julia, athletes including Billie
Jean King and Ted Williams, and now we are presenting the stories of James
Watson and Oliver Sacks in our pantheon of great films. Our series is dedicated to
telling biographies with the utmost care, and for that reason we have been
honored with awards like the Emmy, the Peabody, the Grammy and even an
Oscar.
We would be honored to have you join us in our public television effort to educate
Americans about the domestic and global health issuesthat have been the focus of
your career . This letter is brief because we respect your time, but we sincerely
hope that you will join us in creating a documentary of distinction for a broad and
diverse national audience .
Sincerely yours,
Michael Kantor
Michael Kantor
Executive Producer
American Ma sters
Thirteen IWNET
825 Eighth Avenue
New York, NY 10019-7435
212-560 -6975 (office)
<image001.png>
American Masters website
Facebook !Twitter I Tumblr
Sent: Sun, 12 Apr 2020 18:25:39 +0000
To: Lane, Cliff (NIH/NIAID) [El
Subject: RE:Clarification in the chapters on Human Immunodeficiency virus disease:
AIDS and related disorders ( Chapter 197 ) page 1445 and Toxoplasma infections ( Chapter 223 ) page
1615, in Harrison's principles of internal medicine-20th Ed
Thanks .
--------
From: Lane, Cliff (NIH/NIAID) [El
(b)(6)
To: Fauci, Anthony (NIH/NIAID) (E]------ --~

-------- (b)(6)
Subject: Re: Clarification in the chapters on Human Immunodeficiency virus disease: AIDS and related
disorders ( Chapter 197) page 1445 and Toxoplasma infec t ions ( Chapter 223) page 1615, in Harrison's
principles of internal medicine-20th Ed
I responded to him and copied Kami Kim. He misread the two sections. We are saying the same things.
I did not copy you.
From:Anthony Fauci < Cb)(6)

To: "Lane, Cliff (N IH/NIAID) [E]"-------~~
--------- (b)(6)
Subject: FW: Clarification in th e chapters on Human Immunodefici ency virus dis ease: AIDS and
related disorde rs ( Chapter 197 ) page 1445 and Toxoplasma infections ( Chapter 223 ) page
1615 , in Harrison's pr inc iples of internal medicine-20th Ed
Please take a look at this. We get these inquiries from Ind ians all the time. They read HPIM
very carefully. Is there anything we need to change here?
From:Viswanathan Neelakantan (b)(6)>

----------
To: (b) (6); Fauci, Anthony {NIH/NIAID) [El
__ ..:....;,
___ _;_.:....;_=======--- (b)(6)
Cc: Lane, Cliff (NIH/N IAID) [El (b)(6)
Subject: Clarification in the chapters on Human Immunodeficiency virus disease: AIDS and related
disorders ( Chapter 197) page 1445 and Toxoplasma infec tions ( Chapter 223) page 1615, in Harrison's
principles of internal medicine-20th Ed
Dear Professor Anthony Fauci and Professor Kami Kim,

Greet ings from Pondicherry , India . This is Dr K Neelakantan Viswanathan, Senior Professor of Medicine
in a medical school here.
Going through your excellent chapter, [Chapter 197) in page 1445, on A IDS and related disorders in
HPIM-20, under secondary prophylaxis/ maintenance therapy for Toxoplasmosis it is said that "it may
be discontinued in the setting of effective cART and increases in CD4+ T cell counts to > 200 /
microliter for 6 months".
In page 1615, another wonderfully written chapter, ( Chapter 223) on Toxoplasma infect ions, Professor
Kami Kim has mentioned that " individual s who have completed initial ther a py for TE should receive
treatment indefinitely unless immune reconstitution with a CD4 + T cell cont of >200 occurs as a
consequence of cART".
Since both feature in the same textbook followed worldwide by medicos, could you please clarify the
above?
I stand subject to any correct ions.
Hoping that we fight Covid-19 effective ly very soon . Stay safe.
Regards and best wishes,
Professor Dr K N Viswanathan
Sent : Sun, 12 Apr 2020 18:19:06 +0000
To: Daniel Lucey
Subject : RE:COVID-19:Rembrandt' s Belshazzar's Feast in a time of chiaroscuro 2020 I
ScienceSpeaks:
Thanks , Dan.
·..------- --,.-s-,:;aa.
_
From: Daniel Lucey (b) (
To : Fauci , Anthony (N1H/NIAlD) [E]

Cc: Da ni el Lucey
--------- ~
Scot : Saturday, April 11, 2020 5: 14 PM
(bH >
CbH
Subject: COVTD-19: Rembrandt 's Belshazzar' s Feast in a time of chiaroscuro 2020 I Science Speaks:
Tony, Thank you for the immens e 24/7 contribution you are makin g to our nation. Your wife is right: Pis get more
sleep and m eals! Before Easter tomo rrow I am s haring this brief Old Testament story to which I gave a 2020
interpretation. Today' s IDSA posting I am emphasizing that simultaneous antibody and virus RNA tests shou ld be
done on "relaps ed" or "reinfected " Covid-19 patients e.g. , South Korea (N=91), China , elsewhere. I am looking
forward to giving NIAID Grand Rounds May 1st with Barn ey Graham and John Beig e!. Dan (b)(6)
https://sciences peaksblog .org/2020 /04/ 09/covid-19 -rembrandt s- belshazzars -foast- in-a-time-of-chiaroscuro-2020 /
Sent from my iPhone

Sent : Sun, 12 Apr 2020 18:12:0 1 +0000
To : Barton Haynes, M .D.
Subject : RE:coach Kvi deo for DHVI
Thanks, Bart. Glad to have you working on the COVID-19 issue.
From: Barton Haynes, M .D . ._________ Cb)

_(...,,
6)>
Se nt : Sunday, April 12, 2020 8:47 AM
------~=
Subject: RE:coach K video for DHVI
-------- (b)(6)>
Coach K and I came to duke on the same day in 1980 and (b)(6)
- ...when I was chair and he wasn't quite so famous, he used to see all my division chief
recruits and help me recruit. He is a really good guy, as you know.
Am on the francis Collins-appointed NIH working group for COVID19 vaccines, first meet ing in the am ...
Will continue to flog CoV2 simultanelously while making good progress on HIV. This past week had 4
HIV SABS, CHAVD, an IPCAVD, an HIVRAD we have with Scripps, and our GMP unit.. ...all on line. Not
messing around .... All went really, really well.
Thanks for all you continue to do.
Best bart

-------- (b)(6)>
To: Barton Haynes, M.D . ________ _>

Cb
_~_
6J>
Subject: RE:coach K video for DHVI
Very nice!!
From: Barton Haynes, M .D. (b)(6)

To: Fauci, Anthony (NIH/NIAID) [E)______ """
(b"""'
)(=6)
Subject: coach K video for DHVI
Hi tony; if you get a chance, here is a 3 min. video Coach K did last week for DHVI. I sent it to all 270
DHVI members and they were very inspired!
Thanks for sending your interview with K. it is terrific.
All the best B

From: Jon Jackson (b)(6)>
Sent : Thursday, March 26, 2020 12:59 PM
To : Barton Haynes, M.D. _________ Cb
_>_
C6J>
Subje ct: Re: saw your video
https://www.dropbox.com/s/2f6b142lv63el0f/lMG 0250.MOV?dl=0
Sent from my iPhone

Sent: Sun, 12 Apr 202017:27:46 +0000
To: Folkers, Greg (NIH/NIAID) [E);NIAID OD AM
Cc: Stover, Kathy (NIH/NIAID) [E);Leifman, Laura (NIH/NIAID) [E];Routh, Jennifer
(NIH/NIAID) [El
Subject: RE:Serosurvey
OK. We can discuss .
From: Folkers, Greg {NIH/NIAID) [El

-------- (b)(6)

Cc:Stover, Kathy (NIH/NIAID) [E) (b)( •>; Leitman, Laura (NIH/NIAID) [E)
(b)(6); Routh, Jennifer {NIH/NIAID) [E)
--------
Subject: RE:Serosurvey
(b)(6)
Marilyn Marchione: I'm writing to request a chance to embed with a team doing a coronavirus
serosurvey, to tell a public health story from the front lines as I believe I'm uniquely positioned
t o do.
(b)(5)
Let us d iscuss in a.m.
-----O riginal Message-----

From: Marchione, Marilynn <MMarchione@ap.org >
Sent: Sunday, April 12, 2020 10 :56 AM
------~= CbH6l>
Cc: Folkers, Greg (NIH/NIAID) [E] CbH6l>;Conrad, Patricia (NIH/NIAID) [E]
CbH6);Stover, Kathy (NIH/NIAID) [E] CbH6l>;Leifman,
Laura (NIH/NIAID) [E] (b)(6)
Subject: FW: Serosurvey
Hello Dr . Fauci,
I hope you are stayi ng well in these trying times.
I'm writing to request a chance to embed with a team doing a coronavirus serosurvey, to tell a
public health story from the front lines as I believe I'm uniquely positioned to do. I've made a
similar request to the CDC, but the nationwide reach of the NIAID serosurvey might make my
proposal easier to consider, so I'm coming hat in hand to you as well.
Twenty years ago, as a temporary CDCemployee during a four-month Knight Journalism

fellowship , I had the opportun ity to take the EIScourse in Atlanta and then work on several CDC
outbreak and disease invest igations . One was a serosurvey on Long Island after West Nile virus
had recently emerged in the U.S.
I headed one of a dozen CDCteams that included a driver, a phlebotomist and a health aide
from the New York state and Suffolk County health departments. We went door-to-door to
consent part icipants, get blood samples and do interviews on exposure and symptoms.
I appreciate the tremendous scientific value that serosurveys offer and the kind of attention to
detai l and study rigor that's needed to get reliable information. I'm also a longtime medical
journalist who understands and is sensitive to confidential ity , et hical and privacy concerns. I've
been recognized by my peers as a science writing leader .
https :lj casw.org/ casw/ a rti cle/m ari lyn n-m arch ione-associated-press-wi ns-victor-coh n-prize
I've attached some letters from CDCand othe r health officials regard ing my work on the
serosurvey, a photo of the EISand CDCteam (that's me toward the right in the front row) and
t he MMWR report resulting from our work . The field supe rvisor -- Dr. Anthony Marfin, now
with t he global vaccin e group PATH ( (b)(6) is willing to speak t o you on my
behalf. Dr. Richard Besser, now presiden t of the Robert Wood Johnson Foundat ion, was my
fellowship superviso r and mentor at CDC. Others I worked with include Dr. Anne Schuchat, Dr.
John Ward, Dr. Robert Tauxe and Dr. Lyle Petersen .
And of course, you know me from nearly three decades of medical writ ing, includ ing the
HIV/AIDS government trip to Africa when Tommy Thompson was healt hy secretary.
The Associated Press reaches half of the world 's population every day. I hope to offer a story
t hat I and the AP are uniquely able to provide , to show and explain how public health is done
and how science is accompl ished during a pandemic . Thank you for considering my request.
Marilynn Ma rchione
Chief Med ical Writer
The Associated Press
(b)(6)
mmarchione@ap.org
Twitter: @MMarch ioneAP
The information contained in this communication is intended for the use of the designated
recipients named above. If the reader of this communication is not the intended recipient, you
are hereby notified that you have received this communication in error, and that any review,
dissemination, distribution or copying of this communication is strictly prohibited. If you have
received this communication in error, please notify The Associated Press immediately by
telephone at +1-212-621-1500 and delete this email. Thank you.
Sent : Sun, 12 Apr 202017:12:57 +0000
Subject: RE:Wall Street Journal story
Of course. No problem.
From: Barton Haynes, M.D. (b)(6)

------~=
--------
Subject: RE: Wall Street Journal sto ry
(b)(6)>
If he wants also to talk to me should I also talk to him?
From: Fauci, Anthony {NIH/NIAID) [E] (b) ( >

--------
To: Barton Haynes, M.D. --------~=
----------
Subject: RE: Wall Street Journal story
(b)(6)
Yes to your questions.
From: Barton Haynes, M.D. _________ _,.>

(b) (6)
To: Fauci, Anthony (NIH/NIAID) [E] -----~~ (b)(6)>
I know you don't have time to answer these but if you do fine, if not, ok.
Just don't want to screw something up.
Is it fair to say that shelly was not only a mentor but a father figure. You and shelly were very close.
also fair to say shelly was your most impo rtan t mentor in your career?
Tx bart

--------~
To: Barton Haynes, M.D. _________ Cb~
_)_(6)
_'
Bart:
No problem. Go for it!
Best.
Tony
From: Barton Haynes, M.D. (b)(6)>
------~~
Subject: FW: Wall Street Journal story
-------- (b)(6)
Hi tony; the fellow who wrote the article about you as point guard for St. Regis and the nat ion from the
Wall street journal wants to talk to me about shelly wolff and you per below. is that ok? I will of course
say only those things that are unbelievable but t rue ....which are all wonderful.. ... best bart
From: Ben Cohen <ben .cohen@wsj .com>

To : Barton Haynes, --------~~
M.D . ..._ ________ Cb
_) _(6)
Subject: Wall Street Journ al story
Dr. Haynes ,
I'm a reporter from the Wall Street Journal and, more important , a friend of Ben's from Duke.
l've written quite a bit about your mentor and friend Dr. Fauci in the last few weeks, and I'm
working on another story now that I was hoping you might be able to help w ith.
This story is about his mentor, Dr. Wolff , and how Dr. Wolff helped tum Dr. Fa uci into the
person he is today. I would love to hear more about their relationship from your perspective. I
know this is an insanely busy time, but would you have a few minutes to chat by phone ?
Thanks very much for your help. I hope you're safe and well in Durh am.
All best ,
Ben
Ben Cohen
212-416-3420 (o)
(b)(6) c)
ben.co hen@ws j.com
Sent : Sun, 12 Apr 2020 17:10:22 +0000
Subject : RE:Wall Street Journal story
Thanks.
From: Barton Haynes, M .D. ________ Cb)

_ (...,,
6)>
Se nt : Sunday, April 12 , 2020 1 :10 PM
To : Fauci, Anthony {NIH/NIAID) [E] -----~~ (b)(6)>
Subject: RE: Wall Street Journal sto ry
I am going to refer him to you per the last note. Best bart
From: Fauci, Anthony {NIH/NIAID) [E] (b) ( >

--------
_________
Se nt : Sunday, April 12 , 2020 1:09 PM
To: Barton Haynes, M .D. -------~~
.,
(b)(6)>
Yes to your questions.
From: Barton Haynes, M .D. _________ _,.>

(b) (6)
Sent: Sunday, April 12, 2020 1 :06 PM
To : Fauci, Anthony (NIH/NIAID) [E]------~=
-------- (b)(6)>
I know you don't have time to answer these but if you do fine, if not, ok.
Just don't want to screw something up.
Is it fair to say that shelly was not only a mentor but a father figure. You and shelly were very close.
also fair to say shelly was your most important mentor in your career?
Tx bart
From : Fauci, Anthony (NIH/NIAID) [E] (b)(6)>

--------
Sent : Sunday, April 12 , 2020 12:44 PM
To: Barton Haynes, M.D. --------~
_________ Cb ~_'
_)_(6)
Subjec t : RE:Wall Street Journal story
Bart:
No prob lem. Go for it!
Best.
Tony
From: Barton Haynes, M.D. (b)(6)>
------~~
-------- (b)(6)
Hi tony; the fellow who wrote the article about you as point guard for St. Regis and the nat ion from the
say only those things that are unbelievable but t rue ....which are all wonderful.. ... best bart
From: Ben Cohen <ben .cohen@wsj .com>

-------~~-
To : Barton Haynes, M.D . ________ _ )_ (_6),....
Cb
Subject: Wall Street Journ al story
Dr. Haynes ,
I'm a reporter from the Wall Street Journal and, more important , a friend of Ben's from Duke.
l've written quite a bit about your mentor and friend Dr. Fauci in the last few weeks, and I'm
working on another story now that I was hoping you might be able to help w ith.
This story is about his mentor, Dr. Wolff , and how Dr. Wolff helped tum Dr. Fa uci into the
person he is today. I would love to hear more about their relationship from your perspective. I
know this is an insanely busy time, but would you have a few minutes to chat by phone ?
Thanks very much for your help. I hope you're safe and well in Durh am.
All best ,
Ben
Ben Cohen
212-416-3420 (o)
(b)(6) c)
ben.co hen@ws j.com
Sent : Sun, 12 Apr 2020 17:08:21 +0000
To: Neil Lacey - COOT
Subject : RE:THANK YOU
Thanks, Neil. I appreciate your note.

Best,
Tony
From: Neil Lacey- COOT<neil.lacey@state .co.us>

Se nt : Sunday, April 12, 2020 1:05 PM
To: Fauci, Anthony (NIH/NIAID) [E) ----- -=
(b=H=6J>
Subject: THANK YOU
Thank you Dr. Birx and Dr. Fauci:
At a time when America needs it most both of you have courageously stood at the podium at the White
House press briefings and explained what we all need to be doing during this paralyzing COVID-19
pandemic. When othe rs have failed to lead, multiple task forces have struggled prioritizing safety fi rst
before economics, both of you have tag teamed presenting the data and the analytics of COVID-19 by
decoding its complexities and giving us the "honest t ruth" in language that is easy to understand . The
virus will end when it ends and not before. Thank you both for your service to the nation and for doing
your jobs with conviction and commitment in doing the right thing - sticking to science and not yielding
to politics . America is immensely grate ful for both of you telling us all what we need to hear and what
we need to do . You are both giants in the world of medicine .
Very appreciative,
Neil Lace
(b)(6)
Sent from my iPhone

Sent : Sun, 12 Apr 2020 17:07:23 +0000
Bart:
I would be happy to talk to him about Shelly. People like to make stories as opposed to
reporting on a story. Shelly was one of my best friends and mentor , but I was me way before I
met Shelly, and so I am not really sure what he means by saying that Shelly " ... he lped turn Dr .
Fauci into the person he is today".
Best,
Tony
From: Barton Haynes, M.D

---------- ~=
To: Fauci, Anthony (NIH/NIAID) [E]------
(b)(6)
--------
(b)(6)>
Of course the reason I am asking is tha t it is presumptious for me to talk to him about shellys influence
on you ....perhaps I should just refer him to you?
Don't want to do anything either inappropriate, non helpful or what you don't what. Best bart
From: Barton Haynes, M.D.

-----------------=- :-:-=
To: Fauci, Anthony (NIH/NIAID) [E] _______________ Cb
_>_C6)
Hi tony; the fellow who wrote the article about you as point guard for St. Regis and the nation from the
say only those things that are unbelievable but true ....which are all wonderful.. ... best bart
From: Ben Cohen <ben.cohen@wsj .com>

Sent : Sunday, April 12, 2020 10:31 AM
To: Barton Haynes, M.D. --------
---------- -=-s:"'=<l
(b)(6)
Subject: Wall Street Journal story
Dr. Haynes,
I'm a reporter from the Wall Street Journal and, more important, a friend of Ben's from Duke.
I've written quite a bit abo ut your mentor and friend Dr. Fa uci in the last few weeks, and I'm
working on another story now that I was hoping you might be able to help with .
This story is about his mentor, Dr. Wolff, and how Dr. Wolff helped tum Dr. Fauci into the
person he is today. I would love to hear more about their relationship from your perspective . I
know this is an insanely busy time, but wou ld you have a few minu tes to chat by phone ?
Th anks very much for your help. I hope you're safe and well in Durh am .
All best ,
Ben
Ben Cohen
The Wall Street Journ al
212 -4 16 -3420 (o)
(b)( (c)
ben.cohen@ws j.com
Sent : Sun, 12 Apr 2020 12:30:56 +0000
To : Conley, Sean P. CDR USN WHMO/WHMU;Short, Marc T. EOP/OVP
Cc: Birx, Deborah L. EOP/NSC;Lane, Cliff (NIH/NIAID) [El
Subject: RE: 15 minute Coronavrius machines
Thanks,Sean.
From: Conley, Sean P. CDR USN WHMO/WHMU

--------
---------
~=
(b)(6)
To: Short, Marc T. EOP/OVP •>; Fauci, Anthony (NIH/NIAID) [El

(b) (6) >
---------- (b)(
Cc:Birx, Deborah L. EOP/NSC

(b)( 6) ----------
Subject: Re: 15 minute Coronavrius machines
(b)( >; Lane, Cliff (NIH/NIAID) [E)
I'll look into the possibility of freeing up a machine for investigation.
Sean
Sent from my iPhone
On Apr 11, 2020, at 10:15 PM, Fauci, Anthony (NIH/NIAID) [El (b)(6)>
w rote:
--------
MaLc.
_~
·----------------------------.. ~
(b) (5)
(b) (5)
Tony
Director
Phone : (b) (6)
FAX: (301) 496-4409
E-mail (b)(6)
original intended recipient. If you have received th is e-mail in error please inform the
sender and delete it from your mailbox or any other storage devices . The Nationa l
Sent : Sun, 12 Apr 2020 12:30:19 +0000
To: Short, Marc T. EOP/OVP
Subject : RE: 15 minute Coronavrius machines
Marc:
Thanks for the note . Understood . I wish you a peaceful and enjoyable day with your family.
Best regards,
Tony
From: Short, Marc T. EOP/OVP (b)(6)

-----~~ CbH6J>
Birx, Deborah L. EOP/NSC
Cc: Conley, Sean P. CDR USNWHMO/WHMU
-~-~~====-,:___:_~
(b)(6) >; Lane, Cliff (NIH/NIAID) [E]
(b)(6)>;
----------
Subject: Re: 15 minute Coronavrius machines
(b)(6)
Dr Fauci,
You correctly noticed the symptoms but misdiagnosed the root cause. I
(bXS)PCE
Apologies for a poo r poker face. Best wishes to you and your family for a blessed Easter celebration of
our Savior's resurrection.
Thanks for all you do,
Marc
Sent from my iPhone
On Apr 11, 2020, at 10:15 PM, Fauci, Anthony (NIH/NIAID) [E) _______ _,
(b)(6)
wrote:
Marc:
Tony
Director
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b)(6)
Sent : Sun, 12 Apr 2020 12:28:27 +0000
Subject : FW: Fearing appointment
Please respond as appropriate.
From: Daniel Kolliker _________ ~H=6)>
(b
Sent: Sunday , April 12, 2020 4:53 AM
------~~
To: Fauci , Anthony (NIH/NIAID) [E)._ _____ (b
_)_( _,>
Subject: Fearing appointment
Dear Mr Fauci,
We are really wondering over here in Europe why you don't take a dedicated opinion on COVID-19 and share your
opinion at the daily briefings to the extent of your personal believes.
We really expect you to oppose the president wherever you have a different opinion, which we believe is based on
facts.
Please consider our request and don't let the president keep spre ading his lies to the people of the United States.
We would really appreciate watching you on the briefing s telling the nation the truth that is based on your
experience straight to the point.
Thank you so much ,

Daniel Kolliker and acquaintances
Sent : Sun, 12 Apr 2020 12:27:36 +0000
FW:
--------- (b)(4)
(b)(4)
Please take a look at th is and respond as you see fit. Thanks.
Sent : -----------------
From : (b)(6)
Sunday, April 12, 2020 5 :54 AM
To : Fauci, Anthony (NIH/NIAID) [E] ------ ::;..,..-,=
(b)(6)>
Subject :
==========:---------------------- (b) (4)
Dear Dr. Fauci
I know that you are very occupied .

(b) (4)
Please handle the draft confidentially .
Thank you very much!

Sincerely, D. Novosel, Switzerland
www.novosel.ch
From: (b)(6)
Sent : Sat, 11 Apr 2020 22:57 :51 -0400
Cc: Barasch, Kimberly (NIH/NIAID) [C];Mascola, John (NIH/VRC) [El
Subjec t : Teleconferenc e next week
1 have asked john Mascola to connec t with you to set up a conference call with john, me, Carl, Emily some time next
week. Subject is out of the box chinking about COYID-19
From: Eisinger, Robert {NIH/NIAID) [El on behalf of Fauci, Anthony (NIH/NIAID) [El
Sent : Sat, 11 Apr 2020 22:08 :16 +0000
Subject: FW: Letter sent on behalf ofChancellor Jeffrey P. Gold, M .D.
This is another email f rom Jeff Gold at UNMC in response to an email that you sent him.

National Institute of Allergy and Infect iou s Diseases
Bethesda MD 20892
Telephone: (b)(6)
Email: (b)(6)
From:Gold, Jeffrey P (b)( >

To: Fauci, Anthony {NIH/NIA ID) [E] -------=-=--== (b)(6)>
Subje ct: Re: letter sent on behalf of Chancellor Jeffrey P. Gold, M.O.
Tony,
Many thanks for taking the time to respond. Please let me know if I can help in any way.
Our mobile device app (developed with Apple) has been quite helpful and is growing in use (over lOK) as
a screening, referral and surveillance tool for several user sets.
Just one of the many areas we continue to develop .
Best wishes
jeff
From: "M. Anthony S. Fauci"

---------
Date : Saturday, April 11, 2020 at 1:52 PM
(b)(6)>
To: "Go ld, Jeffrey P" (b)(6)

Subject: RE: let ter sent on behalf o f Chancellor Jeffrey P. Gold, M.D.
Non-UNMC email
Jeff:
M any th anks for your kind not e. Hope that all is well with you .
Best regards ,
Tony
Director
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b)(6)
On Behalf Of Gold, Jeffrey P

From:
--------------------
(b) (6)

~_,: __
-------~~ (b)(6)
_;__:,..:.:==:===:;;---------
Cc: Gold, Jeffrey P (b)(6)
Subject: Letter sent on behalf of Chancellor Jeffrey P. Gold, M.D.
Importance: High
April 10, 2020

Director
5601 Fishers Lane, MSC 9806
(b)(6)
Dear Dr. Fauci:
I write simply to thank you and congratulate you for your incredible efforts during the management of
this pandemic as it reaches across our nation . The unique challenges that this pandemic has
created have also created opportunities , and we here at the University of Nebraska Medical Center
have proudly participated with our federal, state and local partners during this COVID-19 pandemic
as well as over the last 16 years, having matured an extensive program in the research, education,
and clinical components of highly infectious diseases and biocontainment.
The UNMC Center for Global Health Security has been the umbrella organization that has organized
all of these components and continues to have strong leadership from retired military public health
as well as gifted research scientists from across the nation. As a co-founding partner of NETEC , as
a recipient of the Regional Disaster Health Service Awards, and as a close collaborator with the
Department of Health and Human Services, the Department of Defense, the Department of
Homeland Security and the Department of State, we have enjoyed the opportunity to always "lean
in" as the need arises.
I am sure your days are full not only of the complex logistics and tension that fill leadership roles at
this time but also maintaining a "steady hand on the rudder" as we navigate these challenging
waters. I think back to my days at New York Presbyterian and Cornell Med, knowing that we are
both Cornell Med grads, both did our residency and fellowship training in New York, and have had
the opportunity to interact back so many years ago. I do remember quite well the first time that we
met and have always reflected warmly at having even a brief opportunity to interact.
I do not write to ask for anything but to just simply thank you for all that you continue to do and know
that you always have a friend here in Nebraska. I wish you and your family the very best as we
continue this journey.
Most sincerely,
(b)(6)
Jeffrey P. Gold, M.D.

Chancellor
(b)(6)
Administrative Associate I
Chancell or Jeffrey P. Gold's Office
University of Nebraska Medical Center

986605 Nebraska MedicalCenter I Omaha, NE 68198-6605
____ (b_H_6)1 fax 402.559.4396
(b)(6)
UNMCI Facebook[facebook .com] I Twitter [tw itter .com) I lnstagram (instagram.coml I YouTube
[youtube.coml I Flickr lflickr.coml
The informat ion in thi s e-mail may be priv ileged and confidential, intended only for the use of th e
addressee(s) above . Any unauthorized use or disclosu re of this informat ion is prohibited. If you have
received this e-mail by m istake, please delete it and immediately contact the sender .
The information in this e-mail may be privileged and confidentia l, intended only for the use of the
addressee(s) above. Any unauthorized use or disclosure of this informat ion is prohibited. If you have
received this e-mai l by m istake, please delete it and immed iately contact the sender .
Sent : Sat, 11 Apr 2020 22:02 :38 +0000
Subject : FW: Please send me your cell phone#.
Attachme nts: COVID-19 Craig Schirmer Memo 04 .10 .20 .pd f
This email is from Jeffrey Sachs.
Robert W. Eis inger, Ph.D.

Special Ass istant for Scientific Projects
National Institu te of Allergy aod Tnfectious Diseases
31 Center Driv e, Room 7A-03
Bethesda MD 20892
(b)(6)
(b)(
From: Jeffrey Sachs -------, ~=
(b) (
To: Fauci, Anthony (NIH/NIAID) [E] ______
-----~~
Subject: Re: Please send me your cell phone # .
___,>
(b)(6)
(b) (4)
Looking forward to speaking ,
Jeff
On 4/11/20, 4:28 PM, "Fauci, Anthony (NTH/NIA

ID) [E)" wrote:
-------- (b)(
Mine is
----- (b)(6)
From: (b)(6)
Sent : Sat, 11 Apr 2020 16:25 :18 -0400
To: Evans, Michele (NIH/NIA/IRP) [E]
Subject: Re: Covid-19 Health Disparities
Michele:
Many thanks for your note.
Best regards,
Tony
On Apr 7, 2020 , at 8:28 PM, Evans , Michele (NIH/NIA /IRP ) [E]

(b) (6) > w rote:
Dear Dr. Fauci,
Thank you from the bottom of my heart for highl ighting the health
disparities and dispropor tionate burden of disease influencing outcome
of Covid-19 infections in African Amer icans. Participants in my
observational, longitudinal, epidemiologic Baltimore -based study,
HANDLShttps://handls.nih.gov/ are terrified by the level of disease they are
seeing in their communit ies across Baltimore. We have been on the
phone with and texting participants to educate them , support them in
their efforts to get tested, remind them of the importance of social
distancing and self-isolation when appropriate to protec t their
health . We are acutely aware of the ir fragility. Testing in Baltimore is
limited. The National Guard has set up community test ing at the
Pimlico RaceTrack; however , although we have deployed our mobile
medical research vehicles to Pimlico in the past to conduct our study,
the current crime rate is such that our partic ipants and community
residents in general do not go to the Pimlico area especially if they are
on foot. The other issue with testing for African Americans and our
participants is the need to have a health care provide r that one can
contract to discuss symptoms to get a refe rral for testing. The
unravelling of t he Affordable Care Act has severely impacted access for
African Americans across the nation and especially in Baltimore . Our
participants are calling my staff clinician and nur se practitioner for
referrals if they have symptoms. We have reached out to colleagues at
Health Care for the Homeless, JHU and other medical entities to
facilitate access.
Thank you all you are doing . Since I work in Baltimore, I haven't seen
(b)(6)
. The current pandemic however, reminds me

of the days of the AIDS epidemic when I worked as Sam Broder's
special assistant for underserved populations wh ile Peggy Hamburg
worked for you . I was in awe of you and Sam then and I remain in awe
of you today. I have known many Regis men ...but you are clearly head
and shoulders above them all.
Michele K. Evans, M.D.

Deputy Scientific Director &Chief,
Health Disparities Research Section
National Institute on Aging
NIH Biomedical Research Program
251 Bayview Boulevard
Suite 100 Room 4C-222
Batimore, Maryland 21224
Email: (b)(6)
Tel. (b)(6)
https://irp .nih.gov/pi/michele-evans
https://handls .nih.gov/
From: (b)(6)
Sent : Sat, 11 Apr 2020 16:22 :40 -0400
To: Janet Tobias
Cc:
Subject: Re: Updates: Film
·-----------
Conrad, Patricia (NIH/NIAID) [El (b)(6)
Janet
All this sounds fine and workabl e.
Thanks ,
To ny
On Apr 7, 2020 , at 8:3 1 PM, Janet Tobias <janet@ ikan amed ia.com>wrote :
Dear Tony and Patty:

Responses to Burklow 's questions to me from your group call yesterday:
1) I think we have landed in the right place for the film about yom life . Nat Geo,
Di sney, and Bob Iger himse lf, all understand the need for discretion now but are
wi ldly supporti ve about relea sing a film that will celebrat e the importa nce of yo ur
life, science and public hea lth. I wan ted th e bes t hom e, broades t distribution , and
strongest team for your film. You have entrusted me with yo ur sto1y, so I ju st want
to do right by it. We are really happy wit h the filming that we have don e so far
personal (b)(6) home, school) to work ( office etc) .
3) The other film we have been working on (ENDING AIDS), which fo llows
globa lly the H VTN trials/latest Aids research to comp lete " the too lbox" is definitely
still happening. It is now in pause with COVID-19 . . .. but will move forward again
when we get through thi s. Filming at research sites in South Africa, US, and Latin
America has been great...and when you have time - in the future- I w ill outline .
You obviously are a key subjec t in ENDING AIDS also , but ENDING AIDS will
spend a lot of time with doctors at the fie ld research sites and with volunt eers in the
trials. The Aids conference and meetings footage we have shot wi th you wi ll be
shared between films, smart ly and distinctly. END ING AIDS will be released a
year plus later than the release of your biographical film- I am focuse d on your film
now. Howard Hughes Medical Institute remai ns the educational pa1iner on ENDING
AIDS. In the fall we will fina lize the broadcast/streaming partner for ENDI NG
AIDS. So, bottom line it w ill be released a year after your film , and will be a film
focused on showing in detail where we are now with aids research and the key
people in the chain from you 10 a young fem ale voluntee r in South Africa/a you ng
male volunteer in Binningham.
FILMING REQUESTS for your film now.
4) NO more ask ing to film with the Task Force.
5) I do have two persona l filming requests for you - wo uld it be poss ible to drive to
NIH wi th you once or twice a week and capture your working/ap propriat e
conversat ions in the car. That will be so helpful narratively to tracking you r
scientific and comm unic ation leadership . The footage we did that first day is truly
great. We will just tum around and come back after the ride there--- in our follow
car (we have NIH access badges) . Second ly, wou ld it be possible to sit down with
you on camera for J 5 minutes once a week (on the weekend?) at the office or on the
back deck/some safe location to talk with me in real time about what you are
managing with treatments , vaccines , etc. so we can pull the
scientific /conunw1-icatio11nanative on COVID-19 through your film.
6) We love the live truck and the walks, so whenever that works we will be there.
7) l NEV ER ever want to interfere with the work on the Task Force, lives are at
stake. IF something doesn't work for filming no questions asked we don' t do it, we
stop, cancel/pivot. No need to explain, the team here understands and only wants to
do what works for you, your team ... , (b)( '1 .
With appreciation ,
Janet
From: (b)(6)
Sent: Sat, 11 Apr 2020 16:14 :53 -0400
Subject: Fwd: Invitatio n to speak to ABEA in virtual meeting
No
From: "Allen , Clint (NIH/NIDCD) [E]" (b)( >

To: "Fauci, Anthony (NIH/N IAID) [E]" <f (bH6);>
Subject: Invitation to speak to ABEA in virtual meeting
Dr. Fauci-
Almost embarrassed to ask, but would you be willing /able to speak virtually to the
American Broucho-Esophagological Association (abea.ne t) on Friday April 24 th?
Thi s year marks the 100th anniversary of this venerable organi zation that brin gs
together clinic ians (mainly Otolaryngologi sts) who care for patients with complex
upper aerodigestive tract disorders. Our annual National Meeting has been cancelled
and we are hosting a virtual meeting it it's stead.
As Otolaryngologi sts, we are curren tly and expect to continue to be dramatically

impacted by the current pandemic, given that our care for patients rout inely includes
upper airway endoscopy (30-40 scope proc edures a day is routine) which as you
know is a high-risk aerosolizing procedure. As I'm sure you are aware,
Otolaryngolgists have been amongst the hardest hit clinicians in terms of patient-to-
provider transmission of COVID-19.
Your input for 10- l 5 minutes would be an honor. Discussion topics could include
general comments about the pandemic, a sense of what to expect in the coming
months and years, and what we can do as medical leaders to prepare for these
changes in the US and abroad.
If this is something you are intere sted in, with whom on your communications team
could I communicate?
Thanks so much for the consideration - your brief presence and input would mean a
great deal to our society.
Clint Allen
From: (b)(6)
Sent : Sat, 11 Apr 2020 16:08:26 -0400
Subject: Fwd: Council of Scientific Society Presidents Support of Science Award
Attachments : Fauci_CSSP_Award.pdf, ATT00001.htm , CSSPBrochure_2019 v3.pdf,
ATT00002.htm
Le t us discuss. They want to give me an award virtually. Probably should accept if it requires
no time or work
From: "Fauci, Anthony (NIH/NIAID) [E]" (b)( >

To: NIAID OD AM <NIAIDODAM @niaid.nih.gov>
Subject: F,v:Council of Scientific Society Presidents Support of Science
Award
Patricia L. Conrad
(b)(6)
301-496-4409 fax
Disclaimer:
The information in this e-mail and any of its attachments is confiden tial and may contain sensit ive informat ion. It
shou ld not be used by anyone who is not the original intended recipient. If you have rece ived this e-ma il in error
and Infectious Diseases (NIAID) shall not accept liabil ity for any statement made that are sender's own and not
express ly made on behalf of the NIAID by one of its representatives.
From: Mosher, Sharon <smosher@jsg.utex as.edu>

To: Fauci, Anthony (NIH/NIAID) [E] -------,;; (b""'"'
)=
(6)
Cc: Barasch, Kimberly (NIH/NIAID) [CJ (b)(6b; Conrad, Patricia
(NIH/NIAID) [E] (b)( >
Subject: Council of Scientific Society Presidents Support of Science Award
Dear Dr. Fauci;
Council of Scientific Society Presidents (CSSP)would like to honor you with our
Support of Science Award at our May Leadership Workshop (virtual). The purpose of th is
award is to honor those who have pro ven the ir outstand ing support of U.S. science, free
scientific communication, and a support of basic science research . The expertise with
w hi ch you guide the United Sta tes through these unprecedented COVID-19 times simply
reinforces the dedication you exhibit to ensure the greatest safety to the greatest number
of US citizens .
Dr. Martin Apple talked to Kim Barasch earlier this week. Please find the attached formal
invitation letter she indicated that was needed. I have also attached a PDF of a brochure,
though most information is on our webs ite .
If you or Kim have any questions, please let me know by email or phone .
Sincerely,
Sharon M osher
Sharon M osher
FarishChair and Professor
The University of Texasat Austin
JacksonSchoolof Geosciences
2305 Speedway,Stop C1160
Austin, TX 78712-1692
(b) (6) (cell)
smosher@jsg.utexas.edu
From: (b)(6)
Sent : Sat, 11 Apr 2020 16:04 :03 -0400
To: Alison Galvani
Cc: Conrad, Patricia (NIH/NIAID) [E);Seyed Moghadas ;Singer,Burton H
Subject: Re: Your Submission THELANCETID-D-20-01518R1
Thanks, Alison
On Apr 9, 2020, at 7:46 PM, Alison Galvani (b)(6)> wr ote:

----------
Hi Tony,
I thought you might be interested in our projectio ns regard ing vent ilator needs in the
US. The brief report (attached) was accepted at Lancet ID yes terday. Funded by
NIAID :)
Take care,
Alison

From: Phoebe Hall <em@editoria lmanag er.com>
Date: Wed, Apr 8, 2020 at 9:36 AM
Subject: Your Submis sion THELANCE TID-D- 20-01518Rl
To: Galvani, Alison (b)(6)
Dear Professor Galvani,
Reference: THEL ANCETID-D-20-01518Rl, Projecting the demand for ventilators

at the peak of COVID-19 outbreaks in the United States
I am pleased to tell you that your submission , Proj ecting the demand for ventilators
at the peak of COVID-19 outbreaks in the United States, has been accepted for
publication in The Lancet Infectious Diseases .
In due course you will rece ive, electronically , a set of pdf proofs of your article .
Plea se note that because of our varied and internatio nal readership, The Lancet
Infectious Diseases edits heavily to a strict house style. Thus, changes will
inevitably be made to your manuscrip t at this time. Th ere will also probably be a
few final editorial queries at this stage. Please correct and return these pages by the
deadline stated in the covering email.
Finally, please note that The Lancet Infectious Disease s is committed to support
authors in making their work publicly and freely available. The editors encourage
authors to post a word-processed document (NOT the published journ al article as
PDF) of their peer-reviewed, accepted article on personal or institutional websites
any time after publication in print or online . Your document should include the
article citation and a link to The Lancet Infectious Diseases's homepage . Please note
that posting and distribution of PDF or HTML documents, however, is not
acceptable and breaches your copyright agreement.
Please complete the following Journal Publishing Agreement:

https ://nam0 5. safe links. pro tee tion. ou tlook.com/?url =https%3 A %2F%2Fwww. thelan
cet.com%2Ffor-
authors %2Fforms%3Fsec tion%3Djpa&data =02% 7C0 1% 7Calison.galvani%40
yale. edu¾ 7Cl c0ddd00e9ca4 l 3f77 l 008d 7d be 1e529% 7Cdd8cbebb2 l 394df8 b4 l l 4e
3e87abeb5c%7C0 %7C0%7C637219498130294598&amp:sdata =WoXBAmJN sM9 S
Bkf aeGK.AzvAN g%2BSzbZAw94aO5%2BAtP%2FY%3D&amp:reserved =0
Please retain a copy for your files and email a completed copy to
HALLP @science.regn.net. Please ensure all the pages are returned.
WHO AUTHORS
If you or any of your co-authors are employed directly by the World Health
Organization , you have the option of either signing Elsevier 's standard agreement or
our WHO/Elsevier non-exclusive licence agreement. Please contac t our Deputy
Operations Manager, Marco Conforti (m.conforti @elsevier.com) for a copy of the
WHO agreement.
Yours sincerely ,
Phoebe Hall
Senior Editor
The Lancet Infectious Diseases
E-mail: phoebe.hall @lancet.com
In compliance with data protection regulations , you may reque st that we remove
yow-personal registration details at any time. (Use the following URL:
https ://nam05. safe links.pro tee tion.outlook.com /?url =https%3 A %2F%2Fwww. editor
ialman ager.c om%2Fthelance tid%2Flogin.asp%3Fa%3Dr&amp:data =02% 7C0 1% 7C
alison. galvani%40yale.edu% 7C 1c0ddd00e9ca413f77 l 008d7 dbc 1e529% 7Cdd8cbeb
b21394df8b4 114e3e87abeb5c %7C 0% 7C0% 7C637219498130294598&amp:sdata=j
KlkjtzfbMH6UMOPZ%2BvavnATDZkEB9y2up55tmx UA 5A %3D&amp:reserve d
=0). Please contact the publication office if you have any questions.
Alison Galvani , PhD
Director , Yale Center for Infectious Disease Modeling and Analysis (CIDMA)
Burnett and Stender Families Professor of Epidemiology
Yale School of Public Health
Yale School of Medicine
New Haven, CT 06520
(b)(6)
http ://c i dma.yale.e du/
Follow me at @Alison_ Galvan;
Follow CIDMA @YCJDMA
<Briefr eport on ventilator needs.docx>
Sent : Sat, 11 Apr 2020 19:56:00 +0000
To: Jack Killen
Cc: Auchi ncloss, Hugh (NIH/NIAID) [E]
Subjec t : RE: From Jack Killen & Fred Boykin
Jack:
(b)(6)
Many th anks fo r you r kind note.
Best ,
Tony
Director
Phone: (b)(6)
FAX : (301 496-4409
E-mail: (b)(6)
From : Jack Killen (b)(6)

Sent: Tuesday, April 7, 20201 :31 PM
-------~~ (b)(6)
Cc: Auchinclo ss, Hugh (NIH/NIAID) [E]
Subje ct : From Jack Killen & Fred Boykin ----------- (b)(6)
Dear Tony:
This is a quick note to say Fred and I have been watch ing you every day, in awe, fo r weeks now. We
could not be more grateful for your leadership, wisdom, courage, and integrity . Our country could not
be more fortu nate that you are still there in guiding us through this terr ible time. Needless to say, many
memories of our years working together have been in the forefront of our minds.
On a ersonal note (b)(6)

(b)(6)
My epidem ic battling skills are rusty , but if there is anything I can do to help in any way, please know I
are here for you. Fred is as well.
Godspeed, and please take care of yourself. Best to you,
JackKillen MD
------
(b) (6land your family.
(b)(6)
Sent: Sat, 11 Apr 2020 19:50 :06 +0000
To: Georg e GAO
Subject: RE: Vaccine - confidential PPT
Geor ge :
Thank you f or you r kind note . All is well despite some crazy people in thi s
wor ld .
Wa rm regard s,
Tony
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail Cb)(6)
From : George GAO (b)(6)

-------=-:-=,(b)(6)
--------
Subject: Re: Vaccine - confidential PPT
Tony
I saw some news (hope it is fake) that are being attacked by some peopl e. Hope you are we ll und er
such a irrational situation.
___________________________ Cb
_>_(4) Thank you for your
intro du ctio n.
All the best and stay safe .
Bw
George
tt 2020~3~ 29 B, 09:07 , Fauci, Anthony (NIH/NIAID) [El
-------- (b)(6)>
~~ :
George:
Thanks for the note. I understand completely. No problem. We will get through this
toge t her .
Bed regards,
Tony
On Mar 28, 2020, at 8:50 PM, George GAO_____ _H_6J wrote:

Cb
Dear Tony
I know you are working extremely hard with a lot of pressure. Hope the US
situation is getting bettereventully. I saw the Science interview, how could I
say such a word "big mistake" about others? That was journalist's word ing.
Hope you understand. It was NOT a real interview but a QaA through social
media fo r several days when ge asked me what China has done and is
working on. Lets work toget her to get the virus out of the earth.
Best wishes
George
tt 2020~3~ 3 B , 21:10, Fauci, Anthony (NIH/NIAID) [El

(b)(6) ~~ :
--------
George:
Thanks for the note. I will send th is to Dr. John
Mascola Director of the NIAID Vaccine Research
Cente r and Dr. Barney Graham to follow-up with
you .
Best regards,
Tony
Director
Phone: (b)(6)
FAX: (301) 496-4409
E-mail: (b)(6)
confidential and may contain sensitive information. It
should not be used by anyone who is not the original
intended recipien t. If you have received this e-mail in error
please inform the sender and delete it from your mailbox or
any other storage devices. The National Institute of Allergy
and Infectious Diseases (NIAID) shall not accept liabil ity for
any stateme nts made that are the sender's own and not
expressly made on behalf of the NIAID by one of its
representatives.
From: George GAO (b)( 6)

Sent: Tuesday, March 3, 2020 7 :12 AM
To: Fauci, Ant hony (NIH/NIAID) [E] ------~~
Subject : Vaccine- confidentia l PPT
-------- (b)( 6)
DearTony
Hope th is email find s you we ll and t he US will soon get t he
COVID-19 down .
(b) (4)
All t he best
George
~§fta-9 iPhone
<20200303 For Gao laoshi.pptx>
Sent : Sat, 11 Apr 2020 19:27 :03 +0000
Subject : RE:ASF - note from Mary Jane Walker !! FW: Catching up
Than ks, Mary Jane !
Director
Phone: (b)(6)
FAX: (30 496"'4409
E-mail: (b)(6)
---------.....,..,=
From: Folkers, Greg (NIH/NIAID) [El
--------,
(b)(6)>
(b)(6)
Cc: Maryja ne Walk er
_;..
__ ..:...:.-.:.!:==~~~---
(b)(6)
Subject: ASF- note from Mary Jane Walker!! FW: Catching up
From : Maryja ne Walker (b)(6)

Subject: Catching up
Date : Apri l 6, 2020 at 9:23:13 PM EDT
To : CbH6)
Hi Tony,
I hope that you are doing well despite all th at you are dealing with around COVID-19. It has been many
years since I had the opportun ity to work wi th you but my job at NIAID was one of my favorite positions
and gave me a great start to my career . So, when I saw the below graphic, it made me smile and I
wanted to send yo u a note .
I tr uly appreciate how you are handling the COVID-19 situation. Your comments are a breath of fresh air
amidst poli ti cs and uncertainty . With daily Whi t e House press brie fi ngs, increased security and scrutiny,
24/7 media interviews and great popularity, yo u seem to be holding up well - as you always do. Your
recent interview with JAMA's Editor-in-C hief Howard Bauchner was particularly well done and very
enl ightening .
Thank you for everything that you are doing and please stay healthy!
Kind regards,
Mary Jane
Sent: Sat, 11 Apr 2020 18:35 :53 +0000
To: Crawford , Chase (NIH/NIAID) [El
Cc: Conrad, Patricia (NIH/NIA ID) [E);Billet, Courtney (NIH/ NIAID) [El;Haskins,
M elinda (NIH/NIAID) [E);Selgrade, Sara (NIH/NIAID) [E)
Subject: RE:Attn Dr. Fauci: Key Point s for Congressional Black Caucus Briefing Call -
Monday 11:30a .m.
Thanks. Please make sue that it is printed out mand given to me before the
br iefing .
Director
Phone: Cb)(6)
FAX: (301 496-4409
E-mail: (b)(6)
other stor age devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall not
From: Crawford, Chase (NIH/NIAID) [El (b)(6)

Sent: Friday, Apri l 10, 2020 7:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] --------=-:-:-= (b)(6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b)(6) >; Billet, Courtney (NIH/NIAID) [E]
(b)(6)>; Haskins, Mel inda (NIH/NIAID) (E] (b)( >; Selgrade, Sara
(NIH/NIAID ) [E] (b)(6)
Subject; RE: Att n Dr. Fauci : Key Points for Congressiona l Black Caucus Briefing Call - Monday 11:30a.m.
Dr. Fauci,
Attached is an updated "one- pager" for your call on Monday with members of the
Congressional Black Caucus. At Greg's recommendation , we have added
information on the NIH-supported serosurvey tha t was announced this afternoon.
Please let me know if I can be of furthe r assistance {Chase cell :

------ CbH6))
Thanks,
Chase
From:Crawford, Chase (NIH/NIAID) [El

To: Fauci, Anthony (NIH/NIAID) [E] <
-----~ =>
(b)(
Cc: Conrad, Patricia {NIH/NIAID) [E] (b)(6)>; Billet, Courtney (NIH/N IAID) [El
(b)(6)>; Haskins, Mel inda {NIH/NIAID) (E] (b)(6)>; Selgrade, Sara
Subject: Attn Dr. Fauci: Key Points for Congressional Black Caucus Briefing Call - Monday 11:30a.m.
Dr. Fauci,
On Monday, April 13t h, at 11:30 a.m., you are scheduled to part icipate in an
informal di scussion / t elebriefing regard ing health dispari t ies and COVID-19 with
members of the Congressional Black Caucus (CBC). Rep. Barbara Lee (D-CA,
including Oakland and Berkeley) - former CBCchair - made the request. A list of
expected call participan ts is below the signatur e line of thi s email.
I have attached a "one-pager" to p rovi de some background on health disparitie s

and COVID-19 that include s informat ion on NIH COVID-19 research that may be
re levant to the di scussion . As you are aware, we do not have any COVID-19
stud ies directly focused on t he African American community. Hilary and Greg
have provided input .
Please let me know if I can be of furthe r assistance (Chase cell :

------ CbH6))
Thanks,
Chase
List of CBCcall participants

Rep. Barba ra Lee
Rep. Karen Bass (CBC Chair)
Rep. Robin Kelly (CBC Health Braintru st Chair)
Rep. G.K. Butt er fi eld
Rep. Yvette Clarke
Rep. Cedric Richmond
Rep. Brenda Lawrence
Rep. Steve Horsford
Rep. Ayanna Pressley
Sent: Sat, 11 Apr 2020 18:10:39 +0000
To : (b)(6)
Subject : FW: Wpost : Gilead's experimental drug remdesivir shows 'ho pefu l' signs in
small grou p of coronavirus patients https://wapo.st/2wzjsy2
Geeez....
Director
Phone: (b)(6)
FAX: (3 96':44li9
E-mail (b) (6)
From : Folkers, Greg (NIH/NIAID) [E] (b) (6)>

--------
Subject : Wpost: Gilead's experim ental drug remdesivir show s 'hopeful' signs in small group of
coronavirus patients https ://wapo.st/2wzjsy2
Business
Gilead's experimental drug remdesivir shows

'hopeful' signs in small group of coronavirus
patients
Two-thirds of severely ill patients showed improvement in
their oxygen therapy level when treated with the antiviral
drug
wo ampuls of remdesivir
are pictured during a news conference at the University Hospita l Eppendorf (UKE) in Hamburg, April 8,
2020, as the spread of coronavirus disease (covid-19) continues. Ulrich Perrey/Pool via REUTERS
(Pool/Reuters)
By
Christopher Rowland
April 10, 2020 at 5:25 p.m . EDT
A major ity of a small group of patients showed improve ments after being treated with an experimental
coronavirus treatment made by Gilead Sciences, bolstering hopes for finding a treatment for the
disease, according to a study pub lished in the New England Journal of Medicine Friday.
The group of patients received the anti -viral drug remde sivir as part of a "compassionate use" tria l, not a
doub le-blind placebo-control led tria l which wou ld offer more definitive evidence. Also, the cohort of
patients was small, only 53 patients in the United States and around the world . Those lim iting factors
prevent scientists from declaring that the drug works .
Still, the improvements offered positive news about a drug seen by global health authorities as offering
the best shot at becoming a treatment for the disease.
Thirty six patients out of 53 - or two-thirds - showed improvement in oxygen support, trial authors
said. Seventeen of 30 patients who were on ventilators were able to be taken off the life-support
machines.
"We cannot draw definitive conclusions from these data, but the observations from this group of
hospitalized patients who received remdesivir are hopeful," said Jonathan D. Grein, MD, Director of
Hospital Epidemiology, Cedars-Sinai Medical Center, Los Angeles, and lead author of the journal article.
"We look forward to the results of controlled clinical trials to potentially validate these findings ."
While 68 percent of the patients showed improvement in the level of oxygen support they needed, 13
percent died, the NEJM study said. That 13 percent compares favorab ly to mortality rates of 17 to 78
percent in China among severely ill patients, the authors wrote .
Gilead's stock has been bolstered for weeks by expectat ions over remdesivir .
Remdesivir was discovered by Gilead in t he hunt for antiviral drugs about a decade ago, and the
Nationa l Institutes of Health has partnered with the company to explore its benefits. It was shown to
work against an array of viruses in laboratory tests.
It showed effectiveness in primates infected with Ebola but failed in a trial in the Democratic Republican
of Congo in humans with the deadly disease. It has shown effectiveness as a preventive therapy in
primates for MERS,which is a coronavirus cousin of the Covid-19 virus.
There are no treatments approved by the Food and Drug Administration to treat coronavirus, but the
FDA has granted an emergency use authorization for the use of hydroxychloroquine and chloroquine,
two decades-old anti-malarial drugs. There is scant evidence that the therapy works, but President
Trump has repeatedly boosted the promise of the drugs.
Even while multiple full clinical trials of remdesivir continue, Gilead hasbeen swamped with requests for
" compassionate use" of the drug . Under compassionate use rules, physicians can obtain experimental
drugs for their seriously ill patients when there is nothing else to try.
Gilead said last week that it had enough of the experimental drug on hand to trea t up to 140,000 people
under compassionate use programs.
0 Comments
Christopher Rowland
Chris Rowland joined The Washington Post business team in 2018 after serving as the Washington
bureau chief for the Boston Globe, leading coverage of two presidential elections and overseeing
political enterprise reporting . He previously covered health care for the Globe in Boston.Follow
my views nor those of NIAID, NIH, HHS, or the U.S. government.
Sent : Sat, 11 Apr 2020 18:09:19 +0000
(b)(6)
Subje ct: FW: New York er: How Ant hony Fauci Became Am eri ca' s Doct or
https://bit. ly/2y3h3fi
This is th e actual arti cle fo r which I prev iously sent you a link.
Director
Phone Cb)(6)
FAX: (301 496-4409
E-mail: _ __,.,_, (b)(6)

Subject: New Yorker: How Anthony Fauci Became America ' s Doctor https://b it .ly/2y3h3fi
Annals of Medicine
April 20 , 202 0 Issue
How Anthony Fauci Became

America's Doctor
An infectious-diseaseexpert's long crusade against some of
humanity's most virulent threats.
By Michael Specter
April 10, 2020
., I ..
"You stay completely apolitical and non-ideological," Fauci says. "I' m a scientist
and J 'm a p hysic ian. A nd that's it. " Illustration by Tyler Comrie. Photograph by Win McNamee I Getty
Just before 1nidnight on March 22nd, the President of the United States
prepared to tweet. Millions of Americans , in the hope of safeguarding
their health and fighting the rapidly escalating spread of COVID-19 , had
already begun to follow the sober recommendation of Anthony S. Fauci,
the country ' s leading expert on infectious disease. Fauci had warned
Americans to "hunker down significantly more than we as a country are
doing." Donald Trump disagreed. " WE CANNOT LET THE CURE BE WORSE
THAN THE PROBLEM ITSELF ," he tweeted .
Trump had seen enough of "social distancing. " In an election year, he
was watching the stock market collapse , unemployment spike , and the
national mood devolve into collective anxiety. "I would love to have the
country opened up, and just rarin' to go by Easter ," he said, on Fox
News. "You ' ll have packed churches all over our country . I think it'll be
a beautiful time."
Trump ' s Easter forecast came more than two months after the first U .S.
case of COVID-19 was identified , in Washington State, and more than a
hundred days after the novel coronavirus emerged , first from bats and
then from a live-animal market in the Chinese city of Wuhan. Every day,
more people were falling sick and dying. Despite a catastrophic lack of
testing capacity , it was clear that the virus had reached every comer of
the nation. With the Easter holiday just a few weeks away , there was not
a single public-health official in the United States who appeared to share
the President 's rosy surmises.
Anthony Fauci certainly did not. At seventy-nine, Fauci has run the
National Institute of Allergy and Infectious Diseases for thirty-six years ,
through six Administrations and a long procession of viral epidemics:
H.I.V. , SARS, avian influenza , swine flu, Zika, and Ebola ainong them.
As a member of the Administration's coronavirus task force, Fauci
seemed to believe that the government's actions could be directed , even
if the President's pronouncements could not. At White House briefings ,
it has regu larl y fallen to Fauci to gently amend Trump's absurdities ,
half-truths, and outright lies. No, there is no evidence that the malaria
drug hydro xychloroquine will provide a "miracle" treattnent to stave off
the infection . No, there won't be a vaccine for at least a year. When the
President insisted for many weeks on denying the government's inability
to deliver test kits for the virus, Fauci, testifying before Congress , put
the matter bluntly. "That 's a failing," he said. "Let's admit it."
When Trump was not dismissing the sever ity of the crisis , he was
blaming others for it: the Chinese , the Europeans, and, as always, Barack
Obama. He blamed governors who were desperate for federal help and
had been reduced to fighting one another for life saving venti lator s. In
one briefing, Governor Andrew Cuomo , of New York , said, "It's like
being on eBay with fifty other states, bidding on a ventilator." Trump
even accused hospital workers in New York City of pilfering surg ical
masks and other vital protecti ve equipment that they needed to stay
alive. "Are they going out the back door?" Trump wondered aloud.
As a reporter who writes mainly on science and public-health issues ,
I've known Fauci since the H.I.V ./AIDS epidemic exploded , in the rnid-
eighties. He once explained to me that he has developed a method for
dealing with political leaders in times of crisis: "I go to my favorite book
of philosophy , ' The Godfather ,' and say , 'It's nothing personal, it's
strictly business.' " He continued, "You just have a job to do. Even
when somebody's acting ridiculous , you can't chide them for it. You 've
got to deal with them. Because if you don't deal with them , then you're
out of the picture."
Since his days of advising Ronald Reagan and George H. W. Bush,
Fauci has maintained a simple credo: "You stay completely apolitical
and non-ideological, and you stick to what it is that you do. I'm a
scientist and I'm a physician. And that's it." He learned the value of
candor early. "Some wise person who used to be in the White House, in
the Nixon Administration, told me a very interesting dictum to live by,"
he told me in 2016, during a public conversation we had at the fifty-year
reunion of his medical-school class. "He said, 'When you go into the
White House, you should be prepared that that is the last ti1ne you will
ever go in. Because if you go in saying, I'm going to tell somebody
something they want to hear, then you've shot yourself in the foot. ' Now
everybody knows I'm going to tell them exactly what's the truth."
Americans have come to rely on Fauci's authoritative presence. Perhaps
not since the Vietnam era, when Walter Cronkite, the avuncular anchor
of the "CBS Evening News," was routinely described as the most trusted
man in America, has the country depended so completely on one person
to deliver a daily dose of plain talk. In one national poll, released last
Thursday, seventy-eight per cent of participants approved of Fauci's
performance. Only seven per cent disapproved.
On March 23rd, Fauci failed to appear at the daily briefing in the White
House pressroom. Twitter promptly lost its mind. #NoFauci became a
top trending topic, followed closely by #whereisFauci and
#letTonyspeak. There was speculation that Trump, who is inclined to
fire anyone who disagrees with him or, worse, garners some praise in the
media, had lost patience with Fauci . As one of Fauci's old friends told
me, "This is a President who doesn 't give a shit about Fauci's
accomplishments, his history, or his learning. If anything, they're
negatives."
The truth was less alarming. "I was tied up in a task-force meeting , and
we were trying to work out some difficult policies ," Fauci said. "I have
no trouble with the President. When I talk to him, he listens." My
experience with Fauci suggested that this last statement was perhaps a
triu1nph of pragmatism over accuracy. His priority, as he's made clear , is
to do what is necessary to save lives. So I was not surprised to receive an
e-mail from Fauci the following day, saying that he had been asked to
refrain from participating in personal profiles. It seemed that it was one
thing for him to talk about the news with reporters or even to chat on
Instagram with Stephen Curry, the Golden State Warriors star. But
focussing on himself, rather than on the President, was another thing
entirely.
Fauci and Trump are about as odd a duo as American political life has
ever produced . Both men are in their seventies. Both come from the
outer boroughs of New York City. Both are direct, even blunt. But that's
where the resemblance ends. Fauci has always been a person of unusual
discipline. Nearing eighty, he works about eighteen hours a day. Long
ago, when his three children were young , he and his wife , Christine
Grady, who runs the bioethics department at the National Institutes of
Health , decided to maintain the sanctity of family dinners by starting
them when he got home from the office, at around nine o'clock. For
decades , Fauci has taken long lunchtime runs, but, during the crisis, he 's
cut back his routine to power walking- and only on weekends. Fauci
parses his words with care and believes , above all, in the power of facts
and the efficacy of data.
ADVERTISEMENT
David Baltimore , a Nobel laureate and a pioneer of molecular biolog y,

told me, "Tony is unique , in that he has such credibility with politicians
that he's been able to insert hard facts into the conversation. That has
been wonderful for our country and the world." According to David
Relman, a microbiologist at Stanford University who for years has
advised the government on biological threats , "Tony has essentially
become the embodiment of the biomedical and public -health research
enterprise in the United States. Nobody is a more tireless champion of
the truth and the facts. I am not entirely sure what we would do without
him."
Fauci can be impatient with the compromises of politics . In my

conversations with him, he has responded furiously when a dicey
amendment, a bogus rider, or a "poison pill" is attached to a publ ic-
health bill. He recalled one congressional provision, in 2016 , that tried to
make it "legally permissible to fly the Confederate flag at national
cemeteries. I am not kidding. " When dealing with politician s, he told
me, he relies on the pseudo-Latin expression Illegitimi non
carborundum: Don't let the bastards grind you down. But he has
inspired respect throughout the political world and beyond. Fauci ' s
office walls are covered with scores of photographs of him with
Presidents , senators , visiting Prime Ministers , business leaders , actors. In
October, 1988, George H. W. Bush , during a Presidential debate with
Michael Dukakis , was asked who his heroes were. "I think of Dr.
Fauci ," Bush replied. "You 'v e probably never heard of him .... He's a
very fine researcher , a top doctor at the National Institutes of Health ,
working hard, doing something about research on this disease of AIDS. "
These days , nearly everyone has heard of Fauc i. Pandemic-memorab ilia
entrepreneurs have put his face on bottle openers , coffee mugs , and
bumper stickers: "In Dr. Fauci we trust. " The National Bobblehead Hall
of Fame and Museum has produced a seven-inch likeness of him , partly
to raise money to produce protecti ve gear for medical workers. There's a
Facebook group called Dr. Fauci Speaks , We Listen, and another called
Dr. Fauci Memes for Social Distance Teens. A petition has circulated to
nominate him as People' s "sexiest man alive."
On right-wing social media and talk radio, Fauci has a different image:
he is routinely disparaged as a closet lefty who is exaggerating the threat
of the corona virus. "Has anyone else noticed that every suggestion by
Dr. Doom Fauci just happens to also be the worst pos sible thing for the
economy?" the conservati ve Internet TV host Bill Mitchell tweeted .
"That's not an accident folks." An analysis in the Times found more than
seventy Twitter accounts that have pushed the hashtag #FauciFraud ,
with some tweeting out anti-Fauci bile hundreds of times a day. "There
see1ns to be a concerted effort on the part of Tru1np supporters to spread
misinformation about the virus, " Carl Bergstrom, a professor of biology
at the Uni versity of Washington who has studied misinformation , told
the paper. "There is this sense that experts are untrustworthy , and have
agendas that aren 't aligned with the people." Fauci has received so many
personal threats that the Justice Department recently appro ved a security
detail for him. Fauci shrugged it off, telling reporters, "I've chosen this
life."
The crisis that the world now faces comes as no surprise to Fauci. On
January 10, 2017, ten days before Trump took the oath of office, Fauci
delivered the keynote address at a conference at Georgetown University ,
titled "Pandemic Preparedness for the Next Administration. " After
describing his years of managing epidemics, he posed a series of
questions to the audience: "Will there be a resurgence of Zika? We 're
getting into the summer in South America. Are we going to see a
resurgence or not? What about influenza? Are we going to get a new
pandemic?"
Fauci's last point, he emphasi zed, was almost certainly the most
important: the possibility that some unknown , powerfully infectious
pathogen could emerge to threaten the world. "What about things that
we 're not even thinking about?" he said. He let the question drift out
over the hall. "What is for sure," he concluded , "is that, no matter what,
history has told us definitively that it will happen."
On the day that Anthony Stephen Fauci was born , the front-page
headline in the Times was "P RESIDENT TO GIVE EMERGENCY FACTS TO
NATION ON RADIO." It was Christmas Eve, 1940. The Second World
War had begun, and the United States was less than a year away from
joining the fight.
Fauci grew up in southwest Brooklyn , first in Bensonhurst and later in
Dyker Heights , where his family ran a pharmacy and lived in an
apartment upstairs. The pharmacy was across the street from the Shrine
Church of St. Bernadette. When Mass was finished on Sundays , Fauci
recalled, people would walk over to get prescriptions filled and to buy
whatever else they needed for the coming week. Tony's father, Stephen,
dispensed medications , and was known to customers as Doc. His
mother, Eugenia , worked the register, along with his older sister, Denise.
From an early age, Tony spent evenings and weekends riding around the
neighborhood on his Schwinn , making deliveries.
Fauci's parents were born in New York; one set of grandparents had
emigrated from Naples, the other from Sicily. Anthony first took
Communion at the age of seven and was confirmed at twelve. He went
to elementary school at Our Lady of Guadalupe, in Bensonhurst. "I had
no idea at the time when I was there, being taught by the Dominican
nuns, that I would be interested in science," he said. "I was interested in
a lot of things, mostly sports, but certainly not science."
In those days, baseball was the social glue of Brooklyn. The borough
was Dodger territory and Ebbets Field was consecrated ground- but
Fauci was devoted to the Yankees , who played in the faraway Bronx. In
the midst of the coronavirus crisis, I e-mailed to ask about this anomaly,
not necessarily expecting an answer. He replied almost instantly. "You
probably are unaware, but half the kids in Brooklyn were Yankee fans,"
he wrote. "We spent our days arguing who was better: Duke Snider
versus Mickey Mantle ; Roy Campanella versus Yogi Berra ; Pee Wee
Reese versus Phil Rizzuto and on and on. Those were the days, my
friend."
Fauci has often referred to his father as "laid-back," which , if true, must
be a characteristic that skips a generation. "Tony has always been
driven ," Michael Osterholm , the director of the University of
Minnesota's Center for Infectious Disease Research and Policy, and a
longtime friend of Fauci ' s, told me. "Whatever he was doing, he had to
do it better than anybody else. I don't know if it was certainty or
something else. But he was meant to lead. Always. Everyone who knew
him knew that. And Tony knew it, too."
In 1954, he began attending Regis, a private Jesuit high school on the
Upper East Side. Rigorous, small, competitive, and tuition-free, Regis is
considered one of the finest all-male schools in the country. Fauci
thrived there, though the commute between Dyker Heights and Eighty-
fourth and Madison was long. He once estimated that he had spent the
equivalent of seventy days of his teen-age life on the various subways
and buses he took to get to and from school.
Fauci revelled in the demanding coursework. "We took four years of
Greek, four years of Latin , three years of French, ancient history ,
theology ," he recalled. He developed an ability to set out an argument
and to bolster it with evidence- good preparation, it turned out, for
testifying before Congress . Last year, at a dinner that Regis held in his
honor, he said that the school had taught him "to communicate scientific
principles , or principles of basic and clinical research, without getting
very profuse and off on tangents."
At the time, though, Fauci had no interest in becoming a doctor. "I was
captain of the Regis High School basketball team," he once told me. "I
thought this was what I wanted to do with myself. But, being a realist, I
very quickly found out that a five-seven, really fast, good-shooting point
guard will never be as good as a really fast, good-shooting seven-footer.
I decided to change the direction of 1ny career."
At school, Fauci 's accomplished peers were headed to careers in
medicine, engineering, and the law. At home, he was steeped in the
humanities: "Virtually all my relatives on my mother's side-her father,
her brother, and her sister's children-are artists." His mother helped tip
the balance. "She never really pressured me in any way, but I think I
subtly picked up the vibrations that she wanted very much for me to be a
physician," Fauci said. "There was this tension-would it be humanities
and classics, or would it be science? As I analyzed that, it seemed to me
that being a physician was the perfect melding of both of those
aspirations.''
From Regis, Fauci went on to another Jesuit institution , Holy Cross, in
Worcester, Massachusetts. His high-school faculty had left him little
choice in the matter. "They just wouldn't write a recommendation for
you if you wanted to apply to Harvard or to Cornell, or Columbia," he
said. Fauci enrolled in 1958 and was pleased to find that the university
took a broad view of premedical studies. He signed up for a program
called Bachelor of Arts- Greek Classics- Premed. "It was really kind of
bizarre," he recalled. "We did a lot of classics, Greek, Latin, Romance
languages .... We took many credits of philosophy, everything from
epistemology to philosophical psychology, logic, etc. But we took
enough biology and physics and science to get you into medical
school."
During the summers, Fauci worked construction jobs. One year, he
found himself assigned to a crew that was building a new library at
Cornell Medical College, on the Upper East Side. "On lunch break ,
when the crew were eating their hero sandwiches and making catcalls to
nurses, I snuck into the auditorium to take a peek," Fauci recalled in
1998, at the medical school 's centennial celebration. "I got goosebumps
as I entered, looked around the empty room, and imagined what it would
be like to attend this extraordinary institution. After a few minutes at the
doorway, a guard came and politely told me to leave, since my dirty
boots were soiling the floor. I looked at him and said proudly that I
would be attending this institution a year from now. He laughed and
said, 'Right , kid, and next year I am going to be Police
Commissioner. ' "
Fauci graduated first in his class from Cornell in 1966, just as America's
involvement in Vietnam was accelerating. Every new physician was
required to perform some kind of military service. "We were gathered in
the auditorium at Cornell, early in our fourth year of medical school,"
Fauci recalled. "Unlike today, we had only two women in the class and
seventy-nine men. The recruiter from the armed forces came there and
said, 'Believe it or not, when you graduate from medical school at the
end of the year, except for the two women, everyone in this room is
going to be either in the Army, the Air Force, the Navy, or the Public
Health Service. So you're going to have to make your choice. Sign up
and give your preferences.' "
Fauci wanted to work in the U.S. Public Health Service; his fallback was
the Navy. He got his first choice , and ended up at the National Institutes
of Health , which was then establishing itself as the country's primary
center for biomedical research. Nearly everyone in academic medicine
spent some time at one of its branches; except for three years back at
Cornell to complete his internship and residency, Fauci has spent five
decades there.
In 1972, Fauci started as a senior researcher at the National Institute of
Allergy and Infectious Diseases. He was drawn to investigating ailments
that were difficult but not impossible to treat. "I wanted something that
could make you very sick and kill you unless I intervened. And if I
intervene, you're essentially cured," he told Ushma Neill, the editor
of The Journal of Clinical Investigation, in 2014. "Now, that seems a
little bit too simplistic, but that's really the nature of most infectious
diseases."
Working in the lab of Sheldon Wolff, Fauci studied the molecular nature
of fever. The field of immunology was still young, but scientists were
rapidly learning how to manipulate the smallest components of
individual cells, which opened the way to a decade of discovery.
Chronic fevers can have a number of underlying causes, among them an
uncommon condition known as vasculitis- an inflammation of the
blood cells that often occurs when the body's immune system
mistakenly attacks its own blood vessels. Many of Fauci's vasculitis
patients suffered from rare inflammatory diseases, such as
granulomatosis with polyangiitis , which damages blood vessels in the
lungs, kidneys, and other organs. The disease was almost always fatal.
Fauci and his infectious-disease colleagues at the N.I.H. were frequently
asked to visit the National Cancer Institute, which was in the same
building as his lab, to consult on patients who were receiving
chemotherapy. The drugs suppresse d tumors, but they were highly toxic.
And they had another side effect , Fauci told me: "Those people are
susceptible to a lot of things like infections and bleeding, because the
treatment has destroyed their immune systems."
In 1990, Fauci was the government's leading researcher foc ussed on
the AIDS epidemic. Photograph by George Tames/ The New York Times/ Redux
Fauci, together with Wolff, his mentor, wondered if this side effect
could be harnessed to help vasculitis patients, whose immune systems
were overact ive. "I thought if we could somehow give a cancer drug at a
low enough dose perhaps we could tum the disease off without any of
the secondary complications ," he recalled recently. "First we did it in a
few patients, and, much to our delight, they had a total remission. Before
you know it, we ended up curing a very, very lethal, albeit uncommon,
disease."
For the first time, this techn ique enabled researchers to do effective
work on lupus, rheumatoid arthritis, and transplant rejection. "If you
look at innnunology, it has fro1n the very beginning been inextricably
linked to infectious diseases ," Fauci said. "What is the immune system
for? The immune system protects you against invaders from without-
microorganisms - as well as, in some cases, the emergence of certain
tumors from within."
In 1981, a strange new syndrome emerged that transformed Fauci's

research and, eventually , the lives of millions of people around the
world. "All of a sudden, this new disease comes along," Fauci recalled ,
referring to what would soon come to be known as AIDS. "Even before
the cause of it was proven to be H.I.V., everybody in the field knew that
it had to be a virus. I said to myself, 'Here it is, a virus, still to be
determined, that's affecting profoundly and destroying the human
immune system. ' "Fauci believed that he had been training all his life
for a threat like this one. He was an expert in viruses and in the immune
system-and he had always been attracted to combatting serious, even
fatal diseases. "I wanted to be where the action was," he said.
At first, few public-health officials seemed to care. In June of 1981,
the Morbidity and Mortality Weekly Report , a publication of the Centers
for Disease Control , issued a paper that included an account of five
young men, all gay , who had contracted pneumocystis, a form of
pneumonia that had previously been reported only in people with
dramatically impaired immune systems. The young men described in the
study had all been healthy. "I thought it was a fluke," Fauci recalled. "I
put it aside on my desk, thinking that maybe this was some drug that
they had taken that suppressed their immune system."
A month later, an even more alarming report arrived from the C.D.C.
Fauci read it with an uneasy sense that a disaster was looming: "I made
the decision that I was going to stop what I was doing , much to the
chagrin of my mentors, who were saying, 'Why do you want to give up
a great trajectory of a career to study a handful of gay men with this
strange disease?' But, deep down, I really knew that this was going to
explode. "
Fauci wrote a paper to sound the alarm. "I called it my apologia pro vita
sua- an explanation for what I'm doing," he said. In the paper , Fauci
pointed out that, although the disease "seems to selectively affect a
particular segment of our society," it demanded a medical solution.
Moreover, he warned, "any assumption that the syndrome will re1nain
restricted to a particular segment of our society is truly an assumption
without a scientific basis." Fauci sent the manuscript to The New
England Journal of Medicine, in late 1981. It was rejected. "One of the
reviewers said I was being alarmist," Fauci said. He tried a different
journal , The Annals of Internal Medicin e, and the following June the
paper was published.
In the laboratory , Fauci began making progress. He had been
investigating B cells, which are involved in the production of antibodies.
In 1983-before H.I.V. was even known by that name-his lab became
the first to report that B cells became hyperactive in patients with AIDS.
When a healthy person is invaded by a virus , antibodies mount a
defense, but, when H.I.V. hijacked B cells, the antibody system went
awry. Fauci and his team had identified one of the crucial features
of AIDS. "We made that observation without having any idea of what we
were dealing with," he said in an interview for an N.I.H. oral history. "I
think that speaks for sound scientific and clinical observation." The
politics of seeking a cure, though, would be far harder to manage.
On October 11, 1988, more than a thousand AIDS activists gathered

outside the headquarters of the Food and Drug Administration , in
Rockville, Maryland, to protest the agency's glacial reaction to the
epidemic. The activists knew that their community needed new
treatments if they were to avoid catastrophe - but they were stymied by
the F.D.A.'s drug-approval process , a remarkably inflexible system that
typically took years.
That same day, another group of protesters marched onto the campus of
the National Institutes of Health, in Bethesda , Maryland. They were
headed for Building 31, the home of the National Institute of Allergy
and Infectious Diseases. Fauci , who had become the institute's director
in 1984, was now the government's leading scientist focussed on
the AIDS epidemic. Even though he was not running the F .D.A., he
appeared almost daily in the media to discuss the crisis. "My face was
the face of the federal govermnent ," Fauci told me. He was asked the
same question nearly every day: why wasn't the government moving
faster ? It didn't help that the Reagan Administration seemed so
indifferent to the plague.
Fauci watched from his office window as activists surrounded the
building and tried to scale its walls. Some were dressed in black robes
and carried scythes. Many waved pink-and-black banners, bearing the
words "NIH Wake Up!" or "Stop Killing Us!" All over campus , a chant
could be heard: "Fuck you, Fauci!"
"God, I hated him," Larry Kramer, the writer and activist who helped
establish the two most important AIDS advocacy groups in the country,
the Gay Men's Health Crisis and ACT UP , said. "As far as I was
concerned, he was the central focus of evil in the world." Kramer
attacked Fauci relentlessly in the media. He called him an "inco1npetent
idiot" and a "'pill-pushing" tool of the medical establishment, insulted his
wife, and even compared him to Adolf Eichmann. In 1988, Kramer
published a scathing open letter. "Anthony Fauci , you are a murderer,"
he wrote. "Your refusal to hear the screams of AIDS activists early in the
crisis resulted in the deaths of thousands of Queers. "
As the epidemic spread and the death toll rose, it was common for gay
activists to view Fauci and NIAID with rage. Fauci did not control the
drug-approval process , but he was seen as a barrier to opening access to
clinical trials , in which volunteers could receive potentially lifesaving
medications.
For most people infected with H.I.V. , taking experimental drugs was the
only alternative to simply waiting for death. Yet the F .D .A.' s arcane
rules prevented the vast majority of patients from qualifying for trials.
For instance, a significant number of H.I.V. patients suffered from
pneumocystis pneu1nonia. The condition-the same one observed in the
initial C.D.C. report- could be fatal, so many who had it used an
experimental antimicrobial medication called pentamidine, which had
proved highly effective. But people who took experimental medications
were barred from participating in other clinical trials.
At first, Fauci held to the standard N.I.H. line that research need not
focus on the immediate welfare of patients. "When we had clinical trials,
we, the scientific co1nmunity and the regulatory co1nmunity, did not
listen" to the activists , he recalled. "It was, at the time, an attitude that
many of us had, and I probably had it myself." He was right about that. I
covered the AIDS epidemic for the Washington Post, and it was clear to
me that Fauci was inclined to enforce the paternalistic medical tradition
in which he had trained: doctors and scientists were unquestioned
authorities, and drug development had to follow a rigid process that
included animal testing and rigorous clinical trials. Otherwise , the
benefits and the risks of these drugs could not be adequately assessed.
In 1987, the F.D.A. approved the first drug to treat H.I.V.-
azidothymidine, or AZT-and the announcement was met with a burst
of hope. But the drug's liabilities were evident almost instantly. It had
harsh side effects, and the benefits wore off; the virus itself soon became
resistant to the drug. When new clinical studies began , involving
cocktails of AZT and similar compounds, tens of thousands of people
asked to participate. Again, though, volunteers were not accepted if they
used other experimental drugs. The anger among activists grew 1nore
intense. "They started becoming amazingly iconoclastic and
confrontational, and that scared the hell out of the scientists, who were
fundamentally quite conservative ," Fauci told me at his medical-school
reunion. "When they were demonstrating on the N.I.H. campus,
disrupting Wall Street, disrupting St. Patrick 's Cathedral, instead of
listening to them, scientists withdrew."
Without entirely understanding his own motives, Fauci decided to look
beyond the activists' furious rhetoric and style. He recalls telling
himself, "Let me put aside the goth dress-the earrings and the Mohawk
haircuts and the black jackets-and just listen to what they have to say.
And what they were saying made absolutely perfect sense." It helped
that Fauci had something in common with the activists: "They were all
New York guys. I had a little affinity to them because I'm a New
Yorker. And I said, What would I do if I were in their shoes? And it was
very clear: I would have done exactly the same thing."
The activists knew that they were facing a mercilessly lethal disease. In
the summer of 1985, I travelled to New York to write my first long story
on the toll that the epidemic was taking on the city's gay community. I
interviewed dozens of 1nen. To the best of my knowledge, only two of
them are still alive: Larry Kramer , who is now eighty-four, and a
political activist who prefers to remain anonymous.
Fauci, too, came to understand the severity of the crisis. "Everyone
died," he said. "I was used to treating people who had little hope and
then saving their lives-that was so wonderful. But, with AIDS in those
days, I saved no one. It was the darkest time of my life." Faced with
mounting evidence that his cautious approach made no sense , he did
something that few public officials do: he reversed himself. Fauci
transformed from a conventional bench scientist into a public-health
activist who happened to work for the federal government. "I had to
change ," he told me.
When the demonstrators marched on the N.I.H . campus in 1988, Fauci

no longer saw a threat. "I looked at them, and I saw people who were in
pain," he recalled in an article in Holy Cross Magazin e. He asked the
police and the F.B.I. not to arrest any of the1n. Then he invited a handful
of protest leaders to his office. "That began a relationship over many
years ," Fauci said. "They let me into their camp. I went to the gay
bathhouses and spoke to them. I went to San Francisco, to the Castro
District , and I discussed the problems they were having , the degree of
suffering that was going on in the community, the need for them to get
involved in clinical trials , since there were no other possibilities for them
to get access to drugs. And I earned their confidence."
Fauci, in his mid-forties, was the youngest director of an N.I.H. institute
in a century , and he lacked the political influence to act independently.
Even in his own field , he struggled to recruit allies. "I couldn't convince
my own people in infectious-disease leadership to take on H.I.V ./AIDS ,"
he told me. So he created a division within his institute devoted to the
disease.
One day, in the late eighties , Fauci asked me to stop by his office in
Building 31 on the N.I.H. campus. He told me that he had a wild idea: he
wanted to hire Mark Harrington , ACT UP' s point man on drug-treatment
trials. Harrington, a prominent AIDS researcher and activist, had no
formal scientific training. But Fauci , like most of those who had seen
him testify before Congress or speak to a crowd , was dazzled by his
brilliance.
Harrington discussed the idea with Fauci , but decided that the job would
be a disaster for him. "There's no way I could have functioned within
that bureaucracy, " he told me recently. "The people I respect would have
seen me as a sellout." Yet Harrington continued to make a profound
impression on Fauci' s thinking .
Harrington was passionately committed to loosening up the F.D.A.'s
restrictive regime. "It was murder," he told me. "I don't know any other
way to describe it." Harrington, who went on to win a MacArthur
"genius" grant for his work on the disease, established himself as the
most knowledgeable student of the agency ' s byzantine regulations. In
meetings with Fauci and other officials, he urged them to move faster
and with greater compassion for those who were suffering.
There are three stages in most F.D.A. clinical trials. The first tests
whether a drug is safe. The second assesses its efficacy. The last stage ,
conducted in larger groups, confirms that the drug works and that there
are no serious adverse reactions. Harrington argued that people with no
alternative should be granted access to those drugs as soon as they had
been proved safe, even if their effectiveness remained unknown.
At first, Fauci was concerned that, if people taking multiple
experimental medications joined clinical trials , the results would be
hopelessly muddled. He was also afraid that granting sick people
unrestricted access to unapproved drugs would deter them from
participating in the trials at all. Harrington and other activists reassured
him that they were committed to strictly monitored drug trials that would
provide enough data to know what worked and what did not.
Fauci is a realist, and the facts were obvious to anyone who cared to
look. Traditional methods of testing drugs weren't working.
Underground networks were growing everywhere. With so
many AIDS patients taking untested medications , federal health officials
had to concede that their syste1n was broken. Even the most fundamental
protocol of a clinical trial- giving some participants a placebo- came
into question. In a study conducted in San Francisco in 1989, nearly all
the volunteers had their medicine analyzed, to see whether they were
receiving an active dose. Those who learned that they had been given
placebos almost invariably dropped out.
"There was a feeling in science that doctors know best, scientists know
best," Fauci said. "We love our patients, but they don ' t really know
what's best for them. Then, when we dealt with this disease that was
brand new- that was frightening, that was killing people in a way that
was historic-the people who were impacted by the disease wanted to
have something to say about how we conducted research."
There were still moments of confrontation. In May, 1990, hundreds
of ACT UP activists returned to the N.I.H., demanding
more AIDS treatments and greater representation of women and people of
color in clinical trials. At a planning session for the protest, a young
activist named Tony Malliaris performed a rap song called "Storm the
NIH ," which included the lyrics "I don't know what Fauci thinks, but
this ain't Denmark, and something stinks." (Malliaris died five years
later, still in his early thirties.)
Fauci was undeterred. He threw his influence behind a program called
Parallel Track, which made unapproved AIDS drugs available as soon as
they were demonstrated to be safe, even as clinical trials were
continuing. The initiative would not have succeeded without Fauci. But
he always acknowledged that his approach had been shaped largely by
the constructive pressure he received from AIDS advocacy groups and
from leaders like Harrington.
This more inclusive approach ushered in a revolution in American
medicine . Patients today demand as much information as possible about
treatments they might receive , and no longer act as if their doctors '
advice came straight from Mt. Olympus. They scour the Internet,
assemble statistic s, and often arrive at the hospital with a folder full of
medical information. The F.D.A., for its part, will no longer consider
approving a new drug until it has consulted representatives of groups
who would use it. "There are strict scientific principles that have to be
adhered to in medicine ," Fauci told me. "At the same time, a humanistic
touch is needed in dealing with people. You have to combine social
aspects, ethical aspects, personal aspects with cold, clean science."
In 2002 , I wrote a Profile of Larry Kramer for this magazine. By then, he

and Fauci had become friends , with each expressing gratitude for the
other's work in those years. Fauci told me , "In American medicine , there
are two eras: before Larry and after Larry. There is no question in my
mind that Larry helped change medicine in this country. When all the
screaming and the histrionics are forgotten, that will remain." Kramer,
who spent years in a constant rage at Fauci , now calls him "the only true
and great hero" among government officials in the AIDScrisis.
As Trump defends his Administration's response to the pandemic, he

has suggested repeatedly that COVID-19was impossible to predict.
"There's never been anything like this in history ," he said, at a press
conference on March 19th. "Nobody knew there would be a pande1nic or
epidemic of this proportion."
As everyone with even a casual interest in the history of science knows,
pandemics have altered the destiny of humanity at least since 430 B.C.,
when Athens was struck by a plague that killed as many as two-thirds of
its residents , just as the Spartans were laying siege. Beginning in 165
A.D. , smallpox helped ruin the Roman Empire , sowing more destruction
than foreign armies ever could. And, in the fourteenth century, the Black
Death swept through Europe , killing more than half the population,
according to recent estimates.
Yet, by the middle of the twentieth century, many scientists had begun
to conceive of a world that was largely free of infectious epidemics. In
1951, Sir Frank Macfarlane Burnet, a future Nobel laureate in medicine ,
wrote, "The fever hospitals are vanishing or being turned to other uses.
With full use of the knowledge we already possess, the effective control
of every important infectious disease"-with the exception of polio-"is
possible. " His optimism was understandable. Antibiotics had made
many lethal diseases easy to treat; improvements in sanitary conditions
had transformed the lives of hundreds of millions of people. In
developed countries, typhoid, cholera, and measles - major killers
throughout history - had largely passed into memory; even tuberculosis ,
one of the great scourges of humanity, had been in decline for nearly
half a century. By 1972, Macfarlane , writing with the microbiologist
David White, was predicting that the "most likely forecast about the
future of infectious diseases is that it will be very dull."
When Fauci was a young trainee, these kinds of predictions sometimes
made him wonder if he had picked the wrong career. "I became
concerned that I was entering ... an area of biomedical research that
was disappearing ," he recalled in one speech. But , since 1984 , when
Fauci became the director of NIAID, there has not been a single day in
which some epidemic has not threatened the globe. According to the
World Health Organi zation, AIDS has killed more than thirty million
people, and nearly forty million are now living with H.I.V. Tuberculosis,
far from sliding into obscurity, infects roughly a quarter of the human
population ; the W.H.O. says that one and a half 1nillion people died from
the disease in 2018.
But the greatest threat that humanity faces, by far, is a global outbreak of
a lethal virus for which no treatlnent has been found. In just a few
months , COVID-19 has forced billions of people , in nearly every country
on earth , into a panicked withdrawal from society. Another pandemic
like this might appear in two years, or in ten, or in a century. But I have
never met a virologist or an epidemiologist who believes we won't
encounter one.
For a deadly virus to flourish, it must meet three critical conditions.
First, a new virus-one to which no one has yet developed immunity-
must emerge from the animal reservoirs that produce and harbor such
pathogens. Second , the virus has to make humans sick. (The vast
majorit y do not.) Finally, it must be able to spread efficiently, through
coughing, sneezing, or shaking hands. That combination is rare, but ,
when it appears, the consequences are almost always disastrous.
The Nobel Prize-winning molecular biologist Joshua Lederberg, who
died in 2008, was for years the world's most visionary voice about
emerging infectious diseases. "Some people think I am being hysterical ,
but there are catastrophes ahead," he once wrote. "We live in
evolutionary competition with microbes - bacteria and viruses. There is
no guarantee that we will be the survivors."
In 2003 , Lederberg joined the future F.D.A. commissioner Margaret
Hamburg and the pandemic specialist Mark Smolinski to edit a seminal
report, in which prominent scientists argued for a much more aggressive
defense of the planet. Titled "Microbial Threats to Health," the report
recommended that the U.S. greatly expand its early-warning systems,
particularly in the developing world. It also urged leaders to strengthen
their ability to respond to microbial threats, with new efforts on the
federal, state, and local levels. The recommendations were almost
completely ignored.
The next year, a highly pathogenic form of avian influenza, H5Nl,
leaped from waterfowl to chickens and then to humans. Public-health
officials were petrified. In Bangkok , I met with Scott Dowell, who led
the Thailand office of the C.D.C.'s International Emerging Infections
Program. "The world just has no idea what it's going to see if this thing
comes," he told me. He paused and then reframed his thought. "When,
really. It's when. I don't think we can afford the luxury of the word 'if
anymore."
In a sense, the world was lucky with H5Nl. Although the U.S. and other
countries mounted a diffident response, the virus turned out to be deadly
but not very contagious. Five years later, the situation was reversed. A
new influenza virus, designated HINI, infected nearly a quarter of the
global population before vaccines became widely available. This time,
the virus was highly contagious but not nearly as deadly as most strains
of influenza. The fact that the outbreak was less virulent than public-
health officials had feared created its own danger; by encouraging
complacency, it did more to expose the world to the risk of a devastating
new pandemic than anything else that had happened in decades.
Although Congress had appropriated money to stockpi le antiviral
medications and protective gear, many scientists felt that the effort was
grossly insufficient. "We spend many billions of dollars every year on
missile-defense systems," Seth Berkley, a medical epidemiologist who
leads the Global Vaccine Alliance, told me. "And yet we will not spend
pennies on the dollar to prepare for a catastrophe that is far more likely
to affect us all."
After the Ebola outbreak of 2014, Barack Obama implemented one of
Lederberg's central rec01nmendations: he established the White House's
National Security Council Directorate for Global Health Security and
Biodefense, an early-warning system for disease in the developing
world. Trump disbanded it in 2018 , as part of an effort to streamline the
N.S.C. In an appearance before Congress, Fauci was asked if the
decision was a mistake. He responded diplomatically: "I wouldn't
necessarily characterize it as a mistake. I would say we worked very
well with that office. It would be nice if the office was still there."
The combination of mone y and political will can have extraordinary

effects on public health. Under the George W. Bush Administration,
Fauci was the principal architect of a landmark program called PEPFAR,
the President's Emergency Plan for AIDS Relief.
By the time Bush took office, therapies for H.I.V. had become widely
available in Western countries. But, for millions of people in the
developing world, these drugs were too expensive or too difficult to
obtain. Bush felt that it was unacceptable for the poorest people on earth
to die because they could not afford medication that was dispensed
routinely in the rich world. He asked Fauci to implement an initiative to
prevent and treat H.I.V. on a global scale. It has been uniformly held up
as a model of the ways in which global public-health programs can save
lives. "PEPF AR has turned around declining life expectancies in many
countries and likely saved some countries-even an entire continent-
from economic ruin," Harold Varmus, a former director of the N.I.H.
and of the National Cancer Institute , wrote in the quarterly
journal Science & Diplomacy.
But Fauci has at times struggled to compel politicians and businesses to
attack the problems that he considers most worrisome. Over the years,
he has become concerned about the possible impact of new viruses,
particularly a lethal strain of influenza. Other viruses are more
consistently deadly; some , like measles, are more contagious. But no
virus that we know of is capable of killing as rapidly and as efficiently.
"We need a major paradigm shift with influenza vaccines ," Fauci told
me, four years ago. "The situation is a mess."
Because the flu virus evolves so rapidly, experts deciding how to
formulate vaccines can make only a highly educated guess about which
strains are most likely to make people sick. Each February,
epidemiologists study outbreaks around the world-especially in the
Southern Hemisphere, where flu season is under way- to assess which
strains might make their way north. The result is always better than
nothing. In many years, though, it is woefully inadequate. In the flu
season of 2014-15 , the vaccine protected less than a fifth of the people
who received it. In 2017-18, it worked for a little more than a third.
Fauci has long supported the development of an alternative: a universal
influen za vaccine, which would provide lasting defense against all
strai ns. "Similar to tetanus, a universal flu vaccine probably would be
given every ten years, " he said. "A nd, if you get one that is really
universal , you can vaccinate just about everyone in the world." But such
a vaccine would cost hundreds of millions of dollars to develop and
test- and would replace a product that most consumers already think of
as good enough. No one has come close to raising the money that such a
project will require.
By the beginning of the new millennium , it had become clear that the
next microbial threat might not come from a bat or a duck. It could just
as well be created by a human being. After the terrorist attacks of
September 11, 2001, anonymous letters laced with deadly anthrax spores
began arriving at media companies and congressional offices. In the
following months, twenty-two people were infected by inhaling anthrax
and five died. Suddenly , biological terror posed an entirely new threat-
one that has become only more significant and complex in the ensuing
years. In 2016, James Clapper, who was the director of National
Intelligence during the Obama Administration , listed gene editing as a
potential weapon of mass destruction. Many scientists were furious, but
he had a point. Researchers have deployed these tools to rewrite the
genes of mosquitoes so that they are unable to transmit malaria. If their
success in the lab translates to the field, it will be a historic triumph. But
the research also raises an alarming possibility: if a scientist can modify
the genes of an insect to protect people from malaria, he could almost
certainly use the same technology to add a deadly toxin.
Fauci often cites a similar but more immediate paradox. Thanks to
genetic engineering , we are more equipped than ever to respond to the
threat of a viral pandemic. After the COVID -19 outbreak began, it took
scientists less than a month to sequence the genome of the virus. By the
end of February, the instructions were on the Internet, and the virus had
been re-created in laboratories around the world, by scientists seeking to
develop drugs and vaccines.
And yet , despite our mastery of molecular biology, we live in an era in
which someone can wake up with an infection in China-or France ,
Australia, or any other place with an airport - and fly to San Francisco in
time for dinner, spreading the virus long before he suspects that there ' s
anything wrong. For most of human history , a virus like COVlD-19 might
have killed many people in the community where it originated, but then
stopped spreading. According to a comprehensive analysis carried out
by the Times, at least four hundred and thirt y thousand people have
arrived in the U .S. on direct flights from China since the outbreak began.
Forty thousand have arrived in the two months since Trump imposed
restrictions on travellers from China trying to enter the country.
Fauci insists that an adequate defense against future pandemics will have
to be flexible . "I have been saying for eight , ten years that we should
make a list of microbes and try to develop a basic platform vaccine," he
told me in 2016. A platform vaccine addresses an entire class of virus,
not just a particular strain. "We keep trying to develop a vaccine for one
thing-usually the last one-and it's a waste of time ," he said. "Every
time we get hit , it is always something we didn ' t expect. So, instead of
predetermining what it is you're going to prepare for, make universal
platforms. "
Such an approach is eminently possible. Using gene-sequence
information and synthetic DNA , biologists are now capable of making
parts of a vaccine in advance . It takes almost no time to sequence a viral
strain , and with that information it should be poss ible to complete a
bespoke vaccine in a matter of weeks. "You could build a chassis for the
vaccine, and you would have it on the shelf," Fauci said. "Then all you
would need to do is insert the gene of the protein you want to express
and make a gazillion doses and send it out. "
There are even more futuristic aspirations: the genomics pioneer J. Craig
Venter has proposed using a sort of 3-D printer to manufacture vaccines
on demand. It is already possible to print the nucleotides that make up
DNA and asse1nble them. Venter argues that , in the time it takes for an
infected person to fly from one side of the world to the other, we should
be able to print , assemble, and admini ster a vaccine.
To even contemplate creating these kinds of treatments, Fauci says,
would require building an entirely new system for making vaccines
before a pandemic arises. But, in addition to the scientific obstacles , this
would cost billions of dollars , and no company or politician has been
willing to spend the money. Perhaps , just as AIDS transformed our
approach to clinical trials , our experience with co vro-19 will change our
attitudes about preventing infectious diseases. A proper investment in
both research and emergency preparedness would have prevented at
least some of the unspeakable human loss we are now experiencing and
the economic crash that has just begun.
The COVID-19epidemic will eventually fade, but the public will demand
a reckoning. Inevitably, there will be an investigation , along the lines of
the 9/ 11 Commission , to look into the ramifications of the President's
denialism, the shortages in testing and medical equipment, and the
dismissal of so many warning signs. Fauci will not necessarily escape
criticism. He is an excellent spokesman for the value of scientific
research, but he runs a single institute , and he lacks the authority to
broadly reshape our response to pandemics. "The kinds of things we
really desperately need as foundational tools for dealing with this stuff
aren 't necessarily research enterprises," Harold Varmus told me. "Tony
isn't running C.D.C. He's not running FEMA . To tell him to stockpile
defense mechanisms or to move forward surveillance tools into massive
operations around the world- that ' s just not his remit."
Even Fauci' s current value as a scientific adviser has been limited by the
President's conte1npt for expertise. Trump ' s coronavirus kitchen cabinet
consists of people like his son-in-law, Jared Kushner, who has no
medical knowledge or experience managing crises-yet has been
appointed to direct the response to the biggest medical emergency since
the influenza pandemic of 1918. Trump has also turned for advice to Dr.
Mehmet Oz, who for years has endorsed worthless treatments and used
his television show to promote notorious quacks. Trump even seems to
think that his trade adviser, Peter Navarro, should debate Fauci about the
value of specific drugs. When Navarro , who has a doctoral degree in
economics, was asked about his medical qualifications , he said, "I have
a Ph.D. And I understand how to read statistical studies, whether it's in
medicine, the law, economics , or whatever."
Among Navarro ' s enthusiasms is the malaria drug hydroxychloroquine ,
which he believes could cure COVID-19. There is currently no evidence
to support this conclusion , as Fauci has pointed out on several occasions.
On April 5th, as Trump continued to tout the drug as a miracle cure, a
reporter at the daily briefing asked Fauci to com1nent. Trump refused to
allow him to speak. In an appearance two days later, Trump kept up the
hype. "I say try it," he said. "You're not gonna die from this pill." Not
long afterward , he even suggested that zinc might help.
To plan a coherent biological future , rather than simply scramble to
contain each new pandemic , will require an entirely new kind of
political commitment. It would certainly include the creation of a
permanent position , a special assistant to the President for biological
defense. Similar job s have existed in the past, but not for long , and not
with enough influence to matter. David Reiman , the Stanford professor ,
told me, "This kind of job needs somebody with the authorit y to preside
over domestic and international threats, both natural and deliberate. And
that person has to sit in the White House with immediate access to the
President. Without that , we will really have nothing that can work."
Until then, we have Fauci, a seventy-nine-year-old infectious-disease
expert pinned between Donald Tru1np and the American people. It can 't
be easy. As Fauci recently put it, with characteristic candor, "I give the
appearance of being optimistic. But, deep down, I just do everything I
possibly can, assuming that the worst will happen , and I've got to stop
the worst from happening." ♦
Published in the print edition of the April 20, 2020 , issue, with the
headline "The Good Doctor ."
of U.S. copyright law, witho ut further verification of its accuracy/veracity. It does not necessar ily represent
Sent : Sat, 11 Apr 2020 16:30 :40 +0000
To: Del Rio, Carlos; (b)(6)
Cc: (b) (6)·
Subjec t : RE: Infectious Diseases Society of America Guidelines on the Treatment and
Management of Patients with COVID-19 Infection
Thanks, Carlos . As you know since Cliff has been in touch with the lDSA , the HHS guidelines will be coming out
this week.
Best,
Tony
Director
National Institute of Allergy and lofectious Diseases
Phone: (b)(6)
FA X: (301) 496-4409
E-ma il: (b) (6)
The infom1ation in this e-mail and any of its attachments is confidential and may contain sensi tive infom1ation. It
should not be used by anyone who is not the original intended recip ient. lfyou have received this e-mail in error
please inform the sender and delete it from your mailbox or any other storage devices. The National lnstirute of
Allergy and Infectio us Diseases (NIAID) shall not accept liability for any statements made that are the sender's own
From : Del Rio, Ca rlos ______ (b
""')'"""
(=
Sent: Saturday , April J 1, 2020 12:08 PM
To: (b)(6) ; Fauci , Anthony (NTHINIAID) [E] (b)(6)
Subject: Jnfectious Diseases Society of America Guidelines on the Treatment and Management of Patients with
COVID - 19 Infection
IDSA guide lines are out

https://www.idsociety.org /prac ti ce-gu idel ine/ covid- 19-guidel ine-trea tment-and-manag ement/
Carlos de ! Rio, MD.

Sent from my iPhone
This e-mail message (including any attachments) is for the sole use of the int ended recipient(s) and may contain
confident ial and privi leged information. If the reader of this message is not the intended recipient, you are hereby
notified that any dissemination , distribution or copying of this message (includi ng any attachments) is strictly
prohibit ed.
Jfyou have received this message in error, please contact the sender by reply e-mail message and destroy all copies
of the original message (inc luding attachments).
Sent : Sat, 11 Apr 2020 16:25 :29 +0000
To: (b)(6)
Subject : FW: Infectious Diseases Society of Ame rica Guidelines on the Treatment and
Management of Patients with COVID-19 Infection
Let us discuss.
Director
Phone: (b) (6)
FAX: (301) 496-4409
E-mail (b) (6)
should not be used by anyone who is not the original intended recipient. If you have received this e-mail in enor
please infonn the sender and delete it from your mailbox or any other storage devices. The National Institute of
From: Del Rio, Carlos ______ (b
""~"'(=

To: (b)(6); Fauci, Anthony (NIWNIAID) [E] CbH >
Subject: Infectious Disea ses Society of America Guidelines on the Treatment and Management of Patients with
COVID-19 Infection
lDSA guidelines are out

https://www.idsociety.org/practice-guideline/ covid-19-guideline-treattnent-and-management/
Carlos del Rio, MD.

Sent from my iPhone
This e-mail message (including any attachments) is for the sole use of the intended rccipicnt {s) and may coi,tain
confid ential and privi leged information. If the reader of this message is not the intended rec ipient, you are hereby
notified that any dissemina tion, distributio n or copying of this mess age (including any attachments) is strictly
prohibit ed.
lf you have received this message in enor, please contact the sender by reply e-mail message and destroy all copies
of the original message (including attachments).
Sent : Fri, 10 Apr 2020 15:12:24 +0000
(b)(6)
Subject: FW: Atlantic's coverage - Fauci as "h eartthrob"
David Bradley is the Chairman of The Atlantic. Geeez ....
From:David Bradley <dbradley@theatlantic.com>

Sent : Friday, April 10, 2020 10:20 AM
To : Fauci, Anthony (NIH/NIAID) [E] ------ ~~
(b)(6h
Subject: Atlantic's coverage - Fauci as "heartthrob"
Hi Tony,
----- CbH6JI send you greetings and the deepest appreciation.
I am only one of your millions of fol lowers who feel in your debt. But, I am the only one with a
magazine that has dedica ted a who le art icle to "the thirst for Tony Fauci."
This will be the least important item on today's to-do list. But, someday, your grandchildren
and their children, in turn, will want to read
t his: https://www.theatlantic.com/technology/archive/2020/04/anthony -fauci -coronavirus -
crush/6095 44/
My best wishes to you.
David
David G. Bradley
Chairman
Atlantic Media
Sent : Fri, 10 Apr 2020 15:10:47 +0000
To: David Bradley
Subject: RE:At lantic's coverage- Faucias "heartthrob"
David:
Many thanks for sending this. I could not have even begun to make this up ..... Please stay
safe and well.
Warm regards,
Tony
From:David Bradley <dbradley@theatlantic.com>

---------=-c-=
To: Fauci,Anthony (NIH/NIAID) [E]_______ Cb_H _6)
Subject: Atlantic's coverage - Fauci as "heartthrob"
Hi Tony ,
----- (b)(6) I send you greetings and the deepest appreciation.
I am only one of your millions of fol lowers who feel in your debt. But, I am the only one with a
magazine that has dedicated a who le article to "the thirst for Tony Fauci."
This will be the least important item on today's to-do list. But, someday, your grandchildren
and their children , in turn, will want to read
t his: https://www.theatlantic.com/technology/archive/2020/04/anthony-fauci-coronavirus-
crush/609544/
My best wishes to you.
David
David G. Bradley
Chairman
Atlantic Media
Sent : Fri, 10 Apr 2020 01:37:52 +0000
Cc: Haskins, Melinda (N IH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Letter from Rep. C. Smith to Sec Azar and Dir Fauci
Attachments : 2020-04-09 Smith to Azar and Fauci re Lyme and COVID19.pdf
FYI
From: Griswold, Kelsey (b)(6)
Sent: Thu rsday, April 9, 2020 8:41 PM

To: Griswold, Kelsey----------~~ (b)(6)>
Subject: Lette r from Rep. C. Smith to Sec Azar and Dir Fauci
Good Evening All,
Attached is a letter from Congressman Smith to Secreta1y Azar and Director Fauc i. Please let
me know if there are questions or concerns associated with this.
Best,
KelseyA. Griswold I LegislativeDirector

CongressmanChristopher H. Smith (NJ-04)
2373 Rayburn HOB
Washington, DC20515
p: (b)(6)
Sent : Fri, 10 Apr 2020 01:35:00 +0000
To: (b)(6)
Subject: RE:We Believe in You
(b)(6J:
Many thanks for your e-mai l. Stay well and safe.

Best regards,
Tony
From: Cb)(
To: Fauci, Anthony (NIH/NIAID) [E]------~= CbH6J
Subject: Re: We Believe in You
----------
Tony,
I would only hope that one of your staff see my email and are prudent to
know that this is being sent to him by one of his kin and passes it along
to you.
Sincerely,
(b)(6)
On Thursday, April 9, 2020 , 05 :54 :17 PM EDT , Fauci , Anthony (NIH/NIAID) [E] (b)(6)
wrote : -------
emails precludes me or my staff from answering each individual message .
I would encourage you to visit www.coronavirus.gov for the latest
information and guidance related to COVID-19.

Anthony S. Fauci , M.D.
Sent : Thu, 9 Apr 2020 21 :24:50 +0000
Subject : FW: COVID 19 Briefing Document and COVID Vaccine Overview
Attachme nts: Overv iew of COVID-19 Vaccine Development_April9.pdf, Briefing Document
NIAID Involvement with Pharma in COVID19_A pril 9_with table.pdf
The email below is from Larry Corey.

Special Assistant for Scientific Project s
Bethesda MD 20892
Telephone: (b)(6)
Email : (b)(
From : Corey MD, Larry (b)(6)>

To : Fauci, Anthony (NIH/NIAID) [El ------ ~= (b)( ·>; Conrad, Patricia (NIH/NIA ID) [El
(b)( ; Marston, Hilary (NIH/NIAID) [El
---------
Cc: Mascola, John (NIH/VRC) [El
(b)(6)>
(b)(6) ; Erbelding, Emily (NIH/NIAID) [El
-----=~ Cb
_>_C6)
_ >; Dieffenbach, Carl (NIH/NIAID) [El (b)(6)>; Lane, Cliff
(NIH/NIAID) [E] CbH6J
Subject : COVID 19 Briefi ng Document and COVID Vaccine Overview
Tony,
We are sending you two documents relating to our strategy for COVID vaccine development . The
(b) (4)
(b) (4)
Larry
From: (b)(6)
Sent : Thu, 9 Apr 2020 17:18:14- 0400
Subject: Fwd: INTERVIE W REQUEST with Or Anthony Fauci - Radio-CanadaNews
Program 24h/60min
Let us discuss
From: NATHA LIE L EMIEUX <nathalie.lemieux@radio-canada.ca>

To: "NIAID NEWS (NIH/NIAID)" <NWDNEWS@niaid .nih.gov>, "Fauci,
Anthony (NIH/NIAID) [E]" (b)(6l , "Fauci, Anthony
(NIH/NIAID) [E]" (b)C
Subject: INTERVIEW REQUEST with Dr Anthony Fauci - Radio-Canada
News Program 24h/60min
Hello
My name is Nathalie Lemieux and I am a rnsearch journalist for 24b in 60min, an

information and public affairs program hosted by Anne-Marie Dussault and
broadcast on the CBC/Radio-Canada's French national news
network. https://ici.radio-canada.ca/tele/24-60/site We are based in Montreal and the
broadcast is aired across Canada weekdays on prime time (between 7pm and 8PM
ET)
As we are also living thr ough this Covid-19 pandemia , we would be delighted to do
an interview with Dr Anthony Fauci
*Of course, host Anne-Marie Dussault can do the interview in English
When: subject to Dr Fauci's availability ...

How: Skype or Facetime (in respect of containment obligations)
How long: 7-8 min
Cou ld this proposal be of inte rest to Dr Fauci?
Thank you for letting me know the possibilities ... we are aware of Dr Fauci's tight
schedu le
You can reac h me at any time via this emai l natha lie .lemieux@radio-canada.ca or
on my cell phone: Cb) (6)
Nathalie Lemieux
Joumalis te a la recberche
Emission 24 heures en 60 minutes
RDI/Radio-Ca nada
Cell: CbH6)
4il~Rao10
-canaoa
From: (b)(6)
Sent: Thu, 9 Apr 2020 16:51:32 -0400
To: Stover, Kathy (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia
(NIH/NIAID) [E]
Subject: Re: FORASF REVIEW:Draft PR re: SARS-CoV-2 serosurvey study launch
Looks fine ! Thank s
On Apr 9, 2020, at l :48 PM, Stover, Kathy (NIH/NIAID) [E]

(b) (6) wrote:
Hi Dr. Fauci,
Please find attached for your review a draft press release announcing the launch of Dr.
Memoli's serostudy to detect previously undiagnosed coronav irus infections. Your draft
quote is as follows:
"Thi s study will give us a cleare r pichrre of the true magnitude of the
COVID-19 pandemic in the United States by telling us how many people in
different commun ities have been infected without knowing it, because they had a
very mild, undocumented illness or did not access testing while they were sick," said
Anthony S. Fauci, M.D., NIAID director. "The se crucial data will help us measure
the impact of our public health efforts now and guide our COVID-19 response
moving forward."
Thanks much,
Kathy
Kathy Stover
Branch Chief
National Instit ute of Allergy and Infect ious Diseases (NIAID)
Bethesda, MD 20892
Phone:
E-mail: _____
,__
(b)(6)
(b)(6)
<SARSCo V2 serosurvey Rel ease FOG cleared.docx >

<SARSCo V2 seros urvey NSWB Clearance Form.doc >
<SARS _ COV2 _ SERUM _ SAMPLING _ Clean Changes _ Copy_ 4.2.2020.docx >
Sent : Thu, 9 Apr 2020 16 :40:28 +0000
To : Cb) (6>:E)
Subject: FW: New Yorker: Fauci Urges Trump to Attack the Coronavirus as if It Were an
Inspector General
This Borowit z guy is some thin g else ....
Director
Phone Cb)(6)
FAX: (3 96':44li 9
E-mail Cb
) (6)
From : Folkers, Greg (NIH/NIAID) [E] (b)(6)

Sent : Thursday, Apr il 9, 2020 12:33 PM
To : NIAID COGCORE<COGCORE@mail.nih .gov>; NIAID OCGR Leg <NIAIDOCGRLeg@ma il.nih .gov>; NIAID
OD AM <NIAIDODAM@niaid.nih.gov>
Subject: New Yorker : Fauci Urges Tru mp to Attack the Coronavirus as if It We re an Inspector General
Satir e fro m The Bo rowitz Report
Fauci Urges Trump to Attack the Coronavirus

as if It Were an Inspector General
By Andy Borowitz
April 8, 2020
Photograph by Lo Scalzo/ Bloomberg/ Getty
WASHINGTON (The Borowitz Report) - ln what he described as a "potentia lly major breakthrough," Dr.
Anthony Fauci has convinced Donald Trump to attack COVID-19 as if it were an inspector general.
Fauci, who has been frustrated in his efforts to get th rough to Trump, compared the global pandemic to
an inspector general while in a closed-door meeting with the President on Wednesday.
"Wha t do you hate more than anything, M r. President?" Fauci asked.
"Jim Acosta," Trump immed iately replied.
"O.K., fine. But, besides Jim Acosta," Fauci said, "it would be an inspecto r general, right?"
"You're right, Tony," Trump agreed. " I hate those losers."
"Well, think of COV/0-19 as the worst inspector general in the world," Fauci continued. " It's overseeing
everything you do and making you follow the law. It's keeping you fr om spending taxpayer money on
anything you want. You wouldn't stand for that , would you?"
Reportedly, Trump appeared shaken by Fauci's analogy. "Damn it, Tony, when you put it that way, we've
got to do something about COVID-19," he said.
Speaking to reporters, Fauci said that he was "caut iously optimistic" that his inspector -genera l analogy
would finally spur Trump to action, but added, "Jared could still screw this up."
Disclaimer: Any third-party material in this email has been sha red for internal use under fair use provisions
Sent : Thu, 9 Apr 2020 10:17:45 +0000
Subject: FW: Mediaset, Italian television broadcast, interview request
FYI
From: Alessandro Matarante <alessandro.matarante@outlook.it>

To: Fauci, Anthony {NIH/NIAID) [E] <afauci@niaid.nih.gov>
Cc:Barasch,Kimberly (NIH/NIAID) [C) <kimberly.barasch@nih.gov>;Conrad, Patricia {NIH/NIAID) [E)
<conradpa@niaid.nih.gov>
Subject: Mediaset, Italian television broadcast, interview request
Hello Dr. Anthony Fauci,
I'm Alessandro Matarante , an italian reporter , curr ently work ing for M ediaset, Italy's most
imp ortant television broadcast. Specifically , I work fo r Quarta Repubb lica, a progra m aired
every Monday in prime-time, leaded by reporter Nicola Porro.
I'm writing this e-mail because it would be a pleasure and an honor for us to interview you
about the coronavirus emergency and the way the United States are facing it.
Clearly, we are availabl e to cons ider any ki nd of day and hour to make t he intervi ew, and so w e
are to consider together the contents of the interv iew .
Hoping for a posit ive answer,

I wish you a pleasant day .
Alessandro (b)(6)
https://www .mediasetpla y .mediaset.it/programm i-tv/quartarepubblica b100002038

From: (b)(6)
Sent : Wed, 8 Apr 202017 :17:42 -0400
To: Lusso, Paolo (NIH/NIAID) [E]
Subject: Re: Research Day organized by the Italian Embassy
Paolo:
I am very, very sorry, but I just cannot do this right now. I am swamped and my time is not my
own. I hope that they understand .
Best,
Tony
On Apr 8, 2020, at 4:00 PM, Lusso, Paolo (NIH/NIAID) [E]

(b) (6)>wrote:
Dear Tony:
I am sorry to bother you with another request during this period. The Italian Embassy is
organizing its yearly Research Day (Giornata della Ricerca) that this year will be held str ictly
online (via Zoom or other e-meeting tool) and centered entirely on the Coronavirus
pandemic.
The Italian Ambassador, Mr. Varricch io, would be delighted if you accept to be his guest of
honor at the event and asked me to informally enquire with you, before sending an official
invitat ion, if there is any chance you could part icipate. He understands how crazy your
schedule is during this crisis. They would like you to deliver a 30 min lecture on a theme of
your choice, preferably related to the state of the art of the pandemic management. The
tentative date for the event is between April 20 and April 30, but they are waiting to
finalize the date based on your preference, if you are able to accept (even in early May).
Please, let me know if you can accommodate t his additional engagement . You will make
them very very happy!
All the best,
Paolo
Paolo Lusso, M .D., Ph.D.

Chief, Section of Vira l Pathogenesis
Laboratory of lmmunoregulation
Bldg. 10, Rm. 6All
NIAID, NIH
Bethesda, MD 20892
Phone: Cb)(6) (personal)
6) (lab)
________
...._ ___ Cb
_H_,
Fax : (30 1) 480-5291
_.
E-mail (b)(6)
from your mailbox or any other storage devices. The National Institute of Allergy and
Infectious Diseases (NIAID) shall not accept liability for any statement made that are the
From: (b)(6)
Sent : Wed, 8 Apr 2020 16:58:55 -0400
Subject: Fwd: request of interview by Giuseppe Sarcina,corriere della Sera
Let us discus s
From: Sarcina Giuseppe <gsa rcina @rc s.it>

Date: April 8, 2020 at 4: 16:32 PM EDT
To: "Fauci , Anthony (NIH/NIAID) [E]" -------~= (b)(6J:
Subject: R: request of interview by Giuseppe Sarcina, corriere della Sera
Dear Doc. Fauci,

this is Giuseppe Sarcina, the us correspondent of Corriere dell a Sera, the main
italian newspaper.
I understood that you are look ing at the italian case with great attention.
I wonder if you can grant me a short interview.
I have sent an email march 21. But then I saw that you spoke with an other italian
newspaper. So I would like to have a chance to have your voice for our Readers as
well. Corriere della Sera is a newspaper based in Milano, Lombardy, The region
most affected by the coronavirus.
Thank you
Warm Regards
Giuseppe Sarcina
Washington de
(b)(6)>
Oggetto: request of interview by GiuseppeSarcina,corriere della Sera
Dear Doc. Fauci,

this is Giuseppe Sarcina, the us correspondent of Corriere dell a Sera, the main
italian newspaper.
I understood that you are look ing at the italian case with great attention.
I wonder if you can grant me a short interview.
That would be really helpful for our readers
Thank you
Warm Regards
Giuseppe Sarcina
Washington de
From: (b)(6)
Sent: Wed, 8 Apr 2020 16 :57:55 -0400
To: Barasch, Kimberly (NIH/NIAID) [CJ
Subject: Fwd: Global Healt h Leaders Call, Thursday , 8 April at 14:30 CET
Attachments : im age001.png , ATT0000l.htm, COVID19 Strategy Update V3 .2.docx,
ATT00002.htm
Please print out for tomorrow. Thanks
Begin forwarded messag e:
From: "KABIR, Sophia" (b)( >

To: SHOC <shoc@who.int >, Office of the Director-Gen eral <DG0ffice @who.int> ,
"Redfield, Rober t R. (CDC/OD)' (b)(6)
Heym ann ----------

(bH6l , "Felicity Harvey
(b)(6)
>, David
"Chris. Elias"
(b)(6)
I>,"I.Farra r" 4
"Fauci , Anthony
"GREIN , Thoma s" (bH6) , "COX, Paul Michael"

"SCHW ARTLANDER, Bernhard F." (bH · , "MINHAS ,
Raman" (b)(6)
-------------.
"Conrad , Patricia (NIH/NIAID) [E]"
---------. (b)(6) ~, "MAHJOUR,
Jaouad" (b)(6) "FALL , fbrahima Soce" (b) (6) , "Thoma s
R. Frieden" (b)(6)
Lynn Bank s (b)(6) , President I Resolve to Save Live s

<president @resolvetosavelives.org > , (b)(6)
"AL-SHORBAJI, Farah"
Robynn Leidig (b) <
"DRURY, Patrick Anthony" , "Dr VAN KERKHOVE,Maria"
(b)(6)
(b)(6) "GRAAFF, Peter Jan"
CbH6J , "POOLE, Marcia" Cb)(6), Tarik Mohammed
Cb)(6), Carlos
Navarro Colorado (b)(6)
, Ryan Morhard
"BRIAND, Sy lvie" Cb)(6), "MORGAN , Oli ver" CbH
"Han-ies, Jenny" CbH6),"Awwad, David (NIH/NIAI D)
(C]"
---------
>, "SIMONSON , Stewart" CbH6),
---------,,
"SINGER, Peter Alexander" (b)(6) , "Jayatunga, Wik:um"
(b)(6)
"Julie.HALL"
RIOUX
"SHIN, Young-Soo" (b)(6)> ,

Cb)C6)
Q! ·eng Ding
(b)(6)
------------
(b)( · , "AYLWARD, Raymond Bruce J."
"SMITH, Ian Michael"
(b)(6)
Cc: SHOC <shoc@who.int>, Office of the Director-General <DG0ffice@w ho.int> ,

"SCHWARTLANDER, Bernhard F.",________ Cb><6J, "MAHJOUR,
Jaouad" Cb><, "FAL L, Ibrahima Soce" (b)(6) , "GREIN,
Tho mas'' CbH6)>, ~MINHAS, Raman" (b)(6) , "COX, Paul
Michael" ...___ __,, (b)(6) , "AL-SHORBAJI, Farah" Cb)(
"POOLE , Marcia" (b)(6) , "DRURY, Patrick Anthony"
CbH6J , "GRAAFF, Peter Jan" Cb>< , "Dr VAN
-------
KERK.HOVE, Maria" <6J , "FARES, Christine Youssef''
Cb>
(b)(6)
Subject: Global Health Leaders Call, Thursday, 8 April at 14:30 CET
Dear colleagues,
On behalf of M ike Ryan, allow me to share with you the dra ft COVID-19 Strategy Update,
which will be subject of discussion at tomorrow's Global Health Leaders Call at 14.30 CET.
The epidemiological update and analysis, as well as the Zoom connectionw ill be shared
tomorrow morning.
Please find below, the key questions for your consideration and input.
l. What is your view on the latest epidemiology, virus transmission and severity in
affected countries?
2. What are the emerging issues/challenges that you see as impo rta nt?
3 . What should be the priorit ies for the 1-2 weeks?
4 . Any other issues you see as important?
If you experience any technical difficulties jo ining this confe rence call, please contact the
WHO HQ EOCoperator at: +41 22 79 15 533
Kind regards,
Sophia
Sophia Kabir
Executive Officer
Office of the Executive Director
WHO Health Emergencies Programme (WHE)
Tel. (b) (6)
Mobile
------ (b)(6)
Website: WHO in emergencies I WHO Facebook I WHO Tw itter
HEALTH
EMERGENCIES
programme
Sent : Wed, 8 Apr 2020 17 :28 :01 +0000
To: Awwad, David (NIH/NIAID) [C)
Subject : FW: NIAID Information RE: Update Your PIV Card (HHS ID Badge) Cert ificates
Before They Expire
Do I need t o do anyt hing?
Director
Phone: (301) 496 -2263
FAX : (301) 496-4409
E-mail: afauci@niaid.nih.gov
From: NIAID News and Information (NIH/NIAID) <niaidnewsinfo@nia id .nih .gov>

Sent : Wed nesday, Apr il 8, 2020 10:18 AM
To : NIAID Announcements <NIAID-announce@niaid.nih.gov>
Subject: NIAID Information RE: Update Your PIV Card (HHS ID Badge) Certificates Before They Expire
(b) (2)
---- -Original Message---- -

From: ORS Information Line <orsinfo@ors.od.nih.gov >
Sent : Tuesday, Apr il 7, 2020 6:23 PM
To : NIH-STAFF@LIST.NIH.GOV
Subject: Update Your PIV Card (HHS ID Badge) Certificates Before They Expire
(b) (2)
If you need help , please contact t he NIH IT Service Desk: http:// itservicedesk.nih.gov/
301-496 -4357 (HELP). 301-496 -8294 (TTY), or 1-866-319-4357 (HELP)
Sent: Wed, 8 Apr 2020 17:25 :25 +0000
Cc: Folkers, Greg (NIH/NIAID) [E];Conrad, Patr icia (NIH/N IAID) [E];Stover, Kathy
(NIH/N IAID) [E];Routh, Jennifer (NIH/NIAID) [E];Doepel, Laurie (NIH/ NIAID) [E];Lane, Cliff (NIH/ NIAID) [E]
Subject: RE:PR HHS Treatment Guidelines for COVID-19
(b) (5)
We should include in the statement something about
-----------
Director
Phone Cb)(6J
FAX: (301 496-4409
E-mail: (b)(6J
From: Billet, Courtney (NIH/NIA ID) [E) CbH6J>

Sent: Wed nesday, April 8, 2020 12:58 PM
------~~ CbH6J>
Cc: Folkers, Greg (NIH/NIAID) [E] CbH6J;Conrad, Patricia (NIH/ NIAID) [E]
(b)( >; Stover, Kathy (NIH/NIAID) [E] (b)( >; Routh, Jenn ifer
"':':"'."~""'.".""'."'.""'"':--:-:'.:";====-.;.._-_;_ --,;-,,~
(NIH/NIAID ) [E] (b)(6J;Doepel, Laurie (NIH/NIAID) [E] (b)( 6J
Lane, Cliff (NIH/NIAID) [E) (b)(
Subject; ASF: PRHHS Treatment Guidelines for COVID-19
This is a press release t hat we (Laurie) drafted for HHS to announce the HHS treatment guidel ines. Cliff
has revi ewed . I know how slammed you are. In the interest of time , I would like to move th is to Bill Hall
now, with the understanding t hat we can catch up with any changes you might have before the release
is actually issued.
FYI, t he release includes a quote for you as follows:

(b)( 5)
(b)(5
Sent : Wed, 8 Apr 2020 16:59 :29 +0000
To: Barillas, Carolina (NIH/NIAID) [El
Cc: Holland, Steven (NIH/NIA ID) [El;Auchincloss, Hugh (NIH/NIAID) [El
Subjec t : RE:Art icle - BCGprotect ion fr om COVID-19 mortality
Than ks, Caro lina.
Director
Phone : (b)(6)
FAX: (3 96':44li9
E-mail: (b)(6)
From : Bari llas, Carolina (NIH/NIAID) [El (b)(6)>

To : Fauci, Anthony (NIH/NIAID) [El ------~= (b)(6)>
Cc: Holland , Steven (NIH/NIAID) [El ..:=======:".:- (b""""
)(= ; Auchincloss , Hugh (NIH/NIAID) [El
(b)(6} >
Subject: Article - BCG protection from COVID-19 mortality
Hello everyone,
I found this article that comes to a similar conclusion regarding the protective role of universal BCG
vaccination on COVID-19 mort ality . I will be work ing with an epidemiologist from Virginia Tech to see if
we can provide stronger quantitative analysis and modelling.
All the best,
Carolina
Carolina Barillas Mury, M.D ., Ph.D.

Chief, Mosquito Immunity and Vector Competence Section
Laboratory of Malaria and Vector Research
National Inst itutes of Health
12735 Tw inbrook Parkway, Room 2E-20C
Rockville, MD 20852
Phone: (b)(6) Fax:(301) 480 0930
E-mail: (b)(6)
Sent : Wed, 8 Apr 2020 15:09:38 +0000
To: (b)(6)
Subject: FW: Google Alert - Fauci AND Tony OR Anthony
Click on the "Cuomo Crush" and "Fauci Fever" link below. It will blow your mind.
Our society is really totally nuts .
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
From: Google Alerts <googlealerts-noreply@google.com>

To: Fauci, Anthony (NIH/NIAID) [E] ----- -=(b)""(6J
= >
Subject: Google Alert - Fauci AND Tony OR Anthony
Google Alerts
Fauci AND Tony OR Anthony

As-it-happens update Apri 8 2020
NEWS
Dr. Anthon y Fauc L Trump address Iowa's lack of shelter-in-place

Little Village
Speaking at President Trump's press conference late Monday afternoon , Dr. Anthony Fauc i
mentioned Iowa, and a clip of his comments was quick ly ...
Flag as ,rrelev<'!nl
11 CJ
Dr. Fauci: 'We need to put our foot on the accelerator' to see an end to
COVID-19 pandemic
fox4kc.com
WASHINGTON - Even though he says the worst is yet to come. Dr. Anthony Fauci , the nation's top
infectious-disease expert , has seen signs of ...
Fl<'lQas Irrelevant
11 CJ
Fauci: African-American Community at Higher Risk for Coronavirus

Complications
NBC4 Washington
Dr. Anthony Fauci, director of the NIAID, spoke on Tuesday about the impact the coronav irus
pandemic is having on the ... Read More ...
John Calipari Confirms Bill Clinton. Mark Cuban. and Dr. Fauci as Guests on
"Coffee With Cal"
kentuckysportsradio.com
Anthony Fauci. Every Monday for the next 25 weeks , Calipari's show will "feature positive messaging
and conversation with high-profi le guests from the ...
FlaQ as 1rrelev;int
11 CJ
'Cuomo Crush' and 'Fauci Fever' - Sexualization Of

These Men Is a Real Thing on The Internet
Talent Recap
The coronavirus pandemic has led brothers Andrew and Chris Cuomo and Dr.
Anthony Fauci to the forefront COVID news and updates, but it also ...
FlaQ as ,rreJ.,v;mt
11 CJ
Before the White House, Trump called NIH 'terrible,' questioned vaccines
KPQ
President Donald Trump speaks to the press wh ile Director of the National Institute of Allergy and
Infectious Diseases Anthony Fauci speaks during a ...
Fla g as Irrelevant
11 CJ
You have received this email because you have subscribed to Google Alerts.
Unsubscribe
~Receive this alert as RSS feed

Send Feedback
Sent : Wed, 8 Apr 2020 13:23:07 +0000
Subject : RE:On the record
Yes. Please point him to what I said ye sterday.
Director
Building 3 I , Room 7 A-03
31 Center Dri ve, MSC 2520
Bet hesda , MD 20892 -2520
Phone: (b) (6)
FA X: (301 496-4409
E-mail: (b) (6)
The informa tion in this e-ma il and any of its attachme nts is confidential and may contai n sensi tive infom1ation. It
should not be used by anyone who is not the original intended recipie nt. lf you have received this e-mail in error
please inform the sender and delete it from your mailbox or any other storage devices. The Nationa l Institute of
Allergy and Infectio us Disease s (NlAI D) shall not accept liabili ty for any stateme nts made that are the send er's own
From : Conrad, Patricia (NIH/N IAID ) (E]
Sent: Wednesday , April 8, 2020 9:20 AM ---------
-------=-::-=,
(b)(
To: Fauci, Anthon y (NTH/NlAID) [E]

Subject: FW : On the record -------- (b)(
Pis see below ... .Bob Franken ...
From : Billet , Courtney (NJH/NTATD) [E] ______ Cb
_H_ >
Sent: Wednesday , April 8, 2020 9:03 AM
To: Co nrad , Patric ia (NTH/NJATD) [E ------~~ (b)(6) >
Cc: Stover , Kathy (NIH/NIATD) [E] _______ Cb
_)_(6)
_ Routh, Jennife r (NIH/NIAID) [E]
(b) (6)
Subject: RE: On the record
l think he probably knows Bob F ranken pe rso nally so I'm wonderin g if you might want to flag this for him, as he
might decide it warra nts a personal respo nse.
Otherwise, he did speak about health dispariti es at yesterday' s WH pre ss confer ence , and we cou ld certa inly poin t
Frank en to those comm ents and then also direct him to NIMHD. ~
(b) (5)
From: Conrad, Patricia (NIH/N IAID) [E] (b)(6)
To : Billet, Courtney (NIH/NIAID ) [E] ------ ~=
(b)(6) ? ; Stove r, Kathy (NIH/NIAID) [E]
_______ _H_6) Routh , Jennifer (NIH/NIAID) [E]
Cb (b) (
Cc : NlAlD OCGR NSWB <NlAIDOCGRNSWB @mail.nih .gov>
Subject: FW : On the record
Defer to you to decide on this

From: Bob Franke n _______ __,(b
"')...,
(=>
Sent: Wedne:sday , Apr il 8, 2020 5:17 AM

------
To: Fauci, Anthony (NIH/NIATD) [E]______ "="'~
(b
_)_(6)
_>
Subject: On the record
Tony :
For my syndicated colunm, [ want to do a piece on the racial aspect of coronavirus. I'm not seeing any breakdown
of deaths in the poorer areas as opposed to the more prosperous ones.
Jsn 't that the telling statistic here that the economically less well off live in areas where medical services are
inadequate and as a result they have more underlying conditions that make theM more vulnerable? Isn't it relevant
that people of color are predominantly among the poorer in our country for a variety of reasons?
1 will appreciateyour comments, particularly since you have so little to do these days.
Warmest regards,
Bob
Bob Franken
www.bobfranken.tv
From: (b)(6)
Sent : Wed, 8 Apr 2020 07:18:27 -0400
To: (b)(6)
Subject: Re: last questions , i prom ise
In first response , I mean t to say "I always qualified th e statement.. ..." .not "I almost qualified the
statement. .."
On Apr 8, 2020, at 7:04 AM , Michae l Specter

-------- (bH6J
>w rote:
Tha nk you . W ill do all this and take ou (b)(6)

---------
On Wed, Apr 8, 2020 at 03:59 Fauci, Anthony (NIH/NIAID) [E]
(b)< >w rote:
Michael:
See comments be low in red.
Th anks,
To ny
From: Michael Specter (b)(6)

Sent: Wednesday , April 8, 2020 1:25 AM
-------~~
To: Fauc i, An thony (NIH/NIA ID) [E] _______ (b_>_<6)
Subject: last questions, i promise
Hi. Mostly these are two second yes or no answers - thou gh I need to understand
the b cell issue better.
Th ank you for all this . Hang in there:
1.)
Fauci has at times struggled to compel politicians and businesses to attack the prob lems
that he considers most woJTisome.Over the years, he has become especially concerned about
the possible impact of a lethal strain of influenza." True, but I almost qualified the
statementand said it most likely would be inJluenza, but I was concernedwith any type
of novel respiratory virus that efficiently spread from human to human and that had a
high degree of morbidityand mortality
2.) Dyker Heights versus Bensonhurst:

•
• What do we say about where he grew up.? He always says Bensonhurst. The
apartment was technically in Dyker Heights, though the neighborhood lines shift.
And I never see him mention moving neighborhoods. Did he move? Yes. I
moved. I was born at (b) (6>.
n the middle of the Bensonhurst section
of Brooklyn. When I was 9 year s old my father opened a Pharmacy on 8302-13 th
Avenue at the outer edge of the D yker Heights Section of Brooklyn (only We
moved into an apartment over the pharmacy .
•
3.) [ the question below is the meaning of hyperactive. Does it mean producing too
many B cells or that they were too active, as in working too hard, producing too many
antibodies??) Not necessarily too many B cells . It means that the B cells that are there,
are aberrantly turned on
He had been investigating B-cells, which are involved in the production of antibodies.
In 1983-before H.l.V. was even known by that name-his lab became the first to report that
B-cells becam e hyperactive in patients with AIDS. The virus was somehow leading its hosts
to overproduce a defense that normally would keep them healthy. Fauci had ident ified one of
the crucial features of AIDS. "We made that observation without having any idea of what we
were dealing with," he said. "l think that speaks for sound scientific and clinical observation ."
The pol itics of seeking a cure, though, would be far harder to manage.
• 4.). This I asked before you could not speak to me but we can take me out of it. Or
do whatever you like: I asked Fauci if he thought that novel coronavi rus would
force a change in attitude among olitical lea ders and funding agencies . (b) (6)1
(b)(6)
5.). This you lrnve sa id in rnore than one place. People kind of became alarmed when you
were absent so ju st want to be sure you don't mind it in here: No problem .
Fauci said that there was nothing meaningful about his absence from the Mar.23
White House briefing, "I was tied up in a task force meeting, and we were trying to work out
some difficult policies and the topic of the briefing that day was more related to other
members of the Task Force. He also said, '41have no troub le with the President. When .I talk
to him, he listens.''
Michael Specter
Staff Wri ter
The New Yorker
Stanford University
(b)(6)
Phone: (Work, Cell , SMS) (b)(6)
Michael Specter
Staff Writer
The New Yorker
Stanford Univers ity
(b)(6)
Phone: (Work, Cell, SMS) (b)(6)

Sent : Wed, 8 Apr 2020 10:42:24 +0000
To : Perez-Stable, Eliseo (NIH/NIMHD) [E]
Subject : RE:WH Briefing
Thanks, Eliseo. Stay safe and well.

Best,
Tony
From: Perez-Stable, Eliseo (NIH/NIMHD) [E] ________ _>

Cb
_<_·>
Se nt: Tuesday, April 7, 2020 11 :53 PM
Subject: FW: WH Briefing
--------
Hey Tony, you are the man! Best, Eliseo
From: Natasha Williams (b)(6)

------------
To : Eliseo Perez Stable Cb)( >, Courtney Aklin
-------- (b
::-:
)-'c
(6)
,;;;-
> ----------
Su bje ct : WH Briefing
Hello Eliseo and Courtney,
During the White House briefing on COVID-19this evening , there was a discussion on the
disproportionate impact of COVID-19 on African Americans, health disparities and data collection.
Please see CSPANClips below I cued up.
https://www.c-span.org/video/?c4866877 /user-clip-covid-19-african-american-community
https://www.c-span.org/video/?c4866892/user-clip-dr-fauci-hea1th-disparities-african-american-
community
https://www.c-span.org/video/?c4866897 /user-clip-data-collection-guestion-african-american-
community
I know we are not commenting but I would like to recommend that we have some ta lking points
prepared and on hold in case we receive congressional inquiries. These topics are also receiving
coverage on the networks .
Thank you,
Natasha
Natasha H. Williams , PhD, JD, LLM, MPH
Legislative Liaison
National Institut e on Min o rity Healt h and Health Di s pariti es

Bethesda, MD 20892
Email: (b)(6)
Phone·."';=== (b
~ )~ ~;;: 1w-w
6);:-:- - w-.n"".'i
"""':"
m h°".
d ..
.n~ih.go-.
Connect with us: Twitter I Facebook I YouTube I Email Updates
NIMHD
----
.,._
---
Sent: Wed, 8 Apr 2020 03 :06:30 +0000
To: Grogan, Joseph J. EOP/WHO
Cc: Bonner, Maria K. EOP/WHO;Campana, Alexandra D.
-----~~
EOP/WHO; _____ Cb
_)_C6Jr
_.;Barasch, Kimberly (NIH/NIAID) [C];Conrad, Patricia (N IH/NIAID) [E]
Subject: RE: [EXTERNAL]RE: Good news
Joe:
I would be happy to speak with him. However, it wou ld have to wa it until Thursday since
tomorrow is impossible. I bel ie ve that we can work this out. Perhaps we can arrange for a call
between me ,the CEO and some knowledgeable people in my program.
Best regards,
Tony
From: Grogan , Joseph J. EOP/WHO

----------- (b
=),-,(6)
=>
(b)(6)'>
Cc:Bonner,
___ Maria K. EOP/WHO
___;____ _;__......:= ~(b~) ;;
( ai"
>_______ (b)(l>l>;
_ Campana, Alexandra D. EOP/WHO
Subject: Fwd: [EXTERNAL)RE: Good news
Dr., I would never abuse your personal email, but since the ceo of Lilly wants to speak with you, I thought I would
share this request. Just let
------------------- (b
::-:
)-c(5=)
me know how to respond
--------------------
Sent from my iPhone
From:Shawn O'Neail (b)(6)

--------~~
To: "Grogan, JosephJ. EOP/WHO"
Subject:[EXTERNAL)
RE:Good news
(b)( 6) ---------- (b)(6)> , "Bonner, Maria K. EOP/WHO"
You bet.
Joe - Have an enormous req uest-for help or counsel.

(b) (4)
My CEO,Dave Ricks, would like to speak with Dr. Fauci in th is regard (given his role at the
Institute). I know t hat is a tall order-but underscores the importance.
I did reach out to Dr. Fauci' s Chief but received an automated reply indicated he was
behind in email - any though ts in the regard greatly appreciated ....
Best, Shawn
Shawn O'Neail
Vice President, Government Affairs
Eli Lilly and Company
(b)(6) (office) I (b)(6) (mobile)
--------- (b) (6) I >www.lilly.com<
CONFIDENTIALITY NOTICE: This e-mail message (including all attachments) is for the sole use of
the intended recipient(s) and may contain confident ial and privileged information. Any unauthorized
review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended
recipient, please contact the sender by reply e-mail and destroy all copies of the original message.
From: Grogan, Joseph J. EOP/WHO

To: Shawn O'Neail
-----------
(b)(6)
(b) (6)>
Bonner, Maria K. EOP/WHO

------.!::::::==~ (b::;:
) ~(6);----
Subject : [EXTERNAL]RE: Good news
EXTERNAL EMAIL : Use caution before replying, clicking links, and

opening attachments.
This is great. Thank you for sharing and everything you are doing. Joe
From: Shawn O'Neail (b)(6)>

To: Grogan, Joseph J. EOP/WHO ----------=-:--:-= (b)(6)>; Bonner, Maria K.
EOP/WHO (b)( >
Subject: [EXTERNAL]Good news
Hi Joe and Maria
I W<!nt to share an important update about Lilly's efforts to address insulin affo rdability. In
response to the crisis caused by COVID-19, Lilly is introducing the Lilly Insulin Value
Program, allowing anyone with commercia l insurance - and those w ithout insura nce - to
fill their monthly prescription of Lilly insulin for $35 . The program is effective today and
covers most Lillyinsulins. Details and more informa tion can be found in the press release
here attached.
Lilly has introduced several solutions in recent years to help meet the individual financial
circumstances of people living with diabetes that are still in effect during the COVID-19
crisis, including:
• The Lilly Diabetes Solution Center, through which representatives can direct
people to the $35 savings card, as well as affordability option s that may reduce
their out-of-pocke t costs further - such as free insulin for people with minimal
income, or no income at all, that has been donated by Lilly to non-profit
organizati ons.
• Three non-branded versions of our insulin options with list prices 50 percent lower
than the branded versions.
• In January, the company announced plans to donate at least 200,000 KwikPens ® to
relief agencies over the next three years.
Hope all is well with yo u....
Shawn
Shawn O'Neail
E li Lilly and Company
(b)(6)office) I (b)(6) (mobile)
Cb)(6) I >> www .lilly.c om «
----------
the intended recipient(s) and may contain confidential and privileged information. Any unauthorized
review. use. disclosure. copying or distribution is strictly prohibited. If you are not the intended
recipient. please contact the sender by reply e-mail and destroy all copies of the original message.
Sent : Wed, 8 Apr 2020 02 :41 :56 +0000
To: (b)(6)
Subject : FW: [EXTERNAL]RE:Good news
Cliff:
let us discuss this. How do you think that I should respond?
Thanks,
Tony
From: Grogan , Joseph J. EOP/WHO

------------
------~~ CbH6)>
(b) (6),
Cc: Bonner, Maria K. EOP/WHO

.;...;;.::::::========---::-:~
(b)( ; Campana, Alexandra D. EOP/WHO
___ _:_ ____ .:,__..!::::=-- (b=--=
)~
(6)-::--------
Subject: Fwd: [EXTERNAL]RE:Good news
Dr., I wou ld never abuse your perso na l email, bu t since the ceo of Lillywants to speak with you, I thought I would
share this request . Just let
me know how to respond , ------------------- (b
=--:
)--:
(=
5)
Sent from my iPhone
From : Shawn O'Nea il (b) (6)

Dat e: April 7, 2020 at 10:07:37 PM EDT
--------~~
To: "Grogan, Joseph J. EOP/WHO"
(b)( 6) ---------- (b)(6)> , "Bonner, Maria K. EOP/WHO"
Subj ect: [EXTERNA L) RE: Goo d news
You bet.
Joe - Have an enormous req uest -for help or co un sel.

(b)(4)
My CEO, Dave Ricks, would like to speak with Dr. Fauci in th is regard (given his role at the
Institute). I know t hat is a tall order - but underscores the importance .
I did reach out to Dr. Fauci's Chief but received an automated reply indicated he was
behind in email - any thoughts in the regard greatly appreciated ....
Best, Shawn
-------------------------
-------------------------
Shawn O'Neail
(b)(6) (office) I (b)(6) (mob ile)
--------- (b)(6) I >www.lilly.com<
the intended recipient(s)and may contain confidentialand privileged information. Any unauthorized
review, use, disclosure, copying or distributionis strictly prohibited.If you are not the intended
From: Grogan, Joseph J. EOP/WHO

Sent : Tuesday, April 7, 2020 9:31 AM ------------ (b) (6)>
To : Shawn O'Neail (b)(6) Bonner, Maria K. EOP/WHO

------=== (b
=""
)='c'
(6)
::;;-----
Subje ct: [EXTERNAL]RE: Good news
EXTERNAL EMAIL : Use caution before replyin g, clicking links, and

ope ning attachm ents.
This is great. Thank you for sharing and everything you are doing. Joe
From: Shawn O'Neail (b) (6)

To: Grogan, Joseph J. EOP/WHO ---------- --,;=
(b)(6) Bonner, Maria K.
EOP/WHO (b)( >
Subje ct: [EXTERNAL]Good news
Hi Joe and Maria
I want to share an important update about Lilly's efforts to address insulin affordability. In
response to the cr isis caused by COVID-19, Lilly is int roducing the Lilly Insulin Value
Program, allowing anyone with commercia l insurance - and those w ithout insurance - to
fill their monthly prescription of Lilly insulin for $35 . The program is effective today and
covers most Lilly insulins . Details and more information can be found in the press release
here attached .
Lilly has introduced severa l solutions in recent years to help meet the individual financial
circumstances of people living with diabetes that are still in effect during the COVID-19
crisis, including:
• The Lilly Diabetes Solution Center, throu gh which representatives can direct
people to the $35 savings card, as well as affordability options that may reduce
their out-of-pocke t costs further - such as free insulin for people with minimal
income, or no income at all, that has been donated by Lilly to non-profit
organizations.
• Three non-branded versions of our insulin options with list prices 50 percent lower
than the branded versions.
• In January, the company announced plans to donat e at least 200,000 KwikPens ® to
relief agencies over the next three years.
Hope all is well with you ....
Shawn
-------------------------
-------------------------
Shawn O'Neail
Vice President , Government Affairs
(b)(6) (office) I (b)(6) (mobile)
--------- Cb)(6) I »www .lilly.com«
CONFIDENTIALITY NOTICE : This e-mail message (including all attachments) is for the sole use of
the intended recipient(s) and may contain confidential and privileged information. Any unauthorized
review , use, disclosure , copying or distribution is strictly prohibited. If you are not the intended
From: Conrad, Patricia (NIH/NIAID) [El on behalf of Fauci, Anthony (NIH/NIAID) [El
Sent: Tue, 7 Apr 2020 22:58:33 +0000
To: Chris Joffe ;Fauci, Anthony (NIH/NIAID) [El
Subject: RE:Supporting Schools In Covid-19
Due to the high demand on Dr. Fauci's time during th e current outbreak -we
must decline your request at this time. Thank you for your understanding .
Best,
Patricia L. Conrad
National Institut e of Allergy and Infectious Diseases
The National lnstitues of Health
(b)(6) (office)
===;;::,=:~
----- (b)(6) (cell)
From:Chris Joffe <Chris@joffeemergencyservices.com>

To: Fauci, Anthony (NIH/NIAID) [El ------~= (b)(6)
Subject: Support ing Schools In Covid-19
Dr . Fauci -
I'm a safety/security consultan t to independen t and charter schoo ls. I run a firm supporting
~ 1,000 of them. What, if anything , would you wan tth ern to know? I'm wondering if there's
any chance in the world you'd be willing to join us and a few hundred schools for a 15 - 30-
minute webinar one day next week?
Specifically , schools are looking for infom1ation /perspectiv e as it relates to what to expec t as we
return to a new normal and the like. Beyond that , they've begun to ask questions such as what we
can be thinkin g about for this short period of time between the return to schoo l and the
development of a vaccine. What would best prac tic e look like for us to educate, but maintain
social distance ? I believe we can manage a lot of th e operationalizing but would be
immensely grateful for some h igh-level guidance to follow .
I recognize how incredibly busy this time is for you and would be so incredibly grateful for any
time you might be willing to spare for this audience .
With imm ense gratitude,

Chris Joffe
Chris Joffe
CEO I Joffe Emergency Services
HQ I Santa Monic a, CA
Twitter : @joffec hris
(b)(6)
Executive Assistant
E: (b)(6)
P: Cb
H6>
From: (b)(6)
Sent: Tue, 7 Apr 2020 13:12:39 -0400
To: Lane, Cliff (NIH/NIAID) [E]
Fwd:
~-------------------------- (b)(4)
(b)(4)
Here it is
From: "Gelfand , Jeffrey A.,M.D."

___________ __,
(b) (6)l
Date: April 7, 2020 at 9:39:5 1 AM EDT

To: "Callahan , Michael Y.,M.D." ________
------------~~ "Fauci, (b)(__,',
Anthony IH/NIAID E " (b)(
Subject: (b) (4)

Sent: Tue, 7 Apr 2020 15:45:18 +0000
Cc: Billet, Courtney (NIH/ NIAID) [El
Subject : RE:NFLPA-NFLTask Force
(b) (5)
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail (b) (6)
From: Conrad, Patricia (NIH/NIAID) [E] ________ (b_H _ >

To: Fauci, Anthony (NIH/NIAID) [El______ (b_H_6)
Subject: FW: NFLPA-NFL Task Force
(b) (5)
Pis see below -

--------
(b) (6)>
To: Conrad, Patricia (NIH/NIAID) [E] ------- > ~=

;......:.=======~~-
Cc: Folkers, Greg (NIH/NIAID) [E]_______
(bH
Auchincloss, Hugh (NIH/N IAID) [E]
(b_H_6)>;
(b)(6)>
Subject: RE: NFLPA-NFLTask Force
(b) (5)
From :
--------------------
(b)(6)
To: Billet, Courtney {NIH/NIAID) [E] (b)(6)>
Cc: Thom Mayer _________ Cb
_>_C_ >
Subject: NFLPA-NFLTask Force
Hi Courtney,
nd
15 \ I hope you, you r family and your loved ones are harboring safely through this storm . 2 , t hanks for
your efforts and those of Dr. Fauci-he is truly a national treasure during this crisis and it is deeply
appreciated.
I appreciate your help and introductions on how our players can be helpful. As you know Drew and
Brittany Brees made a $SM contribution to the Louisiana coronavirus efforts and they have done a lot of
press. Drew's message has been "Hang in there-hang tough I We are in th is t ogether."
I've done several webinars with our players and their fami lies, both educating them and pointing out
thei r role both with friends and fam ily as well as on social media to let NFLfans know that whether or
not we have an NFLseason depends to a large extent upon those fans following the guidelines
zealously-as zealously as they follow NFLgames!
That message seems to be getting through .
I write now with a request for a litt le bit of Dr. Fauci's time in about 2 weeks. I requested that we stand
up a joint NFLPA-NFL Task Force to scenario plan a pathway to getting NFLClub facilities open, with a
view towards if and when we might look towards an NFL season, even if games are played with no fans.
My request is to have Dr. Fauci give a telephone briefing to our group on this difficult topic, which would
of course be confidential. The floor would be his and I can brief him prior to the call on what we have
been working on. If he were willing, w e can do the call anytime, probably during the week of April 13,
although of course the modeling shows that would be during the peak of the outbreak. We could also
do it the week befo re or after.
Thanks so much fo r conside ring this . We are mindful of the psychological toll the virus is taking and the
lift NFL games would give to a sports-starved population, but only if it can be done safely for the players
and the fans who (ultimately) allow them to play this great game.
Again, thanks!
Best,
Doc
Thom Mayer, MD, FACEP, FAAP, FACHE

Medical Director
■ NFLPA
NFL Players Association
11150 Sunset Hills Road, Ste 305
Reston. VA 20190
-----
Mobile:
NFLPA .COM
(b)(
Sent: Tue, 7 Apr 2020 15:24:35 +0000
To : Barillas, Carolina (NIH/ NIAID) [ El
Cc : Ho lland, Steven (NIH/NIA ID) [E];Auchincloss, Hugh (NIH/NIAID)
[E] ----~ (b~
)(6)
=
Subject : RE: BCGprotect ion from COVID-19 mortal ity
Caroli na:
(b) (5)
Best regar ds,

Tony
Director
Phone: (b)( 6)
FAX: (301 496-4409
E-mail: Cb) (6)
From : Bari llas, Carolina (NIH/NIAID) [E] (b)( >

Sent : Tuesday, April 7, 202011 :04 AM
To : Fauci, Anthony (NIH/ NIAID) [E] ------ ::;..,..-,=
(b)( 6J>
_'";::=======-=~
Cc : Holland , Steven (NIH/N IAID) [E] ________ _H_6); Auchincloss, Hugh (NIH/NIAID) [E]
Cb
(b) (6) >
Subject: BCGprotec t ion from COVID- 19 morta lity
Good mornin g Tony,

(b) (5)
All t he bes t,
Carolina
Carolina Barillas Mury, M.D., Ph.D.

Chief, Mosquito Immunity and Vector Competence Section
Laboratory of Malaria and Vector Research
12735 Twinbrook Parkway, Room 2E-20C
Rockville, MD 20852
Phone: (b)( Fax: (301) 480 0930
E-mail (b) (6)
Sent : Tue, 7 Apr 2020 14:51:59 +0000
To: Alison Galvan i
Subject: RE:Your PNAS articl e " Projecting hospita l utilizat ion during the COVID-19
outbr eaks in the United States" has published
Alison:
Thanks for sending this. I hope that all is well with you. Keep up your great
work.
Best regards,
Tony
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail (b) (6)
behalf of the NIAIDby one of its representatives.
From: Alison Galvani (b)(6)

Sent: Friday, April 3, 2020 3 :34 PM
To : Fauci, Anthony (NIH/NIAID) [E] -------,;-, (b)""'c= ,>
Cc:Conrad, Patricia (NIH/NIAID) [E) (b)(6) •>; Singer,Burton H
(b)(6) ; Seyed Mo ghadas
----------
Subject:
(b)(6)
Fwd: Your PNASarticle "Projecting hospital uti lization during the COVID-19 outbreaks in the
United Stat es" has published
Hi Tony ,
Please find attached our second COVID publ ication. This one focuses on projections of the number of
ICU beds that will be needed at the peak of the outbreak.
Please don't hesitate to let me know ifwe can be of any assistance.
Take care,
Aliso n
From: <journalstaff@pnascentral.org>
Date : Fri, Apr 3, 2020 at 2:06 PM
Subject: Your PNASarticle "Projecting hospital utilization during the COVI0-19 outbreaks in the United
States" has published
To :
---------- (b)(6)
PNASis pleased to announce t hat your paper "Projecting hospital utilization dur ing the COVID-19
outb reaks in the United Sta tes " has published on line at: www .pnas.org. Did you know article-level
metrics dat a and article downloads are now available for all PNASart icles? Article-level metrics provide
a new way of measuring the reac h and impact of an article by tracking the ment ions it receives on line.
Clicking on the "Authors & Info" tab near t he top of each article and scrolling down w ill reveal a
summary of ment ions of the article across news sites, biogs, social media, and other on line sources-
wh ich are visualized in a colorful icon, or "badge." The number in the m iddle of the badge is the
Altmetric score, wh ich is based on the volume , type, and author of the mentions. You can click on the
badge or "view more" to explore th e indiv idua l mentions from each source. Art icle down loads by month
and by article format appear below the badge.
Stay connected to PNAS:
Follow Us on Twitter
Find Us on Facebook
Aliso n Galvan i, PhD
Director, Yale Center for Infectious Disease Modeling and Analysis (CIDMA)
New Haven. CT 06520
(b)(6)
http:ljcidma.yale.edu/
Follow me at @Alison_ Galvani

Follow CIDMA @YCIDMA
Sent : Tue, 7 Apr 2020 14:47:59 +0000
To: Glass, Roger (NIH/FIC) [El
Subject : RE:To cheer you up!
Than ks, Roger !
Director
Phone: (b)( 6)
FAX: (30 496"'4409
E-mail: (b)(6)
From: Glass, Roger (NIH/ FIC) [El

--------
Se nt: Friday, April 3, 2020 12:36 PM
(b)(6)>
To: Fauci, Anthony (NIH/NIAID) [El-------

--------- =-:--:= (b)(6)
Subject : To chee r you up !
Tony
Read the last lines and see the photo! Your words from the past are remembered and have changed the
caree rs of our fellows.
No need to respond .
Roger
Sent from my iPad
From: (b)(6)
Date : April 3, 2020 at 11:30 :23 AM CDT
To: "Glass, Roger (NIH/Fie) [E)" _____ ""(bes"'
~=
c >
Subj ect: Hello
Dr. Glass,
I hope you are well and I wanted to check in to see how you are doing in
this scary and traumatic time for our world.
During these times, I'm especially thankful for the training I

received from the Fogarty Institute. I remember your wise words
at our Fogarty orientation in 2011- on why investing in Global
health is so critical. No truer words have been spoken especially at
times like these!
I'm currently communicating with my former colleagues in Zambia

(Mpanji and Innocent pictured here with
me https ://www.thermofisher.com/blog/behi ndt hebench/ using-sanger-seq uen cing-to -
detect-d rug-resistance-m utations-i n-h iv-i n-zam b ia/) from CIDRZ to see how
testing can be brought up via the public health infrastructure in
place currently. Thankfully, the number of cases is very low,
although the unreported cases are much higher than likely
captured
( https://www .arcgis.com/apps/opsdashboard/index .html#/bda7594740 f d402994 23467b4
My friend who is a Lieutenant Physician actually likely
8e9ecf6 ) .
contracted COVID-19 in January and wrote that she and others
had treated a patient returning from Wuhan who was pregnant of
respiratory illness upon coming back to Lusaka to deliver, only to
die of pleural effusion later. They subsequently developed flu-like
symptoms and resolved, but these are the types of cases that
likely go undetected and can potentially contribute to community
spread of the disease .
Thank you again for being such a wonderful role model, and I look
to leaders like you and Dr. Fauci to help our nation think with
prudent but difficult decisions .
Kind regards,
Lillian
ase Th, at
Implementation: Delivery o
Proven Interventions to
Patients and Populations
Sent: Tue, 7 Apr 2020 14 :44:25 +0000
To : (b)(6)
(b) (4)
(b) (4)
What do yo u thin k of this stud y?
Direc; tor
Phone: (301) 496-2263
FAX: (301) 496-4409
From: Gelfand, Jeffrey A.,M .D. (b) (6)>

-----------
___________
Se nt: Tuesday, April 7, 2020 9:39 AM
To: Callahan, Michael V.,M.D. ---------- ...... -,;-,-.,=
(b)(6J>; Fauci, Anthony {N IH/NIAID) [E]
(b)(6)>
(b) (4)
Importanc e: High
Dear Tony and Michael: (b) (4)

(b) (4)
Mark Poznansky
Vaccine and Immunotherapy Center
Massachusetts General Hospital
CbH6) ( C)-J e ff
------ Cb>
<6)- M ark
From: Chen, Huabiao, M.D . (b)(6)
To: Gelfand, Jeffrey A.,M.D.

___ __;,__
----------,;-;~
.:_..:..,____;~~ (b
~)~(6)
~------
CbH6)>;Poznansky, Mark,M.B.,Ch.8.,Ph.D .
(b) (4)
Dear Jeff and Mark,
(b) (4)
Thanks,
Huabiao
From: Chen, Huabiao, M .D.

------------
(b)(6)
To: Gelfand, Jeffrey A.,M .D. --------~~ (b)(6)>

Subjec t : Re:
====-------------------------- (b) (4)
attached please find the supporting information in PDF
From: Chen, Huabiao, M .D. (b)(6)>

-----------
To: Gelfand, Jeffrey A.,M. ---------- ==
(b)(6)
Subject : Re: (b) (4)
If needed please download the supporting information

------------- (b) (4)
From: Gelfand, Jeffrey A.,M .D.

----------
---------~~
(b)(6)>
To: Chen, Huabiao, M .D.

------------ CbH6)>
(b) (4)
Wow! Reading it now ...Jeff
From:Chen, Huabiao, M.D.

------------
(b)(6)
To: Gelfand, Jeffrey A.,M.D. ---------.. =

-
-'="':========~
Subject: _______________________________
(b)(6b
(b_H_4)
Importance:High
Dear Jeff,
I had a Chance getting this information fro m. (b)( 6)j Dr. Danlei Mou who works very
diligently and seriously on this clinical study. You may be interested in this primary information.
Please keep it confidential.
Best, Huabiao
The information in this e-mail is intended only for the person to whom it is
http://www.partners.org /complianceline . If the e-mai l was sent to you in error
but does not contain patient information , please contact the sender and properly
Sent : Sat, 11 Apr 2020 23:21 :25 +0000
To: Upton, Fred
Subject : RE:GOP lawmakers: Fauci may be doing more harm than good I TheHill
Thanks, Fred. I appreciate your note.

Best rega rds ,
Tony
From: Upton , Fred

_____
-----Original Messa,...,_
e----- ..,,.,.~
(b)(6) >
To: Fauci. Anthony (NTHINIAID)[E] -------~~ (b)(
Subject: Re: GOP lawmakers: Fauci may be doing more hann than good I TheHill
Up date. Biggs and Buck are the only 2 memb ers of Congress that vote d agn the first two bills dea ling with COVID
-19. The first vote had only the 2 of them vote no. NRN
Sent from my iPhone
> On Apr 11, 2020, at 5:45 PM, Upton, Fred

> -------- (b)(6) wrote:
> It's upton again and no need to respond. U may get asked about this story and u sho uld know that both Buck and
Biggs were among the 40 that vote d no on the 2nd package which provided assistance and testing (think it was
$ 13B). It was not a surprise that they voted no as they r joined with Tom Massie in almost everything. Keep being a
science tn1th teller□ C
> http s://thehi 11.com /homen ews/ corona virm-report/ 4923 5 9-gop- lawmakers- fauci-may-be-doin g-more-harm-than-
good
>
>
Sent : Sat, 11 Apr 2020 19:26 :02 +0000
To: Upton, Fred
Subject : RE:It's Fred upton
Fred:
Thanks for the note. The answer is almost certai11lyyes, but there wou ld not be enough of them whereby we can
compare the results in those who were rece iving Hydroxychloroquine or not for their lupus. Large natural history
studies, which we will be initiating could possibly answer that question.
Best regards,
Tony
Anthony S. Fauci. MD
Director
National Institute of Allergy and InfectiousDiseases
3 I Center Drive, MSC 2520
Phone: (b)(6)
FA X: (301 496-4409
E-mail: (b)(6)
please inform the sender and delete it from your mailbox or any other storage devices. The National 1nstitute of
Allergy and Infectious Diseases (NJAID) shall not accept liability for any statements made that are the sender's own
and not express ly made on behalf of the NlA ID by one of its representatives.
From: Upton, Fred ~------~~ (b)(6)
Sent: Friday, April l 0, 2020 6:0 l AM
To: Fauci, Anthony (NIH/NlAlD) [E) --------=-,...,.=
--------- (b)(6) >
Subject: It's Fred upton
U gave me your email at the Capitol briefing. Question, with all the discussion on hydrox.- have there been any
Covid- J9 cases that have stmck.lupus victims? TY
Sent from my iPhone

Sent : Wed, 15 Apr 2020 22:29:20 +0000
To : Bergmann, Kenneth
Subject: RE: a thought on selective vulnerability to SARS-CoV-2
Thanks, Ken. Interesting concept. I will run it by our program people.
From: Bergmann, Kenneth ___________ Cb

_>_<6>i>
To: Fauci,Anthony {NIH/NIAID) [E] ------ (b
=)""'(6)
=>
Subject: RE: a thought on selective vulnerab ility to SARS-CoV-2
Hi, Tony
This is not my field but I had some ideas, so thank you for indulging me in thinking about "why
not kids." I attached citations I found useful. Hope you are not sorry you asked... ©
(b) (5)
(b) (5)
Best regards,
Ken

--------
To: Bergmann, Kenneth -----------~~ (b)(6)
Subject: RE: a thought on selective vu lnerab ility to SARS-CoV-2
Ken:
I have thought about the same or similar issues.
Best regards,
Tony
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: (b) (6)
information. It should not be used bv anyone who is not the original intended recipient. If you
othe r storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not
From: Bergmann, Kenneth (b)( >
Sent: Saturday, Apr il 4, 2020 9:39 AM
To: Fauci, Anthony (NIH/NIAID) [E] ------ -=
(b-s--r
H=6)
Subject: a thought on selective vulnerabil ity to SARS-CoV-2
Dear Dr. Fauci

I read with interest your JAMA View point of February 25.
(b) (6). (b) (5)
Thank you for all you do.

Sincerely
Ken
Kenneth J . Bergmann, MD, FAAN

Sen ior Medical Officer
Division of Neurology I. Office of Neuroscience
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Building 22, Room 4143
10903 New Hampshire Avenue,
Silver Spring, MD 20993-0002
Office: (b) (6)
Mobile: ) §)
Email.._ _______ _._,,.:(,:;,.,
©
Sent : Wed, 15 Apr 2020 22:28:57 +0000
Subject: FW: a thought on selective vulnerability to SARS-CoV-2
Attachments : l_Mab induced Cytoki ne Storm NEJM 2006.pdf , 2_Covid_pregnancy.pdf,
3_ Neon ate _i nnate _im mun ity _2018.pdf, 4_nihms832701.pdf, 5_ 12948_2017 _Article_77.pdf
Please check th is out with program people. Thanks.
From: Bergmann, Kenneth (b)( >

To: Fauci, Anthony (NIH/NIAID) (E]------ ~=
(b)(6)>
Subject: RE:a thought on selective vulnerab ility to SARS-CoV-2
Hi, Tony
This is not my field but I had some ideas, so thank you for indulging me in thinking about "why
not kids." I attached citations I found usefu l. Ho pe you are not sorry you asked ... ©
(b) (5)
(b) (5)
Best regards ,
Ken

To: Bergmann, Kenneth ---------- "=""=
(b)(6)>
Subject: RE: a thought on selective vu lnerab ilit y to SARS-CoV-2
Ken :
Thanks for the note. I have thought about the same or similar issues.
Best regard s,
Tony
Director
Phone: (b) (6)
FAX: (301 496-4409
E-mail: (b)(6)
From: Bergmann, Kenneth (b)(6)

To: Fauci, Anthony (NIH/NIAID) [E] -------= (b)""'(6J
= >
Subject: a thought on selective vulnerabil ity to SARS-CoV-2
Dear Dr. Fauci

I read with interest your JAMA Viewpo int of February 25.
(b) (6), (b) (5)
Thank you for all you do.

Sincerely
Ken
Kenneth J. Bergmann, MD, FAAN

Senior Medica l Officer
Division of Neurology I. Office of Neuroscience
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Building 22, Room 4143
10903 New Hampshire Avenue,
Silver Spring, MD 20993 -0002
Office: (b) (6)
Mobile: > §)
Email: .__ ______ __."'-' @
=
Sent : Sun, 12 Apr 2020 22:44:30 +0000
To : Marston, Hilary {NIH/NIAID) [E)
Subject : FW: Collection of COVID-19 patient data from medical records
Please take a look at this and figure out whether we should do something.
From: Hahn, Stephen (b)( >

Se nt : Thursday, March 26, 2020 5:40 PM
------~=
------ (bH ; Debi Birx
_.:....:...:.=:=====-~
To : Fauci, Anthony {NIH/NIAID) [E] (b)(6)>;
(b)(6)>
Redfield, Robert R. {CDC/OD)
Cc: Abernethy, Amy (FDA/OC) (b)( >; Lenihan, Keagan (FDA/OC)

(b)(6)
Subject: Collection of COVID-19 patient data from medical records
Tony, Bob and Debi,

Amy is working on a pathway to collect data from electronic medical records in selected areas of the
country (addressing all of the appropriate privacy concerns) . We're looking for data elements to collect
and wonder if your teams could give us some insight from a public health perspective. I am copying
Amy to see if she has anything else to add. Perhaps you could assign someone to wo rk with Amy.
Thanks
Steve
Sent : Sat, 18 Apr 2020 18:55:23 +0000
To : Kamoie, Brian
Subject : RE:Thank You
Thanks, Brian. I appr eciate your not e .

Best rega rds,
Tony
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
accept liability fo r any statements made that are the sender's own and not expressly made on
From: Kamoie, Brian

-----------
-------::-::-:-=
(b)( >

Subject: Thank You -------- (b)( >
Tony,
Thank you for all that you are doing in the fight against COVID-19. Your steady leadersh ip and groundi ng
in the science, and your ability to communicate comp lex informat ion clear ly to policymakers and the
public, are what the wor ld needs during this crisis. I know we will see the other side of th is pandem ic,
and you will have once again saved many lives with your wor k.
I am one step removed from this response, as I am on a deta il assignment from FEMA to the Naval
Academy, but have been sharing information with the Superinten dent and his senior leader ship team so
t hat t hey can make good decisions to protect the community w hil e meet ing the Academy's mission. I
have thought back to th e H1N1 response in 2009-2010 many t imes since th is began.
Again, t hank you for what you're do ing. My best wishes to you and your family .
Best,
Brian
(b)(S) - PCR
(bXS) - PCB
Sent : Thu, 16 Apr 2020 03:00:26 +0000
To : Collins, Francis (NIH/OD) [El;Myles, Renate (NIH/OD) [El;Tabak, Lawrence
(NIH/OD) [El;Wo linetz , Carrie (NIH/OD ) [El;Lane, Cliff (NIH/NIAID) [El
Cc: Burklow, John (NIH/OD) [E];Fine, Amanda (NIH/OD) [El;Wojtowicz, Emma
(NIH/OD) [El;Fritz, Craig (NIH/OD ) [El ;Billet, Courtney (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID)
[El;Routh, Jennifer (NIH/NIAID) [El
Subject: RE: For review tonight: draft Sec. Azar statement on ACTIV
Ditto.

Sent: Wednesday, April 15, 2020 10:57 PM ------- (b)(6)
To: Myles, Renate {NIH/OD) [El Cb)( >; Tabak, Lawrence {NIH/OD ) [El
(b)( >; Woli netz, Carrie (NIH/OD) [El (b)( ; Fauci, Anthony
":'---:---'"""".""'."""':'====-.:----=~
(NIH/NIAID) [El (b)(6) >; Lane, Cliff (NIH/NIAID) [El (b)(6)
Cc: Burklow, John (NIH/OD) [E] (b)(6) Fine, Amanda (NIH/OD) [El
-----~~=====-=--_;,_.~
(NIH/OD) [El
(b)( ; Wojtowicz, Emma (NIH/OD) [El
(b)(6)>; Billet, Courtney (NIH/NIAID) [El
(b)(6); Fritz, Craig
CbH6J>;Stover ,
Kathy (NIH/NIAID) [El (b)(6J>; Routh, Jennifer (NIH/NIA ID) [El
_ _;_..;._ __ _;__;_(b
~ )~(6)
=-> -------
Subject: RE: For review tonight: draft Sec. Azar statement on ACTIV
Looks generally OK
FC
From: Myles, Renate (NIH/OD) [El CbH >

--------
To: Collins, Francis (NIH/OD) [El CbH6J>; Tabak, Lawrence (NIH/OD) [E]
------~===::!....:.
(NIH/NIAID) [El
__ ,---;. (b)( >; Wolinetz, Carrie (NIH/OD) [El
CbH6J>;Lane, Cliff (NIH/NIAID) [E]
(b)( >; Fauci, Anthony
(b)(6)
Cc: Burklow, John (NIH/OD) [El CbH6J;Fine, Amanda (NIH/OD) [El
(b)(6)>; Wojtowicz, Emma (NIH/OD) [El (b)(6)>; Fritz, Craig
":'--:-:-:-::-:-:-
-:::-:===:;_;_- ~=
(NIH/OD) [El
--.-~:=====-.;__~
Kathy (NIH/NIAID) [El
~ (b)(6J>; Billet, Courtney (NIH/NIAID) [El
(b)(6)>; Routh, Jennifer {NIH/NIAID) [El
(b)(6) 1>; Stover,
(b)(6)
Subject: FW: For review tonig ht: draft Sec. Azar statement on ACTIV
Importance: High
Good evening :
I'm sending this direct ly to principals given the quick turnaround. I've let ASPA know that the goal is to
issue the release sometime tomorrow .
Thanks,
Renate
From: Brennan, Patrick (OS/ASPA)
----------
(b)(6)
------~~
To : Burklow, John (NIH/OD) [El
Myles, Renate (NIH/OD) [El
Cb)( >; Fritz, Craig (NIH/OD) [El
(b)(6 b; Fine, Amanda (NIH/OD) [El
-------- Cb)( ;
(b)(6 b ; Wojtowicz , Emma (NIH/OD) [El (b)(6 h; Akinso, Woleo la

--.-".'""'."'~==::::::!!;...;.._
(NIH/OD) [El
:....,,= -:--"".";:======~ ~
(b)(6h; Stimson, Brian (HHS/OGC) CbH >; Charrow,
Robert (HHS/OGC) (b)(6)>
Cc: Mu rph y, Ryan (OS/ASPA) (b)(6 b; Pratt, Michael (OS/ASPA)
(b)(6 h; Oakley, Caitlin B. (05/ASPA)
---------
Subject: For review tonight : draft Sec. Azar statement on ACTIV
(b)(6)>
NIH and OGC,
Can you let me know if the below and attached statement from the Secretary looks OK? Assumin g it is
going tonight from NIH, approv al as soon as possible would be great. Thank you!
- Patrick
(b)(5)
Pat rick Brenna n

Director of Speechwr iting
Office: (b) (6) I Cell: (b) (6)
From: Fauci,Anthony {NIH/NIAID) [E)
Sent: Mon, 13 Apr 2020 01:14:17 +0000
To: Mascola,John (NIH/VRC)[E)
Cc: Erbelding, Emily (NIH/NIAID) [E);'Dieffenbach, Carl (NIH/NIAID) [E]' ;Marston,
Hilary (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Pursuant to My Email on Frida y
Attachments: Vaccine strategy-200411-v 13.pptx, Secretary Determination Memorandum-
Project Warp Speed-041120 1825 draft .d oc
John:
Let us br iefly discuss this tomorrow AM . (b) (5)
Best,
Tony

--------- (b) (6)>
To: Hassell, David (Chris) (OS/ASPR/10) CbH6);Collins, Francis (NIH/OD) [El

___ _;_ _ __; _ __;_.;._.;.__,;__,;.:::::====== Cb
::;;
>::;,
<6)
5i"":'"'
Mascola, John (N IH/VRC) [El
(b)(6),;Bright , Rick (OS/ASPR/BARDA) CbH6) ; Fauci,
Anthony {NIH/NIAID) [E] (b)( >; Disbrow, Gary {OS/ASPR/BARDA)
(b)( ; Patrick, Vanessa (OS/ASPR/BARDA) (CTR)
========-~ CbH6)>; Moughalian, Jen {HHS/ASFR) ----------:a- = CbH
----------
Redfie Id, Robert R. (CDC/OD) CbH >; Messonnier, Nancy (CDC/DDID/NCIRD/0D)
CbH ; Lane, Cliff (N IH/NIAID) IE] CbH6)>;Marks, Peter (FDA/CSER)
======::::::.;_-
----------
~= CbH6)>; Yeskey, Kevin (OS/ASPR/10) (b)(6)
Cc: Harrison, Brian (HHS/10S) (b)( ; Dareshori, Zack {HHS/10S)
Stecker, Judy (OS/10S)

----------
(b)(6)>; Conrad, Patricia (NIH/ NIAID) [E]
CbH6)Shuy, Bryan (OS/ASPR/10)
(b)(
(b) (6) >

-------- CbH6)>;Wolinetz, Carrie (NIH/OD) [El
----------
Decision Memo drafted for the Secretary's review t omorrow. I want to thank all those who
contributed over this holiday weekend to offer their ideas and concepts that is represented in
t hese products. Th is represents just a first step of many steps that first outlines a concept that
will then be operationalized into a histor ic effort for not only the Department and agencies who
Sent: Mon, 13 Apr 2020 00:32:55 +0000
Cc: Folkers, Greg (NIH/NIA ID) [E];Conrad, Patricia (NIH/N IAID) [E];Routh, Jennifer
(NIH/NIAID) [E];Mar ston, Hilary (NIH/NIAID) [E]
Subje ct : RE:daily data call from Sec Ofc
Th is looks rea lly good. Th anks.
From: Billet, Courtney (NI H/N IAID) [E) (b)(6)

Sent: Sunday, Apr il 12, 2020 7 :27 PM
To: Fauci, Anthony (NIH/ NIAID) [E] ---------=-:-:-= (bH6>r>
Cc: Folkers, Greg (NIH/NIAID) [E] (b)( >; Conrad, Patr icia (NI H/N IA ID) [E]
Routh, Jennifer (N IH/NIAID) [E]
(bH6)>; (b)(6b;
---------
Marston, Hilary (NIH/NIA ID) [E] (b)(6l
Subject: ASF: dai ly data call from Sec Ofc
Per request from the Secretary's office that I sent you this morning, below is what I propose to submit
tomorrow morning for the new daily 9am data call. I wil l plan to submit pretty much the same thing every
day. I will not Glog your in-box with it unless there is a significant update.
RFI from Staff Sec:
1. For tomorrow's press conference , what information or topics do you

recommend be included in the President's remarks? Please provide talking
point-level details and support.
Nothing specific from NIAID at this time.
2. For tomorrow's press conference , on what information (if any) do you

intend to speak?
SpeGific topics will depend on questions from reporters. Dr. Fauci has been asked about the effect of
social distancing; considerations that would facto r into returning the country to normal life; off-labe l
use of treatments such as hydrochloroquine ; the status of clinical trials ; and the disproportionate
impact of COV ID-19 on communities of color.
NIAID-specif ic talking points:
• NIAID has mobilized a rapid research response to quickly develop effective

countermeasures for COVID-19, including diagnost ics, vaccines to prevent
disease and treatments.
• NIAID is supporting a clinical trial of the antiviral remdesivir and is
investigating other treatments , including antibody therapies and other antivirals ,
for their activity against SARS-CoV-2 . Well-designed clinical trials are the best
way to evaluate potential treatments for safety and efficacy .
• NIAID is supporting an early-stage clinical trial of an investigational vaccine

called mRNA - 1273, developed by NIAID scientists and the biotechnology
company Moderna. The study launched first in Seattle, with a second site
recently added in Atlanta . NIAID is researching additional vaccine candidates.
• NIAID has launched a serosurvey study that aims to determine how many
adults in the United States without a confirmed history of COVID-19 have
antibodies to the virus . Researchers will collect and analyze blood samp les from
as many as 10,000 adu lt volunteers without a confirmed history of COV ID-19 .
The results will help illumina te the extent to which the novel coronavirus has
spread undetected in the United States and provide insights into which
communities and populations are most affected. [NOTE : Thi s serosurvey is for
research purposes. It is not meant to be a way fo r people to access antibody
testing for personal knowledge of prior infection history. If it is portrayed as a way
for people to "get tested " to understand their own infection history , we can expect
that peop le will inaccurately blame the government for not rece iving results in a
timely manner . People can request to learn about their results, which will be
available only after weeks or months of analysis.]
• NIAID is expanding its portfolio of basic research on coronaviruses and

emerging pathogens to characterize SARS-CoV-2 (the virus that causes COVID-
19) and understand how it causes disease. NIAID also is using animal models to
better understand the infection and to investigate optimal ways to trea t and
prevent COV ID-19 .
3. Are there topics or announcements for future press conferences (other

than tomorrow's) that you would like to flag for the President's speechwriting
--
team?
For HHS to consider mentioning:

--------------
(b) (5)
From: Fauci,Anthony (NIH/NIAID) [El (b)(6)
Sent : Sunday,April 12, 2020 1 :55 PM

--------
To: Billet, Courtney (NIH/NIAID) [El ------~ =
(b)(6)
Subject: RE: Staff Sec POC - NIAID
OK. Sounds fine. Do what you can do .
From: Billet, Courtney {NIH/NIAID) [E] CbH6)>

To: Fauci, Anthony {NIH/NIAID) [E] ------~~ (b)( >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b)(6)>; Stover, Kathy (NIH/NIAID) [E]
(b)(6)>; Routh, Jennifer (NIH/NIAID) [E] (b)(6)>; Folkers,
Greg (NIH/NIAID) [E] CbH6)>
Subject: FW: Staff Sec POC- NIAID
FYI- per request below, HHS is setting up a daily data call. We need to tell them at 9am what
you are going to discuss at the daily press conference at the end of the day. My observation is
that this may be hard to predict. However, we can certainly come up with some boilerplate
talking points that we re-subm it every day, emphasizing the importance of properly designed
clinical trials as the best way to identify treatments.
From: Boyse, Natalie (OS/ASPA) (b)(6)

----------
To: Billet, Courtney (NIH/NIAID) [E] ------~~ (b)(6)>
Cc: Bird, Catherine (OS/OGC) (b)(6) ,>; Puesan, Cesar (HHS/OS/I0S)
(b)(6)>; Agnew, Ann (HHS/10S) (b)(6) 1>; Brennan, Patrick
-(o- s-=-
; A_S_P_A '."""
) -=====:!...:__::::____;_ (b
~ )~(6)
Subject: Staff Sec POC - NIAID
Hi Courtney -
I hope you're having a good weekend. Just wanted to touch base because starting tomorrow, we will be
receiving requests for information from Staff Sec each evening ahead of the next day's press conference
- for a turnaround by 9am the following morning. Staff Sec is requesting feedback (see the questions
below) from task force experts, including Dr. Fauci, on informa tion they recommend be included in the
next day's press confe rence.
Could you please help me identify a primary POC at NIAID that I can work with to get information to Staff
Sec?
(b) (5)
(b) (5)
Thank you ,
Natalie
Natalie Boyse
Special Assistant , Immed iate Office of the Secretary
U.S. De artmen t of Health & Human Services
M: (b)(6)
Sent: Sat, 11 Apr 2020 03:05:04 +0000
To: Collins, Francis(NIH/OD) [El
Cc: Tabak, Lawrence (NIH/OD) [El;Lane, Cliff (NIH/NIAID) [El;Mascola, John
(NIH/VRC) [El
Subject: RE:COVID-19Advisory Panel Recommendations Following UP on Secretary
Meeting this Am .
I am sorry, but I am way behind on e-mai ls and I just saw this. What is going on here?
From; Collins, Francis {NIH/OD) [El

------- (b)( >

Cc:Tab ak, Lawrence (NIH/OD) [E] ;;.========:c (b
~) ~
C6l;lane , Cliff (NIH/NIAlD) [E]
(b)(6); Mascola, John (NIH/VRC) [E] (b)(6)
--------
Subject: FW: COVID-19 Advisory Panel Recommendations Following UP on Secret ary Meeting
t his Am.
Importance: High
Just saw this. Huh? (b) (5)
--- ·? -------------------------
From: Kadlec, Robert (OS/ ASPR/10) CbH6)>

To: Hassell, David (Chr is) (OS/ASPR/10) CbH6)>;Conrad, Patricia (NIH/NIAID)
[E] CbH6)>;Collins, Francis (NIH/OD) [E] CbH6);
'shl@fda.hhs.gov ' CbH6)>;Mascola, John (NlH/VRC) [E] CbH6)
Dareshori, Zack (HHS/IOS) (b)(6)>; Bright, Rick (OS/ASPR/BARDA)
-------- CbH6)>;Disbrow, Gary (OS/ASPR/BARDA)

Gretta (OS/ ASPR/BARDA)
CbH6)>;Blatner,
(b)( >; Patr ick, Vanessa (OS/ ASPR/BARDA) (CTR)
...__-:--"""""."'-:--"""""':"'""""':":==
(b=
)(=6):·:...
_
M_o_u.:::,
g_ ha_li_a..,;,
n,~Jen ( HHS/ASFR) CbH6)>;Shuy,
Bryan (OS/ASPR/10) CbH6);Redd, John (OS/ASPR/SPPR)
CbH6) ; Redfie ld, Robert R. (CDC/OD) CbH6);Stre ngth-McGaughey,
--------
Tracie (CDC/DDNID/NCIPC/0D) CbH >; Yeskey, Kevin (OS/ASPR/10)
CbH6)> ; Marks , Peter (FDA/CBER) CbH6)>;Cochran,
Norris (HHS/ASFR) (b)(6)>;Messonnier, Nancy (CDC/DDID/NCIRD/00)
------
(OS/ ASPR/BARDA)
CbH6)>;Lane, Cliff (N lH/ NlAlD) [E]
CbH6)>;Gershman, Lynn E. (CDC/DDPHSlS/0D)
CbH6)>;Johnson, Robert
(b)(6b ; Lenihan , Keagan (FDA/OC) (b)(6); Mark Hartell

____________________ Cb
_H_6) Mascola, John (NIH/VRC) [E]
CbH6)>;Suhana, Tina (NIH/VRC) [El CbH6);Marston,
Hilary (NIH/NIAID) [E] CbH6)>;Fauci, Anthony (NIH/NIAID) [E]
CbH6)>;Mango, Paul (HHS/I0S) CbH6)>;Shuy, Bryan
(OS/ASPR/I0) (b)(6)
Cc: Harrison, Brian (HHS/I05) CbH6)>;Stecker, Judy (05/ 105)
CbH6)>;Ford-Barnes, Arwenthia (OS/ASPR/I0)
========:!....:.--~ ------~~
CbH6);Tignor, Beth (HHS/IOS) ; Moreno,
CbH6)>
--:---"'.'""'.""----::----::----::-:;======~ ~~
Rafael (OS/ASPR) CbH6)>;Callahan, Victoria (OS/ASPR/I0) (CTR)
----------
Holland , Tara (OS/ASPR/EMMO)
(b)(6) ; Kemp, Micha (OS/ASPR/MFHC)
CbH6)>
CbH6);
Subject: RE: COVID-19 Advisory Panel Recommendations Following UP on Secretary Meeting

t his Am.
Importance: High
First thank you all for participating on Wednesday's evening call and producing the briefing
memo for the Secretary's review. As a consequence of that meeting and discussion, he fully
endorsed the recommendations of the vaccine portfolio you recommended .
• (b)(5)
This is an ambitious and challeng ing undertaking but one driven by the necessity to mitigate the
public health, economic and national secur ity threat this virus represents to our citizens, nation
and our way of life. The Secretary is confident that together with our private sector partners
this is achievable.
Have a restful holiday weekend.
Bob
From: Hassell, David (Chris) (OS/ASPR/I0) (b)(6)

To: Kadlec, Robert (OS/ASPR/I0) --------=-:-= CbH6)>;Conrad, Patricia (NIH/NIAID) [E]
--------- (b)(6)>; Collins, Francis (NIH/OD) [E] CbH6)>;

CbH6)>;Dareshor i, Zack (HHS/I0S)
========~;:;;:;----::-:--:-
CbH6)>;Bright, Rick (OS/ASPR/BARDA)--------,;~ CbH6);Disbrow,
---:---:---:--~-;=~....:....--=:........:.-__:.~=
Gary (OS/ASPR/BARDA) CbH6)>;Ford-Barnes, Arwenthia (OS/ASPR/I0)
_:....:..._:_
_ __:_
__ ....:.!:==~~""'.""""---
(b)(6); Blatner, Gretta (OS/ASPR/BARDA)
...=======- Cb
~H~6);>-
--1
;P'.'"'
a-tr""."
ic-:'k, Vanessa (OS/ASPR/BARDA) (CTR)
CbH6) 1
>; Moughalian, Jen (HHS/ASFR)---------.. Cb
"'>.,,.,
<6)>;Shuy,
Bryan (OS/ASPR/I0) CbH6)Redd, John (OS/ASPR/SPPR)
CbH6); Tignor , Beth (HHS/I0S) CbH >; Redfield, Robert R.
"":"-~:---:-::====~=
(CDC/OD) CbH6)>;Strength-McGaughey, Tracie (CDC/DDNID/NCIPC/0D)
.,:.__:__...:...!::~;;:;-----:--
(b)(6)>;Yeskey, Kevin (OS/ASPR/I0) CbH6)>;Callahan, Victoria
-------
(OS/ASPR/I0) (CTR) CbH6)>;Moreno, Rafael (OS/ASPR)
CbH6)>;Marks, Peter (FDA/CBER) CbH6)>;Cochran,
Norris (HHS/ASFR) (b)(6)>; Messonnier, Nancy (CDC/DDID/NCIRD/00)
(b)(6)>;Windom, Robert (OS/ASPR/I0) (b)(6)>;Lane, Cliff
(NIH/ NIAID) [E] (b)(6) Holland, Tara (OS/ASPR/EMMO)
CbH6)>;Johnson, Robert (OS/ASPR/BARDA)_______ --,;-
Cb-s--r
H= >;
---------
Gershman, Lynn E. (CDC/DDPHSIS/0D) CbH6)>;Kemp, Micha (OS/ASPR/MFHC)
(b)( >; Lenihan, Keagan (FDA/OC) (b)(6)>; Mark
Harte II Cb)( >; Mascola, John (NIH/VRC)
[E] (b)(6)>;Suhana, Tina (NIH/VRC) [E] (b)( >; Marston,
Hilary (NIH/NIAID) [E] CbH6)>;Fauci, Anthony (NIH/NI AID) [E]
_ __:__;___.:..__ .:__:_
(b,.:...
)( -c-:
6):---------
Subject: COVID-19 Adv isory Panel Recommendations
Dear Panel members-
Secretary Azar requested a summary paper w ith a recommendation from the Panel re the
BARDA vaccine portfolio. His deadline was 3:30pm today.
Based on the discussion last night and other discussions with the BARDA team, (b)(5)
Please let me know as soon as possible if this is
not the case.
Apologies for the fast turn. Thank you again for your participation in the Panel.
Chris
<< File: COVID Vaccines Briefing Memo V.3.docx >>
-----Origina l Appointment-----
(b)( >
From: Kadlec, Robert (OS/ ASPR/I0)
---------
To: Kadlec, Robert (OS/ASPR/I0); Conrad, Patricia (NIH/NIAID) [E] ; Collins , Francis (NIH/OD) [E];
(b)( 6); Daresho ri, Zack (HHS/I0S); Br ight, Rick (OS/ASPR/BARDA); Disbrow, Gary
------
(OS/ ASPR/BARDA ); Ford-Barnes , Arwenthia (OS/ASPR/I0); Blatner, Gretta (OS/ASPR/BARDA);
Patrick, Vanessa (OS/ AS PR/BARDA) (CTR); Mougha lian, Jen (HHS/ ASFR); Sh uy, Bryan
(OS/ASPR/I0); Redd, John (OS/ASPR/SPPR); Tignor, Beth (HHS/IDS) ; Redfield, Robert R.
(CDC/OD); Strength -McGaughey, Tracie (CDC/DDNID/NCIPC/0D); Hassell, David (Chris)
(OS/ ASPR/I0) ; Yeskey, Kevin (OS/ASPR/I0); Callahan, Victoria (OS/ASPR/I0) (CTR); Moreno,
Rafael (OS/ASPR); Marks, Peter (FDA/CBER); Cochran, Norris (HHS/ASFR); Messonnier, Nancy
(CDC/DDID/NCIRD/0D); Windom , Robert (OS/ASPR/I0) ; Lane, Cliff (NIH/NIA ID) [E]; Holland ,
Tara (OS/ASPR/EMMO); Johnson, Robert (OS/ASPR/BARDA); Gershman, Lynn E.
(CDC/DDPHS IS/00) ; Kemp, Micha (OS/ASPR/MFHC) ; Lenihan , Keagan (FDA/OC) ; Mark Hartel!
----------- (b)(6) Mascola, John (NIH/VRC) [El; Suhana, Tina (N IH/VRC) [E];
Marston, Hilary (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]
Subject: #2 - COVID- 19 Adv isory Panel
When: Wednesday, April 8, 2020 5 :15 PM-6:30 PM (UTC-05 :00) Eastern T ime (US & Canada).
Where: WEBEx - cs)
Cb>
Presentatio n fo r Wedne sday. HIS ISTHE UPDATEDVERSIO ,4:26pm

<< File : BARDA COVID Vaccines Whi t e Paper 20200405b.docx »
Meeting Objective:
(1) Complet e review of BARDAvaccine portfolio (to includ e relat ed NIH and DoD pro grams), w ith emphasis on
discussion amo ng Panel members;
(2) Formu lat e a recomm endation to Secretary Azar to eith er endor se or modify curr ent vaccin e strategy, plans,
proposed funding and contracts.
Agenda
Brief review of vaccine programs
• BARDA (deeper dive after Sunday overview)
• NIA ID
• DoD
Discussion
Recommendat ion to Secretary Azar
For convenienc e, below are the presentation and Whit e Paper from last Sunday evening .
<< File : BARDA COVID Portfolio Review 20200405b.pptx >> << File: Vaccine Discussion with S1
and HHS Leadership V2 FINAL - Gary.pdf >>
Hi Arwenthia Ford-Barnes,
You updated this WebEx meeting:
#2 COVID-19 Advisory Panel on behalf of Dr. Robert Kadlec

Host: Arwenthia Ford-Barnes
When it's time , start your meeting from here:

Start the meeting
When: Wednesday, April 8, 2020, 5:15 pm (1 hr 15 mins), Eastern Daylight Time (New York , GMT-
04:00).
Access Information
Meeting Number :
(b) (5)
Password:
(This meeting does not require a password .)
Host Key:
(b)(5 ) (Use this key during the meeti ng if you ever need to reclaim the host role.)
Audio Connection
---- (b)(5
Access Code:
(Meeting Server Main Number)
(b) (5)
Delivering the power of collaboration

The meetingserver.hhs.gov team
© 2020 Cisco and/or its affiliates. All rights reserved
<< File : BARDA COVID Vaccines White Paper 20200405b.docx » « File: BARDA COVID
Portfolio Review 20200405b .pptx » << File: Vaccine Discussion with 51 and HHS leadersh ip V2
FINAL - Gary.pdf >>
From: (b)(6)
Sent : Thu, 9 Apr 2020 16:48:20 -0400
To: Folkers, Greg (NIH/NIAID) [E);Conrad, Patricia (NIH/NIAID) [E)
Subject: Fwd: Hello
How do we nicely say no to this person?
From: "Sachdev , Amit (HHS /IOS )"

Date: Apr il 9, 2020 at 2:04:56 PM EDT ----------
To: "Fauci, Anthony (NIH/N lAID) [E]" ------~~
Subject: Hello
--------- (b)(6J:
Hi Dr. Fauci, my name is Arn tt Sachdev. I am a Whi te House fellow and physician
most recently at the Brigham .
I know you are super busy and I wo uld love to partner wit h you and w rite a oped on
coronavirus and un ite the nati on.
If you have a few minutes, I would love to speak. I think (b)(S
Sincerely,
Amit
(b)(6)
Sent from my iPhone

From: (b)(6)
Sent : Wed, 8 Apr 2020 20 :14 :10 -0400
To: Adams, Jerome (HHS/OASH)
Subject : Re: Blacks/ minorities
Please text to me your cell phone number
On Apr 8, 2020, at 7:29 PM, Adams, Jerome (HHS/OASH)

(bH
Also, Deb has the data and knows it better than anyone , (b) (5)
(b) (5)
VADM Jerome Adams

On Apr 8, 2020, at 7:13 PM, Adams, Jerome (HHS/OASH)

(b) (6)
>wrote:
With greatest of respec t to the two of you , (b) (5)

(b) (5)
(b)(5
Jerome
VADM Jerome Adams

20th US Surgeon Genera l
Sent : Wed, 8 Apr 2020 14 :38 :40 +0000
Subject: FW: HHS Sponsored Coronavirus Clinical Guidel ines - Heads up
FYI
Director
Phone: (b)(6)
FAX: (30 496"'4409
E-mail: (b)(6)
From: Stecker, Judy (OS/10S)

---------
----------=-:-=
(b)( '
Cc: (b)(6) (OS/10S)

~__;,_.....:...!:=~~----~-
To: Harrison, Brian (HHS/105) (b)(6)
(b)(6)>; Fauci, Anthony (NIH/N IAID) [E] (b)( ·>; Lane,
Cliff (NIH/NIAID) [E]!.======- (b~)(=l>Y> --------
Subject: Re: HHSSponsored Coronavirus Clinical Guidel ines - Heads up
Thank you . Will have Beth connect with Patricia ASAP.
Sent from my iPhone
On Apr 8, 2020, at 9:48 AM, Harrison, Brian (HHS/IOS)

--------- Cb) (6)>
Sounds good, Dr, Fauci - we greatly appreciate the effort that you/Cliff and your team
wrote:
have put into this.
Look forwar d to receiving and d iscussing the guidelines (no need for a separate meeting
w ith me first - we can go straigh t to the Secretary) and agree t hat they w ill not be
subjected to additional layers of fo rmal clearance given the circumstances.
Adding Judy to quickly help coordinate a time to meet with the Secretary.
Thanks again,
BH
Brian Harrison
Chief of Staff
(b)(6)
(b)(6)
Thank you Tony. Obviously we will prio ritize time to meet/discuss . I'm at your
disposal.
AMA
On Apr 7, 2020, at 11:01 PM, Fauci, Anthony (NIH/NIA ID) [E]

(b)( > wrote:
--------
BLian,
_·-------------------------- ~~ -
CbX5)-PC
(b) (5)
H 5> Happy to
Cb
-----------------------
discuss further before I brief the Secretary .
Best regards,
Tony
Director
Phone: (b)(6)
FAX: (301) 496-4409
E-mail: (b)(6)
and may contain sensitive information. It should not be used by anyone
any other storage devices. The National Institute of Allergy and
made that are the sender's own and not expressly made on behalf of the
Sent : Wed, 8 Apr 2020 13 :49 :56 +0000
To : Harrison, Bria n (HHS/IOS)
Subject: RE:HHS Sponsored Coro navirus Clinical Guid elines - Heads up
Thanks, Brian.
Direc tor
Phone: (b)( 6)
FAX: (30 496"'4409
E-mail: (b)(6)
From: Harriso n, Brian (HHS/10S)

---------
To : (b)(6) (OS/10S) (b)(6)>
(b)(6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b)(6) ; Lane, Cliff (NIH/ NIAID) [E]
-------- (b) ~ ; Stecker, Judy (OS/10S)

---------
Subject: Re: HHSSponsored Coronavirus Clinical Guidel ines - Heads up
(b)(
Sounds good, Dr, Fauci - we greatly appreciate the effort that you/Cliff and your team have put into
t his.
Look forwa rd to receiving and discussing the guidel ines (no need for a separate meet ing with me first -
we can go straight to the Secretary) and agree that they will not be subjected t o add itional layers of
formal clearance given the circumstances .
Adding Judy to quickly help coordinate a time to meet with the Secretary.
Thanks again,
BH
Brian Harrison
Chief of Staff
(b)(6)
(b)(6)
wrote :
------ (b)(6)>
Thank you Tony. Obviously we will prioritize time to meet/discuss . I'm at your disposal.
AMA
On Apr 7, 2020, at 11:01 PM, Fauci, Anthony (NIH/NIAID) [E]

(b)(6)> wro t e:
--------
Brian:
(b) (5)
Happy to discuss further before I brie f the

-------------
Secretary.
(b)(S)
Best regards,
Tony
Director
Phone : (b) (6)
FAX: (301) 496-4409
E-mail: (b)(6)
conta in sensitive information . It should not be used by anyone who is not the
original intended recip ient. If you have received th is e-mail in error please inform the
Sent : Tue, 7 Apr 2020 14:48:49 +0000
To: Becks,Karen (HHS/10S)
Subject: RE:Crazy C0VID-19 face cover idea
Karen:
Thanks for your note.
Best regards,
Tony
Director
Phone: (b)( 6)
FAX: (301 496-4409
E-mail: Cb)(6)
From: Becks, Karen (HHS/1OS) (b)(6)

----------
Sent: Friday, April 3, 2020 12 :54 PM
-------~~ CbH6)
----------
Subject: Crazy COVID-19 face cover idea
Hi, Dr . Fauci.
Thank you so much for keeping things honest and know th at I am such a champion of you.
I hope tha t reaching out is okay. I work at HHS/1OSteam. As I sit here at home and have been
t hinking about the shortage of medical supplies, doggie cones actually can be used as
protection for our health care workers. Just a thought that looks and sounds crazy but can
help.
Stay safe .
Kindest Regards,
Karen Becks
Immediate Office of the Secretary
Desk: (b)(6)
Mobi le:
----- (b)(6)
___
Brian Kamoie
DHS/FEMA
,_ (b)(6) (mobile)
Sent : Thu, ~ r 202_022:05:53 +0000
(b)(6)
To:
Subjec t : RE:Greeti ngs from your former employee (UNCLASSIFIED)
(b)(6)
Many thanks for your kind note. I hope that all is well with you.
Best rega rds ,.
Tony

From: (b)(6) (b) (6)
------------------~~
To: Fauci , Anthony (NTH/NIAID) [E] ____________ ......,........,...,..
_______ (b
_)_C_
Subject: Greetings from your former emp loyee (UNCLASSIFIED)
CLASSIFICATION: UNCLASSIFIED
Dear Dr. Fauci ,
1 was in touch with (b)(6) back in January and he sa id you all were underwat er there with corona virus. I
can only imagine how much busier you arc now, with COVID-19 taking bold across America.
We (myself, husband, and family) have followed the news since the start . ln watching, I was reminded of the old
sign we had posted on the printer between (b) (6).and my desk for quite some time that read, "Keep Calm and
Trust Fauci". J can 't recall whe ther we put that up during the Ebola outbreak or Zika, but never has it been more true.
We never cease to be amazed at how well you carry yourself , respond to politically loaded questions, and get the
truth out in such a way that any viewer can understand.
You also never seem to frustrate from answering the same question s which l am sure must get old. There bas been
one question l have yet to hear asked howe ver. Who is cutting your hair? I know you used to have a regular ga l but
with soc ial distancing, we are specul ating that perhaps there is a White Hou se barber you us e. Of course we know
how busy you are so don't expect a reply, just wanted to throw you a question you may not have had yet. I am also
wondering how your office tree is doing. How many bungee cords are sup portin g it these days?
We have found plenty ofreasons to smi le with the who le family gettin g in on what we're dubbing the ASF # I Fan
Club. From memes , to cartoon s, to l-shirt:;, we are all here support ing you and wishing for your continued health and
success. I am attaching some of our shenanigans in hopes you get a kick out of it and to provide so me comic relie f.
You've been thanked over and over but J must say it too. Thank you, Dr. Fauci, for all that you do. And thank you to
the staff behind the sce nes that makes it happen. (b)(6) is no doubt just as busy as you as always C ~, are you
reading this emai l? Hi !). When we see you at all hours from the NIH studio and your office, I think of the media
staff support you receive, and espec ially assistance from (b) (6) for helping the ship run smoothly
wh ile you are constantly engaged, ( (b) (6)}
and your family , the list goes on. Thank you and thanks to your team.
(b)(6)
Directorate of Human Resources

USAG Foti Detrick
NIH-000065
CLASSIFICATION: UNCLASSIFIED
NIH-000066
From: Eisinger, Robert (NIH/NIAID) [E) on behalf of Fauci, Anthony (NIH/NIAID) [E)
Sent : Fri, 27 Mar 2020 11:23 :56 +0000
Subject : FW: Reaching out about partnerships and COVID-19. // confidential
The email below is from Maria Freire .

Bethesda MD 20892
(b)(6)
(b)(6)
From : Freire, Maria (FNIH) [T]

Se nt : Friday, March 27, 2020 6:03 AM ------- (b)(6)

-----~~ (b)(6); Whalley, David (FNIH) [T] (b)(6)>
Cc: Fauci, Anthony (NIH/NIAID) [:"'=.E':'-::
] ;:::::=====~ 6)>; Lane, Cliff (NIH/N IAID)._[_E_
(b)~ (-= ] -----
(b)(6)>
Subject: Re: Reaching out about partnerships and COVID-19. // confidential
Yes, quite a note . It is good to see such willingness to pitch in and the things J&Jis doing. Let us know
what he says. We stand ready to help. Best, M .
From : "Coll ins, Francis (NIH/OD) [El" (b)(6)>

Date: Friday, March 27, 2020 at 4:37:15 AM
To : "Wholley, David (FNIH) [T]" (b)(6)>
Cc: "Fauci, Anthony (NIH/NIAID) [El" (b)(6J>, "Lane, Cliff (NIH/NIAID) [E]"
(b)(6)>, "Freire, Maria (FNIH) [T)"
-------
Subject: FW: Reaching out about partnerships
(b)(6)
and COVID-19. // confidential
HI David,
Quite a message from Pau l below. He seems open to the idea of a virtual meeting, to see what
collaborative efforts might be most important. I'll try to speak with him today or tomorrow.
Francis
From: Stoffels, Paul [JJCUS)

-------
Se nt : Friday, March 27, 2020 3:54 AM
(b) (6)>
NIH-000211
To: Collins, Francis (NIH/OD) [E] (b)(6)
Cc: Castillejos, Carlos [JJCUS
) (b) (6)
Subject: Re: Reaching out about partnerships and COVID-19. // confidential
Francis,
(b) (4)
Lots to talk about. Happy to find a productive way to contribute in the discussion you are planning to
have.
we can talk th is afternoon UStime or over the weekend.

I'm working (b)(6) at the moment.
Carlos can provide more information on the
Best regards,
---- (b) (6) if you want.
NIH-0002 12
Paul
Sent from my iPad
On Mar 27, 2020, at 1:37 AM, Collins, Francis(NIH/OD) [E)

------- (b)(6)> wrote:
WARNING : This email originated from outside the company . Do not click on links unless you recognize
the sender and have confidence the content is safe. If you have concerns about this email , send it as an
attachment to 'SuspiciousEmail@ITS .JNJ.COM '.
Hi again Paul,
One more question - is the pharma collaboration mentioned in the BioCentury

story below the same th ing as the Gates COVID Therapeutic Accelerator Program?
Or is this something different? I'm just trying to understand the landscape.
Best, Francis
Pharmas on one page with action plan to solve COVID-19 together

BIOCENTURYIS PROVIDINGTHIS STORYFOR FREEGIVEN THE URGENTNEED FOR
INFORMATION ABOUT THE COVID-19 CRISIS.
BY C. SIMONE FISHBURN,EDITORIN CHIEF I MAR 25, 2020 I 9:17 PM EDT
A grand-sca le behind -t he-scenes effort by the pharmaceutical companies is under
way to expedite the creation of therapies and vaccines to treat COVID-19.
According to the participants who spoke with BioCentury under conditions of

anonymity, R&D heads from at least 10 companies have been gathering several
times a week, setting in motion an action plan to use their top talent in different
disciplines to produce an industry-wide response, the likes of which haven't been
seen since the private sector's coordinated contribution during World War II.
Regulatory heads and manufacturing heads have been holding meetings as well,
coordinating to minimize duplication of effort, streamline work and advance
efficient testing of compounds and vaccines.
The R&D group is creating working principles to accelerate new COVID-19 therapies
and vaccines agnostic to their market potential , eliminating bureaucratic and
technical or scientific barriers, and focusing on filling gaps not adequately filled by
other initiatives and which the consortium is uniquely suited to address.
NIH-000213
The pharma group's leaders also intend to offer resources to biotechs and
academic groups pursuing countermeasures who may not want to join the effort
but could benefit from expert guidance.
Flying the plane as they build it, the collaborators intend to create a clearing house
of ideas for testing of molecu les and vaccines, with working groups to vet the ideas
and expedite testi ng on the most promising via clinical or preclin ical testing.
According to the participants who spoke to BioCentury, the structure will probably
evolve over time. Currently, the model involves five working groups, for clinical
phase repurposing, novel small molecule antivirals, novel antibodies, prevent ive
vaccines and preclinical repurposing. Each will be headed by a pharma R&D
executive and will be responsible for prioritizing poten ti al compounds and
specifying actions.
Two platform groups will integrate across modalities: a clinical trial acceleration
group and a data sharing group.
"This is not a t ime to think about proprietary information or IP or margins. We

need to break down the barriers and solve the problem," said one participant
involved in the consortium.

To: Stoffels, Paul [JJCUS) (b)(6)>
Subject: RE: Reachingout about partnershipsand COVID-19
Hi Paul,
I have done some work on the idea of an "AMP like" COVID project. As I
mentioned, Mikael Dolsten has been quite enthusiastic. For FDA, Peter Marks,
Janet Woodcock, and Steve Hahn were all extremely positive about this
opportunity for a shared consideration about priorit ies. Tony Fauci and his team
are totally in favor, and the FNIH (David Whalley and Maria Freire) stands ready to
serve as convener . I thought the first step would be a 90 to 120-minute virtual
meeting - hopefully next week. Attached is a draft precis of what t his might look
like; I have left out the roster because that is very much a work in progress.
Meanwhile I saw reports that there are related partnership discussions going on
amongst pharmas: https://www.globenewswire .com/news-
release/2020/03/26/2006713/0/en/Novartis -and-life -sciences-companies-commit -
expert ise-and-assets-to-the-fight-aga inst-COVID-19-pandemic-a Iongsid e-BiiI-
Mel inda-Gates-Foundation. htm I
NIH-000214
I am wondering how this might all fit together.
Do you have a few minutes to speak with me about this? I'm at

----- (b)(
I'd greatly value your advice. Just let me know when you m ight be able to ca ll, so
, and
that I'm not in the midst of a Zoom meeting.
Best, Francis
From: Stoffels, Paul [JJCUS] (b)(6)>

--------
------~~
To: Collins, Francis (NIH/OD) IE]______ Cb
_>_
<6l
Subject: Re: Reaching out about partnerships and COVID-19
Absolutely worthwile . I wi ll write an email in the next hours.

(b)(4) .
Paul
Verstuurd vanaf mijn iPhone
Op 24 mrt. 2020 om 17:55 heeft Collins, Francis (NIH/OD) [E]

(b)(6)> het volgende geschreven:
-------
Hey again Paul,
Really hoping to hear your thoughts on this proposal. FDA is highly

enthusiastic. Dolsten is in. Other pharma R&DChiefs that would be
most helpful? Jay Bradne r ? John Reed? Roger Perlmutter?
Thanks, Francis

To: Stoffels, Paul (b)(6)>
Subject : Reaching out about partnerships and COVID-19
Dear Paul,
I've been thinking that th is is a time where we ought to have the best and
brightest minds from industry, NIH, academia, and FDA around the same
tab le to identi fy ways that we can move the coronavirus agenda forward to
life-saving products as quickly as possible. Several pharmas and biotechs have
been reaching out to NIH to ident ify viral assaysand animal models that can
NIH-0002 15
be run in a BSL-3facility. Other similar contacts I've had with pharma and
biotech tell me that there is a high degree of interest and willingness to
combine forces at this time of crisis.
This isn't exactly a precise recipe for AMP-COVID, but it has some of the same
flavor. Would it be useful for FNIH to convene a virtua l meeting with a few
heads of R&D (hopefully you; Mikael Dolsten has already expressed
enthusiasm; and I'd be interested in your suggestions of others), FDA (Marks
and Woodcock), leaders from NIAID and a few other NIH Institutes with
equity in this space. We might be able to make a short list of catalytic actions
that neither sector can do optimally right now, but together we can do
rapidly .
The focus would be on therapeutics and vaccines. But I can imagine a

separate session on diagnostics .
Does this sound worthwh ile to you?
Thanks, I always value your advice and partnership .
Francis
NIH-000216
Sent : Thu, 2 Apr 2020 10:58:08 +0000
To : Mascola, John (NIHNRC) [E)
Subject: FW: Secretary's Medical Countermeasure Advisory Panel
As per our d iscussion.
From: Kadlec, Robert (OS/ ASPR/IO) (b)(6) >

To: Bright, Rick (OS/ASPR/BARDA) CbH ; Disbrow, Gary (OS/ASPR/BARDA)
< Lambert, Linda (O5/ASPR/BARDA)
CbH6); (b)(6)
Cc:Shuy, Bryan (OS/ASPR/IO) CbH >; Harrison, Brian (HHS/IO5)
(b)( ; Hassell, David (Chris) (OS/ ASPR/IO)
---------
Subje ct: Secretary's Medical Countermeasure Advisory Panel
(b)(6)>
Importance: High
Rick, Ga ry and Linda:
The Secretary has directed me to establish a HHS Senior Adviso ry Panel of key HHS Operating
Divisions( (NIH, CDC & FDA) to include head of agencies or their designees to oversee and
provide recommendations to the Secretary concerning the development and procurement
med ical countermeasures (MCM), (vaccines, therapeutics, diagnostics and devices). In meeting
this direct ive, I have asked Dr. Chris Hassell to organize and serve as the intermediary to
schedu le and coordinate. It is the intent to hold the first virtual meeting of this panel Sunday, 4
April time TBD. The frequency of further meetings wil l be determ ined at the inaugu ral meet ing .
The Agenda should include :
• Overall COVID-19 Strategy & Plan (5 min)

• Activities to Date (e.g. industry outreach, RFP BAA etc.) (5 min)
• High level overview of current MCM portfolio (5 min)
• Detailed briefing of current vaccine technical development efforts, timeline and
costs (30 min)
• Discussion by participants (30 min)
I ask that the materials for this meeting be subm itted by noon April 3 to the APSR 10 to be
reviewed and be distributed to the Panel membership by noon Saturday April 4. Thank you
Bob
NIH-000082
Sent: Tue, 31 Mar 2020 01:57:13 +0000
To : Kavesh, William
Subject : RE:Medical staff need COVID-19 NIH surv ival data on N-95 respirators to help
alleviate shortage
Dr. Kavesh:
Thanks for your note. This issue is now being actively discussed at the Task Force meetings .
No guarantee, but I believe that there will be movement in that direction.
Best regards,
Tony
From : Kavesh, William (b)( >

Subject : Medical staff need COVID-19 NIH surviva l data on N-95 respirators to help alleviate shortage
Dear Dr. Fauci,
The biggest concern of my hospital colleagues is the shortage of protective masks. If any research is
being done that might drive safe reuse of N-95 respirators, no one I know has seen it. These should be
simple studies to do.
If the virus is shown to die within a few days and moisture dries up, then the number of masks
needing disposal could drop drastically.
In that situation, each provider at risk could be given five N-95 masks, one for each day of the week .
The provider would wear the N-95 mask for one working day, say Monday. and then place it into a paper
bag in a secure location. The provider would not use that mask again until the following Monday; ie
seven days later.
The only question, then, would be: how many times can t his be repeated? Will t he mask lose any
protective qualities over time?
Please assign someone to do these studies soon .
I'm also very pleased t hat our national leaders now seem to be listen ing to you more closely.
Thank you for your efforts.
William Kavesh MD, MPH

CMC PhiladelphiaVA Medical Center
NIH-000 117
Sent : Tue, 24 Mar 2020 15:26:47 +0000
To : Gottlieb , Lawrence A.
Subject: RE:Support
Many thanks !
Director
Phone: (b)(6)
FAX: (30 496"44 09
E-mail: (b)(6)
From: Gottlieb, Lawrence A.

-----------
------ --=~
(b)(6)

Subject: Support
-------- (b)(6J>
Dr. Fauci,
Just want to express my support for your indefatigable effo rts to thwart the spread of the Coronavirus.
Many , many years ago, I was a lab assistant for Dr. Edward L. Kuff and Dr. Karen Lueders, at NCI in
building 37 !!! Bravo for all you are doing.
Lawrence Gottl ieb, PMP, MBA, COR,FAC/PPM Ill

Senior IT Project Manager
Enterprise Portfolio Management Division
Office of Information & Technology
US Department of Veterans Affairs
810 Vermont Avenue, NW
(b)(6)
Office: Cb) (6)
Cell: .-!===~~
------ (b)(6)
"Alea iacta est" - Caesar
NIH-000255
VA Core Values: Integ rity Commitment Advocacy Respect Excellence
VA
U.S. Department of Veterans Affairs
Officeof Information andTechnology

nter r st Proa,...m \fo 'll'.l '.1 m, nr ,fnr;
NIH-000256
NIH-000309
NIH-000310
NIH-0003 11
NIH-0003 12
(bX5)-PCI
NIH-000 136
NIH-000 137
NIH-000 138
(bX5) -PCE
NIH-00000 1
~ NIH-000002
Sent : Tue, 7 Apr 2020 13:42:04 +0000
Cc: Greg Folkers (b)(6) )
Subjec t : FW: Keynot e Speaker Invitation - 8t h Interna ti ona l mRNA Health Conference
No!
Director
Phone: (b)(6)
FAX: (301) 496-4409
E-mail: (b) (6)
From: Conrad, Patricia (NIH/NIAID) [E) (b)( •> On Behalf Of Fauci, Anthony
(NIH/NIAID) [E)
Se nt : Tuesday, April 7, 2020 9:33 AM
To: NIAID OD AM (b)(6)>
Subjec t: FW: Keynote Speaker Invitat ion - 8t h Internat ional mRNA Health Conference
From: Pardi, Norbert <pno rbert@pennme d icine.upenn.edu >

Subject: Keynote Speaker Invitation - 8th International mRNA Health Conference
Dear Dr. Fauci,
On behalf of the organiz ing comm ittee, I am writing to invite you to Keynote
the 8th International mRNA Health Conference (http://www.mrna-conference .com/ ) to be held
at the Boston Park Plaza Hotel on Nov 9-10, 2020 .
NIH-000003
The International mRNA Health Conference is a yearly non-profit event collaboratively
organized by Curevac , BioNTech and Moderna. It brings together academic and industry
thought leaders in the mRNA design and delivery space to explore the rapidly evolving science ,
business and regulatory landscape of mRNA medicines. Over the last seven years , this 2-day
conference has become the premier destination for industry and academic professionals to
network with colleagues , learn about the latest advances in mRNA technology, and to attend
scientific presentations given by the most esteemed experts in the field. Notably, it is the only
annual conference dedicated solely to mRNA therapeutics.
As a scientist with tremendous experience and the director of NIAID, the organizing
committee thought that conference attendees would very much appreciate hearing about
your thoughts about mRNA therapeutics, particularly vaccines, and any perspectives you
wish to share.
The organizing committee recognizes that your calendar is likely filled years in advance, but we
all have our fingers crossed that you might be able to fit this into your busy schedule.
I look forward to hearing from you .
all best wishes,
Norbert
P.S. In the event that the COVID- 19 crisis is still curtailing travel in the fall , our backup plan
would be to have a completely virtual meeting on the same dates. We plan to make that
decision in late AugusUearly September.
Norbert Pardi, Ph.D.
Research Assistant Professor of Medicine
Infectious Disease Division
NIH-000004
Philadelphia, PA 19104
PH: 215-746-6552
pnorbert@pennmedicine.upenn.edu
NIH-000005
Sent : Tue, 7 Apr 2020 13:01 :12 +0000
To: Mark Feinberg
Subjec t : RE:Greet ings and an Update : VSV-SARS-CoV-2 Vaccine Development
Thanks, Mark. This e-mail is very inform at ive and helpful.

Best rega rds,
Tony
Director
Phone: (b)(6)
FAX: (301) 496-4409
E-mail (b) (6)
From : Mark Feinberg (b)(6)

--------=-:-:=
(b)(6)>
--------- (b)(6>:>; Fauci, Anthony (NIH/NIAID) [E]
Subje ct: Gr eetings and an Update : VSV-SARS-CoV-2 Vaccine Development
Dear Tony,
I hope you doing well despite yo ur heroically busy schedule and the complexi ty and magnit ude of the
cr itically impo rtant issues you are work ing so hard and effect ively to address. You are providing such
amazing and valuable leadership in the response to COVID-19 and the world is so fortunate to have you
in t hi s key rol e!
(b) (4)
NIH-000006
(b)(4)
Please let me know if you have any questions or would like any additional information . I will keep you
posted (b)(4) .
Be well and hang in there!
Very best,
Mark
NIH-000007
Mark Feinberg, MD, PhD
(b)(6)
NIH-000008
(bX5) -PCP.
NIH-000009
NIH-000010
(b)(S) - PCI
NIH-0000 11
NIH-0000 12
NIH-0000 13
(b)(S) - PC!
NIH-000014
NIH-0000 15
(bX5) -PCE
NIH-000016
(bXS) - PCP
NIH-000017
(bX5)-PCE
NIH-0000 18
Sent : Mon, 6 Apr 2020 17:30:06 +0000
To: Anki Wolf
Subjec t : RE:Elizabeth Glaser
Anki:
Best regards,
Tony
A.nthony S. Fauci, MD
Director
National Institute of Allergy and Iofectious Diseases
National Jnslitutes of Health
Phone: (b)(6)
f AX: (301) 496-4409
E-mail: (b) (6)
The informalion in this e-mail and any of its a1tachmentsis confidential and may contain sensitive information. It
please infonn the sender and delete it from your mailbox or any other storage devices. The National Institute of
Allergy and lnfectious Diseases (NJAID) shall not accept liability for any statements made that are the sender's own
From: Anki Wol____________ (b
""'
)""'
(6)
=

To: Fauci, Anthony (NIH/NlAfD) [E)
Subject: Elizabeth Glaser
--------=-=-=-
------------ Cb)(
HJ Dr. Fauci,
l am (b)(6) you diagnosed with AIDS back in the mid I 980's.

lt was in those early days of the AIDS epidemic that you were instrumental in diagnosing and researching this
dreadful disease.
(b)(6)
My family had been associatedwith the NCI through my uncle, Lou Wasserman, who was a researcher for a period
of time. Lou did much research on polycythemiavera and was a hematologist at Mt. Sinai in NYC. J'm glad that
he's no longer around to witness the devastationof Covid-19.
I was impressed with your knowledge at the time of (b) (6ldiagnosisand I am even more so in these times of the
Covid-19 pandemic. Thanks for being the intelligent and informative face of the facts on the virus. There are many
around the country who rely on your wisdom but also on your facts and data.
Stay well, stay healthy, and keep providing the country with what we need to know and do.
Be st,
NIH-0000 19
Anki Wolf
NIH-000020
Sent : Mo n, 6 Apr 2020 17:27:18 +0000
To: (b)(6)
Subject: FW: clinical trials of Oral LL-37 on COVID-19
Attachments : LL-37 ethic.pdf, three pati ents clinic al study.pdf, CAS001 Subchronic toxicity
experiment.pdf, Internat ional research programme( l ).pdf , Wanzhu Jin CV.pdf
Any suggestion of what to do with this type of thing? Can you have someone
respond to them.
Thanks,
Tony
Director
Phone : (b) (6)
FAX : (301 496-4409
E-mail : (b) (6)
From: JINWan-Zhu (b)(6)>

-------= = ·>; sunok301
-------
Subject: clinical trials of Oral ll-37 on COVID-19
(b)(
-------- (b)(6)
Dear Dr. Anthony S Fauci:
Thank you very much for your hard work on COVID-19. You are the hero of word!
This is Prof. Wanzhu Jin prof. Institute of Zoology, Chinese Academy of Sciences .
(b) (4)
NIH-00002 1
(b) (4)
NIH-000022
(b) (4)
Many thank s in advances !
Wanzhu Jin & Gang Sun
NIH-000023
Sent : Mo n, 6 Apr 2020 16:41 :38 +0000
To : info@marianneorlando.com
Cc: Grady, Christine (NIH/CC/BEP) [El
Subjec t : FW: Fauci superhero
M arianne:
M any than ks for doi ng and sendin g t his.
Best rega rds,
Tony
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
have received this e-mail in enor please inform the sender and delete it from your mailbox or any
From: Marianne Orlando <info@ma rianneorlando .com>

Se nt : Friday, April 3, 2020 6:55 PM
To : Fauci, Ant hony (NIH/NIAID) [E]
------ ~=
(b)(6)
Subject: Than k you, sir
Dear Dr. Fauci,
Being a freelance illustrator, I am tryin g t o keep myself producti ve dur ing thi s
life-altering pandemic by doing a ser ies of COVID-19 inspired drawings.
This is my late st, tha t I call: "My Personal Superhero."
I dedicated it to you like thi s: "In his own, quiet way, he is a BadAss:
Disseminating info about thi s disease calmly and, always, backed by science ."
NIH-000024
Here is my drawing:
So, Thank you, Sir. You are the voice of reason in what has been a dangerous,
frightening situation. You are a real leader.
Thank you,
Marianne Francesca Orl ando
Thank you ,
Marianne Orlando
Marianne Orlando Illustrations (b)(6)
NIH-000025
(b)(6)
cell: .!:-'.-------.
landline: (b)(6)
MARIANNE:44 .. 1.J-gL.,.,.f-;A.,,._.j _
0 RLANOO WM/YV'fMIVIATf'VY
info@marianneorlando.com
www.marianneorlando.com
NIH-000026
Sent: Mo n, 6 Apr 2020 14:57:23 +0000
Subject : FW: Request for yo ur support in promoting new WHO recommendation for
emergency response operation to provide universal accessto mandatory hand hygiene against COVID-
19
Atta chmen ts: who -interim -recommendation-on -obligatory -hand-hygi ene-against-
tr ansmission-of-cov id-19 .pdf
Let us discuss. I am not sure what I should do with this. Thanks.
Director
Phone: (b)(6)
FAX: (301) 496-4409
E-mail : (b)(6)
From: HOYER,Stefan Detlef Leo (b)(6)·>

-------
To: Fauci, Anthony (NIH/ NIAID) [E)------= (b)
""'(6)
=>
Cc: Emanuele CAPOBIANCO
~-:--:-====~~-- Cb)(6>b; GORDON,Bruce Allan
------- (b)( 6)t >; ROGERS,Paul (b)(6)

Subject: Request for your support in promoting new WHO recommendat ion for emergency response
operation to provide universal access to mandato ry hand hygiene against COVID-19
Import ance: High
Dear Dr. Fauci
Please find enclosed the new WHO recommendat ion on establishing universal access to hand hygiene
stat ions at thresholds of pub licly accessible buildings and means of publ ic transport. It is now officially
published at : https://who.int/who-documents-detail/interim-recommendations-on-obligatory-hand-
hygiene-against-transmission-of-covid -19 I attach a pdf copy for easy reference .
I wou ld like to request your support in promoting the recommendation as part of an international
emergency response operation providing un iversal accessto mandatory hand hygiene and/or sanitat ion
against COVID-19 infect ions. Provided it is now made available and made ob ligatory whenever entering
NIH-000027
and leaving a facility to wh ich the general public has access, it could become possible to prevent most
smear infections by decontaminating all hands prior and after each possible contamination, both active
or passive. In addition, the measure should massively reduce transmission of other viruses and bacteria
currently burdening diffe rential diagnosis of COVID-pneumonias. Based on the excellent experiences
made with t he acceptability and adherence during Ebola outbreaks, repeated mandatory hand hygiene
or sanitation should thus become an almost unconscious routine of everyday life for any person having
to leave his or her private home in Corona-affected countries.
I have been asked by senior WHO emergency management to promote the WHO recomme ndati on for
rapid implementation with particular focus on current COVID-19 transmiss ion epicenters such as the
USA. Providing a systematic access to hand hygiene stations and making their use obligatory prior to
entering and whenever leaving any public facility will also provide a safety net whenever current
restrictions on movements and commerce are to be progressively reduced. Given the high resource
settings in the current COVID-epicentres, and the negligi ble cost of implemen ting this public health
emergency measure compa red to prolonged mass confinement without safe exit strategy, I do presume
that the wherewithal to carry it out will not be limiting facto r.
Thank you for considering the collaboration in this emergency measure proposed within th e USA at the
largest possible scale. WHO has requested IFRCto alert the American Red Cross to support large scale
implementation should your Government decide to implement the public health measure proposed.
With best wishes for success in all of your endeavours,
Stefan Hoyer
Dr Stefan Leo Hoyer

Medical Officer
Focal Point for Emergencies
Global Malaria Programme
t:
m: ______
(b) (6)
------
e: (b) (6)
w: www.who.int/ma laria
WorldHeaIth
Organization
NIH-000028
Sent : Mon, 6 Apr 2020 13:40:45 +0000
To : Jameson,James L
Subject : RE:COVID-19 Rx
Than ks, Larry.
Director
Phone: (b)(6)
FAX: (30 496"'4409
E-mail: (b)(6)
From : Jameson, James L (b)(6)>

Sent : Monday, April 6, 2020 9 :35 AM
To: Anthony Fauci (b) (6) >
(b)( 6) >
Subjec t: Re: COVID-19 Rx
---------- (b)( ; Fauci, Antho ny (NIH/NIAID) [E)
Tony,
Tcompletely understand - we are all thinki ng about you as you help the country .navigate this
crisis - thanks so much. Let me know if there is any way that I, or people at Penn, can be helpful. Our
scient ists, severa l of whom are Coro navirus experts (Susan Weiss, Paul Bates), have coalesced form a
Center to focus on potential treatme nts and immuno logy related to the virus. I list few below and you
might triage to others to flu further:
(b) (4)
NIH-000029
(b)(4)
Best regards,
Larry
From: Anthony Faud (b)(6)>

Date: Monday, April 6, 2020 at 8:25 AM
To: "J. Larry Jameson" (b)(6)>
Cc: Dennis Kasper --=========::.....-=-c-"C=s (b)(6)>, Joseph Loscalzo
_____ ....:.,_...:::====- (b;:::
)(;;6);;-J:-a-m_e_s_S
::h- a_n_a-;-
h-a_n_ ---------------, (b
a-:
),...,.
(6)
=
Subje ct : Re: COVID-19 Rx
Larry:
I am so sorry that I have not gotten back to you and others in so long. I am completely swamped (3 to
4 hours sleep per night just does not work very well) and have not been able to even check my non-NIH
(b)(6) . I will try my best to catch up soon. Thank for your understanding .
Best regards,
Tony
On Fri, Mar 13, 2020 at 9:33 AM Jameson, James L

Dennis and Ton
--------- (b)(6)wrote:
(b)(4)
Best rega rds,

Larry

Editor, Harrison's Principles of Internal Medicin e
NIH-000030
From: Fauci,Anthony (NIH/NIAID) [E]
Sent: Mon, 6 Apr 2020 02:27:39 +0000
Cc: Conrad, Patricia (NIH/NIAID) [E);schoofs@usc.edu
Subje ct : FW: 2nd try: Mark Schoofs reaching out
Kim:
Please have me call Mark tomorrow.
Thank s,
Tony
From: Mark Schoofs <schoofs@usc.edu>

Sent: Sunday,April 5, 2020 7:28 PM
To: Fauci, Anthony (NIH/NIAID) [E],------- ~(b-:-
)(= >; Fauci, Anthony (NIH/NIAID) [E]
(b)(6)
Subject : 2nd try: Mark Schoofs reaching out
Hi Tony,
God knows you are doing the world' s most important work right now, but if possible, I would
love to talk with you for my COVID-19 project . I promised to keep it under 10 minutes, probably
just 5.
My cell:
------ (b)(6)
All best ,
Mark
From: Mark Schoofs

Sent: Saturday, March 28, 2020 10:04 AM
To
---------------------------
Subject: Mark Schoofs reaching out
(b)(6)
Hi Tony,
I hope you're hanging in there! If you have 5 minutes - 10 max - I'd like to talk with you for a
COVID-19 project I'm working on .
My cell is
----- (b) (6) .
Thank you .
NIH-00003 1
All best,
Mark Schoofs
Visiting Professor of Journalism
University of Southern California
NIH-000032
NIH-000033
NIH-000034
Sent: Sun, 5 Apr 2020 15:59:51 +0000
Subject: FW: GPMB: M ESSAGEON BEHALFOF THE CO-CHAIRS:PROPOSEDBOARD
TELECONFERENCE - 30 MARCH 15:00 CEST
Attachments: Statement on the COVID-19 pandemic and the Extraord inary G20 leaders'
Summit - 1Apr2020 .pdf, GPMB Teleconference 30 March 2020 - Meeting Report 1 Apr 2020.pdf
Please check th is out and let me know if there is anything we need to do. Thanks.
From: RIOUX,Amelie (b)(6)

To : Fauci, Anthony (NIH/NIAID) [E] --------=~ (b)(6)>
Cc:Marston , Hilary {NIH/NIAID) [El (b)(6)>; Steven T. Smith (b)(6) ;
Conrad, Patricia (NIH/NIAID) [E) (b)(6) >; SMITH, Ian Michael (b)(6)
Subject: FW: GPMB: MESSAGEON BEHALF OF THE CO-CHAIRS:PROPOSEDBOARDTELECONFERENCE -
30 MARCH 15:00 CEST
Dear Dr Fauci,
Please find attached the meeting report fro m the GPMB teleco nference o n 30 Mar ch 2020 and the
GPMB co-Chairs' Statement on the COV/0-19 pandemic and the Extraordinary GlO Leaders' Summit on
COV/0-19. I apologize, your email was deleted by mistake in the last two messages to the GPMB.
With kind regards,
Amelie
GPMB Secretariat
From : RIOUX,Amelie
Sent: Friday, 3 April 2020 14:18
To: 'VDzau@nas.edu' (b)(6)>; J.Farrar (b)( >; 'hfo re@unicef.org'
(b)(6)>; 'Gao Fu' (b)(6)
':'"'.""--::======~,;;--.---:-:--:-:--:-.==========,=;e:;;-
' Gashum ba Diane' (b)(6)> ; Ilona Kiekbusch (b)(6);
---!:==== (b
":":
)=(6)
~--
'Skvortsova Vero nika' (b) ( >; 'Vega Morale s Jeanette'
(b)(6)
Subject: RE:GPMB: MESSAGEON BEHALFOF THE CO-CHAIRS:PROPOSEDBOARDTELECONFERENCE

- 30
MARCH 15:00 CEST
Dear Board Members,
NIH-000035
Please find the link to the GPMB co-Chairs' Statement on the COVID-19 pandemic and the Extraordinary
G20 Leaders' Summit on COVID-19 (also attached):
https://apps.who.int/gpmb/assets/odf/Statement%20on%20the%20COVID-
19%20pandemic%20and%20the%20Extraordinary%20G20%20Leaders'%20Summit%201Apr2020.pdf
We encourage you to circulate the Statement through your channels. You may wish to use the origina l
hashtag fro m our report #AWorldatRisk in social media posts.
Wi th kind regards,
Amelie
GPMB Secretariat
This message is being sent to GPMB members and their designated staff in copy.
From: RIOUX, Amelie

Sent: Wednesday, 1 April 2020 16:42
To: 'VDzau@nas.edu' (b)(6J; J.Farrar (b)(6)
; 'Gao Fu' Cb)(6)
----======-==---::--------=======~=;:-
; 'Gashumba Diane' Ilona Kiekbusch
(b)(6)>; (b)(6J;
'Skvort sova Veronika' (b) ( >; 'Vega Mor ales Jeanette --=======~.---
(b) (6)
(b)(6)
Subject: RE: GPMB: MESSAGEON BEHALFOF THE CO-CHAIRS:PROPOSEDBOARDTELECONFERENCE

- 30
MARCH 15:00 CEST
Dear Board Members,
On behalf of the co-Chairs, please find attached the report from Monday's teleconference.
With kind regards,
Amelie
GPMB Secretariat
This message is being sent to GPMB members and their designated staff in copy .
From : RIOUX, Amelie

Sent: Tuesday, 31 March 202009:17
To : 'VDzau@nas.edu' (b)(6J>; J.Farrar (b)(6)
(b)(6)
>; Ilona Kiekbusch
--------- (b)( (b)(6J>;
NIH-000036
'Skvortsova Veronika' (b) ~ >; 'Vega Morales Jeanette' (b)(6)>;
(b)(6)
(b)(6)
Scott Dowell
(b)(6) W illiam
-H:-a-::-
11==========================. (b
~)~(;::;-
'=T:-
e-re_s_
a ~Miller de
---:-:===================---~-- (b)(6)
(b)(6)
(b)(6)
(b)(6)
; 'office-psa@nic .in' <office-psa@nic.in >; Toomas

(b)(6)>; GPMB Secretariat <gpmbsecretariat@who.int >; GABEDAVA,Tsira
_-...::====::e::::,,,,:;---:--
(b)( 6) >; 'Steve Landry' (b)( >
--------
Subjec t: RE: GPMB: MESSAGEON BEHALFOF THE CO-CHAIRS: PROPOSEDBOARDTELECONFERENCE - 30
MARCH 15:00 CEST
MESSAGEON BEHALFOF THE GPMB CO-CHAIRSDR BRUNDTLANDAND MR SY
Dear GPMB Members,
Many thanks for your contributions to our teleconference, and to Jeremy and Victor for their very
helpful report on the GPMB COVID-19 advocacy.
Several of you mentioned that you had additional points that you might wish to make in writing; please
do so as soon as possible, copying them to all Board members.
If you have not already nominated a 'sherpa ' to represent you in the informal support group that will
work with the secretariat, please do so as soon as possible. The secretariat is organizing a
teleconference with the informal support group to follow up on the direction given by the Board on the
annual report and work plan .
Kind regards,
Gro &As
GPMB Co-chairs
NIH-000037
From: RIOUX, Amelie
Sent : Monday, 30 March 2020 12:19
(b)(6)>; J.Farrar (b)(6)
'Gao Fu' (b)(6)
"'":"'"----:======~~-:---'"""':""~--:--::::====
; 'Gashumba Diane' (b)(6); Ilona Kiekbusch (b)(6)>;
'Skvor ts ova Veronika'
-----!::::::~~;--:------
(b)(6) ; 'Vega Morales Jeanette' (b)(6);
(b)(6)
>
>; SMITH, Ian Michael
(b · SCHWAR , ernhard F. (b)(6) ; RYAN, Michael J.
====~~~ ·
(b)( >; 'Pate Muhamed' (b)(6l; 'Goda I, Tore' (b)( >;
'Tore Godal' (b)(6)>; Alveberg, Bened ikte Louise (b)(6)>;
(b)(6)
Scott Dowell
(b)(6) William
-"'.':":==========================::;: (b:;:
)(~6);-'~T-e-re_s_
a _Miller de
(b)(6)
(b)(6)
(b)(6)
(b)(6)
'office-psa@nic.in' <office-psa@nic.in >; Toomas

(b)(6); GABEDAVA,Tsira
=========-=-
-------- (b)( 6); 'Steve Landry' (b)( >
Subject: RE: GPMB: MESSAGEON BEHALFOF THE CO-CHAIRS:PROPOSEDBOARDTELECONFERENCE - 30
MARCH 15:00 CEST
Dear Board Members and Colleagues,
A kind reminder that Europe has switched to Daylight Saving Time over the weekend.
The call takes place today at 15:00 Geneva time, which is 06:00 Seatt le time, 09:00 DC time, 21:00
Beijing t ime, and 22:00 Tokyo time.
Best,
Amelie
From : SMITH, Ian Michael (bH >

Sent: Friday, 27 March 2020 19:19
(b)(6)>; Chris.Elias (bH >; J.Farrar
To :
------------
NIH-000038
(b)(6)
Fu' Cb)(6)
--".'-:::======-=~~~--"'."".""-~-=======:-=~
umba Diane' (b)( >; Ilona Kiekbusch (b)(6)>;
-----.::::====:~i:'.""'.'"--:-:--
'Skvortsova Veronika' (b)(6)'Vega Morales Jeanette' (b)(6)
(b)(6)
(b)(6)
(b)(6)
(b)(6)
(b)(6)>;
>; 'office -psa@nic.in' <office-psa@nic.in >; Toomas Palu

GPMB Secretariat <gpmbsecretariat@who.int >; GABEDAVA,Tsira ----.!::::==-=~~----
(b)(6); 'Steve Landry'
(b)(6) RIOUX, Amelie (b)(6)
--------------
RE: GPMB: MESSAGEON BEHALFOF THE CO-CHAIRS: PROPOSEDBOARDTELECONFERENCE
Subject: - 30
MARCH 15 :00 CEST
Dear Board members, dear Colleagues,
Thank you very much to those of you who confirmed your participation in t he teleconference on
Monday from 15.00-16.00 CET. If you have not done so yet, we would be grat eful if you could let us
know as soon as possible .
If you cannot attend, the co-Chairs would welcome your written comments in advance of the call.
In prepa rat ion for the call, please find attached:

1. Agenda
2. Extraord inary G20 Leaders' Summit Statement on COVID-19 (shared with you earlier)
3. Update on the GPMB urgent COVID-19 funding call from the GPMB COVID-19 sub group
4. Overv iew of Existing Global Appeals and Funding Mechanisms for COVID-19 (for informatio n)
The call- in details are copied below .
Please note that as several of you have nom inated an Alternate to attend on your behalf, the co-chairs
will invite Board Members to speak first, followed by Alterna tes speaking on behalf of Board memb ers.
NIH-000039
Given the very limited time, the co-Chairs have asked that keep your interventions as short as possible.
We look forward to the call. Please let us know if you have any questions.
With kind regards,
Ian Smith
GPMB Secretariat
********
Call-inDetails:
By clickingon the link Accessvia Web, you will find local and toll-free call-in numbers.
Participant access
-------- (b
'""
)...(.-..
4) Optional dial-in numbers
internationa l
+41 58 262 07 22 (English) +41 58
262 07 44 (Italiano) +41 58 262
Security code: For this 07 11 (Deutsch) +41 58 262 07 33
conference a Security (Fran~ais)
code is not necessary.
Access via Web
From: RIOUX,Amelie
Sent: Wednesday, 25 March 2020 14:16
To: (b)(6)JeremyFarrar' (b)(6)
----==============~
Anthony Fauci (b)(6);Gao Fu (b)(6)>;
(b)(6)· Gashurnba Diane CbH6l>;Ilona Kiekbusch
:;:::::======~~--
(b)( 6) >; Skvortsova Veronika (b)(6)>;Vega Morales Jeanette
(b)(6)
Cc: (b)(6);As Sy CbH6J; SMITH, Ian Michael

SCHWARTLANDER,
Bernhard F.======== Cb
"">
;:;~=
6) RYAN,Michael J_..:====~~ >; Pate
Muhamed (b)(6)>;GodaI, Tore< (b)(6)>;Tore Godal (b)(6);
NIH-000040
Toomas Palu (b)(6J>;GPMB Secretariat CbH6J;GABEDAVA,Tsira
------==~~-----
(b)(6)> -----------
Subject: GPMB: MESSAGEON BEHALFOFTHE CO-CHAIRS:PROPOSED
BOARDTELECONFERENCE
- 30
MARCH15:00 CEST
MESSAGEON BEHALFOFTHE GPMBCO-CHAIRSDR BRUNDTLANDAND MR SY
Dear Board Members,
We wou ld like to propose to hold a Board teleconference on Mond ay 30 March 2020, 15 :00-16:00 CEST
time. The purpose of the call will be to updat e you on the GPMB's COVID-19advocacy and t o discuss
next steps. A more detailed agenda and call-in details will be shared shortly .
------
We wou ld appreciate if you could confirm your participation to Amelie Rioux (b)(6)
Thank you for your continued support and engagement.
With kind regards,
Gro and As
NIH-00004 1
Sent : Sun, 5 Apr 2020 01:57:37 +0000
To: Teri McPeak
Subject: RE:Association between Proton Pump Inhibitors and increased risk of Covid-19
death
Thanks, Teresa.
From: Teri M cPeak <t.mcpeak@live.ca>

To: Fauci,Anthony {NIH/NIAID) [E]______ """
(b""""
)(=6)
Subject: Association between Proton Pump Inhibitors and increased risk of Covid-19 death
Dr. Fauci,
There is a wealth of medical rese arch papers about the association between Proton Pump
Inhib itors (PPI) and increased risk of community acquired pneumonia. Long term use of PPls
reduce the pH of the stomach from 1 to 5. This reduction in stomach acid reduces the body's
ability to fight viruses.
In addition, the lower stomach pH reduce the ability to absorb key nutrients that require
gastric acid for breakdown and absorption (calcium, vitamin C & 812, iron, magnesium,
potassium, zinc). Lack of proper nutrients lead to a compromised immune system.
Seniors and individua ls with chronic illnesses are at higher risk of ploypharmacology and dying
from Covid-19 due to PPls. The more medicat ions an individual tak es, the more likely they will
suffer from acid reflux and thus be prescribed a PPL
Thank you for your commitment and compassion during the pandemic. God bless you.
Regards,
Tere sa McPeak
(b)(6)
NIH-000042
Sent: Sun, 5 Apr 2020 01:54:27 +0000
To: Silver, David (NIH/NCI)[C]
Subject: RE:Question
David:
Thanks for the note. Since they both effected adequa t e quarantine, they are OK with each
other ....provided that they practice physical distancing wit h everyone else, i.e. 6 feet apart and
masks when out in situations where they cannot guarantee 6ft distance. With regard to your
second question, it is not a question of temperature, it is a question of what surface the virus in
on - stainless steel versus cloth, versus cardboard. Each of these have differ time frames of
survival of replicatio n competent vi rus from a couple of hours to about 2 days.
Best regards,
Tony
From:Silver, David (NIH/NCI) [C)

--------
(b)(
To: Fauci,Anthony (NIH/NIAID) [E] -------= (b,.,.

) =,
(6)
Subject: Question
Dr. Fauc i,
You are doing a great job and I am sure that things must be very challenging.
Please let me know your thoughts on this, although I think I know the answer.
Is it safe for them to

see eac h other at this point?
I was also wondering if it has been determined how long COV ID-19 can live in a refrigerato r or
freezer.
Thank you.
Stay Healthy.
David
David Silver - Contractor

(b)(6)
National Institutes of Health , NCI

Center for Biomedical Informatic s and Informati on Techno logy (CBIIT)
9609 Medica l Center Dr.
NIH-000043
NIH-000044
From: (b)(6)
Sent : Sat, 4 Apr 2020 15:50:32 -0400
To: anthony trocchi
Subjec t : Re: An aquaintence from the past
Tony:
Thank you for your note. I hear you!
Best rega rds ,
Tony
> On Apr 4 , 2020, at 12:25 PM , anthony troccbi

>
-------- (b)(6) > wrote:
>
> Hi Tony, You pro bably don't rememb er me, Twas (b) (6) husband back when she was at NIH, you
came to dinner at our hou se once. We also hung out in Boulder and drank beer together. I am just a working clas s
guy, but keep up with science and politics for what it is worth. I don't know what you hear from the street level, but
from here in . NY we are pretty concerned with the risk of Covid-19 and the Federal response to the pandemic. You
have been the only reasonable voice in the administration. The leadership from the top is utterly lacking and
incom pete nt and dangerous to the American people. You have had a long and venerab le career and I am asking you
to stand up to power and speak the harsh truth to the peop le o f this country and the without regard to your personal
consequences. We need a u11ifie d and professiona l federal response to this unprecedented c1is is. I think you may be
the only person of re pute and status that ha s the power to change the course of h istory. I have spoken witti a good
fr iend of mine who is a respected epidemio logist and he said that Covid-19 will infect half the population of the
world an d those numbers are frightening statistically. My dad was born during the first worldwide modern pandemic
and I don't really want to see him leave from this current one. I know I am somewhat out of place writing to you,
b11ton e can onl y do what one can do to influe nce the events that hist ory arises from. With utmost respect. Tony
Trocchi
NIH-000045
From: (b)(6)
Sent : Sat, 4 Apr 2020 15:42:37 -0400
To: Stuart Coulter
Subject: Re:Early Successesin ClinicalTrial on COVID-19Patients with High DoseIV
Vitamin C
Thanks, Stuart. I appreciateyour sendingme this information. I will pass it on to relevant

program people.
Best regards,
Tony
On Apr 4, 2020, at 3:38 PM, Stuart Coulter (b)( >wrote:
Dear Dr. Fauci,

Early Successes
in ClinicalTrial on COVID-19Patientswith High DoseIV Vitamin C
Thank you for the invaluable work that you are doing in guiding the United States
through the current COVID-19 pandemic.
I hope that you do not mind me contacting you, but I wanted to bring your
attention to a clinical trial that is currently taking place in China on COVID-19
patients with high dose IV Vitamin C.
There are reports of some early successes with this treatment and I wondered if
this cou ld be a possible stop gap treatment - that cou ld possibly save many lives -
whi le we awa it the development of suitable drug treatments and a reliable
vaccine.
The trial in China is not due to conclude until September of this year, however,
previous trials of IV Vitamin C have shown it to be a very safe treatment with litt le
or no adverse side effects. I have read tha t the Northwell Hospital Group in New
York, which operates 23 hospitals, have already started to give this treatment
to many of their COVID-19 patients.
This treatment also appears to meet the normally required criteria for a clinic trial.
The treatment has been shown to be:
1) Effective (Please see the link below to the promising tria l results currently taking
place in China).
2) Safe (The treatment has been shown to be safe in many previous tr ials going
back well over 40 years).
3) Correct dosage is understood (The dosage is fully understood - please see the
attached Protocol).
4) The correct patients to give this treatment to (Virtually everyone in hospital
infected with COVID-19).
5) The correct time in the illness to give the treatment (As soon as the infected
patient comes into hospita l).
NIH-000046
I hope that you and your team find the details of this clinica l trial of some interest.
The hospital protocol for this treatment is attached and here is a link to details of
the current trial in China along with some other relevant links:
http://www.orthomolecular.org/resources/omns/v16n18.shtml
http://orthomolecular.org/resources/omns/vl6n21.shtml
https://www.sciencedirect.com/science/article/pii/S2590098620300154?via%3Dih
ub
Kind regards,
Stuart Coulter
<Journal Pre-proof - Can early and high intravenous dose of vitamin C prevent and
treat corona virus disease 2019 .pdt>
<Protocol - IV AA-COVID19-Hospital-Use-Anderson-03.24.2020.pdt>
NIH-000047
From: (b)(6)
Sent: Sat, 4 Apr 2020 12:42:38 -0400

To: Conrad, Patricia (NIH/NIA ID) [E]
Subject: Fwd: Interview Request: #1 Hiking Podcast
FYI
Fro m : Zach Davi s <zac h@thetrek.co >

--------==
To: "Fauci , Anth ony (N IH/N JAID ) [E]"
--------
Subject: ln terview Request: #1 Hikin g Po dcas t
CbH
Hey Dr. Fauci-
My name is Zach Davis, I'm the founder and editor-in-chief at The Trek, a
media company dedicated to long distance backpackers. Thank you for the
tremendous service and leadership you've given this country during a time
of great need.
I'm reaching out to inquire about the possibility of your doing a short
interv iew for our fl agship podcast, Backpacker Radio, the #1 rated hiking
podcast on iTunes. We're putting together an episode related to how
COVID-19 has impacted this year's class of backpackers, and would love to
feature your expert insight on why social distancing is i mportant, and what
the future may hold for our community.
The interv iew would be alx>ut 20-25 minutes, though if you're only
availab le for a shorter period, we'll take what we can get!
Thanks for your time and thank you again for your terrific service to this
country.
Happy hiking,
Zach Davis
founder 11 editor-in-chief
hikerlink I thetrek.co I backpackerradio
NIH-000048
NIH-000049
From : Fauci,Anthony (NIH/NIAID) [E)
Sent : Sat, 4 Apr 2020 16:25:36 +0000
Subjec t : RE:AFRICACDC:STATEMENTON MEDICATIONSTO TREATNOVEL
CORONAVIRUSDISEASE
Good for them!! !
From: Folkers, Greg {NIH/N IAID) (E] (b)(6)

Sen t: Saturday, Apr il 4, 2020 12:2 1 PM
Subject: AFRICA CDC:STATEMENTON MEDICATIONSTO TREATNOVELCORONAVIRUSDISEASE
NIH-000050
Sent : Sat, 4 Apr 2020 15:18:14 +0000
To : Barasch, Kimberly (NIH/NIAID) [CJ
Subjec t : FW: Excellent start to COVID PPP
Attachment s: COVID PPPApril 3 actions.docx , Introductory call short bios - 3 Apr 2020
fi nal.docx
Please pri nt out these attachments and put into a folder labelled "COVID-19 Public Private
Partnerships" Thanks.
From: Collins, Francis (NIH/OD) [El (b)( >

To : (b)(6) (OS/IOS) (b)(6)
Cc: Harrison, Brian (HHS/10S) (b)( ; Tabak, Lawre nce (NIH/OD) [El
---------- (b)(6); Fauci, Anthony (NIH/NIAID) [El

Subject : Excellent star t to COVID PPP
(b)( >
Hi Mr. Secretary,
Just wanted to let you know - we had a very productive and significant two-hou r virtua l meeting with
leaders of industry, FDA, and NIH yesterday . I attach the bios of those who attended - which includes
the heads of R&D of nine major pharmaceutica l companies. There is unanimous support for bringing
together all of the sectors to accelerate development of therapeutics and vaccines for COVID-19. Tony
compared this to what happened in the early 1990s that led to successful ant ivirals for HIV.
I attach the action items t hat came out of this meeting . Working groups for each of the four main top ics
will be rapidly organ ized. I will keep you posted .
Best, Francis
NIH-00005 1
From: (b)(6)
Sent : Fri, 3 Apr 2020 16:42:08 -0400
To: Cantor, Harvey l.,M.D.
Cc: NIAIDODAM
Subject: Re: COVID-19
Harvey:
Thank you for your kind note. It is much apprec iated. I will let the team know about your
willingness to serve on committees and study sections .
Best regards,
Tony
On Apr 3, 2020 , at l :20 PM, Cantor, Harvey I.,M.D.

(b) (6)>wrote:
Dear Tony,
In t hese unsettli ng t imes, you are a much-appreciated voice of reason and

proponen t of rationa l science.
A great credit to NIH and NIAID...we're all very proud of you.
I know that you have long advocated preparation of viral vaccines against
future pandemic threats.
I'm sure tha t it has been difficu lt to convince pharmas, charitable agencies
and even the government to fund these efforts.
which would include vaccine production and storage for indefinite periods.
Perhaps there will be a greater will ingness to
revisit a cost-benefit analysis of this effort in the near future.
I would be happy to serve on comm ittee s, study sections etc. in an effort to

increase our ability to identify and fund first-rate
Immunology research that might accelerate innovative, safe and effective
approaches to improved viral vaccines going forward.
All very best regards, h.
Harvey Cantor, MD
Baruj Benacerraf Professor of Immunology
Department of Immunology,
Harvard Medical School
Dept. of CancerImmunology &Virology,
Dana-Farber CancerInstitute
NIH-000052
Boston MA02215
(b)(6)
addressed. If you believe this e-ma il was sent to you in error and the e-mail
contains patient infonnation, please con tact the Pattners Compliance HelpL ine at
http ://www.partners .org/compliance line. If the e-mail was sent to you in error
but does not conta in patient information, p lease contact the sender and properly
NIH-000053
From: (b)(6)
Sent : Fri, 3 Apr 2020 16:29 :45 -0400
To: Hasenkrug, Kim (NIH/NIA ID) [E]
Subject: Re: Thanks from the troops
Kim:
Many thanks for your kind note .
Best regards ,
Tony
On Apr 3, 2020 , at l :56 PM , Ha senkrng, Kim (N IH/NIAID) [E]

(b)(6)
Hi Tony, I j ust want to express my sincere gratitude for all you are doing
to get us through this crisis. Everyone I've talked to at RML expresses
their deep admiration and apprec iation for your strong leadership, and
we feel proud to be working for you. We listen to your hoarse voice
every day. Personally, I have started two new lines of research to
develop and test possible therapeutics for COVID-19. The cooperation
and collaboration from everyone I've talked to , both here and around
the nation, has been unb elievable. Please take care of yourself and stay
strong and healthy for the sake of all of us !
Best regards,
Kim
Kim J Hasenkrug, Ph.D.

Senior Investigator
Chief, Retroviral Immunology Section
Laboratory of Persistent Viral Diseases
Rocky Mountain Laboratories
National Institut es of Health
903 S. 4th Street
Hamil to n, MT 59840
(b)(6)
phon e
------
NIH-000054
FAX (406)363-9286
(b)(6)
Disclaimer:
The information in this e- mail and any of its attachments is confidential
who
is not the original intended recipient. If you have received this e-mail in
error please inform the sender and delete it from your mailbox or any
other
storage devices. National Institute of Allergy and Infectious Diseases
NIH-000055
(bX5)-PCI
NIH-000056
NIH-000057
NIH-000058
Sent : Fri, 3 Apr 202011:07:58 +0000
To : Ghafoor, Azam (NIH/NCI) [El
Cc: NIAIDODAM
Subject: RE: Help
Thanks for your note. I will circulate to others in NIAID
From: Ghafoor, Azam {NIH/NCI) [E] _______ Cb

_H_6)>
To: Fauci, Anthony {NIH/NIAID) [E] ______ """
(b""""
)(=6)
Subject: Help
Dear Dr. Fauci,
I am thoracic oncologist at the NC I. I wanted to commend you on your tremendous (and

exhaust ing) job on managing and steering our country with the COVID - 19 pandemic. If you
need add itiona l any personnel to help with any clinical or non-clinical aspects of the current
situation, I am more than happy to help. As you know we have scaled down our clinical
operations and trials at the NIH CC and so I have more time.
Best regards,
Azam Ghafoor, MD
Assistant Research Physician & Staff Oncologist
Thoracic Oncology Section
Thoracic and GI Malignancies Branch
National Cancer Institute, National Institutes of Health
10 Center Drive, Building 10, Room: 4G-5330
Bethesda, MD 20892
e: (b)(6)
o: (b)(6)
c: --==--
page ID Cb)(6)
NIH-000059
Sent: Fri, 3 Apr 2020 02:40 :47 +0000
To: David Barr
Cc: Giroir, Brett (HHS/OASH) ;Conrad, Patricia (NIH/NIAID)[El
Subject: Introduction
David:
I am using this e-mail to introduce you to Adm. Brett Giroir who is the Assistan t Secretary for
Health at HHS and a key member of the Coronavirus Task Force. I have explained to Brett the
issues that you and your colleagues brought up over the phone with me the ot her night. Brett
is willing o get on the phone with the group and go over some of t hese issues and per haps help
t o resolve them. He is wait ing o hear from you. Many thanks.
Best regards,
Tony
Director
Phone: (b) (6)
FAX:(301 496-4409
E-mail: (b)(6)
other storage devi ces. The Nat ional Institute of Allergy and Infectious Diseases (NIAID) shall not
NIH-000060
Sent: Fri, 3 Apr 2020 02:10:12 +0000
To: Stephen Hahn
Cc: (b) (6)'
Subject: FDA release
Steve:
My staff just pointed out to me a _proposedFDA press release regarding convalescent plasma
and hyperimmune globulin. The press release reads as follows:
(b) (5)
I just wanted to bring this to your attention for further consideration. Many thanks.
Best regards,
Tony
NIH-00006 1
Sent: Fri, 3 Apr 2020 01:53:59 +0000
To: Emilio Emini
Cc: Conrad, Patricia (NIH/NIAID) [E);Mascola, John (NIH/VRC) [E];Erbelding, Emily
(NIH/NIAID) [E];Bright, Rick (OS/ASPR/BARDA) ;Collins, Francis (NIH/OD) [E] CbH6l;'Trevor
Mundel'
Subject: RE:Connection Request per Bill Gates
Emilio:
Thank s for your note. As I had ment ioned to Bill yesterday evening, I am enthusiastic about
moving towards a collaborative and hopefully synergistic approach to COVID-19 on the part of
NIAID/NIH, BARDA and the BMGF. I will ask John Mas cola and Emily Erbe lding to connect with
you to stay a conversation. Perhaps they can organize a call with you including BARDA. I will
try to engage as much as I can given my current circumstances. We look forward to working
with you.
Best regards,
Tony
From: Emil io Emini

-------------
-------~~
(b)(6)>
(b)(6)>
----------
Subject: Connection Request per Bill Gates
Tony-I received a note from Trevor and Bill that they connected with you yesterday and they asked me
to reach out . I've taken on the role of coordinating the foundat ion's contributions to the global COVID
vaccine efforts, in particular fo r those approaches that are (or soon will be) in early development.
There's an obvious need for coordination among the various primary funders or the focus we need to
have given the state of the pandemic will become lost through uncoordinated activities .
Bill tells me that you will take on a central role in coordinating BARDA'sfunding to t he ongoing efforts .
And, of course, there are the NIH/VRC activities. I'm reaching out to ask how we can coordinate and
cross-inform each other's activities. I am very sensitive to how busy you are and very grateful for your
engagement. I see you on TV almost every day, and although you continue to have considerable energy,
I am seriously worried about you. The nat ion and the wor ld absolutely need your leadership.
As a next step we can connect 1: 1 briefly or you can pass this on to an appropriate member of your
staff.
-
If you wish, you can always reach out to me directly at any time though my personal mobile at
Pleasestay well. ...Emilio
Emilio A. Emini, Ph .D., FCPP , FAAM

(b)(6)
Director
NIH-000062
TB and HIV Program
Bill & Melinda Gates Foundation
NIH-000063
Sent : Thu, 2 Apr 2020 23:50:04 +0000
To : Glass, Roger (NIH/FIC) [El
Subjec t : RE:COVID-19 in Africa: Tanzania
Thanks, Roger.
From: Glass, Roger (NIH/Fie) [E] (b)(6)

--------
------~~
--------
Subject: FW: COVID-19 in Africa: Tanzania
(b)(6)
Tony,
You have a fan club in Tanzania-Julie Makani and Lucio with your textbook!
Keep up the heroic work .
Roger
From : Julie Makani <jmakani@blood.ac. tz>

------~=
To : Glass, Roger (NIH/FIC) [E] ______ Cb
_H_6J
Subject: Re: COVID-19 in Africa: Tanzania
Please pass greetings to Dr Fauci
His authorship on Google Scholar including of Harrison's has been under discussion on social media
Lucio has been writing the chapter on hemo lytic anemia
He is heading to Italy for 3 months. He has been incredible . He was leaving his cop ies with the Sickle cell
programme as we plan on getting keen scientists to read them
Stay safe
Prof Julie Makan i, T:

------ (b)(6) E: jmakan i@blood .ac.tz
NIH-000064
Sent : Thu, 2 Apr 2020 21:52:30 +0000
To: Lerner, Andrea (NIH/N IAID) [El;NIAID OD AM
Subjec t : RE: My take on masks
Thanks, Andrea
From : Lerner, Andrea (NIH/NIAID) [El

----------
Se nt: Thursday, April 2, 2020 1:01 PM
(b)(6)

Subject : My take on masks
Given our discussion this AM, just thought I would summarize my take on masks ac ross varying
scenarios:
(b)(5)
NIH-000067
Sent: Thu, 2 Apr 2020 21:14:40 +0000
To: Balasundaram, David (NIH/CSR) [El
Subject: RE:Correlation between universa l BCGvaccination policy and reduced
morbidity and mortality for COVID-19: an epidemiological study
Thanks, David.
From:Balasundaram, David (NIH/CSR) (E] (b)(6)

To: Fauci, Anthony {NIH/NIAID) (E] ------ (b
= )""'(6)
= >
Cc:Balasundaram, David (NIH/CSR) [El (b)(6)
Subject: Correlation between universal BCGvaccination policy and reduced morbidity and mortality for
COVID-19: an epidemiological study
Importance:High
Dear Dr. Fauci,

I thought that you may be interested in reading this paper (Unless you already know about this of
course!). This is obviously a data -driven set of correlative observations, but could be worth look ing
into.
I salute your outspoken efforts to galvanize this country into action in the midst of so many mixed
messages and dragging of feet.
Cheers,
davtd
David Balasundaram, PhD .,
Scientific Review Officer,
Cell Biology Integrated Review Group,
http://public .csr .nih.gov/S tudySections/ lntegratedReviewGroups /CBIRG /Pages/default .as px
Referral Officer,
Division of Receipt and Referral
~ <:.mf'l'b
~ Sc,gn•l',c ~
Office (b)(6) I Fax: 301-480-1988 I Email: ---------==

6701 Rockledge Drive , Room 5136, Bethesda, MD 20892-7768
(b)(6)
Integrity matters. Say something ! For concerns or quest ions about possible violations of peer review
integrity, please contact your Scientific Review Officer , or the CSR Review Integrity Officer at
csrrio@mail.nih.gov , or the NIH Review Policy Officer at reviewpolicyofficer@mail.nih .gov . See the NIH
Guide Notice on integr ity in review.
NIH-000068
From: (b)(6)
Sent : Thu, 2 Apr 2020 13:29:05 -0400
To: Vollmer, Sebastian
Subjec t : Re: Estimate of undetected COVID-19 infections
Thanks, Sebastian. Very helpful
> On Apr 2, 2020, at 8:43 AM , Vollmer , Sebastian

> ----------------- (b) (6}> wrote:
> Dear Dr. Fauci ,

>
> we have used estimates of COVTD-19 age specifc infection fatality rates and time from onset to death that were
recently published in The Lancet Infectiou s Disease to estimate COVTD- 19 detection rates and the true number of
infected people (in contrast to confirmed cases that are widely repo1ted) for the 40 most affected countries. We
estimate a detection rate of on average six percent and number of cases of a few tenth of mi !lions. We thought you
might be intere sted and have attached the note to this email.
>
> Thanks for doing such a great job in such a difficult time. I lived in Boston for a few year when J was a postdoc
and later adjunct professor at the Harvard Chan School of Public Health. My thoughts are with my friends in the
United States, particularly in New York.
>
> Warmly,
> Sebastian Vollmer
>
>
>
> <Bommer & Vollmer (2020) COVID-19 detection April 2nd .docx>
NIH-000069
From: (b)(6)
Sent: Thu, 2 Apr 2020 13:02:41-0400
To: Jim West
Subject: Re:THANK YOUTONY!
Jim:
Thank you for your kind note. It is much apprec iated.
Best regards,
To ny
On Apr 2, 2020 , at 10:08 AM , Jim West (b)( >wrote:

---------
Dear Tony,
My name is Jim West and (b)(6)
- Most people did not know (b)(6)·, except

his immed iate family, close friends and of course Jack Whitescarver. I am writing
to congratulate you on the job you are doing with the Coronavirus. There is no
doubt in my mind it has been exceedingly stressful for you and your family, and I
just wanted to offer my support and reassurance that you are indeed doing a great
job. I know (b)(6) could have never handled the stress of all of this, and he would
be most proud of the j ob you are doing .
Take good care of yourself and keep steadfast in what you are doing. You are
the true medical advisor of the United States during this pandemic, and mill ions of
us are incre dibly grateful.
Sincerely yours,
Jim West
NIH-000070
(b)(S) - PCf
NIH-00007 1
(bX5) -PCI
NIH-000072
Sent: Thu, 2 Apr 2020 13 :21:29 +0000
To: WAYNEREYNOLDS
Subject: RE:Heads Up - Dr. Fauci Bobblehead w ith a Cause
Wayne and Catherine:

Thank you for your kind note . Much appreciated . Please stay safe and well so
that we can some time soon (I hope) resume our normal lives together.
Best regards,
Tony
Director
Phone : (b)(6)
FAX: (301) 496-4409
E-mail : (b) (6)
have received this e-mail in error please inform the sender and de lete it from your mailbox or any
other storage devices . The National Ins t itute of Allergy and Infectious Diseases (NIAID) shall not
accept liability fo r any statements made that are the sender's own and not expressly made on
From: WAYNE REYNOLDS (b)(6)>

To: Fauci, Anthony {NIH/NIAID) [El------~~ (b)(6):>
Cc; Grady, Christine (NIH/CC/BEP) [El CbH >
Subject: Fwd: Heads Up - Dr. Fauci Bobblehead with a Cause
Tony,
You've finally hit the big time. The National Bobble head Hall of Fame and Museum. Tha nk you for all
you' re do ing for the country.
Warmest wi shes,
Wayne and Catherin e
Sent from my iPhone
NIH-000073
Begin fo rw arded m essage:
From: "Jordan, M ary" <M ary .Jordan@w ashpost.co m>

To: Way ne Reynolds (b)(6)>
Subject: Fw: Heads Up - Dr. Fauci Bobblehead with a Cause
W ho knew there w as a Nat ional Bobblehead Hall of Fame and M useum !
From: Phi l Sklar <phi l.sklar@ bobbleheadhall.com>

Sent : Wednesday, Apri l 1, 2020 3:34 PM
To: Jorda n, Mary <M ary.Jordan@washpost.com>
Subject: Heads Up - Dr. Fauci Bobb lehead with a Cause
ICAUTION:EXTERNALSENDER
Hi Mary ,
I hope you are staying well dur ing these unprecedented times ! I want ed to give you
a heads up that we will be unveiling a bobb lehead of Dr. Anthony Fauc i this Friday,
Apri l 3rd . Dr. Fauci has become Amer ica's voice of reason as one of the lead
member s of the Wh ite House Corona virus Task Force. The Na tional Bobblehead
Ha ll of Fam e and Museum w ill be donatin g $5 from every Dr. Fauci Bobblehead
sold to the American Hosp ita l Association in support of the I 00 M illion Mask
Challenge [icm-track ing.meltwater .com] . The bobb leheads will be available for pre-
order on our website beginning on Friday .
Bobbleheads are the ultimate honor, and we think Dr. Fauci deserves it g iven what
he has don e and continues to do for our country and the world in the battle against
COVID-1 9. Th e bobblehead will j oin a grow ing number of items including donuts,
socks and t-shirts featuring Dr. Fauc i. We rece ived a lot of requests for a bobblehead
of Dr. Fauc i and are excited to be able to use the bobb lehead to raise funds for a
vital organization that is helping limit the spread of the Coronavims whi le makin g
people smi le dur in g these unprecedented times.
Let me know if you would like the press release, pictures and gra phics in advance of
Friday 's release. Please hold off on publicizing anything related to the bobblehead
unt il Friday- any time on Friday is okay. Please also let me know if you would lik e
a samp le when they an-jve or if you have any quest ions.
T hank you,
NIH-000074
Phil
Phil Sklar
Co-Founder and CEO
National Bobblehead Hall of Fame and Museum
Phil.Sklar @bobbleheadhall.com
414-519-2625
www.bobbleheadhall.com [icm-tracking .meltwa ter.com]
This email was sent to mary.jordan@washpost.com

National Bobblehead Hall of Fame and Museum , PO Box 0982 , Milwaukee, WI
53201-0982, us
Unsubscribe [icm-tracking.meltwater.com]
NIH-000075
Sent: Thu, 2 Apr 2020 12:59:53 +0000
To: Auch incloss, Hugh (NIH/N IAID) [CJ
(b)(6)
Subject: FW: COVID-19 Planning
Let us discuss.
Director
Phone: (b)( 6)
FAX: (301) 496-4409
E-mail: (b) (6)
From: Ta bak, Lawrence (NIH/OD) [El (b)(6)

Sent: Wed nesday, Apr il 1, 2020 7:35 PM
To: ICDDIR-L@LIST.NIH .GOV; List DEPDIR-L <DEPDIR-L@list. nih.gov>
Cc:NIH Director's Executive Committee <OD-Sma llStaff@mail.n ih.gov>
Subject: Re: COVID-19 Planning
Importance: High
Colleagues,
The momentum behind a 4 t h COVIDsupplement seems to be building in the Congress even

more quickly than we had expected. We have received a TA request to prov ide rough numbers
for NIH efforts by Friday afternoon. With regrets for adding more burdens to the intense
efforts you are already engaged in, I ask that you submi t a rough estimate of the first year and
t he five year budget for your (i) IC-specif ic init iat ive(s) and/or your (ii) proposa ls to contr ibute
to economic recovery, no later than Friday April 3 at noon. This will be non-binding, and you are
free to revise it fo r the submission that we already asked you for by Friday COE.The only thing
we need Friday at noon is the budget - the narrative can come later in the day (or the night).
Please use the second page of the t emplat e we sent you yesterday to provide this draft budget.
Send to me .
NIH-000076
I apologize for the impossible turn-around and appreciate al l the hard work that will be needed
to get us this information by the Friday noon deadline.
Many thanks,
Larry
From: "Tabak, Lawrence (NIH/OD) [E]" < (b)(6J >

1
Date: Tuesday, March 31, 2020 at 4:20 PM

To: " ICDDIR- L@LIST.NIH.GOV " <ICDDIR- L@LIST.NIH.GOV >, List DEPDIR-L <DEPDIR-
L@list.nih.gov >
Cc: NIH Directo r's Executive Committee <0D -SmallStaff@mail.nih .gov >
Subje ct : COVID-19 Planning
Colleagues,
Francis is sending out a note shortly to the co-chairs of each of the ten tra ns-NIH initiatives, asking for
their assistance in putting together wo rkplans and budgets for those projects. But in addition to these
trans- NIH activities, we invite ICDsto submit a short description of no more than two IC-specific ideas
that you believe merit consideration for support in a fourth supplemental bill, should one be put
forward. Please use the same template that is being used for th e tran s-NIH activities, but ju st check the
appropriate tick box. Your submission should include budget estimates for the first year and subsequent
outyears (for a total of 5 years). (b)(5)
. Pleasesend these to me by COE,Friday,
April 3rd .
Finally, l! we are asked about t echnical assistance regarding economic recovery, please send ideas for
that option. As part of this, Mike Lauer and Michael Gottesman will submit estimates on what might be
needed for extramural institutions and the IRPto "make them whole" . However beyond that there are
infra structu re, training, and other requests that wou ld with help national economic recovery by creating
new jobs (construction, IT, biomedical, etc.) and help prepare the nation for COVID-202X.Pleaseuse the
same template that will be used for the trans-NIH activities (again, checking the correct box) and include
budget estimates for the first year and subsequent outyears (for a total of 5 years). Please send these to
me by COE,Friday, April 3rd .
Many thanks,
Larry
NIH-000077
From: (b)(6)
Sent: Thu, 2 Apr 2020 07:28:32 -0400
Subject: Fwd: media inquiry on COVID-19
From: "stefano. va lentino @globalreporter.it" <s tefano. valen tino @ globalreporter.it >
To: "Fauci, Anthony (NIH/N IAID) [E]" <f (bH6) )>
Subject: media inquiry on COVID-19
Dear Dr. Fauci,
I am a Brussels-based journalist, member of the European Data

Journalism Network (EDJNet) , a digital news-making platform that
affiliates media outlets across Europe.
I found a quote from you in this article which seems to be quite

prophetic: https ://www.theatlantic .com/health /archi ve/2020/02/covid-
vaccine / 607000/
I contact you to have a discussion about the effectiveness of the epidemic

outb reak preparedne ss and response measures put in place by governme nts,
particularly in te1ms of vaccine development.
I would like to know if we could ave a chat on sk:ype. Or, if you prefer, I can send
you some questions by email.
I wait for your kind feedback
Regard s
Stefano Valentino
Founder
MobileReporter
Special Investigations Contributor

VoxEurop
NIH-000078
Fatto Quotidiano
Fullbright Alumni
Berkley School of Journalism
Memberships:
Italian Press Association
European Data Journalism Network
Italian Science Writers Association
Society of Environmenta l Joumas/ists
Online News Association
Tel: .___.., CbH6l

,__,,~
Whatsapp: CbH6)
Skype: globalreporter
Twitter: @M0BILEREP0RTER
i nfo@mobilereporter. info
www.mobilereporter.info
NIH-000079
Sent : Thu, 2 Apr 2020 10:58:29 +0000
Subjec t : FW: Possible lneterview via FaceBook
fyi
From: Brendan Taglianetti <btaglianetti@milfo rd.nh.gov>

To : Fauci, Anthony (NIH/NIAID) [E] ------ ==
(b)(6)>
Subject: Possible lneterview via FaceBook
My name is Brendan Taglianetti; I am a Full-Time Advanced EMT provider for Milford

Ambulance Service in Milford, NH. I want to help relay your message of COVID-19 information for state
of New Hampshire, by conducting a Facebook Live chat with myself to project information and messages
to the citizens of New Hampshire . This is a chance for us to chat for around 10 minutes and ta lk with a
first responde r to the general public.
I have seen you do interviews with the media/ daytime talk shows, a Facebook live chat with
Mark Zuckerberg, and even an lnstagram live video with Stephen Curry from the Golden State Warriors.
I run the social media aspect of the departmen t, and I would love to do a 10-15 minute discussion (with
information to the public, as well as some question and answer) with you on Facebook (live) to have the
general public watch us talk about the pandem ic and the next steps, and also maybe take some
questions asked of the publ ic watch ing when they comment. I also w ill be reaching out to the New
Hampshire State Governor Chris Sununu and Dr. Benjamin P. Chan (who is the state's epidemiologist). I
would love to have them chat with me, and have you join in on the discussion as well. I have no
confirmed with them if they are available yet, but I am putting things in motion.
I know that if I was able to set up a time and date that would work around your busy and
important schedule, then I could with ample time promote it. I would love to not only get the town on
Milford to watch th is, but have the state of New Hampshire and other states nearby tune in. I know this
is a long shot and that you have way more important aspects of your job to complete, but I think th is an
important time to have the public hear you talk.
Please let me know if this could be possible and I would love to set this up, I don't expect to
take too much of your time if this can happen. Sometimes in life you jus t need to ask and see what
happens and this is a t ime where that risk is worth it to have a conversation with you about this
pandemic we are facing, especially as we ramp up for starting to "peak" in the number of people
affected .
NIH-000080
Please let me know if this is possible and tell me if you are interested in doing this with us for
the greater goo d of the general public to keep them informed .
Sincerely,
Brendan J. Taglianett i
Full-Time Advanced EMT/ Field Training Officer
Milford Ambul ance Service
66 Elm Street, Milford , NH 03055
Phone: (603) 249-0610 (ext . 275)
Email: btaglianetti@milford.nh.gov
NIH-000081
From: (b)(6)
Sent : Wed, 1 Apr 2020 22:15:42 -0400
To: McNeil Jr, Donald G
Subjec t : Re: Heads Up - Dr. Fauci Bobblehead w ith a Cause
Yikes!!!
On Apr 1, 2020, at 9:55 PM, McNeil Jr, Donald G <mcneil@nytimes.com>wrote:
-
I'm order ing one for my office desk and maybe anothe r for
---
(b)(6)
----------Forwarded message ---------

From: Phil Sklar <phil.sklar@bobbleheadhall.com>
Date: Wed, Apr I, 2020 at 3:35 PM
Subject: Head s Up - Dr . Fauc i Bobblehead with a Cause
To : <mcn eil@ny times.com>
Hi Donald,
I hope you are staying well during these unprecedented times! I wanted to give you a
heads up that we will be unveiling a bobblehead of Dr. Anthony Fauci this Friday, April 3rd.
Dr. Fauci has become America's voice of reason as one of the lead members of the White
House Coronavirus Task Force. The National Bobblehead Hall of Fame and Museum will be
donating $5 from every Dr. Fauci Bobblehead sold to the American Hospital Association in
support of the 100 Mil lion M ask Challenge. The bobbleheads will be available for pre-order
on our website beginning on Friday.
Bobbleheads are the ultimate honor, and we think Dr. Fauci deserves it given what he has
done and continues to do for our country and the wor ld in the battle against COVID-19.
The bobblehead will join a grow ing number of items including do nuts, socks and t-shirts
feat uring Dr. Fauci. We received a lot of requests for a bobblehead of Dr. Fauci and are
excited to be able to use the bobblehead to raise funds for a vital organ ization that is
helping limit the spread of the Coronavirus while making peop le smile during these
unprecedented times.
Let me know if you would like the press release, pictures and graphics in advance of
Friday's release. Please hold off on publicizing anything related to the bobble head until
Friday-any t ime on Friday is okay. Please also let me know if you would like a sample
when they arrive or if you have any questions.
NIH-000083
Thank you,
Phil
Phil Sklar
Co-Founder and CEO
National Bobblehead Hall of Fame and Museum
Phil.Sklar@bobbleheadhall.com
4 14-519-2625
www.bobbleheadhall.com
This email was sent to mcneil@nytimes.com

National BobbleheadHall of Fame and Museum, PO Box 0982, Milwaukee, WI
53201-0982,us
Unsubscribe

Science Correspondent
l~r~rwflorkeimcs
Tel: (b)(6)
mcneil@nytimes.com
Articles: https://www.nytime s.com/b y/dona ld-g-mcneil- jr
NIH-000084
Sent: Wed, 1 Apr 2020 19 :59 :55 +0000
To : Aw wad, David (NIH/ NIAID) [C]
Attachment s: message,, Re message.oft, Re messagel.oft, u r hypo crite .oft , Call the Nat ional
Guard in.of t, message,
Director
Phone: (b)(6)
FAX: (3 96':44li9
E-mail: (b) (6)
NIH-000085
From: (b)(6)
Sent: Wed, 1 Apr 202017:51:34 -0400

To: Duchin, Jeff
Subject: Re: FEMA Test Kits
Je ff:
Thanks for yo ur note. It was very helpful to me to speak with yo ur group last night. I caused
quite a stir at the Task Force meetin g when I repo rted on our telephone conversat ion. I believe
that this fixed the FEMA issue .
Best regards ,
T ony
On Apr l , 2020, at 5:43 PM, Duchin , Jeff

------------ (b)(6) wrote:
Tony,
Thank you for taking some precious time to hear from some of the folks on the ground
confronting COVID-19 around the country. I can't tell you how much we all value your
engagement and leadership on behalf of the nation. I'd love to get your take on whether
you think the type s of things described it eh recent AEI report are realistic. I have serious
doubts.
Quick question - I ment ioned the problem we had with FEMA test kits being recalled from
us because we did not want to use their call line and lab because too slow, - just
wondering if that came up in your meeting today because I just heard the kits were
released to us without restrictions on how we use them. So either way, apparently
resolved.
Stay well and best regards,
Jeff
Jeffrey S. Duchin, MD
Healt h Officer and Chief, Communicable Disease Epidemiology &Immunization Section
Public Health - Seattle and King County
Professor in Medicine, Division of Infectious Diseases, University of Washington
Adjunct Professor, School of Public Health
401 5th Ave, Suite 1250, Seattle , WA 98104
Tel : (b)(6); Direct : (b)(6); Fax: (206) 296-4803
E-mail:
---------- (b)(6)
NIH-000086
From: (b)(6)
Sent : Wed, 1 Apr 2020 16:54 :57 -0400
To : Kadlec,Robert (OS/ASPR/10 )
Subject: Fwd: (b)(5)
Bob:
See emai l below.
Thanks,
------------------------ (b) (5)
Tony
From: "Mascola , John (NIH N RC ) [E]" (b)(

Date: Apr il 1, 2020 at4:40:39 PM EDT
---------
To: "Fauci, Anthony (NIH/NJAID ) [E]"
Cc: "Conrad , Patricia (NIH/N IAID) [E]" 1, "Erbelding,
(b)<6)
__________---
Emi ly (NIH/N IAID) [E]" (b)(6)
,...
S,- ,-,M
- a-r-st-on_ H_.ilary
(NIH/N IAID) [E]" ' '
____,
Subject:
Tony ,
(b) (5)
John
NIH-000087
(b) (5)
NIH-000088
Sent : Wed, 1 Apr 2020 16:02 :51 +0000
To : Barasch,Kimberly (NIH/NIAID) [C);Conrad, Patricia (NIH/ NIAID) [E)
Subject : (b)(5)- PC
Director
Phone: (b)(6)
FAX: (30 496"'4409
E-mail: (b)(6)
(b)(5)- PCI
NIH-000089
(bX5) -PCl1
NIH-000090
(bX5) -PCl1
NIH-00009 1
Sent : Wed, 1 Apr 2020 16:01:03 +0000
To : Gallo, Robert
Cc: Barasch, Kimberly (NIH/NIAID) [C];Conrad, Patricia (NIH/NIAID) [El
Subject: RE:information
I got it. I will have my staff try to set something up.
Director
Phone: (b)(6)
FAX: (3 96':44li9
E-mail: Cb)(6)
From: Gallo, Robert (b)(6)

To : Fauci, Anthony (NIH/NIAID) [E] ------~~
Subject: RE: information
-------- (b)(6)
TONY-this is from me-Bob Gallo
(b) ~ >
--------
To: Gallo, Robert Cb)(6)
Subject: RE: information
emails precludes me or my staff from answering each individual message. I would
encourage you to visit www.coronavirus .gov for the latest information and
Thank you, and best regards .
NIH-000092
NIH-000093
Sent: Wed, 1 Apr 2020 14:04 :37 +0000
To: Berkowitz, Avrahm J. EOP/WHO;Gidley, Hogan H. EOP/WHO
Subject : RE:Quick call
(b)( 5)
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
From: Berkowitz, Avrahm J. EOP/WHO

------- (b)(6)
-----~~
To: Fauci, Anthony (NIH/ NIAID) [E) ______ Cb_H _,
6)>; Gidley, Hogan H. EOP/WHO
(b) (6) >
Subject: Quick call
Dr Fauci - can you please jump on a quick call with Hogan about a press inqu iry we received at the
White House? He is at (b)(6)
(and I am at (b)( .
Thank you!
Avi
NIH-000094
Sent : Wed, 1 Apr 2020 13:22 :58 +0000
To : (b)(6)
Subjec t : RE:FW: Wpost: Fauci socks, Fauci doughnuts, Fauci fan art: The coronavirus
exper t attracts a cult follow ing
It is not at all pleasant, th at is for sure.
Director
Phone: (b)(6)
FAX: (301) 496-4409
E-mail: Cb)(6)
From : (b)(6)
---------=-::-:-=
--------- (b)(6)
Subject : Re: FW: Wpost: Fauci socks, Fauci doughnuts, Fauci fan art : The coro navirus expert attracts a
cult follow ing
Completely surreal (b)(6)Dizzying, even . Can't imagine wh at it is like for you, especially in the midst of all
t his.
On Tue, Mar 31, 2020 at 10:58 AM Fauci, Anthony (NIH/NIAID) [E] ______ _C_6)> wrote:
Cb>
Truly surrea list ic. Hopefu lly, t his all st ops soon.
A nthonv s. Fauci, MD
Director
Phone: (b)(6)
FAX: (301) 496--4409
E-mail Cb)(
NIH-000095
your mailbox or any other storage devices. The National Institute of Allergy and Infec tious

---------
(b)(6)>
Subje ct: Wpost: Fauci socks, Fauci doughnuts, Fauci fan art: The coronavirus expert attract s a cult
following
Fauci socks, Fauci doughnuts, Fauci fan art:

The coronavirus expert attracts a cult
following
Doughnuts bearing the likeness of Anthony S. Fauci,

director of t he Nation al Institute of Allergy and Infectious Diseases, rest on a plate at Donuts Delite in
Rochester, N.Y., on March 25. (Shawn Dowd/Rochester Democrat & Chronicle/AP)
By
Antonia Noori Farzan
March 31, 2020 at 5:15 a.m. EDT
Early last week, Nick Semeraro wanted to find a way to hono r Antho ny S. Fauci. As the owner of a
small doughnut shop in Rochester, N.Y., he had been closely tracking the latest news about the
coronavi rus pandemic. And night after night, he'd been impressed by how Fauci, the director of the
National Institute of Allergy and Infectious Diseases, approached the crisis in a calm, knowledgeable
manner.
So, as a tribute , Semeraro put th e renowned immunologist's face on a doughnut. Expecting to sell a
few hundred, he was shocked when the store sold out day after day, with thousands flying off the
shelves. Donuts Delite was besieged w ith requests to ship the buttercream-frosted creat ions all over
the country, and one Fauci fan drove three hours just to pick up a dozen. Soon, bakeries in Wisconsin
and Pennsylvania followed suit, using edible paper to decorate pastries with Fauci's likeness.
"We had no idea it was going to blow up thi s big," Semeraro told CNN."We didn't know everyone else
felt the same way we did ."
While Fauci was already a respected scientist before the outbre ak, his appearances during White
House press briefings have made him a household name and an unlikely celebrity . With his
NIH-000096
straightforward demeanor and willingness to contradict President Trump, he's begun to develop the
same kind of cult following as Supreme Court Justice Ruth Bader Ginsburg and former special counsel
Robert S. Mueller Ill, who inspired countless "Plank like RBG" tank tops and a bizarre illustrated
children's book, respectively .
Even as whole swaths of the global economy collapse, the pandemic has created a robust cottage
industry of Fauci-themed merchandise, including bottle openers, magnets and mugs. On Etsy, you can
buy "Honk for Dr. Fauci" bumper stickers, prayer candles depicting "St. Fauci" and socks printed with
Fauci's face. Graphic T-shirts bear slogans such as "I Need a Hero" and "In Dr. Fauci We Trust."
If so inclined, you can even decorate your home with an "I Heart Dr. Fauci" throw pillow, or purchase
a replica of Fauci's jersey from the time he captained the basketball team at Manhattan's Regis High
School. Lingua Franca, which sells cashmere sweaters embroidered with resistance-fr iendly slogans
for $380 and up, recently began taking orders for an army-green "Dr. Fauci Fan Club" knit.
In honor of Fauci's Italian heritage, a clam bar in Long Island named a linguine dish after him this
week . (Available for pickup only, "the linguine with white clam sauce shares origins with Fauci, as the
sauce itself was invented in the Fauci Family's native Sciacca, Italy," the restaurant claimed in a
statement.)
As countless Americans remain glued to the news while trying to stay indoors, a robust Fauci fandom
has flourished on line. On Facebook, the "Dr. Anthony S. Fauci Fan Club" has over 32,000 members.
Thousands more congregate in groups with names such as "Dr. Anthony S. Fauci, the Man, the Myth,
the Legend," "Dr . Fauci Speaks, We Listen" and "Dr. Fauci Memes for Social Distance Teens."
An unassuming 79-year-old public servant who has advised six presidents, Fauci has become a
"reliable constant in a time of uncertainty," The Washington Post's Ellen McCarthy and Ben Terris
reported . But his admirers - and there are a lot of them - worry that it's only a matter of time
before he's sidelined by Trump .
When Fauci missed a White House news conference earlier this month, panic erupted on Twitter,
along with speculation that he could be sick. There was palpable relief when he resumed his regular
position at the podium the following day and appeared to hide some exasperation as Trump
referenced "the deep state."
Fauci later explained that he had simply been trying to dislodge a lozenge from his throat . But the
much-analyzed "Fauci facepalm" had already become a meme, deployed by liberal members of
what's known as the resistance.
Fauci's newfound fame can be partially attributed to his willingness to engage with all forms of media
- in recent weeks, he's gone on a Barstool Sports podcast, chatted with basketball star Steph Curry
on lnstagram Live as Barack Obama listened in, and appeared on "The Daily Show With Trevor Noah."
But it also undoubtedly helps that his fans tend to take social distancing seriously and consequently
have ample spare time to produce fan art or perform songs written (or modified) in his honor .
On social media, Fauci's virtual fan clubs peruse old photos of the infectious disease expert in search
of "comfy turtleneck vibes," stitch his face on embroidery hoops and discuss erecting statues as
tribute . They frost his name on cookies and joke about constructing shrines in his honor. Prominent
activists and entertainers confess to wanting to marry him, or have him tuck them into bed.
Fauci has remained characteristically modest about his new status as a cult figure. "Well, that's very
nice," he responded when McCarthy and Terris mentioned that people all over the country were
praying for him. Of course, that means that his fan base has only continued to grow.
"I never met a guy that, worldwide, he is so loved," Semeraro, the Rochester doughnut shop
owner,to ld CNN. "And a month ago, we never knew his first and last name."
NIH-000097
Disclaimer: Any third-party material in this email has been shared for internal use und er fair use
provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not
necessaril y represent my views nor those of NIAID, NIH, HHS , or the U.S. government.
NIH-000098
From: (b)(6)
Sent : Wed, 1 Apr 2020 06 :26:32 -0400
To: DMID Word Nerds
Subjec t : Fwd: Covid-19 comments on UK response
Attachment s: image001.png , ATT0000l.htm, Covid19, UK pharmavaccine response .pdf,
ATT00002.htm, Covid19, UK Urgent Action response.pdf, ATT00003.htm, VACCINEarticle.pdf,
ATT00004 .htm
Sent from my iPhone
F rom: Karl Simpson (b)( '>

Dat e: Apri l 1, 2020 at 5 :46: 14 AM EDT
To : "Fauci, Anthony (NJH/NIAID) [E]" ------- ==
Subject: Covid-19 comm ents on UK response
---------- (bH6J
Dear Dr Fauci
I was just re-reading your January 23 Viewpoint article in JAMA. So little time has passed,
but so much has changed, and you r comments seem prescient.
I have been working on emergent/ re-emergent infectious agents for some time, and
authored a 2018 report for the UK government on vaccine responses that was summarised
in a Vaccine publication last October attached . As almost everyone else, my attention has
been redirected to Covid-19, although monkeypox remains a focus of my interest.
You and your colleagues may be interested in two short documents I produced for the UK
government on the 20 th and 22 nd of March. That also seems long ago now!
As fellow citizen of our planet, I thank you and colleagues for your unstinting efforts to
control infectious disease and Covid-19 in particular .
Warmest wishes
Karl
NIH-000099
J. Karl Simpson CBiol FRSB
CEO, JKSBioscience Limited
..
......... ..
..
J Sbioscience
NIH-000100
NIH-000101
JKSbioscience
2 Midanbury Court, 44 Midanbury Lane
Southampton S018 4HF, UK
Tel: _____ ___,

(b) (6)
Mobile:
------ (b) (6)
Mail: (b)(6)
Website: http://www.jksb ioscience.co.uk
Skype:
-----(b)(6)
(;ompany Numbe r: 10051396
VAT number: 238 0528 12
NIH-000102
From: Conrad, Patricia (NIH/NIAID) [El on behalf of Fauci, Ant hony (NIH/NIAID) [El
Sent : Tue, 31 Mar 2020 21:07:00 +0000
To: NIAIDODAM
Subjec t : FW: Additiona l data on masks
Att achment s: MacIntyre BMJ.pdf, Figure 3.jpg
Adding everyone since it wa s discussed in am meeting . thx
From: Lerner, Andrea (NIH/NIAID) [El CbH6>>

Se nt : Tuesday, March 31, 2020 5:04 PM
To: Fauci, Anthony (NIH/NIAID) [El ------~=
Cc: Folkers, Greg (NIH/NIAID) [E] (b)( >; Marston, Hilary (NIH/NIAID) [E]
(b)(6) Eisinger, Robert (NIH/NIAID) [E] CbH6>>; Doepel, Laurie
(N
._I_H-:-
/N_I_A__
ID"".""
) -:-- ] :.:::::====---=-..;.,
[ E-:-: (b
"""
)~(6)
Subject: Additional data on masks
Dr. Fauci,
In addition, I found the attachedd review on masks that addresses use in the community settings.
Attached are the paper and figure 3, which summarizes the data from 9 very diverse RCTs(overlapping
with what I had sent earlier) .
Bottom line: generally there were not differences in Ill/URI/or flu rates when masks were used,
although when early use and complian ce was taken into account, a few times a difference was seen.
In addition:
This case cont rol study noted tha t, among SARSpat ients in Hong Kong without a known source of
infect ion, cases {27.9%) were less likely than uninfec ted controls {58.7%) to report wearing a mask
fr equently in public , for what tha t's worth.
https://wwwnc.cdc.gov/eid/article/10/4/03-0628 article
(b)(5)
Andrea
NIH-000103
From: (b)(6)
Sent : Tue, 31 Mar 2020 07:25:55 -0400
Subject: Fwd: Harvard Business School/ Wharton Business School
Sent from my iPhone
From: A.rash Farin < arash @arash.tv>

Date: March 30, 2020 at 10:32:04 PM EDT
To: "Fauci , Anthony (N IH/NIAID ) [E]" ------~~ (b)( >
Subject: Re: Harvard Business School / Wharton Business School
Hi Dr. Fauci,
I just wanted to confirm you received this .
I also just read a great story on you in the WSJ, which discussed your amazing
basketball and leadership skiJls when you were in coUege. Not surprisingly, even
then , your teammates were seeking your advice on leading them through difficult
times.
Talk to you soo n.
Regards,
Ara sh
On Sat, Mar 28, 2020, at 7:54AM, Arash Farin wrote:
Hi Dr. Fauci,
I'm a graduate of both Harvard Business School and The Wharton

School, and have truly enjoyed watching the leadership you have shown
our nation during these challenging times. Your steady hand, calm
demeanor, incisive thoughts, and inteJlectual rigor, have aubeen quite
comforting to us the last few weeks.
I would like to see if you may have a few minutes to participa te in a

webcast interview with myself and classmates from Harvard and
NIH-000104
Wharton this coming week or next week. We would love to hear your
thoughts on dealing with the coronavirus, lessons learned from other
countries, and how we can prepare for a potential recuJTence, as has
been discussed in the media , along with other topics you deem
important.
I may also be able to get students from Oxford University to join, as I

attended there as well, and I know the UK is dealing with its own set of
challenges.
I look forward to hearing from you, and can be reached at

ii. or via email (arash@ara sh.tv). ----
(b)(6)
God bless you, and thank you for everyth ing you have been doing.
Best Regards,
Arash
NIH-000 105
From: (b)(6)
Sent : Tue, 31 Mar 2020 07:24:50 -0400
To: DMID Wo rd Nerds
Subject: Fwd: VVIP informat ion for diagnostic and therapy for COVI0-19- Kindly do not
delete
Sent from my iPhone
From: "anahar." <anahar@abgenics.in>

Date: March 31, 2020 at 3:38:38 AM EDT
--------::-,--:=,(b)(6)
Subject: Fwd: VVIP information for diagnostic and therapy for COVID-19-
Kindly do not delete
Dear Sir
We request you to spare a few minu tes to read this email.
Abge nics is a life-sc iences company (Abgenics Life sciences Pvt Ltd,
www.abgenics.in) based in Pune, India conducting pioneering research in the
area of drug discovery using came lid antibody against infectious diseases in the
past 10 years. Abgen ics Life Sciences was founded in 201 0 and is managed by
Anil Nahar (Entrepreneur) and Dr Sanjib an K Bane1jee (Technical). Dr Banerjee
has studied and lived in the USA for more than 7 y and worked in the area of
infec tious diseases all his life. He has conducted extensive research in the area of
camelid antibody technology in USA. After returning to India and with an urge
to help the people of India in area of infectious diseases. Dr Banerjee in
assoc iation with Ani l Na har started this ventu re. Since then, the company has
extensively worked and developed novel camelid antibody technology for
various infectious diseases causing bacteria (Multi drug resistant) and fungus
like Pseudorno nas, Staphylococcus Aureus, Candida A lbicans and other
NIH-000106
important pathogens . Our company is the only company in India working on
Camelid antibody platform. Camelid antibody is a very robust and novel
technology and can be used to develop drngs against any kind of antigen
generated from bacteria and viruses. The specialty of camel antibody, it occurs
in nanosize, high temperature and high Ph stable. It has very high affinity
towards any antigen . A video explainin g our tec hnology is attached in the
email.
An Abgenics Life science was warded twice by (b) (4)
-
---------
USA in the form of research projects to develop technology for
(b) (4)
NIH-000 107
(b) (4)
~b na virus is a spiked v irus and the sp ikes are used by the virus to first att ach
i.to"\!
, 1d then invade into the host cells. Subsequently the genetic materials, RNA
at~ njected whe re it hijacks the host replication machinery to multiple and re-
infec t more cells. If the initial attachment or the fusion of the vims and host
membranes can be blocked, the virus replication cycle can be stopped, bringing
the infection under control. The spike protein consists of two components, a
globular head, S1 that helps the initial attachment and a spiral part S2 that is
responsible for membrane fusion which forms the channel for the entry of the
NIH-000108
(b)(4)
Regards
Anil Nahar
MD
Ab gen ies Life science s Pvt Ltd
Kant Helix
Bho ir Co lony
Chinchwad
Pune
India
Ph ----- (b
=>=c6)
=
NIH-000 109
From: (b)(6)
Sent : Tue, 31 Mar 2020 07:23:59 -0400
To: DMID Word Nerds
Subject: Fwd: New biological disin fection automates, also effect ive against new Corona
virus and multi -resistant germs, from a Florida Company
Attachments: PastedGraphic-1.png, ATTOOOOl.htm,
MSDS_Saniswiss_biosanitizer_aHP _P_rev_16032018.pdf, ATT00002.htm,
br_automate_aH P_ HTA_EN.pdf, ATT00003.htm, br_ biosanitiz er aHP C_EN2.pdf, ATT00004.htm, ABSA
conclusion Kopie.pdf, ATTOOOOS.htm,SHS_2308201 9_WEB.pdf, ATT00006 .htm
Sent from my iPho ne
From: Alexa nder Friedrich <a.friedrich@ biosan itize.us>

Date: March 31, 2020 at 6:02:53 AM ED T
To: "Fauci, Anthony (NIH/NIAID) [E]" -------~~ (bH6J
Cc: Tayfun Tay lor <mr.t aylo r@ mailbox. org>, "ceo@b iosan itize.us"
<ce o@biosani tize.us>
Subject: New biological disinfection automat es, also effective against new
Corona virus and multi-resistant germs, from a Florida Company
Dear Mr.Fauci,
I know you're busy. But at this special time for all of us, I just need to write to you.
The new Corona Virus is chang ing the world. It affects all of us in health, socia l and
econom ic terms. The importance of hygiene and disinfection can be see n especially
now in the andemic.
(b) (4)
NIH-000110
(b) (6), (b) (4)
NIH-000 111
(b)( 4l
do not hesitate to contact us.

Yours, sincerely
Alexander Friedrich
Repr. Biosanitize USA
Alexander Friedrich
Repr . Biosanitize USA
contact: a.friedrich@biosanitize.us
Bio-San itize USA LCC

12601 New Brittany Blvd
33907 Fort Myers, Florida , USA
tm ci..ner spaces. Slftr places.
✓ ✓ ✓ ✓ ✓
NIH-000112
Sent: Tue, 31 Mar 2020 02:07:49 +0000
To: Moshe Levi
Cc: Graham, Barney (NIH/VRC) [El
Subject: RE: Question from Georgetown
Moshe:
I am not sure that I can help you with this. I am referring your e-mail to Dr. Barney Graham
of the NIAID VRC. Perhaps he can help you.
Best regards,
Tony
From:Moshe Levi
-----------
(b)(6)
To: Fauci, Anthony (NIH/NIAID) [E]------~~ >

Subject: Ques tion from Georgetown-------- (b)(
Dear Tony:
I know that you are busy 7/24 with the current crisis.
BUTI have a question for you or fo r one of your colleagues.

(b) (4)
Please let me know.
Meanwhile there are not adequate ways to thank you for all you do.
I should have seen that when you were my attending while you were at Cornell as a Visiting
Professor Professor around Cb><6>
Moshe
Cell:
----- (b)(6)
Moshe Levi, MD
Dean for Research
Professor of Biochemistry and Molecular & Cellular Biology
Georgetown University
3900 Reservoir Road
NIH-000113
Med Dent NW 105
Wash ington, DC 20057
Office: Cb)
(6)
E-mail:
---------- (b)(6)
NIH-000 114
Sent: Tue, 31 Mar 2020 02:02:50 +0000
To: David Katz
Subject: RE:COVID-19 ·- URGENT(Please do not disregard!)
David:
I know that it is you. I am sorry, but I am getting more than 2000 e-mails pe day. I to tally
agree with you and this issue is being actively discussed as recently as today at the task Force
meet ing. I am not sure what you mean by aerial "eradication" procedures that could be
practically implemented. There are some data from NIH that indicate t hat mere speaking
without coughing elicits aerosols that travel a foot or two. If that is the case, then perhaps
universal wearing of masks in the most practical way to go.
Best regards,
Tony
From: David Katz (b)(6)>

--------=:-:-=
To: Fauci, Anthony (NIH/NIA ID) [E] (b)(6)
Subject: Re: COVID-19 -- URGENT(Please do not disregard!)
For God's sake, Tony -- this is me, not simply an unknown

"messenger" from the general public! We go back together
for many, many years (to our days together at the NIH ,
remember?). As you may recall, we worked (successfully)
during the infamous 1969 "March on Washington", among
other historically im octant events.
Although I am now (b)(6) I continue to pay careful
attention to world events, and this is one that exceeds any

others that have occurred in our lifetime!
As I wrote in my previous e-mail , I have become convinced that COVID-19 is
behaving as an airborne virus, and, therefore, we should be directing our
mitigation efforts toward mo re compr ehen sive aerial eradication
procedures!
Think about the most recent reports -- namely that imprisoned inmates, and
a young baby, have recently been reported as "infected" with thi s virus.
NIH-000115
Person-to-person infection in these circumstances is difficult to explain! But
transmission by viable airborne virus could certainly happen!
I look forward to your response, with best wishes,

David
David H. Katz, M.D.

La Jolla, California
On Sun, Mar 29, 2020 at 11:18 AM Fauci, Anthony (NIH/ NIAID) IE]______ Cb
_H_6l'> wrot e:
ema ils precludes me or my staff from answering each individual message. I
would encourage you to visit w ww .coron avirus.gov for the latest information
and guidance related to COVID-19.
Anthony 5. Fauci, M .D.
NIH-000116
From: (b)(6)
Sent : Mon, 30 Mar 2020 16:29:31-0400
To: (b)(6)
Subject: Fwd: Hello from Canada!
Could you pl ease respond to her for both of us. Thank s
From: "El-Gabalawy , Nadia (PHAC /ASPC)" (b)(6)
Date: March 30, 2020 at 2:48:41 PM EDT ------------

To: "Fauci , Anthony (NIH/NIAID) [E]" -------~~
Subject: Hello from Canada! --------- (b)(6)
Hi Dr. Fauci,
I thought I would reach out to you amidst this crisis; I respect the work you're doing a great
deal. (b)(6) Hani EI-Gabalawy, did a research sabbatical at NIH (b)(6)
-
Amazing work that you're doing. I've been following your discussions and scientific
innovation regarding COVID-19. I've been working for the federal government in
Intelligence for about thirteen years and recently moved to the Canadian Public Health
Laboratory Netwo rk Secretariat to support the Emergency Operati ons Centre at the
National Mic robiology Lab. I've been with the NML for almost my whole career.
Just a quick hello and deep respect for your work. My colleagues and Director have said
that we're on the exact same page as you, in terms of your perspective and assessment of
the pandemic. Although there is a border between us, know that we are in agreement with
your work and I'm thrilled to see you advising the public . There is no better person to do
the job .
Kindest regards,
Nadia EI-Gabalawy
Team Lead, Support Services, Canadian Network for Public Health Intelligence
Public Health Agency of Canada/Government of Canada
(b)(6)
NIH-000118
Chef d'equipe, Services de soutien, Reseau canadien de renseignements sur la sante
publique
Agence de la sante pub lique du Canada/ Gouvernement du Canada
(b)(6)
NIH-000 119
(b)(5) -PCf
NIH-000 120
Sent : Mo n, 30 Mar 2020 12:23:38 +0000
Subjec t : FW: Invitation to be the keynote speaker at an Insurance Medicine Conference
in Washington, DC in October .
RSVPso rry no.
From: Pinho, Paulo <Paulo.Pinho@optimumre .com>

Sen t: Monday, March 30, 2020 8:18 AM
To : Fauci, Anthony {NIH/NIAID) [E]_______ (b
"'"'
),,..,.
(6):
=>
Subject: Invitation to be the keynote speaker at an Insurance Medicine Conference in Washington, DC in
October .
Dear Dr. Fauci,
I hope this email finds you wel l. It is abundantly obvious from the countle ss sifts through data and
tallies of cases, interviews and press conferences, social media appearances, etc. that your schedule is
crazy these days. As a practicing physician and an American, I am proud to be represented by you and
th ank you for your efforts on our behalf. I realize with your schedule and with the t housands of emails,
t his one may not make it, but I wanted to take a shot in the dark.
I am currently the Chief Medical Off icer of a reinsurer and am on the planning committee for the
American Academy of Insurance Medicine's annual meeting wh ich will be held in DC th is year October
18-21. Dr. Michael Osterholm had agreed to speak at the conference back in January as ou r first
keynote speaker on the subject of pandemics, preparedness. I'd heard him speak before at Prudent ial (I
was medical director there and we were a member company of CIDRAP)and his ta lk mirrored his book
which I've also read. Regretfully, 2 weeks ago I received notice from Laurel, his EA, that he is unable to
attend the meeting because he needs to travel to London that week for a meeting he is heading. I think
that a talk on the topic is a must at any medical meeting and after hearing your pressers and coming to
rely on your sage status updates and advice, coupled with the fact that the conference is in DC, I thought
I'd give this a shot . Would you be AAIM's keynote speaker this year?
In the midst of the current COVID-19 pandemic, we understand many industry conferences have had to
be canceled. We are continui ng to closely monitor the trend of the COVID-19virus, and may have to do
the same for the AAIM meeting in October, but if t here is an opportunity to gather and learn, we'd like
to prepare for it .
The audience is medical directors that work in the life, health, disability and longterm care space. Some
are clinically active . Some of them are resources for health emergency planning fo r their com panies.
The audience comes mostly from North America, although other countries/continents are well
represented.
The purpose of the meeting is really to illustrate novel trends in the industry that will likely impact
morbidi ty and mortality in the near or distant future . We've had talks on CRISPR,marijuana, precision
medicine, data analytics. They' re not hard core morbidity or mortality focused, but do touch on it .
NIH-000 121
Given the scope of the meeting and the attendees and industries they represent, I think that a lecture
on pandemics, bioterrorism and emerging infectious disease, especially in light of COVID-19, is
necessary. I think you would teach new concepts to a team of doctors that would identify w ith some of
the system gaps in our current supp ly chain and their impact on human health, wellbeing and survival.
You'd provide experience and insight on what went wrong and what could be fixed in the future to make
us collectively better prepared.
We would be honored to have you speak and I'm glad to continue discussion of logistics with someone
else on your team. If you needed more information about scope, I can certainly provide that. We do
provide an honorarium and will cover travel and hotel expenses.
Thanks so much in advance for any consideration you might give this request/offer and most of all thank
you for your direction, demeanor and dedicat ion at this global time of crisis.
Best,
Paulo
Paulo Bandeira Pinho , MD, FAAP, FACP

Chief Medical Director
OPTIMUM RE INSURANCE COMPANY
% +1 214 528-2020, ext. 30984

~ Paulo.Pinho@optimumre.com
-----------
(8} 1345 River Bend Drive, Suite 100
-----==
Dallas, TX 75247, U.S.A.
c:J optimumre.com
I-~
OPTIMUM
~i, LifeReinsurance
This ema il and its attachments is confidentia l and is inte nded only for the individual(s) to whom it is
addressed . Distribution or copying of this ema il by anyone other than the named recipien t is
prohib ited. If you receive this email in error, please not ify us by email and permanent ly delete this
email and its attachments.
NIH-000122
From: (b)(6)
Sent : Mon, 30 Mar 2020 06:06:00 -0400
Subject: Fwd: Int erview w ith Or Anthony Fauci in The Times of London
Sent from my iPhone
From: "Rivalland, Monique" <monique .rivalland@the-times.co.uk >

To: "Fauci , Anthony (NIH/NIAID ) [E]" ------~~ (b)( >
Subject: Interview with Dr Anthony Fauci in The Times of London
Dear Anthony ,
I'm an editor at The Times of London. I'm gett ing in touch to discuss the possibility
of interviewing you this week for our Saturday Interview slot next weekend. You
have an incredibly tricky role in the fight against coronavir u s and have spoken with
great clarity. We would love to speak to you about your position and predictions for
America.
The interview slot in question is the most prestigious in the weekend edition of The
Times - a double-page spread reserved each week fo r the most influentia l
indi viduals in pub lic life. Fo nn er interv iewees range from B oris Johnson to Jeremy
Farrar.
We would need 40 - 50 minutes of your time before Frida y morn ing, but preferab ly
by Thursday even ing. The interview can be conducted over Skype/Goog le
Han gouts/Zoom or whichever method of video chat you prefer.
We would be delighted if you were to consider om request.
Kind regards
Monique
Monique Rivalland
Features Editor
THE~ TIMES
NIH-000123
(b)(6)
@MoniqueLouiseR
"Please consider the environment before printing this e-mail"
This e-mail and any attachments are confident ial, may be

legally privileged and are the property of News Corp UK &Ireland
Limited on whose systems they were generated . News Corp UK
& Ireland Limited is the holding company for the News UK group ,
is regis tered in England &Wa les unde r number 81701, has its
registered office at 1 London Bridge Street, London, SE1 9GF and
is registered with VAT number GB 243 8054 69. If you have received
this e-mail in error, please notify the sender immed iately and do not
use, distribute, store or copy it in any way . Statements or opinions in
this e-mail or a ny attachment are those of the author and are not
necessari ly agreed or authorised by News Corp UK &Ireland Limited
or any member of its group . News Corp UK & Ireland Limited may
monitor outgoing or incomi ng emails as permitted by law. It accepts
no liability for viruses introduced by this e-mail or attachments .
News Corp UK &Ireland Limited and its titles are committed to abiding by
IPSO's regu lations and the Editors' Code of Practice that IPSO enforces .
NIH-000 124
From: (b)(6)
Sent : Mon, 30 Mar 2020 06:05:28 -0400
To: DMID Wo rd Nerds
Subject: Fwd: Chloroquine is a thromboxane inhib itor: there is a readily available analog
Sent from my iPhone
From: "Dr. Josh Backen" <backon @mail.huji. ac.il>

------~= (b)(6)
Subject: Chloroquine is a thromboxane inhibitor: there is a readily available
analog
Dear Dr. Fauci,
I'm (b) (6) internist.
I have a sugge stion for 2 potent antiviral agent s, cheap and readily
ava ilable, that may prevent viral shedding. No viral shedding? No
infectivity. The concept is that EVERYONE should take these items.
First a short bio:
Dr. Josh Backon was affiliated with the Hebrew University Faculty of
Medicine for over 33 years. He has a good track record (84+
publication s quoted by over 750 other researchers in jou rnal articles
https ://scho lar. google. com/scholar?start =0&q=%22 backon ++j. %22& hl
=en&as sdt= 0,5
and in over 250-300 texts as per
https ://www.google.co m/search ?tbo=p& tbm=bks&q=% 22backon+j.+%
22&num = I 00 ) .
In the 1980's he was Consulting Editor o f the Jomna l of Pediatric
Endocrinology, Editor of Reviews in Pure and Applied Phann acological
Sciences, and Associate Editor of the International Journal of
Ado lescent Medicine and Health . From 1990-2004 , he was a consultant
NIH-000125
on emergency planning and management at Israel's National Police
Headquarters with Nitzav Mishneh Dannny Fisher.
Chloroquine, an antimalarial drug, is now being used to treat Covid-19.

Its mechanism was found in the 1970's to inhibit thromboxane
https ://scholar. goo gle.com/scholar?hl=en&as sdt=0%2C5 &g=chlorogui
ne+thromboxane&btnG = The problem with chloroquine was that it
also elevated level of prostaglandin F2alpha. In 1980, Sriva tava, an
Indian biochemi t working in Denmark found that GINGER i a potent
inhibitor of thromboxane yntheta e. I wrote a number of paper in the
1980's on u e of ginger:
htt :// cholar. oo le.com/ cholar?hl =en&as dt=0%2C5& =backon +
mge
r&btnG=
-
GINGER IS A POTENT ANTIVIRAL
sdt=0%2C5& er+a
-
THE SECOND ANTIVIRAL AGENT IS TURMERIC [add black
pepper since piperine dramatically increases oral bioavailability of
turmeric)
htt s://scholar. oo le.com/scholar?hl =en&as sdt=0%2C5& =turmeric +
anti viral&og=tur
Multisite inhibitors for enteric coronavirus: antiviral

cationic carbon dots based on curcumin
D Ting , N Dong, L Fang, J Lu, J Bi. .. -ACS Applied Nano ... , 2018 -ACS Publications
... These results offer theoretical support for the development of CCM-CDs as a hopeful
antiviral drug for the treatment of coronavirus infections, including PEDV ... Curcumin
(CCM) is a polyphenol compound obtained from turmeric roots ...
NAC AND PIPERINE TO INHIBIT INFLAMMATORY

CYTOKINES (iNOS, NF KappaB, TNFalpha) INVOLVED IN
ARDS
NIH-000126
Morta lity in COVID -19 patients is usua lly from ARDS (acute
respirato ry distress syndrome) via inflammatory cytokines. Apart from
N-acetylcysteine which was found 3 years ago to elevate atrial
natriuretic factor [found by Kiemer in 2001 to zap inflamma tory
cytokines: iNOS, NF KappaB, and TNFa lpha) now piperine in black
pepper was found to inhibit inflamma tory cytoki nes [piperine also
dramatically increases oral bioavai lability of turmeric [which has been
used as a potent antiviral]:
N-ACETYLCYSTEINE
PIPERINE
htt ://scholar. oo le.com/ cholar?h l=en&as sdt=0 5& - i erine%20i
nflammatory%20cytokines&btnG =&fbclid = Iw AR0kXZxI66JPLFPry2
MDTDxOAe lgGnmBZdKBw7 c I v7 8Hfi7t0J Jnx0Y2zuE
BTW the thromboxane hypothe i exp lain the increased male to female ratio in
infectivity a we ll as the low incidence in younger people.
http ://www .ncbi.nlm.nih.gov /pmc/article /PM 1433448/
Gut. 1987 Oct; 28(10): 1323.

doi: 10.1136/qut.28.10.1323
PMCID : PMC1433448
PMID: 18668886
Ginger and carbon dioxideas thromboxane

synthetase inhibitors:potential utilityin treating
peptic ulceration
Josh Backon
NIH-000127
From: Fauci, Ant hony (NIH/ NIAID) [E)
Sent : Mon, 30 Mar 2020 02:06:21 +0000
To: Tim Boyd
Subjec t : RE: You Rock!
Nancy:
Thank you for your kind note .
Best rega rds ,
Tony
----- Orig inal Messag e-----

_...;::;.....----~~
From : T im Boyd (b) (6)
Sent: Sunday. March 29. 2020 8:53 PM
To : Fauci, Anthony (NTH/NIAID)[E] ---------=.,...,-=
Cb)(
Subject: You Rock!
Dea r Dr. Fauci,
Atle r rea ding the article about you on the front of the New York Times this morn ing, 1 was dist resse d to learn that
you have recently been negat ively targe ted via soc ial media by members of a certain US politica l factio n. The
unfairness of these pers onal attacks upo n you is shocking, and I cannot imagine somet hing so bL11t ful happeni ng to
someone like you who possesses such a depth of knowledge and unimpeachable integrity . You are the affable,
truthful and reassu ring centre of calm during this de adly coronavirus storm. Your job is difficult enough without
peop le taking verbal pot-shots every time you speak.
1 wish you all the best during this try ing time. Stay well (and I hope you don 't completely lose your voice , too) ! I
loo k forward to seeing and hearing more from you on CNN and other media out lets.
Best wishes,
Nancy Hill
(b)(6)
Canada
Sent from my iPhone
NIH-000 128
NIH-000 129
NIH-000 130
From: (b)(6)
Sent: Sun, 29 Mar 2020 11:31:58 -040 0
To: Auchincloss, Hugh (NIH/NIAID) [E];DMID Wo rd Nerds
Subject: Fwd: Intro to Tony Fauci
From party
Hugh- I thought u responded to Carmona the former

Surgeon general?
Sent from my iPhone
From: Richard Carmona <rcarmona@canyonranch.com>

To: "Fauci, Anthony (NIH/NJAID) [E]" (bH6Ji
Subject: Fwd: Intro to Tony Fauci
Tony, first and foremost.. .. thank u for ur continued leadership and integrity in the"
combat zone".
I know u r drinking from the proverbial fire hose so I would not send anything ur
way ifI didn't think it may have merit to address our current challenge with
Coronavirus.
I email introduced u to this group some time ago. Their science has advanced and in
particular there seems to be a potential opportu nity to addres s the somet imes lethal "
cytokine storm" in some coronavirus patients as described in the attached e mail.
So I forward to you for your consideration as an adjunc t.
On a daily bas is I receive numerous " ideas" to address coronavirus from many well
intended people. A few have merit. Is there a Fed innovation review group that some
of these potential ideas could be funneled too?
I pray for you and your family
Be well
Rich
Richard Carmon
a
17th Surgeon General of The Un ited States
Chief of Health Innovations
Distinguished Professor University of Arizon
a
NIH-000131
8600 E. Rockcliff Road I Tucson, AZ 85750
0: 520 .749.7754
CANYONRANCH.
M: (b)(6)
canyonranch.com
B egin forwarded message:
From:James Thacker <jim_thacker@therimunex.com>

Date: March 29, 2020 at 06:04:40 MST
To: Richard Carmona <rcarmona @canyonranch.com >
Cc: Patricia Maxwell <PMaxwell @ canyonranc h.com >,
"dgrange @osp reyg lobalsol utions.com"
<dgran ge @ospreyg lobalso luti ons .com >
Subject: Intro to Tony Fa uci
!ExternalSended
Dear Rich,
(b) (4)
NIH-000132
I hope you and the family are healthy . As you can tell, I am still kickin ass and
tak in names. DD
Be we ll and be safe my Brother! DOL!
Sine Pari,
Jim
James D. Thacker, PhD

President/Founder - Head of Discovery &Science
1250 SussexTPKE, Unit 647
Mount Freedom, NJ 07970
Cell: (b)(6)
Email: jim tha cker@therimunex.com
URL: www.therimunex.com
Privileged, confidentia l and/or copyright information may be contained in this

e-mail. This e-mail is intended for the sole use of the addressee. If you are not
the intended addressee, or the person responsible for delivering it to the
intended addressee, you may not copy, forward, disclose or otherwise use
this message, or any part of it in any way whatsoever, to do so is prohibited
and may be unlawful. If you receive this e-mail by mistake, please advise the
sender immediately by using the reply facility in your e-mail software .
NIH-000 133
From: (b)(6)
Sent : Sun, 29 Mar 2020 11:25:38 -0400
Subject: Fwd: Phone Intervie w - COVID19
Sent from my iPhone
F rom: "mton-es8@ myse neca.ca " <mtorre s8@myseneca .ca>

Dat e: March 29, 2020 at 11:06:49 AM EDT
To: "Fauci , Anthony (NIH/NIAID ) [E]" -------~~ (b)(6)
Subject: RE : Phone Inter view- COVID19
Hi Dr. Fauci,
I' m look ing to do a qu ick 10 minute phone interv iew on COVID-19. I've seen your
interview s on CNN and they are very informat ive so I think you would be perfect
for our podcast.
Th is wou ld be fo r a podcast available to faculty and stude nts at Seneca Media

Depa rtment in Toronto .
Thanks,
Mon ika To rres

www .sen ecajoumalism.ca
NIH-000 134
From: (b)(6)
Sent: Sun, 29 Mar 2020 11:24:55 -040 0
To: DMID Word Nerds
Subject: Fwd: URGENTATTN DR FAUCIRE:COVID-19 IDEAFROMAUSTRALIANGP!
Please just read and see it this has the merit I believe it does!!
Sent from my iPhone
From: Stevie <stevie@empowerme.e nterprises>

To: "Fauci, Anthony (NIH/NIAID ) [E]" ---------=-=--:-=
(b)(6)
Subject: URGENT ATTN DR FAUCI RE: COVID-19 IDEA FROM
AUSTRALIAN GP! Please just read and see it this has the merit I believe it
does!!
Dear Sir,
My OP friend, Dr P'ng is a genius. He has a radical idea for fighting COVID- 19.
P lease find his idea , petition, projections and research attached to th e petit ion. I told
him he needed to get this is front of you and Bill Oates . Please cons ider it. I believe
it is viable and the best shot we have . I know you are the expert but I think this is
viable way we can help save millions of lives!
Yours sincerely,
Stephanie
Stephanie Russell-Farnham
Founder &CEO
EmpowerME Enterprises
M (b)(6)
E stevie@empowerme .enterprises
https: //www.cha nge .org/p/world-health-organisation-belp-defeat-covid-

19-save -the-
world?recruiter= 1066780682&utm somce=shar e petition&utm rnediu
m=facebook&utm campaign=share petition&utm term=share petition
&recmited by id=40795060-7lab-llea-a9:f8-
13e6b487f548&utm content =starter 1b share content en-au%3Avl 1
NIH-000135
Sent : Sun, 29 Mar 2020 11:23:39 +0000
Subjec t : FW: New Zealand interview request
fyi
From: Pat Brittenden <info@blindfish .media>

Sent : Sunday, Marc h 29, 2020 7:21 AM
To : Fauci, Anthony (NIH/NIAID) [E]--------,
---------
.....,..,=(b)(6)
Subject : New Zealand interview request
Hey Dr Fauci,
Am wondering if you would be interested in having a chat with us in NZ, over Zoom, as we all sit in our
houses fighting Coronavirus
I do a podcast which is normally live streamed but we currently have a country wide lockdown and lots
of us have moved our gear home to continue providing content for people who are stuck in their homes
the US is like out big brother, we love you guys and would like to connect in solidar ity about COVID19 so
I'm hoping that maybe you could find us sometime to have a chat over the internet . Some content
would also help us give some more content to Kiwi's who have gotten to the end of Netf lix ;)
Find out more about the podcast at www.theDOC.nz and more about me
at www.patbrittenden.com/about
Can make anytime happen, fingers crossed we'll hear back from 'someone'.
Pat Brittenden
www.theDOC.nz
www.patbrittenden.com/about
(b)(6)
NIH-000 139
From: (b)(6)
Sent : Sat, 28 Mar 2020 19:01:58 -0400
To: ldonae Lovetrue
Subject: Re:COVID-19 aetiology and treatment for critically ill patients:
irinotecan+etoposide
Thank you for your note

AS Fauci
Sent from my 1Phone
On Mar 28, 2020, at 6:36 PM , Idonae Lovetrue

<idonae @demiurge. technology >wrot e:
Dear Dr. Fauc i,
In addition , I'd like to share with you the following clin ically relevant genetic
differences between patients in the US and in East Asia:
(b) (4)
Please find attached dosage recomme ndation and my team is standing by if you
need any further assistance.
Sincerely,
ldonae
ldonae Lovetrue I CEO, Demiurge Technologies AG, Switzerland
www . demiurge .technology
This email and any attachments thereto may contain private, confidential, and privileged material for the
so!e use of the intended recipient. Any eview. copying, or distribution of this email (or any attachments
thereto) by others 1sstnctly prohibited. If you are not the intended recipient, please contact the sender
immediately and permanently delete the original and any copies of this email and any attachments thereto.
This email is intended for information purposesonly and is provided without any warranty of any kind,
either expressed or implied. While some information used on th1s document may have been obtained from
NIH-000140
va,1ouspublished and unpublished sourcesconsidered to be reliable, Dem:urge 1echnologiesAG neither
guarantees its accuracy or completeness nor accepts iabil1ty for any direct or consequential losses arising
from its use.Thank you.
From: Idonae Lovetrue <idonae@demiurge.technology >

Date: Saturday , 28 March 2020 at 15:53
To: Cb><
Subject : COVID-19 aetiology and treatment for critically ill patients:
irinotecan +etoposide
Dear Dr. Anthony S Fauci,
This is ldonae , CEO at Demiurge Technologies AG, a Swiss Al-

biopharma company making accurate and rapid drug discoveries for
diseases with limited available clinical data. We are committed to the
non-profit dissemination of our COVID-19 discoveries to the public to
facilitate the search for COVID-19 effective treatments.
SARS-CoV-2 is fundamentally different from all the other viruses that the
world has hitherto known, so treatments must be rationally designed to
avoid fueling the adaptive mutation and the latent infection of SARS-
CoV-2.
Demiurge is the world's first company that has discove red the detailed
aetiology of COVID -19 that consistently explains the clinical features of
COVID-19 and the MoA-based scientific rationale of the candidate
treatments for COV ID-19
(https://www.preprints .org/manuscripV202003.0341 /v1 ).
(b)(4l
NIH-000141
(b) (4)
Thank you for your consideration and my team is stand ing by for any
furt her assistance .
Sincerely ,
ldonae
ldonae Lovetrue I CEO, Demiurge Technologie s AG, Switzerland
NIH-000142
www.demiurg e.technology
This email and any attachments thereto may contain private, confidential, and privileged
material for the sole use of the intended recipient. Any review, copying, or distribution of this
email (or any attachments thereto) by others is strictly prohibited. If you are not the intended
recipient, please contact the sender immediately and permanently delete the original and any
copies of this email and any attachments thereto . This email is intended for information purposes
only and is provided without any warranty of any kind, either expressed or implied. While some
information used on this document may have been obtained from various published and
unpublished sources considered to be reliable, Demiurge Technologies AG neither guarantees its
accuracy or completeness nor accepts liability for any direct or consequential losses arising from
its use.Thank you.
<mime-attachment >
NIH-000143
From: (b)(6)
Sent : Sat, 28 Mar 2020 17:58:32 -0400
To: Hallett, Adr ienne (NIH/OD) [E]
Cc: Collins, Francis (NIH/OD) [E];Tabak, Lawrence (NIH/OD) [E];Wolinetz, Carrie
(NIH/OD) [E];Shapiro, Neil (NIH/OD) [EJ;Lauer, Michael (NIH/OD) [E]
Subject : Re: Brad Sherman
Thanks to everyone.
On Mar 28. 2020, at 5:32 PM , Hallett, Adrie nne (NIH/OD) [E]

(b) (6J>wro te:
Thanks Franc is. I just spoke to his Deputy Chief of Staff ________ (b_H _6)
(b) (5)
I'll share what I see when I see it.

Adrienne
On Mar 28, 2020, at 2:27 PM, Collins, Francis (NIH/OD) [E]

(b)( t:
Hi Adrienne,
NIH-000 144
I spoke with Brad Sherman (D-CA) yesterday . He had origi nally reached out to
Tony, and Cliff Lane spoke to him Thursday, but I stepped in to try to lift one
task off of Tony's plate .
(b) (5)
He said he is sending a letter to Tony and me, asking what we need to go flat
out against COVID-19. He wanted to know who from my office his staff could
work with. I said you!
Francis
NIH-000 145
From: (b)( 6)
Sent : Sat, 28 Mar 202017 :31:25 -0400
To: Jiaxian Zhou Wu
Subjec t : Re: Thank you for your service!
> On Mar 28, 2020, at 4:40 PM, Jiaxian Zhou Wu

> ------------ (b) (6) wrote :
>
> Dear Dr.Fauci,
>
> I am writ ing this emai l to personal ly thank you for your invaluable service to our country. The United States of
America. Th is virus, COVTD-19 , is really dangerous and Jam very scared of it. Tam really worried about my
country , about the count less deaths . Your advice to the president has proven rea lly important to preve nt the spread
of the disease , however, in this nation, there is another epidemic based on lies and self~interest, now the people
behind the fake news are targeting to you, one examp le is the post of an ema il that relates to you with the fonne r
Secretary of State, Hillary Clinton. This is why l decided to write a letter of support, I am sick of fake news ,personal
attacks and violation of the First Amen dment , the 1ight to have an opinion,to civil servants serving this country.
>
> I am still young but I still want to live in a United country. I ask you to continue your job, I want you to know that
most Americans regardless of ideology are grateful of your service and sacrifice . A virus does not understand
boundaries nor ideology , I am not an expert on this topic nor the presiden t and pol iticians. Please guide us with the
truth in these dire and dark days .
NIH-000 146
From :
Sent : ----- (b)( 6) (NIH/N IA ID) [E)
Sat, 28 Mar 2020 19 :43:52 +0000
To : (b)(
Subject: RE: medRxiv: Ant i-hypertensive Angiotens in II receptor blockers associated to

mitig ation of disease severity in eld erly COVID-19 pati ents
(b)( 6)
Thanks for the note.
(b)(6)
Thanks,
Tony
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail (b) (6)
From: (b)(6b
Sent : -----------------
Friday, March
27, 2020 2:37 PM
-------~~
--------- (b)(6)
Subje ct: Re: medRxiv: Anti-hyper tensive Angiotensin II recep tor b lockers associated to mitigation o f
disease severity in elderly COVID-19 patients
Hi Tony,
NIH-000147
Thanks for the update. A ll of th is early science is certai nly confusi ng - (b)(6)
Much t he same th in g t hat we are
hear ing from Am Colle ge of Card iology . I appreciate your keeping me informed.
How are you do i ng? (b)( 6)
Best ,
~
From: Fauci, Anth ony (NIH/N IAID) [E]
Sent: Friday, M arch 27, 202 0 1:29 PM
--------- (b)(6)
To:
---------------- (b)(6) >
Subject: [EXTERNAL)FW: medRxiv: Ant i-hyp ert ensive Angiot ensin II receptor blockers associated t o
miti gat ion of disease severity in eld erly COVID-19 pat ient s
** ATTENTfON: This email originatedfrom outside the MedStar network.

** DO NOT CLlCK links or attachments un less you recognize the sender and know the content is safe.
)(6):
See below. The situ ation continu es to get more comp licated .
Best ,
Tony
Director
Bui ld ing 31, Room 7A-03
Phone : (b)( 6)
FAX: (301 496 -4409
E-mail: (b)(6)
Anti-hypertensive Angiotensin II receptor

blockers associated to mitigation of disease
severity in elderly COVID-19 patients
Yingxia Liu, Feng ming Huang, Jun Xu, Penghui Yang, Yuhao Qin, Mengli Cao, Zhaoqin Wang, Xiaoh e Li,
Shaogeng Zhang, Lu Ye, Jingjun Lv, Jie Wei, Tuxiu Xie, Hong Gao, Kai-Feng Xu, Fusheng Wang, Lei Liu,
Chen gyu Jiang
NIH-000148
doi: https:Udoi.org/10.1101/2020.03 .20.20039586
This article is a preprint and has not been certified by peer review [what does this mean?]. It
re orts new medical research that has et to be evaluated and so should not be used to uide
clinical practice.
• Abstr act
• Info/H isto ry
• Met rics
•
•
• Preview PDF
Abstract
Summary Background The novel coronav irus (CoV) severe acute respiratory syndrome (SARS)-CoV -2
outbreak started at the end of 2019 in Wuhan, China, and spread over 100 countr ies. SARS-CoV-2 uses
the membrane protein Angiotensin I converting enzyme 2(ACE2) as a cell entry receptor . Indeed, it was
reported that the balance of Renin-Angiotensin System (RAS), regulated by both ACEand ACE2,was
altered in COVID-19 patients. It is controversial, however, whether commonly used anti-hypertensive
drugs Angiotensin I converting enzyme inhibitor (ACEI)and Angiotensin II receptor blocker (ARB) shall be
continued in the confirmed COVID-19 patients. This study was designed to investigate any difference in
disease severity between COVID-19 patients with hypertens ion comorbid ity. The included COVID-19
patients used ACEI, ARB, calcium channel blockers (CCB),beta blockers (BB), or th iazide to treat
preexisting hypertens ion prior to the hospital were compared to patients who did not take any of those
drugs. Methods In this multicentre retrospect ive study, clinical data of 511 COVID-19 pat ients were
analyzed. Patients were categor ized into six sub-groups of hypertens ion como rbidity based on
treatment using one of anti -hypertension drugs (ACEI,ARB, CCB,BB, th iazide), or none. A meta -analysis
was performed to evaluate the use of ACEI and ARB associated w ith pneumonia using published stud ies.
Findings Among the elderly (age>65) COVID-19 patients with hypertension comorbidity, the risk of
COVID-19-S (severe disease) was significantly decreased in patients who took ARB drugs prior to
hospitalization compared to patients who took no drugs (OR=0.343, 95% Cl 0.128-0.916, p=0.025) . The
meta -analysis showed that ARB use has positive effects associated with morb idity and mortality of
pneumon ia. Interpretat ion Elderly (age>65) COVID-19 patients with hypertension comorb idity who are
tak ing ARB anti -hypertension drugs may be less likely to develop severe lung disease compared to
patients who take no anti -hypertens ion drugs . Funding Nationa l Natural Science Foundat ion of China,
Chinese Academy of Medica l Sciences
Di claimer: Any third-party material in thi email has been hared for internal use under fair use provisions
of .. copyri0 ht law, without further verification of it accuracy/veracity. It docs not ncccs arily reprc ent
my views nor th ose of IAID , NIH H H , or th e U. . governm ent.
MedStar Health is a not-for-profit, integrated healthcare delivery system, the largest m Maryland and the Washington, D.C., region Nationally
recognized for clinical quality in heart, orthopaedics, cancer and GI
IMPORTANT: This e-mail (Including any attachments) may contain information that 1sprivate, confidential, or protected by attorney-client or
other privilege. If you received this e-mail in error, please delete it from your system without copying it and notify sender by reply e-mail. so
that our records can be corrected ... Thank you.
Help conserve valuable resources - only print this email if necessary.
NIH-000149
Sent : Sat, 28 Mar 2020 19:26:52 +0000
To: Real. Francisco
Subjec t : RE:A thank you note
Paco:
Thank you for yo ur kind not e.
Warm regards,
Tony
Director
Phone : (b) (6)
FAX: (301 496-4409
E-mai l (b) (6)
information. It shou ld not be used by anyone who is not the orig inal intended recipient . If you
other storage devices . The Nat ional Ins t itute of Allergy and Infectious Diseases (NIAID) shall not
behalf of t he NIAID by one of its representa t ives .
From: Real.Francisco <freal@cn io.es>

Sen t: Saturday, March 28, 2020 3:20 PM
To : Fauci, Anthony {NIH/NIAID) [E]------- ~=
Subject: A thank you note
--------- (b)(6)
Dear Tony,
please allow me to call you Tony as I feel somewhat close to you (although there is no reason why you
should rem ember me). In early 19811 was doing a clini cal fellowship in Immunology/Oncology at
Memorial Sloan-Kettering Cancer Center and wrote to you (b) (6)
During my period at Memorial I worked

extensively on AIDS and Kaposi's sarcoma ... and eve r since - I moved in 1988 to Spain, my home country
- I have followed and admired your wo rk.
----------------------- (b)(6) I always felt close to you and your

amazing work . Now, when I see you taking care of your coun t ry's action against Covid-19, I am proud to
have been attracted and inspired by your work in biomedical research and I am proud of what we -
physician-scientists - can do for your societies and fo r human beings .
NIH-000 150
From my very modest end as a human being, thanks for your responsib le, honest, scientific leadership.
Best wishes, we need people like you
Francisco X. Real (Paco)
Epithelial Carcinogenesis Group

Molecular Oncology Programme
Centro Nacional de lnvestigaciones Oncol6gicas
Melchor Fernandez Almagro, 3
28029-Madrid (Spain)
Phone +34 917328000 ext 3660
E-mail preal@cnio.es
www.cnio.es
HAZTE AMIGO/A mas INVESTIGACl6N

DEL CNIO menos CANCER
Fb Hazte Amigo de\ CN\O I Tw @HazteAmigoCNIO I Youtube canalcnio
** ADVERTENCIALEGAL**: Este correo electr6nico, yen su caso los fichero s adjuntos, pueden contener
informaci6n protegida para el uso exclusivo de su destinatario. Se prohfbe la distribuci6n, reproducci6n
o cualquier otro tipo de transmisi6n por parte de otra persona que no sea el destinatario. Si usted recibe
por error este correo, se ruega comunicarlo al rem itente y borrar el mensaje recibido.
De conformidad con lo dispuesto en el Reglamento (UE) 2016/679 relativo a la protecci6n de los datos
personales de las personas ffsicas, la informaci6n personal que nos pueda facilitar a traves de este
correo electr6nico quedara registrada por la Fundaci6n CNIO con la finalidad de tramitar el objeto del
presente correo electr6nico . El tratamiento de sus datos personales se encuentra legitimado por ser
necesario para gestionar el objeto del presente mensaje. Estos datos personales no seran comunicados
a ningun destinatario salvo a aquellos que usted nos auto rice o asf venga exigido por una ley. Ud. podra
NIH-000151
ejercer los derechos de acceso, rectificac i6n , supresi6n, limitaci6n de tratamiento , portabil idad y
oposici6n en la siguiente direcci6n : c/Melchor Fernandez Almagro 3, 28029 (Madrid). Podra ponerse en
contacto con el Delegado de Protecci6n de Datos en: delegado lopd@cnio.es. Para el caso de que Ud.
precise conocer informaci6n adicional sobre el tratamiento de sus datos personales, puede consultar
dicha informaci6n adicional en el siguiente enlace dentro de nuestra pagina web:
https://www.cnio.es/es/privacidad/index .asp
**LEGAL NOTICE**: This email and any attached files may contain protected information for the sole
use of its intended recipient or addressee. Anyone other than the intended recipient or addressee is
strictly prohibited from distributing , reproducing or transmitting the email and its contents in any way. If
you receive this email in error, please notify the sender and delete the message.
Pursuant to the provisions of EU Regulation 2016/679 regarding the protection of personal data, any
personal information you provide through this emai l will be registered by the CNIO Foundation in order
to deal with content of this email. Your personal data must be processed in order to be able to deal with
the content and purpose of this message. Your personal details will not be passed on to anyone else
unless you authorise us to do so or we are required to do so by law. You may exercise your rights
regarding access, rectification, suppression, limitation of processing, portability and opposition by
writing to the following address: c/Melchor Fernandez Almagro 3, 28029 (Madrid). You may contact the
Data Protection Delegate (Delegado de Protecci6n de Datos) at: delegado lopd@cnio.es. If you require
further information about the processing of your personal data, go to the follow ing link on our webpage :
https://www .enio.es/ es/privacidad/index. asp
NIH-000152
Sent: Sat, 28 Mar 2020 19:00 :32 +0000
Auchincloss, Hugh (NIH/N IA ID) [CJ
To:
(NIH/NI A ID) [E];McGowan, Robert (Kyle) (CDC/OD/OCS) ---------- (b)(6);Harper, Jill
Cc: (b)(6)
Subject: FW: Time -Sensitive OSTPRequest - Due 12 pm Monday , March 30
Attachments: 2020-03-28 _ COVID-19 FOAs-Projects .xlsx
Pleaserespond
Direc;tor
Phone: (b)( 6)
FAX: (301 496-4409
E-mail: Cb)(6)
behalf of the NIAID by one of its representa t ives.
From: Schwetz, Tara (NIH/OD) [E] (b)(6) >

To: ICDDIR-L@list.nih.gov
Cc:List DEPDIR-L<DEPDIR-L@list.nih.gov>; NIH Director's Executive Committee <OD-
SmallStaff@mail.nih.gov> ; NIH P&E Principals and Alternates <NIHP&EOfficers@mail.nih.gov>; Wa lsh,
Elizabeth (NIH/OD) [E) (b)( >
Subject: Time-Sensit ive OSTP Request· Due 12 pm Monday, March 30
Importance: High
Good afternoon,
We received a time -sensit ive request from OSTP that we are asking for your help to comp lete . Apo logies
in advance for the short turn -around .
Action - Complete t he attached template to provide FOAs and projects on " innova tio n" and COVID-19,
specifically focus ed on the topics described below . If your ICO has no noth ing to report, please let us
know .
Requestor - OSTP
NIH-000153
(b)(5)
POCs and Due Dat e - Please send the completed template to Elizabeth Walsh
(Elizabeth.walsh@nih.gov) by noon on Monday, March 30
Timeline -
NIH Receipt Institut e Response to OD OD Office Review Date NIH Final Response
Date Due Date Due Date
3/28/20 3/30/20 3/30/20 3/30/20
Additional Instructions -
• I pulled all the COVID-19 FOAsfrom the Guide; however, I did not sort through which ones are
relevant to this request. Please submit only those that your IC is the lead on that meet the
criteria listed above. Delete any that do not apply.
Attachment s -
• Response template (FOAs tab, Grants-Contracts tab)
Do let me know if you have any questions.
Best,
Tara A. Schw etz, PhD

P: (b)(6) I M:
--- ~-,=,
(b)(6)
NIH-000154
Sent : Sat, 28 Mar 202018:43:17 +0000
To : (b)(6)
Subject : FW: Washi ngtonian : You Can Now Buy Ant hony Fauci Swag
Geeeez
Director
Phone: (b)(6)
FAX: (30 496"'4409
E-mail: (b)(6)

--------
Sent : Friday, March 27, 2020 6 :11 PM
(b) ~ >
To: NIAID OD AM <NIAIDODAM@niaid .nih .gov>;

-------------------
Subject : W ashingtonian : You Can Now Buy Anthony Fauci Swag
(b)(
You Can Now Buy Anthony FauciSwag

T-shirts, mugs, pillows-and, yes, even a Fauci prayer candle.
Wr itten by Daniella Byck
I Published on March 27, 2020
NIH-000 155
About Coronavirus 2020
Washingtonian is keeping you up to date on the coronavirus around DC.
More from Coronavirus 2020
Fauci stans, assemble! Dr. Anthony Fauci,director of the National Institute of Allergy and Infectious
Disease, has emerged as the celebrity of th e coronavirus crisis. Like others before him (remember
Mueller mania?), his prominence has yielded but tons , t-shirts, and gifts, all flaunting the Fauci.
NIH-000156
Fauci face socks
Another reason you won' t want to wear your shoes inside. $9.99, Etsy.
NIH-000 157
"Dr. Anthony Fauci Fan Club" button
Fauci-fy any look with this pin. $3 .16, Etsv.
NIH-000 158
"I need a hero" T-shirt
Paying homage to Fauci and Bonnie Tyler? This shirt is working overtime . $19.99, Etsv.
NIH-000 159
"Honk for Dr. Fauci" lawn sign
A social distancing win: Show your support without leaving the house. $14 .95, Etsy.
NIH-000 160
FauciPrayer Candle
Praying you washed your hands . $20.20, Etsy.
NIH-000 161
"Fauci 2020" T-shirt
Finally, a shirt for those White House coronavirus briefings. $18, Etsy.
NIH-000 162
"Hope" sweatshirt
Thanks, Fauci. $18.99, Amazon .
NIH-000 163
KEEP
CALM
AND
WASH
YOUR
HANDS
"Keep calm and wash your hands" mug

A little PSAto go with your morning coffee. $19.95, Etsy.
NIH-000 164
Dr. Anthony Fauci T-shirt
A perfectly acceptable day-to -evening look in your self-quarantine. $29.00, Esty.
"I Heart Dr. Fauci" throw pillow

For sweet, scientific dreams. $20.66, Redbubb/e .
Keep Up on DC' s Latest Fashions with Our Shopping Newsletter
Fashion finds and deals, and the latest trends for you and you r home.
NIH-000 165
Sent : Sat, 28 Mar 2020 18:26:42 +0000
To: (b)(6)
Subjec t : FW: Wpost : How the Viet nam War may have changed Anthony Fauci's life
FYI
Director
Phone: (b)(6)
FAX: (30 496"'4409
E-mail Cb)(6)
From: Folkers , Greg (NIH/NIAID) [E]

---------
(b)(6)
Subject: Wpost: How the Vi etn am War may have changed Anthony Fauci's life
Opinions
How the Vietnam War may have changed

Anthony Fauci's life
nthony S. Fauci, director of the National Institute of Allergy and

Infectio us Diseases, speaks with th e coronavirus task forc e at th e Wh ite House on Tuesday. (Jabin
Botsford/The Wash ington Post)
By Ray Greenberg
March 27, 2020 at 3:34 p.m . EDT
Ray Greenberg is a physician epidemiolog ist, former executive vice chancellor for health affairs at the
University of Texas System and the author of "Medal Winners: How the Vietnam War Launched Nobel
Careers."
NIH-000 166
Americans may have the war in Vietnam to thank for Anthony S. Fauci.
An adviser to six presidents and now the trusted public face of the scientific response to the coronavirus
pandemic, Fauci has worked at the National Institutes of Health (NIH) for more than a half-century -
beginning in 1968 with a group of doctors cheekily known as Yellow Berets.
During the conflicts in Korea and Vietnam, the U.S. military faced a pressing need for physicians. In 1966,
during Fauci's senior year at Cornell University Medical College, a military recruiter came to tell the
assembled students: "After you finish medical school, every one of you except the two women will
either be in the Air Force, the Army, the Navy, or the Public Health Service." The last option, entering
the Public Health Service, entailed assignment at the NIH, the Centers for Disease Control or the Indian
Health Service.
Those who were selected to serve at the NIH were known officially as clinical associates, but informally
they were referred to as Yellow Berets. Whether the designation was born in jest or derision, it was
intended as a foil to the Green Berets of the Army Special Forces. Fauci never liked the label because it
implied an unwillingness to serve in harm's way. "As a physician," Fauci said, "I felt if I had to go [to
Vietnam], I would gladly do my part to try to help."
The competition for the limited number of Yellow Beret slots was so intense that only the best and
brightest young physicians were selected. Fauci, the top graduate in his medical school class, was one of
seven chosen from 140 applicants to train in his laboratory of interest. As described in my book "Medal
Winners: How the Vietnam War Launched Med ical Careers," the class of Yellow Berets that entered with
Fauci included four future Nobel laureates : Joseph Goldstein, Michael Brown, Harold Varmus and Robert
Lefkowitz .
Each new appointee completed two years of clinical training before arriving at the NIH. Their primary
responsibility was learning how to conduct basic research under the guidance of a senior scientist. The
second job was to care for patients at the NIH Clinical Center. Fauci and his fellow infectious disease
colleagues also helped to care for wounded service members at the nearby National Naval Medical
Center.
Fauci, who had some research experience in medical school, trained at the NIH for three years under the
tutelage of Sheldon Wolff - a pioneer in the relationship between the immune system and infectious
diseases. Following a year of additional clinical training back in New York, Fauci returned to the NIH as a
senior scientist conducting pioneering work, first on autoimmune conditions, then transitioning to study
the newly emerging disease that would become known as AIDS.
When he entered the clinical associate program, Fauci's ambition was to become a medical school
professor. Had the Vietnam War not brought him to the NIH, Fauci probably would have remained in
academia and the country never would have benefited from his extraordinary public service.
Instead, from his position as director of the National Institute of Allergy and Infectious Diseases, Fauci
has helped shape national policies related to HIV, bioterrorism and a series of pandemic threats
including avian influenza, H1N1 (swine) influenza, Ebola and severe acute respiratory syndrome. It is
hard to imagine any other physician who has had such a sustained and profound impact on the health of
our nation.
While Fauci remained at the NIH for his entire professional career, most of his fellow Yellow Berets left
Bethesda after their training was completed and headed for jobs at universities . Across the nation, the
former Yellow Berets became medical school scientists, department chairs and deans. More than 60
former clinical associates, including Fauci, were elected to the prestigious National Academy of Sciences,
and he also was one of the more than 125 Yellow Beret alumni elected to the Institute of Medicine (now
the National Academy of Medicine). In addition, Fauci was one of 10 alumni to receive the National
Medal of Science.
NIH-000167
For all the scars left by the Vietnam War, we should not overlook the fact that in its absence, SOyears
late r the country would probably not have Anthony Fauci guiding us through our current crisis. Dr. Fauci,
we salute you and your fellow Yellow Berets.
my views nor those ofNIATD , NTH, HHS , or the U.S. governme nt.
NIH-000168
Sent : Sat, 28 Mar 202017:52:04 +0000
Subject : RE: Dr . Fauci hits and requests
Thanks.
Director
Phone: (b)(6)
FAX: (30 496"'4409
E-mail: (b)(6)
Se nt : Friday, March 27, 2020 6:24 PM

--------
From : Billet , Courtney (NIH/NIAID) [E] (b) (6)>

(b)( 6)
------
-------- ~= (b)( ·>; Conrad, Patrici a (NIH/NIA ID) [E]
Cc: Stover, Kathy (NIH/NIAID) [E]

(b) (6) > -------- (b)(6)>; Routh, Jennifer (NIH/NIAID) [E]
Subject: FW: Dr. Fauci hits and requests
(b) (5)

Sent: Friday, Ma rch 27, 2020 6:23 PM
To: O'Malley, Devin M. EOP/OVP ---------~~ (b)(6) •>
Subject: RE: Dr. Fauci hits and requests
Devin- (b) (5)

Cb)(5l
From : Routh, Jennifer (NIH/N IAID) [E)

Sent : Friday, March 27, 2020 6:18 PM --------- (b)(6)
NIH-000 169
To: O'Malley, Devin M . EOP/OVP~--:-:---:-::-:-::-::-:-".".'":""::--:.:==::.;__.;._......;.
(bH ; Love, Kelly__A. EOP/OVP
..;___,:-:-=,
---------
Bowman,
__ Lauren
___;___;___
(b)(6)>; Henning , Alexa A. EOP/WHO
K. EOP/WHO
.....;._~ (b~)( ~6)'> _________ (b)(6);
_ Porter , Macaulay V. EOP/OVP
(b)(6)>;
Cc: Billet, Courtney (NIH/NIAID) [E] (b)( ; Stover, Kathy (NIH/NIAID) [E]
(b)(6J>; Conrad, Patricia (NIH/NIAID) [E] (b)(6); Hall, Bill
":"----:-----:--:::====~~~=
(HHS/ASPA) (b)(6)>; Mu rphy, Ryan (OS/ASPA) (b)( >
Thanks, Devin. We have declined and scheduled as you advised. Below is an updated list and schedule .
Friday 3/27
• Pittsburgh, PA (also airs in OH and WV) - Bloomdaddy radio - 634 am live hit completed
• Baton Rouge, LA- Morning News w/ Brian Haldane - 7:05 am live hit completed
Saturday 3/28
Showtime Desus and Mero - taping at 2 p.m. scheduled
Sund ay 3/29
CNN State of the Un ion - live hit 9: 15 a .m . scheduled
Monday 3/3 0
• Apple TV+ Oprah - tape 11:30 a.m. scheduled
• Radio - Rantz show Seattle - 8 p.m. live hit schedule d
• Radio - John/Ken show California - 8:30 p.m. live hit scheduled
Tuesday 3/31
• CBS T he Late Show with Step hen Colbert-tape 11 a.m . schedule d
• CNN Coro navir us podcast with Sanjay Gupta - tape 12 noon sche duled
• Wall Street Journa l T he Journa l Podcast - tape 1 p.m . ET
-
Wedne sday 4/ 1
New York Times The Daily podcast- tape 12 noon schedu led
(b)(5)
Thanks,
Jen
Jennifer Routh [E]
NIH-000 170
News and Science Wr iting Branch
Office of Commu nications and Govern ment Relations
NIH/H HS
31 Center Drive Room 7A 17C
Bethesda, MD 20892
Direct: Cb)(6)
(b)(6)
Disclaimor : The information in this e-mail and any of its attachments is confidential and may contain sensi tive information. It should not be
usedby anyone who is not the original intendedrecipient. If you have received this e-mail in error please inform the senderand delete it
fromyour mailbox or any other storage devices. The National Institute of Allergyand Infectious Diseases shall not accept liability for any
statements made that are sender's own and not expressly madeon behalf of the NIAID by one of its representatives.
J:rom : O'Mall ey, Devin M . EOP/OVP

Sent: Thursday , March 26, 2020 6:58 PM -------------- (b)(6)
To: Routh , Jennifer (NIH/N IAID) [El-------=-:~ >; Love, Kelly A. EOP/OVP
----------
6ow man, Lauren K. EOP/WHO
(b)(6)>; Henn ing, Alexa A. EOP
(b)(6)>
(b)(6) ; Porter, Macaulay V. EOP/OVP
(b)(6)
Cc: Billet , Courtn ey (NIH/NIAID) [E] -------~ =

(b)(6); Stover, Kathy (NIH/NIAID ) [E]
H 6); Conrad, Patricia (NIH/NIAID) [E]
Cb CbH6J; Hall, Bill
"':":'":':-:-:--:-:-::::-:--:.=====---,.,_.;
=-
(HHS/ASPA) (b)(6) Mu rphy, Ryan (OS/ASPA) (b)(6)
Yellow means schedule

Green means let's revisit
Crossed out means please decline
From: Rout h, Jennifer (NIH/NIA ID) [E]

Se nt: Thursday , March 26, 2020 6:52 PM --------- (b)(6)
To: O'Malley, Devin M. EOP/OVP ----------~~ (b)( >; Love, Kelly A. EOP/OVP
-:-----:-:-----:--::--:-::-7."'.'"'.".'":""'.'.-.:===:...;_-_.;.
_ _;___ ...;,.._--=-~
-----------
Bowman, Lauren K. EOP/WHO
___ .;__ ____
(b)(6); Henning , Alexa A. EOP/WHO
...;_ _ _,(~
b)~(6)
~> -----------
(b)(6J> ; Porter , Macaulay V. EOP/OVP
(b)(6);
Cc: Billet , Courtney {NIH/NIAID) [E] ------~ =

(b)(6)>; Stover, Kathy (NIH/NIA ID) [El
H 6J>; Conrad, Patri cia (NIH/NIAID)
Cb [El
"':":'":':-:-:--:-:-::::-:--:-;:::===::!....:-~ ~
(HHS/ASPA) (b)(6)>; Mu rphy, Ryan (OS/ASPA)
Subjec t : RE: Dr. Fauci hit s and requests
Good even ing-
Below is a list of pending hits and requests for Dr. Fauci:
Thur sday 3/26

• W TOP- 6:10 a.m . completed
• NPR Morn ing Ed ition - 7 :07 a.m . co m pleted
• YouTube content creato r inte rviews - 11 a .m . completed .
NIH-000171
o The content creators will publish the interviews on YouTube over the next few
days. We expect Trevor Noah will publish tonight.
• lnstagram Live video with Steph Curry- 1 p.m. completed
• CNN Town Hall- scheduled 8 p.m. live
Friday 3/27
• Pittsburgh , PA (also airs in OH and WV) - Bloomdaddy radio - 634 am live hit scheduled
• Baton Rouge, LA - Morning News w/ Brian Haldane - 7:05 am live hit scheduled
(b) (5)
NIH-000 172
(b) (5)
Jennifer Routh [E]

NIH/HHS
Bethesda, MD 20892
Direct: (b) (6)
(b)(6)
Disclaimer : The information in this e-mail and any of its attach ments is confide nti al and may contain se nsitive informat ion. It should not be
used by anyone w ho is not the original intended recipient. If you have received this e-mail in error please inform the sende r and delete it
from you r mailbox or any other storage devices . The National Institute of Allergy and Infectious Diseases shall not accept liability for any
statements made that are sende r's own and not expressly made on behalf of the NIAID by one of its representatives.
From: O'Malley, Devin M. EOP/OVP

--------------
--------~~
(b)(6); Love, Kelly A. EOP/OVP
(b)(6)
----------- (b)(6 b ; Henning , Alexa A. EOP/WHO

(b)(6) ;
(b)(6) ; Porter , Macaulay V. EOP/OVP
(b)(6 )>
Cc:Billet , Courtney {NIH/NIAID) [E] (b)(6J>; Stover, Kathy (NIH/NIAID) [E]
(b)(6)>; Conrad, Patricia {NIH/NIAID) [E] (b)( >; Hall, Bill
"'.'----:-----:-::====-..:_~~
(HHS/ASPA) (b)(6J>; Mu rphy, Ryan (OS/ASPA) (b)(6)>
(b) (5)
From:Rout h, Jennifer (NIH/NIAID) [E] _______ (b)_ (_

6)>
To: O'Malley, Devin M . EOP/OVP.__ _________ ------------=-:-:= (b_) _
<; Love, Kelly A. EOP/OVP
NIH-000173
Henning, Alexa A. EOP/WHO
----------- (b)( (b)(6) ;
___ ____ (b)( 6) >

,:__ ,:___~:;;----------- (b)( >; Porter, Macaulay V. EOP/OVP
Cc : Billet, Courtney (NIH/NIAID) [E] _____ H=6); Stover, Kathy (NIH/NIAID) [E]
--,;;(b-,-.
(b)(6)>; Conrad, Patricia (NIH/NIAID) [E] (b)( >; Hall, Bill
"'.".-"'~~~=====-.;;__ ~=
(HHS/ASPA) (b)(6)>; Murphy, Ryan (OS/ASPA)
--------
Subject: RE:Dr. Fauci hits and requests
(b)(6)
Good evening-
Below is a list of pending hits and requests for Dr. Fauci. Flagginga few new inquiries:
(b) (5)
W edne sday 3/25

• Bob Rose Radio Show - Ga insville Fl - 6:33 am live hit - completed
• Bern ie and Sid Radio Show - NYC - 7:05 am live hit - completed
• CNN Cuomo - scheduled live hit 9 :05 p.m.
Thur sday 3/26

• WTOP- schedu led live hit 6:10 a.m .
• NPR Morning Edition - scheduled live hit 7:07 a.m .
• YouTube content creato r interviews - scheduled 11 a.m.
• lnstag ram Live video with Steph Curry- schedu led remote conversat ion 1 p.m.
• CNN Town Hall - scheduled 8 p. m . live
-Podcasts :
(b) (5)
NIH-000 174
(b) (5)
Jennifer Routh [E]

Office of communications and Government Relations
NIH/HHS
31 Center Drive Room 7 A 17C
Bethesda, MD 20892
Direct: Cb)(6)
(b)(6)
Disclaimer : The information in this e-mail and any of its attachmen ts is confidential and may contain sensitive informat ion. It should not be
used by anyone w ho is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it
from your mailbox or any other storage devices . The Nationa l Institute of Allergy end Infe ctious Diseases shall not accept liabi lity for any
statements made that are sende r's own and not expressly made on behalf of the NIAIO by one of its representative s.
From:Routh, Jennifer (NIH/NIAID) [E]

To: 'O'Malley, Devin M. EOP/OVP' ------------=-~ (b)( '>; 'Love, Kelly A. EOP/OVP'
'Henning, Alexa A. EOP/WHO'
------------ (b)(6)>; (b)(6)>;
___ _:_
_____ ..:,_
___..!=::,,;------------
'Bowman, Lauren K. EOP/WHO'
> (b)( 6)
(b)(6)>; 'Porter, Macaulay V. EOP/OVP'
Cc: Billet, Courtney (NIH/NIAID} [E] >; Stover, Kathy (NIH/NIAID) [E]
"':""-."".""."":--:""'""".""."==
= )=(6)
(b ·C
:::...; _o_n,.....
>,:... ra,...,.
d,;,
, Patricia
(NIH/NIAID) [E] (b)(6); Hall, Bill
(HHS/ASPA) (b)(6); Murphy, Ryan (OS/ASPA) (b)(6)
(b) (5)
Jennifer Routh [El

NIH/H HS
Bethesda, MD 20892
Direct (b) (6)
(b)(6)
Disclaimer : The information in this e-mail and any of its attachmen ts is confidential and may con tain sens itive information. It should not be
used by anyone w ho is not the original intended recipient. If you have received this e-ma il in error please inform the sender and delete it
NIH-000175
from you r mailbox or any other storage devices . The Natio nal Institute of Allergy and Infe ctious Diseases shall not accept liab ility for any
statements made that are sende r's own and not expressly made on behalf of the NIAIO by one of its representatives.
From:Routh , Jennifer (NIH/NIAID) [E]

To : O'Malley, Devin M. EOP/OVP ----------- --=-:~ __
---~----:----::===-.,;__..,:__.,,,:_ (b)( >; Love, Kelly A. EOP/OVP
..:__~ =
_________ _ )_ C_6); Henning , Alexa A. EOP/WHO
Cb (b)(6)
Bowman, Lauren K. EOP/WHO (b)(6)>; Porter, Macaulay V. EOP/OVP
___ .,:______ __:__~ (b
~)~(6)
::::,;-
-----------
>
Cc:Billet, Courtney (NIH/NIAID) [E] >; Stover, Kathy (NIH/NIAID) [E]

(b)(6)>; Conrad, Patricia (NIH/NIAID) [E) (b)(6)>; Hall, Bill
"':":
(H-:-:-
H-:-::
S7.
/A:-::
S-::-
PA:-:-
)-;:::===:::..;..--,;- (b=H=6)>; Murphy, Ryan (OS/ASPA) (b)(6)
(b)(5)
Jennifer Routh [E]

Office of Communications and Government Relat ions
NIH/HHS
Bethesda, MO 20892
Direct: (b) (6)
(b)(6)
Disclaimer : The information in this e-mail and any of its attac hments is confidential and may contain se nsitive informat ion. It should not be
used by anyone w ho is not the original intended recipient. If you have received this e-ma il in error please inform the sende r and delete it
from you r mailbox or any othe r storage devices. The National Institute of Allergy and Infectio us Diseases shall not accept liab ility for any
statements made that are sende r's own and not express ly made o n behalf of the NIAID by one of its representatives .
From:O'Malley, Devin M. EOP/OVP

To: Love, Kelly A. EOP/OVP --------
-------------- (b
-=-=
)"""
(6)
(b)(6)
= >; Routh, Jennife r (NIH/NIA ID) [El

(b)(6); Henning, Alexa A. EOP/WHO
----------
8 ow man, Lauren K. EOP/WHO
___ .,:______ __:__~ (b
~)~(6)
::::;
-----------
>
CbH >; Porter , Macaulay V . EOP/OVP
(b)(6)>;
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E]
(b)(6)>; Conrad, Patricia (NIH/NIAID) [E] (b)(6); Hall, Bill
"'.".
(H""."'.
H""."'.
S'."":
/ ""."
AS~P'.""'.
A-:-
) ===::::..,;:,._ =-
(bS"":
H=6)>; Mu rphy, Ryan (OS/ ASPA) CbH >
(b) (5l
NIH-000176
From: Love, Kelly A. EOP/OVP
---------
To : Routh, Jennifer (NIH/NIAID) [El ------~~
(b) (6)>
(b)( >; Henning, Alexa A. EOP/WHO

(b)(6); Bowman, Lauren K. EOP/WHO
===========-~:-- (b)(6) ; Porter, Macaulay V. EOP/OVP___________-----------~ Cb =
_)_(6)
...
Cc: Billet, Courtney {NIH/NIAID) [El (b)(6)>; Stover, Kathy (NIH/NIAID) [El
.~:-:-:--::-:-:-::=== 6)~; c
(b)=(= _o"""
n..,...
r=
ad, Patricia (NIH/N IAID) [El (b)(6); Hall, Bill
(HHS/ASPA) CbH6)>; Mu rphy, Ryan (O5/ASPA) CbH >; O'Malley,
Devin M . EO':"
P/-:--
0:-:-
V"'."':
P-===== CbT<6l>
(b) (5)
From: Routh, Jennifer (NIH/NIAID) [El (b)(6)

Sent : Tuesday, March 24, 2020 7:26 PM ----------
---------=-=-:-=
__....:.__..:.,_
_____:
__!:=~~------
To : Love, Kelly A. EOP/OVP (b)(6)>; Henning, Alexa A. EOP/WHO
(b)( 6)>
Cc: Billet, Courtney (NIH/NIAID) [El (b)(6)>; Stover, Kathy (NIH/NIAID) [E]
(b)(6)>; Conrad, Patricia (NIH/NIAID) [El
,__"""".""'""""""-0:-::===:::!...,;,-c:-:-:=, --:-:::======~~
(HHS/ASPA) (b)(6)>; Mu rphy, Ryan (OS/ASPA)
Subject: Dr . Fauci hits and requests ---------
Good evening-
Below is an updated list of t he hits and pending requests for Dr. Fauci.
Tuesday 3/24
• 7 am firm live hit Chris Stigall Radio Show (Ph illy) - completed
• WMAL in woe - comp leted
• 10 pm live with Laura Ingraham truck from his house - scheduled
Wednesday 3/25
• Bob Rose Radio Show - Gainsville Fl - 6:33 am live hit - scheduled
• Bernie and Sid Radio Show - NYC - 7:05 am live hit - scheduled
• WTOP - work ing to schedu le
• NPR Morning Edition - wor king to schedule
(b) (5)
NIH-000 177
(b) (5)
Jenn ifer Routh [E]

News and Science Wr iting Branch
Office of Communications and Govern ment Relations
National Institute of Allergy and Infectious Diseases (N IAID)
NIH/HHS
Bethesda, MD 20892
Direct: (b) (6)
(b)(6)
Disclaime r: The information in this e-mail and any of its attach ments is co nfidential and may con tain se nsitive info rmation. It should not be
used by anyone who is not the original intended recipient. If you have received this a-ma il in error please inform the sander and delete it
from your mailbox or any other storage devices . The Natio nal Institute of Allergy and Infectious Diseases shall not accept liabi lity for any
statements made that are sender's own and not express ly made on behalf of the NIAID by one of its representatives.
NIH-000 178
Sent : Sat, 28 Mar 20201 7:17:12 +0000
To: Eisinger, Robert (NIH/N IAID) [E)
Subject: FW: Proposta da un med ico ricercato re it aliano per argi nare l'infezio ne da
Coronav irus
Bob:
Can you figure out a way to get thi s tran slated so th at we ca n figure out wh at he
wan ts and wh et her w e can he lp him.
Thank s,
Tony
Director
Phone: (b)( 6)
FAX: (301 496-4409
E-mail (b) (6)
The information in th is e-mail and any of its attachments is confidential and may contain sensitive
From: sand ragiudic i@libero.it <sandragiudi ci@libero.it>

To: Fauci, Anthony (NIH/ NIAID) [E]------~~ (b)(6)
Subject: Proposta da un medico ricercatore ital iano per arginare l'infez ione da Coronavirus
Importance: High
Egregio Professo r Fauci,

foreign liiigiii gc
NIH-000 179
foreignlaiigiiigc
NIH-000 180
foreign liiigiiige
dott.ssa Sandra Liliana Giudici
Oggetto : Proposal from an Ita lian research doctor to stem th e Coron avir us infect ion
Dear Professor Fauci.
I'm an Italian research doctor, with a qualification in Internal Medicine, who trained at the Polyclinic
Hospital of Milan.
(b) (4)
NIH-000 181
(b) (4)
NIH-000 182
(b) (4)
I'm very grateful for the precious time and for the attention that You will want to devote to my "app lication
hypothesis". Trusting in Your kind reply, I send my best regards.
dr. Sandra Liliana Giudici
NIH-000 183
Sent : Sat, 28 Mar 202017:15:57 +0000
To: Janet Tobias
Cc:
Subject: ·------------
Conrad, Patric ia (NIH/NIA ID) [E),
FW: Update on Film details, Task Force conversation s, etc.
(b)(6)
Janet:
Thanks for the note to Patty. We can do some of #4 below . Patty wil l contact
you and we can also chat by phone today to update me on details. As you might
imagine, thing are very hectic and the most important thing is for me to get my
j ob done. And so we will do what we can but may not be able to do everything
that you would like. I look forward to speaking with you later.
Best regards,
Tony
Director
Phone: (b)(6)
FAX: (301) 496-4409
E-mail: (b)(6)
From:Conrad , Patricia (NIH/NIAID) IE]

--------- (b)( '>
To : Fauci, Anthony (NIH/NIAID) [E] --------=-

-------- = (b)(6)
Subject: Fwd: Update on Film details , Task Force conversa t ions, etc.
Sent from my iPhone
From:Janet Tobias <janet@ikanamedia.com>

Date : March 28, 2020 at 7:24:48 AM EDT
To: "Conrad, Patricia (NIH/N IAID) [E]" _______ """
(b)
,...,
(=6)>
NIH-000184
Cc: "Bil let, Courtney (NIH/NIAID ) [E]" (b)(6)>, " Routh, Jennifer (NIH/NIAID)
[E)" (b)(6)
---------
Subject: Update on Film details, Task Force conversations, etc.
Hi Patty: A few impor t ant updates. And a request for this weekend/Sunday.
(b)(4)
2) We have been working w ith John Burklow/Dr . Collins/HHS on access to the Task Force. The
Task Force came back to us and asked us for more details about our approach, we gave them a
writt en description of the overall approach of docum ent ing for history the role of the Task
Force, it's leadersh ip, NIH, NIAID, and Dr. Fauci. Burklow is working with us on this .
3) Could I have a ten minute phone conversat ion with Dr. Fauci th is w eekend, important- I
think-to update him on details personally.
4) We wou ld like, if possible to start filming wit h Dr. Fauci this weekend . Could we film Dr.
Fauci exiting his house and going to the live truc k for Sunday morn ing inte rviews and then
going back home or off to the WH. We would then match that in the film wi t h the feed from
the truck of him sit ti ng down and get archive from the shows he appears. We are close by. Zac
(DP, who Dr. Fauci knows) has been in complete self-quarantine for two weeks before he left
New York State and we are now here a week . He is comp letely good by self-quarantine rules
for above filming .
Thanks to the th ree of you fo r t he work . The commun ication is life -saving. I have a couple of
close friends on the frontline and they asked me to re lay how deeply grateful they are for the
work you are all doing.
Janet
NIH-000 185
On Mar 24, 2020, at 3:38 PM, Conrad, Patricia (NIH/NIAID) [E]
---------- Cb)<· wrote :
Hi Janet
I gave him a hardcopy of your email earlier today ...he does

have it- we had to add some meetings at the WH prior to
his Task Force meet ing so I know he was a bit distracted ..
Wil I keep trying ...
Patricia L. Con rad

The National Institut es of Health
(b)(6)
301-496-4409 fax
Disclaimer:
The informat ion in this e-mail and any of its attachments is confidential and may contain sensitive
information . It should not be used by anyone who is not the original inten ded recipient. If you
have received this e-ma il in error please inform the sender and delete it from your mailbox or any
other storage devices. Nationa l Institute of Allergy and Infectious Diseases (NIA ID) shall not
accept liability for any statemen t made that are sender 's own and not express ly made on behalf of
the NIAID by one of its representatives.
From: Janet Tobias <janet@ ikanamedia.com>

Sent: Monday, Ma rch 23, 2020 9:26 PM
To: Conrad, Patricia (NIH/NIAID) [E]_______ -,a-
(b),...,
(=6)>
Subject: Here and working
Hi Patty:
Zac and I are here and situated . I know you are dr inki ng th rough ten firehoses. I want
to preserve sleep and health for Dr. Fauci. But it would be fantastic to have a 15
minute video (with distancing) Q and A in the garden of his house or in the house
t his week--- what he is working on just scientifica lly -vaccines, t reatments, disease
understanding. I want to capture the focus and urgency of the real time scientific
work on COVID-19. lfwe need to we can figure out how to do it wi t h audio, but
would love to see if we could do this in 15 minutes on video. Again, anytime this
week .
NIH-000186
Thanks,
Janet
NIH-000187
Sent : Sat, 28 Mar 202017 :00:15 +0000
To: Auchincloss, Hugh (NIH/N IA ID) [El;Erbe lding , Emily (NIH/NIAID) [El
Cc:
Subjec t : ------- (bH ;Conrad, Patricia (NIH/NIAID) [El
FW: NIAID-NIBIB discussion
Attachment s: COVI D_ ICD_ Trom berg.pptx
Hugh/ Emily:
Please handl e th is and respond t o Bruce fo r me.
Thanks,
Tony
Director
Phone : (b) (6)
FAX : (301 496-4409
E-mail : (b) (6)
From: Tromberg , Bruce (NIH/N I BIB) [El (b)(6)

Se nt: Saturday, March 28, 2020 10:55 AM
To: Fauci, Anthony (NIH/NIAID) [El ------~= (b)(6)>;Auchi ncloss, Hugh (NIH/N IAID) [El
________ (b)
_C_6)>; Erbelding, Emily {NIH/N IAID) [El (b)(6)
Cc: Heemskerk , Jill {NIH/NIBIB) [El (b)( >; George , David {NIH/N IBIB) [El
(b)(6)>
Subject : NIAID-NIBIB discussion
Hi Tony, Hugh , and Emily

Hope you are doing well and gett ing a chance to pause (especia lly Tony!) after ano t her breathless sprint
of a week .
The NIBIB comm unity has unique capacity to design, build , and deploy an array of power ful biomedical
technolog ies. Much of our attention over the past year has been on early disease detect ion and
preve ntion, and the integration of digital/pe rsonal health with conventional medicine . The COVID-19
crisis seems to have many challenges that are ideally matched for our capabilities . With the $60M NIBIB
will receive in the supplement, we are in a unique posit ion to make a contribution.
NIH-000 188
I am hoping we can meet with you to refine ideas and coordinate as we develop mechanisms to marshal
these resources. Your insight will play an essential role in helping us move forward wisely. NIBIB has
never received anything remotely like this before and we are in unfamiliar territory. I think it reflects, in
part, the confidence---and hope, that people have in advanced technologies to change lives. We are
determined to convert these dollars into tangible methods and devices and need your help in optimizing
our strategy.
I am forwarding my slide from the science presentation on Wednesday and my follow up email to
Francis and Larry to give you a sense of our direction {apologies for the information blast!). We have
also been drafting a NOSIwith several topic areas that I am adding below ...note that we are in the
process of condensing and refining these to simplify and more closely resemble our pay plan. I had a
great conversation with Francis in a follow up call Thursday and he suggested Cb)(5)
I look forward to your thoughts/comments and hope we {cc'd NIBIB leadership Jill Heemskerk and David
George) can schedule a time to talk. Thank you for considering this, I know you are overflowing with
emails and requests! If it's easierto just give me a call, my cell is (b)(6), I can give you the quick
"cliff notes" summary.
Best,
Bruce
(b) (5)
From: "Tromberg, Bruce (NIH/NI BIB) [E]" (b)( > on behalf of " Tromberg ,
_.;._....;.__ ..;...;;....;;....::::=.~~-------
Bruce (NIH/NIBIB) [E]"
-----------
Date: Thursday, March 26, 2020 at 7:22 AM
CbH6>(>
------~~
To: "Collins, Francis (NIH/OD) [E]" ______ Cb>_ >, "Tabak, Lawrence (NIH/OD) [E]"
_C6)
NIH-000189
(b)(6)
Subject: Summary thoughts
Hi Francis and Larry,

Thanks for the opportuni ty to present yesterday . (b) (5)
(b)( S)
NIH-000190
(b) (5)
Best,
Bruce
Bruce J. Tromberg, Ph.D.

Director
National Institute of Biomedical Imaging and Bioengineering
Building 31, Room 1C14
(b)(6)
301-480-0679 - FAX
(b)(6)
http://www.nibib.nih.gov
NIH-000 191
(b)(5)- PCR
NIH-000 192
(bX5) -PCI
NIH-000 193
Sent : Sat, 28 Mar 2020 16:19:28 +0000
Subject: RE:What's new for 'fauci as' in PubMe d
thanks
Director
Phone: (b)(6)
FAX: (30 496"'4409
E-mail: (b)(6)

--------
(b)(6)>
------
-------- ::;..,..-,=
Subject: FW: What' s new for 'fauci as' in PubMed
(b)(6J>
Will see to that these are on your cv
From: NLM/NCBI efback <efback@ncbi.nlm. nih.gov>

To: Folkers, Greg (NIH/NIAID) [E]..------- -,,
(b._...,
)(= >
Subject: What's new for 'fauci as' in PubMed
This message contains My NCBI what's new results from the National Center for Biotechnology
Information (NCBDat the U.S. National Library of Medicine (NLM).
Do not reply directly to this message.
Sender's message: Search: fauci as
Sent on Saturday, 2020 March 28

Search: fauci as
View comp lete results in PubMed (results may change over time).
NIH-000 194
Edit saved search settings, or unsubscribe from these e-mail updates.
PubMed Results
Items 1 - 2 of 2
1 Covid-19 - Navigating the Uncharted.
Fauci AS, Lane HC, Redfie ld RR.

N Engl J Med. 2020 Mar 26;382(13) :1268-1269. doi : 10.1056/NE JMe2002387 . Epub 2020 Feb 28. No
abstract available.
PMID: 32109011 [PubMed - indexed for MEDLINE]
Similar articles
2 Role of T-cell trafficking in the pathogenesis of HIV disease.
Cicala C, Arthos J, Fauci AS.

Curr Opin HIV AIDS. 2019 Mar;14(2):115 -120. doi: 10.1097 /COH.0000000000000529 . Review .
PMID: 30601238 [PubMed - indexed for MEDLINE]
Similar articles
NIH-000195
Sent : Sat, 28 Mar 2020 14:18:32 +0000
Subjec t : FW: Updates, In DC
Email below from Janet Tobia s.
Robert W. E isinger, Ph.D.

Immediat e Offi ce of the Directo r
Nationa l Institu tes of Health
31 Cen ter Drive , Room 7A-03
Bet besda MD 20892
Tel ephon e: (b)(6)
Emai l: (b)(

From: Janet Tobias <janet @ ikanamedia .com>
To: Fauci, Anthon y (NIH/NlAJD) [E] --------==-=--:=
Subject: Re: Updates, In DC --------- (b) (6)
Dear Ton y: 1 sent a note to Patty with upda tes. Ta sk Force in progress (asked for more information) and we have
finalized plans for dis tribution/release of the film for when this is over next year and we all feel good about being
together in a theater. Will now push to do tiny bit s of filming and audio a couple of times a we ek.
Thanks for everything and thanks yesterday for talking to the frontline. Close friends there have asked me to pas s on
their gratitu de.
See you soon and follow Chris ' advice about taki ng care of yourself.
Jan et
> On Mar 22, 2020 , at I 0: 1.9PM, Fauci , Anthony (Nil-I/NlAID) [E] ______ Cb
._ 6l> wrote:
H....,
>
> My work with the Coronavi rus Task. Force aod tbe large vo lume of incoming email:, preclud es me or my ~taff
from answer ing each individua l messag e. l would encourage yo u to visit www .coronavirus.g ov
<http: //www.coronaviru s.gov> for the latest informati on and guidance related to COVID - 19.
>
> Thank you, and best rega rds .
>
> Anthony S. Fauci, M.D.
>
>
>
NIH-000 196
Sent : Sat, 28 Mar 2020 12:29:3 1 +0000
To : Burklow, John (NIH/OD) [E)
Subjec t : RE:Great videos!
Thanks,John!
From: Burklow, John (NIH/OD) [E) (b)(6)

--------
To : Myles, Renate (NIH/OD) (El
-----~~ (b)( >; Fine, Amanda (NIH/OD) (El
(b)(6); Akinso, Woleola (NIH/OD) [E] (b)( •>;Olander, Alyson
"'."'."'."'."."'."'":'::-::"''.""":":":";:===~-__; ~=
(NIH/OD) (El (b)(6) >; Cox, Todd (NIH/CIT) [E] CbH ; Rosado, Andrew
(NIH/CIT) [E) =======~ ~ (b)(6) Collins, Scott (NIH/CIT) [E (b)(6) Chen,
Josep hin e (NIH/CIT) [E) (b)( ; Welch, Will (NIH/CIT) [E) ~ CbH~ >; Diane
Baker Cb)(6)
--------
; Awwad, David (NIH/NIAID) [CJ Cb)( >; Rice, David (NIH/OD) [E]
Cc: Collins, Francis (NIH/OD) [E] _______ ; Fauci, Anthony (NIH/NIAID) [E]
(b)(6)>; Tabak, Lawrence (NIH/OD) [E] (b)(6); Norris, Andrea
(NIH/CIT) [E] (b)(6) ; Alboum, Stacie (NIH/CIT) [E] (b)(6)>; Johnson,
---:---'.======:f..-~~
Alfre d (NIH/OD) [E] (b)( Prince, Scott (NIH/OD ) [E] (b)(6)] Chew,
Debra (NIH/OD) [E] (b)(6); Folkers, Greg (NIH/NIAID) [E] (b)(6)
Billet, Courtney (NIH/NIAID) [E) (b)(6)]; Conrad, Patricia (NIH/N IAID) [E]
(b)(6)
Subject : Great videos!
Congratulations to all of you who made today's COVID-19 videos a tremendous success! I know t here
were a lot of quickly moving, intricate parts and it went off flaw lessly - all remotely, to boot! Everyone
worked as a team, under very ti ght timelines, and thanks to Renate, who orchestrated the FCHome
Edition! I know NIH staff will greatly appreciate the videos-they're chockful of content! And special
th anks to Dr. Fauci, who took time out of his "leisurely" day to devote more than an hour to the
taping - incredible!
You all make us very proud!
John
NIH-000 197
From: (b)(6)
Sent: Fri, 27 Mar 2020 17:51 :23 -0400
Subject: Fwd: Reaching out from Frame/Urgent
From: Ben Moe <be n@ frame.media >

To: "Fauci , Anthony (NIH/NIAID ) [E]" ------~~
Subject: Re: Reaching out from Frame/Urgent
-------- (b)(6Ji
Dear Dr. Fauci,
I hope all goes well. I wanted to quickly follow up and see if you might be
free for a quick interview on Monday - it would mean so much to include
your voice in the piece.
Is there a time on Monday that might work for you? We can jump on the
phone for a 5 - 1O minute call if that works better for you.
Best,
Ben
On Thu, Mar 26, 2020 at 5: 10 PM Ben Moe <ben@frame.media >wrote:

Dear Dr. Fauci,
I hope this finds you well and thank you for all the work you are doing. I
run the digital magazine, Frame, which publishes interactive
documentaries made for mobile phones. We are working on a story about
the current effort to create a coronavirus vaccine and would love to
interview you for the piece.
We've interviewed Regeneron's Chief Scientific Officer, George

Yancopoulos , and the piece will tell the story of Regeneron's push to
create a coronavirus vaccine in record time. I was hoping you could speak
to the broader issue of the often undercovered global threat of diseases
and the lack of funding going toward infectious diseases .
NIH-000198
Would you potentially be available for a short video interview sometime
between 10am - 7pm EST tomorrow? Alternatively, would you be free
sometime between 12pm - 2pm or 5pm - 7pm EST on Monday?
Look forward to hearing back and we'd be honored to have your voice in
the story.
Here's a brief overview of Frame:
Frame is a newsmagazine that publishes interactive documentaries made

for mobile phones. Every Frame story tells a compel ling, human story that
helps shine a light on a major social or political issue.
Frame stories include interactive features throughout, from maps to
timelines, that allow viewers to engage more deeply with the piece . Our
stories are delivered through a messaging platform that allows subscribers
to have conversations with our journalists and subscribe to news updates
on topics they want to follow, all through SMS. Frame has been covered
by TechCrunch, Poynter, and Journalism.co.uk, and our investors include
Snap lnc.'s Yellow Accelerator.
The very best,
Ben Moe
Founder and CEO , Frame

ben @frame.media
@beneliasm oe
Founder and CEO, Frame

ben @frame.media
@beneliasmoe
NIH-000199
Sent : Fri, 27 Mar 2020 17:48 :31 +0000
To : Hirsch, Vanessa (NIH/NIAID) [E]
Subjec t : RE:appreciat ion
Thanks, Vanessa. I appreciate yo ur note .

Best ,
Tony
Director
Phone: (b)(6)
FAX: (301) 496-4409
E-mail: (b)( 6)
From: Hirsch, Vanessa (N IH/NIAID) [El

Sent : Friday, March 27, 2020 10:28 AM
--------- (b)( 6)
-------::-::-:-=
To : Fauci, Anthony (NIH/NIAI D) [El
Subject: appreciat ion -------- (b)( 6)>
Hi Tony ,
I ju st wa nted to express my appreciat ion for your sane voi ce duri ng the Covid-19 cris is. Keep up the
good work . I know it has to be exhaust ing.
Best regards,
Vanessa Hirsch
NHPVS, NIAID, NIH
NIH-000200
Sent: Fri, 27 Mar 2020 15:57:33 +0000
To: Morens, David (NIH/NIAID) [E)
Cc: Folkers, Greg (NIH/NIA ID) [E]
Subject : RE: (b)(4)
David:
Provided you
---------
that would be great .
(b)(6), if you could do this wit hin t he next 2 to 3 weeks,
Thanks,
Tony
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
From: Morens, David (NIH/NIAID) [E] (b) (6) >
Se nt : Friday, March
----------
27, 2020 11:27 AM
To : Fauci, Anthony (NIH/ NIAID) [E]
-------~~
Cc: Folkers, Greg (NIH/NIAID) [El ..:..==-=====-~~ (b)(6)
Subject : Cb)(4) ---------- (b)(6)
Tony, so I wil l
-----------------------------
start to think about what might work .
(b)(4),
Do you have a hoped-for t imetable? We are both overwhelmed, but I will try to do at least a bit
daily as long as (b)(6) . david
NIH-00020 1
From: Morens, David (NIH/N IAID) [E]
Se nt: Friday, March 27, 2020 11:24 AM
To : Narasimhan, Sri Devi (ELS-CMA)<srnarasimhan@cell.com>
Cc: Fauci, Anthony (NIH/N IAID) [E] <AFAUCl@niaid.nih.gov>
Subject: RE: Subj ect: CbH4)
Dear Sri, thank you and we wish you and colleagues well too. These are certainly d ifficult times
for all.
(b) (4)
We'll ponder that some more and get back to

you later. Thanks, again, and stay saf e
David M. Morens, M.D.

CA PT, Uni t ed States Publi c H ealt h Service
Senior Advi sor t o th e Director
Office of th e Director
National Institut e of Allergy and Infectious Diseases
Nationa l Institut es of Health
Bethes da, MD 20892-2520
CbH assistants: Kimberly Barasch; Whitney Robin son)
Disclaimer: This message is intende d for the exclusive use of the recipient(s) named above. It maycontain information that is PROTECTED,
PRIVILEGED, and/or CONFIDENTIAL, and it should not be disseminated , disttibuted , or copied to persons not authorized to receive such
information . All sensitive documents must be propuly labeled before dissem.in1ctionvia email. If you are not the intended recipient, any
dissemination, distribution, or copyin,g is strictly prohibited. If you h ave received this communication in error , please erase all copies of the message
and its attachments and notify us immediately.
NIH-000202
From: Narasimhan, Sri Devi (ELS-CMA)<>
--------~~
To: Morens, David (NIH/NIAID) [E] (b)(6)

Subject: Re: Subject:
___ ...:....:,....:..:;=======--~.-:=--
--------------- (b)(4)
Dear Tony and David,
Thank ou for writin back. First! I would like to sa thank ou for all that ou are doin . On
(b)(4)
I hope you, your families and colleagues stay safe and healthy through this. Please take care.
I look forward to staying in touch.
Best wishes,
Sri.
Sri Devi Narasimhan, PhD

Deputy Editor, Cell
Cell Press/Reed Elsevier
SOHampshire St., Cambridge, MA 02139
srnarasimhan@cell.com
From: Morens, David (NIH/NIAID) [E] (b)(6)>

---------
To : Narasimhan, Sri Devi (ELS-CMA) <srnarasimhan@cell.com >
Subject: Subject: (b)(4)
Dear Sri, we're responding, at long last, to your inv itation to Tony Fauci severa l weeks back, to
(b) (4)
NIH-000203
First, apologies are in order. We tried to meet about this and get you a quick response the day
after you and Tony emailed, but then coronavirus chaos ensued. We had to cancel 5 successive
meetings to go over this; in one case minutes before we were to start he got an urgent call to
go down to the White Hose asap, and that was that. Few of us in the office have even seen
Tony in recent weeks as he is down at the White Hose daily from early morning until late at
night.
Finally this morning we sat down and had a relaxed discussion. Assuming you are still
4L_.,,_,
(b) (
(b) (4)
________________
..... (b)( 4). Crazy times, for sure.
Thank you, I look forward to hearing from you,
<< OLE Object: Picture (Device Independent Bitmap)>>

CAPT, United States Public Health Service
Senior Advisor to the Director
National Ins ti tute of Allergy and In fectious Diseases
ir (b)(6)stants:Kimberly Barasch; Whitney Robinson)
~
~
Disclaimer:This messageis intended for the exclusiveuse of the recipient(s)named above. It may contain information that is PROTECTED,
PRIVILEGED, and/or CONFIDENTIAL, and it should not be disseminated,distributed, or copied to persons not authorized to receive such
information. All sensitivedocumentsmust be properly labeled beforedisseminationvia email.If you are not the intended recipient, any
dissemination,distribution, or copyingis strictly prohibited. If you have received this communication in error, please erase all copies of the message
NIH-000204
<< OLE Object: Picture (Device Inde pendent Bitmap)>>
From: Narasimhan, Sri Devi (ELS-CMA)<srnarasimhan@cell.com >

Sent: Monday, January 27, 2020 4:00 PM
To: Fauci, Anthony (NIH/NIAID) [E] <------~= CbH>
Subject: Cb)(4)
Dear Tony ,
I hope all is wel l. I had the great pleasure of meeting you in person when you were the
keynote speaker at our Cell Symposium on Emerging and Re-emerging Viruses in 2017. You
t hen gave a wonderful talk that covered AIDS to Zika and your expe riences across different
outbreaks, administrations and the challenges you encountered.
(b) (4)
My best wishes,
Sri.
Sri Devi Narasimhan, PhD

Deputy Editor, Cell
Cell Press/Reed Elsevier
50 Hampshire St., Cambridge, MA 02139
srnarasimhan@cell.com
NIH-000205
Sent: Fri, 27 Mar 2020 15:56 :36 +0000
Subject: FW: Offering help to fight th e Civod-19
Attachments : Presentation Doc-line.pdf
Please check it out and respond
Director
Phone: (b)(6)
FAX: (3 96':44li9
E-mail: Cb)(6)
other storage devi ces . The Nat ional Institute of Allergy and Infectious Diseases (NIAID) shall not
From: Peter Lermen (b) (6)

--------
Subject: Offer ing help to fight the Civod-19
(b)(6)>
Dear Dr. Fauci,
I don 't wan t you to waste too much time in th is stressful situation.
As t he doctor in charge of the hygiene of t he Berner clinic in Crans-M ontana in Swit zerland, as w ell as
being in contact with my colleagues in private practice , I see every day how important the need for
information and consultation of t he popu lation in this situation of insecurity is. At the same time , we are
under threat of a shor tage of doctors if we have to strictly apply the federal swiss guidelines (Art. 10b
and 10c, regulation 2 COVID-19) or if the wave of illness reduces the number of colleague s available for
consulta tio ns.
(b) (4)
NIH-000206
Thank you for your time
Good luck
Best regards,
[) () C-} i 11C
Peter Lermen
MD internal medicine, interna l oncological rehabil itation
Co-President oncoreha.ch
(b)(6)
www .doc-lin e.ch
NIH-000207
Sent : Fri, 27 Mar 2020 13:30 :18 +0000
To: Mascola, John (NIHNRC) [E)
Subject: FW: Vir update
Attachments: Vir Barda TechWatch _05 Ma r20_vF.pptx
Please take a look at this and respond if appropriate.. Too long an e-mail for me
to tackle . I have 745 others .
Thanks,
Tony
Director
Phone Cb)(6)
FAX: (301 496-4409
E-mail: (b)(6)
From: Skip Vi rgin (b)(6)>

Sent: Tuesday , March 10, 2020 11:33 PM
=)""'
(6)
=>
Subject: Vir update
Tony
My apologies for the slow update . You asked that I get back to you after Cb>
C4>and
so here I
am. Notes in sections.
(b)(4)
NIH-000208
(b) (4)
NIH-000209
(b) (4)
Any advice welcome
Happy to talk ____ Cb

_H_6)
Be well and thanks for all of your public work to help us prepare . I wish they listened more .
Skip
Herbert W. 'Skip' Virgin M.D., Ph.D.

Executive Vice President, Research
Chief Scientific Officer
Vir Biotechnology
499 Illinois Avenue
San Francisco CA 94158
he/him/his
NIH-000210
Sent : Thu, 26 Mar 2020 16:19:31 +0000
Cc: Kadlec, Robert (OS/ASPR/IO);Birx, Deborah L
--------------
[E];Redd, Stephen (CDC/DDPHSIS/0D)
Subject:
(b)(6);Lerner,Andrea (NIH/N IAID) [E];Conrad, Patricia (NIH/NIAID)
FW: Draft of email for ASFto send to Brett Giroir cc'ing Kadlec
Attachmen ts: IMG_2072.mov
Brett:
The proposal below was sent to my office by David Margu lies (Harvard/Boston Childrens) who is part of
a group of prominent physicians and healthcare executives in Boston developing this idea (David Martin
of the Brigham, Gary Gottlieb of Partners and others). See this op-ed th ey wrote in the Boston Globe
yesterday regarding their proposal https://www.bostonglobe.com/2020/03/25/opinion/mass-needs-
comprehensive-care-response-coronavirus /l .
(b)(5)
Can you take a look at this and let me know what you think? (b)(5J. David
Margulies can be contacted direc tly at (b)(6) or
-..:=.=======:::::;;::;;;;-:~
(bJ(6) if you need
additional information.
Thanks,
Tony
(b)(4). (b)(5)
NIH-000217
(b) (4), (b) (5)
David Margulies, M.D.

(b)(6)
NIH-0002 18
Sent : Thu, 26 Mar 2020 13:25:30 +0000
Subject: RE:FORTASKFORCEConsiderat ion -- Some sound th inking on COVID-19
We have been discussing each and every one of the se suggestion s and th ey are all
on th e t abl e fo r considerat ion of imp lementati on.
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
have received this e-mail in error please inform the sender and delete it from you r mailbox or any

Sent : Thursday, March 26, 2020 9:08 AM
To : Fauci, Anthony (NIH/ NIAID) [E]------= (b)
""'~= >
Subject: FW: FOR TASKFORCEConsideration -- Some sound thinking on COVID-19
Importance:High
Patricia L. Conrad
Publi c Health Ana lyst and
Special Assist ant to the Directo r
National Instit ute of All ergy and Inf ectious Diseases
The Nati ona l Inst itutes of Healt h
31 Center Drive , MSC 252 0 - Roo m 7A03
Bet hesda, M aryland 20892
(b)(6)
301-496 -440 9 fax
Discla imer:
The informat ion in this e- mail and any of its attachm ents is confide ntial a nd may conta in sensi tive information . It shou ld not be used
by anyon e who is not the original intended recipient. If you have rece ive d this e-m ail in error please inform the sende r and delete it
NIH-0002 19
from your mailbox or any other storage devices. Nationa l Institute of Allergy and Infect ious Diseases (NIAID) shall not accept
liability for any statement made that are sender's own a nd not expressly made on behalf of the NIAID by one of its representatives.
From: Conrad , Patricia (NIH/NIAID) [E] (b)(6J>

Sent: Wednesday, March 25, 2020 6:3 1 PM
To : Conrad, Patricia (NIH/NIAID) [E] --------, ~=
(bH >
Subject: FW: FOR TASK FORCEConsiderat io n --Some sound think ing on COVID-19
Importance: High
From: Pierce, William <wpierce@apcoworldwide .com >

To : Conrad, Patricia (NIH/NIAID) [E] ----------=-::-:-=
(b)(6)
Subje ct: FOR TASK FORCEConsideration -- Some sou nd th ink ing on COVID-19
Importance: High
Patty:
I know Tony is the expert, but I thought this memo would be of interest and perhaps of help to him in
his battles .
The attached memo is from Dr. Paul Offit (U of Penn) and a colleague of his David Rubin. Tony may know
him, I would not be surprised.
But for you, Paul is one of the country's topic vaccinologists and virologists. Paul developed a vaccine for
a deadly disease. I know him well and he's the real deal. Next t o Tony he is my go to science source.
Paul in particular is a highly credible , well known nat ional expert.
They wrote this memo on the 19th of Ma rch and it has many suggestions that are incredibly smart and I
thought tony would want to see th is immediately. Paul and David are obviously available to talk asap .
Let me know.
Bill
William Pierc e
Senior Director
APCO Worldwide
1299 Pennsylvania Ave, N.W.
Suite 300
(t) +1 202 659 7931 (m) ___ _,(l>

_.,.
).,..,,
NIH-000 220
wpierce@apcoworldwide.com
@apcowortdwide
:::::: Learn more about APCO resources available during the COVID-19 outbreak::::.:
CONFIDENTIALITY
This email may contain material that is confidential, privileged and/or work product for the sole use of the intended recipient Any review,
reliance or distribution by others or forwarding without express permission Is strictly prohibited. If you are not the intended recipient, please
contact the sender and delete all copies
William Pierce
APCO Worl<Jvvidt:
~)+12026597931 (m)
-------- (b)(6)
NIH-000221
Sent: Thu, 26 Mar 2020 12:44:24 +0000
Bee: Crew, Page (NIH/NIA ID) [E];Davey, Richard (NIH/N IAID) [E);Doepel, Laurie
(NIH/NIAID) [E];Eisinger, Robert (NIH/NIAID) [E];Higgs, Elizabeth (NIH/NIAID) IE];Kuriakose, Safia (NIH)
[C];Lerner, Andrea (NIH/NIAID ) [E];Nason, Martha (NIH/NIAID) [E];Seam, Nitin (NIH/CC/CCMD) [E];Singh,
Kanai (NIH/NIAID) [El, (b)( ;Brooks, John T. (CDC/DDID/NCHHSTP/DHPSE);Pau,
Alice (NIH/NIAID ) [E];Lane, Cliff (NIH/NIAID) [E]
Subject: Memo to NIH/CDC/VA Support Staff for t he HHS Panel on COVID-19 Treatment
Guidelines
Dear colleagues,
The purpose of t his email is to thank-you for agree ing to provide support to the HHS COVID19
Treatment Guidel ines Panel. As you are aware clinicians are doing the ir best to nav igate a
complicated landscape with little to guide them. I realize everyone is very busy and I appreciate
you taking on this additiona l wor k at a difficult time.
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
NIH-000222
Sent: Thu, 26 Mar 2020 10:42:30 +0000
Cc: Awwad, David (NIH/NIAID) [CJ
Subject: FW: BBC News
Let us see if we can do this from my NIH office today during the day.
From: Chris Foote <chris.foote@bbc.co .uk>

Sent: Thursday, Ma rch 26, 2020 5:02 AM
To : Fauci, Anthony {NIH/NIAID) [E]______ """
(b"""'
)(=6)
Subject: BBC News
Hello Dr Fauci
I'm the programme editor of The Nine, a nightly news and current affairs programme on the BBC. I was
hoping you could spare ten minutes at some point today (March 26) to speak to us over Skype or
FaceTime about the US response the Coronavirus pandemic.
If that's possible, I'll ask one of my producers to arrange it at a time convenient for you .
Chris Foote
Senior Journalist
BBC News
(b)(6)
http://www.bbc.co.uk
This e-mail (and any attachments) is confidential and may contain personal views which are not
the views of the BBC unless specifically stated .
If you have received it in error, plea5e delete it from your system.
Do not use, copy or disclose the information in any way nor act in reliance on it and notify the
sender immediately.
Please note that the BBC monitors e-mails sent or received.
Further conununication will signify your consent to this.
NIH-000223
(bX5)-PCE
NIH-000224
NIH-000225
Sent : Thu, 26 Mar 2020 02:27:28 +0000
To: Joubert, Bonnie (NIH/NIEHS) [El
Subjec t : RE:Thank you
Bonnie:
Thanks for the note. Much appreciated.
Best regards,
Tony
From: Joubert, Bonnie (NIH/NIEHS) [El

---------
------~~ CbH6J>
(b)(6)
Subject : Thank you

--------
Dear Dr. Fauci,
I just want to say THANK YOU for all that you are doing for the country to address the COVID- 19
pandemic. As an epidemiologist at NIEHS,it is inspiring and encourag ing to be part of NIH and to have
leaders like you involved in the national and global response during this critical time.
Regards,
Bonnie
Bonnie Joubert, MPH, PhD

Population Health Branch
Division of Extramural Research and Training
National Institute of Environmental Health Sciences
Research Triangle Park, NC 27709
Phone: (b)(6)
NIH-000226
Sent : Wed, 25 Mar 2020 17:20 :55 +0000
To : Friedmann, Theodore
Subject: RE:George Church interview
Thanks, Ted. I appreciate your note.
Director
Phone: (b)(6)
FAX: (30 496"'4409
E-mail: (b)(6)
From: Friedmann, Theodore <tfriedmann@health.ucsd.edu>

To: Fauci, Anthony (NIH/NIAID) [E] ------- ---,=(b)(6)
Subject: Fwd: George Church interview
Dear Tony : I sent a brief note to my friend Jon Cohen to congratulate him on what I thought was h is fine
interview with you. In his response, he suggested that I should send a copy to you. I've been a little
reluctant to do that because of what I assumed must be a flood of comments and advice that you are
getting in your role on the task force. I attach the message to Jon below and I hope that some of the
thoughts are useful and maybe a little comforting for you. With my very warmest regards and best
wishes,
Ted
Begin forward ed message:
From: The odo re Friedman n <tfriedmann@health .ucsd .edu>

Subject : Re: George Church interview
Date: March 24, 2020 at 12:09:20 PM PDT
To: Jon Cohen <jcohen@ aaas.org>
NIH-000227
Dear Jon: Greetings from La Jolla. Congratulations on your interview w ith Tony Fauci. I
have to admit that, until a couple of weeks ago, I have been quite critical of Tony's
apparent acquiescence with so much dangerous, incorrect and politically motivated
misinformation from the administration. I feared that the upside-down explanations from
the administration had the effect of destroying the concepts and tenets of epidemiology
and even rat ionalizing a completely wrong concept of communicable disease that holds
that it is unnecessary to screen for carriers in an ep idem ic but only important to screen
symptomatic people. That is upside-down from what we all know about dealing with
epidemics and has even been endorsed by Trump, Pence and other members of the
COVID-19 task force. It seems to have become a new normal concept of communicable
disease management. Like so many things in the Trump era, facts and history are thrown
out the window and replaced by governmentally espoused but obviously wrong concepts.
We assume to be preparing to complete ly deny established concepts of communicable
disease - screen only the prime suspects or the afflicted. In conversations with colleagues
here I wondered "where is Tony Fauci?" They suggested that he must be quietly and
heroically working hard being the scenes and at his personal peril to educate our leaders
rather than correcting th em publicly. But I thought that, in desperate times, the public
must hear and see clear truth and denials of lies. My concept of heroes are people who act
at their personal peril - Rosa Parks, Martin Luther King, Martin Niemoller, Dietrich
Bornhoffer, Thankfully, I th ink that the real Tony Fauci has emerged, obviously to his peril.
I wish him good luck and survival. I find myself wondering what the responses will be t o
Trump 's likely premature lifting of isolation and quarantining procedures and if the
concept of disobeying illegal and unethical orders will survive the times.
Ted
On Dec 6, 2018, at 11:17 AM, Jon Cohen <jcohen@aaas.org> wrote:
So good to hear from you and do te ll Carl to contact me.
Yes, George has received ample criticism, but my job is to air his views,
regardless of what I think. And I like his independent, damn the torpedoes
approach. He speaks his mind. As for He, everything about th is is bizarre,
from ethics to science to PRto regulation .
Best,
Jon
NIH-000228
On Dec 6, 2018, at 1:19 PM, Friedmann, Theodore
<t fr iedmann@ucsd.edu> wro te:
Hello Jon - Greetings fro rrC: (b>c<1

. It has been a long time since
we last connected and talked about gene therapy, etc. and
(b)(6)
I was very interested to read George Church's troublesome

responses in your interview with him in Science and to see his
ethical evaluation of He's CCRS editing experiment in China. I'm
not as generous to He as George seems to be and I think that
th is work is clearly unethical. George inexplicably conjures up
the sad history of JessGelsinger and the effect of his death on
the evolut ion of the field of gene therapy. Happily, he's right
about the fact that gene therapy is now proving itself in a
growing list of intractable diseases (underscored by the 2015
Japan Prize). That has happened because stud ies are now much
more carefully designed and carried out. But sadly, we are in an
environment in which some people conclude that human
medical man ipulations - gene therapy, genome editing, stem
cell therapy- are ethical as long as they "work". The rationa le is,
"let's do the study and if it works and doesn't kill or ot herwise
harm, it's OK". It's not a post- factor evaluation that determines
if an instance of human experimen tation is ethica l and
permissible - it is the design of a study that determines if it is
ethical or not. George should be reminded of that fact and
should re-read the Helsinki declarations or similar codes of
human experimentation.
In any event, your interview was fascinating. Best regards,
Ted Friedmann
NIH-00022
9
Sent : Wed, 25 Mar 2020 16:59:20 +0000
To: (b)(6)
Subjec t : FW: Developing Control Charts for Covid 3 24 20 with graphs.docx

Attachment s: Developing Control Charts for Covid 3 24 20 with graphs.docx
Please take a look at this. What do you think ?
Director
National Institute of Allergy and Tnfectious Diseases
31 Ce nter Driv e, MSC 2 520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)
The informa tion in this e-mail and any of its attachm ents is confidential and may contain sensitive infom1ation. It
should not be used by anyone who is not the original intended recip ient. If you have received this e-mail in en-or
please inform the sender and delete it from your mai lbox or any other storage devices. The Nat ional Institute of
AHergy and Infectious Diseases (NlAlD) shall not accept liability for any statements made that are the sender's own
and not express ly made on behalf of the NIAID by one of is representatives.
From: Steve Sternberg ---------=-:-:-= (b) (6)
To: Fauci, Anthony (NlH /NlAlD) [E] --------=-=-=

Sent: Wednesda y , March 25, 202 0 8:39 Al\'[
(b) (6}
Subject: Developing Control Charts for Covid 3 24 20 with graph s.docx
Tony ,
Here are reconfigu red charts which factor in the gui dance from mathematicians at Rockefeller. As you can see , the
trend in the U .S. is visibly worse. If this pattern holds, we're going to see many more deaths before things get better .
We would be grateful for a comment. Could you offer a perspective? We're going to try to publish today.
Steve
NIH-000230
Sent : Wed, 25 M ar 2020 15:01 :21 +0000
To: DELFRAISSY Jean-fr ancois
Cc: (b)(6)
Subject: RE:France situation COVID-19
Jean-Francois:
Thank you for your note . I do not see Yazdan copied on your e-mail, andl so
please forward this e-mail to him. The NIH position is that we should preferably
make drugs available on randomized , controlled clinical trials and not freely
distribute them. There is a strong push in the USA, favored by the President, to
make certain of these drugs more widely available outside of an RCTusing
mechanisms such as "compassionate usage". In the USA, as you know, HC
(plaquenil) is an approved drug for malaria as well as for certain autoimmune
diseases such as SLE. Thus, physicians can prescribe the drug on an "off label"
usage. This likely will be the majo r modality of distribut ion of this drug in the
USA, at least for the foreseeable future.
I am copying Cliff Lane on this e-mail. Please includ e him on any further
correspondence on this subject.
Best regards,
Tony
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
From:DELFRAISSYJean-franco is (b)(6)>
--------------
Sent: Wed nesday, March 25, 2020 10:35 AM
-----~~ CbH6J>
Cc: DELFRAISSYJean-francois ,...:....:;....;;,,!;;=======-----=- )(=6) >
(b"""
Subject: France situation COVID-19
NIH-00023 1
Hello,
I am once again in service since the global sanitary crisis COVID-19 hit France a couple of weeks ago. I
am now leading the Scientific Council for COVID-19, composed of 10 persons, serving the French
President , Emmanuel Macron.
The Council was created on March the 10th and we were heavily involved in advisory activities in relation
to the President's decision to put the generalized quarantine into force, because we didn't have any
better choice.
Firstly
We have a limited number of diagnosis tests, this prevents us from taking up a Korean-like strategy
within the next few days. However, by the end of the quarantine (within the following six weeks), we will
be able to have a generalisation of the diagnosis test and develop korean-like apps, as well as a strategy
for testing and treatment if we have any drugs available by th is time. Before this, we will go through a
difficult phase in the following weeks, because we won't have enough beds in our care units in some part
of France ...
Secondly
On the therapeutic level, Yazdan Yazdanpanah has taken my place and who is now leading REACTing.
Tomorrow morning a french -european medical trial will begin, under the control of the WHO, with 5 arms
(placebo/kalatra/kalatra +interferon beta / product of Guilead / hydroxychloroquine alone or in
combination for next week).
As you may know, we are currently facing a press buzz since the announcement made by Dr. Raoult
about the effectiveness of hydroxy-chloroquine. His data is not particularly convincing. We can dist inguish
a slight positive signal but it must be confirmed by a well made randomised tr ial. We also started a
monkey-model study with HC and we should have the results by the end of next week. Also a cohort of
severe COVID+ patients have been created and some will be treated with HC : we will analyse those
results with all the consciousness needed. It will also be possible to do a prevention trial for healthcare
NIH-000232
professionals and aging peoplewith HC.I have an enormous political pressureto releaseHC and to give
it to everyonebut I am currently resisting...
How is the situation in the USA,especiallyafter Trump's announcement? What is the NIH position ?
What will be put into force ?
Thanksfor your answer.
I put YazdanYazdanpanahin a copy of this email.
Best regard
Pr. Jean-Fran~ois Delfraissy

President IPresident
Comite consultatifnational d'ethique pour !es sciences de la vie et de la sante
National Ethical Consultative Commiteefoe life sciences and health
Ancien Directeur de l' ANRS I ANRS former Director
M
_""::::::::::::
T
NIH-000233
Sent: Wed, 25 Mar 2020 13:57 :28 +0000
Subject:
PANTHEON
RE:
------------------------ (b) (4)
Agree. Skip this and please try to get David back on my morning schedule to start
working on the original paper that we had agreed upon .
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
From: Folkers, Greg (NIH/NIAID) IE]

--------
Sent: Wednesday, March 25, 2020 9:29 AM
(b) (6)>

------~~ Cb)( >
.'.":.========-=-=--:-=
Cc: Conrad, Patricia (NIH/N IAID) [E] Cb)(6)
Subject:
---------------------------- (b) (4)
(b) (5)
NIH-000234
Sent : Wed, 25 M ar 2020 12:08 :27 +0000
To : (b)(6)
Subjec t : RE:wi th love fro m Italy
Rit a:
M any th anks f or you r kind not e. It is much app reciat ed .
Best regards,
Tony
Director
Phone: (b)(6)
FAX: (301) 496-4409
E-mail (b) (6)
From: rita .apgar@alice .it (b)(6)

Se nt : Wed nesday, March 25, 2020 7:58 AM
To : Fauci, Anthony (NIH/NIAID) [E]------= (b)
""'
(6)
=>
Subject: with love from Italy
Dear Doctor Fauci. My name is Rita Apgar and if by chance you not iced my last name, as my father said
many years ago,' (b)(6)!" I have lived in It aly for almost SOyears
and the sagacious finger of desti ny pointed my way to It aly, the true home of my heart , although not a
drop of Italian blood flows t hrough it . But the love of Italy and the Ita lians pumps throug h my heart
every second of my existence .
That sagacious finger of destiny pointed the way, and I followed it in faith to (b)(6)
where I had lived . As soon as I set foot for t he
fi rst t ime in the house in this funky ghost town of a medieval village, I felt t hat we belonged together.
And, practically speaking, at the t ime, it was the perfect solution to some weighty personal problems .
Heart and m ind were in peaceful agreement.
I have a dear frie nd who is an infectious disease specialist at the hospital in Asti. She is, obv iously,
extreme ly busy these days but she took the ti me to call me Sunday evening and we talked about you .
She said to me, "you know, when I was j ust a graduate student, I was a secret group ie of Dr. Fauci, and
once wh en he was at a me eting or a conferenc e or someth ing (I'm not sur e whe re or wh en) I was able to
ask him a few questions ." I was thri lled, of course, since I also try to watch every appearance you make
on TV. I will not add anyth ing in this regard.
NIH-000235
But I did say to Mar ia, Doctor Maria Degioanni, "Maria, I want to invite Dr. Fauci to come and visit us for
a few days when this crisis is over, God willing and maybe he would come together with (b)(6)
. who has promised to come and visit again after 20 years. We can put them
up in the fancy Relais San Damian above lsolalunga where I live and take them out to dinner at Gente di
Mare . Dear Doctor Fauci, I like to joke when peop le ask how we are doing in this time of Covid-19 by
saying : A Name, a guarantee : ISOLAlunga= ISOLAtionI Legend says that the Benedictine monks who got
into mischief centuries ago were sent here as punishment to work in the olive groves: long isolatio n.
Today it's the perfect place to be with a view of the Mediterranean as well as the Maritime Alps from
t he kitchen window and hardly a soul to practice social distancing with!
Grazie per esistere as an Italian song goes, "thank you for being you! I would adore getting a reply from
you, but realize how miraculous tha t woudl be! We would be over the moon if you accepted our
invitation , at any time and at the drop of a hat!
Sincerely, Rita Apgar
NIH-000236
Sent : Wed, 25 M ar 2020 10:27 :40 +0000
To: Jon LaPook
Subjec t : FW: Serology for the novel coronavirus
Try Barney Graham at the NlAID YRC. You have interviewed him more than once .
-----Or iginal Message -----

From : Jon LaPook ______ __,(b'""
)..,.
(6)
=
Sent: Tuesday, March 24 , 2020 2 :17 PM
To : Fauci , Anthony (NTH/NJAlD) [E]..._ ______ --------~~ (b
_ )_(....
Subj ec t: RE: Serology for the nove l coronaviru s
Sigh. Who wou ld you suggest I try to interview?

Thank s,
Jon
-----01i ginal Message- --- -

From: Fauc i, Ant hony (NIH/NIAlD) [E]..._ _____ (b
_ )_(....
Sen t: Tue sday, March 24, 2020 I :57 PM
To: Jo n LaPook (b) (6)>
Subjec t: Re: Serology for the novel coronavirus
Lots of talk. Not sure about progress
> On Mar 23 , 2020 , at 6:27 PM, Jon LaPook

> -------- (b) (6)> wrote:
> Tony ,
> Any progress ? Obviously, if we had widespread serologic testing , we co uld identify people with likely
immunity , and put them on the front lines.
> Thanks ,
> Jon
>
> Jonatha n LaPook , M .D.
> Ch ief Medical Correspondent , CBS News
> Professor of Med icin e
> NYU Langone Healtb
> Twitter @ DrLaPook
NIH-000237
Sent : Wed, 25 M ar 2020 02:26:42 +0000
To: (b)(6)
Subjec t : FW: Serology for the novel coronavirus
Cliff:
Who is the most knowledgeable about serologies for COVID-19? If you know , could you please respond to Jon.
Thanks ,
Tony
From: Jon LaPook ,;-.-----= (b
"')-=
(= >
Sent: Tuesday. March 24. 2020 2: 17 PM...-------~
To: Fauci, Anthony (NTH/NIAID)[E] (b)(
Subject: RE: Serology for the novel coronavirus
Sigh. Who would you suggest I try to interview?

Thanks,
Jon
From: Fauci , Anthony (NIH/N1A ID ) [E] (b)(6)>
Sent : Tuesday, March 24, 2020 1:57 PM --------
To: Jon LaPook (b)(6)
Subject: Re: Serology for the novel corona virus
Lots of talk. Not sure about progress
> On Mar 23, 2020, at 6:27 PM, Jon LaPook

> ------- (6)> wrote:
(b)
> Tony,
> Any progress? Obviously, ifwe had widespreadserologic testing, we could identify people with likely immunity,
and put them on the front lines.
> Thanks,
> Jon
>
> Jonathan LaPook, M.D.
> Chief Medical Correspondent, CBS N ews
> Professor of Medicine
> NYU L ango n e Health
> Twi tter @DrLaPook
NIH-000238
Sent : Wed, 25 Mar 2020 01:53:06 +0000
Subjec t : FW: COVID-19 West Virginia Phenomenon
From: Daniel Ries (b)(6)>

Se nt : Tuesday, March 24 , 2020 8 :59 PM
To : Fauci, Anthony (NIH/NIAID) [E] ------
--------
::;..,..-,=
(b)(6)>
Subject: COVID-19 West Virginia Phenomenon
Dear Dr Anthony Fauci

(b) (4)
Best regards
Daniel Ries
PhD Food Technology
Massey University
NEW ZEALAND
(b) (4)
NIH-000239
(b) (4)
NIH-000240
Sent : Tue, 24 Mar 2020 17:48:57 +0000
Subject: FW: COVID reagent allocation issue
Email response from Jeremy Berg

Imm ediate Office of the Director
Bethesda MD 20892
Telephone: (b)(6)
Email: (b)(
From: Berg, Jeremy (b)(6)

-----~~ (b)(6):>
========= ~
Cc: Lerner, Andrea (NIH/NIAID) [E]
--------
Subject: Re: COVID reagent allocation issue
(b)(6)
You are welcome, Tony. We appreciate anything that you can do with regard to
the reagent allocation issue. The view from the trenches is pretty stark.
Keep up t he good work and do not hesitate to reach out to me if I can be helpful
in any way.
Best, Jeremy
Jeremy M. Berg, Ph.D.

Universityof Pittsburgh
Associate Senior Vice Chance llor for Science Strategy and Planning
in the Healt h Sciences
Profe ssor of Computational and Systems Biology
Scaife Hall , S304
3550 Terrace S1reet
Pittsburoh PA 15213
(b)(6)
(cell)
NIH-000241
From:Anthony Fauci (b)(6)>
Date: Tuesday, March 24, 2020 at 1:44 PM
To: JeremyBerg CbH6J>
(b)( >
--------
Cc: " Lerner, Andrea (NIH/NIAID) [E]"
Subject: Re: COVID reagent allocation issue
Thanks,Jeremy
On Mar 23, 2020 , at 9:00 PM, Berg, Jeremy CbH6J>

wrote:
------
Dear Tony: I am sure you are overwhelmed, but I think it is important
to share the attached with you (which will be sent to you directly
through regular channels) . CbH6)is
a pathologist who is in
charge of testing in a large med ical system in Rochester, New York,
who has been extremely concerned and frustrated by the lack of access
to reagents for the Roche coronavirus testing platform. They have the
platform but cannot use it because of a lack of reagents (which were
apparently pre-purchased by Quest, LabCorp, and other national
groups). The turnaround time for Quest is approximately 5 days and
this is completely useless for making clinical decisions about admission
compared with local testing with 24 hour per around time.
Thank you for your attention and for everything that you are doing to
help our country through this great challenge.
Best, Jeremy
P.S. I enjoyed the interview with you in Scienceand admire your clarity
of purpose.
Jeremy M. Berg, Ph.D.

University of Pittsburgh
Assoc iate Senfor Vice Cha ncellor for Science Strategy and Planning
in the Healt h Sciences
Profess or of Com put ationa l and Sys tem s Biology
Scaife Hall, S304
3550 Terrace Street
(b)(6)
NIH-000242
Cb)(6) ( cell)
(b)(6)
<Fauci-Rochester-Reagents.pdf>
NIH-000243
Sent : Tue, 24 Mar 2020 16:27:17 +0000
Subjec t : FW: You m ay be able to help ....
Linda is a f orm er NIH Insti t ut e Direct or. Please figure out w hat she is ta lkin g
about and respo nd t o her on my behalf
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail (b)(6)
have received this e-mail in error please inform the sender and delete it from you r mailbox or any
From: Birnba um, Linda (NIH/N IEHS)[VJ

Sent : Tuesday, Mar ch 24, 2020 12:22 PM----------
'"'"'
~= >
(b)(6)>
Subject: You may be able to help ....
Hi Tony ,
Thank you for yo ur tireless efforts to clearly communicate about the pandem ic, including correcting the
President when necessary. You do it in such a non -threatening and respectfu l style. I think everyone
appreciate s it .
(b)(6) runs a home health care company in NC and many ot her states in t he nation .
---------
He has managed to get some of the largest home care companies as well as the Home Care Associatio n
of America (their trade organization) to sign off on this call for guidance for their industry which
provides professional care givers, largely CNAs,to those needing assistance with daily living throughout
t he nation .
I am reaching out hoping that you might know to whom this message shoul d really go .
Thanks again for all you do - and take care of yourse lf! The nation needs you.
Sincerely, Linda
NIH-000244
Linda S. Birnbaum, Ph.D., D.A.B.T., A.T.S
Scientist Emeritus (Retired)
Former Director, National Institute of Environmental Health Sciences
and National Toxicology Program
phone: (b)(6)
cell (b)(6)
e-mai l: (b)(6)
""":"""--.-;::======--~~
personal email:
---------- (b) (6)
From: (b)(6)
To : Linda Birnbaum
-----------
Subject: Message to Dr. Fauci
(b)(6)>
Dear Dr. Fauci,
The home care industry cares for tens of millions of our most vulnerable citizens in their homes every
day. We provide assistance with activi ties of daily living and instrumental activities of daily living, which
keeps our clients in their homes and in the lowest risk setting. Our professionalCaregivers are able and
willingto continueto providecareto clients who test positive for COVID-19or have been exposedto
the virus.
But we need your help so that home care companies do not face unreasonab le liability for providing
such care. To that end, we ask for your support in getting a bill through congress like the Public
Readiness and Emergency Preparedness Act (PREPAct), 42 USC247d-6d, that will insulate providers like
us from claims related to the care we will be providing in these extraordinary times.
We also ask that you support creating a fund that will provide appropriate personal protective
equipment to our caregivers. Our clients should not have to bear the additional burden of the added
cost of PPE.
Additionally, we would like you to encourage the CDCto clar ify its guidance on caring for COVID-19
patients (found here, here and here) that the guidance is applicable to "professional, licensed and
insured, home based care agencies."
This clarification will give the industry a workable standard to protect caregivers caring for COVID-19
clients. In essence, it would establish that facemasks and gloves are sufficient PPEto care for COVID-19
clients in the home, and not require its caregivers to comply with the healthcare sett ing requirements of
wearing N95 respirators, eye protec tion (goggles or face shields) or gowns . This is important as a
practical mat ter because respirators and gowns are not readily available at this time. Moreover, most
home care workers are not tra ined in the proper use of respirators.
Finally, we need your help in pressuring congress to provide day care for the children of our caregivers.
If t hey cannot find adequate care fo r thei r children, then our clients will suffer. This is a vital step to
keep our clients in the ir homes.
NIH-000245
With you help, home care companies will be able to:
l. Relieve the burden on the healthcare system by keeping our clients o ut of the hospita l; and
2. Adhere to shelter-in-place measures which w ill flatten the curve of COVID-19's spread.
~~~y
L....:::J
,
On beha lf of:
Michael Coccaro, Chief Operating Officer and General Counsel, Synergy Home Care
Emma Dickison, Chief Executive Officer and President, Home Helpers
Lisa Foster , Chief Clinical Officer, MGA Homecare
Daniel Gottschalk, co-owner and President, Genova Health
Margaret Haynes, Chief Operatin g Officer, Right at Home
Vicki Hoak, Executive Director, Home Care Association of America
Peter Ross, Chief Executive Officer and Co-Founder, Senior Helpers
Timothy Ryan, Genera l Counsel, AccentCare, Inc.
Shelly Sun, Founder, BrightStar Care
(b)(6)
www.nu rsecarenc.com
www.livhome.com
NIH-000246
NIH-000247
(bXS)- PCP.
NIH-000248
NIH-000249
Sent : Tue, 24 Mar 2020 15:33:11 +0000
To : Barasch, Kimberly (NIH/NIAI D) [CJ
Subject : FW: The global healt h leaders call, Wednesday 25 M arch at 13:00 CET
Att achment s: (b)(4 Swisscom Call code.pdf
Please print thi s out f or me for possibilit y doing th e call t omorrow . Thanks.
Director
Phone: (b)(6)
FAX: (301) 496 -4409
E-mail (b)(6)
From : RYAN, Michae l J. (b)(6)

To : SHOC<shoc@who .int>; Offi ce of t he Director-Gene ral <DG0ffice@who .int> ; Redfield, Robert R.
(CDC/OD) (b)(6)
---~~~~~~~~~~~~~----~~~~~~~~~~~--; David
_H_e..:.
y_
m_a_n...;
n=::====~~-:'.':"'"'."" (b
'"'.'.
)~C ; Felicity Harvey (b)(6)
(b)(6)>; Chris.Elias (b)(6);
=======~:;,,;;-_ ----============:::::::;.----=-=-=
(b)(6) J.Farrar (b)(6)
--------- ; Fauci, An-t:-
ho_n_y-:-
{:-
N'."'."'
IH:-:
/ :-
N:-IA"".".
ID
:-:)-:-[:-:
E]:-:===========-- (b
=-=-
)-:-=
(6)
GREIN, Thomas (b)(6)·>;COX,
Raman
SCHWARTLANDER,Bernhard F.
(b)(6);
----------
(b)( 6) '; Conrad, Patricia {NIH/NIA ID) [E]
(b)( ; M AHJOUR, Jaouad (b)(6b ; FALL, lbrahima Soce
(b)( 6),; MINHAS,
====~~------ (b)(6)
(b)(6); Thomas R. Frieden
Lynn Banks --==========~~----:----:--"
(b)( ; President I Resolve to Save Lives
<president@reso lvetosavelives .org>; (b)(6); AL-SHORBAJI,
Farah_=====~-~~------- Cb
_>_<6)
_.; Robynn Leidig
(b)(6); DRURY, Patrick Anthony (b)(6),>; Dr VAN KERKHOVE,
(b)(6)
cherylc (b)( ; GRAAFF,Peter Jan
;____;__::==-,;::,;;~--:-:-:-~
(b)( ~ ; Tarik Mohammed
======~--___:___ ___.:====~~ ,
(b)(6) Carlos Navarro Colorado
=================~ ~
(b)(6) Ryan Morhard
----------------------
NIH-000250
(b)(6) BRIAND,Sylvie (b)(6Jt>;MORGAN,Oliver
========,:~"""."".""----:--":""
====== (b=
)(=6)!.:.
;~H=arries, Jenny___ -:====== (b=)(~6)::--
; ~Awwad, David (NIH/NIAID) [C]
(b)( ; SIMONSON, Stewart (b)(6Jt>;SINGER,Peter Alexander
=====~~~--
(b)( 6) Jayatunga, Wikum (b)(6)
!!===== ; Julie.HALL (b)(6}; Amelie RIOUX (b)(
(b)(6)
SHIN, Young-Soo (b)(6);
(b)(6)
Cc:SHOC<shoc@who.int>; Office of the Director-General <DGOffice@who.int>; SCHWARTLANDER,

Bernhard F. (b)(6); MAHJOUR,Jaouad (b)(6J:>; FALL,lbrahima Soce
(b)(6)·>; GREIN, Thomas (b)(6)·>; MINHAS, Raman (b)( ·; COX,Paul
Michael (b)(6)r>; AL-SHORBAJI,Farah (b)(6J:>; POOLE,Marcia
(b)( ·; DRURY,Patrick Anthony (b)(6J>; GRAAFF,Peter Jan
=====:-=~
(b)(6) ; Dr VAN KERKHOVE, Maria (b)(6); KABIR,Sophia
=====;:~,;-'" (b)(6)>; FARES,Christine Youssef (b)(6); AYLWARD , Raymond Bruce J.
=====:-:-::!...,.;
(b)(6) ·>; SMITH, Ian M ichael (b)(6)
-------
Subject: The global health leaders call, Wednesday 25 March at 13:00 CET
Dear colleagues,
coronavirus.
The teleconference will be hosted on Wednesday, 25 March at 13:00 CET and the dial-in
number with a passcode is attached.
If you experience any technical difficulties joining this conference call, please contact the WHO
HQ EOC operator at: +41227912490
It would be appreciated if you could kindly confirm your participation to Ms Sophia Kabir, email:
kabirso@who.int; mobile no. (b)(6)
Th e agenda and background documents will be shared ahead of the call.
Best,
Mike
NIH-000251
Dear participant
To join the upcoming teleconference, please call:
From inside WHO

(b)(4)
From others countr ies please call:
Country Number Access Code

Argent ina +54 115 984 12 00 (b) (4)
Austra lia +61 280 147 967
Austria +43 720 880 876
Belgium +32 280 835 50
Brazil +55 213 958 07 18
Bulgaria +35 924 917 399
Canada +16136e6 43 59
Chile +56 225 95 28 26
China +86 105 789 7457
Croatia +38 51 777 63 03
Cyprus +35 72 503 02 78
Czech Republic +42 024 €01 95 32
Denmark +45 699 182 15
El Salvador +50 32 113 37 10
Estonia +37 26 68 12 68
Finland +35 894 270 50 03
France +33 1 77 69 68 25
Germany +49 698 991 47 25
Georgia +99 57 067 773 41
Greece +30 211 198 00 81
Hong Kong +85 258 084 851
Hungary +36180 881 90
Ireland +35 314 845 940
India +9 1 11 712 79 153
Israel +97 237 219 661
Italy +39 02 479 211 40
Japan +81 345 209 476
Kazakhstan +771 727274 71
Lathvia +3716 765 25 76
Lithuania +37 052 05 89 83
Luxembourg +352 208 801 72
Malaysia +603 921 220 20
Malta +35 62 778 01 98
Mexico +52 554 E24 02 27
Netherlands +3 1 108 920 271
New Zealand +64 99 25 03 39
Norway +4721018941
Panama +507 836 51 38
Peru +51 17 08 54 63
Philippines +632 2312215
Poland +48 221 168 469
Portugal +351 308 800 872
Puerto Rico +17 879 05 73 62
Russia +749 540 220 27
Romania +40318107181
Singapore +65 315 813 05
Slovakia +42 123 300 69 18
Slovenia +38 61 600 49 18
South Africa +27 10 590 11 04
South Korea +82 707 488 31 02
Sweden +46 840 309 949
Switzerland (English) +4 1 58 2€2 07 22
Switzerland (Italiano) +4 1 58 2E2 07 44
Switzerland (Deutsch) +4 1 58 2€2 07 11
NIH-000252
(b) (4)
Switzerland (Frangais) +4 1 58 2€2 07 33
Spain +34 931 816 661
Tadzhikistan +99 242 782 22 70
Turkey +90 21 290 025 60
United Kingdom +44 203 370 57 19
United States +16463810889
NIH-000253
Sent : Tue, 24 Mar 2020 15:32:02 +0000
Subjec t : FW: interview request
Tell them no.
Director
National Ins titute of Allergy and Infectious Diseases
Nationa l Institu tes of Health
Bet besda , MD 20892 -2520
Phone: (b) (6)
FA X: (301) 496 -4409
E-mail: (b) (6)
The informa tion in this e-mail and any of its attachments is confidential and may contain sensi tive infom1ation. It
should not be used by anyone who is not the original intended recip ient. l fyou have received this e-mail in error
please inform the sender and delete it from your mai lbox or any other storage devices. Tue National lnstimt e of
Alle rgy and Infe ctio us Diseases (Nl AID) shall not accept liability for any statements made that are the send er's own
From : Raphael De Montferrand <rdemontferrand @rttv .fr>
To: Fauci, Anthony (NrH/NlAID) [E] ------~~= (b)(6}
Subject: interview reque st
dr Faucy ,
Hello, my channel is doing a section of its news tonight (at 3:45pm your time) on the coronavirns situation in New
York . T wondered ifwe could interview you over skype. Do you think that might be poss ible at 3:45pm today your
tim e?
We have a simultan eous translator as we operate in trench from our stu dio in Pari s .
Looking forward to hear from you,
Raphael de Montferrand
RT France
0033608662642
NIH-000254
Fauci, Anthony (NIH/N IA ID) [E)
Tue, 24 Mar 2020 14:30:50 +0000
(b)( 6)
Subject : FW: Boston Globe: In orde r to save Dr. Fauci, w e mu st destroy him
Yikes! You have to read t his. Thi ngs are gettin g unbelievably crazy.
Director
Phone: (b)( 6)
FAX: (301) 496-4409
E-mail: Cb)(6)
From : Folkers, Greg (NIH/NIA ID) [E] (b)(6)

To : NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih .gov>; NIAI D OD AM <NIAIDODAM@n iaid .nih .gov>; NIAID
COGCORE<COGCORE@mail.nih.gov>
Subj ect: Boston Globe : In order to save Dr. Fauc i, we must destroy him
In order to save Dr. Fauci, we must destroy

him
Dr. Anthony Fauci, director of the National Institute of Allergy
and Infectious Diseases, is a study of calm and competence in
the middle of a pandemic. Which makes him an endangered
species, working as he does for a boss who is notoriously
insecure and made his name shouting "You're fired!" on a
reality TV show.
ByKevin Cullen Globe Column ist,Updated March 23, 2020, 5:25 p.m.
209
NIH-000257
Dr. Anthony Fauci's
calm, reassuring competence in response to the coronavirus pandemic is placing him at serious risk of
hearing the words tha t made his boss famous: You're fired.Jabin Botsford/The Washington Post
Dr. Anthony Fauci is a bum.
A quack, a snake oil salesman.
He got his degrees on line, not from Holy Cross and Cornell.
He watches Wheel of Fortune but not Jeopardy.
He's a Yankees fan.
Such character assassination is unsavory but necessary because Fauci's calm, reassuring competence in
response to the coronavi rus pandemic is placing him at serious risk of hearing the words that made his
boss famous: You're fi red .
President Trump is watching and listening to the same thing we are, i.e., Fauci going to the podium to
rebut with facts the latest outbreak of paranoid anxiety or the president'sr egu larly reckless
statements.
Fauci is an oasis of rigor and reason in a barren desert of confusion and fear.
Which, given who he works for, makes him an endangered species.
During the Vietnam War, some US Army officer supposedly suggested that in order to save a village
from the Vietcong they had to destroy it.
And so, to save Dr. Fauci, we must destroy him - at least in Trump's eyes.
Now that might sound crazy, but we're dealing with a crazy president in crazy circumstances.
It's not as if there's no relevant precedent here.
Two words: Bill Bratton.
Two other words: Rudy Giuliani. Who happens to be Trump's BFF.
Before Giuliani grew old, deranged, and more qualified to be a spokesman for Miracle Ear than the
president's lawyer, he was the reform -minded mayor of New York City.
Rudy rode into Dodge, which is what Times Square resembled at the time, and vowed to clean it up. His
hand-picked sheriff was Dorchester's own Bill Bratton.
As police commissioner, Bratton did much to stem violent crime in the nation's biggest city, but even
more rema rkably got his cops to reduce the incidence of more minor , so-called quality of life crimes that
NIH-000258
had made New York less livable, from the tony sections of Manhattan to the Tony Fauci sections of
Brooklyn.
Bratton did his job too well. He ended up on the cover of Time magazine, hailed as the guy who pulled
the worm out of the Big Apple. He became more popular than the mayor.
This drove Giuliani nuts. Rudy had to be the smartest guy in the room, had to get all the credit. Sound
familiar?
So Bratton had to go.
That wasn't Bratton's first rodeo. Long before he landed in New York, he became the face of
progressive, modern policing in his hometown, the youngest-ever Boston Police superintendent. Police
Commissioner Joe Jordan resented his overly-ambitious No. 2 so he busted Bratton.
The point is, insecure bosses don't like being shown up by smarter, more competent subordinates. Small
men make big mistakes.
It may be too late to save Fauci. He just got the star treatment from Maureen Dowd in The New
York Times.
There used to be a thing called the Sports Illustrated curse, that after an athlete appeared on its cover
his or her career tanked.
Similarly, being in the Trump administration and getting praised by The New York Times is the kiss of
death.
Now, normally, you could print something in the Times and chances were the president wouldn't read it.
He routinely dismisses the Gray Old Lady as fake news, except when his and his family's lousy books are
mass- bought onto the newspaper's bestsellers list. He is not fond of polysyllabic words and prefers
to get his news from "Fox & Friends" or whatever wh ite nat ional ist website his aide Stephen Miller
might recommend.
But Trump reads Mo Dowd because they have known each other forever and she writes about him at a
nuanced, personal level that drives him especially cuckoo.
We're way past the theoret ical here.
Tony Fauci is in real danger, and by extension so are the rest of us who expect - nay, pray for - one
person in the White House to be trustworthy and competent in a time of unprecedented crisis.
So, again, repeat after me, Dr. Anthony Fauci is a bum.
Long live the bum .
Kevin Cullen is a Globe columnist. He can be reached at kevin .cullen@globe .com.
Di claimer: Any third-party material in thi email has been shared for internal u e under fair use provisions
of U. . copyright law, without further verification of its accuracy/veracity. It does not necessarily repre eat
my views nor those of IAID, NIH HH , or the U.. government.
NIH-000259
Sent: Tue, 24 Mar 2020 14:13:33 +0000
To: (b)(6)
Subject: RE:Update #2: Traffic Advisory: Street Closures
Thanks
Director
Phone: (b)(6)
FAX: (30 496"'4409
E-mail: (b)(6)
From:
-------------------
-------=-:-=,
(b)(6)

-------- (b)(6)
Subject: FW: Updat e #2: Traffic Advi sory: Street Closures
A lot of street closures. I don't think it wi ll inte rfere with your trip downtown, but just in case
From: AlertDC <nore ply@everb ri dge.net >

To:
-------------------
Subject: Update #2: Traffic Advisory: Street Closures
(b) ~ >
This is an important message from the District of Columbia AlertDC system.
On Tuesday , March 24, 2020, in coordination with the National Park Service, the
Metropolitan Police Department will make several street closures beginning at 7:00 a.m.
through approximately 8:00 p.m at the following locations:
• The Memorial Bridge

• Lincoln Memorial Circle
• Potomac River Freeway (all exits to Ohio Drive and Independence Avenue)
NIH-000260
• Rock Creek Parkway/Potomac Parkway Drive between Virginia Avenue and
Independence Avenue , SW (to include Ohio Drive, SW)
• Independence Avenue between Ohio Drive and 14th Street , SW
• 23rd Street between Constitution Avenue and Lincoln Memorial Circle
• Henry Bacon Drive between Constitution Avenue and Lincoln Memorial Circle
• 17th Street between Constitution Avenue , NW and Independence Avenue, SW
• 15th Street between Constitution Avenue , NW and Independence Avenue, SW
• Maine Avenue between Independence and 12th Street, SW
• All vehicular exits to East Potomac Park and West Potomac Park
All street closures and listed times are subject to change based upon prevailing or
unexpected conditions .
The public should expect parking restrictions along the street and should be guided by
the posted emergency no parking signage . All vehicles that are parked in violation of the
emergency no parking signs will be ticketed and towed .
Individuals and groups will encounter delays in the vicinity of this closure . To help flatten
the curve , we strongly discourage any Tidal Basin visits because social distancing has
not been possible due to visitor volume .
For more information about the District 's coronavirus response , visit coronavirus.dc .gov
Click Here to update your profile.
To stop receiving future email notifications from this organization unsubscribe here .
NIH-000261
Sent: Tue, 24 Mar 2020 14:12:54 +0000
To: Mi ller , Katie R. EOP/OVP
Cc: Short , MarcT . EOP/OVP;Conrad, Patricia (NIH/N IAID) [E];Billet, Courtney
(NIH/N IAID) [E];O'Ma lley, Devin M . EOP/OVP
Subject: RE: Please advise
I called the reporter and she was very receptive to my corrections of the record
and presentation of the facts .
Director
Be thesda MD 20892-2520
Phone: (b)( 6)
FAX: (301 496-4409
E-mail: (b)(6)
From: M iller, Katie R. EOP/OVP (b)(6)>

Sent: Tuesday, Mar ch 24, 2020 9:37 AM
------~~
_.;....;....:.:::::=====~~
Cc:Short , Marc T. EOP/OVP Cb)( >; Conrad, Patricia (NIH/NIAID) [E)
(b)(6) Billet , Courtney (NIH/NIAID) [E) (b)( O'Ma lley, Devin M.
":-
E-:-
0--P7/ 0'.""'.'
V"".":
P---::======---.;._- (b
""')""'(~ >
Subject: Re: Please advise
(b)(5)
Sent from my iPhone
On M ar 24, 2020, at 9:27 AM, Fauci, Anthony (NIH/NIAID) [E] CbH >
w ro te: --------
Marc/Katie:
NIH-000262
(b) (5)
Tony
Director
Phone: (b) (6)
FAX: (301) 496-4409
E-mail:
--------- (b)(6)
From: Abuta leb, Yasmeen <Yasmeen.Abutaleb@washpost.com >

--------~~
To: Conrad, Patricia (NIH/NIAID) [E) (b)(6)
Cc: Parker, Ashley <Ashley.Pa rker@washpost.com >
Subject: Washington Post fact check on Fauci/scientists story
Hi Patty,
Thanks very much for your help yesterday and hope you' re doing well . We're working on a
story today about Trump's re lationship with the scientific and medical experts in the
coronavirus response, including Dr. Fauci. We're reporting t his out today but wanted to
send you what we've been hear ing as we get it so there's ample time to fact check
everything today. Here are some points we'd love to discuss with the best person in your
office or, better yet, Dr. Fauci himself .
NIH-000263
• Fauci was apoplectic about Trump's tweet yesterday saying the cure couldn' t be
worse than the virus and indicating that he wants to reopen businesses soon.
• Fauci has been forceful privately that unproven drugs should not be advertised to
Americans as a panacea (and he of course has publicly spoken about these drugs).
• We are also reporting in a separate story that Larry Ellison is building a website for
the federal government that will collect data on the efficacy of remdesivir,
chloroquine and hydroxychloroqulne. our understanding Is Fauci is vehemently
opposed to this idea and has pushed back on it, citing patient privacy concerns
with the website and collecting data in this way outside of an approved FDA trial.
Again, we'd love to speak with Dr. Fauci and any others in your office who may have insight
into these particular issues and other aspects of the coronavirus response. Pleasefeel free
to give me a call on my cell at any time at (b)(6)
Thanks very much,
Yasmeen Abutaleb
The Washington Post
Healt h policy reporter
o: 202-334-8387 c: ___ """
(b)""'(=6)
@yabutaleb7
NIH-000264
From: (b)(6)
Sent : Tue, 24 Mar 2020 07:47:49 -0400
To: Pottinger, Matthew F. EOP/WHO
Subjec t : Re: regarding masks and Covid-19
Very good point.

(b)(5)- PCI
NIH-000265
(bX5)-PCE
NIH-000266
NIH-000267
NIH-000268
From: (b)(6)
Sent: Mon, 23 Mar 2020 15:45:21-0400
Subject: Fwd: Media Request:NPR'slA Show
From: Am anda Williams <amand aw @wamu.org >

Date: March 23 , 2020 at 3:41:06 PM EDT
To: "Fauci , Anthony (NIH/NIAID ) [E] " ------~~
(b)(6Ji
Cc: "NIAID NEWS (NIH/NIAID)" <NIAIDNEWS @niaid.nih .gov>
Subject: Media Req uest: NPR's lA Show
Hello Dr. Fauci,
I'm a producer with National Public Radio's 1A show and we'd like to invite you to
join our program to talk about coronavirus in the near future. We've bui lt our show
on answering our 4+ million listeners' questions and we know Americans have a lot
of questions for you right now. We don't take live calls, but we do curate input
from voicemails and social media.
We would love to have you join us. Please let me know if you are available and
interested anytime soon. We are very flex ible.
A bit more about 1A: We launched in January 2017 and we're ranked among the
top 10 public radio programs on a list that includes Morn ing Edition, All Things
Considered and Marketplace. We reach 4+ million listeners every week and air on
more than 365 stations across the country. Our major markets include Chicago, LA,
NYC, DC, At lanta, Boston, Philadelphia, San Francisco, Miami, Houston, Minneapol is
and Seattle.
Best,
Amanda
Amanda Williams
Across America Producer
lA, from WAMU and NPR
----- (b)(6) (c) I @amandwms I thela.org
NIH-000269
Fauci, Anthony (NIH/NIAID) [E)
Mon, 23 Mar 2020 19:32:28 +0000
(b)(6)
(b)(6)
Subject: Re: USA Today/David M . Rubenstein-- Coronavirus hero: Anthony Fauci is a

great public servant in a time of great public need
Attachments: im age002.jpg
Love you all
On Mar 23, 2020, at 3:0 7 PM , wrote:

--------------- (b)(6)1
So True!
In a message dated 3/23/2020 2:06: 15 PM Easte rn Standard Time,

writes:
--------- Cb)(6)
Lots of a very kind and thoughtful and well-earned words of respect coming
your way Cb) (6)
On Mon, Mar 23, 2020 at 12:35 PM (b)(
wrote: ------------
That' s a very nice piece about you, Cb) (6)
I hope you got some rest this weekend. Sending lots of love.
On Sun, Mar 22, 2020 at 6:34 PM Fauci, Anthony (NIH/NIAID) [E]
--------- Cb>< wrote:
Wow. David Rubenstein

nice to me. ----(b)(6) used to work for him) was really
From: Folkers, Greg (NIH/NIAID) [E] Cb)(6)

Subject: USA Today/David M. Rubenstein-- Corona:virushero:
Anthony Fauci is a great public servant in a time of grea t pub lic need
NIH-000270
Coronavirus hero : Anthony
Fauci is a great public servant in
a time of great public need
Fauci is the world's leading authority on
infectious diseases and the best person in the
country to help us deal with the COVID-19
crisis.
David M. Rubenstein
Opin ion contrib utor
Some viewers of the daily White House coronav irus briefings may
wonder why everyone increasingly defers to a diminutive, Brooklyn-
accented 79-year -old doctor , Tony Fauci.
They do because , as I have learned over many years of talking with and
more recently interviewing this man, he is without doubt the world's
leading authority on infectious diseases. In any area of human activity
or knowledge, there always seems to be one person who is the global
gold standard. In the world of infectious diseases that person is Tony
Fauci.
So the American peo ple - indeed, people around the globe - should
be grateful that Tony has dug into this crisis with the same work-
around-the-clock, j ust-the-facts ma 'a m style that he has used
while serving under and working with six U.S . presidents. He is as
apolitical as anyone can be. I have no idea ifhe is registered with any
poli tical party; I suspec t though that he is rabidly Independent. His only
focus is getting the facts out, provid ing the best health care treatment
and info1mat ion possible, and saving lives.
A top expert from AIDS to Ebola

Tony Fauci joined the Na tional Institutes of Health in 1968, after
completing his medical training at Weill Cornell Medical Center, and
he has led the Nat ional Institute of Allergy and Infectio us Disease since
1984 - 36 years . Hard to believe anyone can run anything that long
and still be at the top of his game. But Tony is. During this period, he
has dealt with every serious infectious disease challenge - malaria ,
NIH-000271
Among Tony's best known accomplishments, beyond simply running
the institute and training dozens of the world's top infectious disease
professionals , has been helping to discover how HIV leads to AIDS
and, later, leading the effort to create (at President George W. Bush's
direction) the President's Emergency Plan for AIDS Relief (PEPFAR),
which has transformed the treatment of HIV /AIDS in Africa, and other
parts of the developing world. Millions of lives have been save d by this
program alone. More recently , he has been an architect and powerful
advocate of President Donald Trump's plan for ending the AIDS
epidemic in the U.S . through HIV antiretrov iral therapy targeted to
disease hot spots .
In his spare time, Tony has been involved with writing or editing more
than 1,100 scholarly articles and several textbooks, and, in the process,
has become one of the most cited authorities of the entire medical
profession.
For these breakthrough activities and his dedicated service (at a

government salary) for more than a half century (he worked at NIH for
16 years before ass uming his current role), Tony has received, and
earned, the Presidential Meda l of Freedom and a Lasker Award (called
the American Nobel by many).
With this long service and universa l acclaim, one migh t think Tony
would let it get to his head, at least a little bit. Not the case, though.
Selfless commitment to public service

He is readily accessible to those who need treatment - he still runs a
lab at NIH - or need information. Tony still lives in the same hou se he
bought when he first moved to Washington , and it is there that he and
his wife Christ ine have raised their three talented daughte rs (thoug h
none of them chose to atte nd med ica l school).
Unt il the latest crisis, Tony has often commuted to NIH

by Metro, typically after running three miles for his daily exercise. And
when he has been invited to make speeches in the Was hington area or
on Capito l Hill, he invariab ly turns down a car and driver for
the Metro . (This practice has had to change of late for the obv ious
reasons).
The re are, of course, many other dedicated federa l serva nts who also
view their comm itment to the countr y and its people over financial
rewards. But surely no federa l civil servant , in any area, can exceed
Tony Fauci's long-term and selfless commitment to this country and
the health of its people.
NIH-000272
<image002.jpg >
I tried years ago, when Tony was approac hing a normal retireme nt age,
to see if he might want after a normal lifetime of federal service, to take
some of his considerable skills and knowledge to the private sector. He
quick ly said no - money did not motivate him, serving the coun try
did. And he stayed at NIH - to the country's good fo1tune.
If there is any one medica l profess ional who can he lp the country deal
with the COVID - 19 crisis, it is Tony Fauci, an example of the best this
country has to offer.
He is not a miracle worker. No one is.
But Tony Fauc i has the decades of experience needed to understand

infectious disease prob lems and prescribe a trea tment that shou ld, in
time , prov ide the requisite comfort , even if, in the short term, the
med icine is painfu l and inconve nient.
David M Rubenstein is the co-executive chairman of The Carlyle

Group.
Disclaimer: Any third-party material in this email has been shared for internal
use under fair use prov isions of U.S. copyright law, wit hout further verification
of its accuracy/veracity. It does not necessarily represent my views nor those of
NIAID, NIH, HHS, or the U.S. government.
(b)(6)
<image002. jpg>
NIH-000273
NIH-000274
NIH-000275
From: (b)(6)
Sent: Mon, 23 Mar 2020 15:16:17 -0400
To: Barasch, Kimberly (NIH/NIAID) [CJ
Subject: Fwd: Me eting on the science of COVID-19, Wed. 3/25, 2 - S pm
Please print out for me and have ready in case I do this on Wednesday
From: "Tromberg, Bruc e (NIH/NIBIB) [E]" (b)(6)>

Date: March 23, 2020 at 1:22: 18 AM EDT
To: "Collin s, Francis (NIH /OD) [E]" -------=-=-=
Cc: "Tabak , Lawrence (NIH /OD) [E]"
Anthony (NlH/NIAID) [E]" (b)C >
Subject: Re: Meeting on the science of COVID-19, Wed. 3/25, 2 - 5 pm
Hi Francis,
Thanks, I'm looking forward to the meeting. Probably not directly relevant to this
upcoming discussion, (b)(S)
(b)(S)
NIH-000276
(b) (5)
Best,
Bruce
From: "Collins, Francis (NIH/OD) [E]" (b)(6)

Date: Sunday, March 22 , 2020 at 9:38 PM
To : "ICDDIR-L@LIST.NIH.GOV " <ICDDIR-L@LIST.NIH .GOV>
Cc: "Tabak, Lawrence (NIH/OD) [E]" (b)(6) "Wolinetz, Carrie
(NIM/OD) [E]" (b)( , "Anderson, James (NIH/OD) [E]"
(b)(6), "Parker, Ashley (NIH/OD) [E]"
=~===~ 7
(b)
;;(6) McManus, Ayanna (N IH/OD) IE]"
;:;->,-::"-:"
(b)(6), "Wood, Gretchen (NIH/OD) [E]"
======::e (b
:c,;:
)::,:,,
(6)
:c;---
$.~bject: Meet ing on the science of COVID-19, Wed. 3/25, 2 - 5 pm
Colleagues,
I'm glad to hear that most of you are able to join a three -hour virtual meeting on
Wednesday March 25 to discussscientific opportunities in the effort to conquer the
COVID-19 pandemic. While NIAID rightly has the lead in this effort for NIH, and is deeply
invested in projects in both their intramural and extramural programs, it' s clear that a
number of other ICs have creative ideas and a strong motivation to try to help with this
global crisis. So this certainly seems like a time where we should gather (virtually of course)
NIH-000277
to brainstorm together, led by NIAID, and seek to identify any additional areas of
contribution that could be subject to acceleration and/or collaboration.
Hilary Marston recently convened a Deputies meeting on this subject, and ICs were then
asked to submit examples last Friday of projects they are pursuing in the COVID-19
space. Those were forwarded from Bob Eisinger to me. I have used those submissions,
including a detailed list of NIAID projects, to put together a tentative agenda for
Wednesday's meeting . That is attached.
(b) (5)
There are admittedly a lot of themes and topics here, so this will require some real
discipline in the one -slide presentations . I will try to serve as time -keeper- or maybe I'll
ask Larry to do that. □ D
All IC Directors are invited to have one or two subject matter experts join them for this
virtual discussion.
Ashley Parker (b)(6) will be helping me with the logistics and will have
further instructions about how the log in w ill work.
Here's the specific follow up request that needs your immediate attention :
1. If your IC is pursuing a highly relevant project that's not listed here, and that you
want the group to hear about, please send me that informa ti on ASAP.
2. If your IC is on t he draft agenda to make a presentation, please submit your one
slide (except for NIAID, who gets more) to me and Ashley by COBTuesday
3/24. That way we can put the whole set together as a single ppt file.
Many thanks! This should provide a welcome respite from the many other tasks we are all
facing right now .
Francis
NIH-000278
Sent: Mon, 23 Mar 2020 19:06:06 +0000
Bee: Aberg, Judith;Adaora Adimora;Grund, Birgit;Glidden, David;Daar,Eric;Erica
Hardy;Gandhi, RajeshTim,M.D.;JasonBaker;JeffLennox;Johnson,Steven C- ID;Kim,Arthur
Y.,M.D.;Marla Keller;Tebas, Pablo (NIH );Susan Davis;Susan Swindells;Susanna Naggie;Tien, Phyllis;Amy
Dzierba;Mitchell Levy;Laura Evans;Cra ig Coopersmith ;Greg Martin;Uyek i, Timothy M .
(CDC/0010/NCIRD/ ID);Walker, Robert (OS/ASPR/BARDA);Sheikh, Virginia (FDA/CDER);Anne
Collie r;Francis, Joe (Contact NLM/OD -External) (b)(6)
Subject: Invitation to j oin the HHSPanel on Guidelines for The Management of COVID-19
Dear Colleague ,
At the request of the Office of the Secretary, HHS and in conjunction with the White House Task
Force we are creating a COVID-19 management guidelines panel to provide frequently updated
information to the pub lic regarding the treatment of patients with COVID-19.
This guidance will be an HHS document, will be updated frequently and will be modeled to
some degree after the ART guidelines. The Panel will include academicians and clinicians
currently caring for persons with COVID-19 and representatives from multiple US government
agencies (CDC, BARDA, FDA, VA, DoD) and professional societies. Cliff Lane, M.D . Henry Masur,
M .D. and Trip Gulick, M.D . will co-chair, and Alice Pau, Pharm.D . will be the exec. sec. for this
new panel. Those of you who are appointed to represent your federal agencies will be ex -
officio. Other federal employees will be vot ing members.
I would like to invite you to be a member of this new Panel based on your expertise. We
anticipate that work will begin this week and we hope to be able to put out the first guidance in
1-2 weeks. We appreciate your will ingness to jo in this very important effort and your work in
caring for pat ients during th is pandemic.
The first meeting (by teleconference) will be Tuesday , March 24 at 11:00AM EDT. More details
will be provided soon.
Thank-you for considering this and for all you are doing during this most challenging time.
Sincerely,
Director
NIH-000279
Phone: (b)(6)
FAX: (301) 496-4409
E-mail (b) (6)
othe r storage devices . The Nat ional Institute of Allergy and Infectious Diseases (NIAID) shall not
NIH-000280
Sent: Mo n, 23 Mar 2020 18:38:21 +0000
To : (b)( 6)
Cc: (b)(6)
Subject: RE: FW: USA Today/David M. Rubenstein-- Coronavir us hero: Anthony f-auci is a
Love you all.
Director
Phone: (b)( 6)
FAX: (301 496-4409
E-mail=--....,. _.
_, (b)(6)
From: (b)(6)>
Sent: Monday , Mar ch 23, 2020 12:35 PM
To: Fauci, Anthony (NIH/NIAID) [E] ------~~ (b)(6) >
(b)(6)
Subject: Re: FW: USA Today/Dav id M. Rubenstein-- Coronavirus hero: Anthony Fauci is a great public
servant in a t ime of great publ ic need
~ (b)=(6)
=
That 's a very nice piece about you,
I hope you got some rest this weekend . Sending lots of love.
On Sun, Mar 22, 2020 at 6:34 PM Fauci, Anthony (NIH/NIAID ) [E]

-------- (b)(6)> w rot e:
Wow. David Rubenstein

---- (b)(6) used to work for him) was really nice to me.

Sent: Sunday, Marc h 22, 2020 11:36 AM
Subject: USAToday/David M. Rubenste in-- Coronavirus hero : Anthony Fauci is a great public servant
in a time of great publ ic need
NIH-000281
Coronavirus hero: Anthony Fauci is a great
public servant in a time of great public need
Fauci is the world 's leading authority on infectious diseases
and the best person in the country to help us deal with the
COVID-19 crisis.
David M . Rubenstein
Opinion contributor
Some viewers of the daily White House coronavirus briefings may wonder why everyone increasingly
defers to a diminutive, Brooklyn -accented 79-year-old doctor, Tony Fauci.
They do because, as I have learned over many years of talking with and more recently interviewing
this man, he is without doubt the world 's leading authority on infectious diseases. In any area of
human activity or knowledge, there always seems to be one person who is the global gold
standard . In the world of infectious diseases that person is Tony Fauci.
So the American people - indeed, people around the globe - should be grateful that Tony has dug
into this crisis with the same work-around-the -clock, just-the-facts ma'am style that he has used
while serving under and working with six U.S. presidents. He is as apolitical as anyone can be. I have
no idea if he is registered with any political party; I suspect though that he is rabidly Independent. His
only focus is getting the facts out, providing the best health care treatment and information possible,
and saving lives.
A top expert from AIDS to Ebola

Tony Fauci joined the National Institutes of Health in 1968, after completing his medical training at
Weill Cornell Medical Center, and he has led the National Institute of Allergy and Infectious Disease
since 1984 - 36 years. Hard to believe anyone can run anything that long and still be at the top of his
game. But Tony is. During this period, he has dealt with every serious infectious disease challenge -
malaria,
Among Tony's best known accomplishments, beyond simply running the institute and training dozens
of the world's top infectious disease professionals, has been helping to discover how HIV leads to
AIDS and, late r, leading the effort to create (at President George W. Bush's direction) the President's
Emergency Plan for AIDS Relief (PEPFAR),which has transformed the treatment of HIV/AIDS in Africa,
and other parts of the developing world. Millions of lives have been saved by this program
alone. More recently, he has been an architect and powerful advocate of President Donald Trump's
plan for ending the AIDS epidemic in the U.S. through HIV antiretroviral therapy targeted to disease
hotspots .
In his spare time, Tony has been involved with writing or editing more than 1,100 scholarly articles
and several textbooks, and, in the process, has become one of the most cited authorities of th e enti re
medical profession.
For these breakthrough activities and his dedicated service (at a government salary) for more than a
half century (he worked at NIH for 16 years before assuming his current role), Tony has received, and
earned, the Presidential Medal of Freedom and a Lasker Award (called the American Nobel by many).
With th is long service and universal acclaim, one might think Tony would let it get to his head, at least
a little bit. Not the case, though .
NIH-000282
He is readily accessible to those who need treatment - he still runs a lab at NIH - or need
information. Tony still lives in the same house he bought when he first moved to Washington, and it is
there that he and his wife Christine have raised their three talented daughters (though none of them
chose to attend medical school).
Until the latest crisis, Tony has often commuted to NIH by Metro, typically after running three miles
for his daily exercise. And when he has been invited to make speeches in the Washington area or on
Capitol Hill, he invariably turns down a car and driver for the Metro. (This practice has had to change
of late for the obvious reasons).
There are, of course, many other dedicated federal servants who also view their commitment to the
country and its people over financial rewards. But surely no federal civil servant, in any area, can
exceed Tony Fauci's long-term and selfless commitment to this country and the health of its people.
I tried years ago, when Tony was approaching a normal retirement age, to see if he might want after a
normal lifetime of federal service, to take some of his considerable skills and knowledge to the private
sector. He quickly said no - money did not motivate him, serving the country did. And he stayed at
NIH - to the country's good fortune.
If there is any one medical professional who can help the country deal with the COVID-19 crisis, it is
Tony Fauci, an example of the best this country has to offer.
But Tony Fauci has the decades of experience needed to understand infectious disease problems and
prescribe a treatment that should, in time, provide the requisite comfort, even if, in the short term,
the medicine is painful and inconvenient.
David M. Rubenstein is the co-executive chairman of The Carlyle Group.
Disclaimer: Any third-party material in this email has been shared for internal use under fair use
provisions of U.S. copyright law, without further verification of its accuracy/veracity. It docs not
necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.
Ali Fauci
NIH-000283
Sent : Mo n, 23 M ar 2020 18:14:25 +0000
To : Barry Albertson
Subject : RE:Pooled $maples
Thanks, Barry.
Director
Phone: (b)(6)
FAX: (30 496"'4409
E-mail: (b)(6)
From : Barry Albertson <barry@fannocreek .com>

-------=-=--==
Subject : FW: Pooled Smaples
Import ance: High
Hi Tony,
I'm forwarding an email I just sent to Paul Cieslak, MD .....one of the lead docs at
the Oregon Health Author ity ; he
CbH6l
gives my clinic's Internal Medicine docs an 'ID Update' for my CME Grand Rounds
each yea r) ...with this email note from Dr. David Brandon ...hope you remember
David....he was w ith Lynn's & Mort Lipsett's group at The Clinical Center .
...I'd bet a coke you know all about pooled sampling .....but wanted to pass it
along.
You have no idea how many people tell me tha t your COVID-19 messages on TV,
etc. are top flight , enormously helpful and encourag ing for them with the best
information , in a sea now of poor information .
NIH-000284
Andrew Cuomo is also doing a great job informing all of NY (and the rest of us)
about what's going on, and his expectations for the public.
Whatever they're paying you ... it's not enough.
You keep your powder dry, and extra flints in your pocket!
Barry
From: Barry Albertson

Sent: Monday, March23, 2020 9:49 AM
To : 'CieslakPaul R'
Subject: PooledSmaples
Importance: High
Good morning, Paul.
Hope you guys at OHA are holding up OK.
I'm fine , fam ily is fine. .. (b)(6) is dong lots of te lemedicine and seeing act ual PEDS
-------
patients at Westside Hosp. now a few days a week.
My clinic is still open but pretty quiet ... we need to stay open at some level no matter wha t .
One of my colleagues from the NIH (Dr. David Brandon ...he actually published with Tony Fauci
back in t he late '70s I believe !) ..sent me this email on Saturday morning
I suspect you all know about poo led sampling, .....David did it at the NIH for a study that I have
long forgotten about. ...thought I'd pass it along to you ......
" I just looked up to see if pooled sampling has been used t o detect viruses in the past, and
found that it has been used in a number of cases including during the HIV scare. I am including
a Iink thttp s://www. israel2 lc. org/israelis-introd uce-method-for-accel erated-covid-19-
testing/ to an article in the lay press reporting on an RT-PCRbased test that uses swabs from
30-60 individuals to dete rmine if the pooled sample has Covid-19. The study was successful
and they are developing it to test workers in the front line work places such as hospitals. There
is a body of literature using t his method for other mass screenings."
Then I heard that CEPHEIDwill be getting their Genexpert instrument validated to measure
COVID-19. Turns out we have one in my Lab, use it for Chlamydia & Gonorrhea (we have lots
of patients here needing this testing). But as you so well know, having the inst rumentation
without the collection swabs/M4 media, etc. Is a bit like biking up a blind alley. I would hope
we'll hear more about t his.
NIH-000285
Give me a shout if I can do anything to help you all ...... best tack for me, I believe, is to stay
out of your way!
Barry
NIH-000286
(b)(5)- PCR
NIH-000287
Sent : Mo n, 23 Mar 2020 18:09:12 +0000
To: O'Grady, Naomi (NIH/CC/CCMD) [El
Subject: RE:vent rat ioning
Naomi :
I am not aware of any efforts on rationing ventilators . They speak of mak ing
sure the high priority areas such as NYCget what they need, but there is no ta lk at
this t ime of "rationing"
Thanks,
Tony
Director
Phone : (b)(6)
FAX : (301 496-4409
E-mail : (b) (6)
From: O'Grady, Naomi (NIH/CC/CCMD) [El (b)(6b

---------
Fauci, Anthony {NIH/NIAID) [El------~~
To :
Subject: vent rationing
-------- (b)(6)>
Hi Tony-
I know you are very busy but I wanted to see if you know of any effort on t he part of the federal
government to issue guidance on the rationing of ventilators when the time comes? Many of my
colleagues in critical care across t he country have been asking for some such guidance on a federal level.
Both for the guidance itself and to protec t themselves from legal liability. Are you aware of any such
efforts? Thanks for any insights on t his. And thanks for all you are doing on the coronavirus effort!
Best regards,
Naomi
Naomi P. O' Grady, MD

Chief, Internal Medici ne Services
NIH Clinical Center
NIH-000288
Sent : Mo n, 23 Mar 2020 16:48:31 +0000
To: Dan Hurley
Subject: RE:2 questions from NY Times Mag reporter who int erviewed you about EV-
D68
Dan:
Thanks for the note . The work on an EV-D68 vaccine will continue . The
Coronavirus vaccine research is the highest prio rity. Both come out of Barney
Graham's group in our VRC. Best to call Barney about the degree of possible
interference. Books are not on my mind right now.
Thanks,
Tony
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
From: Dan Hurley (b)(6)

Sent: Monday, Mar ch 23, 2020 11:46 AM
To: Fauci, Anthony (NIH/NIAID) [E] ------~~ (b)(6>:>
Subject: Re: 2 questions from NY Times Mag reporter who inte rviewed yo u about EV-D68
Hi Dr. Fauci and Patty: In addit ion to the two items mentioned in my original email, the NY Times
Magazine is also interested in publishing an interview wit h Dr. Fauci. Thank you, Dan Hurley
On Thu, M ar 19, 2020 at 6:04 PM Dan Hurley

--------- (b)(6) wrot e:
Hi Dr. Fauci: I interv iewed you by telephone a few months ago for an article in the New York Times
Magazine about enterovi rus D68, the putative causal agent of acute flaccid myelitis. At the t ime you
said that NIAID was work ing hard on developing a vaccine for EV-D68. I have two questions:
NIH-000289
1. Is work on developing a vaccine against the novel coronav irus interrupting or slowing work on EV-
D68? Hard to believe it wouldn't have an effect .
2. When things calm down with COVID-19, would you consider allowing me to write a biography
about you, or helping you write a memoir? This pandemic has kind of turned you into the face of
medical science in the United States. I'm the author of four prior science books, and have profiled
countless scientists in the Times, The Atlantic, and elsewhere. I know this is not the time for such
things. I just want to put the idea out there . I hope and pray you do not find it offensive for me
suggest such a thing at this time of danger and stress.
Let me know about that EV-D68 vaccine if you can. I'm also reaching out to Barney Graham. Thank
you, Dan Hurley
NIH-000290
Sent: Mo n, 23 M ar 2020 14 :51:53 +0000
To : (b)(6)
Subject: FW : Dinarello Proposa l
Attachments : Dinarello Proposal for COVID-19.doc
Cliff :
(b)(5
Thanks,
Tony
Director
Phone: (b)(6)
FAX : (301 496-4409
E-mail: (b)(6)
have received this e-mail in error please info rm the sende r and delete it from your mailbox or any
other storage devices . The National Institute of Allergy and Infecti ous Diseases (NIAID) shall not
accept liability for any statements made that are the sender 's own and not express ly made on
From: char les dinarello (b)(6)>

Sent : Sunday, Marc h 22, 2020 9:31 PM
To : Fauci, Anthony (NIH/ NIAID) [E] -------~~
Subject: Dinarello Proposal --------- (b)(6)
(b)(6)
I watch CNN almost constantly to listen to your impress ive wisdom . The world listens to you.
Shelly would be so proud of you in this world crisis as he was in the HIV-1 crisis. We will not
see each other at the National Academy of Sciences meeting end of April, but hopefully next
year. I very much enjoyed hearing you place the anecdotal use of chloroquine in its correct
context. "Chloroquine is an awfu lly blunt tool and an indication of our desperation" , Peter Libby
wrote me recently. Tony, attached is a propo sal CbH4>
I need your guidanc e. I know you are terribly busy so I am

copying Cliff. If there is anyone else who can help me, just forward the attachment.
(b)(6)
NIH-00029 1
Sent : Mo n, 23 Mar 2020 14:48:07 +0000
To : (b)(6)
Subject: FW: 23-3-2020 FAO Dr Birx and Dr Fauci - Covid -19 Task Force RE:- Favipiravir =
Avigan
Please have someone handle.
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
From: (b)(6Ji
To: (b)(6) Fauci, Anthony (NIH/NIAID) [E] (b)(6)>
Cc:NST Rogers (b) (6)
Subject: 23-3-2020 FAQ Dr Birx and Dr Fauci - Covid-19 Task Force RE:-Favipirav ir = Avigan
Importance: High
23-3-2020
Dear Dr Birx and Dr Fauci,
As promised, sorry about the delay.
Please see below two articles relating to Favipiravir wh ich has the brand name Avigan. This
appears to have some beneficial effects with regard to the treatment of Covid-19.
I have also included the Wikipedia for Favp iravir .
Good Luck w it h regard to managing the epidemic/pandemic.
NIH-000292
Yours Sincerely
Nicholas Rogers
Favipiravir
Drug
Description
Favip iravir, also known as T-705, Avigan, or favilavir is an antiviral drug being developed by Toyama
Chemical of Japan with activity against many RNA viruses . Like certain other experimental antiviral
drugs, it is a pyrazinecarboxamide derivative. Wikipedia
Formula : C5H4FN3O2
ChemSpider ID: 431002
ChemSpider ID: 431002
PubChem CID: 492405
Favipiravir
From Wikipedia, the free encyclopedia
Jump to navigationJump to search
Experimental antiviral drug with activity against many RNA viruses.
Favip irav ir
FYi N~
l N
,c;
OH
Names
lUPAC name
6-Fl uoro-3-hydroxypyrazine-2-carboxamide
Other names
T-705; A vigan; favilavir
Identifiers
NIH-000293
CAS umber • 259793-96-9
3D model (JSmol) • Interactive image
ChEMBL • ChEMBL22 l 722
Chem Spider • 431002
PubChem CID • 492405
UNII • EW5GL2X7E0 ✓y
CompTox Dashboard
• DTXSID60948878 ,
(EPA)
In hi[ how]
In hl= I / 5H4FN3O2/c6-2-1-8-5( 11)3(9-
2)4(7) I 0/h I H,(H2,7, I 0)(H,8, 11)
Key: Z NOVWY BHAU -UHFFFAOY A- N
In hI= I/ 5 H4FN3O2/c6-2-1-8-5( I I )3(9-2)4(7) I 0/h I H,( H2,7, I 0)(H, , I I)
Key: Z GNOVWY BHAU -UHFFFAOYAM
SMILES[ how]
Oc I ncc(F)nc I (=O)
Propert ies
hcmical fon11ula 5H4F 30 2
Molar ma 157. 104 g ·mol- 1
Pharmacology
AT code J05AX27 (WHO)
Except where otherwi e noted , data are given for materia l
in their tandard late (at 25 °C [77 °F], 100 kPa).
Infobox reference
Favip irav ir al o known a T-705 , Av igan or fav ilavir i an antiviral drug being developed by
Toyama hemical (Fujifilm group) of Japan with activity against many RNA viru e . Like
certain other experimental antiviral drug (T-1 105 and T-1106), it i a pyrazinecarboxamide
derivative. In experiment conducted in animal Favipiravir ha hown activity again t influenza
viru e We t Nile viru , yellow fever virus, foot-and-mouth di ea e virus as well a other
flaviviru e , arenaviru e , bunyaviru e and alpbaviru e _[I] Activity again t enteroviru e [2] and
Rift Valley fever virus ha al o been demon tratect.Pl Favipiravir ha howed limited efficacy
again t Zika viru in animal tudie , but wa le effective than other antiviral uch a MK-
608.[4] The agent ha al o hown ome efficacy again t rabie [SJ and ha been u ed
experimentally in some human infected with the viru .[61
In February 2020, Favipiravir wa being tudied in China for experimental treatment of the
emergent COVID-19 (novel coronaviru di ea e).P l[S] On March 17, Chine e officials uggested
the drug had been effective in treating OVID in Wuhan and ShenzhenJ 9HIO]
As of 23 March 2020, it eems that Japan and China have i sued an export ban on the ub tance.
Japan and hina are the only countrie in which favirapir i produced and approved a a medical
NIH-000294
compound. Some Chinese pharmaceutical companies assure that export rights are still granted
via international diplomatic means by the Chinese Ministry of Industry and Information
Technology (MIIT).
ll
Contents
• !Mechanism of action
• 2Approval status
• 3Ebola virus trials
• 4Coronavirus disease 2019 (COVID-19)
• 5See also
• 6Refe rences
Mechanism of action[edit]
The mechanism of its actions is thought to be related to the selective inhibition of viral RNA-
dependent RNA polymerase.[ 1 I] Other research suggests that favipiravir induces lethal RNA
transver sion mutations, producing a nonviable viral phenotype.(1 2] Favipiravir is a prodrug that
is metabolized to its active form, favip iravir-ribofura nosyl-5'-trip hosphate (favip iravir-RTP),
available in both oral and intravenous formulations.[ I3J[t4 ] Human hypoxanthine guanine
phosphoribosyltransferase (HGPRT) is believed to play a key role in this activation process_[IS]
Favipiravir does not inhibit RNA or DNA synthesis in mammalian cells and is not toxic to
them_[l] In 2014, favipiravir was approved in Japan for stockpiling against influenza
pandemics. [161However, favip iravir has not been shown to be effective in primary human
airway cells, cast ing doubt on its efficacy in influenza treatment. [ 17]
Approval status[edit]
In 2014, Japan approved Fav ipirav ir for treating viral strains unresponsive to current
antivirals.l 18l Toyama Chem ica l initially hoped that Avigan would become a new influenza drug
that could replace Tamiflu. However , animal exper iments show the potential for teratogenic
effects on fetuses, and the approval of production by The Ministry of Health , Labor and Welfare
was greatly delayed and the production condition is limited only in an emergency in JapanV 9 l
In March 2015, the US Food and Drug Administration completed a Phase III clinical trial
studying the safety and efficacy of Fa vipiravir in the treatment of influenza. [20]
NIH-000295
On March 15, 2020 the drug was approved in China with the name Favilavir for the trea tment of
influenza .[2 I] The drug was also approved for use in clin ical trials for treating coro naviru s
disease 2019 pneumonia .[21]
On 22 March, 2020 Italy has ap proved the drug for exper imental use against COV ID-19 and has
begun conducting trials in 3 regions most affected by the disease. [22 l The Italian Pharmace utical
Agency , however, has reminded the public that the existing evidence in support of this drug is
scant and prel iminary.[23 ]
Ebola virus trials[edit]

Some research has been done suggesting that in mouse models Favipiravir may have efficacy
against Ebo la. Its efficacy against Ebola in humans is unproven_[24][25][26] During the 2014 West
Africa Ebo la virus outbreak, it was reported that a French nurse who contracted Ebola while
volunteering for MSF in Liberia recovered after receiving a course of favipiravir. [27l A clinical
h·ial investigating the use of favipiravir against Ebo la virus disease was started in Gueckedou,
Guinea, during December 2014.( 281Preliminary results showed a decrease in mortality rate in
patients wit h low-to-moderate levels of Ebola virus in the blood, but no effect on patients with
high leve ls of the viru s, a group at a higher risk of death.[29] The trial design has been critic ised
by Scott Hammer and others for using only histor ica l conh·ols.[30] The results of this clinical trial
were prese nted in February 2016 at the annual Conference on Retroviruses and Opportunist ic
Infections (CROI) by Daouda Sissoko[3l] and published on March 1, 2016 in PLOS
Medicine. [321
Coronavirus disease 2019 (COVID-19)[edit]

On 17 Marc h 2020, Chinese offic ials suggested that Favip iravir seemed to be effective in
treating COV ID-19 in Wuhan and Shenzhen_[33 J[34 ][ 35]
A study on 80 patients comparing it to lopinavir/ritonavir found that it significantly reduced viral

clearance time to 4 days, compared to 11 for the control group, and that 91.43% of patients had
improved CT scans with few side effects.P 6J[37]
As of 23 March 2020, it seems that Japa n and China have issued an export ban on the substance .
Japan and China are the only cotmtries in which favira pir is produced and approved as a med ical
compound. Some Chinese pharmaceutical companies assure that export righ ts are still granted
via interna tional diplomat ic means by the Chinese Ministry of Industry and Informat ion
Technology (MIIT).[citario1111eede
,1]
See also[edit]
NIH-000296
• BCX4430
• Brincidofovir
• FGI-106
• JK-05
• REGN-EB3
• TKM-Ebo la
• Triazav irin
• ZMapp
References [edit]
1. A Jump up to: a b Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL,
Gowen BB, Julander JG, Morrey JD (June 2009). "T-705 (favipiravir) and related
compounds: Novel broad-spectrum inhibitors of RNA viral infections". Antiviral
Res earch. 82 (3): 95- 102. doi:10.1016/j.antivira/.2009.02.198. PMID 19428599.
2. /\ Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL (November
2013). "Favipiravir (T- 705), a novel viral RNA poly merase inhibitor". Antiviral
Research. 100 (2): 446- 54. doi:10.1016/j.antiviral.2013.09 .015. PMC 3880838.
PMID 24084488.
3. /\ Caroline AL, Powell DS, Bethel LM, Oury TD, Reed DS, Hartman AL (April 2014).
"Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal
inhalational Rift Valley Fever". PLOS Neglected Tropical Diseases. 8 (4): e2790.
doi:l0 .1371/journal.pntd.0002790. PMC 3983105. PMID 24722586.
4. I\ Mumtaz N, van Kampen JJ, Reus ken CB, Boucher CA, Koopmans MP (2016). "Zika
Virus: Where Is the Treatment ?". Current Treatment Options in Infectious Diseases. 8
(3): 208- 11. doi:10.1007 /s40506-016-0083-7. PMC 4969322. PMID 27547128.
5. /\ Yamada K, Noguchi K, Komeno T, Furuta Y, Nishizono A (April 2016) . "Efficacy of
Favipiravir (T-705) in Rabies Postexposure Prophy laxis". The Journal of Infectious
Diseases. 213 (8): 1253- 61. doi:10 .1093/infdisljiv586. PMC 4799667. PMID 26655300.
6. I\ Mwphy J, Sifri CD, Pruitt R, Hornberger M, Bonds D, Blanton J, Ellison J, Cagnina
RE, Enfield KB, Shiferaw M, Gigant e C, Condori E, Gruszynski K, Wallace RM (January

2019). "Human Rabies - Virginia, 2017". MMWR. Morbidity and Mortality Weekly
Report. 67 (5152) : 1410- 14. doi:10.15585/mmwr.mm675152a2 . PMC 6334827.
PMID 30605446.
7. I\ Li G, De Clercq E. Therapeutic options for the 2019 novel coronav irus (20 19-nCoV) .
Nature Reviews Drug Discovery 2020 Feb doi: 10.1038/d41573-020-00016-0
8. I\ BRIEF -Corrected -Zhej iang Hisun Pha1ma gets approval for clinical trial to test flu
drug Favipiravir for pneumonia caused by new coronav irus. Reuters Healthcare, February
16, 2020.
9. I\ NHK World News 'China: Avigan effective in tackling coronavirus '
10. /\ Huaxia. "Favipiravir shows good clinical efficacy in treating COVI D-19: officia l."
Xinhuanet.com, 17 March 2020
NIH-000297
11. AJin Z, Smith LK, Rajwanshi VK, Kim B, Deval J (2013). "The ambiguous base -pairing
and high substrate efficiency o.fT-705 (Favipiravir) Ribofuranosyl 5'-triphosphate
towards influenza A virus polymerase". PLOS One. 8 (7): e68347.
Bibcode:2013PLoSO ... 868347J. doi:l0.1371/journal.pone.0068347. PMC 3707847.
PMID 23874596.
12. A Baranovich T, Wong SS, Armstrong J, Marjuki H, Webby RJ, Webster RC, Govorkova
EA (April 20 13). "T- 705 (favipiravir) induces lethal mutagenesis in influenza A HlNl
viruses in vitro". Journal of Virology . 87 (7): 3741- 51. doi:10 .1128/JVI.02346-12 .
PMC 3624194. PMID 23325689.
13. A Guedj J, Piorkowski G, Jacquot F, Madelain V, Nguyen TH, R odallec A, et al. (March
2018). "Antiviral efficacy offavipiravir against Ebola virus: A translational study in
cynomolgus macaques". PLOS Medicine. 15 (3): el 002535.
doi:10.l 37 l/journaL.pmed.1002535. PMC 5870946. PMID 29584730.
14. A Smee DF, Hurst BL, Egawa H, Takahashi K, Kadota T, Furuta Y (October 2009).
"Intracellular metabolism offavipiravir (T- 705) in uninfected and influenza A (H5Nl)
virus-infected cells". The Journal of Antimicrobial Chemotherapy. 64 (4): 741- 46.
doi:10.1093(jac/dkp274. PMC 2740635. PMID 19643775 .
15. A Naesens L, Guddat LW, Keough DT, van Kuilenburg AB, Meijer J, Vande Voorde J,
Balzarini J (October 2013). ''Role of human hypoxanthine guanine
phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir)".
Molecular Pharmacology. 84 (4): 615- 29. doi:10 .1124/mol.113.087247.
PMID 23907213.
16. A Koons C (7 August 2014). "Ebola Drug From Japan May Emerge Among Key
Candidates". Bloomberg. com.
17. A Yoon JJ, Toots M, Lee S, Lee ME, Ludeke B, Lu czo JM, et al. (August 2018). "Orally
Efficacious Broad-Spect rum Ribonucleoside Analog Inhibitor of Influenza and
R espiratory Syncytial Viruses". Antimicrobial Agents and Chemotherapy. 62 (8):
e00766-18 . doi:10 .1128/AAC.00766-18. PMC 6105843. PMID 29891600.
18. A Hayden, Frederick (2019). "Influenza virus polymerase inhibitors in clinical
development". Current Opinion in Infectious Diseases . 32 (2): 176-186.
doi:10.1097/QC0.0000000000000532. PMC 6416007. PMID 30724789.
19. A ~l!/=fif ~:#KJP.r!-!f &/::}Et; tt- li'tl.!ft~-1':.,, 7 J~Jf!(l)"!/!t✓-£''. Retrieved 25
1
Februa,y 2014.
20. A "Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated
Influenza in Adults - T705US316". FDA. Retrieved 17 March 2020.
21. Jump up to: 0 b J!,%-rffi
A "Potential coronavirus drug approved for marketing -
Chinadaily.com.cn". www.chinadaily.com.cn . Retrieved 2020-03 -21.
22. A "Coronavirus, il Veneto sperimenta l'antivirale giapponese Favipiravir. Ma l'Aifa: "Ci
sono scarse evidenze scientifiche su efficacia"". Il Fatto Quotidiano (in Italian). 2020-03-
22. Retrieved 2020-03-23 .
23. A "AIFA precisa, uso favipiravir per CO VJD-19 non autorizzato in Europa e USA, scarse
evidenze scientifiche sull'~fficacia ". aifa .gov . it (in Italian). Retrieved 2020-03-23 .
NIH-000298
24. A Gatherer D (August 2014) . "The 2014 Ebola virus disease outbreak in West Africa".
The Journal o_/General Virology. 95 (Pt8) : 1619- 24. doi:10.1099/vir.0 .067199-0 .
PMID 24795448.
25. A Oestereich L, Ludtke A, Wurr S, Rieger T, Muiioz-Fontela C, Gunther S (May 2014).
"Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a
small animal model". Antiviral Research. 105: 17-21.
doi:10.1016/j.antiviral.2014.02.014. PMID 24583123.
26. A Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS (April 2014) .
"Post-exposure efficacy o_foral T-705 (Favipiravir) against inhalational Ebola virus
infection in a mouse model" . Antiviral Research. 104: 153- 55.
doi:10.1016(j.antiviral.2014 .01.012 . PMID 24462697.
27. A "First French Ebola patient leaves hospital". Reuters. 4 October 2016.
28. A "Guinea : Clinical Trial for Potential Ebola Treatment Started in MSF Clinic in
Guinea''. Al/Africa - All the Time. Retrieved 28 December 2014.
29. A Fink S (4 Februa,y 2015) . "Ebola Drug Aids Some in a Study in West Africa" . The New
York Times.
30 . A Cohen J (26 February 2015). "Results from encouraging Ebola trial scrutinized".
Science. doi:10. l l 26/science.aaa7912. Retrieved 21 Janua,y 2016.
31. A "Favipiravir in Patients with Ebola Virus Disease: Early Results of the JIKI trial in
Guinea I CROI Conference". croiconjerence.org. Retrieved 2016-03-17 .
32. A Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, et al.
(March 2016). "Experimental Treatment with Favipiravir for Ebola Virus Disease (the
JIKI Trial): A Historically Controlled, Single -Arm Proofo_f'-Concept Trial in Guinea".
PLOS Medicine . 13 (3): e1001967 . doi :10.1371/journal.pmed.1001967 . PMC 4773183 .
PMID 26930627.
33. A "Japanese flu drug 'clearly effective ' in treating coronavirus, says China". The
Guardian . 2020-03 -18. Retrieved 2020 -03-18.
34. A NHK World News 'China: Avigan effective in tackling coronavirus'
35. A Hu ax ia. "Fav ipiravi r shows good clin ical efficacy in treating COVI D- 19: officia l."
Xinhuanet.com, 17 March 2020
36. A Cai, Qingxian; Yang, Minghui; Liu, Dongjing; Chen, Jun; Shu, Dan; Xia, Junxia;
Liao, Xuejiao; Gu, Yuanbo; Cai, Qiue; Yang, Yang; Shen, Chenguang (2020-03-18).
"Experimental Treatment with Favipiravirfor COVID-19 : An Open-Label Control
Study" . Engineering . doi: 10.1016/j .eng.2020.03 .007. ISSN 2095 -8099.
37. A Dong, L; Hu , S; Gao, J (2020). "Discovering drugs to treat coronavirus disease 2019
(COVJD-19)". Drug Discoveries & Therapeutics. 14 (]): 58-60.
doi:10.5582/ddt.2020.01012. PMID 32147628.
show
• V
• t
• e
RNA virus antivirals (primarily JOS, also SOIAD and
D06BB)
Hepatitis C NS3/ 4A • Asunaprevir
NIH-000299
protea se • Bocep revi.-i
inhibitors (-
• Cilu previr§
pre vir)
• Danoprevirt
• Faldaprevirt
• Glecaprevi r
• Grazop revir
• Narla previr
• Parita previr
• Simeprevir
• Sovaprevir t
• Telaprevirt
• Vaniprev ir
• Vedroprev ir§
• Voxilaprevir
• Daclatasvir#
• Elbasvir
• Ledipasvir
• Odalasvir t
NSSA
• Omb itasvir
inhibitor s (-
• Pibrentasvi r
asvir)
• Rav idasvi rt
• Ruzasvirt
• Samatasv irt
• Velpatasvir
• Beclabuvirt
• D asabuvir#
• De leobuvi r§
N SSBRN A • Fi libuvir§
polymeras e
• GS-662 0§
inhibitor s (-
buvir) • Setrobuvir§
• Sofosbuvir#
• Radalbuv ir t
• Upr ifosbuvirt
• Elbasvir/grazoprevir
• Glecaprevir /pibrentasv ir
• Ledipasv ir/sofos buvir#
Combination
drugs • Omb itasvir/paritaprevir /ritonavir#
• Sofosbuv ir/daclatasv ir
• Sofosbuv ir/velpatasvi~
• Sofosbuvir/velpatasvi r/voxilaprev ir
Pico ma viru s • viral enhy:P lecona rilt
Anti-influ enza • Baloxavir marboxil
NIH-000300
agents • Pimodivir t
• Umifenovi r
• adamantane derivatives /M2 inhibitors (Adapromine

• Amantadine
• Rimantadine)
• neuraminidase inhibitors/release phase (Ose ltamivir#

• Zanamivir
• Peramivir, Laninamivirt)
• Interfero n alfa 2b
Interferon • Peginterferon alfa-2a#
• Peginterferon alfa-2b#
• EICAR§
• Fav ipiravir
• Galidesivir t
• Remdesivirt
Multiple/genera
I • Mericitabine t
Multiple/unknow • MK-608§
n • NITD008§
• Moroxydine
• Presatovir t
• RibaviriI,#
• Taribavirin t
• Triazavirin
• #WHO-EM
• !Withdrawn from market
• Clinical trials:
o tPhase III
o §Never to phase III
show
• V
• t
• e
Filoviridae
• Bundibugyo ebolavirus
o BDBV
Ebola virus Species
• Reston ebolavirus
o RES TV
NIH-000301
• Sudan ebolavirus
o SUDV
• Tai' For est ebolavirus
o TAFV
• Zair e ebolavirus
o EBOV
• 1976 Sudan outbreak
• 1976 Zai re outbreak
• 2013-2016 West African Ebola virus epidemic
o Timeline
o Reported cases and deaths
o Responses
o United Nations Ebola Response Fund
o Operation United Assistance
o in Guinea
o in Liberia
o in Mal i
Outbreaks
o in Nigeria
o in Sierra Leone
o in Spain
o in the US
o in the UK
o Ouse to Ouse Tock
o Womey massacre
• 2014 DR Congo outbreak

• 2017 DR Congo outbreak
• 2018 Equateur, DR Congo outbreak
• Kivu Ebola epidemic
Dru g • BCX4430
candidates • Brincidofovir
• DZNep
• Favipiravir
• FGI-103
• FGI-104
• FGI-106
• JK-05
• Lamivudine
• mAbl 14
• TKM -Ebo la(failed)
• Triazavirin
• ZMapp
NIH-000302
• Vaccines
o cAd3-ZEBOV
o rVSV -ZEBOV
• William Close
• Jean-Jacq ues Muyemb e-Tamfum
• Peter Piot
• Selected patients
o Ameyo Adadevob
Notable o Kent Brantly
people o Pauline Cafferkey
o Thomas Eric Duncan
o Salome Karwa h
o Sheik Umar Khan
o Matthew Luk:wiya
o Mayinga N'Seka
o Patrick Sawyer
• The Hot Zone(l 995 book by Richar d Preston)
• Outbreak(1995 film)
Popular
• Ebola Syndrome(l 996 film)
culture
• Executive Orders(l996 novel)
• 93 Days(2016 film)
• Ebola virus disease
Miscellaneous
• Ebola vims disease treatment research
• Ebola River
• Marburg marburgvirus
Species
o MARV
o RAVV
• 1967 Marburg virus outbreak in West Germany
Outbreaks
• 2017 Uganda Marburg virus outbreak
1lf arburgvirus
• BCX4430
Drug
• FGI-103
candidates
• FGI-106
Popular
• The Hot Zone(l995 book)
culture
Miscellaneous • Marbur g virus disease
• Marbur g
Cueva virus Species • Lloviu cuevavirus (LLOV)
Di<tnlovirus Species • Mengla virus (MLA V)
• 0c ommons
• ® Wikispecies
Retrieved from "https://en.wikipedia.org /w/ index .php?title =F avipiravir&oldid =946951 I 89"
Catego ries:
• Ant i-RNA virus drugs
NIH-000303
• Pyrazines
• Carboxamide
• Organofluorides
• Ebo la
• Hydroxyarenes
• Experimenta l drug
https://www.theguardian.com/worl d/2020/mar /18/ja pa nese-fl u-drug-clearly-eff ective-i n-

tre at in g-co ro navi ru s-says-ch in a
Guardian Newspaper article dated 18 March 2020 regarding Favi piravir = Avigan (which is the
Brand Name) with URL https ://www .thegua rd ian .com/world/2020/ma r/18/japanese-flu-d rug-
clearly-effective-i n-tr eating -coronavi rus-says-ch i na
Japanese flu drug 'clearly effective' in treating coronavirus, says China
Patient given the medicine in hcn,1.hcnturned negative in a median of four day Photograph:
John Minchillo /AP
Medical authoritie in hina have said a drug u ed in Japan to treat new strain of influenza
appeared to be effective in coronaviru patient , Japane e media aid on Wedne day.
Zhang Xinmin an official at hina ' cience and technology mini try, aid favipiravir,
developed by a ub idiary of Fujifilm, had produced encouraging outcome in clinical trial m
Wuhan and henzhen involving 340 patient .
"It has a high degree of safety and i clearly effective in treatment ,' Zhang told reporter on
Tue day.
Patient who were given the medicine in Shenzhen turned negative for the viru after a median of
four day after becoming po itive, compared with a median of l J day for tho e who were not
treated with the drug public broadcaster HK a id.
In addition, X-ray confirmed improvement in lung condition in about 91% of the patient who
were treated with favipiravir, compared to 62% or tho e without the drug.
Coronavirus: the week explained - our expert correspondents put a week's worth developments
in context in one email newsletter
Fujifilm Toyama hemical which developed the drug - a l o known a Avigan - in 2014 , ha
declined to comment on the claim .
hare in the firm urged on Wedne day fo llowing Zhang' comment , clo ing the morning up
14.7% at 5,207 yen , having briefly hit their daily limit higb of 5,23 yen.
NIH-000304
Doctors in Jap an are u i.ng the same dmg in clinica l studies on coro.navirus patients with mild to
modera te ympto m , hoping it will prevent the virus from multiplying in patient .
But a Japa ne e hea lth mi ni try ource ugge ted the drug wa not a effective in peop le with
mo re severe symptoms. "We've given Avigan to 70 to 80 people , but it doesn't seem to work
that well when the virus has already multiplied ," the source told the Mainichi Shimbun.
The same limitations had been identified in tudies involving co ronaviru patients using a
comb ination of the HIV antiretrovira l lopinavi r and ritonavi r, the ource added.
In 2016 , the Japane e government upp lied favip iravir a an emergency aid to counter the bo la
viru outbreak in Guinea .
Fav ipiravi r wou ld need government approva l for full- ca le use on ovid- l 9 pat ient , ince it wa
orig inally intended to treat flu .
A heal th official told the Mainich i the drug cou ld be approved a early a May . "But if the re ult
of clinica l re earch are delayed , approval could al o be delayed ."
https://asia.nikkei.com/ Business/Pharmaceuticals/China-says-Japan-developed-drug-Avigan-
works -against -coronavi rus2
Nikkei Asian Review article dated 18th March 2020 regarding Favipirav ir = Avigan (which is the
Brand Name) with URL https ://asia. ni kkei .com/Busi ness/Pharmaceutica ls/China -says-Japan-
d eve loped-drug- Av iga n-wo r ks-against-corona virus 2
China says Japan-developed flu drug works against coronav irus - . Fujifilm Toyo ma Chemica l
developed fav ipiravir, sold under the brand Avigan.
Coronavirus
China saysJapan-developedflu drug works

against coronavirus
Fujifilm group member 's Avigan to be recom mended for trea t ment
SHIN WATANABE, Nikkei staff writer March 18, 2020 07:50 JST
NIH-000305
The Chinese government has been conducting clinica l research on a treatment for COVID-19.
©AP
~fi n21
DALIA N, China -- An influenza medicine developed by a Fujifilm Holdings group member is
effective against the novel coronavirus, the Chinese government said Tuesday.
The government plans to officially recommend the drug's use for treatment. Fujifilm Toyoma
Chemical developed favipiravir, sold under the brand Avigan.
"It has a high degree of safety and is clearly effective in treatment," said Zhang Xinmin, director
of the science ministry's China National Center for Biotechnology Development, in a news
conference. Fujifilm Toyoma Chemical developed the drug in 2014, and it has been provided to
patients in Japan as treatment for the novel cornooavirus since February.
Zhejiang Hisun Pharmaceutical signed a patent-licensing agreement for favipiravir with Fujifilm
in 2016. The drugmaker received clearance to produce the drug from Chinese authorities in
February and can ramp up output of a generic version.
The clinical trial was conducted at hospitals in Wuhan and Shenzhen, with 200 patients
participating. Test results for those receiving the drug turned negative in a shorter period, and
their pneumonia symptoms improved at a higher rate.
NIH-000306
Sent : Mo n, 23 M ar 2020 14 :47:18 +0000
To : Beige!, John (NIH) [El
Cc: (b)(6)
Subjec t : FW: IFN trea t ment for COVID-19
Attachment s: Ma nuscript and Supplement .pdf
Jo hn:
Please handle thi s.
Than ks,
Tony
Director
Phone : (b)(6)
FAX : (301 496-4409
E-mail : (b)(6)
From: Young, Howard (NIH/NCI) (E]

---------
Se nt: Monday, March 23, 2020 9:57 AM
------~~
To : Fauci, Anthony (NIH/NIAID) [E]_______
(b)( >
(b_H_. ; Beigel, John (NIH) [E)

(b)( >
Cc: Eleanor Fish (b)(6b
Subject: IFN treatmen t for COVID-19
Dear Ors. Fauci and Seigel
Regards,
Howard
NIH-000307
From: Eleanor Fish
----------------~= (b)(6)>
Sent : Saturday , March 21, 20 20 5 :25 PM
To : Young, Howard (NIH/NCI) [E]________ (b_H_6l
Subje ct: IFN treatment for COVID-19
Dear Howard,
I wanted to share with your our findings from a clinical study (b) (4)
Please keep this confidential.

The manuscript has been submitted fo r consideration for publication .
Eleanor N. Fish, PhD, FAAS

UHN Emerita
Professor & Associate Chair
International Initiatives & Collaborations
Dept . Immunology, University of Toronto
NIH-000308
Sent : Mon, 23 Mar 2020 13:40:42 +0000
Subject: FW:
Please handle.
Director
Phone: (b)(6)
FAX: (30 496"'4409
E-mail: (b)(6)
From: Schur , Peter H.,M.D.

---------
------
(b)(6)>

Subject:
-------- --=-= (b)(6)
Dear Dr Fauci
I am look ing for help and informagtion.
I am still wo rking fu lltime at Brigham and Women's Hospit al (BWH) as a Rheumatologist--

although with the pandemic I am currently working from home
I am also the Medical Director of the BWH Clinical Immunology Lab.
We are looking for a company that can provide us with kits to assess lgG and lgM antibodies
t o COVID-19. Can you, or one of your staff help us find those companies
When I was at WRAIR many years ago (b)(6) they had a walk in -70C freezer with
(b) (4)
NIH-000313
(b) (4)
Thank you for your help. Applaud what you are doing on TV. Applaud what you are doing
for this pandemic
Trust you are well
Peter H Schur MD
Senior Physician Brighasm and Women's Hospital
Professor of Medicine Harvard Medical School
Boston MA
Tel: 617-732-5350
http://www.partners.org /complianceline . If the e-mail was sent to you in error
but does not contain patient information , please contact the sender and properly
NIH-0003 14
Sent : Mo n, 23 M ar 2020 13:02:15 +0000
To : Stephen Hahn
Subject : FW: Quick Review: Press Confe rence Open - March 23
Att achment s: Press Confer e nce Open - M arch 23 - with Fauci edits .do cx
Here it is
Director
Phone: (b)(6)
FAX: (3 96':44li9
E-mail: Cb)(6)
NIH-0003 15
NIH-0003 16
From: (b)(6)
Sent : Mo n, 16 Mar 2020 14:53:22 -0400
To: Adams, Jerome (HHS/OASH);Brett Giroir
Subject : Fwd: Revised social distancing documents - word and powerpoint versions
Attac hmen ts: US Social Distancing Recommendations - CDC 1151am_ 3_16_2020 clean.docx,
ATT00001.htm, US Social Distancing Recommendations - CDC 1151am_ 3_ 16_2020 track changes.docx ,
ATT00002.htm, Social Distancing vs 316 2020.pptx, ATT00003.htm
FYI
Begin forwarded me ssage:
From: "Schucha t, Anne MD (CDC/OD)" (b)(6)

Date: March 16, 2020 at 12:04: 14 PM EDT
To: "Birx, Deborah L. EOP/NSC" ---------- ==
(bH6J > , "Azar , Alex
OS/IO~ " (b) < , "Giroir, Brett (HHS/OASH) "
--------- (bH6) , "Harrison, Brian (HH S/1OS)"

"Fauci , Anthony (NIH/NIAID) [E]'
(OS/ASPR/ 10)" (b)(6)
(b)(6) "Kadlec , Rob ert
(b)(6)
-----::-::-:-=
Cc: "Redfield, Robert R. (CDC/OD)" _____ , "McGowan, Robert (Kyle)
(CDC/OD/OCS)" (b)( >, "Schucha t, Anne MD (CDC/OD)"
______ (b_H _6), "Green , Hugh (CDC /OD/OCS )" (b)( >, "Hoo,
Elizabeth (CD C/OD/OCS)" (b)(6)
Subject: Revised social distancin g docum ents - word and powerpoint versions
On behalf of Dr Redfield, I am forwarding a revised word document (clean and track

changes) and a revised powerpoint w ith two slides.
These drafts incorporate feedback that Dr Redfield received from the WHTF as well as the
emE.Lein e...a.
vide.oce..::bas e..Jh us W.E!...
bavP...,.
com b ined o[i.oc_adv icP...,.
oo vp_c;t e_r_dav.'.,_
c;ver,sinn_th a_~
(b) (5)
Anne Schuchat, MD
Principal Deputy Director
Rear Adm iral, US Public Health Service (Retired)
NIH-000484
Sent : Sat, 14 Mar 202012:37:15 +0000
To : Howard Bauchner;Butler, Jay C. (CDC/DDID/OD);Preeti Malani;Eli
Perencevich;Phil Fontanarosa
Cc: Edward Livingston
Subject: RE:Testing - JAMA - Important
Howard/Jay:
I liked Jay's answers to Howard's questions even though there were still some open issues.
will have to leave it to Jay and the CDC to continue with the discussion since I am really
swamped. Sorry.
Thanks,
Tony

To: Butler, Jay C. (CDC/0010/00) ---- :::-c-r,-=
(b)(6) ; Fauci, Anthony (NIH/NIAID) [E]
(b)(6l; Preeti Malani <pmalani@med.umich.edu>; Eli Perencevich <Eli-
--------
perencevich@uiowa.edu>; Phil Fontanarosa <Phil.Fontanarosa@jamanetwork .org>
Cc: Edward Livingston <Edward.Livingston@jamanetwork .org>
Subject: Re: Test ing - JAMA- Important
Thanks Jay
Have also copied Ed -
This is crossing my desk 4-5 times per day now - and will only get more important (and sadly confusing)
- in the weeks to come.
Some questions would focus on public others on HCW (where I am sure general guide; talk with your
CMO).
I do love the mention of monopo ly -
What you t hink?

------------- (b)(6)
HCB
Howard Bauchner, MD
Please respect the confidentiality of th is email
NIH-000634
listen to my chats with authors
From: "Butler, Jay C. (CDC/DDID/OO)" (b)(6)>

-------
Date: Saturday, March 14, 2020 at 6:42 AM
To: Howard Bauchner <Howard .Bauchner@jamanetwo rk.org>, Tony Fauci
CbH 6b , Preeti Malan i <pmalani@med.um ich.edu>, Eli Perencevich <Eli-
---------
perencev ich@uiowa.edu >, Phil Fontanarosa <Phil.Fonta narosa@jamanetwork.o rg>
Subject: Re: Testing - JAMA - Important

Good morning, Howard-some answers and non -answers. As is the case for most answers, the
most accurate is "it depends", but I realize that is not helpful in busy clinical settings:
No symptoms - get test posit ive - can you work
At this point in the pandemic, no. While we do not know what role asymptomatic infection
may play in transmission and it is plausible that someone who is NOT coughing and sneezing (or
any other respiratory droplet self-generating acts)is going to be less infectious than someone
who is, persons known to be infected should self-isolate. This, of course, is particularly
important for someone who has closed contact with someone at greater risk of severe illness
and health care providers .
Symptoms - test negative - can you work- or do you need 2 negatives - or the test has to be
done 2-3-4 days after you develop symptoms
Even before COVID-19, working while ill with a respiratory illness puts others at risk. Particularly
during when flu activity is high. Not toughing it out and going into work wh ile sick is more
important now than ever and is an important component of social distancing-this is one of the
founda tional ways that we distribute the impact of the pandemic over as long of a period as
possible. (We are all gett ing good a drawing the two pandemic curves in the air on imaginary x-
and y-axes.). One of the critical areas where we need more data is on when someone who is
infected becomes test -positive. Presumably, test-positivity would correla te wi t h viral load in
the respiratory tract and a + would indicate greater likelihood of infectiousness. But the real
challenge of the return-to-work issue lies in your next question:
Test posit ive - back to work when -do you need negative tests- or just time - ? 2 weeks after
first symptoms, first test positive.
Ah, there is the rub-currently, the recommendations vary-CDC has gone with 2 negative
swabs 24 hours apart, but we do not believe that positivity during recovery necessarily proves
infectiousness. This is a crucial question. We are reviewing the available data, examining at
how PCRpositivity, cycle threshold, and v iral culture line up - the goal is to develop good,
NIH-000635
clinical parameters to justify ending precautions, rather than requiring microbiological tests. A
Get Out of Isolation Free card, if you will. The hypothesis we are testing to 2 weeks after onset
and >72 hours without symptoms. Currently the published recommendations are not
satisfying:
https ://www.cdc .gov/co ronav i rus/2019 -nCoV/ la b/guid eli nes-cli nica 1-speci mens.htm I
I may have more information on this topic later today.
Finally, in all complex epidemics, there is a tendency to search for a silver bullet-that one thing
that will solve all of our problems. When an intervention is in short supply, the bullet turns
platinum-"if only we could do x, the problem would be solved". This was vaccine in 2009
HlNl, naloxone in the opioid crisis, and now testing in coronavirus. Increased access to testing
is desperately needed to control the COVID-19 pandemic. However, it is going to take a
scientifically and wholistic and systemic approach to mitigate the impact. You have nicely
outlined some of the "next questions" that are raised when testing is more widely available.
More to follow.
Best regards,
Jay
Get Outl ook fo r iOS
From: Howard Bauchner <Howa rd.Bauchner@jamanetwo rk.org>

To: Butler, Jay C. (CDC/DDID/OD); Fauci, Anthony (NIH/NIAID) [E]; Preeti Malani; Eli
Perencevich; Phil Fontanarosa
Subject: Testing - JAMA - Important
Jay/Tony
Some very complicated questions around testing have come up and w ill only increase.
No symptoms - get test positive - can you work
Symptoms - test negative - can you work - or do you need 2 negatives - or the test has to be done 2-3-
4 days after you develop symptoms
Test positive - back to work when - do you need negat ive tests - or just time - ? 2 weeks after f irst
symptoms, first test positive .
As tests become more w idely available this wi ll be devil folks.
NIH-000636
Any ideas who can write about this.
Jay - does CDChave specific recommendations.
Sorry to bother on Saturday morning -but would like to get up a VP as soon as Tuesday.
HCB
Howard Bauchner, MD
Please respect the confidentiality of this email
NIH-000637
Sent: Sun, 22 Mar 2020 23:06:12 +0000
Subject : FW: Antibody Tests and Follow-on Use of 'Survivors'
From: Estes, Franklin J {Frank) LTC USARMY335 SIG CMD {USA)

Se nt : Sunday, March 22, 2020 12:30 AM ----------- (b)(6)
To: Fauci, Anthony {NIH/NIAID) [E] ------~= (b)(6)>

Subject: Antibody Tests and Follow-on Use of 'Survivors'
Dr. Fauci,
I apologize in advance for bugging you but please read and pass along to the appropriate person, if
useful.
In the coming weeks, an antibody test for COVID-19 should be available (I suspect) . As 'survivors' are
identified in the general population and are determined to be largely 'immune ' to COVID-19, I think those
people should be given the opportunity to administer testing to others in the general population. The
employment of VOLUNTEERsurvivors in the administ ration of tests would allow immune individuals to
quickly learn how to collect samples and deal w ith potential infected patients face-to-face without fear of
j eopardizing their own health or the health of the communities in which they live. This would free up
highly trained nurses and doctors from testing and have an exponential benefit as survivors adm inister
tests for infection and tests for antibodies and, thus, identify additional survivors. This would support
more aggressive testing to bring about the eventual end of this virus when we try to identify every last
infected individual who needs to be quarantined .
Note: I understand we haven't yet determined whether survivors can be re-infected. So early volunteers
may be subjected to further sickness. But the rate of re-in fectio n should be less as a percentage than
the rate of infection among the general population. And re-infection would likely be less severe.
Note2: Creating a VOLUNTARY REIGSTRYof survivors (those wi th suffi cient antibodies) may have a
secondary benefit to businesses. It would allow businesses to quickly hire employees who could come in
contact with the general public (thinking of current food delivery, grocery stores, daycare ...and
later ...teachers, anyone in the medical or dental field, other retail businesses).
I do understand my recommendations would generate HIPAA concerns but these are extraordinary times
which call for out-of-the-box ideas...and this would all be voluntary.
Thank you for taking a couple of minutes to read this and thank you for managing a very diffic ult crisis.
You and others on your team have saved a lot of lives and we are eternally grateful.
Respectfully,
Frank Estes
(b)(6)
----- (cell)
NIH-000333
Sent : Tue, 17 Mar 2020 11:17:11 +0000
To: USARMEDCOM (USA)
Subject : ---------------
RE:Recommendation
(b)(
(b)(6)
Thank you for your note.

Best regards,
Tony
From:
To: Fauci, Anthony(NIH/NIAID) [E]
(b)(6)
------~~
USARMEDCOM (USA)
(b)(6)
----------- (b)(6 )>
Subject : Recommendation
Dr. Fauci,
I am a Nurse Practitioner (b)(6) for the US Army . I have a recommendation as we move
through this terrible time in the US as well as the world. To preserve the healthcare workforce why not
give 25% of all health workers in the military the trial vaccine? Keep these workers away from patients
until which time that t he body can build immun ity . Let 's not expose the entire medical workforce to the
COVID-19. The idea is that this 25% can take care of the population (post-vaccine) without worry of
getting ill and causing further spread of the disease. If there is possibility of the vaccine, trial age cohorts
and demographics could play a crucial part in testing . Thank you for all you are doing to protect the
health of our Nation.
Respectfully,
(b)(6)
NIH-000454
Sent: Fri, 20 Mar 2020 23:47 :21 +0000
To : Hahn,S tephen
Cc: Redfield, Robert R. (CDC/0D);Birx, Deborah L. EOP/NSC;Lane,Cliff (NIH/NIAID }
---------~~
[E]; (b)( ·Rom, Colin (FDA/OC)
-----------
Subject: RE:Treatment Document
Sounds good to me.

Thanks,
Tony
From: Hahn, Stephen (b)( >

To: Fauci, Anthony (NIH/NIAID) (El ------~~ (b)(6)
Cc: Redfield, Robert R. (CDC/OD) (b)(6) Birx, Deborah L. EOP/NSC
>; Lane, Cliff (NIH/NIAID) [E)
(b)(
============~
__________ Cb ..:-.:.::::=====~~
_H_6); Rom, Colin (FDA/OC)_______ _
Subject: Re: Treatment Document
Tony,
Looks like (b)(S). The group wants to make some more edits and
then send out this evening for review . We would like to meet up prio r to or after the task force meeting
tomorrow. Sound OK?
Steve
Sent from my iPad
On Mar 20, 2020, at 7:06 PM, Hahn, Stephen _____ Cb

_>
_<_.> wrote :
I have a couple of comments

(b)(S)
I'll await for other comments.
Thanks
Steve
Sent from my iPad
NIH-000375
On Mar 20, 2020, at 6:45 PM, Fauci, Anthony (NIH/NIAID) [E]
-------- (b)(6)> wrote:
Team :
As per my discussion with Steve a few minutes ago, I have made
some changes in the document. (b)(5J
(b)(5) I am
-------------------------
attaching a tracked version of the document that was your FINAL as
well as a clean copy with all of the changes accepted. Please take a
look and Steve said that he would like to set up a quick call to discuss
after you have had a look . I am very sorry to come in with these
changes at this late point, but I rea lly did not get a chance to have a
good look at the document as I was in a car.
Than ks,
Tony
Director
Phone : (b)(6)
FAX: (301) 496-4409
E-mail : (b)(6)
The information in this e-mail and any of its attachments is confiden tial
and may conta in sensitive informat ion. It should not be used by anyone
<dblnformation for Clinicians on COVID-19 Therapies31hcl - with Fauci and

Lane tracked changes showing.doc><>
<dblnformation for Clinicians on COVID-19 Therapies31hcl - with Fauci and
Lane tracked Clean copy.docx>
NIH-000376
Sent : Mon, 23 Mar 2020 12:58:59 +0000
To: Barasch, Kimberly (NIH/NIAID) [Cl
Subject : FW: Respiratory Protection Program: Temporary Suspension of Fit Testing
For my cli nical center Certifi cat ion f older.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail Cb)(6)
From: Wu, Sarah(NIH/OD/ORS)[El

-------
Sent : Monday, March 23, 2020 8:56 AM
(b)(6)
[El-------=-=--==
-------- (b)((;)>
Subject : Respiratory Protection Program : Temporary Suspension of Fit Testing
RespiratoryProtection ProgramParticipants:
Due to the recent COVID-19 outbreak and supply chain shortage, we are temporarily
suspending annua l fit tests for emp loyees at th is time. You w ill still be required to comp lete fit
testing if:
• you have experienced significant physical changes likely t o impact the fit of your
respirator such as:
o substantial weight loss/gain
o dental surgery
o cosmetic surgery including the neck area and above
o an accident
o a new medical diagnosis
• you are direct ly invo lved in the COVID-19 response and are expected to be in close
contact with potentia l COVID-19 patients
• you are emergency response personnel (police, fire department, etc.) required to be on-
site throughout this pandemic
NIH-0003 17
If you do not meet these criteria, you are not required to complete your fit test at this time.
Please be advised that you will still need to complete the online training despite the suspension
of fit testing. Regular fit testing will resume once the COV/0-19 emergency has subsided.
Any questions concerning the Health Rx website should be directed toward

support@healthrx.com . Please visit the manufacturer's webs ites for details on your particular
respirator model. If you have questions about N95 respirators in general, feel free to email
nihresp irator@ma il.nih.gov. Thank you for your efforts and consideration during this event.
NIH-000318
Sent : Mon, 23 Mar 2020 12:58:16 +0000
To : Karen Backman
Subject : RE:Your Unprecedented Leadership and Professionalism
Kare n:
Many thanks for yo ur kind note .
Best rega rds,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b) (6)
From:Karen Backman (b)(6)

------ --.~
(bH >
Subj ect : Your Unprecedented Leadership and Professionalism
Good morning Dr. Fausi,
I am not one to write emai ls to our leaders in government as I am sure that the message doesn't get to
where it always needs to go . At the risk of you possibly seeing this email, you need to know that you are
doing an incredible job .
I doubt you will be broadcasting th is note but you should know that my husband and I take great
comfort in seeing you up on the podium next to our country's leadership on the COVID-19 pandemic.
You are a steady voice of reason and the right person for the job. Even when the President doesn't get it
quite right , you manage to be professional in your delivery, information and steadfast manner. We can
easily look past the President but we listen when you speak.
From the first time I heard you say on a Sunday morning talk show, "If you th ink we are overacting then
we are probably doing the right things ." I live in Maine and we are a rural state so we probably won't
see the numbers that are elsewhere but we are listening and acting on you r words of caution.
NIH-000319
I can't imagine how much pressure you are under doing your job but we need more leadership such as
yours . How you choose your words so carefully without getting flustered is a gift . I can on ly hope that
you will continue to be the voice to get this country through this unprecedented event.
Stay healthy and keep doing what you're doing as it matters so much to this nation.
Sincerely,
Karen L. Backman
NIH-000320
Sent : Mon, 23 Mar 2020 12:46:08 +0000
To : (b)(6)
Subj ect : Confidential
At tac hment s: Press Conference Open - March 23 - with Fauci edits .docx
Here it is.
Director
Phone : (b) (6)
FAX : (301 496-4409
E-mail : (b)(6)
NIH-00032 1
Sent: Mon, 23 Mar 2020 12:25:31 +0000
To: info@mail.mlblists.com
Subject: RE: Fill the baseball void: Trivia, A-Rod clinic, classic games
My work with t he Coronavirus Task Force and the large volume of incoming emails
precludes me or my staff from answering each individual message. I would encourage
you to visit www.coronavirus .gov for the latest information and guidance related to
COVID-19.
Anthony S. Fauci, M.O.
Director
Phone: Cb)(6)
FAX: (301 496-4409
E-mail. (b)(6)
NIH-000322
From: (b)(6)
Sent : Mo n, 23 Mar 2020 07:32:09 -0400
To: DMID Word Nerds
Subject: Fwd: COVID-19- NOVELDRUG
Attachments : _________ 4) 3_17_2020.pdf, ATT000Ol.htm
(b_H _.
Sent from my iPhone
From: Radka Milanova (b)(6)

Date: March 23, 2020 at 1 :43:46 AM ED T
--------=-=--:=
To: "Fauci, An thony (NIH/NlAI D ) [E]"
Subject: COVID-19-NOVELDRUG
--------- (b)(6>f
Dear Dr. Antho ny Fauci:
(b)(4)
(b) (4)
NIH-000323
(b) (4)
I lo ok forward to hearing from you .
Kind regards,
Radk11Milanova , PhD.
Office: + 604 488 8880
Mobile· (b) (6)
Email: milanova@,sliaw.ca
This message and any aua chme111sare i11te11ded011/y for the use of the addressee and may contain information that ls
privileged and confidential. If the reader of the message is nm the intended recip ient or an authorized representative of the
intended recipient, you are hereby notified that My dissemination of this comm 1micotio11 is s trictly prohibited. If you have
received this communicatio n in error . please notify us immediately by e-mail and delete the message and any a/tachmentsji·o m
your system.
NIH-000324
Se nt: Mon, 23 Mar 2020 01:37:39 +0000
To : David Rubenstein
Subjec t: FW: USAToday/David M . Rubenstein-- Coronavirus hero: Anthony Fauci is a
David:
You were so very kind to me in this article . Thank you so much.
Warm regards,
Tony
Coronavirus hero: Anthony Fauci is a great

public servant in a time of great public need
Fauci is the wo rld's leading authority on infectious diseases
and the best person in the country to help us deal with the
COVID-19 crisis.
David M. Rubenstein
Opinion contributor
Some viewers of the daily White House coronavirus briefings may wonder why everyone increasingly
defers to a diminut ive, Brooklyn -accented 79-year-old doctor, Tony Fauci.
They do because, as I have learned over many years of talking with and more recent ly interviewing this
man, he is without doubt the world's leading authority on infectious diseases. In any area of human
activity or knowledge, there always seems to be one person who is the global gold standard. In the
world of infectious diseases that person is Tony Fauci.
So the American people - indeed, people around the globe - should be grateful that Tony has dug into
this crisis with the same work-around -the-clock, just-the -facts ma'am style that he has used
while serving under and working with six U.S. presidents . He is as apolitical as anyone can be. I have no
idea if he is registered with any politica l party; I suspect though that he is rabidly Independent. His only
focus is getting the facts out, providing the best health care treatment and information possible, and
saving lives.
A top exper t from AIDS to Ebola

Tony Fauci joined the National Institutes of Health in 1968, after completing his medical training at Weill
Cornell Medical Center, and he has led the National Institute of Allergy and Infectious Disease since 1984
- 36 years. Hard to believe anyone can run anything that long and still be at the top of his game. But
Tony is. During this period , he has dealt with every serious infectious disease challenge - malaria,
Among Tony's best known accomplishments, beyond simply running the institute and training dozens of
the world's top infectious disease professionals, has been helping to discover how HIV leads to AIDS
and, later, leading the effort to create (at President George W. Bush's direction) the President's
Emergency Plan for AIDS Relief (PEPFAR),which has transformed the treatment of HIV/AIDS in Africa,
and other parts of the developing world. Millions of lives have been saved by this program alone. More
recently, he has been an architect and powerful advocate of President Donald Trump's plan for ending
the AIDS epidemic in the U.S. through HIV antiretroviral therapy targeted to disease hotspots.
NIH-000325
In his spare time, Tony has been involved with writing or editing more than 1,100 scholarly articles and
several textbooks, and, in the process, has become one of the most cited authorities of the entire
medical profession.
For these breakthrough activities and his dedicated service (at a government salary) for more than a half
century (he worked at NIH for 16 years before assuming his current role), Tony has received, and
earned, the Presidential Medal of Freedom and a Lasker Awa rd (called the Amer ican Nobel by many).
With this long service and universal acclaim, one might think Tony would let it get to his head, at least a
little bit. Not the case, though.

He is read ily accessible to those who need treatment - he still runs a lab at NIH - or need
information. Tony still lives in the same house he bought when he first moved to Washington, and it is
there that he and his wi fe Christine have raised their three talented daughters (though none of them
chose to attend medical school) .
Until the latest crisis, Tony has often commuted to NIH by Metro, typically after running t hree miles for
his daily exercise. And when he has been invited to make speeches in the Washington area or on Capitol
Hill, he invariably turns down a car and driver fo r the Metro. (This practice has had to change of late for
the obvious reasons).
There are, of course, many other dedicated federal servants who also view their commitment to the
country and its people over financial rewards . But surely no federal civil servant, in any area, can exceed
Tony Fauci's long-term and selfless commitment to this count ry and the health of its people .
I tried years ago, when Tony was approaching a normal retirement age, to see if he might want after a
normal lifetime of federal service, to take some of his considerable skills and knowledge to the private
sector. He quickly said no - money did not mot ivate him, serving the country did. And he stayed at NIH
- to the country's good fortune.
If there is any one medical professional who can help the country deal with the COVID-19crisis, it is
Tony Fauci, an example of the best this country has to offer.
But Tony Fauci has the decades of experience needed to understand infectious disease problems and
prescribe a trea t ment that should, in time, provide the requisite comfort, even if, in the short term, the
medicine is painful and inconvenient .
David M. Rubenstein is the co-executive chairman of The Carlyle Group.
Disclaimer: Any third-party material in this email bas been sbarcd for internal use under fair use provisions
of U.S. copyright law, without further verification of its accuracy /veracity . It does not necessarily represent
my views nor those of NIAJD, NIH , HHS, or the U.S. government.
NIH-000326
Sent : Mon, 23 Mar 2020 01:23:55 +0000
To : Marston, Hilary (NIH/NIAID) [E]
----- -=-a=,
Cc:
Subject:
Conrad, Patricia (NIH/NIAID) [E];
FW: Possible agenda for Wednesday
------- (b)(6)
Attachme nts: COVID-19 TransNIH_032520 hm.docx
Please take the lead in putting together slides for Wednesday . If I can make it (which is
uncertain),! will need them to make a presentation .
Thanks,\Tony
From : Marston, Hilary (NIH/N IAID) (E] (b)(6)

Sen t : Sunday, March 22, 2020 7:10 PM
To : Collins, Francis (NIH/OD) [E] -----~~ (b)(6)>
Cc: Tabak, Lawrence (NIH/OD) [E) (b)(6) Wolinetz, Carrie (NIH/OD) [E)
(b)(6); Anderson, James (NIH/OD) [E) (b)( >; Fauci, Anthony
-:--.-----:-:-:-:-:;::===::.:....---=-c-
(NIH/NIAID) [E)
~ (b)(6) Lane, Cliff (NIH/NIAID) [E) (b)(6)>
Subject : Re: Possible agenda for Wednesday
Thanks for the chance to weigh in. I have it blocked on my calendar and would look forward to the
discussion. And I'm happy to pull slides together as outlined.
Here are some minor comments on the agenda, which looks excellent.
Looking forward to it,
Hilary
From: "Collins, Franc is (NI H/OD} [E]" (b)(6)

Date: Sunday, March 22, 2020 at 5:09 PM
To: Hilary Marston (b)(6)>
Cc: "Tabak, Lawrence (NIH/OD} [E]" (b)(6)>, "Wolinetz, Carrie (NIH/OD) [E)"
CbH >, "Anderson, James (NIH/OD} [ E]" CbH6),
"".-~-~---:~===:...:....---,;-,
Anthony Fauci
=
CbH6)>, Henry Lane (b)(6)
Subj e ct: Possib le agenda for Wednesday
Hi Hilary,
I've been through the COVID-19 ideas collected from your Deputies meeting, plus reaching out for a few
other inpu ts. What I hope to do is to assemble this into a lively three-hour discussion on Wednesday
afternoon (2 - S PM). Tony is enthusiast ic about our doing this, but his presence is unfortunately
doubtful, given all of the other demands he faces. I'm counting on you and Cliff to be there, however -
is this etched on your calendars?
NIH-000327
Pleasesee attached for my rather rough first attempt at an agenda. It's a lot of topics and the list will
probably need to be culled- ...,_________....,.___________ ___________ (b)(5)
-
I wou ld want there to be time for discussion in each theme, so that other ideas could be floated.
Please let me know your thoughts, ideally this evening. I'm also asking for input from others who are
cc'd here.
Best, Francis
NIH-000328
Sent: Mo n, 23 Mar 2020 00:56:30 +0000
To: Jon LaPook
Subject : RE:Tony , my three minut e shp iel on CBSSunday Morning today .
Very well done as usua l.
-----Original M essage -----

From : Jo n LaPook ,.....___ _,(""'
b),,..,
(6)
=>
------ --;.-;~
(b)(
Subject: Tony , my three minut e shp iel on CBS Sunday Morning today.
Https ://www.c bsnews.co m/news/ corona v irus-covid- 19-socia I-distanc ing -how -to-reduce-risk-together/
Jon

Chief Medical Corres pondent, CBS News
NYU Langone Health
Twitter @DrLaPook
NIH-000329
Sent: Mon , 23 Mar 2020 00:51:49 +0000
To : McNeil Jr, Donald G
Subject: RE: big story of mine just posted
Donald :
You not only got it right, but it was an extraordinarily comprehensive, informative and
sobering article. I do not agree with everything that is being done by various countries, and
you have indicated that many of these approaches are controversial. However, your repo rting
of them is accurate and well-art iculated. Bottom line is that t his is an outstanding article.
Best,
Tony
From: McNeil Jr, Donald G <mcneil@nytimes.com>

To: Fauci,Anthony (NIH/NIAID) [E)------= (b'"'""
)(=6)
Subject : big story of mine just posted
I would have interviewed you for it, but I know you're busy. I hope you think I got it right.. ..
htt ps://www .nyt imes.com/2020/03/22/hea lth/coronavirus-rest rictions -us.ht ml

Science Correspondent
illlJt
~t\u !Jork
tEime11
Tel: +I 212 556 1142

mcneil @nytim es.com
Artic les: https: //www.nyti.mes.com /by/dona ld-g-mcne il-jr
NIH-000330
Sent: Sun, 22 Mar 2020 23:27:37 +0000
To : Murphy, Philip (NIH/NIAID) [El
Subject: RE: Suggestion
Phil:
Thanks for the note. Very important point .
Best,
Tony
From: Murphy, Philip (NIH/NIAID) [El

---------
------~=
(b)(6)

Subject : Suggest ion
[El
-------- CbH6)>
All the best,

ehil _______________________________ ~ (b
~~~(S)
NIH-00033 1
(b) (5)
Phil
NIH-000332
From: (b)(6)
Sent: Sun, 22 Mar 2020 17:23:08 -0400
To : Cicala, Claudia (NIH/NIAID) [E]
Subject: Re: Your idea about COVID-19
Thanks, Claudia
On Mar 22, 2020, at 5: 17 PM, Cica la, Claudia (NIH/NIAID) [E]

(b)(6)
Dear Tony,
Thank you for taking the time to answer. I want you to know that a huge number of
people here and in It aly asked me to pass along a message of support. Thank you for
all you are doing .
Take a good care of yourse lf,
Claudia
Sent from my iPhone
On Mar 22, 2020 , at 1 :27 PM , Fauci , Anthony (NIH/NlAID) [E]

(b) (6):
Jim:
(b) (5)
I Needless to say, this is a overwhelmingly compelling

pub lic health and scientific issue. Keep me posted.
Thanks,
Tony
Director
Phone : (b)(6)
NIH-000338
FAX: (301) 496-4409
E-mail: Cb
™
NIH-000339
NIH-000344
NIH-000473
From: Fauci, Anthony (NIH/ NIAI0) [E)
Sent: Sun, 22 Mar 2020 17:29:47 +0000
To: Hallett, Adrienne (NIH/OD) [E]
Subject: RE: Senate Supplemental #3
Thanks !
Director
Phone (b) (6)
FAX: (301 496-4409
E-mail Cb)(6)
From: Hallett, Adrienne (NIH/OD) [El (b)(6)>

To: icddir-l@LIST.NIH.GOV
Subject : Senate Supp lemen ta l #3
NAT IONAL INSTITUTES OF HEALTH NATIONAL HEART , LUNG, AND

BLOOD INSTITUTE
For an additional amount for ''N ational Heart, Lung, and Blood Institute'' ,
$ 103,400 ,000 , to remain available until September 30, 2024, to prevent, prepare
for, and respond to coronavirus, domestically or intern ationall y: Pro- vided, That
such amount is designate d by the Congress as being for an emergency requirement
pur suant to section 251(b)(2)(A) (i) of the Balanc ed Budg et and Erner- gency
Defici t Control Act of 1985.
NAT IONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEA SES
For an additional amount for "N ational Institute of Allergy and Infe ctious
Diseases", $706,000,000 , to remain available unt il September 30, 2024, to
prevent , prepare for, and respond to coronavirus, domes tically or internat ionally:
NIH-000345
Provided, That not less than $156,000,000 of the amounts provided under this
heading in this Act shall be provided for the study of, construction of, demolition
of, renovation of, and acquisition of equipment for, vaccine and infectious
diseases research facilities of or used by NIH, including the acquisition of real
property: Provided further, That such amount is designated by
1. 2 the Congress as being for an emergency requirement pur-

2. 3 suant to section 251(b)(2)(A)(i) of the Balanced Budget
3. 4 and Emergency Deficit Control Act of 1985.
4.
s. 5 NATIONAL INSTITUTE OF BIOMEDICAL
6. 6 IMAGING AND BIOENGINEERING
7. 7 For an additional amount for "National Institute of
8. 8 Biomedical Imaging and Bioengineering", $60,000,000, to
9. 9 remain available until September 30, 2024, to prevent,
10. 10 prepare for, and respond to corona virus, domestically or
11. 11 internationally: Provided, That such amount is designated
12. 12 by the Congress as being for an emergency requirement
13. 13 pursuant to section 25l(b)(2)(A)(i) of the Balanced Budg-
14. 14 et and Emergency Deficit Control Act of 1985.
15.
16. 15 NATIONAL LIBRARY OF MEDICINE
17. 16 For an additional amount for "National Library of
18. 17 Medicine'', $10,000,000, to remain available until Sep-
19. 18 tember 30, 2024, to prevent, prepare for, and respond to
20. 19 coronavirus, domestically or internationally: Provided,
21. 20 That such amount is designated by the Congress as being
22. 21 for an emergency requirement pursuant to section
23. 22 25l(b)(2)(A)(i) of the Balanced Budget and Emergency
24. 23 Deficit Control Act of 1985.
HEN20279 S.L.C. 78
1. I NATIONAL CENTER FOR ADVANCING

2. 2 TRANSLATIONAL SCIENCES
3. 3 For an additional amount for ' 'N ational Center for
4. 4 Advancing Translational Sciences" , $36,000,000, to re-
s. 5 main available until September 30, 2024, to prevent, pre-
6. 6 pare for, and respond to coronavirus , domestically or
7. 7 internationally: Provided, That such amount is designated
8. 8 by the Congress as being for an emergency requirement
NIH-000346
9. 9 pursuant to section 251(b)(2)(A)(i) of the Balanced Budg-
10. 10 et and Emergency Deficit Control Act of 1985.
11.
12. 11 OFFICE OF THE DIRECTOR
13. 12 For an additional amount for "Of fice of the Direc-
14. 13 tor", $30,000,000, to remain available until September
15 . 14 30, 2024, to prevent, prepare for, and respond to
16. 15 coronavirus, domestically or internationally: Provided,
17 . 16 That these funds shall be available for the Common Fund
18. 17 established under section 402A( c)( 1) of the PHS Act: Pro-
19. 18 vided further, That such amount is designated by the Con-
20. 19 gress as being for an emergency requirement pursuant to
21. 20 section 251 (b)(2)(A)(i) of the Balanced Budget and
22. 21 Emergency Deficit Control Act of 1985.
NIH-000347
Sent : Sun, 22 Mar 2020 17:28:59 +0000
To: Haskins, Melinda (NIH/NIAID) [E]
Cc: Crawford, Chase (NIH/NIAID) [E];Selgrade, Sara (NIH/NIAID) [E];Mascola, John
(NIH/VRC) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject : RE: Dr. Fauci: Senate Draft COVID-19 Supp
Thanks. (b)(5
Directo r
Phone : (b)(6)
FAX : (301 ) 496-4409
E-mail : (b)(6l
The information in this e-m ai l and any of its atta chments is confidential and may contain sensitive
info rmation. It should not be used by anyon e who is not the o rigi nal intended recipient. If you
other storage devices . The National Institute of Allergy and Infectious Diseas es (NIAID) shall not
behalf of the NIAID by one of its repre sent atives .
From: Haskins, Melinda (NIH/NIAID) [E]

---------- (b)(6)
To: Fauci, Anthony (NIH/NIAID) [E] ------ ==

(b)(6J>
(b)(6)>; Selgrade, Sara {NIH/NIAID) [E]
Cc: Crawford, Chase {NIH/NIAID) [E]
(b)( 6) ---------
Subj ect : Dr. Fauci: Senate Draft COVID-19 Supp
NIH-000348
From: (b)(6)
Sent: Sun, 22 Mar 2020 10:58:06 -0400
To: Miche la Carluccio
Subject : Re: telmisartan and covid -19
Ms. Carluccio:
Thank you for your note .
Best regards ,
AS Fauci
On Mar 22, 2020 , at 9:33 AM, Michela Carluccio

(b)(6)>wrote :
Dear Professor Fauci,
sorry for the disturb.

My name is Michela, I contacted her from Italy
and I am (b)(6)years
old.
I hope you understand my concern, I will
contact you for advice if possible:
(b)(6)
NIH-000349
(b)(6)
Sincerely,
NIH-000350
Ms. Michela Carluccio
NIH-000351
Sent: Sun, 22 Mar 2020 05:29:11 +0000
To : guy@vidaldesigncollaborative.com
Subject: RE:• Suggestion from former Israel Defense Forces member
My work with the Coronavirus Task Force and the large volume of incoming emails
precludes me or my staff from answering each indiv idua l message. I would encourage
you to visit www.coronavirus .gov for the latest information and guidance related to
COVID-19.
NIH-000352
Sent: Sat, 21 Mar 2020 23 :02:34 +0000
Subject: TF Agenda for tomorrow (Sunday)
Att achment s: White House Coronavirus Task Force Agenda 3.22.20.docx
Bob:
See attached TF Agenda for tomorrow. (b) (5)
(b)( S)
(b)(S •. Many thanks,

-----------------
Tony
Director
Phone: (b)(6)
FAX:(301) 496-4409
E-maill (b)(6)
NIH-000353
From: (b)(6)
Sent : Sat, 21 Mar 2020 18:17:02 -0400
To : A uchincloss, Hugh (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E]
Subject : Fwd : Posit ive COVID-19 test result for
---------- (b)(
Sent from my iPhone
From: "Holland, Steven (NIH/N IA]D ) [E]" (b)(6) >
Date: March 2 1, 2020 at 4:40 :28 PM EDT

To: "McGowan , Colleen (NIH/OD /ORS) [E]" CbH6) >,
"Fauci, An thony (NIH/N IAID) [E]"
(NIH/N IAID) [E]" _____ Cb -----
CbH >, "Lane , Cliff
_ , "Harper, Jill (NIH/N IAID ) [E]"
_><
>, "McGowan , John J. (NlH/NIA ID) [E]"
CbH6J
(b)(6)
(b)(6)
Subject: Re: Positiv e COVID-19 test result for

------------ (b)(6)
Thank s, Colleen. Cb)(6), to bring him into

the loop. I am also
know Iedge . -------------- Cb)(6) into this for her
Steve

Nationa l Institute s of Health
Bldg. 10/11N248 MSC 1960
----- (b) (6)voice

301-480-4507 fax
----- (b) (6) email
Assistant lab: Eva Porti llo

(b)( email
===~-.::----
----- (b) (6) voice
NIH-000354
(b)(6)
----- (b)( voice
From: "McGowan, Colleen (NIH/OD/ORS) [E]" CbH6)>

Date: Saturday, March 21, 2020 at 4:17 PM
To : Steven Holland (b)( >, Anthony Fauci
========~Henry Lane (b)(6) CbH >, Jill Harper
--------- John J McGowan(b)(6),

Subject:Positive COVID-19 test result for
CbH6)>
(b)(6)
I'm writing to share that we have received a positive COVID-19 test result of
(b)(6)
These results just came out of the 2pm test run today.
--- supervisor ir CbH6J The person reported being

symptomatic on 3/13/2020, contacted OMS on Monday, but d idn't get
scheduled for testing till Friday 3/20/20. I'm told (b)(6) continued to
work (b)(6) even when feeling ill. I'm not permitted to share PHI, but I
am to ld that OMS has notified the employee, and if they haven't done so
already, OMS will contact the supervisor w ith general information regarding
the person's general health status. They will not divulge a positive test
result for COVID-19, but rather state a general health condition which
precludes the staff member from working.
Since (b)(6) is working in (b)( , I presume (b)(5)

____________________ , but please let me
know if this isn't the case. ORF typically closes down the location for 7 days
to allow environmental dissipation of contact surface contamination. I
know this area is mission critical, so I will help you contact ORF about
prioritizing cleaning procedures. We ask that you take great care in keeping
t hat information as confidentia l as you can.
Thanks
Colleen
Colleen A. McGowan, MHA, FACHE

Director, NIH Office of Research Services
Bldg 31, Room 4B54
Office Phone: ___ ""
(b)""'(=-
6)
NIH-000355
NIH-000356
From: (b)(6)
Sent: Sat, 21 Mar 2020 18:13:55 -0400
Subject : Fw d: Jafri_Research Volunteering
Sent from my iPhone
Beg in forwa rded message:
From: Riaz Jafr i (b)(6) >

Dat e: March 21, 2020 at 5:34 :20 PM EDT
-------~~
Subject: Jafri_Re search Volunte ering --------- (b)(6J.
Hi Dr. F auci,
Hope you are doing well and thanks for your leadership during this pandemic
situation.
I have a medica l deg ree and has exper ience in bas ic and clinical resea rch for almost
30 yea rs . Currently in clinical trials, doing studies monitoring. I would like to
voluntee r during this COVID-19 situations. Please let me know ifl can share in
anyway.
I appreciate it.
Bes t regards and be safe ..
Dr. Syed R . Jafr i

Ph: (b)C6J
Sent from my iPhone
NIH-000357
From: (b)(6)
Sent : Sat, 21 Mar 2020 18:13:34 -0400
To: Cassetti,Cristina (NIH/NIAID) [E];Auchincloss,Hugh (NIH/NIAID)[E];Handley,
Gray (NIH/NIAID)[El
Subject: Fwd: Possible joint collaboration Polish -American Collaboration
Hop ing one of you can handle. Taking this out of ASF inbox
If we need to discuss with him let me know.
Sent from my iPhone
From: Aleksandra W esolowska (b) (6) >

To: "Fauci, Anthony (NIH/NJAID ) [E]"
-------~~ (bH6J
Subject: Possible joint collaboration Polish -American Co llaboration
Dear Dr Anthony Fauci ,
I am w riting in connection to email from Prof Robert Schwartz about possible Polish
- American collaboration in the clinica l trial focus on treatment patients suffer from
COVID-19
As a Polish Medical Research Agency we desire fa cing th is pandemic

with NIAID leading vaccine and therapy efforts against SARS-Cov-2.
F. Gray Handley has got in contact with the President of our Agency last week but
from that time we have no furthe r infor mation in this pressing issue.
I will be very appreciated if we could discussed with you or your eminent staff any
possibility for polish scientists to join t collaboration with NIAID to figh t corona vi rus
for patients all of the world.
I will be personally responsible to hold this topic on behalf of Polish Medical

Research Agency.
NIH-000358
Thank you for your time and incredible efforts you made to global health and
safety.
I remain at your disposal,
AleksandraWesotowska,PhD
Senior ResearchCoordinator
Agencja Sadan Medycznych

ul. Mo niuszki lA
00-014 Wars zawa
www .abm. gov .pl
NIH-000359
From: Conrad, Patricia (NIH/NIAID) [El on behalf of Fauci, Ant hony (NIH/NIAIO) [El
Sent : Sat, 21 Mar 2020 16:43:19 +0000
To : NIAIDODAM
Subject: FW: Virtual Town Hall with College Students (30+ Schools)?
From:John Monahan <John.Monahan@georgetown.edu>

To: Fauci, Anthony (NIH/NIAID) [E] ------ --,;-,~
(b)( >
Subject: Virtual Town Hall with College Students (30+ Schools)?
To ny--
Fi rst of a ll, thank you for all you are doing to lead om country's respo nse duri ng this cr is is.
I hesitate to reach out to you with so much on your plate , but I think this idea might help with the
national response.
In light of the con tinuing cha llenge of engaging young p eople in social dis tancing measures ,
combined with the fact that so many colleges and univer sities are now teaching online,
Georgetown's Globa l Hea lth Initiati ve and Institute for Politics and Public Service are
consideri ng a "vi11ual town hall" in which you could spea k directly with student s at co lleges and
universitie s via Zoom (or some other platform) about the collective challenge of COVID-19 and
its risk to their health and to other members of their communities.
This could be a unique forum for you, as the most trusted per son in the public dialogue , to make
the case directly to young people about thei r vital role in social distancing to flatten the curve in
their communities. W/e would use social media, of course, to push out key segments and
messages from this event more broadly.
While Georgetown would organi ze this "virtua l town ha ll", we would work closely with a
network of more than 30 colleges and universitie s with which our Institute of Politics and Public
Service regularly collaborates. We would also reach out to other schoo ls to ensure a geograp hic
reach and a mix of public and private institutions. Of course, our team wou ld work closely with
your staff to manage all logistics so as to use your scarce time as efficiently as possible.
Before we go any further in pl anning or thinking about this, I wanted to see if you would have
time to participate or think this is a good idea.
Be st!
John
John T. Monahan, JD
NIH-000360
Senior Advisor to the President of Georgetown University
Senior Fellow, McCowt School of Public Policy
Senior Scholar, O'Neill Institute for National and Global Health Law
Georgetown University
3307 M Street NW, Suite 202
202-431-6556
NIH-000361
From: (b)(6)
Sent: Sat, 21 Mar 2020 07:48:05 -0400
To : KENGLEN
Subject: Re: COVID-19

AS Fauci
Sent from my iPhone
On Mar 21, 2020, at 7;43 AM, KEN GLEN

-------- (b)( · wrote:
Good morning, from Vancouver , Canada.
We hope you are keeping yourself, and your families safe.
Your calm approach, and real life experience being shared during the daily briefings
is what everyone looking towards the USA for information needs to see.
As in anything, real knowledge, both sharing and accepting is critical to get

everyone focused on overcoming the current situation.
We don't see social distancing between everyone at the news conferences, and
that is disappointing, we also don't see Donald Trump acquiring the skills and
abilities to truly turn over communication and leadership to people such as
yourself and you r colleagues on the podium.
Whi le that is also disappointing, it has come to be expected, therefore easy to tune
out.
Our Global world needs a Global approach of honesty and transparency, we can't
afford to get this one wrong due to our normal tribal tendencies.
Best regards, be safe,
Ken &Cathy Glen

--------- (b)(6) )
NIH-000362
From: (b)(6)
Sent: Sat, 21 Mar 2020 07:44:54 -0400
To: Lerner, Andrea (NIH/NIAID) [E);Auchincloss, Hugh (NIH/NIAID) [E)
Subject: Fwd: Provider's question!
From Patty
Can one of u pis take this.
Sent from my iPhone
Begin forwarded me ssage :
From: "Ro stami , Nahid" (b)(6)

Date: March 20, 2020 at 7:25 :06 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" --------=-::-:-=
(bH >
Cc: "Rostami, Nahid" (b)(
Subject: Provider 's question!
Dear Dr. Fauci,
I am one of the UCSF neonatologist and I have been
am (b)(6) now. As you know, in neonatal intensive care unit at least

one parent stays at bedside. Considering the recent coronavirus
outbreak, I am (b) (6)· for both potential patient (b) (6)
- and staff exposures. I appreciate your advice and
recommendation for (b)(6) who is working
in an inten sive care unit. Since I have to go to work , do I need to have
extra percuss ions besides hand washing? If so, what would you
recommend?
I appreciate your help.
Thanks,
Nahid Rostami
NIH-000363
From: (b)(6)
Sent: Sat, 21 Mar 2020 07:42:07 -0400
To: Parks, Donna (djholmes@uidaho.edu)
Subject : Re:Thank you

AS Fauci
Sent from my iPhone
> On Mar 20 , 2020 , at 8:49 PM, Parks , Don.na (djho lmes@uidaho .edu) <djholm es@uidaho .edu> wrote:
>
> Dear Dr.Fauci:
>
> I want to thank you and commend you for all you 're doing during the COVID -19 pandemic. You are the voice of
science and reason - and you seem to be able to get through to President Trump in a subtle way yet with a grea t deal
of integrity. I don't envy you this gig - part icu larly with an administration that is so hostile to science, reason, and
preparedness on the federal level.
>
> I'm stil] squirming from Trump 's latest declara tions that hydroxquinolone could be used for COVID. The more
you can explain why this might not be the place to put federal resource s right now , the better. Friends of mine are
buying it off label in Mexico now, and as a biologist and medical educator I find this alarming.
>
> Thank s. You 're the best.
>
> Donna Holmes Parks I djholmes @uidaho.edu
> WWAMI Medical Education Program
> University of Idaho and University of Washington
>
>
NIH-000364
From: (b)(6)
Sent : Sat, 21 Mar 2020 07 :39:16 -0400
Subject : Fwd: Coronavi rus interview
Sent from my iPhone
Begin forwarded m essage:
From: "Lindenberger, Isaac D." <1indenberger.9@buckeyema il.osu.edu>

Date: March 21, 2020 at 1: 19:57AM EDT
To: "Fauci , Anthon y (NIH/NIAID) [E]" ------- --== CbH6)
Subject: Coronaviru s interview
Dr. Fauci,
I have Pau l Offit coming on my podcast tomorrow to discuss coronavirus, and I
would love to have you on after him to talk abo ut your tho ughts and what we should
do. My friend Nikk i Roy recommended you who I have also interviewed for my
vaccine show "Straight To The Point." If you 're interested we can do an interview at
your earliest convenience. My listeners wou ld benefit grea tly from it, thank you for
your cons ideration.
Get Outlook for Andro id
NIH-000365
From: (b)(6)
Sent: Sat, 21 Mar 2020 07:38:39 -0400
To: Friedmann, Theodore
Subject : Re: COVID-19 information for the public

AS Fauci
Sent from my iPhone
> On Mar 21 , 2020 , at 2:0 I AM, Friedmann , Theodo re <tfriedmann @health.ucsd .edu> wrote:
>
> Dear Tony: T'm sure that you realize how dism ayed and saddened many of us are at the inaccurate and harmful
comments coming from our political leaders regarding the COVID-19pandemic. That feeling hit a new height today
with the irresponsi ble and nonsensical announcement from President Trump regarding his claimed effectiveness of
chloroquine and hydroxychloroqu ine. This announcement and many other untru ths were delusional, irrational, un-
scientific and revealed a profound ly harmful and unethical betrayal by President Tmmp his responsib ility to protect
the health of the public that pus th republic in sever danger. I was very glad to hear your pub lic comments that
countered this ho1Tibly danger ous misinfonnation. l hope that your message falls on receptive ears in the public and
leads to a major change in the kind of public announcements that are currently being foisted on the desperat e pub lic
who depend on knowing and acting based on the truth. Please continue and even expand your role as the truth teller
in the who crowded collection of muzzled officia ls and sycophants who seem to be more devoted to deceiving the
public rat her than preparing the public for hard truths and solving the logistics failures of masks, availability of
testing its. Please continue your brave and essential role as honest broker that you play valiantly privately during
your policy discussions that the public also deserves to know about the wrong and unethical self -serving propaganda
that the public is fed by President Tnimp and some other members of the Corona Vims task force. It is a deadly
governmental game. I wish you good luck in alerting the public to this imm oral, uneth ical and deadly plague of
governmental misinformation designed to shape political quandaries rather than public welfare. Please continue
speaking out about public misinformation.
>
> Ted Friedmann, MD
>
NIH-000366
From: (b)(6)
Sent : Sat, 21 Mar 2020 07:38:1 1 -0400
To: DMID Word Nerds
Subject: Fwd: hypertensive drug - ACE2- inhb itor related and our w ork
Attachments : A Combinatorial Antihypertensive Drug (Reserpine and Hydrazi ne) Does Not
Cause Severe Depression .pdf, ATTOOOOl.htm,medrx ivcognitionandadelphanel.pdf, A TT00002.htm
Sent from my iPhone
From: "Dr.Jamuna R Subraman iam" <jamunal 7@sriramachandra .edu.in>

To: "Fauci, Anthony (NlH/NlAID ) [E]" ---------,;-,=
(b)( ·,jamuna
subramaniam (b) (6)>
Subject: hypertensive drug- ACE2- inhbitor related and our work
Dear Prof. Ant hony Fauci ,
Good Morn ing!
I am Dr. Jam una R. Subramaniam. I did my Ph.D from Georgetown University and
postdoc in Johns Hopkin s on neurodegenerative disease s. After r eturning to Indi a I
started working on biogenic amine neuortransmitters. One of the major trajectory of
my research career was on an FDA approved , antihyper tensive drug.
Given the current scena rio of ACE2 being the receptor for Covid - 19, and the widely
used antihype1tensive dru gs also targe t the same. I thought of sensitiz ing you on a
very effect ive antihypertensive drug, adelphane and adelpha ne esidrex made and
sold by Novaritis This contains a historical VMA T - biogenic amines loading in
synaptic vesicles, molecule , reserpine. Here, in India, a well known Nephro logist,
has used this to treat a commun ity of close to 3000 patients for almost two
decades. From him and others I have heard that it is a very effective, well tolerated
antihype rtensive. Res erpine is a historical molecule that it had been used in the
Indi an syste m of medicine, Ayurv eda. But ade lphane has the single specific purified
molecule , reserpine, an alkaloid. Now Nova ritis has stopped making it. One of the
reasons being given is reserpine's nega tive publ icity when it was used an
antipsycho tic drug. The reaso n given was a side effect of severe depression. We did
a study on these patient s on adelphane and find that it had not caused depression .
Fmther, it seems to be reta ining cognitio n in these patients. I could not pub lish these
in big journals as you can understand. I am enclos ing these two papers.
NIH-000367
As many lives are at stake, I thought I will sensitize you on this. Hope something
good will come out of this . I am telling whomever I come across about the same.
That is the best I can do. Hope the current scenario will show the living daylight for
reserpine and helps the humanity.
Thank you
With regards
Jamuna
Dr. Jamun a R. Subramaniam

Associate Professor
Center for Preclinica l and Translational Medicine Research
Central Rese arch Facility
Sri Ramachandra Institute of Higher Education and Research
Porur , Chennai 600 116, India
Extn:8170; Tel: 91-44-45928500;
Cell: CbH6)
www .sriramachandra .edu .in
Academ ic Editor , PLoS One , Public Library of Science, San Franci sco, USA
Website:
Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/?term=Subramaniam+JR
Research Gate: https://www.researchgate.net/profile/Jamuna Subramaniam
Google Scholar :
https://scholar.google.co.i n/citati ons?use r=T4Z2VMAAAAAJ&h l= en
Quote : "I remain an Optimist. Not that I can give any evidence that right is going to
prosper, but because of my unflinchingfaith that right should prosper in the end" -
Mahatma Gandhi
NIH-000368
From: (b)(6)
Sent : Sat, 21 Mar 2020 07:37:38 -0400
To : Mr Chiogna
Subject : Re: The Virucidal Efficacy of Blue light (222 nm) UV light with Respect to
Corona Virus

AS Fauci
Sent from my jpbone
On Ma r 21 , 2020, at 2:46 AM, Mr Chiogna <jchiogna @ho lycross .bc.ca>wrote:
Dear Dr. Fauci ,
My name is John Chiogna. I work as a Physics teacher in Vancouver British

Columbia. Attached below is a short write up on a possible inexpensive means of
quickly san itizing private and public locations such as care facilities, hospitals ,
schoo ls, chu rches , government workplaces, arena s, etc .
I'm sure that the efficacy of 222 run light has been considered by some already.
Howeve r, I have included some numbers that take into account human safety limits ,
as well as references to peer-reviewed journa ls that support my claims . It is my hope
that this may make this simp le idea more p lausible.
Please consider the merits of such an idea and implement it as you wish , thank
you .
Yours since rely ,

John Chiogna
51What is the Viruc idal Efficacy of Blue light (2 ...
Thise-mailis intended onlyfor the individualnamed above.

Any distribution,use or copyingof this e-mail or the information
1tcontainsby other than on Intended recipientIs unauthonzed.
If you have received this e-mail in error, please delete immediately.
NIH-000369
From: (b)(6)
Sent: Sat, 21 Mar 2020 07 :35:58 -040 0
To : DMID Word Nerds
Subject: Fwd: Note from a NIH "alumnus"re . SARS-CoV-2
Sent from my iPhone
From: Robert Wiskocil Cb)<6J

>
------~~ CbH6>:
Subject: Note from a Nm "alumnus" re. SARS-CoV-2
Dear Dr. Fauci,

I used to work in Bob Goldberg's division at the NCI (Blgd 37) from '78-'80. I'm now a
rbeumatologist in the SF Bay Area.
I' m including a Letter to the Editor (submitted 3.19.20) for the NEJM that proposes a cost-
effective therapy for COVID-19. (I've included a slightly longer version with more
references):
N-acetyl cysteinefor Coronavirus

Robert Wiskocil, MD
Affiliation : Private Practice Rheumato logy
Date: March 19, 2020
Telephone Number: (b)(6)
Email: (b)(6)
Abbreviations: N-acety l cysteine (NAC),porcine epidemic diarrhea virus (PEDV)
In a recent letter to Cell Research , Remdesivir and chloroquine were found

to inhibit the SARS CoV-2 (COV ID-19 ) virus activity and replication in Vero
cells (1). That study was the basis for current clinical trials involving those
medicines .
There might be a more cost-effective treatment for the Coronavirus. I believe
it will be sensitive to oral high dose N-acetyl Cysteine
A final common pathway to host destruction (autophagy) in infected cells in

both Corona and Rota viral infec tions involves the Pl3K/AKT/mTOR pathway
(2,3). Thi s pathway is inhibi ted by "rapalogues " (like Rapamycin) where the
NIH-000370
viral infection is stopped and the host cell survives. N-acetyl-cysteine, a
potent anti-oxidant and glutathione precursor, alters the redox state of
treated cells and can quench this same pathway (4,5). NAG (N-acetyl
cysteine) has been used to rapidly clear Rotavirus diarrheal infections in
children (6). Furthermore, the porcine epidemic diarrhea virus
(PEDV) coronavirus has been studied in Vero cells. In vitro, NAG blocks
that particular virus (7), and in vivo, NAG blocks intestinal damage caused
by this virus (8). NAG likely provides a "redox clamp" on the autophagy
pathway this virus exploits.
Since the PEDV coronavirus is effectively blocked in Vero cells by NAC, the
SARS-GoV-2 (COVID-19) will likely also be inhibited. This test should be
done, and if positive, clinical trials ought to follow.
Doses of 2.4-3.5 g/d of NAC have been used to treat patients with Lupus
(4). That dose is well tolerated and inexpensive .
If NAC were effective in symptomatic patients, it could add a cost-effective

measure of protection to healthcare workers and exposed individuals .
References:
1) Wang , M., Cao, R., Zhang, L. et al. Remdesivir and chloroquine

effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in
vitro. Cell Res
Y Yin et. al. Pl3K-AKT-mTOR axis sustains rotavirus infection via the 4E-
BP1 mediated autophagy pathway and represents an antiviral
target. Virulence , 2018 VOL. 9, NO. 1, 83-98
3) J Kindrachuk et. al, Antiviral Potential of ERK/MAPK and

Pl3K/AKT/mTOR Signaling Modulation for Middle East Respiratory
Syndrome Coronavirus Infection as Identified by Temporal Kinome
Analysis Antimicrobial Agents and Chemotherapy February 2015 Volume
59 Number 2 p 1088-1099
4) Zhi-Wei Lai, et al, N-Acetylcysteine reduces disease activity by blocking

mTOR in T cells of Lupus patients, Arthritis Rheum. 2012 September;
64(9): 2937-2946
5) C. C. Xu , S. F. Yang , L. H. Zhu , X. Cai , Y. S. Sheng , S. W. Zhu , J. X. Xu,

Regulation of N-acetyl cysteine on gut redox status and major microbiota in
weaned piglets, Journal of Animal Science , Volume 92, Issue 4, April
2014 , Pages 1504- 1511, https ://doi.org/10.2527/jas .2013-6755
NIH-000371
6) C Guerrero et al. N-Acetylcysteine Treatment of Rotavirus-Associated
Diarrhea in Children Pharmacotherapy
7) Xu X, Xu Y , Zhang Q , et al. Porcine epidemic diarrhea virus infections

induce apoptosis in Vero cells via a reactive oxygen species (ROS)/p53, but
not p38 MAPK and SAPK/JNK signaling pathways. Vet Microbiol.
2019;232:1-12.
8) Wang L, Zhou J, Hou Y, et al. N-Acetylcyst eine supplementat ion

alleviates intestinal injury in piglets infected by porcine epidemic diarrhea
virus . Amino Acids . 2017;49(12):1931-1943 .
I hope you find this helpful!
Sincerely,
(b)(6)
Robert Wiskocil MD
(b)((i}
NIH-000372
From: (b)(6)
Sent: Sat, 21 Mar 2020 07:19:19 -0400
To: PITTMAN,RYAND
Subject: Re:Preparingfor COVID-19in my Neighborhood
Sent from my iPhone
On Mar 21, 2020, at 12:10 AM, PITTMAN , RYAN D

< rpi ttman @ email.sc.edu>wrote:
Good Evening Dr. Fauci,

My name is Ryan Pittman. I live in (b)(6) South Carolina, right outside of (b)(6)
The virus is here. Seeing as this is likely to get worse before it gets better, I want to
be prepared to help people in my neighborhood when they start developing
symptoms and the hospitals are not ready for them.
How do you recommend I go about doing this. I am prepared to acqui re a modest
stockpile of supplies to give to those suffering through this, but I am not entirely
sure what would be best. The hope is to take your information and pass it on to
those in other neighborhood s in the area, so we can come together and help as
many people as we can get through this pandemic.
Thank you for your time.
Ryan Pittman, MS
University of South Carolina Department of Statistics
NIH-000373
Sent : Sat, 21 Mar 2020 02:19:38 +0000
To: Priscilla Kelly
Subject: RE:Thank you from Science
Priscilla :
Thank you for your kind note.
Best regards,
Tony
From:Priscilla Kelly <pkelly@aaas.org>

------~~ CbH6J>
Subject: Thank you from Science
--------
Dear Tony,
I wanted to send our sincerest thank s from everyone at Science, for the supe rb leadership that
you are showing the United States (and the world) during this pandemic. Thank you also for
educating the public that the most productive countermeasures will be based on data-dr iven
science. We wi ll continue to do our part here at Science to publish the strongest COVID-19
studjes to help advance research as rapidly as po ssible.
All the best,
Priscilla
Priscilla N. Kelly , Ph.D
Biomedicine Editor, Science
NIH-000374
From: Fauci, Anthony (NIH/NIAIO)[E)
Sent: Fri, 20 Mar 2020 22:45:24 +0000
To: Stephen Hahn;Redfield, Robert R. (CDC/OD);Birx, Deborah L.
EOP/NSC,----- -:a-
~'""
~c=~
Subject: Treatment Document
Att achments: dblnformation for Clinicians on COVID-19Therapies31hcl - wi th Fauci and Lane
tracked changes showing.docx, dblnformation for Clinicians on COVID-19 Therapies31hcl - with Fauci
and Lane tracked Clean copy.docx
Team:
As per my discussion with Steve a few minutes ago, I have made some changes in the
document. ~)(5)
~)(5)
-------------------------- I am attaching a tracked

~)(5)
version of the document that was your FINAL as we ll as a clean copy wi t h all of the changes
accepted. Please take a look and Steve said that he wou ld like to set up a qu ick call to discuss
after you have had a look. I am very sorry to come in with these changes at this late point, but
I rea lly did not get a chance to have a good look at the document as I was in a car.
Thanks,
Tony
Director
Nationa l Institute of Allergy and Infectious Diseases
Phone : ~)(~
FAX : (301 496-4409
E-mail : ~)(~
NIH-000377
Sent: Fri, 20 Mar 2020 21:08:04 +0000
To : (b)(6)
Subject : therapy
Attachment s: dblnformation for Clinicians on COVID-19 Therapies3.docx
Director
Phone : (b)(6)
FAX: (301 ) 496-4409
E-mail Cb)(6)
accept liabi lity for any statements made that are the sender's own and not expressly made on
NIH-000378
Sent : Fri, 20 Mar 2020 11:52 :45 +0000
Cc: Mars ton, Hilary (NIH/NIAID) [El
Subject: RE: Modeling of COVID-19 from Mike Levit
It would be a good idea to get a feel for what our modelling people think about this .
Thanks,
Tony
From: Lerner , Andrea {NIH/N IAID) [E] (b)(6)

To: Fauci, Anthony {NIH/NIAID) [E]______ _,(b
::-;:
)...,.
(6)
""'
Cc: Marston, Hilary (NIH/NIAID) [El (b)(6)

Subject : FW: Modeling of COVI0-19 from Mike Levit
Dr. Fauci,
Just re-upping this as your in box is hopefully less stuffed now. See original email at the bottom from
Larry Tabak letting you know about this modeling work .
My summary is below and if you'd like me to ask some NIAID modeling SM Es what they think, let me
know .
Andrea
•••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••
Dr. Fauci-
I took a look at this and here is my impress ion:
(b) (5)
NIH-000379
I would defer to our modeling experts at NIAID as to the valid ity of his model - let me know if you' d like
me to reach out to them . (b) (5 .
CCing Hilary if she has additional thoughts.
Sincerely,
Andrea
From: "Fauci, Anthony (NIH/ NIAI D) [E]"

Date : Monday, M arch 16, 2020 at 10:59
PM
--------- (b)(6)>
To: "Lerner, And rea (NIH/N IAID} [E)" -------~~ >

---------
Subject: FW: Modeling of COVID- 19 fr o m Mike Levit
Cb)(
Please t ake a look and see what you think.

---------- (b)(6)
-----~~
To : Collins, Francis (NIH/OD) (E] Fauci, Anthony (NIH/N IAID) [E]
(b) ~ >
------- (b)(6)>;
Cc: Lauer, Michae l (NIH/OD) [E]

---------
Subject : Modeling of COVID-19 from Mike Levit
(b)(6)>
Francis, Tony-
Mike Levit t (Nobel prize in Chemistry, 2013) sent the attached modeling of the COVID-19 epidemic to
Mike Lauer. I don't know if this will prove useful but wanted to pass it along in case.
He indicated t hat he was amazed to see how an Excel level analysis could allow him to predict the China
epidemic would end as early at 2-Feb and get what he considers the best estima tes for case fatality
ratio . His first report from 2-Feb is attached as wel l as his most recent two -part report.
Larry
NIH-000380
From: (b)(6)
Sent : Fri, 20 Mar 2020 06:56 :52 -0400
To: Eisinger, Robert (NIH/NIAID) [E)
Subject: Fwd: COVID-19 multidisciplinary FAQarticle
Attachments : COVIDQuestion_v2.docx, ATT0000l .htm
From: Andreas Kronbichler

-------------
Date: March 20, 2020 at 3 :50:20 AM EDT
(b)(6)
---------=-:-:-=
--------
To: "Fauci , Anthony (NIH/NlAID) [E]" (b)( (b)(6)
Subject: COVID-19 multidisciplinar y FAQ article
Dear Prof. Fauci,

May I briefly introduce myself: My name is Andr eas Kro nbichler, I am nephrologist
based in Austria, and do have an interest in renal autoimmune disease. As suc h, I
know your landmark study about cyclophosphamide use in GPA published in 1971;
and I have learned that you were involved in the management of David Fajgenbaum
MCD, whose story is so impressive.
I am contacting you and asking you for your help regarding a multidisciplinary FAQ
article we would like to write and which does make sense in our eyes, given the
rapid spread of this devastating infectious disease.
We would lik e to invite experts in the field to comment on a selected topic and then
summa rize this as a paper with hopefully high impact in the field.
If you agree , can you answer 1his question (around 400 words max. ):
Can you describe the pathophy siology and some of the immunological aspects of
SARS-CoV-2 infection and COVID-19disea se ?
I wou ld be personally very honored to work together with you. A select ion of topi cs
is attached to this e-mail.
With best regards,
And reas Kronbichler M.D. Ph.D.
NIH-00038 1
Sent : Fri, 20 Mar 2020 10:42:16 +0000
Cc: Conrad, Patricia (NIH/NIAID) [El;Barasch, Kimberly (NIH/NIAID) [Cl;Folkers, Greg
(NIH/NIAID) [El;Myles, Renate (NIH/OD) [El
Subject: RE:COVID-19 science brainstorm at NIH, and town meeting
Thanks , Francis.
From:Collins, Francis (NIH/OD) [E] (b)(6)>

To: Fauci, Anthony {NIH/NIAID) [E)------ (b
=)c-c
(= >
Cc: Conrad, Patricia {NIH/NIAID) [El (b)(6) Barasch, Kimberly {NIH/NIAID) [C]
(b)(6) ; Folkers, Greg (NIH/NIAID) [El (b)( ·>; Myles, Renate
(N
-:l-:--:-
H/-:--:
0:-:D-:--
) :=[E :-;::
] ====~ --- )( =
(b... 6)
Subject: RE:COVID-19 science brainstorm at NIH, and town meeting
Thanks , Tony . The town meeting runs from 1 to 2. If your press conference runs late, I'd be
glad to have you call in at any other time during that hour - we would squeeze you in!
Francis
From: Fauci, Anthony {NIH/NIAID) [E] CbH >

To: Collins, Francis {NIH/OD) [E]
-----~~ (b)(6)>
Cc: Conrad, Patricia (NIH/NIAID) [El CbH ; Barasch, Kimberly {NIH/NIAID) [C]
________ Cb
_>_
<> ; Folkers, Greg (NIH/NIAID) [E] (b)(6)
Subject : RE:COVI0-19 science brainstorm at NIH, and town meeting
Francis:
I was just told by the VP's office that I will have to be at the press conference between 11 :00
and 12:30 PM. And so I definitely cannot be at NIH physically at 1:00 PM and if the press
conference starts and finishes late, I may not even be able t elephone in. My guess is that it will
end before 1:00 PM and so I will likely be able t o phone in. Let us see how tomorrow unfo lds.
Regard ing the session of IC Directors, this would be fine with me .
Best,
Tony
Patty :
Please let us discuss the phone in logist ics if I canno t physically get there.
Thanks,,
Tony
NIH-000382
To : Fauci, Anthony (NIH/NIAID) [E] ------~ =
(b)(6)>
Cc:Tabak, Lawrence (NIH/OD) [E] (b)(6)
Subjec t : COVID-19 science brainstorm at NIH, and town meet ing
Hi Tony,
Nice Facebook session with Zuck! And I heard you were just on CNN, but I missed that one. I did an
interview with Sheila Kaplan late this afternoon - and she greatly appreciated your message of apology.
I don't think (b)(S).
When we spoke yesterday, you were enthusiastic about the convening of a 2 - 3 hour session of IC
Directors and SM Esfrom thei r ICs, to brainstorm about additional scientific efforts that could be
mounted at NIH to address COVID-19. It looks as if th is can be arranged for an early afternoon next
week. Obviously there would be nothing better than to have you there in person for this. While I know
your schedule is not exactly under your control, is there any 2 - 3 hour period next week that might
have a chance of being open for you? If not, who would you want to be the presenter of the current
portfolio of NIAID investments? (b)(S)
We have the NIH virtual Town Meeting at 1 PM tomorrow . Is there any chance you can come to W ilson
Hall in person for that? If not, is there a chance you can call in? I will serve as moderator, and after a
few minutes of opening remarks, would hope to turn this over to you for ten minutes or so of the
unique Fauci perspective. After that, Larry and Alfred will talk for a few minutes abou t the NIH COVID
Response Team, and Jim Gilman w ill talk about what's happening at the CC. Then we' ll open it up to
questions, which we can accept in real time from the estimated 20,000 staff who will be logged in. But
you wouldn't need to stay for all that- if we could somehow have your participation (either in person or
on the phone) from about 1:10 to 1:20, that would be really wonderful. Please let me know if that will
be possible .
Sorry about the long e-mail. Get some sleep!
Best, Francis
NIH-000383
Sent : Fri, 20 Mar 2020 03:01:09 +0000
To : Besser, Richard
Subject : RE: Checking in
Rich:
Thanks for the note. Much appreciated . I hope that all is well with you.
Best regards,
Tony
From: Besser, Richard <rbesser@rwjf .org>

To : Fauci, Anthony (NIH/NIAID) [E] <------ ---=
Subject : Checking in -------- (b)(6J>
Hi Tony:
I hope you are well . I want to applau d you and thank you for your incred ible leadership in
communic ating about this pandemic. I wish CDC were standing with you but I know that is not likely to
happen . I hope that you will continue to ta lk about all that is being do ne to learn what works to mitigate
the impact of the pandemic . Your absence these two days has been quite noticeable. If t here is anything
I can do to support you, please let me know.
Best regards,
Rich
Richard E. Besser, MD. President and CEO

Office (b) (6) 1 rbesser@rwjf.org
Connect with me on Twitter I Linkedln I Facebook
Robert Wood Johnson Foundation

Building a Culture of Health in Amer ica. Learn more at rwjf.orq.
Follow the FoundationTwitter IFacebook I YouTube
Pleas e note: In light of the requests made for increased social dis tancing related to the coronavirus (COVID-19), we
have closed all three RWJF campuses in Princeton , New York City, and Washington until further notice. All RWJF
employees are now working remotely, and all in-person meetings are either cancelled or will be conducted virtually.
For the most up-to-d ate inf ormatio n regar ding COVID-19 p lease see resources on CDC, NIH as well as your state
heal th depa rtment websites.
NIH-000384
Sent : Fri, 20 Mar 2020 02:39:21 +0000
To: Jonathan E. Shoag
Cc: Elemento, Olivier
Subject : RE: Specimens
- ----------------------
Would be much more usefu l (b) (5)
From: Jonathan E. Shoag

----------
-------=-c-c=
(b)(6)
Cc: Elemento , Olivier

_:..__ _:_:-=.!:===~~~--(b)(6)>
Subject : FW: Specimens ---------- (b)(6)
Hi Dr. Fauci,
(b)(5)
All the best,
Jonathan Shoag M D
From: Denny, Joshua (NIH/OD) [El

To: Jonathan E. Shoag
Cc: Olson. Janet E.• Ph.D.: Cicek. M ine: Olivier Elemento : Thibodeau. Steve : Gebo . Kelly (NIH/OD) [Gl
Subject : [EXTERNAL] Re: Specimens
Jonathan -
Thanks for the thoughts and the offer to help . This is indeed something we have discussed
I'm copying our chief med ical & science officer, Kelly Gebo.
Best,
Josh
On Mar 16, 2020, at 2:16 PM, Jonathan E. Shoag (b)(6) wrote :

----------
Hi Dr. Denny,
NIH-000385
(b) (5)
All the best,
Jonathan Shoag MD
________
On Mar 16, 2020, at 12:47 PM, Thibodeau, Stephen N., Ph.D.
_. wrote:
(b)(6J>
Dear Jonathan
I am one of the Co-Pt's of the Biobank for the All of Us Research Program.
Although samples are store here at Mayo, (b) (S
L
(b) (5)
Sorry, the situation is evolving quite rapidly, so no additional information at

this point .
Hope this helps.
Steve
From: Jonathan E. Shoag

....,..,...,....e--,------------
(b)(6)]
··
To: Biobank
Subject: [EXTERNAL] Specimens
To Whom it May Concern,
I imagine someone has thought of this already - but do you know

if (b) (5)
NIH-000386
(b) (5)
I study prostate cancer epidemiology at Weill Cornell, and in

discussing this idea with the head of our precision medicine
initiative, was informed that the AllofUs specimens reside at
Mayo .
All the best,
Jonathan Shoag MD
NIH-000387
Sent : Thu, 19 Mar 2020 22:16:02 +0000
To : (b)(6)
Subject: RE:ATTN: Dr. Fauci/ Good ACE bad ACEdo batt le in lung injury SARS-CoV
coronavirus Nicholls S Peiris M NATURE-Med 9-2005.pdf
)(6)
All of the therapy stuff is anecdotal. We are trying to get randomized clinical trials done
instead of just compassionate use for all of these unproven drugs. (b)(6)
Best regards,
Tony
From : Cb)(6J.>
CbH6J>
Subject : Re: ATTN: Dr. Fauci/ Good ACE bad ACE do battle in lung injury SARS-CoVcoronav irus Nicholls S
Peiris M NATURE-Med 9-2005.pdf
Fascinating - thanks for sharing with me. The question that I have is whether COVID 19 adheres
and infects epithelial cells through the same mechanism as SARS did. Why the increased
lethality and how to we decrease likelihood of infection?
Just saw today that antiretroviral therapy and malaria agents are being touted as potential
therapies - how well founded is this - anything more than anecdotal data to support this?
Hope you are getting a few moments of rest.

call me if I can help.
--------- (b)(6) and do not hesitate to
Best,
Ken

--------
Sent: Wed nesday, Marc h 18, 2020 7:09 PM
To :
Cc: '.-
La-n-e,"""'.
C:".":
I i":":
ff "":"'.
(N
~l'."':'
H/":"'.'
N"."'."
IA
-:-:
1-:-
D:-:
) [~El:-:======~
Subject : [EXTERNAL)FW: ATTN: Dr. Fauci/ Good ACE bad ACE do battle in lung injury SARS-CoV
coronavirus Nicholls S Peiris M NATURE-Med 9-2005.pdf
** A TTENTTON: This emai l origi nated from outs ide the Me dStar netwo rk.
** DO NO T CLICK links or attachme nts unless you recogn ize the sender and know the con tent is safe .
The situation gets confusing. See attached brief commentary and e-mail string. As you can
see, I was too tired to make any sense of it. However , my deputy (Cliff Lane) notes that this
NIH-000388
paper argues the opposite , i.e. that ACE inhibito rs might have a benefit and counters the
argument to stop ACE inhibitor .s Bottom line is that we really do not know what the effect will
be cl ini cally w it h respect to COVID- 19. In any event, (b)(6)
Best,
Tony
From: Lane, Cliff (NIH/N IAID) [El (b)(6)>

Sent : Wed nesday, Marc h 18, 2020 5:51 PM
To: Fauci, Anthony (NIH/ NIAID) [E] (b)(6)
Subject: Re: ATTN: Dr. Fauci/ Good ACE bad ACE do battle in lung inj ury SARS-CoVcoronav irus Nicholls S
Peiris M NATURE-M ed 9-2005 .pdf
A 2005 paper post-SARSadvocating for use of ACE in hibitors to increase ACE2. The opposing argument
to stop ping ACE inhibitors.
From: An thony Fauci Cb)(6)

Date: Wednesday, March 18, 2020 at 5 :22 PM
To : "Lane, Cliff (N IH/NIA ID) [E]" (b)(6J 1>
Subject: FW : ATTN: Dr. Fauci / Good ACE bad ACE do battle in lung inj ury SARS-CoVcoronav ir us
Nicholls S Peiris M NATURE-M ed 9-2005.pdf
I cannot make hea ds or t ails of this. Please ta ke a loo k an d let me know what you
thin k. Thankjs.
Director
Phone : (b)(6)
FAX: (301) 496-4409
E-mail :
-------- (b)(6)
From: Ste McCon Cb)(6)

Sent : Wed nesday, Marc h 18, 2020 5 :09 PM
Subject : ATTN: Dr. Fauci / Good ACE bad ACE do battle in lung injury SARS-CoVcoronavirus Nicholls S
Peiris M NATURE-M ed 9-2005.pdf
NIH-000389
"Clearly, the potentia l th erapeutic utili ty of recombinan t ACE2and angiotensin II receptor-
inhibitors . [ARB's ?)s- already in clinical use for control of blood pressure-for acute lung
inj ury result ing fr om viruses and other causeswill be a productive field for invest igation . This is
part icularly relevant as we prepare to confront a potential avian flu pandemic, [COVID-19 ?
]armed w ith onlya limit ed numbe r of therapeutic opt ions."
Regard s,
St eph en D . McConnell, BS, MSc- CCP, CIS
Lipidemiologi st - Clinical App lication Specia list
Medicare-CMS ACO/MSSP/Direct-Contracting Consultant
Medical Science Liaison
Mob ile: (b)(6)
(b)(6)
Sent from my iPhone
MedStar Health is a not-for-profit, integrated healthcare delivery system, the largest m Maryland and the Washington, D.C., region. Nationally
recogn12ed for clinical quality In heart, orthopaedics, cancer and GI.
IMPORTANT. This e-mail (including any attachments) may conta•n mforrnat,on that Is private, confidential, or protected by attorney-client or
other privilege If you received this e-mail in error, please delete ii from your system without copying it and notify sender by reply e-mail, so
that our records can be corrected ... Thank you.
Help conserve valuable resources - only print this email if necessary.
NIH-000390
From: (b)(6)
Sent : Thu, 19 Mar 2020 08:30:51 -0400
To : Holland, Steven (NIH/NIAID) [E]
Subject: Re: Link to Wash post article re: Kim Hasenkrug
He is a good guy, but this is the second time for him
On Mar 19, 2020, at 8:20 AM, Holland, Steven (NIH/NIAID) [E]

(b)(6)
https://www .washingtonpost.com/health/ trump-ban-on-fetal-lissue-research-blocks -coronavirus-

trealment-effort/2020/03/18/ddd9f754-685c-11 ea-abef-020f086a3fab story.html
Just making you aware of the WP article this morning. This was a surprise to us and I have to
believe that Kim was unaware of its preparation or release.
Steve

Bldg. 10/11N248 MSC 1960
----- (b) (6) voice

301-480-4507 fax
----- (b)(6)emai l
Assistant lab: Eva Porti llo

Cb)(6) email
~==~~~--
----- (b) ( voice

(b)(
----- (b) (6) voice
From : Karyl Barron CbH6)>

Date: Thur sday, March 19, 2020 at 7:35 AM
To : Amy Agrawal (b)(6)
Subject: Link to Wash post article re: Kim Hasenkrug
https://www. wash ingtonpost.com/health/trump-ban-on-fetal-tissue-research-blocks -

coronavi rus-treatment-effort/2020/03/18/ddd9f7 54-685c-11ea-abef-020f086a3fab _story.html
NIH-000391
From: (b)(6)
Sent: Thu, 19 Mar 2020 08:29:22 -0400
To: Verma, Seema(FDA/CDER)(CTR)
Subject: Fwd: Long term care facil ities
See below. As per your prior discussion
From: Dorothy Franklin __________ _,
Date: March 19, 2020 at 8:22:2 4 AM EDT

To: "Fauci , Anthony (NIH/N IAID ) [E] "
-------~~
Subject: Long term care facilities
--------- (b)(6)
Based on studies at Kirkland care facility indicating staff were spreading the
coronavirus to multiple facilities sharing staff, is there or will there be guidance to
requi re these facilitie s to re ta in_a dedica ted staff on ly?
NIH-000392
Sent : Thu, 19 Mar 2020 02:33:41 +0000
To : Redfield, Robert R. (CDC/OD);Stephen Hahn;Birx, Deborah L. EOP/NSC
Cc: (b)( ;Troye, Olivia EOP/NSC;Short, Marc T. EOP/OVP;Miller,
Katie R. EOP/OVP;Hicks, Hope C. EOP/WHO;kellyanne conway
Subject : FW: NEJM: A Trial of Lopinavir - Ritonav ir in Adults Hospitalized with Severe
Covid-19 http://bit.ly/2x91Ji0
As per my prior e-mail. The medical people likely are aware of this. It j ust came out tonight.
(b) (5)
From: Folkers, Greg (NIH/NIA ID) [E)

--------
Se nt : Wednesday, March 18, 2020 10:14 PM
(b) (6)>
Subject: NEJM: A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

http://bit.ly/2x91Ji0
Access provided by NIH Library
A Trial of Lopinavir-Ritonavir in Adults

Hospitalized with Severe Covid-19
List of authors.
• Bin Cao, M .D., et al.
Abstract
Background
No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-
2.
Methods
We conduc te d a randomized, controlled, open-label trial involving hospitalized adult patients with
confirmed SARS-CoV-2infection, which causes the respiratory illness Covid-19, and an oxygen saturation
(Sao2) of 94% or less while they were breathing ambient air or a ratio of the partial pressure of oxyge n
(Pao2) to the fraction of inspired oxygen (Fio 2) of less than 300 mm Hg. Patients were randomly assigned
in a 1:1 ratio to receive either lopinavir - ritonavir (400 mg and 100 mg, respectively) twice a day for 14
days, in addition to standard care, or standard care alone. The primary end point was the time to clinical
improvement, defined as the time from randomization to either an improvement of two points on a
seven-category ordina l scale or d ischarge from the hospital, wh ichever came first.
Results
A tot al of 199 patients with laboratory-confirm ed SARS-CoV-2infection underwent randomization; 99
were assigned to the lopinavir-ritonavir group, and 100 to the standard -care group . Treatment with
lopinavir - ritonavir was not associated with a difference from standard care in the time to clinical
improvement (hazard ratio for clinical improvement, 1.24; 95% confidence interval [Cl], 0.90 to 1.72).
NIH-000397
Mortality at 28 days was similar in the lopinavir - ritonavir group and the standard-care group (19.2% vs.
25.0%; difference , - 5.8 percent age points; 95% Cl, - 17.3 to 5.7). The percentages of pati ents with
detectable viral RNA at various time points were similar . In a modified intention-to -treat analysis,
lopinavi r- ritonavir led to a median time to clinical improvement that was shorter by 1 day tha n t hat
observed with standard care (hazard rat io, 1.39; 95% Cl, 1.00 to 1.91). Gastrointestinal adverse events
were more common in the lopinav ir- ritonavir group, but serious adverse events were more common in
the standard -care group. Lopinavir- rit onavir treatment was stopped early in 13 patients (13.8%)
because of adverse events .
Conclusions
In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir-ritonav i!J
t reatment beyond standard care. Future tr ials in patients with severe illness may help to confirm or
exclude the possibility of a treatment benefit . (Funded by Major Projects of National Science and
Technology on New Drug Creation and Development and others ; Chinese Clinical Trial Register number,
ChiCTR2000029308 . opens in new tab.)
1.0
.. 09 l,opln.11v11
- flton.11v,r
& o.a
l 01
J-~
06
OS
O•
~ OJ
:i
E
:, 02
u
01
0 .0
• I 12 16 20 28
N o. •t Risk
lol)1nav1t- rito1t.11v1t '}9 93 93 18 so 33 26 22
Control 100 100 9& gg 60 39 32 ,o
Figure 2. .__________________________ _. ime to Clinical
Improvement in the Intent ion-to-Treat Population.
Disclaimer: Any third-party material in this emaiJ has been shared for internal use under fair use provisions
of U.S. copyright law, without further verification of its accuracy /veracity . It docs not necessarily represent
my views nor those ofNIAID , NIH, HHS, or the U.S. government.
NIH-000398
Sent: Thu, 19 Mar 2020 02:20:05 +0000
To : sheila.ka plan@nytimes.com
Cc: Collins, Francis {NIH/OD) [El;Conrad, Patricia (NIH/NIAID) [El
Subject : FW: Coronavirus interview with Dr. Collins
Sheila:
I do not recall getting a request from you. I am completely swamped and so it may have just
gotten bur ied in a pile and I did not see it. I apologize. I am mostly locked into the Whi t e
House where we must give up our phones and so it makes it very difficult for me to return
calls. I talk to Francis all the time and he is very well versed in these issues. He will do a fine
job of providing you with the information you need. If you would still like to speak w ith me
later on, we can try to make that work. Again, I am sorry if you felt snubbed.
Best regards,
Tony
From: Kaplan, Sheila <sheila .kaplan@nyt imes .com >

Sent: Wednesday, March 18, 2020 4:10:58 PM
To : Myl es, Renate (NIH/OD) [El (b)(6)
Cc: Burklow, John (NIH/OD) [El (b)(6)> ; Fine, Amanda (NIH/OD) [El
(b)(6)
Subject : Re: Coronavirusinterview with Dr. Collins
Hi Renate,
Thank you.... We appreciate it. SK
On Wed, Ma r 18, 2020 at 3:56 PM Myl es, Renate (NIH/OD) [E] (b)(6) wrote:
Hi Sheila:
The questions you shared with Amanda were really for Dr. Fauci; he's our spokesperson on all
research specific questions. I know he's really backed up and NIAID is doing the best they can with his
incredibly packed schedule . The interview with the Atlant ic was really intended as a profile , but ended
up covering a lot of COVI D questions. We can check in with NIAi D to see what we can do.
Thanks,
Renate
NIH-000399
From: Kaplan, Sheila <sheila.kaplan@nytimes .com >
To : Myles, Renate (NIH/OD) [E] >; Burklow, John (NIH/OD) [E]
-------- (b)(6)>; Fine, Amanda (NIH/OD) [E]

Subject : Re: Coronavirus interv iew with Dr. Collins
(bH >
Hi there,
Why were we told we could not do an interview, when, after our request, he did one with The
Atlantic. You referred us to Dr. Fauci but he isn't t alking, either . This doesn't seem fair to us. Can we
really not speak to either of them for a story this weekend?
Thanks, SK
On Sun, Mar 15, 2020 at 4:00 PM Kaplan, Sheila <sheila.kaplan@nytimes .com > wrote :
Dear Renate, John and Amanda:
Sheri Fink and I would like to interview Dr. Collins as soon as possible for a story on coronavirus.
Can you please let me know when he might be available .
Thank you,
Sheila
Sheila Kaplan
Reporter, Washington Bureau
The New York Times
Office: {202) 862-0312
Cell:
------ (b)(6)1
Sheila Kaplan
NIH-000400
The New York Times
Office: (202) 862-0312
Cell:
----- (b)(6)
Sheila Kaplan
The New York Times
Office: {202} 862 -0312
Cell: (b)(6)
NIH-00040 1
Sent: Thu, 19 Mar 2020 02:13:35 +0000
Subject : RE:Coronavirus interview with Dr. Collins
Francis:
Go for it. We need all the help we can get I do not remember getting a request from
Sheila. I will write and apologize.
Best,
Tony

--------
To: Fauci, Anthony (NIH/NIAID) [E] -------=- (be-
)(= >
Cc: Myles, Renate (NIH/OD) [El (b)(6)>; Burklow, John (NIH/OD) [E)
(b)(6)
Subject: FW: Coronavirus interview with Dr. Collins
Hi Tony ,
I could use your guidance on press interviews. I understand that only Task Force members are
supposed to do television events - and I declined the NewsHour tonight to be consistent with
that. But what is your preference for printed press pieces, when you can't do them all? Wou ld
it help the cause for me to accept some of those, or is it better to hold off? If I were to engage,
I would certainly seek to provide answers that are 100% with what you are doing.
An example is the thread from Sheila Kaplan of the New York Times. I have declined so far -
but is this the kind of query that you would lik e some help with?
Francis
From: Kaplan, Sheila <sheila.kaplan@nytimes.com>

Sent: Wednesday, March 18, 2020 4:10:58 PM
To: Myles, Renate (NIH/OD) [E] (b)(6)
Cc: Burklow, John (NIH/OD) [E]=====~ (b~)(~6)];Fine, Amanda (NIH/OD) [E]
(b)(6)
Subject : Re: Coronavirus interview with Dr. Collins
Hi Renate,
Thank you.... We appreciate it. SK
On Wed, Mar 18, 2020 at 3:56 PM Myles, Renate (NIH/OD) [E]______ Cb _ > wrote:
_)_(6)
NIH-000402
Hi Sheila:
The questions you shared with Amanda were really for Dr. Fauci ; he's our spokesperson on all
research specific questions. I know he's really backed up and NIAID is doing the best they can with his
incredibly packed schedule. The interview with the Atlant ic was really intended as a profile , but ended
up covering a lot of COVID questions . We can check in with NIAID to see what we can do .
Thanks,
Renate
From: Kaplan, Sheila <sheila.kaplan@ nytim es.com >

To : Myles, Renate (NIH/OD) [E) (b)(6)>; Burklow, John (NIH/OD) [E]
-------- CbH >; Fine, Amanda (NIH/OD) [E]

Subject: Re: Coronavirus inte rview with Dr. Collins
CbH >
Hi there,
Atlantic. You referred us to Dr. Fauci but he isn't t alking, either . This doesn't seem fair to us. Can we
Thanks, SK
On Sun, Mar 15, 2020 at 4:00 PM Kaplan, Sheila <sheila.kapla n@nytimes.com > wrote :
Can you please let me know when he might be availa ble.
Thank you,
Sheila
NIH-000403
Sheila Kaplan
The New York Times
Office: (202) 862-0312
Cell:
----- (b)(6)
Sheila Kaplan
The New York Times
Office: {202) 862-0312
-----
Cell: (b)(6)
Sheila Kaplan
The New York Times
Office: {202} 862 -0312
Cell: (b)(
NIH-000404
Sent: Thu, 19 Mar 2020 02:12:30 +0000
To : Eisinger, Robert (NIH/NIAID) [E)
Subject: FW: typo, etc. fixed , (b) (6)
Too long for me to read
From: Erik Nilsen <eni lsen@b io- signal.com>

Sent: W ednesday, March 18, 2020 10: 11 PM
-----~~
Subject: typo, etc. fixed , ______
To: Fauci, Anthony {NIH/ NIAID) [E]
_ __:_.:...:!= (b
~____,
)~(6):;------
(b)(6)
Hi Dr. Fauci,
I'm now back in my office. I typed the orig inal message on

phone. I just noticed a bunch of typos. Below is a better
version.
Regards,
Erik
Dear Dr. Fauci,
You're beyond busy but I hope you read this message.

(b) (4)
I'm only mentioning

this so you don't think I'm a paranoid freak. I'm convinced you
already know the outbreak is way past the point of containment,
and, unfortunately, herd immunity will soon ensue. Then,
outbreak 2 will happen shortly after, and, hopefully, not ad
infinitum.
I'm writing to make sure you already know or at least suspect

everything I'm about to tell you. I need to clear my conscience
NIH-000405
because it's possible (albeit unlikely) that some of what tell you is
new and possibly useful in, at least, saving lives in the USA.
I'm a physicist and have been modeling this outbreak since

January. My panic started minutes after I learned tvSM people
left Wuhan around January 22 a few days before the CCP starting
locking the country down. The SM peop le scattered to 13,000+
cities in China to visit family & friends for the Lunar Festival
(Ch inese New Year). I 've been communicating with quite a few
people around the world including an NYU epidemiologist (b)(6)
. We 've both been warning

our families, to mostly deaf ears at first, since January. It's been
f rustrating and exhausting, but, finally, most are as prepared as
possible for what's about to happen.
I have lots of information about China due to my business,

scientif ic, friendship, and other ties with many there, including
immunologists & virologists at top-tier institutions and
laboratories . My WeChat account (like Skype / Whatapp) was
blocked by the CCP for 3 days late February / early March, but,
after a warning message, it is now unblocked . I'm willing to
share with you everything I know, think I know, or seriously
suspect.
Here are a few examples:
I'm confident t hat China stop counting dead COVID-19 infected

bodies since tvJanuary 7 , 2020. They'v e been add ing fabricated
data daily to show (to save face) the world and their own people
an impressive flattening of China outbreak curve . It's easy to
prove this via data analysis because, for example, improbable
coincidences occurred in much of the data. My suspicions were
eventually confirmed by at least two of my sources in China
(b)(6)
). The data posted by

------------------
Chin a is not only garbage, it has mis led the world into a false
sense of security wrt death rate, age vs death, and other things;
that is, if people analyzed the world's data including China, the
NIH-000406
results are heavily biased towards nonsense, because China's
number of cases accounted for the majority of cases worldwide
(until a day or so ago).
I want to emphasize that I do not believe China intentionally did

this to harm the world. I sincerely believe it was done for saving-
face reasons. Saving face is possibly the most powerful
motivating force in China. it is the key to understanding how
most Chinese think and why they do what they do. China wanted
the world to believe that their Herculean quarantining efforts
contained the outbreak . However, I don't think this is true, even
after spraying ~billions of gallon of "Clorox" all the country. The
number of body bags my contacts told me about about, even
after short 15-minutes walk to/from grocery stores in one city
during CCP-authorized time slots, suggest the number of deaths
is several orders of magnitude larger than what China's posted
data indicates . Also, everyone I know in China continues to be in
lock down ( ~6+ weeks now), and several went "silent" since
about a week ago. This greatly troubles me because those who
went silent live in Wuhan. And, yesterday, the CCP revoked
permits/license for several Foreign reporters who were trying to
learn about about the situation in Wuhan and other parts of
China. Several of my sources have told me, in coded language,
that the situation in at least Wuhan is not under control at all. In
my opinion, China is continues to be extremely concerned about
saving face (first) and their economy (second). Their economy is
already suffering terribly, and they can't afford to lose the many
large manufacturing and other business agreements with foreign
countries . This is why I believe they're trying, and succeeding to
convince many, to convince most of their population that the
outbreak is under control, and it will soon be ok to return to work
-- even though it will not be safe, because of current outbreak
and outbreak # 2 that will likely start soon. Citizens are not
allowed to travel beyond a few stores and, in special cases, their
work office, so even people who live their have no idea what's
really going on especially in Hubei province including Wuhan.
Also, an H 15N outbreak seems to have recently started in
NIH-000407
humans in Hunan province (which neighbors Hubei/Wuhan area) .
I also have lots of information about USA.
Here is some:
I believe that many COVID-19 deaths were incorrectly labelled at

2019-2020 flu deaths. The spreading in the USA is almost
certainly already homogeneous, because it's been going on since
last year without any containment whatsoever. Once massive
testing finally starts, this truth/reality will, unfortunately, become
obvious. It will manifest itself as hyper exponential (hyperbolic)
growth starting a day or two after the millions of testing kits
arrive and start being used . The hyper exponential dynamics will
eventually evolve to a more accurately calibrated exponential
curve once the number to tests is large enough to properly
sample the population. I don't think Italy is ahead of us. I think
we're ahead and by a large amount.
A few other quick bits of info ...
The time between infection and death seems to have decreased

from about ~20 days (a few months) ago to possibly as short as
~8 days. And, the incubation period seems to be significantly
longer. Both, and other data I've looked at, strongly suggest at
least one mutation has occurred. This is extremely concerning to
me. Another concern is the distribution of deaths vs. age appears
to not be as strongly biased, compared to when China data was
included, towards older people and/or people with chronic health
conditions.
Over the past 15+ years, I've traveled to China multiple times
per year. I'm pretty sure you've known this for a while, but I
truly believe the outbreak tsunmai in the USA is either already
happened or is about to happen. As you know, as soon as a
surge is sensed, the Tsunami will immediately follow. I believe
we missed the containment boat quite a while ago. I've been
NIH-000408
closely listening to your comments on TV, and I'm pretty sure
you've already come to the same conclusion but don't want to
cause mass panic (I understand that).
I'm 99% sure that SARS-CoV-2 been spreading in the USA since
late November / earl v December last year. (b)(6)
(b)(6)
---(b)(6)She works at (b)( 6) and
it's possible that everyone in her office got infected too. Who
knows how many people in Alaska got it too, but I suspect many
tens of thousands possible much more. CbH6)
but it has been impossible to get

tested. I've called 5 places in Alaska and none wanted me to
come it for the test.
I've instructed my family and, recently (after family), close

friends to get some Alvesco ( ciclesonide) for emergency use
only. I've been told by colleagues on the front-line in Japan,
China, and Korea, and found several pre-pr int papers, that it is
an effective treatment for late-stage COVID-19 patients. Some
patients on ventilators who were approaching death have fully
recovered after treatment with ciclesonide; ciclesonide has much
smaller particles than other corticosteroids so it reaches deeper
into lungs and alveolis) . Also, the treatment seems to be a
potent suppressor of virus replication. Recovered patients have
tested negative shortly after the treatment. Of course, data is
limited so can't be sure the treatment is effective. However,
because Alvesco has been shown to be safe for infant - 100+
year-old patients, I'm ok with my family and I having it for
emergency use. That is, only if healthcare facilities are unable to
accept them or me as a patient to treat with ventilator,
NIH-000409
corticosteroids ( or whatever the best available treatment is at
that time). Having Alvesco in our emergency kits is a much
better option that someone avoidably dying because of an
overburdened healthcare facility. The other drug I have, and
have told my family and some friends to get, is called
hyro xychloriquine -- also seem to be effective and safe. But , I
think Alvesco is better because it appears to prevent the virus
from replicated so infection is wiped out and no longer
contagious. Alvesco seems to be two silver bullets in one.
I don't believe in coincidences and I'm not a conspiracy theorist,

but there are many things out of Iran that also concern me
greatly . That's all I say right now.
If all of this is old news to you, then I would greatly appreciate a

response. It can be as short as "yes". Anyway, I had to share this
information with you. Now my conscience is clear . My concern is
that it's possible you don't have some of the above info, so I
decided to send you this message .
I wrote this quickly, so I apologize in advance for any typos,

etc .
I truly appreciated your efforts, and I'm now confident that

President Trump, you, and everyone else involved is doing
everything possible to ensure the best possible outcomes. I was
deeply concerned a few weeks ago, when the gravity of the
situation seemed to not be fully recognized by several in DC.
Feel free to call me anytime. My cell # is below. If you do call, I

will keep anything we discuss confidential (if necessary) .
NIH-000410
Sincerely,
Erik
Erik A. Nilsen, PhD
(b)(6) I www .bio-si gnal.com I Request a demo or quote
Bio-Signal
Technologies
NIH-000411
Sent: Thu, 19 Mar 2020 02 :07:41 +0000
Subject: FW: Coronavirus interview with Or. Collins
See yellow highlight. Has Sheila Kaplan tried to get to me and has anyone said that I am " ...not
talking"? I doubt that.

-------
(b)(6)>
To: Fauci, Anthony (NIH/NIAID) (El ------ ::;..,...,=

(b)(6J1>
Cc: Myles, Renate (NIH/OD) [El..:....:~==== (b
~)~~~;~Burklow, John (NIH/OD) (El
(b)(6)
Subject: FW: Coronavirus interview with Dr. Collins
Hi Tony,
I could use your guidance on press interviews. I understand that only Task Force members are
supposed to do televis ion events - and I declined the News Hour tonigh t to be cons istent w ith
that. But what is your preference for printed press pieces, when you can' t do them all? Wou ld
it help the cause for me to accept some of those, or is it better to hold off? If I were to engage,
I would certainly seek to provide answers that are 100% with what you are doing .
An example is the thread from Sheila Kaplan of the New York Times. I have declined so far -
but is this the kind of query that you would like some help with?
Franci s
From: Kaplan, Sheila <sheila.kaplan@nyt imes.com>

Sent : Wednesday, March 18, 2020 4:10:58 PM
To : Myles, Renate (NIH/O D) [El (b)(6)>
Cc: Burklow, John (NIH/OD) [El ""':======~~ (b)(6); Fine, Amanda (NIH/OD) [El
(b)(6)> ----------
Subject: Re: Coronavirus interview with Dr. Collins
Hi Renate,
Thank you .... We appreciate it. SK
On Wed, Mar 18, 2020 at 3:56 PM Myles, Renate (NIH/OD) [El (b)(6)> wrote :
Hi Sheila:
NIH-000412
The questions you shared with Amanda were really for Dr. Fauci ; he's our spokesperson on all
research specific questions . I know he's really backed up and NIAID is doing the best they can with his
incredibly packed schedule. The interview with the Atlantic was really intended as a profile, but ended
up covering a lot of COVID questions. We can check in with NIAID to see what we can do.
Thanks ,
Renate
From: Kaplan, Sheila <sheila.kaplan@nyt imes.com >

To: Myles, Renate (NIH/OD) [E) >; Burklow, John {NIH/OD) [E]
-------- CbH >; Fine, Amanda {NIH/OD) [E)

Subject: Re: Coronavirus interview with Dr. Collins --------- (b)(6)
Hi there,
Atlantic. You referred us to Dr. Fauci but he isn't talking, either. This doesn't seem fair to us. Can we
Thanks, SK
On Sun, Mar 15, 2020 at 4:00 PM Kaplan, Sheila <sheila.kaplan@ny t imes.com > wrote:
Can you please let me know when he might be available.
Thank you,
Sheila
Sheila Kaplan
NIH-000413
The New York Times
Office: {202) 862-0312
-----
Cell: (b)(6)
Sheila Kaplan
The New York Times
Office: (202) 862 -0312
Cell!
----- (b)(6)
Sheila Kaplan
The New York Times
Office: (202} 862-0312
Cell: (b)(6)
NIH-0004 14
Sent: Thu, 19 Mar 2020 02:05:42 +0000
To : Doug Brust
Subject: RE:Please Help
Doug:
Thanks for the note. I have pushed hard on PPEs and as you may know, the POTUS has
involved the Department of Defense to provide 5 million N-95 respirators. Hopefully that will
alleviate at least a portion of the PPE shortage. Regarding the bars and beaches, I have been
screaming on TV 2 to 5 times per night to tell t he younger generation to start tak ing this
seriously. I am very surprised that Gov. Desantis has not completely closed the bars, even if
they serve food. Take out only. I will bring this up at the Task Force meeting tomorrow.
Please take care of yourself. You are an indisp ensable front line warrior.
Best regards,
Tony
From: Doug Brust (b)(6)>

To : Fauci, Anthony (NIH/NIA ID) [E)
------~=
Subject: Please Help
-------- (b)(6J>
Tony-
I know you're ridiculously busy so please do not be upset with me, but I am frustrated and yes angry.
Again, I think you have to hear from the front line while formulating policy .
• Today at the RW clinic I dealt with at least 12 URl's with fever.

• We cannot test .
• We have no PPEin clinic .
• We have a case that tested positive for influen za then SARS-CoV -2--t his scared me the most
given I'm trying to r/o COVID-19 by doing PCRfor other respiratory viruses.
• On the drive home just now, the gyms, bar-grilles and restaurants still packed. Yes, bars are
closed in Florida--but if they serve food (which they all do) .......they're open. Ans, so much for
the 50% capacity "suggestion" .
• The beaches still ful l for Spring Break. Look at the pies of St Pete.
• The DOH? This is from the the FL DOHjust a few hours ago. Yes,this is TODAY.
"If a cluster of confirmed cases were to be discovered in Florida, the department wou ld
move quickly to engage with and isolate any infected individuals to prevent further
spread," said Alberto Moscoso, the state health department's spokesman .
I don't have to explain to you how ridiculousthat statement is.
NIH-000415
• I've written to our DOH and Governor Desantis three times (includ ing speaking with his staff)
asking to close restaurants (aside from take -out), gyms, beaches etc . They are "monitoring".
I'm the HIV doc here. I'm it . You know how seriously I take caring for my patients . I have (b)(6)
- I am putting my life on the line so fo lks can go pump iron, drink beer , have a burger and get a ta n.
The band is playing on. Again.
Please help.
With tons of respect and admiration,

Doug
NIH-0004 16
Sent: Thu, 19 Mar 2020 0 1:59 :12 +0000
Subject : FW: Coronavirus
Please respond to this pe rson.

From: Be th Abramson ______ __,('b"')...,
~=>
-----~~=
To: Fauci, Anthony (NIH/NIAID) [E]...______ (b
_)_C_,>
Subject: Coro navims
Wondering whether it has been considered that only the vulnerable population (those over 60 and/or those with
underlying hea lth cond itions)be isolated? I am a (b)(6)psyc hiatrist and after contemplating this option was
wonde1ing if this could still reduce the risk to healthca re Systems w ith less disruption to our society. I await your
response and apprec iate all you are doing. Beth Abramson MD (b) (6)
Sent from my iPhone
NIH-000417
Sent : Thu, 19 Mar 2020 01:54:06 +0000
Subject : FW: Plaquenil Shortage Causing National Health Emergency for lupus Patients
Please respond.
From: Bruce Wilder Cb)(6)>

Se nt: Wednesday, March 18, 2020 9:52 PM
)(c-=
6)
Subject : Plaquenil Shortage Causing National Health Emergency for Lupus Patients
(b)(6) When I tried to refill Plaqueni l

---------------------------
today, I learned that there was a nationa l shortage due to doctors prescrib ing Plaquenil to their well patients
and themse lves. Recent news articles have reported its success in preventing and treating the coronavirus .
What can you do to protect the life of (b) (6) and the millions of other Americans who depend on this drug
to stay alive?
Brenda Wilder
(b)(6)
NIH-0004 18
Sent: Thu, 19 Mar 2020 0 1:53:32 +0000
Subject : FW: Please read- idea for Mask Shortage
Please take a look and hand le.
From: Dust i Rainey ~ (b)( ~

Sent : Wed nesday, M arch 18, 2020 9:5 1 PM
------- ~=
To: Fauci, Ant hony {NIH/NIAID) [E]
---------
Subje ct: Please read- idea for Mask Shortage
(b)(6)
I have an idea to HELPwith t he MASK SHORTAGE!

Please don't disregard th is, as this could help our whole country!
I know we are concerned as a nation about a mask shortage and I have an idea to what might help.
I Don't know who to go to that can help imp lement this and want your input if you think this is a viable
aid, then maybe you can help me reach the right people to make the biggest impact, maybe even up to
the Coronavirus team in the White House.
I have (b) (6) & when I first heard about China quarantin ing 43 million peop le I got
worried about masks, I looked up how to sew a mask for myself & family. I found a site that talked about
sewing masks for cancer treatment patients and to use 100% quilters cotton for outside & 100% flannel
cotton on inside. I started sewing several. I know they aren't the N95, but they are bette r than nothing
IF needed. My Dr just told me yesterday not to go anywhere without a mask because it's too much of a
risk for my health . It got me thinking. What if while people across the country were in home quarantine,
ALL those who know how to sew, they sew these masks to donate in their communities. Not for use
against Coronavi rus, but for other things normal masks are used (food prep, non-sickness medical
reasons, etc) then they aren't using up the valuab le higher rated masks t hat are needed for doctors,
nurses & first responders fighting Coronavirus . These masks can also be washed as needed again and
again which will just keep saving other masks.
During the WH Press Release this morning, Seema expresses the need for masks & Dr Birx explained
how the virus is being spread from surfaces, but that it can't survive in fabric . Which means maybe t hese
cloth masks will even help against the spread of the virus.
Either way, if you can help ok for these to be used in some manner vs a medical mask being used w ill
help pro long the need for more masks and hopefully 3M can have more made by then so we never have
to exper ience an lack of masks.
What do you think?
Dusti Bacon
(b)(6)
NIH-0004 19
From: (b)(6)
Sent : Wed, 18 Mar 2020 19:56 :42 -0400
To : John Brouse
Subject : Re: Covid19 treatment

A. S. Fauci
Sent from my iPhone
On Mar 18, 2020 , at 7 :02 PM, John Brouse CbH6)

>wrote:
----------
Sent from Mail for Windows 10

Dear Dr. Fauci
I understand that Sout h Korea has been administering Hydroxl Chloroquine, a treatme nt
for Malaria, to her citizens that have contracted Coronavirus . Is America considering this
drug to help lessen the symptoms of t his virus ? This drug may not prevent anyone from
getting ill, but may be a v iable treatment to speed the recovery of individual afflic ted with
this disease.
Respectfully,
John Brouse
NIH-000420
From: (b)(6)
Sent: Wed, 18 Mar 2020 19:55:14 -0400
To: Holly Kreutter
Subject: Re:airport screenings

A.S. Fauci
Sent from my iPhone
On Mar 18, 2020, at 7: 10 PM , Holly Kreutter wrote:

--------- (b)(6)
Dear Dr Fauci,
First of all, thank you for all the hard work you've done to help mitigate the
coronavirus outbreak. We're clearly not there yet, but are further along with your
efforts.
I'm not sure whom to contact about this, and so am writing you because I'm
confidant you can get it to the right hands. With regards to the recent closures to
Europe and so many Americans coming home, I was at first heartened to hear that
all Americans returning would be medically screened and encouraged to/made to
quarantine for 14 days. However, I was then disheartened to learn that that hasn't
been the case, at least through this past Saturday.
(b)(6) was on business in Amsterdam last week and rushed home last Thursday
after hearing on Wednesday evening about President Trump's Friday midnight
shutdown . He came in through LAXfrom Amsterdam, and wasn't asked any
medical questions, nor was he asked to quarantine. Then a friend came in through
Miami from Paris on Saturday, and was only given a short medical form to fill out,
and then let go. No med ical check, no temperature screening, no further questions.
From touchdown to taxi (plus picking up bags), 45 minutes total.
Having lived in Singapore through SARS,I'm deeply disturbed. We had
medical/temperature checks at all airports, and mandatory quarantines for anyone
with possible contact with a SARScontact/patient . The virus was quickly and
efficiently contained, and the same has been done in Singapore to date with Covid
19.
I was heartened last Friday as I learned that the federal government was on board,
and hearing about significant measures that would be taken soon. I must say I've
been disheartened as of today, with not enough tests, mask, respirators and
ventilators in place. And then hearing of the lack of medical screenings at airports.
Please help, as I know you've so desperately been trying to do . And please help to
stem any incorrect information going out from our President, information which
NIH-00042 1
gives us hope for a couple of days, and then dashes that and puts many into a
frenzied despair. We can cope with what's happening, and will continue to change
our behavior per the guidelines , but only with information that's accurate.
Thank you, and keep safe,
Holly Kreutter
Virginia Resident
NIH-000422
From: (b)(6)
Sent: Wed, 18 Mar 2020 19:54:24 -0400
Subject: Fwd: Volunteer status for current nursing students
Sent from my iPhone
From: Ivan Boc ardo Cb)(

Date: March 18, 2020 at7:16:25 PM EDT
To: "Fauci, Anthony (NIH/NlAID ) (E]"
--------~~ CbH6J
·
Subject: Vol unt eer status for current nursing students
My name is Ivan Bocardo, and am a (b)(6) U.S. Army Medic (68W) deployed to
Afghanistan in 2011-2012. I can send you my resume so you can see my skills and abilities that I
can bring to the table. Am currently in nursing school ( R.N. ) in Rego Park, Queens with a
(b)(6) .._ _________ -=-:,~
My school (----=- .-- ,-.-- ,........,,..._..----..---..--. (b) (6)) has

recieved a request from New York Governor Cuomo's office looking for nursing students to help
volunteer. However many students like myself are very hesitant to volun teer for the simple fact
that it will interfere with our studies and we will still have to comply with class assignments and
class exams and especially with final exams this current semester coming up at the middle to
end of April 2020. Yet many of my fellow classmates would love a chance to stand up and
deliver help during these trying times . However our school will not except any excuses for
lateness or absence even though we are now on an online learning as of this moment. So our
greatest fear is that we wont finish this semester and will not be able to start next semester ( it
starts April 28, 2020 for our school ) ... basically 2 semesters wasted and it will push back our
graduation date and furthermore incur more student loans in order to continue with school.
This is why I am writing to your office if an exception can be made and we can have OT J ( on the
job training for nursing) and recieve credit and for our current semester and possibly our next
semester. Many of the students I speak about already have a Bachelor's degree ( I myself have
a B.S. In Biology from (b) < ) and many are or have worked as Nurse
aides in many NYC area local hospitals with many years of excellent experience. Imagine if you
are able to approve this for many nursing school students in j ust the New York City area and
Long Island Suburbs .This would be virtually an untapped experienced workforce of
literally hundreds perhaps maybe thousands of hands on personnel ready to go to help relieve
the over burdened health system workers and provide additional reinforcements due to the
coronavirus. In not only my area of New York city but possibly all over the country where we can
help provid ing help and additional assistance and reinforcemen ts
Dr. Fauci, I am humbly asking for special permission, we all will need all the help we can get.
Please consider this option as this can be a win/ win situation for not only NYC residents but for
other areas of the country hit hard by this crisis . I have spoken to many of my fellow
classmates and they all understand the risk and would be willing to share the burden with the
NIH-000423
extreme pressures put on the health care system at this time . Many of us including myself would
be w illing to work on site or what ever site you may need us the most, many us fully understand
that we could potentially be away from our families for an extensive unknown period of
time which we are ready for and prepared for or possibly put our health on the line too.
I implore you to give us a chance and only ask for special permission for OTJ in order to fully
finish our R.N. nursing degree.
Thank you for your time in reading this letter.
You are doing one fine heck of job in providing outs tanding information and keeping the public
informed
Sincerely ,
Ivan Bocardo
Personal Cell phone ____ (b

_ )_ (_.
6)
NIH-000424
From: (b)(6)
Sent: Wed, 18 Mar 2020 19:52:49 -0400
To: Margaret Wilbur
Subject: Re: coronavirus immunity

A.S. Fauci
Sent from my iPhone
On Mar 18, 2020, at 7:25 PM , Margaret Wilbur (b) <6l>wrote:
Have we reached a time when it might be useful to prove who is immune to

Covid-19? I understand that there is an antibody test already available. If
we could identify who is already immune , we could then let those people
return to daily life, work safely in essential positions, and feed the economy.
I practiced internal medicine in Cleveland, Ohio for (b)(6). I was amazed

on a daily basis by the breakthrough that was PCR testing. Right now old-
fashioned antibody tests might make a critical difference to us.
Margaret Wilbur, MD
(b)(6)
NIH-000425
From: (b)(6)
Sent: Wed, 18 Mar 2020 19:52:29 -0400
To: Ronald Frank
Subject : Re: Dental offices and the coronavirus IMPORTANT

A.S. Fauci
Sent from my iPhone
> On Mar 18, 2020, at 7:28 PM, Ronald Frank

> -------- (b) (6) > wrote:
> Dear Dr Fauci,

>
> Firstly , I would like to commend you on your expertise and leadership.
>
> As we develop a compreh ensive plan lo tackle the coronavirus pandemic , I believe that we have failed to address a
critical piece of the puzzle to contain the virus.
>
> I am a physic ian and urologist, but I mn astutely aware of the dental profession. I have a older brothe r who is a
practicing dentist and I have voiced my concems to him.
>
> Each and everyone of us who has had an appointment with a dentist knows the procedure of pressure irrigation in
the mouth resulting in a mist and aerosol of secretions and saliva depo siting on the faces of patients, the dentist and
on all the surfaces in the treatment rooms. While the dentist wears a face mask, the spray of secretions , in a
potential coronavims carrier, widely contaminates surfaces, other employees and patients.
>
> l pose the question, should dental offices be actively treating patients during this critic al phase in the Coronavirus
pandemic? Everything which J have mentioned is corroborated by several practici ng dentists. ls the he CDC and
the NTHobligated to set guidelines and restrictions on dental care during this critical time as we try to get control of
increasing numbers of cases. Should the ADA take a stronger stance during this crisis?
>
> r respectiv ely reserve these decisions and recommendations to you and your colleagues Thank you
>
> Sincere ly,
>
> Ronald G. Frank , M.D.
> 1500 P leasant Valley Way
> Suite 201
> West Orange, New Jersey 07052
> 0. 973•73 I•6600
>
>
NIH-000426
From: (b)(6)
Sent: Wed, 18 Mar 2020 19:51 :14 -0400
To: dalt222
Subject: Re: Plaquenil for Covid 19
Thank.YOllfor your note.

A.S:;,Fauci
my iPhone
~e1it.fri)i1'1
'On Mar 18, 2020 , at 7:41 PM , _________ (b)(6Jwrote:

....
Dr Fauci,
I hope all is well with you. I am a Dermatologist practicing in the Metropolitan

Detroit area. I have done some literature searching on potential treatments
for the novel coronavirus and stumbled across a few case case reports from
China in 2005 at the time of the SARS outbreak. They detailed some
successes in treatment of severe cases with chloroquine. I saw a more
recent study showing hydroxychloroquine had better in vitro efficacy than
chloroquine. Have you heard of this? Plaquenil is so innocuous, I wonder if
we shouldn't just try it.
I think you are doing phenomenal work and really presenting a level,
measured and realistic view of this epidemic to the world. Please keep up
the great work. It is much appreciated
David A. Altman MD FAAD

Assistant Clinical Professor
Division of Internal Medicine
Michigan State University College
Of Human Medicine
Sent from my Verizon, Samsung Galaxy smartphone
NIH-000427
From: (b)(6)
Sent: Wed, 18 Mar 2020 19:50:23 -0400
To: DMID Word Nerds
Subject: Fwd: Interest in collaboration on COVID-19antibody development
Pls handle
From: Dea Shahinas (b)(6)

To: "Fauci, Anthony (NIH/NlAID ) [E]"
-------~~ (b)(6 J:-
Cc: (b)( >
Subject: Interest in collaboration on COVID-19 antibody development
Dear Dr. Fauci,

We learne d about your research on COVID- 19 at NIAID and are int erested in
collaborating with you in order to fast-track our efforts in developing antibodies
against this infection.
We have two decades of experience with single domain antibody (nanobody)
technology.
I will provide below a brief summ ary about our company:
Virotek is a priva te Canadian biotec h w ith focus on t he development of novel
biologics for the treatment of viral infe ctions. Our primary focus area has been in
the areas of infecti ous diseases and immuno-on cology in animal and hu man
vert icals. (b) (4)
(b) (4)
NIH-000428
We are also proposing (b)(4)
. Please let us know if you are interested and we are happy to arrange for a time
to discuss in further detail with you.
Best regards,
Dea Shahinas
Director, R&D
Virotek Inc.
(b)(6)
NIH-000429
Sent: Wed, 18 Mar 2020 23:09:32 +0000
To: (b)(6)
Cc: (b)(6)
Subject : FW: ATTN: Dr. Fauci/ Good ACE bad ACE do battle in lung injury SARS-CoV
coronavirus Nicholls 5 Peiris M NATURE-Med 9-2005 .pdf
Attachments : Good ACE bad ACEdo battle in lung injury SARS-CoV coronavirus Annotated-
YELLOWNicholls S Peiris M NATURE-Med 9-2005.pdf
)(6)
The situation gets confusing. See attached brief commentary and e-mail string. As you can
see, I was too tired to make any sense of it. However , my deputy (Cliff Lane) notes that this
paper argues the opposite, i.e. that ACE inhibitors might have a benefit and counters the
argument to stop ACE inhibi tor.s Bottom lin e is that we really do not know what the effect will
be c linically wi t h respect to COVID-19. In any event, (b)(6)
Best,
Tony
From:Lane, Cliff (NIH/NIAID) [E) (b)( >

To: Fauci, Anthony (NIH/NIAID) [El------=--c= (b)(6)>
Subject: Re: ATTN: Or. Fauci /Good ACE bad ACE do battle in lung injurySARS-CoV coronav irus Nicholls S
Peiris M NATURE-Med 9-2005 .pdf
A 2005 paper post-SARSadvocating for use of ACE inhibitors to increase ACE2. The opposing argument
to stopping ACE inhibitors .
From: Anthony Fauci (b)(6)

Date: Wednesday, March 18, 2020 at 5:22 PM
To: "Lane, Cliff (NIH/NIAID) [E]" (b)(6)
Subject: FW: ATTN: Dr. Fauci/ Good ACE bad ACE do battle in lung injury SARS-CoV coronavirus
Ni cholls S Peiris M NATURE-Med 9-2005.pdf
I cannot make heads or tails of this. Please take a look and let me know what you
think. Thankjs.
Directo r
Phone : (b)(6)
NIH-000430
FAX: (301) 496-4409
E-mail:
-------- (b)(6)
From: Ste McCon ) (6) >

Cb
Sent: Wednesday,March 18, 2020 5:09 PM
Subject: ATTN: Dr. Fauci/ Good ACE bad ACE do battle in lung injury SARS-CoVcoronavirus Nicholls S
Peiris M NATURE-Med 9-2005.pdf
"C lear ly, the potential therapeutic ACE2 and angioten sin II receptor -
utility of recombinant
inhibitor s. [ARB's ?]s- already in clinical use for control of blood pressure-for acute lung
injury resulting from viruses and other causes will be a productive field for investigation. This is
particu lar ly relevant as we prepare to confront a potent ial avian flu pandemic, [COVID-19?
]armed w ith onlya limited number of therapeutic options."
Regards,
Stephe n D. McConne ll, BS, MSc - CCP, CIS
Lipidemiologist - Clinical Application Specialist
Medicare -CMS ACO/MSSP/Dircct-Contracting Consultant
Med ical Science Lia ison
Mob ile:
----- (b)(6)
Sent from my iPhone
NIH-00043 1
Sent : Wed, 18 Mar 2020 23:03:32 +0000
To: SWAMINATHAN, Soumya
Cc:
[El
Collins, Francis {NIH/OD) [El
------- (b)(6));Marston, Hilary {NIH/NIAID)
Subject : RE: Confidential and urgent request regarding
Thanks, Soumya.
(b)(6)
From: SWAMI NATHAN, Soumya
----------
To: Collins, Francis (NIH/OD) (El (b)(6)>
Cc: Fauci, Anthony {NIH/NIAID) (El
(b)(6) ------- (b)(6)>; Marston, Hilary {NIH/NIAID) [El
Subject : Re: Confidential and urgent request regarding
Dear Francis
I am sure you have seen the results which came out today, and are inconclusive. The DG announced the
launch of the WHO Solidarity trial, which will hopefully provide a definitive answer to all these
questions. Many thanks to NIAID for their support .
Warm regards
Soumya
Sent from my iPhone
On 17 M ar 2020, at 18:50, Collins, Francis {NIH/OD) [El

------- (b)(6)> wrote :
Hi Soumya,
Thanks for any help you can give.
Francis
From: Hudson, Thomas J

-----------
To: Collins, Francis {NIH/OD) [E] ------ (b
(b)(6)>
=)"'"
(6)
=
Cc: Marston, Hilary (NIH/NIAID) [El________ Cb
H_6) Fauci, Anthony (NIH/NIAID)
_
NIH-000432
[El Hudson, Thomas J
(b)(6)>;
Subject : RE: Confident ial and urgent request regarding ------------ (b)(6)>
Dear Francis,
I have not received an response from Dr. Swaminathan to mv message sent yesterday
(b)(4)
I expect tha t we are not the on ly group try ing to get to WHO leaders. A call from Tony or
you may be more successful.
-·
In add itio n to my contact information below, I can be reached via my cell phone: (b)(6)
Tom
THOMAS HUDSON
Senior Vice-President, R&D
AbbVie, North Chicago

1 North Waukegan Rd
R473, Building AP9-1
N Chicago, IL 60064
---~=
EMAIL _________
TEL (OF_F_IC_E..:.
) --==== (b:)(:6)=--="'="
_,
(b)(6)
abbvie.com
NIH-000433
This communication may contain information that is proprietary, confidential, or exempt from disclosure. If you are
not the intended recipient, please note that any other dissemination, distribution, use or copying of this
communication is strict ly proh ibited. Anyone who receives this message in error should notify the sender
immediately by telephone or by return e-mai l and de lete it from his or her computer.
From: Collins, Francis (NIH/OD ) [E] <1

Sent: Monday, March 16, 2020 8:43 AM -------- (b) (6)>
To: Hudson, Thomas J (b)(6)>

-~-""!""'::~======:!.-.~
Cc: Marston, Hilary (NIH/NIAID) [E] ~ >; Fauci, Anthony (NIH/NIAID)
[E] (b) (6)>
---------- (b)(
Subject: [EXTERNAL]RE: Confidential and urgent request regarding
Tom,
Thanks again for reaching out. I can only imagine (b)(4

(b) (4)
The best contacts would be the WHO Chief Scientist Soumya Swaminathan
(b)(6) and pote ntially Director General Tedros
~===== (b)=(..-:
6)~-
Let me know if you hit a roadb lock with WHO. I m ight then want to weigh in too.
Francis

------------
------ ---=
(b)(6)

--------
CbH >
Subject: RE:Confidential and urgent request regarding
Thank you.
THOMAS HUDSON
NIH-000434
~·
AbbVie, North Chicago

1 North Waukegan Rd
N Chicago , IL 60064
TEL (OFFICE) ---= (b)=(6)
=
EMAIL _______ (b
._.)...,
(6)
..,
abbvie .com
This communication may contain information that is proprietary, oonfidential, or exempt from disclosure. If you are
communication is strict ly proh ibited. Anyone who receives this message in error should notify the sender
immediately by telephone or by return e-mail and delete it from his or her computer .
From:Collins, Francis (NIH/OD ) [E] >

Sent: Monday, March 16, 2020 8:14 AM -------- (b)(
To: Hudson, Thomas J (b)(6)

Cc: Marston, Hila ry (N ~
IH'.'":
/ ".":
N".":
IA:-:-
ID~ ):-:[~E"."'
] -::::=====~ ""'
(b=H=6)
Subject: (EXTERNAL] RE: Confidential and urgent request regarding
Hi Tom,
Got your message, am looking into it, hope to get back to you later today.
Best, Francis

Sent: Monday, -------------
March 16, 2020 9:10 AM
To: Collins, Francis (NIH/OD) [E] ------
(b)(6)
6)>; Collins,
= ).-.(=
(b Francis (NIH/OD) [E]
(b)(6)>
Subject : RE:Confidential and urgent request regarding
This follow-up message is a duplicate that I am send ing to another e-mail address that I
have on file.
Dear Francis,
aJJLse.udl ng tbis_br.L
ei..Rote as a..r.: .n ..w.i..tb
eau..estJ.oL gu_idao.ce0.,0 pJLe)Lo \li~ sltu.a__tio _,. ....,.,.., (b) (4)
NIH-000435
(b) (4)
I am reaching out to you to see if you have any suggestions or individuals that we
should contact .
Best wishes,
Tom
THOMAS HUDSON
Chief Scient ific Officer
1 ~ I
AbbVle , North Chicago
1 North Waukegan Rd
TEL (OFFICE) ---= (b),..,(6)
=
EMAIL _______ (b
._.)...,
(6)
_,
abbvie .com
This communication may contain information that is proprietary, confidentia l, or exempt from disclosure. If you are
communication is strict ly prohibited. Anyone who receives this message in error should notify the sender
Immediately by te lephone or by return e-mail and de lete It from his or her computer .
(b) (4)
NIH-000436
Sent : Wed, 18 Mar 2020 20:09:47 +0000
Subj ect : FW: Covid-19
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Ann Beloten (b)(6)

Se nt: Wednesday, Marc h 18, 2020 4:07 PM
-------~~
Subject : Covid-19
--------- (b)(6)
Dear Dr. Fauci,

I am writing to you because I have a question regarding Covid-19. How come you do not tell the
compete truth to t he American people regarding this virus? All I hear is the bad facts about it . Why not
give people some help and tell us t he good facts about it? Good facts such as the number of actual
patients is very small compared to the whole population, most people who get it make a full and
complete recovery. Are you enjoying t he senseless panic you made? Panic where people are
hoarding food/goods , stealing full shopping carts from the elderly, losing their jobs/wages, inadequate
education now that schools are closed.
The number of people who will actually be sickened by the virus will be dramatically dwarfed by the
people who lose their jobs, receive a poor education despite the ir teachers best efforts and miss out on
once in a lifetime events such as weddings, graduations, communions.
What you are doing is not right for the American people!! You need to stop playing GOD and tell the
people the complete truth!! The country and the people need to get back to our normal lives NOW!!
Sincerely,
Ann Beloten
NIH-000437
Sent : Wed, 18 Mar 2020 20:07:28 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subj ect : FW: Rapid diagnostic support for Covid-19
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Tony Lemmo (b)(6)>

Sent : Wednesday, Marc h 18, 2020 3 :52 PM
To: Fauci, Anthony (NIH/NIAID) [E) ------~~ CbH6)>
--------
Subject : Rapid diagnostic support for Covid-19
Hi Dr Fauci,
Hello from
------------ (b)(6)
I'm sure you are swamped . I'll be brief . I am CEOof the world's leading provider of dispensing
equipment for the diagnostics market, BioDot Inc. We have been around for 25 years and provide
enab ling technology to virtually every rapid immunoassay and molecular diagnostics company in the
world. We are actively involved today with companies around the globe to help commercialize lateral
flow point of care products to help fight Covid-19. If there is anybody in your organization or on the task
force that could help facilitate gett ing us involved with companies looking to produce tests - we are here
to help! For example we are actively working with Biomedomics to get their LFDtest into the
community as fast as possible.
We will move heaven and earth to help the country in any way we can .
Thank you for all you have done and best of luck in fighting th is pandemic
(b)(6)
NIH-000438
Tony
Anthony V. Lemmo, Ph.D

CEO and President
BioDot Inc.
2852 Alton Parkway
Irvine, CA 92606
p (b) (6)
F 949-440-3694
www .biodot.com
NIH-00043 9
Sent : Wed, 18 Mar 2020 20:05:50 +0000
Subj ect : FW: Fabric Face Masks
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: AmiSimms (b)(6)>

-------::-::-=,
Subject : Fabric Face Masks -------- (b)((;)>
Dr Fauci,
Thank you for your guidance and expert ise at this difficult time .
My friend and I are quilters. She lives in (b)(6) and I live i (b)(6) _ She has created a pattern fo r
a fabric face mask. We read Dr. Tufekci's oped in the NYT yesterday and have been brainstorming
togethe r ever since on ways we can help.
htt ps://www .nyt imes.com/2020/03/17 /opinion/ coron avirus-face-masks. htm I
Several years ago I mobilized quilters throughout the US and we raised mo re than $1.1 million for
Alzheimer's Disease research . All grass roots, all vo lunteer . There are 7-10 million quilters in the US.
My friend and I would like to make a fabric face mask pattern available at no charge so that quilters,
sewers, and crafters can make face masks. We understand these are nowhere near medical grade, but
they would be better than nothing at all. {See research cited in link above .) They would be made from
fabric scraps and supplies on hand; no trips to the fabric store would be necessary.
At this t ime there are no masks available to the public at all. Sewing for a cause would give purpose to
those of us staying home . Wearing a mask on rare occasions when we do venture outside has the
benefits signaling others to step back even if the masks do not protect against transmission of the virus .
NIH-000440
We are just two individuals wanting to help. I've been advised by an attorney that sharing t his free
pattern might open us up to scrutiny from regulatory agencies or possible law suits . We don't want to
step on any toes, nor do we want any legal entanglements .
Could the NIH make t his pattern available? Or the CDC?There are millions of sewers who would be
delighted to step up and help right now. It would be great for morale , and even t hough it's one step up
from nothing , IT IS SOMETHING. This could even be scaled beyond indiv iduals making fabric face masks
fo r th emselves. Ma sks could be sewn for ot hers .
Could we please work with you?
Thank you for your consideration ,

Ami Simms (b)(6)and Emanuela D'Amico (b)(6)
NIH-00044 1
Sent: Wed, 18 Mar 2020 19:07:06 +0000
Subject : FW: Covid-19 symptoms outside of China
Point this person in the righ t direction
Director
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b)(6)
From : WW (b) (6)
Sent: Wednesday , March 18, 2020 3:05 PM
Subject: Covid-19 symptoms outsideofCh ina
Dear Dr. Fauci,
Many insist on coughs as one of the requirements for self-isolation or testing for covid-19. However , l have read
about instances where coughs were not experienced by those who tested positive.
ls it possible to share a list of covid - 19 symptoms that *exclude* the patients in China and perhaps France due to
their fairly high numb er of smokers? Does coughi ng remain a symptom ? l am concern ed about the health of our
nursing hom e resideni s, as well as the financial well-b eing of service sector workers.
Thank you,
Winnie
NIH-000442
Sent: Wed, 18 Mar 2020 18:27 :08 +0000
To : Redfield, Robert R. (CDC/OD);Stephen Hahn;Birx, Deborah L. EOP/NSC
Cc: (b)( ;Troye, Olivia EOP/NSC;Short, Marc T. EOP/OVP;Miller,
Katie R. EOP/OVP;Hicks, Hope C. EOP/WHO;kellyanne conway
Subject : Follow -up of today's conversation
Folks:
(b) (5)
5J. Hap py to discuss.

---------
Thanks,
CbH
Tony
Director
Phone : (b)(6)
FAX : (301 496-4409
E-mail : (b)(6)
NIH-000443
NIH-000444
Sent: Wed, 18 Mar 2020 15:09 :54 +0000
To: (b)(6)
Subject: FW: Bloomberg: 99% of Those Who Died From Virus Had Other Illn ess, Italy Says
Look at the hypertension percentage
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Folkers, Greg (NIH/NIA ID) [El (b)(6)

Sent: Wed nesday, Marc h 18, 2020 9 :52 AM
Subject: Bloomberg : 99% of Those Who Died From Virus Had Other Illness, Italy Says
99o/oof Those Who Died From Virus

Had Other Illness, Italy Says
By Tommaso Ebhardt, Chiara Remondini , and Marco Bertacche
March 18, 2020 , 8:56 AM EDT
More than 99% of Italy's coronavirus fatalities were people who suffered from
previous medica l conditions, according to a study by the country's national
health authority.
After death s from the virus reached more than 2,500, with a 150% increase in
the past week, health authorities have been combing through data to provide
clues to help combat the spread of the disease.
NIH-000445
Prime Minister Giuseppe Conte' s government is evaluating whether to extend
a nationwide lockdown beyond the beginning of April, daily La Stampa
reported Wednesday. Italy has more than 31,500 confirmed cases of the
illness.
Italy Coronavirus Deaths By prior illnesses(%)
No other illness
0 .8
7
25.1
1 other illness- -
48 .5
--3 or moreillnesses
25 .6
2 other illnesses--
Source: ISS Italy National Health Institute, March 17 sample
The new study could provide insight into why Italy's death rate, at about 8% of
total infected people, is higher than in other countries.
The Rome-based institute has examined medical records of about 18% of the
country 's coronavirus fatalities, finding that just three victims, or o .8% of the
total, had no previous pathology. Almost half of the victims suffered from at
least three prior illnesses and about a fourth had either one or two previous
conditions.
More than 75% had high blood pressure, about 35% had diabetes and a third
suffered from heart disease.
The average age of those who've died from the virus in Italy is 79.5. As of
March 17, 17 people under sohad died from the disease. All of Italy's victims
und er 40 have been males with serious existing medical conditions.
While data released Tuesday point to a slowdown in the increase of cases, with
a 12.6% rise, a separate study shows Italy could be underestimating the real
number of cases by testing only patients present ing symptoms.
NIH-000446
According to the GIMBE Foundation, about 100,000 Italians have contracted
the virus, daily Il Sole 24 Ore reported. That would bring back the country's
death rate closer to th e global average of about 2%.
- With assistance by Karl Maier
NIH-000447
Sent: Tue, 17 Mar 2020 18:13:38 +0000
To : Fauci, Anthony (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];A uchincloss,
Hugh (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E]
Subject : RE:Covid-19 coverage in Nature Reviews Immunology
Dear Alexandra,
Thank you for your kind words.

Yes, we can send yuu references of notable papers
My chief of staff, Greg Folkers (cc'd here), will be my conduit/surrogate.
Regards,
AS Fauci
From:Alexandra Flemming <A.Flemm ing@nature .com>

To: Fauci, Anthony (NIH/NIAID) [E] <O. -----~ = (b)( ~ >
Subject: Covid-19 coverage in Nature Reviews Immunolo gy
Dear Tony,
Thank you again for contributing the fabulous year in review article to Nature reviews Immunology last
year!
Given the current pandemic, we can only imagine how incredibly busy you are at the moment. At Nature
Reviews Immunology we have decided that we would like to introduce an in-brief section that provides
a brief overview of the most notab le/important research on SARS-CoV -2, particular ly with regards to its
immunopathology and vaccine development. To this end, we are recruiting a small number of advisors
to point us in the right direction - this wou ld involve no actual writing, just sending us references to the
papers as and when they come out . Would you, or a member of your team, be willing to act as an
advisor for this project, by sending us between 1-5 references for notable papers per month? We feel
that particularly in th is fast evolving situation, it is of paramount importance that amongst the deluge of
data, scientists are guided towards the most important papers.
I look forward to hearing from you ,
With best regards,
Alexandra
Dr AlexandraFlemming
NIH-000448
Chief Editor
Nature Reviews Im munology
Natu re Research
4 Crinan Street, London Nl 9XW, UK
(b)(6)
a.f lem ming@natu re .com
www .nat ure.com/n ri
i~~ CELEBRATING
1869-2019
150YEARS
nature
DISCLAIMER:This e-mail is confidential and should not be used by anyone who is not the original
intended recipient. If you have received this e-mail in error please inform the sender and delet e it from
your mailbox or any other storage mechan ism. Springer Nature Limited does not accept liability for any
statements made wh ich are clearly the sender's own and not expressly made on behalf of Springer
Nature Ltd or one of their agents.
Please note that Springer Nature Limited and their agents and affiliates do not accept any responsibility
for viruses or malware t hat may be contained in th is e-mail or its attachments and it is your
responsibi lity to scan the e-mail and attachments (if any).
Springer Nature Limited . Registered office: The Campus, 4 Crinan Street, London, Nl 9XW. Registered
Number: 00785998 England.
NIH-00044 9
From: (b)(6)
Sent: Tue, 17 Mar 2020 10:42:33 -0400
Cc: Barasch, Kimberly (NIH/NIAID) [C];Lane, Cliff (NIH/NIAIO) [E];Marston , Hilary
(NIH/NIAID) [E]
Subject: Fwd: Invitatio n: BIO Coronavirus Collaboration Initiat ive
Attachments: INVITATION_FauciBIO COVID19 Virtual Summit 15Mar2020.pdf, ATTOOOOl.htm
Let us discuss and decide one way or another.
From: Hannah Dorsey <hdor sey@bio.org >

Date: March 16, 2020 at 3 :51:02 PM EDT
To: "Fauci, Anthony (N lH/NlAID ) [E] " --------,;-, =
Cc: "Conrad, Patricia (NIH/NIAID) [E]" :r-----,---
>, "Marston,
Hilary (NIH/NIAID) [E]"
<parthur@bio.org> --------- (b) C6
Subject: Invitation: BIO Coronavirus Collaboration Initiative

b, Phyllis Arthur
Dear Dr. Fauci,
On behalf of BIO, I wou ld like to inv ite you to participate in our multi-stakeholder COVID-
19 Collaboration Virtual Summit which will take place March 24-25. We are hosting this
summit in order to facilitate near-term collaboration among indust ry, government,
academic and non-governmental experts to help confront this growing and unpredictable
publ ic health crisis.
We would like you to be a speaker during the Plenary session on March 24th. We would
like you to give 5-10 minutes of opening rema rks to the Summit participants. Please note
that the plenary session of the event will be open to the press, while the remaining
sessions will be closed to just invited guests to ensure a robust discussion and maximum
collabo ration. You are welcome to attend any of the subsequent Breakout sessions
scheduled over the two days.
This virtual meet ing will take place over two days:
• March 24th: 10:00am -11:45am - Plenary Session
• March 24th: 12:00pm - 2:30pm - Treatment Break Out Session
• March 25th: 10:00am - 12:30pm - Prevention Break Out Session
• March 25th: 1:00pm - 3:30pm - Diagnostics Break Out Session
NIH-000450
Attached is the full invitation to our event from our CEOJim Greenwood, the full agenda
will be to follow. Please let us know if you would be available as a speaker for the Plenary
session on March 24th .
Best,
Hannah Dorsey
Coordinator, Health Policy
Biotechnology Innovation Organization (BIO)
1201 Maryland Ave. SW, Ste. 900
Office: (202) 962-6644
hdorsey@bio.org
ww w .b io.org
NIH-000451
From: (b)(6)
Sent : Tue, 17 Mar 2020 07:30:48 -0400
Subject: Fwd: Updates
From: "Fauci, Ant hony (NIH/NIAID) [E]"

Date: March 17, 2020 at 7: 14:00 AM EDT
To: Janet Tob ias <jane t@ikanamedia.com >
Subject: RE: Updates
Thanks, Janet. Please conti nue to work with Patty to make t his happen.
Best regards,
Tony
From: Janet Tobias <janet@ikanamedia.com>

-----~~
To: Fauci, Anthony {NIH/ NIAID) [E]
Subject: Updates
------- (b)(6)
Dear Tony:
Quick updates , we have partnered with Story Syndicate/John Hoffman
(who was in charge of First In Human and Alzheimer's and Obesity
projects) on the film about your life . This will help us make sure that
next year this film has maximum impact and we carry the message
widely of "men serving men" and public health . NIH Communications
head John Burklow, and the main office , knows and is very supportive
and excited about the potential impact. They have worked super
closely with John in the past.
We are putting in the request for filming with the Vice President's
office and we will work with Patty to figure out how to film your work
and NIAID's work on COVID-19, which is important. But safety and
NIH-000452
modelling appropriate behavior always first and foremost. Crews on my
side tiny and all from Unseen Enemy.
Thanks for everything, every day, and stay healthy,
Janet
PSThe Aids project, and the educational partnership with Howard

Hughes Medical lnsitute continues in good state, just on hold as it
should be.
NIH-000453
Sent : Tue, 17 Mar 2020 03:04:31 +0000
Subject : FW: Question about COVI0-19 Mechanism of Transmission
Please respond.
From : EDWARD EITZEN (b)(6)
To : Fauci, Anthony (NIH/NIAID) [E]------- ~=
(b)(6)
Subject : Question about COVI0-19 Mechanism of Transmission
Hi Tony:
Thank you for what you are doing for our country to try and limit the consequences of COVID-19. Many
Americans are hanging on your every word, as they should be, and that includes me.
A question about COVID-19 mechanism of spread: The reported reproductive number from China of
about 2.6 indicates a likelihood of large droplet spread as the mode of transmiss ion from person to
person . My question is - could there be a component of airborne spread (droplet nuclei) wi th this virus?
If super spreaders exist with COVID-19, is airborne spread possible? Knowing the answer to th is question
would help to inform decisions about PPEand Decontamination in settings such as Emergency
Departments . If this is not already known definitively, could NIOSHand some key partners possibly study
it in current quarantine settings?
Thanks, Tony . God bless you and you r important work!
Best, Ed
Edward Eitzen, M.D., M.P.H.

Senior Partner, Biodefense and Public Health Programs
Martin-Blanck and Associates
2034 Eisenhower Avenue, Suite 270
Alexandria, VA 22314-4678
Office Phone: 719-548-9207

Cell Phone: (b)(6)
Email:
------- (b) (6)
NIH-000455
Sent: Tue, 17 Mar 2020 03:02:00 +0000
Subject : FW: Flu statist ics
Please respond for me.

From: Candace Gunn --------- (b-,-..
)(=6)
-----~~ (b)( >
Subject: Flu statist ics
Dear Dr. Fauci,
First of all, thank you so much for the wonderful job you are doing regarding the infomrntionon the coronavirus.
You were excellent with Chris Wallace!
Js it possible to give facts on the FLU - number of people who have had it and how many have died - during the past
month? I wonder if that might perhaps slow down the media frenzy.
Many thanks for yow- consideration of my question.
Best regards ,
Candace Gunn
NIH-000456
Sent : Tue, 17 Mar 2020 03:00:44 +0000
To : Anderson, Roy M
Subject : RE: Lancet Commentary on COVID-19
Roy:
Thank you for your kind note. Very nice article! I hope that all is well with you .
Best,
Tony
From: Anderson, Roy M

-----------
--------,
(b) (6) >
.----..-.=
---------
Subject : Lancet Commentary on COVID-19
(b)(6)
Dear Tony,
I thought the attached may be of interest to you .
You have been doing a very good job in communicating the important issues around this epidem ic - well
done.
Kind regards,
Roy
Professor Sir Roy Anderson FRSFMedSci

Director
London Centre for Neglected Tropical Disease Research (LCNTDR)
Department of Infect ious Disease Research,
Faculty of Medicine
Imperia l College London Praed Street
London W2 lPG
Te (b)(6)
(b)(6)
Assistant - (b)(6)
------.==============---- ~=
Project Manager - (b) (6)1
Man ager LCNTDR -=================~~;-
(b) (6)
NIH-000457
Sent : Tue, 17 Mar 2020 02:59:48 +0000
Subject : FW: Modeling of COVID-19 from Mike Levit
Attachment s: 1.Analysis_of_Coronavirus-2O19_Data_Michael_Levitt-vl.pdf,
1.The_Corona_Chronologies. Part 11- Rest of the World. Michael_Lev itt,Stanford.pdf,
3O.The_Corona_Chronologies. Part I - China. Michael_Levitt,Stanford.pdf
Please take a look and see what you thin k.
From:Tabak, Lawrence (NIH/OD) [El (b)(6)>

Se nt: Friday, March 6, 2020 8 :46 PM
(b) (6) >

------ ==
To: Collins, Francis (NIH/OD) [El (b)(6); Fauci, Anthony (NIH/N IAID) [El
Cc: Lauer, Michael (NIH/OD) [El (b)( >

Subject: Modeling of COVID-19 from Mike Levit
Francis, Tony-
Mike Levitt (Nobel prize in Chemistry, 2013) sent the attached model ing of the COVID-19 epidemic to
Mike Lauer. I don't know if this will prove useful but wanted to pass it along in case.
He indicated that he was amazed to see how an Excel level analysis could allow him to predict the China
epidemic would end as early at 2-Feb and get what he considers the best estimates for case fatality
rat io . His first report from 2-Feb is attached as well as his most recent two-part report.
Larry
NIH-000458
Sent : Tue, 17 Mar 2020 02:54:15 +0000
Subject : FW: Community -Spread Covid-19 Contact Tracking
Take a look and handle.
From:John G. Boland (b)(6b

To: Fauci, Anthony (NIH/NIAID) [E]-------=- (b)c-c
(= >
Subject : Community-Spread Covid-19 Contact Tracking
Dear Dr. Fauci :
Without success. for more than a week, I have tried to reach any techie CDC person about the problem of
community-spread Covid-19 contact tracking.
Though your workload is unimaginable. I thought you might personal ly know and could provide contact
information of an appropriate CDC or NIH epidemio logist.
***Brief Summary of Concept***skip to End, if obvio us***
Had I bee n to a doctor or ER with a virulent disease, they would immediately have asked where I had
been , with whom, and for what duration . With that information, epidem iolog ists can notify and test those
contacts ... and their contacts ... before their symptoms are eviden ced.
This manual contact tracking process is workload intensive, calendar -day wasting, data-poor, and
inaccurate .
"Location tracking" can provide the raw data needed to identify potential contacts automatically , early , and
thorough ly, from information routinely collected by network providers.
The location , at a date and time, of a vast number of anonymo us cell phones , over the preceding two
weeks, wo uld be very useful for identifying the index case and subsequent contacts of an individual.
As an illustration , the New York Times published , on 19 December 2019 . "Twelve Million Phones, One
Dataset , Zero Privacy" about the commercial location tracking industry :
https://www .nytimes.com/interactive/20 19/ 12/19/op inion/location-trackinq-cell-phone .html
***End of Summary***
Ignoring the techie and legal detai ls. can you suggest an appropriate contact, whi le Covid-19 infections in
the United States are few?
Your continuing dedication , candor , and data-driven focus are refreshing and very much appreciated, Dr.
Fauci.
Best ,
John G. Boland
NIH-000459
(b)(6) .__ ___
_____ (24 hr, text or leave msg if no answer)
NIH-000460
Sent : Tue, 17 Mar 2020 02:53:27 +0000
To : Tom Frieden
Subject : RE: FYI
I tried to call you this evening but got voice mail that said you were not accepting calls. Let us try to connect soon.
-----Orig inal Message-----

From: Tom Frieden _________ (b
""~,....
c= -
Sent: Wednesday , March 4, 2020 l J: 12 AM
To: Fauci, Anthony (NIH/NIAID) [E] ._______ ------~~ (b
_)_(6)
_.>
Subje ct: FYI
h tlps ://the h iiI.co m/po Iicy/ healthca re/ 4 8560 4- mee l-the- fede ra I- govern men ts-co ron a virus -exper t
I know you don't read the papers but "super smru1:,super able to communicat e very cleru·ly, with a ve1y deep ethical
commitment to doing the right thing" is exactly what f think , not just what I'm telling the media.
All the best ,
Tom
NIH-00046 1
Sent : Tue, 17 Mar 2020 02:48:31 +0000
To : Pardis Sabeti
Subject : RE: Planning for a hearing on Global Health Security Team
Pardis:
Sorry that I d id not respond sooner. I am getting over 1500 emai ls per day and this one got
lost in the pile . Anything that you can do to help would be welcome.
Best,
Tony
From : Pardis Sabeti (b)(6)

Se nt : Tuesday, March 3, 2020 9:31 PM
To: Fauci, Anthony (NIH/NIAID) [E]-------~= (b)(6)
Subject : Fwd: Planning for a hearing on Global Health Security Team
Dear Tony,
I hope that all is well given our current circumstances. I am sure you are very busy, so apologize for the
intrusion, but wou ld love you r insight if you have a moment .
I just had a very interesting talk today with Wendy Ginsberg on the House Committee on Oversight and
Reform, w ith an opportunity to testify at a hearing next Wednesday {email attached) .
While I am very excited for an opportunity to advocate for further funding and operational support for
pandemic preparedness, I also recognize that th is forma t may not be the right one to do so. Moreover , I
may not be the right person to do so, as I think you, Francis, or Eric Lander would do far better than
me.
I imagine they have already asked you to part icipate, and would just love any insight you might have as
to whether I should consider do ing this, and if so, how I should proceed . I really only would want to do
so if it is a place where I can help the larger infectious disease community and make a positive
nonpolitical impact.
Thanks so much fo r your consideration,
Pardis
From: Ginsberg, Wendy ------------,,~

------------ Cb)C >

Date : Mon, Mar 2, 2020 at 8:54 AM
Subject: Planning for a hearing on Global Health Security Team
To: (b)(6)>
NIH-000462
Richard Preston pointed me in your dire ction, saying you wou ld be the right person to help me think
thro ugh a potential hearing o n codifying the global health security team on the National Security
Council.
The hearing (as of right now in my mind) wou ld
1. Examine the lessons learned from the Ebola and ot her previous outbreaks about how federal
government design and operations can fac ilitate or hinder global healt h and stemming
pandemics;
2. Analyze how eliminating the global health security team has put us several steps behind where
we need to be in figh ting coronavirus ; and
3. Argue for cod ifying th e team and its leader ship as part of th e larger national security apparatus
and avoid kowtowing to outbreak fatigue.
I'm hoping you might be w illing to speak w ith me about your expertise and thoughts in this area. I'm
defin itely not the expert and I would love someone w ith your background to ensure I'm getting this
story right - and that I have the right people at the witness stand to tell it .
Would you have time to ta lk today or some time very soon? We are hoping to have this hearing next
week .
Yours,
Wendy
Wen dy Gins berg. Th.D.

Staff Director
House Committ ee on Oversight and Reform
Su bcommittee on Government Opera tions
(b)(6)

Professor, Harvard University & Harvard School of Public Health
Howard Hughes Med ical Institute
-====~~-----------
Assistant : (b)(6)
Phone:
------ (b)(6)
Website: www .sabet ilab.org
NIH-000463
Sent : Tue, 17 Mar 2020 01:46:44 +0000
Subject : FW: Wall Street Journal request
Please decide if we can do this.
From:Wi llick, Jason <jason .willick@wsj.com>

To : Fauci, Anthony (NIH/NIAID) [E] ------
--------
::;..,..-,=
(b)(6 )1>
Subject : Wall Street Journal request
Dear Dr. Fauci,

My name is Jason Will ick wi th t he Wall Street Journa l. I was wondering if you would be willing to ta lk to
me for the WSJweekend interview section on pandemics and the coronavirus - the US response but
also the broader challenges from infectious disease. I know you are beyond busy, but I thought I'd ask.
Let me know if this is a possibility and I can discuss more details.
Jason
NIH-000464
Sent: Tue, 17 Mar 2020 00:27:13 +0000
To: M ichael liu
Subject: RE: Great advice from Chinese expert
M ichael:
Thank you for your note. We indeed have learned much from our Chinese colleagues .
appreciate your bringing these issues to our attention.
Best regards,
Tony
From: Michael liu (b)( >

------~~
--------
Subject: Great advice from Chinese expert
(b)(6)
Dear Dr. Fauci,
Dr. Wenhong Zhang, has become very famous in China's war against COVID-19 because of his
great excellence in anti-virus. Dr. Zhang is the D irector of the Infectious Disease Department of
Huashan Hospita l in Shanghai. He is very good according to my observation all long. Another
great doctor in China is Dr. Nanshan Zhong.
According to Dr. Zhang's video at https ://www. thepaper.cn/newsDeta il forward 6537248 ,

COVID-19 can really be prevented with 3 key measures, i.e. to keep social distancing , wash
hand s frequently and wear masks. I strongly suggest American people shoul d wear masks like
Chinese, Soutl1 Korean people, etc., because even China ' s highest leader, Mr. Jinping Xi, wears
masks. If it is difficul t for all the US p eople to do this now, I suggest working staff in airport s,
supern1arkets and other pub lic places should wear masks firstly in order to avoid crossing
infection.
Further, Dr. Zhang said, if a p erson is still infected though he/she takes the above 3 measures
carefully, the person must be infected by his/her family members . So I propose the concentrated
isolation of mild confirmed cases should be considered as I advised yesterday.
I strongly sugges t American government should learn precious experience of anti-COVID-19

from and cooperate with the mainland China, Taiwan, South Korea with an open mind. If you
need any help to contact with Dr. Zhang , I will do what I can.
I am very confident that the US government will lead American people to win the anti-COVID-
19 war by you and other great experts. Science, expertise and great learning are best medicines.
God bless you! God bless America, China and the whole world !
Best regards,
NIH-000465
Michael Liu
~f!J:A:Fauci, Anthony (NIH/NIAID) [E] [mailto:

~~la Ia.J:2020if3J:315B 13:28
--------
(b)(6)
IHlf!l:A:
Jingm ing Liu (Michael) < (b)(6)
----------
3:.B:Re: Great Advice on How to Avoid Family Spread of COVID-19
A .S. Fauci.
Sent from my iPhone
On Mar 15, 2020, at 1:26 PM, Jingming Liu (Michael) (b)(6)> wrote :
--------
Dear Dr. Fauci,
My name is Michael Liu. My family are living in now. I have been following
(b)(6)
spread of COVID-19 (Corona Vims) closely because such virns is very contagious and
dangerous.
If a person is mildly sick with COVID-19 , the CDC now suggests the person shou ld "stay home
except to get medical care", i.e. home-isol ation, according to
https ://www.cdc.gov /coronav irus/2019-ncov /downloads /slck-with- 2019-nCoV-fact- sheet.pdf
However, the home isolation may result in family spread of COVID-19 in certain kinds of
families, e.g., parents are infected but their kids are too young to take care of them, adults are
infected but their parent s are too old and risky to look after them (if they live together) , an old
husband /wife is infected but the spouse is too vulnerable to take care of him/her, etc. In such
scenarios, the home isolation may increase family spread and even comm unity spread risks in the
us.
A great method to avoid home-isolation risks is the concentrated isolation, i.e. to isolate
mild symptomatic people in a concentrated place instead of thefr homes.
The concentrated isolation can avoid the above family spread risks, provide professional medical
help to isolated people, reduce menta l pressure of other family members, etc., so that it can
reduce community spread risks. Such method has been proved to be effective by China's war
against COVID - 19.
The conce ntrated place can be a hotel , university dorm building, etc., which should be easily
managed for medica l surveillance.
NIH-000466
The concentration isolation may be voluntarily chosen by relevant families at the beginning, and
adjusted to apply subject to different conditions.
Hope the above advice helpful!
Best regards,
Michael Liu
NIH-000467
Sent: Tue, 17 Mar 2020 00:23:16 +0000
Cc: Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Stover, Kathy
(NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E]
Subject: RE:offer from Mark Zuckerberg
I will write to or call Mark and tell him that I am interested in doing this. I will then tell him
that you will get for him the name of the USG point of contact. I agree it shou ld be Bill Hall
who could then turf to the White House Com ms if he wishes
From: Billet, Courtney (NIH/NIAID) [E] (bH >

Sent: M onday, March 16, 2020 6:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] -----~~ (b)(6)>
Cc: Folkers, Greg (NIH/NIAID) [El (bH ; Conrad, Patricia (NIH/NIAID) [El
(b)(6); Stover, Kathy (NIH/NIAID) [E) (bH >; Routh, Jennifer
"'.'"
(N- 1-H/-:--
N-IA D):--:
- l':"" [':""
El:-===::::::...-____;-= (b'"'""
)(= >
Subject: ASF: offer from Mark Zuckerberg
Per email below, Mark Zuckerberg has extended a few offers to do videos with you that we would be
happy to seek clearance on for you to do, if you are amenable. These would have the weight and impact
of television - really, more so. Please advise if you want to do and we will seek clearance with VP office
and work with Patty to sort out the logistics.
But an even bigger deal is his offer (b)(4)

- The sooner we get that offer up the food-chain the better. I gave Bill Hall a heads-up about this
opportunity and he is standing by to discuss this with HHS and WH comms, but I didn't want him to do
anything without you being aware of the offer. Is it OK if I hand this aspect off to Bill to determine who
the best point of contact would be so the Administration can take advantage of this offer, soonest?
Do you plan to call MZ? His cell number is in his message below.
From: Mark Zuckerberg (b)(6)

------ ..-.-,=
Subject: Thanks and ideas -------- (b)(6J>
Tony:
I wanted to send a note of thanks for your leadership and everything you're doing to make our country's
response to this outbreak as effect ive as possible. I also wanted to share a few ideas of ways we could
help you get your message out, but I understan d you 're incredibly busy, so don't feel a need to reply
unless these seem interest ing.
This isn't public yet, but we 're building a Coronavirus Information Hub that we're going to put at the top
of Facebook for everyone (200+ million Americans, 2.5 billion peop le worldwide) with two goals: (1)
NIH-000468
make sure people can get authoritative information from reliable sources and (2) encourage people to
practice social distance and give people ideas for doing this using internet tools. This will be live within
the next 48 hours.
As a central part of this hub, I think it would be useful to include a video from you because people trust
and want to hear from experts rather than just a bunch of agencies and political leaders. This could be
done in a number of formats if you're open to it. Probably best would be recording a Q&A where you
answer people's top questions , but we'd be open to other fo rmats too.
I'm also doing a series of livest reamed Q&As with health experts to try to use my large following on the
platform {100 million followers) to get authoritative information out as well. I'd love to have you do one
of these Q&As. This could be the video we put in the Coronavirus Hub or it could be a different thing
that we distribute separately, but I think it could be effective as well.
Again, I know you're incredibly busy, so don't feel t he need to respond if this doesn't seem helpful. If it 's
easy to talk live, give me a call anytime on my mobile phone: (b) (6) .
Thanks again for everything you're doing .
Mark
NIH-000469
Sent : Tue, 17 Mar 2020 00:22:45 +0000
To: Mark Zuckerberg
Cc: Conrad, Patricia (NIH/NIAID) [E);Billet, Courtney (NIH/ NIAID) [E];Barasch,
Kimberly (NIH/NIAID) [CJ
Subject: RE:Thanksand ideas
Mark:
Thank you for your kind note. I tried to cal l you, but got voice mai l. FYI, my cell phone
number is (b)(6) Your idea and proposal sound te rr ific. I would be happy to do a
video for your hub. We need to reach as many people as possible and convince them to take
mitigation strateg ies seriously or th ings will get much , much worse. Also, your id ea about (b)(4 )
is vey exciting. I am copying my Special Assist ant, Patty Conrad. Her office numbe r is (b)(6)
----- Cb)( • Please have your people contac t her to arrange for the video. I am also copy in g the
Director of my Communications and Governmen t Relations gro up . She can put your people in
contact with the best person who cou ld be the US Government poin t of con tact for (b)(4).
Best regards,
Tony
From: Mar k Zuckerberg (b)(6)>

To: Fauci, Anthony {NIH/NIAID) [E] ------~~ (b)(6)>
Subject: Thanks and ideas
--------
Tony :
I wanted to send a note of thanks for your leadership and everything you 're doing to make our country's
response to this outbreak as effective as possible. I also wanted to share a few ideas of ways we could
help you get your message out, but I understand you're incredibly busy, so don't feel a need to reply
unless these seem interesting .
This isn't public yet, but we're building a Coronavirus Information Hub that we're going to put at the top
of Facebook for everyone (200+ million Americans, 2.5 billion people worldwide ) with two goals: (1)
make sure people can get author itative information from reliable sources and {2) encourage people to
practice social distance and give people ideas for doing this using internet tools. This will be live wit hin
t he next 48 hours.
As a centra l part of this hub, I think it would be useful to include a video from you because people trust
and want to hear from experts rather than just a bunch of agencies and politi cal leaders. This could be
done in a number of fo rmats if you're open to it . Probably best would be recording a Q&A where you
answer people's top questions, but we'd be open to other fo rmats too.
I'm also doing a series of livest reamed Q&As with health experts to try to use my large following on th e
platform (100 million followers) to get authoritative information out as well. I'd love to have you do one
NIH-000470
of these Q&As. This could be the video we put in the Coronavirus Hub or it could be a different thing
that we distribute separately, but I think it could be effective as well.
Again, I know you're incredibly busy, so don't feel the need to respond if this doesn't seem helpful. If it 's
easy to talk live, give me a call anytime on my mobile phone: (b)( 6)
Thanks again for everything you're doing.
Mark
NIH-00047 1
From: (b)(6)
Sent: Mon, 16 Mar 2020 19:40:27 -0400
Subject: Fwd: Coronavirus antibodies
Please handle
From: Andrew Sprouse (b)(6)

----------
To: "Fauci, Anthony (NIH/NlAID ) [E]" ------~~
Subject: Re: Coronavirus antibodies
--------- (b)(6J:
If millennials are spread ing the corona virus sho uld we allow them to be tested with
milder symptoms? Otherwise they have no idea they have it.
On Mar 13, 2020 , at 5:27 AM , Fauci, Anthony (NIH/NIAID) [E]

(b) (6)>wrote:
It likely would
On Ma r 13, 2020 , at 2:58 AM , Andrew Sprouse

(b)(6J:
How about human breast milk? Would it have the

antibodies as well?
Sent from my iPbone
On Mar 12, 2020, at 7:53 PM,

Andrew Sprouse
---------
Dr. Fauci,
(b) (6l> wrote:
If China is taking patients and using the.

plasma/ant ibodies from them to help cure other
patients why couldn ' t we do that to heaittw
people to give them immunity to the yip.I*?
Andrew
NIH-000472
NIH-000473
(bX5) -PCE
NIH-000474
Sent: Mon, 16 Mar 2020 23:19:56 +0000
To: Monticone, Giulia
Subject: RE:COVID19emergency
Your arguments are solid.
From:Monticone, Giulia (b)(6)>

To: Fauci,Anthony (NIH/NIAID) [E]-------=- (b)c(=
-c >
Subject: COVID19emergency
Dear Dr. Fauci,
I am a postdoc researcher working at LSU health sciences center In New Orleans. I would like to
communicate my concern about the COVID19 in the US.
I am Italian and my partner is Chinese and we have been carefully following the COVID19
spread first in China and now in Italy and Europe. Based on my scientific and personal
knowledge I am confident to say that the US is only few weeks ahead of What is happening in
Italy now and this could on ly be stopped if strict measures will be taken in the enti re country as
soon as possible.
If you have the power , I ask you to please try to convince the government to apply such
measures, even if this means to shut down the entire country for some weeks. I know that the
economy and money interests are what often prevents to take such decision, but in this case
we are ta lking about life and death and we cannot risk this high price.
We have a very clear example of how severe the COVID19 can be if we do not act on t ime and
th is is unfortunately my country at this time. We also have a good example, China, in which
very aggressive measures have been applied and, despite some delay in their application at
first, they now have reached a strong regression in the virus spread and they gradually can
restart the country. China measures were to close every city borders, close working places and
every non essent ial activity. They asked the population to stay at home and go out only for food
and health emergencies. I think th is is what we should do in US too.
A recent study from Italy in which they tested every person in one It alian city showed that the
50-70% of the peop le positive for the virus were asymptomat ic. This is such an impor tant
information that tells us the only way to prevent the spread is to prevent the people from
moving because we cannot really know who is caring the virus. Also, screening is important and
should be ideally extended to everyone. http s:// www .repubblica.it /s alut e/ medicina-e-
rice rca/ 2020/03/16/n ews/ coro navir us st udio ii 50-
75 dei casi a vo sono asintomat ici e molto contagiosi-251474302/
NIH-000475
My lab is based in New Orleans where the number of COVID19 cases is now growing fast.
However, there is no sign from the university or my institute to close. We are working as usual
with only some mild restrictions even if we have colleagues that are at home sick, or worse,
that showed up at work coughing. The city mayor applied some restrictions but the people are
still celebrating events on the street. Up to today we were acknowledged that we have a
presumptive positive case in the building where we live. We are doing what we can as
responsible individuals but tomorrow we will go to work again not knowing if we are spreading
the virus.
I thank you for reading this email and I hope my arguments are solid and accurate enough to
encourage you to take action.
Best wishes,
Giulia
NIH-000476
Sent: Mon, 16 Mar 2020 21:28:51 +0000
Subject: RE: INTERVIEWQUOTE FOR ESPNFROM YOUR CALLWITH CARLODELRIOS
I did not say that they necessar ily should actually cancel the tournament, i.e . not play the
games. They could still play the tournament and have it televised without having many
spectators in the gym. There is a big difference there. And I did not say that all sports should
make a similar call

To: Fauci, Anthony (NIH/NIAID) [E) ------- =---c-c=
(b)(6)
Subject: INTERVIEWQUOTE FOR ESPNFROM YOURCALLWITH CARLODELRIOS
PLEASEADVISE
Patricia L. Conrad
Nat ion al Institute of Allergy and Infectious Diseases
(b)(6)
301-496-4409 fax
Disclaime r:
The informat ion in this e-mail and any of its attachments is confidential and may contain sensitive information. It sh ould not be used
From: Deat rick, Elizabeth (NIH/NIAID) [C) (b)(6)>

To : Conrad, Patricia {NIH/NIA ID) [E) -------~~ (b)(6)>
Cc: NIAID COGCORE<COGCORE@mail.nih .gov>; NIAID Media Inqu iries <mediainqu iries@n iaid.nih.gov>;
NIAID FOG<fog@niaid .nih .gov>
Subject : Interview request: ESPN
ESPN
Tisha Thompson
(b)(6)
Tisha.Thompson@esp n.com
NIH-000477
Deadline: COBtoday
Hi Patty,
This reporter is writing about the NCAA's reaction COVID-19, and would like confirmation that the
following actually occurred:
Dr. Brian Hainline said two members of the NCAA's advisory panel, Dr. Colleen Kraft and Dr. Del Rio,
spoke with Dr. Fauci, who said he would back the NCAA in its decision to cancel the tournament. That Dr.
Fauci 11wholeheartedly" agreed and said to the NCAA reps, "Not only would he back us that this was the
right thing to do ...he believed that all sports should make a similar call. 11
The reporter would like a quick call/confirmation this evening, before they publish the story.
NIH-000478
Sent: Mon, 16 Mar 2020 21:17:44 +0000
To: Jon LaPook
Subject :
_______
RE:Great news.
.., . Thanks again. --------------------- (b)(6]
Wonderful!!
-----Origi11alMessage-----
From: Jon LaPook ,,;::;..----- (b
~)~(6)
=>
Sent: Monday , March 16, 20204:13 PM
To: Fauci, Anthony (.,.
NI.;..H
_ IN
_ I;_
A.;..
JD
-----
_ )::..::..
[E..:.
]....!::=====
-=s:"=<t
(b
=)=(6)
=->---------- ~=
Subject: Great news . (b)(6) . Thanks again .

Chief Medical Correspondent,CBS News
NYU Langone Health
Twitter @DrLaPook
NIH-000479
Sent: Mon, 16 Mar 2020 21:17:06 +0000
Subject: FW: Treatments that may be useful against the novel coronavirus
Please respond.
From: PEAK (b) (6b

'""'
(=
6)>
Subject: Treatments that may be useful against the novel coronavirus
Dear Dr. Fauci:
I am a Cb)(6) assistant attorney general of the States of New York and Oregon. I have received
some information that may be useful in dealing with the novel coronavirus, but I am not able to
evaluate this information personally. It is in an a1iicle authored by a former asst. secretary of the
US Treasury. I would like to make this information available to you for evaluation, and to that
end I am copying it immediately below.
Sincerely ,
Robert Roth
Eugene, Oregon
Treatments for Coronavirus That Have Worked in China
Paul Craig Roberts • March 13, 2020
These are scientific papers showing effective treatments for coronavirus being used in China
Hydrox ychloroqu ine
https ://www.ncbi.nlm.nih.gov/pubmed/32 l 506 18
https://reader.elsevier.com/reader/sd/pii/S0924857920300820?token =92457EBC4 E7 5F28D02F3 l 1f610
OB2D48113£ 501DC04D49C824E6 FD819F77BE34A99 378 4AEAC0D l 15710BDB7BCC2175B5
These research papers show great antiviral promise for both HydroxychJoroquine and Chloroquine. The
Chinese have started using them. So should we. The antiviral effects were originally disco vered in Europe
during SARS, but then forgotten about as SARS was so aggressive it killed the host too quickly and died
out. French ProfRaoult and others have helped the Chinese advising them to p roceed in this way and they
had the good sense to trial it.
Unlike vaccine s and costly new antiv irals, Hydroxychloroquine and Ch loroqu ine are generally safe, very
well tested , cheap and readily available today. They could be a real game changer. Please publish and
dissemina te. Please also re -refer to the Blaylock cytokine paper to emphasize the importance of vitamin
C, D3 etc.
Hydrox ychl oroquine and Chloroqu ine
https :// www .ncbi.n lm .nih .gov/pubmed / 32 l 506 18
https ://reader.elsevier.corn/reader/sd/pi i/S09248 57920300820?token =92457EBC4E7 5F28D02F3 11F610
DB2D48113E50 1DC04D49C 824E6FD819F77BE34A9937B4AEAC0D 1157 10BDB7BC C2175B 5
https ://www.ncbi.nlm.nih .gov/pubmed/?term=chloroquine+coronavirus
(Republi shed from PaulCraigRobe 1ts .org by permission of author or representative)
NIH-000480
More at Roberts' homepage: https://www.paulcraigroberts.org/wp-
content/up loads/2020/03/ 14 2020 .010 12.pdf
NIH-000481
From: (b)(6)
Sent: Mon, 16 Mar 2020 16:23:09 -0400
To: Luo, Yiming (NIH/NIAMS) [E)
Cc: Kadlec, Robert (OS/ASPR/1O)
Subject: Re: concerns regarding CDC recommendations for COVID-19 prevention in
healthcare settings
Yiming:
Thanks for your note. I will forward your email to dr. Robert Kadlec who is in charge of the
SNS.
Best regards ,
To ny
On Mar 16, 2020, at 2:53 PM , Luo, Yiming (NIH/NIAMS) [E]
--------- (b)(6) > wrote:
Dear Dr. Fauci,
My name is Yiming and I am a clinical fe llow in rheumato logy at NIH/NIAMS. I have

colleagues and friends working in community hospita ls fighting against COVID-19 and we
are deeply concerned regarding the CDC inte rim recommendations for COVID-19
prevention in healthcare settings saying that "facemasks are an acceptable alternative
w hen the supply chain of respirators cannot meet the demand" . Currently hospitals in New
York City are asking their healthcare providers to wear surgical mask while t reating COVID-
19
COVID-19 is highly contagious in healthcare settings w ith a large proportion of healthcare

professionals being infected reported in early literature [1]. A recent study suggested that
asymptomatic patients can transmit SARS-CoV-2which puts potentially additional threats
to healthcare providers [2].
Although surgical mask can effectively prevent droplet transm ission, whether and to what
degree SARS-CoV-2can transmit through aerosol approach is still uncerta in. Studies with
2003 SARSvirus suggest a high level of concerns for aerosol transmission [3], and a recent
unpublished study from MedRxiv revealed that SARS-CoV-2has similar aerosol stability
compared to SARS[4).
Healthcare professionals are our frontline force against the coronav irus emergency and we
cannot afford even a slight probability of a large scale infect ions among healthcare workers
due to insufficient personal protective equipment. We hope that accessing the Strategic
National Stockpile (SNS)and any potential mass production program are actively being
considered to protect, and ultimately, save lives for U.S. people.
Sincerely,
NIH-000482
Yiming Luo, MD
[1] Wang et al, Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel
Coronavirus-lnfected Pneumonia in Wuhan, China. JAMA. 2020 Feb 7. Doi:
10.1001/jama.2020.1585.
[2] Chang et al, Protecting health care workers from subclinical coronavirus infect ion,
Lancet Respir Med . 2020 Mar;8(3):e13. doi: 10.1016/52213-2600(20)30066-7.
[3] Jones et al, Aerosol transmission of infectious disease. J Occup Environ Med. 2015
May;57(5) :501-8. doi: 10.1097/JOM.0000000000000448.
[4] Doremalen et al, Aerosol and surface stability of HCoV-19 (SARS-CoV-2)compared to
SARS-CoV-1.doi: https ://doi.org/10 .1101/2020.03.09.20033217 (MedRxiv)
NIH-000483
From: (b)(6)
Sent: Mo n, 16 Mar 2020 14:31:15 -0400
To : Redfield, Robert R. (CDC/OD);Deborah Birx
Algorithm for addressing people with mild upper respiratory symptoms in the age of Covid-19 .
This is a (b) (5)
From: Jon LaPook (b) (6)

To: "Fauci , Anthon y (NIH/NlAID) [E]" ----------==-=--=-=-
(b)( ·
Subject: (b) (4)
______ Algorithm for addressing people with mild upper respiratory

symptoms in the age of Covid-19.
Hi Tony,
Thank you so much for calling me this morning, and for your terrific help last night trying to
think through the issue (b)(4), (b)(6)
Given our discussion this morning, I think it would be very helpful if the task force on
coronavirus came up wi t h a clear algorithm for addressing issues related to people having
symptoms that could be from a cold, flu, or other virus - and not related to the virus that
causes COVID-19.
Let's say there's a hypothetical patient with some combination of sore throat, aches and
pain, low grade fever in the 99's by mouth, and cough; there's no shortness of breath. let's
say they are now proactively self-quarantined at home and are in the process of
evaluation. Questions include :
1. Who, if any, of the person's contacts within the previous days should be
contacted?
2. If it's only "close contacts" - those who were within 6 feet of the person for an
extended period of time:
a. What's t he definition of extended period of time?
b. Does any physical touch ing- such as a hug or handshake - immediately
mean there is significant contact?
c. How far back from the onset of the person's illness do we need to check
for "close contacts?" This gets to the issue of how long before symptoms
begin can asymptomatic shedding occur.
3. If no Covid-19 test ing is available or the person has been told they are not sick
enough for testing: how do we think about the potential risk to that person's
contacts, for example, at home or work?
NIH-000485
4 . If Covid-19 testing is available: before the result is back, what is t he advice for a
corporation or other entity where the person being tested may have infected
others through asymptomatic shedding of virus? Should the possible exposure,
even if relatively "low risk", set off any protocol that deals with trying to minimize
possible spread of the virus?
Thanks!
Jon

Chief Medical Correspondent , CBSNews
NYULangone Health
Twitter @DrlaPook
NIH-000486
From: (b)(6)
Sent: Mon, 16 Mar 2020 14:23:32 -0400
Subject: Fwd: coronavirus vaccine using cow pox-small pox example
Niaid inquiries
From: nishit sawa l (b)(

To: "Fauci, Anthony (NIH/NIAID ) (E]"
------~~ (b)(6J: , "Auchincloss ,
Hugh (NIH/NIAID ) (E]" (b)(6) , "Barasch, Kimberly
(NIH/NIAID) [C]" _____ (b
_>_<, "Conrad, Patricia (NIH/NIAID)
[E]" "Lerner, Andrea (NIH/NIAID) [E]"
(bH6)>,
(bH6), "Mascola, John (NIH/YRC) [E]"
(bH6J , "Graham , Barney (NIWVRC) [E]"
(b)(6)
Subject: coronavirus vaccine using cow pox-small pox example
hi sir,
currently an effective vaccine for covid-19 appears 12-16 months away. in view of
rampant spread of disease, we can use the cow pox-small pox idea to minimize the
disease mortality.
if general population at large was purpo sefu lly infected with human coronavirus
stra ins which classically cause mild URTI's, the chances of them gett ing infected or
more probably getting severe ly ill with covid-19 would be definitely reduced. we do
not need to make a vaccine of these strains - classically they cause mild , self-
limitin g URTI's.
we have these resources and can do this in a ve1y short period.
think over it - time to innovate like Edwa rd Jenn er did.
rega rds,
Dr Nish it sawa l.
Consultant Neurologist
Governmen t Medical Colleg e and Hosp ital .
Chand igarh ,India
NIH-000487
From: (b)(6)
Sent : Mon, 16 Mar 2020 13:45:28 -0400
To : Jethro Pen
Subject : Re: Steven Hilton of Fox News' Covid19 Question to Dr Fauci et al.
Stay tuned
On Mar 16, 2020, at 1:40 PM, Jethro Pen

-------- Cb)(6>\
>wrote :
Dear Dr Fauci:
Apo logies for further burdening your staff at this time of Covidl 9 crisis, by submitting
this question.
Fox News' Host Steven Hilton posed a ques tion to ou on his March 15th program: my
understanding of it - which my wife and I, (b)(6), believe to be a "good"
question - is as follows:
"Given the relative safety of all but the elderly and those whose immune systems are
compromised, and that they are far fewer than the rest of the population, why not
quarantine only them?"
Mr Hilton says he believes t here to be an answer, but it's not yet been given to the
public. For what it's worth, I too believe there's an answer . I'm less certain that it's not
been given . Below is the link to this matter on the Fox website.
https: //www .fox news .com/opin ion/steve -hilton - on-coronavi rus -dr-fauci -offic ials-m ust -
answer -t he-big- quest ion-america ns-are-asking
Thanks for such attention as this may be given. If in the present circumstances, that
means none, I get it; nothing further is necessary or expected.
Happy to t ry to provide anythi ng fu rt her which is needed or helpful.
Sincerely,
/s/ Jethro Pen
NIH-000488
From: (b)(6)
Sent : Mon , 16 Mar 2020 13:36:16 -0400
Subject : Fwd: March 26th hearing postponed
Yeah!
From: "Hallett, Adrienne (NIH/OD) [E]" ________ Cb

_H_6)
Date: March 16, 2020 at 1:23:40PM EDT
To: "Hodes , Richard (NIH/NIA) [E]" ---------=-c-=
------- CbH6), "Volkow , Nora
(NIH/N IDA) [E]"
.------ CbH6), "Sharpless, Norman (NIH/NCI) [E]"
(b)( 6) , "Fauci, Anthony (NIH/NIAID) [E]"
CbH6)"Bianc hi, Diana (NIH/N ICHD ) [E]"
CbH >, "Gordon, Joshua (NIH/NIMH) [E]"
________ _>_<6), "Collins,Francis IH/OD) @,l~ ------~
Cb Cb~H=6>1
Cc: "Kelley, Melinda (NIH /NIA/ERP) [E]" >, "Hobin,
Cb)C6)
Jennifer (NIH/NIDA) [E]" CbH , "Holohan, MK (NIH/NC I)
[E]" Cb>(6) , "Haskins , Melinda (NIH/NIA ID) [E]"
CbH6) >, "Kaeser, Lisa (NIH/NICHD) [E]"
C6J, "Ampofo, Phyllis (NIH/NIMH) [E]"
Cb>
CbH6)"Mitchell, Miche lle (NIH/OD) [E]"
(b)(6)
Subject: March 26th hearin g postponed
0MB is putting a ho ld on sending HHS witnesses to the Hill through the end of March . This
will indefinitely postpone our budget hearing.
Thanks for your patience,

Adrienne
Dear Agency Legislative Affairs Teams:
Due to the full Administration mobil ization underway, we are placing a temporary hold on
sending up government witnesses who are engaged in the coronavirus response. The
Executive Branch needs all of its resources directly focused on executing its day-to-day
respo nse to coronavirus. We will continue to p ractice "radical transparency" with Congress
NIH-000490
and the American people, but participation in hearings cannot continue to divert resources
from our response effort.
This pause is effective immediately. It is intended to last for three weeks, through the end
of March, though we will reevaluate if it needs to be extended at a later date .
Importantly, as noted above, this does not only include witnesses for hearings that are
explicitly focused on coronavirus, but also, to be determined on a case-by-case basis,
witnesses and agencies who are playing vital roles on the Task Force or the broader
Administration response, whether or not the hearing topic is coronavirus .
Therefore, please do not accept hearing invitations from Congress for hearings through
March if you believe they meet the above criteria . If you already have hearings confi rmed
that you believe fits th is cr iteria, please notify us immed iately. You will likely have to
postpone those hearings .
Four corners leadersh ip offices have already been notified of this policy.
Please reach out to 0MB if you have any questions, and we w ill be happy to work with you
as we implement this policy.
Thank you .
NIH-000491
From: (b)(6)
Sent: Mon, 16 Mar 2020 13:34:42 -0400
Subject: Fwd: A SIMPLESTRATEGY FORPREVENTING
CORONAVIRUS
SPREAD
Niai d inquiries
From: Walter T enge lsen (b)(6)

To: "Fauci , Anthony (NIH/N IAID ) [E]"
-------~~ CbH
Subject: A SIMPLE STRATEGY FOR PREVENTING CORONA VIRUS
SPREAD
T o: Dr. Anthony S. Fauci , MD, Head of NIAID
From: Walter Tengelsen , Chmn. of MACROSYSTEMS INST.
First,, allow me to thank and congratulate you for telling the government, and the
press, about our nation's
unpreparedness for the coronavirus spread. But while we wa it for Big P harma to
dev elop a vaccine for this
disease, there is some thing that could be done NOW to prevent the spread of the
virus ... and it wo u ldn't
cost the gove rnment anything! Allow me to exp lain.
Decades ago, when I was a designer in Aerospace , and took my drawing s up to the
blueprint room for copies,
I would always notice the 'aroma' of ammonia in the room. In quiring about the
safety of thi s constant exposure
by the blueprinting staff I was told that there are three groups of people who don't
get co lds: 1) those work ing
in salt mines, 2) those workin g in sewe rs, and 3) tho se working in blueprint rooms!
A few decades later I was
advised, by an MD, that the way to avoid colds is to keep sauce rs of household
ammoniain my house rooms
(and in the office rooms , if allowed), and that one would not even notice the smell
after a few days. Since cold
virus transmission is by aeroso l particles from the already -in fected, and the dilute
ammonia fumes are able to
NIH-000492
'inactivate' them, might these ammonia fumes be able to pro tect us against the
coron aviru s?
Admitted ly, too much ammonia gas can be very irritating (and even fatal, as in
WW!), but evidently people
seem to survive and thrive at the just-noticeab le gas levels being recommended here .
If there is some potential
lung damage from ammonia gas, that might be prevented by taking (freeze-dried)
stinging nettles leaf, a widely
recognized lung-cleaning supplement that is recommended by Naturopathic
Doctors. But it would seem that
the potentia l benefits of limiting the spread of the coronavirus in our entire
population far outweighs the risks
of lung damage . Since most homes already have bottles of anunonia (in their
laundry area), this preventive
strategy could be impl emented immediately, and would provide the public with
the satisfaction of feeling
they are doing 'their part' in combatting this pandemic ...and protecting themselves
and their loved-ones.
NOTE: I am NOT a medical doctor, but an electron ic systems enginee r and scientist
(who takes systems
engineering as a license to meddle in all things), but I was the first male family
member in 4 generations who
did NOT become a pham1acistor physician. I'm emailing my (old address) CV
separately, but the email and
cell phone number --
----~~ Cb)( still reach me as I'm (b)(6)
_ , and then plan to____ ~=
return to my new home in Cb)(6) (IF there's no travel res trictions in force)!
I can be reached via ema il
or cell phone to exp lain this preventive strategy further. Meanwhi le, good luck on
all your efforts to contain
this pandemic; the next four weeks or so will be critical!
NIH-000493
From: (b)(6)
Sent: Mo n, 16 Mar 2020 13:33:40 -0400
To: Carlos del Rio
Subject : Re: FYI...
Thanks, Carlo s
On Mar 16, 2020 , at 1:31 PM , Del Rio, Carlos

--------- (bH6)>wrote:
Dear super -st ar fr iends:
I wanted to give you a heads up abou t a letter (attached} that myself as well as two AAAS
Lesher fellows have been work ing on. Our goal is t o send t his with as many signatures as
possible to the WH. Most of what we ask for is wha t you are already do ing or going to be
doing but we are calling fo r e nforced social distancing mea sures, including closing or
severely limiting all non-essential businessand schools nationwide. I hope t his is useful in
our efforts.
Sincere ly,
Carlos del Rio, MD, FIDSA

Distinguished Professo r fo r Emory Clinical and Academic Affa irs at Grady
Executive Assoc iate Dean for Emory at Grady
Emory University School of Medicine
Professor of Globa l Health and Epidemiology
Rollins School of Public Health
Co-Director , Emor CFAR
Tel : (b)(6)
Tweeter: .___,
(b
""""
)...,.
(6)
=
Pro nouns: he/him/his
This e-mail message (includ ing any attachments) is for the sole use of
the intended recipient(s) and may contain confidentia l and privileged
information . If the reader of this message is not the intended
recipient. you are hereby notified that any dissemination. distribution
prohib ,ted

<Open letter from the Infectious Disease scientific and medical community on
COV TD-19.do cx>
NIH-000494
From: (b)(6)
Sent: Mon, 16 Mar 2020 13:19:42 -0400
Subject: Fwd: Can existing SARSvaccine be used to possibly limit severity of COVID-19
ill ness?
Please bandle
From: Benjamin Cintz (b) C

To: "Fauci, Anthony (NIH/NlAID ) [E]" --------::-:--:-=
(b)(6).
Subject: Can existing SARS vaccine be used to possibly limit severity of
COVID-19 illness? .
Dr. Fauci,
I have read that COVID-19 is close ly related to SARS.
I am wondering if the existing SARS vaccine be used to possibly limit the sever ity of COVID-
19 illness in highly at-risk populations?
Thanks,
Ben Cintz
Mobile: (b)(6)
NIH-000495
From: (b)(6)
Sent : Mon, 16 Mar 2020 13:12:18 -0400
Subject : Fwd: Coronavirus Antidote
Attachments : Zn2+ Inhibits Coronavirus • 14 Mar ch 2020.pdf, ATT000Ol.htm
People respond
From: FH Mughal Cb>

(6)>
To: "Fauci , Anthony (NJH/NIAID) [E]" -------=-c--c
CbH6)
Subject: Fw: Coronavirus Anti dote
I'm anx iou sly waiting for your respo nse. Kindly respond , the
soonest - Thank you
----- Forwarded Message -----
From: FH Mu hal ----~~
To: Cb)(>
Sent: Sunday, March 15, 2020 , 03:54:48 AM PDT
Subject: Coronavirus Antidote
Dear Dr Anthony Fauci and Hilary D. Marston
Kindly enlighten me on the following points:

Can the high temperature (30-35 degrees C) kill the virus?
Can the heatwave ( 40-49 degrees C) kill the v irus?
During last heatwave, t he te mperature in some cities of Pakistan
was 47-49 degrees C.
What is the antidote for coronavir us?
In the fol low ing lin k, Pastor Jim Bakker is suggesting that the
silver solution can kill the coronavirus within 12 hours. What are
your views:
Coronav irus 'Cu re ' Claims Get FTC Warn ing, So Maybe Don't Drink
Silver
NIH-000496
Coronavirus 'Cure' Claims Get FTC Warn ing, So
Maybe Don't Drink Silver
Thomas Brewster
Science says drinking silver won't cure coronavirus, but
companies offering the "cure" are trying to capitalize ..
Coronavirus 'Cure' Claims Get FTC

Warning, So Maybe Don't Drink Silver
Th omas Brews t er
Science says drinkin g silver wo n't cu re

coro nav iru s, but co mp anies offe rin g th e
"c ure" are t ry ing to capita lize ...
In the attached paper, the authors say zinc can inactivate the
virus. Your comments on silver and zinc, please.
Could I kindly request for an early response, please.
Thank you,
Kind regards,
NIH-000497
F H Mughal (Mr)
Karachi, Pakistan
NIH-000498
From: (b)(6)
Sent: Mon, 16 Mar 2020 13:04:59 -0400
Subject : Fw d: Hypothesis for reducing fata lities from Coronavirus
NIAID inquiries
From: Patrick Hackenbe rry (b)(6)

Dat e: March 16, 2020 at 12:59:07 PM EDT
To: "Fauci, Anthony (NIH/N lAID ) [E]" ------~~ (b)(6J:
Subject: Hypothesis for reducing fatalities from Coronavirus
Dear Dr. Fauci / to whom it may concern:
I am not a medical doctor but I have an idea. I know you have every exper t on earth
working on this virus. I am watching the attem pts to slow the transmission and
"flatten the CUJve."
What if we could reduce the fatality rate? Wouldn't that be huge and assis t in
reducing the panic ?
I am hearing that hosp itals are go ing to be short on respirators and that the virus
attacks the lungs. My idea - might help people to breat h more efficien tly .
Summary:
Here is my idea: D octors need to uti lize methods that endurance athle tes have used
in the past to increase their red blood cells in order to increase their body's
blood-o xygen carr ying capacity.
Further descript ion :

Athletes like Lance Armstrong used blood doping and other ways to increase the ir
Ery thropo ietin (EPO). This was called cheating in sports. Howeve r, the result s
gave him an advan tage because his body could get mo re (V0-2 max) oxygen with a
sing le breath compa red to others. T his helped Armstro ng to become more "supe r
human ." I agree that this should be illegal in sports. However, I think it wou ld be
great if a person was fighting for their life to be super human.
NIH-000499
There are natural ways to increase your EPO and there are drugs to trick your body
into producing more EPO. One of the best natural ways is high altitude training
(think Boulder, CO and Kenya marathon runners). Also, the risks involved in
increased red blood cell count obviously include stroke, blood clot, heart attack and
many others. But I think that if monitored closely and as a last resort this method
might help some people to survive this outbreak.
Sincerely ,
Patrick Hackenberry
From (b)(6)
(b) (6) cell
I have NO connections to the website(s) or companies below:

Reference the article below from www.harnmemu trition.c om
By: William Misner, Ph.D.
From 1996 until his retirement in 2006, Dr. Bill worked full-time as Director of
Research & Development at Hammer Nutrition. Among his many accomplishments,
both academically and athletically , he is an AAMA Board Certified Alternative
Medicine Practi tioner and the author of "What Should I Eat? A Food-Endowed
Prescription For Well Being". - Dr Bill's Full Bio
What is EPO?
Erythropoietin (EPO ) is a naturally occurring hormone that stimulates the

production of red blood cells (RBC). Erytbropoietin is a glycoprotein hormone
produced in the kidneys, containing a 165-amino acids structure. Most
erythropoietin is produced by the kidney's renal cortex, but some is also produced in
the liver (mainly in the fetus), the brain and uterus.
Why is it important?
Erythropoietin production is stimulated by low oxygen levels in interst itial cells of

the peritubular capillaries in the kidneys. Following its production in the kidneys ,
EPO travels to the bone marrow where it stimulates production ofred blood cells
NIH-000500
(RBC's) [2]. EPO increases the body's blood-oxygen carrying capacity, but only up
to a point. An ove rabundance may comprom ise health and hinder blood flow
dyna mics with performance-limiting implications . In the absence ofEP O, only a
few RBC's are formed by the bone marrow.
Why are RBC's important?
Red blood cells carry iron-rich hemoglobin for up to 120-days, then they die. Unless
there is a continual supply of Iron, Vitamin B-12, Vitamin C and Folacin, anemia
and reduced oxygen carry ing capac ity manifests in two ways:
Low red blood cell count

Malformed red blood cells.
How can one increase their oxyge n carrying capacity?
There is a distinct difference between unethical , harmfu l, EPO-blood doping

methods and the safe nutr ition that effectively increases indiv idual oxygen-ca rrying
capac ity. Once can improve their hea lth and oxygen carry ing capac ity similar to
EPO without compromising the athlete's health or integrity. EPO levels up to 48%
safely improve performance in males, however beyond this level, the risk of
compro mised health increases . Look to dietary suggestions below regarding
vitam ins, minera ls, proteins, and avoid ing anem ia to ensure oxygen carry ing
capacity.
Can excess EPO can be lethal?
Yes. The margin between effective and letha l quantities of EPO is very narrow. EPO
use can be LETHAL. Many athletes seeking to derive its performance -enhancing
effects have died from incorrec tly-administered EPO . Inappropriate use of
exogeno us EPO can cause elevated hematoc rit levels (i.e. thickened blood that is
difficult to pump). Elevated EPO increases the risk of heart attack due to the
increase in hematocrit. Choosing sustainable, healthy choices is preferred.
Exogenous EPO is totally cleared from the urine with in 48 hours of its
administration and is cleared from the blood within 72 hours of its administration
but its physiologica l effects prevai l for severa l months). [3) A look at EPO's comp lex
pathway further illustrates a complex physiologica l process below, see
PATHWAYS[4]. Resea rch followed over 7,000 middle-aged men for more than 12
years, and discovered that the risk of diabetes increases proportionate to hematocrit
increase.[19) [20). Men with hematocrits above 48 percent have a 400% increased
risk of non-insul in-depe ndent-diabe tes mellitus. The upper recom mended levels for
a female is slightly lower at 45%.
This nutritional intervent ion parallels exerc ise intens itys effect for increasing EPO.
Nutr itional and training interventions for reso lving low EPO levels during iron
NIH-000501
supplementation (only prescribed by a physician who should monitored progress)
shou ld not be permitted above a refere nce ra nge of 48% in males and 45% in
fema les. Similar resea rch confirms this repo rt. [21] [22] [23]
Does exercise intensity increase EPO?
It's comp licated. Roberts & Smit h measured the effects of exerc ise-ind uced hypoxia
on the physiological production of erythropoie tin. Twenty athletes exercised for 3
min at 106-112% maximal oxygen consumption. The fitness of these athletes
prov ides a physiological env ironment for increasing EPO naturally from short 3-
minute all-out intervals . Estimated oxyhemoglobin saturat ion was measured by
reflective probe pulse oximetry (Nellcor N200) and was validated against arterial
oxyhemoglobin saturation by CO-oximetry in eight athletes. Serum erythropoietin
concentrat ions, as mea sured using the IN CST AR Epo-T rac radio immunoassay,
increased significant ly by 19-37% at 24 hour s post-exercise in 11 participants who
also had an arterial oxyhemoglobin saturation< or= 91 %. Decreased ferritin levels
and increased reticulocyte coun ts were observed at 96 hours post-exercise. However ,
no significant changes in EPO levels were observed in nine non-desaturating
athletes and eight non-exe rcise contro ls. Good agreement was shown between
arterial oxyhemoglobin saturation and percent estimated oxyhaemoglobin saturation
(limits of agreement= -3.9 to 3.7. They concluded that a shor t 3 minutes
supramax imal exerc ise pe riod cou ld induce both hypoxem ia and increased
erythropo iet in levels in we ll-train ed indi vid uals . The dec line of arteria l hypoxemia
levels below 91 % during exercise appears to be necessary for the exercise -induced
elevation of serum erythropoietin levels. Furthermore, reflective probe pulse
oxim etry was found to be a valid predic tor of percent arter ial oxyhemoglob in
saturatio n during supramaxima l exercise when percent estimated oxyhemog lob in
satura tion> or= 86%.[9]
What naturally occur ing, nutritional building block s aid in EPO production?
Protein adequacy is a factor in erythropoietin (EPO) production . Inadequate protein

nutrition can reduce the EPO produced. The erythroid response to Erythropoietin
(EPO) is highly dependent on dietary protein adeq uacy and qua lity . The mouse
spleen is an erythropo ietic organ, whic h contains an EPO-responsive cell population
that can be easily amplified by administration of the hormone. Researchers
determined the effect of a protein-free diet offered freely to mice up to two days
afte r injection of r-Hu EPO (l000mU /200 ul) on the response of the above
pop ul ation. Sp lenic ce ll suspen sions from control and experimental mice were
prepared in microwells containing 400 mU r-Hu EPO and appropriate medium. The
response to EPO was evaluated in terms of 3H-thymidine uptake. The results
obta ined indicate that acute ly induced protei n restr iction suppressed the response of
the EPO-responsive splenic ce ll population to EPO when it was imposed on mice
immediately after hormone injection, and suggest the appearance of deficient rates
of differentiation of erythropoietic units by protein restriction .[ 11] Adequate dietary
protein intake is 1.4-1.7 grams /kilogram body weight per day for an end urance
NIH-000502
athlete.
What other nutritional elements and processes affect the natural product ion of EPO
and the body's oxygen carrying capacity?
Dietary Iron. To ensure oxygen carry ing capacity, one shou ld take the recommended
dai ly va lue of iron. Food sources of iron are red meat, liver, and egg yolks. Most
flour , bread, and cereals are iron-fortified. If the diet continues to be iron-deficient ,
only a physician should prescribe and supervise iron supplementation.
Ca lories . Calor ies are needed for EPO production . Calorie sufficie ncy (in spite of
exercise expense) is required for optimal EPO-r elease. If training is causing weight
loss, then EPO loss may be occurring. In order to test the hypo thesis that the early
cessat ion of erythropoi et in (Ep) production during hypobaric hypoxia is induc ed by
lowered food intake, researchers compa red the p lasma Ep titer of rats after expos ure
to continuous hypoxia (42.6 kPa = 7000 m altitud e) for 4 days in fed or fasted rats
after exposure to discontinuous hypoxia. They found that plasma Ep was rather low
afte r 4 days of cont in uous hypoxia . Their findings showed that fast ing lowers the
EPO- response to hypoxia in normal rats [12].
Hormone and Glucose. EPO production also has hormonal-dependant roots

complex ly related to glucose metabolism, and calorie adequacy . The effect of
Thyroid-T3 rep lacement and glucose supplemen tation on erythropo ietin production
was investigated in fasted hypoxic rats. It was found that 48 hr of fasting
significantly reduced the circulating levels of thyroid hormones and the prod uction
of renal and extra renal erythropo iet in in response to hypoxia . These effects of
fast ing were comp lete ly abo lished when the an imals had free access to 25% g lucose
solution as drinking water , despite their Lackof protein intake. Replacement doses of
T3 (0.5 micrograms / 100 gm per day) restored erythropoietin production in the fasted
anima ls but a lso increased the response of the fed contro ls. To avoid the effec t of
endoge nous T3, the experiments were repeated in thyroidectomized rats. EPO
prod uction in athyroid rats was found to be markedly decreased , with values
equivalent to those found in nonnal fasted animals, and were not affected by fasting
or glucose supp lementa tion. Replaceme nt doses of T3 increased EPO product ion in
all three gro ups, but the fasted anima ls needed five t imes as much T3 to obta in a
response similar to that observed in the fed group. Glucose suppl ementation
enhanced the effect ofT3 in the fasted animals but did not completely restore them.
These results indicate that ca loric deprivat ion is primarily respons ible for the
decreased EPO production induced by fasting and that this effec t is proba bly
mediated by both a decreased level of T3 and a decreased responsiveness to it.[13]
A calorie deficit therefore requires 500% more Thyroid Hormone (T3) to maintain
EPO leve ls. Th is is a good reason for monitoring ca lorie intake during high h·aining
ca lori e expense.
Iron abso rbtion . Dietary intervent ions sign ifican tly advance nonheme iron
abso rptio n rate during EPO production. It is very important to include foods to
NIH-000503
enhance nonheme iron absorption, especially when an exercise-induced iron loss is
high or when no heme iron is consumed, such as in a vegetarian diet. Absorption of
heme iron is very efficient; the presence of red meat increases absorption of non-
heme iron +400%. Only 1-7% of the nonheme iron in vegetable staples in rice,
maize, black beans , soybeans, and wheat are absorbed consumed alone. Vitamin C
improves the rate of absorption of nonheme iron from red meats. Diets that include a
minimum of 5 serving s of fruits and vegetables daily provide adequate vitamin C to
boost nonheme iron absorption. Calcium , polyphenols , tannins from tea, and
phytates (a component of plant foods), rice, and grains inhibit the absorption of
nonheme iron. Some of the protein found in soybeans inhibit s nonheme iron
absorpt ion. Most hea lthy individuals maintain normal iron stores when the diet
provides a wide variety of foods. However, if the diet contains large amounts of
oxalates and phytates from dark green leafy vegeta bles and whole cerea l grains the
abso rption of iron decreases due to binding with iron in the gut. High absorption of
heme iron is further advanced by foods containing vitamin C in an acid environment
found of the stomach. The recommended for daily iron intake is between 10-18
milligrams for adult males and postmenopausal females. Most endurance athletes
consume too much iron. Iron is added to breads, cereals, and most packaged foods.
From a computer-generated dietary analysis on 16 endurance athletes and 9 non-

athletes, iron intake from their reported food intake was assessed.
The results of this data is as follows:
GROUP
PERCENT DAILY IRON (RD I/RDA)
MALE ENDURANCE ATHLETE
279%
FEMALE ENDURANCE ATHLETE
193%
MALE SEDENTARY
158%
FEMALE SEDENTARY
115%
What are some food combinations that incr ease the absortion of iron?
NIH-000504
How foods are combined may affect iron absorption rate. Excess iron overdose is
unhealthy and should be avoided. Common side effects of acute iron ove rload are
gastro-intes tinal pain, constipation, nausea, and heartbwn. Excess iron levels may
generate a continuous low-grade infection. Foods are the best source of iron. The
best food source of iron is liver and red meats. These foods contain heme iron,
which is better absorbed than non-heme iron. No n-heme iron can be found in dark
green, leafy vegeta bles (spinach, chard and kale) and whole cereal gra ins (bran and
whole wheat bread). Include dark green, leafy vegetables and who le cerea l grains in
the daily diet. Oxalates and phytates found in dark green leafy vegetables and whole
cereal gra ins decrease the absorption of iron because they bind with iron in the
gash·ointestina l tract. Iron fo11ified cereals increase iron from the diet. Anem ia may
develop on a meat-free diet and/or if the iron store or intake is low.
Red meat contai ns arachidonic acid, an EPO-p recu rsor nutrient, but it also conta ins
high leve ls of saturated fats and chol esterol sugges ting a little (now and then) is
good but too much will harmfully compromise cardiovascular lipid levels. Adding
iron to the diet in supplementa l form is not reconunended except under the
superv isio n of a physician who is monitoring blood serum leve ls for a spec ific
outcome. It has been shown that eating red meat 1-2 per week may contribute to
providing substrates known to regenerate EPO as shown in anima l research . The
ability of Arachidonic Acid (AA), the bisenoic pro staglandin precursor to stimulate
erythropoi esis and Eiythropoietin (EP) Production in exhypox ic polycythemic mice
and the programmed isola ted perfused canine kidney was found to stimul ate
erythropoi esis when adminis tered to exhypoxic polycythernic mice in the lowest
dose tested (50 microgram/kg i.p.). Endogenous ly synthesized prostaglandins, their
intermediates and/or other products of AA metabo lism, such as prostacyclin and
prostaglandins pl ay an importan t role in the control EPO production.[14] Hematocrit
levels are restored through the supplying dietary or supplementa l specific substrates
to support the body's na tural EPO-produ cing mechanisms during endurance exercise
stress .
SUBSTRATES THAT ASSIST EPO METABOLISM[l5]
Acidophilu s - 15-30 Billion Count Probiotics

Coenzyme QlO - 150-300 mg daily
Garlic - 2 cloves or 2 capsules up to 3 x day
Kelp - 100-225 micrograms
V itamin B6 - 50-100 mg
Vitamin B12 - 200-1 ,000 mcg
Folic Acid - 800 mcg
Prot eolytic enzymes - Bromelain & Papain
Selenium - 200 mcg
Vitamin A - 15,000 IU daily or Beta Caro tene - 25,000 IU daily
Vitamin B Compl ex - 50-100 mg
Vitamin C plus Biofla vonoids - 1-3 grams (divided dose)
Vitamin E - 400 IU da ily
NIH-000505
Copper- 2 mg
Zinc 40 mg daily ---->(Do not take zinc in amounts over 40 mg daily as it may
interfere with metabolism of iron and copper)
More Dietary Recommendations
There is a method to improv e iron uptake in the absence of oxalate or phytate rich
foods previously men tioned above. If hematocrit, hemog lobin, or fe1ritin blood lab
measures are low, the athlete may add 1-gram of vitamin C to a 3-4 ounce lean cut
of red meat cooked in an iron skillet one to two times each week. A complete dietary
protoco l for cance r patients going through chemotherapy and radiation was
published and is applicable to over-trained endurance athletes who present low
hematocrit levels. [ 16]
Conclusion
In normal adults, the kidneys produce EPO, which initiates approximately 90% of
natural erythropoietin production. Tissue oxygenation exposure regulates the
production of erythropoietin . Less oxygen saturat ion in the air we inhale (eithe r by
altitude or hypoxic interval training) stimulates the kidneys to activate the chemica l
messengers to instruct the bone marrow to increase the production of EPO to resolve
the lack of oxygen exposure. Hypoxia or Anemi a stimulates the kidney production
of erythropoietin to increase production red blood cells . EPO released from the
kidneys increases the rate of red blood cell division and differentiation of specific
cells in the bone marrow.
Dietary deficiency of spec ific foods and micronutrients, horm one imbalance, and
lack of specific hypoxic training stress inhibit the endogenous (natural) production
of EPO. Additionally, nutritional imbalance from caloric restriction (or exercise
related expense), dehydrat ion, fluid intoxication, excess calcium, excess inositol,
excess oxalates foods, excess phytic acid from cereal gra ins, or a lack of hypoxic
interval trainin g all inhibit the natural production of EPO also. [17] [18],
Manipulating diet for protein and total calor ie adequacy, monitoring hydration,
using supplements, timing food combinations, adding weekly hypoxic exercise
followed by easy or rest days all increases the release of natural EPO for healthy
maximal oxygen carrying capacity. Plus, there are many ways to use diet and
wellness to ensu re that the body's production of red blood cells is sound and that
their oxygen carrying capacity is functioning.
[1] Director of Research & Product Development for HAMMER NUTRITION

LTD. 1-800-336-1977, Whitefish, Montana.
[2] Courtesy of From Wikipedia , the free encyclopedia@:

http ://en.wikipedia.org/wiki/Ma in Page
NIH-000506
[3] In-Tele-Health 2002 (from Hyperhealth Pro CD-ROM)
[4] Cou rtesy ofBioca 1ta@

http://www .biocarta .com/pa thfiles /h eponfkb Pathway.asp
[5] CLINICA L PHARMACOLOGY OF PROCRIT @:

http ://www .procrit.com/profo nly/neph rology/wha t is procrit/clinical pharmaco logy
.html
[6] Fisher JW . Pharmacologic modu lation of erythropoietin production. Ann u Rev

Pharmacol Toxico l. 1988;28:10 1-22.
[7] Plasmapheresis is the process of separating certain cells from the plasma in the
blood by a machine; only the cells are returned to the person. Plasmapheresis can be
used to remove excess antibodies from the blood.
[8] Roberts D, Smith DJ, Donnelly S, Simard S., Plasma-volume contrac tion and
exercise-induced hypoxaemia mod ulate e1ythropoiet in production in healthy
human s. Clin Sci (Lond). 2000 Jan ;98( 1):39-45.
[9] Roberts D, Smith DJ. Erythropo ietin concentration and arterial haemoglobin
saturation with supramaxima l exerc ise. J Sports Sci. 1999 Jun; 17(6):485-93.
[10] Brun JF, Bouchahda C, Chaze D, Benhaddad AA, Mica llef JP, Mercier J. The
paradox of hematocrit in exercise physiology: which is the "normal" range from a
hemorheologist's viewpoint? Clin Hemorheol Microcir c. 2000;22(4):287-303.
[11] Depressed respon se of the erythropoietin-responsive splenic cell population to

erythropoietin in acutely protein restricted mice. In Vivo. 1995 Jan-Feb ;9( 1):71-3.
[12] Jelkmann W, Kurtz A, Bauer C., Effects of fasting on the hypoxia -induced
erythr opoi etin production in rats. Pflugers Arch. 1983 Feb;396(2): 174-5.
[13] Caro J, Silver R, Ers lev AJ, Miller OP, Birgegard G., Eryt hropoietin produ ction
in fasted rats. Effects of thyroid hormones and glucose supplementat ion. J Lab Clin
Med. 1981 Dec ;98(6):860-8.
[14] Fo ley JE, Gros s DM, Ne lson PK , Fishe r JW. The effects of arac hidonic acid on
erythropoietin produc tion in exhypox ic polycythemic mice and the isolated perfused
canine kidney. J Pharmacol Exp Ther. 1978 Nov;207(2):402 -9.
[ 15] As with any supplement , always confirm with your phys ician as to the
appropr iate level and selection prior to use.
[ 16] Nutritional Interventions for Reducin g the Negat ive Side Effec ts of
Chemothera py, Bill Misner, Ph.D. http ://www .cancure.org/Chemo support.htm
NIH-000507
[17] Oxala te-rich foods are: Spinach , Cerea ls, Green Beans (steamed), Potato (raw),
Pean ut Butter, Tea (brewed), Cele ry, Choco late, Rav ioli, and White Bread.
[18] Phytate-rich foods are Grains , Corn, Oats , Rice Bran , Wheat Bran, Legumes ,
Peanuts , Soybeans, and Seeds .
[19] Catalano C, Muscelli E, Natali A, Mazzoni A, Masoni A, Bernardini B,

Seghieri G, Ferrannini E. Reciprocal association between insulin sensitivity and the
haematocr it in man. Eur J Clin Invest. 1997 Jul;27(7):634 -7.
[20] Wannamethee SG, Perry IJ, Shaper AG. Hematocrit and risk ofNIDDM.
Diabetes. 1996 May;45(5):576-9.
[21] Sit D, Kad iroglu AK, Yilmaz ME, Kara TI-I,Isikog lu B. The prevalence of
insulin resistance and its relationship between anemia, secondary
hyperparathyroidism , inflammation , and cardiac parame ters in chronic hemodialysis
patients. Ren Fa il. 2005;27( 4):403- 7.
[22] Evrengul H, Dursunoglu D, Kaftan A, Kilicaslan F, Tanriverdi H, Kilic M.

Relation of insulin resistance and left ventricular function and structure in non -
diabet ic pat ients with esse ntial hype rtension . Acta Cardiol. 2005 Apr;60(2) : 191-8.
[23] Amoah AG, Schuster DP, Gaillard T, Osei K. Insulin resistance, beta cell
function and cardiovascular risk factors in Ghanaians with varying degrees of
glucose tolerance. Ethn Dis. 2002 Fa11;12(4):S3-10-7.
NIH-000508
From: (b)(6)
Sent: Mon , 16 Mar 2020 13:00:10 -0400
To : Lerne r, Andrea (NIH/NI AID) [E)
Subject: Fwd: natu ral course of the coronavi rus pandem ic
Please handle
B egin forwa rded mess age :
From: Martin Gelbaum Cb)< >

Date: Mar ch 16, 2020 at 12:52:24 PM EDT
-----~~
To: "Fauci, Anthony (NIH/NIAID) [E]" CbH6J
Cc: M artin Gelbau m Cb
)(
Subject: natural course of the coronavirus pandemic
Reply-To: Cb)(6)
2020-03-16
Dear Dr. Fauci,
Thank you very much for courageous and tireless efforts to defeat
the coronavirus pandemic .
One of the statements attributed to you puzzled me.
Th e articl e
Dr. Anthony Fauci Says He Would Like a 'Dramatic' Reduction of
Personal Interactions at Social Gatherings to Fight Coronavirus, by
Donica Phifer, newsweek.com
March 15, 2020 02:20 PM
https ://www .newswee k.com/dr-ant hony-fauci-savs-he-would-like-dramatic-
reduction-personal-interactions-socia l-14924 1O"
quotes you as saying ,
"I've said many times if you just leave it alone and left the virus to its own
devices then it'll go way up and it'll come down naturally over a period of
several weeks ," Fauci said. "Unfortunately for our colleagues in Italy, in
France, and certainly in China, that's what happened ."
NIH-000509
Question: Is the implication that the virus would have stopped spreading
rapidly in China even if their government had not instituted drastic measures
to curtail the epidemic?
Put another way: Is it not correct that the drastic measures implemented by
the Chinese government were very helpful in halting the spread of the virus in
China?
From yet another angle: Is it correct that the public health measures adopted in
South Korea and Taiwan have proved very effective in controlling the spread of the
epidemic?
Thank you very much again for your hard work,

Martin
NIH-000510
From: (b)(6)
Sent: Mon, 16 Mar 2020 12:58:37 -0400
Subject: Fwd: thank you
Please handle
From: Robyn Cotter (b)(6)

To: "Fauci, Anthony (NIH/NIAID ) [E]"
-------~~
Subject: thank you
--------- (b)(6)
Hello Dr. Fauci,
--------- (b)(6) I live a very normal life in a Tennes see suburb. We have
a 1ways kept a modest supply of important sw-vival items in our home, so we are
prepared , not panicked. We are carefully following the information and facts
regarcling the Coronavirus and taking the appropriate safety suggestions.
The reason for my email toda y is to thank you for your expertise. You must be
exhausted from the stress. No t to mention having to continually repeat yourself...
and stretch your political diplomacy to the breaking point while walking the fine line
between stating facts and debunking myth s (or outright lies) .
Please know that my family and I thank you for your continued professionalism,
swift communication of facts and overall leadersh ip while we ride this rollercoas ter
with our neighbor s and the rest of the world.
Sincerely,
Robyn Cotter
NIH-000511
From: (b)(6)
Sent: Mo n, 16 Mar 2020 12:56:53 -0400
Subject: Fwd: [EXTERNAL]
Re: Fox News Request for Dr. Fauci
FYI
From: "Koerber, Ashley" <As hley.koe rber@FOXNEWS.COM>

To: "Conrad , Patricia (NIH/NIAID) [E]"
--------~~ (b)(
Cc: "Deatrick , Elizabe th (NIHINIAID) [CJ"
Jenni fer (NIH/NIA ID) [E]"
-------- (b) < , "Routh ,
(b) (6) , "Op linger, Ann e
(NIH/N IAID) [E]" "Fauci, Anthony (NIH/NIA ID) [E]"
(b)(6)
...-----------
(b)( ,
Subject: Re: [EXTERNAL] Re: Fox News Request for Dr. Fauci
Hi Patricia,
Would Dr. Fauci be available to join Bret Baier in th e 6pm hour one night this
week?
I underst and he is very busy , but we wou ld accommodate him any night tba t be is
avai lable.
P lease get back to me when you can - thanks!
-Ashley
As hley Koerber Moir

Booking Producer
Special Report wl Br et Baier
Fox News Channel- DC Bureau
----- (b)(6) ( cell)

Sent from my iPhone
On Mar 13, 2020, at 15:32, Conrad, Patricia (N IH/NIA ID) [E]

(b) (6)>w rote :
I am sorry- we cannot make this work . Apologies .
Patricia L. Conrad
NIH-000512
National Institute of Alle rg y and Infect ious Diseases
The National Inst itutes of Hea lth
31 Center Driv e, M SC 2520- Room 7A03
(b)(6)
30 1-496-4409 fax
Disclaime r:
The information in this e-ma il and any of its attachmen ts is confidential and may contain sensitive
information . It shou ld not be used by anyone who is not the original intended recipient. If you have
received this e-mail in error please inform the sender and de lete it from your mailbox or any other
storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept
liability for any statement made that are sender's own and not expressly made on behalf or the
From : Baier, Bret <bret.baier@FOXNEWS.COM>

To: Koerber, Ashley <Ashley.koerber@FOXNEWS.COM>; Conrad, Patr icia
(NIH/NIAID) [E) (b)(6b
Cc: Deatrick, Elizabeth (NIH/NIAID) [C] (b)(6)>; Routh,
_.;...._....;..;...;.::::==c~=---:-:-:------:---
(NIH/NI A ID) [E]

_ _..:._.:.....:.======~~--
Jennifer (NIH/NIAID) [E] (b)( ; Oplinger , Anne
(b)(6) ; Fauci, Anthony (NIH/NIAID) [E]
(b)(6)
Subject : RE: [EXTERNAL] Re: Fox News Request for Or. Fauci
Thank you for considering .
I know Dr. Fauci has been a lot... and will be this weekend ... but tonight to
wrap th e week .. afte r the national emergency declaration ...
We'd love to have him
Bret
Bret Baier
Chief Political Anchor, Fox News Channel
Anchor &Executive Editor "Special Report with Bret Baier"
From: Koerber , Ashley

To : 'Conrad, Patricia (NIH/NIAID) [E]' -------~~ (b)(6)
Cc : Deatrick, Elizabeth (NIH/NIAID) [C] (b)(6J>; Routh,
Jennifer (NIH/N _IA_I_
D:..
) [:E
.,....:_
....::..
__ .:...:.......:...!:=~=~------
] ...====~~-::"' )(_ >; Oplinger, Anne
(b""".'
(N IH/ NIAID) [E] (b)(6b; Baier, Bret
NIH-000513
<bret.baie r@FOXNEWS.COM>
Subject: RE: [EXTERNAL]Re: Fox News Request for Dr. Fauci
Hi Patricia,
I know this is last minute, but any chance Dr. Fauci can join us in the 6pm
hour tonight? Looping in Bret as well.
Please get back to us when you can - thanks!
-Ashley
Sorry - w ill not work.
Patricia L. Conrad
National Insti tute of Allergy and Infectious Diseases
(b)(6)
301-496-4409 fa x
Disclaime r:
The informat ion in this e-mail and any of its attachments is confidential and may contain sensitive
information. It shou ld not be used by anyone who is not the original intended recipient. If you have
received this e-mail in error please infor m the sender and delete it from your mailbox or any other
storage devices . National Institute of Allergy and Infectious Diseases (NIAID) shall not accept
liability for any statement made that are sender's own and not expressly made on behalf of the
From: Koerber, Ashley <Ashley .koerber@FOXNEWS.COM>

To: Conrad, Patricia (NIH/NIA ID) [E)_______ _,(,b..,
~=(6)
"' >
Cc: Deatrick, Elizabeth (NIH/NIA ID) [C] (b)(6) Routh,

Jennifer {NIH/NIAID) [E] -""""""""'":"=:---------
(b)( >; Oplinger, Anne
NIH-0005 14
(b)( >
(NIH/NIAID) [E]
-----------
Subject: Re: [EXTERNAL]Re: Fox News Request for Dr. Fauci
Hi Patricia,
Would Dr. Fauci be availab le to join Bret tonight in the 6pm hour?
Ashley Koerber Moir

Booking Producer
Special Report w/ Bret Baier
Fox News Channel - DC Bureau
(b)(6)( cell)
Sent from my iPhone
_________
On Mar 10, 2020, at 11:20, Conrad, Patricia (NIH/NIAID) [E]
..... Cb)(6)>wrote:
Oh - tonight is even worse . I don't think it will

work
Patricia L. Conrad
The National Inst itutes of Heal th
(b)(6)
301-496-4409 fax
Disclaimer :
contain sensitive informat ion. It should not be used by anyone who is not the
original intended recipient. If yo u have received this e-mail in error please inform
the sender and de lete it from your mailbox or any other sto rage devices. National
Institute of Allergy and Infect ious Diseases (NIAID) shall not accept liability for
any statement made that are sender 's own and not express ly made on behalf of
the NIAID by one of its represe ntatives.
From: Koerber , Ashley <Ashley.koe rber@FOXNEWS.COM>

To: Conrad, Patricia (NIH/NIAID) [E] ---------=-=-=- (b)(6)
Cc: Deatr ick, Elizabeth (NIH/NIAID) [C]
NIH-000515
Cb)( >; Routh, Jennifer (NIH/NIAID) [E]
--=======~5'""~
Opl inger , Anne (NIH/NIAID) [E]
(b)(6)>;
:========~ (b~)( ~ >
Subje ct: Re: [EXTERNAL]Re: Fox News Request for Dr. Fauci@
6pm on Tuesday
I'm asking about tonight.
Ashley Koerber Moir

Booking Producer
(b)(6)(cell)
Sent from my iPhone
On Mar 10, 2020, at 10:51, Conrad , Patr icia

(NIH/NIAID) [El CbH6>>wrote:
Hi Ashley I don't think we can make this work

tomorrow. If anything changes will let you know.
Sent from my iPhone
On Mar 10, 2020, at 10:49 AM,

Koerber, Ashley
<Ashley. koerbe r@foxnews.com >wro
te:
Hey Patricia ,
Just checking on this!
Ashley Koerber Moir

Booking Producer
------ (b)(6) ( cell)
Sent from my iPhone
On Mar 9, 2020, at
15:11, Koerber, Ashley
NIH-0005 16
<Ashley .koerber@foxne
ws.com >wrote :
Our special is actually

6-8pm tomorrow, so
we could do either
6pm hour or 7pm
hour.
From : Koerber, Ashley

Se nt: Monday, March 9,
2020 11:48 AM
To: Patricia Conrad
(b)(6)
-
Subject : Fox News
Request for Dr. Fauci@
6pm on Tuesday
Hey Patricia,
Wou ld Dr. Fauci be

available to join us in
the 6pm hour
tomorrow (Tuesday)
to discuss the latest
with COVID-19 from
any of the NIH
studios? Bret Baier
and Martha
Maccallum are co-
ancho ring from New
York .
Please get b ack to me

when you can -
thanks!
-Ash ley
Ashley Koerber Moir
NIH-0005 17
Booking Producer
Special Report w/
Bret Baier
Fox News Channel -
DC Bureau
____ Cb 6) ( cell)
_H_
This messageand its attachments

may contain legally privileged or
confidential information . It is
intended solely for the named
addressee. If you are not the
addressee indicated in this message
(or responsible for delivery of the
message to the addressee), you may
not copy o r deliver th is message or
its attachments to anyone . Rat her,
you should permanently delete this
message and its attachments and
kindly noti fy the sender by reply e-
mail. Any content of this message
and its attachments that does not
relate to the official business of Fox
News or Fox Business must not be
taken to have been sent or endorsed
by either of them. No representation
is made that this email or its
attachments are without defect.
NIH-000518
From: (b)(6)
Sent: Mon, 16 Mar 2020 12:55:29 -0400
To: Victor ia Baron
Victoria:
I saw it and thanks for sending it.
Be st rega rds,
Tony
> On Mar 16, 2020 , at 12:53 PM , Victor ia Baron

>
________ (b)( _,> wrote:
> Dear Dr Fauci,

>
> I am a Cal ifornia resident and wanted to take a moment to thank you for your professionalism and integrity during
this crisis with the Coronavirus.
>
> It is so evidently clear that you are forced to work "around" the ignoranc e, ineptness and narcissism of Dona ld
Trump, yet you continue to provide the countly with the truth.
>
> I'm guessing that the odds of you actually seeing this emai l might be slim but l feel better for having sent it. You
will be remembered as a hero during a very dark time.
>
> With Appreciation,
>
> Victoria Baron
> (b) (6)
>
NIH-000519
Sent : Mon, 16 Mar 2020 11:54:30 +0000
Subject : FW: press release and "cheat sheet"
Attachment s: NIAID press release mRNA Phase 1 FINAL.docx, CONDENSEDmRNA phase 1
talking points 3.14 CB.docx
Directo r
Phone : (b)(6)
FAX: (301 ) 496-4409
E-mail : (b)(6l
The information in this e-m ai l and any of its atta chments is confidential and may contain sensitive
info rmation . It should not be used by anyon e who is not the o rigi nal intended recipient. If you
other storage devices . The National Institute of Allergy and Infectious Diseas es (NIAID) shall not
behalf of the NIAID by one of its repre sent atives .

--------- (b)(6)
To : Fauci, Anthony (NIH/NIAID) [El --------, .....,..,=

(b)(6)
Cc: Conrad, Patricia (NIH/NIA ID) [El ~=======~ ~ CbH ; Folkers, Greg (NIH/NIAID) [E]
(b)(6)>; Stover, Kathy (NIH/NIAID) [El (b)(6) Routh, Jennifer
(NIH/NIAID) [E (b)( >; Marston, Hila-ry- (:-:-
N'."'."'.
IH
"'.""
/:"."'.
N~IA~ID
:-:)-::[-::
E]~=~-...:...--.a- (b"'""
H= >
Subject : ASF: press release and "cheat sheet"
Attached, per discussion.
NIH-000527
Sent : Mon, 16 Mar 2020 11:03:39 +0000
To : Marston, Hilary (NIH/NIAID) [E];Collins, Francis (NIH/OD) [E]
Subject: RE: URGENT:Confidential and urgent request regarding (b)(4)
Thanks!
From: Marston, Hi lary (NIH/N IAID) [E] _______ Cb

_ >_C6)
_ >
Se nt: Monday, March 16, 2020 7:00 AM
-----~~ (b)(6)>
Cc: Fauci, Anthony (NIH/NIAID) 1· '=
E-::-.
] ======= (b=)(= ; Tabak, Lawrence (NIH/OD) [E]
'"-'
(b)(6)
Subject : Re: URGENT: Confidential and urgent request regarding (b)(4)
I will draft something for you today .

(b) (5)
I will send a draft later today.
Best,
Hilary
On Mar 16, 2020, at 5:05 AM, Collins, Francis {NIH/OD) [El

------- (b)(6h wrote:
Hi Tony and Hilary,
See message below from Tom Hudson of Abbvie. (b) (5)
Francis

-----------
(b)(6)
NIH-000528
To: Collins, Francis (NIH/OD) [E] (b)(6)>
Subje ct : Confidential and urgent request regarding
Dear Francis,
I am sending this brief note as a request for guidance on an evolving situation w ith
(b) (4)
I am reaching out to you to see if you have any suggestions or individuals that we
should contact .
Best wishe s,
Tom
TH OMAS HUDSON
Senior Vice -President, R&D
AbbVie , North Chicago

1 North Waukegan Rd
R473, Build ing AP9-1
TEL (OFF ICE) --~ (b)~(6)
=
EMAIL(
.-----------
abbvie.com
This communication may contain information that is proprietary, confidential. or exempt from disclosure. If you are
NIH-000529
communication is strict ly prohibited. Anyone who receives this message in error should notify the sender
immediate ly by telephone or by return e-mail and delete it from his or her computer.
NIH-000530
NIH-00053 1
(bXS) - PCP
NIH-000532
From: (b)(6)
Sent: Mon, 16 Mar 2020 06:09:17 -0400
Subject: Fwd: Dental
Respond
Sent from my iPad
From: (b)(6)
-------------------
,-------- ~=
To: "Fauci , Anthony (NIH/NlAID) (E]" (b)(
Subject: Dental
I ask you to addres s the explosion of concern s among the dental community in
regards to COVID-19. We, the dental community , already high risk pe rsonnel , are at
an even higher risk at this point and time. Many of thos e who do not work in the
dental community are not aw are of how high risk our cun-ent situation is. For 8-12
hours a day we are creating aerosols while sitting 8-12 inches from a persons open
mouth. These aerosols contain saliva and blood drop lets, along with billions of other
bacteria and materials . In dentistry , saliva is considered a blood borne pathogen.
Although OSHA requi res Level 3 masks for all aerosol producing procedmes, not
all offices are complying. This DOES NOT matter anyway as we know SURGICAL
MASKS DO NOT FILTER OUT THE COVID-19 virus. I ask that you suspend non
essential dental pro cedures such as dental clean ings and other procedures that are
non-emergent. That we triage patients and accept EMERGENCIES ONLY. We are
at such a HIGH risk , not only to ourselves and our families, but a HIGH RISK to
spreading this virus COMMUNITY wide . Many ofus are taking extra precaut ions
but screeni ng patients, but with a up-to-14 day incubation period, that obvious ly
does not matter.
Plea se hear our plea to addJes s our concerns. The American Dental Association and
the American Dental Hygienists Association has failed us.
Thank you
Alicia Jewell
NIH-000533
Sent: Mon , 16 Mar 2020 10:07:04 +0000
To : Marston, Hilary (N IH/NIAID) [E]
Subject: FW: lifting EUA
Attachments : COVID-19 ASM survey comments.docx
Hilary :
Please take a look at this and see if th e re is anything that we can do h ere.
Th anks,
Tony
From : Bertuzzi, Stefano

--------
------
(b)(6)>
~=
Cc: Segal,
__ ..;;:_ Allen
.;___-======;:;;,,:,;:;---:-----:-~~~----:-- CbH6l;Melissa Miller
...
M-- L~======= (b
=-= (b)(6)>
,-=c~- ; Stevens-Garcia, Jonathan .,__________ (b)(
_, '>; Wat t s,
ary ee ,
--------
Subject : Lifting EUA
Hi Tony-
Per our conversat ion , see the attached email asking FDA to lift the EUA, which would allow
CUA hospital labs to ramp up test capacity significantly . We have sent this letter also to Francis
and to Adam Boehler and were on a call with them . Jeff Shuren at FDA also knows , but we think
it will be important to take action quickly.
Many thanks, let me know if you need anything else from me at this time .
Sincerely ,
Stefano
Stefano Bertuzzi , Ph.D., M.P.H.

Ame rican Society for M icrob iology (ASM)
1752 N St., NW
Washington, DC 20036 -2904
Phone (b)(6)
NIH-000534
Sent : Mon, 16 Mar 2020 10:07:03 +0000
Subject : FW: TytoCare: COVID19Telehealth Support
From: David Bardan (b)(6)>

'""'
(=
6)>
Cc:Shriya Palekar <Shriyap@tytocare .com>
Subject: TytoCare: COVID19 Telehealth Support
Importance: High
Hi Dr. Fauci -good evening. I represent TytoCare, a company that built the industry's first and only all-
in-one medical device that pairs w ith a virtual exam, going beyond the means of audio and visual.
Tyto Home, an OTC and FDA approved/c leared device is meant to either synchronously or
asynchronously examine a patient with capabilit ies to capture heart/lung/gastrointestinal sounds,
ear/throat/skin exams, and temperature .
Due to the outbreak of COVID-19, Tyto has experienced an influx of orders worldwide to support those
that need to be monitored when quarantined. I would like to offer Tyto's assistance here in the U.S. and
think through ways and oppo rtunities that the product can make a difference.
Please see a few a couple of examples on how Tyto is making a difference below :
• Patient Quarantine/Dischargeat Home

o Design: patients receive TytoHome or have it delivered for remote evaluation by infectious
disease specialists
• Example: Home Admission Service with TytoCare
• Create & manage quarantine locations, onsite or offsite
o Setup: Patients do a self-exam with TytoClinic while a prov ider evaluates them from a
distance
• Patient is remotely guided to fully disinfect the device and station before it 's
returned to staff for a second round disinfection
• Example: Nursing Home Triage
Thank you for all that you do during this difficult time .
Thanks,
David
David Bardan
Vice President, Provider Solutions
m: (b)(6)
NIH-000535
2 15 W 40 th Street , 9 th Floor
New York, NY 10018
www.ty toca re.com
~ t~tocare...
NIH-000536
Sent: Mo n, 16 Mar 2020 10:07:03 +0000
Subject : FW: Leronlimab
Please check out and respond .

---------
From: nicho las Agresti ...__________ ..-,a-s-=
<
(b_~.....
-----~~ (b)( >
Subject: Leronlimab
Dr. Fauc i,
Tcan't even imagine how busy you are. r am a gastroen terologis t in
for coronavirus. Any word on results of the clinical trial?
Thank you
----
(b) (6) Geo rgia. I read about Leronlimab
N icholas Agres ti MD
NIH-000537
From: (b)(6)
Sent : Sun, 15 Mar 2020 22:52:4 0 -0400
To : Lerne r, And r ea (N IH/NI A ID) [E)
Subject : Fwd : COVID-19
Please handle
Sent from my iPad
From: Deb W hitney Cb)(6Jl

To : "Fauci , Anthony (NIH/NIAID) [E]" ---------~~
Subject: COVI D-19 ----------- CbH6)
Thank you for you r frank speaking about COVID-19.1 cred it you r willingness to stand up and
speak aloud that "the emperor has no clothes " ... You have already helpe d so many through
the current pandemic . I know you will understand my concern. But, please help me spread this
message as we ll.
In light of public school closures ...these include chil dre n and young people from kindergarten
through high school. These closures also include preschool programs (Volunta ry Pre- Kin
Florida) for 4-year-olds that are part of a public elementary school.
These school closures do not apply to children whose ages range from infants through
preschoo l (including VPK) receiving care and education in pr ivate, corporate , or fa ith - based
centers . My center is one of these , and we are not closing.
This is a business decision.

No kids = No money .
At what price ?
We have more t han 90 infants, todd lers and young children enro lled at ou r center, with 20-plus
employees on premises thro ughout the day between the hours of 6:30 am and 6:00 pm . Ours
is a 5-Star rated, NAEYCaccredited preschool program . I have 17 t h ree-year-old preschool
childre n in my classroom on any given day, with 3 t eachers assigned to this room. This is a high
quality program .
Please expla in how I am supposed to take recomme nded precautions against COVID-19?
Does social distance apply only to adults? If not, please help me know how to maintain social
distance of 3 feet between child ren and adults at arr ival or departure times when I am helping
a child with separation from their prima ry care giver o r saying goodbye at the end of t he day?
How do I maintain social distance between children during center time in the block area , in the
NIH-000538
dramatic play area, in the classroom library or computer center, during story time or music
circle? Our 3 table surfaces are used for multiple activities through the day including meals-
and they seat six children at each table. Friday afternoon, I had 9 children sharing space and
materials engaged in cooperative play for an extended period outside in a sandbox that
measures S'xl0' ...you do the math. Our spacing for cots at nap time is considerably less than 3
feet.
We have no hot water in our classroom for hand washing for children or staff which is
considered a safety measure. We are relentless in our efforts to teach hygiene to 3-year-old
children who cough, sneeze, vomit upon (and occasionally may spit, bite or lick) each other or a
staff member. we work to teach them to use a tissue instead of their hand/arm/shirt to wipe a
runny nose...then throw it in the trash and wash their hands again. Believe me when I say a
determined child can sing "Happy Birthday" twice in an amazingly short time--definitely less
tha n 20 seconds--all the while whipping through instructions to wash the tops, bottoms and
fingers of their hands while they sing. Hand washing is monitored by 3 adults through the day
to ensure it happens after each cough, sneeze, nose wipe and use of the bathroom. Hands are
washed after sensory play indoors or out, before am snack, lunch, and pm snacks (and
sometimes during), and when we transit ion from outside play. At a minimum, these 17 children
are taking turns washing hands (at ou r single sink) six times during a full day at preschool-
before we add in those runny noses, coughs or sneezes.
Avoid touching shared objects ...seriously? We work daily to teach these 3-year-olds to share
materials and space. Yes, we disinfect our toys regularly and our room daily--but that stuffed
animal may move from dramatic play to the reading nook and to a nap cot all in one day and
may be held by a different ch ild with each move. our families send a blanket from home for
their child to use through the week at nap time-along with a soft "s leep toy" if this is needed,
to sooth their child to sleep. These items are stored in the child's open "cubby box" in the
classroom through the week . Do we know how log COVID-19 "l ives" on soft surfaces?
I am convinced school closures are necessary at this time to stem community spread of COVID-
19. I understand the strain on multiple levels this will inevitably put on families to provide care
for and education of their own children for this period. But-young children can contract this
virus and can spread it even though they may not demonstrate symptoms themselves. Or,
what may be dismissed as allergies or "just a cold" may not be. Young children can carry this
virus home to their fam ily and neighborhoods just as easily as a school age child; and, they can
certainly bring it into our center from their home . How many of our children in preschool
depend upon elderly family members for their care? We have infants as young as 6 weeks old
and children th rough 5 years old at our center . How many young children in care are we willing
to expose? How many and which grandparents are we go ing to risk?
(b)(6)
---------------------- (b)(6)l Forget sporting events, museums,

concerts or even worship services--1am worried about going to work on Monday ...and
uncertain what may happen if I stay home.
Again ...
This is a business decision.
NIH-000539
No kids = No money
At what price?
Respectfully,
Deb Whitney
NIH-000540
From: (b)(6)
Sent: Sun, 15 Mar 2020 22:48:23 -0400
To: Glen Goldmark
Glen :
Tha nk you for your kind note.
Be st rega rds,
Tony
Sent from my iPad
> On Mar 15, 2020. at I 0:39 PM. Glen Goldmark _______ _ )_~_ > wrote:
(b
>
> Dr.Fauci,
>
> You are my hero! Thank you for being the voice of reason and credibility dur ing the COVID -19 crisis.
>
> All the best,
>
> Glen Goldmark
NIH-00054 1
From: (b)(6)
Sent: Sun, 15 Mar 2020 22:43:39 -0400
To: EmoryFord
Subject : Re:Great Job
Em ory:
Thank you for your kind note. It is much appreciated .
Best rega rds,
Tony
Sent from my iPad
> On Mar 15, 2020 . at 10:23 PM . Emory Ford ______ (b _. wrote:

_)_(6>
>
> Dear Dr. Fauci:
>
> You are doing a great job and a great service to the cow1try. Amid the chaos you are one of few voices that
provides clear, accurate information on the coronavirus pandemic.
>
> Plea se continue providing that service despite the presid ents continued effort(s) to spin the situation with
misleading and false information. In the end biology wins , the virus ignores political needs and wants.
>
> Emory A. Ford PhD
NIH-000542
From: (b)( 6)
Sent: Sun, 15 Mar 2020 19:38 :20 -0400
Subject: Fwd: "LeadingThrough A Time of CrisisIn Healthcare" - ZRGThought Leadership
Sent from my iPhone
From: Greg Gerson <ggerson@zrgpartners.com>

Date: March 15, 2020 at 7: 34:59 PM EDT
To: "Fauci , Anthony (NIH/NlAID ) (E]"
-------~= (b)( >
Subject: "Leading Through A Time of Crisis In Healthcare" - ZRG Thought
Leadership
Hi Dr. Fauci -
I am reaching out as you have been doing an incred ible job as part of the White
House Coronavirus Task Force. These are difficult times and you seem to prov ide
the most informative interviews without send ing signals of panic to the American
public.
Not sure if you remember, but we we re in touch years back through many executive
clinical leadership searches I conducted during my 18 years at Korn Ferry . I am
now leading the hosp ital/hea lth system practice for ZRG. ZRG is an innova tive
global boutique firm disrupting the traditional execut ive search industry .
As a result of the COVI0-19 crisis, I am speak ing with/ interviewing many heal thcare
leaders (Chief Medical Officers, Hospital CE Os , Lead ing Scie ntists , etc.) as part of
a thought leadership piece .
The topic is "Leading Through a Time of Crisis in Healthcare". I know you are
extremely busy with the task force, but I would very much appreciate if you have
some time for an interview/call.
As you know , strong leaders hip is cruc ial in times of crisis and we are facing
weeks /months of extremely important decis ions by our healthcare leaders
nationwide.
Do you have any avai lability over the next few weeks to connect? I will make myself
availab le to meet and/or have a video or phone call at your convenience.
Hope to hear from you soon.
Regards ,
Greg
NIH-000543
Greg Gerson
Managing Director
ZRG Partners, LLC

Americas EMEA Asia Pacific
C: (b)(6)
0: 215-422-3576
mJ
Z RG p a rtn ers com
•• The informa tion and attachments in this e -mail is the property of ZRG Partners, LLC and is confident ial and may
be privileged . If you are not the intended recipient , please destroy this commun ication and notify the sende r
immediately . You should not reta in, copy or use the contents of this e-mail for any purpose , nor disclose all or any
part of its contents to any othe r person or persons .
NIH-000544
From: (b)(6)
Sent: Sun, 15 Mar 2020 19:37:43 -0400
To: Lei Wu
Subject: Re: Please shut down the country NOW

A.S. Fauci.
Sent from my iPhone
On Mar 15, 2020 , at 7:35 PM , Lei Wu (b)(6)>w rote:

-------
Dr. Fauci. This is Lei Harrison. In the coronavirus crisis , as a former

(b)(6) I have been calin until now. No one
-------------
can anymore after seeing the photos of the international airports today
where hundreds if not thousands of people standing in line for 5-6 hours
and reali zing immediately the virus transmission will explode
exponentially because of this. I strongly request:
1. Shut down the country NOW. Mobility has to be as low as

possible. We have to do the very best RIGHT NOW to break the
transmission chain.
2. Please talk to Dr. Zhong Nanshan (tlfl¥j LU) , the Chiense

doctor and advisor during the coronavirus crisis. His advice and
experience would be of tremendous value for the U.S. now.
3. Sofar, we've been acting in a reactive instead of proactive

fashion. Not anymore. People need to realize that we are entering
war time. We need to act fast, in light speed to beat the virus.
4. Healthcare worker s need to most strongly protected - treat it as

airborne if needed at the hospitals and pharmacies. Supplies of
essential protective medical supplies for healthcare workers are
equally important as supplies needed for the patients. Make sure
supply chain from China is uninterrupted; and have American
companies to start making masks, ventilators etc. Plan ahead.
NIH-000545
5. Grocery store and restaurants can potentially become a hub
too. They need to have high level of hygiene, and ideally no
contact with the customers.
6. Garbage and belongs and bodies need to be burned.
7. Safety protocol at the labs, public and private labs that have
access to the virus or experimental animals with the virus.
8. Plan ahead. Instruct patient to self-treat or be treated by family

at home. If we ever come to it, recruit and train volunteers ( how
and whom?) to help taking care of patients.
Dr. Fauci. Clock is ticking. It's a race against time. And it's time
that every single American takes responsibility. Please lead us
through the crisis.
Respectfully,
Lei Harrison
NIH-000546
From: (b)(6)
Sent: Sun, 15 Mar 2020 19:37:15 -0400
To: Lori Hall
Subject: Re: Real EstateAppraisals-Coronavirus (COVID-19)
Thank yo u for your note.

A.S. Fauc i.
Sent from my iPhone
On Mar 15, 2020, at 7:35 PM , Lori Hall _________ ....

(b)( 6bwrote :
Dr. Fauc i,
Thank you for your impor tant work and for educa ting the public. Earlier today I sent
the message below to President Trum p. I am writ ing out of concern both for my
husband's safety, others in the industry, and knowing refinances (especially with low
rates) will help the American people through this unpre cedented time. I
unde rstand that om Loca l and Nat ional Govern ment continues to look at all potent ial
solutions, with advice from experts such as yourse lf. I fully under stand this
suggestion from one mom and wife might be way too simplist ic for banks/lenders to
even cons ider. I am hoping to be ahead of the curve and that it starts/cont inues what
I cons ider to be a much needed conve rsati on for this indust ry, for the safety for
apprai sers and homeow ners alike, and for the pipeline for the lenders. It's very
much appreciated.
Be Safe. Kindes t Regards,
Lori Ha ll
Dea r Mr President ,
First , our great apprecia tion to you and your staff for all you do every day and in
keep ing our countr y &ci tizen s safe . We have a family real estate appraisal business
(Chicago Metro Area). I hand le all service related items from the comfort of my
home. However, my husband, William Ha ll, who is a Cer tified Gen eral Rea l Estate
Appraise r, is out in the field all day perform ing interior appra isa ls. I have reac hed
out to all our appraisa l management compa nies with this quest ion to ask their
lend ers. Considering the abundance of caution everyone is taking and the refinance
industry seeing unprecedented volume, is there any talk about lender s moving to
exterior only appra isals (and possibly following up after with an interior)? We heard
from ServiceLink, a Fidelity company, and they have not heard any word from their
national banks/lenders changing to exterior only apprai sals at this time . Thank you
very much!
God Bless,
Lori Hall
NIH-000547
Best Regard s,
Lori Hall
For updated real estate news &more, please visit our website
at: www.alphavalues .net
NIH-000548
From: (b)(6)
Sent: Sun, 15 Mar 2020 19:11:49 -0400
To: Gandam, Shyam Kiran
Subject : Re: Front line physicians in limbo need ing reassurance

A.S. Fauci.
Sent from my iPhone
On Mar 15, 2020 , at 4: 13 PM , Gandam , Shyam Kiran

(b) < >wrote :
Dear Dr.Fauci,
I would like to congratulate you for your excellent work and thank you for leading us in
the fight against COVID-19 pandemic .
We are 14 critical care physicians and almost 30 hospitalist physicians at Memorial medical
center and HSHSSt. John medical center in Springfield Illino is and are the frontline workers
in dealing with the situation .
We are developing protocols and creating safety net for the hospitals and community with
the help of your guidance.
I would like to bring up an issue plaguing us with concern for years and now even more so.
It concerns us and more importantly our helpless fami lies. It might be untimely to bring up
this issue but it is very important for us and our families.
(b)(6)
Dur ing thi s pandemic, it's imp ort ant th at
physicians can help oth er areas in the country in nee d.
Immi grant work for ce on Work Visa (H-1 visa) constitute s at least 50% of physicians.
(b)(6)
(b)(6)
Your assist ance in bringin g up t hese issues w ith th e president
will he lp us work with reassuran ce fr om governm ent
and help our communi ty with peace of mind.
NIH-000549
Again, We thank you for the hard work you and your t eam are putting to guide us in these
tumulus times.
Regards,
Shyam Kiran Gandam MD
Critical Care Medicine
Associate professor, SIU school of medicine
Springfield Clinic
Springfield, Illinois
NIH-000550
From: (b)(6)
Sent: Sun, 15 Mar 2020 19:10:41 -0400
To: ABCDEFGHIJK
Subject : Re: COVID-19 • The necessity of using fluo rescent light lamps to prevent or
reduce or slow down the spread of coronavirus

A.S. Fauc i.
Sent from my iPhone
On Mar 15, 2020 , at 4:15 PM , ABCDE FGHIJK

---------- (b)( >wrote :
It's critical to disinfect droplets, aerosols and surfaces continuous ly to prevent or reduce or
slow dow n the spread of COV ID-19.
The best way is using UVC ultraviolet light. UVC's wavelength is germicidal and it is capable
to inactiva te coronavirus by destroying nucleic acids and
disrupting its DNA because Waveleng ths between about 200nm and 300nm are strongly
absorbed by nucleic acids . The absorbed energy can result in
defects including pyrimidine dimers. These dimers can prevent replication or can prevent
the express ion of necessary proteins .resulting in the death or
inactivation of the coronavirus.
Fluorescent light lamps emit ultraviolet (UV) light , including UVC ultraviolet light.
I think it's necessary to use fluorescent tube light lamps and CFL (Compact fluorescent
lamps) lamps in hospita ls, Health centers, stores , supermarkets,
elevators, public lavatory , toilets, restrooms and other public places and should always be
on 24 hours a day, 7 days a week in order to be effective.
Research has shown that Fluorescent light lamps must be installed without any glass shade
or decorat ive shade and should be at least 40 watts .
I hope you find the UVC-based continuous disinfection solution helpful.
Sincerely,
P.Salimi
NIH-000551
From: (b)(6)
Sent: Sun, 15 Mar 2020 19:09:44 -0400
Subject: Fwd:
Sent from my iPhone
From: Sia Hersini (b) (6J

Date: March 15, 2020 at4:15: 21 PM EDT
,------- -;;-c-;=
To: "Fauci, Anthony (NIH/NlAID) (E]" (b)(
Dear Dr. Fauci,
Many yea rs ago, I did so me resea rch on the effect of SIV infect ion on the Macaque
immun e response .
I have some thoughts on the current COVID -19 spread and in general about other
virus with unknown cure or immunity vaccine.
In research, we have adhered to a scientific method necessary for the protection of

the public in the development of new technology and treatment. There are times
how eve r whe n that Boyle method and ph ilosophy should give way to Desca ,t es
approac h.
The current infection has thus far shown a predilection for causing severe illness in
men more than women and in adults over 30 sparing children from mortality.
I believe there is a reason for this and it's not because of past exposure to other
coronovirus strains. I believe it is because of children being in the middle of or
having recently completed their immunization schedule for school. These
immuni zation s are abso lutely not prov idin g an immuni ty to COVID-19, BUT, th ey
are caus ing an increase in the numb ers of gamma delta t ce lls and NK cells . The
child ren are responding better to a viru s with an 5 .1 day median incuba tion period
because of the higher values of gd and nk cells. Women hav e a better gd and nk: cell
response to the flu and other viral infections which could explain why there is a
gender difference in mortality. I would suggest that adults update their vaccines and
especially the hep b. Interestingly, the hep viruses illicit a better gd and nk cell
response and although most Western countries require hep b for health care workers,
the immunization rate in China is only 60% which may explain the high mortality
among health care prov iders.
NIH-000552
This has been on my mind for a few days and I felt I should share.
Th ank you for your time

Sia
NIH-000553
From: (b)(6)
Sent: Sun, 15 Mar 2020 19:09:26 -0400
To: Eliot Robinson
Subject: Re: Pre guidance on coronavirus

A.S . Fauci.
On Mar 15, 2020, at 4: 15 PM, Eliot Robinson

<elio t@robinsonmanagementserv ice.com > wrote:
Dr. Fauci,
thank you for all you do .
one of my chinese friends sent me the attached pre guidance on corona virus. it
includes both western medicine as well as traditional medicine approached. On its
face, it seems to be complete and very up to date.
I apologise for your having to follow of dear leader trump' s instructions to praise
him.
thanks
eliot
Eliot Steele Robin son

Robinson Ma nagemen t Serv ice
4290 Bella Casca da Street
Las Vegas, NV 89135 -2436
----- CbH6)(cell)702-330-9921 (fax)

Eliot@RobinsonManagementService.com
https://www.Rob insonMan agementServ ice.com
DUNS 079879598 CAGE 7EEU6 JCP 0073645
<Guidance +for+Corona+ Virus +Disease +2019 : Prevention ,+Cont:rol,+Dia gnos is+a
nd+Management.pdf>
NIH-000554
From: (b)(6)
Sent: Sun, 15 Mar 2020 19:06:03 -0400
To: Auchincloss, Hugh (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E]
Subject: Fwd: Coronavirus
From patty
Pis respond.
Sent from my iPhone
From: Kathleen Quinlan (b)(6)

To: "Fauci, Anthony (NIH/NIAID) [E]" --------=-::-:-=
(bH >
Subject: Coronavirus --------
Dear Dr . Fa uci,
I have a question which has been troubling me since we began checking people's
temperatures. --------. (b)(6) _ I have
seen the temperature cutoff is 99.5F. (b) (6)
---------------------------- ? I
doubt very much that in screening people the question is asked them whether they
have taken a med icin e for pa in or for fever in the last 24 hour s. I am a nur se and
many people do rea lize that the common pain relieve rs also re lieve feve rs. Shou ld
we up our game and do be tter at screening?
You seem to be the wisest person on the government task force for the Coronavirns.
I hope this reaches you.
Thanks,
Kathy Quinlan
P.S. P lease practice socia l distancing during the White Hou se briefing,etc. It is hard
to watch all of you people bunched around the President and telling the pub lic to
stay 6 feet apart. If you do it maybe the others wi ll follow suit.
Sent from my iPad
NIH-000555
From: (b)(6)
Sent: Sun, 15 Mar 2020 19:04:54 -0400

To: flippi 333333
Subject: Re:Coronovirus

A .S. Fauci.
Sent from my iPhone
On Mar 15, 2020, at 5:22 PM , flippi 333333 (b)(6) wrote:

----------
Dr. Fauci: Sending all students home may be increasing the spread of Covid-19 in
the us because the young people now off college, middle and high school, see this as
a vacation to go out and frequent social businesses, parents are taking kids out to
enterta in them, and they are traveling to visit friends in other cities and states, all aiding
the spread of Covid-19.
Please cons ider more strict MANDATES TO ENFORCE TEMPORARY CLOSING OF

RESTAURANTS, BARS, BOWLING ALLIES, MOVIE THEATERS, MALLS or other
places of gathering and TRAVEL ONLY IF IT IS AN EMERGENCY, to mitigate the
increasing cases of Covid-19 in the US. People are clearly not taking the advice given
to minimize social or publ ic gatherings .
In order for our United States not to follow the same fate as Italy , we need mandated
changes asap. Please conside r telling peop le over 60 or 65 to also stay home from
work for a 2-week period.
Thank you very much for your fine leadership in this critical matter .
Concerned paren t and scientis t,
Robbin.
NIH-000556
From: (b)(6)
Sent: Sun, 15 Mar 2020 19:02:51 -0400
To: Luanne Novak
Subject : Re: Corona virus suggestions

A.S. Fauci.
Sent from my iPhone
> On Mar 15, 2020, at 5:39 PM, Luanne Novak

> ---------- (b) (6)> wrote :
>
> Dear Dr. Fauci:
>
> First, thank you for your honest and forthright testimony and advice during this crisis. Your calm but serious
approach is a great comfort to me. (b) (6)
>
> He is a Pharmacologist by training, and taught physiology at the School of Health Professions at Baylor College of
Medicine until he retired in January. We have been discussing the COVID - 19 situation and he has severa l
sugge stions. (b) ( .
>
> 1. Since South Korea got such a quick handle on this situation, could we buy their tests? Since it has taken such a
Jong time for the US to gear up, could we not just buy their system turn-key?
>
> NPR reported that there is a national stockpile of respirator s - when will those be released ?
> 2. Since China appears to be back online , can the US contract with them to build mechanical respirators to
replenish our "strateg ic reserve"?
>
> l hope that you will continue to be able to speak the truth, and that you stay healthy.
>
> Many thanks,
> Luanne Novak and David Johnson , PhD
> (b) (6)
NIH-000557
From: (b)(6)
Sent: Sun, 15 Mar 2020 19:01:28 -0400
To: Daniel Gutstein
Subject : Re: Daniel Gutstein: Regarding Synagogue Services during the Covid-19
Pandemic

A.S. Fauci.
Sent from my iPhone
> On Mnr 15, 2020 , at 5:53 PM, Dan ie l Gutstein

>
>
--------- (b)(6) > wrote:
> Dear Dr. Fauci ,

> I would like to commend you for providing needed doses of stabi lity and reas sura nce to our nation at this troubl ed
tim e. Your knowledge and professionalism ha ve been indispensable to the masses. I am an assistant to the rabbi of a
Jewish congregation in Chicago which holds services thrice daily. Due to the tight-nit natw·e of the large r Jew ish
community, many synagogues in the city and surrounding suburbs have closed indefinitely in order to limit the
community spread of the Covid - l 9 virus. (One person visiting the community from New York and who interacted
with numerous individuals has so far tested po sitive.) Our synagogue is few in parishione rs though is an essential
sanctum of sustenance and faith to those who make usage of its services. We would like to keep our doors open for
the longest duration possible but remain cognizant of the 1·ealities of the pandemic. Consider ing that we gather in a
sanctuary of impressi ve size with usua lly no more than 20 members who are sta tioned at a distan ce apart from one
another, would it be responsible to continue services for the remainder of the week and this upcoming Sabbath so
lon g as no specific member of the congregation itself has contracted the virus?
> Thank you .
> Wis hing you sustained health and much success ,
> Daniel Gutstein
NIH-000558
Sent: Sun, 15 Mar 2020 23:00:03 +0000
To : Talbert, Patricia Y
Subject: Re: Public Health 101: -- Please listen to my Public Health Cry/Recommendation
Attachments : Outlook-1516124588.jpg

AS . Fauci.
Sent from my iPhone
On Mar 15, 2020, at 6: 14 PM, Talbert, Patricia Y <patr icia.ta lbert@howard.edu>

wrote :
Greetings Dr. Fauci,

As you know, we are currently experiencing a public health pandemic, Coronavirus
(COVID-19). I am asking that you take a moment to listen to Fareed Zakaria's show
that was aired today, Sunday, March 15, 2020, at
(https://www.cnn.com/shows/fareed-zakaria-gps ). Please listen to the message
and review the attached chart that was presented on Fareed's show. This is NOT
about politics, but instead the people. Therefore, let's call to action that the United
States of America government officials and leaders call for a mandate similar to
other countries, such as China, Italy, and Spain (i.e., now, New York & Illinois) to
help reduce the spread of this virus, flatten the curve, reduce the inundation to our
healthcare system, (which is about to experience the worst morbidity and mortality
outcomes), and work to save lives.
There are too many unknowns for us to continue to go on as status quo. Let's be
public health officials and petition to mandate the US Administration to move to
action - by putting in place a Mandatory Shutdown of Movement throughout this
Country.
Currently, we have approximately (9 airports in the United States) in total chaos,

which will be another wave and spread of this virus. We are not proactive; instead,
we continue to react late. This is not the public health that I know and have seen
throughout the duration of my public health vocation. We have to change this
Pandemic, so let's get to work.
#Cry for Pubic Health Action Needed -----****We need this
Administration/Government Committee to LockDown the United States of
America. This can slow down the spread of this disease, save lives, and maybe
within 30 days we can get back on our feet.
Warm and sincere regards - please push action.
NIH-000559
Dr. Pat Talbe rt
Dr. Pat Y.8. Talbert

Patricia Y. B. Talbert, PhD, MPH,MS, CPHA,CHES,cPHN
Associate Dean of Academic Affairs and Administration
Howard University, College of Nursing and Allied Health Sciences
Healt h Sciences Executive Suit e, Towers 6000
2041 Georgia Avenue NW
Washington DC 20059
Email: patric ia.talbert@howard .edu
Howard U: https ://home .howard .edu/
CNAHS: https ://cnahs.howa rd.edu/
Cell#: (b)(6J
"Of all the forms of inequal ity, injustice in health care is the most shocking and
inhumane." Rev. Martin Luther King, Jr.
"Once a task is just begun, never leave it till it's done. Be the labour great or
small, do it well or not at all." Quincy Jones
<Outlook-1516124588.jpg >
<COVID-19 Test ing Data 2020 .jpeg >
THE TIME IS ALWDS NOW
150 HOWARD UNIVERSITY

SESQUICENTENNIAL
--- 1867 - 20 17 ---
ExcellenceanTruthand Service
NIH-000560
THE TIME IS ALWAYS NOW
15Cl
~
HOWARD UNIVERSITY
-Qu:~ -~ENNIAL
Excellencein Truthand Stnict

From: (b)(6)
Sent: Sun, 15 Mar 2020 18:58:40 -0400
To: Lindley Lee
Subject: Re: Under 10 Minute P-O-C Testing Reported by Colorado

A.S. Fauci.
Sent from my iPhone
On Mar 15, 2020 , at 6:22 PM , Lindley Lee (b)(6) wrot e:

----------
Dr. Fauci,
I am not sure you are aware, but there is already a point-of-care

solution available for Coronavirus, and the Denver newsrooms have
been reporting about it. 9News and FoxNews are all reporting about
Aytu Bioscience of Englewood, Colora do. The kits have already been
used in China, and are immed iately available to assist burden the
testing time and ba cklog. Who do we need to inform of this already
available option? Thank you.
Regards,
Lindley Lee
(b)(6)
NIH-000562
From: (b)(6)
Sent: Sun, 15 Mar 2020 18:58:19 -0400
To: JOHN Lightbo dy
Subject : Re:Thank You!

A.S. Fauci.
Sent from my iPhone
On Ma r 15, 2020 , at 6:22 PM , JOHN L ightbod y (bH6)wrote:

---------
Dear Dr. Fauci ,
Thank you for your service and your honesty.
It is difficult for me to watch you telling the truth with all of the people of the
T rump Administration spouting lies constantly!
Keep up the good work!
Our prayers are with you and those who are working to help this country
deal with this coronavirus.
Sincerely,
Sonja C. Lightbody
(proud (bH6)federal employee)
(b)(6)
NIH-000563
From: (b)(6)
Sent: Sun, 15 Mar 2020 18:58:06 -0400
To : Clarence Jones
Subject: Re: A Telemedicine Book to help Doctors & Staff Cope w ith the COVID-19
Overload

A .S. Fauci.
Sent from my jpbone
On Mar 15, 2020, at 6:22 PM, Clarence Jones <cjones@winning-newsmedia.com>

wrote:
Dr. Fauci:
If your predictions come true, the entire medical system will soon be
overwhelmed. Only massive use of telemedicine will be able to cope with the
over load.
I'm a former TV reporter, now full-time wr iter , with nine books in pr int. One of
them - "Webcam Savvy for Telemedicine" -- can help th ose in the medical
community quickly learn how to use this medium. It is available at amazon.com
in both print & digital versions. https://smile .amazon.com/Webcam-Sawy -
Telemedicine-Clarence-
J ones/ dp/1546501894/ref =sr 1 f kmr0 1?keywords=webca%2C+savyy+for+tel
emedicine&gid=1584307097&sr =8- 1-fkm r 0
I'll attach a PDF copy t o this message & also send the same message without an
attachment, just in case your system rejects messageswith att achments. I can
also overnight you a print copy if you'd like . Bulk pricing is available for both
print & digital versions.
You've become a rock star in the current crisis. As a long-time on-camera

coach, I don't think I could teach you a THING you haven't already mastered .
Congratulations.
Cheers,
Clarence Jones
(b) (6).
NIH-000564
(b)(6)
Landline: (b) (6)

Cell:--=~ (b,:,,::
)(~6)r--
website: www.winning -newsmedia.com
Books by Clarence Jones in both print and e-book versions:
LED Basics: Choosing and Using t he Magic Light

Sweet hear t Scams - Online Dat ing's Billion-Doll ar Swindle
They're Gonna Murder You - War Stories From My Life at the News Front
Winning with the News Med ia - A Self -Defense Manual When You 're the Story
Webcam Savvy - For the Job or the Ne ws
W ebcam Savvy- For Telemedic ine
Filming Family History - How t o Save Great Stories fo r Future Generations
Sailboat Projects - Clever Ideas and How to Make Them
More Sailboat Projects - Clever Ideas and How to Make Them
<We beam Savvy for Telemedicine & covers.pdf>
NIH-000565
From: (b)(6)
Sent: Sun, 15 Mar 2020 18:57:17 -0400
To: NIAIDODAM
Subject: Fwd: CANCELUHION amfAR Capitol Hill Briefing, Ending the HIV/AIDS Epidemic
on Thursday, March 26th
Sent from my iPhone
From: (b)(
To: "Fauci , Anthony (NIH/NlAID ) [E]" ---------::-,:-:-=
(b)(6)
Cc: "Folkers, Greg (NIH /NIAID) [E]" (b) (6), "Conrad, P atricia
Subject: CANCELLATION amfAR Capitol Hill Briefing, Ending the
HIV/AIDS Epidemic on Thursday, March 26th
Reply-To: (b)(6)
Dear Tony:
amfAR, The Foundation for A IDS Research will be postponing our Capitol Hill Briefing,
"Ending the HIV/AIDS Pandemic: Lessons Learned for the Coronavirus Outbreak" planned
for Thursday , March 26th, due to the declaration of a National Emergency in our country.
Once the coronavirus public health crisis abates, amfAR will reschedule the briefing and
hope that you will be able to speak as planned. At that meeting , you and several other of
our nation's leading health officials will address two pandemics - AIDS and COVID-19. and
the lessons learned from fighting both of these diseases. We will very much look forward to
hear ing your perspectives about global initiatives for ending AIDS and the work done to
erad icate the coronavirus pandemic. We know your remarks will help provide a roadmap for
ending HIV and other infectious disease threats now and in the years ahead.
I was proud to see the contributions of the US Public Health Service highlighted in today's
WH briefing. You did an excellent job with your remarks.
Tha nks for your work and dedication to safeguarding and advancing globa l health. Hope we
get a chance to catch up soon .
Sincerely,
Susan
Susan Blumenthal , MD, MPA
Senior Policy and Medical Advisor, amfAR
Rear Adm iral (ret)
Former US Assistant Surgeon General
First Deputy Asst Secretary for Women's Health
NIH-000566
From: (b)( 6)
Sent: Sun, 15 Mar 2020 18:56:55 -0400
To: Linda Jones
Subject : Re: Emulating Social Distancing During Press Conference

A.S. Fauci.
Sent from my iPhone
> On Mar 15, 2020 , at 6:25 PM, Linda Jones

> --------- (b) (6) > wrote:
> Thank you so much for all your EXTREMELYIMPORTANT info on COVID-19. You are a national treasure.
Please emulate Social Distancing during ALL press conferences and the press Corp as well.
> Please be safe and stay welI.
> Linda Jones
>
> Sent from my iPad
NIH-000567
From: (b)(6)
Sent : Sun, 15 Mar 2020 18:55:37 -0400
To : el
Subject : Re: Coronavirus Cases in New Jersey

A.S. Fauci.
Sent from my iPhone
On Mar 15, 2020, at 6:30 PM, el CbH >wrote:

--------
De ar Dr. Fauci,
My apo logies if you have already spoken with
Mike Maron, but it seems the political machine
here :inNew Jersey is ignor:ingour own medical
experts and I thought it important that your
team be aware of how this crisis is manifesting
on the front lines:
https://WW1.v.
roi-n j.com/202 0/03/ l 4/opiruon/li fe-at-the-epi center -of-n -j-s-
coronav irus-outbreak/
Om family is keeping you and your team in our
thoughts and prayers.
With infinite respect for you and the daunting task you face,
Rosanna Galluccio
NIH-000568
From: (b)(6)
Sent : Sun, 15 Mar 2020 18:52:24 -0400
To : Eva Sperling MD
Subject : Re: For your urgent attention (COVID-19)

A.S . Fauc i
Sent from my iPhone
On Mar 15, 2020, at 6:38 PM, Eva SperlingMD wrote:

--------- CbH6)
Dear Dr. Fauci,

Thank you for your leadership during the current COV ID-19 crisis. We're writing to ask
you to consider spearheading an additional initiative in this effort.
As you know, one of our greatest immediate needs is an adequate supply

of ventilators for use in hospitals . We will face a severe shortage of this crucial
equipment during a surge of COVID-19 hospitalizations. This will creat e a bottleneck
in our ability to de liver care , a situation where we have to triage who should
live and who should die . Tragically, we see this happening already in Ita ly.
This is a situation we must avoid.
So we propos e to immediately help existing fac tories to increase production , to

convert other existing factorie s for the production of ventilators and to build new
factories to do so.
Some of this will take a long time to accomplish but this pandemic is also predicted
to be w ith us for a long time. We must stay ahead.
We should make an all-out effort to supply our hospitals properly and quickly. We are in
a time of war and we must make the commensurate effort now.
We believe we have the knowledge and the resources to do such a thing.
We just need the will, and the leadership.
We're writing to urge you to use your position of leadership to make this happen.
Here is a link to NPR's report on this crucial issue: https://www .npr.org/sections/health-

shots/2020/03/ 14/8156 7567 8/as-the-pandemic-spreads-will-there-be-enough-
ventilators
Thank you,
Eva Sperling, MD
Elisabeth Sperling
NIH-000569
From: (b)(6)
Sent: Sun, 15 Mar 2020 15:33:20 -0400
To: Xiaoyang Hua, M.D., Ph.D.
Subject : Re:COVID-19some suggestions
Sent from my iPhone
> On Mar 15, 2020 , at 3:17 PM, Xiaoyang Hua, M.D. , Ph.D.
> ---------- (b)( > wrote:
> Dear Dr. Fauci:

> Jam writing to you to express my deepest concerns on the COVTD- 19 outbreak in the USA and would like to
share som e though ts with you.
>
> I am a (b) (6) and an otolaryngo logist at the Duke Medical Center. I completed my training in
Otolaryngology at the University of lowa in 2019. From 2013 to 20 I 5, l did a research fellowship with Dr. Stanley
Per lman , an expe rt in corona virus , to study SARS. Before I came to the States, I was an ENT doctor and had
worked in the epicenter of the COVID- I 9 outbreak, Wuhan, China for several years. Many of my friend s, neighbors,
and colleagues were infected . Some of them have died or are dying. I truly appreciate what you have done to wake
the Americans and warn them about this dangerous virus outbreak. J hope we arc not repeating the mistakes that the
Chinese and Ita lians have made earlier.
>
> I know many physicians and nurses who have been on the frontlines against this coronavirns outbreak in Wuhan
China. Over the past a coup le of months , I have been communicating with them about the COVID-19 ou tbreak. T
have obtained much firsthand information about this virus from medical profess ionals, including the ICU directors
of major hospitals in Wuhan. Here l want to share some thoughts with you and hope that I can help prevent the
worst in the USA .
>
> For the government:
>
> I. Close all public school s immediat e ly. My family is in (b) (6). They are yet to decide if they should close
the schools after the spring break . This is one example that has concerned me a lot. In the email from the (b) (6)
School Distr ict, quote: "there are many factors to be considered any time a decision is made to close schools. These
factors range from eva luating the consequences of missed instruction to providing meals to students who rely on the
school's food service program ", this is extremely short -sighted . These factors, as quoted above, will be very minor
issues and easier to handle, compared with the potential catastrophic consequences should the virus outbreak be out
of control and have para lyzed ow· already -overwhelmed medical system in the USA. I hope the foderal government
can issue an administrati ve order to close the public schoo ls.
>
> 2. Cance l or postpone any large gathering events more than 20 people. Use tele-conference if necessary.
>
> 3. Every county in this country should have contingent plan in place and have one or several isolation
fac ilities/temporary shelters in the remote areas using co!Jege dorms or hotels, in preparation of future large
outbreaks ofCOVJD-19 in the community.
>
> 4. Work with local or state media to inform the pub lic oftbe status of basic life necessity (e.g. food, water, tissue
paper) and essential med ical supplies (including PPE). If there is a shortage, the estimated back-to-stock timeline
should be provided. for PP Es, if the shortage cannot be so lved within a short period of time, they should be saved
for those who truly need them includ ing medical professionals treating patients with COVID-19. All local medical
supply businesses should tum in their inventories since the State Emergency has been declared. These timely
updates will provide assurance to the public to avoid panic and chaos.
NIH-000570
>
> 5. Encourage online shopping and drive-thru pick-up including groceries. Help the local businesses to expand
their delivering capacities.
>
> 6. Provide the public live updates on the outbreak , including the number of confinned cases , their curre nt
clinical status, strategies of tracing their close contacts , as well as the number of tota l cases being tested. From what
T have learned, the more transparent the government is, the less panic the public will be.
>
> 7. Issue laws that prohibit intentional spread of COVID - 19, irresponsible behaviors that put other innocent
peop le or medica l professiona ls at risk of contracting the virus.
>
>
>
> For medical professionals :
>
> Early January in Wuhan, many patients very likely contracted CO YID- I 9 in the local hospita ls when they visited
their physicians for other medical conditions. In addition, the medical system in Wuhan China was almost paralyzed
at that time. One of major reasons is that many medical professionals were infected and sick. The medical
professionals are the backbone in the fight against this vims outbreak . We need to prepare for the worst scenario that
this outbreak can last for a few or several months. We need to protect om medical professionals first.
>
> I. Set up a centralized Fever/COYID-19 hotline operated by trained provider/nursing staff. This telephone line can
use the current available state infom1ation hotline , with expanded functions serving as a gatekeeper and triage
mechanism for potential COVID-19 patients to receive guidance on where to seek help before visiting a busy clinic ,
an urgent care , or a hospital emergency room to minimize the chances of cross-infection and over-whelming large
medical centers.
>
> 2. Establish designated Fever/COVTD- 19 clinics or hospitals led by well-trained ID teams (MD , NP), especially in
highly populated areas. These clinics will serve as the secondary triage and referral centers for the aforementioned
Fever /COVTD-19 hotline, plus for primary care clinics that are not equipped with adequate staff and testing tools .
These clinics should have adequate staff including physic ians and middle level providers, equipped with testing kits
to perfonn COYID -19 test on site. They should have the capacity of testing drive-through patients , securing airway
for ventilation if needed before transferr ing severe patients to tertiary medical facilities. They should be operated
collaboratively with larger healthcare systems like U Iowa , Unity Point , and Mercy who are setting up their own
isolated COVID-19 centers for more severe cases.
>
> 3. Establish a clear conunun ication and transfer protocol between Fever/COVID -19 hotlines, clinics and treating
hospitals for management of suspicious and confirmed cases. For those with mild COVID-19 infection, they should
be self-quarantined at home and monitored closely and remotely. If they cannot perform self-quarantine safely, such
as living by themselves or in nursing homes, they should be kept in the county isolation facilities (as mentioned
above), being monitored there.
>
> 4. If drive-through testing is available at CVS or Walgreen , patients with positive results should call the hotline or
their PCPs first if clinically stable to receive guidance for self-quarantine , monitoring and follow-up. If they cannot
perform self-quarantine safely , they should be kept in the county isolation facilities as mentioned above.
>
> 5. lnform the public and other healthcare providers of the availability of these Fever/COYID-19 hotline and
clinics, encouraging patients with symptoms to utilize these resources first before visiting clinics , emergency rooms
to reduce the chances of cross-infection , and the burden on large medical centers.
>
> 6. Encourage medical professionals to call their clinic patients for screening . Allow the medical providers to
postpone all non-urgent medical visits for annual checkups , stable and non-urgent chronic conditions et al.
>
> 7. Encourage all physicians and healthcare professiona ls who provide direct patient care to wear personal
protective equipment (PPE) such as masks, eye shields and gloves to protect themselves and to minimize the
chances of spreading the virus to other patients, if necessary or based on their screening phone calls.
NIH-000571
>
>
>
>
>
> Sincerely,
>
>
>
> Kind regards ,
> ----------------------- --------
> Xiaoyang Hua, MD/PhD
> Duke Head and Neck Surgery
>
>
>
>
>
>
>
NIH-000572
From: (b)(6)
Sent : Sun, 15 Mar 2020 15:08:54 -0400
To: Jon LaPook
Subject : Re: TIME SENSITIVE;from Jon LaPook to Tony Fauci
I would not use an age number, but if you had to I would say 70. I would say "serious"
underlying condition. Not sure about ACE inhibitor s.
On Mar 15, 2020, at 3:01 PM, Jon LaPook

------- CbH6l wrote:
Tony,
Since "elderly" means different things to different people (to me, it's 10 years older than
me - and l' ~ hould I give a certain age after which people should voluntarily self-
isolate now?
And for underlying conditions, should I say "serious underlying conditions" or leave it
vague at " underlying medical condit ions?" I think the more specific the bet t er.
And, fina lly, I'm hearing that it's puzzling that hypertension is such a risk factor and that
perhaps people on ACE inhibitors are upregulating receptors for ACE2 in the lung. Any
evidence of that? If so, maybe we should switch people off ACE inhibitors for now.
Thanks,
Jon
From: Fauci, Anthony (NIH/NIAID) [E] (b)(6)>

To: Jon LaPook CbH6J>
Subject : RE:TIME SENSITIVE; from Jon LaPook to Tony Fauci
Jon:
Looks quite good. I suggest that you lean out there and explicit ly say that the
elderly and certainly those with underlying conditions should voluntar ily self-iso late
now.
Best regards,
Tony
From: Jon LaPook

------- (b)(6)
-------- == (b)( >
Subject : TIME SENSITIVE; from Jon LaPook to Tony Fauci
Hi Tony,
NIH-000573
I would like to post this widely today , but want your input first. Can you please make
suggestions/add itions/correct ions?
Thanks so much!
Jon
The World Health Organization has declared the Covid-19 outbreak to be a

pandemic -- official recognition that the virus respects no borders and now
affects masses of people in countries all over the world. And there is no
denying the world is changing, in painful ways . We see it in financial
markets, where prices are plunging -- and in supermarkets, where
customers are stripping shelves bare. All driven by fear , as the number of
virus cases grows with each passing day. While we may feel powerless over
this threat, we are not. There are important things we can and must do --
and right now .
To borrow a phrase from the war on terror, the coronavirus only has to be
right once to infect us. We have to be right every time to prevent it. So, every
time you cough or sneeze , use a tissue or the crook of your arm. Every time
you think of it, wash your hands -- as frequently as you can. Every time you
can, practice "social distancing" -- stay away from others during this
outbreak. Social distancing is now being enforced throughout our society.
Schools are closing, sporting events of every kind are being canceled. The
curtain has even come down on Broadway shows as the Great White Way
goes dark.
Despite our best efforts , it's likely many of us will eventually get infected by
the virus , since we have no immunity to it. If that's the case, you may ask,
does it really matter when we get infected? The answer is a resounding
yes! And here's why: slowing the spread of coronavirus -- and consequently
delaying infections -- can make an enormous difference in our ability to
handle the pandemic .
Take a look at this illustration. It appeared in the Economist and is based on

a CDC report . The blue curve shows what happens when you do nothing .
The number of infections peaks relatively quickly. This can overwhelm a
healthcare system that is not prepared to handle such a huge number of
patients. Emergency rooms and hospitals can become overloaded. We may
see shortages of medical supplies -- including protective gear and breathing
machines -- and shortages of healthcare workers, especially if many of them
become infected. But look at the yellow curve. It shows what can happen
when you slow the epidemic. The outbreak is stretched out. And while it may
last longer , the peak number of infections is much lower, putting less stress
on the healthcare system and allowing better care for each patient. It also
gives scientists more time to develop new treatments and vaccines .
NIH-000574
Is there any evidence this works? Absolutely, especially when coupled with
the time-proven technique of aggressive testing to find and isolate infected
people as early as possible. In China , where there has been strict quarantine
and social distancing in the epicenter of the outbreak, new infections have
dramatically slowed. In South Korea, where health officials cleverly used
drive-through testing, we' re also seeing the number of new cases slow
down. And there 's a history lesson from the 1918 flu pandemic . Back then ,
Philadelphia held a parade attended by several hundred thousand people.
Soon , every hospital bed in the city reportedly was filled with sick patients .
Saint Louis , on the other hand , practiced social isolation and saw fewer
cases.
So we have work to do, and it won't be easy, because it means changing the
way we live our daily lives and how we interact with our neighbors . And we
have to start now -- when we can make the most difference .
And here's something we need to keep in mind. We are all in this together.
So even as we keep a distance from each other physically , we need to stay
close emotionally. Social isolation is bad for your health! If ever there was a
time to call or video chat with friends and loved ones. And don't forget to
reach out to the elderly --who may be alone and afraid.
Demonstrating grace under pressure is easier said than done. But that is this
doctor's prescription for getting through this . And , if we treat each other with
kindness and empathy, we will.
Jonathan LaPoo k, M .D.

Prof essor of Medic ine
NYU Langone Health
PLEASE NOTE: IF YOU LEAVE ME A MEDICAL MESSAGE AND DO NOT

HEAR BACK WITHIN 24 HOUR S, PLEA SE CALL MY OFFICE AT 646-754 -
2000 . PLEASE NEV ER LEA VE AN EMAIL ABOUT AN URGENT MEDICAL
ISSUE.
This messageis confidential.

WARNING : THIS EMAIL MAY CONTAIN CONFIDENTIAL MEDICAL INFORMATION
The medical inform ation in this message is confidential and privileged. It is unlawfu l
fo r unauthor ized persons to review, copy, disclose or disseminate confidential
information . If the reader of th is warn ing is not the intended email recipient , or the
intended recipient 's agent, you are hereby notified that you have received t his
email in error and that review or furth er disclosure of the information contained
NIH-000575
therein is strictly prohibited. If you have received this email message in error,
please notify us immediately at 646-754-2000 and delete the original message.
HIPAA regulations require proxy/patient approval before use of electronic media.

By requesting and/or agreeing to email correspondence, you are agreeing to use of
electronic media for transmission of info rmation.
NIH-000576
From: (b)(6)
Sent: Sun, 15 Mar 2020 15:02:52 -0400
To: Liz
Subject : Re: Concern for young 'Vapers' population; this will be serious for them. Vaping
was already it's own epidemic .
Good point
> On Mai 15, 2020, at 2:42 PM, Liz_______ (b _.. wrote:

_.).,.(6)
>
> Hello Dr. Fauci ,
>
> T hop e you will see thi s m essage. T he subject line is part of th e eq ua tion , for Covid - 19, in th e US whi ch is an
unknown . Tam highly concerned how ft will affect this group. Please let all hea lthcare systems know to be awa re
and have thi s on their radar. We keep hearing it's for older adults but it's for people with co mpromised lungs among
other all pre -existing conditions you've mentioned.
>
> Sincere ly,
> Lyzzy Crouse
NIH-000577
From: (b)(6)
Sent: Sun, 15 Mar 2020 15:02:32 -0400
To: Schuchat, Anne MD (CDC/OD)
Subject: Fwd: Concern for young 'Vapers' population; th is will be serious for them.
Vaping was already it's own epidemic.
This pe rson makes a good point.
From: Liz (bH >

To: "Fauci, Anthony (N IH/NlAID ) [E]" --------=-=--:=
(b)( ·
Subject: Concern for young 'Vapers' population; this will be serious for them.
Vaping was already it' s own epidemic.
Hello Dr. Fauc i,
I hope yo u will see this message. The su bject line is part of the equation, for Cov id-
19, in the US which is an unknown . I am highly conce rned how It will affect this
group. Please let all heal thcare sys tems know to be aware and have this on their
radar. We keep hearing it's for older adults but it's for people wi th compromised
lun gs among other all pre-existing condit ions yo u 've mentioned.
Sincerely,
Lyzzy Crouse
NIH-000578
Sent : Sun, 15 Mar 2020 18:33:06 +0000
To : Eisinger, Robert (NIH/NIAID) [E)
Subject : FW: Tools that may help you
Please handle.
From: Landrigan, David

-------------
(b)(6)
To : Fauci, Anthony {NIH/NIAID) [El -------~=

(b)(6) --------- (b)( >; Fauci, Anthony (NIH/NIAID) [El
Subject: Tools that may help you
Tony,
It has been about 20 years since you and I talked about SARSand my model that David Will iams at WHO
used. I didn't know if your old email still worked, so I'm using the directory listing by NIH in addition. I
have some ideas to share with you about the use of tools in the current war on covid-19.
Your 'close the bars' statement is right on target with what I was writing when I heard you say it . It was a
great illustration counterintuit ive to what will work . You could have more correctly said keep the bars
open on ly to those in their twenties and thirties. Five minutes later Mayor DeBlasio said everything is on
the table including closing bars and restaurants! Below you will see me argue why there are better
approaches and this total closure approach is the wrong move. Selective participation will work in our
favor to blunt the curve! Total closure will not work and can wo rk against us!
In a period of two weeks demand for medical treatment can go from 50% of hospital capacity to 200%
due to disease progression and binomial expansion. You know the math and ideas, so there's no need to
go into them. There is a need to closely consider how available tools are being used to mitigate an
overwhelm ing of the health care system. I can tell you now that what needs to be done isn't being done
and that the road we are on now will at most postpone crossing the threshold of 100% capacity. It will
not achieve the desired result of distributing cases over a greater time period so that being
overwhelmed is avoided .
Consider the curves:
The ' with out protective measures' curve is the normal distr ibut ion as modeled by the binomial
distribut ion. The 'w ith protect ive measures' distribution is what we want to achieve, although that
would be fore ign to an exper imenta list. We don't want the number of cases to exceed capacity as
indicated by the horizontal dotted line. If the 'protective measures' are social distancing, school closings,
entertainment/sporting cancelations, restaurant closings, and hygiene and similar uniformly applied
measures, the 'with' curve should have a shape similar to the 'without' curve, just shifted to the right,
unless there is some unpartitioned factor interaction. The flattened curve WILL NOT RESULTbecause
errors should be random and SAMENESSOF TREATMENTPRODUCESSAMENESSOF EFFECT.With
UNIFORM application of measures the curve afte r application will still exceed a height showing the
system capacity has been exceeded .
NIH-000579
We could expect to flatten the mesokurtic 'without' curve into the platykurtic 'with' curve by systematic
time staggering in the use of the protective measures and selectively apply ing the measures to drive
toward herd immunity. As immunity builds toward HIT (Herd Immunity Threshold), there will be greater
and greater slowing of infections as the linkages for transmission decrease. There are two points to
consider here.
The first point is whether measures should be applied in a uniform and blanket manner. The answer is
typically no when the effect is on an existing population because the curve won't flatten. There are two
aspects of the application of measures to consider. Is the effect of the application defining the
population or is it an effect within a defined population. In the instance of halting all air traffic to the US
from China, the population is being defined and altered if influx is allowed and that would both increase
the infections and population turbulence. There would be movement away from HIT. Any measure such
as people influx, which moves the US away from HIT, is to be avoided.
School, restaurant, and sporting event closings need to be examined in relationship to their impact on
an existing, not an increasing population . The actions have many criteria to influence them, but from the
viewpoint of keeping the healthcare system from becoming overwhelmed closings that are staggered,
variable, and alternating will work to increase movement toward HIT and promote flattening of the
'with' curve.
The second point to consider is whether we can move the US toward HIT by age selective application of
available measures. The answer is yes and this could provide the best tool. Susceptibility and strengths
of covid-19 infections covary with age. People less than 30 rarely have severe infections and the younger
ones may not become infected. People under 40 show a low frequency of severe infection. It will be
important to know if there is a large age cohort exempt from infection because that would undermine
part of the result from selective app lication of measures or limit the sampling age because these people
wouldn't develop immunity , but might contribute to delaying herd effects. If they develop immunity
their contribution can be substantial and they can be kept separated from more vulnerable people until
and unless it is established that there isn't a need.
Opening night clubs, sporting events, restaurants, and other places to people in their twenties and
th irties will build immunities, break infection transmission links, and move toward HIT with little or no
risk to the people or the rest of the herd. Have admission to the venues by existing ID, like a driver's
license with age, and have agreement that they do not mingle with vulnerable older people. Leaving the
bars open to people in their 20's and 30's will flatten the curve!
NIH-000580
Sent : Sun, 15 Mar 2020 18:32:34 +0000
To: Birx, Deborah L. EOP/NSC
Subject : RE: [EXTERNAL ] CNN question/German vaccine company?
This is the first that I have heard anything about this subject.
From: Birx, Deborah L. EOP/NSC (b)(6)>

Se nt : Sunday, March 15, 2020 1:38 PM
'""'
(=
6)>
Subject : Fwd: [EXTERNAL]CNN question/German vaccine company?
Do you know anything about this?
Sent from my iPhone
From: "Miller, Kat ie R. EOP/OVP" (b)(6)

To: "Birx, Deborah L. EOP/NSC"
---------~~ (b)(6J>
Subject : Fwd: [EXTERNAL] CNN questi on/ Germ an vaccine comp any?
Sent from my iPhone
From: "Liptak, Kevin" <Kevin.Liptak@turne r.com >

To: "Miller, Katie R. EOP/OVP" ----------=-~ (b)( >, "Fetalvo, Ninio
J. EOP/OVP" (b)(6J>, DL NSC Press
(b)( >
Subject : [EXTERNAL] CNN questi o n/ Germ an va ccine company?
Afternoon - checking to see whether the White House has any comment on
these allegations in German media that President Trump is offering large
sums of money to lure a German vaccine maker to the United
States? >https://www .reuters .com/art icle/us -health -coronav irus-germany -
usa-idUSKBN2120IV<
Thanks
Kevin
NIH-00058 1
KevinLiptak
CNN White House
(b)(6)
NIH-000582
(bX5) - PCl1
NIH-000583
(bX5)-PCI
NIH-000584
NIH-000585
NIH-000586
From: (b)(6)
Sent : Sun, 15 Mar 2020 13:30:08 -0400
To : Soumya Jayaraj
Subject : Re: Concern about Covid spread in South Padre Island Texas

A.S. Fauci.
Sent from my iPhone
On Mar 15, 2020, at l :29 PM, Soumya Jayaraj CbH6)wrote:

----------
Hello Dr . Fauci ,
I hope you get to read this and you can do someth ing about it. I am wr iting from
Cb)~. Here at South Padre Island spring break events are going in full
------
swing with no concern whatsoever about coronavirus spread. We do not have
positive cases yet in the Rio Grande Valley but this is inviting the disease here.
People come from all over USA , especially students in huge numbers for spring
break to SPI. In spite of repeated requests by pre ss and general public the authori tie s
have not shut down the event. I am attach ing a couple of articles below . It is very
concern ing to see the author ities do not seem to understand the gravity of the
situation and the importance of social distancing which is the need of the
hour. Kindly look into this and please do what you can to put a stop to this.
Please note the crowd is expected to increase next week.
Appreciate your help.
Thanks
Regards
Soumya Jayaraj
https://ww w.them onitor.com /2020/03/ 12/ sp i-spring-break-con tinue/
https://www.facebook.com/KRGVChris tian/v ideos/ 1954047085687 68/
NIH-000587
From: (b)(6)
Sent: Sun, 15 Mar 2020 13:29:23 -0400
To: Daphne Coley
Subject : Re:Confidence in you

A.S. Fauci.
Sent from my iPhone
> On Mar 15, 2020, at 1:22 PM, Dap hne Coley

_______
.... (b) ( wrote:
>
> Dear Dr. Fauci.
>
> Out of this whole mess you are the voice of reason that is most comforting. Your intelligence , calm demeanor and
lack of p ersonal agenda (I hope) come through in your explanations of this recent crisis.
>
> I have read how many lives that you saved during the AIDS crisis and Laude you for it. I trust, given enough rein,
that you can do it for the COVID-19 crisis.
>
> You must be feeling the weight of crushing political and media forces_ a real tightrope. Then, of course you do
have to worry about the illness itself, which should be your primary concern but might be probl emat ic given the
infig hting and
> terri torial nature of politic s.
>
> Anyway , I wanted you to know that you have a real fan in (b) (6) . If there are
two there are many , many more . .lust keep on doing what you do so well and know that you are appreciated by lots
of American s.
>
> Best,
> Daphne Coley
NIH-000588
From: (b)(6)
Sent: Sun, 15 Mar 2020 13:28:26 -0400
To: rclavalle
Subject: Re:Thank you!

A.S. Fauci.
Sent from my iPhone
On Mar 15, 2020 , at 1:25 PM , rclavalle (b)( >wrote:

--------
Good afternoon Sir,
Thank you for your continued vigilance in protecting the American people. Your
wise guidance regarding a temporary national lockdown may greatly help in
reducing the spread of COVID-19.
If this action were to occur it should be in phases:
Phase 1: Federal Quarantine. Effective Immediately until 4 MAY 2020 (or further
notice) - ONLY Key and Essential federal employees of all agencies (IC included)
should repo1t to work. Eve1yoneelse is on administrative leave. While buildings are
empty, staff remaining should conduct deep cleaning (air systems, etc.) to ensure a
healthy environment when employees come back to work.
Pha se 2: Federal recall: Be ginning 4 MAY 2020, federal employees are called back
to work on an as-needed basis (indefinitely) depending on how the virus
trends. Excluding postal workers, that accounts for nearly 2 million full-time
employees. There should be a mandatory home-quarantine so people are not out
spreading the disease.
Phase 3: Mitigation and recovery. Federal agenc ies need to produce mitigation
measures (crisis action plans) should something of this nature occur in the
future. F ederal agencies must be ready to respond in an organized manner when a
cn s1soccurs.
Throughout this COVID-19 event, military and law enforcement must have an
increased presence to prevent mass hysteria and mob mentality. Increased military
and law enforcement presence may help enforce the home quarantine measures and
prevent looting and other crimes that tend to occur during crisis events.
NIH-000589
The National messages may include the following:
The top priority is the safety and security of the people

We will make decisions based on health guidance and current conditions here and
elsewhere
We will get through this together (share resources , express kindness etc.)
We need to care for each other - It is vital it is to unite around this crisis
As a Nation , we need to come together as a conununity to survive this international
disaster
This health crisis is challenging each of us to make sacrifices and implement
changes out of the norm.
Ultimately , this crisis is not about us. It's about our responsibility to each other.
Thank you for all you are doing during this difficult time.
Thank you, Sir, for taking the time to review this corres pondence .
Best regards ,
RC La Va lle-McIntosh
NIH-000590
From: (b)(6)
Sent : Sun, 15 Mar 2020 13:21:50 -0400
To : Laetitia Moreau
Subject : Re: Alert: ADVIL= killer with COVID19 , references and more

A.S. Fauci.
Sent from my iPhone
On Mar 15, 2020, at 1:16 PM, Laetitia Moreau

Cb)(6J>wrote
:
Est imated docto r Fauci

Wi t h covi d t he r e ar e dos and don' ts.
An important DON' T f i rst and a DO he r e
I heard fr om Fr ance and Eur ope. USAto be advise d .
Self medication / Unecessary medication of Advil
&corticoids is highl y dangerous with Covid
4 young adults were in critical conditions in France

with no special reasons except they self medicated on
Advil
https : //www.theguardian.com/world/2020/mar/14/anti -
inflammatory - drugs - may- aggravate-coronavirus -
infection?CMP=share btn tw
In French news
https : //www.lefigaro.fr/sc i ences/coronavirus- alerte-sur -
l - ibuprofene - et -autres - anti - inflammatoires - 20200314
French people directly instructed by Health Minister to

avoid Advil
https://twitter.com/ol i vi erveran/status/1238776545398923
264
Reference articles
https://www.thelancet.com/action/showPdf?pii=S2213 -
2600%2820%2930116-8
NIH-00059 1
htt www. t hel an ourna l s lancet artic l e PIISOl
40- 20 30317- 2
Also about oo. I have been sharing about s leep / mor ning
sun and covid.
Sleep protects against virus. we should keep standard
time permanently. A good move alreaqy in normal times.
covid is an additional reason.
https: // www.ucsf. edu{news/ 2015/ 08/ 131411/ short - sleepers -
are-four - times-more- ikely - catch - cold
https ://www.ncbi.nlm.nih .gov/pubmed/26118561
"The impact of daytime light exposures on sleep and mood in office

workers ." High levels in the morning is associated with reduced
sleep onset latency ... and increased sleep
quality . ncbi.nlm.nih.qov/oubmed /2852625
Thank you for your work.

Laetitia Moreau
(b)(6)
<>
NIH-000592
From: (b)(6)
Sent: Sun, 15 Mar 2020 13:19:05 -0400
To: (b)(6)
Subject : Re: Suggestion for the Coronavirus Task Force

A.S. Fauci.
Sent from my iPhone
On Mar 15, 2020 , at 12:05 PM, (b)(6)
wrote :
---------
Dear Director Fauci,

While important stores with pharmacies (Walmart, CVS, Walgreens) remain open, many
elderly folks are afraid to enter due to the mixing of young and old and the increased risk of
coronavirus exposure. I suggest that these stores designate certain hours for for those 60
years of age and older. Now that stores are reduc ing hours to clean and restock the stores
overnight, the best hours might be first thing in the morning . For example for Walmart , the
hours designated for those 60 and over could be 6 a.m. to 9 a.m. This could reduce their
exposure to younger people who might have the virus but who are asymptomatic (or
relatively so) . This same idea could be applied to grocery stores.
Best wishes
Alan R. Ertle MD MPH, MBA
(b)(6)
NIH-000593
From: (b)(6)
Sent : Sun, 15 Mar 2020 13:17:01 -0400
To : Herb
Subject : Re: Coronavirus

A.S. Fauci .
Sent from my iPhone
On Mar 15, 2020 , at 12 :24 PM , Herb CbH6)

>wrot e:
-----------
(b)(6)
I feel that the
information I have might be of interest to your posit io n in this matter . If so, please reply by
return email. Thank you. Herbert E. Johnson
NIH-000594
From: (b)(6)
Sent: Sun, 15 Mar 2020 12:02:05 -0400
Subject: Fwd: Request for interview
Sent from my iPhone
From: Larry Milian < lmilian @slammiami.com >

,------- --;;-~
Cc: Larry Milian <lmilian@slammiami.com> -------- (b)(
Subject: Request for interview
Dr. Fauci,
My name is Larry "The Am igo" Mi lian and I am the Nationa l General Manager and
Progra m Director for SLAM Radio on Sirius XM 145. I would like to respectfully
request to have you on with me on my national morning show to update and discuss
Coronavirus.
I will be on air tomorrow starting at 7am est. While my show normally ends at
11am, [ have decided to stay on air in order to keep our listeners properly infom1ed.
I would like to thank you in advance. Kind ly email me or ca ll me back (b) (6)
~ ) and let me know what might be the best time to come in the air with me .
LaITy'The Amigo " Milian

National GeneralManager/Program Director
SLAM Radio on Sirius XM - Channel 145
LMilian @SLAMMiami.com
(b)(6)
NIH-000595
From: (b)(6)
Sent: Sun, 15 Mar 2020 11:57:49 -0400
To: Alex Tanner
Subject : Re: Nasal spray

A.S. Fauci
Sent from my iPhone
> On Mar 15, 2020, at 11:56 AM, Alex Tanner

> ------------ (b)( > wrote:
> Greetings Dr. Fauci:

>
> Wouldn't some concoction/ratio ofbleach to water put in a nose spray bottle help prevent or kill covid-19? What
about hydrogen peroxide?
>
> Regards,
> Alex
>
> Char les A Tanner
(b)(6)
>
NIH-000596
From: (b)(6)
Sent: Sun, 15 Mar 2020 11:57:34 -0400
To: Deborah Lowery
Subject : Re: Hospitalization of covid-19 positive patients

A.S. Fauci
Sent from my iPhone
> On Mar 15, 2020 , at 11:57 AM , Deborah Lowery

>
--------- (b)(6) wrote:
> Eve ry large US city has several hospitals within city limits . Would it be possible to set up at leas t one hospital for
ONLYcovid - 19 positive pa tients requir ing hospitalizat ion. This cou ld belp prevent transfer of virus to those
hospitalized that do not have the viru s and could help reduce the need for more personal protective supplies needed
for staff, since only thos e staff at that particular hospital would be taking care of those with covid- l 9. Thank You for
your time.
> Deborah Lowery
NIH-000597
From: (b)(6)
Sent: Sun, 15 Mar 2020 10:17:01 -0400
To: Esam.Almarzo uq
Subject : Re:God blessyou all
> On Mar 15, 2020, at 10:13 AM , Esam.Alrnarzouq <esam.almarzouq@jsgroup.com.kw> wrote:

>
> Dear D r Anthony
>
> My name is Esam AIMarzouq from (b) ~ a country that Jam sure you know. My daughter is studying in one of
the un iversit ies in (b) (6)
>
> I ju st wanted to take the oppo 1tunity to say God bless you for all the effo11taken by you along with your
colleagues in NIAID and President office to contain Corona Virus. I am confident, with God he lp we sha ll all
overcome Covid-19 pandemic.
>
> All the best wishes to you all
>
> Regards
> Esam AlMarzouq
> CEO - JS GROUP, private company in the area of general trading and construction in Kuwait
NIH-000598
From: (b)(6)
Sent: Sun, 15 Mar 2020 09:28:21 -0400
To: Mary Lane
Subject : Re: Honest Communication
Than.ks!
> On Mar 15, 2020, at 9: 17 AM , Mary Lan e

> --------- (b) (6)> wrote:
> Thank you so much for being hone st about the coronavinis. We feel we can trust what you say!
>
NIH-000599
From: (b)(6)
Sent: Sun, 15 Mar 2020 09:15:29 -0400
Subject : Fw d: Ind igenous Peoples - Bat Guano Harvesters - COVID-19
Sent from my iPhone
From: Geoffrey Wilcox (b)(6)

Dat e: March 15, 2020 at 9:11:50 AM EDT
,------- -;;-c-;=
Subject: Indigenous Peoples - Bat Guano Harvesters - COVID-19
Dear Mr Fauci:
Is it poss ible to be immune to the virus? W hat if any research has been done on the
indigenous people around the world, including the US, that have harvested guano for
centuries?
Geoff Wilcox
NIH-000600
Sent : Sun, 15 Mar 2020 01:58:46 +0000
Subject : RE: Draft all hands message
Attachment s: Draft_AII_Staff_F irst_NIHStaff_Coronavirus_3 .14.20_ V2 fsc clean - with minor
Fauci edit.docx
Francis:
It looks fine, but I made one minor edit that is tracked.
Thanks,
Tony
From:Collins, Francis (NIH/OD) [E] (b)(6)>

-------
------~~ (b)(6)>
:;.::::======~-,-=,
Subject : Draft all hands message --------- (b)(6)
Hi Tony,
If you have a couple of minutes to review it, please let me know if you see any problems wi t h this draft
all-hands message.
FC
NIH-00060 1
Sent : Sun, 15 Mar 2020 01:11:43 +00 00
To: Robert Jones
Subject : RE: Avoid ing Italy 's Coronaviru s Disaster
Thank you for the note.
From: Rob ert Jone s (b)(6)

Se nt: Saturday , M arch 14, 2020 8 :26 PM
To: Fauci, Anth ony (NIH/ NIAID) [E] -------=- (b)c-c
(= >
Subject : Avoid ing Italy's Coro navirus Disaster
Dear Or. Fauci,
Thank you for your leadership. I ask that you take two minutes to read the following
artic le in today's Boston Globe written by an Italian journalist.
https://www .bostonq lobe .com/2020/03/ 13/ opin ion/coro navirus-ca utionary-ta le-italy-dont-
do-what-we-did/
Bottom line: Please consider a lockdown or some form of a lockdown by the end of this
week.
Best regards ,
Bob Jones
NIH-000602
From: Fauci,Anthony (NIH/NIAIO) [El
Sent: Sun, 15 Mar 2020 01:00:13 +0000
Subject: FW: Covid 19 Minocycline
From:Ramaswamy,Sriram (b)(6)
-------------
To: Fauci,Anthony (NIH/NIAID) [E] -------=- (b)c-c
(= >
Subject: Covid 19 Minocycline
Hi Dr. Fauci,
Pardon the intrusion into your email. I am sure you are super busy spearheading t he fight
against COVID-19, hence I will cut to the chase. If your research team is looking for ideas to
manage this novel virus, perhaps you can consider adjuvant minocycline. Personally I
conducted a sma ll proof of concept study with minocycline in veterans with PTSDand am now
collaborating with the San Francisco VA for a larger and definitive study. The point I am making
that minocycline has potential benefits beyond antibacterial .. I see that the re is preliminary
evidence that it can slow down viral replicat ion.
Anyway you are the international expert and we all THANK YOUfor all that you do!
Best,
Sriram Ramaswamy, MO
Professor of Psych1alry
Vice Chair for Research
Department of Psychiatry
Creighton University School of Medicine
7710 Mercy Road,Suite 601
Omaha, Nebraska 68124-237
NIH-000603
From: (b)(6)
Sent: Sat, 14 Mar 2020 19:24:11 -0400
To: Fabien
Subject: Re: Great talk, as usual ...
Thank you for your note .

A.S . Fauci.
Sent from my iPhone
On Mar 14, 2020, at 3:42 PM , Fabi en CbH >w rote:

---------
Dear Professor,
We see you every where at telev ision in France currently .
I fully understand that you have much more urgent to do than answe ring my previous
email and 1 apologi ze to have bothered you.
Bon courage ...
With all my respect and admiration , for decades,
Fab ien Sordet.
Envoye de mon iPhone
a 19:09, Fabien
Le 10 mars 2020
--------- Cb>< a ecrit:
Great talk at CROI... Thank you.
I follow your works on HIV for 25 years.
----- (b)(6) when I stated to work on HIV myself.

This give me the chance to have your email address, but it is not
as health care professional that I write you today . Just as human,
lambda human ...
My parents are a bit older than you .
Imagine fo r yourself :
If tomorrow, whereas you are already vaccined against Flu, yo u
have significative start of feve r and cough, in an environment
NIH-000604
where Covid-19 is epidemic, would you right away take Kalet ra
and Plaquenil (knowing the fact that if there is a little chance it
works, the soonest is the best) ?
Kind Regards,
(b)(6)
NIH-000605
From: (b)(6)
Sent: Sat, 14 Mar 2020 19:23:16 -0400
To: Janice Strauss
Subject : Re: Truthful science information

A.S. Fauci.
Sent from my iPhone
(b) ( > wrote:

> On Mar 14, 2020, at 4:04 PM, Janic e Strauss
> ----------
> Dr.Fauci.
>
> Thank you for your determ ination and stamina to infonn the American public with science-based upda tes and
information regarding the novel coronavirus .
>
> Without the appropriat e data the virus trajec tory will leave the country in a state of greater uncertainty and fear.
Among many of the public who watch the task force briefing s you rema in a bulwark against chaos and panic.
>
> When politicians announce policy regard ing the virus they may fear accusations of"flip flopping" when a fluid
situation requires nimbleness through recalibration or reversal. That instinct is not party-based. However , an honest,
neutral agent eschewing disinfom1ation, misinforma tion, or omissions might better protect the public than a
politician concerned with polls , contributions, and election results.
>
> Thank you, Dr. Fauci, for being the honest, neutra l agent despi te direct or untoward pressure to ignore science-
based evidence.
>
> Sincerely,
> Janice Straus s
>
>
>
NIH-000606
From: (b)(6)
Sent: Sat, 14 Mar 2020 19:22:43 -0400
Subject: Fwd: Helping to mass produce more dosages of cornavirus vaccines and
antibodies at lower cost wit h potential ly greater potency
Pis respond
Sent from my iPhone
From: Mark Emalfarb (b)( ·

To: "Fauci , Anthony (NIH/N lAID ) [E]" -------=~ (b)(6)
Subject: Helping to mass produce more dosages of cornavirus vaccines and
antibodies at lower cost with potentially greater potency
Dear Dr. Fauci
I don't want to overburden you with a long e1nail, so I'll try and
get to the point.
First, we have developed a gene expression system, our C 1 cell

line which is significantly more efficient than traditional cell
lines being used by Big Pharma to manufacture recombinant
vaccines and drugs . The hyper produc tive Cl cells can be
grown at flexible commercial scales and are proving to be the
most efficient, cost effective way to produce the tens of
millions of preventative vaccine s and/ or antibody treatments
the world so desperately needs.
In a collaborat ion with Sanofi, C 1 cells were developed to

produce recombinant proteins for use in manufacturing a lower
cost better performing influenza vaccine. After conducting a
NIH-000607
mice trial Sanofi concluded that the use of our Cl platform
resulted in equal or better influenza protection, using a lower
amount of vaccine that could be produced at 10-30 times
higher productivity levels.
The Original Sanofi Presentation can be found at the following

link:
https: //www.dyadic.com/wp -content/up loads/2018/01/Sanofi -

Pasteur -C 1-Presentation.pdf
(b) (4)
Wor king togethe r we can "Keep America Safe" by helping

to addre ss the immediate coronavirus outbreak , be better
prepared for future infectious diseases, pandemic, and
epidemic outbreaks, and leveraging this unfortunate situation to
advance biopharmaceutical manufacturing to help speed
development, lower the cost and improve the performance of
NIH-000608
biologic vaccines and drugs such as insulin, seasona l flu and
other vaccines and antibod ies to make healthcare more
accessible and affordable to patients.
I am confident that a meeting with you can be very productive

in further stimulat ing big pharma and other research
institutions to speed effective, low cost vaccines and antibodies
to market.
Given the severity of the current coronavirus situation, I am

prepared to make myself available for a meet ing at your
convemence.
My cell number is
quickly.
----- CbH6) should you want to reach me
Sincerely,
Mark Emalfarb
Mark Emalfarb
CEO
Dyadic International, Inc.
CbH6)(Office)
CbH6)(Cell)
------
www.dyad ic.com
NIH-000609
From: (b)(6)
Sent: Sat, 14 Mar 2020 19:21:17 -0400
To : Richard Lynn
Subject: Re: So proud

A.S. Fauc i.
Sent from my iPhone
On Mar 14, 2020, at4:41 PM, RichardLynn CbH6)

>wrote:
-----------
So well said Carol.
Be we ll
Richard
Richa rd A. Lynn, MD ,FACS ,RPVI

(b)(6)
On Fri, Mar 13, 2020, 5:23 PM Carol Storey-Johnson

<csjohnso@med.cornell.edu>wrote:
Dear Dr. Fauci--
I fully agree with Dr. Lynn's message. I have been following your commentary on
the current COVID-19 pandemic. Our Dean, Dr . Augustine Choi, has also been a
major positive voice at WCM, communicating frequently with our community
and, in his role as an expert in pulmonary diseases, echoing your messages at
WCM as we struggle to educate students and trainees and manage the
overwhelming questions and administrative issues that present themselves at
this time. The measures he has implemented at WCM have been scientifically
sound and commensurate with national expert (yours included)
recommendations .
As a member of the Board of Directors of the Alumn i Association, I am also so
proud of your work in t his critical time for our nation. I'm sure WCM is
appreciative of your representing the quali t y of your train ing, career experience ,
scient ific thinking, and academic acumen in your advice to the nation and its
people in these challenging times.
The Alumn i Association has recognized your work in the past, but your continued
efforts speak so well to the excellence in the rigor and standards of the
NIH-000610
educational, research, and clin ical experience that all of our alumni have had at
WCM.
We wish you well and hope that you have continued influence in these matters.
Sincerely,
carol Storey-Johnson MD
Professor Emerita of Medicine
Weill Cornell Medical College
Note: This information, transmitted from Weill Cornell Medical College, is intended only for
the person or entity named above, and may contain legally confidential and/or privileged
material. Any forwarding, copying, disclosure, distribut ion, or other use of this information
by any person is prohibited . If you are not the intended recipient, any review or taking of any
action in reliance upon this information is strictly prohibited. If you received t his in error,
please contact the sender and dele te the material from all computers. Thank You.
From: Richard Lynn (b)(6)>

------~~ (b)(6)
Cc: nl121 <nl121@cu mc.columbia.edu >; Natasha I Leibel <n l121@columbi a.edu>;
kathleen foley (b)(6); Carol Storey-Johnson
<csjohnso@med .co rn ell.edu>; Lewis M Drusin <ldru sin@med .corn ell .edu >
Subject: [EXTERNAL]So proud
Dear Tony,
As a member of the Board of Directors of We ill Cornell Med
Alumni Association, J am so proud of what you are doing and proud that it all
started in Olin Hall and 1300 York Ave .
Drs McDermott , Hook , Kilbourne, Kean and Johnson must have great prid e in
how you are a voice of science and reaso n during this crisis.
Stay strong and thank you
Ric hard 1(6)
Ric hard A. Lynn, MD,FACS ,RPVI

(b)(6)
NIH-0006 11
From: (b)(6)
Sent: Sat, 14 Mar 2020 19:19:57 -0400
To: Jim Edwards
Subject : Re: Nitrile gloves request for COVID19

A.S. Fauci.
Sent from my iPhone
> On Mar 14, 2020 , at 4:49 PM, Jim Edward s

>
--------- (b) (6) wrote :
>
> Dear Dr. Fauchi:
>
> Regard ing testing by drive through cars ,_______________________ (b_)_(6)
_,
>
> It has been hard for me to grocery shop during this corona virus illness because the retailers are allowing the
employees and baggers to (b) (
>
> l so wish you could address this for u (b)(6)
> --------
> You do no t know how much this would mean to me.
>
> Thank you for your service!
>
> Best Regards,
>
>
>
>
>
NIH-000612
From: (b)(6)
Sent: Sat, 14 Mar 2020 19:19:29 -0400
To: Norm Harris
Subject : Re:Thank you VERYVERYmuch

A.S. Fauci.
Sent from my iPhone
> On Mar 14, 2020 , at 4:51 PM, Norm Harris

> --------- (b) ( > wrot e:
>
> For your recent frequent, focused , knowledgeable and unde rstandable asse ssments and recommendations
regarding the COVID-19pandemic.
>
> A clear and transparent voice makes a very pos itive difference .
>
> Thank you,
>
> Linda and Nonn Harris
> (b) (6)
NIH-0006 13
From: (b)(6)
Sent : Sat, 14 Mar 2020 19:18:47 -0400
To : Auchincloss, Hugh (NIH/NIAID) [E]
Subject : Fwd: Our Company Offer of Assistance During this Critical Time of the
Coronavirus.
Pis hand le.

Sent from my iPhone
From: Kay Savio Cb>lii

b
To : "Fauci, Anthony (NIH/NIAID) [E]" ---------::-,:-:-=--~~
CbH6)
Cc: "Auchincloss, Hugh (NIH/N IAID) [E]"
"McGowan, John J. (NIH/NIAID) [E]" ________ _
Subject: Our Company Offer of Ass istance Dur ing this Critical Time of the
Coronaviru s.
Dear Dr. Fauci:
I work for Focus Pointe Global, a Schlesinger Group Clinical Research Company that has a
data base of over 6 million participants globally. Our company is the largest of its kind in
the world. I wanted to reach out to the NIH &N IAID to see if there is any way our company
can be of help during the coronavirus epidemic.
We have the unique ability to survey this panel of participants on line or in person, asking
various questions getting data back fairly quickly (approximately 2 weeks). Our company
utilizes industry leading techniques and can follow this group for years in the future. We
have worked with the NIH, CDC&such institutions as Northwestern University, Stanford,
Harvard, Battelle, NORC, ICFetc., for many years.
Please contact me if this is of interest and our company can be of help.
Kind Regards,
Kay Savio
VP Client Development &Clinical Research
FocusPointe Global - A Schlesinger Company
___ Cb
_H_6) I (b)(6)
.Fnr GFGlobal
ocusPointe
NIH-0006 14
-
Qualitative &Quantitative Solutions I Visit our website
~~ SCHLESINGERLearning
, Growing& Innovating
., GRO P People,Pass10& Pu pose
NIH-000615
From: (b)(6)
Sent: Sat, 14 Mar 2020 19:16:32 -0400
Subject: Fwd: COVID-19 reporting
Sent from my iPhone
From: G C (b) (6)

,------- --;;-~
To: "Fauci, Anthony (NIH/NlAID ) (E]"
Subject: COVID-19 reporting -------- (b)(
In VA, there is a woman who says she had "the corona" back in November and her
husband had it in Decembe r.
If this is fact, how can we trust om government when it comes to Public Hea lth?
Sent from my iPad
NIH-000616
From: (b)(6)
Sent : Sat, 14 Mar 2020 19:15:18 -0400
Subject: Fwd: Proposal for new treatment of established COVID-19 - CORRECTED EMAIL
Attachments : PastedGraphic-10.tiff, ATTOOOOl.htm
Pis respond.
Sent from my iPhone
From: "Prof.Shimon Slavin" (b)(6)

To: "Fauci, An thony (NIH/NlAI D ) [E]" --------=-=--:= (b)(6>f
Subject: Proposal for new treatment of established COVID-19 - CORRECTED
EMAIL
I APOLOGISE FOR SOME TYPOS IN MY PRE VIOUS EMA IL SENT TO YOU

OUT OF SPONTANEOUS ENTHUSIASM. PLEASE CONSIDER THIS CORRECTED
VERSION INST ED.
Dear Dr. Fauci,

You may not remember but we have met years back when I was at Stanford University and Training
with the late Donald E Thomas to cons ider cell therapy of HIV based on the use of reduced intensity ,
non-mye loablative conditioning in preparatio n for stem cell transp lantation to induce tolerance and
then apply cell therapy with donor lymphocytes wh ich I have proposed for consideration of treatment
of patients with HIV wit h secondary malignancy.
The purpose of this email is to try and capture your attention in order to
consider a new treatm ent option for COVID-19 that can be applied for
patients in need with evidence of disease with no delay. Whereas many
companies focus on development of anti-corona vaccine, I believe the more
rational approach should be to develop treatment for COV ID-19 and then, if
the virus will be deleted and/or the disease controlled or
modified, vaccination will result without the need for specific corona-specific
vaccination which is not yet available and by the time it may be available it
may no longer be relevant.
I am serving as the Medical Director of a company in Hungary and we

believe that one simple and safe experimental treatment of patients with
existing viral disease may already be at hand, (bH 4J
NIH-000617
(b) (4)
I will greatly appreciate if you could give me a call or have one of your
colleagues contact me and then I will be able to discuss the concept in
greater details , after I will provide supportive scientific and clinical literature.
I am available 24/7 on my mobile phone listed below.
Shimon Slavin, M.D.

Scientific &Medical Director , Biotherapy International
The Center for Innovative Cancer lmmunotherapy &Cellular Medicine
Weizmann Center, 14 Weizmann Street
Floor 15, Suite 1503
Tel Aviv 64239 , Israel
Email: _ ___, (b)(6)

Mobile phone: ____ _.Cb
..,) ..,(6)
..,
NIH-000618
, --
~
NIH-000619
~!B iotherapy
In1ernat1onaI
NIH-000620
From: (b)(6)
Sent: Sat, 14 Mar 2020 19:11:42 -0400
To: Alex Amonette
Subject : Re:Thank you for your leadership!

A.S. Fauci.
Sent from my iPhone
On Mar 14, 2020 , at 5:43 PM , Alex Amon ette (b)(6) wrote:
Dea r Dr . Fauci,
Thank you for your leadersh ip and expertise on the coronav irus and for your
other great works . You are a true hero . Thank goodness you are here for all of
us r ight now.
No reply expected .
To your continued good health fo r many many years to come!
Sincerely,
A lexandra Amonette
(b)(6)
NIH-00062 1
Sent: Sat, 14 Mar 2020 19:22:47 +0000
Subject : FW: Use SARSDrugs
From: (b)(6)
Se nt : Saturd ay, March 14, 2020 3:22 PM
-----~~
To: Fauci, Ant hony {NIH/NIAID) [E]
Subject: Use SARS Drugs
------- (b)(6)>
Dr. Fauci; In germany they found the drug camostat mesilate they used on SARS in
2003 kills the coronavirus in a petri dish. why wouldn't you give it a try? Will drug
companies lose too much monies? Makes sense to use an already approved drug with
little side effects. God is watching !!!!!!!!!!!!!
NIH-000622
Sent : Sat, 14 Mar 2020 17:49:09 +0000
To : Halula, Madelon (NIH/NIAID) [E];Fauci, Anthony (NIH/NIAID) [E]
Subject : RE: Thank you - It 's worth it
Thank you!
From: Halula, Madelon (NIH/NIAID) [E] (b)( >

Sent : Monday, March 9, 2020 10:10 AM --------- =
To : Fauci, Anthony (NIH/NIAID) [E] ________..
------~~ (b)( 6h
Subject : Thank you - It's worth it
Dear Dr . Fauci,
Than k you for being willing to step up publ icly and have your life over taken by the coronavi rus.
This can't be easy and is likely to be harder in the coming weeks and months.
Know that we appreciate it and that I am willing to do whatever needs doing to help.
Sincerely,
Madelon Halula
Madelon Halula, PhD

Initiative Coordinator
Email : (I?)(©
Tel (b)(6)
FAX: 240-627-3466
DHHS N IH NIA ID DAIDS
Scient ific Program s & Ope rations Branch
MSC 9831 (rm 8C48}
5601 Fishers Lane
Rockville , MD 20852-9831
.~ The information in this e-mail and any of its attachments is confidential and may contain sensitive information . It
and Infectious Diseases shafl not accept liability for any statements made that are sender's own and not expressly
made on behalf of the NIAID by one of its representatives . ~
NIH-000623
From: (b)(6)
Sent: Sat, 14 Mar 2020 13:15:38 -0400
To: Mike Betts
Subject: Re: Coronavirus response

A.S. Fauci
Sent from my iPhone
On Mar 14, 2020 , at 12 : 19 PM, Mike Bett s (b)(6)>w rote:

-------
I wanted to convey an idea I had with regard to the coronavirus. It

seems to me that trying to contain the virus as we are doing at
present will be futile. Since the virus can be present for many days
without a person having any symptoms, you would literally need to
test everyone at the same time to determine who has it--an
impossible task .
I have a different thought. We know that the virus is

especially dangerous for the old and/or immunosuppressed. IMO
we should be focusing all of our efforts on keeping that group from
becoming infected. To do so that group should be encouraged to
self-isolate, to limit their social interactions and other groups should
be instructed to avoid them. Sort of a reverse-quarantine idea. All
testing would be done within those groups and all groups would also
be encouraged to continue with the hygien ic suggestions they've
already received .
The problem right now is that the media has created a panic. Last
night my wife and I went to the local Whole Foods and many of the
shelves were empty and healthy younger people were wearing
masks .
The message is not getting out that the virus is almost solely
dangerous to the elderly and immunosuppressed. [Why aren't the
demograph ics being released? That in itself could calm many
people.] With my suggestion, exposures to them would be
diminished, significantly reducing the number of deat hs, as well as
NIH-000624
the potential impact on hospitals. Any person outside of that group
that was severely affected could be identified and
treated. Quarantining otherwise healthy people outside of those
groups who finally demonstrate symptoms--like the NBA players--is
ridiculous. They are likely to get the sniffles and have also already
spread the virus. As long as they're not spread ing it to the
endangered group we should not worry about it.
In sum, we need to isolate the vulnerable and realize that the

mortality rate for people outside of that group is likely lower than the
flu.
Of course , while this occurs we are working on finding treatments

and vaccines. But sending home workers who have next to no
likelihood of being significantly impacted by this virus is
ridicu lous. The virus hits hardest the old and infirm , two groups that
are most likely NOT to even be in the workforce!
To me, this solution is a lot simpler than what is being tried right
now and is much more likely of success. To everyone besides the
endangered group this virus is literally less dangerous than the
flu. There is no reason that anyone outside of the endangered group
should have any concern at all and we need to make that
clear. Please let me know what you think.
Sincerely ,
Michael Betts
(b)(
NIH-000625
From: (b)(6)
Sent : Sat, 14 Mar 2020 13:14 :36 -0400
To : Sharon Ganderson
Subject : Re: Subject. Virus recommendat ions
Thank yo u for your note.

A.S . Fauc i
Sent from my iPhone
On Mar 14, 2020, at 12:42 PM , Sharo n Ganderson

Cb)~ wrote:
Dear Dr. Fauci:

Thank you for your incre dible dedicatio n &expert ise in dealing w ith the coronaviru s
situation. My conce rn is that when the President &the virus team and others are seen
together they stand close together &shake bands. This has been ill advised by all the
medical expe rts, includin g yo u.
I m ho ping you and the other expe rts will strong ly advise changes in this behav ior in
accordance with current recommenda tions. We need them to se t a good exam ple for
all.
Many thanks for your help - its greatly app reciated.
Sharon Fink
(b)(6)
NIH-000626
From: (b)(6)
Sent: Sat, 14 Mar 2020 13:12:23 -0400
To: Adrienne Delucca
Subject : Re:THANK YOU

A.S. Fauci
Sent from my iPhone
> On Mar 14, 2020 , at l :04 PM, Adrienne Delucca

>
----------- (b) (6) > wrote:
>
> Dear Dr. Fauci:
>
> My name is Adrienne Delucca and I live in Connecticut. I am a Labor Attorney and repre sent almost 40,000
public school teachers. You may not read this until months from now a~I know you are working tirelessly on the
Coronavirus Task Force. I just felt the need to send you a quick note to thank you. Your expertise and presence
during inter views and Whit e House briefing has offered me so much comfort at such an anxiety ridden time. l have
heard from so many friends and family members who feel the same way about you. Without your involvement we
wouJd be lost as yours is the most credible vo ice that we have come to rely on. Thank you for all you are doing for
our country. We are all so lucky to have you. I pray that you and your family stay healthy.
>
> Sincerely,
> Adrienne Delucca
NIH-000627
Sent : Sat, 14 Mar 2020 13:10:59 +0000
To: Celia Lewis
Subject: RE:No BS
Celia and Jim:

Berst,
Tony
From:Celia Lewis (b)(6)>

sent: Saturday, March 14, 2020 6:44 AM
To: Fauci, Anthony (NIH/NIAID) [E)------= (b)""'(6J
=>
Subject: No BS
Dear Dr. Fauci:
My husband and I are both

----- (b) (6) so we've followed a lot of TV news regarding COVID-19.
We want to express our appreciation for your "no BS" presentation of the realities of the disease spread
and what we, as a country, can expect .
We hear the polit icians and the news anchors, but we find our comfort in the unwav ering truth you
deliver through the lens of your decades of experience and experti se.
And we thank you, more than you know.
Highest regards,
Celia and Jim Lewis
NIH-000628
From: Fauci,Anthony (NIH/NIP.ID)[E]
Sent: Sat, 14 Mar 2020 13:09:28 +GOOO
To: Diane Gaarv
Subject : RE:Thank you
Than.ks, Diane. I will try your suggestions.

From: Diane Gaary ..----- .-,;-,-=
(b) (6)
Sent: Saturday , March 14, 2020 7:45 AM
------~~
To: Fauci , Anthony (NIH/NIAID) [E]..._______ (b =
_)_(6)
...
Subject: Thank you
Dear Dr Fauci,
Thank you.
Your efforts to infonn and help all of us during the Covid-19 situation are greatly appreciated.
You are in our prayers.
Sincerely,
Diane Gaary
PS. I am a speaking voice teacher.

If your voice is tired from the constant talking , here are 2 easy suggestions:
1) a closed mouthed yawn (as one might do in a boring class) is a quick stretch and tension reliever for the entire
vocal mechanism
2) 10-20minutes of constructive rest (on your back with knees bent and head on a book to keep it in line with your
spine) will put your spine into a passive traction and give your back and neck muscles a chance to rest and release
l know you don' t have much time for this sort of thing, but decreasing your physical stress will help your voice
tremendously and help you work even more efficiently.
Once again, Thank you for your knowledge commitment , and integrity.
NIH-000629
Sent: Sat, 14 Mar 2020 13:05:46 +0000
To: Deb Webster
Deborah:
Best,
Tony

From: Deb Webster.-------~ (b
~)~(=
6J
Sent: Saturday, March 14, 2020 9:04 A"'M
;..;;.....
____ ~~
To: Fauci, Anthony (NTH/NIAID) [E]______ _>
Cb
_<_.
Subject: Thank you
Dr. Fauci,
J have been so very heartened and impressed with your forthcoming and rational communications and actions
around the COVID-19 crisis. This includes your insistence on speaking trnth to power and taking more aggressive
steps in thls combat.
Don't relent, and keep up the great work. We all need you.
] wish you well.
Deborah Webster
(b)(6)
NIH-000630
Sent: Sat, 14 Mar 2020 12:58:29 +0000
To: William Templeton
William. Thank you for your kind note.

Best,
Tony
From: William Temple t on __________ Cb

_) _
(6)>
Sent : Saturday, March 14, 2020 8:33 AM
Subject: Thank you -------- (b)(6);,
_____ ......as an
(b)(6) Infectious Diseases physician in southern Indiana and Louisville.
During my career I cared for hundreds of individuals with HIV/AIDS and remember well your tireless
efforts in this regard.
Even in the midst of the cur rent coronavirus pandemic, your know ledge and expertise cont inue to
preva il- a model for many . There has never been a more important time for dissemination of facts not
blind faith .
Again, congratulations !
William C. Templeton, MD
NIH-000631
NIH-000638
(bX5) -PCP.
NIH-000639
Sent : Sat, 14 Mar 2020 00:32:38 +0000
To : Bill Canavan
Subject: RE: REGISv FORDHAM (b)(6)
Billy:
Thank you so much for you note. You brought back a flash of happy memory that was
wedged in the bottom of my brain. What a game that was! Billy Canavan and Donnie Walsh
versus Tony Fauci and Artie Guar ino. You guys were clear ly better than we were; yet we won
which proved to me then that anything is possible. Thanks again for bringing back such
amazing memories. I hope that yo u are well and I wish you all the best.
Warm regards,
Tony
From: Bill Canavan (b)(6)>

To : Fauci, Anthony (NIH/NIAID) [E]-------= (b-:-
)(=6)
Subject: REGISv FORDHAM .... 1958 ...
TONY ...
BEAT CORONAVIRUS THE WAY YOU AND ARTIE BEAT DONNIE AND ME
BILLY CANAVAN ... ---
(b)(6) REGARDS...
NIH-000640
From: Conrad, Patricia (NIH/NIAID) [Elon behalf of Fauci, Anthony (NIH/NIAIO) [El
Sent: Fri, 13 Mar 2020 17:54 :56 +0000
To: Alecia Siuta;Fauci, Anthony (NIH/NIAID) [El
Subject : RE:Thank you and how can I help? From the wife of a hospitalis t
Dr. Fauci asked me to thank you for your note.
Best,
Patricia L Conrad
The National Institute s of Heal th
31 Center Driv e, MSC 2520 - Room 7A03
(b)(6)
301-496-4409 fax
Disclaimer:
The infom1ation in this e-mail and any of its attachments is confidential and may contain sensitive infom1ation . It
please inform the sender and delete it from your mailbox or any other storage devices. Nationa l Institute of Allergy
and Infec tious Diseases (NIAID) sha ll not accep t liabi lity for any statement made that are sender's own and not
expressly made on behalf of the NlAlD by one of its representatives.
from : Alecia Siuta :.:-------- (b
~)-(6)
~
Sent: Friday, Ma rch 13, 2020 1:53 PM
To: Fauci , Anthony (NTH/NTAID)[El -----~~= (b)(6) >
Subject: Tharlk you and how can I help? From the wife of a hosp italist
Dr. Fauc i,
Thank you so much for being the honest, clear minded medical leader that our country needs right now. You are
doing a superb job handling this difficult situation. My ______ (b)(6) a hospitalis t in State College,
PA is on the front lines of this impending crisis in our community (he is (b) (6)ra;'1d also works clinically for
both intemal medicine and pediatrics).
Tappreciate the clear and easy to understand campaign to the genera l public to "flatten the curve" and slow the
inev itable sp read so that we don't overwhelm the medical community's capac ity to care for the seriously ill. I
sugge st that to add to this campaign (espec ially given the serious lack of testing; current ly he is waiting 4-7 days for
test results for hospita lized sus pected covid-19 patients ) that you make it clear to the American public that they
should NOT go to their docto r/hospital/ urgent care and instead stay at home, isolate themselves, and make a phon e
call to their doctor 's office or some sort of dept of health hotline.
If everyone with mi ld/moderate symptoms (and their imme diate contacts) are bringing the virus into medical
fac ilities, it greatly increases exposure and outs healthcare workers (and their families and communities) at
unnecessary risk. We need to convey to the Ame rican public the importance of keeping our healthcare workers
from falling ill (and into quarantine) so that they can treat those that absolute ly need to be hospitalized. There also
should be a mandated no visitor policy for suspected/confirmed patients al every point of care.
NIH-00064 1
I am interested in helping in any way lam able. Please let me know what I can do to increase awareness and
spread the vital messages you are trying to convey.
Thank you for your service and sacrifice for the greater good of the American people,
Sincerely,
Alecia Fay Siuta
(b)(6)
Sent from my iPhone
NIH-000642
From: Conrad, Patricia (NIH/NIAID) [E) on behalf of Fauci, Anthony (NIH/NIA ID) [E)
Sent: Fri, 13 Mar 2020 15:52 :12 +0000
To : Lynda Hayashi;Fauci, Anthony (NIH/NIAID) [E]
Subject: RE: dr ive up covid-19 te sts for Washington State
Dr. Fauci wanted me to thank you for your note.
Best,
Patric ia L. Conrad
(b)(6)
301-496 -4409 fax
Discla imer:
Th e informat ion in this e-mail and any of its attachme nts is confidential and may contain sens itive info rmation. It should not be used
by anyone who is not the original intended recipien t. If you have received this e-mail in error please info rm the sender and delete it
from your mailbox or any other storage devices . National Institu te of Allergy and Infectious Diseases (NIAID ) shall not accept
From : Lynda Hayashi (b)(6)

Sent : Thursd ay, March 12, 202010 :17 PM
To : Fauci, Anthony (NIH/ NIAID) [E]______ (b
...,)"'~= >
Subject : dr ive up covid-19 tests for Washington State
If South Korea can make th is happen why can't we? At least here in t he most hardest hit state .
Please make t his happen. We're all scared.
Lynda C. Hayashi
(b)(6)
NIH-000643
From: (b)(6)
Sent : Fri, 13 Mar 2020 09:23:12 -0400
To : NIAID Pub lic Inquir ies
Subject : Fwd: Coronavirus quest ion - please read
Sent from my iPhone
From: Zofia Agee Cb)(6)>

To: "Fauci , Anthony (NIH/NIAID) [E]" --------~=
Subject: Coronavirus question - please read ---------- CbH6>:
Dr. Fauci,
I'm not a medical professional. I'm just someone who is paying attention to what is going on.
I'm hearing that in many cases people have died because they developed pneumonia due to
coronavirus. Since there is no coronavirus vacc ine and won't be for a while can pneumonia be
prevented by getting pneumonia vacc ination? To me, that seems like a very logical course . I was
actually trying to get that vacc ine but I was turned away because I do not have any medical history
showing that I need it and I'm not 65 yet. Could this be some way to lower the death while working on
the vaccine? I have sent this to a few other places/peop le but not sure I'm reaching the right people,
so I'm hoping it will reach you or someone in your office that will read it:).
lfw e can not cure the virus yet, maybe we could get in front of it and prevent it from being deadly ...
Just a thought.
Zofia Agee
Zofia Agee
(b)(6)
NIH-000644
From: (b)(6)
Sent : Fri, 13 M ar 2020 09:18:32 -0400
To : NIAID Public Inquir ies
Subject : Fwd: thanks very much for your honesty and clear-eyed scientific integ ri ty
about coronav irus ! an analysis you m ight want to read or share
Sent from my iPhone
From: Jonatha n Fritz CbH6)

Dat e: Ma rch 13, 2020 at 8:3 1:51 AM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" --------=-=--=CbH6)
Subject : thanks ver y much for your hone sty and clear-eyed scientific inte grity
about coronavirus! an analysis you might want to read or share
Hello Dr. Fauci,

I wo uld like to thank. you for being one of the few honest and tm stworthy scientific
v01ces
as the world and the US confron t the challenges of coronavirus. I was recently sent
this thoughtful statistical analys is and thought you or one of your colleagues might
wish to see it.
best wishes, yours, Dr. Jonathan Fritz
https: //medium .com/@tomaspueyo/coronavirus-act-today-

or-people -will-die-f4d3d9cd99ca
NIH-000645
From: (b)(6)
Sent: Fri, 13 Ma r 2020 09:16:52 -0400
To : Cassett i, Cr istina (NIH/NIAID) [E];Auchincloss, Hugh {NIH/NIAID) [E]
Subject: Fwd : NK Cells for COVED-19
Pls respond.
Sent from my iPhone
From: Jeffrey Miller CbH6J

-------~~
Cc: "Fauci , Anthony (NIH/NIAID ) [E]"
Subject: Re: NK Cells for COVED-19 --------- CbH6J
Dr. Fauci ,
I am working with Ashley Haase and others at Minneso ta to think through the
feasib ility and wisdom of this appro ach. Let me know your thoughts if you have the
time. You look busy lately !
Jeff
On Fri, Mar 13, 2020 at 7:49 AM Jul ian Adams

--------- CbTI6>i
>wrote:
Dear Dr Fauci (Tony),
You may remember me from the early 90' s as I was the inventor of nevirapine ,
the first NNRTi. We met severa l times at NW D and FDA. I have since turned
my scie ntific interests to cancer research and discovered and developed Velcade
for multip le myelom a. And I have changed career paths again, turning to
immuno therapy to treat cancer . I am curr ently the CEO of Gamida Cell with a
focus on cellular therap ies.
One of our programs is the expansion of allogeneic NK cells. We are

collaborating with Dr Jeff Miller at the University of Minnesota and are
administering 10-20 billion freshly expanded NK cells in combination with
rituximab to pat ients with NHL. The results are stunn ing with 8/ l l patients
NIH-000646
achieving CR or very good PR with a single infusion. (see EBMT abstract
below). In addition, the safety profile has been remarkably good since two thirds
of our pati ents have Karno fsky perform ance <8 0. (NO CRS or Tumor lysis
syndrome or neurotoxicity has been observed)
(b) (4)
I thank you in advance, and look forward to your response, (also copied is Dr
Simantov, our Chief Medical Officer)
Warmest regards ,
Julian Adams, PhD
EBMT Abstract: (the conference due to have taken place in Madrid is postponed
but the abstract is availabl e online)
RESULTS OF A PHASE 1 TRIAL OF GDA-201, NICOTINAMIDE-

EXPANDED ALLOGENEIC NATURAL KILLER CELLS (NAM-NK) IN
PATIENTS WITH REFRACTORY NON-HODGKIN LYMPHOMA (NHL)
AND MULTIPLE MYELOMA
Veronika Bachanova1, David McKenna1, Xianghua Luo1, Todd Defor1,

Murali Janakirami, Claudio Brunstein 1, Daniel Weisdorf 1, Erica
Warlick1, Rose Wangen1, Fiona He1, Joseph Maakaron1, Zuzan Caycii,
Bartosz Grzywacz 1 , Guy Brachya 2, Tony Peled 2 , Jeffrey
NIH-000647
Miller 1 1University of Minnesota, Masonic Cancer Center, Minneapolis, MN,
United States, 2Gamida Cell, Jerusalem, Israel
Background: NK cells have the capacity to kill tumor targets and potential
in cancer therapy. Limitations include specificity, persistence after infusion
and how to maxim ize NK cell activity in vivo. We report results of a Phase 1
clinical trial of GDA-201, a cellular product composed of Natural killer (NK)
cells from healthy donors expanded ex-vivo with nicotinamide (NAM) and
IL-15, a unique ex vivo activation strategy to induce persistence. Prior in
vitro studies and pre-clinical models demonstrated that NAM-exposed NK
cells exhibit augmented resistance against exhaustion and improved killing
function, proliferation, and organ trafficking. We report safety and
preliminary efficacy from a phase I trial of GDA-201 in patients (pts) with
relapsed or refractory (R/R) NHL or MM.
Methods: Following donor apheresis, CD3-depleted mononuclear cells
were cultured for 14-16 days with NAM (5mM) and IL-15 (20ng/m l),
resulting in a 40-fold increase in NK cells and increased expression of
CD62L from 2.9% to 21%. GDA-201 contained ~98% NK cells, and CD3
content was maintained at <0.5% (<5x10s/kg/dose). Pts with R/R B-cell
NHL or MM received cyclophosphamide (400mg/m 2 IV x 3d) and
fludarabine (30 mg/m 2 /d IV x 3d), followed by two doses of GDA-201
(Days 0 and 2) and low-dose IL-2 (6 million units sc). Pts with NHL or MM
received rituximab (375 mg/m or elotuzumab (10 mg/kg), respectively, x
2
)
3 weekly infusions to enhance NK cell targeting through antibody-

dependent cellular cytotoxicity (ADCC).
Results: 25 pts were enrolled:11 with NHL (5 follicular, 5 diffuse large cell
lymphoma, 1 mantle cell lymp homa) and 14 with MM, in 3 cohorts of
escalating GDA-201 dose; 14 pts received the maximum target dose
(median 1.7 x 1Qscells/ kg, range 1.6-2.0 x 1Oscells/kg). There were no dose
lim iting toxicities. The most common grade 3/4 adverse events were
neutropenia and thrombocytopenia, febrile neutropenia (n=2), increased
creatinine, hyponatremia, pulmonary edema; all events were transient.
There were no neurotoxic events, confirmed CRS,GVHD or marrow aplasia.
One patient died of E-coli sepsis.
r4mong 11 NHL pts, there were 7 CR and 1 PR with an overall response rate
of 72%. Median duration of response is 11 months (CR patients) and 3
months (PR pat ients). In MM patients, 1 patient with extramedullary
disease had CR and 4 had SD with median duration 2.5 months. In our
previous study using overnight activated NK cells, persistence 7 days after
adoptive transfer was limited. Using GDA-201, flow cytometry confirmed
NIH-000648
the persistence of donor NAM-NK in peripheral blood up to day 7-10 (day
7 range 2-55% donor NK cells; Figure 1), as well as enhanced in vivo
proliferation (median Ki67 99%). In addition, the enhanced expression of
the homing receptor CD62L correlated with trafficking to bone marrow
and lymp h nodes in vivo as confirmed by flow cytometry of biopsied
tissues at day 4.
Conclusions: Cellular therapy using GDA-201 with mono clona l antibodies
was safe, and demonstrated early evidence of clinical activity in heavily
pre-treated pts with advanced NHL and MM. Laboratory studies show that
the GDA-201 product shows better persistence. Larger phase II studies are
warranted.
Clinical Trial Registry: clinicaltr ials.gov NCT03019666
Disclosure: Funding for the trial is provided by Gamida Cell. BMS is
providing drug only support.
Veronika Bachanova: Research Funding Gamida Cell, Advisory Board:
Gamida Cell
Julian Adams , Ph.D.
Gamida Cell
673 Boylston St 4th Fl
Boston, MA 02116
(b)(6)
Heather DiVeccbia
Chief orStaff
Gamkla Cell Ud. Cell Therapy Technologies
673 Boyls ton Street, 4 th Floor
Boston . MA 02 116
Direct: (b)(6)
NIH-000649
(b)(6)
www.gamida-celJ.com
gamida~ell
Jeffrey s. Mille r , M.D.

Profes sor of Medicine
Deputy Director , 11asonic Cancer Center
Division of Hematol ogy , Oncology and Transplantation, Univers it y of Minnesota
Roger L . and Lynn C. Headrick Famlly Cha i r in Cancer Therapeuti cs
Regular Mail :
Divisio n of Hematology , Oncology , and Transplantation
420 Delaware St . SE, Mayo Mail Code 806
Minneapolis , MN 55455
Federal Express or courier delivery:

University of Minnesota Cancer Center , Room 654A
425 E. Riv er Road
Minneapolis , MN 55455
CONFIDENTCALITY
NOTICE:Electronic messages canoe misctjrectect or Lntercep tect oy unint enctect
parties . '!'he University of Min nesota can not a nd does not g u.;,rantee c he confidentiality of
messages sent over the I n te rnet . Messages sent to or received from work e -mail accounts
also may be monitored or vie wed by your employer . I f you have rece i ved this communication
in error , plea se notify the sender imme diately a nd delete the information .
NIH-000650
From: (b)(6)
Sent: Fri, 13 Mar 2020 09:10 :05 -0400
Subject: Fwd: UV light for COVID-19 prevention
Sent from my iPhone
From: David Levi (b)(6) >

To: "Fauci, Anthony (NIH/NlAID) (E]" ------~~ (bH6J
·
Subject: UV light for COVID-19 prevention
Thank you for all your hard work trying to deal with this horrible pandemic. P lease
cons ider ways to get UV light cleaning devices through out the U.S. that they are
currently using in Wuhan, China to attempt to contain this virus. Closed schools and
sports venues can be cleaned with UV light while workers wear PPE and sunglasses
to protect themselves. This pandemic could be seen as an opportunity to help
prevent the spread of other contagious diseases by impl ementing rational public
policy such as UV cleaning when schools and sporting events have concluded . It
may also help "flatten the curve" and hopefully rebuild consumer confidence so we
can resume activ ities such as travel and commerce that is vital for the healthy of not
on ly our economy but our citizens .
Thank you again for your work and your time.
Sincerely,
Dr. David Levi
NIH-000651
From: (b)(6)
Sent : Fri, 13 Mar 2020 09:09:39 -0400
To : NIAID Public Inquiries
Subject : Fwd: Metr ics
Sent from my iPhone
From: Steve Fisher CbH6)

-------~~
To : "Fauci , Anthony (NIH/NIAID) [E]" CbH6Jr
Subject: Metrics
Thanks for your hard work on Coronavirus. What we desperately need are specific metrics
(available daily to everyone) on the disease. We also need to know how to evaluate
them. When will we know if it is getting better? It is really as bad as the med ia would have
us believe? Please set some goals and objectives on the metrics so we know where we are
and know when we have won or lost .
Yesterday Rush Limbaugh compared this to data on the Swine Flu in 2009 (60 million cases,
275,000 hospitalizations, 12,500 deaths from your website) and suddenly the Corona virus
doesn't sound very bad at all. Yet we have shut down the world economy and done
irreparable harm to many lives. Can you explain this? Frankly no one even remembers the
Swine Flu epidemic on ly 10 years ago.
SieJ>Re
JJ.£.i
sb_e
._._ __ ,.._,,,_,
(b)(6)
NIH-000652
From: (b)(6)
Sent: Fri, 13 Mar 2020 07:22:03 -0400
To : Morris Flaum
Subject: Re: Thank you
Thank s, Morris. I appreciate your note
On Mar 13, 2020, at 12:37 AM, Morris Flaum

--------- (b)(6) wrote:
Dear Ton y,
I had the good fortune of working with you and Ha rvey Gralnick when I was a
Clinical Associate at the NIH from 1977-1979.
I am writing to expre ss my deep app re ciation for speaking truth to power and being
one of the few honest voices in the governme nt at this time of crisis.
Your confidence and approach to articulating the issue and ramifications have
provided critical information to the American population.
Although COVID-19 is a un ique event, we would have been much better prepared
had you been leading the effort,;; in dealing with this outbreak.
Th e US owes you a great deal of gratitude.
Morris Flaum
Morris A Flaum, MD , MBA

Flaum Consultants , LLC
Consultant to the Healthcare Industry
NIH-000653
From: (b)(6)
Sent: Fri, 13 Ma r 2020 07:18:58 -0400
To : Lerner, Andrea (NIH/NIAID) [E)
Subject: Fwd: Trial by fire?
Please handle
From: Aaro n Harber Cb)(6)

--------~~
Subject: Trial by fire?
---------- CbH6)
Dear Tony,
You're doing a grea t job und er terrible circums ta nces so I hop e you hang in th ere . I'm
sure th e President is driving you nuts at t im es.
T know you 're probab ly far too busy to do yet an ot her program with me
(HarberTV.com / Fauci ) but, if you can send me a coupl e of quick answers this
morning, that wo u ld be great.
l. Do you think it' s realistic we could have an effective vacci ne for the COVID-19
virus by this Fall? My guess is it will be more like the Fall of 2021 but tell me if
I might be wrong.
2. Given that we've known abou t the probability of a pan demic, why are we so
poorl y prepared to address it (e.g., mas ks, test ing k its, medical staffing et
cetera)? I rea lize most of the needs rarely occur an d when they do, th ere are
extraordinary spikes in demand for cer tain products and expertise but one
wou ld think the re are ways to address this far bett er than we have.
3. Is there anything people should know that is not being emphasized?
Thanks for any resp onse you can sen d, even if it's a few words. And keep up the good
work . You are greatly appreciate d .
Best wishes,
Aaron
Aaron@HarberTV.com
NIH-000654
P: (b)(6)(+voicemail) C: (b)(6) (+texts)
Ha rberTV .com /I nfo + Har berTV.com /Awa rd
NIH-000655
Sent : Fri, 13 Mar 2020 01:26 :08 +0000
To: Marston, Hilary (NIH/NIAID) [El
Cc: Billet, Courtney (NIH/NIAID) [El;Conrad, Patricia (NIH/NIAID) [El
Subjec t: RE:Moderna trial
Need less to say, ___________________ Cb

_H_5.
-----Origi11alMessage-----
From : Marston, Hilary (Nll-1/NIAID) [El (b)(6)
Sent: Thur sday, March 12, 2020 8:23 PM
To: Grigsby , Garr ett (HHS/OS/OGA) -------~ =
(b)(6) >
Cc: Stecker , Judy (OS/ TOS) (b)(6) >; Pauc i, Anthony (NIH/NIA ID) [E] (b)(6) ;
Mango, Paul (HHS/IOS) (b)( ·; Harrison, Brian (HHS/TOS) ...______ _H....i ; Zebley,
.....,
Cb
Kyle (HHS/0S /OGA)
Su~ject: Re: Modema trial

(b)(6) -----
(b)( >; Richardson, Juliana (HHS/0S /OGA)
Correct - as of right now (b) (5)
Will let you know ifthere is an unforeseen delay.
On Mar 12, 2020, at 7: 19 PM, Grigsby, Ga rrett (HHS/OS/OGA)

>
> Hilary,
--------- (b) ( wrote:
)(5)
>
> Please let us know soonest.
>
> Many thanks!
>
>
>
>
NIH-00066 1
Sent : Wed, 11 Mar 2020 10:28:35 +0000
To : (b)(6) (OS/IOS);Giroir, Brett (HHS/OASH)
Cc: Harrison, Brian (HHS/10S);Stecker, Judy (OS/10S);Redfield, Robert R. (CDC/OD)
Subject: RE: High Risk from CDCWebs ite
Just checked the CDCguidance, which I had not had the t ime to read before. The secret ary w as
correct Here it is: CbH5)
(b)(S)
From: (b)(6) (OS/105) (b)( >

Sent : Wednesday, March 11, 2020 5:28 AM
To: Giroir, Brett (HHS/OASH)'======='--="
Cc: Harrison, Brian (HHS/105) (b)( >; Stecker, Judy (05/105)
(b)( ; Fauci, Anthony (NIH/NIAID) [E] (b)(6J>; Redfield, Robert R.
"'.'--.-'.":=====-=~
(CDC/OD) (b)(6)
Subject : Re: High Riskfrom CDCWebsite
Thanks Brett. Tony and Bob, (b) (5)

(b) (5)
On Mar 10, 2020, at 6:59 PM, Giroir, Brett (HHS/OASH)_______ Cb _ wrote:

_)_C6)
<Picture (Device Independent Bitmap) l.jpg>
Brett P. Giroir, MD
ADM, us Public Health Service
NIH-000690
NIH-000691
Sent : Wed, 11 Mar 2020 01:59:54 +0000
To : Stecker, Judy (OS/10S);Redfield, Robert R. (CDC/OD)
Cc: Conrad, Patricia (NIH/NIAID) [E);McGowan, Robert (Kyle) (CDC/0D/OCS);Lepore,
Loretta (CDC/0D/OCS);Murphy, Ryan (OS/ASPA)
Subject : RE: URGENT- -------,;- ~ (b)(5)
I amok with this
From: Stecker , Judy {OS/10S)

--------
Sent : Tuesday, Ma rch 10, 2020 9 :54 PM
(b)( '
------~ =; Redfield, Robert

(b)( >
-------- (b)( R. (CDC/OD)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b)( ; McGowan, Robert {Kyle) (CDC/0D/OCS)
-
. ---:----:-~===~~
(b)(6) >; Lepore, Loretta (CDC/0D/OCS) (b)( ; Mu rphy, Ryan (OS/ASPA)
(b)( >
Subject: URGENT-.__ _____ (5)
(b)__.
I understand you both know what this is regarding . Are you good with this?
(b)(5)
Sent from my iPhone
NIH-000703
From: (b)(6)
Sent: Sun, 8 Mar 2020 09:02 :09 -0400
To: Bright, Rick (OS/ ASPR/BARDA)
Cc: Lane, Cliff (NIH/NIAID) [El
Subject: Fwd: IL6 R
Rick;
See below.
Tony
Begin forwnrded message:
From: "Lane, Cliff (N IH/NIAID) [E]" (b)(6)i

To: "Fauci, Anthony (N IH/NJA ID ) [E]" ______ ------~~ (b_><_ >
Subject: Re: IL6 R
(b) (5)
lt poss16le, 1t woulo 6e of mterest to receive a copy or1'11eChmese treatment

guidelines you reference.
Thanks,
On Mar 7 , 2020 , at 10: 13 PM , Fauci , Anthony (NIH/NIA ID) [E]

(b)(6) wrote:
Please advise.
From: Bright, Rick (OS/ASPR/BARDA)

Sent: Saturday, March 7, 2020 3:18 PM -------- (b)(6)
To : Fauci, Anthony (NIH/NIAID) [E] -------=-:--= (b)(6),; Kadlec, Robert

(OS/ASPR/I0) (b)(
Cc: Walke r, Robert (OS/ A
_ s_P_R.:..
/B_A_R
_D_A.:.
) ===~~-~-- (b_H_6); Disbrow,
Gary (05/ASPR/BARDA) (b)(6); Johnson, Robert
(OS/ASPR/BARDA) (b)( ; Marston, Hilary (NIH/NIAID)
_______
[E]
Subject: Fwd: ll6 R

(b)(6); Shuy, Bryan (OS/ASPR/10)
_, Redd, John (OS/ASPR/SPPR)
(b)(6); -------- (b)(6)
NIH-000828
Dr Fauci,
I know that Dr Kadlec has mentioned the news we heard from

genentech about the evaluation of monoclonal antibodies to IL-6 and
IL-6R in severely ill COVID-19 patients in China.
Additional information became available yesterday and we learned

that China updated Their clinical guidelines to include anti-I LG.
(b) (4)
(b) (5)
I welcome your thoughts and would also make our team available fo r a
quick call if you prefer.
Many thanks. I know you are very busy.
Rick
(b) (4)
NIH-000829
(b) (4)
NIH-000830
(b) (4)
NIH-00083 1
From: (b)(6)
Sent: Sat, 7 Mar 2020 15:35:47 -0500
To: Lane, Cliff (NIH/NIAID) [E]
Subject: Fwd: IL6 R
Sent from my iPhone
From: "Bright, Rick (OS/ ASPR/BARDA)" (b)(6)

Date: March 7, 2020 at 3: 18:02 PM EST
---------
To: "Fauci , Anthony (NIH/NlAID ) (E]" ------~~ (b)( ·, "Kadlec, Robert
(OS/ASPR/10)" (b)(6)>
Cc: "Walker, Robert (OS/ASPR/BARDA)" ---------=-:-:=
_,------- (b)(6) , "Disbrow,
Gary (OS/ASPR/BARDA)" (bH >, "Johnson, Robert
(OS /ASPR /BARDA)' (b)( >, "Marston, Hilary (NIH/NIAID)
[E]"
,-------
(b)(6)"Shuy, Bry an (OS/ASPR/IO) "
---- ---------=-=-=
--------
Subject: Fwd: IL6 R
(b)( >, "Redd , John (OS/ASPR/SPPR) " (b)(6)
Dr Fauci ,
I know that Dr Kad lec has mentioned the news we heard from genentech abou t the
evaluation of monoclonal antibodies to IL-6 and IL- 6R in seve rely ill COVID-19
patient s in China .
Additional information became available yesterday and we learned that China
updated Their clinical guideline s to include anti-IL6.
(b) (4)
(b) (5)
Many thank s. I know you are very busy.

Rick
NIH-000859
(b) (4)
NIH-000860
(b) (4)
NIH-00086 1
Sent : Wed, 11 Mar 2020 02:58:28 +0000
To: Redfield, Robert R. (CDC/OD);Birx, Deborah L. EOP/NSC
Subject : RE: County specific guidance
Attac hments : Seattle_Community_Mitigtion_3_10 as version final with minor Fauci
ed its ..docx, Santa Clara_Community_Mitigtion_3_10 as (002) - with Fauci minor edits.docx
Bob :
They look pretty good . I have made a few minor changes that are tracked in the attached
documents.
Best regards,
Tony
From: Redfield, Robert R. (CDC/OD)____ _>

Cb
_<_ >
To: Fauci, Anthony (NIH/NIAID) [E)------ (b ~ >; Birx, Debora h L. EOP/NSC
~)-(6)
(b)(6)
Subject : Fwd: County specific guidance
Draft I am reviewing now but wanted you both now so not delay
Get Out look for iOS
From: Schuchat, Anne MD (CDC/OD) CbH6J>

Sent : Tuesday, March 10, 2020 5:58:15 PM
To: Redfield, Robert R. (CDC/OD) (b)(6)>
Cc: Cohn, Amanda (CDC/DDID/NCIRD/OD) (b)(6J>;Jernigan, Daniel B. (CDC/DDID/NCIRD/ID)
----- (b)(6J>;Redd, Stephen {CDC/DDPHSIS/OD)

(CDC/DDID/NCIRD/OD)
CbH6J>; Messonnier, Nancy
(b)( >; Schuchat, Anne MD (CDC/OD) (b)(6J>;McGowan,
Robert (Kyle) (CDC/0D/OCS) (b)(6);Berger, Sherri (CDC/OC00/0D) (b)(6J>;
Warne r, Agnes (CDC/0D/OCS) CbH6J>
Subject : FW: County specific guidance
Or Redfield: Attached please find (b)(5 t

(b)(5)
Note that if you are trying to send to Debbi Birx she mentioned that things going to her CDCemail will
not reach her so you may want to include Olivia Troye to make sure to meet your deadline.
NIH-000702
Sent: Tue, 10 Mar 2020 17:54:45 +0000
To : Mermin, Jonathan (CDC/DDID/NCHHSTP/OD)
Subject: RE:Great talk
Jon:
Thank you for your kind note. It is much appreciated. I hope that you are
well.
Best regards ,
Tony
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
From: Mermin, Jonathan (CDC/DDID/NCHHSTP/OD) CbH >

------
To: Fauci, Anthony (NIH/NIAID) [El -------= ~
CbH6J>
Subject : Great talk
Tony:
Superb presentation on COVID- 19 today!
----------• Excellent work with the media, Congress, and scientific community--you
have made a great difference for the nation and world in a complex time .
Best,
Jona
NIH-0007 10
From: (b)(6)
Sent: Fri, 13 Mar 2020 06:26 :43 -0400
Subject: Fwd: Urgent info rmation about a Corona Virus Management Device
Attachments: M edixair Micro virus report. pdf, ATT000Ol.htm, M edixai r White Paper - 2016
Jan.pdf 1.pdf, ATT00002.htm
Please handl e
From: Ani John (b) (6)>

Date: M arch 13, 2020 at 3 :13:38 AM E DT
To: "Fauci, Anthony (NIH/N IAID ) [E]"
------~~ (b)(6J
Subject: Urgent information about a Corona Virus Management Device
Dear Dr. Fauci

Given the gravity of the corona pandemic, my brother and I are reaching out
to make you aware of product that we think could help mitigate the spread of
the virus and protect health care workers as well as the public . We have
already tried the usual channels to contact the Wh ite House and the
emergency authorization use division at the FDA but also wanted to bring
this to your attention also.
Medixair™ , an ultraviolet (UVc) air sterilizer with proven , well established

unique patented germicidal technology to effectively and safely eradica te
viruses and bacteria up to 99.9%. It is capable of delivering a log6 reduction
in microbial concentration , by penetrating the nucleus of microorganisms,
disrupting their DNA thus destroying the ability of the organism to reproduce ;
effectively rendering it harmless .
Medixair™ is a portable unit and can easily be installed in a variety of

settings including hospitals , emergency rooms , waiting rooms , dentist
offices , cruise ships and airport lounges. In both clinical trials and under in-
vitro testing conditions (see attached white paper) , Medixair™ has been
demonstra ted to be highly effective in protecting patients and health care
workers from pathogens (e.g. MRSA, Clostrid ium Difficile) and also by
preventing cross infection . Specifically , Medixair™ was tested and found
effective for a strain of Coronavirus known as FCoV and thus COVID-19
would have the same susceptibility to eradication with UVc within a relatively
short period of time (attached).
NIH-000656
Medixair™ has been on the market since 2005 and is fully CE marked to EN
standards. Currently it has been safely and effectively used in acute
hospitals , dental surgeries , in UK, Malaysia, India, Israel, and Southern
Africa .
Please let us know how we can help make these units available for use in
the US during this critical period of time.
Kind regards,
Ani John , BSN, MPH, PhD Mathew Kaye,

San Ramon, California Manufacturer of Medixair™
Dudley , United Kingdom
NIH-000657
Sent: Fri, 13 Mar 2020 03:19:54 +0000
Subject: FW: Question from Jefferson Health NE Philadelphia
Please respond or refer.
From:Robert Danoff (b)(6)

To: Fauci,Anthony (NIH/NIAID) [E] ------ -=
(b-c-
)(c-=
6)
Subject: Question from Jefferson Health NE Philadelphia
Hi Dr. Fauci,
Hope all is wel l.
Dr. Fauci, we will be setting up COVID-19 testing facilities and I wanted to ask your opinion
regarding the following:
Is it ok to expand our testing beyond the current strict testing criteria to includ e those with
lesser symptoms or potential exposure whom we want to rule out Covid-19?
We are concerned that while we isolate those with more severe symptoms who currently
qualify for testing, the majority with lesser symptoms would be ambulatory and potentially
spreading the illness to others. Plus, it is hard to get someone to isolate for 14 days without
prov iding a diagnosis.
Just as we can test those we suspect fo r Inf luenza A, Influenza Band RSV,it would be helpful to
be able to test those we suspect with Covid-19, including healthcare workers with no symptoms
but with possible exposure.
Thank you for your time and your leadership for our nation's healthcare.
Be well.
Rob
Rob Danoff DO, MS, FACOFP,FAAFP
Program Director, Family Medicine Residency
Program Director , Combined Family Medicine /Emergency Medicine Residency
NIH-000658
Jefferson Health - No1theast
Clinica l Pro fessor of Famil y and Coilllmmity Medicine
Sidney Kimm el Medi cal College of Thomas Jefferson University
(b)(6)
Jefferson
Philadelphia University +
Thoma s Jeff e~o n Unlversity
HOMEOf 5IDIUYKIMMUMB>ICAI.
CDlLEGf
The info r matio n contained in this tr ansmiss ion contains privilege d and confidential information. It is intended only for the use
of the person named above. I[ you are not the intended recipient. you are hereby notified that any review, dissem ination .
distribution or dup lication of this communication is strict ly prohibited. If you are not the intended recipient, please contact
the sender by reply email and destroy all copies of the original message.
CAUTION: Intended recip ients should NOT use email communication for emergent or urgent hea lth care matte r s.
NIH-000659
Sent : Fri, 13 Mar 2020 03:18:51 +0000
Subject : FW: Varicella vaccine -COVI0-19 connection
Please respond.
From : Rose Marie Codling <rosemarie@literacymatters .education>

Sent : Thursday, March 12, 202011:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] ------- .----..-.
=
(b)(6)
Subject : Varicella vaccine-COVID-19 connection
Dr. Fauci,
Is it possible that the varicella vaccine could be playing a role in why children are not presenting with the
COVID-19 virus? If the vaccine became common around 1995, we wo uld be seeing little to no infection
of children and young adults up to about 25 years old, which seems to be the case. Could something in
the varicella vaccine have provided immunity to COVID-19?
Just an idea from a concerned citizen ...
Thank you for your remarkab le leadersh ip during this crisis.

Sincerely,
Rose Mar ie Codling
Rose Marie Codling, Ph.D.

Educational Consultant
NIH-000660
Sent : Fri, 13 Mar 2020 01:23:58 +0000
To: Collins, Francis (NIH/OD) [El;Tabak, Lawrence (NIH/OD) [El
Cc: Erbelding, Emily (NIH/NIAID) [El
Subject: RE:ASM Recommendat ions for speeding up COVID-19 testing
I would (b) (5)
From : Collins, Francis (NIH/OD) [E]

------- (b)(6)>
Se nt: Thursday, March 12, 2020 8:22 PM
(b)(6)>
_______
------~= (b)( _, ; Tabak, Lawrence (NIH/OD) [El
Cc: Erbelding, Emily (NIH/NIA ID) [E)

---------
(b) ( >
Subject : FW: ASM Recommendations for speeding up COVID-19 testing
Hi Tony and Lar ry,
Bit of a sto ry he re (b) (5)

(b) (5)
Thoughts would be most welcome.
Franc is
From : Collins, Francis (NIH/OD) (E]

Se nt : Thursday , March 12, 2020 8:07 PM
To: Bertuzzi, Stefano (b) (6b; (b) (6)
Cc: Erbelding, Emily (NIH/NIA ID) [E] (b)(6); Miller, Melissa
(b)(6); Stevens-Garcia, Jonathan (b)( >; Segal,
'"':'"'.":'---;;=:::=====~:;;---"".-:''""'
Allen CbH6l;McNult, Peggy
_...=-:----------
(b)(6)>
Subject : RE: ASM Recommendations for speeding up COVID-19 testing
Hi Stefano,
Thanks for this rapid turnaround survey and concise recommendations.
Adam, I'm g lad to help with conveying this message to FDA- though we should involve ADM
Giroir as well. How would you like to proceed?
NIH-000662
Francis
From: Bertuzzi,Stefano Cb)

(6J>
Sent: Thursday , March 12, 2020 7:57 PM
To: Collins, Francis (NIH/OD) [E] ------------~ (b)(6)
Cc: Erbelding, Emily (NIH/NIAID) '":"::":-:============::::_---
[E] -== Miller, (b)(6) ; Melissa
'":":':'---::=====~~--:-:~~
Allen
(b)(6)> ; Stevens-Garcia , Jonathan
(b)(6J>; McNult, Peggy (b)(6)
(b)(6)> ; Segal,
Subject : ASM Recommendat ions for speeding up COVID-19 testing
Dear Francis and Adam -
Sorry for the slight delay in gett ing to you the recommendations that ASM collected from clinical
lab directors . See attached document.
ASM leaders remain availab le for any further discussion that may be helpful to solve the current
impasse. Please do not hesitate to contact us, we are here to serve as a resource to you .
Sincerely ,
Stefano
St efano Bertu zzi, Ph.D., M.P.H.

American Society for Microbiology (ASM)
1752 N St., NW
Washington, DC20036-2904
Phon (b)(6)
NIH-000663
Sent : Thu, 12 Mar 2020 23:20 :57 +0000
To: Tabak, Lawrence (NIH/OD) [E);Collins, Francis (NIH/OD) [E]
Subject : RE:Time-sensitive
Please be "presumptuous" and go for it. Many thanks.
From: Tabak, Lawrence (NIH/OD) [E] CbH >

Se nt: Thursday, March 12, 2020 7:18 PM ---------
To: Collins, Francis (NIH/OD) [E]-------= Cb
"'""
H= ; Fauci, Anthony (NIH/NIA ID) [E]
(b)(6)>
Subject : FW: Time -sensitive
Francis, Tony-
I am certainly w illing to do this so that neither of you have to, but I did not want to be presumptuous in
case either of you preferred a different spokesperson .
Please let me know how I should respond to Mary.
Thanks
Larry
From: Mary Woolley <mwoolley@researchamerica .org >

Date : Thursday, March 12, 2020 at 10:02 AM
To: " Tabak, Lawrence (NIH/OD) [E)" -------- -== (b)(6)
Cc: Ellie Dehaney <edehoney@resea rchamerica .org>
Subject: Time-sensitive
Larry,
I have a favor to ask. Wou ld you or a designee be willing to join a teleconference next week with our
all iance members to discuss NIH's efforts to mitigate the negative impact of COVID-19 on federally -
funded research? We would need no more than 30 minutes of your time, and can schedule around
you. Ideally, though, we could make this happen soon (to state the obvious, everyone is feeling the
need for touch points right now , and you are a wonderfully calming one for our university members!) .
We could arrange the teleconference fo r as early as this Monday , the 16th: ifthere is a 30-minute
window for you or a designee between 1:00 pm and 3:00 pm on that day or within that same block of
time Tuesday, the 1ih, we'll commandeer it!
Thank you, Larry, for considering this ask. I'm sure it comes amidst many ot hers.
NIH-000664
I would love to close by saying something insightful about the indescribable times we were in, but all I
can come up with is "indescribable ."
My Best,
Mary
NIH-000665
Sent: Thu, 12 Mar 2020 23:10:14 +0000
Subject: FW: Feds say Florida has 'community spread' of coronavirus. Florida disagrees.
Check this out and get back to me. Not sure what he is talking about.
From:Robert Tober (b) (6)>

To: Fauci, Anthony (NIH/NIAID) [E]--------=- (b"""
)(=6) Nancy Lascheid (b)(6)>; Gail
Dolan (b)( ; ..
Le - s-:-
li_
e _L-as-c-:-
h-ei'."".
d-:===::!....-....:... ___ -======= (b
-=-
)=(6)
:;:--
----------------
Subject: Fw: Feds say Florida has 'commun ity spread' of coronavirus . Florida disagrees.
Dear Dr. Fauci,
I am medical director of a charity clinic in Nap les, Florida. A lthough we try to screen pts for
cough, fever, sore throat , URI sxs, dyspnea or unusual fatigue, appa rently some patients are
asymptomat ic and neg for these 5 hallmarks but still contagious. There is conflict between what
our Florida governor states and what CDC states. Do you believe all of our staff should be in
goggle s, mask , gown and gloves for AAL PATIENTS that we treat regardless of not meeting one
of the 5 screening criteria above. If indeed there is community spread happening, I and many
others are sitting ducks. It is not if but when !!
Thanks for any guidance you might be able to provide. l am copying to my administrative staff
as well.
Good luck. This is quite the challenge.
Robert Boyd Tober, M.D., F ACEP

Medical Director Neighborhood Health Clinic
Napl es, Florida 34102
(b)(6)-cell
To: Bob Tob er (b)( ,

Sent: Thursday, March 12, 2020, 04:46:08 PM EST
Subject: Feds say Flo1ida has 'communit y spread' of corona virus. Florida d isagrees.
https://www.tampabay.com/news/health/2020/03/ 11/feds-say-:florida-has-community-spread-of-coronavirus-t1orida-
disa grees/
NIH-000666
Sent: Thu, 12 Mar 2020 23:07:14 +0000
Subject: FW: Hi Dr Fauci (re : URGENT : epiqar Systems & Coronavirus 2nd tier events)
Please handle.
From:Jason Ressler (b)(

Subject: Hi Dr Fauci (re: URGENT: epiqar System s & Coronavir us 2nd t ier events)
Hi Dr. Fauci,
epiqar (https://epigar.com/) is the only system in the world that can help experienced
surgeons continue to support teams of less experienced surgeons worldwide, which we're
doing with Coronavirus quarantined surgeons in France & Italy now while we expand to
other theaters.
For Coronavirus care we 've just developed an easy plug in kit for remote hospital surgeries
which US hospitals need to be made aware of before they get overwhelmed the way they
are in Italy & China.
Here 's an article on epiqar from today inThe Hill.
Please let me know how we can help your teams.
Thanks,
Jason Ressler
Director, Business Development
ENGAUGE/EPIQAR
www.en g.us
www .epigar .com
The world's first low -cost telementoring, surgeon tra ining and instanc Cloud-archiving Platform
us 888.615.
7874
EUROPE44 2031399059
NIH-000667
Sent : Thu, 12 Mar 2020 23:06:46 +0000
To: Billet, Cou rtney (NIH/NIAID) [E]
----
Subject : FW: Very urgen t Coron avirus
------ ,a-s-r:=(b)(6)
NIAID inquiries, please.
From: Sushama Talwalkar

---------
(b)(6)>
To: Fauci, Anthony (NIH/NIAID) [ E] --------=- (b)'""'(=

6)>
Cc: Conrad , Patricia (NIH/NIA ID) [E] (b)(6)>; Barasch, Kimber ly (NIH/NIAID ) [CJ
(b) (6)·>
Subject : Very urgent Coronavirus
------ (b)(6)
Marc h 12, 2020

Dr . Fauci,
(b)(6)
Sincerely,
Sushama
Get Out loo k fo r An dro id
NIH-000668
From: (b)(6)
Sent : Thu, 12 Mar 2020 14:22 :38 -0400
To : El-Sadr, Wafaa M.
Subject : Re: Thank you
Thanks , Wafaa
On Mar 11, 2020, at 8:33 PM, El-Sadr, Wafaa M.
------------ Cb)( wrote:
Adding Tony's correct email address.
Dear Zunyou , John, Ralph and Tony ,
Thank you for your superb presentations in the Special COVID-19 Session at the Virtual
CROI 2020. As you can imagine, your presentations were very much appreciated by all the
audience . There is great thirst for more information at this point in time, which made your
presentations particularly timely and impactful.
Al I the best,
Wafaa
Wafaa El-Sadr, MD, MPH, MPA

Director, ICAP at Columbia University
University Professor of Epidemiology and Medicine
Mathilde Krim-amFAR Professor of Global Health
Tel: (b)(6)
Fax: 212 342 1824
www.icap.columb ia.edu
NIH-000669
From: Conrad, Patricia (NIH/NIAID) [Elon behalf of Fauci, Ant hony (NIH/NIAIO) [El
Sent : Thu, 12 Mar 2020 14:09:11 +0000
To: O'Donnell, Norah;Fauci, Anthony (NIH/NIAID) [El
Cc: Verdugo, Adam
Subje ct: RE:Thursday night
WE are working with Adam. Thank you
Patricia L. Conrad
National Inst it ute of Allergy and Infectious Diseases
Th e National Institutes of Health
(b)(6)
301-496-4409 fax
Disclaimer :
The informat ion in this e-ma il and any of its attachments is confidentia l and may conta in sensitive information. It should not be used
liability for any statement made that are sender's own and not expressly made on behalf of the NIAi D by one of its representatives.
From: O'Donnell, Norah <N0D3@cbsnews.com>

To : Fauci, Anthony (NIH/NIAID) [E]--------=- (b"'"'
)(=6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b)( ; Verdugo, Adam
<VerdugoA@ cbsnews.com> ----------
Subject: Thursday night
Dear Tony and Patricia,
Hoping for tonight from the W hite House or in studio . Adam Verdugo has been in touch and hope we
can lock down and confirm ti me.
Thank you W!D~□W!D
Norah O'Donnell
NIH-000670
On Mar 9, 2020, at 8:53 PM, Fauci, Anthony (NIH/NIAID) [E] (b)(6)
wrote:
--------
External Email
Norah:
Sorry that I took so long to get back to you. Just got out of the White
House a little while ago to get to my office where I am now and it is
obviously too late . Please copy my assistant, Patty Conrad, (copied
here) in future correspondence. I am so swamped with coronavirus
"stuff", I rarely get to e-mail until late at night.
Thanks,
Tony
Director
Phone : (b) (6)!
FAX: (301) 496-4409
E-mail (b) (6)
contain sensitive information . It should not be used by anyone who is not th e
original intended recipient. If you have rece ived this e-mail in error please inform the
sender and delete it from your mailbox or any other storage devices . The National
Institute of Allergy and Infect ious Diseases (NIAID) shall not accept liability for any
statements made that are the sender's own and not express ly made on beha lf of the
From: O'Donnell, Norah <N0D3@cbsnews .com>

-------c:-~
--------
Cc: Verdugo, Adam <VerdugoA@cbsnews .com >
(b)(6)
Subject: Monday night
Dear Dr. Fauci,
You are doing an amazing job helping to educate and inform during this crisis.
Are you available tonight or any night this week to join us for the Evening News?
NIH-00067 1
I am also happy to come to your office .
Norah O'Donnell
NIH-000672
Sent: Thu, 12 Mar 2020 10:48:06 +0000
To: Arthur Ammann
Subject: RE:Art again
Art:
Good idea. I will ment ion this to CDCduring this AM's daily meeting. Hope that you are
well.
Best,
Tony
From:Arthur Ammann (b)(6)

-------------
-------=:-:-=,Cb_H_6)
To: Fauci, Anthony (NIH/NIAID) [E)______
Subject: Art again
Tony. So good to see you now on TV in full charge. Your entire expression has changed
almost like when I bumped into you in the Washington Metro after you had gotten off
the plane with President Bush.
I have an interesting question regarding pneumococcal polysaccharide immunization.

One of our staff members phoned. Her father is a physician in France and has many
physician acquaintances. She was told that the doctors believe that the older patients
who received pneumococcal vaccine have less of a mortality than those who did not get
the vaccine.
When we did the studies and got the pneumococcal vaccine approved for the elderly in
1976 there was a battle about who should get it and whether was cost-effective. Since
then, other studies have documented the benefit, especially in older people and you
probably have received it. It is now routine but I know many elderly individuals have
not gotten immunized. Historically, many, if not the majority of deaths from influenza
in some of the past epidemics was a result of secondary infection with pneumococcus.
I'm not hearing anything about urging people to get immunized with pneumococcal
vaccine. The message would need to be clear so they don't confuse pneumococcal
secondary infection with primary coronavirus infection. It would be a good idea for
people to be urged to get the pneumococcal vaccine. If they had not received it. I'm
not seeing any recommendations from the CDC or elsewhere regarding this.
Please note : this document has been produced by a voice recognition program and may contain errors
or words that are out of context. Please let me know if clarification is required .
Arthu r J Ammann M.O.
NIH-000673
(b)(6)
www .Glob alStrat eg ie s.org

Ethics in Health
http :// ethics inhealth.org /
NIH-000674
Sent: Thu, 12 Mar 2020 10:23:36 +0000
Subject: FW: News - Germ/V irus Containment
Attachments: XTI Deck - Key Information OSHA.pdf
Please handle .
From: ___________________ Cb
_)_(6)
To: Fauci, Anthony (NIH/ NIAID) [E]______ (b
""'~""'
(6)
= >
Subject: News - Germ/Virus Containment
Importance: High
Hi Dr. Fauci,
I have been following the news and some interviews with yourself. I was hoping you would be willing to
speak with me about our technology?
Testing for the positive patients and finding a vaccine are essential, but containment is paramount.
We have the only GERM CONTAINMENT TEC HNOLOGY of it's kind.
The ongoing Coronavirus and FLU viruses pose a significant threat to public health globally and here in
the US.
We have the most powerful solution to minimize infection and maximize protection against SARS,
EBOLA , FLU, and all types of germs and viruses.
With local 3rd party tested efficacy of 100%, no other technology anywhere can yield this result or
sustainable 24/7/365 protection .
XTI02 is a world exclusive containmen t technology with self-cleaning functions that can help minimize the
risk of cross-contamination in hospitals, planes, public transportation, elevators, and public places.
XTI02 technology works by forming an invisible protective layer on mostly ALL material surfaces (plastic,
steel, glass , fabric, paper, walls, etc ...). It is green, sustainable, and has yielded up to 100% efficacy
proven by SGS LABS (US).
NIH-000675
I look forward to hearing from you and attached is an information file for you r review.
Thank you,
Michael Holbert
Cleancoati ng LLC
2522 State Rd., BLDG ISPBC
Bensalem , PA 19020
http ://www .cleancoa tinq.us
Email: Cb)(6)
Direct: Cb)(6)
Mobile Cb)(6)
DISCLAIMER
This e-mai l message is intended fo r sole use of the above named recipient(s) . If you are not the intended
recipient, you may not review , copy or forward th is e-mail message . If you have received this
communication incorrectly , please notify Clean Coating Technologies LLC immediately via e-mail or
phone and delete the message accordingly .
NIH-000676
From: (b)(6)
Sent: Wed, 11 Mar 2020 19:14:07 -0400
Subject: Fwd: CORONAVIRUS DATASUPPORTING
PROACTIVE
EFFORT
From: dennis malone (b)(6)>

To: "Fauci, Anthony (NIH/N IAID ) [E]" ---------=-:-:-=
CbH6)
Subject: CORONA VIRUS DATA SUPPORTING PROACTIVE EFFORT
Slr,
I appreci ate the effo rt of your entire team in ident ificati on and reso luti on of the
predicament the chinese government has gotte n us into. That said, I believe you
might add a more proact ive edge by min ing existing data. You' re going to have to
dig deep.
It seems that the commo n denominator in originating vector, at least by your news
releases, is plainly travel-related co-mingling of persons not otherwise in
contact. There fore, l wou ld propose that there is a great trove of existing data
waiting to be filtered within the travel manifest s' histo ry of US-bound airlines and
US-bound cruise vessels. Suggest as a start the collection of every manifest from the
last 4 months or so, filtered and compared with principl e contractees known to exist
in the US , and list every other person on said aircraft/vessel that disembarked on US
soil. DO NOT WAIT FOR PEOPLE TO GET SICK - Employ the National Guard
and Coast Guard to track these folks and put a swab in their nose. If positive, the n
contact trace this smalle r group. If nega tive maintain them on the list and force
complian t reporting if they develop suspected symptoms.
I know it would seem to be a lot of work. However, I presume your are familiar with
the FRAM Oil Filt er Guy from the 1970s, where it's better to pay now than
later because you're going to pay one way or another. Get a proac tive jump on
DETECTIO N, IDE NTI FICATION , CONTROL. We're burning daylight.
Respectfully submitted,
Dennis J. Malone
(b)(6)
NIH-000679
(b)(6)
NIH-000680
Sent : Wed, 11 Mar 2020 23:10:18 +0000
To : Sharon Cumbie
Subject : Re: Need to add cell phone disinfecting to the hand washing messaging
Attachments : image.png, POSTING.jpg
Than ks !
On Mar 11, 2020, at 6:46 PM, Sharon Cumbie wrote :

---------- CbH6)>
Dr. Fauci,
First , thank you for all you are doing to keep the publ ic infonned in a clear , direct ,
and truthful manner. I am writing to offer a suggestion.
The following is a post I just p laced on my Facebook page:
It's a 2-step process!!!

We are seeing the ubiquitous pleas for proper hand-washing as a
preventative against contracting the corona virus. BUT ...I have observed
people doing a great job of hand-washing , then picking up their dirty cell
phones!! The cell phone should FIRST be wiped down using a disinfecting
wipe (do NOT use sprays or household cleaning supplies). After cleaning the
phone , THEN do a proper 20 second hand-washing. Now, CARRY ON!
Step 1: https://www. tomsguide.com /news/how -to-clean -your -phone-to -protect -

aga inst -coronav irus ?tbcl id=lw AR 1WHGawAANyt kUOSmSV2SM -
UcZ5776 l mAsp -XR.k:UEKDsl YhcLRKXFBOJ io
Step 2: Proper Hand Washing

<image. png>
Photo message montage :
<POSTING .jpg >
I hone-stly do not see people disinfecting their cell phone s. I am active in our
----- Cb)(6) community and am trying to get this information across to people in
the comm unity. They have told me it was helpful and something they had not
cons ider ed. I tho ught it would be helpful for me to share with you .
Best Regards ,
Sharon Cumbie
NIH-000681
Sharon Ann Cumbie, PhD, RN, CS, CNE
(b)(6)
Professor of Nursing (b) (6)

Resea rch and Educa tion Cons ultant , Certifi ed Nur se Educator
e.ptal l::lealth Csm ns_eJ_uo
.,__~=
(b)(6)
Skype: _____ (b_H_6l
!&)\\et~LI'ldtt b)~ ,.,.p3"drub (Cl Sp,...u tM Lr.Mf IWff 1<$Mlk•S<.r~lh+so-,p

runnno
wato, PHnSIOQ911lOI
10 WUlO IWluSof the llilndl
1.1'» !)'II In bot;>,_ Ul4fllgt(S
compliw
eor~•
tI) ~/ PMIIC\lla(.ittae11on {9}Prffi t~ 11'1!0 !\) Olylhol:~wlCh I

tolhe~ l~ Pitit!I
of ffeh 11.\/ld dt~n 10'1
,.l
NIH-000682
From: (b)(6)
Sent: Wed, 11 Mar 2020 19:08:46 -0400
Subject: Fwd: Coronavirus
Please handle
From: Terr i Davis (b)(6)

--------::-,--:=,
To: "Fauci , Anthony (NIH/N lAID) [E]"
Subject: Coronavirus --------- (b)(6)
Dear Dr. Fauci;

I live in (b) (6) Last week there was the first incidence
of the Coronavirus. The officials in Media gave no true information on the
individual but that it was a female. When questio ned by the press as to the locat ion
in which the individual was - the respon se was that that information could not be
given. [ have also heard that it is in a violation of a person's privacy. No one is
asking for the person's name or address. If the public were given the general area of
the affected person they would proba bly stay clear of the area. The people directly in
the area wou ld be more cautious . Knowing where the person freq uented, for
example, the market would be pertinent in preventing spread of this virus. There is
so much information about this virus that is unknown yet most officials continue to
underscore the severity of this v irus.
Sincerely,
Teni Davis
Sent from my iPad
NIH-000683
From: (b)(6)
Sent: Wed, 11 Mar 2020 19:08:05 -0400
To: Cassetti,Cristina(NIH/NIAID) [E]
Subject: Fwd:Applicationfor NIH and Dr. BruceAylward from W.H.O.
Please handle
From: David Craig (b) (6)>

To: "Fauci , Anthony (NIH/NIAID ) [E]"
------~~ (b)( >
Subject: Re: Application for NIH and Dr. Bruce Aylward from W.H.O .
Evening Dr. Fauci,

My name is David Craig and I am one of the Founders of the Medsoft Group, a
Analytics, Telemetry and Reporting medical platform out of Canada. We would like
to offer our solution to the NIH free of charge, much like we have done with Dr.
Bruce Aylward and the World Health Organizat ion earlier today.
Our application will track, log and provide a pathway to true two-way real time
communication of COVID-19 as citizens around the US report their symptoms on
their mobile device . We are currently implementing our technology with our
partners at the University of Alberta, but we would like to refocus our immediate
attention in helping with the novel coronavirus .
Deployment of our application would allow the NIH to manage and understand
potential clusters and outbreaks of the pandemic, taking advantage of the
estimated 96% of Americans that use a smart phone to easily record a potential
case, providing all stakeholders across the US with the latest information.
Medsoft Group is ready to offer th is immediately and without delay. With your
cooperation we believe we could be up and running with in a week, providing th is
invaluable too l to better understanding where and what the virus is doing around
the country in real time.
Please let me know if you would like to speak further. We would be happy to
demonstrate our technology as well as discuss how we wou ld put this amb itious
plan into place.
Best,
David Craig
Co-founder &Ch ief Executive Officer
Medsoft Group Inc.
NIH-000684
C: CbH6)T: (b)(6)
-------
U: www .medsoftqroup.com
IMPORTANT: The contents of this email and any attachm ents are confidential. They are
intended for the named recipient(s) only. If you have received th is email by mistake,
please notify the sender immediately and do not disclose the contents to anyone or make
copies thereof .
NIH-000685
From: (b)(6)
Sent: Wed, 11 Mar 2020 18:35:29 -0400
To: Stephen Chiarello
Subject : Re: Treatment of Corona virus
Than.ks, Steve. l will fo1ward to my program staff
> On Mar 11, 2020, at 6:22 PM, Stephen Chiarello

>
___________ (b) (
__,
wrote:
> Anthon..y_: ___ ~~=

> This is
-----------
(b)(6) Stephen Chiar ello from
de rmato Iogist and interni st.
(b)(6) _ I am a board-c ertifi ed
>
> Justa brief note and certainly somew hat quixotic: The treatment of toxic epidermal necrolysis With TVvitamin C
and th iamine (benfotoxamine) May well stop the cytoki ne casca de with the coronav irus. This was used Wayback in
the po lio epidemic before the vaccine w ith great success but limi ted subscrip tion.
> I 'll send you the references.
> Sinc erely,
> Stev e chiarello
>
NIH-000686
From: (b)(6)
Sent: Wed, 11 Mar 2020 18:34:29 -0400
Subject: Fwd: Treatment of Corona virus
Please handl e .
From: Stephen Chia rello (b)( >

-----------
To: "Fauci , Anthon y (NIH/N IAID ) [E]" ------~~
Subject: Treatment of Corona virus
--------- (b)(6J:
Anthony:
This is----- ==
(b)(6) Stephen Chiarello from (b)(6)
1 am a board-certified dermatologi st and internist.

------------
Just a brief note and certa inly somewhat quixot ic : The treatment of toxic epide rmal
necro lysis With IV vitamin C and thiamine (benfoto xamine) May well stop the
cytokine cascade with the coronavirus. This was used Wayback in the polio
epidemic before the vaccine with great success but limited subsc1i ption.
I'll send you the references.
Sincerely ,
Steve chiarello
Sent from my iPhone
NIH-000687
Sent: Wed, 11 Mar 2020 11:53 :45 +0000
Subject : FW: From Whit Clark; possible theory and plausib le new thinking about a
Coronav irus
Please respond.
Anthony S. Fa uci, MD
Director
Nat iona l Ins titute of Allergy and Infectiou s Diseases
Buildi ng 31, Room 7 A-03
Bet hesda, MD 20892-2520
Phone: (b) (6)
FA X: (301) 496-4409
E- mail (b) (6)
The information in this e-mail and any of its attachme nts is confidential and may contain sens itive infom1at ion . It
should not be used by anyone who is not the original intended recipie nt. If you have received this e-mai l in eITor
please inform the sen der and delete it from your mai lbox or any other storage devices. The Nationa l Institute of
Allergy and Infectious Disease s (NJAlD ) shall not accept liability for any statements made that are the sender's own
and not expressly made on behalfofthe NIAID by one of its representa tives.
From : Whit Clark ,,,_..-----= (b,.,.
)""'
(6)
=-
Sent: Wednesday, March 11, 2020 7:39 AJ\'1
To : Fauci, Anthony (NlH/NlAlD) [E] --------=-=--:-= (b) (6}
Subject: From Wh it Clark; poss ible theory and plausib le new thinking about a Coronav irus
Jn Later November,
After a discus sion with my daughte r

yesterday (an Asst. Principal in (b)(6) area) , we theorized that the Co ronavirus May well have already been
here before the close of 2019. China had likely had the outbreak begin much ear lier but neve r acknowledged it;
peop le traveling to Chi na from the US could have returned and brough t the virus with them at a mu ch earlier date .
When thinkin g about the numb er of peo ple my daughte r and I have known that bad a bou t of respiratory illnes s with
a cough that cont inued much longer than the t)'p ical cold, we are propos ing a theory that possibly Coron a made its
entry here much ear lier... .and this new expected outbreak may well be more of a contin uation and less threatening
than possibly theo rized at this time. It is ju st a thought but I thought it was worth sharing. If true, we have already
met the disease and the deaths attributed to "nom1al" flus and respiratory cau ses in the elderly and prev iously
.impaired, may have been caused by Cor onavirus. This cou ld be a slight ly new twist and could pres ent a slightly
lower concern for a new major outbreak. Just a thought .....
Whit Clark William W

(b)(6)
Sent from my iPhone
NIH-000689
From: (b)(6)
Sent: Wed, 11 Mar 2020 06:23:48 -0400
Subject: Fwd: The Coronavirus
Pis respond
Sent from my iPhone
From: LAB (b) C

To: "Fauci, Anthony (NIH/NIAID) [E]" --------::-:--:-=
--------- (b)(6) .
Subject: The Coronavirus
Dear Dr. Fauci,
My name is Sargon Gorjian and I am a research chemist at Clean Plus Chemical in

S dne . Man ears a o I wa5 workin at Nanosonics com any in Sydney on
(b) (4)
I just wanted to share with you my experience with

(b) (4)
-----------
this type of work. I would suggest to have a look at Virox Pat ents. It will not do any
harm. It might be the right way to go.
Sorry to take up your valuable time.
I wish you all the best and good luck!
NIH-000692
Regards
Sargon Gorjian
Laboratory Manager
(b)(6)
Stop the spread. Plus

icals Pty Ltd
Instant Hand Sanitiser Is an alcoholbased gel whichkills
rge Young St .
bacteria(99.9916)w,rhin 30 seconds, no washing or rinsing
required. Testedand approvedaccordingto TGAmelhocl s. 44
Glycerinmoisturiser& Vitamin E. 444 F:
7
Contactus todayto placeyour orde,.
s.co m
Codt numbtr: 36430 (1211SOOmL
ttN )
Any views expressed in this message are those of the 1nd1v1dualsender, except where specifically stated to be the
view of the Company, its subsidiaries or associates. When addressed to our customers, any opinions or advice
contained in this email are subject to the relevani Company terms of business
....... Be earth -smart . Please con.sider the environment and cost of paper before you print.
NIH-000693
From: (b)(6)
Sent: Wed, 11 Mar 2020 06:21:19 -0400
Subject: Fwd: Breakthro ugh: Chloroquine phosphate has shown apparent efficacy in
t reatment of COVID-19 associated pneumonia in clin ical studies
Pis respond
Sent from my iPhone
From: RJ Claymont (b)(

To: "Fauci , An thony (NIH/N lAID ) [E]" ---------=-:-:-=
(b)(6)
Subject: Breakthrough: ChJoroquine phosphate has shown apparent efficacy in
treatment of COVID-19 associated pneumonia in clinical studies
Dr. Fauci -
Just thoug ht I'd brin g this article to your attentio n.
Are your rese arch ers trying Chloroq uin e?
https://www.js tage.jst.go.jp /article/bst/advpu b/O/advpub _ 2020.0104 7/_artic le
Best Regards
RJ Claymon t
NIH-000694
From: (b)(6)
Sent: Wed, 11 Mar 2020 06:20 :35 -0400
Subject: Fwd: NIH ketone ester for Coronavirus treatment?
Pls respond
From: Frank LLosa - KetoneAid (b) (6J

Date: March 11, 2020 at4:14:0 8 AM EDT
,------- --;;-~
Subject: NIH ketone ester for Corooavirus treatment?
Dear Dr. Fauc i
The re was a paper recently showing a ketogen ic diet helped tame the general flu, in
mice.
Meanw hile, there is a drink developed via DARPA and NI H (Dr Veech) that mimics
the benefits of the diet. It is called a ketone ester. Even shown to block effec ts of
nuclear bomb style radiat ion (LD-70 to 100% survival).
Who can I soak to about te sting this drink on mice for the general flu , or even
human s with Coronavirus symptoms?
Can I send you the paper ?
Thank you,
Frank Llosa
CEO KetoneAid
(b)(6)
NIH-000695
From: (b)(6)
Sent: Wed, 11 Mar 2020 06:19:56 -0400
Subject : Fw d: Curevac, meeting w ith President Trump
Please respond
Sent from my iPhone
From: Ingmar Hoen- (b)(6)

Dat e: March 11, 2020 at 2:20 :51 AM EDT
,------- -;;-c-;=
Subject: Cur evac, meetin g with President Trump
Dear Dr. Fauci,

I am the new CEO of CureVac. Would be good to update you on our efforts on
Covid-19 vaccine here in Europe. This is a globa l challenge, we shou ld learn from
each other to act fast and avoid mistakes . I do not accept any barrie rs from Stephane
Banceljust for compe titive reasons. Happy to call or to mee t persona lly.
Best regards, Ingmar Hoerr
Gesendet iiber BlackBerry Work

(www.blackberry.com)
NIH-000696
From: (b)(6)
Sent: Wed, 11 Mar 2020 06:19:13 -0400
Subject: Fwd: Coronavirus bioweapon production method
Sent from my iPhone
From: Adam Gaertner (b) (6)

,------- --;;-~
Subject: Coronavirus bioweapon production method
Hello Anthony ,
This is how the virus was created .
Inte rvirion Fusion. HIV-luc(ACE2) (500 ng ofp24) was mixed with 1,000 ng of p24
of HIV-gfp particles incorporating ASLV-A envelope, SARS-CoV S prote in, or
both envelopes in PBS at 4 °C for 30 min to allow bind ing. Samples were ra ised to
37°C for 15 min to allow for conformational rearrangements. Virions were adjus ted
to the desired pH with 0.1 M citric acid. PB S, TP CK-trypsin (final concentration 10
~tg/ml), CTSL , cat hepsin B (CTSB) (fina l concentrations 2 ~tg/ml) or CTSL buffer
alone was then added . Recombinant CTSL (R &D Systems) was preactivated by
incubat ion for 15 min at 10 µg/ml in 50 mM Mes, pH 6.0, on ice. Recombinant
CTSB (R &D Systems) was preactiv ated in 25 mM Mes, 5 mM OTT, pH 5.0, for 30
min at 25°C. After a 10-min incubation at 25°C, proteolysis was hal ted by the
addit ion of 300 µ1 ofDMEMIO conta ining leupept in (25 µg/ml) and STI (75 µg/m l).
Virions were then incubated at 37°C for 30 min to allow membrane fusion. 100 µl of
the virion mix ture was added in quadrupl icate to HeLa- Tva cells pretreated for 1 h
with leupepti n (20 ~tg/ml). The cells were spin-infect ed and inc ubated at 37°C for 5
h
NIH-000697
From: (b)(6)
Sent: Wed, 11 Mar 2020 06:15:22 -0400
Subject: Fwd: Prevalence of smoking, and reported mortality rates in COVID-19
From: Charles Kni ght (b) (6J

To: "Fauci, Anthony (NIH/NlAID) (E]" ,-------- (b)(
~=
Subject: Prevalence of smoking, and reported mortality rates in COVID-19
To whom it may concern:
I assert that the frequency of clinically significant disease, as well as severe disease
and morta lity of COVID -19 is much higher in smokers, as is the case with any
pulmonary infection, such as influenza, or bacterial pneumonia.
This is clearly in addition to that due to the

prevalence of elderly and immunocompromised patient s; but smoking status overall
may be a more significan t risk factor for clinically significant disease.
In listening to the news med ia, smoking has not been addressed as a significant risk
factor for disease.
I would suspect that smoking is at least one reason that such a high mortality has
recent ly been seen in Italy, and China, and I expect that mortality rates, as well as
rates of clinically significant cases, will also be increased in other populations with
increased prevalences of smokers, and strongly associated with the prevalence of
smoking in the given population.
Of course, the reporting of severe disease will be modulated by the effective ness of
the given population in containing the virus) as well as the effective reporting of
clinical disease within the community, whether severe or not.
ln listen ing to the news media, smok ing has not been addressed as a significant risk
factor for disease. I think that it should be addressed.
One wonde rs if it could be a modifiable risk factor, at least in certain patients (such
as those who have not smoked for very long).
NIH-000698
One also wonders whether this could be another good prognostic factor for limited
reported/ clinically significant cases (and thus limited perceived sprea d) in the
United States, obviously in addition to our early, effective containment measures.
Just thought this might be helpful.
Dr. Charles W. Knight, MD
Sent from my iPhone
NIH-000699
From: (b)(6)
Sent : Wed, 11 Mar 2020 06:12:10 -0400
Cc: Auchincloss, Hugh (NIH/NIAID) [E]
Subje ct: Fwd: Covid-19 patie nt in hospital without negati ve pressure room
Sent from my iPhone
From: 00~
To: "Fauci, Anthony (NIH/NlAI D ) [E]" --------=-=--=
(b)(6)
Subject: Covid-19 patient in hospital without negative pressure room
Hi Dr. Anthony Fauci ,
I saw you on M eet the Pr ess this weekend and you we re so awesome! Ve ry
informative, calm, assuring but with the right amount of inst illing the need for us all
to move fo1wa rd with the appropr iate caut ion for ourse lves. It's extreme ly reas surin g
to have you leading and guiding us during this time .
I'm emai ling you because I work at Kai ser Pem 1anente Hospita l in (b)(6)
- · Our administration init ially sa id if any Covid-19 patient came into the
ho spital needing emer geny care and needing to be admitted they wou ld be given an
N95 mask and put in a negative pressure room . Now they reve rsed that decision and
said they'd be put in a regular positi ve pressure roomn even after I showed them the
CDC's recommend ation for both co nfimed and possib le Covid-19 cases needing to
be placed in negati ve pressure rooms /A IIR.
Well tonight a possible Covid- 19 patient came to the Emergency Room and had to
be admitted to the ICU. The patient was given ju st a regular mask and put in an
elevator to the ICU . Management would not co nfi rm if the patient was in a negative
pres sure room and wouldn't give staffN95 masks. I again showed them the CDC
website hospital protocol Covid-19 recommendations but same response. And even
was ye lled at by the hospit al nur sing superv isor for ask ing about it.
I feel this is not safe at all for other patients , visitors and staff if the air is be ing
recirculated not ven ted outside or through a hepa filter before recirc ulating back
NIH-000700
through the hospital. I don't know what to do. Please help. The hospital main phone
number is Cb)(6) the Chief of the hospital is Cb)(6)
I know you're extremely busy now but any help or guidance is appreciated .. even if
it's just to confirm that any confirmed or suspected Covid - 19 patient needs to be in a
negative pressure room . Thanks so much!
Sincerely,
Kara Smalls
NIH-00070 1
Sent: Wed, 11 Mar 2020 01:38:17 +0000
To: NIAID0DAM
Subject: Fwd: Cancellation of 2020 Stanford Drug Discovery Symposium
Sent from my iPhone
From: Joseph Wu <joewu @stanford.edu>

------~~
To: "Fauci , Anthony (NIH/NIAID) [E]" CbH6>:
Cc: "David L.M.Preston" <preston @stanford.edu >, Amanda Chase
<chaseam a@s tanford.edu >, Sanjay Malhotra <svmalhot @sta nford.edu >
Subject: RE: Cancellation of 2020 Stanford Drug Discovery Symposium
,..-...,
•~
,- -=~j
!==.
SDDS 2020
StanfordDrugOi$<;overy
Symposium
__,# I
111._
April 20-21, 2020
Dear Dr. Fauci,
We greatly appreciate your willingness to participate in the 2020

Stanford Drug Discovery Symposium (SODS). As you undoubtedly
know, with the further spread of the novel coronavirus COVID-19,
Stanford is taking precautionary measures to minimize any
preventable spread of this viral disease. After much consideration,
we feel it is in the best interest of our speakers, guests, and
community to cancel the April 20-21, 2020, symposium.
We apol ogize for th e inconve nience this may cause in your

sche dules . We do hope th at you will agree to be our gues t speaker
NEXT yea r for our April 19-20, 20 21. As soon as your schedu le
allow s, p lea se let us know if you would be able to s eak at our 2021
SDOS meet ing.
NIH-000704
Please feel free to contact Dav id Preston preston@stanford.edu or
Amand a Chase chaseama@stanford .edu or myself
joewu@stanford .edu if you hav e any qu estion s .
Thank you for your und erstanding, and we hop e to see you next
ye ar.
Lastly, THANK YOUfor all service to our country and for educating
the public about the corona virus, we're a big fan of yours on all the
news media.
Sincerely,
Joseph C. Wu, MD, PhD

Sanjay Malhotr a, PhD
Kuldev Singh, MD
Mark Mercol a, PhD
Joseph C. Wu , MD, PhD

Director, Stanford Cardiovascular Institute
Simon H. Stertzer, MD , Professor of Medicine & Radiology
Stanford University School of Medicine
265 Campus Drive, Rm G1120B

Stanford, CA 94305-5454
Ph: 650-736-2246; Fax: 650 -736-0234
Email: joewu@stanford.e du
Tw itter: @StanfordCV I
Lab Websi te: http ://wulab.stanford .edu
Stanford CVI: http://med.stanford.edu/cvi .html
Oi Cardiovascular~
Stan £ord V Institute ,
NIH-000705
From: Conrad, Patricia (NIH/NIAID) [El on behalf of Fauci, Ant hony (NIH/NIAIO) [El
Sent : Tue, 10 Mar 2020 21:25:59 +0000
To : NIAIDODAM
Subject: FW: Fields Symposium
Patricia L. Conrad
Th e National Institutes of Heal th
(b)(6)
301-496-4409 fax
Disclaimer :
The information in this e-ma il and any of its attachments is confidentia l and may conta in sensitive information. It should not be used
by anyone who is not the original intended recipient. If you have received this e-mail in error please Inform the sender and delete it
From:David Knipe <david_knipe@hms.harvard.edu>

To: Fauci, Anthony {NIH/NIAID) [E] ------
(b)( > -=-<"=
Subject: Fields Symposium
Dear Tony,
I am sorry to write that we are going to have to cancel the Fields Symposium for April 24th, but we will
re-schedule when we can. As you may know, Harvard has cancelled all meetings larger than 100 (and
this morning limited that to 25) through at least April 30th. We are sad to have to do this, but we need
to help mitigate the spread of the virus. Harvard even told the undergraduates today to go home this
weekend and take their classes on line for maybe even the rest of the semester.
Thank you for all you are doing to keep everyone informed about the coronavirus outbreak . We are
going to give you the Harvard "Veritas " award when you are next here.
Stay wel l.
Best regards,
David
NIH-000706
David M. Knipe, Ph.D.
Higgins Professor and Head, Program in Virology
Dept. of Microbiology, Blavatnik Institute
NRB Room 9508
77 Avenue Louis Pasteur
Boston, MA 02115
Ph. 617-432-1934
Lab web site : htt p:/ /k nipelab.med .harvard .edu
NIH-000707
Sent : Tue, 10 Mar 2020 17:56:17 +0000
To: Auchincloss, Hugh (NIH/NIAID) [C] --------~~
Subject : FW: Funding, for Dr. Fauci ------------ (b)(6)
Please respond to thi s person.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail (b) (6l
From: Rena Patel (b)(6)>

Tol (b)(6)
Cc: Fauci, Anthony (NIH/NIAID) [E)
Subject: Funding, for Dr. Fauci
--------- (b)(6)
Responsiveness to emerging infect ious disease threats is important. However, I worry that increasing
funding is going away from global health priorities. It appears that the US Ending the HIV Epidemic has
already diverted funding within NIH from global work to domestic . Will the NIH response to COVID-19
only worsen funding available for global health?
Thanks,
Rena
Rena Patel, MD, MPH

She/her
Assistant Professor
Division of Infectious Diseases, Dept . of Medicine
International Clinical Research Center, Dept . of Global Health
Email: (b)(6)
Mobile : (b)(6)
Skype: (b)(
NIH-000709
Sent: Tue, 10 Mar 2020 17:46:08 +0000
To : Gary Spinner
Subject: RE: Testing for Covid-19
Gary:
If you have the resources and capability to do it, you should.
Best regards ,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b) (6)
From: Gary Spinner (b)(6)

------- ~=
Subject : Testing for Covid-19
--------- (b)(6)
Just heard your CROI talk. Thank you so much.

Should we be testing for Covid-19 in patients with flu like symptoms in our Community Health Center by
using commercially available tests for patients without history of travel or known contacts? We have two
cases thus far in (b) (6) where my center is located.
Gary Spinner
Southwest Community Health Center
NIH-000713
Sent: Tue, 10 Mar 2020 16:26:19 +0000
Subject: FW: asymptomatic infections of COVID-19
Attachments : thelancetrm-5-20-00427 .pdf
Please handle.
Director
Phone : (b) (6)
FAX : (301 496-4409
E-mail : (b)(6)
From:1iiJ ~ (b)(6)>
To : Fauci, Anthony {NIH/NIAID) [E]_______ (b
=-,)..,.
(6)
=
Subject : asymptomatic infections of COVID-19
Dear Prof. Anthony Fauci,

At first, I express regret if I am bothering you in your busy schedule.
I know you care about asymptomatic infection of COVID-19. COVID-19 is
spreading rapidly all over the world, especially in Iran and Italy, and possibly even
more widely. Asymptomatic infections and healthy carriers are possible sources for
transmission. However, such sources of infection cannot be effectively identified due
to the symptoms absent. The research evidence is ve1y lacking so far.
(b)(4J
NIH-000714
(b) (4)
This encourages me to write to you to seek help! I will be mo st grateful if you could
give us some suggustio n.
Look forward to hearing from you soon,
With kind regards,
Your s sincerely,
Yong He
NIH-000715
Sent : Tue, 10 Mar 2020 16:21:12 +0000
To: Hahn,S tephen
Cc: Redfield, Robert R. (CDC/OD); (b)(6) ;Cassetti, Crist ina (NIH/NIAID)
[E];Marston, Hilary (NIH/N IAID) [E]; (b)(6);Conrad, Patricia (NIH/NIAID) [E];Graham,
Barney (NIH/VRC) [E];Mascola, John (NIH/VRC) [E];Lerner, Andrea (NIH/NIAID) [E];Eisinger, Robert
(NIH/NIAID) [E]
Subject : FW: Coronavirus test
Attachments: nCoV-ColorimetriclAM P.pdf
St eve:
Let us discuss thi s whe n we are toge th er at t he 4:00 PM TF meet ing.
Thanks,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail (b)(6)
From: Roberts, Rich (b)(6)>

Se nt: Tuesday, March 10, 2020 12:05 AM
------=--c=
Subj ect : Coronavirus test
-------- (b)(6)>
Dear Tony:
If you can find a few minutes, I would very much like to talk with you briefly about a new diagnostic
LAMP test for coronavirus COVID-19 that we have developed here at NEB. I attach a paper now in the
MedRxiv that briefly describes the test. It has been used already in Wuhan and because of its simplicity,
speed and visual output we think it would be very useful for use here in the US. We have just met with
several people at Mass General Hospital and wil l be working with them for local validation here in MA.
The test itself is very inexpensive, does not require any special equipment nor train ing of technicians .
This would appear ideal for the FDA and the CDCto know about, but I have not so far been able to reach
NIH-0007 16
either Stephen Hahn or Robert Redfield . I would emphasize that our goals are to help deal wit h the
humanitarian aspects of the current problems.
I can be reached on my cell at

-----(b)(6) or in my office at the number below.
Rich
Sir Richard J. Roberts Ph.D. F.R.S.

1993 Nobel Laureate in Physiology or Medicine
New England Biolabs
240 County Road
Ipswich, MA 01938-2723 USA
Tel: (b)(6)
Fax: (978) 412 9910
emai l (b)(6)
Executive Assistant:
Tel (b)( ---- (b)(6)
Fax: (978) 412 9910

emai l (b)(6)
NIH-0007 17
From: (b)(6)
Sent : Tue, 10 Mar 2020 11:13:29 -0400
To: Cassetti, Cristina (NIH/NIA ID) [E]
Cc: Auchincloss , Hugh (NIH/NIAID) [E]
Subject: Fwd: Patented System - COVID-19
From P atty
Pis respond.
Sent from my iPhone
Begin forwn rded me ssage:
From: JOHN FLYNN (b) C

To: "Fauci, Anthony (NIH/N JAID ) [E]" -------~~
_______ (b_H_6J
Subject: Patented System - COVID-19
Dear Dr. Fauci,
I know that you are extremely busy, but I would respectfully urge you to take 5
ruins. of your time to review the information below as I believe that I have a
disruptive technolog y that can help prevent the spread of COVID-19.
My name is John Flynn. I previously founded a startup medical equipment company

that was focused within the area of orthop edics , wh ich I ran for twe lve yea rs. I
ultimate ly sold the company to a pub lic competitor, DJO Global. I have worked on
different healthcar e projects, but have exclusiv ely spe nt the last twenty month s
focused on a new medica l product within the area of infection prev ention . My goal
was to introduce what I believe is a disruptiv e product to help healthcare
facilities to prevent the spread of MDRO's in order to reduce HAl's /SSl's;
however , I believe that it can also help to reduce the spread of Coronavirus.
(b) (4)
NIH-000720
(b) (4)
NIH-00072 1
(b) (4)
NIH-000722
(b) (4)
Cb)<4> I hope that

--------------------------
you will have an intere st in further discussion .
a
Respectfully,
John Flynn
Cell: (b)(6)
NIH-000723
Sent: Tue, 10 Mar 2020 10:45:53 +0000
To: Houndsburgh
Subject : RE:Thinking of you
Linda:
Many thanks for your kind note. It is much appreciated.
Best rega rds,
Tony
Director
National Institute of Allergy and Iofectious Diseases
Building 31, Room7A-03
National Jnstitutes of Health
Phone: (b) (6)
f AX: (301) 496-4409
E-ma il (b)(6)
should not be used by anyone who is nol the original intended recip ient. If you have received this e-mail in error
Alle rgy and lnfectious Diseases (N1AID) shall not accept liability for any statements made that are the sender's own
·-----------=.,..,.=-
from : Houndsburgh.,...,,.....,..,,..,...,.....,..,..-,-....,.-----
(b)(6) >
To: Fauci, Anthony (Nlli/N IAID) [E) (b) (6) >
Subject: Thinking of you ---------
Dear Dr. Fauci,
You have been a bulwark for me since Twas a resident in the 1980s, dealing with the ATDS epidemic at LA County
General. For so many years, you have prov ided expert guidan ce in a calm, rational manner. As the Coronavirw;
becomes close r and closer to a pandemic, I know you have so much on your plate (hoarse vo ice, no? ).
I sen d you my best wishes to stay well yowself during these trying times, and hope that you know how much you
have meant , and continue to mean, to all physicians out there. You hav e given so much.
May God bless you always.
Best,
Linda Schmidt, MD
Internal Medicine
NIH-000724
Sent : Tue, 10 Mar 2020 10:16:29 +0000
Cc: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: Predict the potential outbreak of COVID-2019 in the region based on the
age information of reported COVID-2019 infected peop le
Attachment s: COVID2019Prediction20200310.pdf, S1.xlsx
FYI
From: (b) (6)>
Senc: Tuesday , Marcb J0, 2020 5:21 AM
To : Fauci , Anthony (NIH/NIAJD) [E] ------. ~=
(b)( >
Subject: Predict the potential outbrea k of COVTD-2019in the region based on the age infomiation of reported
COVTD-2019 infected peop le
Dear Prof. Anthony Fauci
My name is Chao Wu and I am a research staff in national clinical research center for infectious disea~es. the first
affiliated hospital of college of medicine of Zhejiang University of China .
Based on the public data of COVID-2019 infected people in China, l have developed a simp le model to warn the
potential outbreak of COVID-2019 in a region based on the age information ofieported COYlD-2019 infected
people.
Hope this could provide useful infonnationfor preventing COVI D-2019 spreading in US. And hope the two
countries can be together to fight with COVID-2019
Best wishes!
Chao Wu
Room6A17 13
Qingchun Branch
The First Affiliated Hospital of College ofMedicine of Zhejiang University. Hangzhou
NIH-000725
Sent: Tue, 10 Mar 2020 02:20:57 +0000
To : Eisinger, Robert (NIH/NIAID) [El
Subject: FW: FW: Coronavirus Remote Monitoring
Attachments : image001.png , image001.png
Please take a look.
From: ezriel kornel Cb)(6)

Sent: Monday, March 9, 2020 7 :10 PM
To: Fauci, Anthony (NIH/NIAID) [Elr------ --..(b.._..
)=
c >; Auchincloss, Hugh (NIH/N IAID) [El
(b)(6) >
Subject: Fwd: FW: Coronavirus Remote Monitor ing
I think this may be a very valuable program . I have no involvement but was sent to me for my input .
Ezriel Kornel, MD
---------- Forw arded message --------·

From: King,Nicholas<nicho las.king@bernstein.com >
Date : Mon, Mar 9, 2020, 5:07 PM
Subject: FW: Coronavirus Remote Monitoring
To 00~
Hi Ed,
I thought you'd find this to be of interes t. Greg is ~ (b)( ~ and I think the re may be an opportunity
to help health agencies. Do you know anyone that this could be passed along to?
Nicholas King
Vice President - Financial Advisor
T (b)(6)
nicholas.king@bernstein .com
11 ::-c: I
After Arts Group I Forbes
From : Greg OKeeffe (b)(6)

------------
Sent: Monday, Ma rch 09, 2020 9:05 AM
To: King, Nicholas <nicholas .king@be rnste in.com >
Subject: Coronavirus Remote Monitoring
NIH-000726
External Email. Use caution when clicking links or opening file attachments.
Nick,
Following up on our conversation this weekend, I am including some information below about our Remote Patient
Monitoring platform which we are making available for free to health agencies and organizations partic ipating in
the response to COVID-19 in the United States.
Remote Patient Mo nitoring with FollowApp is a HIPAA-Compliant system that helps health officia ls to diagnose,
contain and treat this highly transmiss ible vira l threat by enab ling the effective screening of large numbers of
potentia l patients and to triage/prioritize targeted clinical interventions including the use of test kits.
FollowApp's monitoring dashboard and patient mob ile applications (iOS and Android) can be used to deliver two of
the keys to an effective response plan: 1) encourage "self-qua rantin ing'' (a fundamenta l epidemiologic te net) and
2) off -load exploding cl inical volume threatening hospital Emergency Departments . Healthcare systems are thus
able to maintain important contact with these populations and recommend targeted escalation of care when
needed, while decreasing exposure to both clinicians and other patients.
The public perception of the lethality of t his globa l pandemic is fueling panic wh ich, in and of itself, is creating its
own logistic issues that are already beginning to overwhelm hospita l Emergency Departments. The dilemma for
health care systems, then, becomes a question of identifying subpopulations at increased risk wh ile at the same
time, keeping t hese patients out of the hospita l.
Please feel free to forward this email along with my contact information (cell
provide a demo to anyone who may be interested.
----- (b) (6)) -- I would be happy to
Thank you again,
Greg
Greg O'Keeffe
President & CEO
Human Resolution Technologies, LLC
www .Patient Monitor ing.com
Linkedln
The informa tion contained in this e-mail is legally privi leged and confidential information intended only for the use of the
individual or enti ty to whom it is addressed. If the reader of this messageis not the intended recipient, you are hereby
notified that any viewing, dissemination, distri bution, or copy of this e-mail messageis strictly proh ibited. If you have
received and/or are viewing th is e-mail in error, please immediately notify the sender by reply e-mail and delete this e-
mail from your system. Thank you.
e Virus-free. www .avast.com
NIH-000727
For further important information about AllianceBemstein please click here
http ://www .alliancebernste in.com/d iscla imer/ema il/discla imer .html
IHI BERNSTEIN
IHI BERNSTEIN
NIH-000728
NIH-000729
BERNSTEI
NIH-000730
BERNSTEI
Sent : Tue, 10 Mar 2020 02:19:50 +0000
To : (b)(6)
Subj ect : FW: Revised Nursing Home Guidance
At tac hment s: QS020-14. COVID-19 Nursing Homes - REVISEDNIAID.docx
I had my staff review this and their edits/suggestions are incorporated into the attached
document.
Best regards,
Tony
Disclaime r:
from your mailbox or any other storage devices. Nationa l Institute of Aller gy and Infectious Diseases (NIAID) shall not accept
liabi lity for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.
From : CMS (b)(6)

Se nt : Sunday, March 8, 2020 9:02 PM
To : (b)(6) Fauci, Anthony (NIH/NIAID) [E] (b)(6)
Subj ect : Fwd: Revised Nursing Home Guidance

----------
Would you mind reviewing our updated guidance to nursing homes? This is upgrading the policies
around visiting etc . Would like to send this out tomorrow.
Thanks.
Sent from my iPhone
Fro m: "Shulman, Evan T. (CMS/CCSQ)"_________ _ )_ C_6)>

Cb
Dat e: March 8, 2020 at 8:52 :14 PM EDT

To: CMS (b) (6)>
Cc:"Hittle, Matthew (CMS/OA)" (b)( >, "Brookes, Brady
(CMS/OA)" "Moody -Williams, Jean D. (CMS/CCSQ)"
(b)( ,
;.,__.:....:......:.......!::::======~=;:---
(b)( 6) >, "Wright, David R. (CMS/CCSQ)"
========::; (b:;::
)(c"=
6>:
">--
Subject : Rev ised Nursing Hom e Guidan ce
Seema,
Attached is the Nursing Home memo with revised guidance (changes are in red/italics).
This includes suggestions from Shari and Patti Meier, but they are still reviewing the full
document. We sent this to the CDCthis afternoon and I just received their feedback (while
NIH-00073 1
on this call). I skimmed through their feedback and while they recommended some
changes, they did not suggest any substantive changes.
Summary of revisions:
(b) (5)
We've also been in contact w ith the industry, and believe they will support the revisions .
Happy to answer any questions .
Thanks,
Evan
Evan Shulman
Director, Division of Nursing Homes
Quality Safety and Oversight Group
Center for Clinical Standards and Quality
Centers for Medicare and Medicaid Services
NIH-000732
From: Fauci, Ant hony (NIH/N IA ID) [El
Sent : Tue, 10 Mar 2020 02:11:06 +000 0
To : Ma rston, Hilary (NIH/N IAID) [El
Subject: FW: Coro navirus Case in Mu nich
Please respond to this person .
From:Rita DiCasagrande Olsen

--------
Sent: Monday, Mar ch 9, 2020 9:20 PM
(b)(6)
-------,;; ~
To : Fauci, Anth o ny (NIH/N IAID) [E]
--------
Subject: Coronavir us Case in M uni ch
(b)(6)
Carissimo Dr. Fauci -
Greetings from Munich, Germany! It 's hard to believe so many years have passed since
our t ime work ing avian influenza preparedness. I have watched every single interview
during the past few months and I could not be more relieved to see you at the helm of
this new, rapidly evolving crisis.
I know you have very little time, so I will make this quick - hopefully to be followed by a
more fulsome and proper hello.
We have a prominent American businessman (age 64) here in Munich who tested
posit ive a little over a week ago after skiing in the Dolomites in Italy. He has a history
of respiratory illnesses, including double pneumonias and various other similar
complicat ions. In short, he is sedated and intubated , and was placed on ECMOduring
the past 24 hours. The team is administering ritonavir and lopinavir, as well as broad
spectrum antibiotics.
The German docto r here would like to acquire Remdesivir to have on hand if all other
treatments fail. Because it is not being tested here, he inquired whether we could
access it in the States. Would you be able to point me in the right direct ion for how, if
even possible, we could transfer some to the Munich-based hospital here?
Thank you so much in advance. Any other insights of course are certainly welcome.
You continue to be a national treasure. All the best - Rit a
NIH-000733
Sent : Tue, 10 Mar 2020 02:09 :14 +0000
Subject : FW: Science of COVID-19 Curriculum?
Please respond to him for me. Try to help him out.
From: michael dispezio (b)(6)

----------
)(c-=
6)
Subject : Science of COVI0-19 Curriculum?
Dr. Fauci,
Twenty years ago, I wrote the US curricu lum "The Science of HIV" and we were honored to
have you featured in our accompanying television broadcast, which was nominated for an Emmy
(Discovery Channe l) . Years prior to that, I snagged my Masters from BU on some nove l,
emergent retrovirus called HIV.
Now , its time for me to do my magic and educate this new generation on COVID-19. This is a
familiar audience (my people ), since most use the science programs I have authored fo r K-8 for
the past 30 yea rs!
How do I best proc eed with developing materials in sync with the national needs that demys tify
the concepts sunounding COVID- 19? My skillset is in education, but my background in biology
and biochem.
Plea se Goog le me and/or check out the links below.
https ://www.ns ta .org/recommendsN iewProduct Print.aspx? ProductlD = 1213 8
ht1ps:// www. hmh co.com /people /m ichael -dispezio
NIH-000734
Sincerely,
M ichael Di Spezio (anothe Cb)< )

--------
Virus-free. www .avg.com
NIH-000735
Sent: Tue, 10 Mar 2020 00:58 :15 +0000
To : Collins, Francis(NIH/OD) [E);Trevor Mundel
Cc: Dan Wattendorf;Jennifer Weisman
Subject : RE: COVID-19
Trevor:
Ditto what Francis said. If Bill is seeing the VP tomorrow, he will surely bring it
up to me at our 4:00 PM daily Task Force meeting.
Thanks,
Tony
Director
Phone : (b) (6)
FAX: (301 496-4409
E-mail : (b)(6)
From:Collins, Francis(NIH/OD) [E] (b)(6)>

-------
To: Trevor Mundel (b)(6) >; Fauci, Anthony {NIH/NIAID) [E)
------ ....-
Cb
~H;;:
6);;-
>------------
Cc: Dan Watt endorf Jennifer
(b) (6>r>; Weisman
--------=======- (b
~~::;;
(6)
:c;------
Subject : RE:COVID-19
Hi Trevor,
Truly interesting opportunity. Tony is doing a media blitz (Sean Hannity on Fox right now) but
I' m sure he will check in - and I would imagine that VP Pence will turn to him to decide how to
respond to Bill' s phone call. Doctor-based testing capability in the US has gone up substantially
in the last couple of days - after admittedly a rocky start. But home testing presents a novel
detection scheme. I assume from what you say that false negat ives are uncommon and false
positives are rare?
NIH-000736
For Africa, this seems like a technology that ought to be deployed as soon as possible. It
astounds me that there are no documented cases in East Africa yet-that defies everything we
know about air traffic with China. Providing an opportunity for low -tech testing in Addis, or
Kampala, or Nairobi, or Dar es Salaam seems like a highly desirable outcome.
My two cents.
Francis
From: Trevor Mundel (b)(6)

Sent: Monday, March -----------------
9, 2020 5 :57 PM
-----~~
To: Collins, Francis (NIH/OD) [E] ______ _H_6)>; Fauci, Anthony (NIH/NIAID) [E]
Cb
(b)(6)>
Cc: Dan Wattendorf (b)(6); Jennifer Weisman
---------!:=====~=-..::~------
> (b)( 6)
Subject:COVID-19
Dear Francis, Tony,
I wanted to give you a heads up on a call that Bill will have with Vice President Pence tomorrow around
the COVID-19 sit uation. As you might be aware, we have been running an inf luenza transmission study
in Seattle for the last 2 years. This involves at-home testing fo r ILi-symptomatic individuals (who log-in
via a web app) and collection of nasal swabs, which are then sequenced for a range of respiratory
pathogens . Dan can give you more details on this study if you have questions. When the Coronavirus
situation arose, we added t his to the list of pathogens and hence were able to detect some of the early
cases in Washington.
The CDChas been very interested in the approach and at one point we had the highest screening
capacity in the US (though only 400 samples per day, so I hope this is no longer true). At the same time,
we have developed a COVID-19 at-home screening and information system with robust software that
approximates what China was doing but also takes into account the opt-in requirements that are
necessary in the US.
We want to propose going beyond the Seattle area- this would be gated only by availability of testing.
We can deploy this ready-now system more broadly in the US. Ideally we would also do a parallel
outreach to some African countries. I'd be interested in your views and would be happy to jump on a
quick call.
Warm regards,
Trevor
Trevor Mund el, MD, PhD

President, Global Health Program
V (b)(6)
F +1.206.494.7041
(b)(6)
E
-------------
NIH-000737
(b)(6)
Executive Assistant
Office of the President, Global Health
V (b) (6)
(b)(6)
Bill & M elinda Gates Foundat ion
www .gatesfoundation.org
NIH-000738
Sent : Tue, 10 Mar 2020 00:47:56 +0000
To: Del Rio, Carlos
Subject : RE:[External] Re:Nice job in PressConference
Attachment s: SSRN-id3549276.pdf
Not for distribution. lt may still be under review
Director
Phone: (b) (6)
FAX: (301) 496-4409
E-mail (b) (6)
and not expressly made on behalfofthe NIAID by one of its representatives.
From: Del Rio, Carlos ------ (b
""),...(=6);
To: Fauci, Anthony (NlH/NlAlD) [E] -------=-=-:-=
(b)( >
Subject: Re: [External] Re: N ice job in Press Conference
Share the Australian paper when you can. Could not find it.
Carlos del Rio, MD.

Sent from my iPhone
> On Mar 9, 2020, at 7:54 PM, Fauci, Anthony (NTH/N[ATD)[E] wrote:

> --------- (b) (6}
> Thanks, Carlos.

>
>> On Mar 9, 2020, at 7:21 PM, Del Rio, Carlos ...______ Cb
_>_<_ wrote:
>>
>>
>>
>> Carlo s del Rio, MD .
>> Sent from my iPhone
>>
>>
>> --------------
>> This e-mail message (including any attachments) is for the sole use
>> of the intended recipient(s) and may contain confidential and
>> privileged information. If the reader of this message is not the
>> intended recipient, you are hereby notified that any dissemination,
>> distribution or copying of this message (including any attachments)
NIH-000739
>> is strictly prohibited.
>>
>> If you have received this message in error, please contact the sender
>> by reply e-mail message and destroy all copies of the ori ginal
>> message (including attachments).
NIH-000740
Sent : Tue, 10 Mar 2020 00:30:13 +0000
Subject : RE: My column, just FYI
Well done!
Director
Phone: (b) (6)
FAX: (30 I) 496-4409
E-mail
-------- (b)(6)
Allergy and Infectious Diseas es (NIAID) shall not accep t liability for any statements made that are the sender's own
and not expressly made on behalf of the NIAID by on e of its representa tives.
From: Michael Gerson--------- (b
~)(=
Sent: Monday,Marcb 9, 2020 5:47 PM
To: Fauci, Anthony (N1H/N1AID)[E]------~-~
______ _ )_(6)
Cb _
Subject: My column,just FYI
https://www.washingtonpost.com/ opinions/ coronavirus-isnt-another-hurricane-katrina-its-

worse/2020/03/09/25c302f2-6224- l l ea-acca-80c22bbee96f story.html
NIH-00074 1
Sent : Tue, 10 Mar 2020 00:26:59 +0000
To : Mark Harrington ;Folkers, Greg (NIH/NIAID ) [El
Subject : RE: NYC community letter to M ayor De Blasio on social distancing measure s to
mitigate COV ID-19
Tha nks, Ma rk. Goo d lett e r.
Director
Phone : (b) (6)
FAX : (301 496-4409
E-mail : (b)(6)
From: Mark Harrington (b) < >

Sent : Monday, Ma rch 9, 2020 5 :42 PM
To: Fauci, Anthony (NIH/NIAID) [E)______ --------=-:~
Cb
_H_ >; Folkers, Greg (NIH/NIA ID) [El
(b)(6)>
Subject : NYC commun ity letter to Mayor De Blasio on social distancing measu res to mit igate COVID-19
At tached.
Hope you're both we ll.
cheers,
Mark
Mark Harrington
Executive Director
Treatment Action Group
90 Broad Street, Suite 2503
New York, NY 10004 USA
(b)(6) - tel.
NIH-000742
(b)(6)
mark.harrington@ t reat ment act iongroup .org
NIH-000743
From: (b)(6)
Sent : Mon, 9 Mar 2020 19:56:50 -0400
Subject : Fwd: Requesting a copy of your article
Pis handle
Sent from my iPhone
From: MahendraDe Silva (b) (6].

------------
Date: March 9, 2020 at 7:52:52 PM ED T
To: "Fauci, Anthony (NIH/NIA ID) [E]" ---------=-:-:-=
--------
Subject: Requesting a copy of your article
Cb)(6).
Dear Dr. Fauci:
Would you be kind enough to send me a copy of this important article (see below)?
Thank you .
Sincerely,
MahendraDe Silva, PhD
January 23, 2020
Coronavirus Infections-More
Than Just the Common Cold
Catharine I. Paules, MD1; Hilary D. Ma rston, MD, MPH2 ; Anthony S . Fauci, MD2
NIH-000744
From: (b)(6)
Sent: Mon, 9 Mar 2020 19:53:18 -0400
To: Krista Conley
Subject : Re:Terry Beirn
Kri sta:
Best rega rds,
Tony
> On Mar 9, 2020 , at 7:25 PM , Krista Conl ey

__________ _,
(b) (6) > wrote:
>
> Good evening Dr. Fauci:
>
> My name is Krista Conley and I was a staff assistant for Senator Kennedy's Labor and Human Resources
Committee in 1987. I was supporting the committee on health-related issues until one day, this smart-aleck of a guy
walked in and said "You work for me, now."
>
> That was Terry Beim, and I spent the next year ofmy life working on the very first legislation for research
funding and for anti-discrimination protections. Terry made me better, stronger, more empathetic than I ever
thought possible. He worked me relentlessly - and it never felt like work. Those were very tough times, and we
never let up, not even to eat.
>
> I fielded a lot of calls from you to Terry , and seeing the coronavirus press conference tonight, I wanted to thank
you for your tireless public health efforts. You changed lives to the good for millions - Terry did his bit, too.
>
> It' s good to hear your voice at the lectern - makes me feel like we'll get through it. Thank you for always jump ing
in - Krista Conley
NIH-000745
From: (b)(6)
Sent: Mon, 9 Mar 2020 19:43:06 -0400
To : Conr ad, Patricia (NIH/NIAID) [E)
Subject: Fwd : The Economist Asks request for Dr. Anthony Fauci
Let us discuss
From: Sujata Thomas <suja tathomas@economist.com>

To: "Conrad, Patricia (NIWNIAID) [E]"
-------~~ CbH6J
>, "Fauci,
Anthony (NIWNIAID) [E]" Cb)
C6>:
Subject: Re: The Economist Asks request for Dr. Anthony Fa uci
Hi,
I just wanted to follow up on this request for The Economist. The interview could
happen at Dr. Fa uci's convenience.
Th anks for the cons iderat ion.
Best,
Sujata
On Thu, 5 Mar 2020 at 08:48, Sujata Thomas

<sujatathoma s@econ omist.com >wrote:
Dear Dr. Fauci,
"The Economist Asks" , The Economist's award-winning interview podcast

would love to have you join the program this spring.
"The Economist Asks" is the Economist's flagship show , a current, frank

and engaging profile-style interview , in a series that includes heads of
state, cultural pioneers and business leaders, and hosted by Anne
McElvoy .
Anne wou ld like to discuss with you, your thoughts on coronavirus, its
spread and the managem ent of this globa l public health emergency.
We'd record 20 mins of interview, very flexible as to date and location -

though we'd love to do it soon - and are open to include subjects you feel
NIH-000746
need to be covered. We know you are likely inundated with requests, so if
you could connect me with the appropriate person handling your speaking
requests, we'd greatly appreciat e it.
Economist Radio has over 12 million listens a month worldwide , with a

core audience in the US and the UK. Previous guests on "The Economist
asks" include Melinda Gates, Tony Blair, Hillary Clinton , lmran Khan ,
Salman Rushdie, Annie Lennox , Anna Wintour, Darren Aronof sky, David
Sedaris , David Mamet, Margaret Atwood, Ursula Burns , Juan Manuel
Santos, Christine Lagarde, Jacinda Ardern, Michael Bloomberg, Pussy
Riot, Pete Buttigieg among many others. You can listen to previous
episodes here acast.co m/theeconom istasks .
Thank you for your consideration and hope to hear from you or someone
from your office .
Thanks ,
Sujata
(b)(6)
This e-mai l may conta in confidential material. If you a re not an intended recipient , please notify the sender and
delete all copies . It may also cont ain persona l views which are not the vie ws of The Economist Group . We may
monitor e -mai l to and from our netw ork .
Sent by a member of The Econom ist Group . The Group's parent co m pany is The Econo mist News paper Limited ,
reg istered in England with com pany number 236383 and registered office at The Adelphi, 1-11 J ohn Adam Street ,
London, WC2N 6HT. For Group company registration details go to http ://le gal.economist grou p.co m
NIH-000747
From: (b)(6)
Sent : Mon, 9 Mar 2020 19:25:47 -0400
To: Nl;\JDPqhliC'lnquiries
Cc: At.ithin d oss, Hugh (NIH/NIAID) [E]
Sent from my iPhone
From: Laura (b)(6)

To: "Fauci , An thony (NIH/NlAI D ) [E]" --------=-=--:=
--------- (b)(6>f
Subject: Still positive after 30 days
De_ar Dr:...£a uc.·._,,

_______________________ _, ...--,,.,
(b)(6)
Thank you ,
Laura Umphries
(b)(6)
NIH-000748
From: (b)(6)
Sent: Mo n, 9 Mar 2020 19:22:39 -0400
To: Auchincloss, Hugh (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E]
Subject : Fwd: Testing for COVID-19
From patty
Pis respond .
From: Robe rt Langston (b)(

Date : March 9, 2020 at 6:38 :20 PM EDT
To: "Fauci, Anthony (NIH/N IAID ) [E]" ---------=-=-:-= (b)(6)
Subject: Testing for COVID-19
Hello Dr. Fauci,

Are you able to provide false posit ive and false negat ive values for patients w ith
Corona Virus infect ion and colonizat ion?
Thank you fo r ta king t ime to read and respond my question .
My regards,
Robert Langston M D
NIH-000749
From: (b)(6)
Sent: Mon, 9 Mar 2020 19:21:36 -0400
To: Handley, Gray (NIH/NIAID) [E]
Subject: Fwd: CoV collabo ration with Polish Medical Research Agency
Attachments: image00l.png
From
Patty. Does asf need to see this
I am trying to empty his emails. Pls advise ASAP
From: "Hand ley, Gray (NIH/NIAID) [E]" (b)(6)

To:--------------. CbH6)
Cc: "Fauc i, Anthony (NIH/NIAID) [E] " CbH6) "Lane, Cliff
[E]" ___________
(NIWNIAID) [E]"
.....
Cb>< , ''Auchincloss , Hugh (NIH/N IAID)
Subject: CoV collaboration with Polish Medical Research Agency
Dear Dr. Sierpinski,
Dr. Fauci referred your message to me and other NIAID colleagues with a request that we
respond on his behalf so as to avoid further delay. We certa inly sympathize with your
situation, as we also are working urgently to prevent, control and manage COVID-19 in the
United States.
During his visit to NIH in 2018, I was pleased to meet Minister Szumowski and, although I
was traveling when you visited Dr. Fauci last year, I am aware that the meeti ng was
productive and that we remain interested in encouraging further U.5.-Poland scientific
collaboration . In part , as a result of that meeting, w e are also very pleased to be planning
an NIH and ABM-sponsored clinical research training workshop in Poland later this year .
As you are likely aware, NIAID is collaborating with a number of organizations to develop
vaccines for SARS-CoV-2.We are expecting the first vaccine to start Phase I t rials within the
next month . As vaccines move through Phase I testing, there may be opportunities to
collaborate .
In addition , with NIAID as the regulatory sponsor , we have initiat ed a rando mized,
controlled clinical tria l to evaluate the safety and efficacy of the investigational antiviral
NIH-000750
remdesivir in hospitalized adults diagnosed with COVID-19. This adaptive design trial w ill
allow for t he addition of new treatment arms as promising new therapeutics fo r COVID-19
become available. Eventually, t his trial may be expanded to include international sites,
potent ially includ ing some that have been affiliated with our INSIGHTNetwork in the
past. Three sites in Poland have part icipated in INSIGHT trials:
Site Name: Wroclawsk ie Centrum Zdrowia (Wroclaw)

Sit e Leader: Brygida Knysz
Site Name: Wojewodzki Szpital Zakazny (Warsaw)

Sit e Leader: Andrzej Jerzy Horban
Site Nam e: Uniwersytecki Szpital Kliniczny (Bialystok)

Site Leader: Robert Flisiak
It might be a good idea to let any Polish sites/investigators considering participation in this
trial know that ABM m ight have available funding to support international collaborat ive
research, if that is the case. This may be importan t info rmation as Polish scientists interact
with other European scientists considering the development of a multi -site clinical tr ial.
In addition, there may be other opportunities for collaborative research engaging Polish
Institutions with accessto COVID-19 patients, particula rly through the sharing of biolog ical
samples and research data. Another approach would be for interested Polish scientists to
explore shared interests with U.S. colleagues who are planning to apply for COVID-19
funding in response to current Funding Opportunity Announcements in the NIH Guide to
Grants and Contracts. To do what we can to facilitate possible collaborations, we would
also welcome receiving additional information on specific COVID-19 research interes ts,
capabi lities and activities current in Poland.
Thank you again for reaching out to Dr. Fauci. We look forward to continuing to discuss
potent ial areas of collaboration.
Best regards,
F. Gray Handley
Associate Directo r for International ResearchAffa irs
National Insti tute of Allergy and Infectious Diseases
National Insti tute of Health
Tel:
----- (b)(6)
Fax: 301 480 2954
5601 Fishers Lane, Room lESO
(b)(6)
Disclaimer:
The info rmation in this e-mail and any of its attachments is confidential and may conta in sensitive info rmat ion . It
should not be used by anyone who is not th e origina l intended recip ient . If you have rece ived this e-mail in error
please inform the sender and delet e it from your mailbox or any ot her storage devices . Nat io nal Institute of Allergy
and Infectious Diseases shall not accept liability fo r any statements made that are sender's ow n and not expressly
made on behalf of the NIAID by one of its representat ives.
NIH-00075 1
From : Radostaw Sierpinski
-------------
Date : March 9, 2020 at 6:42:08 AM EDT
--------="'""""=--
To : "Fauci, Anthony (NIH/NIAID) [El"
(b)(6)>
CbH6)>
Cc: "Gupta, Ranjan (NIH/FIC) [E)"
;....:..-======~~~
--------- (b)(6)
Subject : CoV collaboration w ith Polish Medi cal Rese arch Agency
Dear Doctor Fauci,
I hope this e-mail is finding you well and your efforts in fight against
Coronavirus epidemics is giving some effects. As you know in Poland we have
currently 15 cases of CoV infection and we are also fighting mostly with
general society wo rries than epidemics. We would like also to take part in
research on CoV vaccine or drug and Polish Medical Research Agency is
planning to start financing some project on it as soon as possible. Both polish
medical universities and institutes are fully prepared to take part in such
project .
On behalf of Polish Minister of Health Prof . Lukasz Szumowski I would like to
kindly ask you for some support and collaboration options with NIH in this
very del icate issue. Maybe NIH can take some advisory role in our scientific
project or Polish scientists may take some part in your work bilaterally .
Looking forward to hearing from you,
Radostaw Sierpinski MD , PhD

Preside nt of M ed ical Research Agency in Polan d
(b)(6)
<image0Ol.png>
M edical Research Agency
ul. S. Moniuszki 1A
00-014 Warszawa
www .abm.gov.pl
AGENCJA
BAOAN
MEDYCZNYCH
NIH-000752
AGENCJA
NIH-000753
BAOAN
MEOYCZNYCH
From: Conrad, Patricia (NIH/NIAID) [El on behalf of Fauci, Ant hony (NIH/NIAID) [El
Sent : Mo n, 9 Mar 2020 20:13:17 +0000
To: NIAIDODAM
Subject: FW: Opp to speak to U.S. CEO Commun ity
Attachments : CEOoverview _updated_5_31 _19_ (1) (2).pdf
Patr icia L. Conrad

Nat ion al Inst it ute of Aller gy and Infectious Disease s
Th e National Institutes of Heal t h
(b)(6)
301-496-4409 fax
Disclaimer :
The informat ion in this e-ma il and any of its attachments is confidentia l and may conta in sensitive information. It should not be used
liability for any statement made that are sender's own and not expressly made on behalf of the NIA i D by one of its representatives.
From:Greg Reilly <Greg@theceoforumgroup .com>

Sent: Monday , March 9, 2020 4:06 PM
-------~~ (b)(6J>
Subject: Opp to speak to U.S. CEO Community
Dr. Fauci,
Our national radio and magazine audience is the U.S. CEOcommunity, and th is is an invitation to be
interviewed for The CEOShow and The CEO Forum Magazine. The opportunity is to deliver your words
directly, verbatim , with no reporter's interpretation. [Company Overview attached.]
The line of questioning would be about advice for corporate leaders during a health crisis, such as we
are experiencing now with COVID-19 and such that we may experience again in the future.
We could do the 19-minute interview by phone or in person in New York City.
Certainly w e honor your service and excellence as a spokesperson.
Our out lets would be effective fo r your messages specific to business leaders.
Please consider this invit ation.
NIH-000754
Thank you
Greg Reilly
Greg Reilly I Associate Publisher
----- (b)(6) I greg@theceoforumgroup .com I www .t heceoforumgroup.com
NIH-000755
Sent : Mon , 9 Mar 2020 18:23:56 +0000
Cc:
Subject:
Marston, Hilary {NIH/NIAID) [E]
·------- (b)(6)
RE:Appropriations - second supp for cornavirus - professiona l judgement
request
W e w ill have additi onal needs. Wil l get back to you tod ay about th e amou nt and
wha t th e plan is.
Directo r
Phone : (b)(6)
FAX : (301 496-4409
E-mail : (b)(6)
From: Tabak, Lawrence (NIH/OD) [E] CbH >

To: Collins, Francis (NIH/OD) IE)
-----~~ Fauci, Anthony (NIH/NIAID) [E]
CbH6J>;
(b)( > -------
Subject : FW: Appropriations - second supp for cornav irus - professional judgement request
Import ance: High
How do you want this approached please?

Thanks
Larry
From: "M itch ell, Michelle (NIH/OD) [E]" CbH6J>

Date : Monday, March 9, 2020 at 12:43 PM
To: " Tabak, Lawrence (NIH/OD) [E)" CbH6)>,"Shapiro, Nei l (NIH/OD) [El"
(b)( >, "Hallett, Adrienne (NIH/OD) [E]" CbH6),"Higgins,
Lauren (NI H/OD) [El" CbH6)
Cc: "LaMontagne, Karen (NIH/OD) [El" CbH6)>,"Bauer, Jenna (NIH/OD)
NIH-000756
[E]" >
---------
Subject : Appropriations
(b)(
- second supp for cornav irus - professional judgement request
Hi everyone,
Jen Cama wit h DeLauro just reached out to request our professional judgement on a second
supplemental for the coronavirus . Below is her questio n. Would you let me know what I should tell
her?
Question: Does NIH, in its professional judgment, recommend any additional funding for coronavirus?
Thanks.
Michelle
NIH-000757
From: (b)(6)
Sent: Mon, 9 Mar 2020 13:49:31-0400
To : Oplinger, Anne (NIH/N IAID) [E]
Subject: Fwd : M ed ia Request: CBC News
From Patty pls decline
Sent from my iPhone
From: Adam Miller <adam.miller@cbc .ca>

-------~~
Subject: Media Request: CBC News --------- CbH6J
Hi Dr. Fauci,
I'm a senior journalist with the health unit at Canada's public broad caster, CBC
News, and I'm hoping to speak with you for a national story on COVID-1 9
preparedne ss in th e U.S. and Canada.
I'm wondering if you'd be free for a brief phone interview on how prepared the U.S .
bas been through out this outbreak and wha t further efforts need to be taken.
Thanks , I would only need five minutes of your time by phone.
Best,
Adam
Adam Miller
Senior Writer
CBC News
Desk: 416-205-5719
Cell: Cb>
(6)
Twitter: @adams miller
NIH-000758
From: (b)(6)
Sent: Mon, 9 Mar 2020 13:23:24 -0400
Subject : Fw d: Celiac and Coronav irus
Pls handle
Sent from my iPhone
From: Ten ley W illock (b)(6)

Dat e: March 9, 2020 at 1:00: 11 PM EDT
,------- -;;-c-;=
Subject: Celiac and Corona virus
Hello Dr. Fauci,

I am a teac her from -- -(b~ in a school district that closed this week
due to the vim s scare (b)(6) I am >< years old and I have (b)(6) What
is my vulnerabi lity to getting this virus teaching around young children. I know you
have mentioned heart issues and chemothera py. Can you please give me advice?
Tha nk you so much! Thank you for your hard work!
Sincerely,
Tenley Willock
(b)(6)
NIH-000759
From: (b)(6)
Sent : Mon, 9 Mar 2020 13:22:31 -0400
To: Haskins, Melinda (NIH/NIAID) [E];Selgrade, Sara (NIH/NIAID) [E]
Subject: Fwd: Senator Barbara Boxer
Pis advise. Set this up?
Sent from my iPhone
From: Nicole Burak (b)(

To: "Fauci, Anthony (NIH/NlAID ) [E]" ________
--------=-=--= _,
(b)(6)
Subject: Senator Barbara Boxer
Reply-To: (b)(6).
Dr. Fauci - my name is Nicole Kaneko and I work for Senator Barbara Boxer from California .
I know the Senator is (b)(6) and she is hoping you may have a few minutes to talk
to her via phone regarding an exciting way to test for the COVID-19 virus. Thank you in
advance .
Nicole Kaneko
(b)(6)
NIH-000760
From: (b)(6)
Sent: Mon, 9 Mar 2020 13:19:45 -0400
Subject: Fwd: Virus Transmission
From P atty
Not sure who responded. Canu take this repeat email.
Sent from my iPhone
From: DANIEL GAGNON (b)(6)

-----------
To: "Fauci, Anthony (NIH/NIAID) [E]" --------=-::-:-= >
Subject: Fwd: Virus Transmission -------- (b)(
Dr. Fauci:
I appreciated your office calling me last Thursday regarding my email concern

below on the CoYid 19 virus epidemic. The fact that China has a larger percen tage
of smokers in its population may have something to do with the faster spreading of
the virus ther e. Male smoke rs out number females by a huge number and are
there fore dying in much higher numbers because of that fact.
Has anyone at CDC look ed into when a pe rson is around cigarette smokers that the
particles of smoke land onto a persons clothing . That person then comes home with
those smoke particles on their clothing and they can be shed when the clothes are
removed from their body thus placing the possible virus laden particles back into the
air at home to infect others. Just smell your clothes the next day and you can no
doubt sme ll smoke on them . Has this case in point been looked into as a possible
means of spreading the virus? Since a side effect of the virus is the patient
developing pneumonia wou ld giving an elderly person the Prevar 13 shot help
streng then their immu ne sys tem before the virus ever strike s them?
I wish you &other virologist God Speed with finding a vacc ine that will stop the
spread of this epidemic.
Dan iel Ga non

(b)(6)
NIH-000761
From: DANIEL GAGN ON (b)( >

Subject : Virus Transmission -----------
Date: Februar y 24, 2020 at 3 :48:33 PM EST
To: CbH6
)
Hi Dr. Fauci:
I have been a long time admir er of you in the field of modern med icine.
This ques tion I have re lates to the current Coronavirus circu lating
around the world. For many years I have infom1edpeople that the ways
a virus can be passed from person to person isn't always by a sneeze,
cough or by touching someones face with their hands. Has anyone in
your medica l community thought tha t if someone were smok ing and
was an infected person that once they expel the smoke particles into the
air tha t those micro smoke particles may contain vi.ruses tha t were in the
respiratory system of an infected person. Everyone I mention this to
don 't believe that this is possib le. What are your thoughts on this
matter? If so why hasn't the medical communitywarned the public
about this possibility as I stay away from all establishmentsthat allow
smoking on their premises.
Thank you,
Daniel Gagnon
(b)( 6)
NIH-000762
From: (b)(6)
Sent: Mon, 9 Mar 2020 13:18:14 -0400
Subject: Fwd: Question re: coronavirus infection & pneumococcal vaccination
From patty
Can one of you pls respond. Thx
Sent from my iPhone
From: Manon Cox (b)(

To: "Fauci, Anthony (NIH/NIAID) [E]" --------.
(bH 6J
;..,...,-=
Subject: Question re: coronavirus infection &pneumococcal vaccination
Dear Dr. Fauci,
This is Manon Cox, former CEOof Protein Sciences, the developer of Flublok® .
First of all I would like to thank you for your realist ic comments around the ongoing
coronavirus outbreak. I am glad to see that not everyone is presenting a "Spanish Flu"- like
scenario.
I am reaching out to you b/c I am noticing that so many people including professionals
(MD's!) appear to be think ing that people with a coronavirus infection are dying from a
cytokine st orm whereas my understand ing is that pneumonia (whethe r viral or bacterial) is
generally the underlying of the lung failure.
My question to you is: Do we know whether people that have previously received a
pneumococcal vaccinat ion might be better protected from death after contracting a severe
coronavirus infection? i.e., would it be possible that the coronavirus causes tissue damage
resulting in a secondary pneumococcal infection?
I know bette r than anyone (afte r work ing over 15 years on Flublok approval) that it is not
realistic to expect a coronavirus anytime soon but if we could message that a
pneumococcal vaccine could be beneficial in ultimate outcome it would be good for
vaccines in general as we do have pneumovax and Prevnar available.
NIH-000763
Kind regards, Manon Cox
Sent from M ail for Windows 10
NIH-000764
From: (b)(6)
Sent : Mon, 9 Mar 2020 13:16:15 -0400
To : Oplinger, Anne (NIH/N IAID) [E]
Subject : Fwd: Time for an interview w ith Ame rica Magazine?
This is from patty

Pis decline.
Sent from my iPhone
Begin foiwarded message:
From: Kevin Clarke <clarke@americamedia.org >

To: "Fauci, Anthony (NIH/NIA ID) [E]" ------- CbH6J --..-.
--,
Subject: Time for an interview with A merica Magazine?
Dear Dr. Fauci,
America magazine is the flagship effort of America Media in New York. We are a min istry
of the Jesuits of the United States and Canada. America magazine may be the best known
Catholic publication in the United States, publish for more than 100 years .
I realize you must be supremely busy under the circumstances, but I thought I would ask if
you could spare a few minutes for an interview in New York, over the phone or on remote
via Skype for one of our internet programs to talk about the co ronavirus landfall here in
the United States, how the public can best respond. We would also love to hear how your
faith is helping you cope personally, perhaps how your Jesuit background is assisting your
decision-making in this drama.
Let me know if you think anything might be possible.
Thanks,
Kevin Clarke
Kevin Clarke
Senior Editor and Chief Correspondent
1212 Sixth Ave, 11th Floor
New York, NY 10036
Phone : 2 12-515-0130 (office)
NIH-000765
Phone : (b) (6) (mobile)
Phone (b)( (Friday)
Email: clarke@americamedia.or g
Web: www. americamedia.or g
America1
11~.Ri!~
Jo in the conversation: Twitt er <http://twitter.com /Amer icama g> I Facebook
<http ://facebook .com/Americama g> I YouTube <http://youtube .com /Americamag > I Tumbl r
<http ://americaliterary .tumblr .com/>
NIH-000766
Sent : Mon, 9 Mar 2020 16:07:16 +0000
To: Alison Galvani
Subject : RE: In press paper about impact of travel restrictions attached
Thanks, Alison .
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail Cb)(6)
From: Alison Galvani Cb)(6)

Se nt: Tuesday, March 3, 2020 4:04 PM
-------~~ (b)(6)
Subject : In press paper about impact of travel restrict ions attached
Hi Tony,
It may not be as pertinent as it was w hen we subm itted it, but I thought you might be interested in our
modeling on the global spread of COVID-19. It is in press at PNAS.
We also have a paper submitted to them about ICU and ventilator inadequacy in the US. I'd be happy to
send it to you now or wait until after the peer-review process .
Thank you for everything you do to lead us th rough these crises.
All the best,

Alison
Alison Galvani, PhD
Director , Yale Center for Infectious Disease Modeling and Analysis (CIDMA)
NIH-000767
New Haven, CT 06520
(b)(6)
htt p:// cidma .yale.edu/
NIH-000768
Sent: Mon , 9 Mar 2020 16:02:31 +0000
To: Jacquelyn (Jackie) Madry-Tay lor
Subject: RE: Dr. Marilyn Madry Lightfoote
Thank you .
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail Cb)(6)
--------
From: Jacquelyn (Jackie) Madry-Taylor
(b)(6)>
------~~
--------
Subject: Dr. Marilyn Madry Lightfoote
(b)(6)
Good Morning, Dr. Fauci,
I am CbH6) Dr. Jacquelyn Madry-Taylor. I

know she would want me to congratulate you on the outstanding information
you are providing the nation about the Coronavirus. The success of CbH
career was directly related to you allow ing her to work in your labs as she
began her career in molecular immunology . Your name was mentioned quite
frequently during those early years and throughout her work in the federal
government. I, CbH6)and othe r
fam ily members miss her so much and know that she would be on top of the
information about this new virus as you present it. Thank you so much for
being such a cata lyst for her success and we applaud your efforts in
identifying the source of the virus and finding a vaccine.
Sincerely,
NIH-000769
Jacquelyn Madry-Taylor , EdD
NIH-000770
Sent : Mon, 9 Mar 2020 13:18:02 +0000
To: Kate Dickman
Subject : RE:Thank You
Tha nk yo u!
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail Cb)(6)
From: Kate Dickman

----------
________
Sent : Monday, March 9, 2020 9 :00 AM
--------:a ~aa,
(b) (6) >
,.
(b)(6J>
Subject : Thank You
Dear Dr. Fauci,
I have been reading about your efforts to learn quickly about COVID-19, and subsequently educate the
American public about its risks. I wanted to say how grateful I am for your expertise, perseverance and
candor.
Updates about what Americans should do to keep safe, and understanding what may be deemed risky
for personal and community health, are greatly needed in these days of information (and possibly
misinformation) overload. Giving American people current information and clear, updated guidance is
the best way to create grassroots, coordinated, widespread effort, while the CDC,NIH, and other
government health organizations organize the tops-down approaches to regional screening, emergency
care, and COVID-19 research/testing for hopeful vaccination or treatment protocols .
I'm very relieved and assured to have strong voices of reason, experience, and merit helping 'us'
navigate these murky waters . I'm grateful for your courage.
Thank you again.
Kate Dickman
NIH-00077 1
(b)(6)
resident of
------- Cb)(6) Northern California
Sent from Postbox
NIH-000772
Sent : Mon , 9 M ar 2020 12:57:57 +0000
Subj ect : FW: Containment Measures
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From:Alex Wolf, Esq. (212)717-2 510 <awolf@wolf lawyer.com>

Sent : Monday, March 9, 2020 8 :43 AM
To: Fauci, Anthony (NIH/NIAID) [E
-------~~ (b)(6)
Subject : Containmen t Measures
Dear Dr . Fauci,
Why doesn't CDCcounsel entire country on need for conta inment measures as indi cated by t he
follow ing study:
black box appears in ori .
NIH-000773
Rapid Response was Crucial to Containing
the 1918 Flu Pandemic
Historical Analyses Help Plan for Future Pandemics.
(b)(6)
Would you know whether pulmonary sarcoidosis which has been in remission for years without
medication puts one at greater risk of Covid-19 hospitalization as an underlying condition, or would only
be higher risk if it was active and one was taking immunosuppressive drugs?
Thank you.
Alexander Wolf, Esq.

60 East 42nd Street
Suite 4600
New York, NY 10165
(b)(6)
NlH-000774
From: (b)(6)
Sent: Mon, 9 Mar 2020 06:49:10 -0400
To: Handley, Gray (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) (E];Barasch, Kimberly (NIH/NIAID) (C];Erbelding,
Emily (NIH/NIAID) (E];Lane, Cliff (NIH/NIAID) (E]
Subject: Fwd: CoV collaboration with Polish Medical Research Agency
Gray:
Please work with Emily to see what we can do for this person, if only with advice.
Thanks ,
Tony
From: Rados law Sierpinski Cb><

To: "Fauci, Anthony (NIH/NWD) [E]" --------. .--.,-,-=
Cc: "Gupta, Ranjan (NIH/FIC) [E]" _______ _
Subject: CoV collaborationwith Polish Medical Research Agency
Dear Doctor Fauci,
I hope this e-mai l is finding you well and your efforts in fight against Coronavirus epidemics
is giving some effects. As you know in Poland we have currently 15 cases of CoV infection
and we are also fighting mostly w ith general society worries t han epidemics. We would like
also to take part in research on CoV vaccine or drug and Polish Medical Research Agency is
planning to start financing some project on it as soon as possible. Both polish medical
universities and institutes are fully prepared to take part in such project.
On behalf of Polish Minister of Health Prof. LukaszSzumowski I would like to kindly ask you
for some support and collaboration options with NIH in this very delicate issue. Maybe NIH
can take some advisory role in our scientific project or Polish scientists may take some part
in your work bilaterally .
Looking forward to hearing from you,
RadosfawSierpinskiMD, PhD
President of Medical ResearchAgencyin Poland
(b)(6)
AGENCJA
SADAN
MEOYCZNYCH
NIH-000775
Medical ResearchAgency
ul. S. Moniuszki lA
00-014 Warszawa
www .abm.gov.pl
NIH-000776
Sent : Mon, 9 Mar 2020 09:57:48 +0000
Cc: (b)(6J
Subject: FW: Connecting with Tony Fauci
Attachm e nts: Baricitinib as potential treatment for 2019-nCoV acute respiratory disease .pdf
Please take a look and respond
From: Collins, Francis (NTH/OD) [E] (b)(6) >
Sent: Monday , March 9, 2020 5:29 AM
To : Fauci , Anthony (NTTI/NIAID) [E] ------~~ (b)( >; Erbelding , Emi ly (NTTI/NlAlD) [E]
(b) (6) >; Austin, Cb ristopher (NIH /NCA TS) [E] (b) (6)
-=-....,,,,-,--,-..,,...---,,...,.,,,,.._
Cc: Tabak, Lawrence (NIH /OD) [E) (b) (
Subject: FW : Connecti ng with To ny Fauc i
Passing this on in case Bill Chin's idea mignt be of interest.
Franc is

From : William Chin ________ (b_)~( = >

To: Collins, Francis (NIWOD) [E] ------~~
Cc: Baker, Rebecca (NIH/OD) [E] ; Austin, Christop her (NIH/NCATS) [E]
_______ _, ; Roger Glass ________________
(b_) _(6J (b_) _(6J
_,
Subject: Connecting with Tony Fauci
Hi Francis et al, I write to get a message to Tony, who clearly is on the COVID -19 front lines of these days and
"everyw here." At this early stage , you may agree that it is possible tha t containment and/or mitigation will not
completely solve the current pandemic . Instead, effect ive treatmen t or amelioration of the worst complications is
necessary. 1nthis spirit, I have an idea that was spurred by a letter in Lancet last month authored by Al Benevolent
(attached ). In this com munication they suggest that baricitinib (Oluminant ; a JAK1/2 inhibitor regis tered by Lilly
for the treatment of rheumatoid arthritis ), using in si lico techniques . might be useful in the treatment adva nced
COVID - 19 pneumon ia/ ARDS identified . Baric itinib could possibly blunt the cytokine storm seen in the most
severely affected patient s via inhibiti on of JAK 1/2, but also decrease viral en try in AT2 pulmonary cells and
my ocard ial cells via inhibition ofGAK and AAKI. It is has a relatively short plasma half-life and hence could be
mo re useful than Roche 's tocilizumab / Actemra). Baricitinib has a good safety profile although as a drug to treat
autoimmunity it is fonnally contraindicated in patients with infections, this could be offset by treatment patients
with anti-viraJs such as Gilead's remdesivir, etc. Perhaps you folks have already thought about/discus sed its use bu t
if not J' d like a chance to chat about my additional thoughts. Thanks. Bill
NIH-000777
Sent : Mon , 9 Mar 2020 03:10:28 +0000
To : Glenda Gray;Rancourt, Anne (NIH/NIAIO) [E];Dieffenbac h, Carl (NIH/NIA ID) [E]
Subject : RE: 'You don't want to go to war with a president'
Thanks, Glenda!
From: Glenda Gray <Glenda.Gray@mrc .ac.za>

Se nt: Tuesday, March 3, 2020 9:37 AM
_________
To : Fauci, Anthony (NIH/NIAID) [E]-------=-
.....
(b)
c-c
(6)
= >; Rancourt, Anne (NIH/NIAI D) [E]
Dieffenbach, Carl (NIH/NIAID) [E]
(b)(6)•>; (b)(6)
Subj ect : FW: 'You don't want to go to war with a president'
DearTo ny
wonderful art icle, proud to be associated with you
Subject : 'You don't want to go to war with a president '
https ://www .polit ico.com/ news/2 020/ 03/ 03/a nt hony-fauci-trump -coronavirus -crisis-118961
regards
Glenda
Glenda Gray
President & CEOSouth Afr ican Medical Research Council : Executive Management
South African Medical Research Council

Tel: +27 21 9380905 I Cell: (b)(6)
Francie van Zij l Drive, Parow Valley I Cape Tow n I Western Cape
ww w .sam rc.ac.za
saMR9 i YEARS
19 9-201 9
I
&l
Disclaimer - The information contained in this communication from the sender is confidential. [t is intended solely for use by the
recipient and others authorized to receive it. lf you are not the recipient, you are hereby notified that any disclosure, copying, distribution
or taking action in relation of the contents of this information is strictly prohibited and may be unlawful. This email has been
automatically archived by Mimecast SA (Pty) Ltd This e-mail and its contents are subje ct to tbe South African Medical Research
Co unc il e -mail legal 11oticeavailable at http ://www.samrc .ac.za/about/ EmailLcgalNoticc .htm.
NIH-000778
Sent : Mon, 9 Mar 2020 03:04:02 +0000
To: Birnbaum, Linda (NIH/NIEHS) [VJ
Linda;
Thanks for the note. I wou ld cancel if I were you .
Tony
From: Birnbaum, Linda (NIH/N IEHS) [V]________ Cb

_)_C6)
_,
To: Fauci, Anthony (NIH/NIAID) [E) ----- -=
(b=H=6J>
Subject: Than k you
Hi Tony,
Just wanted to say thank you as a fo r mer colleague and friend for speak ing truth to power during this
coronavirus crisis.
So, am I right in thinking t ravel ing to California for my major science meeting and some university
lectur es in a week should be canceled? I am, (b)( ~
Thx
Linda
NIH-000779
Sent : Mon, 9 Mar 2020 02:59:07 +0000
To : Thomas R. Frieden
Subject : RE: FYI - guess which
----
(b)(6JIwas thinking of ....
Great article. Glad to be the anonymous subject of your discussion. Q
From: Thomas R. Frieden (b)(6)

To: Deborah Birx (b)( ; Deborah Birx CbH6J;Fauci, Anthony (NIH/NIAID) [El
(b)(6J;Redd, Stephen (CDC/DDPHS.':":
IS:-:
/ -:-
0 -:-) ====
D-:. (b
~),,..,.
(= >; Schuchat, Anne MD
"'.'"
(C--D-C-:-
/0- D
-.,====~ (b-)(= >
Subject : FYI - guess whic li.___ ...i I was thinking of ....
_ )_(6)
Cb
New article re nursing home restrictions and more here.

From: Tom Frieden (b)( >
Date : Sunday, March 8, 2020 at 2:35 PM
To: Tom Frieden (b)(6)
Subject: Nursing homes are ground zero for COV ID19 -- and what more we can do to save lives
in the pandemic
Dear Colleague,
Two weeks ago it was clear that COVID-19 would become a pandemic , and, sadly it has.
Now the United States is in the acceleration phase and cases, clusters, and large outbreaks will occur in
many parts of the country.
I outl ine steps we can take to reduce the harms. The core concept to protect the most vulnerable. First,
restrict visits to nursing homes. All of us can play a part reducing infections. Medically vulnerable people
can protect themselves by reducing social contacts . I'm not sure I'd go quite as far as my good friend Bill
Schaffner and say they should become semi-hermits . but that 's certainly a helpful frame of reference.
Health care needs to get much safer, and ready to surge safely. And we need to stop mass gatherings,
consider telework, figure out whether closing schools will help, and more.
Read what I've posted about ground zero in the COVID-19 pandemic in the US here .
I've shared on Twitter if you'd like to disseminate.
We'll all be working together to protect as many people as quickly as possible .
Thank you,
Tom
NIH-000780
Tom Frieden, MD, MPH
President and CEO
(b)( t
TOSAVE
LIVES
ANlfllTIATIVE
OFVITAlSTRATEGIES
RESOLVETO SAVE LIVES
An initiative of Vital Strategies
STAYCONNECTED
www.resolvetosavelives.org facebook twitter
NIH-000781
Sent: Mon, 9 Mar 2020 01:49:23 +0000
To: Mark Feinberg
Subject : RE:Thanks so much
Mark:
Thanks for the note. Much appreciated.
Bet,
Tony

From: Mark Feinberg ------ ~=
(b) (6)>
Sent: Sunday . March 8. 2020 9:48 PM______ ~=
To : Fauci , Anthony (NTH/NIA ID) [E] ______ _>
Cb
_<_.
Subject: Tha nks so much
Dear Tony,
J hope you are doing well despite your extraordinar ily busy schedule address ing the COVID-19 outbreak.
J just wanted to se nd you a note to ofter sincere thanks and deep admiration tbr you r tremendous efforts 10 provide
the public with clear, insightful and accurate iufonn ation about this very ser ious public health threat and for your
great leadership in helping to guide efforts to respond to it in the most effecti ve and scientifically grounded way .
Our nation is so fortunate to have your full and expert engagement in this response.
I can only ima gine how busy you are and you need not worry about responding to this note. However, l did want to
share one voice of appreciation and thanks.
Very best ,
Mark
NIH-000782
Sent: Mo n, 9 Mar 2020 01:37:26 +0000
Subject : FW: Countering COVID-19
From: Clayton Conger (b)( 6)>

Se nt : Sunday, Marc h 8, 2020 9 :36 PM
------~~ =
To: Fa uci, Ant hony {NIH/NIAID) [E]
Subject: Coun t ering COVID-19
--------- (b)(6) >
Dr. An thony Fau ci

Director of the National Institute of Allergy and Infectious D iseases
Dear Dr. Fauci:
It occurred to me that if viruses contain an iron atom , perhaps a form of magnetic treatment might
stop or reduce the severity of the COVID-19 virus , so I investigated and found thatviruses have one atom
of iron. My sugges tion is that experimentation on victims of the v ims be conducted, perhap s by inserting
a tiny magnet into their lungs to see if it might gather up the vu.uses circulating in the victim . Perhaps
externa l application of magnetism would work as well, J'm sw-e yom scientists will have even better
approaches to so lv ing this problem. I'm a probl em so lver, hav ing pub lished a boo k that solves many of
the Earth's problems: "Thinking Outsid e The Oven -- Concomitan t Concepts and Synergi stic Solu tions
for the 21st Century" (availabl e at Barn es & Noble and Amazon ). I'm working on a sequel and if you
find my idea useful I'll includ e a chapter on it.
Very respectfully,
Ned Conger
(b)(6)
C.N. Con er
(b)(6)
NIH-000783
Sent : Mon, 9 Mar 2020 01:33:55 +0000
Subject : FW: Record a short interview with me for a UPenn course?
Sorry no.
From: Scheyder, Elizabeth C (b)(6)>

----------
To: Fauci, Anthony (NIH/NIAID) [E]--------=- (b)'""'
(=
6)>
Subject : Record a short interview with me for a UPenn course?
Dear Dr. Fauci,
I am emba rrassed to admit that I was not familiar with your name when I read the story about you in
today's NY Times, but I was most impressed by the statement in the first sentence that you are "widely
respected for [your] ability to explain science without ta lking down to [your) audience" .
I'm putting together the first offering of CLCH300 : Communicating Science, as part of the University of
Pennsylvania's new online Certificate in Climate
Change. {https :ij lpsonline.sas.upenn .ed u/academ ics/certificates/climate -change) A brief recorded
conversation wi t h you about your strategies for communicating without being patronizing would be
most enlightening for my students .
The students in this course w ill be coming from a wide variety of backgrounds, and potentially from all
over the globe. I think they wou ld love to hear from a scientist who is so good at communicating his field
of study to diffe rent audiences. And let's face it, as soon as you say "NIH" as COVI0-19 swirls around the
globe, their ears will certainly perk up! I think the students would find our interview very engaging and
informative .
The first run of the course will be from May 26 to July 20, 2020, but we can record the interview (on line)
any time, since I know you are already over-extended right now . I think 15 minutes would be plenty, and
I would be happy to send you questions that I plan to use to guide the conversat ion in advance. If a
synchronous conversation is impossible given your schedule, I would be happy to just send you a couple
of questions and ask you to use them to guide a 10-15 minute video that you record yourself .
Please let me know what you think of this, and I will send you the syllabus when it's finalized , including
where our interview would fit. Then I can begin the process of coordinat ing this with the Associate
Director of our Online Learning Studio.
Sincerely,
Elizabeth
Elizabeth C. Scheyder, Ph.D., P.E.

SAS Computing
Senior Instructional Technology Project Leader
NIH-000784
& Lecturer in SAS
Williams 441 B
NIH-000785
Sent : Mon, 9 Mar 2020 01:32:52 +0000
Subject : FW: can you use a miRNA-seq assay to detect covid-19 in blood samples?
Attachment s: GSE81852 MERSvs Mock control PCA p=2.le-8 q=7.79e-7 2 variables
8March2020.tif, GSE81852 MERSvs Mock control Hierarchical clustering heatmap p=2.le-8 q=7.79e-7 2
variables 8March2020.tif, GSE81852 MERSvs Mock control PCA p=6.4e-7 q=4.2e-5 10 variables
8March2020.tif, GSE81852 MERSvs Mock control Hierarch ical clustering heatmap p=6.4e-7 q=4.2e-5 10
variables 8March2020.tif
From : Hellmich, Helen (b)(6)

-------c.c .-.-=
-------- (b)(6)>
Subject : can you use a mi RNA-seq assay to detect covid -19 in blood samples?
Dr. Fauci, how are you sir?
Long ago, in the early 90's, I was a post -doctoral fe llow in the Laboratory of Viral and Molecular
Pathogenesis at NIH. I don't know if the same lab is still there. Now I work on brain injury and
Alzheimer's but my interest in viruses and mechanisms of viral pathogenesis has not waned and the
recent covid-19 outbreak prompted me to do a little investigation on my own.
My studies of blood microRNA changes after TBI and AD suggest that principal component analysis of
distinct changes in circulating miRNAs can identify the patient population. MicroRNA alterations can be
measured by real-time PCRwhich I presume is the basis of the test that is developed for this disease but
I am analyzing blood mi RNA-seq expression profiles and now it is possible to quickly sequence blood
samples in a few hours and get accurate results. Blood gene expression in my studies was more var iable
(lots of RNasesin blood) so I found that microRNAs are much more stable in blood and serum samples.
I attach an example of a PCA/hierarchical clustering heatmap analysis of a GEO dataset for MERs-coV
from 2016 https ://www .ncbi.n lm.nih.gov/geo/query/acc.cgi?acc=GSE8l852
I performed the PCA and heatmap analyses at two differen t stringencies and you can see that the
patients can be unequivocably distinguished from the controls at very significant p and FDRvalues.
Just a thought but many clinical centers , hospitals, academic institutions can quickly perfo rm
transcriptome-wide sequencing. Blood RNA can be isolated in 1-2 hrs, sequencing libraries made in a
few hres and one mi RNA sequencing run can handle up to 48 samples and the data can be quickly
analyzed.
Just my two cents on how NIH could accelerate the analysis of new blood samples for this new strain of
coronanvirus . You could mob ilize hundreds of sequencing centers to help in the analysis.
Regards
NIH-000786
Helen Hellmich, PhD
Associate Professor
Department of Anesthesiology
University of Texas Medical Branch
(b)(6)
NIH-000787
Sent: Mon, 9 Mar 2020 01:32:20 +0000
To : Erik Blutinger
Subject : RE:Fighting the fight
Thanks, Erik.
From: Erik Blutinger (b)(6)

------~~
To : Fauci, Anthony {NIH/ NIAID) [E]
Subje ct: Fighting the fight
-------- (b)(6)>
Tony,
It's been so inspiring seeing you fight tirelessly against COVID-19, sticking to the facts and stepping up to
explain on a daily basis.
If there's anything I can do to help from the world of emergency medicine beyond pat ient care, please
let me know . Whether that means taking on a new project or pushing my specialty organization, the
American College of Emergency Physicians (ACEP).I sit on their board and keep look ing for ideas to help
fight this pandemic .
Best wishes,
Erik
Erik J. Blutinger, MD, MSc

Department of Emergency Medicine
Mount Sinai Queens Hospital
(c (b) (6)
NIH-000788
Sent : Mon , 9 Mar 2020 01:30:35 +0000
To: Cassetti, Cr istina (NIH/NIAID) [E]
Subject : FW: COVID- 19 model
From : William Schiesser (b)(

To: Fauci, Anthony (NIH/NIAID) [E) -------
_:.:...__...:...::....:.!~~-------
.----..-.=
(b)(6)
Cc: William Schiesser (b)( >
Subject : COVI0-19 model
Hello Dr. Fauci,
May I bring to your attention a prototype computer -based

m athematical model for C0V ID-19 dynamics . I will be
glad to send some deta ils if you t hink they would be of
interest .
Thank you for your consideration of this query.
W . E. Schiesser, PhD, ScD

htt p:// ww w .lehigh.edu/~wes1/id cove r 2.pdf
NIH-00078 9
Sent : Mon, 9 Mar 2020 01:27:36 +0000
To : (b)(6)
Subject : RE:Californ ia DMV Coronavirus exposure danger
I recommend that you keep trying to work with Governor Newsom's office since this is vey
specific for the state of California.
From: (b)(6)>
To : Fauci, Anthony (NIH/NIAID) [E] ------ --=-
(b=)(=6)
Cc; Conrad, Patricia (NIH/NIAID) [E] (b)(6)
Subject : Californ ia DMV Coronavir us exposure danger
Dear Dr. Fauci,
I am writing to alert you to what I believe is a serious coronavirus health threat in California
that is being posed by the California Department of Motor Vehicles .
It has long been the policy of the California OMV that all drivers OVER 70 YEARS OLD must
renew their drivers licenses IN PERSON at DMV offices.
DMV offices are notorious for being extremely crowded and requiring long wait times where people are
breathing on each other touching each other and undisinfected surfaces and touch screens for hours.
As far as I am aware DMV offices are never sanitized so germs from thousands of people can remain
there
for weeks on end.
This is obviously a dangerous environment for anyone in the current worldwide coronavirus emergancy
yet nobody in the news media is reporting on it or even seems aware of the danger.
In light of your recent statement warning people over to 60 to avoid crowds this California OMV policy
seems to be incredib ly irresponsi ble and even life threatening but nobody is doing anything about it.
(b)(6)
""
N.,...
e_w_s_o_m__________ __ . Only one day earlier on March 4 California Governor Gavin
declared a State of Emergency in California to prevent the spread of coronav irus.
I find this situation to be utterly absurd since Newsom is allowing California citizens to be exposed to
exactly the kind of coronavirus danger he claims to be preventing and apparently does not even know
that the DMV is totally contradicting his emergency declaration , the CDC recommendations, the
California State Health Departmen t, the Los Ange les County Health Department, and the Pasadena City
Health Departmen t.
(b)(6)
I am concerned that nobody seems to see
the obvious public health threat. None of the relevant public health agencies have any information about
this
NIH-000790
on their websites and the Californ ia DMV website makes NO MENTION WHATSOEVER of Coronavirus
as a health threat in there overcrowded offices.
I would sincerely like to know what you make of this dangerous DMV policy. I also want to tell you that
the Californai OMV is currently advertis ing on the radio asking even more people to crowd OMV offices in
order to
get the REAL ID license.
REAL ID further exacerbates the danger by draw ing in more than NINE MILLION Californians to
leave their germs in OMV offices over 1he next few months at the exact time we are in the midst of the
greatest health emergency of this century and 1he most important recommendation is to AVOID
CROWDS and stay at least six feet away from other people. Try staying six feet away from anyone in a
crowded OMV office where hundreds of people are stuffed in like sardines.
Obviously a rational policy would be to suspend the requirement for drivers over 70 to renew in person
and simply
let them renew by mail until the coronavirus emergency is over .
The same should be done for REAL ID. A total suspension to protect public health in a crisis is the only
sane thing to do.
If I were the Director of the California OMV I would close all offices immediately and disinfect every inch
of them, and not reopen until the coronavirus emergency is over.
I would require that all OMV business should be done by mail or internet until the coronavirus threat is
over .
Please tell me what you think about all this and I will forward your response to local Pasadena officials
since state level officia ls are almost impossible to contact even in an emergency when they most need
to get this kind of information from the public but apparently do not want to know about bad news.
I greatly appreciate your voice of reason in these scary times. I wish the officials of the State of
California
were as reasonable but they are apparently oblivious to a serious and unnecessary danger being
created by
one of their own state agencies.
Sincerely
Robert Maine
(b)(6)
NIH-000791
Sent : Mon, 9 Mar 2020 01:24:37 +0000
Subject :
(b)(4)
Att achm ents:
FW: URGENT:
-----------------------
(b)(4)
(b)(4)
Please handle.
From: Michael Matin <michael.matin@hdltherapeutics.com>

To: Fauci, Anthony {NIH/NIAID) [E]______ (b
'"'~..-.
(6)
=>
Subject : URGENT:
1mp ortan ce: High --------------------------- (b) (4}
Dear Dr. Fauci:

(b)(4l
Please contact us at your earl iest convenience so that we may provide you with further data and
information concerning this treatment.
Best,
Michael M . Mat in
Chairman & CEO
HDL Therapeutics, Inc.
60HDL Theapeu t icsl 21st Street , Suite 300
Vero Beach, FL 32960
(b)(6)
From: (b)(4)
--------------------
6, 2020 6:18
Dat e: Friday, March at PM
To: (b)(4)
===============~------c (b
"")--=-
(4)
(b)(4
Dear (b)(4)::
----------
NIH-000792
(b) (4)
NIH-000793
(b)(4l
NIH-000794
(b)(4l
NIH-000795
(b)(4l
NIH-000796
(b) (4)
NIH-000797
Sent : Mon, 9 Mar 2020 01:23:24 +0000
To : Krasne, Robert
Subject : RE: Thank you!!!
Bob:
Many thanks for your note.
Best,
Tony
From: Krasne, Robert <rkrasne@steinmancommunications.com>

Se nt : Sunday , March 8, 2020 7:59 PM
To : Fauci, Anthony (NIH/NIAID) [E] ------ ..-.-,=
(b)(6J>
Subject : Thank you!!!
Tony,
Thank you for the science-based sani ty you are bringing to the COVID - 19 challenges. I follow
your public comments with great interest (and publish them in our newspapers here in
Pennsy lvania) and find solace that you are leading the efforts to address this extraordinary health
care challenge.
I cannot imagine the challenges you are facing, from disinformation to pure exhaustion, not to
mention the sc ientific challenges that this virus brings. However , if anyone is capab le of
wre stling these challenges to the ground, it is you.
You have my profound appreciation and admiration.
Best wishes to you,
Bob
---- Cb)(6) and your family.
Rob ert M Krasne I Chief Executive Officer

STE INMAN COM MUNI CATI ONS
.,,..,.,.,._..,.Cb
.,.,.. -!.. I SteinmanCommunications.com
~_(6)
8 West King St, Lancaster, PA 17603
NIH-000798
Sent : Mon , 9 Mar 2020 01: 19:21 +0000
Subject : FW: Coronav iru s Tre atment Question
Please handle.
From: Barb E (b)( 6)

------------
)(c-=
6)
Subject : Coronavirus Treatment Question
3-8-2020
Dr. Ant hony S. Fauci;
I have attached an article I read on line abo ut a doctor in Taiwan treating patients w ith Coronavirus, with
a combina t ion of ant i-viral drugs. Since the treatment helped the patients, I was won dering why they
are not t reating patients in the United States with those drugs .
Thank you.
Sincerely,
Barbara Eagan
https ://www.yah oo.com/news /cockta il-flu-hiv-drugs -appears - 124753996 .html
By Parm Wongcba- um
Reuters•Februa ry 2, 2020
Cocktail of flu, HIV drugs appears to

help fight coronavirus: Thai
doctors Reuters
•February
2, 2020
NIH-000799
By Panu W ongcha-um
BANGKOK (Reuters) - Thai doctors have seen success in treating
severe cases of the new corona virus with combinat ion of medications for
flu and HIV , with initial results showing vast impro vement 48 hours
after applying the treattnent, they said on Sunday.
The doctors from Rajavithi Hospital in Bangkok said a new approach in
coronavirus treatment had improved the condition of several patients
under their care, including one 70-year -old Chinese woman from Wuhan
who tested positive for the coronavirus for 10 days.
The drug treatment includes a mixture of anti-HIV drugs lopinavir and
ritonavir, in combination with flu drug oseltami vir in large doses.
"This is not the cure, but the patient' s condition has vastly improved.
From testing positive for 10 days under our care, after applying this
combination of medicine the test result became negative within 48
hours," Dr. Krian gska Atipornwanich , a lung specialist at Rajavithi,
told reporters.
"The outlook is good but we still have to do more study to determine
that this can be a standard treatment."
Chinese health officials have already been administering the HIV and flu
drugs to fight the corona virus. The use of the three together in a cocktail
seemed to improve the treatment, the Thai doctors said.
Another doctor said that a similar approach in two other patients resulted
in one displaying some allergic reaction but the other showed
improvement.
"We have been following internat ional practices , but the doctor
increased the dosage of one of the drugs ," said Somsak Akkslim ,
director-genera l of the Medical Services Department, referring to the flu
medicine Oseltamivir .
Thailand has recorded 19 cases of corona virus. Of the Thai patients ,
eight have recovered and gone home while 11 are still under treatment in
hospitals .
NIH-000800
Somsak said the health ministry will meet on Monday to discuss the
successful treatment in the case of the 70-year-old but said it is still too
soon to say that this approach can be applied to all cases.
Initially we will apply this approach only to severe cases," he said.
(Reporting by Panu W ongcha-um; Editing by Peter Graff)
NIH-000801
Sent from Mai l for Windows 10
• Virus-free . www .avast.com
NIH-000802
Sent : Mon, 9 Mar 2020 00:45:58 +0000
To: Collins , Francis (NIH/OD) [E];Erbelding , Emily (NIH/NIAID) [E];Cassetti, Crist ina
(NIH/NIAID) [E]
Cc: Austin, Christophe r (NIH/NCATS) [E];Tabak, Lawrence (NIH/OD) (E];Conrad,
Patricia (NIH/NIAID) [E] (bH 1·Marston , Hilary (NIH/NIAID) [E]
Subject : RE:ACE2
Em ily/Cristina:
Please contact Chris Austin and see if there is anything that we can do to he lp/coordinate
with them.
Thanks,
Tony

--------
Se nt: Sunday, Ma rch 8, 2020 2:13 PM
(b)(6)
To: Fauci, Anthony (NIH/NIAID) [E] <l

-------=-c-c=
Cc: Austin , Christopher (NIH/NCATS) [E]
(b)(6) -------- >; Tabak, Lawrence (NIH/OD) [E]
Subject: FW: ACE2
Hi Tony,
team help?
Best, Francis
From : Austin, Christopher (NIH/NCATS) [E] (b) ~ >

--------
To: Collins , Francis (NIH/OD) [E) ----- -=
(b"'""
)( =6J>
Subject : RE:ACE2
Hi Francis,
Very interesting paper . Larry likely let you know about the enclosed exchange, but enclosed if not.
(b)(5
NIH-000803
Chris
From : Collins, Francis (NIH/OD) [E]______ Cb

H_6>>
_
------~~
To: Austin , Christopher (NIH/NCATS) [E]_______ Cb
_H_6)
Subject : RE:ACE2
Structure of the coronav irus spike protein and ACE2 interaction is j ust out...
From : Collins, Francis (NIH/OD) [E]

Sen t: Saturday, March 7, 2020 10:58 PM
To: Austin, Christopher (NIH/NCATS) [E]--------=- (b)
,.,(=6)
Subject : ACE2
Yo Chris,
-
Francis
NIH-000804
Sent : Mon , 9 Mar 2020 00:37:42 +0000
To : Greg Simon
Cc: Erbeldi ng, Emily (NIH/NIAID) [E];Cassetti, Cristina (NIH/NIA ID) [E]
Subject: RE:TXA127 for COVID-19 pneumonia --CONFIDENTIAL
Greg:
Thanks for this. I will bring it to our group. I hope that all is well with you.
Warm regards,
Tony
From : Greg Simon (b) ( >

Subject : Fwd: TXA127 for COVID-19 pne umonia --CONFIDENTIAL
here is the paper i ment ioned from a friend of mine fo r yo ur consideration. Thank you for all you'r e
doing
Greg
---------- Forwar ded message ---------

From: Rick Franklin (b)(6)>
Dat e : Mon, Mar 2, 2020 at 5:46 PM
Subject: TXA127 for COVID-19 pneumonia- -CONFIDENTIAL
To: Greg Simon (b)(6)>
Here's the paper. Let me know what you think .
Best, Rick
Greg Simon
(b)(6)
NIH-000805
Sent : Sun, 8 Mar 2020 23:55:07 +0000
To: Redd, Stephen (CDC/DDPHSIS/OD);Birx, Deborah L ( (b)(6)J);Grigsby,
Garrett (HHS/0S/OGA);Kadlec, Robert (OS/ASPR/IO);Redfield, Robert R. (CDC/OD)
Cc: Marston, Hilary (N IH/NIAID) [E] (b) (6) ;Eisinger, Robert
{NIH/NIAID) [E]; Lerner, Andrea {NIH/NIAID ) [ E]
-
Subject :
Attachments:
----------------------~
FW:
SSRN-id3549276.pdf
(b)(5) =
Team:
(b) (5)
Thanks,
Tony
Paper attac hed.
Dalton, Craig and Corbett, Stephen and Katelaris, Anthea, Pre-Emptive Low Cost Social
Distancing and Enhanced Hygiene Implemented before Local COVID-19 Tran smission Could
Decrease the Number and Severity of Cases. (March 5, 2020). Avai lable at SSRN:
https ://ssrn .com/abst ract=3549276 or http ://dx.do i.org/10 .2139/ssrn .3549276
NIH-000806
Sent : Sun, 8 Mar 2020 22:56 :20 +0000
Subject : FW: For Novel Coronavirus of Ant iviral Treatmen t.
FYI
From:IPJ::J~lli-1- ________ (b)__,

(6)>
________
-------=-:--:=
To : Fauci, Anthony (NIH/NIAID) [E] _,
(b)(6)
Subject: For Novel Coronavirus of Antiviral Treatment.
Dear Director of NIAID, Anthony S. Fauci MD . :
Potential inhibitors aga inst papain-like protease of novel coronav irus (SARS-CoV-2) from FDA approved drugs
Version 2
Preprint
revised on 20.02.2020, 00:05 and posted on 20.02.2020, 16:51 by Rimanshee Arya Amit Das Vishal Prashar
Mukesh Kumar
The cases of 2019 novel coronavirus (SARS-CoV-2) infection have been continuously increasing ever since its
outbreak in China last December. Currently, there are no approved drugs to treat the infection . In this scenar io ,
there is a need to utilize the existing repertoire of FDA approved drugs to treat the disease. The rational
selection of these drugs could be made by testing their ability to inhibit any SARS-CoV-2 proteins essential for
viral life-cycle .
We chose one such crucia l viral protein, the papain-like protease (Plpro), to screen the FDA approved drugs in
silico. The homology model of the protease was built based on the SARS-coronavirus Plpro structure, and the
drugs were docked in S3/S4 pockets of the active site of the enzyme. In our docking studies, sixteen FDA
approved drugs , including chloroqu ine ard formoterol, was found to bind the target enzyme with significant
affinity and good geometry, suggesting their potential to be utilized against the virus.
FUNDING
Department of Atomic Energy, Government of India
Dear Dr . Fauci :
NIH-000807
We are an individual researcher from Taiwan Biochemical Papain, my name is Terry Wang. Without
funding support , (b)(4
(b) (4)
I am willing to participate in the process in the United States.
@@@There are many ways to perform the trea t ment !
Sincerely,
Terry Wang in Taiwan .
Please contact me :
Email: (b) (6)
Address: (b)(6)
Cell phones: (b)(6)
Line ID (b)(6)
NIH-000808
Sent : Sun, 8 Mar 2020 18:55:46 +0000
To : Gregg Gonsalves
Subject: RE:We Are Desperate for Advice
Gregg:
Understood . I appreciate your note . I will keep pushing .
Best regards,
Tony
From: Gregg Gonsalves

-----------
------
--.~
(b)(6)
--------
Subject: Re: We Are Desperate for Advice
(b)(6J>
Tony, that part of the message was not directed at you . Peter Staley and I have seen you in action on TV
and I've forced (b)( to watch you talking about social distancing, since she
says the President says she has nothing to worry about. Bob Redfield and Secretary Azar haven' t been as
forth right as you have.
The main thing that concerns many people I know : the roll-out of testing , surveillance has been botched
and we're likely to have cases of COVID in our communities already w ithout knowing it . Meanwhile
some corporations, some universities, some other institutions have started to put social distancing into
place, with a few municipa lities doing the same, but there is no real guidance from CDCon when to act
for most of us. There are plenty of instructions about getting prepared, but all seem to point towards
waiting until there is an outbreak in one's community to do anything substantial, which seems if you'll
excuse my language, ass-backwards, as one you see multiple cases, you're likely to already have
widespread community transmission .
I think this piece by Bill Hanage at Harvard explains where a lot of us are right now :
https ://www.washingtonpost .com/outlook/co ronavirus-test ing-united -states/2020/03/0S/a6ced5aa -
Sf0f- llea-9055 -5fal2981bbbf story. htm l
Stay well, we need you more than ever (and I mean that from the bott om of my heart). Most of the
career civil servants on the email were copied not to chastise, it's the political appointees that most
think got us into this mess.
g
From:Anthony Fauci (b)(6)

Date : Sunday, March 8, 2020 at 1:50 PM
To: Gregg Gonsalves
------------
Subject : RE: We Are Desperate for Advice
(b)( >
Gregg:
I am surprised that you included me in your note. I genuflect to no one but science and
a lways, always speak my m ind when it comes to pub lic hea lth. I have cons istent ly corrected
missta t ements by others and will con t inue to do so. I am including t wo links from Sunday
NIH-0008 12
Shows today where I am extremely explicit and forceful. I would be happy to chat with you
about this.
https ://ap p.crit icalment ion.com/app/#/c lip/publ ic/2beb07d0-f72d -45b9-9ed6-

60754bd93fa7?show sent iment=false
ht tps://app .cri ti calmention .com/app/#/c lip/publ ic/183207e9 -e6e1 -4164 -ble5 -

53e0dddbc363?show sentiment=fa lse
Best regards,
Tony
From: Gregg Gonsalves

-----------
------~~
(b)(6)>
(b)(6)>; JeffTrammell
>; Redfield, Robert R. (CDC/OD)
(b)(6) ---- ==
(b)(6J> ; Collins, Francis
":'--:---~--=-::======-~~--
(NIH/OD) [El (b)(6J>; Lane, Cliff (NIH/NIAID) [E} (b)(6J>; Schuchat, Anne
-======~~-
MD (CDC/OD) (b)(6 b; Messonnier, Nancy (CDC/DDID/NCIRD/OD) (b)(6) Birx,
___ ___,!=====~~
Deborah L (b)(6)>; Azar, Alex (OS/IOS) (b)(6); Redfield, Robert
----------- (b)(6)>; Harrison, Brian (HHS/IOS)

Subject : We Are Desperate for Advice
CbH6J>
Dear Tony, Bob and Deb et al,

The AIDS experts among you know me well. We've been first adversaries then colleagues for over 30
years.
They also know I can't keep my mouth shut, which is a virtue and a failing, depending on the context.
Now :
There are thousands of people waiting for advice from our federal government on broader social
distancing measures in light of the fact that our failure in early testing and surveillance means the
coronavirus is likely already spreading in our communities .
If you thought the ire of AIDS activists 30 years ago was tough, the anger now spreading among
researchers, scientists, clinicians and activistsis going to be a conflagration.
All we see is genuflection in word and deed fr om most of you to a White House that wants thi s all to
magically go away.
Yes, I know you're all doing your best and behind the scenes our federal government is hard at work . For
those I know, I don't doubt your commitment to publ ic service.
But time is running out.
We need vocally, unequ ivocal leadership now, that offers real guidance to communities about what to
do, what might happen next.
Your own legacies will be defined by this moment, what you do and what you don't, what you shy away
from saying because you fear for your jobs or your short-term fortunes in the eyes of the President.
The status quo is untenable.
It's going to get people killed by this virus .
Gregg
NIH-0008 13
Gregg Gonsalves PhD
Assistant Professor, Epidemiology of Microbial Diseases
Associate Professor (Adjunct) and Research Scholar

Yale Law School
Co-Director, Yale Global Health Justice Partnership

Co-Chair, Global Health Studies Faculty Committee, Yale College
Affiliated Faculty, Add iction Medicine
Affiliated Faculty, Jackson Institute for Global Affa irs
(b)(6)
NIH-0008 14
Sent: Sun, 8 Mar 2020 17:06 :22 +0000
To : Conley, Sean P. CDR USN WHMO/WHMU
Cc: Munster , Vincent (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID)
[El
-----~~ (b)(6);Lerner, Andrea (NIH/N IAI D) [El;Eisinger, Robert (NIH/NIAID) [El;Birx, Deborah L
(b)(6))
Subject: FW: Stability data - spoke to Vincent.
Attachments : 2020 -03-03 Manuscript Stability_MASTER .docx
Sean:
As per our recent conversation , here is a paper that is under review at the NEJM . It is from
Dr. Vincent Munster who works in my institut e. It confirms what we surmised that after almost
two weeks, the chances of viable virus being present in the facility is extremely low based on
his stud ies reported in this paper . Figure 18 in the paper is of particular relevance regarding
our discussion of surfaces.
Best regards,
Tony
From: Marston, Hilary (NIH/NIAID) [El (b)(6)

-------::-::-:-=
(b)( 6) > -------- (b)(6)>; Lane, Cliff (NIH/N IAI D) [El

---------
Subject: Stability data - spoke to Vincent.
(b)(6)
Talked to Vincent. Attaching his manuscript, unde r review with NEJM. Vincent is available at (b)(6)
- if you need him.
How the experiments were done:

Aerosol -A solution of live virus was made and aerosolized in a rotating drum (kee pi ng it in aerosol
form) ; at various time point s, air was removed and amount of virus measured (using end-poin t titration
on Vero cells).
Surface - A base solutions of live virus was made and placed on specific surfaces (plastic, etc) and at
various time points, coating was taken away and virus contained was titrated.
Note t hat surface experiments with proteinaceous material (e.g., respiratory secretions) are underway,
as are variations in relative humidity and temperature.
How do you interpret aerosol data?

Decay in aerosols occurs over three hours, so if the virus is aeros ol ized (via aerosol-generat ing
procedures or cough), the moment it drops below a certain threshold, it would be hard to get an
infect ious dose/infection. Of course we do not actually know the infectious dose, which limits our abil ity
to give firm guidance based on this data.
NIH-000815
How do you interpret the surface stability data?
Copper seems to have some virucidal effect, as is seen with other viruses. Plastic and stainless steel
don't have much of an effect on the virus itself, and the virus persists for some time. As for cardboard,
difficult to interpret because the surface absorbs a good deal, but there is some immediate decay.
Should we be concerned about packages based on your data?

This is of far lower concern than droplet and other fomite transm ission. Typical shipping wil l allow ample
time for viral decay, and the card board itself seems to have some direct effect on the virus (either
through absorption or other effect) . For example, in the experiment, Vincent applied
lOeS viral particles/ml and it drops 2 logs to 10e3 immediate ly, ind icating that either due to absorption
or direct effect on the virus .
Of course, if a mail carrier coughs on a package and then someone touches it directly after, there may
be a risk. The typical shipping situation is likely not a concern.
Why are SARS-CoV-2 vs. SARS-CoV-1 different?

For the cardboard data in particular, there is a difference seen between SARS-CoV-2and 1, which is
likely due to error/variation in surface.
NIH-000816
Sent: Sun, 8 Mar 2020 14:30 :13 +0000
Subject : FW: A Coronavirus Deterrent?
From: Ron Jacobs (b)(6)>

------~~
Subje ct: A Coronavirus Deterrent?
--------
To : Fauci, Anthony {NIH/NIAID) [E] (b)(6)
Would the use of a facial steam inhalator cause nonviability of the virus in someone who had contracted
the virus?
Would spending time in a steam room have a similar effect?
NIH-000817
Sent : Sun, 8 Mar 2020 14:29:44 +0000
To : CbH6l;'Birx,Deborah L';Redfield, Robert R. (CDC/OD);Kadlec,
Robert (OS/ASPR/IO);Redd, Stephen (CDC/DDPHS IS/OD)
Subject: FW: Hazardous use of Remdesivir in CoV-19
Attachments: COVIO19linee guida trattamento 0lMAR.pdf .pdf .pdf
There may be nothing to this, but we shou ld at least be aware.
From: rosario leopard i (b) ~ >

--------
Sent: Sunday, March 8, 2020 9 :04 AM
To: Fauci, Anthony (NIH/ NIAID) [E]-----~~
-------
Subject: Hazardous use of Remdesivir in CoV-19
(b)(6)>
Dear Dr Fauci,
I am copying below a let t er I just sent to the ed itors of Lancet and NEJM t hat I th ink you should
also read. It's informal as it is not meant for publication but ju st as a concern. Since I no longe r
work as a virologist, I am forma lly out of the fie ld. I am however active as chief psychiatrist in
Stockholm, Sweden. If you have doubts as to my expertise as a virologist or a physician, Dr
Bernard Roizman at U of C knows me very well, as M ar kus Heili g does here in Sweden .
"I have noticed a striking difference in mortality by Co V-19 in different countries.

China and Italy have a morta lity that 's at least 6-fold higher than that in South Kor ea.
So far Germany and Scandinavia , totalling over 1300 cases, have not rep orted a single
death. That' s over a 35-40 fold difference.
Loo kin g at the data more closely, I have found that China and Ital y have been using
the antivira l Remdesivir (Gilead Sciences) extensive ly on many patients in intensive
care , ju stifie d as "compassionate use" . In the epidemic areas of Italy this drug is now
part of treatment guidelines for hospitalised patients , used on every single patient in
"criti cal conditi on". (see attachment). The "rationale" is simp ly that the first two cases
treated at the SpaHan.zan.iHospital in Rome rec eived this dn1g, and ...we ll, actuall y
surv ived.
NIH-000818
Remd esivir has never passed a Phase 3 trial, but has already made big head lines in
major international newspaper s. Neither South Korea nor Germany or Scandinavian
countries have yet used this drug.
I unde rstand that this is a (relatively) long shot, but given the number oflive s at stake,
I would recommend that a carefully scrutiny by the scientific community on the use of
this drug is warranted.
I have no conflict of interest.
Thank you for your attention".
Sincerely ,
Rosario Leopardi , MD, PhD
____
Forensic Psychiatry Care Clinic
Cb)C6)
, Sweden
(b)(6)
cell :
Sent from Outlook
NIH-000819
From: (b)(6)
Sent: Sun, 8 Mar 2020 09:59 :21 -0400
To : Conrad, Patricia (N IH/ NIAID) [E);Folkor s, Greg (NIH/NIAID) [E);Mar ston , Hilary
(NIH/NIAID) [E];Lerner , And rea (NIH/ NIAID) [E]; t isinger , Robert(N JH/NIAID) [E];Barasch, Kimberly
(NIH/N IAID) [CJ
Subject: Fwd: BIO Coronavirus Collaboration Initiative March 12th Summit - POSTPONED
From: Phylli s Arthur <par thur@bio.or g>

Date: M arch 8, 2020 at 9:51 :46 AM EDT
To: Phyllis Arthur <parthur @bio .org>
Cc: Jenni fe r Alton <jenn .alton@pathwaypolicy .com>, Ellen Carlin
(bH6)
>, Amy Walker <awalker@bio.org>, Grego1yFrank
----------
< gfrank@bio.org>, Hannah Dorsey <hdorsey@bio.org>
Subject: BIO Coro navirus Collaboration Initiative March 12th Summit -
POSTPONED
Dear Colleagues,
BIO is heartened that so many of you have expressed interest in

join ing us for the BIO Coronavirus Collaboration Init iative Summit
planned for March 12, 2020. Given the evo lving circumstances
surrounding the COVID-19 outbreak, and afte r discussions with
our Board leadership, we have decided to postpone the BIO
Summit so that we can make adequate arrangements to hold t he
meeting virtual ly. We made this decis ion out of an abundance of
caution , so as to avoid placing anyone at unnecessary risk of
exposure whi le we work together to improve our nation's ability to
respond to this outbreak. We will re -schedu le this virtua l meeting
within the next two weeks using a digital techno logy that can allow
for robust discussion among the participants.
In the inter im, we plan to send out a short questionnaire on

Monday to all company participants requesting information on your
product, technology or serv ice, which we plan to compile in a
digital "book" and share with all participants in advance of the
meeting . We believe this approach wi ll help to make the meet ing
more efficient, allowing us to quickly shift to discussions of the
NIH-000820
most impo rtan t shared challenges and potential opportunities that
exist between industry members, government leaders and non-
government partners.
Please feel free to reach out to me with any questions. We will

move qu ickly to establ ish a new date for this meeting and
appreciate your flexibility in t h is regard. We look forward to talk ing
with many of you then .
Thanks again for your commitmen t to enhancing the health and

safety of people facing this outbreak around the globe.
Sincerely,
Phyllis A Arthur
Vice President, Infectious Diseases and Diagnostics Policy
Biotechnology Innovat ion Organization (BIO)
1201 Maryland Ave SW, Suite 900
Washington , D.C. 20024
T: 202 -962 -6664
C (b) (6)
parthur@bio.org
Join us at the 2020 BIO International Convention

June 8-11, 2020 in San Diego, CA
www.convention.bio .org
Phyllis A Arthur
Vice President, Infectious Diseases and Diagnostics Policy
Biotechnology Innovat ion Organization (BIO)
1201 Maryland Ave SW, Suite 900
T : 202 -962 -6664
C: (b)(6)
parthur@bio.org
Join us at the 2020 BIO International Convention

June 8-11, 2020 in San Diego, CA
www.convention.bio.org
NIH-00082 1
From: (b)(6)
Sent: Sun, 8 Mar 2020 09:50:00 -0400
Subject: Fwd: COVID19.ACElsand ARBs
Please handle
From: Martin Engman (b)(6)

To: "Fauci, Anthony (NIH/NIAID ) [E]" ------~~
Subject: COVID19, ACEis and ARBs
--------- (b)(6J:
Is there any evidence to suggest that patients already on treatment with angiotensin
receptor blockers have a better or worse COVID-19 outcome than patients not on
these medications?Similar question for initiating ARB treatment once COVID-19
has been diagnosed. And s imilar questions for ACE inhibitor s. Thank you.
NIH-000822
From: (b)(6)
Sent: Sun, 8 Mar 2020 09:23:28 -0400
To : Kristian G. Andersen
Cc: Jeremy Farrar;Collins, Francis (NIH/OD) [E];Robert Garry;Edward
Holmes;Andrew Rambaut;lan Lipkin;Chris Emery
Subject: Re: SARS-CoV-2article to be published in Nature Medicine
Kris tian:
Than.ks for your note. Nice job on the paper.
Tony
On Mar 6, 2020 , at 4:23 PM , Kristian G. Andersen

--------- (b)(6) wrote:
Dear Jeremy, Tony , and Francis ,
Thank you again for your advice and leadership as we have been working through
the SARS-CoV-2 'origins' paper. We' re happy to say that the paper was just accepted
by Nature Medicine and should be published shortly (not qui te sure when).
To keep you in the loop, I just wanted to share the accepted version with you, as
well as a draft press release. We're sti ll waiting for proofs, so please let me know if
you have any comments , suggestions, or questions about the paper or the press
release.
Tony, thank you for your straight talk on CNN last nigh t - it's being noticed.
Best ,
Kristian
Kristian G. Andersen, PhD

Associate Professor, Scripps Research
Director oflnfectious Disease Genomics , Scr ipps Resea rch Translational Institute
Dir ector , Center for V iral System s Biology
The Scripps Research Institute

10550 North Torrey Pines Road, SGM-300A
Depa1tment of Immunology and Microbial Science
La Jolla, CA 92037
(b)(6)
NIH-000823
<Andersen Coronavirus Nature 2020 Press Release Draft 4.docx>
<Manuscript.pdf>
NIH-000824
From: (b)(6)
Sent : Sun, 8 Mar 2020 09:04 :10 -0400
To: Lane, Cliff (NIH/ NIAID) [E]
Subject: Re: COVID-19 Real Time, Sensitive Detection Breakthrough
Please take care of this yourself Thanks
On Mar 7, 2020, at 11:30 PM, Lane, Cliff (NIH/NIAID) [E]

-------- (b) (6) wrote:
They claim to have an improved diagnostic developed through DoD funding. It is a

DNA platform that they claim to have adapted to COVID-19. They prov ide no data ,
o_Jl
)y__
cJaims_________________________ ~
(b) (5)
On Mar 7, 2020 , at 10:03 PM, Fauci, Anthony (NIH/NIAID) [E]

(b) (6) wro te:
Please read this and figure out what th e heck he is talking about and
act accord ing to your jud gment. Only 498 emails to go tonig ht.
From: (b)(6)
To : Fauci, Anthony (NIH/NIAID) (E]
-----~~ (b)(6)
Subject: COVID-19 Real Time, Sensitive Detection Breakthrough
Tony--
It has been awhile since we have worked together since my time
as the senior SES standing up DTRA (with the help of Josh
Lederberg M.D. &Dave Franz DVM who you know), at
Argonne/UofChicago establishing your NIAID RBL with Olaf
Schneewind M.D., and as the OHS Director of Research
reporting to SEC Michael Chertoff &U/S Jay Cohen (RADM-
ret). Michae l &Jay brought me aboard when Jay was our Chief of
Naval Research at ONR and I was ONR's Executive Director
&Chief Scientist. I know you have your hands very full with the
NIH-000825
COVID-19 threat, so I wanted to give you a heads up that a
game changer for enhanced detection of COVID-19 has
emerged. Thanks to DARPA &OHS S&T sponsorship in years
past of ANOE developing a real time Rapid DNA microfluidics
system for human identification, the ANOE group has a
breakthrough for detection of COVID-19 and to the future , other
emerging threat viruses.
As you may know the ANOE system for human identification (e.g.
CT &OHS missions) is mature and now deployed
operationally/tactically by CENTCOM , DIA , the IC and used most
recently by OHS in their recent test bed in EI Paso to
demonstrate its effective capabilities to determine family
relationship in undocumented minors. Additionally ANOE is in
use by law enforcement and by officials responding to mass
casual ty events (CA 2018 Camp Fire disaster , 2019 Conception
dive boat fire, and the very recent 2020 tragic helicopter crash) to
ID the victims .
The ANOE system now provides 2 hour turnaround with no

special training requirements as a stand-alone system for all the
above users . Our wa rfighters and special operators are using
the ANOE system now in field forward operations and it meets
M IL specs &is the only system certified for data submission to the
OoO AB IS/DIA DNA reposi tory and FBI CODIS data base. The
(b) (4)
executive summary and a more in-depth document for your

teams review . Hope the above is helpful and I stand ready to
provide any additional information . I have cc'd Jim Davis (ANOE
Chief Federal Officer) . Additionally since it has been some time
since we have worked together I have attached my bio and that
of ANDE's Chief Scientific Officer &Founder , Richard Selden
M.D. , Ph.D .
Tony thanks for considering this in your very busy life now and I
will look forward to seeing you again.
Best regards--
Starnes
Dr. Starnes E. Walker
NIH-000826
Member-Homeland Security Experts Group , MITRE
Global Strategy Officer -Defense &Homeland Security/Intelligence
ANDE Corporation
p: (b)(6) m:
e: (b)(6)
-------
ANOE
>!:II.ii
' ~
Rap id DNA for a Safer World
(b)(4l
<CUsersstarnDesktopSEWBio, October 2019.docx>

<CUsersstarnDesktopANDEBiosRFS CV 05 March 2020.pdf>
NIH-000827
From: (b)(6)
Sent: Sun, 8 Mar 2020 07:41 :41-0400
Subject: Fwd: Ems Personnel & Ambulance Teams
From: "Nabial, Nasir M " (b)(6)

To: "Fauci, Anthony (NIH/NlAID) (E]" -------=
-------- = (bH
Subject: Ems Personnel &Ambulance Teams
Dear Dr . Fauc i:
Im a first responde r, and I believe an oral vaccine platform is the best

delivery method for situations of national emergency like the
coronav1rus.
lf the vaccine is a tablet, we would be able to keep them on our

ambulances and get medical authorization whenever the situation arises.
First responders can then treat patients before doctors and nurses and
also instead of having the patient make an appointment Or having them
wa it in line for a shot , which can ultimately cause more spread .
This me thod that will enable the EMS teams of the nation to combat
outbreaks because you would allow EMT (Emergency Medical
Technicians) and Paramedics to diffuse situations through our
Ambulances. This w ill lead to more control and get a hold of the
situations as fast as possible and lower the spread of the virus on our
people.
Thank you .
NIH-000832
From: (b)(6)
Sent : Sun, 8 Mar 2020 07:40:53 -0400
Subject : Fwd: from Dr Mike Meyer ( CEO- Sensible Biotherapeut ics) Finding the answer
to halting replication of COVID-19
Pis respond
Sent from my iPhone
From: Michael Meyer Cb)

C
To: "Fauci , Anthony (NIH/NIA ID) [E]" ------~~ CbH> , philip meyer
CbH>, "Perkins, Miriam (NIH/NIAlD) [E]"
(b)(6)
Subject: from Dr Mik e Meyer ( CEO - Sensible Biotherapeutics) Finding the

answer to haltin g replication of COVID-19
DR ANTHONY FAUCI
(b)(6)
Dear Dr. Fauci ,
I am a Neuro logist and Nuclear Medicine Phys ician who has a passionate interest in
developing antisense med ications to treat disease and have formed a drug discovery
company here in Buffalo New York (SENS IBLE BIOTHERAPEUTICS , LLC).
(b)(4)
NIH-000833
(b) (4)
I very much appreciate any advise you may be able to provide about this project
Sincerely,
Michael A. Meyer MD
cell Cb)(6)
NIH-000834
From: (b)(6)
Sent: Sun, 8 Mar 2020 07:39 :47 -0400
Subject: Fwd: Set up county hotline for people to contact if they think they have
coronavirus or are sick instead of go ing to hospita l
Sent from my iPhone
From: rebecca hagenberg (b)(6)

To: "Fauci , An thony (NIH/NlAI D ) [E]" -------~~ (b)(6)
Subject: Set up county hotline for people to contact if they think they have
coronavirus or are sick instead of going to hospital
Dear Sir ,
I am sending this message to assist in an idea to help m inimi ze the impac t of

Coronavirus. Instead of people going to the hospital or urgent care. Each county
health depa rtment needs to have a direct number of a nationa l number that
distributes information to local county governmen t health department. If you are
sick and show or exhib it signs of the coronavirus you shou ld call the appropriate
number , a technician wi ll come to yo ur home, draw lab specimen needed. Of course
if someo ne is extremely ill they shou ld call 9 11 and adv ise 911 they are exhib iting
signs of the virus. The re sho uld be special protocols in p lace for how to transport the
patient into the hosp ital as well ( to limit exposure to everyone involved. This means
finding alternat ive entrance at hospi tals for a suspected coronavirus patient. These
patients shou ld be brought in by a least used locat ion of the hospital into a spec ial
unit that has a barrier from the rest of the emergency department.
Home lab work will keep someone from sitting in a waiting room for 3_ 5 hours.
The county unit to conduct lab wo rk wi ll act in response much like calling 911 or
the po lice. Eac h hospital needc; to set up an emergency entran ce for Coronavirus
patient s only, and the unit must be sealed from the rem ainder of the unit. We begin
having a coronavirus team that does not cross contaminate to any other unit on the
emergency room floor. I am thinking of the best p lausible way to minin1ize
outbreak . This helps .
Rebecca Hagenbe rg
(b)(6)
NIH-000835
Sent: Sun, 8 Mar 2020 03:34 :45 +0000
To : Michael Oldstone
Subject: RE: item
Thanks, M ichael. I appreciate your note.
From: M ichae l Oldstone <mbaobo@scripps.edu>

Sent: Friday, M arc h 6, 2020 2:12 PM
To: Fauci, Anthony {NIH/ NIAID) [E] -----~~ (b)(6)
Subject: item
Dear Tony
A note to let you know how much over the years I have appreciated your
active support of biolog ic research, public health and your directorship of
NIAID . Impressive, intelligent, high integrity and management skills has
placed you at the head of the curve. I reached this conclusion from
personal observat ions of your work and style as wel l as having served as a
consultant for NIAID and several other NIH Institutions, WHO, Pasteur and
Karolinska .
After nearly 50 years of continuous research from my original AI09484

grant studying viral pathogenesis[ acute and persistent infections] using the
LCMV model, I decided to close my laboratory. I have had other generous
NIH support as well especially for investigations of other negative strand
viruses[ primarily measles and influenza, Lassa ,arenavirus receptor] ,
Ebola, cytokine storm and autoimmun ity. The AI09484 grant was credited
by 300 peer reviewed papers, training of 61 postdoctoral fellows[ including
Rafi Ahmed , Christine Biron , Persephone Borrow, Ray Welsh, Ian Lipkin ,
Dorian McGavern and other successes including the late Patrick Sissons
who was the Reagent Professor of Medicine at Cambridge. Over 85% of
these folk are in academic medicine/b iology at research institutes or
universities.
Good luck and smooth sailing with the current coronavirus pandemic. With
your involvement this work is in good hands .
Best wishes
Michael
NIH-000836
Sent : Sun, 8 Mar 2020 03:26:22 +0000
To: Liz Cheney
Cc: Conrad, Patricia (NIH/NIAID) [E);Barasch, Kimberly (NIH/NIAID) [C);Greg Folkers
-------- (b
~ )~(6)
=
Subject: RE:Test Kits
Sorry, Liz. In White House all day. Will try to call tomorrow.
From:Liz Cheney CbH6)>

To: Fauci,Anthony (NIH/NIAID) [ E] -----~ (b).-.(=
6J>
Cc: Barasch,Kimberly (NIH/NIAID) [C) CbH ; Conrad, Patricia (NIH/NIAID) [E)
Cb)( ; Haskins,Melinda (NIH/NIAID) [E) (b) ( '>
---------
Subject : Re: Test Kits ---------
Dr. Fauci - Who can I speak w ith about the status of the test kits ? I am also concerned about reports
from CDCthat there are six states, including Wyoming, with no certified lab in which to conduct tests.
Thank you,
Liz Cheney
(b)(6)
On Tue, 25 Feb 2020 at 10 :28 PM, Fauci, Anthony (NIH/NIAID) [E)

-------- (b)(6J> wro te :
Liz:
Thank you for your note. I would have been very happy to provide remarks at the weekly
meeting of the Republican Conference. However, I have a late afternoon 2nd panel
Congressional Hearing with Secretary Azar followed by a meeting with the President in the
Roosevelt Room of the White House, which over laps with the time frame of your meeting
tomorrow. I would be most happy to do this at another time. If you could have your office
contact my Special Assistant, Patty Conrad (copied here) , she will help arrange setting up
something at a mutually convenient time.
Best regards,
Tony
Director
Phone (b) (6)
FAX : (301) 496-4409
E-mail Cb)(6)
sensitive informa tion . It should not be used by anyone who is not the original intended
NIH-000837
your mailbox or any other storage devices . The National Institute of Allergy and Infectious
From: Liz Cheney (b) (6)

Subject: House GOPConference Mtg
Dr. Fauci - I am the House Republican Conference Chair and we are holding our weekly mtg at S pm
tomorrow in the Capitol. I wanted to see if you'd be available to provide remarks and an update on
Coronavirus. It is by far the topic in which our members are most Interested, and you would be the
best person to provide an update .
I realize th is is short notice . If tomorrow doesn't work , let me know if we could arrange another time.
My eelI is ------ (b)(6), ____

office is ._ (b)(6)
_.
Thank you,
Liz Cheney
NIH-000838
Sent : Sun, 8 Mar 2020 03:23 :05 +0000
To: Hilary Rosen
Subject : RE:You!
Hila ry:
Thanks for your note. I would postpone it. The situation is very fluid.
best,
Tony
From: Hilary Rosen (b)(6)

Subject : You !
-------- (b)(6)
Tony,
I am so proud of you . It is so comforting to see your face on TV explaini ng the world of coronavirus .
know it is exhausting for you but it is so important . Your dedication my friend has always been so
admirab le.
Quick question, CDCisn' t giving much guidance on this. Our company has its annual retreat this week.
About 80 people coming from NYCand LA meeting in a DC Hotel ballroom for two days with an
additional 100 people from DC. SO approximately 180 in total. Would you postpone this if you were
me?
XO
Hilary
Hilary Rose n
Vice Chair
SKDKnickerbo cker
202.4 64 .69 69 w
(b)(6) m
2019 Holmes Report Public Affair s Ag ency of the Year
NIH-000839
Sent : Sun, 8 Mar 2020 03:06 :52 +0000
Cc: Greg Folkers (b) (6)
Subject : FW: medi a request from spain an old journal ist friend , patricia mat ey
Cannot do. No t ime
From: Patricia Matey Corada <pmatey@elconfidencial.com>

Sent : Saturday, M arch 7, 2020 3:31 PM
To: Fauci, Anthony (NIH/NIAID) [E) -------=---c-c= (b)(6)
Subject : media request from spain an old journalist friend, patricia matey
Hi doctor Fauci, Can you remembe r me. I am a Patricia Matey, oldest journalist of health from spain. I
work in the past in El MIU ndo, now I am a chief editor in El Confidencial, the first newspaper online in
Spain. Can you give me little time for answer some questions . I want to do an article of the coronav irus,
but the eyes of science, I read three days ago te article in New Yor Times by Gina Kolata, the best
woman health journalist of the wo rld, I want to do an art icle without panic and false concept
I send you some questions
What is really the differen ce in this conoravirus and the past?

Can one of the mute ate , change in one strain more aggressive in short time
The fl u always affect a all t he count ries in same time . Why the new coronavirus only star enChina,
Is because became from one animal,,,
What are your opinio n for the really impact of this virus
What are you opin ion for the press and the paper in this problem.
What are you op inion for the evolut ion in the next month
Best regard for all, but best regard for yourtime
tC
Patricia Matey
Jefa de Alimente
www.e lconfidencial.com
Via de las Dos Castil/as, 33. Edificio 7. Planta 1- Oficinas E,F, G, H
28224 Pozue lo de Alarcon (Mad rid)
(b)(6)
NIH-000840
From: Fauci, Ant hony (N!H/ NJAID) [E)
Sent : Sun, 8 Ma r 2020 03:03:28 +0000
To: (b)(6)
Cc: Conrad, Patricia (NIH/N it1t.
lD } [ E]
Subject: FW: COVID-19 Real Tim e, Sensiti ve Detect ion Breakth roug h
(b) (4)
CUsersstarnD eskto pSEW Bio,

October 2019.docx, CUsersstarn Desktop ANDE BiosRFS CV 05 M arch 2020 .pdf
Please read th is and fig u re out wha t t he heck he is tal king about and act according to your
j udgm e nt. Only 4 98 em.::iils to go tonigh t .
From: (b)( 6)
-----------------
Sent: Saturday, M arch 7, 2020 4:09 PM
To: Fauci, Anthony (NIH/N IAID) [ E] -------= (b,.,..
)(=6)
Subject: COVID-19 Real Time, Sensitive Detect ion Breakthrough
Tony--
It has been awhile since we have work ed together sin ce my time as the senior SES
standing up OTRA (with the help of Josh Lederberg M.O. & Dave Franz DVM who you
know), at Argonne /UofChicago establishing your NIAID RBL with Olaf Schneewind
M.D ., and as the OHS Direc tor of Research reporting to SEC Michael Chertoff & U/S
Jay Cohen (RADM-ret) . Michael & Jay brought me aboard when Jay was our Chief of
Naval Research at ONR and I was ONR's Execu tive Director & Chief Scientist. I know
you have your hands very full with the COVID-19 threat, so I wan ted to give you a
heads up that a game changer for enhanced detection of COVID-19 has emerged .
Thank s to DARPA & OHS S&T sponsorship in years past of ANOE developing a real
time Rapid DNA microfluidics system fo r human identificat ion, the ANOE group has a
breakthrough for detection of COVI0 -19 and to the future , other emerging threat
viruses .
As you may know the ANOE sys tem for huma n identification (e.g. CT & OHS missions)
is mature and now deployed operationally /tactically by CENTCOM , DIA , the IC and
used most recently by OHS in their recent test bed in El Paso to demonstrate its
effective capabil ities to determine family relationship in undocumente d
minors. Additionally ANO E is in use by law enfor cemen t and by officials responding to
mass casualty events (CA 2018 Camp Fire disaster, 20 19 Con ception dive boat fire ,
and the very recent 2020 tragic helicopter crash) to ID the victims .
The ANOE system now provid es 2 hour turnaround with no special training
requirements as a stand-alone system for all the above users. Our warfighters and
special operat ors are using the ANOE sys tem now in field forward operation s and it
meets MIL specs & is the only system certified for data submission to the DoD
ABIS/ DIA DNA repository and FBI CODIS dat a base. The H4>
Cb
NIH-00084 1
(b) (4)
attac liecJ an executive summary and a more in-dep th document for your teams review.
Hope the above is helpful and I stand ready to provide any additional information. I
have cc'd Jim Davis (ANOE Chief Federal Officer). Additionally since it has been some
time since we have worked together I have attached my bio and that of ANDE's Chief
Scientific Officer & Founder, Richard Selden M.D. , Ph.D.
Tony thanks for considering this in your very busy life now and I will look forward to
seeing you again.
Best regards--
Starnes
Dr. Starnes E. Walker
Member -Homeland Security Experts Group , MITRE
Global Strategy Officer-Defense & Homeland Security/Intelligence
ANOE Corporation
p: (b)( 6) m: ----~
----
______
(b)(6)
'\71
w: www.ANDE.com e: (b)( _.
6)
/A ...
ANO E' 2 ~?
Rapid DNA for a Safer World
NIH-000842
Sent: Sun, 8 Mar 2020 03:00:50 +0000
Subject: FW: Corona Virus plann ing
Please respond.
From: K.A. Traul (b) (6)

------
To: Fauci, Anthony (NIH/NIAID) [E] ==
Subject: Corona Virus planning
-------- (b)(6)
Dear Dr. Fauci;
I am a toxicologist and have spent time, years ago, working in the arena of oncogenic
virology as part of NCI programs. I am very concerned about what I see in the news
media about the NIH approach to the COVID-19 pandemic (yes, pand emic) that has
arrived in our country. There is much talk about development of a vaccine , however , I
believe that this is a long-term strategy. You and I both know , from working as
scientists, that the develop ment and trial of an antiviral vaccine is a months-long
program, at best. I am surprised, even disappointed , that there seems to be no visible
focus on the part of the NIH on the development of anti-viral treatments (drugs etc) . It is
my professional opinion that anti-virals would take a shorter time to develop than
vaccines, yet it appears that this may be a back burner focus of NIH .
I realize that there are many political pressures on your office and I support your strong
efforts to apply science to the resolution of this growing problem . Please do not give
short shrift to th e potential of antiviral treatments in favor of the longer-term promise of a
vaccine.
Respectfully yours,
Karl A. Traul
K.A. Traul , Ph.D.

K.A. Traul Pharmaceu tical Consulting
(b)( 6)
NIH-000846
Sent : Sun, 8 Mar 2020 02:59 :37 +0000
Subject : FW: Interview request
I really do not have time for this.
From: Kopelman, Hannah <Hannah.Kopelman@bmc .org>

To : Fauci, Anthony {NIH/NIAID) [E]------~~ (b)(6)>
Cc:Ross Kopelman _________ Cb
_>_C6)
_
Subject: Interview request
Dear Dr. Fauci,
My name is Dr. Kopelman. I am currently a resident at Boston Medical Center. I am reaching out
because I would like to interview you on my podcast along w ith (b)(6)·, on our
podcast called MedChatMonday wh ich reaches thousands of millenn ia ls a day. We want to discuss
Coronavirus. I know you are very busy so any of your time would be appreciated. I want to discuss the
implications of Coronavirus, symptoms, understanding of why it has become a global scare, what people
should do to combat and lower their risks. Podcast will be done remotely through Skype.
I hope to hear from you soon.
Best regards,
Dr. Hannah Kopelman and Dr. Ross Kopelman
Hannah B. Kopelman
This electron ic transmission may conta in information that is privileged, confidentia l and exempt from
disclosure under applicable law. If you are not the intended recipient , please notify me immediate ly as
use of this information is strictly prohibited.
NIH-000847
Sent: Sun, 8 Mar 2020 02:58:52 +0000
To: (b)(6)
Cc: Marston, Hilary (NIH/NIAID) [E];Conrad , Patricia (NIH/NIAID) [E];Barasch,
Kimberly (NIH/NIAID) [C]
Subject: FW: One Step COVID-19 test kitS - IMMEDIATE AVAILABILITY
Attachments: DoN SARS-CoVtests 200305.pdf, IFU One Step COVID-19 Test.pdf , 002.png,
0005.jpg , 0099.jpg, 9999.jpg, 0001.png
What do you think of this. Do what you need to do.
From: (b)( >

To: vice.president@whitehouse.gov
Cc:secretary@hhs.gov; Hahn, Stephen (FDA) (b)( ; Redfield , Robert R.
(CDC/OD) (b)(6) ; Fauci, Anthony (N...
IH- /7:-
N--IA--ID
:-'.):-:[~E]:.=====::::::.:...--....;_---=- (b)
'""'
(6)
=;
secreta ry@state.gov
Subject: One Step COVID-19 test kit$ - IMMEDIATE AVAILABILITY
Dear Mr . Vice President & Task Force Members -
My name is Jeffrey "Scott" Smith . I live in CbH KS. For the past 35 years I have
been a Purchasing Agent in the private sector. Much of my career has dealt with China
sourcing and supplier development. I have established a wide network of suppliers and
contacts throughout China. You can see from my US Passport number CbH6)that
I have traveled to China for the past 20 years ... including spending nearly CbH6Jmy
time in 2018 & 2019 visiting China suppliers . (Thankfully I returned on 15-Nov-2019 ,
prior to the outbreak... CbH6).)
I was invited by one of my trusted suppliers to offer One Step COV ID-19 test kits to the
United States. The Guangzhou based s~as CbH4>test kits available now for
immediate shipment. T hey can produce ~ kits per week at their factory . Please
see the information below and the materials attached for more information. This is a
very cost effective test - and provides results in 15 minutes. I will trust you to determine
the efficacy of the diagnostics.
To be clear - this is not my business. I will profit in no way from providing these kits to
the American healthcare public -- except for the sat isfaction of doing my patriotic duty to
assist my fellow Americans. I fully understand the gravity and seriousness of this
disease. All of my factories in China have, and are , suffering from the effect and fall
out. My business in CbH6)is dealing with the effects of the supply chain disruptions.
I hope that this offer , and availability of a additional test kit pipeline, will help ease the
test kit shortage that we are experiencing in the USA . If you and your Procurement
NIH-000848
Offices would like more information or would like to secure these test kits, please
contact me . I can assist in arranging supplier contacts and immediate air shipments.
I certainly thank you and the many dedicated leaders in the USA for your great work to
combat COVID-19 - and for the care that you are showing the American public.
Best regards,
Scott Smith
(b)(6)
M: (b)(6)
-------- Original Message --------
Subject:One Step COVID-19test kit

Date: 2020-03-07 2:41 am
From: "JackScientek" <info@scientekpower.com>
To: (b)(6)
Reply-To: <info@scientekpower .com>
Dear Scott,
How are you? It was a great pleasure talking with you on Wechat, As we discussed, I have a
friend who works in Wandfo Biotech Company in Guangzhou (a public listing company).
They have developed a One Step COVID-19 test kit to screen the Corona virus in only 15
minutes. This test kit is been massively used in China and it's been suppl ied to Japan,South
Korea, Ukraine and Iran to cope with the Corona Virus, It has also been certified by Chinese
health organization and EU. I am wondering if you have any connection with any medical
organizations, if they need this kit, Wondfo is able to supply. CbH4>
- • Wondfo provide international shipping worldwide. Maybe this can be helpful

for some people.
Here below please refer to the most concerned informat ion:

Name of the test kit: One Step COVID-19 Test (Chromatography Assay)
Manufacturer: GuangZhou Wondfo Biotech Co.,Ltd
NIH-000849
K:arton ~olume(CB K;ross
Name Quantity Unit Price Packages
One Step COVID-19 Test

- Measurement M) h,veight(Kgs)
(b) (4)
Kit
Kit
Kit
Kit
Price availability : 1 week
Payme nt terms: (b) (4)
Delivery term (b) (4)
Avai labi lity :

--- ---------
productio n capacity
For you r information, this testing kit has been supplied to Japan, and south Korea ,
lran, Ukraine , their production schedule is very tight, the factory may raise up price a
week later.
Other Available documents are attached for your reference.
Best Rega rds
JackJiang
~Scientek
Scientek Electrical Co .,Ltd. I Danzao . I Nanhai District I Foshan,Guangdong I China 528216

~ 86- 189-4246-9075 Q (b)(6) -1J www .scientekpower .com l8l info@scie ntekpower .com
I Mob/WhatsApp/Wechat : CbH6J
NIH-000850
Sent : Sun, 8 Mar 2020 02:57 :55 +0000
Cc: (b) (6)'
Subjec t: RE:NSCinquiry on treatment study
See my changes in Red
From: Marston, Hilary (NIH/NIAID) [E] (b)(6 )>

Sen t : Saturday, March 7, 2020 6 :37 PM
To: Fauci, Anthony (NIH/NIAID) [E]------ (b=H=6); Lane, Cliff (NIH/N IAID) [E]
-=
(b)( >
Cc: Conrad, Patricia (NIH/NIAID) [El (b)( ·>; Lerner, Andrea (NIH/N IAID) [E)
Eisinger, Robert (NIH/NIA ID) [El
-------- (b)(6)>;
Subject : NSCinquiry on t reatment st udy
(b)(6)
Sorry to add to the in box. (b)(5),

(b)(5)
NIH-00085 1
Sent : Sun, 8 Mar 2020 02:08:47 +0000
To: Gregory Klomp
Subject : RE: COVID-19 treatment
We are pursu ing th is idea.
From: Gregory Klomp (b)(6)>

Se nt: Saturday, March 7, 2020 8:06 PM
)(c-=
6)
Subject : COVID-19 treatment
It seems COVID-19 causes greater problems for the elderly and those with chron ic illnesses, as you have
said.
Why not try giving those with active disease, or those at risk, gamma-globu lin, to ame liorate the effects
of the il lness?
It would be especially interesting to prepare batches of gamma globulin using the blood (2,000- 3,000
dono rs) of people who have, or who have recovered from, COVID-19 infection.
There is ample precedent for using Gamma-globulin to prevent or treat viral illnesses (Hepatitis A, B) or
diseases of unknown etiology (ie Kawasaki's).
This could be useful especially while we wait for the development of a vaccine .
What do you think?
Gregory Klomp, MD
(b)(6)
(I trained at Columbia-Presbyterian Hospital
I see you were at Weil Cornell)
NIH-000852
From: (b)(6)
Sent: Sat, 7 Mar 2020 17:06:39-0500
To: NIAIDPublic Inquiries
Subject: Fwd: From ERProvider,SomeCommonsenseCOVID-19addl. suggestions
Sent from my iPhone
From: (b)(6)
,------- --;;-~
To: "Fauci, Anthony (NIH/NlAID ) (E]" (b)(
Subject: From ER Provider, Some Common sense COVID-19 addl. suggestions
Dr. Fauci:
I have been following you and others on CSPANwith appreciation.
1) Please ensure you are all getting adequate sleep.
(There is too much yahoo-machismo in our field) Please put forth
recommendations for providers and their employe rs.
2) I see the CDCwarning about herbals, which I agree with except for one:
echinacea, just about the only herbal with proven medical usefulness, not as it is
recommended on the bottles or websites, but as only a single 2 capsules, on day
one of viral ill ness. Echinacea demarginates the matured bone marrow leukocytes.
Used as a "one shot deal"
may decrease COVID-19 duration/severity as eg.: "take right away on day one,
drink plenty of water and sleep as long as necessary".
Please at least study the use of Echinacea in this manner for COVID-19. (Google is
suddenly missing Echinacea's mechanism/use info, so please have this corrected, if
for nothing else to prevent hoarding. One bottle can be for a whole neighborhood
and please ask the drug stores to offer "two packs" with proper instructions.
eg.: "take only two as soon as ill with cold or flu and not take more, but to
replenish the immune system follow up with fresh fruits and vegetables, etc .
3) Make sure we have enough Ventolin, Proventil available so those with new
asthmatic component due to COVID-19 can call their Dr. for RX if they cannot blow
out a match, for
instance, and use th e drive through i nstead of goin into the pharmacy. Consider
hazmat for drive through testing and Rx pharmacy staff (as in S. Korea). I would be
interested in knowing the percent of COVID-19 respiratory sufferers who can stay
home but will need Ventolin.10%? (just a guess from seeing bronchitis in the ER).
NIH-000854
4) Ensure all the medical providers with offices, give out their office telephone
numbers and have staff trained to triage calls so people can stay home until they
are well.
5) Ensure levothyroxine (the USmost common Rx) is made in the USAfrom
ingred ients made in the USA. Ditto for down the line of the most necessary and
common RX, including Ventolin, and the antibiotics that would treat bacterial
superinfection of COVID-19 (particularly the ones that can be used at home:
macrolides, etc.)
6) Encourage prevention of superinfection with clean respiratory toilet, hydration,
chest PT preferred over suctioning , clean environment, including cleaning floors
daily. One of the most successful methods of chest PT involves the patient lying on
the bed with their face near the floor. Decreasing the load of pulmonary sputum is
critical.
7) There is very large number of semi-retired physicians, such as myself who would
probably like to be utilized (an paid a little) for te lemedicine to assist with triage.
We can do telemedicine at home. I am not set up to do this but will soon be set
up and able. We need to know which companies we can trust to hire us.
There should be telemedicine training and tracking coming from t he CDCor
other state and national governments.
8) Is the 3/3/20 John Kehoe Financial Times art icle correct? Is it not best to predict
mortality so as to more realistically prepare for post-COVID-19 recovery
economically and socially and give confidence by being transparent?
I see recovery j obs being the young taking care of the old after most have had it
and been cured or succumbed. Then the other half of the people w ill get it, too ...
Is there some stigma attached to the word "infrastructure" that would prevent
recovery of our economy?
9) I do not wee the recommendations for Flu and both pneumovax vaccines, but
the recommendation needs to get out broadly right away.
10) Wuhan had to truck in food ...how are we planning? Canned food decreases
one's immu ne system. Fresh fruits and vegetables, frozen or dried are needed.
11) China closed all the theaters ...and we should also start closing the use of public
places, particularly asking folks in their 60's and older to stay home now.
12) Recommend providers write three month supply of Rx for all patients,
to decrease visits out and ensure availability.
13) The closure of schools might spread COVID-19 unless children have food to eat
at home and the parents comply.
14) Will census takers spread it? Should the census be postponed or performed via
hazmat suit or in another fashion?
This is a long list. Please look into 2-packs of Echinacea with instructions .
Get enough sleep/stay wel l.
Thank you.
Best regards,
Gretchen Boise, MD
LL (b)(6) (caller must announce who they are)
NIH-000855
(b)(6)
NIH-000856
From: (b)(6)
Sent: Sat, 7 Mar 2020 16:15:52 -0500
To : Lane, Cliff (NIH/NIAID) [E)
Subject: Fwd: Covid-19 Pandemic -- update
FYI. I get 100 of these per day.
From: David Katz Cb)(6)

Date: March 6, 2020 at 7 :46: 18 PM EST-----~~
To: "Fauci, Anthony (NIH/NIAID) [E]",___ _______ CbH6J
Subject: Covid-19 Pand emic -- update
Dear Tony:
As I continue to follow the evolution of this disastrous calamity, 1

continue to think of possible approaches to dealing with therapeutic
options that might be "off the beaten trail" but nonetheless worth
considering - especially for those patients who are at high risk for
debilitation and, possibly, death . I share one such thought with you
here.
Several years ago, recombinant Human Growth Hormone (rHGH)

was reported to be significantly effective in restoring/ enhancing T
cell anti -viral act ivity in patients infected with HlV (citation below):
Growth hormone resurrects adult human

thymus during HIV-1 infection
Kiki Tesselaar, Frank Miedema
J Cf in In vest. 2008; 118(3):844-847. http s://doi.org/ 10. l 172/JCI351l 2.
My thought is that since, in many ways, elderly patients afflicted

with COVID-19 fall into a similar category, that treatment with
NIH-000857
rHGH might be an effective treatment alternative to employ during
this immediate time frame while you are exploring more specific
alternatives.
I look forward to your thoughts on this, and best wishes,
David
(PS: I think you have handled yourself magnificently during these
incredible press conferences, etc.!)
NIH-000858
Sent : Sat, 7 Mar 2020 19:06:14 +0000
To: Megan 8.
Cc: Conrad, Patricia (NIH/NIAID) [E);Eisinger, Robert (NIH/NIAID) [E];Greg Folkers
-------- (b
~ )~(6)
=
Subject : RE:Thank you, Dr. Fauci
Ms. Fender:
There is no such a th ing right now as "no risk" given the uncertainty of the current situation .
However, in t he context of what we do know, since you are H years old, you have
-----
Go about your usual business. You have no reason to panic.
Best regards,
A.S. Fauci
From: Megan B. CbH6)>

To: Fauci, Anthony (NIH/NIAID) [E] CbH6J>
Subject: Re: Thank you, Dr. Fauci
Dr. Fauci,
I apologize to reach out, I know how extremely busy you must be. But I have always invested a great
deal of trust in you .
(b)(6)
Thank you greatly.
Sincerely,
Megan Fender
NIH-000862
On Sun, Feb 9, 2020, 6:27 PM Fauci, Anthony (NIH/NIAID) [E] Cb
H6J wrote :
---------
Megan:
Many t hanks f or yo ur kind wo rds. They are much appreciated.
Best rega rds,
Tony
Director
Phone : (b)(6)
FAX : (301) 496-4409
E-ma il: (b)(6)
recipient . If you have received this e-mail in error please inform the sender and delete it from
your mailbox or any other storage devices . The National Institute of Allergy and Infectious
From: Megan B. CbH6J>

-------=-c-c=
(b)(6J
Subject: Thank you, Dr. Fauci
Dr. Fauci,
As a citizen and mother , I would just like to take a short moment to say thank you for all of your great
work and service to the American people . I have admired your work for many years, and appreciated
your transparency during the Ebola crisis, as we ll as this most recent situation . As a citizen, I
appreciate that you relay facts, both good and bad, and have established a sense of trust w ith the
people .
(b)(6)
- · W ith the Ebola crisis, and with Coronaviru s, I feel better when I see your press conferences and
hear all of the work you and your team do to protect both UScitizens, and the world commun ity .
Friday I was very happy to hear you announce the extreme progress that's been made in just two
week's time on the vaccine, and that there have been no roadblocks . This has been done at
unprecedented speeds, by what I'm sure are very talented scientists.
Again, thank you for your lifetime of service in disease prevention, and for making citizens like myself
feel bet ter knowing we have people like you and your team working tirelessly for the people. ) (6)
________________ , but I take comfort in knowing we have such great,
11111111
talented individuals leading our public health system.
Dr. Fauci, you are truly a saint. Thank you for all that you do.
NIH-000863
Sincerely,
Megan Fender
NIH-000864
From: (b)( 6)
Sent: Sat, 7 Mar 2020 13:37 :51 -0500
Subject: Fwd: a question
Sent from my iPhone
B eg in forwarded messag e:
From: Leonard Trudell (b)(6)

---------
Date: M arch 7, 2020 at 1:34: 34 PM E ST
-------~~
To: "Fauci, Anthony (NIH/N lAID ) (E]"
Subject: a question --------- (bH6J ·
Dr. Fauci,
May I suggest a question that you might ask of COVID-19 identified
patients? Could you ask them if they had received a current flu shot for this
season? Since the COV ID-19 corona virus basic construct is a basic flu
version with a bio-engineered HIV or other(?) component , is it possible that
our flu vaccines might have some degree of protection agains t this new
COVID-19 viral construct? I think it is important to ask this question!
Dr. Len Trudell
(b)(6)
NIH-000865
Sent: Sat, 7 Mar 2020 18:36:42 +0000
Subject: FW: a question
Please have someone respond.
From: Leonard Trudell (b)(6)

---------
-----~~
Subject: a question
------- (b)(6)>
Dr. Fauci,
May I suggest a question that you might ask of COV ID-19 identified patients? Could you
ask them if they had received a current flu shot for this season? Since the COVID-19
corona virus basic construct is a basic f lu version with a bio-engineered HIV or other(?)
component, is it possible that our flu vaccines might have some degree of protection
against this new COVID-19 viral construct? I think it is important to ask this question!
Dr. Len Trude ll
(b)(6)
NIH-000866
Sent : Sat, 7 Mar 202018:10:15 +0000
To : Richard Carmona
Subject : RE: Kudos
Rich:
Many thanks for your kind note. Much appreciated . I hope that all is well with you .
Best regards,
Tony
From: Richard Carmona

-----------
------
--.~
(b)( >
Subject : Kudos
-------- (b)(6J>
Tony, as always and for many decades and most importantly now, thank you for being the voice of
reason and integrity that emanates from the political swamp to quell uncertainty and fear . Ironically
your words now as a "vaccine" against the disease of public fear and uncertainty may be as important
as the eventual immunologically derived vaccine against coronavirus you are working on.
Be well,
Rich Carmona
Richard Carmona
17th Surgeon General of The United States

Chief of Health Innovations
Distinguished Professor University of Arizona
8600 E. Rockcliff Road I Tucson , AZ 85750
0: 520.749.7754
CAN YONRANCH. M: ___ Cb
...,).,.(6)
__.
canyonranch.com
NIH-000869
From: (b)(6)
Sent: Sat, 7 Mar 2020 11:19:16 -0500
Subject: Fwd: universitycoronavirus
From patty on asf phone.
Pis handle
Sent from my iPhone
From 1<
Date: ~ -ar-ch
- 7,- 2-0-20
- at_ l_0_:0-6-:2_1_A_M
_ E_S_T__
To: "Fauci, Anthony (NIH/NIAID) [E]" ---------::-,:-:-=
Subject: university coronavirus --------- (b)(6)
Hello and thank you for all of your tireless efforts in dealing with the coronavirus.
I have a concern about the universities and the spread of this virus . Many schools
brought back students from study abroad before the 14 day quarantine was put
into place, and even after the quarantine was put in place, many students did not
follow the quarantine rules. Also, with shared dorms and apartments it was not
possible for student's who returned to campuses and not their homes. By the times
schools came up with a plan for quarantining the student's it was well over a week
after some were back. Therefore, there is potential for widespread infection.
The vice president said the elderly and those w ith underlying medical conditions
are at risk and should take caution in where they go, avoid crowded places
etc..Millions of students have asthma, diabetes, auto-immune disorders, and they
do not have a choice other than to go to class. The government does not seemed
concerned about the potential spread among campuses and what a disaster this
could be. They have voiced why grade schools are not closed (since younger are
not at risks better for them to be at school) but they are ignoring college kids are
at risk and the impact of widespread infection on a campus could be huge.
Students i~ colleges travel back and forth to the city all the time , and I am
concerned schools are not temporarily closing until more testing is available and
we see where this goes. At minimum , giving student's with underlying medical
conditions the option to go home and work remotely. Right now they do not have
NIH-000870
any option other than to go to class. When questioned they say they are listening
to the CDC and state government. (b)(6)
and students are not following the advice to stay home sick and nobody seems
concerned about trying to prevent infection.
Can the government please look at a temporary ban on classes at Universit ies in
states where infection is rapidly spreading, especially knowing there are not
enough test available yet. The schools are not taking action on their own and this is
a frustrating situation seeing delays in decisions making.
Thank you for your time in consideration in addressing these concerns,
Prefer to remain anonymous for the protection of (b)(

----------
NIH-00087 1
From: (b)(6)
Sent: Sat, 7 Mar 2020 11:16:57 -0500
Subject: Re: Plasmapherese pediatricians to obtain anti-corona virus antibodies
Sorry this is from patty. I have an iPhone just to manage h is email s so some of these are from
me. Will add the letter p to the ones I send you so you know they are from me.
Sent from my iPhone
On Mar 7, 2020, at 10:46 AM , AuchincJoss , Hugh (NIH/NIAID) [E]

(bH6J > wrote :
Tony, as I told Pany yesterday, I am handling all that you send me but I' m not
going to fill your inbox with an acknowledgement each time.
Sent from my iPad
On Mar 7, 2020 , at 9:15 AM , Fauci , Anthony (NJH/NTAID) [E]

(b) (6) > wrote:
Pls handle
Sent from my iPhone
From: David Chung (b) (6J>

Date: March 6, 2020 at 12:45: 17 PM EST
To: "Fauci, Anthony (NIH/NIAID ) [E]"
(b)(6) >
Subject: Plasmapherese pediatricians to obtain anti-

corona virus antibodies
Dr. Fauci ,
I appreciate the efforts of the WHO taking a look into
the temperature question. It is helpful to understand
the virus and know what to expect. (b)(6) is a
professional data analyst of large datasets like census
NIH-000872
data, for example. I was wondering if it would be
possible to obtain the WHO dataset to see if there
were any angles not considered. I am certain that the
WHO 's biostatisticians know what they are doing, but
data is a funny thing. You get the answers to the
questions you ask. If the right questions were not
asked, you may miss useful information.
Regarding the subject line, if the theory is true that
children have some cross-reactive protection due to
antibody production to the harmless coronavirus
population , that would mean that pediatricians would
also carry very high levels of protective antibody. If
this is true, then plasmapheresis might provide anti-
coronavirus antibody as potential treatment. I do not
know enough about plasmapheresis to know if this
could be applied to scale but I wanted to pass along
the thought CbH6)
David Chung
On Monday, March 2, 2020 , 07:46 :51 AM EST , Fauci , Anthony
(NIH/NIAID) [E) (b)(6)>wrote:
Thank you for your careful and well thought

out note. Worthy of consideration.
Director
Phone: Cb)(
FAX: (301 496-4409
E-mail: Cb)(

confidential and may contain sensitive information. It
should not be used by anyone who is not the original
intended recipient. If you have received this e-mail in error
please inform the sender and delete it from your mailbox or
any other storage devices. The National Institute of Allergy
and Infectious Diseases (NIAID) shall not accept liability for
any statements made that are the sender's own and not
expressly made on behalf of the NIAID by one of its
represe ntatives.
NIH-000873
From: David Chung (b)(6)
Sent: Sunday, March 1, 2020 9:44 P _M_____ ~ =
To: Fauci , Anthony (NIH/NIAID) [E] (b)(6)
Subject: Pis advise to allow return air travel only , stop all other
air travel
Dear Dr. Fauci ,
Thank you for your leadership and guidance in this

difficult time. I am a pediatrician in Massachusetts,
and as you know , direct-linkage from travel cases are
popping up on the East Coast. In order to keep the
community viral load down , keeping new cases from
moving around the country and the world will delay
the spread and amplification of the vira l
load. According to my observations, hot climates
seem to be having a favorable new case rate . Based
on the city of Qom versus the experience in
Singapore and Australia, it appears that the transit ion
temperature for efficient spread is somewhere above
when there are highs around 50 degrees F, similar to
H1N1 . According to my observations, prior to
seasonal flu , the transition temperature was closer to
highs of 40 degrees F. This theory should be
testable . For example , there are new cases in Kuwait
and Bahrain. If I am right , if you tested a subset of
these populations , you would find a very high rate of
asymptomatic infection , probably 80-90%, because
that's how many people it would take to shed small
amounts of virus to create a community viral load to
make someone sick enough to get tested. If this is
true , this bodes well for the virus burning itself out to
endemic status relatively quickly. This would be very
reassuring data you could provide to reduce panic - if
you can tell people you know how long this pandemic
is going to last rather than saying that we don't know .
Although some experts may say that restricting travel

w ill on ly delay the inevitable, this is not a valid
statement if the transition temperature for effect
spread really is 50 degrees. A delay of significant
community spread in the US until highs reach the 50s
for the Northeast where the population is the most
NIH-000874
dense would have a massive life-saving effect , but if
this is to occur, the flight restriction needs to happen
now.
Stopping all flights would be impractical and

inhumane, but allowing return flights only and
stopping all other air travel would be effective . It
would have a massive effect on the economy, but so
will overwhelming corona virus infection. No one will
die because they can't take a vacation or business
trip . Financial losses would need to be settled later,
so this would require emergency declarations , etc. If
you wanted to take it in a step-wise manner , you
could start with international flights and then move on
to domestic flights if necessary - this would probably
be wise and would have a less severe impact on the
economy.
Thank you again, and I am sure this is one of

thousands of unsolicited emails . I wish you the very
best and God grant you w isdom.
Best,
David Chung
Pediatric Associates of Brockton
NIH-000875
From: (b)(6)
Sent : Sat, 7 Mar 2020 09:17:55 -0500
Subject: Fwd: ACE2 neutraliz ing antibody from R&D Systems
Attachments : SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2and is blocked by a
clinically-proven protease inhibitor.pdf , ATTOOOOl.htm,Crystal structure of the 2019-nCoV spike
recept or binding domain bound with ACE2 receptor .pdf, ATT00002.htm
Sent from my iPhone
From: Hung Trinh (b)(

Date: March 5, 2020 at 11:04:5 1 PM EST
To: "Fauci , Anthony (NIH/NIAID ) [E]" -------= =(bH6J
Subject: Fwd: ACE2 neutralizing antibody from R&D Systems
NIH-000876
From: (b)(6)
Sent: Sat, 7 Mar 2020 09:12:07 -0500
To: Auchincloss, Hugh (NIH/NIAID) [E];Folkers, Greg:(NHf/i\llAlD) JE]
Subject: Fwd: Blog Clearance Request: COVID-19: Potent ia l lrfrp!icati6hs for Hfdividuals
with Substance Use Disorders
Attachments: COVID SUD blog ebe3 ew6 sw2 ndv4 CLEAN.docx, ATTOOOOl.htm
Pls handle
Sent from my iPhone
From: "Volkow , Nora (NIH/NIDA) [E]" (b)( >

To: "Fauci , Anthony (NlH/NlAID ) [E]"
-------~~ (bH6J·
Cc: "Hobin , Jennifer (NIH/NIDA) [E]" (bH6J>, "Volkow, Nora
(NIH/N IDA) [E]" (bH6J>
Subject: Blog Clearance Request: COVID-19: Potential Implications for
Individuals with Substance Use Disorders
Dear Toni. John Burklow asked NIAID to review a Blog I wrote on the need to evaluate
vulnerabilities among patients with substance use disorders to COVID-19. Let me know if u
or your staff have concerns or suggestions. I realize u are totally swamped and I apologize
for burdening u with it. Best nora
NIH-000877
From: (b)(6)
Sent : Sat, 7 Mar 2020 09 :11:12 -050 0
To: Auchincloss, Hugh (NIH/ NIAID) [E]
Subject: Fwd: JID 2006, 193:1244 -1249
Attachments : SARS & gd T cells.pdf, ATT00001.h tm
Pis respond if required
Sent from my iPhone
From: MIRO SLA V MALKOVSK Y ....,....

_______ (b)(6)
To: "Redfield, Robert R. (COC/OD) " -----=-:--=- (b)( 6)

Cc: "Fauci, Anthony (NIH/NJAID) [E]" _______ (b_H_6J
Subject: JID 2006, 193:1244-1249
Dear Bob,
Long time, no see. Our SARS study (JID 2006, 193:1244-1249; see the
attachmen t) showed selective expansions of Vy9Vo2 T cells in survivors of
SARS-CoV infection. Interestingly , stimulated Vy9V62 T cells also display
an interferon-y-dependent anti-SARS-CoV activity and are able to directly kill
SARS-CoV-infected cells. Since it is very easy to activate human Vy9Vo2 T
cells in vivo (e.g., using FDA-approv ed and relatively non-toxic drugs for
treating bone-demineraliza tion) and given the simi larities between SARS-
CoV and SARS -CoV-2, I thought that it cou ld be potentially useful to bring
these facts to you r and Tony 's attention , in spite of knowing that both of you
are probably slightly busier these days than you would like to be.
All the best and good luck with everyth ing,

Yours as ever,
Mirek
M. Malkovsky , MD, PhD, FRCPath

Professor Emeritus, UW School of Medicine and Public Health
Mobile: (b) (6)
Office telephone and fax: (b)(6)
E-mail: (b)(6)
NIH-000878
From: (b)(6)
Sent: Sat, 7 Mar 2020 09:07:07 -0500
Subject: Fwd: Pneumococcus vaccination in relation to coronavirus infection .
Pls respond
Sent from my iPhone
From: Lar s Nie lsen (b)(6) >

To: "Fauci, Anthony (NIH/NlAID ) (E]" ,-------- (b)(
~=
Subject: Pneumococcus vaccination in relation to coronavirus infection.
De ar Anthony Fauci,
As l und erstand the fa tal cases of covid-19 develop pneumonia after severa l days of
symptoms of the acute viral infecti on.
In this way the present conoravirus infection is very like our present and previous
fatal influenza virus infections. In the 1918 pand emic many if not most of the fatal
cases were caused by bacterial superinfection with hemolytic streptococci and
pneumococci. The former is rather se ldom now, but the pneumococcal infections are
common.
Should we advice persons over >65 y as well as people with chronic diseases with
increased risk of fatal co ronavirus diseases to be vaccinated against pneumoco cci
now?
My best regards and thank you for your significant contribut ion to inflammato ry
medicine and infections.
Lars P . Nielsen, M.D .
Specia list in Medical Microbiology and Virology
Forme r head of the Danish National Influenza Laboratory.
NIH-000879
Sent : Sat, 7 Mar 2020 13:25:29 +0000
To: Elizabeth Stevens
Subject : RE:Thank you for staying front and center, and in the public eye re COVID-19
Ms. Stevens:
Thank you for your kind note .
Best regards,
A .S. Fauci
From:Elizabeth Stevens
----------
(b)(6)

-------~~
--------- (b)(6)
Subject : Thank you for staying front and center, and in the public eye re COVID-19
Dear Dr. Fauci,
I am so happy to continue seeing you in press conferences and on news broadcasts.
Please keep making those pub lic appearances. Amer icans need to hear the facts from someone who is
trustworthy .
I am sure that tiptoeing around Donald Trump has dramat ically complicated your life . I hope that you
will find ways to " correct" or "clarify" the constan t stream of misstatements that he makes- our lives
depend upon it . (Maybe Trump could wear a hazmat suit - to protect his frag ile ego from any possible
bruising caused by a collision with the truth. Just kidding.)
Seriously, Doctor, it is a huge relief to see and hear you and your expert colleagues . It is to the point that
we cannot believe a single word tha t comes out of Trump's mouth.
Very sincerely,
Elizabeth Stevens
(b)(6)
NIH-000880
Sent:
To :
Subject : FW:
_________________
Sat, 7 Mar 2020 13:23:54 +0000
(b)(6)
___.
(b) (4)
fyi
From: Lipkin, Ian W (b)( >

------------"
Se nt : Saturd ay, March 7, 2020 8:20 AM
To: Fauci, Anthony {NIH/NIAID) [E]------~=
Subject:
___________________ (b)(6)
___.
(b)( 4)
Tony,
Happy to connect you w it h Zhu. (b)(4
(b) (4)
NIH-00088 1
(b)(4 l
NIH-000882
(b) (4)
NIH-000883
(b) (4)
NIH-000884
(b)(4)
NIH-000885
(b) (4)
»» Wit h best regards,

>>>>
»» Zhu
>>>>
>>>>
>»> ~ 1~ A: Lipkin, Ian W.
--------------
» » ~3!Bt fsJ: 2020~2)=19 8 23 :01
(b)(
»» ~~i4 A: Zhu Chen

>»> :t'J>i!:
George Gao; zhangzongwei
»» ~~: Re: important info
>>>>
>>>> Zhu,
»» Please call me on
>>>>
----- (b)(6)
>>>>Ian
>>>>
>>>>
>>>>
»>> W. Ian Lipkin, MD
»» John Snow Professor of Epidemiology and Director
»» Center for Infection and Immunity
>»> Mailman School of Public Health
>>>>
>»> Professor of Pathology and Neurology
»» College of Physicians & Surgeons
>>>> Columbia University
»» 722 West 168th Street, 17th Floor
»>> New York, NY 10032
»» Voice: (b)(6)
>»> Fax: (212) 342-9044
>>» Email:
----------- (b)(6)
NIH-000886
>>>>
»» Administrative Coordinator
>»> (b)(6)
>>>> Voice: (b)(6)
»» Email:
~====::::!!:,__~
=
>>>> --------- (b)(6)
»» www.cii .columbia.edu
»» Follow CII on Twitte r: CII_Columbia I Facebook: ClI.Columbia
>>>>
>>>>
>>>>
>>>>
>>>>
>>>>
>»> On Feb 9, 2020, at 9:43 AM, ZhuChen wrote:
>>>>
------- (b)(6)>
>>>> Dear Ian,

»» I have an important info to be shared with you. According to the latest report from
the National Health Commission, the number of confirmed cases of NCP (2019-nCoV
pneumonia) in other Provinces than Hubei {Wuhan is the capital city) was decreased from
890/day on Feb 3rd to 509/day on Feb 8th . So it is still possible for this outbreak to be
basically contained in China.
»» Therefore, my suggestion is that we support the current public health policies and
strategy to concentrate quality med ical human resources and other resources to save
more life of severe pat ients, even though the cost is high, very high. And then, we shall
continuously analyze the situation for possible adjustment of policies and measures.
>>>> Best,
>>>> Zhu
>>>>
>>
NIH-000887
Sent: Sat, 7 Mar 2020 13:23:10 +0000
To: Lorne Brandes
Subject : RE:Coronavirus immunity
We have thought about it.

From: Lorne Brandes ______ r-:;;
(b'"")'""
(6)
=

------~~=
To: Fauci, Anthony (NIH/NIAID) [E]...______ Cb
_>
_<....
Subject: Coronavims immunity
Hi Dr Fauci ,
Has anyone considered the possib ility that previous coronavims infection(s) associated with common colds may
result in at least partial immw1ity to the COVID-19virus? This may expla in why the disease is generally mild in
80% of adults and apparently rare in children (most of whom get more frequent colds than adults). I would be
pleased to hear your thoughts.
Sincerely,
Lome Brandes, MD, FRCPC
Professor, University of Manitoba (b)(6)
NIH-000888
Sent : Sat, 7 Mar 2020 13:21:56 +0000
To: Ann Job
Subject : RE:2020 Censusand COVID-19
Ms. Job:
Thank you for your note.,
Best regards,
A.S. Fauci
From:Ann Job (b)(6)>

Subject : 2020 Censusand COVID-19
--------- (b)(6)
Dear Dr. Fauci ,
Today I wrote and mailed a letter to both you and Dr. Redfie ld.
I will not duplicate nor attac h it her e, but I did want you to make you aware of my letter in case it
doesn't reach your desk on Monday. In it I ask you and Dr. Redfie ld to explore the possibility of
using 2020 Census Enumerators as an "on-the-gro und army" to help stop COVID-19 .
Because as you know better than anyone else that time is of the essence, I thought it useful to
give you a heads-up about my letter via this email.
I am probably being na ive, but just in case it make s sense to you , I thought it cou ldn't hm1 to
write you .
Thank you for being there for us. We really need you .
Yours,
Ann E. Job (pronounced like the Book of Job in the B ible)
(b) <~(iPhone)
(hom e)
NIH-00088 9
From: Fauci, Ant hony {NIH/ NIAID) [E]
Sent: Sat, 7 Mar 2020 13:13: 58 +0000
To: Eisinger, Robert {NIH/ NIAID) [E]
Subject: FW: A vaccine w ith ant i imm unosuppre ssive prope rties
Attachments: (b)(6)
Please respond on my behalf
From: Avr aham Halbrei ch

---------
Sent: Satur day, Ma rch 7, 2020 7:00 AM
(b)( 6)>
To: Fauc i, Ant hony (NIH/NIAID) [E] ..------ -,.-

(b'""'
H= >
Subject: A vaccine w ith anti lmmunos uppressive properties
Importance : Low
Dear Dr Fauci ,
Common wisdom tells us that the inability to immunize against HIV, malaria etc. as well
as the need to
repeat evry year anti flu vaccination result from the excessive , or limitless, genetic
variability of the underlying pathogens. While not doubting the reality of this genetic
variability , best observed in an orderly manner in the case of HIV, I considered the
possibility that these pathogens are endowed wiith an immunosuppressive capacity
that is not inactivated during vaccine production, and that current vaccines do not
induce immunity against such
immunosuppression. I applied this reasonning when I work ed on an AIDS vaccine in
1991 in Zagury's lab
(Halbreich A et al. (1992) Vaccine Research,4 :397-412 ). Indeed , we tested then , in
suitably immunized animals , the effect of the various preparations on the cellular
response to tuberculin and the capacity of animals to be
Immunized against tuberculin and tetanus as a function of the exrent of treatment. The
immune response to these agents was indeed higher in the presence of hivions
compared to heat inactivated preparations . This HIVION preparat ion was used on 6
patients in Zaire (Zagury et al. ( 1992) J Acquired Immune Deficiency Syndromes,
5 :676-681).
NIH-000890
Unfortunately, when I tried to make a greater prep for a phase I trial , the viral preparation
turned out (too late) ,
by SOS gel elecrophoresis , not to contain any viral protein , due either to degradat ion or
another mishap . I left Zagury 's lab soon after and it was impossib le for me later to obtain
material (either viral or from recombinant protein) to further advance the matter. I do
believe that tuning vaccine preparation to counter immunosuppressive effe ct of the virus
(parasite) while preserving its capacity to induce anti viral immunity should resolve the
need to revaccinate every year against the same virus. In fact, identifying the epitopes ,
acting for immunity and those
acting against immunosuppression, at a later stage should allow a better result than we
obtained. (It is not yet known whether corona virus also mutates rapidly, but I heard that
a woman was reinfected after having recovered from covid-19 infection and this might
indicate a capacity of the virus to counteract the host's immune response.
In H 6) I have been itching ever since to go back to
Cb
unfinished projects , but did not

find an avenue. Now, with the outburst of the corona virus pandemic this surfaces again .
(b)((;J
Sincerely
Avraham Halbreich
NIH-00089 1
Sent: Sat, 7 Mar 2020 13:06:00 +0000
To: Anderson, Jennifer (NIH/NIAID) [E]
Subject: RE: unit heads
If I am available, I would be happy to discuss COVID-19
From:Anderson, Jennifer (NIH/NIAID) [E] (b)(
Sent: Saturday, March 7, 2020 8:03 AM ----------

To: Fauci,Anthony (NIH/NIAID) [E] ------=-c (b)'""'
(6)
=
Subject: Fwd: unit heads
Good morning Dr Fauci
We are - for the momen t - scheduled for a Un itheads meet ing on Tuesday. Tae Wook is next to
pr esent but suggested (see below) that we make it a round table and discuss COVID-19.
Question: IF Unitheads isn' t canceled how do you feel abou t having a Roundtable instead of Tae
Wook presenting? Or would you prefer to take a break from Coronavirus for a moment and
hear about HIV!
Thanks
Jen
Sent from my iPhone
From: "Chun, Tae-Wook (NIH/NIAID) [E]"

Oate: March 6, 2020 at 9:53 :11 AM EST
---------
To: "Anderson, Jennifer (NIH/NIAID ) [E]"
---------~~ CbH6J>
Subject: Re: unit heads
-----------
Can we do round table? I want to talk to him about corona not to mention the MTA
will get canceled anyway . If you want me to I wi ll present .
On Mar 6, 2020, at 9 :47 AM, Ande rson, Jennifer (NIH/NIAID) [E]

(b)(6) wrote :
Hi Tae Wook,
NIH-000892
I thin k you are up for Unit heads? It's been so long, I've lost tr ack . I think you
were supposed to present back on Jan 14th but it got canceled and I don 't
th ink we 've had a pre senta tion since . Im being t old w e might have a UH on
Tuesday-ASF is free so far . Can you present ?
Jen
Jennife r M. Anderson, PhD

Deputy Branch Chief
IAMB/OAS/N IAID
Scientific Operations Manager
LIR/DIR/NIAID
9000 Rockville Pike, Bldg. 10 Rm. 6A19A
Office Phone : (b) (6)
NIH Cell: (b)(6)
Personal Cell:
-----
FAX: 301-402 -4122
(b)(6)
NIH-000893
Sent: Sat, 7 Mar 2020 13:02:34 +0000
To: Cassetti, Cristina (NIH/NIAID) [El;Lane, Cliff (NIH/NIAID) [El
Subject : FW: Plasma therapy
FYI
---------
From : Lipkin, Ian W. _________
Cb
_> ==
_<_,
------~~
To: Fauci, Anthony (NIH/NIAID) [E] ..._______ Cb
_)_(6)
...
Subject: Plasm a therapy
Tony,
Just reviewed paper (b) (4 on pi lot study of plasma therapy for COVlD -19. Sufficiently encouraging that
J' d begin collecting p lasma for compassionate use as well as larger randomiz ed trial.
Jan
Jan
NIH-000894
Sent: Sat, 7 Mar 2020 13:02:18 +0000
To: Lipkin, Ian W.
Subject : RE:Plasmat herapy
Than.ks, Ian
---------, ~=
-----Orig inal M essage -----
From : L ipkin, Ian W. _________
Sent: Saturday, M arch 7, 2020 7: 50 AM
Cb
_)_(_.
6l>
------~~
To: Fauci, Anthony (NIH/NIAID) [E]..._______ Cb
_)_(6)
...
Subject: Plasm a therapy
Tony,
Just reviewed paper (b) (4 on p ilot study of plasma therapy for COVlD-19. Sufficiently encouraging that
J' d begin collecting p lasma for compass ionate use as well as larger randomized trial.
Jan
Jan
NIH-000895
Sent : Fri, 6 Mar 2020 23:44:54 +0000
Cc: Crawford , Chase (NIH/ NIAID) [E]
Subject: Re: ASF------- AIPAC reports that two people who attended its conference
tested positive for the co ronavirus
Attachments: imageOOl.jpg
Yikes!
On Mar 6, 2020, at 6:23 PM , Folke rs, Greg (N IH/NIAID) [E]

(b)(6) wrote:
Just fyi -folks from this delegation wer e in the hallway on the Hill when you and
Chase were the re
From: Folkers, Greg (NIH/NIA ID) [El (b)(6)

Subject : JTA:AIPACreports that two people who attended its conference tested pos itive
for the co ronav irus
AIP AC reports that two people who attended its

conference tested positive for the coronavirus
MARCH 6, 2020 5:45 PM
<image0Ol.jpg>
Outside the American Israel Public Affairs Committee

(AIP AC) annual conference in Washington, DC on
March, 01, 2020. (J\1arvin Joseph/The Washington Post
via Getty Images)
NIH-000896
WASHINGTON (JTA) - The American Israel Public Affairs
Committee said that at least two people who attended the
lobby's policy conference have tested positive for the
.
coronaVIrus.
The conference, which ran from Feb. 28-March 2, drew
18,000 activists to Washington.
The AIPAC statement posted late Friday on Twitter said the

two people who tested positive are from New York. The
outbreak has been especially hard on the Orthodox Jewish
community in Westchester County, and AIPAC listed the
county's health department as among the authorities with
which it is in communication.
The others are the New York Health Department, national
health authorities and the District of Columbia Health
Department. The statement also said the lobby was
consulting with Edward Septimus, a professor of internal
medicine at Texas A&M University.
The statement posted on Twitter said an email was going out
to all attendees as well as to congressional offices. The
conference routinely attracts a majority of Congress members
and their staffers.
BY RON KAMP EAS
NIH-000897
NIH-000898
From: (b)(6)
Sent: Fri, 6 Mar 2020 18:35:49 -0500
Subject: Fwd: Important & EmergencyNature (COVID-19)Related
Sent from my iPhone
From: Udita Katugampola (b) C

Date: March 6, 2020 at 6:29: 16 PM EST
,------- --;;-~
Subject: Important &Emergency Nature (COVID-19) Related
Dear Dr. Fauci,

I saw that you are discussing the steps we need to take to make the impact of
COVID-19 a minimum in CNN and decided to write to you what we did as faculty in
this aspect.
I believe that prevention is m uch more important than treatment later. As a
preparation for the COVID-19 outbreak, two days ago, I made a personal decision
to make all my homework on line submission so that we may avoid the spread of
the virus anymore .
Students work on homework for hours and can easily spread the virus without
knowing it. Once it goes to graders (my TAs), they then spread it to the rest of the
class, again without knowing it. Thus, an innocent act can be devastat ing. So, in
simply two-three days it may spread to another 100 new indiv iduals easily.
Graders may act as hubs in this case. The danger is, it may have spread to another
hundred or more new individua ls even before it comes to a detectable level f rom
any test.
I also want to emphasis the following points:
1. We hear in all news that elderly people are the most vulnerable. But I think
it should be corrected as people with immunodeficiency are the most
vulnerable and elderly are in that category. Some one who is 10 years old
and have diabetic or HIV has the same danger as an elderly person .
2. We should come up with a test such as a pregnancy test, which can be done
at home without leaving their homes. This stops further spreading.
3. We should discuss foods that help cure it fast and th ings that we should not
do.
NIH-000899
I have shared my thoughts with CNN (Dr. Sanjay Gupta and Anderson Cooper as
well). Thank you for your time and everything you do to our community at this
critical moment .
Best,
Udita
Udita Katugampola, Ph.D .
Assistant Professor of Ma themat ics
Florida Polytechnic Univer sity
Office: !ST 2015
Tel: (b)(6)
Email. (b) (6'i,
edu
Web:https ://sites. google.com/site/uditanalin/
NIH-000900
From: (b)(6)
Sent: Fri, 6 Mar 2020 18:32:06 -0500
Subject: Fwd: MOSQUITOES
Sent from my iPhone
From: JAME S NUTILE (b)(6)

----------
,------- --;;-~
To: "Fauci , Anthony (NIH/NlAID ) (E]"
Subject: MOSQUITOES -------- (b)(
Dr. Fauci,
No ones address ing the possibi lity of the Coronav irus being transferred by
mosquitoes this summer. Is that a possib ility?
Thank you,
James Nutile
Sent from my iPhone
NIH-000901
From: (b)(6)
Sent: Fri, 6 Mar 2020 18:31:39 -0500
Subject: Fwd: I am not spam. Possible consideration for Coronavirus
Sent from my iPhone
From: Karen Bender (b)(6) >

To: "Fauci, Anthony (NIH/NlAID ) (E]" -------~~ (bH6J ·
Subject: I am not spam. Possible consideration for Coronavirus
Good Evening Dr Fauci ,

I have an idea for your consideration for the Coronavirus vaccine/treatment.
Noting that the virus is attacki ng ou r elderl y more and knowing their lungs are o lder
and not as functi onal to fight this infection. Have you conside red artific ial surfactant
to boost lung function. (b) (6)
Perhaps if their lungs are stronger to expand they could fight the virus better.
Thank you for listening, My prayers are with our Healthcare Professional s to
achieve a treatment/vaccine.
Karen Bender
NIH-000902
From: (b)(6)
Sent: Fri, 6 Mar 2020 18:28:43 -0500
Subject: Fwd: Kidney Disease (NS-MCD) and Covid-19 Coronavirus
Can one of you take this?
Sent from my iPhone
From: Raja R (b)(6) >

Date: March 6, 2020 at 6: 15:37 PM EST
To: "Fauci , Anthony (NIH/NlAID ) (E]" <{,----~- (b~
Subject: Kidney Disease (NS-MCD) and Covid-19 Coronavirus
Dear Dr. Fauci,
I live in the United Kingdom and listen to your recent press briefings from White House.
First of all, I want to convey my sincerest thanks to you for providing valuable information
to the general public.
I would greatly appreciate it if you can advise on what precautions I should take
--
. Should he try to
avoid all social contact, and of course avoid any cruise, air or pub lic transport to prevent
him from gettin g the infection?
I would greatly appreciate your advice on thi s.
Regards
Raja
NIH-000903
Sent : Fri, 6 Mar 2020 15:26:21 +0000
To: Dzau, Victor J.
Subject : RE: URGENT- GPMB COVID-19 FUNDING NOTE
Please leave m name off . Thanks.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail Cb)(6)
From: Ozau, Victor J. (b)(6)

To: Fauci, Anthony (NIH/NIAID) [El -------::-::-=,
(b)((;)>
Cc: Alex Harris (b)( ; Jeremy Farrar (b) (6)>
Subject: Re: URGENT- GPMB COVID-19 FUNDING NOTE
----------
Tony,
I know you are extremely busy. I am following up on GPMB business.
Given our conversation 3 days ago, would you like to sign on the statement or do you prefer us to leave
you name off? Please let us know ASAP.
Best,
Victor
On Mar 5, 2020, at 9:31 AM , Alex Harris (b)(6)> wrote:

----------
Dear Board Members,
NIH-000904
(b) (4)
With many thanks,
Alex
Alex Harr is
Head of Global Policy & Advocacy
Wellcome
T: (b)(6)
(b)(6)
G7 leadersand Sherpas
Country Rep Sherpa(amendmentswelcome) GPMB lead(s)
(b)(6)
Canada Justin Trudeau,
Prime Minister
France Emmanuel Macron ,
President
Germany Angela Merkel, Jeremy Farrar
Chancellor
It aly Giuseppe Conte, u
Prime Minister
Japan Shinz6 Abe, ~
Prime Minis t er
United Kingdom Boris Johnson , Jeremy Farrar
Prime Min ist er
United States Do nald Trump, Victor Dzau
NIH-000905
President
Participants
(b}(v
European Union Charles Miche l,
President of the
Euro12eanCouncil
European Union Ursula von der Le~en, Victor Dzau
President of the Jeremy Farrar
Euro12ean Comm ission
International financial institut ions

Institution Leadership Sherpa/equivalent or GPMB lead
suggestedcontacts
(b) (6), (b) <4Y Victor Dzau
As Sy
Jeremy Farrar
NIH-000906
From: Alex Harris
Se nt: 03 March 2020 23:06
To: 'Amelie RIoux• -------""' Cb =>; Dzau, Victor J.
"'>""'"
<6) (b)(6)
(b)(6) Jeremy Farrar (b)( >; Anthony
-:---:-.:======~~;---:-
Fauci
--====~~-:----:--
(b)(6)> ; Fore Henrietta (b)(6)>; Gao Fu
--~===: ~ )~( ~ > -; G
(b - as-humba Diane (b) (6) Ilona
Kiekbusch (b)(6)> ; Suzuki Yasuhiro (b)(6) ;

-----!:=====~~-- ::.=======~----
----------- (b)(6); Vega Morales Jeanette
VijayRaghavan Krishnaswamy
(b)(6)>
(b)(6);
(b)(6J>;Skvortsova Veronika
Cc: Gro Brundtland CbH6)>;Elhadi SY

(b)(6)>; Tore Godal ______ ; Godal, Tore (b)(6)>;
(b)(6); SCHWARTLANDER,Bernhard F.
::========~~-:-'."':"":""
(b)(6J>;RYAN, Michael J. (b)(6J>;Pate Muhamed
~======~~- (b)( 6) >; Kanarek, Morgan (b)(6)
; 'Sheila Austria'
; William Hall ._________
":"":":7:'"""---:---:-:----::;========;__---=---c-= __ Teresa
(b)(6);
Miller de Vega (b)( >; 'Marston Hilary'
Subject : RE: GPMB: COVID-19 FUNDING NOTE
Dear Board Members,
Ahead of the GPMB Board call on Wednesday, I'm pleased to attach a note (on behalf of
Jeremy Farrar, Victor Dzau and a small working group) setting out the urgent need for new
funding for th e global COVID-19 response.
You will have seen the strong announcement today from the World Bank of up to $12bn to
support country response, wh ich we warmly welcome . We are asking for your feedback on
the call and (b) (4)
(b) (4)
NIH-000907
(b) (4)
We look forward to the discussion.
With best wishes,
Alex
Alex Harr is
Head of Global Policy & Advocacy
Wellcom e
T: (b)(6)
(b)(6)
NIH-000908
Sent: Fri, 6 Mar 2020 15:23:33 +0000
Cc: Billet, Courtney (NIH/NIAID) [El;Folke rs, Greg (NIH/NIAID) [El;Conrad , Patricia
(NIH/NIAID) [El
Subject: RE: FORASF REVIEW:Draft PRre: Phase 1 mRNA coronavirus vax launch
Looks fine. Thanks.
Director
Phone (b)(6)
FAX : (301) 496-4409
E-mail : (b)(6l
From: Stover, Kathy (NIH/NIAID) [El (b)(6)>

(b)(6J>
Cc: Billet, Courtney (NIH/N IAID) [El (b)(6) >; Folkers, Greg (NIH/NIAID) [E]
_______ Cb <6l;Conrad, Patricia (NIH/NIAID) [E)
_>_ (b)(6)
Subject: FORASF REVIEW:Draft PRre: Phase 1 mRNA coronavirus vax launch
Good morning, Dr . Fauci,
Please fi nd attached for your review a draft press release about the launch of the Phase 1 study
of the mRNA COVID-19 vaccine. We are tentative ly planning to issue the release on Wed .,
March 11 once we ' ve received confirmation that the first participant has been vaccinated. For
ease of reference, the following is the q uote we have crafted for you :
"Finding a safe and effective vaccine to prevent infection with SARS-CoV-2 is an urgent
public health priority," said NIAID Director Antho ny S. Fauci, M.D. "This Phase 1 study, launched
in record speed, is an important first step toward achieving that goal."
Thanks,
NIH-000909
Kathy
Kathy Stover
Branch Chief
Bethesda, MD 20892
(b)(6)
Media line: (301) 402-1663
NIH-000910
Sent : Fri, 6 Mar 2020 14:50:15 +0000
To: (b)(6)
Subject : FW: Developing Immunity to SARS-CoV-2and lvlg
Please respond to th is person.
Director
Phone : (b)(6)
FAX: (301) 496-4409
E-mail (b) (6)
From: Dr. Art Kamm <art@kammconsultinginc.com>

To: Fauci, Anthony (NIH/NIAID) [El -------::-:-:-=
(b)(6>l>;Lane, Cliff (NIH/NIAID) [E]
(b)(6)>
Subject: Developing Immunity to SARS-CoV-2and lvlg
Dear Dr. Fauci and Dr. Lane:
I have been fo llowing the growing international outbreak of COVID-19 and wanted to share a thought with
you, understanding that this may have already been thought of. My early academic research (refe rence
provided, PNAS)involved cancer immunology where it contributed to a growing body of info rmation that
certain tumor cells could possessunique surface antigens that could be used for immunologi c therapy
(https://www .pnas.org/co ntent/pnas/7S/12/S9 12.fu ll.pdf ). My career then too k me to executive and senior
executive/corporate officer positions in publicly-held pharmaceutical corporations (Glaxo and Salix,
respectively) overseeing R&D of therapeutic agents. My experience has included both pharmaceuticals and
biologics.
(b)(6)
Our current understanding of COVID-19 mortality is that it appears to be concentrated in the elderly and
those with underlying medical conditions. In healthy indiv iduals (although still early) it appears that many of
NIH-0009 11
those infected with SARS-CoV - 2 may remain symptom free or develop mi ld disease, or recover from mo re
severe illness. Currently there are te ns of thousands of individua ls who have been identified as having been
infected but are considered 'recovered' . That being case it wou ld seem plausible that they have mounted an
antibody response to the vir us.
The question is whethe r these individua ls are being tested for ant ibody titre to the virus, and if that is
occurring whethe r they are being approached to donate plasma to move into lglv prod uction. With this
illness still in it s early stages and being international, I would imagine that such an effort would involve a
public/private sector endeavor. Understanding the difficulty in developing a vaccine fo r 'cold viruses', lvlG
may be a way to at least reduce the mortality in our most vulne rable patients . So, the slow start we have had
in t esting the US popu lation for this virus goes beyond disease prevention - it would certa inly be affecting our
ability, to some degree, of rapidly developing a more ta rgeted intervention for high risk patients .
Again, you may have already thought of this, but as a concerned citizen having some background and an
---------- (b)(6) ,I wanted to share these thoughts . Understanding your busy schedules, I have
copied both the Director and Deputy Director for Clinica I Research and Special Projects.
Respectfully submitted,
Arthur R. Kamm, PhD
(b)(6)
NIH-000912
Sent: Fri, 6 Mar 2020 14:48:03 +0000
To : Corey MD, Larry
Subject: RE:A query
Visit where?
Director
National Institute s of Health
Phone: CbH6)
FAX: {301) 496-4409

(b)(6)
E-ma il:
--------
The info rmation in this e-mail and any of its attachments is confidential and may
contain sensitive information . It shou ld not be used by anyone who is not the
orig inal intended recipient . If you have received this e-mai l in error please inform
liability for any statements made t hat are the sender's own and not expressly
From : Corey MD, Larry ________

------
_,,
(b) (6)>
To: Fauci, Anthony (NIH/NIAID) [E] ------ ---..---.--.,=

CbH6J>
Subject: A query
Should i and I the younger Glenda Gray give these 702 tal ks at CROIon This
coming Tuesday in Bosto n. If I fly East for this Tuesday evening t alk are you at all
free Wednesday to come visit and tal k about HIV antibodies? Or are you so
progr ammed with coronavirus thi s is not realistic . ?
Sent from my iPhone
NIH-0009 13
Sent : Fri, 6 Mar 2020 12:56:55 +0000
To : McNeil, Donald (mcneil@ nytimes .com)
Subject : FW: NYT: Inside China's All -Out War on the Coronavirus
Donald:
You r interv iew w it h Bruce Ay lwa rd was t he best di scussion of COVID-19 t hat I
have seen t hus far. Great job!
Best,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail (b)(6)
From: Folkers, Greg (NIH/ NIAID) [E] CbH >

Subject : NYT: Inside China's All-Out War on the Coronavirus
Q&A
Inside China's All-Out War on the Coronavirus

Dr. Bruce Aylwa rd, of the W.H.O., got a rare glimpse into Beijing's camp aign to stop the epidemic. Here's
what he saw.
NIH-0009 14
Dr. Bruce Aylward, leader of the W.H.O. team that visited China to assessthe country's response to the
coronavirus outbreak.Cred it ...Salvatore Di Nolfi/Keystone , via Associated Press
By Donald G. McNeil Jr .
• March 4, 2020
As the leader of the World Health Organization team that visited China, Dr. Bruce Aylward feels he has
been to the mountaintop - and has seen what's possible.
During a two -week visit in early February, Dr. Aylward saw how China rapidly suppressed the
coronavirus outbreak that had engulfed Wuhan, and was threatening the rest of the country .
New cases in China have dropped to about 200 a day, from more than 3,000 in early February. The
numbers may rise again as China's economy begins to revive . But for now, far more new cases are
appearing elsewhere in t he world.
China's counterattack can be replicated, Dr. Aylward said, but it wil l requi re speed, money, imagination
and political courage.
For countries that act quickly, containment is sti ll possible ''because we don't have a global pandemic -
we have outbreaks occurring globally," he added.
NIH-000915
Dr. Aylward, who has 30 years experience in fighting polio, Ebola and other global health emergencies,
detailed in an interview w ith The New York Times how he thinks the campa ign against the virus should
be run .
This conversation has been edited and condensed.
Do we know what this virus's lethality is? We hear some estim ates th at it's close to the 1918 Spanish
flu, which killed 2.5 percent of its victim s, and other s that it' s a littl e worse th an the seasonal flu,
which kills only 0 .1 percent. How many cases are missed affects that .
There's this big panic in the West over asymptomatic cases. Many people are asymptomatic when
tested, but develop symptoms within a day or two.
In Guangdong, they went back and retested 320,000 samples originally taken for influenza surveillance
and other screening . Lessthan 0.5 percent came up positive, which is about the same number as the
1,500 known Covid cases in the province . (Covid-19 is the medical name of the illness caused by the
coronavirus.)
There is no evidence that we' re seeing only t he tip of a grand iceberg, with nine-tenths of it made up of
hidden zombies shedding virus. What we're seeing is a pyram id: most of it is aboveground.
Once we can test anti bodies in a bunch of people, maybe I'll be saying, "Guess what? Those data didn't
tell us the story ." But the data we have now don't support it.
That 's good, if there' s little asymptomatic tr ansmission . But it's bad in that it implies that th e death
rate s we 've seen - from 0.7 percent in parts of China to 5.8 percent in Wuhan - are correct, right?
I've heard it said that "t he mortali t y rate is not so bad because the re are actua lly way more mild cases."
Sorry - t he same number of people th at were dying, still die. The real case fatality rate is probably what
it is outside Hubei Province, somewhere between 1 and 2 percent.
Patients wait ing t o be t ransferred from one hospital in Wuhan to Leishenshan Hospit al, a newly bui lt
medical center to address th e epi demic t hat is also in Wuhan, China.Credit ...Agence France-Presse -
Getty Images
NIH-000916
What about children? We know they are rarely hospitalized . But do they get infected? Do they infect
their families?
We don't know. That Guangdong survey also turned up almost no one under 20. Kids got flu , but not
this. We have to do more studies to see if they get it and aren't affected, and if they pass it to family
members . But I asked dozens of doctors : Have you seen a chain of transmission where a child was the
index case? The answer was no.
Why? There's a theory that youngsters get the four known mild coronaviruses so often that they ' re
protected.
That's still a theory. I couldn't get enough people to agree to put it in t he W.H.O. report .
Does that imply that closing schools is pointle ss?
No. That's still a question mark . If a disease is dangerous, and you see clusters, you have to close
schools. We know that causes problems, because as soon as you send kids home, half your wor k force
has to stay home to take care of them. But you don't take chances with children .
Are the cases in China really going down?
I know there ' s suspicion, but at every testing clinic we went to, people would say, "It's not like it was
three weeks ago." It peaked at 46,000 people asking for tests a day; when we left, it was 13,000.
Hospitals had empty beds.
I didn't see anything that suggested manipulation of numbers. A rapidly escalating outbreak has
plateaued, and come down faster than would have been expected . Back of the envelope, it's hundreds
of thousands of people in China that did not get Covid-19 because of this aggressive response.
Is the virus infecting almost everyone, as you would expect a novel flu to?
No - 75 to 80 percent of all clusters are in families. You get the odd ones in hospitals or restaurants or
pr isons, but the vast majority are in families. And only 5 to 15 percent of your close contacts develop
disease. So they try to isolate you from your relatives as quickly as possible, and find everyone you had
contact with in 48 hours before that.
You said differ e nt cities responded differently. How?
It depended on whether they had zero cases, sporadic ones, clusters or widespread transmission.
First, you have to make sure everyone knows the basics: hand-washing, masks, not shaking hands, what
the symptoms are. Then, to find sporadic cases, they do fever checks everywhere, even stopping cars on
highways to check everyone.
As soon as you find clusters, you shut schools, theaters, restaurants. Only Wuhan and the cities near it
went into total lockdown.
How did the Chinese reorganize their medical response?
First, they moved 50 percent of all medical care on line so people didn't come in. Have you ever tried to
reach your doctor on Friday night? Instead, you contacted one online. If you needed prescriptions like
insulin or heart medications, they could prescribe and deliver it.
NIH-000917
Grocery delivery to a quarantine area in Wuhan, China.Credit ...Agence France-Presse - Getty Images
But if you thought you had coronavirus?
You would be sent to a fever clinic. They would take your temperature, your symptoms, medical histo ry,
ask where you'd traveled, your contact with anyone infected. They'd whip you through a CT scan ...
Wait - "whip you through a CT scan"?
Each machine did maybe 200 a day. Five, 10 minutes a scan. Maybe even partial scans. A typical hospital
in the West does one or two an hour. And not X-rays; they could come up normal , but a CT would show
the "ground-glass opacities" they were look ing for .
(Dr. Aylward was referring to lung abnormalities seen in coronavirus patients .)
And then?
If you were still a suspect case, you'd get swabbed. But a lot would be told , "You' re not Covid." People
would come in with colds, flu, runny noses. That's not Covid. If you look at the symptoms, 90 percent
have fever, 70 percent have dry coughs, 30 percent have malaise, trouble breathing. Runny noses were
only 4 percent.
The swab wa s for a PCRtest , right? How fast could they do that? Until recently , we w ere sending all of
ours to Atlanta.
They got it down to four hours .
So people weren't sent home?
No, they had to wait . You don't want someone wandering around spreading virus.
If they were positive, what happened ?
They'd be isolated. In Wuhan, in the beginning, it was 15 days from getting sick to hospitalization . They
got it down to two days from symptoms to isolation . That meant a lot fewer infected - you choke off
this th ing's ability to find susceptibles .
What' s the difference between isolation and hospitalization?
NIH-000918
With mild symptoms, you go to an isolation center. They were set up in gymnasiums, stadiums - up to
1,000 beds. But if you were severe or critical, you'd go straight to hospitals. Anyone with other illnesses
or over age 65 would also go straight to hospitals.
What were mild, severe and critical? We think of "mild" as like a minor cold.
No. "Mild" was a positive test, fever, cough - maybe even pneumonia, but not needing oxygen.
"Severe" was breathing rate up and oxygen saturation down, so needing oxygen or a ventilator.
"Critical" was respiratory failure or multi-organ failure.
So saying 80 percent of all cases are mild doesn't mean what we thought .
I'm Canadian. This is the Wayne Gretzky of viruses - people didn't think it was big enough or fast
enough to have the im pact it does.
A sports stadium converted to a makeshift hospital in Wuhan, China.Credit...China Daily/Reuters

Hospitals were also separated?
Yes. The best hospitals were designated just for Covid, severe and critical. All elective surgeries were
postponed. Patients were moved . Other hospitals were designated just for routine care: women still
have to give birth, people still suffer trauma and heart attacks.
They built two new hospitals, and they rebuilt hospit als. If you had a long ward, they'd build a wall at the
end with a window, so it was an isolation ward with "d irty" and "clean" zones. You'd go in, gown up,
treat patients, and then go out the other way and de-gown . It was like an Ebola treatment unit, but
without as much disinfection because it's not body flu ids.
How good were the severe and critical care?
China is really good at keeping people alive. Its hospitals looked better than some I see here in
Switzerland. We'd ask, "How many ventilators do you have?" They'd say "50 ." Wow! We'd say, "How
many ECMOs?" They'd say "five ." The team member from the Robert Koch Institute said, "Five? In
Germany, you get three, maybe. And just in Berlin."
NIH-000919
(ECMOs are extracorporeal membrane oxygenation machines, which oxygenate the blood when the
lungs fail.)
Who paid for all of thi s?
The governmen t made it clear: testing is free. And if it was Covid-19, when your insurance ended, the
state picked up everything .
In the U.S., that's a barrier to speed. People think: "If I see my doctor, it's going to cost me $100. If I end
up in the I.C.U., what's it going to cost me?" That'll kill you. That's what could wreak havoc. This is where
universal health care coverage and security intersect. The U.S. has to think t his through.
What about the nonmedical response?
It was nationwide. There was th is t remendous sense of, " We've got to help Wuhan ," not "Wuhan got us
into this." Other prov inces sent 40,000 medical workers, many of whom volunteered .
In Wuhan, our special train pulled in at night, and it was the saddest thing - the big intercity tra ins roar
right through, with the blinds down .
We got off, and another group did. I said, "Hang on a minute, I thought we were the only ones allowed
to get off ." They had these little jackets and a flag - it was a medical team from Guangdong coming in
to help .
How did people in Wuhan eat if they had to stay indoors?
Fifteen million people had to order food on line. It was delivered. Yes, there were some screw-ups. But
one woman said to me: "Every now and again there's something missing from a package, but I haven't
lost any weight ."
A yoga class being taught on line from a studio in Beijing.Credit ...Roman Pilipey/EPA, v ia Shutterstock
Lots of gove rnm ent employ ees w ere reassigne d?
From all over society . A highway worker might take temperatures, deliver f ood or become a contact
tracer. In one hospital, I met the woman teaching people how to gown up. I asked, "You're the infection
control expert?" No, she was a receptionist. She'd learned .
NIH-000920
How did technology play a role?
They're managing massive amounts of data, because they're trying to trace every contact of 70,000
cases. When they closed the schools, really, just the buildings closed. The schooling moved on line.
Contact tracers had on-screen forms . If you made a mistake, it flashed yellow. It was idiot -proof.
We went to Sichuan, which is vast but rural. They'd rolled out SG. We were in the capital, at an
emergency center with huge screens. They had a problem understanding one cluster. On one screen,
they got the county headquarte rs. Still didn't solve it.
So they got the field team. Here's this poor team leader 500 kilometers away, and he gets a video call on
his phone, and it's the governor.
What about social media?
They had Weibo and Tencent and WeChat giving out accurate informat ion to all users. You could have
Facebook and Twitter and lnstagram do that.
Isn't all of this impossible in America?
Look, journalists are always saying: "We ll, we can't do this in our country." There has to be a shift in
mind-set to rapid response thinking . Are you just going to throw up your hands? There's a real moral
hazard in that, a judgment call on what you think of your vu lnerable popul ations.
Ask yourself: Can you do the easy stuff? Can you isolate 100 patients? Can you trace 1,000 contacts? If
you don't, this will roar through a community .
Isn't it possibleonly because China is an autocracy?
Journalists also say, "We ll, they're on ly acting out of fear of the government," as if it's some evil fi re-
breathing regime that eats babies. I ta lked to lots of people outside the system - in hotels, on trains, in
the streets at night .
They're mobilized, like in a war , and it's fear of the virus that was driving them. They really saw
themse lves as on t he front lines of protecting the rest of China. And the world.
NIH-000921
A medical worker in a hospital in Wuhan working with traditional medicines to treat
patients.Credit ...Agence France-Presse - Getty Images
China is restarting its economy now. How can it do that without creating a new wave of infections?
It's a "phased restart ." It means different things in different provinces .
Some are keeping schools closed longer. Some are only letting factories that make things crucial to the
supply chain open . For migrant workers who went home - well, Chengdu has 5 million migrant
workers.
First, you have to see a doctor and get a certificate that you're "no risk." It's good for three days.
Then you take the train to where you work. If it's Beijing, you then have to self-quarantine for two
weeks. Your temperature is monitored, sometimes by phone, sometimes by physical check.
What's going on with the tr eatment clinical tri als?
They're double-blind trials, so I don't know the results. We should know more in a couple of weeks.
The biggest challenge was enrolling people. The number of severe patients is dropping, and the re's
competition for them. And every ward is run by a team from anothe r province, so you have to negotiate
with each one, make sure they're doing the protocols right .
And there are 200 trials registered - too many. I told them: "You've got to prioritize things that have
promising antiviral properties."
And they're te sting traditional medicines?
Yes, but it's a few standard formulations. It's not some guy sitting at the end of the bed cooking up
herbs. They think they have some fever -reducing or anti -inflammatory properties. Not antivirals, but it
makes people feel better because they're used to it.
What did you do to protect yourself?
A heap of hand-sanitizer. We wore masks, because it was government policy. We didn't meet patients
or contacts of patients or go into hospital dirty zones.
And we were socially distant. We sat one per row on the bus. We ate meals in our hotel rooms or else
one person per table. In conference rooms, we sat one per table and used microphones or shouted at
each other.
That's why I'm so hoarse. But I was tested, and I know I don't have Covid.
NIH-000922
Dr. Aylward offered an elbow in lieu of a handshake during a briefing in Geneva on the W.H.O. mission
to China.Credit.. .Salvatore Di Nolfi/EPA, via Shutterstock
my views nor those of NTATD, NIH, HHS , or the U.S. government.
NIH-000923
Sent : Fri, 6 Mar 2020 12:31:28 +0000
Subject : FW: Nicolle Wallace/ MS NBC interview request for today or next week ...
FYI
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Robinson, Querry (NBCUniversal) <que rry.robinson@msnbc .com>

(b) ( >
---------=-=-= (b)(6); Fauci, Anthony (NIH/NIAID) [El
Subject : Nicolle Wallace/ MSNBC interview request for today or next week ...
Hi Patricia,
This is Querry Robinson with Nicolle Wallace at MSNBC's 'Deadline: White House' in New
York again.
I am writing to request an interview with Dr. Fauci today during the 4 pm ETor at some
point next week if his schedule may allow.
Nicolle is hoping to speak with Dr. Fauci about growing concerns over the spread
coronavirus and what the public should be doing now in the wake of this pandemic .
We would gladly have Dr. Fauci join us from the NIH camera if his schedule may allow ..
Please let me know if today may be a possibility or if another day next week may be better
for the schedule when you may have a moment.
All the best,
NIH-000924
Querry
Quer ry Robinson
'Deadline: White House' with Nicolle Wallace
30 Rockefeller Plaza, NY, NY 10112
W - 212-664 -3923
C- (b)(6)
querry .robinson@ nbcuni.com
Sent from my iPhone - please overlook any misspellings or grammatical errors
NIH-000925
Sent : Fri, 6 Mar 2020 11:02:56 +0000
To : Cassetti, Cristina (NIH/ NIAID) [El
Subject: FW: Emergency Preparedness , Coronavirus , and Products from MPI
Attachments : MPI - CloroxPro_Scrubs_2019 (1).pdf, MPI - Cloro xPro_LabCoats_2019.pdf, MPI
- PrimeMedical _Curtains_Flyer.pdf, MPI - POW_HOSP_Barrier_Protection_28update29.pdf, MP I -
EvaClean Tri Fold 2019 .pdf
Please take a look and handle if necessary
From: Brad W icklas (b)(6 )>

-------=:-:-=,
Subject: Emergency Prepared ness, Coronavirus, and Products from MPI
Hi Anthony F auci,
I know you're busy, but I wanted to introduce our Company, Medical Partners
Internation al, and talk for a quick minut e about what we do and how it can help you.
As you know, the CDC has asked all healthcare facilitie s to prepare for the "worst
case scenario" around the Novel Coron avirus. As much of our medical supply
manufacturing in the US comes from overseas , it is of critical import to look at
potential shortages of key product s that will be needed to perform basic IP functions
in you r facility . We have already seen challen ges with N95 masks, and I have heard
about potential shortag es of items like disinfect ion wipes . We at MPI have a couple
of uniqu e solution s you need to consider:
PureTabs and PureOne NaDCC tablets that are diluted in tap water to create HOCl for
surface disinfection. They are currently used in electrostatic spraye rs to offer greater
coverage around your equipme nt. If, for some reason , there's a challenge getting the
electrostati c spray ers in the future (and we've already seen shortages and delays in
getting new units), simpl y use our NaDCC tablets with spray bottle s from your local
store to apply the HOCl for disinfe ction. Our tablets have kill claim s for C. diff in
four minutes, and like a number of other cleaning agents , we believe we can be
effectiv e against the Novel Coronaviru s. The prob lem with the other products out
there comes down to availability, particularly of the N95 masks that are required on
their IFU's. With our product, an N95 mask is recommended, but not required, which
is a huge distincti on if you have run out of N95 masks.
Secondly , we have our protective scrub s, lab coats and privacy curtains from Prime
Med ical. Co-branded with Clorox, these products create a 3 log (99.9%) barrier
against bacteria and viruses when washed with bleach. The barrier lasts for 12 weeks,
NIH-000926
so there's a dramatically lower chance of passing something along. These are a great
protective measure for your staff. The CDC mentioned that sodium hypochlorite
(bleach) may be effective against Novel Coronavirus, so it stands to reason that our
scrubs will help against unwanted spreading as well.
Finally, we have our Path-0-Wrap, which protects mattresses and gurneys from the
harsh chemicals used during cleaning. It also can help dramatically when a
catastrophic event happens, as you simply put these on a gurney or mattress and
remove them between patients. It was invented by an EMT for just this purpose , and
may be exactly what you need for your Emergency Preparedness Program.
We also have other great IP products such as:
• UV Disinfection Boxes to create a "touch-less check-in" to protect staff and

patients alike
• HealthySo le UV solutions for the bottom of feet for OR and other sensitive
areas
• Bowman Cover Your Cough Stations
I have attached a couple of brochures for your review. We can provide you with a
quote, or have our local representative bring in samples of some of the products to
show. Simply write me back with what you would like more information on. We feel
our products will make a difference for your facility; let us know how we can help.
Sincerely ,
Medical Partners International
Brad Wicklas
Managing Partner
Cell: CbH6)
Websi te: www .bwicklas @medpint.com
NIH-000927
Medical Partners lnt'I
NIH-000928
Sent: Fri, 6 Mar 2020 11:00:51 +0000
To: Corey MD, Larry;Dieffenbach, Carl (NIH/NIAID) [El
Subject: RE:coronovirus vaccine testing
Anything that works is fine with me.
From:Corey MD, Larry (b)(6)>

Sent: Friday, Ma rch 6, 2020 12:23 AM
To: Dieffenbach, Carl (NIH/NIAID) [E) --------
---------- r,a-s-,~ (b)(6); Fauci, Anthony (NIH/NIAID) [E)
(b)( 6) >
Subject: coronovirus vaccine testing
I know the VTEU's are first in line but I am sure th e HVTN sites would be quite willing to
participate in any coronavirus vaccine testing and if you need international populations the sub
Saharan African sites will I am sure be interested . so our informal polling of sites revealed
enthusiasm.
NIH-000929
Sent : Fri, 6 Mar 2020 04:07:20 +0000
To : Cassetti, Cristina (NIH/NIA ID) [El
Subject : FW: SARSCoV entry inhibition for the masses
Attachment s: Novel Inhib itors of SARSCoV Entry .pdf
Please handle.
From: Chris So rg (b)(6)>

To: Fauci, An th ony (NIH/ NIAID) [E] ------ --=-
(b=)(=6)
Subject: FW: SARScov entry inhibition for the masses
Dear Dr. Fauci: I really think you should look at thi s emai l trail. I can't seem to
(b) (4)
NIH-000930
Respectf u Ily,
John C. Sorg, M.D.

Cell: (b)(6)
Chris Sorg
Hospit alist
Nor th A rkan sas Region al Medical Ce nt er
620 North Main Str eet, Ha r rison, AR 72601
Offic e: ...__ ....:--"
....-.il NORTH ARKANSAS

....... RfG lONAL
MI D I OAL
~
ClNfU'I ~~4~;f;y
OR'S
Award
From: Chris Sorg

Sent : Monday, Ma rch 2, 2020 1:16 PM
To: (b)(6)
Subject : FW: SARSCoV entry inhibition for the masses
Continuing to think outloud.

(b) (4)
J.C. Sorg, M. D.
Chris Sorg
H ospit alist
Nor th Arkan sas Regional Medical Ce nt er
620 Nor t h Main Str eet, Harri son, AR 72601
NIH-000931
Office : (b) (
....-.il NORTH ARKANSAS ~

~ REGlONAL GOVERNOR'S
• • u, c AL c •" T• R QualityAward
From: Chris Sorg

To: (b) (6)
Cc: (b)(6)
--------------------------------
Subject : SARSCoV entry inhibition for the masses
(b) (4)
RespectfullyJ
J.C. SorgJ M. D.
Internal Medicine
Chris Sorg
Hospitalist
North Arkansas Regional Med.icalCenter
620 North Main Street , Harrison , AR 72601
Office (b) (6) '
NORTH ARKANSAS~
....-.il
~ REGlONAL GOYEROR'S
.. ■ DI c• i. c • 11 T • R QualityAward
Confidenlialit~ ~olic~:
I hi- 1:111,111
nnd lll\ l1k, lransn1111~Jw1•h 11,, c-,11fak1nal 111J1111<11d,dsC1kl\ hH !he 11·,~t•l lh, 1•1d1,1d11,ilor~ 1111 \ r,11,hem lite\ ir, 1d<rc-,cd
Th" n.upl\.:llt \ r11i.~ JlilUl"JlldtH.lll ~ H:(JUIJ\ ..J In t.k:-.tn>) 1h..:rnJo,m...ilh.JII ,t.lh.·1ll~ !\l,1,1..·tJ 1-.;~J ha-. bc..:n lullt,lctl 1J )UU Jll 11111lhl JJ1ll..:nJ1..·d
1~up11-..·1u
ofl t• I ~n .. 1111-.,101 1J1 ,lit ·111rlny·c H :H• 1\1 ti.:,pn11,1hl1.. I lrdch\.•flllt 11u...1r:llhll11,,1n111., 1h...111h...·11d
1 ....o FL•up1e111 \01111111,11ml IL\I \
rdru1,n11t ..:<1nvcr1h• 1 r<, u•p\ u>p~ uru,e 1h1~ lrs1sn is,1,111, r Jlll a11,11.n111,111' lr.ltNnllttd \\1lh111 lf",u 1.1,~ r~~cl\ed 1hi- rtln,1111s,11111 •~
c1Tc,rlti, c ,,m prcblcni~ l\'tlh •his ll"m<1111<s1nn, or nc,d Jdd11wnnlmform non. plc,1sc11011t\ the ongmJ ,,r ol Ilic nicss,gc unmcdnwh h1 ph inc
(X '') 41 1·4<100,111l pcm1 1101•11\ li:lc< M1' ~111:111 f'k~,c note lh.u ,lll\', IC\\ <'r ,1ni111,m, prc,.·111et.1,,, lhls ,;;m11 :11es,•ldv lho co: tile au hill
,t11dd,J 1ot m,' ..: s.ud) r\..•('f\! cul l11o~i; \; I t\.<,nh \1k.u1~ h R f.1011,11 ~Ji:du;:..Il\ni...1·
NIH-000932
Sent: Fri, 6 Mar 2020 04:06:51 +0000
To: Eisinger,Robert (NIH/NIAID) [E)
Subject: FW: Meeting to AssessEvaluation of COVID-19vaccine candidates for risk of
enhanced disease
Attachments: Ma rch 12th -Tentative list of questions to be discussed_JPC mg-sb[ 16212]-
version4March-1239 -CLEAN.d ocx, Draft agenda.Ace Assess ED.4Mar20201l_with annexes.pdf
Please handle. I cannot meet with them.
From : Steve Black

---------
(b)(6)
To: Fauci, Anthony (NIH/NIAID) [E] -------=-=--==

(b)(6)>
Cc: Robert Chen (b)(6)
Subject: Meeting to AssessEvaluation of COVID-19 vaccine candidates for risk of enhanced disease
Dear Doctor Fauci,
I am writing to you as a member of the SPEACproject which CEPI has funded to assist with the
evaluation of the safety of vaccines in their portfolio. As part of this effort, we are assisting
with developing preclinical and clinical test ing criteria to evaluate the risk of enhanced disease
fol lowing vaccination with COVID-19 vaccine candidates. As you know, this had been an issue
with some prior SARSvaccine candidates.
We are convening a two day virtual meeting of experts via video conference next week on
March 12 and 13 between 8 am and 1 pm Eastern ti me each day. Participants in the meeting
are shown in the attached agenda but include Paul Henri Lambert from Geneva and Barney
Graham from NIH. The meeting will actively involve the participants on the agenda the first day
and on the second day the meeting will be open for several peer reviewers including Stanley
Plotk in and Andy Pollard to review and comment on possible small and NHP animal models as
well as appropriate immunologic testing to be done in early phase one trials.
I am wanted to make you aware of the meeting so that you could attend all or part as an
observer if you wish but also to invite you to consider joining on day two as one of our formal
peer reviewers. The goal of the meet ing would be to share recommendations with CEPI
COVID-19 developers as well as other interested part ies.
Any comments you have on the agenda or draft questions for consideration would be greatly
appreciated.
I look forward to hearing back from you.
ATTACHMENTS: DRAFTAGENDA; DRAFTQUESTIONSFORCONSIDERATION
NIH-000933
Steve
Steven Black MD
SPEACProject work package lead for CEPI
NIH-000934
Sent : Fri, 6 Mar 2020 04:04:44 +0000
To : 00~
Subject : FW: medRxiv: Detectable serum SARS-CoV-2viral load (RNAaemia) is closely
associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients
fyi
From: Folkers, Greg {NIH/NIA ID) [E) Cb)( >

Se nt: Wednesday, Marc h 4, 2020 4:27 PM
Subject : medRxiv: Detectable serum SARS-CoV-2viral load (RNAaemia) is closely associated w ith
drastically elevated inte rleu kin 6 (IL-6) level in critically ill COVID-19 patients
Detectable serum SARS-CoV-2 viral load

(RNAaemia) is closely associated with
drastically elevated interleukin 6 (IL-6) level in
critically ill COVID-19 patients
Xiaohua Chen, Binghong Zhao, Yueming Qu, Yurou Chen, Jie Xiong, Yong Feng, Dong Men, Qianchuan
Huang, Ying Liu, Bo Yang, Jinya Ding, Feng Li
doi: ht t ps://doi .org/10 .1101/2020.02 .29.20029 520
This article is a preprint and hasnot been peer-reviewed [what doesthis mean?]. It reports
new medicalresearchthat hasyet to be evaluatedand so shouldnot be usedto guide clinical
practice .
• Abstract
• Info/ History
• Metr ics
•
• Preview PDF
Abstract
Background: Although the SARS-CoV-2 vira l load detection of respiratory specimen has been widely used
for novel coronavirus disease (COVID-19) diagnosis, it is undeniable that serum SARS-CoV-2nucleic acid
(RNAaemia) could be detected in a fraction of the COVI0-19 patients. However, it is not clear that if the
incidence of RNAaemia could be correlated with th e occurrence of cytokine storm or with the specific
class of patients. Methods: This study enrolled 48 patients with COVID- 19 admitted to the General
Hospita l of Central Theater Command, PLA,a designated hospital in Wuhan, China. The patients were
divided into three groups according to the Diagnosis and Treatmen t of New Coronavirus Pneumonia
(version 6) published by the Natio nal Health Commission of China. The clinical and laboratory data were
collected . The serum viral load detection and serum IL-6 levels were determined. Except for routine
statistical analysis, Generalized Linear Models (GLMs) analysis was used to establish a patient status
NIH-000935
prediction model based on real-time RT-PCRCt value . Findings: The Result showed that cases with
RNAaemia were exclusively confirmed in critically ill patients group and appeared to reflect the illness
severity. Further more, the inflammatory cytokine IL-6 levels were significantly elevated in critically ill
patients, which is almost 10-folds higher than those in other patients. More importantly, the extremely
high IL-6 level was closely correlated with the incidence of RNAaemia (R=0.902) and the vital signs of
COVID-19 patients (R= -0.682). Interpretation : Serum SARS-CoV-2 viral load (RNAaemia) is strongly
associated with cytokine storm and can be used to predict the poor prognosis of COVID-19 patients.
Moreover, our results strongly suggest that cytokine IL-6 should be considered as a therapeut ic target in
critically ill patients with excessive inflammatory response.
my views nor those of NTAID, NTH, HHS, or the U.S. government.
NIH-000936
Sent : Fri, 6 Mar 2020 04:01:59 +0000
To: James Krellenstein
Subject: RE:2019-nCo\/ Testing fo r Public Health Labs
James:
Thanks for the note. Be ass.~red that I am trying to break this log jam.
Best,
Tony
From:James Krellensteih (b)(6)

sent: Wednesday, March 4, 2020 6:46 PM
To: Fauci, Anthony (NIH/NIAID) [E)______ _.,,
(b.,..
)(=6)
Subject: Re: 2019-nCoV Testing for Public Health Labs
Tony:
I am loath to contact you give n that I am sure you are overwhelmed . However, we are now being
contacted by sources at tertiary academic hospita ls with CUA-high complexity clinical labs who are
alarmed about their inability to scale up SARS-CoV2 qRT-PCRtesting in t heir facilities in the time frame
they feel is neccesary, even after Saturday's FDA regulatory guidance and the availability of Integrated
DNA Technology 's testing reagents. (An example of such an email is below.) I am passing th is along with
the hopes that if you can do something about it , you will. From an email:
"We have experience bringing up laboratory deve loped tests. We have never submitted an
EUA before. For our current LDTs, they are typically for pathogens that we have some
experience with, positiv e clinical samples are readily available, and/or appropriate control
materials (e.g. bact eria, viral genomes) are read ily commerc ially available. None of those
are true for SARS-Co V2. There is tremendous concern about deploying a suboptima l test
into a challenging envirom11ent.
The EUA guidance from FDA is not unreasonable for the validation of a new respiratory
virus test, and it gives an accurate picture of the amount of testing that is required to bring
on a new test by the lab. Federal law requires us to perform accuracy , reproducib ility,
analytica l sensitivity / LOD, and analyt ical specificity (cross reactivity) studies. Those
stud ies require pos itive contro l mater ial includingintact v irus or RNA. Clinica l labs are not
prepared to generate RNA transcript , and we don't usually source these ourselves. We
can't get the virus without filling out extensive paperwork that requires multiple
signatures. Getting control material for validation one of the biggest issues .
NIH-000949
Prior to the EUA change, the calculus for our labs was that it would take 3 to 4 weeks to
actually validate a test, and then we would submit to the FDA for EUA (a process non e of
us has ever done), and then we wou ld wait for the FDA to respond (hopefu lly in the
affirmative). I think we all expected the FDA EUA review to be at least 4 weeks. Based on
that time-line, many commercial vendors would have reagents available with their own
EUAs that would be able to be performed on large automated instruments including
potentially STAT. None of the LDT assays (or CDC assay) can be performed STAT or on
demand.
With the EUA change, the proc ess to va lidate the test is st ill the same and will still take 3
or more weeks. Once validated, we can perform clinical testing (like any other LDT) while
we submit the EUA. This would likely allow us to begin testing several weeks before
commercial vendors have EUA reagents available based upon our best current
infonnation. Most of us expect to transition a commercial EUA at some point.
The recent statement that IDT reage nts can be used under the EUA from CDC is
misleading. It applies to a very limited number of lots ( cunently 1, likely 2 soon), it
assumes reagents are available, and it requires strict adherence to the CDC protocol using
identical extraction methods (2 choices) and amplification/ detection methods ( l
instrument). It still specifies the use of an Nl, N2, and NJ reactions, but CDC has dropped
the N3 reaction . The EUA has not yet been updated. Neither of our hospitals have the
complete extract ion or amplifi cation instruments so we have to do the EUA anyway."
Hope you are coping ok,
James
James 8. Krellenstein
109 S 5th St,
Brooklyn, NY11249
(b)(6) (mobile)
(b)(6)
On Sun, Feb 2, 2020 at 7:36 PM James Krellenstein
Tony:
--------- (b)( > wrote:
I hope this email finds you well. Over the past 48 hours, PrEP4AIIhas received multiple requests from
leaders of public health departments and public healt h practitioners to begin publicly pressuring
NIH-000950
CDC/HHSto ensure that properly equipped publ ic health labs (besides CDC's lab in Atlanta) can
perform real time reverse transcr iption PCR(qRT-PCR)testing for 2019 Novel-Coronavirus (2019-
nCoV).
Our understa nd ing is that given the public health emergency declared by HHS, an emergency use
aut horization (EUA) from the FDA is required for public health labs to perform their own lab
developed test for 2019-nCoV, even if it is using the CDC's published qRT-PCRprotoco l and
primer/probe sequences (
https://www.cdc .gov/coronav irus/20 19-ncov/down loads/rt -pcr-panel-for -detection -instruct ions.pdf
)
, and the lab is capable of handling BSL3+samples.
We understand the extreme delicateness of this situation, and also that it is outside of our normal
wheelhouse. But given the concerns of our colleagues in the public health sector, we thought it wa s
important to give you a heads up regard ing this request .
Let us know if there is anyway we can help .
Sincerely,
James Krellenstein
Data, Science and Policy Committee
The PrEP4AIICollaboration
109 S 5th St, Brooklyn, NY 11249
(b)(6)
James B. Krellenstein
he- him - his
(b)(6)
(Sent from a mobile device)
NIH-00095 1
Sent : Fri, 6 Mar 2020 04:00:31 +0000
To: (b)(6)
Subject : FW: Covid-19 causes CRS(and source of mortality)
Attac hment s: Ruan2020_A rticle_ Clinical PredictorsOfMorta lityD. pdf
FYI
From : Pavletic, Steven (NIH/NCI) [E)

--------
Se nt: Wednesday, March 4, 2020 10:18 PM
(b)(6)>

-------- (b)(6)>
Subject : FW: Covid-19 causes CRS(and source of mortality)
Dear Dr Fauci, this is not an area of my expertise, but given the urgency of situat ion with the Covid-19
and some of our experiences with treating CARTinduced cytokine release syndrome in cancer patients,
just wanted to share this email with you in case you find it of interest . Dr Betts is my brilliant junior BMT
colleague at University of Minnesota. I realize this may be old news to you but wanted to share just in
case.
Warm regards
Steve Pavletic
From : Brian Betts (b)(6)>

Sent : Wednesday, Marc h 4, 2020 2:06 PM
To: Pavletic, Steven (NIH/NCI) [E] ------ --~
(b)(6)>
Subject : Covid-19 causes CRS(and source of mortality)
Hi Steve,
This is an interesting paper from intensivists in Wuhan. The IF of the journal is 18 too .
Looks like covid-19 causes an IL-6 mediated CRSwith myocarditis, which is associated with mortality
(more so than the pneumonitis) .
This suggests we should be more concerned with getting tocilizumab for critically ill covid-19 pat ients,
rather than tam iflu and ARVT...
Do you have a friend at the CDCthat could use this info?
Thanks, Brian
BrianC. Betts MO
Associate Professorof Medicine
Division of Hematology, Oncology and Transplantation
University of Minnesota
NIH-000952
The infor mation transm itte d in this e-mai l is intended only for the per son or entity to which it is addressed and may conta in confidential and/or
privileged material, Including "protected healt h informa tion ." If you are not th e inten ded recipient, you are hereby notified that any review,
retransmission, dissem inat ion, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please
destroy and delete th is message from any computer and contact us immed iately by return e-mail.
NIH-000953
Sent : Fri, 6 Mar 2020 03:57:38 +0000
To: Conrad, Patricia (NIH/NIAID) [E);Greg Folkers (b)(6)
Subject : FW: COVID-19 event Friday @CSISTony March 20, 1:30pm-3:30pm
Let us discuss.
From: Stephen Morrison <SMorriso@csis .org>

Se nt : Thursday, March 5, 2020 7:02 AM
)(c-=
6)
Cc: Conrad, Patricia (NIH/NIA ID) [El (b)(6)>; Samantha Stroman
<SStroman@csis.org> ---------
Subject : Re: COVID-19 event Friday @CSISTony March 20, 1:30pm-3 :30pm
Hi Tony
Will March 20 work for you?
Best Steve
On Mar 2, 2020, at 10:07 AM, Stephen Morrison <SMorriso@cs is.org > wrote:
Tony
I know the demands on you have skyrocketed, so I am circling back to confirm you are still
available on Friday March 20 for the COVID-19 event, and also to seek your advice, as we
amend the layout of the event, including possibly havi ng it run a little longer .
I am still hoping you can do a big picture scene sette r {15-20 minutes with slides)
(i) The state of the science surrou nding the virus, what we know and do not
know,
(ii) Progression of the outbreak
(iii) Testing
(iv) Status of accelerated early work on vaccines, antivirals
We wi ll have a panel that covers China, and we may add a panel on the epicenters in Italy,
ROK,Iran
I would like to carve out ample space for discussion of the United States. In your view, is it
advisable to put a request forward to Secy Azar or VP Pence? Neithe r needs a platform to
have thei r voices heard. But perhaps they would see this sort of sett ing as an opportunity.
If not the Secy or VP, is there anyone else you might propose? I had reached out earlier to
Steve Biegun to speak on the foreign policy dimensions, especially regarding China, but
have not heard back.
I have separately reached out to the NGA about possibly enlisting a governor to speak.
NIH-000954
If you are free and wish to speak by phone about any of this, please let me know.
Best of luck with everything. You seem to be making progress!
Best Steve
-----
Cell (b)(6)
NIH-000955
From: F.aucl,Anthony (NIH/NIAID) [El
Sent : Fri, 6 Mar 2020 03:56:47 +0000
To : MAVILIO Domenico ICH
Subject: RE:Ciao
Domenico:
Thanks for the note. Indeed, this outbreak has changed the lives of many people, including
me. I am doing nothing else but coronavirus. I cannot predict when the travel restriction for
Northern Ita ly will be removed. I hope soon, but I doubt that. STAY WELL.
Best regards,
Tony
From: MAVILIO Domenico ICH

-------------
-------::-::-:-=
(b)(6)

Subject: Ciao -------- (b)(6)>
Hi Tony,
ju st a short notice to tell you that you are becoming even more popular in Italy as your face and
interviews are everywhere on the main Italian broadcasting news and journals .
It seems like to be in USA again for me, as I see you every day and I can tell you are doing well although
you must be overwhelmed with all this. I was supposed to be at NIH in tre weeks from now , but I have
cancelled the flight and travel due to highest restrictions from CDCand HHSfor Italian travellers from
Lombardia and Veneto (and I live in Milan).
Can we estimate how long all this w ill last? Weeks or months according to you knowledge?
Hope to see you soon anyway and I really hope U.S. outbreak will not turn as bad as the Ita lian one.
Indeed, Milan is living a real unprecedented (for modern t ime) and surrealistic situati on with a mix of
fear, panic and incredulity among people. It almost seems a movie! The government shut down half
country by closing all schools and universities, by not allowing meetings of any kind, by limi t ing travels in
many places and by placing severe restrictions in social life. They even stopped the Fashion week in
Milan that is a big thing here.
Maybe too late, but they didi it and we hope it will work somehow to reach a plateau in contagious.
have a nice day

Ciao
Domenico
Domenico Mavilio, M.D., Ph.D.

Associate Professor of Translational Medicine
NIH-000956
Department of Medical Biotechnologies and Translational Medicine
Medical School of Milan University , Milan, Italy
Principal Investigator
Head, Unit of Clinical and Experimental Immunology
Humanitas Research Hospital, Rozzano, Mi lan, Italy
Adjunct Investigator
Laboratory of Cardiovascular Regenerative Medicine,
Nationa l Hearth , Lung and Blood Institute
Nationa l Institutes of Health, Bet hesda, MD, USA
(b)(6)
Phone: (b)(6)
Fax: +39 02 8224 5191
emai ls: (b)(6)
.J========= (b~
)(=6X
(b)(6)
webpage: http ://www .huma nitas-research.org/ category/p ri nci paI-investi gat or/mav il io/
h m Y
NIH-000957
Sent : Fri, 6 Mar 2020 03:51:21 +0000
To: Phillips, Kyra
Subjec t: RE: Hi Tony ! Univ of Nebraska .....
Kyra:
Thank s for the note. You would .have to go through my Special Assistant, Patty Conrad, who is copied on this e-
mail.
Best,
Tony

From : Phillips , Kyra <Kyra .Ph illips@abc.com>
To : Fauci , Anthony (NTH/NIAJD) [E] -------,:,,:-:=
--------- (b)(
Su~ject: Re: Hi Tony! Univ of Nebraska .....
Good morning! I made contact and it's in the works! We even have them in our 20/20 spec ial tomorrow night!
Question: do you think you could go live with me from NIH or WH one day next week for our Noon Coro navirus
show? it 's live steamed so we have millions of viewers . We would take viewer questions (1 wo uld give you ahead of
tim e) and you woul d answer only those you want to.
I t's a half hour show , but we would do whatever amowlt of time your sched ule allows.
It would be so impactful for the average viewer.
V/R
Kyra
@KyraPhillips , ABC News

Jnvestigative Correspondent
KyraPhillips.Com
(b)(
> On Mar 3, 2020, at 10:32 PM, Fauc i, Anthony (NTH/NJATD)[E] (b) (6)> wrote:
> --------
> Kyra:
> They very well mi ght let you do it. It is worth a try . The containment there is exce llent and there is no
evidenc e ofcommuniLy spread in Omaha.
> Best,
> Tony
>
> -----Original Message-----
> From: Phillips , Kyra <Kyra.Phillips @a bc.com >
> Sent: Tuesday, March 3, 2020 6:21 PM
> To: Fauci, Anthony (Nlli/NIAID) (E] ------~~ Cb)( >
> Subject: Hi Ton y! Univ of Nebraska .....
>
> Ton y,
> Do you think the University of Nebraska would let me in to do a story for ABC News on the therapeutics they are
working on?
> Would it even be safe for me to do it?
NIH-000958
> Appreciate how you are holding court during this crisis.
> Respectfully ,
> Kyra
>
>
> @KyraP hillips, ABC News
> Investigative Corre spondent
> KyraPhillips.Com
> (b) (6)
>
NIH-000959
NIH-000688
From: (b)(6)
Sent: Tue, 10 Mar 2020 14:57:59 -0400
To: Short, Marc T. EOP/OVP
Subject : Re: White House Coronavirus Task Force Meeting at **3:30pm** on 3/10/20
Marc:
I likely will be severa l minutes late since 1 have to come down from Bethesda by Metro and the time change
threw me off. Sorry.
Tony
wrot e:
> On Mar l 0, 2020 , at 2:49 PM, Short , Marc T. EOP/ OVP
>
---------- (b) (6)
>
> <White Hou se Coronavirus Task Force Meeting at **3:30pm** on 3_ 10_20>
NIH-000708
NIH-0007 11
(bX5)-PCE
NIH-0007 12
Sent: Tue, 10 Mar 2020 15:59:26 +0000
To: Hurst, Natalie R. EOP/OVP
Cc: Mars ton, Hilary {NIH/NIAID) [E]
Subject: RE: Important Updates - White House Coronavirus Subtask Force Calls
Natalie:
Please add my Assistant, Dr. Hilary Marston, to the list of invitees to the
Subtask Force Calls. She reports directly to me and is my source of de-briefing
after the calls. I am copying her on this e-mail. Many thanks.
Best regards ,
Tony
Director
Phone : (b) (6)
FAX: (301 496-4409
E-mail , (b)(6)
From:Hurst, Natalie R. EOP/OVP (b)(6)

Subject: Important Updates - White House Coronavirus Subtask Force Calls
Importance: High
Good morning all,
I wanted to send a n ote to clarify the White House Coronavirus Subtask Force Calls moving forward.
There will be a Whit e House Coronavirus Subtask Force Call every day, unless otherwi se directed
by Olivia Troye , Dr. Debi Birx, or me.
• Monday - Friday, the call will take place at 9:00am
• Saturday - Sunday, the call will take place at 10:00am
Start ing this evening, I will send a new calenda r invite for the rem ainder of this week's calls
(Wednesday , March 11 / Thursd ay, March 12 / Friday, March 13). On Friday, March 13, I will send a
ca lendar invite for this weekend's calls (Saturd ay, March 14 & Sunday, March 15).
NIH-000718
Looking ah ead -
• Invites for weekday calls will be sent on Sunday nights .
• Invites for weekend calls will be sent on Friday nights.
• Please note : Call-in numbers for Saturday & Sunday will be different from the number
used Mondays - Fridays.
** If you would like to be removed from this distributio n list, please respond to this email before
5:00 pm ton ight, so that you will be removed starting Thursday morni ng.*"
Please do not hesitate to reach out with any quest ions or concerns.
Thank you,
Natalie Hurst
Operat ions Coordinator, White House Coronavirus Task Force
Executive Assistant to the Chief of Staff
The Office of the Vice Pres ident
(b)(6)
NIH-000719
(bX5) -PCP.
NIH-000809
(b)(5) - PCP.
NIH-000810
NIH-0008 11
NIH-000843
NIH-000844
NIH-000845
Sent: Sun, 8 Mar 2020 01:38 :49 +0000
Subject: FW: White House Coronavirus Task Force Meeting on 3.8.20 at 4:00pm
I need WAVES, please. Thanks.
-----------
From: Hurs t , Nat alie R. EOP/OV P
(b)(6)
Subject: Whi te House Coro navirus Task Force Meeting on 3.8.20 at 4:00pm
Importance: High
All-
There will be a White House Coronavirus Task Force Meeting on Sunday , March 8 th at 4:00 pm
in the White House Situation Room. Agenda will be forthcoming .
Thank you ,
Natalie Hurst
Opera tions Coordinator, Wh ite House Coronaviru s Task Force
Executive Assistant to the Chiefo f Staff
Th e Office of th e Vice Pr es id ent
(b)(6)
NIH-000853
Sent : Fri, 6 Mar 2020 04:03:24 +0000
Subject: FW: 2020 03 03 SC POTUSNIH Roundtable. Email #1
Attachments : P20200303SC-0059.jpg, P20200303SC-0066.jpg , P20200303SC-0088.jpg,
P20200303SC-0109 .jpg, P20200303SC-0123.jpg, P20200303SC-0182.jpg, P20200303SC-0272.jpg
For the fi le
From: Hansen, Daniel E. EOP/WHO (b)(6)>

----~~
Subject: FW: 2020 03 03 SC POTUS NIH Roundtable. Email #1
Photos from POTUS visit Tuesday NIH For Your Personal

Archives
2020 03 03 SC POTUS NIH Roundtable. Email #1
P20200303SC 0088
President Donald J. Trump listens as Dr. Francis Collins, director of the

National Institute of Allergy and Infectious Disea ses, addresses his
remarks during a coronavirus roundtable briefing Tuesday, March 3,
2020, at the National Institutes of Health in Bethesda, Md. (Official
White House Photo by Shealah Craighead)
P20200303SC 0066 0109
NIH-000937
President Donald J. Trump participates in a coronavirus roundtable
briefing Tuesday , March 3, 2020 , at the National Institutes of Health in
Bethesda, Md. (Official White House Photo by Shealah Craighead)
P20200303SC 0059 0123 0182
President Donald J. Trump listens as Dr. Anthony S. Fauci, director of

the National Institute of Health , addresses his remarks during a
coronavirus roundtable briefing Tuesday, March 3, 2020, at the National
Institutes of Health in Bethesda , Md. (Official White House Photo by
Shealah Craighead)
P20200303SC 0272
President Donald J. Trump answers questions from reporters during a

coronavirus roundtable briefing Tuesday, March 3, 2020, at the National
Institutes of Health in Bethesda, Md. (Official White House Photo by
Shealah Craighead)
Please note that these photos are being sent to you for personal use
only. If you share them with friends or family, make sure to include the
disclaimer below. Thank you.
If posting to social media the following byline must be used: Official

White House Photo by Shealah Craighead
This photograph is provided by THE WHITE HOUSEas a courtesy and

may be printed by the subject(s) in the photograph for personal use
NIH-000938
only. The photograph may not be manipulated in any way and may not
otherwise be reproduced, disseminated or broadcast, without the
written permission of the White House Photo Office. This photograph
may not be used in any commercial or political materials ,
advertisements, emails, products, promotions that in any way suggests
approval or endorsement of the President, the First Family, or the
White House.
Dan Hansen
WH Photo Office
NIH-000939
NIH-000940
NIH-000941
Sent : Fri, 6 Mar 2020 04:02:46 +0000
Subject: FW: 2020.03.03 WH bSouth Lawn Arrival from NIH and Press gaggle
Attachments : P20200303JB-t34 7 .jpg, P20200303JB-1380.jpg, P20200303J8-1393.jpg,
P20200303JB-1473.jpg, P20200303JB-1531.jpg, P20200303JB-1554.jpg, P20200303JB-1606.jpg,
P20200303JB-1630.jpg, P20200303JB-1708.jpg, P20200303JB-1742.jpg
For the fi le
From: Hansen, Daniel E. EOP/WHO (b)( >

To: Fauci, Anthony (NIH/NIAID) [E) -------=-:-= (b)(6)
Subject: FW: 2020.03.03 WH bSouth Lawn Arrival from NIH and Press gaggle
Subject: 2020.03.03 WH South Lawn Arrival and Press gaggle for Personal Archives
P20200303JB-1347, 1380, 1393

President Donald J. Trump, joined by Dr. Anthony S. Fauci, director of the National Institute of Health,
and Secretary of Health and Human Services Alex Azar, disembarks Mar ine One on the South Lawn of
the White House after attending a coronavirus roundtable briefing Tuesday, March 3, 2020, at the
Natio nal Institutes of Health in Bethesda, Md. (Official White House Photo by Joyce N. Boghosian)
P20200303JB-1473
President Donald J. Trump, joined by Dr. Anthony S. Fauci, director of the National Institute of Health,
listens as Secretary of Health and Human Services Alex Azar answers a reporter's question following
President Trump's return from attending a coronavirus roundtable briefing Tuesday, March 3, 2020, at
t he Nation al Institutes of Health in Bethesda, Md. (Official White House Photo by Joyce N. Boghosian)
P20200303JB-1531, 1554, 1606

President Donald J. Trump, joined by Secretary of Health and Human Services Alex Azar, listens as Dr.
Anthony S. Fauci, directo r of the National Institute of Healt h answers a reporter's question following
President Trump 's return from attending a coronavirus roundtable briefing Tuesday, March 3, 2020, at
t he National Institutes of Health in Bethesda, Md. (Official W hite House Photo by Joyce N. Boghosian)
P20200303JB-1630,1708
President Donald J. Trump, jo ined by Dr. Anthony S. Fauci, director of the National Institute of Health,
and Secretary of Health and Human Services Alex Azar, speaks with reporters following his return to the
White House after attending a coronavirus roundtab le briefing Tuesday, March 3, 2020, at the National
Institutes of Health in Bethesda, Md. (Official White House Photo by Joyce N. Boghosian)
P20200303JB-1742
NIH-000942
President Donald J. Trump, Or. Anthony S. Fauci, director of the National Institute of Health , and
Secretary of Health and Human Services Alex Azar, walk to the Oval Office Tuesday, March 3, 2020, at
the White House. (Official White House Photo by Joyce N. Boghosian)
Dan Hansen
White House Photo Office
(b)(6)
NIH-000943
NIH-000944
NIH-000945
NIH-000946
NIH-000947
NIH-000948
From: (b)(6)
Sent : Mon, 2 Mar 2020 08:32:20-0500
Cc: Collins, Francis (NIH/OD) [E];Marston, Hilary (NIH/NIAID) [E];Conrad, Patricia
(NIH/NIAID) [E]
Subject : Re: TIME SENSITIVE
Larry:
Let Hilary do this. I am on a conference call.
Thanks ,
T ony
On Mar 2, 2020 , at 8:27 AM, Tabak , Lawrence (N IH/OD) [E]

Cb)
(6)> wrote:
Tony-
Could one of your folks give me a quick read out on this please? (should I reach out to
Hilary Marston?) . This is the paper that DOE alluded to in the initial conference call we had
with OSTP. I w ill respond informed by your staff's guidance.
Larry
From: "Mango, Pau l (HH S/10S)" Cb)

(6J>
Date: Monday , March 2, 2020 at 8: 19 AM
To : Stephen Hahn >, "Lenihan, Keagan (FDA/OC)"
CbH6J
---------
Lawrence (NIH/OD) [E]"
(CDC /OD)"
Cb)( >, Anthony Fauci
CbH6)
Cb)( ·, "Tabak,
(6), "Redfield, Robert R.
Cb>
"McGowan, Robert (Ky le) (CDC /OD/OCS)"
CbH6J
>, "Berger, Sherri (CDC /OCOO /OD)" CbH>
-------
Cc: "Harrison, Brian (HHS /JOS)" Cb)<6J
>
Subject : T IME SEN SITIVE
Dr Hahn and the FDA team in particular , but with input from relevant SMEs at CDC
and NIH, please give the brief attached doctunent and quick read on comment on the
usefulness of us sett ing up a sess ion with the folks at DOE today to discuss further .
Many thanks
Sent from my iPhone
NIH-001047
From: ".Harrison, Bri an (HHS /1OS)" (b)(6)
Date : Marc h 1, 2020 at 6:15:54 AM E ST

To: CbH6J(OS /1OS)" CbH6J
--~ =
Cc: "Steck er, Judy (OS/IOS)"
(HHS/IOS)" Cb><>
------- (b)(6) , "Ma ngo, Pau l
Subject: FW:
With attachment. I've asked CDC, FDA, NIH, and ASPRto review .
From: Brouillette, Dan (b)(6)

Sent: Friday, February ----------
28, 2020 9:58 PM
To: Harrison, Brian (HHS/IOS)_______ ""'
(b..,...
H=6)
Subject:
Bria n:
As we discussed earlier this evening, here 's a preliminary finding from

scientists at Oak Ridge National Laboratory using the Summit
supercompute r system. We stand ready to assi st in any manne r helpful
to you and Secretary Azar. Very best,
Dan
Sent with Black.Berry Work

(www.b lackberry .com )
<coronavirus.pdf>
NIH-001048
Sent: Mon, 24 Feb 2020 11:15:02 +0000
To : Kadlec, Robert (OS/ASPR/IO);Redd, John (OS/ASPR/SPPR);Yeskey,Kevin
(OS/ASPR/IO);Shuy, Bryan (OS/ASPR/IO);Phillips, Sally (OS/ASPR/SPPR)
Cc: Redfield, Robert R. (CDC/OD)
Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start
We really need to discuss this.

---------
To: Redd, John (05/ASPR/SPPR)------~
(b)( >
(b~)(=, ; Yeskey, Kevin (OS/ASPR/10)

(b)(6)>; Shuy, Bryan (OS/ASPR/10) (b)( ; Phillips, Sally
(OS/ASPR/SPPR) (b)(6 b
----:---:---:-:.:==!--~
Cc:Redfield, Robert R. (CDC/OD) (b)(6); Fauci, Anthony (NIH/NIAID) [E]
(b)(6) ------
Subject: Fwd: Red Dawn Breaking, CO\IID-19 Collaborative, Feb 16 start
Read this! This is unsettling if true efficient spreading in asymptomatics with negative test . Is that
possible? Report is intermittent shedding is that true or artifact of poor sample collection or lack of
sensitivity of per testing?
From Dr Eva Lee GaTech
"Means of spread A study from AMA confirmed many of the parameters assumed in our
models:
- A 20-yea r old infected wi t h COVID-19 left Wuhan and went on infecting 5 relatives. When
they tested positive, she was finally isolated , but tested negative still, and later tested
positive , and remain normal on chest CT with no fever, stomach or respiratory symptoms
(cough or sore throat as late as Fen 11 (time of the papert study duration).
So spreading and its wide scope is unavoidable because the re exists these very healt hy
individuals who can spread effectively -- even during incubation per iod -- while they
remain perfectly healthy . It also showcases difficulty in testing-- negative test -- may not
be the end of it. "
Sent from my iPhone
NIH-001465
From: "Dr. Eva K Lee" (b)(6)>

Date : February 23, 2020 at 7:37:12 AM EST
To: Carter Mecher (b)(6)>
Cc: Richard Hatchett (b) (6)>, Tracey McNamara
(b)( >, "Caneva, Duane" (b)(6),
==========::::...:...
__ ...;
(b c6)>, "Dodgen, Daniel (OS/ASPR/SPPR)"
,.._.,
~=
(b)(6)>, "DeBord, Kristin (OS/ASPR/SPPR)
"
-=======:::-:,:=:;:-- -------~~
(b)(6)>, "Phillips, Sally (OS/ASPR/SPPR)" (b)( >,
David Marcozz i (b)(6)>, "Hepburn, Matthew J CIV USARMY
(USA)" (b)(6)>, Lisa Koonin (b)( "Walters,
Will iam (STATE.GOV)" (b)(6) , "HARVEY,MELISSA"
(b)(6), "WOLFE, HERBERT" (b)(6)>,
"Eastman, Alexander" (b)(6)>, "EVANS, MARIEFRED"
(b)(6), "Callahan, Michael V.,M.D."
(b)(6)
>, "Johnson, Robert (OS/ASPR/BARDA)"
__
.,;_..;___...;_
--------
(b)(6)>, "Yeskey, Kevin"
~,::;;-""'.'.'"'---:-:--~-:-:--.--
>, "Hassell, David (Chris) (OS/ASPR/1O)"
(b)(6), "Disbrow, Gary
(b)(6)>, "Redd , Johnt(OS/ASPR/SPPR)"
(b)(6)
"Hamel , Joseph (OS/ASPR/1O)" (b)( >, "Dean, Charity A@CDPH"
(b)(6)>, " Lawler , James V" (b)(6), "Kadlec,
Robert (OS/ASPR/1O)" (b)(6) "' M artin, Gregory J
':':'"""--:-~--"'.-:.:========:~;-::-----,______ ...
(b)(6)>, "Borio , Luciana" (b)(6),
"Hanfling, Dan"
__ ___::::...._
_~=====-:=~ --------~=
(b)(6) " McDonald, Eric"
(b)(6) "Wade, David" (b)(6)
"TARANTINO, DAVID A" (b)(6)>, "WI LKINSON, THOMAS"
(b)(6)>, "David Gruber (b)(6) "
===========~c:;---7."."" (b)(6) , "KAUSHIK, SANGEETA"
"""".'":'.~========:=;.~ (b)( >,
Nathaniel Hupert (b)(6)>
Reply-To: "Dr . Eva K Lee" (b)(6)>
A few things I want to highlight --
1. M ea ns of spread A study from AMA confirmed many of the parameters assumed in our
models:
- A 20-year old infected with COVID-19 left Wu han and went on infecting 5 relatives. W hen
they tested positive , she was fina lly isolated, but tes ted negative stil l, and later tested
positive, and remain normal on chest CT wit h no fever, stomach or respiratory symptoms
(cough or sore throat as late as Fen 11 (time of the papert study duration).
So spreading and its wide scope is unavoidable because there exists these very healthy
individuals who can spread effect ively -- even dur ing incubation period -- while they
remain perfectly healthy. It also showcases difficulty in testing -- negative test -- may not
be the end of it.
NIH-001466
2. Iranian cases, though mysterious since the origin was not traced to China, may very well
show that COVID-19 vi rus is very adaptable and mutating rapid ly.
3. Long recovery The long recovery period is troubesome and must be taken seriously by
health providers as they prepare for hospitalization. Therei snot much surge capacity in
hospitals. So they must be innoative in the staggering process and isolation is of
paramount importance. Government/Local should be readied for supplementing medical
tents outside hospit als when needed (clearly extra staff too) .
4. Citizes ' vi ew I was traveling so I did a real-time on-the-road analysis of human behavior
and anxiety level. I overheard many people
-- (a) asked when CDCwould tell us more on what to do.
-- (b) wish t hey could pull their kids out of school but there is no such option as part of the
preventive measure (not announced by CDC).
-- (c) wish CDCwou ld recommend tele-work options so they don't have to travel and
expose themselves and their family to unneccessary risk.
-- (d) have no clue what the government is doing to keep the risk low as it is now. What
exactly is being implemented to keep it low.
5. Resource -limit ed countri es I pray that it would not reach the resource-limited countries
like many in Afri ca (though it seems unavoidable). I cannot imagine the consequence.
6. What we must do : We must leverage the knowledge from other countries to better
prepare ourselves. Japan's Crusis shows the importance of TIMELY proper isolation and
STRATEGICoperations logist ics in testing and in quarantine . South Korea (contrasting with
Hong Kong, Singapore) demonstrates critica l importance of EARLYsocial distancing and
high compliance community NPI intervent ion. China's latest lockdown of 1/2 billion people
truly signifies that gravity and unchartered terrority of this virus. No country would take to
such extreme measure.
7. CFR Since over 90% of influenza is never recorded/known, this COVID-19 seems to fall
into similar spirit now, with so many cases of asymptomtic and transmission while
incubating . While the true CFRremains unknown, the CFRof tested positive cases should
offer a good comparison to the CFRof tested positive flu cases. That gives us a clearer
estimate of health-resource burden.
(b)(6)
mobile:
----- (b)(6)
Sent with Prot onMa il Secure Email.
------- Original Message-------

On Saturday, February 22, 2020 10:19 PM, Carter Mecher wrote:
--------- (b)(6)>
Updates
NIH-001467
South Korea (+123 with +2 deaths)- Total cases 556; Total deaths
4
https://www. cdc. go .kr/boa rd/board.es?m id=a3 0402 0O0O0O&bid=003 0
Singapore (+3)--Total cases 89; Total deaths 0
Hong Kong (unchanged)--Total cases 69; Total deaths 2
Japan- Total cases 135; Total deaths 1
From: Cart er Meche r

To: Richard Hat chett ; Dr. Eva K Lee
Cc: Tra cey McNama ra; Caneva, Duane; (b)(6); Dodgen , Daniel
(OS/ASPR/SPPR); DeBor d, Kristin (OS/ASPR/SPPR); Phill ips, Sally
(OS/ASPR/SPPR); David Marcoz zi; Hepburn, Ma tthew J CIV USARMY (USA);
Lisa Koo ni n; Wa rgo Mi chael ; Walte rs, Willi am (STATE.GOV); HARVEY,
MELISSA; WOLFE. HERBERT; Eastman , Alexander ; EVANS, MARIEFRED;
Callahan, M ichael V.,M .D.; (b)(6);
Johnson , Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow , Gary
(O5/A SPR/BARDA); Redd, Johnt(OS/ASPR/SPPR); Hassell, David (Chris)
(OS/ASPR/IO); Hamel, Joseph (OS/ASPR/1O); Dean, Chari ty A@CDPH; Lawle r,
James V; Kadlec, Robert (OS/ASPR/1O); 'M art in, Grego ry J
------- --
(b)(6) ' ; Borio, Luciana; Hanfli ng, Dan; McDonald, Eric; Wade ,
David; TARANTINO, DAVID A; W ILKINSON, THOMAS; David Gruber
_________ Cb _ ,; KAUSHIK. SANGEETA; Nathan iel Hupert
_ >_<6J
Subject: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 sta rt
Roundup this morning .
NIH-001468
Singapore and Hong Kong are holding steady- both have implemented
NPis pretty early and have good surveillance .
Things are really accelerating in South Korea. Case count increased to

433 with 2 deaths.
https ://www .cdc. go .kr/board/board .es?mid=a30402000000&bid=0030
Report below of COVID hitting Samsung's mobile device factory,

which has now been shut down. This is what will happen here. The
greatest concern is what this would mean for critical infrastructure
sectors (including components of our healthcare system), The strateg ies
I outlined for outpatient clinics could be used by business (most
especially CI sectors) to maintain business continuity. It is as simple as
the old saying, "Don't put all your eggs in one basket." It is both
contingency planning (continuity of operations /continuity of business)
and application ofNPis/fLC (especially social distancing in the
community supported by home isolation and home quarantine).
We now have COVID in several countries across the ME (Iran, Israel,

Egypt, Lebanon , UAE) . We added Iran the day before yesterday and 3
countries yesterday (Israel, Egypt and Lebanon). Iran already appears
to have a well established outbreak that will be tough to slow down
given the estimated size with 5 deaths already (that is where Wuhan
was by Jan-20). Japan is also seeing acceleration with local
transmission (119 cases).
Italy is another area to watch.
htt ps://p rotect2.fi reeye.com / ur l?k=c92f3372 -957b2a0e -c92f02 4d-

0cc47adc5fa2-
9270 140238 19d8ec&u =htt ps://www .ilgazzett ino. it/no rdest/. .. D0yaq109ac4o
84 Numerous infected in the hospital of Schiavonia (Padua)
"And unfortunately, what the experts feared since yesterday has occurred,
when it was discovered that two patients had been hospitalized for about ten
days at the Schiavonia hospital (Padua) without knowing that they had
contracted the Coronavirus: since yesterday evening everyone those who
attended the hospital were subjected to a swab to detect any infections, and
the examination gave positive results in numerous cases. It means that there
are other people, probably among those who attended the ward where tw o
patients were hospitalized , who are now positive for the virus and
consequently could in turn have spread the infect io n. Already yesterday
evening the Governor of Veneta Luca Zaia ordered t he progressive
evacuation of the Padua hospital which should take place within 5-6 days."
NIH-001469
'The hospital is surrounded by a 'sanitary cordon' , with Carabinieri ,
workers of the Red Cross and Civil Protection . Cardiology chief
Giampaolo Pasquetto aITived outside the hospital for a few minutes and
reported the results of the swabs 'as far as I have been able to know
from my colleagues so far,' he said. The modern structure is located
between the towns of Este and Monselice and was recently inaugurated
to serve the Euganean Hills area ."
https://www.reuters.com /article/us-china-health-southkorea -samsung -

elec/samsung-electronics -confirms-coronav irus-case-at-phone-factory-
complex-in-south-korea-idUSKCN20G0CG
SEOUL (Reuters) - Samsung Electronics said on Saturday that one

coronavirus case had been confinned at its mobile device factory
complex in the southeastern city of Gumi, causing a shutdown of its
entire facility there until Monday morning.
Samsung Electronics, the world's top smartp hone maker, said the floor
where the infected employee worked would be shut down until the
morning of Feb. 25.
"The company has placed colleagues who came in contact with the
infected employee in self-quarant ine and taken steps to have them tested
for possible infection," Samsung said in a news release.
Samsung's factory in Gurni accounts for a small portion of its total

smartphone production , and it makes high-end phones, mostly for the
domestic market. Samsung produces most of its smaiiphones in
Vietnam and India.
Gumi is close to the city of Daegu , home to a church at the center of

South Korea's largest coronavirns outbreak.
South Korea said on Saturday that the number of people infected with
the coronavirus in the country had more than doubled to 433.
Samsung said production at its chip and display factories in other parts
of South Korea would not be affected.
From : Carte r Mecher
NIH-001470
To : Richard Hatchett ; Dr. Eva K l ee
Cc : Tracey McNama ra; Caneva, Duanei (b)(6); Dodgen, Daniel
(OS/ASPR/SPPR); 0eBord, Kristin (OS/ASPR/SPPR); Phillips, Sally
(OS/ASPR/SPPR); David M arcozzi; Hepburn, M atthew J CIV USARMY (USA);
Lisa Koon in; Wargo Michae l; Walters, W illiam (STATE.GOV); HARVEY,
MELISSA; W OLFE, HERBERT; Eastman, Alexande r; EVANS, MARIEFRED;
Johnson, Ro bert (OS/ASPR/BARDA) ; Yeskey, Kev in; Disbro w . Gary
(OS/ASPR/BARDA); Redd, Johnt( OS/ASPR/SPPR); Hassell, David (Chris)
(OS/ ASPR/1O); Hamel, Joseph (OS/ ASPR/ 1O); Dean, Charity A@CDPH; Lawler,
James V; Kadlec, Robert (OS/A SPR/1O); 'M art in, Gregor y J
(b)(6) · Borio, Luciana; Hanfli ng. Dan; M cDona ld, Eric; Wade.
---------
David; TARANTI NO, DAVID A; W ILKINSON. THOMA S; David Grube r
----------- CbH6); KAUSHIK. SANGEETA; Natha niel Hupert

Subject : RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start
Wuhan to add 19 addi tional hospital (when combined with the other 3
hosp itals, this would add 30,000 bed s).
Just to put that in perspective.
• There are 2.8 hospita l beds in the US per 1,000 population.

• 30,000 beds is about the number of beds we would have for a
popu lat ion of 11 M .
When you add th e 30,000 beds plus the 13,348 other beds added (total
of 43,300 bed s)
• There are 4.5 hospita l beds in China per 1,000 populatio n

• 43,300 beds is about the number of beds in China for a population of
9 .6 M
• Wuhan will have nearly doub led its bed capacity
How hard wou ld that be for us to double bed capacity in any major US
city ? (Really isolation beds for mild illness)
https: //www .straitstimes .com/ asia/east -asia/coronav irus -wuha n-to-

act ivate -one-more -ternporary-hosp ita l-with -3690-
beds?fbcli d=l wAR lotfl4xNxKiuB RuODJzoTDMJWHueF9gTc06u l I
M9nM2u -3 VTpohO tFt7 s
NIH-001471
WUHAN (XINHUA)- Wuhan, the epicentre of the coronavirus
outbreak , plans to build another 19 mak eshift h osp itals to rece ive more
infected pat ients, local aut horit ies said Frida y (Feb 21).
Upon their completion, all the makeshift hospita ls in Wuhan are

expected to offer 30,000 beds on Feb 25, said Mr Hu Yabo, deputy
mayor of Wuhan at a press briefing on epidemic prevention and
control.
To date, Wuhan has converted 13 existing venues into temporary

hosp itals, with a total of 13,348 beds , and about 9,313 beds have been
put into use to treat patient s with mild symptoms, said Mr Hu.
From: Carte r Mec her

Sent: Friday , February 21, 2020 1:59 PM
To : Richa rd Hatche tt ; Dr. Eva K Lee
Cc: Tracey McNa mara ; Caneva, Duane ; (b)(6) Dod gen, Daniel
(OS/ASPR/S PPR); DeBo rd, Kri st in (OS/ASPR/SPPR); Philli ps, Sally
(OS/ASPR/SPPR); David M arcozzi; Hepburn, M att hew J CIV USARMY (USA);
Lisa Kooni n; Wa rgo M ichael; Wa lte rs, Will iam (STATE.GOV); HARVEY,
MELISSA; W OLFE. HERBERT; Eastm an. Alexande r; EVANS, MARIEFRED:
Call ahan, M ichael V.,M .D.; (b)(6);
Johnson , Ro bert (OS/ASPR/BARDA); Yeskey, Kev in; Disbro w, Gary
(OS/ASPR/BARDA); Redd, Johnt(OS/AS PR/SPPR); Hassell, David (Chris)
(0S/AS PR/10); Hame l, Joseph (OS/ASPR/ 10) ; Dean, Charit y A@CDPH; Law ler,
James V; Kadlec, Robert (OS/ASPR/10); 'M art in, Grego ry J
-------- (b)( ' ; Bo rio, Luciana; Hanfli ng, Dan; M cDo nald, Eric; W ade,
_________ Cb _ ,; KAUSHIK. SANGEETA; Natha niel Hupert
_ >_<6>
Subject: RE: Red Dawn Breaking , COVID-19 Collaborative, Feb 16 start
Week ly CDC update looks like flu m ight be on the downs lope (good
new s). Watch ing the curves of % posi tive flu tests and ILi (should track
one another as flu is receding). Tro uble is the data reported today is for
the week ending Feb 15 (so a week old).
NIH-001472
Our inpatient nursing sick leave is tracking ILI (current thru 2/20)-
nothing unusual
Sent from Mail for Windows l 0
From : Carter Mecher

Sen t: Friday, February 21, 2020 10:54 AM
Cc: Tracey M cNam ara; Caneva, Duane , CbH6)1; Dodgen , Dan iel
(0 S/ASPR/SPPR); DeBor d, Krist in (OS/ASPR/SPPR); Phillips, Sally
(0S/AS PR/SPPR): David M arcozzi; Hepburn. M att hew J CIV USARMY (USA):
Lisa Koonin; W argo M icha el: Walt ers , William (STATE.GOV): HARVEY.
MELISSA; WOLFE, HERBERT; Eastm an, Alexander ; EVANS, MARIEFRED:
Callahan, M ichael V.,M .D.. (b)(6)
Johnson, Rober t (05/AS PR/BARDA); Yeskey, Kev in; Disbrow, Gary
(OS/ASPR/BARDA) ; Redd. Johnt(OS/ASPR/SPPR) ; Hassell , Dav id (Chris)
(OS/ASPR/10) ; Hame l, Joseph (OS/ASPR/10) ; Dean , Charity A@CDPH; Lawler ,
James V; Kadlec. Robert (OS/ASPR/10 ); 'Mart in, Gregory J
-------- (b)(6) '; Borio, Luciana ; Hanfli ng, Dan; M cDona ld. Eric; Wad e,
David ; TARANTINO. DAVID A; W ILKINSON. THOMAS; David Gru ber
(b)(6) KAUSHIK, SANGEETA; Natha niel Hupe rt
------------
Subject : RE: Red Dawn Breaking , COVID-19 Collaborative , Feb 16 start
Singapore and Hong Kong are holding the line. Both implemented
NPls early. No change in numbers from Hong Kong and Singapore saw
its case count increase by only 1 for the past two days.
Japan reported to have 107 case s. First reported case in young children
(se below)
Hokka ido boy 1st Ja pa n case of coronaviru s infection under 10

February 21. 2020 (Mainichi Japan )
NIH-001473
SAPPORO-- Two elementary school brothers and a woman in her 40s in
Hokkaido have been infected with the new coronavirus, wi t h t he younger
sibling becoming the first infection under 10 in Japan, Hokkaido Gov.
Naomichi Suzuki announced on Feb. 21.
Some graphics of the drop off in trave l in China (pretty dramatic)
Jan-23
Feb-13
From : Carter Meche r

To: Richard Hat chett ; Dr . Eva K Lee
Cc: Tracey McNama ra; Can eva, Duane i (b)(6); Dodge n, Daniel
(OS/ASPR/SPPR); DeBord, Kristi n (OS/ASPR/SPPR); Phillips, Sally
(OS/ASPR/SPPR); David Marcozzi ; Hepbu rn . Ma t thew J CIV USARMY (USA);
Lisa Koo nin: Wa rgo Mich ael; Wa lters , W illiam (STATE.GOV): HARVEY,
MELISSA; WO LFE, HERBERT; East man , Alexa nder ; EVANS, MARIEFRED;
Johnson, Rober t (OS/ASPR/BARDA); Yeskey. Kevin; Disbrow, Gary
(OS/ASPR/BARDA); Redd. Johnt (OS/ASPR/SPPR); Hassell. David (Chris)
(OS/ASPR/1O); Hame l, Joseph (OS/ASPR/1O); Dean. Char ity A@CDPH; Law ler,
James V; Kadlec. Robert (OS/ASPR/1O); 'M art in, Grego ry J
(b)(6); Borio. Luciana ; Hanfli ng. Dan; McDon ald, Eric; Wade.
--------
David ; TARANTINO, DAVID A; W ILKINSON. THOMAS : David Grube r
( CbH6XKAUSHIK, SANGEETA: Nathan iel Hupe rt
Subjec t : RE: Red Dawn Breaking , COVID-19 Collaborative, Feb 16 start
NIH-001474
https://www. cdc.go.kr/board/b oard.es?mid=a3040200000 0&bid =0030
Here is the best link to track cases in South Korea. South Korea is now
up to 204 cases and 1 death (South Korea is where Wuhan was 1 month
ago).
Sent from Ma il for Windows l 0
From: Carter Mecher

Sent : Friday, February 21, 2020 10 :02 AM
To: Richard Hatc hett ; Dr. Eva K Lee
Cc: Tracey McNamara ; Caneva, Duane (b)(6); Dodgen, Daniel
(OS/ASPR/SPPR); 0eBord, Kri stin (OS/ASPR/SPPR); Phillips, Sally
(OS/ASPR/SPPR); David M arcozzi; Hepburn, Matthew J CIV USARMY {USA);
Lisa Koon in; Wargo Michael ; Walters, William (STATE.GOV); HARVEY,
MELISSA; WOLFE, HERBERT; Eastman , Alexander ; EVANS, MARIEFRED;
Callahan, M ichael V.,M .D.; (b)(6)
Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow. Gary
(OS/ASPR/BARDA); Redd, Johnt(OS/ASP R/SPPR); Hassell, David (Chris)
(OS/ASPR/IO); Hame l, Joseph (OS/ASPR/1O); Dean, Charity A@CDPH; Lawler,
James V; Kadlec, Robert (OS/ASPR/1O); 'Mart in, Gregory J
(b)(6) · Borio, Luciana; Hanfl ing, Dan; McDonald, Eric; Wad e,
--------
David ; TARANTINO, DAVID A; W ILKINSON, THOMAS; David Gruber
----------- CbH6J;KAUSHIK, SANGEETA; Nathan iel Hupert

On a totally diffe rent note. Others have been plying with and
modify ing the notiona l conops for a healthcare system.
I set up some simple rules :
1. Protect uninfected patients and staff from infectious patients and

staff (using all the tools that we have includin g home isolation and
home quarantine , cohorting/physical separation, PPE, telehealth,
etc.)
2. Provide acute care for COVID pat ie nts (cont inuum of ER-inpatient
care-intensive care)
3. Support mildly ill COVID patients in home isolation --telehealth
4. Support patients in voluntary home quarantine- -te lehea lth
NIH-001475
5. Continue to address the usual mix of healthcare needs for patients
(from outpatient care to acute care to mental health care to long
term care)
a. Outpatient clinics and providers focus on wellness to

minimize ERvisits/hospitalization to unburden the acute
care system-leverage telehealth
b. Continue to provide acute care and inpatient mental health
care (continuum of ER-inpatient care-intensive care) for non-
COVID conditions
c. Protect high-risk patients in residential/long term care
(n ursing homes, hospice, long term psychiatry, etc.)
The notional conops divides the healthcare system into hot and safe
areas. The hot area is only acute care: ER-acute inpatient care-ICU
care. The safe areas include a separate acute care area (ER-acute
inpatient care-ICU care), all the outpatient clinics/care, other inpatient
care areas such as mental health, as well as long term/residential care
(nursing home, hospice , long term psychiatry, etc.).
Triage will not be easy (between hot and safe). Best I could come up
with would be: ( 1) anyone already on home isolation or home
quarantine (may need a medical record flag); (2) anyone with ILI (could
narrow that down with a negative rapid flu test); (3) anyone with a sick
household member with suspected COVID. Could be very difficult for
an unconscious /confused, or trauma patient etc., but would probably err
on the side of hot and think of additional layered strategies to minimize
patient risk within that area (private rooms, patient PPE?). Triage
would need to err on the side of keeping the safe area safe.
The mitigation measures are our best tools to reduce community

transmission and reduce the probability of an infectious patient getting
into a safe area. If we have a breach in a safe inpatient area, it pretty
much converts that inpatient area into a hot area. That also means that
we have the staff in that area exposed (because of limited availability of
PPE, the staff in the safe area would not be PPE-PPE would have been
directed to the staff in the hot area). Those staff would likely need to be
placed on quarant ine. The effect is we now have a much larger hot area
with even fewer staff. That would really be a mess.
NIH-001476
You have the same problem in the outpatient areas. Have a sick patient
slip through and come in contact with a number of the clinic staff (not
in PPE), and we now need to quarantine all those staff. In contrast to a
breach for the inpatient area, the outpatient area can still operate as a
safe area (just minus those staff who would now be on quarantine). But
do that a few times and pretty soon you have nobody left to fight. One
way I thought about dealing with this scenario is to take the outpatient
staff and split them in two. One group works the clinic (physically
present) for the usual clinic hours for a 14 day stretch (1 incubation
period) . Another group works from home (and practices social
distancing, etc., really acting as if they are on home quarant ine) and
leverages telehealth technology to care for patients and help with
monitoring those patien ts in home isolation and home quarantine. After
14 days the groups switch. [All along we monitor employees daily
(whether at work or at home) for symptoms or sick household
membe rs] In the event of a breach , the groups immediately switch and
the group that was working is placed on actual home quarantine (but
still continues to work from home leveraging telehea lth) . That way if a
breach does happen, we have a fallback response (that we are constantly
practicing) that allows us to sustain outpatient care.
For the inpatient areas, I thought about the lone survivor model (holding
back 1 Secretary and staff in the event that the government is
decapitated). So think of a small group (would need to think thru what
the composition of that team would look like for each area (acute care,
inpatient mental health, long term care) that would at least provide the
nucleus of the expertise necessary to reconstitute the service in the
event of a major breach). This smaller group would vary in team
members every 2 weeks and would rotate to work from home for 14
days stretches and pract ice social distancing (acting as if they were on
home quarantine). They could also assist via telehealth (inpatient
consultation , etc., while out of the hospital).
Is anyone thinking along these lines (really continu ity of operations for
the healthcare system)?
NIH-001477
From: Carter Mecher
To: Richard Hatch ett ; Dr. Eva K Lee
Cc: Tracey McNamara ; Caneva, Duane; (b)(6); Dodgen, Daniel
(0S/ASPR/SPPR); OeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally
(0S/ASPR/SPPR); David Marcozzi ; Hepburn, Matthew J CIV USARMY (USA);
Lisa Koonin; Wargo Michael ; Walters, W illiam (STATE.GOV); HARVEY,
MELISSA; WOLFE, HERBERT ; Eastman, Alexander ; EVANS, MARIEFRED;
Callahan. M ichael V.•M .D.; Cb)(
Johnson, Ro bert (0S/ASPR/BARDA); Yeskey, Kev in; Disbrow, Gary
(0S/ASPR/BARDA); Redd, Johnt(OS/ASPR/SPPR); Hassell. David (Chris)
(0S/ASPR/ 10) ; Hamel, Joseph (OS/ASPR/10) ; Dean, Charity A@CDPH; Lawler,
James V; Kadlec, Robert (OS/ASPR/10) ; 'Mart in, Gregor y J
------- -
(b)(6) '; Borio, Luciana; Hanfling, Dan; McDonald, Eric; Wade ,
_________ Cb _ ,; KAUSHIK, SANGEETA; Nathan iel Hupert
_ >_C6)
https: // www.cbc.ca/news / canad a/ ottawa /d iamond -princ ess-coronavirus-

tr enton-comw all-l .54 70386
Canada flies home passengers from cruise line .
Data in article :
47 of 256 Canadians contract
https://protect2.fi reeye.com/url?k=96ebd7bc -cabfcec0 -96ebe683-

0cc47adc5fa2 -
16a39afbe c00c653&u=https ://www.t imesofisrael.com/israe l ... nee-
d iagnosed/
Israel confirms first coronavirus case as cruise ship returnee diagnosed
One of 11 Israel is who arrived in the morning after quarantine aboard
Diamond Princess ship tests positive, after entering 14-day isolation at Sheba
Medical Center
Trying to track cruises ship passenger /crew by country (data is sketchy)
Total ICU
%
Country Passengers/Crew Confirmed Admissions Deaths
Infected
Cases
us 434 58 l? 13%
NIH-001478
Hong Kong 330
Canada 256 47 18%
Australia 241 48 20%
UK 78 6 8%
Ita ly 35
South Korea 14
Israel 11 1 9%
Japan 2
Subtotal 1,399 160
Tota l 3,711 634 17%

To: Richard Hatchett ; Dr. Eva K Lee
Cc: Tracey McNamara; Caneva. Duane; (b)(6); Dodgen. Daniel
(0S/ASPR/SPPR) ; DeBord. Kristin (OS/ASPR/SPP R); Phillips. Sally
(0S/ASPR/SPPR ); David Marcozzi; Hepburn. Matthew J CIV USARMY(USA);
Lisa Koonin; Wargo Michael ; Walters. William (STATE.GOV); HARVEY.
MELISSA ; WOLFE. HERBERT; Eastman. Alexander; EVANS.MARIEFRED;
Callahan, Michael V.,M.D.1 (b)(6);
Johnson, Robert (05/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary
(0S/ASPR/BARDA); Redd, Johnt(OS/ASPR/SPPR) ; Hassell, David (Chris)
(0S/ASPR/10) ; Hamel, Joseph (0S/ASPR/10) ; Dean, Charity A@CDPH; Lawler,
_______
JamesV; Kadlec, Robert (0S/ASPR/10) ; 'Mart in, Gregory J
(b)(6) _...
'· Borio, Luciana; Hanfl ing. Dan; McDonald, Eric; Wade,
David; TARANTINO. DAVID A; WILKINSON,THOMAS; David Gruber
(b)(6); KAUSHIK.SANGEETA; Nathan iel Hupert
----------
Subject: RE:Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start
China ha s again mod ified its reportin g (first it added clin ical cases to
lab confirmed cases on Feb-12). Now it is subtracting out those clinical
cases and limiting numbers to lab confirmed). Have continued to
follow the hospitalization data from Hubei (see below).
NIH-001479
Here is the data being reported by Hubei and Wuhan. Data is pretty
sketchy prior to Jan-21.
Hubei and Wuhan Cases &

Hubei 2019-nCoV Confirmed Hospital Data
Hospi talization Rates
Hubei Wuhan
Tota l Wuh Cum Cum ¾ Hube
Mild Sever Critic Cum Cum Cum Hubei
Current an Hospitali Hospitali i Cases
Date Disea ely ally Discha Death Inpatie Cum
Inpatie Case zation zation Hospita
se Ill Ill rges s nts cases
nts s Rate per Rate per lized
100,000 100,000
1/ 14/
6 6 6 41 41 0.01 0.5
20
1/15/
5 5 2 7 41 41 0.01 0.5
20
1/ 16/
5 5 2 7 45 45 0.01 0.5
20
1/17/
8 8 2 10 62 62 0.02 0.7
20
1/ 18/
136 100 33 3 3 139 121 121 0.2 1.4
20
1/ 19/
170 126 35 9 4 174 198 198 0.3 2.4
20
1/20/
239 176 51 12 7 246 270 258 0.4 3.1
20
1/21/
15 375 320 0.0 3.8
20
1/22/
399 304 71 24 17 416 444 390 0.7 4.7
20
1/23/
494 365 106 23 31 24 549 549 495 0.9 5.9 100%
20
1/24/
658 472 129 57 32 39 729 729 572 1.2 6.8 100%
20
1/25/
915 221 85 52 1,052 J,052 618 1.8 7.4 100%
20
1/26/
1,645 1,013 563 69 44 76 1,423 1,423 698 2.4 8.3 100%
20
1/27/ 1,59
2,567 1,877 563 127 47 100 2,714 2,714 4.6 19.0 100%
20 0
1/28/ 1,90
3,349 2,450 671 228 80 125 3,554 3,554 6.1 22.8 100%
20 5
1/29/ 2,26
4,334 3,346 711 277 90 162 4,586 4,586 7.8 27.0 100%
20 1
1/30/ 5,486 4,392 804 290 116 204 5,806 5,806 2,63 9.9 31.5 100%
NIH-001480
,- -
20 9
l /31I 3,21
6,738 5,444 956 338 166 249 7,153 7, 153 12.2 38.4 100%
20 5
2/1/2 1,118 4,10
8,565 7,003 444 215 294 9,074 9,074 15.5 49.l 100%
0 9
2/2/2 1,223 10,263 11,177 5,14
9,618 7,917 478 295 350 17.5 56.4 92%
0 2
2/3/2 1,557 11,800 13,522 6,38
10,990 8,857 576 396 414 20.2 66.6 87%
0 4
2/4/2 10,10 1,809 13,626 16,678 8,35
12,627 711 520 479 23.3 81.6 82%
0 7 l
2/5/2 11,23 2,328 15,496 19,665 10,1
14,314 756 633 549 26.5 95.3 79%
0 0 17
2/6/2 11,80 3,161 17,239 22,112 11,6
15,804 841 817 618 29.5 108.3 78%
0 2 18
2/7/2 14,64 4,188 1,007 21,647 24,953 13,6
19,835 1,113 699 37.0 141.1 87%
0 0 03
2/8/2 15,74 4,093 1,154 23,212 27,100 14,9
20,993 1,439 780 39 .7 153.4 86%
0 6 82
2/9/2 16,65 4,269 1,236 24,826 29,631 16,9
22,160 1,795 871 42.4 169.3 84%
0 5 02
2/ 10/ 18,74 5,046 1,298 28,283 31,728 18,4
25,087 2,222 974 48.3 196.7 89%
20 3 54
2/11/ 18,88 5,724 1,517 29,828 31,728 18,4
26,121 2,639 1,068 51.0 207 .4 94%
20 0 54
2/12/ 26,60 5,647 1,437 38,444 48,206 32,9
33,693 3,441 1,310 65.7 314 .6 80%
20 9 94
2/13/ 27,08 7,953 1,685 42,276 5 1,986 35,9
36,719 4, 131 1,426 72.3 349 .9 81%
20 ] 91
2/ 14/ 27,95 8,276 1,876 44,338 54,406 37,9
38,107 4,774 1,457 75.8 369.4 81%
20 5 14
2/15/ 29,05 8 439 1,957 46 666 56,249 39,4
39,447 5,623 1,596 79.8 39 1.4 83%
20 1 62
2/ 16/ 31,01 8,024 1,773 49, 149 58,182 41,1
40 814 6,639 1,696 84.0 415 .6 84%
20 7 52
2/17/ 30,98 9,117 1,853 51,608 59,989 42,7
41 957 7,862 1 789 88.2 439 .7 86%
20 7 52
2/ 18/ 32,22 9,289 1,957 54,520 6 1,682 444
43,471 9,128 1,921 93 .2 469 .3 88%
20 5 12
2/19/ 32,56 9,128 2,050 10.337 56,111 62,013 45 ,0
43 745 2,029 95.9 487 .0 90%
20 7 27
2/20/ 3 1,05 8,979 2,018 11,788 55,988 62,422 45,3
42,056 2, 144 95.7 486 .2 90%
20 9 46
NIH-001481
Sent from Mai l for Windows l 0
From: Carte r M eche r

To: Richa rd Hat chett ; Dr . Eva K Lee
Cc: Tracey M cNama ra; Caneva. Duane; Dodgen . Daniel
(b)(6);
(OS/ASPR/SPPR); DeBord , Kri stin (OS/ASPR/SPPR); Phill ips. Sally
(OS/ASPR/SPPR); David M arcozzi ; Hepburn, M atthew J CIV USARMY (USA);
Lisa Koon in; Wa rgo Michael ; Walte rs, William (STATE.GOV); HARVEY,
MELISSA; WO LFE, HERBERT; Eastman, Alexande r; EVANS, MARIEFRED;
Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow , Gary
(OS/ASPR/BARDA); Redd, Johnt (OS/ASPR/SPPR); Hassell, David (Chris )
(OS/ASPR/1O); Hame l, Joseph (OS/ASPR/1O); Dean . Char ity A@CDPH; Lawler .
James V; Kadlec. Robert (OS/ASPR/1O); 'Mart in. Gregory J
(b)(6 ) Borio. Luciana ; Hanfl ing. Dan; McDona ld. Eric; Wade ,
--------
David; TARANTINO, DAVID A ; W ILKINSON, THOMAS ; David Gruber
_________ Cb _ ,; KAUSHIK, SANGEETA ; Nathan iel Hupe rt
_ )_(6)
More on South Korea (soundsjust like what happened at Jefferson

Barracks, just outside St. Louis, in 1918, armed with the exact same
tools they had more than 100 years ago to control an outbreak ). I
assume they must also be taking measures within the base to limit
spread (keeping infect ious individuals apart from those not yet infected
with isolation and quarantineand social distancing).
https://en.yna.co.kr/view/AEN2020022l 003000325?section=national/d
efense
SEOUL, Feb. 21 (Yonhap) -- The military is making all-out efforts to

prevent the new coronavirus from spreading further into the barracks,
offic ials said Friday, after the country's first infections in the armed
forces we re confirmed .
Earlier in the day, a Navy sailor on the southern island of Jeju was
confirmed to have contracted COVID-19 in the first such case among
service_personnelhere.
NIH-001482
Follow ing the confirmat ion, the Navy has checked the temperature of
all personne l at the base where the infec ted sai lor served and
quara ntined all those who had contacts with the pe rson, it said.
"We have carried out disinfec tion work at the base and are devoting all
our efforts to preven ting the spread of the new virus," the Na:vy said in a
release.
An officer each from the Army and the Air Force were also confirmed
to have the virus the same day.
The military is now wo rking to ident ify personnel who have visited the
southeastern city of Daeg u and the suffound ing Nort h Gyeong sang
Province since Feb . 10, as these areas have rece ntly seen a surge in the
number of infected people.
More than 5,000 service persom1el are estimated to have visited the
region during their vacat ion accord ing to the military's preliminary
inve stigatio n.
On Thursday night the defense ministry said all personnel will be

barred from vacationing, staying outside their bases and meeting
v isitors starting Saturday.
The decision was made at a meeting of top defense officials presided

over by Defense Minister Jeong Kyeong-doo, during which he called
for "extraordinary measures" to contain the s read of the virus .
Amid growing fears over the disease , the govemment called off a
planned ceremony to mark the 60th ann iversary of a pro -democracy
movement in Daegu, which was designa ted a "special care zone" over
the virus earlier in the day.
From : Carte r M eche r

To: Richa rd Hat chett ; Dr. Eva K Lee
Cc: Tracey McNama ra; Caneva. Duane; (b)(6); Dodge n. Dani el
(OS/ASPR/SPPR); DeBord. Kristin (OS/AS PR/ SPPR); Phillips. Sally
(OS/ASPR/SPPRl : David M arcozzi: Heob urn , M att hew J CIV USARMY (USA);
Lisa Koo nin ; W argo M ichael; Walt ers, W illiam (STATE.GOV); HARVEY,
NIH-001483
MELISSA; WOLFE. HERBERT; Eastman , Alexa nder ; EVANS. MAR IEFRED;
Johnson, Robert (0S/ASPR/BARDA) ; Yeskey, Kevin; Disbrow, Gary
(0S/ASPR/BARDA) ; Redd, Johnt(OS/ASPR/SPPR); Hassell, David (Chris)
(0S/ASPR/ I0) ; Hame l, Joseph (OS/ASPR/10) ; Dean , Charity A@CDPH; Lawl er,
Jame s V; Kadlec, Robert (OS/ASPR/10 ); 'Ma rt i n, Gregory J
------- - (b)(6) · Borio, Luciana; Hanfli ng, Dan; M cDonald, Eric ; Wad e,
David ; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gru ber
----------- (b)(6)· KAUSHIK, SANGEETA; Nat hanie l Hup ert

S. Korea reports 52 new virus

cases, total now at 156
Welfare /Medicine 10:37 February 21, 2020
SEOUL, Feb. 21 (Yonhap)-- South Korea reported 52 new cases of tbe

new coronavirus Friday, bringing the total numbe r of infections in the
nation to 156, with the potentially fatal illness spreading fast across the
country.
The number of COVID-19 infections here has almost tripled in just

three days, with most new infections traced to church services in the
southeastern city of Daegu.
Of the 52 new cases, 41 are in Dae gu, 300 kilometers southeast of

Seoul, and the neighboring North Gyeongsang Province. Another three
were reported in Seoul, the Korea Center for Disease Control and
Prevention (KCDC) said in a statement.
Tour buses are parked at a logistics terminal in Daegu , 300 ki lometers

southeast of Seoul, on Feb. 20, 2020. Thirty-eight new coronavi rus
cases were reported in the city on Feb. 21, 2010. (Yonhap)
The spike of infections in Daegu and several cases in Seoul , where

routes of infection s are not immediately traceable , have prompted health
offic ials to declare that COVID-19 has begun spl!_ading locally.
The KCDC said two new cases were reported in South Gyeongsang
Prov ince . In a sign that the virus may broadly spread nationwide , six
prov inces, includ ing Gyeong gi, Jeju , Chungcheong and North Jolla,
each repo rted one case.
NIH-001484
Of the 52 new cases, 39 are linked to the Shincheonji Church of Jesus in
Daegu , where the 31st patient, the country 's probab le "super spreader ,"
attended worship serv ices, the KCDC said.
A 61-year-old South Korean woman, who tested positive for the virus
earlier this week, attended worship serv ices at the church on Feb . 9 and
this past Sunday .
KCDC Director Jung Eun-kyeong told reporters Thursday that the

agency is uncertain whether the woman , known as the 31st patient , was
a "super spreader" of the virus but asked 1,001 membe rs of the church
to self -isolate to stem the spread of the virus .
The government decided to designate Daegu and neighboring Cheongdo

as "special management zones," following the spike in the number of
infected people and the nation's first death from the virus.
From: Carte r Mecher

To: Richa rd Hat chet t; Dr. Eva K l ee
Cc: Tracey McNama ra; Caneva, Duane ; (b)(6) Dodgen , Danie l
(OS/ASPR/SPPR); DeBo rd. Kri stin (OS/ ASPR/SPPR); Phill i ps. Sally
(OS/ASPR/SPPR); David Marcozzi : Hepburn. Matthew J CIV USARMY (USA);
Lisa Koon in; Wa rgo Mi chael ; Wal t ers, Will iam (STATE.GOV); HARVEY,
MELISSA; WOLFE, HERBERT; Eastman, Alexande r; EVANS, MARIEFRED;
Callahan , M ichael v .,M .D.; (b)(6)
Johnson , Robert (0S/AS PR/ BARDA); Yeskey, Kev in; Disbrow, Gary
(OS/ASPR/BARDA) ; Redd, Johnt( OS/ASPR/SPPR); Hassell, David (Chris)
(0S/ASP R/ I0) ; Hamel , Joseph (OS/ASPR/ 10) ; Dean , Charity A@CDPH; Lawler ,
James V; Kadlec. Robert (OS/ASPR/10); 'M art in. Grego ry J
(b)(6J 1; Borio. Lucian a; Hanfli ng. Dan; McDona ld, Eric; Wade.
--------
David; TARANTINO, DAVID A; W ILKINSON, THOM AS; David Grube r
__________ Cb
_) _(6J;KAUSHIK, SANGEETA; Nathan iel Hupe rt
Subjec t: RE: Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start
From Feb-15 to Feb-20 the number of confirmed cases increased from

355 to 634 (increase of 279). The number of asymptomatics increased
from 73 to 322 (increase of249) . So from Feb-15 to Feb-20 , 249 of the
NIH-001485
279 confirmed cases (89%) were asymptomatic. Seems a little odd.
Also, read reports that all passengers and crew have beem tested (but
report s only note that 3,066 of the 3,711 have been tested) .
Cumulative
Cumulativ
Number of
Date Eve nt eNumber Notes
Confirmed
of Deaths
Cases
Cruise ship depa1is from Yokohama
20-Jan
Japan
80 year old passenger disembarks in
25-Jan
Hong Kong
80 year old passenger confirmed to
have COVID-19
When results known, certificate of
landing canceled and ship under
1-Feb quarantine. Tests for the virus would
be administered to three groups : those
with symptoms, those who got off in
Hong Kong , and those who had close
contact with the infected passenger.
Ship arrives in port of Yokohama
3-Feb
Japan
5-Feb 10 passengers and crew confirmed + 10
31 more passengers and crew
6-Feb 41
confinned +
30 more passenger and crew
7-Feb 61
confinned +
9 more passenger and crew confirmed
8-Feb 70
+
10-Feb 136 439 tested
confinned +
confinned +
12-Feb 203 4 in ICU
confirmed+
confomed +
confinned +
1,219
15-Feb 355 tested; 73
confirmed+
asymptomatic
NIH-001486
329 American evacuated from cmise
ship (14 of the evacuees
found to be
+) 61
16-Feb 369
Americans remained on
board
44 Amer icans remained hosp italized
in Japa n
1,723
17-Feb 454 tested;
confirmed+
19 serious ly ill
18-Feb 621 3,011 tested
confirmed+
19-Feb 2 deaths 621 2
3,066
tested;
20-Feb 634 2 28 seriously
confirmed+
ill; 322
asymptomatic

To: Richa rd Hat chett ; Dr. Eva K Lee
Cc: Tracey Mc Nama ra; Caneva, Duane; (b)(6); Dodgen, Dan iel
(OS/ASPR/S PPR); DeBo rd, Kri stin (OS/ASPR/SPPR); Phill i ps, Sally
(OS/ASPR/S PPR); David M arcozzi ; Hepburn , Matthew J CIV USARMY (USA);
Lisa Koon in; Wargo Mi chael; Walte rs. Will iam (STATE.GOV): HARVEY.
MELISSA; WOLFE, HERBERT; Eastman, Alexande r; EVANS, MA RIEFRED;
Callahan, M ichael V.,M .D., (b)(6) _;
Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kev in; Disbrow, Gary
(OS/ASPR/BARDA) ; Redd, Johnt(OS/ASP R/S PPR); Hassell, David (Chris)
(OS/ASPR/I0) ; Hame l, Joseph (OS/ASPR/ 10) ; Dean, Charity A@CDPH; Lawler,
James V; Kadlec, Robert (OS/ASPR/10); 'Ma rt in, Grego ry J
-------- (b)(6) · Borio, Luciana ; Hanfli ng, Dan; McDona ld, Eric; Wade,
David; TARANTI NO, DAVID A : W ILKINSON. THOM AS: David Gruber
---------- (b)(6); KAUSHIK, SANGEETA; Nathan iel Hupe rt

Subjec t : RE: Red Dawn Breaking , COVID-19 Collaborative, Feb 16 start
NIH-001487
This is new
• Now 634 cases confirmed on the cruise ship (3,063 tested) (so not all
the ship and crew have been tested 3.711)
• Slightly more than half are asymptomatic (previously we heard that
73 of 355 are asymptomatic)
• 28 in serious condition (4.4%)
Japan's Health Min ister Katsunobu Kato told Parliament the t\vo people
from the Diamond Princess cruise ship who died had "received the best
medica l treatment" but couldn't be saved after catching the novel
corona virus on board. As of Thursday, 634 passengers and crew
members were diagnosed with the virus out of 3,063 tested. Slightly
more than half have no symptoms at all, officials said, and many of the
remainder have only mild fever or a cough. Among patients who tested
positive for the virus, 28 were reported in serious condition Thursday.
Doctors have said the vims can be particularly harmfu l in elderly

patients , and one of the two fatal cases from the Diamond Princess, a
Japanese man in his 80s, had pre-exist ing bronchial asthma and had
been treated for angina. The other, a Japanese woman in her 80s without
underlying illnesses, came down with a fever on Feb. 5, the same day
passengers were told they would be quarantined in their cabins for two
weeks, according to health ministry officials. The next day, she started
suffer ing from dianhea and saw a doctor on board.
She wasn't taken to a hospital until Feb. 12 when she started suffering
shortness of breath. Her virus test came back posi tive the following day,
and despite treatment with antivira l drugs norma lly used to treat HIV
infection, she died Thursday.
Asked about the woman's case, health ministry official Hiroshi Umeda
said, "I believe it was hand led promptly." He said the ship was a
difficult environment for medica l staff but they worked day and night
and tried to prioritize the most serious cases.

Sen t : Thursday, February 20, 2020 11:00 AM
To : Richard Hatc hett ; Dr. Eva K Lee
Cc: Tr acey Mc Nama ra; Caneva, Duane; (b)((;); Dodgen, Daniel
(OS/ASPR/S PPR); DeBord, Kristin (OS/ASPR/SPPR); Phillips, Sally
(OS/ASPR/S PPR); David M arcozzi; Hepburn, M att hew J CIV USARMY (USA);
NIH-001488
Lisa Koo nin; Warg o Mich ael; Walters. W illiam (STATE.GOV); HARVEY.
MELISSA; WOLFE. HERBERT; Eastma n. Alexander; EVANS. MARIEFRED:
Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary
(OS/ASPR/BARDA); Redd, Johnt(OS/ASPR/SPPR); Hassell, David (Chris)
(OS/ASPR/IO); Hamel, Joseph (OS/ASPR/ IO); Dean, Char ity A@CDPH; Lawler,
James V; Kadlec, Robert (OS/ASPR/IO) ; 'M art in, Gregory J
,.._ _____ Cb
_>_<6J ' · Borio, Luciana; Hanfl ing, Dan; M cDonald, Eric; Wade,
_,,_,
David; TARANTINO, DAVID A; W ILKINSON, THOM AS; David Gruber
----------- (b)(6) KAUSHIK, SANGEETA; Nat haniel Hupe rt

Keep an eye on South Korea too. Seeing rapid growth in cases in South
Korea (see story below)
South Korea now reporting 104 cases and 1 death today. South Korea
now implementing NPi s. This story is eerily remini scent of the actions
taken at Jefferson Barracks near St. Louis in 1918.
Also attached are update for Singapore (85 cases; 46 in hospital/4 in

ICU; 4 kids, only l in hospita l) and Hong Kong (69 cases, still no kids
report ed). Both have implemented NPis (small increases in cases
today). Japan has reported 10 new cases today-total now is 94.
South Korea reports first virus death as Daegu struggles to contain outbreak
htt ps://p rot ect 2.fi reeye.com/ur l7k=3b90 7Sda-67c46ca6 -3b9044e5-
0cc47adc5fa2 -
08635f0e3 1f1241 a&u=https://www .stri pes.com/news/p acific ... break-
1.619407
SEOUL,South Korea - South Korea reported its first coronavirus-linked

death Thursday, while the U.S. military tightened restrictions on travel to the
southeastern city of Daegu due to an outbreak in infections in the area.
Daegu also urged resident s to stay home as the city of 2.5 million
people and surrounding areas struggled to contain an outbreak of the
pneumonia-like disease .
The Army garrison in Daegu also restricted access and announced that
schoo ls and nonessential business would be closed for a second day on
Friday.
NIH-001489
In an exception to policy, U.S. service members were authorized to
wear face masks in uniform "regardless of air quality condit ions,"
according to the ga1Tison' s F acebook page.
Fast-moving developments this week were a blow to South Korea's

hope that the crisis was easing.
Instead, dozens of new cases were confirmed in recent days, with the
total number of infections soaring to 104 on Thursday, according to the
Korea Centers for Disease Control and Prevention
U.S. Forces Korea said, "there remains zero confirmed cases ofUSFK
personnel with COVID-19."
The virus first appeared in December in Wuhan, China, and spread to

nearly 30 countries. More than 2,000 people have died - most in
mainland China.
A South Korean man in his 60s died Wednesday at a hospital in the

sout heastern city of Cheongdo and posthumously tested positive for the
virus , the KCDC said Thursday. It was South Korea's first death from
the virus.
USFK raised the risk level for the militar y communit y to moderate
on Wednesday and banned all nonessential travel to Daegu due to an
outbreak linked to a church near the Anny garrison in the city.
On Thursday, USFK added that all travel by American troops to, from
and around Daegu requires authorization from their leadership. The
precaution was "highly encouraged" for all family members, civilians
and contractors as wel l.
"All off-insta llation travel for all USFK populations should be

minimized to reduce potential contam ination," USFK announced on its
website.
U.S. Army Garrison Daegu, about 200 miles southeast of Seoul, also
said visitors not performing mission essential or official business would
be denied access as it implemented health checks at the gates.
Nonessential personnel were not required to go to work on Friday and

most activities would be suspended , including the schools , it said.
The garrison also recommended that members of the military

commun ity avoid public places and transportat ion in the c ity, includin g
NIH-001490
stores, restaurants and other heavily congested areas until the situat ion
is brough t under control.
Self-quarant ine measures were ordered for any Amer ican troops who
had visited the affected New World Church, but garrison commander
Col. Edward Ballanco said earlier Thursday that no Americans were
known to have done so.
He also urged Americans to avoid a local hospital where the woman

believed to have been a carrier was treated.
The garrison also lifted limits on wearing face masks for American
troops in uniform, who normally are only allowed to wear them on days
with extreme pollut ion.

To: Richa rd Hatche tt ; Dr. Eva K Lee
Cc: Tracey McNa mara ; Caneva, Duane ; (b)(6); Dod gen, Daniel
(OS/ASPR/S PPR); DeBo rd, Kri st in (OS/ASPR/SPPR); Philli ps, Sally
(OS/ASPR/SPPR); David M arcozzi; Hepburn, M att hew J CIV USARMY (USA);
Lisa Kooni n; Wa rgo M ichael; Wa lte rs, Will iam (STATE.GOV); HARVEY,
MELISSA; W OLFE. HERBERT; Eastm an. Alexande r; EVANS, MARIEFRED:
Call ahan, M ichael V.,M .D.J (b)(6);
Johnson , Ro bert (OS/ASPR/BARDA); Yeskey, Kev in; Disbro w, Gary
(OS/ASPR/BARDA); Redd, Johnt(OS/AS PR/SPPR); Hassell, David (Chris)
(0S/AS PR/I0) ; Hame l, Joseph (OS/ASPR/ 10) ; Dean, Charit y A@CDPH; Law ler,
-------- (b)( ' ; Bo rio, Luciana; Hanfli ng, Dan; M cDo nald, Eric; W ade,
_________ _>
Cb_ C_6) KAUSHIK. SANGEETA; Natha niel Hupert
Last thing. Keep a very close eye on Japan. The outbreak is starting to
take off there with number s of cases scattered across the country with
no link to known cases. We are also seeing nosocomial transmission (a
number of healthcare workers infected). There is also a large number of
cases hospitalized in Japan related to the cruise ship, and now the
release of large mLmbers of passengers from the cru ise ship into the
community. Yesterday they reported a total of 84 cases-caught up to
NIH-001491
Singapore. But unlike Singa pore , Japan has been slow to implement
NPis. The other concern is that Japan's popu lation is
disproportionately aged (it has the highest% age 65 of any country). In
Ja pan, 27% of the population is :::_
65; in the US, 15.6% of the
population is~ 65. And Japan can also claim the largest city in the
world (metro Toky o with 38 M people - pretty much the populat ion of
California crammed into an area smaller than the size of Conn ecticut).
Japan also has the 1oth largest city in the world (Osaka wi th 19 M
people).
From: Carter Mech er

Sent: Thursday, February 20, 2020 7: 15 AM
To: Richard Hat chett ; Dr. Eva K l ee
Cc : Tracey McNam ara; Caneva, Duan e; (b)(6) Dodg en, Dani el
(OS/ASPR/SPPR); 0 eBord, Kri stin (OS/AS PR/SPPR); Phillips, Sally
(OS/ASPR/SPPR); David M arcozzi; Hepb urn , M atth ew J CIV USARMY (USA);
Lisa Koo nin; Wargo M icha el; Wal te rs, Wi lliam (STATE.GOV); HARVEY,
M ELISSA; W OLFE. HERBERT; East man , Alexan der; EVANS. MARIEFRED;
Callah an. M ichael V.•M .D.; (b)(6)
Jo hnson. Rober t (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary
(OS/ASPR/BARDA); Redd, Johnt (OS/ASPR/SPPR); Hassell, Dav id (Chris)
(OS/ASPR/IO); Ham el, Joseph (OS/ASPR/1O); Dean, Chari ty A@CDPH; Law ler ,
Jame s V; Kadlec, Robert (OS/ASPR/1O); 'M art in, Gregory J
-------- (b)(6) Borio, Luci ana; Hanfli ng, Dan; M cDon ald , Eric; Wade,
David ; TARANTINO, DAVID A; W ILKINSON, THOMAS; David Grub er
_________ _H_6) KAUSHI K. SANGEETA; Nath an iel Hu pert
Cb
Subject : RE: Red Dawn Breaking , COVID-19 Collaborative, Feb 16 start
What has me worried is what happened on the crui se ship is a preview

of what will happen when this virus makes its way to the US healthca re
sys tem (no t to mention institutionali zed h igh-r isk population s in the
US, like nur sing homes) . I'm not sure that folks und erstand what is ju st
over the hor izon.
Remem ber the story about Mann Gulch ? We are at the equiva lent of
abou t 5:44. I anticipate that when we reach 5:45, th ere is go in g to be
chaos and panic to get anything in place. I doubt that what we would
NIH-001492
then hurriedly put in place will be any better than what they did on that
cruise ship. As a conseq uence, would expect much the same results.
I listened to the discussion yesterday. After listening to James and

Michael describe the conditions on and around the cruise ship, I
wondered whether anyone in healthcare leadership ( outside the
expert ise at our biocontainment facilities) is thinking about infection
control practices for any staff entering areas of a hospital caring for
COVID patients (like changing clothes before entering and perhaps
wearing scrubs, not bringing personal items into the area like iphones,
ipads, stethoscopes, white coats, purses, briefcases , etc .)? And
instituting policies that require all patients to phone for clearance to
enter prior to presenting at safe acute and non-acute areas including
community based clinics? Are we confiden t of the infection control
practices of acute care staff (that they know the basics of how to don
and doff PPE and behavior while in PPE?) Would HCWs in outpatient
clinics or long tem1 care facilities be any better prepared than the crew
on board the cruise ship or the responders in Japan? I'm no expert in
infection control and would defer to the expertise in this group. I was
jus t a little smprised how little this seemed to be a concern for the
healthcare leaders gathered yesterday.
I think we are getting close to the point where we need to drop those
things that are not critical and focus on the most imp01tant things.
We are going to have a devil of time with lab confirmation - it is just

too slow (they had a 2 day turnaround on the cruise ship) and we just
don't have the capacity for the volume of tests we would anticipate.
Charity has stressed this point again and again. That means we are
going to have to fly blind early on. Perhaps the best we are going to be
able to do in the near term if things begin to acce lerate is screen all
suspect cases (pretty much anyone with ILi symptoms) with a quick flu
test and assume anyone who tests negative is suspected COVID until
proven otherwise; and treat everyone who tests positive with Tamiflu.
It will prove problematic early on, but as the epidemic barrels along,
COVID will displace everything (at that point we will just assume that
anyone with a fever or ILi has COVID). The problem is in the
beginning . It is going to be so hard to sort things out. Matt, James and
others are pushing for more rapid screening- but we ju st aren't there
yet. The consequence is that we will be placing patients with resp
illness (that is not flu and presumed to be COVID) in areas with actual
NIH-001493
COVID patien ts. I hate to do that, but not sure how it could be avoided
early on. But we wou ld only do that for those who are ill enough to be
hospitalized. The large number of asymptomatic and mildly ill patients
would be under home isolation (so no worries about mixing confinned
and suspected patients). The downside is that we would have larger
number of people is isolation and home quarantine than is really
necessary (and the consequence of increased workplace absenteeism).
And it is because home isolation and home quarantine are so important,

healthcare systems (and not ju st public health) have to grab a hold of
operationalizing those NPi s with both hands. A while back, I created
some prescriptions (tongue in cheek), just to underscore that physicians
do have a role in isolation and quarantine (it is not limited to public
health). We might not have pharmaceutica ls available to treat COVID,
but why can' t we write pre scriptions for non-pharmaceutica ls? I don't
think healthcare leaders appreciate this point. Every COVID pat ient we
admit or see in the ER will require us to follow up with household
members to make sure they know to home quarant ine (need to do the
same anywhere in our system we find a patient who is infected). You
could not imagine the pushback I have received when I proposed that
we must have an active role-people seem to think that state and local
public health is alone respons ible for this. I would think public health
will be overwhelmed and taking charge of this is our best strategy to
keep our safe areas safe.
I would be interested to hear how other healthcare systems and public

health leaders are thinking about this.
From: Carter Mecher

Cc: Tracey McNama ra; Caneva. Duane (bH ; Dodgen. Daniel
(OS/ASPR/SPPR); DeBord, Krist in (OS/ASPR/SPPR); Phillips, Sally
(OS/ASPR/SPPR); David M arcozzi ; Hepb urn, M atthew J CIV USARMY (USA);
Lisa Koon in; Wa rgo Michael ; Wa lters, W ill iam (STATE.GOV); HARVEY,
MELISSA; WO LFE, HERBERT; East man, A lexander ; EVANS, MARIEFRED;
NIH-001494
Callahan. M ichael V.,M .D.; (b)(6);
Johnson, Robert (0S/ASPR/BARDA) ; Yeskey, Kevin; Disbrow, Gary
(0S/ASPR/ I0) ; Hame l, Joseph (0S/ASPR/ 10) ; Dean, Char ity A@CDPH; Lawler,
James V; Kadlec, Robert (OS/ASPR/10); 'Mart in. Gregory J
(b)(6) '; Borio, Luciana ; Hanfling, Dan; McDonald, Eric; Wade,
------- -
David ; TARANTINO, DAVID A; W ILKINSON. THOMAS; David Gruber
----------- (b)(6); KAUSHIK, SANGEETA; Nathan iel Hupert

Keeping track of the outbreak aboard the cruise ship. The latest update
is the announcement of 2 deaths (both patients in their 80s). An 87-
year-old man and an 84-year-old woman, died on the 20th. Both were
Japane se (the 87-year-old man was hospitalized on Feb-11 and the 84-
year-old women on Feb-12). So time to death from recognition of
infection was 8-9 days. On Feb-12 , the total number of confirmed cases
was 203. So estimated CFR back dating the denominator to Feb-12 is
1%. Assuming a denominator of 621, the CFR is 0.3%. if death s are
lagging by 8-10 days (and con finned cases plateau), we should have a
pretty good estimate of CFR for he entire group in another week or so.
Will need to peel off the number of cases involving the crew member to
get a better estimate of CFR in the elderly. These numbers are within
the range we have been estimating .
The 2,666 pass engers are similar in age (and likely in co-morbidities) to
the population we see in a nursing home or residential ca re faci lity. The
1,045 crew are a proxy for a young healthy population. It will be
important to look at the outcomes separately. One of the concerns is
how a 'remake of this movie' could play out in similarly confined
populations of elderly frail Americans. Here are the number s of long
term care facilities /programs in the US that care for the frail elderly. A
large number of loc ations and a large numbe r of residents /p articipa nts. I
know that healthcare leaders were engaged yesterday, is anyone
engaging this sector (long term care)? The healthcare leaders seemed
more concerned about critical supply shortages (akin to the IV fluid
shortage). Listening to them, it felt like their concerns seemed almost
divorced from the threat ofCOVID.
NIH-001495
Number of Number of
Number of Number of Number of
Facilities / Agencies I
Beds Residents Participants
Communities Centers
Nursing Homes 15,600 1,700,000 1,300,000
Residential Care 28,900 996 , 100 811,500
Hospice Care 4,300 1,400,000
Adult Day Care 4,600 286,300
Source: https ://www. cdc. gov/nchs /fas ta ts/nursing -home -care .htm
The outbreak on the cruise ship should be the wake up call for leaders in
long tenn care (and I would think healthcare overall).
Here is a sununary of the cruise ship data (as of Feb 20)
Cumulative
Cumulativ
Number of
Date Event eNumber Notes
Confirmed
of Deaths
Cases
Cruise ship departs from Yokohama
20-Jan
Japan
80 year old passenger disembarks in
25-Jan
Hong Kong
80 year old passenger confnmed to
have COVID-19
When results known , certificate of
landing canceled and ship under
1-Feb quarantine. Tests for the virus would
be administered to three groups : those
with symptoms , those who got off in
Hong Kong, and those who had close
contact with the infected passenger.
Ship arrives in port of Yokohama
3-Feb
Japan
5-Feb 10 passengers and crew confinned + 10
31 more passengers and crew
6-Feb 41
confirmed+
7-Feb 30 more passenger and crew 61
NIH-001496
confirmed+
9 more passenger and crew confirmed
8-Feb 70
+
confirmed+
confirmed+
12-Feb 203 4 in ICU
confirmed+
confinned +
confirmed+
73
15-Feb 355 asymptomatic;
confirmed+
1,219 tested
329 American evacuated from cruise
ship (14 of the evacuees
found to be +)
61 Americans
16-Feb 369
remained on
board
44 Americans remained hospita lized
in Japan
1,723
17-Feb 454 tested;
confinned +
19 serious ly ill
18-Feb 621 3,011 tested
confirmed+
19-Feb 2 deaths 621 2
Data by country is a bit sketchy
Total ICU
Countiy Passengers Confirmed Admissions Deaths
Cases
us 434 58 1
Hong Kong 330
Canada 256 32
Australia 241 46
UK 78 6
Italy 35
NIH-001497
South Korea 14
Japan
Subtotal 1,388 142
New virus cruise ship disembarks and kills two Japanese

passengersin hospital
February 20, 2020 11 :38
Two Japanese men and women in their 80s who were hospitalized and
treated for the virus were killed on the 20th in a cruise ship passenger who
was confirmed to be infected with the new coronavirus . This is the first t ime
a cruise ship passenger has died and three peop le have been killed in the
country .
As of the 19th, 621 cruise ships out of approximately 3,700 crew members
and passengers on the cruise ship where outbreaks of the new coronavirus
were confirmed were confirmed.
Accord ing to government offi cials, two of them, a 87-year-old man and an 84-
year-ol d woma n, died on the 20th.
Both were Japanese and had a basic illness and were confirmed to have been
infe cted w ith the virus, so it was said that men were hospitalized on the 11th
of this month and women on the 12th to be treated.
This is the fir st time a cruise ship passenger has died .
In addit ion, three people have been killed in Japan, following th e death of a
woman in her 80s living in Kanagawa Prefecture on the 13t h of this month.
Sent from M a il for Windows 10
From: Carter Mecher

Cc: Tracey McNama ra; Caneva, Duane; (b)(6); Dodgen , Daniel
(OS/ASPR/SPPR) ; DeBord. Kristin (O5/ASPR/SPPR ); Phillips. Sally
(O5/ASPR/SPPR) ; David Marcozzi; Hepburn. Matthew J CIV USARMY(USA);
Lisa Koo nin; Wargo M ichael; Walters. William (STATE.GOV); HARVEY,
MELISSA; WOLFE, HERBERT; Eastman, Alexander; EVANS,MARIEFRED;
NIH-001498
Callahan. M ichael V.,M .D.; CbH6J
Johnson, Robert (0S/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary
(0S/ASPR/ I0) ; Hamel, Joseph (0S/ASPR/ 10) ; Dean, Char ity A@CDPH; Lawler,
James V; Kadlec, Robert (OS/ASPR/10); 'Mart in. Gregory J
(b)(6) '; Borio, Luciana; Hanf ling, Dan; McDonald, Eric; Wade,
------- -
David ; TARANTINO, DAVID A; W ILKINSON. THOMAS; David Gruber
----------- CbH6J; KAUSHIK, SANGEETA; Nathan iel Hupert

More puzzle pieces.
Italy https: //protec t2.fireeye.com /url?k =e5d0524 7-b9844b3b -e5d063 78-

0cc47adc5 fa2-
el6553f827677d60&u=htt ps ://www .joumalgazette .net/new s/wor ld/202
002 16/ g uarantine -ends- for-germans-italy-to-fly -citizens -from-s hip
Italy plans to evacuate 35 Italians from the cruise ship
• 25 Italian crew members (including the ship's captain)

• 15 passengers
UKhttps: //www .telegraph.co.uk/g lobal -health/sc ience -and -

disease /coronav irus-news -uk- china-s ingapore-death-to ll-Jatest /
UK plans to evacua te British passengers Friday 2/21
78 British passengers on board
4 confirmed COV ID the Fore ign Office
2 passeng ers on board say they are infect ed
Hong Kong
https ://www .japantimes.co .jp/news/2020 /02/ 16/nationa l/science -
health/ canada-evacuat e-passenge rs-coro navirus-covid l 9-diamond-
princess-cruise-s hip/
There are around 330 Hong Kong resident s on board, including 260
holding Special Administrative Region of Hong Kong passpo1ts and
roughly 70 people with foreign ones .
NIH-001499
South Korea
https ://www. japantime s.co . jp/news/2020/02/1 8/nationa l/science -
hea lth/southkorea-evacua te-diamo nd-princess /
The South Korean government is sending a presidential plane to Japan

on Tuesday afternoon to evacuate several citizens on a coronavirus-
stricken cruise ship docked in Yokohama, a government official said
Tuesday.
14 South Koreans - nine passengers and five crew members
Canada
https ://www . japantimes.co . jp/news/2 020/02/18/nationa l/science-
heal th/ cana da-diamond-princess -covid 19/
Global Affairs Canada had confinned that 32 out of 256 Canadians on

the ship had tested pos itive .
Canadian passengers are set to be evac uated from the virus- hit boat
soon, passengers will be screened before boarding the evacuation
aircraft , and those who exhibit symptoms of COVID-19 will be
transferred to the Japanese health care system
,Australia https: //www .news.com.au/ travel /travel-updates/health-

safety/ unusua l-resc ue-fli gbt-ahead-for-aus tralian-evacuees -of-the-
d iamond-pr ince ss/news-story/ 564e590 bec70b 7182 5c897 df85d0bc24
Austra lia evacuated passengers from the cruise ship today.
• ~180 evacuated
• 15 declined evacuation
• 36 confirmed COVID hospitalized in Japan
• 10 newly confirmed had to stay behind
So there were a total of ~241 Australians aboard the ship; 46 tested +

(19%)
The story from Australia sounds familiar (see below).
NIH-001500
Australian cruise passengersarrive
to Darwin after Diamond Princess
virus outbreak ordeal
Feb 20
A rescue mission of Australian cruise ship passengers from Japa n has

officially landed in Darwin, but the ilight wasn't free from drama.
Thousand s of people sharing toilets, pools and buffets - is thi s the petri
dish of the sea?
The Qantas coronavirus rescue flight, carrying about 180 citizens and
permanent residents on board from Japan, has landed in Australia.
Qantas flight 6032 touched down in Darwin at 8. 11am local time, after
being slightly delayed from takeoff our of Haneda.
The last -minu te drama hit the rescue mission when 10 Aus tralians, who
were set to leave the coronavirus-hit Diamond Princess ship and head to
the airport , were told they had tested positive to coronav irus and had to
stay behind.
About 180 citizens and permanent residents , who have spent the past
fortnight on the quarantined cruise ship off the coast of Japan, had taken
up the Federal Government' s offe r of a seat on the repatriation flight to
Austra lia.
They join another 36 Australians who contracted coronavirus on the

Diamond Princes s and are being treated in Japan. About 15 of their
rel atives declined the offer of repatriation to stay with them.
The Australians on board will be screened for coronavirus five times

before they are taken to a quarantine facility at Howard
Qantas boss Alan Joyce praised the crew who took part in the
repatriation flight as well as two previous Qantas chartered flights that
broug ht Austra lians home from virus epicent re Wuhan .
"It took literally thousands of hours to plan complex operations like

these," Mr Joyce said at t press conference today.
"T he crew were all vo lunteers and they did us proud ."
NIH-001501
Yesterday , Australians who were cleared to finally disembark the
Diamond Princess were driven by bus to Haneda Airport for the
chartered flight home.
They first needed to pass a health check to receive an approval of

disembarkation notice by Japanese quarantine officials.
They were then screened several more time s before they could board
the Qantas 74 7.
On the plane , they had no contact with Qantas crew, who remained
upstairs for the flight. Food for passengers was already waiting for them
at their seats when they boarded.
If they passed the latest health check, they would have been given
"approval of disembarkation" notices by Japanese quarantine officials ,
which grant them permission to enter Japan.
From Yokohama Po1t, where the ship was docked, they boarded buses
to Haneda Airport.
Brisbane student Tehya Pfeffer , 18, who has been quarantined on the
Diamond Prin cess with her grandmother Cathy, was among them.
"At 10.30am (local time, 12.30pm AEDT) we will start to be screened

and given luggage tags and wrist bands," Ms Pfeffer told news .com.au
yesterday.
"At 5pm we have to have our luggage put outside, and at 6pm we will
disembark the ship and go through a makeshift customs . This is where
we use our wrist bands.
"And then we will take a bus to the airport and at around 12am
Thursday we will fly to Darwin."
On the evacuation flight , cabin crew would not be making direct contact
with evacuees .
Meals were already waiting for passengers at their seats when they
boarded, and Qantas staff remained upstairs.
All those retw·ning to Austra lia on the Qanta s flight will spend two
weeks in quarant ine at the Howard Springs facility, in add ition to the
two weeks in lockdown they've had on the ship.
NIH-001502

Cc: Tracey McNamara ; Caneva, Duane; (b)( ; Dodgen. Daniel
(OS/ASPR/SPPR); DeBord, Kristi n (OS/ASPR/SPPR); Phillips. Sally
(OS/ASPR/SPPR); David Marcozz i; Hepburn, Matthew J CIV USARMY (USA);
Lisa Koon in; Wa rgo Michael ; Walters. Will iam (STATE.GOV): HARVEY,
MELISSA; WOLFE, HERBERT; Eastman, Alexander ; EVANS, MARIEFRED;
Johnson, Robert (OS/ASPR/BARDA); Yeskey, Kevin; (b)(<;>:w, Gary
(OS/ASPR/10) ; Hame l, Joseph (OS/ASPR/10) ; Dean, Charity A@CDPH; Lawler,
James V; Kadlec, Robert (OS/ASPR/10); 'Mart in, Grego ry J
-------- (b)(6) ; Borio. Luciana ; Hanfling, Dan; McDonald. Eric; Wade,

David ; TARANTINO, DAVID A; W ILKINSON, THOMAS; David Gruber
(b)(6) KAUSHIK, SANGEETA; Nathan iel Hupert
-----------
Subject :RE: Red Dawn Breaking , COVID-19 Collaborative, Feb 16 start
South Korea cases are taking off.
S. Korea reports 31 more cases on 2/20; total now at 82
Singapore, Hong Kong , Japan, and South Korea are the new front lines.
Matt er of time befo re travel from those areas will raise concerns.
From: Carter Mecher

Was listening to the discus sion today. There was a discussion about the
shortages of PPE . There was also discussion re N PIs, but I'm not sure
that most folks appreciate that the NPls that have been arrayed as part
of the TLC strategy to reduce disease transmission in the community
NIH-001503
can be leveraged to create safer compartments or spaces by shunting
disease toward the home. By implementing these interventions, one
could reduce the likelihood of disease in workplaces (by home isolation
and home quarantine-- keeping sick employees at home and keeping
employees who are well but potentially infected because someone is
sick in their household, at home). Adding in other social distancing
measures including social distancing at work, helps to reduce
community transmission (adds additional protection to the workplace).
The consequence is shunting disease to the home --120 M different
compartrnents in the US, and making the workplace the safe place.
That is potentially very important for critical infrastructure. The
answer is not PPE for these employees. And why would we expect that
employees in these sectors would have any better IPC with the use of
PPE than we saw with staff on the Diamond Princess?
Healthcare is a key critical infrastructure. It is different from the other

sectors in that it will be attracting patients with COVID like a magnet.
It is hard to imagine how one could makes healthcare a safe
workplace. But it is only hard to imagine how one could do that unless
you begin to look a little closer at the different components of the
healthcare system and the roles each component might play during this
pandemic .
To illustrate this, I took a stab at developing a conops or roadmap to

look at the various pieces of the healthcare system. The shunting of
disease is really fractal. Just as we can look at shunting disease across a
community into one compartment (the home) to make other
compartments safer, we can do the same within our healthcare system-
shunt disease to the acute care area where COVID patients will be
conce ntrated. What are the strategies to do that?
This conops is notional. It is purposely designed for a severe outbreak

with severe disease and assumes that the hea lthcare system must
somehow continue to limp along and continue to care for the
background disease we see during normal times (strokes , AMis,
fractures and trauma, appendicitis, other serious infections, CHF,
diabetic emergencies, psychotic episodes, preeclampsia, complicated
deliveries, end stage renal disease and dialysis, etc.) as well as sustain
outpatients with chronic conditions that require monitoring and care to
keep them well and out of the ER and out of the hospital.
NIH-001504
From : (b)(
To : Richard Hatchett ; Dr. Eva K Lee
Cc: Tracey McNamara ; Caneva, Duane; (b)(6); Dodgen , Dan iel
(OS/ASPR/SPPR); DeBord. Krist in (O5/ASPR/SPPR); Philli ps. Sally
(OS/ASPR/SPPR); David M arcozzi ; Hepburn . Matthew J CIV USARMY (USA);
Lisa Koon in; Wargo Michael ; Walters , Wil liam (STATE.GOV); HARVEY,
MELISSA; WOLFE, HERBERT; Eastman, Alexander ; EVANS, MARl EFRED;
Callahan, M ichael V.,M .D.1 (b)( ~ ;
Johnson , Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary
(OS/ASPR/BARDA); Redd, Johnt(OS/ASPR/S PPR); Hassell , David (Chris)
(OS/ASPR/IO); Hame l, Joseph (OS/ASPR/1O); Dean, Char ity A@CDPH; Lawle r,
_______
James V; Kadlec, Robert (OS/AS PR/ 1O); "M art in, Grego ry J
Qilld.Q.;
(b)(6)..,.· Borio. Luciana; Hanfling, Dan; McDona ld. Eric; Wade.
TARANTINO, DAVID A ; W ILKINSON, THOMAS; David Gr uber
(b)(6]; KAUSHIK, SANGEETA; Nathan iel Hupert
----------
Update for South Korea (see attached) 51 cases; l child
Colombia confirms first case of Coronavirus -

citizen on Japan cruise ship
February 17th, 2020, 09:06 AM
@Stats Alerts
BREAKING: Colombia conf irms fir st case of Coronaviru s Colombia confirm s
fir st case of coronavi rus: citizen wa s on a Diam ond Princess cruise
Sent from Mail for Windows l 0

Sent : Wednesd ay, February 19, 2020 10 :05 AM
NIH-001505
Cc: Tracey McNama ra; Caneva, Duane ; (b)(6); Dodgen, Daniel
(0S/ASPR/SPPR); DeBord , Kri sti n (0S/ASPR/SPPR); Phillips, Sally
(0S/ASPR/SPPR); David Marcozzi ; Hepburn, Matthew J CIV USARMY (USA);
Lisa Koonin; Wa rgo Michae l; Wa lters, W illiam (STATE.GOV); HARVEY,
MELISSA; WO LFE, HERBERT; Eastman, Alexander ; EVANS, MARIEFRED;
Callah an, M ichael V.,M .D.; (b)(6J
Johnson , Robert (0S/ASPR/BARDA) ; Yeskey, Kevin; Disbrow, Gary
(OS/ASPR/BARDA); Redd, Johnt(OS/ASPR/SP PR); Hassell. David (Chris)
(0S/ASPR/ I0) ; Hamel, Joseph (OS/ASPR/10 ); Dean, Charity A@CDPH; Lawler,
James V; Kadlec. Robert (0S/ASPR/10 ); 'Mart in, Gregor y J
------- -
(b)(6) ' ; Borio, Luciana ; Hanfling, Dan; McDonald, Eric; Wade,
~ TARANTINO, DAVID A; W ILKINSON, THOM AS; David Grub er
_________ Cb _ ,; KAUSHIK, SANGEETA; Nathan iel Hupe rt
_ >_<6J
Update on HK (65 cases; no children) and Singapore (84 cases; 49

currently hospitali zed/4 in ICU; still only 4 children (2 asymptomatic /2
hosp ita lized).

To: Richa rd Hatche tt ; Dr. Eva K Lee
Cc: Tracey McNamara ; Caneva, Duane ; (b)(6J; Dodgen, Danie l
(OS/ASPR/SPPR); DeBord, Kristin (OS/ASPR/SPPR); Phill i ps, Sally
(0S/AS PR/SPPR); David Ma rcozzi; Hepburn. Matt hew J CIV USARMY (USA);
Lisa Koon in; Wa rgo Michae l; Wa lte rs, W illiam (STATE.GOV); HARVEY,
MELISSA; WOLFE, HERBERT; Eastman , Alexander ; EVANS, MARIEFRED;
Johnson, Robert (OS/ASPR/BARDA); Yeskey. Kev in; Disbrow. Gary
(OS/ASPR/BARDA); Redd, Johnt(OS/ASPR/SP PR); Hassell, David (Chris)
(OS/ASPR/I0) ; Hamel. Joseph (OS/ASPR/10) ; Dean, Charity A@CDPH; Lawler,
James V; Kadlec, Robert (OS/ASPR/10); 'Mart in, Grego ry J
------- -
(b)(6) ' ; Borio, Luciana; Hanfling, Dan; M cDona ld, Eric; Wad e,
David; TARANTINO, DAVID A; W ILKINSON, THOMAS; David Grube r
_________ Cb _. ,; KAUSHIK, SANGEETA; Nathan iel Hupe rt
_ >_<6J
NIH-001506
As of yesterday, there are 251 Canadians on board the Diamond
Princess , of whom 34 have tested positive.
https://global news.ca/ news/6567907 / c...hi p-canadia ns/

Canada wa lks back expected departure date for evacuees of Japanese cruise
ship
By Staff The Canadian Press
Posted February 19, 2020 7:47 am
Updated February 19, 2020 7:49 am
Global Affairs says the departure date for a plane that w ill carry Canadians
home from a coronavirus-stricken cruise ship in Japan is yet to be confirmed.
Spokeswoman Barbara Harvey says the departure wil l be settled once final
arrangements are made with the Japanese government and the cruise ship
company . A news release from the company operating the Diamond Princess
cruise ship says the Canadian flight has been "shifted 11 to early Friday
morning .
From: Carter Mecher

Cc: Tracey M cNamara; Caneva, Duane: (b)(6): Dodgen. Dani el
(OS/ASPR/SPPR); DeBo rd, Kristin (O5/ASPR/SPPR); Phillips, Sally
(OS/ASPR/SPPR); David M arcozzi ; Hepburn, Matthew J CIV USARMY (USA);
Lisa Koonin; Wargo Mich ael; Walters, Will iam (STATE.GOV); HARVEY,
Callahan, M ichael V.,M .D.f (b)( 6)1
Johnson. Robert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary
(OS/ASPR/BARDA); Redd, Johnt(OS/ASPR/SPPR); Hassell, David (Chr is)
(OS/ASPR/IO); Hame l. Joseph (OS/ASPR/1O); Dean, Charity A@CDPH; Lawle r,
James V; Kadlec. Robert (OS/ASPR/1O); 'Mart in, Gregory J
.__________ Cb
_)_( _,,_,
'· Borio, Luciana; Hanfli ng, Dan; M cDonald, Eric; Wad e,
David; TARANTINO, DAVID A; WILKINSON, THOMAS; David Grub er
------------ (b)(~; KAUSHIK, SANGEETA; Nat haniel Hupert

NIH-001507
621 cases on cruise sh ip (17% of the passenge rs and crew have been
infected).
https://www.channe lnewsasia.com/news ...it ive-12450498
79 more people test positive for COVID-19 on Diamond Princess cruise ship
19 Feb 2020 06:21PM
(Updated : 19 Feb 2020 06 :30PM)
TOKYO: An additional 79 cases of coronavi rus have been discovered aboard

the Diamond Princess cruise ship in Japan, the health ministry said
Wednesday (Feb 19), bringing the total to 621.

To : Richard Hatchett ; Dr. Eva K Lee
Cc: Tracey McNama ra; Caneva, Duane; (b)( ; Dodgen, Daniel
(OS/ASPR/SPPR); DeBord, Kri stin (OS/ASPR/SPPR); Phillips, Sally
(OS/ASPR/SPPR); David Marcozzi ; Hepburn, Matthew J CIV USARMY (USA);
Lisa Koon in; Wargo Michael ; Walters, William (STATE.GOV); HARVEY,
Callahan. M ichael V.•M .D.; (b)(6);
John son, Robert {OS/ASPR/BARDA); Yeskey, Kevin; Disbrow, Gary
{OS/ASPR/BARDA); Redd, Johnt{OS/ASPR/SPPR); Hassell, David {Chris)
(OS/ASPR/1O); Hamel, Joseph (OS/ASPR/1O); Dean, Charity A@CDPH; Lawler,
James V; Kadlec, Robert (OS/ASPR/1O); 'Mart in, Gregory J
( (b)( 6Yil:_; Borio, Luciana; Hanf ling, Dan; McDonald, Eric; Wade,
David ; TARANTINO, DAVID A; WILKINSON, THOMAS; David Gruber
---------- --
(b)(6) ; KAUSHIK, SANGEETA; Nathan iel Hupert
I saw a news s101y yesterday (WashPost) that testing was comp leted.
So we should know in the next coupe of days.
A lso saw a story abou t the 100 or so Americans left behind (44 in
hosp itals and 61 who declined evacuation) .
https://mainichi.jp /engl ish/articles/20200219 /p2g/00m/0in/028000c
NIH-001508
Hard to find data on the stah 1s of those still ho spita lized in Japan.
James made a very important point yesterday. Altho ugh the passengers
are elderly (2,666 passengers) , the crew membe rs are relati vely young
(1 ,045 crew members). James also expected the attack rates to be very
high among the crew member s (they were housed together in a
relatively small space aboa rd the ship, perfect condit ions for explosive
disease transmission). So this combined data on passengers (elderly)
and crew (young and healthy) will be invaluable in terms of helping
understand seve rity . I wou ld think that Japan also realizes how
invaluable this data is. Japan will be in the best position to assess the
impact on the crew, since they will know the results oflab screening
and hospitalization of all + crew members (as well as the monitoring
qua rantine of the rest of the crew over the next 14 days). But now that
the passengers are being dispersed, it will be important for several
nations to share the data on these passengers - it is really our best
chance to understand severity (would need collabo ration of the US,
Canada, Australia, Ho ng Kong, Japan).
Sen t from Mail for Windows 10
From: Richa rd Hat chet t

To: Dr. Eva K Lee; Carte r M eche r
Cc:Tracey McNama ra; Caneva, Duane; (b)(6) Dodgen , Daniel
(OS/ASPR/SPPR); DeBord, Kri st in (OS/ASPR/SPPR); Philli ps, Sally
(OS/ASPR/SPPR); David Marcozz i; Hepburn, M att hew J CIV USARMY (USA);
Lisa Koon in; Wa rgo M ichae l: Wa lte rs. Will iam (STATE.GOV): HARVEY.
Callahan, M ichael V.,M .D.1 (b)(6) ·
Johnson, Ro bert (OS/ASPR/BARDA); Yeskey, Kevin; Disbrow , Gary
(OS/ASPR/BARDA) ; Redd, Johnt (OS/ASPR/SPPR); Hassell, David (Chris)
(OS/ASPR/ 10) ; Hamel, Joseph (OS/ASPR/ 10) ; Dean , Charity A@CDPH; Law ler,
(b)(6) '; Borio, Luciana; Hanfli ng, Dan; McDonald, Eric; Wade,
--------
David; TARANTINO. DAVID A; W ILKINSON. THOM AS; David Grube r
(b)(6); KAUSHIK, SANGEETA; Nat haniel Hupert
----------- ·
NIH-001509
I understandfrom contacts at WHO that Japan is testing everyone on
the Diamond Princess , so we should have a complete accounting of that
closed population (and thus a nice dataset to inform severity estimate s).
From: Dr. Eva K Lee (b)(6)

----------
Sent: 19 February 2020 03:54
To: Carter Meche rr------- Cb
=>=c6J
=~
Cc: Tracey McNamara I (b)(6))>;Caneva, Duane
Cb)(6))>;Richard Hatchett
======:::,~;-::--:--
(b)(6)jDodgen, Daniel (OS/ASPR/SPPR)
======::::!...-~ ~ (b)(~ DeBord, Kristin (OS/ASPR/SPPR)
=======;~::,;--~
(b)(6) ]>; Phillips, Sally (OS/ASPR/SPPR)
=======~':;;:' ---------~~
-------- CbH6)] David Marcozzi
Hepburn, Matthew J CIV USARMY (USA)
CbH6)]>;
CbH6J>;
Lisa Koonin f (b)(6)J>; Wargo Michae l
CbH6)}>; Walters , William (STATE.GOV)
-:.======= (b
'===
)='(6J
'5i'
t---:-
·H -:-'.
A~R-:-'.
V::::
EY-:-,-:--:
M ELISSA! CbH6))>;
WOLFE, HERBERT ! CbH6))> ; Eastman, Alexander
-------'=====; (b,::::
)(~(6))
,;-
:>-; =EV
-:-A
:-:N
-:-S
:-, -:-
M-:-'.
A:-:R
~IEFRED
(b)(6)j; Callahan, Michael V.,M.D.
(b)(6)};
(b)(6) , Johnson,Robert (05/ASPR/BARDA)
=======~=
---------
CbH6))>; Yeskey, Kevin!
,:..;____ -=======~~~,.......-----
(b)(6)j
Disbrow, Gary (OS/ASPR/BARDA)
.,,:....
__ CbH6J>;Redd,
.:.......::==:::::::;,:;;------:-:---
Johnt (OS/ASPR/SPPR) (b)( >; Hassell, David (Chris)
(OS/ASPR/I0) (b)( >; Hamel, Joseph (OS/ASPR/10)
(b)(6)>; Dean, Charity A@CDPH
~======:=!!'======..::::-..::::-..::::-_-_-~=
(b)(6))>; Lawler, James V
-------~~ (b)(6)}>;
----------
Kadlec, Robert (OS/ASPR/10)1 (b)(6J:>; 'Martin, Gregory J
(b)(6))Borio, Luciana
(b)(6),>; Hanfling, Dani CbH6) 1>; McDonald, Eric
)J>; Wade, David I
(b)(1> (b)(6b;
TARANTINO, DAVID Ar CbH6))>; WILKINSON,
THOMAS( Cb)(6)]; David Gruber
'-:-:---:--::-:'.::-:.:========='c~;;---:--:--:--:- (b v>; KAUSHIK,
- )_(6>:
_,.....
SANGEETAI (b)(6)_ ; Nathaniel Hupert
----!:====~=":"---- (b)( 6)j
Just talked to a lab director in Hong Kong U. They tested 3,600

passengers and crews on World Dream in 24 hours , all using the definitive
RT-PCR test. The tests were performed in government labs . They
disembarked everyone after 3 days (a ll came back negative). And they are
still performing contact tracing and monitoring on all at the moment.
NIH-001510
old news:
https ://www .scmp.com/news /hong -kong/healt h-

environmen t/article/304 97 14/coronavi rus-3600 -passe ngers -and-crew-
members
For surveillance , regional hospitals do an initial screening , then suspected

cases are tested by a governmental lab for confirmation.
Schools are still closed for another month.
(b)(6)
mobile:
----- (b)(6)
Sent with ProtonMa il Secure Emai l.
------- Original Message -------
On Tuesday , February 18, 2020 7:56 PM, Carter Mecher

-------- (b) < ·> wrote:
Japan inching toward mitiga tion
Abe urges people with cold-

like symptoms to avoid
work, school
Today 06:30 am JST 24 Comments
NIH-001511
TOKYO
Prime Ministe r Shinzo Abe on Tuesday advised peop le

across the country not to go to work or schoo l if they
develop cold-like symptoms, as the country grapples with
the spread of a new coronavirus origina ting in China.
Workplaces in the country, known for their long hour s,

need to encourage people to take days off without
hesitation if they do not feel well , Abe said.
"The first thing that I want the people of Japan to keep in

mind is to take time off school or work and refra in from
leaving the hou se if they develop cold-like symptoms such
as fever," Abe told a meeting of a government task force on
the viral outbreak.
Te leworking is an "effect ive alternative" to help prevent the

viru s from spreading fmther, Abe said .
He made the remarks as the governmen t is scrambling to

contain the virus that originated in Wuhan, with more
people with no obvious link to Ch ina gett ing infected in
Japan.
The global outbreak of the disease called COVID -19 has

prompted some even t organizers in Japan to rethink their
plans for hosting mass gather ings.
The number of confi rmed cases in Japan has topped 600,

including over 500 passengers and crew on the Diamond
Princess , a quarantined cruise ship docked at Yokohama
near Tokyo with more than 3,000 confined.
The steady rise in infections in various pa1ts of Japan has

raised public concern , prompting the health ministry to ask
people who develop symptoms such as a temperature of
37.5 C or higher fo r at least four days to cons ult loca l
health care centers and go to designated hospital s. The
period is set shorte r for the elderly , those with underlying
condi tions and pregnan t women.
As Tokyo and othe r major cities in the country are

notor ious for packed rush -hour trains, commute rs have
been encouraged by a government panel of medical experts
to go to work earlier or later than usua l as the risk of
infect ion is increased in crowds .
NIH-001512
On Tuesday, Fujitsu Ltd and Hitach i Ltd said they are
expa nding teleworking , though Japane se companies overall
have been slow to introduce it.
Sent from Mail for Window s 10
From: Tra cey McNama ra
To: Dr. Eva K Lee ; Canev a, Du ane
Cc: Cai1er Mecher ; Richar d Hatchett ;

(bH6); Dodgen, Daniel (OS /ASPR/SPPR t
-------
DeBord , Kristin {OS/ASPR/SPPR ): Phillips. Sally
(OS/ASPR /SPPR) : David Ma rcozzi ; Hepburn . Matthew J
CIV USARMY (USA) ; L isa Koonin ; Wargo Michae l;
Walter s, Will iam (STATE.GOV) ; HARVEY . MELISSA ;
WOLFE, HERBER T; Eastman. Alexander ; EVANS,
MARIE FRED ; Callahan, Michael V.,M .D.;
---------------- (b) (6) Johnson .

Robe rt (OS/ASPR/BARDA) : Yeskey. Kevin ; Disbrow.
Gary (OS/ASPR/BARDA ); Redd. Johnt(OS/ASPR/SPPR ) :
Hassell, David (Chris) (OS/ASPR/1O) ; Hame l, Jos eph
(OSI ASPR /1O) : Dean, Charity A@CDPH ; Lawler, James
V; Kadlec, Robe rt (OS/ASPR/1O) : 'Martin, Gregory J
--------- (b)(6) •; Borio, Luc iana; Hanfl ing. Dan ;

McDon ald, Eric; Wade, David ; TARAN TIN O, DAVID A ;
\VILKINSO N, THOMAS ; David Gruber
----------
Nathaniel Hupert
(bH6); KAUSHIK, SANGEETA ;
Subject: RE: Red Dawn Br eaking, COVID -19

Collaborat ive, Feb 16 sta1t
I must be psychic. This just came

out. Like I said - Oxford Nanopore
NIH-001513
Sequencers are being sent to
China!
Tracey
https://protect2.fireeye.com/url?
k=0a860669-56d21f15-
0a863756-0cc47adc5fa2-
4fc7adc96dfbde59&u=https://glo
balbiodefense.com/newswire/ox
ford-nanopore-sequencers-
have-left-uk-for-china-to-
support-rapid-near-sample-
coronavirus-sequencing-for-
outbreak-surveillance/
To: 'Caneva, Duane'
-- CbH > ·
'
; Richard
Carter Mecher
Hatchett
Cb><6l; Dr. Eva K Lee
(b)(6)
Cc~
> Dodgen, Daniel
(0 /ASPR/SPPR) ________ Cb>
_<6);
DeBord, Kristin (OS/ASPR/SPPR)
<6) ; Phillips , Sally
Cb>
(OS/ ASPR/SPPR) CbH6);
David Marcozzi
> ; Hepburn ,
----------
Matthew J CIV USARMY (USA)
CbH6)
CbH6) • Lisa Koonin

..------ '
__________ <6)>; Wargo Michael
Cb>
Cb>< ,• Walter s '
NIH-001514
William (STATE .GOV) _________ Cb
_><
_6J;
HARVEY, MELISSA
HERBERT ____________
Eastman, Alexander
WOLFE
Cb><6J·
' ' CbH6),.
,
EV ANS,
Cb><6)>;
------------
MARIEFRED
(b)(6)
>.
--------------
Callahan , Michael V.,M .D. '
(b)(6)
Johnson , Robert (OS/ASPR /BARDA)

Cb>< >- Yeskey Kevin
Cb><6)>;
'
Disbrow, '
Gary
(OSI ASPR/BARDA) _______ Cb> _<6J>;
Redd, John (OS/ASPR/SPPR)
Cb><6)>; Hassell, David (Chris)
(OS/ASPR/IO) _______ Cb>
_<6);
Hamel, Joseph (OS/A SPR/1O)
Cb>< > · Dean Charity
' ' CbH6J>- Lawler ,
r--- ,
CbH6); K adl ec,

James V
-----
Robert (OS/ ASPR/1O) (b)(6)
'Martin, Gregory J Cb>

<6)
Cb>< > · Borio Luciana
'
Cb>< ; Hanfling, '
Dan
p ; McDonald , Eric
Cb><6J
CbH6); ---- }>. Wade David

CbH6)
TARANTINO ' ,'
DAVID A Cb><6J> •
--------------
WILKINSON, THOMAS
'
Cb>< >· David
Grub er Cb>< ) '
p-; KAUSHIK,
Cb><6)
SANGEETA Cb><6)t ;
Nathaniel Hupert Cb><
Subject: RE: Red Dawn Breaking, COVID-19
Collaborative, Feb 16 start
NIH-001515
Hello all - Clearly , the most important
thing of all is a reliable , real-time
diagnostic test that can differentiate
between flu and COVID-19. CDCs test
kits were recalled because states said
they were not working. Now they have
to remanufacture the faulty reagent.
How long will that take? If and when
more kits are available , will they be
available in sufficient quantity that all
health care providers will have access?
In all of this, I have not heard anyone
talk about the Nanopore MinION
technology that has been used for
Ebola. What gives??? It is field
deployable and can be run in-house.
Hospital labs can run thousands of
samples at once. It gives results of all
viruses, bacteria, protozoa , fungi, in 2
hours. We all know this technology is
quite promising. Why aren't we going
gangbusters to validate this rapid
technology and get it to all
diagnosticians? If ever there was a time
to invest in a diagnostic technology ,
this is it!
Tracey
NIH-001516
From: Dr. Eva K Lee (b)( >
To : Caneva, Duane
---------- (b) (6)
Cc: Carter Mecher Cb)(6) Richard

;
_________________
Hatchett CbH6);> ; Tracey McNamara
(b) ((ij•,
Dodgen, Dan iel (OS /ASPR/SPPR)
Cb)(6) > ; DeBord, Kristin
(OS/ASPR /SPPR) Cb)C6)> ; Phillip s,
Sally (OS/ASPR/SPPR) Cb)C6); David
Marcozzi Cb)(6); Hepburn,
-------------------
Matthew J CN USARMY (USA)
---- >; L isa Koonin

Cb)(
; Wargo Michael
(b)(6) Walters , William
(STATE . V) Cb)(6) ; HARVEY ,
MEL ISSA CbH6)> ; WOLFE,
HERBER Cb)(6); Eastman,
______________ ;EVANS,
(b)( > ,·
Callahan, Michael V .,M.D .
(b)(6)
Cb)(6) Johnson,
(b) (6) .
Robert (OS/ ASPR/BARDA)
Yeskey, Kevin (b)(6)
..------
; Disbrow, Gary
'
(OS/ASPR /BARDA)
----....,, Cb>(6) ; Redd,
Johnt(OS / ASPR/SPPR) Cb)
(6) ; Hassell ,
David (Chris) (OS/ASPR/ IO) (b)(6) > ;
Hame l, Joseph (OS/ASPR/ 1O) (b)(
Dean, Charity A@CDPH (b)(6) p ;

Lawler, James V ....,..._,..., Cb)<6Y
du>· Kadlec
=-Cb)
~'C6)v
~ > ; 'Martin,
'
Robert (OS/ ASPR/ 1O)
Gregory J (b)(6)
Borio, Luc iana Cb)C ; Hanfling , Dan

(b)(6) > ; McDonald, Eric
--- Cb)(6) ; Wade, David
THOMAS
(b)(6) > ; TARANT INO , DAVID A
Cb)C6)> ; WILKINSON,
(b)(6)•
(b) (6))
___
,
NIH-001517
Cb><6J; KAUSHIK, SANGEETA
Cb)(6); Na thani el Hu pert
========~ (b)
~(6)
~-
Subject: RE: Red Dawn Breaking, COVID-1 9
Carter,
Just listened in to our state COV ID-19 response effort

updat e. Georgia has no COVID-1 9 cases yet , and hence
they remain in the conta inment period where they place
medium-risk individuals on supervised monitoring of home
quarantine, advise them to take temperature daily and
report any respiratory symptoms (24/7). Educate them not
to show up in ED, or any place without facilitation. To
avoid potential disease spread, they are advised to remain at
home.
The next stage will be mitigation when a confirmed case is

reported. That will initiate the pandemic planning and
community-based NPI will be considered. This includes
social di stancing -- telework , teleclass , etc.
I assume at cities where there are confirmed local COV ID-

19 cases, the public health leaders have already begun the
mitigation phase now and hence are practicing some degree
of social distancing and rolling out telework, and various
strategies to protect health in the population and to
maintain business con tinuity already. Is that true or they
are still wa iting to execute their operations?
There are not many tests needed here in Georgia. But rapid
robust and reliable testing kits (Tracey's reporting of
current bottleneck) remain critical in all communities with
positive cases. If we have such mean s, test ing can also be
conducted (sampli ng) on some flu-like cases at strategic
selec ted cities also.
NIH-001518
On Tuesday , February 18, 2020 2:20 PM, Dr. Eva KLee
--------- (bH > wrote:
Duane, Yes. (asymptomatic or mild symptoms)

this is the worry at the very start, and it
remain s the most critical. Hence even 1% of
infection for us -- can balloon out of proportion
and we can't handle . Shedd ing not only during
infection period, bur also post-recove ry. It's a
very long time line that we have to deal with.
Then you have all the university siudents .
Students travelled to China and came back to
school, they asked hea lth service if they
needed to quaran tine or take any actio n,
theadvice -- no need. Those are missed
opportunities. Again, seasonal influenza
affects 8-10% Americans, 0.7% of those
infected requir ed hospitalization , and morality
is roughly 0.1 %. So it is easy to "calculate" all
these numbers backwards ... So 20% ofCOVID-
19 infected may need hospitalization, mortality
is 10-30 times higher than seasona l flu. How
much can we tolerate before anyone would
spring into action? Keep in mind, some begin
to infect rapidly upon contracting the virus, the
incubat ion is so short (and so long) and
infectious too dming that period (with much
being unknown).
Ca1ter, I think you will expect hetero geneous

approaches from different communit ies in the
overall response strategy, since it depends on
the socia l setting and the demographics and
more imp ortant ly the local resources. We have
to optimize for sure.
NIH-001519
On Tuesday , February 18, 2020 1:51 PM ,

Caneva, Duane Cb)(6)
wrote:
Seems to me a big challenge will

be asymptomatic or mild
symptoms in kids, spread through
the schools, shed to parents who
staff both categories acute and
non-acute care clinics. If there are
several days of asymptomatic
shedding, how do you prevent
spread to the vulnerable, high risk
patients in each category?
Wi H mi ld symptoms drive
complace nt compliance?
From: Carter Mecher

(b)(6) >
Sent: Tuesday , February 18, 2020

1:32 PM
Subject: RE : Red Dawn

Breaking, COVID-19
CAliTIO~: This email originated from

outside of OHS. DO NOT click links or
open attachment s unless you recognize
and/o,r trust the sender. Contact your
component SOC w ith questions or
concerns.
NIH-00152 0
My thinking is evolving in terms
of healthcare system response.
Initially I described how I would
refocus the outpatient clinics away
from COVID care and leverage
the NPis of isolation and
quarantine to help keep the
workplace safe (for the clinic staff
and other patients) rather than a
strategy that employs PPE. I
would only use the outpatient
clinic staff to help with
telephone /home care support of
those patients under home
isolation or home quarantine--to
help with compliance /adherence to
isolation and quarantine,
monitoring their health, and
optimizing the care of their other
chronic medical conditions (to
keep them out of the ER and the
hospital). But as I thought more
about this, it occurs to me that this
can be generalized beyond
outpatient clinics.
I would think about dividing our

healthcare system into two big
pieces: ( 1) acute care (EDs, acute
inpatient care, critical care); and
(2) non-acute care including
outpatient clinics (PC/Family
Practice , pediatrics , OB/GYN,
medical specialty, surgical
specialty , dental, mental health,
rehab, etc.), as well as other
inpatient areas (inpatient mental
health, substance abuse, nursing
homes , hospice care, memory
care, assisted living, etc.).
Inpatient surgery (and I suppose
labor and delivery) is part of acute
care, but for this outbreak, it
probably best belongs bundled
with the other non-acute inpatient
NIH-001521
areas. I would anticipate that the
tripwire for implementing NPis
(community transmission), will
also be the trigger for healthcare
systems to dial down or tum off
elective admissions (primarily
surgical) to free up acute care and
ICU/monitored meds. The most
effective way to protect these non-
acute areas is by shunting
potential COVID pat ients away
from these areas and either
providing this type of care while
the patients is hospitalized in acute
care or thru telephone care/home
care for patients with mild illness
receiving care at home. And the
most effective way to shunt these
patients away from non-acute care
areas is thru the implementation of
early and aggressive NPis of
isolation of the ill and home
quarantine of household contacts
(and not fit testing the world and
passing out PPE that we don't
have) .
From: Carter Mecher
Sent: Tuesday , February 18, 2020

11:02 AM
To: R ichard Hatchett; Caneva,

Du ane; Tra cey McN amara; Dr.
Eva K Lee ; (b)(6)
(b)(6)
--------- ; Dodge n,
Danie l (OS/ASPR/SPPR) :
NIH-001522
DeBord. Kristin
(OS/ASPR/SPPR) ; Phill ips, Sally
(OS/ASPR /SPPR) ; David
Marcozzi; Hepburn, Matthew J
CIV USARMY (USA) ; Lisa
Koonin; Wargo Michael; Walters,
William (STATE .GOV) ;
HARVEY, MELISSA; WOLFE ,
HERBERT ; Eastman, Alexander ;
EV ANS, MARIEFRED ; Callahan,
M ichael V .,M.D .;
(b)(6)
------,------ Johnson,
Robe rt (OSI ASPR/BARDA) ;
Yeskey, Kevin ; D isbrow, Gary
(OS/ASPR/BARDA) : Redd, John
(OS/ ASPR/SPPR) : Hassell, David
(Chli s) (OS/ASPR/10) ; Hamel,
Joseph (OS/ASPR/ 10) : Dean,
Charity A@CDPH; Lawler, James
V; Kadlec, Robert (OS/ASPR/10) :
'Martin, Gregory J
--------- (b)( ' ; Borio,
Luciana; Hanfli:ng,Dan;
McDonald , Eric ; Wade, David ;
TARANTINO, DAVID A;
WILKINSON , THOMAS; David
Gruber
(b) (6);
KAUSHlK , SANGEETA ;
Na than iel Ru pert
Subject: RE: Red Dawn

Breaking, COVID-19
More puzzle pieces re the cruise

ship outbreak.
• About
2/3rds of
the
passeng ers
NIH-001523
have been
tested so far
(2,404 out
of 3,711).
• 61
Americans
opted to
remam
onboard and
not be
evacuated.
Japan has completed tests for all

passengers and crew aboard the
ship as of Monday, but the
results for the last batch of tests
aren 't expected until
Wednesday, the day that the
quarantine is slated to end. So far,
results are back for 2,404
passengers and crew , out of the
3,711 who were on board the ship
when the quarantine began on Feb .
5.
Japanese Health Minister

Katsunobu Kato said Tuesday that
people who have tested negative
for the virus would start leaving
on Wednesday, but that the
process of releasing passengers
and crew won't be finished until
Friday , according to the
Washington Post.
The remaining 61 American

passengers on the DP who opted
not to join the evacuat ion will not
be allowed to return to the US
until March 4, according to the
American embassy in Tokyo. The
governments of Australia, Hong
Kong and Canada have also said
they would evacuate passengers.
NIH-001524
Elsewhere, Japan confirmed three
more cases of the virus. This tim e,
they were confirm ed in
W akaya ma, a pr efec ture in eas tern
Japan.
Sent: Tuesday, February 18, 2020

10:50 AM
To: Rich ard Hatchett; Caneva ,

Duane ; Tracey McN amara ; Dr.
Eva K Lee ; Cb) (6)
..,________ __>; Dodgen,

Daniel {OSIASPR/SPPR);
DeBo rd, Kristin
(OSIASPR /SPPR) : Phillips, Sally
(OSIASPR /SPPR) ; David
Mar cozz i; Hepbu rn, Matthew J
Koonin ; Wargo M ichael ; Walters.
W illiam {STATE.GOV) ;
HARVEY, MELISSA ; WOLFE,
EV ANS. MARIEFRED ; Callahan,
Michael V.,M .D .;
(b)(6)
; Johnson,
-------
Robert (OSI ASPR/BARDA) ;
Yeskey , Kevin ; Disbrow, Gary
(OSIASPR/BARDA) ; Redd, John
(OSIASPR/SPPR) ; Hassell, David
(Chris) (OSI ASPR/10) ; Hamel,
Jose ph (OSI ASPR/ IO) ; Dean.
Charity A@CDPH; Law ler, James
NIH-001525
V ; Kadlec, R obert (OSIASP R/1O):
'Martin, Grego ry J
--------- (b)(6l '; B orio,
Lu ci ana ; H an fling , Dan ;
M cDon ald, Er ic ; Wade , Dav id;
TARAN TI NO , DA YID A ;
WIL KINS ON, THOMAS ; Dav id
Grube r
(b)(6)
KAUS HIK , SANGEETA ;

Nath aniel Rupe rt
Subject : RE: Red Dawn

Break ing , COVID-19
Co llaborative, Feb 16 start
Maybe he was misquoted or it was

a typ o- perhaps what was meant
was 4 per 100 (and that would be a
low estimate)
Sent from Mail for Window s l 0
From: Richard Hatchett
Sent: Tuesday, Februaiy 18, 2020

10:45 AM
To : Ca rter M echer; Caneva ,

Dua ne; Tra cey McNamara ; D r.
Eva K Lee ; (b)(6)
'----'------..J-
> ; Dodgen,
Danie 1 (OSIAS PR/S PPR);
DeBo rd, Kristin
(OS/ASPR/SPPR) : P hillips, Sally
(OS/ASPR/S PPR) ; Da vid
NIH-001526
Marcozz i; Hepburn, Matthew J
CIV USARMY (USA); Lisa
Koon in; Wargo Michae l; Walters ,
William (S TATE .GOV) ;
HARVEY , MEL ISSA ; WOLFE ,
HERBERT; Eastman, Alexan der;
EV ANS , MARIEFRED ; Callahan,
Mic hael V .,M.D. ;
(b)(6)
Johnso n,
--------
Robe rt (OSI ASPR/BARDA) ;
Yeskey, Kev in; Disbrow, Gary
(OS/ASPR/BARDA): Redd, John
(OSI ASPR/SPPR): Hassel l, David
(Chr is) (OS /ASPR/ 1O) : Hamel,
Joseph (OS/ASPR/ 1O) : Dean ,
Charity A@CDPH ; Lawler, James
V ; Kadlec, Robert (OS /ASPR/ 1O) ;
'Martin , Gregory J
--------- CbH '; Borio,
Luci ana; Hanfling. Dan ;
McDo nald, Er ic; Wade . David ;
TARAN TINO, DAV ID A;
WILKINSON, THOMAS ; David
,___________
Gruber
(b) (6).,
KAUSHIK, SANGEETA;
Nathanie l Hupe rt

Breaking, COVID -19
Co llaborative , Feb 16 start
No te that 4/ 100,000 woul d imply

that only 440 peop le have been
infec ted.
From:Carter Mec her

(b)(6)
NIH-001527
Sent: 18Febmary202015: 26
To: Caneva, Duane

(b)(6)
Tracey McNamara
Cb)(6) ; Dr.
EvaKLee
> ; Dodgen,
--------
Danie l (OS/ ASPR/SPPR)
(b)(6) > ;
DeBord , Kristin
(OS/ASPR /SPPR)
(b) (6).;
Ph illips, Sally (OS / ASPR/SPPR)

--------
Marcozzi
Cb)< > ; David
(b)(6)
>; Hepburn, Matthew J CN

USARMY (USA)
(b)(6)
>; Lisa Koonin
--------
Michael
Cb)(6) ; Wargo
)(6)
Walters , William
(STATE .GOV )
(b)(
HARVEY, MELISSA
(b)(6) >• ,
WOLFE,HERBERT
(b)(6)
Eastman, Alexander
(b)(6) >
; EV ANS , MARIEFRED
)(6)
Callahan , Michael
V. ,M.D.
_________ ; Johnson,
Robert (OS/ ASPRJBARDA)
(b)(6) > ·
,
NIH-001528
Yeskey, Kevin
(b)(6)
Disbrow , Gary
(OS/ ASPR/BARDA)
---------
John (OS/ASPR/SPPR)
(6) > ; Redd,
Cb>
------- Cb>Hassell ,
(6) >
David (Chris) (OS /ASPR / IO)
;
(b) (6Ji;
Hame l, Jos eph (OS/ ASPR/IO)

CbH6) >; Dean,
---------
Charity A@CDPH
CbH>·
Richard Hatchett '
(b)( >;
Lawler, James V
(b)( ;
Kadlec , Robert (OS / ASPR/IO)

(b)(6)
'Marti n, Gregory J
(b)(6)
Luciana
------
Hanfling, Dan
(b)(
McDonald, Eric
(b)(6)
; Wade , David
(b)( >;
TARANTINO, DAVID A
(b) (6) > ;
WILKINSON , THOMAS
(b)(6)
David Gruber
KAUSHIK , SANGE ETA

>·
-----------
Nathaniel R upert
(b)(
'
(b)( >

Break ing , COVID-19
Collaborative , Feb 16 start
NIH-001529
WHO estimates 80% of patient
with COVID-19 have mild disease
and recover; that implies that 20%
have severe disease. WHO
estimated that 14% develop
pneumonia and 5% are considered
critical. [We were estimating that
12% of cases needed
hospitalization (so 88% did not)
and 2% needed ICU care (with
mortality of patients with
pneumonia in the ICU generally
between 15%-50% so a CFR of
0,3%-1.0%). Also noet his
comment on sparing children. The
latter comments are reminiscent of
the early comments of public
health leaders during the 1918
pandemic-always minimizing. I
have no idea where an attack rate
of 4 per 100,000 comes from.]
https://www .channelnewsa sia.com

/news/world/covid-19-
coronavirus -who-china -patien ts-
ha ve-mild-disease-124450 10
GENEY A: The new novel

coronavirus only causes mild
disease for 80 per cent of infected
patients, said the World Health
Organization on Monday (Feb
17). Speaking to reporters , WHO
chiefTedros Adhanom
Ghebreyesus said that 14 per cent
of patients would have severe
diseases such as pneumonia.
"Around five percent of cases are

cons idered critical with possible
multi-organ failure, septic shock
and respiratory failure and, in
some cases, death," he added.
NIH-001530
Tedros also said there were
"relative ly few cases" among
children and more research was
needed to understand why.
The WHO chief also warned

against "blanket measu res" over
the novel coronavirus outbreak,
pointing out the epidemic outside
of China was only affecting a
"tiny" proportion of the
population.
Ryan said that even at the

epicentre of the crisis in the city of
Wuhan in centra l Hubei Province,
the "attack rate" - a measure of the
speed of spread of the virus - was
four per 100,000.
"This is a very serious outbreak

and it has the potential to grow,
but we need to balance that in
terms of the number of people
infected . Outside Hubei this
epidemic is affecting a very, very
tiny , tiny proportion of people," be
said.
T edros also referred to an apparent

decline in new cases of the disease
in recent days but said that the
trend "must be interpreted very
cautiously".
Sent from M ail for Windows 10
From: Carter Mecher
NIH-001531
Sent: Tues day, Feb ruary 18, 2020
10: 15 AM
To : Canev a, Du ane; Tr acey

McNamara ; Dr. Eva K Lee ;
(b)( 6)
,__ ______ Dodgen,

..z-> ;
D anie l (OSI ASPRJSPPR ) :
DeBord , Kr istin
(OS/AS PR /SPP R) ; Phill ips, Sa lly
(OS/AS PR/ SPPR) ; David
CIV USARMY(USA ); Lisa
Koonin ; Warg o M ichael ; Walters ,
Wi lliam (STA TE .GOV) ;
HAR VEY. MELISSA ; WO LF E.
EV ANS , MARIEFRED ; Ca llahan,
Michael V .,M.D .;
(b)(6) ;
Cb)( ; Johnson,
-------
Robe rt (O S/ASPR/ B ARDA) ;
Yeskey, Kev in; D isbrow, Gary
(OS/ASPR/BARDA ): Redd. John
(OS/ASPR/ SPPR) : Hassell. Davi d
(Chris) (OS/ASPR/1O): Hame l,
Joseph (OS/ASPR/ 1O): Dean,
Ch arity A@CDPH ; Rich ard
Hatchett ; Lawler, James V;
Kadlec , Rober t (OS / ASPR/1O);
'Martin, Gregory J
CbH6)'; Borio,
---------
Luciana; Hanfling. Dan;
McDonald, Eric: Wade . David;
TARANTINO , DAVID A ;
WILK INSON, THOMAS ; David
Gru ber
(b)( 6);
KAUSHIK,SANGEET A ;
Nathan iel R upert
Subject: RE: R ed D aw n
Br eaking, COVID -19
Co llaborativ e, Fe b 16 sta1t
NIH-001532
Update on cruise ship, Japan
(implementing NPis) and South
Korea (evacuating passengers)
https://www .channelnewsas ia.com

/news/asia/covid l 9-japan-virus -
testing -comple te-quarant ine-
cru ise-ship- 12445788
88 more people test positive for

COVID-19 on Diamond Princess
cruise ship.
The new cases take the total

number of confirmed cases on the
Diamond Princess to 542 - the
biggest cluster outside the
epicentre in China . [Almost 15%
of the crew and passengers have
been infected.]
Japan has also confirmed at least

65 cases domesticalJy, including
many involving people with no
history of recent travel to China.
Author ities have said the virus is
being transmitted locally now, and
have asked citizens to avoid
crowds and non-essential
gather ings. On Monday, the
amateur portion of the Tokyo
Marathon, which had been
expected to attract some 38,000
runners, was cancelled. Only elite
athletes wilJ now be able to take
part. The public celebration for
Emperor Naruh ito's birthday has
NIH-001533
also been scrapped over virus
fears.
South Korea will send a

presidential aircraft on Tuesday to
fly back four nationals and one
Japanese spouse, an official told
reporters. There are 14 South
Koreans on board in total, but the
othe r ten have declined to be
evacuated from the ship because
they live in Japan, the Yon.hap
news agency reported.
V ietnam NPis
https://protect2.fireeye .com/url?k=
5a2fa482-067bbdfe-5a2f95bd -
0cc4 7adc5fa2-
a5b86bc 1581cf39c&u=https ://saig
oneer. com/sai gon-health / ...ue-to-
cov id- 19
Due to COVID-19: As of
February 15, all 63 provinces and
cities in Vietnam have extended
their schoo l closing time, 56 of
which - including Saigon -
have announced that schoo ls will
be closed until the end of
Fe bruary. Ho Chi Minh City's
People Committee proposing
students stay at home until the end
of March.
NIH-001534
Sent: Tuesday, February 18, 2020

7:10AM
To: Canev a, Duan e; Tracey

(b)(6)
Cc·<
\,
.__ .i- _____ _._
>; Dodgen,
Daniel {OSIASPR/SPPR) ;
DeBo rd, Kristin
(OSI ASPR/SPPR) ; P hillips, Sally
(OS/AS PR/SPPR) : David
Marcozzi ; Hepburn, M atthew J
Koonin ; Wargo M ichael ; Walter s,
Willi am (STATE.GOV) ;
HARVEY, MELISS A; WOLFE ,
HERBER T; Eastm an, Alexande r;
EV ANS, MARIEFRED ; Callahan ,
Michael V .,M.D .;
(b)(6)
------- ; Johnson,
Robert (OS/ASPR/BARDA) ;
Yeskey , Kevin; Disbrow , Gary
(OSI ASPR/BARDA) ; Redd, John
(OS/ASPR/SPPR) : Ha ssell, Davi d
{Chris) {OS/ASPR/1O); Hamel,
Joseph (OS/ ASPR/1O) ; D ean,
Charity A@CDPH ; Richard
Hatchett; Lawle r, James V;
Kadlec, Rober t (OSI ASPR/1O):
'Martin, Gregory J
-------- CbH6) Borio,

Luci an a; Hanfling , Dan;
McDonald. Eric ; Wade, David ;
TARAN TINO . DAVID A;
WI LKINSON , THOM AS; David
Gruber
(b)(6);
KAUSHrK, SANGEE T A;
Nathan iel R upert
NIH-001535
Breaking, COVID-19
Collaborat ive, Feb 16 start
More things to keep an eye on

(attached links of stories and
trans lations of news reports):
Yesterday a 5th flight of evacuees

from Hube i arrived in Japan.
There were 65 on board and 7
peop le were symptomatic (11 %).
Watch for the number of
confirmed - it will provide a point
est imate of prevalence of COVID-
19 in Hubei as of yeste rday.
Sounds like this is the last flight
japan will accept.
Yesterday , Japan provided an

update of all cases in Japan:
• 53 people
were
infec ted in
Japan and
trave lers
from China
• 454
passengers
and crew
members on
cruise ships,
and
• 13 people
returned on
NIH-001536
charter
aircraft.
• 520 people
in total.
• 23 people
were
determined
to be
seriously ill
Watching for other countr ies to

evacuate passengers from cruise
ship
• 256
Canadians
on the
Diamond
Prince ss
cruise ship
• 32 tested +
(as of Feb-
17)
• A plane
chartered by
the
Canadian
gover nment
has left for
Japan to
evacua te its
nationals
aboard a
virus -hit
cruise ship
off
Yokohama ,
TV Asahi
reported on
Tuesday,
citing a
NIH-001537
tweet by
Canada's
foreign
minister
Can't find anything about other

countries evacuating passenge rs
(UK, Hong Kong , Italy, etc.)
La st thing . Am seeing stories

from Japan re patients going from
clinic to clinic with resp
symptoms and fever and being
confomed . They are finding
nosocomial transmission- so
underscores the concerns outlined
in the proposal I outlined for re-
aligning outpatient clinics .
From: Ca rter Mecher
Sent: Monday, February 17, 2020

10:39 PM
To: Canev a, Duane ; Tracey

McNamara: Dr. Eva K Lee :
(b)(6)
(b)(6)
Dodgen,
---------
Dan iel (OSI ASPR/SPPR) :
DeBord, Kristin
(OS/ASPR/SPPR): Phillips, Sally
(OS/ASPR/SPPR): David
Mar cozzi ; Hepbu rn, Matthew J
NIH-001538
Koonin ; Wargo Mic hael ; Walters .
W illiam (ST ATE .GOV) ;
HAR VEY , ME LISSA ; WOLF E,
EV ANS . MARIEFRED ; Callahan,
M ich ael V. ,M .D .;
; Johns on ,
--------
Robe rt (OSIASPRJBARDA) ;
Yeske y, Ke vin ; Disbrow, Gary
(OSI ASPR/BARDA) : Redd , John
(OSIASPR/SPPR) ; Has sell. Davi d
(Chris) (OSIASPR/10) : Hamel.
Joseph (OSI ASPR/ 10 ): Dean ,
Charity A@CDPH ; Rich ard
Hatchett ; Lawle r. James V;
Kad lec. Rober t (OS / ASPR/IO) ;
'Martin, Gregory J
-------- Cb)(6); B orio,

Luci an a; Hanfling. Dan ;
McDo nald, Eric; Wade. David ;
TARANTINO , DAVID A;
WILKINSON, THOMA S; Davi d
Gruber
(b)(6)
KA USH lK, SANGEETA ;

Nathan iel Hupert
Subject: RE: R ed Dawn

Breaking, COVI D- 19
Co llaborat ive , Feb 16 stait
I really need help thinking tbru the

testing piece (screening for
COV ID-19). How do we protect
the staff in outpatient clinics
(where all the ILI is typically
seen) and conserve PPE by
shifting all the mi ld illness away
from clinics and toward patien ts'
homes using telephone
careltelehealth and home
healthcare and emp loying home
NIH-001539
isolation for those who are
infected and voluntary home
quarantine for otherwise well (but
exposed and potentially infected)
household contacts? Having all
the suspected patients coming in
to clinics to be screened rea lly
defeats the purpose. So how
would very large numbers of
outpatients get screened? Home
screening? Drive thru screening?
Or creating a free standing
screening facility for rapid
screening? Has anyone thought
this thru (how you screen for
disease plus promote
adherence /compliance to home
isolation and home quarantine and
shift outpat ient care of patients
with mild disease to
telephone /home care to protect
outpatient clinic staff? Looking for
practica l solutions .
Just to remind you , here are the

estimates of demand (assuming we
would need to screen all ILI)-
about 88K per day in primary care
clinics across the US.
I
US Data
US population 325,700 ,000
Hospital Beds 924,107
ICU Beds 81,790
Hospital Admissions 36,353,946.00
ER Visits 145,600,000
Family Practice/PC Visits 481,963,000
Total Deaths 2,813,503
A Day in the US
Hospital Admissions 99,600
NIH-001540
Inpatient Census (85% occupancy) 785 ,491
ICU Census (85% occupancy) 69,522
ER Visits 398,904
Family Practice /PC Visits 1,320,447
Deaths 7,708
Current Background of Illn ess Simila r to COVID-19
2019-20 Flu Season MMWR Week 5 ILI Rate 6.7%
1.4M hospitalizations annually for pneumo nia
Medicare Average LOS Pneumonia 6 days
55,672 pneumonia & influenz a death s annually
Daily Hospital Admissions Pneumonia 3,836
Hospital Census Pneumonia 23,014
Da ily ILI cases seen in ERs 26,727
Dai ly ILi cases seen in FP/PC clinics 88,470
Dai ly pneumonia & influenza death s 153
Sent from Mai l for Window s 10

9:04 PM
To: Canev a, Duane ; Tracey

(b)(6)
Cc:C
b
.___,_ _____ > ; Dodgen,..,r-
Dan ie I (OS/ ASPR/SPPR) :

DeBord , Kr istin
(OS/ASPR /SPPR) ; Phill ips, Sally
NIH-001541
(OS/ASPR /SPPR) : David
Marcozzi ; Hepb urn, Matthew J
CIV USARMY (USA) : Lisa
Koonin ; Wargo M ichael ; Walters,
William (STATE .GOV) :
HAR VEYL MELISSA; WOLF E,
HERB ERT ; Eastman , Alexander ;
EVANS, MARTEFRED; Callahan,
Michael V .,M.D .;
,_ ______ ; John son,

Rob ert (OS/ASPR/BARDA) ;
Yeskey, Kevin ; Disbrow, Gary
(OSI ASPR/BARDA) : Redd , John
(OS/ASPR /SPPR) : Ha ssell, David
(Chr is) (OS/AS PR/IO) : Hamel,
Joseph (OS/AS PR/IO) : D ean,
Charity A@C DPH ; Richard
Hatchett ; Lawle r, James V;
Kad lec, Rober t {OS/ASPR/10) ;
'Marti n, Gregorv J
-------- Cb)(6) ' ; Bo rio,
Luci an a ; Hanfling. Dan ;
McDonald, Er ic; Wade. David ;
TARAN TINO , DA YID A;
WI LKINSON, T HOM AS ; Davi d
Grube r
(b)(6)•
KAUSHIK, SANGE ETA ;

Nathan iel Hupert

Breaking, COVID-19
I tinkered with the strategy for

integrating outpat ient clinics and
hospital s for the care of COVID-
19 patient s. Proposing this for my
system.
NIH-001542
From: Car ter Mecher

7:17 PM
To: Caneva , Duane ; Tracey

(b)(6)
(b)(6)
Dodgen,
---------
Danie l (OS/ASPR/SPPR) ;
DeBord, Kristin
(OSI ASPR /SPPR) : Phill ips, Sa lly
(OS/AS PR/SPPR) ; David
Marco zzi; Hepburn, Matthew J
Koonin ; Wa rgo Michael ; Walters,
W illiam (STAT E .GOV) ;
HERBER T ; Eastman, Alexander ;
EV ANS, MARIEFRED ; Callahan .
Michael V.,M.D .;
(b)(6)
-------- Johnson.
Robe rt (OS/ASPR/ BARDA) ;
Yeskey, Kev in; Disbrow, Gary
(OS/ASPR/BARDA) ; Redd , John
(OS/AS PR/ SPPR) : Hassell, David
(Chr is) (OS/ASPR/ 1O); Hamel,
Joseph (OS/ASPR/ 1O); Dean,
Charity A@CDP H ; Richard
Hatchett; Lawler, James V;
Kadlec, Robert (OS /ASPR/IO) :
'Martin, Gregory J
Cb)( '; Borio,
----------
Luci an a; Hanfl ing. Dan ;
McDonald, Er ic; Wade . David ;
TARANTINO, DAVID A;
WILKINSON,THOMAS ; David
Gruber
NIH-001543
(b)(
KAUSHIK, SANGEETA ;
Nathan iel Hupert

Breaking, COVID-19
More details on evacuation of

American passengers aboa rd the
cru ise ship .
Total evacuated: 177 + 151 = 328
bttps: //www .usatoday .com/story /tr

ave l/cruises /2020 /02/ 17/coronavir
us -diamond -princess -evacuees -
test-pos itive -allowe d-fly-united-
state s/ 4 783787002 /
Fourteen evacuees from the

Diamond Princess cruise
ship quarantined in Japan were
allowed to fly back to the United
States Sunday de spite testing
positive for coronav irus, the U .S.
State Departme nt and Health and
Hwnan Services said in a jo int
stateme nt. The evacuees were not
symptomatic.
"These individuals were mov ed in

the most expeditious and safe
manner to a specialized
containment area on the
evacuat ion aircraft to isolate them
in accordance with standar d
protoco ls," the
statemen t, pub lished Sunday ,
read.
NIH-001544
The State Department was
unaware the individuals had
coronavirus when they were being
removed from the ship; they had
tested negative just a few days
before, Robert Kadlec, the
assistant secre tary for
preparedness and response at the
U.S. Department of Health &
Human Services, said on a phone
call with repmiers.
"If those results had come back

four hours earlier before we'd
started to disembark the ship and
before these people were evacuees
within an evacuation system, then
it would've been a different
discussion." Dr. William Walters,
director of operational medicine at
the U.S . Department of State, said
on the call.
Kadlec said that individuals

received multiple screenings when
moving from ship to bus to
plane and a more extensive
medical assessment upon arrival.
Two charter flight s carry ing

the Diamond Princ ess passenger s
landed at military bases in
Ca lifornia and Texas overn ight,
starting the clock on a 14-day
quarantine period to ensure those
passengers don't have
coronavirus . In tota l,
approximately 380 Americans
were on board the Diamond
Princ ess ship for the duration of
the cruise and quarant ine at sea.
'Something went awry': Why did

US break Diamond Princess
coronavirus quaran tine?
NIH-001545
One plane carrying American
passengers touched down at Travis
Air Force Base in northern
California just before 11:30 p.m.
Sunday local time. A second flight
arrived at Lackland Air Force
Base in Texas around 2 ½ hours
later, early Monday.
The California flight had 177

people on it, seven of whom tested
positive for coronavirns, Walters
said. An additional three people
were isolated during the flight for
fever. Upon arrival, 171 stayed in
Travis while six traveled to
Omaha.
It's unclear which passengers were

transferred there and whether
initial tests were positive or
whether they were at risk for the
vrrus.
The Texas flight had 151 people

board and included the other seven
who tested positive for
coronavirus. Two additional
passengers were isolated on
account of fever . All passengers
who tested positive for
coronavirus then moved on to
Omaha.
The aircraft design allowed

passengers to sit in isolation
thanks to a plastic divider at the
tail of the aircraft.
13 high-risk
passengers awa it test
results at Nebraska
Medical Center
NIH-001546
Officials from the University of
Nebra ska Medical Center and
Nebraska Medicine confirmed that
they are assessing 13 adults at
their quarantine and
bioconta inment facility in Omaha.
"Late last night at about 2 or 3

a.m., we were asked to bring some
individuals here who had either
tested positive or had a high
likelihood of testing positive
because of symptoms they were
exhibiting ," said Dr. Chris
Kratochv il, the exec utive director
at the Univers ity ofNebraska
Medical Center ' s Global Center
for Health Security.
Twelve of them are housed in the

quarant ine cente r while one man
was transferred to the hospital's
biocontainment unit for testing
and observat ion because of
symptoms including cough, fever,
shortness of breath,
lightheadedness and an
undisclosed chron ic cond ition that
wou ld make him particularly
vulnerable to the COVID-19
VITUS.
"He is doing good and in stable

condition at this time ," reported
Shelly Schwedhelm , Nebraska
Medicine's executive director of
emergency management and
biopreparedness .
She went on to note that "the folks

in the quarantine center have all
been tested, and we're waiting for
those results ."
She added that the other 12 are

isolated in "very nice rooms with
WiFi , TV and a sma ll refrigerator
NIH-001547
- a lot of the amenities at hotels
but with eng ineering contro ls" to
prevent contaminated air from
escapmg.
Their test results , which are due

back Monday afternoon, will
determine whether the patients
will be allowed to see their
spouses or leave their rooms.
Regardless of whether they test

positive or negative, all of the new
arrivals will spend at least 14 days
in the facility , and any who test
positive will likely stay longer,
said Dr. Mike Wadman, the co-
medical director of the National
Quarantine Unit.
Kratochvil says it's possible that

they may be asked to take more
patients should more of the
Diamond Princess passengers now
in quarantine at the airbases test
positive.
Dr. Anthony Fauci , director of the

Nationa l Institute of Allergy and
Infectious Diseases at the Nat ional
Institutes of Health, told the USA
TOD AY editorial board and
reporters Monday that the original
idea to keep people safely
quarantined on the ship wasn't
unreasonable. But even with the
quarantine process on the ship,
virus transmissio n still occurred.
"The quarantine process failed ,"

Fauci said. "I'd like to sugarcoat it
and try to be diplomatic about it,
but it failed. People were getting
infected on that ship. Something
went awry in the process of the
quarantining on that ship. I don't
NIH-001548
know what it was, but a lot of
people got infected on that sh ip."
USA TODAY reached out to

Princess Cruises for clarification
on how many Americans from the
ship have the virus.
From: Caneva, Duane

4:51 PM
To : Carter Meche r; Tracey

(b)(6)
Dodgen,
Daniel (OS/ASPR/SPPR):
DeBo rd, Kris tin
(OS/ASPR/SPPR) ; David
Koonin; Wargo Mic hael ; Walters,
William (STATE.GOV):
HERBERT ; Eastman , Alexander ;
EVANS , MARIEFRED ; Ca llahan ,
Mic hae l V .,M.D. ;
(b)(6)
------,------ Johnson,
Robert (OSI ASPR/BARDA);
Yeskey , Kevi n; Disbrow , Gary
(OSI ASPR/BARDA) : Red d, John
(OS/ASPRJSPPR); Hassell, David
(Chris) (OSI ASPR/ 1O); Hame l,
NIH-001549
Joseph (OSI ASPR/ 1O); Dean ,
Char ity A@CDP H ; Rich ard
Hatchett ; La wle r, James V;
Kadle c, Rober t (OSI ASPR/1O);
'Martin , Gregory J
CbH6l'; Borio ,
----------
Luciana; Hanfling. Dan;
McDonald, Eric; Wad e, David ;
TARAN TINO, DA YID A ;
WILKINS ON, THOMAS ; David
Gruber
(b)(
KAUSHIK, SANGEETA;
Nath an iel Hupert
Subject: Re: Red Daw n Breaki ng,

COV ID- 19 Collaborative , Feb 16
start
+ Bob Glass
From: Carter Mecher

(b)(

4:47:38 PM
To: T racey McNamara
Cb)C6J> ; Dr.
EvaKLee
Duane
Dodgen, Dan iel (OS/ASPR/SPPR)

Cb)C6)
b ;
DeBord, Kristin
(OS/AS PR/ SPPR)
NIH-001550
________ (b) (6)
Phillips, Sally (OS/ASPR/SP PR)

,.
--------
Ma rcozzi
Cb)< > ; David
(b)(6)
>; Hepburn, Matthew J CIV

USARMY (USA)
(b)(6)
>; Lisa Koonin

Cb)(6) Wargo
---------
Michael
(b)(6)
>; Walters, William

(STATE.GOY )
(b)( >·
'
HARVEY, MELISSA
(b)(
WOLFE , HERBERT
(b)(6)
Eas tman, Alexande r

(b) (6) >
; EVANS, MARIEFRED
(b)(6)
>; Callahan , Mic hael

V.,M.D.
Johnson, Robert
(OS/AS PR/BARDA)
________
Ye skey, Kevin
Disbrow , Gary
(b)(
(b)(6) > ;
>·
,
(OS/ASPR/BARDA)
--------
John (OS/ASPR/SP PR)
Cb> Redd,
(6) > ;
-------- Hassell,
Cb>
(6)
David (Chris) (OS/ASPR/10 )
(b)(6)
Hame l, Joseph (OS/ASPR/ 10)

--------
Charity A@CDPH
Cb)(6) ; Dean,
(b)(6)
NIH-001551
Richard Hatchett
(b) (6} .
'
Lawler, Jame s V
(b) (6) ;
___________
Kadlec, Robert (OS/ASPR/10)
(b) (6)1,•
'Martin, Grego ry J
(b)(6)
Lu ciana
-------
Hanfling , Dan
(b)(6) > •
McDonald,Eric '
(b)(6)
; Wade , David
(b)(6)
TARANTINO, DAVID A
(b)(6) > •
'
WILKINSON, THOMAS
(b)(6)
David Gruber
(b)(6)
------------
KAUSHIK , SANOEE TA
>·
'
(b)( >·
Nathan iel Hupert
'
(b) (6)

Breaking, COVID -19
Co llaborat ive, Feb 16 stait
('AL Tl o:-,,i:This email originated from

outside of DHS. DO NOT click links or
open attachmentsunJess you recognize
and/or trust the sender. Contactyour
component SOC with questions or
concerns.
A correction . Shou ld not have

included breakdown of
hospitalized since we have spotty
data 9or could have used a range).
Only solid data we have is numb er
NIH-001552
confirmed (58), number in
hospital (44), and number in ICU
(.:::1). Mix of hospital pat ients is
unknown (from the Singapore data
the ratio of hospitalized to ICU
has ranged from 6: 1 to 13: 1 from
two data points).
So estimates of severity looking

only at the American passengers :
~400 total American passengers
58 confirmed to have COVID-19
12 Asymptomatic
(20%)
46 Symptomatic (80%)
(44 cases actually hospitalized)
~2% of total
cases requiring ICU admiss ion ( 1
case)
Expected mortality
for patients with
pneumorua
adm itted to ICU
(15-50%) ;
assuming 2% of
those who become
infected with
COVID-19 require
ICU care, these
mortality rates
equate to a CFR of
0.3%-1.0%
NIH-001553
Sent: Monday , Februa ry 17, 2020

4:15 PM
To: Tracey McNam ara ; Dr. Eva K

Lee
(b)(6)
--------
Du ane; Dodg en , Danie l
Caneva,
(OS/ASPR/ SPPR) ; De Bo rd,

Kri stin (OSI AS PR/ SPPR) ;
Phi llips, Sally ( OSI ASPR/ SPPR ):
David Marcozz i; Hepburn,
Matthew J CIV USARMY (USA) :
L isa Koon in; Warg o M ichael ;
Walters, W illiam (STATE .GOV) ;
HARVEY. MEL ISSA ; WO LF E.
HERBERT ; Eastm an, Alexande r ;
EVANS, MARIEFRED; Call ahan ,
Michael V .,M.D.;
(b)(6)
-------- John son,

Rob e rt {OS/ASPR/BARDA) ;
Yeskey . Kevin ; Disbrow . Gary
(O S/ASPR/B ARDA) : Redd, John
(O S/AS PR/ SPPR) ; Ha ssell, David
{Chris) {OS/ASPR/ 1O): Ha mel,
Joseph (OS/AS PR/1O) : D ean,
Charity A@C DPH ; Ri chard
Hat chett ; Lawler, Jame s V;
Kad lec, Robert (OS / ASPR/1O) ;
'Mart in, Gregorv J
------------ Cb)< ; Borio,

Lu ciana; Hanfling. Dan;
McDonald , E ric; Wade, David ;
TARAN TINO. DAV ID A;
WI LKINS ON , TH OMAS ; David
Grube r
(b)(6) ;
KA USHIK. SANGEE TA ;
Na than iel R upert
NIH-001554
Breaking, COVID-19
Latest data from Singapore (77

cases; 4 children, 2 are
asymptomatic) and Hong Kong
(60 cases; no children)
More puzzle pieces .
Singapore status:
h ttps://protect2 .fireeye .com/url?k=
f6750fe4-aa21 1698-f6 753edb-
0cc4 7adc5 fa2-
76d29cc40fd8c03f&u =https: //ww
w.moh .gov .sg/news-
highligh ...tion-confirmed
Update on condition of
confirmed cases
To date, a total of 24 cases have

fully recovered from the infection
and have been discharged from
hospital. Of the 53 confirmed
cases who are still in hospital,
most are stable or improving. Four
are in critical condition in the
inten sive care unit.
[Ratio of hospitalized to ICU of

53/4 or ~ 13:1] Consistent with
estimates in earlier emai l. [On
Feb - 12 Singapore reported that 8
patients were in ICU.]
NIH-001555
From: Carter Mecl1er

2:57PM
To: T racey McNam ara ; Dr . Eva K

Lee
Cc: Canev a, Duan e; Do dgen,

Daniel (OS/AS PR/SPPR) :
DeBord, Kristin
(OS/ ASPR/SPPR); P hillips, Sally
(OS/ASPR/SPPR): David
Mar cozzi; Hepburn, Mat thew J
CIV USARMY (USA ) : Lisa
Koonin ; War go M ichael; Walters ,
William (STATE .GOV) :
HARVEY, MELISSA; WOLFE,
HERBERT; Eastman, Alexander ;
EVANS . MARIEFRED; Callahan,
Michael V.,M .D .;
(b)(6)
-------- Johnson,
Robert {OS/ ASPR/BARDA) ;
Yeskey, Kevi n; Disbrow, Gary
(OS/ASPR/BARDA): Redd, John
(OS/ASPR/SPPR): Hassell, David
(Chris) (OS/ASPR/1O): Hame l,
Jose ph (OS/ ASPR/ 1O): Dean,
Charity A@CDP H ; Rich ard
Kadlec, Robert (OS/ASPR/1O):
'Marti n, Gregorv J
Cb) Borio,
(6)
---------
Luci an a; Han fling, Da n;
McDo nald, Er ic; Wade, Da vid ;
TARAN TINO , DAVID A ;
WILKINSON, THOMAS; David
Gruber
NIH-001556
(b)(6);
KAUSHIK, SANGEETA ;
Nathan iel Hupert ;
(b)(6)

Break ing, COVID-19
Try ing to estimate severity by

bringing a number of pieces
together.
The Diamond Princess Cruise

Ship had a crew of l ,745 and
2,666 passengers (total pf3 ,7 11)
Approximately 400 of the
passengers are Americans (11 %) .
Severa l days ago (Feb-13) we
attempted to estimate disease
severity using the current data
being reported by the media
(number of confirmed cases and
ICU cases) as well as data on the
outbreak in Singapore (number of
confinned cases, number
hospitalized , and number in ICU)
(see attached Word file).
Given the additional information

becoming available (includ ing
more specific information being
reported by the media on the
n umbers of Americans infected), I
was interested in an updated crude
estimate of severity (and to see
how well the early predictions of
severity matched with what was
being reported by the media on
illness in the Americans. See
NIH-001557
latest re the cruise ship outbreak
below (two stories). We can glean
from these stories that the number
infected is now up to 454. And 14
positive passengers were included
among the Americans who were
evacuated to the US. Canada,
South Korea , Italy and Hong Kong
announced Sunday that they
would also an-ange charter flights
to evacuate their citizens. A few
additional pieces of data. News
reports yesterday stated that 73 of
the 355 confirmed cases from the
cruise ship were asymptomatic
(20%). Also , yesterday the media
quoted Dr. Fauci that the total
number of Americans who were
confirmed to have COVID
yesterday and who remained at
hospitals in Japan at 44.
Assuming that this number does
not include the 14 confirmed cases
that were evacuated, suggest s that
the total number of Americans
with confirmed COVID is 58. An
ear lier news report from Feb-12 re
a couple from California, noted
the husband was in the ICU in
Japan (so at least 1 American in
the ICU). [" ...remained in a
hospital intensive care unit and
has been able to communica te
with his family, his wife said in a
phone interv iew from the ship,
where she remained in
quarantine. "
https://protect2 .fireeye. com/ur l?k=
5b0 l 4cc3-075555bf -5b0 l 7dfc-
0cc4 7adc5fa2-
5be62cfl a816fc6d& u=https: //web.
archive.org/web/202002 12093725
/https://www .ocregister .com/2020/
02/11/sout hern-california -man-on-
cru ise-sent-to-a-hosp ital-in-tokyo-
NIH-001558
with -a-high-fever-tested-for-
coronaviru s/ ]
So, piecing all the data together:
The ~400 Americans account for

11% of the 3,711 passengers and
crew of the Diamond Princess.
The 5 8 confirmed cases among

Americans account for 12% of the
454 total confirmed COVID cases
Assuming that proportion of

asymptomatic cases in Americans
is similar to the proportion of
asymptomatic cases for the entire
ship (73/355 or 20%), we would
estimate the number of Americans
with asymptomatic infection at
~12. Symptomatics would be 46.
If 2% of cases result in ICU
admission (based on earlier
estimates on Feb -12 where 4 ICU
cases were reported with 203 total
confirmed cases), we would
expect ~9 ICU cases overall with
454 infected. Media repo1ts from
today note 19 of the passengers
are "seriously ill, with some of
whom treated in intensive care
units." (Would be helpful to
quantify "some" - from the earlier
data, we would estimate about half
that number would require ICU
care at some point). For the 54
Americans confirmed to have
COVID, we would estimate 1
would require ICU care if 2% of
cases required ICU care (we are
already aware of at least 1
American who was receiving ICU
care in Japan).
NIH-001559
So estimates of seve 1ity looking
only at the American passengers:
~400 total American passengers
58 confirmed to have COVID-19
12 Asymptomatic
(20%)
46 Symptomatic (80%)
~ 55% of total
cases mildly ill (hospitalized for
isolation only) (31 cases)
~25% of total
cases acute ly ill requiring inpatient
care ( 15 cases)
~2%
of total cases requiring ICU
admission ( 1 cases)
Exp
ecte
d
mort
ality
for
patie
nts
with
pneu
mon
la
admi
tted
to
ICU
(15-
50%
);
assu
mm
g
NIH-001560
2%
of
thos
e
who
beco
me
infec
ted
with
co
YID
-19
requ
ire
ICU
care,
thes
e
mor
talit
y
rates
equa
te to
a
CFR
of
0.3
%-
1.0
%
Those estimates fit pretty well

with the estimates from Feb-13 .
To firm up these numbers it would
be useful to have actual numbers
from Japan on ICU admissions,
number requiring mechanical
ventilation, number in the hospital
because they are acutely ill, and
number in the hospital because of
isolation only (mildly ill or
asymptomatic). Also would be
helpful to have more granular
NIH-001561
information on the Americans
(hospita l data in Japan including
number acutely ill, number
needing ICU admission , and
number only in the hospital for
isolation). Wou ld also be critical
to gather/compile the same
infonnation from Canada, South
Korea, Italy, Hong Kong , and
other nations as they also evac uate
their citizens. The cruise ship is a
circumscribed population where it
is possible to get a handle on
severity fairly early in an
epidemic . The limitation though,
is the population on board that
ship is elderly (so need to be
careful about genera lizing to the
entire population). But it is the
best data we have.
The reason why th is is so

important is decisions re the
implementation ofNPis depend
upon severity (the more severe the
more intense the NPis). The
sooner we have a more accurate
assessment of severity , the better
for making plans for NPis.
Sto1y # 1
https ://protect2 .fire eye .com/url?k=

fb4e 1b73-a7 1a020f-fb4e2a4c-
0cc4 7adc5fa2 -
6b 70ca 76908c 81a4&u=https: //ww
w3.nhk.or.jp/news/html/202002 17
NIH-001562
/kl 00 12289341000 .html?utm int=
news contents new s-main 00 I
Translation
New virus cruise ship confirmed

99 new infections
February 17, 2020 18:54
A new outbreak of the coronavirus

was confirmed on February 17,
with 99 new passengers and crew
members infected on a cruise ship.
As a result, 454 passengers and
crew members of cruise ships
have been infected, of which 19
are severely affected.
According to the Ministry of

Health, Labor and Welfare, a total
of 99 new passengers, including
85 passengers and 14
crewmembers, were revealed on
March 17 on the cruise ship
"Diamond Princess" anchored in
Yokohama Port. Among them,
there are 43 Japanese.
This means that a total of 1723

passengers and crew members
were inspected on the cruise ship,
and a total of 454 infection s were
confirmed.

Health , Labor and Welfare, 19 of
the confim1ed individuals are
seriously ill, some of whom are
being treated in intensive care
units.

Health , Labor and Welfare, the
Minist1y of Health , Labor and
Welfare said that infections were
confirmed one after another on
NIH-001563
cruise ships. Need to be analyzed
quickly."
The Ministry of Health, Labor and

Welfare has a policy to conduct a
virus test on all passengers and
crew members remain ing on
board, and those who have a
negative result will be asked to
leave the ship after the 19th.
Story #2
Fourteen peop le who were

evacuated from the Diamond
Princess cruise ship and flown
back to the United States on
charter flights tested positive
fornovel coronavirus , according to
a joint statement from the US
Departments of State and Health
and Human Services.
The passengers are among the

more than 300 people removed
from the ship, which is docked off
the Japanese port city of
Yokohama , Sunday night and
flown to milita1y bases in the
Un ited States .
US officials were notified that

they had tested positive for
coro naviru s during the evacuation
process, after passengers had
disembarked the ship, the agencies
said in the joint statement
Monday . The passenge rs had been
tested two to three days before the
NIH-001564
evacuation flights, the statement
said.
"After consultation with HHS

officials, including experts from
the HHS Office of the Assistant
Secretary for Preparedness and
Response, the State Department
made the decision to allow the 14
individuals, who were in isolation,
separated from other passengers,
and continued to be asymptomat ic,
to remain on the aircraft to
complete the evacuation process,"
the agencies said.
One charter flight carrying

evacuated Americans arrived at
Travis Air Force Base near
Fairfield, Californ ia, around 11:28
p.m. loca l time Sunday. A second
anived at Joint Base San Antonio-
Lackland in San Antonio, Texas at
3:56 a.m . local time Monday.
The passengers who tested

positive were isolated from the
other passengers during the
flights, the statement said. And all
passengers are being "closely
monitored" throughout the flight.
"Any who become symptomatic

will be moved to the specialized
conta inment area, where they will
be treated," the statement said.
After the flights land , any

passengers that developed
symptoms on the flights and those
who had already tested positive
will be transported to "an
appropr iate location for continued
isolation and care ."
NIH-001565
The remaining passengers will
remain under quarant ine for 14
days.
Passengers arriving to Travis Air

Force Base will be housed in the
same facility as evacuees who
arrived from Wuhan ear lier this
month, a spokesperson for the
base told CNN. New evacuees will
be kept in a separate area of the
Westwind Inn on the base, the
spokesperson said.
Before the announcement about

the infected flight passengers,
some Americans aboard the
Diamond Princess said they didn't
want to take a chance being
evacuated for fear they would be
subject to possible infect ion.
Sacramento resident Matthew

Smith told CNN affiliate KOVR
that he would rather deal with
issues in Japan than be evacuated
and quarantined in the United
States.
"We decided we would j ust face

whatever consequences here rather
than exposing ourselves to that
situation ," Smith told the
affi liate ."It kind of didn't make
any sense if the us was fearful that
these were infected people which
is why they're going to quarantine
them for anot her 2 weeks to have
thrown them all together"
Smith's wife Katherine Codekas

was met with some surprise when
she told authoriti es that she and
her husband weren't going to go
with the other American evacuees,
KOVR reported.
NIH-001566
"They came back around again
and I said no we're not going and
they very sincerely wis hed us luck
but there was a little look of
surprise on their face ," Codekas
explained to the affi liate.
"You know, it's not like we're the

last helicopter off the roof top in
Ho Chi Mihn City ," she told
KO VR . "We're on a boat and
we're watching peop le go away
and people just make different
choices about how they want to
confront the virus."
From: Carter Mecher

Sent: Monday , February 17, 2020
11:00 AM
To: Tracey McNa mara ; Dr . Eva K

Lee
Cc: Canev a, Duane ; Dodgen,

Daniel (OSIASPR/SPPR );
DeBord , Kristin
(OS/AS PRJSPPR) : Phill ips, Sally
(OS/AS PRJSPPR) ; David
Marcozzi ; Hepb urn, Matthew J
CIV USARMY (USA): Lisa
Koonin ; Wargo Micha el; Walters,
William (STA TE.GOV) :
HARVEY, ME LISSA; WOLFE ,
HERBERT ; Eastm an, Alexander ;
________
EV ANS. MA RIE FRED ; Ca llahan .
Michae l V .,M.D .;
(b) (6) ,.
NIH-001567
Cb)C ; Johnson,
--------
Robe rt (OS/ASPR/BARDA) ;
Yeskey, Kevin ; D isbrow, Gmy
(OS/ASP .R/BARDA) ; Redd, John
(OS/ASPR/SPPR) ; Hassell, David
(Chris) (OS/ASPR/10); Hame l,
Joseph (OSI ASPR/10) : Dean ,
Charity A@CDPH ; Richard
Hatchett ; Lawler, James V;
Kad lec, Robert (OS / ASPR/ IO) ;
'Martin, Gregory J
Cb)(6); Bor io,
--------
Luci ana; Han fling, Dan ;
McDona ld, Eric; Wade , David ;
T ARANTfNO, DAVID A;
WILKINSON, THOMAS ; David
Gruber
(b)(6);
KAUSH CK, SANGEE TA ;

Nathaniel Ru pert

Breaking, COVID-19
Collaborat ive, Feb 16 stait
Attac hed is Bob Glass' origina l

paper- his co-autho r was his
high-schoo l age daugh ter.
Here is a link to anothe r pape r.
Glass RJ, Glass LM, Beye ler WE,

Min HJ. Targeted social
distancing designs for pandemic
influenza. Emerg Infect Dis [serial
on the In ternet]. 2006 Nov [date
cited].
http: //dx.do i.org/ 10.3201/eidl 211.
060255
NIH-001568
From: Carter Mecl1er

9:59 AM
To: T racey McNam ara ; Dr . Eva K

Lee
Cc: Canev a, Duan e; Do dgen,

Dan iel (OS/AS PR/SPPR) :
DeBord, Kristin
(O S/ ASPR/SPPR); P hillips, Sally
(OS/ASPR /SPPR) : Da vid
Mar cozzi; Hepburn, Mat thew J
CIV USARMY (USA ) : Lisa
Koonin ; War go M ichael; Walters ,
W illiam (STATE .GOV) :
HARVEY, MELISSA; WOLFE,
HERBERT; Eastman, Alexander ;
EVANS. MARIEFRED; Callahan,
Michael V.,M .D .;
(b)(6)
-------- Johnson,
Robert {OS/ ASPR/BARDA) ;
Yeskey, Kevi n; Disbrow, Gary
(OS/AS PR/BARDA) : Red d, John
(OS/AS PR/ SPPR) : Hassell, David
(Chris) (OS/ASPR/1O): Hamel,
Jose ph (OS/ ASPR/1O): Dean,
Charity A@CDP H ; Rich ard
Kadlec, Robert (OS/ASPR/1O):
'Marti n, Gregorv J
Cb)(6) Borio,
---------
Luci ana; Hanfling, Dan;
McDo nald, Er ic; Wade, Da vid ;
TARAN TINO , DAVID A;
WILKINSON, THOMAS; David
Gruber
NIH-001569
(b)(6);
KAUS HI K, SANGEETA ;
Nathan iel Hupert
Subject: RE: R ed Dawn

Breaking , COVI D-19
Collaborative , Feb 16 start
This is the origi nal graph of Bob

Gla ss' data. He modeled the
various interventions alone or in
combination. Along one axis are
the social distancing measures
from doin g nothing, to ju st closing
schools but allowing kids to mix
in the community , to social
distancing of ki ds in th e
community but keep ing school s
open , to only social distancing of
adults in the community , to
closing school s and adults socia l
distancing, to kid s and adult s
socia l distancing in the
community, to closing school s and
socia l distancing of kid s in the
community, to a combo of all 3.
Along the other axis are other
interventions including doing
nothing, to quarantine (Q) ,
treatm ent of the ill wit h antivirals
(T), proph ylaxis of con tacts (P),
and variou s combinations. We
observed what we called a " cliff
effect" or phase tr ansition or a
discontinuity once you closed
scho ols and implemented social
distanc ing among kids. The effect
was non -line ar and drama tic. As a
consequence we began a deep dive
to better understand the sch ool
env ironme nt (includi ng the
NIH-001570
transportation system half the
school age kids use each day) and
school age kids. An unsung hero
in all this was Lisa Koonin (who
was at CDC at the time). If
Richard birthed TLC, Lisa kept
the baby alive in the neonata l
ICU.
We still have much to learn about

this virus. Thus far, it seems to be
sparing kids (just like SARS). We
have been monitoring the reports
from Ch ina as we ll as the detailed
data we can see from Hong Kong ,
Singapore , and Japan - the
numbers of kids remain very low
and disease appears to be mild.
Nonet heless, TLC (and the NPis)
is focused on reducing disease
transmission (effective ly
decreasing Ro )- the interventions
are rea lly agnostic to sever ity. It is
why CDC had to scale the
implementation of TLC (later
called CMG) to severi ty. Despi te
the abse nce of severe disease in
kids , we really are still in the dark
in tem1s of the amount of
asympto matic disease or mild sub-
clinical disease in kid s becau se we
just haven ' t been able to look.
I never forgot this gra ph of the

data from Bob Glass and the
inflection point that was observed
when the combo of closing
schools and social distancing of
kids was imp lemented in his
model. Although closing schools
is complicated by its 2nd and 3 rd
order impacts , it is actua lly a
pretty clean intervent ion in tenns
NIH-001571
of actually pulling the trigger
(much cleaner than the other
component s ofTLC) . If this
outbreak proves to be as severe as
our initial estimates, we should
think long and hard before
dismi ssing the early
implementation of th is strategy
(closing schools and social
distancing of kids).
From : Cart er Mecher

8:57 AM
To: Trac ey M cN amara ; Dr . Ev a K

Lee
Cc: Caneva, Duane ; Dodgen,

Danie l (OS/ ASPR/SP PR) :
DeBo rd, Kr istin
(OS/ASPR/ SPPR) ; David
Ma rcozz i; Hepburn , Matthew J
Koonin ; Warg o M ich ael ; W alters,
Willi am (STA TE .GOV) :
HARVEY , MELISSA ; WOL FE,
HERB ER T ; Ea stman , Alexander ;
EV ANS, MARIEFRED ; Ca llahan,
M ichael V. ,M.D .;
(b)(6)
--------- ; Johnson,
Rob e rt (OS/ASPR/BARDA) ;
Yeskey, Kev in; Disbrow , Gary
(OS/ASPR/BARDA ): Redd, John
(OS/ASPR /SPPR) ; Ha sse ll. Davi d
(Chr is) (OS/ASPR/ 1O) : Hamel,
NIH-001572
Joseph (OSI ASPR/ 10 ); Dean ,
Char ity A@CDP H ; Rich ard
Hatchett ; La wle r, James V;
Kadle c, Rober t (OSI ASPR/1O);
'Martin , Gregory J
(b)(6) ' ; Borio ,
'-------- ~
Lu ciana; H anflin g. Dan;
McDonald, Eric; Wad e, David ;
TARAN TINO, DA YID A ;
WILKINS ON, THOMAS ; David
Grube r
(b) (6);
KAUSHIK, SANGEE TA ;
Nath an iel Hupert

Breaking, COVID-19
N Pi s are going to be central to our

response to this outbreak
(assuming our estimates of
sever ity prove accurate). Th is
email group has grovvn since we
began (not quite epidemic-level
growth, but getting there) .
Lo oking ahead, I anticipate we
might encoun ter pushback over
the implemen tation ofN Pls and
would exp ect s imi lar
concerns/arguments as were raised
back in 2006 when this strategy
first emerged. It was one of the
reasons I shared the updated data
on US household s from American
Community Survey, data on
USDA programs for nutrit ional
support (inc luding schoo l meal
program s), data on schoo ls and
enro llment, and even data on
juvenile crime. The data that was
gathered back in 2006 on socia l
density in var ious environments
NIH-001573
(homes , offices /workplaces,
schools, daycare , etc., is
unchanged) . For additional
background and context, we
attached are 3 papers on NPis and
TLC for those who are interested.
Richard Hatchett deserves full
credit for birthing the idea of TLC
(it was actually developed in
response to the threat of HSN 1 and
later adopted for pandemic
influenza response). Duane,
perhaps you can store these
documents on MAX for safe
keeping and access?
The first paper is an historical

review of the 1918 pandemic (the
comparison of Philadelphia and
St. Louis is emblematic of the
lesson from 1918 that timing
matters when deploying NPls-
need to be early) . The second
paper is modeling work that was
done to evaluate these strategies.
At the time, modelers were
focused on how best to contain an
outbreak overseas (really focusing
on using antivirals primarily for
treatment and prophylaxis). They
focused their models to evaluate
the effectiveness of various
strategies and quantities of
antiviral medications required to
quench an emerging outbreak .
There were 3 groups who were
doing this work back then. They
each present their data in that
paper . A few things to note. In all
the model runs, they did not model
perfection or 100% adherence
(actually far from it). You will see
scenarios from 30/60 (meaning
30% compliance and 60%
ascertainment) on up to 90/80 ).
(See figures 1) Even leaky
implementation can reduce overall
NIH-001574
attack rates. The modelers also
looked at timing of
implementation (see figure 3). At
the time there was a great deal of
skepticism-was hard for people
to believe this was possible . Or
even if TLC could be effective,
was implementation practical
given the challenges trying to
implement and the 2nd and 3 rd
order consequences (especially of
closing schools). But the
modeling data combined with the
histolical data was the tipping
point. Marty Cetron from CDC
and Howard Markel from U of
Michigan, published a more
extensive historical review of the
1918 pandemic showing much the
same. Since then, a group within
CDC continued to work on this
(collecting additional data from
the 2009 pandemic and
elsewhere). They published an
update of CMG in MMWR in
2017.
https://protect2 .fireeye .com/ur l?k=
3985fc87 -65d l e5fb-3985cdb8 -
0cc4 7adc5 fa2-
bb4a28 993 b5aa9e0& u=https://ww
w .cdc.gov/media /dpk/cdc-24-
7/preven ting-pandemic -
influenza /community -mitigation -
guidelines-for-preven ting-
pandem ic-flu.html
The third paper, is a more recent

paper (from 201 7) that Richard
shared with me. The paper is a
little dense, but
I found this paper useful because it

provides a vocabulary for
strategies that we have raised
(Symptom Monitoling vs
NIH-001575
Quarantine of potentially infected
but symptom-free contacts during
an epidemic). This paper
identifi es those conditions where
SM or Q is preferred. Figure 1 is
useful for und erstanding the
challenges given the picture that
seems to be emerging with this
virus. This outbreak seems closer
to pandemic flu than SARS in
terms of transm ission dynamics
(and hence the NPis we would
need to employ).
Lastly, another person, Bob Glass

at Los Alamos, also did work on
this separately from the MIDAS
group. He actually began this
work as pa1t of a science fair
project for his daughter (using
social contacts of his daughter and
her classmat es at school to model
disease transmission). He knew
someone at VA who forwarded his
work to us (chain of
transmission). Early on (even
before the MIDAS group modeled
TLC), we had a "Eureka" moment
when we graphed his data in Excel
(I can share that single graph to
anyone interested). Bob Glass was
also interested in trying to
determine when you could let up
on the NPis during a pandemic.
Here is a story about Bob Glas s
and that work published in Fast
Company
https: //protect2.fueeye. com/ur l?k=
3862f880 -6436e l fc-3862c9 bf-
0cc4 7adc5fa2-
9ce5afJ 1e3c2cd6 4&u=https ://ww
w .fastcompany .corn/3058542 /the-
scientist s-who-simulate-the-end-
of -the-world I will see if I can
find his work on when to reopen
schools. Deci sions in terms of
NIH-001576
letting up on NPis could be critical
dow n the line.
From: Tra cey M cNa mar a

Sent: Sunday, February 16, 2020
7:10 PM
To: Carter M ec her ; Dr. Eva K

Lee
Cc: Canev a, Duan e; Dodgen,

Dan iel (OS/ASPR/SPPR ):
DeBo rd, Kristin
(OS/ASPR/SPPR) ; Phill ips, Sally
(OS/ASPR/SPPR) ; David
Marcozzi ; Hepburn , Mat thew J
Koon in; Wargo M ichae l; Walters ,
W illiam (STA TE .GOV) :
HARVEY , MELIS SA ; WOLFE,
HERBERT ; Eastma n, Alexan der ;
EV ANS, MARIEFRED ; Ca llaha n,
M icha el V .,M.D. ;
(b)(6)
Johnson,
--------
Ro be rt (OS/ ASPR/BARDA) ;
Yeskey, Kevin ; Disbrow, Gary
(OS/AS PR/BARDA ); Red d, John
(OS/ASPR /SPPR) ; Hassell , David
(Clni s) (OSI ASPR/IO) : Hamel,
Joseph (OS/ ASPR/1O) ; D ean,
Charity A@CDPH ; Rich ard
H atchett ; Lawle r, Ja mes V;
Kad lec , Rober t (OS /ASPR/IO) ;
'Martin, Gregory J
Cb)( ' ; B or io,
---------
Luci an a ; Ha nfling , Dan;
M cDonal d, Er ic; Wade. Davi d ;
NIH-001577
T ARAN TINO, DAV ID A;
WILKINSO N , THOMAS ; David
Grube r
(b)(6)
KAUSHIK, SANGE ETA ;

Nathan iel R upert
Subject: Re: Red Dawn Breaking,

COVID-19 Collaborative , Feb 16
start
Here is the link to a town hall

mtg at the Munich Security
Conference. Shared by Dr
Christian Haggenmiller ,
Dorector of the German
Defense Institute.
htt ps ://pro tect2.firee ye.com/url

?k=ec4e0592-b01a1cee -
ec4e34ad-0cc4 7 adc5fa2-
c00af41a186 719a2&u=https://s
ecur ityconference .org/en/ medi
al ibrary/asse t/town hal1-on-the -
coronavirus-o utbreak-
20200215 -1000/
Tracey
Get Outlook for Android
From: Dr. Eva K L ee

> ---
(b)(6)
Sent: Sunday, February 16, 2020

3:05:43 PM
To: Carter Mecher
(b)(6) >
Cc: Caneva, Duane

(b)(6)
Dodgen, Dan iel (OS /ASPR/SPPR)
NIH-001578
_________
DeBord , Kristin
(b)(6) > •
,
(OS/ ASPR /SPPR)

(b) (6) ;
Phillips , Sally (OS/AS PR/S PPR )
--------
Marcozzi
(6) ; David
Cb>
(b)(6)
>; Hepbu rn, Matthew J CIV
USARMY (USA)
(b)(6)
>; Lisa Koonin
(6) Wargo
Cb>
--------
Mich ael
Walters, William
(STATE .GOV )
(b)(6)
HARVEY, MELISSA
(b)(6)
WOLFE, HERBERT
(b)(6)
E astman , Alexande r
(b)(6)>
; EV ANS , MARIEFRED
(b)(6)
> ; Callahan , Michael
V. ,M.D.
Johnson, Robert
(OS/ASPR/BARDA)
(b)(6)
Yeskey, Kevin
(b)(6)> ;
Disbrow , Gary
(OSIAS PR/BARDA)
---------
John (OS /ASPR/SPP R)
C6)Redd,
Cb>
Cb)(6)> ; Hassell,
--------
Da vid (Chris) (OS /ASPR/ 1O)
(b)(6)
Hame l, Joseph (OS/ASPR/1O)
NIH-001579
(b) (6) ;
Tracey McNamara
(b)(
Dean, Charity A@CDPH

(b) (6);
Richard Hatchett
(b) (6);
Lawler, James V
(b) (6) ;
Kadlec, Robert (OS/ ASPR/IO)

(b)(6)
'Martin, Gregory J
(b)(6)
Lu ciana
------
Hanfling, Dan
(b)(6)>;
McDonald, Eric
(b)(6)
Wade, David
(b)(6)
TARANTINO, DAVIDA
(b)(6)
WILKINSON, THOMAS
(b)(6)
David Gruber
KAUSHIK, SANGEETA
(b)(6)
Nathaniel Rupert
(b)(6)

Break ing, COVID-19
Collaborative , Feb 16 sta 1t
Hi Carter, great points.
l. Separate current ED/ ICU

patients from COVID-19 is a
must.
NIH-001580
2. Migrating current ED/ICU
(non-COVID) patients to other
care sites is great idea .
3. Caring for COVID-19

patients: leveraging ED/I CU
personnel for high comp liance and
usage of limited resources (PPE
everything that goes with it) is
very critical. Strategic usage and
minimizing non-medical staff is
necessary --- either these operators
are well-trained and protected, or
they cannot be there.
4. Concentrating care within

ED/ICU for COVID-19 ensures
rap id learning and sharing of
knowledge among workers as they
take care of these patients.
Clearly from the standpoint of
data collection and clinical
symptoms record ing and
organization, it is more feasible
and allow for immediate analysis
and feedback.
5. Strategic prioritization of
limited resources is extremely
impo1tant. We must do it now ,
because the supp ly chain is
already being affected and it can
go worse.
6. Primaiy care and call centers

are good. If you want to do
strategic testing , this is also a good
place to involve .
NIH-001581
7. So few children are reported
among the confirmed positive
case s . They may be good
spreaders (not necessarily have to
be super) and the more vulnerable
people would be ones show up
with symptomatic disease
characteristics (or no/mild
symptoms).
Best, Eva
(b)(6)
mobi le (b)(
Sent with ProtonMail Secure

Email.
On Sunday, Febmary 16, 2020

4:30 PM, Carter Mecher
(b) (6) > wrote:
Wanted to bounce
something off this
group.
I have been concerned

about some of the
preparedness efforts
of healthcare systems
NIH-001582
as they are ramping
up their capab ilities to
care for patients with
COVID -19 presenting
anywhere in their
system. Staff
working in ERs and
ICUs are pretty
familiar with the care
of these types of
patients and the use of
appropriate PPE
(standard contact and
airborne precautions
including eye
protection). The staff
at the hospitals
undergo fit test ing for
respirators, etc. Staff
in outpatient clinics
(especially remote
comm unity based
outpatient clinics)
don't typically
undergo fit testing for
respirators. So ERs
and ICUs have
muscle memory for
isolating patien ts and
prov iding care to
patients with
infectious respiratory
disease. Community
based outpatient
clinics do not.
As part of the
preparedness efforts,
there has been interest
in fit testing
outpatient clinic staff
and supp lying these
clinics with PPE and
establishing
procedures for
NIH-001583
evaluating COVID-19
patients in the
commun ity based
clinics. Given the
projected shortages of
PPE, that just doesn't
seem like the most
prudent approach.
Rather than expand

the care of potential
COVID-19 patients to
community based
outpat ient clinics, I
wou ld focus on
hospital care--ERs
and inpatient areas
(especially ICUs). I
would not pursue fit
testing for staff
working in outlying
clinics. As a strategy,
I suggested dividing
COVID patients into
two categories-(1 )
those with illness that
is mild enough to be
cared for at home
( self care or care by
other family
members); or (2)
those who are sick
enough to be seen in
the ER for possible
hosp italizat ion. I
would refocus the
efforts of outlying
clinics away from
COVID and toward
keeping non-COVID
patients with the usual
mix of acute and
chro nic illnesses we
see from hypertension
to CHF to diabetes,
NIH-001584
etc., out of the ER and
out of the hospital.
That is what they can
do to help unburden
ERs and hospitals for
the surge in COVID
patients in ERs and
hospitals. I would
leverage telephone
care as much as
possible to handle
patients with mild
disease seeking care
related to COVID
(and quickly develop
algorithms to
detennine who has
mild disease and can
be managed by
telephone at home
and who needs to
evaluated in the ER) .
Think of it like the
program Lisa
developed for
pandemic influenza
(Nurse On Call) on
steroids , minus the
antivira l piece. Could
we repurpose and
leverage that program
for COVID? Such a
strategy would help to
conse rve om PPE
supply (avo id the
expansion of fit
testing and the
redirection of already
limited supplies of
PPE to outlying
clinics) and not ask
outlying clinics to do
something they don't
typically do (that
usually doesn't out
turn out very well). If
NIH-001585
the outlying clinics
focused on what they
normally do (caring
for patients with
chronic diseases),
they could help the
ER and hospitals cope
with the demands of
COVID. I would
think about Urgent
Care centers in the
same way- to help to
decompress ERs.
I also think that we

need to start thinking
about strategies to
conserve PPE for
hospitals. I'm
concerned about the
projected burn rates
and the supply chains
for PPE. Click on
Amazon and check
out the prices now.
Or click on WalMart
(can't pick up any
masks from Wa lMart
now). I saw one
supplier selling 200
surgica l masks on
WalMaii's site for
only $459.99. Such a
deal.
As a conservation
strategy , we might
think about limiting
the amount of staff
interacting with
infected patients and
cohorting patients
(even thinking of
strateg ies to minimize
need for
NIH-001586
housekeeping or food
service or lab services
from enter ing areas
with COVID patients-
-think Ebola-like
strateg ies (not out of
concern of disease
transmission but
simply to limit
number of staff to
conserve PPE).
Could do something
similar with ERs
(akin to what
pediatricians do to
separate sick call
patients from other
appointments). I
have recommend
prioritizing PPE for
EDs and ICUs as well
as specific inpatient
areas where we would
likely initially cohort
patients , not pursuing
fit testing of
outpatient clinic staff,
and shifting patients
with mild COVID
disease to telephone
care and away from
outpatient clinics.
I know several of you

are part of large
healthcare systems.
Am curious how
others are
approaching this
challenge.
I am also resending
the questions I posed
NIH-001587
for handling sick
ER/ho spital staff or
staff members with a
confinned case of
COVID in their
hou seho ld. Ca11er
Sent from Mai l for

Windows 10
From: Caneva,
Duane
Sent: Sunday,
February 16, 2020
3:24 PM
To: Dodgen , Daniel

(OSI ASPR/SPPR) ;
DeBord, Krist in
( OSIASPR/SPPR);
Phi llips, Sally
(OS /ASPR/SPPR) ;
Dav id Marcozz i;
Hepburn, Matthew J
CIV USARMY
(USA); Lisa Koonin ;
Wargo Michae l;
Walters, William
(STAT E.GOV) ;
HARVEY,
MELISSA ; WOLFE,
HERBERT; Eastman,
Alexander; EVANS,
MARIEFRED;
Ca llahan, M ichae l
V.,M.D. ;
)(6)
; Johnson. Robert
NIH-001588
(OSIAS PR/BARDA) :
Yeskey, Kev in;
Disbrow, Gary
(OSI ASPR/BARDA) :
Redd, John
(OS IASP R/SPP R) :
Hasse ll, David (Clu-is)
(OS /ASPR/10 ):
Ham el, Joseph
(OSIASPR/JO) :
Tra cey McNamara ;
Dean , Charity
A@CDPH ; Ric hard
Hatch ett ; Lawler,
Jame s V ; Kadlec,
Robert
(OSI ASPR/10) ;
'Ma11in, Greg ory J
(b)(6)
:t; Borio , Luciana ;

Hanfling, Dan ;
McDonald, Er ic;
Wad e, David ;
TARAN TINO,
DAVIDA ;
WlLKINSON,
THOMAS ; Dav id
Gruber
KA USHIK,
SANGEET A; Dr . Eva
K Lee ; Nathan iel
Hupert ; Carter
Mecher
Subject: Re: Red

Dawn Breaking,
COVID-19
Co llaborative , Feb 16
start
Sorry for spam.
+ Carrer
NIH-001589
Get Outloo k for iOS
From: Caneva ,
Duane
Sent: Sunday,
February 16, 2020
10:21:38 AM
To: Dodgen , Danie l
(OS /ASPR/SPP R)
(b)(6)
>; DeBord,
Kristin
( OSIASPR/S PPR)
(b)(6)
>; Phillips , Sally

(OS/ ASPR/S PPR)
(b)(6)
D avid Marcozzi
(b)(6)
Hepb urn, Matthew J

CIVUSARMY
(USA)
(b)(6)
; Lisa
Koon in
(b)(6)
Walt ers, William

(STAT E.GOVJ
(b)(6)
>; H ARVEY ,
MELISSA
(b)(6)
WOLFE ,
HE RBERT
)(6)
; Eastman,
A lexander
)(6)
NIH-001590
EVANS,
MARIEFRED
(b)(6)
Callahan, Michael
V.,M.D.
l> ;Johnson, Robert

(OS / ASPR/BARDA)
)(6)
> ; Yeskey,
Kevin
)(6)
Disbrow, Gary
S/ ASPR/BARDA)
)(6)
>; Redd, John

(OS / ASPR/S PPR)
(b)(6)
>; Hassell, David

(Chris)
(OS /ASPR/ 1O)
)(6)
Hame l, Joseph
(OS /ASPR/1O)
(b)(6)
> ; Tracey
McNamara
)(6)
Dean,
Char ity A@CDPH
)(6)
; Richard
H tc ett
)(6)
Lawler ,
James V
)(6)
; Kadlec, Robert
NIH-001591
(OS/ASPR/IO)
)(6)
; 'M artin,
Gregory J
(b)(6)
>; Borio, Luciana

(b)(
Hanfling , Dan
(b)(
; McDonald , Eric
(b)(6)
Wad e, Dav id
)(6)
TARANTINO,
DAVID A
)(6)
Barie ,
Ralph S
(b)(6)
■ WILKINSON,
THOMAS
>; Hassell,
David (Chris)
(OS/ASPR/10)
(b)(6)
> ; David Grub er

(b)(
KA USHIK ,
SANGEETA
(b)(6)
KLee
Nathaniel Rupert
)(6)
>
Subject: RE: Red
Dawn Breaking,
COVID-19
NIH-001592
Collaborative , Feb 16
start
Some Mark Lipsitcb

Tweets copied.
Sorry, might not be in
the right order ...
"So far, we have

conducted tests for
1,219 individuals. Of
those , 355 people
tested positive. Of
those, 73 individuals
are not showing
symptom s," Japan ' s
health minister says
Marc Lipsitch (@mlipsitch)
14/02/2020, 17:42
I did actually say the quote that is going around , but

the article contained vital context -- we don't know
what propor tion are symptomatic. Also we have only
a rough estimate of what proportion of symptomat ic
people will have severe outcomes .
pie .twitte r.comic W zvINSZ Bm
Marc
Lipsitch
(@mlipsitc
h)
14/02/2020, 17:43
Why do I think a pandem ic is likely? The infect ion is

in many parts of China and many count r ies in the
world , with meaning ful numbers of secondary
transmissions . The scale is much larger than SARS
for examp le (where the US had many introduct ions
and no known onward transmissio n)
NIH-001593
Marc
Lipsitch
(@mlipsitc
h)
14/02/2020, 17:45
Why do I think 40-70% infected?

Simpl e math models with oversimp le
assumpt ions would pred ict far more
than that given the ROestimates in the
2-3 range (80-90%) . Making more
realistic assumptions about mixing,
perhaps a little help from seasonality,
brings the numb ers down
Marc Lipsitch
(@mlipsitch )
14/02/2020 , 17 :48
pandemic flu in 1968 was estimated to

_symptomatically_ infect 40% of the
population, and in 1918 30%. Tho se
likely had RO less than COVID- 19.
Belo w is from
stacks .cdc.gov /view/cdc/ 11425
pic.tw itter .com/EMwjE pA49s
Marc Lipsitch
(@mlipsitch )
14/02/2020, 17:49
What cou ld make this scenario not

happen ? 1) cond itions in ·wuhan could
be so different in some fundamental
way from elsewh ere that we are
mistaken in expecting further
outbreaks to have basic aspects in
common. No reason I know of to
think that but a forma l possibility
NIH-001594
Marc Lipsitch
(@ mlipsitch)
14/02/2020, 17:53
2) There could be a higher degree of

superspreading than has been
appreciated ("dispers ion in RO")
which could mean that many locations
outside Wuhan could "get lucky" and
escape major onward transmission.
hopkinsidd.github.io/nCo V-
Sandbox/D ... .
Ma rc Lipsitch
(@mlipsitch)
14/02/2020, 17 :53
2) There could be a higher deg ree of superspreading

than has been appreciated ("dispersion in RO") which
could mean that many locations outside Wuhan could
"get lucky" and escape major onward transmission .
hopkinsidd. github .io/nCo V-Sandbox/D ... .
Marc Lip sitch

(@mlipsitch)
14/02/2020 , 17:55
3) Control measures could be extremely effective

in locations that have had time to prepare. Maybe
in a few, but seems unlikely that is the case in all,
especially countries with stretched health
systems.
Marc Lip sitch

(@mlipsitch )
NIH-001595
14/02/2020, 17:56
4) Seasonalfactors could be much more

powerful at reducingtransmissionthan we
currently expect. That doesn't help the
Southern hemisphere , and is not consisten t
wi th behavior in Ch ina (preprint in queue
from D @Ma uSantil lana D et al.)
From: Caneva,
Duane
Sent: Sunday,
February 16, 2020
9:39 AM
To: Dodgen , Daniel

(OS /ASPR/S P PR)
(b)(6)
>; DeBord,
Kristin
(OS / ASPR/SPPR)
(b)(6)
>; Phillips , Sally

(OS / ASPR/S PPR)
(b)(6)
Hepburn , Matthew J
CIVUSARMY
(USA)
(b)(6)
; Lisa
Koonin
(b)(6)
Walters, William
(b)(6)
H ARVEY ,
M ELISSA
NIH-001596
)(6)
>; WOLFE,
HERBERT
(b) (6)_
111111>
;Eastman,
Alexa nder
(b)(6)
EVANS,
__.. ;
MARIEFRED
(b)(6)
Callahan, Michael
V.,M.D.
; Johnson, Robert
(OS / ASPR/BARDA)
(b)(6)
1111111>
;Yeskey,
Kevin
(b)(
Disbrow , Gary
(OS /ASPR/BARDA)
(b)(6)
1111Redd, John
(OS / ASPR/SPPR)
(b)(6)
>; Hassell, David

(Chris)
.>;
(0S /ASPR/IO)
Hamel, Joseph
(0S /ASPR/IO)
(b)(6)
(b)(6)
Ill> ; Tracey
McNamara
(b)(6)
> ; Dean ,
Char ity A@CDPH
(b)(6)
Caneva,
Duane
NIH-001597
)(6)
; Richard
Hatchett
)(6)
; Lawler,
James V
(b)(6)
>; Kadlec, Robert

(OS/ASPR/10)
)(6)
>; 'Martin,
Gregory J
(b) (6),
>; Borio, Luci ana

(b)(
Hanfling, Dan
(b)(6)>
; McDonald , Eric
)(6) _
Wade, David
)(6)
TARANTINO,
DAVID A
(b)(6)
>; Barie,
Ralph S
)(6)
WILKINSON,
THOMAS
(b)(6)
>; Hassell,
Dav id (Chris)
(OS/ASPR/10)
(b)(6)
Da vid Gruber
(b)(
KA US HIK,
SANGEETA
(b)(6)
NIH-001598
Subject: Red Dawn
Breaking , COVID-19
Co llaborat ive, Feb 16
start
Purpose: This is a
new Red Dawn String
to cut down the size
from the previous
string, opportunity to
provide thoughts,
concerns, raise issues,
share information
across various
co lleagues responding
to COVID-19.
Including all from

previous string plus a
few additional folks.
Duane C. Caneva,
MD, MS
Chief Medical
Officer
Department of
Homeland Security
(b)(6)
Executive Assistant:
(b)(6)
NIH-001599
(b)(6)
(U) Warning : This

document is
UNCLASS
IFIED!/FOR
OFFICIAL USE ONLY
(U//FO UO). It
contains informatio n
that may be exempt
from public release
under the Freedom of
Infor m ation Act
NIH-001600
Sent: Mon, 24 Feb 2020 11:08:54 +0000
To: Gilman, James (NIH/CC/OD) [El;Tabak, Lawrence (NIH/OD) [El
Cc: Davey, Richard (NIH/NIAID) [El
Subject: RE: 3 COVID-19Asymptomatic Positive Individuals Identified at Travis AFB
We should probably also inc lude Rick Davey on all commun ication regarding such patients
From: Gilman, James {NIH/CC/OD) [E] _______ Cb)

_C6>r
_>
To: Tabak, Lawrence (NIH/OD) [E]
-------~~ (b)(6J; Fauci, Anthony (NIH/NIAID) [E]
(b)( >
---------
Subject : Re: 3 COVID-19Asymptomatic Positive Individuals Identified at Travis AFB
Larry
Best POCis Dr Palmore.
Jim
From: "Tabak, Lawrence (NIH/OD) [E]"

---------
Date: Sunday, February 23, 2020 at 10:02:41 PM
(b)(6)>
To: "Fauci, Anthony {NIH/N IAID) [E]" -------=- (b"""

)(=6l, "Gilman, James (NIH/CC/OD) [E]"
(b)( >
Subject : FW: 3 COVID-19 Asymptomatic Positive Individuals Identified at Travis AFB
Who is P-O-C, related to transfer? Pius
From: "Kadlec, Robert (OS/ASPR/ 1O) " (b)(6J>

---------
Date : Sunday, Februa ry 23, 2020 at 9:56 PM
To : "Ha rrison, Brian (HHS/ 1OS)"
-------~= (b)( >, "Stecker, Judy (OS/ 10S)"
CbH6J>,"Mango, Paul (HHS/ 1O5)" CbH6J>,"Mu rphy, Ryan
(OS/ASPA)" < (b)( >,
Anthony
__ ___:, Fauci"".":::======~~ CbH6J>,"Arbes, Sarah (HHS/ASL)"
CbH6J>, "Tabak
__ -====.;~:::-::----:-::::--:-- , Lawrence (NIH/OD) [E]"
----------- 6)" Red fie Id, Robert R. (CDC/OD)"

(b)(
Robe rt (Kyle) (CDC/OD/OCS)" CbH6J>
-------- 1, "McGowan,
CbH6J
Cc:"Lee, Scott (OS/ASPR/EMMO)" CbH6J>,"Yeskey, Kevin (OS/ASPR/1O)"

CbH6J,"Waters, Cicely (OS/ASPR/OEA)" CbH6J,"Shuy,
_________
Bryan {OS/ASPR/10)" CbH6J,"Greene, Jonathan (OS/ASPR/EMMO)"
_, ,>, " Imbriale, Samue l {OS/ASPR/SIIM)"
CbH6J CbH6J,
"Austin, Meredith (uscg.mil)" (b)(6) "Herrmann, Jack (OS/ASPR/OEA)"
(b)(6j
Subje ct: 3 COVID-19 Asymptomatic Positive Individuals Identified at Travis AFB
NIH-001601
Initial CDC testing of the 100 individuals repatriated from the Diamond Princess yielded three individuals
COVID-19 POSwho are currently asymptomatic at Travis. These individuals are being transferred to
local hospital for evaluation and admission. Currentl Y.,ASPRTEAM at Travis is asce_rt""a_in_i_n~g
,_____ ..,._.,.,,.,
(b)(5)
My team is working the details of transfer via aeromedical aircraft. Dr Kevin Yeskey and CAPTScott Lee
copied here are leading the operational planning
nr_3_c_
o1u:.se.c;_
of_actio.,..,._
· _____________________________ ..,.,.""'
(b) (5)
Will advise as these course are pursued in parallel.
WILL NEED A POC at NIH to connect with Dr Yeskey and CAPT Lee ASAP to begin arrangements .
NIH-001602
Sent : Sat, 22 Feb 2020 14:01:20 +0000
To: Grigsby, Garrett (HHS/0S/OGA)
Subject : RE: CDC L2 THN Korea
Thanks, Garrett.
From: Grigsby, Garrett (HHS/OS/OGA) (b)(6)
Se nt : Saturday, February 22, 2020 8:56 AM ---------

6)>
Subject : Re: CDC L2 THN Korea
Dr F,
Here it is:
--------- (b)(6)
Sent from my iPhone
On Feb 21, 2020, at 9:41 PM, Fauci, Anthony (NIH/NIAID) [E) _______ _,
(b)(6)
wrote:
Garrett:
Please send me the call in number for tomorrow's call at 11:00 AM
Thanks,
Tony
From: Grigsby, Garrett (HHS/0S/OGA) (b)(6)

To: Phil Ferro (b)(6); Fauci, Anthony (NIH/NIAID) [E]
(b)(6)>
Cc: Zebley, Kyle {HHS/OS/OGA) (b)(6)>; Harrison, Brian {HHS/10S)
>; Shuy, Bryan {OS/ASPR/10) <
--------- (b)(
Subje ct : Fwd: CDCL2 THN Korea
(b)(6)
Gentlemen,
Can you please circulate this for discussion at the 11am call tomorrow?
Many thanks!!
Sent from my iPhone
NIH-001656
(b)(6)
From : "Cetro n, Marty (CDC/DDID/NCEZID/DGMQ)"
Date : February 21, 2020 at 9:01 :06 PM EST
-------
To: (b)(6) {OS/10S)' (b)(6)>, " Harrison, Brian (HHS/IOS)"
(b)(6) "Grigsby , Garrett (HHS/05/0GA) "
========' (b
~)=:-
(6)
~>
Cc: "Redfield, Robert R. (CDC/OD)" CbH6),"Cetron , Marty

(CDC/DDID/NCEZID/DGMQ)"
·-..:.....:::== (b
==::
)::c:
(6)
:c;-
>- ...
Subject: CDCL2THN Korea
Per WHTF request CDC l2 THN RoK. Please share w Sec Biegun at DOS.We
w ill post whe n he is ready presumably Sat
Thks
MSC
<Coronavir us L2 - South Korea.docx>
NIH-001657
Sent : Sat, 22 Feb 2020 02:40:45 +0000
To: Grigsby, Garrett (HHS/OS/OGA)
Subject : FW: CDC L2 THN Korea
Attachment s: Coronavirus L2 - South Korea.docx, ATT0O0Ol.htm
Garrett:
Please send me the call in number for tomorrow's call at 11:00 AM
Thanks,
Tony
From : Grigsby, Garrett (HHS/OS/OGA) (b)(6)

To: Phil Ferro (b)(6)>; Fauci, Anthony (NIH/NIAID) [E]_______ Cb
_H_6)
Cc: Zebley, Kyle {HHS/OS/OGA) CbH6>!>;
Harrison, Brian (HHS/IOS)
--------- (b)(6) Shuy, Bryan (OS/ASPR/IO)

Subject : Fwd: CDC L2 THN Korea
(b)( >
Gentlemen,
Can you please circulate this for discussion at the 11am call tomorrow?
Many thanks !!
Sent from my iPhone
From: "Cetron, Marty (CDC/DDID/NCEZID/DGMQ )" (b)(6)>

_________
To: (b)(6) (O5/IOS)" (b)(6)>, "Ha rrison, Brian (HHS/1O5)"
(b)(6), , "Grigsby, Garrett (HHS/OS/OGA)
Cc: "Redf ield, Robert R. (CDC/OD)"
---------..,
---------
(b)(6), "Cetron, Marty
~ (b)(6)>
(CDC/DDID/NCEZID/DGMQ)" (b)(6)
Subject: CDCL2 THN Korea
Per WHTF request CDC L2 THN RoK. Please share w Sec Biegun at DOS. We will post when
he is ready presumably Sat
Thks
MSC
NIH-001680
Sent: Fri, 21 Feb 2020 10:55:47 +0000
To : Kadlec, Robert (OS/ASPR/10 )
Subject : RE:Good morning
Bob:
No problem . Got you covered .
Best,
Tony
From: Kadlec, Robert (OS/ASPR/10) (b)(6)>

---------
Se nt: Friday, Februa ry 21, 2020 5:53 AM
------~~
--------
To : Fauci, Anthony (NIH/N IAID) [E]
Subj ect : Good morn ing
Cb)( >
Im port ance: High
Tony during today's t able top as we walk through the placement I will ask you to walk through
t he Critica l Info r mation Requirements and ask you to highlight what we know, don't know and
what we th ink about the this coronavi rus. l et me know if you have any questions . Best Bob
NIH-001697
Sent : Thu, 20 Feb 2020 21:26:05 +0000
To : Eisinger, Robert (NIH/NIAID) [El
Subject: FW: HHS COVID 19 Response TIX Concept Placemat_Senior
Leader _19Feb2020 v2 .pptx
Attachments : HHS COVID 19 Response TTX Concept Placemat_Senior
Leader _19Feb20 20v2 .pptx , ATTOOOOl.htm
Here it is
Director
Phone : Cb)
(6)
FAX: (301 496-4409
E-mail : (b)(6)
From : Kadlec, Robert (OS/ASPR/10) <

--------
(b)( >
To: Fauci, Anthony (NIH/NIAID) (El -------::--:--;=

(b)(6)
Subject: Fwd: HHS COVID 19 Response TTX Concept Placemat _Senior Leader _1 9Feb2020v2 .pptx
Sent from my iPhone
From: "Mackay, Thomas (OS/ASPR/EEAA)" (b)(6)>
To: "Kadlec, Robert (OS/ASPR/10)" ---------=c-=

(b)(6), "Yeskey, Kevin
(OS/ASPR/10)" (b)(6)>
Cc: "Ford-Barnes, Arwent hia (OS/ASPR/10)" CbH6J>,
"Hol land,
Tara (OS/ASPR/EMMO)" (b)((;)>, "Callahan, Victoria (OS/ASPR/10) (CTR)"
(b)(6)>
Subject : HHS COVID 19 Response TIX Concept Placemat_Senior
leader_19Feb2020v2 .pptx
NIH-001712
Gentlemen - attached is the latest version of the Placemat . The reason there are four
slides is to give you the option of how the backside is laid out . Slide one and three are
identical, the information on slides two and four are also identical just laid out differently .
Standing by for corrections as necessary.
v/rTom
NIH-001713
Sent : Thu, 20 Feb 2020 04:02:40 +0000
To : Jernigan, Daniel B. (CDC/DDID/NCIRD/ID);Giroir, Brett (HHS/OASH);Shuy, Bryan
(OS/ASPR/IO);Schuchat, Anne MD (CDC/0D);Cetron, Marty (CDC/DDID/NCEZID/DGMQ);McGowan,
Robert (Kyle) (CDC/0D/OCS);Grigsby, Garrett (HHS/0S/OGA);Zebley, Kyle (HHS/0S/OGA);Redfield,
Robert R. (CDC/OD)
Subject : RE: Updated Draft in Track Changes
Attachme nts: Phases of USG nCoV Response _WHTF_13 Feb_PCC_Master.Final ASPREdits -
CDC BG.docx
HHS Tea m :
I have been following these various iterations closely over the past couple of hours and I agree
with Dan. It looks like we have actua lly finally arrived at a good place and a point of
comfortable agreement between ASPR and CDC. Am I correct and do we all agree with the
latest tracked document (see attached)?
Thanks,
Tony
From: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) (b)(6)

To : Giroir, Brett {HHS/OASH) CbH6J>; Shuy, Bryan (OS/ASPR/I0)
------- (b)(
(CDC/DDID/NCEZID/DGMQ)
>; Schuchat, Anne MD (CDC/OD) (b)(6)>; Cetron, Marty
(b)(6)>; Fauci, Anthony (N IH/NIAID) [E)
-----~~ (b)( >;
McGowan, Robert (Kyle) (CDC/00/0CS) (b)(6)>; Grigsby, Garrett (HHS/0S/OGA)
(b)(6)>; Zebley, Kyle (HHS/0S/OGA) (b)(6)>; Redfield, Robert R.
7( C
::--
D-:C-:-
/0:-D
---:-
)===::,:: (b:)(~
;:: >
Here with Adm Giroir's input as well. I think we may have arrived?
Dan.
From: Giroir, Brett (HHS/OASH) (b)(6)

Sent : Wednesday, February 19, 2020 10 :06 PM
To : Shuy, Bryan (OS/ASPR/10) CbH6)>; Schuchat, Anne MD (CDC/OD) (b)(6);
Cetron, Marty {CDC/DDID/NCEZID/DGMQ) <q" CbH§ >; Jernigan, Daniel B. {CDC/DDID/NCIRD/ID)
CbH6)>;Fauci, Anthony (NIH/NIAID) [E) CbH6)>;McGowan , Robert (Kyle)
(CDC/0D/OCS) CbH6)>; Grigsby, Garrett (HHS/0S/OGA) CbH6J>; Zebley,
Kyle (HHS/0S/OGA) (b)(6)
(b) (5)
Please include me on the emai l exchange .
NIH-001726
I am happy to point force the issue, which I can and will, but I assume it was an accidental
om mission
BG
Brett P. Giroir, MD
From: Giroir, Brett (HHS/OASH)

Sent: Wed nesday, February 19, 2020 10 :02 PM
To : Shuy, Bryan (OS/ASPR/I0) (b)(6)>; Schuchat , Anne MD (CDC/OD) (b)(6)>;
Cetron , Marty (CDC/DDID/NCEZID/DGMQ) (b)(6)>; Jernigan, Daniel 8. (CDC/DDID/NCIRD/10)
____ _<_6)>; Antho ny (NIH/NIAID) Fauci [E]
Cb> (b)(6)> ;
McGowan, Robert (Kyle) (CDC/00/0CS) (b)(6); Grigsby, Garrett (HHS/0S/OGA)
--------- ·
(b)(6)> ; Zebley, Kyle (HHS/OS/OGA)
Subject: RE: Updat ed Draft in Track Changes
(b)(6)>
Importance: High
(b) (5)
Brett P. Giroir, MD
NIH-001727
From: "Kadlec , Robert (OS/ASPR/IO)" (b)(6)
To: "Schuchat, Anne MD (CDC /OD)"
---~~ CbH6J>, "Cetron, Marty
(CDC/DDID/NCEZID/DGMQ)" p, , "Jernigan, Daniel B.
CbH6)
(CDC/DDID/NCIRD/ID)"
(b)( ----- 6}, "Fauci, Anthony (NIH/NWD)
CbH [E]"
Cc: "McGowan , Robert (Kyle) (CDC/OD/OCS)" , "Shuy , B1yan

Cb><6J
(OS/ASPR /1O)" CbH6J >, "Grig sby , Garrett (HHS/OS/OGA)"
Cb><, "Zebley , Kyle (HHS/OS /OGA)"
(b)(6)>
Subject: Updated Draft in Track Changes
Please accept my apologies for the delay I had a competing priority action but please find
attached .
NIH-001728
Sent : Wed, 19 Feb 2020 01:38:52 +0000
Subj ect : RE: CDC Media Statement: Update on the Diamond Princess Cruise Ship in Japan
From : Billet, Courtney (NIH/NIAID) [E] (b)(6)>

To: Fauci, Anthony (NIH/NIAID) [~ -------=-:-:=
E]:.======= (b:-:-
)(=6)~>
Cc: Folkers, Greg (NIH/NIAID) [El (b)(6); Conrad , Patricia (NIH/NIAID) [E]
(b)(6)
---------
Subj ect : Fwd: CDC Media Statement: Update on the Diamond Princess Cruise Ship in Japan
From : "Hall, Bill (HHS/ASPA)" (b)(6)>

Dat e: Tuesday, February 18, 2020 at 4:52:06 PM
Subj ect : FW: CDC Media Statement: Update on the Diamond Princess Cruise Ship in Japan
From: MMWR Media List <MMWR -MEDIA@LISTSERV

.CDC.GOV> On Beha lf Of Media@cdc .gov (CDC)
To: MMWR-MEDIA@LISTSERV.CDC.GOV
Subje ct : CDC Media Statement : Update on the Diamond Princess Cruise Ship in Japan
Media Statement
For Immediate Release
Tuesday, February 18, 2020
Contact: CDC Media Relation s

(404) 639-3286
NIH-001766
Update on the Diamond Princess Cruise Ship in Japan
We commend the extraordinary efforts by the Government of Japan to institute quarantine

measures onboard the Diamond Princess. While the quarantine potentially conferred a
significant public health benefit in slowing transmission, CDC's assessment is that it may not
have been sufficient to prevent transmission among individuals on the ship. CDC believes the
rate of new infections on board, especially among those witho ut symptoms , represents an
ongoing risk. Therefore, to protect the health of the American public, all passengers and crew of
the ship have been placed under travel restrictions, preventing them from returning to the United
States for at least 14 days after they had left the Diamond Princess.
Currently , there are more than 100 U.S. citizens still onboard the Diamond Princess cruise ship
or in hospitals in Japan. These citizens have been placed under the restrictions, as have the ship's
other passenge rs and crew .
After disembarkation from the Diamond Princess, these passengers and crew will be required to
wait 14 days without having symptoms or a positive coronavirus test result before they are
permitted to board flights to the United States.
If an individual from this cruise arrives in the United States before the 14-day period ends, they
will still be subject to a mandatory quarantine until they have completed the 14-day period with
no symptoms or positive coronavirus test results.
Because of their high-risk exposure, there may be additional confirmed cases of COVID-19
among the remaining passengers on board the Diamond Princess.
CDC is committed to protecting the health and safety of all Americans. We continue to believe
that the risk of exposure to COVID-19 to the general public in the United States is currently
low. The U.S. Government is taking these measures to protect the Diamond Princess passengers
and crew, their loved ones, the traveling public, and communities within the Un ited States.
###
U.S . Department of Hea lth and Human Services
CDC works 2417 protecting America's health, safety and security. Whether diseases start at
home or abroad, are curable or preventable , chronic or acute, or from human activity or
deliberate attack, CDC responds to America's most pressing health threats. CDC is
headquartered in Atlanta and has experts located throughout the United States and the world.
If you would like to unsubscribe from this ListServ LIST , please send an email to
LIST@cdc.gov, enter CDC in the email Subject , and include the following "one" line in the
Body of the email: signoffMMWR-MEDIA
NIH-001767
Sent : Mon , 17 Feb 2020 20:16:44 +0000
Bee: Marston, Hilary (NIH/NIAID) [E]
Subject : RE: Larry, does NIH have a single point person through which all Coronavirus
intel bu bbles up?
Larry:
(b)(5)
Thanks for the note .
5> The person who
--------------------------- CbH
usu a11y subs for me when I cannot be on a call or at a meeti ng is Hilary Marston .
She is up to speed on virtually all this stuff and is the name that you should send
to Paul. You can t ell Paul that he should channel everything t hro ugh m e and I
can turf to Hilary when necessary and appropriate. Hilary is right here in my
office and is very close to me.
Best,
Tony
Director
Phone : (b)(6)
FAX : (301 496-4409
E-mail : (b)( 6)
The information in this e-ma i l and any of its attachments is confidential and may contain sensitive

--------
Subject: Fwd: Larry, does NIH have a single point person th rough which all Coronav irus intel bubbles
up?
Tony
Do want this to be one of your folks or me?
Thanks
Larry
NIH-001820
Sent from my iPhone
From: "Mango, Paul (HHS/10S)" (b)(6)>

To: "Tabak, Lawrence (NIH/OD) [E]" <------- =(b..,
H=6)
Subject: Larry,does NIH have a single point person through which all Coronavirusintel
bubbles up?
Larry- we are trying to integrate some of the department communications channels. Dr

Fauci is on just about every call, but do you have someone else as well who is representing
NIH and would be aware of any developments?
Sent from my iPhone
NIH-001821
Sent: Sat, 15 Feb 2020 18:57:22 +0000
To : Harrison, Brian (HHS/10S)
Subject: FW: WaPo - fact check on coronavirus story
FYI. See below.

Director
Phone : (b)(6)
FAX : (301 496-4409
E-mail : (b)(6)

To: Oakley, Caitlin B. (OS/ASPA)--------,;-- =
Cc: Stecker, Judy (OS/IOS) Cb)( ; Conrad, Patricia (NIH/NIAID) [El
(b)(6) >; Billet, Courtney (NIH/NIAIO) [El
---------
Subject : RE: WaPo - fact check on coronavi rus story
(b)(6)
Caitlin/Judy:
I had a long and good conversation with Yasmeen Abutaleb and went over (and
countered) all of the issues that had any negative connotations for the Secretary
and/or the President. I spoke on the record and gave her permission to use my
quotes as she so wishes. Mission accomplished.
Best regards .,
Tony
Director
Phone : (b)(6)
NIH-001858
FAX : (301) 496-4409
E-mail : (b)(6)
From: Oakley, Caitlin B. {OS/ASPA) (b)(6)

To: Fauci, Anthony {NIH/NIAID) [E]------= (b)
'""(=
6)>
Cc: Stecker, Judy (OS/1O5) (b)(6); Conrad, Patricia {NIH/NIAID) [E]
Cb)( >; Billet, Courtney {NIH/NIA ID) [El
---------
Subject: FW: WaPo - fact check on coronavirus story
(b)(6)
Dr. Fauci- Thank you fo r the chat. Here is the reporter's contact info and she is expecting your call.
Yasmeen Abutaleb
The Washington Post
Health policy reporter
---~~
o: 202-334 -8387 c:
-----
(b) (
Yasmeen.Abuta leb@washpo st .com
C aitlin B . Oakley
Deputy Assistant Secretary, National Spokesperson
Office of the Assistant Secretary for Public Affairs
(b)(6)
From: Abutaleb, Yasmeen <Yasmeen.Abut aleb@was hpost .com>

Se nt: Friday, February 14, 2020 4:40 PM
To: Oakley, Caitlin B. (OS/ASPA) --------~~ CbH6J>;McKeogh, Katherine {OS/ASPA)
(b)(6)
Subject : WaPo - fact check on coronavirus story
Hey Caitlin and Katie,
Happy Friday! I'm wo rking on a story about the coronavirus response, aim ing to publish tomorrow. The
story is about how President Trump has praised China and President Xi, but that has made some of his
advisors uncomfortable given the lack of transparency from China and the inability to get CDCscientists
in to the country. We also have some details about the response and the task force , and some
disagreements that have arisen. I've listed the points we have in the story that pertain to HHS- would
you be able to take a look, let me know if there are any issues and potentially provide a comment? I
included some quotes from Sec. Azar's interviews on Friday with CNN and CNBCbut also happy to
include a quote from the agency.
NIH-001859
I realize I'm sending this at the end of the day, so would it be possible for you to get back to me by 1 pm
tomorrow? Let me know what works on your end. Thanks so much.
• President Trump has lavished praise on China and its ruler, Xi Jinping, for its handling of the
growing coronavirus outbreak - a posture some in his administration are growing increasingly
uncomfortable with as his advisors remain concerned about China's transparency and handling
of the epidemic .
• Trump's praise towards Xi has irked some advisors, who say those comments and others about
how the virus wil l likely behave reflect how the president is being briefed, underscoring tensions
within the admin istration over its handling of the outbreak and the message it should be
sending to the American public.
• Worries about the market and tenuous negotiations with China over a trade deal have played a
large role in influencing Trump 's friendly posture .
• Trump has told advisors he does not want the administration to do or say anything that would
further spook the markets, but remains worried that any large-scale outbreak in the U.S. could
hurt his reelection bid .
• For weeks, the adm inistration's messaging was that the th reat to the American public remained
low and the virus was not spreading within communities. But some advisors pushed for a more
balanced message because they expect there to eventually be some commun ity spread as the
outbreak grows, and the administration has since adjusted its message to reflect that.
• In an effort to keep Trump calm and restrained, Azar has been briefing the president that
"everything is under control, totally under control," which has kept Trump from doing or saying
anyth ing drastic.
• HHSofficials have also told Trump that the number of infections could go down in the spring
when it gets warmer, which is mainly an educated guess.
• Some officials have complained that Trump's comments emanate from his briefings with Azar,
who they say has sought to control the response . He has told other doctors , including Anthony
Fauci, not to get too far into the details of the virus and outbreak with Trump . Instead, Azar has
instructed doctors to let him handle it.
• Azar has also wanted to be the one to announce major updates about the administ ration's
response to the virus . On Thursday, he briefed the Senate Finance Committee that the CDC
would use public health labs in five cities that normally test for infl uenza to also test for
coronavirus, taking state health officials by surprise.
• Some officials said the response has become smoother and better coordinated in recent weeks.
Yasmeen Abutaleb
The Washington Post
Health policy reporter
@yabutaleb7 -----
o: 202-334-8387 c: ---~ (b
~)~(6)
=
NIH-001860
Sent : Sat, 22 Feb 2020 21:07:26 +0000
To : Messonnier, Nancy (CDC/DDID/NCIRD/OD)
Cc: Redfield, Robert R. (CDC/OD);Cetron, Marty
(CDC/DDID/NCEZID/DGMQ);Jernigan, Daniel B. (CDC/DDID/NCIRD/1D)
Subject : RE: Wpost: New developments suggest coronavirus incubat ion cou ld be longer
than 14 days, as global infections rise
Sou nd s good to me. Thanks.
Director
Phone : Cb)
(6)
FAX: (301 496-4409
E-mail : (b)(6)
From : Messonn ier, Nancy (CDC/DDID/NCIRD/OD) (b)(6)

Sent : Saturday, Februar y 22, 2020 4:06 PM
------
To: Fauci, Anth ony (NIH/NIAID) (E] --=-<~
(b)(6)
Cc: Redfield, Robert R. (CDC/OD) (b)(6)>; Cetron, M arty (CDC/DDID/NCEZID/DGMQ)
CbH6J>;Jernigan, Daniel 8. (CDC/DDID/NCIRD/ID)
------ (b)(6)>
Subject : Re: Wpost: New developments suggest coronavirus incubation could be longer than 14 days, as
global infections rise
(b) (5)
Soundgood?
From: Fauci, Anthony (NIH/N IAID) [E] (b)( >

Sent : Saturday, February 22, 2020 3:12:02 PM
_____
To: Redfield, Robert R. (CDC/OD) (b)(6)>; Messonnier, Nancy (CDC/DDID/NCIRD/OD)
_, Cetron, Marty (CDC/DDID/NCEZID/DGMQ)
(b)(6)>; (b)(6)>
Subject : FW: Wpost : New developments suggest coronavirus incubation could be longer than 14 days,
as global infec tion s rise
NIH-001620
Folks:
(b) (5)
Ton y
Director
Phone : (b) (6)
FAX: (301) 496-4409
E-mail (b) (6)
---------
From: Folkers, Greg (NIH/ NIAID) [E)
Sent : Saturda y, February 22, 2020 10:52 AM
(b)(6)
Subj ect : Wpost: New developments suggest coronavi rus incubation could be longe r than 14 days, as
New developments suggest coronavirus

incubation could be longer than 14 days, as
NIH-001621
Medical workers in protective suits gather Friday at a temporary hospital at Tazihu Gymnasium in
Wuhan in central China's Hubei province. (AP)
By
Anna Fifield,
M in Joo Kim and
Simon Denyer
Feb. 22, 2020 at 10:17 a.m. EST
There are new indications that the incubation period for the virus could be longer than the currently
believed 14 days, with patients testing positive after much longer quarantine periods. This development
came as infections rose in South Korea, Japan, Iran and It aly and the head of the World Health
Organization warned that the w indow for stopping the epidemic was narrowing .
Here's wh at w e know:
• Chinese leader Xi Jinping has been advised that the situat ion in Wuhan "remains grim and com pie><."
• South Korea and Japan both reported a sharp spike in cases Saturday, with the number of cases in
South Korea doubling in a day. A fifth person died in Iran from the virus, while Italy now has 50
confirmed cases, making it the largest hot spot in Europe.
• China reported only 397 new cases Saturday, as the rate of increase continued to decline, but an
addit ional 109 people have died . There continues to be a great deal of skepticism about China's
numbers as t he criteria for diagnosing coronavirus keep changing.
• A team of international epidemic experts had Wuhan added to their itinerary in China, following
quest ions about why they wouldn't go to the center of the coronavirus outbreak tha t has caused more
than 2,000 deaths in the country .
• Scientists in China said they had isolated coronavirus strains in urine , raising the possibility that it
might be transmissible that way, as well as through feca l matter and respiratory droplets .
NIH-001622
BEIJING - Scientists are studying reports that the incubatio n period for coronavirus could be longer
than the cur rent ly believed 14 days, potentially casting doubt on current quarant ine crite ria for
contain ing the vir us amid an increasingly urgent effort to stop the epidemic from spreading in northeast
Asia and across the world.
South Korea and Japan both reported a sharp spike in cases Saturday, wh ile in China, an addit ional 109
people died and a fifth person died from the virus in Iran. Italian authorities on Saturday said the
country was seeing a sudden rise in coronav irus cases, w ith roug hly 50 confi rmed in the past two days
- an outb reak that represents the largest yet across Europe.
Meanwhi le, scientist s in China reported indications that the virus might be transmissib le through urine.
A team of experts from the World Health Organization was due to arr ive Saturday in Wuhan, the
epicente r of the coronav iru s outbreak.
WHO director-gene ral Tedros Adhanom Ghebreyesus on Friday stressed the urgency of conta ining the
spread of the coronavirus, after cases were reported earlier in Iran and Lebanon.
"Although the w indow of opportun ity is narrowing to conta in the outbreak , we still have a chance to
contain it ," he told reporters in Geneva. "If we don't, if we squander the opportunity, then there w ill be
a serious problem on our hands."
Chinese leader Xi Jinping, who has not visited Wuhan since the outbreak began, was briefed t hat the
situation in the city and in surround ing Hubei prov ince "rema ins grim and comp lex," according to a
repo rt by the official Xinhua News Agency published Saturday.
"The nationw ide inflect ion point of the epidemic has not yet arri ved," the report said after a meeting of
Communist Party leaders.
China' s National Health Commission reported Saturday that 397 new cases of coronav irus had been
diagnosed Friday, tak ing the tota l to more than 76,000. The rate of infection outside Hubei appears to
have slowed markedly, althoug h there has been a great deal of conf usion about the statistics th is week
as officials have repeatedly changed the crite ria for confi rming cases.
Among the new cases discovered Friday were a 70-year-old man in Hubei who was confirmed as
infected after 27 days in isolation, while a man in Jiangxi prov ince tested posit ive after 14 days of
entralized quarantine and five days of isolation at home. On Thursday, autho rit ies reported that a man
in Hubei had tested positive for coronav irus after what appeared to be a 38-day incubation period w ith
no symptoms.
Coronaviruscasesin South Korea skyrocket; casestriple in Japan
In Seoul, the Korea Centers fo r Disease Control and Prevent ion reported Saturday that 229 addit ional
cases of the coronav irus had been detected, tak ing the tota l to 433, more than doubling in the space of
a day. This makes it the worst -affected count ry outs ide China.
"Apart from the Diamond Princess cruise ship, [Sout h] Korea now has the most cases outs ide China, and
we're work ing closely w ith the government to f ully unde rstand the transmission dynam ics that led t o
th is increase," Tedros said.
The majo rity of the new cases have been traced to existing clusters at a churc h in southern city of Daegu
and a hospital in nearby Cheongdo County, according to the KCDC.
The South Korean government has designated Daegu and surro unding Nort h Gyeongsang prov ince as
"special care zones" whe re conta inment efforts and support will be concentrated.
More than half of South Korea' s cases are connected to Daegu branch of the Shincheonj i Church of Jesus
the Temple of t he Tabernacle of the Testimony .
Since members of the chu rch attended a fune ral at nearby Cheongdo Daenam hospital , 111 coronavirus
cases have been repo rted the re, includ ing two patients w ho died from the virus .
NIH-001623
The mass infection at the hospital is centered on its locked psychiatric ward, where a confined
environment could have aggravated transmissions, said Jung Eun-Kyeong, director of the KCDC.
A man in his 40s was found dead at his home in city of Gyeongj u, east of Daegu, after becoming infected
with the virus. He is the third person to die from the virus in South Korea.
Trump was not t old coronavirus-infected Americans would be fl ow n home from cruise ship
In Japan, the number of coronavirus cases rose to 121 on Saturday, more t han tripling in a week. That
number excludes the 634 people on board the Diamond Princess who contracted the virus.
One of the latest cases was a teacher in her 60s at a public junior high school east of Tokyo, who
complained of nausea whi le working. The mayor of Chiba city said the school w ill be closed until
Wednesday, public broadcaster NHK reported.
The teacher had not traveled abroad in the past two weeks and has no record of having been in contact
with a known infected person, underl ining the fact that the virus is now spreading almost invisibly
throughout the country, experts say.
Quarantines in effect in parts of Italy amid sudden spike in cases
As numbers suddenly rose in Italy, the government has scrambled to contain the new outbreak, asking
some 50,000 people to stay indoors and suspending all public events - including religious ceremonies
and school - in 10 small towns to the south of Milan.
Until a few days ago, Italy had seen only three confirmed infections, including a pair of Chinese tourists.
"There is quite an evident contagion, a very strong one," said Giulio Gallera, health chief of the northern
Lombardy region, which has seen the majority of the cases.
Italian officials on Friday attributed the country's first death to the coronavirus, and on Saturday said
that a 77-year-old woman had also tested positive for the virus after being found dead in her home. But
Italian authorities said the woman suffered from other health conditions, and were unsure if it was the
virus that had killed her.
As of Saturday afternoon, there were 39 confirmed cases in the prosperous Lombardy region, which
includes the country's financial hub, Milan . There were another 12 cases in the neighboring northern
region of Veneto.
The regional president of Veneto, Luca Zaia, said it is becoming harder to figure out how the virus is
jumping from one place to the next .
"It goes to show you that having other cases of contagion is absolutely possible," Zaia said.
According to Italian media reports , one of the first peop le to come down with the virus was a 38-year-
old who'd had dinner with somebody who had j ust come back from China. But some three wee ks passed
between that dinner and the time the man came down with a fever. In between, he ran a half-
marathon, played soccer and traveled to several towns, according to La Repubblica, a maj or Italian
daily .
Iran, meanwhile, announced its fifth death from t he virus, raising the country's overa ll total confirmed
cases to twenty eight .
Efforts to clear the Diamond Princess cruise ship continue
Meanwhile, tests are continuing on the crew members on board the Diamond Princess. At least 74 crew
members have so far been found to have the virus.
All of the passengers have now been tested and almost all have left the ship, either to go home if they
tested negative, to local hospitals or government facilities if they have the virus, or back to their home
countries.
Some passengers were asked to stay on board to serve an additional quarantine if their cabin mate
contracted the virus, but this group is also disembarking Saturday to serve out the rest of their
quarantine in a government facility, local media reported .
In China's 'w ar' on coro navirus. hospita ls turn away ot her pat ient s - w ith dire result s
NIH-001624
More than 200 port calls in Japan by international cruise ships have been canceled since the beginning
of February due to the coronavirus outbreak, a Kyodo News survey showed Saturday, with the lost
revenue from passengers coming ashore dealing another blow to Japan's weak economy .
Controversy continues to simmer about the infection control procedures on board the ship, after a
doctor complained on Tuesday about "chaotic" and scary conditions on board .
Six people working on the boat or with the passengers, including four government officials, a medic and
an ambulance driver, have contracted the virus.
Media reports questioned why about 90 government officials who worked on the ship have returned to
work without being tested for the coronavirus . Asked about this, Health Minister Katsunobu Kato said
the government is "trying to confirm what operations staff were involved in specifically."
Amer ican woman in Malays ia declared free of coronavirus
The 83-year-old woman who tested positive for the coronavirus when she arrived at Kuala Lumpur
airport after disembarking in Cambodia from the MS Westerdam cruise ship has recovered, Malaysia
health authorities said Saturday.
The woman "is showing good improvement and signs of recovery, however, she is still being mon itored
and managed in hospital for a slight cough," Malaysia's director general of health, Noor Hisham
Abdullah, said in a st atement.
The woman repeatedly tested negative while on board the ship and when she disembarked in
Sihanoukville, then twice tested positive wh ile transiting in Kuala Lumpur airport on Feb. 15. That set off
a global scramble to track the hundreds of other passengers who had also disembarked then boa rded
planes bound for home.
The woman was taken to a hospital and given antiviral treatment and supplementary oxygen, and she
showed improvement after 72 hours of treatment initiation, Abdullah said. Two more tests, conducted
24 hours apart, both came back negative for coronavirus.
But the U.S. Centers for Disease Control and Prevention cast doubt on whether the woman was ever
infected, saying she "never had coronavirus to our knowledge ."
"I have confirmed that all the passengers were tested, and they have come back negative for
coronavirus, including the person who initially tested positive ," USAToday quot ed CDCspokesperson
Richard Quartarone as saying. The woman " may have had a respiratory ill ness, but if she did, it was not
covid- 19," he said, using the official name for the virus.
Cambodia's Ministry of Health had previously cleared the 747 crew members who were still on board
the Westerdam and the 781 passengers who were still in the country of coronavirus infection .
Chinese scientists isolate coronavirus strains in urine as WHO prepares visit
Separately, scientists in China are continuing to study how the virus is transmitted .
A research team led by renowned Chinese pulmonologist Zhong Nanshan had isolated live coronav irus
strains in urine samples from infected patients, Zhao Jincun, a respiratory expert at the State Key
Laboratory, told reporters in Guangdong on Saturday.
The team of scientists had previously said the virus, in addition to being carried in respiratory drop lets,
appeared to be transmissible through fecal matter, underscoring the need to practice good hand
washing as a preventive measure .
Zhao did not directly say that the virus could be transmitted through urine, simply noting that the strains
had been isolated and that this had implications for public health control. They are cont inuing to work
on isolating the virus and on a cure, the Guangzhou Daily reported.
But he said people should pay more attention to personal and family hygiene to prevent the spread of
the virus and recommended frequently washing hands, closing the toilet lid before flushing and making
sure bathroom drains are not blocked.
NIH-001625
WHO experts have also been on an investigative mission in China this week, holding meetings in Beijing
and traveling to the prov inces of Sichuan and Guangdong. But they had not been scheduled to travel to
Wuhan , where the outbreak began at a live animal market and which remains under strict lockdown in
an effort to contain the virus.
This had led to speculation that the Chinese government, which has come under fire for its slow
response to the outbreak and where medical workers are stretched to the limit, did not want the
experts to visit.
But the WHO said late Friday that the experts would be travel ing to the center of the outbreak on
Saturday, although they gave no further information about their itinerary .
Kim reported from Seoul and Denyer from Tokyo. Lyric Li in Beijing, Akiko Kashiwagi in Tokyo and Chico
Harlan and Stefano Pitrelli in Rome contributed reporting.
Two Beijing hospit als qua rantine d amid fears coronav irus infect ions w ill spike in t he capita l
Confusion mount s over China' s count ing met hods as coronav irus numbers swing w ildly
Coronavirus claims lives of two passengers fr om Diamond Princess cruise ship, Japanese med ia says
Today1scoverage from Post corr espondents around t he wo rld
Like Washingt on Post Wo rld on Faceboo k and stay updat ed on fo reign news
Disclaimer : Any third-party material in this email has been shared for internal use under fair use provisions
my views nor those ofNIATD, NTH, HHS, or the U.S. government.
NIH-001626
Sent : Sat, 22 Feb 2020 18:35:29 +0000
To : Mermin, Jonathan (CDC/DDID/NCHHSTP/OD)
Subject : RE: COVID-19
Jono :
Ma ny t hanks for yo u r kind note. Much appreciated. I ho pe th at all is we ll w ith
yo u.
Best regards,
Tony
Director
Phone Cb)(6)
FAX : (301 496-4409
E-mail : (b)(6)
From: Mermin, Jonathan (CDC/DDID/NCHHSTP/OD) CbH >

------
To: Fauci, Anthony (NIH/NIAID) [El------=--c=CbH6)>
Subject : COVIO-19
Tony:
I just wanted to send you a quick note of compliment. I have seen and heard you speak on COVID-19
over the past few weeks, eloquent ly, accurately, and as definitively as the data allow. Outstanding
work .
Best,
Jono
NIH-001651
Sent : Fri, 21 Feb 202011:59:09 +0000
To: Cetron, Marty (CDC/0010/NCEZID/DGMQ) ;Collins, Francis (NIH/OD) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Charles, Julia (CDC/00/0CS);Eidex, Rachel
Barw ick (CDC/0D1D/NCEZID/DGMQ)
Subject : RE: Infectious d isease advice for NSO Asia tour
Thanks, Marty .
Director
Phone : (b)(6)
FAX: (301 ) 496-4409
E-mail : (b)(6l
From: Cetron, Marty (CDC/DDID/NCEZID/DGMQ)

Se nt : Friday, February 21, 2020 6:31 AM ------ (b)( >

(b)(
-------=
--------- = (b)( ; Collins, Francis (NIH/OD) [El
Cc: Conrad, Patricia (NIH/NIA ID) [E] (b)( ; Charles, Julia (CDC/00/0CS)
(b)( ; Eidex, Rachel Barwick {CDC/DDID/NCEZID/DGMQ) CbH >
------
Subject : Re: Infectious disease advice for NSOAsia tour
Tony and Francis

Happy to be a POCfo r Deborah . She can text me (b)(6)and we can arrange a time to speak. My
cell recept ion in EOCnot great. Alternative ly EOCcan track me down (b)(6)
Email pretty clogged these days ...

Best,
MSC

-------- CbH >
Se nt: Friday, February 21, 2020 5:46:50 AM
-------- (b)(6)
NIH-001694
Cc:Cetron, Marty (CDC/DDID/NCEZID/DGMQ)
(b)(6)
_____
..... (b)( >; Conrad, Patricia (NIH/NIA ID) [E]
Subject: RE: Infectious disease advice for NSO Asia tour
Francis:
(b)(5)
------------- The best person in the wor ld for this is Marty Cetron at the CDC.
(b) (5)
am copy ing him on this e-mail. Perhaps he can direc tly get back to you.
Best,
Tony
--------
(b)(6)
-------=-:-:=
--------- (b)(6)
Subject: FW: Infectious disease advice for NSO Asia tour
Hi Tony,
See below from Deborah Rutter, t he head of the Kennedy Center .

------------ (b) (5)
Who would you recommend at NIH or CDCto be a contact?
Francis
From: Rutter, Deborah F.<DFRutter@Kennedy-Center .org>
To : Collins, Francis (NIH/OD) [El (b)( >
Cc: Ginstling, Gary <GGinstling@Kennedy-Center .org>
Subject : Infectious disease advice for NSOAsia tour
Dear Francis
As you may know, the National Symphony Orchest ra has long had an Asia your on its schedule for March
this year, leaving in just two weeks or so. The China portion of the tour was cancelled a few weeks ago
but the Japan portion of the trip has been sustained. Now, with increased focus on Japan, some of the
members and our management are looking for addit ional advice on travel concerns and any infectious
disease warning/direction. Would you have someone amongst your brilliant colleagues who could be a
resource to our team?
I have included Gary Ginstling on this email as he is our Executive Director of the NSO. Thank you so
much for any direction you can offer us!
Deborah
NIH-001695
This e-mail message is intended only for the recipient(s) named above. This message may contain trade
secrets, attorney -client communication, or other privileged and confidential information . Any review, re-
transmission , dissemination, reproduction or other use of , or taking of any action in reliance upon , this
information by persons or entities other than the intended recipient is prohibited. If you received this in
error , please contact the Sender and delete the material from any computer .
NIH-001696
From: (b)(6)
Sent: Tue, 18 Feb 2020 15:41:35 -0500
Subject: Fwd: Lunch with AMB at Thai Residence on 27 Feb or 4 March
Let us discuss.
From: "Wolfe , Mitchell (CDC/OD)" (b)(6)

-------
Date: Februa ry 18, 2020 at l :08:55 PM EST
To: "Fauci, Anthony (NIH/NIAID ) [E]" -------~~
(b)(
Subject: F,v:Lunch with AMB at Thai Residence on 27 Feb or 4 March
Tony,
The Thai Ambassador has invited you, and CDC, to lunch at his residence either 27 Feb or 4
March. They didn't have your contact and asked (per below) if I could contact you to
ask. Dr. Redfield is in Washington, DC on 27 Feb and I will ask if he wants to attend. If you
or your staff can let me know, I will get back with them.
Best regards,
Mitchell Wolfe, MD, MPH

RADM, USPHS
Chief Medical Officer, Office of the Director
Ph:
----- (b)(6)
From: Panupat Chavananikul <panupatc@thaiembdc.org>

To: Wolfe, Mitchell (CDC/OD) (b)(6)
Cc:Chuliepote lsarankura Na Ayudhaya <chuliepotei@thaiembdc .org>
Subject: Lunch with AMB at Thai Residence on 27 Feb or 4 March
Dear P Mitch krub,

Ref: invita t ion for Lunch on 27 Feb OR 4 March
1. Hope all is well with you. Hopefully you had some rest last weekend. Since you were
living in Thailand for a while you must be missing authentic Thai food . Ambassador Thani
NIH-001780
w iould like to extend his invitation to you and CDC colleagues to have lunch at Thai
residence either on Thursday27 Feb or Wednesday4 March at 12.30 pm. His residence
located at (b)(6) You may invite your colleagues who involve in
Coronavirus or Thailand, and please let me know their name and ranking as we ll as your
available date.
For the Embassy's side, there will be Ambassador+ Ms. Chuliepote +me+ and some of
our colleagues.
2. Also, Ambassador Thani and I attended Dr. Tony Fauci's briefing, organized by NSC,
on Feb 6., but unfortunate ly we didn't have much time to talk to him. Dr. Fauci also
received Prince Mahido l award back in 2013 . Ambassador would also like to have him join
our lunch at his residence as we ll.
Is it possible that you may reach out to him to see whether he can have lunch with us or
not, OR you may provide me his contact detai ls.
Thank you krub &Best wishes,
Panupat (boat)
Mr .Panupat Chavananikul
Counsellor (Consul)
Royal Thai Embassy
Cell Cb)(6)
Work 202 640-5308
NIH-001781
Sent : Tue, 18 Feb 2020 14:57:27 +0000
Subject : RE: Severity Assessment for U.S. Response - CDC
Attachments : Severity Assessment for U.S. Response - CDC.docx
Bob:
See my minor tra cked edits.
Thanks,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From : Redfield, Robert R. (CDC/OD) (b) (6)

To: Fauci, Anthony (NIH/NIAID) [E)______ _,(b
__)-,-
(6)
=
Subject : Fwd: Severity Assessment for U.S. Response - CDC
Take a look ?edits thoughts

Or. Robert Redfield
From : Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) (b)(6)

Sent: Monday, February 17, 2020 10:48:48 PM
To: Redfield, Robert R. (CDC/OD) (b)(6)
Cc: Schuchat, Anne MD (CDC/OD) CbH6J> ; Cetron, Marty (CDC/DDID/NCEZID/DGMQ)
CbH6J>; Butler, Jay C. (CDC/DDID/O0) CbH6J>
------
Subject : Severity Assessment for U.S. Response - CDC
Dr. Redfield:
Here is the severity assessment in response to your request from yesterday. Take a look and see if this
addresses your request.
Dan
NIH-001784
Sent: Wed, 19 Feb 2020 12:03:04 +0000
To: Marks, Peter;Schuchat, Anne MD (CDC/OD)
Cc: Cho, David S (CBER)(FDA/CBER);Munster, Vincent (NIH/NIAID) [E];Marston,
Hilary (NIH/NIAID) [E]
Subject: RE: Covid-19 Survival on Surfaces
Peter:
Vincent Mun ster at NIAi D's RML has done work on thi s. I am copying him on
thi s e-mail.
Best,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail (b) (6)
From: Marks, Peter Cb) ( >

To: Schuchat, Anne MD (CDC/OD) (b)(6)'>; Fauci, Anthony (NIH/NIAID) [E]
(b)(6)
Cc: Cho, David S (CBER)(FDA/CBER)
Subject : Covid-19 Survival on Surfaces--------- (b)(6)
Dear Anne and Tony,
I am sorry to bother you, but I am hoping that you can direct me to anyone at NIAID or CDCwho is
work ing on the survival of Covid-19 on surfaces. This could include shipping boxes, but also on various
products and other perishab le items. The food safety people here at FDA are quite concerned about the
latter, given published reports of differential coronavirus surv ival on various surfaces.
If it turns out that this has not been evaluated, or is not in the process of being evaluat ed, we are happy
to work on this in our BSL-3 labs, which are now in receipt of the v irus.
NIH-001763
Thanks so much for any direction that you can provide.
Best Regards,
Peter
NIH-001764
Sent : Sat, 15 Feb 2020 12:55:47 +0000
To : Gilman, James (NIH/CC/OD) [El;Collins, Francis (NIH/OD) [El;Gottesman,
Michael (NIH/OD) [E);Tabak, Lawrence (NIH/OD) [El;Schwetz, Tara (NIH/OD) [El
Cc: Holland, Steven (N IH/NIAID) [E);Johnson, Alfred (NIH/OD) [E);McGowan, Colleen
(NIH/OD/ORS) [El;Schmitt, James (NIH/OD/ORS) [El
Subject : RE: COVID-19 messaging
(b) (5)
From: Gilman , James (NIH/CC/OD) [El (b)(6)

Sen t : Friday, February 14, 2020 11:32 PM
To: Collins, Francis (NIH/OD) [El ----- ~= (b)(6)> ; Gottesman, Michael (NIH/OD) [El
(b)( ; Tabak, Lawrence (NIH/OD) [El (b)(6); Schwetz, Tara
":":
(N"".".'
l~
H/-:-::
0:--:
D~) ":":
[E~] ====~__,_., = >; Fauci, Anthony (NIH/N IAID) [E]
(b).,..;
(6) CbH >
Cc: Holland, Steven (NIH/NIAID) [E] CbH6J>;Johnson, Alfred (NIH/OD) [E]
(b)(6); McGowan, Colleen (NIH/OD/ORS) [E] Cb)( ; Schmitt,
James (NIH/OD/ORS) [El (b)(6)
Subject : Re: COVID-19 messaging
(b) (5)
Jim
From: "Collins , Francis (NIH/OD) [El" CbH6J>

Date : Friday, February 14, 2020 at 8:04:30 PM
To: "Gottesman , Michael (NIH/OD) [E)"--------aa- ~H=6J>, "Tabak , Lawrence (NIH/OD) [E]"
Cb
(b)(6)>, "Schwetz, Tara (NIH/OD) [E]" (b)( >, "Fauci, Anthony
---:----:-~~==:::!....:--~~
(NIH/NIAID) [El" Cb)( >
Cc: "Holland, Steven (NIH/NIAID) [El " (b)( >, "Johnson, Alfred (NIH/OD) [El"
(b)(6)> , "McGowan, Colleen (NIH/OD/ORS) [El"
----------
11Schmitt, James (NIH/OD/ORS) [El"
(b)(6) ,
(b)(6), "Gilman, James (NIH/CC/OD) [El"
(b)(6)>
1111Looping in Jim Gilman .
FC
From: Gottesman, Michael (NIH/OD) [E] (b)(6)>

NIH-001869
To: Tabak, Lawrence (NIH/OD) [El Cb)( >; Schwetz, Tara (NIH/OD) [El
(b)(6); Collins, Francis (NIH/OD) [El (b)(6)>; Fauci, Anthony
--.--.~~==:!:...,__ _ ___;~~
(NIH/NIAID) [El (b)(6)>
Cc: Holland, Steven (NIH/NIAID) [El CbH >; Johnson, Alfred (NIH/OD) [E]
(b)(6); McGowan, Colleen (NIH/OD/ORS) [El (b)( >; Schmitt,
James (NIH/OD/ORS) [El CbH6J>
Subject : COVID-19 messaging
We have had many requests for additional guidance concerning staff potentially exposed to COVID-19.
OMS has prepared the attached message which has been reviewed by Steve Holland and HR.
The intent is to send t his from OMS to all hands.
Michael
NIH-001870
Sent : Sat, 15 Feb 2020 02:23:37 +0000
Attachments : COVID-smh - with Fauci edits .docx
Steve:
See m',' tracked edits. (b) (5)
(b)(5)
Thanks,
Tony
From: Holland, Steven (NIH/NIAID) [E] (6)>

--------- (b)

______ ~=
Cb
>
_<_ >
Subject : FW: COVID-19 messaging
Tony,
Could you please look at the attached and make any edits you think would help . (b)(5) ~
(b)(5)
Steve
Director , Division of Intramural Research

Bldg. 10/11N248 MSC 1960
----- (b) (6)voice

301-480-4507 fax
----- (b) (6) email
Assistan t lab: Eva Portillo

(b)(6) emai l
~==~~---
----- (b) (6) voice
NIH-001871
(b)(6)
----
(b) (6) voice
(b)(6 )>
From: "Gottesman, M ichae l (NIH/OD) [E]"
Date: Friday, February 14, 2020 at 6:12 PM ---------
To: "Schmitt, James (NIH/OD/ORS) [E]"-------~~
Cc: "Moss, Bradley (NIH/OD/ORS) [E)"
..========;:-=-,;:--
Steven Holland
(b)(6)
(b)( 6) --------- (b)(6)
Subject : Re: COVID-19 messaging
(b) (5)
- · This can wait until next week.

Michael
From : "Schmitt, James (NIH/OD/ORS) [E]"

Date: Friday, February 14, 2020 at 6:07 PM ---------
-------~=
(b)(6)
To: "Gottesman, Michae l (NIH/OD) [E]" Cb)( >

Subject: FW: COVID-19 messaging
I meant to copy you on this Michael. Jim
From : Schmitt, James(NIH/OD/ORS) [El

To: Moss, Bradley (NIH/OD/ORS) [El
------~= (b)(6)>; Bailin, Heike
(b)(6)
---------
Cc:Newcomer, Derek (NIH/OD/ORS) [El (b)(6)
(b)(6)>; Wheeland, Daniel (NIH/OD/ORF) [E)
-----------
McGowan, Colleen (NIH/OD/ORS) [E) (b)(6)>; Tosten, Timothy
(b)(6);
(NIH/OD/ORS) [E) (b)(6)

Subject: FW: COVID-19 messaging
Hi Bra d,
It sounds like Dr. Gottesman wants this sent from OMS to everyone.
I don ' t know how to do that. Can you help us with this and how soon can it be sent?
I'm heading out of town and won ' t retmn to the clin ic until Tuesday . Dr. Bai lin will be
in charge of OMS in my ab sence.
Jim
James M. Schmill, M.D., M.S.

Medical Director
Occupational Medjcal Service, DOHS
NIH-001872
National In stitutes of Hea lth
IOCen ter Drive
(b)(6)
From: Gottesman, Michael (NIH/OD) [E] (b)(6)>

To: Tabak, Lawrence (NIH/OD) (E] ------- ~= >; Schwetz , Tara {NIH/OD)
(b)( [E]
(b)(6); Collins, Francis (NIH/OD) [E) (b)(6)>; Fauci, Anthony
7( N H/7 N- IA
- l'."'" "".'"
l-:-
D-:-
) :-: ) ==:::::;.--~
[E-:. (b
"'~=(6)>
Cc : Holland, Steven (NIH/NIA ID) [E] (b)(6)>; Johnson, Alfred (NIH/OD) [E]
(b)(6); McGowan, Colleen (NIH/OD/ORS) [E] >;
---------
Schmitt , James (NIH/OD/ORS ) [E] CbH6)>
(b)(
Subject : COVID-19 messag ing
We have had many reques ts for additional guidance concerning staff potentially exposed to
COVID-19. OMS has prepared the attached message which has been reviewed by Steve Holland
and HR.
The intent is to send this from OMS to all hands.
Michael
NIH-001873
Sent : Sat, 15 Feb 2020 02:08:57 +0000
Cc: Conrad, Patricia (NIH/NIAID) [E);Barasch, Kimberly (NIH/NIAID) [C);Marston,
Hilary (NIH/NIAID) [E);Eisinger, Robert {NIH/NIAID) [E);Lerner, Andrea (NIH/NIAID) [El
Subject: RE: Rapid instrument-free NAAT for COVID-19
Attachments : VisbyMedical_ TechWatch_Feb2020_nCoV_NIH.pdf
See attachment as per prior e-mai l.

To: Gary K. Schoolnik (b)(6)>
Cc : Conrad, Patricia (NIH/NIAID) (El (b)(6 h ; Barasch, Kimberly (NIH/NIAID) [CJ
(b)(6) ; Marston, Hilary (NIH/NIAID) [E (b)(6)>; Eisinger,
---:---:---:---'""'.""":''"""."::==.:.---:...._~ ~
Robert (NIH/NIAID) [El (b)(6)>; Lerner, Andrea (NIH/NIAID) [E)
CbH ; Cassetti, Cristina (NIH/NIAID) [E]
----------
Subject: RE: Rapid instrument -free NAAT for COVID-19
(b)(6)>
Gary:
Thanks for the note. I would be happy to discuss this with you. Please have your office
contact my Special Assistant, Patty Conrad, (copied here) to set up a mutually convenient time
when we can chat.
Best regards,
Tony
From:Gary K. Schoolnik (b)(6)>

-----~~ (b)(6)>
Cc: Adam de la Zerda (b)(6)
Subject : Rapid instrument-free NAATfor COVID-19
Dear Tony ,
In addition to my role as a Stanford Medical School professor, I am the Chief Medical Officer of
Visby Medical, a relatively new Silicon Valley diagnostics company focused on rapid detection of
infectious agents. Visby Medical has developed a rap id (~25 min sample-to-answer) palm-sized,
40 cycle PCR (or RT-PCR) single-use device that does not requ ire an instrument; it is used once,
and then discarded or recycled . (b)(4)
device is stable at room temperature for up to two years and thus it could be deployed widely.
NIH-001874
We are seriously considering using this platform to develop a rapid test to detect COVID-19.
Proof of principles that have been achieved toward that end are our demonstration that the
device can use two-step RT-PCRto detect influenza A and Bin NP swab samples. The main
features of the device are described in the brief accompanying PDF.
I write now because we are unsure, if we were to produce a COVID-19 device, how it would be
deployed, by whom it would be used and who might be willing to purchase it. I would be very
grateful if you might be able to speak briefly with me and my colleagues about these open
questions. I am convinced this device can meet a major unmet need in clinical care and disease
control for this epidemic and we, as a group, want to make a difference. Your advice would be
invaluable as we weigh the risks and benefits of pivoting the company to this application.
With all best wishes; I hope all is well with you and your family.
gary
Gary Schoolnik, M.D.

Stanford Medical School
Attending Physician (Internal Medicine , Infectious Diseases)
Stanford University Hospital
Chief Medical officer
Visby Medical
NIH-001875
From: (b)(6)
Sent: Fri, 14 Feb 2020 18:45:53 -0500
To : Julia Belluz
Subject: Re: call
My pleasure!
On Feb 14, 2020, at 6: 10 PM, Jul ia Belluz <ju lia.belluz @vox.com>wrote :
Thank you so much for making the time to comment at what I know is a crushingly
busy time. As usual don't hesitate to ping if you have any fmther comments or
questions! Julia
https://wwv,, .vox.com/2020/2 / 14/2 l l 344 73/coronavirus -outbreak -singa pore-us-

sym ptoms-pan demic
Sent from my iPhone
On Feb 14, 2020, at 1:2 1 PM, Fauci, Anthony (NIH/NlAID) [E]

Cb)(6) wrote:
Julia:
I j ust called you now (7:20 AM Washington, DC time) and
got mvoice mail in German that I could not understand. You
can call me at CbH6J
Thanks,
Tony
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mai l : (b)(6)
and may contain sensitive Information. It shou ld not be used by anyone
NIH-001878
NIH-001879
Sent: Fri, 14 Feb 2020 21:09:40 +0000
Subject: RE:Your Expertise requested/COVID -19 Forum
OK. Let us d iscuss. As long as it is remote ...
Director
Phone : (b)(6)
FAX: (301 ) 496-4409
E-mail : (b)(6)

---------- (b)(6)
Subject : FW: Your Expertise requested/COVID -19 Forum
Patricia L. Conrad
(b)(6)
301-496-4409 fax
Disclaimer:
from your mailbox or any other storage devices. National Institute of Aller gy and Infectious Diseases (NIAID) shall not accept
liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representalives.
NIH-001880
From: Roache, Christina (b)(6)>
------~~ (b)(6)
!.=======~=
---------
Subject : Your Expertise requested/COVID-19 Forum
(b)(6)>
Dear Dr . Fauci,
You have been kind enough to be a panelist on our Forums at the Harvard T. H. Chan Schoo l of
Pub lic Health , and I wanted to see if you were available to participate remotely in a Fomm that
we are organizing on March 2 about COVID -19.
The Forum will live stream on the websites of The World and The Forum, as welJ as on
Facebook and YouTube.
The World will send a journa list to moderate and co-promot e.
The Forum is called "The Coronavirus Outbreak: Tracking COVID-19", presented jointly
with The World from PRX & WGBH.
Should you agree to part icipate, we ask that you jo in us remotely from 11:40am-lpm ET on
March 2; the actual live we bcast will be noon-lp m ET.
We have been active is cover ing this outbreak . We did a high ly successfu l Facebo ok Live Q&A
last week and are doing another Q&A next week.
As a reminde r, Forum webcasts are one-hour long and are pan el discussions, typically with 3-4
pane lists, plus a moderator. As noted, these discu ssions are live streamed from our Leadership
Studio at our school in front of a stud io audience (about 40 seats) and an onli ne audience.
Anyone with an Int ernet connection can watch the live webcasts; no registration or fee is
required.
NIH-00188 1
Previous speakers in The Forum series have included Gina McCarthy , former EPA
Administrator; Anthony Foxx, then U.S. Secretary of Transportation; Eric Holder, then U.S.
Attorney General ; Kathleen Sebelius, then U.S. Secretary of Health and Human Services;
Gordon Brown, former UK Prime Minister ; as well as numerous former governors and key
public health policymakers and officials from a range of public and private sector entities.
The Forum live webcasts are also streamed on The Forum website, where they are
accompanied by a live chat and online commenting, and on Facebook and YouTube. These
webcasts are later posted as on-demand videos to our site and to Harvard's Y ouTube and
iTunesU channels . We also make available podcasts, transcripts and other materials.
Collective ly, the programs and complementary content have resulted in nearly five million
viewer engagements so far, and our website has received visits from more than 200 countries and
territories and every U.S. state.
Please share your thoughts when you are able .
Cheers,
ChristinaRoache
AssociateDirector, Productionand Web, The LeadershipStudio
HarvardT.H. ChanSchool of PublicHealth
(b)(6)
NIH-001882
Sent : Fri, 14 Feb 2020 20:23:04 +0000
To: Clayton , Janine (NIH/OD) [El
Subject : RE: Sex differences in COVID-19
------------------------- (b) (5)

Not much at th is poi nt .
Director
Phone : (b)(6)
FAX : (301 496-4409
E-mail : (b)(6)
From : Clayton, Janine (NIH/OD) [El (b)( >

--------
-:-::~
(b)(6)
Subject : Sex differences in COVID-19
Hi Ton
(b) (5)
Janine
NIH-001883
Sent: Fri, 14 Feb 2020 20:21:51 +0000
To : Richard Allen Johnson
Subject: RE: 2020.02. 14 Friday
Dick:
Thanks for the note. I certainly appreciate your concerns about WHO. Not
much sleep for me lately. Just like internship.
Best regards ,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From : Richard Allen Johnson (b)(6)

Sent: ----------
Friday, February 14, 2020 3:18 PM
To: Fauci, Anthony (NIH/NIAID) [E) ,------- --,.
(b._..
)=
c >; Richard Allen Johnson
(b)(6)
Subject : 2020.02.14 Friday
Hi, Tony,
I am very distressed by the Face of the WHO. Their publ ic face, their news updates, are of the quality of
t hose of a third world country . I only hope that they function bette r than their news updates suggest.
They need a wo rld class public relations firm.
I am deeply concerned re Covid-19 in Ind ia (w ith a population of 1500 million) and Africa (pop ulation
100 million). News rep orts do not mention anything of th is pandemic wa it ing to happen.
Hope that you are w ell and gett ing a good night' s rest.
Best,
Dick
NIH-001884
Sent : Fri, 14 Feb 2020 18:27:24 +0000
Subj ect : FW: inhaled buformin for coronavi rus
(b)(4)
Please han dle .
Director
Phone : (b)(6)
FAX : (301 ) 496-4409
E-mail : (b)(6l
have re ce ived this e -mail in error please inform the sender and delete it from your mailbox or any
From : Steven Lehrer

----------
------
(b) (6) >

(b) (6) > -------- --==
CbH >; Erbelding, Emily (NIH/NIAID) [E)
Subject :
------ (b)(4) for coronavirus
Dr. Fauci,
(b) (4)
Steven Lehrer, MD
(b) (4)
NIH-001887
Sent : Fri, 14 Feb 202017:39:33 +0000
Cc: Conrad, Patricia (NIH/NIAID) [E];Billet , Courtney (NIH/NIAID) [E];Stover, Kathy
(NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E]
Subject : RE: for review: proposed responses for Ital ian med ia request
Nice Job . I have made o ne mino r ed it in the fi rst response. Oth erwise, it is ready
to go. Thanks.
Director
Phone : (b)(6)
FAX : (301 496-4409
E-mail : (b)(6)
From: Routh, Jennifer (NIH/NIAID) [E] (b)( >

Cc: Conrad, Patricia (NIH/NIA ID) [El (b)(6) >; Billet, Courtney (NIH/NIAID) [E)
(b)(6); Stover, Kathy (NIH/NIAID) [El (b)( Folkers, Greg
(NIH/NIAID) [El (b)(6 b
Subject : for review: proposed responses for Italian media request
Dr. Fauci -
This is not urgent for today . A reporter from the Italian health website Pazienti.it reached out to you
directly with questions about coronavirus vaccine development. I have drafted proposed responses for
your review attached and pasted below. I will send the final responses to the reporter attributed to you.
Coronaviru s vaccine: when will it be avail able? What are th e diffi culties?
The National Institutes of Health is on track to test an experimental messenger RNA (rnRNA) vaccine in a
Phase 1 clinical trial this spring. This first phase of clinica l testing will involve giving the vaccine to
healthy adults in the United States to see if it is safe and if it can induce an immune response in
recip ients . It is importa nt to realize that the development of investigat ional vaccines and the clinical
testing to establish their safety and effectiveness takes t ime . A vaccine against the novel coronavirus will
likely not be widely available for at least a year .
NIH-001890
Couldthe Coronavirus mutate, if a vaccine cannot be found in time?
We are learning more about the novel coronavirus every day . At this tim e, we are not awar e of any
mutations that might affect vaccine development . Based on our exper ience w ith ot her coronav iruses,
including SARS-CoVand MERS-CoV, it is unlikely - but not impossible - that the novel coronav irus will
mutate in a way that would have an impact on the development of medical countermeasur es. We are
conti nuing to mon ito r this .
Will the vaccine be the solution against Coronavirus?
A safe and effective vaccine would be an extremely v aluable tool to help stop the spread of in fection
and prevent future outbreaks. However, proven public health practices of ident ifying cases, isolating
patients, and tracing contacts must continue alongside a vaccination program.
Thanks,
Jen
Jennifer Routh [E]

Office of Communicatio ns and Government Relations
NIH/ HHS
Bethesda, MD 20892
Direct: (b) ~
Di sc lai mer: The informat ion in this e-mail and any of its attachment s is confide ntial and may cont ain sensitive information . It should not be
used by anyone who is not the original intended recipient. If you have rece ived th is e-mai l in error please inform the sender and delete it
from your mai lbox or any other storage dev ices . The National Institute of Alle rgy and Infectious Diseases shall not accept liab ility for any
statements made that are sender's own and not expressly made on behalf of th e N IAID by one of its representatives.
N IH-00189 1
Sent : Fri, 14 Feb 202017:23:43 +0000
Subject : FW: (b)( 4)
Please han dle. Tha nks.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Hardham , John M

-----------
-------::-::-=,
(b)(6)>

Subject : (b) (4
-------- (b)((;)>
Tony:
It was good to see you again at the ASM Biothreats Conference. We had worked toge t her on t he
Medical Counte rmeasure Init iative when I was the Medical Officer for the DOD Chem Bio Program
(under ASDAnd rew Weber) several years ago.
(b) (4)
If you or your staff have any interest, please feel free t o reach out to me.
Hope you have a wonderful day !
John
NIH-001892
John M . Hardham , Ph.D. I Resear ch Director , Global Biologics Research
Director , Zoetis Center for Transboundary and Emerging Diseases
Zoetis I 333 Portage Street, KZO-300-204 .3, Kalamazoo , Ml 49007
Office : (b)(6) I Mobile (b)(6) I (b)(6)
Visit Us: zoetis .com
zgetis Erne ectious Diseases

FORANIMAlS.
FOR YOU.
HEAlJH.
FOR -- First coknow.Fasttomarket
NIH-001893
From: Fauci, Anthony (NIH/ NIAID) [E)
Sent: Fri, 14 Feb 2020 15:52:49 +0000
To: Strauss, Nico le
Cc: Mascola, John (NIH/VRC) [E];Graham, Barney (NIH/VRC) [E];Conrad, Patricia
(NIH/NIAID) [E]
Subject: RE: (b) (4) I
(b) (4)
----------------------
Nicole:
Thank you for your note and interest. I will copy on this e-mai l Ors. John
Mascola and Barney Graham of our Vaccine Research Center who are developing
the vaccine with Moderna so that they can respond directly to you.
Best regards ,
Tony
Director
Phone: Cb)(6J
FAX : (301 496-4409
E-mail : (b)(6J
From: Strauss, Nicole

----------
(b)(

.,;...__;_
__ .:......:....:..:::===-;:;;::;---- (b)(6J
Cc: Weisser, Karen (b)(6J
Subject : _____________________ Cb ) I ___
_>_C4_, Cb
_>_C4_)
Dear Dr . Anthony Fauci,
(b) (4)
NIH-001894
Best regards,
Nicole
• CentreOne
Nicole Strauss
Pipeline Development & Innovat ion Lead
T: (b)(6) I M: (b)(6)
500 Arcola Road, Collegeville, PA 19426
Website I Linkedln
NIH-001895
Sent : Fri, 14 Feb 2020 14:22:00 +0000
Subj ect : NEJM
----------
Attac hment s: NEJM Editorial - Fauci et al -1st draft - 02-13-2020.docx, nejmoa2001316.pdf
Here it is.
Director
Phone : (b) (6)
FAX : (301 496-4409
E-mail : (b)(6)
NIH-001896
Sent : Fri, 14 Feb 2020 03:20:06 +0000
To : Embry, Alan (NIH/N IAID) [El
Subject: RE: Instit utional request for information
Thanks, Alan.
From: Embry, Alan (NIH/NIAID ) [E]_______ Cb

_H_6)
Sent : Thursday, February 13, 20 20 10 :18 PM
To: Fauci, Anthony (NIH/NIAID) [E] ------ (b = >; Fried, Linda P.
=)""'(6)
----------- (b)(6) >; Redfield, Robert R. (CDC/OD)

(b)(6)
CbH ; Goldman , Lee
Cb) (6) >; Booth, Jane Cb) ( >; Katznelson, Ira I.
~========-.,;-- (b)( 6) >; Marston, Hilary (NIH/NIAID) [El CbH6) ; Eisinger, Robert
"'!"'
(N- IH
- /':""
N-IA--10
-:-)-:-
[E-:-:
) ::::::=====-_;,_-- ~(b"""'
)( =
6)
Subject : RE: Institutional request for information
Dear Dr. Fried,
Answers to your questions are below .
1. Is th e CDC or NIH over seeing the distrib ution of th e live viru s in the U.S. ?
There is an interagency working group convened by the Assistant Secretary for Preparedness and
Response oversee ing samples, and NIH and CDCare central to this . Virus is being deposited in BEi
Resources (a NIAID contract resource ) for characterization, growth and distrib ution. The WA isolate
is available now and a Hong Kong isolate may be added soon.
2. Will you be the sole sour ce of dist ribution in the U.S., or will institut ions be permitte d to obt ain it
directly fr om oth er sources?
Assuming appropriate permits are in place, there is no limitation on an institution obtaining samples
directly from BEi or other sources. In a public health emergency, the U.S. government seeks to make
isolates availab le under a Simple Letter Agreement that does not impose IP restrictions on
academics or developers (see attached language).
3. If it can be obt ained from other sources, wh at sources will be perm itt ed? For exa mpl e, th e China
or Hong Kong CDC or University of Hong Kong?
Assuming appropriate permits and safety controls, there is no limitation on from where samples can
be obt ained . However, there may be intellectual property restrictions from some sources and your
technology transfer office would need to negotiate if requested directly.
4 . If you are to be th e sole sour ce, w hen would you expect to have a process for considering
requests?
BEi resources already has a process for sharing in place and is currently sharing the vira l isolate
obtained from the first Washington case. NIAID ant icipates t hat other viral isolates will be obtained
soon, and BEi is committed to making those available to t he scientif ic community as soon as
NIH-001897
possib le. We {NIAID/ USG) do not expect to be the only source, but will likely be one of the main
sources for this research resource based on experience w ith Zika.
S. If someone wishes to travel to China to work on the live virus, are there any travel restrictions other
than the self isolation/quarantine already in place (and of course subject to change over time)?
For that, contacting CDC directly would make sense. If you would like us to inquire, we can. For high
consequence viruses, use of proper PPEhas been a mitigating factor in quarantine consideration.
Please feel free to contact me if you have additional questions.
Thanks,
Alan
Alan Embry, Ph.D.

Chief, Respiratory Diseases Branch
Division of Microbiology and Infectious Diseases, NIAID, NIH
5601 Fishers Lane, Room 8E31
Rockville, MD 20892
(b)(6)
(b)(6)

-------- (b)(6)
To: Fried, Linda P. (b)(6J>;Redfield, Robert R. (CDC/OD) (b)(6)>

Cc: Conrad, Patricia (NIH/NIAID) [E] (b)(6); Goldman, Lee
(b)(6) ,>; Booth, Jane (b)(6)>; Katznelson, Ira I.
=======~~~
(b)(6)>; Marston , Hilary {NIH/NIAID) [E] CbH6l>;Embry, Alan
"."--.--.-:--:~==~...:..,_--~=
(NIH/NIAID) [E] (b)(6); Eisinger, Robert (NIH/NIAID) [E] CbH6J>
Subject: RE: Institutional request for information
Linda:
There is a "sample sharing" working group involving NIH and CDC. I have
copied both Hilary Marston and Alan Embry from NIAID who are involved in this
group and will ask them by this e-mail to respond to items #1 through 4.
Regarding returning tr avelers from China {item #5) if in Wuhan {Hubei province)
within previous 14 days, they submit to institutional quarantine ; if in non-Hubei
province part of China, then they face self-isolation.
Hope t hat this is helpful.
Best regards,
Tony
NIH-001898
Director
Phone : (b)(6)
FAX : (301 496-4409
E-mail (b)(6)
From : Fried, Linda P . (b)(6)

To: Redfield , Robert R. (CDC/OD) (b)(6); Fauci, Anthony (NIH/NIAID) [E]
(b)(6)
Cc: Conrad, Patricia (NIH/NIA ID) [E] -:-"""."""-::===== (b

= )=(=;..; =o
G= ldman, Lee
(b)(6)>; Booth, Jane (b)(6)>; Katznelson, Ira I.
======== (b
;;:;
)::c
(6)
~
Subject : Institutional request for information
Dear Ors. Redfield and Fauci,
I am writing on behalf of Columbia University, w hich has received a request from Dr. Ian Lipkin to
trans fer live novel coronav irus from Hong Kong to his BSL3facility at the Univers ity. As we evaluate his
request , we note that he has approval from a CDCofficial to import the virus (see attached). Howeve r,
as we consider the risks and benefits of Dr. Lipkin's proposal, we ask the two of you:
1. Is the CDCor NIH overseeing the distribution of t he live virus in the U.S.?
2. Will you be the sole source of distribution in the U.S., or will institutions be permitted to obtain
it directly from other sources?
3. If it can be obtained from other sources, w hat sources will be permitted? For example, the
China or Hong Kong CDCor University of Hong Kong?
4. If you are to be the sole source, when wou ld you expect to have a process for considering
requests?
5. If someone wishes to travel to China to work on the live virus, are there any trave l restrictions
other than the self isolation/qu arantine already in place (and of course subject to change over
t ime)?
Thank you ve ry much fo r your help with these important questions as we all try to do our best to
contribute solutions to this health crisis.
With best regards,

Linda
NIH-001899
Linda P. Fried, M .D., M .P.H.
Dean and Delamar Professor of Public Health
Professor of Epidemiology
Mai lman School of Public Health
Professor of Medicine, Vagelos College of Physicians and Surgeons
Senior Vice President, Columbia University Irving Medical Center
Columbia University
NIH-001900
Sent : Fri, 14 Feb 2020 03:00:23 +0000
To : Mansoura, Monique K.
Cc: Conrad, Patricia (NIH/NIAID) [E);Andrew W Lo;Cassetti, Cristina (NIH/NIAID) [E)
Subject: RE: A proposed solution to finance COVID-19 vaccines - Introducing MIT's
Professor Andrew Lo
Thanks, Monique. Please have Andrew send the proposal to Cristina Cassetti (copied here) and
she can then brief me on it.
Best,
Tony
From: Mansoura, Monique K. (b)( '>

To: Fauci, Anthony (NIH/NIAID) [ E] ----- -- (b,...
)(=6)
Cc: Conrad, Patricia (NIH/NIA ID) [E] (b)(6); Andrew W Lo (b)(6)>
Subject : A proposed solution to finance COVID-19 vaccines - Introducing MIT's Professor Andrew Lo
Dr. Fauci,
The nation again is fortunate to have your leadership for this latest public health emergency . Thank you
for all you are do ing. r know you are extraordinari ly busy, so I'll be brief.
I want t0 introduce you to MIT Sloan Professor Andrew Lo, a world leader in healthcare finance who has
focused much of his work recently on accelerating bi.omedical innovation via novel financing srrucn1res. :1
have worked with him to explore financial engineering approaches to estab lish more durable public-private
partnerships for medical countermeasures. The persistent challenges you articulated at the Aspen Institute
event this week resonate loudly with Andrew and me.
He has proposal for COVID-19 that he would like to present to you. I defer to him to provide fu1tber
information.
Respectfully,
Monique
MON IQUE K. MANSOURA, PH.D., M.B .A .

Executive Director, Global Health security and Biotechno logy
The MITRE Corpo ration
202 Burl ington Road I Bedford, MA I 01730-1420
Office: (b) (6)
(b)(6)
The MITRE Corporation is a not-for-profit organization that operates federally funded research and
development centers for the United States government.
NIH-001901
Sent : Fri, 14 Feb 2020 02:56:17 +0000
To : Greg Folkers (b)(6))
Subject : FW: FYI-- images of SARS-CoV-2now up
Let us make some power point slides from these. Thanks.
From: Billet, Courtney (NIH/NIAID) [E) (b) ~ >

--------
To: NIAID OD AM <NIAIDODAM@niaid.nih .gov>
Subject : FYI -- images of SARS-CoV-2 now up
https://www.niaid .nih .gov/news-events/nove1-coronavirus-s arscov2-images

https://www.flickr .com/photos/niaid/albums/721 57712 9 14621487
NIH-001902
Sent : Fri, 14 Feb 2020 02:42:53 +0000
Cc: Greg Folkers (b) ( ·)
Subject: FW: PBS'SFIRING LINE REQUEST// DR. ANTHONY S. FAUCI
Patty: Let us discuss.
Greg: Are they a big dea l?
From: Melanie Starling <melanie@thedocumentarygroup .com>

To: NIAID NEWS (NIH/N IAID) <NIAIDNEWS@niaid.nih.gov>; Fauci, Anthony (NIH/NIAID) [E)
(b)(6)
Subject: PBS'SFIRING LINE REQUES
T // DR. ANTHONY S. FAUCI
Import ance: High
Good Evening,
Please see below for Dr. Anthony S. Fauci for PBS'S FIRING LINE WfTH MARGARET HOOVER .
Due to a last minute cancellation, we are crashing on a deadline and need to know if he is able
to jo in us ASAP.
I look forward to hear ing your thoughts and all best ,

Melanie
Melan ie Starling
Firing Line with Margaret Hoover
Cell: (b)(6)
Email: melanie@thedocumen t arygroup .com
___.------- --
Fl RI n G LlnE
W ith MA RGARET HOOVER
Good Evening,
NIH-001906
This is Melanie Starling writing on behalf of PBS'SFIRING LINE WITH MARGARET HOOVER.
FIRING LINE is the rare program in the political landscape that seeks a rigorous and earnest
exchange of ideas, with the luxury to let the conversation breathe. Margaret has brought back
the spirit of this venerated show, which aired from 1966 to 1999, that is lacking in today's
polarized cable news ecosystem - at a time when we need it more than ever. One guest. 30
minutes. Airing to a thoughtful and engaged PBS audience.
We would be honored to have Dr. Anthony S. Fauci join Firing Linefor an

interview.
Dr. Fauci has dedicated his career to understanding, preventing, and protecting people across
the globe from infectious diseases, which is why we would be so honored to share our stage
with him at this time. As the coronavirus continues to spread, we are interested in better
understanding the deadly virus the world is racing to contain. Equally, we are interested in
highlighting any other public health issues or policies close to Dr. Fauci's heart. Most
importantly, with our program, we have the luxury of time-where we can truly delve into
these issues in a substantive, nuanced manner that is missing in much of today's 24-hour news
cycle.
THE DETAILSFORTAPING
TAPE DATE: TARGETING FEBRUARY19TH - EVENING TAPING IS PREFERED
TAPE TIME: 45 MINUTES
LOCATION: NYC (WNET STUDIOS NEAR LINCOLN CENTER)
TRAVEL, HAIR, & MAKE-UP IS PROVIDED ON REQUEST.
f lRING LINE is carr ied nationwide on PBSwith 99% market pick-up, and is suggested
programming for PBS's8:30 PM ET on Friday nights with multiple airings through the week. On
Twitter, we have a growing 2.9M+ monthly impressions. Equally, as you know, PBSremains a
coveted home for intellectual, elevated programming- and stands out as a top 5 outlet to
reach persuadable voters.
HIGHLIGHT REEL
FIRING LINE is produced by the Oscar-nominated Tom Yellin at The Documentary Group.
Please reach out to me if there is any interest . We will bend over backwards to get it done.
Thank you in advance for your consideration, and please feel free to reach out to me 24/7 with
questions or concerns.
All the best,
NIH-001907
Melanie
Melanie Sta rling

Firing Line with Margaret Hoover
Cell: (b)(6)
Email: melanie@ t hedocumentarygroup.com
ABOUT FIRING LINE WITH MARGARET HOOVER

Firing Line with Margaret Hoover is a refreshing reprisal of William F. Buckley's icon ic PBS
program, a smart, civil and engaging contest of ideas. The series maintains the character of the
original, providing a platform that is diligent in its commitment to civility and the rigorous
exchange of opinion. Firing Line with Margaret Hoover comes at a time when mean ingfu l
discourse is needed more than ever. Interviews and debates will highlight leading lights from
the left and right, complemented by archiva l footage from the original Firing Line to rem ind
viewers of longstanding conservat ive and libera l arguments, where they've been disproved or
reinforced over time. It is an opportunity to engage in the debate about the America tha t we
want to create fo r the 21st centu ry - and summon Americans of every politica l persuasion to a
rigorous examination of the choices we must make together in the challenging years ahead .
Showrunner is Emmy, Dupont and Murrow-winning producer Alyssa Litoff.
ABOUT MARGARET HOOVER

Margaret Hoover is an American political commentator . In addition, she is also an author,
fem inist, and gay rights activist. Current ly, she wo rks as a polit ical commentator for CNN.
HIGHLIGHT S ON FIRING LINE WITH MARGARET HOOVER

Speaker Paul Ryan, Sen. Ben Sasse (R-NE), Gov. Chris Christie, Gov. Mitch Daniels, Gov. John
Kasich, Gov. Scott Wa lker, Rep. Alexandria Ocasio-Cortez (D-NY), Rep. Eric Swalwell (D-
CA), Stacey Abrams, Donna Brazile. Gretchen Carlson. Caitlyn Jenner. Christine Lagarde, Peter
Navarro, Oliver North, Andrew McCabe, Tom Steyer, H.R. McMaster, Rep. Tulsi Gabbard, Ann
Coulter, Tony Blair, Jose Andres, Rep. Liz Cheney (R-WY), Rep. Jim Clyburn (D-SC), Rep. Pramila
Jayapa l (D-WA), Sen. Ted Cruz (R-TX), Gen. Jim Matt is, Condoleezza Rice, Andrew Yang, Michael
Bloomberg, Michael Moore, Paul Krugman, Amb. Nikki Haley, Adam Schiff (D-CA)
Melanie Starling
PBS's Firing Line with Margaret Hoover
Cell: Cb)(6)
Email: melanie@thedocumentaryqroup.com
-FIRlnG
----LlnE
-
NIH-001908
Sent: Fri, 14 Feb 2020 02:36:46 +0000
To: ncalio@airlines.org
Cc: Conrad, Patricia (NIH/NIAID) [E);Redfield, Robert R. (CDC/0D);Cetron, Marty
(C0C/0010/NCEZID/DGMQ)
Subject: FW: Coronavirus Task Force
Attachments: Fauci A4A Letter to Coronavirus Task Force .pdf
Nick:
Many thanks for sending this. The CDC would be very interested in your willingness to move
in the d irection of having complete contact information on passengers available to them. I am
copying CDC Directo r Bob Redfield and his CDC colleague Marty Cetron on this e- mai l. I am
sure that one o f them will contact you about this issue.
Best regards,
Tony
From:Calio, Nicholas <ncalio@airlines.org>

To: Fauci, Anthony (NIH/NIAID) [E]--------=- (b):--:
(6)
=>
Subject: Coronavirus Task Force
Dear Dr. Fauci ,
Please see the attached letter.
Thank you,
Nick Calio
NIH-001909
Sent: Fri, 14 Feb 2020 02:09:44 +0000
Subject: RE: Invitation: 388393 Santos (Coronavirus Preparedness Workshop)
Tell them that I turned down the same invitation and he should turn it down also. It is not a
major event

Sent: Thursday, February 13, 2020 8:21 AM ---------- (b)(6)
To : Fauci, Anthony (NIH/NIAID) [El ------~~

,..;.::=======:,;,~
---------
Subject : FW: Invitation : 388393 Santos (Coronavirus Preparedness Workshop)
Please see below . You were invited to this - it was discussed in our daily meet ing
and we decided to decline it for you. we d id decline it. would you recommend the
same as they are now asking Dr Collins.
Pis advise.
Patricia L. Conrad
Public Hea lth Analyst and
Spec ial Assistant to the Director
(b)(6)
301-496-4409 fax
Disclaime r:
The information in this e-mail and any of its attachme nts is confidential and may contain sensitive info rmation. It should not be used
by anyone who is not the orig inal intended recipient. If you have rece ived this e-mail in error please inform the sender and delete it
from your mailbox or any other storage devices. Nationa l Institute of Aller gy and Infectious Diseases (NIAID) shall not accept
liabi lity for any statement made that are sender 's own and not expressly made on behalf of the NIAID by one or its representatives.
From: Harris, Kara (NIH/NIAID) [El (b)(6)>

--------
To: Conrad, Patricia (NIH/NIA ID) [E)-------~~ (b)(6)>
Cc: Billet , Courtney (NIH/N IAID) [E)· .=.====~ (b
~) ~(6)~ >-; ~
Haskins, Me linda (NIH/NIAID) [E]
(b)(6)
Subject : Invitation : 388393 Santos (Coronavirus Preparedness Workshop)
NIH-001910
Hi, Patty -
Exec Sec would like Dr. Fauci's opinion on whether Dr. Collins should accept the attached invitation to
speak at an upcoming Coronavirus Preparedness Summit & Workshop being held this June in
Washington, DC. The conference is being organized by Syllabusx, a group of "international specialists in
public health and emergency planning events and disaster recovery conferences ."
Given the nature of the conference topics, do you concur with recommending Dr. Collins decline the
invitation and refer to CDC?
Thanks for your input.

Kara
NIH-001911
Sent: Thu, 13 Feb 2020 23:22:27 +0000
To : Alison Galvani
Subject: RE: Lancet special issue proposal
Alison:
Thanks for the note . I really appreciate your kind invitation, but unfortunately, I
will have to decline. My plate is already overflowing and I just cannot take on
any additional editorial responsibilities . In addition, I am swamped with
coronavirus "stuff" that is not going to end soon. I hope that you understand .
Best regards,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail Cb
) (6)
From: Alison Galvani (b) (6)

To: Fauci, Anthony (NIH/NIAID) [E]------ ..-.-,=
H >
Cb
Subject : Lancet special issue proposal
Hi Tony,
(b) (4)
Thank you so much for your consideration.
NIH-001912
Warmest regards,
Alison
Alison Galvani, PhD
Director, Yale Center for Infectious Disease Modeling and Analysis (CIDMA)
New Haven, CT 06520
(b)(6)
htt p://c idma .yale .edu/
NIH-0019 13
Sent: Thu, 13 Feb 2020 23:10:07 +0000
Subject: FW: Personal connection
Please set this up (5 minutes) for Monday.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
---------
-------=-,-:-=
(b)(6)]

Subject : FW: Personal connection -------- (b)(6)
This guy called last night and seemed to know you - let me know if and where you
want me to direct him.
Or maybe do a call with you on a quieter day - Monday on Pres day holiday?
Patricia L. Conrad
(b)(6)
301-496-4409 fax
Disclaime r:
NIH-0019 14
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used
by anyone w ho is not the original intended recipient. II you have received this e-mail in error please inform the sender and delete it
from your mailbox or any other storage devices. Nationa l Institute of Allergy and Infectious Diseases (NIAID) shall not accept
liability for any statement made that are sender's own and not expressly made on behalf of the NIA ID by one of its representatives .
From : Banner, Jon {PEP} (b)(6)>

Se nt: Tuesday, February 11, 2020 9:44 PM
To : (b)(6) Conrad, Patr icia (NIH/NIAID) [E]
Subject : Personal connection ----------- (b)(6)
Dear Dr. Fauci,
Jon Banner here. You may remember me from my days at ABC News, where I was Executive Producer of
World News Tonight with Peter Jennings, Charlie Gibson, and Diane Sawyer . I was also Executive
Producer of This Week with George Stephanopoulos and early on I was George Strait 's producer. Back
then, you were the most engaging, eloquent guests on the subject of HIV/AIDS and other life and death
issues of our time, and your input was of enormous value to our viewers and the general public.
Today, I am President of the PepsiCo Foundation and EVP of Global Communications for the company . I
was hoping you could help us identify an expert to provide similar insight and analysis for our company
as we deal with the impact of the Wuhan coronavirus . While we would of course welcome your counsel,
I recognize that you have a full plate of critica l responsibilit ies with NIH and don' t want t o take up too
much of your time.
If you have a few minutes for a quick call, I'd love to get your take and catch up. If not, I would deeply
appreciate it if you could connect me with another expert over email.
Thanks very much, and hope you are doing well!
Warm regards,
Jon
NIH-001915
Sent : Thu, 13 Feb 2020 22:47:23 +0000
Subject : FW: Institutional request for information
Attachment s: Cll 2020 CDC import permit .pdf
Director
Phone : (b) (6)
FAX : (301 496-4409
E-mail : (b)(6)
From: Fried, Linda P. (b)(6)

To : Redfield, Robert R. (CDC/OD) (b)(6) Fauci, Anthony (NIH/NIAID) [E]
(b)(6)
Cc: Conrad, Patricia (NIH/NIA ID) [E] >; Goldman, Lee
----======~~~
(b)(6); Booth, Jane ________ Cb
(b)(6)
_H_ ; Katznelson, Ira I.
======== (b
~)~(6)
;;--
Subject : Institutional request for information
Dear Ors. Redfield and Fauci,
I am writing on behalf of Columbia University, w hich has received a request from Dr. Ian Lipkin to
transfer live novel coronav irus from Hong Kong to his BSL3facility at the Univers ity. As we evaluate his
request , we note that he has approval from a CDC official to import the virus (see attached) . However,
as we consider the risks and benefits of Dr. Lipkin's proposal, we ask the two of you :
1. Is the CDCor NIH overseeing the distribution of the live virus in the U.S.?
2. Will you be the sole source of distribution in the U.S., or will institutions be permitted to obtain
it directly from other sources?
3. If it can be obtained from other sources, what sources will be permitted? For example, the
China or Hong Kong CDCor University of Hong Kong?
4. If you are to be the sole source, when wou ld you expect to have a process for considering
requests?
NIH-0019 16
5. If someone w ishes to travel to China to work on the live virus, are there any travel restrictions
other than the self isolation/quarantine already in place (and of course subject to change over
time)?
Thank you very much for your help with these important questions as we all try to do our best to
contribute solutions to this health crisis.
With best regards,

Linda
Linda P. Fried, M.D., M.P.H.

Dean and Delamar Professor of Public Health
Professor of Epidemiology
Mailman School of Public Health
Professor of Medicine, Vagelos College of Physicians and Surgeons
Senior Vice President, Columbia University Irving Medical Center
Columbia University
NIH-001917
Sent : Thu, 13 Feb 2020 22:44:12 +0000
To : Stoffels, Paul [JJCUS]
Cc: Riccobene, Kim [JJCUS];VanHoof, Johan [JRDBE);Conrad, Patr icia (NIH/NIAID)
[E);Barasch, Kimberly (NIH/NIAID) [(] ;Eisinger, Robert (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID)
[E];Lerner, Andrea (NIH/NIAID) [E];Mascola, John (NIH/VRC) [E];Erbelding, Emily (NIH/NIAID) [E]
Subject : RE:COVID-19 vacc ine development
Paul:
Thanks for the note. I will have Patty Conrad {copied here) try to work
something out for Feb.21 st . My schedule is at the mercy of t he White House and
the Congress and so I cannot guarantee anything right now.
Best Regards,
Tony
Directo r
Phone : (b)(6)
FAX : (301 496-4409
E-mail (b)(6)
accept liability for any statements made that are the sender 's own and n ot expre ssly made on
From : Stoffels, Paul [JJCUS]

Sent : Thursday, February -------
13,
2020 9:42 AM
(b)(6)>
To: Fauci, Anthony (NIH/NIAID) [E) ----- --:a

(b=H=6)>
Cc : Riccobene, Kim [JJCUS)
--------
Subject : COVID-19 vaccine development
(b)(6);
--------
Van Hoof, Johan [JRDBE) (b)(6)>
Dear Tony,
Four weeks ago our team kicked of the experimental work on the development of a COVID-19 - vaccine.
(b) (4)
NIH-001918
(b) (4)
If you have time for a meeting on the 21st in the afternoon or a call in the course of the next 10 days, I
would much very appreciate .
Feel free to call me or have you assistant connect with my assistant Kim Riccobene to set up a call. I will
be in Europe till the 19th .
Best regards,
Paul
Paul Stoffels, MD
Vice Chairman & CSO
Johnson & Johnson
(b)(6) (Mobi le Europe)

(Office US)
NIH-001919
Sent: Thu, 13 Feb 2020 03:16:08 +0000
To : Barasch, Kimberly (NIH/NIAID) [C)
Subject: FW: Run of show- 2/13, 9-l0am Wh ite House Roundtable on COVID-19
Make sure that this is in my folder.
From:Selgrade, Sara (NIH/NIA ID) [El (b)(6}>

--------
To : Fauci, Anthony {NIH/NIAID) [El-----~~ (b)(6)
Cc:NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; Conrad, Patr icia (NIH/NIAID) [El
(b)(6)Barasch, Kimberly (NIH/NIAID ) [C] (b)(6) Billet,
Courtney (NIH/N IAID) [E] (b)(6)
Subject: Run of show - 2/13 , 9-lOam White House Roundtable on COVID-19
Dr. Fauci,
Please see below for information we have received from HHS thus far regarding
tomorrow's briefing on coronavirus at the White House. Patty has subm itted your
inf onnation via the WAYES link for the event. We are checking with HHS ASL
to make sure your clearance has been proce ssed.
We will share any additional information as we receive it. Please let me know if
you have any questions.
Thanks ,
Sara
White Hou se Congressional Roundtable on Coronavirus

Date: Thursday, February 13
Time: 9:00 - I 0:00 a.m.
Location: Roosevelt Room
Run of show:
• Acting Chief of Staff Mulvaney will open the proceedings and briefly frame
all that we are doing and why we have asked the Members to assemble (to
gain their insight and to seek their wisdom).
NIH-001923
• Anne Schuchat will give a brief overview of current status and material
issues .
• Anthony Fauci will give a brief explanation of our understanding of the
virus and development of countermeasures.
• Brig Gen. Paul Friedrichs of DoD will provide a brief status report on force
protection.
• Acting Chief of Staff Mulvaney will open the floor for questions and
moderate the proceedin gs - possible that White House legislative affairs will
stand in here (Eric Ueland or Mike McKenna).
Expected participant s:
Members (confirmed RSVPs thus far)

Senator James Risch
Leader McCarthy
Rep. Kay Granger
Rep. Greg Walden
Rep. Nita Lowey
Briefers
DHS-Alex Zemek
CDC- Dr. Anne Schuchat
NIAID-Dr. Tony Fauci
ASPR- Dr . Bob Kadlec
FDA-Dr. Steve Hahn
DHS - Ken Cuccinelli
NSC - Anthony Riggiero
NSC - Matt Pottinger
State - Stephen Biegun (tentative)
DOD - Brig Gen. Paul Friedrichs
NIH-001924
From: (b)(6)
Sent : Wed, 12 Feb 2020 11:02:30 -0500
To : John Lauerman
Subject : Re: Interview
I tried calling but the call would not go through
On Feb 12, 2020 , at 6: 15 AM , John Lauerman (BLOOMB ERG/ NEWSROOM:)

<jlauemmn @bloomb erg .net>wro te:
Hi Dr. Fau c i : I saw t hat you spo ke about t he lac k of major

drugmakers stepping up to make coron av irus vaccine , a n d my
colleague James Paton is working on a story about that issue .
J ames ' s story has to do with a bi osecurity initia t ive related to
these types of t hreats at GSK tha t was started in 2016 and quickly
pu t on t he bac k bu r ner . I do n 't know whe t h e r you ' d want t o commen t
on the company or its activities i tse lf , bu t wou ld b e he l pfu l if
you could talk about t he im p ortance of ge ttin g big drugmakers
involve d in helping t o fill t he need f or new vaccin es . I ' m in
Geneva ri gh t now at the WHO coronavirus science foru m, b ut ho pe we
can t a l k for a mi nut e or t wo . Bes t way to r each me is via Whatsapp ,
where my number i s (b)(6). Ple ase let me know if/when
you ' re free . Thanks and regards , JL
From : John La uerman (BLOOMBERG/ NEWSROOM: ) At : 02/07/20 15 :53 : 34

To : (b)(6)
Sub j ect : RE : Int erv i ew
Und er stood . Hope you ge t a chanc e to r es t
From : a f auci@niaid . nih . g ov At : 02/07/20 15 : 51 : 39

To : J ohn Laue r man (BLOOMBERG / NEWSROOM : )
Sub jec t : RE : Interview
Sorry John. I am totally tied up right now and besides, I

am completely hoarse and can barely speak. Let us try
some other time.
Director
Phone : (b)(6)
NIH-001925
FAX : (301) 496-4409
E-mail: Cb
) (6)

who is not the original intended recipient . If you have received this e-
Infe ctious Diseases (N IAID) shall not accept liability for any statements
From: John Lauerman (BLOOMBERG/ NEWSROOM :)

<jlauerman@bloomberg .net>
Sent : Monday , February 3, 2020 8 :18 AM
To : Fauci, Anthony (NIH/NiAiD) [E] ------~~
(b)(6)
Subje ct: Interview
Hi Dr . Fauci : How are you? I ' m wri t ing t o see

whether we can talk again fo r a few minutes.
We' r e worki n g on a b i gg i s h p iece abou t t he
l arger b i o-secur i t y i ssue wor l dwi de a n d wh a t t he
coronavi r u s outbreak tells u s abo u t it . What can
we do abou t t he weakes t lin ks in d i sease co n t ro l
in p oore r n a t ion s in Af r ic a , Asia a n d e l sew here?
The WHO today bro ug ht up the impo r tance of
access to health care along with spending on
p ub li c h ea l t h, a n d c l ear l y t hi s i s a n issue in
poo r co un ties . Is it also important in
infectio us disease in the US and if so, is it
ad e qua t ely recognized? Compa nie s a nd research
centers have made h ug e strides in q u ick
development of vaccines and dr ug s ; what can take
i t t o t he nex t level? Is t he r e a ny t hing t ha t
co ul d be done to attract more companies to this
field? What kind of n e w t e chnologi e s can help u s
t rack ne w v i ruses in t he commu ni t y? I ' ve bee n
t a l k in g wi t h peop le using h a nd hel d n a no por e
seq u ence r s to track coronavi r u s and Ebola ; what
el se i s ou t t here? Do we nee d t o do a b e tt er job
of t racking t he move men t of peop le a n d goods?
Also glad to get any other observations . Please
c a l l t oday or t omorrow mornin g at ~
o r le t me k no w when a nd a t wh a t (
number to call you . Thanks and re g ards , look
forward t o he ar in g from you , JL
NIH-001926
3 Queen Victoria Street, London , UK
tel. +44 (0) 2035 251028 cell --------=--=-:=
http ://www .bloombe rg.com
--------- Cb)(6)
http://www .bloom berg .com /prog nos is
NIH-001927
From: (b)(6)
Sent : Wed, 12 Feb 2020 10 :24:06 -0500
To : Daniel Lucey
Subject : Re: Update IDSA Science Speaks post today# 10: PPEmass production and
POlyclonal/mAbs Rx PReP and PEP
Thanks dan
On Feb 12, 2020, at 9:34 AM, Daniel Lucey Cb)(6)

>wrote:
---------
Bob K., Tony and Bob (Redfield),
Given the news of health care personnel in Wuhan and Hubei being infected, and
acute shortage of PPE for COVID-19, I posted these Q&A s on the ID Society
America "Science Speaks" website as the 10th in a series of my updates since
January 6th.
The final Question asks and answers that mass production of COVID-19 PPE
should occur now.
Dan
Hong Kong Feb. 12, 2020
bttps ://sciencespeaksblog.org/2020/02/ l 2/immune-survivors-of-covid-19-protective-

antibody-for-treatmen t-and -prophylax is/
NIH-001928
Sent: Wed, 12 Feb 2020 15:23:15 +0000
Cc: Conrad, Patricia (NIH/NIAID) [E);Barasch, Kimberly (NIH/NIAID) [C]
!';ubject: Re: Business Counci l - Invitation to speak at the February 20-21, 2020 meeting
at the Ritz Carlton (22nd and M St. NW), Washington, D.C.
Attach ment s: image003.jpg, image004.jpg, imageOOS.jpg
Okay. Go with it
On Feb 12, 2020, at 9 :38 AM , Folkers, Greg (NIH/NIAID) [E]

(b)(6) wrote:
Will add
I would vote fo r: no slides-
I would send these three papers (all on director's page) - CoV, Ebola, Ending HIV
<image003 .jp g>
Foreign Policy
<image004 .jpg >
<image005 .jpg>
From : Conrad, Patricia (NIH/NIAJD) [E) (b)(6)

---------
To: Folkers, Greg (NIH/NIA ID) [El
~======'~~Cb>
Cc: Fauci, Ant hony (NIH/NIAID) [El _______ _<_.; Barasch, Kimber ly (NIH/NIAID)
[CJ (b)(6)
Subject : FW: Business Council - Invitation to speak at the February 20-21, 2020 meeting at
the Ritz Carlton (22nd and M St. NW), Washington, D.C.
Kim - pis add all t o th e f olde r t hx
NIH-001929
G - this needs to be added to matrix. IT was a "fires ide chat" that we
thought would not include slides but see below -they are ok with a
few slides
Will need to discuss things to send and topics given the "theme"
Patricia L. Con rad

Nation al Inst itute of Allergy and Infectious Diseases
The National Institutes of Healt h
(b)(6)
301-496-4409 fax
Disclaime r:
The information in this e-mai l and any of its attachments is confidential and may contain sensit ive information. It
shou ld not be used by anyone who is not the original intende d recipient. If you have received this e-mail in error
please inform the sender and delete it from your mailbox or any other storage devices. Nationa l Institute of A llergy
and Infect ious Diseases (NIAID ) shall not accept liabil ity for any statement made that are sender's own and not
express ly made on behalf of the NIAID by one of its representatives.
From: Marlene Colucci <mcolucci@businesscouncil.com>

To: Conrad, Patricia (NIH/NIAID) [El --------=- (bs-
)( =6)
Cc:Adrienne Ball <aball@businesscoun cil.com >; Gillian Auger
<gauger@bus inesscounc il.com >
Subject : Re: Business Council - Invitation to speak at th e February 20-21, 2020 meeting at
the Ritz Carlton (22nd and M St. NW), Washington , D.C.
Patty,
I wanted to check back with you and Dr. Fauci on a few things in advance of his fireside
chat with David Rubenstein on Friday, February 21.
• Are there any art icles tha t Dr. Fauci thinks would be useful to send out to our CEOs
in advance of the discussion (it may be something related to the Coronavirus or
something that looks at the future of health and what CEOsshould be thinking
about in the next decade?
NIH-001930
• The theme for our upcoming meeting is "The Next Decade - Major trends in
technology, geopolitics, politics, economy and health" . I have attached a copy of
our Draft CONFIDENTIALand list of attendees for Dr. Fauci's reference .
• During his discussion with David Rubenstein, are there any slides he would like to
use for reference? We do not use a lot of these but thought there might be slides
that wou ld aid in his discussion? Just let us know.
Warmest regards,
Marlene
Marlene Colucci
EXECUTIVE
DIRECTOR
T: 202-298-7650
'I BUSI1 TESS C: (b)(6)
~ l0L \.C.L.. F : 202-785-0296
On Feb 5, 2020, at 9:19 AM, Ma rlene Colucci

<mcolucci@businesscouncil.com> wrote:
Thank you Patty for checking. As soon as I can find out whether Dr. Collins
wi ll also be a part of the discussion I will work on setting up t hat call. Ive
been pressing their office so fingers crossed!
Marlene
Marlene Colucci
EXECUTIVE
DIRECTOR
"I
~
BUSINESS
COL.:\JCIL
T : 202-298-7650
C: (b)( 6)
F: 202-785-0296
NIH-001931
On Feb 5, 2020, at 9:01 AM, Conrad, Patricia (NIH/N IAID) [E]
---------- (b)( wrote:
Good morni ng:
Dr. Fauci w ill not be abl e t o att end th e di nne r th e

night befor e but want ed me t o thank you f or
t hink ing of him.
Best ,
-patt y
From : Marlene Colucci <mcolucci@businesscouncil.com >

Sent: Friday, January 31, 2020 2:00 PM
To: Fauci, Anthony (NIH/NIA ID) [E] ------ .-..
(b..,
H=6J
Cc: Conrad, Patricia (NIH/NIAID) [E] CbH6J
;
David Rubenstein (b)( ; MaryPat
Decker
------------ (b)(6)
Subject : Business Council - Invitat ion to speak at the February
20-21, 2020 meeting at the Ritz Carlton (22nd and M St. NW),
Washington , D.C.
Dear Dr. Fauci,
On behalf of our co-chairs for the winte r meeting of The

Business Council, David Rubenstein of The Carlyle Group and
Ginni Rometty of IBM, we wou ld like to formally invite you to
participate in our meeting on February 20-21, 2020 in
Washington, D.C. The theme of the meeting is "The Next
Decade." (See formal invitation attached as well as list of CEO
members).
We would like for you to participate in a 50 minute fireside chat

with David Rubenstein (and possibly Dr. Francis Collins) to
discuss the current coronavirus as well as what we should
expect in the next decade. We want to give our CEOsinsights
into what the next 10 years will bring in terms of detection,
diagnosis and treatment of diseases. All conversations are
strictly off the record and closed press. We wil l cover all lodging
and transportation.
As you know, The Business Council is comprised of the chief

executive officers of the largest global corporations,
representing all segments of the economy . We expect at least
150 CEO members, spouses and speakers to be in attendance.
NIH-001932
As a participant you and your spouse are also invited to join us
for our special reception, dinner and speaker at the REACH
(Kennedy Center) on Thursday, February 20 at 6:30pm. It is the
best opportunity for you to meet our CEOmembers and
spouses, speakers and other special guests in an informal
atmosphere.
If you are interested and available, please let me know. We can

also set up a very brief call with you to discuss any additiona l
details and answer any questions you may have. We look
forward to hearing from you and would be honored to have you
participate wit h us again.
Warmest regards,
Marlene
Marlene Colucci
EXECUT IVE
DIRECTOR
·11•
~
~
BUSINESS
COL '!CTL
T : 202 -298-7650
C: (b)(6)
F : 202- 785-0296
i:@H@Vitw\
304.257
c.t.at.anso Al!ll1etric 2109
Vl~wpoint
January23. 2020
CoronavirusInfections-More Than Justthe

CommonCold
e,,11.. w, P""""'-1o10•
• ....,.,0 """"°"·"°'..,,,.,,.,,,llooy~
f.1W.l.fl>1
,....,,.,,...,.f.i.,-
I """'-l~1t!o<,.,.,..,
/Ml,\. P\.ll»ihNl<>nl
.. S,,,--, l).10/0, cir, IQ1001/1,oN.JQX)flm
NIH-001933
AI\OUl'!fNI
On the Front Lines of the Trump

Administration's Ebola Response
l\.'15mounlOOn wide ~ (t,JlOO.SC\0
The IJnilal S\.11CS the~ onfy ~
<l.ool)•ou1bfc:l.l,;."-1
on.
Ending the Human Immunodeficiency Virus

Pandemic: Optimizing the Prevention and
Treatment Toolkit s o
ClinicoJ f11k<.~ Di~.>e~, Volu1TW' 69, b,ue 11, LS De<.e,nbt-r20 tt. P•g~ 1n :>-2>l1,
.,UJ>~/irtn, MY ICJIC"~ilffd/c ,,,,.lH
PubUJhe d: 24Octobet2019 Arlk le hlstory •
NIH-001934
1/§·MU Vlew. 304.2S7 C.t•t.oclMO Alun<,tric 2t09
Viewpoint
January 23, 2020
Coronavirus Infections-More Than Just the

Common Cold
c..uiann.tl'Me5,MD 1,......,D NIH-001935
-,MO, MPl◄1;Andlo,,y'd.Ml.W
>A11thofAff11,,f1'0f1'\
I M-.1l"~f ~ •tton
"'-'" ~- -13.1010. dol10100t/!,,m,ll0l001'>1
ARGUNCN
T
On the Front Lines of the Trump

Administration's Ebola Response
osonly~
to the btelt dc:>dl)'outbrc-'11<.
The t:nitcdSlatesti,., mounteda wide r.mgiQgrcspoo.<e
can.
NIH-001936
Ending the Human Immunodeficiency Virus
Pandemic: Optimizing the Prevention and
Treatment Toolkit s o
C/inicollnf«IX>U1D,seo=, Volmnf' NIH-001937

69, Issue 12, IS Oecembe00l9 , P•ges 2212- 2117,
I tlJ)';//dol.org/ l O.lO'J]/cid 1<1t' :IS
Pubtiffled: 24 Oelobet 2019 Artkle history •
Sent: Wed, 12 Feb 2020 12:04:55 +0000
Subject: FW: epiqar for Coronavirus assistance
From: Daniel Goldberg <daniel@eng.us>

To: Fauci, Anthony (NIH/NIAID) [El <afauci@niaid.nih.gov>
Subject: epiqar for Coronavirus assistance
Dr. Fauci,
I wanted to reach out to see if epiqar (https://ep iqar .com/) can help your efforts with the
Coronavirus- we are the only system in the world built for remote surgical help & interactive
emergency surgeon support over the web browser.
epiqar has created the most advanced surgical video collaboration technology, allowing
surgeons to consult and train remotely on a low-cost and easy-to-use online surgical
collaboration platform and Cloud-archiving system built for the operating room. With the
outbreak of Coronavirus, this has become more vital as surgeon mobility and access to critical
surgical spaces in need of more help are severely limited, and specialists will not risk entering
spreading viral hot zones.
Patient care isn't just a concern with the virus itself, but with the host of medical issues facing
patients that will no longer be treated by local specialists easily, and facing caregivers: surgeon
involvement from around the world is needed urgently.
Although epiqar is an American company, our rollout in recent months has been in
France, making selected French institutions the most prepared in the world for remote video
care. We obviously weren't anticipating the Coronavirus and now we're dedicated to delivering
our technology to where the world needs it asap.
epiqar 's parent company ENGAUGE (https://eng.us/ ) is a state-of-the-art online healthcare

company for surgeon training and has served clients such as Johnson & Johnson , Intuitive
Surgical, and many other of the world largest & smallest medical device companies.
ENGAUGE has helped surgeons all over the world have access to secure online training that
has improved their understanding of the innovations in robotics and many of the latest surgical
techniques and medical devices for best patient care.
I've linked a whitepaper below with details of the system's use. Please let me know if you would
like to speak further and/or need anything additional.
Thanks,
NIH-001938
Danny
www .epigar. com
epiqa r I whitepaper
Daniel Goldberg
CEO
ENGAUGE
www .eng.us
www .epiqar.com
The world 's first low-cost telementoring, surgeon training and instant Cloud-archiving Platform
us 888.615.7874
EUROPE44 2031399059
NIH-001939
Sent : Wed, 12 Feb 2020 00 :16:12 +0000
Subject : FW: AMA news interview request: What to tell your patients about COVID-19
Let us di scuss.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Sara Berg <Sara.Berg@ama -assn.org>

To: Fauci, Anthony (NIH/NIAID) [El -------=-=-c= (b)((;)>
Subject : AMA news inte rv iew request: What to tell your patients about COVID-19
Dear Dr. Fauci,
My name is Sara Berg and I am a senior wr iter for the AMA . I am reach ing out to you today because you
have shared a lot of great information about COVID-19 with the JAMA networ k. I know you are very
busy, but I was wondering if you wou ld be available tomorrow or Thursday for a quick phone inte rview
about what to tell patients who suspect they have COVID-19? This would be an AMA news art icle for
physicians about what to tell patients. The CDC has a list of preventive steps :
https ://www .cdc .gov/coronavirus/2019-nc ov/hcp/gu idance -prevent -spread .html .
This would be what phys icians should tell patients who suspect they have COVID-19. One tip might be
"Call before you come in." Do you think this is something you would be available to participate in?
Thank you ,
NIH-001940
AMA~
Sara Berg
Senior Communications Specialist
Sara.Berg@ama-assn.org
Office: (312) 464-4104
00000
AMA membership: Join or renew today!
MEMBERSHIP
MOVES
MEDICINE ...
NIH-001941
Sent: Wed, 12 Feb 2020 00:13:52 +0000
To : Cassetti, Cristi na (NIH/NIAID) [E]
Subject: FW: 2019 nCoV brief fyi (2+ pages)
Attachments : Brief 2019 nCoV host Se status.doc
Director
Phone : (b) (6)
FAX : (301 496-4409
E-mail : (b)(6)
From: Michalann Harthill (b)(6)

To: Fauci, Anthony (NIH/NIAID) [E) -------=-:--:=
:.::========-=.,~ (b)(6)
Cc: Morens, David (NIH/NIAID) [E]
----------
Subject : 2019 nCoV brief fyi {2+ pages)
(b)(6)
Dear Dr. Fauci,
Please find attached, FYI, my synopsis Emergence of a novel coronavirus (2019-nCoV), Wuhan, Hubei
Province, China: human host selenium-deficient status as a possible "driving" etiological determinant. (2 1/4
pages, ~70 refs, no graphics)
Best regards,
Michal Harthill
GHI, Inc., Frederick, MD
(b)(6)
NIH-001942
Sent : Wed, 12 Feb 2020 00:05:00 +0000
To : (b)(6)
Subject : FW: take a look at figure 3 of the new nejm paper
Attachment s: nejmoa2001316.pdf
See Greg/ David comm ent below .
Director
Phone : (b) (6)
FAX : (301 496-4409
E-mail. (b)(6)
From: Folkers, Greg (NIH/NIA ID) [E) (b) (6)>

---------
To: NIAID OD AM <NIAIDODAM@niaid.nih .gov>
Subject : take a look at figure 3 of the new nejm paper
(b) (5)
Thanks david
NIH-001943
(b) (5l
From: Folkers, Greg {NIH/N IAID) [E)

Sent : Tuesday, February 11, 2020 10 :04 AM
To: NIAID OD AM <NIAIDODAM @niaid.nih .gov>
Subject : this is t he nej m paper discussed this a.m .
That asf is op ining on
Disclaimer: Any third-party material in this email bas been shared for internal use under fair use provi sions
of U.S. copyright law, without further verification of its accuracy/veracity . 1t does not necessarily repre sent
my views nor tho se of NIAJD , NIH, HHS, or the U.S. gove rnment.
NIH-001944
Sent : Tue, 11 Feb 2020 23:58:00 +0000
To: NIAIDODAM
Subject: FW: Keynote Invitation: 3/20 CSISCoronavirus Public Event
This coul d be good since it is local. Let us discuss.
Director
Phone : (b)(6)
FAX: (301 ) 496-4409
E-mail : (b)(6)
From: Stephen Morrison <SMorriso@csis.org>

--------=-,,-:-=
--------- (b)(6)
Cc: Anna Carroll <ACarroll@csis.org>; Samantha Stroman <SStroman@csis.org>; Conrad, Patricia
(NIH/NIAID) [El (b)(6)
Subject : Keynote Invitat ion: 3/20 CSIS Coronavirus Public Event
Dear Dr. Fauci,
I hope this note finds you well. It is my pleasure to invite you to be the opening keynote speaker at a
CSIS public event on coronavirus on Friday, March 20, 1:30-3:30 pm at CSIS (1616 Rhode Island Avenue
NW) . The event will focus on the science, economics, and politics of the coronavirus and will feat ure
experts on Chinese and international politics and economics, as well as public health . We would ask you
to speak approximately 1:30-Z:OOpm. Your keynote would be followed by a panel discussion and a
closing address, and we invite you to stay for as much of the event as you are able . Please find the full
draft agenda and speakers for the event below for your reference .
We would be honored to have you participate in this important and timely event. Thank you for your
conside rat ion, and please let us know if you would like to discuss further or if we can answer any
questions. We loo k forward to hearing from you .
Best,
Steve
NIH-001945
Draft Agenda:
1:30-2 :00 pm - Opening Keynote
Dr. Anthony Fauci, NIAID
Introduced by Steve Morrison, CSISGlobal Health Policy Center
2:00 -2:50 pm - Panel Discussion

{The economics/business] Joyce Chang, JP Morgan (confirmed)
{The politics] Jude Blanchette, CSISFreeman Chair in China Studies (confirmed)
[The foreign politics] Melanie Hart, Center for American Progress (to be invited), or Bonnie
Glaser, CSISChina Power Project
{The public health] Steve Morrison, CSISGlobal Health Policy Center (confirmed)
Moderato r : Scott Kennedy, CSISTrustee Chair in Chinese Business and Economics
2:50-3 :30 pm - Newsmaker Speech

Matt Pottinger, NSC(to be invited)
Moderato r and Follow-up Interview: Bonnie Glaser, CSISChina Power Project
J. Stephen Morrison
Senior Vice President & Direct or, Global Health Policy Center
Center for Strategic and International Studies (CSIS)
1616 Rhode Island Ave NW
Washington D.C. 20036
(202) 775 -3276
NIH-001946
From: Fauci, Anthony (NIH/ NIAIO) [El
Sent : Tue, 11 Feb 2020 23:45: 51 +0000
To : Lerner, Andrea (NIH/NI AID) [El
Subject : FW: Pharmacist's/ Prescriber 's Lett er Review Request - Coron av irus
Please t ake a look at thi s and respo nd for me.

Tha nks,
Tony
Directo r
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)( 6)
other storage devices . The National Institute of Allergy and Infectiou s Diseases (NIAID) shall not
From: Jennife r Nieman <jnieman@pl et te r .com>

Se nt : Tuesday, Februa ry 11, 2020 11:00 AM
-------
To : Fauci, Anth ony (NIH/ NIAID) [E]
--------- =---c-c=(b)( 6)
Subject : Pharm acist's/ Prescri ber's Lette r Revi ew Request - Coron aviru s
Dear Dr. Fauci,
In the March 2020 issues of Pharmacist 's Letter and Pre scr iber's Letter, we plan to write about
coronavirus.
Pharmacist 's and Prescriber 's Letter is an independent advisory service for pharmacists and physicians.
We are not affiliated with any other group , organization, or company. We are 100% subscriber
supported. Our focus is providing practica l, unbiased advice to subsc ribers on issues related to drug
therapy . Each month we turn to experts like you to help us pin down the most relevant and important
informatio n to share with our reade rs. Our newsletter is well known for being concise and accurate. You
will notice the excerpt we are sending you is relatively short .
NIH-001947
We would be most appreciative if you would take j ust a few moments to review what we have written for
accuracy and content. Please share any comments or suggestions for changes you may have on the
article .
In order to incorporate your comments into the final Letter, please let me hear from you by Monday , Feb .
17th . I can be reached by email jnieman@P Letter.com or phone (402) 660-4715.
I look forward to your reply.
INFECTION CONTROL
The ongoing ou tb reak of t he novel coronavirus wi ll raise

quest i o n s about h ow t o li mi t t he spread of r e sp i ratory
infec t ion s .
Managing this situation is similar to outbreaks of SARS and

MERS ... s in ce coro n av i ruses are spread by resp i ratory secret i ons .
Pu t t he risk in perspect i ve t o calm worr ie d

patients . .. since it doesn ' t come close to the risk of influenza .
For example, over 35 MILLIO N U. S . patients got the flu last

seaso n . . . wi t h about 500 ,000 ho sp i ta li za t i o n s a nd 34 ,000 deaths .
Emphasize getting a flu vaccine each year .
And us e this coronavirus outbrea k as an opportunity to

stress infection control ... since there ' s no treatment o r vaccine
yet .
Reinforce p roper han d h yg iene . Educate t ha t h a n dwas hing

wi t h soap a n d water i s t he best way t o g e t r i d of germs . Advise
was hin g for 20 seco nds ... about t he t ime i t tak es t o s in g t he ABC
so n g .
Or recommend using a han d sani t izer wi t h a t leas t 60%

alcohol if handwashing isn ' t practical . Many prod u cts contain
this much .
But tell patients to be wary of efficacy claims . For

e xamp l e, h a n d sa ni t i zers are s ho wn t o k ill en v e l oped v i ruses .
Coronavir u ses are enveloped viruses ... b u t they aren ' t
specifically st u died .
NIH-001948
Tell patients to avoid touching their eyes, nose , and
mouth .
Clear up confusion about mas ks. Emphasize that mas ks are

for SICK patients ... to help keep their germs from g ettin g into
t he a ir .
But d i scourage surgica l masks for mos t patients withOU T

symp t oms ... t here ' s no e v i d ence t he y he l p . The y ' r e t oo l oo s e t o
l imi t inh a l ing germs ... a nd v i rus e s ca n a l so ge t in t h ro ugh th e
e y es .
I f pat ien ts ask about N95 res p ira t ors , t e ll t hem t hese
req u ire fittin g and training before us e . Save them for
healthcare workers .
Caution that unnecessary mask use may contribute to

shortages .
Continue to ask patients WITH respiratory symptoms to put a

s ur g ic a l mask on when t he y co me to c l inic .
And suggest that sick patients wear a mask at home if in

close contact with infants , elderly , or immunocompromised
patients .
Te ll pat ien t s t o discard masks when da mp ... and t o use a

fresh one at least daily .
Encourage pat ien ts t o s tay home wh en t hey ' re sick.
1. https://www.who.int/emergencies/diseases/novel-coronavirus-2019
2. https://www.cdc
.gov/coronavirus/2019-ncov/index.html
3. https://www .cdc.gov/f lu/professionals/infect ioncont rol/maskguidance .htm
4. https://www.who. int/publications-detail/advice-on- the-use -of-mas ks-the-comm unity-durinq-home-care-a nd-in-health-care-
settinqs-in-the-context-of-the-novel-coronavirus-(20 19-ncov) -out break
Sincerely,
Jennifer A. Nieman, PharmD , BCPS

Associa te Editor, TRC Healthcare
M: 402-660 -4715 E : jnieman@pletter.com W : TRCHealthcare .com

Pham1acist's Letter I Prescriber's Letter I Natural Medicines I Pharmacy Technic ian's Letter I Pharmacy Technicians University
NIH-001949
Sent: Tue, 11 Feb 2020 23:06:37 +0000
Subject : FW: [ Dear Prof. Anthony Letter of inte rview from China Science Daily]
Can we please get someone to fashion answers for me to edit and send to her.
Director
Phone: (b)(6)
FAX : (301 496-4409
E-mail Cb)(6)
From: ~fm/§ <ymhan@stimes.cn>

To: Fauci, Anthony (NIH/NIAID) [E]------ ..-.-,=
(bH >
Subject: [ Dear Prof. Anthony Letter of interview from China Science Daily]
Dear Prof. Anthony,
I am yangmei Han, a journal ist from CHINASCIENCEDAILY.

China Sc i ence Dai Iy IS
a newspaper in Chinese, pub I i shed by The Chinese Academy of Sciences.
Recently, your article " Coronaviru "

s Infectio ns- More Than Just the Common Cold
mention about vaccines research 1n NI AID. We are

interested and there are some questions and I want to
get more informations.
1, What is the current research progress about vaccines 1n NIAID?
NIH-001950
2-.. What are the factors restricting the development of vaccines? and did you break
through them?
3 .. What is the standard of vaccine that can be injected to patients? and according
your forecasting, how will it work?
4 .. Can this vaccines research play a role in the 2019 -nCoV ? Or as a treatment for a
common infectious disease in the future?
5, Does vaccines have side effects? how can we restrain it?
6, If vaccines research success in a certain country, Will it be open to the

world? if it will , what conditions will need for open?
if you could, we would I ike you rep l y as soon as possible

Thank you very much
I am looking forwa r d to your reply!
Si nee re I y yours ,
Yangmei Han (Miss)
~tw~
q:ioof:.I.~tt* tnc::p
:1& ,1) tc~
BlB~B : ymhan@stimes .cn;576942717@qq .eom
it i! : (b)(6)
i'!EiJt:~t:l¥nn;i;;El&J:P**1ffi-~Z:,g:i~N~:J:
IH±
q:iOOf:.1.~
~tt:~~~M ~ ~-q:i~ I ~~-~*~~M~B~•m~~c::p~M ~ ~ * ~~~~
· §&~~~m-~~~~~$·~-~~~~-%~M~••·
NIH-001951
Sent: Tue, 11 Feb 2020 20:54:02 +0000
To : Natalie Rahhal
Subject: RE: Interview re: coronavirus patient characteristics
If th is is true, which it might not be, there is no clear explanation for why right
now . There will likely be studies coming out that say that the relative proportion
of male:female is closer to 50:50. Even one of the ones that you quoted was
54%
Director
Phone Cb)
(6)
FAX: (301 496-4409
E-mail : (b) (6)
From: Natalie Rahhal <Natalie .Rahhal@mai lonline .com>

To: Fauci, Anthony (NIH/NIAID) [E] ------- ~=
(b)(6)
Subject: Interview re: coronavirus patient characteristics
Hi Dr Fauci,
I'm sure you're extraordinarily busy righ t now, but I've seen several stud ies and reports that coronavirus
seems to dispropo rtionate ly strike men (making up 54-68% of cases, depending on which study you
reference). I was wondering if you might have any comments to offer on why this mig ht be?
Thank you,
Natalie A Rahhal
Acting US Hea.lth Editor
Daily
lll4'lil.com
NIH-001952
Daily M ail Online I51 Astor Place, 9th floor, New York NY 10003
Tel: +1212402 9086

Mobile : (b) (6)
Tw itter : https ://twi t ter .co m/nata lier78?1ang=en
Email: Natalie.rahhal@mailonline.com
Disclaimer
This e-mail and any attached files are intended for the named addressee only. It contains information, which may
be confidential and legally privileged and also protected by copyright. Unless you are the named addressee ( or
authorised to receive for the addressee) you may not copy or use it, or disclose it to anyone else. If you received it
in error please notify the sender im mediately and then delete it from your system. Associated Newspapers Ltd.
Registered Office: Northcliffe House, 2 Derry St, Kensington, London, W8 STT. Registered No 84121 England.
NIH-001953
From: Fauci, Ant hony (NIH/N IA ID) [E)
Sent: Tue, 11 Feb 2020 20:10:45 +0000
To: Nabel, Gary / US
Subject : RE: W HO meeti ng
Gary:
Thanks for the note. (b) (4)
Best,
Tony
Anthony S. Fauci. MD
Director
3 I CenterDrive, MSC2520
National Jnstitutes of Health
Bethesda, M D 20892 -2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b)(6)
The infom1ation in this e-mail and any of its attachmen ts is confidential and may contain sensitive infom1ation . It
should not be used by anyone who is not the origina l intended recip ient. If you have received this e-mai l in error
please inform the sender and delete it from your mailbox or any other storage devices. The Nationa l 1nstitute of
Allergy and lnfectious Diseases (NIAI D) shall not accept liability for any statements made that are the sender's own
and not express ly made on behalf of the NIA ID by one of its representatives.
from : Nabel, Gary /US ---------=-=-=
Sent: Tuesday, February l l , 2020 1:19 PM
(b) (
To: Fauci, Anthony (N1H/N1AJD)[E)

Subject: RE: WHO meeting --------- (b)(
No t a problem. I j ust wanted you to know that I was w illing to help.

(b) (4)
Best
Gary
From: Fauci, Anthony (NlH/NlAID) [E]
Sent: Monday, February 10, 2020 3:07 PM --------- (b)(
To: Nabel , Gary / US (b)( 6)>
NIH-001954
Subject: [EXTERNAL] RE: WHO meeting
EXTERNAL: Real sender is

_______ _,
(b)(6)
T submitted your name to the group as one ofmy priority suggestions. T have no idea whom they wil l select.
Director
National Institute of Allergy and Infectious Diseases Building 3 1, Room 7A-03
Phone: (301) 496-2263
FAX: (301) 496-4409
The infom1ationin this e-mail and any of its attachments is confidential and may contain sensitive information. lt
please inform the sender and delete it from your mailbox.or any other storage devices. The National Instinite of
and not express ly made on behalf of the NIA.lDby one of its representatives.
-----O riginal Message- ----

From: Nabel, Gary / US ---------=--=-=
Sent: Monday, February I 0, 2020 2: 17 PM
(b) (
To: Fauci. Anthony (NTH/NIAlD)[E]-------~~

______ _ )_C_,
Cb
Subject: WHO meeting
Hi Tony
Thanks for taking the time to talk and help with the HTVtrispecific work last week. I appreciate your efforts.
While 1 was there, you mentioned a WHO Coronavirus meeting you thought l should join. I'm happy to attend but
have not yet received an invite. Sometimes WHO excludes companies from such meetings, which is unfortunate
and to their detriment. In any case, please let me know ifl can help in any way.
Best regards
Gary
Sent from my iPhone
NIH-001955
From: (b)(6)
Sent: Tue, 11 Feb 2020 11:22:43 -0500
To : Mart in Blaser
Cc: Conrad, Patricia (NIH/NIAID) [E];Cassetti,Cristina (NIH/NIAID) [E];Lane, Cliff
(NIH/NIAID) [E]
Subject: Re: SARS2003, Influenza 2009 and the present
Marty:
Than.ks for the note . Indeed, immune sera is foremost on our mind as are mAbs . Hope that all
is well with you.
Best,
Tony
On Feb 11, 2020 , at 9:55 AM , Martin Blase r

wrote:
------------ Cb)(
Dear Tony,
I dont mean to bother you, but I have a suggestion, in case you have not
considered it.
China will have hundreds of thousands of Coronavirus surv ivors . Thei r convalescent
(immune) serum is valuable. China should try to collect it and give it as a good-will
gesture to people around the world.
For moderately to seriously ill people, Immune serum should save many lives.
If cases start to come here, we also should collect serum from survivors, but
hopefully we will be very late in t he pandemic, and it is not needed because of all
of the others th ings you are doing.
Thank you for everything you and NIAID are doing!
Best wishes, Marty
(Just as in SARS,the Ro for nCo-2019 is higher in hospitals than in the community,
but it still is too high in the community).
Martin J. Blaser, M.D.

Henry Rutgers Chair of the Human Microbiome
Professor of Medicine and Microbiology-RWJMS
Director, Center for Advanced Biotechnology and Medicine
Rutgers University
679 Hoes Lane West, Room 106A
Piscataway, NJ 08854
Office Phone:
------
Fax: 7 2-235- fi._
Emili
3__
(b)(6)
1_8 ______ ~=
oo~
NIH-001956
httPs ://cab m .rutgers.edu
Sent: Sunday, January 26, 2020 7:16 PM
________ ......
(b)(6)
To: Martin Blaser (b)(6):

Cc: Conrad, Patricia (NIH/NIAID) (El (b)(6)
Subject: RE:SARS2003, Influenza 2009 and the present
Marty:
Many thanks. Th is is very helpful.
Best regards,
Tony
From: Martin Blaser (b) (6)

Sent: Saturday, January 25, 2020 9:35 AM
------~ =
(b)(6)
Subject : SARS2003, Influenza 2009 and the present
Webb G, Blaser MJ, Zhu H, Ardal S, Wu J. Critic al role of nosocomial transm ission
in the Toronto SARS outbreak. Mathematical Bioscie nces and Engineering 2004 ; 1:
1-13. [PMID: 203699561 [Paper of the year, 2004]
Webb GF, Hsieh Y-H, Wu J, Blaser MJ. Pre -symptomatic influenza

transmission, surveillance, and school closings: implicat ions for novel
influenza A (HlNl). Mathematical Modelling of Natural Ph enomena
2010 ; 5:191-205.
Dear Tony,
Thank s for your JAMA piece on 2019-nCoV. Perh aps I can help in a
small way:
In 2003, with SARS, the Ro was initially considered to be over 2, but in

fact that was the conflation of the nosocomial and community rates. In the
2004 paper , we showed that nosocomial rate was much higher, and that the
Ro in the commun ity was between 1 and 2. A lower Ro in the community
accounts for why modera te public health action s could mo ve it toward
extinction--and why it propagated in Beijing , but not Shanghai , in Toronto
NIH-001957
but not in Vancouver--the Ro in North America became less than
one pretty quickly.
To me , one important aspect is the control of respiratory tran smission in

the hospital, avoiding extensive nebulization /aerosolization, or doing so in
negative pressure rooms , as for TB isolation.
(Treating patient s with robot s is a good idea!)
In the communit y, standard public health quarantine, contact tracing should

be sufficient for staiie rs.
Although hundreds of cases are reported in China, the actua l number of

infections is likely much higher. The 41 deaths are the tip of the iceberg of
not 800 infections (5% fatality rate), but maybe 8,000 infect ions (0.5%) .
Although that rate is much better, if the mutating virus becomes very
contagious- then the impac t could be similar to 1918 flu. That's why
containment is so important-and although draconia n, the Chinese
government is doing the right thing (as far as we know).
When a new pathogen arrives, children often have mild disease but they
are important vectors for transmi ssion in the cotrununity , reaching many
households. The second paper is the imp01iance of closing school s to minimi ze
transmi ssion- This was for flu with a short (pre-symptomatic) incubation , but may
be even more relevant for 2019-nCo V. It is much too eai·ly to even think of this in
the USA , but it may come to this--and sooner will be better than later , when that
time point comes .
Happy to help, any way that I can. Thank you for all you and NIAID are
doing!!!
Best wishes , Marty
NIH-001958
Martin J. Blaser, M.D.
Henry Rutgers Chair of the Human Microbiome
Profe ssor of Medicine and Microbi ology- RWJMS
Director, Center for Advanced Biotechnology and Medicine
Rutgers Uni vers ity
679 Hoe s Lane West , Room 106A
Piscatawa y, NJ 08854
Office Phon e: (b)(6)
Fax: 732-235-53 ·-18

------~ =
Emai l
----------------
http s: I Icabm.rutgers.edu
(b) (6)
NIH-001959
Sent: Tue, 11 Feb 2020 13:22:53 +0000
Subject : FW: Interview/ Coronavirus vaccine - Pazienti.it
Have Jen Routh or someone prepare bri ef responses that I can check. Thank s.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Alessandra Lucivero <alessandra.lucivero@pazienti.it>

Cc: Camilla Mantegazza <camilla.mantegazza@pazienti.it>; Irene Bacca <irene.bocca@pazienti.it>
Subject : Interview/ Coronavirus vaccine - Pazienti.it
Good morning prof. Fauci,

my name is Alessandra Lucivero and I'm the Editorial Manager of Pazienti.it , an It alian health webs ite,
followed by over 3 million users every month .
We would like to ask you some questions related to the Coronavirus vaccine.
We will publish the interview in Ita lian on our blog here: htt ps://www .pazient i.it /n ews-di-salute.
The questions are:
• Coronavirus vaccine: when will it be available? What are the difficulties?

• Could the Coronavirus mutate, if a vaccine cannot be found in time?
• Will the vaccine be the solution against Coronavirus?
I hope you can be kind enough to answer my questions .
Thank you very much fo r you r time.
Alessandra Lucivero
NIH-001960
Alessandra Lucivero
Responsabile editoriale
alessandra. I ucivero@ pazienti.it
Pa z Ie n T 1.it
II portale della salute dove farsi vedere da uno bravo.
Pa:u enTL
Questo messaggio e i suoi al/egati sono indirizzati esclusivamente a/le persone indicate . La diffusione, la
modifica, la riproduzione di queste informazioni sono vietate . Qualora abbiate ricevuto questo
documento per errore, vi preghiamo di comunicarlo al mittente e di provvedere al/a sua eliminazione . Vi
injormiamo inoltre che questo indirizzo di posta eutilizzato solo a scopo professionale: non si garantisce
che la corrispondenza verso questa easel/a venga Jetta dal solo destinatario poiche, in determinate
circostante, /'accesso puo avvenire anche da parte di terzi appartenenti al/a Societa. Pertanto si consiglia
di non inviare messaggi di natura personale. Grazie.
NIH-001961
Sent : Tue, 11 Feb 2020 13:14:45 +0000
Subject : FW: Coronavirus Auto Terminat ion
Attachment s: Retrovirus Auto Termination.PDF
Director
Phone : (b) (6)
FAX : (301 496-4409
E-mail : (b)(6)
From: Pali Nazir (b)(6)>

To: Fauci, Anthony (NIH/NIAID) [E) ---------=-:-= Chun, Tae-Wook (NIH/NIAID) [E]
(b)(6)
(b)( ; Connors , Mark {NIH/NIA ID) [E] (b)( ; Lane, Cliff
'7"":°'.":"":'"'.:-'.'"'.""'.":'-:-7::-;::===.;,__--
~=
(NIH/NIAID) [El (b)(6); lusso, Paolo {NIH/N IAID) [El (b)(6J>; Sereti, lrini
(NIH/NIAID) [El =====~ (b::;:
) ~(6)
Subject : Coronavirus Auto Term ination
Dear Mrs . / Sir,
We have a solution to the new recent global problem Coronavir us (2019-nCoV).
Best Regards,
Dr. Pali Nazir
NIH-001962
Sent: Tue, 11 Feb 202013:12:28 +0000
To: Cassetti, Cristina (NIH/NIAID) [E)
Subject : FW: coronaviruses
Director
31 Cen ter Driv e, MSC 2520
Bethe sda , MD 20892 -2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b)(6)
From : (b)( ·
Sent: Tuesday, February 11, 2020 8:0 I AM
To (b)(6)
Holbrook , Michael
(NIH/NlAID) [CJ .__ ______ Cb
_H....,>; Fauc i, Anthony (NIH/NlA1D)[E].__ _____ Cb
_H_,,
Subject: coronaviruses
He llo,
Working as an occupational physi cian iu F1ance, I would like to draw you r attention to the antiviral activity of
proton pump inhibitors , includin g for the Gibbon Ape Leukemia vims , a virus which does not requir e acidification
of eod osomes for entry into ce lls, as is the case with corona viruses.
Indeed, in 2015 Long et al. (I) found that« ... The common ly used proton pump inhib itors, Om eprazole and
Esomep razole were also able to inhibit entry of all PV s tested but at high er dru g concentrations than may be
achiev ed in vivo ... >>
.
Us ing omepra zole and esomeprazole magncsi11m hydrate, prepared in sterile DMSO (Sigma ), they conc luded that«
... OM and ESOM appeared to decrease fluorescence, and therefore increase endosomal pH , only at a concentration
of200µM, higher than that required to inhi bit PV entry . Moreover cellular toxicity was observed at this
concentration after 24 hours ... ».
In 2016, Dowa ll et al. (2) found : « ...Whereas omeprazole and esomeprazole demonstrated in vitro activity against
EBOV , the results were in line with a previou s report using pseudotyped viruses where the values of drug
concentration caus ing 50% inh ibition (IC50) were in the region of 50 µM [10). This suggeste d that doses requi red
for potent inh ibition wou ld be difficult to achieve without concomitant and significant toxicity (the licenced dosing
for 40 mg esomeprazole , 20 mg esomep razole and 20 mg omeprazo le generates median maximum plasma
concentrations of 1.59- 9.61 ~tM, 0.51-4.78 µMand 0.15-3.51 µM , respectively .. . >>.
However, omeprazole is marketed in a non-ionized form and must be ionized (in acidic environment) to be
NIH-001963
transformed into an active molecule(3). lt is the ionized form which establishes covalent bonds with the SH group of
the cysteine of the a subunit of the proton pump.
The solution used in 2015 by Jason Long et al. was , as in 2016 by Dowall et al., DMSO(Dimethyl Sulfoxide).
DMSO is a polar and aprotic organic solvent with dissociation constant pKa = 35.1 This is probably an exp lanation
for the surpr ising findings from these studies regarding proton pump inhibitors: Inhibition of viruses at I 00 µM (at
50 µM esomeprazo le for 4 of the 5 viruses tested) and increase in endosomal pH only at a concentration of200 ~1M.
This is a situat ion which, from my point of view, does not reflect the human tissue situation, because in this sin,ation
omeprazole can be ionized in the intracellular space but also already in the extrace llular space.
Besides, that's probably its advantage: to be ionized and activated where there is an acidic enviro nmen t.
Without taking into account the tissue situatio n and the need that omeprazole must be ionized to be transformed into
an active molecule, it would not be possible to explain the following publications , since it would be impo ssible to
obtain tissue concentrations required:
<<Proton pump inhibitors as anti vacuolar-A TPases drugs: a novel anticancer strategy>> (4)
<<Anti-Rhinovirus activity of lansoprazole, whkh was probably due to an endosomal anti-acidic mechanism »
(5)
« The use of omeprazole family compounds was associated with a lower probability of influenza-like illness»
(6)
« PPls exert an antiviral function by effectively inhibiting virus-specific serine proteases>> (7)
« Proton pump inhibitors for chronic obstrnctive pulmonmy disease » (8)
« The ngH,K-A TPase shares approximately 65% sequence homology with the gH,K-ATPase » (9)
« Omeprazole blocked another P-type ATPase, ATP7 A (Men kes protein) in human epidermal melanocytes »
(10)
« pH-dependent anti tumor activity of proton pump inhibitors» ( 11)
« V-ATPase as a candidate target molecrtle or biomarker for cancer treatment and provide a potential role for
omeprazole as a chemosensitizer in clear cell carcinoma of the ovaiy » (12)
« Proton pump inhibitors such as omeprazole, used clinically to suppress gastric acid ity in gastritis, are
activated by acidic conditions and tend to decrease intracellular pH and increase the extrace llular pH via inhibition
of V-ATPases in a covalent interaction» ( 13)
« proton pump inhibitors have been shown to be highly effective at inhibiting V-ATPases in vitro» (14)
Specifically at the pulmonary level, we observe concerning proton pump inhibitors:
« ... Since ATP 12A shares approximately 65% identity with the gastric H+/K+-ATPase (ATP4A), we
investigated the potential of using clinically approved A TP4A proton pump inhibitors (PPTs) for their ability to
restore ASL pH in CF hAECs. We show that, despite not expressing ATP4A transcripts, acute exposure to the PPJ
esomeprezo le, produced changes in intracellular pH that were consistent with the inhibition ofH + secretion , but this
response was independent of ATP 12A. More importantly , chronic exposu re of CF hAECs to esomeprazo le
alka linized the ASL without disrupting the epithe lial barrier integrity, but this increase in ASL pH was cons istent
with a decrease in mRNA expression of ATPI.2A. We conc lude that PPis may offer a new approach to restore ASL
pH in CF airways , which is independent ofCFTR .... » (15)
NIH-001964
« ... On the other hand, even though the gastric H+/K +-ATPase was not expressed in airway epithelial cells,
exposure to esomeprazole acidified the cytosol and increased ASL pH of primary CF hAECs. We show that
esomeprazo le had a dual mechanism of action: acutely , it induced intracellular acidification in an ATP l 2A-
independent manner but, chronic exposure, which importantly did not have any deleterious effect on epithelial
integrity , was linked to decreased ATP 12A mRNA levels. These results open up the possibility ofrepurposing PPTs
as a new therapeutic approach for treating CF lung disease ... » ( 15)
« ... we found that the mRNA of ATP 12A, the non-gastric H+/K +-A TPase , shares 70% identity with the
gastric H+/K+-ATPase, ATP4A mRNA, which translates to around 65% identity in the protein products ... » (15)
« Proton pump inhibitor therapy predisposes to increased risk of developing pneumonia » ( 16)
« Na+/H+ Exchangers Are Required for the Development and Function of Vertebrate Mucociliary Epithelia »
(17)
« ATP4a is required for development and function of the Xenopus mucoci liary epidermis - a potential model
to study proton pump inhibitor-associated pneumonia>> (18)
Regarding coronaviruses and Golgi complex:
« ...Coronavirnses (Co Vs) acquire their envelopes from the endoplasmic reticulum-Golgi intermediate
compartment( ... ), also called the cis-Golgi network( ... ). The three main envelope proteins (S, Mand E) are
synthesized in the ER and move to the ERGIC /Golgi region where they orchestrate assembly of virus by interacting
with the viral nucleocapsid ( ... ).Once virions have budded into the lumen of the ERGlC, the ~ 120 nm particles
must move through the host secretory pathway to be released from infected cells. Coronaviruses are believed to
follow the constitutive secretory pathway for exocytosis , although only a few stud ies have addressed the release of
virions. During infection , a progressive dismption of Golgi structure is observed , with swollen unstacked cistemae
late in infection ... >>
« . .. Weak bases (w hich disrupt acid ification), v-ATPase inhibitors , and expression of a pH activated proton channel
all block a number of membrane trafficking steps( . . .) One mechanism for how luminal pH can affect vesicu lar
trafficking involves a subunit of the membrane sector of the v-A TPase, which has been shown to act as a pH sensor
in endosomes. This subun it undergoes a conformationa l change as the luminal pH drops, which recruits cytoplasmic
machinery leading to subsequent vesicle fonnation ... » (19)
« ... Phannacological and other manipulations of the pH gradient that resu lt in neutralization of the lumen
have all been shown to cause slow trafficking of cargo through the Golgi complex as well as alteration in Golgi
morphology ... »
« ... Similar to M2, the infectious bronchitis virus (IBV) coronavirus E protein elicits multiple secretory pathway
disruption phenotypes when overexpressed in mammalian cells ... » (20)
« ...The envelope protein (E) of corona v iruses plays an important role in virus assembly ( ... ) Using
coronavirus infectious clones , it was shown that the transmissible gastroenteritis virus E protein is essential for vims
production , and murine hepatitis virus lacking E protein is viable but extremely debilitated ... >>
« ... The exact mechanism of coronavirus release after budding into the endoplasmic reticulum--Golgi intermediate
compartment is not known. Large vacuoles containing budded virions are obse1ved in infected cells , presumably en
route to the plasma membrane where fusion of the vacuole results in release of virions ... » (21, 22)
« ... It might be worth investigating whether ion-channel inhibitors, such as amantadine, or proton pump
inhibitors specifically are able to inhibit this increase in Go lgi pH . For now, though , it still remains to be seen
whether Co V release is mediated by viroporin ion channel activity or through PP Is with host proteins of the
secretory pathway ... » (23)
« V-A TPases are also important for transportation of new ly synthesized acid hydrolases from Golgi to
lysosomes » (24)
NIH-001965
«...cardiotonic steroids ouabain and bufalin, wbicb are known not to affect tbe transport function ofNa+,K +-
AT Pase, inhibited infection of ceUs with MHV, FIPV, Mid dle East respiratory syndrome (MERS)-CoV, and VSV,
but not IAV, when the compounds were present during virus inoculation . Card iotonic steroids were shown to inhibit
entry ofMHV at an early stage, resulting in accumulation ofvirions close to the cell surface and, as a consequence,
in reduced fusion. In agreement with an early block in infection, the inhibition ofVSV by CTSs could be bypassed
by low-pH shock. Viral RNA replication was not affected when thes e compounds were added after virus entry. The
antiviral effect of ouabain could be relieved by the addition of different Src kinase inhibitors , indicating that Src
signaling mediated via ATPIAI plays a crucial role in the inhibition ofCoV and VSV infections ...» (25)
In conclusion, in order to verify the possible efficacy of omeprazole and esomeprazo le in the control of infection by
coronaviruses :
Tbe equivalent oftbe maximum serum concentration that can be obtained in the human bod y should be used
and tested in active (ionized) form in vitro .
Unlike an in vitro test, the human body is an open system, a dissipative system. However, local concentrations oftbe
ionized form should not exceed serum concentrations of the inactive non-ionized form in the absence of active
transport.
But the transfonnation from the non-ionized form to the ionized form could continue until the saturation of the
reactions at the cellular ]eve] or until the depletion of the transformation capacity from the inact ive form to an active
form, linked to a change in acidity or the depletion of the inactive form.
As omeprazole can modify or even inhibit the action of the M2 protein of the influenza virus at the cellular
level (26), based on a computer simulation test, it would be desirable to cbeck the interaction capabilities of
omeprazole with protein E of the corona virus . Prot ein E is likely to resemb le the protein M2 in its mode of action.
In the absence of a treatment recognized as effective in the context of a coronavirus infection and in the
absence of data clearly demonstrating the ineffectiveness of omeprazole , personally, l would be tempted to take
omeprazole after being in contact (at a distance of less than 2 to 3 meters) with people at risk of contamination or if l
had the first symptoms, hoping for the inhibitory activity of omeprazole on P-type ATPases (27, 28) in the context
of coronavirus exocytosis , in analogy to the action "off target on the endosoma l v ATPase" during endocytosis
processes.
This step, if effective, will not prevent infection , but could lesse n its importance, slow the process down and give tbe
immun e syste m a complementary option to defend itself...
Personal experience, using omeprazole in the context of seasonal respiratory v iral infections since 2007,
reminds me of the indication to divide the daily dose into two daily doses (omeprazole 10mg morning and evening is
usually already effective for seasonal respiratory viral infections). According to tbe evolution and the importance of
inflammatory state I associate an antihistamine, eg cetirizine.
In the context of the coronavirus , I would be tempted
share tbe maximum permissible daily dose of omeprazole in 3 divided doses after being in contact with
people at risk of contamination at a distance of less than 2 to 3 meters
divide tbe daily dose of omeprazole into two daily doses in case of minor symptoms
take the daily dose of omeprazole in a single dose if the symptom s worsen with repercu ssions on the genera l
condition
to resume the daily dose of omeprazole in two daily doses when the symptoms of sever ity diminish.
Th e effectiveness of esomeprazole may be greater than omeprazole.
NIH-001966
Taking into account the aforement ioned publications , it should not be forgotten that omeprazo le will reduce
sec retions at the respiratory level. A posit ive effect on respiratory secret ions dur ing acute vira l respi ratory diseases
which can become negative (by modifying the pH, the cil iary mobility and the volume of secretio ns) during
prolo nged use, thus promoting the risk of bacterial pneumonia (29).
The adva ntages and d isadvantages may vary depending on the user phenotype of omeprazole with regard to
cytochrome P 450 (30).
Best regards
Johann es Hambura
I. Long J, Wright E, Mo lesti E, Temperton N, Barclay W. Antiviral therapies against Ebola and other emerging
vira l diseases using existing medicines that block v irus entry. Fl000Res. 2015;4:30 . Published 2015 Jan 29.
doi: 10.12688/fl000research .6085 .2
2. Dowall SD, Bewley K, Watson RJ, et al. Antiviral Screening of Multiple Compounds again st Ebo la Virus.
Viruses. 2016;8(11):277. Published 2016 Oct 27. doi : 10.3390/v8110277
3. Shin JM , Kim N. Pbarmacokinetics and pharmacodynamics oftbe proton pump inhibitors. J

Neurogastroenterol Motil. 2013;19(1):25-35 . doi: 10.5056/jnm.2013.19.1.25
4. Spugnini EP, Citro G, Fais S. Proton pump inhibitors as anti vacuo lar-ATPases drugs: a novel antica ncer
strategy. J Exp Clin Cance r Res.20 10;29( 1):44. Pub lished 2010 May 8. doi: 10.1186/1756-9966 -29-44
5. Sasaki T, Yamaya M, Yasuda H, Inoue D, Yamada M, Kub o H, Nish imur a H, Sasak i H. The proton pump
inhibitor lansoprazole inhibit s rhinoviru s infection in cultured human tracheal epit helia l cells. Eur J Pharmacol.
2005;14:201 - 2 10. do i: 10.1016/j .ejphar.2004 . 12.042.
6. Gaspari ni R, La i PL, Casabona F, et a l. Do the omeprazole fami ly compounds exert a protect ive effect against
influenza- like illness? . BMC Infect Dis. 20 14 ; 14:297. Publ ished 2014 Jun 2. do i: 10.1186/1471 -2334-14 -297
7. Moorn1ann AEBDP , Flynn DL, Hui LI, Villam il CI, Inventor method of using (H+/K+)ATPase inhibitors as
antiviral agents . United States 1999 Jun. 14, 2005.
8. Kikuchi S, Naoki Y, Tajiri T, Watanabe N . Proton pump inhibitors for chronic obstructi ve pulmonary disease.
Cochrane Database Syst Rev . 2018;2018(8) :CD013 l 13. Published 2018 Aug 30. doi:10.1002 / 14651858.CD013 I 13
9. Modyanov N, Pestov N, Adams G, Crambert G, Tillekeratne M, Zhao H, Korneenko T, Shakhparonov M,

Geering K. Nongastric H ,K-ATPase: structure and func tional properties. Ann NY Acad Sci. 2003 Apr; 986():183-7 .
10. Matsui MS, Petris MJ , Niki Y, Karaman-Jurukovska N, Muizzuddin N, Ichihashi M, Yarosh DB. Omeprazole ,
a gastric proton pump inhibitor , inhibits melanogenesis by blocking ATP7 A trafficking. J Invest Dermatol. 2015
Mar ; 135(3):834-841.
l I . De Milito A, Canese R , Mari no ML, Borghi M, Tero M, Villa A, Venturi G, Lozupone F, Jessi E , Logozzi M,
Mina PD, Santi nam i M , Rodo lfo M, Podo F, Rivoltini L, Fais S. pH-dependent antih tmor activity of proto n pump
inhibitors aga inst human melanoma is mediated by inhibitio n of tumor acid ity. Int J Ca ncer. 2009 .
12. Lee YY, Jeon HK, Hong JE, et al. Proton pump inhibit ors enhanc e the effects of cytotoxic agents in
chemo resistant epit helial ovar ian carcinoma. Oncotarg et. 2015;6(33):35040 - 35050 . doi:10.18632 /oncotarget.5319
13. Larsson H, Mattson H, Sundell G, Carlsson E. Animal pharma codynamics of omeprazole. A survey of its
NIH-001967
pharmacological properties in vivo. Scand J Gastroenterol Suppl. l 985; I08:23-35.
14. Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, Marra M, Lugini L, Logozzi M,
Lozupone F, Federici C, Tessi E, Panniani G, Arancia G, Belardelli F, Fais S. Effect of proton pump inhibitor
pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst. 2004;96: 1702-1713.
15. Delpiano L, Thomas JJ, Yates AR, Rice SJ, Gray MA, Saint-Criq V. Esomeprazo le Increases Airway Surface
Liquid pH in Primary Cystic Fibros is Epithelial Cells. Front Pharmacol.2018 ;9: 1462. Published 20 18 Dec 11.
doi: 10.3389/ fphar.2018.01462
16. de Jager CP, Wever PC, Gemen EF, van Oijen MG, van Gageldonk -Lafeber AB, Siersema PD, Kusters GC,
Laheij RJ. Proton pump inhibitor therapy predisposes to community-acquired Streptococcus pneumonjae
pneumonia. A liment Phannacol Ther. 2012 Nov;36(10):94l-9. doi : 10.1111/apt.12069. Epub 2012 Oct 3.
17. Sun DI, Tasca A, Haas M , et al. Na+/H+ Exchangers Are Required for the Development and Function of
Vertebrate Mucociliary Epithelia. Cells Tissues Organs. 2018;205(5-6):279 - 292. doi: 10.1159/000492973
18. Walentek P, Beyer T, Hagenlocher C, et al. ATP4a is required for development and function of the Xenopus
mucociliary epidermis - a potential model to study proton pump inhibitor-associated pneumonia. Dev Biol.
2015;408(2):292-304. doi: I0.1016/j.ydbio.2015.03.013
19. Machamer CE. Accommodation of large cargo within Golgi cisternae. Histochem Cell Biol. 2013; 140(3):261-
269. doi: 10.1007/s00418-013-1120-y
20. Jason W. Westerbeck, Carolyn E. Machamer. The Infectious Bronchitis Coronavirus Envelope Protein Alters
Golgi pH To Protect the Spike Protein and Promote the Release oflnfectious Virus. Journal of Virology May 2019,
93 (11) e00015- 19; DOI: 10.l 128/M .00015-19
21. Machamer CE 1, Youn S. The transmembrane domain of the infectious bronchitis vims E protein is required for
efficient virus release . Johns Hopkins University School of Medicine , Baltimore , Ma1yland 21205, USA. PMID:
17037529 DOI: 10.1007/978-0-387-33012-9 33
22. Tooze, J., Tooze, S. A., and Fuller, S. D., 1987, Sorting of progeny coronavirus from condensed secretory
proteins at the exit from the trans-Golgi network of AtT20 cells, J. Cell Biol. I05: 1215.
23. Schoeman, D., Fielding, B.C. Coronavirus envelope protein: current knowledge. Virol J 16, 69 (2019).
https://doi.org/ 10.1186/s l2985-019-1182-0
24. Pamar thy S, Kulshrestha A, Katara GK, Beaman KD. The curious case ofvacuolar ATPase: regulation of
signaling pathways. Mo] Cancer. 2018; 17(1):4 L Published 2018 Feb 15. doi: I0.1 I 86/s 12943-018-0811-3
25. Burkard C, Verheije MH, Haagmans BL, van Kuppeveld FJ, Rottier PJM, Bosch B-J, de Haan CAM. 2015.
ATPlAl-mediated Src signaling inhibits coronavirus entry into host cells. J Virol 89:4434-4448.
doi:10.l 128/JVI.03274-14
26. Bozdaganyan M, Orekhov Ph, Bragazzi N, Panatto D, Amicizia D, Pechkova E, Nicolini C, Gasparini R.
Docking and Molecular Dynamics (MD) Simulations in Potential Drngs Discovery: An Application to Influenza
Virus M2 Protein. American Journal of Biochemistry and Biotechnology 2014/ 11/08. 10.3844/ajbbsp.2014.180.188
27. Lisa A. Dunbar and Michael J. Caplan. Jon Pumps in Polarized Ce lls: So1iing and Regulation of the Na+ ,K+-
and H+,K+-ATPases. J. Biol. Chem. 2001 276: 29617-. doi: I 0.1074/jbc.R I 00023200
28. Amarelle L, Lecuona E. The Antiviral Effects ofNa ,K-ATPase Inhibition: A Minireview. Int J Mol Sci.
2018;19(8):2154. Published 2018 Jul 24. doi: 10.3390/ijmsl 9082154
29. Yu LY, Sun LN, Zhang XH, et al. A Review of the Novel Application and Potential Adverse Effects of Proton
NIH-001968
Pump Inhibitors. Adv Ther. 2017 ;34(5): I 070-1086. doi: I 0.1007 /s12325-017-0532-9
30. E l Rouby N, Lima JJ, Johnson JA . Proton pump inhibitors: from CYP2C 19 pharmacogenetics to precision
medicine. Expert Opin Drug Metab Toxicol. 2018; 14(4):447-460. doi: 10.1080/17425255.2018.146 1835
NIH-001969
Sent : Tue, 11 Feb 2020 12:52:45 +0000
Subj ect : RE: WTOP Request
OK by me. Please set it up.
Director
Phone : (b)(6)
FAX: (301 ) 496-4409
E-mail : (b)(6)
From: Conrad, Patricia (NIH/NIAID) [El (b)(6)>

--------, .....,....,=
Subj ect : Fwd: WTOP Request
--------- (b)(6)
1040 before you depart for aspen event?
Sent from my iPhone
From: "Chesson, Joslyn" <jchesson@wtop .com >

Dat e: February 11, 2020 at 7:16:26 AM EST
To: "Conrad, Patricia (NIH/NIAID) [E]" _______ -,;;-
(b)~ (=6)>
Subject : WTOP Requ est
Good morning,
Hoping Dr. Fauci has some availability this late morning and early afternoon to discuss the
coronavirus and the quarantining on cruise ships.
We have 10:40a, 11:lOa, and 12:10pm all open .
NIH-001973
Let me know if any of those times work for him!
Thanks,
Joslyn Chesson
Editor
WTOP News
(202) 895-5060
NIH-001974
Sent : Tue, 11 Feb 2020 12:20:02 +0000
To : Lisa Monaco
Subject : RE:The Coronavirus Shows Why the U.S. Must Make Pandemic Disease a
National Security Priority - Lawfare
Lisa:
Thanks for the note and for sending this. Very ruce piece! I hope that all is well w ith you. I miss very much
our interactions.
Best regards ,
Tony
Director
Nat ional Institute of Allergy and Tnfectious Disease s
National In stitutes of Health
Be thesda , MD 20892-2520
Phone: (b) (6)
FAX: (30 I) 496 -4409
E-mail (b) (6)
The infom1ation in this e-ma il and any of its attachments is confidential and may contain sensitive infom1ation. It
please inform the sender and delete it from your mailbox or any other storage de vices. The National Institute of
Allergy and Tnfectious Diseases (NIAID) shall not accept liability for any statement s made that are the sender's own
and not express ly made on behal f of the NIAID by on e of its representatives.

From: Lisa Monaco _______ ...,
(b
"~"'
...,
(6)
=
Sent: Monday,febrnary 10, 2020 8:09 PM
To: Lisa Monaco (b)(6)
Subject: The Coronavirus Shows Why the U.S. Must Make Pandemic Disease a National Security Priority - Lawfare
In case you missed this, my latest on the coronovirus.
https:/lwww .lawfareb log .com/co ronavirus -show s-whv-us-must-make -pandemic-disease -national-security-priority
Sent from my iPad
NIH-001975
Sent : Mon , 10 Feb 2020 22:44:53 +0000
Cc: Conrad, Patricia (NIH/NIAID) [E];Billet , Courtney (NIH/NIAID) [E];Stover, Kathy
(NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID ) [E];Folkers, Greg (NIH/NIAID ) [E]
Subject : RE: for review: responses for Washington Times
Att achment s: responses to Washington Times 2.10.2020 AL - wit h Fauci tracked changes.docx
See my tr acke d changes in at tached docum ent . Thank s.
Director
Phone : (b) (6)
FAX: (301 496-4409
E-mail : (b)(6)
From : Routh, Jennifer (NIH/NIAID) [E] (b)(6)

Sen t : Monday, February 10, 2020 4:07 PM ---------
(bH >
~======~~ (b)(6)>; Billet, Courtney (NIH/NIA ID) [E)
(b)(6); Stover, Kathy (NIH/NIAID) [El (b)( ·; Lerner, Andrea
(NIH/NIAID) [E_______ Cb ""-:--:--"'"""'."'-:-:-::-==:::::.:...--,.;_-=-c-c-=-t
_>_<6JFolkers, Greg (NIH/N IAID) [E]_______ Cb
_H_6)>
Subject: for review: responses for Wash ington Times
Dr. Fauci -
The reporter Shen Wu Tan from the Washington Times reached out to us this morning with some
questions about 2019-nCoV. I drafted proposed responses t o t hese questions with input from Andrea.
Please see attached. Please let me know if you have edits . I w ill send the final responses back to t he
reporter, and I will note they are attributed to you .
Thanks,
Jen
Jennifer Routh [E]

News and Science Writ ing Branch
NIH-001980
National Institute of Allergy a nd Infectious Diseases (NIAID)
NIH/HHS
Bethesda, MD 20892
Direct: Cb)(6)
CbH
Disclaimer : The information in this e-mail and any of its attachments is confidential and may conta in sensitive informa tion. It should not be
used by anyone who is not the original intended recipient. If you have rece ived this e-mail in error please inform the sende r and delete ii
from you r mail box or any other storage dev ices. The National Institute of Allergy and Infectious Diseases shall not accept liab ility for any
statements made that are sender's own and not express ly made on behalf of the NIAID by one of its representat ives.
NIH-00198 1
Sent : Mon , 10 Feb 2020 20:22:28 +0000
Subject : FW: Wpos t : Q&A with Anthony Fauci: Are we past the point of containment for
coronavirus?
Let us di scuss.
Director
Phone : (b) (6)
FAX : (301 496-4409
E-mail : (b)(6)
From: Folkers, Greg (NIH/NIA ID) [E) (b) (6)>

--------
Subject : Wpost: Q&A with Anthony Fauci: Are we past the point of containment for coronavirus?
Opinions
Q&A with Anthony Fauci: Are we past the

point of containment for coronavirus?
NIH-001982
man wears a protective mask while walking in
Wuhan, China, on Feb. 10. (Stringer/AFP/Getty Images)
By
Robert Gebelhoff
Assistant editor and Opinions contribu t or
Feb. 10, 2020 at 2:22 p.m. EST
The latest strain of corona virus continues to rage across Chino. Its death tolf has surpassed 900, eclipsing
the body count from Chino's SARS outbreak in 2002 and 2003 .
To get a better sense of the disease and the U.S. government's response to it, we spoke to Anthony 5.
Fauci, immunologist and director of the National Institute of Allergy and Infectious Diseases at the
National Institutes of Health. Below is a transcript of an interview with Fauci, edited for clarity and
brevity .
Robert Gebelhoff: Right off the bat, what makes this virus different?
Anthony Fauci: Well, we have to be concerned whenever there's a virus that has - and I'm going to use
a big word here - pathogenic potential. ... [The coronavirus] is brand-new, and there's no real
underlying experience with it, so the general population is naive with regard to protection . And it has
serious potential, because it's already spreading rapidly . It' s the unknown aspect of something that
already tells you it's a serious problem. We don' t know where it's going.
Gebelhoff : Are we past the point of containment for this coronavirus?

Fauci: No, we're not. The short answer is we're not past the point of containment. But it really does
have the potential to turn into a global pandemic . What we have now is a very serious epidemic in
China.. .. [But outside of China,] there is very little - but some - transmission from person to person .
Once you get mult iple countries that have sustained transmission from person to person, then it 's
beyond the situation where you can contain it. You can only mitigate it.
In the United States, we are clearly in the containment phase .... And what we've done is we've
identified . We've isolated . And we've done contact-tracing [identifying who might have come in contact
with an infected person]. That seems to be successful. But once it it starts spreading all over the world ...
then it's almost inevitable that it's going to start spreading here .
Gebelhoff : The Post reported last week t hat China withheld information from the public, including
silencing medical professionals, and that this made the spread of the virus worse. How does the United
States work with a governm ent t hat we can't even trust to tell the tru th to its people?
NIH-001983
Fauci: That is an issue. And it's the reason why I have been saying that we need some of our people -
CDC,NIH people - there on the ground , both help ing and seeing with their own eyes exactly the extent
of this. We want to be part of a [World Health Organization] convening group that goes there. But thus
far, we've not been able to make that a reality.
Gebelhoff: And why's that?
Fauci: I don't know . We have asked. We have colleagues - scientific colleagues - in China that we've
dealt with for years if not decades. Many of them have trained in the United States. And we know them
as friends and as colleagues. They are the ones that are not holding back.... But they're not the ones
that make the official proclamations of what comes out. The solution to the problem in the question
you're posing is that we really do want people there, so that we can not only help them but also provide
some expertise that might supplement or complement their own expertise.
Gebelhoff : What does the United States do if [the coronavirus] does become a pandemic in the
developing world?
Fauci: We ll obviously we will try to help them to contain as best as possible .... Right now, by definition,
it is not truly a global pandemic. It is a very serious outbreak and epidemic in China, but the amount of
sustained transmission outside of China is still minimal. ... But there are some countries where it is going
to be very difficult to stop the evolution into sustained transmission. Obviously the [World Health
Organization] and the global security network that we put up over the years will try to help those
countries, but there's no guarantee that we'll be successful.
Gebelhoff: On that point, the head of the WHO has crit icized travel bans and restrictions around the
world as not helpful to stopping the outbreak. He said it was potentially "increas ing fear and stigma ."
What
Fauci: Everyone agrees that travel bans and restrictions are almost never successful In completely
stopping something is that invariably going to turn into a pandemic .... What we are trying to do is to
pause temporarily and give China enough time to put the lid on [th is virus] to prevent it from becoming
global and to give us a little more time to prepare. There's no indication or imagination that if this
becomes a global pandemic that travel restrictions are going to mean anything . But they can mean
something , as a temporizing activity.
Gebelhoff : What should the average person be doing right now about coronavirus?
Fauci: It's a good question . 1) They should realize at this point, it is a low risk. And 2) that risk can
change, so pay attention to what's going on [and] to the ... announcements coming from the CDC.... The
things that you do for influenza - get vaccinated, wash your hands, avoid crowded places - are exactly
the same things that you would do if we did get coronavirus here. So the question is, should we do
anything different from what we're already doing? No. Should we all be wearing a mask? Absolutely
not.
Read more:
The Post's View : The virus th at shook China's system
Chen Guangcheng : Warning: Chinese aut horit arianism is hazardous t o your healt h
David Ignatius: The coron avirus out break shows t he vulnerability of t he 'Chinese model'
John M. Barry: Can th is virus be contained ? Pro bably not .
John Pomfr et: The coro navirus reawakens old racist t ropes against Chinese peop le
Robert Gebelhoff
NIH-001984
Robert Gebelhoff is an assistant editor for The Post's Opinions section . He has been with The Post since
2015 .Follow
my views nor those ofNTATD, NTH, HHS , or the U.S. governme nt.
NIH-001985
Sent : Mon , 10 Feb 2020 20:18:24 +0000
Subject : FW: Potentia l Treament Strategy to Reduce Motality Caused by Coronavirus
Infec tion
NIAID in quiri es, Please
Director
Phone : (b) (6)
FAX : (301 496-4409
E-mail : (b)(6)
From: (b)(6)
-----------------------~~
=
Subject : Potential Treament Strate gy to Reduce Motality Caused by Coronavi rus Infectio n
Dear Dr. Fauci:
One effect ive way to get th ings done is through the individuals like yo u at t he frontline with authorities .
I know tha t you are very busy, and I am sorry to bother you. You probably already knew what I'm going
to say and appear to be so relaxed.
With the significant concern for the quick spread of coronavirus infect ion, I would like to propose a cell-
based immunomodulation strategy to reduce the "cytokine storm", the main pathophysiologcal cause
for t he mortal ity . The scientific rationale regarding this strategy has been parti ally discussed in an art icle
entitled " Extending t he Hor izon of Cell Based lmmunotherapy by Understand ing the Mechanisms of
Actio n of Photopheresis" and ot her related arti cles o n this topic .
Several potent ial treatment modal ity could be derived from th is concept if more laboratory and clinical
data support this motion , which include : (1) ozone therapy ( w it hdraw about SO ml -100 ml blood
from patie nt in transfusion bag, mix ing with small amount of ozone ex vivo and re-infuse back to pat ient
in 30 minutes); (2) Cupping therapy (medically ind uced subcutaneous hemorrhage by heat and vacuums
effec ts) to expose self ant igens to the abundant dendrit ic cells in the subcutaneous tissue in order to
reinforce the self ant igen tolerance . The best t iming for these interventions in theory would be at the
NIH-001986
period of fever, viremia stage. These simple approaches can be incorporated with the other medical
treatments and support ive care.
I cannot be certain, but want to help as a holistic physician. Thank you very much for reading this email
and providing your insight as well as help.
Sincerely,
Ching Y. Voss, M.D.
NIH-001987
Sent : Mon, 10 Feb 2020 20:10:11 +0000
Subject : RE: Invitat ion to Speak at US-Asia Institute Event: February 26, Washington DC
Sorry. Cannot do. Congressional Hearin g.
Director
Phone : (b)(6)
FAX: (301 ) 496-4409
E-mail : (b)(6)
From: Zev Moses <zev.moses@usasiainstitute .org>

To: Oplinger, Anne (NIH/NIAID) [E) -------~~ CbH6)>;Fauci, Anthony (NIH/N IAID) [E)
-------- CbH ; Conrad, Patricia (NIH/NIAID) [El (b)(6)

Subject : Invitation to Speak at US-Asia Institute Event: February 26, Washington DC
Good afternoon,
The US-Asia Institute would like to formally invite Director Dr. Anthony Fauci to speak at an event on
February 26 in Rayburn House Office Building, Room 2253, at 1:00 pm. Our fo rmal invitation is
attached.
This event will focus on the public health impacts of the novel coronavirus, the facts on the ground,
trajectory of the virus, and work to contain the outbreak. The event aims to educate Congressional staff
on these topics and to dispel rumors associated with the virus . We believe that Director Dr. Fauci's
curr ent research is vital to support ing productive and informative dialogue.
Please let us know if Director Dr. Fauci, or another NIAID representative, is available to participate in this
event. We would be honored to host him or others from NIAID and our audience would be extremely
interested to learn from your agency's research.
Sincerely,
Zev Moses
NIH-001988
Zev Moses I Director , International & Government Affairs
US-Asia Institute
232 East Cap itol St. NE
202-544-3181
www .usasiainstitute.org
NIH-001989
Sent : Mon, 10 Feb 2020 19:19:42 +0000
Subject : FW: Invitation to Speak at the March 13-15 Trilateral Commission Meeting in
Washington, D.C.
Atta chm ents: Dr. Anthony Fauci - Trilateral Plenary Meeting Speaking lnvitation.pdf
Let us di scuss. We do not need t o bring befo re th e OD AM grou p. I wo uld like to

do t his if possible. It is an invitat ion f ro m Meghan O'Sullivan w ho was one of th e
secur ity crew fr om Bush 43.
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Richard Fontaine <rfontaine@trilateral.org>

To: Fauci, Anthony (NIH/NIAID) [E)______ (b
=)'""'
(6)
=>
Cc: Meghan O'Sullivan (b)(6) Torrey Taussig <ttaussig@tr ilateral.org>
Subject : Invitation to Speak at the March 13-15 Trilateral Comm ission Meeting in Washington, D.C.
Dear Dr. Fauci,
The Trilateral Commission will hold its invitation-only annual plenary meeting in Washington, D.C., on
March 13-15, 2020. I would like to invite you to participate in a conversation at the meeting on
responding to the coronavirus and global pandemics .
As you may know, the Trilateral Commission was launched by David Rockefeller in 1973 to think through
the shared challenges and leadership responsibi lities of the three principal industrialized democratic
areas of the world: Europe, North American, and Japan (now Asia). Today, the Commission believes its
original mission of bring ing democrat ic countries together to tackle international challenges should once
again be a majo r priority for our country and our partners . This year's plenary meeting is a major, three -
day gathering of our global membership during which we will explore the theme "Democracy and
Capitalism at a Crossroads."
NIH-001990
Your participation would make a great difference if you are available. Attached to this email you will find
an invitation from North American chair Meghan O'Sullivan. Please do let us know if you have any
questions about the event or your potential role in it, and we hope that you are able to accept our
invitation .
Best wishes,
Richard
Richard Fontaine
Executive Director
Trilatera l Commission - North America
NIH-001991
Sent: Mon , 10 Feb 2020 18:52:31 +0000
To: Strauss, Eric M.
Subject : RE: Heat kills novel Coronavirus
Eric:
The following is all on background. Coronaviruses in general tend to circulate
and infe ct predominantly in the winter season {Northern and Southern
hemispheres have opposite seasons) . We do not know for sure why th is is t he
case; however , many believe that the enclosed spaces in winter {mostly indoor
because it is cold) allows better spread of a respiratory borne virus. Also, some
viruses tend to thrive in cold, dry weather as opposed to warm, mo ist weather.
Remember, however, that when it is summer here , it is winter in Australia and
Argentina . This may be the genesis of the information given to President Xi and
President Trump that the virus may "go away" in the warm weather. However ,
this is a brand new virus with which we have no pr ior experience and it is entirely
conceivable that seasonal changes will not have any impact on the spread.
Best,
Tony
Director
Phone : (b)(6)
FAX : (301 496-4409
E-mail : (b)(6]
information . It should not be used by anyone who is not the original intended rec ipient . If you
From:Strauss, Eric M.<Eric.M.S tr auss@abc.com>

-----~~ (b)(6)>
Subject: Heat ki lls novel Coronavirus
NIH-001992
Dr. Fauci:
We've been seeing a lot about people saying the heat will kill the novel coronavirus? Is this medically
sound?
Trump discussed Coronavirus briefly: He said he had a long talk with President Xi two nights ago, and the
Chinese president told him "the heat generally kills this kind of virus."
The president claimed the virus will go away in Apr il as the seasons change: "The virus that we're talking
about having to do a lot of people. We think that goes away in April with the heat," he said.
Eric M. Strauss, ABC News

www.ericmstrauss .com
Phone: 212 -456 -2016
Connect on Social: T/1/F = @ericMstrauss
NIH-001993
Sent : Mon , 10 Feb 2020 18:08:29 +0000
To : Jon LaPook
Subject : FW: "Coronavirus is airbo rne, Chinese official confi rms"
Attachment s: Amoy Gardens and SARS.pdf
Jon:
Thanks for the note. See attaclunent for our future discussion.
Best,
Tony
Director
Nat ional Institute of Allergy and lnfoctious Diseases
Nat ional In stitutes of Hca llh
Be thesda , MD 20892-2520
Phone: (b)(6)
FAX: (30 I) 496-4409
E-mail: (b)(6)
The infom1ation in this e-ma il and any of its attachments is confiden tial and may contain sensitive infom1ation . It
should not be used by anyone who is not the origina l intended recipient. If you have received this e-mail in error
please inform the sender and delete it from your mailbox or any other storage de vices. The National Institute of
Allergy and Infectious Diseases (NlA lD ) sha ll not accept liability for any statements mad e that are the send er's own
and not express ly made on behalf of the NIAID by one of its represe ntatives.

From : Jon LaPook ,.::;....---~ (b
~)~(6)
=>
Sent: Monday , febrnary 10, 2020 10:08 AM
To : Fau ci, Anthony (NlH/NIAID) [E) ------~-= (b)(6) >
Cc: amb @cbsnews.com ; Kev in Finnegan <kpf@cbsnews.com >; Alturo Rhymes <RhymesA @cbsnews.com > ; Jay
Shaylor <Shaylor @ cbsnews.com > ; CBS LaPook <lapoo]tj@cbsnews.com >
Subject: "Coro naviru s is airborne , Chi nese official confirm s"
H i To ny,
I need a Fauci brain dump.
You may have seen this:
https :/fwww .nzherald .co .nz/wor ld/news /article.cfm?c id=2&objecti d= 12307276
Is this news? Don' t we already know that the virus spread via droplet tran sm issio n? Thi s article says aerosol
transmissio n means "it can float a long distanc e to the air and cause infection later when it is breathed in." Tha t
makes it so und like the kind of spread that happ ens with measles, where the v irus can linger in a room and infect
some body 2 hours after some body with mea sles lea ves the room.
Tomorrow, I wi ll be giving an hour an d a half of affiliate debriefings on this virus. So we wi ll be reaching mill ions
of people. I'd love to get the latest and greatest public health mes sage . Incidentally, Howard Zucker and the
infect ious disease folks at NYU Langone are very concerned about overloading our emergency rooms with pat ients
wh o have upper respiratory infection symptoms. What is the right message? If somebody calls thinking they have
coronavirus , do you tell them to come in - risking infection of othe rs? Do they stay home and wait for symptoms to
get wo rse? Of course , it would be grea t if you could send them a kit and happen to home testing . But that 's nowhere
in the n ear future , right ?
NIH-001998
Thanks,
Jon

Chief Medical Corresponde nt, CBS News
NYU Langone Hea lth
Twitt er @DrLaPook
NIH-001999
Sent: Mon , 10 Feb 2020 12:54:14 +0000
To : Sciutto, Jim
Subject: RE: Long time, no see!
Jim:
Thanks for the note . All is well here except that I am not getting much sleep -
coronavirus 24/7. I look forward to being on your show.
Best regards ,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b) (6)
From: Sciutto, Jim <Jim.Sciutto@cnn .com >

------~=
Subject: Long time, no see!
-------- (b)( >
Glad to have you on the show today. Looking forward. Hope all is well. Jim
Jim Sciutto
Newsroom Anchor & Chief National Security Correspondent
CNN
Email: jim.sciut to@cnn.com
Mobile : ___ (b)( 6Y
Twitter: @jimsciutto
NIH-002002
Sent : Mon, 10 Feb 2020 11:18:00 +0000
Cc: Awwad, David (NIH/NIAID) [CJ
Subject: FW: REQUESTFORA TV INTERVIEW ON WION TV INDIA
We did this before, but we cannot do it at 7:30 AM (b)(6) If

they want t o do it later in the day and we can fit them in, th en fine. If not, tha t is OK too. Not
the highest prior ity
From:Lati ka Chugh {WION) <latika.chugh@zeemedia.esselgroup.com>

To: Awwad, David (NIH/NIAID) [CJ ------~~ (b)(6)>; Fauci, Anthony (NIH/ NIAID) [El
------- (b)(6) >; Fauci, Anthony (NIH/NIAID) [El

Cc:Conrad, Patricia (NIH/NIAID) [El
(b)(6)>
; Barasch, Kimbe rly (NIH/NIAID) [CJ
(b)(6)>; Oplinger, Anne {NIH/N IAI D) [E] (b)(6); Richa Sharma
---------
N) <Richa.sharma@zeemedia.esselgroup
(W 10 .com>
Subject: REQUEST FORA TV INTERV IEW ON WION TV INDIA
Dear Anthony S. Fauci ,
M.D., NIAJD Director
Greetings from WION!
I wou ld like to request for your time for an interv iew w ith us today for 10-15
minutes at 7:30 am Monday, in Maryland , USA via Skype .
It's regarding the upd ate in the story of Coronavirus -The World Health
Organization chief says there have been 'c oncerning instances' of onward
transmission of coronavirus among people who hadn't been to China.
Waiting for your confirma tion.
CLICK HERE TO WATCH WIO N LIVE :
NIH-002003
https://www.wion ews.com/live-tv
Live TV, News I wionews.com

© 1998-2019 Zee Media Corporation Ltd (An EsselGroup Company),All rights reserved.
www.wionews.com
Look forward hearing from you .
Regards
Latika Chugh
WION TV , India
From: Awwad, David (NIH/NIAID) [CJ

---------
(b) (6)>
To: Latika Chugh {WION) <lat ika.chugh@zeemed ia.esselgroup.com >; KUMAR SUNNY
< KUM AR.SUNNY@zeemedia.esselgroup .com >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b)(6) >; Barasch, Kimberly (NIH/NIAID ) [CJ
1
---------- (b)(6) ; Oplinger, Anne (NIH/NIAID) [E]

{WION) <Richa.sharma@zeemed ia.esselgroup .com >
Subject: RE: REQUESTFORA TV INTERVIEWON WION TV INDIA
Cb)( >; Richa Sharma
Our pleasure. Thank you again .
David
David Awwad, Contractor

Customer Services Branch, NIH\NIAID\OCICB
NTT DATA Services Federal , LLC
Phone : (b) (6)
(b)(6)
Disclai mer :
NIH-002004
received this e-mail in error please inform the sender and delete it from your mailbox or any other
storage devices. National Institute of Allergy and Infectious Diseases shall not accept liab il ity fo r any
statements made that are sender's own and not expressly made on behalf of the NIAID by one of its
representatives.
From: Latika Chugh {WION) <lati ka.chugh@zeemed ia.esselgroup .com >

To: Awwad, David (NIH/NIAID) [CJ (b)( >; KUMAR SUNNY
<KUMAR.SUNNY@zeemedia.esselgroup .com >
Cc: Conrad, Patricia {NIH/NIAID) [E]
-------~~ (b)(6)>; Barasch, Kimber ly {NIH/NIAID ) [CJ
(b)( >; Oplinger, Anne {NIH/NIAID) [E] (b)( >; Richa Sharma
----------
(WION) <Richa.sharma@zeemed ia.esselgro up.com>
Subject : Re: REQUESTFORA TV INTERVIEWON WION TV INDIA
David,
Many thanks for the Interview.
He really added value in our show.
We look forward to have his presence in future on WION.
Regards
Latika Chugh
From: Awwad, David (NIH/NIAID) [C] (b)(6)

To: Latika Chugh {WION) <lat ika.chugh@ zeemed ia.esselgrou p.com >; KUMAR SUNNY
<KUM AR.SUNNY@zeemedia.esselgroup.com >
_________
Cc: Conrad, Patricia {NIH/NIAID) [E]
.....
(b)( .>; Barasch, Kimberly (NIH/NIAID ) [CJ
(b)(6) ; Oplinger, Anne {NIH/NIAID) (E] (b)( 1
>; Richa Sharma
{WION) <Richa.sharma@zeemed ia.esselgroup.com >
Subject: RE: REQUESTFORA TV INTERVIEW ON WION TV INDIA
Thank you much.
From: Latika Chugh {WION) <lat ika.chugh@zeemed ia.esselgrou p.com >

To: Awwad, David (NIH/NIAID) [CJ -------~ =
(b)( >; KUMAR SUNNY
<KUM AR.SUNNY@zeemed ia.esselgroup. com >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b)(6)>; Barasch, Kimberly (NIH/NIAID ) [CJ
---------- (b)(6) ; Oplinger , Anne (NIH/NIAID) [E]

{WION) <Richa.sharma@zeemed ia.esselgroup .com >
Subject: Re: REQUESTFORA TV INTERVIEWON WION TV INDIA
CbH6); Richa Sharma
NIH-002005
Dear David,
It will be live Interview on WION with Dr. Fauci at 7 am Maryland Time for 10 -15 m inutes only
on Skype.
My colleague Mr. Sunny (marked in email) will patch the Skype sharp in 30 minutes from now.
Also, We have send you Skype Request from WION Skype Id some hours ago. I request you to
please add us.
Regards
Latika Chugh
From:Awwad, David (NIH/NIAID) [CJ Cb)(

To: Latika Chugh (WION) <lat ika.chugh@zeemedia.esselgroup.com>
Cc: Conrad, Patricia {NIH/NIAID) [El (b)(6)>; Barasch, Kimberly (NIH/NIAID ) (Cl
---------- (b)(6) ; Oplinger, Anne (NIH/NIAID) [EJ

Subject : RE: REQUESTFORA TV INTERVIEWON WION TV INDIA
(b)(6)>
Let me know if you would like to connect a couple minutes earlier. I am on standby .
David
----- (b)(6) (cell)
David Awwad , Contractor

Customer Services Branch, NIH\NIAID\OCICB
NTT DATA Services Fede ral, LLC
Phone : Cb)(6)
(b)(6)
Disclaimer:
The information in this e-mail and any of i ts attachments is confidential and may conta in sensitive
informa t ion. It should not be used by anyone who is not the original intended recipient. If you have
received this e -mail in error please inform the sender and delete it from your mailbox or any other
storage devices. National Institute of Allergy and Infectious Diseasesshall not accept liability for any
statements made that are sender's own and not expressly made on behalf of the NIAID by one of its
representatives.
From: Latika Chugh (WION) <lat ika.chugh@zeemedia.esselgroup.com>

To: Awwad, David (NIH/NIAID) [CJ -------oc-c- =
".":=:=======~
Cc: Conrad, Patricia (NIH/NIAID) [El _________ ~ ; Barasch, Kimberly (NIH/NIAID ) [CJ
NIH-002006
Cb)( ,> ; Oplinger, Anne (NIH/NIAID) [E] (b)(6)
---------
Subject : Re: REQUESTFORA TV INTERVIEWON WION TV INDIA ---------
Thanks
See you tomorrow
Latika :
------ (b)(6)
Get Outlook for And roid
From: Awwad, David (N IH/NIAID) [C]

---------
Sent : Wednesday, February 5, 2020 7:50 :26 PM
(b)(6)
To : Latika Chugh (WION) <lat ika.chugh@ zeemed ia.esselgroup .co m>

Cc: Conrad, Patricia (NIH/NIA ID) [E] (b)( ; Barasch, Kimber ly (NIH/NIAID ) [CJ
________ Cb
_H_6J; Oplinger, Anne (NIH/NIAID) [E] (b)(6)
Subject : Re: REQUESTFORA TV INTERVIEWON WION TV INDIA
Skype Handle: Live:niaidithelp or niaidit help@outlook.com
David: (b)(6)
Sent from my iPhone
On Feb 5, 2020, at 9:16 AM, Latika Chugh (WION)

<latika .chugh@zeemedia .esselgr oup.com > wrote:
Yes,
It completely fine w ith us.
Our Skype Id - wion record. Please share your Skype id with us.
We will be online at 7 AM ET TIME WHICH WILL BE 5:3 0 PM OUR TIME IN 1ST.
Regards
Latika Chugh
Producer , Wion
India

---------
To: Latika Chugh (WION) <latika .chugh@zeemed ia.esselgro up .com >
Cc: Barasch, Kimber ly (NIH/NIAID ) [C] (b)(6)>; Awwad, David
NIH-002007
(NIH/NIAID)
,,;__;_ _
[C)
__;..;:_;.::::=:,;: (b:::::
)(c=
6)::-
> ____
(b)(6J>;
_
Oplinger, Anne (NIH/NIAID) [E]
Subje ct : FW: REQUESTFOR A TV INTERVIEW ON WION TV INDIA
Dr. Fauci can do a skype int erview Thu rsday mo rn ing 7 am - 7 :15 am ET
by skype. Please let us know asap if that wo rks.
Patricia L. Conrad
Special Assistan t to the Director
National Institute of All ergy and Infectious Diseases
The National Institutes of Healt h
(b)(6)
301-496-4409 fax
Disclaimer:
T he info rmation in thi s e-mail and any of its attachments is confidential and may contai n sensitive informat ion. It
should not be used by anyone who is not the original inten ded recipient. If you have received this e-mail in erro r
plea se inform the sender and delete it from your mailbox or any other storage devices . National Institute of A llergy
and Infectious Diseases (NIAID ) shall not accept liabil ity for any stateme nt made that are sender's own and not
expressly made on behalf of the NIAID by one of its representat ives.
From: Latika Chugh {W ION) <lat ika .chugh@zeemed ia.esselgroup.com >

Sent: Tuesday , February 4, 2020 5:15 AM
To : Fauci, Ant hony {NIH/NIAID ) [E]
-------=-c-c=
(b)(6)>
Cc: Wion Guest Relations<wion.guestrelations@zeemedia.esselgroup.com>
Subject: REQUEST FOR A TV INTERVIEW ON WION TV INDIA
Dear Anthony S. Fauci,

M .D., NIAID Director
Greet ings from WION!
World Is One News (WION)is an internat iona l English news channel from the Zee
Media Group, India's premier television brand. WION is un iquely positioned as the
'Globa l Voice of Ind ia', present ing its own perspective on international issues of
critical significance. W ION is the prefe rred channel for most op i nion makers across
the wor ld as they happi ly attend our shows bringing in credible
viewpoints on many issues. WION is currently available in India, Indones ia, The
Republic of Philippines, Australia, Vietnam, Hong Kong, UAE, Malaysia ,
Singapore and South Africa etc .
NIH-002008
WION's shows have featured Indian Political scenario & global leaders
speaking on issues facing their country and the world in general.
I would like to request for your time for an interview with us anytime soon today
for 10-15 minutes. We usually conduct Interview via Skype. Request you to share
your Skype Id.
It's regarding CORONAVIRUS.
Please let us know when is the best time for you to join us via Skype. Wa it ing for
your confirmation.
CLICKHERE TO WATCH WION LIVE :

https://www .wionews.com/live -tv

© 1998-2019 Zee Media Corporation Ltd (An Essel Group Company), All rights reserved.
www .wionews .com
Look forward hearing from you .
Regards
L atik a Chu gh
WION TV , India
Zee Disclaimer: Confidentia lity/ Proprietary Note: This commun ication is confidentia l
/proprietary and is intended for use only by the addressee. Zee Med ia Corporation Ltd.
accepts no responsibility for any mistransmission of, orinterference with , th is
commun ication
NIH-002009
Sent : Mon, 10 Feb 2020 00:49:33 +0000
Subject : RE: CNN Interview CONFIRMATION: Dr. Anthony Fauci
Thanks.

)(c-=
6)
Subject : Fwd: CNN Interview CONFIRMATION: Dr. Anthony Fauci
Sent from my iPhone
From: "Griffin, Janelle" <Janelle.Griffin@turner.com >

To: "Conrad, Patricia (NIH/NIAID) [E]" --------~~ (b)(6)
Cc: "Stover, Kathy (NIH/NIAID) [El" (b)(6) , "Routh, Jennifer (NIH/NIAID)
[El" (b)(6), "Akinso, Woleo la (NIH/OD) [El" (b)(6),
"Greene, Nyja " <Nyja.Greene@turner .com>
Subject : CNN Inte rview CONFIRMA TION : Dr. Ant hony Fauci
Hello,
We're all set for tomorrow! Q
Dr. Fauc i is confirmed for a live seg ment at 10: I Sa et on Newsroom w/Poppy Harlow & Jim
Sciutto.
Please ensure he ' s seate d no later than 10:0Sa et. (the show is aware that Dr. Fauci has a
hard at 10:20a et)
Nyja Greene , cc' d on this email , will be your Atlanta based show point of contact
tomorrow.
Any issues or changes please don 't hesitate to reach out to her in the morning.
Mo11day's segmen t will focus on latest Coronav irus deve lopments: Dr. Fauci covered the
SARS outbreak almost 17 years ago- from wbat he's seeing now with the Coronavirus, how
bad do think this could become? How does the Coronavirus comp are/contrast with others
like Ebola or Zika? How effective are quarantine s in situatio ns like this? What, if any,
precautions shou ld we be taking right now in America? Any thoughts /talking points you can
send ove.r from Dr. Fauci evening would be super helpful.
NIH-002010
Patrici a- thank you sooo much for all of your help with organizin g. We really appreciate it
and look forward to Dr. Fauci jo ining the show .
From: Conrad, Patricia (NIH/NIAID) [E] CbH >

To: Griffin, Janelle <Janelle.Gr iffin@turne r.com>
Cc: Stover, Kathy (NIH/NIAID) [El (b) ( >; Routh, Jennifer (NIH/N IAID) [El
--------- (b)(6) Akinso, Woleola (NIH/OD) [El

Subject: Re: CNN Interview Request: Dr. Anthony Fauci
(b)(6b
Ok thx
Sent from my iPhone
On Feb 8, 2020, at 12:54 PM, Griffin, Janelle <Janelle.Griffin@turner .com >

wrote:
Great- thank you!
Let's keep things for a segment at 10:lSa on Monday .
I'll be back in touch after my 6p show planning conferen ce call Sunday

evening.
Thank so much Patricia Q
From: Conrad, Patricia (NIH/NIAID) [El (b)(6)

Sent : Saturday, February 8, 2020 12:53 PM ---------
To: Griffin, Janelle <Janelle.Griff in@turner.com >
Cc : Stover, Kathy (NIH/NIA ID) [E] (b)(6); Routh, Jennifer
(NIH/NIAID) [El (b)(6); Akinso, Woleola (NIH/OD) [E]
,,;_ ___ ;_;_.;..::::~
(b?H;;;;->------
Subject: Re: CNN Interview Request: Dr. Anthony Fauci
We can make the 9 am hour wo rk too. Pis let us know ASAP so I can make
sure our studio is available. When wi ll you have a final answer?
My cell is ____ Cb> _ and

_C6) am always on email which is better for me .
Sent from my iPhone
NIH-002011
On Feb 8, 2020, at 12:48 PM, Griffin, Janelle
<Janelle.Griffi n@tu rner .com> wrote:
That's great- thanks Patricia !

We'll add him to our calendar for 10:lSa et.
If we needed to move him his segment to the 9a et hour would

that also work?
May I have your cell number for my records?

(b)(6)>
To: Griffin, Janelle <Janelle.Griffi n@tu rner .com>
Subject : Fwd: CNNInterv iew Request: Dr. Anthony Fauci
Hi Janelle
We can make this work - it would need to be from between 10

am - 1020 am hard stop.
Will that work?
It wou ld need to be from our NIH Readycam studio with

Videol ink
Let me know if that works
From: Griffin, Janelle

<Janelle.Griffin@turne r.com >
(b)(6)
Subject : CNNInterview Request: Dr. Anthony
NIH-002012
Fauci
Importance: High
Good morning Dr . Fauci ,
I hope this email finds you doing well .
I'm reaching out on behalf of Newsroom w/Poppy

Harlow & Jim Sciutto hoping you can join for an
interview .
Are you available to joi n CNN this M onday
Febmary lOth in the 10a et hour?
This would be live for about 5-7 minutes to discuss
developments regarding the coronavirns.
Please feel free to contact me via email or at (404)

452- 7769 to let me know.
Thanks for your time - I look fo1ward to hearing

from you soo n.
Janelle Griffin-Butts
Editorial Producer, CNN
Email: janelle .griffin@turner.com I Twitter:
@janellegCNN
NIH-002013
From: (b)(6)
Sent : Sun, 9 Feb 2020 16:36:38 -0500
To: autotell I
Subject : Re: Help Re: Novel Rx for Coronavirus
Thanks, Andy.
Best regards,
Tony
On Feb 9, 2020, at 4:29 PM, autotelll CbH wrote:

-----------
Thank you my friend, hope it leads to something good for patients and the public .
I was at a meeting of the "Philosophical Societ y of Texas" this week end and meet with a
lot of Bush alums like Don Evans and Margaret Spellings etc and Margaret was
commenting on the coronavirus scare and how fortunate we are to have you there at NIH
looking after us!! If you ever decide to relocate to Texas you have a fan club here!
All my best
Andy

Sent: Sunday, February 9, 2020 7 :24 AM -------- (b)( >
To: autotell I Cb)C >

Subje ct: RE: Help Re: Novel Rx for Coronav irus
Andy:
Thanks for the note. I wi ll take a look at this and more important ly, I wil l run it by
the peop le here at NIAID who are r unning the nCoV research initiative. I will get
back to you with their and my assessment. I hope that all is well with you. We are
doing a lot of late nighters here . Fee ls like my internship. DD
Best regards,
Tony
From: autotell I Cb)( >

To: Fauci, Anthony (NIH/NIAID} [E] ------~= (b)(6)>; Fauci, Anthony (NIH/NIAID) [E)
(b)( 6) >
--------
Cc: Xiaokui Zhang (b)(6) >; Robert Hariri
(b)(6)>
Subject : Help Re: Novel Rx for Coronavirus
Tony
NIH-0020 19
Greetings . Always proud to see you at the White House (with Alex) leading the fight
against th is latest infect io us disease threat (b)( 4)
(b) (4)
I trust this email finds my Paisano happy and content as you cont inue to be a gift to this
nation and the world. Please let me know you received this email.
My best to you and your family . Hope our paths cross soon
Andy
NIH-002020
Sent : Sun, 9 Feb 2020 18:23:24 +0000
Subject : RE: lnvestigational compound remdesivir, developed by UAB and NIH
researchers, being used for treatment of novel coronavirus
WOW! I did not know tha t. Good talking point for press conferences.
From: Folkers, Greg (NIH/N IA ID) [E) (b)(6)

Subject : lnvestigat ional compound remdesivir, developed by UAB and NIH researchers, being used for
treatment of novel coronavirus
lnvestigationalcompound remdesivir,developed by UAB and

NIH researchers, being used for treatment of novel
coronavirus
by Savanna h Koplon
• February 07, 2020

• Print
• Email
___ --- - ,Richard Whitley, M .0 ., Distinguished Professor at UAB and principal investigator
of the U19 grant
The investigationa l drug remdesivir, developed through research cond ucted through the Ant iviral Drug
Discovery and Developm ent Cent er, or AD3C, and centered at the University of Alabama at Birm ingham,
is being used to treat select infected patients in the United States and in China who have been affected
by the outbreak of nove l coronavirus (2019-nCoV).
UAB was awarded a $37.5 million, five-year U19 grant from the Nati onal Inst it ute of Allergy and
Infectio us Diseases Centers of Excelle nce fo r Translat ional Research to study and develop treatment for
high-priority emerging infections. Work has been taking place in earnest to develop drugs for emerging
influenza, flaviviruses (dengue, West Nile virus and Zika), coronaviruses that cause SARSand MERS,and
alphaviruses such as Venezuelan equine encephalitis virus and chikungunya. The grant is a multi -
NIH-002021
institutional collaboration to accelerate drug discovery for these emerg ing infections and is a public-
pr ivate partnership between academic institutions and Gilead Sciences.
Remdesivir, developed to treat the coronavirus causing MERS,was found to have significant activ ity
against the 2019-nCoV strain when the outbreak began in the Chinese city of Wuhan. Importantly,
remdesivir had demonstrated efficacy in treating other medically important coronav iruses MERS and
SARSin cell culture and animal models . Based on the compassionate plea requests of treating physicians
in the United States, Gilead Sciences released remdesivir for use in a few patients, although the drug has
not yet been tested for safety or efficacy in these diseases. "The release of remdesiv ir for safety and
efficacy studies is a major accompl ishment for the AD3C - namely the U19 grant - as it shows significant
and swift advance of antiv iral drugs to help treat and respond to emerging infectious disease outbreaks
on an international scale and, importantly, to anticipate the introduction of these infections in the
United States," said Richard Whitley , M.D., Distinguished Professor at UAB and princ ipal investigator of
the U19 grant.
WATCH: UAB inf ect ious disease expert s prov ide info rmat ion on the 2019 novel coronav irus.
Gilead Sciences and supporting researchers and clinicians are working with health authorities from the
World Health Organization and in China to establish a placebo-controlled study to determine whether
remdesivir is safe and effective in treating 2019- nCoV.
"This is a prime example of how the research we
are conducting at UAB plays a critical role in
treating patients on a global scale and our
contribution of substantial scientific advances."
- Richard Whitley, M .D., UAB Distinguished

Professor
"The collaboration between UAB, our colleagues at Southern Research, Vanderbilt University and the
University of North Carolina, along with our pharmaceutical partner Gilead Sciences, is indicative of our
collaborat ive approach to respond to outbreaks in real time, and in helping commun ities worldwide
fight 2019-nCoV. This is a pr ime examp le of how the research we are conducting at UAB plays a critical
role in treat ing patients on a global scale and our contribution of substantial scientific advances,"
Whitley continued .
Whitley expressed that the potent ial for mutation of 2019-nCoV means that UAB's AD3C and partners
wi ll need to build backup molecules for potential testing and treatment in the near future.
The World Health Organization has declared the 2019-nCoV outbreak a "public health emergency of
international concern ."
UAB is the lead institution for AD3C and research conducted; but the team unifies scientists experienced
in virology, viral immunology, pathogenesis, medicinal chemistry and trans lation to human disease from
UAB, University of North Carolina, Vanderbilt University, Emory University, Washington University , The
University of Texas Medical Branch, Southern Research, the Emory Institute of Drug Discovery, the
University of Colorado, Denver, and Oregon Health & Science University.
Disclaim er : Any third-party material in this email has been shared for internal use under fai1· use provision s
of U.S. copyright law, without further ver ification of its accuracy/veracity . It does not necessaril y represent
my views nor those of NIAID, NIH, HHS, or the U.S. gover nment.
NIH-002022
Sent : Sun, 9 Feb 2020 18:20:45 +0000
To : Liz Szabo
Subject: RE: Plumbing as possible means of spread of coronaviruses
Attachme nts: Amoy Gardens and SARS.pdf
Liz:
Thanks for the note . I do not know enough about the plumbing system on the cruise ships to
make any meaningful comments, certain ly not any comments that could be att ributable to
me. And so, I will pass on this one, The best person to comment or opine on this would be
Mart Cetron of CDC. FYI, in case you do not have it in front of you, I am attaching the original
NEJM article on the Amoy Gardens Apartment story in Hong Kong w ith SARS.
Best regards,
Tony
From : Liz Szabo <LSzabo@kff.org>

To : Fauci, Anthony (NIH/NIAID) [E] ------ ~~(b)(6)
Subject : Plumbing as possible means of spread of coronaviruses
HI Dr. Fauci,
I hope you're doing well. I know you must be very busy.
Our editor, Dr. Elizabeth Rosenthal, is wondering whether the new coronavirus might be
spreading through plumbing on the cruise ship? She sent me these links, below, about how
plumbing played a role in spreading SARS in the Amoy Gardens apa1tment complex in Hong
Kong. Libby lived in China during the SA.RSoutbreaks and remembers that the sinks there don't
ha ve the typ ical U-bend trap tha t sinks have here, which allows sewer gases and unpleasant
odors to come through.
If plumbing is a risk for spreading coronavimses, what could be done to protect passengers on
cruise ships?
T'd love to hea r your thoughts on this, even if just by email.
Thanks for your time.
Liz Szabo
Kaiser Health News
571-201-9009
https://www.cbsnews.com/news/leaky-plumbing-Linked-to-sars-spread/
NIH-002023
https://www .cnn.com/2013/02/21/world/asia/sars -amoy-qardens/ index.htm l
https://plumb inqconnection .com.au/new-report -proves-plumbinq-link-to-sars/
https://www .infectioncontro ltoday.com/persona l-protective -equipment/sars-

and-plumbing-role-sewage-plays-spreading-disease
https:/ /jamanetwork .com/journals / jama /fullarticle /27 61044 ?guestAcces

sKey=f 6 l bd430-07 d8-4b 86-a 749-
bec05bfffb65&utm source=For The Media&utm medium=referral&u
tm campaign =ftm links&u tm content=tfl&utm tenn =020720
NIH-002024
Sent : Sun, 9 Feb 2020 17:59:10 +0000
Cc: Schwetz, Tara !NIH/OD) [E];Erbelding, Emily (NIH/NIAID) [E];Conrad, Patricia
(NIH/NIAID) [El;Marston, Hilary (NIH/NIAID) [El;Eisinger, Robert (NIH/NIAID) [E];Lerner, Andrea
(NIH/NIAID) [El;Auchincloss, Hugh (NIH/NIAID) [CJ (b)(6))
Subject: RE:NCATsrequest re. Coronavirus
Larry :
'--------------------------------, (b
"'~""'
(S)
Best,
Tony
From: Tabak, Lawrence (NIH/OD) [E) (b)(6)>

---------
-----~~ (b)(6)
..;;...;.:...:::====:~=-----
Cc: Schwetz, Tara (NIH/OD) [El
Subject : NCATsrequest re. Coronavirus --------- (b)( >
Ton' '-------------------------------~ ~
(b) (5)
Thanks,
Larry
NIH-002025
Sent : Sun, 9 Feb 202017:53:04 +0000
Subject : RE: CNN Anderson Cooper Full Circle Request- Dr. Anthony Fauci
OK. Thanks.

)(c-=
6)
Subject : Fwd: CNN Anderson Cooper Full Circle Request- Dr. Anthony Fauci
I am working on this.
Sent from my iPhone
From: "Varon, Sophie" <Sophie.Varon@turner.com >

-------~= (b)(6)>, "Fauci, Anthony
Subject : CNN And e rson Cooper Full Circle Request- Dr . Anthony Fauci
Hello Dr. Fauci and Patricia ,
I hope you're both doing well.

I'm reach ing out to see if Dr. Fauci could be available for an interview wi th
Anderson Cooper on Monday for hi s CNN digit al program, Full Circle . Full Circle
is an intere sting platform because it allows us to take live viewer questions . This
taped interview would air on Tuesday at 5PM and Anderson cou ld tape tomorrow in
the 4PM hour or after 5:45PM.
The topic is of course the Corona virus.
Thank you for considering this request!
Sophie Varon
Ed itorial Producer , CNN AC360
cell- (bH
NIH-002026
Sent : Sun, 9 Feb 2020 17:52:22 +0000
Subject : FW: CNN Anderson Cooper Full Circle Request- Dr. Anthony Fauci
If we can do this, I w ou ld be happy to.
From:Varon, Sophie <Sophie.Varon@turner .com>

-------~ =
To : Conrad, Patricia (NIH/ NIAID) (E]
(b)(6) --------- (b)(6)>; Fauci, Anthony (NIH/ NIAID) (E]
Subject: CNN Ande rson Cooper Full Circle Request - Dr. Anthony Fauci
Hello Dr. Fauci and Pa tricia ,
I hope you're both doi ng wel l.
I'm reaching out to see if Dr. Fauci could be ava ilable for an interview wit h Ande rson Coope r on
Monday for his CNN digital program, Full Circle. Full Circle is an interes ting platform because
it allows us to take live viewer questions. This taped interview would air on Tuesday at 5PM and
Anderson could tape tomorrow in the 4PM hour or after 5:45PM .
The top ic is of course the Coronavirus.
Thank yo u for cons idering this request!
Sophie Varon
Editorial Producer , CNN AC360
cell (b)(6)
NIH-002027
Sent : Sun, 9 Feb 202017:5 1:21 +0000
To: Hall, Bill (HHS/ASPA)
Subject : FW: CNNI Interview with Dr. Anthony Fauci,
Bill:
Th is link below is for an interview that I gave for CNN International this morning . As we all
know, it makes such a big difference when the interviewer knows the subject and asks good
questions that this interviewer did. Would that they were all like her.
Best regards,
Tony
From: Hynds, Joanna (NE) <Joanna.Hynds@turner .com>

Se nt : Sunday, February 9, 2020 12:30 PM
To: Conrad, Patricia (NIH/NIA ID) [El-------'"="'""C=t CbH6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b)(6J>
Subject : RE: CNNI Interview Request: Dr. Anthony Fauci,
We are so glad to!
Here is the clip https:ljwe .tl/t - BOkVJSyQVB
Al I the best,
Joanna

Sent: 09 February 2020 16:15 --------- (b)(6)>
To: Hynds, Joanna (NE) <Joanna.Hynds@turner .com>

Subject : Re: CNNI Interview Request: Dr. Anthony Fauci,
My pleasure- so glad we could make it wor k. Please do send us the the video segment
Best,
Patty .
Sent from my iPhone
On Feb 9, 2020, at 11:06 AM, Hynds, Joanna (NE) <Joanna.Hynds@turner .com> wrote:
Dear Mr Fauci,
NIH-002028
I just wanted to thank you for your accommodation at such short not ice for the earlier
interview. I do apologise for the miscommunication on my part.
We really enjoyed having you on the show!
Thanks too to Patricia, for helping coordinate this all at last minute.
I hope you both have a great evening.
Many thanks again for your patience and understanding.
If you would like a video segment of your hit I will gladly send you it on request.
Best,
Joanna

To: Hynds, Joanna (NE) <Joanna.Hynds@turner .com >
Cc:Pfeifer, Hazel <Hazel.Pfeife r@turner.com >; Lovejoy, Hannah (NE)
-------=-c--=-(b)(6)>
<Hann ah.Lovejoy@ turner .com>; Fauci, Anthony (NIH/NIAID) [E]
Subject: Re: CNNI Interview Request: Dr. Anthony Fauci,
--------
Do you have the hit time and contact info please send ASAP.
Sent from my iPhone
On Feb 9, 2020, at 8:38 AM, Hynds, Joanna (NE)

<Joanna.Hynds@turner .com > wrote:
Perfect - we really appreciate this.
I will get you these deta ils ASAP.
Does Dr Fauci need a car?
Best,
Joanna
NIH-002029
From: Conrad, Patricia (NIH/NIAID) [E) (b)(6)>
Sent: 09 February 2020 13 :33
To: Hynds, Joanna (NE) <Joanna.Hynds@turner.com >
Cc: Pfeifer, Hazel <Hazel.Pfeifer@turner.com >; Lovejoy, Hannah (NE)
<Hannah.Lovejoy@turner.com >; Fauci, Anthony (NIH/NIAID) [E]
(b)(6)
Adding Dr Fauci here
He can come to the WDC CNN studio. Please send us the exact live hit time as
well as the studio address and on-site contact name, number and cell number
ASAP. Dr Fauci cell is (b)(6)andyou have mine.
Thank you .
Sent from my iPhone

<Joanna.Hynds@turner.com > wrote:
Dear Patricia,
Just following up from our phone conversation , unfortunately I

won't be ab le to facilitate a StudioGo t ruck for this interview.
We are still really keen to get Dr Fauci on the show-w ill he be

able to come to the bureau?
I will be able to book him a car if he needs.
Let me know what suits,
Best,
Joanna

(b)~ >
To: Hynds, Joanna (NE) <Joanna.Hynds@turner .com >
Subje ct: Re: CNNI Interview Request: Dr. Ant hony Fauci,
NIH-002030
For the t rick- the location is northwest Washington DC. Near
American university.
Sent from my iPhone
On Feb 9, 2020, at 7:51 AM, Conrad, Patricia

{NIH/NIAID) [El (b)(6)> wrot e:
Please call me ASAP at

request. ----- (b)(6)for this
From: "Fauci, Anthony (NIH/NIAID)

[El" Cb)C >
Dat e: February 9, 2020 at 7:08:54
AM EST
To: "Conrad, Patr icia (NIH/NIAID) [E]"
(b)(6)
Subject: Fwd: CNNI Int erview
Request: Dr. Anthony Fauci,
Sent from my iPhone
From : "Hynds, Joanna

(NE)"
<Joanna.Hynds@turner
.com >
Date : February 9, 2020
at 6:06:15 AM EST
To: "Fauci, Anthony
(NIH/NIAID) [El"
(b)(6)>
Cc: "Tejera, Isabel
{Intern)"
<isabel.Tejera@turner.c
om >, "Lovejoy, Hannah
NIH-00203 1
(NE)"
<Hannah.Lovejoy@turn
er .com>
Subject: CNNI
Interview Request: Dr.
Anthony Fauci,
Dear Dr Fauci,
I hope you are well! I

am reaching out from
CNN International to
enquire if you are
available today to join
us on Connect the
World at llaET to
discuss the coronavirus.
Might this be a
possibility? It would be
great to arrange this.
Background on CNN
• CNN
International
reaches more
than 250
million
households
worldwide
including in the
US via DIRECTV.
• CNN
International is
the number
one
international
TV news
channel
according to all
major media
surveys across
Europe, the
Middle East and
Africa, the Asia
NIH-002032
Pacific region
and Latin
Americ a.
• In September
2019 CNN.com
had 162 million
unique readers
globally per
month and 114
mi llion mobile
readers a
month, leading
the BBC,Yahoo
and New York
Times.
Best,
Joanna Hynds
Planning Desk
CNN Intern ation al
+ 44 207 693 1640
(office)
+ (b)(6) ( cell)
joanna.hynds@turner.c
om
<image0O1.png>
Information in t his
emai l including any
attachments may be
privileged or
confidential and is
intended exclusively for
the addressee. The
views expressed may
not be official policy,
but the personal views
of the orig inator . If you
have received this email
in error, please notify
the sender by return e-
mail and delete it from
your system . You
should not reproduce,
d istr ibute, store,
NIH-002033
retransmit, use or
disclose its contents to
anyone. Please note we
reserve the right to
monitor all e-mail
communicat ion
through our internal
and external networks.
Turner and the Turner
marks are trade marks
of Turner Broadcasting
System Inc and are
used under licence .
Turner Broadcasting
System Europe Limited
(Company No.
1927955), Turner
Enterta inment
Networks Internationa l
Limited (Company No.
2803512), Turner
Broadcasting System
Holdings (Europe)
Limited (Company
Number 2802926) and
Cable News
Internationa l Limited
(Company No.
5001368) are
incorporated in England
and Wales and share
the same registered
off ice at Turner House,
16 Great Marlborough
Street, London WlF
7HS.
Information in th is email including any attachments may be

privileged or confident ial and is intended exclusively for the
addressee. The views expressed may not be official policy, but
the personal views of the or iginator. If you have received th is
email in error, please not ify the sender by return e-mail and
delete it from your system . You should not reproduce,
distribute, store, retransmit, use or disclose its contents to
anyone . Please note we reserve the right to mon itor all e-mail
commun ication through our internal and external networks.
NIH-002034
Turner and the Turner marks are trade marks of Turner
Broadcasting System Inc and are used under licence.
Turner Broadcasting System Europe Limited (Company No.

1927955), Turner Entertainment Networks Internat ional Limited
(Company No. 2803512), Turner Broadcasting System Holdings
(Europe) Limited (Company Number 2802926) and Cable News
Internat ional Limited (Company No. 5001368) are incorporated
in England and Wales and share the same registered office at
Turner House, 16 Great Mar lborough Street, London W l F 7HS.
Informat ion in this email includ ing any attachments may be privileged or
confidential and is intended exclusively fo r the addressee. The views
expressed may not be officia l policy, but the personal views of the originator .
If you have received th is email in error, please notify the sender by return e-
mail and delete it from you r system. You should not reproduce, distribute ,
store, retransmit, use or disclose its contents to anyone. Please note we
reserve the right to monitor all e-mail comm unication through our interna l
and externa l networks . Turne r and the Turner marks are trade marks of
Turner Broadcasting System Inc and are used under licence.

Enterta inment Networks Internationa l Limited (Company No. 28035 12),
Turner Broadcasting System Holdings (Europe) Limited (Company Number
2802926) and Cable News Internat ional Limited (Company No. 5001368) are
incorporated in England and Wales and share the same registered office at
Turne r House, 16 Great Marlborough Street, London WlF 7HS.
Information in th is email including any attachments may be priv ileged or confidentia l and
is intended exclusively for the addressee. The views expressed may not be off icial policy,
but the personal views of the originator. If you have received th is email in error, please
notify the sender by return e-mail and delete it from your system. You should not
rep roduce, distr ibute, store , retransm it, use or disclose its contents to anyone. Please note
we reserve the right to mon itor all e-mail communicat ion through our internal and
externa l netwo rks. Turne r and the Turner marks are trade marks of Turne r Broadcasting

Entertainment Netwo rks Internat ional Limited (Company No. 2803512), Turner
Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable
News Internat ional Limited (Company No. 5001368) are incorporated in England and
Wales and share the same registered off ice at Turner House, 16 Great Marlborough Street,
London WlF 7HS.
Informat ion in this email includ ing any attachments may be privileged or confident ial and is intended
exclusively for the addressee. The views expressed may not be off icial pol icy, but the personal views of
the originator . If you have received this email in error, please not ify the sender by return e-mail and
NIH-002035
delete it from your system . You should not reproduce, distribute, store, retransmit , use or disclose its
internal and external networks . Turner and the Turner marks are trade marks of Turner Broadcasting
International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited
(Company Number 2802926) and Cable News International Limited (Company No. 5001368) are
incorporated in England and Wales and share the same registered office at Turner House, 16 Great
NIH-002036
Sent : Sun, 9 Feb 2020 17:34:16 +0000
To: Denise Ober
Subject : RE: HEART WRENCHINGQUESTION! Will
The State Department and CDC travel alerts for China, which advise only absolutely essential travel, do not
officially include Hong Kong and so there is no official restriction right now (but this could change), and there is no
quarantin e requir ement upon returning from Hong Kong. However , thi:; all could chang e quickly . (b)(6)
-----Original Mes sage -----

From: Denise Ober ;;-- ------- (b
~)~(=6)
To: Fauci, Anthony (NIH/NIAJD)[E] ------

--------
--:,,:,~ (b)(6) >
Subject: HEART WRENCHING QUESTION1 WO
Dear Dr. Fauci,

l realize this is a long shot for you to answer this email. Please forgive me since Im sure you are so extremely busy
and so very importantly needed at this time. I do apologize for taking even a moment from your high demand
schedule. But thought I'd try to reach out anywayin case you did see this.
l saw an interview recently you bad with Dr Baucher posted by JAMA. From your expertise and knowledge about
the coronavirus thus far if ou had lannedto travel to Thailand mid March via stop over at Hon Kono-would ou?
(b)(6)
Thank you from my concerned heart!

Thank you for EVERYTHINGyou do and have done in the past!
Best to you,
Denise Ober
Sent from my iPad
NIH-002037
Sent: Sun, 9 Feb 2020 17:26:01 +0000
Cc: Conrad, Patricia (NIH/NIAID) [E);Erbeld ing, Emily (NIH/NIAID) [E];Auchincloss,
Hugh (NIH/NIAID) [C] (b)(6) ;Barasch, Kimberly (NIH/N IAID) [C];Greg Folkers
(b)(6J;Marston, Hilary (NIH/NIAID) [E);Eisinger, Robert (NIH/NIAID) [E];Lerner,
---------
Andre a (NIH/NIAID) [E]
Subject: FW: Help Re: Novel Rx for Coronavirus
Attachments: __ Cb _) in 2019-CoV Proposal 07Feb2020.docx
_>_C4
Cristina :
This is not jus t your ordinary person writing to us. Th is is Dr. Andrew von Eschenbach, former
Director of NCI and Former Commissioner of FDA. I have no idea if this proposal has any merit;
however, please have someone go over it carefully and put together a response. Also, only if
appropriate, and feasible, see if there is any way we can be of assistance to him. Th anks.
Best regards,
Tony
From:autotell I
-----------
------~~
(b)(6)
(b)( >; Fauci, Anthony (NIH/NIAID) [E]

(b)( 6) --------
(b)(6)
_____ ....::.===~~------
Cc: Xiaokui Zhang
(b)( 6)
(b) (6) >; Robert Hariri
----------
Subject: Help Re: Novel Rx for Coronavirus
Tony
Greet ings. Always proud to see you at the Wh ite House (with Alex) leading the fight against this latest
infect ious disease threat. Cb)(4)
(b) (4)
I trust this email finds my Paisano happy and content as you continue to be a gift to this nation and the
world. Please let me know you received this email.
My best to you and your family. Hope our paths cross soon
Andy
NIH-002038
Sent: Sun, 9 Feb 202017:17:07 +0000
Cc: Billet, Courtney (NIH/NIAID) [El;Conrad, Patricia (NIH/NIAID) [El;Folkers, Greg
(NIH/NIAID) [El
Subject: RE: FORASF REVIEW:Draft responses to questions from Italian news agency
See my edits in red.
From:Stover, Kathy (NIH/NIAID) [E] (b)(6)>

To: Fauci, Anthony (NIH/NIAID) [El------ (b
=)'""'
(6)
=>
Cc: Billet, Courtney (NIH/N IAID) [El (b)(6),; Conrad, Patricia (NIH/NIA ID) [E)
(b)( >; Folkers, Greg (NIH/NIAID) [E) (b)(6)
----------
Subject : FORASF REVIEW:Draft responses to questi ons from It alian news agency
Hi Dr. Fauci,
Below are draft responses t o questions from a reporter with the Italian news agency ANSA.
Please let me know if you have any suggested edits, and I'll move it along.
Thanks,
Kathy
Enrica Battifoglia
Science and Technology Head Editor
ANSA news agency (Italian news)
Enrica .Batt ifogl ia@ansa .it
Expected place of publication: ANSA Science web page (www .ansa.it/scienza )
Dear Professor Fauci ,
I am Enrica Battifoglia of the Italian news agency ANSA, I already have had the ple asure to
interview you several times at the AIDS world conferences.
I would like to ask you some questions about Coronavirus 2019-nCoV, to be published on the
ANSA Science web page (www .ansa.it/scienza ), the main online science news resource in Italy
with over 1.5M contacts each month. I am sure that your clarity and competence will be highly
valuable to put some much-needed order among so many contrasting news and data, and would
be much appreciat ed by our readers .
NIH-002039
1. Do the current available data allow to understand the threat level of coronavirus 2019-
nCoV in terms of both lethality and diffusion speed, and about the possible evolution
scenarios of the disease?
There is much that we do not know about the novel coronav irus. Curre ntly, there have been more
than 37,000 confirmed cases in China, and China has reported more than 800 deaths. As you
know, there have been three confirmed cases in Italy to date. The reported case fatality rate
(lethality) among the 37,000 cases that have come to the attention of the health care system
is 2%. However , given that there are likely many more cases that are without symptoms
or with minimal symptoms, the actual death rate is probably lower than 2%.
It is impossible to predict how the virus will evolve. It is our hope that the extraordinary
containment measures that China has implemented will help prevent the outbreak from
becoming a global pandemic. But given that the virus is present in 27 countr ies to date and can
be transmitted from person-to-person, it may take a footho ld and evolve into a global pandemic .
2) What exactly do we know about its modes of transmission, especially from people who
do not yet have the symptoms?
Again, there is much that we do not know about the novel coronavirus, including its specific
transmission abilities. Based on initial findings that have been reported, we suspect its
transmission is similar to influenza and other respiratory viruses, namely that is transm itted
through respiratory droplets when an infected person coughs or sneezes, and by touching
surfaces, such as door handles, that recently have virus on them and then touching your face.
There have also been reports that the virus is present in feces and vomit. However, it is still
uncertain that the virus can be transmitted through this route.
Traditionally, most viruses are transmitted when someone has symptoms. With the novel
coronavirus; however, there appears to be asymptomatic transmission occurring. We do not
know how many cases are being driven by asym ptomatic transm ission or by those with
symptoms . Typ ically, viruses are largely transmitted by infected peop le experiencing symptoms.
3) Are the genetic sequences provided by China enough to start working on a vaccine?
The genet ic sequences provided by Chin a enabled researchers to quickly deve lop a diagnostic
that is being used to dete1mine whether someone is infected with the novel coronavirus. The
genetic information has also been useful in work to develop a preventive vaccine. The National
Inst itute of Allergy and Infectious Diseases, part of the U.S. Natio nal Institutes of Health, is
building on its experience with the SARS and MERS corona viruses to better understand the virus
as well as develop and test rapid point-of-care diagnostics , vaccines and treatments, including
broad-spectrum antivirals and antibody therapies. In terms of vaccines specifically , we are
NIH-002040
working with the biotechnolog y company Moderna and the Coalition for Epidemic Prep aredness
Innovation (CEPI) to develop a "messenger RNA" vacci ne for the novel coronav irus. Other
countries and companies are working to develop a vaccine as well.
4) What are the technical times to develop a working vaccine in terms of scientific research,
and what are the approx times for the necessary legal certifications, and for industrial
production and distribution?
In terms of our work with Moderna and CEPI to develop a vaccine , we anticipate having an
experimental vaccine ready for Phase 1 clinical trials within 2 to 3 months. This Phase 1 clinical
trial will involve administering the vaccine to a sma ll number of healthy adults in the United
States to see if it is safe and has some ability to induce an immun e response. If that is successful
and the outbreak has not ended, we will move to a larger Phase 2 clinical trial with the
expectation of proving the efficacy (or not) of the vaccine within 1 to 1.5 years. If
efficacious, it will still take additional months to produce enough vaccine to distribute
widely ..
In addition to this vaccine, NIAID is also supporting scientists and companies to develop other
vaccine candidates.
5) 2019-nCov is the third Coronavirus aggressive for humans that has appeared in the East
in the last 20 years and in 2009 the virus responsible for the flu pandemic too did come
from China: what sort of preventive measures could be practicable to reduce the risk of
repetition of these events?
To clarify, the 2009 HlNl influenza virus was first reported in Mexico, not China.
Viruses affecting humans have occurred throughout history, from the Bubonic Plague to the
1918 flu. We cannot predict what emerging infectious diseases will occur nor prevent the
unknown from occurring in the first place. What we can do is learn as much as we can about
emerging viruses, so that we can rapidly develop safe and effective point-of-care diagnostics,
treatments and vaccines to protect against infection.
NIH-002041
Sent : Sun, 9 Feb2020 16:41:33 +0000
Subject : FW: Cowen Health Care Conference in Boston - China Pharma Market Panel -
March 2, 2020 in Boston
Please RSVPno.
From: Scala,Steve<Steve.Scala@cowen .com>

Se nt: Sunday, February 9, 2020 11:39 AM
------~~
To: Fauci,Anthony (NIH/NIAID) [El
-------- (b)(6)
Cc: Nadeau, Phil <Phil.Nadeau@cowen.com>;Miner, Kathy <Kathy.Miner@cowen.com>; Nedelcovych,
Michael <Michael.Nedelcovych@cowen.com>
Subject : Cowen Health Care Conference in Boston - China Pharma Market Panel - March 2, 2020 in
Boston
Hi Dr. Fauci
I am a pharmaceutical industry analyst at Cowen and Company, a New York City based
investment company that specializes in health care. Each year we host a Health Care
Conference in Boston in March that attracts 200+ companies and 1000+ investors. During this
year's conference, we had planned to host a one-hour panel discussion on the evolution of and
reforms within the China Health Care System and China Pharmaceutical market. However,
given global concerns around Coronavirus, we have decided to focus the panel instead on the
virus and the outlook for emerging treatments. This perspective is critical to health care
companies and therefore the institutions that invest in them.
Our panel will take place during Cowen ' s 40th Annual Health Care Conference, which will be
held at the Marriott Copley Place in Boston on March 2-4, 2020. We plan to host this panel on
Monday morning, March 2 nd, between 9:05-10:0SAM. Attendees at our conference include
institutional investors from insurance companies, mutual funds, pension funds, banks, and
other types of funds, mainly in the U.S. and EU.
Cowen would provide you an honorarium for your time during the one-hour panel. We propose
an honorarium of $1,500, and we reimburse conference-related travel expenses.
The discussion will be Q&A only and no presentation on your part is requested .
We look forward to hearing from you.
Sincerely,
Steve Scala
NIH-002042
In line with best practices suggested for brokerage firms, Cowen has a policy regarding our
interaction with subject matter experts such as yourself, and by accepting and participating in
this engagement, you agree to the conditions of this policy, including that you will not
knowingly disclose any material non-public and/or confidential information; that your current
employer permits you to participate in our event; that you are not employed by any of the
companies anticipated to be discussed; and that your participation will not cause you to
knowingly violate any contract (e.g., employment contract or consulting contract), agreement
(e.g., confidentiality agreement) or other duty of confidentiality (e.g., serving on a board of
directors) that you may have.
COWEN
Steve Scala
Pharmaceut ical Industry Analyst
Equity Research
Cowen and Company , LLC

Two Internat ional Place , 28th Fl.
Boston , MA 02110
617-946-3923
steve.sca la@cowen.com
www .cowen.com
This message and any attachments are confident ial. If you are not the intended recipient, please notif y
t he sender immediately and destroy this email. Any unauthor ized use or dissemination is prohibited. All
email sent to or from our system is subject to review and ret ention . Nothing contained in this email shall
be considered an offer or solicit ation with respect to the purchase or sale of any securit y in any
jurisdiction where such an offer or solicitation would be illegal. Neither Cowen Inc. nor any of its
affiliates ("Cowen") represent that any of the information contained herein is accurate, complete or up
to date, nor shall Cowen have any responsibility to update any opinions or other information contained
herein .
NIH-002043
Sent : Sun, 9 Feb 2020 16:41:04 +0000
Cc: Billet, Courtney (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Podcast: Newt's World Ep 56: China's Coronavi rus http;//bit.ly/2Sud2am
Definitely for the Director's page
From: Folkers, Greg (NIH/N IA ID) [E) (b)(6)

Subject : Podcast: Newt's World Ep 56: China's Coronavirus http://bit .ly/2Sud2am
Is the Coronavirus the next global pandemic or will the disease be eradicated in a short period of
time? Newt's guests, Dr. Anthony Fauci and Dr. Peter Daszak, provide the information you need to
know about the Coronavirus crisis.
of U.S. copyright law, without furth er verifica tion of its accuracy/veracity . It does not necessa rily repre sent
my views nor those of NIAJD, NIB , HHS , or the U.S. government.
NIH-002044
From: (b)(6)
Sent: Sun, 9 Feb 2020 10:53:02 -0500
Cc: Billet, Courtney (NIH/NIAID) [El;Routh, Jennifer (NIH/NIAID) [El
Subject : Fwd: CNNI Interview Request: Dr. Anthony Fauci,
Done
From: "Hynds,Joanna (NE)" <Joanna.Hynds@tumer.com>

Date: February 9, 2020 at 9:49:2 1 AM EST
To: "Conrad , Patricia (NIH/NIAlD) [E]" -----------=~ CbH6)
Cc: "Pfeifer, Hazel" <Ha zel.P feifer @tumer.com >, "Lovejoy , Hannah (NE)"
<Hannah.Lovejoy @tumer.com >, "Fauci, Antho ny (NIH/N IAID) [E]"
(b)(6) >
Subject: RE: CNNI Interview Request: Dr. Anthony Fauci,
Hi Patricia,
I have let DC know, Angie will be there to greet him at 10.20a and bring him straight up .
DC Number: + l 2025100172 .
Best,
Joanna

To: Hynds, Joanna (NE) <Joanna.Hynds@turner.com>
Cc:Pfeifer, Hazel <Hazel.Pfeife r@turner.com>; Lovejoy, Hannah (NE)
<Hannah.Lovejoy@turner.com> ; Fauci, Anthony (NIH/NIAID) [El ------"-="'""C"-='I
-------- (b)(6J>
We are good . 1030 am ET his is firm . He will arrive the wdc cnn studio at 820 am ETso if
you can have someone meet him at the entrance lobby to get him upstairs quickly that
would be helpful.
Sent from my iPhone
NIH-002045
<Joanna .Hynds@turne r.com>wr ote :
Hi Pat ricia,
That would be perfect. I am so sorry on the miscommun icat ion on my part.
We really appreciate you accommodating us at this short notice .
Best,
Joanna

To: Hynds, Joanna (NE) <Joanna .Hynds@turner .com >
Cc: Pfeifer, Hazel <Hazel.Pfeifer@ t urner .com >; Lovejoy, Hannah (NE)
<Hannah .Lovejoy@turner .com >; Fauci, Anthony (NIH/NIAID) [E]
(b)( >
Subject : Re: CNNI Interview Request: Dr. Anthony Fauci,
Dr DrFauci can be there for a 1030 am hit
We need to know ASAP if this is firm and what the exact hit time
Sent from my iPhone

<Joanna .Hynds@turne r. com>wrot e :
Just wanted to let you know the Flash Studio will be DC G Studio
CAM23
Our Bureau Address is

820 First ST NE
20002 Washington
Please contact the bureau at +1-202-898-7911
NIH-002046
Please arrive at 10.40, you will be on around 11 - 1will update
with exact hit time as soon as I have it.
Best,
Joanna
From : Conrad, Patricia (NIH/NIAID) [E)

(b)(6)>
Se nt: 09 February 2020 13:33
To : Hynds, Joanna (NE) <Joanna.Hynds@turner .com >
Cc: Pfeifer, Hazel <Hazel.Pfeife r@turner .com>; Lovejoy, Hannah
(NE) <Hannah.Lovejoy@turne r.com >; Fauci, Anthony
Subject: Re: CNNI Interview Request: Dr. Ant hony Fauci,
Adding Dr Fauci here
He can come to the WDC CNN studio. Please send us the exact
live hit time as well as the stud io address and on-site contact
name, number and cell numbe r ASAP. Dr Fauci cell is (b)(
- and you have mine.
Thank you.
Sent from my iPhone

<Joanna.Hynds@turner .com >wrote:
Dear Pat ricia,
Just following up from our phone conversation,

unfortunately I won't be able to facilitate a
StudioGo truck for this interview .
We are still really keen to get Dr Fauci on the show

- will he be able to come to the bureau?
I will be able to book him a car if he needs.
Let me know what suits,
NIH-002047
Best,
Joanna

(b)(6)>
Sent : 09 February 2020 13:00
To:H ynd~Joanna(NE)
<Joanna.Hynds@turner .com >
Subject : Re: CNNI Interview Request : Dr. Anthony
Fauci,
For the trick- the location is northwest Washington

DC. Near American university.
Sent from my iPhone
On Feb 9, 2020, at 7:51 AM, Conrad,

Patricia (NIH/NIA ID) [E)
--------- (b)( >wrote:
Please call me ASAP at

for this reques t. ----- (b)(6)
Sent from my iPhone
From : " Fauci, Anthony

(N IH/NIAID) [El"
(b)(6)
Date : February 9, 2020
at 7:08:54 AM EST
To: "Conrad, Patricia
(N IH/NIAID) [El"
•
(b)(6)
Subject : Fwd : CNNI

Interview Request: Dr.
Anthony Fauci,
NIH-002048
Sent from my iPhone
Begin forwarded
message:
From:
"Hynds,
Joanna
(NE)"
<Joanna.H
ynds@tur
ner .com >
Date :
February
9, 2020 at
6:06:15
AM EST
To: " Fauci,
Anthony
(NIH/NIAi
D) [E]"
-
■
Cc:
(b)(6)
"Tejera,
Isabel
(Intern)"
<isabel.Tej
era@turn
er.com >,
"Lovejoy,
Hannah
(NE)"
<Hannah.L
ovejoy@t
urner .com
>
Subject:
CNNI
Interview
Request:
Dr.
Anthony
Fauci,
NIH-002049
Dear Dr
Fauci,
I hope you
are well! I
am
reaching
out from
CNN
lnternatio
nal to
enquire if
you are
available
today to
jo in us on
Connect
the World
at llaET
to discuss
the
coronavir
us.
Might this
be a
possibility
? It would
be great
to arrange
this.
Backgroun
don CNN
• C
N
N
In
te
rn
ati
on
al
re
ac
he
s
NIH-002050
m
or
e
th
an
25
0
mi
Iii
on
ho
us
eh
ol
ds
w
or
Id
wi
de
in
cl
ud
in
g
in
th
e
u
s
vi
a
DI
RE
CT
V.
• C
N
N
In
te
rn
ati
on
al
is
th
e
NIH-002051
nu
m
be
r
on
e
int
er
na
ti
on
al
TV
ne
w
s
ch
an
ne
ac
co
rd
in
g
to
all
m
aj
or
m
ed
ia
SU
rv
ey
s
ac
ro
ss
Eu
ro
pe
th
e
Mi
dd
NIH-002052
le
Ea
st
an
d
Af
ric
a,
th
e
As
ia
Pa
cif
ic
re
gi
on
an
d
La
tin
A
m
eri
ca
• In
Se
pt
e
m
be
r
20
19
~
N
N.
co
m
ha
d
16
2
mi
Iii
on
NIH-002053
un
iq
ue
re
ad
er
s
gl
ob
all
y
pe
r
m
on
th
an
d
11
4
mi
Iii
on
m
ob
ile
re
ad
er
s
a
m
on
th
le
ad
in
g
th
e
BB
C,
Ya
ho
0
an
d
NIH-002054
N
e
w
Yo
rk
Ti
m
es
Best,
Jo anna
Hynds
Planning
Desk
CNN
Internati
onal
+ 44 207
693 1640
( office)
(b)(6)
~ (cell)
joanna.hy
nds@turn
er.com
<imageOO
1.png>
lnformatio
n in this
email
including
any
attachme
nts may
be
priv ileged
or
confidenti
al and is
intended
exclusive ly
for the
addressee
NIH-002055
. The
views
expressed
may not
be official
policy, but
the
personal
views of
the
originator.
If you
have
received
this email
in error ,
please
notify the
sender by
return e-
mail and
delete it
from your
system .
You
should not
reproduce
distribute,
store,
retransmit
, use or
disclose
its
contents
to anyone .
Please
note we
reserve
the right
to
monitor
all e-mail
communic
ation
through
our
internal
NIH-002056
and
external
networks.
Turner
and the
Turner
marks are
trade
marks of
Turner
Broadcasti
ng System
Inc and
are used
under
licence.
Turner
Broadcasti
ng System
Europe
Limited
(Company
No.
1927955),
Turner
Entertain
ment
Netwo rks
lnternat io
nal
Limited
(Company
No.
2803512),
Turner
Broadcasti
ng System
Holdings
(Europe)
Limited
(Company
Number
2802926)
and Cable
News
lnternat io
nal
NIH-002057
Limited
(Company
No.
5001368)
are
incorporat
edin
England
and Wales
and share
the same
registered
office at
Turner
House, 16
Great
Mar lboro
ugh
Street,
London
WlF 7HS.
Informat ion in this emai l including any

attachments may be privileged or conf identia l and
is intended exclusively for the addressee. The
views expressed may not be official policy, but the
personal views of the or iginator. If you have
received this email in error , please not ify the
sender by return e-mail and delete it from you r
system . You should not reproduce, distribute ,
store, retransmit, use or disclose its contents to
anyone. Please note we reserve the right to
monitor all e-ma il communication through our
internal and external networks . Turner and the
Turner marks are trade marks of Turner
Broadcasting System Inc and are used under
licence.
Turner Broadcasting System Europe Limited

(Company No. 1927955), Turne r Enterta inment
Networks Internationa l Limited (Company No.
2803512), Turner Broadcasting System Holdings
(Europe) Limited (Company Number 2802926) and
Cable News International Limited (Company No.
5001368) are incorporated in England and Wa les
and share the same registered off ice at Turner
NIH-002058
House, 16 Great Marlborough Street, London WlF
7HS.
Information in this email including any attachments may be

privileged or confidential and is intended exclusively for the
addressee. The views expressed may not be official policy, but
the personal views of the originator. If you have received this
email in error, please notify the sender by return e-mail and
delete it from your system. You should not reproduce,
distribute, store, retransmit, use or disclose its contents to
anyone. Please note we reserve the right to monitor all e-mail
communication through our internal and external networks.
Turner and the Turner marks are trade marks of Turner
Broadcasting System Inc and are used under licence.
Turner Broadcasting System Europe Limited (Company No.

1927955), Turner Entertainment Networks International Limited
(Company No. 2803512), Turner Broadcasting System Holdings
(Europe) Limited (Company Number 2802926) and Cable News
International Limited (Company No. 5001368) are incorporated
in England and Wales and share the same registered office at
Turner House, 16 Great Marlborough Street, London WlF 7HS.
Information in this email including any attachments may be privileged or

confidential and is intended exclusively for the addressee. The views
expressed may not be official policy, but the personal views of the originator.
If you have received this email in error, please notify the sender by return e-
mail and delete it from your system. You should not reproduce, distribute,
store, retransmit, use or disclose its contents to anyone. Please note we
reserve the right to monitor all e-mail communication through our internal
and external networks. Turner and the Turner marks are trade marks of
Turner Broadcasting System Inc and are used under licence.

Entertainment Networks International Limited (Company No. 2803512),
Turner Broadcasting System Holdings (Europe) Limited (Company Number
2802926) and Cable News International Limited (Company No. 5001368) are
incorporated in England and Wales and share the same registered office at
Turner House, 16 Great Marlborough Street, London WlF 7HS.

confidential and is intended exclusively for the addressee. The views expressed may
not be official policy, but the personal views of the originator. If you have received
this email in error , please notify the sender by return e-mail and delete it from your
system. You should not reproduce, distribute , store, retransmit, use or disclose its
NIH-002059
communication through our internal and external networks. Turn er and the Turner
marks are trade marks of Turner Broadca sting System Inc and are used under
licence.

Entertainment Netwo rks International Limited (Company No. 2803512), Turner
Broadca sting System Holding s (Europe) Limited (Company Number 2802926) and
England and Wales and share the same registered office at Turner House, 16 Great
Marlborough Street, London W 1F 7HS .
NIH-002060
Sent : Sun, 9 Feb 2020 13:05:06 +0000
To : Kaplan, Edward H
Cc: Redfield, Robert R. (CDC/OD);Cetron, Marty
(CDC/DDI0/NCEZID/0GMQ);Messonnier, Nancy (CDC/DDID/NCIRD/OD)
Subject : RE: Coronavirus containment modeling
Attachment s: hems_Wuhan_Feb7_2020_1n_Press.pdf
Ed:
Many thanks for sendj ng the manuscript . I hope that all is well with you.
Best regards,
Tony
From: Kaplan , Edward H -------~~ (b) (6) >
Sent: Saturday , February 8, 2020 I 0: 13 PM
To: Fauci , Anthony (NTH/NlAID)[E] ------~~ (b)(6) >
Subject: Coronavirus containment modeLing
Dear Dr. Fauci,
It has been many years since we corresponded regarding smallpox bioterrorism and vaccination conlTOI.
The attached paper on containing a community coronavirus outbreak from a few initial cases via isolation and
quarantine might interest you. The news is mostly good - isolation and quarantine can ge1the transmission rate
below epidemic thresho ld - but the key is rapid detection of infect ed persons . Also discussed are some ideas for
alleviating congestion in the hospital. I hope that you find it helpful.
Best, Ed Kaplan
Edward H. Kaplan, Ph .D.

William N. and Mar ie A. Beach Professor of Operation s Research Professor of Public Health Professor of
Engineering Yale School of Management Box 208200 New H aven, Conne cticut 06520-8 200
Phone: (b)(6)
e-mai l: _______ Cb
_)_C6)
_
http://faculty.som.yale.edu/EdKaplan/
NIH-00206 1
Sent : Sun, 9 Feb 2020 12:40:23 +0000
Subject : RE: CNNI Interview Request: Dr. Anthony Fauci,
I w ill do this and if they can bring a truck to the house like they did last time, it was great. Let
us discuss.
From: Hynds, Joanna (NE) <Joanna.Hynds@turner.com>

Se nt : Sunday, February 9, 2020 6:06 AM
------ ~=
(b)(6)
Cc: Tejera, Isabel (Intern) <isabel.Tejera@turner.com>; Lovejoy, Hannah (NE)
<Hannah.Lovejoy@turner.com>
Subject: CNNI Interview Request: Dr. Anthony Fauci,
Dear Dr Fauci,
I hope you are well! I am reaching out from CNN International to enquire if you are available today to
join us on Connect the World at llaET to discuss the coronav irus.
Migh t this be a possibility? It would be great to arrange this.
Background on CNN
• CNN International reaches more than 250 million households worldwide including in the USvia
DIRECTV.
• CNN International is the number one internat ional TV news channel according to all major
media surveys across Europe, the Middle East and Africa, the Asia Pacific region and Latin
America.
• In September 2019 CNN .com had 162 million unique readers globally per month and 114 million
mobile reade rs a month, leading the BBC,Yahoo and New York Times.
Best,
Joanna Hynds
Planning Desk
CNN International
+ 44 207 693 1640 (office)
+ (b)(6) {cell)
joanna.hynds@turner .com
■ go there
NIH-002062
Information in this email including any attachments may be privileged or confidential and is intended
the originator. If you have received this email in error, please notify the sender by return e-mail and
delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its
internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting
Internationa l Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited
(Company Number 2802926) and Cable News Interna t ional Limited (Company No. 5001368) are
incorpo rated in England and Wales and share the same registered office at Turner House, 16 Great
NIH-002063
From: (b)(6)
Sent : Sun, 9 Feb 2020 07:08: 49 -0500
Subject : Fwd: CNNI Interview Request: Or. Anthony Fauci,
Sent from my iPhone
From: "Hynds, Joanna (NE)" <Joanna.Hynds@tumer.com>

To : "Fauci , Anthony (NIH/NIAID) [E]"
------~~ CbH >
Cc: "Tejera, Isabel (Intern)" <isabel.Tejera @turner.com > , "Lovejoy , Hannah (NE)"
<Hannah.Lovejoy @turner.com >
Subject: CNN I Interview Request: Dr. A nthony Fauci,
Dear Dr Fauci,
I hope you are well ! I am reaching out from CNN International to enqui re if you are
available today to join us on Conne ct th e World at ll a ET to discuss the coronavirus.
Might this be a possibilit y? It would be great to arrange this.
Background on CNN
• CNN International reaches more than 250 million households wor ldwide including
in the US via DIRECTV.
• CNN International is the number one international TV news channel according to
all major media surveys across Europe, the Middle East and Afr ica, the Asia Pacific
region and Latin America .
• In September 2019 CNN.com had 162 million uniqu e readers globally per mont h
and 114 mil lion mobi le readers a mont h, leading the BBC, Yahoo and New York
Times.
Best,
Joanna Hynds
Planning Desk
CNN International
+ 44 207 693 1640 (office)
+ (b)(6) ( cell)
NIH-002064
joanna.hynds@turner.com
mm
go there

confidential and is intended exclusively for the addressee. The views expressed may
not be official policy , but the personal views of the originator. If you have received
this email in en-or, please notify the sender by return e-mail and delete it from your
system . You should not reproduce, distribute, store, retransmit, use or disclose its
communication through our internal and external networks. Turner and the Turner
marks are trade marks of Tmner Broadcasting System Inc and are used under
licence.

Entertainment Networks International Limited (Company No. 2803512) , Tmner
Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and
England and Wales and share the same registered office at Turner House, 16 Great
NIH-002065
Sent: Sun, 9 Feb 2020 03:33:50 +0000
To: Janet Tobias
Subject : RE:Backgroundquestion
Janee:
Nothing definite on this . To my knowledge , no one has specifically looked at real cross-reactivity although there
have been specu lation that because there is about 80-90% homology between nCo V and SARS that there may be
some use of the mAbs made against SARS for nCo V. I have not seen any data where people took sera from
patients with nCoV and checked if it neutralized SARS and vice versa.
Best,
Tony
From: Janet Tobias <janet@ikanamed ia.com>
Sent: Sanrrday,February 8, 2020 6:27 PM
--------=,-,--:=
To: Fauci, Anthony (NIH/NIAID) [E] ______ _>
Cb
_<_·
Subject: Backgroundquestion
Dear Tony: I have a background question as I am wading through reading as much as possible on the 2019
coronavirus. Do we know if the antibodies 1hatcan neutralize SARS are also effective against the 2019 coronavirus?
] may be complete ly off track, but just liying to think through some things l am reading.
Janet
Sent from my iPhone
NIH-002066
Sent : Sun, 9 Feb 2020 03:28:39 +0000
To: Lenardo, Michael (NIH/NIAID) [E]
Subject : RE: Hope you're doing well.
Thanks, Mike. Am hanging in there.
From: Lenardo, Michael (NIH/NIAID) [E] (b) ~ >

Se nt: Saturday, February 8, 2020 5:18 PM ---------
To: Fauci, Anthony (NIH/NIAID) [ E] -------=- (b)c-c
(= >
Subject : Hope you're doing well.
Hi Tony,
Was just leaving the lab and saw your car out in front of build ing 31. Hope you're doing well! I'm sure
you're busy with the coronav irus crisis.
You continue to be my inspiration!
Best wishes, Mike
Michael Lenardo M.D.

NIH Distinguished Investigator
Chief, Molecular Development of the Immune System Section
Laboratory of Immune System Biology,
Director, Clinical Genomics Program,
Building 10, Room 11D14
Bethesda, MD 20892-1892 USA
Tel: (b)(6) (O); (b)(6)(M)

FAX: 301-402-8530
Email: (b)(6)
------
ASSISTANT:Gloria Rodela
Tel: (b)(6)
Email (b)(6)
NIH-002067
Sent: Sat, 8 Feb 2020 20 :54:52 +0000
To : (b)(6)
Subject: FW: Invite
Attachments : nejmoa2001316.pdf
Here it is. As discussed, let us re-rea d and convene sometime tomorrow to

outline our approach.
Director
Phone Cb)(6)
FAX : (301 496-4409
E-mail : Cb)(6)
From: Baden, Lindsey, M.D.<lbaden@nejm.org>

Subject: Invite
Tony,
As I am sure you are aware we recently web released the attached paper providing some initial
estimates of key transmiss ion paramete rs associated with nCoV-2019 virus . It will soon be coming out in
a print issue and we would like an editorial to go with it. Might you be w illing/interested in authoring
such a piece? Our editorials are typically about 800 words wit h up to 10 references . As soon as you
provide it to us we will web release it and the n link it with the attached article in an upcoming print
issue. Are you interested?
Please confirm no potential COis.
Thank you for considering,
Lindsey
Lindsey R. Baden, MD
Deputy Editor
NIH-002068
This email message is a private communication. The information transmitted, including attachments , is
NIH-002069
Sent : Sat, 8 Feb 2020 17 :44:45 +0000
To: Robinson, Sae;Conrad, Patricia (NIH/NIAID) [El
Cc: naugenstein@wtop.com
Subject: RE: request for info from WTOP's Neal Augenstein
Sae:
I assume that this is taken care of with the interview that I just gave fo r WTOP today
Thanks,
Tony
From : Robinson, Sae <srobinson@wtop.com>

Se nt : Saturday, February 8, 2020 7:57 AM
To: Conrad, Patricia (NIH/NIA ID) [El-------~= (b)(6)>
Cc: Fauci, Anthony (NIH/NIAID) [E) (b)(6)
Subject : Re: request for info from WTOP's Neal Augenstein
We will call at 11:20 am. Thank you both!
On Feb 8, 2020, at 07:52, Conrad, Patricia (NIH/NIAID) [El

wrote: --------- (b)(6)>
Dr Fauci can be available for an interview between 11 am ET and 1130 am ET. Please call
him at (b)(6) back up cell at (b)(6)
What is the exact hit time?
Sent from my iPhone
-------- (b)( > wrote:
Sae:
Patty wi ll get back to you today.
Best,
Tony
From : Robinson, Sae <srobinso n@wtop.com >

To: Conrad, Patricia (NIH/NIA ID) [EI-------~~
________ _>_C_,; Fauci,
Cb
NIH-002070
Anthony (NIH/NIAID) [E] (b)(6)
--------
Subject : Re: request for info from WTOP's Neal Augenstein
Good morning.
I'd like to follow up on yesterday's inquiry from our repo rter Neal.
If Dr. Fauci is available to address the concerns of this cruise ship in Japan
with Corona virus (re: air circulation system) today, we'd love him to have
him on.
Unfortunately, the first available interview time is after 11 a.m.
If it works, please let me know. This time, we'd like to record an interview to
be used for air so we have some flexibility.
Thank you !
Sae Robinson
WTOP News
202-895-5060
On Feb 7, 2020, at 12:59, Augenstein, Neal

<naugenste in@wtop .com> wrote
From: "Conrad, Patricia (NIH/NIAID) [E]"

(b)( >
To: "Augenstein, Neal" <naugenstein@wtop .com>
Subject : RE: request for info from WTOP's Neal
Augenstein
Dr Fauci asked that I respond - he is in

back to back meeting today up until
about 7 pm. If you want to speak with
him tomorrow-we might be able to
make that work
Patricia L. Conrad
NIH-00207 1
National Institute of Allergy and Infectious
Diseases
(b)(6)
301 -496 -4409 fax
Disclai mer:
confidential and may contain sensitive information. It should not
shall not accept liabi lity for any statement made that are
sender 's own and not expressly made on behalf of the NIAID by
From: Augenstein, Neal

<naugenstein@wtop .com >
(b) (6)>
Subject: request for info from WTOP's Neal
Augenstein
Hi, Dr. Fauci. Hope you're well
Spokewith some passengersaboardthe Diamond

Princesscruise ship in Japan, where the numberof
coronaviruscasesonboardare jumping. Can we do
a brief interview re: thoughts on quarantiningon
board ship (with, I would assumea closed
circulatingair system) versusevacuatingthem?
I'm available at your earliest convenience.Or, if

you'd like to just email some thoughts, that'd be
great. Thanksand best.
NIH-002072
Neal Augenstein
Reporter
103.SFMand wtop.com
Washington, DC
(b)(6) cell
202-895-5060 newsroom
naugenstein@wtop.com
Twitter: @AugensteinWTOP
Skype: WTOPNealAugenstein
NIH-002073
Sent : Sat, 8 Feb 2020 17:30:45 +0000
To: Awwad, David (NIH/NIAID) [C];Folkers, Greg (NIH/NIAID) [El
Cc: NIAID ODAM
Subject : RE: David ·• how do we put a link to the Coronavirus public folder on ASF'
desktop?
Monday is fine .
From:Awwad, David (NIH/NIAID) [C)

---------
(b)( >
To: Folkers, Greg (NIH/NIAID) [E]--------=- (b"""

)(=6)>
Cc: NIAID OD AM <NIAIDODAM@niaid .nih .gov>
Subject : Re: David -- how do we put a link to the Coronavirus public folder on ASF' desktop?
I will add Monday, unless you want me to connect now.
Sent from my iPhone
On Feb 8, 2020, at 11:42 AM, Folkers, Greg (NIH/NIAID ) [El (b)(6)

wrote:
<image0Ol. j pg>
Disclaimer: Any third-part y material iu this email has been shared for internal use under fair
use provisions of U.S. copyright law, without further verification of its accuracy/veracity. Lt
does not necessa rily repr esent my views nor those of NIA ID, N IH, HHS, or the U.S.
gove rumeut.
NIH-002074
Sent : Sat, 8 Feb 2020 17 :29 :51 +0000
Subject : FW: Fox and Friends video -- US confirms first Ame rican coronavirus death/ AS
Fauci http;/ /bit.ly /2tltgne
Fyi. It came out well.
From: Folkers, Greg {NIH/N IA ID) [E) (b)(6)

Subject : Fox and Friends video -- US confirms first American coronav irus death/ AS Fauci
http://bit .ly/2tltgne
Disclaimer : Any third-party materia l in this email bas been sbared for internal use under fair use provisions
of U.S. copyrig ht law, without further verification of its accuracy /veracity . It docs not necessarily repre sent
my view s nor those of NlAlD, NIH , HHS, or the U.S. government.
NIH-002075
Sent : Sat, 8 Feb 2020 17 :24 :25 +0000
Subject: RE: CNN Interview Request : Dr. Anthony Fauci
I believe that we can do t his if they do it ear ly in the 10:00 AM segment on Monday . We may
also be able to encroach a bit on Diane Reh m's podcast (10:30) since I believe that t his is
taped. I leave this up to you and so please get back to them and work it out if you can. Jim
Sciutto CbH6)), Thanks.
From : Griffin, Janelle <Janelle.Griffin@turner.com>

To: Fauci, Anthony (NIH/NIAID) [E)-------~= (b)(6)
Subject : CNN Interview Request: Dr. Anthony Fauci
Importance: High
Good mornin g Dr. Fauci ,
I hop e this email finds you doing well.
I'm reaching ou t on behal f of Newsroom w/ Popp y Harlow & Jim Sciutto hop ing you can join for an
interview.
Are you available to join CNN this Monday February l 0th in the 1Oa et hour?
This would be live for about 5-7 minutes to discuss developments regarding the coronavirus.
Please feel free to contact me via email or at

------ Cb)(6) to let me know.
Thanks for your time- I look forward to hearing from you soon.
Janelle Griffin-Butts
Editorial Producer, CNN
Email: jane lle.gr iffin@tu rn er.com I Twltter: @janellegCN N
NIH-002076
Sent : Sat, 8 Feb 2020 03:23:51 +0000
Subject : RE: Details for "Fox & Friends" Tomorrow (Saturday) LIVEat 8:30am ET
I am OK with their coming to the house w ithout a truck. I will call you in the AM.
From:Conrad, Patricia (NIH/NIAID) [E) (b)(6)>

'""'
(=
6)>
Subject : Fwd: Details for "Fox & Friends " Tomorrow (Saturday) LIVE at 8 :30am ET
Am at din ner. Will call u later
Sent from my iPhone
From: "Zuccaro, Alexandra" <Alexandra.Zuccaro@FOXNEWS.COM>

-------~= (b)(6)>
Subject: RE: Detail s for "Fox & Friends" Tomorrow (Saturday) LIVE at 8:30am ET
They'll be at his house. Sorry, the truck wasn't available, but th is will work just as well too!
From: Conrad, Patricia (NIH/NIAID) [E)

Sent: Friday, February 7, 2020 6:51 PM -----------
To: Zuccaro, Alexandra <Alexand ra.Zuccaro@FOXNEWS.COM>
(b)(6)
Subject: (EXTERNAL]Re: Details for "Fox & Friends" Tomorrow (Saturday) LIVE at 8:30am
ET
Will they set up outside his house or is this the trick that he goes into it for the interview?
Sent from my iPhone
On Feb 7, 2020, at 6:49 PM, Zuccaro, Alexandra

<Alexand ra.Zuccaro@foxnews.com > wrote:
Hi Everyone,
NIH-002078
Babu Aryankalayil is set to arrive at (b)(6)
around 7:30am/est tomorrow for our interview with Dr . Anthony Fauci. Babu,
please give Dr. Fauci a call on his cell about 15 minutes before arrival. The IFB
and Pl Numbers are below. Please let us know if you have any questions, and
please also let us know what REM this will be on.
"Fox & Friends"
DATE: Saturday, February 8th
CREW ARRIVAL TIME : 7:30am ET
ADDRESS:
------------- (b)(6)
LIVE TALK BACK:8 :35am ET - 8:40am ET with Pete Hegseth, Emily Compagno,
& Jason Chaffetz
Satellite Window : 0700 -0800
GUEST: Dr. Anthony Fauci
TOPIC: CORONAVIRUSCRUISESHIP LATEST
GUESTCONTACT: Dr. Anthony Fauci, (b)(6) / Media contact Patricia

Conrad cell : (b)(6)cell:-_:..!:====:::!..: (b
~ )- (~
6)
CREW CONTACT: Babu Aryankalayi l,

(b)(6) ----- (b)(6)/
F&F NYC CONTACTS:
Technical Director: Todd Boone: Phone -

todd.boone@foxnews.com -----
(b)(6) email:
F&F Control Room Contact: Tami Radabaugh, (b)(6) email:

Tami .Radabaugh@FOXNEWS.COM
Pl: 800-369-5815, Camera and Tech: (b)(4) Producers: (b)(4)
IFS: 800-369-6719
ACQ and REM Coordinator : 212-301-3200
NY Transmission : 212-301-3100
NY Sat Desk {Bookings) 212-301-3400
A.M . Emergency Contac t: Mary Carol Butterfield: Cell: (b)(6) & NYC
Greenroom (212) 301-1983 email: Mary.Butterf ield@FOXNEWS.COM
Thanks,
Alexandra Zuccaro
NIH-002079
"Fox& Friends"
Fox News Channel
1211 Avenue of the Americas, 2nd Floor
New York, NY 10036
Cell : (b)(6)
Alexandra .Zuccaro@FOXNEWS .COM
This message and its attachments may contain legally privileged or

confidential information. It is intended solely for the named addressee .
If you are not the addressee indicated in this message (or responsible for
delivery of the message to the addressee) , you may not copy or delive r
this message or its attac hments to anyone . Rather, you should
permanently delete this message and its attachments and kindly notify
the sender by reply e-ma il. Any content of this message and its
attachments that does not relate to the official business of Fox News or
Fox Business must not be taken to have been sent or endorsed by either
of them. No representation is made that this ema il or its attachments are
without defect.
NIH-002080
Sent : Fri, 7 Feb 2020 20:20:58 +0000
To: Mellors, John W
Cc: Conrad, Patricia (NIH/NIAID) [E);Barasch, Kimberly (NIH/NIAID) [Cl
Subject: Re: Important Brief Conversation
Attachments : image0Ol.gif
I know. Glad we could work it out
On Feb 7, 2020, at 11:48 AM, Mellors, John W

------ (b)(6) wrote:
Dear Tony,
Approva l receive d from DHHS. The shipm ent of remdesivir to China is on it's way.
No need to connect.
Thanks,
John
From: Fauci, Anthony (NIH/N IAID) [E) (b)(6)>
Sent: Thursday, February 6, 2020 7:04:53 PM
To: Me llors, John W
-~------------~~
(b) ( >
Cc: Conrad, Patricia (NIH/N IAID) [E] (b)( ; Barasch, Kimberly
{NIH/NIAID) [C] (b)(6)
Subject: RE: Important Brief Conversation
John:
Please give me office a call tomorrow and they will set up a time to connect us.
Best,
Tony
From: Me llors, John W (b)(6)

---------------=~
__:....:.,..:.~--------------
To: Fauci, Anthony (NIH/N IAID) [El
·_...:._
(b)(6)
Cc: Mellors, John W (b)(6)>
Subject: Importan t Brief Conversation
Dear To ny , Cliff
Could we speak brief ly about an important interna tio nal coronavirus trial that is in
je opardy?
My mob ile phone number is

----- (b)(6)
John
NIH-00208 1
John W . Mellors, M.D.
Distinguished Professo r and Endowed Chair for Elimination of HIV and AIDS
University of Pittsburgh Schoo l of Medic ine
Scaife Hall , Suite 818
3550 Terrace Street
Tel : (b)(6)
Fax: 412 383-7982
E-mail: (b)(6)
Visit our Division website: http://www. dept-med .pitt.edu/l D/
Read the "ID Pitt Stop" blog: https://idpittstop.word press.com
Like us
<image001.gif>
NIH-002082
Sent : Fri, 7 Feb 2020 15:37:53 +0000
To : (b)(6)
Subject : RE: NIH posit ion on travel to Singapore???
Go t o CDC we bsite. There are no t rave l alert s fo r Singapore and so f or now it is

OK t o trave l t here.
Director
Phone : (b)(6)
FAX : (301 496-4409
E-mail : (b)(6)
From:
-----------------
-------= ~
(b)(6)

--------
Subject : Fwd: NIH position o n travel to Singapore???
(b)(6)>
jim lynch is asking for sources of info for travel advice re: coronavirus . ___ Cb
_>
_<_6) is planning to go to
Singapore . any suggestions?

From: James L (b)(6)>
Date : Thu, Feb 6, 2020 at 8:16 AM
Subject: NIH position on travel to Singapore???
To: 00~
Hi (b)(6)
(b)(6) is scheduled to t ravel to Singapore on March 9th for a week .
-------
What is the best source of up-to -date information and travel recommendations related to the
coronavirus?
Thanks
NIH-002083
Jim
(b)(6)
NIH-002084
Sent: Fri, 7 Feb 2020 10:46:54 +0000
To: NIAIDODAM
Subject : FW: Royal Society of Medicine london
Let us discus.

From: Ian Hosein _________ (b
",a"S"'"
)(=

------~~=
To: Fauci, Anthony (NIH/NIAID) [E]._______ _>
Cb
_<....
Subject: Royal Society of Medicine londo n
Hello Dr Fauci,
By way of introduction , 1was Jim Mac Lowry 's last fellow at the NIH and have been work ing in the UK since then
as a medi cal microbio logist and hospital epidemio logis t.
J am the lead medical microbiologist at the Royal Society of Medicine in the UK and was wondering about your
availabili ty please to speak at a conference on emergent Coronavirus threats to be held at the RSM on November
24th coming?
The RSM is a unigue educa tional cha1ity here and we have councils covering all aspects of healthcare. The program
is still developing but I wanted to check on your avai lability quick ly- we have an academ ic fond to which I can
apply to cover your trip but will need to do so soon.
Jt was both exciting and inspirational being a senior staff fellow at the Nll-1- my background is international;
(b) (6) and the internationa l perspective s
--,------------,---,-,,-----,-....,...,.,...-----,,--,-,---
at the NIH were so encouraging. All non- American fellows recognised the nationa l strateg ic remit of the NIH for
the US , but I have often wondered if an assessment has ever been made of how fellows like myself have brought the
spirit of that institution to other nations.
With kind regards ,
lan
lan K Hosein MD FCAP FRCPath MBA

Royal Society of Medicine
London
Mobi le--- (b
~)~(=
6)
Sent from my iPad
NIH-002085
Sent : Fri, 7 Feb 2020 03:56:15 +0000
Subject : FW: Comment on NEJM details of "asymptomat ic" contact in Germany
Attachment s: nejmc2001468_appendix.pdf
Please set up a call. Happy to do over the weekend or Friday evening.
From : Ian Ingram <iingram@medpagetoday.com>

To: Fauci, Anthony (NIH/NIAID) [El ------~~ (b)( >
Subject : Comment on NEJM details of "asymptomatic " contact in Germany
Hi Or. Fauci,
I'm fi lling in for Molly Walker on the coronavirus beat while she's covering a meeting for MedPage
Today, but I wanted to see if you could were available to offer your quick reaction to the Supplement ary
Index publ ished today (attached) in the New England Journal of Medicine regarding the widely reported
asymptomati c contact in Germa ny.
Looking at the patient's daily take on how she felt it's unclear to me whether this qualifies as
symptomatic or not . I imagine this will be disputed.
Best regards,
- Ian
Ian Ingram
Dep uty Managing Edi tor
MedP age Today LLC
(b)(6)
iin gram @m edpaget oday.com
medpagetoday. com
NIH-002086
Sent : Fri, 7 Feb 2020 03:53: 47 +0000
Subject : FW: BuzzFeed News; 2019-nCoV vaccine development questions
Please set up a call with this person. Happy to do over the weekend.
From: Dan Vergano <dan.vergano@buzzfeed .com>

------- ~=
(b)(6)
Cc: Stover, Kathy (NIH/NIA ID) [E] (b)(6)
Subject : BuzzFeed News: 2019-nCoV vaccine development questions
Dr. Fauci,
As you may recall, I'm a science reporter at BuzzFeed News. We wonder if you might have any
perspective (or might recommend someone to commen t) for a novel coronavirus story we are w riting
for this weekend, regarding vaccine efforts .
In short, we wonder how you see an eventual vaccine playing a role in the future of the outbreak? CDC
has described the virus as not mutating as much as influenza -- does that suggest a vaccine would
provide more than seasonal protection?
In the long te rm, we had a few other questions. Is thi s something you could see added to the MM R
protoco l for the general public, or only in regions where there are local outbreaks (is there an analogy to
SARSor MERSvaccines in this contemplated use)? Is the re any aspect of a race against time in vaccine
development if this coronavirus is seasonal like influenz a?
We are basically trying to understand where a vaccine fits into the future response to this new virus. we
asked you these sort of quest ions about the Zika vaccine efforts and your perspective really helped a lot.
Apologies for all the quest ions, if you had any perspective, we'd be grateful
Dan Vergano
BuzzFeed News
(b)(6)
cc: Kathy Stover
Dan Verg ano I Science Desk (DC) I

BuzzFeed News ----- (b)(6)
1630 Connecticut Ave. 7th Floor, Washington DC 20009

Send secure tips -- cont act .buzzfeed.co m
NIH-002089
Sent : Fri, 7 Feb 2020 03:45:34 +0000
Subject : RE: ASF / please see tab le from 1-29-2019 NEJM paper on Wuhan cases
Very interesting! !
From:Folkers, Greg (NIH/NIAID) [E] (b)(6)>

To: Fauci, Anthony (NIH/NIAID) [E]--------=-c-c=
Cc: Ooepel, Laurie (NIH/NIAID) [El (b)( •>; Eisinger, Robert (NIH/NIAID) [El
(b)(6); Folkers, Greg (NIH/NIAID) [E] (b)( >; Lerner, Andrea
":'---:----:-~===:::.;..--~~
(NIH/NIAID) (E] (b)(6)]; Marston , Hilar y (NIH/ NIAID) (El (b)(6)
Subject : ASF / please see table from 1-29-20 19 NEJM paper on Wuhan cases
Please see next to last line, wh ich gives% of transmissions with "no exposure to either market
or person w ith respiratory symptoms"
(b) (5)
N Engl J Med . 2020 Jan 29. doi: 10.1056/N EJMoa2001316. [Epub ahead of print]
Early Transmission Dynamics in Wuhan, China,

of Novel Coronavirus-lnfected Pneumonia.
Li Q1, Guan x1, Wu x1, Zhou L1, Tong v1, Ren R1, Leung KSM1, Lau EHY1, Wong JY1, Xing x1,
P1, Wang
Xiang N 1, Wu Y1, Li C1, Chen Q1 , Li D1, Liu r 1, Zhao J1, Li M 1, Tu W 1 , Chen c1, Jin L1, Yang R1, Wang Q1 ,
Zhou s1, Wang R1, Liu H1, Luo Y1, Liu Y1, Shao G1, Li H1, Tao z1, Yang Y1, Deng z1, Liu 8 1, Ma z1, Zhang Y1,
Shi G1, Lam TTY1, Wu JTK1, Gao GF1, Cowl ing BJ1, Yang B1, Leung GM 1, Feng z1.
DOl: 10.1056/NEJMoa2001316
NIH-002090
lklore January l January l 1 an11 r,r 11 -:I u
JanLE&l'Yl2 22
(N • 471 [ - u•1 (N • llO)
e(r 11:&e)-y S6 (26--32) 60(21 9) 6 ( S.-89)
_ - no./cowno. (")
els yr 0/47 0/243 OJlJO
1S yr 12/◄ 7 (26) 39[24 (16) H/130(25)
'1S-64 r 24/47 (5 ) 06/24 (0) 49/lJO(lSJ
65 ~' 11/47 (23) 03/:J.48(42) &/ 30 (37)
e, - no./tot no. (%) 31/47 (66) 147/24 (59) 62/ 30 (48)
posure 15 OI)'- no./tot I no. (")
We1ma et posur J0/O (641 12/196116) s (6)
Hu II n SeafoodWholewle M ,kc 26/ 47 (5S) 19/196 (10) 5/81 (6)
Other muk b-ulnot Hu1n•n S 1food U/196 (7) 0/81
H C n:c-1 "''' (9)
Con Hi/47(30 30/196 (15) 21/83 (25)
12f47 (26) 141(196 {72) 59/81 (73)
He,I c~rl' wor c-r- no /tot1I no , ('(,) 0/1.7 a,m (1)

Rc,duc~ denom1na ors 1ndic le m1ssin da t P ccMu es m1r no to 100 b« use o round n
Disclaimer: Any third-party materia l in this email has been shared for internal use under fair use provisions
my views nor those ofNIAID , NIH , HHS , or the U.S. government.
NIH-002091
Sent : Fri, 7 Feb 2020 03:38:45 +0000
Subject: FW: Latest
Please set up a call with David for the weekend.
From : davidwillman (b)(6)

To: Fauci, Anthony (NIH/NIAID) [E)------~~
_______ Cb
_H_6)
Subject : Latest
Hi Tony,
I know you must be swamped by matters related to the coronavirus. Nonethe less, I'd really like to
confer, even if briefly. Would you have any window by phone today, over the weekend or next week? I'll
also call Kim Barasch, per your recent guidance.
I'm researching an article that will chiefly explore the status of the Defense Department's advanced
development and manufacturing facility in Alachua, Florida. On a related note, I'm also curious re the
three HHS/BARDAfacilities.
Best, David
David Willman
Washington Post
202-334-7081-desk
------ Cb)(6) -mobile

301-656-3401 --alternate desk
david.w illman@washpost .co m
(b)(6)
NIH-002092
Sent : Fri, 7 Feb 2020 03:11: 47 +0000
Subject : FW: Reporter working on coronavirus vaccine story
Let us discuss. Maybe over the weekend
From: Morris , Amanda <Amanda.Morris@gannett.com>

(6)
=
Subject : Reporter working on coronavirus vaccine story
Hi Anthony,
I hope this emai l finds you well! My name is Amanda Morris and I'm a bioscience reporter at the Arizona
Republic, part of the USAToday network. I'm reaching out because I'm currently working on a story
about how some ASU researchers (Brenda Hogue, Bert Jacobs and Shawn Chen) are trying to develop
strategies to make a vaccine against the new coronav irus as well as a general platform they can use in
the case of future new coronavirus strain out breaks in humans.
I know globally there are many researchers trying to develop a vaccine for this new coronavirus, and
that the NIH is working with Moderna to do so -and hopes to start testing with in a few months. I'm
wondering if I can talk to you over the phone and ask a few questions about the work that NIH is doing,
and what the broader challenges are for developing a vaccine? I'd like to have broader context about
vaccines for our readers.
Please let me know as soon as possible. You can call or text me at

-----
(b)(6) Thank you!
All my best,
Amanda Mo r ris
Bioscience Reporter for The Arizona Republic

Work phone: 602-444-8739
After hours and weekends, you can call or text my cell: ___ (b
_ )_(6J
_.
Email : amor ris@gannett .com
NIH-002095
Sent: Fri, 7 Feb 2020 03:04:53 +0000
To: Mellors, John W
Cc: Conrad, Patricia (NIH/NIAID) [E);Barasch,Kimberly (NIH/NIAID)[CJ
Subject : RE: Important Brief Conversation
John:
Please give me office a call tomorrow and they will set up a time to connect us.
Best,
Tony
From : Mellors, John W (b) (6)

To: Fauci,Anthony (_
N_IH.:..
/_N_IA_ID
..:.
)...:. -------------~~
[__.;
E)~ ~------------ (b)
_(_
6)
Cc: Mellors, John W (b)(6)
Subject : Important Brief Conversation
Dear Tony, Cliff
Could we speak briefly about an importan t international coronavirus trial that is in jeopar dy?
My mobile phone number is

----- (b)(6)
John
John W. Mellors, M.D.

Distinguished Professor and Endowed Chair for Elimination of HIV and AIDS
Univer sity of Pittsburgh School of Medicine
Scaife Hall, Suite 818
3550 Terrace Street
Pittsburgh , PA 15261
Tel: CbH6)
Fax : 412 383-7982
E-mail Cb)
(6)l
Visit our Division website: http ://www .dept-me d.pitt.edu/ lD/
Read the "ID Pitt Stop" blog: https://idpittstop .wor dpress .com
Like us (I
NIH-002096
Sent : Fri, 7 Feb 2020 03:01:07 +0000
To : Howard Bauchner
Subject : RE: Subtitled Coronavirus Video
Howard:
Thanks for the feedback.
Best,
Tony

------ (b)(6J>
--.~
Subject : FW: Subtitled Coronavirus Video
Tony
First live stream/podcast now with Chinese interpretation. URL below .
Second live stream/podcast will be put up tomorrow. URLbelow .
Couple big thank yous from prominent science writers - NYT/WSJ - said learned more listening to you
for 30 minutes then everything they read in the last few weeks.
My response whe n you have a very wise scientist, who hears the question and answers the question,
and has 40+ years of experience we should listen and learn.
Be well.
HCB
Howard Bauchner, MD
Editor in Chief of JAMA and the JAMA Netwo rk
Please respect the confidentiality of t his email
listen to my chats with author s
From: Karen Adams- Taylor <Karen.Adams-Taylor@ama-assn .org >

Date : Thursday, February 6, 2020 at 4:59 PM
To: Howard Bauchner < Howard .Bauchner@ jamanetwork.org >, Annette Flanagin
<Annette .Flanag in@jamanetwork.o rg>, Michae l Berkwits
< Michael.Berkwits@jamanetwo rk.org >, Tom Easley <Tom .Easley@ama-assn.org >, Brian Shields
< Brian.Sh ields@ama -assn.o rg>, Betsy Solaro <Elizabeth .Solaro@ama -assn.o rg>, Sean O'Donnell
NIH-002097
<Sean.O' Donnel l@ama-assn.org>, Tiffany Jones <Tiffany .Jones@ama-assn.erg>
Subject : Subtitled Coronav irus Video
The 1/27 Fauci subtit led video is now live: https ://jamanetwork .com/journals/jama/pages/coronavirus -
alert The 2/6 Fauci update video will go to the trans lator tomorrow.
-Karen
Kare n Ad ams-Taylor
Vice President, Publishing Production Operations
JAMA Network ™
330 N Wabash Ave, Ste 39300, Chicago, IL 60611
T
----- (b)(6)
jamanetwork.com
NIH-002098
Sent : Fri, 7 Feb 2020 03:00:35 +0000
To: Greg Folkers (b)(6) ;Billet , Courtney (NIH/NIAID) [E]; Routh,
Jennifer (NIH/NIAID) [El;Conrad, Patricia (NIH/NIAID) [El
Subject: FW: Subtitled Coronavirus Video
fyi
From: Howard Bauchner <Howard .Bauchner@jamanetwork.org>

To: Fauci, Anthony (NIH/ NIAID) [El ------~= (b)( >
Subject: FW: Subti tled Coronavirus Video
Tony
First live stream/podcast now with Chinese interpretation . URLbelow.
Second live stream/podcast will be put up tomorrow . URLbelow .
Couple big thank yous from prominent science writers - NYT/WSJ - said learned more listening to you
for 30 minutes then everything they read in the last few weeks.
My response whe n you have a very wise scientist, who hears the question and answers the quest ion,
and has 40+ years of experience we should listen and learn.
Be well.
HCB
Howard Bauchner, MD
Edito r in Chief of JAMA and the JAMA Network
Please respect the confidentiality of t his email
From: Karen Adams-Tay lo r <Karen.Adams -Taylor@ama - assn.org>

Date : Thursday, February 6, 2020 at 4:59 PM
To: Howard Bauchner <Howa rd .Bauchner@jamanetwork .org >, Annette Flanag in
<Annette .Flanagin@jamanetwork.org >, Michae l Berkwits
< Michael.Berkw its@jamanetwork.org >, Tom Easley <Tom.Easley@ama -assn.org >, Brian Shields
<Brian.Shields@ama-assn.org >, Betsy Solaro <Elizabeth .Solaro@ama -assn.org >, Sean O'Donnell
<Sean.O'Donne ll @ama-assn.org>, Tiffany Jones <Tiffany.Jones@ama-assn .org >
Subje ct: Subtitled Coronav irus Video
NIH-002099
The 1/27 Fauci subtit led video is now liv e: https :// jamanetwor k.com/journa ls/jama/pages/coronav irus-
alert The 2/6 Fauci update video will go to the trans lator tomorrow.
-Karen
Karen Adam s-Taylor

Vice President, Publishing Production Operations
JAMA Network rM
330 N Wabash Ave, Ste 39300, Chicago, IL 60611
T
----- (b)(6)
jamanetwork.com
NIH-002100
From: (b)(6)
Sent: Thu, 6 Feb 202015:09:43 -0500
Cc: Conrad, Patricia (NIH/NIAID) [E];Eisinger, Robert (NIH/NIAID) [E];Lerner, Andrea
(NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E]
Subject: Re: ASF--- Morens + Daszak +Taubeneberger paper
I agree. I will not be a co-author
On Feb 6, 2020, at l :59 PM, Folkers, Greg (NIH/NIAID) [E]
----------- CbH wrote:
(b) (4)
So the question to you - do you want to be part of this? ie be a

coauthor
I would vote no - it wud look weird to add you as a coauthor now. Plus,
plate too full. .....
Disclaimer: Any third-party material in this email has been shared for internal use under fair
use provisionsof U.S. copyright law, without further verification of its accuracy/veracity. It
does not necessarily represent my views nor those ofNWD , NIH, HHS, or the U.S.
governme nt.
NIH-002 104
Sent: Thu, 6 Feb 2020 17:36:11 +0000
To: (b)(6)
Cc: (b)(6)
Subject: RE: nCoV: Heads-up
Thanks, Jim.
Director
Phone : (b)(6)
FAX : (301 496-4409
E-mai l (b)(
other storage devices . The Nationa l Institute of Allergy and Infectious Diseases (NIAID) shall not
From:
-------------------
------ --~
(b)(6)

Cc: (b) (6)
-------- (b)(6)
Subject: nCoV: Heads-up
. We will keep you updated. Best. John and Jim

French dru gmaker Sanofi workin g on coronavirus initiative
CHINA-HEALTH/SANOFI (PIX):French drugmaker Sanofi working on coronavirus
initiative
PARIS, Feb 6 (Reuters) - French drugmaker Sanofi will announce a new coronavirus initiative
within the next two weeks, its chief executive said on Thursday , adding that it wants to present
something concrete and not add to "fantasies".
At least a dozen drngmake rs are working on vaccines or antivira ls to help those infected with the
fast-spreading virus that has killed more than 500 people in China, but several have warned that
development of treatments will take time.
NIH-002105
"We have seen a flurry of activities from other companies," CEO Paul Hudson told a news
conference after Sanofi published 2019 results on Thursday.
"We are one of the few companies that has the expe1iise to know when it is just a fantasy, or
when it could be real. In the next week or two, you will see something more confinnatory about
the approach we will take."
Hudson declined to give further details.
Sanofi had already said it was sharing its expertise and data acquired from other outbreaks with
the Coalition for Epidemic Preparedness Innovations (CEPI), which is working with biotech
businesses to try to develop a vaccine candidate for the coronavirus.
Britain's GlaxoSmithKline is also collaborating with CEPI.
"The objective here is not a newspaper headline, it is real work that will make a difference ,"
Hudson said.
(Reporting by Matthias Blamont Writing by Sarah White Editing by David Goodman)
NIH-002106
Sent: Thu, 6 Feb 2020 16:28:04 +0000
To: h iattf@washpost.com
Cc: Redfield, Robert R. (CDC/0D);Fauci, Anthony (NIH/N IAID) [E]
Subject: Proposed OpEd
Attachments: Redfield and Fauci - Coronavirus OpEd - 02-06-2020 - FINAL.docx
Fred:
(b)(6)
I hope that all is well with you .
Within this context, Bob Redfield
-------------------- (bH6J.
and I have written an OpEd on the government response to the novel coronavirus
outbreak. Would the Post have any interest in this? Many thanks.
Best regards ,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
NIH-002107
Sent : Thu, 6 Feb 2020 14:34:57 +0000
Cc: Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Marston, Hilary
(NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E]
Subject: RE: Requested coronavirus talking points for press conference
Attachments : Talking Points for NIAID Director Dr. Fauci - press conference - 02-06-2020 -
Fauci Press remarks with tracked edits.docx
Oooops! Forgot the attachment. Here it is.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)

To: Billet , Courtney (NIH/NIAID) [E) ------~= (b)(6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b)(6) >; Folkers, Greg (NIH/NIAID) [E]
(b)(6)>; Marston, Hilary (NIH/NIAID) [E] (b)(6); Routh, Jennifer
":":
(N
"".".'
l'."':"
H/-::-
N"."."'
IA
'."".'
l':":
D):-:[~E]:-====-.:--_.;.. )(= ; Stover, Kathy (NIH/NIAI D) [E]
(bc-c (b)( >
Subject: RE: Requested coronav irus talking points for press conference
Here is my revised and updated press remarks with my tracked edits showing.
Please accept edits, do a spell and grammar check and resubmit. Also, put a copy
in my fol der . Thanks.
Director
Phone : (b)(6)
NIH-002 114
FAX : (301 496-4409
E-mail : (b)(6)
From: Billet, Courtney (NIH/NIAID) [El (b)(6)

'""(=
6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b)(6)>; Folkers, Greg (NIH/NIAID) [E]
1
(b)(6); Marston, Hilary (NIH/NIAID) [El (b)( >; Routh, Jennifer

":":
(N H/7N"."."'
"".":'
1:-:- IA
'.'"':'
l-::-
D):-:[~El:-===~--~ (b"""'
)(,=,;
6); Stover, Kathy (NIH/NIAI D) [El (b)(6)
Subject: FW: Requested coronavirus talking points for press conference
HHS has asked us for your talking points fo r the press conference by 11am. We were planning to
resubmit these. As was the case last time, this is a placeholder for the WH to know the outlines of what
you would say. This is not a script.
Is it OK for us to send th is to Bill?
From: Selgrade, Sara (NIH/NIAID) [El (b)( >

To: Fauci, Anthony (NIH/NIAID) [E]______ """'
(b"""
)(=6)
Cc: Conrad, Patricia (NIH/NIAID) [El (b)(6)>; Billet, Courtney (NIH/NIAID) [E]
(b)(6); Routh, Jennifer (NIH/NIAID) [El (b)(6); Folkers, Greg
(NIH/NIAID) [El (b)(6)
Subject: Requested coronavirus talking points for press conference
Dr. Fauci,
Attachedplease find the requested talking points from your last coronavirus press conference.
Plea se let us know if you need anything else .
Thanks,
Sara
NIH-002 115
Sent : Thu, 6 Feb 2020 10:58:13 +0000
To : Collins , Francis (NIH/OD) [El
Cc: Cassetti , Cristina {NIH/NIAID) [El; Erbelding , Emily {NIH/NIA ID) [E];Conra d,
Patricia {NIH/NIAID) [El
Subject : RE: Follow up on Addis Meeting
Francis:
Thanks for the note . Best to have Trevor have his program person who will be leading this
effort contact Cristina Cassetti in DMID . Cristina and Emily Erbelding cou ld do all of the
necessary and approp riate coordination .
Thanks,
Tony
From: Coll ins, Francis (N IH/OD) [El

--------
Sent: Thur sday, February 6, 2020 4:56 AM
(b)(6)
-------=-,--="
To : Fauci, Anthony {NIH/NIAID) [El
Subject : FW: Follow up on Addis Meeting-------- (b)(6)
See reference to coronav irus research in the note from Trevor. How would you like to
coordinate this?
FC
From: Trevor Mundel _____________ ..,

(b)(6)>
Sent : Wed nesday, February 5, 2020 10 :55 PM
To : Collins , Francis (NIH/OD) [El (b)(6)
Cc: Eiss, Robert (NIH/ FIC) [El ,.;....;;-======- (b,;,;
H;;6;J;-
;-:G:-:-"
lass, Roger {N IH/FIC) [El (b)(6);
Kedest Tesfagio rgis (b)(6)>
Subject : Re: Follow up on Add is Meeting
That would be great Francis. You might have seen our announcement th is morni ng on the Coronavirus
reponse fundin g and $60M of the 100 is fo r R&D especia lly therapeutics rather than vaccines so we
mi ght want a quick call in the next few days to thin k about how we coordinat e this - I've been in touch
with Jeremy as we ll. Trevor
Trev or Mu ndel , MD, Ph D

President , Global Health Program
V (b)(
F +1.206 .494 .7041
E
-------------
(b)(6)
(b)((ij
Execut ive Assistant

Office of the President, Global Health
NIH-002 118
(b)(6)
(b)(6)
(b)(6)
Bill & Melinda Gates Foundation
www .gatesfounda tion.org

To: Trevor Mundel
Cc: Eiss, Robert (NIH/FIC) [El; Glass, Roger (NIH/FIC) [El
Subject : RE: Follow up on Addis Meeting
Hey Trevor,
This is an excellent development. How about I send you a proposal of possible CARITPs for
Elioda - in the next 24 hours?
Franc is
From: Trevor Mundel (b)(6)

To: Tumwesigye Elioda
Cc: (b)(6)
CbH6l>;Collins, Francis (NIH/OD) [El
-------- (b) ( >
Subject : Re: Follow up on Addis Meeting
That's great to hear Elioda and congrat ulations, many thanks for letting us know . We will certain ly get
back to you shortly to enlist your help w ith the CARI initiative at AU level.
Warm regards,
Trevor
From: Tumwesigye Elioda (b)( >

To: Trevor M undel; Francis Collins
Cc: (b)(6)
Subject : Follow up on Addis Meeting
Dear Trevor,
Greetings from Uganda and indeed Africa . It was pleasure meeting you at the Grand Challenges Meeting
in Ethiopia late last year. While there you, Francis Collins and I among others discussed the CARI
Initiative and the need to support research, entrepreneurship and innovation in a big way in Africa. We
also explored the mechanism for CARI Funding. We were also looking for a mechanism to reach the
Committee of Ten (ClO) Heads of State and Government championing Education, Science and
Technology in Africa.
NIH-002 119
Well allow me to inform you that on 13th Dec 2019, I was elected to chair for 2 years the Ministers of
Education and of Science and Technology in all the 55 Members States in Africa. We do this under the
Specialized Technical Committee on Education, Science and Technology (STC-ES T). This Saturday on 8th
Feb in Addis, as chair of the ST -EST I will attend and speak at the Meeting of the above-mentioned Cl0.
The purpose of this message is to let you know of my added responsibilities and related opportunities as
well as seek for any update or latest information regarding the CARI init iative . I look forward to
intensified communication and collaboration.
Regards
Dr. Elioda Tumwesigye

Minister Science, Technology and Innovation
Republic of Uganda
Tel: (b)(6)
Sent from my iPad
NIH-002 120
Sent : Thu, 6 Feb 2020 04 :10:50 +0000
To: Cassetti, Cristina (NIH/N IAID) [El
Subject: FW : PandemicThreat Reduct ion
Simil ar e-Om ail from Dr. Tubb.
From: Richard Tubb

-------
Sent : Thu rsday, January 30, 2020 11:35 AM
(b)(6)>
_To....!
: ===~~----- Cb
_>_C6)Fauci, Ant hony (NIH/N IAID) [E]
(b)(6)
Subject: Fwd: Pandemic Threat Reductio n
Good morning Tony.

Given your most recent appointment , I wanted to show
you the courtesy of letting you know what I have alread y
provided to senior leaders at the White House regarding a
possible mitigating strategy until the definitive solution to
the CoV is available and implemented. The string below
includes additional information as to how titanium dioxide
can fit into both the White House and the
National / International solutions, and the open-source
website for the company. Please keep in mind that
because this product is already approved and in use in the
EU for a variety of commercial uses, the data provided
does not specifically address the applications I, and you,
are interested in. Ho-\ivever, with a deep understanding of
the White House mission, I can say that there is not a big
leap in that thought migration.
Dr. Jackson has already provided the same material to

some of your White House Commission colleagues. I will
also be reaching out to another friend of mine from the
Bush-now-Trump Administration, Steve Biegun.
NIH-002121
I encourage your representatives to meet with the
company leadership and scientists while they are in the US
next week. Please let me know if you have any questions
that I can address. Thank you for once again stepping up
to the plate for our Country.
v/r
Dick
ps .. .I remembered this morning where you and I last

spoke--Bush (41) funeral.
From: Richard Tubb (b) (6) >
-----------
Date : Thu, Jan 30, 2020 at 8:54 AM
Subject: Re: Pandemic Threat Reduction
Good morning Gentlemen,
I just spoke with Ronny and believe I need to offer A relevant update and one point of explanation.
First, the company's joint venture partner in India is meeting with the Indian government as we speak.
It appears likely that in light of the news of India's introduction to the corona virus the government will
utilize their "Natio nal Catastrophe Budget" to expedite the funding necessary to secure and execute a
contract with this company.
Secondly, I w ill attach the open source web site for the company to provide you background information
that, out of respect for your time and for the sake of brevity, I left out of yesterday's note. It's
important to note a couple of things:
This product is already proved and is in use in the EU with all the approvals appropriate for the same.
Secondly, in our language, this is a "standoff produ ctr'' -I.e. you apply it once and it continues to
decontamina t e and disinfect in the background for up to 1-5 years before retreating. (Depending on the
type of use, norma l daily cleaning using their cleaning solution-that is cheaper and more effective than
what the application normally would use, e.g. in a hotel-cont inues). The chemical treats anything
organic, I.e. bacteria, viruses, voe,bio threats, etc. because it is a catalyst, it is neither used up, nor
NIH-002122
does it produce microbial resistance or superbugs. It decontaminates and disinfects surfaces (e,g,
airplanes and government cri tical infrastructures) and the air around the surface (and HVACfi lters and
air handlers).
The leadership will be in DC next week. I highly encou rage any and all potential stakeholders make time
to meet with them while they are here . To that end, I had already emailed Dr. Fauci (with whom I
worked a great deal on similar chalenges during the Bush Admin istrat ion) before the announcement of
his participat ion on the new coronavirus commission, I will also reach out to an old friend and colleague
Steve BIEGUN now that he is in the commission . Please feel free to forward the information to others as
you deem appropr iate .
Thanks,
Dick Tubb
htt ps://act.g lobal/
Ps...once again, in my haste to get this to you , via iPad, please forgive typos and other apparent crimes
against the dictionary .
Sent from my iPad
On Jan 29, 2020, at 3:15 PM, Richard Tubb

--------- (b)(6J> wrote:
Gentlemen, Brother s, and Others ...
This is Dick Tubb , writing on behalf of

Admiral Jack son and Dr. Hofmann (both
copied herein). It feels like "old times"- -I'm
undecid ed as to wheth er the y are good old
times , or otherwise. Regardless , it does feel
like we've been down a very simil ar road
before . Perh aps we can apply some of th e
lessons -learned to th e inevitable problems
ahead.
NIH-002 123
In light of the current and evolving threat
presented by the corona virus, I am writing
to you as a courtesy to inform you of a
project that Admiral Jackson, Dr.
Hofmann, and I have been consulting on.
We believe so strongly in the technology,
people, and potential that we have been
consulting pro bono and currently have no
financial stake in the project. While not
developed specifically designed for such
purposes, I increasingly believe that until a
vaccination and treatment for the corona
virus is available, this technology may be
the last best chance in containing, and
eradicating the virus, thereby protecting
the homeland, our economy, the Continuity
of the Presidency, an Enduring
Constitutional Government, our people and
our Country. Moreover, reverting to my
"lessons-learned, problems-ahead"
statement, even after this crisis is over, and
a vaccine and treatment procured, it will
only be a matter of time until "next time."
This letter is proof-positive of that reality.
My experiences, especially in the early
2ooo's (e.g. anthrax and other biothreats,
SARs, etc.) underpin my beliefs.
The technology that provides the solution,

both now and in the future, involves a
unique formulation of a photo catalytic
NIH-002124
nano titanium dioxide solution (the Air
Force guys will, of course, understand what
that means, so you non-Air Force folks, just
buy them a beer and they'll explain it to
you) that is safer, more effective, and more
cost effective than any other solution. It
was developed and approved in the EU, and
I have asked the senior leadership of the
company to come to Washington DC next
week. Dr. Hofmann and I spent the day
yesterday with a Chinese "titan" respected
by and with access to the most senior
government officials, academic and medical
giants, and investment and industry
captains. I have encouraged , and he has
agreed in principal, to follow our
recommendations as they relate to their
largest airline, and their key facilities.
In short, our strategic priority is to first

fortify the weak link in the pandemic chain:
the airlines. Doing so will provide the time
necessary to isolate, contain, and ultimately
destroy the threat at its source
(Wuhan) ,and in its home (China). As
President Bush so commonly stated about a
very different threat, we need to fight the
battle over there, so that we don't have to
fight the battle here. Although President
Bush was a true believer in the threat of a
pandemic, I believe this threat, and the
NIH-002125
threats that are surely to fallow are, in
reality , many, many times greater than the
threat he envisioned when making that
statement. By fighting a possible
impending pandemic at its source we will
preserve and protect the safety and
confidence of our people, and the strength
of our economy.
Once we have interrupted the threat supply

chain, we can then shore up our critical
infrastructure using the same technology
and process, then assist the Chinese in
addressing their challenges, and protect
our international allies elsewhere . In that
vein, in addition to the Chinese, I have also
discussed this technology and strategy with
senior proxies for another of my former
patients, His Royal Highness, the Crown
Prince of Saudi Arabia, and his father, the
King.
As I noted above , I have asked the

leadership of the company to come to
Washington (from Germany and Denmark)
next week for a variety of meetings. While
Admiral Jackson will be "tied up in Texas"
for the foreseeable future, please let me
know if you would like to meet with myself
or Dr. Hofmann, or the company
NIH-002126
leadership while they are here, to learn
more.
Thank you and my best to you all as you

plan for and continue to protect our
Country,
Very Respectfully,
Dick Tubb
ps. For your SA, I have also attached below

the latest sit rep on the coronavirus.
Richard J. Tubb, MD
Brigadier General (retired)
White House Physician Emeritus
Shoreland's Travax News Alert Service-

Abbreviated
China: More than 2,800 Cases of 2019-nCoV in 30

Provinces/Municipalities , Mainly in Wuhan ; Cases
Exported to 16 Countries
WHAT'S NEW
According to regional health authorities, more than 1,800 additional ,

confirmed cases (including 25 deaths) of pneumonia caused by 2019
novel coronavirus (2019-nCoV) have been reported since January 27,
2020, throughout the country, mainly in the provinces of Hubei (1,291) ,
Guangdong (207), Zhejiang (173), Henan (168) , and Hunan (143) and in
the cities of Chongqing (132), Beijing (19) , and Shanghai (13). Most new
cases had a travel history to Wuhan . Almost all the recent deaths occurred
in Hubei Province . Twenty more patients have recovered and been
NIH-002127
discharged. More than 4,600 confirmed cases (including> 100 deaths)
have occurred since December 8, 2019.
A total of 13 additional , exported, confirmed cases have been reported

(through January 28, 2:00 p.m. EST) since Monday, January 27. More
than 25 cases have been exported in the past 7 days. Cases reported
since Monday arrived in the following countries on the dates shown:
Singapore (January 19 and 23), Taiwan (January 22) , Japan (January 20
and 21 ), France (arrival date unknown), and Thailand (arrival dates
unknown). All of these cases had travel history to Wuhan or contact with
an ill person from Wuhan while in China .
In addition to these exported cases, 7 locally acquired cases have been

reported since Monday in Germany (4), Japan , Taiwan and Vietnam. The
cases in Japan, Taiwan , and Vietnam reported contact with an obviously ill
person from China . In Germany all 4 cases had close contact in a
business seminar with an apparently asymptomatic Chinese woman on
January 21 (who previously had contact with relatives from Wuhan) ; the
women states symptom onset was on a flight to Shanghai on January 23,
and she was later confirmed to have 2019-nCoV. Incubation periods in
these cases have been as short as 3 days. In light of the secondary cases
in Germany in a business setting , the most cautious approach of having
arrivals stay at home or in a hotel for 14 days after their last possible
exposure in China is increasingly justified.
Updated travel advisories include: 1) Australia: reconsider travel to China ;

2) Canada: avoid all travel to Hubei Province; 3) Finland: avoid
nonessential travel to Hubei Province; 4) France: avoid all travel to Hubei
Province; 5) Germany: avoid nonessential travel to China and avoid all
travel to Hubei Province; 6) India: avoid all nonessential travel to China; 7)
New Zealand: avoid all travel to Hubei Province ; 8) Taiwan: avoid all
nonessential travel to China.
Singapore now denies entry to residents of Hubei Province and those who
have traveled there in the past 14 days.
Mongolia and 3 regions (Amur Oblast, Khabarovsk Kray, Yevreyskaya

Oblast) in Far Eastern Federal District, Russia have closed their land
borders with China .
Bangladesh , Canada , India, Kazakhstan , Russia, and South Korea are

arranging flights to repatriate their respective citizens from Wuhan. These
persons will be closely monitored and present little threat of onward
transmission.
All tourist attractions in Tibet Autonomous Region have been closed .
Current influenza vaccination is recommended to decrease the risk of

simple influenza being mistaken for 2019-nCoV upon return.
Infection control supplies have been depleted in medical facilities in the

smaller cities in central China ; the situation is critical in many areas and
resupply is uncertain.
NIH-002128
OVERALL RISK ASSESSMENT
The epidemic in China is months from peaking . A report indicates that just
prior to the cordoning off of Wuhan, over 5 million residents (many
potentially infectious) left for other parts of China, and many thousands left
for Hong Kong, Singapore, Thailand, and Japan. Exported cases have so
far been to countries likely to be capable of controlling (but not preventing)
ongoing transmission, which will inevitably occur. In light of the secondary
cases in Germany in a business setting , the most cautious approach of
having arrivals stay at home or in a hotel for 14 days after their last
possible exposure in China is increasingly justified.
Based on increasing data on virology, clinical presentation, and

transmission, this coronavirus closely resembles SARS-CoV in many
behaviors. Fortunately , sequential sequencing of viral isolates over time
indicate no significant new viral mutations ; mutations often increase
transmission or virulence . WHO assesses the risk of this event to be very
high in China , high at the regional level, and high at the global level. The
closing of Wuhan airport and the major cities of Hubei province have yet to
stem the flow of exported cases . The originally implicated animal market,
now closed indefinitely, bears little relevance to the ongoing situation.
Whether the market was the focus of a species jump from animals to
humans or merely one of multiple amplification settings for initial cases is
increasingly unclear. The degree of human-to-human spread outside of
Hubei province remains unclear . A reproductive number, Ro, is estimated
at 1.4-2 .5 by Chinese authorities and up to 5.5 by other scientists . An Ro
greater than 1 indicates that each case leads to more than 1 subsequent
case, making control much more difficult. The spectrum of disease
manifestations in a large cohort study has yet to be disclosed; a severe
case rate of 20% has been consistent. The existence of mildly
symptomatic and asymptomatic infectious cases could increase the risk of
global spread. Case fatality is impossible to ascertain at present, and
lesser or greater clinical virulence compared to MERS-CoV or SARS-CoV
remains speculative.
See 20 19 Nove l Coronav irus Outbreak for detailed information .
© 2020 Shoreland , Inc. All rights reserved .
Travax News Alert items are incorporated into Shoreland's subscriptions .

Travax content represents decision-relevant, expert synthesis of real-time
data reconciled with new and existing available advice from authoritative
national and international bodies .
For email service changes , please forward this message to

service@shore land .com with your request. If the change should apply to
all email subscriptions (Content Changes , Literature Watch and News
Alert), please specify that in your request. [Account: SI53213; Recipient:
bg .richard.tubb@gmail.co m)
NIH-002129
2019 Novel Coronavirus Outbreak Report-
comprehensive
Last updated January 28, 2020 .
What's New
According to regional health authorities, more than 1,800 additional, confirmed cases
(including 25 deaths) of pneumonia caused by 2019 novel coronavirus (2019-nCoV)
have been reported since January 27, 2020, throughout the country, mainly in the
provinces of Hubei (1,291), Guangdong (207), Zhejiang (173), Henan (168), and Hunan
(143) and in the cities of Chongqing (132), Beijing (19), and Shanghai (13). Most new
cases had a travel history to Wuhan. Almost all the recent deaths occurred in Hubei
Province. Twenty more patients have recovered and been discharged. More than 4,600
confirmed cases (including> 100 deaths) have occurred since December 8, 2019.
A total of 13 additional, exported, confirmed cases have been reported (through

January 28 , 2:00 p.m. EST) since Monday, January 27. More than 25 cases have been
exported in the past 7 days. Cases reported since Monday arrived in the following
countries on the dates shown: Singapore (January 19 and 23), Taiwan (January 22),
Japan (January 20 and 21 ), France (arrival date unknown), and Thailand (arrival dates
unknown) . All of these cases had travel history to Wuhan or contact with an ill person
from Wuhan while in China.
In addition to these exported cases , 7 locally acquired cases have been reported since
Monday in Germany (4), Japan, Taiwan, and Vietnam. The cases in Japan , Taiwan,
and Vietnam reported contact with an obviously ill person from China. In Germany , all 4
cases had close contact in a business seminar with an apparently asymptomatic
Chinese woman on January 21 (who previously had contact with relatives from Wuhan);
the woman states symptom onset was on a flight to Shanghai on January 23, and she
was later confirmed to have 2019-nCoV. Incubation periods in these cases have been
as short as 3 days. In light of the secondary cases in Germany in a business setting,
the most cautious approach of having arrivals stay at home or in a hotel for 14 days
after their last possible exposure in China is increasingly justified .
Updated travel advisories include: 1) Australia: reconsider travel to China; 2) Canada:

avoid all travel to Hubei Province; 3) Finland: avoid nonessential travel to Hubei
Province ; 4) France: avoid all travel to Hubei Province; 5) Germany: avoid nonessential
travel to China and avoid all travel to Hubei Province; 6) India: avoid all nonessential
travel to China; 7) New Zealand: avoid all travel to Hubei Province; 8) Taiwan: avoid all
nonessential travel to China .
Singapore now denies entry to residents of Hubei Province and those who have
traveled there in the past 14 days.
Mongolia and 3 regions (Amur Oblast, Khabarovsk Krai, Jewish Autonomous Oblast) in
Far Eastern Federal District, Russia have closed their land borders with China .
Bangladesh, Canada , India, Kazakhstan, Russia, and South Korea are arranging flights
to repatriate their respective citizens from Wuhan. These persons will be closely
monitored and present little threat of onward transmission.
NIH-002130
All tourist attractions in Tibet Autonomous Region have been closed.
Current influenza vaccination is recommended to decrease the risk of simple influenza

being mistaken for 2019-nCoV upon return.
Infection control supplies have been depleted in medical facilities in the smaller cities in
central China; the situation is critical in many areas and resupply is uncertain.
Overall Risk Assessment

The epidemic in China is months from peaking. A report indicates that just prior to the
cordoning off of Wuhan, over 5 million residents (many potentially infectious) left for
other parts of China, and many thousands left for Hong Kong, Singapore, Thailand, and
Japan. Exported cases have so far been to countries likely to be capable of controlling
(but not preventing) ongoing transmission, which will inevitably occur. In light of the
secondary cases in Germany in a business setting, the most cautious approach of
having arrivals stay at home or in a hotel for 14 days after their last possible exposure
in China is increasingly justified.
Based on increasing data on virology, clinical presentation , and transmission, this

coronavirus closely resembles SARS-CoV in many behaviors. Fortunately, sequential
sequencing of viral isolates over time indicates no significant new viral mutations;
mutations often increase transmission or virulence. WHO assesses the risk of this event
to be very high in China , high at the regional level , and high at the global level. The
closing of Wuhan airport and the major cities of Hubei province have yet to stem the
flow of exported cases. The originally implicated animal market , now closed indefinitely ,
bears little relevance to the ongoing situation. Whether the market was the focus of a
species jump from animals to humans or merely one of multiple amplification settings
for initial cases is increasingly unclear . The degree of human-to-human spread outside
of Hubei province remains unclear. A reproductive number, Ro, is estimated at 1.4-
2.5 by Chinese authorities and up to 5.5 by other scientists . An Ro greater than 1
indicates that each case leads to more than 1 subsequent case, making control much
more difficult. The spectrum of disease manifestations in a large cohort study has yet to
be disclosed; a severe case rate of 20% has been consistent. The existence of mildly
symptomatic and asymptomatic infectious cases could increase the risk of global
spread . Case fatality is impossible to ascertain at present , and lesser or greater clinical
virulence compared to MERS-CoV or SARS-CoV remains speculative .
Current Disease Situation

More than 4,600 confirmed cases (976 severe and critical cases and 106 deaths) have
occurred since December 8, 2019, in the provinces of Hubei (> 2,700; mainly in
Wuhan), Guangdong (207), Zhejiang (173), Henan (168), Hunan (143), and Anhui
(106) ; in the cities of Chongqing (132), Beijing (91 ), and Shanghai (66); and in 21 other
provinces throughout the country. An additional 6,900 suspected cases have been
reported since January 21, 2020. In the setting of a large outbreak and with increased
delays in testing, a high proportion of suspected cases will evolve into confirmed cases.
Seventy-nine cases have been discharged. Two-thirds of the cases are male. The
youngest case is 10 years old and the oldest is 89; more than 70% of cases are over 40
years old, but the co-morbidity profiles of most cases are unknown .
NIH-002131
The number of persons becoming infected with the virus has been doubling every six
days. The outbreak in China is not approaching peak, and modeling indicates that is
months away.
Exported Cases
Seventy-seven imported cases of 2019-nCoV (confirmed after arrival) presented at
international ports of entry January 6-25 in 16 countries. Of these cases, more than 25
cases arrived in the past 7 days.
All 77 cases had exposure in Wuhan or exposure to ill persons from Wuhan in China
and symptom onset dates after December 31, 2019; none had visited the implicated
market.
Australia (5 cases): One case traveled while asymptomatic aboard China Southern
Airlines flight CZ231 to Melbourne, Victoria State on January 19 and was hospitalized
on January 23. Contact tracing is underway ; movement around Melbourne was limited
prior to isolation. The remaining 4 cases traveled while asymptomatic aboard flights to
Sydney , New South Wales State on January 6, 18, 20, and 23, and were hospitalized
on January 15, 20, and 24. One of the patients had limited movement around Sydney
prior to isolation; movement history for the other 3 cases is unknown.
Cambodia (1 case): The case traveled while asymptomatic to the city of Sihanoukville
on January 23, 2020, and developed symptoms on January 25.
Canada (2 cases): Both cases (a couple) traveled aboard China Southern Airlines
flight CZ311 to Toronto, Ontario Province on January 22. The first case was
symptomatic while traveling and was hospitalized on January 23. The second case was
under self-isolation and was confirmed on January 27. Contact tracing is underway;
patient movement around Toronto was limited prior to isolation .
France (4 cases): Two cases traveled while asymptomatic aboard a flight to Paris on
January 18, and 1 case traveled aboard a flight to Bordeaux on January 22. Travel
history for the fourth case in unknown. All cases were hospitalized.
Hong Kong (8 cases): Three cases traveled while symptomatic on January 19 and 25;
the first aboard a train to West Kowloon , the second aboard a flight to Hong Kong
International Airport , and the third to Lo Wu Control Point. Four of the cases traveled
while asymptomatic aboard trains on January 19 and 22. The last case traveled with
diminished symptoms aboard a train on January 23. All cases were hospitalized .
Japan (6 cases): Two cases traveled while symptomatic; the first aboard a flight to
Kanagawa Prefecture on January 6 and the second aboard a flight to Tokyo on January
19. The first was hospitalized on January 10 and discharged on January 15 following
recovery, and the second was hospitalized on January 22. Another 2 cases traveled
while asymptomatic: the first aboard a flight to Tokyo on January 18 and the second
aboard a flight to Aichi Prefecture on January 22. The first was hospitalized on January
23, and the second was hospitalized on January 24. The remaining 2 cases arrived on
January 20 and 21 in Aichi and Tokyo prefectures.
Macau (7 cases): The first case traveled while asymptomatic aboard a train and a bus
on January 19, and the second case traveled while symptomatic (travel method
unknown) on January 22. The first case was hospitalized on January 19 and the second
NIH-002132
case on January 2 1. The third case traveled aboard a ferry on January 23 and was
immediately hospitalized. Three cases traveled (methods unknown) on January 22; all
were hospitalized. The last case traveled while asymptomatic on January 23 and was
hospitalized January 27.
Ma laysia (4 cases) : The first case traveled while asymptomatic aboard a bus to Johar
Baharu on January 22 and was hospitalized on January 23. The remaining 3 cases
traveled (method unknown) to Johar Baharu on January 23; all were hospitalized .
Nepal (1 case): The case traveled to Kathmandu on January 5, was hospitalized on

January 13, and was discharged on January 17 following recovery.
Singapo re (7 cases): All 7 cases traveled while asymptomatic aboard flights on

January 18, 19, 20, 21, 22, and 23.
South Korea (4 cases): Two cases traveled while symptomatic to lncheon International
Airport and to Gimpo International Airport on January 19 and 23, and both were
immediately hospitalized. The remaining cases traveled while asymptomatic on January
20 and were hospitalized on January 25.
Sri Lanka (1 case): The case traveled while asymptomatic on January 29, 2020, and
developed symptoms on January 25.
Taiwan (7 cases) : The cases arrived on January 20, 21, 22, and 25; at least 3 cases
arrived at Taiwan Taoyuan International Airport.
Thailand (14 cases): Three cases traveled while symptomatic to Suvarnabhumi Airport
on January 8, 13, and 19 and were hospitalized; the travel history of the fourth case is
unknown. The fifth case traveled to Bangkok on January 21 and was hospitalized on
January 23. The travel histories of the remaining 9 cases are unknown.
U.S. (5 cases) : Two cases traveled while asymptomatic: the first to O'Hare Internationa l
Airport on January 13 and the second to Seattle-Tacoma International Airport on
January 15. The first was hospitalized several days after arrival, and the second was
hospitalized on January 19. The remaining 3 cases were reported in Maricopa County ,
Arizona and Los Angeles and Orange counties, California ; information on the patients'
travel histories are unknown. Contact tracing for all cases is underway. The first case
reported limited movement around Chicago prior to hospitalization; movement history
for the other 2 cases in unknown.
V ietnam (1 case): The case arrived in Hanoi on January 13 and was hospitalized on
January 22 in Ho Chi Minh City .
In addition to these exported cases , 7 locally acquired cases have been reported since
Monday in Germany (4), Japan, Taiwan, and Vietnam. The cases in Japan , Taiwan,
and Vietnam reported contact with an obviously ill person from China. In Germany, all 4
cases had close contact in a business seminar with an apparently asymptoma tic
Chinese woman on January 21 (who previously had contact with relatives from Wuhan);
the woman states symptom onset was on a flight to Shanghai on January 23 , and she
was later confirmed to have 2019-nCoV . Incubation periods in these cases have been
as short as 3 days.
Entry/Exit Screening
NIH-002133
In a reversal of long-standing policy , WHO now recommends that all countries
implement temperature screening at points of entry for passengers arriving from 2019-
nCoV-affected countries. Screening should be accompanied by dissemination of risk-
communication messages at points of entry to later capture asymptomatic persons who
are in the incubation phase.
In early January , some exit screening was implemented at Wuhan Tianhe International
Airport (nonstop flights to Istanbul , London, New York , Osaka , Paris, Rome, San
Francisco , Tokyo, and major hubs throughout Southeast Asia) , as well as at 3 major rail
stations in Wuhan . More restrictive screening was instituted on January 15 in Hubei
until cessation of international flights on January 23. Despite exit screening at all
international airports in China in the past week, significant numbers of cases continue to
be exported.
Entry screening at international ports of entry has been or is being implemented as

noted below , and anyone with fever and respiratory symptoms who has been to 2019-
nCoV-affected areas in the previous 14 days will be detained and isolated at these
locations:
Algeria: Houari Boumediene Airport, Mohamed Boudiaf International Airport , Oran

Ahmed Ben Balla Airport
Burma (Myanmar) : Yangon International Airport
Egypt: Cairo International Airport (all flights from China)
Hong Kong : All border checkpoints , including Hong Kong Internationa l Airport and the
railway station in West Kowloon
India : Bengaluru , Chennai, Delhi, Hyderabad , Kochi, Kolkata, and Mumbai international
airports (all flights from China and Hong Kong)
Italy: Leonardo da Vinci-Fiumicino Airport
Iran: Teh ran Imam Khomeini International Airport (all flights from China)
Macau : Macau International Airport
North Macedonia: Skopje International Airport (connect ing flights from Asia)
Qatar: Hamad International Airport (all flights from China)
Russia: Moscow, Irkutsk Oblast , and Yekaterinburg international airports and points of
entry in Amur Oblast
Singapore : Changi Airport
South Africa : O.R. Tambo International Airport (all flights from China)
South Korea : lncheon International Airport
Taiwan: All international airports
NIH-002134
Thailand : Krabi , Suvarnabhumi, Don Mueang , Phuket , and Chiang Mai airports
Turkey: All international airports (all flights from China)
United Arab Emirates: Abu Dhabi International Airport and Dubai International Airport
(all flights from China)
U.K.: Heathrow International Airport
U.S.: Twenty points of entry, including Hartsfield -Jackson Atlanta International Airport,
John F. Kennedy International Airport, Los Angeles International Airport , O'Hare
International Airport , and San Francisco International Airport. Travelers from Wuhan
may have their temperatures taken and/or be required to complete a symptom
quest ionnaire; travelers with symptoms (fever , cough , difficulty breathing) will be
deta ined for additional assessment.
Australia, Bahrain, Bangladesh, Belarus, Canada, Cote d'Ivoire, Ghana,

Indonesia, Japan, Kazakhstan, Kenya, Kyrgyzstan, Madagascar, Malaysia, Nepal,
Nigeria, North Korea, Philippines, Saudi Arabia, Serbia, Senegal, Sri Lanka,
Tajikistan, Tunisia, Vietnam : Airports and other ports of entry
Travel Advisories
The following countries and/or organizations have published travel recommendations:
Avoid All Travel to Hubei Province: Australia , Canada, China (see below) , France ,
Germany , Japan, Mexico , New Zealand , U.K., U.S.
Avoid Nonessential Travel to Hubei Province: Finland, Ukraine
Avoid All Travel to China : None at present
Avoid Nonessential Travel to China : Australia, Germany, India , Taiwan , U.S.
No Advisory: WHO
Travel Restrictions
Different levels of travel restrictions are in effect:
No Flights from China: Finnair Airlines (flights from Beijing and Nanjing), Air Seoul
No Flights from Wuhan: Wuhan Airport is closed to all international and domestic
flights.
Land Borders with China Closed : Kyrgyzstan , Mongolia , North Korea , Russia (Amur
Oblast , Khabarovsk Krai , Jewish Autonomous Oblast in Far Eastern Federal District) ;
high speed rails and ferry services suspended in Hong Kong
No Residents from Hubei Province: Hong Kong, Macau, and Singapore (including
visitors in past 14 days), Malaysia , and Taiwan
NIH-002135
Internal Travel Restrictions in China: Major cities in Hubei Province have instituted a
travel ban on occupants of their cities, suspending urban buses, subways , ferries , and
long-distance passenger transport from the cities, including flights and trains , and
closing intercity roads. lnterprovince shuttle buses in major areas have stopped. Many
bars, restaurants, shops, and museums are closed in Hubei Province, Guangdong , and
many other affected areas. Major tourist attractions have closed in Beijing, Shanghai ,
Sanya (Hainan Province) , Hong Kong, and Tibet Autonomous Region. China has
stopped all inbound and outbound tour groups but not individual travel. Internal travel
for the Lunar New Year Holiday has been severely limited by the government , and
public gatherings are forbidden. The reopening of schools and universities has been
postponed in many areas. Shanghai has temporarily closed all nonessential
workplaces. Visitors from Hubei Province will be actively monitored for 14 days in
Haikou, Hainan Province.
No Flights from 2019-nCoV-Affected Countries: Travelers going to Samoa must

spend at least 14 days in a country free of 2019-nCoV and undergo medical clearance
prior to travel to Samoa.
Australia , Bangladesh, Belgium , Canada , France, Germany , India, Japan, Kazakhstan ,

Morocco, Netherlands, Russia, South Korea, Spain, Thailand, U.K., and U.S. are
arranging flights to repatriate their respective citizens from Wuhan . These persons will
be closely monitored and present little threat of onward transmission .
Transmission
The detailed epidemiology of possible causative animal exposures and zoonotic
transmiss ion remains unclear. Many (27 of 41) earlier cases were directly linked to
South China Seafood City market in Jianghan District, which sold seafood and other
wildlife (including birds). More than 580 environmental samples , without indication as to
whether animal tissue was included , were collected from the implicated market. Of
these , 33 tested positive for 2019-nCoV , indicating that the market was an-or the-origin
point of the large-scale outbreak. Thirty-one of the positive samples (94%) were
collected from the western part of the market, where wildlife was traded. The first
published epi-curve shows that the symptom onset date of the first patient identified in
the outbreak was December 1, 2019. The patient reported no exposure to the
implicated market; no epidemiological link has been detected between this case and
later cases . This finding raises the possibility of an initial jump of 2019-nCoV directly
from bat to human, with subsequent initial human-to-human propagation within the
seafood market.
Infected intermediate animal hosts , if they exist, may still be present in the supply chain.
South China Seafood City market, now closed indefinitely , remained in operation
through December 31, 2019. Other points of infection would be likely because many
subsequent cases had no contact with the implicated market. Chinese authorities have
now stated that human-to-human transmission is in the fourth generation in Wuhan and
at least the second generation elsewhere (mostly in clusters). A reproductive number,
Ro, is estimated at 1.4-2.5by Chinese authorities and at up to 5.5 by some scientists.
An R0 greater than 1 indicates that each case leads to more than 1 subsequent case,
making control much more difficult. Ro is not a constant number and changes with the
ongoing circumstances and evolution of an outbreak . One published cluster study
indicates asymptomatic shedding (but not transmission) by a single patient. Sequence
data from several small clusters indicate identical virus in all subjects within the cluster.
NIH-002136
More than 47,800 close contacts remain under surveillance (> 1,200 have been
released), and contact tracing is ongoing in affected provinces and municipalities.
However, not all contacts are being ascertained or monitored adequately. As many as
16 health care workers (HCWs) have been confirmed as infected by at least 1 case in
Wuhan in a potential super-spreading event, but overall infectivity for HCWs has not
been established. No case of 2019-nCoV has been attributed to transmission on an
aircraft .
The survival rate of the virus on surfaces or in the environment is unknown. Disinfection
processes that are effective for other zoonotic coronaviruses should be followed for
now. Clean daily all "high-touch" surfaces, such as counters, tabletops, doorknobs,
bathroom fixtures, toilets, phones, keyboards, tables, and bedside tables. Also, clean
any surfaces that may have blood, bodily fluids, and/or secretions or excretions on
them. Use a diluted bleach solution or a household disinfectant with a label that says
"EPA-approved ." To make a bleach solution, add 15 ml (1 tablespoon) of bleach to 1 l
(1 quart) of water; for a larger supply, add 60 ml (2 oz) of bleach to 4 l (1 gallon) of
water.
Clinical Manifestations
Most cases have reportedly exhibited symptoms of fever, respiratory compromise, and
bilateral pneumonia with diffuse, ground glass-like infiltrates on chest x-ray or CT scan.
Unlike SARS-CoV, upper respiratory illness symptoms (rhinorrhea, sneezing, sore
throat) and diarrhea are not common. Overall, about 20% of the cases have been
severe or critical, including pneumonia , respiratory failure, and in some cases death.
The existence of asymptomatic cases has not been ascertained. No known treatment
exists for 2019-nCoV, although remdesivir will be available shortly from the U.S . CDC
for compassionate use. Usual antiviral drugs, including oseltamivir (Tamiflu), baloxavir,
ribavirin, and acyclovir, are ineffective. Steroids should not be used. Based on earlier
literature , the combined use of lopinavir and ritonavir is under study in China. Current
influenza vaccination is recommended to decrease the risk of simple influenza being
mistaken for 2019-nCoV upon return.
In a small cohort of 41 patients (median age was 49 years; interquartile range: 41-58)
conducted early in the epidemic (presentation before January 2), the most common
symptoms at onset of illness were fever (98%), cough (76%), and myalgia or fatigue
(44%). Dyspnea developed in 55% of patients at a median of 8 days. All cases except 1
had bilateral pneumonia. Milder cases had chest CTs that showed bilateral ground-
glass opacity with subsegmental areas of consolidation, whereas ICU patients had
bilateral lobar and subsegmental areas of consolidation . Only 66% of cases (even in
this early cohort) had been exposed to the South China Seafood City market. The case-
fatality rate was estimated to be 15%, but more severe cases tend to predominate early
in an epidemic. Limited data from another published cluster study indicate a 3- to 6-day
incubation period similar to SARS-CoV and clinical and radiologic features similar to
SARS-CoV cases in 2003. Another report indicates an incubation period ranging from 1
to 14 days.
Virology
2019-nCoV was initially isolated from 1 case and entirely sequenced; this information
was published internationally by Chinese scientists on January 10. Electron microscopy
of 1 specimen demonstrated classic coronavirus particles. 2019-nCoV is the seventh
NIH-002137
member of the family of coronaviruses that infect humans . Novel coronaviruses from
Wuhan , together with 2 bat-derived SARS-like strains, form a distinct clade in lineage B
of the subgenus sarbecovirus. 2019-nCov is a group 2b coronavirus (as are MERS-CoV
and SARS-CoV), with a whole genome similarity of up to 80% to SARS-CoV but with a
similarity between different gene segments ranging from 60% to 90%. 2019-nCoV
exhibits a 96.5% similarity to the known bat coronavirus precursors in the same viral
clade.
Sequence data allowed national laboratories to rapidly develop diagnostic kits, which
are now available in most developed countries and most Asian countries. HKU1, NL63,
229E , and OC43 are human coronaviruses that are detected by some routine multiplex
PCR panels used in routine clinical practice . These coronaviruses are associated with
minor upper respiratory infections and viral pneumonia, but unlike SARS-CoV , MERS-
CoV, and 2019-nCoV , these agents are not associated with major outbreaks or severe
respiratory distress syndrome. 2019-nCoV is not reactive in these tests . The findings so
far strongly favor (but do not prove) causation. 2019-nCoV has been shown to use the
same cell-entry receptor as SARS-CoV. Viral loads appear to be highest in lower
respiratory tract specimens, which should be the primary specimen obtained. Prediction
of human-to -human transmissibility from sequence data is difficult because
coronaviruses vary widely in their transmissibility; coronaviruses acquired from animals
generally have some potential for human-to-human transmission. Evidence from
subsequent whole genome sequences acquired over the last several weeks show little
genetic variation, indicating that the virus jumped from an animal reservoir to humans
within the last few months. Identical recent mutations in epidemiologically unlinked
cases support sustained human-to-human transmission.
Criteria for Testing of Suspected Cases
U.S. CDC
Persons meeting the following criteria (clinical features and epidemiologic risk) for
suspected cases of 2019-nCoV will be considered persons under investigation (PUI):
• Fever and symptoms of lower respiratory illness (e.g., cough, shortness of
breath) plus a history of travel to Wuhan or close contact with a PUI for 2019-nCoV
while that person was ill in the past 14 days before symptom onset
• Fever or symptoms of lower respiratory illness (e.g., cough, shortness of
breath) plus close contact with an ill, laboratory-confirmed 2019-nCoV case in the past
14 days before symptom onset
HCWs entering the room with a PUI should use standard precautions, contact
precautions , airborne precautions , and eye protection (e.g., goggles or a face shield).
PUis for 2019-nCoV should be asked to wear a surgical mask as soon as they are
identified and be evaluated in a private room with the door closed, ideally an airborne-
infection isolation room if available.
Prevention
Travelers going to Wuhan should avoid animals (alive or dead), animal markets,
products that come from animals (such as uncooked meat), and contact with ill-
appearing persons. Quality of infection control at medical facilities in Wuhan is
uncertain , and those with minor medical problems should avoid busy medical settings.
NIH-002138
Infection control supplies have been depleted in medical facilities in the smaller cities in
central China; the situation is critical in many areas and resupply is uncertain . Travelers
who develop fever and respiratory symptoms within 14 days of travel to Wuhan should
immediately be isolated, and public health authorities should be alerted.
Employees , Students , Visitors , All Others Coming from Wuhan

Whether asymptomatic individuals infected with 2019-nCoV are infectious to others is
unknown. Influenza viruses can be transmitted 1 to 2 days prior to symptom onset.
SARS-CoV did not transmit until 4 days after symptom onset, which led to its
eradication because all contacts with fever could be promptly identified and isolated .
If 2019-nCoV is similar to SARS-CoV , asymptomatic arrivals from Wuhan should self-

monitor by taking a temperature reading immediately prior to coming into the workplace
or school for 14 days after their last exposure in Wuhan. Arrivals with fever at any time
should self-report to public health authorities (or telephone ahead before presenting to
a hospital) and should wear a mask as soon as possible. A more stringent approach
would require that an employee, student, or visitor-upon arrival to a workplace or
school- be instructed to perform an additional temperature check in the presence of
medical personnel to ensure compliance with local self-monitoring requirements. In
addition , prior to any gathering of~ 2 persons , attendees could be required to perform
additional self-monitoring .
Based on advanced information and employee or visitor medical screening, additional

preventive measures may be required (e.g. , increased ventilation, larger meeting rooms
with more personal space per participant , disinfection of work areas and lavatories, and
provision of alcohol wipes).
The most cautious approach would be for arrivals to stay at home or in a hotel for 14
days after their last possible exposure in China . To date, all known cases exported to
other countries had either visited Wuhan or had contact with an ill person from Wuhan
while in China .
Sent from my magical iPad!
On Jan 29, 2020, at 2:46 PM, Richard Tubb <bg.richard.tubb@gmai l.com>

wrote:
Richard J. Tubb, MD
Brigadier General (retired)
White House Physician Emeritus
NIH-002139
Sent : Thu, 6 Feb 2020 04:03:31 +0000
To: Howard Bauchner
Subjec t: RE:
Study+claiming+new+coronavirus+can +be+transmitted+by+people+without+symptoms+was+flawed
Thanks, Howard. Talk soon.
From: Howard Bauchner <Ho war d.Bauch11er@jamanetwork .org>
Sent: Wednesday , February 5, 2020 6:37 AM
To : Fauci , Anthony (NTTI/NIAID) [E] ------~~
Cc : Conrad , Patric ia (NJH/NIA ID) [E]
-----,,-----,----..,...
Subject: RE: Study+claim ing+new+coronavi rus+can+be+t ran smi tted+by +peopl e+ w ithout+ symptom s+was+ fl awed
The author of our case-series - proof today will send to you - is an ICU do c in Wuhan - trained with Derek Angus -
he has been great - but I have asked him about himself, bis family - we loss track of the personal - wh ich is so
important.
J have had a few "emergencies" like this - at BCH - with Jerry Klein - some infect ious disea se outbreaks; a couple
major car accidents; etc. A lso worked at the Berhorst Clin ic in Gua temala in 1978 (before there was global health)
numerous 5-l 0-15 people emergencies - always end though - for you this is the pandemic that never sto ps giving.
Try to take a break; have a good glass of Claret on me .
HC B

From: Fauci , Anthony (NTH/NIAID) [E] (b) (6)>
Sent : Wedne sday , February 05 , 2020 5:3 1 AM
To: How ard Bauchner <How ard.Bauchner@jamanetwork.org>
Cc: Co nrad , Patric ia (NIH/NIAJD) [E] (b) (6) >
Subject: RE: Study+claiming+new+coronavirus +can+be + transmitted+by +people +without+ symptoms +was +flawed
[Warning External Email)
Howard:
Your outline look s fine. Am hangi ng in there. Feels like my intern ship and first year residency when I was on
eve ry other night and every other weekend, hut actually never left the hospital because the patients were so sick.
Best,
Tony
----- Original Messag e-----

From: Howard Bauchner <Howard .Bauchn er@jamanetwork.org>
To: Fauci, Anthon y (NIH/NIAID) [E] --------, a-s-r,=

CbH
Subject: RE: Study+claiming+new+corona virus +can+be +transmitted+by +people +without+symptoms +was +flawed
L ikely come up tomorrow in our discussio n - not NEJM pape r but just the concept.
Outline if OK with you
NIH-002 140
What's up in China
What's up around the world
What's up in US
And then more specific questions
ls this more like HIN! than MERS
Can we really know mortality risk (denom inator problem).
Incubation period
How "infectious"
News on treatment
Quarantine working
Sound OK?
You surviving - worried a bit about your workload.
HCB

Fro m: Fa uci , Anthony (NTH/NlAID)[E] (b)(6) >
Sent: Wednesday, February 05 , 2020 5:20 AM
To: Howard Bauchner <Howard.Bauchner @jama netwo rk.org>
Subject: RE : Srudy +claimi ng+new+corona virus+can+be+ transm itted+by+people +without +symptoms +was+tlawed
[Warning External Emai l]
The paper was flawed, Embarrassment for NEJM . However, the concept is correct. Spoke in detail to the
Director of the Chinese CDC (confidential) and they are seeing asymptomatic transmission (low level) in China.
From: Howard Bauchner < Howard .Bau chner@jamanetvvork .org>
To: Fauci , Anthony (NlH/NlAID) [E] ------~-= (b)(6) >
Subject: FW: Study +claiming+new+coronavirus+can +be+transmitted +by+people+without+symptoms+was+flawed
Tony
Suspect you saw this. Big problem if true - rushin g to publication - leads to big mistakes.
HCB
------
-----Original Mcssage -----
From: Redberg, Rita --:;;=a<,
(b) (
Sent: Wednesday , February 05 , 2020 5: 13 AM
NIH-002141
To: Howard Bauchner <Howard.Bauchner @jamanetwork.org >; Phil Fontanarosa
<Phil.Fontanarosa @jamanetwork.org >
Subject: Study+claiming+new +coronavirus +can+be+transmitted+by+people+withou t+symptoms+was+flawed
Assume you saw, but.
hltps ://urldcfense .proofi?oint.com/v2/url?u=h ttps-3A www.sc iencemag .org news 2020 02 paper-2Dnon -
2Dsymp tomatic-2Dpatient-2Dtransmitting-2Dcoronaviru s-
2Dwrong& d=DwIF Ag&c=iqcSL Yk:BTKTEV8nJYtdW A&r=Cp YvDJwpp PNcFU Z7y8a6zr8BltWA4gtfR WytiK tF
o VM&m=4xruNHF PsXovM miMLZW-
iD9OzCN hiiGOKmt HhrZcP8c&s=afNfNjVB5x iV3y8BiCPHkwB nAiRXsktAbH l rM9a3j PY&e=
NIH-002142
Sent: Thu, 6 Feb 2020 03:59:46 +0000
To : A uchincloss, Hugh (NIH/ NIAID) [C]
Subject: ----------- (b)(6)
FW: touc hing base abou t Texas Biom ed ical Research Institut e
Please t ake care of this.
From:Larry Schlesinger (b)(6)

-----------
Sent: Wed nesday, February 5, 2020 8:42 AM
To: Auchincl oss, Hugh (NIH/NIAID) [ E] ----------=- (b)'""'(= >; Fauci, Antho ny (NIH/N IAID) [E]
(b)(6)
Subject: to uching base about Texas Bio medical Research Insti t ute
Hi Tony and Hugh.
I know that I am writing to you at a busy time during yet another infectious disease
outbreak that is rapidly evolving . However, I wanted to send you a brief note to update
you about the transformational change going on in the landscape of our free standing
institut e with its new , sharply defined goal to be the global leader in eradicating
infectiou s disease threats in the world . I know that you are familiar with us.
I have been leading the institute since June of 2017 and currently finishing year one of a
10 year board-approved plan of growth in our scientists , educationa l programming and
campus modernization. I believe that you are aware that we house the only private
BSL4 . We also just opened our newest of 5 BSL3 facilities , this newest one being nearly
8000 sq . ft. with capacity for ~100 NHPs , small animals, a complete aerosol suite and a
PET CT . We also house the SNPRC, now under the leadership of Deepak Kaushal
(who replaced Robert Lanford) and with the largest marmoset colony as a result of
restructuring our building facilities (in addition to our other species . 4J
CbH
Please check out our newly designed website: www .txb iomed .org .
The bottom line is that I left university life to lead an organiza tion that is determi ned to
not only discover critical, new fundamental science but also effectively and efficiently
bring it full forward to create portfolios for the FDA through our business model ,
nimbleness, regulated scienc e culture (GLP level), longstanding public and private
partners through contract science (esp. BARDA) , culture and community support .
NIH-002 143
We want to help! Please let us know if and how we can contribute to this outbreak and
undoubtedly others going forward .
I truly appreciate your leadership. The country gets the voice of reason on infectious
disease outbreaks through your public efforts. I enjoyed learning more about this during
my time on council.
Best,
Larry
Larry Schlesinger, MD
Professor
President and CEO
Texas Biomedical Research Institute
8715 W. Military Drive, San Antonio, TX 78227
Email: (b)(6)
Teamwork I Integrity I Diversity I Excellence I Safety
Executive assistant:
(b)(~
(b) (6) Phone
==== (b
~ )~(6)
~ Mobi le
Email: I
--------- (b)(6)j
CONFIDENTIALITYNOTICE:This e-mail and any files and/or attachments transmitted, may contain
privileged and confidential information and is intended solely for the exclusive use of the individual or
entity to whom it is addressed. If you are not the int ended recipient, you are hereby notified that any
review, dissemination, dist ribution or copying of this e-mail and/or attachments is strictly prohibited. If
you have received this e-mail in error, please immediately notify the sender stating that this
transmission was misdirected; return the e-mail to sender; destroy all paper copies and delete all
electronic copies from your system without disclosing its contents.
NIH-002144
Sent : Thu, 6 Feb 2020 03:49:36 +0000
To: Robert Knob ler
Cc: Cassett i, Cristina (NIH/N IAID) [E];Conrad, Patricia (NIH/NIAID) [El
Subjec t: RE: Potential Approa ch to Wuhan Coronavirus
Bob:
Thanks for your no te. It was good to bear from you. I am copying Cr istina Cassetti on this e-mail. Cristina
directs the extramural coronavirus research activities. Perhaps you two can connect to discuss research
opportunities.
Best,
Tony

From: Robert Knobler ______ ""'
(b
")'""'
c=
To: Fauci , Anthony (NIH/N IAJD) [E] --------:,,:,~

Sent: Wednesday , Febru ary 5, 2020 10:55 AM
----,----- (b)(6) >
Su~j e ct: Pote ntial Approach to Wuhan Coronavirus
Dea r Dr. Fauc i,

You likely do not recall meeting me when J was looking at potential fellowships in 1978, however , l never forgot
your enthusiasm. 1 went out to San Diego and worked with Mike Oldstone, between 1979 and 1984.
l did study a mouse coronavirus while there, mouse hepatitis virus (MHV) . l focused on genetic resistance, and
eventually desc ribed a mouse locus for suscept ibility, which coded for the MHV receptor.
Lacking the correct receptor or blocking binding of the virus spike protein to the receptor wi th monoclonal
antibodies blocked infection .
On to the prese nt problem of human coronaviruses . Vaccines will take a long time for the current crisis. The
angiotensin converting enzyme 2 receptor has been identified as the relevant human coronavirus receptor in earlier
studies ofSARS and MERS human corona virns outbreaks. I am writing to suggest the investigat ion of ARBs as
potential block ing agents to eithe r reduce or completely block infection . Perhap s this can be checked . if correct ,
there may still be sufficient untainted supplies of ARBs, such as irbesartan, available, or production can be scaled
up, if this truly is the eve of a pandem ic.
Wishing you success in this endeavor. I am willing to cont ribute in any way l can. Please feel free to contact me by
e-mail or my cell phone.
Talso did do clinical trials whil e with M ike, and then when I joined the neu rology faculty of Jefferson in
Phi ladelphia. I have been out on my own since Decemb er 1998, but I have never lost my interest in this work . For
another tim e, I also have so me novel ideas on how HIV become s AIDS , as well. Ironica lly, the se ideas we re based
upon observati ons I made during my analy sis ofMHV.
All the Best ,
Rober t L Knobler, MD, PhD
(b)(6)
NIH-002 147
Sent : Thu, 6 Feb 2020 03:28:54 +0000
To: Cohen, Elizabeth
Subject : RE:treatment protocols
The Chinese are putting together protoco ls to test certain drugs such as remdesivir.
From: Cohen, Eli zabeth <Elizabeth.Cohen@turner.com>

To: Fauci, Anthony (NIH/NIAID) [E]-------=- (b)
c-c
(= >
Subject : treatment protocols
Hi Tony,
We were wondering if there are any part icular protocols being suggested for treating the Wuhan
coronavirus cases in the US. Are there discussions among the teams caring for these patien ts about the
best approach?
Many thanks.
Best,
Elizabeth
Elizabeth Cohen, MPH

CNN Senior Medical Correspondent
NIH-002 148
Sent : Thu, 6 Feb 2020 02:54:42 +0000
Subject : FW: Corona virus/sepsis treatment
Attachment s: CBR Baum Satz (5) .pdf, Kim Brechbiel Satz.pdf, Kim supplement-01.doc,
REFERENCES Corona Virus .docx
Please handle.
From : stanley satz (b)(6)

To : Fauci, Anthony (NIH/NIAID) [E] _______
------ == _.
(b)(6)>
Subject : Corona virus/sepsis treatment
Dear Dr. Fauci,

(b) (4)
NIH-002150
(b) (4)
Best regar ds,
Stanley Satz, Ph.D.

Chairman and Chief Scientific Officer
Advanced Innovativ e Partners, Inc .
Professor, Florida Atlantic University,

Universi ty of Miami School of Medicine
www .advanced innovativepartners .com

www .bionucleo nics.com
(b)(6)
Confidentiality Notice
This message is being sent by or on behalf of Dr. Satz. It is intended exclusively for the individual or entity to
which it is addressed . This communication may contain information that is proprietary, privileged or confidential
or otherwise legally exempt from disclosure. If you are not the named addressee, you are not authorized to
read, print, retain, copy or disseminate this message or any part of it. If you have received this message in
error, please notify the sender immediately by e-mail and delete all copies of the message.
NIH-002151
Sent: Thu, 6 Feb 2020 02:54:19 +0000
Cc: Haskins, Melinda (NIH/NIAID) [E];Billet, Courtney (NIH/NIAID) [El
Subject: FW: Dr. Levitt summar izes CDC2019-nCoV Committee Report released today 5
Feb 2020
Attachments: M and M Wuhan Virus .pdf
See me about getting someone to prepare a response.
From: Robert Levitt (b)(6b

To: Azar, Alex (OS/10S )
--------
(b)(6)> ; Fauci, Anthony (NIH/NIA ID) [E)
Subject: Dr. Levitt summarizes CDC 2019-nCoV Committee Report released today 5 Feb 2020
(b)(6)
Dear Secretary Azar and Dr. Fauci,
I have read carefully the CDC's report issued this morning on the Wuhan virus (2019-nCoV)
epidemic originating in Wuhan, Hubei Prov ince, PRC. The Report was prepared by CDC's best
Ph.D.s, M.D.s, and D.V.M.s See the pdf attached above for the complete report.
Below I have recorded what I think the most important facts in the report for Secretary Azar
and other federal officials who must stop the spread of 2019-nCoV in the U.S. by identifying all
infected persons and their contacts . I have also added my personal thoughts on how to stop
t he spread of this novel coronavirus and a persona l fear I have communicated to Secretary Azar
in the past:
-- President Trump signed an order preventing entry into the U.S. of any person who has
trave led to mai n land China (PRC). Exceptions in clude U.S. citizens and permanent residents and
t heir famil ies. Thank you Mr. Trump.
-- CDC maintains an office in the PRC. So info rmat ion from Wuhan, Hubei, PRC, shou ld be 'r eal
t ime'.
-- Enhanced screening of persons entering the U.S. is taking place at 18 ports and 5 airport s.
The number of ports and especia lly airports needs to be increased. The Report states that
14 ,000 Chinese enter the U .S. daily. If the 5 airports receive 85% of these Chinese, then 2,1 00
Chinese enter the U .S. daily at other airports without enhanced screening.
-- CDChas developed its own RT-PCRtest to detect 2019-nCoV in respiratory specimens. I have read
case reports where state laboratories have required too much proof of suspected Wuhan virus from
clinicians before perfo rming RT-PCRtesting of specimens . CDC should provide their improved RT-PCR
test to all states and HHS should insure that all states have sufficient equipment and trained
personnel for rapid turn-around time.
NIH-002 152
-- CDChas grown the 2019-nCoV virus. CDC should expedite distribution of the grown virus to
researchers with verified credentials and vetting in a safe and monitored procedure.
-- CDC recommends that persons suspected by clinicians of having 2019-nCoV be placed in a

separate room with a N95 face mask so that they are not in range of other patients. HCW
should wear personal protection: gloves, gown, face shield or N95 mask and goggles.
-- Clinicians have identified 8 of the current 11 patients infected with 2019-nCoV in the U.S.
CDC is doing a terrific job in getting the message out to clinicians and the public.
Sent from Outlook
NIH-002153
Sent: Thu, 6 Feb 2020 00:56:18 +0000
To : Mak, Tak
Cc: Cassetti , Cristina {NIH/NIAID) [E];Conrad, Patricia {NIH/NIAID) [E]
Subject: RE:An Idea
Tak:
Thanks for the note . It likely w ill be more efficient if I refer you to the program
people in my Institute who could go over these data with you and then get me
involved later . The reason that is tha t I am doing 18 hours pe day (seriously) as
part of the White House Task Force and it would very difficult for me to fit in a
meeting to go over data. I have copied Dr. Cristina Cassetti who runs our
coronavirus extramural research program . I will ask her by this e-mail to contact
you to have our people discuss your work with you.
Best regards,
Tony
Director
Phone Cb)
(6)
FAX : (301 496-4409
E-mail : (b)(6)
From:Mak, Tak (b)(6)

-------=-,--=,
Subject: An Idea
-------- (b)(6)
Dear Tony,
It has been a while since we discussed science. (b) (4)

(b) (4)
NIH-002 155
(b)(4)
Best regards, Tak
This e-mail may contain confidential and/or privileged informat ion for the sole use of the intended
recipient.
Any review or distribution by anyone other than the person for whom it was originally intended is
strictly prohibited.
If you have received this e-mai l in error, please contact the sender and delete all copies.
Opinions, conclusions or other information contained in this e-mail may not be that of the organ ization.
If you feel you have received an email from UHN of a commercial nature and would like to be removed
from the sender's mailing list please do one of the following :
(1) Follow any unsubscribe process the sender has included in their email
(2) Where no unsubscribe process has been included, reply to the sender and type "unsubscribe" in the
subject line. If you require additional information please go to our UHN Newsletters and Mailing Lists
page.
Please note that we are unable to automatically unsubscribe individuals from all UHN mailing lists.
NIH-002156
Sent: Thu, 6 Feb 2020 00:00:36 +0000
To : Jeremy Farrar;Collins, Francis (NIH/OD) [El
Cc: Josie Golding;Tabak, Lawrence (NIH/OD) [El
Subject : RE: Prevalence of infect ion and stage of the epidemic in Wuhan
Jeremy:
I left out an important name for the coro naviru s evolution working group.
Please include her: Pardis Sabeti at the Broad Institute of MIT and Harvard
Thanks,
Tony
Director
Phone: (b)(6)
FAX : (301 496-4409
E-mail Cb)(6)

To: Jeremy Farrar
Cc:Josie Golding (b)( >; Tabak, Lawrence (NIH/OD) (E]
-------
(b)(6)>; Collins, Francis (NIH/OD) [E] (b)(6)
(b)(6)
Subject: RE: Prevalence of infection and stage of the epidemic in Wuhan
Jeremy:
Thanks for the note. Looks like things are moving along with WHO. I will list below a
number of names for potential members of the working group to examine the evolutionary origin
of the 2019-nCoV in addition to the individuals who were on the call with us last Saturday:
Harold Vannus - Weill Cornell Medical Center - New York City

Feng Zhang - MIT (CRISPR expe11)
Joseph DeRisi- Chan Zuckerberg (CZ) BioHub (he's paying close attention to the Wuhan
strain vs other bat viruses and the SARS virus)
NIH-002157
Don Ganem - University of California at San Francisco (UCSF) and the CZ BioHub (knows
more about hepadnaviru ses but an outstanding clinical and basic viro logist)
John Coffin - Tufts and National Cancer Institute , NIH (worked out the confusion over the
alleged Chronic Fat igue Syndrome retrovirus that proved to be a xenotropic MLV)
Eugene Koonin - NCBI/National Libreary of Medicine , NIH;
ht1ps://www.ncbi .nlm .nih.gov/research/groups/koon in/)
Wayne Hendrickson - Columbia University and the New York Structura l Biology Center
Gary Nabel - Sano:fi (Boston)
Best regards,
Tony
Director
Phone : (b)(6)
FAX : (301 496-4409
E-mail : (b)(6)
From: Jeremy Farrar (b)(6)

Sen t: Wednesday, February 5, 2020 6:21 AM
To: Fauci, Anthony (NIH/NIAID) [E] -------= (b-:-
)(-==
6); Collins, Francis (NIH/OD) [E]
(b)(6)>
Cc: Josie Golding (b)(6)
Subject : Re: Prevalence of infection and stage of the epidemic in Wuhan
Francis and Tony
Couple of things:
• I spoke again with WHO this morning. I believe they have listened and acted. Let me know if
you agree
o At the WHO meeting next week they will set up the Group who will "look at the origins
and evolution of 2019n-CoV"
o They have asked for names to sit on that Group - please do send any names
NIH-002 158
o We can have a call this week with a core group of that to frame the work of the Group
includ ing - if you could join?
o I think this puts it under the umbrella of WHO, with action this week and into next
o With names to be put forward into the Group from us and pressure on this group from
your and our teams next wee k.
• The team will update the draft today and I will forward immediate ly -they will add further
comments on the glycans
Does that sound reasonable to you?
Jeremy
From: "Fauci, Anthony (NIH/NIAID) [E]"

Date : Tuesday, 4 February 2020 at 13:18 --------- (b)(6)
(b)(6)
To: Francis Collins CbH6)>, Jeremy Farrar
-----------
Subject: RE:Prevalence of infect io n and stage of the epidemic in Wuhan
?7 (b) (4)
Director
Bu ilding 31, Room 7A-03
Phone : (b)(6)
E-mail ________
FAX: (301) 496-4409
.. (b)(6)
From : Collins, Francis (NIH/OD) [E] (b)(6)

To: Jeremy Farrar (b)(6)
Subject: RE:Prevalence of inf ection and stage of the epidemic in Wuhan
Yes,
--------------------------------- (b) (4)
Francis
NIH-002159
From : Jeremy Farrar (b)(6)
-----~~ (b)(6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b)(6)>
Subject : Re: Prevalence of infection and stage of the epidemic in Wuhan
(b) (4)
On 4 Feb 2020, at 10:58, Collins, Francis (NIH/OD) [El

------- (bH > wrote:
Very thoughtful analysis. (b)(4)

(b) (4)
Francis

To: Fauci, Anthony (NIH/NIAID) [El --------=-<-=Collins, Francis (NIH/OD) [E)
(b)(6J>;
(b)(6)
Subject : FW: Prevalence of infection and stage of the epidemic in Wuhan
Pleasetreat in confidence - a very rough first draft from Eddie and team - they will send
on the edited , cleaner version later .
Pushing WHO again today
From: Edward Holmes (b)(6J>

Date: Tuesday, 4 February 2020 at 06 :33
To: Jeremy Farrar (b)(6J>
Subject: Re: Prevalence of infection and stage of the epidemic in Wuhan
Here's our summary so far . Will be edited further.
It's fu ndamental science and completely neutral as written. Did not mention other
anomalies as this will make us look like loons. As it stands it is excellent basic science I
think, which is a service in itself.
NIH-002160
Will finish as soon as we can.
PROFESSOREDWARDC. HOLMES FAA FRS

ARC AustralianLaureate Fellow
THE UNIVERSITY OF SYDNEY

Marie Bashir Institutefor Infectious Diseases & Biosecurity,
School of Life & Environmental Sciences and School of Medical Sciences,
The University of Sydney I Sydney I NSW 120061Australia
(b)(6)
(b)(
NIH-002161
Sent: Wed, 5 Feb 2020 20:52:29 +0000
Subject: FW: note to Patty -- and Tony Fauci
Let us discuss. Steve is a good guy, but I do not want to kill myse lf trying to do
too many thingsdat the same time .
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail Cb) (6)

--------- (b)(6)>
Subject: FW: note to Patty-- and Tony Fauci
Patricia L. Conrad
(b)(6)
301-496-4409 fax
Disclaime r:
The information in this e-mail and any of its attachmen ts is confidential and may contain sensitive info rma tion. It shOuld not be used
NIH-002164
From: Steve Clemons <sclemons@t hehill .com>

-----------------~=
To: Conrad, Patricia (NIH/NIAID) [E)________________ Cb
_H_6)
Subject : note to Patty -- and Tony Fauci
Greetings Patty and Tony -- I see you on TV constantly guiding us through the terrain on our
preparedness fo r outbreaks such as what we have seen in China. I want to see if I can add one more
request to your pile to think about.. ..and I am trying to see if what I am suggesting might work right
before your Aspen talk next Tuesday at noon.
In addit ion to my great role at The Hill, I am host of a new show called "The Bottom Line" on Al Jazeera
English that runs four times a week on thei r global network and is garnering between 100k-200k views a
week on YouTube in the US. The show is doing really well and is a 24 minute panel discussion of three
experts on a single topic that I facilitate. I would love to have you, Tony, be the anchor commentator on
what we should do not only on the coronavirus but in general on the infrastructure of pandemic
preparedness in the country -- sort of a shorter form of that great PBSshow you did called Invisible
Killers.
We would want to tape in our studio at 21st and M Streets NW from 11:00 am - 11:30 am (we don' t go
over), or I could move it 15 to 30 minutes earlier if you like next Tuesday, 11 February. I know you have
t o be at Aspen at noon {I was invited too) -- so I could take yo u if you like.
I realize that this may be too much. -- but in these times, I t hink it's important to get smart commentary
and analysis out there -- and I think I can add a couple hundred thousand eyeballs and ears to the
millions you are already reaching. The producers are also able to provide car and driver (b)( 4)
(b) (4)
Hope this might work my frie nd . I may send a short form of this to your cell phone.
Call me if you want to chat, eit her of you, at

----- (b) (6).
a II best, STEVE
Steve Clemons
Editor at Large, The Hill
1625 K Street NW, Suite 900
Tel: .,.1.202.628.8500
Cell: (6)
Email: SClemons@TheHill.com
TheHlll.com
Follow me on Twitter @SCCl emons
NIH-002165
From: (b)(6)
Sent: Wed, 5 Feb 2020 10:33:15 -0500

Subject: Fwd: NTV Broadcasting Interview Request
FYI
From: Cecpep6eKOB
Xa,1l)
Ku-MypaTKapaxaHOBHq
<HSeferbekov@ntv.ru>
Date: Fehmary 5, 2020 at I0:21: 15 AM EST
To: "Fauci, Anthony (NIH /NIA ID) [E]" -------~= CbH6l
>
Subject: NTV Broadcasting Interview Request
Mr . Fauci, my name is Murat, I am a producer of "Week Summary" for NTV Broadcasting

company .
We would like to film a brief interview with you about coronavirus, and different hypotheses
about its appearance . We want to solve the problem with mass disinformation about this
virus, and need a professional opinion.
Will it be possible to do th is at 6th , or 7 t h of February?
Best regards,
Seferbekov Murat
NTV Broadcasting Company
NIH-002170
From : Fauci, Anthony (NIH/NIAI0) [E)
Sent : Wed, 5 Feb 2020 14:36:13 +0000
Subj ect : FW: Interview request by BBCChinese
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail (b) (6)
From: Tsung-Hsien Lee <zach.lee@bbc.co.uk>

-------""="""-:-=
---------
Subject : Interview request by BBCChinese
(b)(6)
Dear Dr Anthony s Fauci,
This is Zachary from BBCChinese.
I am now writing a piece regarding the treatment of people in isolation or quarantine over coronavirus
in different countries .
Most of the countries told the pub lic where the people evacuated from Wuhan reside for quara ntine
and some drew local's protests . They expressed concern over close vicin ity and some even went to
protest in these places.
Others like Taiwan, the authority decided to keep the quarantine locat ion confidential. The reason is to
avoid unnecessary worr isome and let people rest wel l.
I would like to have an interview with you by e-mail or Skype phone with you to give some insights or
comments on this issue.
If you could be quoted, the questions are as below
1. Why does the government t ell the public the quarantine location? Is it necessary? Or why not?
NIH-002171
2. Many residents protested because they don't want the quarantine Center for Coronavirus in their
neighborhood . Do they need to worry about it?
3. Wh at is your suggestion regarding th e location of quarantine those people from Wuhan. And wh at
is essenti al for Quarantin e Center for Coronaviru s?
Thank you very much for your time .

Zachary Lee
BBC Chinese
NIH-002172
Sent : Sun, 1 Mar 2020 01:17:02 +0000
To: Harper, Jill (NIH/N IAID) [E]
Subject : RE:Approps TA: DOE Reimbu rsement for Coronavirus Super Computing
(b) (5)
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Harper, Jill (NIH/NIAID) [E]

---------
(b)(6)
To: Fauci, Anthony (NIH/NIAID) [E] ------ -==--

(b)(6J>
Cc: Haskins, Me linda {NIH/NIAID) [E]
"":":======~~ ~
---------- (b)(
Subject : Re: Approps TA: DOE Reimbursement for Coronav irus Super Computing
Tony ,
(b) (5)
Thanks,
Jill
From: "Harper, Jill (NIH/NIAID) [E)"

---------
Date: Friday, February 28, 2020 at 5:33:38 PM
(b)(6)
NIH-001 137
To: "Fauci, Anthony (NIH/NIA ID) [El" _______ _.
(b) (6)>
Subject: Fwd: Approps TA: DOE Reimbursement for Coronavirus Super Computing
Tony, I will call you about this in a minute
From: "Haskins, Melinda (NIH/NIAID) [E]" (b)(6)

Date : Friday, February 28, 2020 at 5:24:43 PM
To: "Mitchell, Michelle (NIH/OD) [El" -------- -:a.-r=
(b)(6)>
Cc: "NIAID OCGRLeg" <NIAIDOCGRLeg@mail.nih.gov>, "LaMontagne, Karen (NIH/OD) [El"
(b)(6) "Harper, Jill (NIH/NIAID) [El" (b)(6), "Johnson, Mart in
-~--:---"""."""'---::====--_.:...__:__~=
S. (NIH/NIAID) [E]" (b)(6) "Billet, Courtney (NIH/NIA ID) [E)"
CbH6),"Shapiro, Neil (NIH/OD) [El" CbH
--------
Subject : Re: Approps TA: (b)(S)
(b) (5)
Sent from my iPhone
On Feb 28, 2020, at 5:17 PM, Mitchell, Michelle (NIH/OD) [El

wrote: ---------- (b)( >
Hi Melinda,
Would you let me know what you all think of this language?
Thanks.
MM
From: Friedel, Laura (Appropriations) (b)( >

Sent: Friday, February 28, 2020 5:13 PM ------------
To: Haskins, Melinda (NIH/NIA ID) [E] -------~= (b)(6) >; Mitchell, Michelle
(NIH/OD) (E] (b)(6)
Subject : RE: DOE Reimbu rsement for Coronavirus Super Computing
Any progress on this Michelle? Here is language that I'm thinking of.
For an additionalamount for "National Institute of Allergy and Infectious

Di seases", to prevent, prepare for, and respond to SARS-CoV-2, a v irus sb·ain
mutat ing therefrom ("coronavirus"), or other emerging or reemerging infect ious
disease threa ts, domestically or internationally , $xxx,0O0,0O0, to remain avai lable
NIH-001138
until September 30, 2024: [Provided.That up to $99.500.000 of such amount s may
be tran sferr ed to the D epai1rnent of Energy to provide sup po1t an d acc ess to
scient ific user fac ilities , includin g equ ipm ent, ena blin g techn olog ies, and personne l
ass ocia ted w ith the opernt ions of those scienti fic user fac ilities:]
Laura Friedel
Majority Clerk
Committee on Appropriations
Subcommittee on Labor, HHS and Education
136 Dirksen Senate Office Building
Washington, DC20510
(b)(6)
From : Friedel, Laura (Appropriations)

To: Haskins, Melinda (NIH/NIA ID) [E]--------=- Cb
""'
H""'>; Michelle Mitchell
(b)(6)
Subje ct: DOE Reimbursement for Coronavirus Super Computing
Hi,
Dept. of Energy is looking for $99.5 mi llion. They are concerned that NIH wil l use their
super computers for coronavirus (which NIH doesn't pay for) and displace paying
customers. What is the expectation that NIH will need to use DOEsuper computers? We
would include addit ional funds (please make sure TF knows I would not take his funds and
give to DOE), but this seems extremely high to me and I was trying to understand the need
from your perspective for these super computers . Happy to jump on the phone if that is
easier, but need this as fast as you can get it to me please- within the next hour or so.
Language is below . Thank you !
Sec._. (a) Funds appropriated in this title may be made available to

restore amounts , either directly or through reimbursement , for obligations incurred
by agencies of the Department of Health and Hum an Services for the purpo ses
provided herein pr ior to the date of enactment of this Act. This subsection shall not
apply to obligations incurred by the Infectious Diseases Rapid Response Reserve
Fund .
(b) Funds appropriated in this title [may /shall] be used when [awarding /to
aw ard] grants and cooperative agreements in fiscal yea r 2020 to reimburse State or
local costs incurred for the purposes provided herein after January 20, 2020 , and
prior to the issuance of such awards.
[(c) Funds appropriated in this title shall be transferred to other federal

agenc ies for costs related to medical screening for coronavirus including any costs
NIH-001 139
incurred through a grant , coopera tive agreement, other transaction, or contract and,
once transferred, may be used to reimbur se obligation s incurred for such purpo ses
prior to enactme nt of thi s Act.]
(d) U_pto $99,500,000 of the funds a ro~riated in th is title may be

transferred to the Depa rtment of Energy to_provide su1;mortand access to
sc ient ific user facilit ies, includin g e uipm ent, enabling technologies, and
personnel associated with the o erations of those scientific user facilities.
(e) If any funds have been reprogrammed or trans ferred from an

appropriation , as described in the notification submitt ed by the Secretary to the
Committees on Appropr ia tion s of the Hou se of Repr ese ntatives and the Senate on
February 2, 2020, prior to th e dat e of enactment of this Ac t, such amounts shall be
repro grammed or transferred back to that appropriation with in 45 days of the date of
enactment of this Act.
Laura Friedel
Maj ority Clerk
Committee on Appropriations
Subcommittee on Labor, HHS and Education
136 Dirksen Senate Office Building
(b)(6)
NIH-001 140
Sent: Thu, 13 Feb 2020 22:36:17 +0000
To: Messonnier, Nancy (CDC/DDID/NCIRD/0D)
Subject: RE: NAS
Nancy:
The official USGgroup will be convened by NAS. Bob Kadlec is the person with
di rect knowledge of that. In addition, there is an ad hoc group informally led by
Jeremy Farrar of Wellcome Trust. This group has about 15 people, all of whom
are highly respected scientists, mostly evolutionary biologists who are convening
by e-mail and conference calls (I have been on 2 of these calls since Jeremy
invited me) to look at all of the bat, pangolin and human coronavirus sequences
to try and determine the evolutionary origin. This is not my area of expertise and
so I have backed off and am leaving it all to Jeremy.
Best,
Tony
Director
Phone: (b) (6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Messonnier, Nancy (CDC/DDID/NCIRD/0D) (b)( >

------
To: Fauci, Anthony (NIH/NIAID) [E) ..-.-,=
(b)(6)>
Subject: RE: NAS
Thanks . Is someone conven ing th em?
From: Fauci, Anthony (NIH/NIAID) [E] _______ (b_H_6)

NIH-001920
To: Messonnier, Nancy (CDC/0010/NCIRD/OD) (b)(6)
Subject: RE: NAS
------
Nancy:
It is not a report. It is a letter from NASto OSTP saying that it is important to
bring together a group of experts to study the evolutionary origin the COVID19. I
am attaching it here. I have no idea if it has been widely distributed and so please
keep it internal.
Best,
Tony
Director
Phone Cb)(6)
FAX: (301 496-4409
E-mail (b)(6)
From: Messonnier, Nancy (CDC/00 10/ NCIRD/OD)

Sent: Thursda y, February 13, 2020 1:31 PM
------- (b)(6)

Subject: NAS
-------- (b)(6)
Either you or Bob Kadlec made reference to a NAS report on th e orig ins of SARS- COV2.
--
Thanks.
Nancy
NIH-001921
Sent: Thu, 13 Feb 2020 22:06:37 +0000
To: Messonnier, Nancy (CDC/DDID/NCIRD/OD)
Subject: RE: NAS
Attachments: NASEM Response t o OSTP re Coronavirus_February 6 2020.pdf
Nancy:
It is not a report. It is a letter from NAS to OSTP saying that it is important to
bring together a group of experts to study the evolutionary origin the COVID19. I
am attaching it here. I have no idea if it has been widely distributed and so please
keep it internal.
Best,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Messonnier, Nancy (CDC/0010/NCIRD/OD) CbH >

------~= CbH6)>
Subject: NAS
Either you or Bob Kadlec made reference to a NAS report on the orig ins of SARS - COV2 .
--
Thanks.
Nancy
NIH-001922
Sent: Thu, 6 Feb 202015:21:22 +0000
Cc: Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Routh, Jennifer
(NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E]
Subject : RE: Redfield/Fauci nCoV op-ed
Att achment s: Coronavirus OpEd - Redfield and Fauci - 02-06-2020.docx
Here it is.
Director
Phone : (b) (6)
FAX: (301 496-4409
E-mail : (b)(6)

Cc: Conrad, Patricia (NIH/NIA ID) [El ~=======-~= ; Folkers, Greg (NIH/NIAID) [E)
(NIH/NI A ID) [E]

(b)(6J>; Routh, Jennifer (NIH/NIAID) [E)
(b)(6)>
--------- (b)( ; Stover, Kathy
Subject: FW: Redfield/Fauci nCoV op-ed
Here is the op-ed as cleared by WH .

Any issues with this?
(b) (5)
From: Brennan, Patrick (OS/ASPA) (b)(6)

To: Routh,Jennifer (NIH/NIAID) [E] -------~~ (b)(6); Lepore, Loretta (CDC/0D/OCS)
(b)( 6) ---------
Cc: Fine, Amanda (NIH/OD) [E] (b)(6) Galatas, Kate (CDC/0D/OADC)
(b)(6J>; Bonds, M ichelle E. (CDC/0D/OADC) (b)(6)>; Conrad, Patricia (NIH/NIA ID)
':":
[E::-
)====..,.._ (b)(6J>; Billet, Courtney (NIH/NIAID) [El (b)(6); McGowan,
Robert (Kyle) (CDC/0D/OCS) (b)(6)>; Campbell, Amanda (CDC/0D/OCS) (b)(6);
NIH-002 108
Stecker, Judy (OS/IOS) CbH6J;Murphy, Ryan (OS/ ASPA) CbH6J
Pratt , Michael (OS/ASPA) (b)(6)0akley, Caitlin 8. (OS/ASPA)
(b)(6J>; Hall, Bill (HHS/ASPA) (b)(6)> ; Myles, Renate (NIH/OD) [E]
========,~';5""=-- (b)( 6); Burk low, John (NIH/OD) [E] (b)(6J>; Stover, Kathy (NIH/NIAID)
~[E~l =====~ (b~)(=6)
Attached is a tracked changes version and a clean version of what cleared the WH - they had a few
sentences they would like to be added (wh ich, in the tracekd changes version, I have added comments
to explain who suggested it and in some cases why), but almost all of these edits are non-substantive.
Assuming CDC and NIAID are good with these (feel free to mod ify the addit ions as needed), you all are
good to pitch this as you wish - (b) (5)
From: Rout h, Jenn ifer (NIH/NIAID) [E] (b)(6)

To : Lepore, Loretta (CDC/OD/OCS)
---~~
<j (b)( ~ >
Cc: Fine, Amanda (NIH/OD) [El CbH >; Galatas , Kate (CDC/OD/OADC)
------ (b)(6)>; Brennan, Patr ick (OS/ASPA)

(CDC/OD/OADC) (b)(6J>; Conrad, Patricia (NIH/NIAID) [E]
(b)( >; Bonds, Michelle E.
(b)(6)>; Billet,
Courtney (NIH/NIAID) [El (b)(6)>; McGowan, Robert (Kyle) (CDC/0D/OCS)
CbH >; Campbell, Amanda (CDC/0D/OCS) CbH6J>;Stecker, Judy (OS/IOS)
:::======~=---c-c=
'
--~--~====:::!,_.:,___~~
(OS/ASPA)
(b)(6)>; Murphy, Ryan (OS/ASPA)
(b)(6)>; Oakley, Caitlin B. (OS/ASPA)
(b)(6)>; Pratt, Michae l
CbH6J>; Hall, Bill
(HHS/ ASPA) (b)(6); Myles, Renate (NIH/OD) [E] (b)(6) ; Burklow, John
(NIH/OD) [El (b)(6J; Stover, Kathy (NIH/NIAID) [E] (b)(6)
All - attached is a track changes draft and a clean version with input from NIAID and Dr. Fauci.
Thanks,
Jen
Jennifer Routh [E]

Office of Communi cations and Government Rela tions
National Institute of Allergy and Infectio us Diseases (NIAID)
NIH/HHS
Bethesda, MD 20892
Direct: Cb)(
Disc laim er: The information in this e-mail and any of its attachments is confidential and may conta in sensitive information . It should not be
used by anyone who is not the original intende d recipient. If you have rece ived th is e-mail in error please inform the sender and delete it
from your mailbox or any other storage dev ices . The National Institute or Allergy and Infectious Diseases shall not accept liability for any
statements made that are sender's own and not express ly made on behalf or the NIAID by one of its representatives.
From: Lepore, Loretta (CDC/OD/OCS) ____ Cb

_>_C6)
_
NIH-002109
To: Fine, Amanda (NIH/OD) [E]; Galatas, Kate (CDC/00/0ADC ); Brennan, Patrick (OS/ASPA); Bonds,
Michelle E. (CDC/0D/OADC}; Conrad, Patricia (NIH/NIAID} [El; Billet, Cou rtney (NIH/NIAID} [El
Cc: McGowan, Robert (Kyle) (CDC/OD/OCS); Campbell, Amanda (CDC/0D/OCS}; Stecker, Judy (OS/10S};
Murphy, Ryan (OS/ASPA}; Pratt, Michael (OS/ASPA); Oakley, Caitlin B. (OS/ASPA); Hall, Bill (HHS/ASPA};
Myles, Renate (NIH/OD} [E]
Good afternoon all,
I am forwarding the op-ed drafted by CDC and reviewed by Dr. Redfie ld for review by Dr. Fauci and ou r
co lleagues at NIH.
Please reach out with any quest ions.
Best,
Loretta
From: Fine, Amanda (NIH/OD) [El

Se nt: Friday, January 31, 2020 6:36 PM
To: Galatas, Kate (CDC/0D/OADC}
--------
-----,.=
(b)(6)
(b)(6)>; Brennan, Patrick (OS/ASPA}

(b)(6)>; Bonds, Michelle E. (CDC/0D/OADC} (b)(6)>; Conrad, Patricia
":":
(N":".'
l'."':'
H/":':'
N"."'."
IA
~l-:-
D}:-:[~E]:-::::::===-,:_-~ (b
;a-,-
~=c6); Billet, Courtney (NIH/NIAID} [E] (b)(6)>;
Lepore, Loretta (CDC/00/0CS} (b)(6)>
Cc: McGowan, Robert (Kyle) (CDC/00/0CS) (b)(6) • Campbell, Amanda (CDC/0D/OCS)
(b)(6)>; Stecker, Judy (OS/IOS}.,..;..::::=====:=;. (b""'
)(=6); Murphy, Ryan (OS/ASPA}
7( 0:-:S
:-:
/A-:-S
:-:P:-:-
A-:-
(NIH/OD) [E] ______
(b)(6); Pratt, Michael (OS/ASPA}
} -.======;...._--=
Cb
_>_
C6)
(b"'"(6)>; Hall, BiII ( HHS/ASPA}
) """' _____ (b)(6); Oakley, Caitl in 8.
_,, Myles, Renate
(b) (6)>;
Subject : RE: Redfie ld/Fauci nCoV op-ed
+ Renate Myles for awareness
From: Galatas, Kate (CDC/OD/OADC}

Sent : Friday, January 31, 2020 6:34 PM
------ (b)(6)
To: Brennan, Patrick (OS/ASPA} ------~~ (b)(6) >; Bonds, Michelle E. (CDC/0D/OADC)
1
(b)(6); Fine, Amanda ":'

(~
N :-:-
IH:-:-
/O~ D:-:
} [::-
E-:-
] -:=====...:....__, (b
a-,-
~~<6)>;Conrad, Patricia (NIH/N IAID) [E]
=====:=;..--=-
(CDC/00/0CS}
6)>; Billet, Courtney (NIH/NIA ID) [E]
(b.,.:,
)( =
(b)(6)
------- (b)(6)1
>; Lepore, Loretta
Cc: McGowan, Robert (Kyle) (CDC/0D/OCS) (b)(6)>; Campbell , Amanda (CDC/OD/OCS)

,..:..!::====::::::_:_~
(b)(6)>; Stecker, Judy (OS/10S} (b)(6); M urphy, Ryan (OS/ASPA}
(b)(6)>; Pratt, Michael (OS/ ASPA} (b)(6) Oakley, Caitl in B.
(05/ASPA} (b)(6); Hall, Bill (HHS/ASPA} (b)(6)
Subject : Re: Redfield/Fauc i nCoV op-ed
Hi, Patrick -
We've put t his in motion - once it's cleared thru CDC, we wi ll send back to this group so NIH comms
can move thru with thei r editing/revisions.
NIH-002 110
let me know if that sounds OK. We will likely not have a cleared version out of CDCuntil late Saturday
at the earliest.
Take care,
Kate

Sent : Friday, January 31, 2020 5:31:46 PM
To: Bonds, Michelle E. (CDC/0D/OADC)____ (b = > ; Fine,Amanda (NIH/OD) [El
~ )- (6)
(b)(6)>; Conrad, Patricia (NIH/NIAID) [El < (b)(6)>; Billet , Courtney
(NIH/NIAID) [El (b)( >; Lepore, Loretta (CDC/O0/OCS) (b)(6)>
Cc: McGowan, Robert (Kyle) (CDC/OD/OCS) (b)(6) ; Campbell, Amanda (CDC/OD/OCS)
(b)(6)>; Stecker, Judy (OS/1OS) (b)(6); Mu rphy, Ryan (OS/ASPA)
(b)(6); Pratt, Michael (O5/ASPA) (b)(6); Oakley, Caitlin B.
":"::":--:-'.:-:-::--:-:-::=====::....-~~
(OS/ASPA) (b)(6)>; Hall, Bill (HHS/ASPA) (b)(6)>; Galatas, Kate
(CDC/OD/OADC) (b)( >
Subject : Redfield/Fauci nCoV op-ed
CDC and NIH folks,
Per some discussion after the presser, we'd like Dr. Redfield and Dr. Fauci to pen an op-ed regarding the
reasons/thinking behind the policy announced today. I assume the right building blocks for it would be
the remarks they made today- which I believe you all should have the copy/notes for? I have the
Secretary's, which we'll be send ing around/post ing shortly and I'll make sure to re-up it here so you all
have it.
It would be great to have a draft of this cleared to get to the WH over the weekend. (I anticipate faster -
than-average clearance from them!)
Please let me know how I can help wi th t his.
Best,
Patrick
Patrick Brennan
Depa rtmen t of Health and Hum an Services
Office: (b) (6) I Cell (b) (
Predecisional/deliberative communication
NIH-002111
From: Fauci,Anthony (NIH/NIAI0) [E)
Sent : Tue, 11 Feb 2020 12:54:11 +0000
To : (b)(6)
Subj ect : FW: Following Up If We can Be of Any Assistance
FYI
Directo r
Phone : Cb)(6)
FAX : (301 496-4409
E-mail : (b)(6)
From: Kadlec, Robert (OS/ASPR/1O)

Sent: Tuesday, February 11, 2020 7:28 AM--------- (b)( >
To: CbH
Cc: (b)(6) Elvander, Erika (OS/OGA) Lamana,
CbH6);
Joseph (OS/ASPR/EMMO) Cb)( ; Disbrow, Gary
__ ...;_-=====~:;;;---:------:----:-----:---:--
(OS/ ASPR/BARD A) CbH6); Yeskey, Kevin (OS/ASPR/1O)
;........:....
_ _;_ __ ..:.!:=~"""'.'.'"-~-.--.---
--------- (b)( >; Fauci, Anthony (NIH/NIAID) [E]
Subject: RE: Following Up If We can Be of Any Assistance --------- (b)(6)
Dear Dr. Suzuki we hear d f rom Jun the new s that your Prime M iniste r gave app roval fo r t he
deplo ym ent of o ur team. W e are moving expediti ous ly t o get them th ere to assist. In light of
the situ at io n and t he increasing nu m bers of cases on the ship, CbH5>
(b) (5)
NIH-001970
Again, we are grateful and excited that we have the opportunity to work together.
Kanpail
Bob
From: Kadlec, Robert /OS/ASPR/10)

To: (b)(6)
Cc: (b)(6); Elvander, Erika (OS/OGA) CbH6); Lamana,

Joseph (HHS/ASPR/OEM)
_.......=====::""""'~~:--
Cb)(6)
(b)(6)
Subject: Following Up If We can Be of Any Assistance
Dear Dr. Suzuki -
I hope this finds you I good health and expect that you are deeply involved in the events of
coronavirus in your region . I understand from various communications with the MHLW that is
considering ending the quarantine early and releasing passengers from the Diamond Princess,
especially those who are 80 years of age or older. Given the media reports and public
perception there is pressure to do th is. However, as medical experts, you and I both know that
days 3 - 8 are within the norma l incubation period and these new positives do not likely
represent shipboard transmission. As such, HHS is willing to coordinate U.S. medical experts
who can engage with English language media explaining and reassuring the passengers, crew,
and public.
Regarding support for the quarant ine, ASPRis ready to deploy a team of 3-5 people quickly, and
as many 12 people to Japan to support as suggested in the previous call. If we can assist you
and your team in managing the Americans currently in quarantine please let me know . If there
is other support do let me know and ASPRwill work to assist. As we've talked for the past 18
months about such a scenario, this may not be the one we envisioned, but it is a perfect case as
we can clearly ident ify the Americans, they are in a contained area. Our mutual efforts and
planning have paid unexpected dividends.
I am availab le to discuss via teleconference at your convenience. I am grateful fo r all MHLW

has done to support this complicated response on top of your work supporting repatriation and
domestic monitoring of your own citizens . We are grateful for Dr. Sugihara's herculean
information sharing efforts and the rest of your MHLW team support during this event; it
NIH-001971
validates of the importance of our ongoing liaison program and the long term benefits of our
mutual commitment to each other's public health security
Please remain well and I look forward to see you again soon.
Best wishes and warm regards.
Dr Bob Kadlec
ASPR
NIH-001972
Sent: Mon , 10 Feb 2020 18:43:59 +0000
To : Brennan, Patrick (OS/ASPA)
Cc: Hall, Bill (HHS/ASPA);Conrad, Patricia (N IH/NIAID) [E]
Subject: RE: Draft of email
Attachments : 2 10 20 email - with Fauciedits.docx
Here is the document with my tracked changes. G
Director
Phone : (b)(6)
FAX : (301 496-4409
E-mail : (b) (6)
From: Brennan, Patrick (OS/ASPA)

----------
--------=-c-=
(b)(6)
To: Fauci, Anthony (NIH/NIAID) [E] (b)( >

Cc: Hall, Bill (HHS/ASPA) <Bill.Hall @HHS.GOV>
Subject: Draft of email
Dr. Fauci - below and in the attached is our proposed draft response , and then Cuccinelli's
email text below for context. W e're waiting on a potential detail/point or two from ASPRthat
may help flesh it out a bit but we'll see if we actually need it. Thank you !
<< File : 2 10 20 email.docx >>

Draft HHS response
Fell ow t ask for ce m emb ers,
Thanks for your message, Ken, and I loo k fo rw ard to ou r di scussio n tod ay.
NIH-001994
(b) (5)
Looking forward to discussing more later today.
Ken
To mv fellow task force members

(b) (5)
NIH-001995
(b) (5)
NIH-001996
I look forward to speaking with you all again this afternoon.
Patrick Bre nnan

Director of Speechwrit ing
Depar t ment of Health and Human Services
Off ice : (b)(6) I Cell: (b)(6)
NIH-001997
Sent : Sun, 9 Feb 2020 23:54:27 +0000
To: (b)(6)
Subject : FW: WHO advance team on coronavirus on way to China - Tedros tweet
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Grigsby, Garrett (HHS/OS/OGA) (b)(6)•>

--------=-:-=:-i
(b)( 6) -------- (b)( ; Harrison, Brian (HHS/10S)
Cc: Kerr, Lawrence (HHS/0S/OGA) (b)( ; Elvander, Erika (05/0GA)

(b)( ·>;Zebley, Kyle (HHS/0S/OGA) (b)(6) Redfield, Robert R.
"':'-"--:----:-::====~
(CDC/OD) ".-:=======~=
(b)(6) ; Kadlec, Robert (OS/ASPR/10) (b)(
(FDA/OC) (b)(6)>; Bright, Rick (OS/ASPR/BARDA)
--------- ---------
Subject : RE: WHO advance team on coronavirus on way to China - Tedros tweet
Dr F,
(b)(5)
From: Fauci, Anthony (NIH/N IAID) [E] (b) ~ >

--------
To: Grigsby, Garrett (HHS/OS/OGA)------- .-..
Cb
..,
H=6)>; Harrison, Brian (HHS/105)
(b)(6j>
NIH-0020 14
Cc: Kerr, Lawrence (HHS/0S/OGA) Cb)( >; Elvander, Erika (OS/OGA)
(b)(6);Zebley, Kyle (HHS/0S/OGA) Cb)C >; Redfield, Robert R.
":-:
(C:-:D~C:"':".
/0::"::
D
:"':'
);===='c (b~)(~ >; Kadlec, Robert (OS/ASPR/I0) ~======~~ (b)(6)>;Abram , Anna
(FDA/OC)
--------- (b)(6)>; Bright, Rick (OS/ASPR/BARDA)
Subjec t : RE; WHO advance team on coronavirus on way to China - Tedros tweet -------- (b)(6)
(b)(5)
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
behalf of the NIA ID by one of its representatives.
From: Grigsby, Garrett (HHS/0S/OGA) (b)(6)

To: Harrison, Brian (HHS/IOS) -------~~ (b)(6)
--:-::.::=========!~=
Cc: Kerr, Lawrence (HHS/0S/OGA) CbH6J ; Elvander, Erika (OS/OGA)
(b)(6); Zebley, Kyle (HHS/0S/OGA) CbH6J>; Redfield, Robert R.
(C
~D
:-C
:-/:-::
0:-:::
D-:-
) :.===== (b
=s ~ ; Fauci, Anthony (NIH/N IAID) 7[E
),::;
(6) ::--:
]-.::=====~ (b~
)(=6)>; KadIec, Robert
(OS/ASPR/10) (b)(6)>;Abram, Anna (FDA/OC) (b)(6)>;Bright,
Rick (OS/ASPR ""-:
/ -BA
_R_D_A~)--======~ (b
=)-(6)
~
Subject : FW: WHO advance team on coronavirus on way to China - Tedros tweet
Brian - more clarity from "the horse's mouth" on this advance trip ...see below .
From: Grigsby, Garrett (HHS/OS/OGA)

To: SCHWARTLANDER,Bernhard F. --------=-cc-c=
(b)(6)
Cc: SIMONSON, Stewart (b)(6)>
Subject : RE: WHO advance team on coronavirus on way to China - Tedros tweet
Many thanks, Bernard! I know I'll be asked, so I will pass your email up the
chain ...
NIH-0020 15
Take care and thanks again!
From:SCHWARTLANDER,Bernhard F. (b)(6)
----------
To: Grigsby, Garrett (HHS/OS/OGA)------- -=
(b=
H=6)>
Cc: SIMONSON,Stewart (b)(6)
Subject: Re: WHO advance team on coronavirus on way to China - Tedros tweet
Hi Garrett,
We have th ree people on the way to Beijing who will work with our Chinese counterparts on finalizing
the TOR and composition of the joint WHO - China mission. As you are much aware, the US has given us
a number of names who will be able and wi lling to jo in such a mission. We have received similar
proposals from other countries and will now match the "long list" of experts with the required specific
expertise.
W e are hoping to have more clarity over the coming days and will obviously keep you in the loop. The
overall number will be kept at a level to make sure that the team is fully operational.
With my warmest wishes
Bernhard
Dr Bernhard Schwartlander
Chef de Cabinet
World Health Organization
On 9 Feb 2020, at 23:24, Grigsby, Garrett (HHS/OS/OGA) (b)(6)>

wrote: ---------
Bernard,
Hope you had a good weekend.
I'm reaching out to get more clarity on the WHO experts team issue -
please see article below . I've heard everything from an advance group
of one or two individuals to 15 people discussed in the article. I haven't
heard any word about US people, and I was just with Dr Redfield late
this afternoon and he was in the dark too.
NIH-002016
Any additional information wil l be deeply appreciated.
Thanks!
From: Kerr, Lawrence (HHS/OS/OGA) (b)( >

To: Grigsby, Garrett (HHS/OS/OGA) -------- ==
(b)(6); Zebley, Kyle
(HHS/O5/OGA) (b)(6J>; Elvander, Erika (OS/OGA)
---------- (b)(6); Tracy Carson (b)(6) 1>

Subject : WHO advance team on coronavirus on way to China - Tedros tweet
February 9, 2020 / 4:01 PM/ Updated an hour ago
UPDATE 1-WHO advance team on

coronavirus on way to China - Tedros
tweet
Stephanie Nebehay
By Stephanie Nebehay
GENEVA,Feb 9 (Reuters)• An advance team of international experts led by the World
Health Organization (WHO) has left for Beijing to help invest igate China's coronav irus
epidemic, the Geneva-based agency said on Sunday.
WHO director-general Tedros Adhanom Ghebreyesus, who made a trip to Beijing fo r talks
with President Xi Jinping and Chinese ministers in late January, returned with an
agreement on sending an international mission.
But it has taken nearly two weeks to get the government 's green light on its composition,
which was not announced, other than to say that WHO vetera n Dr. Bruce Aylward, a
Canadian epidemiologist and emergencies expert, was heading it.
"I've just been at the airport seeing off members of an advance team for the @WHO-led
#2019nCoV internationa l expert mission to #China, led by Dr Bruce Aylward, veteran of
past public health emergencies," Tedros said in a tweet from Geneva.
Dr. Sylvie Briand, who accompanied Tedros last month and stayed behind for talks with top
Chinese health officials, told Reuters last week that they were discussing a list of experts
with China.
"Because it is a joint mission, they need to be on board, it's not just an int ernational group
going there. We have about 15 people, " said Briand, director of Global Infectious Hazard
Preparedness at WHO .
China raised the death toll from the coronavirus outbreak to 811 on Sunday, passing the
number killed globally by the SARSepidemic, as authorities made plans for millions of
people returning to work after an extended Lunar New Year break .
The virus , which has spread to two dozen countries, has killed some 2% of more than
37,550 cases wor ldwide, with 99 percent of infections in China, WHO figures show.
The WHO declared the outbreak a global emergency on Jan. 30, days after the Chinese
central government imposed a lockdown on 60 million people in Hubei province and its
capital Wuhan, epicentre of the virus that emerged in December in a seafood marke t.
NIH-002017
Tedros said on Saturday that he hoped the team would include experts from the U.S.
Centers for Disease Control (CDC).
"It has to be meaningful on the ground," Lawrence Gostin, professor of global health law at
Georgetown Law, said in an interview in Geneva this week.
Gostin called for a "genuine partnership with transparent flows of information and
accountability for the response", adding that there should be a strong CDC presence.
"CDC has got no peer in terms of its experience and technical expertise in dealing with
international outbreaks," he said.
"But the other benefit is the smart diplomacy, what it could signal is that despite all of our
differences in ideology, trade , politics, that when faced with a common threat to humanity,
we come together as a human community to tackle it, " Gostin said.
Reporting by Stephanie Nebehay; Editing by Pravin Char, Kirsten Donovan
Our Standards:The Thomson Reuters Trust Prin cip les.
NIH-002018
Sent : Fri, 7 Feb 2020 03:55:22 +0000
To: Shapiro , Neil (NIH/OD) [El;Collins, Francis (NIH/OD ) [El;Tabak, Lawrence
{NIH/OD) [El;Johnson, Alfred {NIH/OD) [E];Hallett , Adrienne (NIH/OD) [El
Cc: Shaya, Cecile (NIH/OD) [El
Subject : RE: Coronavirus - HHS Supplemental Table - Close Hold
(b) (5)
From : Shapiro, Neil {NIH/OD) [El (b)(6)

To: Collins, Francis (NIH/OD) [El -----~ =
(b)( >; Tabak, Lawrence (NIH/OD) [El
(b)(6)>; Johnson, Alfred (NIH/OD) [El (b)(6) >; Hallett, Adrienne
"":"----:----:-:-:-::-====::!.....:.--~~
(NIH/OD) [El (b)( ; Fauci, Anthony (NIH/NIA ID) [El (b)(6)
Cc: Shaya, Cecile (NIH/OD) [El (b)(6)
(b) (5)
Neil
From : Collins, Francis (NIH/OD) [El (b)(6)

To: Shapiro, Neil (NIH/OD) [E] (b)(6); Tabak, Lawrence {N IH/OD) [El
(b)(6)>; Johnson, Alfred (NIH/OD) [El (b)(6)>; Hallett, Adrienne
"":"----:-:-:-:-:-:-::.:====:::::..;,-- ~=
(NIH/OD) [El (b)(6)>; Fauci, Anthony {NIH/NIAID) [El (b)(6)
Cc: Shaya, Cecile (NIH/OD) [El (b)(6)>
(b)(S)
FC
From : Shapiro, Neil {NIH/OD) [E]

-------
(b)(6)>
To: Collins, Francis {NIH/OD) [El ------- ------=

(b)(6); Tabak, Lawrence {NIH/OD) [E]
(b)(6)>; Johnson, Alfred (NIH/OD) [E) (b)(6)>; Hallett, Adrienne
"":"----:----:-:-:-::-====::t....:--___:~
(N IH/OD) [E) (b)( Fauci, Anthony (NIH/NIAID) [E] (b)(6)
Cc:Shaya,Ce ...c:-:-
ile- (:-:-
N~IH~/:--::
0-::-
07'"
) [:-::
E-::-.
l ====--..;_ (b
""'
)-:--=-
(6)
Subject : FW: Coronavirus - HHS Supplemental Table - Close Hold

Impo rt ance: High
NIH-002087
ASFRprovided the pdf attachment and the explanation below. They emphasized on the phone too that
this is very close hold . Cb) (5
i
(b) (5)
Neil
From: Cabezas, Miriam (HHS/ASFR)

-----------
To: Kelly, Alison (CDC/OCOO/OFR/OA) ----~~ (b)(6)>;Berger, Sherri (CDC/OCOO/O0)
CbH ; Shapiro, Neil (NIH/OD) [E) Shaya, Cecile (NIH/OD) [E]
CbH6)>;
=====~ 7
Cb~>; Peti llo, Jay (OS/ASP':"'
R/ M-:-F
::-:-
H-:-:
C~) -====~ CbH6J>;
Dubay, Johanna
(OS/ASPR/M FHC) (b)(6)
Cc: Goyle, Suraj (OS/ASFR) (b)(6)>;Falisi, Angela (OS/ASFR) (b) (6)>;
White, RaeShawn (OS/ASFR) CbH6J>; Cormier, Justin (HHS/ASFR)
(b) ( >
Subject: Coronavirus - HHS Supplemental Table - Close Hold
Information in this email is close hold.
Good afternoon -
Attached you w ill find CDC, ASPR, and NIH specific totals that were provided to 0MB last night. We
want to make sure you have awareness of the activities that are identified across these three agencies.
Let us know if you have any questions . This information should not be shared broadly.
Miriam
NIH-002088
Sent : Fri, 7 Feb 2020 03:38:07 +0000
Subject : RE:** Time-Sensitive Clearance** DUE BY 3:30 TODAY- Coronavirus - Minister
Ma of China Response Letter - 00430215
Please t ake care of this on my behalf. Thanks.
From: Marston , Hilary (NIH/NIAID) [E] (b)(6)

To: Harris, Kara (NIH/NIAID) [E]
------~~ (b)( ; Handley, Gray (NIH/NIAID) [E]
< (b)(6J>; Lerner, Andrea {NIH/N IAID) [El (b)(6J> ; Eisinger, Robert
{NIH/NIAID) [E] (b)(6)>; Harper, Jill (NIH/NIA ID) [El CbH >;
McGowan, John J. {NIH/NIAID) [E] (b)( ; Billet, Courtney {NIH/NIAID) [E]
------- CbH >; Auchincloss, Hugh {NIH/N IAID) (E]

Cc: NIAID OCGRCorrespondence <NIAIDOCGRCorrespondence@mail.nih.gov>; Gilles, Sharon
CbH6J>
(NIH/NIAID) [E) (b)(6) Fauci, Anth ony (NIH/N IAID) [E) (b)(6);
Conrad, Patricia (NIH/NIAID) [E) (b)( >
Subject : RE:** Time-Sensitive Clearance** DUE BY 3:30 TODAY- Coronavirus- Minister Ma of China
Response Letter - 00430215
(b)(5)
From: Harris, Kara (NIH/NIAID) [El CbH6)>

To: Handley, Gray (NIH/NIAID) [E]---------=- (b"""
)(=6) Marston, Hilary (NIH/NIAID) [El
(b)(6)>; Lerner, Andrea (NIH/NIAID) [E] (b)(6); Eisinger, Robert
(NIH/NIAID) [E] (b)(6) Harper, Jill (NIH/NIA ID) [El (b)(
McGowan, John J. {NIH/NIAID) [E] < (b)(6) >; Billet, Courtney (NIH/NIAID) [El
(bH >; Auchincloss, Hugh (NIH/N IAID) [E] (b)(6)>
---------
Cc: NIAID OCGRCorresponde nce <NIAIDOCGRCorrespondence@mail.nih.gov>; Gilles, Sharon
NIH-002093
Subject: FW: ** Time-Sensiti ve Clearance** DUE BY3:30 TODAY- Coronavirus - Minister Ma of China
Response Letter - 00430215
Importance: High
All-
Please see the note below from ExecSec. Please provide any comments to NIAID OCGR
Correspondence by 3:30 p.m. Please note - ExecSec is looking for show-stoppingcommentsonly.
Thank you,
Kara
From : Malliou , Ekaterini (OS/10S)

----------
---------=-c-=,
(b)(6)>
To : Stannard, Paula (HHS/IOS) (b)(6); Hoffmann, Lauren (CDC/OD/OCS)

(b)(6)>; Clark, Cynthia K. (CDC/OD/OCS) (b)(6); Stimson, Brian (HHS/OGC)
(b)(6) Chang, William {HHS/OGC) (b)(6)>; Barry, Daniel J
--~-.-:::====:!.--
(HHS/OGC)"'~~-.-:::====
..;;.:.
~ >.:..;_sh_u.:.,y;,.,B~ryan (OS/ASPR/10)
(b=)(=6)::.. (b)(6); Bird,
Catherine (05/0GC) (b)(6) OSOGC-10<Contro1Desk.OGCl0@hhs .gov>; ASPRExec
Sec (OS/ASPR)<ASPRExecSec@hhs .gov>
Cc: Steele, Danielle (HHS/IOS) (b)(6); Agnew, Ann (HHS/10S)
(b)(6) >; Hawk
~i-ns-,-:-
Ja
-m- ar- (:-:-
H:-:-
H-:-:
S-:
/0".:"":"'.
S):-.:==:;.....::;._...:,__...:...~ (6); Horska, Katerina
(b:.,.
) .,-=,
(HHS/IOS) (b)(6)>; Varnado, Martina (FDA/OC) (b)(6);
Zebley, Kyle (HHS/0S/OGA)
-------- (b)(6)>; Allen-Gifford, Patrice (NIH/OD) [E] (b)(6)
Subject : Clearance Due 6pm (2/6): **Time -Sensitive** Coronavirus - Min iste r Ma of China Response
Lette r - 004302 15
Please find attached for your clearance a response to Minister Ma's letter to the Secretary,and a
recent conversationwith him. (b) (5)
Please note that the Secretary has already reviewed and edited the attached response
We appreciateyour expedited review and clearance by 6pm today, 2/6.
Thank you,
Kat
****************************************
Ekaterini (Kat) Malliou , DrPH, MPH
Senior Policy Coordinator
[mmediate Office of the Secretary, U.S. Department of Health and Human Serv ices
200 Independence Ave SW, Suite 619H, Washington, DC 20201, USA
Tel: (b)(6) Cell : (b)( , Email: (b)(6)
NIH-002094
From: (b)(6)
Sent : Thu, 6 Feb 2020 18:56:07 -0500
Subject: Re: FROM CAITLIN OAKLEY-Atlantic reporter responded
Please schedule call for tomorrow.
On Feb 6, 2020, at 4:17 PM, Conrad, Patricia (NIH/N IAID ) [E]

wrote:
---------- (b)(6)
See below -the reporter responded to Caitlyn - not Courtney- he can

speak today or tomo rrow. Do you want to call tonight or have me
schedule for tomorrow?
Tomorrow is quite full but can make it happen ...let me know
Yes, happy to talk today or tomorrow.

I'm at (b) (6)
If D r. Fauc i is avai lable, that would be great.
Be st,
Peter Nicholas
Patr icia L. Conrad

National Institute of Allergy and Inf ect ious Diseases
(b)(6)
301-496-4409 fax
Disclaimer:
The informationin this e-mail and any of its attachmentsis confidential and may contain sensitiveinformation. It
NIH-002101
shou ld not be used by anyone who is not the origina l intended recipient. If you have rece ived this e-ma il in error
please inform the sender and delete it from your mailbox or any other storage devioes. National Institute of Allergy
and Infectious Diseases (NIAID ) shall not accept liability for any statement made that are sender's own and not
express ly made on behalf of the NIAID by one of its representatives .
From: Oakley, Caitlin B. (OS/ASPA) ~

---------- (b)(6)>
To : Billet, Courtney (NIH/N IAID) [El
[El (b) (6)
_______
------ ~= (b)(_, >; Conrad, Patricia (NIH/NIAID)
Subject: FW: follow up re: Coronavirus story
Caitlin B. Oakley
Deputy Assis tant Secretary, Nat ional Spokesperson
U.S. Departmentof Health and Human Services
(b)(6))
From: Peter Nicholas <pnicho las@t heat lant ic.com >

To: Oakley, Caitlin B. {OS/ASPA) --------
-----------=---= (bH >
Subject: Re: follow up re: Coronavirus story
Hi,
Yes, happy to talk today or tomorrow.

I'm at (b)(6). If Dr. Fauci is available, that would be great.
Best,
Peter
On Thu, Feb 6, 2020 at 11:09 AM Oakley, Caitlin B. (OS/ASPA)

(b)(6) wrote:
-----------
Fo11owing up on this .... does today work?
And I know Dr. Fauci's office is trying to get in contact as well. He's a member
of the taskforce. Can we make this happen?
Caitlin B. Oakley
Deputy Assistant Secretary, National Spokesperson
(b)(6)
NIH-002102
From: Oakley, Caitlin B. (OS/ASPA)
Sent: Wednesday , February 5, 2020 3:55 PM
To: pnicho las@theat lant ic.com
Cc: Hall, Bill (HHS/ASPA)_____ Cb
_ )_(6)
_>
Subject: follow up re: Coronavirus story
Pete r- Thanks for the chat yesterday. Have a few folks that I'd like to get you on
the phone with about your p iece. Wou ld you have time to chat with Bi ll Ha ll and I
later today ?
And when is your deadline for the piece?
Talk soon,
Caitlin B. Oakley
Deputy Assistant Secretary, Natio nal Spokesper son
U.S. Departmentof Health and Human Services
(b)(
NIH-002103
Sent: Thu, 6 Feb 202015:21:22 +0000
Cc: Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Routh, Jennifer
(NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E]
Att achment s: Coronavirus OpEd - Redfield and Fauci - 02-06-2020.docx
Here it is.
Director
Phone : (b) (6)
FAX: (301 496-4409
E-mail : (b)(6)

Cc: Conrad, Patricia (NIH/NIA ID) [El ~=======-~= ; Folkers, Greg (NIH/NIAID) [E)
(NIH/NI A ID) [E]

(b)(6J>; Routh, Jennifer (NIH/NIAID) [E)
(b)(6)>
--------- (b)( ; Stover, Kathy
Subject: FW: Redfield/Fauci nCoV op-ed
Here is the op-ed as cleared by WH .

Any issues with this?
(b) (5)

To: Routh,Jennifer (NIH/NIAID) [E] -------~~ (b)(6); Lepore, Loretta (CDC/0D/OCS)
(b)( 6) ---------
Cc: Fine, Amanda (NIH/OD) [E] (b)(6) Galatas, Kate (CDC/0D/OADC)
(b)(6J>; Bonds, M ichelle E. (CDC/0D/OADC) (b)(6)>; Conrad, Patricia (NIH/NIA ID)
':":
[E::-
)====..,.._ (b)(6J>; Billet, Courtney (NIH/NIAID) [El (b)(6); McGowan,
Robert (Kyle) (CDC/0D/OCS) (b)(6)>; Campbell, Amanda (CDC/0D/OCS) (b)(6);
NIH-002 108
Stecker, Judy (OS/IOS) CbH6J;Murphy, Ryan (OS/ ASPA) CbH6J
Pratt , Michael (OS/ASPA) (b)(6)0akley, Caitlin 8. (OS/ASPA)
(b)(6J>; Hall, Bill (HHS/ASPA) (b)(6)> ; Myles, Renate (NIH/OD) [E]
========,~';5""=-- (b)( 6); Burk low, John (NIH/OD) [E] (b)(6J>; Stover, Kathy (NIH/NIAID)
~[E~l =====~ (b~)(=6)
Attached is a tracked changes version and a clean version of what cleared the WH - they had a few
sentences they would like to be added (wh ich, in the tracekd changes version, I have added comments
to explain who suggested it and in some cases why), but almost all of these edits are non-substantive.
Assuming CDC and NIAID are good with these (feel free to mod ify the addit ions as needed), you all are
good to pitch this as you wish - (b) (5)
From: Rout h, Jenn ifer (NIH/NIAID) [E] (b)(6)

To : Lepore, Loretta (CDC/OD/OCS)
---~~
<j (b)( ~ >
Cc: Fine, Amanda (NIH/OD) [El CbH >; Galatas , Kate (CDC/OD/OADC)
------ (b)(6)>; Brennan, Patr ick (OS/ASPA)

(CDC/OD/OADC) (b)(6J>; Conrad, Patricia (NIH/NIAID) [E]
(b)( >; Bonds, Michelle E.
(b)(6)>; Billet,
Courtney (NIH/NIAID) [El (b)(6)>; McGowan, Robert (Kyle) (CDC/0D/OCS)
CbH >; Campbell, Amanda (CDC/0D/OCS) CbH6J>;Stecker, Judy (OS/IOS)
:::======~=---c-c=
'
--~--~====:::!,_.:,___~~
(OS/ASPA)
(b)(6)>; Murphy, Ryan (OS/ASPA)
(b)(6)>; Oakley, Caitlin B. (OS/ASPA)
(b)(6)>; Pratt, Michae l
CbH6J>; Hall, Bill
(HHS/ ASPA) (b)(6); Myles, Renate (NIH/OD) [E] (b)(6) ; Burklow, John
(NIH/OD) [El (b)(6J; Stover, Kathy (NIH/NIAID) [E] (b)(6)
All - attached is a track changes draft and a clean version with input from NIAID and Dr. Fauci.
Thanks,
Jen
Jennifer Routh [E]

Office of Communi cations and Government Rela tions
National Institute of Allergy and Infectio us Diseases (NIAID)
NIH/HHS
Bethesda, MD 20892
Direct: Cb)(
Disc laim er: The information in this e-mail and any of its attachments is confidential and may conta in sensitive information . It should not be
used by anyone who is not the original intende d recipient. If you have rece ived th is e-mail in error please inform the sender and delete it
from your mailbox or any other storage dev ices . The National Institute or Allergy and Infectious Diseases shall not accept liability for any
statements made that are sender's own and not express ly made on behalf or the NIAID by one of its representatives.
From: Lepore, Loretta (CDC/OD/OCS) ____ Cb

_>_C6)
_
NIH-002109
To: Fine, Amanda (NIH/OD) [E]; Galatas, Kate (CDC/00/0ADC ); Brennan, Patrick (OS/ASPA); Bonds,
Michelle E. (CDC/0D/OADC}; Conrad, Patricia (NIH/NIAID} [El; Billet, Cou rtney (NIH/NIAID} [El
Cc: McGowan, Robert (Kyle) (CDC/OD/OCS); Campbell, Amanda (CDC/0D/OCS}; Stecker, Judy (OS/10S};
Murphy, Ryan (OS/ASPA}; Pratt, Michael (OS/ASPA); Oakley, Caitlin B. (OS/ASPA); Hall, Bill (HHS/ASPA};
Myles, Renate (NIH/OD} [E]
Good afternoon all,
I am forwarding the op-ed drafted by CDC and reviewed by Dr. Redfie ld for review by Dr. Fauci and ou r
co lleagues at NIH.
Please reach out with any quest ions.
Best,
Loretta
From: Fine, Amanda (NIH/OD) [El

To: Galatas, Kate (CDC/0D/OADC}
--------
-----,.=
(b)(6)
(b)(6)>; Brennan, Patrick (OS/ASPA}

(b)(6)>; Bonds, Michelle E. (CDC/0D/OADC} (b)(6)>; Conrad, Patricia
":":
(N":".'
l'."':'
H/":':'
N"."'."
IA
~l-:-
D}:-:[~E]:-::::::===-,:_-~ (b
;a-,-
~=c6); Billet, Courtney (NIH/NIAID} [E] (b)(6)>;
Lepore, Loretta (CDC/00/0CS} (b)(6)>
Cc: McGowan, Robert (Kyle) (CDC/00/0CS) (b)(6) • Campbell, Amanda (CDC/0D/OCS)
(b)(6)>; Stecker, Judy (OS/IOS}.,..;..::::=====:=;. (b""'
)(=6); Murphy, Ryan (OS/ASPA}
7( 0:-:S
:-:
/A-:-S
:-:P:-:-
A-:-
(NIH/OD) [E] ______
(b)(6); Pratt, Michael (OS/ASPA}
} -.======;...._--=
Cb
_>_
C6)
(b"'"(6)>; Hall, BiII ( HHS/ASPA}
) """' _____ (b)(6); Oakley, Caitl in 8.
_,, Myles, Renate
(b) (6)>;
Subject : RE: Redfie ld/Fauci nCoV op-ed
+ Renate Myles for awareness
From: Galatas, Kate (CDC/OD/OADC}

------ (b)(6)
To: Brennan, Patrick (OS/ASPA} ------~~ (b)(6) >; Bonds, Michelle E. (CDC/0D/OADC)
1
(b)(6); Fine, Amanda ":'

(~
N :-:-
IH:-:-
/O~ D:-:
} [::-
E-:-
] -:=====...:....__, (b
a-,-
~~<6)>;Conrad, Patricia (NIH/N IAID) [E]
=====:=;..--=-
(CDC/00/0CS}
6)>; Billet, Courtney (NIH/NIA ID) [E]
(b.,.:,
)( =
(b)(6)
------- (b)(6)1
>; Lepore, Loretta
Cc: McGowan, Robert (Kyle) (CDC/0D/OCS) (b)(6)>; Campbell , Amanda (CDC/OD/OCS)

,..:..!::====::::::_:_~
(b)(6)>; Stecker, Judy (OS/10S} (b)(6); M urphy, Ryan (OS/ASPA}
(b)(6)>; Pratt, Michael (OS/ ASPA} (b)(6) Oakley, Caitl in B.
(05/ASPA} (b)(6); Hall, Bill (HHS/ASPA} (b)(6)
Subject : Re: Redfield/Fauc i nCoV op-ed
Hi, Patrick -
We've put t his in motion - once it's cleared thru CDC, we wi ll send back to this group so NIH comms
can move thru with thei r editing/revisions.
NIH-002 110
let me know if that sounds OK. We will likely not have a cleared version out of CDCuntil late Saturday
at the earliest.
Take care,
Kate

Sent : Friday, January 31, 2020 5:31:46 PM
To: Bonds, Michelle E. (CDC/0D/OADC)____ (b = > ; Fine,Amanda (NIH/OD) [El
~ )- (6)
(b)(6)>; Conrad, Patricia (NIH/NIAID) [El < (b)(6)>; Billet , Courtney
(NIH/NIAID) [El (b)( >; Lepore, Loretta (CDC/O0/OCS) (b)(6)>
Cc: McGowan, Robert (Kyle) (CDC/OD/OCS) (b)(6) ; Campbell, Amanda (CDC/OD/OCS)
(b)(6)>; Stecker, Judy (OS/1OS) (b)(6); Mu rphy, Ryan (OS/ASPA)
(b)(6); Pratt, Michael (O5/ASPA) (b)(6); Oakley, Caitlin B.
":"::":--:-'.:-:-::--:-:-::=====::....-~~
(OS/ASPA) (b)(6)>; Hall, Bill (HHS/ASPA) (b)(6)>; Galatas, Kate
(CDC/OD/OADC) (b)( >
Subject : Redfield/Fauci nCoV op-ed
CDC and NIH folks,
Per some discussion after the presser, we'd like Dr. Redfield and Dr. Fauci to pen an op-ed regarding the
reasons/thinking behind the policy announced today. I assume the right building blocks for it would be
the remarks they made today- which I believe you all should have the copy/notes for? I have the
Secretary's, which we'll be send ing around/post ing shortly and I'll make sure to re-up it here so you all
have it.
It would be great to have a draft of this cleared to get to the WH over the weekend. (I anticipate faster -
than-average clearance from them!)
Please let me know how I can help wi th t his.
Best,
Patrick
Patrick Brennan
Depa rtmen t of Health and Hum an Services
Office: (b) (6) I Cell (b) (
Predecisional/deliberative communication
NIH-002111
Sent : Thu, 6 Feb 2020 14:54:16 +0000
To : Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Marston, Hilary
(NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E]
Subject : RE:ASF: rAzar/Pompeo op-ed
Att achment s: 2 5 20 pompeo azar op-ed State - with Fauci tracked edits..docx
Here are my tr acke d ed its. Tha nks.
Director
Phone : (b) (6)
FAX : (301 496-4409
E-mail : (b)(6)

Sen t : Thursday, February 6, 2020 7:31 AM
_______ Cb
_>_
------ == (bH >; Folkers, Greg (NIH/NIA ID) [E]
C6);Marston, Hilary (NIH/NIAID) [E] (b)(6)
Cc: Conrad, Patricia (NIH/NIA ID) [E] CbH ; Routh, Jennifer (NIH/NIAID) [E]
(b)( >
Subject: ASF: rAzar/Pompeo op-ed
Sending to all of you simultaneously, in the interest of time. Our comments are due back at noon .
From: " Brennan, Patrick (O5/ASPA)" (b)(6)>

Dat e: Thursday, February 6, 2020 at 1:23:26 AM
To : "Routh, Jennifer (NIH/NIAID) [E]" ------- = H=6)>, "Bonds, Michelle E. (CDC/OO/OADC)"
(b....,
(b)(6), "Galatas, Kate (CDC/OD/OADC)" (b)(6)>, "Fine, Amanda (NIH/OD) [El "
:::::======~~(b)(6)>, "Conrad, Patricia (NIH/NIAID) (E]" (b)(6)>, "Kane, EIieen
(OS/ASPR/OE A)" ---------
(b)(6J>, " Michael, Gretchen (O5/ASPR/OEA)"
,;___;__ _;____,:_::::==:::;(b~~~<6)
;-,-::-
,,:-:
Bi:lle
::---:t----:=
, Courtney (NIH/NIA I D) [E]" (b)(6)>, "Lepo re,
Loretta (CDC/OD/OCS)" (b)(6), "McGowan, Robert (Kyle) (CDC/OD/OCS)" (b)(6),
" Campbell, Amanda (CDC/OD/OCS)" (b)(6J>, "Zebley, Kyle (HHS/O5/OGA)"
NIH-002 112
(b)(6)> , "Chang, Will iam (HHS/OGC)" (b)(6), "Keveney, Sean
---:-:-'.".""."::-:-:"-:-:'":-:"-:--:-:'.:.==:::::.---..:.:..-_.,,-:-:=
(HHS/OGC)" (b)( >, "Grigsby, Garrett (HHS/OS/OGA)"
Cc: "Billet, Courtney (NIH/NIAID ) [E]"
Deput ies@hhs .gov >
(b)( >, "ASPA-Deputies" <ASPA- ---------- (b)(6)
Subject : For review by noon Thurs: revised Azar/Pompeo op-ed
Hi all ,
At t ached is a largely new draft of the Azar/Pompeo op-ed tha t
-------------------------------
couple additions and ed its to their new version , which I've tracked/flagged.
(b) (5) I've made a
NIAID, CDC, and OGC, please let me know if thi s looks OK by noon tomorrow . Thank you!
Best,
Pat rick
NIH-002 113
Sent: Thu, 6 Feb 2020 14:24:54 +0000
Cc: Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Routh, Jennifer
(NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E]
Subject: RE:ASF: for review, Azar coronavirus presser remarks
Attachments: Secretary's remarks with minor Fauci edits.docx
Here are my edits for Azar' s press comments
Director
Phone (b) (6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Billet, Courtney (NIH/NIAID) [E] (b)(6)

To: Fauci, Anthony (NIH/NIAID) [E] --------=-<~ (b)(6)
Cc: Folkers, Greg (NIH/NIAID) [El (b)(6)>; Conrad, Patricia (NIH/NIAID) [El
(b)(6); Routh, Jennifer (NIH/NIAID) [El CbH6>1;
Marston, Hilary
-:--.-----:-:-:-:-:::====~-___:-~=
(NIH/NIAID) [El (b)(6); Stover, Kathy (NIH/NIAID) [El (b)(6)>
Subject: ASF: for review , Azar coronavirus presser remarks
Pis see Secretary's remarks for press conf and let us know if anything glaring needs to be fixed.
They also would like talking points from us, covering what you would say. These are really just a
placeholder. We could resubmit what we sent last time. Is there anything new you would anticipate
saying?
From: "Brennan, Patrick (05/ASPA)"

---------
Date: Wednesday, February 5, 2020 at 11:25 :33 PM
To: "Routh, Jennifer (NIH/NIAID) [El" (b)(6)>, "Bonds , Michelle E. (CDC/00/0ADC)"
(b)( >, "Galatas, Kate (CD.
":C'."-:-
/O::-D
::-/:-:
O:-:
A-::
D-::
77
==.,..........
C)' :-::
' (b)(6), "Fine, Amanda (NIH/OD) [E]"
=====::::!.--=-=-~
(b)(6)>, "Conra d, Patricia (NIH/NIAID) [El" (b)(6J>, "Kane, EIieen
--------
NIH-002116
(OS/ASPR/OEA)" CbH6J>," M ichael, Gret chen (OS/ASPR/OEA)"
,;._..;___..;______;_::::==' (b
:;;)::;,
(6)
=a" Bi~lle-t~, Courtney (NIH/NIA I D) [El"
>-,-::-
,,:"'. (b)(6), "Steele,
Danielle (HHS/105)" (b)(6)>, "Arbes, Sarah (HHS/ASL)" (b)(6)>,
" Moughalian, Jen (HHS/ASFR)" (b)(6) , "Shuy, Caitrin (HHS/ASFR)"
(b)(6), "Caliguiri , laura (FDA/OC)" (b)(6)>, "Janik, Heather
(FDA/OC)" (b)(6)>, "Lepore, Loretta (CDC/0D/OCS)" (b)(6)1,
" McGowan, Robert (Kyle) (CDC/0D/OCS)" (b)(6)>, "Campbell, Amanda (CDC/0D/OCS)"
CbH, "Zebley, Kyle (HHS/OS/OGA)" (b)(6), "Chang, William (HHS/OGC)"
(b)(6)>, "Keveney, Sean (HHS/OGC)" (b)(6)>, "Pence, Laura
----:~~====~:___-~..;,·
(HHS/ASL)" (b)(6)"Grigsby, Garrett (HHS/OS/OGA)" (b)(6)>
Cc: "Billet, Courtney (NIH/NIAID) [E]" (b)( >, "Stover , Kathy (NIH/NIAID) [E]"
(b)(6)>, "ASPA-Deputies" <ASPA-Deputies@hhs.gov >
--------
Subject : For review by 11 AM Thurs: Sec. Azar coronavirus presser remarks
Hi all,
Attached are draft remarks for the Secretary to deliver tomorrow evening at the scheduled press
conference on coronavirus- after which the plan is for Dr. Redfie ld and then Dr. Fauci, and then
whoever from State and OHS (I think?) to speak.
Can CDC, NIAID, OGC, FDA, and ASPR let me know if thi s looks OK by 11 AM tomorrow?
And once CDC and NIAID have their draft TPs, it would be great to see those as well.
Thank you!
- Patrick
NIH-002117
Sent : Thu, 6 Feb 2020 03:59:18 +0000
To : Grigsby, Garrett (HHS/0S/OGA);Lane, Cliff (NIH/NIAID) [El
Cc: Marston, Hilary (NIH/NIAID) [E];Zebley, Kyle (HHS/0S/OGA);Kerr, Lawrence
(HHS/0S/OGA);Burr, Mara (HHS/0S/OGA);Levine, Maya (OS/OGA);Mciff, Colin (HHS/0S/OGA);Arboleda,
Nelson (HHS/0S/OGA);Alexander, Thomas (OS/OGA)
Subject: RE:Coronavirus collaborating center
Yes. Thanks you.
From: Grigsby , Garrett (HHS/OS/OGA)
--------- (b) (6) >
Sent: Wednesday , February 5, 2020 8:42 At'vl
To: Fauci , Anthony (NIH/NIAJD) [E] ------, ,,.,..,-=
>; Lane, Cliff (NTH/NJACD
(b)( ) [E]
--------
....................... ----,
(b)(6)
Cc: Marston , Hilary (NTH/NTATD)[E]
-------
(b)(6) ; Zebley, Kyle (HHS/OS/OGA)
(b) (6) ; Kerr, Lawrence (J-lHS/OS/OGA) .....,.,._.,. (b) ( ; Burr , Mara
(HHS/OS/OGA) (b) (6) > ; Levine, Maya (OS/OGA) ..... ___ (b)(6); Mciff , Colin
(HHS/OS/OGA) (b) (6) Arboleda , Nelson (HHS/OS/OGA) (b) ( ;
Alexander, Thomas (OS/OGA)
Subject: FW: Coronavirus collaborat ing center ---,--------- (b) (6)>
lmportance: High
DrsF & L,
Confinning that you want me to reply in the affirmative asap ...?
f rom: Lamourelle , Gabrielle (HHS/OS/OGA)
__________ _,
(b)(6) >
Sent: Wednesday , Febrnary 5, 2020 6:50 AM
To: Grigsby , Garrett (HHS/OS/OGA) ------~ ~=
(HHS/OS/OGA)
-------
(b) (6) ; Kerr , Lawrence (HHS/OS/OGA )
(b) (6); Mciff, Colin (HHS/OS/OGA)
(b) (6) ; Elvander, Erika (OS/OGA)

(b) ( >; Burr, Mara
(b) (
Cc: Tracy Carson (b)( ; Smith , Steven T (Geneva) (b) ( art, Jessica L.
(HHS/OS/OGA) Cb)C ; Levine, Maya (OS/OGA) (b ood, Rachel
(HHS/OS/OGA) (b)( ·; Fernandez, Jose (OS/OGA)
Subject: FW : Coronavirus collaborat ing center ---------
lmportance: High
Dear Garrett and all,

I have received the hard copy of the attached letter from Matias Tuler (WHO Collaborating Centers team) with the
request that we review and provide a reply as quickly as possible. The letter, as usual form, says they will go
forward in 8 weeks if they hear no objection from us.
(b) (5)
If you have any questions, let me know.
Thank you,
Gabrielle
From: TULER, Matias ----
Cb)(6) --,;-;=
NIH-002 145
To: Lamourelle, Gabrielle (HHS /0S /OGA) (b)(
Cc: OGA Multilateral <OGAmu ltilateral@hhs.gov >
Subject: RE: Coronavirus collaborating center
Dear Gabrielle ,
Many thanks for the email.
1 sent you an email with the letter just after we talked. 1do not know if you received it. ram attaching the letter to
this email again, just in case.
Thank you very much in advance.
Best regards ,
Matias
Matia s Tuler
Programme Manager
WHO Collaborating Centres, and WHO Expert Advisory Panels and Committees World Health Organization
Geneva , Switzerland
Office: (b) (6)
Web: http://www .who .int/collabora tingcentre s/infonnat ion/en/
http://www .who.i nt/about/collabo rations/expert panels/en/
Follow WHOon Facebook, Twitter, YouTube, Instagram

From: Lamourelle , Gabrielle (HHS/0S /OGA)
Sent: Wednesday , February 5, 2020 9: 17
To: T ULER, Matias (b)(6)
------------ (b)(6) >
Cc: OGA Multilateral <OGArnu ltilateral @hhs.gov >

Subje ct: Coronaviru s collaborating center
Dear Matia s,
Thank you for sharing the hard copy of the Corona virus col laborating center letter. Please send me an electronic
copy as well and J will send back immediately to our office for a rapid reply.
With best wishes,

Gabrielle Lamourelle
Deputy Director, Multilateral Relations

HHS Office of Global Affairs
Sent from my iPhone
NIH-002 146
Sent : Thu, 6 Feb 2020 02:55:19 +0000
To : Kerr, Lawrence (HHS/0S/OGA)
Cc: Grigsby, Garrett (HHS/0S/OGA)
Subjec t: RE:Spoke with Soumya re: evolut ionary origin of nCoV
I do not see any prob lem with your doing this. Go for it.
Best,
Tony
From:Kerr, Lawrence (HHS/0S/OGA)

----------
------~~ (b)( >
Cc: Grigsby, Garrett (HHS/OS/OGA)'"=======~ (b
""'
)~(6)>
Subject: Spoke with Soumya re: evolut ionary origin of nCoV
Dr . Fauci,
(b) (5)
I welcome you r advice please . Much thanks,
Larry
NIH-002 149
From: (b)(6)
Sent : Wed, 11 Mar 2020 19:30 :25 -0400

To : John M Jessup
Subject : Re: You are great - a thought
Kim:
Thanks for the note. That is exactly what the cdc is sta1i ing to do.
Best,
Tony
On Mar 11, 2020 , at 7:22 PM, John M Jessup wrote:

--------- (b)(6)
Tony,
We have seen each othe r over the decades. I am the (b)(6) from NCI
who decreid the lack of info r mation about Eboal since it was limited to fruit bats as a
reservoir.
An idea about testing . Maryland sti ll has testing limited to subjects with
symptoms who have contact with people from affec t ed areas or who real ly ill with a
respiratory infection
Why not forget the contacts and t est those with flu-like symptoms without the
need for contacts but instead test for fl u and if that is negative move on to covid -19.
That would still be a tr emendous demand so ... go to a formal two -ti er t est wh er e
PCR is done with approved PCR primers and if that is positive then the confirmation is with
a FDA t est for covid - 19.
There are a lot of manufacturers of PCR primers, most clinical labs have PCR
machines so that screening t ests ought to be supported wit hou t a lengthy FDA clearance if
it w innows the number of patients who need a formal test.
You are terrific . Keep it up with common sense as opposed to whatever the t op of
the administration suggests. I bet that the primer manufacturers would be supportive .
Kim
J. M ilburn Jessup, MD, FACS

Research Scientist
Division of Research
Washington DCVAMC
50 Irving Street NW
(b)(6) or_______ °" )'""'
(b (=6)
Affil iate Professor - Systems Biology
NIH-000677
College of Science
George Mason University
(b)(6)
----- (b)(6) Diagnostics Evaluation Branch, CDP, DCTD, NCI, NIH
NIH-000678
From: (b)(6)
Sent : Wed, 5 Feb 2020 08:56:13 -0500
To : Baden, Lindsey, M.D .
Cc: Mars ton, Hilary (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Lerner, Andrea
(NIH/NIAID) [E];Lane, Cliff (NIH/NIAID) [E];Morens, David (NIH/NIAID) [E]
Subject : Re:favor
(b)(6).(b)(4)
On Feb 5, 2020, at 8:29 AM, Baden, Lindsey, M .D. <lbaden @nejm.org>wrote:
Ton'l,'------------------------- (b
,...,
)"(6)
" . ..
(b"') ..,..,
~l
Lindsey
(b)(6)
From : "Fauci, Anthony (NIH/N IAID) [E]"
Date: Tuesday, February 4, 2020 at 7:06 PM --------
To: "Baden, Lindsey, M .D." <lbaden@ne j m.org>
--------~=
Cc:"Marston, Hilary (NIH/ NIAID) [E]" CbH6)"Conrad, Patricia
(NIH/ NIAID) [E]" Cb)( , " Lerner, Andrea (NIH/ NIAID) [E]"
,;.__:_ _ __;_...:......:....:::=
(b
~)~C6)
;;-,--:,:-:-
,L-a n-e-, -=
c::-:
lif::-
f -:-:- H/ N IAID) [El"
( N-:-:-
1:--:-'. (b)(6)>,
"Mo rens, David (NIH/N IAID) [El" CbH6)>
Subject : RE:favor
Lindse :
(b)(6).(b)(4)
Best regard s,
To ny
Director
NIH-002173
Phone : Cb)(6)
FAX : (301) 496-4409
E-mai l: (b) (6)
contain sensit ive information . It should not be used by anyone who is not the original
and delete it from your mailbox or any other storage dev ices . The National Institute of
made that are the sender 's own and not express ly made on behalf of the NIAID by
From: Baden, Lindsey, M.D. <lbaden@nejm.org>

---------=-c-c=
To: Fauci, Anthony (NIH/NIAID) [E)"======= (b=)( ::-!
6)~
Cc: Marston, Hilary (NIH/NIAID) [E] (b)(6); Conrad, Patricia
Subject: Re: favor
Tony (and Hilary),

Much appreciated. (b) (6), (b) (4) .
Thank you,
-------
Lindsey
From : "Fauci, Anthony (NIH/NIAID) [E]"

--------- (b)(6)
To : "Baden, Lindsey, M.D." <lbaden@nejm.org >

Cc: "Marston, Hilary (NIH/NIAID) [E]" J Cb)C6J, "Conrad, Patricia
(NIH/N IAID) [E]" (b)(6)
Subject: RE: favor
Lindsa :
(b) (6), (b) (4)
Tony
Director
NIH-002174
Phone: Cb
) (6)
FAX: (301) 496-4409
E-mail:
-------- (b)(6)
From: Baden, Lindsey, M.D. <lbaden@nejm.org >

--------::-:-c-=
To: Fauci, Anthony (NIH/NIAID ) [E)
Subje ct: favor
-------- (b)(6)
Tonv.
(b) (6). (b) (4)

Lindsey
attachments, is intended on ly for the person or entity to which it is addressed and may
contain confidential, privileged, and/or proprietary mater ial. Any review, duplication,
retransm ission, distribution, or other use of , or ta king of any action in reliance upon, this
information by persons or entities other than t he intended recipient is unauthorized by the
sender and is prohibited . If you have received this message in error, please contact the
sender immed iately by return email and delete the original message from all computer
systems. Thank you.
This email message is a private communication . The information transmitted, including
contain confidential , privileged, and/or proprietary mater ial. Any review, duplication,
retransm ission, distribution, or other use of, or taking of any action in reliance upon, this
This email message is a private communication. The infonnation transmitted ,
includin g attachments, is intend ed only for the person or entity to which it is
addre ssed and may contain confidential, privileged , and/or proprietary materia l. Any
review , duplication , retransmis sion, distr ibution , or other use of, or taking of any
action in relianc e upon, this information by person s or entiti es other than the
intended recipient is unauthorized by the sender and is prohibited. If you have
NIH-002 175
received this message in error , please contact the sender immediately by return
email and delete the original message from all computer systems. Thank you.
NIH-002176
From: (b)(6)
Sent : Wed, 5 Feb 2020 08:41:40 -0500
To : Baden, Lindsey, M.D .
Subject : Re: favor
Thanks , Lindsey. I am always happy to help in any way I can
On Feb 5, 2020, at 8:32 AM, Baden , Lindsey, M .D. <lbaden @nejm.org >wrote:
Tony,
On a different note, as the spread of the nCoV-2019 virus is so comp lex and fast moving,
any advice on how we at the Journal can help in the response would be great.
Your advice is always appreciated as we all try to get it right and be responsive.
Lindsey
From: "Fauci, Anthony (NIH/N IAID) [E]" (b)(6)
Dat e: Tuesday, February 4, 2020 at 7:06 PM

----------
To : "Baden, Lindsey, M .D." <lbaden@nejm.org>
Cc: "Marston, Hil ary (N IH/ N IAID) [E]" -------- ==(b)(6), "Conrad, Patricia
(NIH/ NIAID) [E)" CbH6), "Lerner, Andrea (NIH/ NIAID) [E]"
~___;___ ..:....:,...:.....====:;~----::---"""":"".''."':':'":--- .
---------
"Mo r ens, David (NIH/N IAID)
CbH >, " Lane, Cliff (NIH/ NIAID) [El"
[EJ' (b)(6)
CbH6)
Subject : RE: favor
Lindsey:
(b) (6). (b) (4)
Best regar ds,

Tony
Director
NIH-002 177
Phone : Cb
)(
FAX : (301) 496-4409
E-mail : (b)(6)
---------
From: Baden, Lindsey, M.D. <lbaden@nejm.org>

To: Fauci, Anthony (NIH/NIAID) [E) -------=- (b'""'
)( =6)
Cc: Marston, Hila ry (NIH/NIAID) [E) CbH ; Conrad, Patricia
Subject: Re: favor
Tony (and Hilary),

---- ~=--c~=
Much appreciated
Thank you,
-------- (b)(6) . (b)(4).
Lindsey
From: "Fauci, Anthony (NIH/ NIAID) [E]" (b)(6)

----------
To: "Baden, Lindsey, M.D." <lbaden@nejm .org >
Cc: "Marston, Hilary (NIH/NIAID) [E]" (b)(6), "Conrad, Patricia
(NIH/NIAID) [E]" CbH6)
Subject: RE: favor
Lindsay :
(b) (6). (b) (4)
Tony
Ant hony S. Fauci , MD

Director
Bet hesda, MD 20892-2520
Phone : Cb)(6)
NIH-002 178
FAX: (301) 496-4409
E-mail:
-------- (b)(6)
and delete it from your mailbox or any other storage devices. The National Institute of
From: Baden, Lindsey, M.D. <lbaden@nejm.o rg>

To : Fauci, Anthony (NIH/NIAID) [E) ------~~ (b)(6)>
Subject : favor
Ton ~-------------------------- ~(b~~=

(6)~. ~
(b)~(=
~

Lindsey
contain confidential, privileged, and/or proprietary mate rial. Any review, duplication,
retransm ission, distribution, or other use of, or taking of any action in reliance upon, this
information by persons or ent iti es other than t he intended recipient is unauthorized by the
sender and is pro hibited . If you have received this message in error, please contact the
systems. Thank you.
cont ain confidential, privileged, and/or proprietary material. Any review, duplication,
retransmiss ion, distribution, or other use of, or taking of any action in reliance upon, this
Thi s email message is a private communication. The infomrntion transmitted,
including attachments, is intended only for the person or entity to which it is
addre ssed and may contain confidential, privileg ed, and/or propri etary material. Any
review, duplication , retransmis sion, dis tribution, or other use of, or taking of any
action in reliance upon, this information by persons or entities other than the
intended recipient is unauthorized by the sender and is prohibited. If you have
received this messagein error, please contact the sender immediatelyby return
email and delete the origi nal mes sage from all compute r systems . Thank you.
NIH-002 179
From: Fauci,Anthony {NIH/NIAID) [El
Sent : Wed, 5 Feb 2020 11:52:41 +0000
To: Conrad, Patricia {NIH/NIAID) [El
Subje ct: FW: INTERVIEW-AHABER/A NEWS
For discussion.
From: GULSEN EDA ULUSOY <EDA.ULUSOY@ahaber .com .tr>
To: Fauci, Anthony (NIH/NIAID) [E]_______

--------=-:-= _,
(b)(6)
Subject : INTERVIEW-AHABER/A NEWS
Dear Mr. Fauci,
This is Eda Ulusoy from Turkey 's number one ranking news channel A Haber/ A News.
We wou ld like to take few minutes of your ti me and kindly ask if we could possibly have the
opportunity to make a Skype interview with you about China coronavirus outbreak.
We can have the interview this week or next week. I can arrange it according to your
programme.
It will on ly take 15 minutes of your time.
We would really apprecia t e if we can make this interview.
Thank you for your kind consideration.
I'm look ing forward to your reply.
Sincerely,
Eda Ulusoy
Correspondent
NIH-002 180
Sent : Wed, 5 Feb 2020 11:52:11 +0000
Subject : FW: Interview invitation from Dialogue CGTN
:et us discuss.
From: Bai Jacinta (b)(6)

To : Fauci, Anthony (NIH/NIAID) [E] ------ --==,
(b)( >; Fauci, Anthony {NIH/N IAID) [E]
(b)( 6) >
--------
Subj ec t : Interview invitation from Dialogue CGTN
Dear Mr. Fauci,
This is Jacinta from Dialogue, CGTN of China Central Television. I hope this email finds you well.
I'm reaching out to ask if you have time for a satellite interview at 6:30 am on Feb 6, Thursday, DC time.
I read the interview to you on New York Times and sincerely wish that you could share more with our
global audience. It would be our honor to have you on.
Topics will cover the evolution of coronavirus and its mortality rate, difficulties in controlling the
outbreak, cooperat ion in international communities, prevention measures and so on.
Please kindly let me know if you are available for the show . I'll send the proposed questions beforehand
and book the closest st udio for you.
Appreciate it!
Best,
Jacinta Bai
Dialogue, CGTN
NIH-002 181
Sent : Wed, 5 Feb 2020 11:34:46 +0000
To : Ho, David D.
Cc: Conrad, Patricia (NIH/NIAID) [E);Barasch, Kimberly (NIH/NIAID) [Cl
Subje ct: RE:2019-nCo\/
David:
Thanks for the note. Please have your office contact my Special Assistant, Patty Conrad
(copied here) to set up a call. I down at the Congress and White House most of the day, but we
can probably squeeze a call in between meetings .
Best,
Tony
From: Ho, David D (b)(6)>

-------~~ (b)(6)>
Subject: 2019-nCoV
Tony,
Greet ings. As you can see below, our institute has moved. We are now part of Columbia.
Do you have a brief moment to chat about the new coronavirus?
Best,
David
David D. Ho, M .D.

Director, Aaron Diamond AIDSResearchCenter
Clyde and Helen Wu Professor of Medicine
Director, Wu Family China Center
Columbia University Vagelos College of Physicians and Surgeons
701 W. 168th Street, HHSC1102
New York , NY 10032
NIH-002 182
Sent : Wed, 5 Feb 2020 11:17:05 +0000
Cc: Harper, Jill (NIH/NIAID) (El;Johnson, Martin S. (NIH/NIAID) [El;Conrad, Patricia
(NIH/NIAID) [El;Tabak, Lawrence (NIH/OD) [El;Shapiro, Neil (NIH/OD) [El;McGowan, John J. (NIH/NIAID)
(b)( ;Auchincloss, Hugh (NIH/NIAID) [CJ
---------
(b)(6)
Francis:
(b)(5)
--------------
Thanks,
(b)(5) Happy to discuss further.
Tony
From: Coll ins, Francis (NIH/OD) [El (b)(6)

To: Fauci, Anthony (NIH/NIAID) [E;!
] ======
------~~ (b=-;
)(~6)~
Cc: Tabak, Lawrence (NIH/OD) [El CbH6)>; Shapiro, Neil {NIH/OD) [El
(b)(6)
Subject: FW: Coronavirus
Import ance: High
Hey there Tony,
(b) (5)
Thanks, Francis
From: Shapiro, Neil (NIH/OD) [El (b)(6)>

--------
Se nt : Tuesday, February 4, 2020 8 :31 PM
To: Collins , Francis (NIH/OD) [El
----~~ CbH6)>; Tabak, Lawrence (NIH/OD) [El
(b)(6)>; Johnson, Alfred (NIH/OD) [El (b)(6); Wolinetz, Carrie
----:-~~:-====::L.:.--~~
(NIH/OD) [El (b)(6)> ; Hallett, Adrienne (NIH/OD) [E] (b)(6)
Schwetz, Ta r,_
a -:-:
(N
-:-:H/7 0:-::D:-:-)-:-[=:
l-:-: El:.:====---...,_ (b,.._..
) =(6)>
NIH-002 183
Cc: Shaya, Cecile {NIH/OD) [El _______
.... (b)(6)
Import ance: High
(b)(5)
From: Shapiro, Neil {NIH/OD) [El

Sent: Tuesday, February 4, 2020 4 :46 PM
To: Collins, Francis {NIH/OD) [E]----- --=-
(b"'""
)(=6J>; Tabak, Lawrence (NIH/OD) [El
(b)( ; Johnson, Alfred (NIH/OD) [El (b)(6)>; Wolinetz, Carrie
--~~~~====!:,__-~~
{NIH/OD) [El CbH6J; Hallett , Adrienne (NIH/OD) [El (b)(6)
Schwetz, Tar ...
a -:-:
(N H/7 0:-:D
-:-:
1-:-: :-::
Cc: Shaya, Cecile {NIH/OD) [El
)-:-
[ ::-:
_______
El:--====::.;__--,;,-
....
(b"S"'"
H=6)
(b)(6)
Francis,
(b) (5)
Neil
NIH-002 184
From : Shapiro, Neil (NIH/OD) [E]
Sent: Wed nesday, January 29, 2020 2:34 PM
To: Collins, Francis (NIH/OD) [E] (b)(6)>; Tabak, Lawrence (NIH/OD) [El
CbH ; Johnson, Alfred (NIH/OD) [El (b)(6)>; Wolinetz , Carrie
":""."'."".""."-:-:-:-:-:-:::-====~~-~.;.,
(NIH/OD) [El (b)( >; Hallett, Adrienne (NIH/OD) [E] (b)(6)>
I'm sending them the first part, thanks .
From : Collins, Francis (NIH/OD) [E] (b)(6)

Sent: Wed nesday, January 29, 2020 5:23 AM
To: Tabak, Lawrence (NIH/OD) [E) -------~~ Shapiro, Neil (NIH/OD) [E)
(b)(6)
(b)(6) Johnson, Alfred (NIH/OD) [El CbH >; Wolinetz, Carrie
-~---~==:=:!.. __ __:_~=
(NIH/OD) [E) (b)( >; Hallett , Adrienne (NIH/OD) [El (b)(6)
(b) (4)
FC

Sent: Tuesday, January 28, 2020 6:25 PM
To: Shapiro, Neil (NIH/OD) [E]------~= (b)(6) Collins, Francis (NIH/OD) [E]
(b)(6)>; Johnson, Alfred (NIH/OD) [E] (b)(6); Wolinetz, Carrie
(NIH/OD) [El (b)(6) ; Hallett , Adrienne (NIH/OD) [El (b)(6)
Subject : Re: Coronavirus
(b)(5
Larry
From: "Shapiro, Neil (NIH/OD) [E]" (b)(6)>

---------
Date : Tuesday, Jan uary 28, 2020 at 5:31 PM
To: Francis Collins (b)(6), "Tabak, Lawrence (NIH/OD) [E]"
CbH "Johnson, Alfred (NIH/OD) [E]"
---------
W o Ii net z, Carrie (N IH/OD) [E]"
11
>, (b)(6)
CbH >, "Hallett, Adrienne (NIH /OD) [E]"
(b)(
(b)(5)
NIH-002185
(b) (5)
Neil
NIH-002 186
Sent : Wed, 5 Feb 2020 04:18:25 +0000
Subject : RE: Business Council - Invitation to speak at the February 20-21, 2020 meeting
No dinner.

----------
-------~~ (b)(6)
(b)(6)>
Cc: Barasch, Kimberly (NIH/NIAID) ~ [c::.========-- cc-

(b)'""(=6)
Subject : FW: Business Council - Invitation to speak at the February 20-21, 2020 meeting at the Ritz
Carlton (22nd and M St. NW), Washington, D.C.
See highlight - w ill you and

---- · att end the dinner. Pis advise.
Cb><
Patricia L. Conrad
National Institute of All ergy and Infectious Diseases
The National Institutes of Hea lth
(b)(6)
301 -496 -4409 fax
Disclai mer:
The informat ion in this e-mail and any of its attachments is confiden tial and may conta in sensitive information . It sh ould not be used
from your mailbox or any other storage devices . National Institute of Allergy and Infectious Diseases (NIAID) shall not accept
From: Marlene Colucci <mco lucci@businesscouncil.com>

To: Fauci, Anthony (NIH/NIAID) [E)-------= (b-c-
)(c-=
6)
Cc: Conrad, Patricia (NIH/NIA ID) [El (b)( ; David Rubenstein
<David .Rubenstein@carlyle.com>; MaryPat Decker <marypat.decker@carly le.com>
Subject : Business Council - Invitation to speak at the February 20-21, 2020 meeting at the Ritz Carlton
(22nd and M St. NW), Washington, D.C.
Dear Dr. Fauci,
NIH-002 191
On behalf of our co-chairs for the winter meeting of The Business Council, David Rubenstein of The
Carlyle Group and Ginni Rometty of IBM, we would like to formally invite you to participate in our
meet ing on February 20-21, 2020 in Washington, O.C. The theme of the meeting is "The Next Decade."
{See form al invitat ion attached as we ll as list of CEO members).
We would like for you to part icipate in a 50 minute fireside chat wi t h David Rubenstein {and possibly Dr.
Francis Collins) to discuss the current coronavirus as we ll as what we should expect in the next decade.
We want to give our CEOsinsights into what the next 10 years will bring in terms of detection, diagnosis
and t reatment of diseases. All conversations are strictly off the record and closed press. We will cover
all lodging and t ransportat ion.
As you know, The BusinessCouncil is comprised of the chief executive officers of the largest global
corporations, representing all segments of the economy . We expect at least 150 CEO members, spouses
and speakers to be in attendance.
As a participant you and your spouse are also invited to join us for our special reception, dinner and
speaker at the REACH(Kennedy Center) on Thursday, February 20 at 6:30pm. It is the best opportunity
for you to meet our CEOmembers and spouses, speakers and othe r special guests in an informal
atmosphere.
If you are interested and available, please let me know. We can also set up a very brief call with you to
discuss any additiona l details and answer any questions you may have. We look forward to hearing
from you and wou ld be honored to have you participate with us again.
Warmest regards,
Marlene
Marlene Colucci
EXECUTIVE
DIRECTOR
'I B
~
1
USINESS
COL \JClL
T: 202-298-7650
C Cb)(6)
F: 202-785-0296
NIH-002 192
Sent : Wed, 5 Feb 2020 04:17:19 +0000
Cc: Billet, Courtney (NIH/NIAID) [E]
Subject: FW: Comment on story about how confident people feel about the ir govt's
response to a health epidemic
Please try to draft a response for me. Thanks .
From: Rajeshni Naidu-Ghelani <Rajeshni.Naidu-Ghelani@ipsos.com>

To: Fauci, Anthony (NIH/NIAID) [E] ------ (b
..--.
),..,
(6)
=
Subject : Comment on story about how confident people feel about their govt's response to a health
epidemic
Hi Dr. Fauci,
I hope all is well. I'm working on a news story tied to the coronavirus outbreak and tying it to how
people responded to a recent global lpsos poll about the threat of a major health epidemic in their
country in the next 12 months . https ://www .ipsos.com/sites/defau lt/files/ct/news/documents/20 19-
11/ a-more -dangerous-world -fear-2019.pdf
I was hoping to get your comments on this, considering your expertise in infectious disease control.
Below are some questions. If you could respond via email, that would be great as I am on a tight
dead line to get this story up. If it's easier to give you a call, I can do that as well. Please let me know
what works best. The story will be published on lpsos.com, on social media and our various country
webs ites. Thank you and I look forward to your response.
1. In our survey of more than 18,500 people in 28 countries done in late last summer, more than
half (51%) of peop le said there was threat of a major health epidemic in their country in t he next
12 months w ith peop le in emerging markets at the top of the list. Are you surprised by this
result? It's among the highest reading for this questio n since the Ebola outbreak in 2014 when
the percentage climbed to 59%.
2. The U.S. is the only developed country in the top 10 list where most people think a major health
epidemic will occur. Why do you think this is?
3. A follow up question to t he previous one is how confident people are that their government
could protect them or respond effectively if such an outbreak was to occur. Over half globally
said they were confident in their gov't's response. Do you think people have a lot of trust in
those in power to do the right thing in times of an outbreak?
4. Seven of the top 10 countries where people had the most confidence in govts are in the
developed world . How important are developed healthcare systems when it comes to outbreaks
like the coronavirus?
5. Likewise, many countries at the bottom of this list are emerging markets. What can govts in
these countries do to ease peop les' fears on how they are or will handle an outbreak like the
coronavirus?
NIH-002 193
6. How difficult is it for governments and health officials to prevent the spreading of a virus like
this before it becomes a pandemic? What measures can be taken?
Please free to add any add itional information that you thin k may be relevant . I hope to hear from you
soon.
Regards,
Rajeshni
RajeshniNaidu-Ghelani I Data Journalist

PublicAffairs
160 Bloor Street East, Suite 300

M4W 189 Toronto - Canada Ctt,\NQE THE OAt.'!1
Phone: +1416 572 5143
Mobile: ,.._ __ ...>;;<~
rajesbni .naidu-ghe lani@ ipsos.com

www .ipsos.com
GAMECHANGERS II
NIH-002194
Sent : Wed, 5 Feb 2020 04:12:18 +0000
Cc: Billet, Courtney (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E];Conrad, Patricia
(NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E]
Subject : RE:for review: responses for Elemental news site (not urgent)
I made some modifications. You can send it. Th anks.
From:Routh, Jennifer (NIH/NIAID) [E) (b)( >

'"'~..-.
(6)
=>
Cc: Billet, Courtney (NIH/NIAID) [E] (b)(6),; Stover, Kathy (NIH/NIAID) [E]
(b)( ; Conrad, Patricia (NIH/NIAID) [E] (b)( >; Folkers, Greg
Subject : for review: responses for Elemental news site (not urgent)
Dr. Fauci -
This request is not urgent for today . The reporter Rob Britt (writes for Elemental, a health and wellness
news site) reached out to you directly on Sunday with some questions about 2019-nCoV. I have drafted
proposed responses for you in red below . Please let me know if you have edits. I will send responses
back to the reporter attributed to you.
Thanks,
Jen
From: Rob Britt (b) (6)
--------
---..-,~
(b)(6J>
Subject: Coronavirus - reporter's questions
Hi Dr. Fauci: We are updating our coronav irus story periodically, keeping it factual and
level-headed , and I have seen your comments on NPR Friday and in the NYTimes over the
weekend , so I hope you could comment very briefly for our story:
-- What's your expectation for whether this will become a pandemic?

The nove l coronavirus ou tbreak will likely become a pandemic. We know the virus is very
transmissible. The infection continues to accelerate and there is efficient transmission in
china. If sustained transm ission also occurs in other countries throughout the world, the
outbreak would fulfill the definitive of a pandemic
-- Pandemic does not necessarily equate to a terrible situation, compared to, say bad flu
seasons. What 's your expectation on the potential severity of this coronavirus?
It is difficult to pred ict the severity at th is time. Even if the morta lity rate of a virus remains
low , if it is easily t ransmissible, the global impact can be significant .
-- And your suggestion to people in the U.S. who might be very concerned?
NIH-002195
We are treating t he emergence of a nove l coronavirus as a very serious pub lic health
threat. However , the risk to the general Amer ican publ ic remains low at this time . We
understand that peop le may be wor ried . We ask that people not let fear or panic guide
the ir actions .
Thanks for any help you can provide.
Cheers,
Rob
Robert Roy Britt

Top Writ er on Medium in Science & Health.
Contributor to OneZero (science) & Elementa l (health).
Former editor-in-chief of Live Science and Space.com.
(b)(6)
(b)(6)
NIH-002 196
Sent : Wed, 5 Feb 2020 04:06:33 +0000
Subject : FW: For Dr. Anthony Fauci {NIAID/NIH) - forward of my email letter to Dr.
Gregory Poland (Mayo Clinic) regarding Chinese 15 minute Coronavirus test and other concerns
Please handle.
From: Jon M (b) (61
To: Fauci , Anthony (NTH/NlAID) [E] --------, a-s-r,= (b) ~
Subject: For Dr. Anthony Fauci (NIA i D/NlH) - forward of my emai I letter to Dr. Gregory Poland (Mayo C linic)
regar ding Chinese 15 minute Coronavirus test and other concerns
From: Jon M (b) (6}

To: ocpostoffice @niaid .nih.gov
Subject: Atten tion Meylin - Forward of my emai l lietter to Dr Gregory Poland (Mayo Clinic) for Dr Anthony Fauci
(NlAID/NII-1}
Date: Feb 4, 2020 I :45 PM
Hello Meylin,
Thank you for taking my call yesterday and forwarding the following email I sent to Dr. Gregory Poland care of his
assistant, Joseph Roberts, to Dr. Fauci.
Jon Markowitz
From : Jon M (b) (61

To: (b)(6)
Subject: JOE - We spoke on phone today ... Please forward my email with reference links to Dr. Gregory Poland
Date: Feb 4, 2020 12:57 PM
Hello Joseph Roberts (Mayo Clinic),

We spoke on phone today ...
Pleas e forward my email with reference links to Dr. Gregory Poland Tha nk you, Jon Ma rkowitz
Feb 4 , 2020
Dear Dr. Gregory Poland
I saw your appearance Feb 3 on a CNBC news program:

https ://wvvw .youtube .eom/wa tch? v-=Wq33oZdO -R4
'We're basically at a pandemic now' : Mayo Clinic physician on corooavirus
Fyi, I am not a doctor, nurse or medical student nor do I work in the medical field. I am a musician. I am 65 years
old and live in Los Angeles.
A news article publi shed on rt.com Feb 31, 2020 (see link below) announced the Chinese have developed a 15
minute test for the Corona virus, yet I've not seen or heard about this news anywhere else. [ bad heard there were
efforts here to develp a faster test than what is being employed currently by the CDC, but believe its critical the
NIH-002 197
White House arrange for the new Chinese test to be available in the US everywhere immediately.
This news should have been mentioned by NIH doctor Anthony Fauc hi at the White House Briefing on Jan 31, 2020
but was not, nor was it mentioned by Mayor Di Blasio on Feb 1 at Bellevue Hospital in NY .
At this point , the NTH, CDC and White Hous e shou ld have already obtained the Chinese 15 minute test for the virus
and implement at all US medical centers and airports receiving travele rs from the infectious regions.
Due to the exponential growth of infection rates from 'seed' individuals who are asymptomatic but don't know they
are infectious, whether returni ng from infection zones or are infected by others already here, I am hoping you and
other infect ious disease experts waste no time in vigorously pursuading the White House , NTH, CDC and all other
agencies as to the necessity to test ALL travelers (not just those who are symp tomatic) coming into the country by
air and sea with the Chinese 15 minute test as well as pull out all the stops to develop an eve n quicker test that's
portable.
As the numbers of infections increases exponentially in the US and other countries this next 2 to 4 weeks from
increasing numbers of asymptomatic 'seed' individuals unknowingly spreading the disease , we are certainly on the
precipice of an unstopable runaway epidemic.
What is also desperately needed from the federal government are frank and honest recommendations regarding what
is necessary to prevent becoming infected such as:
surgical or constmction respirators that seal to the face, eye protection goggles, nitrile exam gloves, sanitizer wipes
along with specific protocols on how not to bring the vims particles back to ones car, borne and possessions.
It is imperative that manufacturing of EFFECTIVE respirator masks or equivalent non-disposable respirators be

ramped up to huge scale. Without adequate numbers of these , exam gloves and eye protection this country will not
be capable of containing this epidemic .
Below this article, I've pasted in a number of useful you tube links of relevant and timely information in refere nce.
Thank you very much for your attention to this issue.
Jon Markowitz
Los Angeles
References:
https://www .rt.com/news /4 79705-china-develo p-coronav irus-rap id-test/

China develop s rapid Coronavirus test that works in under 15 MINUTES
3 I Jan, 2020 I0:48
Scientists in China have reportedly developed an express test which can detect the 2019-nCoV novel coronavirus in
under fifteen minutes , in a major breakthrough which will hopefully help stem the tide of infe.ction.
Experts from a tech company based in Wuxi in eastern China's Jiangsu Province, working with the National Institute
for Viral Disease Control and Prevention , developed the rapid nucleic test kit in ju st ten days, according to the
Xinhua news agency.
The test takes between eight and 15 minutes to produce a result and is currently being mass-manufactured at a rate
of 4,000 kits per day, with the city government in Wuxi explo ring efforts to boost production even further.
The first batch of kits has reported ly already been deployed to the frontlines at the epicen tre of the outbreak, Wuhan ,
in Hubei province.
https://www .youtube.co m/watch?v= Wg33oZd0- R4

'We're basically at a pandemic now': Mayo Clinic physician on coronavirus
114,173 views
NIH-002198
•Feb 3, 2020
CNBC Television
https://www.youtube.com/watch?v=VdU i kwuw7T
11 confinned US coronavirus cases, experts warn of pandemic I ABC News
157,773 views
•Feb 3, 2020
ABC News
https://www .youtube.com/wa tch?v=8Hjy3UfaTSc

Coronavirus Epidem ic Update 9: Fecal -Oral Transmission , Recove1y vs Death Rate
129,190 views
•Feb 3, 2020
MedCram
https://www .youtu be.com/watc h?v=GpbUoLvpd Co

Coronavirus Outbreak Update 8: Travel Ban, Spread Outside of China, Quarantine , & MRSA
329,919 views
•Feb 2, 2020
MedCram
https://www .youtube.com/user/MEDCRAMv ideos/v ideos

MedCram youtube channel
[Dr. Roger Seheult - https://W'.vw.medcram .com/]
https://www.youtube.com/watch?v=z05Z rMfKUDc
Coronavirns , Contag ion and Complications
228 ,007 views
•Feb 2, 2020
Dr. John Campbell
https: //www.yo utube.com/watch?v=u7D3AoNdp84

Wuhan virus compared to MERS and SARS
45,569 views
•Feb 3, 2020
Dr. John Campbell
https://www.yo utube.com/user/Camp bellteaching/videos

Dr. John Campbell youtube channe l
https://www.youtu be.com/wa tch?v= zczkLZN 194

Mayor de Blasio Holds Media Availability
334 views
Feb l , 2020
NYC Mayor's Office
https://,vww .youtube.com/wa tch?v=oMl-9Kvoj7O

Coronavirus: U.S. Declares Public Health Emergency , Will Quarantine China Travelers [White House Briefing]
121,648 views
•Streamed live on Jan 3 l , 2020
QuickTake by Bloomberg
NIH-002199
Sent : Wed, 5 Feb 2020 04:03:41 +0000
Attachment s: Wuhan Coronavirus Vaccine.docx
Please handle.
From: John Howard _________ Cb

_>_<_ ·>
To: Fauci, Anthony (NIH/NIAID) [E]______ ..,,
(b"""
)(=6)
Subject: coronavirus
Dear Dr, Fauchi,
I understand you are leading an effort on the Wuhan Coronavirus . I am writing to enquire how we may
help in this effort. (b)(4
,___ (b
,...,)"(4
")"
Thanks for your attention regarding this matter.
Sincerely,
John Howard, PhD

President ABI
(b)(6)
NIH-002200
Sent: Wed, 5 Feb 2020 03:49:07 +0000
To: Fleisher, Thomas (NIH/CC/OLM) [V)
Subject: RE: Question
No problem.
From:Fleisher, Thomas (NIH/CC/OLM) (V) (b) (6) >

-------
To: Fauci, Anthony (NIH/NIAID) [E] -------=- Cb
c--
H= >
Subject: Re: Question
Tony,
Would you be willing to have your statement "we are in the middle of influenza season..." included in
the Academy 's on line Practi ce Matters email Thursday going out to all members (attri buted to you)
along w ith a link to the CDCwebs ite devoted to Coronavirus?
Than ks,
Tom
From: "Fauci, Anthony (NIH/NIAID) (E)" (b)( >

Date: Tuesday, February 4, 2020 at 3:14:47 PM
To: "Fleisher, Thomas (NIH/CC/DLM) IV]"----- ~=
Subject: RE: Question ---------
Tom:
Right now nothing specific to communicate except that we are still in the middle
of an influenza season and the things that we do to prevent spread of flu (i.e.
hand washing, social distancing from crowds) are the same things that we would
do if we have transmissions of nCoV here .
Best,
Tony
Directo r
National Institute of Allergy and Infectiou s Disease s
Phon e: (b)(6)
FAX : (301 ) 496-4409
E-mail :
-------- (b)(6)
NIH-002201
From: Fleisher, Thomas (NIH/CC/DLM) [V]

--------- (6)> (b)
To: Fauci, Anthony (NIH/NIAID) [E]------~~ CbH6J>

Subject : Question
--------
Tony,
I was asked if th ere is any message th at the A&I community should receive in regards to the curr ent
Coronavirus outbreak in China and potential impact on the US. I recognize the CDC and state medical
boards are releasing updates and recommendat ions but t he question posed to me was is there anything
AAAAI should communicate to our membe rs? Thank yo u for considering this question.
Regards,
Tom
NIH-002202
Sent: Wed, 5 Feb 2020 03:48:11 +0000
To: Sylvia Burwell
Subject: RE:A couple of quick quest ions.
Sylvia:
Masks are really for infected people to prevent them from spreading infection to people who
are not inf ected rather than protecting uninfected people from acquiring infection. The typ ical
mask you buy in the drug store is not really effective in keeping out virus, which is small enough
to pass through the material. It might, however, provide some slight benefit in keep out gross
droplets if someone coughs or sneezes on you. I do not recommend that you wear a mask,
particu larly since you are going to a vey low risk location. Your inst incts are correct, money is
best spent on med ical countermeasures such as diagnostics and vaccines.
Safe travels.
Best regard s,
Tony
From:Sylvia Burwell (b)(6)>

Sent : Tuesday, February4, 2020 10:24 PM
To: Fauci,Anthony (NIH/NIAID) [El ------~~ (b)(6)
Subject : A couple of quick questions .
From:Sylvia Burwell (b)(6)

Date: February4, 2020 at 9:35:03 PM EST
To: Sylvia Burwell (b)(6)
Subject: Fwd: Advice re a donation
EXTERNAL EMAIL : Use caution with links and attachments.
From: Sylvia Burwell (b)(6)

-----------
To: Tony Fauci (b)(6)>
Subject: Fwd: Advicere a donation
NIH-002203
Tony
Two quick questions
1. I am travel ing to (b)(6) Folks are

suggesting I take a mask for the airport. Is this something I should do.
2. Please see below. Do the Chinese have needs for support right now?
Would money be better spent on diagnostics or vaccine work?
Thanks!
Sylvia
From: Richard Falkenrath

----------
(b)(6)
To: (b)(6) Sylvia Mathews Burwell

(b)(6)
Subject: Advice re a donation
Hi Sylvia
I hope this find you well.
Quick quest io n, a little bit from left field, but drawing on your
experience at Gates and HHS. Ray Dalio and Bridgewate r are
interested in making a very sizable donation to help China deal
with the globa l public health challenge arising from the new
coronavirus. Any suggestions of where we should look to
donate the funds?
Thanks so much.
-----------
forward to seeing you again soon.
(b) (6) looking
Richard
(b)(6)
NIH-002204
Sent: Wed, 5 Feb 2020 00:42:06 +0000
Subject : FW: Interview wi t h Voice of America
Let us discuss.
Director
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b)(6)
From : Rattaphol Onsanit <ronsanit @v oanews.com >
Subject: Interview with Voice of America
Dear Dr. Fauci,
l' m Chief of Voice of America 's Thai Serv ices. We met at the Thai Embassy on a Mahidol Award ceremony years
ago.
l' m now working on a news story about ho w developing countries equip themselves with medical readiness and
policy responsiveness in the wake of the coronaviru s outbreak. T'm interested in this aspect because when T looked at
Global Health Sec11rityIndex, Tha iland was ranked the highes t in its ability to tack le epidemics ahead of Japan ,
Korea and Singapore. It's also by far the highest among developing countries.
I'm curious to find out about contributing factors for developing countries' readiness to effectively handl e an
outbreak like coronavims. There may be some esse ntial aspects each counlTy can learn from one another during this
outbreak and Thop e that this story cou ld shed lights on tha t.
If you are free in the coming days, I would like to have an interview with you, if possible, on Skype. I would really
appreciate the opportunity to spea k with you again.
Thank you,
Rattaphol
Rattaphol "Ahn" Onsanil

Chief of VOA Thai
NIH-002205
Sent from my iPhone
NIH-002206
Sent : Wed, 5 Feb 2020 00:31:31 +0000
To : Messonnier, Nancy (CDC/DDID/NCIRD/0D)
Subject : FW: WSJ In Japan, a local bus dr iver in his 60s te sted positive aft er he drove
tou rists from Wuhan, none of w hom had exhibited severe symptoms
Nancy:
See yellow highlight below . Did they misquot e the CDC?
Thanks,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From : Folkers, Greg (NIH/N IAID) [E)

--------
(b)(6)>
To: Fauci, Anthony (NIH/NIAID) [E)______ _,(b

__)-,-
(6)
=
Subject : WSJ In Japan, a local bus driver in his 60s tested positive afte r he drove tour ists from Wuhan ,
none of whom had exhibited severe symptoms
From: Folkers, Greg {NIH/NIA ID) [E) (b)( >

--------
Subject: WSJ: Experts Race to Figure Out How Contagio us the Coronav irus Is
Experts Race to Figure Out How Contagious

the Coronavirus Is
NIH-002207
The outbreak of novel coronavirus appears more contagious
than seasonal flu and is on par with SARS in 2002 and 2003,
studies say
China says that as of Saturday there were 4,109 infected people in the city of Wuhan . Photo: china
daily/Reuters
By
Chao Deng and
Jeremy Page
Updated Feb. 2, 2020 7:34 pm ET
BEIJING-Public-health experts around the world have been crunching numbers about the advance of
China's dangerous new coronavi rus to estimate how far and fast it could spread.
Studies pub lished in recent days say the new virus appears to be more contag io us than seasonal flu and
on par with the simi lar pathogen behind an o utbreak of severe acute respiratory syndrome in 2002 and
2003. The new virus' mortality rate, however, is far below that of SARS.
China says that as of Sunday there were 5,142 infected people in Wuhan, the locked-down city where
the outbreak began. Some scientists estimate based on statistical models that the number could be in
the tens of thousands.
As health autho rities race to control the outbreak, they are also scramb ling to fi gu re out. based on
imperfect data, how the virus is transmitted, the length of the incubation period and the degree to
which people w ithout symptoms can spread the disease.
China's health commission says incubation is generally between three and seven days, with the longest
period being 14 days, and that people can spread the v irus before appearing ill. That makes a two-week
NIH-002208
quarantine an important prevention measure-and casts doubt on the efficacy of temperature checks,
the main screening method at immigration and other checkpoints.
"For a given level of transmissibility, more asymptomatic transmission makes a disease harder to
control," said Christi A. Donnelly, a professor at University of Oxford and Imperial College London.
The U.S. Centers for Disease Control and Prevention, which warns against nonessential trave l to China,
says it isn't clear how easily or sustainably the virus is spreading between people, but notes its abil ity to
spread from infected patients without symptoms to close contacts within about 6 feet.
A study led by a researcher from Boston's Northeastern University-using mathematical probability
models based on travel patterns and confirmed international cases-estimated the median number of
infections in Wuhan at 31,200 as of Wednesday, compared with that day's official tally of 2,261.
Professors at the University of Hong Kong using similar methods published a study in the Lancet on
Friday that estimated there were 75,815 infected in Wuhan as of Jan. 25, when official counts were still
in the hundreds.
"We think only 1 in 20 people who are getting infected are actually being diagnosed" in Wuhan, said
Jonathan M. Read, lead author of a study from Britain's Lancaster University that also put Wuhan
numbers in the tens of thousands as of Jan. 22. "It's quite a bit more transmissible than seasonal flu."
Several recent studies published by scientists estimate that each person infected will, on average, infect
two to three others. Epidemiologists call that the reproduction number .
A reproduction number over 2 suggests an epidemic will expand rapidly, while below 1 suggests the
problem is dwindling. Estimates of the reproduction number differ widely, with some studies using
probability models and others based on regression analysis of cases over different time periods .
Still, "they all point in the same direction," said Christian L. Althaus, an epidemiologist at the University
of Bern in Switzerland who co-wrote a study estimating the basic reproduction number of the virus at
2.2. "There is a potential threat of a global pandemic if this reproduction number cannot be reduced."
In Japan, a local bus driver in his 60s tested positive after he drove tourists from Wuhan, none of whom
had exhibited severe symptoms . In Germany, four employees at an auto-parts supplier contracted the
virus after attending a training session with a colleague from China, according to the company . The
Chinese woman didn't exhibit symptoms, but started feeling ill on her flight home, where she tested
positive for the new coronavirus.
A study published in the New England Journal of Medicine study by Chinese authors including at the
Chinese Center for Disease Control and Prevention says the virus spread between people as early as
mid-December. The researchers analyzed 425 patients, with more than half of the cases linked to the
Huanan seafood wholesale market where authorities believe the virus first spread to humans from wild
animals.
The researchers started identifying and collecting cases around the start of the year, by interviewing
patients, relatives and other close contacts. They estimated the reproduction number at 2.2 and said
that the majority of patients weren't hospitalized unti l after five days of being ill.
Researchers of recent studies cautioned that even their estimates of the virus ' reproduction number are
based on early and incomplete data and only assess its potential to spread before trave l restrictions and
other control measures begin. Thereafter, the reproduction number can vary depending on those
measures' effectiveness and other circumstances of the outbreak.
Chinese officials have said the outbreak could peak or even begin to subside by Feb. 8, though some
overseas experts have suggested the outbreak might not peak for several weeks.
They note that the reproduction number doesn't necessarily predict an outbreak ' s severity, as many
other factors come into play. Measles, for example, has a reproduction number of 12 to 18, but doesn' t
spread that fast because there is a widely used vaccine.
As yet, there are no vaccines for the new coronavirus, so Chinese authorities are relying on physical
intervention measures, including locking down entire cities and forced quarantine .
NIH-002209
Recent studies ind icate that stringent control measures will be needed not just in China, but in several
other countries, to curtail the outbreak .
"This is unprecedented both in terms of the virus and the control measures that have been put in place,"
says Adam Kucharski, associate professor at the London School of Hygiene and Tropical Medicine.
- Raffaele Huang, Miho lnada and Ruth Bender contributed to this article.
Write to Chao Deng at Chao.Deng@wsj.com and Jeremy Page at jeremy .page@wsj.com
Copyright ©2019 Dow Jones & Company, Inc. All Rights Reserved.
87990cbe856818d5eddac44c7blcdeb8
Disclaimer: Any third-party mater ial in this email has been shared for internal use under fair use provisions
of U.S. copyright law , without further verification of its accuracy /veracity . It does not necessarily represent
my views nor those of NTATD, NIH , HHS , or the U.S. government .
NIH-002210
Sent : Wed, 5 Feb 2020 00:05:35 +0000
To: Baden, Lindsey, M.D .
Cc: Mars ton, Hilary (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Lerner, Andrea
(NIH/NIAID) [E]______ Cb_H_6);Morens , David (NIH/NIAID) [E]
Subj ect : RE: favor
Att achment s: ------------- (b
~)~(6)
~.~(b~)~
(4)
Lindsey:
(b)(6),(b)(4)
Best regard s,
Tony
Director
Phone: (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From : Baden, Lindsey, M.D.<lb aden@nejm.org>

Sent ; Tuesday, February 4, 2020 3 :35 PM
To: Fauci, Anthony (NIH/NIAID) [E]______ _,(__
b)..,.(6)
"""
Cc: Marston , Hilary (NIH/NIAID) [E] _______ Cb

_>_C6)
_ >; Conrad, Patricia (NIH/NIAID) [E]
(b)(6)
Subj ect : Re: favor
Tony (and Hilary) ,

Much apprec iated .
Thank you,
------- (b)(6),(b)(4).
Lindsey
NIH-002211
Fro m: "Fauci, Anthony (NIH/ NIAID) [E]" (b)(6)
Date : Tuesday, February 4, 2020 at 2:16---------

PM
To: "Baden, Lindsey, M.D." <lbaden@ne jm.o rg>
Cc: "Marston, Hilary (NI H/N IAID) [E]"
[E]" (b) (6) ---------- Cb)( >, "Conrad, Patricia (NIH/N IAID)
Subject : RE:favor
Lindsay:
(b) (6), (b) (4)
Tony
Director
Phone : (b)(6)
FAX : (301) 496-4409
--------
E-mail : (b)(6)
accept liability for any statements made that are the sende r' s own and not expressly made on
From: Baden, Lindsey, M.D.< lbaden@ne jm.org>

Se nt: Tuesday, February 4, 2020 12:31 PM
Subject : favor
-------- (b)(6)
[~ (b) (6), (b) (4)

Lindsey
intended only for the person or entity to which it is addressed and may contain confidentia l, privileged,
and/or proprietary material. Any review , duplication, retransmission, distribution, or other use of, or
recip ient is unauthorized by the sender and is proh ibited. If you have received this message in error,
NIH-0022 12
NIH-002213
Sent: Tue, 4 Feb 2020 22:59:29 +0000
To: Lane, Cliff (NIH/NIAID) [E)
Subject: RE: favor
Thanks. Safe trave ls
Director
Phone : (b)(6)
FAX : (301 496-4409
E-mail : (b)(6)
--------
From: Lane, Cliff(NIH/NIAID) [El
(b)( >
To: Fauci, Anthony (NIH/NIAID) [El -------=-:~ (b)(6)

.========~=
Subject : Re: favor ----------
Cc: Marston, Hilary (NIH/NIAID) [El (b)(6)
(b) (6), (b) (4)
On Feb 4, 2020, at 9:13 PM, Lane, Cliff (NIH/NIAID) [E]

--------- CbH6J>wrote:
(b) (6), (b) (4)
NIH-002218
On Feb 4, 2020, at 8:46 PM, Fauci, Anthony (NI H/N IAID) [E] (b)(6)
wrote:
---------
(b) (6), (b)(4)
. Thanks.
Director
Phone : (b)(6)
FAX : (301 ) 496-4409
E-mail
-------- (b)(6)
who is not the orig inal intended recipient. If you have received this e-
mail in error please Inform the sender and delete it from your mailbox or
Infectious Diseases (NIAID) shall not accept liability for any sta tements
made that are the sender 's own and not expressly made on beha lf of the
From : Baden, Lindsey, M .D. <lbaden@nejm .org >

Sent : Tuesday, February 4, 2020 3 :35 PM
Cc: Marston, Hilary (NIH/NIA ID) [E] >; Conrad,
Patricia (NIH/N IAID) [E] (b)(6)
Subject : Re: favor
Tony (and Hilary),

----~~~=(b)(6),(b)(4)
Much appreciated.
Thank you ,
--------
Lindsey
From : "Fauci, Anthony (NIH/ NIAID) [E]" (b)(6)>

Date: Tuesd ay, February 4, 2020 at 2:16 PM
To: "Baden, Lindsey, M.D." <lbaden@nejm.org >
Cc: "Marston, Hilary (NI H/N IAI D) [E]" CbH6J
...:--==========~;;- ..
"Conrad, Patricia (N IH/NIA ID) [E]"
Subject: RE: favo r ---------- Cb)(6)
NIH-0022 19
Lindsay:
(b) (6), (b) (4)
Tony
Director
Phone : (b)(6)
FAX : (301 ) 496-4409
E-mail: (b)(6)
The information in this e-ma il and any of its attachments is confidential
who is not the original intended recipient. If you have rece ived this e-
any other storage devi ces . The National Institute of Allergy and
Infectious Diseases (N IAID) shall not accept liability for any statements
From: Baden, Lindsey, M.D.< lbaden@ne jm.or g>

------~~ =
Subject: favor
--------- (b)(6)>
Ton
(b) (6), (b) (4)

Lindsey
Th is email message is a private communication. The information transmitted,
including attachments, is intended only for the person or entity to which it is
addressed and may contain confidential, privileged, and/or proprietary
mate rial. Any review, duplication, retransmission, distribut ion, or other use
of, or taking of any action in reliance upon, this information by persons or
entities other than the intended recipient is unauthorized by the sender and
is prohibited. If you have received this message in error, please contact the
sender immediately by return ema il and delete the original message from all
NIH-002220
This email message is a private communication. The information transm itted,
including attachments, is intended only for the person or ent ity to which it is
addressed and may contain confidential, privileged , and/or proprietary
mater ial. Any review, duplication, retransmission , distribution, or other use
of, or taking of any action in reliance upon, this informa t ion by persons or
ent ities other t han the intended recipient is unautho rized by the sender and
is prohib ited. If you have received this message in error , please contact the
sender immediately by return email and delete the orig inal message from all
(b) (6), (b) (4l
NIH-002221
Sent: Tue, 4 Feb 2020 21:28:48 +0000
To : Seder, Robert (NIH/VRC) [E]
Subject: (b)(6)
Bob:
I am drowning here in
------------------------
coronavirus. Hope to talk to you soon.
(b)(6)
Best,
Tony
Director
Phone: (b)(6)
FAX : (301 ) 496-4409
E-mail (b)(6)
information. It should not be used by anyone who is not the or iginal intended recipient. If you
NIH-002222
Sent : Tue, 4 Feb 2020 21:0 1:39 +0000
Subj ect : FW: Media Request: CBCNews
FYI
Director
Phone : (b)(6)
FAX: (301) 496-4409
E-mail : (b)(6)
From:Adam Miller <adam.miller@cbc.ca>

-------~~
Subject : Media Request: CBCNews
--------- (b)(6)
Hi Dr. Fauci,
I'm a senior writer with Canada's public bro adcaster, CBCNews, and I'm working on a national feature
story about the containment efforts of the coronavirus outbreak and what future scenarios could be
possible with the coronavirus globally.
You spoke with my colleague Kelly Crowe by phone recently, and I'm hoping you could spare a few
minu te s by phone to talk about the possibi lity and implications of the outbreak becoming endemic.
Would it be possible to speak briefly by phone this week? I would only need a few minutes of your time
and your expertise would be very beneficial for Canadians in the ir understand ing of this story .
Thanks very much,
Adam
Adam Miller
NIH-002223
Senior Digital Writer
CBCNews
Desk : 416-205-5719
Cell: (b)(6)
Twitter : @adamsmiller
NIH-002224
Sent: Tue, 4 Feb 2020 20:46:18 +0000
To: (b)(6)
Subject: FW: favor
Attachments : (b) (6), (b) (4)
(b) (6), (b) (4)
CbH6).CbH 4J Thanks.
Director
Phone : Cb)(6)
FAX : (301 496-4409
E-mail : Cb) (6)
From: Baden, Lindsey, M.D.<lbaden@nejm.org>

To: Fauci, Anthony (NIH/NIAID) [E) '====== ------~~ (b==
)(=-'
6)!-=-,
Cc: Marston, Hilary (NIH/NIAID) [E] Cb)( ; Conrad, Patricia (NIH/NIAID) [E)
(b)(6)
Subject : Re: favor
Tony (and Hilary),

Much appreciated .
Thank you,
-------- (b) (6), (b) (4)
Lindsey
Date: Tuesday , February 4, 2020 at 2:16---------

PM
To: "Baden, Lindsey, M.D." <lbaden @ne jm .org >
Cc: "Marston, Hilary (NIH/NIAID) [E]"
[E]" (b) (6) ---------- Cb)( >, "Conrad, Patricia (NIH/NIAID)
Subject: RE:favor
NIH-002225
Lindsay:
(b) (6), (b) (4)
Tony
Director
Phone : (b)(6)
FAX: (301) 496-4409
E-mail : (b)(6)
information . It should not be used by anyone who is not the or igina l intended recipient. If you
From: Baden, Lindsey, M .D. <lbaden@nejm .org>

-------=---c-c=
To: Fauci, Anthony (NIH/NIAID) [E]_______ Cb
_H_6)
Subject : favor
Ton
(b) (6), (b) (4)

Lindsey
intended only for the person or entity to which it is addressed and may cont ain confidentia l, privileged,
and/or prop rietary material. Any review, duplication, retransmission, distribution, or othe r use of, or
recip ient is unauthorized by the sender and is proh ibited . If you have received this message in error ,
intended only for the person or entity to w hich it is addressed and may cont ain confidentia l, priv ileged,
and/or proprietary material. Any review , duplication, retransmission, distribution, or other use of, or
recip ient is unauthorized by the sender and is proh ibited. If you have received this message in error,
NIH-002226
Sent : Tue, 4 Feb 2020 19:36:10 +0000
Subject : FW: Delivery Status Not ification {Failure)
Please t ake a look and handle.
Director
Phone (b)(6)
FAX: (301 496-4409
E-mail : (b)(6l
From: Robert Knobler Cb)(6) >

-------~~ (b)(6)
Subject : Fwd: Delivery Status Notification (Failure)
------- --- Forwarded message -------- -

From: Mail Delivery Subsystem -------------=""''"'"-="
(b) (6)
Date: Tue, Feb 4, 2020 at 1:30 PM
Subject : Delivery Status Notification (Fai lure)
To: (b)(6)
?
•
NIH-002231
Address not found
Your message wasn't delivered to

------------
co u Id n 't be found, or is unable to receive mail.
(b)(6) because the address
The response fr om the remote server was:
550 #5 . 1 . 0 Address r e j ected .
------- --- Forwarded message -------- --

From: Robert Knobler Cb)(6)
-----------
Toi
Cc:
Bee:
(b)(6)
Date: Tue, 4 Feb 2020 13:29:23 -0500

Subject: Potential Coronavirus Prophylaxis
Dear Dr. Fauci,
You likely do not recall meeting me when I was looking at potential
fellowships in 1978, however, I never forgot your enthusiasm. I went
out to San Diego and worked with Mike Oldstone between 1979 and 11984.
I did study a mouse coronavirus while there, mouse hepatitis virus
(MHV) . I focused on genetic resistance, and eventually described a
mouse locus for susceptibi lity, which coded for the MHV receptor. On
to the present problem of human coronaviruses, Vaccines will take a
long time for the current crisis. The angiotens in convertin enzyme 2
receptor has been ident ifed as t he relevant human coronavirus
receptor. I am writing to suggest the investigation of ARBs as
potential blocking agents to either reduce or completely block
infection. Perhaps this can be checked. There may sti ll be sufficient
untai nted suppl ies of ARBs, such as irbesar tan, available , or
production can be scaled up, if t his truly is t he eve of a pandemic .
Wish ing you success in th is endeavor. I am willing to cont ribu te in
any way I can. Please feel free to contact me by e-mail or my cell
phone .
I did do clinical trial while with Mike, and then when I joined t he
NIH-002232
neurology faculty of Jefferson in Philadelphia. I have been out on my
own since December 1998, but I have never lost my interest in this
work . I have some novel ideas on how HIV becomes AIDS, as well.
All the Best,
Robert L Knobler , MD, PhD
(b)(6)
(b)( Cell
NIH-002233
Sent : Tue, 4 Feb 2020 15:54:25 +0000
To: 00~
Subj ect : FW: STAT: Quick retract ion of a faulty coro naviru s paper was a good moment
for science http:/ /bit.ly/389QguM
Heat her:
As per our recent conve rsation. This is your story (see below).
Best,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
The Watchdogs
Quick retraction of a faulty coronavirus paper

was a good moment for science
By Ivan Oranskyand Adam Marcus
February 3, 2020
NIH-002237
- -- ----• ,Hyacinth Empinado/STAT
As fears of the novel coronav irus 2019-nCoV continued to spread last Friday, an inflammatory new
paper appeared on bioRxiv, a preprin t server, where scientists post work that hasn't been vetted.
Titled " Uncanny similarity of unique insert s in the 2019-nCoV spike prot ein t o HIV-1 gp120 and Gag," the
paper claimed to find similarities between t he new coronavirus and HIV, the virus that causes AIDS. The
use of the word "uncanny" in the t itle , together with "unlikely to be fortuitous" in t he abstract, led some
to th ink that the authors were suggesting the virus had somehow been engineered by humans.
The paper, from academic institutions in New Delhi, India, was critical and alarming, if true. Except that
it wasn't.
The paper was almost immediately withdrawn, but not before plenty of handwringing from researchers
who comp lained that the appearance of such shoddy work on a preprint server without vetting by peer
reviewers is precisely why the hoary old model of science publishing is better at keeping junk science
out of the literature.
Except that's not true, eit her. The old model has its advantages, to be sure, but it, too, is prone to the
menace of pseudoscience, bad data, and other flaws - despite traditional academic journals' army of
peer reviewers. And when these publications publish bad or erroneous research, it can take months or
years for the papers to be corrected or retracted - if they ever are.
In contrast, the reaction from the scientific community to the bioRxiv paper was swift. In a nutshell,
commenters on bioRxiv and Twitter said, the author's methods seemed rushed, and the findings were at
most a coincidence. By Saturday morning, bioRxiv had placed a special warning on all papers about
coronavirus. Later Saturday, the authors commented on their paper, saying they were w ithdrawing it .
And on Sunday, a more forma l ret raction appeared: "This paper has been withdrawn by its authors .
They intend to revise it in response to comments received from the research community on their
technical approach and their interpre tation of the results."
All of that happened before a single news outlet with any reach covered the paper, as best we can tell.
But none of it was quite fast enough for some critics. "This is why preprints can be bad," said one
scient ist on Tw itte r. That scientist, Michael Shiloh, said he had even used bioRxiv to post preprints.
"What bugs me about this preprint is that had this manuscript undergone legitimate peer review, these
flaws would have led to a swift rejection and it wouldn't be contributing to the conspiracy theories and
fear surrounding this outbreak," Shil oh cont inued .
History suggests that Shiloh's confidence in peer review's ability to suss out pseudoscience may be a bit
misplaced . The fraudulent 1998 paper that set off the vaccine-autism scare was published in The Lancet,
one of the world's leading peer-reviewed medical journals. Other examples - including a paper by an
NIH-002238
intelligent design advocate questioning the validity of the second law of thermodynamics as it pertained
to evolution - abound . Papers claiming a link between autism and vaccines pop up near ly every year.
Preprints can fill a void in times of rapidly changing science

And even when peer-reviewed jou rnals do realize they've been had, retractions can take months or
years. The Lancet took 12 years. Another journa l took five years to retract a paper claiming that HIV did
not cause AIDS. We could go on, and the list includes papers that have never even been corrected.
Those who claim preprint servers are dangerous because they lack peer review - bioRxiv has a
perfunctory screening process - sometimes acknowledge that journals have had to speed up their
game to meet the pressures of an outbreak like coronavirus, or SARSin the early part of this century.
Angela Cochran, president of the Society for Scholarly Publishing, a trade group for publishers, said on
Twitter : "Earlier this week, folks celebrated that coronavirus papers were popping up in preprint servers.
Now there is a reminder not to use them to guide clinical practice because they haven't been reviewed.
Journals ARE reviewing coronavirus papers and getting [them] pub'd quickly."
Kent Anderson, another publishing industry veteran, put it more bluntly: "Journals Win The Coronavirus
Race."
Publishers have been looking for ways to score points against - and shut down - preprints for at least
half a century . Journals have speedily published a number of important papers on the new coronavirus
already, no doubt. Publishing industry champions are often quick to say that speedy peer review does
not mean sloppy peer review - even in cases that requ ire massive correct ions.
It now turns out that one of the world's leading peer-reviewed medical journals, the New England
Journal of Medicine, pub lished a lette r last week about apparent coronavirus transmission from an
asymptomatic person that turns out to be wrong . Such letters to the editor are not typically peer-
reviewed, or at least not as rigorously as a full study. But it's a glaring example of how a peer-reviewed
journal can end up getting things wrong. Now we get to wait and see how long it takes NEJM to correct
the record.
We'll see whether peer-review champions, who are often unwilling - with some notab le and we lcome
exceptions - to acknowledge how slow and ineffective correction in science can be, note this apparent
failure of one of their gatekeepers. Doing so might, after all, make some people question the expe nsive
subscript ion deals universities agree to w ith publ ishers, as well as the article processing charges that can
run into the thousands of dollars for open access publications.
Peer review can add a valuable filter. But those who work in publishing seem to be so wedded to the
existing process that they can't admit its fl aws - or that it might be a good idea to also embrace
preprint servers that could upend their business models. Just like in politics, maybe it's time to agree
that the publishing process is a messy one, and stop using single episodes, free of context, to score
points against one's rivals.
This article has been updated with information about a flawed report in the New England Journal of
Medicine.
my views nor those of NIAID , NTH, HHS, or the U.S. government.
NIH-002239
Sent: Tue, 4 Feb 2020 15:03:33 +0000
To: Mascola, John (NIH/VRC) [E);Graham, Barney (NIH/VRC) [E);Erbelding, Emily
(NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E];Eisinger, Robert
(NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID ) [E]
Subject : Universal coronavirus vaccine
(b) (5)
Director
Phone: (b)(6)
FAX: (301) 496-4409
E-mail: (b) (6)
NIH-00224 0
Sent : Tue, 4 Feb 2020 14:32:42 +0000
To : Greg Folkers (b)(6));Marston, Hilary (NIH/NIAID)
[E];Eisinger, Robert (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E]
Att achments: JVP200014(1).pdf, Coronavirus clean ve rsion 2-3-2020pbf-DCA.docx,
JVP200011(1). pdf
FYI. Confid enti al for now
Director
Phone : Cb)(6)
FAX: (301 496-4409
E-mail (b)(6)

Sent : Tuesday, February 4, 2020 9 :19 AM
To : Fauci, Anthony (NIH/NIAID) [E] ------ (bH > -==--
Tony
See attachment- accepted case series - likely to be pub lished Friday - after we talk - but like ly to
mention it on Thursday - thought you should see it .
HCB
From: Howard Bauchner

To : Annette Flanagin <Annette.Fla nagin@ jamanet w ork .org>; Christiansen, Stacy
<stacy.christ iansen@ jama -arch ives.o rg>; Christopher Muth <Christopher . M uth@jama network .o rg>;
Demetrios Kyriacou <Demet rios.Kyri acou@i amanetwo rk .o rg>; Edward Livingston
--------------- CbH6>>; Fontanaros, Phil <phil.fontanar o sa@jama-archives.org >;

GoIub, Robert <ro bert.golu b@jama-a rchives.org>; Gregory Curfman
NIH-002241
<Gregory.Curfm an@jamanetwork.org >; howard.bauchner@jama-archives.org ; Jody Zylke
<Jody.Zylke@jamanetwork .org>; McDermott, Mary (b)(6)>; Mike Berkwits
<michael.be rkwits@jamanetwork .org>; (b)(6); Anne Cappola
------------ (b)(6)> ; Basch, Ethan Marti (b)(6)>; David Mark

<David.Mark@ jam anet work .or g>; Demetrios Kyriacou <Demetrios.Kyr iacou@jamanetwork.o rg>; Derek
Angus (b)(6)>; Feero, Greg CbH >; George O'Connor
(b)(6) Goff, Donald (b)(6)>; Jeff Savei
=====-~;"""'."'(b)(6); Joynt Maddox, Karen
(b)(6)
(b)(6) Preeti
Malani (b)(6)>; Robert Golub <Robert.Go lub@jamanetwo rk.org>; Saitz, Richard
(b)(6) Schrag, Deborah,M.D. (b)(6)
Tom Cole (b)(6)>; Winkel mayer, Wo lfgang C. (b)(6);
Armstrong, Katrina,M .D. (b)(6)
; Cutler, David (b)(6); Eric
(b)(6J>; Goldman,Lee
---
':-:---:::--~=====~--~
~ (b)(6)JohnWong Eu Li (Div Head, Med Dept) ~-.:-:=======~
~
......:.c========~~,;-"
>; Josh
Sharfstein (b)(6)>; Julie Freischlag, M.D. (b)( ; Merchant,
Raina (b)(6)>; 'Rodgers, Griffin (NIH/NIDDK) [E]'
(b)(6); Steven E. Nissen ------=--:-:-= (b)(6)>;Vokes,
Everett [MED] (b)( Zeke
Emanu eI
----=-.========~--------===========~---
(b)(6)>; Andy Josephson (b)(6)
(b)(6) Bonow, Robert, M.D. (b)(6)
-----.=======~~------
Bressler, Neil (b)(6); Dimitri A. Christakis, MD, MPH
_.:..__..!=====~~~
(b)(6)
=====-_;__.,;__ _ _.::::======~::;:;;--=--
>; Disis, Nora
....
(b)(6)>; Fred Rivara, MD ----------
(b)(6); Ongur, Dost (b)(6)
-; R
::".
i:--
ta-=-
Re- d-:-:-
b-e-rg-,-:-
M-:-=-
D.:::::::==~ (b)(6)l_
>; Shinkai, Kanade
======== (b
~ )- (6)
~
Subject : Coronavirus
So a quick update.
Attached is a VP that will go up tomorrow - information for clinicians by Carlos del Rio and Preeti. They
worked on it this weekend - thanks to both .
Attached is a VP from Don and Ken Shine that came in before the epidemic/pandemic- but is definite ly
related. Going up this week.
- it will be published on Friday. A big thank you to Phil and Derek.
A Rl has also been accepted - it wi ll go up Thursday.
I cannot thank Stacy and her team (and publishing)- everyone has been working overtime to process
manuscripts in record time, put up a microsite; add CME for US clinicians; etc . Mike (and his team) and
Ed have been a big help.
As we have done in the past everything wi ll be free to the world.
NIH-002242
I am interviewing Tony Fauci again on Thursday- the last podcast, video has close to 150K views- Tony
- as I have said many times - is a national treasure.
(b) (4)
All that said we are definitely interested in novel research report (many can be research letters) . Just let
me know .
HCB
Howa rd Bauchner, MD
Edito r in Chief, JAMA and The JAMA Network
Email: howard.bauchner@ jamanetwork.org

Telephone: 312-464-2400
Please respect the confidential nature of this email.
For my chats wi th authors please see: https :// jamane two rk.com/journa ls/ jama/pages/jama -autho r-
inte rviews
NIH-002243
Sent: Tue, 4 Feb 2020 14:09: 40 +0000
To : Billet, Courtney (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Cc: Haskins, Melinda (NIH/NIAID) [E);NIAID OD AM
Subject : RE:Thanks and filming
I am leaving it up to you all to determine what is doable, feasible and/or

appropr iate . We can discuss at our OD AM meeting .
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Billet, Courtney (NIH/NIAID) [E] _______ Cb

_H_6)
To: Fauci, Anthony (NIH/NIAID) [E]------~=
______ _H_ ; Conrad, Patr icia (NIH/NIAID) [E)
Cb
(b)(6)>
Cc: Haskins, Melinda (NIH/NIAID) [E)_______ Cb
H _.>; NIAID OD AM
_
<NIAIDODAM@niaid.nih .gov>
Subject: RE:Thanks and filming
Just to kee in mind: (b) (4), (b) (5)

(b)(4), (b)(5)
From: Fauci, Anthony (NIH/NIAID) [E] _______ ...,

(b)(6)
Sent: Tuesday, February 4, 2020 6 :42 AM
To: Conrad, Patricia (NIH/NIA IO) [E)-------~~
<NIA IDODAM@ n iaid .n i h,gov > ---------- (b)(6)>; NIAID OD AM
Cc: Haskins, Melinda (NIH/NIAID) [E] (b)( >

Subject : RE:Thanks and filming
--------
NIH-002244
OK

--------
(b)(6)>

(b)(6)
Cc: Haskins, Melinda (NIH/NIAID) [E]
Subject : Fwd: Thanks and filming
---------
For discussion.
------------------------ (b) (4). (b) (5)
Sent from my iPhone
From: Janet Tobias <janet@ikanamed ia.com >

--------~~ CbH6>
Cc: "Robinson, Whitney (NIH/NIAID) [CJ" -:-:-:.===========--=-=-=
__ ..:...:,_:_.===~:;;;------- (b)(6) "Barasch,
.....;.
Kimber Iy (NIH/NIAID) [C]" CbH6)>
Subject: Re: Thanksand filming
(b)(4)
Janet
Sent from my iPhone
On Feb 3, 2020, at 12:27 PM, Conrad, Patricia (NIH/NIAID) IE]

CbH > wrote:
---------
Just called you . sorry crazy morning
Call me a .__ _____

_ _ they can pull me from a meeting
Cb)(6)
Patricia L. Conrad
NIH-002245
(b)(6)
301-496-4409 fax
Disclaimer:
have received this e-mail in e rror please inform the sender a nd dele te it from your mai lbox or any
other storage devices . National Institute of Allergy and Infectious Diseases (NIAID) shall not
accept liability for any statement made that are sender 's own and not express ly made on behalf of
the NIAID by one of its representatives.
From: Janet Tobias <janet@ikanamedia.com>

To: Conrad, Patricia (NIH/NIA ID) [E) --------~= CbH6J>
Subject: Re: Thanks and film ing ----------
Patty can I call you quickly about something-wil l take 3 m inutes.
Sent from my iPhone
On Jan 30, 2020, at 10:02 PM, Conrad, Patricia (NIH/NIAID)

[E] wrote:
CbH6J>
It's been super busy. Will group with others tomorrow

and get back to you.
Sent from my iPhone
On Jan 30, 2020, at 7:51 PM, Janet Tobias

<ianet@ikanamedia .com> wrote :
Hi Patty: Thanks for arranging the

phone call. CbH4)
(b) (4)
NIH-002246
(b) (4)
Never a dull moment in your world!
Janet
NIH-002247
Sent: Tue, 4 Feb 2020 13:58:53 +0000
To: Sylvia Burwell
Subject: RE:Travel restriction policy
Thanks, Sylvia. I miss our late night phone calls during the Ebola and Zika crises.
It was tough , but we got it right.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Sylvia Burwell (b) (6)

To: Fauci, Anthony (NIH/NIAID) [E] ------ ::;..,..-,=
CbH6J>
Subject: RE:Travel restr iction policy
Tony,
Thanks so much fo r sending this AND for your very valuable time on Sunday.
Our students that returned last week are in self-quarantine ...
let me know if I can be helpful to you in any way .
Best,
Sylvia
From: Fauci, Anthony (NIH/NIAID) [E]_______ Cb

_H_6J
To: Sylvia Burwell Cb)(6)
Subject : Travel rest riction policy
NIH-002248
EXTERNAL EMAIL : Use caution with links and attachments.
Sylvia:
You probably already have this information, but here is the official policy as pe
our recent discussion (see link).
https :// china.usembassy-ch ina.o rg.cn/procla mat ion-on-suspension-of-e ntry-as-imm igra nts-and-
nonim migrants-bof-persons-who-pose-a-risk-of-transm itt i ng-2019-novel-coronavi rus/
Best regards ,
Tony
Director
Phone : (b)(6)
FAX: (301) 496-4409
E-mail (b) (6)
NIH-002249
Sent : Tue, 4 Feb 202013:07:15 +0000
Subject : FW: Phone interview request from Seoul, Korea
Let us di scuss.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail Cb)(6)
From: The Scoop tbs eFM

------------
(b)(6)

-------~~
Cc: (b)(6)
--------- (b)(6)
Subject : Phone interview request from Seoul, Korea
Hello, Dr. Anthony Fauci.
This is Seyoung, a writer of an English radio show, The Scoop, in Seoul, South Korea.
We deliver local and international trend ing news to English speaking listeners around the world .
We'd like to invite you to talk with us on the phone for a special interview regarding the novel
coronavirus outbreak.
If you are interested and available to talk to us through a phone call at 10;30 am Friday or Saturd ay this
w e e k, OR
sometime betwee n 9:30 and 10:30 am next Mond ay, please let us know.
And if you're not available for the given time, please also let us know other times feasible for you .
The interview will run for about 10 minutes and you'll get your questions in advance.
If you could provide your knowledge that is essential especially at this time, it'll be highly appreciated.
NIH-002250
I look forward to hearing from you soon .
Thank you very much .
Seyoung Lee
NIH-002251
Sent: Tue, 4 Feb 2020 13:05:59 +0000
Subject: FW: 2019-nCoV: potential infection on CD4 cells.
Attachments : Insert positions in HIV gp120.pdf
Please have someone respond to this person.
Director
Phone : (b) (6)
FAX : (301 496-4409
E-mail (b)(6)
From: (b) (6)

To : Fauci, Anthony (NIH/NIAID) [E) ------~~
Subject : 2019-nCoV: potential
--------
infection on CD4 cells.
(b)(6)
Dear Dr. Fauci,
As you reali ze d the Indian resea rche r published a paper few days ago entitled "Uncann y
similarjty of unique inserts in the 2019-nCoV spike prote in to HIV-I.gp120 and Gag", which
was latterly withdrawn due to the controversial indication. I did a quick SWISS-MODEL on line
calcu lation. Page 1-3 of the attachm ent show the flexible loops of insertion "1", "2", and "3"
originally from V4, V5 and Vl ofHIV-1 gp120, respectively. But they are in presence on the
spike protein of both bat and 20 19 corona virus (page 4 and 6). These inse rtions are potential
CD4 binding domains (no proof yet but highly likely) and spatially won't interfere with ACE-2
binding domain (both SARS and 2019 coro navirus targetACE-2, page 5 and 6). In another word,
the 2019 virus could be poten tially dual-targeting, infecting the lung and potentially CD4 T cells
too (like HIV, see page 6) !
It is VERY URGENT to have clinicians follow up the confirmed cases such as by isolating their
CD4 cells and doing RT-PCR. Please reach out to them. Rese arch labs including mine after
obta inin g Spike protein of 20 19-nCoV shall examine its interaction with CD4.
NIH-002252
Thank you for your immediateattention.Please keep me anonymous.
God bless us,

(b)(6J
NIH-002253
Sent: Tue, 4 Feb 2020 12:36:50 +0000
Subject: names for W HO working group
Francis:
Derek Kan, Acting Deputy Director of 0MB and a member of the President's
Coronavirus Task Force called me last night and in a very nice way said he would
like to send me a list of names for consideration to be on the working groups to
examine the evo lution of the nCoV. He worked as an executive in biotech prior
to joining the USG and knows these individuals well. They are all people that we
know and so I am just passing them on to you for our consideration.
(b) (5)
Thanks,
Tony
Director
Phone : (b)(6)
FAX : (301 496-4409
E-mail : (b)( 6)
information. It should not be used by anyone who is not the origina l intended recipient. If you
behalf of the NIAID by one of its represe ntatives .
NIH-002254
Sent: Tue, 4 Feb 2020 11:43:36 +0000
Subject: FW: REQUEST FORA TV INTERVIEWON WION TV INDIA
Let us discuss.
From:Latika Chugh {WION) <latika.chugh@zeemedia.esselgroup.com>

To: Fauci,Anthony (NIH/NIAID) [E]-------= (b-c-
)(c-=
6)
Cc:Wion Guest Relations <wion.guestrelations@zeemedia.esselgroup.com>
Subject: REQUEST FORA TV INTERVIEWON WION TV INDIA
Dear Anthony S. Fauci,

M.D., NIAID Director
Greetings from WION!
World Is One News (WION)is an international English news channe l from the Zee Med ia Group,
Ind ia's premier te levision brand . WION is uniquely positioned as the 'Global Voice of India',
presenting its own perspective on internationa l issues of critical significance. WION is the
preferred channel for most opinion makers across the world as they happily attend our shows
bringing in credible viewpoints on many issues. WION is currently available in Ind ia, Indonesia,
The Republic of Philippines, Australia, Vietnam, Hong Kong, UAE, Malaysia, Singapore and
South Africa etc.
W ION's shows have featured Indian Political scenario & global leaders speaking on issues facing
their country and the world in general.
I would like to request for your ti me for an interview with us anytime soon today for 10-15
minutes. We usually conduct Interview via Skype. Request you to share your Skype Id.
It's regarding CORONAVIRUS.
Please let us know when is the best time for you t o join us via Skype. Waiting for your
confirmation.
CLICKHERETO WATCH WION LIVE:

http s://www .wion ews.com/live-tv

l
NIH-002255
© 1998-2019 Zee Media Corporation Ltd (An Essel Group Company), All rights reserved .
www .wionews. com
Look fo1ward hearing from you .
Reg ards
Latika Chugh
WION TV , India
Zee Disclaimer: Confident iality/ Proprietary Note : This communicat ion is confident ial /propr ietary and is
intended for use on ly by the addressee. Zee Med ia Corporation Ltd. accepts no responsibility for any
mistransmission of, orinterference with, th is communication
NIH-002256
Sent: Tue, 4 Feb 2020 03:02:57 +0000
To : Shalimar Adorno
Cc: Conrad, Patricia (NIH/NIAID) [E);Barasch, Kimberly (NIH/NIAID) [CJ
Subject : RE: Message from Dr . Jim Yong Kim
Shalimar:
Than k you for your note. I certainly will speak with Dr. Kim. My schedule is packed due to
the coronav irus situation, and so please contact my Special Assistant , Patty Conrad (copied here
and at (b)(6) to squeeze in a time that works for Jim and me. Thank you.
Best regards,
Tony
From: Shalimar Adorno (b)(6)

Subject : Message from
--------
Dr. Jim Yong Kim
(b)(6)
Good evening Dr. Fauci,
I am writing on behalf of Dr. Jim Yong Kim who would like to have a call with you tomorrow.
Can you please advise if you have any availability ?
Kindly,
Shalima r Adorno
Assistant Vice President
Globa l Infrastructure Partners
1345 Avenue of the Ame ricas . 30th Floor
New York, NY 10105
T (b) (6)
.______ (b
= )~(6)
=
NIH-002257
Sent: Tue, 4 Feb 2020 01:14:05 +0000
(b) (5)
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From:Collins, Francis (NIH/OD) [E] (b) (6) >

---------
Sent : Monday,
To: Fauci, Anthony (NIH/ NIA ID) [E] ________
February 3, 2020 7:26 PM
-------~~ _.
(b)(6)
From:Shapiro, Neil (NIH/OD) [E] (b)(6)

To: Collins, Francis (NIH/OD) IE]
------~= (b)(6) Tabak, Lawrence (NIH/OD) [E]
CbH6l;Johnson, Alfred (NIH/OD) [E] (b)(6) Wolinetz,
.......
---:---:---""."':"'"""".""".:--:":===:..--__;--=--=-~
Carrie (NIH/OD) [E] (b)(6)>; Hallett, Adrienne (NIH/OD) [E]
(b)(6)
Cc: Shaya, Cecile (NIH/OD) [E)

--------- (b)(6)
NIH-002258
(b) (5)
From: Shapiro, Neil (NIH/OD) [E]

Sent: Monday, February 3, 2020 4 :05 PM
-----~~
To: Collins, Francis (NIH/OD) IE] (b)( >; Tabak, Lawrence (NIH/OD) [E]
(b)(6)>; Johnson, Alfred (NIH/OD) [E] (b)(6)>; Wolinetz,
Carrie (NIH/OD) [E] (bH6J>; Hallett, Adrienne (NIH/OD) [E]
(b)(6)
Cc: Shaya, Cecile (NIH/OD) [E]

-------- (b)(6)
(b)(S)
From: Collins, Francis (NIH/OD) [ E] (bH6J>

To: Shapiro, Neil (NIH/OD) [E]
-----~~ (b)(6)>; Tabak, Lawrence (NIH/OD) [E]
(bH >; Johnson , Alfred (NIH/OD) [E] (b)(6J Wolinetz,
Carrie (NIH/OD) [E] (bH >; Hallett, Adrienne (NIH/OD) [E]
(b)(6)
Cc: Shaya, Cecile (NIH/OD) [E)

-------- (b)(6)
NIH-002259
(b)(5)
FC
From: Shapiro, Neil (NIH/OD) [El Cb)( >

Sent: Monday, February 3, 2020 11 :33 AM
To: Collins, Francis (NIH/OD) IE]
-----~~ CbH6b ; Tabak, Lawrence (NIH/OD) [E]
CbH6)>; Johnson, Alfred (NIH/OD) [El CbH6); Wolinetz,
Carrie (NIH/OD) [E] Hallett, Adrienne (NIH/OD) [E]
CbH6)>;
(b)(6)
Cc: Shaya, Cecile (NIH/OD) [E] (b)(6)>
Importance: High
(b)(5)
Neil
NIH-002260
Sent: Tue, 4 Feb 2020 01:08:37 +0000
To : Kai Kupferschm idt
Cc: Greg Folkers------- --=~ (b)(6);Billet, Courtney (NIH/NIAID) [E];Conrad,
Patricia (NIH/NIAID) [E]
Subject: RE: coronavirus quick question
Kai:
Error in my statement to you. I meant to say that " ......most t ransmissions occur
from someone who is symptomatic" - not asymptomatic. I am really tired . Not
much sleep these days.
Best,
Tony
Director
Phone: (b)(6)
FAX:(301 496-4409
E-mail : (b) (6)
From: Kai Kupferschmidt

----------
------
(b)(6)
=--c=
Cc: Folkers, Greg (NIH/NIAID) [E] ...:.======~ ; Billet, Courtney (NIH/NIAID) [E]
(b)~(':.ai
<billetc@niaid .nih .gov>
Subject : Re: coronavirus quick question
Thanks Tony,
this is interesting and I'm sorry I didn't have more time to get a comment from you . I can only imag ine
your workload at the moment. I will include comment from you now .
Best
Kai
NIH-002261
On 4. Feb 2020, at 01:29 , Fauci, Anthony (NIH/NIAID) [E]....______ (b_H_.
6)>wrote:
Sorry that I got to this so late . I have been swamped. I just read
your story in Science. It is unfortunate that they did not interview the
patient. Obviously, this changes the conclusion of the paper. My
comment: "There1 s no doubt after reading [the NEJM] paper that
asymptomatic transmission is occurr ing" was made because there has
been a lot of discussion among Chinese investigators that
asymptomatic infection is occurring in Wuhan City and Hubei Province,
yet no publication came out and said this. Since th is was the first
publication supposedly documenting this phenomenon, that is why I
referred to the paper and made my comment. It is unfortunate that
this error was published, but it still does not really change anything.
Rather than rely on rumors, this evening I telephoned one of my
col leagues in China who is a highly respected infectious diseases
scientist and health official. He said that he is convinced that there is
asymptomatic infection and that some asymptomatic people are
transmitting infection . The NEJM paper may be incorrect, but
according to reputable Chinese scientists , my statement is correct .
Having said that, I have been saying for some time that even if
asymptomatic infection occurs, it is very unlikely to be a major driver of
the outbreak since most transmissions occur from someo ne who is
asymptomatic.
Best regards,
Tony
NIH-002262
From: Fauci, Ant hony (NIH/NIAID) [E)
Sent: Tue, 4 Feb 2020 00:37:32 +0000
To: Conrad, Patri cia (NIH/NIAID) [E)
Subject : RE: Tony and Conronavirus
Set up a caLIfor me with Ed Henry
Director
National Ins titute of Allergy and Infectious Dise ases
Building 31 , Room 7 A-03
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b)(6)
should not be used by anyone who is not the original intended recipient. l f you have received this e-mail in eITor
and not express ly made on behalf of the NlA ID by one of its representatives.
From: Conrad, Patricia (NIH/NIAID) (E]
Sent: Monday , February 3, 2020 12:28 PM ----------
------~~
(b) (6}
To: Fauci, Anthony (NlH/NlAID) [E]

(b)( 6) -------- (b)( 6) > ; Folkers, Greg (NlH/NIAID) (E]
Subject: FW: Tony and Conronavirus
f irm for Feb 11
ASF will you cancel DDCF or do r need to? Please advise
Patricia L Conrad
National Institute of Allergy and Infectiou:sDiseases The National Institutes of Health
(b)( 6)
30 1-496 -4409 fax
Disclaimer:
From : Katz , Ruth <Ruth.Kat z@ aspenin stitute.org>
Sent: Monday , f ebr1.1a1y3, 2020 12:20 PM
NIH-002263
To: Conrad, Patricia (NIH/NWD) [E]
----------
Cc: Katz, Ruth <Ruth.Katz@aspeninstitute.org>
(b)(
Subject: RE: Tony and Conronavirus
We have a room on the 11th. Ron is available and holding the date. Think time would work for you guys. Time
wou ld be over lunch. At tendees arrive around 11:30 to grab lunch. Program sta rts at noon and runs to about I-
I : 15. Of course , Tony is more than welcome to come in time for lunch. But he need not actually arr ive until shortly
before noon so we can mike him up.
J might also try to get someone from CDC 10 round out the discussion. But if only Tony and Ron, we will run with
it. Also need to line up the moderator. But that shouldn't be a problem. Would run options by you first.
Our comms team is really interested in pushing this --
Ruth
RUTH J. KATZ
Vice President, Aspen Institute
Executive Director, Health, Medicine and Society Program The Aspen Institute
rnth.katz @a speninstitute .org

202-736-5827
From: Conrad, Patricia (NIH/NTAJD) [E]
Sent: Monday, February 3, 2020 11:57 AM ----------
To: Katz, Ruth <Ruth.Katz@aspeninstitute.org>
(b)(6) >
Tf you have a room and Mr. Kia in is available on Feb 11 - please let me know. Best between 11 am - 3 or 4 pm
Let me know
Patricia L. Conrad
Natio nal Ins titute of Allergy and Infectious Disea ses The National Institut es of Health
(b)(6)
301-496-4409 fax
Disclaimer:
The infonnation in this e-mail and any of its attachments is confidential and may contain sensitive infonnation. It
and Jnfectious Diseases (NJAID) shall not accept liability for any statement made that are sender 's own and not
expressly made on behalf of the NIATDby one of its representatives.
-----Original Mes:sage-----
From: Katz , Ruth <Ruth .Katz @aspenin stitute.org>
Sent : Monday , Fcbniary 3, 2020 11:43 AM
To: Conrad, Patric ia (NIH/N IAID) [E] -------r:,,:,~(b)(6) >
Cc: Katz , Ruth <Ruth .Katz @aspeninstitut e.org>
NIH-002264
Subject: RE: Tony and Coruonavirus
Hi Patty,
Thanks :so much and understand comple tely. Can only imagine how crazt::<lyou all must be.
Definitely don't want to do this without Tony. Jf next week doesn ' t work , please send some potential options.
Getting a room can be the real challenge here. So I'd like to at least reserve space and cance l if need be. Also trying
to coordinat e with Ron Klain who is very eager to participat e.
Let me know ifI shou ld definitely cance l our space for February 11 or continue to hold for now.
Thanks again for everything!
Ruth
RUTH J . KATZ
Exec utive Directo r, Health, Medicine and Society Program The Aspen Institute
rnth.katz @ aspeninstitute.org
202-736-5827
From: Conrad , Patricia (NIH/NTAJD)[E]
Sent: Monday , Feb ruary 3, 2020 11:36 AM ----------
To: Katz, Ruth <Ruth.Katz @aspeninstitute.org >
(b)(l>t
Hi Ruth - circling back - hope we can make this work - will get back to you in a day or two ....
Patr icia L. Conrad

Pub lic Health Analyst and
Specia l Assistant to the Dir ector
National l nstitu te of Allergy and Infectious Di seases The National Inst itutes of Health
(b)(6)
301-496-4409 fax
Disclaimer:
The infonnation in this e-mail and any of its attachments is confidential and may contain sensitive infonnation. It
please inform the sender and delete it from your mai lbox or any other storage devices. Nationa l Institute of Allergy
and Infec tious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not
expressly made on behalf of the NlAlD by one of its representatives.

From: Conrad , Patricia (NlH/NIAID) [E]
Sent: Monday , Feb ruary 3, 2020 8:40 AM
To: Katz , Ruth <Ruth .Ka tz@aspeninstitute.org >
Hi - sorry for the delay - its been insane ly busy .
NIH-002265
He would love to do this but our schedu le has been changing literally by the minute - so much so that we have had
to cancel meetings , events and 2 trips he had scheduled for out of town last week. So - whi le he would love to do
this and would make himself available ... it might be better to do later when things hopefuJly quiet down a bit.
Defer to you tho as to when you want to do your event. Happy to chat more ....
Patricia L. Conrad
Special Assistant to the Dir ector
National Institu te of Allergy and Infectious Diseases The National Inst itutes of Health
(b)(6)
301-496-4409 fax
Disclaimer:
The infom1ation in this e-mail and any of its attachments is confidential and may contain sensitive information. It
please inform the sender and delete it from your mailbox. or any other storage devices. Nationa l Institute of Allergy
and Infec tious Diseases (NIAID) shall not accept liability for any statement made that arc sender ' s own and not
expressly made on behalf of the NlAlD by one of its represen tatives.
From: Katz , Ruth <Ruth.Katz @ aspenin stitute.org >
Sent: Friday , January 31 , 2020 5:33 PM
--------~~
To: Conrad , Patric ia (NIH/NTAID} [E]
----------
Cc: Katz , Ruth <Ruth.Katz @aspenin stitute.org >
Subject: Re: Tony and Conronavims
(b)(6}
Hi Patty,
Sorry to bother you. Just checking in to see if you have any update. We con tinue to hold the date and room.
Thank s so much. Hope all is well -
Ruth
Sent from my iPhone
On Jan 27, 2020, at 2:45 PM, Conrad, Patricia (N IH/NIAID) [E]
---------------------- (b) ( >> wrote:
Hi ruth - will get back to you as soon as we can
Patricia L. Conrad
National Institu te of Allergy and Infectiou s Di seases The Nat ional Inst itut es of Health
31 Center Drive , MSC 2520 - Room 7A03
(b)(6)
301-496 -4409 fax
NIH-002266
Disclaimer:
The informa tion in this e-mail and any of its attachments is confidential and may contain sensitive information. lt
should not be used by anyone wh o is not the original intended recip ient. If you have receiv ed this e-mail in error
please inform the sender and delete it from your mai lbox or any other storage devices. Nationa l Institute of Allergy
and Infectious Diseases (NJATD) sha ll not accept liabi lity for any statement made that are send er\ own and not
expressly made on behalf of the NIA ID by one of its represen tat ives.
From: Katz , Ruth <Ruth .Katz@aspe ninstitute.org <rnai Ito:Ruth.Katz @aspeninst itute.org >>
Sent : Monday , January 27, 2020 4:25 PM
--------------------~~=
To: Comad , Patri cia (NIH/NIAID) [E]__________________ Cb
_H_6)
Cc: Katz, Ruth <Ruth.Kat z@aspen insti tute .org<mailto:Ruth.Katz @aspen institu te.org >>
Subject: Tony and Conronavirus
Hi Pat ty,
Hope all is well and that your 2020 is off to a good, if no doubt, busy start.
Conta cting you direc tly because you have always been my best "go to" person when it comes to Tony and acti vities
at the Institute. Hope you can be of help again.
1would like to do a Public Health Grand Rounds session on the coronavirus here at our Aspen DC offices -
hopefully on February 11 (from 12 until about 1: 15pm; lunch is made avai lable to attendees). Ron Klain, former
Obama Ebo la czar -- is availab le -- and hope Tony might be as we ll. Tony and Ron are my first two cho ices.
Perhaps we might add someone from CDC. 1 suspect we could get some good press, especially if Tony is in the
lineup .
Know how terribly busy Tony is, but hope 1his might be a possibility. Any chance?
As always, many thanks -
All best ,
Ruth
RUTH J. KATZ
Execu tive Director, Health , Medicine and Society Program The Aspen Institute
ruth.katz @ aspeninstin1te.org <mailto:ruth.katz @ aspen insti tute.org >

202-736-5827
NIH-002267
Sent: Tue, 4 Feb 2020 00:29:06 +0000
To :
Cc: Greg Folker~--------=-:-=-
Kai Kupferschm idt
--------- (b)(6) ;Billet, Courtney (NIH/NIAID) [E]

Subject : RE;coronavirus quick question
Kai:
Sorry that I got to this so late. I have been swamped. I just read your story in
Science. It is unfortunate that t hey did not interview the patient. Obviously, t his
changes the conclusion of the paper . My comment: "There's no doubt after
reading [the NEJM] paper that asymptomatic transmission is occurring" was made
because there has been a lot of discussion among Chinese investigators that
asymptomatic infection is occurring in Wuhan City and Hubei Province, yet no
pub licat ion came out and said this . Since this was the first publication
supposedly docum ent ing this phenomenon , that is why I referred to t he paper
and made my comment. It is unfortunate that this error was published , but it still
does not really change anything. Rather than rely on rumors, this evening I
telephoned one of my colleagues in China who is a highly respected infectious
di seases scientist and health official. He said that he is convinced that there is
asymptomatic infection and that some asymptomatic people are transmitting
infection . The NEJM paper may be incorrect , but according to reputab le Chinese
scientists, my statement is correct. Having said that , I have been saying for some
time that even if asymptomatic infection occurs, it is very unlikely to be a major
driver of the outbreak since most transmi ssions occur from someone who is
asymptomatic.
Best regards,
Tony
Director
Phone : Cb)(6)
FAX: (301) 496-4409
E-mail : (b)(6)
NIH-002268
From: Kai Kupferschmidt

------------
(b)(6)
To: Fauci, Anthony (NIH/NIAID) [E] ------~~ CbH6J>

--------
Subject : coronavirus quick question
Tony,
do you have 5 minutes for a quick phone call? Wr it ing a story about the German paper claiming an
asymptomatic case. Turns out the woman did have symptoms . You gave the paper a lot importance, so
really wanted to get your reaction on this.
Cheers
Kai
Kai Kupferschmidt
contributing correspondent "Science"
(b)(6)
(b)(
t wit t er: @kakape
NIH-002269
Sent : Mon , 3 Feb 2020 22:28:34 +0000
Subject : FW: Coronav iru s - reporter 's questions
NIA ID in qu ir ies, please.
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
From: Rob Britt Cb)(6)

To: Fauci, Anthony (NIH/NIAID) [E) ------~~ CbH6)>
--------
Subject : Coronavirus - reporter's quest ions
Hi Dr. Fauci: We are updat ing our coronavirus st ory per iodi cally, keeping it factual and level-headed, and
I have seen your comment s o n NPR Friday and in the NV Times ove r the weekend, so I hope you could
comment very briefly for our story :
-- What's your expectation fo r whether thi s will become a pandemic?
-- Pandemic does not necessarily equate to a terrible situat io n, comp ared to , say bad flu seasons. What 's
your expectation on the pote ntial severity of t his coronavirus?
-- And your suggestion to people in the U.S. who m ight be very concerned?
Thanks for any help you can provide.

Cheers,
Rob
Robert Roy Britt

Top Write r on Medium in Science & Healt h.
Contr ibutor to OneZero (science) & Element al (health).
Former ed itor-in -chief of Live Science and Space.com.
NIH-002270
(b)(6)
(b)(6)
NIH-002271
Sent : Mon , 3 Feb 2020 22:27:31 +0000
To : Seth Lederman
Cc: Erbelding, Emily (NIH/NIAID) [E];Cassetti, Cristina (NIH/NIA ID) [E]
Subject: RE: New NHP data on our vaccine for smallpox & monkeypox
Seth:
I am swamped with coronavirus stuf f, and so I am forwarding thi s to Emily
Erbelding to tak e a look and respond. Thanks.
Best regard s,
Tony
Directo r
Phone : (b) (6)
FAX: (301 496-4409
E-mail : (b)(6)
informat ion. It shou ld not be used by anyone who is not the origina l intended recipient . If you
From: Seth Lederman

-------------
Sent : Friday, January 31, 2020 11:05 AM
-------~~
(b)(6)>

--------- (b)(6)
Subject: New NHP data on our vaccine for smallpox & monkeypox
Dear Tony,
I enjoyed your corona virus presentation at ASM Biothreats, and understand why you couldn't linger.
I'm writing w ith an update on our horsepox-based vaccine program. On Wednesday, we presented a
poster on our further work w ith TNX-801 (horsepox) as a potent ial vaccine for smallpox and
monkeypox. We found that vaccination of cynos with TNX-801 resulted in sterilizing immunity (no
lesions) in 8/8 animals compared to a synthesized ACAM-like vaccinia wh ich resulted in prot ection, but
lesions on 2/3 animals. More complete information is on th e poster attached, which is available on our
webs ite at (https ://conten t .egu isolve.net/tonixpharma/medi a/10929ac27f4fb5f5204f5cf41d59a121 .pdf
). The press release is also attached and available on our website at (https :// ir.tonixpharma .com/press -
releases/ detail/118 6).
NIH-002272
(b)(4)
-
We'd welcome the opportunity to discuss the data with you and your team.
Best, Seth
(b) (4)
Seth Lederman , MD I Chief Executive Officer

Tonix Pharmaceuticals Holding Cor p. I NASDAQ: TNXP
509 M adison Ave nu e . Suite 160 8, New Yo r k, NY 10 022
Tel____ _.hl@ I Fax 212 923 5700
--------- -'-'"""=
I www .To nixPharm a.corn
NIH-002273
Sent: Mon , 3 Feb 2020 22:21:41 +0000
To : Steinberg, Danielle
Cc: Conrad, Patricia (NIH/NIAID) [E);Billet , Courtney (N IH/NIAID) [E)
Subject: RE: PBS Nature inquiry about Coronavirus
Danielle:
Many coronaviruses exist in animal reservoirs , particularly in bats. Remember
that for t he SARSoutbreak in 2002, bats infected palm civet cats who were sold in
live/wet markets and the civet cats spread the virus to human . Same for MERS-
bats to camels to humans. You ask that there have been animal markets for a
long time, and so why now. The fact is that this is likely pure chance+/- more
interactions in the human-animal interface . Animal viruses mutate and most of
the time the mutations have no significant impact on virus transmission to
humans . Sometimes they mutate and allow single "dead end" transmissions to
individual humans with no efficiency in going human to human and so we get
individual infections and no outbreak as we have seen with HSNl and H7N9
influenzas that jump from chickens to humans but do not go from human to
human. And then rarely, animal viruses mutate and the mutat ion allows them
not only to jump species t o humans, but to also efficiently spread from human to
human . That is what we saw in SARSand now we see this with 2019-nCoV, which
seems to have adapted itself very well to human to human transmission, as per
what is happening in China.
Best regards,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
NIH-002274
From: Steinberg, Danie lle <SteinbergD@th irteen.org>
------~~
To : Fauci, Anthony (NIH/NIAID) [E_______ Cb)
_C_
6)>
Subject : PBS Nature inquiry about Coronavirus
Hi Dr. Fauci,
Hari Sreenivasan of PBSNewsHour suggested I reach out to you with a specific nature questi on that
we're writing about. I hope you'll be able to give us some insights - I'm sure you're extremely busy!
We 'r e wo ndering about the impact of animals on the virus and specifi cally, why now? Presumably, China
has been using animal markets/wildlife trade in these exact ways for a while, so what changed or is
different now to cause this illness and outbreak? Any other information you can provide on how animals
are involved wo uld be greatly appreciated.
Thank you !
Best,
Danielle Steinberg
Danielle SteinbergI Digital Lead, NATUREI + 1 (212) 560-3049 (office)

I l I 825 EighthAvenue 14th Fl. I New York, NY 10019-7435
pbs.orq/natureI Facebook I Twitter I lnstagram I YouTube
NIH-002275
Sent: Mon , 3 Feb 2020 16:43:08 +0000
Subject : FW: Bloomberg Radio 2/4
This is Bloomberg and so if we can do this, let us try. If it is too much of a hassle
then say sorry no . Thanks.
Director
Phone : (b) (6)
FAX : (301 496-4409
E-mail (b) (6)
From: Jameelah D Robinson (BLOOMBERG/ NEWSROOM:) <jrobinson158@bloomberg .net >

------~~
Subject: Bloomberg Radio 2/4
Hi Dr. Fauci!
I Hope this email finds you well. I'm emailing to see if you can join Tom Keene,
Bloomberg Suveillance Anchor/Editor-at-Large on his radio show tomorrow morning as
a PHONER at 8:00am or 8:15am Et to discuss the Coronavirus. Please let me know if
we can make this happen. Many thanks!
-Jameelah
Jameelah Robinson , M.S.

Bloomberg Surveillance
Television & Radio
Bloomberg TV is the world's most-watched business news network, available in more

than 360 million homes worldwide . Watch us live on our website, smartphones, iPad
NIH-002276
app and the Bloomberg Professional Service.
http://Bloombe rg .com/tv/
Bloomberg Radio can be heard live in NY (Bloomberg 1130AM) , Boston (1200AM), San
Francisco (960AM) and now Washington O.C. (99.1 FM) via our local stations. You can
hear us nationally on Sirus/XM Channel 119, and globally via the Radio+, I Heart, and
Tune-In Radio Apps, or 24/7 at http://www .bloomberg .com/audio
NIH-002277
Sent : Mon , 3 Feb 2020 15:17:23 +0000
To: Walensky, Loren D.,M.D.,Ph .D.;Glimcher, Laurie,M.D.;Auchincloss, Hugh
(NIH/NIAID) [E]
Subj ect: RE: Wuhan nCoV Inhibitors
Loren:
(b)(6)
Thanks fo r t he note.
Best regards,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail: (b)(6)
(b)(6)
From : Walensky, Loren D.,M.D .,Ph .D.
-------------
Sent : Sunday, Februa ry 2, 2020 11:28 PM
To: Glim cher, Laurie,M .D.------------ -.a-s-=
(b)(6J>; Fauci, Anthony (NIH/NIAID) [El
-------- (b)( ; Auchincloss , Hugh (NIH/NIA ID) [E]

Subj ect : RE: Wuhan nCoV Inh ibitors
----------- (b)(6)
(b) (4)
NIH-002278
(b)(4)
PS; Dr. Fauci, (b)(6)

------------------------
Thank you again for any guidance you can provide so that we can try to be of help.
Best,
Loren
Loren D. Walensky, M.D., Ph.D.

Principal Investigator , Linde Program in Cancer Chemical Biology
Attending Physician in Pediatric Oncology
Director, Harvard/MIT MD-PhD Program
Dana-Farber Cancer Institute/ Harvard Medical School
450 Brookline Avenue, LC3216
Boston, MA 02215
Office: (b) (6)
Fax: 617-582-8240
Email; (b)(6)
Twitter: (b)(6)
------
From : Glimcher, Laurie,M.D .
---------------
To : Anthony (NIH/NIAID) Fauci---------,.- (b.--.
(b)(6)
H=6) Hugh Jr Auchincloss

(b)(6)
Cc: Walensky, Loren D.,M .D.,Ph.D.
Subject : Fwd: Wuhan nCoV Inhibitors -------------- (b)(6)
Tony and Hugh,

Loren Walensky is a superb physician -scientist at Dana-Farber
-----------------
If this is of interest to you, please let me know or contac t him directly.
Many thanks,
Laurie
Laurie H. Glimcher, M.D.
President and CEO
NIH-002279
Dana-Farber Cancer Inst itute
Richard and Susan Smit h
450 Brookline Avenue, Dana 1628

Boston, MA 02215
) §) tel.
617.632.2161 fax
From: "Walensky , Loren D.,M .D.,Ph.D." (b)(6)>

Subject : Wuhan nCoV Inhibitors
Date : January 30, 2020 at 7 :23:54 PM EST
To: "Glimcher, Laurie,M .D." ---------------
---------------- ~= (b)(6J>
Hi Laurie . I hope all is well on your end . (b) (4)

(b) (4)
NIH-002280
(b) (4)
Thanks so much,
Loren

Principal Investigator, Linde Program in Cancer Chemical Biology
Director, Harvard/MIT MD-PhD Program
Dana-Farber Cancer Inst itute/ Harvard Medical School
Boston, MA 02215
Office: (b) (6)
Fax: 617-582-8240
Email:
------------ (b)(6)
·
The information in this e-ma il is intended only for the person to whom it is
addressed. If you believe this e-mail was sent to you in en-or and the e-ma il
contains patient informa tion , please contact the Partn ers Compliance HelpLine at
http ://www. partners .org/compli anceline . If the e-mail was sent to you in error
but does not contain patient info1mation, please contact the sender and properly
NIH-002281
Sent : Mon , 3 Feb 2020 15:12:39 +0000
To: Routh, Jennifer (NIH/NIAID) [El
Subject: FW: ANSA news agency
Please get someone to provide answers for me to send to this person. I do not
have time to do it myself ,
Anthony s. Fauci , MD
Director
Phone : (b)(6)
FAX : (301 496-4409
E-mail (b)(6)
other storage devices . The Natio nal Institute of Allergy and Infectious Diseases (NIAID) shall not
From: Battifoglia Enrica <Enric a.Battifoglia@ansa.it>

Subject : ANSA news agency
I am Enrica Battifoglia of the Italian news agency AN SA, I already hav e had the ple asure to
intervi ew you several times at the AIDSworld conferences.
I would like to ask you some questions about Coronoravirus 2019-nCo V, to be published on the
ANSA Science web page (www.a nsa.it/scienza ), the main online science news resource in Ital y
with over 1.5M contacts each mon th. I am sure that your clarity and comp etence will be highly
va luable to put some much-needed order among so many contrasting news and data , and wou ld
be much appreciated by our reader s.
NIH-002282
1) Do the current available data allow to understand the threat level of coronarivus 2019-nCo V
in terms of both lethality and diffusion speed, and about the possible evolution scenarios of the
disease?
2) What exactly we know about its modes of transmission, especially from people who do not
yet have the symptoms?
3) Are the genetic sequences provided by China enough to start working on a vaccine?
What are the technical times to develop a working vaccine in terms of scientific research, and
what are the approx times for the necessary legal certifications, and for industrial production and
distribution?
4) 2019-nCov is the third Coronavirus aggressive for humans that has appeared in the East in the
last 20 years and in 2009 the virus responsible for the flu pandemic too did come from China:
what sort of preventive measures could be practicable to reduce the risk ofrepetition of these
events?
Thank you so much for your time your attention!
Kindest Regards
Enrica Battifoglia
Science and Technology Head Editor
ANSA News Agency
II contenuto di questa e-mail e rivolto unicamente a/le persone a/le quali e indirizzato; le relative informazioni sono do
considerarsi strettamente riservate e tutelate ai sensi de/ Regolamento UE 2016/679 (GDPR) per la Protezione dei Doti
Personali, nonche de/ D. lgs. n. 196/2003 e successive modifiche. Sono vietati la riproduzione, la diffusione e /'uso di questa e-
mail in mancanza di autarizzazione def destinatario. In caso di ricezione de/la presente e-mail per errore, si prega di non
NIH-002283
diffonderla, di informare immediatamente ii mittente e di eliminarne ogni copia. Le opinioni espresse in questa e-mail
appartengono esc/usivamente al mittente e potrebbero non riflettere necessariamente que/le dell'Agenzia ANSA.
The content of this e-mail is only addressed to the people to whom it is addressed; the relevant information has to be
considered as confidential and protected under the Regulation EU2016/679 (GDPR),General Data Protection Regulation, as
well as the Legislative Decree 196/2003 and subsequent amendments. The reproduction, distribution and use of this e-mail in
the absence of the recipient's authorization is forbidden. If you receive this e-mail by mistake, please do not disseminate it,
inform the sender immediately and delete any copies. The opinions expressed in this message belong to sender alone and
may not necessarily reflect those of ANSA AGENCY.
NIH-002284
Sent: Mon , 3 Feb 2020 15:10:32 +0000
To : Joe Palca
Subject: RE: Coronavirus vaccine
Joe:
Thanks for the note. The has nothing to do with t he validity of the test. We see
this w ith other viruses when you look at shedding. When there is a low titer of
virus, any specific site (in this case a nose or throat swab) may vary between
positive and negative even though the person is clearly still infected . It could be
that the virus is there in the throat at one point and cleared at another and comes
back again. Alternatively, it may be that the virus is always there, but at different
titers and at some points it is pre sent below the sensitivity of the test, even
though the test is in general quite sensitive.
Best regard s,
Tony
Director
Phone : (b)(6)
FAX: (301) 496-4409
E-mail (b) (6)
From:Joe Palca <JPalca@npr.org>

To: Fauci, Anth ony (NIH/NIAID) [E)
-----~~
-------
Subject : FW: Coronav irus vaccine
(b)( >
From:Joe Palea
NIH-002285
To: 'anthony.facui@nih.gov ' (b)(6)>
Cc: 'Deatrick, Elizabeth (NIH/:-:-
N'."."
IA-:-:
1-:-
0-:-
) :-:
[C'.":".
] ,~====-----= (b"'""
)~( >; Scott Hensley
(b)(6)
Subject : RE: Coronavirus vaccine
Hi Tony,
It's been nice hearing you on the various press conferences ...can't believe we're still both doing this.
Have a question about something Redfield said in Friday in the White House briefing about nCoV. He
said using their PCRassay, the virus can be detectable one day, then not the next, then detectab le.
I'm curious about this . I see a few possibilities:
1. The test isn't as sensitive as CDC hopes

2. The sample was taken from different places
3. With low viral ti ter, it may seem like the virus "disappears" from one day to the next.
4. The virus may be hanging out in the terminal bronchioles, and only pop up t o t he upper
respiratory system from time to time.
Arn I on the right track? Wou ld you have a few minutes today to record an interview with me?
Joe
NIH-002286
From: (b)(6)
Sent: Mon, 3 Feb 2020 05:45:35 -0500
Subject : Fw d: Interview request (Seoul, Korea)
Sent from my iPhone
} ~ '-t
From: ;;'< (b)(6) >
To: "Fauci, A nthony (NIH/N JAID) [E]' -------'=""'""'=
--------- (bH6l >
Subject: Interview request (Seoul, Korea)
Dear Or. Fauc i.
I am Mrs. Hyun-Na Cha of TBS, metropolitan radio statio n of Seoul. South Korea.
I am the directo r of currun t- issue radio show of TBS and I'd like to have a telephone
interview with you on my radio program about co ronavirus issue all over the wor ld.
As Korea is a very close count·y to China and many people are very concerned about
this issue.
I wou ld like to hear your op inion as a world authority on this issue.
The time fo r phone interview would be about 6 a.m . at Maryland time and I want to
proceed it through an English-Korean interp rete r.
I wou ld apprec iate it if you could reply to me if you are poss ible .
The host of my prog ram is a political expert who is a Ph.D. from MIT, Or.Kim.
Respec tf ully,
Mrs. Hyun- na Cha
(b)(6)
TBS. Seoul. Korea
NIH-002287
Sent: Mon, 3 Feb 2020 03:47:33 +0000
To: Howard Schatz
Subject : RE: If too busy then pass---l'd understand
Too soon to predict. It probably will evolve into a widespread infection (pandemic) with lower mortality than we
are now seeing (2%). More similar to 2009 HlNl flu than SARS even though the virns (coronavirus) is in the same
family of viruses as SARS.
From: Howard Schatz ----------- (b
~)~(=
Sent: Friday , January 31, 2020 8:51 AM
To: Fauci . Anthony (NIH/NIAID) [E] ------ =
CH=
sb--.,
6)
Subject: If too busy then pass---T'dunderstand
Tony,
New Coronavirus: saw you on national news with a dozen others at DT's table yesterday.
Seems like this new one though serious and very contagious is not as lethal (40: I ?) as SARS, others.
What is your cunent thinking on it?
Hope all is well, otherwi se.
Thanks ,
howard
NIH-002288
Sent : Mon, 3 Feb 2020 03:45:59 +0000
Subject : FW: Wuhan nCoV Inhibitors
(b)( 4
Please handle this . T hanks .
From: Glimcher, Laurie,M .D. (b)( >

--------------
To: Fauci, Anthony {NIH/NIAID) [ E] ------ (b
= )c-c
(= >; Auchinclo ss, Hugh (NIH/N IAID) [ E]
(b)(
Cc: Walensky , Loren D.,M .D.,Ph.D. (b)(6)
---------------
Subject : Fwd: Wuhan nCoV Inhibitors
Tony and Hugh,

Loren Walensky is a superb physician-scientist at Dana-Farber
-----------------
If th is is of interest to you, please let me know or contact him directly .
Many thanks,
Laurie
Laur ie H. Glimcher , M.D.
President and CEO
Dana -Farber Cancer Institute
Richard and Susan Smi t h
Profes sor of Medicine
450 Brookline Avenue, Dana 1628

Boston, MA 02215
"--- ~~ @.!.!te l.
617.632.2161 fax
From: "Wa lensky, Loren D.,M .D.,Ph.D."

Subject : Wuhan nCoV Inhibitors ------------- (b)(6)>
Date : January 30, 2020 at 7:23:54 PM EST

To: "Glimcher, Laurie,M.D." -------------
--------------- r;a-.-,--.= (b)(6)
NIH-002289
Hi Laurie. I hope all is we ll on your end . (b) (4)
(b) (4)
Thanks so much,
Loren

Principal Investigator, Linde Program in Cancer Chemical Biology
Director, Harvard/MIT MD -PhD Program
Dana-Farber Cancer Institute/ Harvard Med ical School
Boston, MA 02215
Office: (b)(6)
Fax: 617-582-8240
Email (b)(6)
NIH-002290
addressed. If you believe this e-ma il was sent to you in error and the e-mail
contains patient information, please contact the Partners Compliance HelpLine at
http://www .partners .org/complianceline . If the e-mail was sent to you in error
but does not contain patient information, please contact the sender and properly
NIH-002291
Sent : Mon, 3 Feb 2020 02:10:49 +0000
Subject : FW: Homozygous for Alpha-1 antitrypsin and coronavirus?
Please handle.
From: Ulrica Molstad (b)(6)>

-----------
Sent : Sunday, February 2, 2020 9 :07 PM
------~~
_.:__:,__ _:...;:,_.:J===~=---- (b)(6)>
Cc : Ulrica Molstad _________ Cb
_)_C6)
_>
Subject: Homozygous for Alpha-1 antitrypsin and coronavirus?
H·1
I.
I read that you are an expert working for NIAID and that you got interviewed about treatments for the
corona viru s.
I am a Swedish physician specialized in clinical chemistry. (b)(6) and wanted to

share a hypothesis I have. I believe that some patients who are seriously ill in corona virus {or flue/SARS)
with lung symptoms have a lack of normal/well functioning Alpha-1-antitrypsin for example PiZZ. Alpha-
1 anti trypsin is an acute phase reactan t and increases in sick people. I have seen that the Alpha-1-
antitrypsin level can be elevated in a severely ill person (HlNl) if measured in a laboratory, even
t hought the patient was homozygous for mutations in the Alpha-1-a ntit rypsin gene. An elevated level of
Alpha-1 antitrypsin is misleading and can result in the physician believing t hat there is nothing wrong
with the patients function of Alpha-1-antitrypsin.
I also guess that critically ill ECMO-treated patients with lung symptoms migh t benefit from receiving
Alpha-1 anti protease inhibitor in addition to other medicatio ns given to them. What do you think?
I believe that this information can contribute in understanding why some supposedly healthy individuals
gets really sick and even die in corona virus, flue/HlNl or SARS. (b)(4
I wou ld appreciate if you replied shortly to me so that I know that my e-mail has been read .
Best regards, Ulrica Molstad, M .D.
NIH-002292
Sent : Mon, 3 Feb 2020 00:50:43 +0000
To : James Krellenstein
Subject: RE: 2019-nCoV Testing for Public Health Labs
James:
Thanks for the heads-up. I will see what I can do.
Best,
Tony
From: James Krellenstein

----------
(b)(6)

--------. ~
Cc: David Barr (b)(6) >; Lord, Aaron (b)(6)Peter Staley
------====~~----- (b)( 6) -------------
Subject: 2019-nCoV Testing for Public Health Labs
Tony:
I hope this emai l finds you well. Over the past 48 hours, PrEP4AII has received multiple requests from
leaders of public health departments and public health practitioners to begin publicly pressuring
CDC/HHS to ensure that properly equipped publ ic health labs (besides CDC's lab in Atlanta) can perform
real time reverse transcription PCR(qRT-PCR)testing for 2019 Novel-Coronavirus (2019-nCoV).
Our understanding is that given the public health emergency decla red by HHS, an emergency use
authorization (EUA) from the FDA is required for public health labs to perform their own lab developed
test for 2019-nCoV, even if it is using the CDC's published qRT-PCRprotocol and primer/probe
sequences (
htt ps:/ /www .cdc .gov/ coronav i rus/2 019-ncov /down loads/ rt -pcr-pane l-fo r- detect ion- i nstr uctions . pdf )
, and the lab is capab le of handling BSL3+samples.
We understand the extreme delicateness of this situa t ion, and also that it is outside of our normal
wheelhouse . But given the concerns of our colleagues in the public health sector, we thought it was
important to give you a heads up regarding this request .
Let us know if there is anyway we can help .
Sincerely,
James Krellenstein
Data, Science and Policy Committee
The PrEP4AII Collaboration
109 S 5th St, Brooklyn, NY 11249
(b)(6)
NIH-002293
James B. Krellenstein
he - him - his
(b)(6)
(Sent from a mobile device)
NIH-002294
Sent: Sun, 2 Feb 2020 23:54:27 +0000
To: NIAIDODAM
Subject: FW: Invitation for an expert panel webinar on the role of micronutrients and
coronavirus
Attachments: 2020.02.02 Expert panel objectives.docx
Let us discuss. Probably no.
From:
---------------------
(b)(6)>
To: Fauci, Anthony (N IH/NIAID) [E] ------,;-. = (b)(6)1>

Cc: Peter van-Dael .,,;.__.;.
__ .;...;;...;,_.=== (b
c:"
):=('='
6);----
Subject: Invitation for an expert panel webinar on the role of micronutrients and coronavirus
Dear Dr. Fanci,
I wou ld like to address you for an expert panel webinar on the role of micronutrients and
corona virus
Du e to the new coronavirus outbreak and the rapidly escalating global spread, lots of questions
are raised regarding the role of micronutrients in support ing the immune system. DSM has
reached out to me with a request to organize rapidly a focused expert panel in order to
estab lish expert guida nce summa rizing key points with respect to the role of micronutrients in
supp orting our body 's immun e response, in light of the current genera l consciousness that
among other factors nutrition is important in combatting infectious diseases. Peter Van Dael,
head of Nutrition Science & Advocacy, is responsible for the coordination of this activity at
DSM .
I agreed to take on this challenge and therefore intend to organize this expert panel through
webinar in order to manage the challenges related to busy agendas and travel within the next
week , if possible. The webinar is expe cted to last for about 3 hours maxinmm and would be
facilitate through the distribution of a short background document I will share in order to
facilitate the discussion.
J will try to reach out to you tomorrow by phone in order to rev iew whethe r you would be
available for this engagemen t and whe ther you would you have potentia l questions prior to
agree ing to participate.
With our best regards,
Manfred Peter
NIH-002295
Dr. Manfred Eggersdorfer Dr. Peter Van Dael
Professor for Healt hy Age ing DSM Nutr ition Science & Advocacy
(b)(6)
(b)(6)
NIH-002296
From: (b)(6)
Sent: Sun, 2 Feb 2020 18:20:17 -0500
To: Carlos del Rio
Subject: Re: [External] RE:Mexican researchers have defined the structure of the Corona
virus
Very inte resting.
On Feb 2, 2020, at 9:07 AM, Del Rio, Carlos (bH6)>wrote:

----------
sent me this update. Thought you would enjoy.
(b)(6)
---------
Interesting to see how they view outbreaks .....
Coronavirus new s over the weekend was a sma ll net positive (although there were
plenty of nega tives). Encouragingly, doctors appear to be having some success
treating patients with existing antiviral drugs - GILD's remdesivir improved the
clinica l con dit ions of a coronavirus patien t in Washington state (WSJ) while
Thailand said it had achieved good resu lts using antiviral drugs originally designed
for the flu and HIV (Bloomberg). It's way too early to tell whether these drugs will
perfom1 well in othe r patients (and a vaccine is still some time away) , but the
progress noted in the US and Thail and is positive. The PBOC said it would inject
CNY 1.2T worth of liquidity on Monday 2/3 to ensure markets operate smooth ly
when they reopen from the New Year holiday (this works out to about CNY150B of
net incremental liquidity given CNY1.05 T of reverse reports are set to mature on
Monday). The gov' t also announced other steps (including waiving equity
ownership limits for some insurers) aimed to bolstering market confidence . The
global corona viru s case count cont inues to rise (it now stands at ~ 15K as of Sunday
morning withe death toll north of 300) whi le more travel restrictions are being
impo sed by governments and companies around the world (Apple said it would
shutte r all its stores and offices in China until Feb 9). According to a CNBC update ,
areas of China responsible for ~8 0% of GDP and ~90% of exports are set to stay
closed until at least Feb 10.
Carlos del Rio, MD.

Sent from my iPhone
On Feb 1, 2020, at 11: 13 PM , Fauci , Anthony (N IH/NIAID) [E]

-------- (b) (6)>wrote:
I love it! □□
NIH-002297
From : Del Rio, Carlos 4
------~~ Cb><
~>
Sent: Friday, January 31, 2020 10:05 AM
To: Fauci, Anthony (NIH/NIAID) [E] ------ --=-=
(b)(6)
Subject: Mexican researchers have defined the structure of the Corona
virus
This e-mail message (including any attachments) is for the sole use of
the intended recipient(s) and may contain confidential and privileged
information. If the reader of this message is not the intended recipient ,
you are hereby notified that any dissemination, distribution or copying
of this message (including any attachments) is strictly prohibited.
If you have received this message in error, please contact the sender
by reply e-mail message and destroy all copies of the original message
(including attachments).
NIH-002298
Sent: Sun, 2 Feb 2020 22:56:05 +0000
From: Dr.h.c. Richard Hajdu

------- (b)( >
------~~
To : Fauci, Anthony {NIH/ NIAID) [E]
Subje ct: coronavirus
-------- (b)(6)
Dear Anthony Fauci.

I speak hard English so I write to you using google trans lator .
I have a cured corona virus cure . I am will ing to provide you . In laboratory conditions you can t ry. This
medicine can destroy the virus within 12 hours .
If you are interested, it is necessary to provide a way to deliver the rned ici ne to you. J live in the Czech
Republic. In the city of Brno .
Dr. Richard Hajdu
NIH-002299
Sent : Sun, 2 Feb 2020 22:43:15 +0000
Subject : FW: coronavirus - easy, safe, and likely highly effective treatment.
Attac hmen ts: Corona Virus Solution b.docx, MedGasRes_2019_9_ 4_232_273962.pdf,
published article on ozone and ebola 3578-10714-4-PB.pdf
Please handle.
From: Robert Jay Rowen (b)( >

------
-------- ~~ (b)(6)>
Subject: coronavirus - easy, safe, and likely highly effective trea t ment.
Dear Dr. Fauci,

I am a mere clinician . But I have published repeatedly on a therapy which, I believe, will remedy patients
with coronavirus and spare a possible catastrophe, if the virus is as lethal as it appears.
The therapy is ozone . It can be performed, depending on the method, for mere pennies in mater ials. It is
not patentable, so, it lacks profitability needed for some payback for t he basic research to get it
"approved" .
It attacks a key vulnerabi lity on this virus and even Ebola. We got to 5 Ebola cases in Sierra Leone. All 5
recovered almost immed iately. No sequela. No one has repo rted anyth ing like that.
I have used ozone therapy for 33 years, ;longer than anyone in North America . It absolutely changed my
practice. I write essentially no prescriptions for antib iotics, including for Lyme disease. This therapy, I
recent ly published, might be the solution the world desperately needs for the emerging crisis in
resistant infections.
I am attaching 2 papers I recently published on ozone therapy, And a manuscript we just got done to
address corona virus, wh ich I am try ing to get published. It is not easy. The medical world is vested in
Pharmaceuticals.
I urge you to please look at this. Not patentable, it will never be a darling of industry. But just for that
reason (dirt cheap), it could be a savior for thousands or more who might die from a pandemic. I am
coming to you abo ut t his as one physicist came to President Roosevelt about harnessing the power of
the atom at the dawn of world war 2. I do hope you will take note of what I am forwarding to you .
The first file is a word document I am seeking to get published. Usually, an author will hold
up on making material like this public until he get published. However, wi th lives
immediately on the line, we want to alert people that the does exist an available very
inexpensive and extremely safe medical treatment for this and other infections .
If you have questions, please contact me here.

Sincerely,
NIH-002300
Robert Ja Rowen , MD
(b)(6)
www.D rRowenDrSu .com

http://www .youtube.com/user/Robe rtRowenMD
https://www .faceboo k.com/D rRobertJRowen
"The doctor of the future will no longer treat the human frame with drugs , but rather w ill
cure and prevent disease with nutrition" , Thomas Edison
HIPAA Notification : This electronic message (includ ing any attachments) is

intended only for the exclusive use of the individual to whom it is addressed. This emai l,
including any attachments , is confidential and is legally privileged. If you have received
it in error please advise the sender immediately by return email and then delete it from
your system. The unauthorized use, distribution, copying or alterations of this email is
strictly forbidden. If you need assistance please contac (b)(6) Note to
Patients : There are inherent confidentiality risks in communicating by email. While
safeguards are in place to ensure your privacy , you should not use email
communication if you are concerned about any breaches of privacy that
might inadvertently occur.
NIH-002301
Sent : Sun, 2 Feb 2020 22:40:07 +0000
To: Greg Folkers (b)(6))
Subject: FW: Getty images from coronavirus presser etc http://bit.ly/2GJ3u5F
See below the link that CbH6>sent

me. It is a picture of me briefing President Reagan at the NIH
in 1988 . Please insert it into our flickr file with the legend that I just gave . Thanks.
From: (b)(6) {NIH/CC/BEP)[El (b)(6)

To: Fauci, Anthony {NIH/NIAID) [E] ------ ..---.-.-=
(b)(6)
Subject : RE:Getty images from coronavirus presser etc http:/ /bit.ly/2GJ3uSF
The oldest one in the batch:
https://www.gettyimages .com/detai l/news-photo/dr -anthony -fauci -lectur ing-to -pres-ronald -w-reagan-

a nd-news-photo/50454084 ?adppopup=true
From: Fauci, Anthony (NIH/N IAID) [El CbH >

To: (b)(6) {NIH/CC/BEP) [El
-----~~ (b)(6)
Subject: FW: Getty images from coronavirus presser etc http ://b it .ly/2GJ3u5F
fyi
From: Folkers, Greg {NIH/ NIAID) [El

---------
(b)(6)
To: NIAID OD AM <NIAIDODAM@niaid.n ih.gov>

Subject : Getty images from coronavirus presser etc http://bit .ly/2GJ3u5F
NIH-002302
of U.S. copyright law, without further verification of its accuracy /veracity . It does uot necessarily represent
my views nor those of NIAJD , NIH , HHS , or the U.S. government.
NIH-002303
Sent : Sun, 2 Feb 2020 22:36:41 +0000
Cc: Billet, Courtney (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E];Folkers, Greg
(NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E]
Subject : RE: Fauci/Redfield op-ed for review
Attachment s: Redfield-Fauci Joint Op-Ed V2 020120_EOC Cleared Revised wR3 2.2.20 JR HM
GF - wit h additional Fauci tracked changes still showing.docx , Redfield-Fauci Joint Op-Ed V2 020120 _EOC
Cleared Revised wR3 2.2.20 JR HM GF - wit h Fauci changes added -clean copy.docx
I have gone over the document and have made a numbe r of t racked changes. In addition, for
ease of reading I have accepted all the tracked changes and am sending a clean copy. Hence
there are 2 attachments : 1) one w ith al l tracked changes; 2) a clean copy accepting all
changes. Please note that the CDC has not announced the 3 additional cases and so depending
on when this goes out we need to make sure that the offic ial number is 11 and not st ill
8Thanks !
From : Routh, Jennifer (NIH/N IAID) [E] CbH

Se nt : Sunday, February 2, 2020 4 :36 PM
To: Fauci, Anthony (NIH/NIAID) [E] ------~~(b)(6)>
Cc: Billet, Courtney {NIH/N IAID) [El CbH6)>;Stover, Kathy (NIH/NIAID) [El
(b)(6)>; Folkers, Greg {NIH/NIAID) [El CbH6)>;Conrad, Patricia
(NIH/NIAID) [El (b)(6); Marston, Hilary (NIH/NIAID) [El (b)(6)>
Subject : Fauci/Redfie ld op-ed for review
Dr. Fauci -
Attached is the draft op-ed for you r review. Greg, Hilary and I have added proposed edits in track
changes. We will send back to CDC/HHSone document with all NIAID edits in track changes. HHSwould
like to get a draft to the White House at some point this evening.
Thanks,
Jen
Jennifer Routh [E]

NIH/HHS
Bethesda, MD 20892
Direct (b) (6)
Disc laimer: The information in this e-mai l and any of its attachments is confident ial and may conta in sensitive informat ion. It should not be
used by anyone who is not the original intende d recipient. If you have received th is e-mail in error please inform the sender and delete it
from your mail box or any other storage devices . The National Institute of Allergy and Infectious Diseases shall not accept liability for any
statements made that are sender's own and not express ly made on behalf of the NIAID by one of its representat ives.
N IH-002304
Sent : Sun, 2 Feb 2020 19:24:26 +0000
Subject : FW: Specific Questions About CoronaVirus
Please handle.
From : Rafael C. R. (b) (6)>

To: Fauci, Anthony (NIH/NIAID) [E] -------
--------- .----..-.=
(b)(6)
Subject : Specific Questions About CoronaVirus
Hi Or. Fauci, you might not remember me from my previous email. I'm a Brazilian who asked you some
months ago about the influenza virus differences across regions. I recently t raveled to DC and NY and
had a great time there (before the Corona Virus outbreak)
I have some specific questions about the new Corona Virus, and would be very grateful if you can
answer them :
1- Using availab le data, I've made a simple spreadsheet attempting to pred ict the virus
behavior : https://do cs.google .com/spre adsheets/d/1DAHQt FzXO-
FKU405k8p864JBVHAlfzsHQghuywaTNbE/ed it#gid=O
I've used exponent ial tr end, although it seems to be spreading slower than the expected, I'd like to
know if there's an accurate model for pred icting th is virus. Also, I assume virus don't always spread
exponentially?
2- I listened to your interview podcast https ://edhub .ama-assn.org/j n-learning/aud io-player/18197306 .

Really amazing content. Let's assume this is going to be a wor ldwide outbreak. How can I get prepared
for the worst? Buy water, dry food , stay indoors, w ithdraw money, etc?
Once again, I'd like to thank you very much for reading this emai l. I bet t his is a very busy time for you,
so it means a lot to me
Thank you,
Rafael
NIH-002305
Sent: Sun, 2 Feb 202018:33:43 +0000
To : Liang, Jake (NIH/NIDDK) [E)
Cc: Mark Dybul;Conrad, Patricia (NIH/NIAID) [E);Barasch,Kimberly (NIH/NIAID) [C]
Subject : RE:Favor
Thank s, Jake. Mark will contact you directly .
From:Liang, Jake (NIH/NIDDK) [E]________ Cb

_>_C6b
To: Fauci, Anthony (NIH/NIAID) [E) ------~~ (b)(6)
Cc: Mark Dybul
___ ......;._-===~~-----:-----:-----:----:--~ (b)(6); Conrad, Patricia (NIH/NIAID) [E)
---------
Subject : Re: Favor
(b)(6); Barasch, Kimberly (NIH/NIAID) [CJ (b)(6)
Hi, Tony, I just returned from an overseas trip but should be around tomorrow and can certainly clear
some time to meet with Mark. I met Mark at the NAM meeting last year and would love to hear what
they have to say. Let me know what works. Good luck in dealing with the new coronavirus pandemic
(not sure whether it is qualified as one yet; if not, pretty close)!! Jake
From: Anthony Fauci (b)(6)
Date: Sunday, February 2, 2020 at 12:20 PM

To: Jake Liang CbH6>>
Cc: Mark Dybul CbH6>>,"Conrad, Patricia (NIH/NIAID) [E)"
"Barasch, Kimberly (NIH/NIAID) (C)"
CbH6>, CbH6>>
-----------
Subject: Favor
Jake :
Sorry for this last minute ask, but Cb)( , Ambassador Mark Dybul, who is the
former Head of PEPFARand the former Director of the Global Fund to Fight AIDS, TB, and
Malaria will be at the NIH tomorrow with a scientist who has some very interesting data on
hepatitis B. I was supposed to meet with them, but I am swamped with the coronavirus. Is
there any chance that you can meet with them briefly tomorrow. I believe that you might be
interested in seeing them. I have copied Mark on this e-mail and so I will ask him to e-mail you
to see if you can make this happen. Many thanks.
Best regards,
Tony
Director
NIH-002306
Phone : (b) (6)
FAX : (301) 496-4409
E-mail : (b)(6)
NIH-002307
Sent : Sun, 2 Feb 2020 18:02:22 +0000
Subject : RE: Seeking comment on Indian paper about new Coronavirus
Geeeez
(b)(6)
---------
To: Fauci, Anthony (NIH/NIAID) [E] ------ -=
(b-c-
)(c-=
6)
Cc: M arston , Hilary (NIH/N IAID) [E] ·; Folkers, Greg (NIH/NIAID) [E]
(b)(6J>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Stover, Kathy
(NIH/NIAID) [E]
-------- (b)(6J>; Routh, Jennifer (NIH/N IAID) [E]
Subject : Fwd: Seeking comment on Indian paper about new Coronavirus
--------- (b) ( ·>
FYI re the paper from the Indian researchers .

Talk about trying to put the genie back in the bot tle! Yeesh.
From : " M ascola, John (NIH/VRC) [E]" (b)(6)

Date : Sunday, February 2, 2020 at 10:39:42 AM
To: "Routh, Jennifer (NIH/NIAID) [E]" ------- ~= (b)( >, "Graham, Barney (NIH/VRC) [E]"
(b)(6) "Hiatt, Nis...
sa
-:-:-
(N".':'.
IH:-:-
/-::-
V-::
R~C':""
) :-::
[C~]":":==::::::...;___ _,_,(b);.,~=6)>
----------
Cc: "Ma rston , Hilary (NIH/NIAID ) [E)" (b)(6)>, "Billet, Courtney (NIH/NIA ID) [E]"
-------- >, "Stover, Kathy (NIH/NIAID) [E]"

(b)(
Subject : RE: Seeking comment on Indian paper about new Coronaviru s
(b)(6)>
Also note the following from the author on the BioRxiv comment sect ion:
PrashantPradhan 8 hours ago

This is a preliminary study . Cons idering the grave situati on, it was shared in BioRxiv as soon as
possible to have creative discussion on the fast evolution of SARS-like corona viruses. It was not our
intention to feed into the conspiracy theories and no such claims are made here. While we appreciate
the criticisms and comments provide d by scient ific co lleagues at BioRxiv forum and elsewhe re, the
story has been differently interprete d and shared by social med ia and news platforms . We have
positively receive d all criticisms and comments . To avoid further misinterpretati on and confusions
world-over, we have decided to withdraw the current version of the preprint and will get back with a
revised version afte r reanalysis, addressing the comments and concerns . Thank you to all who
contributed in this open-review process .
: Authors of the Manuscript
NIH-002308
From: Routh, Jennifer (NIH/NIAID) [El
_________
.. (b)(6)
To: Graham, Barney (NIH/YRC) [El ________ --------~= _H_6); Hiatt, Nissa (NIH/VRC) (CJ
Cb
(b)(6)
Cc: Marston , Hilary (NIH/NIAID) [El CbH ; Mascola, John (NIH/VRC) [El
CbH6)>;Billet, Courtney (NIH/NIAID) [El CbH6)>;Stover, Kath y
Subject : RE: Seeking comment on Indian paper about new Coronavirus
Hi Barney -
We consulted with HHS and ASF. OCGRis going to send a note to the reporter to decline, noting that the
paper is not peer-reviewed. Please let us know if you receive similar requests.
Thanks,
Jen
Jennifer Routh [El

NIH/HHS
Bethesda , MD 20892
Direct: Cb)~
Disclai mer: The informatio n in this e-mai l and any of its attachments is confident ial and may contain sensitive information . It should not be
used by anyone who is not the original intende d recipient. If you have rece ived this e-mail in error please inform the se nder and delete it
from your mailbox or any other storage dev ices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any
statements made that are sender"s own and not express ly made on behalf of the NIAID by one of its representa tives.
From: Graham, Barney (NIH/YRC) [El (b)(

Sent : Saturday, February 1, 2020 2:11 PM -----------
To: Hiatt, Nissa (NIH/VRC) (CJ (b)( ; Routh, Jennifer (NIH/NIAID) [El
(b)( 6) > --------
Cc: Marston , Hilary (NIH/NIAID) [El _______ Cb _ >; Mascola, John (NIH/YRC) [El
_>_<6J
(b)(6)
Subject : FW: Seeking comment on Indian paper about new Coronavirus
Hi Nissa and Jen,
This is one we don't want to answer without high-level input, but wanted you to know about the rising
controversy .
BG
NIH-002309
From : lssam AHMED <lssam.AHMED@afp.com >
--------
To: Graham, Barney (NIH/YRC) [E]________ ~=
Cb
_H_6)
Subject : Seeking comment on Indian paper about new Coronavirus
Dear Dr Graham,
I'm a science journalist with news agency Agence France-Presse wr iting with a request -- apologies for
reaching out on a Friday evening! I was to ld by a contact you may be willing to give an opinion on this
paper that has just gone live https:ljwww .biorxiv.org/content/10 .1101/2020.01.30.927871v1.fu ll.pdf it
suggests the new Coronavirus has four inserts similar to HIV-1 and this is not a coincidence.
Thanks you very much, if you are able.
lssam Ahmed
lssam AHMED
Health, Science and Environment Correspondent
1500 K St. NW - 20005 Washington
Tel : (202) 414-0521
June 24 , 2020
Virusdeathtoll nears half a million ascasessurge in US, Latin America
Join us on:
I) Clafp.com
NIH-002310
Sent: Sun, 2 Feb 2020 17:13:03 +0000
To: Mark Dybul
Subject : RE:A connection to jake
Mark:
Thanks for the note. Sony that l had to cancel. This is Wbite House i11full overdrive and I am in the middle of
it. Reminiscent of post -anthrax days. I will send an email to Jake toda y to introduce you. Again , sorry about the
cancellation. Hope to see you soon. Regards to Jason.
Best ,
Tony
-----Original Messa...
g""-
e-------------~~
From: Mark Dybul (b) (6) >
Sent: Sunday, February2, 2020 11:37 AM
To: Fauci, Anthony (NIH/NIAID)[E] (b)(6)
Subject: A connection to jake
Hey tony
Know you are buried in coronavirus. Totally understand need to cancel meeting tomorrow. We will set up a zoom
in hen things calm down.
We have made additiona l progres s on hbv including data from 2 new mouse models. We were going to share
Monday
Realize this is last minute but mig ht it be possible for you to connect me to jak e Jiang in case we can squeeze in a
meeting with him (serhat is already on east coast - we took a risk knowing you might have to cancel)?
Jfyou are not comfortablewith that 1 could send him a cold caUemail mentioningwe have shared the data with
you. You were kind enough to introduce us at the nam dinner when (b) (6).
Hope you at least have time to enjoy Super Bowl. Hang in there - am sure everyone is leaning heavily on you as
usual.
Thanks much
Mark
Sent from my iPhone
NIH-0023 13
Sent : Sun, 2 Feb 2020 16:49:35 +0000
Subject: FW: Teleconference
Francis:
Do you have a minute for a quick call?
Tony

To: Fauci, Anthony (NIH/NIAID) [E] -------= (b=)(= ; Collins, Francis (NIH/OD) [E]
(b)( .
Cc: Tabak, Lawrence (NIH/OD) [E) (b) (6)>
Subject : Re: Teleconference ---------
Tedros and Bernhard have apparently gone into conclave ....they need to decide today in my view. If
they do prevaricate, I would appreciate a call with you later tonight or tomorrow to think how we might
take forward .
Meanwhile ....
https ://www .zerohe dge.com/geopo lit ical/coronav irus-contains-hiv -insertions-stok ing-fears-over -

a rt ificia lly-created-b iowea pon
From: "Fauci, Anthony (NIH/ NIAID) [E]" CbH6)>

Date : Sunday, 2 February 2020 at 15:30
To: Jeremy Farrar CbH6J>,Francis Collins (b) (6)>
Cc: "Tabak, Lawrence (NIH/OD) [E]" (b)(6)
Subje ct: RE: Teleconference
Jeremy:
Sorry that I took so long to weigh in on your e-mails with Francis and me. I was on
conference calls. (b)(5)
Cb)(5l
Best regards,
Tony
From : Jeremy Farrar (b)(6)>

NIH-0023 14
To: Collins, Francis (NIH/OD) [E] (b)(6)>
Cc:Fauci, Anthony (NIH/NIAID) [.'::
E-:.
] =====~ )( =, > ; Tabak,
(b'""' Lawrence (NIH/OD) [E]
(b)(6)
Subject: Re: Teleconference
....Really apprec iate us thinking through the options ... (b)(5

----------------
From: Francis Collins (b)(6)>

Date: Sunday, 2 February 2020 at 12:03
To: Jeremy Farrar CbH6)>
Cc: "Fauci, Anthony (NIH/N IAID ) [E]"
(b)(6) --------- (b)(6), "Tabak, Lawrence (NIH/OD) [E]"
Subject: RE:Teleconference
Hi Jeremy,
Thanks for forwarding these additional reflections from Mike and Bob. (b)(5) ~
(b) (5)
Francis

To: Collins, Francis (NIH/OD) [E] ------- ~=
c6J
(b...
Cc: Fauci, Anthony (NIH/NIAID) [E] (b)(6J>; Tabak, Lawrence (NIH/OD) [E]
(b)(6)
Thank you
See thoughts overnight from others.

(b) (5)
NIH-002315
Jeremy
(b)(5)
NIH-002316
From: Francis Collins CbH6)>
Date: Sunday, 2 February 2020 at 10:27
To: Jeremy Farrar (b)(6)
"'""'"".---:---:-:--:-::~===-----=-,,"='
Cc: "Fauci, Anthony (NIH/N IA ID) [E]"
(b)(6)
--------- CbH6), "Tabak, Lawrence (NIH/OD) [E]"
Subject : RE:Teleconference
Jeremy,
(b) (5)
I'm avai lable any time today except 3:15 - 5:45 pm EST (on a plane) for a call to Tedros . Let me
know if I can help get through his thicket of protectors.
Francis

Se nt : Sunday, February 2, 2020 4 :48 AM
To: Andrew Rambaut (b)( >
Cc: R.A.M. Fouchier (b)(6); Fauci, Ant hony (NIH/NIAID) [E)
(b)( Patrick Vallance (b)(6); Drosten, Christian
==========-~=(b)(6)> ; M.P.G. Koopmans (b)(6) ; Eddie Holmes
(b)(6); Kristian G. Andersen (b)(
":"-""'."":'-:--:--:==============~-=-c---=-
Paul Schreier (b)(6); Ferguson, Mike
(b)(6); Collins, Francis (NIH/OD) [El (b)(6)>; Tabak, Lawrence
~".""'.'"':"~~:-::======::!.:....
(NIH/OD) [E)
..,,.._..,=
(b)( >; Josie Golding (b)(6)
Subject : Re: Teleconference
This is a very complex issue.
lwill:
(b) (5)
NIH-0023 17
(b)(5)
I suggest we don't get into a further scientific discussion here, but wait for that group to be establis hed.
Jeremy
From: ' Cb>

(6)
Date: Sunday, 2 February 2020 at 09 :38

To: Jeremy Farrar CbH6)J>
Cc: f CbH6)
[>, "Fauci, Anthony (NIH/ NIAID) [E]"
CbH
~, Patrick Vall ance ( CbH6)>,"Drosten,
Christian" I---=========~----_;_ CbH~,Marion Koopmans CbH6)J,
__ ..!::::=="='=:,0::-- _____ _
Edward Holmes r CbH6)j
~ , "Kristian G. Andersen" I
CbH (b)(6) J, Paul Schreier
CbH
~ M ichae l FMedSci
==========::=:~-------:::=======-==:,:,,:;---
(b)( ~
>, Francis Coll ins( Cb)(
~
CbH~Josie Gold ing
~=========,,..,_...---------
(b)( 6)j
Dear Jeremey, Ron and all,
Thanks for invitin g_m__e

on the call vesterda . (b)(5) ~
(b)( 5)
NIH-0023 18
(b)(5)
Best,
Andrew
On 2 Feb 2020, at 08:40, Jeremy Farrar________ Cb

_>_<6)
... wrote :
Thanks Ron
(b) (5)
Thoughts on tbat very welcom e.
On 2 Feb 2020, at 08:30, R.A.M. Fouchier.._ _____ ....i..._'-"> wrote:
Dear Jeremy and others,
This was a very useful teleconference. (b) (5)

(b) (5)
Thanks for organizing this on such short notice,

Kind regards
NIH-0023 19
Ron
Ron's noUtfe~s?
_;,
:______________________ 71i
(b,JiH
~5J
NIH-002320
(b)( 5)
NIH-002321
(b)(5)
Van : Jeremy Farrar (b)(

Datum : zaterdag 1 februari 2020 om 21:59
Aan: "Fauci, Anthony (NIH/NIA ID) [ E]" ------- Cb.-.-6)>, Patrick
-H=
Vallance (b)(6)
CC: Christian Drosten (b)(6) "M . Koopmans"
-------.....::=~~;-7."'.::-:-"'"".""".'-:---:-:--::--
(b)( 6), "R.A.M. Fouchier"
=========~~--- (b)( , Edward Holmes
========:------ (b)(6)
CbH6), Andrew Rambau (b)(6)

"Kristian G. Andersen" (b)(6), Paul Schreier
(b)(
(b)(6), "Ferguson, Mike"

(b)(6) Francis Collins (b)(6),
(b)(6)>, Josie Golding
...========= (b
:):::
:::
(6)~--------
0nd erwerp: Re: Teleconference
Thank you to everyone for joining.
There is clearly much to understand understand in this. This call was very
helpful to hear some of our current understanding and the many gaps in our
knowledge. (b)(5)
(b)(5)
NIH-002322
(b) (5)
I hope that is a reasonable approach, please send any thoughts or

suggestions.
Once again, thank you for making time over a weekend and for such an
informed discussion on a complex issue.
Thank you and best wishes Jeremy

Date: Saturday, 1 February 2020 at 15:34
To: "Fauci, Anthony (NIH/NIA ID} [E]"
-------~ =
(b)(6)>, Patrick
Vallance (b)(6)
Cc:"Drosten, Christ ian" (b)( >, Marion
Koopmans (b)(6)
II
(b) (6) Edward
rHolmes _...
...=====================...... ~ )~<6)
(b ~.~-------------
(b)(6)
(b)( ~ "Kristi an G. Andersen "

=========-=-=~
(b)( ~, Paul Schreier(
----------~= (b)( ~
(bH ~> , Michael FMedSci
===========-~~--- (b)( ~
Subject: Teleconference
1st February (2nd Feb for Eddie)

Information and discussion is shared in total confidence and not to be
shared until agreement on next steps.
Dial in details attached.

Please mute phones.
I will be on email throughout - email Paul or I Paul if any problems
If you cannot make it, I will phone you afterwards to update .
One Hour
NIH-002323
6am Sydney
8pmCET
7pm GMT
2pm EST
11am PST
(Hope I have the times right!)
Thank you for the series of calls and for agreeing to join this call.
Agenda
• Introduction, focus and desired outcomes - JF
• Summary - KA
• Comments - EH
• Q&A-AII
• Summary and next steps - JF
Kristian Anderson
Bob Garry- I have not been able to contact Bob. Please forward if you can.
Christian Drosten
Tony Fauci
Mike Ferguson
Ron Fouchier
Eddie Holmes
Marion Koopmans
Stefan Pohlmann
Andrew Rambaut
Paul Schreier
Patrick Vallance
An drew Rambaut
Institute for Evo lutionary Biolog y
Ashworth Laboratorie s, University of Edinburgh , Ed inburgh , EH9 3FL , UK
conta c t - _____ ....,_( .,,. I http://tree.b1o.ed.ac.uk

~..,_ I te l ____ ..,._,,
)..,§)
The University of Edinburg h is a charitable body, registered in Scotland, with registration number
SC005336.
NIH-002324
Sent : Sun, 2 Feb 2020 15:45:28 +0000
To: Goldner, Shannah (NBCUniversal);Conrad, Patri cia (NIH/NIAID) [E]
Subject : RE:Thank you so much
My pleasure!
From: Goldner, Shannah (NBCUniversal) <shannah .goldner@nbcuni.com>

To: Conrad, Patricia (NIH/NIA ID) [E)------- -=-
(bc-
)(=6) Fauci, Anthony {NIH/NIA ID) [El
(b)(6)
Subject : Thank you so much
Dr. Fauci, thank you so much for mak ing time for our show th is morning. We are very grateful to have
you on, sharing your know ledge on this issue. I know you are extremely busy, but again, so many thanks .
Sincerely - and have a good day, though I know a busy one . Shannah
And Patric ia, thank you so much for your help and patience w ith me, I appreciate it.
Shannah

To: Goldner, Shannah (NBCUniversal) <shanna h.goldner@nbcuni. com>; Fauci, Anthony (NIH/NIAID ) [El
(b)(6)
Cc : Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>
Subject : [EXTERNAL] Re: details re tomo rrow's MSNBC morning interview
Adding dr Fauci here - he will arrive at the Nebraska ave stud io no later than 710 am for your 730 am ET
live hit as per below.
If there are any changes or cancellations in the morning please call his cell at
(b)(6) ----- (b)(6) , My cell is
Thank you.
Sent from my iPhone
On Feb 1, 2020, at 8:32 PM, Goldner, Shannah (NBCUniversal)

<shan na h.goldner@n bcun i .com> wrote:
NIH-002328
Patricia, hi. ..the contact at the NBC bureau (4001 Nebraska Ave) is Parita Desai. The
number at the studio is 202-885-4800. The bureau is aware that Dr. Fauci is driving himself
and he can park at the bureau.
The interview time is scheduled for approx 7:30am, so if he can be at the studio by 7am for
powder and to be seated, that would be appreciated .
The producer in NY who will email you the information details for the segment tomorrow
is Cyndi Antoniak . If you need to reach her before she reaches you in the morning , her
email is Cynthia .ant oniak@nbcuni.com and her phone number is (b)(6)
The interview is one on one with our anchors Kendis Gibson and Cori Coffin .
If you need more information, please let me know . Thank you for your help and your
pat ience today, I appreciate it.
All the best,

Shannah
Shannah Goldner
MSNBC
W: 212-664-1289
C: (b)(6)
From : Conrad, Patricia (NIH/NIAID) [El

Sent: Saturday, February 01, 2020 7:54 PM -----------
To: Goldner , Shannah (NBCUniversal) <shannah .goldner@nbcun i.com>
(b)(6)
Subject : [EXTERNAL]RE:Thank you so much
Hi - are we firm for to morrow ? need onsit e cont act info ..t hx

To: Conrad, Patricia (NIH/NIAID) [El --------..-;:=
Cc: Routh, Jennifer (NIH/N IAID) [E]:.=======~ H~ Stover, Kathy {NIH/NIAID)
(b~
[El CbH6)>
Subject : RE:Thank you so much
I will forward all tha t soon . Thank you!
From: Conrad, Patricia (NIH/NIAID) [E] CbH ,>

To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcun i.com>
Cc: Routh, Jennifer (NIH/NIAID) [E] (b)(6); Stover, Kathy (NIH/NIAID)
[E] (b) (6)
Subject : [EXTERNAL]RE: Thank you so much
NIH-002329
Yes - he can do that hit time - just let us know when it is firm. He will
drive his car to the studio .
I will need an onsite name and cell number for him at the studio herein
de

To: Conrad, Patricia (NIH/N IAID) (E]-------- (b
...)""'(6)
=
Cc: Routh, Jennifer (NIH/N IAID) [E] (b)(6); Stover, Kathy {NIH/NIA ID)
[E] (b) (6)
Subject : Thank you so much
Import ance: High
Patricia, hi, thank you so much fo r getting back to me and again, apologies to Dr. Fauci, I do
understand how swamped he.
With that said, I'll confirm the exact time at around 2pm our time, but I think the interview
will be at approx 7:30am.
Would you like me to arrange transportation to and from the studio? We'd like Dr. Fauci to
be at the studio by 7:10am-ish?
Thank you so much . Shannah
From: Conrad, Patricia (NIH/N IAID) [E] (b)(6)

---------
Cc: Routh, Jennifer (NIH/N IAID) [E] (b)(6)>; Stover, Kathy {NIH/NIA ID)
[E) (b)(6)
Subject : [EXTERNAL]FW: request for a live interview tomorrow morning, on MSNBC
Importance : High
Good afternoon -
I believe we can make this work - if we can - it would need to be done

in your NBC Studio in WDC at 4001 Nebraska Ave NW
Will that work and what would the exact hit time be?
NIH-002330
From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni. com >
------~~
To: Fauci, Ant hony (NIH/NIAID ) [E] (b)(6)
Subject: request for a live interview tomorrow morning, on MSNBC
Import ance: High
Dr. Fauci, goo d morning.

Are you available to do an inte rview tomorrow sometime in the 7:30 to 8am ET hour, to
discuss the latest news about the Coronavirus? The interview would be one on one and
approx 5mins . I saw you on t he Today show yesterday and I would love to get you on
MSNBCto discuss this, I know our viewers will have a better understanding of the situation
if you can take us through it
I can arrange a satellite location/transportation/whatever is needed to make this work out.
Thank you for your consideration and I hope to hear from you soon.
All the best,
Shannah
Shannah Goldner
MSNBC
W: 212-664-1289
C:
----- (b)(6)
NIH-00233 1
Sent : Sun, 2 Feb 2020 15:44:24 +0000
To : Daley, George Q.
Cc:
[El;Graham, Barney(NIH/VRC) [El
------
Collins, Francis {NIH/OD) [El (b)(6));Marston, Hilary {NIH/NIAID)
Subject : RE: Inquiry and possible pone call
George:
Thanks for the note . There is a lot of communications between scientists in China and their
colleagues in the USA, many with whom they have been collaborating prior to the outbreak.
There is no real "coordination" of this response since we do not know who is doing what until
we are to ld - just like you have done here. Dr. Soumya Swaminathan, Chief Scientist at WHO is
organizing a meeting on Feb. 11 -12 in Geneva to try and develop a research agenda for nCoV. I
am sure tha t Chinese scientist s will be there. It might be helpful to contact her. Her e-ma il
address is (b)( .
I hope that this is helpful. I wi ll follow-up with a call.
Best,
Tony
From : Daley,George Q. (b)(6)>

-------------
-----~~
To : Fauci, Anthony {NIH/NIAID) [El (b)( ; Fauci, Anthony {NIH/N IAID) (El
(b)( > ---------
Subject : Inquiry and possiblepone call
Dear Tony ,
Alan Garber , Harvard 's Provost , and I met yesterday with a team
led by Jack Xia , the CEO of China's Evergrande Company , and
Dr Jack Liu, Evergrande 's chief health officer, who stated thy
were acting on behalf of Dr Zhong Nanshan , China's ke point
4
person on the coronavirus outbre ak see below . CbH>
, and
---------------------------
they arranged a conference call for tomorrow morning EST with
Dr. Zhong.
While I have been mobilizing efforts of our community to react to

the virus and to this request , I am not na"i"v
e to the challenging
politics of such a relat ionship. I do not want to compl icate or
duplicate efforts already underw ay, and am writing to request
NIH-002332
whatever information you are willing to share on your current
efforts to coordinate a response.
If a phone call is more facile, please do not hesitate to try my cell:

(b)(6)
anytime today.
------
Sincerely,
George
George Q. Daley, MD, PhD

Dean, Harvard Medical School
Caroline Shields Walker Professor of Medicine
Professor of Biolog ical Chemistry and Molecular Pharmacology
Office of the Dean, Gordon Hall

25 Shattuck Street, Boston MA 02115
Contact: (6)
Cb>
(b)(6)
From: Jack Liu Cb)(6)

Date: Saturday, February 1, 2020 at 11:26 PM
To: Public HMS Email CbH6)
Cc: i~fflf!'f (b)(6),
M~~ Min Chen
(b)(6)
Subject: Follow up on today's meeting
Dear Dr. Daley:

Per our discussion this afternoon in the conference room at your school,
--------
NIH-002333
(b) (4)
Jack Liu, MD
NIH-002334
Sent : Sun, 2 Feb 2020 15:33:34 +0000
Cc: Tabak, Lawrence (NIH/OD) [E];Wolinetz, Carrie {NIH/OD) [El;Conrad, Patricia
(NIH/NIAID) [El;Cassetti, Cristina (NIH/N IAID) [El;Marston, Hilary {NIH/NIAID) [El
Subject: RE:2019 novel Coronavirus Global research and innovation forum: towards a
research roadmap Feb 11-12, 2020 Geneva WHO HQ
Francis:
Th is is a meeting aimed at setting research priorities and I do not believe that it impacts or
overlaps with the Tedro s proposal. I will have my staff submit some names (mostly high level
program people) to represent us at this meeting.
Tony

Sent: Sunday, February --------
2, 2020 10:11 AM
(b)(6)
To: Fauci, Anthony (NIH/NIAID) [El------ (b

=)c-c
(= >
(b)( 6) --------- (b)(6) ; Wolinetz, Carrie (NIH/OD) [E)
Subject : FW: 2019 novel Coronavirus Global research and innov ation forum : towards a research
roadmap Feb 11-12, 2020 Geneva WHO HQ
Hi Tony ,
Just encounte red this message from Soumya of WHO, inviting attendance at a meeting in
Geneva on Feb. 11- 12. I'm not sure how that will fit with the Tedros proposal.
Who would be the right persons from NIH to propose for Soumya's meeting?
Francis
From: SWAMINATHAN, Soumya ________ Cb)

_C
_>
Sent: Friday, January 31, 2020 4 :41 AM
(b)(6)
Collins, Francis {NIH/OD) [E] (b)(6)

------- (b)(6)
Cc: SATHIYAMOORTHY,Vaseeharan (b)(6)>; RIVEROSBALTA,Alina Ximena
(b)(6); BORGES,Andrea (b)(6); MCLELLAN, Faith (b)(6)>; HILL,
Suzanne Rose (b)(6); GARAPO,Charity Helen (b)(6)>
NIH-002335
Subject: 2019 novel Coronavirus Global research and innovation forum: towards a research roadmap
Feb 11-12, 2020 Geneva WHO HQ
Dear All,
I am delighted to inform you that WHO is organizing a global research partners forum on February 11th
and 12th in Geneva, to discuss research priorities related to the novel Corona virus. The expected
outcome is a research roadmap with clearly defined priorit ies and a governance framework to take each
thematic area forward . Several thematic areas will be considered at the meeting, namely: virus,
diagnostics; natural history and transmission; clinical; therapeutics; vaccines; ethics; regulatory science;
animal health; data/samples analysis and sharing and; social sciences. We believe that this meeting will
be critical in consensus building on the most important research questions, as well as in building global
partnerships and collaborations to take this work forward.
This meeting is being organized in partnership with GLOPIDRand is being supported by the Bill and
Melinda Gates foundation, DFID, Wellcome Trust and several other partners. The secretariat within
WHO is the R&D blueprint, co-chaired by Dr Mike Ryan and myself.
As the head of an agency that would play an impor t ant role in addressing this new viral outbreak, either
by undertaking or funding research, or both, I take great pleasure in inviting you to this meeting. I
apologize for the short notice, but you will understand that we have had to plan this in the past few
days, keeping in mind the evolving situation.
Kindly let me know if you (or your nominee) will be able to attend and if you need any support from us.
Please copy (bH and (b)(6) in your response.
With best wishes,

Soumya
Chief Scientist
NIH-002336
Sent: Sun, 2 Feb 2020 12:35:48 +0000
To: Lorsch,Jon (NIH/NIGMS) [El
Subject : RE:Update from Ming
Exhausted, but OK. Thanks.
From : Lorsch, Jon (NIH/NIGMS) [E] (b)(6)
------~=
To: Fauci, Anthony (NIH/NIAID) [E] ...______ _>
Cb
_<....
Subject: Re: Update from Ming
(b)(6)
J hope you are hanging in there!
Jon
On 2/1/20, 11 :20 PM, "Fauci, Anthony (NIH/NIAID) [E]" ______ Cb

_H_6)> wrote:
Jon:
(b)(6)
Best,
Tony
From: Lors ch, Jon (NlH/NIGMS)[E] .....,.
Sent: Friday, January 31, 2020 6:57 AM
_____
_ (b)(
To: Fauci, Anthony (NIH/NlAID) [E]._______ Cb

_H_6l
Subject: FW: Update from Ming
Tony,
(b)(6)
Jon
On 1/31/20 . 5:32 AM, "Lei. Ming (NIHNIGMS) [E]" CbH > wrote:
-------
Thanks~J~o=n_._
. ------------------------------~~ (b)(6)
Ming
Sent from my iPad
NIH-002337
-
> On Jan 31, 2020,
>
> T hanks, Ming.
>
at 6:08 PM , Lorsch, Jon (NIH/NIG MS) [E]
---------------
> On I /30/20, 9: IO PM, "Lei, Min g (NTH/NIGMS ) [E]" ______
-------
Cb
(b) (6) >
_ > wrote:
_)_(6)
wrote:
(b)(6)
>
> Jon ,
>
> Here is an uodate of mv situation:
(b)(6)
>
> Best.
> Ming
>
NIH-002338
Sent : Sun, 2 Feb 2020 11:26:13 +0000
To: Collins, Francis (NIH/OD) [El;Tabak, Lawrence (NIH/OD) [E];Wolinetz, Carrie
(NIH/OD) [El
Subject: RE: More on evolution of coronavirus
The Indian paper is really out landish. Agree about Jon Cohen's nice summary.

To: Fauci, Anthony (NIH/NIAID) [El------~~ (b)(6);Tabak, Lawrence (NIH/OD) [El
--------- (b)(6)>; Wo linetz, Carrie (NIH/OD) [El

Subject : More on evolution of coronavirus
CbH >
In case you haven' t seen, attached is the Indian paper claiming HIV sequences have been inserted into
2019-nCoV, which has been roundly debunked.
I found Jon Cohen's piece in Science to be a pretty useful summary :
https://www .sciencemag .org/news/2020/01/mining -coronavirus -genomes -clues-outb reak-s-origins
FC
NIH-002339
Sent : Sun, 2 Feb 2020 04:24:27 +0000
Subject : (b)(4l
Attachment s:
Pleasehandle.
-------------
From: Ryan Muldoon
Se nt: Thursday, January 30, 2020 3:33 PM
(b)(6)
(b)(6)
Subject:
------------
Dear Tony,
(b)(4)
(b) (4)
Kind regards,
Ryan
PrEPB1opharrn
Ryan Muldoon
CEO
Tel : (b)(6)
Email --=======L----- ~= (b) (6)
------------
www .prepbiop harm.com
NIH-002340
Sent : Sun, 2 Feb 2020 04:2 1:44 +0000
Subject : FW: Dear Prof. Anthony Fauci, here is a request from MIT Technology
Review ( Chinese)
NIA ID inquiries, p lease.
From: Tao Sun Cb)(6)

Se nt : Friday, January 31, 2020 2:06 AM
------~~
To: Fauci, Anthony (NIH/NIAID) [E]______ Cb>
_C6)
_>
Subject : Re: Dear Prof. Anthony Fauci, here is a request from MIT Technology Review (Chinese)
Dear Prof. Anthony Fauci,
Thank you. Dr. Catharine provided me useful information . As the epidemic develops, here are a few new
questions to ask. Chinese readers want to know the opinions of foreign independent experts
1 Some media said Wuhan vi rus' fatality rate approaches that of the flu, saying that people need not
panic. What do you think of this view? In reality, Chinese residents are already scared and are already
rushing to buy masks.
2 ROis a developing number, and it is not easy to calculate. Does it make sense to talk about ROat this
stage?
3 You had talked about asymptomatic patients, and how public health workers should treat
asymptomatic people? AND why are some viral infections asymptomatic? Can they wear masks to help
prevent epidemics?
4 To what extent will the closure of Wuhan preven t the epidemic?
Looking forward to your reply .
Best
Tao Sun CbH6)>-=f2020~1.F3 24 B ffl]3i '"F.q:.3:4S~ii :

--------
Dear Prof . Anthony Fauci,
I am Tao Sun, a repor ter from Beijing. I am currently writing reports for t he M IT Technology
Review (Chinese) .
JAMA published your article Coronavirus Infections-More Than Just the Common Cold, and Xinhua
News Agency reported this article . Here are some questions I would like to ask you .
1 Some peop le think that it is not necessary to develop a new vaccine against SARSor coronavirus in
NIH-00234 1
Wuhan. The reason is that, firstly, there is no commercial interest to pharmaceutical manufacturers,
and secondly, such outbreaks may not return after the extinction.
What do you think of these views?
2 For the Wuhan virus vaccine being developed, the epidemic is likely to be elimina ted after three
months, so is it still necessary to develop a vaccine?
3 You can talk about SARS.How muc h does a vaccine against SARSactually play?
Looking forward to your reply .
TAO SUN
DEEPTECH MIT Tech nology Review
(b)(6)
suntao@mittrchina.com
7th FL, Tower AB Office Park, 10 Jintong Wes t Road, Chaoyaa g District, Beijing
htt p ://www. m it tr ch ina .co m
TAO SUN
DEEPTECH MIT Technology Review
(b)(6)
suntao@mittrc h ina .com
7th FL, Tower AB Office Park, 10 Jintong West Road, Chaoyang District, Beijing
ht tp :// www.m itt rchina.com
NIH-002342
Sent : Sun, 2 Feb 2020 04:08:48 +0000
Subje ct : FW: Strategy to attack 2019-nCoV coronavirus
Please handle.
From: Jingyue Ju (b)(6)

· _:_
-----------------
_ _ ___:
_;.,
~-------------------
To : Fauci, Anthony (NIH/NIAID) [E] -,;-;-=
(b)(6); Redfield,
Robert R. (CDC/OD) (b)(6)
Cc: Mary C Boyce (bH ; Lee Goldman (b)(6)>; Shelanski, Michael
----------
L.
----------- (b)(6)
Subje ct : Strategy to attack 2019-nCoV coronavirus
Dear Drs. Fauci and Redfield,

(b) (4)
Please let me know if you would like to receive the full manuscript.
Thank you very much for your consideration .
Sincerely,
Jingyue
Jingyue Ju, Ph.D.

Samuel Ruben-Peter G. Viele Profe ssor of Engineering
Director, Center for Genome Technology & Biomolecular Engineering
Columbia University
Northwest Corner Building, Room lOOOMl
NIH-002343
Phone: (b)(6)(0ffice) ____ _, (Cell)
(b)(6)
Fax: 212-851-9330
Email: (b)(6)
NIH-002344
Sent : Sun, 2 Feb 2020 04:08:13 +0000
To: Arnold Manto
Subject : RE:Coronavirus issues
Arnold:
Thanks for the note. I actually have recommended to several press people that they contact
you when they ask for non-government experts. I will continue to do that.
Best,
Tony
From : Arnold Manto (b) ( >

To: Fauci, Anthony (NIH/NIAID) [E] ------~~ >
Subject : Coronavirus issues
-------- (b)(
Hi, Tony:
As this progresses, and as other news items quiet, I am concerned that this is not being handled like the
2009 pandemic when you and Rich Besser functioned as someth ing like a tag team . This gets really t ricky
when public health interventions are the way SARSwas handled and remain the focus. I am being
contacted by the media currently, not because I was in Beijing at the end of SAR$but because of general
epidemiology creden t ials I am t rying to put things into context based on past histo ry, even though I
know other sensational information may come to light which will further muddy the waters. And we
know who will be the main muddiers
Keiji put me on the 2009 WHO Emergency Committee as a non-governmental person who was not
bound by clearances etc I am trying to figure out if I can play that role here I have not yet been
contacted by Elizabeth Cohen, our mutual friend, but I am sure I will.The one thing I can do is to try to
(b) (4)
I am attaching a paper which I wrote post 2009 wh ich shows how the way it was handled adversely
affected programs in much of Europe It might be of interest to those who were not around at that
time .
Regards
Arnold
Arnold S. Manto, M.D. 1415 Washington Heights

Thomas Francis Collegiate Professor Ann Arbor, Ml 48109-2029
Department of Epidemiology Tel: (b)(6)
School of Public Health Fax: (734) 764-3192
University of Mich igan (b)(6)
NIH-002345
Sent: Sun, 2 Feb 2020 04:01:50 +0000
To : toygar civelek
Many thanks!
(b) (6) >

From: toygar civelek
----------
Se nt : Friday, January 3 1, 2020 2:09 PM
------- ~=
--------- (b)(6)
Dear Mr. Fauci,
I am hoping that this email reaches you as I saw this email address on line on the NIH
website.
As we as the public get to hear, read and see with the current coronavirus scare, here in
the US and worldwide, it is comforting to have professionals and experts like you, who
really know what t hey are talking about , wha t is going on, what can be done, timelines,
action plans, and inform the public in a reliable and comforting way, yet being very
transparent, informing the public on social media.
Kudos to you sir and please keep up the excellent work.
Sincerely,
Mur. Civelek
NIH-002349
Sent : Sun, 2 Feb 2020 04:01:28 +0000
Cc: Greg Folkers (b)( ·Barasch, Kimberly (NIH/NIAID) [C];Greg
Folkers-------- (b~
~ )(=6)
Subject : FW: Business Council - Invitation to speak at the February 20-21, 2020 meeting
Attachments : Fauci, Anthony Feb. 2020 lnvitation .docx, BCActive Members Jan. 2020.pdf
I defin itely want o do this. Please respond. Thanks.
From:Marlene Colucci <mcolucci@businesscouncil.com>

To: Fauci, Anthony (NIH/NIAID) [E]------- ~=
(b)(6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b)(6) David Rubenstein
<David.Rubenstein@carlyle .com>; MaryPat Decker <marypat.decker@carlyle .com>
Subject: Business Council - Invitation to speak at the February 20-21, 2020 meeting at the Ritz Carlton
(22nd and M St. NW), Washington, D.C.
Dear Dr. Fauci,
On behalf of our co-chairs for the winter meeting of The Business Council, David Rubenstein of The
Carlyle Group and Ginni Rometty of IBM, we would like to formally invite you to participate in our
meeting on February 20-21, 2020 in Washington, D.C. The theme of the meeting is "The Next Decade."
(See formal inv itation attached as well as list of CEO members).
We wou ld like for you to participate in a 50 minute fireside chat with David Rubenstein (and possibly Dr.
Francis Collins) to discuss the current coronavirus as well as what we should expect in the next decade.
We want to give our CEOsinsights into wha t the next 10 years will bring in terms of detect ion, diagnosis
and treatment of diseases. All conversations are strictly off the record and closed press. We will cover
all lodging and transportation.
As you know, The Business Council is comprised of the chief executive officers of the largest global
corporations, representing all segments of the economy. We expect at least 150 CEOmembers, spouses
and speakers to be in attendance.
As a participant you and your spouse are also invited to join us for our special reception, dinner and
speaker at the REACH(Kennedy Center) on Thursday, February 20 at 6:30pm. It is the best op portunity
for you to meet our CEO members and spouses, speakers and other special guests in an informal
atmosphere.
If you are interested and available, please let me know. We can also set up a very brief call with you to
discuss any additional details and answer any questions you may have. We look forward to hearing
from you and would be honored to have you participate with us again.
Warmest regards,
NIH-002350
Marlene
Marlene Colucci
EXECUTIVE
DIRECTOR
'I
~
BUSINESS
COL NCIL
T: 202-298 -7650
C: (b)(6)
F: 202-785-0296
NIH-002351
Sent: Sun, 2 Feb 2020 03:48:52 +0000
To: Morens, David (NIH/NIAID) [E]
Subject: RE: Potential PHS Officer Deployment
Got it.
From:Morens, David (NIH/NIAID) [E] (b)(6)

----------
)(c-=
6); Auchincloss, Hugh (NIH/N IAID) [ E]
(b) (6) >
Subject: Potential PHS Officer Deployment
Tony & Hugh, in follow up, the PHShas informed all PHSofficers that as of 2/3
they are subject to deployment for coronavirus work "without supervisory
approval", meaning that if needed, officers can be deployed and assigned
anywhere, for indefinite periods, by the Assistant Secretary of Health.
We are hearing that many officers, especially physicians and nurses, may be
deployed for quarantine efforts and to assist State agencies.
I haven't heard anything personally, but just want to let you know. These
deployment orders can come with almost no advance warning, although I don't
expect that.

Senior Advisor to the Director
a (b)(6) (assistants : Kimberly Barasch; Whitney Robinson)
[l§] 301 496 4409
Q (b)(6)
Disclaimer: This messageis intended for the exclusiveuse of the recipient(s)named above. It may contain information that is PROTECTED,
PRIVILEGED,and/or CONFIDENTIAL, and it should not be disseminated,distributed, or copiedto persons not authorized to receive such
NIH-002354
information. All sensitive documents must be properly labeled before dissemination via email. If you are not the intended recipient, any
dissemination, distribution, or copying is strictly prohibited. If you have received this communication in error, please erase all copies of the message
NIH-002355
Sent: Sun, 2 Feb 2020 03:28:01 +0000
Subject : FW: Control 2019-nCoV Wuhan
Please handle.
From: (b)(6)
------~~
Subje ct: Control 2019-nCoV Wuhan
-------- (b)(6)>
Tri-Prime Gene Pharmaceut ical Co

Beijing China
Cheng YongQing
CEOTri-Prime Gene.
regards
My name is Robert Vera. I amEj years old. I live in (b)(6) Ecuador South Amer ica. Here in Ecuador in
1999 in shrimp farms in Ecuador there was a lethal disease among shrim p called the white spot vir us
syndrome . He appeared in 1999 in Ecuador and made shrimp sick and eliminated them. In China it
appeared in 1993. White spot virus syndrome is caused by a virus from the nimavir idae family that
infects a vi bran parahaemolitycus . I applied more than 10 billion liters of natural and organic biolog ical
molecules of my invention for 10 years from 2002 to 2011 in more than 10 thousand hectares of shrimp
farms. These molecules have antiviral characteristics and inhibit the glycoproteins of viruses. These
glycoproteins are what open cell receptors to infect and replicate. Also these nat ural molecules invented
in (b)(6) Ecuador in 2001 inhibit the cytokinins that inflame hepat opancreas. Cytokinins cause the
desquamation of epithelial cells from t ubules that end up collapsing to the liver and shrimp pancreas.
These viruses infect the parahaernolitycus vibrating bacteria and create an incurable syndrome in the
shrimp. In 2002 we defeated this disease and contro lled it ... with this Ecuador to produce little shrimp,
now in 2019 it is the number one in the world to export shrimp. In the same way, the coronavirus 2019-
nCoV Wuhan infects the pneumococci of the lung and the respiratory syndrome develops. Wuhan
coronavirus is the seventh among the coronavi ruses after sars and mers. Another 4 are simpler in
animals th at cause the flu. 2019-nCoV causes 2% of deaths. There are 250 dead as of January 31, 2020
and more than 10 thousand infected in China. 20 count ries have infections. It is tr ansmitted even
without symptoms and its incubation is 2 to 14 days.
We can spray with more than 1000 million liters of these virus inhibitory molecules throughout Wuhan .
1 million hectares (10,000 m2) can be fumigated by fumigation planes as they are made in banana
plantations in Ecuador. We can inhibit all viruses with bacteria and biological molecules to inhibit
viruses. And we can give them more than 100 million liters to take for more than 100 million liters for
humans to more than 100 million inhabitants of the entire province of Hubei in China, so that they do
not transm it coronaviruses ... and the seriously ill can also heal They are natural antibacterial, anviral
and antifungal biological molecules ... they are immune regenerati ng cell bioimmunmodulato rs and
immune boosting imm une response in immunocompromised people who have diabetes and high blood
pressure. Others may have cytokinin and immunoglobulin problems . We can fi nish with the 2019-nCoV
Wuhan in the environment and in humans so be found in the lungs whose epithelial cells are already
collapsing with an increase in inflammation and difficulty breathing . We can beat the coronav iruses
NIH-002366
thro ughout China.
At te
Robert Vera
Graduated from the (b)(6)
What asp p ----.!:=======~~----------
a. 1919 ------------- (b) (6)
,.,, 4¾ e <J·,6
s -;:; ~ 1
(D abc.es <
AB C SOCIEOAO
n ~CHI N
Los farm acos que pu eden

comb atir el coronavirus chino
• Clcnt1lu :o<idC'Ilm,lll uto lk S,1lud de Lsl.id<l'i
l nidoi; p,·or,<ml'n reutitiz:.lranth irate,
di,ei1 :uJo, contra L'Is :\risJl,1ra ncc1L•1.11· l:l
IIL'~ad.1dL' l ~1tamicnto-. . Un., fllll'\ ,1\:,1cuna
podrta <.'star lisla en solo lrt?, mcs<.'s, dict>n
N. R. C.
I.a. C,t?I A...tua ado 27/01/2020 10;0'1,
Enviadodesde mi smartphone Samsung Galaxy.
NIH-002367
Sent : Sat, 1 Feb 2020 23:56:07 +0000
To : Jason Gale
Subject : RE: (BN) Coronavirus Lurking in Feces May Reveal Hidden Risk of Spread
Thanks, Jason.
Best regards,
Tony
From: Jason Gale (BLOOMBERG/ NEWSROOM:) <j.gale@bloomberg.net>

To: Fauci, Anthony (NIH/NIAID) [E)______ ..,,
(b"""
)(=6)
Subject: (BN) Coronavirus Lurking in Feces May Reveal Hidden Risk of Spread
Hello Dr Fauci ,
Just been watching the press conference on You Tube with you and your federal colleagues.
Thought you might find this in teresting, if you have time to breat he let alone read media reports!
All the best and hope to see you at the end of next month .
Jason
Coronav irus Lurking in Feces May Reveal Hidden Risk of Spread

2020-02 -01 06:55 :00.469 GMT
By Jason Gale
(Bloomberg) -- While doctors have focused on respiratory
samples from pneumonia cases to identify coronavirus patients,
they might have ignored a less apparent and hidden source of the
spread: diarrhea .
The novel coronavirus was detected in the loose stool of
the first U.S. case -- a finding that hasn't featured among case
reports from Wuhan, China, the epicenter of the outbreak.
However, that doesn't surprise scientists who have studied
coronaviruses , nor doctors familiar wit h the bug that caused
SARS.
Diarrhea occurred in about 10-20% of patients afflicted
with severe acute respiratory syndrome about 17 years ago and
was the source of an exp losive SARSoutbreak in the Amoy Gardens
residential complex in Hong Kong.
SARSand Wuhan viruses bind to the same distinctly shaped
protein receptors in the body that are expressed in the lungs
and intestines, making these organs the primary targets for both
viruses, said Fang Li, an associate professor of veterinary and
biomedical sciences at the University of Minnesota.
The discovery of the Wuhan virus, dubbed 2019-nCoV, in the
fecal material of the 35-year-old man treated at the Providence
NIH-002370
Regional Medical Center Everett in Washington is "interesting,"
said Scott Lindquist, the state epidemiologist for infectious
disease at Washington's Department of Health.
"That adds to the knowledge about this,'1 he told reporters
on a conference call Friday. "It's not only excreted in your
respiratory secretions, it's also secreted in your stool."
Read More: What You Need to Know About the Spreading
Coronavirus
Researchers don't yet know how exactly 2019- nCoV spreads
from person to person, but suspect it's most likely from coming
into contact with virus -containing droplets that could be
emitted by an infected person's cough and transferred to their
hands or surfaces and objects.
Face Masks
That's led to a run on face masks. But those may be of

limited benefit in the event the virus is being transmitted via
the fecal-oral route, said John Nicholls, a clinical professor
of pathology at the University of Hong Kong.
Squat latrines, common in China, lacking covers and hands
that aren't washed thoroughly with soap and water after visiting
the bathroom could be a source of virus t ransmission, said
Nicholls, who was part of the research team t hat isolated and
characterized the SARSvirus.
A virus-laden aerosol plume emanating from a SARSpatient
with diarrhea was implicated in possibly hundreds of cases at
Hong Kong's Amoy Gardens housing complex in 2003. That led the
city's researchers to understand the importance of the virus's
spread through the gastrointestinal tract, and to recognize both
the limitation of face masks and importance of cleanliness and
hygiene, Nicholls said in an interview.
"I think in Wuhan, that would be a very likely place where
you might get the transmission" from fecal material , he said.
"If it's using the same receptor as for SARS,I can't see why it
shouldn't be replicating in the gut."
Nicholls and colleagues at the University of Hong Kong are
testing laboratory models of human tissues and specimens to
understand where and how the Wuhan virus replicates, he said.
Emerging Evidence
Doctors have reported diarrhea infrequently in 2019-nCoV

patientsadmitted to Wuhan hospitals , though it's been more
prominent among reported cases outside the city, including
members of a Shenzhen family infected in Wuhan, and more
recently in the first U.S. case in Washington state . That
patient exper ienced a two -day bout of diarrhea from which a
NIH-002371
sample tested positive.
The lab in Washington didn't attempt to grow the virus from
that specimen, said Lindquist, the state epidemiologist,
"because it wasn't going to add anything to his care."
Many of the emerging coronaviruses are so-called
pneumoenteric viruses, meaning they can replicate both in the
respiratory tract and the gastrointestinal system, said Ralph
Barie, professor of microbiology and immunology at the Gillings
School of Global Public Health at the University of North
Carolina at Chapel Hill, who has studied coronaviruses for
decades.
Overwhelmed by hundreds of severely sick pneumonia
patients, doctors in Wuhan might not have focused on any gastric
signs, Barie said in a phone interview.
'So Overwhelmed'
"The Chinese are so overwhelmed at the moment and trying to

do a combination of treating patients and dealing with t he scope
of the outbreak, and then trying to get out papers that describe
what's happening," he said.
Any virus in stool is more likely to be present during the
acute phase of an infection, occuring before hospitalized
patients develop a life -threatening complication known as acute
respiratory distress syndrome, Barie said.
"I have also spent most of my time focusing on the
respiratory tract symptomology rather than the gut because of
the relationship between these different emerging viruses and
acute respiratory distress syndrome," he said.
Zijian Feng, deputy director general of Chinese Center for
Disease Control and Prevention, and colleagues released a report
Wednesday on the first 425 Wuhan cases, and noted that early
infections that didn't appear to display typical signs -- such
as fever and viral pneumonia -- or had mild symptoms might have
been missed.
"The initial focus of case detection was on patients with
pneumonia, but we now understand that some patients can present
with gastrointestinal symptoms," Feng and co-authors said in
their report, which was published in the New England Journal of
Medicine.
Emerging evidence of virus-containing diarrhea warrants
further investigation, said Peter Collignon, a professor of
clinical medicine at the Australian Nationa l University Medical
School in Canberra, who advises the Australian government on
infection control.
"This is something new," Collignon said in an interview.
"We presume it's respiratory droplets, but with SARSthere was
evidence of other routes . We have to keep an open mind."
NIH-002372
To contact the reporter on this story:
Jason Gale in Melbourne at j.gale@bloomberg.net
To contact the editors responsible for this story:
Brian Bremner at bbremner@bloomberg.net ;
Shamim Adam at sadam2@bloomberg.net
NIH-002373
Sent : Sat, 1 Feb 2020 23:19:46 +0000
Subject : FW: article from IIT/lndia on Coronovirus
(b) (4)
Please handle.
From: Hong Cai (b)(6)

To: WRB Gmail <wrbrody@gmail.com>; Fauci, Anthony (NIH/NIAID) [E]
Subject : Re: article from Ill /India on Coronovirus -------- (b) (6) >
Dear Fauci,
I knew you must be super busy with the recent Coronavirus outbreak. (b)(4 J
--"e-':========-
(b) (4)
Thank you for your assistance in advance!
-mesabiotec
~,(-
h""
Hong Cai, Ph.D
Co-Founder and CEO
Mesa Biotech, Inc.
6190 Cornerstone Court East, Suite 220
San Diego, CA 92121
www.mesabiotech.com
(b)(6)
(b)(6)
From: WRB
-----------
Date : Saturday, February 1, 2020 at 7:27 AM
(b)(6)
NIH-002374
To: "Anthony (NIH/NIAID) Fauci [E]" (b)(6)
Cc: Hong Cai (b)(6)
Subject: article from IIT/lndia on Coronovirus
Hi Tony,
I hope you are coping with the chaos around coronavirus.
(b) (4)
No doubt you have seen, but in case not, I am sending a copy.
Hopefully someone at NIH is try ing to replicate this study or to find problems with the ir
methodology.
With best wishes,

Bill
William R. Brody
(b)(6J
~ohns Hopkins University
Salk Institute for Biological Studies
--------
NIH-002375
Sent : Sat, 1 Feb 2020 22:06:26 +0000
To: Jeremy Farrar;Collins, Francis (NIH/OD) [El
Thanks, Jeremy. We really appreciate what you are do ing here. Pleasure to work w ith you.
Best,
Tony
From: Jeremy Farrar ________ Cb

_H_6)>
To: Collins, Francis (NIH/OD) [El ----- ~=
(b)(6)>
Subject : Re: Teleconference -------- (b)(6)
We are altogether as you know! Conversations with you and Tony, and Patrick and others - always
great working with you both
From: Francis Collins (b)(6)>

Date : Saturday, 1 Februa ry 2020 at 20:50
To : Jeremy Farrar (b)(6)
Cc: "Fauci, Anthony (NIH/N IA ID) [E]" (b)(

----------
Hi Jeremy,
I can make myself available at any time 24/7 for the call with Tedros. Just let me know.
Thanks for your leadership on this critical and sensitive issue.
Francis
Sent from my iPhone
On Feb 1, 2020, at 3:07 PM, Jeremy Farrar ________ _H_ > wrote:
Cb
I have rejoined so a line is open if any help to rejo in.
From: Jeremy Farrar (b)(6)>

----------
To: "Fauci, Anthony (NIH/NIA ID) (E]" _______ Cb
~>~<, Francis Collins
CbH >, M ichael FMedSci CbH6),Patrick
Vallance
-------------
(b)(6)
NIH-002376
Can I suggest we shut down the call and then redial in?
Just for 5-l0m ins?
(b)(6)
From : Mar ion Koopmans
------------
To : Jere my Farrar CbH6J>
Cc:"Fauci, Anthony (NIH/NIA ID) [E)" ._____________ Cb_H_6)>, Patrick Vallance
Cb)(~"Drosten, Christian"
(b)(~
(b)({;j1>, Edward Holmes ! (b)(~,
CbH6)>,"Kristian G. Andersen" ! CbH~,Paul

"":'
S-:
ch_r_e".""
ie-r=1====-..;__----------====~ Cb
"='
H"='
6)]
::----
Cb)(
~ M ichael FMedSci f Cb)(
~ Francis
--======--~~
Collins I CbH
~>
---------------
(b) (5)
On 1 Feb 2020, at 19:12, Jeremy Farrar (b)(6)> wrote:

----------
Kristen and Eddie have shared this and will ta lk through it on the call. Thank
you.
Hope it will help frame the discussions.
From : Jeremy Farrar CbH6J>

Dat e: Satu rday, 1 February 2020 at 15:34
NIH-002377
Information and discussion is shared in total confidence and not to be
shared until agreement on next steps.
Dial in detail s attached.

Please mute phones.
I will be on email throughout - email Paul or I Paul if any problem s
One Hour
6am Sydney
8pm CET
7pm GMT
2pm EST
11am PST
{Hope I have the times right!)
Thank you for the series of calls and for agreeing to join this call.
Agenda
• Summary - KA
• Comments - EH
• Q&A-AII
Kristian Anderson
Bob Garry - I have not been able to contact Bob. Please forward if you can.
Christian Drosten
Tony Fauci
Mike Ferguson
Ron Fouchier
Eddie Holmes
Marion Koopmans
Stefan Pohlmann
Andrew Rambaut
NIH-002378
Paul Schreier
Patrick Vallance
<Coronavirus sequence comparison[l] .pdf>
NIH-002379
Sent : Sat, 1 Feb 2020 22:00:47 +0000
Subject: FW: FORYOUR REVIEW:Staff Communication on Novel Coronavirus
Attachme nts: Draft_AIIStaff_Novel_Coronavirus_2.1.2020.docx,
Draft_ OHR_Flexibilities_Novel_ Coronavirus_2 .1.2020.docx
Please handle this. Thanks
From: Myles, Renate (NIH/OD) [E] ·>

--------
(b) (

------ ..-.-,=
(b)(6b;Billet, Courtney (NIH/NIAID) [E]
(b)( >; Stover, Kathy (NIH/NIAID) [El (b)(6 h ; Routh, Jennifer
(NIH/NIAID) [E) (b)( >
Cc: Tabak, Lawrence (NIH/OD) [E] (b)( >; Gottesman, Michael (NIH/OD) [E]
Cb)( ·; Johnson, Alfred (NIH/OD) [E] CbH >; Berko, Julie
-:--.-:-:-:-:-:7.::====,........_
{NIH/OD) [El Cb)( ; McGowan, Colleen (NIH/OD/ORS) [El
(b)(6); Burklow, John (NIH/OD) [E] Cb)( >; Chandler, Beth
":""
(N- IH
- /-:-:
0-:-
D-:-
) :-: ) =====:...~
[E :-:; Cb
~) ~(6)
Subject : FORYOUR REVIEW: Staff Communication on Nove l Coronavirus
Good afternoon, Dr. Fauci and team:
Working in coordinat ion with OHR, ORS,OIR, and others, we have developed two communication
products to address questions/concerns that are being raised by NIH staff related to the novel
coronavirus. The two products are:
1. All staff emai l from Dr. Collins to provide genera l information and guidance to NIH staff
2. QA for use by Executive Officers (not for broad distribution) on human resources flexibilities in
response to coronavirus
These products are provided for your review and guidance. We also plan to share with HHSfor
review/awareness. The current plan to disseminate these products on Monday. We look forward to your
input.
Best,
Renate
Renate Myles, MBA

Deputy Director for Public Affairs
Office of Communicationsand Public Liaison
NationalInstitutes of Health
Tel: (b) (6)
NIH-002380
Sent : Sat, 1 Feb 2020 20:03 :12 +0000
To: Jeremy Farrar
Yes

To: Fauci, Anthony (NIH/NIAID) [E]-------= c >; Collins, Francis (NIH/OD) [E]
(b"'""
)=
(b)( ·; Ferguson, Mike (b)( ; Patrick Vallance
(b)(6)
Can I suggest we shut down the call and then redial in?
Just for 5-lOmins?
From: Marion Koopmans

------------
(b)(6)
To: Jeremy Farrar ! (b)(~

Cc: "Fauci, Anthony (NIH/N IA ID) [E]"f Patrick Vallance
(bH ~ ,
(b)( ~ >,
----""."-----:-:-:==:...-------~~
"Drosten, Christian" I (b)(6) i>,
(b)( ~ Edward Holmes
(b)(~ >,
(b)( ~ "Kristian G. Andersen" !
Pau l Schreier ! (b)( ~
--===========~~-----~======~~-
M ichaeI FMedSci l FrancisCollins!
------------
Subject: Re: Teleconference --------- (bH ~ >, (bH ~ >
(b)(5)
On 1 Feb 2020, at 19:12, Jeremy Farrar wrote :

--------- (b)(6)>
Kristen and Eddie have shared this and will talk through it on the call. Thank you.
NIH-00238 1
From:Jeremy Farrar CbH6J>

1st February(2nd Feb for Eddie)

Information and discussionis sharedin total confidenceand not to be shareduntil
agreement on next steps.

Please mute phones.
If you cannot make it, I will phone you afterwards to update.
One Hour
6am Sydney
8pm CET
7pm GMT
2pm EST
11am PST
(Hope I have the times right !)
Thank you for t he series of calls and for agreeing to join this call.
Agenda
• Summary- KA
• Comments - EH
• Q&A-AII
Kristian Anderson
Christian Drosten
NIH-002382
Tony Fauci
Mike Ferguson
Ron Fouchier
Eddie Holmes
Marion Koopmans
Stefan Pohlmann
Andrew Rambaut
Paul Schreier
Patrick Vallance
<Coronavirus sequence comparison[l] .pdf>
NIH-002383
Sent : Sat, 1 Feb 2020 19:02:40 +0000
To : Auchincloss,Hugh (NIH/NIAID) [El
Subject: FW: Offering assistanceduring this public health emergency
Please handle.
From:Albert Rizzo (b)(6)

--------
To: Fauci,Anthony {NIH/NIAID) [E]------~~
·_ _;__ _:_..:....:
.!::::===-~:--- (b)(6)
Cc:Harold Wimmer (b)(
Subject: Offering assistanceduring this public health emergency
Hello Dr. Fauci:
As the coronavirus continues to be a public health emergency, the American Lung Association is
closely following guidance and repo rts being issued by NIAID, WHO, and CDC. Our Association
is working to help relay impo rtan t public health information provided by the various agencies.
As Chief Medical Officer for the American Lung Association, and with the full support of our
CEO, Haro ld Wimmer, and our Board of Directors, I would like to offer the American Lung
Association support on strategies that wou ld be appropriate for our organization to participate
in or communicate.
I am happy to discuss any potent ial opportunities in which you feel we may be of assistance .
Sincerely,
Albert A. Rizzo MD FACPFCCP

Chief Medical Officer
American Lung Association
Cell (b)(6)
NIH-002384
Sent : Sat, 1 Feb 2020 18:55:58 +0000
Subject : FW: Consultancy request - Coronavirus
Pleasehandle.
From:Tatsch, Fernando Franciosi (b)(6)>

6)>
Cc: Bacher, Hans P (b)(6)>; Vallabh, Bhadrish (b) (6) >
Subject : RE: Consultancy reque st - Coronavirus
Dear Dr. Fauci,
The below invitation is for a meeting identica l to an advisory board .
We wonder if a short phone call could be beneficial to offer further context.
With best regards, Fernando Tatsch
FERNANDO TATSCH, MD, MBA

Therapeutic Area Head - HCV / RSV
Global Med ical Affairs
2SW 102 08 I 1 N Wauk egan Rd I North Chicago, IL 60064

OFFICE (b) (6) I CELL (b) (6) I EMAIL -------- (b
= )~(6)
=
abbvie.com
This commu nic;,ti on may con t;iin info r mation t hat is pro pr ietary, confident ial, or exemp t from disclosure. If you are not the inten ded r ecip ient,
please note that any oth er dissemination , distrib ution, use or copying of this comm unication is strictly prohibi ted. Anyone w ho receives t his
message in erro r should not ify the sender immed iately by telephone or by return e-mail and delete it from his or her computer.
From:Tatsch, Fernando Franciosi

Sent : Thursday, January 30, 2020 4:53 PM
To· (b)(6)
Subject: Consultancy request - Coronavirus
Dear Dr. Fauci,
On behalf of AbbV ie, I would like to explore your interes t and availabi lity for a scientific consultation.
AbbVie is interested in your scientific view of the 2019-nCoV epidemic.
Your assessment will be very informa t ive for us in the context of

--------------- (b)(4)
NIH-002385
If you are interested, we will need a brief CV in ord er to elaborate a consultation contract .
Once the contract is executed, we would like to invite you for a phone conference which will include few
medical AbbVie colleagues .
Looking fo rward to hearing from you .
With best regards, Fernando Tatsch
FERNANDOTATSCH, MD, MBA

Therapeutic Area Head - HCV/ RSV
Global Medical Affairs
25W 102 08 I 1 N Waukegan Rd I North Chicago, IL 60064

OFFICE-t (b)(6) I CELLJ (b) (6)1
1EMAIL________ (b
'"'~"'c=
abbvie.com
This commu nicati on may contain info rmation t hat is prop rietary, confident ial, or exemp t from disclosure. If you are not the inten ded recipient ,
please note that any oth er dissemination, distr ibut ion, use or copying of t his comm unication is strictly proh ibited. Anyone who receives th is
message in error should not ify the sender immediate ly by telephone or by return e-mail and de lete it from his or her compute r.
NIH-002386
Sent: Sat, 1 Feb 2020 18 :50 :25 +0000
Cc: Billet , Courtney (NIH/NIAID) [El;Barasch, Kimbe rly (NIH/NIAID) [C]
Subject: FW: 60 Minu tes/ Coronav irus
If we can fit this in next week depending on what is hitt ing t he fan, I will do it.

Sent: Friday, January 31, 2020 7:53 PM---------
-----~~
To: Fauci, Anthony (NIH/NIAID) [El "i._______ Cb>~>
_<....
(b)(6)>
Subject: Fwd: 60 Minute s / Coronavirus
Pis advise
Sent from my iPhone
From: "Stover, Kathy (NIH/NIA ID) [EJ" ______ Cb

_H_j;j>
Date : January 31, 2020 at 7 :52 :16 PM EST
-------..,,.,..,(b:-::--
To: "Conrad, Patricia (NIH/NIAID) (E]"~=====,::~ )_<=
,..>
Cc: "Billet, Courtney (NIH/NIAID) [E]" (b)(6)>, "Routh, Jennifer (NIH/NIAID)
[E)" (b) (6)
--------
Subject: Fwd: 60 Minute s/ Coronavirus
Hi Patty,
See below. Would Dr. Fauci want to meet with this 60 Mins produce r, or shall I suggest an
alternative? Note, this isn't for on-camera - -it's background fo r a potential story .
Sent from my iPhone
From : " Lieberm an, Marc E." <MLP@cbsnews.com>

Date : January 31, 2020 at 5:57 :24 PM EST
(b)(6)
Subject : 60 Minutes / Coronavirus
Hi, I am a producer at 60 Minutes researching a possible story about t he

coronavirus outbreak. The effort to find a vaccine strikes me as interest ing
and I wonder if we m ight be to chat about it. I am going to be in th e DC area
next week. Would you have time for a brief meeting either Wednesday
morning o r Tuesday? Than ks in advance fo r your help .
Best,
NIH-002387
Marc Lieberman
Marc Lieberman I Producer I 60 Minutes

m lp@cbsnews .com
I w: 212-975-6385 c:
-----
(b)(6) I
NIH-002388
Sent : Sat, 1 Feb 2020 18:4 5:22 +0000
Subject : RE:ASF: Dan Chertow invitation
No prob lem with Dan doing this.

-------- CbH >
To: Billet, Courtney (NIH/NIAID) [E]-------=- (b'""'

)(= Fauci, Anthony (NIH/NIAID) [E]
(b)(6)>
Cc: Marston, Hilary (NIH/N IAID) [E] (b)(6); Conrad, Patricia (NIH/N IAID) [E]
(b)(6)>; Stover, Kathy (NIH/NIAID) [E] (b)(6) Routh, Jennifer
-~---~==:::!......:___....:...~ ~
Subject: RE:ASF: Dan Chertow invitation
Agree with Courtney
Dan is a good speaker and would represent nih we ll

-------- (b)(6)>
To: Fauci, Anthony (NIH/NIAID) [El ------= = CbH6J1>

Cc: Marston, Hilary (NIH/NIAID) [El (b)( Folkers, Greg (NIH/NIAID) [El
CbH ; Conrad, Patricia (NIH/NIAID) [E] (b)(6J>; Stover, Kathy
':":"'."~:-'."'."":'"".":'":-:-::"::-===:::!:..--~~
(NIH/NIAID) [El Cb)( >; Routh, Jennifer (NIH/N IAID)[E] CbH6)>
Subject : ASF: Dan Chertow invitation
Dan Chertow has been asked to speak at this event, which has some rather high profile participants and
media attendance. He would like to do it.
■ Do you agree?
From: "Cohen, Justin (NIH/CC/OD) [E]" (b)(6)>

Date : Friday, January 31, 2020 at 4:43:08 PM
--------
To: "Myles, Renate (NIH/OD) [E]" ------~= CbH ·, "Fine, Amanda (NIH/OD) [E]"
CbH6)>, "Routh, Jennifer (NIH/NIAIO) [E]" Cb)( >, "Billet, Courtney
-:":"".":"'.-:-:-::-:-:--:-::-:~==---- :;;;-;-,-,=
Cc: "Burklow, John (NIH/OD) [El"
-------- (b)(6) , "Wojtowicz, Emma (NIH/OD) [El"
NIH-002389
---------- "NIAID NEWS {NIH/NIAID)" <NIAIDNEWS@n iaid.nih.gov>
(b)(6),
Subject: FW: coronavirus speaking opportunity
Obvious ly given the current environment (not to ment ion some of the names involved in the event),
want to make sure I'm in lockstep with you all from square one . How would you like me to proceed with
the request below? The event is open to the public/ press.
From: Chertow, Daniel (NIH/CC/CCMD) (El (b)(6)>

Sent: Thursday, January 30, 2020 6:16 PM
--------
To: Cohen, Justin {NIH/CC/OD) [El
------~= >; Freimuth, Molly {NIH/CC/OC) [El
(bH >
-------- (b)(
Cc: Suffredini, Anthony (NIH/CC/CCMD) [El_______ _H_6)>; Masur, Henry (NIH/CC/CCMD) [El
Cb
(b)(6)
Subject: FW: Hudson Institute speaking request
Dear Justin,
I am checking back in with you regarding the below invitation to speak.
I would like to participate in this if possible.
Please confirm that you have received my email.
Thank you.
Sincerely,
Dan
From: "Asha M. George" <asha .geo rge@b iode fensecomm ission .org >
Date: Thursday , January 30, 2020 at 6:09 PM
To: "Chertow, Daniel (NIH/CC/CCMD) [E]" ------~~ CbH6J>
Subject: Re: Hudson Institu te speaking request
Dear Dan,
Sorry, we have changed something slightly. Instead of taking questions directly from the
audience, we will obtain questions from the audience via email while the first part of the
event occurs, curate them, and then have them available for Senator Lieberman to ask
them of the speakers.
Asha
Asha M. George, DrPH

Executive Director
NIH-002390
BIPARTISAN COMMISSION ON BIODEFENSE
202.974.2416
biodefensecommission.org
Linkedln I Tw itter I Facebook I lnstagram
I~~ BIPARTISAN
COMMISSION
ONBIODEFENSE
Beyond
the blueprint
From:Asha M. George <asha.geor ge@biodefe nsecomm issio n.o rg>

Sent : Thursday, January 30, 2020 6:02 PM
To: Chertow, Daniel (NIH/CC/CCMD) [E]------ --=
(b"H=6)
Subject : Re: Hudson Institute speaking request
Dear Dan,
Here are some more specifics regarding the event we will holding at Hudson Institute on
novel coronavirus. The meeting will be on February 10th , from 2:00 - 3:30 pm in the
Stern Conference Center at Hudson Institu te, which is located at 1201 Pennsyl vania
Avenue, NW, 4th floor, Washington, DC 20004.
We also have the executive conference room reserv ed from 1:30 pm on. Please plan to
arrive around then, so that you can talk with Senator Lieberman and the other speakers
before the event starts at 2:00 pm. Just ask the receptionist to direct you where to go.
Here are the speakers:

• Forme r Senator Joe Lieberman , co-chair, Bipartisan Commission on Biodefense
• Dr. Julie Gerberding, Executive Vice President & Chief Patient Officer, Strategic
Communications, Global Public Policy and Population Health , Merck; former
Director, Centers for Disease Control and Prevention
• Dr. Billy Karesh, ex officio , Bipartisan Commission on Biodefense ; Executive VP,
EcoHealth Alliance
• The Honorable Tim Morrison, Senior Fellow, Hudson Institute ; former Deputy
Assistant to President Trump for National Security; former Special Assistant to
the President and Senior Director for Weapons of Mass Destruction and
Biodefense
• Mr. Eric Brown, Senior Fellow, Hudson Institute
NIH-002391
• Dr. Daniel S. Chertow (CAPT - US Public Health Service) , Head, Emerging
Pathogens Section , Critical Care Medicine Department , Clinical Center &
Laboratory of lmmunoregulation , National Institute of Allergy and Infectious
Diseases , National Institutes of Health (invited)
The setting will be relatively informal. Scooter Libby will first introduce Senator
Lieberman . Then Senator Lieberman will make a short opening statement, and look to
Billy to set the stage and talk about the zoonotic nature of the disease , associated
disease management considerations , etc., in about 5 minutes. The Senator will then ask
each of the other speakers to say a few words from their perspectives . Afte r that,
Senator Lieberman will ask some questions of the group, allowing you all to answer and
converse. All of this should take about 45 minutes. Then we will allow the audience to
ask questions .
We are planning for Senator Lieberman to moderate the discussion and take questions
from the audience , but if for some reason he cannot do so, then Billy Karesh will.
I hope you will be able to make it, Dan. Let me know if you have any questions (and if
you will be able to make it, of course) and I look forward to seeing you on February
10th.
Asha

Executive Director
202.974.2416
Linkedln I Twitter I Facebook I lnstagram
I~~ BIPARTISAN
COMMISSION
ONBIODEFENSE
Beyondthe blueprint
NIH-002392
From: Chertow, Daniel (NIH/CC/CCMD) [E] ______ Cb
_>_C6)
_>
Sent: Tuesday, January 28, 2020 7 :18 PM
To: Asha M. George <asha.george@b iodefen secomm ission.o rg>
Dear Asha,
Given that this is a publi c/press event, I wi ll require additional clearance from my organizat ion in order
to participate.
I will reach out to them now and get back to you.
Thank you .
Dan
From: "Asha M. George" <asha .george@ bio defe nsecomm ission .o rg >
Date: Tuesday , January 28, 2020 at 7:15 PM
To: "Chertow, Daniel (NIH/CC/CCMD) [E]" ------~~ (b)( >
Subject: Re: Hudson Institute speaking request
Dear Dan ,
Thank you! The meeting will be held on February 1oth . We are still trying to nail down a
time with Senator Lieberman and Governor Ridge, so I will get back to you about that as
soon as possible , hopefully tomorrow.
The meeting will be open to the public and to the press, but Hudson Institute is a think
tank , so it's never a negative or rowdy crowd.
Asha

Executive Director
202.974.2416
NIH-002393
Linkedln I Twitter I Facebook I lnstagram
i~M. BIPARTISAN
COMMISSION
ONBIODEFENSE
Beyond
the blueprint
From: Chertow, Daniel (NIH/CC/CCMD) (E) ________

... (b)(6)
Sent : Tuesday, January 28, 2020 5:53 PM
To : Asha M . George <asha.geo rge@b iode fensecomm issio n.o rg>
Dear Asha,
I am available Feb 10th or 13th and would be happy to present to the group.
Please clarify who will be in attendance and if the event is open or closed to press/public as this would
requi re add itional clearance on my end .
Thank you.
Sincerely,
Dan
Daniel S. Chertow, MD, MPH, FCCM, FIDSA

Head, Emerging Pathogens Section
Critical Care Medicine Department , NIH Clinical Center &
Laboratory of lmmunoregulation, NIAID
From: "Asha M . Ge org e " <asha .geo rge@b iode fensecomm issio n.o rg>
Date: M onday , January 27, 2020 at 6:09 PM
NIH-002394
To: "Chertow, Daniel (NIH/CC/CCMD)[E]" (b)( 6)
Subject: Hudson Inst itute speak ing request
Dear Dr. Chertow,

I am the Executive Director of the Bipartisan Commission on Biodefense , co-chaired by
former Senator Joe Lieberman and Governor Tom Ridge . Our fiscal sponsor is Hudson
Institute, one of the think tanks here in DC. Hudson lnstitute's chair of the board of
trustees (Sarah May Stern) has asked Hudson Institute to run a 90 minu te mee ting on
the novel coronavirus situa tion. Hudson has asked us to help them pull a brief meet ing
together in short order .
Considering your experience on the ground dealing with other outbreaks , Hudson
Institute invites you to speak at this event. In addition to one of Hudson lnstitute's China
experts , we are also seeing whether Senator Lieberman and Governor Ridge are
available to speak.
Here are the dates they are a looking at: February 6, February 1O, and February 13.
Cou ld you let me know if you are available and if so , when on those dates?
Thank you for your consideration, Dan. I look forward to hearing from you soon.
Asha

Executive Director
202 .974.2416
biodefensecommission .org
Linkedln I Tw itter I Facebook I lnsta gram
I~~ BIPARTISAN
COMMISSION
ONBIODEFENSE
Beyond
the blueprint
NIH-002395
Sent : Sat, 1 Feb 2020 18:43:31 +0000
To : Kristian G. Andersen
Subject : RE: FW: Science: Mining coronavirus genomes for clues to the outbreak's origins
Thanks, Kristian. Talk soon on the call.
From: Kristian G. Andersen

--------
-------
(b) (6)1>
.----..-.= (b)(6)
,;....:._..:__......:...:....:.!:::::=~~------
Cc: Jeremy Farrar (b) ( >
Subject : Re: FW: Science: Mining coronavirus genomes for clues to the outbreak 's origins
Hi Tony,
Thanks for shari ng. Yes, I saw th is ear lier today and both Eddie and myself are actually quoted in it . It's a
great article, but the problem is that our phylogenetic analyses aren't able to answer whether the
sequences are unusual at indivi dual residues, except if they are completely of f. On a phylogeneti c t ree
the virus looks totally normal and the close clustering with bats suggest that bats serve as the reservoir .
The unusual fea tures of the virus make up a really small part of the genome (<0.1%) so one has to look
really closely at all the sequences to see that some of the features (potentially) look engineered.
We have a good team lined up to look very critically at this, so w e should know much more at the end of
the weekend . I should mention that after discussions earlier today, Eddie, Bob, Mike, and myself all find
the genome inconsistent wit h expectations from evolutionary theory . But w e have t o look at this much
more closely and th ere are still further analyses to be done, so tho se opinions could still change.
Best,
Kristian
On Fri, Jan 31, 2020 at 18:47 Fauci, Anthony (NIH/NIA ID) [E)
-------- (b)(6)> wrote:
Jeremy/Kristian:
This just came ou t today. You may have seen it. If not, it is of interest to the cu r rent
discuss ion.
Best,
Tony
From: Folkers, Greg (NIH/NIA ID) [E)_______ _ >_C6)

Cb _
Subject : Science: Mining coronavirus genome s for clues t o t he outbreak 's origins
NIH-002396
As part of a long-running effort to see what viruses bats harbor, researchers in China collect one from
a cave in Guandong.
EcoHealth Alliance
Mining coronavirus genomes for clues to the

outbreak's origins
By Jon CohenJan. 31, 2020, 6:20 PM
attaaaggtt tataccttcc caggtaacaa accaaccaact ttcgatctc ttgtagatct ...
That string of apparent gibberish is anything but: It's a snippet of a DNA sequence from the viral
pathogen, dubbed 2019 novel coronavirus (2019-nCoV), that is overwhelming China and frightening
the entire world. Scientists are publicly sharing an ever-growing number of full sequences of the virus
from patients-53 at last count in the Global Init iat ive on Sharing All Influenza Data database. These
viral genomes are being intensely studied to try to understand the origin of 2019-nCoV and how it fits
on the family tree of related viruses found in bats and other species. They have also given glimpses
into what this new ly discovered virus physically looks like . how it's changing, and how it might be
st opped .
"One of the biggest takeaway messages [from the viral sequences] is that there was a single
introduction into humans and then human -to -human spread," says Trevor Bedford, a bioinformatics
specialist at t he University of Washington, Seattle. The role of Huanan Seafood Wholesale Market in
Wuhan, China, in spreading 2019-nCoV remains murky, though such sequencing, combined with
sampling the market's environment for the presence of the virus, is clarifying that it indeed had an
important early role in amplifying the outbreak. The vira l sequences, most researchers say, also knock
down the idea the pathogen came from a virology institute in Wuhan.
In all, 2019-nCoV has nearly 29,000 nucleotides bases that hold the genetic instruction book to
produce the virus. Although it's one of the many viruses whose genes are in the form of RNA,
scientists convert the viral genome into DNA, with bases known in shorthand as A, T, C, and G, to
make it easier to study. Many analyses of 2019-nCoV's sequences have already appeared on
viro logical.org, nextstrain.org , preprint servers like bioRxiv, and even in peer-rev iewed journals. The
sharing of the sequences by Chinese researchers allowed public health labs around the wor ld to
develop their own diagnostics for the virus, which now has been found in 18 other countries.
(Science's news stories on the outbreak can be found here.)
NIH-002397
When the first 2019-nCoV sequence became available, researchers placed it on a family tree of
known coronaviruses-wh ich are abundant and infect many species-and found that it was most
closely related to relatives found in bats. A team led by Shi Zheng-Li, a coronavirus specialist at the
Wuhan Institute of Virology, reported on 23 January on bioRxiv that 2019-nCoV's sequence was
96.2% similar to a bat vi rus and had 79.5% similarity to the coronavirus that causes severe acute
respiratory syndrome (SARS),a disease whose initial outbreak was also in China more than 15 years
ago. But the SARScoronavirus has a similarly close relationship to bat v iruses, and sequence data
make a powerful case that it jumped into people from a coronavirus in civets that differed from
human SARSviruses by as few as 10 nucleotides. That's one reason why many scientists suspect
there's an "intermediary" host species-or several-between bats and 2019-nCoV.
According to Bedford 's analysis, the bat corona viru s sequence that Shi Zheng-Li's team highlighted,
dubbed RaTG13,differs from 2019-nCoV by nearly 1100 nucleotides. On next strain.org , a site he co-
founded, Bedford has created coronavirus family trees (example below) that include bat, civet, SARS,
and 2019-nCoV sequences. (The t rees are int eract ive-by dragging a computer mouse over them, it's
easy to see the differences and similar ities between the sequences.)
~
--
......
.-.11
...
-.-·--
,_
--
~ -.
111(4::-1
,_.
-u ,
Ill
~..J~
----------.....
0 00 om
.....-----
----------r
'"" '""
.._...
c::=.~,:::::::•
fl lJ OJ•
_-_....
Ot •
-~-
_1...........
Bedford's analyses of RaTG13 and 2019-nCoV suggest that the two v iruses shared a common ancestor
25 to 65 years ago, an estimate he arrived at by comb ining the difference in nucleotides between the
viruses with the presumed rates of mutation in other coronav iruse s. So it likely took decades for
RaTG13-like viruses to mutate into 2019-nCoV.
Middle East respiratory syndrome (MERS),another human disease caused by a coronavirus, similarly
has a link to bat viruses. But studies have built a compelling case it jumped to humans from camels.
And the phylogenetic tree from Shi's bioRxiv paper (below) makes the camel-MERS link easy to see.
NIH-002398
100 TGEV
MlnkCoV
100 FerretCoV
Bat CoV CDP HE15
Scotophilus bat CoV 512
PEDV
Bat CoV HKU10
Mlnlopterus bat CoV 1
Miniopterus bat CoV HKU8
100
Human CoV NL63
Bal NL63-related CoV
Human CoV 229E
SADS-CoV
Rhinolophus bat CoV HKU2
Human CoV OC43
100 Murine hepatitis virus
Rat CoV HKU24
Human CoV HKU1
100 Human MERS-CoV
Came l MERS-CoV
Pfplstra/lus bat CoV HKUS
Tytonycteris Bat CoV HKU4
Hedge hog CoV
100 100 SARS-CoV BJ0 1
Civet SARS-CoV S23
Bat SARSr -CoV WIV1
Bat SARSr-CoV SHC01 4
Bat SARSr-CoV LYRa11
go Bat SARSr-CoV Rf1
97
Bat SARSr-COV ZC45
Bat SARSr-CoV HKU3-1
Bat SARSr-CoV BM48-31
BetaCoV/Wuha n/WIV0S /2 019
100 B ataCo V /Wuha n/WIV02 /201 9
100
BetaCoV/Wuha n/WIV0-4/2 019
8e t aCoVrNuha nlWIV06 / 20 19
100 BctaCoV/Wuha n/WIV07 /201 9
Bat CoV RaTG13
97
Bat Hp BetaCoV Zhejiang 2013
Rousettusbat CoV HKU 9
100 Bat CoV GCCDC1
IBV
0. 1
The longer a virus circulates in a human popu lations, the more time it has to develop mutations that
differentia te strains in infected people, and given that the 2019-nCoV sequences analyzed to date
differ from each other by seven nucleotides at most, this suggests it jumped into humans very
rece ntly. But it remains a mystery wh ich animal spread the virus to humans . "There' s a very large gray
area between viruses detected in bats and the virus now isolated in humans," says Vincent Munster,
a virologist at the U.S. National Institute of Allergy and Infectious Diseases who studies coronaviruses
in bats, camels, and others species.
Strong evidence suggests the marketplace played an early role in spread ing 2019-nCoV, but w hether
it was the origin of the outbreak remains uncertain . Many of the initially confirmed 2019-nCoV
cases-27 of the fi rst 41 in one repor t , 26 of 47 in another -wer e connected to the Wuhan market,
but up to 45%, including the earliest handful, were not . This raises the possibi lity that the initial jump
into people happened elsewhe re.
NIH-002399
Accord ing t o Xinhua. the state-run news agency. "environmental sampling" of the Wuhan seafood
market has found evidence of 2019-nCoV. Of the 585 samples tested, 33 were positive for 2019-nCoV
and all were in the huge market's western portion, which is whe re wildlife were sold. "The positive
tests from the wet market are hugely important," says Edward Holmes, an evolutionary biologist at
the University of Sydney who collaborated with the first group to publicly release a 2019-nCoV
sequence . "Such a high rate of positive tests would strongly imply that animals in the market played a
key role in the emergence of the virus ."
Yet there have been no preprints or official scientific reports on the sampling, so it's not clear which,
if any, animals tested positive. "Until you consistently isolate the virus out of a single species, it's
really, really difficult to try and determine what the natural host is," says Kristian Andersen, an
evolutionary biologist at Scripps Research.
One possible explanation for the confusion about where the virus first entered humans is if there was
a batch of recently infected animals sold at different marketplaces. Or an infected animal trader could
have transmitted the virus to different people at different markets. Or, Bedford suggests, those early
cases could have been infected by viruses that didn't easily transmit and sputtered out. "It would be
hugely helpful to have just a sequence or two from the marketplace [environmental sampling] that
could illuminate how man zoonoses occurred and when they occurred," Bedford says.
A research group sent fecal and other bodi ly samples from bats they trapped in caves to the Wuhan
Institute of Virology to search for coronaviruses.
EcoHealth All iance
In t he absence of clear conclusions about the outbreak's origin, theories thrive, and some have been
scientifica lly shaky. A sequence analysis led by Wei Ji of Peking University and published on line by the
Journal of Medical Virology received substantial press coverage when it suggested that "snake is the
most probable wildlife anima l reservoir for the 2019-nCoV." Sequence specialists, however. pillor ied
!!-
Conspiracy theories also abound. A CBCNews report about the Canadian government deporting
Chinese scientists who worked in a Winnipeg lab that studies dangerous pathogens was disto rted on
social media to suggest that they were spies who had smuggled out coronaviruses. The Wuhan
Institute of Virology, wh ich is the premier lab in China that studies bat and human coronaviruses, has
also come under fi re. "Experts debunk fringe theory linking China's coronavirus to weapons
research," read a headline on a story in The Washington Post that focused on the facility.
Concerns about the inst itute predate this outbreak. Nature ran a story in 2017 about it building a new
blosafety level 4 lab and Included molecular biologist Richard Ebright of Rutgers University,
Piscataway, expressing concerns about accidental infections, which he noted repeat edly happened
NIH-002400
with lab workers handling SARSin Beiji ng. Ebright, who has a long history of raising red flags about
studies with dangerous pathogens, also in 2015 crit icized an experiment in which modifications were
made to a SARS-likevirus circulating in Chinese bats to see whether it had the potential to cause
disease in humans. Earlier this week, Ebright quest ioned t he accuracy of Bedford's calculation that
there are at least 25 years of evolutionary distance between RaTG13- the virus held in the Wuhan
virology institute - and 2019-nCoV, arguing that the mutation rate may have been different as it
passed through different hosts before humans. Ebright tells Sciencelnsiderthat the 2019-nCoV data
are "consistent with entry into the human population as a natural accident."
Shi did not reply to emails from Science,but her longtime collaborator, disease ecologist Peter Daszak
of the EcoHealth Alliance, dismissed Ebright's conjecture. "Every time there's an emerging disease, a
new virus, the same story comes out: This is a spillover or the release of an agent or a bioengineered
virus," Daszaksays. "It's just a shame. It seems humans can't resist controversy and these myths, yet
it's staring us right in the face. There's this incredible diversity of viruses in wildlife and we've just
scratched the surface. Within that diversity, there will be some that can infect people and within that
group will be some that cause illness."
A team of researchers from the Wuhan Institute of Virology and the EcoHealth Alliance have trapped
bat s in caves all over China, like this one in Guangdong, to sample them for coronaviruses.
EcoHealth All iance
Daszak and Shi's group have for 8 years been trapping bats in caves around China to sample their
feces and blood for viruses. He says they have sampled more than 10,000 bats and 2000 other
species. They have found some 500 novel coronaviruses, about 50 of wh ich fall relatively close to the
SARSvirus on the family tree, including RaTG13-it was fished out of a bat fecal sample they collected
in 2013 from a cave in Moglang in Yunnan province . "We cannot assume that just because this virus
from Yunnan has high sequence identity with the new one that that's the origin," Daszaksays, noting
that only a tiny fraction of coronaviruses that infect bats have been discovered. "I expect that once
we've sampled and sampled and sampled across southern China and central China that we're going to
find many other viruses and some of them will be closer [to 2019-nCoV]."
It's not just a "curious interest" to figure out what sparked the current outbreak, Daszak says. "If we
don't find the origin, it could still be a raging infection at a farm somewhere, and once this outbreak
dies, there could be a cont inued spillover that's really hard to stop. But the jury is still out on what the
real origins of this are."
Posted in:
• Asia/ Pacific
NIH-002401
• Healt h
• Coro navi rus
doi:10 .11 26/science.abb1256
Jon Cohen
Jon is a staff writer for Science.
• Email Jon
• Tw it te r
Disclaimer : Any third-part y material in this email bas been shared for internal use under fair use
provisions of U.S. copyright law, without further verification of its accuracy /veracity . It does not
necessaril y represent my views nor those of NIAID, NIH, HHS, or the U.S. government.
NIH-002402
Sent : Sat, 1 Feb 2020 18:39:50 +0000
Subject : FW: Possible cure medically to the new coronav irus,corona virus,from wuhan
china.
Attachme nts: medicalcure.docx
NIA ID inquiries, p lease
From: andrew igla (b)(6)>

'"'~..-.
(6)
=>
Subject : Fw: Possible cure medically to the new coronavirus,corona virus,from wuhan china .
read t hi s emai l.
From: andrew igla (b)(6)

Se nt: Tuesday, 28 January 2020 6:36 PM
To: secretary@hhs .gov <secretary@hhs.gov >
Subject : Fw: Possible cure medically to the new coronavirus,corona vi rus,from wuhan china .
From : andrew igla (b)(6)>

Sent : Sunday, 26 January 2020 9:10 PM
To: secretary@ hhs.gov <secretary@hhs .gov >
Subject : Possible cure medically to the new coronavirus,corona virus,from wuhan china .
For secreta ry Azar th is emai l.
From : andrew igla (b)(6)>

Sent : Sunday, 26 January 2020 8:59 PM
To: secretary@ HHS.gov <secreta ry@ HHS.gov>
Subject : Possible cure medically to the new coronavirus,corona virus,from wuhan china.
NIH-002403
From:andrew igla (b)(6)
Sent: Sunday,26 January2020 1:25
This ema il is to be sent to the doctors treating medically patients in hospitals involving
the new coronavirus,corona virus, from wuhan china.This email contains the possible
medical cure to the new coronavirus,corona virus,from wuhan china.URGENT.Discovered
from an australian friend of the amer ican people,andrew igla.
This email is about orally tak ing zovirax and ciproxin together for one day.
Orally taking ciproxin,inhibiting gyrase,orally taking zovi rax,inhibit ing viral DNA polymerase,
together at the same time, stops viral dna moving medically curing viruses in host cells
stoping duplica ting viral infected cells and stoping a virus invading new uninfected cells.
Attached document contains possible medical cure to new corona virus from wuhan in
china to help you win over this virus.
Dear professor and politic an,

My name is andrew igla and work as a research science person in dengue
virus and anaconda sea snake virus.
Attached is a business document for you.
Thanks,
Andrew igla. me lbourne australia.
NIH-002404
Sent: Sat, 1 Feb 2020 18:35:10 +0000
Subject: FW: 2019-nCoV
Attachments : Aminopeptidase N inhibitors and Coronaviruses-LANCET2003.pdf
Pleasehandle.
From: Kontoyiannis,Dimitrios P_________ Cb

_H_6)>
To: Fauci, Anthony (NIH/NIAID) [E]_______
------~~ _.
(b)(6)>
Subject: FW: 2019-nCoV
Dear Dr Fauci, I enjoyed your recen t editorial in JAMA re Coronaviruses

Although the viral disease is not an area of my expertise, you might want to take a look
at a hypothesis we had proposed, long ago (back in the era of SARS), re the potential of
immune-modulating Coronavirus infection natural history with blockage of
aminopeptidase N.
I am not aware of any studies whether aminopeptidase is a receptor of China 2019-
nCoV, though.
Sincerely
DPK
Dimitrios P. Kontoyiannis. MD. ScD. PhD (Hon). FACP. F/DSA. FECMM. FAAM. FAAAS
Texas 4000 Distinguished Endowed Professor For Cancer Research
Deputy Head , Division of Internal Medicine
The University of Texas MD Anderson Cancer Center
ECMM Diamond Excellence in Mycology Center/www .ecmm .info
Adj Professor Baylor College of Medicine

Adj Professor UT School of Public Health
Adj Professor University of Houston
The informat ion contained in this e-mail message may be privileged, confidentia l, and/or protected from
disclosure. This e-ma il message may contain protected health information (PHI); dissemination of PHI
should comply with applicable federa l and state laws. If you are not the intended recipient, or an
authorized representative of the intended recipient, any further review, disclosure, use, disseminat ion,
distribution, or copying of this message or any attachment (or the information contained therein) is
strictly prohibited. If you think that you have received this e-mail message in error, please not ify the
sender by return e-mail and delete all references to it and its contents from your systems.
NIH-002405
Sent: Sat, 1 Feb 2020 18 :34 :43 +0000
Subject: FW: Teleconference
Attachments : Coro navirus sequence comparison[l].pdf
FYI
From:Jeremy Farrar (b)(6)>

To: Fauci, Anthony (NIH/NIAID) [E] ------~= >; Patrick Vallance (b)(6)
(b) (
------
Cc: Drosten , Christian (b)(6); Marion Koopmans
(b)(6)>; R.A.M. Fouchier (b)( ; Edward Holmes
(b)(6) Andrew Rambaut (b)(6)
-----~--======~~:;;---:--:--
Krist ian G. Andersen Paul Schreier (b)( ; (b)( ;
======-;- CbH ; Ferguson, Mike .___________

(b~)(~ (b)(6)
_ ; Collins, Francis {NIH/OD) [E)
Kristen and Eddie have shared this and will ta lk through it on the call. Thank you.
From:Jeremy Farrar (b)(6)


Information and discussion is shared in total confidence and not to be shared until agreement on next
steps.

Please mute phones .
One Hour
6am Sydney
8pm CET
NIH-002406
7pm GMT
2pm EST
11am PST
(Hope I have the times right!)
Thank you for the series of calls and for agreeing to jo in this call.
Agenda
• Introduction , focus and desired outcomes - JF
• Summary - KA
• Comments - EH
• Q&A-AII
Kristian Anderson
Christian Drosten
Tony Fauci
Mike Ferguson
Ron Fouchier
Eddie Holmes
Marion Koopmans
Stefan Pohlmann
Andrew Rambaut
Paul Schreier
Patrick Vallance
NIH-002407
Sent: Sat, 1 Feb 2020 18:23:07 +0000
To : Kay Johnson
Subject: RE: thank you for continuing leadership
Kay:
Thank you for your kind note. Much appreciated.
Best regards,
Tony
From: KayJohnson
-----------
-------=-,-=,
(b)(6)

--------
Subject : thank you for continuing leadership
(b)(6)
Dear Dr. Fauci - We met long ago when I was a young health policy staff person at the
Children's Defense Fund and you gave a talk on HIV/AIDS at the annual CDF conference around
1984-86.
When I served on the National Vaccine Advisory Committee (NVAC) during the 1990-9 1 measles
epidemic and helped to write the measles whitepaper, I had other occasions to hear your
insights.
Since that time, I have frequently heard you on the PBSNewsHour and NPR, I see your
perspectives in JAMA and other journals. (For examp le, this week I heard NPR piece and read
JAMA opinion piece on coronavirus.) In every instance, I am struck again by how clearly you
articulate the science, the issues for public concern, and options for our nation 's response.
While I've worked with many public health leaders and watched others in the media over the
past 35 years of my Maternal and Child Health public policy career, I believe no one is better at
communications than you. It is in some ways a thank less job. I am writing to say that your
continuing leadership and dedication to our nation's health is deeply appreciated by me and
millions of others.
Best regards, Kay
Kay Johnson
President, Johnson Group Consult ing, Inc.
voice: Cb)(6)
fax: 802-482-3008
Email:
---------- (b)(6)
NIH-002408
Sent : Sat, 1 Feb 2020 17:56:42 +0000
Subject: FW: article from IIT/India on Coronovirus
Attachments : 20200130.2019-nCOVsequence paper.927871vl.full.pdf
Please handle.
From: WRB Gmail CbH >

To: Fauci, Anthony (NIH/NIAID) [E]------~= (b)(6)
Cc:Hong Cai (b)(6)
Subject: article from IIT/India on Coronovirus
Hi Tony,
I hope you are coping with the chaos around coronavirus.
I am (b)(6)1 but still active, currently chair of Mesa Biotech, (b)(4)

(b) (4)
No doubt you have seen, but in case not, I am sending a copy.
Hopefully someone at NIH is trying to replicate this study or to find problems with the ir
methodology .
With best wishes,

Bill
NIH-002409
William R. Brody
(b)(6)
l ohns Hopkins University
Salk Institute for Biological Studies
NIH-0024 10
Sent : Sat, 1 Feb 2020 17:54:38 +0000
Subject: FW: POLITICO: New FDA chief plans for 'the most serious scenarios' of
coronavirus outbreak
We should make a similar slide for upcoming talks.
---------
From: Folkers, Greg (NIH/N IAID) [E)
(b)(6)
Subject : POLITICO:New FDA chief plans for 'the most serious scenarios' of coronavirus outbreak
EXCLUSIVE
New FDAchief plansfor 'the most seriousscenarios'of

coronavirusoutbreak
CBD, drug prices, safety - plus Wuhan coronavi rus - make for a crowded agenda for Stephen Hahn.
The FDA for years has mostly stayed out of the debate around drug prices I Jacquelyn Martin, File/ AP
Photo
By SARAH OWERMOHLE and SARAH KARLIN-SMITH
01/31/2020 04:54 PM EST
Updated: 01/31/2020 05:28 PM EST
New FDA commissioner Stephen Hahn faced a jam-packed agenda: opioids , CBD, vaping, and how to let
states safely import drugs. Then the Wuhan coronavirus broke out.
The virus was declared a public health emergency by HHSjust a few hours after Hahn's exclusive
interview with POLITICOFriday. That kicks the agency into overdrive in multiple roles - helping speed
vaccine, drug and diagnostic test development while also trying to avoid shortages of drugs and devices
the United States needs that are made in China.
Advertisement
Hahn said there have not been any reports yet of disruption of the supply chain or shortages, but the
agency is looking ahead and planning for "what could potentially be the most serious of scenarios." As of
now FDA inspections in China are being conducted on a case-by-case basis.
NIH-002411
"We are taking on an individual -by-individual basis what's the regulatory need for anything in China ...
versus what are the personnel risks associated," he said.
Monitoring the the situation in China could soon get trickier as the State Department expands
mandatory evacuation from affected areas of the country.
The coronavirus also broke out in an election year when President Donald Trump wants to deliver on his
promise to bring down drug prices - not traditionally the province of the FDA, a regulatory agency
designed to focus on safety and efficacy .
"If my patients couldn't get access to something because of cost - that was a real problem for me as a
doctor . Now I'm on the other end of that, but what can we do to make sure that that pipeline flows in
the best way possible?" said Hahn, 60, an oncolog ist, researcher and Washington newcomer.
Hahn was confi rmed as commissioner on Dec. 18, the night before the administrat ion announced its
plan to let states import cheaper medicines from Canada - an approach that prior FDA commissioners
opposed over fears it would jeopardize the safety of the drug supply . Trump has endorsed letting states
such as Florida do this.
NIH-002412
WHOdeclares global 9,826
health emergency
The novel coronavirusthat first infected
people in Wuhan.China. has spread to
more than 20 other countries, with
Russia and the U.K. report ing their first
cases of the viral pneumonia on Jan . 31.
7,818
6.065
2019-nCoVis a coronav1rus.
a type of
virus similarto the comm°"cold,SARS
artdMERS.Ir is spreadby close contact 4,593
with peoplewho are inleaed.One
study suggestsmen might be more
susceptible to che virus than women.
Cases confirmed by WHO

ASOFJAH.31
2,798
2,01G
1,320
581
-------
282 314
Cont, ed deaths
170 213
6 6 17 25 "' 56 BO 106 132 -
Jan. 20 21 23 24 25 26 27 28 29 30 31
Sour~s WHO.SouthChinaMorningPo-it.newsrf!pons
By PattttSOn Clark. POLITICO Pro OataP(llnl
Patterson Clark/POLITICO Pro DataPoint
"There is a compe lling reason that the American peop le want us to cons ider this and so we're go ing to
have to figure th is one out and balance both of those issues," Hahn said, referring to safety and
affordability.
NIH-0024 13
The FDAfor years has mostly stayed out of the debate around drug prices; the agency doesn't regulate
the cost of medicines or health insurance coverage. But Hahn talked up FDA's role in getting prices down
by approving more generics, acknowledging that "the American people are expecting us to do more."
Trump has touted the FDA's record on boosting competition via generic approvals .
As FDA works on finalizing the importation rule , Hahn said the agency will be open to addressing
criticism that states can't save money bringing in drugs from Canada if the pathway is too burdensome.
But he stressed safety is tantamount. "Our primary concern is the protection of the drug supply," he
said.
Hahn said he has also talked with CMS Administrator Seema Verma about addressing costs of new
brand-name products that are approved with limited data sets, similar to the way CMS decides to cover
some medical devices. That approach - known as coverage with evidence development - let s CMS
cover a new prod uct on the condition that manufacturers keep providing data.
FDA has not done that, but new medicines are increasingly being approved on smaller clinical trials
without hard data on clinical benefits - and can come with six-figure price tags.
As an academic, Hahn had co-written an editorial suggesting that payments for newly approved
radiation oncology devices cou ld be linked t o olde r products unt il enough evidence builds up to show
that the new products are superior. Only then would manufacturers have more pricing leeway .
"It's a CMS call about coverage with evidence development, but I do think in this world where we are
concerned, and rightfully so, about the cost of medicine and health et cetera, that we should be looking
at all avenues to approach that, " he told POLITICO.
Over the last few years, some cr it ics have said t he FDA is overcorrecting and moving too quickly to
approve drugs without adequate evidence. But Hahn did not indicate he would put the brakes on.
"At the end of the day there is this balance between the gold standard and being efficient and getting
th ings in people's hands I'm totally confident in the agency's ability to do that."
Hahn must balance all that while leading the FDA's response t o t he Wuhan crisis, which has heightened
some lawmakers' concern about U.S. reliance on Chinese drug manufacturing after incidents of
contamination with carcinogens.
"We have to be concerned about the supply chain to make sure that we have enough of what we need if
there are any potential outbreaks here," Rep. Susan Brooks (R-lnd .) said after a closed-door briefing
Thursday for Energy and Commerce committee members with top health officials . The fact that China
manufactures much of the protective medical gear used in U.S. hospitals and clinics "should cause us to
be reexamining what we're doing in China versus what should be brought back to this country." she
said.
Outside of the coronavirus, a host of thorny regulatory issues await Hahn. Industry and lawmakers have
pressed for a clear FDAframework on selling cannabidiol, the popular hemp and marijuana byproduct
decriminalized by the 2018 farm bill - and since sold as medicine, dietary supplements and infused in
food, cosmetics and skincare products .
"You cannot walk down the street without seeing the products " but there is a dearth of solid data on
how safe and effective CBD actually is, said Hahn.
Those CBD challenges have fueled larger discussions about how to better regulate the vast dietary
supplement market, where manufacturers often push legal boundaries by making unverified claims
about how herbal or homeopathic products can help peop le.
"It will be something else next," said Hahn. We don't want to overstep our boun ds but we want to make
sure that safe and effective products are in the hands of people."
my views nor those ofNIAID , NIH , HHS, or the U.S. government .
NIH-002414
Sent: Sat, 1 Feb 2020 17:51 :31 +0000
To: Auchincloss, Hugh (NIH/NIA ID) [El
Subject : RE: Continu ed
OK. Stay tuned.
-----Orig inal M essage -----

From : Auchinclos s, Hugh (NlH/N IAJD) [E]...________ _~
(b_ <..,.
Sent : Saturday, Febrnary 1, 2020 11:47 AM
-----~~ (b)( >
Subject: Con tinued
The paper you sent me says the experim ents were perfonn ed before the ga in of fun ction pause but have since been
rev iewe d and appr oved by NIH. Not sure what that means since Emily is sure that no Coronavirus work bas gone
through the P3 framewo rk. She will try to detem 1ine if we have any distant ties to this work abroad.
Sent from my iPad
NIH-0024 15
Sent: Sat, 1 Feb 2020 17:32:40 +0000
Subject : FW: 2019 Novel Coronavirus:NanoViric ides Confirms It Has Been Working On A
Treatment For The Novel Wuhan Coronavirus
Pea se handle.
---<-Origi11alMessage-----
From: Amit Gup ta ,,;:;;...-------~~ (b) ( >
--------,;..,.,-,,
S~nt: Saturcl..ay,Fe bruary I, 2020 12:23 PM
To : Fauci , Anthony (NIH/NIAJD) [E] = (b)(6) >
Subject: 20 19 Nove l Coronavirus:NanoVir icides Con:finn s Tt Has Bee n Working On A Treahne nt For The Novel
Wuhan Coronavims
Dear Dr. Fauci.
Wondering if you have see the corona virus treatmen t news. I know you were involved in Ebola previously. You are
a great Scientist and Do ctor.
Coronavirus update: WHO says prepare for local corona virus outbreaks in other countries;
What do you think about this treatment.

Regards,
Amit
SHEL TON, CONNECT JCUT -- Thur sday, January 30, 2020 -- Nano Viricides, Joe. (NYSE Amer.: NNVC) (the
"Company"), a global leader in the deve lopment of highly effective antiviral therapies based on a novel
nanomedicin es platform , is confirm ing public disclosures in articles by various industry journals and other articles ,
that it is working on developing a treatmen t for the novel coronavirus 20 l 9-nCoV , or the Wuhan coronavirus.
"We have already initiated a program for developing a treatment for the 2019-nCOV ," said Anil R. D iwan , PhD,
President and Executive Chairman of the Company , adding, "Our platform technology enables possib ly the most
rap id pathway for new drug deve lopment against viral diseases. Of course , we wi II need suppo rt from governmen tal
and international agencies suc h as the US CDC, WHO , and Chinese CDC to successfu lly develop these treatments,
and, if developed , to get them to the patients in the fastest possible time. At this time, the Co mpany does no t have a
col labora tion with any of these agencies, and we have not been contacted by any of these ent ities or asked to
develop a treat ment for this virus. We had collaborations with the CDC and USAMRII D in the past. The Company
intends to pursue a relevant collaboration for testing of our drug candidates soo n."
The new 20 19-nCoV is known to be closely related to the SARS-CoV of 2002-2003 epidemic. In fact it has been
shown to use the same cell surface receptor as SARS -Co V, nam ely ACE2 .
"We hav e already found some lead candida te ligands in our chemical librar y tha t can bind to the SARS-CoV spike
pro tein in the same fash ion as it binds to the cognate recep tor , ACE2, using molecu lar modeling tools ," explained
Dr. Diwan, add ing , "We believe this means we may already be significantly ahead in developing a po tential
treatm ent for the new Wuhan virus. "
While the Company commissions synthesi s of the anti-nCo V nanoviricide drug candidates for test ing , some of
which are already in our hands , in pa rallel, the Company has also started preparing for testing of the candidates in
cell cultures against certain known BSL2 coronaviruses , including ones that use the ACE2 receptor. Less threatfu l
viruses in the same family that use the same receptor can serve as valid test viruses for screening our broad-spectrum
antiviral drug candidates . The Company ha, its own BSL2-certified virology laboratory at its Shelton campus where
NIH-0024 16
it intends to perform this testing.
The Company has its own cGMP -capable drug manufa ctu ring facility. This highly custom izab le facility can be
employed to produce severa l thousand doses of drugs per batch for treating coronavirus patients , if the Company's
drug successfu lly transitions to obtai ning an explo ratory treatment approval for use in patients .
The Company's platform technology has already proven that it can result in safe drugs. The Company 's first IND-
ready clinica l drug candidate , namely NV-HHV- 101, has successfu lly undergon e a standard battery of Safety and
Toxicological testing , as previously disclosed by the Company in press releases and SEC fil ings.
The Company is building on its previous work against coronaviruses . The Company's technology relies on copying
the human cell-surface receptor to which the virus binds, and making small chemicals that are called "ligands" that
will bind to the virus in the same fashion as the cognate receptor. These ligands are chemically attached to a
nanomice lle, to create a nanov iricide®. It is antic ipated that when a virus comes in contact with the nanoviricidc, not
only woul d it land on the nanov iricide surface , binding to the copious number of ligands presented there, but it
would also get entrapped because the nanomicelle polymer would turn around and fuse with the virus lipid envelo p,
harnessing a well known biophysica l phenomenon.
"It is like a 'Venus-Fly- Trap' for the virus, " explained Dr. Diwan .
The Company focuses on developing broad-spectrum ligands and, thereby, broad-spectrum nanoviiicides , copying
the specific human cellu lar receptor. No matter how much a virus mutates, it lands on the same cell surface receptor,
and binds in the same fashion. Thus , it is highly unli.kely that a virus mjght escape a nanoviricide against it, in spite
of mutations.
Tn2014 , the Company had worked on developing antiviral treatment s against MERS-CoV , and coronaviruses in
general. lt bad deve loped potential candidates for testing in anima l models. The MERS-CoV threat was eclipsed by
the Ebola epide mic of 2015 . The Compa ny developed viable drug cand idates against Ebola in a rapid response time
of a few weeks and sent them for testing to USAMRJID. These initial candidates showed significan t activity. The
Company believes that another cycle of optimization would have resulted in a candidate ready for animal testing
under the criteria estab lished by USAMRTJD then.
During these previous ciises , the Company did not have the modern labs, the cGMP drug manufacturing faci lity or
the BSL2 virology testing facility, all of which were commi ssioned after 2015 at its modern campus in Shelton, CT.
The Company is preparing an IND application for its first clinica l drug candidate to go into human clinical trials.
This drug candidate, NV -HHV -101, is a skin cream with the treatment of shingles rash as its first indicat ion . It has
shown broad-spectrum activ ity against HSY- I (cause of "cold sores"), HSV-2 (cause of "gerutal ulcers"), and VZV
(the varice lla-zoster virus, that causes chickenpox in children and immune-compromised humans , and shing les in
adults).
NV-HHV-101 has already gone through standard battery of safety-toxico logical testing, which provides confidence
that our platform is capable of creating safe drugs.
The Company has its own cGMP-c apable drug manufacturing facility where it intends to produce the drugs for
clinical supply.
The Company's top priority remruns working on its first IND application for NV- HHV-l01. The Company intends
to so licit interest and financing from gove rnment agencies in order to accelerate its work on the coronaviruses .
The market size for the treatment of shing les is estimated at approximately one billion dollars by various estimates.
These estimates take into account the Shingrix ® vaccine as well as existing vaccines. About 500,000 to 1million
cases of shing les occur in the USA alone every year.
The market size for our immediate target drugs in the HerpeCid e™ program is variously estimate d at billions to tens
of billions of dollars. The Company believes that its dermal topica l cream for the treatment of shing les rash will be
NIH-002417
its first drug heading into clinical trials. The Company believes that additional topical treatment candidates in the
HerpeCide™ program, namely , HSY-I "cold sores" treatment, and HSV-2 "genital ulcers" treatment are expected to
follow the shing les candidate into IND-enabling development and then into human clinical trials . These additional
candidates are based on NV-HHV-101, thereby maximizing return on investments and shareholder value.
The Company develops its class of drugs , that we call nanoviricides ®, using a platform technology. This approach
enables rapid development of new drugs against a number of different viruses. A nanoviricide is a "biomimetic" - it
is designed to "look like" the cell surface to the virus . The nanoviricide ® technology enables direct attacks at
multip le points on a virus particle. It is believed that such attacks would lead to the virus particle becoming
ineffective at infecting cells. Antibodies in contrast attack a virus particle at on ly a maximum of two attachment
points per antibody. In add ition, the nanovi ricide technology also simultaneously enables attacking the rapid
intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APls) within
the core of the nanovi1icide. The nanoviricide technology is the only technology in the world, to the best of our
knowledge , that is capable of both (a) attacking extracellular vims, thereby breaking the reinfection cycle, and
simu ltaneously (b) disrupting intracellular production of the virus, thereby enabling complete control of a virus
infection.
About NanoYiricides
NanoYiricides, Inc.(www.nanoviricides.com)is a development stage company that is creating special purpose
nanomaterials for antiviral therapy. The Company's novel nanoviricide ® class of drug candidates are designed to
specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHY-101 with
its first indication as dermal topical cream for the treatment of shingles rash. The Company is also developing drugs
against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and
herpes keratitis , HIN l swine flu, H5Nl bird flu, seasonal Influenza, HlV , Hepatitis C, Rabies , Dengue fever, and
Ebola virus , among others. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to
dtugs developed in these areas from TheraCour Pharma, lnc. This press release contains forward-looking statements
that reflect the Company's current expectation regarding future events. Actua l events could differ materially and
substantially from those projected hereiD and depend on a number of factors. Ce11ainstatements in this release , and
other written or oral statements made by NanoViricides , Inc. are "forward -looking statements" within the meaning
of Section 27 A of the Securities Act of 1933 and Section 2 l E of the Securities Exchange Act of 1934. You should
not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties
and other factors whicb are, in some cases , beyond the Company's control and which could, and likely will,
materially affect actual results , levels of activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons
actual results could differ materially from those anticipated in these fo1ward-looking statements, even if new
infonnation becomes available in the future. Important factors that could cause actual results to differ materially
from the company's expectations include , but are not limited to, those factors that are disclosed under the heading
"Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such
factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide
is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory
approvals, including with respect to the indications we are seeking; the successful cotmnercialization of our product
candidates; and market acceptance of our products. FDA refers to US Food and Drug Administration . IND
application refers to "lnvestigational New Drug" application. CMC refers to "Chemistry, MaDufacture, and
Controls".
Contact:
NanoViricides , Inc.
info@nanoviricides.com
NIH-002418
Sent : Sat, 1 Feb 2020 13 :19:06 +0000
Subj ect : FW: IMPORTANT
At tac hment s: Barie, Shi et al - Natu re medicine - SARS Gain of function.pdf
Here it is
Director
Phone : (b)(6)
FAX: (301) 496-4409
E-mail: (b)(6)
NIH-002421
Sent : Sat, 1 Feb 2020 12:43:22 +0000
Subject : FW: 2019 novel Coronavirus Global research and innovation forum : towards a
Attachment s: Global Research Forum dv2AMHR AM.PDF
We need to talk about this later in the day .. I am on Conference calls now. I w ill call you later.
Apparently Soumya is reaching out separate ly t o other people in NIA ID.
From : SWAMI NATHAN, Soumya

----------
To : Fauci, Anthony (NIH/NIAID) [E)______
(b)(6)
"""
(b""""
)(=6)
Subject : 2019 novel Coronavirus Global research and innovat ion forum: towards a research roadmap
DearTony
and 12th in Geneva, to discuss research prior ities related to the novel Corona virus . The expected
t hematic area forward. Several thematic areas will be considered at the meeting, namely: virus,
partnerships and collaborations to take this work forward.
Melinda Gates foundation, DFID, Wellcome Trust and several other partners. The secretariat within
WHO is the R&D blueprint, co-chaired by Dr Mike Ryan and myself .
As the head of an agency that would play an impor tant role in addressing this new viral outbreak, either
by undertaking or funding research, or both, I ta ke great pleasure in inviting you to this meeting. I
apologize for the short not ice, but you will understand that we have had to plan this in the past few
days, keeping in mind the evolving situation .
Please copy (b)(6) and (b)(6) in your response.
With best wishes,

Soumya
Dr Soumya Swaminathan
NIH-002422
Chief Scient ist
PS: Sorry if this is a duplication - just want to make sure the key people receive the invite . Sorry about
the short notice!
NIH-002423
Sent : Sat, 1 Feb 2020 12:32:57 +0000
To : 00~
Subject : FW: 2019 novel Coronavirus Global research and innovation forum: towards a
Attachme nts: Global Research Forum dv2AMHR AM.PDF
Cliff:
Whom should I nominate? See ye llow highlight
Tony
From: SWAMI NATHAN, Soumya <! (b)(6)

To: Fauci, Anthony (NIH/NIAID) [E] <!----- -..
(b..,
H=6)>
Subject : 2019 novel Coronavirus Global research and innovation forum: towards a research roadmap
DearTony
and 12th in Geneva, to discuss research priorities related to the novel Corona virus . The expected
thematic area forward. Several thematic areas will be considered at the meeting , namely : virus,
partnerships and collaborations to take this work forward .
Melinda Gates foundation, DFID, Wellcome Trust and several other partners . The secretariat within
WHO is the R&D blueprint, co-chaired by Dr Mike Ryan and myself.
As the head of an agency that would play an important role in addressing this new viral outbreak, either
by undertaking or funding research, or both, I take great pleasure in inviting you to this meeting . I
apologize for the short notice, but you will understand that we have had to plan this in the past few
days, keeping in mind the evolving situation.
Please copy (b)( and (b)(6linyour response.
With best wishes,

Soumya
Dr Soumya Swaminathan
NIH-002424
Chief Scient ist
PS: Sorry if this is a duplication - just want to make sure the key people receive the invite . Sorry about
the short notice!
NIH-002425
Sent : Sat, 1 Feb 2020 12:29:36 +0000
To : Auchincloss, Hugh (NIH/NIAID) [C] (b)(6)
Cc: (b)( 6) ----------
Subject: FW: Science: Mining coronavirus genomes for clues to the outbreak's or igins
As per my prior e-mail.
From: Folkers, Greg (NIH/NIA ID) [El

---------
(b)(6)
Subject : Science: Mining coronavirus genomes for clues to the outbreak's origins
As part of a long-running effort to see what viruses bats harbor, researchers in China collect one from a
cave in Guandong.
EcoHealth Alliance

outbreak's origins
attaaaggtt tataccttcc caggtaacaa accaaccaactttcgatctc ttgtagatct ...
That str ing of apparent gibberish is anything but: It 's a snippet of a DNA sequence from the viral
pathogen, dubbed 2019 novel coronavirus (2019-nCoV), that is overwhe lming China and frightening the
entire world. Scientists are publicly sharing an ever-growing number of full sequences of the virus from
patients - 53 at last count in the Global Init iative on Sharing All Influe nza Data database . These v iral
genomes are being intensely studied to try to understand the or igin of 2019-nCoV and how it fits on the
family tree of related viruses found in bats and other species. They have also given glimpses into what
this newly discovered virus physically look s like, how it' s changing, and how it might be stopped .
introduction into humans and then human-to-human spread," says Trevor Bedford, a bioinformatics
specialist at the University of Washington, Seattle. The role of Huanan Seafood Wholesale Market in
NIH-002426
important early role in amplifying the outbreak. The viral sequences, most researchers say, also knock
In all, 2019-nCoV has nearly 29,000 nucleotides bases that ho ld the genetic instruction book to produce
the virus. Although it's one of the many viruses whose genes are in the form of RNA, scientists convert
the viral genome into DNA, with bases known in shorthand as A, T, C, and G, to make it easier to study.
Many analyses of 2019-nCoV's sequences have already appeared on virological.org, nextstra in.o rg,
preprint servers like bioRxiv, and even in peer-reviewed journals. The sharing of the sequences by
Chinese researchers allowed public health labs around the world to develop their ow n diagnostics for
the virus, which now has been found in 18 other countries. (Science's news stories on the outbreak can
be found here.)
When the first 2019-nCoV sequence became available, researchers placed it on a family tree of known
co ronaviruses-which are abundant and infect many species-and found that it was most closely
related to relatives found in bats. A team led by Shi Zheng-Li, a coronavirus specialist at the Wuhan
Institute of Virology, reported on 23 January on bioRxiv that 2019-nCoV's sequence was 96.2% simi lar to
a bat virus and had 79.5% similarity to the coronav irus that causes severe acute respiratory syndrome
(SARS),a disease whose initial outbreak was also in China more than 15 years ago. But the SARS
coronavirus has a similarly close relat ionsh ip to bat viruses, and sequence data make a powerful case
that it jumped into people from a coronavirus in civets that differed from human SARSviruses by as few
as 10 nucleotides. That's one reason why many scientists suspect there's an "intermedia ry" host
species-or several-between bats and 2019-nCoV.
According to Bedford's analysis, the bat coronavirus sequence that Shi Zheng-Li's team highlighted,
dubbed RaTG13,differs from 2019-nCoV by nearly 1100 nucleotides. On nextstrain.org, a site he co-
and 2019-nCoV sequences. (The t rees are inte ract ive-by dragging a computer mouse over them, it's
easy to see the differences and similarities between the sequences.)
~
--- .... 10
_ ,.
,_,
-- --
-
F======:: ~:s::;:
'<.-
~
=-:
__
-u ,
,a
NIH-002427
Bedford's analyses of RaTG13 and 2019 -nCoV suggest that the two viruses shared a common ancestor
25 to 65 years ago, an estimate he arrived at by combining the d ifference in nucleotides bet ween the
viruses with the presumed ra te s of mutation in other coronaviruses. So it likely took decades for
RaTG13-like viruses to mutate into 2019 -nCoV.
Middle East respiratory syndrome (MERS), another human disease caused by a coronavirus, simi larly has
a link to bat viruses. But studies have built a compelling case it jumped to huma ns from camels. And the
phylogene ti c tree from Sh i's bioRxiv paper (below) makes the camel-MER$ link easy to see.
,...-----TGEV
,---- Mink CoV
,..__
__ FerretCoV
.----- Bat CoV COPHE15
,----- Scotophifus bat CoV 512
._____ PEDV
.----- Bat CoV HKU10
..---- Minlopterus bat CoV 1
._ ___ Miniopterus bat CoV HKU8
100
~-- Human CoV NL63
---- Bat NL63-related CoV
.______ Human CoV 229E
---~~ SAOS-CoV
Rhinolophusbat CoV HKU2
Human CoV OC43
,...___ Murine hepatitis virus
100
---R at CoV HKU24
,____ Huma n CoV HKU1
,,__ 100
-1 Human MERS-CoV
Camel MERS-CoV
100
,...._
__ Plpistrellus bat CoV HKUS
,....___ TytonycterisBat CoV HKU4
Hedgehog CoV
too too SARS -CoV BJ0 1
Civet SARS-CoV SZ3
Bat SARSr -GoV WIV1
Bat SARSr-CoV SHC014
Bat SARSr-CoV LYRa11
90
Bat SARSr-CoV Rf1
97
Bat SARSr-CoV ZC45
,....___ Bat SARSr-CoV BM48-31
BetaCoV/Wuhan/W IV0S/2019
1oo BetaCoV/Wuhan/WIV02 /2019
BetaCoV/Wuhan/WIV04/2019
BetaCoV/Wuh.in/WlV06 / 2019
100 BctaCoV/Wuhan/W1V07 /2019
Bat CoV RaTG13
.__ _____ Bat Hp BetaCoV Zhejiang2013
.______ .----- Rousettusbat CoV HKU9
100 Bat CoV GCCOC1
------IBV
0.1
The longer a virus circulates in a human populat ions, the more time it has to develop mutations that
differentiate strains in infected people, and give n that the 2019-nCoV sequences analyzed to date differ
from each other by seven nucleotides at most, this suggests it jumped into hum ans very recently. But it
rema ins a mystery which animal spread the virus to humans. "There's a very large gray area between
viruses detec ted in bats and the virus now isolated in humans," says Vince nt Munster, a virologist at the
NIH-002428
U.S. National Institute of Allergy and Infectious Diseaseswho studies coronaviruses in bats, camels, and
others species.
Strong evidence suggests the marketplace played an early role in spreading 2019-nCoV, but whether it
was the or igin of the outbreak remains uncertain. Many of the initially confirmed 2019-nCoV cases- 27
of the first 41 in one repo rt, 26 of 47 in anot her -were connected to the Wuhan market, but up to 45%,
including the earliest handful , were not . This raises the possibility that the initial jump into people
happened elsewhere .
According to Xinhua, the state-run news agency, "environmenta l sampling" of the Wuhan seafood
and all were in the huge market's western portion, which is where wildlife were sold. "The positive tests
from the wet market are hugely important," says Edward Holmes, an evolut ionary biologist at the
University of Sydney who collaborated with the fi rst group to publicly release a 2019-nCoV sequence.
"Such a high rate of positive tests would strongly imply that animals in the market played a key role in
the emergence of the virus."
Yet there have been no preprints or official scientific reports on the sampling, so it's not clear which, if
any, animals tested positive. "Until you consistently isolate the virus out of a single species, it's really,
really difficult to try and dete rmine what the natural host is," says Kristian Andersen, an evolutionary
biologist at Scripps Research.
One possible explanat ion for the confusion about where the virus first entered humans is if there was a
batch of recently infected animals sold at different marketplaces . Or an infected animal trader could
have transmitted the virus to different people at different markets . Or, Bedford suggests, those early
could illuminate how many zoonoses occurred and when they occurred," Bedford says.
A research group sent fecal and other bodily samples from bats they trapped in caves to the Wuhan
EcoHealth Alliance
In the absence of clear conclusions about the outbreak's origin, theories thrive, and some have been
scientifically shaky. A sequence analysis led by Wei Ji of Peking University and published on line by the
Journal of Medical Virology received substant ial press coverage when it suggested that "snake is the
most probable wildlife anima l reservoir for the 2019-nCoV." Sequence specialists, however, pilloried it .
Conspiracy theories also abound. A CBCNews report about the Canadian government deporting Chinese
scientists who worked in a Winnipeg lab that studies dangerous pathogens was disto rt ed on social
med ia to suggest that they were spies who had smuggled out coronaviruses. The Wuhan Institute of
NIH-002429
Virology, which is the premier lab in China that studies bat and human coronaviruses, has also come
under fi re. "Experts debunk fringe theory linking China's coronavirus to weapons research," read a
headline on a story in The Washington Post that focused on the facility.
Concerns about the institute predate this outbreak. Nature ran a st o ry in 2017 about it building a new
biosafety level 4 lab and included molecular biolog ist Richard Ebright of Rutgers Universi ty, Piscataway,
expressing concerns about accidental infections, which he noted repeatedly happened with lab workers
handling SARSin Beijing. Ebright, who has a long history of raising red flags about studies with
dangerous pathogens, also in 2015 crit icized an experiment in which modifications were made to a
SARS-likevirus circulating in Chinese bats to see whether it had the potential to cause disease in
humans. Earlier this week, Ebright quest ioned t he accuracy of Bedford's calculat ion that there are at
least 25 years of evolutionar y distance between RaTG13-the virus held in the Wuhan virology
institute-and 2019-nCoV, arguing that the mutation rate may have been different as it passed through
different hosts before humans. Ebright tells 5ciencelnsider that t he 2019-nCoV data are "consistent with
entry into the human population as a natural accident."
Shi did not reply to emails from Science, but her longt ime collaborator, disease ecologist Peter Daszakof
the EcoHealth Alliance, dismissed Ebright's conjecture. "Every time there's an emerging disease, a new
virus, the same story comes out : This is a spillover or the release of an agent or a bioengineered virus,"
Daszak says. "It's just a shame. It seems hum ans can't resist controversy and these myths, yet it's staring
us right in t he face. There' s this incredible diversity of viruses in wildlife and we've just scratched the
surface . Within that diversity, there will be some t hat can infect peop le and within that group wi ll be
some that cause il lness."
bats in caves all over China, like this one in Guangdong, to sample them for coronaviruses.
EcoHealth Allia nce
Daszak and Shi's group have for 8 years been trapping bats in caves around China to sample their feces
and blood for viruses. He says they have sampled more than 10,000 bats and 2000 other species. They
have found some 500 novel coronaviruses, about 50 of which fall relatively close to the SARSvirus on
the family tree, including RaTG13-it was fished out of a bat fecal sample they collected in 2013 from a
cave in Moglang in Yunnan province. "We cannot assume that just because th is virus from Yunnan has
high sequence identity with the new one t hat th at's the origin," Daszak says, noting that only a tiny
fraction of coronaviruses that infect bats have been discovered . "I expect that once we've sampled and
sampled and sampled across southern China and central China that we' re going to find many other
viruses and some of them will be closer [to 2019-nCoV] ."
NIH-002430
It's not just a "curious interest" to figure out what sparked the current outbreak, Daszak says. "If we
don't find the origin, it could still be a raging infection at a farm somewhere, and once this outbreak
dies, there could be a cont inued spillover that's really hard to stop. But the jury is still out on what the
Posted in;
• Asia/Pacifi c
• Health
• Coronaviru s
doi:10.1126/science .abb1256
Jon Cohen
Jon is a staff writer for Science.
• Email Jon
• Twitt er
Disclaimer : Any third-party material in this email has been sbared for internal use under fair use provisions
of U.S. copyright law, without further verification of its accuracy /veracity . It does not necessarily repre sent
my views nor those of NlAID , NIH , HHS , or the U.S. government.
NIH-002431
Sent: Sat, 1 Feb 2020 12:29:0 1 +0000
To: Auchincloss, Hugh (NIH/NIAID) [C] (b)(6)
Cc: (b)(6)
-----------
Subject : IMPORTANT
Attachments: Barie, Shi et al - Nature medicine - SARSGain of function.pdf
Hugh:
It is essential that we speak th is AM. Keep your cell phone on. I have a conference call at
7:45 AM with Azar. It like ly will be over at 8:45 AM. Readthis paper as well as the e-mail that
I will forward to you now. You will have tasks today that must be done.
Thanks,
Tony
Director
Phone : (b)(6)
FAX: (301 496-4409
E-mail : (b)(6)
NIH-002432
Sent : Sat, 1 Feb 2020 02:48:59 +0000
To : Kadlec, Robert (OS/ASPR/IO)
Cc: (b)(6)
Subject: FW: Science: Mining coronavirus genomes for clues to the outbreak's or igins
Bob:
This just came out today. Gives a balanced view.
Best,
Tony
From : Folkers, Greg (NIH/NIA ID) [E) (b)(6)>

Se nt : Friday, January 31, 2020 8:43 PM
Subject : Science: Mining coronavirus genomes for clues to the outbreak's origins
cave in Guandong.
EcoHealth Alliance

outbreak's origins
attaaaggtt tataccttcc caggtaacaa accaaccaac tttcgatctc ttgtagatct ...
That str ing of apparent gibberish is anything but: It's a snippet of a DNA sequence from the viral
pathogen, dubbed 2019 novel coronavirus (2019-nCoV), that is overwhe lming China and frightening the
entire world . Scientists are publicly shar ing an ever-growing number of full sequences of the virus from
patients - 53 at last count in the Global Initiative on Shari ng All Influenza Data database. These v iral
this newly discovered vi rus physically looks like, how it' s changing, and how it might be stopped .
NIH-002433
introduction into humans and then human-to -human spread," says Trevor Bedford, a bioinformatics
specialist at the University of Washington, Seattle. The role of Huanan Seafood Wholesale Market in
In all, 2019-nCoV has nearly 29,000 nucleotides bases that hold the genetic instruction book to produce
Many analyses of 2019-nCoV's sequences have already appeared on virological.org. nextstrain.org .
Chinese researchers allowed public health labs around the world to develop their own diagnostics for
the virus, which now has been found in 18 other countries. (Science's news stories on the outbreak can
be found here.)
coronaviruses-which are abundant and infect many species-and found that it was most closely
Institute of Virology, repo rted on 23 January on bioRxiv that 2019-nCoV's sequence was 96.2% similar to
a bat virus and had 79.5% similarity to the coronavirus that causes severe acute respiratory syndrome
coronavirus has a similarly close relat ionship to bat viruses, and sequence data make a powerful case
as 10 nucleotides. That's one reason why many scient ists suspect there's an "intermediary" host
Accord ing to Bedford's analysis, the bat coronavirus sequence that Shi Zheng-Li's team highlighted,
dubbed RaTG13,differs from 2019-nCoV by nearly 1100 nucleotides. On nextstra in.org, a site he co-
and 2019-nCoV sequences. (The trees are inte ractive -by dragging a computer mouse over them, it's
NIH-002434
~
.
--
■-
..,.., ··•-
A
.....
......
....
,...,
,_
-II
--
,.._,__,,
r:===~~s
--
_.,
=,
•ou
..,
------------------c= -----------1 =.•M.""l'"l_..l

-
__ ..-·~·
..
....,
__
tf.C-,Xt1
I=-=
---'-'-"'
=~
om Cl ,u 014 au
Bedford's analyses of RaTG13 and 2019-nCoV suggest that the two viruses shared a common ancestor
25 to 65 years ago, an estimate he arrived at by combining the difference in nucleotides between the
viruses with the presumed rates of mutation in other coronaviruses. So it likely took decades for
Middle East respiratory syndrome (MERS),another human disease caused by a coronavirus, simi larly has
a link to bat viruses . But studies have built a compelling case it jumped to humans from camels. And the
phylogene ti c tree from Shi's bioRxiv paper (below) makes the camel-MERS link easy to see.
NIH-002435
.~---TGE V
.....--- M ink CoV
,____ FerretCoV
.....---- Bat CoV CDPHE15
.----- Sootophifus bat CoV 512
L----PE DV
~--- Bat CoV HKU 10
Minlopterus bat CoV 1
,_____ Miniopterus bat CoV HKU8
100
.---- Human CoV NL63
---- Bat NL63-related CoV
.______ Human CoV 229 E
'-------,-,~ SADS-CoV
Rhfnolophus bat CoV HKU2
Human CoV OC43
100 --- Murine hepatitis virus
---R at CoV HKU24
---- Huma n CoV HKU1
__ 100-1Human MER S-CoV
Camel MER S-CoV
100 Plplstrell us bat CoV HKUS
--- Tytonycteris Bat CoV HKU4
~- Hedgehog CoV
100 SARS-CoV 8J01
100
Civet SARS-CoV SZ3

Bat SARSr -CoV wrv1
Bat SARSr -CoV SHC01 4
Bat SARSr-CoV LYR a11
to Ba1SARSr-CoVRf1
91
Bat SARSr-COV ZC4 5
Bat SARSr-CoV HKU3- 1
--- Bal SARSr-CoV BM48-31
BetaCoV/Wuhan/WlV0S /2019
100 Beh1CoV/Wuhan/WIV02 / 2019
IQO
BetaCo V/Wuhan/W IV0-4/ 2019
BetaCo V/Wuhan/W IV06/ 2019
100 BeuCoV/Wuhan/W IV07 / 2019
Bat CoV RaTG13
97 ,__ _____ Bat Hp BetaCoV Zhejiang 2013
____ ,,......
___ Rousettusbat CoV HKU9
100 Bat CoV GCCOC 1
------ISV
differentiate strains in infected people, and given that the 2O19-nCoV sequences analyzed to date differ
from each other by seven nucleotides at most, this suggests it jumped into humans very recently . But it
remains a mystery which animal spread the virus to humans . "There's a very large gray area between
viruses detected in bats and the virus now isolated in humans," says Vincent Munster, a virologist at the
U.S. National Institute of Allergy and Infectious Diseaseswho studies coronaviruses in bats, camels, and
others species.
was the or igin of the out break remains uncertain. Many of the initially confirmed 2019-nCoV cases- 27
of the first 41 in one report , 26 of 47 in anothe r-were connected to the Wuhan market, but up to 45%,
including the earliest handful , were not. This raises the possibility that the initial jump into people
NIH-002436
According to Xinhua, the state-run news agency, "environmenta l sampling" of the Wuhan seafood
and all were in the huge market's western portion, which is where wildlife were sold. "The positive tests
from the wet market are hugely important/' says Edward Holmes, an evolutionary biologist at the
really difficult to try and dete rmine what the natural host is," says Kristian Andersen, an evolutionary
One possible explanat ion for the confusion about where the virus first entered humans is if there was a
batch of recently infected animals sold at different marketplaces. Or an infected animal trader could
have transmi tted the virus to different people at different markets. Or, Bedford suggests, those early
could illuminate how man zoonoses occurred and when they occurred," Bedford says.
EcoHealth Alliance
In the absence of clear conclusions about the outbreak's origin, theories thrive, and some have been
scientifical ly shaky. A sequence analysis led by Wei Ji of Peking University and published on line by the
most probable wildlife animal reservoir for the 2019-nCoV." Sequence specialists, however, pilloried it .
Conspiracy theories also abound. A CBCNews report about the Canadian government deporting Chinese
scientists who worked in a Winnipeg lab that studies dangerous pathogens was distort ed on social
media to suggest that they were spies who had smuggled out coronaviruses. The Wuhan Institute of
Concerns about the institute predate this outbreak. Nature ran a story in 2017 about it building a new
biosafety level 4 lab and included molecular biologist Richard Ebright of Rutgers University, Piscataway,
expressing concerns about accidental infections, which he noted repeatedly happened with lab workers
NIH-002437
dangerous pathogens, also in 2015 crit icized an exper iment in which modifications were made to a
humans. Earlier this week, Ebright quest ioned t he accuracy of Bedford's calculat ion that there are at
least 25 years of evolutionary distance between RaTG13- the virus held in the Wuhan virology
institute - and 2019-nCoV, arguing that the mutation rate may have been different as it passed through
different hosts before humans. Ebright tells 5ciencelnsider that the 2019-nCoV data are "consistent with
Shi did not reply to emails from Science,but her longt ime collaborator, disease ecologist Peter Daszak of
virus, the same story comes out: This is a spillover or the release of an agent or a bioengineered virus,"
Daszak says. "It's just a shame. It seems humans can't resist controversy and these myths, yet it's staring
us right in the face. There's this incredible diversity of viruses in wildlife and we've just scratched the
surface. Within that diversity, there will be some that can infect people and within that group wi ll be
some that cause illness."
bats in caves all over China, like this one in Guangdong, to sample them for coronaviruses .
EcoHealth Alliance
have found some 500 novel coronaviruses , about 50 of which fall relatively close to the SARSvirus on
high sequence identity with the new one that that's the origin," Daszak says, noting that only a tiny
fraction of coronaviruses that infect bats have been discovered. "I expect that once we've sampled and
sampled and sampled across southern China and central China that we're going to find many other
viruses and some of them will be closer [to 2019-nCoV]."
It's not just a "curious interest" to figure out what sparked the current outbreak , Daszak says. "If we
don't find the origin, it cou ld still be a raging infection at a farm somewhere, and once this outbreak
dies, there could be a cont inued spillover that's really hard to stop. But the jury is st ill out on what the
Posted in:
• Asia/ Pacific
• Health
NIH-002438
• Coronav irus
doi :10.1126/science.abb1256
Jon Cohen
Jon is a staff writer f or Science.
• Email Jon
• Twitter
Disclaimer: Any third -party material in this email has been shared for ittternal use unde1· fair use provisions
of U.S. copyright law , without fm·ther verification of its accuracy /veracity . It does not necessarily repre sent
my views nor those ofNTATD, NTH, HHS , or the U.S. government.
NIH-00243 9
Sent : Sat, 1 Feb 2020 02:46:21 +0000
To : Mascola, John (NIH/VRC) [E)
Subject : FW: Science: Mining coronavirus genomes for clues to the outbreak's or igins
Here is the Jon Cohen article.
From:Folkers, Greg (NIH/NIAID) [E] (b)(6)

Subject : Science: M ining coronavirus genomes for clues to the outbreak's or igins
cave in Guandong.
EcoHealth Allia nce

outbreak's origins
attaaaggtt ta taccttcc caggtaacaa accaaccaac tttcgatctc ttgtagatct ...
That str ing of apparent gibberish is anything but: It 's a snippet of a DNA sequence from the viral
pathogen, dubbed 2019 novel coronavirus (2019-nCoV), that is overw helmi ng China and frightening the
entire world. Scientists are publicly shar ing an ever-growing number of full sequences of the virus from
patients-53 at last count in the Global Initiative on Sharing All Influ enza Data database. These viral
this newly discove red vi rus physically looks like, how it's changing, and how it might be st opped .
intr oduction into humans and then human-to-human spread," says Trevor Bedford, a bioinformatics
specialist at the Univers ity of Washington, Seattle . The role of Huanan Seafood Wholesale Ma rket in
Wuhan , China, in spreading 2019-nCoV remains murky, though such sequencing, combined w ith
NIH-002440
In all, 2019-nCoV has nearly 29,000 nucleotides bases that ho ld the genetic instruction book to produce
Many analyses of 2019-nCoV's sequences have already appeared on viro logical.org, nextstra in.o rg,
Chinese researchers allowed public health labs around the world to develop their own diagnostics for
the virus, which now has been found in 18 other countries. (Science'snews stories on the outbreak can
be found here. )
co ronaviruses-which are abundant and infect many species-and found that it was most closely
Institute of Virology, repor ted on 23 January on bioRxiv that 2019-nCoV's sequence was 96.2% simi lar to
a bat virus and had 79.5% similarity to the coronav irus that causes severe acute respiratory syndrome
coronavirus has a similarly close relat ionship to bat viruses, and sequence data make a powerful case
as 10 nucleotides . That's one reason why many scientists suspect there's an "intermedia ry" host
According to Bedford's analysis, the bat coronavirus sequence that Shi Zheng-Li's team highlighted,
dubbed RaTG13,differs from 2019-nCoV by nearly 1100 nucleotides. On nextstrain.org, a site he co-
and 2019-nCoV sequences. (The t rees are inte ract ive-by dragging a computer mouse over them, it's
---
---
_
,_,,.
~
--
~==:: ~;s;:.
~
=
__
,uu
ID
,
Bedford's analyses of RaTG13and 2019-nCoV suggest that the two viruses shared a common ancestor
25 to 65 years ago, an estimate he arrived at by combining the difference in nucleotides between the
NIH-002441
viruses with the presumed rates of mutation in other coronaviruses. So it likely took decades for
Middle East respiratory syndrome (MERS), another human disease caused by a coronavirus, simi larly has
a link to bat viruses. But stud ies have built a compelling case it jumped to humans from camels. And the
phylogene tic tree from Shi's bioRxiv paper (below) makes the camel-MERS link easy to see.
,...-----TGEV
,---- M ink CoV
'----ferret CoV
.----- Bat CoV COPHE15
,----- Scotophifusbat CoV 512
.__ ___ PEDV
.----- Bat CoV HKU10
..---- Miniopterusbat CoV 1
Miniopterusbat CoV HKU8
100 ...---- Human CoV NL63
---- Bat NL63-re lated CoV
...._____ Human CoV 229E
,____ ___,..,,,..
SADS-CoV
Rhinolophusbat CoV HKU2
Human CoV OC43
100 Murine hepatitis virus
.____ Rat CoV HKU24
,____ Human CoV HKU1
,__•oo~ Human MERS-CoV
Camel MERS-CoV
100
'---- Pfplstre/lL
JSbat CoV HKU5
,____ Tytonycteris Bat CoV HKU4
....___ Hedgehog CoV
100 tooSARS-CoVBJ01
CivetSARS-CoVSZ3
Bat SARSr-CoV WIV1
Bat SARSr-CoVSHC014
Bat SARSr -CoV LYRa11
90
Bat SARSr-CoV Rf1
97
Bat SARSr-COV ZC45
.____ Bat SARSr-CoVBM48-31
BetaCoV/Wuha nlWIVOS/2O19
100 BetaCoV/Wuha nlWIVO2/2O19
100
BetaCoV/Wuha n/WIV04/2 019
BetaCoV/Wuha n/WIVO6f2O19
100 BetaCoVIWuha n/WIV07/2019
Bat CoV RaTG13
97 .______ BatHp BetaCoVZhejiang2013
,___
___ .----- Rousettusbat CoV HKU9
._______ ,av 100 Bat CoV GCCOC1
Q.1
differentiate strains in infected people, and given that the 2019-nCoV sequences analyzed to date differ
from each other by seven nucleotides at most, this suggests it jumped into hum ans very recently . But it
rema ins a mystery which animal spread the virus to humans. "There's a very large gray area between
viruses detected in bats and the virus now isolated in humans," says Vincent Munster, a virologist at the
U.S. National Inst itute of Allergy and Infectio us Diseases who studies coronaviruses in bats, camels, and
others species.
NIH-002442
was the or igin of the outbreak remains uncertain. Many of the initially confirmed 2019-nCoV cases-2 7
of the first 41 in one repor t, 26 of 47 in another - were connected to the Wuhan market , but up to 45%,
including the earliest handful , were not . This raises the possibility that the initial jump into people
According to Xinhua, the state-run news agency, "en vironmenta l sampling" of the Wuhan seafood
and all were in the huge market's western portion, which is where wildlife were sold . "The positive tests
from the wet market are hugely important," says Edward Holmes, an evolut ionary biologist at the
really difficu lt to try and dete rmine what the natural host is," says Kristian Andersen, an evolutionary
One possible explanat ion for the confusion about where the virus first entered huma ns is if there was a
batch of recently infected animals sold at different marketplaces. Or an infected animal trader could
have transmi tted the virus to different people at different markets. Or, Bedford suggests, those early
cases could have been infected by viruses that didn't easily transmit and sputtered out. "It woul d be
could illuminate how many zoonoses occurred and when they occurred," Bedford says.
EcoHealth Alliance
In the absence of clear conclusions about t he outbreak's origin, theories thrive, and some have been
scientifically shaky. A sequence analysis led by Wei Ji of Peking University and published on line by the
most probable wildlife animal reservoir for the 2019-nCoV." Sequence specialists, however, pillo ried it.
Conspiracy theor ies also abound. A CBCNews report about the Canadian government deporting Chinese
scientists who worked in a Winnipeg lab that studies dangerous pathogens was distorted on social
med ia to suggest that they we re spies who had smuggled out coronaviruses. The Wuhan Institute of
NIH-002443
Concerns about the institute predate this outbreak. Nature ran a story in 2017 about it building a new
biosafety level 4 lab and included molecular biolog ist Richard Ebright of Rutgers University, Piscataway,
expressing concerns about accidental infections, which he noted repeatedly happened with lab worke rs
dangerous pathogens, also in 2015 crit icized an experiment in which modif ications were made to a
humans . Earlier this week, Ebright quest ioned t he accuracy of Bedford's calculat ion that there are at
least 25 years of evolutionary distance between RaTG13-the virus held in the Wuhan virology
institute-and 2019-nCoV, arguing that t he mutation rate may have been different as it passed through
different hosts before humans. Ebright tells Sciencelnsider that the 2019-nCoV data are "consistent with
Shi did not reply to emails from Science, but her longt ime collaborator, disease ecologist Peter Daszak of
virus, the same story comes out: This is a spillover or the release of an agent or a bioengineered virus,"
Daszak says. "It's just a shame. It seems humans can't resist controversy and these myths, yet it's staring
us right in the face . There's this incredible diversity of viruses in wildlife and we've just scratched the
surface. Within that diversity, there will be some that can infect people and within that group wi ll be
some that cause illness."
bats in caves all over China, like this one in Guangdong, to sample them for coronaviruses.
EcoHealth Alliance
have found some 500 novel coronaviruses, about 50 of which fall relatively close to the SARSvirus on
high sequence identity with the new one that that's the origin," Daszak says, noting that only a tiny
fraction of coronaviruses that infect bats have been discovered . " I expect that once we've sampled and
sampled and sampled across southern China and central China that we're going to find many other
viruses and some of them will be closer [to 2019-nCoV)."
It's not just a "curious interest" to figure out what sparked the current outbreak , Daszak says. "If we
don't find the origin, it cou ld still be a raging infection at a farm somewhere, and once this outbreak
NIH-002444
dies, there could be a cont inued spillover that's really hard to stop. But t he jury is st ill out on what the
Posted in:
• Asia/Pacific
• Health
• Coronavirus
doi:10.1126/science .abb1256
Jon Cohen
Jon is a staff writer for Science .
• Email Jon
• Twitter
Disclaim er: Any third-party material in this email has been shared for internal use under fair use prov isions
of U.S. copyright law, without further verification of its accurac y/veracity. It does not necessa rily repre sent
my views nor those of NlAlD, Nill, HHS, or the U.S. government.
NIH-002445

Fauci Emails

Uploaded by

Copyright:

Available Formats

You might also like

Fauci Emails

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Fauci Emails

Uploaded by

Copyright:

Available Formats

From: Fauci, Anthony (NIH/NIAID) [El

Sent: Fri, 6 Mar 2020 03:49:45 +0000

From: Haskins, Melinda (NIH/NIAID) [El (b)( >

From : Muniz, Maria de Los Angeles <MMuniz@vitalant.org>

Maria De Los Angeles Muniz (Angie) , MD

From: M ichelle Whitten - Global <mswhitten@gl oba ldownsynd rome.org>

Dear Dr. Fauci,

All the Best, Michelle and family

What do you think? I see the FDACommissioner every day in person.

From: Kalil, Andre C (b)(6)>

I would appreciate hearing your thoughts on this critical issue.

Andre Kalil, MD, MPH , FACP , FIDSA , FCCM

UNMC I Facebook I Tw itter I YouTube I Flickr

-----Original Message- ----

Dear Dr. Fauci

I look forward to your reply .

From: Aliantha Angel (b)(6)

Is there anything I can do for you besides being grateful?

You and yours are in my prayers!

Dear Ms. Angel:

From: Aliantha Angel (b)(6)

From:Gordon, Joshua (N IH/NIMH) [El

To: Fauci, Anthony (NIH/NIAID) [E]------~=

Subject : Question re:

I know you are swamped but

Do you think that we can do this? I like Jennifer Ashton.

From: Strauss, Eric M.< Eric.M .St rauss@abc.com>

Thank you for your consideration .

Keep up with our latest on the developingnovel coronavirusoutbreak:

Eric M. Strauss, ABC News

Dear Dr. Fauci,

From: Basser, Peter (NIH/NICHD) [E] (b)(6)

Dear Dr. Fauci,

Peter J. Basser, Ph.D.

National Institut es of Health (NIH)

(b) (6) (0)

Smoking is terr ible under any circumstance

> On Mar 4, 2020, at 6:04 PM, Marc Reinoso wrote:

> Hello Dr. Fauci ,

From:Steve Black (b)(6)

Dear Doctor Fauci,

I look forward to hear ing back from you.

ATTACHMENTS: DRAFTAGENDA; DRAFTQUESTIONSFORCONSIDERATION

From: Alice Park <alice.park@time.com>

PLEASENOTE NEW PHONE NUMBER

Talk later. Am in Hearing

> Can this be true?

From: Emanuel, Ezekiel J (b)(6)

Ezek iel J. Emanuel, M.D. , Ph.D.

Vice Provost of Global Initiatives

Levy University Professor

Co-Director , Healthcare Transformation Institute

Perelman School of Medicine and The Wha1ton School

From : Fauci, Anthony (NIH/NIAID) [E]

Question:. Lilelynimmunitynince a person has the Coronavirus infection?.

Ezekiel J. Emanuel, M.D. Ph.D.

Sent from my iPhone

Begin forwarded message:

From: Patti Taylor (b) C